IL-2	1
gene	2
expression	0
and	0
NF-kappa	9
B	10
activation	0
through	0
CD28	9
requires	0
reactive	0
oxygen	0
production	0
by	0
5-lipoxygenase	9
.	0

Activation	0
of	0
the	0
CD28	9
surface	10
receptor	10
provides	0
a	0
major	0
costimulatory	0
signal	0
for	0
T	0
cell	0
activation	0
resulting	0
in	0
enhanced	0
production	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
and	0
cell	0
proliferation	0
.	0

In	0
primary	7
T	8
lymphocytes	8
we	0
show	0
that	0
CD28	9
ligation	0
leads	0
to	0
the	0
rapid	0
intracellular	0
formation	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROIs	0
)	0
which	0
are	0
required	0
for	0
CD28	9
-mediated	0
activation	0
of	0
the	0
NF-kappa	9
B	10
/	0
CD28-responsive	9
complex	10
and	0
IL-2	9
expression	0
.	0

Delineation	0
of	0
the	0
CD28	9
signaling	0
cascade	0
was	0
found	0
to	0
involve	0
protein	9
tyrosine	10
kinase	10
activity	0
,	0
followed	0
by	0
the	0
activation	0
of	0
phospholipase	9
A2	10
and	0
5-lipoxygenase	9
.	0

Our	0
data	0
suggest	0
that	0
lipoxygenase	9
metabolites	10
activate	0
ROI	0
formation	0
which	0
then	0
induce	0
IL-2	9
expression	0
via	0
NF-kappa	9
B	10
activation	0
.	0

These	0
findings	0
should	0
be	0
useful	0
for	0
therapeutic	0
strategies	0
and	0
the	0
development	0
of	0
immunosuppressants	0
targeting	0
the	0
CD28	9
costimulatory	0
pathway	0
.	0

The	0
peri-kappa	1
B	2
site	2
mediates	0
human	1
immunodeficiency	2
virus	2
type	2
2	2
enhancer	2
activation	0
in	0
monocytes	7
but	0
not	0
in	0
T	7
cells	8
.	0

Human	0
immunodeficiency	0
virus	0
type	0
2	0
(	0
HIV-2	0
)	0
,	0
like	0
HIV-1	0
,	0
causes	0
AIDS	0
and	0
is	0
associated	0
with	0
AIDS	0
cases	0
primarily	0
in	0
West	0
Africa	0
.	0

HIV-1	0
and	0
HIV-2	0
display	0
significant	0
differences	0
in	0
nucleic	0
acid	0
sequence	0
and	0
in	0
the	0
natural	0
history	0
of	0
clinical	0
disease	0
.	0

Consistent	0
with	0
these	0
differences	0
,	0
we	0
have	0
previously	0
demonstrated	0
that	0
the	0
enhancer/promoter	1
region	2
of	0
HIV-2	0
functions	0
quite	0
differently	0
from	0
that	0
of	0
HIV-1	0
.	0

Whereas	0
activation	0
of	0
the	0
HIV-1	1
enhancer	2
following	0
T-cell	0
stimulation	0
is	0
mediated	0
largely	0
through	0
binding	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
to	0
two	0
adjacent	0
kappa	1
B	2
sites	2
in	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
,	0
activation	0
of	0
the	0
HIV-2	1
enhancer	2
in	0
monocytes	7
and	0
T	7
cells	8
is	0
dependent	0
on	0
four	0
cis-acting	1
elements	2
:	0
a	0
single	0
kappa	1
B	2
site	2
,	0
two	0
purine-rich	1
binding	2
sites	2
,	0
PuB1	1
and	0
PuB2	1
,	0
and	0
a	0
pets	1
site	2
.	0

We	0
have	0
now	0
identified	0
a	0
novel	0
cis-acting	1
element	2
within	0
the	0
HIV-2	1
enhancer	2
,	0
immediately	0
upstream	0
of	0
the	0
kappa	1
B	2
site	2
,	0
designated	0
peri-kappa	1
B	2
.	0

This	0
site	0
is	0
conserved	0
among	0
isolates	0
of	0
HIV-2	0
and	0
the	0
closely	0
related	0
simian	0
immunodeficiency	0
virus	0
,	0
and	0
transfection	0
assays	0
show	0
this	0
site	0
to	0
mediate	0
HIV-2	1
enhancer	2
activation	0
following	0
stimulation	0
of	0
monocytic	5
but	0
not	0
T-cell	5
lines	6
.	0

This	0
is	0
the	0
first	0
description	0
of	0
an	0
HIV-2	1
enhancer	2
element	2
which	0
displays	0
such	0
monocyte	0
specificity	0
,	0
and	0
no	0
comparable	0
enhancer	1
element	2
has	0
been	0
clearly	0
defined	0
for	0
HIV-1	0
.	0

While	0
a	0
nuclear	9
factor	10
(	0
s	0
)	0
from	0
both	0
peripheral	7
blood	8
monocytes	8
and	0
T	7
cells	8
binds	0
the	0
peri-kappa	1
B	2
site	2
,	0
electrophoretic	0
mobility	0
shift	0
assays	0
suggest	0
that	0
either	0
a	0
different	0
protein	0
binds	0
to	0
this	0
site	0
in	0
monocytes	7
versus	0
T	7
cells	8
or	0
that	0
the	0
protein	0
recognizing	0
this	0
enhancer	1
element	2
undergoes	0
differential	0
modification	0
in	0
monocytes	7
and	0
T	7
cells	8
,	0
thus	0
supporting	0
the	0
transfection	0
data	0
.	0

Further	0
,	0
while	0
specific	0
constitutive	0
binding	0
to	0
the	0
peri-kappa	1
B	2
site	2
is	0
seen	0
in	0
monocytes	7
,	0
stimulation	0
with	0
phorbol	0
esters	0
induces	0
additional	0
,	0
specific	0
binding	0
.	0

Understanding	0
the	0
monocyte-specific	0
function	0
of	0
the	0
peri-kappa	9
B	10
factor	10
may	0
ultimately	0
provide	0
insight	0
into	0
the	0
different	0
role	0
monocytes	7
and	0
T	7
cells	8
play	0
in	0
HIV	0
pathogenesis	0
.	0

E1A	1
gene	2
expression	0
induces	0
susceptibility	0
to	0
killing	0
by	0
NK	7
cells	8
following	0
immortalization	0
but	0
not	0
adenovirus	0
infection	0
of	0
human	7
cells	8
.	0

Adenovirus	0
(	0
Ad	0
)	0
infection	0
and	0
E1A	9
transfection	0
were	0
used	0
to	0
model	0
changes	0
in	0
susceptibility	0
to	0
NK	0
cell	0
killing	0
caused	0
by	0
transient	0
vs	0
stable	0
E1A	9
expression	0
in	0
human	7
cells	8
.	0

Only	0
stably	0
transfected	5
target	6
cells	6
exhibited	0
cytolytic	0
susceptibility	0
,	0
despite	0
expression	0
of	0
equivalent	0
levels	0
of	0
E1A	9
proteins	10
in	0
Ad-infected	5
targets	6
.	0

The	0
inability	0
of	0
E1A	1
gene	2
products	0
to	0
induce	0
cytolytic	0
susceptibility	0
during	0
infection	0
was	0
not	0
explained	0
by	0
an	0
inhibitory	0
effect	0
of	0
viral	0
infection	0
on	0
otherwise	0
susceptible	0
target	7
cells	8
or	0
by	0
viral	1
gene	2
effects	0
on	0
class	9
I	10
MHC	10
antigen	10
expression	0
on	0
target	7
cells	8
.	0

This	0
differential	0
effect	0
of	0
E1A	9
expression	0
on	0
the	0
cytolytic	0
phenotypes	0
of	0
infected	0
and	0
stably	0
transfected	0
human	7
cells	8
suggests	0
that	0
human	7
NK	8
cells	8
provide	0
an	0
effective	0
immunologic	0
barrier	0
against	0
the	0
in	0
vivo	0
survival	0
and	0
neoplastic	0
progression	0
of	0
E1A-immortalized	5
cells	6
that	0
may	0
emerge	0
from	0
the	0
reservoir	0
of	0
persistently	7
infected	8
cells	8
in	0
the	0
human	0
host	0
.	0

Distinct	0
signaling	0
properties	0
identify	0
functionally	0
different	0
CD4	9
epitopes	10
.	0

The	0
CD4	9
coreceptor	10
interacts	0
with	0
non-polymorphic	9
regions	10
of	0
major	9
histocompatibility	10
complex	10
class	10
II	10
molecules	10
on	0
antigen-presenting	7
cells	8
and	0
contributes	0
to	0
T	0
cell	0
activation	0
.	0

We	0
have	0
investigated	0
the	0
effect	0
of	0
CD4	9
triggering	0
on	0
T	0
cell	0
activating	0
signals	0
in	0
a	0
lymphoma	0
model	0
using	0
monoclonal	9
antibodies	10
(	0
mAb	9
)	0
which	0
recognize	0
different	0
CD4	9
epitopes	10
.	0

We	0
demonstrate	0
that	0
CD4	9
triggering	0
delivers	0
signals	0
capable	0
of	0
activating	0
the	0
NF-AT	9
transcription	10
factor	10
which	0
is	0
required	0
for	0
interleukin-2	9
gene	0
expression	0
.	0

Whereas	0
different	0
anti-CD4	9
mAb	10
or	0
HIV-1	9
gp120	10
could	0
all	0
trigger	0
activation	0
of	0
the	0
protein	9
tyrosine	10
kinases	10
p56lck	9
and	0
p59fyn	9
and	0
phosphorylation	0
of	0
the	0
Shc	9
adaptor	10
protein	10
,	0
which	0
mediates	0
signals	0
to	0
Ras	9
,	0
they	0
differed	0
significantly	0
in	0
their	0
ability	0
to	0
activate	0
NF-AT	9
.	0

Lack	0
of	0
full	0
activation	0
of	0
NF-AT	9
could	0
be	0
correlated	0
to	0
a	0
dramatically	0
reduced	0
capacity	0
to	0
induce	0
calcium	0
flux	0
and	0
could	0
be	0
complemented	0
with	0
a	0
calcium	0
ionophore	0
.	0

The	0
results	0
identify	0
functionally	0
distinct	0
epitopes	9
on	0
the	0
CD4	9
coreceptor	10
involved	0
in	0
activation	0
of	0
the	0
Ras/protein	9
kinase	10
C	10
and	0
calcium	0
pathways	0
.	0

Ligand-dependent	0
repression	0
of	0
the	0
erythroid	9
transcription	10
factor	10
GATA-1	9
by	0
the	0
estrogen	9
receptor	10
.	0

High-dose	0
estrogen	0
administration	0
induces	0
anemia	0
in	0
mammals	0
.	0

In	0
chickens	0
,	0
estrogens	0
stimulate	0
outgrowth	0
of	0
bone	7
marrow-derived	8
erythroid	8
progenitor	8
cells	8
and	0
delay	0
their	0
maturation	0
.	0

This	0
delay	0
is	0
associated	0
with	0
down-regulation	0
of	0
many	0
erythroid	1
cell-specific	2
genes	2
,	0
including	0
alpha-	1
and	2
beta-globin	2
,	0
band	0
3	0
,	0
band	0
4.1	0
,	0
and	0
the	0
erythroid	9
cell-specific	10
histone	10
H5	9
.	0

We	0
show	0
here	0
that	0
estrogens	0
also	0
reduce	0
the	0
number	0
of	0
erythroid	7
progenitor	8
cells	8
in	0
primary	5
human	6
bone	6
marrow	6
cultures	6
.	0

To	0
address	0
potential	0
mechanisms	0
by	0
which	0
estrogens	0
suppress	0
erythropoiesis	0
,	0
we	0
have	0
examined	0
their	0
effects	0
on	0
GATA-1	9
,	0
an	0
erythroid	9
transcription	10
factor	10
that	0
participates	0
in	0
the	0
regulation	0
of	0
the	0
majority	0
of	0
erythroid	1
cell-specific	2
genes	2
and	0
is	0
necessary	0
for	0
full	0
maturation	0
of	0
erythrocytes	7
.	0

We	0
demonstrate	0
that	0
the	0
transcriptional	0
activity	0
of	0
GATA-1	9
is	0
strongly	0
repressed	0
by	0
the	0
estrogen	9
receptor	10
(	0
ER	9
)	0
in	0
a	0
ligand-dependent	0
manner	0
and	0
that	0
this	0
repression	0
is	0
reversible	0
in	0
the	0
presence	0
of	0
4-hydroxytamoxifen	0
.	0

ER	9
-mediated	0
repression	0
of	0
GATA-1	9
activity	0
occurs	0
on	0
an	0
artificial	1
promoter	2
containing	0
a	0
single	0
GATA-binding	1
site	2
,	0
as	0
well	0
as	0
in	0
the	0
context	0
of	0
an	0
intact	1
promoter	2
which	0
is	0
normally	0
regulated	0
by	0
GATA-1	9
.	0

GATA-1	9
and	0
ER	9
bind	0
to	0
each	0
other	0
in	0
vitro	0
in	0
the	0
absence	0
of	0
DNA	0
.	0

In	0
coimmunoprecipitation	0
experiments	0
using	0
transfected	0
COS	5
cells	6
,	0
GATA-1	9
and	0
ER	9
associate	0
in	0
a	0
ligand-dependent	0
manner	0
.	0

Mapping	0
experiments	0
indicate	0
that	0
GATA-1	9
and	0
the	0
ER	9
form	0
at	0
least	0
two	0
contacts	0
,	0
which	0
involve	0
the	0
finger	0
region	0
and	0
the	0
N-terminal	9
activation	10
domain	10
of	0
GATA-1	9
.	0

We	0
speculate	0
that	0
estrogens	0
exert	0
effects	0
on	0
erythropoiesis	0
by	0
modulating	0
GATA-1	9
activity	0
through	0
protein-protein	0
interaction	0
with	0
the	0
ER	9
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Mouse	1
interleukin-2	2
receptor	2
alpha	2
gene	2
expression	0
.	0

Interleukin-1	9
and	0
interleukin-2	9
control	0
transcription	0
via	0
distinct	0
cis-acting	1
elements	2
.	0

We	0
have	0
shown	0
that	0
interleukin-1	9
(	0
IL-1	9
)	0
and	0
IL-2	9
control	0
IL-2	1
receptor	2
alpha	2
(	2
IL-2R	2
alpha	2
)	2
gene	2
transcription	0
in	0
CD4-CD8-	5
murine	6
T	6
lymphocyte	6
precursors	6
.	0

Here	0
we	0
map	0
the	0
cis-acting	1
elements	2
that	0
mediate	0
interleukin	0
responsiveness	0
of	0
the	0
mouse	1
IL-2R	2
alpha	2
gene	2
using	0
a	0
thymic	5
lymphoma-derived	6
hybridoma	6
(	0
PC60	5
)	0
.	0

The	0
transcriptional	0
response	0
of	0
the	0
IL-2R	1
alpha	2
gene	2
to	0
stimulation	0
by	0
IL-1	9
+	0
IL-2	9
is	0
biphasic	0
.	0

IL-1	9
induces	0
a	0
rapid	0
,	0
protein	0
synthesis-independent	0
appearance	0
of	0
IL-2R	3
alpha	4
mRNA	4
that	0
is	0
blocked	0
by	0
inhibitors	0
of	0
NF-kappa	9
B	10
activation	0
.	0

It	0
also	0
primes	0
cells	0
to	0
become	0
IL-2	9
responsive	0
and	0
thereby	0
prepares	0
the	0
second	0
phase	0
,	0
in	0
which	0
IL-2	9
induces	0
a	0
100-fold	0
further	0
increase	0
in	0
IL-2R	3
alpha	4
transcripts	4
.	0

Transient	0
transfection	0
experiments	0
show	0
that	0
several	0
elements	0
in	0
the	0
promoter-proximal	1
region	2
of	0
the	0
IL-2R	1
alpha	2
gene	2
contribute	0
to	0
IL-1	9
responsiveness	0
,	0
most	0
importantly	0
an	0
NF-kappa	1
B	2
site	2
conserved	0
in	0
the	0
human	1
and	2
mouse	2
gene	2
.	0

IL-2	9
responsiveness	0
,	0
on	0
the	0
other	0
hand	0
,	0
depends	0
on	0
a	0
78-nucleotide	1
segment	2
1.3	0
kilobases	0
upstream	0
of	0
the	0
major	1
transcription	2
start	2
site	2
.	0

This	0
segment	0
functions	0
as	0
an	0
IL-2-inducible	1
enhancer	2
and	0
lies	0
within	0
a	0
region	0
that	0
becomes	0
DNase	9
I	10
hypersensitive	0
in	0
normal	0
T	7
cells	8
in	0
which	0
IL-2R	9
alpha	10
expression	0
has	0
been	0
induced	0
.	0

IL-2	9
responsiveness	0
requires	0
three	0
distinct	0
elements	1
within	0
the	0
enhancer	1
.	0

Two	0
of	0
these	0
are	0
potential	0
binding	0
sites	0
for	0
STAT	9
proteins	10
.	0

Hematopoietic	7
lineage	8
commitment	0
:	0
role	0
of	0
transcription	9
factors	10
.	0

This	0
review	0
focuses	0
on	0
the	0
roles	0
of	0
transcription	9
factors	10
in	0
hematopoietic	0
lineage	0
commitment	0
.	0

A	0
brief	0
introduction	0
to	0
lineage	0
commitment	0
and	0
asymmetric	0
cell	0
division	0
is	0
followed	0
by	0
a	0
discussion	0
of	0
several	0
methods	0
used	0
to	0
identify	0
transcription	9
factors	10
important	0
in	0
specifying	0
hematopoietic	7
cell	8
types	8
.	0

Next	0
is	0
presented	0
a	0
discussion	0
of	0
the	0
use	0
of	0
embryonic	7
stem	8
cells	8
in	0
the	0
analysis	0
of	0
hematopoietic	1
gene	2
expression	0
and	0
the	0
use	0
of	0
targeted	0
gene	0
disruption	0
to	0
analyze	0
the	0
role	0
of	0
transcription	9
factors	10
in	0
hematopoiesis	0
.	0

Finally	0
,	0
the	0
status	0
of	0
our	0
current	0
knowledge	0
concerning	0
the	0
roles	0
of	0
transcription	9
factors	10
in	0
the	0
commitment	0
to	0
erythroid	7
,	8
myeloid	8
and	8
lymphoid	8
cell	8
types	8
is	0
summarized	0
.	0

Epstein-Barr	0
virus	0
replicative	0
gene	0
transcription	0
during	0
de	0
novo	0
infection	0
of	0
human	7
thymocytes	8
:	0
simultaneous	0
early	0
expression	0
of	0
BZLF-1	9
and	0
its	0
repressor	0
RAZ	9
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
known	0
to	0
infect	0
B	7
cells	8
and	0
epithelial	7
cells	8
.	0

We	0
and	0
others	0
have	0
shown	0
that	0
EBV	0
can	0
also	0
infect	0
a	0
subset	0
of	0
thymocytes	7
.	0

Infection	0
of	0
thymocytes	7
was	0
accompanied	0
by	0
the	0
appearance	0
of	0
linear	1
EBV	2
genome	2
within	0
8	0
hr	0
of	0
infection	0
.	0

Circularization	0
of	0
the	0
EBV	1
genome	2
was	0
not	0
detected	0
.	0

This	0
is	0
in	0
contrast	0
to	0
the	0
infection	0
in	0
B	7
cells	8
where	0
the	0
genome	0
can	0
circularize	0
within	0
24	0
hr	0
of	0
infection	0
.	0

The	0
appearance	0
of	0
the	0
BamHI	9
ZLF-1	10
gene	10
product	10
,	0
ZEBRA	9
,	0
by	0
RT-PCR	0
,	0
was	0
observed	0
within	0
8	0
hr	0
of	0
infection	0
.	0

The	0
appearance	0
of	0
a	0
novel	0
fusion	9
transcript	10
(	0
RAZ	9
)	0
,	0
which	0
comprised	0
regions	0
of	0
the	0
BZLF-1	1
locus	2
and	0
the	0
adjacent	0
BRLF-1	1
locus	2
,	0
was	0
detected	0
by	0
RT-PCR	0
.	0

ZEBRA	9
protein	10
was	0
also	0
identified	0
in	0
infected	0
thymocytes	7
by	0
immunoprecipitation	0
.	0

In	0
addition	0
,	0
we	0
demonstrated	0
that	0
the	0
EBNA-1	1
gene	2
in	0
infected	0
thymocytes	7
was	0
transcribed	0
from	0
the	0
Fp	1
promoter	2
,	0
rather	0
than	0
from	0
the	0
Cp/Wp	1
promoter	2
which	0
is	0
used	0
in	0
latently	7
infected	8
B	8
cells	8
.	0

Transcripts	0
encoding	0
gp350/220	9
,	0
the	0
major	9
coat	10
protein	10
of	0
EBV	0
,	0
were	0
identified	0
,	0
but	0
we	0
did	0
not	0
find	0
any	0
evidence	0
of	0
transcription	0
from	0
the	0
LMP-2A	1
or	0
EBER-1	1
loci	2
in	0
infected	0
thymocytes	7
.	0

These	0
observations	0
suggest	0
that	0
de	0
novo	0
EBV	0
infection	0
of	0
thymocytes	7
differs	0
from	0
infection	0
of	0
B	7
cells	8
.	0

The	0
main	0
difference	0
is	0
that	0
with	0
thymocytes	7
,	0
no	0
evidence	0
could	0
be	0
found	0
that	0
the	0
virus	0
ever	0
circularizes	0
.	0

Rather	0
,	0
EBV	0
remains	0
in	0
a	0
linear	0
configuration	0
from	0
which	0
replicative	1
genes	2
are	0
transcribed	0
.	0

Identification	0
and	0
purification	0
of	0
human	9
Stat	10
proteins	10
activated	0
in	0
response	0
to	0
interleukin-2	9
.	0

A	0
key	0
cytokine	9
induced	0
during	0
the	0
immune	0
response	0
is	0
IL-2	9
.	0

Following	0
T	0
cell	0
activation	0
,	0
the	0
genes	0
encoding	0
IL-2	9
and	0
the	0
various	0
chains	0
of	0
its	0
receptor	0
are	0
transcriptionally	0
induced	0
.	0

In	0
turn	0
,	0
secreted	0
IL-2	9
serves	0
to	0
stimulate	0
the	0
proliferation	0
and	0
differentiation	0
of	0
T	7
lymphocytes	8
.	0

Several	0
recent	0
studies	0
have	0
implicated	0
Jak	0
kinases	0
in	0
the	0
signaling	0
pathway	0
induced	0
by	0
IL-2	9
.	0

Following	0
this	0
lead	0
,	0
we	0
set	0
out	0
to	0
identify	0
transcription	9
factors	10
induced	0
in	0
response	0
to	0
IL-2	9
.	0

Human	7
peripheral	8
blood	8
lymphocytes	8
were	0
observed	0
to	0
contain	0
several	0
IL-2	9
-inducible	0
DNA	0
binding	0
activities	0
.	0

Similar	0
activities	0
were	0
also	0
observed	0
in	0
a	0
transformed	5
human	6
lymphocyte	6
line	6
,	0
termed	0
YT	5
.	0

We	0
have	0
purified	0
these	0
activities	0
and	0
found	0
that	0
the	0
principal	0
IL-2-inducible	9
component	10
bears	0
significant	0
relatedness	0
to	0
a	0
prolactin-induced	9
transcription	10
factor	10
first	0
identified	0
in	0
sheep	7
mammary	8
gland	8
tissue	8
.	0

We	0
hypothesize	0
that	0
activation	0
of	0
this	0
protein	0
,	0
designated	0
hStat5	9
,	0
helps	0
govern	0
the	0
biological	0
effects	0
of	0
IL-2	9
during	0
the	0
immune	0
response	0
.	0

E2F-1	9
and	0
a	0
cyclin-like	9
DNA	10
repair	10
enzyme	10
,	0
uracil-DNA	9
glycosylase	10
,	0
provide	0
evidence	0
for	0
an	0
autoregulatory	0
mechanism	0
for	0
transcription	0
.	0

The	0
cell	9
cycle-dependent	10
transcription	10
factor	10
,	0
E2F-1	9
,	0
regulates	0
the	0
cyclin	9
-like	0
species	0
of	0
the	0
DNA	9
repair	10
enzyme	10
uracil-DNA	1
glycosylase	2
(	2
UDG	2
)	2
gene	2
in	0
human	5
osteosarcoma	6
(	6
Saos-2	6
)	6
cells	6
.	0

We	0
demonstrate	0
,	0
through	0
the	0
deletion	0
of	0
the	0
human	1
UDG	2
promoter	2
sequences	2
,	0
that	0
expression	0
of	0
E2F-1	9
activates	0
the	0
UDG	1
promoter	2
through	0
several	0
E2F	1
sites	2
.	0

The	0
major	1
putative	2
downstream	2
site	2
for	0
E2F	9
,	0
located	0
in	0
the	0
first	1
exon	2
,	0
serves	0
as	0
a	0
target	0
for	0
E2F-1/DP1	9
complex	10
binding	0
in	0
vitro	0
.	0

We	0
also	0
provide	0
evidence	0
for	0
the	0
functional	0
relationship	0
between	0
the	0
cyclin-like	9
UDG	10
gene	10
product	10
and	0
E2F	9
.	0

High	0
levels	0
of	0
UDG	9
expression	0
in	0
a	0
transient	0
transfection	0
assay	0
result	0
in	0
the	0
down-regulation	0
of	0
transcriptional	0
activity	0
through	0
elements	1
specific	0
for	0
E2F	9
-mediated	0
transcription	0
.	0

Overexpression	0
of	0
UDG	9
in	0
Saos	5
2	6
cells	6
was	0
observed	0
to	0
delay	0
growth	0
late	0
in	0
G1	0
phase	0
and	0
transiently	0
arrest	0
these	0
cells	0
from	0
progressing	0
into	0
the	0
S	0
phase	0
.	0

This	0
hypothetical	0
model	0
integrates	0
one	0
mechanism	0
of	0
DNA	0
repair	0
with	0
the	0
cell	0
cycle	0
control	0
of	0
gene	0
transcription	0
,	0
likely	0
through	0
E2F	9
.	0

This	0
implicates	0
E2F	9
as	0
a	0
multifunctional	0
target	0
for	0
proteins	0
and	0
enzymes	0
,	0
possibly	0
,	0
responsive	0
to	0
DNA	0
damage	0
through	0
the	0
negative	0
effect	0
of	0
UDG	9
on	0
E2F	9
-mediated	0
transcriptional	0
activity	0
.	0

Cellular	0
and	0
molecular	0
mechanisms	0
of	0
IFN-gamma	9
production	0
induced	0
by	0
IL-2	9
and	0
IL-12	9
in	0
a	0
human	5
NK	6
cell	6
line	6
.	0

Interferon-gamma	9
(	0
IFN-gamma	9
)	0
is	0
an	0
important	0
immunoregulatory	9
protein	10
produced	0
predominantly	0
by	0
T	7
cells	8
and	0
large	7
granular	8
lymphocytes	8
(	0
LGL	7
)	0
in	0
response	0
to	0
different	0
extracellular	0
signals	0
.	0

In	0
particular	0
,	0
two	0
interleukins	9
(	0
ILs	9
)	0
,	0
IL-2	9
and	0
IL-12	9
,	0
have	0
been	0
shown	0
to	0
be	0
potent	0
inducers	0
of	0
IFN-gamma	9
gene	0
expression	0
in	0
both	0
T	7
cells	8
and	0
LGL	7
.	0

Although	0
it	0
has	0
been	0
reported	0
that	0
there	0
are	0
some	0
T	5
cell	6
lines	6
that	0
produce	0
IFN-gamma	9
in	0
response	0
to	0
IL-2	0
and	0
IL-12	0
stimulation	0
,	0
there	0
has	0
as	0
yet	0
been	0
no	0
report	0
of	0
a	0
natural	5
killer	6
(	6
NK	6
)	6
cell	6
line	6
that	0
responds	0
in	0
a	0
similar	0
manner	0
.	0

In	0
this	0
report	0
we	0
present	0
evidence	0
that	0
the	0
cell	5
line	6
NK3.3	6
derived	0
from	0
human	7
NK	8
cells	8
,	0
responds	0
to	0
both	0
IL-2	9
and	0
IL-12	9
,	0
as	0
measured	0
by	0
increases	0
in	0
IFN-gamma	9
and	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
cytoplasmic	0
mRNA	0
and	0
protein	0
expression	0
.	0

In	0
addition	0
,	0
when	0
used	0
together	0
IL-2	9
and	0
IL-12	9
synergized	0
in	0
the	0
induction	0
of	0
IFN-gamma	9
and	0
GM-CSF	9
and	0
this	0
synergy	0
was	0
attributed	0
to	0
an	0
increased	0
accumulation	0
and	0
stability	0
of	0
the	0
IFN-gamma	3
and	4
GM-CSF	4
mRNAs	4
.	0

To	0
investigate	0
the	0
signaling	0
pathways	0
involved	0
in	0
the	0
gene	0
induction	0
,	0
five	0
inhibitors	0
,	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
,	0
transforming	9
growth	10
factor-beta	10
,	0
cycloheximide	0
,	0
genistein	0
,	0
and	0
staurosporine	0
A	0
,	0
were	0
used	0
in	0
analyzing	0
the	0
effects	0
of	0
IL-2	9
and	0
IL-12	9
on	0
NK3.3	5
cells	6
.	0

The	0
results	0
suggest	0
that	0
activation	0
of	0
protein	9
kinase	10
C	10
,	0
but	0
not	0
new	0
protein	0
synthesis	0
,	0
is	0
required	0
for	0
IL-2	9
induction	0
of	0
IFN-gamma	3
and	4
GM-CSF	4
cytoplasmic	4
mRNA	4
.	0

In	0
contrast	0
,	0
IL-12	9
induction	0
of	0
IFN-gamma	3
cytoplasmic	4
mRNA	4
appears	0
to	0
only	0
partially	0
depend	0
on	0
activation	0
of	0
protein	9
kinase	10
C	10
.	0

Furthermore	0
,	0
both	0
transforming	9
growth	10
factor-beta	10
and	0
genistein	0
,	0
a	0
tyrosine	0
kinase	0
inhibitor	0
,	0
could	0
suppress	0
IL-2	9
and	0
IL-12	9
signaling	0
but	0
CsA	0
was	0
generally	0
inactive	0
.	0

It	0
also	0
was	0
observed	0
that	0
suppression	0
of	0
cytokine	1
gene	2
expression	0
by	0
these	0
agents	0
was	0
independent	0
of	0
the	0
inhibition	0
of	0
proliferation	0
.	0

In	0
addition	0
,	0
IL-2	9
but	0
not	0
IL-12	9
induced	0
nuclear	9
factors	10
NF-kappa	9
B	10
and	0
AP1	9
,	0
and	0
regulation	0
of	0
the	0
nuclear	0
levels	0
of	0
these	0
two	0
DNA	9
binding	10
protein	10
complexes	10
is	0
correlated	0
with	0
IFN-gamma	0
and	0
GM-CSF	0
gene	0
expression	0
.	0

These	0
data	0
indicate	0
that	0
IL-2	9
and	0
IL-12	9
may	0
have	0
distinct	0
signaling	0
pathways	0
leading	0
to	0
the	0
induction	0
of	0
IFN-gamma	9
and	0
GM-CSF	9
gene	0
expression	0
,	0
and	0
that	0
the	0
NK3.3	5
cell	6
line	6
may	0
serve	0
as	0
a	0
novel	0
model	0
for	0
dissecting	0
the	0
biochemical	0
and	0
molecular	0
events	0
involved	0
in	0
these	0
pathways	0
.	0

A	0
functional	0
T-cell	9
receptor	10
signaling	0
pathway	0
is	0
required	0
for	0
p95vav	9
activity	0
.	0

Stimulation	0
of	0
the	0
T-cell	9
antigen	10
receptor	10
(	0
TCR	9
)	0
induces	0
activation	0
of	0
multiple	0
tyrosine	9
kinases	10
,	0
resulting	0
in	0
phosphorylation	0
of	0
numerous	0
intracellular	0
substrates	0
.	0

One	0
substrate	0
is	0
p95vav	9
,	0
which	0
is	0
expressed	0
exclusively	0
in	0
hematopoietic	7
and	8
trophoblast	8
cells	8
.	0

It	0
contains	0
a	0
number	0
of	0
structural	9
motifs	10
,	0
including	0
Src	9
homology	10
2	10
,	10
Src	10
homology	10
3	10
,	10
and	10
pleckstrin	10
homology	10
domains	10
and	0
a	0
putative	9
guanine	10
nucleotide	10
exchange	10
domain	10
.	0

The	0
role	0
of	0
p95vav	9
in	0
TCR	9
-mediated	0
signaling	0
processes	0
is	0
unclear	0
.	0

Here	0
,	0
we	0
show	0
that	0
overexpression	0
of	0
p95vav	9
alone	0
in	0
Jurkat	0
T	7
cells	8
leads	0
to	0
activation	0
of	0
the	0
nuclear	9
factors	10
,	0
including	0
NFAT	9
,	0
involved	0
in	0
interleukin-2	9
expression	0
.	0

Furthermore	0
,	0
p95vav	9
synergizes	0
with	0
TCR	9
stimulation	0
in	0
inducing	0
NFAT-	0
and	0
interleukin-2-dependent	0
transcription	0
.	0

In	0
contrast	0
,	0
NFAT	9
activation	0
by	0
a	0
G-protein-coupled	9
receptor	10
is	0
not	0
modulated	0
by	0
p95vav	9
overexpression	0
,	0
suggesting	0
that	0
the	0
effect	0
is	0
specific	0
to	0
the	0
TCR	9
signaling	0
pathways	0
.	0

Although	0
removal	0
of	0
the	0
first	9
67	10
amino	10
acids	10
of	0
p95vav	9
activates	0
its	0
transforming	0
potential	0
in	0
NIH	5
3T3	6
cells	6
,	0
this	0
region	0
appears	0
to	0
be	0
required	0
for	0
its	0
function	0
in	0
T	7
cells	8
.	0

We	0
further	0
demonstrate	0
that	0
the	0
p95vav	9
-induced	0
NFAT	9
activation	0
is	0
not	0
mimicked	0
by	0
Ras	9
activation	0
,	0
though	0
its	0
function	0
is	0
dependent	0
upon	0
Ras	9
and	0
Raf	9
.	0

Furthermore	0
,	0
the	0
activating	0
function	0
of	0
p95vav	9
is	0
blocked	0
by	0
FK506	0
,	0
suggesting	0
that	0
its	0
activity	0
also	0
depends	0
on	0
calcineurin	9
.	0

To	0
further	0
dissect	0
p95vav	9
involvement	0
in	0
TCR	9
signaling	0
,	0
we	0
analyzed	0
various	0
Jurkat	5
mutants	6
deficient	0
in	0
TCR	9
signaling	0
function	0
or	0
TCR	9
expression	0
and	0
showed	0
that	0
an	0
intact	0
TCR	9
signaling	0
pathway	0
is	0
required	0
for	0
p95vav	9
to	0
function	0
.	0

However	0
,	0
overexpression	0
of	0
p95vav	9
does	0
not	0
appear	0
to	0
influence	0
TCR	9
-induced	0
protein	0
tyrosine	0
phosphorylation	0
or	0
increases	0
in	0
cytoplasmic	0
free	0
calcium	0
.	0

Taken	0
together	0
,	0
our	0
data	0
suggest	0
that	0
p95vav	9
plays	0
an	0
important	0
role	0
at	0
an	0
yet	0
unidentified	0
proximal	0
position	0
in	0
the	0
TCR	9
signaling	0
cascade	0
.	0

Positive	0
and	0
negative	0
regulation	0
of	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
promoter	0
activity	0
by	0
AML1-related	9
transcription	10
factor	10
,	0
PEBP2	9
.	0

The	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
gene	2
promoter	2
contains	0
a	0
consensus	0
sequence	0
for	0
the	0
polyomavirus	9
enhancer	10
binding-protein	10
2	10
(	10
PEBP2	10
)	10
transcription	10
factor	10
,	0
which	0
consists	0
of	0
alpha	9
and	10
beta	10
subunits	10
.	0

There	0
are	0
at	0
least	0
two	0
genes	0
,	0
alpha	1
A	2
and	0
alpha	1
B	2
,	0
encoding	0
the	0
alpha	9
subunit	10
.	0

alpha	1
B	2
is	0
the	0
mouse	1
homologue	2
of	0
human	1
AML1	2
gene	2
detected	0
at	0
the	0
breakpoints	0
of	0
t	0
(	0
8	0
;	0
21	0
)	0
and	0
t	0
(	0
3	0
;	0
21	0
)	0
myeloid	0
leukemias	0
.	0

We	0
examined	0
alpha	9
A1	10
(	0
an	0
alpha	9
A-gene	10
product	10
)	0
and	0
alpha	9
B1	10
and	0
alpha	9
B2	10
(	0
two	0
alpha	9
B-encoded	10
isomers	10
)	0
for	0
their	0
effects	0
on	0
the	0
GM-CSF	1
promoter	2
.	0

PEBP2	9
alpha	10
A1	10
,	0
alpha	9
B1	10
,	0
and	0
alpha	9
B2	10
proteins	10
bound	0
the	0
PEBP2	1
site	2
within	0
the	0
mouse	1
GM-CSF	2
promoter	2
.	0

PEBP2	9
alpha	10
A1	10
and	0
alpha	9
B1	10
enhanced	0
the	0
expression	0
of	0
the	0
GM-CSF	1
promoter-driven	2
reporter	2
plasmid	2
in	0
unstimulated	5
and	6
12-O-tetradecanoylphorbol	6
13-acetate/phytohemagglutinin-stimulated	6
human	6
Jurkat	6
T	6
cells	6
.	0

In	0
contrast	0
,	0
the	0
promoter	0
activity	0
was	0
suppressed	0
by	0
alpha	9
B2	10
.	0

Coexpression	0
of	0
alpha	9
B1	10
and	0
alpha	9
B2	10
showed	0
that	0
the	0
promoter	0
activity	0
could	0
be	0
determined	0
by	0
the	0
alpha	9
B1	10
/alpha	9
B2	10
ratio	0
.	0

Jurkat	0
cell	0
extract	0
contained	0
PEBP2	9
site-binding	10
protein	10
(	0
s	0
)	0
that	0
cross-reacted	0
with	0
antimouse	9
alpha	10
A1	10
antibodies	10
.	0

Northern	0
blot	0
analysis	0
indicated	0
the	0
expression	0
of	0
human	0
PEBP2	9
alpha	10
A	10
,	0
alpha	1
B	2
(	0
AML1	1
)	0
,	0
and	0
beta	1
genes	2
in	0
Jurkat	5
cells	6
.	0

Although	0
further	0
studies	0
are	0
required	0
to	0
determine	0
the	0
precise	0
role	0
of	0
PEBP2	9
in	0
the	0
GM-CSF	9
promoter	0
activity	0
,	0
the	0
present	0
findings	0
suggested	0
the	0
importance	0
of	0
the	0
relative	0
ratio	0
of	0
different	0
PEBP2	9
isoforms	10
in	0
regulating	0
the	0
levels	0
of	0
the	0
promoter	0
activity	0
.	0

IFN-gamma	9
priming	0
of	0
monocytes	7
enhances	0
LPS-induced	0
TNF	9
production	0
by	0
augmenting	0
both	0
transcription	0
and	0
MRNA	0
stability	0
.	0

The	0
induction	0
of	0
cytokine	9
expression	0
in	0
monocytes	7
/	0
macrophages	7
by	0
bacterial	9
endotoxin	10
or	0
lipopolysaccharide	0
is	0
a	0
critical	0
,	0
highly	0
regulated	0
host	0
defence	0
response	0
.	0

The	0
augmentation	0
of	0
LPS	0
responses	0
by	0
interferon	9
gamma	10
(	0
IFN-gamma	9
)	0
,	0
referred	0
to	0
as	0
priming	0
,	0
is	0
well	0
established	0
.	0

However	0
,	0
the	0
mechanism	0
(	0
s	0
)	0
by	0
which	0
priming	0
occurs	0
is	0
poorly	0
defined	0
.	0

Using	0
tumour	9
necrosis	10
factor	10
(	0
TNF	9
)	0
induction	0
as	0
a	0
model	0
,	0
experiments	0
were	0
designed	0
to	0
analyse	0
in	0
detail	0
the	0
priming	0
effect	0
on	0
the	0
LPS	0
response	0
in	0
human	7
monocytes	8
.	0

Priming	0
by	0
IFN-gamma	9
was	0
primarily	0
manifested	0
at	0
the	0
level	0
of	0
TNF	3
mRNA	4
accumulation	0
.	0

IFN-gamma	9
pre-treatment	0
affected	0
the	0
magnitude	0
rather	0
than	0
the	0
sensitivity	0
of	0
the	0
LPS	0
response	0
.	0

Priming	0
occurred	0
after	0
several	0
hours	0
of	0
treatment	0
,	0
and	0
the	0
primed	0
state	0
was	0
induced	0
by	0
either	0
IFN-gamma	9
or	0
GM-CSF	9
,	0
but	0
not	0
M-CSF	9
.	0

Primed	0
monocytes	7
transcribed	0
TNF	3
mRNA	4
at	0
a	0
higher	0
rate	0
than	0
freshly	0
isolated	0
monocytes	7
upon	0
activation	0
with	0
LPS	0
.	0

The	0
increased	0
transcriptional	0
rate	0
correlated	0
with	0
a	0
marked	0
increase	0
in	0
nuclear	9
factor-kappa	10
B	10
activity	0
in	0
these	0
cells	0
as	0
determined	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
using	0
a	0
consensus	1
NF-kappa	2
B	2
oligonucleotide	2
.	0

An	0
additional	0
significant	0
finding	0
was	0
than	0
TNF	3
mRNA	4
induced	0
in	0
primed	5
cells	6
was	0
much	0
more	0
stable	0
than	0
in	0
unprimed	5
cells	6
(	0
T1/2	0
increased	0
6-8-fold	0
)	0
.	0

Consistent	0
with	0
the	0
increased	0
mRNA	3
stability	0
,	0
the	0
duration	0
of	0
mRNA	3
accumulation	0
was	0
longer	0
following	0
LPS	0
stimulation	0
in	0
primed	0
monocytes	7
,	0
in	0
addition	0
to	0
being	0
of	0
greater	0
magnitude	0
.	0

Finally	0
,	0
primed	0
and	0
unprimed	0
cells	0
possessed	0
a	0
differential	0
sensitivity	0
to	0
the	0
kinase	0
inhibitor	0
H-89	0
.	0

H-89	0
substantially	0
suppressed	0
LPS-induced	0
TNF	3
mRNA	4
accumulation	0
in	0
unprimed	5
cells	6
,	0
but	0
had	0
no	0
effect	0
on	0
primed	5
monocytes	6
following	0
LPS	0
stimulation	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

A	0
Myc-associated	1
zinc	2
finger	2
protein	2
binding	2
site	2
is	0
one	0
of	0
four	0
important	0
functional	1
regions	2
in	0
the	0
CD4	1
promoter	2
.	0

The	0
CD4	1
promoter	2
plays	0
an	0
important	0
role	0
in	0
the	0
developmental	0
control	0
of	0
CD4	9
transcription	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
the	0
minimal	0
CD4	1
promoter	2
has	0
four	0
factor	1
binding	2
sites	2
,	0
each	0
of	0
which	0
is	0
required	0
for	0
full	0
function	0
.	0

Using	0
biochemical	0
and	0
mutagenesis	0
analyses	0
,	0
we	0
determined	0
that	0
multiple	0
nuclear	9
factors	10
bind	0
to	0
these	0
independent	0
sites	0
.	0

We	0
determined	0
that	0
an	0
initiator-like	1
sequence	2
present	0
at	0
the	0
cap	1
site	2
and	0
an	0
Ets	1
consensus	2
sequence	2
are	0
required	0
for	0
full	0
promoter	1
function	0
.	0

We	0
also	0
demonstrate	0
that	0
the	0
Myc-associated	9
zinc	10
finger	10
protein	10
(	0
MAZ	9
)	0
appears	0
to	0
be	0
the	0
predominant	9
factor	10
binding	0
to	0
one	0
of	0
these	0
sites	0
.	0

This	0
last	0
site	0
closely	0
resembles	0
the	0
ME1a1	1
G3AG4AG3	2
motif	2
previously	0
shown	0
to	0
be	0
a	0
critical	0
element	0
in	0
the	0
P2	1
promoter	2
of	0
the	0
c-myc	1
gene	2
.	0

We	0
therefore	0
believe	0
that	0
the	0
MAZ	9
transcription	10
factor	10
is	0
also	0
likely	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
control	0
of	0
developmental	0
expression	0
of	0
the	0
CD4	1
gene	2
.	0

Erythropoietin	9
stimulates	0
transcription	0
of	0
the	0
TAL1/SCL	1
gene	2
and	0
phosphorylation	0
of	0
its	0
protein	9
products	10
.	0

Activation	0
of	0
the	0
TAL1	1
(	2
or	2
SCL	2
)	2
gene	2
,	0
originally	0
identified	0
through	0
its	0
involvement	0
by	0
a	0
recurrent	0
chromosomal	0
translocation	0
,	0
is	0
the	0
most	0
frequent	0
molecular	0
lesion	0
recognized	0
in	0
T-cell	0
acute	0
lymphoblastic	0
leukemia	0
.	0

The	0
protein	9
products	10
of	0
this	0
gene	0
contain	0
the	0
basic-helix-loop-helix	9
motif	10
characteristic	0
of	0
a	0
large	0
family	0
of	0
transcription	9
factors	10
that	0
bind	0
to	0
the	0
canonical	1
DNA	2
sequence	2
CANNTG	2
as	0
protein	9
heterodimers	10
.	0

TAL1	9
expression	0
by	0
erythroid	7
cells	8
in	0
vivo	0
and	0
in	0
chemical-induced	5
erythroleukemia	6
cell	6
lines	6
in	0
vivo	0
suggested	0
the	0
gene	0
might	0
regulate	0
aspects	0
of	0
erythroid	0
differentiation	0
.	0

Since	0
the	0
terminal	0
events	0
of	0
erythropoiesis	0
are	0
controlled	0
by	0
the	0
glycoprotein	9
hormone	10
erythropoietin	10
(	0
Epo	9
)	0
,	0
we	0
investigated	0
whether	0
the	0
expression	0
or	0
activity	0
of	0
the	0
TAL1	1
gene	2
and	0
its	0
protein	9
products	10
were	0
affected	0
by	0
Epo	9
in	0
splenic	7
erythroblasts	8
from	0
mice	0
infected	0
with	0
an	0
anemia-inducing	0
strain	0
of	0
Friend	0
virus	0
(	0
FVA	0
cells	0
)	0
.	0

Epo	9
elicited	0
a	0
rapid	0
,	0
dose-related	0
increase	0
in	0
TAL1	3
mRNA	4
by	0
increasing	0
transcription	0
of	0
the	0
gene	0
and	0
stabilizing	0
one	0
of	0
its	0
mRNAs	3
.	0

An	0
Epo	9
-inducible	0
TAL1	9
DNA	0
binding	0
activity	0
was	0
identified	0
in	0
FVA	0
cell	0
nuclear	0
extracts	0
that	0
subsequently	0
decayed	0
despite	0
accumulating	0
mRNA	3
and	0
protein	0
.	0

Induction	0
of	0
DNA	0
binding	0
activity	0
was	0
associated	0
temporally	0
with	0
Epo	9
-induced	0
phosphorylation	0
of	0
nuclear	9
TAL1	10
protein	10
.	0

These	0
results	0
indicate	0
that	0
Epo	9
acts	0
at	0
both	0
transcriptional	0
and	0
posttranscriptional	0
levels	0
on	0
the	0
TAL1	9
locus	0
in	0
Friend	5
virus-induced	6
erythroblasts	6
and	0
establish	0
a	0
link	0
between	0
Epo	9
signaling	0
mechanisms	0
and	0
a	0
member	0
of	0
a	0
family	0
of	0
transcription	9
factors	10
involved	0
in	0
the	0
differentiation	0
of	0
diverse	7
cell	8
lineages	8
.	0

Nonradioactive	0
quantification	0
of	0
glucocorticoid	9
receptor	10
expression	0
during	0
differentiation	0
of	0
human	0
monocytic	7
cells	8
(	0
U937	5
)	0
.	0

We	0
describe	0
a	0
method	0
for	0
relative	0
quantification	0
of	0
specific	0
mRNA	3
using	0
a	0
nonradioactive	0
assay	0
based	0
on	0
DNA	0
strand	0
competition	0
between	0
identical	0
sequences	0
of	0
biotin-	0
and	0
fluorescein-labeled	0
amplicon	0
(	0
probe	0
)	0
and	0
unlabeled	0
amplicon	0
(	0
target	0
)	0
during	0
hybridization	0
.	0

As	0
the	0
target	0
quantity	0
increased	0
,	0
that	0
of	0
the	0
double-labeled	0
probe	0
decreased	0
in	0
accordance	0
with	0
the	0
mass	0
action	0
law	0
.	0

This	0
technique	0
was	0
successfully	0
applied	0
to	0
evaluate	0
differences	0
in	0
glucocorticoid	9
receptor	10
expression	0
in	0
U937	5
cells	6
before	0
and	0
after	0
the	0
addition	0
of	0
potent	0
differentiation	0
inducers	0
:	0
12-O-tetradecanoylphorbol	0
13-acetate	0
(	0
TPA	0
)	0
and	0
a	0
combination	0
of	0
all-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
and	0
1	0
,	0
25-dihydroxyvitamin	0
D2	0
(	0
VD	0
)	0
.	0

We	0
observed	0
that	0
TPA	0
treatment	0
was	0
associated	0
with	0
an	0
increase	0
in	0
specific	0
binding	0
of	0
[	0
3H	0
]	0
dexamethasone	0
and	0
up-regulation	0
of	0
GR	3
mRNA	4
while	0
no	0
enhanced	0
GR	9
expression	0
was	0
perceived	0
with	0
RA/VD	0
treatment	0
.	0

Induction	0
of	0
Sp1	9
phosphorylation	0
and	0
NF-kappa	1
B-independent	2
HIV	2
promoter	2
domain	0
activity	0
in	0
T	7
lymphocytes	8
stimulated	0
by	0
okadaic	0
acid	0
.	0

In	0
contrast	0
to	0
the	0
purely	0
enhancer-dependent	0
effect	0
of	0
cytokines	9
such	0
as	0
TNF	9
on	0
the	0
activity	0
of	0
the	0
HIV	1
regulatory	2
region	2
(	0
LTR	1
)	0
,	0
we	0
observed	0
that	0
okadaic	0
acid	0
(	0
OKA	0
)	0
activates	0
HIV	0
transcription	0
through	0
both	0
the	0
enhancer	0
,	0
responding	0
to	0
the	0
factor	0
NF-kappa	9
B	10
,	0
and	0
the	0
promoter	1
domain	2
of	0
the	0
LTR	1
.	0

The	0
inducibility	0
of	0
HIV	1
LTR-driven	2
luciferase	2
expression	2
constructs	2
in	0
lymphoblastoid	7
cells	8
stimulated	0
by	0
OKA	0
depended	0
on	0
both	0
functional	1
Sp1	2
binding	2
elements	2
and	0
the	0
ability	0
of	0
the	0
TATA	1
box	2
to	0
bind	0
the	0
protein	0
TBP	9
.	0

In	0
both	0
transformed	7
and	8
normal	8
lymphocytes	8
,	0
OKA	0
stimulation	0
induced	0
intense	0
phosphorylation	0
of	0
the	0
constitutively	0
expressed	0
Sp1	9
protein	10
in	0
the	0
nucleus	0
,	0
a	0
property	0
of	0
OKA	0
not	0
shared	0
by	0
TNF	9
,	0
phorbol	0
ester	0
,	0
or	0
PHA	9
and	0
interleukin	9
2	10
.	0

Responsiveness	0
of	0
LTR	1
constructs	2
deleted	0
of	0
kappa	1
B	2
elements	2
to	0
HIV	9
Tat	10
expression	0
was	0
increased	0
upon	0
OKA	0
but	0
not	0
TNF	9
stimulation	0
.	0

Our	0
results	0
suggest	0
that	0
SP1	9
phosphorylation	0
induced	0
by	0
OKA	0
,	0
a	0
selective	0
inhibitor	0
of	0
the	0
serine-threonine	9
phosphatase	10
PP2A	9
,	0
facilitates	0
the	0
formation	0
of	0
a	0
transcription	9
complex	10
involving	0
general	0
transcription	9
factors	10
,	0
HIV	9
Tat	10
,	0
and	0
Sp1	9
proteins	10
.	0

The	0
formation	0
of	0
this	0
complex	0
would	0
increase	0
,	0
independently	0
of	0
an	0
in	0
synergy	0
with	0
NF-kappa	9
B	10
,	0
the	0
low	0
basal	0
activity	0
of	0
the	0
HIV	1
LTR	2
observed	0
in	0
normal	7
T	8
lymphocytes	8
.	0

The	0
role	0
of	0
shared	9
receptor	10
motifs	10
and	0
common	9
Stat	10
proteins	10
in	0
the	0
generation	0
of	0
cytokine	9
pleiotropy	0
and	0
redundancy	0
by	0
IL-2	9
,	0
IL-4	9
,	0
IL-7	9
,	0
IL-13	9
,	0
and	0
IL-15	9
.	0

To	0
understand	0
the	0
molecular	0
bases	0
for	0
cytokine	0
redundancy	0
and	0
pleiotropy	0
,	0
we	0
have	0
compared	0
the	0
Stat	9
proteins	10
activated	0
in	0
peripheral	7
blood	8
lymphocytes	8
(	0
PBLs	7
)	0
by	0
cytokines	9
with	0
shared	0
and	0
distinct	0
actions	0
.	0

Interleukin-2	9
(	0
IL-2	9
)	0
rapidly	0
activated	0
Stat5	9
in	0
fresh	0
PBL	7
,	0
and	0
Stat3	9
and	0
Stat5	9
in	0
preactivated	7
PBL	8
.	0

IL-7	9
and	0
IL-15	9
induced	0
the	0
same	0
complexes	0
as	0
IL-2	9
,	0
a	0
feature	0
explained	0
by	0
the	0
existence	0
of	0
similar	0
tyrosine-phosphorylated	9
motifs	10
in	0
the	0
cytoplasmic	9
domains	10
of	0
IL-2R	9
beta	10
and	0
IL-7R	9
that	0
can	0
serve	0
as	0
docking	0
sites	0
for	0
Stat	9
proteins	10
.	0

IL-13	9
Induced	0
the	0
same	0
complexes	0
as	0
IL-4	9
,	0
a	0
finding	0
explained	0
by	0
our	0
studies	0
implicating	0
IL-4R	9
as	0
a	0
shared	0
component	0
of	0
the	0
receptors	9
.	0

These	0
studies	0
demonstrate	0
that	0
a	0
single	0
cytokine	9
can	0
activate	0
different	0
combinations	0
of	0
Stat	9
proteins	10
under	0
different	0
physiological	0
conditions	0
,	0
and	0
also	0
indicate	0
two	0
mechanisms	0
by	0
which	0
distinct	0
cytokines	9
can	0
activate	0
the	0
same	0
Stat	9
protein	10
.	0

Control	0
of	0
I	9
kappa	10
B-alpha	10
proteolysis	0
by	0
site-specific	0
,	0
signal-induced	0
phosphorylation	0
.	0

I	9
kappa	10
B-alpha	10
inhibits	0
transcription	9
factor	10
NF-kappa	9
B	10
by	0
retaining	0
it	0
in	0
the	0
cytoplasm	0
.	0

Various	0
stimuli	0
,	0
typically	0
those	0
associated	0
with	0
stress	0
or	0
pathogens	0
,	0
rapidly	0
inactivate	0
I	9
kappa	10
B-alpha	10
.	0

This	0
liberates	0
NF-kappa	9
B	10
to	0
translocate	0
to	0
the	0
nucleus	0
and	0
initiate	0
transcription	0
of	0
genes	1
important	0
for	0
the	0
defense	0
of	0
the	0
organism	0
.	0

Activation	0
of	0
NF-kappa	9
B	10
correlates	0
with	0
phosphorylation	0
of	0
I	9
kappa	10
B-alpha	10
and	0
requires	0
the	0
proteolysis	0
of	0
this	0
inhibitor	0
.	0

When	0
either	0
serine-32	0
or	0
serine-36	0
of	0
I	9
kappa	10
B-alpha	10
was	0
mutated	0
,	0
the	0
protein	0
did	0
not	0
undergo	0
signal-induced	0
phosphorylation	0
or	0
degradation	0
,	0
and	0
NF-kappa	9
B	10
could	0
not	0
be	0
activated	0
.	0

These	0
results	0
suggest	0
that	0
phosphorylation	0
at	0
one	0
or	0
both	0
of	0
these	0
residues	0
is	0
critical	0
for	0
activation	0
of	0
NF-kappa	9
B	10
.	0

Regulation	0
of	0
transcription	0
of	0
the	0
human	1
erythropoietin	2
receptor	2
gene	2
by	0
proteins	0
binding	0
to	0
GATA-1	1
and	2
Sp1	2
motifs	2
.	0

Erythropoietin	9
(	0
Epo	9
)	0
,	0
the	0
primary	0
regulator	0
of	0
the	0
production	0
of	0
erythroid	7
cells	8
,	0
acts	0
by	0
binding	0
to	0
a	0
cell	9
surface	10
receptor	10
(	0
EpoR	9
)	0
on	0
erythroid	7
progenitors	8
.	0

We	0
used	0
deletion	0
analysis	0
and	0
transfection	0
assays	0
with	0
reporter	1
gene	2
constructs	2
to	0
examine	0
the	0
transcription	1
control	2
elements	2
in	0
the	0
5	1
'	2
flanking	2
region	2
of	0
the	0
human	1
EpoR	2
gene	2
.	0

In	0
erythroid	7
cells	8
most	0
of	0
the	0
transcription	0
activity	0
was	0
contained	0
in	0
a	0
150	1
bp	2
promoter	2
fragment	0
with	0
binding	1
sites	2
for	0
transcription	9
factors	10
AP2	9
,	0
Sp1	9
and	0
the	0
erythroid-specific	9
GATA-1	10
.	0

The	0
150	1
bp	2
hEpoR	2
promoter	2
exhibited	0
high	0
and	0
low	0
activity	0
in	0
erythroid	0
OCIM1	5
and	0
K562	5
cells	6
,	0
respectively	0
,	0
reflecting	0
the	0
high	0
and	0
low	0
levels	0
of	0
constitutive	0
hEpoR	9
expression	0
.	0

The	0
GATA-1	1
and	2
Sp1	2
binding	2
sites	2
in	0
this	0
promoter	0
lacking	0
a	0
TATA	1
sequence	2
were	0
necessary	0
for	0
a	0
high	0
level	0
of	0
transcription	0
activation	0
.	0

Protein-DNA	0
binding	0
studies	0
suggested	0
that	0
Sp1	9
and	0
two	0
other	0
CCGCCC	9
binding	10
proteins	10
from	0
erythroid	7
and	8
non-erythroid	8
cells	8
could	0
bind	0
to	0
the	0
Sp1	1
binding	2
motif	2
.	0

By	0
increasing	0
GATA-1	9
levels	0
via	0
co-transfection	0
,	0
we	0
were	0
able	0
to	0
transactivate	0
the	0
hEpoR	1
promoter	2
in	0
K562	5
cells	6
and	0
non-erythroid	7
cells	8
,	0
but	0
not	0
in	0
the	0
highly	0
active	0
OCIM1	7
cells	8
,	0
although	0
GATA-1	3
mRNA	4
levels	0
were	0
comparable	0
in	0
OCIM1	5
and	0
K562	5
.	0

Interestingly	0
,	0
when	0
we	0
mutated	0
the	0
Sp1	1
site	2
,	0
resulting	0
in	0
a	0
marked	0
decrease	0
in	0
hEpoR	1
promoter	2
activity	0
,	0
we	0
could	0
restore	0
transactivation	0
by	0
increasing	0
GATA-1	9
levels	0
in	0
OCIM1	7
cells	8
.	0

These	0
data	0
suggest	0
that	0
while	0
GATA-1	9
can	0
transactivate	0
the	0
EpoR	1
promoter	2
,	0
the	0
level	0
of	0
hEpoR	1
gene	2
expression	0
does	0
not	0
depend	0
on	0
GATA-1	9
alone	0
.	0

Rather	0
,	0
hEpoR	9
transcription	0
activity	0
depends	0
on	0
coordination	0
between	0
Sp1	9
and	0
GATA-1	9
with	0
other	0
cell-specific	9
factors	10
,	0
including	0
possibly	0
other	0
Sp1-like	9
binding	10
proteins	10
,	0
to	0
provide	0
high	0
level	0
,	0
tissue-specific	0
expression	0
.	0

Overexpression	0
of	0
DR-nm23	9
,	0
a	0
protein	0
encoded	0
by	0
a	0
member	0
of	0
the	0
nm23	1
gene	2
family	2
,	0
inhibits	0
granulocyte	7
differentiation	0
and	0
induces	0
apoptosis	0
in	0
32Dc13	5
myeloid	6
cells	6
.	0

Chronic	0
myelogenous	0
leukemia	0
evolves	0
in	0
two	0
clinically	0
distinct	0
stages	0
:	0
a	0
chronic	0
and	0
a	0
blast	0
crisis	0
phase	0
.	0

The	0
molecular	0
changes	0
associated	0
with	0
chronic	0
phase	0
to	0
blast	0
crisis	0
transition	0
are	0
largely	0
unknown	0
.	0

We	0
have	0
identified	0
a	0
cDNA	1
clone	2
,	0
DR-nm23	9
,	0
differentially	0
expressed	0
in	0
a	0
blast-crisis	1
cDNA	2
library	2
,	2
which	0
has	0
approximately	0
70	0
%	0
sequence	0
similarity	0
to	0
the	0
putative	1
metastatic	2
suppressor	2
genes	2
,	0
nm23-H1	1
and	0
nm23-H2	1
.	0

The	0
deduced	0
amino	0
acid	0
sequence	0
similarity	0
to	0
the	0
proteins	0
encoded	0
by	0
these	0
two	0
latter	0
genes	0
is	0
approximately	0
65	0
%	0
and	0
includes	0
domains	0
and	0
amino	0
acid	0
residues	0
(	0
the	0
leucine	9
zipper-like	10
and	0
the	0
RGD	9
domain	10
,	0
a	0
serine	0
and	0
a	0
histidine	0
residue	0
in	0
the	0
NH2-	9
and	0
in	0
the	0
COOH-terminal	9
portion	10
of	0
the	0
protein	0
,	0
respectively	0
)	0
postulated	0
to	0
be	0
important	0
for	0
nm23	9
function	0
.	0

DR-nm23	3
mRNA	4
is	0
preferentially	0
expressed	0
at	0
early	0
stages	0
of	0
myeloid	0
differentiation	0
of	0
highly	5
purified	6
CD34+	6
cells	6
.	0

Its	0
constitutive	0
expression	0
in	0
the	0
myeloid	5
precursor	6
32Dc13	6
cell	6
line	6
,	0
which	0
is	0
growth-factor	0
dependent	0
for	0
both	0
proliferation	0
and	0
differentiation	0
,	0
results	0
in	0
inhibition	0
of	0
granulocytic	0
differentiation	0
induced	0
by	0
granulocyte	9
colony-stimulating	10
factor	10
and	0
causes	0
apoptotic	0
cell	0
death	0
.	0

These	0
results	0
are	0
consistent	0
with	0
a	0
role	0
for	0
DR-nm23	9
in	0
normal	0
hematopoiesis	0
and	0
raise	0
the	0
possibility	0
that	0
its	0
overexpression	0
contributes	0
to	0
differentiation	0
arrest	0
,	0
a	0
feature	0
of	0
blastic	0
transformation	0
in	0
chronic	0
myelogenous	0
leukemia	0
.	0

An	0
interferon-gamma	1
activation	2
sequence	2
mediates	0
the	0
transcriptional	0
regulation	0
of	0
the	0
IgG	1
Fc	2
receptor	2
type	2
IC	2
gene	2
by	0
interferon-gamma	9
.	0

Expression	0
of	0
the	0
IgG	9
Fc	10
receptor	10
type	10
I	10
(	0
Fc	9
gamma	10
RI	10
)	0
on	0
myeloid	7
cells	8
is	0
dramatically	0
increased	0
by	0
treatment	0
with	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
.	0

We	0
observed	0
that	0
Fc	9
gamma	10
RI	10
transcript	0
levels	0
in	0
monoblast-like	5
U937	6
cells	6
were	0
elevated	0
within	0
3	0
hr	0
and	0
peaked	0
12	0
hr	0
after	0
exposure	0
to	0
IFN-gamma	9
.	0

Treatment	0
of	0
U937	5
with	0
IFN-gamma	9
for	0
9	0
hr	0
in	0
the	0
presence	0
of	0
cycloheximide	0
led	0
to	0
super-induction	0
of	0
Fc	9
gamma	10
RI	10
expression	0
.	0

Nuclear	0
run-on	0
analysis	0
revealed	0
that	0
the	0
rate	0
of	0
Fc	9
gamma	10
RI	10
transcription	0
was	0
increased	0
by	0
IFN-gamma	9
.	0

Genomic	0
sequence	0
upstream	0
of	0
the	0
Fc	1
gamma	2
RIC	2
gene	2
was	0
cloned	0
and	0
subjected	0
to	0
primer	0
extension	0
analysis	0
,	0
which	0
demonstrated	0
a	0
single	0
transcription	1
initiation	2
site	2
without	0
a	0
TATA	1
box	2
.	0

Transient	0
transfections	0
of	0
CAT	1
reporter	2
gene	2
constructs	2
containing	0
various	0
Fc	1
gamma	2
RIC	2
promoter	2
sequences	2
into	0
U937	5
cells	6
revealed	0
that	0
a	0
20-bp	1
region	2
surrounding	0
the	0
transcription	1
start	2
site	2
(	0
-7	0
to	0
+13	0
)	0
was	0
capable	0
of	0
mediating	0
transcription	0
initiation	0
and	0
that	0
an	0
IFN-gamma	1
responsive	2
element	2
(	0
GIRE	1
)	0
was	0
present	0
within	0
74	1
bp	2
upstream	2
of	0
the	0
transcription	1
initiation	2
site	2
.	0

A	0
17-bp	1
sequence	2
between	0
positions	0
-51	0
and	0
-35	0
conferred	0
IFN-gamma	9
responsiveness	0
on	0
a	0
heterologous	1
promoter	2
.	0

Double-stranded	1
GIRE	2
sequence	2
,	0
but	0
not	0
a	0
scrambled	1
sequence	2
,	0
was	0
specifically	0
bound	0
by	0
nuclear	9
proteins	10
from	0
IFN-gamma	5
treated	6
U937	6
cells	6
.	0

Gel	0
shift	0
experiments	0
further	0
showed	0
that	0
the	0
STAT1	9
alpha	10
protein	10
bound	0
to	0
the	0
Fc	1
gamma	2
RIC	2
GIRE	2
in	0
response	0
to	0
IFN-gamma	9
treatment	0
of	0
U937	5
cells	6
.	0

The	0
Fc	1
gamma	2
RIC	2
GIRE	2
is	0
homologous	0
to	0
the	0
IFN-gamma	1
activation	2
sequence	2
(	0
GAS	1
)	0
of	0
the	0
guanylate	9
binding	10
protein	10
and	0
to	0
X	1
box	2
elements	2
of	0
class	1
II	2
MHC	2
genes	2
.	0

Our	0
results	0
demonstrate	0
that	0
transcriptional	0
regulation	0
of	0
the	0
Fc	1
gamma	2
RIC	2
gene	2
by	0
IFN-gamma	9
involves	0
the	0
binding	0
of	0
STAT1	9
alpha	10
to	0
a	0
17-bp	1
GAS	2
homology	2
in	0
the	0
proximal	1
promoter	2
.	0

Constitutively	0
activated	0
Jak	9
-STAT	9
pathway	0
in	0
T	7
cells	8
transformed	0
with	0
HTLV-I	0
.	0

Human	0
T	0
cell	0
lymphotropic	0
virus	0
I	0
(	0
HTLV-I	0
)	0
is	0
the	0
etiological	0
agent	0
for	0
adult	0
T	0
cell	0
leukemia	0
and	0
tropical	0
spastic	0
paraparesis	0
(	0
also	0
termed	0
HTLV-I-associated	0
myelopathy	0
)	0
.	0

HTLV-I-infected	7
peripheral	8
blood	8
T	8
cells	8
exhibit	0
an	0
initial	0
phase	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
-dependent	0
growth	0
;	0
over	0
time	0
,	0
by	0
an	0
unknown	0
mechanism	0
,	0
the	0
cells	0
become	0
IL-2	9
-independent	0
.	0

Whereas	0
the	0
Jak	9
kinases	10
Jak1	9
and	0
Jak3	9
and	0
the	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	9
proteins	10
Stat3	9
and	0
Stat5	9
are	0
activated	0
in	0
normal	7
T	8
cells	8
in	0
response	0
to	0
IL-2	9
,	0
this	0
signaling	0
pathway	0
was	0
constitutively	0
activated	0
in	0
HTLV-I-transformed	5
cells	6
.	0

In	0
HTLV-I-infected	5
cord	6
blood	6
lymphocytes	6
,	0
the	0
transition	0
from	0
IL-2	9
-dependent	0
to	0
IL-2	9
-independent	0
growth	0
correlated	0
with	0
the	0
acquisition	0
of	0
a	0
constitutively	0
activated	0
Jak	9
-STAT	9
pathway	0
,	0
which	0
suggests	0
that	0
this	0
pathway	0
participates	0
in	0
HTLV-I-mediated	0
T	0
cell	0
transformation	0
.	0

Nitric	0
oxide	0
decreases	0
cytokine	9
-induced	0
endothelial	0
activation	0
.	0

Nitric	0
oxide	0
selectively	0
reduces	0
endothelial	0
expression	0
of	0
adhesion	9
molecules	10
and	0
proinflammatory	9
cytokines	10
.	0

To	0
test	0
the	0
hypothesis	0
that	0
nitric	0
oxide	0
(	0
NO	0
)	0
limits	0
endothelial	0
activation	0
,	0
we	0
treated	0
cytokine-stimulated	5
human	6
saphenous	6
vein	6
endothelial	6
cells	6
with	0
several	0
NO	0
donors	0
and	0
assessed	0
their	0
effects	0
on	0
the	0
inducible	0
expression	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
.	0

In	0
a	0
concentration-dependent	0
manner	0
,	0
NO	0
inhibited	0
interleukin	9
(	10
IL	10
)	10
-1	10
alpha-stimulated	0
VCAM-1	9
expression	0
by	0
35-55	0
%	0
as	0
determined	0
by	0
cell	0
surface	0
enzyme	0
immunoassays	0
and	0
flow	0
cytometry	0
.	0

This	0
inhibition	0
was	0
paralleled	0
by	0
reduced	0
monocyte	0
adhesion	0
to	0
endothelial	0
monolayers	0
in	0
nonstatic	0
assays	0
,	0
was	0
unaffected	0
by	0
cGMP	0
analogues	0
,	0
and	0
was	0
quantitatively	0
similar	0
after	0
stimulation	0
by	0
either	0
IL-1	9
alpha	10
,	0
IL-1	9
beta	10
,	0
IL-4	9
,	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
alpha	10
)	0
,	0
or	0
bacterial	0
lipopolysaccharide	0
.	0

NO	0
also	0
decreased	0
the	0
endothelial	0
expression	0
of	0
other	0
leukocyte	9
adhesion	10
molecules	10
(	0
E-selectin	9
and	0
to	0
a	0
lesser	0
extent	0
,	0
intercellular	9
adhesion	10
molecule-1	10
)	0
and	0
secretable	0
cytokines	9
(	0
IL-6	9
and	0
IL-8	9
)	0
.	0

Inhibition	0
of	0
endogenous	0
NO	0
production	0
by	0
L-N-monomethyl-arginine	0
also	0
induced	0
the	0
expression	0
of	0
VCAM-1	9
,	0
but	0
did	0
not	0
augment	0
cytokine-induced	0
VCAM-1	9
expression	0
.	0

Nuclear	0
run-on	0
assays	0
,	0
transfection	0
studies	0
using	0
various	0
VCAM-1	1
promoter	2
reporter	2
gene	2
constructs	2
,	0
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
indicated	0
that	0
NO	0
represses	0
VCAM-1	9
gene	0
transcription	0
,	0
in	0
part	0
,	0
by	0
inhibiting	0
NF-kappa	9
B	10
.	0

We	0
propose	0
that	0
NO	0
's	0
ability	0
to	0
limit	0
endothelial	0
activation	0
and	0
inhibit	0
monocyte	0
adhesion	0
may	0
contribute	0
to	0
some	0
of	0
its	0
antiatherogenic	0
and	0
antiinflammatory	0
properties	0
within	0
the	0
vessel	0
wall	0
.	0

MIP1	9
alpha	10
nuclear	10
protein	10
(	0
MNP	9
)	0
,	0
a	0
novel	0
transcription	9
factor	10
expressed	0
in	0
hematopoietic	0
cells	0
that	0
is	0
crucial	0
for	0
transcription	0
of	0
the	0
human	1
MIP-1	2
alpha	2
gene	2
.	0

Murine	9
macrophage	10
inflammatory	10
protein	10
1	10
alpha	10
(	0
MIP-1	9
alpha	10
)	0
and	0
its	0
human	9
equivalent	10
(	0
GOS19	9
,	0
LD78	9
,	0
or	0
AT464	9
)	0
are	0
members	0
of	0
the	0
-C-C	9
family	10
of	0
low-molecular-weight	9
chemokines	10
.	0

Secreted	0
from	0
activated	7
T	8
cells	8
and	0
macrophages	7
,	0
bone	0
marrow-derived	9
MIP-1	10
alpha/GOS19	10
inhibits	0
primitive	7
hematopoietic	8
stem	8
cells	8
and	0
appears	0
to	0
be	0
involved	0
in	0
the	0
homeostatic	0
control	0
of	0
stem	7
cell	8
proliferation	0
.	0

It	0
also	0
induces	0
chemotaxis	0
and	0
inflammatory	0
responses	0
in	0
mature	7
cell	8
types	8
.	0

Therefore	0
,	0
it	0
is	0
important	0
to	0
understand	0
the	0
mechanisms	0
which	0
control	0
the	0
expression	0
of	0
MIP-1	9
alpha	10
/GOS19	9
.	0

Previous	0
work	0
has	0
shown	0
that	0
in	0
Jurkat	5
T	6
cells	6
,	0
a	0
set	0
of	0
widely	0
expressed	0
transcription	9
factors	10
(	0
the	0
ICK-1	9
family	10
)	0
affect	0
the	0
GOS19	1
promoter	2
.	0

One	0
member	0
,	0
ICK-1A	9
,	0
behaves	0
as	0
a	0
strong	9
negative	10
regulator	10
.	0

In	0
this	0
communication	0
,	0
we	0
provide	0
evidence	0
that	0
the	0
pathway	0
of	0
induction	0
in	0
the	0
macrophage	5
cell	6
line	6
U937	5
is	0
different	0
from	0
that	0
in	0
Jurkat	5
cells	6
.	0

Furthermore	0
,	0
we	0
show	0
that	0
the	0
ICK-1	1
binding	2
site	2
does	0
not	0
confer	0
negative	0
regulation	0
in	0
U937	5
cells	6
.	0

We	0
provide	0
evidence	0
for	0
an	0
additional	0
binding	1
site	2
,	0
the	0
MIP-1	1
alpha	2
nuclear	2
protein	2
(	2
MNP	2
)	2
site	2
,	0
which	0
overlaps	0
the	0
ICK-1	1
site	2
.	0

Interaction	0
of	0
nuclear	0
extracts	0
from	0
various	5
cell	6
lines	6
and	0
tissue	0
with	0
the	0
MNP	1
site	2
leads	0
to	0
the	0
formation	0
of	0
fast-migrating	9
protein-DNA	10
complexes	10
with	0
similar	0
but	0
distinct	0
electrophoretic	0
mobilities	0
.	0

A	0
mutation	0
of	0
the	0
MNP	1
site	2
which	0
does	0
not	0
abrogate	0
ICK-1	0
binding	0
inactivates	0
the	0
GOS19.1	1
promoter	2
in	0
U937	5
cells	6
and	0
reduces	0
its	0
activity	0
by	0
fourfold	0
in	0
Jurkat	5
cells	6
.	0

We	0
propose	0
that	0
the	0
MNP	9
protein	10
(	0
s	0
)	0
binding	0
at	0
the	0
MNP	1
site	2
constitutes	0
a	0
novel	0
transcription	9
factor	10
(	0
s	0
)	0
expressed	0
in	0
hematopoietic	7
cells	8
.	0

The	0
effect	0
of	0
Toremifene	0
on	0
the	0
expression	0
of	0
some	0
genes	0
in	0
human	7
mononuclear	8
cells	8
.	0

Toremifene	0
exerts	0
multiple	0
and	0
varied	0
effects	0
on	0
the	0
gene	0
expression	0
of	0
human	7
peripheral	8
mononuclear	8
cells	8
.	0

After	0
short-term	0
,	0
in	0
vitro	0
exposure	0
to	0
therapeutical	0
levels	0
,	0
distinct	0
changes	0
in	0
P-glycoprotein	0
,	0
steroid	0
receptors	0
,	0
p53	0
and	0
Bcl-2	0
expression	0
take	0
place	0
.	0

In	0
view	0
of	0
the	0
increasing	0
use	0
of	0
antiestrogens	0
in	0
cancer	0
therapy	0
and	0
prevention	0
,	0
there	0
is	0
obvious	0
merit	0
in	0
long-term	0
in	0
vivo	0
studies	0
to	0
be	0
conducted	0
.	0

The	0
interleukin-5	9
/receptor	0
interaction	0
activates	0
Lyn	9
and	10
Jak2	10
tyrosine	10
kinases	10
and	0
propagates	0
signals	0
via	0
the	0
Ras-Raf-1-MAP	9
kinase	10
and	0
the	0
Jak	9
-STAT	9
pathways	0
in	0
eosinophils	7
.	0

We	0
have	0
shown	0
that	0
the	0
interaction	0
of	0
interleukin	9
(	10
IL	10
)	10
-5	10
with	0
the	0
receptor	0
activates	0
Lyn	9
tyrosine	10
kinase	10
within	0
1	0
min	0
and	0
Jak2	9
tyrosine	10
kinase	10
within	0
1-3	0
min	0
.	0

IL-5	9
also	0
stimulates	0
GTP	0
binding	0
to	0
p21ras	9
.	0

The	0
signal	0
is	0
subsequently	0
propagated	0
through	0
the	0
activation	0
of	0
Raf-1	9
,	0
MEK	9
,	0
and	0
MAP	9
kinases	10
as	0
shown	0
by	0
their	0
increased	0
autophosphorylation	0
in	0
vitro	0
and	0
phosphorylation	0
in	0
situ	0
.	0

Jak2	9
kinase	10
has	0
been	0
shown	0
to	0
phosphorylate	0
STAT	9
nuclear	10
proteins	10
.	0

The	0
activation	0
of	0
STAT	9
nuclear	10
factors	10
was	0
studied	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
using	0
a	0
gamma	1
activation	2
site	2
(	0
GAS	1
)	0
probe	0
.	0

We	0
found	0
that	0
IL-5	9
induces	0
two	0
GAS-binding	9
proteins	10
in	0
eosinophils	7
,	0
one	0
of	0
which	0
is	0
STAT1	9
.	0

We	0
conclude	0
that	0
IL-5	9
induced	0
signals	0
are	0
propagated	0
through	0
two	0
distinct	0
pathways	0
:	0
(	0
1	0
)	0
Lyn	9
--	0
>	0
Ras	9
--	0
>	0
Raf-1	9
--	0
>	0
MEK	9
--	0
>	0
MAP	9
kinase	10
and	0
(	0
2	0
)	0
Jak2	9
--	0
>	0
STAT1	9
.	0

The	0
retinoblastoma	9
gene	10
product	10
negatively	0
regulates	0
transcriptional	0
activation	0
mediated	0
by	0
the	0
human	9
cytomegalovirus	10
IE2	10
protein	10
.	0

The	0
IE2	9
gene	10
product	10
of	0
human	0
cytomegalovirus	0
(	0
HCMV	0
)	0
is	0
one	0
of	0
a	0
few	0
viral	9
regulatory	10
proteins	10
expressed	0
immediately	0
upon	0
infection	0
of	0
the	0
host	7
cell	8
.	0

It	0
is	0
a	0
potent	0
transcriptional	9
activator	10
of	0
many	0
viral	1
and	2
cellular	2
promoters	2
.	0

We	0
found	0
that	0
the	0
retinoblastoma	9
susceptibility	10
gene	10
product	10
(	0
Rb	9
)	0
dramatically	0
suppressed	0
this	0
IE2	9
transactivation	0
of	0
various	1
promoters	2
.	0

However	0
,	0
unlike	0
another	0
tumor	9
suppressor	10
protein	10
,	0
p53	9
,	0
Rb	9
did	0
not	0
have	0
any	0
significant	0
effect	0
on	0
basal	0
levels	0
of	0
transcription	0
,	0
suggesting	0
that	0
Rb	9
specifically	0
interacts	0
with	0
IE2	9
rather	0
than	0
other	0
cellular	9
factors	10
involved	0
in	0
the	0
general	0
transcription	0
machinery	0
.	0

We	0
found	0
by	0
protein-affinity	0
chromatography	0
that	0
Rb	9
in	0
nuclear	0
extracts	0
or	0
produced	0
by	0
in	0
vitro	0
translation	0
directly	0
bound	0
to	0
IE2	9
.	0

Our	0
results	0
suggest	0
that	0
Rb	9
may	0
regulate	0
the	0
life	0
cycle	0
of	0
HCMV	0
,	0
which	0
is	0
endemic	0
in	0
the	0
human	0
population	0
.	0

Furthermore	0
,	0
these	0
data	0
may	0
provide	0
new	0
insights	0
into	0
the	0
slow	0
rate	0
of	0
HCMV	0
DNA	0
replication	0
in	0
cells	0
and	0
the	0
possible	0
involvement	0
of	0
HCMV	0
in	0
tumorigenesis	0
.	0

Expression	0
of	0
the	0
nucleoside	9
diphosphate	10
kinase	10
in	0
human	0
skin	0
cancers	0
:	0
an	0
immunohistochemical	0
study	0
.	0

Expression	0
of	0
nucleoside	9
diphosphate	10
(	10
NDP	10
)	10
kinase	10
,	0
which	0
is	0
homologous	0
to	0
the	0
nm23	9
gene	10
product	10
in	0
a	0
variety	0
of	0
species	0
,	0
has	0
been	0
found	0
to	0
be	0
inversely	0
associated	0
with	0
metastatic	0
potential	0
.	0

However	0
,	0
the	0
relationship	0
remains	0
controversial	0
according	0
to	0
the	0
tumor	7
cell	8
types	8
and	0
experimental	0
system	0
,	0
with	0
conflicting	0
results	0
from	0
different	0
research	0
groups	0
.	0

In	0
order	0
to	0
determine	0
whether	0
NDP	9
kinase	10
expression	0
serves	0
as	0
a	0
marker	0
for	0
metastatic	0
potential	0
in	0
human	0
skin	0
cancer	0
,	0
we	0
assessed	0
the	0
levels	0
of	0
NDP	9
kinase	10
expression	0
in	0
9	0
keratoacanthomas	0
(	0
KAs	0
)	0
,	0
26	0
squamous	0
cell	0
carcinomas	0
(	0
SCCs	0
)	0
,	0
and	0
25	0
basal	0
cell	0
carcinomas	0
(	0
BCCs	0
)	0
using	0
immunohistochemistry	0
.	0

The	0
expression	0
of	0
NDP	9
kinase	10
was	0
intense	0
in	0
KA	0
and	0
SCC	0
compared	0
with	0
BCC	0
.	0

However	0
,	0
the	0
difference	0
of	0
NDP	9
kinase	10
expression	0
between	0
KA	0
and	0
SCC	0
was	0
not	0
statistically	0
significant	0
.	0

And	0
there	0
was	0
no	0
statistically	0
significant	0
difference	0
in	0
NDP	9
kinase	10
expression	0
between	0
SCC	0
with	0
metastasis	0
and	0
SCC	0
without	0
metastasis	0
.	0

Our	0
results	0
contradict	0
the	0
hypothesis	0
concerning	0
the	0
possible	0
role	0
of	0
nm23	1
gene	2
as	0
a	0
metastatic	0
suppressor	0
gene	0
in	0
human	0
skin	0
cancer	0
.	0

The	0
mechanism	0
of	0
overexpression	0
in	0
various	0
tumor	7
cell	8
types	8
and	0
its	0
biological	0
significance	0
in	0
cutaneous	0
carcinogenesis	0
remain	0
to	0
be	0
determined	0
.	0

RB	9
and	0
a	0
novel	0
E2F-1	9
binding	10
protein	10
in	0
MHC	5
class	6
II	6
deficient	6
B-cell	6
lines	6
and	0
normal	0
IFN-gamma	9
induction	0
of	0
the	0
class	1
IL	2
transactivator	2
CIITA	1
in	0
class	5
II	6
non-inducible	6
RB-defective	6
tumor	6
lines	6
.	0

The	0
major	1
histocompatibility	2
(	2
MHC	2
)	2
class	2
II	2
genes	2
encode	0
cell	9
surface	10
proteins	10
that	0
bind	0
antigenic	0
peptide	0
for	0
presentation	0
to	0
T-cells	7
.	0

The	0
class	9
II	10
proteins	10
are	0
expressed	0
constitutively	0
on	0
B-cells	7
and	0
EBV-transformed	5
B-cells	6
,	6
and	0
are	0
inducible	0
by	0
IFN-gamma	9
on	0
a	0
wide	0
variety	0
of	0
cell	7
types	8
.	0

Retinoblastoma	9
protein	10
(	0
RB	9
)	0
is	0
a	0
tumor	0
suppressor	0
and	0
functions	0
as	0
a	0
transcriptional	9
repressor	10
by	0
binding	0
and	0
inactivating	0
the	0
transactivator	1
E2F-I	2
.	0

RB-defective	5
tumor	6
lines	6
are	0
non-inducible	0
for	0
MHC	9
class	10
II	10
by	0
IFN-gamma	9
,	0
or	0
very	0
weakly	0
inducible	0
,	0
but	0
transfection	0
of	0
2	0
different	0
lines	0
with	0
RB	1
expression	2
vectors	2
re-establishes	0
or	0
substantially	0
enhances	0
class	0
II	0
inducibility	0
.	0

Therefore	0
,	0
we	0
examined	0
the	0
RB	9
status	0
of	0
a	0
series	0
of	0
B-cell	0
mutants	0
that	0
are	0
defective	0
in	0
class	0
II	0
expression	0
,	0
generated	0
either	0
in	0
vitro	0
or	0
derived	0
from	0
Bare	0
Lymphocyte	0
Syndrome	0
(	0
BLS	0
)	0
patients	0
.	0

Nuclear	0
matrix-bound	0
RB	9
was	0
detectable	0
in	0
all	0
cases	0
,	0
indicating	0
that	0
loss	0
of	0
RB	9
is	0
not	0
responsible	0
for	0
decreased	0
class	0
II	0
expression	0
in	0
these	0
lines	0
.	0

A	0
second	0
E2F-I	0
binding	0
protein	0
,	0
most	0
likely	0
DP-I	0
,	0
was	0
also	0
apparently	0
normal	0
in	0
both	0
class	0
II-positive	0
and	0
-negative	0
B-cell	0
lines	0
.	0

We	0
also	0
examined	0
the	0
IFN-gamma	9
induction	0
of	0
CIITA	1
in	0
RB	9
-defective	0
lines	0
.	0

CIITA	1
is	0
a	0
class	1
II	2
gene	2
transactivator	2
known	0
to	0
be	0
defective	0
in	0
one	0
form	0
of	0
BLS	0
and	0
to	0
be	0
required	0
for	0
the	0
induction	0
of	0
MHC	9
class	10
II	10
by	0
IFN-gamma	9
.	0

CIITA	3
mRNA	4
is	0
normally	0
inducible	0
by	0
IFN-gamma	9
in	0
class	5
II	6
non-inducible	6
,	6
RB-defective	6
lines	6
,	0
and	0
in	0
one	0
line	0
,	0
re-expression	0
of	0
RB	9
has	0
no	0
effect	0
on	0
CIITA	3
mRNA	4
induction	0
levels	0
.	0

Thus	0
,	0
the	0
block	0
in	0
MHC	0
class	0
II	0
inducibility	0
in	0
RB-defective	5
cells	6
is	0
not	0
due	0
to	0
a	0
block	0
in	0
CIITA	1
inducibility	0
.	0

Interleukin	9
12	10
induces	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
STAT4	9
in	0
human	7
lymphocytes	8
.	0

Interleukin	9
12	10
(	0
IL-12	9
)	0
is	0
an	0
important	0
immunoregulatory	9
cytokine	10
whose	0
receptor	0
is	0
a	0
member	0
of	0
the	0
hematopoietin	9
receptor	10
superfamily	10
.	0

We	0
have	0
recently	0
demonstrated	0
that	0
stimulation	0
of	0
human	7
T	8
and	8
natural	8
killer	8
cells	8
with	0
IL-12	9
induces	0
tyrosine	0
phosphorylation	0
of	0
the	0
Janus	9
family	10
tyrosine	10
kinase	10
JAK2	9
and	0
Tyk2	9
,	0
implicating	0
these	0
kinases	9
in	0
the	0
immediate	0
biochemical	0
response	0
to	0
IL-12	9
.	0

Recently	0
,	0
transcription	9
factors	10
known	0
as	0
STATs	9
(	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
)	0
have	0
been	0
shown	0
to	0
be	0
tyrosine	0
phosphorylated	0
and	0
activated	0
in	0
response	0
to	0
a	0
number	0
of	0
cytokines	9
that	0
bind	0
hematopoietin	9
receptors	10
and	0
activate	0
JAK	9
kinases	10
.	0

In	0
this	0
report	0
we	0
demonstrate	0
that	0
IL-12	9
induces	0
tyrosine	0
phosphorylation	0
of	0
a	0
recently	0
identified	0
STAT	9
family	10
member	10
,	0
STAT4	9
,	0
and	0
show	0
that	0
STAT4	9
expression	0
is	0
regulated	0
by	0
T-cell	0
activation	0
.	0

Furthermore	0
,	0
we	0
show	0
that	0
IL-12	9
stimulates	0
formation	0
of	0
a	0
DNA-binding	9
complex	10
that	0
recognizes	0
a	0
DNA	0
sequence	0
previously	0
shown	0
to	0
bind	0
STAT	9
proteins	10
and	0
that	0
this	0
complex	0
contains	0
STAT4	9
.	0

These	0
data	0
,	0
and	0
the	0
recent	0
demonstration	0
of	0
JAK	9
phosphorylation	0
by	0
IL-12	9
,	0
identify	0
a	0
rapid	0
signal-transduction	0
pathway	0
likely	0
to	0
mediate	0
IL-12	9
-induced	0
gene	0
expression	0
.	0

Temperature-induced	0
down-regulation	0
of	0
the	0
glucocorticoid	9
receptor	10
in	0
peripheral	7
blood	8
mononuclear	8
leucocyte	8
in	0
patients	0
with	0
sepsis	0
or	0
septic	0
shock	0
.	0

OBJECTIVE	0
:	0
Activation	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
axis	0
is	0
of	0
vital	0
importance	0
during	0
critical	0
illness	0
.	0

We	0
have	0
studied	0
the	0
adaptive	0
mechanisms	0
which	0
occur	0
at	0
the	0
level	0
of	0
the	0
glucocorticoid	9
receptor	10
in	0
glucocorticoid	0
target	0
tissues	0
in	0
patients	0
with	0
sepsis	0
or	0
septic	0
shock	0
.	0

DESIGN	0
:	0
The	0
effects	0
of	0
hypercortisolaemia	0
,	0
hyperthermia	0
and	0
cellular	0
composition	0
on	0
number	0
of	0
glucocorticoid	9
receptors	10
per	0
cell	0
and	0
their	0
affinity	0
were	0
evaluated	0
,	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
,	0
in	0
peripheral	7
blood	8
mononuclear	8
leucocytes	8
of	0
control	0
subjects	0
and	0
in	0
patients	0
with	0
sepsis	0
or	0
septic	0
shock	0
.	0

SUBJECTS	0
:	0
Fifteen	0
patients	0
(	0
age	0
25-79	0
)	0
with	0
sepsis	0
or	0
septic	0
shock	0
who	0
were	0
admitted	0
to	0
an	0
intensive	0
care	0
unit	0
were	0
studied	0
.	0

The	0
control	0
group	0
consisted	0
of	0
24	0
healthy	0
laboratory	0
employees	0
.	0

MEASUREMENTS	0
:	0
The	0
binding	0
capacity	0
and	0
affinity	0
of	0
the	0
glucocorticoid	9
receptors	10
were	0
measured	0
and	0
compared	0
to	0
clinical	0
data	0
and	0
the	0
plasma	0
cortisol	0
concentrations	0
.	0

RESULTS	0
:	0
Hypercortisolaemia	0
,	0
in	0
vitro	0
,	0
resulted	0
in	0
a	0
decreased	0
affinity	0
and	0
a	0
decreased	0
binding	0
capacity	0
of	0
the	0
glucocorticoid	9
receptor	10
.	0

In	0
vitro	0
,	0
hyperthermia	0
as	0
well	0
as	0
variations	0
in	0
the	0
cellular	0
composition	0
did	0
not	0
influence	0
the	0
glucocorticoid	0
receptor	0
.	0

In	0
vivo	0
,	0
there	0
was	0
no	0
change	0
in	0
the	0
number	0
of	0
receptors	0
per	0
cell	0
in	0
patients	0
with	0
sepsis	0
or	0
septic	0
shock	0
as	0
compared	0
to	0
healthy	0
controls	0
.	0

However	0
,	0
a	0
decreased	0
affinity	0
of	0
the	0
glucocorticoid	9
receptor	10
was	0
observed	0
.	0

There	0
was	0
a	0
weak	0
but	0
significant	0
negative	0
correlation	0
between	0
body	0
temperature	0
and	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
the	0
patient	0
group	0
.	0

There	0
was	0
no	0
relation	0
between	0
circulating	0
cortisol	0
concentrations	0
and	0
glucocorticoid	9
receptor	10
affinity	0
and	0
number	0
.	0

CONCLUSIONS	0
:	0
There	0
is	0
no	0
obvious	0
regulation	0
of	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
by	0
plasma	0
cortisol	0
concentrations	0
in	0
vivo	0
.	0

The	0
decreased	0
affinity	0
of	0
the	0
glucocorticoid	9
receptor	10
together	0
with	0
the	0
negative	0
correlation	0
between	0
hyperthermia	0
and	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
patients	0
with	0
sepsis	0
or	0
septic	0
shock	0
suggest	0
that	0
hypothalamic-pituitary-adrenal	0
axis	0
activation	0
during	0
critical	0
illness	0
is	0
accompanied	0
by	0
peripheral	0
adaptation	0
in	0
glucocorticoid	9
receptor	10
number	0
and	0
affinity	0
.	0

Integrin-mediated	0
tyrosine	0
phosphorylation	0
and	0
cytokine	9
message	0
induction	0
in	0
monocytic	7
cells	8
.	0

A	0
possible	0
signaling	0
role	0
for	0
the	0
Syk	9
tyrosine	10
kinase	10
.	0

Activation	0
of	0
cytoplasmic	9
tyrosine	10
kinases	10
is	0
an	0
important	0
aspect	0
of	0
signal	0
transduction	0
mediated	0
by	0
integrins	9
.	0

In	0
the	0
human	5
monocytic	6
cell	6
line	6
THP-1	6
,	0
either	0
integrin	9
-dependent	0
cell	0
adhesion	0
to	0
fibronectin	9
or	0
ligation	0
of	0
beta	0
1	0
integrins	0
with	0
antibodies	9
causes	0
a	0
rapid	0
and	0
intense	0
tyrosine	0
phosphorylation	0
of	0
two	0
sets	0
of	0
proteins	0
of	0
about	0
65-75	9
and	10
120-125	10
kDa	10
.	0

In	0
addition	0
,	0
integrin	9
ligation	0
leads	0
to	0
nuclear	0
translocation	0
of	0
the	0
p50	9
and	0
p65	9
subunits	10
of	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
,	0
to	0
activation	0
of	0
a	0
reporter	1
gene	2
driven	0
by	0
a	0
promoter	1
containing	0
NF-kappa	1
B	2
sites	2
,	0
and	0
to	0
increased	0
levels	0
of	0
mRNAs	3
for	0
immediate-early	1
genes	2
,	0
including	0
the	0
cytokine	9
interleukin	10
(	10
IL	10
)	10
-1	10
beta	10
.	0

The	0
tyrosine	0
kinase	0
inhibitors	0
genistein	0
and	0
herbimycin	0
A	0
block	0
both	0
integrin	9
-mediated	0
tyrosine	0
phosphorylation	0
and	0
increases	0
in	0
IL-1	9
beta	10
message	0
levels	0
,	0
indicating	0
a	0
causal	0
relationship	0
between	0
the	0
two	0
events	0
.	0

The	0
components	0
tyrosine	0
phosphorylated	0
subsequent	0
to	0
cell	0
adhesion	0
include	0
paxillin	9
,	0
pp125FAK	9
,	0
and	0
the	0
SH2	9
domain	10
containing	10
tyrosine	10
kinase	10
Syk	10
.	0

In	0
contrast	0
,	0
integrin	9
ligation	0
with	0
antibodies	9
induces	0
tyrosine	0
phosphorylation	0
of	0
Syk	9
but	0
not	0
of	0
FAK	9
or	0
paxillin	9
.	0

In	0
adhering	7
cells	8
,	0
pre-treatment	0
with	0
cytochalasin	0
D	0
suppresses	0
tyrosine	0
phosphorylation	0
of	0
FAK	9
and	0
paxillin	9
but	0
not	0
of	0
Syk	9
,	0
while	0
IL-1	9
beta	10
message	0
induction	0
is	0
unaffected	0
.	0

These	0
observations	0
indicate	0
that	0
the	0
Syk	9
tyrosine	0
kinase	0
may	0
be	0
an	0
important	0
component	0
of	0
an	0
integrin	9
signaling	0
pathway	0
in	0
monocytic	7
cells	8
,	0
leading	0
to	0
activation	0
of	0
NF-kappa	9
B	10
and	0
to	0
increased	0
levels	0
of	0
cytokine	9
messages	0
.	0

Inhibition	0
of	0
dexamethasone	0
binding	0
to	0
human	9
glucocorticoid	10
receptor	10
by	0
New	0
World	0
primate	0
cell	0
extracts	0
.	0

To	0
determine	0
if	0
New	0
World	0
primates	0
express	0
an	0
inhibitor	0
that	0
influences	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
binding	0
characteristics	0
,	0
we	0
examined	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
in	0
cytosol	0
prepared	0
from	0
B95-8	5
lymphoid	6
cells	6
,	0
derived	0
from	0
the	0
cotton	0
top	0
tamarin	0
(	0
Saguinus	0
oedipus	0
)	0
,	0
in	0
combination	0
with	0
cytosol	0
prepared	0
from	0
human	0
or	0
rat	0
tissues	0
.	0

B95-8	0
cytosol	0
inhibited	0
specific	0
binding	0
of	0
[	0
3H	0
]	0
dexamethasone	0
(	0
P	0
<	0
0.01	0
)	0
when	0
mixed	0
with	0
cytosol	0
prepared	0
from	0
either	0
a	0
human	5
lymphoid	6
cell	6
line	6
(	0
HL	5
)	0
or	0
rat	0
thymus	0
.	0

The	0
inhibitory	0
activity	0
was	0
heat	0
labile	0
and	0
trypsin	9
sensitive	0
.	0

Peak	0
inhibitory	0
activity	0
was	0
found	0
in	0
the	0
150-200	0
kd	0
fractions	0
after	0
Sephacryl	0
G-200	0
ultrafiltration	0
.	0

Scatchard	0
analysis	0
of	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
using	0
mixed	0
cytosol	0
showed	0
a	0
diminished	0
GR	9
apparent	0
binding	0
affinity	0
when	0
compared	0
to	0
HL	0
cytosol	0
.	0

Kinetic	0
studies	0
using	0
mixed	0
cytosol	0
indicated	0
that	0
B95-8	0
cytosol	0
did	0
not	0
affect	0
the	0
apparent	0
dissociation	0
rate	0
of	0
[	0
3H	0
]	0
dexamethasone	0
.	0

These	0
data	0
demonstrate	0
that	0
B95-8	7
cells	8
contain	0
a	0
competitive	0
inhibitor	0
that	0
prevents	0
binding	0
of	0
dexamethasone	0
to	0
its	0
cognate	9
receptor	10
.	0

Disruption	0
of	0
a	0
GATA	1
motif	2
in	0
the	0
Duffy	1
gene	2
promoter	2
abolishes	0
erythroid	1
gene	2
expression	0
in	0
Duffy-negative	0
individuals	0
.	0

The	0
mRNA	3
for	0
the	0
Duffy	9
blood	10
group	10
antigen	10
,	0
the	0
erythrocyte	9
receptor	10
for	0
the	0
Plasmodium	0
vivax	0
malaria	0
parasite	0
,	0
has	0
recently	0
been	0
cloned	0
and	0
shown	0
to	0
encode	0
a	0
widely	0
expressed	0
chemokine	9
receptor	10
.	0

Here	0
,	0
we	0
show	0
that	0
the	0
Duffy	1
antigen/chemokine	2
receptor	2
gene	2
(	0
DARC	1
)	0
is	0
composed	0
of	0
a	0
single	0
exon	1
and	0
that	0
most	0
Duffy-negative	0
blacks	0
carry	0
a	0
silent	1
FY*B	2
allele	2
with	0
a	0
single	0
T	0
to	0
C	0
substitution	0
at	0
nucleotide	0
-46	0
.	0

This	0
mutation	0
impairs	0
the	0
promoter	0
activity	0
in	0
erythroid	7
cells	8
by	0
disrupting	0
a	0
binding	1
site	2
for	0
the	0
GATA1	9
erythroid	10
transcription	10
factor	10
.	0

With	0
the	0
recent	0
characterization	0
of	0
the	0
FY*A	1
and	2
FY*B	2
alleles	2
,	0
these	0
findings	0
provide	0
the	0
molecular	0
basis	0
of	0
the	0
Duffy	0
blood	0
group	0
system	0
and	0
an	0
explanation	0
for	0
the	0
erythroid-specific	0
repression	0
of	0
the	0
DARC	1
gene	2
in	0
Duffy-negative	0
individuals	0
.	0

Activation	0
of	0
pp90rsk	9
and	0
early	1
growth	2
response-1	2
gene	2
expression	0
by	0
pokeweed	9
mitogen	10
in	0
human	7
B	8
cells	8
.	0

The	0
present	0
studies	0
have	0
examined	0
the	0
effects	0
of	0
pokeweed	9
mitogen	10
(	0
PWM	9
)	0
on	0
the	0
induction	0
of	0
early	1
growth	2
response-1	2
gene	2
(	0
EGR-1	1
)	0
in	0
normal	7
human	8
B	8
cells	8
.	0

PWM	9
regulates	0
EGR-1	1
gene	0
expression	0
by	0
both	0
transcriptional	0
and	0
post-transcriptional	0
mechanisms	0
.	0

Transient	0
transfection	0
assays	0
with	0
EGR-1	1
promoter	2
fragments	2
linked	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
gene	2
demonstrated	0
that	0
PWM	9
induced	0
EGR-1	1
transcription	0
is	0
conferred	0
by	0
the	0
CArG	1
motif	2
(	0
C	1
C	2
[	2
AT	2
]	2
6GG	2
)	0
in	0
the	0
EGR-1	1
promoter	2
.	0

The	0
results	0
further	0
demonstrated	0
the	0
activation	0
of	0
S6	9
kinase	10
(	0
pp90rsk	9
)	0
,	0
evidenced	0
by	0
phosphorylation	0
of	0
S6	9
and	0
serum	0
response	0
factor	0
(	0
SRF	0
)	0
peptides	0
,	0
in	0
PWM	5
treated	6
B	6
cells	6
.	0

Taken	0
together	0
,	0
these	0
findings	0
suggest	0
that	0
PWM	9
is	0
able	0
to	0
initiate	0
an	0
intracytoplasmic	0
signalling	0
cascade	0
and	0
EGR-1	1
induction	0
in	0
normal	7
human	8
B	8
cells	8
.	0

A	0
conserved	1
motif	2
in	0
the	0
promoters	1
of	0
several	0
cytokines	9
expressed	0
by	0
human	5
Th2-type	6
lymphocytes	6
.	0

We	0
have	0
recently	0
found	0
a	0
novel	0
conserved	1
motif	2
in	0
the	0
promoters	1
of	0
several	0
T-cell-expressed	9
cytokines	10
[	0
human	9
interleukin-2	10
,	10
-4	10
,	10
-5	10
and	10
-13	10
and	0
human	9
and	10
mouse	10
granulocyte/macrophage-colony	10
stimulating	10
factor	10
(	0
GM-CSF	9
)	0
]	0
.	0

It	0
contains	0
a	0
core	1
sequence	2
CTTGG	0
...	0
CCAAG	0
which	0
is	0
present	0
as	0
part	0
of	0
larger	0
palindromic	1
sequences	2
in	0
each	0
gene	0
.	0

This	0
suggest	0
that	0
they	0
may	0
interact	0
with	0
a	0
new	0
family	0
of	0
trans-acting	9
factors	10
.	0

In	0
transfection	0
assays	0
,	0
the	0
human	1
GM-CSF	2
element	2
has	0
a	0
strong	0
positive	0
effect	0
on	0
the	0
expression	0
of	0
a	0
reporter	1
gene	2
by	0
the	0
human	5
T	6
cell	6
line	6
Jurkat	5
J6	6
upon	0
stimulation	0
.	0

In	0
DNA	0
mobility	0
shift	0
assays	0
,	0
this	0
sequence	0
can	0
give	0
either	0
six	0
different	0
specific	0
bands	0
which	0
are	0
competed	0
out	0
by	0
different	0
parts	0
of	0
the	0
sequence	0
or	0
one	0
specific	0
band	0
which	0
is	0
competed	0
out	0
by	0
each	0
of	0
the	0
inverted	0
repeats	0
,	0
depending	0
on	0
the	0
reconstitution	0
conditions	0
.	0

In	0
different	0
genes	1
,	0
the	0
core	1
sequences	2
are	0
separated	0
by	0
integer	0
numbers	0
of	0
helical	0
turns	0
.	0

Considering	0
the	0
strong	0
positive	0
regulatory	0
effect	0
of	0
this	0
element	1
and	0
its	0
presence	0
in	0
several	0
T-cell-expressed	1
cytokine	2
genes	2
,	0
it	0
may	0
be	0
crucial	0
to	0
the	0
coordinated	0
expression	0
of	0
these	0
cytokines	9
in	0
T	7
helper	8
cells	8
.	0

cDNA	1
cloning	0
of	0
a	0
NGFI-B/nur77-related	9
transcription	10
factor	10
from	0
an	0
apoptotic	5
human	6
T	6
cell	6
line	6
.	0

A	0
human	5
T	6
lymphoid	6
cell	6
line	6
,	0
PEER	5
,	0
dies	0
by	0
apoptosis	0
in	0
the	0
presence	0
of	0
PMA	0
and	0
calcium	0
ionophore	0
.	0

A	0
new	0
gene	1
,	0
TINUR	1
,	0
was	0
cloned	0
from	0
apoptotic	5
PEER	6
cells	6
.	0

The	0
expression	0
of	0
the	0
TINUR	1
gene	2
is	0
induced	0
within	0
1	0
h	0
after	0
the	0
cross-linking	0
of	0
the	0
T	9
cell	10
Ag	10
receptor	10
complex	10
.	0

TINUR	1
belongs	0
to	0
the	0
NGFI-B/nur77	9
family	10
of	0
the	0
steroid	9
receptor	10
superfamily	10
and	0
is	0
an	0
orphan	9
receptor	10
.	0

TINUR	1
binds	0
to	0
the	0
same	0
DNA	1
sequence	2
as	0
NGFI-B/nur77	9
.	0

We	0
also	0
propose	0
that	0
the	0
NGFI-B/nur77	9
family	10
can	0
be	0
classified	0
into	0
two	0
subtypes	0
.	0

Aspirin	0
inhibits	0
nuclear	9
factor-kappa	10
B	10
mobilization	0
and	0
monocyte	0
adhesion	0
in	0
stimulated	5
human	6
endothelial	6
cells	6
.	0

BACKGROUND	0
:	0
The	0
induction	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
and	0
E-selectin	9
by	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF	9
)	0
is	0
mediated	0
by	0
mobilization	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

Since	0
salicylates	0
have	0
been	0
reported	0
to	0
inhibit	0
NF-kappa	9
B	10
activation	0
by	0
preventing	0
the	0
degradation	0
of	0
its	0
inhibitor	0
I	9
kappa	10
B	10
,	0
we	0
studied	0
a	0
potential	0
inhibition	0
of	0
this	0
pathway	0
by	0
acetylsalicylate	0
(	0
aspirin	0
)	0
in	0
human	5
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVECs	5
)	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
Gel-shift	0
analyses	0
demonstrated	0
dose-dependent	0
inhibition	0
of	0
TNF	9
-induced	0
NF-kappa	9
B	10
mobilization	0
by	0
aspirin	0
at	0
concentrations	0
ranging	0
from	0
1	0
to	0
10	0
mmol/L	0
.	0

Induction	0
of	0
VCAM-1	9
and	0
E-selectin	9
surface	0
expression	0
by	0
TNF	9
was	0
dose-dependently	0
reduced	0
by	0
aspirin	0
over	0
the	0
same	0
range	0
,	0
while	0
induction	0
of	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
was	0
hardly	0
affected	0
.	0

Aspirin	0
appeared	0
to	0
prevent	0
VCAM-1	9
transcription	0
,	0
since	0
it	0
dose-dependently	0
inhibited	0
induction	0
of	0
VCAM-1	3
mRNA	4
by	0
TNF	9
.	0

As	0
a	0
functional	0
consequence	0
,	0
adhesion	0
of	0
U937	5
monocytes	6
to	0
TNF-stimulated	5
HUVECs	6
was	0
markedly	0
reduced	0
by	0
aspirin	0
due	0
to	0
suppression	0
of	0
VCAM-1	9
and	0
E-selectin	9
upregulation	0
.	0

These	0
effects	0
of	0
aspirin	0
were	0
not	0
related	0
to	0
the	0
inhibition	0
of	0
cyclooxygenase	9
activity	0
,	0
since	0
indomethacin	0
was	0
ineffective	0
.	0

CONCLUSIONS	0
:	0
Our	0
data	0
suggest	0
that	0
aspirin	0
inhibits	0
NF-kappa	9
B	10
mobilization	0
,	0
induction	0
of	0
VCAM-1	9
and	0
E-selectin	9
,	0
and	0
subsequent	0
monocyte	0
adhesion	0
in	0
endothelial	7
cells	8
stimulated	0
by	0
TNF	9
,	0
thereby	0
providing	0
an	0
additional	0
mechanism	0
for	0
therapeutic	0
effects	0
of	0
aspirin	0
.	0

Activation	0
of	0
NF-kappa	9
B	10
by	0
phosphatase	9
inhibitors	0
involves	0
the	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
at	0
phosphatase	9
2A-sensitive	10
sites	10
.	0

Activation	0
of	0
NF-kappa	9
B	10
by	0
various	0
cellular	0
stimuli	0
involves	0
the	0
phosphorylation	0
and	0
subsequent	0
degradation	0
of	0
its	0
inhibitor	0
,	0
I	9
kappa	10
B	10
alpha	10
,	0
although	0
the	0
underlying	0
mechanism	0
remains	0
unclear	0
.	0

In	0
the	0
present	0
study	0
,	0
the	0
role	0
of	0
serine/threonine	9
phosphatases	10
in	0
the	0
regulation	0
of	0
I	9
kappa	10
B	10
alpha	10
phosphorylation	0
was	0
investigated	0
.	0

Our	0
studies	0
demonstrate	0
that	0
incubation	0
of	0
human	7
T	8
cells	8
with	0
low	0
concentrations	0
(	0
approximately	0
1-5	0
nM	0
)	0
of	0
calyculin	0
A	0
or	0
okadaic	0
acid	0
,	0
potent	0
inhibitors	0
of	0
protein	9
phosphatase	10
type	10
1	10
(	10
PP-1	10
)	10
and	10
type	10
2A	10
(	0
PP-2A	9
)	0
,	0
induces	0
the	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
even	0
in	0
the	0
absence	0
of	0
any	0
cellular	0
stimulus	0
.	0

This	0
action	0
of	0
the	0
phosphatase	0
inhibitors	0
,	0
which	0
is	0
associated	0
with	0
the	0
activation	0
of	0
the	0
RelA.p50	9
NF-kappa	10
B	10
heterodimer	10
,	0
is	0
not	0
affected	0
by	0
agents	0
that	0
block	0
the	0
induction	0
of	0
I	9
kappa	10
B	10
alpha	10
phosphorylation	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
.	0

Furthermore	0
,	0
the	0
phosphorylated	9
I	10
kappa	10
B	10
alpha	10
from	0
calyculin	5
A-treated	6
cells	6
,	0
but	0
not	0
that	0
from	0
TNF-alpha-stimulated	5
cells	6
,	0
is	0
sensitive	0
to	0
PP-2A	9
in	0
vitro	0
,	0
suggesting	0
the	0
existence	0
of	0
fundamental	0
differences	0
in	0
the	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
induced	0
by	0
the	0
two	0
different	0
NF-kappa	9
B	10
inducers	0
.	0

However	0
,	0
induction	0
of	0
I	9
kappa	10
B	10
alpha	10
phosphorylation	0
by	0
both	0
TNF-alpha	9
and	0
the	0
phosphatase	0
inhibitors	0
is	0
associated	0
with	0
the	0
subsequent	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

We	0
further	0
demonstrate	0
that	0
TNF-alpha-	0
and	0
calyculin	0
A-induced	0
I	0
kappa	0
B	0
alpha	0
degradation	0
exhibits	0
similar	0
but	0
not	0
identical	0
sensitivities	0
to	0
a	0
proteasome	0
inhibitor	0
.	0

Together	0
,	0
these	0
results	0
suggest	0
that	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
,	0
mediated	0
through	0
both	0
the	0
TNF-alpha	9
-inducible	0
and	0
the	0
PP-2A-opposing	9
kinases	10
,	0
may	0
serve	0
to	0
target	0
I	9
kappa	10
B	10
alpha	10
for	0
proteasome	9
-mediated	0
degradation	0
.	0

Sp1	9
functions	0
in	0
a	0
chromatin	1
-dependent	0
manner	0
to	0
augment	0
human	1
alpha-globin	2
promoter	2
activity	0
.	0

The	0
5	1
'	2
flanking	2
region	2
of	0
the	0
human	1
alpha-globin	2
gene	2
is	0
highly	0
G	0
+	0
C	0
rich	0
and	0
contains	0
multiple	0
copies	0
of	0
the	0
consensus	1
sequence	2
for	0
the	0
Sp1	1
binding	2
site	2
.	0

We	0
investigated	0
the	0
role	0
of	0
this	0
G	1
+	2
C-rich	2
region	2
in	0
augmenting	0
alpha-globin	1
promoter	2
activity	0
in	0
the	0
presence	0
of	0
the	0
far-upstream	1
alpha-globin	2
enhancer	2
,	0
HS-40	1
.	0

We	0
show	0
that	0
in	0
transiently	5
transfected	6
erythroid	6
cells	6
,	0
deletion	0
of	0
the	0
alpha-globin	1
G	2
+	2
C-rich	2
5	2
'	2
flanking	2
region	2
has	0
no	0
effect	0
on	0
alpha-globin	1
promoter	2
activity	0
.	0

However	0
,	0
upon	0
stable	0
integration	0
into	0
chromatin	1
,	0
deletion	0
of	0
this	0
region	0
causes	0
a	0
nearly	0
90	0
%	0
decrease	0
in	0
promoter	0
activity	0
compared	0
with	0
expression	0
from	0
an	0
alpha-globin	1
promoter	2
retaining	0
this	0
region	0
.	0

These	0
results	0
suggest	0
that	0
the	0
alpha-globin	1
G	2
+	2
C-rich	2
5	2
'	2
flanking	2
region	2
augments	0
alpha-globin	1
promoter	2
activity	0
in	0
a	0
chromatin	1
-dependent	0
manner	0
.	0

We	0
further	0
show	0
that	0
this	0
G	1
+	2
C-rich	2
region	2
is	0
required	0
for	0
the	0
activation	0
of	0
alpha-globin	1
gene	2
expression	0
during	0
erythroid	0
differentiation	0
.	0

Finally	0
,	0
we	0
show	0
by	0
both	0
footprint	0
analysis	0
and	0
functional	0
assays	0
that	0
the	0
ability	0
of	0
the	0
G	1
+	2
C-rich	2
region	2
to	0
increase	0
alpha-globin	1
promoter	2
activity	0
from	0
a	0
stably	0
integrated	0
alpha-globin	1
gene	2
is	0
mediated	0
by	0
its	0
multiple	1
binding	2
sites	2
for	0
the	0
transcription	9
factor	10
Sp1	9
.	0

Costimulation	0
of	0
human	5
CD4+	6
T	6
cells	6
with	0
LFA-3	9
and	0
B7	9
induce	0
distinct	0
effects	0
on	0
AP-1	0
and	0
NF-kappa	9
B	10
transcription	9
factors	10
.	0

We	0
have	0
earlier	0
shown	0
that	0
stimulation	0
of	0
human	5
CD4+	6
T	6
cells	6
with	0
SEA	0
presented	0
on	0
Chinese	5
hamster	6
ovary	6
(	6
CHO	6
)	6
-DR	6
transfectants	6
coexpressing	0
either	0
B7	9
or	0
LFA-3	9
resulted	0
in	0
distinct	0
cytokine	9
profiles	0
.	0

We	0
now	0
demonstrate	0
that	0
B7	9
,	0
but	0
not	0
LFA-3	9
,	0
strongly	0
costimulated	0
IL-2	9
transcription	0
and	0
mRNA	0
expression	0
in	0
CD4+	5
T	6
cells	6
.	0

Maximal	0
increase	0
in	0
IL-2	9
transcription	0
was	0
recorded	0
with	0
CHO-DR/B7/LFA-3	9
,	0
suggesting	0
a	0
cooperative	0
effect	0
of	0
B7	9
and	0
LFA-3	9
at	0
the	0
transcriptional	0
level	0
.	0

Gel-shift	0
analysis	0
demonstrated	0
that	0
stimulation	0
of	0
CD4+	5
T	6
cells	6
with	0
CHO-DR	9
and	0
staphylococcal	0
enterotoxin	0
A	0
was	0
sufficient	0
to	0
induce	0
significant	0
amounts	0
of	0
NF-kappa	9
B	10
binding	0
proteins	0
,	0
whereas	0
induction	0
of	0
AP-1	9
binding	10
proteins	10
required	0
costimulation	0
.	0

LFA-3	9
induced	0
moderate	0
levels	0
of	0
AP-1	9
,	0
but	0
did	0
not	0
influence	0
the	0
levels	0
of	0
NF-kappa	9
B	10
,	0
while	0
B7	9
costimulation	0
strongly	0
induced	0
both	0
AP-1	9
and	0
substantially	0
enhanced	0
NF-kappa	9
B	10
binding	10
proteins	10
.	0

The	0
CHO-DR/B7/LFA-3	5
triple	6
transfectant	6
induced	0
a	0
further	0
increase	0
in	0
AP-1	9
and	0
NF-kappa	9
B	10
binding	9
proteins	10
compared	0
with	0
the	0
double	5
transfectants	6
.	0

The	0
level	0
of	0
Oct-1	9
binding	10
proteins	10
remained	0
similar	0
in	0
all	0
samples	0
.	0

Super-shift	0
analysis	0
revealed	0
that	0
the	0
NF-kappa	9
B	10
complex	10
of	0
costimulated	5
CD4+	6
T	6
cells	6
contained	0
large	0
amounts	0
of	0
p50	9
,	0
substantial	0
amounts	0
of	0
p65	9
,	0
and	0
marginal	0
levels	0
of	0
c-Rel	9
proteins	10
.	0

The	0
AP-1	9
binding	10
proteins	10
contained	0
c-Jun	9
,	0
Jun-D	9
,	0
and	0
Fra-1	9
,	0
but	0
marginal	0
amounts	0
of	0
Jun-B	9
and	0
c-Fos	9
.	0

Our	0
results	0
indicate	0
distinct	0
effects	0
of	0
B7	9
and	0
LFA-3	9
costimulation	0
on	0
the	0
activity	0
of	0
AP-1	9
and	0
NF-kappa	9
B	10
.	0

These	0
may	0
partly	0
account	0
for	0
the	0
differential	0
effects	0
of	0
B7	9
and	0
LFA-3	9
costimulation	0
on	0
IL-2	9
expression	0
.	0

The	0
Ah	9
receptor	10
recognizes	0
DNA	1
binding	2
sites	2
for	0
the	0
B	9
cell	10
transcription	10
factor	10
,	0
BSAP	9
:	0
a	0
possible	0
mechanism	0
for	0
dioxin-mediated	0
alteration	0
of	0
CD19	1
gene	2
expression	0
in	0
human	7
B	8
lymphocytes	8
.	0

2	0
,	0
3	0
,	0
7	0
,	0
8-tetrachlorodibenzo-p-dioxin	0
(	0
TCDD	0
)	0
inhibits	0
murine	0
and	0
human	0
B	0
lymphocyte	0
immunoglobulin	0
production	0
through	0
an	0
unknown	0
mechanism	0
.	0

This	0
study	0
investigated	0
the	0
effect	0
of	0
TCDD	0
on	0
expression	0
of	0
the	0
CD19	1
gene	2
in	0
a	0
human	5
B	6
lymphocyte	6
cell	6
line	6
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
TCDD	0
treatment	0
decreased	0
steady	0
state	0
levels	0
of	0
CD19	3
mRNA	4
by	0
67	0
%	0
in	0
the	0
IM-9	5
cell	6
line	6
.	0

Using	0
a	0
gel	0
mobility	0
shift	0
assay	0
,	0
we	0
identified	0
a	0
DNA-binding	9
complex	10
in	0
IM-9	0
nuclear	0
extracts	0
that	0
by	0
several	0
criteria	0
appears	0
to	0
be	0
the	0
Ah	9
receptor	10
.	0

In	0
addition	0
,	0
the	0
Ah	9
receptor	10
complex	10
recognized	0
a	0
DNA	1
binding	2
site	2
for	0
B	9
cell	10
lineage-specific	10
activator	10
protein	10
(	0
BSAP	9
)	0
in	0
the	0
promoter	1
region	2
of	0
the	0
human	0
CD19	1
gene	2
which	0
is	0
similar	0
to	0
the	0
consensus	1
Ah	2
receptor	2
DNA	2
binding	2
site	2
.	0

These	0
results	0
suggest	0
that	0
the	0
AhR	9
could	0
interfere	0
with	0
BSAP	9
-stimulated	0
CD19	1
gene	2
transcription	0
by	0
competition	0
for	0
a	0
common	0
DNA	1
binding	2
site	2
.	0

Inhibitory	0
action	0
of	0
nm23	9
proteins	10
on	0
induction	0
of	0
erythroid	0
differentiation	0
of	0
human	7
leukemia	8
cells	8
.	0

We	0
recently	0
identified	0
a	0
differentiation	9
inhibitory	10
factor	10
(	0
I-factor	9
)	0
in	0
mouse	5
myeloid	6
leukemia	6
M1	6
cells	6
as	0
a	0
murine	9
homolog	10
of	0
the	0
human	9
nm23-H2	10
gene	10
product	10
.	0

nm23	1
genes	2
encode	0
proteins	0
that	0
participate	0
in	0
tumor	0
metastasis	0
regulation	0
and	0
in	0
various	0
fundamental	0
cellular	0
processes	0
,	0
although	0
their	0
mechanisms	0
of	0
action	0
are	0
still	0
unknown	0
.	0

Although	0
all	0
nm23	9
proteins	10
contain	0
nucleoside	9
diphosphate	10
(	10
NDP	10
)	10
kinase	10
activity	0
,	0
it	0
has	0
not	0
been	0
established	0
that	0
the	0
enzyme	0
activity	0
mediated	0
the	0
various	0
functions	0
of	0
nm23	9
proteins	10
.	0

In	0
the	0
present	0
experiment	0
,	0
we	0
examined	0
the	0
effect	0
of	0
nm23	9
proteins	10
on	0
various	0
differentiation	0
induction	0
systems	0
of	0
human	7
leukemic	8
cells	8
including	0
HL-60	5
,	6
U937	6
,	6
HEL/S	6
,	6
KU812F	6
,	6
K562	6
,	6
and	6
HEL	6
cells	6
.	0

Native	9
human	10
erythrocyte	10
NDP	10
kinase	10
protein	10
inhibited	0
the	0
induction	0
of	0
erythroid	0
differentiation	0
of	0
HEL	5
,	6
KU812	6
and	6
K562	6
cells	6
,	0
but	0
not	0
the	0
induction	0
of	0
monocytic	0
or	0
granulocytic	0
differentiation	0
of	0
HL-60	5
,	6
U937	6
and	6
HEL/S	6
cells	6
.	0

The	0
erythroid	0
differentiation	0
of	0
HEL	5
cells	6
was	0
inhibited	0
by	0
recombinant	9
human	10
nm23-H1	10
,	10
-H2	10
,	10
mouse	10
nm23-M1	10
,	10
and	10
-M2	10
proteins	10
.	0

Moreover	0
,	0
both	0
the	0
mutant	9
nm23-H2His	10
protein	10
and	0
truncated	9
nm23-H2	10
protein	10
containing	0
N-terminal	9
(	10
1-60	10
)	10
peptide	10
,	0
which	0
do	0
not	0
have	0
NDP	9
kinase	10
activity	0
,	0
also	0
inhibited	0
erythroid	0
differentiation	0
of	0
HEL	5
cells	6
.	0

These	0
results	0
suggest	0
that	0
(	0
1	0
)	0
the	0
differentiation	0
inhibitory	0
activity	0
of	0
I-factor/nm23	9
protein	10
is	0
not	0
restricted	0
to	0
monocytic	0
differentiation	0
of	0
M1	5
cells	6
,	0
(	0
2	0
)	0
the	0
inhibitory	0
activity	0
is	0
exhibited	0
without	0
species	0
specificity	0
,	0
and	0
(	0
3	0
)	0
the	0
differentiation	0
inhibitory	0
activity	0
of	0
the	0
nm23/NDP	9
kinase	10
protein	10
is	0
independent	0
of	0
its	0
enzyme	0
activity	0
and	0
requires	0
the	0
presence	0
of	0
N-terminal	0
peptides	0
.	0

Lipopolysaccharide-induced	0
E-selectin	9
expression	0
requires	0
continuous	0
presence	0
of	0
LPS	0
and	0
is	0
inhibited	0
by	0
bactericidal/permeability-increasing	9
protein	10
.	0

Endothelial	7
cells	8
stimulated	0
by	0
LPS	0
express	0
E-selectin	9
,	0
which	0
plays	0
an	0
important	0
role	0
in	0
mediating	0
neutrophil	7
adhesion	0
during	0
inflammation	0
.	0

E-selectin	9
is	0
induced	0
within	0
1-2	0
h	0
,	0
peaks	0
at	0
4-6	0
h	0
,	0
and	0
gradually	0
returns	0
to	0
basal	0
level	0
by	0
24	0
h	0
.	0

rBPI21	9
,	0
a	0
recombinant	9
N-terminal	10
fragment	10
of	0
human	9
bactericidal/permeability-increasing	10
protein	10
(	0
BPI	9
)	0
,	0
inhibited	0
LPS-induced	0
E-selectin	9
expression	0
when	0
added	0
at	0
the	0
same	0
time	0
as	0
,	0
and	0
up	0
to	0
6	0
h	0
after	0
,	0
LPS	0
.	0

Delayed	0
administration	0
of	0
rBPI21	9
also	0
affected	0
LPS-mediated	0
activation	0
of	0
the	0
nuclear	9
factor	10
,	0
NF-kappa	9
B	10
.	0

Two	0
to	0
4	0
h	0
following	0
LPS	0
addition	0
to	0
endothelial	7
cells	8
,	0
when	0
NF-kappa	9
B	10
was	0
already	0
activated	0
,	0
addition	0
of	0
rBPI21	9
resulted	0
in	0
marked	0
reduction	0
of	0
NF-kappa	9
B	10
detectable	0
at	0
4	0
or	0
6	0
h	0
.	0

These	0
results	0
indicate	0
that	0
endothelial	0
activation	0
requires	0
continuous	0
presence	0
of	0
LPS	0
,	0
and	0
rBPI21	9
acts	0
to	0
reverse	0
LPS-mediated	0
endothelial	0
activation	0
by	0
interrupting	0
the	0
on-going	0
LPS	0
signal	0
.	0

GM-CSF	9
and	0
IL-2	9
share	0
common	0
control	0
mechanisms	0
in	0
response	0
to	0
costimulatory	0
signals	0
in	0
T	7
cells	8
.	0

Antigen	0
complexed	0
with	0
major	9
histocompatibility	10
complex	10
class	10
I	10
or	10
II	10
molecules	10
on	0
the	0
surface	0
of	0
antigen	7
presenting	8
cells	8
interacts	0
with	0
the	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
on	0
the	0
surface	0
of	0
T	7
cells	8
and	0
initiates	0
an	0
activation	0
cascade	0
.	0

So	0
called	0
costimulatory	0
signals	0
,	0
mediated	0
by	0
other	0
cell	0
surface	0
interactions	0
or	0
soluble	9
cytokines	10
produced	0
by	0
antigen	7
presenting	8
cells	8
,	0
are	0
also	0
required	0
for	0
complete	0
T	0
cell	0
activation	0
.	0

High	0
levels	0
of	0
cytokine	9
gene	0
expression	0
in	0
T	7
cells	8
also	0
required	0
both	0
TCR	9
and	0
costimulatory	0
signals	0
.	0

The	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
requires	0
sequences	0
in	0
the	0
promoter	1
as	0
well	0
as	0
a	0
powerful	0
enhancer	1
located	0
3kb	0
upstream	0
to	0
respond	0
to	0
TCR	9
-like	0
signals	0
.	0

These	0
promoter	1
and	2
enhancer	2
regions	2
are	0
mainly	0
activated	0
by	0
the	0
transcription	9
factor	10
nuclear	10
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
.	0

The	0
activation	0
of	0
NFAT	9
by	0
TCR	9
signals	0
has	0
been	0
well	0
described	0
for	0
interleukin-2	0
(	0
IL-2	9
)	0
and	0
IL-4	0
gene	0
transcription	0
in	0
T	7
cells	8
.	0

Costimulatory	0
signals	0
,	0
such	0
as	0
activation	0
of	0
the	0
CD28	9
cell	10
surface	10
molecule	10
on	0
T	7
cells	8
,	0
lead	0
to	0
activation	0
through	0
a	0
distinct	0
region	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
promoter	2
.	0

This	0
region	0
is	0
termed	0
the	0
CK-1	1
or	0
CD28RE	1
and	0
appears	0
to	0
bind	0
specific	0
members	0
of	0
the	0
NF-kappa	9
B	10
family	10
of	0
transcription	9
factors	10
.	0

Human	0
T	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
infects	0
T	7
cells	8
and	0
can	0
lead	0
to	0
increase	0
GM-CSF	9
expression	0
.	0

We	0
have	0
found	0
that	0
the	0
HTLV-1	9
transactivator	10
protein	10
,	0
tax	9
,	0
acts	0
as	0
a	0
costimulatory	0
signal	0
for	0
GM-CSF	0
and	0
IL-2	0
gene	0
transcription	0
,	0
in	0
that	0
it	0
can	0
cooperate	0
with	0
TCR	9
signals	0
to	0
mediate	0
high	0
level	0
gene	0
expression	0
.	0

Tax	0
activates	0
the	0
GM-CSF	1
promoter	2
through	0
the	0
CK-1	1
/CD28RE	1
region	0
and	0
also	0
activates	0
nuclear	9
factor-kappa	10
B	10
binding	0
to	0
this	0
region	0
.	0

However	0
,	0
other	0
transcription	9
factors	10
or	0
coactivators	0
of	0
NF-kappa	9
B	10
are	0
required	0
for	0
tax	9
activation	0
but	0
these	0
remain	0
to	0
be	0
identified	0
.	0

The	0
CK-1	1
/CD28RE	1
of	0
GM-CSF	9
shows	0
a	0
high	0
degree	0
of	0
similarity	0
to	0
the	0
IL-2	9
CD28RE	1
and	0
the	0
IL-3	1
gene	2
also	0
contains	0
a	0
related	0
region	0
.	0

This	0
observation	0
,	0
together	0
with	0
the	0
fact	0
that	0
both	0
GM-CSF	9
and	0
IL-2	9
respond	0
to	0
TCR	9
signals	0
via	0
NFAT	9
,	0
implies	0
a	0
high	0
degree	0
of	0
conservation	0
in	0
the	0
regulation	0
of	0
cytokine	9
gene	0
expression	0
in	0
T	7
cells	8
.	0

Danazol	0
decreases	0
transcription	0
of	0
estrogen	1
receptor	2
gene	2
in	0
human	7
monocytes	8
.	0

1.	0
Administration	0
of	0
danazol	0
for	0
over	0
one	0
month	0
reduced	0
the	0
levels	0
of	0
estrogen	9
receptor	10
(	0
ER	9
)	0
and	0
its	0
mRNA	3
to	0
approximately	0
50	0
and	0
20	0
%	0
,	0
respectively	0
in	0
monocytes	7
.	0

2.	0
Danazol	0
did	0
not	0
alter	0
the	0
degradation	0
rate	0
of	0
ER	3
mRNA	4
in	0
monocytes	7
.	0

3.	0
Danazol	0
decreased	0
the	0
transcription	0
rate	0
of	0
ER	1
gene	2
to	0
approximately	0
50	0
%	0
in	0
monocytes	7
in	0
a	0
run-on	0
assay	0
.	0

4.	0
Danazol	0
may	0
release	0
estrogen	0
predominance	0
via	0
the	0
reduction	0
of	0
transcription	0
for	0
ER	1
gene	2
,	0
which	0
leads	0
to	0
the	0
reduction	0
of	0
ER	3
mRNA	4
and	0
ER	9
expressions	0
in	0
monocytes	7
.	0

Functional	0
characterization	0
of	0
novel	0
IL-2	9
transcriptional	0
inhibitors	0
.	0

IL-2	9
-mediated	0
T	7
cell	8
proliferation	0
is	0
a	0
critical	0
early	0
event	0
in	0
the	0
inflammatory	0
process	0
.	0

Formation	0
of	0
the	0
NFAT-1	9
transcriptional	10
complex	10
on	0
the	0
IL-2	1
promoter	2
is	0
essential	0
for	0
IL-2	9
transcription	0
.	0

Using	0
a	0
cell	0
line	0
that	0
is	0
stably	0
transfected	0
with	0
a	0
trimer	0
of	0
the	0
NFAT-1	1
regulatory	2
element	2
linked	0
to	0
a	0
lac-Z	1
reporter	2
gene	2
,	0
we	0
screened	0
for	0
inhibitors	0
of	0
NFAT	9
-1-mediated	0
beta-galactosidase	9
activity	0
.	0

WIN	0
61058	0
and	0
WIN	0
53071	0
were	0
identified	0
as	0
microM	0
inhibitors	0
.	0

These	0
compounds	0
also	0
inhibited	0
beta-galactosidase	3
mRNA	4
levels	0
.	0

Similar	0
inhibition	0
of	0
NFAT	9
-1-mediated	0
gene	0
expression	0
was	0
observed	0
in	0
a	0
second	0
cell	5
line	6
,	0
which	0
is	0
stably	0
transfected	0
with	0
NFAT-1	1
regulatory	2
elements	2
linked	0
to	0
the	0
reporter	1
gene	2
for	2
sCD8	2
.	0

At	0
10	0
microM	0
,	0
both	0
compounds	0
inhibited	0
IL-2	0
mRNA	0
and	0
protein	0
levels	0
in	0
the	0
NFAT-1-linked	5
lac-Z	6
transfectants	6
,	0
and	0
in	0
human	7
lymphocytes	8
.	0

Both	0
compounds	0
inhibited	0
the	0
mixed	0
lymphocyte	0
reaction	0
,	0
and	0
this	0
inhibition	0
was	0
reversed	0
by	0
exogenous	0
IL-2	9
.	0

WIN	0
53071	0
inhibited	0
IL-2	9
production	0
induced	0
in	0
the	0
calcium-dependent	0
PMA	0
and	0
ionomycin	0
pathway	0
.	0

Conversely	0
,	0
calcium-independent	9
anti-CD28	10
Ab	10
and	0
PMA-induced	0
IL-2	9
production	0
was	0
resistant	0
.	0

Both	0
compounds	0
altered	0
the	0
NFAT-1	9
transcriptional	10
complex	10
,	0
causing	0
its	0
retarded	0
mobility	0
on	0
gels	0
.	0

By	0
these	0
functional	0
criteria	0
,	0
we	0
believe	0
we	0
have	0
identified	0
two	0
structurally	0
distinct	0
,	0
novel	0
inhibitors	0
of	0
NFAT	9
-1-mediated	0
transcription	0
.	0

Transcriptional	0
regulation	0
of	0
the	0
vacuolar	1
H	2
(	2
+	2
)	2
-ATPase	2
B2	2
subunit	2
gene	2
in	0
differentiating	5
THP-1	6
cells	6
.	0

Monocyte-macrophage	0
differentiation	0
was	0
used	0
as	0
a	0
model	0
system	0
for	0
studying	0
gene	0
regulation	0
of	0
the	0
human	9
vacuolar	10
H	10
(	10
+	10
)	10
-ATPase	10
(	0
V-ATPase	9
)	0
.	0

We	0
examined	0
mRNA	3
levels	0
of	0
various	0
V-ATPase	9
subunits	0
during	0
differentiation	0
of	0
both	0
native	7
monocytes	8
and	0
the	0
cell	5
line	6
THP-1	5
,	0
and	0
found	0
that	0
transcriptional	0
and	0
post-transcriptional	0
mechanisms	0
could	0
account	0
for	0
increases	0
in	0
cell	0
V-ATPase	9
content	0
.	0

From	0
nuclear	0
runoff	0
experiments	0
,	0
we	0
found	0
that	0
one	0
subunit	0
in	0
particular	0
,	0
the	0
B2	9
isoform	10
(	0
Mr	0
=	0
56	0
,	0
000	0
)	0
,	0
was	0
amplified	0
primarily	0
by	0
transcriptional	0
means	0
.	0

We	0
have	0
begun	0
to	0
examine	0
the	0
structure	0
of	0
the	0
B2	1
subunit	2
promoter	2
region	2
.	0

Isolation	0
and	0
sequencing	0
of	0
the	0
first	1
exon	2
and	0
5'-flanking	1
region	2
of	0
this	0
gene	0
reveal	0
a	0
TATA-less	1
promoter	2
with	0
a	0
high	0
G	0
+	0
C	0
content	0
.	0

Primer	0
extension	0
and	0
ribonuclease	9
protection	0
analyses	0
indicate	0
a	0
single	0
major	1
transcriptional	2
start	2
site	2
.	0

We	0
transfected	0
promoter-luciferase	1
reporter	2
plasmids	2
into	0
THP-1	5
cells	6
to	0
define	0
sequences	0
that	0
mediate	0
transcriptional	0
control	0
during	0
monocyte	0
differentiation	0
.	0

We	0
found	0
that	0
sequences	0
downstream	0
from	0
the	0
transcriptional	0
start	0
site	0
were	0
sufficient	0
to	0
confer	0
increased	0
expression	0
during	0
THP-1	5
differentiation	0
.	0

DNase	9
I	10
footprinting	0
and	0
sequence	0
analysis	0
revealed	0
the	0
existence	0
of	0
multiple	0
AP2	1
and	2
Sp1	2
binding	2
sites	2
in	0
the	0
5'-untranslated	1
and	2
proximal	2
coding	2
regions	2
.	0

Synergy	0
between	0
signal	0
transduction	0
pathways	0
is	0
obligatory	0
for	0
expression	0
of	0
c-fos	1
in	0
B	5
and	6
T	6
cell	6
lines	6
:	0
implication	0
for	0
c-fos	1
control	0
via	0
surface	9
immunoglobulin	10
and	0
T	9
cell	10
antigen	10
receptors	10
.	0

Expression	0
of	0
the	0
protooncogene	1
c-fos	2
is	0
controlled	0
by	0
three	0
main	0
regulatory	0
pathways	0
involving	0
kinase	9
C	10
,	0
cAMP	0
,	0
and	0
calcium	0
.	0

Kinase	9
C	10
mediates	0
its	0
effects	0
via	0
phosphorylation	0
of	0
serum	9
response	10
factor	10
(	0
SRF	9
)	0
which	0
interacts	0
with	0
the	0
serum	1
response	2
element	2
(	0
SRE	1
)	0
;	0
cAMP	0
and	0
calcium	0
mediate	0
their	0
effects	0
via	0
phosphorylation	0
of	0
CREB	9
(	0
cAMP	9
regulatory	10
element	10
binding	10
protein	10
)	0
presumably	0
by	0
activation	0
of	0
a	0
protein	9
kinase	10
A	10
or	0
calmodulin-regulated	9
kinase	10
.	0

We	0
have	0
examined	0
the	0
function	0
of	0
these	0
elements	0
in	0
Burkitt	5
's	6
lymphoma	6
cells	6
(	0
Ramos	5
and	0
Daudi	5
)	0
as	0
well	0
as	0
a	0
T	5
lymphocytic	6
cell	6
line	6
(	0
Jurkat	5
)	0
.	0

We	0
have	0
found	0
that	0
stimulation	0
of	0
any	0
one	0
of	0
these	0
pathways	0
alone	0
has	0
little	0
or	0
no	0
effect	0
on	0
c-fos	1
induction	0
.	0

However	0
,	0
kinase	9
C	10
activation	0
(	0
PMA	0
stimulation	0
)	0
combined	0
with	0
either	0
cAMP	0
(	0
forskolin	0
plus	0
MIX	0
)	0
or	0
calcium	0
stimulation	0
(	0
ionophore	0
)	0
leads	0
to	0
greatly	0
enhanced	0
c-fos	1
induction	0
.	0

By	0
contrast	0
,	0
cAMP	0
in	0
the	0
presence	0
of	0
calcium	0
shows	0
no	0
synergy	0
in	0
c-fos	1
induction	0
.	0

Okadaic	0
acid	0
augments	0
PMA-	0
as	0
well	0
as	0
calcium-mediated	0
activation	0
of	0
c-fos	1
,	0
and	0
has	0
little	0
or	0
no	0
effect	0
when	0
combined	0
with	0
cAMP	0
.	0

The	0
main	0
difference	0
between	0
Ramos	5
(	0
B	7
cells	8
)	0
and	0
Jurkat	5
(	0
T	7
cells	8
)	0
in	0
the	0
regulation	0
of	0
c-fos	1
is	0
that	0
cAMP	0
plus	0
calcium	0
is	0
strongly	0
synergistic	0
in	0
Jurkat	5
and	0
is	0
without	0
effect	0
in	0
Ramos	5
.	0

Analysis	0
of	0
AP-1	9
activity	0
using	0
gel	0
mobility	0
shift	0
assays	0
confirms	0
that	0
the	0
requirements	0
for	0
synergy	0
in	0
c-fos	3
mRNA	4
induction	0
are	0
paralleled	0
by	0
requirements	0
for	0
synergy	0
in	0
induction	0
of	0
AP-1	9
activity	0
.	0

Signaling	0
in	0
B	7
cells	8
due	0
to	0
anti-Ig	9
stimulation	0
involves	0
both	0
kinase	9
C	10
activation	0
and	0
release	0
of	0
intracellular	0
calcium	0
,	0
and	0
results	0
in	0
c-fos	3
mRNA	4
induction	0
.	0

Our	0
results	0
indicate	0
that	0
synergy	0
between	0
the	0
kinase	9
C	10
activation	0
and	0
calcium	0
is	0
needed	0
for	0
efficient	0
c-fos	1
induction	0
since	0
neither	0
of	0
these	0
two	0
alone	0
induces	0
c-fos	1
well	0
.	0

That	0
synergy	0
of	0
signaling	0
pathways	0
is	0
relevant	0
for	0
the	0
anti-Ig	9
induction	0
of	0
c-fos	1
is	0
supported	0
by	0
the	0
fact	0
that	0
cAMP-inducing	0
agents	0
and	0
okadaic	0
acid	0
further	0
enhance	0
anti-Ig	9
induction	0
of	0
c-fos	1
.	0

These	0
results	0
suggest	0
that	0
cell-specific	0
patterns	0
of	0
synergy	0
are	0
an	0
essential	0
feature	0
for	0
c-fos	1
induction	0
and	0
may	0
be	0
relevant	0
for	0
c-fos	1
control	0
through	0
B	9
and	10
T	10
cell	10
antigen	10
receptors	10
.	0

Multiple	0
signals	0
are	0
required	0
for	0
function	0
of	0
the	0
human	1
granulocyte-macrophage	2
colony-stimulating	2
factor	2
gene	2
promoter	2
in	0
T	7
cells	8
.	0

The	0
human	1
granulocyte-macrophage	2
CSF	2
(	2
GM-CSF	2
)	2
gene	2
is	0
expressed	0
in	0
T	7
cells	8
in	0
response	0
to	0
TCR	9
activation	0
that	0
can	0
be	0
mimicked	0
by	0
treatment	0
of	0
the	0
cells	0
with	0
PMA	0
and	0
Ca2+	0
ionophore	0
.	0

The	0
gene	0
contains	0
a	0
proximal	1
functional	2
promoter	2
region	2
(	0
-620	1
to	2
+34	2
)	0
,	0
as	0
well	0
as	0
a	0
powerful	0
enhancer	1
located	0
3	0
kb	0
upstream	0
,	0
both	0
of	0
which	0
are	0
involved	0
in	0
the	0
response	0
of	0
the	0
gene	0
to	0
TCR	9
activation	0
.	0

The	0
proximal	1
promoter	2
contains	0
a	0
region	0
termed	0
CLEO	1
(	0
-54	1
to	2
-31	2
)	0
that	0
consists	0
of	0
a	0
purine-rich	1
element	2
abutting	0
an	0
activator	1
protein-1	2
(	2
AP-1	2
)	2
-like	2
site	2
,	0
as	0
well	0
as	0
an	0
upstream	1
nuclear	2
factor-kappa	2
B	2
(	2
NF-kappa	2
B	2
)	2
site	2
(	0
-85	1
to	2
-76	2
)	0
and	0
a	0
CK-1	1
element	2
(	0
-101	1
to	2
-92	2
)	0
.	0

We	0
show	0
in	0
this	0
work	0
that	0
mutations	0
in	0
either	0
the	0
purine-rich	1
region	2
of	0
the	0
CLEO	1
element	2
or	0
the	0
NF-kappa	1
B	2
site	2
result	0
in	0
reduced	0
PMA/Ca2+	0
activation	0
of	0
a	0
620-bp	1
human	2
GM-CSF	2
promoter-luciferase	2
reporter	2
construct	2
in	0
Jurkat	5
T	6
cells	6
by	0
65	0
%	0
and	0
50	0
%	0
,	0
respectively	0
.	0

The	0
major	0
inducible	9
protein	10
complex	10
that	0
binds	0
to	0
the	0
human	1
CLEO	2
(	2
hCLEO	2
)	2
element	2
is	0
an	0
AP-1-like	9
complex	10
that	0
is	0
inducible	0
by	0
PMA	0
alone	0
,	0
but	0
shows	0
increased	0
binding	0
in	0
response	0
to	0
PMA	0
together	0
with	0
Ca2+	0
ionophore	0
.	0

Although	0
the	0
binding	0
of	0
this	0
complex	0
is	0
not	0
cyclosporin-sensitive	0
,	0
promoter	0
induction	0
is	0
inhibited	0
by	0
cyclosporin	0
treatment	0
.	0

A	0
second	0
weak	0
inducible	0
complex	0
resembling	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
was	0
also	0
observed	0
binding	0
to	0
the	0
hCLEO	1
region	2
.	0

By	0
using	0
recombinant	9
proteins	10
,	0
we	0
confirmed	0
that	0
AP-1	9
,	0
NF-ATp	9
,	0
and	0
a	0
higher	0
order	0
NF-ATp/AP-1	9
complex	10
could	0
all	0
form	0
with	0
the	0
hCLEO	1
element	2
,	0
and	0
we	0
have	0
also	0
defined	0
the	0
sequence	0
requirements	0
for	0
binding	0
of	0
each	0
of	0
these	0
complexes	0
.	0

We	0
found	0
that	0
expression	0
of	0
a	0
constitutively	0
active	0
form	0
of	0
calcineurin	9
could	0
substitute	0
for	0
Ca2+	0
ionophore	0
and	0
synergize	0
with	0
PMA	0
to	0
activate	0
the	0
GM-CSF	1
promoter	2
,	0
and	0
conversely	0
that	0
mutant-activated	9
Ras	10
could	0
substitute	0
for	0
PMA	0
and	0
cooperate	0
with	0
Ca2+	0
ionophore	0
.	0

Co-expression	0
of	0
Ras	9
and	0
calcineurin	9
,	0
however	0
,	0
did	0
not	0
activate	0
the	0
GM-CSF	1
promoter	2
,	0
but	0
required	0
the	0
additional	0
expression	0
of	0
NF-kappa	9
B	10
p65	10
.	0

These	0
results	0
imply	0
that	0
at	0
least	0
three	0
signals	0
are	0
required	0
to	0
activate	0
the	0
GM-CSF	1
proximal	2
promoter	2
,	0
and	0
that	0
the	0
signals	0
impinge	0
on	0
distinct	0
transcription	9
factors	10
that	0
bind	0
to	0
the	0
hCLEO	1
and	2
NF-kappa	2
B	2
regions	2
of	0
the	0
promoter	1
.	0

IL-10	0
induces	0
the	0
tyrosine	0
phosphorylation	0
of	0
tyk2	9
and	0
Jak1	9
and	0
the	0
differential	0
assembly	0
of	0
STAT1	9
alpha	10
and	0
STAT3	9
complexes	10
in	0
human	7
T	8
cells	8
and	0
monocytes	7
.	0

IL-10	9
affects	0
monocytes	7
and	0
T	7
cells	8
by	0
driving	0
the	0
progression	0
of	0
immune	0
responsiveness	0
such	0
that	0
Th2	0
lymphocyte-mediated	0
effects	0
predominate	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
in	0
monocytes	7
and	0
T	7
cells	8
IL-10	9
stimulates	0
tyrosine	0
phosphorylation	0
of	0
the	0
signal	9
transducers	10
and	0
activators	9
of	10
transcription	10
,	0
STAT1	9
alpha	10
and	0
STAT3	9
,	0
in	0
a	0
differential	0
manner	0
such	0
that	0
the	0
relative	0
formation	0
of	0
homo-	9
and	10
heterodimers	10
varies	0
between	0
the	0
two	0
cell	0
types	0
.	0

Moreover	0
,	0
monocytes	7
express	0
a	0
novel	0
IL-10-stimulated	9
STAT	10
protein	10
with	0
an	0
M	0
(	0
r	0
)	0
of	0
70	9
kDa	10
that	0
is	0
recognized	0
by	0
the	0
anti-STAT3	9
Ab	10
but	0
is	0
not	0
observed	0
in	0
T	7
cells	8
.	0

IL-10	9
treatment	0
of	0
both	0
T	7
cells	8
and	0
monocytes	7
results	0
in	0
the	0
ligand-induced	0
tyrosine	0
phosphorylation	0
of	0
tyk2	9
and	0
Jak1	9
,	0
but	0
not	0
Jak2	9
or	0
Jak3	9
.	0

Selective	0
modulation	0
of	0
immune	0
responsiveness	0
by	0
IL-10	9
in	0
cells	0
such	0
as	0
monocytes	7
and	0
T	7
cells	8
may	0
result	0
in	0
part	0
from	0
the	0
differential	0
activation	0
of	0
STAT	9
protein	10
pairs	10
.	0

Use	0
of	0
new	0
biologic	0
markers	0
in	0
the	0
ovulation	0
induction	0
.	0

Biological	0
markers	0
of	0
ovulation	0
,	0
after	0
a	0
great	0
in	0
the	0
past	0
,	0
have	0
been	0
fallen	0
into	0
disuse	0
for	0
the	0
large	0
diffusion	0
of	0
biochemical	0
and	0
biophysical	0
ones	0
.	0

However	0
,	0
the	0
real	0
effect	0
of	0
hormones	0
involved	0
in	0
ovulation	0
is	0
expressed	0
by	0
biological	0
modifications	0
on	0
target	7
tissues	8
.	0

To	0
explore	0
the	0
modifications	0
of	0
not	0
reproductive	0
target	0
tissues	0
as	0
ovulation	0
markers	0
we	0
studied	0
the	0
behaviour	0
of	0
Albuminemia	0
,	0
Platelet	9
Factor	10
IV	10
(	0
as	0
indicator	0
of	0
Platelet	0
Aggregation	0
)	0
,	0
Type	9
II	10
estrogenic	10
receptors	10
in	0
42	0
ovulation	0
induced	0
women	0
,	0
undergoing	0
our	0
observation	0
.	0

33	0
of	0
them	0
had	0
ovulation	0
and	0
9	0
developed	0
a	0
LUF	0
syndrome	0
,	0
constituting	0
two	0
biological	0
models	0
of	0
an	0
opposite	0
situation	0
for	0
the	0
three	0
markers	0
observed	0
.	0

All	0
the	0
markers	0
considered	0
were	0
sufficiently	0
sensitive	0
,	0
but	0
among	0
them	0
,	0
Platelet	9
Factor	10
IV	10
was	0
the	0
most	0
reliable	0
to	0
the	0
hormonal	0
ovulatory	0
situation	0
.	0

Abnormal	0
regulation	0
of	0
the	0
IL-2	1
promoter	2
in	0
lpr	0
CD4-CD8-	5
T	6
lymphocytes	6
results	0
in	0
constitutive	0
expression	0
of	0
a	0
novel	9
nuclear	10
factor	10
of	10
activated	10
T	10
cells-binding	10
factor	10
.	0

The	0
inert	0
quality	0
of	0
MRL-Ipr/Ipr	5
(	6
Ipr	6
)	6
peripheral	6
CD4-CD8-	6
(	6
CD4-8-	6
)	6
T	6
cells	6
manifests	0
primarily	0
as	0
an	0
inability	0
to	0
proliferate	0
or	0
produce	0
IL-2	9
in	0
response	0
to	0
TCR	9
or	0
mitogenic	0
stimulation	0
.	0

Yet	0
these	0
same	0
cells	0
do	0
initiate	0
early	0
TCR	9
-mediated	0
signaling	0
events	0
,	0
such	0
as	0
generation	0
of	0
inositol	0
phosphates	0
and	0
increased	0
intracellular	0
calcium	0
.	0

They	0
also	0
display	0
constitutively	0
high	0
levels	0
of	0
p59fyn	9
and	0
CD3	9
zeta	10
tyrosine	0
phosphorylation	0
.	0

The	0
generation	0
of	0
second	0
messengers	0
in	0
T	7
cells	8
normally	0
leads	0
to	0
downstream	0
signaling	0
that	0
results	0
in	0
transcriptional	0
activation	0
of	0
the	0
IL-2	1
gene	2
.	0

We	0
,	0
therefore	0
,	0
compared	0
the	0
activation	0
state	0
of	0
the	0
IL-2	1
gene	2
promoter	2
region	2
in	0
freshly	0
isolated	0
and	0
stimulated	0
Ipr	5
CD4-8-	6
T	6
cells	6
with	0
that	0
of	0
normal	7
T	8
lymphocytes	8
.	0

Levels	0
of	0
the	0
octamer	0
,	0
NF-kappa	9
B	10
(	0
p50-p65	9
heterodimer	10
)	0
,	0
and	0
AP-1	9
transcriptional	10
factors	10
are	0
constitutively	0
elevated	0
in	0
freshly	0
isolated	0
Ipr	5
CD4-8-	6
T	6
cells	6
,	0
consistent	0
with	0
the	0
activated	0
phenotype	0
of	0
these	0
cells	0
.	0

Upon	0
stimulation	0
with	0
mitogens	0
,	0
formation	0
of	0
the	0
transactivating	0
complex	0
,	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
,	0
occurs	0
with	0
normal	0
kinetics	0
in	0
Ipr	5
CD4-8-	6
T	6
cells	6
.	0

Yet	0
,	0
the	0
levels	0
of	0
the	0
activating	0
NF-AT	9
complex	10
never	0
reach	0
those	0
observed	0
in	0
similarly	0
stimulated	0
normal	0
T	7
cells	8
.	0

Furthermore	0
,	0
nuclear	0
extracts	0
from	0
Ipr	5
CD4-8-	6
T	6
cells	6
display	0
high	0
levels	0
of	0
a	0
novel	0
specific	0
binding	0
activity	0
at	0
the	0
NF-AT	1
site	2
,	0
which	0
is	0
present	0
at	0
much	0
lower	0
levels	0
in	0
freshly	0
isolated	0
normal	7
T	8
lymphocytes	8
.	0

Upon	0
mitogenic	0
stimulation	0
,	0
the	0
binding	0
activity	0
of	0
the	0
novel	0
NF-AT-binding	9
factor	10
is	0
rapidly	0
down-regulated	0
in	0
normal	0
T	7
cells	8
,	0
but	0
persists	0
at	0
high	0
levels	0
in	0
Ipr	5
CD4-8-	6
T	6
cells	6
.	0

These	0
two	0
abnormalities	0
at	0
the	0
NF-AT	1
site	2
provide	0
a	0
potential	0
mechanism	0
to	0
account	0
for	0
the	0
defect	0
in	0
IL-2	9
production	0
from	0
Ipr	5
CD4-8-	6
T	6
cells	6
.	0

Cross-linking	0
of	0
CD30	9
induces	0
HIV	0
expression	0
in	0
chronically	0
infected	0
T	7
cells	8
.	0

CD30	9
,	0
a	0
member	0
of	0
the	0
tumor	0
necrosis	0
factor	0
(	0
TNF	0
)	0
receptor	0
family	0
,	0
is	0
expressed	0
constitutively	0
on	0
the	0
surface	0
of	0
the	0
human	0
T	0
cell	0
line	0
ACH-2	0
,	0
which	0
is	0
chronically	0
infected	0
with	0
human	0
immunodeficiency	0
virus	0
type-1	0
(	0
HIV	0
)	0
-1	0
.	0

We	0
demonstrate	0
that	0
cross-linking	0
CD30	9
with	0
an	0
anti-	0
CD30	9
-specific	0
monoclonal	0
antibody	0
,	0
which	0
mimics	0
the	0
described	0
biological	0
activities	0
of	0
the	0
CD30	9
ligand	10
(	0
CD30L	9
)	0
,	0
results	0
in	0
HIV	0
expression	0
.	0

CD30	9
cross-linking	0
does	0
not	0
alter	0
proliferation	0
of	0
ACH-2	5
cells	6
and	0
the	0
induction	0
of	0
HIV	0
expression	0
is	0
not	0
mediated	0
by	0
endogenous	0
TNF	9
alpha/beta	10
.	0

Furthermore	0
,	0
cross-linking	0
of	0
CD30	9
leads	0
to	0
NF-kappa	9
B	10
activation	0
and	0
enhanced	0
HIV	0
transcription	0
.	0

Thus	0
,	0
CD30	9
-CD30L	9
interactions	0
mediate	0
the	0
induction	0
of	0
HIV	0
expression	0
by	0
a	0
kappa	0
B-dependent	0
pathway	0
that	0
is	0
independent	0
of	0
TNF	9
.	0

This	0
mechanism	0
may	0
be	0
important	0
in	0
the	0
activation	0
of	0
HIV	0
expression	0
from	0
latently	0
infected	0
CD4+	5
T	6
cells	6
,	0
especially	0
in	0
lymphoid	0
organs	0
where	0
cell	0
to	0
cell	0
contact	0
is	0
conducive	0
to	0
receptor-ligand	0
interactions	0
.	0

Human	0
MHC	1
class	2
II	2
gene	2
transcription	0
directed	0
by	0
the	0
carboxyl	9
terminus	10
of	0
CIITA	1
,	0
one	0
of	0
the	0
defective	1
genes	2
in	0
type	0
II	0
MHC	9
combined	0
immune	0
deficiency	0
.	0

Type	9
II	10
major	10
histocompatibility	10
complex	10
combined	0
immune	0
deficiency	0
(	0
type	0
II	0
MHC	9
CID	0
or	0
bare	0
lymphocyte	0
syndrome	0
)	0
is	0
a	0
congenital	0
immunodeficiency	0
disease	0
characterized	0
by	0
absent	0
MHC	9
class	10
II	10
expression	0
.	0

Four	0
distinct	0
complementation	0
groups	0
have	0
been	0
identified	0
.	0

Recently	0
,	0
the	0
defective	1
gene	2
in	0
group	0
II	0
type	0
II	0
MHC	9
CID	0
has	0
been	0
isolated	0
and	0
termed	0
CIITA	1
.	0

Here	0
,	0
we	0
demonstrate	0
that	0
CIITA	1
is	0
an	0
MHC	1
class	2
II	2
gene-specific	2
transcription	2
activator	2
.	0

The	0
transcription	0
activation	0
function	0
is	0
provided	0
by	0
the	0
N-terminal	9
acidic	10
domain	10
(	0
amino	9
acids	10
26-137	10
)	0
,	0
which	0
is	0
experimentally	0
exchangeable	0
with	0
a	0
heterologous	9
viral	10
transcription-activating	10
domain	10
.	0

The	0
specificity	0
of	0
CIITA	9
for	0
three	0
major	0
MHC	1
class	2
II	2
genes	2
,	0
DR	1
,	0
DQ	1
and	0
DP	1
,	0
is	0
mediated	0
by	0
its	0
remaining	0
C-terminal	9
residues	10
(	0
amino	9
acids	10
317-1130	10
)	0
.	0

The	0
transactivation	0
of	0
multiple	1
cis	2
elements	2
,	0
especially	0
S	1
and	0
X2	1
,	0
of	0
the	0
DR	1
alpha	2
proximal	2
promoter	2
in	0
group	5
II	6
CID	6
cells	6
is	0
CIITA	9
dependent	0
.	0

Since	0
CIITA	9
overexpression	0
in	0
normal	7
cells	8
did	0
not	0
increase	0
class	0
II	0
expression	0
,	0
we	0
propose	0
that	0
initiation	0
of	0
CIITA	9
expression	0
serves	0
as	0
the	0
on-off	0
switch	0
,	0
while	0
availability	0
of	0
downstream	0
interactor	0
(	0
s	0
)	0
limits	0
transcription	0
.	0

Monocyte	0
tethering	0
by	0
P-selectin	9
regulates	0
monocyte	9
chemotactic	10
protein-1	10
and	0
tumor	9
necrosis	10
factor-alpha	10
secretion	0
.	0

Signal	0
integration	0
and	0
NF-kappa	9
B	10
translocation	0
[	0
see	0
comments	0
]	0

Adhesion	9
molecules	10
that	0
tether	0
circulating	7
leukocytes	8
to	0
endothelial	7
cells	8
may	0
also	0
transduce	0
or	0
modulate	0
outside-in	0
signals	0
for	0
cellular	0
activation	0
,	0
providing	0
an	0
initial	0
regulatory	0
point	0
in	0
the	0
inflammatory	0
response	0
.	0

Adhesion	0
of	0
human	7
monocytes	8
to	0
P-selectin	9
,	0
the	0
most	0
rapidly	0
expressed	0
endothelial	9
tethering	10
factor	10
,	0
increased	0
the	0
secretion	0
of	0
monocyte	9
chemotactic	10
protein-1	10
(	0
MCP-1	9
)	0
and	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
by	0
the	0
leukocytes	7
when	0
they	0
were	0
stimulated	0
with	0
platelet-activating	9
factor	10
.	0

Increased	0
cytokine	0
secretion	0
was	0
specifically	0
inhibited	0
by	0
G1	9
,	0
an	0
anti-P-selectin	9
mAb	10
that	0
prevents	0
P-selectin	9
from	0
binding	0
to	0
its	0
ligand	0
(	0
P-selectin	9
glycoprotein	10
ligand-1	10
)	0
on	0
myeloid	7
cells	8
.	0

Moreover	0
,	0
tethering	0
by	0
P-selectin	9
specifically	0
enhanced	0
nuclear	0
translocation	0
of	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
a	0
transcription	9
factor	10
required	0
for	0
expression	0
of	0
MCP-1	9
,	0
TNF-alpha	9
,	0
and	0
other	0
immediate-early	1
genes	2
.	0

These	0
results	0
demonstrate	0
that	0
P-selectin	9
,	0
through	0
its	0
ligands	0
on	0
monocytes	7
,	0
may	0
locally	0
regulate	0
cytokine	9
secretion	0
in	0
inflamed	0
tissues	0
.	0

Functional	0
roles	0
of	0
in	1
vivo	2
footprinted	2
DNA	2
motifs	2
within	0
an	0
alpha-globin	1
enhancer	2
.	0

Erythroid	0
lineage	0
and	0
developmental	0
stage	0
specificities	0
.	0

Transcriptional	0
regulation	0
of	0
the	0
human	1
alpha-like	2
globin	2
genes	2
,	0
embryonic	1
zeta	2
2	2
and	0
adult	1
alpha	2
,	0
during	0
erythroid	0
development	0
is	0
mediated	0
by	0
a	0
distal	1
enhancer	2
,	0
HS-40	1
.	0

Previous	0
protein-DNA	0
binding	0
studies	0
have	0
shown	0
that	0
HS-40	1
consists	0
of	0
multiple	0
nuclear	1
factor	2
binding	2
motifs	2
that	0
are	0
occupied	0
in	0
vivo	0
in	0
an	0
erythroid	0
lineage-	0
and	0
developmental	0
stage-specific	0
manner	0
.	0

We	0
have	0
systematically	0
analyzed	0
the	0
functional	0
roles	0
of	0
these	0
factor	1
binding	2
motifs	2
of	0
HS-40	1
by	0
site-directed	0
mutagenesis	0
and	0
transient	0
expression	0
assay	0
in	0
erythroid	5
cell	6
cultures	6
.	0

Three	0
of	0
these	0
HS-40	1
enhancer	2
motifs	2
,	0
5'NF-E2/AP1	1
,	0
GT	1
II	2
,	0
and	0
GATA-1	1
(	2
c	2
)	2
,	0
positively	0
regulate	0
the	0
zeta	1
2-globin	2
promoter	2
activity	0
in	0
embryonic/fetal	5
erythroid	6
K562	6
cells	6
and	0
the	0
adult	1
alpha-globin	2
promoter	2
activity	0
in	0
adult	5
erythroid	6
MEL	6
cells	6
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
3'NF-E2/AP1	1
motif	2
is	0
able	0
to	0
exert	0
both	0
positive	0
and	0
negative	0
regulatory	0
effects	0
on	0
the	0
zeta	1
2-globin	2
promoter	2
activity	0
in	0
K562	5
cells	6
,	0
and	0
this	0
dual	0
function	0
appears	0
to	0
be	0
modulated	0
through	0
differential	0
binding	0
of	0
the	0
ubiquitous	9
AP1	10
factors	10
and	0
the	0
erythroid-enriched	9
NF-E2	10
factor	10
.	0

Mutation	0
in	0
the	0
GATA-1	1
(	2
d	2
)	2
motif	2
,	0
which	0
exhibits	0
an	0
adult	1
erythroid-specific	2
genomic	2
footprint	2
,	0
decreases	0
the	0
HS-40	1
enhancer	2
function	0
in	0
dimethyl	5
sulfoxide-induced	6
MEL	6
cells	6
but	0
not	0
in	0
K562	5
cells	6
.	0

These	0
studies	0
have	0
defined	0
the	0
regulatory	0
roles	0
of	0
the	0
different	0
HS-40	1
motifs	2
.	0

The	0
remarkable	0
correlation	0
between	0
genomic	0
footprinting	0
data	0
and	0
the	0
mutagenesis	0
results	0
also	0
suggests	0
that	0
the	0
erythroid	0
lineage-	0
and	0
developmental	0
stage-specific	0
regulation	0
of	0
human	1
alpha-like	2
globin	2
promoters	2
is	0
indeed	0
modulated	0
by	0
stable	0
binding	0
of	0
specific	9
nuclear	10
factors	10
in	0
vivo	0
.	0

Nitric	0
oxide-stimulated	0
guanine	0
nucleotide	0
exchange	0
on	0
p21ras	9
.	0

The	0
protooncogene	1
p21ras	2
,	0
a	0
monomeric	9
G	10
protein	10
family	10
member	10
,	0
plays	0
a	0
critical	0
role	0
in	0
converting	0
extracellular	0
signals	0
into	0
intracellular	0
biochemical	0
events	0
.	0

Here	0
,	0
we	0
report	0
that	0
nitric	0
oxide	0
(	0
NO	0
)	0
activates	0
p21ras	1
in	0
human	7
T	8
cells	8
as	0
evidenced	0
by	0
an	0
increase	0
in	0
GTP-bound	9
p21ras	10
.	0

In	0
vitro	0
studies	0
using	0
pure	9
recombinant	10
p21ras	10
demonstrate	0
that	0
the	0
activation	0
is	0
direct	0
and	0
reversible	0
.	0

Circular	0
dichroism	0
analysis	0
reveals	0
that	0
NO	0
induces	0
a	0
profound	0
conformational	0
change	0
in	0
p21ras	1
in	0
association	0
with	0
GDP/GTP	0
exchange	0
.	0

The	0
mechanism	0
of	0
activation	0
is	0
due	0
to	0
S-nitrosylation	0
of	0
a	0
critical	0
cysteine	0
residue	0
which	0
stimulates	0
guanine	0
nucleotide	0
exchange	0
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
p21ras	9
is	0
essential	0
for	0
NO-induced	0
downstream	0
signaling	0
,	0
such	0
as	0
NF-kappa	9
B	10
activation	0
,	0
and	0
that	0
endogenous	0
NO	0
can	0
activate	0
p21ras	9
in	0
the	0
same	0
cell	0
.	0

These	0
studies	0
identify	0
p21ras	1
as	0
a	0
target	0
of	0
the	0
same	0
cell	0
.	0

These	0
studies	0
identify	0
p21ras	1
as	0
a	0
target	0
of	0
NO	0
in	0
T	7
cells	8
and	0
suggest	0
that	0
NO	0
activates	0
p21ras	1
by	0
an	0
action	0
which	0
mimics	0
that	0
of	0
guanine	9
nucleotide	10
exchange	10
factors	10
.	0

Interleukin-2	1
promoter	2
activity	0
in	0
Epstein-Barr	5
virus-transformed	6
B	6
lymphocytes	6
is	0
controlled	0
by	0
nuclear	9
factor-chi	10
B	10
.	0

The	0
regulation	0
of	0
interleukin	1
(	2
IL	2
)	2
-2	2
gene	2
expression	0
has	0
been	0
investigated	0
mainly	0
in	0
T	7
lymphocytes	8
,	0
the	0
predominant	0
producers	0
of	0
IL-2	9
.	0

However	0
,	0
B	7
cells	8
can	0
also	0
synthesize	0
IL-2	9
.	0

In	0
the	0
present	0
study	0
we	0
analyzed	0
the	0
control	0
of	0
IL-2	1
promoter	2
activity	0
in	0
Epstein-Barr	5
virus	6
(	6
EBV	6
)	6
-transformed	6
B	6
cell	6
clones	6
which	0
are	0
capable	0
of	0
secreting	0
IL-2	9
at	0
a	0
low	0
level	0
after	0
stimulation	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
the	0
Ca2+	0
ionophore	0
ionomycin	0
.	0

Transient	0
transfections	0
using	0
reporter	1
constructs	2
with	0
multiples	0
of	0
transcription	1
factor	2
binding	2
sites	2
from	0
the	0
IL-2	1
promoter	2
[	0
distal	9
nuclear	10
factor	10
(	10
NF	10
)	10
-AT	10
,	0
proximal	9
NF-AT	10
,	0
AP-1/Octamer	9
(	0
UPS	9
)	0
or	0
NF-chi	9
B	10
(	0
TCEd	9
)	0
sites	0
]	0
were	0
performed	0
.	0

In	0
EBV-transformed	5
B	6
clones	6
,	0
the	0
chi	1
B	2
site	2
exerted	0
the	0
strongest	0
inducible	0
activity	0
;	0
the	0
NF-AT	1
binding	2
sites	2
showed	0
either	0
no	0
or	0
only	0
weak	0
activity	0
compared	0
to	0
Jurkat	5
T	6
cells	6
.	0

An	0
IL-2	1
promoter	2
bearing	0
a	0
defective	0
NF-chi	1
B	2
site	2
was	0
completely	0
inactive	0
in	0
EBV-transformed	5
B	6
cells	6
,	0
while	0
it	0
still	0
had	0
activity	0
in	0
Jurkat	5
T	6
cells	6
.	0

In	0
seven	0
EBV-B	5
cell	6
clones	6
or	0
lines	0
differing	0
in	0
their	0
capacity	0
to	0
secrete	0
IL-2	9
,	0
the	0
activity	0
of	0
the	0
IL-2	1
promoter	2
correlated	0
well	0
with	0
the	0
status	0
of	0
IL-2	9
secretion	0
.	0

Similarly	0
,	0
a	0
human	1
immunodeficiency	2
virus	2
promoter	2
,	0
whose	0
activity	0
is	0
controlled	0
through	0
chi	9
B	10
factors	10
,	0
was	0
found	0
to	0
be	0
active	0
in	0
the	0
IL-2	5
producing	6
EBV-B	6
cells	6
,	0
but	0
inactive	0
in	0
the	0
non-IL-2-producing	5
cells	6
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
using	0
protein	0
extracts	0
from	0
EBV-B	5
cells	6
and	0
the	0
IL-2	9
NF-chi	9
B	10
probe	0
revealed	0
the	0
constitutive	0
generation	0
of	0
chi	9
B	10
complexes	10
in	0
IL-2-secreting	5
cells	6
consisting	0
mainly	0
of	0
heterodimeric	9
p50/p65	10
complexes	10
.	0

A	0
weaker	0
chi	1
B	2
complex	0
formation	0
and	0
faster-migrating	0
complexes	0
were	0
detected	0
in	0
non-IL-2-secreting	5
cells	6
.	0

These	0
results	0
demonstrate	0
that	0
the	0
IL-2	1
NF-chi	2
B	2
site	2
is	0
indispensable	0
for	0
the	0
activity	0
of	0
the	0
IL-2	1
promoter	2
in	0
EBV-transformed	5
B	6
cells	6
,	0
whereas	0
other	0
transcription	9
factors	10
appear	0
to	0
be	0
less	0
important	0
for	0
IL-2	9
expression	0
in	0
these	0
cells	0
.	0

Latent	9
membrane	10
protein-1	10
induces	0
cyclin	9
D2	10
expression	0
,	0
pRb	9
hyperphosphorylation	0
,	0
and	0
loss	0
of	0
TGF-beta	9
1	10
-mediated	0
growth	0
inhibition	0
in	0
EBV-positive	7
B	8
cells	8
.	0

The	0
normal	0
cell	0
cycle	0
is	0
regulated	0
by	0
several	0
molecules	0
,	0
such	0
as	0
the	0
tumor-suppressor	9
protein	10
pRb	10
,	0
the	0
G1	9
cyclins	10
,	0
the	0
cyclin-dependent	9
kinases	10
,	0
and	0
their	0
inhibitors	0
.	0

These	0
regulators	0
are	0
targeted	0
by	0
negative	0
growth	0
regulatory	0
signals	0
,	0
such	0
as	0
that	0
provided	0
by	0
TGF-beta	9
.	0

Here	0
,	0
we	0
show	0
that	0
the	0
presence	0
of	0
either	0
wild-type	0
EBV	0
or	0
its	0
transforming	9
latent	10
membrane	10
protein-1	10
(	0
LMP-1	9
)	0
results	0
in	0
the	0
loss	0
of	0
TGF-beta	9
1	10
-mediated	0
growth	0
inhibition	0
in	0
human	7
B	8
cells	8
.	0

Chemical	0
cross-linking	0
with	0
125I-labeled	9
TGF-beta	10
1	10
showed	0
an	0
essentially	0
normal	0
TGF-beta	9
receptor	10
profile	0
in	0
EBV-positive	5
and	6
EBV-negative	6
Burkitt	6
's	6
lymphoma	6
cell	6
lines	6
,	0
and	0
these	0
receptors	0
were	0
shown	0
to	0
be	0
functional	0
in	0
transducing	0
signals	0
,	0
as	0
evidenced	0
by	0
the	0
TGF-beta	9
1	10
-mediated	0
modulation	0
of	0
junB	1
gene	2
expression	0
.	0

However	0
,	0
TGF-beta	9
1	10
did	0
not	0
induce	0
dephosphorylation	0
of	0
pRb	9
in	0
EBV	5
(	6
or	6
LMP-1	6
)	6
-positive	6
cells	6
as	0
opposed	0
to	0
EBV-negative	5
cells	6
,	0
suggesting	0
a	0
dichotomy	0
in	0
the	0
TGF-beta	9
1	10
signaling	0
pathway	0
leading	0
to	0
separable	0
gene	0
regulatory	0
and	0
growth	0
inhibitory	0
responses	0
.	0

Furthermore	0
,	0
LMP-1	9
was	0
found	0
to	0
induce	0
the	0
expression	0
of	0
cyclin	9
D2	10
;	0
normal	0
B	7
cells	8
or	0
EBV-negative	5
Burkitt	6
's	6
lymphoma	6
cells	6
do	0
not	0
express	0
D-type	9
cyclins	10
.	0

Taken	0
together	0
,	0
these	0
data	0
point	0
to	0
a	0
potential	0
mechanism	0
underlying	0
EBV-mediated	0
B	0
cell	0
transformation	0
whereby	0
constitutive	0
induction	0
of	0
key	9
cell	10
cycle	10
regulators	10
by	0
LMP-1	9
can	0
lead	0
to	0
pRb	9
hyperphosphorylation	0
and	0
uncontrolled	0
cell	0
proliferation	0
.	0

Does	0
thyroidectomy	0
,	0
radioactive	0
iodine	0
therapy	0
,	0
or	0
antithyroid	0
drug	0
treatment	0
alter	0
reactivity	0
of	0
patients	0
'	0
T	7
cells	8
to	0
epitopes	0
of	0
thyrotropin	9
receptor	10
in	0
autoimmune	0
thyroid	0
diseases	0
?	0

The	0
effect	0
of	0
treatment	0
on	0
thyroid	0
antibody	0
production	0
and	0
T	0
cell	0
reactivity	0
to	0
thyroid	0
antigens	0
was	0
studied	0
in	0
15	0
patients	0
with	0
Graves	0
'	0
disease	0
(	0
GD	0
)	0
before	0
and	0
after	0
thyroidectomy	0
,	0
19	0
patients	0
with	0
GD	0
before	0
and	0
after	0
radioactive	0
iodine	0
(	0
RAI	0
)	0
therapy	0
,	0
and	0
9	0
patients	0
maintained	0
euthyroid	0
on	0
antithyroid	0
drugs	0
(	0
ATD	0
)	0
.	0

Twenty	0
subjects	0
matched	0
for	0
age	0
and	0
sex	0
without	0
known	0
thyroid	0
disease	0
served	0
as	0
controls	0
.	0

In	0
GD	0
patients	0
,	0
the	0
responses	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
and	0
TSH	5
receptor	6
(	6
TSHR	6
)	6
-specific	6
T	6
cell	6
lines	6
to	0
recombinant	9
human	10
TSHR	10
extracellular	10
domain	10
,	0
thyroglobulin	9
,	0
and	0
TSHR	9
peptides	0
were	0
examined	0
on	0
the	0
day	0
of	0
surgery	0
or	0
RAI	0
therapy	0
(	0
day	0
0	0
)	0
and	0
also	0
6-8	0
weeks	0
and	0
3-6	0
months	0
thereafter	0
.	0

Reactivity	0
to	0
TSHR	9
peptides	0
before	0
surgery	0
was	0
heterogeneous	0
and	0
spanned	0
the	0
entire	0
extracellular	9
domain	10
.	0

Six	0
to	0
8	0
weeks	0
after	0
subtotal	0
thyroidectomy	0
,	0
the	0
number	0
of	0
patients	0
'	0
PBMC	7
responding	0
to	0
any	0
peptide	0
and	0
the	0
average	0
number	0
of	0
recognized	0
peptides	0
decreased	0
.	0

A	0
further	0
decrease	0
in	0
the	0
T	0
cell	0
reactivity	0
to	0
TSHR	9
peptides	0
was	0
observed	0
3-6	0
months	0
after	0
surgery	0
.	0

The	0
responses	0
of	0
PBMC	7
from	0
Graves	0
'	0
patients	0
before	0
RAI	0
therapy	0
were	0
less	0
than	0
those	0
in	0
the	0
presurgical	0
group	0
.	0

Six	0
to	0
8	0
weeks	0
after	0
RAI	0
therapy	0
,	0
the	0
number	0
of	0
patients	0
responding	0
to	0
any	0
peptide	0
and	0
the	0
average	0
number	0
of	0
recognized	0
peptides	0
increased	0
.	0

Three	0
to	0
6	0
months	0
after	0
RAI	0
,	0
T	0
cell	0
responses	0
to	0
TSHR	9
peptides	0
were	0
less	0
than	0
those	0
6-8	0
weeks	0
after	0
RAI	0
therapy	0
,	0
but	0
still	0
higher	0
than	0
the	0
values	0
on	0
day	0
0	0
.	0

Responses	0
of	0
PBMC	7
from	0
patients	0
with	0
GD	0
,	0
maintained	0
euthyroid	0
on	0
ATD	0
,	0
were	0
lower	0
than	0
those	0
before	0
surgery	0
or	0
RAI	0
therapy	0
.	0

The	0
reactivity	0
of	0
T	5
cell	6
lines	6
in	0
different	0
groups	0
reflected	0
a	0
pattern	0
similar	0
to	0
PBMC	7
after	0
treatment	0
.	0

TSHR	9
antibody	10
and	0
microsomal	9
antibody	10
levels	0
decreased	0
after	0
surgery	0
,	0
but	0
increased	0
after	0
RAI	0
therapy	0
.	0

The	0
difference	0
in	0
the	0
number	0
of	0
recognized	0
peptides	0
by	0
patients	0
'	0
PBMC	7
before	0
RAI	0
and	0
surgery	0
may	0
reflect	0
the	0
effect	0
of	0
long	0
term	0
therapy	0
with	0
ATD	0
in	0
the	0
patients	0
before	0
RAI	0
vs.	0
the	0
shorter	0
period	0
in	0
patients	0
before	0
surgery	0
.	0

The	0
decreased	0
T	0
cell	0
reactivity	0
to	0
thyroid	9
antigens	10
after	0
thyroidectomy	0
could	0
be	0
the	0
result	0
of	0
removal	0
of	0
a	0
major	0
part	0
of	0
the	0
thyroid	0
gland	0
or	0
redistribution	0
of	0
suppressor-inducer	0
T	7
cells	8
.	0

The	0
increased	0
T	0
cell	0
response	0
after	0
RAI	0
therapy	0
is	0
probably	0
epitope	0
specific	0
,	0
rather	0
than	0
a	0
response	0
to	0
the	0
whole	0
TSHR	9
molecule	0
.	0

Synchronous	0
recognition	0
of	0
peptides	0
158-176	0
and	0
248-263	0
is	0
important	0
for	0
the	0
development	0
of	0
GD	0
,	0
and	0
the	0
loss	0
of	0
recognition	0
of	0
one	0
of	0
these	0
epitopes	9
may	0
be	0
an	0
early	0
sign	0
of	0
immune	0
remission	0
and	0
a	0
predictor	0
of	0
euthyroidism	0
.	0

Circumvention	0
of	0
tolerance	0
for	0
the	0
nuclear	9
T	10
cell	10
protein	10
TCF-1	9
by	0
immunization	0
of	0
TCF-1	9
knock-out	0
mice	0
.	0

Molecular	0
events	0
that	0
underlie	0
the	0
well-defined	0
phenotypic	0
changes	0
of	0
the	0
differentiating	7
thymocyte	8
are	0
poorly	0
understood	0
.	0

A	0
candidate	0
gene	0
to	0
control	0
thymocyte	7
differentiation	0
,	0
T	9
cell	10
factor-1	10
(	0
TCF-1	9
)	0
*	0
encodes	0
a	0
DNA-binding	9
protein	10
.	0

Its	0
mRNA	0
expression	0
pattern	0
is	0
complex	0
during	0
embryogenesis	0
,	0
yet	0
restricted	0
to	0
lymphocytes	7
postnatally	0
.	0

Expression	0
studies	0
on	0
TCF-1	9
protein	10
have	0
been	0
hampered	0
by	0
the	0
difficulty	0
to	0
raise	0
antibodies	9
due	0
to	0
extreme	0
evolutionary	0
conservation	0
.	0

TCF-1	9
knock-out	0
mice	0
,	0
generated	0
recently	0
in	0
our	0
laboratory	0
,	0
have	0
strongly	0
decreased	0
numbers	0
of	0
thymocytes	7
,	0
but	0
are	0
otherwise	0
normal	0
.	0

We	0
have	0
used	0
these	0
mice	0
to	0
generate	0
anti-TCF-1	9
antibodies	10
.	0

By	0
immunization	0
with	0
a	0
recombinant	9
fusion	10
protein	10
,	0
we	0
show	0
that	0
TCF-1	9
knock-out	0
mice	0
readily	0
yield	0
antiserum	0
titers	0
against	0
human	0
and	0
mouse	0
TCF-1	0
protein	0
.	0

Wild-type	0
littermates	0
remain	0
unresponsive	0
to	0
TCF-1	9
while	0
they	0
mount	0
a	0
high-titer	0
antibody	0
response	0
to	0
the	0
fusion	9
protein	10
,	0
Maltose	9
Binding	10
Protein	10
(	0
MBP	9
)	0
.	0

Subsequently	0
,	0
TCF-1-specific	5
hybridomas	6
could	0
be	0
prepared	0
from	0
the	0
spleens	0
of	0
immunized	0
knock-out	0
mice	0
.	0

This	0
study	0
illustrates	0
the	0
almost	0
complete	0
tolerance	0
of	0
mice	0
for	0
human	9
TCF-1	10
and	0
demonstrates	0
that	0
this	0
tolerance	0
is	0
readily	0
broken	0
by	0
gene	0
knock-out	0
.	0

Furthermore	0
,	0
the	0
usefulness	0
of	0
knock-out	0
mice	0
for	0
the	0
generation	0
of	0
monoclonal	9
antibodies	10
against	0
the	0
gene	0
product	0
of	0
interest	0
is	0
underscored	0
.	0

The	0
transcription	9
factor	10
,	0
Nm23H2	9
,	0
binds	0
to	0
and	0
activates	0
the	0
translocated	0
c-myc	1
allele	2
in	0
Burkitt	0
's	0
lymphoma	0
.	0

We	0
have	0
identified	0
an	0
in	0
vivo	0
footprint	0
over	0
the	0
PuF	1
site	2
on	0
the	0
translocated	0
c-myc	1
allele	2
in	0
Burkitt	0
's	0
lymphoma	0
cells	0
.	0

The	0
PuF	1
site	2
on	0
the	0
silent	1
normal	2
c-myc	2
allele	2
was	0
unoccupied	0
.	0

We	0
demonstrated	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
electrophoretic	0
mobility	0
shift	0
assay	0
with	0
antibody	0
,	0
UV	0
cross-linking	0
followed	0
by	0
SDS-gel	0
electrophoresis	0
,	0
and	0
Western	0
analysis	0
that	0
Nm23H2	9
in	0
B	0
cell	0
nuclear	0
extracts	0
bound	0
to	0
the	0
c-myc	0
PuF	1
site	2
.	0

Transfection	0
experiments	0
with	0
c-myc	1
promoter	2
constructs	2
in	0
both	0
DHL-9	5
and	0
Raji	5
cells	6
revealed	0
that	0
the	0
PuF	1
site	2
functioned	0
as	0
a	0
positive	1
regulatory	2
element	2
in	0
B	7
cells	8
with	0
a	0
drop	0
in	0
activity	0
with	0
mutation	0
of	0
this	0
site	0
.	0

Access	0
to	0
this	0
site	0
is	0
blocked	0
in	0
the	0
normal	1
silent	2
c-myc	2
allele	2
;	0
these	0
data	0
suggest	0
that	0
the	0
Nm23H2	9
protein	0
is	0
involved	0
in	0
deregulation	0
of	0
the	0
translocated	0
c-myc	1
allele	2
in	0
Burkitt	5
's	6
lymphoma	6
cells	6
.	0

Identification	0
of	0
two	0
novel	0
regulatory	1
elements	2
within	0
the	0
5'-untranslated	1
region	2
of	0
the	0
human	1
A	2
gamma-globin	2
gene	2
.	0

Interaction	0
between	0
the	0
stage	1
selector	2
element	2
(	0
SSE	0
)	0
in	0
the	0
proximal	1
gamma-globin	2
promoter	2
and	0
hypersensitivity	1
site	2
2	2
in	0
the	0
locus	1
control	2
region	2
partly	0
mediates	0
the	0
competitive	0
silencing	0
of	0
the	0
beta-globin	1
promoter	2
in	0
the	0
fetal	0
developmental	0
stage	0
.	0

We	0
have	0
now	0
demonstrated	0
that	0
a	0
second	0
SSE-like	1
element	2
in	0
the	0
5'-untranslated	1
region	2
of	0
the	0
gamma-gene	1
also	0
contributes	0
to	0
this	0
competitive	0
silencing	0
of	0
the	0
beta-gene	1
.	0

Utilizing	0
transient	0
transfection	0
assays	0
in	0
the	0
fetal	5
erythroid	6
cell	6
line	6
,	0
K562	5
,	0
we	0
have	0
shown	0
that	0
the	0
core	1
enhancer	2
of	0
hypersensitivity	1
site	2
2	2
can	0
preferentially	0
interact	0
with	0
the	0
proximal	1
gamma-promoter	2
in	0
the	0
absence	0
of	0
the	0
SSE	1
,	0
completely	0
silencing	0
a	0
linked	1
beta-promoter	2
.	0

Mutation	0
of	0
a	0
20-base	0
pair	0
sequence	0
of	0
the	0
gamma-gene	1
5'-untranslated	2
region	2
(	0
UTR	1
)	0
led	0
to	0
derepression	0
of	0
beta-promoter	1
activity	0
.	0

A	0
marked	0
activation	0
of	0
gamma-promoter	1
activity	0
was	0
also	0
observed	0
with	0
this	0
mutation	0
,	0
suggesting	0
the	0
presence	0
of	0
a	0
repressor	0
.	0

Fine	0
mutagenesis	0
dissected	0
these	0
activities	0
to	0
different	0
regions	0
of	0
the	0
5'-UTR	1
.	0

The	0
stage	0
selector	0
activity	0
was	0
localized	0
to	0
a	0
region	0
centered	0
on	0
nucleotides	1
+13	2
to	2
+15	2
.	0

Electromobility	0
shift	0
assays	0
utilizing	0
this	0
sequence	0
demonstrated	0
binding	0
of	0
a	0
fetal	9
and	10
erythroid-specific	10
protein	10
.	0

The	0
repressor	0
activity	0
of	0
the	0
5'-UTR	1
was	0
localized	0
to	0
tandem	0
GATA-like	1
sites	2
,	0
which	0
appear	0
to	0
bind	0
a	0
complex	0
of	0
two	0
proteins	0
,	0
one	0
of	0
which	0
is	0
the	0
erythroid	9
transcription	10
factor	10
GATA-1	9
.	0

These	0
results	0
indicate	0
that	0
the	0
5'-UTR	1
of	0
the	0
gamma-gene	1
contains	0
sequences	0
that	0
may	0
be	0
important	0
for	0
its	0
transcriptional	0
and	0
developmental	0
regulation	0
.	0

Coupling	0
of	0
a	0
signal	9
response	10
domain	10
in	0
I	9
kappa	10
B	10
alpha	10
to	0
multiple	0
pathways	0
for	0
NF-kappa	9
B	10
activation	0
.	0

The	0
eukaryotic	9
transcription	10
factor	10
NF-kappa	9
B	10
plays	0
a	0
central	0
role	0
in	0
the	0
induced	0
expression	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
and	0
in	0
many	0
aspects	0
of	0
the	0
genetic	0
program	0
mediating	0
normal	0
T-cell	0
activation	0
and	0
growth	0
.	0

The	0
nuclear	0
activity	0
of	0
NF-kappa	9
B	10
is	0
tightly	0
regulated	0
from	0
the	0
cytoplasmic	0
compartment	0
by	0
an	0
inhibitory	9
subunit	10
called	0
I	9
kappa	10
B	10
alpha	10
.	0

This	0
cytoplasmic	0
inhibitor	0
is	0
rapidly	0
phosphorylated	0
and	0
degraded	0
in	0
response	0
to	0
a	0
diverse	0
set	0
of	0
NF-kappa	9
B-inducing	10
agents	10
,	0
including	0
T-cell	9
mitogens	10
,	10
proinflammatory	9
cytokines	10
,	0
and	0
viral	9
transactivators	10
such	0
as	0
the	0
Tax	9
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
.	0

To	0
explore	0
these	0
I	9
kappa	10
B	10
alpha	10
-dependent	0
mechanisms	0
for	0
NF-kappa	9
B	10
induction	0
,	0
we	0
identified	0
novel	0
mutants	0
of	0
I	9
kappa	10
B	10
alpha	10
that	0
uncouple	0
its	0
inhibitory	0
and	0
signal-transducing	0
functions	0
in	0
human	7
T	8
lymphocytes	8
.	0

Specifically	0
,	0
removal	0
of	0
the	0
N-terminal	9
36	10
amino	10
acids	10
of	0
I	9
kappa	10
B	10
alpha	10
failed	0
to	0
disrupt	0
its	0
ability	0
to	0
form	0
latent	0
complexes	0
with	0
NF-kappa	9
B	10
in	0
the	0
cytoplasm	0
.	0

However	0
,	0
this	0
deletion	0
mutation	0
prevented	0
the	0
induced	0
phosphorylation	0
,	0
degradative	0
loss	0
,	0
and	0
functional	0
release	0
of	0
I	9
kappa	10
B	10
alpha	10
from	0
NF-kappa	9
B	10
in	0
Tax-expressing	5
cells	6
.	0

Alanine	0
substitutions	0
introduced	0
at	0
two	0
serine	0
residues	0
positioned	0
within	0
this	0
N-terminal	9
regulatory	10
region	10
of	0
I	9
kappa	10
B	10
alpha	10
also	0
yielded	0
constitutive	0
repressors	0
that	0
escaped	0
from	0
Tax	9
-induced	0
turnover	0
and	0
that	0
potently	0
inhibited	0
immune	0
activation	0
pathways	0
for	0
NF-kappa	9
B	10
induction	0
,	0
including	0
those	0
initiated	0
from	0
antigen	9
and	10
cytokine	10
receptors	10
.	0

In	0
contrast	0
,	0
introduction	0
of	0
a	0
phosphoserine	0
mimetic	0
at	0
these	0
sites	0
rectified	0
this	0
functional	0
defect	0
,	0
a	0
finding	0
consistent	0
with	0
a	0
causal	0
linkage	0
between	0
the	0
phosphorylation	0
status	0
and	0
proteolytic	0
stability	0
of	0
this	0
cytoplasmic	9
inhibitor	10
.	0

Together	0
,	0
these	0
in	0
vivo	0
studies	0
define	0
a	0
critical	0
signal	0
response	0
domain	0
in	0
I	9
kappa	10
B	10
alpha	10
that	0
coordinately	0
controls	0
the	0
biologic	0
activities	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
NF-kappa	9
B	10
in	0
response	0
to	0
viral	0
and	0
immune	0
stimuli	0
.	0

Growth	0
regulation	0
and	0
cellular	0
changes	0
during	0
differentiation	0
of	0
human	5
prostatic	6
cancer	6
LNCaP	6
cells	6
as	0
induced	0
by	0
T	0
lymphocyte-conditioned	0
medium	0
.	0

Human	5
prostatic	6
epithelial	6
cells	6
from	0
an	0
androgen-dependent	5
LNCaP	6
cell	6
line	6
were	0
examined	0
in	0
response	0
to	0
conditioned	0
medium	0
(	0
CM	0
)	0
derived	0
from	0
phytohemagglutinin	5
(	6
PHA	6
)	6
-stimulated	6
lymphocytes	6
.	0

Addition	0
of	0
CM	0
caused	0
a	0
greater	0
than	0
70	0
%	0
reduction	0
of	0
cell	0
proliferation	0
by	0
cell	0
counting	0
and	0
cell	0
cycle	0
.	0

These	0
cells	0
showed	0
G1	0
phase	0
arrest	0
and	0
the	0
clonogenicity	0
was	0
reduced	0
.	0

The	0
growth-modulating	0
effect	0
was	0
dose-dependent	0
and	0
not	0
due	0
to	0
cell	0
lysis	0
or	0
apoptosis	0
.	0

The	0
binding	0
of	0
androgen	0
to	0
androgen	9
receptor	10
on	0
these	0
cells	0
showed	0
approximately	0
50	0
%	0
reduction	0
,	0
underlining	0
a	0
proliferation	0
reduction	0
mechanism	0
.	0

The	0
prostate-specific	9
antigen	10
(	0
PSA	9
)	0
was	0
downregulated	0
to	0
approximately	0
75	0
%	0
during	0
the	0
process	0
.	0

Cell	0
morphology	0
showed	0
dendritic	0
processes	0
extending	0
from	0
cytoplasm	0
and	0
other	0
neuroendocrine	7
cell	8
characteristics	0
.	0

The	0
expression	0
of	0
several	0
cytoskeleton	9
and	10
intracellular	10
proteins	10
increased	0
as	0
determined	0
by	0
immunostaining	0
on	0
slides	0
and	0
by	0
ELISA	0
procedures	0
.	0

These	0
included	0
vimentin	9
,	0
correlating	0
to	0
cell	0
shape	0
changes	0
,	0
cytokeratins	9
8	10
and	10
18	10
,	0
associated	0
with	0
differentiated	7
cell	8
types	8
of	0
prostate	0
epithelia	0
,	0
and	0
neuron-specific	9
enolase	10
and	0
serotonin	0
,	0
associated	0
with	0
neuroendocrine	7
cells	8
.	0

From	0
these	0
cellular	0
changes	0
,	0
we	0
can	0
infer	0
that	0
the	0
cell	0
growth	0
was	0
modulated	0
along	0
with	0
induction	0
of	0
terminal	0
differentiation	0
.	0

Activated	0
T	7
cells	8
were	0
demonstrated	0
to	0
be	0
important	0
in	0
providing	0
the	0
modulating	0
activity	0
.	0

This	0
growth	9
modulator	10
was	0
semipurified	0
and	0
had	0
an	0
estimated	0
molecular	0
weight	0
13	0
,	0
000	0
to	0
24	0
,	0
000	0
Da	0
.	0

The	0
activity	0
was	0
determined	0
to	0
be	0
distinct	0
from	0
TGF	9
,	0
TNF	9
,	0
and	0
some	0
commonly	0
known	0
lymphokines	9
.	0

The	0
interaction	0
between	0
lymphoid	7
and	8
prostatic	8
cells	8
in	0
growth	0
and	0
development	0
is	0
described	0
.	0

Platelet-activating	9
factor	10
stimulates	0
transcription	0
of	0
the	0
heparin-binding	9
epidermal	10
growth	10
factor-like	10
growth	10
factor	10
in	0
monocytes	7
.	0

Correlation	0
with	0
an	0
increased	0
kappa	0
B	0
binding	0
activity	0
.	0

Human	0
peripheral	0
blood	0
monocytes	7
responded	0
to	0
stimulation	0
of	0
platelet-activating	9
factor	10
(	0
PAF	9
)	0
with	0
up-regulation	0
of	0
the	0
transcript	0
for	0
heparin-binding	9
epidermal	10
growth	10
factor-like	10
growth	10
factor	10
(	0
HB-EGF	9
)	0
,	0
a	0
potent	9
mitogen	10
for	0
vascular	7
smooth	8
muscle	8
cells	8
.	0

This	0
function	0
of	0
PAF	9
was	0
observed	0
at	0
nanomolar	0
concentrations	0
of	0
the	0
ligand	0
,	0
starting	0
at	0
30	0
min	0
after	0
stimulation	0
.	0

The	0
PAF	9
-induced	0
up-regulation	0
of	0
HB-EGF	3
mRNA	4
was	0
accompanied	0
by	0
an	0
increase	0
in	0
kappa	0
B	0
binding	0
activity	0
.	0

These	0
functions	0
of	0
PAF	9
appeared	0
to	0
be	0
mediated	0
through	0
the	0
cell	9
surface	10
PAF	10
receptors	10
,	0
as	0
two	0
PAF	9
receptor	0
antagonists	0
,	0
WEB	0
2086	0
and	0
L-659	0
,	0
989	0
,	0
blocked	0
both	0
the	0
up-regulation	0
of	0
HB-EGF	3
mRNA	4
and	0
kappa	0
B	0
binding	0
activity	0
induced	0
by	0
PAF	9
.	0

The	0
antagonists	0
,	0
however	0
,	0
had	0
no	0
effect	0
on	0
phorbol	0
ester-induced	0
up-regulation	0
of	0
HB-EGF	3
mRNA	4
and	0
kappa	0
B	0
binding	0
activity	0
.	0

Pretreatment	0
of	0
monocytes	7
with	0
pertussis	0
toxin	0
inhibited	0
these	0
functions	0
of	0
PAF	9
,	0
whereas	0
cholera	0
toxin	0
had	0
no	0
inhibitory	0
effect	0
.	0

Pyrrolidine	0
dithiocarbamate	0
,	0
an	0
inhibitor	0
for	0
NF-kappa	9
B	10
activation	0
,	0
markedly	0
reduced	0
PAF	9
-stimulated	0
kappa	0
B	0
binding	0
activity	0
as	0
well	0
as	0
up-regulation	0
of	0
HB-EGF	3
mRNA	4
.	0

These	0
results	0
suggest	0
a	0
potential	0
role	0
of	0
PAF	9
in	0
HB-EGF	9
expression	0
and	0
provide	0
evidence	0
that	0
this	0
stimulation	0
may	0
occur	0
through	0
increased	0
kappa	0
B	0
binding	0
activity	0
.	0

Mapping	0
of	0
the	0
interaction	9
site	10
of	0
the	0
defective	9
transcription	10
factor	10
in	0
the	0
class	5
II	6
major	6
histocompatibility	6
complex	6
mutant	6
cell	6
line	6
clone-13	6
to	0
the	0
divergent	1
X2-box	2
.	0

We	0
have	0
previously	0
described	0
a	0
mutant	5
B	6
lymphoblastoid	6
cell	6
line	6
,	0
Clone-13	5
,	6
that	0
expresses	0
HLA-DQ	9
in	0
the	0
absence	0
of	0
HLA-DR	9
and	10
-DP	10
.	0

Several	0
criteria	0
indicated	0
that	0
the	0
defect	0
in	0
this	0
cell	0
line	0
influences	0
the	0
activity	0
of	0
an	0
isotype-specific	9
transcription	10
factor	10
.	0

Indeed	0
,	0
transient	0
transfection	0
of	0
HLA-DRA	1
and	2
DQB	2
reporter	2
constructs	2
indicated	0
that	0
the	0
affected	0
factor	0
operates	0
via	0
cis-elements	1
located	0
between	0
-141	1
base	2
pairs	2
and	0
the	0
transcription	1
initiation	2
site	2
.	0

A	0
series	0
of	0
hybrid	1
DRA/DQB	2
reporter	2
constructs	2
was	0
generated	0
to	0
further	0
map	0
the	0
relevant	0
cis-elements	1
in	0
this	0
system	0
.	0

Insertion	0
of	0
oligonucleotides	0
spanning	0
the	0
DQB	1
X-box	2
(	0
but	0
not	0
the	0
DQB-W	1
region	2
or	0
the	0
DQB	1
Y-box	2
)	0
upstream	1
of	2
-141	2
in	0
a	0
DRA	1
reporter	2
plasmid	2
rescued	0
expression	0
to	0
nearly	0
wild-type	0
levels	0
.	0

Substitution	0
promoters	0
were	0
then	0
generated	0
where	0
the	0
entire	0
X-box	1
,	0
or	0
only	0
the	0
X1-	1
or	2
X2-boxes	2
of	0
HLA-DRA	1
were	0
replaced	0
with	0
the	0
analogous	0
regions	0
of	0
HLA-DQB	1
.	0

The	0
DQB	1
X2-box	2
was	0
able	0
to	0
restore	0
expression	0
to	0
the	0
silent	1
DRA	2
reporter	2
construct	2
.	0

Moreover	0
,	0
replacement	0
of	0
the	0
DQB	1
X2-box	2
with	0
the	0
DRA	1
X2-box	2
markedly	0
diminished	0
the	0
activity	0
of	0
the	0
DQB	1
promoter	2
in	0
the	0
mutant	5
cell	6
.	0

None	0
of	0
the	0
hybrid	1
reporter	2
constructs	2
were	0
defective	0
when	0
transfected	0
into	0
the	0
wild-type	9
,	0
HLA-DR/-DQ	5
positive	6
parental	6
cell	6
line	6
,	0
Jijoye	5
.	0

These	0
studies	0
suggest	0
that	0
the	0
divergent	1
X2-box	2
of	0
the	0
class	1
II	2
major	2
histocompatibility	2
complex	2
promoters	2
plays	0
an	0
important	0
role	0
in	0
influencing	0
differential	0
expression	0
of	0
the	0
human	1
class	2
II	2
isotypes	2
.	0

Restoration	0
of	0
the	0
Epstein-Barr	9
virus	10
ZEBRA	10
protein	10
's	0
capacity	0
to	0
disrupt	0
latency	0
by	0
the	0
addition	0
of	0
heterologous	9
activation	10
regions	10
.	0

The	0
ZEBRA	9
protein	10
has	0
a	0
unique	0
biological	0
function	0
among	0
herpesviral	9
proteins	10
.	0

It	0
is	0
responsible	0
for	0
the	0
disruption	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
latency	0
and	0
the	0
induction	0
of	0
the	0
lytic	0
cycle	0
.	0

ZEBRA	9
is	0
a	0
bZIP	9
transcriptional	10
activator	10
which	0
binds	0
as	0
a	0
dimer	0
to	0
7-bp	1
response	2
elements	2
within	0
EBV	1
promoters	2
and	0
is	0
directly	0
involved	0
in	0
the	0
stimulation	0
of	0
virus	0
replication	0
at	0
the	0
EBV	1
lytic	2
origin	2
.	0

We	0
have	0
employed	0
the	0
ZEBRA	9
/EBV	0
biological	0
system	0
to	0
test	0
whether	0
a	0
heterologous	9
activation	10
domain	10
can	0
substitute	0
for	0
another	0
activation	0
domain	0
(	0
the	0
ZEBRA	9
domain	10
)	0
.	0

The	0
ZEBRA	9
activation	10
region	10
was	0
replaced	0
with	0
the	0
potent	0
acid	9
activation	10
region	10
from	0
the	0
herpes	9
simplex	10
virus	10
VP16	10
protein	10
or	0
with	0
the	0
activation	9
region	10
of	0
the	0
EBV	9
R	10
protein	10
.	0

Both	0
chimeras	0
were	0
found	0
to	0
transactivate	0
model	0
and	0
native	0
promoters	0
at	0
equivalent	0
or	0
better	0
levels	0
than	0
ZEBRA	9
itself	0
.	0

Activation	0
was	0
not	0
target-	0
or	0
cell-type	0
dependent	0
,	0
nor	0
was	0
it	0
dependent	0
on	0
the	0
presence	0
of	0
virus	0
.	0

These	0
activation	0
domains	0
restored	0
ZEBRA	9
's	0
ability	0
to	0
induce	0
early	9
antigen	10
and	0
to	0
stimulate	0
origin	0
replication	0
to	0
levels	0
that	0
were	0
equal	0
to	0
or	0
greater	0
than	0
those	0
of	0
wild	0
type	0
.	0

These	0
studies	0
suggest	0
that	0
the	0
specificities	0
of	0
some	0
of	0
the	0
known	0
biological	0
functions	0
of	0
ZEBRA	9
are	0
not	0
dependent	0
upon	0
the	0
nature	0
of	0
the	0
activation	9
domain	10
present	10
within	0
ZEBRA	9
.	0

Interleukin	9
4	10
activates	0
a	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	9
(	10
Stat	10
)	10
protein	10
which	0
interacts	0
with	0
an	0
interferon-gamma	1
activation	2
site-like	2
sequence	2
upstream	0
of	0
the	0
I	1
epsilon	2
exon	2
in	0
a	0
human	5
B	6
cell	6
line	6
.	0

Evidence	0
for	0
the	0
involvement	0
of	0
Janus	9
kinase	10
3	10
and	0
interleukin-4	9
Stat	10
.	0

Germ	3
line	4
C	4
transcripts	4
can	0
be	0
induced	0
by	0
IL-4	9
in	0
the	0
human	5
B	6
cell	6
line	6
,	0
BL-2	5
.	0

Utilizing	0
a	0
IFN-gamma	1
activation	2
site-like	2
DNA	2
sequence	2
element	2
located	0
upstream	0
of	0
the	0
I	1
epsilon	2
exon	2
,	0
we	0
demonstrated	0
by	0
gel	0
mobility	0
shift	0
assays	0
that	0
IL-4	9
induced	0
a	0
binding	0
activity	0
in	0
the	0
cytosol	0
and	0
nucleus	0
of	0
BL-2	5
cells	6
.	0

This	0
factor	0
was	0
designated	0
IL-4	9
NAF	10
(	0
IL-4-induced	9
nuclear-activating	10
factors	10
)	0
and	0
was	0
identified	0
as	0
a	0
tyrosine	9
phosphoprotein	10
,	0
which	0
translocates	0
from	0
the	0
cytosol	0
to	0
the	0
nucleus	0
upon	0
IL-4	9
treatment	0
.	0

Because	0
these	0
are	0
the	0
characteristics	0
of	0
a	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
Stat	10
)	10
protein	10
,	0
we	0
determined	0
whether	0
antibodies	9
to	10
Stat	10
proteins	10
will	0
interfere	0
with	0
gel	0
mobility	0
shift	0
and	0
found	0
that	0
antibodies	9
to	10
IL-4	10
Stat	10
,	0
also	0
known	0
as	0
Stat6	9
,	0
but	0
not	0
antibodies	9
to	0
other	0
Stat	9
proteins	10
,	0
interfere	0
with	0
the	0
formation	0
of	0
the	0
IL-4	9
NAF	10
complex	10
.	0

Congruous	0
with	0
the	0
involvement	0
of	0
a	0
Stat	9
protein	10
,	0
IL-4	9
induced	0
robust	0
Janus	9
kinase	10
3	10
(	0
JAK3	9
)	0
activity	0
in	0
BL-2	5
cells	6
.	0

Cotransfection	0
of	0
JAK3	9
with	0
IL-4	9
Stat	10
into	0
COS-7	5
cells	6
produced	0
an	0
intracellular	0
activity	0
which	0
bound	0
the	0
same	0
IFN-gamma	1
activation	2
site-like	2
sequence	2
and	0
comigrated	0
with	0
IL-4	9
NAF	10
in	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

These	0
results	0
show	0
that	0
IL-4	9
NAF	10
is	0
IL-4	9
Stat	10
,	0
which	0
is	0
activated	0
by	0
JAK3	9
in	0
response	0
to	0
IL-4	9
receptor	0
engagement	0
.	0

Does	0
activation	0
of	0
the	0
TAL1	1
gene	2
occur	0
in	0
a	0
majority	0
of	0
patients	0
with	0
T-cell	0
acute	0
lymphoblastic	0
leukemia	0
?	0
A	0
pediatric	0
oncology	0
group	0
study	0
.	0

Almost	0
25	0
%	0
of	0
patients	0
with	0
T-cell	0
acute	0
lymphoblastic	0
leukemia	0
(	0
T-ALL	0
)	0
have	0
tumor-specific	0
rearrangements	0
of	0
the	0
TAL1	1
gene	2
.	0

Although	0
TAL1	9
expression	0
has	0
not	0
been	0
observed	0
in	0
normal	7
lymphocytes	8
,	0
TAL1	9
gene	10
products	10
are	0
readily	0
detected	0
in	0
leukemic	7
cells	8
that	0
harbor	0
a	0
rearranged	1
TAL1	2
allele	2
.	0

Hence	0
,	0
it	0
has	0
been	0
proposed	0
that	0
ectopic	0
expression	0
of	0
TAL1	9
promotes	0
the	0
development	0
of	0
T-ALL	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
TAL1	9
is	0
expressed	0
in	0
the	0
leukemic	7
cells	8
of	0
most	0
patients	0
with	0
T-ALL	0
,	0
including	0
many	0
that	0
do	0
not	0
display	0
an	0
apparent	0
TAL1	1
gene	2
alteration	0
.	0

A	0
polymorphic	0
dinucleotide	0
repeat	0
in	0
the	0
transcribed	0
sequences	0
of	0
TAL1	9
was	0
used	0
to	0
determine	0
the	0
allele	0
specificity	0
of	0
TAL1	9
transcription	0
in	0
primary	7
T-ALL	8
cells	8
.	0

Monoallelic	0
expression	0
of	0
TAL1	9
was	0
observed	0
in	0
the	0
leukemic	7
cells	8
of	0
all	0
patients	0
(	0
8	0
of	0
8	0
)	0
bearing	0
a	0
TAL1	1
gene	2
rearrangement	0
.	0

In	0
the	0
leukemic	7
cells	8
of	0
patients	0
without	0
detectable	0
TAL1	9
rearrangements	0
,	0
TAL1	9
transcription	0
occurred	0
in	0
either	0
a	0
monoallelic	0
(	0
3	0
of	0
7	0
patients	0
)	0
or	0
a	0
biallelic	0
(	0
4	0
of	0
7	0
patients	0
)	0
fashion	0
.	0

Thus	0
,	0
TAL1	9
activation	0
in	0
these	0
patients	0
may	0
result	0
from	0
subtle	0
alterations	0
in	0
cis-acting	1
regulatory	2
sequences	2
(	0
affecting	0
expression	0
of	0
a	0
single	1
TAL1	2
allele	2
)	0
or	0
changes	0
in	0
trans-acting	0
factors	0
that	0
control	0
TAL1	9
transcription	0
(	0
affecting	0
expression	0
of	0
both	0
TAL1	1
alleles	2
)	0
.	0

Expression	0
of	0
erythroid-specific	1
genes	2
in	0
acute	0
megakaryoblastic	0
leukaemia	0
and	0
transient	0
myeloproliferative	0
disorder	0
in	0
Down	0
's	0
syndrome	0
.	0

Acute	0
megakaryoblastic	0
leukaemia	0
(	0
M7	0
)	0
and	0
transient	0
myeloproliferative	0
disorder	0
in	0
Down	0
's	0
syndrome	0
(	0
TMD	0
)	0
are	0
characterized	0
by	0
rapid	0
growth	0
of	0
abnormal	7
blast	8
cells	8
which	0
express	0
megakaryocytic	9
markers	10
.	0

To	0
clarify	0
properties	0
of	0
the	0
blast	7
cells	8
in	0
M7	0
and	0
TMD	0
cases	0
,	0
we	0
examined	0
erythroid	0
markers	0
expression	0
in	0
blasts	7
from	0
six	0
cases	0
with	0
M7	0
and	0
seven	0
cases	0
with	0
TMD	0
in	0
this	0
study	0
.	0

Erythroid-specific	3
mRNAs	4
encoding	0
gamma-globin	9
and	0
erythroid	9
delta-aminolevulinate	10
synthase	10
were	0
found	0
to	0
be	0
expressed	0
in	0
blasts	7
from	0
most	0
of	0
these	0
cases	0
,	0
indicating	0
that	0
majorities	0
of	0
the	0
blasts	7
in	0
M7	0
and	0
TMD	0
cases	0
have	0
erythroid	0
and	0
megakaryocytic	0
phenotypes	0
.	0

We	0
also	0
found	0
that	0
mRNAs	3
encoding	0
GATA-1	9
and	0
GATA-2	9
are	0
expressed	0
in	0
all	0
these	0
cases	0
.	0

These	0
results	0
suggest	0
that	0
M7	7
blasts	8
and	0
TMD	7
blasts	8
correspond	0
to	0
the	0
erythroid/megakaryocytic	7
bipotential	8
progenitor	8
cells	8
.	0

Expression	0
of	0
Ah	9
receptor	10
(	0
TCDD	9
receptor	10
)	0
during	0
human	0
monocytic	0
differentiation	0
.	0

We	0
have	0
previously	0
found	0
a	0
high	0
expression	0
of	0
human	3
Ah	4
receptor	4
(	4
TCDD	4
receptor	4
)	4
mRNA	4
in	0
peripheral	7
blood	8
cells	8
of	0
individuals	0
.	0

In	0
this	0
paper	0
,	0
the	0
expression	0
of	0
this	0
gene	0
in	0
blood	7
cells	8
was	0
first	0
investigated	0
in	0
fractions	0
of	0
nucleated	7
cells	8
,	0
revealing	0
predominant	0
expression	0
of	0
the	0
Ah	1
receptor	2
gene	2
in	0
the	0
monocyte	7
fraction	8
.	0

Then	0
the	0
expression	0
levels	0
of	0
AhR	3
mRNA	4
in	0
various	0
hematopoietic	5
cell	6
lines	6
were	0
examined	0
together	0
with	0
those	0
of	0
Arnt	9
and	0
P450IA1	9
.	0

AhR	9
was	0
expressed	0
at	0
high	0
levels	0
in	0
monocytoid	5
U937	6
,	0
THP1	5
,	0
and	0
HEL/S	5
cells	6
,	0
and	0
at	0
moderate	0
levels	0
in	0
promyelocytic	5
HL60	6
cells	6
and	0
erythroblastic	5
HEL	6
cells	6
.	0

However	0
,	0
it	0
was	0
not	0
detected	0
in	0
lymphoid	7
cells	8
MOLT4	5
(	0
T	7
cell	8
)	0
and	0
BALL1	5
(	0
B	7
cell	8
)	0
,	0
nor	0
in	0
K562	5
erythroblasts	6
.	0

Furthermore	0
,	0
a	0
specific	0
induction	0
of	0
AhR	9
during	0
monocytic	0
differentiation	0
was	0
investigated	0
in	0
HL60	5
and	0
HEL	5
cells	6
.	0

HL60	5
cells	6
were	0
induced	0
to	0
differentiate	0
toward	0
monocytes-macrophages	7
by	0
incubation	0
with	0
phorbol	0
ester	0
,	0
showing	0
a	0
5-	0
to	0
2-fold	0
increase	0
of	0
AhR	3
mRNA	4
.	0

The	0
incubation	0
with	0
transforming	9
growth	10
factor	10
beta	10
1	10
and	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
resulted	0
in	0
a	0
5-	0
to	0
7-fold	0
increase	0
of	0
AhR	3
mRNA	4
.	0

The	0
HEL	5
cells	6
also	0
exhibited	0
a	0
similar	0
elevation	0
of	0
AhR	3
mRNA	4
level	0
,	0
when	0
they	0
had	0
differentiated	0
toward	0
monocyte-macrophage	7
cells	8
by	0
these	0
combined	0
inducers	0
,	0
but	0
little	0
change	0
in	0
the	0
mRNA	0
level	0
was	0
observed	0
when	0
the	0
cells	0
were	0
induced	0
to	0
differentiate	0
into	0
other	0
cell	0
types	0
.	0

Treatment	0
of	0
the	0
differentiated	5
HL60	6
cells	6
with	0
3-methylcholanthrene	0
,	0
a	0
ligand	0
of	0
AhR	9
,	0
induced	0
the	0
expression	0
of	0
the	0
P450IA1	9
gene	0
.	0

These	0
results	0
indicated	0
that	0
expression	0
of	0
AhR	3
mRNA	4
was	0
significantly	0
induced	0
during	0
monocytic	0
differentiation	0
and	0
that	0
the	0
differentiated	7
cells	8
were	0
responsive	0
to	0
xenobiotics	0
.	0

Our	0
results	0
suggest	0
that	0
AhR	9
may	0
play	0
an	0
important	0
role	0
in	0
the	0
function	0
of	0
monocytes	7
and	0
also	0
in	0
the	0
eventual	0
activation	0
of	0
environmental	0
carcinogens	0
.	0

Neutrophils	7
and	0
monocytes	7
express	0
high	0
levels	0
of	0
PU.1	9
(	0
Spi-1	9
)	0
but	0
not	0
Spi-B	9
.	0

PU.1	9
(	0
the	0
Spi-1	1
oncogene	2
)	0
and	0
Spi-B	9
are	0
closely	0
related	0
members	0
of	0
the	0
ets	9
transcription	10
factor	10
family	10
,	0
sharing	0
similar	0
DNA	0
binding	0
specificities	0
mediated	0
by	0
similar	0
DNA	9
binding	10
domains	10
.	0

PU.1	9
and	0
Spi-B	9
have	0
been	0
previously	0
described	0
as	0
being	0
predominantly	0
expressed	0
coordinately	0
in	0
macrophages	7
and	0
B	7
cells	8
,	0
but	0
their	0
expression	0
in	0
early	0
hematopoietic	0
stages	0
and	0
during	0
the	0
course	0
of	0
myeloid	0
differentiation	0
to	0
monocytes	7
and	0
macrophages	7
or	0
to	0
neutrophils	7
has	0
not	0
been	0
extensively	0
investigated	0
.	0

Here	0
,	0
we	0
report	0
that	0
PU.1	3
mRNA	4
is	0
upregulated	0
during	0
myeloid	0
differentiation	0
of	0
human	5
purified	6
CD34+	6
cells	6
and	0
murine	5
multipotential	6
FDCP-mix	6
A4	6
cells	6
,	0
suggesting	0
that	0
PU.1	9
is	0
upregulated	0
as	0
an	0
early	0
event	0
during	0
differentiation	0
of	0
multipotential	7
progenitor	8
cells	8
.	0

PU.1	9
expression	0
is	0
maintained	0
at	0
stable	0
levels	0
during	0
differentiation	0
of	0
myeloid	5
cell	6
lines	6
U937	5
and	0
HL-60	5
to	0
monocytic	7
and	8
neutrophilic	8
cells	8
.	0

PU.1	9
is	0
expressed	0
at	0
highest	0
levels	0
in	0
mature	7
human	8
monocytes	8
and	0
human	7
peripheral	8
blood	8
neutrophils	8
.	0

In	0
contrast	0
to	0
PU.1	9
,	0
significant	0
levels	0
of	0
Spi-B	3
mRNA	4
and	0
protein	0
are	0
found	0
only	0
in	0
some	0
B-cell	5
lines	6
and	0
spleen	0
but	0
are	0
not	0
found	0
in	0
myeloid	5
cell	6
lines	6
,	0
neutrophils	7
,	0
or	0
macrophages	7
.	0

In	0
vitro	0
translated	0
Spi-B	9
protein	10
can	0
bind	0
to	0
PU.1	1
binding	2
sites	2
in	0
myeloid	1
promoters	2
and	0
transactivate	0
these	0
promoters	1
in	0
nonmyeloid	7
cells	8
.	0

Therefore	0
,	0
although	0
PU.1	9
and	0
Spi-B	9
may	0
bind	0
to	0
similar	0
DNA	0
control	0
elements	0
and	0
have	0
redundancy	0
of	0
transactivation	0
function	0
in	0
vitro	0
,	0
the	0
lack	0
of	0
significant	0
levels	0
of	0
Spi-B	9
in	0
myeloid	7
cells	8
makes	0
it	0
unlikely	0
that	0
Spi-B	9
plays	0
a	0
significant	0
role	0
in	0
myeloid	0
lineage	0
development	0
and	0
gene	0
expression	0
.	0

In	0
contrast	0
,	0
PU.1	9
is	0
expressed	0
at	0
high	0
levels	0
not	0
only	0
in	0
monocytes	7
and	0
macrophages	7
but	0
also	0
in	0
neutrophils	7
,	0
indicating	0
that	0
PU.1	9
can	0
activate	0
gene	0
expression	0
in	0
both	0
major	7
myeloid	8
lineages	8
.	0

Identification	0
of	0
a	0
major	0
positive	1
regulatory	2
element	2
located	0
5	0
'	0
to	0
the	0
human	1
zeta-globin	2
gene	2
.	0

The	0
function	0
of	0
the	0
zeta-globin	1
promoter	2
was	0
studied	0
using	0
a	0
series	0
of	0
zeta-globin	1
promoter	2
deletion	2
constructs	2
to	0
drive	0
luciferase	9
expression	0
in	0
transiently	5
transfected	6
human	6
erythroleukemia	6
cells	6
.	0

The	0
promoters	1
were	0
used	0
without	0
enhancers	1
,	0
or	0
with	0
enhancers	1
derived	0
from	0
the	0
beta-globin	1
locus	2
control	2
region	2
and	0
the	0
alpha-globin	1
HS-40	2
enhancer	2
.	0

When	0
transfected	0
into	0
K562	5
cells	6
,	0
which	0
express	0
zeta-globin	9
,	0
comparable	0
amounts	0
of	0
activity	0
were	0
obtained	0
from	0
the	0
-557	1
and	2
-417	2
zeta-luciferase	2
constructs	2
and	0
the	0
alpha-luciferase	1
constructs	2
when	0
no	0
enhancers	1
or	0
the	0
alpha-globin	1
locus	2
enhancers	2
were	0
used	0
.	0

When	0
the	0
constructs	0
were	0
transfected	0
into	0
OCIM1	5
cells	6
,	0
which	0
do	0
not	0
express	0
zeta-globin	9
,	0
the	0
zeta-globin	1
promoters	2
were	0
at	0
best	0
20	0
%	0
as	0
active	0
as	0
the	0
alpha-globin	1
promoters	2
.	0

When	0
sequences	1
from	2
-417	2
to	2
-207	2
5	2
'	2
to	0
the	0
zeta-globin	3
mRNA	4
cap	4
site	4
were	0
deleted	0
,	0
up	0
to	0
95	0
%	0
of	0
the	0
zeta-globin	1
promoter	2
activity	0
was	0
lost	0
in	0
K562	5
cells	6
.	0

Reinsertion	0
of	0
these	0
sequences	0
into	0
zeta-luciferase	1
constructs	2
missing	0
the	0
-417	0
to	0
-207	0
region	0
showed	0
that	0
the	0
sequences	0
lack	0
classical	0
enhancer	0
activity	0
.	0

Point	0
mutation	0
of	0
a	0
GATA-1	1
site	2
at	0
-230	0
reduced	0
promoter	0
activity	0
by	0
37	0
%	0
.	0

Point	0
mutation	0
of	0
a	0
CCACC	1
site	2
at	0
-240	0
had	0
no	0
effect	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
indicated	0
that	0
the	0
-230	1
GATA-1	2
site	2
has	0
a	0
relatively	0
low	0
affinity	0
for	0
GATA-1	9
.	0

These	0
experiments	0
show	0
the	0
presence	0
of	0
a	0
strong	0
positive-acting	1
element	2
,	0
located	0
between	0
-417	1
and	2
-207	2
bp	2
5	2
'	2
to	0
the	0
zeta-globin	1
mRNA	2
cap	2
site	2
,	0
is	0
necessary	0
for	0
high-level	0
promoter	0
activity	0
in	0
K562	5
cells	6
.	0

This	0
element	0
requires	0
GATA-1	9
and	0
additional	9
unknown	10
factors	10
for	0
maximal	0
activity	0
.	0

Analysis	0
of	0
the	0
role	0
of	0
protein	9
kinase	10
C-alpha	10
,	10
-epsilon	10
,	10
and	10
-zeta	10
in	0
T	0
cell	0
activation	0
.	0

T	7
cells	8
express	0
multiple	0
isotypes	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
and	0
although	0
it	0
is	0
well	0
accepted	0
that	0
PKCs	9
have	0
an	0
important	0
role	0
in	0
T	0
cell	0
activation	0
,	0
little	0
is	0
known	0
about	0
the	0
function	0
of	0
individual	0
PKC	9
isotypes	10
.	0

To	0
address	0
this	0
issue	0
,	0
mutationally	0
active	0
PKC-alpha	9
,	10
-epsilon	10
,	10
or	10
-zeta	10
have	0
been	0
transfected	0
into	0
T	7
cells	8
and	0
the	0
consequences	0
for	0
T	0
cell	0
activation	0
determined	0
.	0

p21ras	9
plays	0
an	0
essential	0
role	0
in	0
T	0
cell	0
activation	0
.	0

Accordingly	0
,	0
the	0
effects	0
of	0
the	0
constitutively	9
active	10
PKCs	10
were	0
compared	0
to	0
the	0
effects	0
of	0
mutationally	0
activated	0
p21ras	9
.	0

The	0
data	0
indicate	0
that	0
PKC-epsilon	9
and	0
,	0
to	0
a	0
lesser	0
extent	0
PKC-alpha	9
but	0
not	0
-zeta	9
,	0
can	0
regulate	0
the	0
transcription	9
factors	10
AP-1	9
and	0
nuclear	0
factor	9
of	10
activated	10
T	10
cells	10
(	0
NF-AT-1	9
)	0
.	0

The	0
ability	0
of	0
PKC-epsilon	9
to	0
induce	0
transactivation	0
of	0
NF-AT-1	9
and	0
AP-1	9
was	0
similar	0
to	0
the	0
stimulatory	0
effect	0
of	0
a	0
constitutively	9
activated	10
p21ras	10
.	0

PKC-epsilon	9
,	0
but	0
not	0
PKC-alpha	9
nor	0
activated	0
p21ras	9
,	0
was	0
able	0
to	0
induce	0
NF-KB	9
activity	0
.	0

Phorbol	0
esters	0
induce	0
expression	0
of	0
CD69	9
whereas	0
none	0
of	0
the	0
activated	9
PKC	10
isotypes	10
tested	0
were	0
able	0
to	0
have	0
this	0
effect	0
.	0

Activated	0
Src	9
and	0
p21ras	9
were	0
able	0
to	0
induce	0
CD69	9
expression	0
.	0

These	0
results	0
indicate	0
selective	0
functions	0
for	0
different	0
PKC	9
isotypes	10
in	0
T	7
cells	8
.	0

Moreover	0
,	0
the	0
data	0
comparing	0
the	0
effects	0
of	0
activated	9
Ras	10
and	0
PKC	9
mutants	10
suggest	0
that	0
PKC-alpha	9
,	0
p21ras	9
,	0
and	0
PKC-epsilon	9
are	0
not	0
positioned	0
linearly	0
on	0
a	0
single	0
signal	0
transduction	0
pathway	0
.	0

Differences	0
in	0
binding	0
of	0
glucocorticoid	9
receptor	10
to	0
DNA	0
in	0
steroid-resistant	0
asthma	0
.	0

Although	0
glucocorticosteroids	0
are	0
a	0
very	0
effective	0
treatment	0
for	0
asthma	0
and	0
other	0
chronic	0
inflammatory	0
diseases	0
,	0
a	0
small	0
proportion	0
of	0
patients	0
are	0
resistant	0
to	0
their	0
therapeutic	0
effects	0
.	0

The	0
molecular	0
mechanism	0
for	0
this	0
steroid	0
resistance	0
is	0
unclear	0
.	0

Steroid	0
resistance	0
can	0
not	0
be	0
explained	0
by	0
pharmacokinetic	0
mechanisms	0
,	0
by	0
a	0
defect	0
in	0
the	0
binding	0
of	0
steroids	0
to	0
glucocorticoid	9
receptors	10
,	0
nor	0
by	0
defective	0
nuclear	0
translocation	0
of	0
this	0
receptor	0
,	0
thereby	0
suggesting	0
that	0
the	0
molecular	0
abnormality	0
lies	0
distal	0
to	0
nuclear	0
translocation	0
.	0

We	0
examined	0
the	0
ability	0
of	0
nuclear	0
translocated	0
glucocorticoid	9
receptors	10
to	0
bind	0
to	0
their	0
DNA	1
binding	2
sites	2
(	0
GRE	1
)	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
in	0
PBMC	7
from	0
patients	0
with	0
steroid-sensitive	0
and	0
steroid-resistant	0
asthma	0
.	0

The	0
binding	0
of	0
the	0
glucocorticoid	9
receptor	10
to	0
DNA	0
in	0
these	0
patients	0
was	0
also	0
studied	0
using	0
Scatchard	0
analysis	0
.	0

Dexamethasone	0
induced	0
a	0
significant	0
rapid	0
and	0
sustained	0
twofold	0
increase	0
in	0
GRE	1
binding	0
in	0
PBMCs	7
from	0
steroid-sensitive	0
asthmatic	0
patients	0
and	0
nonasthmatic	0
individuals	0
,	0
but	0
this	0
was	0
markedly	0
reduced	0
in	0
steroid-resistant	0
asthmatic	0
patients	0
.	0

Scatchard	0
analysis	0
of	0
glucocorticoid	9
receptor	10
-	0
GRE	1
binding	0
showed	0
no	0
change	0
in	0
binding	0
affinity	0
but	0
did	0
show	0
a	0
reduced	0
number	0
of	0
receptors	9
available	0
for	0
DNA	0
binding	0
in	0
the	0
steroid-resistant	0
patients	0
.	0

These	0
results	0
suggest	0
that	0
the	0
ability	0
of	0
the	0
glucocorticoid	9
receptor	10
to	0
bind	0
to	0
GRE	1
is	0
impaired	0
in	0
steroid-resistant	0
patients	0
because	0
of	0
a	0
reduced	0
number	0
of	0
receptors	9
available	0
for	0
binding	0
to	0
DNA	0
.	0

Interleukin-5	9
signaling	0
in	0
human	7
eosinophils	8
involves	0
JAK2	9
tyrosine	10
kinase	10
and	0
Stat1	9
alpha	10
.	0

Signaling	0
by	0
a	0
wide	0
variety	0
of	0
cytokines	9
,	0
including	0
interferons	9
,	0
interleukins	9
,	0
and	0
growth	9
factors	10
,	0
involves	0
activation	0
of	0
JAK	9
kinases	10
and	0
Stat	9
(	10
Signal	10
transducers	10
and	10
activators	10
of	10
transcription	10
)	10
proteins	10
.	0

At	0
present	0
,	0
not	0
much	0
is	0
known	0
about	0
the	0
molecular	0
mechanisms	0
by	0
which	0
interleukin-5	9
(	0
IL-5	9
)	0
exerts	0
its	0
diverse	0
biologic	0
effects	0
.	0

Human	7
eosinophils	8
are	0
one	0
of	0
the	0
most	0
important	0
target	7
cells	8
for	0
IL-5	9
and	0
were	0
used	0
here	0
to	0
study	0
IL-5	9
signaling	0
in	0
a	0
primary	7
human	8
cell	8
.	0

IL-5	9
induced	0
rapid	0
and	0
transient	0
tyrosine	0
phosphorylation	0
of	0
JAK2	9
.	0

Moreover	0
,	0
IL-5	9
induced	0
at	0
least	0
two	0
DNA-binding	9
complexes	10
,	0
using	0
nuclear	0
extracts	0
from	0
normal	0
human	7
eosinophils	8
and	0
the	0
IL-6/interferon-gamma	1
response	2
element	2
of	0
the	0
ICAM-1	1
promoter	2
(	0
ICAM-1	1
pIRE	2
)	0
in	0
an	0
electromobility	0
shift	0
assay	0
.	0

From	0
supershift	0
experiments	0
it	0
was	0
concluded	0
that	0
one	0
DNA-binding	9
complex	10
contained	0
Stat1	9
alpha	10
,	0
probably	0
as	0
a	0
homodimer	0
.	0

Both	0
DNA-binding	9
complexes	10
were	0
inhibited	0
by	0
a	0
phosphotyrosine	9
antibody	10
(	0
4G10	9
)	0
,	0
suggesting	0
that	0
tyrosine	0
phosphorylation	0
is	0
required	0
for	0
complex	0
formation	0
.	0

IL-3	9
and	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
induced	0
,	0
similar	0
to	0
IL-5	9
,	0
two	0
DNA-binding	9
complexes	10
in	0
human	7
eosinophils	8
,	0
including	0
Stat1	9
alpha	10
.	0

These	0
data	0
show	0
for	0
the	0
first	0
time	0
that	0
molecular	0
mechanisms	0
of	0
IL-5	9
signaling	0
in	0
human	7
eosinophils	8
involve	0
members	0
of	0
the	0
JAK	9
kinase	10
family	10
as	0
well	0
as	0
members	0
of	0
the	0
Stat	9
family	10
.	0

Infection	0
and	0
replication	0
of	0
Tat-	0
human	0
immunodeficiency	0
viruses	0
:	0
genetic	0
analyses	0
of	0
LTR	1
and	0
tat	9
mutations	10
in	0
primary	7
and	8
long-term	8
human	8
lymphoid	8
cells	8
.	0

Tat	9
is	0
an	0
essential	0
regulatory	9
protein	10
for	0
the	0
replication	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
.	0

Mutations	0
in	0
the	0
tat	1
gene	2
have	0
been	0
shown	0
to	0
block	0
HIV	0
replication	0
in	0
human	7
T	8
cells	8
.	0

Several	0
studies	0
have	0
established	0
that	0
Tat	9
releases	0
an	0
elongation	9
block	10
to	0
the	0
transcription	0
of	0
HIV	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
;	0
however	0
,	0
it	0
is	0
not	0
known	0
whether	0
this	0
mechanism	0
alone	0
is	0
sufficient	0
to	0
explain	0
the	0
block	0
to	0
HIV	0
replication	0
in	0
human	7
T	8
cells	8
when	0
Tat	9
is	0
absent	0
.	0

It	0
is	0
possible	0
that	0
Tat	9
is	0
also	0
needed	0
for	0
other	0
functions	0
during	0
HIV	0
replication	0
.	0

To	0
test	0
these	0
hypotheses	0
,	0
we	0
studied	0
several	0
tat	9
mutants	10
,	0
including	0
two	0
stop	9
codon	10
mutants	10
and	0
one	0
deletion	9
mutant	10
using	0
replication-competent	1
HIV-1	2
constructs	2
carrying	0
wild-type	1
or	2
mutant	2
LTRs	2
with	0
modifications	0
in	0
the	0
NF-kappa	1
B	2
and/or	2
Sp1	2
binding	2
sites	2
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
Tat-	0
HIV-1	0
with	0
wild-type	1
LTRs	2
can	0
replicate	0
in	0
HeLa	5
cells	6
,	0
and	0
the	0
virus	0
produced	0
from	0
HeLa	5
cells	6
can	0
infect	0
primary	0
peripheral	7
blood	8
lymphocytes	8
and	0
macrophages	7
.	0

It	0
was	0
found	0
that	0
the	0
propagation	0
of	0
the	0
Tat	9
mutants	10
containing	0
wild-type	1
LTRs	2
was	0
less	0
efficient	0
than	0
that	0
of	0
the	0
LTR-modified	9
Tat	10
mutants	10
.	0

Large	0
amounts	0
of	0
viral	3
RNA	4
and	0
particles	0
were	0
synthesized	0
in	0
infections	0
established	0
using	0
the	0
tat	9
mutants	10
that	0
contain	0
modified	1
LTRs	2
.	0

However	0
,	0
this	0
efficient	0
propagation	0
of	0
the	0
LTR-modified	9
tat	10
mutants	10
was	0
restricted	0
to	0
some	0
lymphoid	5
cell	6
lines	6
that	0
have	0
been	0
transformed	0
with	0
other	0
viruses	0
.	0

Thus	0
,	0
despite	0
its	0
essential	0
role	0
for	0
releasing	0
an	0
elongation	9
block	10
,	0
Tat	9
is	0
not	0
otherwise	0
absolutely	0
required	0
for	0
synthesis	0
of	0
full-length	3
HIV	4
transcripts	4
and	0
assembly	0
of	0
virus	0
particles	0
.	0

Direct	0
sequencing	0
of	0
the	0
viral	1
genomes	2
and	0
reinfection	0
kinetics	0
showed	0
no	0
evidence	0
of	0
wild-type	0
reversion	0
even	0
after	0
prolonged	0
infection	0
with	0
the	0
Tat	9
-virus	0
.	0

The	0
implications	0
for	0
in	0
vivo	0
HIV-1	0
replication	0
and	0
potential	0
application	0
of	0
this	0
system	0
to	0
the	0
study	0
of	0
alternative	0
Tat	9
function	0
are	0
discussed	0
.	0

Functional	0
roles	0
of	0
the	0
transcription	9
factor	10
Oct-2A	10
and	0
the	0
high	9
mobility	10
group	10
protein	10
I/Y	9
in	0
HLA-DRA	1
gene	2
expression	0
.	0

The	0
class	1
II	2
major	2
histocompatibility	2
complex	2
gene	2
HLA-DRA	1
is	0
expressed	0
in	0
B	7
cells	8
,	0
activated	0
T	7
lymphocytes	8
,	0
and	0
in	0
antigen-presenting	7
cells	8
.	0

In	0
addition	0
,	0
HLA-DRA	1
gene	2
expression	0
is	0
inducible	0
in	0
a	0
variety	0
of	0
cell	0
types	0
by	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
.	0

Here	0
we	0
show	0
that	0
the	0
lymphoid-specific	9
transcription	10
factor	10
Oct-2A	10
plays	0
a	0
critical	0
role	0
in	0
HLA-DRA	1
gene	2
expression	0
in	0
class	5
II-positive	6
B	6
cell	6
lines	6
,	0
and	0
that	0
the	0
high	9
mobility	10
group	10
protein	10
(	0
HMG	9
)	0
I/Y	9
binds	0
to	0
multiple	0
sites	0
within	0
the	0
DRA	1
promoter	2
,	0
including	0
the	0
Oct-2A	1
binding	2
site	2
.	0

Coexpression	0
of	0
HMG	9
I/Y	10
and	0
Oct-2	9
in	0
cell	5
lines	6
lacking	0
Oct-2	9
results	0
in	0
high	0
levels	0
of	0
HLA-DRA	1
gene	2
expression	0
,	0
and	0
in	0
vitro	0
DNA-binding	0
studies	0
reveal	0
that	0
HMG	0
I/Y	9
stimulates	0
Oct-2A	9
binding	0
to	0
the	0
HLA-DRA	1
promoter	2
.	0

Thus	0
,	0
Oct-2A	9
and	0
HMG	9
I/Y	10
may	0
synergize	0
to	0
activate	0
HLA-DRA	1
expression	0
in	0
B	7
cells	8
.	0

By	0
contrast	0
,	0
Oct-2A	9
is	0
not	0
involved	0
in	0
the	0
IFN-gamma	9
induction	0
of	0
the	0
HLA-DRA	1
gene	2
in	0
HeLa	5
cells	6
,	0
but	0
antisense	1
HMG	2
I/Y	2
dramatically	0
decreases	0
the	0
level	0
of	0
induction	0
.	0

We	0
conclude	0
that	0
distinct	0
sets	0
of	0
transcription	9
factors	10
are	0
involved	0
in	0
the	0
two	0
modes	0
of	0
HLA-DRA	1
expression	0
,	0
and	0
that	0
HMG	9
I/Y	10
may	0
be	0
important	0
for	0
B	0
cell-specific	0
expression	0
,	0
and	0
is	0
essential	0
for	0
IFN-gamma	9
induction	0
.	0

Heterogeneous	0
expression	0
of	0
Epstein-Barr	9
virus	10
latent	10
proteins	10
in	0
endemic	0
Burkitt	0
's	0
lymphoma	0
.	0

Epstein-Barr	7
virus	8
(	8
EBV	8
)	8
-infected	8
cells	8
may	0
sustain	0
three	0
distinct	0
forms	0
of	0
virus	0
latency	0
.	0

In	0
lymphoblastoid	5
cell	6
lines	6
,	0
six	0
EBV-encoded	9
nuclear	10
antigens	10
(	0
EBNA1	9
,	10
2	10
,	10
3A	10
,	10
3B	10
,	10
3C	10
,	10
-LP	10
)	0
,	0
three	0
latent	9
membrane	10
proteins	10
(	0
LMP1	9
,	0
2A	9
,	0
2B	9
)	0
,	0
and	0
two	0
nuclear	3
RNAs	4
(	0
EBERs	3
)	0
are	0
expressed	0
.	0

This	0
form	0
of	0
latency	0
,	0
termed	0
latency	0
III	0
,	0
is	0
also	0
encountered	0
in	0
some	0
posttransplant	0
lymphoproliferative	0
disorders	0
.	0

In	0
EBV-positive	0
cases	0
of	0
Hodgkin	0
's	0
disease	0
,	0
the	0
EBERs	3
,	0
EBNA1	9
,	0
and	0
the	0
LMPs	9
are	0
expressed	0
(	0
latency	0
II	0
)	0
,	0
whereas	0
in	0
Burkitt	0
's	0
lymphoma	0
(	0
BL	0
)	0
only	0
the	0
EBERs	3
and	0
EBNA1	9
have	0
been	0
detected	0
(	0
latency	0
I	0
)	0
.	0

We	0
have	0
studied	0
the	0
expression	0
of	0
EBV	9
proteins	10
in	0
17	0
cases	0
of	0
EBV-positive	0
endemic	0
BL	0
by	0
immunohistology	0
.	0

Expression	0
of	0
LMP1	9
was	0
seen	0
in	0
variable	0
proportions	0
of	0
tumor	7
cells	8
in	0
two	0
cases	0
and	0
EBNA2	9
was	0
detected	0
in	0
some	0
tumor	7
cells	8
in	0
three	0
other	0
cases	0
.	0

Also	0
,	0
the	0
BZLF1	9
trans-activator	10
protein	10
was	0
expressed	0
in	0
a	0
few	0
tumor	7
cells	8
in	0
6	0
cases	0
,	0
indicating	0
entry	0
into	0
the	0
lytic	0
cycle	0
.	0

A	0
phenotypic	0
drift	0
from	0
latency	0
I	0
to	0
latency	0
III	0
has	0
been	0
observed	0
previously	0
in	0
some	0
BL	5
cell	6
lines	6
.	0

Our	0
results	0
suggest	0
that	0
a	0
similar	0
phenomenon	0
may	0
occur	0
in	0
BL	0
in	0
vivo	0
and	0
indicate	0
that	0
the	0
operational	0
definition	0
of	0
EBV	0
latencies	0
is	0
not	0
easily	0
applied	0
to	0
human	0
tumors	0
.	0

The	0
activation	0
of	0
the	0
Jak	9
-STAT	9
1	10
signaling	0
pathway	0
by	0
IL-5	9
in	0
eosinophils	7
.	0

The	0
intracellular	0
signal	0
transduction	0
of	0
IL-5	9
in	0
eosinophils	7
is	0
unknown	0
.	0

The	0
objective	0
of	0
this	0
study	0
was	0
to	0
investigate	0
the	0
involvement	0
of	0
the	0
newly	0
discovered	0
Jak	9
-STAT	9
pathway	0
in	0
the	0
IL-5	9
signal	0
transduction	0
mechanism	0
.	0

Eosinophils	7
were	0
purified	0
from	0
peripheral	0
blood	0
by	0
discontinuous	0
Percoll	0
gradients	0
and	0
stimulated	0
with	0
IL-5	9
.	0

The	0
involvement	0
of	0
Jak	9
2	10
was	0
investigated	0
by	0
immunoprecipitation	0
followed	0
by	0
immunoblotting	0
for	0
tyrosine	0
phosphorylation	0
.	0

The	0
activation	0
of	0
Jak	9
2	10
was	0
studied	0
by	0
autophosphorylation	0
of	0
the	0
immunoprecipitated	9
kinase	10
.	0

Jak	9
2	10
was	0
tyrosine	0
phosphorylated	0
within	0
1	0
to	0
3	0
min	0
after	0
stimulation	0
of	0
eosinophils	7
with	0
IL-5	9
.	0

Further	0
,	0
the	0
immunoprecipitated	9
Jak	10
2	10
obtained	0
from	0
IL-5-stimulated	5
cells	6
underwent	0
autophosphorylation	0
.	0

Jak	9
2	10
coprecipitated	0
with	0
the	0
beta-subunit	0
of	0
the	0
IL-5	9
receptor	10
,	0
suggesting	0
a	0
physical	0
association	0
of	0
the	0
kinase	9
with	0
the	0
receptor	0
.	0

The	0
nuclear	9
factor	10
STAT-1	10
(	0
p91	9
)	0
was	0
investigated	0
by	0
immunoprecipitation	0
followed	0
by	0
immunoblotting	0
for	0
tyrosine	0
phosphorylation	0
.	0

STAT-1	9
was	0
tyrosine	0
phosphorylated	0
within	0
15	0
min	0
of	0
IL-5	9
stimulation	0
.	0

The	0
presence	0
of	0
STAT-1	9
in	0
the	0
nuclear	0
extract	0
was	0
studied	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

IL-5	9
induced	0
two	0
proteins	0
that	0
bound	0
to	0
the	0
gamma-activating	1
sequence	2
.	0

In	0
the	0
presence	0
of	0
an	0
anti-STAT-1	9
Ab	10
,	0
the	0
band	0
was	0
supershifted	0
.	0

Thus	0
,	0
we	0
demonstrated	0
that	0
IL-5	9
activated	0
the	0
Jak	9
2	10
-STAT	9
1	10
signaling	0
pathway	0
in	0
eosinophils	7
.	0

We	0
speculate	0
that	0
the	0
Jak	9
2	10
-STAT	9
1	10
pathway	0
may	0
be	0
involved	0
in	0
the	0
activation	0
of	0
IL-5-inducible	1
genes	2
in	0
eosinophils	7
.	0

Reduced	0
mitogenic	0
stimulation	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
as	0
a	0
prognostic	0
parameter	0
for	0
the	0
course	0
of	0
breast	0
cancer	0
:	0
a	0
prospective	0
longitudinal	0
study	0
.	0

Immunosuppression	0
has	0
been	0
often	0
associated	0
with	0
the	0
course	0
of	0
malignant	0
diseases	0
.	0

In	0
the	0
present	0
study	0
,	0
the	0
proliferation	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
in	0
response	0
to	0
mitogenic	0
stimulation	0
with	0
phytohaemagglutinin	9
(	0
PHA	9
)	0
was	0
assessed	0
prospectively	0
in	0
90	0
patients	0
with	0
stage	0
I-III	0
breast	0
cancer	0
.	0

Whereas	0
PHA	9
-induced	0
proliferation	0
of	0
PBMCs	7
derived	0
from	0
patients	0
with	0
breast	0
cancer	0
preoperatively	0
was	0
significantly	0
decreased	0
when	0
compared	0
with	0
data	0
obtained	0
in	0
healthy	0
control	0
individuals	0
(	0
P	0
<	0
0.001	0
)	0
,	0
the	0
degree	0
of	0
the	0
defect	0
in	0
PHA	9
-induced	0
proliferation	0
of	0
PBMCs	7
depended	0
upon	0
the	0
tumour	0
burden	0
as	0
manifested	0
by	0
tumour	0
size	0
and	0
axillary	0
lymph	0
node	0
involvement	0
(	0
P	0
<	0
0.003	0
in	0
each	0
case	0
)	0
.	0

PHA	9
-induced	0
proliferation	0
of	0
PBMCs	7
dropped	0
significantly	0
in	0
patients	0
who	0
received	0
adjuvant	0
chemotherapy	0
consisting	0
of	0
cyclophosphamide	0
,	0
methotrexate	0
and	0
fluorouracil	0
(	0
CMF	0
)	0
after	0
an	0
observation	0
period	0
of	0
6	0
months	0
(	0
P	0
<	0
0.01	0
)	0
,	0
but	0
not	0
in	0
patients	0
under	0
adjuvant	0
treatment	0
with	0
tamoxifen	0
only	0
.	0

After	0
an	0
additional	0
6	0
months	0
(	0
i.e.	0
12	0
months	0
after	0
surgery	0
)	0
,	0
PHA	9
-induced	0
proliferation	0
of	0
PBMCs	7
was	0
similar	0
in	0
patients	0
after	0
adjuvant	0
chemotherapy	0
with	0
CMF	0
and	0
in	0
those	0
receiving	0
continued	0
adjuvant	0
tamoxifen	0
treatment	0
(	0
P	0
>	0
0.1	0
)	0
,	0
but	0
in	0
all	0
patients	0
still	0
significantly	0
decreased	0
as	0
compared	0
with	0
healthy	0
controls	0
(	0
P	0
<	0
0.001	0
)	0
.	0

When	0
data	0
obtained	0
preoperatively	0
and	0
after	0
12	0
months	0
were	0
compared	0
,	0
it	0
was	0
found	0
that	0
out	0
of	0
23	0
patients	0
whose	0
PBMCs	7
had	0
experienced	0
a	0
drop	0
in	0
their	0
PHA	9
-induced	0
proliferation	0
,	0
14	0
(	0
61	0
%	0
)	0
had	0
developed	0
metastatic	0
disease	0
within	0
the	0
subsequent	0
24	0
months	0
(	0
i.e.	0
36	0
months	0
after	0
surgery	0
)	0
.	0

In	0
contrast	0
,	0
out	0
of	0
59	0
patients	0
whose	0
PBMCs	7
showed	0
an	0
increase	0
in	0
their	0
PHA	9
-induced	0
proliferation	0
within	0
the	0
first	0
12	0
months	0
after	0
surgery	0
,	0
only	0
one	0
(	0
2	0
%	0
)	0
presented	0
with	0
disease	0
progression	0
.	0

We	0
thus	0
conclude	0
that	0
PHA	9
-induced	0
proliferation	0
of	0
PBMCs	7
derived	0
from	0
patients	0
with	0
breast	0
cancer	0
depends	0
upon	0
the	0
tumour	0
load	0
and	0
is	0
a	0
good	0
clinical	0
predictor	0
for	0
the	0
further	0
course	0
of	0
the	0
disease	0
.	0

Activation	0
of	0
transcription	0
by	0
binding	0
of	0
NF-E1	9
(	0
YY1	9
)	0
to	0
a	0
newly	0
identified	0
element	0
in	0
the	0
first	0
exon	0
of	0
the	0
human	1
DR	2
alpha	2
gene	2
.	0

A	0
previously	0
unrecognized	0
element	0
,	0
located	0
downstream	0
of	0
the	0
start	1
site	2
of	2
transcription	2
in	0
the	0
first	0
exon	1
of	0
the	0
DR	1
alpha	2
gene	2
,	0
has	0
been	0
defined	0
that	0
enhances	0
promoter	0
activity	0
up	0
to	0
eightfold	0
in	0
a	0
position-dependent	0
manner	0
.	0

Mutations	0
in	0
this	0
DNA-binding	1
site	2
abolished	0
binding	0
of	0
a	0
nuclear	9
factor	10
in	0
human	0
B	0
cell	0
nuclear	0
extract	0
and	0
decreased	0
the	0
activity	0
of	0
the	0
DR	1
alpha	2
promoter	2
to	0
a	0
basal	0
level	0
.	0

Significant	0
sequence	0
homology	0
of	0
this	0
element	1
was	0
found	0
in	0
the	0
DNA	0
of	0
the	0
DR	1
beta	2
,	2
DP	2
alpha	2
and	2
-beta	2
,	2
and	2
DQ	2
alpha	2
genes	2
,	0
always	0
located	0
downstream	0
of	0
the	0
transcriptional	1
start	2
site	2
.	0

The	0
nuclear	0
factor	0
binds	0
to	0
the	0
DR	1
alpha	2
and	2
DP	2
alpha	2
element	2
but	0
not	0
to	0
the	0
element	0
in	0
the	0
DQ	1
alpha	2
gene	2
.	0

It	0
was	0
identified	0
as	0
NF-E1	9
(	0
YY1	9
)	0
.	0

This	0
protein	0
,	0
previously	0
identified	0
by	0
its	0
binding	0
to	0
the	0
Ig	1
kappa	2
3	2
'	2
enhancer	2
and	0
the	0
Ig	1
heavy	2
chain	2
mu	2
E1	2
site	2
,	0
thus	0
also	0
appears	0
to	0
be	0
quite	0
important	0
in	0
the	0
regulation	0
of	0
MHC	1
class	2
II	2
gene	2
expression	0
.	0

Transcriptional	0
activity	0
of	0
core	9
binding	10
factor-alpha	10
(	10
AML1	10
)	10
and	10
beta	10
subunits	0
on	0
murine	1
leukemia	2
virus	2
enhancer	2
cores	2
.	0

Core	9
binding	10
factor	10
(	0
CBF	9
)	0
,	0
also	0
known	0
as	0
polyomavirus	9
enhancer-binding	10
protein	10
2	10
and	0
SL3	9
enhancer	10
factor	10
1	10
,	0
is	0
a	0
mammalian	9
transcription	10
factor	10
that	0
binds	0
to	0
an	0
element	0
termed	0
the	0
core	0
within	0
the	0
enhancers	1
of	0
the	0
murine	0
leukemia	0
virus	0
family	0
of	0
retroviruses	0
.	0

The	0
core	1
elements	2
of	0
the	0
SL3	0
virus	0
are	0
important	0
genetic	0
determinants	0
of	0
the	0
ability	0
of	0
this	0
virus	0
to	0
induce	0
T-cell	0
lymphomas	0
and	0
the	0
transcriptional	0
activity	0
of	0
the	0
viral	1
long	2
terminal	2
repeat	2
in	0
T	7
lymphocytes	8
.	0

CBF	9
consists	0
of	0
two	0
subunits	0
,	0
a	0
DNA	9
binding	10
subunit	10
,	0
CBF	9
alpha	10
,	0
and	0
a	0
second	0
subunit	0
,	0
CBF	9
beta	10
,	0
that	0
stimulates	0
the	0
DNA	0
binding	0
activity	0
of	0
CBF	9
alpha	10
.	0

One	0
of	0
the	0
genes	0
that	0
encodes	0
a	0
CBF	9
alpha	10
subunit	10
is	0
AML1	9
,	0
also	0
called	0
Cbf	9
alpha	10
2	10
.	0

This	0
locus	0
is	0
rearranged	0
by	0
chromosomal	0
translocations	0
in	0
human	0
myeloproliferative	0
disorders	0
and	0
leukemias	0
.	0

An	0
exogenously	0
expressed	0
Cbf	9
alpha	10
2-encoded	10
subunit	10
(	0
CBF	9
alpha	10
2-451	10
)	0
stimulated	0
transcription	0
from	0
the	0
SL3	1
enhancer	2
in	0
P19	9
and	0
HeLa	5
cells	6
.	0

Activity	0
was	0
mediated	0
through	0
the	0
core	1
elements	2
.	0

Three	0
different	0
isoforms	0
of	0
CBF	9
beta	10
were	0
also	0
tested	0
for	0
transcriptional	0
activity	0
on	0
the	0
SL3	1
enhancer	2
.	0

The	0
longest	0
form	0
,	0
CBF	9
beta-187	10
,	0
increased	0
the	0
transcriptional	0
stimulation	0
by	0
CBF	9
alpha	10
2-451	10
twofold	0
in	0
HeLa	5
cells	6
,	0
although	0
it	0
had	0
no	0
effect	0
in	0
P19	5
cells	6
.	0

Transcriptional	0
activation	0
by	0
CBF	9
beta	10
required	0
binding	0
to	0
the	0
CBF	9
alpha	10
subunit	10
,	0
as	0
a	0
form	0
of	0
CBF	9
beta	10
that	0
lacked	0
binding	0
ability	0
,	0
CBF	9
beta-148	10
,	0
failed	0
to	0
increase	0
activity	0
.	0

These	0
results	0
indicated	0
that	0
at	0
least	0
in	0
certain	0
cell	0
types	0
,	0
the	0
maximum	0
activity	0
of	0
CBF	9
required	0
both	0
subunits	0
.	0

They	0
also	0
provided	0
support	0
for	0
the	0
hypothesis	0
that	0
CBF	9
is	0
a	0
factor	0
in	0
T	7
lymphocytes	8
that	0
is	0
responsible	0
for	0
recognition	0
of	0
the	0
SL3	1
cores	2
.	0

We	0
also	0
examined	0
whether	0
CBF	9
could	0
distinguish	0
a	0
1-bp	0
difference	0
between	0
the	0
enhancer	0
core	0
of	0
SL3	0
and	0
the	0
core	0
of	0
the	0
nonleukemogenic	0
virus	0
,	0
Akv	0
.	0

This	0
difference	0
strongly	0
affects	0
transcription	0
in	0
T	0
cells	0
and	0
leukemogenicity	0
of	0
SL3	1
.	0

However	0
,	0
no	0
combination	0
of	0
CBF	9
alpha	10
and	0
CBF	9
beta	10
subunits	0
that	0
we	0
tested	0
was	0
able	0
to	0
distinguish	0
the	0
1-bp	0
difference	0
in	0
transcription	0
assays	0
.	0

Thus	0
,	0
a	0
complete	0
understanding	0
of	0
how	0
T	7
cells	8
recognize	0
the	0
SL3	1
core	2
remains	0
to	0
be	0
elucidated	0
.	0

Interleukin	9
(	10
IL	10
)	10
-10	10
inhibits	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF	9
kappa	10
B	10
)	0
activation	0
in	0
human	7
monocytes	8
.	0

IL-10	9
and	0
IL-4	9
suppress	0
cytokine	9
synthesis	0
by	0
different	0
mechanisms	0
.	0

Our	0
previous	0
studies	0
in	0
human	7
monocytes	8
have	0
demonstrated	0
that	0
interleukin	9
(	10
IL	10
)	10
-10	10
inhibits	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-stimulated	0
production	0
of	0
inflammatory	9
cytokines	10
,	0
IL-1	9
beta	10
,	0
IL-6	9
,	0
IL-8	9
,	0
and	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
by	0
blocking	0
gene	0
transcription	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
,	0
we	0
now	0
show	0
that	0
,	0
in	0
monocytes	0
stimulated	0
with	0
LPS	0
or	0
TNF	9
alpha	10
,	0
IL-10	9
inhibits	0
nuclear	0
stimulation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF	9
kappa	10
B	10
)	0
,	0
a	0
transcription	9
factor	10
involved	0
in	0
the	0
expression	0
of	0
inflammatory	1
cytokine	2
genes	2
.	0
Several	0
other	0
transcription	9
factors	10
including	0
NF-	0
IL-6	9
,	0
AP-1	9
,	0
AP-2	9
,	0
GR	9
,	0
CREB	9
,	0
Oct-1	9
,	0
and	0
Sp-1	9
are	0
not	0
affected	0
by	0
IL-10	9
.	0

This	0
selective	0
inhibition	0
by	0
IL-10	9
of	0
NF	9
kappa	10
B	10
activation	0
occurs	0
rapidly	0
and	0
in	0
a	0
dose-dependent	0
manner	0
and	0
correlates	0
well	0
with	0
IL-10	9
's	0
cytokine	9
synthesis	0
inhibitory	0
activity	0
in	0
terms	0
of	0
both	0
kinetics	0
and	0
dose	0
responsiveness	0
.	0

Furthermore	0
,	0
compounds	0
such	0
as	0
tosylphenylalanyl	0
chloromethyl	0
ketone	0
and	0
pyrrolidinedithiocarbamate	0
that	0
are	0
known	0
to	0
selectively	0
inhibit	0
NF	9
kappa	10
B	10
activation	0
block	0
cytokine	0
gene	0
transcription	0
in	0
LPS-stimulated	5
monocytes	6
.	0

Taken	0
together	0
,	0
these	0
results	0
suggest	0
that	0
inhibition	0
of	0
NF	9
kappa	10
B	10
activation	0
may	0
be	0
an	0
important	0
mechanism	0
for	0
IL-10	9
suppression	0
of	0
cytokine	0
gene	0
transcription	0
in	0
human	7
monocytes	8
.	0

IL-4	9
,	0
another	0
cytokine	9
that	0
inhibits	0
cytokine	3
mRNA	4
accumulation	0
in	0
monocytes	7
,	0
shows	0
little	0
inhibitory	0
effect	0
on	0
LPS-induced	0
NF	9
kappa	10
B	10
activation	0
.	0

Further	0
examination	0
reveals	0
that	0
,	0
unlike	0
IL-10	9
,	0
IL-4	9
enhances	0
mRNA	3
degradation	0
and	0
does	0
not	0
suppress	0
cytokine	0
gene	0
transcription	0
.	0

These	0
data	0
indicate	0
that	0
IL-10	9
and	0
IL-4	9
inhibit	0
cytokine	9
production	0
by	0
different	0
mechanisms	0
.	0

LMP-1	9
activates	0
NF-kappa	9
B	10
by	0
targeting	0
the	0
inhibitory	9
molecule	10
I	10
kappa	10
B	10
alpha	10
.	0

LMP-1	9
,	0
an	0
Epstein-Barr	9
virus	10
membrane	10
protein	10
expressed	0
during	0
latent	0
infection	0
,	0
has	0
oncogenic	0
properties	0
,	0
as	0
judged	0
from	0
its	0
ability	0
to	0
transform	0
B	0
lymphocytes	7
and	0
rodent	7
fibroblasts	8
.	0

LMP-1	9
induces	0
the	0
expression	0
of	0
bcl2	1
,	0
an	0
oncogene	1
which	0
protects	0
cells	0
from	0
apoptosis	0
,	0
as	0
well	0
as	0
of	0
genes	0
encoding	0
other	0
proteins	0
involved	0
in	0
cell	0
regulation	0
and	0
growth	0
control	0
.	0

The	0
mechanisms	0
by	0
which	0
LMP-1	9
upregulates	0
these	0
proteins	0
is	0
unknown	0
,	0
but	0
it	0
is	0
plausible	0
that	0
LMP-1	9
modifies	0
signal	0
transduction	0
pathways	0
that	0
result	0
in	0
the	0
activation	0
of	0
one	0
or	0
more	0
transcription	9
factors	10
that	0
ultimately	0
regulate	0
transcription	0
of	0
oncogenic	1
genes	2
.	0

NF-kappa	9
B	10
,	0
a	0
transcription	9
factor	10
controlling	0
the	0
expression	0
of	0
genes	1
involved	0
in	0
cell	0
activation	0
and	0
growth	0
control	0
,	0
has	0
been	0
shown	0
to	0
be	0
activated	0
by	0
LMP-1	9
.	0

The	0
mechanism	0
(	0
s	0
)	0
regulating	0
this	0
activation	0
remains	0
unknown	0
.	0

Our	0
data	0
indicate	0
that	0
increased	0
NF-kappa	9
B	10
DNA	0
binding	0
and	0
functional	0
activity	0
are	0
present	0
in	0
B-lymphoid	7
cells	8
stably	0
or	0
transiently	0
expressing	0
LMP-1	9
.	0

I	9
kappa	10
B	10
alpha	10
is	0
selectively	0
modified	0
in	0
LMP-1-expressing	5
B	6
cells	6
.	0

A	0
phosphorylated	0
form	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
increased	0
protein	0
turnover-degradation	0
correlate	0
with	0
increased	0
NF-kappa	9
B	10
nuclear	0
translocation	0
.	0

This	0
results	0
in	0
increased	0
transcription	0
of	0
NF-kappa	1
B-dependent-genes	2
,	0
including	0
those	0
encoding	0
p105	9
and	0
I	9
kappa	10
B	10
alpha	10
(	0
MAD3	1
)	0
.	0

These	0
results	0
indicate	0
that	0
LMP-1	9
activates	0
NF-kappa	9
B	10
in	0
B-cell	5
lines	6
by	0
targeting	0
I	9
kappa	10
B	10
alpha	10
.	0

Identification	0
of	0
the	0
pathways	0
activated	0
by	0
LMP-1	9
to	0
result	0
in	0
posttranslational	0
modifications	0
of	0
I	9
kappa	10
B	10
alpha	10
will	0
aid	0
in	0
determining	0
the	0
role	0
of	0
this	0
virus-host	0
cell	0
protein	0
interaction	0
in	0
Epstein-Barr	0
virus-mediated	0
oncogenesis	0
.	0

Identification	0
of	0
human	1
TR2	2
orphan	2
receptor	2
response	2
element	2
in	0
the	0
transcriptional	1
initiation	2
site	2
of	0
the	0
simian	1
virus	2
40	2
major	2
late	2
promoter	2
[	0
published	0
erratum	0
appears	0
in	0
J	0
Biol	0
Chem	0
1995	0
Nov	0
3	0
;	0
270	0
(	0
44	0
)	0
:	0
26721	0
]	0

A	0
DNA	1
response	2
element	2
(	0
TR2RE-SV40	1
)	0
for	0
the	0
TR2	9
orphan	10
receptor	10
,	0
a	0
member	0
of	0
the	0
steroid-thyroid	9
hormone	10
receptor	10
superfamily	10
,	0
has	0
been	0
identified	0
in	0
the	0
simian	1
virus	2
40	2
(	2
SV40	2
)	2
+55	2
region	2
(	0
nucleotide	1
numbers	2
368-389	2
,	0
5'-GTTAAGGTTCGTAGGTCATGGA-3	0
'	0
)	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
,	0
using	0
in	0
vitro	0
translated	0
TR2	9
orphan	10
receptor	10
with	0
a	0
molecular	0
mass	0
of	0
67	9
kilodaltons	10
,	0
showed	0
a	0
specific	0
binding	0
with	0
high	0
affinity	0
(	0
dissociation	0
constant	0
=	0
9	0
nM	0
)	0
for	0
this	0
DNA	0
sequence	0
.	0

DNA-swap	0
experiments	0
using	0
chloramphenicol	9
acetyl-transferase	10
assay	0
demonstrated	0
that	0
androgen	0
can	0
suppress	0
the	0
transcriptional	0
activities	0
of	0
SV40	1
early	2
promoter	2
via	0
the	0
interaction	0
between	0
this	0
TR2RE-SV40	1
and	0
the	0
chimeric	9
receptor	10
AR/TR2/AR	10
with	0
the	0
DNA-binding	9
domain	10
of	0
the	0
TR2	9
orphan	10
receptor	10
flanked	0
by	0
the	0
N-terminal	9
and	10
androgen-binding	10
domains	10
of	0
the	0
androgen	9
receptor	10
.	0

In	0
addition	0
,	0
this	0
TR2RE-SV40	1
can	0
function	0
as	0
a	0
repressor	0
to	0
suppress	0
the	0
transcriptional	0
activities	0
of	0
both	0
SV40	1
early	2
and	2
late	2
promoters	2
.	0

Together	0
,	0
these	0
data	0
suggest	0
the	0
TR2RE-SV40	1
may	0
represent	0
the	0
first	0
identified	0
natural	0
DNA	1
response	2
element	2
for	0
the	0
TR2	9
orphan	10
receptor	10
that	0
may	0
function	0
as	0
a	0
repressor	0
for	0
the	0
SV40	0
gene	0
expression	0
.	0

Detection	0
of	0
the	0
chromosome	3
16	4
CBF	4
beta-MYH11	4
fusion	4
transcript	4
in	0
myelomonocytic	0
leukemias	0
.	0

Karyotypic	0
detection	0
of	0
chromosomal	0
16	0
abnormalities	0
classically	0
associated	0
with	0
AML	0
M4Eo	0
can	0
be	0
difficult	0
.	0

Characterization	0
of	0
the	0
two	0
genes	0
involved	0
in	0
the	0
inv	0
(	0
16	0
)	0
(	0
p13q22	0
)	0
,	0
CBF	1
beta	2
and	0
MYH11	1
,	0
has	0
allowed	0
the	0
detection	0
of	0
fusion	3
transcripts	4
by	0
reverse-transcriptase	0
polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
.	0

We	0
have	0
analyzed	0
CBF	3
beta-MYH11	4
fusion	4
transcripts	4
by	0
RT-PCR	0
in	0
myelomonocytic	0
leukemias	0
,	0
with	0
or	0
without	0
eosinophilia	0
,	0
to	0
determine	0
whether	0
their	0
presence	0
correlates	0
with	0
morphology	0
.	0

Fifty-three	0
cases	0
(	0
11	0
AML	0
M4Eo	0
;	0
1	0
AML	0
M4	0
with	0
atypical	7
abnormal	8
eosinophils	8
(	0
AML	0
M4	0
``	0
Eo	0
''	0
)	0
;	0
29	0
AML	0
M4	0
;	0
8	0
AML	0
M5	0
;	0
3	0
CMML	0
;	0
and	0
1	0
AML	0
M2	0
with	0
eosinophilia	0
)	0
were	0
analyzed	0
.	0

All	0
11	0
typical	0
AML	0
M4Eo	0
were	0
CBF	1
beta	2
-MYH11	1
positive	0
.	0

The	0
single	0
case	0
of	0
AML	0
M4	0
with	0
distinctive	0
eosinophil	0
abnormalities	0
was	0
negative	0
by	0
karyotype	0
,	0
RT-PCR	0
and	0
fluorescent	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
.	0

Three	0
of	0
29	0
(	0
10	0
%	0
)	0
AML	0
M4	0
without	0
abnormal	7
eosinophils	8
were	0
CBF	1
beta	2
-MYH11	1
positive	0
,	0
1	0
of	0
which	0
did	0
not	0
show	0
any	0
apparent	0
chromosome	1
16	2
abnormalities	0
by	0
classical	0
metaphase	0
analysis	0
(	0
2	0
not	0
tested	0
)	0
.	0

Both	0
cases	0
tested	0
also	0
showed	0
MYH11	1
genomic	0
rearrangement	0
.	0

None	0
of	0
the	0
other	0
leukemias	0
were	0
RT-PCR	0
positive	0
.	0

Follow-up	0
of	0
three	0
patient	0
showed	0
residual	0
positivity	0
in	0
apparent	0
complete	0
remission	0
.	0

These	0
data	0
show	0
that	0
CBF	3
beta-MYH11	4
fusion	4
transcripts	4
occur	0
not	0
only	0
in	0
the	0
vast	0
majority	0
of	0
typical	0
AML	0
M4Eo	0
,	0
but	0
also	0
in	0
approximately	0
10	0
%	0
of	0
AML	0
M4	0
without	0
eosinophilic	0
abnormalities	0
,	0
a	0
much	0
higher	0
incidence	0
than	0
the	0
sporadic	0
reports	0
of	0
chromosome	1
16	2
abnormalities	0
in	0
AML	0
M4	0
would	0
suggest	0
.	0

Taken	0
together	0
with	0
the	0
detection	0
of	0
CBF	1
beta	2
-	0
MYH11	3
transcripts	4
in	0
the	0
absence	0
of	0
apparent	0
chromosome	1
16	2
abnormalities	0
by	0
classical	0
banding	0
techniques	0
,	0
these	0
data	0
show	0
that	0
additional	0
screening	0
by	0
either	0
RT-PCR	0
or	0
FISH	0
should	0
be	0
performed	0
in	0
all	0
AML	0
M4	0
,	0
regardless	0
of	0
morphologic	0
features	0
,	0
to	0
allow	0
accurate	0
evaluation	0
of	0
the	0
prognostic	0
importance	0
of	0
this	0
fusion	3
transcript	4
.	0

HIV-1	9
Tat	10
potentiates	0
TNF	9
-induced	0
NF-kappa	9
B	10
activation	0
and	0
cytotoxicity	0
by	0
altering	0
the	0
cellular	0
redox	0
state	0
.	0

This	0
study	0
demonstrates	0
that	0
human	9
immunodeficiency	10
virus	10
type	10
1	10
(	10
HIV-1	10
)	10
Tat	10
protein	10
amplifies	0
the	0
activity	0
of	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
,	0
a	0
cytokine	0
that	0
stimulates	0
HIV-1	0
replication	0
through	0
activation	0
of	0
NF-kappa	9
B	10
.	0

In	0
HeLa	5
cells	6
stably	0
transfected	0
with	0
the	0
HIV-1	1
tat	2
gene	2
(	0
HeLa-tat	5
cells	6
)	0
,	0
expression	0
of	0
the	0
Tat	9
protein	10
enhanced	0
both	0
TNF	9
-induced	0
activation	0
of	0
NF-kappa	9
B	10
and	0
TNF	9
-mediated	0
cytotoxicity	0
.	0

A	0
similar	0
potentiation	0
of	0
TNF	9
effects	0
was	0
observed	0
in	0
Jurkat	0
T	0
cells	0
and	0
HeLa	5
cells	6
treated	0
with	0
soluble	0
Tat	9
protein	10
.	0

TNF	9
-mediated	0
activation	0
of	0
NF-kappa	9
B	10
and	0
cytotoxicity	0
involves	0
the	0
intracellular	0
formation	0
of	0
reactive	0
oxygen	0
intermediates	0
.	0

Therefore	0
,	0
Tat	9
-mediated	0
effects	0
on	0
the	0
cellular	0
redox	0
state	0
were	0
analyzed	0
.	0

In	0
both	0
T	7
cells	8
and	0
HeLa	5
cells	6
HIV-1	9
Tat	10
suppressed	0
the	0
expression	0
of	0
Mn-dependent	9
superoxide	10
dismutase	10
(	0
Mn-SOD	9
)	0
,	0
a	0
mitochondrial	9
enzyme	10
that	0
is	0
part	0
of	0
the	0
cellular	0
defense	0
system	0
against	0
oxidative	0
stress	0
.	0

Thus	0
,	0
Mn-SOD	9
RNA	0
protein	0
levels	0
and	0
activity	0
were	0
markedly	0
reduced	0
in	0
the	0
presence	0
of	0
Tat	9
.	0

Decreased	0
Mn-SOD	9
expression	0
was	0
associated	0
with	0
decreased	0
levels	0
of	0
glutathione	0
and	0
a	0
lower	0
ratio	0
of	0
reduced	0
:	0
oxidized	0
glutathione	0
.	0

A	0
truncated	0
Tat	9
protein	10
(	0
Tat1-72	9
)	0
,	0
known	0
to	0
transactivate	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
,	0
no	0
longer	0
affected	0
Mn-SOD	9
expression	0
,	0
the	0
cellular	0
redox	0
state	0
or	0
TNF	9
-mediated	0
cytotoxicity	0
.	0

Thus	0
,	0
our	0
experiments	0
demonstrate	0
that	0
the	0
C-terminal	9
region	10
of	0
HIV-1	9
Tat	10
is	0
required	0
to	0
suppress	0
Mn-SOD	9
expression	0
and	0
to	0
induce	0
pro-oxidative	0
conditions	0
reflected	0
by	0
a	0
drop	0
in	0
reduced	0
glutathione	0
(	0
GSH	9
)	0
and	0
the	0
GSH	0
:	0
oxidized	0
GSH	0
(	0
GSSG	0
)	0
ratio	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

The	0
use	0
of	0
glucocorticoids	0
in	0
acute	0
lymphoblastic	0
leukemia	0
of	0
childhood	0
.	0

Molecular	0
,	0
cellular	0
,	0
and	0
clinical	0
considerations	0
.	0

Glucocorticoids	0
have	0
been	0
included	0
in	0
almost	0
all	0
treatment	0
regimens	0
for	0
childhood	0
acute	0
lymphoblastic	0
leukemia	0
for	0
decades	0
.	0

However	0
,	0
optimal	0
agents	0
,	0
doses	0
,	0
and/or	0
schedules	0
have	0
yet	0
to	0
be	0
defined	0
despite	0
extensive	0
clinical	0
application	0
.	0

New	0
data	0
on	0
the	0
pharmacokinetics	0
,	0
pharmacodynamics	0
,	0
and	0
molecular	0
mechanisms	0
of	0
action	0
of	0
glucocorticoids	0
have	0
suggested	0
alternative	0
approaches	0
in	0
ALL	0
.	0

These	0
suggest	0
that	0
prolonged	0
,	0
i.e.	0
28	0
day	0
,	0
glucocorticoid	0
therapy	0
may	0
be	0
unnecessary	0
as	0
exposure	0
to	0
glucocorticoid	0
induces	0
down-regulation	0
of	0
glucocorticoid	9
receptors	10
.	0

Dexamethasone	0
may	0
be	0
superior	0
to	0
prednisone	0
in	0
conventional	0
equi-effective	0
doses	0
.	0

Blast	0
sensitivity	0
to	0
glucocorticoids	0
correlates	0
closely	0
with	0
sensitivity	0
to	0
other	0
,	0
putatively	0
non-cross-resisting	0
agents	0
and	0
with	0
outcome	0
after	0
multi-agent	0
therapy	0
,	0
suggesting	0
overlapping	0
mechanisms	0
of	0
action	0
,	0
and	0
focusing	0
attention	0
on	0
the	0
determinants	0
of	0
the	0
threshold	0
for	0
apoptosis	0
.	0

Increasing	0
success	0
in	0
the	0
treatment	0
of	0
childhood	0
acute	0
lymphoblastic	0
leukemia	0
has	0
led	0
to	0
increasing	0
awareness	0
of	0
avascular	0
necrosis	0
of	0
bone	0
as	0
a	0
potentially	0
disabling	0
sequela	0
of	0
glucocorticoid	0
therapy	0
,	0
especially	0
in	0
adolescent	0
and	0
young	0
adult	0
patients	0
.	0

Epstein-Barr	9
virus	10
nuclear	10
protein	10
2	10
transactivation	0
of	0
the	0
latent	1
membrane	2
protein	2
1	2
promoter	2
is	0
mediated	0
by	0
J	9
kappa	10
and	0
PU.1	9
.	0

Expression	0
of	0
the	0
Epstein-Barr	1
virus	2
(	2
EBV	2
)	2
latent	2
membrane	2
protein	2
1	2
(	2
LMP-1	2
)	2
oncogene	2
is	0
regulated	0
by	0
the	0
EBV	9
nuclear	10
protein	10
2	10
(	10
EBNA-2	10
)	10
transactivator	10
.	0

EBNA-2	9
is	0
known	0
to	0
interact	0
with	0
the	0
cellular	9
DNA-binding	10
protein	10
J	9
kappa	10
and	0
is	0
recruited	0
to	0
promoters	1
containing	0
the	0
GTGGGAA	0
J	1
kappa	2
recognition	2
sequence	2
.	0

The	0
minimal	1
EBNA-2-responsive	2
LMP-1	2
promoter	2
includes	0
one	0
J	1
kappa-binding	2
site	2
,	0
and	0
we	0
now	0
show	0
that	0
mutation	0
of	0
that	0
site	0
,	0
such	0
that	0
J	9
kappa	10
can	0
not	0
bind	0
,	0
reduces	0
EBNA-2	9
responsiveness	0
by	0
60	0
%	0
.	0

To	0
identify	0
other	0
factors	0
which	0
interact	0
with	0
the	0
LMP-1	1
EBNA-2	2
response	2
element	2
(	0
E2RE	1
)	0
,	0
a	0
-236/-145	1
minimal	2
E2RE	2
was	0
used	0
as	0
a	0
probe	0
in	0
an	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

The	0
previously	0
characterized	0
factors	0
J	9
kappa	10
,	0
PU.1	9
,	0
and	0
AML1	9
bind	0
to	0
the	0
LMP-1	1
E2RE	2
,	0
along	0
with	0
six	0
other	0
unidentified	0
factors	0
(	0
LBF2	9
to	0
LBF7	9
)	0
.	0

Binding	0
sites	0
were	0
mapped	0
for	0
each	0
factor	0
.	0

LBF4	9
is	0
B-	0
and	0
T-cell	0
specific	0
and	0
recognizes	0
the	0
PU.1	1
GGAA	2
core	2
sequence	2
as	0
shown	0
by	0
methylation	0
interference	0
.	0

LBF4	9
has	0
a	0
molecular	0
mass	0
of	0
105	0
kDa	0
and	0
is	0
probably	0
unrelated	0
to	0
PU.1	9
.	0

LBF2	9
was	0
found	0
only	0
in	0
epithelial	5
cell	6
lines	6
,	0
whereas	0
LBF3	9
,	0
LBF5	9
,	0
LBF6	9
,	0
and	0
LBF7	9
were	0
not	0
cell	0
type	0
specific	0
.	0

Mutations	0
of	0
the	0
AML1-	1
or	2
LBF4-binding	2
sites	2
had	0
no	0
effect	0
on	0
EBNA-2	9
transactivation	0
,	0
whereas	0
mutation	0
of	0
the	0
PU.1-binding	1
site	2
completely	0
eliminated	0
EBNA-2	9
responses	0
.	0

A	0
gst-EBNA-2	9
fusion	10
protein	10
specifically	0
depleted	0
PU.1	9
from	0
nuclear	0
extracts	0
and	0
bound	0
in	0
vitro	0
translated	0
PU.1	9
,	0
providing	0
biochemical	0
evidence	0
for	0
a	0
direct	0
EBNA-2	9
-PU.1	9
interaction	0
.	0

Thus	0
,	0
EBNA-2	9
transactivation	0
of	0
the	0
LMP-1	1
promoter	2
is	0
dependent	0
on	0
interaction	0
with	0
at	0
least	0
two	0
distinct	0
sequence-specific	0
DNA-binding	9
proteins	10
,	0
J	9
kappa	10
and	0
PU.1	9
.	0

LBF3	9
,	0
LBF5	9
,	0
LBF6	9
,	0
or	0
LBF7	9
may	0
also	0
be	0
involved	0
,	0
since	0
their	0
binding	0
sites	0
also	0
contribute	0
to	0
EBNA-2	9
responsiveness	0
.	0

Lymphocyte	9
glucocorticoid	10
receptor	10
:	0
predictor	0
of	0
sertraline	0
response	0
in	0
adolescent	0
major	0
depressive	0
disorder	0
(	0
MDD	0
)	0
.	0

Major	0
depressive	0
disorder	0
(	0
MDD	0
)	0
in	0
adolescents	0
demonstrates	0
resistance	0
to	0
tricyclic	0
antidepressants	0
and	0
absence	0
of	0
hypercortisolemia	0
.	0

The	0
efficacy	0
of	0
serotonin	0
reuptake	0
inhibitors	0
(	0
SRIs	0
)	0
is	0
uncertain	0
,	0
and	0
response	0
predictors	0
are	0
unavailable	0
.	0

Abnormal	0
fast	0
feedback	0
and	0
negative	0
feedback	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
axis	0
implicates	0
a	0
dampened	0
limbic-hippocampal	9
glucocorticoid	10
type	10
II	10
receptor	10
(	0
GCII	9
)	0
.	0

We	0
hypothesized	0
that	0
lymphocyte	9
GCII	10
is	0
altered	0
in	0
adolescent	0
MDD	0
and	0
could	0
serve	0
as	0
a	0
marker	0
for	0
response	0
to	0
SRIs	0
.	0

In	0
an	0
open-label	0
study	0
,	0
adolescents	0
(	0
n	0
=	0
20	0
)	0
meeting	0
DSM-III-R	0
criteria	0
for	0
MDD	0
showed	0
baseline	0
lymphocyte	9
GCII	10
sites	10
per	0
cell	0
(	0
sites/cell	0
)	0
values	0
of	0
793	0
+/-	0
106	0
versus	0
2	0
,	0
563	0
+/-	0
499	0
(	0
+/-	0
SEM	0
)	0
for	0
matched	0
controls	0
(	0
n	0
=	0
18	0
)	0
(	0
t	0
=	0
3.5	0
;	0
df	0
=	0
36	0
;	0
p	0
<	0
.001	0
)	0
.	0

GCII	9
was	0
bimodally	0
distributed	0
,	0
with	0
SRI	0
responders	0
differing	0
from	0
nonresponders	0
(	0
t	0
=	0
3.9	0
;	0
df	0
=	0
14	0
;	0
p	0
<	0
.001	0
)	0
.	0

GCII	9
accurately	0
classified	0
90	0
percent	0
of	0
sertraline	0
responders	0
and	0
80	0
percent	0
of	0
nonresponders	0
.	0

Only	0
SRI	0
responders	0
showed	0
GCII	9
sites/cell	0
upregulated	0
after	0
6	0
weeks	0
of	0
treatment	0
(	0
t	0
=	0
2.1	0
,	0
df	0
=	0
10	0
;	0
p	0
<	0
.05	0
)	0
.	0

The	0
role	0
of	0
NFATp	9
in	0
cyclosporin	1
A-sensitive	2
tumor	2
necrosis	2
factor-alpha	2
gene	2
transcription	0
.	0

The	0
tumor	1
necrosis	2
factor-alpha	2
(	2
TNF	2
alpha	2
)	2
gene	2
is	0
an	0
immediate	0
early	0
gene	0
in	0
activated	0
T	7
cells	8
,	0
in	0
that	0
it	0
is	0
rapidly	0
induced	0
without	0
a	0
requirement	0
for	0
protein	0
synthesis	0
.	0

Maximal	0
induction	0
of	0
TNF	3
alpha	4
mRNA	4
can	0
be	0
induced	0
by	0
treatment	0
of	0
T	7
cells	8
with	0
calcium	0
ionophores	0
alone	0
,	0
via	0
a	0
calcineurin	9
-dependent	0
process	0
that	0
is	0
blocked	0
by	0
cyclosporin	0
A	0
.	0

We	0
have	0
previously	0
identified	0
a	0
promoter	1
element	2
,	0
kappa	1
3	2
,	0
that	0
is	0
required	0
for	0
calcium-stimulated	0
,	0
cyclosporin	0
A-sensitive	0
induction	0
of	0
the	0
TNF	1
alpha	2
gene	2
in	0
activated	0
T	7
cells	8
.	0

Here	0
,	0
we	0
demonstrate	0
that	0
the	0
kappa	9
3	10
binding	10
factor	10
contains	0
NFATp	9
,	0
a	0
cyclosporin-sensitive	9
DNA-binding	10
protein	10
required	0
for	0
interleukin-2	1
gene	2
transcription	0
.	0

NFATp	9
binds	0
to	0
two	0
sites	0
within	0
the	0
kappa	1
3	2
element	2
,	0
and	0
occupancy	0
of	0
both	0
sites	0
is	0
required	0
for	0
TNF	9
alpha	0
gene	0
induction	0
.	0

Thus	0
,	0
although	0
the	0
kappa	1
3	2
element	2
has	0
little	0
sequence	0
similarity	0
to	0
other	0
NFATp-binding	1
sites	2
,	0
it	0
appears	0
to	0
function	0
as	0
a	0
cyclosporin-sensitive	1
promoter	2
element	2
in	0
T	7
cells	8
by	0
virtue	0
of	0
its	0
ability	0
to	0
bind	0
NFATp	9
.	0

The	0
involvement	0
of	0
NFATp	9
in	0
transcriptional	0
activation	0
of	0
both	0
the	0
interleukin-2	9
and	0
TNF	1
alpha	2
genes	2
suggests	0
that	0
this	0
factor	0
plays	0
an	0
important	0
role	0
in	0
the	0
coordinate	0
induction	0
of	0
multiple	0
cytokine	1
genes	2
,	0
starting	0
at	0
the	0
earliest	0
stages	0
of	0
T	0
cell	0
activation	0
.	0

Regulation	0
and	0
specificity	0
of	0
MNDA	9
expression	0
in	0
monocytes	7
,	0
macrophages	7
,	0
and	0
leukemia/B	5
lymphoma	6
cell	6
lines	6
.	0

The	0
expression	0
of	0
the	0
human	9
myeloid	10
cell	10
nuclear	10
differentiation	10
antigen	10
(	0
MNDA	9
)	0
was	0
observed	0
specifically	0
in	0
cells	0
of	0
the	0
granulocyte-macrophage	0
lineage	0
in	0
our	0
earlier	0
reports	0
.	0

The	0
specificity	0
of	0
MNDA	9
expression	0
for	0
cells	0
in	0
the	0
granulocyte-macrophage	0
lineage	0
was	0
reexamined	0
in	0
cell	5
lines	6
established	0
from	0
patients	0
with	0
Philadelphia	0
chromosome-positive	0
chronic	0
myeloid	0
leukemia	0
.	0

Cell	0
lines	0
that	0
expressed	0
MNDA	9
exhibited	0
myeloid	0
cell	0
features	0
and	0
granulocyte	0
or	0
monocyte	0
differentiation	0
could	0
be	0
induced	0
in	0
vitro	0
,	0
while	0
cell	0
lines	0
exhibiting	0
properties	0
of	0
very	0
early	0
stage	0
cells	0
or	0
multipotential	7
cells	8
did	0
not	0
express	0
MNDA	9
.	0

Cells	0
originating	0
from	0
cases	0
of	0
Burkitt	0
's	0
lymphoma	0
were	0
negative	0
.	0

By	0
contrast	0
,	0
three	0
lymphoblastoid	5
cell	6
lines	6
(	0
immortalized	0
in	0
vitro	0
with	0
Epstein-Barr	0
virus	0
)	0
were	0
weakly	0
positive	0
and	0
MNDA	9
was	0
up-regulated	0
by	0
interferon-alpha	9
(	0
IFN-alpha	9
)	0
treatment	0
.	0

As	0
we	0
reported	0
previously	0
,	0
MNDA	3
mRNA	4
level	0
in	0
adherent	0
monocytes	7
is	0
elevated	0
by	0
IFN-alpha	9
;	0
in	0
this	0
study	0
,	0
we	0
further	0
assessed	0
MNDA	9
expression	0
in	0
in	0
vitro	0
monocyte-derived	0
macrophages	7
.	0

Three	0
additional	0
agents	0
(	0
endotoxin	0
,	0
phytohemagglutinin	9
,	0
and	0
phorbol	0
ester	0
)	0
and	0
other	0
conditions	0
that	0
affect	0
function	0
,	0
cytokine	9
production	0
,	0
differentiation	0
,	0
and/or	0
growth	0
of	0
monocytes	7
were	0
examined	0
for	0
their	0
ability	0
to	0
alter	0
MNDA	9
expression	0
.	0

The	0
results	0
varied	0
with	0
the	0
agent	0
,	0
cell	0
type	0
,	0
and	0
stage	0
of	0
differentiation	0
.	0

Changes	0
in	0
MNDA	9
expression	0
occurred	0
slowly	0
(	0
hours	0
to	0
days	0
)	0
,	0
suggesting	0
that	0
MNDA	9
could	0
mediate	0
changes	0
realized	0
over	0
a	0
long	0
period	0
.	0

The	0
results	0
also	0
reveal	0
a	0
discordance	0
in	0
certain	0
MNDA	5
positive	6
cells	6
between	0
steady-state	0
levels	0
or	0
changes	0
in	0
levels	0
of	0
protein	0
and	0
mRNA	3
indicating	0
that	0
the	0
regulation	0
of	0
MNDA	9
expression	0
occurs	0
at	0
more	0
than	0
one	0
point	0
.	0

Changes	0
in	0
MNDA	9
expression	0
are	0
consistent	0
with	0
a	0
role	0
in	0
opposing	0
macrophage	0
differentiation	0
and	0
activation	0
of	0
monocytes	7
/macrophages	7
.	0

DNA-binding	0
studies	0
of	0
the	0
Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
(	0
EBNA-2	9
)	0
:	0
evidence	0
for	0
complex	0
formation	0
by	0
latent	9
membrane	10
protein	10
gene	10
promoter-binding	10
proteins	10
in	0
EBNA-2-positive	5
cell	6
lines	6
.	0

The	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
nuclear	10
antigen	10
2	10
(	0
EBNA-2	9
)	0
protein	0
is	0
essential	0
for	0
the	0
immortalization	0
of	0
human	7
primary	8
B	8
cells	8
by	0
EBV	0
.	0

EBNA-2	9
trans-activates	0
cellular	1
and	2
viral	2
genes	2
like	0
CD23	1
,	0
c-fgr	1
,	0
latent	9
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
and	0
terminal	9
protein	10
1	10
(	0
TP1	9
)	0
.	0

Trans-activation	0
of	0
the	0
TP1	1
promoter	2
and	0
of	0
the	0
BamHI	1
C	2
promoter	2
has	0
already	0
been	0
investigated	0
in	0
detail	0
and	0
appears	0
to	0
be	0
mediated	0
via	0
protein-protein	0
interactions	0
and	0
not	0
by	0
direct	0
binding	0
of	0
EBNA-2	9
type	10
A	10
(	0
of	0
EBV	0
type	0
1	0
)	0
to	0
the	0
DNA	0
.	0

EBNA-2	9
is	0
able	0
to	0
trans-activate	0
the	0
expression	0
of	0
the	0
LMP	1
gene	2
in	0
several	0
cell	0
lines	0
.	0

Various	0
reports	0
have	0
delineated	0
the	0
cis-acting	1
elements	2
of	0
the	0
LMP	1
promoter	2
through	0
which	0
EBNA-2	9
mediates	0
trans-activation	0
.	0

To	0
determine	0
whether	0
EBNA-2	9
also	0
trans-activates	0
the	0
LMP	1
promoter	2
by	0
protein-protein	0
interactions	0
,	0
we	0
performed	0
a	0
series	0
of	0
gel	0
retardation	0
assays	0
and	0
competition	0
experiments	0
with	0
LMP	1
promoter	2
fragments	2
of	0
different	0
sizes	0
.	0

We	0
determined	0
that	0
the	0
protein-binding	1
region	2
on	0
the	0
LMP	1
promoter	2
was	0
within	0
a	0
42	1
bp	2
fragment	2
encompassing	0
nucleotides	0
-135	0
to	0
-176	0
relative	0
to	0
the	0
LMP	1
transcriptional	2
start	2
site	2
.	0

None	0
of	0
the	0
DNA	0
fragments	0
investigated	0
indicated	0
interaction	0
of	0
EBNA-2	9
with	0
the	0
DNA	0
via	0
protein-protein	0
interactions	0
.	0

No	0
significant	0
differences	0
between	0
EBNA-2	9
-positive	0
and	0
EBNA-2	9
-negative	0
nuclear	0
extracts	0
could	0
be	0
seen	0
in	0
the	0
gel	0
retardation	0
assay	0
under	0
conditions	0
that	0
clearly	0
showed	0
binding	0
of	0
EBNA-2A	9
to	0
the	0
TP1	1
promoter	2
.	0

However	0
,	0
analysis	0
of	0
sucrose	0
gradient	0
fractions	0
in	0
the	0
gel	0
retardation	0
assay	0
provided	0
evidence	0
that	0
the	0
LMP	9
promoter-binding	10
proteins	10
form	0
a	0
complex	0
of	0
higher	0
M	0
(	0
r	0
)	0
in	0
EBNA-2-positive	7
cell	8
extracts	0
.	0

These	0
complexes	0
were	0
destroyed	0
by	0
detergent	0
.	0

We	0
deduce	0
from	0
these	0
results	0
that	0
EBNA-2-positive	5
cells	6
might	0
indeed	0
contain	0
specific	9
complexes	10
bound	0
to	0
the	0
LMP	1
promoter	2
which	0
are	0
,	0
however	0
,	0
too	0
labile	0
to	0
be	0
detected	0
in	0
a	0
standard	0
gel	0
retardation	0
assay	0
.	0

Simultaneous	0
activation	0
of	0
Ig	9
and	0
Oct-2	9
synthesis	0
and	0
reduction	0
of	0
surface	0
MHC	9
class	10
II	10
expression	0
by	0
IL-6	9
.	0

Terminal	0
differentiation	0
of	0
B	7
cells	8
to	0
plasma	7
cells	8
in	0
vivo	0
is	0
characterized	0
by	0
secretion	0
of	0
Ig	9
and	0
extinction	0
of	0
MHC	9
class	10
II	10
expression	0
on	0
the	0
cell	0
surface	0
.	0

We	0
show	0
that	0
IL-6	9
signaling	0
leads	0
to	0
marked	0
increases	0
in	0
the	0
synthesis	0
and	0
secretion	0
of	0
Ig	9
in	0
clonal	5
human	6
B	6
cell	6
lines	6
and	0
newly	0
isolated	7
polyclonal	8
B	8
lymphocytes	8
in	0
vitro	0
.	0

The	0
IL-6-induced	5
cells	6
resemble	0
plasma	7
cells	8
in	0
ultrastructure	0
and	0
in	0
reduced	0
expression	0
of	0
surface	9
MHC	10
class	10
II	10
.	0

Enhanced	0
Ig	9
synthesis	0
is	0
a	0
result	0
of	0
coordinated	0
transcriptional	0
activation	0
of	0
Ig	1
genes	2
without	0
promoter	0
or	0
isotype	0
specificity	0
,	0
and	0
differential	0
accumulation	0
of	0
the	0
mRNA	3
encoding	0
the	0
secreted	0
form	0
of	0
Ig	9
heavy	10
chain	10
.	0

It	0
is	0
saturable	0
and	0
subject	0
to	0
negative	0
control	0
when	0
IL-6	9
stimulation	0
is	0
prolonged	0
.	0

Coordinate	0
with	0
temporal	0
changes	0
in	0
Ig	9
synthesis	0
,	0
the	0
DNA-binding	0
activity	0
and	0
the	0
synthesis	0
of	0
the	0
B	9
cell-enriched	10
transcription	10
factor	10
Oct-2	9
are	0
regulated	0
.	0

Thus	0
,	0
differentiation	0
of	0
B	7
cells	8
with	0
IL-6	9
in	0
vitro	0
recapitulates	0
the	0
hallmarks	0
of	0
terminal	0
B	0
differentiation	0
in	0
vivo	0
;	0
Oct-2	9
may	0
have	0
a	0
role	0
in	0
this	0
process	0
.	0

T-cell	1
functional	2
regions	2
of	0
the	0
human	1
IL-3	2
proximal	2
promoter	2
.	0

The	0
human	1
interleukin-3	2
(	2
IL-3	2
)	2
gene	2
is	0
expressed	0
almost	0
exclusively	0
in	0
activated	0
T	7
cells	8
.	0

Its	0
expression	0
is	0
regulated	0
at	0
both	0
the	0
transcriptional	0
and	0
post-transcriptional	0
level	0
.	0

We	0
have	0
previously	0
shown	0
that	0
treatment	0
of	0
Jurkat	5
T	6
cells	6
with	0
phytohemaglutinin	9
(	0
PHA	9
)	0
and	0
the	0
phorbol	0
ester	0
,	0
PMA	0
,	0
activated	0
transcription	0
initiation	0
from	0
the	0
IL-3	1
gene	2
.	0

To	0
define	0
the	0
regions	0
of	0
the	0
gene	0
required	0
for	0
transcription	0
activation	0
,	0
we	0
generated	0
a	0
series	0
of	0
reporter	0
constructs	0
containing	0
different	0
regions	0
of	0
the	0
IL-3	1
gene	2
5	2
'	2
and	2
3	2
'	2
flanking	2
sequences	2
.	0

Both	0
positive	1
and	2
negative	2
regulatory	2
elements	2
were	0
identified	0
in	0
the	0
proximal	1
5	2
'	2
flanking	2
region	2
of	0
the	0
IL-3	1
gene	2
.	0

The	0
promoter	1
region	2
between	0
-173	1
and	2
-60	2
contained	0
the	0
strongest	0
activating	1
elements	2
.	0

The	0
transcription	9
factor	10
AP-1	9
could	0
bind	0
to	0
this	0
positive	0
activator	0
region	0
of	0
the	0
promoter	0
.	0

We	0
also	0
examined	0
the	0
function	0
of	0
the	0
IL-3	1
CK-1/CK-2	2
elements	2
that	0
are	0
present	0
in	0
many	0
cytokine	1
genes	2
and	0
found	0
that	0
they	0
acted	0
as	0
a	0
repressor	0
of	0
basal	0
level	0
expression	0
when	0
cloned	0
upstream	0
of	0
a	0
heterologous	1
promoter	2
but	0
were	0
also	0
inducible	0
by	0
PMA	0
/PHA	9
.	0

Expression	0
of	0
the	0
Runt	1
domain-encoding	2
PEBP2	2
alpha	2
genes	2
in	0
T	7
cells	8
during	0
thymic	0
development	0
.	0

The	0
PEBP2	1
alpha	2
A	2
and	2
PEBP2	2
alpha	2
B	2
genes	2
encode	0
the	0
DNA-binding	9
subunit	10
of	0
a	0
murine	9
transcription	10
factor	10
,	0
PEBP2	9
,	0
which	0
is	0
implicated	0
as	0
a	0
T-cell-specific	9
transcriptional	10
regulator	10
.	0

These	0
two	0
related	0
genes	0
share	0
the	0
evolutionarily	0
conserved	0
region	0
encoding	0
the	0
Runt	9
domain	10
.	0

PEBP2	9
alpha	10
B	10
is	0
the	0
murine	9
counterpart	10
of	0
human	9
AML1	10
,	0
which	0
is	0
located	0
at	0
the	0
breakpoints	0
of	0
the	0
8	1
;	2
21	2
and	2
3	2
;	2
21	2
chromosome	2
translocations	2
associated	0
with	0
acute	0
myeloid	0
leukemia	0
.	0

Northern	0
(	0
RNA	0
)	0
blots	0
of	0
various	0
adult	0
mouse	0
tissues	0
revealed	0
that	0
the	0
levels	0
of	0
expression	0
of	0
both	0
genes	0
were	0
most	0
prominent	0
in	0
the	0
thymus	0
.	0

Furthermore	0
,	0
transcripts	0
of	0
PEBP2	9
alpha	10
A	10
and	0
mouse	9
AML1/PEBP2	10
alpha	10
B	10
were	0
detected	0
in	0
T	7
lymphocytes	8
in	0
the	0
thymuses	0
from	0
day	0
16	0
embryos	0
and	0
newborns	0
,	0
as	0
well	0
as	0
4-week-old	0
adult	0
mice	0
,	0
by	0
in	0
situ	0
hybridization	0
.	0

The	0
expression	0
of	0
the	0
genes	0
persisted	0
in	0
peripheral	0
lymph	0
nodes	0
of	0
adult	0
mice	0
.	0

The	0
transcripts	0
were	0
detected	0
in	0
all	0
the	0
CD4-	7
CD8-	8
,	8
CD4+	8
CD8+	8
,	8
CD4+	8
CD8-	8
,	8
and	8
CD4-	8
CD8+	8
cell	8
populations	8
.	0

The	0
results	0
indicated	0
that	0
both	0
genes	0
are	0
expressed	0
in	0
T	7
cells	8
throughout	0
their	0
development	0
,	0
supporting	0
the	0
notion	0
that	0
PEBP2	9
is	0
a	0
T-cell-specific	9
transcription	10
factor	10
.	0

Transcripts	0
of	0
mouse	9
AML1/PEBP2	10
alpha	10
B	10
were	0
also	0
detected	0
in	0
day	0
12	0
fetal	0
hematopoietic	0
liver	0
and	0
in	0
the	0
bone	7
marrow	8
cells	8
of	0
newborn	0
mice	0
.	0

The	0
implication	0
of	0
mouse	0
AML1/PEBP2	9
alpha	10
B	10
expression	0
in	0
hematopoietic	7
cells	8
other	0
than	0
those	0
of	0
T-cell	7
lineage	8
is	0
discussed	0
in	0
relation	0
to	0
myeloid	0
leukemogenesis	0
.	0

Effects	0
of	0
glucocorticoids	0
on	0
transcription	0
factor	0
activation	0
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

Glucocorticoids	0
have	0
an	0
inhibitory	0
effect	0
on	0
inflammatory	0
and	0
immune	0
responses	0
,	0
and	0
this	0
may	0
be	0
through	0
the	0
modulation	0
of	0
transcription	9
factor	10
binding	0
to	0
DNA	0
.	0

The	0
interaction	0
of	0
the	0
transcription	9
factors	10
,	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
,	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF	9
kappa	10
B	10
)	0
,	0
and	0
cAMP-responsive	9
element	10
binding	10
protein	10
(	0
CREB	9
)	0
with	0
DNA	0
and	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
was	0
analyzed	0
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
by	0
gel	0
mobility	0
shift	0
assays	0
.	0

TNF-alpha	0
,	0
IL-1	0
beta	0
and	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
treatment	0
increased	0
AP-1	9
and	0
NF	0
kappa	0
B	0
DNA	0
binding	0
by	0
up	0
to	0
200	0
%	0
but	0
decreased	0
CREB	9
binding	0
(	0
38	0
%	0
)	0
over	0
a	0
60-min	0
time	0
course	0
.	0

Dexamethasone	0
produced	0
a	0
rapid	0
and	0
sustained	0
increase	0
in	0
glucocorticoid	1
response	2
element	2
binding	0
and	0
a	0
concomitant	0
40-50	0
%	0
decrease	0
in	0
AP-1	0
,	0
NF	0
kappa	0
B	0
,	0
and	0
CREB	0
DNA	0
binding	0
that	0
was	0
blocked	0
by	0
combined	0
dexamethasone	0
and	0
cytokine	9
or	0
PMA	0
treatment	0
.	0

These	0
latter	0
effects	0
were	0
due	0
to	0
increases	0
in	0
the	0
nuclear	0
localization	0
of	0
GR	9
,	0
not	0
to	0
reduced	0
amounts	0
of	0
the	0
other	0
transcription	9
factors	10
.	0

This	0
suggests	0
that	0
in	0
these	0
cells	0
GR	9
within	0
the	0
nucleus	0
interacts	0
with	0
cytokine-stimulated	9
transcription	10
factors	10
by	0
the	0
process	0
of	0
cross	0
coupling	0
.	0

This	0
may	0
be	0
an	0
important	0
molecular	0
site	0
of	0
steroid	0
action	0
.	0

Differential	0
induction	0
of	0
the	0
NF-AT	9
complex	10
during	0
restimulation	0
and	0
the	0
induction	0
of	0
T-cell	0
anergy	0
.	0

Stimulation	0
of	0
human	5
CD4+	6
T-cell	6
clones	6
through	0
the	0
T-cell	9
receptor	10
(	0
TcR	9
)	0
by	0
high	0
doses	0
of	0
specific	0
peptide	0
results	0
in	0
the	0
induction	0
of	0
a	0
long-lived	0
state	0
of	0
nonresponsiveness	0
that	0
has	0
been	0
called	0
anergy	0
.	0

During	0
the	0
induction	0
of	0
anergy	0
,	0
T	7
cells	8
are	0
phenotypically	0
similar	0
to	0
cells	0
responding	0
to	0
an	0
immunogenic	0
stimulus	0
.	0

The	0
amount	0
of	0
TcR	9
at	0
the	0
cell	0
surface	0
is	0
downmodulated	0
,	0
whereas	0
the	0
CD2	9
and	10
CD25	10
receptors	10
are	0
increased	0
.	0

When	0
restimulated	0
,	0
however	0
,	0
anergic	7
T	8
cells	8
fail	0
to	0
up-regulate	0
transcription	0
of	0
the	0
IL-2	1
gene	2
and	0
in	0
consequence	0
do	0
not	0
produce	0
IL-2	9
.	0

In	0
this	0
study	0
,	0
we	0
have	0
compared	0
the	0
ability	0
of	0
various	0
transcription	9
factors	10
to	0
bind	0
to	0
their	0
appropriate	0
site	0
on	0
DNA	0
.	0

Factors	0
were	0
isolated	0
from	0
the	0
nuclei	0
of	0
T	7
cells	8
that	0
were	0
in	0
the	0
induction	0
phase	0
of	0
anergy	0
or	0
were	0
undergoing	0
activation	0
.	0

The	0
pattern	0
of	0
binding	0
activity	0
in	0
restimulated	0
T	7
cells	8
is	0
consistent	0
with	0
the	0
pattern	0
that	0
has	0
previously	0
been	0
shown	0
to	0
regulate	0
T-cell-specific	0
expression	0
of	0
the	0
IL-2	9
and	0
the	0
beta	0
chain	0
of	0
the	0
TcR	1
genes	2
.	0

The	0
measured	0
binding	0
to	0
a	0
TCF-1	1
site	2
is	0
the	0
same	0
in	0
the	0
nuclei	0
of	0
resting	7
,	8
activated	8
,	8
and	8
anergized	8
cells	8
.	0

The	0
inducible	9
factors	10
NK-kappa	9
B	10
,	0
beta	9
E2	10
,	0
CD28RC	9
,	0
and	0
AP-1	9
are	0
not	0
expressed	0
in	0
resting	7
cells	8
and	0
are	0
twofold	0
lower	0
in	0
anergized	0
as	0
compared	0
with	0
activated	0
cells	0
.	0

In	0
contrast	0
,	0
anergic	7
T	8
cells	8
express	0
approximately	0
eightfold	0
lower	0
amounts	0
of	0
NF-AT	9
,	0
a	0
member	0
of	0
the	0
class	0
of	0
inducible	9
factors	10
that	0
regulates	0
IL-2	1
gene	2
transcription	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

The	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
peripheral	7
human	8
lymphocytes	8
is	0
elevated	0
by	0
a	0
zinc	0
containing	0
trace	0
element	0
preparation	0
.	0

A	0
trace	0
element	0
preparation	0
(	0
Beres	0
Drops	0
Plus	0
,	0
BDP	0
)	0
elevates	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
(	0
gcR	9
)	0
in	0
peripheral	7
lymphocytes	8
isolated	0
both	0
from	0
healthy	0
blood	0
donors	0
and	0
rheumatoid	0
arthritis	0
patients	0
.	0

This	0
enhancement	0
by	0
BDP	0
was	0
found	0
either	0
for	0
constitutive	0
expression	0
of	0
gcRs	9
or	0
in	0
experiments	0
when	0
the	0
lymphocytes	7
were	0
stimulated	0
by	0
interleukin	9
(	10
IL	10
)	10
-6	10
.	0

There	0
was	0
no	0
significant	0
effect	0
of	0
BDP	0
on	0
IL-1	9
and	0
tumour	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
-induced	0
changes	0
of	0
gcRs	9
.	0

The	0
effect	0
of	0
BDP	0
was	0
greatly	0
dependent	0
on	0
the	0
presence	0
of	0
Zn++	0
ions	0
in	0
the	0
preparation	0
,	0
since	0
the	0
augmenting	0
effect	0
was	0
abolished	0
if	0
BDP	0
did	0
not	0
contain	0
zinc	0
.	0

The	0
DNA	0
and	0
steroid	9
binding	10
domains	10
of	0
the	0
glucocorticoid	9
receptor	10
are	0
not	0
altered	0
in	0
mononuclear	7
cells	8
of	0
treated	0
CLL	0
patients	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
investigate	0
whether	0
mutations	0
in	0
the	0
glucocorticoid	9
receptor	10
could	0
account	0
for	0
the	0
increasing	0
unresponsiveness	0
of	0
patients	0
with	0
chronic	0
lymphatic	0
leukemia	0
(	0
CLL	0
)	0
to	0
combination	0
chemotherapy	0
.	0

The	0
receptor	0
was	0
tested	0
immunocytochemically	0
,	0
in	0
steroid	0
binding	0
assays	0
,	0
and	0
by	0
a	0
mutation	0
screening	0
(	0
denaturing	0
gradient	0
gel	0
electrophoresis	0
)	0
of	0
the	0
receptor-cDNA	9
.	0

The	0
receptor	0
concentration	0
,	0
as	0
measured	0
by	0
staining	0
and	0
steroid	0
binding	0
test	0
,	0
varied	0
considerably	0
but	0
showed	0
no	0
clear	0
correlation	0
to	0
clinical	0
response	0
.	0

Using	0
a	0
highly	0
sensitive	0
mutation	0
screening	0
assay	0
of	0
the	0
DNA-	9
and	10
the	10
steroid-binding	10
region	10
,	0
none	0
of	0
the	0
treated	0
patients	0
revealed	0
any	0
mutation	0
,	0
suggesting	0
that	0
the	0
glucocorticoid	9
receptor	10
in	0
the	0
CLL	0
patients	0
tested	0
is	0
not	0
altered	0
in	0
these	0
domains	0
.	0

In	0
one	0
individual	0
who	0
had	0
not	0
been	0
treated	0
before	0
analysis	0
a	0
silent	0
mutation	0
was	0
found	0
in	0
one	0
receptor	0
allele	0
.	0

The	0
results	0
suggest	0
that	0
mechanisms	0
other	0
than	0
altered	0
ligand	0
or	0
DNA	0
binding	0
of	0
the	0
receptor	0
may	0
be	0
responsible	0
for	0
the	0
lack	0
of	0
response	0
to	0
chemotherapy	0
.	0

This	0
conclusion	0
is	0
discussed	0
in	0
relation	0
to	0
the	0
mechanism	0
of	0
corticoid	0
resistance	0
in	0
mouse	5
and	6
human	6
lymphoma	6
cells	6
in	0
culture	0
.	0

An	0
AP1	1
binding	2
site	2
upstream	0
of	0
the	0
kappa	1
immunoglobulin	2
intron	2
enhancer	2
binds	0
inducible	9
factors	10
and	0
contributes	0
to	0
expression	0
.	0

Expression	0
of	0
the	0
kappa	0
immunoglobulin	0
light	0
chain	0
gene	0
requires	0
developmental-	0
and	0
tissue-specific	0
regulation	0
by	0
trans-acting	9
factors	10
which	0
interact	0
with	0
two	0
distinct	0
enhancer	1
elements	2
.	0

A	0
new	0
protein-DNA	0
interaction	0
has	0
been	0
identified	0
upstream	0
of	0
the	0
intron	1
enhancer	2
,	0
within	0
the	0
matrix-associated	1
region	2
of	0
the	0
J-C	1
intron	2
.	0

The	0
binding	0
activity	0
is	0
greatly	0
inducible	0
in	0
pre-B	7
cells	8
by	0
bacterial	0
lipopolysaccharide	0
and	0
interleukin-1	9
but	0
specific	0
complexes	0
are	0
found	0
at	0
all	0
stages	0
of	0
B	0
cell	0
development	0
tested	0
.	0

The	0
footprinted	1
binding	2
site	2
is	0
homologous	0
to	0
the	0
consensus	1
AP1	2
motif	2
.	0

The	0
protein	0
components	0
of	0
this	0
complex	0
are	0
specifically	0
competed	0
by	0
an	0
AP1	1
consensus	2
motif	2
and	0
were	0
shown	0
by	0
supershift	0
to	0
include	0
c-Jun	9
and	0
c-Fos	9
,	0
suggesting	0
that	0
this	0
binding	1
site	2
is	0
an	0
AP1	1
motif	2
and	0
that	0
the	0
Jun	9
and	10
Fos	10
families	10
of	0
transcription	9
factors	10
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
the	0
kappa	1
light	2
chain	2
gene	2
.	0

Mutation	0
of	0
the	0
AP1	1
motif	2
in	0
the	0
context	0
of	0
the	0
intron	1
enhancer	2
was	0
shown	0
to	0
decrease	0
enhancer-mediated	0
activation	0
of	0
the	0
promoter	0
in	0
both	0
pre-B	7
cells	8
induced	0
with	0
LPS	0
and	0
constitutive	0
expression	0
in	0
mature	7
B	8
cells	8
.	0

Distinct	0
DNase-I	1
hypersensitive	2
sites	2
are	0
associated	0
with	0
TAL-1	9
transcription	0
in	0
erythroid	5
and	6
T-cell	6
lines	6
.	0

The	0
tal-1	1
gene	2
,	0
frequently	0
activated	0
in	0
human	0
T-cell	0
acute	0
lymphoblastic	0
leukemia	0
(	0
T-ALL	0
)	0
,	0
is	0
expressed	0
in	0
the	0
erythroid	7
,	8
megakaryocytic	8
,	8
and	8
mast	8
cell	8
lineages	8
during	0
normal	0
hematopoiesis	0
.	0

To	0
gain	0
further	0
insight	0
into	0
the	0
molecular	0
mechanisms	0
that	0
control	0
tal-1	1
expression	0
,	0
we	0
investigated	0
tal-1	1
chromatin	0
structure	0
in	0
erythroid/megakaryocytic	5
cell	6
lines	6
and	0
in	0
T-cell	5
lines	6
either	0
with	0
or	0
without	0
tal-1	1
rearrangements	2
.	0

Tal-1	0
transcription	0
was	0
shown	0
to	0
be	0
monoallelic	0
in	0
Jurkat	5
,	0
a	0
T-cell	0
line	0
that	0
expresses	0
tal-1	1
in	0
the	0
absence	0
of	0
apparent	0
genomic	0
alteration	0
of	0
the	0
locus	0
.	0

Methylation	0
studies	0
indicated	0
that	0
the	0
tal-15	1
'	2
GC-rich	2
region	2
behaves	0
like	0
a	0
CpG	1
island	2
,	0
hypomethylated	0
in	0
normal	7
cells	8
,	0
and	0
methylated	0
de	0
novo	0
on	0
transcriptionally	1
inactive	2
alleles	2
in	0
established	5
cell	6
lines	6
.	0

Five	0
major	0
DNase-I	1
hypersensitive	2
sites	2
(	0
HS	1
)	0
were	0
mapped	0
in	0
the	0
tal-1	1
locus	0
.	0

HS	1
I	2
,	2
IV	2
,	2
and	2
V	2
were	0
exclusively	0
observed	0
in	0
the	0
erythroid/megakaryocytic	5
cell	6
lines	6
that	0
express	0
tal-1	1
from	0
the	0
promoters	1
1a	2
and	2
1b	2
.	0

HS	1
II	2
was	0
weak	0
in	0
hematopoietic	5
cell	6
lines	6
,	0
absent	0
in	0
Hela	5
,	0
and	0
greatly	0
enhanced	0
in	0
Jurkat	5
,	0
suggesting	0
that	0
this	0
region	0
might	0
be	0
implicated	0
in	0
the	0
cis-activation	0
of	0
tal-1	1
promoter	2
1b	2
in	0
this	0
cell	0
line	0
.	0

HS	1
III	2
was	0
weak	0
in	0
HEL	5
and	0
Jurkat	5
,	0
and	0
greatly	0
enhanced	0
in	0
DU528	5
,	0
a	0
T-cell	5
line	6
that	0
bears	0
a	1
t	2
(	2
1	2
;	2
14	2
)	2
and	0
initiates	0
tal-1	1
transcription	0
within	0
exon	1
4	2
.	0

These	0
results	0
suggest	0
that	0
distinct	0
regulatory	1
elements	2
are	0
associated	0
with	0
the	0
use	0
of	0
the	0
different	0
tal-1	1
promoters	2
.	0

Erythropoietin	9
-dependent	0
induction	0
of	0
hemoglobin	9
synthesis	0
in	0
a	0
cytokine-dependent	5
cell	6
line	6
M-TAT	5
.	0

M-TAT	5
is	0
a	0
cytokine-dependent	5
cell	6
line	6
with	0
the	0
potential	0
to	0
differentiate	0
along	0
the	0
erythroid	7
and	8
megakaryocytic	8
lineages	8
.	0

We	0
cultured	0
M-TAT	5
cells	6
long	0
term	0
(	0
>	0
1	0
year	0
)	0
in	0
the	0
continuous	0
presence	0
of	0
erythropoietin	9
(	0
EPO	9
)	0
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
,	0
or	0
stem	9
cell	10
factor	10
(	0
SCF	9
)	0
.	0

These	0
long	0
term	0
cultures	0
are	0
referred	0
to	0
as	0
M-TAT/EPO	5
,	6
M-TAT/GM-CSF	6
,	6
and	6
M-TAT/SCF	6
cells	6
,	0
respectively	0
.	0

Hemoglobin	9
concentration	0
and	0
gamma-globin	9
and	0
erythroid	3
delta-aminolevulinate	4
synthase	4
mRNA	4
levels	0
were	0
significantly	0
higher	0
in	0
M-TAT/EPO	5
cells	6
than	0
in	0
M-TAT/GM-CSF	5
cells	6
.	0

When	0
the	0
supplemented	0
cytokine	9
was	0
switched	0
from	0
GM-CSF	9
to	0
EPO	9
,	0
hemoglobin	9
synthesis	0
in	0
M-TAT/GM-CSF	5
cells	6
increased	0
rapidly	0
(	0
within	0
5	0
h	0
)	0
,	0
and	0
the	0
level	0
of	0
GATA-1	3
mRNA	4
increased	0
.	0

In	0
contrast	0
,	0
the	0
addition	0
of	0
GM-CSF	9
to	0
the	0
M-TAT/EPO	5
cell	6
culture	6
decreased	0
the	0
amount	0
of	0
hemoglobin	0
,	0
even	0
in	0
the	0
presence	0
of	0
EPO	9
,	0
indicating	0
that	0
the	0
EPO	9
signal	0
for	0
erythroid	0
differentiation	0
is	0
suppressed	0
by	0
GM-CSF	9
.	0

Thus	0
,	0
erythroid	0
development	0
of	0
M-TAT	5
cells	6
is	0
promoted	0
by	0
EPO	9
and	0
suppressed	0
by	0
GM-CSF	9
.	0

These	0
results	0
support	0
the	0
hypothesis	0
that	0
EPO	9
actively	0
influences	0
the	0
programming	0
of	0
gene	0
expression	0
required	0
for	0
erythroid	7
progenitor	8
cell	8
differentiation	0
.	0

The	0
role	0
of	0
cellular	9
transcription	10
factor	10
E2F	10
in	0
the	0
regulation	0
of	0
cdc2	3
mRNA	4
expression	0
and	0
cell	0
cycle	0
control	0
of	0
human	0
hematopoietic	7
cells	8
.	0

cdc2	3
mRNA	4
transcripts	4
were	0
detected	0
in	0
immature	7
bone	8
marrow	8
cells	8
and	0
became	0
undetectable	0
along	0
with	0
differentiation	0
.	0

Peripheral	7
blood	8
resting	8
cells	8
did	0
not	0
express	0
cdc2	3
mRNA	4
,	0
but	0
it	0
was	0
induced	0
in	0
T-lymphocytes	7
when	0
the	0
cells	0
reentered	0
the	0
cell	0
cycle	0
in	0
response	0
to	0
specific	0
mitogens	0
.	0

In	0
contrast	0
,	0
cdc2	3
mRNA	4
could	0
not	0
be	0
induced	0
in	0
granulocytes	7
and	0
monocytes	7
even	0
after	0
the	0
culture	0
with	0
the	0
appropriate	0
stimulants	0
.	0

In	0
order	0
to	0
investigate	0
the	0
mechanism	0
of	0
the	0
regulation	0
of	0
cdc2	3
mRNA	4
expression	0
in	0
hematopoietic	7
cells	8
,	0
we	0
isolated	0
the	0
5'-flanking	1
sequence	2
of	0
the	0
cdc2	1
gene	2
and	0
found	0
the	0
putative	0
E2F	0
binding	1
site	2
at	0
the	0
position	0
of	0
nucleotides	1
-124	2
to	2
-117	2
.	0

The	0
binding	0
of	0
E2F	9
at	0
this	0
region	0
was	0
detected	0
by	0
a	0
gel-retardation	0
assay	0
and	0
DNaseI	9
footprinting	0
in	0
phytohemagglutinin-stimulated	5
T-lymphocytes	6
,	0
which	0
was	0
coincident	0
with	0
the	0
expression	0
of	0
cdc2	3
mRNA	4
.	0

E2F	9
binding	0
was	0
not	0
observed	0
in	0
both	0
granulocytes	7
and	0
monocytes	7
.	0

Transient	0
chloramphenicol	9
acetyltransferase	10
assay	0
revealed	0
that	0
the	0
region	0
containing	0
E2F	1
binding	2
site	2
had	0
a	0
strong	0
promoter	0
activity	0
,	0
and	0
introduction	0
of	0
the	0
mutation	0
at	0
the	0
E2F	1
binding	2
site	2
resulted	0
in	0
a	0
significant	0
loss	0
of	0
the	0
activity	0
.	0

E2F-1	3
and	4
DP-1	4
mRNAs	4
were	0
not	0
detectable	0
in	0
granulocytes	7
,	0
monocytes	7
and	0
resting	7
T-lymphocytes	8
but	0
were	0
induced	0
after	0
the	0
mitogenic	0
stimulation	0
of	0
T-lymphocytes	7
.	0

The	0
induction	0
of	0
E2F	9
activity	0
preceded	0
the	0
appearance	0
of	0
cdc2	3
mRNA	4
,	0
which	0
is	0
consistent	0
with	0
the	0
role	0
of	0
E2F	9
in	0
the	0
regulation	0
of	0
cdc2	7
mRNA	8
expression	8
.	0

These	0
results	0
suggest	0
that	0
cdc2	3
mRNA	4
expression	0
is	0
related	0
to	0
the	0
cell	0
cycling	0
of	0
normal	7
human	8
hematopoietic	8
cells	8
and	0
that	0
E2F	9
plays	0
some	0
roles	0
in	0
the	0
regulation	0
of	0
its	0
expression	0
.	0

Association	0
of	0
alterations	0
in	0
NF-kappa	9
B	10
moieties	10
with	0
HIV	0
type	0
1	0
proviral	0
latency	0
in	0
certain	0
monocytic	7
cells	8
.	0

Human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replication	0
is	0
controlled	0
by	0
a	0
complex	0
array	0
of	0
virally	9
encoded	10
and	10
cellular	10
proteins	10
.	0

A	0
wide	0
spectrum	0
of	0
levels	0
of	0
HIV-1	0
expression	0
have	0
been	0
demonstrated	0
in	0
various	0
cells	0
,	0
both	0
in	0
cell	0
culture	0
and	0
in	0
vivo	0
.	0

Molecular	0
mechanisms	0
leading	0
to	0
restricted	0
HIV-1	0
replication	0
may	0
differ	0
between	0
certain	0
cell	0
types	0
.	0

It	0
is	0
now	0
demonstrated	0
that	0
HIV-1	0
proviral	0
latency	0
in	0
the	0
monocytic	5
cell	6
line	6
U1	6
,	0
in	0
which	0
only	0
extremely	0
low	0
levels	0
of	0
HIV-1	0
expression	0
are	0
detected	0
in	0
the	0
baseline	0
unstimulated	0
state	0
,	0
is	0
associated	0
with	0
alterations	0
in	0
nuclear	0
factor-kappa	9
B	10
(	10
NF-kappa	10
B	10
)	10
moieties	10
demonstrated	0
in	0
these	0
cells	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
and	0
in	0
situ	0
UV	0
cross-linking	0
studies	0
.	0

A	0
predominance	0
of	0
p50	9
NF-kappa	10
B	10
moieties	10
and	0
possibly	0
p50	9
homodimers	10
or	0
closely	0
related	0
species	0
,	0
rather	0
than	0
the	0
p50-p56	9
heterodimer	10
of	0
NF-kappa	9
B	10
that	0
is	0
the	0
predominant	0
NF-kappa	9
B	10
species	0
in	0
most	0
T	7
lymphocytic	8
and	8
monocytic	8
cells	8
,	0
is	0
demonstrated	0
in	0
the	0
nuclei	0
of	0
U1	5
cells	6
.	0

This	0
pattern	0
of	0
NF-kappa	9
B-related	10
moieties	10
differs	0
from	0
the	0
latently	5
infected	6
T	6
lymphocytic	6
cell	6
line	6
ACH-2	6
,	0
and	0
from	0
the	0
U937	5
monocytic	6
line	6
,	0
the	0
parental	5
cell	6
line	6
of	0
the	0
U1	5
cellular	6
clone	6
.	0

As	0
such	0
,	0
these	0
data	0
suggest	0
that	0
different	0
proximal	0
mechanisms	0
may	0
lead	0
to	0
restricted	0
HIV-1	0
replication	0
in	0
various	0
cell	0
types	0
.	0

[	0
Regulation	0
of	0
transcription	0
of	0
the	0
interleukin-2	1
gene	2
in	0
B-lymphocytes	7
]	0

Since	0
most	0
B	5
cell	6
clones	6
immortalized	0
with	0
EBV	0
virus	0
can	0
be	0
induced	0
to	0
produce	0
interleukin-2	9
,	0
a	0
typical	0
T	9
cell	10
cytokine	10
,	0
we	0
studied	0
the	0
role	0
of	0
different	0
elements	0
of	0
the	0
IL-2	1
promoter	2
in	0
such	0
clones	0
by	0
transfection	0
.	0

It	0
was	0
found	0
,	0
in	0
particular	0
,	0
that	0
the	0
element	0
TCEd	1
,	0
which	0
binds	0
the	0
transcription	9
factor	10
NF-kB	9
,	0
is	0
very	0
active	0
in	0
all	0
three	0
B	5
clones	6
tested	0
.	0

This	0
element	0
has	0
no	0
activity	0
in	0
T	7
cells	8
of	0
the	0
Jurkat	5
line	6
.	0

The	0
NFATd	1
element	2
,	0
which	0
binds	0
the	0
transcription	9
factor	10
NFAT-1	9
and	0
is	0
very	0
active	0
in	0
T	7
cells	8
,	0
is	0
only	0
weakly	0
active	0
in	0
one	0
B	5
clone	6
and	0
not	0
at	0
all	0
in	0
another	0
.	0

Different	0
elements	0
thus	0
contribute	0
to	0
IL-2	1
promoter	2
activity	0
in	0
different	0
cells	0
.	0

Regulation	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
p105	9
in	0
monocytes	7
and	0
macrophages	7
persistently	0
infected	0
with	0
human	0
immunodeficiency	0
virus	0
.	0

The	0
mechanisms	0
regulating	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
persistence	0
in	0
human	0
monocytes	7
/macrophages	7
are	0
partially	0
understood	0
.	0

Persistent	0
HIV	0
infection	0
of	0
U937	5
monocytic	6
cells	6
results	0
in	0
NF-kappa	9
B	10
activation	0
.	0

Whether	0
virus-induced	0
NF-kappa	9
B	10
activation	0
is	0
a	0
mechanism	0
that	0
favors	0
continuous	0
viral	0
replication	0
in	0
macrophages	7
remains	0
unknown	0
.	0

To	0
further	0
delineate	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
the	0
activation	0
of	0
NF-kappa	9
B	10
in	0
HIV-infected	0
monocytes	7
and	0
macrophages	7
,	0
we	0
have	0
focused	0
on	0
the	0
regulation	0
of	0
the	0
I	0
kappa	0
B	0
molecules	0
.	0

First	0
,	0
we	0
show	0
that	0
persistent	0
HIV	0
infection	0
results	0
in	0
the	0
activation	0
of	0
NF-kappa	0
B	0
not	0
only	0
in	0
monocytic	0
cells	0
but	0
also	0
in	0
macrophages	7
.	0

In	0
HIV-infected	0
cells	0
,	0
I	9
kappa	10
B	10
alpha	10
protein	0
levels	0
are	0
decreased	0
secondary	0
to	0
enhanced	0
protein	0
degradation	0
.	0

This	0
parallels	0
the	0
increased	0
I	9
kappa	10
B	10
alpha	10
synthesis	0
secondary	0
to	0
increased	0
I	9
kappa	10
B	10
alpha	10
gene	0
transcription	0
,	0
i.e.	0
,	0
increased	0
RNA	0
and	0
transcriptional	0
activity	0
of	0
its	0
promoter-enhancer	0
.	0

Another	0
protein	0
with	0
I	0
kappa	0
B	0
function	0
,	0
p105	9
,	0
is	0
also	0
modified	0
in	0
HIV-infected	0
cells	0
:	0
p105	9
and	0
p50	9
steady-state	0
protein	0
levels	0
are	0
increased	0
as	0
a	0
result	0
of	0
increased	0
synthesis	0
and	0
proteolytic	0
processing	0
of	0
p105	9
.	0

Transcriptional	0
activity	0
of	0
p105	9
is	0
also	0
increased	0
in	0
infected	7
cells	8
and	0
is	0
also	0
mediated	0
by	0
NF-kappa	9
B	10
through	0
a	0
specific	0
kappa	1
B	2
motif	2
.	0

These	0
results	0
demonstrate	0
the	0
existence	0
of	0
a	0
triple	0
autoregulatory	0
loop	0
in	0
monocytes	7
and	0
macrophages	7
involving	0
HIV	0
,	0
p105	9
and	0
p50	9
,	0
and	0
MAD3	9
,	0
with	0
the	0
end	0
result	0
of	0
persistent	0
NF-kappa	0
B	0
activation	0
and	0
viral	0
persistence	0
.	0

Furthermore	0
,	0
persistent	0
HIV	0
infection	0
of	0
monocytes	7
and	0
macrophages	7
provides	0
a	0
useful	0
model	0
with	0
which	0
to	0
study	0
concomitant	0
modifications	0
of	0
different	0
I	9
kappa	10
B	10
molecules	10
.	0

Glucocorticoid-induced	0
apoptosis	0
of	0
human	7
leukemic	8
cells	8
is	0
caused	0
by	0
the	0
repressive	0
function	0
of	0
the	0
glucocorticoid	9
receptor	10
.	0

Induction	0
of	0
apoptosis	0
in	0
lymphocytes	7
,	0
which	0
may	0
account	0
for	0
the	0
therapeutic	0
effects	0
of	0
glucocorticoids	0
in	0
various	0
diseases	0
including	0
leukemia	0
,	0
depends	0
on	0
the	0
glucocorticoid	9
receptor	10
.	0

However	0
,	0
the	0
events	0
leading	0
from	0
the	0
activated	0
receptor	0
to	0
cell	0
lysis	0
are	0
not	0
understood	0
.	0

A	0
prevailing	0
hypothesis	0
postulates	0
induction	0
of	0
so-called	0
'	0
lysis	1
genes	2
'	0
by	0
the	0
activated	9
receptor	10
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
an	0
activation-deficient	9
glucocorticoid	10
receptor	10
mutant	10
is	0
as	0
effective	0
as	0
the	0
wild-type	9
receptor	10
in	0
repression	0
of	0
AP-1	9
activity	0
,	0
inhibition	0
of	0
interleukin-2	9
production	0
,	0
inhibition	0
of	0
c-myc	1
expression	0
and	0
induction	0
of	0
apoptosis	0
.	0

Furthermore	0
,	0
we	0
show	0
that	0
retinoic	0
acid	0
can	0
also	0
induce	0
apoptosis	0
in	0
these	0
cells	0
through	0
the	0
retinoic	9
acid	10
receptor	10
,	0
whose	0
repressive	0
functions	0
but	0
not	0
target	0
site	0
specificity	0
,	0
are	0
similar	0
to	0
those	0
of	0
the	0
glucocorticoid	9
receptor	10
.	0

Therefore	0
,	0
the	0
primary	0
effect	0
of	0
the	0
receptor	0
in	0
glucocorticoid-mediated	0
apoptosis	0
correlates	0
with	0
transcriptional	0
repression	0
rather	0
than	0
activation	0
and	0
could	0
be	0
mediated	0
by	0
interference	0
with	0
other	0
transcription	9
factors	10
required	0
for	0
cell	0
survival	0
.	0

HIV	0
type	0
1	0
protease	9
activation	0
of	0
NF-kappa	9
B	10
within	0
T	7
lymphoid	8
cells	8
.	0

NF-kappa	9
B	10
is	0
a	0
nuclear	9
protein	10
of	0
the	0
rel	9
oncogene	10
family	10
capable	0
of	0
enhancing	0
transcription	0
of	0
several	1
cellular	2
genes	2
,	0
including	0
IL-2	9
and	0
the	0
IL-2	9
receptor	10
,	0
and	0
viral	1
genes	2
transcribed	0
from	0
the	0
HIV-1	1
LTR	2
.	0

It	0
has	0
been	0
reported	0
that	0
HIV-1	9
protease	10
may	0
cleave	0
the	0
NF-kappa	9
B	10
precursor	0
to	0
its	0
active	0
form	0
in	0
vitro	0
.	0

In	0
this	0
study	0
the	0
effects	0
of	0
HIV	0
protease	0
on	0
NF-kappa	9
B	10
precursor	0
activation	0
were	0
examined	0
in	0
Jurkat	0
T	7
cells	8
by	0
introducing	0
a	0
protease	1
expression	2
vector	2
into	0
the	0
cells	0
.	0

Increased	0
NF-kappa	9
B	10
activity	0
was	0
observed	0
and	0
this	0
increased	0
activity	0
was	0
blocked	0
by	0
a	0
specific	0
inhibitor	0
of	0
the	0
viral	9
protease	10
.	0

Viral	0
transcription	0
,	0
as	0
measured	0
using	0
LTR	1
-CAT	9
assays	0
,	0
was	0
only	0
slightly	0
enhanced	0
in	0
the	0
HIV-protease	7
expressing	8
cells	8
,	0
while	0
secretion	0
of	0
IL-2	9
and	0
expression	0
of	0
the	0
IL-2	9
receptor	0
were	0
not	0
affected	0
.	0

The	0
limited	0
activation	0
of	0
NF-kappa	9
B	10
by	0
HIV	9
protease	10
appears	0
unlikely	0
to	0
have	0
a	0
significant	0
effect	0
on	0
virus	0
expression	0
or	0
T	0
cell	0
function	0
.	0

Inhibition	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
replication	0
by	0
a	0
Tat-activated	1
,	2
transduced	2
interferon	2
gene	2
:	0
targeted	0
expression	0
to	0
human	7
immunodeficiency	8
virus	8
type	8
1-infected	8
cells	8
.	0

We	0
have	0
examined	0
the	0
feasibility	0
of	0
using	0
interferon	9
(	0
IFN	9
)	0
gene	0
transfer	0
as	0
a	0
novel	0
approach	0
to	0
anti-human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
therapy	0
in	0
this	0
study	0
.	0

To	0
limit	0
expression	0
of	0
a	0
transduced	0
HIV-1	1
long	2
terminal	2
repeat	2
(	2
LTR	2
)	2
-IFNA2	2
(	0
the	0
new	0
approved	0
nomenclature	0
for	0
IFN	1
genes	2
is	0
used	0
throughout	0
this	0
article	0
)	0
hybrid	1
gene	2
to	0
the	0
HIV-1-infected	5
cells	6
,	0
HIV-1	1
LTR	2
was	0
modified	0
.	0

Deletion	0
of	0
the	0
NF-kappa	1
B	2
elements	2
of	0
the	0
HIV-1	1
LTR	2
significantly	0
inhibited	0
Tat	9
-mediated	0
transactivation	0
in	0
T-cell	5
lines	6
,	0
as	0
well	0
as	0
in	0
a	0
monocyte	5
line	6
,	0
U937	5
.	0

Replacement	0
of	0
the	0
NF-kappa	1
B	2
elements	2
in	0
the	0
HIV-1	1
LTR	2
by	0
a	0
DNA	1
fragment	2
derived	0
from	0
the	0
5'-flanking	1
region	2
of	0
IFN-stimulated	1
gene	2
15	2
(	0
ISG15	1
)	0
,	0
containing	0
the	0
IFN-stimulated	1
response	2
element	2
,	0
partially	0
restored	0
Tat	9
-mediated	0
activation	0
of	0
LTR	1
in	0
T	7
cells	8
as	0
well	0
as	0
in	0
monocytes	7
.	0

Insertion	0
of	0
this	0
chimeric	1
promoter	2
(	0
ISG15	1
LTR	2
)	0
upstream	0
of	0
the	0
human	1
IFNA2	2
gene	2
directed	0
high	0
levels	0
of	0
IFN	9
synthesis	0
in	0
Tat-expressing	5
cells	6
,	0
while	0
this	0
promoter	0
was	0
not	0
responsive	0
to	0
tumor	9
necrosis	10
factor	10
alpha	10
-mediated	0
activation	0
.	0

ISG15-LTR-IFN	1
hybrid	2
gene	2
inserted	0
into	0
the	0
retrovirus	1
vector	2
was	0
transduced	0
into	0
Jurkat	5
and	0
U937	5
cells	6
.	0

Selected	0
transfected	5
clones	6
produced	0
low	0
levels	0
of	0
IFN	9
A	10
(	0
IFNA	9
)	0
constitutively	0
,	0
and	0
their	0
abilities	0
to	0
express	0
interleukin-2	9
and	0
interleukin-2	9
receptor	10
upon	0
stimulation	0
with	0
phytohemagglutinin	9
and	0
phorbol	0
myristate	0
acetate	0
were	0
retained	0
.	0

Enhancement	0
of	0
IFNA	9
synthesis	0
observed	0
upon	0
HIV-1	0
infection	0
resulted	0
in	0
significant	0
inhibition	0
of	0
HIV-1	0
replication	0
for	0
a	0
period	0
of	0
at	0
least	0
30	0
days	0
.	0

Virus	0
isolated	0
from	0
IFNA-producing	5
cells	6
was	0
able	0
to	0
replicate	0
in	0
the	0
U937	5
cells	6
but	0
did	0
not	0
replicate	0
efficiently	0
in	0
U937	5
cells	6
transduced	0
with	0
the	0
IFNA	1
gene	2
.	0

These	0
results	0
suggest	0
that	0
targeting	0
IFN	9
synthesis	0
to	0
HIV-1-infected	5
cells	6
is	0
an	0
attainable	0
goal	0
and	0
that	0
autocrine	0
IFN	9
synthesis	0
results	0
in	0
a	0
long-lasting	0
and	0
permanent	0
suppression	0
of	0
HIV-1	0
replication	0
.	0

Chromosomal	0
localization	0
of	0
two	0
KOX	1
zinc	2
finger	2
genes	2
on	0
chromosome	1
bands	2
7q21-q22	1
.	0

Human	1
cDNAs	2
encoding	0
Kruppel-type	9
zinc	10
finger	10
domains	10
,	0
designated	0
KOX	1
1-32	2
,	0
have	0
been	0
cloned	0
from	0
human	1
T	2
lymphocyte	2
cell	2
line	2
libraries	2
.	0

We	0
report	0
here	0
the	0
regional	0
localizations	0
by	0
in	0
situ	0
hybridization	0
of	0
KOX	1
18	2
and	0
KOX	1
25	2
on	0
chromosome	1
bands	2
7q21q22	2
.	0

Pulse-field	0
gel	0
electrophoresis	0
(	0
PFGE	0
)	0
analysis	0
showed	0
that	0
these	0
genes	0
are	0
physically	0
located	0
within	0
a	0
DNA	1
fragment	2
of	0
250	1
kb	2
.	0

The	0
genes	0
KOX	1
4	2
and	0
KOX	1
9	2
,	0
mapped	0
on	0
chromosome	1
8q24	2
,	0
were	0
found	0
to	0
be	0
located	0
within	0
a	0
DNA	1
fragment	2
of	0
450	0
kb	0
.	0

From	0
the	0
present	0
and	0
previous	0
data	0
,	0
eighteen	0
different	0
KOX	1
genes	2
have	0
been	0
located	0
at	0
least	0
two	0
by	0
two	0
within	0
nine	0
DNA	1
fragments	2
of	0
200	0
to	0
580	0
kb	0
.	0

Influence	0
of	0
age	0
on	0
the	0
production	0
of	0
Fos	9
and	0
Jun	9
by	0
influenza	7
virus-exposed	8
T	8
cells	8
.	0

This	0
study	0
investigated	0
age-related	0
T	0
cell	0
responses	0
after	0
in	0
vitro	0
exposure	0
to	0
influenza	0
A	0
virus	0
.	0

Mononuclear	7
leukocytes	8
from	0
young	0
or	0
elderly	0
persons	0
were	0
sham-exposed	0
or	0
exposed	0
to	0
influenza	0
virus	0
for	0
1	0
,	0
24	0
,	0
and	0
72	0
h	0
.	0

Immunofluorescent	0
staining	0
and	0
flow	0
cytometric	0
analysis	0
were	0
then	0
used	0
to	0
detect	0
T	7
cells	8
producing	0
the	0
transcriptional	9
regulating	10
proteins	10
Fos	9
and	0
Jun	9
.	0

Fewer	0
virus-exposed	0
cells	0
from	0
elderly	0
donors	0
stained	0
for	0
Fos	9
and	0
Jun	9
at	0
each	0
data	0
point	0
compared	0
with	0
cells	0
from	0
young	0
donors	0
.	0

Flow	0
cytometric	0
analysis	0
also	0
showed	0
that	0
at	0
72	0
h	0
of	0
virus	0
exposure	0
fewer	0
T	7
cells	8
from	0
the	0
elderly	0
produced	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
,	0
suggesting	0
a	0
link	0
between	0
the	0
magnitude	0
of	0
the	0
Fos	9
and	0
Jun	9
and	0
IFN-gamma	9
responses	0
.	0

Thus	0
,	0
failure	0
of	0
virus-exposed	7
T	8
cells	8
to	0
produce	0
Fos	9
and	0
Jun	9
could	0
contribute	0
to	0
the	0
increase	0
in	0
illness	0
due	0
to	0
influenza	0
virus	0
in	0
the	0
elderly	0
.	0

The	0
regulation	0
of	0
HIV	0
by	0
retinoic	0
acid	0
correlates	0
with	0
cellular	0
expression	0
of	0
the	0
retinoic	9
acid	10
receptors	10
.	0

OBJECTIVES	0
:	0
To	0
analyze	0
the	0
effect	0
of	0
retinoic	0
acids	0
(	0
RA	0
)	0
on	0
HIV-1	0
expression	0
and	0
correlate	0
this	0
effect	0
with	0
expression	0
levels	0
of	0
RA	9
receptors	10
(	0
RARs	9
)	0
in	0
T-lymphoid	5
and	6
monocytoid	6
cell	6
lines	6
.	0

DESIGN	0
AND	0
METHODS	0
:	0
The	0
effect	0
of	0
all-trans	0
and	0
9-cis	0
RA	0
on	0
HIV-1	0
production	0
in	0
T-lymphoid	5
(	0
H9	5
,	6
CEM	6
)	0
and	0
monocytoid	5
(	6
U937	6
,	6
THP-1	6
)	6
cell	6
lines	6
was	0
measured	0
during	0
acute	0
and	0
chronic	0
infection	0
.	0

The	0
expression	0
levels	0
of	0
human	9
RAR	10
alpha	10
(	0
hRAR	9
alpha	10
,	10
receptor	10
for	0
all-trans	0
RA	0
)	0
and	0
the	0
human	9
retinoid-X	10
receptor	10
alpha	10
(	0
hRXR	9
alpha	10
receptor	10
for	0
9-cis	0
RA	0
)	0
were	0
determined	0
by	0
Northern	0
blot	0
analysis	0
.	0

RESULTS	0
:	0
Both	0
all-trans	0
and	0
9-cis	0
RA	0
inhibited	0
virus	0
replication	0
in	0
HIV-1	5
IIIB-infected	6
monocytoid	6
cells	6
,	0
in	0
the	0
presence	0
and	0
absence	0
of	0
the	0
co-stimulatory	0
agent	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
.	0

The	0
retinoids	0
had	0
weak	0
or	0
no	0
stimulatory	0
effects	0
on	0
HIV	0
production	0
by	0
T-cell	5
lines	6
.	0

HIV	0
production	0
by	0
PMA-stimulated	5
T-cell	6
lines	6
was	0
inhibited	0
by	0
these	0
retinoids	0
.	0

The	0
9-cis	0
RA	0
was	0
generally	0
more	0
effective	0
than	0
all-trans	0
RA	0
in	0
inhibiting	0
HIV	0
production	0
and	0
in	0
combination	0
generally	0
more	0
effective	0
than	0
the	0
single	0
agents	0
alone	0
.	0

Human	9
RAR	10
alpha	10
was	0
expressed	0
in	0
H9	5
,	0
U937	5
and	0
THP-1	5
cells	6
,	0
but	0
almost	0
undetectable	0
in	0
CEM	5
cells	6
.	0

Human	9
RXR	10
alpha	10
was	0
significantly	0
expressed	0
in	0
U937	5
and	6
THP-1	6
cells	6
,	0
weakly	0
expressed	0
in	0
H9	5
cells	6
and	0
not	0
detectable	0
in	0
CEM	5
cells	6
.	0

After	0
stimulation	0
by	0
PMA	0
,	0
RXR	9
alpha	10
expression	0
increased	0
in	0
H9	5
and	0
U937	5
cells	6
but	0
not	0
in	0
CEM	5
cells	6
.	0

Human	0
RAR	0
alpha	0
expression	0
was	0
unchanged	0
in	0
H9	5
and	0
CEM	5
cells	6
,	0
and	0
elevated	0
in	0
U937	5
cells	6
,	0
after	0
PMA	0
stimulation	0
.	0

CONCLUSION	0
:	0
The	0
effect	0
of	0
RA	0
on	0
HIV-1	0
expression	0
was	0
cell-type-dependent	0
and	0
partially	0
correlated	0
with	0
cellular	0
expression	0
of	0
RARs	9
.	0

Endogenous	0
or	0
exogenously	0
administered	0
RA	0
may	0
have	0
a	0
significant	0
role	0
in	0
HIV	0
regulation	0
.	0

Functions	0
of	0
glutathione	0
and	0
glutathione	0
disulfide	0
in	0
immunology	0
and	0
immunopathology	0
.	0

Even	0
a	0
moderate	0
increase	0
in	0
the	0
cellular	0
cysteine	0
supply	0
elevates	0
the	0
intracellular	0
glutathione	0
(	0
GSH	0
)	0
and	0
glutathione	0
disulfide	0
(	0
GSSG	0
)	0
levels	0
and	0
potentiates	0
immunological	0
functions	0
of	0
lymphocytes	7
in	0
vitro	0
.	0

At	0
low	0
GSSG	0
levels	0
,	0
T	7
cells	8
can	0
not	0
optimally	0
activate	0
the	0
immunologically	0
important	0
transcription	9
factor	10
NF	9
kappa	10
B	10
,	0
whereas	0
high	0
GSSG	0
levels	0
inhibit	0
the	0
DNA	0
binding	0
activity	0
of	0
NF	9
kappa	10
B	10
.	0

The	0
effects	0
of	0
GSSG	0
are	0
antagonized	0
by	0
reduced	0
thioredoxin	9
(	0
TRX	9
)	0
.	0

As	0
the	0
protein	9
tyrosine	10
kinase	10
activities	0
p56lck	9
and	0
p59fyn	9
are	0
activated	0
in	0
intact	0
cells	0
by	0
hydrogen	0
peroxide	0
,	0
they	0
are	0
likely	0
targets	0
for	0
GSSG	0
action	0
.	0

These	0
redox-regulated	9
enzymes	10
trigger	0
signal	0
cascades	0
for	0
NF	9
kappa	10
B	10
activation	0
and	0
transduce	0
signals	0
from	0
the	0
T	9
cell	10
antigen	10
receptor	10
,	0
from	0
CD4	9
and	0
CD8	9
molecules	10
,	0
and	0
from	0
the	0
IL-2	9
receptor	10
beta-chain	10
.	0

The	0
effector	0
phase	0
of	0
cytotoxic	7
T	8
cell	8
responses	0
and	0
IL-2	9
-dependent	0
functions	0
are	0
inhibited	0
even	0
by	0
a	0
partial	0
depletion	0
of	0
the	0
intracellular	0
GSH	0
pool	0
.	0

As	0
signal	0
transduction	0
is	0
facilitated	0
by	0
prooxidant	0
conditions	0
,	0
we	0
propose	0
that	0
the	0
well-known	0
immunological	0
consequences	0
of	0
GSH	0
depletion	0
ultimately	0
may	0
be	0
results	0
of	0
the	0
accompanying	0
GSSG	0
deficiency	0
.	0

As	0
HIV-infected	0
patients	0
and	0
SIV-infected	0
rhesus	0
macaques	0
have	0
,	0
on	0
the	0
average	0
,	0
significantly	0
decreased	0
plasma	0
cyst	0
(	0
e	0
)	0
ine	0
and	0
intracellular	0
GSH	0
levels	0
,	0
we	0
also	0
hypothesize	0
that	0
AIDS	0
may	0
be	0
the	0
consequence	0
of	0
a	0
GSSG	0
deficiency	0
as	0
well	0
.	0

T	7
cells	8
from	0
renal	0
cell	0
carcinoma	0
patients	0
exhibit	0
an	0
abnormal	0
pattern	0
of	0
kappa	0
B-specific	0
DNA-binding	0
activity	0
:	0
a	0
preliminary	0
report	0
.	0

Recent	0
data	0
suggest	0
that	0
the	0
poor	0
induction	0
of	0
a	0
T-cell	0
response	0
to	0
human	0
renal	0
cell	0
carcinoma	0
(	0
RCC	0
)	0
may	0
be	0
related	0
to	0
alterations	0
in	0
signal	0
transduction	0
pathways	0
.	0

We	0
report	0
that	0
T	7
cells	8
from	0
RCC	0
patients	0
have	0
two	0
alterations	0
in	0
kappa	0
B	0
motif-specific	0
DNA-binding	0
activity	0
.	0

The	0
first	0
alteration	0
involves	0
the	0
constitutive	0
expression	0
of	0
substantial	0
kappa	0
B-binding	0
activity	0
in	0
nuclear	0
extracts	0
,	0
which	0
was	0
observed	0
in	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

The	0
magnitude	0
of	0
kappa	0
B	0
activity	0
in	0
unstimulated	7
patient	8
T	8
cells	8
was	0
similar	0
to	0
that	0
observed	0
in	0
T	7
cells	8
from	0
normal	0
individuals	0
that	0
had	0
been	0
activated	0
in	0
vitro	0
.	0

On	0
the	0
basis	0
of	0
Western	0
blotting	0
experiments	0
using	0
antibodies	9
to	0
kappa	9
B/Rel	10
family	10
proteins	10
,	0
the	0
kappa	0
B-binding	0
activity	0
constitutively	0
expressed	0
in	0
T	7
cells	8
from	0
RCC	0
patients	0
is	0
composed	0
mostly	0
of	0
the	0
NF-kappa	9
B1	10
(	10
p50	10
)	10
subunit	10
.	0

The	0
second	0
abnormality	0
in	0
kappa	0
B-binding	0
activity	0
in	0
T	7
cells	8
from	0
these	0
patients	0
is	0
that	0
RelA	9
,	0
a	0
member	0
of	0
the	0
Rel	9
homology	10
family	10
which	0
is	0
part	0
of	0
the	0
normal	0
NF-kappa	9
B	10
complex	10
,	0
was	0
not	0
induced	0
in	0
the	0
nucleus	0
following	0
activation	0
.	0

Western	0
blotting	0
analysis	0
did	0
not	0
detect	0
any	0
RelA	9
in	0
nuclear	0
extracts	0
either	0
before	0
or	0
after	0
stimulation	0
of	0
T	7
cells	8
.	0

The	0
altered	0
kappa	0
B-binding	0
activity	0
in	0
T	7
cells	8
from	0
RCC	0
patients	0
may	0
impair	0
their	0
capacity	0
to	0
respond	0
normally	0
to	0
various	0
stimuli	0
.	0

Hemoglobin	9
switching	0
in	0
humans	0
is	0
accompanied	0
by	0
changes	0
in	0
the	0
ratio	0
of	0
the	0
transcription	9
factors	10
,	0
GATA-1	9
and	0
SP1	9
.	0

BACKGROUND	0
:	0
Understanding	0
the	0
mechanism	0
of	0
developmental	0
regulation	0
of	0
hemoglobin	9
switching	0
has	0
scientific	0
as	0
well	0
as	0
clinical	0
relevance	0
because	0
of	0
the	0
influence	0
of	0
fetal	0
hemoglobin	9
(	0
HbF	9
)	0
production	0
in	0
adulthood	0
on	0
the	0
clinical	0
manifestation	0
of	0
thalassemia	0
and	0
sickle	0
cell	0
anemia	0
.	0

We	0
have	0
previously	0
found	0
that	0
the	0
normal	0
developmental	0
patterns	0
of	0
globin	1
gene	2
expression	0
are	0
recapitulated	0
in	0
an	0
experimental	0
system	0
of	0
primary	5
cultures	6
that	0
support	0
differentiation	0
of	0
erythroid	7
progenitors	8
.	0

We	0
further	0
found	0
that	0
high	0
activities	0
of	0
the	0
transcriptional	9
activators	10
,	0
GATA-1	9
and	0
SP1	9
,	0
are	0
associated	0
with	0
normal	0
adult	0
erythroid	0
differentiation	0
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
In	0
the	0
present	0
work	0
,	0
we	0
have	0
studied	0
,	0
the	0
activities	0
of	0
GATA-1	9
and	0
SP1	9
during	0
differentiation	0
of	0
cultured	0
erythroid	7
progenitors	8
derived	0
from	0
cord	0
blood	0
and	0
from	0
fetal	0
livers	0
,	0
as	0
well	0
as	0
from	0
beta	0
zero-thalassemia	0
patients	0
.	0

RESULTS	0
:	0
The	0
results	0
showed	0
high	0
GATA-1	9
binding	0
activity	0
and	0
very	0
low	0
SP1	9
activity	0
in	0
the	0
fetal	5
liver	6
cultures	6
.	0

This	0
pattern	0
was	0
in	0
contrast	0
to	0
cultures	0
derived	0
from	0
normal	0
adult	0
peripheral	0
blood	0
,	0
in	0
which	0
both	0
GATA-1	9
and	0
SP1	9
activities	0
were	0
high	0
.	0

Cord	0
blood	0
cultures	0
showed	0
an	0
additive	0
combination	0
of	0
``	0
adult	0
''	0
and	0
``	0
fetal	0
''	0
patterns	0
.	0

The	0
progenitors	0
derived	0
from	0
a	0
beta	0
zero-thalassemia	0
patient	0
with	0
high	0
HbF	9
production	0
showed	0
``	0
fetal	0
''	0
pattern	0
.	0

On	0
the	0
other	0
hand	0
,	0
in	0
cultures	0
of	0
2	0
beta	0
zero-thalassemia	0
patients	0
without	0
high	0
HbF	9
,	0
``	0
adult	0
''	0
pattern	0
was	0
observed	0
.	0

CONCLUSIONS	0
:	0
In	0
the	0
present	0
work	0
,	0
we	0
show	0
that	0
human	7
fetal	8
and	8
adult	8
erythroid	8
progenitors	8
are	0
distinct	0
in	0
their	0
transcription	9
factors	10
,	0
and	0
that	0
the	0
commitment	0
to	0
fetal	0
or	0
adult	0
program	0
occurs	0
at	0
a	0
very	0
early	0
differentiation	0
stage	0
.	0

Our	0
studies	0
also	0
demonstrate	0
that	0
under	0
anemic	0
stress	0
,	0
recruitment	0
of	0
fetal	7
progenitors	8
may	0
occur	0
in	0
adulthood	0
.	0

Transcription-independent	0
turnover	0
of	0
I	9
kappa	10
B	10
alpha	10
during	0
monocyte	0
adherence	0
:	0
implications	0
for	0
a	0
translational	0
component	0
regulating	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
levels	0
.	0

We	0
identified	0
I	9
kappa	10
B	10
alpha/MAD-3	10
as	0
an	0
immediate-early	1
gene	2
in	0
human	7
monocytes	8
that	0
is	0
expressed	0
in	0
response	0
to	0
a	0
variety	0
of	0
signals	0
,	0
including	0
adhesion	0
,	0
lipopolysaccharide	0
,	0
and	0
phorbol	0
myristate	0
acetate	0
.	0

Within	0
5	0
min	0
of	0
monocyte	0
adhesion	0
,	0
the	0
level	0
of	0
the	0
I	9
kappa	10
B	10
alpha	10
protein	10
is	0
markedly	0
diminished	0
but	0
is	0
rapidly	0
replaced	0
in	0
a	0
cycloheximide-sensitive	0
manner	0
within	0
20	0
min	0
.	0

Accompanying	0
the	0
rapid	0
turnover	0
of	0
the	0
I	9
kappa	10
B	10
alpha	10
protein	10
is	0
simultaneous	0
translocation	0
of	0
NF-kappa	9
B-related	10
transcription	10
factors	10
to	0
nuclei	0
of	0
adhered	0
monocytes	0
.	0

The	0
demonstration	0
that	0
NF-kappa	9
B	10
can	0
regulate	0
I	1
kappa	2
B	2
alpha/MAD-3	2
gene	2
transcription	0
in	0
other	0
cell	0
types	0
suggested	0
that	0
the	0
rapid	0
increase	0
in	0
steady-state	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
levels	0
we	0
observed	0
within	0
30	0
min	0
of	0
monocyte	0
adherence	0
would	0
result	0
from	0
NF-kappa	9
B	10
-dependent	0
transcriptional	0
stimulation	0
of	0
the	0
I	1
kappa	2
B	2
alpha/MAD-3	2
gene	2
.	0

Nuclear	0
run-on	0
analyses	0
indicated	0
that	0
,	0
instead	0
,	0
while	0
several	0
immediate-early	1
cytokine	2
genes	2
,	0
such	0
as	0
the	0
interleukin	1
1	2
beta	2
(	2
IL-1	2
beta	2
)	2
gene	2
,	0
were	0
transcriptionally	0
activated	0
during	0
monocyte	0
adhesion	0
,	0
the	0
rate	0
of	0
I	1
kappa	2
B	2
alpha/MAD-3	2
gene	2
transcription	0
remained	0
constant	0
.	0

The	0
adherence-dependent	0
increase	0
in	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
levels	0
was	0
also	0
not	0
a	0
consequence	0
of	0
mRNA	3
stabilization	0
events	0
.	0

Interestingly	0
,	0
while	0
increases	0
in	0
both	0
IL-1	0
beta	0
and	0
I	0
kappa	0
B	0
alpha/MAD-3	0
mRNA	0
levels	0
were	0
detected	0
in	0
nuclei	0
of	0
adherent	7
monocytes	8
,	0
cytoplasmic	0
levels	0
of	0
IL-1	3
beta	4
mRNA	4
increased	0
during	0
adherence	0
whereas	0
those	0
of	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
did	0
not	0
.	0

Taken	0
together	0
,	0
our	0
data	0
suggest	0
that	0
two	0
interactive	0
mechanisms	0
regulate	0
monocytic	3
I	4
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
levels	0
.	0

We	0
propose	0
that	0
adherent	7
monocytes	8
regulate	0
nuclear	0
processing	0
(	0
or	0
decay	0
)	0
of	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
,	0
thereby	0
increasing	0
mRNA	0
levels	0
without	0
stimulating	0
I	1
kappa	2
B	2
alpha/MAD-3	2
gene	2
transcription	0
.	0

Moreover	0
,	0
since	0
inhibition	0
of	0
protein	0
synthesis	0
leads	0
to	0
accumulation	0
of	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
without	0
stimulating	0
I	1
kappa	2
B	2
alpha/MAD-3	2
gene	2
transcription	0
,	0
we	0
suggest	0
that	0
low	0
cytoplasmic	0
levels	0
of	0
I	3
kappa	4
B	4
alpha/MAD-3	4
mRNA	4
are	0
maintained	0
by	0
a	0
translation-dependent	0
degradation	0
mechanism	0
.	0

Distinct	0
roles	0
of	0
the	0
molecular	0
chaperone	9
hsp90	10
in	0
modulating	0
dioxin	0
receptor	0
function	0
via	0
the	0
basic	0
helix-loop-helix	9
and	0
PAS	9
domains	10
.	0

The	0
intracellular	9
dioxin	10
receptor	10
mediates	0
signal	0
transduction	0
by	0
dioxin	0
and	0
functions	0
as	0
a	0
ligand-activated	9
transcription	10
factor	10
.	0

It	0
contains	0
a	0
basic	9
helix-loop-helix	10
(	10
bHLH	10
)	10
motif	10
contiguous	0
with	0
a	0
Per-Arnt-Sim	9
(	10
PAS	10
)	10
homology	10
region	10
.	0

In	0
extracts	0
from	0
nonstimulated	0
cells	0
the	0
receptor	0
is	0
recovered	0
in	0
an	0
inducible	0
cytoplasmic	0
form	0
associated	0
with	0
the	0
90-kDa	9
heat	10
shock	10
protein	10
(	0
hsp90	9
)	0
,	0
a	0
molecular	9
chaperone	10
.	0

We	0
have	0
reconstituted	0
ligand-dependent	0
activation	0
of	0
the	0
receptor	0
to	0
a	0
DNA-binding	9
form	10
by	0
using	0
the	0
dioxin	9
receptor	10
and	0
its	0
bHLH-PAS	9
partner	10
factor	10
Arnt	9
expressed	0
by	0
in	0
vitro	0
translation	0
in	0
reticulocyte	0
lysate	0
.	0

Deletion	0
of	0
the	0
PAS	9
domain	10
of	0
the	0
receptor	0
resulted	0
in	0
constitutive	0
dimerization	0
with	0
Arnt	9
.	0

In	0
contrast	0
,	0
this	0
receptor	0
mutant	0
showed	0
low	0
levels	0
of	0
xenobiotic	0
response	0
element-binding	0
activity	0
,	0
indicating	0
that	0
the	0
PAS	9
domain	10
may	0
be	0
important	0
for	0
DNA-binding	0
affinity	0
and/or	0
specificity	0
of	0
the	0
receptor	0
.	0

It	0
was	0
not	0
possible	0
to	0
reconstitute	0
dioxin	9
receptor	10
function	0
with	0
proteins	0
expressed	0
in	0
wheat	0
germ	0
lysate	0
.	0

In	0
line	0
with	0
these	0
observations	0
,	0
reticulocyte	0
lysate	0
but	0
not	0
wheat	0
germ	0
lysate	0
promoted	0
the	0
association	0
of	0
de	0
novo	0
synthesized	0
dioxin	9
receptor	10
with	0
hsp90	9
.	0

At	0
least	0
two	0
distinct	0
domains	0
of	0
the	0
receptor	0
mediated	0
interaction	0
with	0
hsp90	9
:	0
the	0
ligand-binding	9
domain	10
located	0
within	0
the	0
PAS	9
region	10
and	0
,	0
surprisingly	0
,	0
the	0
bHLH	9
domain	10
.	0

Whereas	0
ligand-binding	0
activity	0
correlated	0
with	0
association	0
with	0
hsp90	9
,	0
bHLH-	0
hsp90	9
interaction	0
appeared	0
to	0
be	0
important	0
for	0
DNA-binding	0
activity	0
but	0
not	0
for	0
dimerization	0
of	0
the	0
receptor	0
.	0

Several	0
distinct	0
roles	0
for	0
hsp90	9
in	0
modulating	0
dioxin	9
receptor	10
function	0
are	0
therefore	0
likely	0
:	0
correct	0
folding	0
of	0
the	0
ligand-binding	0
domain	0
,	0
interference	0
with	0
Arnt	9
heterodimerization	0
,	0
and	0
folding	0
of	0
a	0
DNA-binding	0
conformation	0
of	0
the	0
bHLH	9
domain	10
.	0

Thus	0
,	0
the	0
dioxin	9
receptor	10
system	0
provides	0
a	0
complex	0
and	0
interesting	0
model	0
of	0
the	0
regulation	0
of	0
transcription	9
factors	10
by	0
hsp90	9
.	0

Induction	0
of	0
transcription	9
factors	10
in	0
human	7
T	8
lymphocytes	8
by	0
aspirin-like	0
drugs	0
.	0

Aspirin-like	0
drugs	0
(	0
ALD	0
)	0
induce	0
calcium	0
mobilization	0
,	0
an	0
essential	0
component	0
of	0
T	0
cell	0
activation	0
,	0
but	0
do	0
not	0
induce	0
the	0
biosynthesis	0
of	0
IL-2	9
.	0

To	0
understand	0
the	0
extent	0
to	0
which	0
ALD	0
may	0
mimic	0
mitogenic	0
stimulation	0
,	0
we	0
studied	0
cytoplasmic	0
and	0
nuclear	0
signaling	0
steps	0
in	0
ALD-treated	5
T	6
cells	6
.	0

We	0
found	0
that	0
ALD	0
induce	0
a	0
transient	0
activation	0
of	0
protein	9
kinase	10
(	0
PKC	9
)	0
but	0
have	0
no	0
effect	0
(	0
in	0
comparison	0
to	0
anti-CD3	9
antibodies	10
)	0
on	0
protein	0
tyrosine	0
phosphorylation	0
nor	0
on	0
PCL	0
gamma	0
1	0
tyrosine	0
phosphorylation	0
.	0

ALD-induced	0
calcium	0
mobilization	0
and	0
PKC	9
activation	0
are	0
independent	0
of	0
tyrosine	9
protein	10
kinase	10
activity	0
as	0
shown	0
by	0
the	0
lack	0
of	0
effect	0
of	0
herbimycin	0
,	0
a	0
tyrosine-protein	9
kinase	10
-specific	0
inhibitor	0
.	0

Although	0
we	0
detected	0
no	0
IL-2	3
mRNA	4
in	0
ALD-treated	5
cells	6
,	0
the	0
nuclei	0
of	0
these	0
cells	0
contain	0
proteins	0
capable	0
of	0
binding	0
to	0
three	0
regulatory	1
sequences	2
in	0
the	0
IL-2	1
promoter	2
region	2
:	0
NFAT	9
,	0
NF	9
kappa	10
B	10
,	0
and	0
AP-1	9
.	0

These	0
binding	0
activities	0
are	0
expressed	0
only	0
in	0
activated	7
T	8
cells	8
.	0

The	0
expression	0
of	0
AP-1	9
depended	0
on	0
calcium	0
mobilization	0
and	0
PKC	9
activation	0
.	0

These	0
data	0
suggest	0
that	0
ALD	0
cause	0
transient	0
but	0
significant	0
changes	0
in	0
T	0
cell	0
transmembrane	0
signaling	0
,	0
although	0
some	0
events	0
induced	0
by	0
stimulation	0
with	0
anti-CD3	9
antibodies	10
are	0
not	0
induced	0
by	0
ALD	0
.	0

The	0
signal	0
is	0
transmitted	0
to	0
the	0
nucleus	0
and	0
induces	0
DNA-binding	0
activity	0
by	0
several	0
transcription	9
factors	10
.	0

However	0
,	0
the	0
ALD	0
stimulus	0
is	0
not	0
capable	0
of	0
causing	0
complete	0
T	0
cell	0
activation	0
.	0

Protein	9
kinase	10
C	10
is	0
not	0
a	0
downstream	0
effector	0
of	0
p21ras	1
in	0
activated	7
T	8
cells	8
.	0

The	0
aim	0
of	0
this	0
present	0
study	0
was	0
to	0
investigate	0
the	0
role	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
,	0
downstream	0
of	0
p21ras	1
,	0
in	0
activating	0
interleukin-2	1
(	2
IL-2	2
)	2
gene	2
expression	0
.	0

It	0
has	0
been	0
reported	0
that	0
PKC	9
is	0
an	0
effector	9
of	0
p21ras	1
in	0
T	7
cells	8
.	0

Data	0
is	0
presented	0
,	0
using	0
the	0
potent	0
and	0
selective	0
PKC	9
inhibitor	0
Ro	0
31-8425	0
and	0
transient	0
expression	0
of	0
a	0
constitutively	0
active	0
ras	0
mutant	0
,	0
which	0
clearly	0
shows	0
that	0
PKC	9
is	0
not	0
downstream	0
of	0
p21ras	1
in	0
the	0
induction	0
of	0
NF-AT	9
and	0
AP-1	9
transcriptional	0
activity	0
and	0
in	0
the	0
expression	0
of	0
IL-2	9
in	0
human	5
Jurkat	6
T	6
cells	6
.	0

Reporter	0
gene	0
experiments	0
demonstrated	0
that	0
NF-kappa	9
B	10
transcriptional	0
activity	0
is	0
not	0
affected	0
by	0
expression	0
of	0
activated	0
p21ras	1
.	0

The	0
signaling	0
pathways	0
involving	0
PKC	9
activation	0
,	0
calcium	0
mobilization	0
and	0
ras	9
activation	0
combine	0
to	0
provide	0
the	0
necessary	0
components	0
for	0
production	0
of	0
IL-2	9
during	0
T	0
cell	0
activation	0
.	0

The	0
C-terminus	9
of	0
the	0
B	9
cell	10
activator	10
Oct-2	9
functions	0
as	0
an	0
activation	9
domain	10
in	0
yeast	0
.	0

Oct-1	9
and	0
Oct-2	9
are	0
human	0
transcriptional	9
activators	10
that	0
bind	0
to	0
the	0
same	0
DNA	0
element	0
but	0
activate	0
distinct	0
sets	0
of	0
genes	0
.	0

We	0
expressed	0
these	0
factors	0
in	0
S.	0
cerevisiae	0
and	0
observed	0
greater	0
than	0
5-fold	0
stimulation	0
of	0
a	0
lacZ	1
reporter	2
gene	2
only	0
with	0
Oct-2	9
.	0

Transfer	0
of	0
the	0
Oct-2	9
C-terminal	10
domain	10
onto	0
either	0
Oct-1	9
(	0
Oct1.2	9
)	0
or	0
a	0
nonactivating	9
DNA-binding	10
domain	10
from	0
GAL4	9
created	0
activators	0
capable	0
of	0
greater	0
than	0
15	0
and	0
10-fold	0
stimulation	0
of	0
activity	0
,	0
respectively	0
.	0

Thus	0
,	0
the	0
C-terminus	9
of	0
Oct-2	9
is	0
sufficient	0
to	0
confer	0
activation	0
potential	0
to	0
nonactive	0
DNA-binding	1
fragments	2
in	0
yeast	0
.	0

Glucocorticoid-induced	0
apoptosis	0
of	0
lymphoid	7
cells	8
.	0

The	0
induction	0
of	0
cell	0
death	0
in	0
lymphoid	7
cells	8
by	0
glucocorticoids	0
is	0
one	0
of	0
the	0
earliest	0
and	0
most	0
thoroughly	0
studied	0
models	0
of	0
apoptosis	0
.	0

Although	0
the	0
exact	0
mechanism	0
by	0
which	0
apoptosis	0
occurs	0
in	0
lymphocytes	7
is	0
unknown	0
many	0
biochemical	0
and	0
molecular	0
changes	0
have	0
been	0
shown	0
to	0
occur	0
in	0
these	0
cells	0
in	0
response	0
to	0
glucocorticoids	0
.	0

The	0
role	0
of	0
chromatin	1
degradation	0
and	0
endonucleases	9
in	0
the	0
apoptotic	0
process	0
has	0
been	0
closely	0
studied	0
,	0
as	0
well	0
as	0
the	0
involvement	0
of	0
several	0
oncogenes	1
in	0
glucocorticoid-induced	0
cell	0
lysis	0
.	0

In	0
addition	0
,	0
the	0
clinical	0
importance	0
of	0
glucocorticoid-induced	0
apoptosis	0
in	0
the	0
treatment	0
of	0
lymphoid	0
neoplasms	0
has	0
recently	0
received	0
increased	0
attention	0
.	0

Interleukin-2	9
induces	0
tyrosine	0
phosphorylation	0
and	0
nuclear	0
translocation	0
of	0
stat3	9
in	0
human	7
T	8
lymphocytes	8
.	0

An	0
early	0
biochemical	0
event	0
associated	0
with	0
T	0
cell	0
activation	0
through	0
the	0
interleukin-2	9
receptor	10
(	0
IL-2R	9
)	0
is	0
tyrosine	0
phosphorylation	0
of	0
several	0
intracellular	0
substrates	0
.	0

The	0
exact	0
mechanism	0
by	0
which	0
IL-2	9
regulates	0
transcription	0
of	0
different	0
genes	0
is	0
presently	0
unknown	0
.	0

Here	0
,	0
we	0
report	0
that	0
stimulation	0
through	0
the	0
IL-2R	9
induced	0
tyrosine	0
phosphorylation	0
and	0
subsequent	0
nuclear	0
translocation	0
of	0
stat3	9
,	0
a	0
newly	0
identified	0
member	0
of	0
the	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
family	10
of	0
proteins	0
.	0

In	0
contrast	0
,	0
stat1	0
proteins	0
were	0
not	0
tyrosine	0
phosphorylated	0
after	0
IL-2	9
ligation	0
,	0
whereas	0
tyrosine-phosphorylated	9
stat1	10
proteins	10
(	0
91	9
and	10
84	10
kDa	10
proteins	10
)	0
were	0
translocated	0
to	0
the	0
nucleus	0
following	0
interferon-gamma	9
treatment	0
of	0
HeLa	5
cells	6
.	0

Apart	0
from	0
stat3	9
,	0
another	0
cytoplasmic	9
protein	10
was	0
tyrosine	0
phosphorylated	0
and	0
subsequently	0
translocated	0
to	0
the	0
nucleus	0
in	0
response	0
to	0
IL-2	9
.	0

This	0
protein	0
had	0
an	0
apparent	0
molecular	0
mass	0
of	0
84	0
kDa	0
and	0
was	0
not	0
recognized	0
by	0
stat3	9
or	0
stat1	9
mAb	10
or	0
antisera	0
.	0

Since	0
IL-2	9
induced	0
nuclear	0
translocation	0
of	0
the	0
84	9
kDa	10
protein	10
and	0
stat3	9
followed	0
identical	0
kinetics	0
,	0
p84	9
is	0
a	0
candidate	0
for	0
a	0
new	0
,	0
yet	0
undefined	0
,	0
member	0
of	0
the	0
STAT	0
family	0
.	0

Taken	0
together	0
,	0
we	0
report	0
that	0
IL-2	9
induces	0
tyrosine	0
phosphorylation	0
and	0
subsequent	0
nuclear	0
translocation	0
of	0
stat3	9
and	0
an	0
as	0
yet	0
undefined	0
84-kDa	9
protein	10
in	0
antigen-specific	5
human	6
T	6
cell	6
lines	6
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
Tax	9
activation	0
of	0
NF-kappa	9
B/Rel	10
involves	0
phosphorylation	0
and	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
RelA	9
(	0
p65	9
)	0
-mediated	0
induction	0
of	0
the	0
c-rel	1
gene	2
.	0

The	0
tax	0
gene	0
product	0
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
is	0
a	0
potent	0
transcriptional	9
activator	10
that	0
both	0
stimulates	0
viral	0
gene	0
expression	0
and	0
activates	0
an	0
array	0
of	0
cellular	1
genes	2
involved	0
in	0
T-cell	7
growth	0
.	0

Tax	0
acts	0
indirectly	0
by	0
inducing	0
or	0
modifying	0
the	0
action	0
of	0
various	0
host	0
transcription	9
factors	10
,	0
including	0
members	0
of	0
the	0
NF-kappa	9
B/Rel	10
family	10
of	0
enhancer-binding	9
proteins	10
.	0

In	0
resting	7
T	8
cells	8
,	0
many	0
of	0
these	0
NF-kappa	9
B/Rel	10
factors	10
are	0
sequestered	0
in	0
the	0
cytoplasm	0
by	0
various	0
ankyrin-rich	9
inhibitory	10
proteins	10
,	0
including	0
I	9
kappa	10
B	10
alpha	10
.	0

HTLV-I	9
Tax	10
expression	0
leads	0
to	0
the	0
constitutive	0
nuclear	0
expression	0
of	0
biologically	0
active	0
NF-kappa	9
B	10
and	0
c-Rel	9
complexes	10
;	0
however	0
,	0
the	0
biochemical	0
mechanism	0
(	0
s	0
)	0
underlying	0
this	0
response	0
remains	0
poorly	0
understood	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
Tax	9
-stimulated	0
nuclear	0
expression	0
of	0
NF-kappa	9
B	10
in	0
both	0
HTLV-I-infected	5
and	6
Tax-transfected	6
human	6
T	6
cells	6
is	0
associated	0
with	0
the	0
phosphorylation	0
and	0
rapid	0
proteolytic	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

In	0
contrast	0
to	0
prior	0
in	0
vitro	0
studies	0
,	0
at	0
least	0
a	0
fraction	0
of	0
the	0
phosphorylated	0
form	0
of	0
I	9
kappa	10
B	10
alpha	10
remains	0
physically	0
associated	0
with	0
the	0
NF-kappa	9
B	10
complex	10
in	0
vivo	0
but	0
is	0
subject	0
to	0
rapid	0
degradation	0
,	0
thereby	0
promoting	0
the	0
nuclear	0
translocation	0
of	0
the	0
active	0
NF-kappa	9
B	10
complex	10
.	0

We	0
further	0
demonstrate	0
that	0
Tax	9
induction	0
of	0
nuclear	0
c-Rel	9
expression	0
is	0
activated	0
by	0
the	0
RelA	9
(	0
p65	9
)	0
subunit	0
of	0
NF-kappa	9
B	10
,	0
which	0
activates	0
transcription	0
of	0
the	0
c-rel	1
gene	2
through	0
an	0
intrinsic	0
kappa	1
B	2
enhancer	2
element	2
.	0

In	0
normal	0
cells	0
,	0
the	0
subsequent	0
accumulation	0
of	0
nuclear	9
c-Rel	10
acts	0
to	0
inhibit	0
its	0
own	0
continued	0
production	0
,	0
indicating	0
the	0
presence	0
of	0
an	0
autoregulatory	0
loop	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Activation	0
of	0
NF-kappa	9
B	10
in	0
vivo	0
is	0
regulated	0
by	0
multiple	0
phosphorylations	0
.	0

The	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
in	0
intact	0
cells	0
is	0
mechanistically	0
not	0
well	0
understood	0
.	0

Therefore	0
we	0
investigated	0
the	0
modifications	0
imposed	0
on	0
NF-kappa	9
B/I	10
kappa	10
B	10
components	10
following	0
stimulation	0
and	0
show	0
that	0
the	0
final	0
step	0
of	0
NF-kappa	9
B	10
induction	0
in	0
vivo	0
involves	0
phosphorylation	0
of	0
several	0
members	0
of	0
the	0
NF-kappa	9
B/I	10
kappa	10
B	10
protein	10
families	10
.	0

In	0
HeLa	5
cells	6
as	0
well	0
as	0
in	0
B	7
cells	8
,	0
TNF-alpha	0
rapidly	0
induced	0
nuclear	0
translocation	0
primarily	0
of	0
p50-p65	9
,	0
but	0
not	0
of	0
c-rel	9
.	0

Both	0
NF-kappa	9
B	10
precursors	0
and	0
I	9
kappa	10
B	10
alpha	10
became	0
strongly	0
phosphorylated	0
with	0
the	0
same	0
kinetics	0
.	0

In	0
addition	0
to	0
the	0
inducible	0
phosphorylation	0
after	0
stimulation	0
,	0
B	7
lymphocytes	8
containing	0
constitutive	0
nuclear	0
NF-kappa	9
B	10
revealed	0
constitutively	0
phosphorylated	0
p65	9
and	0
I	9
kappa	10
B	10
alpha	10
.	0

Phosphorylation	0
was	0
accompanied	0
by	0
induced	0
processing	0
of	0
the	0
precursors	0
p100	9
and	0
p105	9
and	0
by	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

As	0
an	0
in	0
vitro	0
model	0
we	0
show	0
that	0
phosphorylation	0
of	0
p105	9
impedes	0
its	0
ability	0
to	0
interact	0
with	0
NF-kappa	9
B	10
,	0
as	0
has	0
been	0
shown	0
before	0
for	0
I	9
kappa	10
B	10
alpha	10
.	0

Surprisingly	0
,	0
even	0
p65	9
,	0
but	0
not	0
c-rel	9
,	0
was	0
phosphorylated	0
after	0
induction	0
in	0
vivo	0
,	0
suggesting	0
that	0
TNF-alpha	9
selectively	0
activates	0
only	0
specific	0
NF-kappa	9
B	10
heteromers	0
and	0
that	0
modifications	0
regulate	0
not	0
only	0
I	9
kappa	10
B	10
molecules	10
but	0
also	0
NF-kappa	9
B	10
molecules	0
.	0

In	0
fact	0
,	0
cellular	0
NF-kappa	9
B	10
activity	0
was	0
phosphorylation-dependent	0
and	0
the	0
DNA	0
binding	0
activity	0
of	0
p65-containing	9
NF-kappa	10
B	10
was	0
enhanced	0
by	0
phosphorylation	0
in	0
vitro	0
.	0

Furthermore	0
,	0
we	0
found	0
that	0
the	0
induction	0
by	0
hydrogen	0
peroxide	0
of	0
NF-kappa	9
B	10
translocation	0
to	0
the	0
nucleus	0
,	0
which	0
is	0
assumed	0
to	0
be	0
triggered	0
by	0
reactive	0
oxygen	0
intermediates	0
,	0
also	0
coincided	0
with	0
incorporation	0
of	0
phosphate	0
into	0
the	0
same	0
subunits	0
that	0
were	0
modified	0
after	0
stimulation	0
by	0
TNF-alpha	9
.	0

Thus	0
,	0
phosphorylation	0
appears	0
to	0
be	0
a	0
general	0
mechanism	0
for	0
activation	0
of	0
NF-kappa	9
B	10
in	0
vivo	0
.	0

Treatment	0
of	0
HL60	5
cells	6
with	0
various	0
combinations	0
of	0
retinoids	0
and	0
1	0
alpha	0
,	0
25	0
dihydroxyvitamin	0
D3	0
results	0
in	0
differentiation	0
towards	0
neutrophils	7
or	0
monocytes	7
or	0
a	0
failure	0
to	0
differentiate	0
and	0
apoptosis	0
.	0

It	0
is	0
well	0
documented	0
that	0
treatment	0
of	0
serum-grown	5
HL60	6
cells	6
with	0
10	0
(	0
-7	0
)	0
M	0
all-trans	0
retinoic	0
acid	0
(	0
all-trans	0
RA	0
)	0
induces	0
neutrophil	7
differentiation	0
,	0
whereas	0
treatment	0
with	0
10	0
(	0
-7	0
)	0
M	0
1	0
alpha	0
,	0
25	0
dihydroxyvitamin	0
D3	0
(	0
D3	0
)	0
induces	0
differentiation	0
towards	0
monocytes	7
.	0

In	0
recent	0
investigations	0
,	0
using	0
serum-free	5
grown	6
HL60	6
cells	6
,	0
we	0
observed	0
that	0
all-trans	0
RA	0
,	0
at	0
10	0
(	0
-7	0
)	0
M	0
,	0
did	0
not	0
induce	0
neutrophil	0
differentiation	0
and	0
that	0
all-trans	0
RA	0
,	0
at	0
10	0
(	0
-8	0
)	0
M	0
,	0
reduced	0
the	0
D3	0
concentration	0
required	0
for	0
monocyte	7
differentiation	0
to	0
5	0
x	0
10	0
(	0
-9	0
)	0
M	0
.	0

In	0
this	0
study	0
,	0
co-operative	0
interactions	0
between	0
all-trans	0
and	0
9-cis	0
RA	0
and	0
D3	0
which	0
promote	0
neutrophil	0
and	0
monocyte	0
differentiation	0
of	0
HL60	5
cells	6
have	0
been	0
analysed	0
in	0
detail	0
.	0

Treatment	0
of	0
serum-free	5
grown	6
HL60	6
cells	6
with	0
5	0
x	0
10	0
(	0
-7	0
)	0
M	0
all-trans	0
RA	0
or	0
9-cis	0
RA	0
resulted	0
in	0
sub-optimal	0
neutrophil	0
differentiation	0
(	0
up	0
to	0
25	0
%	0
mature	0
cells	0
)	0
.	0

As	0
shown	0
for	0
all-trans	0
RA	0
,	0
9-cis	0
RA	0
cooperated	0
with	0
D3	0
to	0
promote	0
monocyte	0
differentiation	0
.	0

Culture	0
of	0
HL60	5
cells	6
in	0
5	0
x	0
10	0
(	0
-7	0
)	0
M	0
9-cis	0
RA	0
together	0
with	0
a	0
wide	0
range	0
of	0
concentrations	0
of	0
D3	0
resulted	0
in	0
promotion	0
of	0
neutrophil	0
differentiation	0
at	0
10	0
(	0
-15	0
)	0
-10	0
(	0
-12	0
)	0
D3	0
,	0
a	0
failure	0
to	0
differentiate	0
and	0
apoptosis	0
at	0
10	0
(	0
-11	0
)	0
-10	0
(	0
-10	0
)	0
M	0
D3	0
,	0
followed	0
by	0
co-operativity	0
between	0
9-cis	0
RA	0
and	0
5	0
x	0
10	0
(	0
-9	0
)	0
M	0
D3	0
in	0
inducing	0
monocyte	0
differentiation	0
in	0
the	0
absence	0
of	0
neutrophil	0
differentiation	0
.	0

Similar	0
results	0
were	0
obtained	0
when	0
HL60	5
cells	6
were	0
treated	0
with	0
5	0
x	0
10	0
(	0
-7	0
)	0
all-trans	0
RA	0
together	0
with	0
a	0
wide	0
range	0
of	0
concentrations	0
of	0
D3	0
.	0

Cross	0
titration	0
analyses	0
of	0
the	0
effects	0
of	0
9-cis	0
RA	0
and	0
D3	0
on	0
HL60	5
cell	6
differentiation	0
were	0
undertaken	0
to	0
determine	0
the	0
boundaries	0
of	0
the	0
concentrations	0
of	0
each	0
agent	0
,	0
alone	0
and	0
in	0
combination	0
,	0
that	0
give	0
rise	0
to	0
optimal	0
neutrophil	0
and	0
monocyte	0
differentiation	0
of	0
HL60	5
cells	6
.	0

The	0
observed	0
cooperativities	0
between	0
either	0
9-cis	0
RA	0
or	0
all-trans	0
RA	0
and	0
D3	0
have	0
important	0
implications	0
for	0
the	0
use	0
of	0
combinations	0
of	0
these	0
agents	0
in	0
differentiation	0
therapy	0
.	0

Isolation	0
of	0
differentially	0
expressed	0
sequence	0
tags	0
from	0
steroid-responsive	7
cells	8
using	0
mRNA	3
differential	0
display	0
.	0

Transcriptional	0
control	0
of	0
steroid-regulated	1
gene	2
networks	2
by	0
nuclear	9
receptor	10
proteins	10
results	0
in	0
the	0
coordinate	0
expression	0
of	0
a	0
limited	0
number	0
of	0
target	1
genes	2
.	0

Although	0
much	0
is	0
known	0
about	0
the	0
structure	0
and	0
function	0
of	0
steroid	0
receptors	0
,	0
relatively	0
few	0
cell-specific	0
steroid-regulated	0
genes	0
have	0
been	0
isolated	0
and	0
characterized	0
.	0

In	0
this	0
paper	0
we	0
describe	0
results	0
using	0
mRNA	3
differential	0
display	0
reverse	9
transcriptase	10
PCR	0
(	0
DDPCR	0
)	0
to	0
identify	0
and	0
isolate	0
short	0
cDNA	0
sequence	0
tags	0
from	0
thymocyte	7
and	0
prostate	7
cells	8
under	0
various	0
hormone	0
conditions	0
.	0

Using	0
this	0
technique	0
we	0
have	0
isolated	0
several	0
differentially	1
expressed	2
sequence	2
tags	2
(	0
DESTs	1
)	0
from	0
the	0
mouse	5
thymocyte	6
cell	6
line	6
WEHI	5
7.2	6
.	0

Two	0
of	0
these	0
DESTs	1
,	0
GIG10	1
and	0
GIG18	1
,	0
are	0
rapidly	0
induced	0
by	0
dexamethasone	0
within	0
2	0
h	0
of	0
treatment	0
.	0

GIG10	1
is	0
a	0
novel	0
sequence	0
and	0
GIG18	1
is	0
the	0
mouse	0
homologue	0
of	0
a	0
human	1
expressed	2
sequence	2
tag	2
isolated	0
from	0
activated	7
B	8
lymphocytes	8
.	0

We	0
also	0
used	0
DDPCR	0
to	0
isolate	0
DESTs	1
from	0
androgen-modulated	0
rat	0
ventral	0
prostate	0
tissue	0
,	0
one	0
of	0
which	0
we	0
characterized	0
and	0
found	0
to	0
correspond	0
to	0
the	0
3	3
'	4
end	4
of	0
prostatic	3
spermine	4
binding	4
protein	4
mRNA	4
,	0
a	0
known	0
androgen-regulated	1
gene	2
.	0

Modifications	0
of	0
the	0
original	0
DDPCR	0
protocol	0
,	0
which	0
we	0
found	0
can	0
potentially	0
decrease	0
the	0
frequency	0
of	0
isolating	0
false-positive	0
DESTs	1
,	0
are	0
described	0
and	0
the	0
merits	0
of	0
DDPCR	0
,	0
relative	0
to	0
other	0
differential	0
cDNA	0
cloning	0
strategies	0
,	0
are	0
discussed	0
.	0

Activation	0
of	0
human	7
thymocytes	8
after	0
infection	0
by	0
EBV	0
.	0

The	0
discovery	0
of	0
EBV	0
in	0
certain	0
T	0
cell	0
malignancies	0
and	0
the	0
expression	0
of	0
the	0
EBV	9
receptor	10
,	0
CR2/CD21	9
,	0
on	0
a	0
population	0
of	0
immature	7
thymocytes	8
,	0
T	5
lymphoblastoid	6
cell	6
lines	6
,	0
and	0
childhood	7
acute	8
T	8
lymphoblastic	8
leukemia	8
cells	8
suggested	0
that	0
EBV-receptor	0
interactions	0
on	0
T	7
cells	8
may	0
be	0
of	0
importance	0
.	0

We	0
have	0
shown	0
that	0
,	0
within	0
the	0
thymus	0
,	0
a	0
population	0
of	0
large	7
,	8
immature	8
cells	8
expresses	0
CD21	9
.	0

EBV	0
altered	0
the	0
activation	0
responses	0
of	0
immature	7
thymocytes	8
in	0
vitro	0
.	0

Triggering	0
through	0
CD2	9
is	0
mitogenic	0
for	0
mature	0
,	0
but	0
not	0
immature	0
,	0
T	7
cells	8
.	0

However	0
,	0
during	0
infection	0
by	0
EBV	0
,	0
ligation	0
of	0
CD2	9
caused	0
thymocytes	7
to	0
proliferate	0
in	0
the	0
absence	0
of	0
exogenous	9
cytokines	10
.	0

This	0
function	0
was	0
a	0
result	0
of	0
the	0
interaction	0
of	0
EBV	0
with	0
its	0
receptor	0
,	0
CD21	9
,	0
but	0
was	0
caused	0
by	0
infection	0
rather	0
than	0
surface	0
signaling	0
,	0
because	0
neither	0
specific	9
mAb	10
nor	0
the	0
P3HR-1	0
strain	0
of	0
virus	0
mimicked	0
the	0
effect	0
of	0
B95-8	0
.	0

Immature	0
thymocytes	7
were	0
infected	0
by	0
EBV	0
,	0
as	0
determined	0
by	0
the	0
internalization	0
of	0
the	0
viral	1
genome	2
and	0
its	0
transcriptional	0
activity	0
.	0

Consistent	0
with	0
the	0
activity	0
of	0
B95-8	9
,	0
EBNA-2	3
transcripts	4
were	0
identified	0
within	0
infected	5
thymocyte	6
populations	6
.	0

In	0
addition	0
,	0
components	0
of	0
the	0
viral	0
replicative	0
pathway	0
were	0
expressed	0
during	0
infection	0
of	0
thymocytes	7
.	0

These	0
components	0
included	0
transcription	0
of	0
BZLF-1	1
,	0
an	0
early	1
gene	2
that	0
characterizes	0
EBV-infected	7
B	8
cells	8
after	0
disruption	0
of	0
latency	0
.	0

A	0
second	0
transcript	0
was	0
identified	0
as	0
encoding	0
the	0
recently	0
characterized	0
RAZ	9
,	0
which	0
also	0
is	0
associated	0
with	0
replicative	0
infection	0
.	0

The	0
consequences	0
of	0
EBV	0
infection	0
of	0
T	7
cells	8
at	0
an	0
early	0
stage	0
of	0
differentiation	0
may	0
lead	0
to	0
failure	0
of	0
normal	0
T	0
cell	0
repertoire	0
development	0
,	0
autoimmunity	0
,	0
or	0
malignancy	0
.	0

Effects	0
of	0
intranasal	0
glucocorticoids	0
on	0
endogenous	0
glucocorticoid	0
peripheral	0
and	0
central	0
function	0
.	0

Glucocorticoids	0
are	0
among	0
the	0
most	0
potent	0
antiinflammatory	0
agents	0
that	0
can	0
be	0
used	0
in	0
the	0
treatment	0
of	0
rhinitis	0
.	0

Their	0
mechanisms	0
of	0
action	0
are	0
multiple	0
and	0
complex	0
and	0
a	0
number	0
of	0
reports	0
describe	0
significant	0
systemic	0
effects	0
of	0
locally	0
administered	0
glucocorticoids	0
.	0

In	0
order	0
to	0
evaluate	0
the	0
short-term	0
systemic	0
effects	0
of	0
intranasally	0
administered	0
glucocorticoids	0
,	0
14	0
normal	0
healthy	0
subjects	0
were	0
treated	0
with	0
two	0
doses	0
of	0
either	0
budesonide	0
(	0
BUD	0
)	0
or	0
fluticasone	0
propionate	0
(	0
FP	0
)	0
for	0
2	0
weeks	0
.	0

Before	0
treatment	0
,	0
at	0
regular	0
intervals	0
during	0
the	0
treatment	0
,	0
1	0
week	0
and	0
finally	0
6	0
weeks	0
after	0
termination	0
of	0
treatment	0
,	0
the	0
effects	0
on	0
glucocorticoid	0
receptor	0
(	0
GR	0
)	0
and	0
methallothionein	0
(	0
MTIIa	0
)	0
mRNA	0
expression	0
levels	0
were	0
examined	0
in	0
peripheral	7
lymphocytes	8
using	0
a	0
solution	0
hybridization	0
assay	0
.	0

Serum	0
cortisol	0
,	0
osteocalcin	0
and	0
urinary	0
cortisol	0
levels	0
were	0
also	0
determined	0
.	0

An	0
insulin	0
tolerance	0
test	0
(	0
ITT	0
)	0
was	0
performed	0
at	0
the	0
end	0
of	0
the	0
second	0
week	0
of	0
treatment	0
and	0
at	0
the	0
end	0
of	0
the	0
6-week	0
washout	0
period	0
with	0
no	0
statistically	0
significant	0
change	0
in	0
cortisol	0
response	0
.	0

In	0
peripheral	7
lymphocytes	8
,	0
GR	3
mRNA	4
levels	0
were	0
significantly	0
down-regulated	0
.	0

MTIIa	3
mRNA	4
levels	0
increased	0
significantly	0
.	0

Serum	0
osteocalcin	9
decreased	0
significantly	0
during	0
treatment	0
with	0
both	0
BUD	0
and	0
FP	0
.	0

Serum	0
cortisol	0
decreased	0
after	0
1	0
week	0
of	0
treatment	0
whereas	0
urinary	0
cortisol	0
was	0
not	0
affected	0
until	0
the	0
second	0
week	0
of	0
treatment	0
.	0

In	0
conclusion	0
,	0
intranasal	0
glucocorticoids	0
at	0
clinically	0
recommended	0
doses	0
have	0
not	0
only	0
significant	0
systemic	0
effects	0
on	0
adrenal	0
function	0
,	0
but	0
also	0
have	0
an	0
effect	0
on	0
specific	0
gene	0
expression	0
in	0
peripheral	7
lymphocytes	8
.	0

These	0
effects	0
are	0
receptor-dependent	0
,	0
reversible	0
,	0
and	0
according	0
to	0
serum	0
and	0
urinary	0
cortisol	0
levels	0
and	0
ITT	0
,	0
leave	0
the	0
hypothalamic-pituitary-adrenal	0
function	0
intact	0
.	0

Finally	0
,	0
these	0
short-term	0
systemic	0
effects	0
were	0
not	0
associated	0
with	0
any	0
of	0
the	0
noticeable	0
side-effects	0
usually	0
observed	0
during	0
long-term	0
treatment	0
with	0
glucocorticoids	0
.	0

Biphasic	0
control	0
of	0
nuclear	9
factor-kappa	10
B	10
activation	0
by	0
the	0
T	9
cell	10
receptor	10
complex	10
:	0
role	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
.	0

The	0
regulation	0
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
activation	0
by	0
the	0
T	9
cell	10
receptor	10
(	10
TcR	10
)	10
/CD3	10
complex	10
in	0
primary	0
human	0
T	7
cells	8
has	0
been	0
studied	0
at	0
various	0
times	0
after	0
activation	0
.	0

Only	0
p50	9
NF-kappa	10
B	10
protein	10
bound	0
the	0
kappa	1
B	2
element	2
of	0
interleukin-2	1
receptor	2
(	2
IL-2R	2
)	2
alpha	2
chain	2
promoter	2
on	0
resting	0
T	7
cells	8
.	0

However	0
,	0
immediately	0
after	0
TcR/CD3	9
cross-linking	0
(	0
after	0
approximately	0
1	0
h	0
;	0
immediate	0
)	0
binding	0
of	0
p50.p65	9
heterodimers	10
was	0
observed	0
.	0

p50.c-rel	9
heterodimers	10
were	0
also	0
detected	0
bound	0
to	0
this	0
sequence	0
at	0
early	0
time	0
points	0
(	0
7-16	0
h	0
;	0
early	0
)	0
,	0
and	0
both	0
remained	0
active	0
at	0
later	0
time	0
points	0
(	0
40	0
h	0
;	0
late	0
)	0
after	0
activation	0
.	0

This	0
regulation	0
takes	0
place	0
mainly	0
at	0
the	0
level	0
of	0
nuclear	0
translocation	0
of	0
p65	9
and	0
c-rel	9
,	0
at	0
immediate	0
and	0
early	0
time	0
points	0
.	0

Activation	0
also	0
induced	0
c-rel	0
and	0
p105/p50	0
mRNA	0
synthesis	0
,	0
but	0
not	0
p65	3
mRNA	4
whose	0
expression	0
was	0
constitutive	0
.	0

Interestingly	0
,	0
all	0
those	0
early	0
and	0
late	0
events	0
,	0
but	0
not	0
the	0
immediate	0
ones	0
,	0
were	0
inhibited	0
by	0
a	0
neutralizing	0
anti-tumor	9
necrosis	10
factor	10
alpha	10
(	10
TNF-alpha	10
)	10
monoclonal	10
antibody	10
.	0

Similarly	0
,	0
cycloheximide	0
prevented	0
the	0
p65	9
and	0
c-rel	9
translocation	0
and	0
consequent	0
formation	0
of	0
active	0
binding	0
heterodimers	0
,	0
at	0
early	0
and	0
late	0
times	0
.	0

Cyclosporin	0
A	0
impaired	0
not	0
only	0
early	0
and	0
late	0
,	0
but	0
also	0
immediate	0
events	0
;	0
however	0
,	0
addition	0
of	0
TNF-alpha	9
prevented	0
all	0
inhibition	0
.	0

These	0
results	0
indicate	0
that	0
the	0
regulation	0
of	0
NF-kappa	9
B	10
activation	0
during	0
T	0
cell	0
activation	0
by	0
TcR/CD3	9
signals	0
is	0
biphasic	0
:	0
TcR/CD3	9
triggers	0
its	0
immediate	0
translocation	0
,	0
which	0
is	0
transient	0
if	0
no	0
TNF-alpha	9
is	0
present	0
.	0

TNF-alpha	9
,	0
therefore	0
,	0
emerges	0
as	0
the	0
main	0
factor	0
responsible	0
for	0
a	0
second	0
phase	0
of	0
NF-kappa	9
B	10
regulation	0
,	0
controlling	0
both	0
translocation	0
of	0
p65	9
and	0
c-rel	9
,	0
and	0
new	0
mRNA	3
synthesis	0
for	0
c-rel	9
and	0
p105/p50	9
.	0

The	0
transcription	9
factor	10
Sp1	10
is	0
required	0
for	0
induction	0
of	0
the	0
murine	1
GM-CSF	2
promoter	2
in	0
T	7
cells	8
.	0

The	0
cis-acting	1
region	2
,	0
GM-kappa	1
B/GC-box	2
(	0
positions	1
-95	2
and	0
-73	1
)	0
,	0
within	0
the	0
murine	1
GM-CSF	2
gene	2
promoter	2
is	0
required	0
for	0
maximal	0
induction	0
by	0
stimulation	0
with	0
phorbol-12-myristate	0
acetate	0
(	0
PMA	0
)	0
and	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
in	0
T	7
cells	8
.	0

GM-kappa	9
B	10
defines	0
a	0
binding	0
site	0
for	0
NF-kappa	9
B	10
,	0
and	0
GC-box	1
defines	0
a	0
binding	0
site	0
for	0
three	0
(	0
A1	9
,	0
A2	9
,	0
B	9
)	0
constitutive	9
proteins	10
.	0

We	0
report	0
here	0
that	0
three	0
copies	0
of	0
the	0
GC-box	1
can	0
functionally	0
compensate	0
for	0
the	0
GM-kappa	1
B/GC-box	2
region	2
,	0
suggesting	0
that	0
the	0
GC-motif	0
can	0
function	0
independently	0
of	0
the	0
GM-kappa	1
B	2
motif	2
.	0

The	0
major	0
GC-box	1
binding	0
activity	0
A1	9
was	0
purified	0
and	0
identified	0
as	0
the	0
transcription	9
factor	10
Sp1	10
.	0

We	0
show	0
that	0
depletion	0
of	0
Sp1	9
(	0
A1	9
)	0
from	0
nuclear	0
extracts	0
specifically	0
decreases	0
in	0
vitro	0
transcription	0
activity	0
on	0
GM-CSF	9
templates	0
.	0

Since	0
the	0
human	1
GM-CSF	2
promoter	2
has	0
a	0
base	0
difference	0
within	0
the	0
GC-box	1
,	0
we	0
speculate	0
that	0
this	0
may	0
explain	0
why	0
the	0
human	0
promoter	0
is	0
weak	0
and	0
that	0
an	0
upstream	1
enhancer	2
is	0
required	0
for	0
the	0
induction	0
of	0
the	0
human	1
GM-CSF	2
gene	2
.	0

A	0
factor	0
that	0
regulates	0
the	0
class	1
II	2
major	2
histocompatibility	2
complex	2
gene	2
DPA	1
is	0
a	0
member	0
of	0
a	0
subfamily	0
of	0
zinc	9
finger	10
proteins	10
that	0
includes	0
a	0
Drosophila	9
developmental	10
control	10
protein	10
.	0

A	0
novel	0
DNA	1
sequence	2
element	2
termed	0
the	0
J	1
element	2
involved	0
in	0
the	0
regulated	0
expression	0
of	0
class	1
II	2
major	2
histocompatibility	2
complex	2
genes	2
was	0
recently	0
described	0
.	0

To	0
study	0
this	0
element	0
and	0
its	0
role	0
in	0
class	1
II	2
gene	2
regulation	0
further	0
,	0
a	0
cDNA	1
library	2
was	0
screened	0
with	0
oligonucleotide	0
probes	0
containing	0
both	0
the	0
S	1
element	2
and	0
the	0
nearby	0
J	1
element	2
of	0
the	0
human	1
DPA	2
gene	2
.	0

Several	0
DNA	1
clones	2
were	0
obtained	0
by	0
this	0
procedure	0
,	0
one	0
of	0
which	0
,	0
clone	1
18	2
,	0
is	0
reported	0
and	0
characterized	0
here	0
.	0

It	0
encodes	0
a	0
protein	0
predicted	0
to	0
contain	0
688	0
amino	0
acid	0
residues	0
,	0
including	0
11	0
zinc	9
finger	10
motifs	10
of	0
the	0
C2H2	9
type	10
in	0
the	0
C-terminal	9
region	10
,	0
that	0
are	0
Kruppel-like	0
in	0
the	0
conservation	0
of	0
the	0
H/C	9
link	10
sequence	10
connecting	0
them	0
.	0

The	0
160	9
N-terminal	10
amino	10
acids	10
in	0
the	0
nonfinger	9
region	10
of	0
clone	9
18	10
are	0
highly	0
homologous	0
with	0
similar	0
regions	0
of	0
several	0
other	0
human	1
,	2
mouse	2
,	2
and	2
Drosophila	2
sequences	2
,	0
defining	0
a	0
subfamily	0
of	0
Kruppel-like	0
zinc	9
finger	10
proteins	10
termed	0
TAB	9
(	0
tramtrack	9
[	10
ttk	10
]	10
-associated	10
box	10
)	0
here	0
.	0

One	0
of	0
the	0
Drosophila	1
sequences	2
,	0
ttk	1
,	0
is	0
a	0
developmental	1
control	2
gene	2
,	0
while	0
a	0
second	0
does	0
not	0
contain	0
a	0
zinc	9
finger	10
region	10
but	0
encodes	0
a	0
structure	0
important	0
in	0
oocyte	0
development	0
.	0

An	0
acidic	9
activation	10
domain	10
is	0
located	0
between	0
the	0
N-terminal	9
conserved	10
region	10
of	0
clone	9
18	10
and	0
its	0
zinc	9
fingers	10
.	0

This	0
protein	0
appears	0
to	0
require	0
both	0
the	0
S	1
and	2
J	2
elements	2
,	0
which	0
are	0
separated	0
by	0
10	0
bp	0
for	0
optimal	0
binding	0
.	0

Antisense	0
cDNA	0
to	0
clone	9
18	10
inhibited	0
the	0
expression	0
of	0
a	0
reporter	0
construct	0
containing	0
the	0
DPA	1
promoter	2
,	0
indicating	0
its	0
functional	0
importance	0
in	0
the	0
expression	0
of	0
this	0
class	1
II	2
gene	2
.	0

Separation	0
of	0
oxidant-initiated	0
and	0
redox-regulated	0
steps	0
in	0
the	0
NF-kappa	9
B	10
signal	0
transduction	0
pathway	0
.	0

Studies	0
presented	0
here	0
show	0
that	0
overall	0
NF-kappa	9
B	10
signal	0
transduction	0
begins	0
with	0
a	0
parallel	0
series	0
of	0
stimuli-specific	0
pathways	0
through	0
which	0
cytokines	9
(	0
tumor	9
necrosis	10
factor	10
alpha	10
)	0
,	0
oxidants	0
(	0
hydrogen	0
peroxide	0
and	0
mitomycin	0
C	0
)	0
,	0
and	0
phorbol	0
ester	0
(	0
phorbol	0
12-myristate	0
13-acetate	0
)	0
individually	0
initiate	0
signaling	0
.	0

These	0
initial	0
pathways	0
culminate	0
in	0
a	0
common	0
pathway	0
through	0
which	0
all	0
of	0
the	0
stimulating	0
agents	0
ultimately	0
signal	0
NF-kappa	9
B	10
activation	0
.	0

We	0
distinguish	0
the	0
stimuli-specific	0
pathways	0
by	0
showing	0
that	0
the	0
oxidative	0
stimuli	0
trigger	0
NF-kappa	9
B	10
activation	0
in	0
only	0
one	0
of	0
two	0
human	5
T-cell	6
lines	6
(	0
Wurzburg	5
but	0
not	0
Jurkat	5
)	0
,	0
whereas	0
tumor	9
necrosis	10
factor	10
alpha	10
and	0
phorbol	0
12-myristate	0
13-acetate	0
readily	0
stimulate	0
in	0
both	0
lines	0
.	0

We	0
propose	0
the	0
common	0
pathway	0
as	0
the	0
simplest	0
way	0
of	0
accounting	0
for	0
the	0
common	0
requirements	0
and	0
properties	0
of	0
the	0
signaling	0
pathway	0
.	0

We	0
include	0
a	0
redox-regulatory	0
mechanism	0
(	0
s	0
)	0
in	0
this	0
common	0
pathway	0
to	0
account	0
for	0
the	0
previously	0
demonstrated	0
redox	0
regulation	0
of	0
NF-kappa	9
B	10
activation	0
in	0
Jurkat	5
cells	6
(	0
in	0
which	0
oxidants	0
do	0
n't	0
activate	0
NF-kappa	9
B	10
)	0
;	0
we	0
put	0
tyrosine	0
phosphorylation	0
in	0
the	0
common	0
pathway	0
by	0
showing	0
that	0
kinase	0
activity	0
(	0
inhibitable	0
by	0
herbimycin	0
A	0
and	0
tyrphostin	0
47	0
)	0
is	0
required	0
for	0
NF-kappa	9
B	10
activation	0
by	0
all	0
stimuli	0
tested	0
in	0
both	0
cell	0
lines	0
.	0

Since	0
internal	0
sites	0
of	0
oxidant	0
production	0
have	0
been	0
shown	0
to	0
play	0
a	0
key	0
role	0
in	0
the	0
cytokine	9
-stimulated	0
activation	0
of	0
NF-kappa	9
B	10
,	0
and	0
since	0
tyrosine	0
kinase	0
and	0
phosphatase	0
activities	0
are	0
known	0
to	0
be	0
altered	0
by	0
oxidants	0
,	0
these	0
findings	0
suggest	0
that	0
intracellular	0
redox	0
status	0
controls	0
NF-kappa	9
B	10
activation	0
by	0
regulating	0
tyrosine	0
phosphorylation	0
event	0
(	0
s	0
)	0
within	0
the	0
common	0
step	0
of	0
the	0
NF-kappa	9
B	10
signal	0
transduction	0
pathway	0
.	0

Deleted	0
chromosome	1
20	2
from	0
a	0
patient	0
with	0
Alagille	0
syndrome	0
isolated	0
in	0
a	0
cell	0
hybrid	0
through	0
leucine	0
transport	0
selection	0
:	0
study	0
of	0
three	0
candidate	0
genes	0
.	0

Alagille	0
syndrome	0
(	0
AGS	0
)	0
is	0
a	0
well-defined	0
genetic	0
entity	0
assigned	0
to	0
the	0
short	1
arm	2
of	0
Chromosome	1
(	2
Chr	2
)	2
20	2
by	0
a	0
series	0
of	0
observations	0
of	0
AGS	0
patients	0
associated	0
with	0
microdeletions	0
in	0
this	0
region	0
.	0

By	0
fusing	0
lymphoblastoid	7
cells	8
of	0
an	0
AGS	0
patient	0
that	0
exhibited	0
a	0
microdeletion	0
in	0
the	0
short	1
arm	2
of	2
Chr	2
20	2
encompassing	0
bands	0
p11.23	1
to	2
p12.3	2
with	0
rodent	5
thermosensitive	6
mutant	6
cells	6
(	0
CHOtsH1-1	5
)	0
deficient	0
in-leucyl-tRNA	9
synthetase	10
,	0
we	0
isolated	0
a	0
somatic	5
cell	6
hybrid	6
segregating	0
the	0
deleted	0
human	0
Chr	1
20	2
.	0

This	0
hybrid	0
clone	0
,	0
designated	0
NR2	5
,	0
was	0
characterized	0
by	0
several	0
methods	0
,	0
including	0
PCR	0
,	0
with	0
eight	0
pairs	0
of	0
oligonucleotides	0
mapped	0
to	0
Chr	1
20	2
:	0
D20S5	1
,	0
D20S41	1
,	0
D20S42	1
,	0
D20S56	1
,	0
D20S57	1
,	0
D20S58	1
,	0
adenosine	1
deaminase	2
(	0
ADA	9
)	0
,	0
and	0
Prion	1
protein	2
(	0
PRIP	9
)	0
;	0
Restriction	0
Fragment	0
Length	0
Polymorphism	0
(	0
RFLP	1
)	0
analyses	0
with	0
four	0
genomic	1
anonymous	2
probes	2
(	0
D20S5	1
,	0
cD3H12	1
,	0
D20S17	1
,	0
D20S18	1
)	0
;	0
and	0
fluorescent	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
with	0
total	1
human	2
DNA	2
and	0
D20Z1	1
,	0
a	0
sequence	0
specific	0
to	0
the	0
human	1
Chr	2
20	2
centromere	2
,	0
as	0
probes	0
.	0

The	0
NR2	5
hybrid	6
allowed	0
us	0
to	0
exclude	0
three	0
candidate	1
genes	2
for	0
AGS	0
:	0
hepatic	1
nuclear	2
factor	2
3	2
beta	2
(	0
HNF3	1
beta	2
)	0
,	0
paired	1
box	2
1	2
(	0
PAX1	1
)	0
,	0
and	0
cystatin	1
C	2
(	0
CST3	1
)	0
as	0
shown	0
by	0
their	0
localization	0
outside	0
of	0
the	0
deletion	0
.	0

The	0
NR2	5
hybrid	6
is	0
a	0
powerful	0
tool	0
for	0
the	0
mapping	0
of	0
new	0
probes	0
of	0
this	0
region	0
,	0
as	0
well	0
as	0
for	0
obtaining	0
new	0
informative	0
probes	0
specific	0
for	0
the	0
deletion	0
by	0
subtractive	0
cloning	0
of	0
the	0
region	0
.	0

Such	0
markers	0
will	0
be	0
useful	0
for	0
linkage	0
analysis	0
and	0
screening	0
of	0
cDNA	1
libraries	2
.	0

Positive	0
and	0
negative	0
regulation	0
of	0
the	0
composite	1
octamer	2
motif	2
of	0
the	0
interleukin	1
2	2
enhancer	2
by	0
AP-1	9
,	0
Oct-2	9
,	0
and	0
retinoic	9
acid	10
receptor	10
.	0

The	0
differentiating	0
agent	0
retinoic	0
acid	0
(	0
RA	0
)	0
has	0
been	0
previously	0
reported	0
to	0
interfere	0
with	0
12-O-tetradecanoyl-phorbol-13-acetate	0
(	0
TPA	0
)	0
/Ca	0
(	0
2+	0
)	0
-induced	0
signals	0
for	0
the	0
regulation	0
of	0
the	0
-96	1
to	2
-66-bp	2
octamer	2
motif	2
found	0
in	0
the	0
enhancer	0
for	0
the	0
interleukin	1
(	2
IL	2
)	2
-2	2
gene	2
,	0
which	0
encodes	0
a	0
major	0
T	9
lymphocyte	10
growth	10
factor	10
.	0

The	0
IL-2	1
octamer	2
motif	2
is	0
a	0
composite	0
cis-element	1
which	0
binds	0
Oct-1	9
and	0
Oct-2	9
as	0
well	0
as	0
a	0
TPA/Ca	9
(	10
2+	10
)	10
-inducible	10
nuclear	10
factor	10
,	0
previously	0
termed	0
octamer-associated	9
protein	10
(	0
OAP40	9
)	0
.	0

We	0
show	0
here	0
that	0
Oct-2	9
,	0
despite	0
the	0
presence	0
of	0
an	0
active	0
transcriptional	0
activation	0
domain	0
,	0
requires	0
TPA/Ca	0
(	0
2+	0
)	0
-induced	0
signals	0
to	0
strongly	0
transactivate	0
the	0
IL-2	1
octamer	2
motif	2
in	0
Jurkat	0
T	0
cells	0
.	0

This	0
Oct-2	9
-dependent	0
transactivation	0
is	0
inhibited	0
by	0
RA	0
.	0

The	0
presence	0
of	0
an	0
intact	9
COOH-terminal	10
domain	10
of	0
Oct-2	9
contributes	0
to	0
both	0
TPA/Ca	0
(	0
2+	0
)	0
-induced	0
transactivation	0
and	0
the	0
RA-mediated	0
repression	0
.	0

We	0
also	0
show	0
that	0
both	0
Fos	9
and	0
Jun	9
components	0
of	0
the	0
AP-1	9
factors	0
participate	0
in	0
the	0
OAP40	9
complex	10
.	0

Furthermore	0
,	0
transfected	0
c-jun	1
,	2
jun-B	2
,	2
jun-D	2
,	2
c-fos	2
,	2
or	2
Fos-B	2
expression	2
vectors	2
partially	0
substitute	0
for	0
TPA	0
and	0
Ca2+	0
and	0
cooperate	0
with	0
Oct-2	9
for	0
the	0
transactivation	0
of	0
the	0
combined	0
OAP/octamer	1
cis-element	2
.	0

Mutations	0
of	0
the	0
genuine	1
octamer-binding	2
site	2
abrogate	0
both	0
the	0
binding	0
of	0
Oct-1	9
and	0
Oct-2	9
and	0
the	0
TPA/Ca	0
(	0
2+	0
)	0
-induced	0
transactivation	0
of	0
the	0
OAP/octamer	1
motif	2
.	0

OAP	9
confers	0
to	0
Oct-2	9
responsivity	0
to	0
both	0
TPA/Ca2+	0
and	0
RA	0
,	0
since	0
specific	0
mutations	0
of	0
the	0
AP-1/OAP-binding	1
site	2
significantly	0
reduce	0
the	0
transactivation	0
by	0
Oct-2	9
in	0
response	0
to	0
TPA	0
and	0
Ca2+	0
and	0
abolish	0
the	0
inhibition	0
by	0
RA	0
.	0

Furthermore	0
,	0
retinoic	9
acid	10
receptor	10
(	0
RAR	9
)	0
alpha	0
is	0
able	0
to	0
inhibit	0
in	0
vitro	0
the	0
formation	0
of	0
the	0
complex	0
between	0
the	0
nuclear	0
AP-1	9
/OAP	9
and	0
its	0
specific	0
binding	0
site	0
,	0
resulting	0
in	0
the	0
interference	0
with	0
Oct-2	9
-dependent	0
cis-regulatory	0
function	0
of	0
this	0
AP-1	9
element	0
.	0

Therefore	0
,	0
we	0
propose	0
that	0
the	0
TPA/calcium-activated	0
AP-1	9
/OAP	9
element	0
is	0
the	0
main	0
target	0
of	0
positive	0
or	0
negative	0
regulatory	0
signals	0
influencing	0
the	0
IL-2	1
octamer	2
motif	2
,	0
through	0
synergism	0
with	0
Oct-2	9
and	0
antagonism	0
by	0
RAR	9
.	0

Missense	0
mutation	0
in	0
exon	1
7	2
of	0
the	0
common	1
gamma	2
chain	2
gene	2
causes	0
a	0
moderate	0
form	0
of	0
X-linked	0
combined	0
immunodeficiency	0
.	0

Clinical	0
and	0
immunologic	0
features	0
of	0
a	0
recently	0
recognized	0
X-linked	0
combined	0
immunodeficiency	0
disease	0
(	0
XCID	0
)	0
suggested	0
that	0
XCID	0
and	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
(	0
XSCID	0
)	0
might	0
arise	0
from	0
different	0
genetic	0
defects	0
.	0

The	0
recent	0
discovery	0
of	0
mutations	0
in	0
the	0
common	1
gamma	2
chain	2
(	2
gamma	2
c	2
)	2
gene	2
,	0
a	0
constituent	0
of	0
several	0
cytokine	9
receptors	10
,	0
in	0
XSCID	0
provided	0
an	0
opportunity	0
to	0
test	0
directly	0
whether	0
a	0
previously	0
unrecognized	0
mutation	0
in	0
this	0
same	0
gene	0
was	0
responsible	0
for	0
XCID	0
.	0

The	0
status	0
of	0
X	1
chromosome	2
inactivation	0
in	0
blood	0
leukocytes	0
from	0
obligate	0
carriers	0
of	0
XCID	0
was	0
determined	0
from	0
the	0
polymorphic	0
,	0
short	0
tandem	0
repeats	0
(	0
CAG	0
)	0
,	0
in	0
the	0
androgen	1
receptor	2
gene	2
,	0
which	0
also	0
contains	0
a	0
methylation-sensitive	1
HpaII	2
site	2
.	0

As	0
in	0
XSCID	0
,	0
X-chromosome	0
inactivation	0
in	0
obligate	0
carriers	0
of	0
XCID	0
was	0
nonrandom	0
in	0
T	7
and	8
B	8
lymphocytes	8
.	0

In	0
addition	0
,	0
X	1
chromosome	2
inactivation	0
in	0
PMNs	0
was	0
variable	0
.	0

Findings	0
from	0
this	0
analysis	0
prompted	0
sequencing	0
of	0
the	0
gamma	1
c	2
gene	2
in	0
this	0
pedigree	0
.	0

A	0
missense	0
mutation	0
in	0
the	0
region	0
coding	0
for	0
the	0
cytoplasmic	0
portion	0
of	0
the	0
gamma	1
c	2
gene	2
was	0
found	0
in	0
three	0
affected	0
males	0
but	0
not	0
in	0
a	0
normal	0
brother	0
.	0

Therefore	0
,	0
this	0
point	0
mutation	0
in	0
the	0
gamma	1
c	2
gene	2
leads	0
to	0
a	0
less	0
severe	0
degree	0
of	0
deficiency	0
in	0
cellular	0
and	0
humoral	0
immunity	0
than	0
that	0
seen	0
in	0
XSCID	0
.	0

Posttranscriptional	0
regulation	0
of	0
macrophage	0
tissue	9
factor	10
expression	0
by	0
antioxidants	0
.	0

Tissue	9
factor	10
(	0
TF	9
)	0
expression	0
by	0
cells	0
of	0
monocyte/macrophage	7
lineage	8
represents	0
an	0
important	0
mechanism	0
underlying	0
the	0
initiation	0
of	0
fibrin	9
deposition	0
at	0
sites	0
of	0
extravascular	0
inflammation	0
.	0

Recent	0
evidence	0
suggests	0
a	0
role	0
for	0
oxidant	0
stress	0
in	0
the	0
signalling	0
pathway	0
of	0
various	0
cell	0
types	0
by	0
virtue	0
of	0
its	0
ability	0
to	0
induce	0
DNA	0
binding	0
of	0
various	0
transcription	9
factors	10
,	0
including	0
nuclear	9
factor	10
kappa	10
B	10
and	0
AP-1	9
.	0

The	0
effect	0
of	0
antioxidant	0
treatment	0
on	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-induced	0
TF	9
expression	0
was	0
examined	0
in	0
murine	7
peritoneal	8
macrophages	8
and	0
human	7
monocytes	8
.	0

Both	0
pyrrolidine	0
dithiocarbamate	0
,	0
an	0
oxidant	0
scavenger	0
,	0
and	0
N-acetyl-cysteine	0
,	0
a	0
precursor	0
of	0
the	0
endogenous	0
antioxidant	0
glutathione	0
,	0
inhibited	0
stimulation	0
of	0
macrophage	0
procoagulant	0
activity	0
by	0
LPS	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
neither	0
of	0
these	0
agents	0
reduced	0
LPS-stimulated	0
TF	9
mRNA	0
accumulation	0
,	0
thereby	0
suggesting	0
a	0
posttranscriptional	0
mechanism	0
for	0
the	0
effect	0
.	0

Immunofluorescence	0
studies	0
of	0
human	7
monocytes	8
using	0
polyclonal	0
anti-TF	9
antibody	10
showed	0
that	0
N-acetyl-cysteine	0
treatment	0
prevented	0
the	0
characteristic	0
plasmalemmal	0
localization	0
of	0
TF	9
antigen	10
that	0
occurs	0
in	0
response	0
to	0
LPS	0
.	0

Western	0
blot	0
analysis	0
showed	0
that	0
N-acetyl-cysteine	0
reduced	0
the	0
accumulation	0
of	0
the	0
47-kD	9
mature	10
glycoprotein	10
in	0
LPS-treated	5
cells	6
,	0
a	0
finding	0
consistent	0
with	0
the	0
results	0
of	0
the	0
immunofluorescence	0
studies	0
.	0

Furthermore	0
,	0
these	0
conditions	0
did	0
not	0
result	0
in	0
an	0
accumulation	0
of	0
the	0
less	0
mature	0
forms	0
of	0
TF	9
.	0

When	0
considered	0
together	0
,	0
these	0
data	0
suggest	0
that	0
antioxidants	0
exert	0
their	0
effects	0
by	0
impairing	0
translation	0
and/or	0
by	0
causing	0
degradation	0
of	0
newly	0
translated	9
protein	10
.	0

The	0
effect	0
of	0
antioxidants	0
on	0
tumor	9
necrosis	10
factor	10
appeared	0
to	0
be	0
species	0
specific	0
,	0
with	0
no	0
effect	0
on	0
LPS-induced	0
tumor	0
necrosis	0
factor	0
in	0
murine	0
cells	0
,	0
but	0
with	0
inhibition	0
in	0
human	7
monocytes	8
.	0

The	0
posttranscriptional	0
effect	0
of	0
antioxidants	0
on	0
TF	9
expression	0
data	0
suggests	0
a	0
novel	0
mechanism	0
whereby	0
these	0
agents	0
might	0
modulate	0
monocyte	7
/macrophage	7
activation	0
.	0

Characterization	0
of	0
the	0
CD48	1
gene	2
demonstrates	0
a	0
positive	0
element	0
that	0
is	0
specific	0
to	0
Epstein-Barr	7
virus-immortalized	8
B-cell	8
lines	8
and	0
contains	0
an	0
essential	0
NF-kappa	1
B	2
site	2
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
infection	0
of	0
mature	0
,	0
resting	7
B	8
cells	8
drives	0
them	0
to	0
become	0
lymphoblasts	0
expressing	0
high	0
levels	0
of	0
cell	0
surface	0
molecules	0
,	0
such	0
as	0
CD48	9
,	0
characteristically	0
expressed	0
on	0
normal	7
activated	8
B	8
cells	8
.	0

Here	0
,	0
we	0
report	0
on	0
the	0
identification	0
of	0
an	0
enhancer	1
element	2
in	0
the	0
CD48	1
gene	2
which	0
reproducibly	0
confers	0
strong	0
transcriptional	0
activity	0
only	0
in	0
EBV-positive	5
B-lymphoblastoid	6
cell	6
lines	6
.	0

The	0
element	0
is	0
not	0
activated	0
upon	0
infection	0
of	0
established	0
EBV-negative	5
B-cell	6
lines	6
,	0
indicating	0
that	0
EBV	0
fails	0
to	0
drive	0
these	0
cells	0
to	0
a	0
fully	0
lymphoblastoid	7
phenotype	8
.	0

An	0
NF-kappa	9
B	10
binding	0
site	0
is	0
an	0
essential	0
component	0
of	0
the	0
element	0
but	0
alone	0
is	0
not	0
sufficient	0
to	0
account	0
for	0
the	0
activity	0
or	0
the	0
specificity	0
of	0
the	0
element	0
.	0

We	0
have	0
detected	0
a	0
specific	0
nuclear	9
protein	10
complex	10
that	0
binds	0
to	0
the	0
element	0
and	0
show	0
that	0
NF-kappa	9
B1	10
(	0
p50	9
)	0
is	0
a	0
part	0
of	0
this	0
complex	0
.	0

The	0
EBV-encoded	9
latent	10
membrane	10
protein	10
1	10
is	0
capable	0
of	0
transactivating	0
the	0
isolated	0
CD48	9
NF-kappa	1
B	2
site	2
but	0
not	0
the	0
intact	1
element	2
,	0
suggesting	0
that	0
the	0
latent	9
membrane	10
protein	10
1	10
-driven	0
activation	0
of	0
NF-kappa	9
B/Rel	10
must	0
interact	0
with	0
other	0
regulatory	0
pathways	0
to	0
control	0
expression	0
of	0
cellular	0
genes	0
as	0
EBV	0
drives	0
resting	7
B	8
cells	8
into	0
the	0
cell	0
cycle	0
.	0

Thapsigargin	0
induces	0
IL-2	9
receptor	10
alpha-chain	10
in	0
human	7
peripheral	8
and	0
Jurkat	5
T	6
cells	6
via	0
a	0
protein	9
kinase	10
C	10
-independent	0
mechanism	0
.	0

Thapsigargin	0
(	0
TG	0
)	0
,	0
an	0
inhibitor	0
of	0
Ca	9
(	10
2+	10
)	10
-ATPase	10
,	0
depletes	0
intracellular	0
Ca2+	0
stores	0
and	0
induces	0
a	0
sustained	0
Ca2+	0
influx	0
without	0
altering	0
phosphatidyl	0
inositol	0
levels	0
.	0

TG	0
plus	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
but	0
not	0
TG	0
alone	0
induced	0
IL-2	9
in	0
Jurkat	5
T	6
cells	6
,	0
suggesting	0
that	0
TG	0
had	0
no	0
effect	0
on	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
.	0

However	0
,	0
TG	0
induced	0
increases	0
in	0
IL-2R	9
alpha	10
protein	10
as	0
well	0
as	0
IL-2R	3
alpha	4
mRNA	4
in	0
Jurkat	5
T	6
cells	6
in	0
a	0
dose-dependent	0
manner	0
.	0

A	0
similar	0
increase	0
in	0
IL-2R	9
alpha	10
by	0
TG	0
was	0
also	0
observed	0
in	0
human	7
peripheral	8
T	8
cells	8
.	0

Further	0
,	0
like	0
PMA	0
,	0
TG	0
markedly	0
induced	0
NF	9
kappa	10
B	10
in	0
Jurkat	5
T	6
cells	6
.	0

However	0
,	0
TG	0
and	0
PMA	0
exhibited	0
a	0
synergistic	0
action	0
on	0
IL-2R	9
alpha	10
expression	0
,	0
suggesting	0
that	0
TG	0
and	0
PMA	0
induce	0
IL-2R	9
alpha	10
through	0
distinct	0
pathways	0
.	0

PMA	9
-but	10
not	10
TG-induced	10
IL-2R	10
alpha	10
is	0
inhibited	0
by	0
the	0
PKC	9
inhibitor	0
H7	0
,	0
whereas	0
TG	9
-but	10
not	10
PMA-induced	10
IL-2R	10
alpha	10
was	0
inhibited	0
by	0
cholera	0
toxin	0
,	0
forskolin	0
and	0
1	0
,	0
9-dideoxy	0
forskolin	0
.	0

In	0
toto	0
,	0
these	0
results	0
suggest	0
that	0
TG	0
induces	0
IL-2R	9
alpha	10
in	0
human	7
T	8
cells	8
through	0
a	0
PKC	9
-independent	0
pathway	0
.	0

Physiological	0
concentration	0
of	0
estradiol	0
inhibits	0
polymorphonuclear	7
leukocyte	8
chemotaxis	0
via	0
a	0
receptor	0
mediated	0
system	0
.	0

Estrogen	0
exhibits	0
a	0
variety	0
of	0
actions	0
,	0
including	0
immuno-modulatory	0
effects	0
,	0
in	0
vivo	0
and	0
in	0
vitro	0
.	0

The	0
mechanism	0
by	0
which	0
estrogen	0
exerts	0
its	0
anti-inflammatory	0
effect	0
is	0
not	0
yet	0
understood	0
.	0

We	0
investigated	0
the	0
possible	0
mechanisms	0
of	0
estradiol	0
acting	0
via	0
the	0
polymorphonuclear	7
leukocytes	8
(	0
PMNs	7
)	0
,	0
which	0
are	0
important	0
in	0
the	0
immune	0
response	0
.	0

The	0
agent	0
,	0
17	0
beta-estradiol	0
,	0
but	0
not	0
17	0
alpha-estradiol	0
,	0
significantly	0
reduced	0
PMNs	7
chemotaxis	0
to	0
FMLP	0
in	0
a	0
dose-dependent	0
manner	0
(	0
control	0
vs	0
estrogen	0
10	0
(	0
-10	0
)	0
-	0
(	0
-6	0
)	0
M	0
,	0
P	0
<	0
0.05	0
)	0
.	0

Physiological	0
concentrations	0
of	0
estradiol	0
significantly	0
reduced	0
the	0
chemotaxis	0
of	0
PMNs	7
(	0
10	0
(	0
-10	0
)	0
mol	0
)	0
.	0

Pre-incubation	0
with	0
clomiphene	0
or	0
tamoxifen	0
which	0
are	0
estrogen	0
receptor	0
antagonists	0
,	0
eliminated	0
the	0
inhibitory	0
effect	0
of	0
17	0
beta-estradiol	0
on	0
the	0
chemotaxis	0
of	0
PMNs	7
,	0
restoring	0
it	0
to	0
the	0
control	0
level	0
.	0

These	0
observations	0
suggest	0
that	0
17	0
beta-estradiol	0
suppressed	0
the	0
chemotaxis	0
of	0
PMNs	7
by	0
a	0
receptor-dependent	0
mechanism	0
.	0

In	0
addition	0
,	0
the	0
level	0
of	0
estradiol	0
in	0
human	7
plasma	8
,	0
which	0
PMNs	7
were	0
drawn	0
,	0
showed	0
a	0
close	0
,	0
inverse	0
correlation	0
with	0
the	0
PMNs	7
chemotaxis	0
to	0
FMLP	0
(	0
r	0
=	0
-0.821	0
p	0
<	0
0.001	0
)	0
.	0

Estrogen	0
may	0
modify	0
the	0
activity	0
of	0
neutrophils	7
during	0
the	0
normal	0
menstrual	0
cycle	0
,	0
not	0
only	0
during	0
pregnancy	0
,	0
and	0
influence	0
inflammation	0
.	0

Identification	0
of	0
the	0
TCL1	1
gene	2
involved	0
in	0
T-cell	7
malignancies	0
.	0

The	0
TCL1	1
locus	2
on	0
chromosome	1
14q32.1	2
is	0
frequently	0
involved	0
in	0
chromosomal	0
translocations	0
and	0
inversions	0
with	0
one	0
of	0
the	0
T-cell	1
receptor	2
loci	2
in	0
human	0
T-cell	0
leukemias	0
and	0
lymphomas	0
.	0

The	0
chromosome	1
14	2
region	2
translocated	0
or	0
rearranged	0
involves	0
approximately	0
350	0
kb	0
of	0
DNA	0
at	0
chromosome	0
band	0
14q32.1	0
.	0

Within	0
this	0
region	0
we	0
have	0
identified	0
a	0
gene	0
coding	0
for	0
a	0
1.3-kb	3
transcript	4
,	0
expressed	0
only	0
in	0
restricted	0
subsets	0
of	0
cells	0
within	0
the	0
lymphoid	7
lineage	8
and	0
expressed	0
at	0
high	0
levels	0
in	0
leukemic	7
cells	8
carrying	0
a	0
t	0
(	0
14	0
;	0
14	0
)	0
(	0
q11	0
;	0
q32	0
)	0
chromosome	0
translocation	0
or	0
a	0
inv	0
(	0
14	0
)	0
(	0
q11	0
;	0
q32	0
)	0
chromosome	0
inversion	0
.	0

The	0
cognate	1
cDNA	2
sequence	2
reveals	0
an	0
open	1
reading	2
frame	2
of	0
342	0
nt	0
encoding	0
a	0
protein	9
of	10
14	10
kDa	10
.	0

The	0
TCL1	1
gene	2
sequence	0
,	0
which	0
,	0
to	0
our	0
knowledge	0
,	0
shows	0
no	0
sequence	0
homology	0
with	0
other	0
human	1
genes	2
,	0
is	0
preferentially	0
expressed	0
early	0
in	0
T-	7
and	8
B-lymphocyte	8
differentiation	0
.	0

Identification	0
of	0
a	0
region	0
which	0
directs	0
the	0
monocytic	0
activity	0
of	0
the	0
colony-stimulating	1
factor	2
1	2
(	2
macrophage	2
colony-stimulating	2
factor	2
)	2
receptor	2
promoter	2
and	0
binds	0
PEBP2/CBF	9
(	0
AML1	9
)	0
.	0

The	0
receptor	0
for	0
the	0
macrophage	9
colony-stimulating	10
factor	10
(	0
or	0
colony-stimulating	9
factor	10
1	10
[	0
CSF-1	9
]	0
)	0
is	0
expressed	0
from	0
different	0
promoters	0
in	0
monocytic	7
cells	8
and	0
placental	7
trophoblasts	8
.	0

We	0
have	0
demonstrated	0
that	0
the	0
monocyte-specific	0
expression	0
of	0
the	0
CSF-1	9
receptor	10
is	0
regulated	0
at	0
the	0
level	0
of	0
transcription	0
by	0
a	0
tissue-specific	1
promoter	2
whose	0
activity	0
is	0
stimulated	0
by	0
the	0
monocyte/B-cell-specific	9
transcription	10
factor	10
PU.1	9
(	0
D.-E.Zhang	0
,	0
C.J.Hetherington	0
,	0
H.-M.Chen	0
,	0
and	0
D.G.Tenen	0
,	0
Mol.Cell.	0
Biol.14	0
:	0
373-381	0
,	0
1994	0
)	0
.	0

Here	0
we	0
report	0
that	0
the	0
tissue	0
specificity	0
of	0
this	0
promoter	1
is	0
also	0
mediated	0
by	0
sequences	0
in	0
a	0
region	1
II	2
(	0
bp	0
-88	0
to	0
-	0
59	0
)	0
,	0
which	0
lies	0
10	1
bp	2
upstream	2
from	0
the	0
PU.1-binding	1
site	2
.	0

When	0
analyzed	0
by	0
DNase	9
footprinting	0
,	0
region	1
II	2
was	0
protected	0
preferentially	0
in	0
monocytic	7
cells	8
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
confirmed	0
that	0
region	1
II	2
interacts	0
specifically	0
with	0
nuclear	9
proteins	10
from	0
monocytic	7
cells	8
.	0

Two	0
gel	9
shift	10
complexes	10
(	0
Mono	9
A	10
and	0
Mono	9
B	10
)	0
were	0
formed	0
with	0
separate	0
sequence	0
elements	0
within	0
this	0
region	0
.	0

Competition	0
and	0
supershift	0
experiments	0
indicate	0
that	0
Mono	9
B	10
contains	0
a	0
member	0
of	0
the	0
polyomavirus	9
enhancer-binding	10
protein	10
2/core-binding	10
factor	10
(	10
PEBP2/CBF	10
)	10
family	10
,	10
which	0
includes	0
the	0
AML1	0
gene	0
product	0
,	0
while	0
Mono	9
A	10
is	0
a	0
distinct	0
complex	0
preferentially	0
expressed	0
in	0
monocytic	7
cells	8
.	0

Promoter	1
constructs	2
with	0
mutations	0
in	0
these	0
sequence	0
elements	0
were	0
no	0
longer	0
expressed	0
specifically	0
in	0
monocytes	7
.	0

Furthermore	0
,	0
multimerized	1
region	2
II	2
sequence	2
elements	2
enhanced	0
the	0
activity	0
of	0
a	0
heterologous	0
thymidine	0
kinase	0
promoter	0
in	0
monocytic	7
cells	8
but	0
not	0
other	0
cell	0
types	0
tested	0
.	0

These	0
results	0
indicate	0
that	0
the	0
monocyte/B-cell-specific	9
transcription	10
factor	10
PU.1	9
and	0
the	0
Mono	9
A	10
and	10
Mono	10
B	10
protein	10
complexes	10
act	0
in	0
concert	0
to	0
regulate	0
monocyte-specific	0
transcription	0
of	0
the	0
CSF-1	9
receptor	10
.	0

Pyrrolidine	0
dithiocarbamate	0
,	0
a	0
potent	0
inhibitor	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
,	0
prevents	0
apoptosis	0
in	0
human	0
promyelocytic	5
leukemia	6
HL-60	6
cells	6
and	0
thymocytes	7
.	0

We	0
examined	0
the	0
effect	0
of	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
,	0
which	0
potently	0
blocks	0
the	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
on	0
the	0
induction	0
of	0
apoptosis	0
by	0
a	0
variety	0
of	0
agents	0
.	0

Treatment	0
of	0
a	0
human	5
promyelocytic	6
leukemia	6
cell	6
line	6
,	0
HL-60	5
,	0
with	0
10	0
micrograms/mL	0
etoposide	0
or	0
2	0
microM	0
1-beta-D-arabinofuranosylcytosine	0
induced	0
NF-kappa	9
B	10
activation	0
within	0
1	0
hr	0
and	0
subsequently	0
caused	0
apoptosis	0
within	0
3-4	0
hr	0
.	0

The	0
simultaneous	0
addition	0
of	0
50-500	0
microM	0
PDTC	0
with	0
these	0
agents	0
blocked	0
NF-kappa	9
B	10
activation	0
and	0
completely	0
abrogated	0
both	0
morphologically	0
apoptotic	0
changes	0
and	0
internucleosomal	0
DNA	0
fragmentation	0
for	0
up	0
to	0
6	0
hr	0
.	0

However	0
,	0
PDTC	0
failed	0
to	0
inhibit	0
the	0
endonuclease	9
activity	0
contained	0
in	0
the	0
whole	0
cell	0
lysates	0
.	0

The	0
inhibitory	0
effect	0
of	0
PDTC	0
was	0
also	0
observed	0
in	0
etoposide	0
-and	0
dexamethasone-induced	0
apoptosis	0
in	0
human	7
thymocytes	8
at	0
a	0
concentration	0
of	0
1-10	0
microM	0
.	0

Since	0
PDTC	0
has	0
both	0
antioxidant	0
and	0
metal-ion	0
chelating	0
activities	0
,	0
we	0
tested	0
the	0
effects	0
of	0
N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
(	0
antioxidant	0
)	0
or	0
o-phenanthroline	0
(	0
OP	0
)	0
(	0
metal-ion	0
chelator	0
)	0
on	0
the	0
induction	0
of	0
apoptosis	0
.	0

Pretreatment	0
of	0
HL-60	0
cells	0
or	0
thymocytes	7
with	0
100-500	0
microM	0
OP	0
for	0
2	0
hr	0
,	0
but	0
not	0
10-60	0
mM	0
NAC	0
,	0
suppressed	0
subsequent	0
occurrence	0
of	0
apoptosis	0
induced	0
by	0
etoposide	0
.	0

These	0
results	0
suggest	0
that	0
the	0
activation	0
of	0
NF-kappa	9
B	10
plays	0
an	0
important	0
role	0
in	0
the	0
apoptotic	0
process	0
of	0
human	7
hematopoietic	8
cells	8
.	0

Overexpression	0
of	0
protein	9
kinase	10
C-zeta	10
stimulates	0
leukemic	7
cell	8
differentiation	0
.	0

A	0
function	0
for	0
protein	9
kinase	10
C-zeta	10
(	0
PKC-zeta	9
)	0
,	0
a	0
member	0
of	0
the	0
phorbol	0
ester	0
nonresponsive	0
atypical	0
protein	9
kinase	10
C	10
subfamily	10
,	0
in	0
modulating	0
differentiation	0
was	0
examined	0
in	0
the	0
leukemic	5
U937	6
cell	6
.	0

Transfected	0
U937	5
cells	6
stably	0
overexpressing	0
PKC-zeta	9
displayed	0
a	0
longer	0
doubling	0
time	0
,	0
lower	0
saturation	0
density	0
at	0
confluency	0
,	0
and	0
an	0
increase	0
in	0
adherence	0
to	0
plastic	0
as	0
compared	0
to	0
control	5
cells	6
.	0

PKC-zeta	5
cells	6
expressed	0
a	0
more	0
differentiated	0
phenotype	0
as	0
assessed	0
by	0
changes	0
in	0
morphology	0
,	0
surface	0
antigen	0
expression	0
,	0
and	0
lysosomal	9
enzyme	10
activities	0
and	0
were	0
distinct	0
from	0
parental	5
U937	6
cells	6
stimulated	0
to	0
differentiate	0
by	0
exposure	0
to	0
phorbol	0
esters	0
.	0

In	0
contrast	0
to	0
parental	0
U937	5
cells	6
,	0
PKC-zeta	5
cells	6
constitutively	0
expressed	0
mRNA	3
transcripts	4
for	0
c-jun	1
and	0
a	0
low	0
mobility	0
AP-1	9
binding	0
activity	0
.	0

Thus	0
,	0
PKC-zeta	9
overexpression	0
stimulates	0
a	0
type	0
of	0
phenotypic	0
differentiation	0
that	0
differs	0
significantly	0
from	0
maturation	0
occurring	0
upon	0
activation	0
of	0
other	0
PKC	9
subfamilies	10
induced	0
by	0
phorbol	0
ester	0
treatment	0
.	0

Increased	0
expression	0
of	0
the	0
c-jun	1
protooncogene	0
and	0
an	0
increase	0
in	0
AP-1	9
binding	0
activity	0
in	0
PKC-zeta	5
cells	6
provides	0
a	0
potential	0
mechanism	0
for	0
explaining	0
the	0
altered	0
differentiation	0
status	0
of	0
this	0
cell	0
.	0

A	0
family	0
of	0
serine	9
proteases	10
expressed	0
exclusively	0
in	0
myelo-	0
monocytic	7
cells	8
specifically	0
processes	0
the	0
nuclear	9
factor-kappa	10
B	10
subunit	10
p65	10
in	0
vitro	0
and	0
may	0
impair	0
human	0
immunodeficiency	0
virus	0
replication	0
in	0
these	0
cells	0
.	0

Two	0
groups	0
of	0
U937	5
promonocytic	6
cells	6
were	0
obtained	0
by	0
limiting	0
dilution	0
cloning	0
which	0
differed	0
strikingly	0
in	0
their	0
ability	0
to	0
support	0
human	0
immunodeficiency	0
virus	0
1	0
(	0
HIV-1	0
)	0
replication	0
.	0

``	5
Plus	6
''	6
clones	6
replicated	0
the	0
virus	0
efficiently	0
,	0
whereas	0
``	5
minus	6
''	6
clones	6
did	0
not	0
.	0

We	0
examined	0
these	0
clones	0
for	0
differences	0
in	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
activity	0
which	0
might	0
account	0
for	0
the	0
observed	0
phenomenon	0
.	0

Stimulation	0
of	0
plus	5
clones	6
liberated	0
the	0
classical	0
p50-p65	9
complex	10
from	0
cytoplasmic	0
pools	0
,	0
whereas	0
minus	5
clones	6
produced	0
an	0
apparently	0
novel	0
,	0
faster-migrating	9
complex	10
,	0
as	0
judged	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

It	0
is	0
surprising	0
that	0
the	0
faster-migrating	9
complex	10
was	0
composed	0
also	0
of	0
p50	9
and	0
p65	9
.	0

However	0
,	0
the	0
p65	9
subunit	10
was	0
COOH-terminally	0
truncated	0
,	0
as	0
shown	0
by	0
immunoprecipitation	0
.	0

The	0
truncation	0
resulted	0
from	0
limited	0
proteolysis	0
of	0
p65	9
during	0
cellular	0
extraction	0
which	0
released	0
particular	0
lysosomal	9
serine	10
proteases	10
,	0
such	0
as	0
elastase	9
,	0
cathepsin	9
G	10
,	0
and	0
proteinase	9
3	10
.	0

These	0
specific	0
proteases	0
are	0
coordinately	0
expressed	0
and	0
were	0
present	0
exclusively	0
in	0
the	0
minus	5
U937	6
clones	6
,	0
but	0
not	0
in	0
the	0
plus	5
clones	6
,	0
as	0
demonstrated	0
in	0
the	0
case	0
of	0
cathepsin	9
G	10
.	0

In	0
addition	0
,	0
these	0
proteases	0
were	0
detected	0
in	0
certain	0
subclones	0
of	0
THP-1	5
and	0
HL-60	5
cells	6
and	0
in	0
primary	0
monocytes	7
,	0
in	0
each	0
case	0
correlating	0
with	0
the	0
truncated	0
from	0
of	0
p65	9
.	0

We	0
demonstrate	0
in	0
vitro	0
cleavage	0
of	0
p65	9
by	0
purified	0
elastase	9
and	0
cathepsin	9
G	10
.	0

It	0
is	0
possible	0
that	0
particular	0
serine	9
proteases	10
may	0
have	0
inhibiting	0
effects	0
on	0
the	0
replication	0
of	0
HIV-1	0
in	0
myelo-monocytic	5
cells	6
.	0

The	0
data	0
also	0
demonstrate	0
that	0
special	0
precautions	0
must	0
be	0
taken	0
when	0
making	0
extracts	0
from	0
myelo-monocytic	5
cells	6
.	0

A	0
germline	1
TaqI	2
restriction	2
fragment	2
length	2
polymorphism	2
in	0
the	0
progesterone	1
receptor	2
gene	2
in	0
ovarian	0
carcinoma	0
[	0
see	0
comments	0
]	0

Clinical	0
outcome	0
in	0
ovarian	0
carcinoma	0
is	0
predicted	0
by	0
progesterone	9
receptor	10
status	0
,	0
indicating	0
an	0
endocrine	0
aspect	0
to	0
this	0
disease	0
.	0

Peripheral	1
leucocyte	2
genomic	2
DNAs	2
were	0
obtained	0
from	0
41	0
patients	0
with	0
primary	0
ovarian	0
carcinoma	0
and	0
83	0
controls	0
from	0
Ireland	0
,	0
as	0
well	0
as	0
from	0
26	0
primary	0
ovarian	0
carcinoma	0
patients	0
and	0
101	0
controls	0
in	0
Germany	0
.	0

Southern	0
analysis	0
using	0
a	0
human	1
progesterone	2
receptor	2
(	2
hPR	2
)	2
cDNA	2
probe	2
identified	0
a	0
germline	1
TaqI	2
restriction	2
fragment	2
length	2
polymorphism	2
(	0
RFLP	1
)	0
defined	0
by	0
two	0
alleles	0
:	0
T1	1
,	0
represented	0
by	0
a	0
2.7	1
kb	2
fragment	2
;	0
and	0
T2	1
,	0
represented	0
by	0
a	0
1.9	1
kb	2
fragment	2
and	0
characterised	0
by	0
an	0
additional	0
TaqI	1
restriction	2
site	2
with	0
respect	0
to	0
T1	1
.	0

An	0
over-representation	0
of	0
T2	1
in	0
ovarian	0
cancer	0
patients	0
compared	0
with	0
controls	0
in	0
the	0
pooled	0
Irish/German	0
population	0
(	0
P	0
<	0
0.025	0
)	0
was	0
observed	0
.	0

A	0
difference	0
(	0
P	0
<	0
0.02	0
)	0
in	0
the	0
distribution	0
of	0
the	0
RFLP	1
genotypes	0
between	0
Irish	0
and	0
German	0
control	0
populations	0
was	0
also	0
observed	0
.	0

The	0
allele	0
distributions	0
could	0
not	0
be	0
shown	0
to	0
differ	0
significantly	0
from	0
Hardy-Weinberg	0
distribution	0
in	0
any	0
subgroup	0
.	0

Using	0
hPR	1
cDNA	2
region-specific	2
probes	2
,	0
the	0
extra	0
TaqI	0
restriction	0
site	0
was	0
mapped	0
to	0
intron	1
G	2
of	0
the	0
hPR	1
gene	2
.	0

OBF-1	9
,	0
a	0
novel	9
B	10
cell-specific	10
coactivator	10
that	0
stimulates	0
immunoglobulin	1
promoter	2
activity	0
through	0
association	0
with	0
octamer-binding	9
proteins	10
.	0

Recent	0
biochemical	0
and	0
genetic	0
studies	0
indicate	0
that	0
in	0
addition	0
to	0
the	0
octamer-binding	9
proteins	10
Oct-1	9
and	0
Oct-2	9
,	0
other	0
B	9
cell	10
components	10
are	0
required	0
for	0
lymphoid-restricted	0
,	0
octamer	0
site-mediated	0
immunoglobulin	1
gene	2
promoter	2
activity	0
.	0

Using	0
a	0
genetic	0
screen	0
in	0
yeast	0
,	0
we	0
have	0
isolated	0
B	1
cell-derived	2
cDNAs	2
encoding	0
Oct-binding	9
factor	10
1	10
(	0
OBF-1	9
)	0
,	0
a	0
novel	0
protein	0
that	0
specifically	0
associates	0
with	0
Oct-1	9
and	0
Oct-2	9
.	0

Biochemical	0
studies	0
demonstrate	0
that	0
OBF-1	9
has	0
no	0
intrinsic	0
DNA-binding	0
activity	0
and	0
recognizes	0
the	0
POU	9
domains	10
of	0
Oct-1	9
and	0
Oct-2	9
,	0
but	0
not	0
those	0
of	0
Oct-4	9
and	0
Oct-6	9
.	0

The	0
OBF-1	3
mRNA	4
is	0
expressed	0
in	0
a	0
highly	0
cell-specific	0
manner	0
,	0
being	0
most	0
abundant	0
in	0
B	7
cells	8
and	0
essentially	0
absent	0
in	0
most	0
of	0
the	0
other	0
cells	0
or	0
tissues	0
tested	0
.	0

Furthermore	0
,	0
expression	0
of	0
OBF-1	9
in	0
HeLa	5
cells	6
selectively	0
stimulates	0
the	0
activity	0
of	0
a	0
natural	0
immunoglobulin	1
promoter	2
in	0
an	0
octamer	1
site	2
-dependent	0
manner	0
.	0

Thus	0
,	0
OBF-1	9
has	0
all	0
the	0
properties	0
expected	0
for	0
a	0
B	9
cell-specific	10
transcriptional	10
coactivator	10
protein	10
.	0

Modulation	0
of	0
transcription	9
factor	10
NF	10
kappa	10
B	10
activity	0
by	0
intracellular	0
glutathione	0
levels	0
and	0
by	0
variations	0
of	0
the	0
extracellular	0
cysteine	0
supply	0
.	0

HIV-infected	0
individuals	0
and	0
SIV-infected	0
rhesus	0
macaques	0
have	0
,	0
on	0
the	0
average	0
,	0
decreased	0
plasma	0
cysteine	0
and	0
cystine	0
concentrations	0
and	0
decreased	0
intracellular	0
glutathione	0
levels	0
.	0

We	0
now	0
show	0
that	0
a	0
depletion	0
of	0
intracellular	0
glutathione	0
in	0
a	0
human	5
T	6
cell	6
line	6
(	0
Molt-4	5
)	0
inhibits	0
the	0
activation	0
and	0
nuclear	0
translocation	0
of	0
the	0
transcription	9
factor	10
NF	10
kappa	10
B	10
,	0
whereas	0
incubation	0
with	0
increasing	0
extracellular	0
concentrations	0
of	0
cysteine	0
inhibits	0
the	0
DNA-binding	0
and	0
transactivating	0
activity	0
of	0
NF	9
kappa	10
B	10
.	0

Because	0
inhibition	0
of	0
DNA-binding	0
activity	0
is	0
associated	0
with	0
increasing	0
intracellular	0
glutathione	0
disulfide	0
levels	0
and	0
GSSG	9
can	0
be	0
shown	0
to	0
inhibit	0
the	0
DNA-binding	0
activity	0
directly	0
in	0
cell-free	0
systems	0
,	0
our	0
studies	0
suggest	0
that	0
GSSG	9
is	0
a	0
physiologically	0
relevant	0
inhibitor	0
in	0
intact	7
cells	8
also	0
.	0

NF	9
kappa	10
B	10
controls	0
many	0
immunologically	1
important	2
genes	2
,	0
so	0
our	0
studies	0
suggest	0
that	0
the	0
immune	0
system	0
may	0
be	0
sensitive	0
not	0
only	0
against	0
a	0
cysteine	0
and	0
glutathione	0
deficiency	0
but	0
also	0
against	0
an	0
excess	0
of	0
cysteine	0
.	0

Two	0
distinct	0
signalling	0
pathways	0
are	0
involved	0
in	0
the	0
control	0
of	0
the	0
biphasic	0
junB	1
transcription	0
induced	0
by	0
interleukin-6	9
in	0
the	0
B	5
cell	6
hybridoma	6
7TD1	6
.	0

We	0
have	0
measured	0
the	0
level	0
of	0
junB	3
mRNA	4
in	0
the	0
B	5
hybridoma	6
cell	6
line	6
7TD1	6
,	0
under	0
interleukin-6	9
(	0
IL-6	9
)	0
stimulation	0
.	0

IL-6	9
increases	0
junB	3
mRNA	4
in	0
a	0
biphasic	0
fashion	0
.	0

The	0
first	0
early-induced	0
peak	0
was	0
transient	0
and	0
likely	0
corresponds	0
to	0
the	0
well	0
documented	0
typical	0
junB	3
mRNA	4
,	0
stimulated	0
in	0
response	0
to	0
numerous	0
growth	9
factors	10
,	0
including	0
IL-6	9
.	0

At	0
variance	0
,	0
the	0
second	0
peak	0
which	0
has	0
never	0
been	0
reported	0
previously	0
,	0
lasted	0
several	0
hours	0
.	0

As	0
a	0
consequence	0
of	0
its	0
effect	0
on	0
junB	3
mRNA	4
,	0
IL-6	9
stimulated	0
,	0
in	0
a	0
biphasic	0
fashion	0
,	0
the	0
nuclear	0
accumulation	0
of	0
the	0
JunB	9
protein	10
.	0

In	0
this	0
study	0
,	0
we	0
demonstrated	0
that	0
IL-6	9
regulation	0
occurred	0
exclusively	0
at	0
the	0
transcriptional	0
level	0
and	0
that	0
the	0
bimodal	0
increase	0
of	0
junB	3
mRNA	4
and	0
JunB	9
protein	10
can	0
be	0
accounted	0
for	0
by	0
a	0
biphasic	0
stimulation	0
of	0
junB	1
transcription	0
.	0

Furthermore	0
,	0
our	0
data	0
point	0
to	0
two	0
major	0
differences	0
between	0
the	0
mechanism	0
of	0
control	0
of	0
the	0
early	0
and	0
the	0
late	0
IL-6	9
-induced	0
junB	1
transcription	0
waves	0
.	0

First	0
,	0
cycloheximide	0
strongly	0
potentiated	0
the	0
transcription	0
of	0
the	0
second	0
wave	0
,	0
whereas	0
it	0
failed	0
to	0
affect	0
the	0
early-induced	0
burst	0
.	0

Second	0
,	0
tyrphostin	0
,	0
a	0
tyrosine	0
kinase	0
inhibitor	0
,	0
impaired	0
the	0
expression	0
of	0
the	0
first	0
but	0
not	0
the	0
second	0
junB	3
mRNA	4
peak	0
.	0

Conversely	0
,	0
genistein	0
,	0
another	0
tyrosine	0
kinase	0
inhibitor	0
,	0
totally	0
abolished	0
the	0
expression	0
of	0
the	0
second	0
peak	0
of	0
junB	3
mRNA	4
whereas	0
it	0
did	0
not	0
affect	0
the	0
expression	0
of	0
the	0
first	0
peak	0
.	0

Altogether	0
these	0
data	0
indicate	0
that	0
,	0
in	0
7TD1	5
cells	6
,	0
IL-6	9
controls	0
junB	1
transcription	0
in	0
a	0
biphasic	0
fashion	0
by	0
means	0
of	0
two	0
separate	0
transduction	0
pathways	0
.	0

A	0
newly	0
established	0
megakaryoblastic/erythroid	5
cell	6
line	6
that	0
differentiates	0
to	0
red	7
cells	8
in	0
the	0
presence	0
of	0
erythropoietin	9
and	0
produces	0
platelet-like	7
particles	8
.	0

In	0
August	0
,	0
1992	0
,	0
we	0
established	0
a	0
leukemic	5
cell	6
line	6
(	0
NS-Meg	5
)	0
from	0
a	0
patient	0
in	0
megakaryoblastic	0
transformation	0
of	0
Philadelphia	0
chromosome-positive	0
chronic	0
myeloid	0
leukemia	0
.	0

The	0
NS-Meg	5
cells	6
were	0
positive	0
for	0
alpha-naphthyl	9
acetate	10
esterase	10
and	0
periodic	0
acid-Schiff	0
(	0
PAS	0
)	0
staining	0
and	0
for	0
surface	0
CD4	9
,	0
CD7	9
,	0
CD13	9
,	0
CD34	9
,	0
CD41a	9
,	0
and	0
glycophorin	9
A	10
antigens	10
.	0

Ultrastructurally	0
,	0
the	0
cells	0
had	0
alpha-granules	0
,	0
demarcation	0
membranes	0
,	0
and	0
platelet	9
peroxidase	10
activity	0
.	0

The	0
NS-Meg	5
cells	6
spontaneously	0
produced	0
platelet-like	7
particles	8
which	0
contained	0
alpha-granules	0
,	0
mitochondria	0
and	0
dense	0
bodies	0
,	0
strongly	0
suggesting	0
platelet	0
production	0
.	0

Erythropoietin	9
(	0
Epo	9
)	0
,	0
granulocyte/macrophage	9
colony	10
stimulating	10
factor	10
(	0
GM-CSF	9
)	0
,	0
and	0
interleukin	9
3	10
(	0
IL-3	9
)	0
promoted	0
the	0
growth	0
of	0
NS-Meg	5
cells	6
.	0

Phorbol-12-myristate-13-acetate	0
increased	0
the	0
expression	0
of	0
both	0
CD41a	9
and	0
CD61	0
antigens	0
.	0

Ten-day	0
exposure	0
to	0
Epo	9
induced	0
mature	7
erythroblasts	8
and	0
red	7
cells	8
.	0

These	0
benzidine-positive	5
cells	6
were	0
positive	0
for	0
hemoglobin	9
F	0
staining	0
.	0

Untreated	0
NS-Meg	5
cells	6
expressed	0
mRNA	3
for	0
the	0
Epo	9
receptor	10
(	0
EpoR	9
)	0
,	0
for	0
GATA-1	9
,	0
and	0
for	0
alpha	1
1	2
,	2
alpha	2
2	2
and	2
gamma	2
globin	2
genes	2
.	0

These	0
results	0
indicate	0
that	0
NS-Meg	5
cells	6
undergo	0
terminal	0
differentiation	0
of	0
both	0
megakaryocytic	7
and	8
erythroid	8
lineages	8
.	0

This	0
cell	5
line	6
should	0
be	0
a	0
very	0
useful	0
tool	0
for	0
the	0
investigation	0
of	0
both	0
megakaryocytic	0
and	0
erythroid	0
maturation	0
.	0

Differential	0
regulation	0
of	0
proto-oncogenes	1
c-jun	1
and	0
c-fos	1
in	0
T	7
lymphocytes	8
activated	0
through	0
CD28	9
.	0

The	0
T	9
cell	10
surface	10
molecule	10
CD28	9
binds	0
to	0
ligands	0
on	0
accessory	7
cells	8
and	0
APCs	7
,	0
playing	0
an	0
important	0
costimulatory	0
role	0
in	0
the	0
response	0
of	0
T	7
cells	8
to	0
Ags	9
.	0

Our	0
knowledge	0
of	0
the	0
intracellular	0
signaling	0
pathways	0
coupled	0
to	0
this	0
receptor	0
is	0
incomplete	0
.	0

In	0
addition	0
to	0
activation	0
of	0
phospholipase	9
C	10
gamma	10
1	10
,	0
ligation	0
of	0
this	0
receptor	0
also	0
seems	0
to	0
activate	0
a	0
calcium-independent	0
,	0
CD28	9
-specific	0
pathway	0
.	0

In	0
this	0
paper	0
,	0
we	0
report	0
that	0
cross-linking	0
of	0
CD28	9
(	0
but	0
not	0
CD2	9
,	0
CD5	9
,	0
LFA-1	9
,	0
or	0
CD7	9
)	0
leads	0
to	0
an	0
elevation	0
of	0
c-jun	3
mRNA	4
,	0
with	0
only	0
minimal	0
activation	0
of	0
c-fos	1
expression	0
.	0

CD28	9
-dependent	0
induction	0
of	0
c-jun	1
expression	0
requires	0
protein	9
tyrosine	10
kinase	10
activity	0
,	0
but	0
does	0
not	0
depend	0
on	0
activation	0
of	0
a	0
phorbol	9
ester-responsive	10
protein	10
kinase	10
C	10
or	0
elevation	0
of	0
cytosolic	0
calcium	0
.	0

Furthermore	0
,	0
CD28	9
-dependent	0
elevation	0
of	0
c-jun	3
mRNA	4
does	0
not	0
appear	0
to	0
be	0
mediated	0
at	0
the	0
level	0
of	0
mRNA	0
stability	0
.	0

A	0
mechanism	0
is	0
suggested	0
whereby	0
expression	0
of	0
c-jun	1
and	0
junB	1
,	0
in	0
the	0
absence	0
of	0
members	0
of	0
the	0
fos	1
family	2
,	0
can	0
prevent	0
inappropriate	0
activation	0
of	0
T	7
cells	8
caused	0
by	0
ligation	0
of	0
CD28	9
in	0
the	0
absence	0
of	0
a	0
specific	0
antigenic	0
stimulus	0
.	0

Enhanced	0
responsiveness	0
to	0
nuclear	9
factor	10
kappa	10
B	10
contributes	0
to	0
the	0
unique	0
phenotype	0
of	0
simian	0
immunodeficiency	0
virus	0
variant	0
SIVsmmPBj14	0
.	0

Infection	0
with	0
a	0
variant	0
of	0
simian	0
immunodeficiency	0
virus	0
,	0
SIVsmmPBj14	0
,	0
leads	0
to	0
severe	0
acute	0
disease	0
in	0
macaques	0
.	0

This	0
study	0
was	0
designed	0
to	0
investigate	0
the	0
functional	0
significance	0
of	0
previously	0
described	0
mutations	0
in	0
the	0
viral	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
and	0
to	0
elucidate	0
their	0
contribution	0
to	0
the	0
unique	0
phenotype	0
of	0
SIVsmmPBj14	0
.	0

LTR	1
-directed	0
transcription	0
was	0
measured	0
by	0
using	0
luciferase	1
reporter	2
constructs	2
that	0
were	0
transiently	0
transfected	0
into	0
cultured	5
cells	6
.	0

In	0
a	0
wide	0
range	0
of	0
cell	0
types	0
,	0
the	0
basal	0
transcriptional	0
activity	0
of	0
the	0
LTR	1
from	0
SIVsmmPBj14	0
was	0
found	0
to	0
be	0
2-	0
to	0
4.5-fold	0
higher	0
than	0
that	0
of	0
an	0
LTR	1
from	0
a	0
non-acutely	0
pathogenic	0
strain	0
.	0

These	0
LTRs	1
differ	0
by	0
five	0
point	0
mutations	0
and	0
a	0
22-bp	1
duplication	2
in	0
SIVsmmPBj14	0
,	0
which	0
includes	0
a	0
nuclear	1
factor	2
kappa	2
B	2
(	2
NF	2
kappa	2
B	2
)	2
site	2
.	0

Transcriptional	0
differences	0
between	0
these	0
LTRs	1
were	0
further	0
enhanced	0
by	0
two-	0
to	0
threefold	0
upon	0
treatment	0
of	0
cells	0
with	0
phorbol	0
ester	0
or	0
tumor	9
necrosis	10
factor	10
alpha	10
or	0
by	0
cotransfection	0
with	0
plasmids	1
expressing	0
NF	9
kappa	10
B	10
subunits	0
.	0

Mutagenesis	0
studies	0
,	0
and	0
the	0
use	0
of	0
a	0
reporter	0
construct	0
containing	0
an	0
enhancerless	0
promoter	0
,	0
indicate	0
that	0
these	0
transcriptional	0
effects	0
are	0
due	0
principally	0
to	0
the	0
22-bp	1
sequence	2
duplication	2
and	0
the	0
NF	1
kappa	2
B	2
site	2
contained	0
within	0
it	0
.	0

Finally	0
,	0
infectious	0
virus	0
stocks	0
that	0
were	0
isogenic	0
except	0
for	0
the	0
LTR	1
were	0
generated	0
.	0

The	0
LTR	1
from	0
SIVsmmPBj14	0
was	0
found	0
to	0
confer	0
an	0
increase	0
in	0
the	0
kinetics	0
of	0
virus	0
replication	0
in	0
cultured	5
cells	6
.	0

Inclusion	0
of	0
this	0
LTR	1
in	0
recombinant	0
SIVs	0
also	0
resulted	0
in	0
a	0
two-	0
to	0
threefold	0
rise	0
in	0
the	0
extent	0
of	0
cellular	0
proliferation	0
that	0
was	0
induced	0
in	0
quiescent	5
simian	6
peripheral	6
blood	6
mononuclear	6
cells	6
.	0

These	0
studies	0
are	0
consistent	0
with	0
the	0
hypothesis	0
that	0
LTR	1
mutations	0
assist	0
SIVsmmPBj14	0
in	0
responding	0
efficiently	0
to	0
cellular	0
stimulation	0
and	0
allow	0
it	0
to	0
replicate	0
to	0
high	0
titers	0
during	0
the	0
acute	0
phase	0
of	0
viral	0
infection	0
.	0

Constitutive	0
nuclear	9
NF-kappa	10
B	10
in	0
cells	0
of	0
the	0
monocyte	0
lineage	0
.	0

In	0
monocytes	7
,	0
the	0
nuclear	9
factor	10
NF-kappa	10
B	10
has	0
been	0
invoked	0
as	0
an	0
important	0
transcription	9
factor	10
in	0
the	0
expression	0
of	0
cytokine	1
genes	2
,	0
of	0
cell-surface	9
receptors	10
and	0
in	0
the	0
expression	0
of	0
human	0
immunodeficiency	0
virus	0
.	0

In	0
such	0
cells	0
,	0
DNA	0
binding	0
activity	0
of	0
NF-kappa	9
B	10
can	0
be	0
detected	0
without	0
intentional	0
stimulation	0
.	0

In	0
our	0
studies	0
,	0
cells	0
of	0
the	0
human	5
monocytic	6
line	6
Mono	5
Mac	6
6	6
,	0
cultured	0
in	0
medium	0
containing	0
fetal-calf	0
serum	0
and	0
low	0
levels	0
of	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
also	0
exhibit	0
such	0
'constitutive	0
'	0
NF-kappa	9
B	10
,	0
as	0
demonstrated	0
by	0
mobility-shift	0
analysis	0
of	0
nuclear	0
extracts	0
.	0

This	0
nuclear	9
NF-kappa	10
B	10
was	0
still	0
present	0
when	0
contaminant	0
LPS	0
was	0
removed	0
by	0
ultrafiltration	0
and	0
when	0
serum	0
was	0
omitted	0
.	0

Protein-DNA	0
complexes	0
of	0
constitutive	0
NF-kappa	9
B	10
are	0
similar	0
in	0
mobility	0
to	0
the	0
LPS-induced	9
NF-kappa	10
B	10
and	0
both	0
are	0
recognized	0
by	0
an	0
antibody	0
specific	0
to	0
the	0
p50	9
subunit	10
of	0
NF-kappa	9
B	10
.	0

By	0
contrast	0
,	0
treatment	0
of	0
cells	0
with	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
will	0
only	0
block	0
LPS-induced	9
NF-kappa	10
B	10
,	0
but	0
not	0
the	0
constitutive	9
binding	10
protein	10
.	0

Using	0
LPS-free	0
and	0
serum-free	0
conditions	0
,	0
constitutive	0
NF-kappa	9
B	10
can	0
be	0
detected	0
in	0
different	0
cell	5
lines	6
of	0
the	0
monocytic	7
lineage	8
(	0
HL60	5
,	0
U937	5
,	0
THP-1	5
,	0
Mono	5
Mac	6
1	6
and	0
Mono	5
Mac	6
6	6
)	0
,	0
but	0
not	0
in	0
Molt	5
4	6
T	6
cells	6
or	0
K562	5
stem	6
cells	6
.	0

When	0
ordered	0
according	0
to	0
stage	0
of	0
maturation	0
,	0
the	0
amount	0
of	0
constitutive	0
NF-kappa	9
B	10
was	0
not	0
increased	0
in	0
more	0
mature	5
cell	6
lines	6
.	0

Furthermore	0
,	0
when	0
inducing	0
differentiation	0
in	0
Mono	5
Mac	6
6	6
cells	6
,	0
with	0
vitamin	0
D3	0
,	0
no	0
change	0
in	0
constitutive	0
or	0
inducible	0
NF-kappa	9
B	10
can	0
be	0
detected	0
.	0

Analysis	0
of	0
primary	0
cells	0
revealed	0
substantial	0
constitutive	0
NF-kappa	9
B	10
-binding	0
activity	0
in	0
blood	7
monocytes	8
,	0
pleural	7
macrophages	8
and	0
alveolar	7
macrophages	8
.	0

The	0
constitutive	0
NF-kappa	9
B	10
appears	0
to	0
be	0
functionally	0
active	0
,	0
since	0
a	0
low	0
level	0
of	0
tumour	3
necrosis	4
factor	4
(	4
TNF	4
)	4
transcript	4
is	0
detectable	0
in	0
monocytes	7
,	0
and	0
this	0
level	0
can	0
be	0
increased	0
by	0
blocking	0
transcript	0
degradation	0
using	0
cycloheximide	0
.	0

The	0
level	0
of	0
constitutive	0
NF-kappa	9
B	10
in	0
these	0
cells	0
is	0
variable	0
and	0
is	0
frequently	0
found	0
to	0
be	0
lower	0
in	0
the	0
more	0
mature	7
macrophages	8
.	0

Constitutive	0
NF-kappa	9
B	10
was	0
not	0
maintained	0
by	0
autocrine	0
action	0
of	0
cytokines	9
TNF	9
,	0
interleukin	9
6	10
,	0
interleukin	9
10	0
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
or	0
macrophage	9
colony-stimulating	10
factor	10
,	0
since	0
neutralizing	0
antibodies	0
did	0
not	0
reduce	0
constitutive	0
DNA-binding	0
activity	0
.	0

Furthermore	0
,	0
blockade	0
of	0
prostaglandin	0
or	0
leukotriene	0
biosynthesis	0
did	0
not	0
affect	0
constitutive	0
NF-kappa	9
B	10
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
400	0
WORDS	0
)	0

Steel	9
factor	10
affects	0
SCL	9
expression	0
during	0
normal	0
erythroid	0
differentiation	0
.	0

Steel	9
factor	10
is	0
one	0
of	0
the	0
growth	9
factors	10
that	0
controls	0
the	0
proliferation	0
and	0
differentiation	0
of	0
hematopoietic	7
cells	8
and	0
SCL	9
,	0
also	0
known	0
as	0
Tcl-5	9
or	0
Tal-1	9
,	0
is	0
a	0
transcription	9
factor	10
involved	0
in	0
erythropoiesis	0
.	0

In	0
this	0
report	0
,	0
we	0
studied	0
the	0
role	0
of	0
SCL	0
in	0
the	0
proliferation	0
of	0
human	7
peripheral	8
blood	8
burst-forming	8
unit-erythroid	8
(	0
BFU-E	7
)	0
and	0
the	0
effects	0
of	0
Steel	9
factor	10
on	0
SCL	9
expression	0
in	0
proliferating	7
erythroid	8
cells	8
.	0

BFU-E-derived	5
colonies	6
increase	0
progressively	0
in	0
size	0
,	0
as	0
determined	0
by	0
cell	0
number	0
,	0
from	0
day	0
7	0
to	0
day	0
14	0
of	0
culture	0
,	0
with	0
the	0
greatest	0
increase	0
in	0
colony	0
size	0
(	0
10-fold	0
expansion	0
)	0
occurring	0
between	0
day	0
7	0
and	0
day	0
10	0
.	0

SCL	9
protein	10
levels	0
in	0
BFU-E-derived	5
cells	6
were	0
highest	0
in	0
day	0
7	0
cells	0
and	0
decreased	0
progressively	0
from	0
day	0
7	0
to	0
day	0
14	0
of	0
culture	0
,	0
suggesting	0
an	0
association	0
of	0
SCL	9
with	0
erythroid	0
proliferation	0
.	0

In	0
contrast	0
,	0
SCL	3
mRNA	4
levels	0
did	0
not	0
decrease	0
significantly	0
between	0
day	0
7	0
and	0
day	0
14	0
cells	0
,	0
suggesting	0
that	0
posttranscriptional	0
mechanisms	0
are	0
largely	0
responsible	0
for	0
the	0
decrease	0
in	0
SCL	9
protein	10
observed	0
.	0

The	0
role	0
of	0
SCL	9
in	0
Steel	9
factor	10
-induced	0
erythroid	0
proliferation	0
was	0
then	0
examined	0
.	0

In	0
BFU-E-derived	5
colonies	6
cultured	0
with	0
Steel	9
factor	10
,	0
colony	0
size	0
was	0
significantly	0
increased	0
compared	0
to	0
control	0
.	0

In	0
day	0
7	0
and	0
day	0
10	0
erythroid	7
precursors	8
cultured	0
with	0
Steel	9
factor	10
,	0
SCL	9
protein	10
was	0
increased	0
significantly	0
compared	0
to	0
control	0
.	0

The	0
increase	0
in	0
SCL	9
protein	0
levels	0
in	0
early	0
erythroid	7
precursors	8
stimulated	0
with	0
Steel	9
factor	10
suggests	0
one	0
mechanism	0
through	0
which	0
Steel	9
factor	10
may	0
enhance	0
normal	0
erythroid	0
proliferation	0
.	0

SCL	3
mRNA	4
levels	0
assessed	0
by	0
Northern	0
blot	0
in	0
day	0
7	0
cells	0
did	0
not	0
increase	0
significantly	0
in	0
response	0
to	0
Steel	9
factor	10
stimulation	0
,	0
suggesting	0
that	0
posttranscriptional	0
mechanisms	0
may	0
also	0
be	0
important	0
in	0
the	0
increase	0
in	0
SCL	9
protein	10
observed	0
in	0
response	0
to	0
Steel	9
.	0

C/EBP	9
beta	10
regulation	0
of	0
the	0
tumor	1
necrosis	2
factor	2
alpha	2
gene	2
.	0

Activated	7
macrophages	8
contribute	0
to	0
chronic	0
inflammation	0
by	0
the	0
secretion	0
of	0
cytokines	9
and	0
proteinases	9
.	0

Tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
is	0
particularly	0
important	0
in	0
this	0
process	0
because	0
of	0
its	0
ability	0
to	0
regulate	0
other	0
inflammatory	0
mediators	0
in	0
an	0
autocrine	0
and	0
paracrine	0
fashion	0
.	0

The	0
mechanism	0
(	0
s	0
)	0
responsible	0
for	0
the	0
cell	0
type-specific	0
regulation	0
of	0
TNF	9
alpha	10
is	0
not	0
known	0
.	0

We	0
present	0
data	0
to	0
show	0
that	0
the	0
expression	0
of	0
TNF	9
alpha	10
is	0
regulated	0
by	0
the	0
transcription	9
factor	10
C/EBP	9
beta	10
(	0
NF-IL6	9
)	0
.	0

C/EBP	9
beta	10
activated	0
the	0
TNF	1
alpha	2
gene	2
promoter	2
in	0
cotransfection	0
assays	0
and	0
bound	0
to	0
it	0
at	0
a	0
site	0
which	0
failed	0
to	0
bind	0
the	0
closely	0
related	0
protein	0
C/EBP	9
alpha	10
.	0

Finally	0
,	0
a	0
dominant-negative	0
version	0
of	0
C/EBP	9
beta	10
blocked	0
TNF	1
alpha	2
promoter	2
activation	0
in	0
myeloid	7
cells	8
.	0

Our	0
results	0
implicate	0
C/EBP	9
beta	10
as	0
an	0
important	0
regulator	0
of	0
TNF	9
alpha	10
by	0
myelomonocytic	7
cells	8
.	0

Calcium/calmodulin-dependent	9
protein	10
kinase	10
II	10
downregulates	0
both	0
calcineurin	0
and	0
protein	0
kinase	0
C-mediated	0
pathways	0
for	0
cytokine	1
gene	2
transcription	0
in	0
human	7
T	8
cells	8
.	0

Engagement	0
of	0
the	0
T	9
cell	10
receptor	10
for	0
antigen	0
activates	0
phospholipase	9
C	10
resulting	0
in	0
an	0
increase	0
in	0
intracellular	0
free	0
calcium	0
concentration	0
(	0
[	0
Ca2+	0
]	0
i	0
)	0
and	0
activation	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
.	0

Increased	0
[	0
Ca2+	0
]	0
i	0
activates	0
Ca2+/calmodulin-dependent	9
kinases	10
including	0
the	0
multifunctional	0
Ca2+/calmodulin-dependent	9
protein	10
kinase	10
II	10
(	0
CaM-K	9
II	10
)	0
,	0
as	0
well	0
as	0
calcineurin	9
,	0
a	0
type	9
2B	10
protein	10
phosphatase	10
.	0

Recent	0
studies	0
have	0
identified	0
calcineurin	9
as	0
a	0
key	0
enzyme	0
for	0
interleukin	0
(	0
IL	0
)	0
-2	0
and	0
IL-4	0
promoter	0
activation	0
.	0

However	0
,	0
the	0
role	0
of	0
CaM-K	9
II	10
remains	0
unknown	0
.	0

We	0
have	0
used	0
mutants	0
of	0
these	0
kinases	9
and	0
phosphatases	9
(	0
gamma	9
B*CaM-K	10
and	0
delta	9
CaM-AI	10
,	0
respectively	0
)	0
to	0
explore	0
their	0
relative	0
role	0
in	0
cytokine	1
gene	2
transcription	0
and	0
their	0
interactions	0
with	0
PKC	9
-dependent	0
signaling	0
systems	0
.	0

gamma	9
B*CaM-K	10
and	0
delta	9
CaM-AI	10
,	0
known	0
to	0
exhibit	0
constitutive	0
Ca	0
(	0
2+	0
)	0
-independent	0
activity	0
,	0
were	0
cotransfected	0
(	0
alone	0
or	0
in	0
combination	0
)	0
in	0
Jurkat	5
T	6
cells	6
with	0
a	0
plasmid	0
containing	0
the	0
intact	0
IL-2	1
promoter	2
driving	0
the	0
expression	0
of	0
the	0
chloramphenicol	1
acetyltransferase	2
reporter	2
gene	2
.	0

Cotransfection	0
of	0
gamma	9
B*CaM-K	10
with	0
the	0
IL-2	1
promoter	2
construct	2
downregulated	0
its	0
transcription	0
in	0
response	0
to	0
stimulation	0
with	0
ionomycin	0
and	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
.	0

The	0
inhibitory	0
effect	0
of	0
CaM-K	9
II	10
on	0
IL-2	1
promoter	2
was	0
associated	0
with	0
decreased	0
transcription	0
of	0
its	0
AP-1	0
and	0
NF-AT	0
transactivating	0
pathways	0
.	0

Under	0
the	0
same	0
conditions	0
,	0
delta	9
CaM-AI	10
superinduced	0
IL-2	1
promoter	2
activity	0
(	0
approximately	0
twofold	0
increase	0
)	0
.	0

When	0
both	0
mutants	0
were	0
used	0
in	0
combination	0
,	0
gamma	9
B*CaM-K	10
inhibited	0
the	0
induction	0
of	0
the	0
IL-2	1
promoter	2
by	0
delta	9
CaM-AI	10
.	0

Similar	0
results	0
were	0
obtained	0
when	0
a	0
construct	0
containing	0
the	0
IL-4	1
promoter	2
also	0
was	0
used	0
.	0

gamma	9
B*CaM-K	10
also	0
downregulated	0
the	0
activation	0
of	0
AP-1	9
in	0
response	0
to	0
transfection	0
with	0
a	0
constitutively	0
active	0
mutant	0
of	0
PKC	9
or	0
stimulation	0
with	0
PMA	0
.	0

These	0
results	0
suggest	0
that	0
CaM-K	9
II	10
may	0
exert	0
negative	0
influences	0
on	0
cytokine	1
gene	2
transcription	0
in	0
human	7
T	8
cells	8
,	0
and	0
provide	0
preliminary	0
evidence	0
for	0
negative	0
cross-talk	0
with	0
the	0
calcineurin-	0
and	0
PKC-	0
dependent	0
signaling	0
systems	0
.	0

Induction	0
of	0
ICAM-1	9
and	0
LFA-3	9
by	0
Tax1	9
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
and	0
mechanism	0
of	0
down-regulation	0
of	0
ICAM-1	9
or	0
LFA-1	9
in	0
adult-T-cell-leukemia	5
cell	6
lines	6
.	0

The	0
present	0
study	0
was	0
undertaken	0
to	0
determine	0
the	0
role	0
of	0
HTLV-I	9
TaxI	10
in	0
the	0
up-regulation	0
of	0
ICAM-I	9
and	0
LFA-3	9
in	0
human	7
T	8
cells	8
transformed	0
with	0
HTLV-I	0
and	0
the	0
mechanism	0
of	0
down-regulation	0
of	0
ICAM-I	9
and	0
LFA-I	9
in	0
ATL-derived	5
cell	6
lines	6
.	0

Induction	0
of	0
TaxI	9
in	0
a	0
human	5
T-cell	6
line	6
Jurkat	6
carrying	0
the	0
TaxI	1
gene	2
under	0
the	0
metallothionein	1
promoter	2
led	0
to	0
increases	0
in	0
mRNA	3
and	0
surface	0
expression	0
of	0
ICAM-I	9
.	0

The	0
response	0
of	0
LFA-3	9
to	0
TaxI	9
induction	0
was	0
,	0
on	0
the	0
other	0
hand	0
,	0
relatively	0
slow	0
and	0
weak	0
,	0
and	0
might	0
be	0
indirect	0
.	0

Transactivation	0
of	0
the	0
ICAM-I	1
promoter	2
by	0
TaxI	9
was	0
further	0
shown	0
by	0
co-transfection	0
of	0
a	0
CAT	1
reporter	2
construct	2
with	0
the	0
ICAM-I	1
promoter	2
and	0
a	0
plasmid	1
expressing	0
TaxI	9
.	0

The	0
mechanism	0
of	0
down-regulation	0
of	0
ICAM-I	9
or	0
LFA-I	9
in	0
4	5
ATL	6
cell	6
lines	6
was	0
next	0
examined	0
.	0

ICAM-I	3
mRNA	4
was	0
quite	0
low	0
in	0
MT-I	5
,	0
but	0
no	0
genomic	0
changes	0
were	0
found	0
.	0

The	0
CAT	1
reporter	2
with	0
the	0
ICAM-I	1
promoter	2
was	0
inactive	0
in	0
MT-I	5
.	0

Finally	0
,	0
combined	0
treatment	0
of	0
MT-I	5
with	0
5-azacytidine	0
and	0
IFN-gamma	9
induced	0
re-expression	0
of	0
ICAM-I	9
.	0

Collectively	0
,	0
(	0
a	0
)	0
transcriptional	9
factor	10
(	0
s	0
)	0
necessary	0
for	0
expression	0
of	0
ICAM-I	1
gene	2
may	0
be	0
repressed	0
in	0
MT-I	5
through	0
DNA	0
methylation	0
.	0

Three	0
other	0
ATL	5
cell	6
lines	6
(	0
TL-OmI	5
,	0
H582	5
,	0
HuT102	5
)	0
were	0
found	0
to	0
have	0
little	0
mRNA	3
for	0
the	0
LFA-I	9
beta	10
chain	10
(	0
CD18	9
)	0
.	0

H582	5
and	0
HuT102	5
were	0
also	0
negative	0
for	0
the	0
LFA-I	3
alpha	4
chain	4
(	4
CDIIa	4
)	4
mRNA	4
.	0

No	0
genomic	0
changes	0
were	0
found	0
,	0
and	0
a	0
CAT	1
reporter	2
gene	2
with	0
the	0
CD18	1
promoter	2
was	0
inactive	0
in	0
the	0
3	0
of	0
them	0
,	0
again	0
suggesting	0
lack	0
of	0
(	0
a	0
)	0
transcriptional	9
factor	10
(	0
s	0
)	0
necessary	0
for	0
CD18	9
expression	0
.	0

Infection	0
with	0
Theileria	0
annulata	0
induces	0
expression	0
of	0
matrix	9
metalloproteinase	10
9	10
and	0
transcription	9
factor	10
AP-1	9
in	0
bovine	7
leucocytes	8
.	0

Theileria	0
annulata	0
infects	0
bovine	7
leucocytes	8
and	0
results	0
in	0
their	0
reversible	0
transformation	0
such	0
that	0
they	0
become	0
immortalised	0
and	0
metastatic	0
.	0

The	0
present	0
study	0
describes	0
parasite-induced	0
changes	0
in	0
host	1
cell	2
gene	2
expression	0
which	0
have	0
a	0
direct	0
bearing	0
on	0
this	0
transformation	0
process	0
.	0

T.	7
annulata-infected	8
leucocytes	8
produce	0
a	0
number	0
of	0
novel	0
metalloproteinase	9
activities	0
.	0

One	0
of	0
these	0
,	0
previously	0
called	0
B1	9
,	0
is	0
a	0
97-kDa	9
protein	10
which	0
is	0
secreted	0
in	0
large	0
amounts	0
and	0
has	0
been	0
purified	0
from	0
protein-free	0
,	0
conditioned	0
medium	0
.	0

An	0
antiserum	0
to	0
this	0
enzyme	0
was	0
used	0
to	0
isolate	0
a	0
cDNA	1
clone	2
.	0

The	0
predicted	0
protein	0
sequence	0
of	0
B1	9
is	0
81	0
%	0
identical	0
to	0
human	0
matrix	9
metalloproteinase	10
9	10
(	0
MMP9	9
)	0
,	0
demonstrating	0
that	0
it	0
is	0
the	0
bovine	0
homologue	0
of	0
this	0
enzyme	0
.	0

RNAase	9
protection	0
assays	0
demonstrated	0
that	0
the	0
MMP9	9
activity	0
,	0
unique	0
to	0
infected	7
cells	8
,	0
is	0
due	0
to	0
increased	0
MMP9	9
mRNA	0
levels	0
.	0

We	0
also	0
assayed	0
the	0
levels	0
of	0
transcription	9
factor	10
AP-1	9
and	0
demonstrated	0
that	0
it	0
was	0
constitutively	0
present	0
in	0
increased	0
amounts	0
in	0
Theileria-infected	7
cells	8
.	0

In	0
addition	0
we	0
assayed	0
the	0
level	0
of	0
mRNA	3
encoding	0
c-Fos	9
,	0
a	0
common	0
component	0
of	0
AP-1	9
and	0
observed	0
that	0
it	0
was	0
indeed	0
up-regulated	0
in	0
infected	7
cells	8
.	0

Since	0
AP-1	9
is	0
implicated	0
in	0
the	0
control	0
of	0
the	0
cell	0
cycle	0
,	0
and	0
MMP9	9
can	0
confer	0
metastatic	0
properties	0
,	0
these	0
results	0
are	0
of	0
considerable	0
significance	0
with	0
respect	0
to	0
the	0
transformed	0
phenotype	0
induced	0
by	0
Theileria	0
infection	0
.	0

B-cell	7
proliferation	0
and	0
induction	0
of	0
early	0
G1-regulating	9
proteins	10
by	0
Epstein-Barr	0
virus	0
mutants	0
conditional	0
for	0
EBNA2	9
.	0

Infection	0
of	0
primary	7
B-lymphocytes	8
by	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
leads	0
to	0
growth	0
transformation	0
of	0
these	0
B-cells	7
in	0
vitro	0
.	0

EBV	0
nuclear	0
antigen	0
2	0
(	0
EBNA2	9
)	0
,	0
one	0
of	0
the	0
first	0
genes	0
expressed	0
after	0
EBV	0
infection	0
of	0
B-cells	7
,	0
is	0
a	0
transcriptional	0
activator	0
of	0
viral	1
and	2
cellular	2
genes	2
and	0
is	0
essential	0
for	0
the	0
transforming	0
potential	0
of	0
the	0
virus	0
.	0

We	0
generated	0
conditional	0
EBV	0
mutants	0
by	0
expressing	0
EBNA2	9
as	0
chimeric	9
fusion	10
protein	10
with	0
the	0
hormone	0
binding	0
domain	0
of	0
the	0
estrogen	9
receptor	10
on	0
the	0
genetic	0
background	0
of	0
the	0
virus	0
.	0

Growth	0
transformation	0
of	0
primary	7
normal	8
B-cells	8
by	0
mutant	0
virus	0
resulted	0
in	0
estrogen-dependent	5
lymphoblastoid	6
cell	6
lines	6
expressing	0
the	0
chimeric	0
EBNA2	9
protein	10
.	0

In	0
the	0
absence	0
of	0
estrogen	0
about	0
half	0
of	0
the	0
cells	0
enter	0
a	0
quiescent	0
non-proliferative	0
state	0
whereas	0
the	0
others	0
die	0
by	0
apoptosis	0
.	0

EBNA2	9
is	0
thus	0
required	0
not	0
only	0
for	0
initiation	0
but	0
also	0
for	0
maintenance	0
of	0
transformation	0
.	0

Growth	0
arrest	0
occurred	0
at	0
G1	0
and	0
G2	0
stages	0
of	0
the	0
cell	0
cycle	0
,	0
indicating	0
that	0
functional	0
EBNA2	9
is	0
required	0
at	0
different	0
restriction	0
points	0
of	0
the	0
cell	0
cycle	0
.	0

Growth	0
arrest	0
is	0
reversible	0
for	0
G1/G0	7
cells	8
as	0
indicated	0
by	0
the	0
sequential	0
accumulation	0
and	0
modification	0
of	0
cell	9
cycle	10
regulating	10
proteins	10
.	0

EBV	0
induces	0
the	0
same	0
cell	0
cycle	0
regulating	0
proteins	0
as	0
polyclonal	0
stimuli	0
in	0
primary	0
B-cells	7
.	0

These	0
data	0
suggest	0
that	0
EBV	0
is	0
using	0
a	0
common	0
pathway	0
for	0
B-cell	0
activation	0
bypassing	0
the	0
requirement	0
for	0
antigen	0
,	0
T-cell	0
signals	0
and	0
growth	9
factors	10
.	0

IL-1	9
receptor	10
and	0
TCR	9
signals	0
synergize	0
to	0
activate	0
NF-kappa	9
B	10
-mediated	0
gene	0
transcription	0
.	0

Previous	0
studies	0
have	0
demonstrated	0
that	0
IL-1	9
receptor	10
(	0
IL-1R	9
)	0
-	0
and	0
TCR	9
-initiated	0
signals	0
can	0
interact	0
synergistically	0
to	0
increase	0
the	0
rate	0
of	0
transcription	0
of	0
several	0
lymphokine	1
and	2
lymphokine	2
receptor	2
genes	2
during	0
the	0
competence	0
phase	0
of	0
the	0
activation	0
program	0
in	0
T	7
helper	8
lymphocytes	8
.	0

In	0
this	0
report	0
we	0
describe	0
how	0
signals	0
initiated	0
through	0
the	0
type	9
I	10
IL-1R	10
interact	0
with	0
signals	0
from	0
the	0
antigen	0
receptor	0
to	0
synergistically	0
augment	0
the	0
transactivating	0
properties	0
of	0
NF-kappa	9
B	10
.	0

The	0
synergistic	0
antigen	9
receptor	10
initiated	0
signals	0
are	0
mediated	0
through	0
protein	9
kinase	10
C	10
because	0
they	0
can	0
be	0
mimicked	0
by	0
the	0
phorbol	0
ester	0
,	0
12-O-tetradecanoylphorbol-13-acetate	0
,	0
but	0
not	0
with	0
calcium	0
ionophores	0
;	0
and	0
are	0
staurosporine	0
sensitive	0
but	0
cyclosporine	0
resistant	0
.	0

Gel	0
shift	0
analyses	0
demonstrate	0
that	0
NF-kappa	9
B	10
nuclear	0
translocation	0
is	0
stimulated	0
primarily	0
by	0
IL-1	9
rather	0
than	0
by	0
antigen	9
receptor	10
signals	0
.	0

Western	0
blot	0
and	0
phosphorylation	0
analyses	0
demonstrate	0
that	0
the	0
synergistic	0
effect	0
on	0
NF-kappa	9
B	10
functional	0
activity	0
is	0
independent	0
of	0
I	9
kappa	10
B	10
alpha	10
(	0
MAD3	9
)	0
-	0
NF-kappa	9
B	10
dissociation	0
in	0
the	0
cytosol	0
and	0
is	0
not	0
associated	0
with	0
I	9
kappa	10
B	10
nuclear	0
translocation	0
.	0

The	0
IL-1	9
-induced	0
NF-kappa	9
B	10
DNA	0
nuclear	0
localization	0
is	0
transient	0
and	0
can	0
be	0
prolonged	0
either	0
by	0
an	0
antigen	0
receptor-initiated	0
signal	0
or	0
by	0
inhibiting	0
protein	0
synthesis	0
.	0

These	0
results	0
suggest	0
that	0
IL-1	9
induces	0
both	0
NF-kappa	9
B	10
nuclear	0
translocation	0
and	0
the	0
synthesis	0
of	0
a	0
protein	0
(	0
s	0
)	0
responsible	0
for	0
terminating	0
NF-kappa	9
B	10
-DNA	0
interaction	0
in	0
the	0
nucleus	0
.	0

Antigen	0
receptor	0
signals	0
prolong	0
NF-kappa	9
B	10
-DNA	0
interaction	0
,	0
probably	0
by	0
functionally	0
antagonizing	0
the	0
IL-1	9
-induced	0
synthesis	0
of	0
a	0
protein	0
(	0
s	0
)	0
responsible	0
for	0
the	0
transient	0
NF-kappa	9
B	10
-DNA	0
interaction	0
and	0
consequently	0
synergistically	0
enhance	0
IL-1	9
-induced	0
NF-kappa	9
B	10
-dependent	0
gene	0
transcription	0
.	0

Identification	0
of	0
the	0
promoter	1
region	2
of	0
chicken	0
anemia	0
virus	0
(	0
CAV	0
)	0
containing	0
a	0
novel	0
enhancer-like	1
element	2
.	0

The	0
single	0
promoter	1
region	2
in	0
the	0
cloned	0
genome	0
[	0
Noteborn	0
et	0
al.	0
,	0
J.	0
Virol.	0
65	0
(	0
1991	0
)	0
3131-3139	0
]	0
of	0
chicken	0
anemia	0
virus	0
(	0
CAV	0
)	0
in	0
chicken	7
T-cells	8
was	0
analysed	0
via	0
CAT	9
assays	0
.	0

A	0
unique	0
region	0
containing	0
four	0
or	0
five	0
near-perfect	0
direct	0
repeats	0
(	0
DR	0
)	0
of	0
21	0
bp	0
with	0
one	0
12-bp	1
insert	2
was	0
proven	0
to	0
be	0
the	0
main	0
transcription-activation	1
element	2
,	0
with	0
enhancer-like	0
characteristics	0
.	0

PCR	0
studies	0
revealed	0
that	0
CAV	0
isolates	0
from	0
across	0
the	0
world	0
all	0
contained	0
this	0
promoter	1
sequence	2
.	0

Electrophoretic	0
mobility-shift	0
assays	0
(	0
EMSA	0
)	0
showed	0
that	0
individual	1
DR	2
units	2
,	0
as	0
well	0
as	0
the	0
12-bp	1
insert	2
,	0
can	0
bind	0
to	0
nuclear	9
factors	10
of	0
chicken	7
T-cells	8
.	0

Competition	0
assays	0
revealed	0
that	0
the	0
DR	1
units	2
bound	0
to	0
factors	0
other	0
than	0
the	0
12-bp	1
insert	2
.	0

A	0
synthetic	0
oligodeoxyribonucleotide	0
containing	0
an	0
SP1-box	1
(	0
5'-GGGCGG	0
)	0
could	0
compete	0
with	0
factors	0
binding	0
to	0
the	0
12-bp	1
insert	2
.	0

Purified	0
human	9
SP1	10
was	0
shown	0
to	0
have	0
very	0
strong	0
affinity	0
for	0
the	0
12-bp	1
insert	2
.	0

Functional	0
Myc-Max	9
heterodimer	10
is	0
required	0
for	0
activation-induced	0
apoptosis	0
in	0
T	5
cell	6
hybridomas	6
.	0

T	5
cell	6
hybridomas	6
respond	0
to	0
activation	0
signals	0
by	0
undergoing	0
apoptotic	0
cell	0
death	0
,	0
and	0
this	0
is	0
likely	0
to	0
represent	0
comparable	0
events	0
related	0
to	0
tolerance	0
induction	0
in	0
immature	7
and	8
mature	8
T	8
cells	8
in	0
vivo	0
.	0

Previous	0
studies	0
using	0
antisense	0
oligonucleotides	0
implicated	0
the	0
c-Myc	9
protein	10
in	0
the	0
phenomenon	0
of	0
activation-induced	0
apoptosis	0
.	0

This	0
role	0
for	0
c-Myc	9
in	0
apoptosis	0
is	0
now	0
confirmed	0
in	0
studies	0
using	0
a	0
dominant	0
negative	0
form	0
of	0
its	0
heterodimeric	0
binding	0
partner	0
,	0
Max	9
,	0
which	0
we	0
show	0
here	0
inhibits	0
activation-induced	0
apoptosis	0
.	0

Further	0
,	0
coexpression	0
of	0
a	0
reciprocally	9
mutant	10
Myc	10
protein	10
capable	0
of	0
forming	0
functional	0
heterodimers	9
with	0
the	0
mutant	0
Max	9
can	0
compensate	0
for	0
the	0
dominant	0
negative	0
activity	0
and	0
restore	0
activation-induced	0
apoptosis	0
.	0

These	0
results	0
imply	0
that	0
Myc	9
promotes	0
activation-induced	0
apoptosis	0
by	0
obligatory	0
heterodimerization	0
with	0
Max	9
,	0
and	0
therefore	0
,	0
by	0
regulating	0
gene	0
transcription	0
.	0

Epstein-Barr	9
virus	10
SM	10
protein	10
.	0

The	0
protein	0
products	0
of	0
the	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
BMLF1	0
open	0
reading	0
frame	0
have	0
been	0
characterized	0
in	0
the	0
early	0
productive	0
cycle	0
in	0
B95-8	5
and	0
Akata	5
cells	6
.	0

The	0
SM	9
protein	10
derived	0
from	0
the	0
spliced	0
RNA	0
joining	0
BSLF2	9
to	0
BMLF1	9
is	0
much	0
the	0
most	0
abundant	0
protein	0
.	0

SM	9
is	0
a	0
phosphoprotein	9
in	0
EBV	0
-infected	7
cells	8
and	0
can	0
be	0
phosphorylated	0
in	0
vitro	0
with	0
casein	9
kinase	10
II	10
(	0
CKII	9
)	0
.	0

Computer	0
analysis	0
of	0
the	0
SM	9
protein	10
sequence	0
showed	0
a	0
C	9
terminal	10
section	10
of	0
SM	9
to	0
be	0
related	0
to	0
genome	9
positional	10
homologues	10
of	0
four	0
other	0
herpesviruses	0
and	0
revealed	0
consensus	9
CKII	10
sites	10
near	0
the	0
N	9
termini	10
of	0
the	0
EBV	9
SM	10
protein	10
,	0
the	0
herpes	9
simplex	10
virus	10
(	10
HSV	10
)	10
ICP27	10
protein	10
and	0
the	0
herpesvirus	9
saimiri	10
(	10
HVS	10
)	10
open	10
reading	10
frame	10
57	10
protein	10
.	0

Site-directed	0
mutagenesis	0
of	0
the	0
consensus	1
CKII	2
site	2
in	0
EBV	0
SM	0
greatly	0
reduced	0
the	0
in	0
vitro	0
phosphorylation	0
of	0
SM	9
by	0
CKII	9
.	0

The	0
mechanism	0
of	0
transactivation	0
by	0
BMLF1	9
proteins	10
has	0
been	0
controversial	0
but	0
SM	9
was	0
shown	0
to	0
transactivate	0
gene	0
expression	0
from	0
a	0
CAT	1
reporter	2
construct	2
by	0
increasing	0
the	0
amount	0
of	0
cytoplasmic	3
CAT	4
mRNA	4
.	0

Mutagenesis	0
of	0
the	0
CKII	9
site	0
in	0
SM	9
made	0
no	0
difference	0
to	0
the	0
transactivation	0
in	0
this	0
transient	0
transfection	0
assay	0
.	0

Inducible	0
binding	0
to	0
the	0
c-fos	0
serum	0
response	0
element	0
during	0
T	0
cell	0
activation	0
is	0
regulated	0
by	0
a	0
phosphotyrosine-containing	9
protein	10
.	0

The	0
proto-oncogene	1
c-fos	2
is	0
an	0
immediate-early	1
gene	2
,	0
and	0
one	0
of	0
the	0
first	0
genes	0
transcribed	0
after	0
stimulation	0
of	0
most	0
cells	0
with	0
a	0
variety	0
of	0
ligands	0
.	0

Fos	0
expression	0
may	0
be	0
a	0
pivotal	0
event	0
in	0
converting	0
ligand-receptor	0
interactions	0
at	0
the	0
membrane	0
into	0
functional	0
modulation	0
of	0
cell	0
phenotype	0
.	0

The	0
serum	1
response	2
element	2
(	0
SRE	1
)	0
in	0
the	0
c-fos	1
regulatory	2
region	2
participates	0
in	0
induction	0
of	0
transcription	0
by	0
various	0
growth	9
factors	10
and	0
by	0
phorbol	0
esters	0
and	0
subsequent	0
squelching	0
of	0
transcription	0
.	0

We	0
show	0
that	0
an	0
inducible	0
protein	9
complex	10
(	0
Band	9
A	10
)	0
binds	0
to	0
SRE	1
DNA	2
within	0
10	0
min	0
after	0
mitogenic	0
stimulation	0
of	0
human	5
PBL-T	6
,	0
and	0
becomes	0
nondetectable	0
by	0
60	0
min	0
.	0

Band	9
A	10
contains	0
the	0
serum	9
response	10
factor	10
plus	0
additional	0
factor	0
(	0
s	0
)	0
.	0

A	0
protein	0
that	0
is	0
phosphorylated	0
on	0
a	0
tyrosine	0
residue	0
in	0
resting	5
PBL-T	6
suppresses	0
binding	0
of	0
a	0
component	0
of	0
Band	9
A	10
to	0
the	0
SRE	1
motif	2
.	0

Upon	0
stimulation	0
of	0
the	0
cells	0
,	0
this	0
protein	0
no	0
longer	0
prevents	0
binding	0
of	0
DNA	0
by	0
Band	9
A	10
,	0
and	0
suppression	0
of	0
binding	0
is	0
restored	0
within	0
30	0
min	0
.	0

The	0
phosphorylated	0
tyrosine	0
residue	0
itself	0
is	0
important	0
for	0
the	0
protein-protein	0
interaction	0
.	0

In	0
vivo	0
modification	0
of	0
major	1
histocompatibility	2
complex	2
class	2
II	2
DRA	2
promoter	2
occupancy	0
mediated	0
by	0
the	0
AIR-1	9
trans-activator	10
.	0

RJ	5
2.2.5	6
is	0
a	0
human	5
B	6
cell	6
mutant	6
derived	0
from	0
the	0
Burkitt	5
lymphoma	6
Raji	6
cell	6
which	0
is	0
defective	0
in	0
the	0
AIR-1	0
locus	0
function	0
.	0

This	0
locus	0
encodes	0
a	0
transcriptional	0
trans-activator	0
required	0
for	0
the	0
constitutive	0
expression	0
of	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
genes	2
.	0

Here	0
we	0
show	0
,	0
by	0
in	0
vivo	0
DNase	9
I	10
footprinting	0
,	0
that	0
the	0
AIR-1	1
locus	2
defect	2
correlates	0
with	0
changes	0
in	0
the	0
DRA	1
promoter	2
occupancy	0
.	0

Interestingly	0
,	0
reexpression	0
of	0
human	1
MHC	2
class	2
II	2
genes	2
in	0
RJ	5
2.2.5	6
x	6
mouse	6
spleen	6
cell	6
hybrids	6
is	0
associated	0
with	0
partial	0
reversion	0
of	0
DRA	1
promoter	2
occupancy	0
to	0
the	0
Raji	0
pattern	0
.	0

DRA	1
promoter	2
occupancy	0
in	0
other	0
class	5
II-negative	6
B	6
cell	6
lines	6
,	0
derived	0
from	0
patients	0
with	0
bare	0
lymphocyte	0
syndrome	0
,	0
is	0
drastically	0
different	0
from	0
the	0
one	0
observed	0
in	0
RJ	5
2.2.5	6
and	0
Raji	5
cells	6
.	0

Moreover	0
,	0
the	0
use	0
of	0
the	0
DNase	9
I	10
as	0
an	0
in	0
vivo	0
footprinting	0
agent	0
reveals	0
that	0
the	0
patients	5
'	6
cell	6
lines	6
do	0
not	0
display	0
a	0
completely	0
``	0
bare	1
promoter	2
``	0
as	0
previously	0
reported	0
using	0
dimethyl	0
sulfate	0
as	0
the	0
footprinting	0
agent	0
.	0

Thus	0
,	0
the	0
use	0
of	0
DNase	9
I	10
allowed	0
us	0
,	0
for	0
the	0
first	0
time	0
,	0
to	0
correlate	0
the	0
AIR-1	1
locus	2
defect	2
with	0
class	1
II	2
promoter	2
occupancy	0
alterations	0
and	0
distinguish	0
these	0
alterations	0
from	0
the	0
ones	0
observed	0
in	0
phenotypically	0
similar	0
but	0
genetically	0
distinct	0
MHC	5
class	6
II-negative	6
cells	6
.	0

Regulation	0
of	0
cell-type-specific	0
interleukin-2	9
receptor	10
alpha-chain	10
gene	0
expression	0
:	0
potential	0
role	0
of	0
physical	0
interactions	0
between	0
Elf-1	9
,	0
HMG-I	9
(	10
Y	10
)	10
,	0
and	0
NF-kappa	9
B	10
family	10
proteins	10
.	0

The	0
interleukin	1
2	2
receptor	2
alpha-chain	2
(	2
IL-2R	2
alpha	2
)	2
gene	2
is	0
rapidly	0
and	0
potently	0
induced	0
in	0
T	7
cells	8
in	0
response	0
to	0
mitogenic	0
stimuli	0
.	0

Previously	0
,	0
an	0
inducible	1
enhancer	2
between	0
nucleotides	1
-299	2
and	2
-228	2
that	0
contains	0
NF-kappa	1
B	2
and	2
CArG	2
motifs	2
was	0
identified	0
.	0

We	0
now	0
report	0
the	0
characterization	0
of	0
a	0
second	0
essential	1
positive	2
regulatory	2
element	2
located	0
between	0
nucleotides	1
-137	2
and	2
-64	2
that	0
binds	0
Elf-1	9
and	0
HMG-I	9
(	10
Y	10
)	10
.	0

This	0
element	0
had	0
maximal	0
activity	0
in	0
lymphoid	7
cells	8
,	0
paralleling	0
the	0
cell	0
type	0
specificity	0
of	0
Elf-1	9
expression	0
.	0

Transcription	0
from	0
the	0
IL-2R	1
alpha	2
promoter	2
was	0
inhibited	0
when	0
either	0
the	0
Elf-1	1
or	2
the	2
HMG-I	2
(	2
Y	2
)	2
binding	2
site	2
was	0
mutated	0
.	0

Coexpression	0
of	0
both	0
proteins	0
activated	0
transcription	0
of	0
the	0
-137	1
to	2
-64	2
element	2
in	0
COS-7	5
cells	6
.	0

Elf-1	9
physically	0
associated	0
with	0
HMG-I	9
and	0
with	0
NF-kappa	9
B	10
p50	9
and	0
c-Rel	9
in	0
vitro	0
,	0
suggesting	0
that	0
protein-protein	0
interactions	0
might	0
functionally	0
coordinate	0
the	0
actions	0
of	0
the	0
upstream	1
and	2
downstream	2
positive	2
regulatory	2
elements	2
.	0

This	0
is	0
the	0
first	0
report	0
of	0
a	0
physical	0
interaction	0
between	0
an	0
Ets	0
family	0
member	0
and	0
NF-kappa	9
B	10
family	10
proteins	10
.	0

These	0
findings	0
provide	0
significant	0
new	0
insights	0
into	0
the	0
protein-protein	0
and	0
protein-DNA	0
interactions	0
that	0
regulate	0
cell-type-specific	0
and	0
inducible	0
IL-2R	9
alpha	10
gene	0
expression	0
and	0
also	0
have	0
implications	0
for	0
other	0
genes	0
regulated	0
by	0
Elf-1	9
and	0
NF-kappa	9
B	10
family	10
proteins	10
.	0

Isolation	0
of	0
cDNA	1
clones	2
for	0
42	0
different	0
Kruppel-related	9
zinc	10
finger	10
proteins	10
expressed	0
in	0
the	0
human	5
monoblast	6
cell	6
line	6
U-937	6
.	0

To	0
study	0
the	0
complexity	0
and	0
structural	0
characteristics	0
of	0
zinc	9
finger	10
proteins	10
expressed	0
during	0
human	0
hematopoiesis	0
and	0
to	0
isolate	0
novel	0
regulators	0
of	0
blood	0
cell	0
development	0
,	0
a	0
degenerate	0
oligonucleotide	0
probe	0
specific	0
for	0
a	0
consensus	9
zinc	10
finger	10
peptide	10
domain	10
was	0
used	0
to	0
isolate	0
63	0
cDNA	1
clones	2
for	0
Kruppel-related	1
zinc	2
finger	2
genes	2
from	0
the	0
human	5
monoblast	6
cell	6
line	6
U-937	6
.	0

By	0
extensive	0
nucleotide	0
sequence	0
and	0
Northern	0
blot	0
analysis	0
,	0
these	0
cDNA	1
clones	2
were	0
found	0
to	0
originate	0
from	0
approximately	0
42	0
different	0
genes	0
(	0
HZF	1
1-42	2
)	0
of	0
which	0
only	0
8	0
have	0
previously	0
been	0
described	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
a	0
majority	0
of	0
these	0
genes	0
were	0
expressed	0
at	0
comparable	0
levels	0
in	0
U-937	5
and	0
HeLa	5
cells	6
.	0

The	0
large	0
number	0
of	0
individual	0
genes	0
represented	0
among	0
the	0
63	0
clones	0
and	0
their	0
apparent	0
non-cell-type-specific	0
expression	0
suggest	0
that	0
the	0
majority	0
of	0
the	0
Kruppel-related	1
zinc	2
finger	2
genes	2
are	0
likely	0
to	0
be	0
expressed	0
in	0
most	0
human	0
tissues	0
.	0

In	0
contrast	0
,	0
some	0
of	0
the	0
genes	0
displayed	0
a	0
restricted	0
expression	0
pattern	0
,	0
indicating	0
that	0
they	0
represent	0
potential	0
regulators	0
of	0
monocyte	0
differentiation	0
or	0
proliferation	0
.	0

Detailed	0
structural	0
analysis	0
of	0
the	0
first	0
12	0
cDNAs	1
(	0
HZF	1
1-10	2
)	0
and	0
a	0
partial	0
characterization	0
of	0
HZF	1
11-42	2
revealed	0
that	0
a	0
common	0
feature	0
of	0
human	9
Kruppel-related	10
zinc	10
finger	10
proteins	10
is	0
the	0
presence	0
of	0
tandem	0
arrays	0
of	0
zinc	9
fingers	10
ranging	0
in	0
number	0
from	0
3	0
to	0
over	0
20	0
that	0
are	0
preferentially	0
located	0
in	0
the	0
carboxy-terminal	9
regions	10
of	0
the	0
proteins	0
.	0

In	0
addition	0
,	0
several	0
novel	0
KRAB-containing	1
zinc	2
finger	2
genes	2
and	0
a	0
novel	0
conserved	1
sequence	2
element	2
were	0
identified	0
.	0

CAG	0
repeat	0
length	0
variation	0
in	0
sperm	7
from	0
a	0
patient	0
with	0
Kennedy	0
's	0
disease	0
.	0

Using	0
a	0
modified	0
sperm	7
typing	0
protocol	0
,	0
the	0
mutation	0
frequency	0
of	0
the	0
CAG	1
repeat	2
region	2
at	0
the	0
androgen	1
receptor	2
locus	2
has	0
been	0
measured	0
using	0
a	0
rare	0
semen	0
sample	0
from	0
an	0
individual	0
with	0
spinal	0
and	0
bulbar	0
muscular	0
atrophy	0
(	0
SBMA	0
)	0
.	0

Among	0
258	0
X	7
chromosome-containing	8
sperm	8
,	0
19	0
%	0
had	0
a	0
repeat	0
number	0
equal	0
to	0
the	0
donor	1
's	2
somatic	2
DNA	2
(	0
47	0
repeats	0
)	0
,	0
66	0
%	0
were	0
expansions	0
and	0
15	0
%	0
were	0
contractions	0
.	0

The	0
average	0
expansion	0
was	0
2.7	0
repeats	0
.	0

More	0
than	0
half	0
of	0
the	0
expansions	0
involved	0
one	0
or	0
two	0
repeats	0
;	0
the	0
largest	0
was	0
11	0
repeats	0
.	0

68	0
%	0
of	0
the	0
contractions	0
were	0
also	0
one	0
or	0
two	0
repeats	0
but	0
six	0
(	0
16	0
%	0
)	0
were	0
very	0
large	0
(	0
12-25	0
repeats	0
)	0
.	0

One	0
contraction	0
generated	0
an	0
allele	0
in	0
an	0
intermediate	0
size	0
range	0
(	0
33-39	0
repeats	0
)	0
.	0

Such	0
alleles	0
have	0
not	0
been	0
observed	0
among	0
more	0
than	0
900	0
normal	0
and	0
SBMA	1
X-chromosomes	2
that	0
have	0
been	0
examined	0
.	0

Comparison	0
of	0
the	0
SBMA	0
sperm	7
typing	0
results	0
with	0
mutation	0
frequency	0
data	0
on	0
normal	0
alleles	0
supports	0
the	0
hypothesis	0
that	0
trinucleotide	1
repeat	2
expansions	0
may	0
have	0
a	0
different	0
molecular	0
origin	0
than	0
contractions	0
.	0

Aspirin-like	0
drugs	0
can	0
protect	0
human	7
T	8
lymphocytes	8
against	0
benzoquinone	0
cytotoxicity	0
:	0
evidence	0
for	0
a	0
NAD	9
(	10
P	10
)	10
H	10
:	10
quinone	10
reductase	10
-dependent	0
mechanism	0
.	0

Benzene	0
toxicity	0
towards	0
lymphocytes	7
is	0
thought	0
to	0
be	0
mediated	0
by	0
metabolites	0
of	0
benzene	0
including	0
benzoquinone	0
(	0
BQ	0
)	0
.	0

NAD	9
(	10
P	10
)	10
H	10
:	10
quinone	10
reductase	10
(	0
QR	9
)	0
is	0
known	0
to	0
protect	0
against	0
BQ	0
toxicity	0
.	0

The	0
expression	0
of	0
the	0
QR	1
gene	2
is	0
regulated	0
by	0
the	0
transcription	9
factor	10
AP-1	9
.	0

We	0
had	0
previously	0
found	0
that	0
aspirin-like	0
drugs	0
(	0
ALD	0
)	0
induce	0
AP-1	9
in	0
human	7
T	8
lymphocytes	8
.	0

It	0
was	0
therefore	0
hypothesized	0
that	0
ALD	0
would	0
protect	0
lymphocytes	7
against	0
BQ	0
toxicity	0
by	0
inducing	0
QR	9
.	0

Molt-4	5
cells	6
(	0
M4	5
)	0
,	0
a	0
human	5
T	6
lymphocyte	6
cell	6
line	6
,	0
were	0
incubated	0
with	0
different	0
concentrations	0
of	0
two	0
ALD	0
,	0
flurbiprofen	0
and	0
sodium	0
diclofenac	0
,	0
and	0
then	0
exposed	0
to	0
BQ	0
.	0

Toxicity	0
was	0
measured	0
by	0
viability	0
(	0
trypan	0
blue	0
exclusion	0
)	0
.	0

Both	0
drugs	0
protected	0
the	0
cells	0
against	0
BQ	0
cytotoxicity	0
in	0
a	0
dose-dependent	0
manner	0
,	0
e.g.	0
,	0
sodium	0
diclofenac	0
at	0
15	0
microM	0
reduced	0
the	0
fraction	0
of	0
BQ-treated	0
dead	0
cells	0
by	0
70	0
%	0
.	0

ALDs	0
induced	0
QR	9
activity	0
in	0
the	0
M4	0
cells	0
in	0
the	0
same	0
range	0
of	0
concentrations	0
that	0
protected	0
the	0
cells	0
against	0
BQ	0
toxicity	0
.	0

The	0
protective	0
effect	0
of	0
ALD	0
was	0
significantly	0
reduced	0
by	0
dicoumarol	0
,	0
a	0
QR	9
-specific	0
inhibitor	0
.	0

Since	0
human	7
T	8
cells	8
and	0
T	7
cell	8
lines	8
do	0
not	0
metabolize	0
arachidonic	0
acid	0
,	0
our	0
data	0
suggest	0
that	0
ALD	0
can	0
protect	0
human	7
T	8
lymphocytes	8
against	0
a	0
metabolite	0
of	0
benzene	0
by	0
induction	0
of	0
QR	9
activity	0
.	0

Correlation	0
of	0
differentiation-inducing	0
activity	0
of	0
retinoids	0
on	0
human	5
leukemia	6
cell	6
lines	6
HL-60	5
and	0
NB4	5
.	0

Retinoids	0
,	0
including	0
all-trans-retinoic	0
acid	0
,	0
its	0
isomers	0
,	0
and	0
fifty	0
synthetic	0
retinoids	0
(	0
retinobenzoic	0
acids	0
)	0
,	0
were	0
tested	0
for	0
differentiation-inducing	0
activity	0
on	0
human	5
leukemia	6
cell	6
lines	6
HL-60	5
and	0
NB4	5
.	0

A	0
good	0
linear	0
correlation	0
,	0
with	0
an	0
r	0
value	0
of	0
0.91	0
,	0
between	0
the	0
ED50	0
values	0
for	0
the	0
differentiation-inducing	0
activity	0
towards	0
HL-60	5
cells	6
and	0
that	0
towards	0
NB4	5
cells	6
was	0
found	0
.	0

Platelet-activating	9
factor	10
(	0
PAF	9
)	0
positively	0
auto-regulates	0
the	0
expression	0
of	0
human	9
PAF	10
receptor	10
transcript	10
1	10
(	0
leukocyte-type	0
)	0
through	0
NF-kappa	9
B	10
.	0

The	0
human	1
platelet-activating	2
factor	2
receptor	2
(	2
PAFR	2
)	2
gene	2
is	0
transcribed	0
by	0
two	0
distinct	0
promoters	1
(	0
promoter	1
1	2
and	0
promoter	1
2	2
)	0
to	0
generate	0
two	0
transcripts	0
(	0
designated	0
as	0
PAFR	3
transcript	4
1	4
and	0
PAFR	3
transcript	4
2	4
)	0
,	0
though	0
their	0
open	0
reading	0
frames	0
are	0
identical	0
.	0

By	0
primer	0
extension	0
analysis	0
to	0
discriminate	0
two	0
transcripts	0
,	0
we	0
found	0
that	0
the	0
levels	0
of	0
PAFR	3
transcript	4
1	4
(	0
leukocyte-type	0
)	0
,	0
but	0
not	0
PAFR	3
transcript	4
2	4
(	0
tissue-type	0
)	0
,	0
are	0
upregulated	0
by	0
PAF	9
as	0
well	0
as	0
by	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
in	0
the	0
human	5
stomach	6
cancer	6
cell	6
line	6
(	0
JR-St	5
cells	6
)	0
which	0
expresses	0
both	0
functional	0
PAFR	3
transcript	4
1	4
and	0
PAFR	3
transcript	4
2	4
endogenously	0
.	0

Functional	0
analysis	0
of	0
the	0
promoter	1
1	2
with	0
a	0
transient	0
expression	0
assay	0
using	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
gene	2
as	0
a	0
reporter	0
showed	0
that	0
both	0
PAF	9
and	0
TPA	0
activated	0
the	0
promoter	1
1	2
but	0
not	0
the	0
deleted	0
promoter	0
lacking	0
the	0
three	0
consensus	1
binding	2
sites	2
for	0
NF-kappa	9
B	10
located	0
from	0
-571	0
bp	0
to	0
-459	0
bp	0
.	0

These	0
findings	0
suggest	0
a	0
molecular	0
mechanism	0
of	0
positive	0
regulation	0
of	0
PAFR	9
gene	0
expression	0
by	0
PAF	9
through	0
NF-kappa	9
B	10
,	0
possibly	0
by	0
a	0
phosphorylation	0
reaction	0
involving	0
protein	9
kinase	10
C	10
by	0
PAF	9
.	0

One	0
gene	0
,	0
two	0
transcripts	3
:	0
isolation	0
of	0
an	0
alternative	0
transcript	0
encoding	0
for	0
the	0
autoantigen	9
La/SS-B	10
from	0
a	0
cDNA	1
library	2
of	0
a	0
patient	0
with	0
primary	0
Sjogrens	0
'	0
syndrome	0
.	0

A	0
cDNA	1
library	2
was	0
prepared	0
from	0
peripheral	0
blood	0
lymphocytes	7
of	0
an	0
autoimmune	0
patient	0
with	0
primary	0
Sjogrens	0
'	0
syndrome	0
.	0

The	0
cDNA	1
library	2
was	0
screened	0
with	0
the	0
patients	0
own	0
autoimmune	0
serum	0
being	0
monospecific	0
for	0
the	0
nuclear	9
autoantigen	10
La/SS-B	10
.	0

Thereby	0
an	0
alternative	0
type	0
of	0
La	3
mRNA	4
was	0
identified	0
that	0
differed	0
from	0
the	0
known	0
La	3
mRNA	4
due	0
to	0
an	0
exchange	0
of	0
the	0
exon	1
1	2
.	0

Sequencing	0
of	0
the	0
genomic	0
region	0
between	0
the	0
exons	1
1	2
and	2
2	2
showed	0
that	0
the	0
alternative	1
5'-end	2
is	0
a	0
part	0
of	0
the	0
intron	1
.	0

In	0
addition	0
,	0
the	0
presence	0
of	0
an	0
alternative	1
promoter	2
site	2
,	0
which	0
exists	0
within	0
the	0
intron	1
downstream	0
of	0
the	0
exon	1
1	2
,	0
became	0
evident	0
.	0

In	0
consequence	0
,	0
the	0
alternative	3
La	4
mRNA	4
is	0
the	0
result	0
of	0
a	0
promoter	0
switching	0
combined	0
with	0
an	0
alternative	0
splicing	0
mechanism	0
.	0

In	0
the	0
intron	0
,	0
further	0
transcription	9
factor	10
binding	0
sites	0
,	0
including	0
a	0
NF-kappa	1
B	2
element	2
,	0
were	0
identified	0
leading	0
to	0
the	0
suggestion	0
that	0
the	0
expression	0
of	0
the	0
gene	0
encoding	0
for	0
the	0
nuclear	9
autoantigen	10
La/SS-B	10
alters	0
in	0
dependence	0
on	0
disease	0
conditions	0
.	0

Cross-linking	0
CD40	9
on	0
B	7
cells	8
rapidly	0
activates	0
nuclear	9
factor-kappa	10
B	10
.	0

The	0
B	9
cell-associated	10
surface	10
molecule	10
CD40	10
functions	0
to	0
regulate	0
B	0
cell	0
responses	0
.	0

Cross-linking	0
CD40	9
on	0
B	7
cells	8
can	0
lead	0
to	0
homotypic	0
cell	0
adhesion	0
,	0
IL-6	9
production	0
,	0
and	0
,	0
in	0
combination	0
with	0
cytokines	9
,	0
to	0
Ig	0
isotype	0
switching	0
.	0

Tyrosine	0
kinase	0
activity	0
is	0
increased	0
shortly	0
after	0
engagement	0
of	0
this	0
receptor	0
.	0

Little	0
is	0
known	0
about	0
how	0
the	0
very	0
early	0
events	0
induced	0
by	0
CD40	9
cross-linking	0
link	0
to	0
cellular	0
responses	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
and	0
NF-kappa	9
B-like	10
transcription	10
factors	10
are	0
activated	0
after	0
cross-linking	0
CD40	9
on	0
resting	0
human	7
tonsillar	8
B	8
cells	8
and	0
on	0
B	5
cell	6
lines	6
.	0

The	0
activation	0
is	0
rapid	0
and	0
is	0
mediated	0
through	0
a	0
tyrosine	0
kinase-dependent	0
pathway	0
.	0

The	0
complexes	0
detected	0
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
contain	0
p50	9
,	0
p65	9
(	0
RelA	9
)	0
,	0
c-Rel	9
,	0
and	0
most	0
likely	0
other	0
components	0
.	0

By	0
using	0
transient	0
transfection	0
assays	0
,	0
we	0
found	0
that	0
cross-linking	0
CD40	9
supports	0
NF-kappa	9
B	10
-dependent	0
gene	0
expression	0
.	0

Our	0
results	0
define	0
the	0
NF-kappa	9
B	10
system	0
as	0
an	0
intermediate	0
event	0
in	0
CD40	9
signaling	0
and	0
suggest	0
that	0
the	0
CD40	9
pathway	0
can	0
influence	0
the	0
expression	0
of	0
B	1
cell-associated	2
genes	2
with	0
NF-kappa	1
B	2
consensus	2
sites	2
.	0

Protease	0
inhibitors	0
block	0
lipopolysaccharide	0
induction	0
of	0
tissue	0
factor	0
gene	0
expression	0
in	0
human	7
monocytic	8
cells	8
by	0
preventing	0
activation	0
of	0
c-Rel/p65	9
heterodimers	10
.	0

Tissue	9
factor	10
(	0
TF	9
)	0
is	0
expressed	0
rapidly	0
by	0
human	7
monocytes	8
exposed	0
to	0
bacterial	9
endotoxin	10
(	0
lipopolysaccharide	0
,	0
or	0
LPS	0
)	0
.	0

Transcriptional	0
regulation	0
is	0
mediated	0
by	0
binding	0
of	0
c-Rel/p65	9
heterodimers	10
to	0
a	0
kappa	1
B-like	2
site	2
in	0
the	0
TF	1
promoter	2
.	0

Nuclear	0
translocation	0
of	0
cytosolic	9
c-Rel/p65	10
heterodimers	10
and	0
other	0
members	0
of	0
the	0
NF-kappa	9
B/Rel	10
family	10
requires	0
dissociation	0
and	0
proteolytic	0
degradation	0
of	0
the	0
inhibitor	9
protein	10
,	0
I	9
kappa	10
B	10
alpha	10
.	0

The	0
protease	0
inhibitors	0
N	0
alpha-tosylphenylalanyl	0
chloromethyl	0
ketone	0
(	0
TPCK	0
)	0
and	0
N	0
alpha-tosyl-L-lysine	0
chloromethyl	0
ketone	0
(	0
TLCK	0
)	0
block	0
activation	0
of	0
NF-kappa	9
B/Rel	10
proteins	10
by	0
preventing	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

To	0
determine	0
if	0
TPCK	0
and	0
TLCK	0
inhibited	0
LPS	0
induction	0
of	0
TF	9
expression	0
,	0
freshly	0
isolated	0
human	7
monocytes	8
and	0
monocytic	5
THP-1	6
cells	6
were	0
pretreated	0
with	0
these	0
inhibitors	0
for	0
30	0
min	0
before	0
LPS	0
stimulation	0
.	0

Both	0
TPCK	0
and	0
TLCK	0
inhibited	0
LPS	0
induction	0
of	0
TF	9
protein	10
,	0
TF	3
mRNA	4
and	0
TF	9
promoter	0
activity	0
in	0
a	0
dose-dependent	0
manner	0
.	0

These	0
inhibitors	0
specifically	0
prevented	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
nuclear	0
translocation	0
of	0
c-Rel/p65	9
heterodimers	10
.	0

In	0
contrast	0
,	0
TPCK	0
and	0
TLCK	0
did	0
not	0
block	0
induction	0
of	0
an	0
immediate-early	1
gene	2
encoding	0
the	0
transcription	9
factor	10
,	0
Egr-1	9
.	0

Taken	0
together	0
,	0
these	0
data	0
indicated	0
that	0
inhibiting	0
nuclear	0
translocation	0
of	0
c-Rel/p65	9
heterodimers	10
prevented	0
LPS	0
induction	0
of	0
TF	9
gene	0
transcription	0
in	0
monocytic	7
cells	8
.	0

1	9
,	10
25-Dihydroxyvitamin	10
D3	10
receptors	10
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
patients	0
with	0
primary	0
and	0
secondary	0
hyperparathyroidism	0
.	0

A	0
decreased	0
number	0
of	0
calcitriol	9
(	10
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
)	10
receptors	10
has	0
been	0
observed	0
in	0
parathyroid	0
glands	0
of	0
uremic	0
animals	0
.	0

In	0
humans	0
,	0
studies	0
carried	0
out	0
in	0
surgically	0
removed	0
parathyroid	0
glands	0
have	0
shown	0
that	0
calcitriol	0
binding	0
is	0
higher	0
in	0
primary	0
than	0
in	0
secondary	0
hyperparathyroidism	0
.	0

Since	0
specific	0
receptors	0
for	0
calcitriol	0
have	0
been	0
described	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
,	0
we	0
have	0
investigated	0
the	0
specific	0
uptake	0
of	0
3H-labelled	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
in	0
PBMC	7
of	0
12	0
women	0
with	0
primary	0
hyperparathyroidism	0
(	0
PHP	0
)	0
,	0
8	0
women	0
with	0
hyperparathyroidism	0
secondary	0
to	0
chronic	0
renal	0
failure	0
(	0
SH	0
)	0
,	0
9	0
women	0
with	0
renal	0
transplant	0
(	0
RT	0
)	0
,	0
and	0
23	0
healthy	0
women	0
.	0

The	0
median	0
dissociation	0
constant	0
(	0
Kd	0
)	0
was	0
similar	0
in	0
all	0
three	0
groups	0
of	0
patients	0
and	0
in	0
healthy	0
women	0
(	0
mean	0
+/-	0
S.D.	0
(	0
range	0
)	0
:	0
PHP	0
,	0
1.2	0
+/-	0
1.0	0
(	0
0.2-4	0
)	0
x	0
10	0
(	0
-10	0
)	0
M	0
;	0
SH	0
,	0
0.6	0
+/-	0
0.4	0
(	0
0.2-1.2	0
)	0
x	0
10	0
(	0
-10	0
)	0
M	0
;	0
RT	0
,	0
1.1	0
+/-	0
0.5	0
(	0
0.4-1.9	0
)	0
x	0
10	0
(	0
-10	0
)	0
M	0
;	0
controls	0
,	0
1.0	0
+/-	0
0.6	0
(	0
0.3-2.6	0
)	0
x	0
10	0
(	0
-10	0
)	0
M	0
)	0
.	0
However	0
,	0
the	0
maximal	0
binding	0
capacity	0
(	0
Nmax	0
)	0
was	0
significantly	0
enhanced	0
in	0
PHP	0
(	0
3.9	0
+/-	0
1.9	0
(	0
1.3-7.6	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
vs.	0
2.3	0
+/-	0
0.9	0
(	0
1.1-4.4	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
in	0
controls	0
;	0
P	0
=	0
0.0006	0
)	0
and	0
decreased	0
in	0
SH	0
(	0
0.8	0
+/-	0
0.5	0
(	0
0.2-1.6	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
vs.	0
2.3	0
+/-	0
0.9	0
(	0
1.1-4.4	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
in	0
controls	0
;	0
P	0
=	0
0.0001	0
)	0
,	0
whereas	0
no	0
changes	0
were	0
seen	0
in	0
RT	0
(	0
2.3	0
+/-	0
0.7	0
(	0
1.2-3.3	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
vs.	0
2.3	0
+/-	0
0.9	0
(	0
1.1-4.4	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
in	0
controls	0
)	0
.	0

In	0
three	0
patients	0
with	0
PHP	0
who	0
were	0
subjected	0
to	0
parathyroidectomy	0
,	0
the	0
calcitriol	0
number	0
came	0
down	0
to	0
normal	0
.	0

Changes	0
of	0
calcitriol	9
receptors	10
in	0
primary	0
and	0
secondary	0
hyperparathyroidism	0
could	0
magnify	0
the	0
consequences	0
of	0
disturbances	0
in	0
serum	0
concentration	0
of	0
calcitriol	0
itself	0
and	0
might	0
play	0
an	0
important	0
role	0
in	0
the	0
development	0
of	0
secondary	0
hyperparathyroidism	0
in	0
uremia	0
.	0

The	0
severe	0
phenotype	0
of	0
females	0
with	0
tiny	1
ring	2
X	2
chromosomes	2
is	0
associated	0
with	0
inability	0
of	0
these	0
chromosomes	1
to	0
undergo	0
X	0
inactivation	0
.	0

Mental	0
retardation	0
and	0
a	0
constellation	0
of	0
congenital	0
malformations	0
not	0
usually	0
associated	0
with	0
Turner	0
syndrome	0
are	0
seen	0
in	0
some	0
females	0
with	0
a	0
mosaic	0
45	0
,	0
X/46	0
,	0
X	0
,	0
r	0
(	0
X	0
)	0
karyotype	0
.	0

Studies	0
of	0
these	0
females	0
show	0
that	0
the	0
XIST	1
locus	2
on	0
their	0
tiny	1
ring	2
X	2
chromosomes	2
is	0
either	0
not	0
present	0
or	0
not	0
expressed	0
.	0

As	0
XIST	1
transcription	0
is	0
well	0
correlated	0
with	0
inactivation	0
of	0
the	0
X	1
chromosome	2
in	0
female	7
somatic	8
cells	8
and	0
spermatogonia	7
,	0
nonexpression	0
of	0
the	0
locus	0
even	0
when	0
it	0
is	0
present	0
suggests	0
that	0
these	0
chromosomes	1
are	0
transcriptionally	0
active	0
.	0

We	0
examined	0
the	0
transcriptional	0
activity	0
of	0
ring	0
X	1
chromosomes	2
lacking	0
XIST	1
expression	0
(	0
XISTE-	0
)	0
,	0
from	0
three	0
females	0
with	0
severe	0
phenotypes	0
.	0

The	0
two	0
tiny	0
ring	0
X	1
chromosomes	2
studied	0
with	0
an	0
antibody	9
specific	0
for	0
the	0
acetylated	0
isoforms	0
of	0
histone	9
H4	10
marking	0
transcribed	1
chromatin	2
domains	2
were	0
labeled	0
at	0
a	0
level	0
consistent	0
with	0
their	0
being	0
active	0
.	0

We	0
also	0
examined	0
tow	0
of	0
the	0
XISTE-	1
ring	2
chromosomes	2
to	0
determine	0
whether	0
genes	1
that	0
are	0
normally	0
silent	0
on	0
an	0
inactive	1
X	2
are	0
expressed	0
from	0
these	0
chromosomes	1
.	0

Analyses	0
of	0
hybrid	5
cells	6
show	0
that	0
TIMP	1
,	0
ZXDA	1
,	0
and	0
ZXDB	1
loci	2
on	0
the	0
proximal	1
short	2
arm	2
,	0
and	0
AR	1
and	0
PHKA1	1
loci	2
on	0
the	0
long	0
arm	0
,	0
are	0
well	0
expressed	0
from	0
the	0
tiny	1
ring	2
X	2
chromosome	2
lacking	0
XIST	1
DNA	2
.	0

Studies	0
of	0
the	0
ring	1
chromosome	2
that	0
has	0
XIST	1
DNA	2
but	0
does	0
not	0
transcribe	0
it	0
show	0
that	0
its	0
AR	0
allele	0
is	0
transcribed	0
along	0
with	0
the	0
one	0
on	0
the	0
normal	0
X	0
allele	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Inhibition	0
of	0
activation	0
of	0
transcription	9
factor	10
AP-1	10
by	0
CD28	9
signalling	0
in	0
human	7
T-cells	8
.	0

Co-stimulation	0
of	0
T-lymphocytes	7
by	0
T-cell	9
receptor	10
(	0
TcR	9
)	0
occupancy	0
and	0
activation	0
of	0
the	0
CD28	9
surface	10
molecule	10
results	0
in	0
enhanced	0
proliferation	0
and	0
interleukin	9
2	10
(	0
IL-2	9
)	0
production	0
.	0

The	0
increase	0
in	0
IL-2	9
gene	0
expression	0
triggered	0
by	0
CD28	9
involves	0
a	0
kappa	1
B-like	2
sequence	2
in	0
the	0
5'-regulatory	1
region	2
of	0
the	0
IL-2	1
promoter	2
,	0
called	0
CD28-responsive	1
element	2
.	0

Stimulation	0
of	0
T-cells	7
by	0
agonistic	0
anti-CD28	9
antibodies	10
in	0
conjunction	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
-	0
or	0
TcR	9
-derived	0
signals	0
induces	0
the	0
enhanced	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
.	0

Here	0
we	0
report	0
that	0
CD28	9
engagement	0
,	0
however	0
,	0
exerts	0
opposite	0
effects	0
on	0
the	0
transcription	9
factor	10
AP-1	10
.	0

Whereas	0
anti-CD28	9
together	0
with	0
PMA	0
increased	0
the	0
DNA	0
binding	0
and	0
trans-activation	0
activity	0
of	0
NF-kappa	9
B	10
,	0
PMA-induced	0
activation	0
of	0
AP-1	9
was	0
significantly	0
suppressed	0
.	0

The	0
inhibitory	0
effect	0
exerted	0
by	0
anti-CD28	9
was	0
observed	0
at	0
the	0
level	0
of	0
DNA	0
binding	0
as	0
well	0
as	0
in	0
functional	0
reporter-gene	0
assays	0
.	0

These	0
results	0
suggest	0
that	0
the	0
two	0
transcription	9
factors	10
are	0
independently	0
regulated	0
and	0
may	0
perform	0
different	0
functions	0
during	0
T-cell	0
activation	0
.	0

HIV-1	9
Nef	10
leads	0
to	0
inhibition	0
or	0
activation	0
of	0
T	7
cells	8
depending	0
on	0
its	0
intracellular	0
localization	0
.	0

Nef	9
of	0
primate	0
lentiviruses	0
is	0
required	0
for	0
viremia	0
and	0
progression	0
to	0
AIDS	0
in	0
monkeys	0
.	0

Negative	0
,	0
positive	0
,	0
and	0
no	0
effects	0
of	0
Nef	9
have	0
also	0
been	0
reported	0
on	0
viral	0
replication	0
in	0
cells	0
.	0

To	0
reconcile	0
these	0
observations	0
,	0
we	0
expressed	0
a	0
hybrid	9
CD8-Nef	10
protein	10
in	0
Jurkat	5
cells	6
.	0

Two	0
opposite	0
phenotypes	0
were	0
found	0
,	0
which	0
depended	0
on	0
the	0
intracellular	0
localization	0
of	0
Nef	9
.	0

Expressed	0
in	0
the	0
cytoplasm	0
or	0
on	0
the	0
cell	0
surface	0
,	0
the	0
chimera	9
inhibited	0
or	0
activated	0
early	0
signaling	0
events	0
from	0
the	0
T	9
cell	10
antigen	10
receptor	10
.	0

Activated	0
Jurkat	5
cells	6
died	0
by	0
apoptosis	0
,	0
and	0
only	0
cells	0
with	0
mutated	0
nef	1
genes	2
expressing	0
truncated	0
Nefs	9
survived	0
,	0
which	0
rendered	0
Nef	9
nonfunctional	0
.	0

These	0
mutations	0
paralleled	0
those	0
in	0
other	0
viral	0
strains	0
passaged	0
in	0
vitro	0
.	0

Not	0
only	0
do	0
these	0
positional	0
effects	0
of	0
Nef	9
reconcile	0
diverse	0
phenotypes	0
of	0
Nef	9
and	0
suggest	0
a	0
role	0
for	0
its	0
N-terminal	0
myristylation	0
,	0
but	0
they	0
also	0
explain	0
effects	0
of	0
Nef	9
in	0
HIV	0
infection	0
and	0
progression	0
to	0
AIDS	0
.	0

An	0
intricate	0
arrangement	0
of	0
binding	0
sites	0
for	0
the	0
Ets	9
family	10
of	0
transcription	9
factors	10
regulates	0
activity	0
of	0
the	0
alpha	1
4	2
integrin	2
gene	2
promoter	2
.	0

alpha	9
4	10
integrins	10
mediate	0
cell-cell	0
and	0
cell-extracellular	0
matrix	0
interactions	0
that	0
are	0
critical	0
for	0
maturation	0
and	0
function	0
of	0
the	0
immune	0
system	0
as	0
well	0
as	0
differentiation	0
of	0
skeletal	0
muscle	0
.	0

Here	0
we	0
examine	0
molecular	0
mechanisms	0
controlling	0
the	0
pattern	0
of	0
alpha	9
4	10
expression	0
.	0

The	0
activity	0
of	0
constructs	0
containing	0
5	1
'	2
deletion	2
mutants	2
of	0
the	0
alpha	1
4	2
gene	2
promoter	2
was	0
compared	0
in	0
transfection	0
assays	0
into	0
cell	5
lines	6
that	0
express	0
alpha	9
4	10
and	0
cell	5
lines	6
that	0
do	0
not	0
.	0

The	0
sequence	0
between	0
position	0
-42	1
and	2
-76	2
base	2
pairs	2
(	0
bp	0
)	0
was	0
required	0
for	0
efficient	0
transcription	0
in	0
cells	0
that	0
express	0
alpha	9
4	10
,	0
but	0
it	0
showed	0
no	0
activity	0
in	0
HeLa	5
cells	6
,	0
which	0
do	0
not	0
express	0
alpha	9
4	10
.	0

Three	0
binding	1
sites	2
for	0
the	0
Ets	9
family	10
of	0
transcription	9
factors	10
are	0
found	0
in	0
this	0
region	0
:	0
two	0
adjacent	0
sites	0
at	0
positions	0
-50	1
and	2
-54	2
bp	2
and	0
a	0
more	0
5	1
'	2
site	2
at	0
position	0
-67	1
bp	2
.	0

Using	0
a	0
series	0
of	0
constructs	0
containing	0
deletions	0
and	0
mutations	0
in	0
this	0
region	0
,	0
we	0
found	0
that	0
the	0
3'-most	1
site	2
alone	0
was	0
sufficient	0
for	0
binding	0
GA-binding	9
protein	10
alpha	10
(	0
GABP	9
alpha	10
)	10
/GABP	10
beta	10
and	0
for	0
a	0
low	0
level	0
of	0
transcriptional	0
activation	0
.	0

When	0
all	0
three	0
sites	0
were	0
present	0
,	0
a	0
second	0
complex	0
``	0
a	0
''	0
was	0
detected	0
,	0
which	0
contains	0
an	0
unknown	0
member	0
of	0
the	0
Ets	9
family	10
.	0

Formation	0
of	0
complex	0
a	0
was	0
cell-type	0
specific	0
and	0
correlated	0
with	0
a	0
high	0
level	0
of	0
transcription	0
.	0

Deletion	0
of	0
the	0
5'-most	1
Ets	2
site	2
had	0
no	0
effect	0
on	0
binding	0
to	0
GABP	9
alpha/GABP	10
beta	10
,	0
but	0
it	0
eliminated	0
a	0
.	0

Concomitant	0
with	0
this	0
loss	0
of	0
a	0
,	0
a	0
new	9
Ets-1-containing	10
complex	10
``	0
c	9
``	0
appeared	0
.	0

Complex	0
c	0
substituted	0
efficiently	0
for	0
complex	0
a	0
in	0
transcriptional	0
activation	0
.	0

We	0
conclude	0
that	0
although	0
neither	0
of	0
the	0
two	0
5'-most	1
Ets	2
sites	2
alone	0
binds	0
nuclear	9
protein	10
,	0
they	0
appear	0
to	0
act	0
as	0
modulators	0
which	0
control	0
the	0
pattern	0
of	0
Ets	9
proteins	10
that	0
bind	0
the	0
alpha	1
4	2
gene	2
promoter	2
.	0

This	0
arrangement	0
of	0
Ets	1
sites	2
,	0
coupled	0
with	0
the	0
tissue-	0
and	0
developmental-specific	0
expression	0
of	0
Ets	9
members	10
,	0
likely	0
play	0
a	0
key	0
role	0
in	0
defining	0
the	0
pattern	0
of	0
alpha	9
4	10
integrin	10
.	0

Mechanism	0
of	0
antiandrogen	0
action	0
:	0
conformational	0
changes	0
of	0
the	0
receptor	0
.	0

Androgen	3
receptor	4
mRNA	4
was	0
translated	0
in	0
vitro	0
,	0
and	0
androgen-	9
and	10
antiandrogen-bound	10
receptor	10
complexes	10
were	0
studied	0
using	0
limited	0
proteolytic	0
digestion	0
by	0
trypsin	9
.	0

Partial	0
proteolysis	0
of	0
androgen-bound	9
receptor	10
protein	10
resulted	0
in	0
a	0
29-kDa	9
proteolysis-resisting	10
fragment	10
,	0
whereas	0
antiandrogen	0
binding	0
stabilised	0
a	0
35-kDa	9
fragment	10
.	0

Both	0
fragments	0
contain	0
the	0
entire	0
ligand	9
binding	10
domain	10
,	0
and	0
the	0
35-kDa	9
fragment	10
extended	0
into	0
the	0
hinge	9
region	10
of	0
the	0
receptor	0
.	0

Several	0
antiandrogens	0
show	0
agonistic	0
properties	0
for	0
a	0
mutated	9
androgen	10
receptor	10
(	0
LNCaP	5
cell	6
variant	6
)	0
;	0
trypsin	9
digestion	0
of	0
antiandrogen-bound	9
mutated	10
receptor	10
also	0
resulted	0
in	0
a	0
29-kDa	9
fragment	10
.	0

Our	0
results	0
point	0
to	0
an	0
important	0
difference	0
between	0
antiandrogens	0
and	0
antagonists	0
of	0
other	0
steroid	9
hormone	10
receptors	10
.	0

Antiandrogens	0
result	0
in	0
protection	0
of	0
both	0
the	0
hinge	9
region	10
and	0
C-terminus	9
of	0
the	0
androgen	9
receptor	10
agonist	0
proteolytic	0
attack	0
,	0
whereas	0
other	0
studies	0
showed	0
that	0
antiestrogens	0
and	0
antiprogestagens	0
expose	0
the	0
C-terminal	9
end	10
of	0
the	0
ligand	9
binding	10
domain	10
of	0
their	0
respective	0
receptors	0
to	0
protease	9
.	0

Differences	0
in	0
conformation	0
of	0
the	0
hinge	9
region	10
distinguish	0
androgen-bound	9
from	0
antiandrogen-bound	9
receptor	10
complexes	10
,	0
which	0
represents	0
an	0
important	0
feature	0
of	0
antiandrogen	0
action	0
.	0

Activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
in	0
human	5
neuroblastoma	6
cell	6
lines	6
.	0

The	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
a	0
eukaryotic	0
transcription	9
factor	10
.	0

In	0
B	7
cells	8
and	0
macrophages	7
it	0
is	0
constitutively	0
present	0
in	0
cell	0
nuclei	0
,	0
whereas	0
in	0
many	0
other	0
cell	0
types	0
,	0
NF-kappa	9
B	10
translocates	0
from	0
cytosol	0
to	0
nucleus	0
as	0
a	0
result	0
of	0
transduction	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
,	0
phorbol	0
ester	0
,	0
and	0
other	0
polyclonal	0
signals	0
.	0

Using	0
neuroblastoma	5
cell	6
lines	6
as	0
models	0
,	0
we	0
have	0
shown	0
that	0
in	0
neural	7
cells	8
NF-kappa	9
B	10
was	0
present	0
in	0
the	0
cytosol	0
and	0
translocated	0
into	0
nuclei	0
as	0
a	0
result	0
of	0
TNF	9
alpha	10
treatment	0
.	0

The	0
TNF	9
alpha	10
-activated	0
NF-kappa	9
B	10
was	0
transcriptionally	0
functional	0
.	0

NF-kappa	9
B	10
activation	0
by	0
TNF	9
alpha	10
was	0
not	0
correlated	0
with	0
cell	0
differentiation	0
or	0
proliferation	0
.	0

However	0
,	0
reagents	0
such	0
as	0
nerve	9
growth	10
factor	10
(	0
NGF	9
)	0
and	0
the	0
phorbol	0
ester	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
,	0
which	0
induce	0
phenotypical	0
differentiation	0
of	0
the	0
SH-SY5Y	5
neuroblastoma	6
cell	6
line	6
,	0
activated	0
NF-kappa	9
B	10
,	0
but	0
only	0
in	0
that	0
particular	0
cell	5
line	6
.	0

In	0
a	0
NGF-responsive	5
rat	6
pheochromocytoma	6
cell	6
line	6
,	0
PC12	5
,	0
PMA	0
activated	0
NF-kappa	9
B	10
,	0
whereas	0
NGF	9
did	0
not	0
.	0

In	0
other	0
neuroblastoma	5
cell	6
lines	6
,	0
such	0
as	0
SK-N-Be	5
(	6
2	6
)	6
,	0
the	0
lack	0
of	0
PMA	0
induction	0
of	0
differentiation	0
was	0
correlated	0
with	0
the	0
lack	0
of	0
NF-kappa	9
B	10
activation	0
.	0

We	0
found	0
,	0
moreover	0
,	0
that	0
in	0
SK-N-Be	5
(	6
2	6
)	6
cells	6
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
enzymatic	0
activity	0
was	0
much	0
lower	0
compared	0
with	0
that	0
in	0
a	0
control	5
cell	6
line	6
and	0
that	0
the	0
low	0
PKC	9
enzymatic	0
activity	0
was	0
due	0
to	0
low	0
PKC	9
protein	0
expression	0
.	0

NF-kappa	9
B	10
was	0
not	0
activated	0
by	0
retinoic	0
acid	0
,	0
which	0
induced	0
morphological	0
differentiation	0
of	0
all	0
the	0
neuroblastoma	5
cell	6
lines	6
used	0
in	0
the	0
present	0
study	0
.	0

Thus	0
,	0
NF-kappa	9
B	10
activation	0
was	0
not	0
required	0
for	0
neuroblastoma	7
cell	0
differentiation	0
.	0

Furthermore	0
,	0
the	0
results	0
obtained	0
with	0
TNF	9
alpha	10
proved	0
that	0
NF-kappa	9
B	10
activation	0
was	0
not	0
sufficient	0
for	0
induction	0
of	0
neuroblastoma	7
differentiation	0
.	0

ERP	9
,	0
a	0
new	0
member	0
of	0
the	0
ets	9
transcription	10
factor/oncoprotein	10
family	10
:	0
cloning	0
,	0
characterization	0
,	0
and	0
differential	0
expression	0
during	0
B-lymphocyte	0
development	0
.	0

The	0
ets	1
gene	2
family	2
encodes	0
a	0
group	0
of	0
proteins	0
which	0
function	0
as	0
transcription	9
factors	10
under	0
physiological	0
conditions	0
and	0
,	0
if	0
aberrantly	0
expressed	0
,	0
can	0
cause	0
cellular	0
transformation	0
.	0

We	0
have	0
recently	0
identified	0
two	0
regulatory	0
elements	0
in	0
the	0
murine	1
immunoglobulin	2
heavy-chain	2
(	2
IgH	2
)	2
enhancer	2
,	0
pi	1
and	0
microB	1
,	0
which	0
exhibit	0
striking	0
similarity	0
to	0
binding	1
sites	2
for	0
ets-related	1
proteins	2
.	0

To	0
identify	0
ets-related	9
transcriptional	10
regulators	10
expressed	0
in	0
pre-B	7
lymphocytes	8
that	0
may	0
interact	0
with	0
either	0
the	0
pi	1
or	0
the	0
microB	1
site	2
,	0
we	0
have	0
used	0
a	0
PCR	0
approach	0
with	0
degenerate	0
oligonucleotides	0
encoding	0
conserved	0
sequences	0
in	0
all	0
members	0
of	0
the	0
ets	1
family	2
.	0

We	0
have	0
cloned	0
the	0
gene	0
for	0
a	0
new	0
ets-related	9
transcription	10
factor	10
,	0
ERP	9
(	0
ets-related	9
protein	10
)	0
,	0
from	0
the	0
murine	5
pre-B	6
cell	6
line	6
BASC	5
6C2	6
and	0
from	0
mouse	0
lung	0
tissue	0
.	0

The	0
ERP	9
protein	0
contains	0
a	0
region	0
of	0
high	0
homology	0
with	0
the	0
ETS	0
DNA-binding	0
domain	0
common	0
to	0
all	0
members	0
of	0
the	0
ets	9
transcription	10
factor/oncoprotein	10
family	10
.	0

Three	0
additional	0
smaller	0
regions	0
show	0
homology	0
to	0
the	0
ELK-1	0
and	0
SAP-1	9
genes	0
,	0
a	0
subgroup	0
of	0
the	0
ets	1
gene	2
family	2
that	0
interacts	0
with	0
the	0
serum	9
response	10
factor	10
.	0

Full-length	0
ERP	9
expresses	0
only	0
negligible	0
DNA-binding	0
activity	0
by	0
itself	0
.	0

Removal	0
of	0
the	0
carboxy	9
terminus	10
enables	0
ERP	9
to	0
interact	0
with	0
a	0
variety	0
of	0
ets-binding	1
sites	2
including	0
the	0
E74	1
site	2
,	0
the	0
IgH	1
enhancer	2
pi	2
site	2
,	0
and	0
the	0
lck	1
promoter	2
ets	2
site	2
,	0
suggesting	0
a	0
carboxy-terminal	9
negative	10
regulatory	10
domain	10
.	0

At	0
least	0
three	0
ERP-related	9
transcripts	10
are	0
expressed	0
in	0
a	0
variety	0
of	0
tissues	0
.	0

However	0
,	0
within	0
the	0
B-cell	7
lineage	8
,	0
ERP	9
is	0
highly	0
expressed	0
primarily	0
at	0
early	0
stages	0
of	0
B-lymphocyte	7
development	0
,	0
and	0
expression	0
declines	0
drastically	0
upon	0
B-cell	0
maturation	0
,	0
correlating	0
with	0
the	0
enhancer	0
activity	0
of	0
the	0
IgH	1
pi	2
site	2
.	0

These	0
data	0
suggest	0
that	0
ERP	9
might	0
play	0
a	0
role	0
in	0
B-cell	7
development	0
and	0
in	0
IgH	1
gene	2
regulation	0
.	0

Gene	0
for	0
a	0
tissue-specific	9
transcriptional	10
activator	10
(	0
EBF	9
or	0
Olf-1	9
)	0
,	0
expressed	0
in	0
early	7
B	8
lymphocytes	8
,	0
adipocytes	7
,	0
and	0
olfactory	7
neurons	8
,	0
is	0
located	0
on	0
human	1
chromosome	2
5	2
,	0
band	1
q34	2
,	0
and	0
proximal	1
mouse	2
chromosome	2
11	2
.	0

Murine	7
B	8
lymphocytes	8
,	0
adipocytes	7
,	0
and	0
olfactory	7
neurons	8
contain	0
a	0
DNA-binding	9
protein	10
that	0
participates	0
in	0
the	0
regulation	0
of	0
genes	1
encoding	0
tissue-specific	0
components	0
of	0
signal	0
transduction	0
.	0

Purification	0
and	0
cloning	0
of	0
this	0
protein	0
,	0
termed	0
early	0
B-cell	9
factor	10
(	0
EBF	9
)	0
,	0
from	0
murine	7
B	8
lymphocytes	8
and	0
independent	0
cloning	0
of	0
a	0
protein	0
,	0
termed	0
Olf-1	9
,	0
from	0
olfactory	7
neuronal	8
cells	8
revealed	0
virtual	0
complete	0
amino	0
acid	0
sequence	0
identity	0
between	0
these	0
proteins	0
.	0

As	0
a	0
first	0
step	0
towards	0
identifying	0
a	0
human	0
genetic	0
disorder	0
or	0
mouse	0
mutation	0
for	0
which	0
EBF	9
could	0
be	0
a	0
candidate	0
gene	0
,	0
we	0
have	0
chromosomally	0
mapped	0
the	0
corresponding	0
locus	0
in	0
both	0
species	0
.	0

By	0
Southern	0
hybridization	0
analyses	0
of	0
somatic	0
cell	0
hybrid	0
panels	0
with	0
murine	1
cDNA	2
probe	2
,	0
fluorescence	0
chromosomal	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
of	0
human	1
genomic	2
clones	2
,	0
and	0
analysis	0
of	0
recombinant	5
inbred	6
mouse	6
strains	6
,	0
we	0
have	0
found	0
single	0
sites	0
for	0
EBF	1
homologous	2
sequences	2
on	0
human	0
Chromosome	0
(	0
Chr	0
)	0
5	0
,	0
band	1
q34	2
,	0
and	0
on	0
proximal	1
mouse	2
Chr	2
11	2
,	0
in	0
an	0
evolutionarily	1
conserved	2
region	2
.	0

Calcineurin	9
activates	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
in	0
synergy	0
with	0
either	0
protein	9
kinase	10
C	10
or	0
NF-kappa	9
B	10
/AP-1	9
in	0
T	7
cells	8
.	0

Two	0
cis-acting	1
elements	2
GM-kappa	1
B/GC-box	2
and	0
CLE0	1
,	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
gene	2
are	0
required	0
for	0
maximal	0
induction	0
in	0
Jurkat	5
T	6
cells	6
by	0
costimulation	0
with	0
phorbol-12-myristate	0
acetate	0
(	0
PMA	0
)	0
and	0
Ca2+	0
ionophore	0
(	0
A23187	0
)	0
.	0

The	0
GM-kappa	1
B	2
sequence	2
is	0
recognized	0
by	0
NF-kappa	9
B	10
,	0
which	0
is	0
mainly	0
induced	0
by	0
PMA	0
.	0

The	0
CLE0	1
sequence	2
interacts	0
with	0
factors	0
,	0
related	0
to	0
a	0
PMA-induced	9
AP-1	10
and	0
a	0
PMA/A23187-induced	9
NF-AT	10
.	0

We	0
examined	0
whether	0
signal	0
transducing	0
components	0
in	0
T	7
cells	8
can	0
activate	0
transcription	0
of	0
the	0
GM-CSF	1
gene	2
.	0

Cotransfection	0
of	0
NF-kappa	1
B	2
(	2
p50/p65	2
)	2
-	2
or	2
AP-1	2
(	2
c-Jun/c-Fos	2
)	2
-	2
expression	2
vectors	2
into	0
Jurkat	5
cells	6
with	0
a	0
luciferase	1
reporter	2
containing	0
the	0
GM-CSF	1
promoter	2
did	0
not	0
stimulate	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
.	0

In	0
contrast	0
,	0
cotransfection	0
with	0
a	0
combination	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
significantly	0
augmented	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
containing	0
the	0
GM-kappa	1
B/GC-box	2
and	0
the	0
CLE0	1
(	0
AP-1/NF-AT	9
)	0
.	0

Expression	0
of	0
a	0
constitutively	0
active	0
calcineurin	9
(	0
CN	9
)	0
,	0
a	0
Ca2+/calmodulin-dependent	9
protein	10
phosphatase	10
,	0
potentiated	0
by	0
two	0
fold	0
the	0
transcriptional	0
activation	0
by	0
NF-kappa	9
B	10
/AP-1	9
.	0

Both	0
constitutively	0
active	0
forms	0
of	0
CN	9
and	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
synergistically	0
activated	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
.	0

These	0
results	0
suggest	0
that	0
cooperation	0
among	0
NF-kappa	1
B-	2
,	2
AP-1-	2
and	2
NF-AT-binding	2
sequences	2
is	0
required	0
for	0
induction	0
of	0
the	0
GM-CSF	1
gene	2
through	0
PKC-	0
and	0
Ca2+-	0
signaling	0
pathways	0
downstream	0
of	0
T	0
cell	0
activation	0
.	0

Nonpituitary	1
human	2
prolactin	2
gene	2
transcription	0
is	0
independent	0
of	0
Pit-1	9
and	0
differentially	0
controlled	0
in	0
lymphocytes	7
and	0
in	0
endometrial	0
stroma	0
.	0

Expression	0
of	0
the	0
human	1
PRL	2
(	2
hPRL	2
)	2
gene	2
in	0
extrapituitary	0
sites	0
such	0
as	0
the	0
uterus	0
(	0
decidualized	0
endometrial	0
stroma	0
and	0
myometrium	0
)	0
and	0
cells	0
of	0
the	0
hematopoietic	7
lineage	8
is	0
directed	0
by	0
an	0
alternative	1
promoter	2
which	0
is	0
located	0
approximately	0
6	1
kilobases	2
(	2
kb	2
)	2
upstream	2
of	0
the	0
pituitary-specific	1
start	2
site	2
.	0

In	0
order	0
to	0
delineate	0
the	0
tissue-specific	0
mechanisms	0
governing	0
the	0
control	0
of	0
nonpituitary	0
PRL	1
gene	2
expression	0
,	0
we	0
have	0
cloned	0
and	0
sequenced	0
3	1
kb	2
5'-flanking	2
DNA	2
of	0
the	0
upstream	0
decidual/lymphoid	1
(	2
dPRL	2
)	2
promoter	2
.	0

Based	0
on	0
sequence	0
homology	0
we	0
identified	0
two	0
binding	1
motifs	2
for	0
Pit-1	9
and	0
seven	0
half-sites	1
for	0
glucocorticoid	9
receptor/progesterone	10
receptor	10
(	0
PR	9
)	0
binding	0
.	0

We	0
focused	0
our	0
studies	0
on	0
the	0
role	0
of	0
Pit-1	9
and	0
of	0
PR	9
as	0
potential	0
transcriptional	9
regulators	10
,	0
since	0
the	0
POU	9
domain	10
protein	10
Pit-1	9
is	0
essential	0
in	0
the	0
control	0
of	0
pituitary	0
PRL	9
expression	0
,	0
and	0
progesterone	0
induces	0
decidual	0
transformation	0
of	0
the	0
endometrial	0
stroma	0
,	0
a	0
differentiation	0
process	0
during	0
which	0
the	0
decidual	0
PRL	1
gene	2
is	0
activated	0
.	0

We	0
demonstrate	0
in	0
a	0
variety	0
of	0
cell	0
types	0
,	0
including	0
lymphocytes	7
and	0
endometrial	0
stroma	0
,	0
that	0
Pit-1	9
is	0
not	0
involved	0
in	0
the	0
regulation	0
of	0
dPRL	1
promoter/reporter	2
gene	2
constructs	2
carrying	0
3	1
kb	2
5'-flanking	2
DNA	2
.	0

Our	0
experiments	0
also	0
show	0
that	0
activated	0
PR	9
does	0
not	0
confer	0
direct	0
transcriptional	0
control	0
on	0
the	0
dPRL	1
promoter	2
.	0

When	0
we	0
compared	0
the	0
activity	0
of	0
the	0
transfected	0
dPRL	1
promoter	2
in	0
PRL-secreting	7
and	8
nonsecreting	8
lymphoid	8
cells	8
,	0
we	0
found	0
that	0
the	0
3	1
kb	2
5'-flanking	2
region	2
of	0
the	0
dPRL	1
promoter	2
did	0
not	0
contain	0
elements	0
restricting	0
expression	0
to	0
only	0
those	0
lymphocytes	7
that	0
produce	0
PRL	0
but	0
allowed	0
expression	0
of	0
fusion	0
reporter	0
genes	0
irrespective	0
of	0
the	0
status	0
of	0
the	0
endogenous	0
PRL	1
gene	2
.	0

This	0
was	0
in	0
sharp	0
contrast	0
to	0
endometrial	0
cells	0
where	0
3	0
kb	0
5'-flanking	0
DNA	0
conferred	0
strong	0
transcriptional	0
activation	0
on	0
the	0
dPRL	1
promoter	2
in	0
decidualized	0
endometrial	7
stromal	8
cells	8
actively	0
secreting	0
PRL	9
,	0
but	0
did	0
not	0
allow	0
transcription	0
in	0
undifferentiated	0
non-PRL-secreting	7
endometrial	8
stromal	8
cells	8
.	0

Activation	0
of	0
the	0
dPRL	1
promoter	2
construct	0
in	0
these	0
undifferentiated	0
cells	0
could	0
however	0
be	0
induced	0
by	0
the	0
addition	0
of	0
cAMP	0
,	0
in	0
the	0
absence	0
of	0
progesterone	0
,	0
suggesting	0
that	0
a	0
signal	0
transduced	0
through	0
the	0
cAMP	0
signaling	0
pathway	0
is	0
a	0
primary	0
inducer	0
of	0
decidual	0
PRL	1
gene	2
expression	0
.	0

Signals	0
and	0
nuclear	9
factors	10
that	0
regulate	0
the	0
expression	0
of	0
interleukin-4	1
and	2
interleukin-5	2
genes	2
in	0
helper	7
T	8
cells	8
.	0

Mouse	5
thymoma	6
line	6
EL-4	6
cells	6
produce	0
cytokines	9
such	0
as	0
interleukin	9
(	10
IL	10
)	10
-2	10
,	0
IL-3	9
,	0
IL-4	9
,	0
IL-10	9
,	0
and	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
in	0
response	0
to	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
.	0

EL-4	5
cells	6
also	0
produce	0
low	0
levels	0
of	0
IL-5	9
when	0
stimulated	0
by	0
PMA	0
alone	0
;	0
however	0
,	0
cAMP	0
greatly	0
augments	0
PMA-dependent	0
IL-5	9
production	0
.	0

A	0
transient	0
transfection	0
assay	0
revealed	0
that	0
two	0
signals	0
,	0
PMA	0
and	0
cAMP	0
,	0
are	0
required	0
for	0
optimal	0
activation	0
of	0
the	0
IL-5	1
promoter	2
.	0

In	0
contrast	0
,	0
cAMP	0
almost	0
completely	0
inhibited	0
the	0
PMA-dependent	0
activation	0
of	0
the	0
endogenous	1
IL-2	2
gene	2
,	0
as	0
well	0
as	0
the	0
transfected	0
IL-2	1
promoter	2
.	0

These	0
results	0
indicate	0
that	0
the	0
IL-5	1
gene	2
is	0
positively	0
regulated	0
by	0
cAMP	0
in	0
a	0
manner	0
opposite	0
to	0
that	0
for	0
the	0
IL-2	1
gene	2
.	0

One	0
of	0
the	0
nuclear	9
factors	10
(	0
NFs	9
)	0
that	0
regulates	0
the	0
response	0
of	0
the	0
IL-5	1
promoter	2
to	0
cAMP	0
and	0
PMA	0
has	0
properties	0
similar	0
to	0
NF	9
for	0
activated	7
t	8
cell	8
.	0

The	0
P	1
sequence	2
of	0
the	0
IL-4	1
gene	2
,	0
defined	0
as	0
a	0
responsive	1
element	2
for	0
PMA	0
and	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
,	0
shares	0
sequence	0
similarity	0
with	0
the	0
NF	1
kappa	2
B	2
and	2
the	2
NF-activated	2
T	2
cell	2
binding	2
sites	2
.	0

We	0
attempted	0
to	0
determine	0
whether	0
NF	9
(	10
P	10
)	10
,	0
a	0
nuclear	0
factor	0
specific	0
for	0
the	0
P	1
sequence	2
,	0
is	0
related	0
to	0
NF-kappa	9
B	10
and	0
nuclear	9
factor	10
for	10
activated	10
T	10
cell	10
(	0
NF-AT	9
)	0
.	0

In	0
electromobility	0
shift	0
assays	0
both	0
NF-kappa	9
B	10
(	0
P65	9
or	0
P65/P50	9
heterodimer	10
)	0
and	0
NF-AT	9
bound	0
to	0
the	0
P	1
sequence	2
.	0

However	0
,	0
sequence	0
specificity	0
of	0
NF-AT	9
was	0
more	0
similar	0
to	0
that	0
of	0
NF	9
(	10
P	10
)	10
,	0
and	0
only	0
a	0
small	0
amount	0
of	0
P65	9
was	0
detected	0
in	0
NF	9
(	10
P	10
)	10
.	0

These	0
results	0
indicate	0
that	0
a	0
component	0
or	0
components	0
of	0
NF-AT	9
have	0
the	0
potential	0
to	0
reconstitute	0
NF	9
(	10
P	10
)	10
,	0
whereas	0
NF-kappa	9
B	10
alone	0
does	0
not	0
account	0
for	0
NF	9
(	10
P	10
)	10
in	0
Jurkat	0
crude	0
extract	0
.	0

Taken	0
together	0
,	0
these	0
results	0
suggest	0
that	0
NF-AT-like	9
factors	10
are	0
involved	0
in	0
the	0
regulation	0
of	0
IL-4	1
and	2
IL-5	2
genes	2
.	0

Solution	0
structure	0
of	0
a	0
POU-specific	9
homeodomain	10
:	0
3D-NMR	0
studies	0
of	0
human	0
B-cell	9
transcription	10
factor	10
Oct-2	9
.	0

The	0
POU	9
DNA-binding	10
motif	10
defines	0
a	0
conserved	0
family	0
of	0
eukaryotic	9
transcription	10
factors	10
involved	0
in	0
regulation	0
of	0
gene	0
expression	0
.	0

This	0
bipartite	9
motif	10
consists	0
of	0
an	0
N-terminal	9
POU-specific	10
domain	10
(	0
POUs	9
)	0
,	0
a	0
flexible	9
linker	10
,	0
and	0
a	0
C-terminal	9
POU-specific	10
homeodomain	10
(	0
POUHD	9
)	0
.	0

Here	0
we	0
describe	0
the	0
solution	0
structure	0
of	0
a	0
POU-specific	9
homeodomain	10
.	0

An	0
NMR	0
model	0
is	0
obtained	0
from	0
Oct-2	9
,	0
a	0
human	9
B-cell	10
specific	10
transcription	10
factor	10
which	0
participates	0
in	0
the	0
regulation	0
of	0
immunoglobulin	1
genes	2
.	0

A	0
fragment	0
of	0
Oct-2	9
containing	0
POUHD	9
and	0
an	0
adjoining	0
linker	0
was	0
expressed	0
in	0
Escherichia	0
coli	0
and	0
characterized	0
by	0
three-dimensional	0
nuclear	0
magnetic	0
resonance	0
(	0
3D-NMR	0
)	0
spectroscopy	0
.	0

Complete	0
1H	0
and	0
15N	0
resonance	0
assignment	0
of	0
the	0
POUHD	9
moiety	10
is	0
presented	0
.	0

The	0
POUHD	9
solution	0
structure	0
,	0
as	0
calculated	0
by	0
distance	0
geometry	0
and	0
simulated	0
annealing	0
(	0
DG/SA	0
)	0
,	0
is	0
similar	0
to	0
that	0
of	0
canonical	9
homeodomains	10
.	0

A	0
salient	0
difference	0
between	0
solution	0
and	0
crystal	0
structures	0
is	0
observed	0
in	0
the	0
C-terminal	9
segment	10
of	0
alpha-helix	9
3	10
(	0
the	0
HTH	9
recognition	10
helix	10
)	0
,	0
which	0
is	0
not	0
well	0
ordered	0
in	0
solution	0
.	0

Because	0
this	0
segment	0
presumably	0
folds	0
upon	0
specific	0
DNA	0
binding	0
,	0
its	0
flexibility	0
in	0
solution	0
may	0
reduce	0
the	0
intrinsic	0
DNA	0
affinity	0
of	0
POUHD	9
in	0
the	0
absence	0
of	0
POUs	9
.	0

NF-kappa	0
B-dependent	0
and	0
-independent	0
pathways	0
of	0
HIV	0
activation	0
in	0
a	0
chronically	5
infected	6
T	6
cell	6
line	6
.	0

J	5
delta	6
K	6
cells	6
were	0
isolated	0
as	0
a	0
chronically	5
infected	6
survivor	6
cell	6
line	6
,	0
following	0
infection	0
of	0
Jurkat	5
CD4+	6
T	6
cells	6
with	0
dl-NF	0
,	0
a	0
mutated	0
strain	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
containing	0
a	0
deletion	0
of	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
NF-kappa	9
B	10
sites	0
.	0

J	5
delta	6
K	6
cells	6
exhibited	0
very	0
low	0
levels	0
of	0
constitutive	0
HIV	0
production	0
.	0

HIV-1	0
expression	0
was	0
activated	0
from	0
J	5
delta	6
K	6
cells	6
by	0
treatment	0
with	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
,	0
sodium	0
butyrate	0
(	0
NaB	0
)	0
,	0
or	0
hexamethylene	0
bisacetamide	0
(	0
HMBA	0
)	0
,	0
but	0
not	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
,	0
confirming	0
the	0
role	0
of	0
NF-kappa	9
B	10
in	0
mediating	0
TNF-alpha	9
induction	0
of	0
HIV	0
transcription	0
.	0

The	0
strong	0
induction	0
of	0
HIV	0
expression	0
by	0
NaB	0
or	0
HMBA	0
in	0
J	5
delta	6
K	6
cells	6
clearly	0
demonstrates	0
the	0
existence	0
of	0
NF-kappa	9
B	10
-independent	0
mechanisms	0
of	0
HIV	0
activation	0
in	0
chronically	7
infected	8
cells	8
.	0

J	5
delta	6
K	6
cells	6
may	0
provide	0
a	0
useful	0
model	0
for	0
characterizing	0
NF-kappa	9
B	10
-independent	0
transcriptional	0
activation	0
of	0
the	0
HIV	1
LTR	2
.	0

JNK	9
is	0
involved	0
in	0
signal	0
integration	0
during	0
costimulation	0
of	0
T	7
lymphocytes	8
.	0

T	7
lymphocyte	8
activation	0
and	0
interleukin-2	9
(	0
IL-2	9
)	0
production	0
require	0
at	0
least	0
two	0
signals	0
,	0
generated	0
by	0
phorbol	0
ester	0
(	0
TPA	0
)	0
and	0
Ca2+	0
ionophore	0
or	0
costimulation	0
of	0
the	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
and	0
the	0
CD28	9
auxiliary	10
receptor	10
.	0

We	0
investigated	0
how	0
these	0
stimuli	0
affect	0
mitogen	9
activated	10
protein	10
(	10
MAP	10
)	10
kinases	10
.	0

Full	0
activation	0
of	0
the	0
MAP	9
kinases	10
that	0
phosphorylate	0
the	0
Jun	9
activation	10
domain	10
,	0
JNK1	9
and	0
JNK2	9
,	0
required	0
costimulation	0
of	0
T	7
cells	8
with	0
either	0
TPA	0
and	0
Ca2+	0
ionophore	0
or	0
antibodies	0
to	0
TCR	9
and	0
CD28	9
.	0

Alone	0
,	0
each	0
stimulus	0
resulted	0
in	0
little	0
or	0
no	0
activation	0
.	0

Similar	0
to	0
its	0
effect	0
on	0
IL-2	9
induction	0
,	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
inhibited	0
the	0
synergistic	0
activation	0
of	0
JNK	9
,	0
and	0
a	0
competitive	0
inhibitor	0
of	0
Jun	9
phosphorylation	0
by	0
JNK	9
inhibited	0
IL-2	1
promoter	2
activation	0
.	0

By	0
contrast	0
,	0
the	0
MAP	9
kinases	10
ERK1	9
and	0
ERK2	9
were	0
fully	0
activated	0
by	0
TPA	0
or	0
TCR	9
stimulation	0
and	0
were	0
not	0
affected	0
by	0
Ca2+	0
,	0
CD28	0
,	0
or	0
CsA	0
.	0

Hence	0
,	0
integration	0
of	0
signals	0
that	0
lead	0
to	0
T	0
cell	0
activation	0
occurs	0
at	0
the	0
level	0
of	0
JNK	9
activation	0
.	0

Inhibition	0
of	0
rat	7
splenocyte	8
proliferation	0
with	0
methylprednisolone	0
:	0
in	0
vivo	0
effect	0
of	0
liposomal	0
formulation	0
.	0

The	0
effect	0
of	0
a	0
liposomal	0
formulation	0
of	0
methylprednisolone	0
(	0
MPL	0
)	0
on	0
the	0
inhibition	0
of	0
lymphocyte	0
proliferation	0
in	0
spleen	7
cells	8
was	0
investigated	0
following	0
IV	0
dosing	0
in	0
rats	0
.	0

Liposomes	0
do	0
not	0
alter	0
the	0
suppressive	0
action	0
of	0
MPL	0
when	0
placed	0
in	0
lymphocyte	5
culture	6
.	0

Rat	7
splenocytes	8
were	0
found	0
to	0
have	0
greater	0
sensitivity	0
to	0
MPL	0
(	0
EC50	0
=	0
7.9	0
nM	0
)	0
than	0
do	0
human	7
peripheral	8
blood	8
lymphocytes	8
(	0
EC50	0
=	0
28	0
nM	0
)	0
.	0

In	0
vivo	0
studies	0
in	0
rats	0
utilized	0
2	0
mg/kg	0
IV	0
bolus	0
doses	0
of	0
liposomal	0
MPL	0
compared	0
to	0
drug	0
in	0
solution	0
.	0

Animals	0
were	0
sacrificed	0
at	0
various	0
times	0
post-dosing	0
until	0
120	0
h	0
,	0
spleen	0
was	0
excised	0
and	0
,	0
after	0
incubation	0
of	0
lymphocytes	7
with	0
PHA	9
,	0
splenocyte	0
blastogenic	0
responses	0
were	0
assessed	0
by	0
measuring	0
cellular	0
incorporation	0
of	0
3H-thymidine	0
.	0

The	0
suppressive	0
effect	0
of	0
liposomal	0
MPL	0
in	0
comparison	0
with	0
free	0
drug	0
was	0
significantly	0
prolonged	0
(	0
>	0
120	0
h	0
vs	0
<	0
18	0
h	0
)	0
.	0

Inhibition	0
effects	0
versus	0
time	0
were	0
described	0
by	0
a	0
pharmacodynamic	0
model	0
using	0
MPL	0
concentrations	0
in	0
plasma	7
as	0
an	0
input	0
function	0
.	0

A	0
nonlinear	0
relationship	0
was	0
found	0
between	0
suppression	0
of	0
splenocyte	7
proliferation	0
and	0
the	0
concentration	0
of	0
bound	0
glucocorticoid	9
receptors	10
in	0
spleen	0
.	0

Only	0
partial	0
receptor	0
occupancy	0
accompanied	0
complete	0
lymphocyte	0
suppression	0
.	0

The	0
suppression	0
of	0
endogenous	0
corticosterone	0
in	0
plasma	7
for	0
both	0
treatments	0
was	0
similar	0
with	0
values	0
from	0
L-MPL	0
rats	0
returning	0
to	0
baseline	0
after	0
24	0
h	0
.	0

These	0
results	0
demonstrate	0
enhanced	0
efficacy	0
of	0
local	0
immunosuppression	0
by	0
targeting	0
spleen	0
with	0
liposomal	0
MPL	0
.	0

Function	0
of	0
NF-kappa	1
B/Rel	2
binding	2
sites	2
in	0
the	0
major	1
histocompatibility	2
complex	2
class	2
II	2
invariant	2
chain	2
promoter	2
is	0
dependent	0
on	0
cell-specific	0
binding	0
of	0
different	0
NF-kappa	9
B/Rel	10
subunits	10
.	0

The	0
promoter	1
of	0
the	0
human	0
major	0
histocompatibility	1
complex	2
class	2
II-associated	2
invariant-chain	2
gene	2
(	0
Ii	1
)	0
contains	0
two	0
NF-kappa	1
B/Rel	2
binding	2
sites	2
located	0
at	0
-109	1
to	2
-118	2
(	0
Ii	1
kappa	2
B-1	2
)	0
and	0
-163	1
to	2
-172	2
(	0
Ii	1
kappa	2
B-2	2
)	0
from	0
the	0
transcription	0
start	0
site	0
.	0

We	0
report	0
here	0
that	0
the	0
differential	0
function	0
of	0
each	0
of	0
these	0
NF-kappa	1
B/Rel	2
sites	2
in	0
several	0
distinct	0
cell	0
types	0
depends	0
on	0
cell-specific	0
binding	0
of	0
NF-kappa	9
B/Rel	10
transcription	10
factors	10
.	0

Ii	1
kappa	2
B-1	2
is	0
a	0
positive	1
regulatory	2
element	2
in	0
B-cell	5
lines	6
and	0
in	0
the	0
Ii-expressing	5
T-cell	6
line	6
,	0
H9	5
,	0
but	0
acts	0
as	0
a	0
negative	1
regulatory	2
element	2
in	0
myelomonocytic	5
and	6
glia	6
cell	6
lines	6
.	0

In	0
vivo	0
protein-DNA	0
contacts	0
are	0
detectable	0
at	0
Ii	1
kappa	2
B-1	2
in	0
cell	5
lines	6
in	0
which	0
this	0
site	0
is	0
functional	0
as	0
either	0
a	0
positive	1
or	2
negative	2
regulator	2
.	0

Electrophoretic	0
mobility	0
supershift	0
assays	0
determine	0
that	0
members	0
of	0
the	0
NF-kappa	9
B/Rel	10
family	10
of	0
transcription	9
factors	10
can	0
bind	0
to	0
this	0
site	0
in	0
vitro	0
and	0
that	0
DNA-binding	9
complexes	10
that	0
contain	0
p50	9
,	0
p52	9
,	0
p65	9
,	0
and	0
cRel	9
correlate	0
with	0
positive	0
regulation	0
whereas	0
the	0
presence	0
of	0
p50	9
correlates	0
with	0
negative	0
regulation	0
.	0

Ii	1
kappa	2
B-2	2
is	0
a	0
site	0
of	0
positive	0
regulation	0
in	0
B-cell	5
lines	6
and	0
a	0
site	0
of	0
negative	0
regulation	0
in	0
H9	5
T	6
cells	6
,	0
myelomonocytic	5
,	6
and	6
glial	6
cell	6
lines	6
.	0

In	0
vivo	0
occupancy	0
of	0
this	0
site	0
is	0
observed	0
only	0
in	0
the	0
H9	5
T-cell	6
line	6
.	0

Again	0
,	0
in	0
vitro	0
supershift	0
studies	0
indicate	0
that	0
the	0
presence	0
of	0
p50	9
,	0
p52	9
,	0
p65	9
,	0
and	0
cRel	9
correlates	0
with	0
positive	0
function	0
whereas	0
the	0
presence	0
of	0
only	0
p50	9
and	0
p52	9
correlates	0
with	0
negative	0
function	0
.	0

This	0
differential	0
binding	0
of	0
specific	0
NF-kappa	9
B/Rel	10
subunits	10
is	0
likely	0
to	0
mediate	0
the	0
disparate	0
functions	0
of	0
these	0
two	0
NF-kappa	1
B/Rel	2
binding	2
sites	2
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
replicative	0
gene	0
expression	0
in	0
tumour	7
cells	8
of	0
AIDS-related	0
non-Hodgkin	0
's	0
lymphoma	0
in	0
relation	0
to	0
CD4	9
cell	0
number	0
and	0
antibody	0
titres	0
to	0
EBV	0
.	0

OBJECTIVE	0
:	0
To	0
determine	0
whether	0
activation	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
replication	0
in	0
tumour	7
cells	8
of	0
AIDS-related	0
non-Hodgkin	0
's	0
lymphoma	0
(	0
ARNHL	0
)	0
is	0
correlated	0
with	0
CD4+	9
cell	0
counts	0
and	0
influences	0
antibody	0
response	0
to	0
EBV	0
[	0
anti-Z	9
Epstein-Barr	10
replicative	10
activator	10
(	0
ZEBRA	9
)	0
,	0
anti-early	9
antigen	10
(	0
EA	9
)	0
,	0
anti-viral	9
capsid	10
antigen	10
(	0
VCA	9
)	0
]	0
.	0

DESIGN	0
:	0
Retrospective	0
study	0
based	0
on	0
immunohistochemistry	0
and	0
in	0
situ	0
hybridization	0
to	0
detect	0
EBV	0
replicative	0
gene	0
products	0
in	0
tissue	0
samples	0
from	0
patients	0
affected	0
by	0
ARNHL	0
and	0
correlation	0
with	0
CD4+	9
cell	0
counts	0
and	0
results	0
of	0
EBV	0
serology	0
(	0
including	0
anti-	0
ZEBRA	9
activity	0
)	0
in	0
sera	0
from	0
the	0
same	0
patients	0
.	0

METHODS	0
:	0
Seventeen	0
out	0
of	0
22	0
cases	0
of	0
ARNHL	0
were	0
selected	0
for	0
the	0
presence	0
of	0
EBV	0
[	0
Epstein-Barr	0
early	0
region	0
(	0
EBER	0
)	0
RNA-positive	0
]	0
.	0

Immunohistochemistry	0
was	0
performed	0
with	0
anti-ZEBRA	9
,	0
anti-EA-restricted	9
,	10
anti-VCA	10
antibodies	10
and	0
in	0
situ	0
hybridization	0
with	0
BHLF1/NotI	0
oligoprobes	0
on	0
tumour	0
samples	0
.	0

Results	0
were	0
statistically	0
correlated	0
with	0
those	0
of	0
CD4+	9
cell	0
counts	0
(	0
17	0
out	0
of	0
17	0
)	0
and	0
with	0
anti-EBV	0
antibody	0
titres	0
(	0
13	0
out	0
of	0
17	0
)	0
assessed	0
using	0
standard	0
immunofluorescence	0
method	0
and	0
enzyme-linked	0
immunosorbent	0
assay	0
procedure	0
using	0
recombinant	9
ZEBRA	10
protein	10
and	0
synthetic	0
peptides	0
as	0
antigens	9
.	0

RESULTS	0
:	0
BZLF1	9
(	0
ZEBRA	9
)	0
or	0
early	9
gene	10
products	10
(	0
EA-R	9
and	0
EA-D/BHLF1/NotI	9
)	0
were	0
detected	0
in	0
a	0
small	0
proportion	0
(	0
<	0
0.01-5	0
%	0
)	0
of	0
tumour	7
cells	8
in	0
eight	0
of	0
these	0
17	0
cases	0
by	0
immunohistochemistry	0
and	0
in	0
situ	0
hybridization	0
.	0

Demonstration	0
of	0
replicative	0
gene	0
expression	0
did	0
not	0
correlate	0
with	0
either	0
low	0
CD4+	9
cell	0
counts	0
(	0
P	0
>	0
0.05	0
)	0
or	0
anti-EBV	0
antibody	0
titres	0
(	0
P	0
>	0
0.05	0
)	0
.	0

Anti-	0
ZEBRA	9
activity	0
was	0
not	0
significantly	0
increased	0
in	0
patients	0
affected	0
with	0
ARNHL	0
,	0
the	0
cells	0
of	0
which	0
expressed	0
replicative	0
gene	0
products	0
(	0
P	0
>	0
0.05	0
)	0
.	0

CONCLUSION	0
:	0
The	0
degree	0
of	0
immunodeficiency	0
does	0
not	0
clearly	0
enhance	0
replicative	0
gene	0
expression	0
in	0
tumour	7
cells	8
of	0
ARNHL	0
.	0

EBV	0
serology	0
,	0
including	0
anti-	0
ZEBRA	9
activity	0
,	0
is	0
not	0
a	0
reliable	0
tool	0
for	0
predicting	0
the	0
occurrence	0
of	0
such	0
proliferations	0
.	0

Effects	0
of	0
prostaglandin	9
E2	10
on	0
Th0-type	5
human	6
T	6
cell	6
clones	6
:	0
modulation	0
of	0
functions	0
of	0
nuclear	9
proteins	10
involved	0
in	0
cytokine	9
production	0
.	0

The	0
effects	0
of	0
prostaglandin	9
E2	10
(	0
PGE2	9
)	0
on	0
cytokine	9
production	0
and	0
proliferation	0
of	0
the	0
CD4+	5
human	6
helper	6
T	6
cell	6
clone	6
SP-B21	6
were	0
investigated	0
.	0

In	0
cells	0
stimulated	0
with	0
anti-CD3	9
mAb	10
,	0
PGE2	9
inhibited	0
cell	0
proliferation	0
and	0
the	0
production	0
of	0
all	0
the	0
cytokines	9
examined	0
.	0

Addition	0
of	0
rIL-2	9
fully	0
restored	0
the	0
proliferative	0
response	0
and	0
partially	0
restored	0
the	0
production	0
of	0
IL-4	9
and	0
IL-5	9
,	0
but	0
not	0
that	0
of	0
other	0
cytokines	9
.	0

In	0
contrast	0
,	0
in	0
cells	0
stimulated	0
with	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
/A23187	0
,	0
PGE2	9
enhanced	0
the	0
production	0
of	0
IL-4	9
and	0
IL-5	9
,	0
and	0
only	0
partially	0
inhibited	0
the	0
production	0
of	0
other	0
cytokines	9
.	0

Therefore	0
,	0
the	0
effects	0
of	0
PGE2	9
vary	0
depending	0
on	0
the	0
mode	0
of	0
T	0
cell	0
activation	0
,	0
and	0
the	0
IL-4	9
and	0
IL-5	9
are	0
regulated	0
differently	0
from	0
other	0
cytokines	9
.	0

In	0
a	0
mobility	0
shift	0
assay	0
,	0
only	0
the	0
NF-kappa	9
B	10
(	10
p50/p50	10
)	10
homodimer	10
was	0
observed	0
in	0
a	0
complex	0
formed	0
with	0
the	0
kappa	1
B	2
sequence	2
in	0
unstimulated	0
SP-B21	0
cells	0
.	0

When	0
cells	0
were	0
stimulated	0
with	0
anti-CD3	9
mAb	10
or	0
PMA/A23187	0
,	0
a	0
complex	0
formation	0
of	0
NF-kappa	9
B	10
(	0
p50	9
/p65	9
)	0
heterodimer	0
with	0
the	0
kappa	1
B	2
sequence	2
was	0
induced	0
.	0

Interestingly	0
,	0
PGE2	9
or	0
di-butyryl	0
(	0
Bt2	0
)	0
cAMP	0
abolished	0
the	0
binding	0
of	0
NF-kappa	9
B	10
(	10
p50/p65	10
)	10
heterodimer	10
to	0
the	0
kappa	1
B	2
sequence	2
in	0
cells	0
stimulated	0
with	0
anti-CD3	9
mAb	10
but	0
not	0
with	0
PMA/A23187	0
.	0

Our	0
results	0
suggest	0
that	0
the	0
target	0
of	0
PGE2	9
action	0
is	0
a	0
component	0
in	0
the	0
signal	0
transduction	0
pathway	0
leading	0
to	0
the	0
activation	0
of	0
protein	9
kinase	10
C	10
.	0

However	0
,	0
the	0
inhibition	0
of	0
the	0
T	0
cell	0
activation	0
signals	0
by	0
PGE2	9
is	0
selective	0
.	0

PGE2	9
enhanced	0
the	0
complex	0
formation	0
with	0
NF-AT	1
,	2
AP-1	2
and	2
CLE0	2
sequences	2
when	0
the	0
cells	0
were	0
activated	0
by	0
either	0
anti-CD3	9
mAb	10
or	0
PMA/A23187	0
stimulation	0
.	0

It	0
seems	0
therefore	0
that	0
PGE2	9
,	0
by	0
elevating	0
cAMP	0
levels	0
,	0
interferes	0
with	0
the	0
activation	0
pathway	0
for	0
NF-kappa	9
B	10
but	0
not	0
for	0
NF-AT	9
,	0
AP-1	9
or	0
CLE0	9
binding	10
protein	10
.	0

Characterization	0
of	0
NF	9
(	10
P	10
)	10
,	0
the	0
nuclear	9
factor	10
that	0
interacts	0
with	0
the	0
regulatory	0
P	1
sequence	2
(	0
5'-CGAAAATTTCC-3	0
'	0
)	0
of	0
the	0
human	1
interleukin-4	2
gene	2
:	0
relationship	0
to	0
NF-kappa	9
B	10
and	0
NF-AT	9
.	0

The	0
P	1
sequence	2
of	0
the	0
human	1
interleukin-4	2
(	2
IL-4	2
)	2
gene	2
,	0
which	0
was	0
defined	0
as	0
a	0
responsive	1
element	2
for	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
in	0
Jurkat	5
T	6
cells	6
,	0
shares	0
sequence	0
similarity	0
with	0
the	0
NF-kappa	1
B	2
and	2
the	2
NF-AT	2
binding	2
sites	2
.	0

We	0
examined	0
whether	0
NF	9
(	10
P	10
)	10
,	0
a	0
nuclear	9
factor	10
specific	0
for	0
the	0
P	1
sequence	2
,	0
is	0
related	0
to	0
NF-kappa	9
B	10
and	0
NF-AT	9
.	0

NF-kappa	9
B	10
(	0
P65	9
or	0
P65/P50	9
heterodimer	10
)	0
bound	0
to	0
the	0
P	1
sequence	2
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
and	0
activated	0
transcription	0
through	0
the	0
P	1
sequence	2
when	0
expression	1
plasmids	2
were	0
cotransfected	0
with	0
P	1
sequence-driven	2
reporter	2
plasmids	2
in	0
Jurkat	5
T	6
cells	6
.	0

In	0
EMSAs	0
,	0
NF	9
(	10
P	10
)	10
binding	0
was	0
inhibited	0
by	0
the	0
unlabeled	1
NF-AT	2
binding	2
site	2
but	0
not	0
by	0
the	0
unlabeled	1
AP1	2
binding	2
site	2
and	0
purified	9
NF-AT	10
contained	0
an	0
activity	0
that	0
bound	0
to	0
the	0
P	1
sequence	2
.	0

Both	0
mobility	0
shift	0
and	0
sequence	0
specificity	0
of	0
NF-AT	9
were	0
similar	0
to	0
those	0
of	0
NF	9
(	10
P	10
)	10
and	0
only	0
a	0
small	0
amount	0
of	0
P65	9
was	0
detected	0
in	0
NF	9
(	10
P	10
)	10
in	0
crude	0
nuclear	0
extracts	0
.	0

These	0
results	0
indicate	0
that	0
the	0
component	0
(	0
s	0
)	0
of	0
NF-AT	9
has	0
the	0
potential	0
to	0
reconstitute	0
NF	9
(	10
P	10
)	10
whereas	0
NF-kappa	9
B	10
alone	0
can	0
not	0
account	0
for	0
NF	9
(	10
P	10
)	10
in	0
crude	0
extracts	0
.	0

Unlike	0
NF-AT	9
,	0
NF	9
(	10
P	10
)	10
does	0
not	0
contain	0
AP1	9
as	0
its	0
DNA	9
binding	10
component	10
.	0

Activation	0
of	0
early	1
growth	2
response	2
1	2
gene	2
transcription	0
and	0
pp90rsk	9
during	0
induction	0
of	0
monocytic	0
differentiation	0
.	0

The	0
present	0
work	0
has	0
studied	0
mechanisms	0
responsible	0
for	0
induction	0
of	0
early	1
growth	2
response	2
1	2
(	2
EGR-1	2
)	2
gene	2
expression	0
during	0
monocytic	0
differentiation	0
of	0
U-937	5
myeloid	6
leukemia	6
cells	6
.	0

Differentiation	0
of	0
U-937	5
cells	6
with	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
,	0
an	0
activator	0
of	0
the	0
serine/threonine	9
protein	10
kinase	10
C	10
,	0
was	0
associated	0
with	0
transcriptional	0
activation	0
of	0
EGR-1	1
promoter-reporter	2
constructs	2
.	0

The	0
EGR-1	1
promoter	2
contains	0
six	0
CC	0
(	0
A/T	0
)	0
6GG	0
(	0
CArG	0
)	0
motifs	0
.	0

The	0
two	0
5'-most	1
distal	2
CArG	2
sequences	2
conferred	0
TPA	0
inducibility	0
.	0

In	0
contrast	0
,	0
there	0
was	0
little	0
effect	0
of	0
TPA	0
on	0
EGR-1	1
transcription	0
in	0
a	0
TPA-resistant	5
U-937	6
cell	6
variant	6
,	0
designated	0
TUR	5
.	0

Treatment	0
of	0
both	0
U-937	5
and	0
TUR	5
cells	6
with	0
okadaic	0
acid	0
,	0
an	0
inhibitor	0
of	0
serine/threonine	9
protein	10
phosphatases	10
1	10
and	10
2A	10
,	0
was	0
associated	0
with	0
induction	0
of	0
monocytic	0
differentiation	0
and	0
EGR-1	1
transcription	0
through	0
the	0
5'-most	1
CArG	2
element	2
.	0

Since	0
these	0
findings	0
supported	0
the	0
involvement	0
of	0
serine/threonine	0
protein	0
phosphorylation	0
in	0
the	0
regulation	0
of	0
EGR-1	1
expression	0
,	0
we	0
studied	0
activation	0
of	0
the	0
40S	9
ribosomal	10
protein	10
S6	10
serine/threonine	10
kinases	10
,	0
pp70S6K	9
and	0
pp90rsk	9
.	0

Although	0
both	0
kinases	0
participate	0
in	0
regulating	0
cell	0
growth	0
,	0
there	0
was	0
no	0
detectable	0
activation	0
of	0
pp70S6K	9
during	0
TPA-	0
or	0
okadaic	0
acid-induced	0
monocytic	0
differentiation	0
.	0

Moreover	0
,	0
rapamycin	0
,	0
an	0
inhibitor	0
of	0
pp70S6K	9
activation	0
,	0
had	0
no	0
effect	0
on	0
induction	0
of	0
EGR-1	1
expression	0
.	0

In	0
contrast	0
,	0
analysis	0
of	0
pp90rsk	9
activity	0
by	0
phosphorylation	0
of	0
a	0
peptide	0
derived	0
from	0
S6	9
protein	10
demonstrated	0
stimulation	0
of	0
this	0
kinase	9
in	0
TPA-treated	5
U-937	6
,	6
and	6
not	6
TUR	6
,	6
cells	6
.	0

Okadaic	0
acid	0
treatment	0
of	0
both	0
cell	0
types	0
was	0
associated	0
with	0
activation	0
of	0
pp90rsk	9
.	0

Antioxidants	0
inhibit	0
monocyte	7
adhesion	0
by	0
suppressing	0
nuclear	9
factor-kappa	10
B	10
mobilization	0
and	0
induction	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
in	0
endothelial	7
cells	8
stimulated	0
to	0
generate	0
radicals	0
.	0

Cell	0
adhesion	0
to	0
endothelial	7
cells	8
stimulated	9
by	10
tumor	10
necrosis	10
factor-alpha	10
(	0
TNF	9
)	0
is	0
due	0
to	0
induction	0
of	0
surface	9
receptors	10
,	0
such	0
as	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
.	0

The	0
antioxidant	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
specifically	0
inhibits	0
activation	0
of	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

Since	0
kappa	1
B	2
motifs	2
are	0
present	0
in	0
VCAM-1	1
and	2
intercellular	2
adhesion	2
molecule-1	2
(	2
ICAM-1	2
)	2
promoters	2
,	0
we	0
used	0
PDTC	0
to	0
study	0
the	0
regulatory	0
mechanisms	0
of	0
VCAM-1	9
and	0
ICAM-1	9
induction	0
and	0
subsequent	0
monocyte	7
adhesion	0
in	0
TNF-treated	5
human	6
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVECs	5
)	0
.	0

PDTC	0
or	0
N-acetylcysteine	0
dose	0
dependently	0
reduced	0
TNF-induced	9
VCAM-1	10
but	0
not	0
ICAM-1	9
surface	10
protein	10
(	0
also	0
in	0
human	7
umbilical	8
arterial	8
endothelial	8
cells	8
)	0
and	0
mRNA	0
expression	0
(	0
by	0
70	0
%	0
at	0
100	0
mumol/L	0
PDTC	0
)	0
in	0
HUVECs	5
as	0
assessed	0
by	0
flow	0
cytometry	0
and	0
polymerase	0
chain	0
reaction	0
.	0

Gel-shift	0
analysis	0
in	0
HUVECs	5
demonstrated	0
that	0
PDTC	0
prevented	0
NF-kappa	9
B	10
mobilization	0
by	0
TNF	9
,	0
suggesting	0
that	0
only	0
VCAM-1	9
induction	0
was	0
controlled	0
by	0
NF-kappa	9
B	10
.	0

Since	0
HUVECs	5
released	0
superoxide	0
anions	0
in	0
response	0
to	0
TNF	0
,	0
and	0
H2O2	0
induces	0
VCAM-1	9
,	0
PDTC	0
may	0
act	0
as	0
a	0
radical	0
scavenger	0
.	0

Although	0
ICAM-1	9
induction	0
was	0
unaffected	0
,	0
inhibitors	0
of	0
NADPH	9
oxidase	10
(	0
apocynin	0
)	0
or	0
cytochrome	9
P-450	10
(	0
SKF525a	0
)	0
suppressed	0
VCAM-1	9
induction	0
by	0
TNF	0
,	0
revealing	0
that	0
several	0
radical-generating	0
systems	0
are	0
involved	0
in	0
its	0
regulation	0
.	0

PDTC	0
,	0
apocynin	0
,	0
or	0
SKF525a	0
decreased	0
adhesion	0
of	0
monocytic	5
U937	6
cells	6
to	0
TNF-treated	5
HUVECs	6
(	0
by	0
75	0
%	0
at	0
100	0
mumol/L	0
PDTC	0
)	0
.	0

Inhibition	0
by	0
anti-VCAM-1	9
monoclonal	10
antibody	10
1G11	9
indicated	0
that	0
U937	5
adhesion	0
was	0
VCAM-1	9
dependent	0
and	0
suppression	0
by	0
antioxidants	0
was	0
due	0
to	0
reduced	0
VCAM-1	9
induction	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Displacement	0
of	0
an	0
E-box-binding	9
repressor	10
by	0
basic	9
helix-loop-helix	10
proteins	10
:	0
implications	0
for	0
B-cell	0
specificity	0
of	0
the	0
immunoglobulin	1
heavy-chain	2
enhancer	2
.	0

The	0
activity	0
of	0
the	0
immunoglobulin	1
heavy-chain	2
(	2
IgH	2
)	2
enhancer	2
is	0
restricted	0
to	0
B	7
cells	8
,	0
although	0
it	0
binds	0
both	0
B-cell-restricted	9
and	10
ubiquitous	10
transcription	10
factors	10
.	0

Activation	0
of	0
the	0
enhancer	1
in	0
non-B	7
cells	8
upon	0
overexpression	0
of	0
the	0
basic	9
helix-loop-helix	10
(	10
bHLH	10
)	10
protein	10
E2A	9
appears	0
to	0
be	0
mediated	0
not	0
only	0
by	0
the	0
binding	0
of	0
E2A	9
to	0
its	0
cognate	0
E	1
box	2
but	0
also	0
by	0
the	0
resulting	0
displacement	0
of	0
a	0
repressor	9
from	0
that	0
same	0
site	0
.	0

We	0
have	0
identified	0
a	0
``	9
two-handed	10
''	10
zinc	10
finger	10
protein	10
,	0
denoted	0
ZEB	9
,	0
the	0
DNA-binding	0
specificity	0
of	0
which	0
mimics	0
that	0
of	0
the	0
cellular	9
repressor	10
.	0

By	0
employing	0
a	0
derivative	0
E	1
box	2
that	0
binds	0
ZEB	9
but	0
not	0
E2A	9
,	0
we	0
have	0
shown	0
that	0
the	0
repressor	9
is	0
active	0
in	0
B	7
cells	8
and	0
the	0
IgH	1
enhancer	2
is	0
silenced	0
in	0
the	0
absence	0
of	0
binding	0
competition	0
by	0
bHLH	9
proteins	10
.	0

Hence	0
,	0
we	0
propose	0
that	0
a	0
necessary	0
prerequisite	0
of	0
enhancer	1
activity	0
is	0
the	0
B-cell-specific	0
displacement	0
of	0
a	0
ZEB-like	9
repressor	10
by	0
bHLH	9
proteins	10
.	0

Inhibition	0
of	0
NF-kappa	9
B	10
by	0
sodium	0
salicylate	0
and	0
aspirin	0
[	0
see	0
comments	0
]	0

The	0
transcription	9
factor	10
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
critical	0
for	0
the	0
inducible	0
expression	0
of	0
multiple	0
cellular	1
and	2
viral	2
genes	2
involved	0
in	0
inflammation	0
and	0
infection	0
including	0
interleukin-1	9
(	0
IL-1	9
)	0
,	0
IL-6	9
,	0
and	0
adhesion	9
molecules	10
.	0

The	0
anti-inflammatory	0
drugs	0
sodium	0
salicylate	0
and	0
aspirin	0
inhibited	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
which	0
further	0
explains	0
the	0
mechanism	0
of	0
action	0
of	0
these	0
drugs	0
.	0

This	0
inhibition	0
prevented	0
the	0
degradation	0
of	0
the	0
NF-kappa	9
B	10
inhibitor	10
,	0
I	9
kappa	10
B	10
,	0
and	0
therefore	0
NF-kappa	9
B	10
was	0
retained	0
in	0
the	0
cytosol	0
.	0

Sodium	0
salicylate	0
and	0
aspirin	0
also	0
inhibited	0
NF-kappa	9
B	10
-dependent	0
transcription	0
from	0
the	0
Ig	1
kappa	2
enhancer	2
and	0
the	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
in	0
transfected	5
T	6
cells	6
.	0

Effects	0
of	0
the	0
antisense	0
myb	0
expression	0
on	0
hemin-	0
and	0
erythropoietin-	0
induced	0
erythroid	0
differentiation	0
of	0
K562	5
cells	6
.	0

In	0
order	0
to	0
elucidate	0
the	0
role	0
of	0
c-myb	1
gene	2
in	0
erythroid	0
differentiation	0
of	0
K562	5
cell	6
induced	0
by	0
hemin	9
(	0
Hm	9
)	0
and	0
erythropoietin	9
(	0
Epo	9
)	0
,	0
we	0
constructed	0
recombinant	1
plasmid	2
that	0
could	0
produce	0
antisense	3
myb	4
RNA	4
after	0
induction	0
with	0
dexamethasone	0
.	0

During	0
treatment	0
with	0
Hm	9
,	0
K562	5
cells	6
constitutively	0
expressed	0
c-myb	3
mRNA	4
,	0
and	0
50	0
%	0
of	0
them	0
began	0
to	0
synthesize	0
hemoglobin	9
(	0
Hb	9
)	0
.	0

Expression	0
of	0
antisense	3
myb	4
RNA	4
reduced	0
the	0
amount	0
of	0
c-myb	3
mRNA	4
,	0
and	0
the	0
percentage	0
of	0
Hb-synthesizing	5
cells	6
was	0
decreased	0
to	0
20	0
%	0
.	0

In	0
the	0
presence	0
of	0
Epo	9
,	0
c-myb	3
mRNA	4
declined	0
and	0
20	0
%	0
of	0
K562	5
cells	6
synthesized	0
Hb	9
regardless	0
of	0
antisense	3
myb	4
RNA	4
expression	0
.	0

It	0
is	0
suggested	0
that	0
constitutive	0
expression	0
of	0
c-myb	3
mRNA	4
is	0
necessary	0
for	0
Hm	9
-induced	0
differentiation	0
,	0
and	0
that	0
a	0
decrease	0
in	0
the	0
amount	0
of	0
c-myb	3
mRNA	4
induced	0
by	0
antisense	3
myb	4
RNA	4
expression	0
suppresses	0
Hm	9
-induced	0
differentiation	0
.	0

The	0
amount	0
of	0
c-myb	3
mRNA	4
in	0
K562	5
cells	6
was	0
reduced	0
during	0
the	0
differentiation	0
induced	0
by	0
Epo	9
.	0

Expression	0
of	0
GATA-1	3
mRNA	4
was	0
almost	0
constant	0
during	0
Hm	9
-induced	0
differentiation	0
,	0
but	0
increased	0
during	0
Epo	9
treatment	0
.	0

It	0
is	0
supposed	0
that	0
the	0
mechanism	0
of	0
Hm	9
-induced	0
differentiation	0
is	0
distinguished	0
from	0
that	0
of	0
Epo	9
-induced	0
differentiation	0
in	0
K562	5
cells	6
.	0

Prenatal	0
immune	0
challenge	0
alters	0
the	0
hypothalamic-pituitary-adrenocortical	0
axis	0
in	0
adult	0
rats	0
.	0

We	0
investigated	0
whether	0
non-abortive	0
maternal	0
infections	0
would	0
compromise	0
fetal	0
brain	0
development	0
and	0
alter	0
hypothalamic-pituitary-adrenocortical	0
(	0
HPA	0
)	0
axis	0
functioning	0
when	0
adult	0
.	0

To	0
study	0
putative	0
teratogenic	0
effects	0
of	0
a	0
T	0
cell-mediated	0
immune	0
response	0
versus	0
an	0
endotoxic	0
challenge	0
,	0
10-d-pregnant	0
rats	0
received	0
a	0
single	0
intraperitoneal	0
injection	0
of	0
5	0
x	0
10	0
(	0
8	0
)	0
human	7
red	8
blood	8
cells	8
(	0
HRBC	7
)	0
or	0
gram-negative	0
bacterial	0
endotoxin	0
(	0
Escherichia	0
coli	0
LPS	0
:	0
30	0
micrograms/kg	0
)	0
.	0

The	0
adult	0
male	0
progeny	0
(	0
3	0
mo	0
old	0
)	0
of	0
both	0
experimental	0
groups	0
showed	0
increased	0
basal	0
plasma	0
corticosterone	0
levels	0
.	0

In	0
addition	0
,	0
after	0
novelty	0
stress	0
the	0
HRBC	7
group	0
,	0
but	0
not	0
the	0
LPS	5
group	6
,	0
showed	0
increased	0
ACTH	0
and	0
corticosterone	0
levels	0
.	0

Both	0
groups	0
showed	0
substantial	0
decreases	0
in	0
mineralocorticoid	0
(	0
MR	0
)	0
and	0
glucocorticoid	0
receptor	0
(	0
GR	0
)	0
levels	0
in	0
the	0
hippocampus	0
,	0
a	0
limbic	0
brain	0
structure	0
critical	0
for	0
HPA	0
axis	0
regulation	0
,	0
whereas	0
GR	9
concentrations	0
in	0
the	0
hypothalamus	0
were	0
unchanged	0
and	0
in	0
anterior	0
pituitary	0
were	0
slightly	0
increased	0
.	0

HRBC	7
and	0
LPS	0
indeed	0
stimulated	0
the	0
maternal	0
immune	0
system	0
as	0
revealed	0
by	0
specific	0
anti-HRBC	9
antibody	10
production	0
and	0
enhanced	0
IL-1	0
beta	0
mRNA	0
expression	0
in	0
splenocytes	7
,	0
respectively	0
.	0

This	0
study	0
demonstrates	0
that	0
a	0
T	0
cell-mediated	0
immune	0
response	0
as	0
well	0
as	0
an	0
endotoxic	0
challenge	0
during	0
pregnancy	0
can	0
induce	0
anomalies	0
in	0
HPA	0
axis	0
function	0
in	0
adulthood	0
.	0

Clinically	0
,	0
it	0
may	0
be	0
postulated	0
that	0
disturbed	0
fetal	0
brain	0
development	0
due	0
to	0
prenatal	0
immune	0
challenge	0
increases	0
the	0
vulnerability	0
to	0
develop	0
mental	0
illness	0
involving	0
inadequate	0
responses	0
to	0
stress	0
.	0

A	0
low	0
NM23.H1	1
gene	2
expression	0
identifying	0
high	0
malignancy	0
human	0
melanomas	0
.	0

The	0
NM23	1
gene	2
has	0
been	0
proposed	0
as	0
a	0
metastasis-suppressor	1
gene	2
,	0
and	0
its	0
use	0
has	0
been	0
suggested	0
as	0
prognostic	0
factor	0
.	0

NM23	9
was	0
identified	0
in	0
a	0
system	0
of	0
murine	5
melanoma	6
cell	6
lines	6
,	0
in	0
which	0
an	0
inverse	0
relationship	0
was	0
found	0
between	0
NM23	9
expression	0
and	0
metastatic	0
ability	0
.	0

In	0
a	0
human	0
malignant	0
melanoma	0
study	0
NM23	9
expression	0
was	0
found	0
to	0
be	0
significantly	0
lower	0
in	0
metastases	0
that	0
developed	0
less	0
than	0
24	0
months	0
after	0
diagnosis	0
of	0
the	0
primary	0
tumours	0
.	0

The	0
present	0
paper	0
studies	0
the	0
expression	0
of	0
the	0
NM23.H1	1
gene	2
in	0
cell	5
lines	6
which	0
derive	0
from	0
primary	0
or	0
metastatic	0
human	0
malignant	0
melanomas	0
in	0
relation	0
to	0
staging	0
,	0
infiltration	0
degree	0
,	0
lymphocytic	0
infiltration	0
,	0
cell	0
morphology	0
,	0
cell	0
pigmentation	0
,	0
karyotype	0
,	0
and	0
disease-free	0
survival	0
.	0

The	0
level	0
of	0
mRNA	0
expression	0
of	0
the	0
NM23	1
gene	2
is	0
significantly	0
lower	0
in	0
cell	5
lines	6
that	0
derive	0
from	0
more	0
infiltrating	0
primary	0
melanomas	0
than	0
in	0
cell	5
lines	6
obtained	0
from	0
less	0
infiltrating	0
tumours	0
.	0

Moreover	0
,	0
cell	5
lines	6
derived	0
from	0
tumours	0
of	0
patients	0
with	0
a	0
disease-free	0
survival	0
of	0
more	0
than	0
24	0
months	0
(	0
24-58	0
months	0
)	0
express	0
the	0
NM23	1
gene	2
at	0
higher	0
levels	0
than	0
cell	5
lines	6
obtained	0
from	0
melanomas	0
of	0
patients	0
with	0
a	0
disease-free	0
survival	0
of	0
less	0
than	0
24	0
months	0
(	0
6-15	0
months	0
)	0
.	0

Activation	0
of	0
a	0
novel	0
serine/threonine	9
kinase	10
that	0
phosphorylates	0
c-Fos	9
upon	0
stimulation	0
of	0
T	7
and	8
B	8
lymphocytes	8
via	0
antigen	0
and	0
cytokine	9
receptors	10
.	0

Ligation	0
of	0
Ag	9
receptors	10
in	0
T	7
and	8
B	8
lymphocytes	8
initiates	0
signal	0
transduction	0
cascades	0
which	0
alter	0
the	0
expression	0
of	0
genes	0
that	0
regulate	0
cellular	0
proliferation	0
and	0
differentiation	0
.	0

The	0
transmission	0
of	0
signals	0
from	0
the	0
membrane	0
to	0
the	0
nucleus	0
is	0
mediated	0
principally	0
through	0
the	0
action	0
of	0
protein	9
tyrosine	10
and	10
serine/threonine	10
kinases	10
.	0

We	0
have	0
identified	0
and	0
characterized	0
a	0
novel	0
serine/threonine	9
kinase	10
that	0
phosphorylated	0
the	0
proto-oncogene	9
product	10
,	0
c-Fos	9
,	0
and	0
is	0
termed	0
Fos	9
kinase	10
.	0

Fos	9
kinase	10
was	0
rapidly	0
activated	0
after	0
ligation	0
of	0
the	0
CD3	9
and	10
CD2	10
receptors	10
in	0
Jurkat	5
and	0
normal	7
human	8
T	8
lymphocytes	8
and	0
in	0
response	0
to	0
IL-6	9
and	0
anti-IgM	9
in	0
the	0
human	5
B	6
cell	6
lines	6
AF10	5
and	0
Ramos	5
,	0
respectively	0
.	0

The	0
phorbol	0
ester	0
,	0
PMA	0
,	0
was	0
also	0
a	0
potent	0
inducer	0
of	0
Fos	9
kinase	10
activity	0
in	0
all	0
of	0
the	0
above	0
populations	0
,	0
suggesting	0
that	0
PKC	9
plays	0
a	0
role	0
in	0
the	0
regulation	0
of	0
this	0
enzyme	9
.	0

Fos	9
kinase	10
phosphorylates	0
c-Fos	9
at	0
a	0
site	0
near	0
the	0
C-terminus	9
,	0
as	0
well	0
as	0
a	0
peptide	0
derived	0
from	0
this	0
region	0
(	0
residues	9
359-370	10
,	0
RKGSSSNEPSSD	9
)	0
,	0
and	0
Fos	0
peptide	0
competitively	0
inhibited	0
c-Fos	9
phosphorylation	0
.	0

Fos	9
kinase	10
was	0
shown	0
to	0
be	0
distinct	0
from	0
other	0
identified	0
serine/threonine	9
kinases	10
,	0
including	0
protein	9
kinase	10
A	10
,	0
protein	9
kinase	10
C	10
,	0
casein	9
kinase	10
II	10
,	0
MAP	9
kinases	10
,	0
p70S6K	9
and	0
p90RSK	9
.	0

Fos	9
kinase	10
was	0
purified	0
by	0
anion	0
exchange	0
chromatography	0
and	0
exhibited	0
an	0
apparent	0
M	0
(	0
r	0
)	0
=	0
65	0
,	0
000	0
and	0
isoelectric	0
point	0
=	0
6.1	0
.	0

Fos	9
kinase	10
may	0
play	0
a	0
role	0
in	0
transcriptional	0
regulation	0
through	0
its	0
capacity	0
to	0
phosphorylate	0
c-Fos	9
at	0
a	0
site	0
required	0
for	0
expression	0
of	0
the	0
transcriptional	0
transrepressive	0
activity	0
of	0
this	0
molecule	0
.	0

Moreover	0
,	0
its	0
rapid	0
activation	0
suggests	0
it	0
may	0
have	0
a	0
wider	0
role	0
within	0
signal	0
transduction	0
cascades	0
in	0
lymphocytes	7
.	0

Antigenic	0
specificities	0
of	0
human	5
CD4+	6
T-cell	6
clones	6
recovered	0
from	0
recurrent	0
genital	0
herpes	0
simplex	0
virus	0
type	0
2	0
lesions	0
.	0

Lesions	0
resulting	0
from	0
recurrent	0
genital	0
herpes	0
simplex	0
virus	0
(	0
HSV	0
)	0
infection	0
are	0
characterized	0
by	0
infiltration	0
of	0
CD4+	7
lymphocytes	8
.	0

We	0
have	0
investigated	0
the	0
antigenic	0
specificity	0
of	0
47	0
HSV-specific	5
CD4+	6
T-cell	6
clones	6
recovered	0
from	0
the	0
HSV-2	0
buttock	0
and	0
thigh	0
lesions	0
of	0
five	0
patients	0
.	0

Clones	0
with	0
proliferative	0
responses	0
to	0
recombinant	9
truncated	10
glycoprotein	10
B	10
(	0
gB	9
)	0
or	0
gD	9
of	0
HSV-2	0
or	0
purified	0
natural	0
gC	0
of	0
HSV-2	0
comprised	0
a	0
minority	0
of	0
the	0
total	0
number	0
of	0
HSV-specific	5
clones	6
isolated	0
from	0
lesions	0
.	0

The	0
gC2-	5
and	6
gD2-specific	6
CD4+	6
clones	6
had	0
cytotoxic	0
activity	0
.	0

The	0
approximate	0
locations	0
of	0
the	0
HSV-2	0
genes	0
encoding	0
HSV-2	0
type-specific	0
CD4+	9
antigens	10
have	0
been	0
determined	0
by	0
using	0
HSV-1	0
x	0
HSV-2	0
intertypic	0
recombinant	0
virus	0
and	0
include	0
the	0
approximate	0
map	0
regions	0
0.30	0
to	0
0.46	0
,	0
0.59	0
to	0
0.67	0
,	0
0.67	0
to	0
0.73	0
,	0
and	0
0.82	0
to	0
1.0	0
units	0
.	0

The	0
antigenic	0
specificity	0
of	0
an	0
HLA	5
DQ2-restricted	6
,	6
HSV-2	6
type-specific	6
T-cell	6
clone	6
was	0
mapped	0
to	0
amino	9
acids	10
425	10
to	10
444	10
of	0
VP16	9
of	0
HSV-2	0
by	0
sequential	0
use	0
of	0
an	0
intertypic	0
recombinant	0
virus	0
containing	0
VP16	9
of	0
HSV-2	0
in	0
an	0
HSV-1	0
background	0
,	0
recombinant	9
VP16	10
fusion	10
proteins	10
,	0
and	0
synthetic	0
peptides	0
.	0

Each	0
of	0
the	0
remaining	0
four	0
patients	0
also	0
yielded	0
at	0
least	0
one	0
type-specific	5
T-cell	6
clone	6
reactive	0
with	0
an	0
HSV-2	0
epitope	0
mapping	0
to	0
approximately	0
0.67	0
to	0
0.73	0
map	0
units	0
.	0

The	0
antigenic	0
specificities	0
of	0
lesion-derived	5
CD4+	6
T-cell	6
clones	6
are	0
quite	0
diverse	0
and	0
include	0
at	0
least	0
10	0
epitopes	0
.	0

Human	5
T-cell	6
clones	6
reactive	0
with	0
gC	9
and	0
VP16	9
are	0
reported	0
here	0
for	0
the	0
first	0
time	0
.	0

Marked	0
basophilia	0
in	0
acute	0
promyelocytic	0
leukaemia	0
treated	0
with	0
all-trans	0
retinoic	0
acid	0
:	0
molecular	0
analysis	0
of	0
the	0
cell	0
origin	0
of	0
the	0
basophils	7
.	0

We	0
report	0
a	0
patient	0
with	0
acute	0
promyelocytic	0
leukaemia	0
who	0
developed	0
marked	0
basophilia	0
during	0
all-trans	0
retinoic	0
acid	0
treatment	0
.	0

We	0
studied	0
genomic	1
DNA	2
and	0
RNA	0
extracted	0
from	0
the	0
patient	0
's	0
peripheral	7
leucocytes	8
in	0
order	0
to	0
determine	0
the	0
origin	0
of	0
the	0
basophils	7
.	0

The	0
RAR	9
alpha	10
rearranged	0
band	0
in	0
the	0
Southern	0
blot	0
analysis	0
and	0
a	0
chimaeric	9
product	10
of	0
PML-RAR	9
alpha	10
by	0
polymerase	0
chain	0
reaction	0
were	0
strongly	0
visible	0
before	0
ATRA	0
treatment	0
,	0
but	0
at	0
the	0
time	0
of	0
maximal	0
basophilia	0
both	0
of	0
them	0
were	0
markedly	0
diminished	0
.	0

These	0
findings	0
suggest	0
that	0
the	0
basophils	7
which	0
appeared	0
during	0
the	0
ATRA	0
treatment	0
are	0
reactive	0
in	0
nature	0
rather	0
than	0
a	0
leukaemic	5
clone	6
.	0

Activation	0
of	0
the	0
interleukin	1
6	2
gene	2
by	0
Mycobacterium	0
tuberculosis	0
or	0
lipopolysaccharide	0
is	0
mediated	0
by	0
nuclear	9
factors	10
NF-IL6	10
and	0
NF-kappa	9
B	10
[	0
published	0
erratum	0
appears	0
in	0
Proc	0
Natl	0
Acad	0
Sci	0
U	0
S	0
A	0
1995	0
Apr	0
11	0
;	0
92	0
(	0
8	0
)	0
:	0
3632	0
]	0

The	0
host	0
response	0
to	0
Mycobacterium	0
tuberculosis	0
includes	0
granuloma	0
formation	0
at	0
sites	0
of	0
infection	0
and	0
systemic	0
symptoms	0
.	0

Cytokines	9
have	0
been	0
identified	0
by	0
immunohistochemistry	0
in	0
granulomas	0
in	0
animal	0
models	0
of	0
bacillus	0
Calmette-Guerin	0
(	0
BCG	0
)	0
infection	0
and	0
are	0
released	0
by	0
mononuclear	7
phagocytes	8
upon	0
stimulation	0
by	0
mycobacterial	0
proteins	0
.	0

In	0
this	0
regard	0
,	0
the	0
cytokine	9
interleukin	9
6	10
(	0
IL-6	9
)	0
may	0
play	0
a	0
role	0
in	0
the	0
clinical	0
manifestations	0
and	0
pathological	0
events	0
of	0
tuberculosis	0
infection	0
.	0

We	0
have	0
demonstrated	0
that	0
lipoarabinomannan	9
(	0
LAM	9
)	0
from	0
the	0
mycobacterial	0
cell	0
wall	0
,	0
which	0
was	0
virtually	0
devoid	0
of	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
stimulated	0
mononuclear	7
phagocytes	8
to	0
release	0
IL-6	9
in	0
a	0
dose-response	0
manner	0
.	0

LAM	9
and	0
LPS	0
were	0
potent	0
inducers	0
of	0
IL-6	1
gene	2
expression	0
in	0
peripheral	7
blood	8
monocytes	8
.	0

Both	0
LAM	9
-and	0
LPS-inducible	1
IL-6	2
promoter	2
activity	0
was	0
localized	0
to	0
a	0
DNA	1
fragment	2
,	0
positions	0
-158	1
to	2
-49	2
,	0
by	0
deletion	0
analysis	0
and	0
chloramphenicol	9
acetyltransferase	10
assay	0
.	0

Two	0
nuclear	9
factor	10
NF-IL6	10
(	0
positions	0
-153	1
to	2
-145	2
and	0
-83	0
to	0
-75	0
)	0
and	0
one	0
nuclear	1
factor	2
NF-kappa	2
B	2
(	2
positions	2
-72	2
to	2
-63	2
)	2
motifs	2
are	0
present	0
within	0
this	0
fragment	0
.	0

Site-directed	0
mutagenesis	0
of	0
one	0
or	0
more	0
of	0
these	0
motifs	0
within	0
the	0
IL-6	9
promoter	0
demonstrated	0
that	0
each	0
has	0
positive	0
regulatory	0
activity	0
and	0
that	0
they	0
could	0
act	0
in	0
a	0
function-	0
and	0
orientation-independent	0
manner	0
.	0

Deletion	0
of	0
all	0
three	0
elements	0
abolished	0
inducibility	0
of	0
IL-6	1
promoter	2
activity	0
by	0
both	0
LAM	9
and	0
LPS	0
.	0

We	0
conclude	0
that	0
the	0
NF-IL6	1
and	2
NF-kappa	2
B	2
sites	2
mediate	0
IL-6	9
induction	0
in	0
response	0
to	0
both	0
LPS	0
and	0
LAM	9
,	0
acting	0
as	0
bacterial	1
or	2
mycobacterial	2
response	2
elements	2
.	0

Regulation	0
of	0
CD14	9
expression	0
during	0
monocytic	0
differentiation	0
induced	0
with	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
.	0

CD14	9
,	0
a	0
monocyte/macrophage	9
receptor	10
for	0
the	0
complex	0
of	0
LPS	0
and	0
LPS	9
binding	10
protein	10
,	0
is	0
a	0
differentiation	0
marker	0
for	0
the	0
monocyte/macrophage	7
lineage	8
.	0

We	0
have	0
analyzed	0
the	0
regulation	0
of	0
CD14	9
expression	0
during	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
VitD3	0
)	0
-induced	0
monocytic	0
differentiation	0
.	0

Using	0
FACS	0
,	0
Northern	0
blotting	0
,	0
and	0
nuclear	0
run-on	0
analyses	0
,	0
we	0
demonstrate	0
that	0
the	0
up-regulation	0
of	0
CD14	9
expression	0
during	0
monocytic	0
cell	0
maturation	0
is	0
regulated	0
mainly	0
at	0
the	0
level	0
of	0
gene	0
transcription	0
,	0
and	0
that	0
new	0
protein	0
synthesis	0
is	0
required	0
for	0
CD14	9
induction	0
.	0

We	0
have	0
recently	0
cloned	0
the	0
CD14	1
5	2
'	2
upstream	2
sequence	2
and	0
demonstrated	0
its	0
tissue-specific	1
promoter	2
activity	0
.	0

Using	0
stable	0
transfection	0
of	0
the	0
monocytoid	5
U937	6
cell	6
line	6
with	0
a	0
series	0
of	0
deletion	0
mutants	0
of	0
the	0
CD14	1
5	2
'	2
upstream	2
sequence	2
coupled	0
to	0
a	0
reporter	0
gene	0
construct	0
,	0
we	0
show	0
that	0
bp	1
-128	2
to	2
-70	2
is	0
the	0
critical	0
region	0
for	0
the	0
induction	0
of	0
CD14	9
expression	0
.	0

This	0
region	0
contains	0
two	0
binding	1
sites	2
for	0
the	0
Sp1	9
transcription	10
factor	10
.	0

A	0
3-bp	0
mutation	0
at	0
the	0
distal	0
Sp1-binding	1
site	2
not	0
only	0
eliminates	0
Sp1	9
interaction	0
,	0
but	0
also	0
abolishes	0
most	0
of	0
the	0
VitD3	0
induction	0
of	0
CD14	9
expression	0
.	0

Electrophoretic	0
mobility	0
shift	0
analysis	0
does	0
not	0
detect	0
a	0
direct	0
interaction	0
of	0
the	0
CD14	9
distal	0
Sp1-binding	1
site	2
with	0
the	0
vitamin	9
D3	10
receptor	10
and	0
its	0
partner	0
,	0
the	0
retinoid	9
X	10
receptor	10
.	0

These	0
data	0
demonstrate	0
that	0
VitD3	0
induces	0
CD14	9
indirectly	0
through	0
some	0
intermediary	9
factor	10
,	0
and	0
suggest	0
a	0
critical	0
role	0
for	0
Sp1	9
in	0
this	0
process	0
.	0

DNA-binding	0
and	0
transcriptional	0
regulatory	0
properties	0
of	0
hepatic	9
leukemia	10
factor	10
(	0
HLF	9
)	0
and	0
the	0
t	0
(	0
17	0
;	0
19	0
)	0
acute	9
lymphoblastic	10
leukemia	10
chimera	10
E2A-HLF	10
.	0

The	0
t	1
(	2
17	2
;	2
19	2
)	2
translocation	0
in	0
acute	0
lymphoblastic	0
leukemias	0
results	0
in	0
creation	0
of	0
E2A-hepatic	9
leukemia	10
factor	10
(	0
HLF	9
)	0
chimeric	9
proteins	10
that	0
contain	0
the	0
DNA-binding	9
and	10
protein	10
dimerization	10
domains	10
of	0
the	0
basic	9
leucine	10
zipper	10
(	10
bZIP	10
)	10
protein	10
HLF	9
fused	0
to	0
a	0
portion	0
of	0
E2A	9
proteins	10
with	0
transcriptional	0
activation	0
properties	0
.	0

An	0
in	0
vitro	0
binding	0
site	0
selection	0
procedure	0
was	0
used	0
to	0
determine	0
DNA	0
sequences	0
preferentially	0
bound	0
by	0
wild-type	9
HLF	10
and	0
chimeric	9
E2A-HLF	10
proteins	0
isolated	0
from	0
various	0
t	5
(	6
17	6
;	6
19	6
)	6
-bearing	6
leukemias	6
.	0

All	0
were	0
found	0
to	0
selectively	0
bind	0
the	0
consensus	1
sequence	2
5'-GTTACGTAAT-3	0
'	0
with	0
high	0
affinity	0
.	0

Wild-type	0
and	0
chimeric	9
HLF	10
proteins	10
also	0
bound	0
closely	0
related	0
sites	0
identified	0
previously	0
for	0
bZIP	9
proteins	10
of	0
both	0
the	0
proline	9
-and	0
acidic	0
amino	0
acid-rich	0
(	0
PAR	9
)	0
and	0
C/EBP	9
subfamilies	10
;	0
however	0
,	0
E2A-HLF	9
proteins	0
were	0
significantly	0
less	0
tolerant	0
of	0
certain	0
deviations	0
from	0
the	0
HLF	1
consensus	2
binding	2
site	2
.	0

These	0
differences	0
were	0
directly	0
attributable	0
to	0
loss	0
of	0
an	0
HLF	1
ancillary	2
DNA-binding	2
domain	2
in	0
all	0
E2A-HLF	9
chimeras	10
and	0
were	0
further	0
exacerbated	0
by	0
a	0
zipper	0
mutation	0
in	0
one	0
isolate	0
.	0

Both	0
wild-type	9
and	0
chimeric	9
HLF	10
proteins	10
displayed	0
transcriptional	9
activator	10
properties	0
in	0
lymphoid	7
and	8
nonlymphoid	8
cells	8
on	0
reporter	1
genes	2
containing	0
HLF	1
or	2
C/EBP	2
consensus	2
binding	2
sites	2
.	0

But	0
on	0
reporter	1
genes	2
with	0
nonoptimal	1
binding	2
sites	2
,	0
their	0
transcriptional	0
properties	0
diverged	0
and	0
E2A-HLF	9
competitively	0
inhibited	0
activation	0
by	0
wild-type	9
PAR	10
proteins	10
.	0

These	0
findings	0
establish	0
a	0
spectrum	0
of	0
binding	0
site-specific	0
transcriptional	0
properties	0
for	0
E2A-HLF	9
which	0
may	0
preferentially	0
activate	0
expression	0
of	0
select	0
subordinate	0
genes	0
as	0
a	0
homodimer	0
and	0
potentially	0
antagonize	0
expression	0
of	0
others	0
through	0
heteromeric	0
interactions	0
.	0

ZAP-70	9
tyrosine	10
kinase	10
,	0
CD45	9
,	0
and	0
T	9
cell	10
receptor	10
involvement	0
in	0
UV-	0
and	0
H2O2-induced	0
T	0
cell	0
signal	0
transduction	0
.	0

Several	0
mammalian	0
responses	0
to	0
UV	0
irradiation	0
,	0
including	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
are	0
believed	0
to	0
involve	0
tyrosine	0
phosphorylation	0
.	0

UV	0
irradiation	0
and	0
H2O2	0
treatment	0
of	0
T	7
lymphocytes	8
induce	0
protein	0
tyrosine	0
phosphorylation	0
and	0
Ca2+	0
signals	0
similar	0
to	0
those	0
observed	0
following	0
biological	0
stimulation	0
.	0

We	0
have	0
examined	0
the	0
role	0
of	0
cell	0
surface	0
molecules	0
in	0
these	0
responses	0
.	0

Normal	0
T	7
lymphocytes	8
whose	0
surface	0
expression	0
of	0
CD3	9
was	0
depleted	0
showed	0
impaired	0
UV-induced	0
tyrosine	0
phosphorylation	0
and	0
Ca2+	0
signals	0
.	0

Similarly	0
,	0
Jurkat	5
T	6
cell	6
lines	6
deficient	0
in	0
CD3	0
or	0
CD45	0
expression	0
also	0
gave	0
impaired	0
UV	0
responses	0
.	0

However	0
,	0
all	0
these	0
cell	0
types	0
still	0
gave	0
strong	0
Ca2+	0
and	0
tyrosine	0
phosphorylation	0
responses	0
to	0
H2O2	0
.	0

The	0
T	0
cell	0
tyrosine	0
kinase	9
ZAP-70	10
was	0
found	0
to	0
be	0
highly	0
responsive	0
to	0
UV	0
and	0
H2O2	0
treatment	0
.	0

ZAP-70	9
responsiveness	0
to	0
UV	0
required	0
expression	0
of	0
both	0
CD3	9
and	0
CD45	9
,	0
whereas	0
only	0
CD3	9
was	0
required	0
for	0
the	0
response	0
to	0
H2O2	0
.	0

UV-induced	0
activation	0
of	0
NF-kappa	9
B	10
was	0
blocked	0
by	0
CD3	9
depletion	0
,	0
indicating	0
the	0
importance	0
of	0
such	0
cell	9
surface	10
molecules	10
in	0
biological	0
responses	0
to	0
UV	0
.	0

In	0
nonlymphoid	7
cells	8
,	0
the	0
epidermal	9
growth	10
factor	10
receptor	10
displayed	0
increased	0
tyrosine	0
phosphorylation	0
within	0
seconds	0
of	0
UV	0
irradiation	0
.	0

These	0
results	0
suggest	0
that	0
UV-induced	0
signal	0
transduction	0
is	0
mediated	0
via	0
cell	9
surface	10
receptors	10
that	0
normally	0
respond	0
to	0
biological	0
stimulation	0
,	0
whereas	0
H2O2	0
is	0
able	0
to	0
partially	0
bypass	0
this	0
requirement	0
.	0

Inhibition	0
of	0
the	0
differentiation	0
of	0
human	5
myeloid	6
cell	6
lines	6
by	0
redox	0
changes	0
induced	0
through	0
glutathione	0
depletion	0
.	0

We	0
have	0
investigated	0
the	0
effect	0
of	0
redox	0
changes	0
in	0
vivo	0
on	0
the	0
differentiation	0
of	0
two	0
human	5
myeloid	6
cell	6
lines	6
,	0
HL-60	5
and	0
KG-1	5
.	0

The	0
glutathione-depleting	0
agent	0
diethyl	0
maleate	0
(	0
DEM	0
)	0
prevented	0
the	0
development	0
of	0
differentiated	0
features	0
in	0
response	0
to	0
phorbol	0
esters	0
,	0
including	0
adherence	0
of	0
the	0
cells	0
to	0
plastic	0
surfaces	0
and	0
repression	0
of	0
the	0
myeloperoxidase	1
and	2
CD34	2
genes	2
.	0

Moreover	0
,	0
DEM	0
abolished	0
phorbol	0
12-myristate	0
13-acetate-induced	0
activation	0
of	0
the	0
transcription	9
factors	10
AP-1	9
and	0
Egr-1	9
,	0
suggesting	0
that	0
inhibition	0
of	0
differentiation	0
may	0
be	0
due	0
,	0
at	0
least	0
in	0
part	0
,	0
to	0
redox	0
modifications	0
of	0
these	0
proteins	9
.	0

Lipopolysaccharide	0
induction	0
of	0
tissue	1
factor	2
gene	2
expression	0
in	0
monocytic	7
cells	8
is	0
mediated	0
by	0
binding	0
of	0
c-Rel/p65	9
heterodimers	10
to	0
a	0
kappa	1
B-like	2
site	2
.	0

Exposure	0
of	0
monocytic	7
cells	8
to	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
activates	0
the	0
NF-kappa	9
B/Rel	10
family	10
of	0
proteins	0
and	0
leads	0
to	0
the	0
rapid	0
induction	0
of	0
inflammatory	9
gene	10
products	10
,	0
including	0
tissue	9
factor	10
(	0
TF	9
)	0
.	0

TF	9
is	0
the	0
primary	0
cellular	0
initiator	0
of	0
the	0
coagulation	9
protease	10
cascades	0
.	0

Here	0
we	0
report	0
the	0
characterization	0
of	0
a	0
nuclear	9
complex	10
from	0
human	0
monocytic	7
cells	8
that	0
bound	0
to	0
a	0
kappa	1
B-like	2
site	2
,	0
5'-CGGAGTTTCC-3	1
'	2
,	0
in	0
the	0
5'-flanking	1
region	2
of	0
the	0
human	1
TF	2
gene	2
.	0

This	0
nuclear	9
complex	10
was	0
activated	0
by	0
LPS	0
with	0
kinetics	0
that	0
preceded	0
induction	0
of	0
the	0
TF	1
gene	2
.	0

In	0
vitro	0
binding	0
studies	0
demonstrated	0
that	0
the	0
TF	1
site	2
bound	0
translated	0
c-Rel	9
and	10
p65	10
homodimers	10
but	0
not	0
p50/p65	9
heterodimers	10
or	0
p50	9
homodimers	10
.	0

Base-pair	0
substitutions	0
in	0
the	0
TF	1
site	2
indicated	0
that	0
the	0
presence	0
of	0
a	0
cytosine	0
at	0
position	9
1	10
precluded	0
binding	0
of	0
NF-kappa	9
B	10
.	0

In	0
fact	0
,	0
under	0
low-ionic-strength	0
conditions	0
,	0
the	0
TF	9
complex	10
did	0
not	0
migrate	0
with	0
translated	0
p50/p65	9
dimers	10
but	0
instead	0
comigrated	0
with	0
c-Rel/p65	9
dimers	10
.	0

Antibodies	0
against	0
the	0
NF-kappa	9
B	10
and	0
Rel	0
proteins	0
and	0
UV	0
cross-linking	0
studies	0
revealed	0
the	0
presence	0
of	0
c-Rel	9
and	0
p65	0
and	0
the	0
absence	0
of	0
p50	9
in	0
the	0
TF	9
complex	10
and	0
further	0
showed	0
that	0
c-Rel/p65	9
heterodimers	10
selectively	0
bound	0
to	0
the	0
TF	1
kappa	2
B-like	2
site	2
.	0

Functional	0
studies	0
indicated	0
that	0
the	0
TF	1
site	2
conferred	0
LPS	0
inducibility	0
on	0
a	0
heterologous	1
promoter	2
and	0
was	0
transactivated	0
by	0
c-Rel	9
or	0
p65	0
.	0

Taken	0
together	0
,	0
our	0
results	0
demonstrated	0
that	0
binding	0
of	0
c-Rel/p65	9
heterodimers	10
to	0
a	0
novel	0
kappa	1
B-like	2
site	2
mediated	0
LPS	0
induction	0
of	0
TF	9
gene	0
expression	0
in	0
monocytic	7
cells	8
.	0

Inhibition	0
of	0
T	0
cell	0
activation	0
by	0
the	0
extracellular	9
matrix	10
protein	10
tenascin	9
.	0

Tenascin	9
(	0
TN	9
)	0
is	0
an	0
extracellular	9
matrix	10
protein	10
that	0
is	0
expressed	0
widely	0
in	0
the	0
fetus	0
and	0
sparingly	0
in	0
the	0
adult	0
,	0
but	0
reappears	0
at	0
high	0
levels	0
in	0
certain	0
areas	0
of	0
tissue	0
insult	0
such	0
as	0
tumor	0
matrices	0
and	0
sites	0
of	0
wound	0
healing	0
.	0

We	0
show	0
here	0
that	0
soluble	0
TN	9
inhibits	0
proliferation	0
of	0
human	7
T	8
cells	8
in	0
response	0
to	0
alpha	9
CD3	10
Ab	10
co-immobilized	0
with	0
the	0
extracellular	9
matrix	10
protein	10
fibronectin	9
(	0
FN	9
)	0
.	0

TN	9
also	0
inhibits	0
proliferation	0
driven	0
by	0
alpha	9
CD3/IL-2	10
or	0
by	0
phorbol	9
ester/IL-2	10
,	10
and	0
it	0
prevents	0
high	0
level	0
induction	0
of	0
IL-2R	9
.	0

The	0
presence	0
of	0
TN	9
in	0
culture	0
medium	0
does	0
not	0
detectably	0
alter	0
the	0
pattern	0
of	0
tyrosine	0
phosphorylation	0
resulting	0
from	0
T	0
cell	0
triggering	0
with	0
alpha	9
CD3	10
,	0
but	0
at	0
later	0
time	0
points	0
prevents	0
the	0
appearance	0
of	0
functional	0
NF-AT1	9
transcription	10
factor	10
complexes	10
in	0
T	0
cell	0
nuclear	0
extracts	0
.	0

These	0
findings	0
are	0
consistent	0
with	0
the	0
postulated	0
role	0
for	0
TN	9
as	0
a	0
natural	0
antagonist	0
to	0
FN	9
action	0
,	0
and	0
suggest	0
that	0
T	0
cell	0
responses	0
occurring	0
at	0
tissue	0
sites	0
in	0
which	0
TN	9
is	0
expressed	0
could	0
be	0
influenced	0
by	0
its	0
presence	0
.	0

Human	0
immunodeficiency	0
virus	0
type	0
1	0
Nef	0
protein	0
down-regulates	0
transcription	9
factors	10
NF-kappa	9
B	10
and	0
AP-1	9
in	0
human	7
T	8
cells	8
in	0
vitro	0
after	0
T-cell	0
receptor	0
stimulation	0
.	0

Human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
negative	9
factor	10
(	0
Nef	9
)	0
has	0
been	0
shown	0
to	0
down-regulate	0
the	0
transcription	9
factors	10
NF-kappa	9
B	10
and	0
AP-1	9
in	0
vitro	0
.	0

To	0
define	0
the	0
mechanism	0
of	0
action	0
of	0
the	0
Nef	9
protein	0
,	0
the	0
signal	0
transduction	0
pathways	0
which	0
may	0
be	0
affected	0
in	0
T	7
cells	8
by	0
constitutive	0
expression	0
of	0
the	0
nef	0
gene	0
were	0
examined	0
.	0

Stimulation	0
of	0
T	7
cells	8
with	0
tumor	0
necrosis	0
factor	0
,	0
interleukin-1	0
,	0
or	0
lipopolysaccharide	0
resulted	0
in	0
the	0
recruitment	0
of	0
transcriptional	0
factors	0
to	0
a	0
similar	0
level	0
whether	0
or	0
not	0
the	0
cells	0
expressed	0
the	0
nef	0
gene	0
.	0

On	0
the	0
other	0
hand	0
,	0
stimulation	0
of	0
T	7
cells	8
by	0
mitogens	0
or	0
antibodies	0
to	0
the	0
T-cell	0
receptor	0
(	0
TCR	0
)	0
-	0
CD3	9
complex	0
resulted	0
in	0
the	0
down-regulation	0
of	0
transcriptional	0
factors	0
NF-kappa	9
B	10
and	0
AP-1	9
in	0
cells	0
expressing	0
the	0
nef	0
gene	0
compared	0
with	0
cells	0
not	0
expressing	0
the	0
nef	0
gene	0
.	0

Because	0
the	0
Nef	9
protein	0
does	0
not	0
affect	0
the	0
surface	0
expression	0
of	0
the	0
CD3	9
-TCR	0
complex	0
,	0
we	0
conclude	0
that	0
the	0
Nef	9
protein	0
down-regulates	0
the	0
transcriptional	0
factors	0
NF-kappa	9
B	10
and	0
AP-1	9
in	0
T	7
cells	8
in	0
vitro	0
through	0
an	0
effect	0
on	0
the	0
TCR-dependent	0
signal	0
transduction	0
pathway	0
.	0

Effects	0
of	0
alpha-lipoic	0
acid	0
and	0
dihydrolipoic	0
acid	0
on	0
expression	0
of	0
proto-oncogene	1
c-fos	2
.	0

The	0
transcription	9
factor	10
AP-1	9
is	0
an	0
important	0
human	0
mediator	0
of	0
the	0
cellular	0
response	0
to	0
serum	0
,	0
growth	9
factors	10
,	0
and	0
phorbol	0
esters	0
such	0
as	0
12-O-tetradecanoyl-phorbol-13	0
acetate	0
(	0
TPA	0
)	0
.	0

The	0
AP-1	9
complex	0
consists	0
of	0
distinct	0
protein	9
heterodimers	10
encoded	0
by	0
the	0
proto-oncogene	1
c-fos	2
and	0
c-jun	3
mRNA	4
whose	0
gene	0
expression	0
can	0
be	0
induced	0
by	0
TPA	0
,	0
cyclic	0
AMP	0
and	0
growth	9
factors	10
.	0

Recent	0
findings	0
suggest	0
an	0
involvement	0
of	0
reactive	0
oxygen	0
species	0
in	0
the	0
pathway	0
of	0
TPA	0
and	0
protein	9
kinase	10
C	10
leading	0
to	0
expression	0
of	0
c-fos	3
and	4
c-jun	4
mRNA	4
.	0

To	0
investigate	0
the	0
role	0
of	0
reactive	0
oxygen	0
species	0
we	0
studied	0
the	0
effects	0
of	0
alpha-lipoic	0
acid	0
and	0
dihydrolipoic	0
acid	0
(	0
natural	0
thiol	0
antioxidants	0
)	0
on	0
the	0
expression	0
of	0
c-fos	3
mRNA	4
in	0
human	5
Jurkat	6
T	6
cells	6
.	0

When	0
cells	0
were	0
preincubated	0
with	0
dihydrolipoic	0
acid	0
(	0
0.2	0
mM	0
)	0
the	0
expression	0
of	0
c-fos	3
mRNA	4
was	0
suppressed	0
at	0
30	0
min	0
after	0
stimulation	0
of	0
TPA	0
(	0
0.5	0
microM	0
)	0
whereas	0
in	0
the	0
case	0
of	0
preincubation	0
of	0
alpha-lipoic	0
acid	0
(	0
0.2	0
microM	0
)	0
,	0
the	0
expression	0
was	0
enhanced	0
at	0
30	0
min	0
.	0

These	0
studies	0
support	0
the	0
idea	0
that	0
superoxide	0
anion	0
radical	0
plays	0
a	0
role	0
in	0
the	0
expression	0
of	0
c-fos	3
mRNA	4
.	0

Appraisal	0
of	0
potential	0
therapeutic	0
index	0
of	0
antioxidants	0
on	0
the	0
basis	0
of	0
their	0
in	0
vitro	0
effects	0
on	0
HIV	0
replication	0
in	0
monocytes	7
and	0
interleukin	9
2	10
-induced	0
lymphocyte	0
proliferation	0
.	0

Antioxidant	0
molecules	0
have	0
been	0
suggested	0
to	0
be	0
of	0
therapeutic	0
value	0
in	0
the	0
treatment	0
of	0
HIV-infected	0
patients	0
.	0

To	0
evaluate	0
this	0
possibility	0
,	0
we	0
examined	0
in	0
vitro	0
the	0
effects	0
of	0
two	0
types	0
of	0
antioxidant	0
molecules	0
in	0
terms	0
of	0
inhibition	0
of	0
HIV	0
replication	0
in	0
monocytes	7
,	0
one	0
of	0
the	0
main	0
reservoirs	0
of	0
HIV	0
,	0
and	0
also	0
in	0
terms	0
of	0
modulation	0
of	0
the	0
immune	0
competence	0
as	0
measured	0
by	0
PBMC	7
proliferation	0
.	0

We	0
tested	0
the	0
effects	0
of	0
BHA	0
,	0
a	0
phenolic	0
,	0
lipid-soluble	0
,	0
chain-breaking	0
antioxidant	0
,	0
and	0
NAC	0
,	0
a	0
known	0
glutathione	0
precursor	0
with	0
some	0
direct	0
free-radical	0
scavenging	0
properties	0
as	0
well	0
,	0
on	0
the	0
regulation	0
of	0
HIV-1	0
expression	0
in	0
latently	0
infected	0
U1	5
cells	6
and	0
in	0
productively	0
and	0
chronically	0
infected	0
U937	5
cells	6
.	0

Both	0
antioxidants	0
inhibited	0
TNF	9
-or	0
PMA-induced	0
NF-kappa	9
B	10
activity	0
in	0
U1	5
cells	6
,	0
as	0
well	0
as	0
the	0
sustained	0
NF-kappa	9
B	10
activity	0
permanently	0
induced	0
by	0
the	0
virus	0
itself	0
in	0
chronically	0
HIV-infected	0
U937	5
cells	6
.	0

This	0
resulted	0
in	0
only	0
a	0
partial	0
inhibition	0
of	0
TNF	9
-or	0
PMA-	0
induced	0
HIV	0
replication	0
in	0
U1	5
cells	6
,	0
and	0
no	0
detectable	0
effect	0
on	0
HIV	0
replication	0
in	0
chronically	5
infected	6
U937	6
cells	6
.	0

This	0
may	0
be	0
the	0
first	0
limitation	0
to	0
potential	0
antiviral	0
effects	0
of	0
antioxidant	0
therapies	0
.	0

Another	0
limitation	0
is	0
that	0
antioxidant	0
concentrations	0
high	0
enough	0
to	0
block	0
NK-kappa	9
B	10
activation	0
were	0
shown	0
to	0
have	0
a	0
suppressive	0
effect	0
on	0
immune	0
functions	0
in	0
vitro	0
,	0
because	0
NAC	0
and	0
BHA	0
blocked	0
IL-2-induced	7
PBMC	8
proliferation	0
.	0

These	0
data	0
warrant	0
prudence	0
in	0
the	0
design	0
of	0
antioxidant-based	0
therapies	0
aimed	0
at	0
suppressing	0
HIV	0
replication	0
.	0

Isolation	0
and	0
characterization	0
of	0
gelatinase	0
granules	0
from	0
human	7
neutrophils	8
.	0

We	0
recently	0
confirmed	0
the	0
existence	0
of	0
gelatinase	0
granules	0
as	0
a	0
subpopulation	0
of	0
peroxidase-negative	0
granules	0
by	0
double-labeling	0
immunogold	0
electron	0
microscopy	0
on	0
intact	0
cells	0
and	0
by	0
subcellular	0
fractionation	0
.	0

Further	0
characterization	0
of	0
gelatinase	0
granules	0
has	0
been	0
hampered	0
by	0
poor	0
separation	0
of	0
specific	0
and	0
gelatinase	0
granules	0
on	0
both	0
two-layer	0
Percoll	0
gradients	0
and	0
sucrose	0
gradients	0
.	0

We	0
have	0
developed	0
a	0
three-layer	0
Percoll	0
density	0
gradient	0
that	0
allows	0
separation	0
of	0
the	0
different	0
granules	0
and	0
vesicles	0
from	0
human	7
neutrophils	8
;	0
in	0
particular	0
,	0
it	0
allows	0
separation	0
of	0
specific	0
and	0
gelatinase	0
granules	0
.	0

This	0
allows	0
us	0
to	0
characterize	0
these	0
two	0
granule	0
populations	0
with	0
regard	0
to	0
their	0
content	0
of	0
membrane	9
proteins	10
,	0
which	0
become	0
incorporated	0
into	0
the	0
plasma	0
membrane	0
during	0
exocytosis	0
.	0

We	0
found	0
that	0
gelatinase	0
granules	0
,	0
defined	0
as	0
peroxidase-negative	0
granules	0
containing	0
gelatinase	9
but	0
lacking	0
lactoferrin	9
,	0
contain	0
50	0
%	0
of	0
total	0
cell	0
gelatinase	9
,	0
with	0
the	0
remaining	0
residing	0
in	0
specific	0
granules	0
.	0

Furthermore	0
,	0
we	0
found	0
that	0
20	0
%	0
to	0
25	0
%	0
of	0
both	0
the	0
adhesion	9
protein	10
Mac-1	10
and	0
the	0
NADPH-oxidase	9
component	10
cytochrome	10
b558	9
is	0
localized	0
in	0
gelatinase	9
granules	0
.	0

Although	0
no	0
qualitative	0
difference	0
was	0
observed	0
between	0
specific	0
granules	0
and	0
gelatinase	9
granules	0
with	0
respect	0
to	0
cytochrome	9
b558	10
and	0
Mac-1	9
,	0
stimulation	0
of	0
the	0
neutrophil	7
with	0
FMLP	9
resulted	0
in	0
a	0
selective	0
mobilization	0
of	0
the	0
least	0
dense	0
peroxidase-negative	0
granules	0
,	0
ie	0
,	0
gelatinase	9
granules	0
,	0
which	0
,	0
in	0
concert	0
with	0
secretory	0
vesicles	0
,	0
furnish	0
the	0
plasma	0
membrane	0
with	0
Mac-1	9
and	0
cytochrome	9
b558	10
.	0

This	0
shows	0
that	0
gelatinase	9
granules	0
are	0
functionally	0
important	0
relative	0
to	0
specific	0
granules	0
in	0
mediating	0
early	0
inflammatory	0
responses	0
.	0

Regulation	0
of	0
interleukin-2	9
receptor	10
alpha	10
chain	10
expression	0
and	0
nuclear	9
factor.kappa	10
B	10
activation	0
by	0
protein	9
kinase	10
C	10
in	0
T	7
lymphocytes	8
.	0

Autocrine	0
role	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
.	0

The	0
regulation	0
of	0
interleukin-2	9
receptor	10
alpha	10
chain	10
(	0
IL-2R	9
alpha	10
)	0
expression	0
and	0
nuclear	9
factor	10
(	0
NF	0
)	0
activation	0
by	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
in	0
resting	7
T	8
cells	8
,	0
has	0
been	0
studied	0
.	0

Treatment	0
of	0
human	0
resting	7
T	8
cells	8
with	0
phorbol	0
esters	0
strongly	0
induced	0
the	0
expression	0
of	0
IL-2R	9
alpha	10
and	0
the	0
activation	0
of	0
NF.kappa	9
B	10
.	0

This	0
activation	0
was	0
due	0
to	0
the	0
translocation	0
of	0
p65	9
and	0
c-Rel	9
NF.kappa	9
B	10
proteins	0
from	0
cytoplasmic	0
stores	0
to	0
the	0
nucleus	0
,	0
where	0
they	0
bound	0
the	0
kappa	1
B	2
sequence	2
of	0
the	0
IL-2R	1
alpha	2
promoter	2
either	0
as	0
p50.p65	9
or	0
as	0
p50.c-Rel	9
heterodimers	0
.	0

Interestingly	0
,	0
all	0
of	0
those	0
events	0
were	0
largely	0
indirect	0
and	0
mediated	0
by	0
endogenously	0
secreted	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
,	0
as	0
they	0
were	0
strongly	0
inhibited	0
by	0
a	0
neutralizing	9
anti-TNF	10
alpha	10
monoclonal	10
antibody	10
.	0

Furthermore	0
,	0
cyclosporin	0
A	0
,	0
which	0
blocked	0
TNF	9
alpha	10
production	0
induced	0
by	0
PKC	9
,	0
strongly	0
inhibited	0
IL-2R	9
alpha	10
and	0
NF.kappa	9
B	10
activation	0
.	0

The	0
addition	0
of	0
either	0
TNF	9
alpha	10
or	0
IL-2	9
partially	0
recovered	0
cyclosporin	0
A-induced	0
IL-2R	9
alpha	10
inhibition	0
,	0
but	0
only	0
TNF	9
alpha	10
completely	0
recovered	0
NF.kappa	9
B	10
activation	0
.	0

Those	0
results	0
indicate	0
that	0
,	0
in	0
resting	7
T	8
cells	8
,	0
PKC	9
activation	0
has	0
only	0
a	0
triggering	0
role	0
,	0
whereas	0
the	0
endogenously	0
secreted	0
TNF	9
alpha	10
plays	0
an	0
essential	0
role	0
in	0
the	0
quantitative	0
control	0
of	0
the	0
expression	0
of	0
IL-2R	9
alpha	10
chain	0
or	0
NF.kappa	9
B	10
activation	0
.	0

Superantigens	9
activate	0
HIV-1	0
gene	0
expression	0
in	0
monocytic	7
cells	8
.	0

Binding	0
of	0
superantigens	0
to	0
MHC	9
class	10
II	10
molecules	10
results	0
in	0
transduction	0
of	0
biochemical	0
signals	0
leading	0
to	0
cellular	0
activation	0
and	0
gene	0
expression	0
.	0

We	0
demonstrate	0
that	0
the	0
staphylococcal	9
superantigens	10
toxic	9
shock	10
syndrome	10
toxin-1	10
(	0
TSST-1	9
)	0
and	0
staphylococcal	9
enterotoxin	10
A	10
(	0
SEA	9
)	0
activate	0
HIV-1-LTR	1
-driven	0
transcription	0
of	0
chloramphenicol	9
acetyl	10
transferase	10
in	0
the	0
human	5
monocytic	6
cell	6
line	6
THP-1	5
.	0

Induction	0
of	0
HIV-1-	0
LTR	1
-driven	0
transcription	0
in	0
THP-1	5
cells	6
by	0
superantigens	9
was	0
associated	0
with	0
the	0
induction	0
of	0
nuclear	9
factor-kappa	10
B	10
DNA-binding	0
activity	0
.	0

Superantigens	9
also	0
increased	0
viral	0
protein	0
secretion	0
from	0
the	0
granulocyte-macrophage	5
colony-stimulating	6
factor-pretreated	6
chronically	6
infected	6
human	6
monocytic	6
cell	6
line	6
U1	6
.	0

Induction	0
of	0
HIV-1	0
gene	0
expression	0
in	0
monocytic	7
cells	8
by	0
superantigens	9
occurred	0
via	0
tumor	0
necrosis	0
factor-alpha-dependent	0
and	0
-independent	0
mechanisms	0
.	0

Our	0
results	0
suggest	0
that	0
superantigens	9
and	0
other	0
MHC	9
class	10
II	10
ligands	10
may	0
activate	0
HIV-1	0
gene	0
expression	0
in	0
monocytes/macrophages	7
.	0

Mitogen	0
activation	0
of	0
human	7
peripheral	8
T	8
lymphocytes	8
induces	0
the	0
formation	0
of	0
new	0
cyclic	9
AMP	10
response	10
element-binding	10
protein	10
nuclear	10
complexes	10
.	0

A	0
large	0
body	0
of	0
evidence	0
indicates	0
that	0
experimental	0
agents	0
which	0
raise	0
cellular	0
cAMP	0
levels	0
inhibit	0
T	0
cell	0
growth	0
and	0
division	0
.	0

By	0
contrast	0
,	0
many	0
studies	0
have	0
reported	0
that	0
mitogen	9
activation	0
of	0
T	7
cells	8
increases	0
cAMP	0
levels	0
,	0
implying	0
a	0
positive	0
physiological	0
role	0
for	0
cAMP	0
in	0
the	0
activation	0
process	0
.	0

In	0
the	0
present	0
study	0
we	0
demonstrate	0
that	0
mitogen	9
activation	0
of	0
human	7
peripheral	8
T	8
lymphocytes	8
induces	0
nuclear	0
factors	0
that	0
form	0
complexes	0
with	0
cyclic	9
AMP	10
response	10
element-binding	10
protein	10
(	0
CREB	9
)	0
.	0

Four	0
complexes	0
are	0
identified	0
by	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
two	0
of	0
which	0
are	0
induced	0
by	0
mitogen	9
activation	0
.	0

All	0
four	0
complexes	0
contain	0
CREB	9
and	0
are	0
bound	0
to	0
the	0
cAMP	1
response	2
element	2
(	2
CRE	2
)	2
core	2
sequence	2
(	0
TGACGTCA	0
)	0
,	0
as	0
indicated	0
by	0
antibody	0
and	0
oligonucleotide	0
competition	0
experiments	0
.	0

Binding	0
of	0
the	0
four	0
complexes	0
to	0
CRE	1
is	0
prevented	0
by	0
dephosphorylation	0
of	0
nuclear	0
extracts	0
and	0
is	0
restored	0
by	0
rephosphorylation	0
with	0
cAMP-dependent	9
protein	10
kinase	10
or	0
endogenous	9
kinases	10
.	0

Similar	0
complexes	0
are	0
detected	0
in	0
nuclear	0
extracts	0
of	0
Jurkat	5
cells	6
.	0

Mitogen	0
induction	0
of	0
the	0
electrophoretic	9
mobility	10
shift	10
assay	10
complexes	10
is	0
not	0
accounted	0
for	0
by	0
protein	0
phosphorylation	0
or	0
by	0
induction	0
of	0
CREB	9
.	0

Rather	0
,	0
the	0
data	0
indicate	0
that	0
mitogen	0
increases	0
the	0
levels	0
of	0
a	0
nuclear	0
factor	0
(	0
s	0
)	0
that	0
dimerizes	0
with	0
CREB	9
.	0

Induction	0
of	0
new	0
CREB	9
complexes	10
implies	0
a	0
physiological	0
role	0
for	0
cAMP	0
in	0
mitogen	9
activation	0
of	0
T	7
lymphocytes	8
.	0

Alpha-tocopherol	0
inhibits	0
agonist-induced	0
monocytic	0
cell	0
adhesion	0
to	0
cultured	5
human	6
endothelial	6
cells	6
.	0

Antioxidants	0
have	0
been	0
proposed	0
to	0
be	0
anti-atherosclerotic	0
agents	0
;	0
however	0
,	0
the	0
mechanisms	0
underlying	0
their	0
beneficial	0
effects	0
are	0
poorly	0
understood	0
.	0

We	0
have	0
examined	0
the	0
effect	0
of	0
alpha-tocopherol	0
(	0
alpha-tcp	0
)	0
on	0
one	0
cellular	0
event	0
in	0
atherosclerotic	0
plaque	0
development	0
,	0
monocyte	0
adhesion	0
to	0
stimulated	7
endothelial	8
cells	8
(	0
ECs	7
)	0
.	0

Human	0
umbilical	0
vein	0
ECs	7
were	0
pretreated	0
with	0
alpha-tcp	0
before	0
stimulation	0
with	0
known	0
agonists	0
of	0
monocyte	0
adhesion	0
:	0
IL-1	9
(	0
10	0
ng/ml	0
)	0
,	0
LPS	0
(	0
10	0
ng/ml	0
)	0
,	0
thrombin	9
(	0
30	0
U/ml	0
)	0
,	0
or	0
PMA	0
(	0
10	0
nM	0
)	0
.	0

Agonist-induced	0
monocytic	0
cell	0
adhesion	0
,	0
but	0
not	0
basal	0
adhesion	0
,	0
was	0
inhibited	0
in	0
a	0
time-	0
and	0
concentration-dependent	0
manner	0
by	0
alpha-tcp	0
.	0

The	0
IC50	0
of	0
alpha-tcp	0
on	0
an	0
IL-1	9
-induced	0
response	0
was	0
45	0
microM	0
.	0

The	0
inhibition	0
correlated	0
with	0
a	0
decrease	0
in	0
steady	0
state	0
levels	0
of	0
E-selectin	3
mRNA	4
and	0
cell	0
surface	0
expression	0
of	0
E-selectin	9
which	0
is	0
consistent	0
with	0
the	0
ability	0
of	0
a	0
monoclonal	9
antibody	10
to	0
E-selectin	9
to	0
inhibit	0
monocytic	0
cell	0
adhesion	0
in	0
this	0
system	0
.	0

Probucol	0
(	0
50	0
microM	0
)	0
and	0
N-acetylcysteine	0
(	0
20	0
mM	0
)	0
also	0
inhibited	0
agonist-induced	0
monocytic	0
cell	0
adhesion	0
;	0
whereas	0
,	0
several	0
other	0
antioxidants	0
had	0
no	0
significant	0
effect	0
.	0

Protein	9
kinase	10
C	10
(	0
PKC	9
)	0
does	0
not	0
appear	0
to	0
play	0
a	0
role	0
in	0
the	0
alpha-tcp	0
effect	0
since	0
no	0
suppression	0
of	0
phosphorylation	0
of	0
PKC	9
substrates	0
was	0
observed	0
.	0

Activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
is	0
reported	0
to	0
be	0
necessary	0
but	0
not	0
sufficient	0
for	0
E-selectin	9
expression	0
in	0
EC	5
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
failed	0
to	0
show	0
an	0
alpha-tcp-induced	0
decrease	0
in	0
activation	0
of	0
this	0
transcription	9
factor	10
after	0
cytokine	9
stimulation	0
.	0

It	0
has	0
been	0
hypothesized	0
that	0
alpha-tcp	0
acts	0
as	0
an	0
anti-atherosclerotic	0
molecule	0
by	0
inhibiting	0
generation	0
of	0
oxidized	0
LDL	0
--	0
a	0
putative	0
triggering	0
molecule	0
in	0
the	0
atherosclerotic	0
process	0
.	0

Our	0
results	0
point	0
to	0
a	0
novel	0
alternative	0
mechanism	0
of	0
action	0
of	0
alpha-tcp	0
.	0

Central	7
nervous	8
system-derived	8
cells	8
express	0
a	0
kappa	0
B-binding	0
activity	0
that	0
enhances	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
transcription	0
in	0
vitro	0
and	0
facilitates	0
TAR	1
-independent	0
transactivation	0
by	0
Tat	9
.	0

The	0
Tat	9
protein	10
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
is	0
a	0
potent	0
activator	0
of	0
long	1
terminal	2
repeat	2
-directed	0
transcription	0
.	0

While	0
in	0
most	0
cell	0
types	0
,	0
activation	0
requires	0
interaction	0
of	0
Tat	0
with	0
the	0
unusual	0
transcription	1
element	2
TAR	1
,	0
astrocytic	7
glial	8
cells	8
support	0
TAR	1
-independent	0
transactivation	0
of	0
HIV-1	0
transcription	0
by	0
Tat	0
.	0

This	0
alternative	0
pathway	0
of	0
Tat	9
activation	0
is	0
mediated	0
by	0
the	0
viral	1
enhancer	2
,	0
a	0
kappa	0
B	0
domain	0
capable	0
of	0
binding	0
the	0
prototypical	0
form	0
of	0
the	0
transcription	9
factor	10
nuclear	0
factor	0
kappa	0
B	0
(	0
NF-kappa	9
B	10
)	0
present	0
in	0
many	0
cell	0
types	0
,	0
including	0
T	7
lymphocytes	8
.	0

Tat	9
transactivation	0
mediated	0
by	0
the	0
kappa	1
B	2
domain	2
is	0
sufficient	0
to	0
allow	0
replication	0
of	0
TAR	1
-deleted	0
mutant	0
HIV-1	0
in	0
astrocytes	7
.	0

The	0
present	0
study	0
demonstrates	0
the	0
existence	0
of	0
kappa	9
B-specific	10
binding	10
factors	10
present	0
in	0
human	7
glial	8
astrocytes	8
that	0
differ	0
from	0
prototypical	0
NF-kappa	9
B	10
.	0

The	0
novel	0
astrocyte-derived	0
kappa	0
B-binding	0
activity	0
is	0
retained	0
on	0
an	0
HIV-1	0
Tat	9
affinity	0
column	0
,	0
while	0
prototypical	0
NF-kappa	9
B	10
from	0
Jurkat	5
T	6
cells	6
is	0
not	0
.	0

In	0
vitro	0
transcription	0
studies	0
demonstrate	0
that	0
astrocyte-derived	9
kappa	10
B-binding	10
factors	10
activate	0
transcription	0
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
and	0
that	0
this	0
activation	0
is	0
dependent	0
on	0
the	0
kappa	1
B	2
domain	2
.	0

Moreover	0
,	0
TAR	1
-independent	0
transactivation	0
of	0
HIV-1	0
transcription	0
is	0
reproduced	0
in	0
vitro	0
in	0
an	0
astrocyte	0
factor-dependent	0
manner	0
which	0
correlates	0
with	0
kappa	0
B-binding	0
activity	0
.	0

The	0
importance	0
of	0
the	0
central	9
nervous	10
system-enriched	10
kappa	10
B	10
transcription	9
factor	10
in	0
the	0
regulation	0
of	0
HIV-1	0
expression	0
is	0
discussed	0
.	0

Human	9
interleukin-13	10
activates	0
the	0
interleukin-4-dependent	9
transcription	10
factor	10
NF-IL4	9
sharing	0
a	0
DNA	9
binding	10
motif	10
with	0
an	0
interferon-gamma-induced	9
nuclear	10
binding	10
factor	10
.	0

The	0
effects	0
of	0
interleukin-13	9
(	0
IL-13	9
)	0
and	0
interleukin-4	9
(	0
IL-4	9
)	0
on	0
cellular	0
functions	0
were	0
shown	0
to	0
be	0
quite	0
similar	0
.	0

We	0
provide	0
evidence	0
that	0
in	0
monocytes	0
as	0
well	0
as	0
in	0
T	7
lymphocytes	8
both	0
IL-4	9
and	0
IL-13	9
activate	0
the	0
same	0
recently	0
identified	0
transcription	9
factor	10
NF-IL4	9
which	0
binds	0
to	0
the	0
specific	1
responsive	2
element	2
IL-4RE	2
.	0

In	0
addition	0
,	0
we	0
show	0
that	0
a	0
nuclear	9
factor	10
activated	0
by	0
interferon-gamma	0
also	0
interacts	0
with	0
the	0
IL-4RE	1
.	0

It	0
differs	0
from	0
NF-IL4	9
in	0
the	0
electrophoretic	0
mobility	0
of	0
the	0
complex	0
with	0
DNA	0
,	0
in	0
its	0
DNA-binding	0
specificity	0
and	0
in	0
the	0
proteins	0
interacting	0
with	0
the	0
DNA	1
sequence	2
.	0

Sensitivity	0
against	0
various	0
enzyme	0
inhibitors	0
suggests	0
that	0
components	0
of	0
the	0
signal	0
transduction	0
pathway	0
are	0
shared	0
by	0
all	0
three	0
cytokines	9
.	0

Encephalomyocarditis	0
virus	0
internal	0
ribosomal	0
entry	0
site	0
RNA-protein	0
interactions	0
.	0

Translational	0
initiation	0
of	0
encephalomyocarditis	3
virus	4
(	4
EMCV	4
)	4
mRNA	4
occurs	0
by	0
ribosomal	0
entry	0
into	0
the	0
5	1
'	2
nontranslated	2
region	2
of	0
the	0
EMCV	3
mRNA	4
,	0
rather	0
than	0
by	0
ribosomal	0
scanning	0
.	0

Internal	0
ribosomal	0
binding	0
requires	0
a	0
cis-acting	1
element	2
termed	0
the	0
internal	1
ribosomal	2
entry	2
site	2
(	0
IRES	1
)	0
.	0

IRES	1
elements	2
have	0
been	0
proposed	0
to	0
be	0
involved	0
in	0
the	0
translation	0
of	0
picornavirus	3
mRNAs	4
and	0
some	0
cellular	3
mRNAs	4
.	0

Internal	0
ribosome	0
binding	0
likely	0
requires	0
the	0
interaction	0
of	0
trans-acting	9
factors	10
that	0
recognize	0
both	0
the	0
mRNA	3
and	0
the	0
ribosomal	9
complex	10
.	0

Five	0
cellular	9
proteins	10
(	0
p52	9
,	0
p57	9
,	0
p70	9
,	0
p72	9
,	0
and	0
p100	9
)	0
cross-link	0
the	0
EMCV	0
IRES	1
or	0
fragments	0
of	0
the	0
IRES	1
.	0

For	0
one	0
of	0
these	0
proteins	0
,	0
p57	9
,	0
binding	0
to	0
the	0
IRES	1
correlates	0
with	0
translation	0
.	0

Recently	0
,	0
p57	9
was	0
identified	0
to	0
be	0
very	0
similar	0
,	0
if	0
not	0
identical	0
,	0
to	0
polypyrimidine	9
tract-binding	10
protein	10
.	0

On	0
the	0
basis	0
of	0
cross-linking	0
results	0
with	0
21	0
different	0
EMCV	1
IRES	2
fragments	2
and	0
cytoplasmic	0
HeLa	0
extract	0
or	0
rabbit	0
reticulocyte	0
lysate	0
as	0
the	0
source	0
of	0
polypeptides	0
,	0
consensus	1
binding	2
sites	2
for	0
p52	9
,	0
p57	9
,	0
p70	9
,	0
and	0
p100	9
are	0
proposed	0
.	0

It	0
is	0
suggested	0
that	0
each	0
of	0
these	0
proteins	0
recognizes	0
primarily	0
a	0
structural	0
feature	0
of	0
the	0
RNA	0
rather	0
than	0
a	0
specific	0
sequence	0
.	0

A	0
novel	0
heterodimerization	9
partner	10
for	0
thyroid	9
hormone	10
receptor	10
.	0

Peroxisome	9
proliferator-activated	10
receptor	10
.	0

Retinoid-like	9
receptors	10
play	0
a	0
central	0
role	0
in	0
hormonal	0
responses	0
by	0
forming	0
heterodimers	9
with	0
other	0
nuclear	9
hormone	10
receptors	10
.	0

In	0
this	0
study	0
we	0
have	0
identified	0
the	0
peroxisome	9
proliferator-activated	10
receptor	10
(	0
PPAR	9
)	0
as	0
a	0
new	0
thyroid	9
hormone	10
receptor	10
(	10
THR	10
)	10
auxiliary	10
nuclear	10
protein	10
,	0
heterodimerizing	0
with	0
THR	9
in	0
solution	0
.	0

Although	0
these	0
heterodimers	9
do	0
not	0
recognize	0
a	0
classical	0
thyroid	1
hormone	2
response	2
element	2
(	0
TRE	1
)	0
characterized	0
by	0
direct	0
repeat	0
separated	0
by	0
four	0
nucleotides	0
(	0
DR+4	1
)	0
,	0
PPAR	9
behaves	0
as	0
a	0
dominant	0
negative	0
regulator	0
of	0
thyroid	0
hormone	0
(	0
TH	0
)	0
action	0
.	0

However	0
,	0
a	0
TH-dependent	0
positive	0
effect	0
is	0
elicited	0
by	0
selective	0
interaction	0
of	0
the	0
THR	9
beta-PPAR	10
but	0
not	0
the	0
THR	9
alpha-PPAR	10
heterodimer	10
with	0
a	0
novel	0
TRE	1
(	0
DR+2	1
)	0
.	0

The	0
critical	0
region	0
of	0
THR	9
beta	0
was	0
mapped	0
to	0
3	0
amino	0
acids	0
in	0
the	0
distal	9
box	10
of	0
the	0
DNA	9
binding	10
domain	10
.	0

Hence	0
,	0
PPAR	9
can	0
positively	0
or	0
negatively	0
influence	0
TH	0
action	0
depending	0
on	0
TRE	1
structure	0
and	0
THR	9
isotype	10
.	0

Comparison	0
of	0
retinoic	0
acid	0
and	0
phorbol	0
myristate	0
acetate	0
as	0
inducers	0
of	0
monocytic	0
differentiation	0
.	0

Several	0
human	5
myeloid	6
leukemia	6
cell	6
lines	6
growing	0
in	0
vitro	0
can	0
be	0
induced	0
to	0
differentiate	0
to	0
more	0
mature	0
monocyte/macrophage-like	7
cells	8
by	0
treatment	0
with	0
protein	9
kinase	10
C	10
-activating	0
phorbol	0
esters	0
,	0
such	0
as	0
PMA	0
.	0

In	0
addition	0
to	0
PMA	0
,	0
cells	0
of	0
the	0
THP-1	5
myeloid	6
leukemia	6
cell	6
line	6
acquire	0
macrophage-like	0
characteristics	0
after	0
treatment	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
.	0

To	0
analyze	0
the	0
signal	0
transduction	0
mechanisms	0
induced	0
by	0
RA	0
,	0
we	0
first	0
compared	0
the	0
effects	0
of	0
PMA	0
and	0
RA	0
on	0
the	0
expression	0
of	0
genes	0
which	0
are	0
known	0
to	0
be	0
regulated	0
during	0
monocytic	0
differentiation	0
.	0

Both	0
RA	0
and	0
PMA	0
effectively	0
down-regulated	0
c-myc	1
expression	0
,	0
while	0
c-myb	1
expression	0
decreased	0
only	0
after	0
PMA	0
treatment	0
.	0

Expression	0
of	0
the	0
beta	1
2-integrin	2
genes	2
,	0
CD11a	1
and	0
CD11b	1
,	0
was	0
clearly	0
increased	0
after	0
both	0
of	0
these	0
treatments	0
.	0

Their	0
effects	0
on	0
the	0
src-family	1
tyrosine	2
kinase	2
genes	2
were	0
different	0
:	0
hck	1
expression	0
was	0
similarly	0
induced	0
by	0
these	0
agents	0
but	0
lyn	0
expression	0
was	0
stronger	0
and	0
more	0
rapid	0
after	0
RA	0
treatment	0
.	0

RA	0
also	0
enhanced	0
lyn	3
mRNA	4
production	0
rapidly	0
in	0
HL-60	5
,	0
indicating	0
that	0
the	0
activation	0
of	0
lyn	1
gene	2
expression	0
is	0
common	0
in	0
monocytic	0
and	0
granulocytic	0
maturation	0
of	0
myeloid	7
leukemia	8
cells	8
.	0

To	0
examine	0
whether	0
the	0
AP-1	1
enhancer	2
activity	0
is	0
involved	0
in	0
RA-induced	0
monocytic	0
differentiation	0
,	0
THP-1	5
cells	6
were	0
transiently	0
transfected	0
with	0
a	0
chloramphenicol	1
acetyl	2
transferase	2
(	2
CAT	2
)	2
-reporter	2
gene	2
containing	0
5	0
copies	0
of	0
the	0
AP-1	1
binding	2
sites	2
.	0

In	0
contrast	0
to	0
PMA	0
,	0
RA	0
did	0
not	0
induce	0
any	0
CAT	9
activity	0
in	0
these	0
cells	0
,	0
thus	0
suggesting	0
that	0
the	0
RA-induced	0
changes	0
in	0
the	0
expression	0
of	0
those	0
genes	0
described	0
above	0
were	0
not	0
dependent	0
on	0
the	0
AP-1	1
enhancer	2
activity	0
.	0

An	0
active	0
v-abl	9
protein	10
tyrosine	10
kinase	10
blocks	0
immunoglobulin	1
light-chain	2
gene	2
rearrangement	0
.	0

Lymphoid	7
cells	8
transformed	0
by	0
Abelson	0
murine	0
leukemia	0
virus	0
have	0
provided	0
one	0
of	0
the	0
classic	0
models	0
for	0
study	0
of	0
early	0
B-cell	0
development	0
and	0
immunoglobulin	9
rearrangement	0
.	0

Most	0
of	0
these	0
cells	0
have	0
rearranged	0
their	0
heavy-chain	1
locus	2
but	0
not	0
their	0
light	1
chain	2
genes	2
,	0
suggesting	0
that	0
an	0
active	0
v-abl	9
protein	10
interferes	0
with	0
this	0
differentiation	0
step	0
.	0

To	0
test	0
this	0
hypothesis	0
,	0
light-chain	1
gene	2
structure	2
was	0
examined	0
in	0
pre-B	5
cells	6
transformed	0
by	0
temperature-sensitive	0
mutants	0
of	0
the	0
Abelson	0
virus	0
and	0
in	0
derivatives	0
that	0
survive	0
at	0
the	0
nonpermissive	0
temperature	0
because	0
they	0
express	0
a	0
human	1
BCL-2	2
gene	2
.	0

Our	0
studies	0
reveal	0
that	0
inactivation	0
of	0
the	0
v-abl	9
protein	10
tyrosine	10
kinase	10
triggers	0
high-frequency	0
rearrangement	0
of	0
kappa	1
and	2
lambda	2
light-chain	2
genes	2
.	0

These	0
events	0
are	0
accompanied	0
by	0
marked	0
increases	0
in	0
the	0
expression	0
of	0
RAG-1	3
and	4
RAG-2	4
RNAs	4
.	0

These	0
increases	0
occur	0
in	0
the	0
absence	0
of	0
protein	0
synthesis	0
but	0
are	0
dependent	0
on	0
inactivation	0
of	0
the	0
v-abl	9
protein	10
tyrosine	10
kinase	10
.	0

As	0
documented	0
in	0
the	0
accompanying	0
paper	0
(	0
Klug	0
et	0
al.	0
,	0
this	0
issue	0
)	0
,	0
an	0
active	0
v-abl	9
protein	10
also	0
suppresses	0
the	0
activity	0
of	0
NF-kappa	9
B/rel	10
and	0
expression	0
controlled	0
by	0
the	0
kappa	1
intron	2
enhancer	2
.	0

Together	0
these	0
data	0
demonstrate	0
that	0
the	0
v-abl	9
protein	10
specifically	0
interferes	0
with	0
light-chain	1
gene	2
rearrangement	0
by	0
suppressing	0
at	0
least	0
two	0
pathways	0
essential	0
for	0
this	0
stage	0
of	0
B-cell	7
differentiation	0
and	0
suggest	0
that	0
tyrosine	0
phosphorylation	0
is	0
important	0
in	0
regulating	0
RAG	1
gene	2
expression	0
.	0

Calcium	0
signalling	0
in	0
T	7
cells	8
stimulated	0
by	0
a	0
cyclophilin	9
B-binding	10
protein	10
.	0

The	0
immunosuppressant	0
drug	0
cyclosporin	0
A	0
blocks	0
a	0
calcium-dependent	0
signal	0
from	0
the	0
T-cell	9
receptor	10
(	0
TCR	9
)	0
that	0
normally	0
leads	0
to	0
T-cell	0
activation	0
.	0

When	0
bound	0
to	0
cyclophilin	9
,	0
cyclosporin	0
A	0
binds	0
and	0
inactivates	0
the	0
key	0
signalling	0
intermediate	0
calcineurin	9
.	0

To	0
identify	0
potential	0
cellular	0
homologues	0
of	0
cyclosporin	0
A	0
that	0
might	0
regulate	0
calcium	0
signalling	0
,	0
we	0
have	0
cloned	0
human	0
genes	0
encoding	0
cyclophilin	9
B-binding-proteins	10
using	0
the	0
yeast	0
two-hybrid	0
system	0
.	0

One	0
gene	0
product	0
,	0
when	0
overexpressed	0
in	0
Jurkat	5
T	6
cells	6
,	0
specifically	0
induced	0
transcription	0
from	0
the	0
interleukin-2	1
enhancer	2
,	0
by	0
activating	0
the	0
T-cell-specific	9
transcription	10
factors	10
NF-AT	9
and	0
NF-IL2A	9
.	0

This	0
protein	0
,	0
termed	0
calcium-signal	9
modulating	10
cyclophilin	10
ligand	10
(	0
CAML	9
)	0
,	0
acts	0
downstream	0
of	0
the	0
TCR	9
and	0
upstream	0
of	0
calcineurin	9
by	0
causing	0
an	0
influx	0
of	0
calcium	0
.	0

CAML	9
appears	0
to	0
be	0
a	0
new	0
participant	0
in	0
the	0
calcium-signal	0
transduction	0
pathway	0
,	0
implicating	0
cyclophilin	9
B	10
in	0
calcium	0
signalling	0
,	0
even	0
in	0
the	0
absence	0
of	0
cyclosporin	0
.	0

Expression	0
and	0
genomic	0
configuration	0
of	0
GM-CSF	9
,	0
IL-3	9
,	0
M-CSF	9
receptor	10
(	0
C-FMS	9
)	0
,	0
early	1
growth	2
response	2
gene-1	2
(	0
EGR-1	1
)	0
and	0
M-CSF	1
genes	2
in	0
primary	0
myelodysplastic	0
syndromes	0
.	0

Peripheral	0
blood	0
mononuclear	0
cells	0
from	0
seventeen	0
patients	0
with	0
primary	0
myelodysplastic	0
syndromes	0
(	0
MDS	0
)	0
in	0
advanced	0
stage	0
were	0
enriched	0
for	0
blasts	7
and	0
tested	0
for	0
(	0
1	0
)	0
karyotype	0
,	0
(	0
2	0
)	0
genomic	0
configuration	0
and	0
(	0
3	0
)	0
expression	0
of	0
IL-3	1
,	2
GM-CSF	2
,	2
FMS	2
and	2
EGR-1	2
genes	2
which	0
are	0
all	0
located	0
on	0
the	0
long	1
arm	2
of	2
chromosome	2
5	2
.	0

The	0
expression	0
of	0
the	0
M-CSF	1
gene	2
,	0
that	0
has	0
been	0
recently	0
reassigned	0
to	0
the	0
short	1
arm	2
of	2
chromosome	2
1	2
(	0
lp	1
)	0
,	0
was	0
also	0
investigated	0
.	0

Aims	0
of	0
the	0
study	0
were	0
to	0
(	0
1	0
)	0
assess	0
the	0
potential	0
role	0
of	0
the	0
expression	0
of	0
these	0
genes	0
in	0
the	0
maintenance	0
and	0
expansion	0
of	0
the	0
neoplastic	5
clones	6
and	0
(	0
2	0
)	0
search	0
for	0
constitutional	0
losses	0
or	0
rearrangements	0
of	0
one	0
allele	1
followed	0
by	0
a	0
deletion	0
of	0
the	0
second	0
allele	1
of	0
the	0
same	0
genes	0
in	0
the	0
leukemic	7
cells	8
.	0

The	0
latter	0
issue	0
was	0
investigated	0
by	0
comparing	0
,	0
in	0
8	0
cases	0
,	0
constitutive	1
DNA	2
from	0
skin	7
fibroblasts	8
with	0
leukemic	1
DNA	2
.	0

Eleven	0
of	0
the	0
17	0
patients	0
had	0
abnormal	0
karyotypes	0
.	0

The	0
M-CSF	1
gene	2
was	0
expressed	0
in	0
6	0
cases	0
and	0
the	0
FMS	1
and	0
the	0
EGR-1	1
genes	2
were	0
expressed	0
in	0
2	0
of	0
the	0
latter	0
cases	0
.	0

An	0
autocrine	0
mechanism	0
of	0
growth	0
could	0
be	0
hypothesized	0
only	0
for	0
the	0
2	0
patients	0
whose	0
cells	0
expressed	0
both	0
the	0
M-CSF	1
and	2
FMS	2
genes	2
.	0

No	0
germline	0
changes	0
or	0
rearrangements	0
were	0
observed	0
in	0
any	0
of	0
the	0
genes	0
studied	0
.	0

Thus	0
,	0
deregulation	0
of	0
genes	0
encoding	0
for	0
certain	0
hemopoietic	9
growth	10
factors	10
or	0
receptors	0
does	0
not	0
seem	0
to	0
represent	0
a	0
major	0
mechanism	0
of	0
MDS	0
progression	0
.	0

A	0
novel	0
human	1
homeobox	2
gene	2
distantly	0
related	0
to	0
proboscipedia	1
is	0
expressed	0
in	0
lymphoid	0
and	0
pancreatic	0
tissues	0
.	0

A	0
novel	0
human	1
homeobox	2
gene	2
,	0
HB9	1
,	0
was	0
isolated	0
from	0
a	0
cDNA	1
library	2
prepared	0
from	0
in	0
vitro	7
stimulated	8
human	8
tonsil	8
B	8
lymphocytes	8
and	0
from	0
a	0
human	1
genomic	2
library	2
.	0

The	0
HB9	1
gene	2
is	0
composed	0
of	0
3	0
exons	1
spread	0
over	0
6	0
kilobases	0
of	0
DNA	0
.	0

An	0
open	1
reading	2
frame	2
of	0
1206	0
nucleotides	0
is	0
in	0
frame	0
with	0
a	0
diverged	1
homeodomain	2
.	0

The	0
predicted	0
HB9	9
protein	10
has	0
a	0
molecular	0
mass	0
of	0
41	0
kilodaltons	0
and	0
is	0
enriched	0
for	0
alanine	0
,	0
glycine	0
,	0
and	0
leucine	0
.	0

The	0
HB9	1
homeodomain	2
is	0
most	0
similar	0
to	0
that	0
of	0
the	0
Drosophila	1
melanogaster	2
homeobox	2
gene	2
proboscipedia	1
.	0

Northern	0
blot	0
analysis	0
of	0
poly	3
(	4
A	4
)	4
RNA	4
purified	0
from	0
the	0
human	5
B	6
cell	6
line	6
RPMI	6
8226	6
and	0
from	0
activated	7
T	8
cells	8
revealed	0
a	0
major	3
mRNA	4
transcript	4
of	0
2.2	0
kilobases	0
.	0

Similar	0
analysis	0
of	0
poly	3
(	4
A	4
)	4
RNA	4
from	0
a	0
variety	0
of	0
adult	0
tissues	0
demonstrated	0
HB9	1
transcripts	0
in	0
pancreas	0
,	0
small	0
intestine	0
,	0
and	0
colon	0
.	0

Reverse	0
transcriptase-polymerase	0
chain	0
reaction	0
was	0
used	0
to	0
examine	0
HB9	3
RNA	4
transcripts	4
in	0
hematopoietic	5
cell	6
lines	6
.	0

HB9	3
RNA	4
transcripts	4
were	0
most	0
prevalent	0
in	0
several	0
human	5
B	6
cell	6
lines	6
and	0
K562	5
cells	6
.	0

In	0
addition	0
,	0
transcripts	0
were	0
detected	0
in	0
RNA	0
prepared	0
from	0
tonsil	7
B	8
cells	8
and	0
in	0
situ	0
hybridization	0
studies	0
localized	0
them	0
in	0
the	0
germinal	0
center	0
region	0
of	0
adult	0
tonsil	0
.	0

These	0
findings	0
suggest	0
the	0
involvement	0
of	0
HB9	1
in	0
regulating	0
gene	0
transcription	0
in	0
lymphoid	0
and	0
pancreatic	0
tissues	0
.	0

Human	9
immunodeficiency	10
virus	10
type	10
1	10
Tat	10
upregulates	0
interleukin-2	9
secretion	0
in	0
activated	7
T	8
cells	8
.	0

Dysregulation	0
of	0
cytokines	9
secreted	0
by	0
T	7
cells	8
may	0
play	0
an	0
important	0
role	0
in	0
the	0
pathogenesis	0
of	0
AIDS	0
.	0

To	0
investigate	0
the	0
effects	0
of	0
human	9
immunodeficiency	10
virus	10
type	10
1	10
(	10
HIV-1	10
)	10
Tat	10
on	0
interleukin-2	9
(	0
IL-2	9
)	0
expression	0
,	0
we	0
used	0
IL-2	1
promoter-chloramphenicol	2
acetyltransferase	2
constructs	2
and	0
IL-2-secreting	5
Jurkat	6
T	6
cells	6
as	0
a	0
model	0
system	0
.	0

Transient	0
expression	0
of	0
HIV-1	9
Tat	10
induced	0
a	0
five-	0
to	0
eightfold	0
increase	0
in	0
IL-2	1
promoter	2
activity	0
in	0
Jurkat	5
T	6
cells	6
stimulated	0
with	0
phytohemagglutinin	9
and	0
phorbol	0
myristate	0
acetate	0
.	0

IL-2	9
secretion	0
was	0
increased	0
more	0
than	0
twofold	0
in	0
both	0
Jurkat	5
T	6
cells	6
and	0
primary	5
T	6
cells	6
stimulated	0
by	0
extracellular	9
HIV-1	10
Tat	10
protein	10
.	0

Analysis	0
of	0
mRNA	3
suggested	0
that	0
Tat	0
exerts	0
its	0
effect	0
on	0
IL-2	9
primarily	0
at	0
the	0
transcriptional	0
level	0
.	0

The	0
NF-kappa	1
B	2
site	2
at	0
positions	0
-206	1
to	2
-195	2
of	0
the	0
IL-2	1
promoter	2
was	0
required	0
but	0
not	0
sufficient	0
for	0
the	0
Tat	9
effect	0
.	0

The	0
Tat	9
-mediated	0
increase	0
in	0
IL-2	1
promoter	2
activity	0
could	0
selectively	0
be	0
blocked	0
by	0
antisense	0
tat	0
or-unlike	0
the	0
analogous	0
effect	0
of	0
human	9
T-cell	10
lymphotropic	10
virus	10
type	10
1	10
Tax	10
-by	0
cyclosporin	0
A	0
.	0

The	0
observed	0
increase	0
in	0
IL-2	9
levels	0
might	0
facilitate	0
virus	0
spread	0
from	0
or	0
to	0
T	7
cells	8
.	0

Furthermore	0
,	0
it	0
might	0
contribute	0
to	0
the	0
hypergammaglobulinemia	0
or	0
,	0
together	0
with	0
other	0
cytokines	9
found	0
to	0
be	0
dysregulated	0
,	0
the	0
T-helper	0
cell	0
dysfunctions	0
observed	0
in	0
AIDS	0
patients	0
.	0

Activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
in	0
human	7
lymphoblastoid	8
cells	8
by	0
low-dose	0
ionizing	0
radiation	0
.	0

Nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
a	0
pleiotropic	9
transcription	10
factor	10
which	0
is	0
involved	0
in	0
the	0
transcriptional	0
regulation	0
of	0
several	0
specific	0
genes	0
.	0

Recent	0
reports	0
demonstrated	0
that	0
ionizing	0
radiation	0
in	0
the	0
dose	0
range	0
of	0
2-50	0
Gy	0
results	0
in	0
expression	0
of	0
NF-kappa	9
B	10
in	0
human	5
KG-1	6
myeloid	6
leukemia	6
cells	6
and	0
human	7
B-lymphocyte	8
precursor	8
cells	8
;	0
the	0
precise	0
mechanism	0
involved	0
and	0
the	0
significance	0
are	0
not	0
yet	0
known	0
.	0

The	0
present	0
report	0
demonstrates	0
that	0
even	0
lower	0
doses	0
of	0
ionizing	0
radiation	0
,	0
0.25-2.0	0
Gy	0
,	0
are	0
capable	0
of	0
inducing	0
expression	0
of	0
NF-kappa	9
B	10
in	0
EBV-transformed	5
244B	6
human	6
lymphoblastoid	6
cells	6
.	0

These	0
results	0
are	0
in	0
a	0
dose	0
range	0
where	0
the	0
viability	0
of	0
the	0
cells	0
remains	0
very	0
high	0
.	0

After	0
exposure	0
to	0
137Cs	0
gamma	0
rays	0
at	0
a	0
dose	0
rate	0
of	0
1.17	0
Gy/min	0
,	0
a	0
maximum	0
in	0
expression	0
of	0
NF-kappa	9
B	10
was	0
seen	0
at	0
8	0
h	0
after	0
a	0
0.5-Gy	0
exposure	0
.	0

Time-course	0
studies	0
revealed	0
a	0
biphasic	0
time-dependent	0
expression	0
after	0
0.5-	0
,	0
1-	0
and	0
2-Gy	0
exposures	0
.	0

However	0
,	0
for	0
each	0
time	0
examined	0
,	0
the	0
expression	0
of	0
NF-kappa	9
B	10
was	0
maximum	0
after	0
the	0
0.5-Gy	0
exposure	0
.	0

The	0
expression	0
of	0
the	0
p50	9
and	10
p65	10
NF-kappa	10
B	10
subunits	10
was	0
also	0
shown	0
to	0
be	0
regulated	0
differentially	0
after	0
exposures	0
to	0
1.0	0
and	0
2.0	0
Gy	0
.	0

Alternative	0
splicing	0
of	0
RNA	3
transcripts	4
encoded	0
by	0
the	0
murine	1
p105	2
NF-kappa	2
B	2
gene	2
generates	0
I	9
kappa	10
B	10
gamma	10
isoforms	10
with	0
different	0
inhibitory	0
activities	0
.	0

The	0
gene	0
encoding	0
the	0
105-kDa	9
protein	10
(	10
p105	10
)	10
precursor	10
of	0
the	0
p50	9
subunit	0
of	0
transcription	0
factor	0
NF-kappa	9
B	10
also	0
encodes	0
a	0
p70	9
I	10
kappa	10
B	10
protein	10
,	0
I	9
kappa	10
B	10
gamma	10
,	0
which	0
is	0
identical	0
to	0
the	0
C-terminal	9
607	10
amino	10
acids	10
of	0
p105	9
.	0

Here	0
we	0
show	0
that	0
alternative	0
RNA	0
splicing	0
generates	0
I	9
kappa	10
B	10
gamma	10
isoforms	10
with	0
properties	0
different	0
from	0
those	0
of	0
p70	9
.	0

One	0
63-kDa	9
isoform	10
,	0
termed	0
I	9
kappa	10
B	10
gamma-1	10
,	0
which	0
lacks	0
59	0
amino	0
acids	0
C-terminal	0
to	0
ankyrin	9
repeat	10
7	10
,	0
has	0
a	0
novel	0
35-amino	9
acid	10
C	10
terminus	10
encoded	0
by	0
an	0
alternative	1
reading	2
frame	2
of	0
the	0
p105	1
gene	2
.	0

A	0
55-kDa	9
isoform	10
,	0
I	9
kappa	10
B	10
gamma-2	10
,	0
lacks	0
the	0
190	9
C-terminal	10
amino	10
acids	10
of	0
p70	9
I	9
kappa	10
B	10
gamma	10
.	0

In	0
contrast	0
to	0
p70	9
I	9
kappa	10
B	10
gamma	10
,	0
which	0
is	0
a	0
cytoplasmic	9
protein	10
,	0
I	9
kappa	10
B	10
gamma-1	10
is	0
found	0
in	0
both	0
the	0
cytoplasm	0
and	0
nucleus	0
,	0
whereas	0
I	9
kappa	10
B	10
gamma-2	10
is	0
predominantly	0
nuclear	0
.	0

The	0
I	9
kappa	10
B	10
gamma	10
isoforms	10
also	0
display	0
differences	0
in	0
specificity	0
and	0
affinity	0
for	0
Rel/NF-kappa	9
B	10
proteins	10
.	0

While	0
p70	9
I	9
kappa	10
B	10
gamma	10
inhibits	0
p50-	0
,	0
p65-	0
,	0
and	0
c-Rel-mediated	0
transactivation	0
and/or	0
DNA	0
binding	0
,	0
both	0
I	9
kappa	10
B	10
gamma-1	10
and	0
I	9
kappa	10
B	10
gamma-2	10
are	0
specific	0
for	0
p50	9
and	0
have	0
different	0
affinities	0
for	0
this	0
subunit	0
.	0

The	0
absence	0
in	0
I	9
kappa	10
B	10
gamma-1	10
and	0
I	9
kappa	10
B	10
gamma-2	10
of	0
a	0
protein	1
kinase	2
A	2
site	2
whose	0
phosphorylation	0
modulates	0
p70	9
I	9
kappa	10
B	10
gamma	10
inhibitory	0
activity	0
suggests	0
that	0
alternative	0
RNA	0
splicing	0
may	0
be	0
used	0
to	0
generate	0
I	9
kappa	10
B	10
gamma	10
isoforms	10
that	0
respond	0
differently	0
to	0
intracellular	0
signals	0
.	0

Structure	0
and	0
expression	0
of	0
the	0
human	1
GATA3	2
gene	2
.	0

GATA3	9
,	0
a	0
member	0
of	0
the	0
GATA	9
family	10
that	0
is	0
abundantly	0
expressed	0
in	0
the	0
T-lymphocyte	7
lineage	8
,	0
is	0
thought	0
to	0
participate	0
in	0
T-cell	9
receptor	10
gene	0
activation	0
through	0
binding	0
to	0
enhancers	1
.	0

To	0
understand	0
GATA3	1
gene	2
regulation	0
,	0
we	0
cloned	0
the	0
human	1
gene	2
and	0
the	0
5	1
'	2
end	2
of	0
the	0
mouse	1
GATA3	2
gene	2
.	0

We	0
show	0
that	0
the	0
human	1
GATA3	2
gene	2
contains	0
six	0
exons	1
distributed	0
over	0
17	0
kb	0
of	0
DNA	0
.	0

The	0
two	0
human	9
GATA3	10
zinc	10
fingers	10
are	0
encoded	0
by	0
two	0
separate	0
exons	1
highly	0
conserved	0
with	0
those	0
of	0
GATA1	9
,	0
but	0
no	0
other	0
structural	0
homologies	0
between	0
these	0
two	0
genes	0
can	0
be	0
found	0
.	0

The	0
human	1
and	2
mouse	2
GATA3	2
transcription	2
units	2
start	0
at	0
a	0
major	1
initiation	2
site	2
.	0

The	0
promoter	0
sequence	0
analysis	0
of	0
these	0
two	0
genes	0
revealed	0
that	0
they	0
are	0
embedded	0
within	0
a	0
CpG	1
island	2
and	0
share	0
structural	0
features	0
often	0
found	0
in	0
the	0
promoters	1
of	0
housekeeping	1
genes	2
.	0

Finally	0
,	0
we	0
show	0
that	0
a	0
DNA	1
fragment	2
containing	0
the	0
human	1
GATA3	2
transcription	2
unit	2
,	0
3	1
kb	2
upstream	2
from	0
the	0
initiation	1
site	2
and	0
4	1
kb	2
downstream	2
from	0
the	0
polyadenylation	1
site	2
,	0
displays	0
T-cell	0
specificity	0
.	0

Characterization	0
of	0
the	0
human	1
gene	2
encoding	0
LBR	9
,	0
an	0
integral	9
protein	10
of	0
the	0
nuclear	0
envelope	0
inner	0
membrane	0
.	0

We	0
have	0
characterized	0
the	0
human	1
gene	2
encoding	0
LBR	9
,	0
an	0
integral	9
protein	10
of	0
the	0
nuclear	0
envelope	0
inner	0
membrane	0
.	0

Restriction	0
mapping	0
shows	0
that	0
the	0
transcription	1
unit	2
spans	0
approximately	0
35	0
kilobases	0
.	0

A	0
transcription	0
start	0
site	0
is	0
located	0
approximately	0
4	0
kilobases	0
5	0
'	0
to	0
the	0
translation	1
initiation	2
codon	2
,	0
and	0
an	0
RNA	0
splice	0
of	0
3863	0
bases	0
occurs	0
in	0
the	0
5'-untranslated	1
region	2
to	0
generate	0
mature	3
HeLa	4
cell	4
mRNA	4
.	0

5	0
'	0
to	0
the	0
identified	0
transcription	1
start	2
site	2
are	0
two	0
CCAAT	1
sequences	2
and	0
potential	1
recognition	2
sites	2
for	0
several	0
transcription	9
factors	10
including	0
Sp1	9
,	0
AP-1	9
,	0
AP-2	9
,	0
and	0
NF-kB	9
.	0

There	0
are	0
13	0
protein	0
coding	0
exons	1
in	0
the	0
LBR	1
gene	2
.	0

LBR	9
's	0
nucleoplasmic	9
domain	10
is	0
encoded	0
by	0
exons	1
1-4	2
,	0
and	0
its	0
hydrophobic	9
domain	10
,	0
with	0
eight	0
putative	0
transmembrane	9
segments	10
,	0
is	0
encoded	0
by	0
exons	1
5-13	2
.	0

The	0
hydrophobic	9
domain	10
is	0
homologous	0
to	0
three	0
yeast	0
polypeptides	0
,	0
suggesting	0
that	0
this	0
higher	1
eukaryotic	2
gene	2
could	0
have	0
evolved	0
from	0
recombination	0
between	0
a	0
gene	0
that	0
encoded	0
a	0
soluble	9
nuclear	10
protein	10
and	0
a	0
membrane	1
protein	2
gene	2
similar	0
to	0
those	0
in	0
yeast	0
.	0

These	0
results	0
are	0
the	0
first	0
to	0
demonstrate	0
the	0
structural	0
organization	0
of	0
a	0
vertebrate	1
gene	2
encoding	0
an	0
integral	9
membrane	10
protein	10
of	0
the	0
nuclear	0
envelope	0
that	0
may	0
be	0
a	0
member	0
of	0
a	0
family	0
of	0
polypeptides	0
conserved	0
in	0
evolution	0
.	0

Retinoic	0
acid-induced	0
expression	0
of	0
CD38	9
antigen	10
in	0
myeloid	7
cells	8
is	0
mediated	0
through	0
retinoic	9
acid	10
receptor-alpha	10
.	0

CD38	9
is	0
a	0
leukocyte	9
differentiation	10
antigen	10
that	0
has	0
been	0
thought	0
to	0
be	0
a	0
phenotypic	0
marker	0
of	0
different	0
subpopulations	0
of	0
T-	7
and	8
B-	8
lymphocytes	8
.	0

In	0
myeloid	7
cells	8
,	0
CD38	9
is	0
expressed	0
during	0
early	0
stages	0
of	0
differentiation	0
.	0

Virtually	0
no	0
information	0
is	0
available	0
on	0
regulation	0
and	0
functions	0
of	0
CD38	9
.	0

Recently	0
we	0
reported	0
that	0
all-trans-retinoic	0
acid	0
(	0
ATRA	0
)	0
is	0
a	0
potent	0
and	0
highly	0
specific	0
inducer	0
of	0
CD38	9
expression	0
in	0
human	7
promyelocytic	8
leukemia	8
cells	8
.	0

Here	0
we	0
report	0
that	0
ATRA-induced	0
expression	0
of	0
CD38	9
antigen	10
in	0
myeloid	7
cells	8
is	0
mediated	0
through	0
retinoic	9
acid-alpha	10
receptor	10
(	0
RAR	9
alpha	10
)	0
.	0

ATRA	0
failed	0
to	0
induce	0
CD38	9
expression	0
in	0
a	0
mutant	5
subclone	6
of	0
the	0
HL-60	5
myeloid	6
leukemia	6
cell	6
line	6
(	0
designated	0
HL-60R	5
)	0
that	0
is	0
relatively	0
resistant	0
to	0
ATRA-induced	0
granulocytic	0
differentiation	0
.	0

Retroviral	0
vector-mediated	0
transduction	0
of	0
RA	9
receptor	10
(	0
RAR	9
alpha	10
)	0
into	0
this	0
HL-60R	5
subclone	6
completely	0
restored	0
the	0
sensitivity	0
of	0
these	0
cells	0
to	0
ATRA	0
in	0
terms	0
of	0
their	0
ability	0
to	0
express	0
CD38	9
.	0

In	0
contrast	0
,	0
CD38	9
expression	0
was	0
not	0
inducible	0
by	0
ATRA	0
in	0
HL-60R	5
cells	6
,	0
transfected	0
with	0
a	0
functional	0
RAR	9
beta	10
,	0
RAR	9
gamma	10
,	0
or	0
RXR	9
alpha	10
receptor	10
.	0

Induction	0
of	0
CD38	9
in	0
acute	7
promyelocytic	8
and	8
acute	8
myeloblastic	8
leukemia	8
cells	8
was	0
independent	0
of	0
ATRA-induced	0
cytodifferentiation	0
.	0

Following	0
culture	0
with	0
ATRA	0
,	0
increased	0
CD38	9
protein	0
levels	0
were	0
also	0
observed	0
in	0
normal	7
CD34+	8
bone	8
marrow	8
cells	8
,	0
but	0
not	0
on	0
normal	7
circulating	8
granulocytes	8
.	0

From	0
these	0
results	0
,	0
we	0
conclude	0
that	0
CD38	9
is	0
ATRA	0
inducible	0
in	0
myeloid	7
leukemia	8
cells	8
and	0
normal	7
CD34+	8
bone	8
marrow	8
cells	8
.	0

This	0
effect	0
is	0
independent	0
of	0
differentiation	0
and	0
is	0
mediated	0
by	0
RAR	9
alpha	10
in	0
HL-60	7
cells	8
,	0
suggesting	0
a	0
similar	0
role	0
for	0
RAR	9
alpha	10
in	0
CD38	9
expression	0
in	0
other	0
hematopoietic	7
cells	8
.	0

Some	0
antioxidants	0
inhibit	0
,	0
in	0
a	0
co-ordinate	0
fashion	0
,	0
the	0
production	0
of	0
tumor	9
necrosis	10
factor-alpha	10
,	0
IL-beta	9
,	0
and	0
IL-6	9
by	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

Some	0
antioxidants	0
,	0
including	0
butylated	0
hydroxyanisole	0
(	0
BHA	0
)	0
,	0
tetrahydropapaveroline	0
(	0
THP	0
)	0
,	0
nordihydroguiauretic	0
acid	0
,	0
and	0
10	0
,	0
11-dihydroxyaporphine	0
(	0
DHA	0
)	0
,	0
were	0
found	0
to	0
be	0
potent	0
inhibitors	0
of	0
the	0
production	0
of	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
,	0
IL-1	9
beta	10
,	0
and	0
IL-6	9
by	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
stimulated	0
by	0
lipopolysaccharide	0
(	0
LPS	0
)	0
(	0
IC50s	0
in	0
the	0
low	0
micromolar	0
range	0
)	0
.	0

Inhibition	0
of	0
cytokine	9
production	0
was	0
gene	0
selective	0
and	0
not	0
due	0
to	0
general	0
effects	0
on	0
protein	0
synthesis	0
.	0

Inhibition	0
of	0
cytokine	9
production	0
by	0
PBMC	7
was	0
observed	0
also	0
when	0
other	0
inducers	0
were	0
used	0
(	0
staphylococci	0
,	0
silica	0
,	0
zymosan	0
)	0
.	0

Much	0
higher	0
concentrations	0
of	0
other	0
antioxidants	0
--	0
including	0
ascorbic	0
acid	0
,	0
trolox	0
,	0
alpha-tocopherol	0
,	0
butylated	0
hydroxytoluene	0
,	0
and	0
the	0
5-lipoxygenase	0
inhibitor	0
zileuton	0
--	0
did	0
not	0
affect	0
the	0
production	0
of	0
these	0
cytokines	9
.	0

The	0
active	0
compounds	0
did	0
not	0
inhibit	0
IL-1	9
-induced	0
production	0
of	0
IL-6	9
in	0
fibroblasts	7
,	0
showing	0
the	0
cell	0
selectivity	0
of	0
the	0
effect	0
.	0

Antioxidant-mediated	0
inhibition	0
of	0
cytokine	9
production	0
was	0
correlated	0
with	0
low	0
levels	0
of	0
the	0
corresponding	0
messenger	3
RNAs	4
.	0

Nuclear	0
run-on	0
experiments	0
showed	0
that	0
THP	0
inhibited	0
transcription	0
of	0
the	0
IL-1	1
beta	2
gene	2
.	0

THP	0
decreased	0
the	0
concentration	0
of	0
the	0
transcription	9
factors	10
NF-kappa	9
B	10
and	0
AP-1	9
detected	0
in	0
nuclear	0
extracts	0
of	0
PBMC	7
cultured	0
in	0
the	0
presence	0
or	0
absence	0
of	0
LPS	0
.	0

THP	0
and	0
DHA	0
markedly	0
decreased	0
the	0
levels	0
of	0
TNF-alpha	9
and	0
IL-1	9
beta	10
in	0
the	0
circulation	0
of	0
mice	0
following	0
LPS	0
injection	0
.	0

Thus	0
antioxidants	0
vary	0
widely	0
in	0
potency	0
as	0
inhibitors	0
of	0
the	0
activation	0
of	0
transcription	9
factors	10
and	0
of	0
the	0
transcription	0
of	0
genes	1
for	0
pro-inflammatory	9
cytokines	10
.	0

Coordinate	0
inhibition	0
of	0
the	0
transcription	0
of	0
genes	0
for	0
inflammatory	0
cytokines	9
could	0
provide	0
a	0
strategy	0
for	0
therapy	0
of	0
diseases	0
with	0
inflammatory	0
pathogenesis	0
and	0
for	0
septic	0
shock	0
.	0

An	0
interleukin-4-induced	9
transcription	10
factor	10
:	0
IL-4	9
Stat	10
.	0

Interleukin-4	9
(	0
IL-4	9
)	0
is	0
an	0
immunomodulatory	0
cytokine	0
secreted	0
by	0
activated	0
T	7
lymphocytes	8
,	0
basophils	7
,	0
and	0
mast	7
cells	8
.	0

It	0
plays	0
an	0
important	0
role	0
in	0
modulating	0
the	0
balance	0
of	0
T	7
helper	8
(	8
Th	8
)	8
cell	8
subsets	8
,	0
favoring	0
expansion	0
of	0
the	0
Th2	7
lineage	8
relative	0
to	0
Th1	7
.	0

Imbalance	0
of	0
these	0
T	7
lymphocyte	8
subsets	8
has	0
been	0
implicated	0
in	0
immunological	0
diseases	0
including	0
allergy	0
,	0
inflammation	0
,	0
and	0
autoimmune	0
disease	0
.	0

IL-4	9
may	0
mediate	0
its	0
biological	0
effects	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
activating	0
a	0
tyrosine-phosphorylated	9
DNA	10
binding	10
protein	10
.	0

This	0
protein	0
has	0
now	0
been	0
purified	0
and	0
its	0
encoding	0
gene	0
cloned	0
.	0

Examination	0
of	0
the	0
primary	0
amino	0
acid	0
sequence	0
of	0
this	0
protein	0
indicates	0
that	0
it	0
is	0
a	0
member	0
of	0
the	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
Stat	10
)	10
family	10
of	0
DNA	9
binding	10
proteins	10
,	0
hereby	0
designated	0
IL-4	9
Stat	10
.	0

Study	0
of	0
the	0
inhibitory	0
activities	0
of	0
phosphotyrosine-containing	0
peptides	0
derived	0
from	0
the	0
intracellular	9
domain	10
of	10
the	10
IL-4	10
receptor	10
provided	0
evidence	0
for	0
direct	0
coupling	0
of	0
receptor	9
and	0
transcription	9
factor	10
during	0
the	0
IL-4	9
Stat	10
activation	0
cycle	0
.	0

Such	0
observations	0
indicate	0
that	0
IL-4	9
Stat	10
has	0
the	0
same	0
functional	9
domain	10
for	0
both	0
receptor	0
coupling	0
and	0
dimerization	0
.	0

Evaluation	0
of	0
the	0
respiratory	0
epithelium	0
of	0
normals	0
and	0
individuals	0
with	0
cystic	0
fibrosis	0
for	0
the	0
presence	0
of	0
adenovirus	1
E1a	2
sequences	2
relevant	0
to	0
the	0
use	0
of	0
E1a-	0
adenovirus	0
vectors	0
for	0
gene	0
therapy	0
for	0
the	0
respiratory	0
manifestations	0
of	0
cystic	0
fibrosis	0
.	0

Lung	0
disease	0
associated	0
with	0
disorders	0
such	0
as	0
cystic	0
fibrosis	0
(	0
CF	0
)	0
may	0
be	0
amenable	0
to	0
somatic	0
gene	0
therapy	0
in	0
which	0
there	0
is	0
delivery	0
of	0
the	0
normal	1
gene	2
directly	0
to	0
the	0
respiratory	0
epithelium	0
using	0
E1a-	0
adenovirus	0
(	0
Ad	0
)	0
type	0
2-	0
or	0
5-based	0
vectors	0
.	0

For	0
safety	0
reasons	0
,	0
the	0
Ad	0
vectors	0
are	0
rendered	0
replication	0
deficient	0
by	0
deletion	0
of	0
the	0
E1a	1
region	2
.	0

Because	0
there	0
is	0
the	0
theoretical	0
possibility	0
of	0
an	0
E1a-	0
replication-deficient	0
vector	0
replicating	0
as	0
a	0
result	0
of	0
recombination	0
or	0
complementation	0
with	0
Ad	1
2/5	2
E1a	2
sequences	2
present	0
in	0
the	0
target	0
cell	0
,	0
this	0
study	0
is	0
directed	0
toward	0
evaluating	0
respiratory	0
epithelium	0
of	0
normals	0
and	0
individuals	0
with	0
CF	0
for	0
the	0
presence	0
of	0
E1a	0
sequences	0
.	0

Using	0
Ad	1
2/5	2
E1a-specific	2
primers	2
and	0
the	0
polymerase	0
chain	0
reaction	0
to	0
evaluate	0
DNA	0
recovered	0
from	0
freshly	0
isolated	0
nasal	0
and	0
bronchial	0
epithelium	0
recovered	0
by	0
brushing	0
,	0
E1a	1
sequences	2
were	0
detected	0
in	0
respiratory	0
epithelium	0
of	0
19	0
of	0
91	0
normals	0
(	0
21	0
%	0
)	0
.	0

In	0
the	0
E1a-positive	0
samples	0
,	0
the	0
average	0
of	0
E1a	0
copy	0
number	0
was	0
55	0
+/-	0
18/10	0
(	0
3	0
)	0
recovered	0
cells	0
.	0

In	0
CF	0
individuals	0
,	0
7	0
of	0
52	0
(	0
13	0
%	0
)	0
had	0
detectable	0
E1a	1
sequences	2
in	0
the	0
respiratory	0
epithelium	0
,	0
with	0
E1a	0
copy	0
number	0
in	0
the	0
positive	0
samples	0
of	0
80	0
+/-	0
21/10	0
(	0
3	0
)	0
recovered	0
cells	0
.	0

These	0
results	0
demonstrate	0
that	0
there	0
are	0
detectable	0
Ad	1
2/5	2
E1a	2
sequences	2
in	0
the	0
respiratory	0
epithelium	0
of	0
a	0
small	0
percentage	0
of	0
normals	0
and	0
individuals	0
with	0
CF	0
.	0

Because	0
of	0
the	0
theoretical	0
potential	0
of	0
such	0
sequences	0
supporting	0
replication	0
of	0
E1a-	0
Ad	0
vectors	0
,	0
human	0
gene	0
therapy	0
protocols	0
for	0
CF	0
utilizing	0
such	0
vectors	0
should	0
consider	0
evaluating	0
study	0
individuals	0
for	0
the	0
presence	0
of	0
Ad	1
2/5	2
E1a	2
sequences	2
in	0
the	0
respiratory	0
epithelium	0
.	0

Leiomyosarcoma	0
of	0
the	0
vulva	0
:	0
report	0
of	0
a	0
case	0
.	0

A	0
52-year-old	0
female	0
presented	0
with	0
a	0
progressively	0
enlarging	0
vulvar	0
mass	0
.	0

Pathological	0
evaluation	0
revealed	0
a	0
high-grade	0
vulvar	0
leiomyosarcoma	0
.	0

Immunohistochemical	0
and	0
ultrastructural	0
studies	0
were	0
performed	0
to	0
support	0
the	0
diagnosis	0
.	0

In	0
an	0
effort	0
to	0
better	0
understand	0
the	0
biology	0
of	0
this	0
tumor	0
additional	0
immunohistochemical	0
studies	0
for	0
the	0
protein	9
product	10
of	0
p53	1
tumor	2
suppressor	2
gene	2
and	0
estrogen	9
receptor	10
expression	0
by	0
tumor	7
cells	8
,	0
as	0
well	0
as	0
the	0
type	0
of	0
immune	7
cells	8
infiltrating	0
the	0
tumor	0
were	0
performed	0
.	0

Tumor	7
cells	8
showed	0
an	0
overexpression	0
of	0
p53	9
protein	10
and	0
were	0
estrogen	9
receptor	10
-positive	0
.	0

Macrophages	7
and	0
T	7
and	8
B	8
lymphocytes	8
infiltrated	0
the	0
tumor	0
in	0
moderate	0
numbers	0
with	0
occasional	0
lymphoid	0
aggregate	0
formation	0
.	0

This	0
study	0
is	0
the	0
first	0
attempt	0
to	0
better	0
understand	0
the	0
biology	0
of	0
these	0
tumors	0
.	0

Stimulation	0
of	0
HIV	0
replication	0
in	0
mononuclear	7
phagocytes	8
by	0
leukemia	9
inhibitory	10
factor	10
.	0

This	0
study	0
examined	0
the	0
effects	0
of	0
leukemia	9
inhibitory	10
factor	10
(	0
LIF	9
)	0
on	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
replication	0
in	0
mononuclear	7
phagocytes	8
(	0
MNP	7
)	0
.	0

LIF	9
induced	0
a	0
dose-dependent	0
increase	0
in	0
p24	9
antigen	10
production	0
in	0
the	0
chronically	5
infected	6
promonocytic	6
cell	6
line	6
U1	6
.	0

The	0
magnitude	0
and	0
time	0
kinetics	0
of	0
the	0
LIF	9
effects	0
were	0
similar	0
to	0
interleukin	9
1	10
(	0
IL-1	9
)	0
,	0
IL-6	9
,	0
and	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
,	0
other	0
cytokines	0
known	0
to	0
induce	0
HIV	0
replication	0
in	0
this	0
cell	0
line	0
.	0

To	0
characterize	0
mechanisms	0
responsible	0
for	0
these	0
LIF	9
effects	0
,	0
levels	0
of	0
HIV	3
mRNA	4
,	0
activation	0
of	0
the	0
DNA	9
binding	10
protein	10
nuclear	10
factor	10
(	9
NF	10
)	10
-kB	10
,	0
signal	0
transduction	0
pathways	0
,	0
and	0
potential	0
interactions	0
with	0
other	0
cytokines	9
were	0
analyzed	0
.	0

LIF	9
increased	0
steady-state	0
levels	0
of	0
HIV	3
mRNA	4
at	0
2.0	0
,	0
4.3	0
,	0
and	0
9.2	0
kB	0
.	0

This	0
was	0
detectable	0
by	0
24	0
h	0
and	0
persisted	0
until	0
72	0
h	0
.	0

The	0
DNA	9
binding	10
protein	10
NF-kB	10
is	0
a	0
central	0
mediator	0
in	0
cytokine	9
activation	0
of	0
HIV	0
transcription	0
.	0

NF-kB	9
levels	0
were	0
higher	0
in	0
unstimulated	5
U1	6
cells	6
as	0
compared	0
to	0
the	0
parent	5
cell	6
line	6
U937	5
.	0

In	0
both	0
cell	0
lines	0
LIF	9
increased	0
NF-kB	9
activity	0
.	0

Induction	0
of	0
NF-kB	9
and	0
HIV	0
replication	0
by	0
cytokines	9
are	0
at	0
least	0
in	0
part	0
dependent	0
on	0
reactive	0
oxygen	0
intermediates	0
.	0

The	0
oxygen	0
radical	0
scavenger	0
N-acetyl-L-cysteine	0
,	0
but	0
not	0
an	0
inhibitor	0
of	0
nitric	9
oxide	10
synthase	10
,	0
inhibited	0
LIF	9
-induced	0
HIV	0
replication	0
.	0

LIF	9
induces	0
the	0
production	0
of	0
other	0
cytokines	9
in	0
monocytes	0
but	0
its	0
effects	0
on	0
HIV	0
replication	0
were	0
not	0
inhibited	0
by	0
antibodies	9
to	0
IL-1	9
,	0
TNF	9
,	0
or	0
IL-6	9
.	0

These	0
results	0
identify	0
LIF	9
as	0
a	0
stimulus	0
of	0
HIV	0
replication	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Mechanisms	0
involved	0
in	0
the	0
inhibition	0
of	0
growth	0
of	0
a	0
human	5
B	6
lymphoma	6
cell	6
line	6
,	0
B104	5
,	0
by	0
anti-MHC	9
class	10
II	10
antibodies	10
.	0

The	0
mechanisms	0
involved	0
in	0
the	0
inhibition	0
of	0
growth	0
of	0
a	0
human	5
B	6
lymphoma	6
cell	6
line	6
,	0
B104	5
,	0
by	0
anti-MHC	9
class	10
II	10
antibodies	10
(	0
Ab	9
)	0
were	0
compared	0
with	0
those	0
in	0
anti-IgM	9
Ab	10
-induced	0
B104	0
growth	0
inhibition	0
.	0

Two	0
anti-MHC	9
class	10
II	10
Ab	10
,	0
L227	9
and	0
2.06	9
,	0
inhibited	0
the	0
growth	0
of	0
B104	5
cells	6
,	0
although	0
2.06	9
,	0
but	0
not	0
L227	9
,	0
needed	0
to	0
be	0
further	0
cross-linked	0
with	0
a	0
goat	9
anti-mouse	10
IgG	10
Ab	10
(	0
GAM	9
)	0
to	0
show	0
the	0
effect	0
.	0

L227	9
induced	0
an	0
increase	0
in	0
intracellular	0
free	0
Ca2+	0
concentration	0
(	0
[	0
Ca2+	0
]	0
i	0
)	0
from	0
the	0
intracellular	0
pool	0
and	0
little	0
or	0
no	0
protein	0
tyrosine	0
phosphorylation	0
,	0
phosphatidyl	0
inositol	0
turnover	0
,	0
or	0
expression	0
of	0
Egr-1	3
mRNA	4
,	0
whereas	0
2.06	9
plus	0
GAM	9
induced	0
an	0
increase	0
in	0
[	0
Ca2+	0
]	0
i	0
from	0
both	0
the	0
intracellular	0
and	0
,	0
in	0
particular	0
,	0
the	0
extracellular	0
pools	0
.	0

The	0
inhibition	0
of	0
B104	5
cell	6
growth	0
induced	0
by	0
anti-MHC	9
class	10
II	10
Ab	10
was	0
Ca	0
(	0
2+	0
)	0
-independent	0
and	0
not	0
inhibited	0
by	0
actinomycin	0
D	0
or	0
cyclosporin	0
A	0
,	0
and	0
cell	0
cycle	0
arrest	0
at	0
the	0
G2/M	0
interphase	0
was	0
not	0
observed	0
.	0

These	0
features	0
are	0
very	0
different	0
from	0
those	0
observed	0
in	0
B104	5
cell	6
death	0
induced	0
by	0
anti-IgM	9
Ab	10
.	0

Neither	0
DNA	0
fragmentation	0
nor	0
the	0
morphology	0
of	0
apoptosis	0
was	0
observed	0
.	0

These	0
findings	0
demonstrate	0
that	0
cross-linking	0
of	0
MHC	9
class	10
II	10
molecules	10
transduced	0
the	0
negative	0
signals	0
through	0
intracellular	0
mechanisms	0
different	0
from	0
those	0
present	0
in	0
the	0
cross-linking	0
of	0
surface	0
IgM	9
.	0

Functional	0
block	0
for	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3-mediated	0
gene	0
regulation	0
in	0
human	7
B	8
lymphocytes	8
.	0

Elements	0
necessary	0
for	0
the	0
steroid	0
hormone	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
)	0
to	0
induce	0
a	0
biological	0
response	0
include	0
the	0
presence	0
of	0
specific	0
intracellular	9
receptors	10
(	0
vitamin	9
D3	10
receptors	10
(	0
VDR	9
)	0
)	0
and	0
modulation	0
of	0
gene	0
expression	0
via	0
hormone-activated	0
receptor	0
binding	0
to	0
regulatory	9
regions	10
of	0
target	1
genes	2
.	0

These	0
parameters	0
were	0
examined	0
in	0
normal	0
and	0
Epstein-Barr	5
virus-immortalized	6
human	6
B	6
cells	6
and	0
compared	0
with	0
1	5
alpha	6
,	6
25-	6
(	6
OH	6
)	6
2D3-responsive	6
cells	6
of	0
the	0
T	7
and	8
monocytic	8
lineages	8
.	0

Although	0
resting	0
tonsillar	0
B	0
cells	0
did	0
not	0
express	0
VDR	3
mRNA	4
,	0
activation	0
of	0
these	0
cells	0
with	0
interleukin-4	9
induced	0
VDR	9
in	0
the	0
absence	0
of	0
exogenously	0
supplemented	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
.	0

As	0
indicators	0
of	0
hormone-mediated	0
gene	0
regulation	0
we	0
analyzed	0
modulation	0
of	0
CD23	9
,	0
a	0
common	9
B	10
cell/monocyte	10
surface	10
antigen	10
,	0
and	0
24-hydroxylase	9
.	0

1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
inhibited	0
CD23	9
expression	0
in	0
U937	5
cells	6
,	0
yet	0
failed	0
to	0
modulate	0
CD23	9
expression	0
in	0
B	7
cells	8
.	0

Furthermore	0
,	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
induced	0
24-hydroxylase	9
mRNA	0
expression	0
and	0
metabolic	0
activity	0
in	0
both	0
U937	5
cells	6
and	0
lectin-activated	7
T	8
cells	8
,	0
yet	0
failed	0
to	0
induce	0
24-hydroxylase	3
mRNA	4
or	0
its	0
metabolic	0
activity	0
in	0
B	7
cells	8
.	0

These	0
findings	0
suggest	0
that	0
although	0
human	7
B	8
lymphocytes	8
can	0
express	0
VDR	3
mRNA	4
and	0
protein	9
,	0
they	0
exhibit	0
a	0
functional	0
block	0
for	0
vitamin	0
D-dependent	0
gene	0
regulation	0
.	0

Positive	0
and	0
negative	0
regulation	0
of	0
IL-2	9
gene	0
expression	0
:	0
role	0
of	0
multiple	0
regulatory	0
sites	0
.	0

Interleukin	0
2	0
(	0
IL-2	9
)	0
is	0
an	0
important	0
lymphokine	9
required	0
in	0
the	0
process	0
of	0
T	0
cell	0
activation	0
,	0
proliferation	0
,	0
clonal	0
expansion	0
and	0
differentiation	0
.	0

The	0
IL-2	1
gene	2
displays	0
both	0
T	0
cell	0
specific	0
and	0
inducible	0
expression	0
:	0
it	0
is	0
only	0
expressed	0
in	0
CD4+	7
T	8
cells	8
after	0
antigenic	0
or	0
mitogenic	0
stimulation	0
.	0

Several	0
cis-acting	1
regulatory	2
sites	2
are	0
required	0
for	0
induction	0
of	0
the	0
IL-2	1
gene	2
after	0
stimulation	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
analysed	0
the	0
function	0
of	0
these	0
cis-acting	1
regulatory	2
sites	2
in	0
the	0
context	0
of	0
the	0
native	0
IL-2	1
enhancer	2
and	0
promoter	1
sequence	2
.	0

The	0
results	0
of	0
this	0
study	0
suggest	0
that	0
the	0
NFAT	9
(	0
-276	1
to	2
-261	2
)	0
,	0
the	0
distal	1
octamer	2
(	0
-256	1
to	2
-248	2
)	0
and	0
the	0
proximal	1
octamer	2
(	0
-75	1
to	2
-66	2
)	0
sites	0
not	0
only	0
act	0
as	0
enhancers	0
of	0
IL-2	1
gene	2
transcription	0
in	0
the	0
presence	0
of	0
cellular	0
stimulation	0
,	0
but	0
also	0
have	0
a	0
silencing	0
effect	0
on	0
IL-2	1
gene	2
expression	0
in	0
resting	0
cells	0
.	0

Two	0
other	0
sites	0
display	0
disparate	0
effects	0
on	0
IL-2	1
gene	2
expression	0
in	0
different	0
T	5
leukemia	6
cell	6
lines	6
:	0
the	0
distal	1
purine	2
box	2
(	0
-291	1
to	2
-277	2
)	0
and	0
the	0
proximal	1
purine	2
box	2
sites	2
(	0
-145	1
to	2
-128	2
)	0
.	0

Finally	0
,	0
the	0
AP-1	1
(	2
-186	2
to	2
-176	2
)	2
and	2
the	2
kappa	2
B	2
sites	2
(	0
-206	1
to	2
-195	2
)	0
respond	0
to	0
different	0
cellular	0
activation	0
in	0
EL4	5
cells	6
.	0

The	0
AP-1	1
site	2
mediated	0
the	0
response	0
to	0
PMA	0
stimulation	0
while	0
the	0
kappa	1
B	2
site	2
responded	0
to	0
IL-1	9
stimulation	0
.	0

These	0
data	0
suggest	0
that	0
the	0
regulation	0
of	0
IL-2	1
gene	2
expression	0
is	0
a	0
complex	0
process	0
and	0
multiple	0
cis-acting	1
regulatory	2
sites	2
interact	0
to	0
exert	0
different	0
effects	0
in	0
T	7
cells	8
representative	0
of	0
alternative	0
stages	0
of	0
differentiation	0
.	0

Sp1	9
is	0
a	0
critical	0
factor	0
for	0
the	0
monocytic	0
specific	0
expression	0
of	0
human	9
CD14	10
.	0

CD14	9
is	0
a	0
membrane	9
glycoprotein	10
expressed	0
specifically	0
on	0
monocytes	7
and	0
macrophages	7
,	0
and	0
its	0
expression	0
is	0
markedly	0
increased	0
during	0
the	0
process	0
of	0
monocyte	7
differentiation	0
.	0

In	0
order	0
to	0
study	0
CD14	1
gene	2
regulation	0
,	0
the	0
human	1
CD14	2
gene	2
was	0
cloned	0
from	0
a	0
partial	0
EcoRI	1
digested	2
chromosome	2
5	2
library	2
.	0

A	0
5.5-kilobase	1
genomic	2
clone	2
contained	0
the	0
full-length	0
CD14	1
coding	2
sequence	2
and	0
4.2	1
kilobases	2
of	2
5'-upstream	2
sequence	2
.	0

One	0
major	1
and	2
one	2
minor	2
transcription	2
start	2
site	2
were	0
identified	0
101	1
and	2
130	2
base	2
pairs	2
(	2
bp	2
)	2
upstream	2
,	0
respectively	0
,	0
from	0
the	0
protein	1
translation	2
start	2
ATG	2
.	0

A	0
DNA	1
fragment	2
containing	0
128	1
bp	2
of	2
upstream	2
sequence	2
had	0
strong	0
,	0
monocyte-specific	0
promoter	0
activity	0
in	0
the	0
CD14	5
positive	6
monocytic	6
cell	6
line	6
Mono	5
Mac	6
6	6
as	0
compared	0
to	0
the	0
nonmonocytic	5
cell	6
lines	6
HeLa	5
and	0
REX	5
.	0

Four	0
regions	0
in	0
this	0
DNA	1
fragment	2
interact	0
with	0
nuclear	9
proteins	10
isolated	0
from	0
monocytic	7
cells	8
.	0

The	0
Sp1	9
transcription	9
factor	10
bound	0
to	0
three	0
different	0
regions	0
in	0
the	0
CD14	1
promoter	2
.	0

Mutation	0
of	0
the	0
major	1
Sp1	2
binding	2
site	2
(	0
-110	1
bp	2
)	0
decreased	0
tissue-specific	0
promoter	0
activity	0
,	0
and	0
these	0
results	0
,	0
together	0
with	0
transactivation	0
experiments	0
,	0
demonstrate	0
that	0
Sp1	9
plays	0
a	0
critical	0
role	0
in	0
the	0
tissue-specific	0
expression	0
of	0
CD14	9
in	0
monocytic	7
cells	8
.	0

CD14	9
Sp1	9
site	0
oligonucleotides	0
bound	0
preferentially	0
to	0
a	0
105-kDa	9
Sp1	10
species	10
,	0
which	0
is	0
present	0
in	0
higher	0
relative	0
levels	0
in	0
monocytic	7
than	0
non-monocytic	7
cells	8
,	0
suggesting	0
that	0
modification	0
of	0
Sp1	9
,	0
such	0
as	0
phosphorylation	0
,	0
may	0
explain	0
how	0
the	0
Sp1	9
site	0
mediates	0
monocytic	0
specific	0
promoter	0
activity	0
.	0

The	0
interleukin-8	1
AP-1	2
and	2
kappa	2
B-like	2
sites	2
are	0
genetic	0
end	0
targets	0
of	0
FK506-sensitive	0
pathway	0
accompanied	0
by	0
calcium	0
mobilization	0
.	0

FK506	0
,	0
an	0
immunosuppressant	0
,	0
inhibits	0
the	0
production	0
of	0
several	0
cytokines	9
in	0
T	7
lymphocytes	8
.	0

We	0
observed	0
that	0
FK506	0
suppressed	0
the	0
transcription	0
of	0
a	0
chemotactic	9
cytokine	10
,	0
interleukin-8	9
(	0
IL-8	9
)	0
in	0
a	0
human	5
T	6
cell	6
line	6
,	0
Jurkat	5
cells	6
,	0
activated	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
calcium	0
(	0
Ca2+	0
)	0
ionophore	0
(	0
ionomycin	0
)	0
.	0

By	0
deleted	0
and	0
mutated	0
analysis	0
of	0
the	0
IL-8	1
promoters	2
,	0
the	0
AP-1	1
and	2
kappa	2
B-like	2
sites	2
were	0
identified	0
as	0
the	0
responsive	0
elements	0
for	0
PMA	0
and	0
ionomycin	0
.	0

FK506	0
suppressed	0
the	0
transcriptions	0
through	0
the	0
AP-1	1
or	0
kappa	1
B-like	2
sites	2
induced	0
by	0
PMA	0
plus	0
Ca	0
(	0
2+	0
)	0
-mobilizing	0
agents	0
,	0
but	0
not	0
those	0
induced	0
by	0
Ca	0
(	0
2+	0
)	0
-independent	0
stimuli	0
.	0

In	0
gel	0
retardation	0
analysis	0
,	0
FK506	0
had	0
little	0
effect	0
on	0
the	0
binding	0
to	0
the	0
AP-1	1
site	2
of	0
PMA/ionomycin-induced	0
nuclear	0
factors	0
,	0
which	0
were	0
recognized	0
with	0
anti-JunD	9
or	0
c-Fos	9
antibody	10
.	0

In	0
contrast	0
,	0
FK506	0
or	0
EGTA	0
(	0
Ca2+	0
chelator	0
)	0
similarly	0
affected	0
the	0
formation	0
of	0
kappa	9
B-like	10
site	10
binding	10
complexes	10
,	0
which	0
were	0
not	0
recognized	0
by	0
any	0
antibodies	9
against	0
the	0
human	9
Rel	10
family	10
proteins	10
(	0
c-Rel	9
,	0
p65	9
,	0
p50	9
,	0
and	0
p49	9
)	0
.	0

Furthermore	0
,	0
we	0
confirmed	0
the	0
previous	0
report	0
that	0
FK506	0
suppressed	0
the	0
PMA/ionomycin-induced	0
activation	0
through	0
authentic	0
kappa	1
B	2
site	2
of	0
immunoglobulin	1
(	2
Ig	2
)	2
gene	2
,	0
to	0
which	0
NF-kappa	9
B	10
binding	0
was	0
also	0
decreased	0
by	0
FK506	0
,	0
indicating	0
that	0
both	0
IL-8	1
kappa	2
B-like	2
site	2
and	0
Ig	0
kappa	1
B	2
site	2
are	0
FK506-sensitive	0
in	0
spite	0
of	0
the	0
difference	0
of	0
binding	9
factors	10
.	0

Our	0
results	0
indicate	0
that	0
not	0
only	0
the	0
reported	0
IL-2	1
NF-AT	2
and	2
NFIL-2A	2
sites	2
and	0
Ig	0
kappa	1
B	2
site	2
,	0
but	0
also	0
the	0
IL-8	9
AP-1	1
and	0
kappa	1
B-like	2
sites	2
are	0
terminals	0
of	0
FK506-sensitive	0
pathway	0
involving	0
Ca2+	0
mobilization	0
.	0

Androgen	9
binding	10
sites	10
in	0
peripheral	7
human	8
mononuclear	8
leukocytes	8
of	0
healthy	0
males	0
and	0
females	0
.	0

Androgen	9
binding	10
sites	10
have	0
been	0
identified	0
in	0
circulating	7
human	8
mononuclear	8
leukocytes	8
of	0
healthy	0
donors	0
of	0
both	0
sexes	0
.	0

Cells	0
were	0
separated	0
from	0
blood	0
samples	0
on	0
a	0
Ficoll	0
gradient	0
and	0
incubated	0
with	0
different	0
concentrations	0
of	0
[	0
3H	0
]	0
testosterone	0
in	0
the	0
presence	0
or	0
absence	0
of	0
a	0
400-fold	0
excess	0
of	0
unlabelled	0
testosterone	0
.	0

Binding	0
data	0
were	0
derived	0
from	0
Scatchard	0
analysis	0
.	0

The	0
binding	9
sites	10
fulfil	0
the	0
required	0
criteria	0
for	0
specific	0
steroid	9
binding	10
sites	10
however	0
differ	0
somewhat	0
from	0
the	0
classic	0
androgen	9
receptors	10
from	0
genital	7
skin	8
fibroblast	8
:	0
in	0
fertile	0
adult	0
males	0
(	0
n	0
=	0
20	0
)	0
the	0
binding	9
sites	10
showed	0
(	0
1	0
)	0
a	0
high	0
affinity	0
for	0
testosterone	0
(	0
1.32	0
+/-	0
0.49	0
nM	0
;	0
mean	0
+/-	0
SD	0
)	0
,	0
(	0
2	0
)	0
a	0
saturable	0
capacity	0
(	0
184	0
+/-	0
52	0
binding	9
sites	10
per	0
cell	0
;	0
mean	0
+/-	0
SD	0
)	0
,	0
and	0
(	0
3	0
)	0
a	0
characteristic	0
competitive	0
binding	0
profile	0
for	0
other	0
steroid	0
hormones	0
(	0
relative	0
binding	0
affinities	0
:	0
testosterone	0
=	0
dihydrotestosterone	0
>	0
17	0
beta-estradiol	0
>	0
progesterone	0
,	0
whereas	0
aldosterone	0
,	0
17-hydroxy-progesterone	0
and	0
cortisol	0
did	0
not	0
compete	0
appreciably	0
)	0
.	0

Furthermore	0
the	0
number	0
of	0
binding	9
sites	10
determined	0
using	0
[	0
3H	0
]	0
dihydrotestosterone	0
,	0
[	0
3H	0
]	0
RU-1881	0
,	0
or	0
[	0
3H	0
]	0
testosterone	0
were	0
comparable	0
.	0

This	0
raises	0
the	0
possibility	0
that	0
androgen	9
receptors	10
in	0
peripheral	7
mononuclear	8
leukocytes	8
differ	0
from	0
those	0
in	0
genital	7
skin	8
fibroblasts	8
.	0

There	0
was	0
no	0
apparent	0
correlation	0
between	0
serum	0
testosterone	0
concentrations	0
and	0
androgen	9
binding	10
sites	10
.	0

In	0
fertile	0
women	0
remarkable	0
changes	0
in	0
androgen	9
binding	10
sites	10
were	0
seen	0
in	0
the	0
course	0
of	0
the	0
menstrual	0
cycle	0
,	0
with	0
a	0
significant	0
increase	0
in	0
the	0
immediate	0
preovulatory	0
period	0
.	0

The	0
presence	0
of	0
androgen	9
receptors	10
in	0
peripheral	7
mononuclear	8
leukocytes	8
provides	0
for	0
the	0
first	0
time	0
the	0
experimental	0
basis	0
for	0
an	0
hypothesis	0
of	0
direct	0
,	0
receptor-mediated	0
effects	0
of	0
androgens	0
on	0
mature	7
immunocompetent	8
cells	8
.	0

The	0
immunological	0
implications	0
of	0
these	0
results	0
are	0
discussed	0
.	0

Induction	0
of	0
IL-8	9
expression	0
in	0
T	7
cells	8
uses	0
the	0
CD28	9
costimulatory	0
pathway	0
.	0

IL-8	9
,	0
a	0
potent	0
chemotactic	9
factor	10
for	0
neutrophil	7
granulocytes	8
and	0
lymphocytes	7
,	0
is	0
a	0
proinflammatory	0
cytokine	0
secreted	0
by	0
a	0
variety	0
of	0
cell	0
types	0
,	0
including	0
T	7
cells	8
.	0

Stimulation	0
of	0
the	0
CD28	9
cell	10
surface	10
molecule	10
delivers	0
costimulatory	0
signals	0
essential	0
for	0
lymphokine	9
production	0
in	0
activated	7
T	8
cells	8
via	0
a	0
conserved	1
sequence	2
element	2
found	0
in	0
the	0
promoter	1
of	0
several	0
lymphokine	1
genes	2
.	0

Anti-CD28-stimulated	5
T	6
cells	6
produced	0
significant	0
amounts	0
of	0
IL-8	9
;	0
additionally	0
,	0
costimulation	0
with	0
anti-CD3	9
and	0
anti-CD28	9
Abs	10
resulted	0
in	0
a	0
synergistic	0
induction	0
of	0
IL-8	9
secretion	0
.	0

Sequence	0
homology	0
,	0
single	0
nucleotide	0
mutations	0
,	0
and	0
anti-CD28	9
Ab	10
stimulation	0
studies	0
established	0
that	0
the	0
NF-kappa	1
B-like	2
sequence	2
in	0
the	0
promoter	1
of	0
the	0
IL-8	1
gene	2
functioned	0
as	0
a	0
CD28	1
response	2
element	2
.	0

Furthermore	0
,	0
cyclosporin	0
A	0
,	0
but	0
not	0
rapamycin	0
,	0
blocked	0
the	0
synergistic	0
induction	0
of	0
IL-8	9
expression	0
achieved	0
with	0
anti-CD3	9
and	0
anti-	0
CD28	9
costimulation	0
.	0

The	0
involvement	0
of	0
a	0
CD28	1
response	2
element	2
in	0
the	0
induction	0
of	0
IL-8	9
expression	0
in	0
activated	7
T	8
cells	8
may	0
provide	0
new	0
insights	0
into	0
the	0
pathogenesis	0
and	0
persistence	0
of	0
immune	0
disorders	0
characterized	0
by	0
increased	0
levels	0
of	0
IL-8	9
,	0
such	0
as	0
psoriasis	0
and	0
rheumatoid	0
arthritis	0
.	0

MHC	9
class	10
II	10
signaling	0
in	0
B-cell	7
activation	0
[	0
see	0
comments	0
]	0

The	0
cognate	0
interaction	0
between	0
T	7
cells	8
and	0
antigen-presenting	7
cells	8
(	0
APCs	7
)	0
,	0
mediated	0
by	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
II	10
molecules	10
,	0
results	0
in	0
the	0
delivery	0
of	0
activation	0
signals	0
to	0
the	0
APC	7
.	0

These	0
signals	0
contribute	0
to	0
the	0
expression	0
of	0
co-stimulatory	0
activity	0
by	0
APCs	7
and	0
have	0
important	0
consequences	0
for	0
cell	0
effector	0
function	0
.	0

MHC	9
class	10
II	10
molecules	0
also	0
serve	0
as	0
receptors	0
for	0
B-cell	7
stimulation	0
by	0
microbial	9
superantigens	10
.	0

In	0
this	0
review	0
,	0
Paul	0
Scholl	0
and	0
Raif	0
Geha	0
discuss	0
recent	0
advances	0
in	0
our	0
understanding	0
of	0
mechanisms	0
of	0
MHC	9
class	10
II	10
signaling	0
and	0
analyse	0
their	0
role	0
in	0
human	0
B-cell	7
activation	0
.	0

Effects	0
of	0
glucocorticoids	0
in	0
rheumatoid	0
arthritis	0
.	0

Diminished	0
glucocorticoid	9
receptors	10
do	0
not	0
result	0
in	0
glucocorticoid	0
resistance	0
.	0

OBJECTIVE	0
.	0

Lymphocytes	0
of	0
patients	0
with	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
have	0
diminished	0
receptor	0
density	0
;	0
thus	0
,	0
patients	0
with	0
RA	0
should	0
show	0
partial	0
resistance	0
to	0
glucocorticoids	0
.	0

We	0
investigated	0
the	0
glucocorticoid	0
sensitivity	0
of	0
lymphocytes	7
in	0
RA	0
patients	0
compared	0
with	0
healthy	0
subjects	0
.	0

METHODS	0
.	0

We	0
determined	0
the	0
effects	0
of	0
glucocorticoids	0
on	0
lymphocyte	7
proliferation	0
and	0
cytokine	9
release	0
.	0

RESULTS	0
.	0

Proliferation	0
and	0
cytokine	9
release	0
were	0
inhibited	0
in	0
RA	0
patients	0
to	0
the	0
same	0
extent	0
as	0
in	0
healthy	0
controls	0
.	0

CONCLUSION	0
.	0

Diminished	0
receptor	0
density	0
in	0
RA	0
patients	0
does	0
not	0
result	0
in	0
glucocorticoid	0
resistance	0
.	0

Arrested	0
development	0
:	0
understanding	0
v-abl	1
.	0

The	0
protein	9
tyrosine	10
kinase	10
activity	0
of	0
the	0
v-abl	1
oncogene	2
has	0
been	0
demonstrated	0
to	0
subvert	0
the	0
normal	0
second	0
messenger	0
systems	0
used	0
by	0
lymphoid	7
cells	8
for	0
growth	0
and	0
differentiation	0
.	0

Transformation	0
of	0
bone	0
marrow	0
with	0
the	0
Abelson	0
murine	0
leukemia	0
virus	0
results	0
in	0
the	0
appearance	0
of	0
B	7
cell	8
lineage	8
cells	8
arrested	0
at	0
the	0
pre-B	0
cell	0
stage	0
.	0

Recent	0
reports	0
have	0
characterized	0
these	0
cells	0
expressing	0
high	0
v-abl	1
kinase	0
activity	0
as	0
deficient	0
in	0
detectable	0
NF-kappaB	9
DNA	0
binding	0
activity	0
and	0
low	0
level	0
RAG	1
gene	2
expression	0
.	0

These	0
observations	0
suggest	0
that	0
v-abl	1
may	0
be	0
inhibiting	0
the	0
differentiation	0
of	0
B	7
cells	8
by	0
blocking	0
these	0
two	0
crucial	0
elements	0
in	0
the	0
maturation	0
pathway	0
.	0

Corticosteroid	9
receptors	10
in	0
lymphocytes	7
:	0
a	0
possible	0
marker	0
of	0
brain	0
involution	0
?	0

A	0
similarity	0
has	0
recently	0
been	0
found	0
between	0
the	0
regulation	0
of	0
corticosteroid	9
receptors	10
in	0
brain	0
and	0
in	0
lymphoid	0
tissue	0
.	0

We	0
have	0
studied	0
the	0
regulation	0
of	0
corticosteroid	9
receptors	10
in	0
human	7
mononuclear	8
leukocytes	8
as	0
a	0
possible	0
marker	0
of	0
brain	0
involution	0
.	0

Type	9
I	10
corticosteroid	10
receptors	10
are	0
down	0
regulated	0
by	0
excess	0
of	0
mineralocorticoids	0
(	0
primary	0
and	0
secondary	0
hyperaldosteronism	0
,	0
pseudohyperaldosteronism	0
)	0
and	0
of	0
glucocorticoids	0
(	0
Cushing	0
's	0
syndrome	0
)	0
.	0
Type	9
II	10
corticosteroid	10
receptors	10
are	0
not	0
reduced	0
by	0
excess	0
of	0
endogenous	0
corticosteroids	0
(	0
Cushing	0
's	0
syndrome	0
)	0
.	0

In	0
normal	0
adults	0
there	0
is	0
a	0
direct	0
significant	0
correlation	0
between	0
plasma	0
cortisol	0
and	0
Type	9
I	10
and	0
between	0
plasma	0
cortisol	0
and	0
Type	9
II	10
receptors	10
in	0
mononuclear	7
leukocytes	8
,	0
while	0
in	0
Cushing	0
's	0
syndrome	0
the	0
correlation	0
is	0
inverse	0
between	0
plasma	0
cortisol	0
at	0
8	0
a.m.	0
and	0
Type	9
II	10
receptors	10
.	0

In	0
an	0
aged	0
population	0
the	0
mean	0
numbers	0
of	0
Type	9
I	10
and	0
of	0
Type	9
II	10
receptors	10
are	0
lower	0
and	0
plasma	0
cortisol	0
is	0
higher	0
than	0
in	0
adult	0
controls	0
,	0
but	0
the	0
increase	0
of	0
plasma	0
cortisol	0
is	0
not	0
followed	0
by	0
a	0
clinical	0
picture	0
of	0
hypercorticism	0
.	0

Corticosteroid	9
Type	10
I	10
and	10
Type	10
II	10
receptors	10
are	0
inversely	0
correlated	0
with	0
age	0
.	0

After	0
dexamethasone	0
suppression	0
(	0
1	0
mg	0
at	0
11	0
p.m.	0
)	0
Type	9
I	10
receptors	10
always	0
decrease	0
in	0
controls	0
while	0
the	0
response	0
of	0
Type	9
II	10
is	0
not	0
homogeneous	0
.	0

In	0
an	0
aged	0
group	0
of	0
patients	0
,	0
both	0
receptors	0
are	0
reduced	0
by	0
dexamethasone	0
.	0

We	0
conclude	0
that	0
the	0
decrease	0
with	0
age	0
of	0
corticosteroid	9
receptors	10
is	0
possibly	0
related	0
to	0
a	0
physiological	0
involution	0
of	0
corticosteroid	9
receptors	10
and	0
that	0
this	0
reduction	0
does	0
increase	0
plasma	0
cortisol	0
concentration	0
,	0
without	0
affecting	0
the	0
glucocorticoid	0
effector	0
mechanism	0
.	0

All-trans	0
retinoic	0
acid	0
and	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
co-operate	0
to	0
promote	0
differentiation	0
of	0
the	0
human	5
promyeloid	6
leukemia	6
cell	6
line	6
HL60	5
to	0
monocytes	7
.	0

A	0
basis	0
for	0
differentiation	0
therapy	0
of	0
leukemias	0
is	0
provided	0
by	0
knowledge	0
of	0
agents	0
which	0
induce	0
specific	0
lineage	0
maturation	0
.	0

All-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
induces	0
differentiation	0
of	0
HL60	5
cells	6
to	0
neutrophils	7
and	0
is	0
used	0
to	0
treat	0
acute	0
promyelocytic	0
leukemia	0
.	0

We	0
observed	0
that	0
RA	0
did	0
not	0
induced	0
neutrophil	0
differentiation	0
in	0
serum-free	5
grown	6
HL60	6
cells	6
whereas	0
50	0
nM	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
D3	0
)	0
induced	0
maximal	0
monocyte	0
differentiation	0
.	0

Increasing	0
RA	0
concentrations	0
reduced	0
the	0
D3	0
concentration	0
required	0
for	0
monocyte	0
differentiation	0
.	0

Cells	0
treated	0
with	0
5	0
nM	0
D3	0
showed	0
little	0
response	0
,	0
but	0
differentiated	0
maximally	0
with	0
5	0
nM	0
D3	0
and	0
10	0
nM	0
RA	0
.	0

The	0
D3	0
analogs	0
MC903	0
,	0
EB1089	0
and	0
KH1060	0
were	0
more	0
potent	0
inducers	0
of	0
monocyte	0
differentiation	0
.	0

The	0
extent	0
to	0
which	0
analog	0
activity	0
was	0
increased	0
after	0
cotreatment	0
with	0
RA	0
was	0
inversely	0
related	0
to	0
potency	0
.	0

Twenty-four	0
hour	0
treatment	0
with	0
10	0
nM	0
RA	5
primed	6
cells	6
for	0
response	0
to	0
5	0
nM	0
D3	0
;	0
the	0
reverse	0
sequence	0
being	0
ineffective	0
.	0

Priming	0
with	0
10	0
nM	0
RA	0
,	0
or	0
subsequent	0
treatment	0
with	0
D3	0
(	0
5	0
nM	0
)	0
,	0
did	0
not	0
alter	0
expression	0
of	0
mRNAs	3
encoding	0
receptors	9
for	0
D3	0
(	0
VDR	9
)	0
,	0
RA	0
(	0
RAR	9
alpha	10
)	0
or	0
9-CIS	0
RA	0
(	0
RXR	9
alpha	10
,	10
beta	10
,	10
gamma	10
)	0
.	0

That	0
RA	0
promotes	0
both	0
neutrophil	0
and	0
monocyte	0
differentiation	0
has	0
implications	0
for	0
the	0
use	0
of	0
RA	0
and	0
D3	0
in	0
treatment	0
of	0
leukemias	0
and	0
provides	0
insight	0
into	0
mechanisms	0
whereby	0
RAR	0
,	0
VDR	9
and	0
RXR	9
facilitate	0
monocyte	0
differentiation	0
.	0

[	0
An	0
overexpression	0
of	0
retinoic	9
acid	10
receptor	10
alpha	10
blocks	0
myeloid	7
cell	8
differentiation	0
at	0
the	0
promyelocyte	0
stage	0
]	0

Retinoic	0
acid	0
(	0
RA	0
)	0
,	0
a	0
vitamin	0
A	0
derivative	0
,	0
exerts	0
a	0
wide	0
range	0
of	0
biological	0
effects	0
related	0
to	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

The	0
pleiotropic	0
effects	0
of	0
RA	0
are	0
thought	0
to	0
be	0
mediated	0
through	0
specific	0
nuclear	0
RA	9
receptors	10
(	0
RARs	9
)	0
.	0

RARs	9
are	0
members	0
of	0
the	0
steroid/thyroid	9
hormone	10
receptor	10
superfamily	10
and	0
exhibit	0
a	0
molecular	0
structure	0
that	0
possess	0
discrete	0
DNA-binding	0
and	0
RA	9
(	10
ligand	10
)	10
-binding	10
domains	10
.	0

In	0
hematopoietic	0
system	0
,	0
RA	0
and	0
RARs	9
,	0
predominantly	0
RAR	9
alpha	10
may	0
play	0
key	0
roles	0
for	0
the	0
proliferation	0
and	0
differentiation	0
of	0
hematopoietic	7
progenitors	8
.	0

However	0
,	0
it	0
is	0
currently	0
unknown	0
how	0
RA	0
and	0
RARs	9
are	0
involved	0
in	0
regulating	0
normal	0
hematopoietic	0
differentiation	0
.	0

To	0
make	0
clear	0
the	0
roles	0
of	0
RA	0
and	0
RAR	9
alpha	10
in	0
the	0
normal	0
hematopoiesis	0
,	0
I	0
have	0
introduced	0
the	0
construct	0
of	0
human	9
RAR	10
alpha	10
(	0
hRAR	9
alpha	10
)	0
into	0
murine	7
bone	8
marrow	8
cells	8
with	0
retroviral	0
vector	0
,	0
and	0
selected	0
infected	0
cells	0
with	0
drug	1
resistant	2
marker	2
(	0
Neo	1
(	2
r	2
)	2
)	0
cultured	0
on	0
the	0
stroma	5
cell	6
line	6
(	0
PA6-neo	5
)	0
,	0
and	0
analyzed	0
the	0
behavior	0
of	0
infected	7
cells	8
.	0

All	0
of	0
procedure	0
were	0
done	0
in	0
vitro	0
.	0

Most	0
cells	0
infected	0
with	0
hRAR	9
alpha	10
exhibited	0
promyelocytic	7
morphology	8
and	0
were	0
thought	0
to	0
be	0
blocked	0
at	0
the	0
promyelocytic	0
stage	0
in	0
their	0
myeloid	0
differentiation	0
.	0

Furthermore	0
,	0
these	0
immature	7
cells	8
differentiated	0
terminally	0
into	0
mature	0
granulocytes	0
by	0
adding	0
with	0
RA	0
(	0
10	0
(	0
-6	0
)	0
M	0
)	0
.	0

RAR	9
alpha	10
infected	7
cells	8
were	0
also	0
able	0
to	0
differentiate	0
into	0
mature	7
macrophages	8
in	0
the	0
both	0
of	0
long	0
term	0
culture	0
and	0
IL3	5
colony	6
.	0

These	0
observations	0
suggest	0
that	0
an	0
overexpression	0
of	0
RAR	9
alpha	10
alone	0
is	0
effective	0
to	0
suppress	0
myeloid	7
cell	8
differentiation	0
and	0
RAR	9
alpha	10
plays	0
a	0
crucial	0
role	0
in	0
the	0
terminal	0
differentiation	0
of	0
myeloid	0
precursors	0
.	0

The	0
system	0
described	0
here	0
may	0
serve	0
as	0
a	0
model	0
for	0
studying	0
the	0
the	0
essential	1
genes	2
for	0
differentiation	0
of	0
normal	7
bone	8
marrow	8
cells	8
.	0

Hypoxic	0
induction	0
of	0
interleukin-8	1
gene	2
expression	0
in	0
human	7
endothelial	8
cells	8
.	0

Because	0
leukocyte-mediated	0
tissue	0
damage	0
is	0
an	0
important	0
component	0
of	0
the	0
pathologic	0
picture	0
in	0
ischemia/reperfusion	0
,	0
we	0
have	0
sought	0
mechanisms	0
by	0
which	0
PMNs	7
are	0
directed	0
into	0
hypoxic	0
tissue	0
.	0

Incubation	0
of	0
human	7
endothelial	8
cells	8
(	0
ECs	7
)	0
in	0
hypoxia	0
,	0
PO2	0
approximately	0
14-18	0
Torr	0
,	0
led	0
to	0
time-dependent	0
release	0
of	0
IL-8	9
antigen	0
into	0
the	0
conditioned	0
medium	0
;	0
this	0
was	0
accompanied	0
by	0
increased	0
chemotactic	0
activity	0
for	0
PMNs	7
,	0
blocked	0
by	0
antibody	0
to	0
IL-8	9
.	0

Production	0
of	0
IL-8	9
by	0
hypoxic	0
ECs	7
occurred	0
concomitantly	0
with	0
both	0
increased	0
levels	0
of	0
IL-8	3
mRNA	4
,	0
based	0
on	0
polymerase	0
chain	0
reaction	0
analysis	0
,	0
and	0
increased	0
IL-8	9
transcription	0
,	0
based	0
on	0
nuclear	0
run-on	0
assays	0
.	0

Northern	0
analysis	0
of	0
mRNA	0
from	0
hypoxic	0
ECs	7
also	0
demonstrated	0
increased	0
levels	0
of	0
mRNA	3
for	0
macrophage	9
chemotactic	10
protein-1	10
,	0
another	0
member	0
of	0
the	0
chemokine	9
superfamily	10
of	0
proinflammatory	9
cytokines	10
.	0

IL-8	1
gene	2
induction	0
was	0
associated	0
with	0
the	0
presence	0
of	0
increased	0
binding	0
activity	0
in	0
nuclear	0
extracts	0
from	0
hypoxic	7
ECs	8
for	0
the	0
NF-kB	0
site	0
.	0

Studies	0
with	0
human	0
umbilical	0
vein	0
segments	0
exposed	0
to	0
hypoxia	0
also	0
demonstrated	0
increased	0
elaboration	0
of	0
IL-8	9
antigen	10
compared	0
with	0
normoxic	0
controls	0
.	0

In	0
mice	0
exposed	0
to	0
hypoxia	0
(	0
PO2	0
approximately	0
30-40	0
Torr	0
)	0
,	0
there	0
was	0
increased	0
pulmonary	0
leukostasis	0
,	0
as	0
evidenced	0
by	0
increased	0
myeloperoxidase	9
activity	0
in	0
tissue	0
homogenates	0
.	0

In	0
parallel	0
,	0
increased	0
levels	0
of	0
transcripts	0
for	0
IP-10	9
,	0
a	0
murine	0
homologue	0
in	0
the	0
chemokine	9
family	10
related	0
to	0
IL-8	9
,	0
were	0
observed	0
in	0
hypoxic	0
lung	0
tissue	0
.	0

Taken	0
together	0
,	0
these	0
data	0
suggest	0
that	0
hypoxia	0
constitutes	0
a	0
stimulus	0
for	0
leukocyte	0
chemotaxis	0
and	0
tissue	0
leukostasis	0
.	0

Thrombin	9
and	0
thrombin	9
receptor	10
agonist	0
peptide	0
induce	0
early	0
events	0
of	0
T	0
cell	0
activation	0
and	0
synergize	0
with	0
TCR	9
cross-linking	0
for	0
CD69	9
expression	0
and	0
interleukin	0
2	0
production	0
.	0

Thrombin	9
stimulation	0
of	0
the	0
T	5
leukemic	6
cell	6
line	6
Jurkat	6
induced	0
a	0
transient	0
increase	0
in	0
[	0
Ca2+	0
]	0
i	0
.	0

Proteolytic	0
activity	0
of	0
the	0
enzyme	9
was	0
required	0
for	0
this	0
effect	0
since	0
diisopropyl	9
fluorophosphate-thrombin	10
failed	0
to	0
increase	0
[	0
Ca2+	0
]	0
i	0
.	0

Furthermore	0
,	0
hirudin	0
and	0
anti-thrombin	9
III	10
inhibited	0
the	0
thrombin-induced	0
[	0
Ca2+	0
]	0
i	0
rise	0
in	0
Jurkat	5
T	6
cells	6
.	0

A	0
synthetic	0
thrombin	9
receptor	10
agonist	0
peptide	0
(	0
TRP	0
)	0
of	0
7	0
residues	0
(	0
SFLLRNP	0
)	0
was	0
found	0
to	0
be	0
as	0
effective	0
as	0
thrombin	9
for	0
[	0
Ca2+	0
]	0
i	0
mobilization	0
,	0
and	0
both	0
agonists	0
induced	0
Ca2+	0
release	0
exclusively	0
from	0
internal	0
stores	0
.	0

Thrombin	9
stimulated	0
tyrosine	0
phosphorylation	0
of	0
several	0
proteins	0
of	0
molecular	9
mass	10
40	10
,	10
42	10
,	10
70	10
,	10
120	10
,	10
and	10
130	10
kDa	10
.	0

There	0
was	0
a	0
good	0
correlation	0
between	0
thrombin	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
the	0
latter	0
three	0
proteins	0
and	0
Ca2+	0
mobilization	0
.	0

Thrombin	9
and	0
TRP	0
also	0
caused	0
translocation	0
of	0
protein	9
kinase	10
C	10
from	0
the	0
cytosol	0
to	0
the	0
plasma	0
membrane	0
.	0

As	0
a	0
likely	0
consequence	0
of	0
these	0
events	0
,	0
thrombin	9
activated	0
the	0
nuclear	9
factor	10
NF-kB	10
.	0

Several	0
cell	0
lines	0
of	0
hematopoietic	0
origin	0
including	0
the	0
leukemic	5
T	6
cell	6
line	6
HPB.ALL	6
and	0
the	0
erythroleukemic	5
cell	6
line	6
K562	6
were	0
responsive	0
to	0
thrombin	9
,	0
whereas	0
others	0
such	0
as	0
THP1	5
,	0
a	0
myelomonocytic	5
cell	6
line	6
,	0
and	0
BL2	5
,	6
a	0
Burkitt	5
lymphoma	6
were	0
refractory	0
to	0
thrombin	9
or	0
TRP	0
stimulation	0
.	0

The	0
magnitude	0
of	0
the	0
thrombin	9
response	0
in	0
the	0
different	0
cell	0
types	0
paralleled	0
the	0
expression	0
of	0
the	0
thrombin	3
receptor	4
mRNA	4
.	0

We	0
found	0
that	0
activation	0
of	0
Jurkat	5
T	6
cells	6
by	0
a	0
combination	0
of	0
phytohemagglutinin	9
and	0
phorbol	0
12-myristate	0
13-acetate	0
led	0
to	0
a	0
dramatic	0
inhibition	0
of	0
thrombin	3
receptor	4
mRNA	4
expression	0
and	0
to	0
a	0
concomitant	0
loss	0
of	0
the	0
thrombin	9
response	0
.	0

Finally	0
,	0
we	0
demonstrate	0
that	0
thrombin	9
and	0
TRP	0
enhanced	0
CD69	9
expression	0
and	0
interleukin	9
2	10
production	0
induced	0
by	0
T	9
cell	10
receptor	10
cross-linking	0
in	0
both	0
Jurkat	5
T	6
cells	6
and	0
peripheral	0
blood	0
lymphocytes	7
.	0

These	0
findings	0
highlight	0
the	0
role	0
of	0
thrombin	9
as	0
a	0
potential	0
regulator	0
of	0
T	7
lymphocyte	8
activation	0
.	0

Stress	0
response	0
of	0
senescent	7
T	8
lymphocytes	8
:	0
reduced	0
hsp70	9
is	0
independent	0
of	0
the	0
proliferative	0
block	0
.	0

Senescent	5
human	6
T	6
lymphocyte	6
cultures	6
are	0
unable	0
to	0
undergo	0
proliferation	0
,	0
but	0
show	0
no	0
difference	0
from	0
early	5
passage	6
cells	6
in	0
cytotoxic	0
function	0
or	0
surface	0
antigenic	0
profile	0
.	0

A	0
second	0
feature	0
of	0
senescent	5
T	6
cells	6
is	0
the	0
dramatic	0
reduction	0
in	0
hsp70	9
production	0
in	0
response	0
to	0
heat	0
shock	0
.	0

This	0
decline	0
is	0
associated	0
with	0
a	0
decrease	0
in	0
binding	0
of	0
nuclear	0
extracts	0
to	0
the	0
consensus	1
heat	2
shock	2
element	2
.	0

Interestingly	0
,	0
the	0
progressive	0
decline	0
in	0
the	0
heat	0
shock	0
response	0
of	0
cultured	5
T	6
cells	6
correlates	0
with	0
the	0
percent	0
proliferative	0
life	0
span	0
completed	0
rather	0
than	0
with	0
the	0
actual	0
proliferative	0
activity	0
at	0
the	0
time	0
of	0
heat	0
shock	0
.	0

This	0
suggests	0
that	0
for	0
senescent	7
T	8
cells	8
the	0
reduced	0
ability	0
to	0
respond	0
to	0
heat	0
shock	0
by	0
producing	0
hsp70	9
,	0
although	0
possibly	0
lying	0
at	0
the	0
level	0
of	0
transcriptional	0
control	0
,	0
may	0
nevertheless	0
be	0
unrelated	0
to	0
the	0
reduced	0
DNA	0
synthesis	0
or	0
the	0
diminished	0
proliferative	0
activity	0
also	0
manifested	0
by	0
these	0
cells	0
.	0

Involvement	0
of	0
phospholipase	9
D	10
in	0
the	0
activation	0
of	0
transcription	9
factor	10
AP-1	10
in	0
human	5
T	6
lymphoid	6
Jurkat	6
cells	6
.	0

The	0
induction	0
of	0
the	0
AP-1	9
transcription	9
factor	10
has	0
been	0
ascribed	0
to	0
the	0
early	0
events	0
leading	0
to	0
T	0
lymphocyte	0
activation	0
.	0

We	0
have	0
examined	0
the	0
possibility	0
that	0
stimulation	0
of	0
phospholipase	9
D	10
(	0
PLD	9
)	0
may	0
regulate	0
activation	0
of	0
transcription	9
factor	10
AP-1	10
in	0
human	0
T	0
cells	0
by	0
transfecting	0
human	0
T	5
lymphocyte	6
Jurkat	6
cells	6
with	0
a	0
plasmid	0
containing	0
an	0
AP-1	1
enhancer	2
element	2
and	0
a	0
chloramphenicol	1
acetyltransferase	2
reporter	2
gene	2
.	0

We	0
have	0
detected	0
activatable	0
PLD	9
in	0
Jurkat	5
cells	6
,	0
and	0
we	0
have	0
found	0
that	0
addition	0
of	0
phosphatidic	0
acid	0
(	0
PA	0
)	0
,	0
the	0
physiologic	0
product	0
of	0
PLD	9
action	0
on	0
phospholipids	0
,	0
is	0
rapidly	0
incorporated	0
into	0
Jurkat	5
cells	6
and	0
leads	0
to	0
activation	0
of	0
transcription	9
factor	10
AP-1	10
.	0

Treatment	0
of	0
Jurkat	5
cells	6
with	0
anti-CD3	9
mAb	10
activated	0
both	0
PLD	9
and	0
transcription	9
factor	10
AP-1	10
.	0

Wortmannin	0
,	0
an	0
inhibitor	0
of	0
receptor-coupled	0
PLD	9
activation	0
,	0
blocked	0
the	0
anti-CD3	9
-induced	0
increases	0
in	0
both	0
PLD	9
activity	0
and	0
AP-1	1
enhancer	2
activity	0
.	0

We	0
found	0
a	0
good	0
correlation	0
in	0
the	0
transfected	5
cells	6
between	0
PLD	9
activation	0
and	0
induction	0
of	0
AP-1	1
enhancer	2
activity	0
under	0
different	0
experimental	0
conditions	0
.	0

Furthermore	0
,	0
ethanol	0
,	0
an	0
inhibitor	0
of	0
the	0
PLD	9
pathway	0
,	0
blocked	0
the	0
anti-CD3-stimulated	0
AP-1	1
enhancer	2
activity	0
.	0

However	0
,	0
this	0
anti-CD3	9
-mediated	0
response	0
was	0
not	0
inhibited	0
by	0
neomycin	0
,	0
an	0
inhibitor	0
of	0
phosphoinositide	0
hydrolysis	0
.	0

The	0
increases	0
in	0
AP-1	1
enhancer	2
activity	0
induced	0
by	0
PA	0
or	0
anti-CD3	9
mAb	10
were	0
efficiently	0
abrogated	0
by	0
the	0
presence	0
of	0
propranolol	0
,	0
an	0
inhibitor	0
of	0
PA	0
phosphohydrolase	9
and	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
.	0

Furthermore	0
,	0
the	0
PA	0
-and	0
the	0
anti-CD3	9
-induced	0
increases	0
in	0
AP-1	1
enhancer	2
activity	0
were	0
blocked	0
by	0
the	0
presence	0
of	0
PKC	9
inhibitors	0
or	0
by	0
PKC	9
down-regulation	0
.	0

These	0
data	0
indicate	0
that	0
PLD	9
stimulation	0
can	0
activate	0
the	0
transcription	9
factor	10
AP-1	10
in	0
T	7
lymphocytes	8
,	0
and	0
suggest	0
that	0
the	0
induction	0
of	0
AP-1	1
enhancer	2
factor	0
activity	0
by	0
PA	0
is	0
mediated	0
via	0
PKC	9
stimulation	0
,	0
either	0
through	0
a	0
direct	0
activating	0
effect	0
of	0
PA	0
or	0
through	0
PA-derived	0
diacylglycerol	0
formation	0
.	0

These	0
data	0
also	0
provide	0
evidence	0
for	0
a	0
role	0
of	0
PLD	9
-derived	0
lipids	0
in	0
the	0
induction	0
of	0
AP-1	1
enhancer	2
activity	0
resulting	0
from	0
stimulation	0
of	0
the	0
TCR/CD3	9
complex	10
,	0
suggesting	0
that	0
increased	0
PLD	9
activity	0
can	0
play	0
an	0
important	0
role	0
in	0
T	7
lymphocyte	8
activation	0
.	0

Upregulation	0
of	0
bcl-2	1
by	0
the	0
Epstein-Barr	9
virus	10
latent	10
membrane	10
protein	10
LMP1	9
:	0
a	0
B-cell-specific	0
response	0
that	0
is	0
delayed	0
relative	0
to	0
NF-kappa	9
B	10
activation	0
and	0
to	0
induction	0
of	0
cell	9
surface	10
markers	10
.	0

An	0
ability	0
of	0
the	0
Epstein-Barr	9
virus	10
latent	10
membrane	10
protein	10
LMP1	9
to	0
enhance	0
the	0
survival	0
of	0
infected	7
B	8
cells	8
through	0
upregulation	0
of	0
the	0
bcl-2	1
oncogene	2
was	0
first	0
suggested	0
by	0
experiments	0
involving	0
gene	0
transfection	0
and	0
the	0
selection	0
of	0
stable	0
LMP1+	5
clones	6
(	0
S.Henderson	0
,	0
M.	0
Rowe	0
,	0
C.Gregory	0
,	0
F.Wang	0
,	0
E.Kieff	0
,	0
and	0
A.Rickinson	0
,	0
Cell	0
65	0
:	0
1107-1115	0
,	0
1991	0
)	0
.	0

However	0
,	0
it	0
was	0
not	0
possible	0
to	0
ascertain	0
whether	0
Bcl-2	9
upregulation	0
was	0
a	0
specific	0
consequence	0
of	0
LMP1	9
expression	0
or	0
an	0
artifact	0
of	0
the	0
selection	0
procedure	0
whereby	0
rare	0
Bcl-2+	5
cells	6
already	0
present	0
in	0
the	0
starting	0
population	0
might	0
best	0
be	0
able	0
to	0
tolerate	0
the	0
potentially	0
toxic	0
effects	0
of	0
LMP1	9
.	0

We	0
therefore	0
reexamined	0
this	0
issue	0
by	0
using	0
two	0
different	0
experimental	0
approaches	0
that	0
allowed	0
LMP1	9
-induced	0
effects	0
to	0
be	0
monitored	0
immediately	0
following	0
expression	0
of	0
the	0
viral	0
protein	0
and	0
in	0
the	0
absence	0
of	0
selective	0
pressures	0
;	0
activation	0
of	0
the	0
NF-kappa	9
B	10
transcription	9
factor	10
and	0
upregulation	0
of	0
the	0
cell	9
adhesion	10
molecule	10
ICAM-1	9
were	0
used	0
as	0
early	0
indices	0
of	0
LMP1	9
function	0
.	0

In	0
the	0
first	0
approach	0
,	0
stable	0
clones	0
of	0
two	0
B-cell	5
lines	6
carrying	0
an	0
LMP1	9
gene	0
under	0
the	0
control	0
of	0
an	0
inducible	0
metallothionein	1
promoter	2
were	0
induced	0
to	0
express	0
LMP1	9
in	0
all	0
cells	0
.	0

Activation	0
of	0
NK-kappa	9
B	10
and	0
upregulation	0
of	0
ICAM-1	9
occurred	0
within	0
24	0
h	0
and	0
were	0
followed	0
at	0
48	0
to	0
72	0
h	0
by	0
upregulation	0
of	0
Bcl-2	9
.	0

In	0
the	0
second	0
approach	0
,	0
we	0
tested	0
the	0
generality	0
of	0
this	0
phenomenon	0
by	0
transiently	0
expressing	0
LMP1	9
from	0
a	0
strong	0
constitutively	0
active	0
promoter	0
in	0
a	0
range	0
of	0
different	0
cell	0
types	0
.	0

All	0
six	0
B-cell	5
lines	6
tested	0
showed	0
NF-kappa	9
B	10
activation	0
in	0
response	0
to	0
LMP1	9
expression	0
,	0
and	0
this	0
was	0
followed	0
in	0
five	0
of	0
six	0
lines	0
by	0
expression	0
of	0
ICAM-1	9
and	0
Bcl-2	9
.	0

In	0
the	0
same	0
experiments	0
,	0
all	0
three	0
non-	0
B-cell	5
lines	6
showed	0
NF-kappa	9
B	10
activation	0
and	0
ICAM-1	9
upregulation	0
but	0
never	0
any	0
effect	0
upon	0
Bcl-2	9
.	0

We	0
therefore	0
conclude	0
that	0
Bcl-2	9
upregulation	0
is	0
part	0
of	0
the	0
panoply	0
of	0
cellular	0
changes	0
induced	0
by	0
LMP1	9
but	0
that	0
the	0
effect	0
is	0
cell	0
type	0
specific	0
.	0

Our	0
data	0
also	0
suggest	0
that	0
whilst	0
NF-kappa	9
B	10
may	0
be	0
an	0
essential	0
component	0
of	0
LMP1	9
signal	0
transduction	0
,	0
other	0
cell-specific	9
factors	10
may	0
be	0
required	0
to	0
effect	0
some	0
functions	0
of	0
the	0
viral	9
protein	10
.	0

Long-term	0
inositol	0
phosphate	0
release	0
,	0
but	0
not	0
tyrosine	9
kinase	10
activity	0
,	0
correlates	0
with	0
IL-2	9
secretion	0
and	0
NF-AT	9
induction	0
in	0
anti-CD3-activated	5
peripheral	6
human	6
T	6
lymphocytes	6
.	0

The	0
cascade	0
of	0
events	0
within	0
the	0
first	0
few	0
minutes	0
of	0
T	7
cell	8
stimulation	0
has	0
been	0
well	0
characterized	0
.	0

Although	0
many	0
second	0
messengers	0
have	0
been	0
shown	0
to	0
be	0
necessary	0
and	0
sufficient	0
for	0
T	7
cell	8
activation	0
in	0
a	0
number	0
of	0
model	0
systems	0
,	0
the	0
rate-limiting	0
step	0
in	0
peripheral	7
T	8
cells	8
has	0
not	0
been	0
demonstrated	0
.	0

To	0
model	0
effective	0
versus	0
ineffective	0
CD3	9
-mediated	0
stimulation	0
in	0
peripheral	7
T	8
cells	8
,	0
we	0
used	0
two	0
anti-CD3	9
mAbs	10
that	0
differ	0
in	0
their	0
ability	0
to	0
stimulate	0
purified	7
T	8
cells	8
:	0
OKT3	9
,	0
which	0
causes	0
early	0
second	0
messenger	0
generation	0
but	0
is	0
unable	0
to	0
activate	0
T	7
cells	8
without	0
a	0
second	0
signal	0
,	0
and	0
64.1	9
,	0
which	0
stimulates	0
T	7
cell	8
proliferation	0
on	0
its	0
own	0
.	0

We	0
found	0
that	0
tyrosine	9
kinase	10
activity	0
was	0
similar	0
for	0
both	0
mAbs	9
over	0
a	0
period	0
of	0
hours	0
.	0

However	0
,	0
the	0
inositol	0
phosphate	0
response	0
was	0
stronger	0
for	0
64.1	9
than	0
for	0
OKT3	9
.	0

To	0
tie	0
these	0
events	0
to	0
gene	0
activation	0
,	0
we	0
measured	0
NF-kappa	9
B	10
and	0
NF-AT	9
activity	0
in	0
the	0
nucleus	0
after	0
anti-CD3	9
stimulation	0
.	0

Both	0
stimuli	0
induced	0
the	0
appearance	0
of	0
the	0
NF-kappa	9
B	10
components	10
(	0
c-Rel	9
,	0
p65	9
(	0
RelA	9
)	0
,	0
and	0
p50	9
(	0
NF-kappa	9
B1	10
)	0
)	0
and	0
NF-kappa	9
B	10
DNA	0
binding	0
activity	0
in	0
the	0
nucleus	0
.	0

However	0
,	0
only	0
64.1	9
induced	0
NF-AT	9
in	0
the	0
nucleus	0
,	0
correlating	0
with	0
its	0
ability	0
to	0
activate	0
T	7
cells	8
.	0

Thus	0
,	0
NF-AT	9
induction	0
and	0
IL-2	9
secretion	0
were	0
correlated	0
with	0
the	0
levels	0
of	0
inositol	0
phosphate	0
release	0
but	0
not	0
with	0
gross	0
levels	0
of	0
tyrosine	9
kinase	10
activity	0
induced	0
late	0
following	0
the	0
response	0
.	0

On	0
the	0
other	0
hand	0
,	0
NF-kappa	9
B	10
induction	0
and	0
IL-2	9
receptor	0
expression	0
occurred	0
even	0
with	0
the	0
smaller	0
second	0
messenger	0
response	0
generated	0
by	0
OKT3	9
.	0

HLA-DR-	0
,	0
CD33+	0
,	0
CD56+	0
,	0
CD16-	0
myeloid/natural	0
killer	0
cell	0
acute	0
leukemia	0
:	0
a	0
previously	0
unrecognized	0
form	0
of	0
acute	0
leukemia	0
potentially	0
misdiagnosed	0
as	0
French-American-British	0
acute	0
myeloid	0
leukemia-M3	0
[	0
see	0
comments	0
]	0

We	0
have	0
identified	0
and	0
characterized	0
a	0
previously	0
unrecognized	0
form	0
of	0
acute	0
leukemia	0
that	0
shares	0
features	0
of	0
both	0
myeloid	7
and	8
natural	8
killer	8
(	8
NK	8
)	8
cells	8
.	0

From	0
a	0
consecutive	0
series	0
of	0
350	0
cases	0
of	0
adult	0
de	0
novo	0
acute	0
myeloid	0
leukemia	0
(	0
AML	0
)	0
,	0
we	0
identified	0
20	0
cases	0
(	0
6	0
%	0
)	0
with	0
a	0
unique	0
immunophenotype	0
:	0
CD33+	0
,	0
CD56+	0
,	0
CD11a+	0
,	0
CD13lo	0
,	0
CD15lo	0
,	0
CD34+/-	0
,	0
HLA-DR	9
-	0
,	0
CD16	9
-	0
.	0

Multicolor	0
flow	0
cytometric	0
assays	0
confirmed	0
the	0
coexpression	0
of	0
myeloid	9
(	10
CD33	10
,	10
CD13	10
,	10
CD15	10
)	10
and	10
NK	10
cell-associated	10
(	10
CD56	10
)	10
antigens	10
in	0
each	0
case	0
,	0
whereas	0
reverse	0
transcription	0
polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
assays	0
confirmed	0
the	0
identity	0
of	0
CD56	9
(	0
neural	9
cell	10
adhesion	10
molecule	10
)	0
in	0
leukemic	7
blasts	8
.	0

Although	0
two	0
cases	0
expressed	0
CD4	9
,	0
no	0
case	0
expressed	0
CD2	9
,	0
CD3	9
,	0
or	0
CD8	9
and	0
no	0
case	0
showed	0
clonal	0
rearrangement	0
of	0
genes	0
encoding	0
the	0
T-cell	9
receptor	10
(	0
TCR	9
beta	10
,	10
gamma	10
,	10
delta	10
)	0
.	0

Leukemic	0
blasts	0
in	0
the	0
majority	0
of	0
cases	0
shared	0
unique	0
morphologic	0
features	0
(	0
deeply	0
invaginated	0
nuclear	0
membranes	0
,	0
scant	0
cytoplasm	0
with	0
fine	0
azurophilic	0
granularity	0
,	0
and	0
finely	0
granular	0
Sudan	0
black	0
B	0
and	0
myeloperoxidase	9
cytochemical	0
reactivity	0
)	0
that	0
were	0
remarkably	0
similar	0
to	0
those	0
of	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
;	0
particularly	0
the	0
microgranular	9
variant	10
(	0
FAB	9
AML-M3v	10
)	0
.	0

However	0
,	0
all	0
20	0
cases	0
lacked	0
the	0
t	0
(	0
15	0
;	0
17	0
)	0
and	0
17	0
cases	0
tested	0
lacked	0
the	0
promyelocytic/retinoic	3
acid	4
receptor	4
alpha	4
(	4
RAR	4
alpha	4
)	4
fusion	4
transcript	4
in	0
RT-PCR	0
assays	0
;	0
12	0
cases	0
had	0
46	0
,	0
XX	0
or	0
46	0
,	0
XY	0
karyotypes	0
,	0
whereas	0
2	0
cases	0
had	0
abnormalities	0
of	0
chromosome	1
17q	2
:	0
1	0
with	0
del	1
(	2
17	2
)	2
(	2
q25	2
)	2
and	0
the	0
other	0
with	0
t	1
(	2
11	2
;	2
17	2
)	2
(	2
q23	2
;	2
q21	2
)	2
and	0
the	0
promyelocytic	3
leukemia	4
zinc	4
finger/RAR	4
alpha	4
fusion	4
transcript	4
.	0

All	0
cases	0
tested	0
(	0
6/20	0
)	0
,	0
including	0
the	0
case	0
with	0
t	1
(	2
11	2
;	2
17	2
)	2
,	0
failed	0
to	0
differentiate	0
in	0
vitro	0
in	0
response	0
to	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
,	0
suggesting	0
that	0
these	0
cases	0
may	0
account	0
for	0
some	0
APLs	0
that	0
have	0
not	0
shown	0
a	0
clinical	0
response	0
to	0
ATRA	0
.	0

Four	0
of	0
6	0
cases	0
tested	0
showed	0
functional	0
NK	0
cell-mediated	0
cytotoxicity	0
,	0
suggesting	0
a	0
relationship	0
between	0
these	0
unique	0
CD33+	0
,	0
CD56+	0
,	0
CD16	9
-acute	0
leukemias	0
and	0
normal	7
CD56+	8
,	8
CD16-	8
NK	8
precursor	8
cells	8
.	0

Using	0
a	0
combination	0
of	0
panning	0
and	0
multiparameter	0
flow	0
cytometric	0
sorting	0
,	0
we	0
identified	0
a	0
normal	7
CD56+	8
,	8
CD33+	8
,	8
CD16-	8
counterpart	8
cell	8
at	0
a	0
frequency	0
of	0
1	0
%	0
to	0
2	0
%	0
in	0
the	0
peripheral	0
blood	0
of	0
healthy	0
individuals	0
.	0

Our	0
studies	0
suggest	0
that	0
this	0
form	0
of	0
acute	0
leukemia	0
may	0
arise	0
from	0
transformation	0
of	0
a	0
precursor	0
cell	0
common	0
to	0
both	0
the	0
myeloid	7
and	8
NK	8
cell	8
lineages	8
;	0
thus	0
we	0
propose	0
the	0
designation	0
myeloid/NK	0
acute	0
leukemia	0
.	0

Recognition	0
of	0
this	0
new	0
leukemic	0
entity	0
will	0
be	0
important	0
in	0
distinguishing	0
these	0
ATRA-nonresponsive	0
cases	0
from	0
ATRA-responsive	0
true	0
APL	0
.	0

IL-4	9
down-regulates	0
IL-2	9
-	0
,	0
IL-3	9
-	0
,	0
and	0
GM-CSF	9
-induced	0
cytokine	0
gene	0
expression	0
in	0
peripheral	0
blood	0
monocytes	0
.	0

IL-4	9
,	0
a	0
product	0
of	0
the	0
T-helper	7
0	8
(	8
Th0	8
)	8
and	8
2	8
(	8
Th2	8
)	8
subset	8
,	0
was	0
originally	0
described	0
as	0
a	0
B-cell	9
stimulatory	10
factor	10
and	0
has	0
subsequently	0
been	0
found	0
to	0
suppress	0
IL-1	0
alpha	0
,	0
IL-1	0
beta	0
,	0
IL-6	0
,	0
IL-8	0
,	0
and	0
TNF-alpha	0
gene	0
expression	0
in	0
monocytes	7
stimulated	0
with	0
LPS	0
,	0
and	0
to	0
upregulate	0
IL-1	1
receptor	2
antagonist	2
(	2
IL1-RA	2
)	2
gene	2
expression	0
.	0

In	0
this	0
study	0
we	0
investigated	0
the	0
effect	0
of	0
IL-4	9
on	0
the	0
expression	0
of	0
cytokine	1
genes	2
in	0
monocytes	7
evoked	0
by	0
other	0
T-helper	9
cell	10
cytokines	10
:	0
IL-2	9
,	0
IL-3	9
,	0
and	0
GM-CSF	9
.	0

IL-4	9
down-regulated	0
mRNA	0
accumulation	0
of	0
the	0
proinflammatory	9
cytokines	10
IL-1	9
beta	10
,	0
IL-8	9
,	0
and	0
TNF-alpha	9
in	0
monocytes	7
stimulated	0
with	0
IL-2	9
,	0
IL-3	9
,	0
and	0
GM-CSF	9
.	0

IL-4	9
also	0
suppressed	0
the	0
IL-2	9
-induced	0
IL-6	9
mRNA	0
expression	0
.	0

Temporal	0
analysis	0
of	0
the	0
IL-4	9
down-regulatory	0
effect	0
on	0
the	0
IL-2-	0
,	0
IL-3-	0
,	0
or	0
GM-CSF-induced	0
proinflammatory	0
cytokine	0
gene	0
expression	0
in	0
monocytes	7
provided	0
evidence	0
that	0
IL-4	9
acts	0
predominantly	0
on	0
the	0
post-transcriptional	0
level	0
.	0

This	0
was	0
supported	0
by	0
the	0
observation	0
that	0
the	0
down-regulatory	0
capacity	0
of	0
IL-4	9
appeared	0
to	0
be	0
dependent	0
on	0
de	0
novo	0
protein	0
synthesis	0
.	0

IL-4	9
did	0
not	0
exert	0
significant	0
influence	0
on	0
the	0
induction	0
of	0
expression	0
of	0
IL-1-RA	9
or	0
various	0
CSFs	9
by	0
IL-2	9
,	0
IL-3	9
,	0
and	0
GM-CSF	9
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Induction	0
of	0
proto-oncogene	1
and	0
cytokine	9
expression	0
in	0
human	0
peripheral	0
blood	0
monocytes	7
and	0
the	0
monocytic	5
cell	6
line	6
THP-1	5
after	0
stimulation	0
with	0
mycoplasma-derived	0
material	0
MDHM	0
.	0

Mycoplasma	0
fermentans-derived	0
high-molecular-weight	0
material	0
(	0
MDHM	0
)	0
was	0
originally	0
described	0
to	0
induce	0
differentiation	0
of	0
murine	7
thymocytes	8
to	0
cytolytic	7
effector	8
T-cells	8
by	0
stimulating	0
IL-6	9
release	0
from	0
adherent	7
cells	8
.	0

This	0
study	0
shows	0
that	0
human	0
peripheral	0
blood	0
monocytes	7
(	0
PBMo	7
)	0
also	0
respond	0
to	0
MDHM	0
with	0
increases	0
in	0
IL-1	9
beta	10
,	0
IL-6	9
and	0
TNF	9
alpha	10
expression	0
,	0
both	0
at	0
the	0
mRNA	0
and	0
protein	0
level	0
.	0

The	0
induced	0
expression	0
of	0
IL-1	3
beta	4
and	4
TNF	4
alpha	4
mRNA	4
in	0
the	0
monocytic	0
THP-1	5
cell	6
line	6
increased	0
as	0
quickly	0
as	0
in	0
primary	7
cells	8
.	0

In	0
contrast	0
to	0
PBMo	7
,	0
THP-1	5
and	0
14	0
other	0
monocytic/myeloid	5
leukemia-derived	6
cell	6
lines	6
did	0
not	0
secrete	0
measurable	0
amounts	0
of	0
the	0
cytokines	9
upon	0
treatment	0
with	0
MDHM	0
.	0

IL-1	1
beta	2
and	2
IL-6	2
genes	2
contain	0
AP-1	1
binding	2
sites	2
as	0
regulatory	1
elements	2
,	0
the	0
AP-1	9
protein	0
being	0
composed	0
of	0
c-jun	9
and	10
c-fos	10
gene	10
products	10
.	0

In	0
THP-1	5
cells	6
c-jun	3
mRNA	4
expression	0
increased	0
after	0
incubation	0
with	0
MDHM	0
while	0
positive	0
c-fos	1
expression	0
remained	0
unaffected	0
.	0

Although	0
these	0
data	0
suggest	0
AP-1	9
regulated	0
cytokine	9
mRNA	0
expression	0
,	0
results	0
from	0
PBMo	7
are	0
not	0
in	0
accordance	0
with	0
this	0
notion	0
.	0

In	0
the	0
primary	7
cells	8
MDHM-induced	0
elevation	0
of	0
cytokine	3
mRNA	4
levels	0
was	0
preceded	0
by	0
a	0
downregulation	0
of	0
c-fos	1
expression	0
while	0
positive	0
c-jun	1
expression	0
was	0
not	0
modulated	0
.	0

c-myc	3
mRNA	4
expression	0
,	0
constitutively	0
high	0
in	0
THP-1	5
cells	6
,	0
was	0
induced	0
in	0
MDHM-stimulated	0
PBMo	7
.	0

In	0
conclusion	0
,	0
MDHM-stimulated	0
induction	0
of	0
cytokine	3
mRNA	4
expression	0
was	0
accompanied	0
by	0
different	0
proto-oncogene	1
responses	0
in	0
PBMo	7
and	0
THP-1	5
cells	6
.	0

These	0
differences	0
may	0
represent	0
different	0
regulatory	0
pathways	0
of	0
the	0
two	0
cell	0
systems	0
.	0

Alternatively	0
,	0
these	0
data	0
support	0
the	0
notion	0
that	0
neither	0
AP-1	9
nor	0
the	0
c-myc	9
protein	10
are	0
involved	0
in	0
the	0
MDHM-induced	0
increase	0
in	0
IL-1	0
beta	0
,	0
IL-6	0
or	0
TNF	0
alpha	0
mRNA	0
levels	0
.	0

Furthermore	0
,	0
the	0
present	0
results	0
demonstrate	0
clearly	0
that	0
mycoplasma	9
products	10
can	0
have	0
a	0
profound	0
impact	0
on	0
the	0
activation	0
status	0
of	0
eukaryotic	7
cells	8
.	0

Novel	9
membrane	10
receptors	10
for	0
aldosterone	0
in	0
human	7
lymphocytes	8
:	0
a	0
50	9
kDa	10
protein	10
on	0
SDS-PAGE	0
.	0

Fast	0
in	0
vitro	0
effects	0
of	0
aldosterone	0
on	0
the	0
Na+/H	9
(	10
+	10
)	10
-exchanger	10
,	0
inositoltrisphosphate	0
generation	0
and	0
corresponding	0
specific	0
binding	0
to	0
plasma	0
membranes	0
at	0
Kd-values	0
of	0
approximately	0
0.1	0
nM	0
have	0
been	0
found	0
in	0
human	7
mononuclear	8
leukocytes	8
and	0
vascular	7
smooth	8
muscle	8
cells	8
.	0

The	0
novel	0
aldosterone	0
membrane	0
receptor	0
was	0
analyzed	0
on	0
SDS-PAGE	0
after	0
labeling	0
of	0
microsomal	0
membranes	0
from	0
human	7
mononuclear	8
leukocytes	8
with	0
a	0
[	0
125I	0
]	0
-aldosterone-derivative	0
by	0
use	0
of	0
BASED	0
as	0
a	0
photoactivatable	0
crosslinker	0
.	0

Binding	0
of	0
1	0
nM	0
[	0
125I	0
]	0
-aldosterone	0
was	0
found	0
at	0
a	0
molecular	0
weight	0
of	0
approximately	0
50	0
kDa	0
which	0
was	0
absent	0
with	0
1	0
microM	0
cold	0
aldosterone	0
,	0
but	0
not	0
cortisol	0
in	0
the	0
binding	0
media	0
.	0

This	0
aldosterone-selectivity	0
is	0
typical	0
and	0
discriminatory	0
for	0
the	0
new	0
aldosterone	9
membrane	10
receptor	10
.	0

Solubilization	0
of	0
the	0
receptor	9
protein	10
from	0
membranes	0
by	0
high	0
salt	0
concentrations	0
(	0
1	0
M	0
NaCl	0
,	0
1	0
mM	0
EDTA	0
)	0
was	0
not	0
achieved	0
.	0

It	0
,	0
thus	0
,	0
appears	0
as	0
an	0
integral	9
membrane	10
protein	10
.	0

Dithiothreitol	0
,	0
a	0
sulfhydryl	0
agent	0
,	0
does	0
not	0
reduce	0
specific	0
aldosterone	0
binding	0
indicating	0
the	0
absence	0
of	0
SH-groups	9
in	0
the	0
binding	9
domain	10
or	0
sensitive	0
structures	0
of	0
the	0
receptors	0
.	0

The	0
results	0
are	0
the	0
first	0
to	0
characterize	0
the	0
novel	9
membrane	10
receptor	10
for	0
aldosterone	0
with	0
regard	0
to	0
molecular	0
weight	0
and	0
basic	0
properties	0
.	0

These	0
findings	0
and	0
other	0
related	0
results	0
are	0
reviewed	0
here	0
.	0

A	0
transcriptional	1
regulatory	2
element	2
is	0
associated	0
with	0
a	0
nuclease-hypersensitive	1
site	2
in	0
the	0
pol	1
gene	2
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
.	0

Analysis	0
of	0
the	0
chromatin	0
organization	0
of	0
the	0
integrated	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
(	2
HIV-1	2
)	2
genome	2
has	0
previously	0
revealed	0
a	0
major	1
constitutive	2
DNase	2
I-hypersensitive	2
site	2
associated	0
with	0
the	0
pol	1
gene	2
(	0
E.	0
Verdin	0
,	0
J.	0
Virol.	0
65	0
:	0
6790-6799	0
,	0
1991	0
)	0
.	0

In	0
the	0
present	0
report	0
,	0
high-resolution	0
mapping	0
of	0
this	0
site	0
with	0
DNase	9
I	10
and	0
micrococcal	9
nuclease	10
identified	0
a	0
nucleosome-free	1
region	2
centered	0
around	0
nucleotides	1
(	2
nt	2
)	2
4490	2
to	2
4766	2
.	0

A	0
500-bp	1
fragment	2
encompassing	0
this	0
hypersensitive	1
site	2
(	0
nt	1
4481	2
to	2
4982	2
)	0
exhibited	0
transcription-enhancing	0
activity	0
(	0
two-	0
to	0
threefold	0
)	0
when	0
it	0
was	0
cloned	0
in	0
its	0
natural	0
position	0
with	0
respect	0
to	0
the	0
HIV-1	1
promoter	2
after	0
transient	0
transfection	0
in	0
U937	5
and	0
CEM	5
cells	6
.	0

Using	0
in	0
vitro	0
footprinting	0
and	0
gel	0
shift	0
assays	0
,	0
we	0
have	0
identified	0
four	0
distinct	0
binding	1
sites	2
for	0
nuclear	9
proteins	10
within	0
this	0
positive	1
regulatory	2
element	2
.	0

Site	1
B	2
(	0
nt	1
4519	2
to	2
4545	2
)	0
specifically	0
bound	0
four	0
distinct	0
nuclear	9
protein	10
complexes	10
:	0
a	0
ubiquitous	9
factor	10
,	0
a	0
T-cell-specific	9
factor	10
,	0
a	0
B-cell-specific	9
factor	10
,	0
and	0
the	0
monocyte/macrophage-	9
and	10
B-cell-specific	10
transcription	10
factor	10
PU.1/Spi-1	9
.	0

In	0
most	0
HIV-1	0
isolates	0
in	0
which	0
this	0
PU	1
box	2
was	0
not	0
conserved	0
,	0
it	0
was	0
replaced	0
by	0
a	0
binding	1
site	2
for	0
the	0
related	0
factor	0
Ets1	9
.	0

Factors	0
binding	0
to	0
site	1
C	2
(	0
nt	1
4681	2
to	2
4701	2
)	0
had	0
a	0
DNA-binding	0
specificity	0
similar	0
to	0
that	0
of	0
factors	0
binding	0
to	0
site	1
B	2
,	0
except	0
for	0
PU.1/Spi-1	9
.	0

A	0
GC	1
box	2
containing	0
a	0
binding	1
site	2
for	0
Sp1	9
was	0
identified	0
(	0
nt	1
4623	2
to	2
4631	2
)	0
.	0

Site	1
D	2
(	0
nt	1
4816	2
to	2
4851	2
)	0
specifically	0
bound	0
a	0
ubiquitously	9
expressed	10
factor	10
.	0

These	0
results	0
identify	0
a	0
transcriptional	1
regulatory	2
element	2
associated	0
with	0
a	0
nuclease-hypersensitive	1
site	2
in	0
the	0
pol	1
gene	2
of	0
HIV-1	0
and	0
suggest	0
that	0
its	0
activity	0
may	0
be	0
controlled	0
by	0
a	0
complex	0
interplay	0
of	0
cis-	0
regulatory	1
elements	2
.	0

Expression	0
of	0
v-src	1
in	0
T	7
cells	8
correlates	0
with	0
nuclear	0
expression	0
of	0
NF-kappa	9
B	10
.	0

NF-kappa	9
B	10
is	0
a	0
rapidly	0
inducible	0
transcriptional	1
activator	2
that	0
responds	0
to	0
a	0
variety	0
of	0
signals	0
and	0
influences	0
the	0
expression	0
of	0
many	0
genes	0
involved	0
in	0
the	0
immune	0
response	0
.	0

Protein	0
tyrosine	9
kinases	10
transmit	0
signals	0
from	0
cytokine	9
and	10
immune	10
receptors	10
.	0

Very	0
little	0
information	0
exists	0
linking	0
these	0
two	0
important	0
classes	0
of	0
signaling	9
molecules	10
.	0

We	0
now	0
demonstrate	0
that	0
v-src	1
expression	0
correlates	0
with	0
nuclear	0
expression	0
of	0
a	0
kappa	9
B	10
binding	10
complex	10
similar	0
to	0
that	0
induced	0
by	0
phorbol	0
ester	0
and	0
ionomycin	0
,	0
as	0
detected	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
using	0
a	0
variety	0
of	0
kappa	1
B	2
sites	2
.	0

This	0
complex	0
was	0
blocked	0
by	0
the	0
tyrosine	9
kinase	10
inhibitor	0
,	0
herbimycin	0
A	0
.	0

The	0
v-src-induced	9
complex	10
comprised	0
the	0
p50	9
and	0
p65	9
components	0
of	0
NF-kappa	9
B	10
,	0
as	0
determined	0
by	0
supershift	0
and	0
immunoblot	0
analysis	0
.	0

As	0
a	0
functional	0
correlate	0
of	0
this	0
finding	0
,	0
transient	0
co-transfection	0
of	0
HIV-1	1
LTR	2
reporter	2
constructs	2
in	0
a	0
different	0
T	5
cell	6
line	6
demonstrated	0
that	0
v-src	1
activated	0
this	0
promoter	9
in	0
a	0
kappa	0
B-dependent	0
manner	0
.	0

We	0
found	0
that	0
transactivation	0
of	0
the	0
HIV-1	1
LTR	2
by	0
v-src	1
was	0
more	0
sensitive	0
to	0
mutations	0
of	0
the	0
proximal	0
,	0
rather	0
than	0
the	0
distal	0
,	0
kappa	1
B	2
element	2
.	0

The	0
implications	0
for	0
T	9
cell	10
receptor	10
signaling	0
and	0
HIV-1	1
gene	2
expression	0
are	0
considered	0
.	0

trans-activation	0
of	0
the	0
HIV	1
promoter	2
by	0
a	0
cDNA	0
and	0
its	0
genomic	0
clones	0
of	0
human	0
herpesvirus-6	0
.	0

Human	0
herpesvirus	0
6	0
(	0
HHV-6	0
)	0
is	0
a	0
lymphotropic	0
herpesvirus	0
,	0
and	0
in	0
vitro	0
,	0
it	0
can	0
productively	0
infect	0
human	0
CD4+	5
T	6
cells	6
as	0
HIV-1	0
.	0

Co-infection	0
of	0
T	7
cells	8
by	0
HIV-1	0
and	0
HHV-6	0
can	0
lead	0
to	0
both	0
activation	0
of	0
the	0
HIV-1	1
promoter	2
and	0
acceleration	0
of	0
the	0
cytopathic	0
effects	0
.	0

An	0
HHV-6	1
(	2
GS	2
)	2
cDNA	2
clone	2
,	0
pCD41	1
,	0
encoding	0
for	0
a	0
41-kDa	9
nuclear	10
protein	10
was	0
identified	0
and	0
characterized	0
previously	0
(	0
Chang	0
and	0
Balachandran	0
,	0
J.	0
Virol.	0
65	0
,	0
2884-2894	0
and	0
7085	0
,	0
1991	0
)	0
.	0

Sequence	0
analyses	0
show	0
that	0
this	0
protein	0
has	0
significant	0
homology	0
with	0
the	0
human	1
cytomegalovirus	2
UL44	2
gene	2
coding	0
for	0
the	0
ICP36	9
family	10
of	0
early-late-class	9
phosphoprotein	10
.	0

Using	0
this	0
cDNA	1
as	0
the	0
probe	0
,	0
a	0
3.8-kb	1
EcoRI	2
genomic	2
fragment	2
encoding	0
the	0
HHV-6	9
(	10
GS	10
)	10
P41	10
was	0
cloned	0
and	0
designated	0
as	0
pGD41	1
.	0

When	0
cotransfected	0
with	0
the	0
HIV	1
LTR	2
CAT	2
into	0
CV-1	5
cells	6
,	0
both	0
the	0
pCD41	1
and	0
pGD41	1
clones	0
trans-activated	0
the	0
HIV	1
LTR	2
.	0

Sequence	0
analyses	0
of	0
pCD41	1
indicate	0
that	0
there	0
are	0
two	0
potential	0
open	1
reading	2
frames	2
(	0
ORFs	1
)	0
,	0
A	1
and	0
B	1
,	0
which	0
are	0
homologous	0
to	0
the	0
ORFs	1
found	0
in	0
the	0
genomic	0
clone	0
pGD41	1
.	0

Deletion	0
constructs	0
of	0
the	0
pCD41	1
clone	2
demonstrated	0
that	0
ORF-A	9
was	0
critical	0
for	0
the	0
HIV	1
LTR	2
activation	0
.	0

Deletion	0
analyses	0
of	0
the	0
pCD41	1
ORF-A	9
and	0
the	0
use	0
of	0
promoter	1
constructs	2
further	0
mapped	0
an	0
internal	0
functional	0
promoter	0
within	0
the	0
pCD41	1
sequence	0
that	0
can	0
direct	0
the	0
synthesis	0
of	0
the	0
trans-activating	9
protein	10
.	0

By	0
using	0
HIV	1
LTR	2
deletion	2
mutants	2
,	0
the	0
NF-kappa	9
B	10
binding	1
sites	2
were	0
found	0
to	0
be	0
critical	0
for	0
response	0
to	0
the	0
pCD41	1
trans-activation	0
.	0

CD14	9
-mediated	0
translocation	0
of	0
nuclear	9
factor-kappa	10
B	10
induced	0
by	0
lipopolysaccharide	0
does	0
not	0
require	0
tyrosine	9
kinase	10
activity	0
.	0

During	0
the	0
course	0
of	0
serious	0
bacterial	0
infections	0
,	0
lipopolysaccharide	0
(	0
LPS	0
)	0
is	0
believed	0
to	0
interact	0
with	0
macrophage	9
receptors	10
,	0
resulting	0
in	0
the	0
generation	0
of	0
inflammatory	0
mediators	0
and	0
systemic	0
symptoms	0
including	0
hemodynamic	0
instability	0
and	0
shock	0
.	0

CD14	9
,	0
a	0
glycosylphosphatidylinositol-linked	9
antigen	10
,	0
functions	0
as	0
an	0
LPS	9
signaling	10
receptor	10
.	0

A	0
critical	0
issue	0
concerns	0
the	0
mechanism	0
by	0
which	0
CD14	9
,	0
which	0
has	0
no	0
transmembrane	9
domain	10
,	0
transduces	0
its	0
signal	0
following	0
LPS	0
binding	0
.	0

Recently	0
,	0
investigators	0
have	0
hypothesized	0
that	0
CD14	9
-mediated	0
signaling	0
is	0
effected	0
through	0
a	0
receptor-associated	0
tyrosine	9
kinase	10
(	0
TK	0
)	0
,	0
suggesting	0
a	0
multicomponent	0
receptor	0
model	0
of	0
LPS	0
signaling	0
.	0

Wild-type	0
Chinese	5
hamster	6
ovary	6
(	6
CHO	6
)	6
-K1	6
cells	6
can	0
be	0
activated	0
by	0
endotoxin	0
to	0
release	0
arachidonate	0
following	0
transfection	0
with	0
human	0
CD14	9
(	0
CHO/CD14	9
)	0
.	0

Nuclear	0
translocation	0
of	0
cytosolic	0
NF-kappa	0
B	0
is	0
correlated	0
with	0
a	0
number	0
of	0
LPS-inducible	0
responses	0
.	0

We	0
sought	0
to	0
determine	0
if	0
this	0
pathway	0
were	0
present	0
in	0
CHO/CD14	5
cells	6
and	0
to	0
elucidate	0
the	0
relationship	0
of	0
NF-kappa	9
B	10
activation	0
to	0
the	0
CD14	9
receptor	0
system	0
.	0

LPS-stimulated	0
translocation	0
of	0
NF-kappa	9
B	10
in	0
CHO/CD14	5
cells	6
resembled	0
the	0
same	0
response	0
in	0
the	0
murine	5
macrophage-like	6
cell	6
line	6
RAW	5
264.7	6
.	0

Protein	0
synthesis	0
inhibitors	0
and	0
corticosteroids	0
,	0
which	0
suppress	0
arachidonate	0
release	0
and	0
the	0
synthesis	0
of	0
proinflammatory	9
cytokines	10
,	0
had	0
no	0
effect	0
on	0
translocation	0
of	0
NF-kappa	9
B	10
in	0
CHO/	0
CD14	9
or	0
RAW	5
264.7	6
cells	6
,	0
demonstrating	0
that	0
NF-kappa	9
B	10
translocation	0
is	0
an	0
early	0
event	0
.	0

Although	0
TK	0
activity	0
was	0
consistently	0
observed	0
by	0
immunoblotting	0
extracts	0
from	0
activated	0
RAW	5
264.7	6
cells	6
,	0
LPS-induced	0
phosphotyrosine	0
residues	0
were	0
not	0
observed	0
from	0
similarly	0
treated	0
CHO/CD14	5
cells	6
.	0

Furthermore	0
,	0
the	0
TK	0
inhibitors	0
herbimycin	0
A	0
and	0
genistein	0
failed	0
to	0
inhibit	0
translocation	0
of	0
NF-kappa	9
B	10
in	0
CHO/CD14	5
or	0
RAW	5
264.7	6
cells	6
,	0
although	0
both	0
of	0
these	0
agents	0
inhibited	0
LPS-induced	0
TK	0
activity	0
in	0
RAW	5
264.7	6
cells	6
.	0

These	0
results	0
imply	0
that	0
TK	0
activity	0
is	0
not	0
obligatory	0
for	0
CD14	9
-mediated	0
signal	0
transduction	0
to	0
occur	0
in	0
response	0
to	0
LPS	0
.	0

Signals	0
transduced	0
through	0
the	0
CD4	9
molecule	10
on	0
T	7
lymphocytes	8
activate	0
NF-kappa	9
B	10
.	0

We	0
have	0
demonstrated	0
that	0
native	9
envelope	10
glycoproteins	10
of	0
HIV-1	0
,	0
gp160	0
can	0
induce	0
activation	0
of	0
the	0
transcription	9
factor	10
,	0
NF-kappa	9
B	10
.	0

The	0
stimulatory	0
effects	0
of	0
gp160	0
are	0
mediated	0
through	0
the	0
CD4	9
molecule	10
,	0
since	0
pretreatment	0
with	0
soluble	0
CD4	9
abrogates	0
its	0
activity	0
.	0

The	0
gp160-induced	9
NF-kappa	10
B	10
complex	10
consists	0
of	0
p65	9
,	0
p50	9
and	0
c-rel	9
proteins	10
.	0

The	0
stimulatory	0
effect	0
of	0
gp160	0
on	0
NF-kappa	9
B	10
activation	0
is	0
protein	0
synthesis	0
independent	0
,	0
is	0
dependent	0
upon	0
protein	0
tyrosine	0
phosphorylation	0
,	0
and	0
abrogated	0
by	0
inhibitors	0
of	0
protein	9
kinase	10
C	10
.	0

The	0
gp160-mediated	0
activation	0
of	0
NF-kappa	9
B	10
in	0
CD4	7
positive	8
T	8
cells	8
may	0
be	0
involved	0
in	0
biological	0
effects	0
,	0
e.g.	0
,	0
enhanced	0
HIV	0
replication	0
,	0
hypergammaglobulinemia	0
,	0
increased	0
cytokine	9
secretion	0
,	0
hypercellularity	0
in	0
bone	0
marrow	0
and	0
apoptosis	0
.	0

No	0
evidence	0
for	0
the	0
expression	0
of	0
the	0
progesterone	9
receptor	10
on	0
peripheral	7
blood	8
lymphocytes	8
during	0
pregnancy	0
[	0
see	0
comments	0
]	0

The	0
expression	0
of	0
the	0
progesterone	9
receptor	10
in	0
human	7
peripheral	8
blood	8
lymphocytes	8
was	0
analysed	0
,	0
using	0
an	0
enzyme	0
linked	0
immunosorbent	0
assay	0
(	0
Abbott	0
PgR-EIA	0
monoclonal	0
)	0
,	0
in	0
order	0
to	0
evaluate	0
its	0
prognostic	0
character	0
in	0
the	0
context	0
of	0
spontaneous	0
abortion	0
.	0

Cytosols	0
were	0
prepared	0
from	0
lymphocytes	0
of	0
24	0
healthy	0
pregnant	0
women	0
(	0
11	0
first	0
,	0
10	0
second	0
and	0
three	0
third	0
trimester	0
)	0
,	0
seven	0
healthy	0
non-pregnant	0
women	0
,	0
nine	0
women	0
with	0
recurrent	0
spontaneous	0
abortion	0
,	0
and	0
six	0
healthy	0
men	0
.	0

In	0
addition	0
,	0
a	0
human	5
breast	6
carcinoma	6
cell	6
line	6
(	0
ZR-75-1	5
)	0
,	0
which	0
expresses	0
the	0
progesterone	9
receptor	10
,	0
was	0
analysed	0
throughout	0
.	0

The	0
ZR-75-1	5
cell	6
line	6
showed	0
an	0
expression	0
of	0
642	0
fmol/mg	0
whereas	0
lymphocytes	0
of	0
pregnant	0
women	0
showed	0
an	0
expression	0
<	0
or	0
=	0
4	0
fmol/mg	0
.	0

Lymphocytes	7
of	0
non-pregnant	0
women	0
,	0
women	0
with	0
threatened	0
pre-term	0
delivery	0
,	0
and	0
men	0
showed	0
equivalent	0
levels	0
:	0
3	0
+/-	0
1	0
,	0
3	0
+/-	0
2	0
and	0
5	0
+/-	0
4	0
fmol/mg	0
respectively	0
.	0

These	0
results	0
show	0
that	0
there	0
is	0
no	0
evidence	0
of	0
specific	0
expression	0
of	0
the	0
progesterone	9
receptor	10
in	0
pregnancy	0
and	0
exclude	0
any	0
prognostic	0
character	0
in	0
spontaneous	0
abortion	0
.	0

A	0
role	0
for	0
the	0
progesterone	9
receptor	10
in	0
the	0
mechanism	0
of	0
the	0
known	0
effect	0
of	0
progesterone	0
on	0
peripheral	7
blood	8
lymphocytes	8
is	0
also	0
excluded	0
.	0

Tolerance	0
to	0
lipopolysaccharide	0
involves	0
mobilization	0
of	0
nuclear	9
factor	10
kappa	10
B	10
with	0
predominance	0
of	0
p50	9
homodimers	0
.	0

Stimulation	0
of	0
the	0
human	5
monocytic	6
cell	6
line	6
Mono	5
Mac	6
6	6
with	0
lipopolysaccharide	0
(	0
LPS	0
)	0
leads	0
to	0
rapid	0
and	0
transient	0
expression	0
of	0
cytokines	9
like	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
.	0

When	0
such	0
cells	0
are	0
precultured	0
for	0
2	0
days	0
with	0
a	0
low	0
dose	0
of	0
LPS	0
(	0
20	0
ng/ml	0
)	0
followed	0
by	0
stimulation	0
with	0
a	0
high	0
dose	0
of	0
LPS	0
(	0
1	0
microgram/ml	0
)	0
,	0
expression	0
of	0
the	0
TNF	1
gene	2
is	0
minimal	0
,	0
i.e.	0
the	0
cells	0
are	0
tolerant	0
.	0

In	0
nuclear	0
run-on	0
analysis	0
,	0
such	0
tolerant	7
cells	8
show	0
only	0
a	0
low	0
degree	0
of	0
transcription	0
,	0
indicating	0
that	0
tolerance	0
operates	0
at	0
or	0
upstream	0
of	0
the	0
transcription	0
level	0
.	0

The	0
CD14	9
LPS	0
receptor	0
is	0
,	0
however	0
,	0
up-regulated	0
(	0
not	0
down-regulated	0
)	0
in	0
tolerant	5
cells	6
,	0
and	0
LPS	0
can	0
,	0
in	0
fact	0
,	0
still	0
lead	0
to	0
activation	0
of	0
tolerant	5
cells	6
as	0
evidenced	0
by	0
mobilization	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

Resolution	0
of	0
the	0
NF-kappa	9
B	10
complex	10
in	0
gel	0
shift	0
analysis	0
shows	0
that	0
the	0
binding	9
protein	10
,	0
mobilized	0
in	0
naive	5
Mono	6
Mac	6
6	6
cells	6
,	0
consists	0
mainly	0
of	0
p50-p65	9
heterodimers	10
,	0
while	0
in	0
tolerant	5
cells	6
,	0
the	0
p50	9
homodimer	10
is	0
predominant	0
.	0

This	0
increase	0
in	0
p50	9
homodimers	10
coincides	0
with	0
an	0
increase	0
in	0
p105	3
mRNA	4
,	0
suggestive	0
of	0
a	0
transcriptional	0
up-regulation	0
of	0
p50	9
.	0

Reporter	0
gene	0
analysis	0
reveals	0
that	0
the	0
NF-kappa	9
B	10
complex	10
mobilized	0
in	0
tolerant	5
cells	6
is	0
functionally	0
inactive	0
in	0
that	0
NF-kappa	1
B-dependent	2
luciferase	2
constructs	2
containing	0
the	0
human	1
immunodeficiency	2
virus	2
long	2
terminal	2
repeat	2
or	0
the	0
TNF	1
5'-region	2
show	0
only	0
minimal	0
transactivation	0
after	0
LPS	0
stimulation	0
.	0

Similar	0
to	0
Mono	5
Mac	6
6	6
cells	6
,	0
primary	7
blood	8
monocytes	8
,	0
when	0
precultured	0
with	0
a	0
low	0
dose	0
of	0
LPS	0
,	0
also	0
become	0
tolerant	0
and	0
produce	0
little	0
TNF	9
after	0
LPS	0
stimulation	0
.	0

The	0
tolerant	7
blood	8
monocytes	8
also	0
up-regulate	0
CD14	9
,	0
and	0
they	0
mobilize	0
NF-kappa	9
B	10
with	0
a	0
predominance	0
of	0
p50	9
homodimers	10
.	0

Taken	0
together	0
,	0
these	0
results	0
demonstrate	0
that	0
tolerance	0
to	0
LPS	0
is	0
determined	0
by	0
post-receptor	0
mechanisms	0
that	0
involve	0
an	0
altered	0
composition	0
of	0
the	0
NF-kappa	9
B	10
complex	10
.	0

Analysis	0
of	0
Oct2-isoform	9
expression	0
in	0
lipopolysaccharide-stimulated	5
B	6
lymphocytes	6
.	0

Oct2-isoform	9
expression	0
in	0
splenic	7
B	8
cells	8
stimulated	0
with	0
lipopolysaccharide	0
or	0
lipopolysaccharide	0
plus	0
phorbol-di-butyrate	0
was	0
analysed	0
by	0
cDNA	0
cloning	0
.	0

The	0
frequency	0
of	0
Oct2-positive	5
clones	6
was	0
1/15	0
,	0
000	0
in	0
both	0
libraries	0
.	0

Two	0
new	0
isoforms	0
were	0
found	0
that	0
generate	0
novel	0
amino-	9
or	10
carboxy-terminal	10
sequences	10
.	0

An	0
isoform	0
lacking	0
exon	1
11	2
destroyed	0
the	0
carboxy-terminal	9
leucin-zipper	10
region	10
and	0
introduced	0
a	0
frame	0
shift	0
creating	0
a	0
novel	0
,	0
proline-rich	9
carboxy	10
terminus	10
.	0

A	0
new	0
exon	1
containing	0
a	0
highly	0
basic	0
region	0
(	0
4c	0
)	0
was	0
characterized	0
,	0
between	1
exons	2
4	2
and	2
5	2
.	0

This	0
exon	0
was	0
inserted	0
between	1
glutamine-rich	2
regions	2
2	2
and	2
3	2
,	0
carboxy	9
terminal	10
of	0
a	0
tentative	0
leucine-zipper	9
structure	10
.	0

In	0
addition	0
,	0
a	0
new	0
combination	0
isoform	0
containing	0
Oct2a	9
's	10
amino	10
terminal	10
insert	10
(	0
exon	1
7a	2
)	0
and	0
Oct2b	9
's	10
carboxy	10
terminal	10
insert	10
(	0
exon	1
13	2
)	0
was	0
found	0
that	0
created	0
a	0
novel	0
large	0
isoform	0
,	0
Oct2ab	9
.	0

More	0
frequent	0
use	0
of	0
the	0
classical	0
Oct2a	9
and	0
Oct2b	9
isoforms	0
was	0
observed	0
in	0
the	0
lipopolysaccharide-stimulated	5
B	6
cells	6
,	0
while	0
a	0
preference	0
for	0
the	0
Oct2ab	9
and	0
Oct2ba	9
isoforms	0
was	0
observed	0
in	0
lipopolysaccharide	5
plus	6
phorbol-di-butyrate-treated	6
cells	6
.	0

Positive	0
regulators	0
of	0
the	0
lineage-specific	0
transcription	9
factor	10
GATA-1	9
in	0
differentiating	7
erythroid	8
cells	8
.	0

The	0
zinc	9
finger	10
transcription	10
factor	10
GATA-1	9
is	0
a	0
major	0
regulator	0
of	0
gene	0
expression	0
in	0
erythroid	7
,	8
megakaryocyte	8
,	8
and	8
mast	8
cell	8
lineages	8
.	0

GATA-1	9
binds	0
to	0
WGATAR	1
consensus	2
motifs	2
in	0
the	0
regulatory	1
regions	2
of	0
virtually	0
all	0
erythroid	1
cell-specific	2
genes	2
.	0

Analyses	0
with	0
cultured	5
cells	6
and	0
cell-free	0
systems	0
have	0
provided	0
strong	0
evidence	0
that	0
GATA-1	9
is	0
involved	0
in	0
control	0
of	0
globin	1
gene	2
expression	0
during	0
erythroid	0
differentiation	0
.	0

Targeted	0
mutagenesis	0
of	0
the	0
GATA-1	1
gene	2
in	0
embryonic	7
stem	8
cells	8
has	0
demonstrated	0
its	0
requirement	0
in	0
normal	0
erythroid	0
development	0
.	0

Efficient	0
rescue	0
of	0
the	0
defect	0
requires	0
an	0
intact	0
GATA	1
element	2
in	0
the	0
distal	1
promoter	2
,	0
suggesting	0
autoregulatory	0
control	0
of	0
GATA-1	9
transcription	0
.	0

To	0
examine	0
whether	0
GATA-1	9
expression	0
involves	0
additional	0
regulatory	9
factors	10
or	0
is	0
maintained	0
entirely	0
by	0
an	0
autoregulatory	0
loop	0
,	0
we	0
have	0
used	0
a	0
transient	0
heterokaryon	0
system	0
to	0
test	0
the	0
ability	0
of	0
erythroid	9
factors	10
to	0
activate	0
the	0
GATA-1	1
gene	2
in	0
nonerythroid	0
nuclei	0
.	0

We	0
show	0
here	0
that	0
proerythroblasts	7
and	0
mature	7
erythroid	8
cells	8
contain	0
a	0
diffusible	0
activity	0
(	0
TAG	0
)	0
capable	0
of	0
transcriptional	0
activation	0
of	0
GATA-1	9
and	0
that	0
this	0
activity	0
decreases	0
during	0
the	0
terminal	0
differentiation	0
of	0
erythroid	7
cells	8
.	0

Nuclei	0
from	0
GATA-1	5
-mutant	6
embryonic	6
stem	6
cells	6
can	0
still	0
be	0
reprogrammed	0
to	0
express	0
their	0
globin	1
genes	2
in	0
erythroid	7
heterokaryons	8
,	0
indicating	0
that	0
de	0
novo	0
induction	0
of	0
GATA-1	9
is	0
not	0
required	0
for	0
globin	1
gene	2
activation	0
following	0
cell	0
fusion	0
.	0

Role	0
of	0
HIV-1	9
Nef	10
expression	0
in	0
activation	0
pathways	0
in	0
CD4	9
+	0
T	0
cells	0
.	0

The	0
role	0
of	0
the	0
human	9
immunodeficiency	10
virus	10
(	10
HIV-1	10
)	10
Nef	10
protein	10
in	0
T	0
cell	0
activation	0
pathways	0
was	0
investigated	0
using	0
a	0
Jurkat	5
CD4+	6
cell	6
line	6
stably	0
transfected	0
with	0
a	0
Nef	0
expression	0
vector	0
.	0

Secretion	0
of	0
IL-2	9
and	0
TNF-alpha	9
,	0
surface	0
expression	0
of	0
IL-2R	9
,	0
and	0
DNA-binding	0
activity	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
(	10
Fos/Jun	10
)	10
complex	10
in	0
response	0
to	0
phorbol	0
myristate	0
acetate	0
,	0
TNF-alpha	9
,	0
or	0
immobilized	0
antibodies	0
to	0
CD3	9
were	0
monitored	0
.	0

These	0
parameters	0
were	0
not	0
modified	0
by	0
Nef	9
expression	0
in	0
Jurkat	5
cells	6
,	0
whereas	0
stimulation	0
with	0
the	0
same	0
stimuli	0
resulted	0
in	0
partial	0
inhibition	0
of	0
LTR	1
activation	0
in	0
Nef+	5
Jurkat	6
cells	6
.	0

This	0
inhibition	0
was	0
not	0
mediated	0
through	0
Nef	9
phosphorylation	0
on	0
Thr-15	0
or	0
GTP-binding	0
activity	0
because	0
mutations	0
in	0
critical	0
sites	0
did	0
not	0
alter	0
this	0
inhibition	0
.	0

Analysis	0
of	0
truncated	0
LTRs	1
confirmed	0
that	0
inhibition	0
of	0
LTR	1
activation	0
was	0
not	0
mediated	0
through	0
NF-kappa	9
B	10
-binding	0
activity	0
but	0
through	0
the	0
region	0
containing	0
the	0
negative	1
responding	2
elements	2
(	0
NREs	1
)	0
.	0

These	0
results	0
suggest	0
that	0
Nef	9
downmodulates	0
LTR	1
activation	0
without	0
significantly	0
inhibiting	0
the	0
capacity	0
of	0
T	7
cells	8
to	0
respond	0
to	0
immunological	0
activations	0
.	0

Tat-binding	9
protein	10
7	10
is	0
a	0
subunit	0
of	0
the	0
26S	9
protease	10
.	0

Subunit	9
6	10
(	0
S6	9
)	0
,	0
an	0
integral	0
component	0
of	0
the	0
26S	9
protease	10
from	0
human	7
erythrocytes	8
,	0
has	0
been	0
studied	0
by	0
SDS-PAGE	0
,	0
peptide	0
mapping	0
and	0
sequence	0
analysis	0
.	0

S6	9
was	0
cleaved	0
with	0
CNBr	9
and	0
three	0
internal	0
peptides	0
were	0
sequenced	0
.	0

A	0
comparison	0
with	0
known	0
proteins	0
in	0
Genbank	0
revealed	0
that	0
all	0
three	0
S6	9
peptides	0
match	0
the	0
predicted	0
sequence	0
of	0
TBP7	9
,	0
Tat-binding	9
protein	10
7	10
.	0

Based	0
on	0
peptide	0
matches	0
covering	0
more	0
than	0
10	0
%	0
of	0
the	0
TBP7	9
sequence	0
,	0
and	0
the	0
fact	0
that	0
the	0
migration	0
of	0
S6	9
on	0
SDS-PAGE	0
is	0
consistent	0
with	0
the	0
estimated	0
molecular	0
mass	0
for	0
TBP7	9
,	0
we	0
conclude	0
that	0
subunit	9
6	10
of	0
the	0
26S	9
protease	10
is	0
TBP7	9
.	0

Hypoxia	0
causes	0
the	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
through	0
the	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
on	0
tyrosine	0
residues	0
.	0

The	0
response	0
of	0
mammalian	7
cells	8
to	0
stress	0
is	0
controlled	0
by	0
transcriptional	9
regulatory	10
proteins	10
such	0
as	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
to	0
induce	0
a	0
wide	0
variety	0
of	0
early	1
response	2
genes	2
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
exposure	0
of	0
cells	0
to	0
hypoxia	0
(	0
0.02	0
%	0
O2	0
)	0
results	0
in	0
I	9
kappa	10
B	10
alpha	10
degradation	0
,	0
increased	0
NF-kappa	9
B	10
DNA	0
binding	0
activity	0
,	0
and	0
transactivation	0
of	0
a	0
reporter	1
gene	2
construct	2
containing	0
two	0
NF-kappa	1
B	2
DNA	2
binding	2
sites	2
.	0

Pretreatment	0
of	0
cells	0
with	0
protein	0
tyrosine	9
kinase	10
inhibitors	0
and	0
the	0
dominant	1
negative	2
allele	2
of	0
c-Raf-1	1
(	0
Raf	9
301	10
)	0
inhibited	0
I	9
kappa	10
B	10
alpha	10
degradation	0
,	0
NF-kappa	9
B	10
binding	0
,	0
and	0
transactivation	0
of	0
kappa	1
B	2
reporter	2
constructs	2
by	0
hypoxia	0
.	0

To	0
demonstrate	0
a	0
direct	0
link	0
between	0
changes	0
in	0
the	0
phosphorylation	0
pattern	0
of	0
I	9
kappa	10
B	10
alpha	10
with	0
NF-kappa	9
B	10
activation	0
,	0
we	0
immunoprecipitated	0
I	9
kappa	10
B	10
alpha	10
after	0
varying	0
times	0
of	0
hypoxic	0
exposure	0
and	0
found	0
that	0
its	0
tyrosine	0
phosphorylation	0
status	0
increased	0
during	0
hypoxic	0
exposure	0
.	0

Inhibition	0
of	0
the	0
transfer	0
of	0
tyrosine	0
phosphoryl	0
groups	0
onto	0
I	9
kappa	10
B	10
alpha	10
prevented	0
I	9
kappa	10
B	10
alpha	10
degradation	0
and	0
NF-kappa	9
B	10
binding	0
.	0

In	0
comparison	0
to	0
other	0
activators	0
of	0
NF-kappa	9
B	10
such	0
as	0
phorbol	0
myristate	0
acetate	0
or	0
tumor	9
necrosis	10
factor	10
,	0
we	0
did	0
not	0
detect	0
changes	0
in	0
the	0
tyrosine	0
phosphorylation	0
status	0
of	0
I	9
kappa	10
B	10
alpha	10
following	0
treatment	0
with	0
either	0
of	0
these	0
agents	0
.	0

These	0
results	0
suggest	0
that	0
tyrosine	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
during	0
hypoxia	0
is	0
an	0
important	0
proximal	0
step	0
which	0
precedes	0
its	0
dissociation	0
and	0
degradation	0
from	0
NF-kappa	9
B	10
.	0

Overproduction	0
of	0
NFKB2	9
(	0
lyt-10	9
)	0
and	0
c-Rel	9
:	0
a	0
mechanism	0
for	0
HTLV-I	9
Tax	10
-mediated	0
trans-activation	0
via	0
the	0
NF-kappa	9
B	10
signalling	0
pathway	0
.	0

Molecular	0
,	0
biochemical	0
and	0
epidemiological	0
evidence	0
implicate	0
HTLV-I	0
as	0
an	0
etiologic	0
agent	0
of	0
adult	0
T	0
cell	0
leukemia	0
(	0
ATL	0
)	0
.	0

The	0
Tax	9
protein	10
of	0
HTLV-I	0
,	0
a	0
positive	9
transcriptional	10
activator	10
of	0
HTLV-I	0
gene	0
expression	0
,	0
is	0
a	0
viral	0
oncogene	0
that	0
also	0
increases	0
transcription	0
of	0
cellular	1
genes	2
including	0
GM-CSF	9
,	0
IL-2R	9
alpha	10
and	0
IL-2	9
.	0

One	0
of	0
the	0
cellular	0
targets	0
of	0
the	0
trans-activating	0
effects	0
of	0
Tax	0
is	0
the	0
NF-kappa	9
B/Rel	10
family	10
of	0
transcription	9
factors	10
,	0
pleiotropic	9
regulators	10
of	0
immunoregulatory	0
,	0
cytokine	0
and	0
viral	0
gene	0
expression	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
NFKB2	9
(	0
lyt-10	9
)	0
and	0
c-Rel	9
are	0
overexpressed	0
in	0
HTLV-I	0
infected	0
and	0
Tax-expressing	7
cells	8
and	0
,	0
together	0
,	0
account	0
for	0
the	0
majority	0
of	0
the	0
constitutive	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
these	0
cells	0
before	0
and	0
after	0
PMA	0
stimulation	0
.	0

Most	0
importantly	0
,	0
we	0
show	0
a	0
Tax	9
-dependent	0
correlation	0
between	0
expression	0
of	0
NFKB2	9
(	0
p100	9
)	0
and	0
processing	0
to	0
the	0
DNA	0
binding	0
NFKB2	9
(	0
p52	9
)	0
form	0
,	0
induction	0
of	0
c-Rel	9
,	0
and	0
trans-activation	0
of	0
NF-kappa	9
B	10
-mediated	0
gene	0
expression	0
.	0

Furthermore	0
,	0
the	0
NFKB2	9
precursor	0
is	0
physically	0
associated	0
with	0
c-Rel	9
and	0
with	0
Tax	9
in	0
HTLV-I	7
infected	8
cells	8
.	0

We	0
propose	0
that	0
NFKB2	9
synthesis	0
and	0
processing	0
allows	0
continuous	0
nuclear	0
expression	0
of	0
an	0
otherwise	0
cytoplasmic	9
protein	10
and	0
,	0
in	0
conjunction	0
with	0
overexpression	0
of	0
c-Rel	9
,	0
NFKB2	9
alters	0
the	0
NF-kappa	9
B	10
signalling	0
pathway	0
and	0
contributes	0
to	0
leukemic	0
transformation	0
of	0
T	7
cells	8
by	0
HTLV-I	0
.	0

Retinoic	0
acid	0
downmodulates	0
erythroid	0
differentiation	0
and	0
GATA1	9
expression	0
in	0
purified	5
adult-progenitor	6
culture	6
.	0

All-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
is	0
an	0
important	0
morphogen	0
in	0
vertebrate	0
development	0
,	0
a	0
normal	0
constituent	0
in	0
human	0
adult	0
blood	0
and	0
is	0
also	0
involved	0
in	0
the	0
control	0
of	0
cell	0
growth	0
and	0
differentiation	0
in	0
acute	0
promyelocytic	0
leukemia	0
.	0

We	0
have	0
examined	0
the	0
effects	0
of	0
RA	0
on	0
normal	0
hematopoiesis	0
by	0
using	0
early	0
hematopoietic	7
progenitor	8
cells	8
(	0
HPC	7
)	0
stringently	0
purified	0
from	0
adult	0
peripheral	0
blood	0
.	0

In	0
clonogenetic	5
fetal	6
calf	6
serum-supplemented	6
(	6
FCS+	6
)	6
or	6
-nonsupplemented	6
(	6
FCS-	6
)	6
culture	6
treated	0
with	0
saturating	0
levels	0
of	0
interleukin-3	9
(	0
IL-3	9
)	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
and	0
erythropoietin	9
(	0
Ep	9
)	0
(	0
combined	0
with	0
c-kit	9
ligand	0
in	0
FCS	0
(	0
-	0
)	0
-culture	0
conditions	0
)	0
,	0
RA	0
induces	0
a	0
dramatic	0
dose-dependent	0
shift	0
from	0
erythroid	0
to	0
granulomonocytic	0
colony	0
formation	0
,	0
the	0
latter	0
colonies	0
being	0
essentially	0
represented	0
by	0
granulocytic	5
clones	6
.	0

This	0
shift	0
is	0
apparently	0
not	0
caused	0
by	0
a	0
recruitment	0
phenomenon	0
,	0
because	0
in	0
FCS+	5
culture	6
,	0
the	0
total	0
number	0
of	0
colonies	0
is	0
not	0
significantly	0
modified	0
by	0
RA	0
addition	0
.	0

In	0
FCS-	5
liquid-suspension	6
culture	6
supplemented	0
with	0
saturating	0
Ep	9
level	0
and	0
low-dose	9
IL-3/GM-CSF	10
,	0
adult	0
HPC	7
undergo	0
unilineage	0
erythropoietic	0
differentiation	0
:	0
Here	0
again	0
,	0
treatment	0
with	0
high-dose	0
RA	0
induces	0
a	0
shift	0
from	0
the	0
erythroid	0
to	0
granulocytic	0
differentiation	0
pathway	0
.	0

Studies	0
on	0
RA	0
time-response	0
or	0
pulse	0
treatment	0
in	0
semisolid	0
or	0
liquid	0
culture	0
show	0
that	0
early	0
RA	0
addition	0
is	0
most	0
effective	0
,	0
thus	0
indicating	0
that	0
early	0
but	0
not	0
late	0
HPC	7
are	0
sensitive	0
to	0
its	0
action	0
.	0

We	0
then	0
analyzed	0
the	0
expression	0
of	0
the	0
master	1
GATA1	2
gene	2
,	0
which	0
encodes	0
a	0
finger	9
transcription	10
factor	10
required	0
for	0
normal	0
erythroid	0
development	0
;	0
addition	0
of	0
RA	0
to	0
HPC	7
stimulated	0
into	0
unilineage	0
erythropoietic	0
differentiation	0
in	0
liquid	0
culture	0
caused	0
a	0
virtually	0
complete	0
inhibition	0
of	0
GATA1	3
mRNA	4
induction	0
.	0

These	0
results	0
indicate	0
that	0
RA	0
directly	0
inhibits	0
the	0
erythroid	0
differentiation	0
program	0
at	0
the	0
level	0
of	0
early	0
adult	0
HPC	7
,	0
and	0
may	0
lead	0
to	0
a	0
shift	0
from	0
the	0
erythroid	0
to	0
granulocytic	0
differentiation	0
pathway	0
.	0

This	0
phenomenon	0
is	0
correlated	0
with	0
inhibition	0
of	0
GATA1	9
induction	0
in	0
the	0
early	0
stages	0
of	0
erythropoietic	0
differentiation	0
.	0

Induction	0
of	0
phosphatidylinositol	0
turnover	0
and	0
EGR-1	3
mRNA	4
expression	0
by	0
crosslinking	0
of	0
surface	0
IgM	9
and	0
IgD	9
in	0
the	0
human	5
B	6
cell	6
line	6
B104	6
.	0

We	0
have	0
previously	0
shown	0
that	0
a	0
human	5
B	6
lymphoma	6
cell	6
line	6
,	6
B104	6
,	0
expressed	0
surface	9
IgM	10
(	0
sIgM	9
)	0
and	0
surface	9
IgD	10
(	0
sIgD	9
)	0
,	0
and	0
that	0
crosslinking	0
of	0
sIgM	9
and	0
sIgD	9
by	0
anti-IgM	9
antibody	10
(	10
Ab	10
)	10
and	0
anti-IgD	9
Ab	10
,	0
respectively	0
,	0
induced	0
Ca2+	0
influx	0
to	0
almost	0
the	0
same	0
degree	0
,	0
whereas	0
only	0
sIgM	9
-crosslinking	0
caused	0
B104	5
cell	6
death	0
.	0

Here	0
,	0
we	0
investigated	0
the	0
accumulation	0
of	0
cyclic	0
AMP	0
(	0
cAMP	0
)	0
,	0
the	0
hydrolysis	0
of	0
inositol	0
phosphates	0
,	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
activity	0
and	0
the	0
induction	0
of	0
Egr-1	0
and	0
c-fos	0
mRNA	0
expression	0
by	0
sIgM-	0
and	0
sIgD-crosslinking	0
to	0
examine	0
differences	0
in	0
the	0
signals	0
mediated	0
through	0
sIgM	9
and	0
sIgD	9
in	0
B104	5
cells	6
.	0

Both	0
sIgM-	0
and	0
sIgD-crosslinking	0
with	0
antibodies	0
induced	0
elevation	0
of	0
cAMP	0
levels	0
,	0
phosphatidylinositol	0
turnover	0
,	0
PKC	9
activation	0
and	0
expression	0
of	0
Egr-1	3
and	4
c-fos	4
mRNA	4
,	0
although	0
sIgM	9
-crosslinking	0
was	0
more	0
effective	0
than	0
sIgD	9
-crosslinking	0
,	0
presumably	0
due	0
to	0
the	0
higher	0
expression	0
of	0
sIgM	9
than	0
of	0
sIgD	9
.	0

Egr-1	3
mRNA	4
expression	0
induced	0
by	0
sIgM-	0
and	0
sIgD-crosslinking	0
was	0
inhibited	0
by	0
H7	9
,	0
erbstatin	0
and	0
genistein	0
,	0
but	0
not	0
by	0
HA1004	0
.	0

Erbstatin	0
and	0
genistein	0
inhibited	0
the	0
sIg-crosslinking-induced	0
Egr-1	3
mRNA	4
expression	0
in	0
a	0
dose-dependent	0
manner	0
parallel	0
to	0
that	0
observed	0
in	0
the	0
inhibition	0
of	0
sIg-crosslinking-induced	0
protein	0
tyrosine	0
phosphorylation	0
.	0

Phorbol	0
myristate	0
acetate	0
induced	0
Egr-1	3
mRNA	4
expression	0
but	0
forskolin	0
and	0
dibutyryl	0
cyclic	0
AMP	0
did	0
not	0
.	0

These	0
findings	0
suggest	0
that	0
the	0
Egr-1	3
mRNA	4
activating	0
signals	0
through	0
sIgM	9
and	0
sIgD	9
are	0
protein	0
tyrosine	0
kinase-	0
and	0
PKC-dependent	0
,	0
but	0
protein	9
kinase	10
A	10
-independent	0
.	0

Cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
rescued	0
B104	5
cells	6
from	0
death	0
induced	0
by	0
anti-IgM	9
Ab	10
,	0
but	0
did	0
not	0
affect	0
the	0
expression	0
of	0
Egr-1	9
and	0
c-fos	3
mRNA	4
,	0
showing	0
that	0
CsA	0
and	0
FK506	0
affect	0
signal	0
transducers	0
differently	0
from	0
or	0
downstream	0
to	0
these	0
molecules	0
.	0

The	0
difference	0
in	0
signals	0
transduced	0
through	0
sIgM	9
and	0
sIgD	9
in	0
B104	5
cells	6
is	0
discussed	0
.	0

Direct	0
exposure	0
to	0
2	0
,	0
3	0
,	0
7	0
,	0
8-tetrachlorodibenzo-p-dioxin	0
(	0
TCDD	0
)	0
increases	0
infectivity	0
of	0
human	7
erythrocytes	8
to	0
a	0
malarial	0
parasite	0
.	0

Direct	0
exposure	0
to	0
10	0
nM	0
2	0
,	0
3	0
,	0
7	0
,	0
8-TCDD	0
caused	0
a	0
75	0
%	0
increase	0
and	0
a	0
2-fold	0
increase	0
in	0
the	0
infectivity	0
of	0
isolated	0
human	7
erythrocytes	8
to	0
P.	0
falciparum	0
after	0
48	0
hours	0
when	0
the	0
parasites	0
were	0
in	0
an	0
unsynchronized	0
or	0
synchronized	0
state	0
of	0
growth	0
,	0
respectively	0
.	0

Treatment	0
of	0
human	7
erythrocytes	8
with	0
10	0
microM	0
sodium	0
orthovanadate	0
(	0
NaOV	0
)	0
,	0
an	0
inhibitor	0
of	0
plasma	9
membrane	10
Ca-ATPase	10
and	0
phosphotyrosine	9
phosphatase	10
,	0
decreased	0
parasitemia	0
by	0
30	0
%	0
.	0

Co-treatment	0
of	0
RBCs	7
with	0
TCDD	0
and	0
NaOV	0
completely	0
blocked	0
the	0
TCDD-induced	0
increase	0
in	0
parasitemia	0
.	0

Because	0
erythrocytes	7
are	0
anucleated	0
,	0
these	0
results	0
are	0
discussed	0
as	0
evidence	0
for	0
biochemical	0
changes	0
by	0
TCDD	0
without	0
requiring	0
the	0
activation	0
of	0
gene	9
products	10
.	0

Evidence	0
for	0
a	0
trans-acting	9
activator	10
function	0
regulating	0
the	0
expression	0
of	0
the	0
human	9
CD5	10
antigen	10
.	0

Interspecies	0
somatic	5
cell	6
hybrids	6
were	0
generated	0
by	0
fusing	0
the	0
mouse	5
T-lymphoma	6
cell	6
line	6
,	0
BW5147	5
,	0
with	0
normal	7
human	8
T	8
lymphocytes	8
at	0
different	0
stages	0
of	0
differentiation	0
.	0

Thymocytes	7
,	0
activated	7
peripheral	8
T	8
lymphocytes	8
,	0
or	0
an	0
activated	5
T-cell	6
clone	6
were	0
used	0
as	0
human	0
partners	0
,	0
respectively	0
,	0
in	0
three	0
independent	0
fusions	0
.	0

Irrespective	0
of	0
the	0
human	0
cell	0
partner	0
used	0
for	0
fusion	0
,	0
a	0
certain	0
number	0
of	0
hybrids	5
lost	0
CD5	9
surface	0
expression	0
over	0
a	0
period	0
of	0
time	0
in	0
culture	0
.	0

Analysis	0
at	0
the	0
phenotype	0
and	0
genetic	0
level	0
showed	0
that	0
lack	0
of	0
CD5	9
expression	0
was	0
due	0
neither	0
to	0
segregation	0
of	0
human	1
autosome	2
11	2
,	0
on	0
which	0
the	0
CD5	1
gene	2
has	0
been	0
mapped	0
,	0
nor	0
to	0
deletion	0
of	0
the	0
CD5	1
structural	2
gene	2
.	0

Furthermore	0
,	0
loss	0
of	0
CD5	9
surface	0
expression	0
correlated	0
with	0
the	0
absence	0
of	0
specific	0
mRNA	3
.	0

Since	0
these	0
hybrids	0
preferentially	0
segregate	0
human	0
chromosomes	0
,	0
these	0
results	0
indicate	0
the	0
existence	0
of	0
a	0
non-syntenic	1
trans-active	2
locus	2
,	0
or	0
loci	0
,	0
positively	0
controlling	0
the	0
expression	0
of	0
the	0
human	1
CD5	2
gene	2
.	0

Induction	0
of	0
the	0
CD11b	1
gene	2
during	0
activation	0
of	0
the	0
monocytic	5
cell	6
line	6
U937	6
requires	0
a	0
novel	0
nuclear	9
factor	10
MS-2	9
[	0
published	0
erratum	0
appears	0
in	0
J	0
Immunol	0
1999	0
Jul	0
15	0
;	0
163	0
(	0
2	0
)	0
:	0
1091	0
]	0

The	0
differentiation	0
of	0
myeloid	7
precursors	8
into	0
mature	0
myelomonocytic	7
cells	8
is	0
characterized	0
by	0
the	0
induction	0
of	0
the	0
gene	0
encoding	0
the	0
beta2	9
integrin	10
CD11b	9
.	0

The	0
transcription	9
factors	10
Sp1	9
and	0
PU.1	9
prime	10
the	0
CD11b	1
promoter	2
,	0
but	0
the	0
nature	0
of	0
the	0
factors	0
responsible	0
for	0
its	0
inducible	0
expression	0
are	0
unknown	0
.	0

In	0
addition	0
to	0
the	0
CD11b	1
gene	2
,	0
the	0
homologous	0
genes	0
encoding	0
CD11a	9
and	0
CD11c	9
also	0
exhibit	0
inducible	0
expression	0
during	0
myeloid	0
differentiation	0
.	0

Therefore	0
,	0
we	0
compared	0
the	0
nucleotide	1
sequences	2
of	0
the	0
CD11a	1
,	2
CD11b	2
,	2
and	2
CD11c	2
gene	2
promoters	2
to	0
identify	0
common	0
elements	0
that	0
might	0
contribute	0
to	0
inducible	0
expression	0
.	0

This	0
analysis	0
identified	0
one	0
such	0
element	0
repeated	0
four	0
times	0
within	0
the	0
CD11b	1
promoter	2
.	0

Mutation	0
of	0
these	0
elements	0
indicated	0
that	0
two	0
,	0
MS-2beta	9
and	0
MS-2gamma	9
,	0
are	0
critical	0
to	0
the	0
induction	0
of	0
the	0
CD11b	1
gene	2
during	0
differentiation	0
of	0
the	0
pro-monocytic	5
cell	6
line	6
U937	6
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
indicate	0
that	0
MS-2beta	9
and	0
MS-2gamma	9
interact	0
with	0
nuclear	9
factors	10
that	0
are	0
induced	0
during	0
U937	5
differentiation	0
.	0

These	0
factors	0
are	0
detected	0
at	0
the	0
time	0
the	0
CD11b	1
promoter	2
is	0
activated	0
.	0

The	0
molecular	0
mass	0
of	0
these	0
factors	0
is	0
approximately	0
28	0
kDa	0
,	0
and	0
their	0
DNA	0
binding	0
characteristics	0
are	0
indistinguishable	0
from	0
those	0
of	0
the	0
novel	0
nuclear	9
factor	10
MS-2	9
.	0

Taken	0
together	0
,	0
our	0
data	0
indicate	0
that	0
MS-2	9
mediates	0
induction	0
of	0
the	0
CD11b	1
gene	2
as	0
cells	0
of	0
the	0
monocytic	0
lineage	0
mature	0
.	0

The	0
presence	0
of	0
multiple	0
potential	0
binding	0
sites	0
for	0
MS-2	9
in	0
the	0
promoter	0
regions	0
of	0
a	0
wide	0
range	0
of	0
genes	0
expressed	0
in	0
mature	7
myeloid	8
cells	8
suggests	0
this	0
factor	0
plays	0
a	0
general	0
role	0
in	0
myeloid	0
differentiation	0
.	0

Acetylsalicylic	0
acid	0
and	0
sodium	0
salicylate	0
inhibit	0
LPS-induced	0
NF-kappa	9
B/c-Rel	10
nuclear	0
translocation	0
,	0
and	0
synthesis	0
of	0
tissue	9
factor	10
(	0
TF	9
)	0
and	0
tumor	9
necrosis	10
factor	10
alfa	10
(	0
TNF-alpha	9
)	0
in	0
human	7
monocytes	8
.	0

We	0
have	0
investigated	0
the	0
effects	0
of	0
acetylsalicylic	0
acid	0
and	0
sodium	0
salicylate	0
on	0
the	0
LPS-induced	0
synthesis	0
of	0
the	0
pro-coagulant	0
protein	0
tissue	0
factor	0
(	0
TF	0
)	0
and	0
the	0
pro-inflammatory	0
protein	0
tumor	0
necrosis	0
factor-alpha	0
(	0
TNF-alpha	9
)	0
,	0
as	0
well	0
as	0
the	0
prostaglandin	9
PGE2	10
in	0
human	7
monocytes	8
.	0

Both	0
drugs	0
dose-dependently	0
inhibited	0
LPS-induced	9
TF	10
and	0
TNF-alpha	9
synthesis	0
at	0
the	0
mRNA	3
and	0
the	0
protein	0
level	0
,	0
and	0
reduced	0
PGE2	9
production	0
.	0

As	0
evidenced	0
by	0
electro	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
and	0
the	0
use	0
of	0
a	0
NF-kappa	1
B	2
prototypic	2
probe	2
,	0
these	0
drugs	0
probably	0
exert	0
their	0
inhibitory	0
effects	0
by	0
interference	0
with	0
the	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B/c-Rel	10
proteins	10
.	0

These	0
data	0
may	0
expand	0
the	0
understanding	0
of	0
the	0
anti-thrombotic	0
and	0
anti-inflammatory	0
effects	0
of	0
these	0
drugs	0
when	0
activation	0
of	0
monocytes	7
occurs	0
.	0

Interferon	0
augments	0
PML	9
and	0
PML/RAR	9
alpha	10
expression	0
in	0
normal	0
myeloid	7
and	0
acute	7
promyelocytic	8
cells	8
and	0
cooperates	0
with	0
all-trans	0
retinoic	0
acid	0
to	0
induce	0
maturation	0
of	0
a	0
retinoid-resistant	5
promyelocytic	6
cell	6
line	6
.	0

The	0
PML	1
gene	2
is	0
fused	0
to	0
the	0
retinoic	1
acid	2
receptor	2
alpha	2
gene	2
(	0
RAR	1
alpha	2
)	0
in	0
the	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
15	0
;	0
17	0
translocation	0
.	0

PML	9
is	0
expressed	0
in	0
diverse	0
tissues	0
and	0
cell	0
lines	0
and	0
localized	0
in	0
the	0
nucleus	0
with	0
a	0
typical	0
speckled	0
pattern	0
.	0

In	0
the	0
bone	0
marrow	0
,	0
it	0
is	0
preferentially	0
expressed	0
in	0
myeloid	7
cells	8
.	0

PML	9
appears	0
to	0
be	0
transcriptionally	0
regulated	0
by	0
class	9
I	10
and	10
II	10
interferons	10
,	0
which	0
raises	0
the	0
possibility	0
that	0
interferons	0
modulate	0
the	0
function	0
and	0
growth	0
and	0
differentiation	0
potential	0
of	0
normal	0
myeloid	7
cells	8
and	0
precursors	0
by	0
activating	0
PML	9
-dependent	0
pathways	0
.	0

Similarly	0
,	0
interferons	0
could	0
act	0
on	0
APL	7
cells	8
,	0
alone	0
or	0
in	0
combination	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
,	0
especially	0
if	0
the	0
PML/RAR	3
alpha	4
fusion	4
transcript	4
that	0
results	0
from	0
the	0
t	1
(	2
15	2
;	2
17	2
)	2
is	0
induced	0
by	0
interferon	9
.	0

We	0
report	0
here	0
that	0
PML	9
is	0
expressed	0
at	0
low	0
levels	0
or	0
not	0
expressed	0
in	0
normal	0
circulating	0
human	7
monocytes	8
,	0
lymphocytes	7
,	0
and	0
polymorphonucleate	7
cells	8
,	0
but	0
is	0
markedly	0
induced	0
by	0
interferon	9
;	0
that	0
PML	9
and	0
PML/RAR	9
alpha	10
expression	0
is	0
augmented	0
by	0
interferon	9
in	0
the	0
NB4	5
APL	6
cell	6
line	6
,	0
which	0
carries	0
the	0
t	1
(	2
15	2
;	2
17	2
)	2
,	0
and	0
in	0
APL	7
blasts	8
from	0
patients	0
;	0
that	0
interferon	9
inhibits	0
growth	0
and	0
survival	0
of	0
NB4	0
APL	7
cells	8
in	0
cooperation	0
with	0
RA	0
;	0
that	0
interferons	0
alone	0
have	0
minimal	0
maturation	0
effect	0
on	0
NB4	5
cells	6
;	0
and	0
,	0
finally	0
,	0
that	0
interferon	9
gamma	10
,	10
but	10
not	10
alpha	10
or	10
beta	10
,	0
induces	0
maturation	0
and	0
growth	0
suppression	0
of	0
NB4	5
cells	6
with	0
de	0
novo	0
retinoid	0
resistance	0
,	0
and	0
partially	0
restores	0
RA	0
response	0
.	0

Effects	0
of	0
Ara-C	0
on	0
neutral	9
sphingomyelinase	10
and	0
mitogen-	9
and	10
stress-	10
activated	10
protein	10
kinases	10
in	0
T-lymphocyte	5
cell	6
lines	6
.	0

Neutral	9
sphingomyelinase	10
(	0
SMase	9
)	0
can	0
be	0
activated	0
by	0
extracellular	0
signals	0
to	0
produce	0
ceramide	0
,	0
which	0
may	0
affect	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
activities	0
.	0

Neutral	0
SMase	9
activity	0
was	0
assessed	0
in	0
membranes	0
from	0
Jurkat	5
,	0
a	0
human	5
T-cell	6
line	6
,	0
and	0
EL4	5
,	0
a	0
murine	5
T-cell	6
line	6
.	0

Ara-C	0
activated	0
SMase	9
with	0
10	0
minutes	0
in	0
both	0
Jurkat	0
and	0
EL4	5
cells	6
,	0
while	0
phorbol	0
ester	0
(	0
PMA	0
)	0
had	0
no	0
effect	0
.	0

PMA	0
,	0
but	0
not	0
Ara-C	0
or	0
ceramides	0
,	0
activated	0
ERK	9
MAPKS	10
,	0
in	0
Jurkat	5
and	0
EL4	5
.	0

PMA	0
acted	0
synergistically	0
with	0
ionomycin	0
to	0
activate	0
JNK	9
MAPKs	10
in	0
Jurkat	5
and	0
EL4	5
within	0
10	0
minutes	0
.	0

Ara-C	0
activated	0
JNKs	9
only	0
after	0
prolonged	0
incubation	0
(	0
90-120	0
minutes	0
)	0
.	0

Thus	0
,	0
ceramide	0
is	0
not	0
a	0
positive	0
signal	0
for	0
ERK	9
activation	0
in	0
T-cell	5
lines	6
.	0

The	0
effects	0
of	0
Ara-C	0
on	0
JNK	9
activity	0
may	0
be	0
mediated	0
through	0
secondary	0
response	0
pathways	0
.	0

Comparative	0
analysis	0
identifies	0
conserved	0
tumor	1
necrosis	2
factor	2
receptor-associated	2
factor	2
3	2
binding	2
sites	2
in	0
the	0
human	1
and	2
simian	2
Epstein-Barr	2
virus	2
oncogene	2
LMP1	2
.	0

Nonhuman	0
primates	0
are	0
naturally	0
infected	0
with	0
a	0
B-lymphotropic	0
herpesvirus	0
closely	0
related	0
to	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
.	0

These	0
simian	0
EBV	0
share	0
considerable	0
genetic	0
,	0
biologic	0
,	0
and	0
epidemiologic	0
features	0
with	0
human	0
EBV	0
,	0
including	0
virus-induced	0
tumorigenesis	0
.	0

However	0
,	0
latent	0
,	0
transformation-associated	0
viral	0
genes	0
demonstrate	0
marked	0
sequence	0
divergence	0
among	0
species	0
despite	0
the	0
conserved	0
functions	0
.	0

We	0
have	0
cloned	0
the	0
latent	9
membrane	10
protein	10
1	10
(	10
LMP1	10
)	10
homologs	10
from	0
the	0
simian	0
EBV	0
naturally	0
infecting	0
baboons	0
(	0
cercopithicine	0
herpesvirus	0
12	0
,	0
herpesvirus	0
papio	0
)	0
and	0
rhesus	0
monkeys	0
(	0
cercopithicine	0
herpesvirus	0
15	0
)	0
for	0
a	0
comparative	0
study	0
with	0
the	0
human	0
EBV	0
oncogene	0
.	0

The	0
transmembrane	0
domains	0
are	0
well	0
conserved	0
,	0
but	0
there	0
is	0
striking	0
sequence	0
divergence	0
of	0
the	0
carboxy-terminal	9
cytoplasmic	10
domain	10
essential	0
for	0
B-cell	7
immortalization	0
and	0
interaction	0
with	0
the	0
tumor	9
necrosis	10
factor	10
receptor	10
signaling	0
pathway	0
.	0

Nevertheless	0
,	0
the	0
simian	9
EBV	10
LMP1s	10
retain	0
most	0
functions	0
in	0
common	0
with	0
EBV	0
LMP1	9
,	0
including	0
the	0
ability	0
to	0
induce	0
NF-	9
(	10
kappa	10
)	10
B	10
activity	0
in	0
human	7
cells	8
,	0
to	0
bind	0
the	0
tumor	9
necrosis	10
factor-associated	10
factor	10
3	10
(	0
TRAF3	9
)	0
in	0
vitro	0
,	0
and	0
to	0
induce	0
expression	0
of	0
tumor	1
necrosis	2
factor-responsive	2
genes	2
,	0
such	0
as	0
ICAM1	1
,	0
in	0
human	7
B	8
lymphocytes	8
.	0

Multiple	0
TRAF3	1
binding	2
sites	2
containing	0
a	0
PXQXT/S	1
core	2
sequence	2
can	0
be	0
identified	0
in	0
the	0
simian	9
EBV	10
LMP1s	10
by	0
an	0
in	0
vitro	0
binding	0
assay	0
.	0

A	0
PXQXT/S-containing	1
sequence	2
is	0
also	0
present	0
in	0
the	0
cytoplasmic	9
domain	10
of	0
the	0
Hodgkin	0
's	0
disease	0
marker	0
,	0
CD30	9
,	0
and	0
binds	0
TRAF3	9
in	0
vitro	0
.	0

The	0
last	9
13	10
amino	10
acids	10
containing	0
a	0
PXQXT/S	1
sequence	2
are	0
highly	0
conserved	0
in	0
human	0
and	0
simian	0
EBV	0
LMP1	9
but	0
do	0
not	0
bind	0
TRAF3	9
,	0
suggesting	0
a	0
distinct	0
role	0
for	0
this	0
conserved	0
region	0
of	0
LMP1	9
.	0

The	0
conserved	0
TRAF3	1
binding	2
sites	2
in	0
LMP1	9
and	0
the	0
CD30	9
Hodgkin	10
's	10
disease	10
marker	10
provides	0
further	0
evidence	0
that	0
a	0
TRAF3	9
-mediated	0
signal	0
transduction	0
pathway	0
may	0
be	0
important	0
in	0
malignant	0
transformation	0
.	0

Chromosome	1
1	2
aneusomy	0
with	0
1p36	1
under-representation	0
is	0
related	0
to	0
histologic	0
grade	0
,	0
DNA	0
aneuploidy	0
,	0
high	0
c-erb	9
B-2	10
and	0
loss	0
of	0
bcl-2	1
expression	0
in	0
ductal	0
breast	0
carcinoma	0
.	0

Chromosome	1
1	2
abnormalities	0
with	0
loss	0
of	0
1p36	1
have	0
been	0
investigated	0
in	0
95	0
breast-cancer	0
samples	0
by	0
means	0
of	0
a	0
dual-target	0
fluorescence	0
in-situ	0
hybridization	0
(	0
FISH	0
)	0
technique	0
using	0
the	0
pUC	1
1.77	2
and	0
p1-79	1
probes	2
,	0
specific	0
for	0
the	0
1q12	1
and	2
1p36	2
regions	2
,	0
respectively	0
.	0

Abnormalities	0
for	0
one	0
or	0
both	0
probes	0
were	0
detected	0
in	0
83/95	0
samples	0
.	0

Relative	0
1p36	1
under-representation	0
was	0
found	0
in	0
79/95	0
.	0

The	0
clinical	0
relevance	0
of	0
these	0
alterations	0
was	0
studied	0
by	0
comparing	0
the	0
FISH	0
results	0
with	0
several	0
parameters	0
currently	0
used	0
in	0
breast-cancer	0
pathology	0
.	0

Distinct	0
patterns	0
of	0
chromosome	1
1	2
abnormalities	0
were	0
found	0
among	0
the	0
histologic	0
types	0
of	0
breast	0
carcinoma	0
.	0

Lobular	0
or	0
mucinous	0
samples	0
showed	0
few	0
or	0
no	0
alterations	0
,	0
whereas	0
most	0
ductal	0
samples	0
had	0
high	0
chromosome	1
1	2
polysomy	0
with	0
under-representation	0
of	0
1p36	1
.	0

In	0
ductal	0
carcinomas	0
,	0
chromosome	1
1	2
alterations	0
increased	0
with	0
histologic	0
grade	0
,	0
DNA	0
aneuploidy	0
,	0
loss	0
of	0
bcl-2	0
and	0
high	0
c-erb	9
B-2	10
expression	0
.	0

These	0
associations	0
were	0
found	0
to	0
be	0
statistically	0
significant	0
.	0

No	0
correlation	0
between	0
chromosome	1
1	2
alterations	0
and	0
nuclear	0
grade	0
,	0
age	0
,	0
size	0
,	0
lymph-node	0
involvement	0
,	0
hormonal	0
receptor	0
presence	0
,	0
proliferation	0
activity	0
or	0
p53	9
protein	0
expression	0
was	0
detected	0
.	0

These	0
results	0
indicate	0
the	0
utility	0
of	0
this	0
FISH	0
technique	0
for	0
a	0
better	0
definition	0
of	0
the	0
biological	0
characteristics	0
of	0
ductal	0
carcinomas	0
.	0

G	0
(	0
Anh	0
)	0
MTetra	0
,	0
a	0
natural	0
bacterial	0
cell	0
wall	0
breakdown	0
product	0
,	0
induces	0
interleukin-1	9
beta	10
and	0
interleukin-6	9
expression	0
in	0
human	7
monocytes	8
.	0

A	0
study	0
of	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
inflammatory	9
cytokine	10
expression	0
[	0
published	0
erratum	0
appears	0
in	0
J	0
Biol	0
Chem	0
1994	0
Jun	0
17	0
;	0
269	0
(	0
24	0
)	0
:	0
16983	0
]	0

It	0
is	0
believed	0
that	0
induction	0
of	0
cytokine	9
expression	0
by	0
bacterial	0
cell	0
wall	0
components	0
plays	0
a	0
role	0
in	0
the	0
development	0
and	0
course	0
of	0
sepsis	0
.	0

However	0
,	0
most	0
attention	0
has	0
been	0
focused	0
on	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

We	0
studied	0
the	0
ability	0
of	0
N-acetylglucosaminyl-1	0
,	0
6-anhydro-N-acetylmuramyl-L-alanyl-D-	0
isoglutamyl-m-diaminopimelyl-D-alanine	0
(	0
G	0
(	0
Anh	0
)	0
MTetra	0
)	0
,	0
a	0
naturally	0
occurring	0
breakdown	0
product	0
of	0
peptidoglycan	0
that	0
is	0
produced	0
by	0
soluble	0
lytic	9
transglycosylase	10
of	0
Escherichia	0
coli	0
,	0
to	0
induce	0
cytokine	9
expression	0
in	0
human	7
monocytes	8
.	0

G	0
(	0
Anh	0
)	0
MTetra	0
was	0
found	0
to	0
strongly	0
induce	0
interleukin	9
(	10
IL	10
)	10
-1	10
beta	10
and	0
IL-6	3
mRNA	4
expression	0
after	0
2	0
h	0
and	0
IL-1	9
beta	10
and	0
IL-6	9
protein	10
secretion	0
after	0
48	0
h	0
of	0
activation	0
.	0

The	0
increase	0
in	0
mRNA	0
accumulation	0
was	0
at	0
least	0
partly	0
due	0
to	0
an	0
increase	0
in	0
the	0
transcription	0
rates	0
of	0
the	0
respective	0
genes	1
and	0
was	0
accompanied	0
by	0
a	0
strong	0
induction	0
of	0
nuclear	0
factor-kappa	0
B	0
and	0
activator	0
protein-1	0
transcription	0
factor	0
expression	0
.	0

Experiments	0
using	0
inhibitors	0
of	0
protein	9
kinase	10
C	10
,	0
protein	9
kinase	10
A	10
,	0
and	0
tyrosine	0
kinase-dependent	0
pathways	0
revealed	0
that	0
G	0
(	0
Anh	0
)	0
MTetra-induced	0
IL-1	9
beta	10
and	0
IL-6	3
mRNA	4
expression	0
involves	0
activation	0
of	0
an	0
H7-inhibitable	0
pathway	0
.	0

By	0
using	0
the	0
protein	0
synthesis	0
inhibitor	0
cycloheximide	0
,	0
it	0
was	0
shown	0
that	0
G	0
(	0
Anh	0
)	0
MTetra-induced	0
IL-6	3
mRNA	4
expression	0
depends	0
on	0
the	0
synthesis	0
of	0
new	0
protein	0
,	0
whereas	0
G	0
(	0
Anh	0
)	0
MTetra-induced	0
IL-1	9
beta	10
mRNA	0
accumulation	0
does	0
not	0
.	0

When	0
responses	0
to	0
G	0
(	0
Anh	0
)	0
MTetra	0
were	0
compared	0
with	0
those	0
to	0
LPS	0
and	0
muramyldipeptide	0
(	0
MDP	0
)	0
,	0
it	0
was	0
found	0
that	0
the	0
optimal	0
response	0
to	0
G	0
(	0
Anh	0
)	0
MTetra	0
induction	0
was	0
similar	0
to	0
that	0
of	0
LPS	0
but	0
significantly	0
higher	0
than	0
the	0
response	0
to	0
MDP	0
.	0

Furthermore	0
,	0
maximal	0
G	0
(	0
Anh	0
)	0
MTetra-induced	0
IL-1	9
beta	10
and	0
IL-6	3
mRNA	4
expression	0
could	0
be	0
enhanced	0
by	0
co-stimulation	0
with	0
LPS	0
or	0
MDP	0
,	0
suggesting	0
that	0
different	0
receptors	0
and/or	0
transduction	0
pathways	0
were	0
involved	0
.	0

These	0
results	0
indicate	0
that	0
G	0
(	0
Anh	0
)	0
MTetra	0
induces	0
IL-1	9
beta	10
and	0
IL-6	9
expression	0
in	0
human	7
monocytes	8
suggesting	0
a	0
possible	0
role	0
for	0
G	0
(	0
Anh	0
)	0
MTetra	0
in	0
the	0
release	0
of	0
cytokines	9
during	0
sepsis	0
.	0

Increased	0
proliferation	0
,	0
cytotoxicity	0
,	0
and	0
gene	0
expression	0
after	0
stimulation	0
of	0
human	7
peripheral	8
blood	8
T	8
lymphocytes	8
through	0
a	0
surface	0
ganglioside	0
(	0
GD3	0
)	0
[	0
published	0
erratum	0
appears	0
in	0
J	0
Immunol	0
1994	0
Jul	0
15	0
;	0
153	0
(	0
2	0
)	0
:	0
910	0
]	0

Previous	0
studies	0
have	0
suggested	0
that	0
gangliosides	0
have	0
an	0
important	0
role	0
in	0
cell	0
signaling	0
and	0
recognition	0
.	0

However	0
,	0
their	0
specific	0
function	0
in	0
these	0
processes	0
has	0
not	0
been	0
clearly	0
defined	0
.	0

A	0
mAb	9
,	0
R24	9
,	0
that	0
reacts	0
specifically	0
with	0
a	0
cell	0
surface	0
ganglioside	0
(	0
GD3	0
)	0
has	0
been	0
demonstrated	0
to	0
stimulate	0
proliferation	0
of	0
T	7
cells	8
derived	0
from	0
human	0
peripheral	0
blood	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
investigated	0
the	0
mechanisms	0
by	0
which	0
the	0
R24	9
mAb	10
affects	0
T	0
cell	0
functions	0
.	0

We	0
have	0
observed	0
that	0
the	0
R24	9
mAb	10
stimulates	0
GD3+	0
T	0
cell	0
proliferation	0
,	0
cytotoxicity	0
,	0
and	0
surface	0
marker	0
expression	0
of	0
IL-2R	9
alpha-chain	10
,	0
IL-2R	9
beta-chain	10
,	0
HLA-DR	9
,	0
CD11a	9
,	0
and	0
CD11c	9
.	0

Additionally	0
,	0
IFN-gamma	9
activity	0
but	0
not	0
IL-1	0
,	0
IL-2	0
,	0
or	0
IL-4	0
activity	0
was	0
present	0
in	0
culture	0
supernatants	0
72	0
h	0
after	0
R24	9
stimulation	0
.	0

In	0
some	0
donors	0
,	0
increased	0
IL-6	9
and	0
TNF-alpha	9
activity	0
also	0
was	0
detected	0
after	0
R24	9
treatment	0
.	0

Furthermore	0
,	0
R24	9
treatment	0
resulted	0
in	0
translocation	0
of	0
c-rel	9
,	0
but	0
little	0
or	0
no	0
NF	9
kappa	10
B	10
p50	10
or	0
p65	9
,	0
from	0
the	0
cytoplasm	0
to	0
the	0
nucleus	0
and	0
an	0
increase	0
of	0
NF	9
kappa	10
B	10
binding	10
complexes	10
containing	0
c-rel	9
and	0
p50	9
.	0

This	0
treatment	0
also	0
caused	0
increased	0
tyrosine	0
phosphorylation	0
of	0
specific	0
protein	0
substrates	0
.	0

R24	9
-stimulated	0
increases	0
in	0
proliferation	0
,	0
cytotoxicity	0
,	0
and	0
cell	0
surface	0
protein	0
expression	0
could	0
be	0
blocked	0
by	0
cyclosporin	0
and	0
staurosporin	0
,	0
indicating	0
that	0
cyclophilin/calcineurin	9
and	0
protein	9
kinase	10
C	10
may	0
be	0
involved	0
in	0
the	0
R24	9
signaling	0
pathway	0
.	0

Additionally	0
,	0
herbimycin	0
A	0
,	0
a	0
tyrosine	9
kinase	10
inhibitor	0
,	0
blocked	0
the	0
R24	9
-stimulated	0
increase	0
in	0
proliferation	0
but	0
not	0
cytotoxicity	0
at	0
concentrations	0
consistent	0
with	0
specificity	0
for	0
tyrosine	9
kinases	10
.	0

These	0
results	0
suggest	0
that	0
multiple	0
biochemical	0
pathways	0
are	0
involved	0
in	0
the	0
activation	0
of	0
human	7
T	8
cells	8
by	0
R24	9
.	0

Genes	0
encoding	0
general	9
initiation	10
factors	10
for	0
RNA	9
polymerase	10
II	10
transcription	0
are	0
dispersed	0
in	0
the	0
human	1
genome	2
.	0

General	9
transcription	10
factors	10
are	0
required	0
for	0
accurate	0
initiation	0
of	0
transcription	0
by	0
RNA	9
polymerase	10
II	10
.	0

Human	1
cDNAs	2
encoding	0
subunits	0
of	0
these	0
factors	0
have	0
been	0
cloned	0
and	0
sequenced	0
.	0

Using	0
fluorescence	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
,	0
we	0
show	0
here	0
that	0
the	0
genes	1
encoding	0
the	0
TATA-box	9
binding	10
protein	10
(	0
TBP	9
)	0
,	0
TFIIB	9
,	0
TFIIE	9
alpha	10
,	0
TFIIE	9
beta	10
,	0
RAP30	9
,	0
RAP74	9
and	0
the	0
62	9
kDa	10
subunit	10
,	0
of	0
TFIIH	9
are	0
located	0
at	0
the	0
human	1
chromosomal	2
bands	2
6q26-27	2
,	2
1p21-22	2
,	2
3q21-24	2
,	2
8p12	2
,	2
13q14	2
,	2
19p13.3	2
and	2
11p14-15.1	2
,	0
respectively	0
.	0

This	0
dispersed	0
localization	0
of	0
a	0
group	0
of	0
functionally	0
related	0
gene	0
provides	0
insights	0
into	0
the	0
molecular	0
mechanism	0
of	0
human	1
genome	2
evolution	0
and	0
their	0
possible	0
involvement	0
in	0
human	0
diseases	0
.	0

BCL-6	9
and	0
the	0
molecular	0
pathogenesis	0
of	0
B-cell	0
lymphoma	0
.	0

The	0
results	0
presented	0
identify	0
the	0
first	0
genetic	0
lesion	0
associated	0
with	0
DLCL	0
,	0
the	0
most	0
clinically	0
relevant	0
form	0
of	0
NHL	0
.	0

Although	0
no	0
proof	0
yet	0
exists	0
of	0
a	0
role	0
for	0
these	0
lesions	0
in	0
DLCL	0
pathogenesis	0
,	0
the	0
feature	0
of	0
the	0
BCL-6	9
gene	10
product	10
,	0
its	0
specific	0
pattern	0
of	0
expression	0
in	0
B	7
cells	8
,	0
and	0
the	0
clustering	0
of	0
lesions	0
disrupting	0
its	0
regulatory	0
domain	0
strongly	0
suggest	0
that	0
deregulation	0
of	0
BCL-6	9
expression	0
may	0
contribute	0
to	0
DLCL	0
development	0
.	0

A	0
more	0
precise	0
definition	0
of	0
the	0
role	0
of	0
BCL-6	9
in	0
normal	0
and	0
neoplastic	0
B-cell	0
development	0
is	0
the	0
goal	0
of	0
ongoing	0
study	0
of	0
transgenic	0
mice	0
engineered	0
either	0
to	0
express	0
BCL-6	9
under	0
heterologous	1
promoters	2
or	0
lacking	0
BCL-6	9
function	0
due	0
to	0
targeted	0
deletions	0
.	0

In	0
addition	0
to	0
contributing	0
to	0
the	0
understanding	0
of	0
DLCL	0
pathogenesis	0
,	0
the	0
identification	0
of	0
BCL-6	9
lesions	0
may	0
have	0
relevant	0
clinical	0
implications	0
.	0

DLCL	0
represent	0
a	0
heterogeneous	0
group	0
of	0
neoplasms	0
which	0
are	0
treated	0
homogeneously	0
despite	0
the	0
fact	0
that	0
only	0
50	0
%	0
of	0
patients	0
experience	0
long-term	0
disease-free	0
survival	0
(	0
Schneider	0
et	0
al.	0
1990	0
)	0
.	0

The	0
fact	0
that	0
BCL-6	9
rearrangements	0
identify	0
biologically	0
and	0
clinically	0
distinct	0
subsets	0
of	0
DLCL	0
suggests	0
that	0
these	0
lesions	0
may	0
be	0
useful	0
as	0
markers	0
in	0
selection	0
of	0
differential	0
therapeutic	0
strategies	0
based	0
on	0
different	0
risk	0
groups	0
.	0

Furthermore	0
,	0
the	0
BCL-6	9
rearrangements	0
can	0
be	0
used	0
to	0
identify	0
and	0
monitor	0
the	0
malignant	7
clone	8
with	0
sensitive	0
PCR-based	0
techniques	0
.	0

Since	0
clinical	0
remission	0
has	0
been	0
observed	0
in	0
a	0
significant	0
fraction	0
of	0
DLCL	0
cases	0
,	0
these	0
markers	0
may	0
serve	0
as	0
critical	0
tools	0
for	0
sensitive	0
monitoring	0
of	0
minimal	0
residual	0
disease	0
and	0
early	0
diagnosis	0
of	0
relapse	0
(	0
Gribben	0
et	0
al.	0
1993	0
)	0
.	0

Pancreatic	0
development	0
and	0
maturation	0
of	0
the	0
islet	7
B	8
cell	8
.	0

Studies	0
of	0
pluripotent	5
islet	6
cultures	6
.	0

Pancreas	0
organogenesis	0
is	0
a	0
highly	0
regulated	0
process	0
,	0
in	0
which	0
two	0
anlage	0
evaginate	0
from	0
the	0
primitive	0
gut	0
.	0

They	0
later	0
fuse	0
,	0
and	0
,	0
under	0
the	0
influence	0
of	0
the	0
surrounding	0
mesenchyme	0
,	0
the	0
mature	0
organ	0
develops	0
,	0
being	0
mainly	0
composed	0
of	0
ductal	0
,	0
exocrine	0
and	0
endocrine	0
compartments	0
.	0

Early	0
buds	0
are	0
characterized	0
by	0
a	0
branching	0
morphogenesis	0
of	0
the	0
ductal	0
epithelium	0
from	0
which	0
endocrine	7
and	8
exocrine	8
precursor	8
cells	8
bud	0
to	0
eventually	0
form	0
the	0
two	0
other	0
compartments	0
.	0

The	0
three	0
compartments	0
are	0
thought	0
to	0
be	0
of	0
common	0
endodermal	0
origin	0
;	0
in	0
contrast	0
to	0
earlier	0
hypotheses	0
,	0
which	0
suggested	0
that	0
the	0
endocrine	0
compartment	0
was	0
of	0
neuroectodermal	0
origin	0
.	0

It	0
is	0
thus	0
generally	0
believed	0
that	0
the	0
pancreatic	0
endocrine-lineage	0
possesses	0
the	0
ability	0
to	0
mature	0
along	0
a	0
differentiation	0
pathway	0
that	0
shares	0
many	0
characteristics	0
with	0
those	0
of	0
neuronal	0
differentiation	0
.	0

During	0
recent	0
years	0
,	0
studies	0
of	0
insulin-gene	1
regulation	0
and	0
,	0
in	0
particular	0
,	0
the	0
tissue-specific	0
transcriptional	0
control	0
of	0
insulin-gene	1
activity	0
have	0
provided	0
information	0
on	0
pancreas	0
development	0
in	0
general	0
.	0

The	0
present	0
review	0
summarizes	0
these	0
findings	0
,	0
with	0
a	0
special	0
focus	0
on	0
our	0
own	0
studies	0
on	0
pluripotent	5
endocrine	6
cultures	6
of	0
rat	0
pancreas	0
.	0

Octamer	0
independent	0
activation	0
of	0
transcription	0
from	0
the	0
kappa	1
immunoglobulin	2
germline	2
promoter	2
.	0

Previous	0
analyses	0
of	0
immunoglobulin	1
V	2
region	2
promoters	2
has	0
led	0
to	0
the	0
discovery	0
of	0
a	0
common	0
octamer	1
motif	2
which	0
is	0
functionally	0
important	0
in	0
the	0
tissue-specific	0
and	0
developmentally	0
regulated	0
transcriptional	0
activation	0
of	0
immunoglobulin	1
genes	2
.	0

The	0
germline	1
promoters	2
(	0
Ko	1
)	0
located	0
upstream	0
of	0
the	0
J	1
region	2
gene	2
segments	2
of	0
the	0
kappa	1
locus	2
also	0
contain	0
an	0
octamer	1
motif	2
(	0
containing	0
a	0
single	0
base	1
pair	2
mutation	2
and	0
referred	0
to	0
as	0
the	0
variant	0
octamer	0
)	0
which	0
has	0
been	0
shown	0
previously	0
to	0
bind	0
Oct-1	9
and	0
Oct-2	9
transcription	9
factors	10
in	0
vitro	0
.	0

To	0
further	0
elucidate	0
the	0
role	0
of	0
this	0
variant	0
octamer	1
motif	2
in	0
the	0
regulation	0
of	0
germline	1
transcription	0
from	0
the	0
unrearranged	0
kappa	1
locus	2
,	0
we	0
have	0
quantitated	0
the	0
relative	0
binding	0
affinity	0
of	0
Oct-1	9
and	0
Oct-2	9
for	0
the	0
variant	0
octamer	1
motif	2
and	0
determined	0
the	0
functional	0
role	0
of	0
this	0
octamer	1
motif	2
in	0
transcriptional	0
activation	0
.	0

We	0
find	0
that	0
,	0
although	0
the	0
variant	0
octamer	1
motif	2
binds	0
Oct-1	9
and	0
Oct-2	9
in	0
vitro	0
with	0
5-fold	0
lower	0
affinity	0
than	0
the	0
consensus	1
octamer	2
motif	2
,	0
mutation	0
of	0
the	0
variant	0
octamer	1
motif	2
to	0
either	0
a	0
consensus	1
octamer	2
or	0
non-octamer	1
motif	2
has	0
no	0
effect	0
on	0
transcriptional	0
activation	0
from	0
the	0
germline	1
promoter	2
.	0

We	0
also	0
find	0
significant	0
differences	0
in	0
activation	0
of	0
germline	1
and	0
V	1
region	2
promoters	2
by	0
kappa	1
enhancers	2
.	0

Our	0
results	0
suggest	0
that	0
the	0
germline	1
promoters	2
and	0
V	1
region	2
promoters	2
differ	0
in	0
their	0
dependence	0
on	0
octamer	1
for	0
activation	0
and	0
respond	0
differently	0
to	0
enhancer	0
activation	0
.	0

These	0
findings	0
have	0
important	0
implications	0
in	0
regulation	0
of	0
germline	1
transcription	0
as	0
well	0
as	0
concomitant	0
activation	0
of	0
the	0
V-J	0
recombination	0
of	0
the	0
kappa	1
light	2
chain	2
locus	2
.	0

Generation	0
of	0
CD1+RelB+	7
dendritic	8
cells	8
and	0
tartrate-resistant	7
acid	8
phosphatase-positive	8
osteoclast-like	8
multinucleated	8
giant	8
cells	8
from	0
human	7
monocytes	8
.	0

We	0
previously	0
showed	0
that	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
and	0
macrophage	9
colony-stimulating	10
factor	10
(	0
M-CSF	9
)	0
stimulate	0
the	0
differentiation	0
of	0
human	7
monocytes	8
into	0
two	0
phenotypically	0
distinct	0
types	0
of	0
macrophages	7
.	0

However	0
,	0
in	0
vivo	0
,	0
not	0
only	0
CSF	9
but	0
also	0
many	0
other	0
cytokines	9
are	0
produced	0
under	0
various	0
conditions	0
.	0

Those	0
cytokines	9
may	0
modulate	0
the	0
differentiation	0
of	0
monocytes	7
by	0
CSFs	9
.	0

In	0
the	0
present	0
study	0
,	0
we	0
showed	0
that	0
CD14+	7
adherent	8
human	8
monocytes	8
can	0
differentiate	0
into	0
CD1+relB+	7
dendritic	8
cells	8
(	0
DC	7
)	0
by	0
the	0
combination	0
of	0
GM-CSF	9
plus	0
interleukin-4	9
(	0
IL-4	9
)	0
and	0
that	0
they	0
differentiate	0
into	0
tartrate-resistant	7
acid	8
phosphatase	8
(	8
TRAP	8
)	8
-positive	8
osteoclast-like	8
multinucleated	8
giant	8
cells	8
(	0
MGC	7
)	0
by	0
the	0
combination	0
of	0
M-CSF	9
plus	0
IL-4	9
.	0

However	0
,	0
the	0
monocyte-derived	5
DC	6
were	0
not	0
terminally	5
differentiated	6
cells	6
;	0
they	0
could	0
still	0
convert	0
to	0
macrophages	7
in	0
response	0
to	0
M-CSF	9
.	0

Tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
stimulated	0
the	0
terminal	0
differentiation	0
of	0
the	0
DC	7
by	0
downregulating	0
the	0
expression	0
of	0
the	0
M-CSF	9
receptor	10
,	0
cfms	3
mRNA	4
,	0
and	0
aborting	0
the	0
potential	0
to	0
convert	0
to	0
macrophages	7
.	0

In	0
contrast	0
to	0
IL-4	9
,	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
had	0
no	0
demonstrable	0
effect	0
on	0
the	0
differentiation	0
of	0
monocytes	7
.	0

Rather	0
,	0
IFN-gamma	9
antagonized	0
the	0
effect	0
of	0
IL-4	9
and	0
suppressed	0
the	0
DC	7
and	0
MGC	7
formation	0
induced	0
by	0
GM-CSF	9
+	0
IL-4	9
and	0
M-CSF	9
+	0
IL-4	9
,	0
respectively	0
.	0

Taken	0
together	0
,	0
these	0
results	0
provide	0
a	0
new	0
aspect	0
to	0
our	0
knowledge	0
of	0
monocyte	0
differentiation	0
and	0
provide	0
evidence	0
that	0
human	7
monocytes	8
are	0
flexible	0
in	0
their	0
differentiation	0
potential	0
and	0
are	0
precursors	0
not	0
only	0
of	0
macrophages	7
but	0
also	0
of	0
CD1+relB+DC	7
and	0
TRAP-positive	7
MGC	8
.	0

Such	0
a	0
diverse	0
pathway	0
of	0
monocyte	0
differentiation	0
may	0
constitute	0
one	0
of	0
the	0
basic	0
mechanisms	0
of	0
immune	0
regulation	0
.	0

The	0
NF-kappa	9
B	10
inhibitor	0
,	0
tepoxalin	0
,	0
suppresses	0
surface	0
expression	0
of	0
the	0
cell	9
adhesion	10
molecules	10
CD62E	9
,	0
CD11b/CD18	9
and	0
CD106	9
.	0

Tepoxalin	0
,	0
a	0
dual	0
enzyme	0
inhibitor	0
of	0
cyclooxygenase	9
and	0
5-lipoxygenase	9
has	0
been	0
shown	0
to	0
inhibit	0
T-cell	0
activation	0
.	0

Its	0
immunosuppressive	0
property	0
is	0
distinct	0
from	0
cyclosporin	0
because	0
only	0
tepoxalin	0
,	0
but	0
not	0
cyclosporin	0
,	0
suppresses	0
NF-kappa	9
B	10
activation	0
.	0

Here	0
we	0
report	0
that	0
tepoxalin	0
selectively	0
inhibits	0
intercellular	9
adhesion	10
molecule-1	10
(	9
ICAM-1	10
,	10
CD54	10
)	10
/MAC-1	10
(	0
CD11b/CD18	9
)	0
dependent	0
adhesion	0
of	0
polymorphonuclear	7
cells	8
to	0
IL-1	9
activated	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
.	0

The	0
mechanism	0
of	0
inhibition	0
is	0
related	0
to	0
the	0
surface	0
expression	0
of	0
several	0
cell	0
adhesion	9
molecules	10
.	0

Flow	0
cytometry	0
analyses	0
on	0
cultured	0
cells	0
that	0
were	0
treated	0
with	0
tepoxalin	0
or	0
antisense	0
oligonucleotides	0
to	0
the	0
P65/p50	9
subunit	10
of	0
NF-kappa	9
B	10
,	0
and	0
then	0
stimulated	0
with	0
PMA	0
,	0
revealed	0
a	0
reduced	0
expression	0
of	0
CD11b/CD18	9
on	0
monocytic	5
HL60	6
cells	6
,	0
and	0
endothelial	9
adhesion	10
molecule-1	10
(	0
CD62E	9
)	0
and	0
vascular	9
adhesion	10
molecule-1	10
(	0
CD106	9
)	0
on	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
.	0

Expression	0
of	0
other	0
adhesion	9
molecules	10
such	0
as	0
lymphocyte	9
function	10
associated-antigen-1	10
(	0
CD11a/CD18	9
)	0
and	0
CD54	9
were	0
unaffected	0
.	0

Tepoxalin	0
also	0
inhibited	0
the	0
secretion	0
of	0
a	0
NF-kappa	9
B	10
regulated	10
chemokine	10
,	0
IL-8	9
,	0
a	0
known	0
inducer	0
of	0
CD11b/CD18	9
expression	0
.	0

Thus	0
the	0
suppression	0
of	0
CD11b/CD18	9
expression	0
by	0
tepoxalin	0
may	0
involve	0
IL-8	9
.	0

Our	0
results	0
suggest	0
that	0
by	0
inhibiting	0
NF-kappa	9
B	10
activation	0
,	0
surface	0
expression	0
of	0
several	0
adhesion	9
molecules	10
can	0
be	0
modulated	0
and	0
that	0
tepoxalin	0
may	0
be	0
useful	0
in	0
treating	0
selected	0
adhesion	0
mediated	0
events	0
such	0
as	0
leukocyte	0
migration	0
or	0
atherosclerotic	0
plaque	0
formation	0
.	0

Characterization	0
of	0
a	0
CD43/leukosialin	9
-mediated	0
pathway	0
for	0
inducing	0
apoptosis	0
in	0
human	7
T-lymphoblastoid	8
cells	8
.	0

The	0
monoclonal	9
antibody	10
(	0
mAb	9
)	0
J393	9
induces	0
apoptosis	0
in	0
Jurkat	5
T-cells	6
.	0

NH2	9
-terminal	0
amino	0
acid	0
sequence	0
analysis	0
identified	0
the	0
140-kDa	9
surface	10
antigen	10
for	0
mAb	9
J393	10
as	0
CD43/leukosialin	9
,	0
the	0
major	0
sialoglycoprotein	9
of	0
leukocytes	7
.	0

While	0
Jurkat	5
cells	6
co-expressed	0
two	0
discrete	0
cell-surface	9
isoforms	10
of	0
CD43	9
,	0
recognized	0
by	0
mAb	9
J393	10
and	0
mAb	9
G10-2	10
,	0
respectively	0
,	0
only	0
J393/CD43	9
signaled	0
apoptosis	0
.	0

J393/CD43	9
was	0
found	0
to	0
be	0
hyposialylated	0
,	0
bearing	0
predominantly	0
O-linked	0
monosaccharide	0
glycans	0
,	0
whereas	0
G10-2/CD43	9
bore	0
complex	0
sialylated	0
tetra-	0
and	0
hexasaccharide	0
chains	0
.	0

Treatment	0
with	0
soluble	0
,	0
bivalent	0
mAb	9
J393	10
killed	0
25-50	0
%	0
of	0
the	0
cell	5
population	6
,	0
while	0
concomitant	0
engagement	0
of	0
either	0
the	0
CD3.TcR	9
complex	10
or	0
the	0
integrins	9
CD18	9
and	0
CD29	9
significantly	0
potentiated	0
this	0
effect	0
.	0

Treatment	0
of	0
Jurkat	5
cells	6
with	0
mAb	9
J393	10
induced	0
tyrosine	0
phosphorylation	0
of	0
specific	0
protein	9
substrates	10
that	0
underwent	0
hyperphosphorylation	0
upon	0
antigen	9
receptor	10
costimulation	0
.	0

Tyrosine	9
kinase	10
inhibition	0
by	0
herbimycin	0
A	0
diminished	0
J393/CD43	9
-mediated	0
apoptosis	0
,	0
whereas	0
inhibition	0
of	0
phosphotyrosine	9
phosphatase	10
activity	0
by	0
bis	0
(	0
maltolato	0
)	0
oxovanadium-IV	0
enhanced	0
cell	0
death	0
.	0

Signal	0
transduction	0
through	0
tyrosine	0
kinase	0
activation	0
may	0
lead	0
to	0
altered	0
gene	0
expression	0
,	0
as	0
J393/	0
CD43	9
ligation	0
prompted	0
decreases	0
in	0
the	0
nuclear	0
localization	0
of	0
the	0
transcriptional	9
regulatory	10
protein	10
NF-kappaB	9
and	0
proteins	0
binding	0
the	0
interferon-inducible	1
regulatory	2
element	2
.	0

Since	0
peripheral	7
blood	8
T-lymphocytes	8
express	0
cryptic	9
epitopes	10
for	0
mAb	9
J393	10
,	0
these	0
findings	0
demonstrate	0
the	0
existence	0
of	0
a	0
tightly	0
regulated	0
CD43	9
-mediated	0
pathway	0
for	0
inducing	0
apoptosis	0
in	0
human	7
T-cell	8
lineages	8
.	0

Sterol	0
dependent	0
LDL-receptor	1
gene	2
transcription	0
in	0
lymphocytes	7
from	0
normal	0
and	0
CML	0
patients	0
.	0

Sterol	1
regulatory	2
element	2
(	0
SRE	1
)	0
has	0
been	0
recognized	0
to	0
regulate	0
various	0
key	0
genes	1
coding	0
for	0
especially	0
low	9
density	10
lipoprotein	10
(	10
LDL	10
)	10
-receptor	10
,	0
3-hydroxy-3-methylglutaryl	9
coenzyme	10
A	10
(	10
HMG-CoA	10
)	10
reductase	10
and	0
HMG-CoA	9
synthase	10
known	0
to	0
play	0
a	0
crucial	0
role	0
in	0
the	0
cholesterol	0
feedback	0
mechanism	0
.	0

The	0
deranged	0
cholesterol	0
feedback	0
mechanism	0
has	0
been	0
widely	0
recognised	0
in	0
initiation	0
as	0
well	0
as	0
progression	0
of	0
various	0
types	0
of	0
cancers	0
including	0
chronic	0
myeloid	0
leukaemia	0
(	0
CML	0
)	0
.	0

Consequently	0
,	0
the	0
present	0
study	0
was	0
addressed	0
to	0
understand	0
this	0
phenomenon	0
and	0
revealed	0
the	0
existence	0
of	0
a	0
unique	9
47	10
kDa	10
protein	10
factor	10
having	0
affinity	0
for	0
this	0
SRE	1
sequence	2
in	0
lymphocytes	7
from	0
normal	0
subjects	0
as	0
well	0
as	0
its	0
absence	0
in	0
lymphocytes	7
from	0
untreated	0
CML	0
patients	0
.	0

However	0
,	0
this	0
factor	0
appeared	0
when	0
the	0
CML	0
patients	0
achieved	0
complete	0
haematological	0
remission	0
(	0
CHR	0
)	0
through	0
alpha-interferon	9
therapy	0
.	0

Further	0
,	0
an	0
inverse	0
relationship	0
was	0
also	0
observed	0
between	0
sterol	0
modulated	0
LDL-receptor	1
gene	2
transcription	0
and	0
the	0
binding	0
affinity	0
of	0
this	0
47	9
kDa	10
factor	10
to	0
the	0
SRE	1
sequence	2
.	0

Based	0
upon	0
these	0
results	0
we	0
propose	0
that	0
alpha-interferon	9
through	0
its	0
receptor	0
initiates	0
phosphatidic	0
acid	0
dependent	0
signalling	0
which	0
in	0
turn	0
regulates	0
the	0
affinity	0
of	0
47	9
kDa	10
sterol	10
regulatory	10
element	10
binding	10
factor	10
as	0
well	0
as	0
LDL-receptor	1
gene	2
transcription	0
in	0
lymphocytes	7
from	0
CML	0
patients	0
.	0

Multiple	0
prolactin-responsive	1
elements	2
mediate	0
G1	0
and	0
S	0
phase	0
expression	0
of	0
the	0
interferon	1
regulatory	2
factor-1	2
gene	2
.	0

The	0
interferon	1
regulatory	2
factor-1	2
(	2
IRF-1	2
)	2
gene	2
is	0
both	0
an	0
immediate-early	1
G1	2
phase	2
gene	2
and	0
an	0
S	1
phase	2
gene	2
inducible	0
by	0
PRL	9
in	0
rat	5
Nb2	6
T	6
lymphocytes	6
.	0

To	0
understand	0
the	0
mechanism	0
by	0
which	0
PRL	9
regulates	0
the	0
biphasic	0
expression	0
of	0
IRF-1	9
,	0
we	0
cloned	0
the	0
rat	1
IRF-1	2
gene	2
and	0
functionally	0
characterized	0
the	0
IRF-1	1
promoter	2
.	0

Upon	0
transfection	0
into	0
Nb2	5
T	6
cells	6
,	0
1.7	0
kilobases	0
(	0
kb	0
)	0
of	0
IRF-1	1
5'-flanking	2
DNA	2
linked	0
to	0
a	0
chloramphenicol	1
acetyl	2
transferase	2
(	2
CAT	2
)	2
reporter	2
gene	2
mediated	0
a	0
30-fold	0
induction	0
of	0
CAT	9
enzyme	10
activity	0
in	0
response	0
to	0
24	0
h	0
of	0
PRL	9
stimulation	0
.	0

Deletion	0
mutants	0
containing	0
1.3	1
,	2
0.6	2
,	2
and	2
0.2	2
kb	2
5'-flanking	2
DNA	2
were	0
incrementally	0
less	0
transcriptionally	0
active	0
,	0
although	0
0.2	0
kb	0
still	0
mediated	0
a	0
12-fold	0
induction	0
by	0
PRL	9
.	0

The	0
sequence	0
between	0
-1.7	0
and	0
-0.2	0
kb	0
linked	0
to	0
a	0
heterologous	1
thymidine	2
kinase	2
promoter	2
failed	0
to	0
respond	0
to	0
PRL	9
stimulation	0
,	0
suggesting	0
that	0
the	0
activity	0
of	0
upstream	1
PRL	2
response	2
elements	2
may	0
require	0
an	0
interaction	0
with	0
promoter-proximal	1
elements	2
.	0

By	0
assaying	0
CAT	9
enzyme	10
activity	0
across	0
a	0
24-h	0
PRL	9
induction	0
time	0
course	0
,	0
we	0
were	0
able	0
to	0
assign	0
G1	0
vs.	0
S	0
phase	0
PRL	9
responses	0
of	0
the	0
IRF-1	1
gene	2
to	0
different	0
regions	0
of	0
the	0
IRF-1	9
5'-flanking	1
and	0
promoter	1
DNA	2
.	0

The	0
0.2-kb	0
IRF-CAT	1
construct	2
was	0
induced	0
by	0
PRL	9
stimulation	0
during	0
the	0
G1	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

In	0
contrast	0
,	0
the	0
1.7-kb	0
IRF-	0
CAT	9
construct	0
was	0
inducible	0
by	0
PRL	9
during	0
both	0
G1	0
and	0
S	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

Hence	0
,	0
the	0
PRL	9
-induced	0
biphasic	0
expression	0
of	0
the	0
IRF-1	1
gene	2
appears	0
to	0
be	0
controlled	0
by	0
separate	0
PRL-responsive	1
elements	2
:	0
elements	0
in	0
the	0
first	0
0.2	0
kb	0
of	0
the	0
IRF-1	1
promoter	2
region	2
act	0
during	0
early	0
activation	0
,	0
and	0
elements	0
between	0
0.2	0
and	0
1.7	0
kb	0
act	0
in	0
concert	0
with	0
the	0
proximal	0
0.2-kb	0
region	0
during	0
S	0
phase	0
progression	0
.	0

Regulation	0
of	0
the	0
BZLF1	1
promoter	2
of	0
Epstein-Barr	0
virus	0
by	0
second	0
messengers	0
in	0
anti-immunoglobulin-treated	5
B	6
cells	6
.	0

Initiation	0
of	0
the	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
lytic	0
cycle	0
is	0
dependent	0
on	0
the	0
transcription	0
of	0
the	0
BZLF1	1
gene	2
.	0

The	0
BZLF1	1
gene	2
promoter	2
(	0
Zp	1
)	0
was	0
activated	0
by	0
crosslinking	0
of	0
cell	9
surface	10
immunoglobulin	10
(	0
Ig	9
)	0
with	0
anti-Ig	9
antibody	10
in	0
B	7
cells	8
,	0
even	0
in	0
the	0
absence	0
of	0
other	0
viral	0
genes	0
.	0

We	0
identified	0
several	0
anti-Ig	0
response	0
elements	0
within	0
Zp	1
,	0
which	0
were	0
originally	0
defined	0
as	0
12-O-tetradecanoylphorbol-13-acetate	1
(	2
TPA	2
)	2
response	2
elements	2
(	0
ZI	0
repeats	0
and	0
ZII	1
,	0
an	0
AP-1-like	1
domain	2
)	0
.	0

Since	0
anti-Ig	0
crosslinking	0
leads	0
to	0
activation	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
and	0
an	0
increase	0
in	0
intracellular	0
calcium	0
level	0
,	0
Zp	1
was	0
tested	0
for	0
the	0
response	0
to	0
these	0
cellular	9
factors	10
.	0

Treatment	0
with	0
calcium	0
ionophore	0
A23187	0
increased	0
Zp	1
activity	0
.	0

When	0
the	0
calcium	0
ionophore	0
was	0
used	0
in	0
conjunction	0
with	0
TPA	0
,	0
a	0
PKC	9
activator	0
,	0
the	0
Zp	1
induction	0
was	0
synergistically	0
enhanced	0
.	0

1-	0
(	0
5-Isoquinolinyl	0
sulfonyl	0
)	0
-2-methylpiperazine	0
,	0
an	0
inhibitor	0
of	0
PKC	9
,	0
inhibited	0
the	0
anti-Ig	9
inducibility	0
of	0
Zp	1
.	0

Calmodulin	0
antagonists	0
,	0
compound	0
R24571	0
and	0
trifluoperazine	0
,	0
blocked	0
the	0
Zp	1
activation	0
with	0
anti-Ig	9
.	0

These	0
findings	0
suggest	0
that	0
Zp	1
responds	0
directly	0
to	0
changes	0
in	0
the	0
activity	0
of	0
both	0
PKC	9
and	0
calcium/calmodulin-dependent	9
protein	10
kinase	10
.	0

Requirement	0
of	0
tyrosine	9
kinase	10
activation	0
for	0
the	0
anti-Ig	9
-mediated	0
Zp	1
activation	0
was	0
also	0
demonstrated	0
through	0
the	0
use	0
of	0
the	0
tyrosine	0
kinase	0
inhibitor	0
herbimycin	0
.	0

These	0
cellular	9
gene	10
regulatory	10
molecules	10
induced	0
with	0
anti-Ig	0
may	0
cooperatively	0
play	0
an	0
important	0
part	0
in	0
achieving	0
efficient	0
EBV	0
activation	0
as	0
seen	0
with	0
anti-Ig	9
treatment	0
in	0
B	7
cells	8
.	0

The	0
SCL	9
protein	10
displays	0
cell-specific	0
heterogeneity	0
in	0
size	0
.	0

SCL	9
protein	10
production	0
was	0
examined	0
in	0
a	0
variety	0
of	0
hemopoietic	5
cell	6
lines	6
by	0
immunoblotting	0
using	0
specific	0
polyclonal	0
antisera	0
.	0

SCL	9
protein	10
was	0
detected	0
in	0
erythroid	5
,	6
megakaryocyte	6
,	6
mast	6
and	6
early	6
myeloid	6
cell	6
lines	6
,	0
as	0
well	0
as	0
in	0
several	0
lymphoid	5
leukemia	6
cell	6
lines	6
which	0
are	0
known	0
to	0
harbor	0
SCL	1
gene	2
rearrangements	2
.	0

In	0
most	0
cell	0
lines	0
,	0
proteins	0
of	0
molecular	0
weight	0
49	0
and	0
44	0
kDa	0
were	0
found	0
,	0
however	0
two	0
myeloid	0
cell	0
lines	0
expressed	0
only	0
lower	0
molecular	9
weight	10
species	10
of	10
24	10
and	10
22	10
kDa	10
.	0

This	0
size	0
discrepancy	0
appeared	0
to	0
be	0
due	0
to	0
cell-specific	0
translational	0
regulation	0
,	0
since	0
overexpression	0
of	0
a	0
retrovirally	0
transfected	0
SCL	1
gene	2
yielded	0
the	0
higher	0
molecular	0
weight	0
forms	0
in	0
most	0
cell	5
lines	6
(	0
GP+E-86	5
,	0
AT2.5	5
,	0
M1	5
)	0
but	0
only	0
the	0
22	9
kDa	10
form	10
in	0
the	0
myeloid	5
cell	6
line	6
,	0
WEHI-3B/D+	5
.	0

Overexpression	0
of	0
full-length	0
SCL	9
protein	10
in	0
the	0
lymphoid	5
cell	6
lines	6
,	0
SupT1	0
and	0
Raji	0
,	0
did	0
not	0
alter	0
cell	0
phenotype	0
and	0
there	0
was	0
no	0
evidence	0
for	0
autoregulation	0
of	0
SCL	9
transcription	0
.	0

The	0
restricted	0
pattern	0
of	0
SCL	9
protein	10
synthesis	0
is	0
consistent	0
with	0
the	0
restricted	0
expression	0
of	0
SCL	3
mRNA	4
documented	0
previously	0
.	0

In	0
addition	0
,	0
the	0
present	0
results	0
indicate	0
that	0
SCL	9
protein	10
size	0
was	0
determined	0
by	0
regulation	0
of	0
translation	0
in	0
a	0
cell-specific	0
manner	0
.	0

Description	0
and	0
functional	0
implications	0
of	0
a	0
novel	0
mutation	0
in	0
the	0
sex-determining	1
gene	2
SRY	1
.	0

The	0
sex-determining	0
gene	0
SRY	1
was	0
screened	0
for	0
molecular	0
alteration	0
in	0
an	0
XY	0
sex-reversed	0
female	0
by	0
single-strand	0
conformation	0
polymorphism	0
(	0
SSCP	0
)	0
technique	0
.	0

An	0
A-to-G	0
transition	0
was	0
detected	0
which	0
leads	0
to	0
an	0
exchange	0
of	0
a	0
tyrosine	0
by	0
a	0
cysteine	0
in	0
the	0
SRY	9
protein	10
.	0

The	0
affected	0
tyrosine	0
residue	0
located	0
at	0
the	0
C	9
terminus	10
of	0
the	0
DNA	9
binding	10
protein	10
is	0
evolutionarily	0
strongly	0
conserved	0
among	0
the	0
members	0
of	0
the	0
HMG	9
box	10
containing	10
proteins	10
.	0

Using	0
gel	0
shift	0
assay	0
and	0
peptide	0
synthesis	0
such	0
a	0
mutation	0
is	0
shown	0
to	0
abolish	0
the	0
SRY	1
protein	0
DNA	0
binding	0
ability	0
.	0

The	0
involvement	0
of	0
this	0
particular	0
amino	0
acid	0
in	0
the	0
binding	0
specificity	0
is	0
also	0
discussed	0
.	0

Induction	0
of	0
tyrosine	0
phosphorylation	0
and	0
T-cell	7
activation	0
by	0
vanadate	0
peroxide	0
,	0
an	0
inhibitor	0
of	0
protein	9
tyrosine	10
phosphatases	10
.	0

Rapid	0
tyrosine	0
phosphorylation	0
of	0
key	0
cellular	0
proteins	0
is	0
a	0
crucial	0
event	0
in	0
the	0
transduction	0
of	0
activation	0
signals	0
to	0
T-lymphocytes	7
.	0

The	0
regulatory	0
role	0
of	0
protein	9
tyrosine	10
phosphatases	10
(	0
PTPases	9
)	0
in	0
this	0
process	0
was	0
explored	0
by	0
studying	0
the	0
effects	0
of	0
a	0
powerful	0
PTPase	9
inhibitor	0
,	0
vanadate	0
peroxide	0
(	0
pervanadate	0
)	0
,	0
on	0
the	0
activation	0
cascade	0
of	0
Jurkat	5
human	6
leukaemic	6
T-cells	6
.	0

Pervanadate	0
induced	0
activation	0
of	0
the	0
tyrosine	9
kinases	10
lck	9
and	0
fyn	9
(	0
4-	0
and	0
3-fold	0
respectively	0
)	0
and	0
a	0
dramatic	0
increase	0
in	0
tyrosine	0
phosphorylation	0
of	0
cellular	9
proteins	10
,	0
notably	0
phospholipase	9
C	10
gamma	10
1	10
.	0

After	0
this	0
event	0
,	0
we	0
observed	0
a	0
rise	0
in	0
intracellular	0
Ca2+	0
concentration	0
,	0
corresponding	0
to	0
an	0
influx	0
.	0

This	0
effect	0
required	0
surface	0
expression	0
of	0
the	0
CD45	9
PTPase	10
and	0
was	0
not	0
observed	0
in	0
CD45-deficient	5
variants	6
of	0
Jurkat	5
cells	6
.	0

In	0
the	0
CD45-negative	5
variant	6
,	0
the	0
effect	0
of	0
pervanadate	0
on	0
tyrosine	0
phosphorylation	0
was	0
globally	0
decreased	0
and	0
some	0
phosphorylated	0
substrates	0
were	0
specifically	0
missing	0
.	0

Pervanadate	0
also	0
stimulated	0
transcription	0
of	0
the	0
c-fos	1
gene	2
and	0
accumulation	0
of	0
its	0
mRNA	3
as	0
well	0
as	0
several	0
other	0
hallmarks	0
of	0
T-lymphocyte	7
activation	0
such	0
as	0
surface	0
expression	0
of	0
the	0
CD69	0
antigen	0
and	0
the	0
interleukin	0
2	0
receptor	0
alpha-chain	0
(	0
CD25	0
)	0
.	0

Pervanadate	0
synergized	0
with	0
signals	0
delivered	0
by	0
T-cell	7
antigen	9
receptor	10
engagement	0
or	0
by	0
a	0
phorbol	0
ester	0
to	0
induce	0
interleukin	0
2	0
production	0
.	0

Pervanadate	9
activated	10
NF-kappa	10
B	10
,	0
as	0
shown	0
by	0
an	0
increase	0
in	0
DNA-binding	0
activity	0
of	0
this	0
transcription	9
factor	10
.	0

We	0
thus	0
conclude	0
that	0
PTPases	9
play	0
a	0
crucial	0
role	0
in	0
the	0
negative	0
regulation	0
of	0
signal	0
transduction	0
culminating	0
in	0
T-lymphocyte	7
activation	0
.	0

Moreover	0
,	0
induction	0
of	0
tyrosine	0
phosphorylation	0
appears	0
sufficient	0
per	0
se	0
to	0
initiate	0
a	0
complete	0
activation	0
programme	0
.	0

Activation	0
of	0
nuclear	9
factor-kappaB	10
via	0
T	9
cell	10
receptor	10
requires	0
a	0
Raf	9
kinase	10
and	0
Ca2+	0
influx	0
.	0

Functional	0
synergy	0
between	0
Raf	9
and	0
calcineurin	9
.	0

Signals	0
transduced	0
via	0
the	0
TCR	9
activate	0
the	0
transcription	9
factor	10
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
,	0
which	0
,	0
in	0
turn	0
,	0
is	0
critical	0
to	0
the	0
transcriptional	0
induction	0
of	0
many	0
genes	0
important	0
for	0
the	0
proliferation	0
and	0
expression	0
of	0
a	0
differentiated	0
phenotype	0
.	0

Treatment	0
of	0
T	7
cells	8
with	0
the	0
protein	9
kinase	10
C	10
activator	0
PMA	0
in	0
combination	0
with	0
Ca2+	0
ionophores	0
mimics	0
this	0
process	0
,	0
and	0
the	0
two	0
agents	0
are	0
often	0
substituted	0
for	0
TCR	9
stimulation	0
,	0
bypassing	0
the	0
TCR	9
.	0

Here	0
we	0
identify	0
intracellular	0
signaling	0
components	0
involved	0
in	0
activation	0
of	0
NF-kappaB	9
following	0
TCR	9
stimulation	0
.	0

TCR	9
signaling	0
was	0
triggered	0
by	0
treating	0
Jurkat	5
T	6
cells	6
with	0
PHA	9
or	0
anti-CD3	9
Abs	10
,	0
and	0
NF-kappaB	9
activation	0
was	0
monitored	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
and/or	0
by	0
kappaB	9
-dependent	0
reporter	0
assays	0
.	0

Contrary	0
to	0
the	0
idea	0
that	0
protein	9
kinase	10
C	10
is	0
involved	0
in	0
TCR	9
-mediated	0
activation	0
of	0
NF-kappaB	9
,	0
high	0
doses	0
of	0
staurosporine	0
did	0
not	0
interfere	0
with	0
activation	0
of	0
NF-kappaB	9
by	0
PHA	9
,	0
while	0
the	0
same	0
dose	0
of	0
staurosporine	0
completely	0
blocked	0
activation	0
by	0
PMA	0
.	0

PHA	9
-induced	0
kappaB-dependent	0
reporter	0
activity	0
was	0
,	0
however	0
,	0
effectively	0
blocked	0
by	0
a	0
dominant	0
negative	0
form	0
of	0
Raf-1	9
,	0
suggesting	0
a	0
critical	0
role	0
for	0
a	0
Raf	9
kinase	10
.	0

The	0
TCR	9
-mediated	0
activation	0
of	0
NF-kappaB	9
was	0
also	0
dependent	0
on	0
a	0
Ca2+	0
influx	0
,	0
because	0
the	0
Ca2+	0
channel	0
blocker	0
,	0
SK	0
&	0
F	0
96365	0
,	0
as	0
well	0
as	0
other	0
agents	0
that	0
prevented	0
the	0
Ca2+	0
influx	0
,	0
inhibited	0
NF-kappaB	9
activation	0
.	0

Cotransfection	0
of	0
a	0
constitutively	0
active	0
form	0
of	0
calcineurin	9
largely	0
substituted	0
for	0
the	0
Ca2+	0
requirement	0
and	0
reversed	0
the	0
blockade	0
by	0
SK	0
&	0
F	0
96365	0
.	0

Consistent	0
with	0
these	0
observations	0
,	0
coexpression	0
of	0
constitutively	0
active	0
forms	0
of	0
Raf-1	9
and	0
calcineurin	9
synergistically	0
induced	0
kappaB	9
-dependent	0
reporter	0
activity	0
,	0
suggesting	0
a	0
physiologically	0
relevant	0
functional	0
interaction	0
between	0
the	0
kinase	9
and	0
the	0
phosphatase	9
.	0

Synergistic	0
interactions	0
between	0
overlapping	1
binding	2
sites	2
for	0
the	0
serum	9
response	10
factor	10
and	0
ELK-1	9
proteins	10
mediate	0
both	0
basal	0
enhancement	0
and	0
phorbol	0
ester	0
responsiveness	0
of	0
primate	1
cytomegalovirus	2
major	2
immediate-early	2
promoters	2
in	0
monocyte	0
and	0
T-lymphocyte	7
cell	0
types	0
.	0

Cytomegalovirus	0
(	0
CMV	0
)	0
infection	0
is	0
nonpermissive	0
or	0
persistent	0
in	0
many	0
lymphoid	7
and	8
myeloid	8
cell	8
types	8
but	0
can	0
be	0
activated	0
in	0
differentiated	7
macrophages	8
.	0

We	0
have	0
shown	0
elsewhere	0
that	0
both	0
the	0
major	1
immediate-early	2
gene	2
(	0
MIE	1
)	0
and	0
lytic	0
cycle	0
infectious	0
progeny	0
virus	0
expression	0
can	0
be	0
induced	0
in	0
otherwise	0
nonpermissive	0
monocyte-like	5
U-937	6
cell	6
cultures	6
infected	0
with	0
either	0
human	0
CMV	0
(	0
HCMV	0
)	0
or	0
simian	0
CMV	0
(	0
SCMV	0
)	0
by	0
treatment	0
with	0
the	0
phorbol	0
ester	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
.	0

Two	0
multicopy	1
basal	2
enhancer	2
motifs	2
within	0
the	0
SCMV	0
MIE	1
enhancer	2
,	0
namely	0
,	0
11	0
copies	0
of	0
the	0
16-bp	0
cyclic	1
AMP	2
response	2
element	2
(	0
CRE	1
)	0
and	0
3	0
copies	0
of	0
novel	0
17-bp	0
serum	1
response	2
factor	2
(	2
SRF	2
)	2
binding	2
sites	2
referred	0
to	0
as	0
the	0
SNE	1
(	0
SRF/NFkappaB-like	1
element	2
)	0
,	0
as	0
well	0
as	0
four	0
classical	0
NFkappaB	1
sites	2
within	0
the	0
HCMV	0
version	0
,	0
contribute	0
to	0
TPA	0
responsiveness	0
in	0
transient	0
assays	0
in	0
monocyte	7
and	8
T-cell	8
types	8
.	0

The	0
SCMV	1
SNE	2
sites	2
contain	0
potential	0
overlapping	0
core	0
recognition	0
binding	0
motifs	0
for	0
SRF	9
,	0
Rel/NFkappaB	9
,	0
ETS	9
,	0
and	0
YY1	9
class	10
transcription	10
factors	10
but	0
fail	0
to	0
respond	0
to	0
either	0
serum	9
or	10
tumor	10
necrosis	10
factor	10
alpha	10
.	0

Therefore	0
,	0
to	0
evaluate	0
the	0
mechanism	0
of	0
TPA	0
responsiveness	0
of	0
the	0
SNE	1
motifs	2
and	0
of	0
a	0
related	0
16-bp	0
SEE	1
(	0
SRF/ETS	1
element	2
)	0
motif	0
found	0
in	0
the	0
HCMV	1
and	2
chimpanzee	2
CMV	2
MIE	2
enhancers	2
,	0
we	0
have	0
examined	0
the	0
functional	0
responses	0
and	0
protein	0
binding	0
properties	0
of	0
multimerized	1
wild-type	2
and	2
mutant	2
elements	2
added	0
upstream	0
to	0
the	0
SCMV	1
MIE	2
or	0
simian	1
virus	2
40	2
minimal	2
promoter	2
regions	2
in	0
the	0
U-937	5
,	0
K-562	5
,	0
HL-60	5
,	0
THP-1	5
,	0
and	0
Jurkat	5
cell	6
lines	6
.	0

Unlike	0
classical	0
NFkappaB	1
sites	2
,	0
neither	0
the	0
SNE	1
nor	0
the	0
SEE	1
motif	2
responded	0
to	0
phosphatase	0
inhibition	0
by	0
okadaic	0
acid	0
.	0

However	0
,	0
the	0
TPA	0
responsiveness	0
of	0
both	0
CMV	1
elements	2
proved	0
to	0
involve	0
synergistic	0
interactions	0
between	0
the	0
core	0
SRF	1
binding	2
site	2
(	0
CCATATATGG	0
)	0
and	0
the	0
adjacent	0
inverted	0
ETS	1
binding	2
motifs	2
(	0
TTCC	0
)	0
,	0
which	0
correlated	0
directly	0
with	0
formation	0
of	0
a	0
bound	0
tripartite	9
complex	10
containing	0
both	0
the	0
cellular	0
SRF	9
and	0
ELK-1	9
proteins	10
.	0

This	0
protein	9
complex	10
was	0
more	0
abundant	0
in	0
U-937	0
,	0
K-562	0
,	0
and	0
HeLa	0
cell	0
extracts	0
than	0
in	0
Raji	5
,	0
HF	5
,	0
BALB/c	5
3T3	6
,	0
or	0
HL-60	5
cells	6
,	0
but	0
the	0
binding	0
activity	0
was	0
altered	0
only	0
twofold	0
after	0
TPA	0
treatment	0
.	0

A	0
40-fold	0
stimulation	0
of	0
chloramphenicol	9
acetyltransferase	10
activity	0
mediated	0
by	0
four	0
tandem	1
repeats	2
of	0
the	0
SNE	1
could	0
be	0
induced	0
within	0
2	0
h	0
(	0
and	0
up	0
to	0
250-fold	0
within	0
6	0
h	0
)	0
after	0
addition	0
of	0
TPA	0
in	0
DNA-transfected	5
U-937	6
cells	6
,	0
indicating	0
that	0
the	0
stimulation	0
appeared	0
likely	0
to	0
be	0
a	0
true	0
protein	9
kinase	10
C	10
-mediated	0
signal	0
transduction	0
event	0
rather	0
than	0
a	0
differentiation	0
response	0
.	0

Slight	0
differences	0
in	0
the	0
sequence	0
of	0
the	0
core	1
SRF	2
binding	2
site	2
compared	0
with	0
that	0
of	0
the	0
classical	0
c-Fos	1
promoter	2
serum	2
response	2
element	2
,	0
together	0
with	0
differences	0
in	0
the	0
spacing	0
between	0
the	0
SRF	1
and	2
ETS	2
motifs	2
,	0
appear	0
to	0
account	0
for	0
the	0
inability	0
of	0
the	0
SCMV	1
SNEs	2
to	0
respond	0
to	0
serum	0
induction	0
.	0

T-cell	7
-directed	0
TAL-1	9
expression	0
induces	0
T-cell	0
malignancies	0
in	0
transgenic	0
mice	0
.	0

The	0
TAL-1	1
gene	2
specifies	0
for	0
a	0
basic	0
domain-helix-loop-helix	9
protein	10
,	0
which	0
is	0
involved	0
in	0
the	0
control	0
of	0
normal	0
hematopoiesis	0
.	0

In	0
human	0
pathology	0
,	0
the	0
TAL-1	9
gene	10
product	10
is	0
expressed	0
in	0
a	0
high	0
percentage	0
of	0
T-cell	7
acute	0
lymphoblastic	0
leukemias	0
in	0
the	0
pediatric	0
age	0
range	0
;	0
however	0
,	0
it	0
has	0
not	0
been	0
established	0
whether	0
the	0
expression	0
has	0
a	0
causal	0
role	0
in	0
oncogenesis	0
.	0

In	0
this	0
report	0
,	0
we	0
describe	0
the	0
phenotype	0
of	0
mouse	5
transgenic	6
lines	6
obtained	0
by	0
inducing	0
tal-1	9
protein	10
expression	0
in	0
lymphoid	0
tissues	0
using	0
the	0
LCK	1
promoter	2
.	0

The	0
survival	0
rate	0
of	0
tal-1	1
transgenic	0
animals	0
was	0
much	0
lower	0
as	0
compared	0
with	0
control	0
mice	0
.	0

Histopathological	0
analysis	0
revealed	0
lymphomas	0
of	0
T-cell	0
type	0
,	0
often	0
comprising	0
a	0
minor	0
B-cell	0
component	0
.	0

Some	0
mice	0
showed	0
marked	0
splenic	0
lymphocyte	0
depletion	0
.	0

Primary	5
lymphocyte	6
cultures	6
showed	0
partial	0
independence	0
from	0
exogenous	0
growth	0
stimuli	0
and	0
increased	0
resistance	0
to	0
low-serum	0
apoptosis	0
.	0

To	0
further	0
unravel	0
the	0
tal-1	1
oncogenic	0
potential	0
,	0
a	0
strain	0
of	0
tal-1	1
transgenic	0
mice	0
was	0
crossbred	0
with	0
p53-/-	0
mice	0
;	0
the	0
survival	0
rate	0
in	0
these	0
animals	0
was	0
reduced	0
by	0
more	0
than	0
one-half	0
when	0
compared	0
with	0
that	0
of	0
tal-1	1
mice	0
,	0
and	0
histopathological	0
analysis	0
revealed	0
exclusively	0
T-cell	7
lymphomas	0
.	0

These	0
data	0
indicate	0
that	0
TAL-1	9
,	0
expressed	0
in	0
T	7
cells	8
,	0
is	0
per	0
se	0
a	0
potent	0
oncogene	0
,	0
which	0
may	0
exert	0
a	0
key	0
leukemogenetic	0
role	0
in	0
the	0
majority	0
of	0
T-cell	7
acute	0
lymphoblastic	0
leukemias	0
.	0

Tissue	0
and	0
cell-type	0
specific	0
expression	0
of	0
the	0
tuberous	1
sclerosis	2
gene	2
,	0
TSC2	1
,	0
in	0
human	0
tissues	0
.	0

TSC2	1
is	0
a	0
gene	0
on	0
chromosome	1
16p13.3	2
associated	0
with	0
the	0
autosomal	0
dominant	0
neurocutaneous	0
disorder	0
,	0
tuberous	0
sclerosis	0
complex	0
(	0
TSC	0
)	0
.	0

By	0
using	0
a	0
partial	0
nucleotide	0
sequence	0
from	0
the	0
cloned	0
TSC2	1
and	0
polymerase	0
chain	0
reaction	0
methodology	0
,	0
we	0
constructed	0
a	0
digoxigenin-labeled	1
complementary	2
DNA	2
probe	2
to	0
examine	0
TSC2	1
gene	0
expression	0
in	0
autopsy-	0
or	0
biopsy-derived	0
human	0
tissues	0
by	0
in	0
situ	0
hybridization	0
.	0

TSC2	3
messenger	4
RNA	4
was	0
widely	0
expressed	0
in	0
various	0
cell	0
types	0
throughout	0
the	0
body	0
,	0
including	0
epithelia	0
,	0
lymphocytes	7
,	0
and	0
cells	0
with	0
endocrine	0
functions	0
,	0
e.g.	0
,	0
adrenal	0
cortex	0
and	0
anterior	0
pituitary	0
.	0

It	0
was	0
prominently	0
and	0
selectively	0
(	0
within	0
the	0
central	0
nervous	0
system	0
)	0
expressed	0
in	0
pyramidal	7
cells	8
of	0
the	0
cerebral	0
cortex	0
and	0
other	0
motor	7
neurons	8
,	0
e.g.	0
,	0
in	0
spinal	0
cord	0
and	0
brainstem	0
nuclei	0
.	0

Visceral	0
TSC2	1
expression	0
was	0
comparable	0
in	0
autopsy	0
tissues	0
from	0
patients	0
with	0
and	0
without	0
TSC	0
;	0
TSC2	1
messenger	0
RNA	0
expression	0
was	0
most	0
prominent	0
in	0
cells	0
with	0
a	0
rapid	0
mitotic	0
rate	0
and	0
turnover	0
,	0
e.g.	0
,	0
epithelia	0
and	0
lymphocytes	7
,	0
with	0
central	0
nervous	0
system	0
pyramidal	7
cells	8
and	0
other	0
neurons	0
being	0
an	0
obvious	0
exception	0
,	0
and/or	0
in	0
cells	0
with	0
important	0
secretory/transport	0
functions	0
.	0

This	0
widespread	0
expression	0
of	0
the	0
TSC2	1
gene	2
supports	0
the	0
view	0
that	0
it	0
encodes	0
a	0
protein	0
vital	0
to	0
cell	0
growth	0
and	0
metabolism	0
or	0
one	0
that	0
functions	0
as	0
a	0
tumor/growth	0
suppressor	0
.	0

Apoptosis	0
signaling	0
pathways	0
in	0
normal	0
T	7
cells	8
:	0
differential	0
activity	0
of	0
Bcl-2	9
and	0
IL-1beta-converting	9
enzyme	10
family	10
protease	0
inhibitors	0
on	0
glucocorticoid-	0
and	0
Fas-mediated	0
cytotoxicity	0
.	0

Fas	9
-mediated	0
apoptosis	0
plays	0
an	0
important	0
role	0
in	0
regulating	0
the	0
immune	0
response	0
in	0
peripheral	7
T	8
cells	8
.	0

Restimulation	0
of	0
T	7
cell	8
blasts	8
up-regulates	0
Fas	9
and	0
Fas	9
ligand	0
expression	0
,	0
with	0
subsequent	0
interaction	0
leading	0
to	0
cell	0
death	0
.	0

Overexpression	0
of	0
Bcl-2	9
in	0
tumor	7
cells	8
blocks	0
apoptosis	0
induced	0
by	0
many	0
stimuli	0
,	0
but	0
inhibition	0
of	0
Fas	9
-mediated	0
killing	0
has	0
not	0
been	0
consistently	0
observed	0
.	0

To	0
examine	0
the	0
behavior	0
of	0
Bcl-2	9
in	0
normal	7
cells	8
,	0
T	7
cell	8
blasts	8
were	0
transiently	0
transfected	0
with	0
Bcl-2	9
and	0
related	0
gene	9
products	10
to	0
determine	0
the	0
effect	0
on	0
apoptotic	0
signaling	0
.	0

Transient	0
overexpression	0
of	0
Bcl-2	9
in	0
mouse	0
and	0
human	0
T	7
cell	8
blasts	8
did	0
not	0
block	0
Fas	9
-mediated	0
apoptosis	0
,	0
whereas	0
etoposide-	0
and	0
glucocorticoid-induced	0
cytotoxicity	0
was	0
potently	0
inhibited	0
.	0

Expression	0
of	0
Bcl-xL	9
and	0
adenovirus	9
E1B	10
19K	10
did	0
not	0
interfere	0
with	0
anti-	0
Fas	9
killing	0
.	0

In	0
contrast	0
,	0
interleukin-1beta-converting	0
enzyme	0
family	0
protease	0
inhibitors	0
Ac-DEVD-CHO	0
and	0
CrmA	0
blocked	0
Fas	9
-mediated	0
apoptosis	0
.	0

These	0
results	0
suggest	0
that	0
peripheral	7
T	8
cells	8
use	0
distinct	0
apoptosis	0
signaling	0
pathways	0
with	0
differential	0
sensitivity	0
to	0
Bcl-2	9
and	0
interleukin-1beta-converting	0
enzyme	0
family	0
protease	0
inhibitors	0
.	0

Since	0
T	7
cells	8
normally	0
express	0
Bcl-2	9
and	0
Bcl-xL	9
following	0
activation	0
,	0
their	0
inability	0
to	0
block	0
Fas	9
-mediated	0
apoptosis	0
may	0
allow	0
for	0
the	0
elimination	0
of	0
self-reactive	7
cells	8
and	0
the	0
appropriate	0
regulation	0
of	0
immune	0
responses	0
.	0

Increased	0
interleukin	9
2	10
transcription	0
in	0
murine	7
lymphocytes	8
by	0
ciprofloxacin	0
.	0

The	0
fluoroquinolone	0
antibiotic	0
,	0
ciprofloxacin	0
(	0
cipro	0
)	0
,	0
induces	0
hyperproduction	0
of	0
interleukin	9
2	10
(	0
IL-2	9
)	0
and	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
in	0
stimulated	0
human	7
peripheral	8
blood	8
lymphocytes	8
.	0

In	0
this	0
investigation	0
an	0
enhanced	0
and	0
prolonged	0
IL-2	9
and	0
IL-2	3
mRNA	4
response	0
was	0
also	0
detected	0
in	0
both	0
stimulated	0
(	0
T	9
cell	10
mitogens	10
or	0
alloantigens	9
)	0
murine	7
splenocytes	8
and	0
in	0
the	0
stimulated	0
murine	5
T	6
cell	6
line	6
EL-4	6
in	0
the	0
presence	0
of	0
ciprofloxacin	0
(	0
5-80	0
micrograms/ml	0
)	0
as	0
compared	0
to	0
control	0
cells	0
without	0
antibiotics	0
.	0

However	0
,	0
in	0
contrast	0
to	0
human	7
lymphocytes	8
,	0
IFN-gamma	9
production	0
was	0
inhibited	0
and	0
IFN-gamma	3
mRNA	4
levels	0
were	0
unaffected	0
at	0
24	0
h	0
and	0
only	0
slightly	0
upregulated	0
at	0
48	0
and	0
72	0
h	0
of	0
culture	0
in	0
murine	7
splenocytes	8
incubated	0
with	0
cipro	0
(	0
20	0
micrograms/ml	0
)	0
.	0

EL-4	7
cells	8
were	0
transfected	0
with	0
a	0
plasmid	0
containing	0
the	0
IL-2	1
promoter	2
and	0
enhancer	1
region	2
linked	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
reporter	2
gene	2
.	0

Analysis	0
of	0
CAT	9
activity	0
revealed	0
that	0
cipro	0
enhanced	0
IL-2	0
gene	0
induction	0
.	0

In	0
addition	0
,	0
EL-4	7
cells	8
incubated	0
with	0
ciprofloxacin	0
showed	0
an	0
early	0
peak	0
and	0
more	0
activated	0
nuclear	0
factor	0
of	0
activated	7
T	8
cells	8
(	0
NFAT-1	9
)	0
as	0
compared	0
to	0
control	0
cells	0
without	0
antibiotics	0
.	0

Cipro	0
did	0
not	0
affect	0
the	0
nuclear	9
transcription	10
factors	10
AP-1	9
or	0
NFIL-2A	9
.	0

Taken	0
together	0
,	0
cipro	0
inhibited	0
IFN-gamma	9
synthesis	0
,	0
but	0
enhanced	0
IL-2	9
production	0
in	0
murine	7
lymphocytes	8
by	0
means	0
of	0
influencing	0
NFAT-1	9
and	0
causing	0
an	0
increased	0
IL-2	9
transcription	0
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
Tax	9
associates	0
with	0
and	0
is	0
negatively	0
regulated	0
by	0
the	0
NF-kappa	9
B2	10
p100	10
gene	10
product	10
:	0
implications	0
for	0
viral	0
latency	0
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
is	0
the	0
etiologic	0
agent	0
of	0
the	0
adult	0
T-cell	0
leukemia	0
,	0
an	0
aggressive	0
and	0
often	0
fatal	0
malignancy	0
of	0
activated	5
human	6
CD4	6
T	6
cells	6
.	0

HTLV-I	0
encodes	0
an	0
essential	0
40-kDa	9
protein	10
termed	0
Tax	9
that	0
not	0
only	0
transactivates	0
the	0
long	0
terminal	0
repeat	0
of	0
this	0
retrovirus	0
but	0
also	0
induces	0
an	0
array	0
of	0
cellular	1
genes	2
.	0

Tax	9
-mediated	0
transformation	0
of	0
T	7
cells	8
likely	0
involves	0
the	0
deregulated	0
expression	0
of	0
various	0
cellular	1
genes	2
that	0
normally	0
regulate	0
lymphocyte	7
growth	0
produced	0
by	0
altered	0
activity	0
of	0
various	0
endogenous	0
host	0
transcription	9
factors	10
.	0

In	0
particular	0
,	0
Tax	9
is	0
capable	0
of	0
modulating	0
the	0
expression	0
or	0
activity	0
of	0
various	0
host	0
transcription	9
factors	10
,	0
including	0
members	0
of	0
the	0
NF-kappa	9
B/Rel	10
and	0
CREB/ATF	9
families	10
,	0
as	0
well	0
as	0
the	0
cellular	9
factors	10
HEB-1	9
and	0
p67SRF	9
.	0

An	0
additional	0
distinguishing	0
characteristic	0
of	0
HTLV-I	0
infection	0
is	0
the	0
profound	0
state	0
of	0
viral	0
latency	0
that	0
is	0
present	0
in	0
circulating	0
primary	7
leukemic	8
T	8
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
HTLV-I	0
Tax	9
can	0
physically	0
associate	0
with	0
p100	9
,	0
the	0
product	0
of	0
the	0
Rel-related	1
NF-kappa	2
B2	2
gene	2
,	0
both	0
in	0
transfected	5
cells	6
and	0
in	0
HTLV-I-infected	5
leukemic	6
T-cell	6
lines	6
.	0

Furthermore	0
,	0
the	0
physical	0
interaction	0
of	0
Tax	9
with	0
p100	9
leads	0
to	0
the	0
inhibition	0
of	0
Tax	9
-induced	0
activation	0
of	0
the	0
HTLV-I	0
and	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeats	2
,	0
reflecting	0
p100	9
-mediated	0
cytoplasmic	0
sequestration	0
of	0
the	0
normally	0
nuclearly	0
expressed	0
Tax	9
protein	10
.	0

In	0
contrast	0
,	0
a	0
mutant	0
of	0
Tax	9
that	0
selectively	0
fails	0
to	0
activate	0
nuclear	0
NF-kappa	9
B	10
expression	0
does	0
not	0
associate	0
with	0
p100	9
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Rhabdomyosarcomas	0
do	0
not	0
contain	0
mutations	0
in	0
the	0
DNA	0
binding	0
domains	0
of	0
myogenic	0
transcription	9
factors	10
.	0

Skeletal	0
myogenesis	0
is	0
regulated	0
by	0
a	0
group	0
of	0
transcription	9
factors	10
(	0
MyoD	9
,	0
myogenin	9
,	0
myf5	9
,	0
and	0
myf6	9
)	0
that	0
are	0
``	9
basic	10
helix-loop-helix	10
''	10
proteins	10
that	0
bind	0
to	0
the	0
promoters	1
of	0
muscle-specific	1
genes	2
and	0
promote	0
their	0
expression	0
.	0

We	0
have	0
previously	0
shown	0
that	0
after	0
a	0
mutation	0
of	0
Leu122	0
to	0
Arg	0
the	0
DNA	9
binding	10
basic	10
domain	10
of	0
MyoD	9
confers	0
c-myc	1
-like	0
functional	0
characteristics	0
to	0
the	0
protein	0
.	0

In	0
this	0
study	0
we	0
used	0
single-strand	0
conformation	0
polymorphism	0
analysis	0
to	0
determine	0
whether	0
such	0
mutations	0
occur	0
naturally	0
in	0
rhabdomyosarcomas	0
.	0

We	0
have	0
found	0
that	0
the	0
basic	9
domains	10
of	0
all	0
the	0
myogenic	9
factors	10
remain	0
unaltered	0
in	0
rhabdomyosarcomas	0
.	0

Selection	0
against	0
such	0
mutations	0
may	0
be	0
the	0
result	0
of	0
functional	0
redundancy	0
of	0
these	0
myogenic	9
transcription	10
factors	10
.	0

Function	0
and	0
activation	0
of	0
NF-kappa	9
B	10
in	0
the	0
immune	0
system	0
.	0

NF-kappa	9
B	10
is	0
a	0
ubiquitous	9
transcription	10
factor	10
.	0

Nevertheless	0
,	0
its	0
properties	0
seem	0
to	0
be	0
most	0
extensively	0
exploited	0
in	0
cells	0
of	0
the	0
immune	0
system	0
.	0

Among	0
these	0
properties	0
are	0
NF-kappa	9
B	10
's	0
rapid	0
posttranslational	0
activation	0
in	0
response	0
to	0
many	0
pathogenic	0
signals	0
,	0
its	0
direct	0
participation	0
in	0
cytoplasmic/nuclear	0
signaling	0
,	0
and	0
its	0
potency	0
to	0
activate	0
transcription	0
of	0
a	0
great	0
variety	0
of	0
genes	0
encoding	0
immunologically	9
relevant	10
proteins	10
.	0

In	0
vertebrates	0
,	0
five	0
distinct	0
DNA	9
binding	10
subunits	10
are	0
currently	0
known	0
which	0
might	0
extensively	0
heterodimerize	0
,	0
thereby	0
forming	0
complexes	0
with	0
distinct	0
transcriptional	0
activity	0
,	0
DNA	0
sequence	0
specificity	0
,	0
and	0
cell	0
type-	0
and	0
cell	0
stage-specific	0
distribution	0
.	0

The	0
activity	0
of	0
DNA	9
binding	10
NF-kappa	10
B	10
dimers	10
is	0
tightly	0
controlled	0
by	0
accessory	9
proteins	10
called	0
I	9
kappa	10
B	10
subunits	10
of	0
which	0
there	0
are	0
also	0
five	0
different	0
species	0
currently	0
known	0
in	0
vertebrates	0
.	0

I	9
kappa	10
B	10
proteins	10
inhibit	0
DNA	0
binding	0
and	0
prevent	0
nuclear	0
uptake	0
of	0
NF-kappa	9
B	10
complexes	10
.	0

An	0
exception	0
is	0
the	0
Bcl-3	9
protein	10
which	0
in	0
addition	0
can	0
function	0
as	0
a	0
transcription	9
activating	10
subunit	10
in	0
th	0
nucleus	0
.	0

Other	0
I	9
kappa	10
B	10
proteins	10
are	0
rather	0
involved	0
in	0
terminating	0
NF-kappa	9
B	10
's	0
activity	0
in	0
the	0
nucleus	0
.	0

The	0
intracellular	0
events	0
that	0
lead	0
to	0
the	0
inactivation	0
of	0
I	9
kappa	10
B	10
,	0
i.e.	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
are	0
complex	0
.	0

They	0
involve	0
phosphorylation	0
and	0
proteolytic	0
reactions	0
and	0
seem	0
to	0
be	0
controlled	0
by	0
the	0
cells	0
'	0
redox	0
status	0
.	0

Interference	0
with	0
the	0
activation	0
or	0
activity	0
of	0
NF-kappa	9
B	10
may	0
be	0
beneficial	0
in	0
suppressing	0
toxic/septic	0
shock	0
,	0
graft-vs-host	0
reactions	0
,	0
acute	0
inflammatory	0
reactions	0
,	0
acute	0
phase	0
response	0
,	0
and	0
radiation	0
damage	0
.	0

The	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
by	0
antioxidants	0
and	0
specific	0
protease	0
inhibitors	0
may	0
provide	0
a	0
pharmacological	0
basis	0
for	0
interfering	0
with	0
these	0
acute	0
processes	0
.	0

Lack	0
of	0
T-cell-mediated	0
recognition	0
of	0
the	0
fusion	0
region	0
of	0
the	0
pml/RAR-alpha	9
hybrid	10
protein	10
by	0
lymphocytes	7
of	0
acute	0
promyelocytic	0
leukemia	0
patients	0
.	0

In	0
previous	0
studies	0
,	0
it	0
was	0
shown	0
that	0
the	0
fusion	0
region	0
of	0
the	0
pml/RAR-alpha	9
protein	10
,	0
expressed	0
by	0
acute	5
promyelocytic	6
leukemia	6
(	6
APL	6
)	6
cells	6
,	0
can	0
be	0
specifically	0
recognized	0
in	0
vitro	0
by	0
donor	0
(	0
D.	0
E.	0
)	0
CD4	5
T	6
cells	6
in	0
a	0
HLA	9
class	10
II	10
DR11-restricted	0
fashion	0
.	0

We	0
present	0
here	0
the	0
results	0
on	0
the	0
recognition	0
of	0
several	0
pml/RAR-alpha	0
peptides	0
by	0
APL	0
patients	0
expressing	0
HLA	9
DR11	10
.	0

The	0
in	0
vitro	0
immunization	0
of	0
peripheral	7
blood	8
lymphocytes	8
from	0
four	0
patients	0
in	0
remission	0
(	0
S.R.	0
,	0
F.R.	0
,	0
M.M.	0
,	0
P.	0
G.	0
)	0
with	0
BCR1/25	0
,	0
a	0
25-mer	0
pml/	0
RAR-alpha	9
,	0
did	0
not	0
elicit	0
either	0
a	0
polyclonal	0
or	0
a	0
clonal	0
immune	0
response	0
specific	0
to	0
the	0
peptide	0
.	0

We	0
then	0
generated	0
new	0
donor	0
anti-pml/RAR-alpha	5
CD4	6
(	6
+	6
)	6
T-cell	6
clones	6
.	0

These	0
clones	0
were	0
tested	0
for	0
their	0
recognition	0
of	0
BCR1/25	0
.	0

One	0
clone	0
(	0
C3/5	5
,	6
CD3	6
(	6
+	6
)	6
,	6
CD4	6
(	6
+	6
)	6
,	6
CD8	6
(	6
-	6
)	6
)	0
was	0
selected	0
for	0
further	0
analysis	0
.	0

Clone	5
C3/5	6
showed	0
specific	0
proliferation	0
,	0
cytotoxicity	0
,	0
and	0
cytokine	0
(	0
tumor	9
necrosis	10
factor	10
alpha	10
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
)	0
production	0
when	0
challenged	0
with	0
autologous	5
lymphoblastic	6
cell	6
lines	6
pulsed	0
with	0
peptide	0
BCR1/25	0
.	0

C3/5	5
cells	6
developed	0
specific	0
proliferation	0
and	0
cytotoxicity	0
when	0
challenged	0
with	0
peptide-pulsed	5
lymphoblastic	6
cell	6
lines	6
and	0
peripheral	7
blood	8
lymphocytes	8
from	0
the	0
four	0
DR11	0
(	0
+	0
)	0
APL	0
patients	0
.	0

APL	7
blasts	8
,	0
available	0
only	0
from	0
patients	0
F.R.	0
and	0
P.G.	0
,	0
were	0
not	0
lysed	0
by	0
C3/5	5
and	0
were	0
unable	0
to	0
present	0
peptide	0
BCR1/25	0
.	0

Incubation	0
of	0
APL	5
cells	6
with	0
IFN-gamma	9
failed	0
to	0
induce	0
HLA	9
class	10
II	10
molecules	10
and	0
recognition	0
by	0
the	0
C3/5	5
clone	6
.	0

Since	0
APL	5
cells	6
do	0
not	0
express	0
HLA	9
class	10
II	10
molecules	10
,	0
we	0
tested	0
in	0
two	0
donors	0
(	0
D.E.	0
and	0
C.H.R.	0
)	0
and	0
in	0
patients	0
S.R.and	0
P.G.whether	0
the	0
use	0
of	0
9-mer	0
peptides	0
(	0
BCR1/9	0
)	0
would	0
generate	0
a	0
CD8	9
/HLA	9
class	10
I	10
-restricted	0
response	0
.	0

No	0
peptide-specific	5
T-cell	6
line	6
or	0
clone	0
could	0
be	0
generated	0
from	0
both	0
donors	0
and	0
patients	0
.	0

These	0
findings	0
are	0
discussed	0
in	0
relation	0
to	0
possible	0
therapeutic	0
approaches	0
to	0
the	0
immunotherapy	0
of	0
APL	0
.	0

The	0
proximal	0
regulatory	0
element	0
of	0
the	0
interferon-gamma	1
promoter	2
mediates	0
selective	0
expression	0
in	0
T	7
cells	8
.	0

Interferon-gamma	9
(	0
IFN-gamma	9
)	0
is	0
produced	0
by	0
natural	7
killer	8
cells	8
and	0
certain	0
subsets	0
of	0
T	7
cells	8
,	0
but	0
the	0
basis	0
for	0
its	0
selective	0
expression	0
is	0
unknown	0
.	0

Within	0
the	0
region	0
between	0
-108	0
and	0
-40	0
base	0
pairs	0
of	0
the	0
IFN-gamma	9
promoter	0
are	0
two	0
conserved	0
and	0
essential	0
regulatory	1
elements	2
,	0
which	0
confer	0
activation-specific	0
expression	0
in	0
T	7
cells	8
.	0

This	0
report	0
describes	0
studies	0
indicating	0
that	0
the	0
most	0
proximal	0
of	0
these	0
two	0
regulatory	1
elements	2
is	0
an	0
important	0
determinant	0
of	0
its	0
restricted	0
expression	0
.	0

The	0
proximal	0
element	0
is	0
a	0
composite	0
site	0
that	0
binds	0
members	0
of	0
the	0
CREB/ATF	9
,	0
AP-1	9
,	0
and	0
octamer	9
families	10
of	0
transcription	9
factors	10
.	0

Jun	9
is	0
essential	0
for	0
activation-induced	0
transcription	0
and	0
binds	0
preferably	0
as	0
a	0
heterodimer	0
with	0
ATF-2	9
.	0

In	0
contrast	0
,	0
CREB	9
appears	0
to	0
dampen	0
transcription	0
from	0
this	0
element	0
.	0

The	0
CpG	0
dinucleotide	0
in	0
this	0
element	1
is	0
selectively	0
methylated	0
in	0
Th2	7
T	8
cells	8
and	0
other	0
cells	0
that	0
do	0
not	0
express	0
IFN-gamma	9
,	0
and	0
methylation	0
markedly	0
reduces	0
transcription	9
factor	10
binding	0
.	0

As	0
a	0
target	0
for	0
DNA	0
methylation	0
and	0
for	0
binding	0
of	0
transcription	9
factors	10
that	0
mediate	0
or	0
impede	0
transcription	0
,	0
this	0
element	0
appears	0
to	0
play	0
a	0
central	0
role	0
in	0
controlling	0
IFN-gamma	9
expression	0
.	0

CD40	9
,	0
but	0
not	0
lipopolysaccharide	0
and	0
anti-IgM	9
stimulation	0
of	0
primary	7
B	8
lymphocytes	8
,	0
leads	0
to	0
a	0
persistent	0
nuclear	0
accumulation	0
of	0
RelB	9
.	0

In	0
this	0
study	0
we	0
analyzed	0
the	0
effect	0
of	0
CD40	9
stimulation	0
on	0
the	0
activity	0
and	0
nuclear	0
appearance	0
of	0
Rel/nuclear	9
factor	10
kappaB	10
(	10
NF-kappaB	10
)	10
factors	10
in	0
primary	7
murine	8
B	8
lymphocytes	8
.	0

We	0
show	0
that	0
triggering	0
of	0
CD40	9
signaling	0
pathway	0
(	0
s	0
)	0
by	0
CD40	9
ligands	10
expressed	0
on	0
L	7
cells	8
led	0
to	0
strong	0
activation	0
of	0
an	0
NF-kappaB-controlled	1
beta-globin	2
reporter	2
gene	2
in	0
primary	7
B	8
lymphocytes	8
from	0
transgenic	0
mice	0
.	0

Analyses	0
of	0
nuclear	0
translocation	0
of	0
individual	0
members	0
of	0
Rel	9
proteins	10
after	0
CD40	9
induction	0
of	0
primary	7
B	8
cells	8
showed	0
a	0
strong	0
and	0
long-lasting	0
accumulation	0
of	0
RelB	9
and	0
,	0
less	0
pronounced	0
,	0
of	0
c-Rel	9
.	0

LPS	0
stimulation	0
did	0
not	0
give	0
rise	0
to	0
a	0
persistent	0
nuclear	0
accumulation	0
of	0
RelB	9
and	0
c-Rel	9
,	0
whereas	0
nuclear	0
c-Rel	9
,	0
but	0
not	0
RelB	9
,	0
accumulated	0
after	0
B	0
cell	0
receptor	0
stimulation	0
.	0

CD40	9
induced	0
not	0
only	0
nuclear	0
translocation	0
but	0
also	0
de	0
novo	0
synthesis	0
of	0
RelB	3
RNA	4
and	0
protein	0
.	0

S107	5
plasmacytoma	6
cells	6
,	0
which	0
express	0
CD40	9
but	0
are	0
defective	0
for	0
the	0
nuclear	0
appearance	0
of	0
p50/p65-NF-kappaB	9
,	0
do	0
not	0
express	0
RelB	9
after	0
CD40	9
stimulation	0
.	0

In	0
S107	5
cells	6
stably	0
transfected	0
with	0
relB	1
genes	2
,	0
stimulation	0
of	0
nuclear	0
RelB	9
translocation	0
by	0
CD40	9
was	0
observed	0
.	0

These	0
results	0
indicate	0
that	0
stimulation	0
of	0
CD40	9
signaling	0
pathways	0
exerts	0
a	0
long-lasting	0
stimulatory	0
effect	0
on	0
both	0
the	0
transcription	0
and	0
nuclear	0
translocation	0
of	0
RelB	9
.	0

Since	0
LPS	0
and	0
anti-IgM	9
were	0
unable	0
to	0
activate	0
RelB	9
,	0
CD40	9
appears	0
to	0
trigger	0
a	0
special	0
program	0
of	0
gene	0
expression	0
involved	0
in	0
the	0
proliferation	0
and/or	0
differentiation	0
of	0
B	7
lymphocytes	8
.	0

Identification	0
and	0
characterization	0
of	0
a	0
leukocyte-specific	0
component	0
of	0
the	0
nuclear	0
body	0
.	0

The	0
nuclear	0
body	0
(	0
NB	0
)	0
is	0
a	0
cellular	0
organelle	0
that	0
is	0
involved	0
in	0
the	0
pathogenesis	0
of	0
acute	0
promyelocytic	0
leukemia	0
and	0
viral	0
infection	0
.	0

The	0
NB	0
is	0
also	0
a	0
target	0
of	0
antibodies	9
in	0
the	0
serum	0
of	0
patients	0
with	0
the	0
autoimmune	0
disease	0
primary	0
biliary	0
cirrhosis	0
.	0

In	0
this	0
study	0
,	0
serum	0
from	0
a	0
patient	0
with	0
primary	0
biliary	0
cirrhosis	0
was	0
used	0
to	0
identify	0
a	0
cDNA	0
encoding	0
a	0
novel	0
component	0
of	0
the	0
NB	0
,	0
a	0
140-kDa	9
protein	10
designated	0
Sp140	9
.	0

The	0
predicted	0
amino	0
acid	0
sequence	0
of	0
the	0
amino-terminal	9
portion	10
of	0
Sp140	9
was	0
similar	0
to	0
Sp100	9
,	0
a	0
previously	0
identified	0
NB	9
protein	10
.	0

The	0
carboxyl	9
portion	10
of	0
Sp140	9
contained	0
a	0
zinc-finger	9
domain	10
and	0
a	0
bromodomain	9
,	0
motifs	0
that	0
are	0
present	0
in	0
proteins	0
regulating	0
gene	0
transcription	0
.	0

High	0
levels	0
of	0
Sp140	3
mRNA	4
were	0
detected	0
in	0
human	0
spleen	0
and	0
peripheral	7
blood	8
leukocytes	8
,	0
but	0
not	0
other	0
human	0
tissues	0
.	0

The	0
level	0
of	0
SP140	3
mRNA	4
in	0
myeloid	5
precursor	6
cell	6
lines	6
HL60	5
and	0
NB4	5
markedly	0
increased	0
in	0
response	0
to	0
chemically	0
induced	0
cellular	0
differentiation	0
.	0

Immunohistochemical	0
techniques	0
were	0
used	0
to	0
demonstrate	0
that	0
SP140	9
localized	0
to	0
the	0
NB	0
in	0
differentiated	0
HL60	5
and	0
NB4	5
cells	6
.	0

The	0
location	0
of	0
Sp140	9
in	0
the	0
NB	0
,	0
and	0
expression	0
of	0
this	0
gene	0
in	0
cells	0
involved	0
in	0
host	0
defense	0
,	0
suggest	0
that	0
Sp140	9
may	0
be	0
involved	0
in	0
the	0
pathogenesis	0
of	0
acute	0
promyelocytic	0
leukemia	0
and	0
viral	0
infection	0
.	0

Regulation	0
of	0
cytokine	9
and	0
cytokine	9
receptor	10
expression	0
by	0
glucocorticoids	0
.	0

Glucocorticoids	0
(	0
GCS	0
)	0
profoundly	0
inhibit	0
several	0
aspects	0
of	0
T	0
cell	0
immunity	0
largely	0
through	0
inhibition	0
of	0
cytokine	9
expression	0
at	0
the	0
transcriptional	0
and	0
posttranscriptional	0
levels	0
.	0

GCS	0
were	0
also	0
reported	0
to	0
act	0
indirectly	0
by	0
inducing	0
transforming	0
growth	9
factor-beta	10
expression	0
,	0
which	0
in	0
turn	0
blocks	0
T	0
cell	0
immunity	0
.	0

In	0
exerting	0
their	0
antiproliferative	0
effects	0
,	0
GCS	0
diffuse	0
into	0
target	7
cells	8
where	0
they	0
bind	0
their	0
cytoplasmic	9
receptor	10
,	0
which	0
in	0
turn	0
translocates	0
to	0
the	0
nucleus	0
where	0
it	0
inhibits	0
transcription	0
of	0
cytokine	1
genes	2
through	0
direct	0
binding	0
to	0
the	0
glucocorticoid	1
response	2
elements	2
(	0
GRE	1
)	0
,	0
which	0
are	0
located	0
in	0
the	0
promoter	0
region	0
of	0
cytokine	1
genes	2
or	0
,	0
alternatively	0
,	0
through	0
antagonism	0
of	0
the	0
action	0
of	0
transcription	9
factors	10
required	0
for	0
optimal	0
transcriptional	0
activation	0
.	0

In	0
contrast	0
to	0
their	0
inhibitory	0
effects	0
on	0
cytokine	9
expression	0
,	0
GCS	0
up-regulate	0
cytokine	9
receptor	10
expression	0
that	0
correlates	0
with	0
enhanced	0
cytokine	9
effects	0
on	0
target	7
cells	8
.	0

In	0
this	0
review	0
,	0
we	0
summarize	0
the	0
current	0
state	0
of	0
knowledge	0
of	0
the	0
mechanism	0
of	0
action	0
of	0
GCS	0
,	0
including	0
the	0
phenomenon	0
of	0
steroid-induced	0
rebound	0
,	0
which	0
ensues	0
upon	0
GCS	0
withdrawal	0
.	0

Isolation	0
and	0
characterization	0
of	0
murine	1
fra-1	2
:	0
induction	0
mediated	0
by	0
CD40	9
and	0
surface	9
Ig	10
is	0
protein	9
kinase	10
C	10
dependent	0
.	0

The	0
murine	1
fra-1	2
gene	2
,	0
encoding	0
Fos-related	9
Ag	10
1	10
,	0
was	0
isolated	0
from	0
a	0
splenic	1
cDNA	2
library	2
and	0
sequenced	0
.	0

Murine	1
fra-1	2
was	0
highly	0
homologous	0
to	0
rat	1
and	2
human	2
fra-1	2
.	0

Oligonucleotide	0
primers	0
based	0
on	0
the	0
murine	1
sequence	2
were	0
used	0
to	0
construct	0
a	0
quantitative	0
reverse	0
transcription-PCR	0
assay	0
for	0
gene	0
expression	0
.	0

B	7
lymphocyte	8
stimulation	0
via	0
both	0
CD40	9
and	0
surface	9
Ig	10
(	10
sIg	10
)	10
receptors	10
substantially	0
induced	0
fra-1	1
expression	0
,	0
and	0
for	0
both	0
receptors	0
,	0
induction	0
was	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
dependent	0
.	0

This	0
contrasts	0
with	0
induction	0
of	0
c-fos	1
by	0
both	0
CD40	9
and	0
sIg	9
,	0
which	0
is	0
PKC	9
independent	0
and	0
indicates	0
that	0
CD40	9
is	0
capable	0
of	0
signaling	0
through	0
PKC	9
or	0
a	0
closely	0
related	0
kinase	9
.	0

Induction	0
of	0
fra-1	1
following	0
engagement	0
of	0
CD40	9
did	0
not	0
require	0
protein	0
synthesis	0
,	0
suggesting	0
that	0
the	0
PKC	9
-dependent	0
linkage	0
between	0
CD40	9
and	0
fra-1	1
is	0
direct	0
.	0

CD40	9
-mediated	0
fra-1	1
induction	0
did	0
require	0
tyrosine	9
kinase	10
activity	0
.	0

These	0
results	0
demonstrate	0
that	0
CD40	9
,	0
like	0
sIg	9
,	0
may	0
employ	0
PKC	9
in	0
producing	0
select	0
outcomes	0
,	0
that	0
individual	0
B	9
cell	10
receptors	10
may	0
signal	0
downstream	0
events	0
via	0
both	0
PKC-dependent	0
and	0
PKC-independent	0
pathways	0
,	0
and	0
that	0
multiple	0
signal	0
transduction	0
pathways	0
may	0
be	0
used	0
to	0
activate	0
the	0
expression	0
of	0
closely	0
related	0
genes	1
.	0

Pentoxifylline	0
for	0
the	0
treatment	0
of	0
infection	0
with	0
human	0
immunodeficiency	0
virus	0
.	0

Cytokine	0
dysregulation	0
in	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
has	0
been	0
documented	0
in	0
numerous	0
studies	0
and	0
has	0
been	0
cited	0
as	0
an	0
important	0
component	0
in	0
the	0
pathogenesis	0
of	0
this	0
retroviral	0
infection	0
.	0

Pharmacological	0
modification	0
of	0
cytokine	9
dysregulation	0
,	0
therefore	0
,	0
has	0
been	0
suggested	0
as	0
a	0
therapeutic	0
modality	0
for	0
HIV-1	0
infection	0
.	0

Dr.	0
Dezube	0
of	0
Beth	0
Israel	0
Hospital	0
(	0
Boston	0
)	0
concisely	0
reviews	0
the	0
state	0
of	0
our	0
knowledge	0
regarding	0
the	0
effects	0
of	0
pentoxifylline	0
on	0
expression	0
of	0
tumor	9
necrosis	10
factor-alpha	10
,	0
a	0
cytokine	9
known	0
to	0
influence	0
HIV-1	0
replication	0
and	0
to	0
play	0
a	0
possible	0
role	0
in	0
the	0
clinical	0
manifestations	0
of	0
advanced	0
infection	0
with	0
this	0
virus	0
.	0

Pentoxifylline	0
,	0
a	0
trisubstituted	0
xanthine	0
derivative	0
,	0
has	0
been	0
used	0
to	0
decrease	0
blood	0
viscosity	0
and	0
is	0
reasonably	0
well	0
tolerated	0
by	0
most	0
recipients	0
of	0
the	0
drug	0
.	0

Results	0
of	0
preliminary	0
studies	0
,	0
many	0
of	0
which	0
were	0
conducted	0
by	0
Dr.	0
Dezube	0
,	0
suggest	0
that	0
use	0
of	0
this	0
agent	0
in	0
combination	0
with	0
antiretroviral	0
compounds	0
may	0
prove	0
useful	0
in	0
the	0
treatment	0
of	0
patients	0
with	0
HIV-1	0
infection	0
.	0

Activation	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
promoter	2
in	0
T	7
cells	8
requires	0
cooperative	0
binding	0
of	0
Elf-1	9
and	0
AP-1	9
transcription	9
factors	10
.	0

The	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
gene	2
has	0
been	0
studied	0
extensively	0
as	0
a	0
model	0
system	0
of	0
transcriptional	0
induction	0
during	0
T-lymphocyte	0
activation	0
.	0

The	0
GM-CSF	1
gene	2
is	0
not	0
expressed	0
in	0
resting	7
peripheral	8
blood	8
T	8
cells	8
but	0
is	0
rapidly	0
induced	0
at	0
the	0
transcriptional	0
level	0
following	0
activation	0
through	0
the	0
cell	9
surface	10
T-cell	10
receptor	10
.	0

A	0
highly	0
conserved	0
19-bp	0
element	0
located	0
immediately	0
5	0
'	0
of	0
the	0
human	1
GM-CSF	2
TATA	2
box	2
(	0
bp	1
-34	2
to	2
-52	2
)	0
,	0
herein	0
called	0
purine	1
box	2
1	2
(	0
PB1	1
)	0
,	0
has	0
been	0
shown	0
to	0
bind	0
a	0
T-cell	9
nuclear	10
protein	10
complex	10
and	0
to	0
be	0
required	0
for	0
transcriptional	0
induction	0
of	0
the	0
GM-CSF	1
gene	2
following	0
T-cell	0
activation	0
.	0

The	0
PB1	1
sequence	0
motif	0
is	0
highly	0
conserved	0
in	0
both	0
human	1
and	2
murine	2
GM-CSF	2
genes	2
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
the	0
PB1	1
element	2
alone	0
confers	0
inducibility	0
on	0
a	0
heterologous	0
promoter	0
following	0
transfection	0
into	0
human	5
Jurkat	6
T	6
cells	6
.	0

In	0
addition	0
,	0
we	0
identify	0
a	0
major	0
PB1	9
nuclear	10
protein-binding	10
complex	10
that	0
is	0
not	0
present	0
in	0
resting	7
peripheral	8
blood	8
T	8
cells	8
but	0
is	0
rapidly	0
induced	0
following	0
T-cell	0
activation	0
.	0

Sequence	0
analysis	0
revealed	0
that	0
PB1	1
is	0
composed	0
of	0
adjacent	1
binding	2
sites	2
for	0
Ets	9
and	0
AP-1	9
transcription	9
factors	10
.	0

In	0
vitro	0
mutagenesis	0
experiments	0
demonstrated	0
that	0
both	0
the	0
Ets	1
and	2
AP-1	2
sites	2
are	0
required	0
for	0
binding	0
of	0
the	0
inducible	0
PB1	9
nuclear	10
protein	10
complex	10
and	0
for	0
the	0
transcriptional	0
activity	0
of	0
this	0
element	0
and	0
the	0
GM-CSF	1
promoter	2
in	0
activated	7
T	8
cells	8
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Steroid-resistant	0
asthma	0
.	0

Cellular	0
mechanisms	0
contributing	0
to	0
inadequate	0
response	0
to	0
glucocorticoid	0
therapy	0
.	0

The	0
current	0
study	0
examined	0
whether	0
alterations	0
in	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
binding	0
contribute	0
to	0
poor	0
response	0
to	0
glucocorticoid	0
therapy	0
in	0
asthma	0
.	0

29	0
asthma	0
patients	0
with	0
forced	0
expiratory	0
volume	0
in	0
1	0
s	0
(	0
FEV1	0
)	0
<	0
70	0
%	0
predicted	0
were	0
studied	0
.	0

Patients	0
were	0
classified	0
as	0
steroid	0
sensitive	0
(	0
SS	0
)	0
if	0
their	0
morning	0
FEV1	0
increased	0
>	0
30	0
%	0
after	0
a	0
1-wk	0
course	0
of	0
oral	0
prednisone	0
20	0
mg	0
twice	0
daily	0
and	0
steroid	0
resistant	0
(	0
SR	0
)	0
if	0
they	0
failed	0
to	0
increase	0
>	0
15	0
%	0
.	0

PBMC	0
obtained	0
from	0
these	0
two	0
groups	0
,	0
17	0
SR	0
and	0
12	0
SS	0
,	0
as	0
well	0
as	0
12	0
normal	0
controls	0
were	0
analyzed.	0
SR	0
patients	0
had	0
two	0
distinguishable	0
GR	9
binding	0
abnormalities	0
:	0
15	0
of	0
the	0
17	0
SR	0
patients	0
demonstrated	0
a	0
significantly	0
reduced	0
GR	9
binding	0
affinity	0
,	0
as	0
compared	0
with	0
SS	0
patients	0
(	0
P	0
=	0
0.0001	0
)	0
and	0
normal	0
controls	0
(	0
P	0
=	0
0.0001	0
)	0
.	0

This	0
defect	0
was	0
localized	0
to	0
T	7
cells	8
and	0
reverted	0
to	0
normal	0
after	0
48	0
h	0
in	0
culture	0
media	0
.	0

However	0
,	0
incubation	0
with	0
a	0
combination	0
of	0
IL-2	9
and	0
IL-4	9
sustained	0
this	0
abnormality	0
.	0

The	0
other	0
two	0
SR	0
patients	0
had	0
an	0
abnormally	0
low	0
GR	9
number	0
with	0
normal	0
binding	0
affinity	0
that	0
was	0
not	0
limited	0
to	0
T	7
cells	8
.	0

Furthermore	0
,	0
GR	9
number	0
failed	0
to	0
normalize	0
after	0
incubation	0
in	0
media	0
alone	0
or	0
IL-2	9
and	0
IL-4	9
.	0

Therefore	0
,	0
SR	0
asthma	0
may	0
be	0
due	0
to	0
more	0
than	0
one	0
abnormality	0
,	0
the	0
majority	0
related	0
to	0
a	0
reversible	0
cytokine	9
-induced	0
reduction	0
in	0
GR	9
binding	0
affinity	0
and	0
the	0
second	0
related	0
to	0
an	0
irreversible	0
reduction	0
in	0
GR	9
number	0
.	0

These	0
findings	0
may	0
have	0
important	0
implications	0
for	0
the	0
design	0
of	0
alternative	0
treatment	0
approaches	0
for	0
recalcitrant	0
asthma	0
.	0

Prevalence	0
of	0
aneuploidy	0
,	0
overexpressed	0
ER	9
,	0
and	0
overexpressed	0
EGFR	9
in	0
random	0
breast	0
aspirates	0
of	0
women	0
at	0
high	0
and	0
low	0
risk	0
for	0
breast	0
cancer	0
.	0

Breast	0
tissue	0
biomarkers	0
which	0
accurately	0
predict	0
breast	0
cancer	0
development	0
within	0
a	0
10	0
year	0
period	0
in	0
high	0
risk	0
women	0
are	0
needed	0
but	0
currently	0
not	0
available	0
.	0

We	0
initiated	0
this	0
study	0
to	0
determine	0
1	0
)	0
the	0
prevalence	0
of	0
one	0
or	0
more	0
breast	0
tissue	0
abnormalities	0
in	0
a	0
group	0
of	0
women	0
at	0
high	0
risk	0
for	0
breast	0
cancer	0
,	0
and	0
2	0
)	0
if	0
the	0
prevalence	0
of	0
biomarker	0
abnormalities	0
is	0
greater	0
in	0
high	0
risk	0
than	0
in	0
low	0
risk	0
women	0
.	0

Eligible	0
high	0
risk	0
women	0
were	0
those	0
with	0
a	0
first	0
degree	0
relative	0
with	0
breast	0
cancer	0
,	0
prior	0
breast	0
cancer	0
,	0
or	0
precancerous	0
mastopathy	0
.	0

Low	0
risk	0
women	0
were	0
those	0
without	0
these	0
or	0
other	0
major	0
identifiable	0
risk	0
factors	0
.	0

Ductal	7
cells	8
were	0
obtained	0
via	0
random	0
fine	0
needle	0
aspirations	0
and	0
cytologically	0
classified	0
.	0

Biomarkers	0
included	0
DNA	0
ploidy	0
,	0
estrogen	9
receptor	10
(	0
ER	9
)	0
,	0
and	0
epidermal	9
growth	10
factor	10
receptor	10
(	0
EGFR	9
)	0
.	0

The	0
prevalence	0
of	0
DNA	0
aneuploidy	0
was	0
30	0
%	0
,	0
overexpression	0
of	0
ER	9
10	0
%	0
,	0
and	0
overexpression	0
of	0
EGFR	9
35	0
%	0
,	0
in	0
the	0
206	0
high	0
risk	0
women	0
whose	0
median	0
10	0
year	0
Gail	0
risk	0
(	0
projected	0
probability	0
)	0
of	0
developing	0
breast	0
cancer	0
was	0
4.5	0
%	0
.	0

The	0
prevalence	0
of	0
aneuploidy	0
and	0
overexpressed	0
EGFR	9
was	0
significantly	0
higher	0
in	0
the	0
high	0
risk	0
women	0
than	0
in	0
the	0
25	0
low	0
risk	0
controls	0
(	0
p	0
<	0
0.002	0
)	0
,	0
whose	0
median	0
10	0
year	0
Gail	0
risk	0
was	0
0.7	0
%	0
.	0

The	0
difference	0
in	0
the	0
prevalence	0
of	0
ER	9
overexpression	0
between	0
high	0
and	0
low	0
risk	0
groups	0
was	0
not	0
statistically	0
significant	0
(	0
p	0
=	0
0.095	0
)	0
.	0

This	0
may	0
be	0
due	0
to	0
the	0
low	0
prevalence	0
of	0
overexpressed	0
ER	9
and	0
the	0
small	0
number	0
of	0
controls	0
.	0

A	0
significant	0
difference	0
was	0
noted	0
in	0
the	0
prevalence	0
of	0
one	0
or	0
more	0
abnormal	0
biomarkers	0
between	0
the	0
high	0
risk	0
and	0
low	0
risk	0
women	0
(	0
p	0
<	0
0.001	0
)	0
.	0

A	0
large	0
prospective	0
trial	0
is	0
needed	0
to	0
determine	0
if	0
one	0
or	0
more	0
of	0
these	0
biomarkers	0
,	0
is	0
predictive	0
of	0
breast	0
cancer	0
development	0
.	0

Inhibition	0
of	0
nuclear	3
factor	4
kappa	4
B	4
subunit	4
p65	4
mRNA	4
accumulation	0
in	0
lipopolysaccharide-stimulated	5
human	6
monocytic	6
cells	6
treated	0
with	0
sodium	0
salicylate	0
.	0

Lipopolysaccharide	0
is	0
one	0
of	0
the	0
most	0
potent	0
trigger	0
substances	0
for	0
monocytes	0
and	0
macrophages	0
causing	0
secretion	0
of	0
inflammatory	9
mediators	10
such	0
as	0
tumor	9
necrosis	10
factor	10
and	0
interleukin-1	9
.	0

The	0
nature	0
of	0
the	0
nuclear	0
factors	0
involved	0
in	0
regulation	0
of	0
these	0
cytokine	1
genes	2
is	0
still	0
unknown	0
.	0

Nuclear	9
factor	10
kappa	10
B	10
(	10
NF-kappa	10
B	10
;	10
heterodimer	10
of	10
p50	10
and	10
p65	10
)	10
proteins	10
have	0
been	0
suggested	0
to	0
play	0
an	0
important	0
role	0
in	0
gene	0
transcription	0
of	0
inflammatory	9
mediators	10
when	0
monocytes	7
are	0
stimulated	0
with	0
lipopolysaccharide	0
.	0

Nonsteroidal	0
anti-inflammatory	0
drugs	0
such	0
as	0
salicylates	0
have	0
been	0
used	0
to	0
treat	0
symptoms	0
of	0
inflammation	0
,	0
and	0
a	0
new	0
mechanism	0
of	0
drug	0
action	0
was	0
suggested	0
recently	0
.	0

Salicylates	0
have	0
been	0
shown	0
to	0
inhibit	0
lipopolysaccharide-induced	0
gene	0
transcription	0
via	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
by	0
preventing	0
the	0
degradation	0
of	0
NF-kappa	9
B	10
inhibitor	10
``	0
I	9
kappa	10
B	10
``	0
,	0
blocking	0
the	0
translocation	0
of	0
NF-kappa	9
B	10
into	0
the	0
nuclear	0
compartment	0
.	0

However	0
,	0
the	0
nature	0
of	0
the	0
subunit	0
involved	0
in	0
this	0
mechanism	0
has	0
not	0
been	0
defined	0
.	0

To	0
examine	0
the	0
mechanisms	0
by	0
which	0
salicylates	0
affect	0
cytokine	9
gene	0
transcription	0
,	0
the	0
amount	0
of	0
active	0
and	0
inactive	0
NF-kappa	9
B	10
and	0
NF-kappa	3
B	4
mRNA	4
,	0
in	0
Porphyromonas	0
gingivalis	0
lipopolysaccharide-stimulated	5
human	6
monocytic	6
cells	6
was	0
assessed	0
.	0

High	0
doses	0
of	0
sodium	0
salicylate	0
suppressed	0
NF-kappa	9
B	10
p65	3
mRNA	4
accumulation	0
,	0
resulting	0
in	0
suppression	0
of	0
total	0
NF-kappa	9
B	10
,	0
p50	9
on	0
tissue	0
oligonucleotide	0
had	0
no	0
effects	0
on	0
lipopolysaccharide-induced	0
NF-kappa	9
B	10
activation	0
.	0

The	0
data	0
demonstrate	0
that	0
the	0
p65	9
subunit	0
of	0
NF-kappa	9
B	10
is	0
inhibited	0
by	0
salicylate	0
treatment	0
and	0
highlight	0
the	0
role	0
of	0
salicylate	0
in	0
the	0
control	0
of	0
gene	0
expression	0
of	0
inflammatory	9
mediators	10
.	0

Glucocorticoid-mediated	0
inhibition	0
of	0
RANTES	9
expression	0
in	0
human	7
T	8
lymphocytes	8
.	0

The	0
chemokine	9
RANTES	9
has	0
been	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
allergic	0
inflammatory	0
diseases	0
including	0
asthma	0
and	0
rhinitis	0
which	0
are	0
frequently	0
treated	0
with	0
glucocorticoids	0
.	0

We	0
observed	0
that	0
dexamethasone	0
dramatically	0
inhibited	0
RANTES	3
mRNA	4
expression	0
dose	0
dependently	0
in	0
anti-CD3	5
activated	6
Hut-78	6
T	6
cells	6
and	0
human	7
PBMCs	8
.	0

Inhibition	0
of	0
RANTES	9
expression	0
did	0
not	0
appear	0
to	0
be	0
secondary	0
to	0
IL-2	9
inhibition	0
and	0
required	0
binding	0
to	0
the	0
intracellular	0
glucocorticoid	9
receptor	10
.	0

The	0
down-regulation	0
of	0
RANTES	9
expression	0
by	0
glucocorticoids	0
in	0
T	7
cells	8
may	0
directly	0
contribute	0
to	0
the	0
efficacy	0
of	0
these	0
agents	0
in	0
suppressing	0
cellular	0
infiltration	0
and	0
to	0
their	0
anti-inflammatory	0
properties	0
.	0

Association	0
of	0
TRAF1	9
,	0
TRAF2	9
,	0
and	0
TRAF3	9
with	0
an	0
Epstein-Barr	1
virus	2
LMP1	2
domain	2
important	0
for	0
B-lymphocyte	7
transformation	0
:	0
role	0
in	0
NF-kappaB	9
activation	0
.	0

The	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
transforming	10
protein	10
LMP1	10
appears	0
to	0
be	0
a	0
constitutively	9
activated	10
tumor	10
necrosis	10
factor	10
receptor	10
(	0
TNFR	9
)	0
on	0
the	0
basis	0
of	0
an	0
intrinsic	0
ability	0
to	0
aggregate	0
in	0
the	0
plasma	0
membrane	0
and	0
an	0
association	0
of	0
its	0
cytoplasmic	9
carboxyl	10
terminus	10
(	0
CT	9
)	0
with	0
TNFR-associated	9
factors	10
(	0
TRAFs	9
)	0
.	0

We	0
now	0
show	0
that	0
in	0
EBV-transformed	5
B	6
lymphocytes	6
most	0
of	0
TRAF1	9
or	0
TRAF3	9
and	0
5	0
%	0
of	0
TRAF2	9
are	0
associated	0
with	0
LMP1	9
and	0
that	0
most	0
of	0
LMP1	9
is	0
associated	0
with	0
TRAF1	9
or	0
TRAF3	9
.	0

TRAF1	9
,	0
TRAF2	9
,	0
and	0
TRAF3	9
bind	0
to	0
a	0
single	0
site	0
in	0
the	0
LMP1	9
CT	10
corresponding	0
to	0
amino	0
acids	0
(	0
aa	0
)	0
199	0
to	0
214	0
,	0
within	0
a	0
domain	0
which	0
is	0
important	0
for	0
B-lymphocyte	0
growth	0
transformation	0
(	0
aa	0
187	0
to	0
231	0
)	0
.	0

Further	0
deletional	0
and	0
alanine	0
mutagenesis	0
analyses	0
and	0
comparison	0
with	0
TRAF	1
binding	2
sequences	2
in	0
CD40	0
,	0
in	0
CD30	0
,	0
and	0
in	0
the	0
LMP1	9
of	0
other	0
lymphycryptoviruses	0
provide	0
the	0
first	0
evidence	0
that	0
PXQXT/S	1
is	0
a	0
core	0
TRAF	1
binding	2
motif	2
.	0

The	0
negative	0
effects	0
of	0
point	0
mutations	0
in	0
the	0
LMP1	1
(	2
1-231	2
)	2
core	2
TRAF	2
binding	2
motif	2
on	0
TRAF	0
binding	0
and	0
NF-kappaB	9
activation	0
genetically	0
link	0
the	0
TRAFs	9
to	0
LMP1	9
(	0
1-231	0
)	0
-mediated	0
NF-kappaB	9
activation	0
.	0

NF-kappaB	9
activation	0
by	0
LMP1	9
(	0
1-231	0
)	0
is	0
likely	0
to	0
be	0
mediated	0
by	0
TRAF1	9
/TRAF2	9
heteroaggregates	0
since	0
TRAF1	9
is	0
unique	0
among	0
the	0
TRAFs	9
in	0
coactivating	0
NF-kappaB	9
with	0
LMP1	9
(	0
1-231	0
)	0
,	0
a	0
TRAF2	9
dominant-negative	0
mutant	0
can	0
block	0
LMP1	9
(	0
1-231	0
)	0
-mediated	0
NF-kappaB	9
activation	0
as	0
well	0
as	0
TRAF1	9
coactivation	0
,	0
and	0
30	0
%	0
of	0
TRAF2	9
is	0
associated	0
with	0
TRAF1	9
in	0
EBV-transformed	0
B	0
cells	0
.	0

TRAF3	9
is	0
a	0
negative	0
modulator	0
of	0
LMP1	9
(	0
1-231	0
)	0
-mediated	0
NF-kappaB	9
activation	0
.	0

Surprisingly	0
,	0
TRAF1	9
,	10
-2	10
,	10
or	10
-3	10
does	0
not	0
interact	0
with	0
the	0
terminal	9
LMP1	10
CT	10
aa	0
333	0
to	0
386	0
which	0
can	0
independently	0
mediate	0
NF-kappaB	9
activation	0
.	0

The	0
constitutive	0
association	0
of	0
TRAFs	9
with	0
LMP1	9
through	0
the	0
aa	9
187	10
to	10
231	10
domain	10
which	0
is	0
important	0
in	0
NF-kappaB	9
activation	0
and	0
primary	0
B-lymphocyte	7
growth	0
transformation	0
implicates	0
TRAF	9
aggregation	0
in	0
LMP1	9
signaling	0
.	0

Lack	0
of	0
IL-12	9
signaling	0
in	0
human	5
allergen-specific	6
Th2	6
cells	6
.	0

IL-12	9
is	0
a	0
powerful	0
skewer	0
of	0
CD4+	7
T	8
cell	8
responses	0
toward	0
the	0
Th1	0
phenotype	0
by	0
inducing	0
IFN-gamma	9
production	0
in	0
naive	5
Th	6
cells	6
.	0

In	0
the	0
present	0
study	0
we	0
addressed	0
the	0
question	0
of	0
whether	0
IL-12	9
can	0
reverse	0
established	0
Th2	0
responses	0
into	0
Th1/Th0	0
responses	0
by	0
inducing	0
IFN-gamma	9
production	0
in	0
memory	5
Th2	6
cells	6
.	0

To	0
this	0
aim	0
,	0
allergen-specific	5
CD4+	6
T	6
cell	6
clones	6
(	0
TCC	5
)	0
were	0
generated	0
from	0
the	0
peripheral	0
blood	0
of	0
three	0
atopic	0
patients	0
,	0
and	0
their	0
cytokine	9
profiles	0
were	0
analyzed	0
.	0

The	0
majority	0
of	0
these	0
TCC	5
exhibited	0
a	0
strongly	0
polarized	0
Th2	0
cytokine	9
profile	0
,	0
and	0
the	0
production	0
of	0
IFN-gamma	9
could	0
not	0
be	0
induced	0
by	0
exogenous	0
IL-12	9
.	0

Only	0
those	0
TCC	5
with	0
low	0
IFN-gamma	9
levels	0
in	0
the	0
absence	0
of	0
IL-12	9
responded	0
to	0
IL-12	9
by	0
additional	0
enhancement	0
of	0
IFN-gamma	9
production	0
.	0

The	0
IL-12	9
nonresponsiveness	0
of	0
the	0
Th2	5
clones	6
was	0
further	0
evident	0
by	0
the	0
total	0
lack	0
of	0
IL-12	9
-induced	0
phosphorylation	0
of	0
STAT4	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription-4	10
)	0
,	0
a	0
transcription	9
factor	10
that	0
is	0
typically	0
involved	0
in	0
IL-12	9
signaling	0
.	0

Consequently	0
,	0
IL-12	9
also	0
failed	0
to	0
induce	0
the	0
DNA-binding	0
activity	0
of	0
STAT4-containing	9
complexes	10
in	0
the	0
nuclei	0
of	0
these	0
Th2	5
clones	6
.	0

All	0
TCC	5
expressed	0
equal	0
levels	0
of	0
the	0
low-affinity	9
IL-12R	10
beta1	10
subunit	10
.	0

Our	0
results	0
indicate	0
that	0
human	0
allergen-specific	0
Th	0
cells	0
with	0
strongly	0
polarized	0
Th2	0
cytokine	9
profiles	0
do	0
not	0
respond	0
to	0
IL-12	9
and	0
,	0
therefore	0
,	0
can	0
not	0
be	0
induced	0
to	0
produce	0
IFN-gamma	9
.	0

The	0
apparent	0
high	0
frequency	0
of	0
IL-12-nonresponsive	5
Th	6
cells	6
within	0
the	0
allergen-specific	0
populations	0
in	0
atopic	0
patients	0
predicts	0
a	0
limited	0
skewing	0
potential	0
of	0
IL-12	9
in	0
the	0
case	0
of	0
established	0
Th2	0
responses	0
,	0
but	0
only	0
affecting	0
newly	0
recruited	0
naive	0
Th	5
cells	6
.	0

Cloning	0
and	0
expression	0
of	0
the	0
Epstein-Barr	9
virus-encoded	10
dUTPase	10
:	0
patients	0
with	0
acute	0
,	0
reactivated	0
or	0
chronic	0
virus	0
infection	0
develop	0
antibodies	9
against	0
the	0
enzyme	9
.	0

The	0
gene	0
encoding	0
the	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
-specific	10
dUTPase	10
was	0
amplified	0
from	0
virus	1
DNA	2
by	0
PCR	0
.	0

The	0
active	0
enzyme	0
was	0
expressed	0
in	0
Escherichia	0
coli	0
and	0
in	0
insect	7
cells	8
as	0
a	0
non-fusion	9
protein	10
.	0

The	0
protein	0
from	0
E.	0
coli	0
specifically	0
converted	0
dUTP	0
to	0
dUMP	0
and	0
did	0
not	0
react	0
with	0
other	0
dNTPs	0
or	0
NTPs	0
.	0

Preliminary	0
experiments	0
yielded	0
a	0
Km	0
value	0
of	0
about	0
0.8	0
microM	0
for	0
dUTP	0
.	0

MAbs	0
against	0
the	0
dUTPase	9
reacted	0
with	0
a	0
protein	0
of	0
approximately	0
31	0
kDa	0
in	0
12-O-tetradecanoyl-phorbol-13-acetate	5
(	6
TPA	6
)	6
-stimulated	6
B	6
cells	6
harbouring	0
either	0
type	0
1	0
or	0
type	0
2	0
EBV	0
.	0

The	0
protein	0
was	0
found	0
in	0
untreated	7
cells	8
at	0
low	0
levels	0
,	0
whereas	0
induction	0
of	0
the	0
lytic	0
replication	0
cycle	0
by	0
TPA	0
treatment	0
or	0
by	0
providing	0
the	0
immediate	9
early	10
transactivator	10
BZLF1	9
in	0
trans	0
resulted	0
in	0
increased	0
expression	0
.	0

We	0
demonstrated	0
that	0
the	0
virus	9
dUTPase	10
isolated	0
from	0
EBV-infected	7
cells	8
is	0
a	0
phosphoprotein	9
.	0

The	0
protein	0
expressed	0
in	0
insect	7
cells	8
was	0
used	0
to	0
test	0
for	0
the	0
presence	0
of	0
specific	9
antibodies	10
in	0
sera	0
from	0
normal	0
,	0
healthy	0
carriers	0
and	0
from	0
patients	0
with	0
various	0
diseases	0
.	0

While	0
the	0
sera	0
of	0
EBV-negative	0
individuals	0
(	0
0/3	0
)	0
or	0
healthy	0
carriers	0
(	0
0/33	0
)	0
did	0
not	0
contain	0
detectable	0
levels	0
of	0
antibodies	0
,	0
patients	0
with	0
mononucleosis	0
(	0
5/18	0
)	0
,	0
chronic	0
EBV	0
infection	0
(	0
2/7	0
)	0
,	0
EBV	0
reactivation	0
(	0
7/20	0
)	0
and	0
human	0
immunodeficiency	0
virus	0
infection	0
(	0
5/24	0
)	0
showed	0
elevated	0
antibody	0
titres	0
against	0
the	0
enzyme	0
.	0

This	0
indicated	0
that	0
the	0
dUTPase	0
is	0
expressed	0
during	0
EBV	0
replication	0
and	0
reactivation	0
.	0

The	0
enzyme	0
might	0
therefore	0
be	0
a	0
potential	0
target	0
for	0
drug	0
therapy	0
under	0
conditions	0
of	0
active	0
DNA	0
replication	0
.	0

The	0
catalytic	9
domain	10
of	0
pp56	9
(	10
lck	10
)	10
,	0
but	0
not	0
its	0
regulatory	9
domain	10
,	0
is	0
sufficient	0
for	0
inducing	0
IL-2	9
production	0
.	0

The	0
lymphoid	9
src	10
kinase	10
pp56	9
(	10
lck	10
)	10
has	0
been	0
shown	0
to	0
be	0
essential	0
for	0
the	0
induction	0
of	0
different	0
T	7
lymphocyte	8
responses	0
,	0
including	0
CD4	9
-mediated	0
enhancement	0
of	0
Ag-induced	0
T	0
cell	0
activation	0
,	0
early	0
T	0
cell	0
differentiation	0
,	0
induction	0
of	0
IL-2	9
production	0
,	0
and	0
cytotoxicity	0
.	0

It	0
is	0
assumed	0
that	0
pp56	9
(	10
lck	10
)	10
acts	0
on	0
these	0
processes	0
by	0
phosphorylating	0
substrates	0
.	0

However	0
,	0
it	0
has	0
been	0
recently	0
reported	0
that	0
the	0
NH2	9
regulatory	9
domain	10
is	0
sufficient	0
to	0
mediate	0
CD4	9
accessory	0
function	0
.	0

In	0
this	0
report	0
we	0
address	0
the	0
contribution	0
of	0
the	0
regulatory	9
and	10
catalytic	10
domains	10
of	0
pp56	9
(	10
lck	10
)	10
to	0
another	0
function	0
of	0
this	0
enzyme	0
independent	0
of	0
CD4	9
:	0
TCR-induced	0
IL-2	9
production	0
.	0

Two	0
pp56	9
(	10
lck	10
)	10
mutants	10
lacking	0
either	0
the	0
entire	0
catalytic	9
domain	10
or	0
the	0
entire	0
NH2	9
regulatory	9
domain	10
were	0
generated	0
,	0
and	0
their	0
abilities	0
to	0
trigger	0
transactivation	0
of	0
the	0
TCR-regulated	1
nuclear	2
factor	2
of	2
activated	2
T	2
cells	2
(	2
NF-AT	2
)	2
region	2
of	0
the	0
IL-2	1
promoter	2
were	0
compared	0
.	0

Only	0
the	0
catalytic	0
,	0
but	0
not	0
the	0
NH2	9
regulatory	0
,	0
domain	0
of	0
pp56	9
(	10
lck	10
)	10
was	0
able	0
to	0
induce	0
NF-AT	9
region	0
transactivation	0
on	0
its	0
own	0
and	0
to	0
cooperate	0
with	0
other	0
intracellular	0
signals	0
to	0
trigger	0
this	0
response	0
.	0

Moreover	0
,	0
the	0
catalytic	9
domain	10
of	0
pp56	9
(	10
lck	10
)	10
was	0
able	0
to	0
induce	0
IL-2	9
cytokine	9
production	0
to	0
an	0
extent	0
similar	0
to	0
that	0
of	0
wild-type	0
pp56	9
(	10
lck	10
)	10
.	0

We	0
conclude	0
that	0
different	0
domains	0
of	0
the	0
pp56	9
(	10
lck	10
)	10
molecule	0
contribute	0
to	0
regulate	0
distinct	0
biologic	0
functions	0
.	0

In	0
fact	0
,	0
while	0
the	0
NH2	9
regulatory	9
domain	10
is	0
sufficient	0
to	0
mediate	0
CD4	9
accessory	0
function	0
,	0
we	0
show	0
here	0
that	0
the	0
catalytic	9
domain	10
of	0
pp56	9
(	10
lck	10
)	10
is	0
sufficient	0
for	0
induction	0
of	0
IL-2	9
production	0
,	0
mimicking	0
TCR	9
ligation	0
.	0

[	0
The	0
changes	0
in	0
glucocorticoid	0
receptors	0
in	0
peripheral	7
leukocytes	8
in	0
asthmatic	0
subjects	0
]	0

The	0
number	0
of	0
glucocorticoid	9
receptors	10
(	0
GCR	9
)	0
in	0
peripheral	7
leukocytes	8
was	0
determined	0
by	0
radioligand-binding	0
assay	0
in	0
extrinsic	0
and	0
intrinsic	0
asthmatics	0
.	0

Their	0
corresponding	0
plasma	0
cortisol	0
levels	0
were	0
assessed	0
.	0

The	0
results	0
showed	0
that	0
the	0
average	0
number	0
of	0
GCR	9
in	0
asthmatics	0
was	0
significantly	0
lower	0
than	0
that	0
in	0
healthy	0
subjects	0
(	0
P	0
<	0
0.01	0
)	0
,	0
and	0
there	0
was	0
a	0
linear	0
correlation	0
between	0
the	0
number	0
of	0
GCR	9
and	0
the	0
course	0
of	0
asthma	0
.	0

Besides	0
,	0
there	0
was	0
also	0
a	0
linear	0
correlation	0
between	0
the	0
number	0
of	0
GCR	9
and	0
the	0
age	0
of	0
the	0
initial	0
attack	0
of	0
asthma	0
.	0

No	0
difference	0
in	0
plasma	0
cortisol	0
level	0
was	0
found	0
between	0
asthmatics	0
and	0
healthy	0
subjects	0
.	0

These	0
findings	0
suggest	0
that	0
there	0
is	0
no	0
primary	0
and	0
general	0
impairment	0
of	0
glucocorticoid	0
metabolism	0
in	0
the	0
asthmatics	0
,	0
but	0
the	0
number	0
of	0
GCR	9
in	0
the	0
asthmatics	0
is	0
lower	0
than	0
that	0
in	0
healthy	0
controls	0
.	0

The	0
decrease	0
of	0
the	0
number	0
of	0
GCR	9
in	0
asthmatics	0
,	0
we	0
think	0
,	0
is	0
related	0
to	0
heredity	0
and	0
repeated	0
attacks	0
of	0
asthma	0
.	0

Novel	0
aldosterone	9
receptors	10
:	0
specificity-conferring	0
mechanism	0
at	0
the	0
level	0
of	0
the	0
cell	0
membrane	0
.	0

Functional	0
studies	0
in	0
extra-renal	7
,	8
nonepithelial	8
cells	8
such	0
as	0
smooth	7
muscle	8
cells	8
and	0
more	0
recently	0
circulating	0
human	7
lymphocytes	8
have	0
provided	0
increasing	0
evidence	0
that	0
aldosterone	0
produces	0
not	0
only	0
classical	0
genomic	0
effects	0
,	0
but	0
also	0
rapid	0
non-genomic	0
effects	0
on	0
transmembrane	0
electrolyte	0
movements	0
.	0

These	0
involve	0
activation	0
of	0
the	0
sodium/proton-exchanger	9
of	0
the	0
cell	0
membrane	0
at	0
very	0
low	0
,	0
physiological	0
concentrations	0
of	0
aldosterone	0
with	0
an	0
acute	0
onset	0
within	0
1-2	0
minutes	0
.	0

A	0
second	0
messenger	0
cascade	0
involved	0
is	0
the	0
inositol-1	0
,	0
4	0
,	0
5-trisphosphate/calcium	0
pathway	0
which	0
responds	0
over	0
the	0
same	0
rapid	0
time	0
course	0
.	0

Such	0
changes	0
clearly	0
can	0
not	0
be	0
explained	0
by	0
genomic	0
mechanisms	0
,	0
which	0
are	0
responsible	0
for	0
later	0
effects	0
than	0
the	0
membrane-related	0
rapid	0
responses	0
.	0

In	0
addition	0
to	0
its	0
rapid	0
time	0
course	0
the	0
unique	0
characteristics	0
of	0
this	0
new	0
pathway	0
for	0
steroid	0
action	0
include	0
a	0
10000-fold	0
selectivity	0
for	0
aldosterone	0
over	0
cortisol	0
and	0
the	0
ineffectiveness	0
of	0
spironolactones	0
,	0
classical	0
mineralocorticoid	0
antagonists	0
,	0
as	0
antagonists	0
of	0
the	0
response	0
.	0

Subsequently	0
binding	0
sites	0
have	0
been	0
demonstrated	0
in	0
the	0
plasma	0
membrane	0
of	0
human	7
lymphocytes	8
which	0
show	0
pharmacological	0
(	0
aldosterone	0
specificity	0
)	0
and	0
kinetic	0
(	0
high	0
turnover	0
)	0
properties	0
identical	0
with	0
those	0
of	0
the	0
rapid	0
aldosterone	0
effects	0
in	0
the	0
same	0
cells	0
.	0

SDS-PAGE	0
analysis	0
of	0
the	0
receptor	9
protein	10
has	0
shown	0
a	0
molecular	0
weight	0
of	0
approximately	0
50	0
kD	0
.	0

The	0
present	0
paper	0
reviews	0
the	0
data	0
supporting	0
a	0
new	0
,	0
two-step	0
model	0
for	0
non-genomic	0
and	0
genomic	0
aldosterone	0
effects	0
.	0

It	0
also	0
suggests	0
a	0
novel	0
specificity-conferring	0
mechanism	0
for	0
mineralocorticoid	0
action	0
at	0
the	0
membrane	0
level	0
.	0

The	0
macrophage	9
transcription	10
factor	10
PU.1	9
directs	0
tissue-specific	0
expression	0
of	0
the	0
macrophage	9
colony-stimulating	10
factor	10
receptor	10
.	0

The	0
macrophage	9
colony-stimulating	10
factor	10
(	10
M-CSF	10
)	10
receptor	10
is	0
expressed	0
in	0
a	0
tissue-specific	0
fashion	0
from	0
two	0
distinct	0
promoters	1
in	0
monocytes/macrophages	7
and	0
the	0
placenta	0
.	0

In	0
order	0
to	0
further	0
understand	0
the	0
transcription	0
factors	0
which	0
play	0
a	0
role	0
in	0
the	0
commitment	0
of	0
multipotential	7
progenitors	8
to	0
the	0
monocyte/macrophage	0
lineage	0
,	0
we	0
have	0
initiated	0
an	0
investigation	0
of	0
the	0
factors	0
which	0
activate	0
the	0
M-CSF	9
receptor	10
very	0
early	0
during	0
the	0
monocyte	0
differentiation	0
process	0
.	0

Here	0
we	0
demonstrate	0
that	0
the	0
human	1
monocytic	2
M-CSF	2
receptor	2
promoter	2
directs	0
reporter	0
gene	0
activity	0
in	0
a	0
tissue-specific	0
fashion	0
.	0

Since	0
one	0
of	0
the	0
few	0
transcription	9
factors	10
which	0
have	0
been	0
implicated	0
in	0
the	0
regulation	0
of	0
monocyte	1
genes	2
is	0
the	0
macrophage-	9
and	10
B-cell-specific	10
PU.1	10
transcription	9
factor	10
,	0
we	0
investigated	0
whether	0
PU.1	9
binds	0
and	0
activates	0
the	0
M-CSF	1
receptor	2
promoter	2
.	0

Here	0
we	0
demonstrate	0
that	0
both	0
in	0
vitro-translated	9
PU.1	10
and	0
PU.1	9
from	0
nuclear	0
extracts	0
bind	0
to	0
a	0
specific	0
site	0
in	0
the	0
M-CSF	1
receptor	2
promoter	2
just	0
upstream	0
from	0
the	0
major	1
transcription	2
initiation	2
site	2
.	0

Mutations	0
in	0
this	0
site	0
which	0
eliminate	0
PU.1	9
binding	0
decrease	0
M-CSF	9
receptor	10
promoter	0
activity	0
significantly	0
in	0
macrophage	5
cell	6
lines	6
only	0
.	0

Furthermore	0
,	0
PU.1	9
transactivates	0
the	0
M-CSF	1
receptor	2
promoter	2
in	0
nonmacrophage	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
PU.1	9
plays	0
a	0
major	0
role	0
in	0
macrophage	0
gene	0
regulation	0
and	0
development	0
by	0
directing	0
the	0
expression	0
of	0
a	0
receptor	0
for	0
a	0
key	9
macrophage	10
growth	10
factor	10
.	0

Increased	0
natural	0
killer	0
cell	0
activity	0
correlates	0
with	0
low	0
or	0
negative	0
expression	0
of	0
the	0
HER-2/neu	1
oncogene	2
in	0
patients	0
with	0
breast	0
cancer	0
.	0

BACKGROUND	0
.	0

Increased	0
expression	0
of	0
the	0
HER-2/neu	1
oncogene	2
in	0
breast	0
cancer	0
correlates	0
with	0
decreased	0
estrogen	9
receptor	10
concentration	0
and	0
seems	0
to	0
be	0
an	0
important	0
prognostic	0
factor	0
.	0

The	0
authors	0
investigated	0
whether	0
there	0
is	0
a	0
correlation	0
between	0
HER-2/neu	9
expression	0
and	0
immunologic	0
parameters	0
representing	0
tumor	0
defense	0
in	0
patients	0
with	0
breast	0
cancer	0
.	0

METHOD	0
.	0

A	0
Western	0
blot	0
analysis	0
was	0
used	0
to	0
investigate	0
HER-2/neu	9
expression	0
,	0
whereas	0
a	0
chromium-release	0
assay	0
using	0
the	0
K562	5
cell	6
line	6
as	0
target	0
was	0
used	0
to	0
measure	0
natural	7
killer	8
(	8
NK	8
)	8
cell	8
activity	0
.	0

RESULTS	0
.	0

In	0
patients	0
with	0
breast	0
cancer	0
,	0
NK	7
cell	8
activity	0
was	0
significantly	0
higher	0
compared	0
with	0
patients	0
with	0
benign	7
tumors	8
(	0
P	0
=	0
0.006	0
)	0
or	0
healthy	0
control	0
subjects	0
(	0
P	0
=	0
0.002	0
)	0
.	0

Moreover	0
,	0
23.3	0
%	0
of	0
patients	0
with	0
breast	0
cancer	0
showed	0
an	0
overexpression	0
of	0
HER-2/neu	9
protein	10
.	0

Within	0
this	0
group	0
of	0
patients	0
,	0
NK	7
cell	8
activity	0
was	0
significantly	0
lower	0
(	0
45.6	0
+/-	0
16.1	0
%	0
)	0
compared	0
with	0
the	0
group	0
with	0
no	0
HER-2/neu	9
overexpression	0
(	0
57.3	0
+/-	0
11.0	0
%	0
)	0
.	0

NK	7
cell	8
activity	0
did	0
not	0
increase	0
in	0
patients	0
with	0
HER-2/neu	9
overexpression	0
.	0

Thus	0
,	0
there	0
was	0
a	0
statistically	0
significant	0
correlation	0
of	0
cytolytic	0
effector	0
cell	0
function	0
with	0
HER-2/neu	9
expression	0
of	0
the	0
tumor	0
(	0
P	0
=	0
0.003	0
)	0
,	0
and	0
HER-2/neu	9
overexpression	0
correlated	0
with	0
a	0
negative	0
estrogen	9
receptor	10
status	0
(	0
P	0
=	0
0.005	0
)	0
.	0

CONCLUSION	0
.	0

These	0
data	0
add	0
further	0
evidence	0
to	0
previous	0
observations	0
from	0
the	0
authors	0
'	0
laboratory	0
that	0
certain	0
tumor	0
characteristics	0
may	0
be	0
associated	0
with	0
reactions	0
of	0
the	0
host	0
with	0
breast	0
cancer	0
.	0

[	0
The	0
value	0
of	0
the	0
clinical	0
test	0
of	0
glucocorticoid	9
receptors	10
of	0
peripheral	7
blood	8
leukocytes	8
in	0
patients	0
with	0
chronic	0
pulmonary	0
heart	0
disease	0
]	0

In	0
order	0
to	0
inquire	0
into	0
the	0
functional	0
state	0
of	0
adrenal	0
cortex	0
in	0
patients	0
with	0
pulmonary	0
heart	0
disease	0
,	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
(	0
GCR	9
)	0
of	0
peripheral	7
blood	8
leukocytes	8
in	0
patients	0
with	0
chronic	0
pulmonary	0
heart	0
disease	0
was	0
determined	0
with	0
radioligand-binding	0
assay	0
and	0
the	0
corresponding	0
plasma	0
cortisol	0
levels	0
were	0
assessed	0
with	0
radioimmune	0
assays	0
.	0

The	0
results	0
showed	0
that	0
the	0
number	0
of	0
GCR	9
in	0
the	0
patients	0
was	0
significantly	0
reduced	0
(	0
P	0
<	0
0.01	0
)	0
and	0
it	0
was	0
increased	0
when	0
their	0
health	0
state	0
was	0
improved	0
.	0

However	0
,	0
it	0
was	0
still	0
lower	0
than	0
that	0
in	0
healthy	0
subjects	0
(	0
P	0
<	0
0.01	0
)	0
.	0

The	0
number	0
of	0
GCR	9
in	0
the	0
patients	0
was	0
greatly	0
increased	0
when	0
these	0
patients	0
were	0
treated	0
with	0
oxygen	0
(	0
P	0
<	0
0.01	0
)	0
.	0

No	0
difference	0
in	0
plasma	0
cortisol	0
was	0
found	0
between	0
the	0
patients	0
and	0
the	0
healthy	0
subjects	0
(	0
P	0
>	0
0.05	0
)	0
.	0

These	0
results	0
indicate	0
that	0
the	0
function	0
of	0
adrenal	0
cortex	0
may	0
be	0
improved	0
by	0
the	0
compensation	0
mechanism	0
of	0
the	0
patients	0
,	0
but	0
the	0
lower	0
GCR	9
number	0
was	0
the	0
result	0
of	0
lacking	0
of	0
oxygen	0
in	0
the	0
patients	0
.	0

The	0
number	0
of	0
GCR	9
may	0
be	0
improved	0
by	0
inhalation	0
of	0
oxygen	0
.	0

Therefore	0
oxygen	0
therapy	0
is	0
helpful	0
in	0
raising	0
the	0
activity	0
of	0
glucocorticoid	9
receptors	10
and	0
controlling	0
the	0
development	0
of	0
the	0
disease	0
.	0

Signaling	0
via	0
IL-2	9
and	0
IL-4	9
in	0
JAK3-deficient	5
severe	6
combined	6
immunodeficiency	6
lymphocytes	6
:	0
JAK3	9
-dependent	0
and	0
independent	0
pathways	0
.	0

Both	0
IL-2	9
and	0
IL-4	9
bind	0
to	0
receptors	0
containing	0
the	0
common	9
gamma	10
chain	10
and	0
JAK3	9
.	0

Although	0
JAK3	9
is	0
required	0
for	0
proper	0
lymphoid	0
development	0
,	0
the	0
precise	0
roles	0
of	0
this	0
kinase	0
in	0
IL-2	9
and	0
IL-4	9
signaling	0
in	0
lymphocytes	7
have	0
not	0
been	0
defined	0
.	0

Here	0
,	0
we	0
have	0
studied	0
IL-2	9
and	0
IL-4	9
signaling	0
in	0
B	5
cell	6
lines	6
lacking	0
JAK3	9
.	0

Although	0
IL-2	9
-induced	0
phosphorylation	0
of	0
IL-2R	9
beta	10
,	0
JAK1	9
,	0
and	0
STAT5	9
all	0
required	0
the	0
presence	0
of	0
JAK3	9
,	0
IL-4	9
-mediated	0
phosphorylation	0
of	0
JAK1	9
,	0
STAT6	9
,	0
and	0
insulin	9
receptor	10
substrates	0
1	0
and	0
2	0
did	0
not	0
.	0

However	0
,	0
IL-4	9
-induced	0
effects	0
were	0
clearly	0
improved	0
following	0
JAK3	9
expression	0
.	0

These	0
data	0
indicate	0
that	0
IL-4	9
signaling	0
occurs	0
in	0
the	0
absence	0
of	0
of	0
JAK3	9
,	0
but	0
is	0
comparatively	0
inefficient	0
.	0

These	0
findings	0
may	0
help	0
in	0
understanding	0
the	0
pathogenesis	0
of	0
the	0
immunodeficiency	0
that	0
occurs	0
with	0
mutations	0
of	0
JAK3	9
and	0
may	0
suggest	0
a	0
mechanism	0
for	0
the	0
pleiotropic	0
effects	0
of	0
IL-4	9
.	0

Elf-1	9
and	0
Stat5	9
bind	0
to	0
a	0
critical	0
element	0
in	0
a	0
new	0
enhancer	0
of	0
the	0
human	1
interleukin-2	2
receptor	2
alpha	2
gene	2
[	0
published	0
erratum	0
appears	0
in	0
Mol	0
Cell	0
Biol	0
1997	0
Apr	0
;	0
17	0
(	0
4	0
)	0
:	0
2351	0
]	0

The	0
interleukin	1
2	2
receptor	2
alpha-chain	2
(	2
IL-2R	2
alpha	2
)	2
gene	2
is	0
a	0
key	0
regulator	0
of	0
lymphocyte	0
proliferation	0
.	0

IL-2R	9
alpha	10
is	0
rapidly	0
and	0
potently	0
induced	0
in	0
T	7
cells	8
in	0
response	0
to	0
mitogenic	0
stimuli	0
.	0

Interleukin	9
2	10
(	0
IL-2	9
)	0
stimulates	0
IL-2R	9
alpha	10
.	0

transcription	0
,	0
thereby	0
amplifying	0
expression	0
of	0
its	0
own	0
high-affinity	9
receptor	10
.	0

IL-2R	9
alpha	10
transcription	0
is	0
at	0
least	0
in	0
part	0
controlled	0
by	0
two	0
positive	9
regulatory	10
regions	10
,	0
PRRI	1
and	0
PRRII	1
.	0

PRRI	1
is	0
an	0
inducible	1
proximal	2
enhancer	2
,	0
located	0
between	1
nucleotides	2
-276	2
and	2
-244	2
,	0
which	0
contains	0
NF-kappaB	1
and	2
SRE/CArG	2
motifs	2
.	0

PRRII	1
is	0
a	0
T-cell-specific	1
enhancer	2
,	0
located	0
between	0
nucleotides	0
-137	0
and	0
-64	0
,	0
which	0
binds	0
the	0
T-cell-specific	9
Ets	10
protein	10
Elf-1	9
and	0
HMG-I	9
(	10
Y	10
)	10
proteins	10
.	0

However	0
,	0
none	0
of	0
these	0
proximal	0
regions	0
account	0
for	0
the	0
induction	0
of	0
IL-2R	0
alpha	0
transcription	0
by	0
IL-2	9
.	0

To	0
find	0
new	0
regulatory	1
regions	2
of	0
the	0
IL-2R	1
alpha	2
gene	2
,	0
8.5	0
kb	0
of	0
the	0
5	0
'	0
end	0
noncoding	0
sequence	0
of	0
the	0
IL-2R	1
alpha	2
gene	2
have	0
been	0
sequenced	0
.	0

We	0
identified	0
an	0
86-nucleotide	0
fragment	0
that	0
is	0
90	0
%	0
identical	0
to	0
the	0
recently	0
characterized	0
murine	1
IL-2-responsive	2
element	2
(	0
mIL-2rE	1
)	0
.	0

This	0
putative	0
human	1
IL-2rE	2
,	0
designated	0
PRRIII	1
,	0
confers	0
IL-2	9
responsiveness	0
on	0
a	0
heterologous	1
promoter	2
.	0

PRRIII	1
contains	0
a	0
Stat	1
protein	2
binding	2
site	2
that	0
overlaps	0
with	0
an	0
EBS	1
motif	2
(	0
GASd/EBSd	1
)	0
.	0

These	0
are	0
essential	0
for	0
IL-2	9
inducibility	0
of	0
PRRIII/CAT	1
reporter	2
constructs	2
.	0

IL-2	9
induced	0
the	0
binding	0
of	0
Stat5a	9
and	10
b	10
proteins	10
to	0
the	0
human	1
GASd	2
element	2
.	0

To	0
confirm	0
the	0
physiological	0
relevance	0
of	0
these	0
findings	0
,	0
we	0
carried	0
out	0
in	0
vivo	0
footprinting	0
experiments	0
which	0
showed	0
that	0
stimulation	0
of	0
IL-2R	9
alpha	10
expression	0
correlated	0
with	0
occupancy	0
of	0
the	0
GASd	1
element	2
.	0

Our	0
data	0
demonstrate	0
a	0
major	0
role	0
of	0
the	0
GASd/EBSd	1
element	2
in	0
IL-2R	9
alpha	10
regulation	0
and	0
suggest	0
that	0
the	0
T-cell-specific	9
Elf-1	10
factor	10
can	0
serve	0
as	0
a	0
transcriptional	9
repressor	10
.	0

Signal	0
transduction	0
by	0
DR3	9
,	0
a	0
death	9
domain-containing	10
receptor	10
related	0
to	0
TNFR-1	9
and	0
CD95	9
.	0

Tumor	9
necrosis	10
factor	10
receptor-1	10
(	0
TNFR-1	9
)	0
and	0
CD95	9
(	0
also	0
called	0
Fas	9
or	0
APO-1	9
)	0
are	0
cytokine	9
receptors	10
that	0
engage	0
the	0
apoptosis	0
pathway	0
through	0
a	0
region	0
of	0
intracellular	0
homology	0
,	0
designated	0
the	0
``	0
death	9
domain	10
.	0
''	0
Another	0
death	9
domain-containing	10
member	10
of	0
the	0
TNFR	9
family	10
,	0
death	9
receptor	10
3	10
(	0
DR3	9
)	0
,	0
was	0
identified	0
and	0
was	0
shown	0
to	0
induce	0
both	0
apoptosis	0
and	0
activation	0
of	0
nuclear	9
factor	10
kappaB	10
.	0

Expression	0
of	0
DR3	9
appears	0
to	0
be	0
restricted	0
to	0
tissues	0
enriched	0
in	0
lymphocytes	7
.	0

DR3	9
signal	0
transduction	0
is	0
mediated	0
by	0
a	0
complex	0
of	0
intracellular	9
signaling	10
molecules	10
including	0
TRADD	9
,	0
TRAF2	9
,	0
FADD	9
,	0
and	0
FLICE	9
.	0

Thus	0
,	0
DR3	9
likely	0
plays	0
a	0
role	0
in	0
regulating	0
lymphocyte	0
homeostasis	0
.	0

Differential	0
nuclear	0
localization	0
of	0
p50	9
,	0
p52	9
,	0
and	0
RelB	9
proteins	0
in	0
human	7
accessory	8
cells	8
of	0
the	0
immune	0
response	0
in	0
situ	0
.	0

The	0
Rel/NF-kappa	9
B	10
proteins	10
,	0
p50	9
,	0
p52	9
,	0
p65	9
,	0
c-Rel	9
,	0
and	0
RelB	9
,	0
constitute	0
a	0
family	0
of	0
transcription	9
factors	10
involved	0
in	0
the	0
positive	0
regulation	0
of	0
a	0
variety	0
of	0
genes	0
during	0
the	0
immune	0
response	0
.	0

Recently	0
,	0
it	0
has	0
been	0
shown	0
that	0
RelB	9
knockout	0
mice	0
have	0
no	0
dendritic	7
cells	8
(	0
DC	7
)	0
.	0

An	0
overexpression	0
of	0
p50	9
has	0
been	0
described	0
in	0
follicular	7
dendritic	8
cells	8
(	0
FDC	7
)	0
.	0

A	0
constitutive	0
NF-kappa	9
B	10
activity	0
has	0
been	0
reported	0
in	0
mature	7
macrophages	8
.	0

This	0
led	0
to	0
the	0
hypothesis	0
that	0
some	0
of	0
the	0
Rel/NF-kappa	9
B	10
proteins	10
were	0
key	0
nuclear	9
factors	10
in	0
functions	0
of	0
accessory	7
cells	8
of	0
the	0
immune	0
response	0
.	0

Therefore	0
,	0
we	0
investigated	0
in	0
situ	0
the	0
nuclear	0
localization	0
of	0
Rel/NF-kappa	9
B	10
proteins	10
in	0
accessory	7
cells	8
of	0
the	0
immune	0
system	0
by	0
immunohistochemistry	0
and	0
double	0
labeling	0
by	0
immunofluorescence	0
from	0
five	0
normal	0
human	0
tonsils	0
and	0
five	0
lymph	0
nodes	0
with	0
follicular	0
hyperplasia	0
.	0

Nuclear	0
p65	9
and	0
c-Rel	9
proteins	0
were	0
found	0
in	0
all	0
cell	0
types	0
including	0
lymphocytes	7
.	0

In	0
germinal	0
centers	0
GC	0
,	0
p50	9
,	0
p52	9
,	0
and	0
RelB	9
were	0
found	0
in	0
the	0
nuclei	0
of	0
FDC	7
only	0
and	0
were	0
not	0
detected	0
in	0
the	0
nuclei	0
of	0
CD68+	5
cells	6
.	0

In	0
T	0
cell	0
areas	0
,	0
p50	9
,	0
p52	9
,	0
and	0
RelB	9
were	0
found	0
in	0
the	0
nuclei	0
of	0
HLA-DR+	5
cells	6
with	0
an	0
antigen-presenting	0
cell	0
(	0
APC	0
)	0
morphology	0
.	0

p52	9
and	0
RelB	9
were	0
detected	0
in	0
the	0
nuclei	0
in	0
both	0
CD1a+	5
and	0
CD68+	5
cells	6
from	0
the	0
T	0
cell	0
area	0
,	0
whereas	0
p50	9
was	0
found	0
only	0
in	0
CD68-	5
and	6
CD1a-	6
cells	6
.	0

Cells	0
with	0
nuclear	0
p50	9
were	0
negative	0
for	0
the	0
CD38	9
,	0
CD20	9
and	0
CD2	9
markers	10
.	0

These	0
results	0
show	0
that	0
,	0
physiologically	0
,	0
high	0
levels	0
of	0
nuclear	0
of	0
p50	9
,	0
p52	9
and	0
RelB	9
are	0
restricted	0
to	0
accessory	7
cells	8
of	0
the	0
immune	0
system	0
,	0
which	0
include	0
FDC	7
in	0
GC	0
,	0
and	0
DC	7
and	0
macrophages	0
in	0
the	0
T	0
cell	0
zone	0
,	0
that	0
specialized	0
scavenger	7
macrophages	8
from	0
GC	7
do	0
not	0
have	0
detectable	0
levels	0
of	0
p52	9
and	0
RelB	9
,	0
whereas	0
macrophages	7
from	0
the	0
T	0
cell	0
area	0
,	0
known	0
to	0
present	0
the	0
antigen	0
to	0
T	7
cells	8
,	0
do	0
have	0
both	0
nuclear	0
p52	9
and	0
RelB	9
,	0
and	0
that	0
in	0
the	0
T	0
cell	0
zone	0
,	0
p52	9
and	0
RelB	9
are	0
located	0
in	0
nuclei	0
of	0
both	0
CD1a+	5
,	0
CD68+	5
or	0
both	0
,	0
cells	0
APC	7
,	0
whereas	0
p50	9
is	0
restricted	0
to	0
CD1a-	7
and	0
CD68-	7
APC	8
.	0

The	0
different	0
patterns	0
of	0
p50	9
,	0
p52	9
and	0
RelB	9
protein	0
nuclear	0
localization	0
may	0
provide	0
insight	0
into	0
their	0
different	0
roles	0
during	0
the	0
immune	0
response	0
in	0
vivo	0
.	0

Tyrosines	0
113	0
,	0
128	0
,	0
and	0
145	0
of	0
SLP-76	9
are	0
required	0
for	0
optimal	0
augmentation	0
of	0
NFAT	1
promoter	2
activity	0
.	0

SLP-76	9
(	0
SH2	9
domain	10
leukocyte	10
protein	10
of	0
76	0
kDa	0
)	0
is	0
a	0
recently	0
identified	0
substrate	0
of	0
the	0
TCR-stimulated	9
protein	10
tyrosine	9
kinases	10
that	0
functions	0
in	0
the	0
signal	0
transduction	0
cascade	0
linking	0
the	0
TCR	9
with	0
IL-2	9
gene	0
expression	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
engagement	0
of	0
the	0
TCR	9
results	0
in	0
tyrosine	0
phosphorylation	0
of	0
SLP-76	9
in	0
its	0
amino-terminal	9
acidic	10
region	10
.	0

Two	0
tyrosines	0
(	0
Y113	0
and	0
Y128	0
)	0
fall	0
within	0
an	0
identical	0
five	0
amino-acid	0
motif	0
and	0
are	0
shown	0
to	0
be	0
phosphorylated	0
upon	0
TCR	9
ligation	0
.	0

Although	0
mutation	0
of	0
either	0
Y113	0
and	0
Y128	0
has	0
a	0
minimal	0
effect	0
on	0
SLP-76	9
function	0
,	0
mutation	0
of	0
both	0
residues	0
decreases	0
significantly	0
the	0
ability	0
of	0
SLP-76	9
to	0
promote	0
T	0
cell	0
activation	0
.	0

A	0
third	0
tyrosine	0
within	0
the	0
amino-terminal	9
region	10
(	0
Y145	0
)	0
appears	0
to	0
be	0
the	0
most	0
important	0
for	0
optimal	0
SLP-76	9
function	0
,	0
as	0
altering	0
it	0
alone	0
to	0
phenylalanine	0
has	0
a	0
potent	0
impact	0
on	0
SLP-76	9
augmentation	0
of	0
NFAT	1
promoter	2
activity	0
.	0

Human	1
interferon	2
regulatory	2
factor	2
2	2
gene	2
.	0

Intron-exon	0
organization	0
and	0
functional	0
analysis	0
of	0
5'-flanking	1
region	2
.	0

Interferon	9
regulatory	10
factor	10
2	10
(	0
IRF-2	9
)	0
is	0
a	0
transcriptional	9
regulatory	10
protein	10
that	0
terminates	0
interferon	9
beta	10
expression	0
initiated	0
by	0
interferon	9
regulatory	10
factor	10
1	10
.	0

In	0
this	0
study	0
,	0
we	0
isolated	0
the	0
genomic	1
DNA	2
for	0
human	1
IRF-2	2
gene	2
,	0
determined	0
the	0
intron-exon	0
structure	0
of	0
the	0
human	1
IRF-2	2
gene	2
,	0
mapped	0
the	0
major	1
transcription	2
initiation	2
site	2
,	0
identified	0
a	0
number	0
of	0
potential	0
regulatory	0
elements	0
in	0
the	0
5'-flanking	1
region	2
,	0
and	0
localized	0
the	0
IRF-2	1
gene	2
on	0
human	1
chromosome	2
4	2
.	0

The	0
IRF-2	9
promoter	1
region	2
contains	0
a	0
CpG	0
island	0
,	0
with	0
several	0
GC	1
boxes	2
,	0
a	0
putative	0
NF-kappa	1
B-binding	2
site	2
,	0
and	0
a	0
CAAT	1
box	2
,	0
but	0
no	0
TATA	1
box	2
.	0

When	0
the	0
promoter	1
region	2
was	0
linked	0
with	0
a	0
heterologous	1
reporter	2
gene	2
,	0
we	0
found	0
that	0
the	0
promoter	1
region	2
is	0
inducible	0
by	0
both	0
interferons	9
(	0
interferon-alpha	9
and	10
-gamma	10
)	0
and	0
interferon	9
regulatory	10
factor	10
1	10
.	0

The	0
region	0
which	0
induced	0
these	0
inductions	0
was	0
identified	0
as	0
being	0
confined	0
to	0
40	1
nucleotides	2
5	2
'	2
to	0
the	0
major	1
transcriptional	2
initiation	2
site	2
by	0
testing	0
a	0
series	0
of	0
clones	0
with	0
truncated	1
promoter	2
of	0
IRF-2	9
.	0

This	0
region	0
contains	0
elements	0
which	0
are	0
shared	0
with	0
the	0
transcriptional	1
enhancers	2
of	0
other	0
genes	0
including	0
interferon	9
regulatory	10
factor	10
1	10
,	0
interferon	9
beta	10
,	0
and	0
interferon-inducible	1
genes	2
.	0

These	0
data	0
suggest	0
that	0
interferon	9
regulatory	10
factor	10
1	10
not	0
only	0
triggers	0
the	0
activation	0
of	0
the	0
interferon	9
signal	0
transduction	0
pathway	0
,	0
but	0
also	0
may	0
play	0
a	0
role	0
in	0
limiting	0
the	0
duration	0
of	0
this	0
response	0
by	0
activating	0
the	0
transcription	0
of	0
IRF-2	9
.	0

Interferon	9
alpha	10
selectively	0
affects	0
expression	0
of	0
the	0
human	9
myeloid	10
cell	10
nuclear	10
differentiation	10
antigen	10
in	0
late	7
stage	8
cells	8
in	0
the	0
monocytic	7
but	0
not	0
the	0
granulocytic	7
lineage	8
.	0

The	0
human	9
myeloid	10
cell	10
nuclear	10
differentiation	10
antigen	10
(	0
MNDA	9
)	0
is	0
expressed	0
constitutively	0
in	0
cells	0
of	0
the	0
myeloid	7
lineage	8
,	0
appearing	0
in	0
myeloblast	7
cells	8
in	0
some	0
cases	0
of	0
acute	0
myeloid	0
leukemia	0
and	0
consistently	0
being	0
detected	0
in	0
promyelocyte	7
stage	8
cells	8
as	0
well	0
as	0
in	0
all	0
later	7
stage	8
cells	8
including	0
peripheral	7
blood	8
monocytes	8
and	0
granulocytes	7
.	0

The	0
human	5
myeloid	6
leukemia	6
cell	6
lines	6
,	0
HL-60	5
,	0
U937	5
,	0
and	0
THP-1	5
,	0
express	0
similar	0
levels	0
of	0
immunochemically	0
detectable	0
MNDA	9
.	0

Although	0
,	0
the	0
level	0
of	0
MNDA	3
mRNA	4
in	0
primary	7
monocytes	8
is	0
very	0
low	0
it	0
was	0
up-regulated	0
at	0
6	0
h	0
following	0
the	0
addition	0
of	0
interferon	9
alpha	10
.	0

The	0
effect	0
of	0
interferon	9
alpha	10
on	0
the	0
MNDA	3
mRNA	4
is	0
also	0
observed	0
in	0
the	0
cell	5
lines	6
HL-60	5
,	0
U937	5
,	0
and	0
THP-1	5
.	0

The	0
MNDA	3
mRNA	4
level	0
in	0
primary	7
granulocytes	8
was	0
unaffected	0
by	0
addition	0
of	0
interferon	9
alpha	10
and	0
other	0
agents	0
including	0
interferon	9
gamma	10
,	0
endotoxin	9
,	0
poly	9
(	10
I	10
)	10
.poly	10
(	10
C	10
)	10
,	0
and	0
FMLP	9
.	0

The	0
MNDA	3
mRNA	4
level	0
in	0
the	0
myeloid	5
cell	6
lines	6
was	0
also	0
unaffected	0
by	0
the	0
latter	0
four	0
agents	0
.	0

Induction	0
of	0
differentiation	0
in	0
the	0
myeloid	5
cell	6
lines	6
with	0
phorbol	0
ester	0
induces	0
monocyte	0
differentiation	0
which	0
was	0
accompanied	0
by	0
a	0
decrease	0
in	0
MNDA	3
mRNA	4
level	0
.	0

This	0
reduced	0
level	0
of	0
mRNA	3
could	0
then	0
be	0
elevated	0
with	0
subsequent	0
interferon	9
alpha	10
treatment	0
.	0

The	0
effects	0
of	0
phorbol	0
ester	0
on	0
MNDA	3
mRNA	4
appeared	0
to	0
be	0
associated	0
with	0
induced	0
differentiation	0
since	0
inhibiting	0
cell	0
proliferation	0
did	0
not	0
alter	0
the	0
level	0
of	0
MNDA	3
mRNA	4
and	0
cell	0
cycle	0
variation	0
in	0
MNDA	3
mRNA	4
levels	0
were	0
not	0
observed	0
.	0

The	0
ability	0
of	0
interferon	9
alpha	10
to	0
up-regulate	0
MNDA	3
mRNA	4
in	0
phorbol	0
ester	0
treated	0
myeloid	5
cell	6
lines	6
is	0
consistent	0
with	0
the	0
observations	0
made	0
in	0
primary	7
monocytes	8
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Involvement	0
of	0
transcription	9
factor	10
YB-1	9
in	0
human	0
T-cell	0
lymphotropic	0
virus	0
type	0
I	0
basal	0
gene	0
expression	0
.	0

Sequences	0
which	0
control	0
basal	0
human	0
T-cell	0
lymphotropic	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
transcription	0
likely	0
play	0
an	0
important	0
role	0
in	0
initiation	0
and	0
maintenance	0
of	0
virus	0
replication	0
.	0

We	0
previously	0
identified	0
and	0
analyzed	0
a	0
45-nucleotide	1
sequence	2
(	0
downstream	1
regulatory	2
element	2
1	2
[	0
DRE	1
1	2
]	0
)	0
,	0
+195	1
to	2
+240	2
,	0
at	0
the	0
boundary	0
of	0
the	0
R/U5	1
region	2
of	0
the	0
long	1
terminal	2
repeat	2
which	0
is	0
required	0
for	0
HTLV-I	0
basal	0
transcription	0
.	0

We	0
identified	0
a	0
protein	0
,	0
p37	0
,	0
which	0
specifically	0
bound	0
to	0
DRE	1
1	2
.	0

An	0
affinity	0
column	0
fraction	0
,	0
containing	0
p37	9
,	0
stimulated	0
HTLV-I	0
transcription	0
approximately	0
12-fold	0
in	0
vitro	0
.	0

We	0
now	0
report	0
the	0
identification	0
of	0
a	0
cDNA	1
clone	2
(	0
15B-7	1
)	0
,	0
from	0
a	0
Jurkat	1
expression	2
library	2
,	0
that	0
binds	0
specifically	0
to	0
the	0
DRE	1
1	2
regulatory	2
sequence	2
.	0

Binding	0
of	0
the	0
cDNA	9
fusion	10
protein	10
,	0
similarly	0
to	0
the	0
results	0
obtained	0
with	0
purified	0
Jurkat	0
protein	0
,	0
was	0
decreased	0
by	0
introduction	0
of	0
site-specific	0
mutations	0
in	0
the	0
DRE	1
1	2
regulatory	2
sequence	2
.	0

In	0
vitro	0
transcription	0
and	0
translation	0
of	0
15B-7	1
cDNA	2
produced	0
a	0
fusion	9
protein	10
which	0
bound	0
specifically	0
to	0
the	0
HTLV-I	0
+195	0
to	0
+240	0
oligonucleotide	0
.	0

The	0
partial	1
cDNA	2
encodes	0
a	0
protein	0
which	0
is	0
homologous	0
to	0
the	0
C-terminal	9
196	10
amino	10
acids	10
of	0
the	0
36-kDa	9
transcription	10
factor	10
,	0
YB-1	9
.	0

Cotransfection	0
of	0
a	0
YB-1	1
expression	2
plasmid	2
increases	0
HTLV-I	0
basal	0
transcription	0
approximately	0
14-fold	0
in	0
Jurkat	5
T	6
lymphocytes	6
.	0

On	0
the	0
basis	0
of	0
the	0
molecular	0
weight	0
,	0
DNA-binding	0
characteristics	0
,	0
and	0
in	0
vivo	0
transactivation	0
activity	0
,	0
we	0
suggest	0
that	0
the	0
previously	0
identified	0
DRE	1
1	2
-binding	0
protein	0
,	0
p37	9
,	0
is	0
YB-1	9
.	0

Changes	0
in	0
triiodothyronine	0
(	0
T3	0
)	0
mononuclear	0
leukocyte	0
receptor	0
kinetics	0
after	0
T3	0
administration	0
and	0
multiple	0
cold-air	0
exposures	0
.	0

Repeated	0
cold-air	0
exposures	0
increase	0
human	0
triiodothyronine	0
(	0
T3	0
)	0
plasma	0
clearance	0
rates	0
.	0

To	0
study	0
the	0
response	0
of	0
the	0
nuclear	9
T3	10
receptor	10
(	0
NT3R	9
)	0
in	0
this	0
condition	0
,	0
binding	0
characteristics	0
were	0
analyzed	0
in	0
human	7
mononuclear	8
leukocytes	8
(	0
MNL	7
)	0
.	0

In	0
addition	0
,	0
we	0
supplemented	0
one	0
group	0
of	0
individuals	0
with	0
a	0
daily	0
oral	0
replacement	0
dose	0
of	0
T3	0
to	0
isolate	0
the	0
influence	0
of	0
serum	0
thyroxine	0
(	0
T4	0
)	0
and	0
thyrotropin	0
(	0
TSH	0
)	0
levels	0
on	0
receptor	0
kinetics	0
.	0

The	0
subjects	0
were	0
exposed	0
to	0
cold	0
air	0
(	0
4	0
degrees	0
C	0
)	0
twice/d	0
,	0
30	0
min/exposure	0
,	0
for	0
a	0
total	0
of	0
80	0
exposures	0
.	0

The	0
T3-subjects	0
received	0
placebo	0
[	0
n	0
=	0
8	0
]	0
and	0
the	0
T3	0
+	0
subjects	0
received	0
T3	0
(	0
30	0
micrograms/d	0
)	0
[	0
n	0
=	0
8	0
]	0
in	0
a	0
double-blind	0
fashion	0
.	0

Mononuclear	7
leukocytes	8
were	0
isolated	0
from	0
peripheral	0
blood	0
before	0
the	0
cold	0
exposure	0
and	0
drug	0
regimen	0
began	0
,	0
and	0
then	0
after	0
every	0
20	0
exposures	0
.	0

The	0
dissociation	0
constant	0
(	0
Kd	0
)	0
and	0
maximum	0
binding	0
capacity	0
(	0
MBC	0
)	0
of	0
the	0
NT3R	9
values	0
were	0
log	0
transformed	0
to	0
minimize	0
between-subject	0
variability	0
.	0

In	0
the	0
T3+	0
group	0
,	0
serum	0
total	0
thyroxine	0
(	0
TT4	0
)	0
,	0
free	0
T4	0
(	0
FT4	0
)	0
,	0
and	0
TSH	0
were	0
approx	0
50	0
%	0
lower	0
than	0
both	0
basal	0
and	0
T3-values	0
.	0

The	0
log10Kd	0
increased	0
0.304	0
+/-	0
0.139	0
(	0
p	0
<	0
0.04	0
)	0
and	0
the	0
log10MBC	0
increased	0
0.49	0
+/-	0
0.10	0
(	0
p	0
<	0
0.001	0
)	0
in	0
the	0
T3+	0
subjects	0
compared	0
to	0
baseline	0
.	0

This	0
change	0
in	0
MBC	0
represents	0
a	0
311	0
%	0
increase	0
in	0
the	0
MBC	0
over	0
baseline	0
and	0
a	0
fivefold	0
increase	0
over	0
placebo-treated	0
subjects	0
.	0

The	0
T3	0
-group	0
showed	0
no	0
change	0
in	0
MBC	0
over	0
the	0
study	0
.	0

These	0
results	0
describe	0
for	0
the	0
first	0
time	0
the	0
rapid	0
modulation	0
of	0
the	0
NT3R	9
in	0
response	0
to	0
the	0
combined	0
influence	0
of	0
cold	0
exposure	0
and	0
reduced	0
circulating	0
T4	0
and	0
TSH	0
.	0

HIV-1	1
LTR	2
activity	0
in	0
human	5
CD40-activated	6
B	6
lymphocytes	6
is	0
dependent	0
on	0
NF-kappaB	9
.	0

CD40-stimulated	5
human	6
B	6
lymphocytes	6
are	0
highly	0
permissive	0
to	0
a	0
productive	0
infection	0
by	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
.	0

In	0
these	0
cells	0
,	0
nuclear	9
factors	10
involved	0
in	0
activation	0
of	0
the	0
HIV-1	1
LTR	2
,	0
which	0
contains	0
the	0
transcriptional	1
control	2
elements	2
of	0
the	0
virus	0
,	0
are	0
unknown	0
.	0

Transient	0
expression	0
assays	0
with	0
plasmids	0
containing	0
deleted	0
parts	0
of	0
the	0
LTR	1
region	2
linked	0
to	0
a	0
reporter	0
gene	0
showed	0
that	0
the	0
NF-kappaB	1
binding	2
site	2
was	0
essential	0
for	0
HIV-1	1
LTR	2
activity	0
in	0
CD40-stimulated	5
B	6
lymphocytes	6
.	0

In	0
addition	0
,	0
electrophoretic	0
mobility	0
shift	0
and	0
supershift	0
assays	0
revealed	0
that	0
important	0
NF-kappaB	9
binding	0
activity	0
composed	0
of	0
at	0
least	0
p50	9
,	0
p65	9
,	0
and	0
c-Rel	9
NF-kappaB	9
subunits	10
was	0
present	0
in	0
nuclei	0
of	0
CD40-stimulated	5
B	6
cells	6
.	0

These	0
results	0
confirm	0
at	0
a	0
molecular	0
level	0
the	0
ability	0
of	0
HIV-1	0
to	0
replicate	0
in	0
B	7
cells	8
and	0
that	0
this	0
activity	0
is	0
strongly	0
associated	0
with	0
NF-kappaB	9
.	0

Sequence	0
analysis	0
and	0
expression	0
in	0
cultured	7
lymphocytes	8
of	0
the	0
human	0
FOSB	1
gene	2
(	0
G0S3	1
)	0
.	0

G0S3	1
is	0
a	0
member	0
of	0
a	0
set	0
of	0
putative	1
G0/G1	2
switch	2
regulatory	2
genes	2
(	0
G0S	1
genes	2
)	0
selected	0
by	0
screening	0
cDNA	1
libraries	2
prepared	0
from	0
human	7
blood	8
mononuclear	8
cells	8
cultured	0
for	0
2	0
hr	0
with	0
lectin	9
and	0
cycloheximide	0
.	0

The	0
sequence	0
shows	0
high	0
homology	0
with	0
the	0
murine	1
FOSB	2
gene	2
,	0
which	0
encodes	0
a	0
component	0
of	0
the	0
AP1	9
transcriptional	10
regulator	10
.	0

Comparison	0
of	0
cDNA	1
and	0
genomic	0
sequences	0
reveals	0
a	0
4-exon	1
structure	2
characteristic	0
of	0
the	0
FOS	1
family	2
of	2
genes	2
.	0

Freshly	0
isolated	0
cells	0
show	0
high	0
levels	0
of	0
FOSB/G0S3	3
and	4
FOS/G0S7	4
mRNAs	4
,	0
which	0
decline	0
rapidly	0
during	0
incubation	0
in	0
culture	0
medium	0
.	0

The	0
kinetics	0
of	0
expression	0
suggest	0
that	0
the	0
high	0
initial	0
levels	0
are	0
caused	0
by	0
the	0
isolation	0
procedure	0
,	0
and	0
do	0
not	0
reflect	0
constitutive	0
expression	0
.	0

In	0
cells	0
preincubated	0
for	0
a	0
day	0
,	0
levels	0
of	0
FOS	3
mRNA	4
reach	0
a	0
maximum	0
20	0
min	0
after	0
the	0
addition	0
of	0
lectin	9
and	0
decline	0
to	0
control	0
levels	0
over	0
the	0
next	0
3	0
hr	0
.	0

Levels	0
of	0
FOSB	3
mRNA	4
reach	0
a	0
maximum	0
40	0
min	0
after	0
the	0
addition	0
of	0
lectin	9
and	0
decline	0
to	0
control	0
levels	0
over	0
the	0
next	0
6	0
hr	0
.	0

In	0
freshly	0
isolated	0
cells	0
,	0
both	0
FOS	3
and	4
FOSB	4
mRNAs	4
increase	0
dramatically	0
in	0
response	0
to	0
the	0
protein	0
synthesis	0
inhibitor	0
cycloheximide	0
.	0

In	0
preincubated	0
cells	0
,	0
the	0
cycloheximide	0
response	0
is	0
decreased	0
,	0
especially	0
in	0
the	0
case	0
of	0
FOSB	1
.	0

These	0
differences	0
in	0
expression	0
of	0
FOS	1
and	0
FOSB	1
suggest	0
different	0
roles	0
and	0
regulation	0
.	0

Regions	0
of	0
low	0
base	0
order-dependent	0
stem-loop	0
potential	0
in	0
the	0
region	0
of	0
the	0
gene	0
are	0
defined	0
.	0

These	0
indicate	0
where	0
base	0
order	0
has	0
been	0
adapted	0
for	0
purposes	0
other	0
than	0
stem-loop	0
stability	0
(	0
e.g.	0
,	0
encoding	0
proteins	0
or	0
gene	0
regulation	0
)	0
.	0

Regions	0
of	0
low	0
potential	0
in	0
a	0
68.5-kb	0
genomic	0
segment	0
containing	0
the	0
FOSB	1
gene	2
suggest	0
that	0
the	0
potential	0
may	0
help	0
locate	0
genes	0
in	0
uncharted	1
DNA	2
sequences	2
.	0

Susceptibility	0
to	0
natural	7
killer	8
cells	8
and	0
down	0
regulation	0
of	0
MHC	9
class	0
I	0
expression	0
in	0
adenovirus	5
12	6
transformed	6
cells	6
are	0
regulated	0
by	0
different	0
E1A	1
domains	2
.	0

All	0
human	0
adenoviruses	0
transform	0
rodent	7
cells	8
in	0
vitro	0
,	0
but	0
only	0
cells	0
transformed	0
by	0
serotypes	0
belonging	0
to	0
subgroups	0
A	0
(	0
Ad12	0
)	0
and	0
B	0
(	0
Ad3	0
)	0
are	0
tumorigenic	0
for	0
immunocompetent	0
animals	0
.	0

In	0
these	0
cells	0
,	0
the	0
expression	0
of	0
MHC-class	9
I	10
antigens	10
is	0
repressed	0
and	0
might	0
allow	0
them	0
to	0
escape	0
from	0
recognition	0
by	0
cytotoxic	7
T	8
lymphocytes	8
(	0
CTL	7
)	0
and	0
to	0
develop	0
in	0
tumor	0
.	0

Furthermore	0
,	0
these	0
cell	5
lines	6
appear	0
resistant	0
to	0
lysis	0
by	0
natural	7
killer	8
(	8
NK	8
)	8
cells	8
.	0

To	0
determine	0
the	0
E1A	1
domain	2
(	0
s	0
)	0
responsible	0
for	0
these	0
properties	0
several	0
cell	5
lines	6
were	0
created	0
by	0
transforming	0
baby	5
rat	6
kidney	6
(	6
BRK	6
)	6
cells	6
with	0
a	0
set	0
of	0
plasmids	1
expressing	0
different	0
Ad2/Ad12	9
hybrid	10
E1A	10
gene	10
products	10
.	0

The	0
MHC	1
class	2
1	2
gene	2
expression	0
was	0
inhibited	0
in	0
cells	0
expressing	0
the	0
Ad12	9
13S	10
mRNA	10
product	10
and	0
in	0
cells	0
transformed	0
with	0
Ad2/Ad12	9
hybrid	10
E1A	10
gene	10
product	10
harboring	0
the	0
C-terminal	9
part	10
of	0
the	0
conserved	1
region	2
(	2
CR	2
)	2
3	2
of	0
Ad12	0
.	0

Susceptibility	0
of	0
these	0
transformed	0
cell	5
lines	6
to	0
NK	7
cells	8
was	0
determined	0
by	0
cytolytic	0
assays	0
.	0

The	0
results	0
obtained	0
suggest	0
that	0
two	0
Ad12	1
E1A	2
domains	2
are	0
required	0
to	0
induce	0
resistance	0
of	0
the	0
cell	5
lines	6
to	0
NK	7
cells	8
.	0

Cell	0
specific	0
expression	0
of	0
human	1
Bruton	2
's	2
agammaglobulinemia	2
tyrosine	2
kinase	2
gene	2
(	0
Btk	9
)	0
is	0
regulated	0
by	0
Sp1-	9
and	0
Spi-1/PU.1-family	9
members	10
.	0

Bruton	9
's	10
agammaglobulinemia	10
tyrosine	10
kinase	10
(	0
Btk	9
)	0
is	0
a	0
cytoplasmic	9
tyrosine	10
kinase	10
involved	0
in	0
the	0
human	0
disease	0
X-linked	0
agammaglobulinemia	0
(	0
XLA	0
)	0
.	0

The	0
gene	0
is	0
expressed	0
in	0
all	0
hematopoietic	7
cells	8
with	0
the	0
exception	0
of	0
T-cells	7
and	0
plasma	7
cells	8
.	0

For	0
this	0
expression	0
pattern	0
the	0
first	0
280	1
bp	2
upstream	2
of	0
the	0
major	1
transcriptional	2
start	2
site	2
seems	0
to	0
be	0
sufficient	0
.	0

In	0
vitro	0
footprinting	0
analysis	0
within	0
this	0
part	0
of	0
the	0
promoter	1
revealed	0
two	0
Sp1	1
binding	2
sites	2
as	0
well	0
as	0
a	0
PU-box	1
.	0

The	0
transcription	9
factor	10
Spi-1/PU.1	9
as	0
well	0
as	0
the	0
closely	0
related	0
factor	0
Spi-B	9
bound	0
to	0
the	0
PU-box	1
in	0
B-cells	0
.	0

In	0
the	0
erythroleukemia	5
cell	6
line	6
K562	6
,	0
due	0
to	0
the	0
absence	0
of	0
Spi-B	9
,	0
only	0
PU.1	9
bound	0
to	0
the	0
Btk	1
promoter	2
.	0

Mutation	0
of	0
either	0
site	0
reduced	0
the	0
expression	0
in	0
transient	0
transfection	0
experiments	0
.	0

However	0
,	0
mutation	0
of	0
the	0
PU	1
box	2
had	0
no	0
effect	0
in	0
the	0
T-cell	5
line	6
Jurkat	6
,	0
where	0
none	0
of	0
the	0
Spi-1	9
family	10
members	10
is	0
expressed	0
.	0

In	0
addition	0
Spi-B	9
as	0
well	0
as	0
PU.1	9
were	0
able	0
to	0
transactivate	0
Btk	9
expression	0
.	0

In	0
fetal	0
liver	0
of	0
PU.1-/-	0
mice	0
,	0
which	0
lack	0
lymphoid	7
and	8
myeloid	8
cells	8
,	0
expression	0
of	0
Btk	9
was	0
reduced	0
two-	0
to	0
threefold	0
but	0
not	0
abolished	0
.	0

Collectively	0
this	0
study	0
shows	0
that	0
expression	0
of	0
the	0
Btk	1
gene	2
is	0
regulated	0
by	0
the	0
combined	0
action	0
of	0
Sp1-	9
and	10
PU.1-family	10
members	10
.	0

T	0
cell	0
response	0
to	0
Epstein-Barr	9
virus	10
transactivators	10
in	0
chronic	0
rheumatoid	0
arthritis	0
.	0

Rheumatoid	0
arthritis	0
is	0
a	0
multistep	0
disorder	0
associated	0
with	0
autoimmune	0
features	0
of	0
yet	0
unknown	0
etiology	0
.	0

Implication	0
of	0
viruses	0
such	0
as	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
in	0
rheumatoid	0
arthritis	0
pathogenesis	0
has	0
been	0
suspected	0
on	0
the	0
basis	0
of	0
several	0
indirect	0
observations	0
,	0
but	0
thus	0
far	0
,	0
a	0
direct	0
link	0
between	0
EBV	0
and	0
rheumatoid	0
arthritis	0
has	0
not	0
been	0
provided	0
.	0

Here	0
we	0
show	0
that	0
a	0
large	0
fraction	0
of	0
T	7
cells	8
infiltrating	0
affected	0
joints	0
from	0
a	0
patient	0
with	0
chronic	0
rheumatoid	0
arthritis	0
recognizes	0
two	0
EBV	9
transactivators	10
(	0
BZLF1	9
and	0
BMLF1	9
)	0
in	0
a	0
major	9
histocompatibility	10
complex	10
-restricted	0
fashion	0
.	0

Responses	0
to	0
these	0
EBV	9
antigens	10
by	0
synovial	0
lymphocytes	0
from	0
several	0
other	0
chronic	0
rheumatoid	0
arthritis	0
patients	0
were	0
readily	0
detectable	0
.	0

Thus	0
these	0
results	0
suggest	0
a	0
direct	0
contribution	0
of	0
EBV	0
to	0
chronic	0
rheumatoid	0
arthritis	0
pathogenesis	0
.	0

They	0
also	0
demonstrate	0
for	0
the	0
first	0
time	0
the	0
occurrence	0
of	0
T	0
cell	0
responses	0
against	0
EBV	9
transactivating	10
factors	10
,	0
which	0
might	0
be	0
central	0
in	0
the	0
control	0
of	0
virus	0
reactivation	0
.	0

CD14	9
-mediated	0
signal	0
pathway	0
of	0
Porphyromonas	0
gingivalis	0
lipopolysaccharide	0
in	0
human	7
gingival	8
fibroblasts	8
.	0

Lipopolysaccharide	0
(	0
LPS	0
)	0
induces	0
expression	0
of	0
inflammatory	9
cytokines	10
in	0
monocytes/macrophages	7
via	0
CD14	9
,	0
one	0
of	0
the	0
LPS	9
receptors	10
,	0
which	0
is	0
expressed	0
predominantly	0
in	0
these	0
cells	0
.	0

It	0
has	0
been	0
demonstrated	0
that	0
Porphyromonas	0
gingivalis	0
LPS	0
(	0
P-LPS	0
)	0
also	0
is	0
able	0
to	0
induce	0
inflammatory	9
cytokines	10
in	0
human	7
gingival	8
fibroblasts	8
.	0

Therefore	0
,	0
it	0
is	0
important	0
to	0
determine	0
whether	0
CD14	9
is	0
expressed	0
in	0
gingival	7
fibroblasts	8
and	0
to	0
define	0
the	0
P-LPS-mediated	0
signal-transducing	9
mechanism	0
in	0
the	0
cells	0
.	0

In	0
this	0
study	0
,	0
we	0
observed	0
unexpectedly	0
by	0
immunohistochemical	0
,	0
Western	0
blotting	0
(	0
immunoblotting	0
)	0
,	0
and	0
Northern	0
(	0
RNA	0
)	0
blotting	0
assays	0
that	0
CD14	9
is	0
expressed	0
at	0
high	0
density	0
in	0
human	7
gingival	8
fibroblasts	8
.	0

P-LPS-induced	0
expression	0
of	0
the	0
monocyte	1
chemoattractant	2
protein	2
1	2
(	2
MCP-1	2
)	2
gene	2
in	0
the	0
cells	0
was	0
inhibited	0
markedly	0
by	0
treatment	0
with	0
anti-human	0
CD14	9
antibody	0
and	0
was	0
completely	0
inhibited	0
by	0
herbimycin	0
A	0
,	0
a	0
potent	0
inhibitor	0
of	0
tyrosine	9
kinase	10
.	0

The	0
inhibitor	0
also	0
dramatically	0
inhibited	0
monocyte	0
chemotactic	0
activity	0
of	0
and	0
MCP-1	9
production	0
by	0
the	0
cells	0
.	0

Furthermore	0
,	0
P-LPS-induced	0
expression	0
of	0
the	0
MCP-1	1
gene	2
in	0
the	0
cells	0
also	0
was	0
blocked	0
by	0
inhibitors	0
of	0
two	0
transcription	9
factors	10
,	0
i.e.	0
,	0
curcumin	0
,	0
an	0
inhibitor	0
of	0
AP-1	9
,	0
and	0
pyrolidine	0
dithiocarbamate	0
,	0
an	0
inhibitor	0
of	0
NF-kappaB	9
.	0

Both	0
inhibitors	0
inhibited	0
monocyte	0
chemotactic	0
activity	0
in	0
the	0
culture	0
supernatant	0
of	0
P-LPS-treated	0
cells	0
.	0

Gel	0
shift	0
mobility	0
assay	0
showed	0
stimulation	0
of	0
the	0
AP-1	9
and	0
NF-kappaB	9
contents	0
in	0
P-LPS-treated	0
cells	0
.	0

This	0
study	0
is	0
the	0
first	0
to	0
demonstrate	0
the	0
expression	0
of	0
CD14	9
in	0
human	7
gingival	8
fibroblasts	8
and	0
to	0
show	0
that	0
the	0
signal-transducing	0
pathway	0
of	0
P-LPS	0
in	0
the	0
cells	0
is	0
mediated	0
by	0
CD14	9
.	0

rel	9
Is	0
rapidly	0
tyrosine-phosphorylated	0
following	0
granulocyte-colony	9
stimulating	10
factor	10
treatment	0
of	0
human	0
neutrophils	0
.	0

Stimulation	0
of	0
neutrophils	7
with	0
granulocyte-colony	9
stimulating	10
factor	10
(	0
G-CSF	9
)	0
results	0
in	0
an	0
enhanced	0
respiratory	0
burst	0
,	0
prolonged	0
survival	0
,	0
and	0
increased	0
tumor	0
cell	0
killing	0
.	0

The	0
effects	0
of	0
G-CSF	9
are	0
mediated	0
by	0
binding	0
to	0
specific	0
,	0
high	0
affinity	9
receptors	10
.	0

G-CSF	9
receptors	10
lack	0
intrinsic	0
tyrosine	9
kinase	10
activity	0
,	0
but	0
activation	0
of	0
the	0
receptor	0
results	0
in	0
the	0
rapid	0
induction	0
of	0
tyrosine	0
kinase	0
activity	0
.	0

Antiphosphotyrosine	0
immunoblots	0
of	0
whole	0
cell	0
lysates	0
prepared	0
from	0
neutrophils	7
show	0
that	0
the	0
G-CSF	9
rapidly	0
induces	0
prominent	0
tyrosine	0
phosphorylation	0
of	0
a	0
protein	0
of	0
a	0
relative	0
molecular	0
mass	0
of	0
80	0
kDa	0
.	0

Using	0
monospecific	9
antibodies	10
,	0
the	0
80-kDa	0
tyrosine-phosphorylated	9
protein	10
has	0
been	0
shown	0
to	0
be	0
p80c-rel	9
,	0
a	0
proto-oncogene	1
belonging	0
to	0
a	0
family	0
of	0
transcriptional	9
regulators	10
which	0
include	0
NF-kB	9
.	0

The	0
induction	0
of	0
tyrosine	0
phosphorylation	0
of	0
p80c-rel	9
was	0
unique	0
to	0
G-CSF	9
in	0
that	0
granulocyte-macrophage	9
colony	10
stimulating	10
factor	10
which	0
also	0
stimulates	0
neutrophils	7
and	0
induces	0
tyrosine	0
phosphorylation	0
does	0
not	0
result	0
in	0
tyrosine	0
phosphorylation	0
of	0
p80c-rel	9
.	0

The	0
consequences	0
of	0
p80c-rel	9
tyrosine	0
phosphorylation	0
are	0
not	0
yet	0
known	0
;	0
however	0
,	0
tyrosine-phosphorylated	0
p80c-rel	9
is	0
capable	0
of	0
binding	0
to	0
DNA	0
,	0
and	0
G-CSF	9
stimulation	0
results	0
in	0
an	0
increase	0
in	0
the	0
amount	0
of	0
p80c-rel	9
which	0
binds	0
to	0
DNA	0
.	0

These	0
results	0
demonstrate	0
that	0
one	0
of	0
the	0
first	0
biochemical	0
events	0
which	0
occurs	0
in	0
neutrophils	7
following	0
G-CSF	9
stimulation	0
,	0
activation	0
of	0
a	0
tyrosine	9
kinase	10
,	0
leads	0
directly	0
to	0
the	0
tyrosine	0
phosphorylation	0
of	0
p80c-rel	9
.	0

Thus	0
,	0
the	0
tyrosine	9
kinase	10
activated	0
by	0
G-CSF	9
appears	0
to	0
directly	0
transduce	0
a	0
signal	0
to	0
a	0
protein	0
which	0
functions	0
as	0
a	0
transcriptional	9
regulator	10
.	0

Patterns	0
of	0
Pan	9
expression	0
and	0
role	0
of	0
Pan	9
proteins	10
in	0
endocrine	0
cell	0
type-specific	0
complex	0
formation	0
.	0

The	0
Pan	1
gene	2
encodes	0
at	0
least	0
two	0
distinct	0
transcripts	0
,	0
Pan-1	9
and	0
Pan-2	9
(	0
also	0
known	0
as	0
E47	9
and	0
E12	9
,	0
respectively	0
)	0
,	0
by	0
the	0
mechanism	0
of	0
alternative	0
RNA	0
splicing	0
.	0

Northern	0
blot	0
analyses	0
performed	0
on	0
rat	0
and	0
mouse	0
tissues	0
have	0
detected	0
ubiquitously	0
expressed	0
Pan	0
transcripts	0
,	0
but	0
the	0
abundance	0
,	0
distribution	0
,	0
and	0
form	0
of	0
Pan	9
proteins	10
have	0
not	0
been	0
clearly	0
defined	0
.	0

Studies	0
of	0
cell	5
lines	6
representing	0
endocrine	7
,	8
fibroblast	8
,	8
and	8
lymphoid	8
lineages	8
using	0
polyclonal	0
antisera	0
to	0
detect	0
E2A	9
proteins	10
have	0
suggested	0
that	0
significant	0
E2A	9
protein	10
expression	0
is	0
restricted	0
to	0
B-lymphocytes	7
.	0

We	0
have	0
developed	0
a	0
monoclonal	9
antibody	10
,	0
Yae	9
,	0
which	0
is	0
specific	0
for	0
Pan/E2A	9
proteins	10
,	0
and	0
have	0
used	0
the	0
Yae	9
antibody	10
to	0
examine	0
a	0
variety	0
of	0
endocrine	7
and	8
nonendocrine	8
cell	8
lineages	8
for	0
differences	0
in	0
Pan/	0
E2A	9
protein	10
expression	0
,	0
subcellular	0
localization	0
,	0
and	0
heteromeric	0
complex	0
formation	0
.	0

In	0
contrast	0
to	0
previous	0
results	0
obtained	0
using	0
polyclonal	0
antiseras	0
to	0
detect	0
Pan/	0
E2A	9
proteins	10
,	0
we	0
report	0
comparable	0
levels	0
of	0
Pan	9
proteins	10
in	0
GH/PRL-	5
and	6
insulin-producing	6
,	6
B-	6
and	6
T-lymphocyte	6
cells	6
.	0

IEF-1	9
,	0
a	0
pancreatic	0
beta-cell	0
type-specific	0
complex	0
believed	0
to	0
regulate	0
insulin	0
expression	0
,	0
is	0
demonstrated	0
to	0
consist	0
of	0
at	0
least	0
two	0
distinct	0
species	0
,	0
one	0
of	0
which	0
does	0
not	0
contain	0
Pan	9
molecules	10
.	0

Although	0
it	0
has	0
been	0
postulated	0
that	0
pituitary	7
endocrine	8
cells	8
and	0
pancreatic	7
endocrine	8
beta-cells	8
share	0
identical	0
Pan/E2A	9
complexes	10
,	0
native-Western	0
analyses	0
of	0
pituitary	0
and	0
endocrine	7
beta-cells	8
detect	0
Pan	9
proteins	10
in	0
distinct	0
cell	9
type-specific	10
complexes	10
.	0

Visualization	0
of	0
the	0
endogenous	9
NF-kappa	10
B	10
p50	10
subunit	10
in	0
the	0
nucleus	0
of	0
follicular	7
dendritic	8
cells	8
in	0
germinal	0
centers	0
.	0

NF-kappa	9
B	10
,	0
a	0
50	9
kDa/65	10
kDa	10
(	10
p50/p65	10
)	10
heterodimer	10
,	0
is	0
a	0
ubiquitous	9
transcription	10
factor	10
involved	0
in	0
the	0
positive	0
regulation	0
of	0
various	0
immune	1
genes	2
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
determine	0
whether	0
NF-kappa	9
B	10
is	0
related	0
to	0
a	0
particular	0
cell	0
type	0
and/or	0
differentiation	0
step	0
during	0
immunopoiesis	0
.	0

Using	0
in	0
situ	0
hybridization	0
on	0
sections	0
from	0
non	0
HIV	0
hyperplastic	0
lymph	0
nodes	0
,	0
we	0
found	0
that	0
the	0
gene	0
of	0
the	0
105	9
kDa	10
precursor	10
of	0
p50	9
was	0
overexpressed	0
in	0
the	0
light	0
zone	0
of	0
germinal	0
centers	0
,	0
with	0
a	0
network	0
aspect	0
,	0
which	0
suggested	0
the	0
involvement	0
of	0
follicular	7
dendritic	8
cells	8
(	0
FDC	7
)	0
.	0

By	0
immunohistochemistry	0
,	0
p50	9
protein	0
was	0
detected	0
in	0
the	0
cytoplasm	0
and	0
nucleus	0
of	0
FDC	7
,	0
confirming	0
the	0
involvement	0
of	0
FDC	7
.	0

Furthermore	0
,	0
p50	9
protein	0
was	0
detected	0
in	0
the	0
cytoplasm	0
of	0
all	0
lymphocytes	7
.	0

Thus	0
,	0
we	0
focused	0
our	0
study	0
on	0
isolated	0
FDC	7
clusters	0
from	0
normal	0
tonsils	0
.	0

As	0
showed	0
on	0
tissue	0
sections	0
,	0
we	0
detected	0
the	0
p50	9
in	0
both	0
cytoplasm	0
and	0
nucleus	0
of	0
FDC	7
.	0

Nuclei	0
of	0
lymphocytes	7
from	0
FDC	7
clusters	0
were	0
negative	0
.	0

We	0
next	0
studied	0
p65	0
and	0
c-Rel	0
protein	0
expression	0
in	0
FDC	7
clusters	0
.	0

p65	9
was	0
detected	0
in	0
the	0
cytoplasm	0
of	0
FDC	7
,	0
whereas	0
nuclei	0
were	0
negative	0
.	0

Furthermore	0
,	0
p65	9
was	0
detected	0
in	0
the	0
nuclei	0
of	0
some	0
lymphocytes	7
.	0

c-Rel	9
protein	10
was	0
detected	0
only	0
in	0
the	0
cytoplasm	0
of	0
lymphocytes	7
and	0
not	0
in	0
the	0
nucleus	0
and	0
cytoplasm	0
of	0
FDC	7
.	0

Our	0
results	0
indicated	0
that	0
,	0
in	0
the	0
context	0
of	0
T	0
cell-dependent	0
B	0
cell	0
immunopoiesis	0
occurring	0
in	0
FDC	7
clusters	0
,	0
p50	9
is	0
mainly	0
related	0
to	0
FDC	7
with	0
a	0
massive	0
overexpression	0
in	0
the	0
nuclei	0
,	0
whereas	0
p65	9
is	0
expressed	0
in	0
a	0
scattered	0
manner	0
in	0
the	0
nuclei	0
of	0
lymphocytes	7
and	0
c-Rel	0
protein	0
exclusively	0
in	0
the	0
cytoplasm	0
of	0
lymphocytes	7
from	0
FDC	7
clusters	0
.	0

These	0
results	0
suggested	0
that	0
the	0
two	0
subunits	0
of	0
NF-kappa	9
B	10
and	0
the	0
c-Rel	9
protein	10
have	0
different	0
roles	0
in	0
different	0
cell	0
types	0
during	0
B	0
cell	0
immunopoiesis	0
.	0

Cloning	0
and	0
characterization	0
of	0
NF-ATc	9
and	0
NF-ATp	9
:	0
the	0
cytoplasmic	0
components	0
of	0
NF-AT	9
.	0

Present	0
evidence	0
indicates	0
a	0
pathway	0
of	0
signal	0
transmission	0
in	0
T	7
cells	8
that	0
is	0
outlined	0
in	0
figure	0
1	0
.	0

The	0
elevation	0
in	0
intracellular	0
calcium	0
that	0
is	0
induced	0
by	0
interactions	0
at	0
the	0
antigen	9
receptor	10
leads	0
to	0
the	0
activation	0
of	0
the	0
calcium-dependent	9
phosphatase	10
calcineurin	9
.	0

This	0
in	0
turn	0
leads	0
to	0
the	0
nuclear	0
association	0
of	0
the	0
cytosolic	9
component	10
of	0
NF-ATc	9
.	0

The	0
activation	0
of	0
calcineurin	9
and	0
the	0
nuclear	0
import	0
of	0
NF-ATc	9
can	0
both	0
be	0
blocked	0
by	0
cyclosporin	0
A	0
or	0
FK506	0
in	0
complex	0
with	0
their	0
respective	0
immunophilins	9
.	0

Once	0
in	0
the	0
nucleus	0
,	0
NF-ATc	9
interacts	0
with	0
NF-ATn	9
to	0
form	0
an	0
active	9
transcriptional	10
complex	10
.	0

NF-ATn	9
is	0
a	0
ubiquitous	0
protein	0
,	0
can	0
be	0
synthesized	0
in	0
response	0
to	0
PMA	0
,	0
and	0
has	0
many	0
similarities	0
to	0
AP-1	9
.	0

The	0
mechanism	0
by	0
which	0
NF-ATc	9
enters	0
the	0
nucleus	0
is	0
unknown	0
,	0
and	0
although	0
it	0
appears	0
to	0
require	0
calcineurin	9
,	0
NF-ATc	9
has	0
not	0
yet	0
been	0
shown	0
to	0
be	0
an	0
in	0
vivo	0
substrate	0
of	0
calcineurin	9
.	0

Alternative	0
mechanisms	0
include	0
the	0
possibility	0
that	0
NF-ATc	9
operates	0
on	0
some	0
cytoplasmic	9
anchor	10
or	0
that	0
other	0
proteins	0
that	0
are	0
controlled	0
by	0
calcineurin	9
carry	0
out	0
the	0
nuclear	0
import	0
of	0
NF-ATc	9
.	0

Although	0
NF-ATp	9
copurifies	0
with	0
NF-ATc	9
,	0
there	0
is	0
as	0
yet	0
no	0
understanding	0
of	0
how	0
NF-ATp	9
is	0
functioning	0
in	0
vivo	0
.	0

Now	0
that	0
these	0
proteins	0
are	0
purified	0
and	0
cloned	0
,	0
the	0
major	0
goals	0
will	0
be	0
to	0
understand	0
their	0
role	0
and	0
the	0
roles	0
of	0
other	0
family	0
members	0
in	0
thymic	0
development	0
.	0

Induction	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
by	0
low-density	9
lipoprotein	10
.	0

Low-density	9
lipoprotein	10
(	0
LDL	9
)	0
is	0
a	0
well-established	0
risk	0
factor	0
for	0
atherosclerosis	0
.	0

When	0
endothelial	0
cells	0
are	0
incubated	0
with	0
this	0
lipoprotein	0
in	0
pathophysiologic	0
amounts	0
,	0
the	0
cells	0
are	0
activated	0
.	0

Among	0
the	0
documented	0
cellular	0
responses	0
to	0
LDL	9
is	0
increased	0
recruitment	0
of	0
monocytes	7
,	0
which	0
are	0
believed	0
to	0
play	0
a	0
major	0
role	0
in	0
promoting	0
intimal	0
plaque	0
formation	0
.	0

The	0
findings	0
presented	0
here	0
link	0
an	0
atheogenic	9
lipoprotein	10
,	0
LDL	9
,	0
with	0
the	0
induction	0
of	0
an	0
adhesion	0
molecule	0
important	0
in	0
atherogenesis	0
Human	0
LDL	9
induces	0
the	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
transcriptionally	0
with	0
an	0
increase	0
in	0
mRNA	0
levels	0
through	0
activation	0
of	0
the	0
VCAM	1
promoter	2
.	0

This	0
effect	0
is	0
blocked	0
by	0
anti-VCAM	9
antibodies	10
.	0

After	0
a	0
2-day	0
incubation	0
in	0
LDL	9
,	0
the	0
binding	0
of	0
NF-kappa	9
B	10
,	0
which	0
is	0
believed	0
to	0
be	0
a	0
key	0
oxidative-stress	0
sensor	0
for	0
VCAM	9
regulation	0
,	0
remains	0
at	0
basal	0
level	0
.	0

In	0
contrast	0
,	0
the	0
binding	0
activities	0
of	0
AP-1	9
and	0
GATA	9
,	0
on	0
the	0
other	0
hand	0
,	0
are	0
increased	0
by	0
LDL	9
.	0

Thus	0
,	0
a	0
component	0
of	0
LDL	9
-enhanced	0
endothelial	0
recruitment	0
of	0
monocytes	7
is	0
attributed	0
to	0
VCAM-1	9
expression	0
,	0
which	0
appears	0
to	0
be	0
mediated	0
through	0
AP-1	9
and	0
GATA	9
.	0

These	0
data	0
identify	0
LDL	9
as	0
a	0
VCAM	9
-inducer	0
possibly	0
distinct	0
from	0
cytokines	9
and	0
endotoxin	9
.	0

Involvement	0
of	0
nuclear	9
factor-kappa	10
B	10
activation	0
in	0
IgE	9
synthesis	0
in	0
human	7
B	8
cells	8
.	0

Nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
a	0
transcription	0
factor	0
that	0
binds	0
to	0
the	0
consensus	1
DNA	2
sequence	2
in	0
the	0
cis-acting	1
elements	2
of	0
various	1
genes	2
.	0

Although	0
NF-kappa	9
B	10
activates	0
the	0
expression	0
of	0
many	0
genes	0
involved	0
in	0
immune	0
and	0
inflammatory	0
responses	0
,	0
little	0
is	0
known	0
about	0
the	0
role	0
of	0
NF-kappa	9
B	10
activation	0
in	0
the	0
induction	0
of	0
IgE	0
synthesis	0
in	0
human	7
B	8
cells	8
.	0

Therefore	0
we	0
first	0
examined	0
the	0
participation	0
of	0
NF-kappa	9
B	10
in	0
germline	5
C	6
epsilon	6
transcription	0
in	0
a	0
human	5
Burkitt	6
lymphoma	6
B	6
cell	6
line	6
,	0
DND39	5
.	0

Stimulation	0
of	0
DND39	5
cells	6
with	0
IL-4	9
or	0
anti-CD40	9
monoclonal	10
antibody	10
(	0
mAb	9
)	0
activated	0
phosphatidylinositol	9
3-kinase	10
and	0
subsequently	0
induced	0
nuclear	0
expression	0
of	0
NF-kappa	9
B	10
,	0
which	0
was	0
identified	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

n-Acetyl-L-cysteine	0
(	0
NAC	0
)	0
,	0
a	0
potent	0
antioxidant	0
,	0
blocked	0
NF-kappa	9
B	10
activation	0
caused	0
by	0
IL-4	9
and	0
by	0
anti-CD40	9
mAb	10
.	0

Although	0
inhibition	0
of	0
IL-4-driven	5
germline	6
C	6
epsilon	6
transcription	0
by	0
NAC	0
was	0
not	0
sufficient	0
,	0
the	0
agent	0
remarkably	0
diminished	0
anti-CD40	9
mAb	10
-mediated	0
up-regulation	0
of	0
germline	1
C	0
epsilon	0
transcription	0
.	0

Second	0
,	0
we	0
studied	0
the	0
effect	0
of	0
NAC	0
on	0
IgE	9
synthesis	0
in	0
human	0
normal	0
B	0
cells	0
costimulated	0
with	0
IL-4	9
and	0
anti-CD40	9
mAb	10
.	0

NAC	0
was	0
effective	0
in	0
inhibiting	0
mature	0
C	0
epsilon	0
transcription	0
and	0
IgE	9
synthesis	0
in	0
the	0
T	0
cell-independent	0
culture	0
system	0
.	0

However	0
,	0
NAC	0
did	0
not	0
significantly	0
affect	0
the	0
spontaneous	0
production	0
of	0
IgE	9
by	0
atopic	7
B	8
cells	8
.	0

These	0
results	0
indicate	0
that	0
NF-kappa	9
B	10
activity	0
is	0
commonly	0
inducible	0
in	0
DND39	5
cells	6
by	0
IL-4	9
and	0
anti-CD40	9
mAb	10
and	0
suggest	0
that	0
NF-kappa	9
B	10
sensitive	0
to	0
NAC	0
may	0
play	0
a	0
role	0
in	0
regulating	0
IgE	9
synthesis	0
in	0
B	7
cells	8
.	0

Prostaglandin	0
E2	0
induction	0
of	0
binding	0
activity	0
to	0
CRE	1
and	0
AP-2	1
elements	2
in	0
human	7
T	8
lymphocytes	8
.	0

Prostaglandins	0
of	0
the	0
E	0
series	0
are	0
immunomodulatory	0
agents	0
which	0
exert	0
inhibitory	0
as	0
well	0
as	0
stimulatory	0
effects	0
on	0
a	0
variety	0
of	0
immune	0
responses	0
.	0

Since	0
it	0
is	0
known	0
that	0
PGE2	0
is	0
able	0
to	0
increase	0
cAMP	0
levels	0
,	0
we	0
investigated	0
whether	0
it	0
can	0
affect	0
gene	0
expression	0
through	0
the	0
activation	0
of	0
the	0
transcription	9
factors	10
which	0
bind	0
enhancer	0
elements	0
in	0
the	0
promoter	0
regions	0
of	0
cAMP-regulated	1
genes	2
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
we	0
demonstrated	0
that	0
a	0
short	0
treatment	0
of	0
human	7
T	8
lymphocytes	8
with	0
PGE2	0
induces	0
specific	0
binding	0
activity	0
to	0
CRE	1
and	0
AP-2	1
,	0
but	0
not	0
AP-1	1
,	2
DNA	2
elements	2
.	0

Since	0
the	0
okadaic	0
acid	0
,	0
a	0
potent	0
protein	0
phosphatase	0
inhibitor	0
,	0
prolongs	0
the	0
induction	0
of	0
the	0
binding	0
activity	0
,	0
phosphorylation	0
events	0
are	0
likely	0
to	0
occur	0
.	0

This	0
activity	0
seems	0
to	0
be	0
due	0
to	0
increased	0
cAMP	0
levels	0
because	0
forskolin	0
and	0
IBMX	0
mimic	0
the	0
effects	0
of	0
PGE2	0
.	0

More	0
interestingly	0
,	0
transfection	0
experiments	0
with	0
CRE-CAT	1
plasmide	2
show	0
that	0
PGE2	0
activates	0
the	0
transcription	0
of	0
a	0
CRE-containing	1
promoter	2
.	0

These	0
data	0
support	0
the	0
positive	0
role	0
for	0
PGE2	0
on	0
some	0
immune	0
functions	0
.	0

Nasal	7
NK-	8
and	8
T-cell	8
lymphomas	8
share	0
the	0
same	0
type	0
of	0
Epstein-Barr	0
virus	0
latency	0
as	0
nasopharyngeal	0
carcinoma	0
and	0
Hodgkin	0
's	0
disease	0
.	0

Nasal	7
T/NK-cell	8
lymphomas	8
can	0
be	0
further	0
separated	0
into	0
those	0
of	0
natural	7
killer	8
(	8
NK	8
)	8
cell	8
lineage	8
or	0
of	0
T-cell	7
lineage	8
,	0
with	0
differences	0
in	0
cellular	0
phenotype	0
,	0
T-cell	1
receptor	2
(	2
TcR	2
)	2
gene	2
rearrangement	0
and	0
TcR	0
transcript	0
expression	0
.	0

Both	0
NK-	7
and	8
T-cell	8
subtypes	8
are	0
closely	0
associated	0
with	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
.	0

In	0
this	0
study	0
,	0
EBV	1
gene	2
expression	0
was	0
determined	0
in	0
23	0
cases	0
of	0
nasal	0
lymphoma	0
(	0
NL	0
)	0
by	0
in	0
situ	0
hybridisation	0
(	0
ISH	0
)	0
,	0
reverse	9
transcriptase	10
-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
and	0
immunohistochemistry	0
(	0
IH	0
)	0
.	0

Of	0
the	0
23	0
cases	0
,	0
19	0
were	0
classified	0
as	0
NK-cell	0
and	0
4	0
as	0
T-cell	0
tumours	0
.	0

ISH	0
for	0
EBV-encoded	3
small	4
non-polyadenylated	4
RNAs	4
showed	0
that	0
all	0
cases	0
,	0
whether	0
NK	0
or	0
T	0
,	0
harboured	0
EBV	0
in	0
virtually	0
all	0
tumour	7
cells	8
.	0

RT-PCR	0
demonstrated	0
that	0
NL	7
of	0
both	0
subtypes	0
expressed	0
EBNAI	9
of	0
the	0
QUK	0
splice	0
pattern	0
,	0
the	0
latent	9
membrane	10
proteins	10
,	0
LMP1	9
and	10
2	10
and	0
the	0
BamHI	3
A	4
rightward	4
transcripts	4
in	0
the	0
absence	0
of	0
EBNA2	3
mRNAs	4
,	0
compatible	0
with	0
the	0
latency	0
type	0
II	0
pattern	0
.	0

In	0
addition	0
,	0
analysis	0
of	0
EBV	0
protein	0
expression	0
by	0
IH	0
revealed	0
a	0
heterogeneous	0
pattern	0
of	0
EBV	1
gene	2
expression	0
at	0
the	0
single-cell	0
level	0
consisting	0
of	0
both	0
LMP1+	7
and	8
LMP1-	8
tumour	8
cells	8
,	0
suggesting	0
a	0
mixture	0
of	0
latency	0
I	0
and	0
II	0
.	0

Although	0
2	0
early	9
lytic	10
transcripts	10
,	0
BZLF1	9
and	0
BHRF1	9
,	0
were	0
also	0
detected	0
in	0
13	0
and	0
10	0
cases	0
,	0
respectively	0
,	0
the	0
lack	0
of	0
ZEBRA	9
staining	0
in	0
any	0
case	0
indicates	0
that	0
these	0
lytic	0
transcripts	0
are	0
most	0
likely	0
expressed	0
by	0
rare	0
cells	0
in	0
the	0
biopsies	0
entering	0
lytic	0
cycle	0
.	0

The	0
viral	0
transcriptional	0
pattern	0
similar	0
to	0
that	0
of	0
nasopharyngeal	0
carcinoma	0
and	0
Hodgkin	0
's	0
disease	0
suggests	0
that	0
EBV	0
can	0
exploit	0
common	0
regulatory	0
mechanisms	0
for	0
gene	0
transcription	0
in	0
diverse	0
host	0
cell	0
types	0
.	0

Down-regulation	0
of	0
immunogenic	9
proteins	10
(	0
EBNA2-EBNA6	9
)	0
in	0
nasal	0
lymphoma	0
may	0
enable	0
tumour	7
cells	8
to	0
evade	0
host	0
cytotoxic	0
T-cell	0
surveillance	0
.	0

Potent	0
gene	0
regulatory	0
and	0
antiproliferative	0
activities	0
of	0
20-methyl	0
analogues	0
of	0
1	0
,	0
25	0
dihydroxyvitamin	0
D3	0
.	0

The	0
biological	0
active	0
form	0
of	0
vitamin	0
D3	0
,	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
VD	0
)	0
,	0
regulates	0
cellular	0
growth	0
and	0
differentiation	0
.	0

This	0
provides	0
the	0
hormone	0
with	0
an	0
interesting	0
therapeutic	0
potential	0
.	0

However	0
,	0
hypercalcemia	0
is	0
a	0
side	0
effect	0
,	0
which	0
is	0
caused	0
by	0
VD	0
's	0
classical	0
action	0
,	0
the	0
regulation	0
of	0
calcium	0
homeostasis	0
.	0

This	0
made	0
the	0
need	0
for	0
VD	0
analogues	0
with	0
selectively	0
increased	0
cell	0
regulatory	0
properties	0
.	0

Studies	0
with	0
20-epi	0
analogues	0
pointed	0
out	0
the	0
importance	0
of	0
the	0
carbon-20	0
position	0
and	0
led	0
to	0
the	0
development	0
of	0
20-methyl	0
derivatives	0
of	0
VD	0
.	0

In	0
this	0
report	0
the	0
biological	0
properties	0
of	0
the	0
compounds	0
ZK161422	0
and	0
ZK157202	0
,	0
which	0
are	0
20-methyl-	0
and	0
20-methyl-23-eneanalogues	0
,	0
respectively	0
,	0
have	0
been	0
analyzed	0
in	0
comparison	0
with	0
VD	0
.	0

Both	0
compounds	0
show	0
about	0
2-fold	0
lower	0
affinity	0
to	0
the	0
VD	0
receptor	0
(	0
VDR	0
)	0
than	0
VD	0
.	0

However	0
,	0
compared	0
to	0
VD	0
,	0
their	0
antiproliferative	0
effect	0
is	0
up	0
to	0
30-fold	0
higher	0
on	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
and	0
even	0
up	0
to	0
300-fold	0
higher	0
on	0
human	5
breast	6
cancer	6
MCF-7	6
cells	6
.	0

Whereas	0
the	0
hypercalcemic	0
effect	0
for	0
ZK157202	0
is	0
also	0
increased	0
10-fold	0
,	0
ZK161422	0
has	0
the	0
same	0
calcium-mobilizing	0
potency	0
as	0
VD	0
.	0

Moreover	0
,	0
ZK161422	0
,	0
but	0
not	0
ZK157202	0
,	0
showed	0
preference	0
for	0
gene	0
activation	0
from	0
a	0
promoter	1
carrying	0
a	0
VD	1
response	2
element	2
with	0
a	0
palindromic	0
arrangement	0
of	0
two	0
hexameric	1
receptor	2
binding	2
sites	2
spaced	0
by	0
9	0
nucleotides	0
(	0
IP9	0
)	0
rather	0
than	0
for	0
activation	0
from	0
a	0
response	1
element	2
formed	0
by	0
a	0
direct	0
repeat	0
spaced	0
by	0
3	0
nucleotides	0
(	0
DR3	0
)	0
.	0

This	0
observation	0
supports	0
a	0
model	0
,	0
in	0
which	0
promoter	0
selectivity	0
reflects	0
the	0
selectively	0
increased	0
antiproliferative	0
effect	0
of	0
VD	0
analogues	0
.	0

Calcium-dependent	0
immediate-early	1
gene	2
induction	0
in	0
lymphocytes	7
is	0
negatively	0
regulated	0
by	0
p21Ha-ras	9
.	0

The	0
induction	0
of	0
immediate-early	1
(	2
IE	2
)	2
response	2
genes	2
,	0
such	0
as	0
egr-1	1
,	0
c-fos	1
,	0
and	0
c-jun	1
,	0
occurs	0
rapidly	0
after	0
the	0
activation	0
of	0
T	7
lymphocytes	8
.	0

The	0
process	0
of	0
activation	0
involves	0
calcium	0
mobilization	0
,	0
activation	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
,	0
and	0
phosphorylation	0
of	0
tyrosine	9
kinases	10
.	0

p21	9
(	10
ras	10
)	10
,	0
a	0
guanine	9
nucleotide	10
binding	10
factor	10
,	0
mediates	0
T-cell	0
signal	0
transduction	0
through	0
PKC	9
-dependent	0
and	0
PKC	9
-independent	0
pathways	0
.	0

The	0
involvement	0
of	0
p21	9
(	10
ras	10
)	10
in	0
the	0
regulation	0
of	0
calcium-dependent	0
signals	0
has	0
been	0
suggested	0
through	0
analysis	0
of	0
its	0
role	0
in	0
the	0
activation	0
of	0
NF-AT	9
.	0

We	0
have	0
investigated	0
the	0
inductions	0
of	0
the	0
IE	1
genes	2
in	0
response	0
to	0
calcium	0
signals	0
in	0
Jurkat	5
cells	6
(	0
in	0
the	0
presence	0
of	0
activated	0
p21	9
(	10
ras	10
)	10
)	0
and	0
their	0
correlated	0
consequences	0
.	0

The	0
expression	0
of	0
activated	0
p21	9
(	10
ras	10
)	10
negatively	0
regulated	0
the	0
induction	0
of	0
IE	1
genes	2
by	0
calcium	0
ionophore	0
.	0

This	0
inhibition	0
of	0
calcium-activated	0
IE	1
gene	2
induction	0
was	0
reversed	0
by	0
treatment	0
with	0
cyclosporin	0
A	0
,	0
suggesting	0
the	0
involvement	0
of	0
calcineurin	9
in	0
this	0
regulation	0
.	0

A	0
later	0
result	0
of	0
inhibition	0
of	0
this	0
activation	0
pathway	0
by	0
p21	9
(	10
ras	10
)	10
was	0
down-regulation	0
of	0
the	0
activity	0
of	0
the	0
transcription	9
factor	10
AP-1	9
and	0
subsequent	0
coordinate	0
reductions	0
in	0
IL-2	1
gene	2
expression	0
and	0
protein	0
production	0
.	0

These	0
results	0
suggest	0
that	0
p2l	9
(	10
ras	10
)	10
is	0
an	0
essential	0
mediator	0
in	0
generating	0
not	0
only	0
positive	0
but	0
also	0
negative	0
modulatory	0
mechanisms	0
controlling	0
the	0
competence	0
of	0
T	7
cells	8
in	0
response	0
to	0
inductive	0
stimulations	0
.	0

Calcineurin	9
acts	0
in	0
synergy	0
with	0
PMA	0
to	0
inactivate	0
I	9
kappa	10
B/MAD3	10
,	0
an	0
inhibitor	0
of	0
NF-kappa	9
B	10
.	0

The	0
interleukin-2	1
(	2
IL-2	2
)	2
promoter	2
consists	0
of	0
several	0
independent	0
T	1
cell	2
receptor	2
(	2
TcR	2
)	2
responsive	2
elements	2
.	0

The	0
induction	0
of	0
promoters	1
dependent	0
on	0
these	0
elements	0
is	0
inhibitable	0
by	0
the	0
immunosuppressants	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
tacrolimus	0
(	0
FK-506	0
)	0
.	0

Calcineurin	9
,	0
a	0
Ca2+/calmodulin-dependent	9
protein	10
phosphatase	10
,	0
is	0
the	0
FK-506	0
-and	0
CsA-sensitive	0
enzyme	0
required	0
for	0
TcR	0
mediated	0
activation	0
of	0
the	0
IL-2	1
promoter	2
.	0

We	0
report	0
that	0
a	0
constitutively	0
active	0
form	0
of	0
calcineurin	9
partially	0
substitutes	0
for	0
the	0
Ca2+	0
co-stimulus	0
required	0
to	0
activate	0
the	0
IL-2	1
promoter	2
elements	2
IL-2A	1
(	0
which	0
binds	0
the	0
factors	0
OAP	9
and	0
Oct-1	9
)	0
and	0
IL-2E	1
(	0
which	0
binds	0
NF-AT	9
)	0
,	0
and	0
completely	0
substitutes	0
for	0
the	0
Ca2+	0
co-stimulus	0
required	0
to	0
stimulate	0
an	0
NF-kappa	9
B	10
-dependent	0
element	0
.	0

Calcineurin	9
stimulates	0
the	0
NF-kappa	1
B	2
element	2
by	0
enhancing	0
inactivation	0
of	0
I	9
kappa	10
B/MAD3	10
,	0
an	0
inhibitor	0
of	0
NF-kappa	9
B	10
,	0
thereby	0
increasing	0
the	0
amount	0
of	0
nuclear	0
NF-kappa	9
B	10
DNA	0
binding	0
activity	0
.	0

These	0
data	0
provide	0
the	0
first	0
demonstration	0
in	0
vivo	0
that	0
activation	0
of	0
a	0
protein	9
phosphatase	10
can	0
inactivate	0
I	9
kappa	10
B	10
,	0
and	0
suggest	0
one	0
possible	0
explanation	0
for	0
mechanism-based	0
toxicities	0
associated	0
with	0
FK-506	0
and	0
CsA	0
by	0
demonstrating	0
that	0
these	0
drugs	0
can	0
inhibit	0
the	0
calcineurin	9
-dependent	0
activation	0
of	0
a	0
virtually	0
ubiquitous	9
transcription	10
factor	10
.	0

Detection	0
of	0
minimal	0
residual	0
disease	0
in	0
a	0
patient	0
with	0
acute	0
promyelocytic	0
leukemia	0
by	0
RT-PCR	0
:	0
necessity	0
of	0
chemotherapy	0
following	0
ATRA	0
therapy	0
.	0

The	0
PML/RAR	1
alpha	2
fusion	2
gene	2
resulting	0
from	0
the	0
t	1
(	2
15	2
;	2
17	2
)	2
translocation	2
is	0
a	0
specific	0
marker	0
for	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
.	0

We	0
examined	0
bone	0
marrow	0
cells	0
by	0
reverse	0
transcriptase-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
to	0
detect	0
residual	0
PML/RAR	7
alpha	8
mRNA-containing	8
cells	8
following	0
treatment	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
and	0
cytotoxic	0
chemotherapy	0
in	0
a	0
patient	0
with	0
APL	0
.	0

This	0
RT-PCR	0
assay	0
can	0
detect	0
one	0
leukemic	7
cell	8
in	0
10	0
(	0
2	0
)	0
normal	7
cells	8
in	0
vitro	0
.	0

We	0
show	0
that	0
PML/RAR	3
alpha	4
mRNA	4
was	0
still	0
detectable	0
despite	0
clinical	0
remission	0
following	0
ATRA	0
treatment	0
,	0
but	0
undetectable	0
following	0
consolidation	0
with	0
chemotherapy	0
.	0

These	0
data	0
show	0
that	0
this	0
technique	0
is	0
useful	0
for	0
the	0
identification	0
of	0
minimal	0
residual	0
disease	0
in	0
patients	0
with	0
APL	0
and	0
that	0
cytotoxic	0
chemotherapy	0
following	0
ATRA	0
therapy	0
is	0
required	0
for	0
the	0
elimination	0
of	0
APL	7
cells	8
.	0

Glucocorticoid-mediated	0
inhibition	0
of	0
interleukin-2	0
receptor	0
alpha	0
and	0
-beta	0
subunit	0
expression	0
by	0
human	0
T	0
cells	0
.	0

To	0
determine	0
the	0
mechanism	0
of	0
glucocorticoid	0
(	0
GC	0
)	0
-mediated	0
inhibition	0
of	0
T	0
cell	0
functions	0
,	0
the	0
effect	0
of	0
dexamethasone	0
(	0
DM	0
)	0
on	0
T	7
cell	8
proliferation	0
and	0
interleukin-2	9
receptor	10
(	0
IL-2R	9
)	0
generation	0
were	0
studied	0
.	0

Dexamethasone	0
inhibited	0
IL-2	9
-induced	0
T	7
cell	8
proliferation	0
by	0
30	0
%	0
-88	0
%	0
,	0
relative	0
to	0
its	0
concentration	0
within	0
the	0
cultures	0
.	0

The	0
effect	0
of	0
DM	0
on	0
expression	0
of	0
IL-2R	9
alpha	10
(	0
Tac	9
,	0
p55	9
,	0
CD25	9
)	0
and	0
beta	1
(	2
p75	2
)	2
genes	2
in	0
activated	7
T	8
cells	8
was	0
examined	0
next	0
.	0

In	0
T	7
cells	8
stimulated	0
with	0
purified	0
phytohemagglutinin	9
(	0
PHA-p	9
)	0
and	0
4	0
beta-phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
addition	0
of	0
DM	0
to	0
the	0
cultures	0
resulted	0
in	0
a	0
60	0
%	0
reduction	0
in	0
IL-2R	9
alpha	10
and	0
a	0
30	0
%	0
reduction	0
in	0
IL-2R	9
beta	10
membrane	0
expression	0
compared	0
to	0
T	7
cells	8
cultured	0
in	0
the	0
absence	0
of	0
DM	0
(	0
p	0
<	0
0.01	0
)	0
.	0

Inhibition	0
of	0
membrane	0
IL-2R	9
alpha	10
and	0
IL-2R	9
beta	10
expression	0
by	0
10	0
(	0
-6	0
)	0
M	0
DM	0
was	0
partially	0
reversible	0
by	0
recombinant	9
human	10
IL-2	10
(	0
rhIL-2	9
)	0
.	0

By	0
Northern	0
blot	0
analysis	0
,	0
DM	0
caused	0
a	0
comparable	0
decrease	0
in	0
IL-2R	9
alpha	10
and	0
in	0
IL-2R	9
beta	10
mRNA	0
levels	0
to	0
membrane	0
receptor	0
expression	0
in	0
mitogen-stimulated	7
T	8
cells	8
.	0

By	0
in	0
vitro	0
transcription	0
assays	0
,	0
DM	0
regulated	0
IL-2R	9
alpha	10
gene	0
expression	0
at	0
a	0
transcriptional	0
level	0
while	0
transcription	0
of	0
IL-2R	1
beta	2
gene	2
was	0
unaffected	0
by	0
DM	0
.	0

The	0
mechanism	0
of	0
action	0
of	0
DM	0
on	0
IL-2R	9
alpha	10
transcription	0
was	0
examined	0
by	0
determining	0
the	0
mRNA	0
levels	0
of	0
the	0
p50	0
subunit	0
of	0
nuclear	0
factor	0
kappa	0
B	0
(	0
NF-kappa	9
B	10
)	0
,	0
a	0
transcription	9
factor	10
that	0
stimulates	0
IL-2R	9
alpha	10
gene	0
expression	0
.	0

The	0
data	0
indicate	0
that	0
10	0
(	0
-6	0
)	0
M	0
DM	0
increased	0
T	7
cell	8
p50	0
NF-kappa	3
B	4
mRNA	4
levels	0
by	0
four-fold	0
compared	0
to	0
the	0
levels	0
obtained	0
in	0
the	0
absence	0
of	0
DM	0
.	0

Further	0
,	0
the	0
level	0
of	0
nuclear	9
proteins	10
capable	0
of	0
binding	0
to	0
the	0
NF-kappa	1
B	2
sites	2
in	0
activated	7
T	8
cells	8
increased	0
in	0
response	0
to	0
DM	0
.	0

In	0
sum	0
,	0
DM	0
regulates	0
T	7
cell	8
membrane	0
expression	0
of	0
IL-2R	9
by	0
more	0
than	0
one	0
molecular	0
mechanism	0
.	0

Alteration	0
of	0
structural	0
order	0
of	0
human	0
erythrocyte	0
ghost	0
membrane	0
by	0
glucocorticoids	0
and	0
the	0
influence	0
of	0
the	0
glucocorticoid	0
receptor	0
antagonist	0
RU	0
486	0
.	0

High-dose	0
pulse	0
glucocorticoid	0
therapy	0
has	0
been	0
used	0
successfully	0
in	0
the	0
clinic	0
in	0
severe	0
pathological	0
conditions	0
for	0
about	0
20	0
years	0
.	0

The	0
mode	0
of	0
glucocorticoid	0
action	0
after	0
administration	0
of	0
such	0
megadoses	0
is	0
inexplicable	0
up	0
to	0
now	0
.	0

It	0
is	0
supposed	0
that	0
some	0
effects	0
may	0
be	0
due	0
to	0
membrane	0
alterations	0
.	0

In	0
the	0
present	0
in-vitro	0
experiments	0
the	0
effect	0
of	0
dexamethasone	0
,	0
of	0
further	0
glucocorticoids	0
,	0
and	0
of	0
the	0
glucocorticoid	0
receptor	0
antagonist	0
RU	0
486	0
,	0
on	0
structural	0
order	0
of	0
human	0
erythrocyte	0
ghost	0
membranes	0
was	0
investigated	0
by	0
determining	0
the	0
steady-state	0
fluorescence	0
anisotropy	0
of	0
diphenylhexatriene	0
(	0
DPH	0
)	0
.	0

Dexamethasone	0
was	0
found	0
to	0
induce	0
a	0
significant	0
decrease	0
in	0
membrane	0
structural	0
order	0
at	0
concentrations	0
of	0
about	0
10	0
(	0
-6	0
)	0
M	0
in	0
a	0
concentration-dependent	0
manner	0
.	0

We	0
found	0
a	0
correlation	0
between	0
the	0
uptake	0
of	0
dexamethasone	0
by	0
the	0
ghost	0
membranes	0
and	0
the	0
decrease	0
in	0
the	0
structural	0
order	0
.	0

The	0
other	0
glucocorticoids	0
tested	0
,	0
methylprednisolone	0
and	0
corticosterone	0
,	0
were	0
also	0
effective	0
at	0
concentrations	0
of	0
10	0
(	0
-5	0
)	0
M	0
or	0
greater	0
.	0

We	0
observed	0
no	0
change	0
in	0
membrane	0
structural	0
order	0
with	0
RU	0
486	0
up	0
to	0
a	0
concentration	0
of	0
10	0
(	0
-4	0
)	0
M	0
.	0

However	0
,	0
simultaneous	0
incubation	0
of	0
RU	0
486	0
with	0
dexamethasone	0
caused	0
a	0
distinct	0
interference	0
of	0
RU	0
486	0
with	0
dexamethasone	0
.	0

Thus	0
,	0
the	0
glucocorticoid-induced	0
membrane	0
perturbation	0
,	0
the	0
possibility	0
to	0
inhibit	0
it	0
by	0
RU	0
486	0
,	0
and	0
the	0
inactivity	0
of	0
the	0
structurally	0
related	0
progesterone	0
,	0
refer	0
to	0
relatively	0
specific	0
binding	1
sites	2
for	0
the	0
glucocorticoids	0
in	0
the	0
membrane	0
of	0
erythrocyte	7
ghosts	8
.	0

Mutation	0
of	0
tyrosines	0
492/493	0
in	0
the	0
kinase	9
domain	10
of	0
ZAP-70	9
affects	0
multiple	0
T-cell	9
receptor	10
signaling	0
pathways	0
.	0

The	0
protein-tyrosine	9
kinase	10
ZAP-70	9
is	0
implicated	0
,	0
together	0
with	0
the	0
Src	9
kinase	10
p56	9
(	10
lck	10
)	10
,	0
in	0
controlling	0
the	0
early	0
steps	0
of	0
the	0
T-cell	0
antigen	0
receptor	0
(	0
TCR	9
)	0
signaling	0
cascade	0
.	0

To	0
help	0
elucidate	0
further	0
the	0
mechanism	0
by	0
which	0
ZAP-70	9
regulates	0
these	0
initial	0
events	0
,	0
we	0
used	0
a	0
dominant-negative	0
mutant	0
approach	0
.	0

We	0
overexpressed	0
in	0
the	0
Jurkat	5
T-cell	6
line	6
ZAP-70	9
mutated	0
on	0
Tyr-492	0
and	0
Tyr-493	0
in	0
the	0
putative	0
regulatory	0
loop	0
of	0
its	0
kinase	9
domain	10
.	0

This	0
mutant	0
inhibited	0
TCR	9
-induced	0
activation	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
by	0
interfering	0
with	0
both	0
intracellular	0
calcium	0
increase	0
and	0
Ras	9
-regulated	0
activation	0
of	0
extracellular	9
signal-regulated	10
kinases	10
.	0

Moreover	0
,	0
TCR	9
-induced	0
phosphorylation	0
of	0
pp36-38	9
,	0
thought	0
to	0
play	0
a	0
role	0
upstream	0
of	0
these	0
pathways	0
,	0
was	0
found	0
to	0
be	0
reduced	0
.	0

In	0
contrast	0
,	0
overexpression	0
of	0
wild-type	9
ZAP-70	10
induced	0
constitutive	0
activation	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

The	0
ZAP-70	9
mutant	0
studied	0
here	0
could	0
be	0
phosphorylated	0
on	0
tyrosine	0
when	0
associated	0
to	0
the	0
TCR	9
zeta	10
chain	10
and	0
was	0
able	0
to	0
bind	0
p56	9
(	10
lck	10
)	10
.	0

This	0
result	0
demonstrates	0
that	0
Tyr-492	0
and	0
Tyr-493	0
are	0
not	0
responsible	0
for	0
the	0
Src	0
homology	0
domain	0
2-mediated	0
association	0
of	0
p56	9
(	10
lck	10
)	10
with	0
ZAP-70	9
.	0

Our	0
data	0
are	0
most	0
consistent	0
with	0
a	0
model	0
in	0
which	0
recruitment	0
to	0
the	0
TCR	9
allows	0
ZAP-70	9
autophosphorylation	0
and	0
binding	0
to	0
p56	9
(	10
lck	10
)	10
,	0
which	0
in	0
turn	0
phosphorylates	0
Tyr-492	0
and/or	0
Tyr-493	0
with	0
consequent	0
up-regulation	0
of	0
the	0
ZAP-70	9
kinase	0
activity	0
.	0

ZAP-70	9
will	0
then	0
be	0
able	0
to	0
effectively	0
control	0
phosphorylation	0
of	0
its	0
substrates	0
and	0
lead	0
to	0
gene	0
activation	0
.	0

Effects	0
of	0
glucocorticoids	0
on	0
lymphocyte	0
activation	0
in	0
patients	0
with	0
steroid-sensitive	0
and	0
steroid-resistant	0
asthma	0
.	0

BACKGROUND	0
:	0
Glucocorticoids	0
are	0
important	0
medications	0
used	0
to	0
control	0
the	0
airway	0
inflammation	0
associated	0
with	0
asthma	0
.	0

Synthetic	0
glucocorticoids	0
vary	0
in	0
their	0
binding	0
affinity	0
for	0
the	0
glucocorticoid	0
receptor	0
(	0
GCR	0
)	0
.	0

METHODS	0
:	0
We	0
compared	0
hydrocortisone	0
,	0
beclomethasone	0
dipropionate	0
,	0
triamcinolone	0
acetonide	0
,	0
flunisolide	0
,	0
and	0
budesonide	0
with	0
regard	0
to	0
their	0
capacity	0
to	0
inhibit	0
phytohemagglutinin	9
-induced	0
peripheral	7
blood	8
mononuclear	8
cell	8
proliferation	0
from	0
six	0
patients	0
with	0
steroid-sensitive	0
asthma	0
and	0
seven	0
patients	0
with	0
steroid-resistant	0
asthma	0
.	0

Peripheral	0
blood	0
mononuclear	0
cell	0
GCR	9
binding	0
affinities	0
for	0
dexamethasone	0
and	0
budesonide	0
were	0
also	0
determined	0
for	0
both	0
patient	0
groups	0
by	0
using	0
a	0
radioligand	0
binding	0
assay	0
and	0
Scatchard	0
analysis	0
.	0

RESULTS	0
:	0
Dose-dependent	0
inhibition	0
was	0
demonstrated	0
for	0
all	0
glucocorticoids	0
in	0
both	0
patient	0
groups	0
,	0
with	0
the	0
steroid-resistant	0
group	0
requiring	0
approximately	0
2	0
log-fold	0
more	0
glucocorticoids	0
for	0
an	0
equivalent	0
degree	0
of	0
inhibition	0
.	0

The	0
mean	0
concentrations	0
necessary	0
to	0
cause	0
50	0
%	0
inhibition	0
of	0
lymphocyte	0
proliferation	0
(	0
IC50s	0
)	0
for	0
the	0
steroid-sensitive	0
group	0
ranged	0
from	0
2	0
x	0
10	0
(	0
-10	0
)	0
mol/L	0
for	0
budesonide	0
to	0
7	0
x	0
10	0
(	0
-8	0
)	0
mol/L	0
for	0
hydrocortisone	0
,	0
whereas	0
the	0
mean	0
IC50s	0
for	0
the	0
steroid-resistant	0
group	0
ranged	0
from	0
approximately	0
2	0
x	0
10	0
(	0
-8	0
)	0
mol/L	0
for	0
budesonide	0
to	0
greater	0
than	0
10	0
(	0
-6	0
)	0
mol/L	0
for	0
hydrocortisone	0
.	0

In	0
addition	0
,	0
a	0
significant	0
correlation	0
was	0
noted	0
between	0
the	0
degree	0
of	0
inhibition	0
of	0
lymphocyte	0
proliferation	0
(	0
IC50	0
)	0
and	0
the	0
binding	0
affinity	0
of	0
dexamethasone	0
to	0
the	0
GCR	9
.	0

Patients	0
with	0
steroid-resistant	0
asthma	0
have	0
been	0
shown	0
to	0
have	0
a	0
reduced	0
GCR	9
binding	0
affinity	0
.	0

The	0
GCR	9
binding	0
affinity	0
for	0
budesonide	0
was	0
significantly	0
higher	0
in	0
both	0
groups	0
(	0
i.e.	0
,	0
lower	0
dissociation	0
constant	0
)	0
than	0
that	0
obtained	0
for	0
dexamethasone	0
.	0

CONCLUSION	0
:	0
These	0
data	0
suggest	0
that	0
glucocorticoids	0
such	0
as	0
budesonide	0
,	0
by	0
virtue	0
of	0
their	0
high	0
GCR	9
binding	0
affinities	0
and	0
greater	0
ability	0
to	0
suppress	0
lymphocyte	0
proliferation	0
,	0
may	0
therefore	0
be	0
beneficial	0
in	0
the	0
management	0
of	0
difficult-to-control	0
asthma	0
.	0

Characterization	0
of	0
the	0
murine	1
cyclin-dependent	2
kinase	2
inhibitor	2
gene	2
p27Kip1	1
.	0

The	0
cyclin-dependent	1
kinase	2
inhibitor	2
p27Kip1	1
plays	0
an	0
important	0
role	0
in	0
regulating	0
cell-cycle	0
progression	0
.	0

p27Kip1	1
directly	0
inhibits	0
the	0
catalytic	0
activity	0
of	0
cyclin/cdks	9
(	10
cyclin-dependent	10
kinase	10
)	10
complexes	10
and/or	0
interferes	0
physically	0
with	0
cyclin/cdks	9
activation	0
by	0
CAK	9
.	0

Interestingly	0
,	0
the	0
expression	0
level	0
of	0
p27Kip1	3
mRNA	4
was	0
maximal	0
in	0
resting	7
Go	8
T-cells	8
and	0
rapidly	0
declined	0
following	0
anti-CD3	9
activation	0
.	0

We	0
report	0
here	0
the	0
cloning	0
of	0
p27Kip1	1
gene	2
from	0
murine	1
genomic	2
DNA	2
and	0
the	0
functional	0
analysis	0
of	0
the	0
promoter	0
of	0
the	0
p27Kip1	1
gene	0
.	0

The	0
gene	0
consists	0
of	0
at	0
least	0
three	0
exons	0
and	0
spans	0
more	0
than	0
5.6	1
kb	2
of	2
DNA	2
.	0

Primer	0
extension	0
and	0
nuclease	0
S1	0
protection	0
analysis	0
revealed	0
two	0
major	0
transcription	1
initiation	2
sites	2
.	0

The	0
promoter	1
region	2
lacked	0
a	0
TATA	1
box	2
but	0
contained	0
potential	0
binding	0
sites	0
for	0
the	0
transcriptional	9
factors	10
including	0
two	0
Sp1	9
,	0
CRE	9
,	0
Myb	9
and	0
NFkB	9
located	0
at	0
positions	1
-153	2
,	2
-178	2
,	2
-286	2
,	2
-875	2
,	2
and	2
-1011	2
,	0
respectively	0
.	0

To	0
analyze	0
the	0
regulatory	0
mechanisms	0
controlling	0
p27Kip1	1
gene	0
expression	0
,	0
we	0
characterized	0
the	0
5'-flanking	1
region	2
from	0
nt	1
-1609	2
to	2
+178	2
.	0

The	0
-326	1
to	2
-615	2
region	2
contained	0
positive	1
regulatory	2
elements	2
.	0

Nuclear	9
NF-ATp	10
is	0
a	0
hallmark	0
of	0
unstimulated	7
B	8
cells	8
from	0
B-CLL	0
patients	0
.	0

B	7
lymphocytes	8
from	0
the	0
peripheral	0
blood	0
of	0
patients	0
with	0
chronic	0
lymphocytic	0
leukaemia	0
(	0
CLL	0
)	0
were	0
analysed	0
for	0
the	0
nuclear	0
presence	0
and	0
DNA	0
binding	0
of	0
a	0
panel	0
of	0
transcription	9
factors	10
which	0
are	0
involved	0
in	0
the	0
gene	0
control	0
of	0
lymphoid	7
cells	8
.	0

The	0
following	0
transcription	9
factors	10
were	0
studied	0
:	0
the	0
Octamer	9
factors	10
Oct-1	9
and	0
Oct-2	9
,	0
members	0
of	0
the	0
AP-1	9
factor	10
family	10
,	0
NF-AT	9
factors	10
,	0
in	0
particular	0
NF-ATp	9
,	0
and	0
members	0
of	0
the	0
Rel/NF-kB	9
family	10
.	0

We	0
show	0
that	0
the	0
constitutive	0
nuclear	0
translocation	0
of	0
NF-ATp	9
,	0
a	0
member	0
of	0
the	0
growing	0
family	0
of	0
NF-AT	9
factors	10
,	0
is	0
a	0
hallmark	0
of	0
nonstimulated	7
B	8
cells	8
from	0
CLL	0
patients	0
that	0
distinguishes	0
B-CLL	7
cells	8
from	0
'normal	7
'	8
B	8
lymphocytes	8
.	0

Constitutive	0
nuclear	0
appearance	0
was	0
also	0
observed	0
for	0
NF-kB2/p52	0
.	0

Constitutive	0
binding	0
of	0
further	0
factor	9
proteins	10
to	0
DNA	0
,	0
such	0
as	0
JunD	9
,	0
c-Fos	9
and	0
FosB	9
,	0
was	0
detected	0
in	0
several	0
patients	0
whereas	0
the	0
localisation	0
and	0
DNA	0
binding	0
of	0
other	0
factors	0
such	0
as	0
c-Jun	9
,	0
RelA/p65	9
and	0
c-Rel	9
was	0
unaltered	0
.	0

It	0
is	0
remarkable	0
that	0
in	0
B-CLL	7
cells	8
the	0
nuclear	0
appearance	0
and	0
DNA	0
binding	0
of	0
specific	0
transcription	9
factors	10
is	0
dramatically	0
affected	0
whereas	0
other	0
members	0
of	0
the	0
same	0
factor	9
family	10
remained	0
unaltered	0
in	0
these	0
leukemic	0
cells	0
.	0

It	0
remains	0
to	0
be	0
shown	0
which	0
molecular	0
events	0
lead	0
to	0
the	0
specific	0
'pre-activation	0
'	0
,	0
i.e	0
.	0

constitutive	0
nuclear	0
translocation	0
and	0
DNA	0
binding	0
,	0
of	0
these	0
members	0
of	0
NF-AT	9
,	0
NF-kB	9
and	0
AP-1	9
factor	10
families	10
.	0

Naive	7
(	8
CD45RA+	8
)	8
T	8
lymphocytes	8
are	0
more	0
sensitive	0
to	0
oxidative	0
stress-induced	0
signals	0
than	0
memory	7
(	8
CD45RO+	8
)	8
cells	8
.	0

Formation	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROI	0
)	0
after	0
oxidative	0
stress	0
has	0
been	0
shown	0
to	0
be	0
an	0
activation	0
signal	0
for	0
T	7
lymphocytes	8
,	0
e.g.	0
,	0
expression	0
of	0
IL-2	9
and	0
its	0
receptor	9
are	0
induced	0
.	0

These	0
ROI-induced	0
effects	0
can	0
,	0
to	0
a	0
large	0
extent	0
,	0
be	0
attributed	0
to	0
the	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
.	0

Now	0
we	0
have	0
examined	0
whether	0
naive	7
and	8
memory	8
T	8
lymphocytes	8
differ	0
in	0
their	0
sensitivity	0
to	0
ROI-mediated	0
signals	0
.	0

When	0
CD45RA+	7
(	8
naive	8
)	8
and	0
CD45RO+	7
(	8
memory	8
)	8
T	8
lymphocytes	8
were	0
directly	0
stimulated	0
with	0
H2O2	0
,	0
NF-kappaB	9
nuclear	0
translocation	0
was	0
stronger	0
in	0
naive	7
cells	8
than	0
in	0
memory	7
cells	8
and	0
it	0
could	0
be	0
induced	0
with	0
lower	0
doses	0
.	0

The	0
composition	0
of	0
the	0
induced	0
nuclear	9
NF-kappaB	10
(	0
levels	0
of	0
p50	9
and	0
RelA	9
proteins	10
)	0
was	0
similar	0
in	0
these	0
cell	0
types	0
.	0

The	0
magnitude	0
and	0
kinetics	0
of	0
intracellular	0
ROI	0
were	0
similar	0
,	0
suggesting	0
that	0
there	0
were	0
no	0
differences	0
in	0
ROI-forming	0
mechanisms	0
or	0
antioxidative	0
capacities	0
.	0

The	0
probable	0
regulatory	0
point	0
was	0
the	0
cytoplasmic	0
IkappaB	9
inhibitor	0
:	0
in	0
CD45RA+	0
cells	0
,	0
H2O2	0
caused	0
a	0
more	0
profound	0
depression	0
in	0
the	0
levels	0
of	0
IkappaB	9
alpha	10
.	0

These	0
findings	0
indicate	0
that	0
T	7
cells	8
representing	0
different	0
activation	0
and/or	0
differentiation	0
stages	0
can	0
be	0
differentially	0
responsive	0
to	0
ROI-mediated	0
signals	0
.	0

Rapid	0
shuttling	0
of	0
NF-AT	9
in	0
discrimination	0
of	0
Ca2+	0
signals	0
and	0
immunosuppression	0
.	0

Cells	0
need	0
to	0
distinguish	0
between	0
transient	0
Ca2+	0
signals	0
that	0
induce	0
events	0
such	0
as	0
muscle	0
contraction	0
,	0
secretion	0
,	0
adhesion	0
and	0
synaptic	0
transmission	0
,	0
and	0
sustained	0
Ca2+	0
signals	0
that	0
are	0
involved	0
in	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

The	0
latter	0
class	0
of	0
events	0
is	0
blocked	0
in	0
lymphocytes	7
by	0
the	0
immunosuppressive	0
drugs	0
cyclosporin	0
A	0
and	0
FK506	0
,	0
which	0
inhibit	0
calcineurin	9
,	0
a	0
Ca2+-activated	9
serine/threonine	10
phosphatase	10
necessary	0
for	0
the	0
nuclear	0
import	0
of	0
NF-AT	9
transcription	9
factors	10
.	0

Here	0
we	0
report	0
that	0
sustained	0
high	0
concentrations	0
of	0
Ca2+	0
,	0
but	0
not	0
transient	0
pulses	0
,	0
are	0
required	0
to	0
maintain	0
NF-AT	9
transcription	9
factors	10
in	0
the	0
nucleus	0
,	0
where	0
they	0
participate	0
in	0
Ca2+-dependent	0
induction	0
of	0
genes	1
required	0
for	0
lymphocyte	7
activation	0
and	0
proliferation	0
.	0

Furthermore	0
,	0
overexpression	0
and	0
constitutive	0
nuclear	0
localization	0
of	0
NF-AT	9
,	0
but	0
not	0
Jun	9
,	10
Fos	10
,	10
NF-kappaB	10
,	10
Oct	10
or	10
Ets	10
family	10
members	10
,	0
renders	0
the	0
interleukin-2	1
enhancer	2
in	0
Jurkat	5
T	6
lymphocytes	6
resistant	0
to	0
FK506	0
and	0
cyclosporin	0
A	0
.	0

Thus	0
a	0
primary	0
effect	0
of	0
these	0
immunosuppressive	0
reagents	0
is	0
to	0
control	0
the	0
subcellular	0
localization	0
of	0
the	0
NF-AT	9
family	0
of	0
transcription	9
factors	10
.	0

Autoregulation	0
of	0
the	0
NF-kappa	9
B	10
transactivator	10
RelA	9
(	0
p65	9
)	0
by	0
multiple	0
cytoplasmic	9
inhibitors	10
containing	0
ankyrin	9
motifs	10
.	0

RelA	9
(	0
p65	9
)	0
functions	0
as	0
the	0
critical	0
transactivating	0
component	0
of	0
the	0
heterodimeric	9
p50-p65	10
NF-kappa	10
B	10
complex	10
and	0
contains	0
a	0
high-affinity	9
binding	10
site	10
for	0
its	0
cytoplasmic	9
inhibitor	10
,	0
I	9
kappa	10
B	10
alpha	10
.	0

After	0
cellular	0
activation	0
,	0
I	9
kappa	10
B	10
alpha	10
is	0
rapidly	0
degraded	0
in	0
concert	0
with	0
the	0
induced	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B	10
.	0

The	0
present	0
study	0
demonstrates	0
that	0
tumor	9
necrosis	10
factor	10
alpha	10
-induced	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
in	0
human	7
T	8
cells	8
is	0
preceded	0
by	0
its	0
rapid	0
phosphorylation	0
in	0
vivo	0
.	0

However	0
,	0
these	0
effects	0
on	0
I	9
kappa	10
B	10
alpha	10
result	0
in	0
nuclear	0
mobilization	0
of	0
only	0
a	0
fraction	0
of	0
the	0
entire	0
cytoplasmic	0
pool	0
of	0
RelA	9
.	0

Subsequent	0
studies	0
have	0
revealed	0
that	0
(	0
i	0
)	0
cytoplasmic	9
RelA	10
is	0
stably	0
associated	0
not	0
only	0
with	0
I	9
kappa	10
B	10
alpha	10
but	0
also	0
with	0
other	0
ankyrin	9
motif-rich	10
proteins	10
including	0
the	0
products	0
of	0
the	0
NF-kappa	1
B2	2
(	2
p100	2
)	2
and	2
NF-kappa	2
B1	2
(	2
p105	2
)	2
genes	2
;	0
(	0
ii	0
)	0
in	0
contrast	0
to	0
RelA	9
-I	9
kappa	10
B	10
alpha	10
,	0
RelA-p100	9
cytoplasmic	10
complexes	10
are	0
not	0
dissociated	0
following	0
tumor	9
necrosis	10
factor	10
alpha	10
activation	0
;	0
(	0
iii	0
)	0
p100	9
functions	0
as	0
a	0
potent	0
inhibitor	0
of	0
RelA	9
-mediated	0
transcription	0
in	0
vivo	0
;	0
(	0
iv	0
)	0
the	0
interaction	0
of	0
RelA	9
and	0
p100	9
involves	0
the	0
conserved	9
Rel	10
homology	10
domain	10
of	0
both	0
proteins	0
but	0
not	0
the	0
nuclear	9
localization	10
signal	10
of	0
RelA	9
,	0
which	0
is	0
required	0
for	0
I	9
kappa	10
B	10
alpha	10
binding	0
;	0
(	0
v	0
)	0
p100	9
inhibition	0
of	0
RelA	9
function	0
requires	0
the	0
C-terminal	9
ankyrin	10
motif	10
domain	10
,	0
which	0
mediates	0
cytoplasmic	0
retention	0
of	0
RelA	9
;	0
and	0
(	0
vi	0
)	0
as	0
observed	0
with	0
I	9
kappa	10
B	10
alpha	10
,	0
nuclear	0
RelA	9
stimulates	0
p100	3
mRNA	4
and	0
protein	0
expression	0
.	0

These	0
findings	0
thus	0
reveal	0
the	0
presence	0
of	0
a	0
second	0
inducible	0
autoregulated	0
inhibitory	0
pathway	0
that	0
helps	0
ensure	0
the	0
rapid	0
but	0
transient	0
action	0
of	0
nuclear	9
NF-kappa	10
B	10
.	0

Effects	0
of	0
CD45	9
on	0
NF-kappa	9
B	10
.	0

Implications	0
for	0
replication	0
of	0
HIV-1	0
.	0

Increased	0
levels	0
of	0
replication	0
of	0
the	0
HIV	0
type	0
1	0
are	0
observed	0
after	0
the	0
activation	0
of	0
infected	7
T	8
cells	8
through	0
the	0
TCR	9
.	0

However	0
,	0
anti-	0
CD45	9
antibodies	0
inhibit	0
these	0
effects	0
in	0
cells	0
from	0
infected	0
individuals	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
interrelationships	0
between	0
CD45	9
and	0
HIV-1	0
further	0
.	0

We	0
measured	0
effects	0
on	0
the	0
HIV-1	1
LTR	2
in	0
T	5
cell	6
lines	6
that	0
were	0
stimulated	0
with	0
antibodies	0
against	0
CD45	9
and	0
in	0
those	0
that	0
lacked	0
the	0
expression	0
of	0
CD45	9
on	0
their	0
surfaces	0
.	0

First	0
,	0
anti-CD45	9
antibodies	10
did	0
not	0
affect	0
basal	0
but	0
decreased	0
activated	0
levels	0
of	0
expression	0
from	0
the	0
HIV-1	1
LTR	2
.	0

Second	0
,	0
T	7
cells	8
,	0
which	0
lack	0
CD45	9
and	0
can	0
not	0
signal	0
via	0
the	0
TCR	9
,	0
supported	0
higher	0
levels	0
of	0
viral	0
replication	0
and	0
gene	0
expression	0
.	0

This	0
was	0
due	0
to	0
the	0
presence	0
of	0
active	0
NF-kappa	9
B	10
complexes	10
in	0
the	0
nucleus	0
of	0
CD45	9
-T	0
cells	0
.	0

Additionally	0
,	0
infected	7
T	8
cells	8
displayed	0
lower	0
levels	0
of	0
CD45	9
on	0
their	0
surfaces	0
.	0

Thus	0
,	0
CD45	9
plays	0
an	0
active	0
role	0
in	0
the	0
physiology	0
of	0
T	7
cells	8
and	0
in	0
the	0
replication	0
of	0
HIV-1	0
.	0

Calcineurin	9
potentiates	0
activation	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
gene	2
in	0
T	7
cells	8
:	0
involvement	0
of	0
the	0
conserved	1
lymphokine	2
element	2
0	2
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
and	0
interleukin-2	9
(	0
IL-2	9
)	0
are	0
produced	0
by	0
stimulation	0
with	0
phorbol-12-myristate	0
acetate	0
(	0
PMA	0
)	0
and	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
in	0
human	5
T	6
cell	6
leukemia	6
Jurkat	6
cells	6
.	0

The	0
expression	0
of	0
GM-CSF	9
and	0
IL-2	9
is	0
inhibited	0
by	0
immunosuppressive	0
drugs	0
such	0
as	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
.	0

Earlier	0
studies	0
on	0
the	0
IL-2	9
gene	0
expression	0
showed	0
that	0
overexpression	0
of	0
calcineurin	9
(	0
CN	9
)	0
,	0
a	0
Ca2+/calmodulin-dependent	9
protein	10
phosphatase	10
,	0
can	0
stimulate	0
transcription	0
from	0
the	0
IL-2	1
promoter	2
through	0
the	0
NF-AT-binding	1
site	2
.	0

In	0
this	0
study	0
,	0
we	0
obtained	0
evidence	0
that	0
transfection	0
of	0
the	0
cDNAs	1
for	0
CN	9
A	10
(	10
catalytic	10
)	10
and	10
CN	10
B	10
(	10
regulatory	10
)	10
subunits	10
also	0
augments	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
and	0
recovers	0
the	0
transcription	0
inhibited	0
by	0
CsA	0
.	0

The	0
constitutively	0
active	0
type	0
of	0
the	0
CN	9
A	10
subunit	10
,	0
which	0
lacks	0
the	0
auto-inhibitory	9
and	0
calmodulin-binding	9
domains	10
,	0
acts	0
in	0
synergy	0
with	0
PMA	0
to	0
activate	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
.	0

We	0
also	0
found	0
that	0
the	0
active	0
CN	9
partially	0
replaces	0
calcium	0
ionophore	0
in	0
synergy	0
with	0
PMA	0
to	0
induce	0
expression	0
of	0
endogenous	0
GM-CSF	9
and	0
IL-2	9
.	0

By	0
multimerizing	0
the	0
regulatory	1
elements	2
of	0
the	0
GM-CSF	1
promoter	2
,	0
we	0
found	0
that	0
one	0
of	0
the	0
target	1
sites	2
for	0
the	0
CN	9
action	0
is	0
the	0
conserved	1
lymphokine	2
element	2
0	2
(	0
CLE0	1
)	0
,	0
located	0
at	0
positions	0
between	0
-54	0
and	0
-40	0
.	0

Mobility	0
shift	0
assays	0
showed	0
that	0
the	0
CLE0	1
sequence	0
has	0
an	0
AP1-binding	1
site	2
and	0
is	0
associated	0
with	0
an	0
NF-AT-like	9
factor	10
,	0
termed	0
NF-CLE0	9
gamma	10
.	0

NF-	0
CLE0	1
gamma	0
binding	0
is	0
induced	0
by	0
PMA/A23187	0
and	0
is	0
inhibited	0
by	0
treatment	0
with	0
CsA	0
.	0

These	0
results	0
suggest	0
that	0
CN	9
is	0
involved	0
in	0
the	0
coordinated	0
induction	0
of	0
the	0
GM-CSF	1
and	2
IL-2	2
genes	2
and	0
that	0
the	0
CLE0	1
sequence	2
of	0
the	0
GM-CSF	1
gene	2
is	0
a	0
functional	0
analogue	0
of	0
the	0
NF-AT-binding	1
site	2
in	0
the	0
IL-2	1
promoter	2
,	0
which	0
mediates	0
signals	0
downstream	0
of	0
T	0
cell	0
activation	0
.	0

Alternate	0
immune	0
system	0
targets	0
for	0
TCDD	0
:	0
lymphocyte	7
stem	8
cells	8
and	0
extrathymic	7
T-cell	8
development	0
.	0

We	0
here	0
summarize	0
evidence	0
that	0
thymic	0
atrophy	0
induced	0
by	0
2	0
,	0
3	0
,	0
7	0
,	0
8-tetrachlorodibenzo-p-dioxin	0
(	0
TCDD	0
)	0
can	0
be	0
mediated	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
damage	0
to	0
extrathymic	7
T-cell	8
precursors	8
in	0
bone	0
marrow	0
and	0
fetal	0
liver	0
.	0

This	0
atrophy	0
induction	0
does	0
not	0
involve	0
apoptotic	0
mechanisms	0
in	0
thymocytes	7
affected	0
by	0
the	0
bcl-2	1
proto-oncogene	2
.	0

TCDD	0
mediates	0
atrophy	0
induction	0
through	0
its	0
specific	0
receptor	0
(	0
the	0
AhR	9
)	0
and	0
not	0
through	0
effects	0
on	0
the	0
estrogen	0
receptor	0
.	0

Both	0
TCDD	0
and	0
estradiol	0
induce	0
extrathymic	0
T-cell	0
differentiation	0
in	0
the	0
liver	0
.	0

These	0
extrathymic	7
T-cell	8
populations	8
include	0
cells	0
expressing	0
elevated	0
levels	0
of	0
V	9
beta	10
T-cell	10
receptors	10
that	0
are	0
normally	0
deleted	0
in	0
thymic	0
development	0
.	0

Identification	0
of	0
Bcd	1
,	0
a	0
novel	0
proto-oncogene	1
expressed	0
in	0
B-cells	7
.	0

A	0
novel	7
B-cell	8
derived	0
(	0
Bcd	1
)	0
oncogene	1
has	0
been	0
isolated	0
from	0
the	0
peripheral	0
blood	0
lymphocytes	0
of	0
one	0
B-cell	0
chronic	0
lymphocytic	0
leukemia	0
(	0
B-CLL	0
)	0
patient	0
using	0
DNA	0
transfer	0
and	0
a	0
mouse	0
tumorigenicity	0
assay	0
.	0

The	0
Bcd	1
proto-oncogene	1
was	0
activated	0
by	0
a	0
truncation	0
in	0
the	0
5	1
'	2
UTR	2
.	0

It	0
predicts	0
for	0
two	0
open	1
reading	2
frames	2
(	0
ORFs	1
)	0
.	0

ORF1	1
consists	0
of	0
240	0
bp	0
that	0
would	0
encode	0
80	0
amino	0
acids	0
,	0
while	0
the	0
major	1
ORF2	2
consists	0
of	0
648	0
bp	0
capable	0
of	0
coding	0
for	0
216	0
amino	0
acids	0
.	0

Predicted	9
peptide	10
sequence	10
of	0
ORF2	1
contained	0
a	0
zinc	9
finger	10
domain	10
which	0
showed	0
significant	0
homology	0
to	0
GC	9
box	10
binding	10
proteins	10
BTEB2	9
and	0
SP1	9
.	0

Transfection	0
of	0
an	0
expression	1
vector	2
containing	0
ORF2	1
but	0
not	0
full	1
length	2
cDNA	2
was	0
able	0
to	0
transform	0
NIH3T3	5
cells	6
and	0
induce	0
tumors	0
in	0
nude	0
mice	0
.	0

Bcd	3
mRNA	4
transcripts	4
of	0
<	0
or	0
=	0
2.6	0
kb	0
were	0
selectively	0
expressed	0
in	0
PBL	5
and	0
testis	0
of	0
healthy	0
individuals	0
.	0

Within	0
the	0
PBL	7
,	0
Bcd	1
gene	0
expression	0
was	0
restricted	0
to	0
CD19+	7
B-cells	8
and	0
absent	0
from	0
CD14+	7
monocytes	8
and	0
T-cells	7
.	0

Bcd	1
transcripts	0
were	0
detected	0
in	0
all	0
normal	0
PBL	7
samples	0
tested	0
but	0
not	0
in	0
several	0
malignant	5
human	6
B-cell	6
lines	6
and	0
not	0
in	0
50	0
%	0
of	0
B-cells	7
from	0
B-CLL	0
patients	0
.	0

However	0
,	0
stimulation	0
of	0
B-cells	7
from	0
B-CLL	0
patients	0
under	0
conditions	0
which	0
induced	0
differentiation	0
into	0
plasma	7
cells	8
was	0
associated	0
with	0
induction	0
of	0
Bcd	1
gene	0
expression	0
.	0

The	0
Bcd	1
gene	2
may	0
therefore	0
play	0
an	0
important	0
role	0
in	0
B-cell	0
growth	0
and	0
development	0
.	0

A	0
novel	1
SP-1	2
site	2
in	0
the	0
human	1
interleukin-1	2
beta	2
promoter	2
confers	0
preferential	0
transcriptional	0
activity	0
in	0
keratinocytes	7
.	0

To	0
investigate	0
the	0
mechanisms	0
of	0
transcriptional	0
activation	0
of	0
interleukin-1beta	9
(	0
IL-1beta	9
)	0
in	0
non-monocytic	0
cells	0
,	0
we	0
constructed	0
a	0
series	0
of	0
reporter	0
plasmids	0
with	0
the	0
bacterial	0
chloramphenicol	0
acetyltransferase	0
gene	0
linked	0
to	0
various	0
parts	0
of	0
the	0
human	1
IL-1beta	2
promoter	2
and	0
performed	0
transient	0
transfection	0
experiments	0
.	0

We	0
identified	0
a	0
promoter	0
segment	0
that	0
activates	0
transcription	0
most	0
efficiently	0
in	0
keratinocytes	7
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
with	0
a	0
43-mer	1
oligonucleotide	2
derived	0
from	0
the	0
functionally	0
identified	0
cis-acting	1
element	2
revealed	0
specific	0
complexes	0
.	0

By	0
competition	0
analysis	0
with	0
transcription	1
factor	2
consensus	2
sequence	2
oligonucleotides	2
and	0
by	0
immunosupershift	0
,	0
transcription	9
factor	10
SP-1	10
or	0
a	0
closely	0
related	0
protein	0
was	0
shown	0
to	0
bind	0
to	0
this	0
regulatory	1
element	2
.	0

The	0
closest	0
match	0
to	0
the	0
known	0
SP-1	1
consensus	2
sequence	2
within	0
the	0
respective	0
region	0
is	0
a	0
TCCCCTCCCCT	1
motif	2
.	0

Mutation	0
of	0
this	0
motif	0
almost	0
completely	0
,	0
and	0
specifically	0
,	0
abolished	0
the	0
binding	0
of	0
two	0
low-mobility	9
complexes	10
and	0
led	0
to	0
a	0
95	0
%	0
decrease	0
of	0
constitutive	0
transcriptional	0
activation	0
of	0
a	0
reporter	0
construct	0
IL-1beta	9
(	0
-170/+108	0
)	0
.	0

Likewise	0
,	0
activation	0
of	0
this	0
reporter	0
construct	0
by	0
tumor	9
necrosis	10
factor-alpha	10
depended	0
on	0
the	0
SP-1	1
site	2
.	0

These	0
observations	0
suggest	0
that	0
a	0
so-far-unrecognized	0
SP-1	1
site	2
in	0
the	0
human	1
IL-1beta	2
promoter	2
may	0
participate	0
in	0
the	0
transcriptional	0
regulation	0
of	0
this	0
gene	0
in	0
keratinocytes	7
.	0

Expression	0
of	0
Egr-1	9
correlates	0
with	0
the	0
transformed	0
phenotype	0
and	0
the	0
type	0
of	0
viral	0
latency	0
in	0
EBV	5
genome	6
positive	6
lymphoid	6
cell	6
lines	6
.	0

In	0
this	0
paper	0
we	0
have	0
investigated	0
the	0
role	0
of	0
Egr-1	9
in	0
B	0
cell	0
growth	0
regulation	0
by	0
examining	0
the	0
gene	0
expression	0
in	0
a	0
panel	0
of	0
B	5
cell	6
lines	6
,	0
including	0
both	0
EBV	1
genome	2
negative	0
and	0
EBV	5
carrying	6
cell	6
lines	6
.	0

Egr-1	9
expression	0
correlates	0
with	0
the	0
cellular	0
phenotype	0
and	0
the	0
specific	0
pattern	0
of	0
viral	0
latency	0
established	0
within	0
the	0
individual	5
cell	6
lines	6
.	0

Thus	0
,	0
constitutive	0
activation	0
of	0
Egr-1	9
gene	0
is	0
invariably	0
associated	0
with	0
unrestricted	0
expression	0
of	0
viral	0
latent	0
genes	0
in	0
all	0
group	5
III	6
EBV	6
genome	6
carrying	6
cell	6
lines	6
.	0

In	0
contrast	0
,	0
Egr-1	9
expression	0
is	0
abrogated	0
in	0
group	5
I	6
Burkitt	6
tumor	6
cells	6
,	0
irrespective	0
of	0
the	0
EBV	1
genome	2
carrying	0
status	0
.	0

Activated	0
viral	0
gene	0
expression	0
associated	0
with	0
phenotypic	0
conversion	0
of	0
group	5
I	6
cell	6
lines	6
in	0
to	0
group	5
II	6
or	0
III	5
restores	0
the	0
Egr-1	1
gene	2
expression	0
.	0

Several	0
forms	0
of	0
EGR-1	9
protein	10
are	0
found	0
within	0
the	0
different	0
groups	0
of	0
cell	0
lines	0
,	0
and	0
the	0
binding	0
activity	0
to	0
DNA	1
consensus	2
sequences	2
was	0
investigated	0
.	0

Finally	0
,	0
time	0
course	0
analysis	0
of	0
Egr-1	9
expression	0
during	0
the	0
early	0
steps	0
of	0
EBV	0
infection	0
in	0
vitro	0
demonstrated	0
that	0
Egr-1	9
is	0
upregulated	0
within	0
minutes	0
from	0
the	0
initial	0
interaction	0
with	0
the	0
B	7
lymphocyte	8
.	0

Expression	0
of	0
erythroid-specific	1
genes	2
in	0
megakaryoblastic	0
disorders	0
.	0

Currently	0
available	0
data	0
indicate	0
that	0
erythroid	0
and	0
megakaryocytic	0
differentiation	0
pathways	0
are	0
closely	0
related	0
to	0
each	0
other	0
,	0
and	0
there	0
may	0
exist	0
progenitor	7
cells	8
common	0
to	0
those	0
two	0
lineages	0
may	0
exist	0
.	0

Acute	0
megakaryoblastic	0
leukemia	0
(	0
AML-M7	0
)	0
and	0
transient	0
myeloproliferative	0
disorder	0
in	0
Down	0
's	0
syndrome	0
(	0
TMD	0
)	0
are	0
characterized	0
by	0
rapid	0
growth	0
of	0
abnormal	7
blast	8
cells	8
which	0
express	0
megakaryocytic	9
markers	10
.	0

These	0
blast	7
cells	8
express	0
lineage-specific	9
transcription	10
factors	10
such	0
as	0
GATA-1	9
common	0
to	0
these	0
lineages	0
and	0
frequently	0
express	0
erythroid-specific	3
mRNAs	4
such	0
as	0
gamma-globin	9
and	0
erythroid	9
delta-aminolevulinate	10
synthase	10
(	0
ALAS-E	9
)	0
,	0
indicating	0
that	0
most	0
of	0
the	0
blasts	0
in	0
M7	0
and	0
TMD	0
cases	0
have	0
erythroid	0
and	0
megakaryocytic	0
phenotypes	0
.	0

These	0
results	0
suggest	0
that	0
blasts	7
in	0
M7	0
and	0
TMD	0
may	0
correspond	0
to	0
progenitors	7
of	0
both	0
erythroid	7
and	8
megakaryocytic	8
lineages	8
.	0

Stat3	9
recruitment	0
by	0
two	0
distinct	0
ligand-induced	9
,	10
tyrosine-phosphorylated	10
docking	10
sites	10
in	0
the	0
interleukin-10	9
receptor	10
intracellular	10
domain	10
.	0

Recent	0
work	0
has	0
shown	0
that	0
IL-10	9
induces	0
activation	0
of	0
the	0
JAK	9
-STAT	9
signaling	0
pathway	0
.	0

To	0
define	0
the	0
mechanism	0
underlying	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
protein	10
recruitment	0
to	0
the	0
interleukin	9
10	10
(	10
IL-10	10
)	10
receptor	10
,	0
the	0
STAT	9
proteins	10
activated	0
by	0
IL-10	9
in	0
different	0
cell	0
populations	0
were	0
first	0
defined	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

In	0
all	0
cells	0
tested	0
,	0
IL-10	9
activated	0
Stat1	9
and	0
Stat3	9
and	0
induced	0
the	0
formation	0
of	0
three	0
distinct	0
DNA	9
binding	10
complexes	10
that	0
contained	0
different	0
combinations	0
of	0
these	0
two	0
transcription	9
factors	10
.	0

IL-10	9
also	0
activated	0
Stat5	9
in	0
Ba/F3	5
cells	6
that	0
stably	0
expressed	0
the	0
murine	0
IL-10	9
receptor	10
.	0

Using	0
a	0
structure-function	0
mutagenesis	0
approach	0
,	0
two	0
tyrosine	0
residues	0
(	0
Tyr427	0
and	0
Tyr477	0
)	0
in	0
the	0
intracellular	9
domain	10
of	0
the	0
murine	0
IL-10	9
receptor	0
were	0
found	0
to	0
be	0
redundantly	0
required	0
for	0
receptor	0
function	0
and	0
for	0
activation	0
of	0
Stat3	9
but	0
not	0
for	0
Stat1	9
or	0
Stat5	9
.	0

Twelve	0
amino	0
acid	0
peptides	0
encompassing	0
either	0
of	0
these	0
two	0
tyrosine	0
residues	0
in	0
phosphorylated	9
form	10
coprecipitated	0
Stat3	9
but	0
not	0
Stat1	9
and	0
blocked	0
IL-10	9
-induced	0
Stat3	9
phosphorylation	0
in	0
a	0
cell-free	0
system	0
.	0

In	0
contrast	0
,	0
tyrosine-phosphorylated	0
peptides	0
containing	0
Tyr374	0
or	0
Tyr396	0
did	0
not	0
interact	0
with	0
Stat3	9
or	0
block	0
Stat3	9
activation	0
.	0

These	0
data	0
demonstrate	0
that	0
Stat3	9
but	0
not	0
Stat1	9
or	0
Stat5	9
is	0
directly	0
recruited	0
to	0
the	0
ligand-activated	9
IL-10	10
receptor	10
by	0
binding	0
to	0
specific	0
but	0
redundant	0
receptor	9
intracellular	10
domain	10
sequences	10
containing	0
phosphotyrosine	0
.	0

This	0
study	0
thus	0
supports	0
the	0
concept	0
that	0
utilization	0
of	0
distinct	0
STAT	9
proteins	10
by	0
different	0
cytokine	9
receptors	10
is	0
dependent	0
on	0
the	0
expression	0
of	0
particular	0
ligand-activatable	0
,	0
tyrosine-containing	9
STAT	10
docking	10
sites	10
in	0
receptor	9
intracellular	10
domains	10
.	0

Silencing	0
of	0
human	0
fetal	0
globin	9
expression	0
is	0
impaired	0
in	0
the	0
absence	0
of	0
the	0
adult	9
beta-globin	10
gene	10
activator	10
protein	10
EKLF	9
.	0

Globin	1
genes	2
are	0
subject	0
to	0
tissue-specific	0
and	0
developmental	0
stage-specific	0
regulation	0
.	0

A	0
switch	0
from	0
human	9
fetal	10
(	10
gamma	10
)	10
-to	0
adult	9
(	10
beta	10
)	10
-globin	10
expression	0
occurs	0
within	0
erythroid	7
precursor	8
cells	8
of	0
the	0
adult	7
lineage	8
.	0

Previously	0
we	0
and	0
others	0
showed	0
by	0
targeted	0
gene	0
disruption	0
that	0
the	0
zinc	1
finger	2
gene	2
,	0
erythroid	9
Kruppel-like	10
factor	10
(	0
EKLF	9
)	0
,	0
is	0
required	0
for	0
expression	0
of	0
the	0
beta-globin	1
gene	2
in	0
mice	0
,	0
presumably	0
through	0
interaction	0
with	0
a	0
high-affinity	1
binding	2
site	2
in	0
the	0
proximal	1
promoter	2
.	0

To	0
examine	0
the	0
role	0
of	0
EKLF	9
in	0
the	0
developmental	0
regulation	0
of	0
the	0
human	1
gamma-globin	2
gene	2
we	0
interbred	0
EKLF	9
heterozygotes	10
(	0
+/-	0
)	0
with	0
mice	0
harboring	0
a	0
human	1
beta-globin	2
yeast	2
artificial	2
chromosome	2
transgene	2
.	0

We	0
find	0
that	0
in	0
the	0
absence	0
of	0
EKLF	9
,	0
while	0
human	9
beta-globin	10
expression	0
is	0
dramatically	0
reduced	0
,	0
gamma-globin	3
transcripts	4
are	0
elevated	0
approximately	0
5-fold	0
.	0

Impaired	0
silencing	0
of	0
gamma-globin	9
expression	0
identifies	0
EKLF	9
as	0
the	0
first	0
transcription	9
factor	10
participating	0
quantitatively	0
in	0
the	0
gamma-globin	9
to	0
beta-globin	9
switch	0
.	0

Our	0
findings	0
are	0
compatible	0
with	0
a	0
competitive	0
model	0
of	0
switching	0
in	0
which	0
EKLF	9
mediates	0
an	0
adult	0
stage-specific	0
interaction	0
between	0
the	0
beta-globin	1
gene	2
promoter	2
and	0
the	0
locus	1
control	2
region	2
that	0
excludes	0
the	0
gamma-globin	1
gene	2
.	0

Stimulation	0
of	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
by	0
zinc	0
and	0
related	0
cations	0
.	0

Zinc	0
is	0
an	0
important	0
trace	0
element	0
for	0
immune	0
function	0
.	0

Here	0
,	0
we	0
show	0
that	0
zinc	0
addition	0
in	0
a	0
serum-	0
and	0
lipopolysaccharide-free	0
cell	0
culture	0
system	0
leads	0
to	0
significantly	0
enhanced	0
levels	0
of	0
interleukin	9
1	10
beta	10
(	0
IL-1	9
beta	10
)	0
and	0
tumour	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
and	0
to	0
expression	0
of	0
the	0
corresponding	0
mRNA	3
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

Structurally	0
related	0
divalent	0
cations	0
like	0
cobalt	0
,	0
nickel	0
,	0
and	0
mercury	0
also	0
partially	0
increase	0
monokine	0
secretion	0
but	0
to	0
a	0
much	0
lower	0
and	0
thus	0
insignificant	0
extent	0
.	0

They	0
fail	0
to	0
induce	0
mRNA	3
of	0
TNF-alpha	9
after	0
3	0
h	0
of	0
culture	0
.	0

Therefore	0
,	0
monokine	0
induction	0
is	0
a	0
zinc-specific	0
effect	0
influenced	0
by	0
the	0
physicochemical	0
properties	0
of	0
the	0
ion	0
.	0

Confirmation	0
of	0
the	0
unique	0
significance	0
of	0
zinc	0
for	0
immune	0
function	0
provides	0
a	0
better	0
understanding	0
of	0
the	0
mechanisms	0
of	0
specific	0
zinc-mediated	0
immune	0
modulation	0
.	0

E3	9
,	0
a	0
hematopoietic-specific	9
transcript	10
directly	0
regulated	0
by	0
the	0
retinoic	9
acid	10
receptor	10
alpha	10
.	0

Retinoic	0
acid	0
(	0
RA	0
)	0
-induced	0
maturation	0
mediated	0
by	0
the	0
retinoic	9
acid	10
receptor	10
alpha	10
(	0
RAR	9
alpha	10
)	0
has	0
been	0
implicated	0
in	0
myeloid	0
development	0
.	0

We	0
have	0
used	0
differential	0
hybridization	0
analysis	0
of	0
a	0
cDNA	1
library	2
constructed	0
from	0
the	0
murine	0
RA-inducible	5
MPRO	6
promyelocyte	6
cell	6
line	6
to	0
identify	0
immediate-early	1
genes	2
induced	0
by	0
RA	0
during	0
granulocytic	0
differentiation	0
.	0

E3	9
,	0
one	0
of	0
nine	0
sequences	0
identified	0
,	0
was	0
upregulated	0
in	0
an	0
immediate-early	0
manner	0
,	0
with	0
transcript	0
levels	0
peaking	0
after	0
60	0
minutes	0
exposure	0
to	0
RA	0
.	0

E3	9
transcripts	10
were	0
RA-inducible	0
in	0
HL60	5
cells	6
,	0
but	0
not	0
in	0
an	0
RA-resistant	5
subclone	6
,	0
HL60R	5
,	0
that	0
harbors	0
a	0
mutated	0
RAR	1
alpha	2
gene	2
.	0

However	0
,	0
when	0
HL60R	5
cells	6
were	0
transduced	0
with	0
a	0
functional	0
copy	0
of	0
the	0
RAR	1
alpha	2
gene	2
,	0
RA	0
induced	0
a	0
10-fold	0
increase	0
in	0
E3	9
mRNA	0
levels	0
.	0

E3	9
transcripts	10
are	0
present	0
in	0
the	0
myeloid	7
,	8
B-lymphoid	8
,	8
and	8
erythroid	8
lineages	8
,	0
absent	0
in	0
nonhematopoietic	7
cells	8
,	0
and	0
encode	0
a	0
highly	0
hydrophobic	0
,	0
potentially	0
phosphorylated	0
polypeptide	0
of	0
unknown	0
function	0
with	0
significant	0
homology	0
to	0
a	0
putative	0
protein	0
expressed	0
in	0
myeloid	7
cells	8
.	0

The	0
murine	0
E3	1
promoter	2
harbors	0
a	0
single	0
bipartite	1
retinoic	2
acid	2
response	2
element	2
which	0
in	0
transient	0
transfection	0
assays	0
conferred	0
RA	0
sensitivity	0
.	0

These	0
results	0
indicate	0
that	0
E3	9
is	0
a	0
hematopoietic-specific	1
gene	2
that	0
is	0
an	0
immediate	0
target	0
for	0
the	0
activated	0
RAR	9
alpha	10
during	0
myelopoiesis	0
.	0

Multifactor	0
cis-dominant	0
negative	0
regulation	0
of	0
IL-2	1
gene	2
expression	0
in	0
anergized	7
T	8
cells	8
.	0

The	0
molecular	0
mechanism	0
underlying	0
IL-2	9
transcriptional	0
blockade	0
in	0
anergic	5
T	6
cell	6
clones	6
is	0
not	0
fully	0
understood	0
.	0

To	0
examine	0
whether	0
an	0
active	0
negative	0
regulatory	0
process	0
occurs	0
,	0
we	0
created	0
a	0
reporter	1
construct	2
containing	0
as	0
an	0
enhancer	1
four	0
copies	0
of	0
the	0
NF-AT	1
site	2
and	0
one	0
copy	0
of	0
the	0
octamer	1
site	2
(	0
4X	1
NF-AT-Oct	2
)	0
.	0

This	0
construct	0
was	0
only	0
slightly	0
reduced	0
(	0
1.3-fold	0
)	0
in	0
its	0
expression	0
when	0
stimulated	0
under	0
anergic	0
conditions	0
,	0
while	0
a	0
whole	0
mouse	0
IL-2	1
enhancer	2
construct	2
showed	0
a	0
reduction	0
of	0
4.3-fold	0
.	0

Addition	0
of	0
the	0
-176	1
to	2
-96	2
sequence	2
to	0
the	0
4X	1
NF-AT-Oct	2
construct	2
did	0
not	0
impart	0
the	0
ability	0
to	0
be	0
affected	0
by	0
anergy	0
,	0
but	0
addition	0
of	0
the	0
-236	1
to	2
-96	2
sequence	2
did	0
,	0
demonstrating	0
that	0
anergy	0
is	0
an	0
active	0
inhibitory	0
process	0
and	0
that	0
more	0
than	0
the	0
presence	0
of	0
the	0
-150	1
AP-1	2
binding	2
site	2
(	0
-152	1
to	2
-147	2
)	0
is	0
required	0
to	0
mediate	0
the	0
effect	0
.	0

Mutational	0
studies	0
of	0
the	0
-236	1
to	2
-96	2
sequence	2
indicated	0
that	0
the	0
presence	0
of	0
both	0
the	0
-130	1
AP-1-like	2
site	2
(	0
-187	1
to	2
-181	2
)	0
and	0
the	0
-150	1
proximal	2
AP-1	2
site	2
were	0
necessary	0
to	0
observe	0
anergy	0
.	0

Because	0
the	0
-180	1
site	2
is	0
not	0
required	0
for	0
trans-activation	0
,	0
it	0
was	0
possible	0
to	0
confirm	0
by	0
mutation	0
in	0
the	0
normal	0
mouse	1
IL-2	2
enhancer	2
that	0
this	0
site	0
is	0
absolutely	0
essential	0
for	0
anergy	0
induction	0
.	0

The	0
simplest	0
model	0
to	0
explain	0
these	0
results	0
is	0
that	0
anergy	0
is	0
mediated	0
by	0
a	0
complex	0
of	0
multiple	0
transcription	9
factors	10
that	0
exert	0
a	0
cis-acting	0
dominant	0
negative	0
regulatory	0
effect	0
on	0
the	0
trans-activation	0
of	0
the	0
IL-2	1
gene	2
.	0

Severe	0
combined	0
immunodeficiency	0
due	0
to	0
defective	0
binding	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
in	0
T	7
lymphocytes	8
of	0
two	0
male	0
siblings	0
.	0

Peripheral	7
blood	8
lymphocytes	8
(	0
PBL	7
)	0
and	0
alloreactive	5
T	6
cell	6
lines	6
of	0
two	0
male	0
infants	0
born	0
to	0
consanguinous	0
parents	0
and	0
presenting	0
with	0
severe	0
combined	0
immunodeficiency	0
(	0
SCID	0
)	0
showed	0
a	0
pronounced	0
deficiency	0
in	0
T	0
cell	0
activation	0
.	0

Although	0
phenotypically	0
normal	0
,	0
the	0
proliferative	0
response	0
of	0
the	0
childrens	0
'	0
T	7
cells	8
was	0
strongly	0
reduced	0
but	0
could	0
be	0
improved	0
by	0
the	0
addition	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
.	0

Furthermore	0
both	0
childrens	0
'	0
T	7
cells	8
were	0
unable	0
to	0
produce	0
the	0
cytokines	9
IL-2	9
,	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
,	0
IL-4	9
and	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

This	0
multiple	0
cytokine	9
production	0
deficiency	0
could	0
not	0
be	0
restored	0
by	0
IL-2	9
or	0
co-stimulatory	0
signals	0
provided	0
by	0
antigen-presenting	7
cells	8
(	0
APC	7
)	0
.	0

Moreover	0
,	0
mRNA	3
for	0
IL-2	9
and	0
IFN-gamma	9
could	0
not	0
be	0
detected	0
.	0

In	0
contrast	0
,	0
expression	0
of	0
the	0
activation-dependent	9
cell	10
surface	10
markers	10
CD25	9
and	0
CD69	9
was	0
within	0
normal	0
limits	0
.	0

To	0
determine	0
whether	0
the	0
functional	0
defect	0
of	0
the	0
patients	0
'	0
T	7
cells	8
was	0
due	0
to	0
the	0
absence	0
or	0
abnormal	0
binding	0
of	0
transcription	9
factors	10
involved	0
in	0
cytokine	1
gene	2
expression	0
,	0
electrophoretic	0
mobility	0
shift	0
assays	0
were	0
used	0
to	0
examine	0
the	0
DNA	0
binding	0
of	0
AP-1	9
,	0
Oct	9
,	0
CREB	9
,	0
SP1	9
,	0
NF-kappa	9
B	10
and	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
to	0
their	0
respective	0
response	1
elements	2
in	0
the	0
promoter	1
of	0
the	0
IL-2	1
gene	2
.	0

Whereas	0
AP-1	9
,	0
NF-kappa	0
B	0
,	0
Oct	9
,	0
CREB	9
and	0
SP1	9
displayed	0
normal	0
binding	0
activities	0
in	0
nuclear	0
extracts	0
,	0
the	0
binding	0
of	0
NF-AT	9
to	0
its	0
IL-2	9
promoter	0
response	0
element	0
was	0
barely	0
detectable	0
both	0
before	0
and	0
after	0
T	0
cell	0
stimulation	0
.	0

Our	0
results	0
strongly	0
suggest	0
that	0
this	0
NF-AT	9
/DNA	0
binding	0
defect	0
is	0
responsible	0
for	0
the	0
multiple	0
cytokine	9
deficiency	0
and	0
the	0
SCID	0
phenotype	0
observed	0
in	0
the	0
two	0
infant	0
brothers	0
.	0

oriP	1
is	0
essential	0
for	0
EBNA	1
gene	2
promoter	0
activity	0
in	0
Epstein-Barr	5
virus-immortalized	6
lymphoblastoid	6
cell	6
lines	6
.	0

During	0
Epstein-Barr	0
virus	0
latent	0
infection	0
of	0
B	7
lymphocytes	8
in	0
vitro	0
,	0
six	0
viral	9
nuclear	10
antigens	10
(	0
EBNAs	9
)	0
are	0
expressed	0
from	0
one	0
of	0
two	0
promoters	1
,	0
Cp	1
or	0
Wp	1
,	0
whose	0
activities	0
are	0
mutually	0
exclusive	0
.	0

Upon	0
infection	0
,	0
Wp	1
is	0
initially	0
active	0
,	0
followed	0
by	0
a	0
switch	0
to	0
Cp	1
for	0
the	0
duration	0
of	0
latency	0
.	0

In	0
this	0
study	0
,	0
the	0
region	0
upstream	0
of	0
Cp	1
was	0
analyzed	0
for	0
the	0
presence	0
of	0
cis	0
elements	0
involved	0
in	0
regulating	0
the	0
activities	0
of	0
the	0
EBNA	1
gene	2
promoters	2
in	0
established	0
in	5
vitro	6
immortalized	6
lymphoblastoid	6
cell	6
lines	6
(	0
LCLs	5
)	0
.	0

It	0
was	0
determined	0
that	0
oriP	1
,	0
the	0
origin	0
for	0
episomal	0
maintenance	0
during	0
latency	0
,	0
is	0
essential	0
for	0
efficient	0
transcription	0
initiation	0
from	0
either	0
Cp	1
or	0
Wp	1
in	0
LCLs	5
,	0
as	0
well	0
as	0
in	0
some	0
Burkitt	5
's	6
lymphoma	6
cell	6
lines	6
.	0

Deletion	0
of	0
the	0
EBNA2-dependent	1
enhancer	2
located	0
upstream	0
of	0
Cp	1
resulted	0
in	0
a	0
ca.	0
two-	0
to	0
fivefold	0
reduction	0
in	0
Cp	1
activity	0
in	0
the	0
LCLs	5
assayed	0
.	0

More	0
extensive	0
deletion	0
of	0
sequences	0
upstream	0
of	0
Cp	1
,	0
including	0
the	0
EBNA2-dependent	1
enhancer	2
,	0
resulted	0
in	0
nearly	0
complete	0
loss	0
of	0
Cp	1
activity	0
.	0

This	0
loss	0
of	0
activity	0
was	0
shown	0
to	0
correlate	0
with	0
deletion	0
of	0
two	0
CCAAT	1
boxes	2
,	0
a	0
proximal	1
CCAAT	2
box	2
located	0
at	0
bp	1
-61	2
to	2
-65	2
and	0
a	0
distal	0
CCAAT	1
box	2
located	0
at	0
bp	0
-253	1
to	2
-257	2
,	0
upstream	0
of	0
Cp	1
.	0

Site-directed	0
mutagenesis	0
of	0
these	0
cis	1
elements	2
demonstrated	0
that	0
Cp	1
activity	0
is	0
highly	0
dependent	0
on	0
the	0
presence	0
of	0
a	0
properly	0
positioned	0
CCAAT	1
box	2
,	0
with	0
the	0
dependence	0
on	0
the	0
distal	1
CCAAT	2
box	2
apparent	0
only	0
when	0
the	0
proximal	1
CCAAT	2
box	2
was	0
deleted	0
or	0
mutated	0
.	0

Deletion	0
of	0
the	0
glucocorticoid	0
response	0
elements	0
located	0
at	0
ca.	1
bp	2
-850	2
upstream	0
of	0
Cp	1
did	0
not	0
result	0
in	0
a	0
significant	0
loss	0
in	0
activity	0
.	0

In	0
general	0
,	0
deletions	0
which	0
diminished	0
Cp	1
activity	0
resulted	0
in	0
induction	0
of	0
Wp	1
activity	0
,	0
consistent	0
with	0
suppression	0
of	0
Wp	1
activity	0
by	0
transcriptional	0
interference	0
from	0
Cp	1
.	0

The	0
identification	0
of	0
oriP	1
and	0
the	0
EBNA2-dependent	1
enhancer	2
as	0
the	0
major	0
positive	0
cis	1
elements	2
involved	0
in	0
regulating	0
Cp	1
activity	0
in	0
LCL	5
suggests	0
that	0
EBNA	1
gene	2
transcription	0
is	0
largely	0
autoregulated	0
by	0
EBNA	9
1	10
and	0
EBNA	9
2	10
.	0

Protein-tyrosine	0
kinase	0
activation	0
is	0
required	0
for	0
lipopolysaccharide	0
induction	0
of	0
interleukin	9
1beta	10
and	0
NFkappaB	9
activation	0
,	0
but	0
not	0
NFkappaB	9
nuclear	0
translocation	0
.	0

In	0
human	7
monocytes	8
,	0
interleukin	9
1beta	10
protein	0
production	0
and	0
steady	0
state	0
mRNA	0
levels	0
are	0
increased	0
in	0
response	0
to	0
lipopolysaccharide	0
,	0
predominantly	0
as	0
a	0
result	0
of	0
increased	0
transcription	0
of	0
the	0
interleukin	9
1beta	10
gene	0
.	0

Expression	0
of	0
interleukin	9
1beta	10
and	0
other	0
cytokines	9
,	0
such	0
as	0
interleukin	9
6	10
and	0
tumor	9
necrosis	10
factor	10
alpha	10
,	0
has	0
been	0
shown	0
to	0
be	0
dependent	0
on	0
the	0
activation	0
of	0
the	0
transcription	9
factor	10
,	0
NFkappaB	9
.	0

Since	0
recent	0
studies	0
have	0
shown	0
that	0
lipopolysaccharide-induced	0
tyrosine	9
kinase	10
activation	0
is	0
not	0
required	0
for	0
NFkappaB	9
nuclear	0
translocation	0
,	0
we	0
sought	0
to	0
determine	0
whether	0
NFkappaB	9
translocated	0
in	0
the	0
absence	0
of	0
tyrosine	9
kinase	10
activity	0
was	0
active	0
in	0
stimulating	0
transcription	0
.	0

We	0
have	0
found	0
that	0
,	0
in	0
the	0
human	0
pro-monocytic	5
cell	6
line	6
,	0
THP-1	5
,	0
the	0
lipopolysaccharide-induced	0
expression	0
of	0
interleukin	9
1beta	10
is	0
dependent	0
on	0
tyrosine	9
kinase	10
activation	0
.	0

Tyrosine	0
kinases	0
are	0
not	0
required	0
for	0
lipopolysaccharide-mediated	0
nuclear	0
translocation	0
of	0
NFkappaB	9
.	0

However	0
,	0
in	0
the	0
absence	0
of	0
tyrosine	9
kinase	10
activity	0
,	0
the	0
ability	0
of	0
NFkappaB	9
to	0
stimulate	0
transcription	0
is	0
impaired	0
.	0

This	0
inhibition	0
of	0
transcription	0
is	0
specific	0
for	0
NFkappaB	9
;	0
in	0
the	0
absence	0
of	0
tyrosine	9
kinase	10
activity	0
,	0
AP-1	9
-dependent	0
transcription	0
is	0
enhanced	0
.	0

These	0
results	0
suggest	0
that	0
,	0
while	0
lipopolysaccharide-induced	0
expression	0
of	0
inflammatory	9
mediators	10
requires	0
tyrosine	9
kinase	10
activity	0
,	0
tyrosine	9
kinase	10
activity	0
is	0
not	0
obligatory	0
for	0
lipopolysaccharide	0
signal	0
transduction	0
.	0

Chronic	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
infection	0
of	0
myeloid	7
cells	8
disrupts	0
the	0
autoregulatory	0
control	0
of	0
the	0
NF-kappaB/Rel	9
pathway	0
via	0
enhanced	0
IkappaBalpha	9
degradation	0
.	0

Productive	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
causes	0
sustained	0
NF-kappaB	9
DNA-binding	0
activity	0
in	0
chronically	0
infected	0
monocytic	0
cells	0
.	0

A	0
direct	0
temporal	0
correlation	0
exists	0
between	0
HIV	0
infection	0
and	0
the	0
appearance	0
of	0
NF-kappaB	9
DNA-binding	0
activity	0
in	0
myelomonoblastic	5
PLB-985	6
cells	6
.	0

To	0
examine	0
the	0
molecular	0
basis	0
of	0
constitutive	0
NF-kappaB	9
DNA-binding	0
activity	0
in	0
HIV1	7
-infected	8
cells	8
,	0
we	0
analyzed	0
the	0
phosphorylation	0
and	0
turnover	0
of	0
IkappaBalpha	9
protein	0
,	0
the	0
activity	0
of	0
the	0
double-stranded	9
RNA-dependent	10
protein	10
kinase	10
(	0
PKR	9
)	0
and	0
the	0
intracellular	0
levels	0
of	0
NF-kappaB	9
subunits	10
in	0
the	0
PLB-985	5
and	0
U937	5
myeloid	6
cell	6
models	6
.	0

HIV-1	0
infection	0
resulted	0
in	0
constitutive	0
,	0
low-level	0
expression	0
of	0
type	9
1	10
interferon	10
(	0
IFN	9
)	0
at	0
the	0
mRNA	0
level	0
.	0

Constitutive	0
PKR	9
activity	0
was	0
also	0
detected	0
in	0
HIV-1-infected	5
cells	6
as	0
a	0
result	0
of	0
low-level	0
IFN	9
production	0
,	0
since	0
the	0
addition	0
of	0
anti-IFN-alpha/beta	9
antibody	10
to	0
the	0
cells	0
decreased	0
PKR	9
expression	0
.	0

Furthermore	0
,	0
the	0
analysis	0
of	0
IkappaBalpha	9
turnover	0
demonstrated	0
an	0
increased	0
degradation	0
of	0
IkappaBalpha	9
in	0
HIV-1-infected	5
cells	6
that	0
may	0
account	0
for	0
the	0
constitutive	1
DNA	2
binding	0
activity	0
.	0

A	0
dramatic	0
increase	0
in	0
the	0
intracellular	0
levels	0
of	0
NF-kappaB	9
subunits	0
c-Rel	9
and	0
NF-kappaB2	9
p100	10
and	0
a	0
moderate	0
increase	0
in	0
NF-kappaB2	9
p52	10
and	0
RelA	9
(	10
p65	10
)	10
were	0
detected	0
in	0
HIV-1-infected	5
cells	6
,	0
whereas	0
NF-kappaB1	9
p105/p50	10
levels	0
were	0
not	0
altered	0
relative	0
to	0
the	0
levels	0
in	0
uninfected	7
cells	8
.	0

We	0
suggest	0
that	0
HIV-1	0
infection	0
of	0
myeloid	7
cells	8
induces	0
IFN	9
production	0
and	0
PKR	9
activity	0
,	0
which	0
in	0
turn	0
contribute	0
to	0
enhanced	0
IkappaBalpha	9
phosphorylation	0
and	0
subsequent	0
degradation	0
.	0

Nuclear	0
translocation	0
of	0
NF-kappaB	9
subunits	10
may	0
ultimately	0
increase	0
the	0
intracellular	0
pool	0
of	0
NF-kappaB/IkappaBalpha	9
by	0
an	0
autoregulatory	0
mechanism	0
.	0

Enhanced	0
turnover	0
of	0
IkappaBalpha	9
and	0
the	0
accumulation	0
of	0
NF-kappaB/Rel	9
proteins	10
may	0
contribute	0
to	0
the	0
chronically	0
activated	0
state	0
of	0
HIV-1-infected	5
cells	6
.	0

The	0
c-Jun	9
delta-domain	10
inhibits	0
neuroendocrine	1
promoter	2
activity	0
in	0
a	0
DNA	0
sequence-	0
and	0
pituitary-specific	0
manner	0
.	0

The	0
transcription	0
and	0
transformation	0
activity	0
of	0
c-Jun	9
is	0
governed	0
by	0
a	0
27-amino	9
acid	10
regulatory	10
motif	10
,	0
labeled	0
the	0
delta-domain	9
,	0
which	0
is	0
deleted	0
in	0
v-Jun	9
.	0

We	0
have	0
previously	0
shown	0
that	0
c-Jun	9
is	0
a	0
potent	0
inhibitor	0
of	0
the	0
rat	1
prolactin	2
(	2
rPRL	2
)	2
promoter	2
activity	0
induced	0
by	0
either	0
oncogenic	9
Ras	10
or	0
phorbol	0
esters	0
.	0

Here	0
,	0
we	0
have	0
characterized	0
the	0
structural	0
and	0
cell-specific	0
requirements	0
for	0
this	0
c-Jun	9
inhibitory	0
response	0
,	0
and	0
we	0
show	0
that	0
this	0
c-Jun	9
inhibitory	0
response	0
mapped	0
to	0
the	0
rPRL	1
footprint	2
II	2
repressor	2
site	2
,	0
was	0
pituitary-specific	0
and	0
required	0
the	0
c-Jun	9
delta-domain	10
.	0

Moreover	0
,	0
alteration	0
of	0
any	0
one	0
of	0
these	0
features	0
(	0
e.g.	0
,	0
cis-element	1
,	0
trans-factor	1
,	0
or	0
cell-specific	0
background	0
)	0
switched	0
c-Jun	9
to	0
a	0
transcriptional	9
activator	10
of	0
the	0
rPRL	1
promoter	2
.	0

In	0
HeLa	5
nonpituitary	6
cells	6
,	0
c-Jun	9
alone	0
activated	0
the	0
rPRL	1
promoter	2
via	0
the	0
most	0
proximal	0
GHF-1/Pit-1	1
binding	2
site	2
,	0
footprint	1
I	2
,	0
and	0
synergized	0
with	0
GHF-1	9
.	0

Finally	0
,	0
recombinant	0
GHF-1	9
interacted	0
directly	0
with	0
c-Jun	9
but	0
not	0
c-Fos	9
proteins	10
.	0

These	0
data	0
provide	0
important	0
fundamental	0
insights	0
into	0
the	0
molecular	0
mechanisms	0
by	0
which	0
the	0
c-Jun	9
delta-domain	10
functions	0
as	0
a	0
modulatory	0
switch	0
and	0
further	0
imply	0
that	0
the	0
functional	0
role	0
of	0
c-Jun	9
is	0
dictated	0
by	0
cell-specific	0
influences	0
and	0
the	0
delta-domain	9
motif	10
.	0

Retinoic	0
acid	0
activates	0
interferon	9
regulatory	10
factor-1	10
gene	0
expression	0
in	0
myeloid	7
cells	8
.	0

All-trans-retinoic	0
acid	0
(	0
ATRA	0
)	0
is	0
the	0
drug	0
of	0
choice	0
in	0
the	0
treatment	0
of	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
.	0

ATRA	0
induces	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
differentiation	0
of	0
APL	5
cells	6
into	0
mature	7
granulocytes	8
.	0

However	0
,	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
ATRA-dependent	0
growth	0
inhibition	0
and	0
cellular	0
differentiation	0
are	0
not	0
presently	0
understood	0
.	0

The	0
NB4	5
cell	6
line	6
,	0
which	0
is	0
derived	0
from	0
the	0
bone	0
marrow	0
of	0
a	0
patient	0
with	0
APL	0
during	0
relapse	0
,	0
can	0
be	0
used	0
as	0
a	0
model	0
system	0
to	0
study	0
the	0
growth	0
and	0
differentiation	0
of	0
APL	5
cells	6
.	0

Because	0
interferon	9
(	10
IFN	10
)	10
regulatory	10
factors	10
(	0
IRF-1	9
and	0
IRF-2	9
)	0
and	0
other	0
IFN-inducible	9
gene	10
products	10
regulate	0
cell	0
growth	0
,	0
we	0
analyzed	0
the	0
effects	0
of	0
ATRA	0
on	0
the	0
expression	0
of	0
these	0
genes	0
.	0

We	0
show	0
that	0
ATRA	0
directly	0
activates	0
IRF-1	1
gene	2
expression	0
,	0
followed	0
by	0
activation	0
of	0
IRF-2	9
and	0
2'-5	9
'	10
oligoadenylate	10
synthetase	10
(	0
OAS	0
)	0
gene	0
expression	0
with	0
slower	0
kinetics	0
.	0

In	0
addition	0
to	0
NB4	0
cells	0
,	0
ATRA	0
also	0
activated	0
IRF-1	1
gene	2
expression	0
in	0
HL-60	5
,	0
U937	5
,	0
and	0
THP-1	5
cells	6
,	0
which	0
all	0
respond	0
to	0
ATRA	0
by	0
growth	0
inhibition	0
.	0

A	0
more	0
than	0
additive	0
increase	0
in	0
IRF-1	1
gene	2
expression	0
was	0
seen	0
with	0
ATRA	0
and	0
IFN-gamma	9
in	0
NB4	5
cells	6
.	0

ATRA	0
did	0
not	0
activate	0
nuclear	0
factor	0
kappa	0
B	0
or	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
(	0
STAT	0
)	0
activation	0
pathways	0
,	0
suggesting	0
that	0
an	0
alternate	0
mechanism	0
is	0
involved	0
in	0
IRF-1	1
gene	2
activation	0
.	0

The	0
ATRA-induced	0
expression	0
of	0
IRF-1	9
,	0
an	0
activator	0
of	0
transcription	0
and	0
repressor	0
of	0
transformation	0
,	0
may	0
be	0
one	0
of	0
the	0
molecular	0
mechanisms	0
of	0
ATRA-induced	0
growth	0
inhibition	0
,	0
and	0
the	0
basis	0
for	0
the	0
synergistic	0
actions	0
of	0
ATRA	0
and	0
IFNs	9
in	0
myeloid	5
leukemia	6
cells	6
.	0

Recombinant	0
NFAT1	9
(	0
NFATp	0
)	0
is	0
regulated	0
by	0
calcineurin	0
in	0
T	7
cells	8
and	0
mediates	0
transcription	0
of	0
several	0
cytokine	1
genes	2
.	0

Transcription	9
factors	10
of	0
the	0
NFAT	9
family	10
play	0
a	0
key	0
role	0
in	0
the	0
transcription	0
of	0
cytokine	1
genes	2
and	0
other	0
genes	0
during	0
the	0
immune	0
response	0
.	0

We	0
have	0
identified	0
two	0
new	0
isoforms	0
of	0
the	0
transcription	9
factor	10
NFAT1	9
(	0
previously	0
termed	0
NFATp	9
)	0
that	0
are	0
the	0
predominant	0
isoforms	0
expressed	0
in	0
murine	7
and	8
human	8
T	8
cells	8
.	0

When	0
expressed	0
in	0
Jurkat	5
T	6
cells	6
,	0
recombinant	0
NFAT1	9
is	0
regulated	0
,	0
as	0
expected	0
,	0
by	0
the	0
calmodulin-dependent	9
phosphatase	10
calcineurin	9
,	0
and	0
its	0
function	0
is	0
inhibited	0
by	0
the	0
immunosuppressive	0
agent	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
.	0

Transactivation	0
by	0
recombinant	0
NFAT1	9
in	0
Jurkat	5
T	6
cells	6
requires	0
dual	0
stimulation	0
with	0
ionomycin	0
and	0
phorbol	0
12-myristate	0
13-acetate	0
;	0
this	0
activity	0
is	0
potentiated	0
by	0
coexpression	0
of	0
constitutively	0
active	0
calcineurin	9
and	0
is	0
inhibited	0
by	0
CsA	0
.	0

Immunocytochemical	0
analysis	0
indicates	0
that	0
recombinant	0
NFAT1	9
localizes	0
in	0
the	0
cytoplasm	0
of	0
transiently	7
transfected	8
T	8
cells	8
and	0
translocates	0
into	0
the	0
nucleus	0
in	0
a	0
CsA-sensitive	0
manner	0
following	0
ionomycin	0
stimulation	0
.	0

When	0
expressed	0
in	0
COS	5
cells	6
,	0
however	0
,	0
NFAT1	9
is	0
capable	0
of	0
transactivation	0
,	0
but	0
it	0
is	0
not	0
regulated	0
correctly	0
:	0
its	0
subcellular	0
localization	0
and	0
transcriptional	0
function	0
are	0
not	0
affected	0
by	0
stimulation	0
of	0
the	0
COS	5
cells	6
with	0
ionomycin	0
and	0
phorbol	0
12-myristate	0
13-acetate	0
.	0

Recombinant	0
NFAT1	9
can	0
mediate	0
transcription	0
of	0
the	0
interleukin-2	9
,	0
interleukin-4	0
,	0
tumor	9
necrosis	10
factor	10
alpha	10
,	0
and	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
promoters	2
in	0
T	7
cells	8
,	0
suggesting	0
that	0
NFAT1	9
contributes	0
to	0
the	0
CsA-sensitive	0
transcription	0
of	0
these	0
genes	1
during	0
the	0
immune	0
response	0
.	0

Human	9
TAFII	10
105	10
is	0
a	0
cell	9
type-specific	10
TFIID	10
subunit	10
related	0
to	0
hTAFII130	9
.	0

We	0
previously	0
characterized	0
Drosophila	9
and	10
human	10
TAF	10
subunits	10
that	0
make	0
up	0
the	0
core	0
TFIID	9
complex	10
found	0
in	0
all	0
cells	0
.	0

Here	0
,	0
we	0
report	0
that	0
differentiated	7
B	8
cells	8
contain	0
a	0
novel	0
substoichiometric	0
TAF	9
of	0
105	0
kDa	0
not	0
found	0
associated	0
with	0
TFIID	9
isolated	0
from	0
other	0
cell	0
types	0
.	0

The	0
cDNA	1
encoding	0
hTAFII105	9
reveals	0
a	0
highly	0
conserved	0
C-terminal	9
domain	10
shared	0
by	0
hTAFII130	9
and	0
oTAFII110	9
,	0
while	0
the	0
N-terminal	9
coactivator	10
domain	10
has	0
diverged	0
significantly	0
.	0

All	0
cells	0
tested	0
express	0
TAFII105	3
mRNA	4
,	0
but	0
only	0
B	7
cells	8
contain	0
significant	0
levels	0
of	0
protein	0
associated	0
with	0
TFIID	9
.	0

Transient	0
overexpression	0
of	0
hTAFII105	9
selectively	0
squelches	0
the	0
transcription	0
of	0
some	0
genes	0
in	0
B	7
cells	8
.	0

These	0
properties	0
suggest	0
that	0
TAFII105	9
is	0
a	0
cell	0
type-specific	0
subunit	0
of	0
TFIID	9
that	0
may	0
be	0
responsible	0
for	0
mediating	0
transcription	0
by	0
a	0
subset	0
of	0
activators	0
in	0
B	7
cells	8
.	0

Interstitial	0
deletion	0
constitutes	0
the	0
major	0
mechanism	0
for	0
loss	0
of	0
heterozygosity	0
on	0
chromosome	1
20q	2
in	0
polycythemia	0
vera	0
.	0

An	0
acquired	0
deletion	0
of	0
the	0
long	0
arm	0
of	0
chromosome	1
20	2
is	0
a	0
recurrent	0
abnormality	0
in	0
myeloproliferative	0
disorders	0
,	0
particularly	0
polycythemia	0
vera	0
and	0
myelodysplastic	0
syndromes	0
.	0

The	0
association	0
of	0
20q	1
deletions	2
with	0
myeloid	0
``	0
stem	0
cell	0
''	0
disorders	0
suggests	0
that	0
the	0
deletions	0
mark	0
the	0
site	0
of	0
one	0
or	0
more	0
genes	0
,	0
loss	0
or	0
inactivation	0
of	0
which	0
plays	0
a	0
role	0
in	0
the	0
regulation	0
of	0
normal	7
hematopoietic	8
progenitors	8
.	0

We	0
have	0
recently	0
performed	0
a	0
detailed	0
molecular	0
analysis	0
of	0
20q	1
deletions	2
in	0
peripheral	7
blood	8
(	8
PB	8
)	8
granulocytes	8
and	0
defined	0
a	0
commonly	1
deleted	2
region	2
of	0
16	0
to	0
21	0
centimorgan	0
(	0
cM	0
)	0
.	0

To	0
further	0
reduce	0
the	0
size	0
of	0
the	0
common	0
deleted	0
region	0
we	0
have	0
searched	0
for	0
small	0
deletions	0
or	0
mitotic	0
recombination	0
events	0
,	0
neither	0
of	0
which	0
would	0
be	0
detected	0
by	0
conventional	0
cytogenetics	0
.	0

We	0
have	0
studied	0
48	0
patients	0
with	0
polycythemia	0
vera	0
and	0
four	0
patients	0
with	0
idiopathic	0
myelofibrosis	0
.	0

In	0
each	0
case	0
,	0
cytogenetic	0
analysis	0
had	0
either	0
failed	0
or	0
had	0
shown	0
no	0
abnormalities	0
of	0
chromosome	1
20	2
.	0

Seventeen	0
microsatellite	1
markers	2
that	0
span	0
the	0
common	0
deleted	0
region	0
were	0
used	0
to	0
search	0
for	0
loss	0
of	0
heterozygosity	0
in	0
granulocyte	1
DNA	2
.	0

No	0
instance	0
of	0
microsatellite	0
instability	0
was	0
observed	0
in	0
a	0
total	0
of	0
880	0
comparisons	0
of	0
granulocyte	1
and	2
T-cell	2
DNA	2
.	0

Granulocyte	0
DNA	0
from	0
four	0
patients	0
exhibited	0
allele	0
loss	0
on	0
20q	1
.	0

In	0
each	0
case	0
the	0
allele	0
loss	0
was	0
caused	0
by	0
an	0
interstitial	0
deletion	0
because	0
heterozygosity	0
at	0
distal	1
markers	2
was	0
retained	0
and	0
because	0
quantitative	0
Southern	0
blotting	0
demonstrated	0
hemizygosity	0
.	0

Loss	0
of	0
heterozygosity	0
in	0
PB	7
granulocytes	8
would	0
be	0
masked	0
by	0
the	0
presence	0
of	0
significant	0
numbers	0
of	0
normal	7
granulocytes	8
not	0
derived	0
from	0
the	0
malignant	5
clone	6
.	0

Therefore	0
,	0
the	0
human	9
androgen	10
receptor	10
assay	0
(	0
HUMARA	0
)	0
was	0
used	0
to	0
determine	0
granulocyte	0
clonality	0
.	0

In	0
21	0
of	0
27	0
informative	0
female	0
patients	0
the	0
majority	0
of	0
the	0
granulocytes	7
were	0
clonally	0
derived	0
.	0

In	0
5	0
patients	0
the	0
granulocytes	7
appeared	0
polyclonal	0
and	0
in	0
1	0
patient	0
unilateral	0
X	0
inactivation	0
was	0
observed	0
in	0
both	0
granulocytes	7
and	0
T	7
cells	8
.	0

These	0
results	0
show	0
that	0
,	0
in	0
the	0
vast	0
majority	0
of	0
patients	0
presented	0
here	0
,	0
the	0
failure	0
to	0
detect	0
loss	0
of	0
heterozygosity	0
can	0
not	0
be	0
attributed	0
to	0
the	0
presence	0
of	0
normal	5
polyclonal	6
granulocytes	6
.	0

Our	0
results	0
therefore	0
show	0
that	0
allele	0
loss	0
on	0
chromosome	1
20q	2
in	0
polycythemia	0
vera	0
does	0
not	0
commonly	0
involve	0
mitotic	0
recombination	0
or	0
chromosome	1
loss	0
and	0
that	0
microsatellite	0
instability	0
is	0
a	0
rare	0
event	0
in	0
this	0
disorder	0
.	0

Interleukin-6	9
promotes	0
multiple	0
myeloma	0
cell	0
growth	0
via	0
phosphorylation	0
of	0
retinoblastoma	9
protein	10
.	0

Interleukin-6	9
(	0
IL-6	9
)	0
mediates	0
autocrine	0
and	0
paracrine	0
growth	0
of	0
multiple	5
myeloma	6
(	6
MM	6
)	6
cells	6
and	0
inhibits	0
tumor	0
cell	0
apoptosis	0
.	0

Abnormalities	0
of	0
retinoblastoma	9
protein	10
(	0
pRB	9
)	0
and	0
mutations	0
of	0
RB	0
gene	0
have	0
been	0
reported	0
in	0
up	0
to	0
70	0
%	0
of	0
MM	0
patients	0
and	0
80	0
%	0
of	0
MM-derived	5
cell	6
lines	6
.	0

Because	0
dephosphorylated	9
(	10
activated	10
)	10
pRB	10
blocks	0
transition	0
from	0
G1	0
to	0
S	0
phase	0
of	0
the	0
cell	0
cycle	0
whereas	0
phosphorylated	9
(	10
inactivated	10
)	10
pRB	10
releases	0
this	0
growth	0
arrest	0
,	0
we	0
characterized	0
the	0
role	0
of	0
pRB	9
in	0
IL-6	9
-mediated	0
MM	0
cell	0
growth	0
.	0

Both	0
phosphorylated	0
and	0
dephosphorylated	0
pRB	9
were	0
expressed	0
in	0
all	0
serum-starved	0
MM	0
patient	0
cells	0
and	0
MM-derived	5
cell	6
lines	6
,	0
but	0
pRB	9
was	0
predominantly	0
in	0
its	0
phosphorylated	0
form	0
.	0

In	0
MM	5
cells	6
that	0
proliferated	0
in	0
response	0
to	0
IL-6	9
,	0
exogenous	0
IL-6	9
downregulated	0
dephosphorylated	9
pRB	10
and	0
decreased	0
dephosphorylated	0
pRB-E2F	9
complexes	10
.	0

Importantly	0
,	0
culture	0
of	0
MM	5
cells	6
with	0
RB	0
antisense	0
,	0
but	0
not	0
RB	0
sense	0
,	0
oligonucleotide	0
(	0
ODN	0
)	0
triggered	0
IL-6	9
secretion	0
and	0
proliferation	0
in	0
MM	5
cells	6
;	0
however	0
,	0
proliferation	0
was	0
only	0
partially	0
inhibited	0
by	0
neutralizing	0
anti-IL-6	9
monoclonal	10
antibody	10
(	0
MoAb	9
)	0
.	0

In	0
contrast	0
to	0
MM	5
cells	6
,	0
normal	0
splenic	7
B	8
cells	8
express	0
dephosphorylated	9
pRB	10
.	0

Although	0
CD40	9
ligand	10
(	0
CD40L	9
)	0
triggers	0
a	0
shift	0
from	0
dephosphorylated	0
to	0
phosphorylated	0
pRB	9
and	0
proliferation	0
of	0
B	7
cells	8
,	0
the	0
addition	0
of	0
exogenous	0
IL-6	9
to	0
CD40L	9
-treated	0
B	7
cells	8
does	0
not	0
alter	0
either	0
pRB	9
or	0
proliferation	0
,	0
as	0
observed	0
in	0
MM	5
cells	6
.	0

These	0
results	0
suggest	0
that	0
phosphorylated	9
pRB	10
is	0
constitutively	0
expressed	0
in	0
MM	5
cells	6
and	0
that	0
IL-6	9
further	0
shifts	0
pRB	9
from	0
its	0
dephosphorylated	0
to	0
its	0
phosphorylated	0
form	0
,	0
thereby	0
promoting	0
MM	0
cell	0
growth	0
via	0
two	0
mechanisms	0
;	0
by	0
decreasing	0
the	0
amount	0
of	0
E2F	0
bound	0
by	0
dephosphorylated	9
pRB	10
due	0
to	0
reduced	0
dephosphorylated	9
pRB	10
,	0
thereby	0
releasing	0
growth	0
arrest	0
;	0
and	0
by	0
upregulating	0
IL-6	9
secretion	0
by	0
MM	5
cells	6
and	0
related	0
IL-6	9
-mediated	0
autocrine	0
tumor	0
cell	0
growth	0
.	0

Soluble	9
factors	10
secreted	0
by	0
activated	7
T-lymphocytes	8
modulate	0
the	0
transcription	0
of	0
the	0
immunosuppressive	9
cytokine	10
TGF-beta	9
2	10
in	0
glial	7
cells	8
.	0

Coordination	0
of	0
the	0
immune	0
response	0
to	0
injury	0
or	0
disease	0
in	0
the	0
brain	0
is	0
postulated	0
to	0
involve	0
bi-directional	0
discourse	0
between	0
the	0
immune	0
system	0
and	0
the	0
central	0
nervous	0
system	0
.	0

This	0
cross	0
communication	0
involves	0
soluble	0
mediators	0
,	0
including	0
various	0
growth	9
factors	10
,	0
cytokines	9
,	0
and	0
neuropeptides	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
the	0
supernatant	0
from	0
activated	7
T-lymphocytes	8
is	0
able	0
to	0
induce	0
the	0
transcription	0
of	0
a	0
potent	0
cytokine	9
,	0
TGF-beta	9
2	10
in	0
glial	7
cells	8
.	0

The	0
activating	0
stimulus	0
invokes	0
signaling	0
mechanisms	0
distinct	0
from	0
known	0
kinase	0
or	0
protease	0
pathways	0
.	0

Activation	0
of	0
TGF-beta	9
2	10
transcription	0
correlates	0
with	0
the	0
loss	0
of	0
binding	0
activity	0
for	0
an	0
80	9
kDA	10
glial	10
labile	10
repressor	10
protein	10
,	0
GLRP	9
,	0
to	0
a	0
responsive	0
region	0
within	0
the	0
TFG-beta	1
2	2
promoter	2
.	0

Although	0
GLRP	9
shares	0
some	0
characteristics	0
with	0
the	0
inducible	0
transcription	9
factor	10
AP-1	9
,	0
it	0
appears	0
to	0
be	0
distinct	0
from	0
known	0
AP-1	9
family	10
members	10
.	0

These	0
data	0
along	0
with	0
previous	0
observations	0
demonstrating	0
the	0
potent	0
immunosuppressive	0
activity	0
of	0
TGF-beta	9
2	10
,	0
support	0
a	0
model	0
for	0
a	0
feedback	0
mechanism	0
between	0
the	0
activated	0
T-lymphocytes	7
and	0
astrocytes	7
via	0
TGF-beta	9
2	10
to	0
regulate	0
the	0
immune	0
response	0
.	0

Various	0
modes	0
of	0
basic	9
helix-loop-helix	10
protein	10
-mediated	0
regulation	0
of	0
murine	0
leukemia	0
virus	0
transcription	0
in	0
lymphoid	5
cell	6
lines	6
.	0

The	0
transcriptionally	1
regulatory	2
regions	2
of	0
the	0
lymphomagenic	0
Akv	0
and	0
SL3-3	0
murine	0
leukemia	0
retroviruses	0
(	0
MLVs	0
)	0
contain	0
two	0
types	0
of	0
E-box	1
consensus	2
motifs	2
,	0
CAGATG	0
.	0

One	0
type	0
,	0
EA/S	1
,	0
is	0
located	0
in	0
the	0
upstream	1
promoter	2
region	2
,	0
and	0
the	0
other	0
,	0
E	1
(	2
gre	2
)	2
,	0
is	0
located	0
in	0
a	0
tandem	1
repeat	2
with	0
enhancer	0
properties	0
.	0

We	0
have	0
examined	0
the	0
requirements	0
of	0
the	0
individual	0
E-boxes	1
in	0
MLV	0
transcriptional	0
regulation	0
.	0

In	0
lymphoid	5
cell	6
lines	6
only	0
,	0
the	0
E	9
(	10
gre	10
)	10
-binding	10
protein	10
complexes	10
included	0
ALF1	9
or	0
HEB	9
and	0
E2A	9
basic	10
helix-loop-helix	10
proteins	10
.	0

Ectopic	0
ALF1	9
and	0
E2A	9
proteins	10
required	0
intact	0
E	1
(	2
gre	2
)	2
motifs	2
for	0
mediating	0
transcriptional	0
activation	0
.	0

ALF1	9
transactivated	0
transcription	0
of	0
Akv	0
MLV	0
through	0
the	0
two	0
E	1
(	2
gre	2
)	2
motifs	2
equally	0
,	0
whereas	0
E2A	9
protein	10
required	0
the	0
promoter-proximal	0
E	1
(	2
gre	2
)	2
motif	0
.	0

In	0
T-	5
and	6
B-cell	6
lines	6
,	0
the	0
E	1
(	2
gre	2
)	2
motifs	2
were	0
of	0
major	0
importance	0
for	0
Akv	0
MLV	0
transcriptional	0
activity	0
,	0
while	0
the	0
EA/S	1
motif	2
had	0
some	0
effect	0
.	0

In	0
contrast	0
,	0
neither	0
E	1
(	2
gre	2
)	2
nor	0
EA/S	1
motifs	2
contributed	0
pronouncedly	0
to	0
Akv	0
MLV	0
transcription	0
in	0
NIH	5
3T3	6
cells	6
lacking	0
DNA-binding	0
ALF1	9
or	0
HEB	9
and	0
E2A	9
proteins	10
.	0

The	0
Id1	0
protein	0
was	0
found	0
to	0
repress	0
ALF1	9
activity	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Moreover	0
,	0
ectopic	9
Id1	10
repressed	0
E	1
(	2
gre	2
)	2
-directed	0
but	0
not	0
EA/S	1
-directed	0
MLV	0
transcription	0
in	0
lymphoid	5
cell	6
lines	6
.	0

In	0
conclusion	0
,	0
E	1
(	2
gre	2
)	2
motifs	0
and	0
interacting	0
basic	9
helix-loop-helix	10
proteins	10
are	0
important	0
determinants	0
for	0
MLV	0
transcriptional	0
activity	0
in	0
lymphocytic	5
cell	6
lines	6
.	0

Reversal	0
of	0
apoptosis	0
by	0
the	0
leukaemia-associated	0
E2A-HLF	9
chimaeric	10
transcription	10
factor	10
.	0

The	0
E2A-HLF	1
(	2
for	2
hepatic	2
leukaemia	2
factor	2
)	2
fusion	2
gene	2
,	0
formed	0
by	0
action	0
of	0
the	0
t	1
(	2
17	2
;	2
19	2
)	2
(	2
q22	2
;	2
p13	2
)	2
chromosomal	0
translocation	0
,	0
drives	0
the	0
leukaemic	0
transformation	0
of	0
early	0
B-cell	7
precursors	8
,	0
but	0
the	0
mechanism	0
of	0
this	0
activity	0
remains	0
unknown	0
.	0

Here	0
we	0
report	0
that	0
human	7
leukaemia	8
cells	8
carrying	0
the	0
translocation	0
t	1
(	2
17	2
;	2
19	2
)	2
rapidly	0
died	0
by	0
apoptosis	0
when	0
programmed	0
to	0
express	0
a	0
dominant-negative	0
suppressor	0
of	0
the	0
fusion	0
protein	0
E2A-HLF	9
,	0
indicating	0
that	0
the	0
chimaeric	9
oncoprotein	10
probably	0
affects	0
cell	0
survival	0
rather	0
than	0
cell	0
growth	0
.	0

Moreover	0
,	0
when	0
introduced	0
into	0
murine	5
pro-B	6
lymphocytes	6
,	0
the	0
oncogenic	9
E2A-HLF	10
fusion	10
protein	10
reversed	0
both	0
interleukin-3-dependent	0
and	0
p53-mediated	0
apoptosis	0
.	0

The	0
close	0
homology	0
of	0
the	0
basic	9
region/leucine	10
zipper	10
(	0
bZIP	9
)	0
DNA-binding	0
and	0
dimerization	9
domain	10
of	0
HLF	9
to	0
that	0
of	0
the	0
CES-2	9
cell-death	10
specification	10
protein	10
of	0
Caenorhabditis	0
elegans	0
suggests	0
a	0
model	0
of	0
leukaemogenesis	0
in	0
which	0
E2A-HLF	9
blocks	0
an	0
early	0
step	0
within	0
an	0
evolutionarily	0
conserved	0
cell-death	0
pathway	0
.	0

The	0
role	0
of	0
early	1
growth	2
response	2
gene	2
1	2
(	0
egr-1	1
)	0
in	0
regulation	0
of	0
the	0
immune	0
response	0
.	0

The	0
induction	0
of	0
immediate	1
early	2
genes	2
in	0
cells	0
of	0
the	0
immune	0
system	0
is	0
critical	0
to	0
determining	0
the	0
ultimate	0
outcome	0
of	0
exposure	0
to	0
antigen	0
.	0

The	0
importance	0
of	0
many	0
of	0
these	0
genes	0
relates	0
to	0
the	0
role	0
their	0
transcription	9
factor	10
products	10
play	0
in	0
dictating	0
patterns	0
of	0
expression	0
of	0
downstream	0
,	0
function-related	1
genes	2
.	0

Evidence	0
from	0
several	0
systems	0
indicates	0
that	0
the	0
immediate	1
early	2
gene	2
,	0
egr-1	1
may	0
be	0
of	0
particular	0
importance	0
in	0
the	0
immune	0
system	0
.	0

Recently	0
,	0
the	0
egr-1	1
promoter	2
has	0
been	0
shown	0
to	0
be	0
highly	0
responsive	0
to	0
the	0
diverse	0
biochemical	0
signals	0
generated	0
by	0
antigen	0
and	0
cytokines	9
in	0
cells	0
of	0
the	0
immune	0
system	0
.	0

Furthermore	0
,	0
an	0
important	0
role	0
for	0
egr-1	1
in	0
determining	0
the	0
differentiation	0
pathway	0
of	0
myeloid	7
cell	8
precursors	8
has	0
been	0
recently	0
elaborated	0
.	0

Finally	0
,	0
potential	0
targets	0
of	0
regulation	0
by	0
the	0
zinc-finger	9
transcription	10
factor	10
encoded	0
by	0
egr-1	1
include	0
the	0
interleukin-2	1
,	2
CD44	2
,	2
ICAM-1	2
,	2
and	2
tumor	2
necrosis	2
factor	2
genes	2
.	0

The	0
role	0
of	0
egr-1	1
in	0
regulation	0
of	0
the	0
immune	0
response	0
will	0
be	0
discussed	0
in	0
the	0
context	0
of	0
these	0
recent	0
studies	0
.	0

Peptide	0
vaccination	0
can	0
lead	0
to	0
enhanced	0
tumor	0
growth	0
through	0
specific	0
T-cell	0
tolerance	0
induction	0
.	0

Vaccination	0
with	0
synthetic	0
peptides	0
representing	0
cytotoxic	0
T	0
lymphocyte	0
(	0
CTL	0
)	0
epitopes	0
can	0
lead	0
to	0
a	0
protective	0
CTL-mediated	0
immunity	0
against	0
tumors	0
or	0
viruses	0
.	0

We	0
now	0
report	0
that	0
vaccination	0
with	0
a	0
CTL	0
epitope	0
derived	0
from	0
the	0
human	1
adenovirus	2
type	2
5	2
E1A-region	2
(	0
Ad5E1A234-243	1
)	0
,	0
which	0
can	0
serve	0
as	0
a	0
target	0
for	0
tumor-eradicating	7
CTL	8
,	0
enhances	0
rather	0
than	0
inhibits	0
the	0
growth	0
of	0
Ad5E1A-expressing	0
tumors	0
.	0

This	0
adverse	0
effect	0
of	0
peptide	0
vaccination	0
was	0
rapidly	0
evoked	0
,	0
required	0
low	0
doses	0
of	0
peptide	0
(	0
10	0
micrograms	0
)	0
,	0
and	0
was	0
achieved	0
by	0
a	0
mode	0
of	0
peptide	0
delivery	0
that	0
induces	0
protective	0
T-cell-mediated	0
immunity	0
in	0
other	0
models	0
.	0

Ad5E1A	9
-specific	0
CTL	0
activity	0
could	0
no	0
longer	0
be	0
isolated	0
from	0
mice	0
after	0
injection	0
of	0
Ad5E1A-peptide	0
,	0
indicating	0
that	0
tolerization	0
of	0
Ad5E1A	9
-specific	0
CTL	0
activity	0
causes	0
the	0
enhanced	0
tumor	0
outgrowth	0
.	0

In	0
contrast	0
to	0
peptide	0
vaccination	0
,	0
immunization	0
with	0
adenovirus	0
,	0
expressing	0
Ad5E1A	9
,	0
induced	0
Ad5E1A	9
-specific	0
immunity	0
and	0
prevented	0
the	0
outgrowth	0
of	0
Ad5E1A	9
-expressing	0
tumors	0
.	0

These	0
results	0
show	0
that	0
immunization	0
with	0
synthetic	0
peptides	0
can	0
lead	0
to	0
the	0
elimination	0
of	0
anti-tumor	0
CTL	0
responses	0
.	0

These	0
findings	0
are	0
important	0
for	0
the	0
design	0
of	0
safe	0
peptide-based	0
vaccines	0
against	0
tumors	0
,	0
allogeneic	0
organ	0
transplants	0
,	0
and	0
T-cell-mediated	0
autoimmune	0
diseases	0
.	0

[	0
NGFI-B/nur77	9
family	10
involved	0
in	0
T-cell	0
apoptosis	0
]	0

NGFI-B/nur77	9
is	0
a	0
member	0
of	0
the	0
steroid	9
receptor	10
superfamily	10
.	0

NGFI-B/nur77	9
and	0
its	0
related	0
genes	0
constitute	0
a	0
family	0
and	0
the	0
NGFI-B/nur77	9
family	10
consists	0
of	0
three	0
subtypes	0
,	0
named	0
nur77	9
alpha	10
,	0
nur77	9
beta	10
,	0
nur77	9
gamma	10
.	0

We	0
cloned	0
human	0
nur77	1
beta	2
cDNA	2
,	0
called	0
TINUR	1
.	0

Although	0
NGFI-B/nur77	9
is	0
essential	0
for	0
TCR-mediated	0
apoptosis	0
in	0
T-cell	9
hybridomas	10
,	0
the	0
reports	0
on	0
nur77	0
knock-out	0
mice	0
and	0
nur77	0
dominant	0
negative	0
transgenic	0
mice	0
suggest	0
that	0
there	0
is	0
a	0
functional	0
redundancy	0
among	0
NGFI-B/nur77	9
family	10
.	0

NGFI-B/nur77	9
binds	0
to	0
the	0
response	1
element	2
by	0
monomer	0
or	0
heterodimer	0
with	0
retinoid	9
X	10
receptor	10
(	0
RXR	9
)	0
.	0

Assuming	0
that	0
9-cis-retinoic	0
acid	0
(	0
9-cis-RA	0
)	0
inhibits	0
TCR-mediated	0
apoptosis	0
,	0
nur77	9
may	0
cause	0
apoptosis	0
by	0
monomer	0
in	0
the	0
absence	0
of	0
9-cis-RA	0
and	0
may	0
inhibit	0
apoptosis	0
by	0
heterodimer	0
with	0
RXR	9
in	0
the	0
presence	0
of	0
9-cis-RA	0
.	0

Glucocorticoids	0
and	0
interferon-alpha	9
in	0
the	0
acquired	0
immunodeficiency	0
syndrome	0
.	0

Some	0
patients	0
with	0
acquired	0
immunodeficiency	0
syndrome	0
(	0
AIDS	0
)	0
develop	0
glucocorticoid	0
resistance	0
characterized	0
by	0
low	0
receptor	0
affinity	0
(	0
Kd	0
)	0
for	0
glucocorticoids	0
in	0
mononuclear	7
,	0
cells	0
and	0
high	0
values	0
of	0
ACTH	0
and	0
cortisol	0
.	0

As	0
glucocorticoids	0
regulate	0
interferon-alpha	9
(	0
IFN	9
alpha	10
)	0
production	0
,	0
we	0
hypothesized	0
that	0
IFN	9
alpha	10
,	0
a	0
cytokine	9
produced	0
predominantly	0
by	0
monocytes	7
in	0
AIDS	0
,	0
should	0
be	0
increased	0
in	0
cortisol-resistant	0
AIDS	0
,	0
attributing	0
the	0
lack	0
of	0
cortisol	0
inhibition	0
to	0
IFN	9
alpha	10
production	0
.	0

Therefore	0
,	0
we	0
examined	0
glucocorticoid	9
receptor	10
characteristics	0
on	0
monocytes	7
by	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
and	0
measured	0
IFN	9
alpha	10
,	0
cortisol	0
,	0
and	0
ACTH	0
in	0
AIDS	0
patients	0
with	0
(	0
AIDS-GR	0
)	0
or	0
without	0
glucocorticoid	0
resistance	0
(	0
AIDS-C	0
)	0
and	0
controls	0
(	0
C	0
)	0
.	0

Monocytes	0
of	0
AIDS-GR	0
patients	0
had	0
a	0
receptor	0
Kd	0
of	0
10.5	0
+/-	0
4.2	0
nmol/L	0
that	0
was	0
higher	0
than	0
that	0
in	0
the	0
AIDS-C	0
group	0
(	0
2.9	0
+/-	0
0.8	0
nmol/L	0
)	0
and	0
normal	0
subjects	0
(	0
2.0	0
+/-	0
0.8	0
nmol/L	0
;	0
P	0
<	0
0.01	0
)	0
.	0

IFN	9
alpha	10
levels	0
were	0
increased	0
in	0
the	0
AIDS-GR	0
group	0
(	0
17	0
+/-	0
6	0
vs	0
.	0

4	0
+/-	0
1	0
U/mL	0
in	0
the	0
AIDS-C	0
group	0
and	0
2	0
+/-	0
0.5	0
U/mL	0
in	0
the	0
C	0
group	0
;	0
P	0
<	0
0.01	0
)	0
.	0

Correlations	0
were	0
found	0
between	0
plasma	9
IFN	10
alpha	10
and	0
receptor	0
Kd	0
on	0
monocytes	7
of	0
AIDS-GR	0
(	0
r	0
=	0
0.77	0
)	0
and	0
between	0
IFN	9
alpha	10
and	0
plasma	0
cortisol	0
in	0
the	0
same	0
group	0
(	0
r	0
=	0
0.74	0
)	0
.	0

The	0
poly	9
(	10
I	10
)	10
-poly	10
(	10
C	10
)	10
-induced	10
IFN	10
alpha	10
production	0
by	0
monocytes	7
was	0
inhibited	0
by	0
glucocorticoids	0
in	0
the	0
C	0
and	0
AIDS-C	0
groups	0
(	0
approximately	0
80	0
%	0
inhibition	0
in	0
both	0
groups	0
)	0
;	0
the	0
effect	0
was	0
reversed	0
by	0
the	0
receptor	0
antagonist	0
RU-38486	0
.	0

By	0
contrast	0
,	0
glucocorticoids	0
failed	0
to	0
inhibit	0
IFNalpha	9
production	0
from	0
AIDS-GR	7
monocytes	8
(	0
approximately	0
20	0
%	0
inhibition	0
)	0
.	0

In	0
conclusion	0
,	0
elevated	0
IFN	9
alpha	10
levels	0
in	0
AIDS-GR	0
may	0
be	0
due	0
to	0
the	0
lack	0
of	0
inhibitory	0
effect	0
of	0
cortisol	0
on	0
IFN	9
alpha	10
production	0
due	0
to	0
cortisol	0
resistance	0
in	0
monocytes	7

JNK	9
(	0
c-Jun	9
NH2-terminal	10
kinase	10
)	0
is	0
a	0
target	0
for	0
antioxidants	0
in	0
T	7
lymphocytes	8
.	0

AP-1	9
has	0
been	0
shown	0
to	0
behave	0
as	0
a	0
redox-sensitive	9
transcription	10
factor	10
that	0
can	0
be	0
activated	0
by	0
both	0
oxidant	0
and	0
antioxidant	0
stimuli	0
.	0

However	0
,	0
the	0
mechanisms	0
involved	0
in	0
the	0
activation	0
of	0
AP-1	9
by	0
antioxidants	0
are	0
largely	0
unknown	0
.	0

In	0
this	0
study	0
we	0
show	0
that	0
the	0
structurally	0
unrelated	0
antioxidant	0
agents	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
,	0
butylated	0
hydroxyanisole	0
,	0
and	0
Nacetylcysteine	0
activated	0
JNK	9
(	0
c-Jun	9
NH2-terminal	10
kinase	10
)	0
in	0
Jurkat	5
T	6
cells	6
.	0

This	0
activation	0
differed	0
substantially	0
from	0
that	0
mediated	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
Ca2+	0
ionophore	0
or	0
produced	0
by	0
costimulation	0
with	0
antibodies	9
against	0
the	0
T	9
cell	10
receptor-CD3	10
complex	10
and	0
to	0
CD28	9
.	0

The	0
activation	0
of	0
JNK	9
by	0
classical	0
T	0
cell	0
stimuli	0
was	0
transient	0
,	0
whereas	0
that	0
mediated	0
by	0
PDTC	0
and	0
butylated	0
hydroxyanisole	0
(	0
but	0
not	0
N-acetylcysteine	0
)	0
was	0
sustained	0
.	0

The	0
kinetics	0
of	0
JNK	9
activation	0
correlated	0
with	0
the	0
expression	0
of	0
c-jun	1
which	0
was	0
transient	0
after	0
stimulation	0
with	0
PMA	0
plus	0
ionophore	0
and	0
prolonged	0
in	0
response	0
to	0
PDTC	0
,	0
which	0
also	0
transiently	0
induced	0
c-fos	1
.	0

In	0
addition	0
,	0
JNK	9
activation	0
by	0
PMA	0
plus	0
ionophore	0
was	0
sensitive	0
to	0
inhibitors	0
of	0
signaling	0
pathways	0
involving	0
Ca2+	0
,	0
protein	9
kinase	10
C	10
,	0
and	0
tyrosine	0
phosphorylation	0
,	0
which	0
failed	0
to	0
inhibit	0
the	0
activation	0
mediated	0
by	0
PDTC	0
.	0

Transfection	0
of	0
trans-dominant	1
negative	2
expression	2
vectors	2
of	0
ras	1
and	0
raf	1
,	0
together	0
with	0
AP-1-dependent	1
reporter	2
constructs	2
,	0
as	0
well	0
as	0
Western	0
blot	0
analysis	0
using	0
anti-ERK	9
(	10
extracellular	10
signal-regulated	10
kinase	10
)	10
antibodies	10
,	0
indicated	0
that	0
the	0
Ras/Raf/ERK	0
pathway	0
did	0
not	0
appear	0
to	0
mediate	0
the	0
effect	0
of	0
the	0
antioxidant	0
.	0

However	0
,	0
the	0
combined	0
treatment	0
with	0
PDTC	0
and	0
PMA	0
,	0
two	0
agents	0
that	0
synergize	0
on	0
AP-1	9
activation	0
,	0
resulted	0
in	0
the	0
persistent	0
phosphorylation	0
of	0
ERK-2	9
.	0

In	0
conclusion	0
,	0
our	0
results	0
identify	0
JNK	9
as	0
a	0
target	0
of	0
antioxidant	0
agents	0
which	0
can	0
be	0
regulated	0
differentially	0
under	0
oxidant	0
and	0
antioxidant	0
conditions	0
.	0

[	0
Molecular	0
mechanisms	0
of	0
age-related	0
lymphocyte	0
dysfunction	0
]	0

Aging	0
is	0
classically	0
accompanied	0
by	0
a	0
dysregulation	0
of	0
the	0
immunologic	0
machinery	0
.	0

As	0
a	0
consequence	0
,	0
the	0
immune	0
response	0
developed	0
in	0
senescent	0
organisms	0
is	0
usually	0
inappropriate	0
,	0
often	0
inefficient	0
,	0
sometimes	0
aberrant	0
,	0
and	0
potentially	0
detrimental	0
.	0

The	0
age-associated	0
immune	0
dysfunction	0
may	0
be	0
implicated	0
to	0
some	0
degree	0
in	0
the	0
extreme	0
susceptibility	0
of	0
the	0
elderly	0
to	0
infection	0
and	0
neoplasia	0
and	0
may	0
even	0
participate	0
in	0
various	0
aspects	0
of	0
senescence	0
.	0

The	0
current	0
understanding	0
of	0
the	0
molecular	0
mechanisms	0
underlying	0
immunosenescence	0
is	0
still	0
fragmentary	0
.	0

The	0
most	0
extensively	0
studied	0
phenomenon	0
is	0
the	0
progressive	0
decline	0
in	0
the	0
proliferative	0
capacities	0
of	0
T	7
lymphocytes	8
with	0
aging	0
.	0

The	0
loss	0
of	0
proliferative	0
potential	0
in	0
response	0
to	0
antigenic	0
challenge	0
is	0
a	0
characteristic	0
feature	0
of	0
immune	0
senescence	0
.	0

It	0
is	0
directly	0
implicated	0
in	0
the	0
emergence	0
of	0
the	0
age-related	0
immune	0
deficiency	0
.	0

The	0
purpose	0
of	0
this	0
review	0
is	0
to	0
show	0
how	0
the	0
accumulation	0
of	0
various	0
biochemical	0
lesions	0
with	0
advancing	0
age	0
leads	0
to	0
the	0
failure	0
of	0
a	0
critical	0
cell	0
function	0
,	0
namely	0
the	0
activation-induced	0
lymphocyte	0
proliferation	0
.	0

The	0
biochemical	0
modifications	0
responsible	0
for	0
the	0
defect	0
in	0
transduction	0
and	0
execution	0
of	0
the	0
proliferative	0
signal	0
are	0
analyzed	0
as	0
a	0
function	0
of	0
age	0
.	0

The	0
multiple	0
alterations	0
observed	0
on	0
the	0
various	0
biochemical	0
pathways	0
may	0
appear	0
as	0
a	0
consequence	0
of	0
a	0
unique	0
deleterious	0
mechanism	0
more	0
fundamentally	0
related	0
to	0
the	0
process	0
of	0
senescence	0
such	0
as	0
the	0
inability	0
to	0
cope	0
with	0
oxidative	0
stress	0
.	0

Induction	0
of	0
bcl-2	9
expression	0
by	0
phosphorylated	0
CREB	0
proteins	0
during	0
B-cell	0
activation	0
and	0
rescue	0
from	0
apoptosis	0
.	0

Engagement	0
of	0
surface	0
immunoglobulin	0
on	0
mature	0
B	0
cells	0
leads	0
to	0
rescue	0
from	0
apoptosis	0
and	0
to	0
proliferation	0
.	0

Levels	0
of	0
bcl-2	3
mRNA	4
and	0
protein	0
increase	0
with	0
cross-linking	0
of	0
surface	9
immunoglobulin	10
.	0

We	0
have	0
located	0
the	0
major	0
positive	0
regulatory	0
region	0
for	0
control	0
of	0
bcl-2	9
expression	0
in	0
B	7
cells	8
in	0
the	0
5'-flanking	1
region	2
.	0

The	0
positive	0
region	0
can	0
be	0
divided	0
into	0
an	0
upstream	1
and	2
a	2
downstream	2
regulatory	2
region	2
.	0

The	0
downstream	0
regulatory	0
region	0
contains	0
a	0
cyclic	1
AMP-responsive	2
element	2
(	0
CRE	1
)	0
.	0

We	0
show	0
by	0
antibody	0
supershift	0
experiments	0
and	0
UV	0
cross-linking	0
followed	0
by	0
denaturing	0
polyacrylamide	0
gel	0
electrophoresis	0
that	0
both	0
CREB	0
and	0
ATF	0
family	0
members	0
bind	0
to	0
this	0
region	0
in	0
vitro	0
.	0

Mutations	0
of	0
the	0
CRE	1
site	2
that	0
result	0
in	0
loss	0
of	0
CREB	9
binding	0
also	0
lead	0
to	0
loss	0
of	0
functional	0
activity	0
of	0
the	0
bcl-2	0
promoter	0
in	0
transient-transfection	0
assays	0
.	0

The	0
presence	0
of	0
an	0
active	0
CRE	1
site	2
in	0
the	0
bcl-2	1
promoter	2
implies	0
that	0
the	0
regulation	0
of	0
bcl-2	9
expression	0
is	0
linked	0
to	0
a	0
signal	0
transduction	0
pathway	0
in	0
B	7
cells	8
.	0

Treatment	0
of	0
the	0
mature	5
B-cell	6
line	6
BAL-17	6
with	0
either	0
anti-immunoglobulin	0
M	0
or	0
phorbol	0
12-myristate	0
13-acetate	0
leads	0
to	0
an	0
increase	0
in	0
bcl-2	9
expression	0
that	0
is	0
mediated	0
by	0
the	0
CRE	1
site	2
.	0

Treatment	0
of	0
the	0
more	0
immature	5
B-cell	6
line	6
,	0
Ramos	5
,	0
with	0
phorbol	0
esters	0
rescues	0
the	0
cells	0
from	0
calcium-dependent	0
apoptosis	0
.	0

bcl-2	9
expression	0
is	0
increased	0
following	0
phorbol	0
ester	0
treatment	0
,	0
and	0
the	0
increased	0
expression	0
is	0
dependent	0
on	0
the	0
CRE	1
site	2
.	0

These	0
stimuli	0
result	0
in	0
phosphorylation	0
of	0
CREB	9
at	0
serine	0
133	0
.	0

The	0
phosphorylation	0
of	0
CREB	9
that	0
results	0
in	0
activation	0
is	0
mediated	0
by	0
protein	9
kinase	10
C	10
rather	0
than	0
by	0
protein	9
kinase	10
A	10
.	0

Although	0
the	0
CRE	1
site	2
is	0
necessary	0
,	0
optimal	0
induction	0
of	0
bcl-2	9
expression	0
requires	0
participation	0
of	0
the	0
upstream	1
regulatory	2
element	2
,	0
suggesting	0
that	0
phosphorylation	0
of	0
CREB	9
alters	0
its	0
interaction	0
with	0
the	0
upstream	1
regulatory	2
element	2
.	0

The	0
CRE	1
site	2
in	0
the	0
bcl-2	1
promoter	2
appears	0
to	0
play	0
a	0
major	0
role	0
in	0
the	0
induction	0
of	0
bcl-2	9
expression	0
during	0
the	0
activation	0
of	0
mature	7
B	8
cells	8
and	0
during	0
the	0
rescue	0
of	0
immature	7
B	8
cells	8
from	0
apoptosis	0
.	0

It	0
is	0
possible	0
that	0
the	0
CRE	1
site	2
is	0
responsible	0
for	0
induction	0
of	0
bcl-2	9
expression	0
in	0
other	0
cell	0
types	0
,	0
particularly	0
those	0
in	0
which	0
protein	9
kinase	10
C	10
is	0
involved	0
.	0

Characterization	0
of	0
the	0
human	1
myeloid	2
cell	2
nuclear	2
differentiation	2
antigen	2
gene	2
promoter	2
.	0

MNDA	9
(	0
myeloid	9
cell	10
nuclear	10
differentiation	10
antigen	10
)	0
is	0
an	0
interferon	9
alpha	10
regulated	10
nuclear	10
protein	10
expressed	0
only	0
in	0
cells	0
of	0
the	0
human	7
myelomonocytic	8
lineage	8
.	0

To	0
identify	0
mechanisms	0
responsible	0
for	0
this	0
lineage-specific	0
and	0
interferon-regulated	0
expression	0
,	0
the	0
5	1
'	2
flanking	2
sequence	2
of	0
the	0
gene	0
has	0
been	0
characterized	0
.	0

Two	0
interferon-stimulated	1
response	2
elements	2
(	0
ISRE	1
)	0
flank	0
a	0
multiple	0
transcription	0
start	0
site	0
region	0
identifying	0
MNDA	9
as	0
a	0
TATA-less	1
interferon-regulated	2
gene	2
.	0

Other	0
DNA	1
elements	2
present	0
include	0
a	0
cluster	0
of	0
Myb	1
sites	2
,	0
several	0
Ets	1
,	0
an	0
Ets	1
related	2
PU.1	2
site	2
and	0
an	0
Sp1	1
site	2
located	0
within	0
600	0
bp	0
of	0
the	0
transcription	1
start	2
sites	2
.	0

In	0
addition	0
,	0
DNA	0
methylation	0
was	0
revealed	0
as	0
one	0
of	0
the	0
possible	0
factors	0
in	0
establishing	0
MNDA	9
expression	0
.	0

The	0
5	1
'	2
flanking	2
sequence	2
has	0
promoter	0
activity	0
which	0
is	0
elevated	0
by	0
interferon	9
alpha	10
.	0

The	0
findings	0
indicate	0
that	0
MNDA	9
expression	0
is	0
regulated	0
by	0
mechanisms	0
similar	0
to	0
other	0
myelomonocytic	1
cell	2
specific	2
genes	2
and	0
genes	0
up-regulated	0
by	0
interferon	9
alpha	10
.	0

Abnormality	0
of	0
Oct-1	9
DNA	0
binding	0
in	0
T	7
cells	8
from	0
Sjogren	0
's	0
syndrome	0
patients	0
.	0

Primary	0
Sjogren	0
's	0
syndrome	0
(	0
SS	0
)	0
is	0
an	0
autoimmune	0
rheumatic	0
disease	0
characterized	0
by	0
T	0
cell	0
hypoactivity	0
.	0

To	0
understand	0
the	0
diminished	0
T	0
cell	0
response	0
to	0
activation	0
signals	0
,	0
we	0
measured	0
nucleoprotein	0
DNA-binding	0
activities	0
regulating	0
gene	0
expression	0
during	0
T	0
cell	0
activation	0
using	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

Peripheral	7
blood	8
lymphocytes	8
from	0
9/19	0
SS	0
patients	0
were	0
found	0
to	0
be	0
defective	0
in	0
their	0
ability	0
to	0
bind	0
an	0
october	9
sequence	10
(	0
Oct-1	9
)	0
.	0

This	0
Oct-1	9
-binding	0
phenotype	0
remained	0
stable	0
in	0
culture	0
for	0
up	0
to	0
3	0
days	0
prior	0
to	0
activation	0
.	0

This	0
abnormality	0
was	0
not	0
seen	0
in	0
resting	7
T	8
cells	8
nor	0
T	7
cells	8
from	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
,	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
,	0
or	0
SS	0
accompanied	0
by	0
RA	0
.	0

The	0
SS	0
Oct-1	9
DNA-binding	0
abnormality	0
correlated	0
significantly	0
with	0
an	0
inability	0
of	0
cells	0
to	0
exit	0
the	0
Gzero/G1	0
cell	0
cycle	0
phase	0
when	0
stimulated	0
in	0
vitro	0
.	0

Importantly	0
,	0
nucleoprotein	0
extracts	0
showing	0
decreased	0
DNA-binding	0
activity	0
had	0
normal	0
amounts	0
of	0
Oct-1	9
proteins	0
as	0
determined	0
by	0
immunoprecipitation	0
,	0
implying	0
a	0
functional	0
defect	0
in	0
the	0
Oct-1	9
protein	10
.	0

Moreover	0
,	0
defective	0
DNA	0
binding	0
was	0
corrected	0
by	0
treatment	0
with	0
acid	0
phosphatase	0
.	0

Characterization	0
of	0
a	0
new	0
isoform	0
of	0
the	0
NFAT	9
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
)	0
gene	0
family	0
member	0
NFATc	9
[	0
published	0
erratum	0
appears	0
in	0
J	0
Biol	0
Chem	0
1996	0
Dec	0
27	0
;	0
271	0
(	0
52	0
)	0
:	0
33705	0
]	0

The	0
cyclosporin	9
A	10
(	10
CsA	10
)	10
/FK506-sensitive	10
nuclear	10
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
plays	0
a	0
key	0
role	0
in	0
the	0
inducible	0
expression	0
of	0
cytokine	1
genes	2
in	0
T	7
cells	8
.	0

Although	0
NFAT	9
has	0
been	0
recently	0
shown	0
to	0
be	0
inducible	0
in	0
several	0
non-T	7
immune	8
cells	8
,	0
the	0
NFAT	1
gene	2
family	2
members	2
characterized	0
to	0
date	0
have	0
been	0
isolated	0
only	0
from	0
T	7
cells	8
.	0

To	0
further	0
characterize	0
NFAT	9
function	0
in	0
human	7
B	8
cells	8
and	0
to	0
demonstrate	0
cytokine	0
gene	0
specificity	0
of	0
NFAT	9
proteins	10
,	0
we	0
report	0
here	0
the	0
isolation	0
and	0
characterization	0
of	0
a	0
cDNA	1
clone	2
from	0
the	0
Raji	5
B	6
cell	6
line	6
.	0

The	0
cDNA	1
clone	2
encodes	0
a	0
new	0
isoform	0
,	0
NFATc.beta	9
,	0
of	0
the	0
NFAT	9
gene	10
family	10
member	10
NFATc	9
(	0
designated	0
here	0
NFATc.alpha	9
)	0
.	0

The	0
amino	9
acid	10
sequence	10
of	0
NFATc.beta	9
differs	0
from	0
that	0
of	0
NFATc	9
.	0

alpha	0
in	0
the	0
first	0
NH2-terminal	9
29	10
residues	10
and	0
contains	0
an	0
additional	0
region	0
of	0
142	9
residues	10
at	0
the	0
COOH	9
terminus	10
.	0

Northern	0
analysis	0
using	0
a	0
probe	0
encompassing	0
a	0
common	0
region	0
of	0
both	0
isoforms	0
showed	0
two	0
mRNA	3
species	4
of	0
2.7	3
and	4
4.5	4
kilobase	4
pairs	4
,	0
while	0
an	0
NFATc.beta-specific	1
probe	2
detected	0
only	0
the	0
4.5-kilobase	3
pair	4
mRNA	4
which	0
was	0
preferentially	0
expressed	0
in	0
the	0
spleen	0
.	0

Transient	0
expression	0
of	0
NFATc.beta	9
was	0
capable	0
of	0
activating	0
an	0
interleukin-2	1
NFAT-driven	2
reporter	2
gene	2
in	0
stimulated	5
Jurkat	6
cells	6
in	0
a	0
CsA-sensitive	0
manner	0
.	0

However	0
,	0
NFATc.beta	9
neither	0
bound	0
to	0
the	0
kappa3	1
element	2
(	0
an	0
NFAT-binding	1
site	2
)	0
in	0
the	0
tumor	1
necrosis	2
factor-alpha	2
promoter	2
nor	0
activated	0
the	0
tumor	1
necrosis	2
factor-alpha	2
promoter	2
in	0
cotransfection	0
assays	0
.	0

These	0
data	0
suggest	0
that	0
different	0
members	0
or	0
isoforms	0
of	0
NFAT	1
gene	2
family	0
may	0
regulate	0
inducible	0
expression	0
of	0
different	0
cytokine	1
genes	2
.	0

Regulation	0
of	0
interferon-gamma	9
gene	0
expression	0
.	0

Interferon-gamma	0
(	0
IFN-gamma	9
)	0
,	0
also	0
known	0
as	0
type	9
II	10
interferon	10
,	0
is	0
an	0
important	0
immunoregulatory	0
gene	0
that	0
has	0
multiple	0
effects	0
on	0
the	0
development	0
,	0
maturation	0
,	0
and	0
function	0
of	0
the	0
immune	0
system	0
.	0

IFN-gamma	3
mRNA	4
and	0
protein	0
are	0
expressed	0
predominantly	0
by	0
T	7
cells	8
and	0
large	7
granular	8
lymphocytes	8
.	0

The	0
IFN-gamma	3
mRNA	4
is	0
induced/inhibited	0
in	0
these	0
cell	0
types	0
by	0
a	0
wide	0
variety	0
of	0
extracellular	0
signals	0
,	0
thus	0
implicating	0
a	0
number	0
of	0
diverse	0
,	0
yet	0
convergent	0
signal	0
transduction	0
pathways	0
in	0
its	0
transcriptional	0
control	0
.	0

In	0
this	0
review	0
,	0
I	0
describe	0
how	0
DNA	0
methylation	0
and	0
specific	0
DNA	9
binding	10
proteins	10
may	0
regulate	0
transcription	0
of	0
the	0
IFN-gamma	1
gene	2
in	0
response	0
to	0
extracellular	0
signals	0
.	0

Transcriptional	0
analysis	0
of	0
Epstein-Barr	0
virus	0
gene	0
expression	0
in	0
EBV-positive	0
gastric	0
carcinoma	0
:	0
unique	0
viral	0
latency	0
in	0
the	0
tumour	7
cells	8
.	0

Although	0
case-oriented	0
evidence	0
for	0
an	0
association	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
with	0
gastric	0
carcinoma	0
has	0
been	0
accumulating	0
recently	0
,	0
the	0
interaction	0
(	0
s	0
)	0
between	0
EBV	0
and	0
gastric	7
epithelial	8
cells	8
is/are	0
largely	0
unknown	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
seven	0
EBV-positive	0
gastric	0
carcinoma	0
tissues	0
for	0
viral	0
gene	0
expression	0
at	0
the	0
mRNA	0
level	0
,	0
from	0
which	0
studies	0
on	0
the	0
EBV	0
oncogenicity	0
in	0
human	7
epithelial	8
cells	8
will	0
benefit	0
.	0

Reverse	0
transcription-PCR	0
analysis	0
showed	0
that	0
all	0
seven	0
EBV-positive	0
tumour	0
tissues	0
constitutively	0
expressed	0
EBV	3
nuclear	4
antigen	4
(	4
EBNA	4
)	4
1	4
mRNA	4
,	0
but	0
not	0
EBNA2	3
mRNA	4
.	0

The	0
EBNA	9
transcription	0
was	0
initiated	0
from	0
one	0
of	0
three	0
EBNA	1
promoters	2
,	0
Qp	1
:	0
by	0
contrast	0
,	0
both	0
Cp	1
and	0
Wp	1
were	0
silent	0
,	0
thus	0
resulting	0
in	0
the	0
lack	0
of	0
EBNA2	3
mRNA	4
.	0

Latent	3
membrane	4
protein	4
(	4
LMP	4
)	4
2A	4
mRNA	4
was	0
detected	0
in	0
three	0
of	0
seven	0
cases	0
;	0
however	0
,	0
neither	3
LMP1	4
nor	4
LMP2B	4
mRNA	4
was	0
detected	0
in	0
any	0
of	0
the	0
tumours	0
tested	0
.	0

Transcripts	0
from	0
the	0
BamHI-A	1
region	2
of	0
the	0
viral	1
genome	2
were	0
detectable	0
in	0
all	0
cases	0
.	0

BZLF1	3
mRNA	4
and	0
the	0
product	0
,	0
an	0
immediate-early	1
gene	2
for	0
EBV	0
replication	0
,	0
was	0
not	0
expressed	0
in	0
any	0
of	0
them	0
,	0
thereby	0
suggesting	0
that	0
the	0
tumour	7
cells	8
carried	0
EBV	1
genomes	2
in	0
a	0
tightly	0
latent	0
form	0
.	0

These	0
findings	0
further	0
extended	0
our	0
previous	0
data	0
regarding	0
EBV	0
latency	0
in	0
gastric	7
carcinoma	8
cells	8
at	0
the	0
protein	0
level	0
,	0
and	0
have	0
affirmed	0
that	0
the	0
programme	0
of	0
viral	0
gene	0
expression	0
in	0
the	0
tumour	0
more	0
closely	0
resembles	0
'latency	0
I	0
'	0
represented	0
by	0
Burkitt	0
's	0
lymphoma	0
than	0
'latency	0
II	0
'	0
represented	0
by	0
the	0
majority	0
of	0
nasopharyngeal	0
carcinomas	0
.	0

Characterization	0
of	0
Grb2-binding	9
proteins	10
in	0
human	7
platelets	8
activated	0
by	0
Fc	9
gamma	10
RIIA	10
cross-linking	0
.	0

Glutathione-S-transferase	9
(	10
GST	10
)	10
-Grb2	10
fusion	10
proteins	10
have	0
been	0
used	0
to	0
identify	0
the	0
potential	0
role	0
of	0
Grb2-binding	9
proteins	10
in	0
platelet	7
activation	0
by	0
the	0
platelet	9
low-affinity	10
IgG	10
receptor	10
,	0
Fc	9
gamma	10
RIIA	10
.	0

Two	0
tyrosine	9
phosphoproteins	10
of	0
38	0
and	0
63	0
kD	0
bind	0
to	0
the	0
SH2	9
domain	10
of	0
Grb2	9
following	0
Fc	9
gamma	10
RIIA	10
stimulation	0
of	0
platelets	7
.	0

Both	0
are	0
located	0
in	0
the	0
particulate	0
fraction	0
following	0
platelet	7
activation	0
and	0
are	0
also	0
able	0
to	0
bind	0
to	0
a	0
GST-construct	9
containing	0
the	0
SH2	9
and	10
SH3	10
domains	10
of	0
phospholipase	9
C	10
gamma	10
1	10
.	0

p38	0
also	0
forms	0
a	0
complex	0
with	0
the	0
tyrosine	9
kinase	10
csk	10
in	0
stimulated	7
cells	8
and	0
is	0
a	0
substrate	0
for	0
the	0
kinase	9
.	0

The	0
SH3	9
domains	10
of	0
Grb2	9
form	0
a	0
stable	0
complex	0
with	0
SOS1	9
and	0
two	0
proteins	0
of	0
75	9
kD	10
and	0
120	9
kD	10
,	0
which	0
undergo	0
tyrosine	0
phosphorylation	0
in	0
Fc	5
gamma	6
RIIA	6
stimulated	6
cells	6
.	0

The	0
75-kD	9
protein	10
is	0
recognized	0
by	0
antibodies	0
to	0
SLP-76	9
,	0
which	0
has	0
recently	0
been	0
isolated	0
from	0
T	7
cells	8
and	0
sequenced	0
.	0

Tyrosine	0
phosphorylation	0
of	0
p38	9
and	0
p63	9
is	0
also	0
observed	0
in	0
platelets	7
stimulated	0
by	0
the	0
tyrosine	9
kinase	10
-linked	0
receptor	0
agonist	0
collagen	9
and	0
by	0
the	0
G	9
protein	10
-coupled	0
receptor	0
agonist	0
thrombin	9
,	0
although	0
phosphorylation	0
of	0
SLP-76	9
is	0
only	0
observed	0
in	0
collagen	9
-stimulated	0
platelets	7
.	0

p38	9
and	0
p63	9
may	0
provide	0
a	0
docking	0
site	0
for	0
Grb2	9
,	0
thereby	0
linking	0
Grb2	9
SH3-binding	10
proteins	10
SOS1	9
,	0
SLP-76	9
,	0
and	0
p120	9
to	0
downstream	0
signalling	0
events	0
.	0

Constitutive	0
expression	0
of	0
specific	0
interferon	9
isotypes	10
in	0
peripheral	7
blood	8
leukocytes	8
from	0
normal	0
individuals	0
and	0
in	0
promonocytic	5
U937	6
cells	6
.	0

Constitutive	0
expression	0
of	0
IFN-alpha5	9
and	0
IFN-beta	9
was	0
detected	0
in	0
different	0
lymphoid	7
cells	8
including	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
normal	0
individuals	0
following	0
amplification	0
of	0
IFN	3
mRNA	4
by	0
reverse	9
transcriptase	10
-polymerase	0
chain	0
reaction	0
and	0
direct	0
sequencing	0
of	0
the	0
amplified	1
product	2
.	0

The	0
activated	0
form	0
of	0
the	0
interferon-induced	9
transcription	10
factor	10
complex	10
ISGF3	9
was	0
also	0
detected	0
in	0
nuclear	0
extracts	0
from	0
uninduced	5
cells	6
.	0

Culture	0
supernatants	0
from	0
uninduced	5
U937	6
cells	6
were	0
also	0
found	0
to	0
activate	0
an	0
ISRE	1
cloned	0
upstream	0
of	0
the	0
luciferase	1
reporter	2
gene	2
,	0
indicating	0
the	0
presence	0
of	0
endogenous	9
IFN	10
activity	0
equivalent	0
to	0
approximately	0
0.3	0
to	0
0.5	0
IU/mL	0
.	0

This	0
endogenous	9
IFN	10
was	0
also	0
shown	0
to	0
play	0
a	0
role	0
in	0
maintaining	0
the	0
basal	0
level	0
of	0
expression	0
of	0
the	0
major	1
histocompatibility	2
class	2
I	2
genes	2
in	0
lymphoid	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
IFN-alpha5	9
and	0
IFN-beta	9
are	0
produced	0
at	0
low	0
levels	0
in	0
normal	0
tissues	0
and	0
play	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
cell	0
function	0
and	0
in	0
the	0
maintenance	0
of	0
homeostasis	0
.	0

An	0
IL-2	1
response	2
element	2
in	0
the	0
human	1
IL-2	2
receptor	2
alpha	2
chain	2
promoter	2
is	0
a	0
composite	1
element	2
that	0
binds	0
Stat5	9
,	0
Elf-1	9
,	0
HMG-I	9
(	10
Y	10
)	10
and	0
a	0
GATA	9
family	10
protein	10
.	0

Expression	0
of	0
the	0
human	1
interleukin-2	2
(	2
IL-2	2
)	2
receptor	2
alpha	2
chain	2
gene	2
is	0
potently	0
upregulated	0
by	0
its	0
own	0
ligand	0
,	0
IL-2	9
.	0

In	0
this	0
study	0
,	0
we	0
characterize	0
an	0
essential	0
upstream	0
IL-2	1
response	2
element	2
that	0
contains	0
both	0
consensus	1
and	2
non-consensus	2
GAS	2
motifs	2
,	0
two	0
putative	0
Ets	1
binding	2
sites	2
(	0
EBS	1
)	0
,	0
one	0
of	0
which	0
overlaps	0
the	0
consensus	1
GAS	2
motif	2
,	0
and	0
a	0
GATA	1
motif	2
,	0
which	0
overlaps	0
the	0
non-consensus	1
GAS	2
motif	2
.	0

We	0
demonstrate	0
that	0
although	0
the	0
individual	0
components	0
of	0
this	0
element	0
do	0
not	0
respond	0
to	0
IL-2	9
,	0
together	0
they	0
form	0
a	0
composite	0
element	0
capable	0
of	0
conferring	0
IL-2	9
responsiveness	0
to	0
a	0
heterologous	1
promoter	2
.	0

Multiple	0
factors	0
including	0
Stat5	9
,	0
Elf-1	9
,	0
HMG-I	9
(	10
Y	10
)	10
and	0
GATA	9
family	10
proteins	10
bind	0
to	0
the	0
IL-2	1
response	2
element	2
and	0
mutation	0
of	0
any	0
one	0
of	0
these	0
binding	0
sites	0
diminishes	0
the	0
activity	0
of	0
this	0
element	0
.	0

An	0
unidentified	0
Ets	9
family	10
protein	10
binds	0
to	0
the	0
EBS	1
overlapping	0
the	0
consensus	1
GAS	2
motif	2
and	0
appears	0
to	0
negatively	0
regulate	0
the	0
human	1
IL-2R	2
alpha	2
promoter	2
.	0

Thus	0
,	0
IL-2	9
-induced	0
IL-2R	1
alpha	2
promoter	2
activity	0
requires	0
a	0
complex	1
upstream	2
element	2
,	0
which	0
appears	0
to	0
contain	0
binding	1
sites	2
for	0
both	0
positive	9
and	10
negative	10
regulatory	10
factors	10
.	0

Lymphocytes	7
from	0
CML	0
patients	0
lack	0
a	0
47	9
kDa	10
factor	10
having	0
affinity	0
for	0
a	0
genomic	1
sterol	2
regulatory	2
sequence	2
.	0

Deranged	0
cellular	0
cholesterol	0
homeostasis	0
has	0
been	0
widely	0
recognized	0
in	0
the	0
initiation	0
as	0
well	0
as	0
progression	0
of	0
various	0
types	0
of	0
cancers	0
including	0
chronic	0
myeloid	0
leukaemia	0
(	0
CML	0
)	0
.	0

Since	0
the	0
human	1
genomic	2
sterol	2
regulatory	2
element	2
(	0
SRE	1
)	0
has	0
been	0
shown	0
to	0
regulate	0
various	0
key	0
genes	0
involved	0
in	0
this	0
phenomenon	0
,	0
the	0
present	0
study	0
revealed	0
the	0
existence	0
of	0
a	0
unique	0
47	9
kDa	10
protein	10
factor	10
having	0
affinity	0
for	0
this	0
SRE	1
sequence	2
in	0
lymphocytes	7
from	0
normal	0
subjects	0
,	0
as	0
well	0
as	0
its	0
absence	0
in	0
lymphocytes	7
from	0
untreated	0
CML	0
patients	0
.	0

However	0
,	0
this	0
factor	0
appeared	0
when	0
these	0
CML	0
patients	0
achieved	0
complete	0
haematological	0
remission	0
(	0
CHR	0
)	0
through	0
alpha-interferon	9
therapy	0
.	0

Furthermore	0
,	0
an	0
inverse	0
relationship	0
was	0
also	0
observed	0
between	0
the	0
LDL	1
receptor	2
gene	2
expression	0
at	0
the	0
transcriptional	0
level	0
and	0
the	0
binding	0
affinity	0
of	0
this	0
47	9
kDa	10
protein	10
factor	10
to	0
the	0
SRE	1
sequence	2
.	0

Based	0
upon	0
these	0
results	0
we	0
propose	0
that	0
this	0
factor	0
may	0
have	0
a	0
role	0
in	0
pathophysiology	0
of	0
chronic	0
myeloid	0
leukaemia	0
.	0

Cloning	0
and	0
characterization	0
of	0
the	0
beta	9
subunit	10
of	0
human	9
proximal	10
sequence	10
element-binding	10
transcription	10
factor	10
and	0
its	0
involvement	0
in	0
transcription	0
of	0
small	1
nuclear	2
RNA	2
genes	2
by	0
RNA	9
polymerases	10
II	10
and	10
III	10
.	0

The	0
proximal	9
sequence	10
element	10
(	10
PSE	10
)	10
-binding	10
transcription	10
factor	10
(	0
PTF	9
)	0
,	0
which	0
binds	0
the	0
PSE	1
of	0
both	0
RNA	1
polymerase	2
II	2
-and	2
RNA	2
polymerase	2
III-transcribed	2
mammalian	2
small	2
nuclear	2
RNA	2
(	2
snRNA	2
)	2
genes	2
,	0
is	0
essential	0
for	0
their	0
transcription	0
.	0

We	0
previously	0
reported	0
the	0
purification	0
of	0
human	9
PTF	10
,	0
a	0
complex	0
of	0
four	9
subunits	10
,	0
and	0
the	0
molecular	0
cloning	0
and	0
characterization	0
of	0
PTF	9
gamma	10
and	10
delta	10
subunits	10
.	0

Here	0
we	0
describe	0
the	0
isolation	0
and	0
expression	0
of	0
a	0
cDNA	1
encoding	0
PTF	9
beta	10
,	0
as	0
well	0
as	0
functional	0
studies	0
using	0
anti-PTF	9
beta	10
antibodies	10
.	0

Native	0
PTF	9
beta	10
,	0
in	0
either	0
protein	0
fractions	0
or	0
a	0
PTF-Oct-1-DNA	9
complex	10
,	0
can	0
be	0
recognized	0
by	0
polyclonal	9
antibodies	10
raised	0
against	0
recombinant	9
PTF	10
beta	10
.	0

Immunodepletion	0
studies	0
show	0
that	0
PTF	9
beta	10
is	0
required	0
for	0
transcription	0
of	0
both	0
classes	0
of	0
snRNA	1
genes	2
in	0
vitro	0
.	0

In	0
addition	0
,	0
immunoprecipitation	0
analyses	0
demonstrate	0
that	0
substantial	0
and	0
similar	0
molar	0
amounts	0
of	0
TATA-binding	9
protein	10
(	0
TBP	9
)	0
and	0
TFIIIB90	9
can	0
weakly	0
associate	0
with	0
PTF	9
at	0
low	0
salt	0
conditions	0
,	0
but	0
this	0
association	0
is	0
dramatically	0
reduced	0
at	0
high	0
salt	0
concentrations	0
.	0

Along	0
with	0
our	0
previous	0
demonstration	0
of	0
both	0
physical	0
interactions	0
between	0
PTF	9
gamma/PTF	10
delta	10
and	0
TBP	9
and	0
the	0
involvement	0
of	0
TFIIIB90	9
in	0
the	0
transcription	0
of	0
class	1
III	2
snRNA	2
genes	2
,	0
these	0
results	0
are	0
consistent	0
with	0
the	0
notion	0
that	0
a	0
TBP-containing	9
complex	10
related	0
to	0
TFIIIB	9
is	0
required	0
for	0
the	0
transcription	0
of	0
class	1
III	2
snRNA	2
genes	2
,	0
and	0
acts	0
through	0
weak	0
interaction	0
with	0
the	0
four-subunit	9
PTF	10
.	0

Attenuated	0
function	0
of	0
a	0
variant	0
form	0
of	0
the	0
helix-loop-helix	9
protein	10
,	0
Id-3	9
,	0
generated	0
by	0
an	0
alternative	0
splicing	0
mechanism	0
.	0

The	0
Id	0
family	0
of	0
helix-loop-helix	9
proteins	10
function	0
as	0
negative	0
regulators	0
of	0
DNA	0
binding	0
,	0
basic	0
helix-loop-helix	9
proteins	10
in	0
the	0
regulation	0
of	0
cell	0
growth	0
and	0
differentiation	0
.	0

We	0
report	0
here	0
on	0
the	0
identification	0
of	0
a	0
17	9
kDa	10
variant	10
of	0
the	0
14	9
kDa	10
Id-3	10
protein	0
termed	0
Id-3L	9
(	0
long	0
version	0
)	0
which	0
possesses	0
a	0
unique	0
60	9
amino	10
acid	10
carboxy-terminus	10
generated	0
by	0
read	0
through	0
of	0
a	0
'	0
coding	1
intron	2
'	0
and	0
alternative	0
splicing	0
.	0

Northern	0
analysis	0
revealed	0
expression	0
of	0
a	0
minor	0
1.1	3
kb	4
Id-3L	4
transcript	4
together	0
with	0
the	0
predominant	0
0.95	3
kb	4
Id-3	4
transcript	4
in	0
the	0
majority	0
of	0
adult	0
human	0
tissues	0
analysed	0
.	0

The	0
variant	0
Id-3L	9
protein	10
is	0
functionally	0
distinguishable	0
from	0
conventional	0
Id-3	9
since	0
in	0
in	0
vitro	0
DNA	0
mobility	0
shift	0
assays	0
,	0
it	0
was	0
greatly	0
impaired	0
in	0
its	0
ability	0
to	0
abrogate	0
binding	0
of	0
the	0
basic	0
helix-loop-helix	9
protein	10
,	0
E47	9
,	0
to	0
an	0
E	1
box	2
recognition	2
sequence	2
.	0

Tyloxapol	0
inhibits	0
NF-kappa	9
B	10
and	0
cytokine	9
release	0
,	0
scavenges	0
HOCI	9
,	0
and	0
reduces	0
viscosity	0
of	0
cystic	0
fibrosis	0
sputum	0
.	0

Cystic	0
fibrosis	0
(	0
CF	0
)	0
patients	0
develop	0
progressive	0
cytokine	9
-mediated	0
inflammatory	0
lung	0
disease	0
,	0
with	0
abundant	0
production	0
of	0
thick	0
,	0
tenacious	0
,	0
protease	9
-and	0
oxidant-rich	0
purulent	0
airway	0
secretions	0
that	0
are	0
difficult	0
to	0
clear	0
even	0
with	0
physiotherapy	0
.	0

In	0
the	0
search	0
for	0
a	0
potential	0
treatment	0
,	0
we	0
have	0
tested	0
tyloxapol	0
,	0
an	0
alkylaryl	0
polyether	0
alcohol	0
polymer	0
detergent	0
previously	0
used	0
as	0
a	0
mucolytic	0
agent	0
in	0
adult	0
chronic	0
bronchitis	0
.	0

Tyloxapol	0
inhibits	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	10
factor-kappa	10
B	10
(	0
NK-kappa	9
B	10
)	0
,	0
reduces	0
resting	0
secretion	0
of	0
the	0
cytokine	9
interleukin-8	9
(	0
IL-8	9
)	0
in	0
cultured	5
human	6
monocytes	6
,	0
and	0
inhibits	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-stimulated	0
release	0
of	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
,	0
IL-1	9
beta	10
,	0
IL-6	9
,	0
IL-8	9
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
,	0
and	0
the	0
eiconsanoids	0
thromboxane	0
A2	0
and	0
leukotriene	0
B4	0
(	0
LTB4	0
)	0
.	0

We	0
have	0
previously	0
shown	0
that	0
tyloxapol	0
is	0
a	0
potent	0
antioxidant	0
for	0
hydroxyl	0
radicals	0
(	0
OH	0
)	0
.	0

Tyloxapol	0
(	0
0.05	0
to	0
0.1	0
%	0
wt/vol	0
)	0
effectively	0
scavenges	0
the	0
oxidant	0
hypochlorous	0
acid	0
(	0
HOCl	0
;	0
1	0
to	0
7.5	0
mM	0
)	0
in	0
vitro	0
,	0
and	0
protects	0
from	0
HOCl-mediated	0
lung	0
injury	0
in	0
rats	0
.	0

Tyloxapol	0
also	0
reduces	0
the	0
viscosity	0
of	0
CF	0
sputum	0
(	0
from	0
463	0
+/-	0
133	0
to	0
128	0
+/-	0
52	0
centipoise	0
)	0
.	0

We	0
conclude	0
that	0
tyloxapol	0
is	0
potentially	0
useful	0
as	0
a	0
new	0
antiinflammatory	0
therapy	0
for	0
CF	0
lung	0
disease	0
,	0
and	0
could	0
possibly	0
promote	0
clearance	0
of	0
secretions	0
in	0
the	0
CF	0
airway	0
.	0

Elevated	0
cyclic	0
AMP	0
inhibits	0
NF-kappaB	9
-mediated	0
transcription	0
in	0
human	0
monocytic	0
cells	0
and	0
endothelial	0
cells	0
.	0

The	0
NF-kappaB/Rel	9
family	10
of	0
transcription	9
factors	10
regulates	0
the	0
inducible	0
expression	0
of	0
many	0
genes	0
in	0
activated	7
human	8
monocytes	8
and	0
endothelial	7
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
molecular	0
mechanism	0
by	0
which	0
agents	0
that	0
elevate	0
intracellular	0
cAMP	0
inhibit	0
the	0
expression	0
of	0
the	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNFalpha	9
)	0
,	0
tissue	9
factor	10
,	0
endothelial	9
leukocyte	10
adhesion	10
molecule-1	10
,	0
and	0
vascular	1
cell	2
adhesion	2
molecule-1	2
genes	2
.	0

Both	0
forskolin	0
and	0
dibutyryl	0
cAMP	0
,	0
which	0
elevate	0
intracellular	0
cAMP	0
by	0
independent	0
mechanisms	0
,	0
inhibited	0
TNFalpha	9
and	0
tissue	9
factor	10
expression	0
at	0
the	0
level	0
of	0
transcription	0
.	0

Induction	0
of	0
NF-kappaB	9
-dependent	0
gene	0
expression	0
in	0
transiently	0
transfected	0
human	5
monocytic	6
THP-1	6
cells	6
and	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
was	0
inhibited	0
by	0
elevated	0
cAMP	0
and	0
by	0
overexpression	0
of	0
the	0
catalytic	9
subunit	10
of	0
protein	9
kinase	10
A	10
(	0
PKA	9
)	0
.	0

Elevated	0
cAMP	0
did	0
not	0
prevent	0
nuclear	0
translocation	0
of	0
p50/p65	9
and	0
c-Rel/p65	9
heterodimers	10
,	0
decrease	0
nuclear	0
translocation	0
of	0
p65	9
,	0
or	0
significantly	0
modify	0
TNFalpha	9
-induced	0
phosphorylation	0
of	0
p65	9
.	0

Functional	0
studies	0
demonstrated	0
that	0
transcriptional	0
activation	0
of	0
a	0
plasmid	1
containing	0
multimerized	1
kappaB	2
sites	2
by	0
p65	9
was	0
inhibited	0
by	0
agents	0
that	0
elevate	0
cAMP	0
and	0
by	0
overexpression	0
of	0
the	0
catalytic	9
subunit	10
of	0
PKA	9
.	0

This	0
study	0
indicates	0
that	0
activation	0
of	0
PKA	9
reduces	0
the	0
induction	0
of	0
a	0
distinct	0
set	0
of	0
genes	1
in	0
monocytes	7
and	0
endothelial	7
cells	8
by	0
inhibiting	0
NF-kappaB	9
-mediated	0
transcription	0
.	0

Molecular	0
mechanisms	0
of	0
steroid	0
action	0
:	0
a	0
novel	0
type	0
of	0
cross-talk	0
between	0
glucocorticoids	0
and	0
NF-kappa	9
B	10
transcription	9
factors	10
.	0

Despite	0
the	0
widespread	0
use	0
of	0
glucocorticoids	0
in	0
the	0
treatment	0
of	0
diseases	0
characterized	0
by	0
inflammation	0
,	0
the	0
molecular	0
mechanism	0
(	0
s	0
)	0
by	0
which	0
these	0
hormones	0
exert	0
this	0
beneficial	0
effect	0
in	0
patients	0
with	0
asthma	0
remains	0
to	0
be	0
elucidated	0
.	0

Therefore	0
,	0
we	0
have	0
studied	0
the	0
transcriptional	0
regulation	0
of	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
as	0
adhesion	9
molecules	10
are	0
likely	0
to	0
play	0
a	0
causal	0
role	0
in	0
inflammation	0
in	0
promoting	0
cell-cell	0
and	0
cell-matrix	0
interactions	0
.	0

We	0
observed	0
that	0
in	0
a	0
monocytic	5
(	6
U937	6
)	6
and	0
a	0
bronchial	5
epithelial	6
(	6
H292	6
)	6
cell-line	6
dexamethasone	0
strongly	0
suppressed	0
basal	0
and	0
induced	0
ICAM-1	9
expression	0
.	0

Subsequent	0
analysis	0
of	0
the	0
human	1
ICAM-1	2
promoter	2
has	0
revealed	0
that	0
both	0
12-O-tetradecanoylphorbol	0
13-acetate	0
(	0
TPA	0
)	0
and	0
tumour	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
upregulate	0
ICAM-1	9
expression	0
through	0
the	0
presence	0
of	0
a	0
nuclear	1
factor	2
(	2
NF-kappa	2
B	2
)	2
target	2
sequence	2
(	0
TGGAAATTCC	0
)	0
.	0

No	0
glucocorticoid	1
recognition	2
sequences	2
are	0
present	0
in	0
this	0
promoter	1
region	2
and	0
dexamethasone	0
is	0
still	0
able	0
to	0
repress	0
transcription	0
when	0
the	0
multimerized	1
NF-kappa	2
B	2
sequence	2
is	0
transactivated	0
by	0
TNF-alpha	9
upon	0
transfection	0
in	0
293	5
cells	6
.	0

We	0
propose	0
that	0
direct	0
interaction	0
between	0
the	0
glucocorticoid	9
receptor	10
and	0
nuclear	9
factor-kappa	10
B	10
factors	10
is	0
at	0
least	0
a	0
partial	0
explanation	0
for	0
the	0
effects	0
of	0
this	0
hormone	0
in	0
inflammatory	0
diseases	0
.	0

Abnormalities	0
of	0
p16	1
,	2
p15	2
and	2
CDK4	2
genes	2
in	0
recurrent	0
malignant	0
astrocytomas	0
.	0

Abnormalities	0
in	0
the	0
p16	1
,	2
p15	2
and	2
CDK4	2
genes	2
that	0
regulate	0
transition	0
through	0
the	0
G1	0
phase	0
of	0
the	0
cell	0
cycle	0
have	0
been	0
implicated	0
in	0
the	0
malignant	0
progression	0
of	0
astrocytomas	0
.	0

The	0
results	0
of	0
the	0
present	0
study	0
demonstrate	0
that	0
dysfunction	0
of	0
these	0
genes	1
also	0
occurs	0
during	0
recurrence	0
of	0
glial	0
tumors	0
that	0
were	0
highly	0
malignant	0
at	0
first	0
presentation	0
.	0

Analysis	0
of	0
10	0
matched	0
pairs	0
of	0
high	0
grade	0
malignant	0
astrocytomas	0
and	0
their	0
subsequent	0
recurrences	0
identified	0
three	0
distinct	0
groups	0
.	0

The	0
primary	0
and	0
recurrent	0
tumors	0
in	0
Group	0
A	0
did	0
not	0
show	0
structural	0
alterations	0
in	0
the	0
p16	1
,	2
p15	2
or	2
CDK4	2
genes	2
,	0
whereas	0
homozygous	0
codeletion	0
of	0
p16	1
and	0
p15	1
was	0
observed	0
in	0
both	0
primary	0
and	0
recurrent	0
tumors	0
in	0
Group	0
B	0
.	0

The	0
primary	0
tumors	0
in	0
Group	0
C	0
had	0
a	0
normal	0
profile	0
of	0
p16	9
,	0
p15	9
and	0
CDK4	9
at	0
presentation	0
.	0

Upon	0
recurrence	0
,	0
however	0
,	0
the	0
tumors	0
sustained	0
either	0
deletion	0
of	0
p16	9
alone	0
or	0
codeletion	0
of	0
both	0
p16	9
and	0
p15	9
or	0
amplification	0
of	0
CDK4	9
.	0

Analysis	0
of	0
the	0
molecular	0
differences	0
between	0
primary	0
anaplastic	0
astrocytomas/glioblastomas	0
and	0
their	0
subsequent	0
recurrences	0
,	0
which	0
are	0
clinically	0
indistinguishable	0
,	0
may	0
provide	0
better	0
therapeutic	0
options	0
for	0
treatment	0
.	0

BCL-6	9
,	0
a	0
POZ/zinc-finger	9
protein	10
,	0
is	0
a	0
sequence-specific	9
transcriptional	10
repressor	10
.	0

Approximately	0
40	0
%	0
of	0
diffuse	0
large	0
cell	0
lymphoma	0
are	0
associated	0
with	0
chromosomal	0
translocations	0
that	0
deregulate	0
the	0
expression	0
of	0
the	0
BCL6	1
gene	2
by	0
juxtaposing	0
heterologous	1
promoters	2
to	0
the	0
BCL-6	1
coding	2
domain	2
.	0

The	0
BCL6	1
gene	2
encodes	0
a	0
95-kDa	9
protein	10
containing	0
six	0
C-terminal	9
zinc-finger	10
motifs	10
and	0
an	0
N-terminal	9
POZ	10
domain	10
,	0
suggesting	0
that	0
it	0
may	0
function	0
as	0
a	0
transcription	9
factor	10
.	0

By	0
using	0
a	0
DNA	1
sequence	2
selected	0
for	0
its	0
ability	0
to	0
bind	0
recombinant	9
BCL-6	10
in	0
vitro	0
,	0
we	0
show	0
here	0
that	0
BCL-6	9
is	0
present	0
in	0
DNA-binding	9
complexes	10
in	0
nuclear	0
extracts	0
from	0
various	0
B-cell	5
lines	6
.	0

In	0
transient	0
transfectin	0
experiments	0
,	0
BCL6	9
can	0
repress	0
transcription	0
from	0
promoters	1
linked	0
to	0
its	0
DNA	1
target	2
sequence	2
and	0
this	0
activity	0
is	0
dependent	0
upon	0
specific	0
DNA-binding	0
and	0
the	0
presence	0
of	0
an	0
intact	0
N-terminal	9
half	10
of	0
the	0
protein	0
.	0

We	0
demonstrate	0
that	0
this	0
part	0
of	0
the	0
BCL6	9
molecule	10
contains	0
an	0
autonomous	9
transrepressor	10
domain	10
and	0
that	0
two	0
noncontiguous	9
regions	10
,	0
including	0
the	0
POZ	9
motif	10
,	0
mediate	0
maximum	0
transrepressive	0
activity	0
.	0

These	0
results	0
indicate	0
that	0
the	0
BCL-6	9
protein	10
can	0
function	0
as	0
a	0
sequence-specific	9
transcriptional	10
repressor	10
and	0
have	0
implications	0
for	0
the	0
role	0
of	0
BCL6	9
in	0
normal	0
lymphoid	0
development	0
and	0
lymphomagenesis	0
.	0

Signals	0
leading	0
to	0
the	0
activation	0
of	0
NF-kappa	9
B	10
transcription	10
factor	10
are	0
stronger	0
in	0
neonatal	7
than	8
adult	8
T	8
lymphocytes	8
.	0

The	0
molecular	0
background	0
of	0
the	0
defects	0
in	0
the	0
immune	0
reactivity	0
of	0
human	0
neonates	0
has	0
not	0
been	0
fully	0
elucidated	0
.	0

As	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
has	0
a	0
central	0
role	0
in	0
the	0
control	0
of	0
transcription	0
of	0
several	0
genes	1
involved	0
in	0
immune	0
and	0
inflammatory	0
responses	0
,	0
the	0
authors	0
have	0
analysed	0
the	0
activation	0
of	0
NF-kappa	9
B	10
in	0
human	7
umbilical	8
cord	8
T	8
lymphocytes	8
.	0

The	0
activity	0
was	0
tested	0
by	0
quantitating	0
the	0
nuclear	9
proteins	10
binding	0
to	0
an	0
oligonucleotide	0
containing	0
the	0
consensus	1
kappa	2
B	2
binding	2
sequence	2
(	0
electrophoretic	0
mobility	0
shift	0
assay	0
)	0
.	0

The	0
data	0
obtained	0
demonstrate	0
that	0
phorbol	0
dibutyrate/calcium	0
ionophore	0
A23187	0
(	0
PDBu/iono	0
)	0
combination	0
induced	0
a	0
clearly	0
higher	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B	10
in	0
neonatal	7
than	8
adult	8
T	8
cells	8
.	0

This	0
higher	0
NF-kappa	9
B	10
activity	0
was	0
restricted	0
to	0
the	0
CD4+	7
T-cell	8
subset	8
.	0

Analysis	0
of	0
the	0
nuclear	0
extracts	0
with	0
antibodies	9
directed	0
against	0
the	0
major	0
components	0
of	0
NF-kappa	9
B	10
the	0
p50	9
and	10
RelA	10
(	10
p65	10
)	10
proteins	10
,	0
indicated	0
that	0
the	0
composition	0
of	0
NF-kappa	9
B	10
was	0
similar	0
in	0
neonatal	7
and	8
adult	8
cells	8
.	0

These	0
results	0
suggest	0
that	0
neonatal	7
T	8
cells	8
are	0
exposed	0
to	0
oxidative	0
stress-inducing	0
signals	0
during	0
delivery	0
and/or	0
are	0
inherently	0
more	0
sensitive	0
to	0
NF-kappa	9
B	10
activating	0
signals	0
than	0
adult	7
T	8
cells	8
.	0

Dual	0
action	0
of	0
retinoic	0
acid	0
on	0
human	0
embryonic/fetal	0
hematopoiesis	0
:	0
blockade	0
of	0
primitive	0
progenitor	0
proliferation	0
and	0
shift	0
from	0
multipotent/erythroid/monocytic	0
to	0
granulocytic	0
differentiation	0
program	0
.	0

In	0
preliminary	0
studies	0
,	0
we	0
have	0
analyzed	0
the	0
hematopoietic	9
growth	10
factor	10
(	0
HGF	9
)	0
requirement	0
of	0
hematopoietic	7
progenitor	8
cells	8
(	0
HPCs	7
)	0
purified	0
from	0
embryonic-fetal	0
liver	0
(	0
FL	0
)	0
and	0
grown	0
in	0
fetal	0
calf	0
serum-supplemented	0
(	0
FCS+	0
)	0
clonogenic	0
culture	0
.	0

The	0
key	0
role	0
of	0
erythropoietin	9
(	0
Epo	9
)	0
for	0
colony	0
formation	0
by	0
early	7
erythroid	8
progenitors	8
(	0
burst-forming	7
units-erythroid	8
[	0
BFU-E	7
]	0
)	0
has	0
been	0
confirmed	0
.	0

Furthermore	0
,	0
in	0
the	0
absence	0
of	0
exogenous	0
HGFs	9
,	0
FL	7
monocytic	8
progenitors	8
(	0
colony-forming	7
unit	8
monocyte	8
[	0
CFU-M	7
]	0
)	0
generate	0
large	0
colonies	0
exclusively	0
composed	0
of	0
monocytes-macrophages	0
;	0
these	0
colonies	0
are	0
absent	0
in	0
FCS-	0
clonogenic	0
culture	0
.	0

On	0
this	0
basis	0
,	0
we	0
have	0
investigated	0
the	0
role	0
of	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
and	0
its	0
isomer	0
9-cis	0
RA	0
in	0
FL	0
hematopoiesis	0
.	0

Both	0
compounds	0
modulate	0
the	0
growth	0
of	0
purified	5
FL	6
HPCs	6
,	0
which	0
show	0
a	0
dose-dependent	0
shift	0
from	0
mixed/erythroid/monocytic	0
to	0
granulocytic	0
colony	0
formation	0
.	0

Studies	0
on	0
unicellular	5
and	6
paired	6
daughter	6
cell	6
culture	6
unequivocally	0
indicate	0
that	0
the	0
shift	0
is	0
mediated	0
by	0
modulation	0
of	0
the	0
HPC	0
differentiation	0
program	0
to	0
the	0
granulopoietic	0
pathway	0
(	0
rather	0
than	0
RA-induced	0
down-modulation	0
of	0
multipotent	0
/erythroid/monocytic	0
HPC	0
growth	0
coupled	0
with	0
recruitment	0
of	0
granulocytic	7
HPCs	8
)	0
.	0

ATRA	0
and	0
9-cis	0
RA	0
also	0
exert	0
their	0
effect	0
on	0
the	0
proliferation	0
of	0
primitive	7
HPCs	8
(	0
high-proliferative	5
potential	6
colony-forming	6
cells	6
[	0
HPP-CFCs	5
]	0
)	0
and	0
putative	7
hematopoietic	8
stem	8
cells	8
(	0
HSCs	7
;	0
assayed	0
in	0
Dexter-type	0
long-term	0
culture	0
)	0
.	0

High	0
concentrations	0
of	0
either	0
compound	0
(	0
1	0
)	0
drastically	0
reduced	0
the	0
number	0
of	0
primary	0
HPP-CFC	5
colonies	6
and	0
totally	0
abolished	0
their	0
recloning	0
capacity	0
and	0
(	0
2	0
)	0
inhibited	0
HSC	7
proliferation	0
.	0

It	0
is	0
crucial	0
that	0
these	0
results	0
mirror	0
recent	0
observations	0
indicating	0
that	0
murine	0
adult	0
HPCs	7
transduced	0
with	0
dominant	0
negative	0
ATRA	1
receptor	2
(	2
RAR	2
)	2
gene	2
are	0
immortalized	0
and	0
show	0
a	0
selective	0
blockade	0
of	0
granulocytic	0
differentiation	0
.	0

Altogether	0
,	0
these	0
results	0
suggest	0
that	0
ATRA/9-cis	0
RA	0
may	0
play	0
a	0
key	0
role	0
in	0
FL	0
hematopoiesis	0
via	0
a	0
dual	0
effect	0
hypothetically	0
mediated	0
by	0
interaction	0
with	0
the	0
RAR/RXR	9
heterodimer	10
,	0
ie	0
,	0
inhibition	0
of	0
HSC/	5
primitive	6
HPC	6
proliferation	0
and	0
induction	0
of	0
CFU-GEMM/	0
BFU-E/CFU-M	0
shift	0
from	0
the	0
multipotent/erythroid/monocytic	0
to	0
the	0
granulocytic-neutrophilic	0
differentiation	0
program	0
.	0

Dexamethasone	0
suppression	0
test	0
:	0
corticosteroid	9
receptors	10
regulation	0
in	0
mononuclear	7
leukocytes	8
of	0
young	0
and	0
aged	0
subjects	0
.	0

The	0
dexamethasone	0
suppression	0
test	0
(	0
DST	0
)	0
is	0
considered	0
an	0
indicator	0
of	0
the	0
function	0
of	0
the	0
adrenal	0
pituitary	0
axis	0
.	0

The	0
effect	0
of	0
the	0
steroid	0
is	0
mediated	0
by	0
its	0
binding	0
to	0
corticosteroid	9
receptors	10
.	0

We	0
previously	0
suggested	0
that	0
the	0
measurement	0
of	0
corticosteroid	9
receptors	10
in	0
lymphocytes	7
is	0
an	0
index	0
of	0
an	0
analogous	0
pattern	0
in	0
brain	0
.	0

In	0
the	0
present	0
study	0
,	0
corticosteroid	9
Type	10
I	10
and	10
Type	10
II	10
receptors	10
in	0
mononuclear	7
leukocytes	8
were	0
measured	0
in	0
10	0
elderly	0
subjects	0
and	0
in	0
9	0
young	0
adults	0
,	0
before	0
and	0
after	0
overnight	0
DST	0
(	0
1	0
mg	0
)	0
.	0

Receptors	0
were	0
measured	0
by	0
radioreceptor	0
assay	0
.	0

In	0
all	0
the	0
subjects	0
,	0
dexamethasone	0
was	0
able	0
to	0
suppress	0
plasma	0
cortisol	0
.	0

The	0
number	0
of	0
Type	9
I	10
and	10
Type	10
II	10
receptors	10
before	0
the	0
test	0
was	0
lower	0
in	0
elderly	0
subjects	0
than	0
in	0
adults	0
.	0

In	0
the	0
control	0
group	0
,	0
dexamethasone	0
produced	0
a	0
significant	0
depression	0
of	0
Type	9
I	10
receptors	10
(	0
from	0
267	0
+/-	0
72	0
to	0
169	0
+/-	0
71	0
receptors	0
per	0
cell	0
)	0
,	0
which	0
can	0
be	0
interpreted	0
as	0
a	0
primary	0
involvement	0
of	0
Type	9
I	10
receptors	10
in	0
the	0
response	0
to	0
dexamethasone	0
;	0
Type	9
II	10
receptors	10
decreased	0
in	0
half	0
the	0
subjects	0
(	0
from	0
2849	0
+/-	0
703	0
to	0
2345	0
+/-	0
569	0
receptors	0
per	0
cell	0
)	0
.	0

In	0
elderly	0
healthy	0
subjects	0
,	0
Type	9
II	10
receptors	10
were	0
also	0
significantly	0
decreased	0
(	0
from	0
1796	0
+/-	0
671	0
to	0
720	0
+/-	0
345	0
)	0
.	0

We	0
suggest	0
that	0
in	0
young	0
subjects	0
Type	9
II	10
receptors	10
are	0
initially	0
up-regulated	0
by	0
dexamethasone	0
,	0
and	0
then	0
down-regulated	0
,	0
while	0
in	0
aged	0
subjects	0
an	0
up-regulation	0
can	0
not	0
be	0
achieved	0
,	0
as	0
suggested	0
by	0
the	0
higher	0
values	0
of	0
plasma	0
cortisol	0
usually	0
found	0
in	0
aging	0
subjects	0
.	0

Analysis	0
of	0
the	0
ligand-binding	9
domain	10
of	0
human	9
retinoic	10
acid	10
receptor	10
alpha	10
by	0
site-directed	0
mutagenesis	0
.	0

Three	0
subtypes	0
of	0
retinoic	9
acid	10
receptors	10
(	0
RAR	9
)	0
,	0
termed	0
RAR	9
alpha	10
,	0
RAR	9
beta	10
,	0
and	0
RAR	9
gamma	10
,	0
have	0
been	0
described	0
.	0

They	0
are	0
composed	0
of	0
different	0
structural	9
domains	10
,	0
including	0
distinct	0
domains	0
for	0
DNA	0
and	0
ligand	0
binding	0
.	0

RARs	9
specifically	0
bind	0
all-trans-retinoic	0
acid	0
(	0
RA	0
)	0
,	0
9-cis-RA	0
,	0
and	0
retinoid	0
analogs	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
functional	0
role	0
of	0
cysteine	0
and	0
arginine	0
residues	0
in	0
the	0
ligand-binding	9
domain	10
of	0
hRAR	9
alpha	10
(	0
hRAR	9
alpha-LBD	10
,	0
amino	9
acids	10
154	10
to	10
462	10
)	0
.	0

All	0
conserved	0
cysteine	0
and	0
arginine	0
residues	0
in	0
this	0
domain	0
were	0
mutated	0
by	0
site-directed	0
mutagenesis	0
,	0
and	0
the	0
mutant	9
proteins	10
were	0
characterized	0
by	0
blocking	0
reactions	0
,	0
ligand-binding	0
experiments	0
,	0
transactivation	0
assays	0
,	0
and	0
protease	9
mapping	0
.	0

Changes	0
of	0
any	0
cysteine	0
residue	0
of	0
the	0
hRAR	9
alpha-LBD	10
had	0
no	0
significant	0
influence	0
on	0
the	0
binding	0
of	0
all-trans	0
RA	0
or	0
9-cis	0
RA	0
.	0

Interestingly	0
,	0
residue	0
C-235	0
is	0
specifically	0
important	0
in	0
antagonist	0
binding	0
.	0

With	0
respect	0
to	0
arginine	0
residues	0
,	0
only	0
the	0
two	0
single	0
mutations	0
of	0
R-276	0
and	0
R-394	0
to	0
alanine	0
showed	0
a	0
dramatic	0
decrease	0
of	0
agonist	0
and	0
antagonist	0
binding	0
whereas	0
the	0
R272A	0
mutation	0
showed	0
only	0
a	0
slight	0
effect	0
.	0

For	0
all	0
other	0
arginine	0
mutations	0
,	0
no	0
differences	0
in	0
affinity	0
were	0
detectable	0
.	0

The	0
two	0
mutations	0
R217A	0
and	0
R294A	0
caused	0
an	0
increased	0
binding	0
efficiency	0
for	0
antagonists	0
but	0
no	0
change	0
in	0
agonist	0
binding	0
.	0

From	0
these	0
results	0
,	0
we	0
can	0
conclude	0
that	0
electrostatic	0
interactions	0
of	0
retinoids	0
with	0
the	0
RAR	9
alpha-LBD	10
play	0
a	0
significant	0
role	0
in	0
ligand	0
binding	0
.	0

In	0
addition	0
,	0
antagonists	0
show	0
distinctly	0
different	0
requirements	0
for	0
efficient	0
binding	0
,	0
which	0
may	0
contribute	0
to	0
their	0
interference	0
in	0
the	0
ligand-inducible	0
transactivation	0
function	0
of	0
RAR	9
alpha	10
.	0

IL4	9
and	10
IL13	10
receptors	10
share	0
the	0
gamma	9
c	10
chain	10
and	0
activate	0
STAT6	9
,	10
STAT3	10
and	10
STAT5	10
proteins	10
in	0
normal	7
human	8
B	8
cells	8
.	0

IL13	9
induces	0
the	0
same	0
biological	0
effects	0
as	0
IL4	9
in	0
normal	7
human	8
B	8
cells	8
.	0

We	0
show	0
that	0
as	0
in	0
the	0
IL4R	9
complex	10
,	0
both	0
IL4R	9
alpha	10
and	0
IL2R	9
gamma	10
c	10
are	0
components	0
of	0
the	0
IL13R	9
and	0
that	0
both	0
cytokines	9
induced	0
STAT6	9
,	0
STAT3	9
and	0
STAT5	9
activation	0
in	0
B	7
cells	8
.	0

In	0
spite	0
of	0
this	0
similar	0
downstream	0
signalling	0
,	0
IL4	9
and	0
IL13	9
used	0
a	0
different	0
set	0
of	0
Janus	9
kinases	10
:	0
IL13	9
is	0
unable	0
to	0
activate	0
JAK1	9
and	0
JAK3	9
.	0

Calcineurin	9
mutants	10
render	0
T	7
lymphocytes	8
resistant	0
to	0
cyclosporin	0
A	0
.	0

The	0
immunosuppressants	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
have	0
been	0
widely	0
used	0
to	0
prevent	0
and	0
treat	0
graft	0
rejection	0
after	0
human	0
organ	0
and	0
tissue	0
transplantations	0
.	0

CsA	0
and	0
FK506	0
associate	0
with	0
intracellular	9
binding	10
proteins	10
(	0
i.e.	0
,	0
CsA	0
with	0
cyclophilin	9
A	10
and	0
FK506	0
with	0
FKBP12	9
)	0
to	0
form	0
protein/drug	0
complexes	0
that	0
suppress	0
the	0
immune	0
system	0
by	0
preventing	0
activation	0
of	0
T	7
cells	8
in	0
response	0
to	0
antigen	0
presentation	0
.	0

The	0
common	0
target	0
of	0
CsA	0
and	0
FK506	0
is	0
calcineurin	9
,	0
a	0
Ca2+/calmodulin-regulated	9
,	10
serine/threonine-specific	10
protein	10
phosphatase	10
that	0
regulates	0
the	0
nuclear	0
import	0
of	0
a	0
transcription	9
factor	10
,	0
NF-AT	9
,	0
required	0
for	0
expression	0
of	0
T	1
cell	2
activation	2
genes	2
.	0

In	0
previous	0
studies	0
,	0
we	0
identified	0
calcineurin	9
mutations	0
that	0
block	0
binding	0
by	0
the	0
cyclophilin	9
A/CsA	10
or	10
FKBP12/FK506	10
complexes	10
and	0
thereby	0
render	0
yeast	0
cells	0
resistant	0
to	0
the	0
antifungal	0
effects	0
of	0
CsA	0
or	0
FK506	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
the	0
corresponding	0
mutations	0
in	0
murine	0
calcineurin	9
render	0
the	0
T	9
cell	10
receptor	10
signal	0
transduction	0
cascade	0
CsA	0
resistant	0
in	0
human	5
Jurkat	6
T	6
cells	6
.	0

Our	0
findings	0
support	0
the	0
recently	0
determined	0
calcineurin	9
X-ray	0
crystal	0
structure	0
,	0
provide	0
evidence	0
that	0
calcineurin	9
is	0
the	0
only	0
CsA-sensitive	9
component	10
limiting	0
signaling	0
from	0
the	0
T	9
cell	10
receptor	10
to	0
the	0
nucleus	0
,	0
and	0
suggest	0
a	0
means	0
to	0
render	0
cells	0
and	0
tissues	0
resistant	0
to	0
the	0
toxic	0
side	0
effects	0
of	0
CsA	0
and	0
FK506	0
.	0

Epstein-Barr	0
viral	0
latency	0
is	0
disrupted	0
by	0
the	0
immediate-early	9
BRLF1	10
protein	10
through	0
a	0
cell-specific	0
mechanism	0
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
,	0
the	0
causative	0
agent	0
of	0
infectious	0
mononucleosis	0
,	0
is	0
a	0
human	0
herpesvirus	0
associated	0
with	0
epithelial	0
cell	0
malignancies	0
(	0
nasopharyngeal	0
carcinoma	0
)	0
as	0
well	0
as	0
B-cell	0
malignancies	0
.	0

Understanding	0
how	0
viral	0
latency	0
is	0
disrupted	0
is	0
a	0
central	0
issue	0
in	0
herpesvirus	0
biology	0
.	0

Epithelial	0
cells	0
are	0
the	0
major	0
site	0
of	0
lytic	0
EBV	0
replication	0
within	0
the	0
human	0
host	0
,	0
and	0
viral	0
reactivation	0
occurs	0
in	0
EBV-associated	0
nasopharyngeal	0
carcinomas	0
.	0

It	0
is	0
known	0
that	0
expression	0
of	0
a	0
single	0
viral	9
immediate-early	10
protein	10
,	0
BZLF1	9
,	0
is	0
sufficient	0
to	0
initiate	0
the	0
switch	0
from	0
latent	0
to	0
lytic	0
infection	0
in	0
B	7
cells	8
.	0

Cellular	0
regulation	0
of	0
BZLF1	9
transcription	0
is	0
therefore	0
thought	0
to	0
play	0
a	0
key	0
role	0
in	0
regulating	0
the	0
stringency	0
of	0
viral	0
latency	0
.	0

Here	0
we	0
show	0
that	0
,	0
unexpectedly	0
,	0
expression	0
of	0
another	0
viral	9
immediate-early	10
protein	10
,	0
BRLF1	9
,	0
can	0
disrupt	0
viral	0
latency	0
in	0
an	0
epithelial	0
cell-specific	0
fashion	0
.	0

Therefore	0
,	0
the	0
mechanisms	0
leading	0
to	0
disruption	0
of	0
EBV	0
latency	0
appear	0
to	0
be	0
cell-type	0
specific	0
.	0

Eosinophil	7
priming	0
by	0
cytokines	9
:	0
from	0
cellular	0
signal	0
to	0
in	0
vivo	0
modulation	0
.	0

Eosinophils	7
play	0
an	0
important	0
role	0
in	0
the	0
effector	0
phase	0
of	0
allergic	0
inflammation	0
.	0

This	0
review	0
will	0
focus	0
on	0
the	0
conversion	0
of	0
the	0
unprimed	0
eosinophil	0
phenotype	0
in	0
the	0
peripheral	0
blood	0
of	0
normal	0
individuals	0
to	0
the	0
primed	0
phenotype	0
found	0
in	0
the	0
peripheral	0
blood	0
and	0
tissues	0
of	0
allergic	0
patients	0
,	0
a	0
phenomenon	0
called	0
priming	0
.	0

Recent	0
data	0
on	0
the	0
signals	0
initiated	0
after	0
cytokine	9
receptor	10
activation	0
on	0
eosinophils	7
will	0
be	0
reviewed	0
.	0

CTL	0
recognition	0
of	0
an	0
altered	0
peptide	0
associated	0
with	0
asparagine	0
bond	0
rearrangement	0
.	0

Implications	0
for	0
immunity	0
and	0
vaccine	0
design	0
.	0

The	0
extent	0
to	0
which	0
peptides	0
containing	0
chemically	0
and	0
post-translationally	0
modified	0
amino	9
acid	10
side	10
chains	10
are	0
recognized	0
by	0
primed	5
CTL	6
has	0
not	0
been	0
clearly	0
defined	0
.	0

We	0
report	0
on	0
the	0
CTL	0
recognition	0
of	0
a	0
MHC	0
class	0
I-restricted	0
peptide	0
containing	0
a	0
cyclized	0
asparagine	0
(	0
succinimide	0
)	0
residue	0
.	0

This	0
modification	0
of	0
the	0
asparagine	0
side	0
chain	0
is	0
a	0
common	0
intermediate	0
structure	0
during	0
deamidation	0
,	0
isomerization	0
,	0
and	0
bond	0
rearrangements	0
of	0
amide-containing	0
amino	0
acids	0
and	0
also	0
occurs	0
as	0
a	0
side	0
reaction	0
in	0
peptide	0
synthesis	0
.	0

The	0
CTL	7
specifically	0
recognized	0
the	0
succinimide-containing	0
peptide	0
showing	0
only	0
weak	0
cross-reactivity	0
at	0
high	0
concentrations	0
of	0
the	0
parent	0
peptide	0
containing	0
unmodified	0
asparagine	0
.	0

Similarly	0
,	0
CTL	7
raised	0
against	0
the	0
parent	0
peptide	0
did	0
not	0
recognize	0
the	0
succinimide	0
derivative	0
of	0
this	0
peptide	0
.	0

Naturally	0
processed	0
forms	0
of	0
these	0
structures	0
are	0
likely	0
to	0
occur	0
given	0
the	0
importance	0
and	0
frequency	0
of	0
deamidation	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Moreover	0
,	0
since	0
succinimide	0
intermediates	0
of	0
deamidated	0
peptides	0
can	0
occasionally	0
be	0
very	0
stable	0
,	0
these	0
peptides	0
have	0
the	0
potential	0
to	0
act	0
as	0
altered	0
self-Ags	0
with	0
significant	0
implications	0
for	0
autoimmunity	0
.	0

In	0
addition	0
,	0
unwanted	0
and	0
potentially	0
hazardous	0
specificities	0
may	0
be	0
elicited	0
when	0
using	0
synthetic	0
peptides	0
in	0
subunit	0
vaccines	0
in	0
which	0
succinimide	0
residues	0
may	0
form	0
spontaneously	0
during	0
storage	0
or	0
chemical	0
synthesis	0
.	0

A	0
3	0
'	0
--	0
>	0
5	0
'	0
XPB	9
helicase	10
defect	0
in	0
repair/transcription	9
factor	10
TFIIH	9
of	0
xeroderma	0
pigmentosum	0
group	0
B	0
affects	0
both	0
DNA	0
repair	0
and	0
transcription	0
.	0

XPB	9
is	0
a	0
subunit	0
of	0
the	0
basal	0
transcription	9
factor	10
TFIIH	9
,	0
which	0
is	0
also	0
involved	0
in	0
nucleotide	0
excision	0
repair	0
(	0
NER	0
)	0
and	0
potentially	0
in	0
cell	0
cycle	0
regulation	0
.	0

A	0
frameshift	0
mutation	0
in	0
the	0
3'-end	0
of	0
the	0
XPB	1
gene	2
is	0
responsible	0
for	0
a	0
concurrence	0
of	0
two	0
disorders	0
:	0
xeroderma	0
pigmentosum	0
(	0
XP	0
)	0
and	0
Cockayne	0
's	0
syndrome	0
(	0
CS	0
)	0
.	0

We	0
have	0
isolated	0
TFIIH	9
from	0
cells	0
derived	0
from	0
a	0
patient	0
(	0
XP11BE	0
)	0
who	0
carries	0
this	0
frameshift	0
mutation	0
(	0
TFIIHmut	9
)	0
and	0
from	0
the	0
mother	0
of	0
this	0
patient	0
(	0
TFIIHwt	9
)	0
to	0
determine	0
the	0
biochemical	0
consequences	0
of	0
the	0
mutation	0
.	0

Although	0
identical	0
in	0
composition	0
and	0
stoichiometry	0
to	0
TFIIHwt	9
,	0
TFIIHmut	9
shows	0
a	0
reduced	0
3	0
'	0
--	0
>	0
5	0
'	0
XPB	9
helicase	0
activity	0
.	0

A	0
decrease	0
in	0
helicase	0
and	0
DNA-dependent	9
ATPase	10
activities	0
was	0
also	0
observed	0
with	0
the	0
mutated	0
recombinant	0
XPB	9
protein	10
.	0

The	0
XPB	9
mutation	0
causes	0
a	0
severe	0
NER	0
defect	0
.	0

In	0
addition	0
,	0
we	0
provide	0
evidence	0
for	0
a	0
decrease	0
in	0
basal	0
transcription	0
activity	0
in	0
vitro	0
.	0

The	0
latter	0
defect	0
may	0
provide	0
an	0
explanation	0
for	0
many	0
of	0
the	0
XP	0
and	0
CS	0
symptoms	0
that	0
are	0
difficult	0
to	0
rationalize	0
based	0
solely	0
on	0
an	0
NER	0
defect	0
.	0

Thus	0
,	0
this	0
work	0
presents	0
the	0
first	0
detailed	0
analysis	0
of	0
a	0
naturally	0
occurring	0
mutation	0
in	0
a	0
basal	9
transcription	10
factor	10
and	0
supports	0
the	0
concept	0
that	0
the	0
combined	0
XP/CS	0
clinical	0
entity	0
is	0
actually	0
the	0
result	0
of	0
a	0
combined	0
transcription/repair	0
deficiency	0
.	0

The	0
Ets	0
protein	0
Spi-B	9
is	0
expressed	0
exclusively	0
in	0
B	7
cells	8
and	0
T	7
cells	8
during	0
development	0
.	0

Spi-B	9
and	0
PU.1	9
are	0
hematopoietic-specific	9
transcription	10
factors	10
that	0
constitute	0
a	0
subfamily	0
of	0
the	0
Ets	9
family	10
of	0
DNA-binding	9
proteins	10
.	0

Here	0
we	0
show	0
that	0
contrary	0
to	0
previous	0
reports	0
,	0
PU.1	9
and	0
Spi-B	9
have	0
very	0
different	0
expression	0
patterns	0
.	0

PU.1	9
is	0
expressed	0
at	0
high	0
levels	0
in	0
B	7
cells	8
,	0
mast	7
cells	8
,	0
megakaryocytes	7
,	0
macrophages	7
,	0
neutrophils	7
,	0
and	0
immature	7
erythroid	8
cells	8
and	0
at	0
lower	0
levels	0
in	0
mature	7
erythrocytes	8
.	0

PU.1	9
is	0
completely	0
absent	0
from	0
peripheral	7
T	8
cells	8
and	0
most	0
T	5
cell	6
lines	6
based	0
on	0
sensitive	0
RT-PCR	0
assays	0
.	0

In	0
contrast	0
,	0
Spi-B	9
is	0
expressed	0
exclusively	0
in	0
lymphoid	7
cells	8
and	0
can	0
be	0
detected	0
in	0
early	0
fetal	0
thymus	0
and	0
spleen	0
.	0

In	0
situ	0
hybridizations	0
of	0
adult	0
murine	0
tissues	0
demonstrate	0
Spi-B	3
mRNA	4
in	0
the	0
medulla	0
of	0
the	0
thymus	0
,	0
the	0
white	0
pulp	0
of	0
the	0
spleen	0
,	0
and	0
the	0
germinal	0
centers	0
of	0
lymph	0
nodes	0
.	0

Spi-B	9
expression	0
is	0
very	0
abundant	0
in	0
B	7
cells	8
and	0
both	0
Spi-B	3
mRNA	4
and	0
protein	0
are	0
detected	0
in	0
some	0
T	7
cells	8
.	0

In	0
situ	0
hybridization	0
and	0
Northern	0
blot	0
analysis	0
suggest	0
that	0
Spi-B	9
gene	0
expression	0
increases	0
during	0
B	0
cell	0
maturation	0
and	0
decreases	0
during	0
T	0
cell	0
maturation	0
.	0

Gel-retardation	0
experiments	0
show	0
that	0
Spi-B	9
can	0
bind	0
to	0
all	0
putative	1
PU.1	2
binding	2
sites	2
,	0
but	0
do	0
not	0
reveal	0
any	0
preferred	0
Spi-B	1
binding	2
site	2
.	0

Finally	0
,	0
both	0
PU.1	9
and	0
Spi-B	9
function	0
as	0
transcriptional	0
activators	0
of	0
the	0
immunoglobulin	1
light-chain	2
enhancer	2
E	2
lambda	2
2.4	2
when	0
coexpressed	0
with	0
Pip	9
(	0
PU.1-interaction	9
partner	10
)	0
in	0
NIH-3T3	5
cells	6
.	0

Taken	0
together	0
,	0
these	0
data	0
suggest	0
that	0
differences	0
in	0
patterns	0
of	0
expression	0
between	0
Spi-B	9
and	0
PU.1	9
distinguish	0
the	0
function	0
of	0
each	0
protein	0
during	0
development	0
of	0
the	0
immune	0
system	0
.	0

A	0
critical	0
role	0
of	0
Sp1-	9
and	10
Ets-related	10
transcription	10
factors	10
in	0
maintaining	0
CTL-specific	0
expression	0
of	0
the	0
mouse	1
perforin	2
gene	2
.	0

This	0
study	0
was	0
designed	0
to	0
determine	0
the	0
potential	0
cis-elements	1
involved	0
in	0
transcriptional	0
regulation	0
of	0
the	0
mouse	1
perforin	2
gene	2
.	0

DNase	1
I	2
hypersensitive	2
site	2
(	0
DHS	1
)	0
mapping	0
revealed	0
that	0
the	0
perforin	1
locus	2
contained	0
six	0
DHS	1
within	0
7.0	0
kb	0
of	0
the	0
5	1
'	2
upstream	2
sequence	2
(	0
-7.0	0
kb	0
)	0
and	0
two	0
DHS	1
in	0
intron	1
2	2
.	0

The	0
six	0
5	1
'	2
upstream	2
and	0
one	0
intronic	1
DHS	2
were	0
detected	0
in	0
only	0
perforin-expressing	7
lymphocytes	8
.	0

Chloramphenicol	9
acetyltransferase	10
(	0
CAT	9
)	0
activities	0
directed	0
by	0
5	1
'	2
upstream	2
promoter	2
were	0
detected	0
preferentially	0
in	0
perforin-expressing	5
cell	6
lines	6
.	0

A	0
construct	0
termed	0
PFP5a	1
containing	0
-795	1
bp	2
exhibited	0
the	0
highest	0
CAT	9
activity	0
,	0
and	0
PFP9a20	1
containing	0
only	0
-73	1
bp	2
also	0
produced	0
significantly	0
high	0
CAT	9
activity	0
in	0
CTLL-R8	5
cells	6
.	0

The	0
proximal	1
region	2
in	0
PFP9a20	1
contained	0
two	0
potential	0
Sp1	1
binding	2
sites	2
(	0
GC	1
box	2
and	0
GT	1
box	2
)	0
and	0
one	0
Ets	1
binding	2
site	2
(	0
EBS	1
)	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
showed	0
that	0
each	0
of	0
the	0
cis-elements	1
bound	0
specific	0
protein	9
factors	10
.	0

When	0
single-point	0
mutation	0
was	0
introduced	0
to	0
each	0
GC	1
box	2
,	0
EBS	1
,	0
and	0
GT	1
box	2
in	0
PFP9a20	1
,	0
at	0
least	0
3-fold	0
less	0
CAT	9
activity	0
was	0
observed	0
in	0
CTLL-R8	5
cells	6
.	0

To	0
confirm	0
the	0
importance	0
of	0
the	0
three	0
cis-acting	1
elements	2
in	0
the	0
perforin	1
gene	2
expression	0
,	0
point	0
mutation	0
was	0
introduced	0
again	0
to	0
each	0
proximal	1
GC	2
box	2
,	0
EBS	1
,	0
and	0
GT	1
box	2
of	0
PFP5a	1
.	0

The	0
point	0
mutations	0
resulted	0
in	0
a	0
2.5-	0
to	0
3-fold	0
reduction	0
of	0
CAT	9
activity	0
.	0

The	0
results	0
suggest	0
that	0
a	0
combination	0
of	0
the	0
three	0
proximal	0
cis-acting	1
elements	2
may	0
constitute	0
a	0
minimal	0
region	0
responsible	0
for	0
CTL-specific	0
expression	0
of	0
perforin	9
.	0

The	0
Oct-2	9
transcription	10
factor	10
.	0

The	0
Oct-2	9
transcription	10
factor	10
is	0
a	0
member	0
of	0
the	0
POU	9
(	10
Pit-Oct-Unc	10
)	10
family	10
of	0
transcription	9
factors	10
and	0
is	0
expressed	0
only	0
in	0
B	7
lymphocytes	8
and	0
in	0
neuronal	7
cells	8
but	0
not	0
in	0
other	0
cell	0
types	0
.	0

The	0
primary	3
RNA	4
transcript	4
of	0
the	0
gene	0
is	0
subject	0
to	0
alternative	0
splicing	0
to	0
yield	0
different	0
variants	0
which	0
can	0
either	0
activate	0
or	0
repress	0
gene	0
expression	0
.	0

The	0
forms	0
produced	0
in	0
B	7
lymphocytes	8
have	0
a	0
predominantly	0
activating	0
effect	0
on	0
gene	0
expression	0
whereas	0
those	0
produced	0
in	0
neuronal	7
cells	8
have	0
a	0
predominantly	0
inhibitory	0
effect	0
and	0
can	0
repress	0
the	0
expression	0
of	0
both	0
the	0
herpes	1
simplex	2
virus	2
immediate-early	2
genes	2
and	0
the	0
cellular	1
tyrosine	2
hydroxylase	2
gene	2
.	0

Thus	0
Oct-2	9
plays	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
cellular	0
gene	0
expression	0
in	0
both	0
B	7
cells	8
and	0
neuronal	7
cells	8
as	0
well	0
as	0
in	0
the	0
control	0
of	0
viral	0
latency	0
.	0

Cell-type-specific	0
regulation	0
of	0
the	0
human	1
tumor	2
necrosis	2
factor	2
alpha	2
gene	2
in	0
B	7
cells	8
and	0
T	7
cells	8
by	0
NFATp	9
and	0
ATF-2/JUN	9
.	0

The	0
human	1
tumor	2
necrosis	2
factor	2
alpha	2
(	2
TNF-alpha	2
)	2
gene	2
is	0
one	0
of	0
the	0
earliest	0
genes	0
transcribed	0
after	0
the	0
stimulation	0
of	0
a	0
B	7
cell	8
through	0
its	0
antigen	9
receptor	10
or	0
via	0
the	0
CD-40	0
pathway	0
.	0

In	0
both	0
cases	0
,	0
induction	0
of	0
TNF-alpha	1
gene	2
transcription	0
can	0
be	0
blocked	0
by	0
the	0
immunosuppressants	0
cyclosporin	0
A	0
and	0
FK506	0
,	0
which	0
suggested	0
a	0
role	0
for	0
the	0
NFAT	9
family	10
of	0
proteins	0
in	0
the	0
regulation	0
of	0
the	0
gene	0
in	0
B	7
cells	8
.	0

Furthermore	0
,	0
in	0
T	7
cells	8
,	0
two	0
molecules	0
of	0
NFATp	9
bind	0
to	0
the	0
TNF-alpha	1
promoter	2
element	2
kappa	2
3	2
in	0
association	0
with	0
ATF-2	9
and	0
Jun	9
proteins	10
bound	0
to	0
an	0
immediately	0
adjacent	0
cyclic	1
AMP	2
response	2
element	2
(	2
CRE	2
)	2
site	2
.	0

Here	0
,	0
using	0
the	0
murine	5
B-cell	6
lymphoma	6
cell	6
line	6
A20	5
,	0
we	0
show	0
that	0
the	0
TNF-alpha	1
gene	2
is	0
regulated	0
in	0
a	0
cell-type-specific	0
manner	0
.	0

In	0
A20	5
B	6
cells	6
,	0
the	0
TNF-alpha	1
gene	2
is	0
not	0
regulated	0
by	0
NFATp	9
bound	0
to	0
the	0
kappa	1
3	2
element	2
.	0

Instead	0
,	0
ATF-2	9
and	0
Jun	9
proteins	10
bind	0
to	0
the	0
composite	1
kappa	2
3/CRE	2
site	2
and	0
NFATp	9
binds	0
to	0
a	0
newly	0
identified	0
second	0
NFAT	1
site	2
centered	0
at	0
-76	1
nucleotides	2
relative	0
to	0
the	0
TNF-alpha	1
transcription	2
start	2
site	2
.	0

This	0
new	0
site	0
plays	0
a	0
critical	0
role	0
in	0
the	0
calcium-mediated	0
,	0
cyclosporin	0
A-sensitive	0
induction	0
of	0
TNF-alpha	9
in	0
both	0
A20	5
B	6
cells	6
and	0
Ar-5	5
cells	6
.	0

Consistent	0
with	0
these	0
results	0
,	0
quantitative	0
DNase	9
footprinting	0
of	0
the	0
TNF-alpha	1
promoter	2
using	0
increasing	0
amounts	0
of	0
recombinant	0
NFATp	9
demonstrated	0
that	0
the	0
-76	1
site	2
binds	0
to	0
NFATp	9
with	0
a	0
higher	0
affinity	0
than	0
the	0
kappa	1
3	2
site	2
.	0

Two	0
other	0
previously	0
unrecognized	0
NFATp-binding	1
sites	2
in	0
the	0
proximal	0
TNF-alpha	1
promoter	2
were	0
also	0
identified	0
by	0
this	0
analysis	0
.	0

Thus	0
,	0
through	0
the	0
differential	0
use	0
of	0
the	0
same	0
promoter	1
element	2
,	0
the	0
composite	1
kappa	2
3/CRE	2
site	2
,	0
the	0
TNF-alpha	1
gene	2
is	0
regulated	0
in	0
a	0
cell-type-specific	0
manner	0
in	0
response	0
to	0
the	0
same	0
extracellular	0
signal	0
.	0

Activation	0
of	0
Stat	9
5b	10
in	0
erythroid	7
progenitors	8
correlates	0
with	0
the	0
ability	0
of	0
ErbB	9
to	0
induce	0
sustained	0
cell	0
proliferation	0
.	0

Self	0
renewal	0
of	0
normal	0
erythroid	7
progenitors	8
is	0
induced	0
by	0
the	0
receptor	9
tyrosine	10
kinase	10
c-ErbB	9
,	0
whereas	0
other	0
receptors	9
(	0
c-Kit/Epo-R	9
)	0
regulate	0
erythroid	0
differentiation	0
.	0

To	0
address	0
possible	0
mechanisms	0
that	0
could	0
explain	0
this	0
selective	0
activity	0
of	0
c-ErbB	9
,	0
we	0
analyzed	0
the	0
ability	0
of	0
these	0
receptors	0
to	0
activate	0
the	0
different	0
members	0
of	0
the	0
Stat	9
transcription	10
factor	10
family	10
.	0

Ligand	0
activation	0
of	0
c-ErbB	9
induced	0
the	0
tyrosine	0
phosphorylation	0
,	0
DNA-binding	0
,	0
and	0
reporter	1
gene	2
transcription	0
of	0
Stat	9
5b	10
in	0
erythroblasts	7
.	0

In	0
contrast	0
,	0
ligand	0
activation	0
of	0
c-Kit	9
was	0
unable	0
to	0
induce	0
any	0
of	0
these	0
effects	0
in	0
the	0
same	0
cells	0
.	0

Activation	0
of	0
the	0
erythropoietin	9
receptor	10
caused	0
specific	0
DNA-binding	0
of	0
Stat	9
5b	10
,	0
but	0
failed	0
to	0
induce	0
reporter	1
gene	2
transcription	0
.	0

These	0
biochemical	0
findings	0
correlate	0
perfectly	0
with	0
the	0
selective	0
ability	0
of	0
c-ErbB	9
to	0
cause	0
sustained	0
self	0
renewal	0
in	0
erythroid	7
progenitors	8
.	0

Defective	0
transcription	0
of	0
the	0
IL-2	1
gene	2
is	0
associated	0
with	0
impaired	0
expression	0
of	0
c-Fos	9
,	0
FosB	9
,	0
and	0
JunB	9
in	0
anergic	5
T	6
helper	6
1	6
cells	6
.	0

Anergic	5
CD4+	6
Th	6
cells	6
do	0
not	0
produce	0
IL-2	9
when	0
challenged	0
with	0
Ag-pulsed	5
accessory	6
cells	6
because	0
of	0
a	0
transcriptional	0
defect	0
.	0

In	0
this	0
work	0
,	0
we	0
report	0
that	0
these	0
anergic	5
T	6
cells	6
are	0
defective	0
in	0
their	0
ability	0
to	0
up-regulate	0
protein	0
binding	0
and	0
transactivation	0
at	0
two	0
critical	0
IL-2	1
DNA	2
enhancer	2
elements	2
:	0
NF-AT	9
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
;	0
a	0
sequence	0
that	0
binds	0
a	0
heterotrimeric	9
NFATp	10
,	10
Fos	10
,	10
and	10
Jun	10
protein	10
complex	10
)	0
and	0
Activator	9
Protein-1	10
(	0
AP-1	9
)	0
(	0
that	0
binds	0
Fos	9
and	10
Jun	10
heterodimers	10
)	0
.	0

Western	0
blot	0
analysis	0
of	0
nuclear	0
extracts	0
showed	0
that	0
the	0
impaired	0
DNA-protein	0
interactions	0
in	0
anergic	5
T	6
cells	6
were	0
associated	0
with	0
poor	0
expression	0
of	0
the	0
inducible	0
AP-1	9
family	0
members	0
c-Fos	9
,	0
FosB	9
,	0
and	0
JunB	9
.	0

However	0
,	0
the	0
reduced	0
expression	0
of	0
these	0
proteins	0
was	0
not	0
the	0
result	0
of	0
a	0
global	0
TCR/CD3	9
-signaling	0
defect	0
because	0
CD3	9
cross-linking	0
induced	0
an	0
equivalent	0
increase	0
in	0
intracellular-free	0
calcium	0
ions	0
,	0
as	0
well	0
as	0
NFATp	9
dephosphorylation	0
,	0
translocation	0
to	0
the	0
nucleus	0
,	0
and	0
DNA	0
binding	0
in	0
both	0
normal	7
and	0
anergic	5
T	6
cells	6
.	0

Thus	0
,	0
defective	0
IL-2	1
gene	2
transcription	0
appears	0
to	0
be	0
due	0
,	0
at	0
least	0
in	0
part	0
,	0
to	0
a	0
selective	0
block	0
in	0
the	0
expression	0
of	0
the	0
AP-1	9
Fos	10
and	10
Jun	10
family	10
members	10
in	0
anergic	5
T	6
cells	6
.	0

Sequence-specific	0
DNA	0
binding	0
of	0
the	0
B-cell-specific	9
coactivator	10
OCA-B	9
.	0

B-cell-specific	0
transcription	0
of	0
immunoglobulin	1
genes	2
is	0
mediated	0
by	0
the	0
interaction	0
of	0
a	0
POU	1
domain	2
containing	0
transcription	9
factor	10
Oct-1	9
or	0
Oct-2	9
,	0
with	0
the	0
B-cell-specific	9
coactivator	10
OCA-B	9
(	0
Bob-1	9
,	0
OBF-1	9
)	0
and	0
a	0
prototype	1
octamer	2
element	2
.	0

We	0
find	0
that	0
OCA-B	9
binds	0
DNA	0
directly	0
in	0
the	0
major	0
groove	0
between	0
the	0
two	0
subdomains	0
of	0
the	0
POU	1
domain	2
,	0
requiring	0
both	0
an	0
A	0
at	0
the	0
fifth	1
position	2
of	0
the	0
octamer	1
element	2
and	0
contact	0
with	0
the	0
POU	1
domain	2
.	0

An	0
amino-terminal	9
fragment	10
of	0
OCA-B	9
binds	0
the	0
octamer	1
site	2
in	0
the	0
absence	0
of	0
a	0
POU	1
domain	2
with	0
the	0
same	0
sequence	0
specificity	0
.	0

Coactivator	0
OCA-B	9
may	0
undergo	0
a	0
POU-dependent	0
conformational	0
change	0
that	0
exposes	0
its	0
amino	0
terminus	0
,	0
allowing	0
it	0
to	0
recognize	0
specific	0
DNA	1
sequences	2
in	0
the	0
major	0
groove	0
within	0
the	0
binding	0
site	0
for	0
Oct-1	9
or	0
Oct-2	9
.	0

The	0
recognition	0
of	0
both	0
the	0
POU	1
domain	2
and	0
the	0
octamer	1
sequence	2
by	0
OCA-B	9
provides	0
a	0
mechanism	0
for	0
differential	0
regulation	0
of	0
octamer	1
sites	2
containing	0
genes	0
by	0
the	0
ubiquitous	9
factor	10
Oct-1	9
.	0

Uneven	0
X	1
inactivation	0
in	0
a	0
female	0
monozygotic	0
twin	0
pair	0
with	0
Fabry	0
disease	0
and	0
discordant	0
expression	0
of	0
a	0
novel	0
mutation	0
in	0
the	0
alpha-galactosidase	1
A	2
gene	2
.	0

We	0
describe	0
two	0
female	0
monozygotic	0
(	0
MZ	0
)	0
twins	0
heterozygous	0
for	0
Fabry	0
disease	0
,	0
an	0
X	0
linked	0
disorder	0
resulting	0
from	0
the	0
deficient	0
activity	0
of	0
alpha-galactosidase	9
A	10
.	0

While	0
one	0
of	0
the	0
twins	0
was	0
clinically	0
affected	0
,	0
the	0
other	0
was	0
asymptomatic	0
.	0

Enzymatic	0
assay	0
of	0
alpha-galactosidase	9
in	0
blood	7
leucocytes	8
,	0
skin	7
fibroblasts	8
,	0
Epstein-Barr	5
virus	6
transformed	6
lymphoid	6
cell	6
lines	6
,	0
and	0
hair	0
follicles	0
of	0
the	0
twins	0
and	0
their	0
parents	0
confirmed	0
the	0
heterozygous	0
status	0
of	0
the	0
twins	0
and	0
indicated	0
that	0
Fabry	0
disease	0
had	0
occurred	0
as	0
a	0
result	0
of	0
a	0
de	0
novo	0
mutation	0
.	0

The	0
son	0
of	0
the	0
unaffected	0
twin	0
sister	0
was	0
shown	0
to	0
be	0
hemizygous	0
.	0

Molecular	0
analysis	0
of	0
the	0
alpha-galactosidase	1
A	2
gene	2
permitted	0
the	0
identification	0
of	0
an	0
as	0
yet	0
undescribed	0
point	0
mutation	0
at	0
position	1
10182	2
of	2
exon	2
5	2
which	0
causes	0
an	0
Asp	0
to	0
Asn	0
substitution	0
at	0
codon	1
231	2
.	0

Single	0
strand	0
conformation	0
polymorphism	0
(	0
SSCP	0
)	0
analysis	0
again	0
showed	0
the	0
heterozygous	0
status	0
of	0
the	0
twins	0
and	0
a	0
normal	0
pattern	0
in	0
their	0
parents	0
.	0

The	0
basis	0
for	0
the	0
discordant	0
expression	0
of	0
this	0
d	0
novo	0
mutation	0
in	0
the	0
twins	0
was	0
investigated	0
by	0
studying	0
their	0
X	0
inactivation	0
status	0
.	0

Analysis	0
of	0
the	0
inactive	1
X	2
specific	0
methylation	0
at	0
the	0
androgen	1
receptor	2
gene	2
showed	0
unbalanced	0
inactivation	0
in	0
the	0
twins	0
'	0
fibroblasts	0
and	0
in	0
opposite	0
directions	0
.	0

While	0
the	0
maternally	1
derived	2
X	2
chromosome	2
was	0
preferentially	0
active	0
in	0
the	0
asymptomatic	0
twin	0
,	0
the	0
paternal	1
X	2
chromosome	2
was	0
active	0
in	0
the	0
other	0
,	0
affected	0
twin	0
and	0
was	0
found	0
in	0
her	0
hemizygotic	0
nephew	0
.	0

These	0
data	0
suggest	0
that	0
the	0
paternal	1
X	2
chromosome	2
carries	0
the	0
de	0
novo	0
alpha-galactosidase	9
A	10
mutation	0
and	0
that	0
uneven	0
X	0
inactivation	0
is	0
the	0
underlying	0
mechanism	0
for	0
disease	0
expression	0
in	0
this	0
novel	0
female	0
MZ	0
twin	0
pair	0
.	0

This	0
is	0
the	0
first	0
documented	0
case	0
of	0
female	0
twins	0
discordant	0
for	0
Fabry	0
disease	0
.	0

Precise	0
alignment	1
of	2
sites	2
required	0
for	0
mu	1
enhancer	2
activation	0
in	0
B	7
cells	8
.	0

The	0
lymphocyte-specific	1
immunoglobulin	2
mu	2
heavy-chain	2
gene	2
intronic	2
enhancer	2
is	0
regulated	0
by	0
multiple	0
nuclear	9
factors	10
.	0

The	0
previously	0
defined	0
minimal	1
enhancer	2
containing	0
the	0
muA	1
,	2
muE3	2
,	2
and	2
muB	2
sites	2
is	0
transactivated	0
by	0
a	0
combination	0
of	0
the	0
ETS-domain	9
proteins	10
PU.1	9
and	0
Ets-1	9
in	0
nonlymphoid	7
cells	8
.	0

The	0
core	0
GGAAs	0
of	0
the	0
muA	1
and	2
muB	2
sites	2
are	0
separated	0
by	0
30	0
nucleotides	0
,	0
suggesting	0
that	0
ETS	9
proteins	10
bind	0
to	0
these	0
sites	0
from	0
these	0
same	0
side	0
of	0
the	0
DNA	0
helix	0
.	0

We	0
tested	0
the	0
necessity	0
for	0
appropriate	0
spatial	0
alignment	0
of	0
these	0
elements	1
by	0
using	0
mutated	1
enhancers	2
with	0
altered	0
spacings	0
.	0

A	0
4-	0
or	0
10-bp	0
insertion	0
between	0
muE3	1
and	0
muB	1
inactivated	0
the	0
mu	1
enhancer	2
in	0
S194	5
plasma	6
cells	6
but	0
did	0
not	0
affect	0
in	0
vitro	0
binding	0
of	0
Ets-1	0
,	0
PU.1	9
,	0
or	0
the	0
muE3-binding	9
protein	10
TFE3	9
,	0
alone	0
or	0
in	0
pairwise	0
combinations	0
.	0

Circular	0
permutation	0
and	0
phasing	0
analyses	0
demonstrated	0
that	0
PU.1	9
binding	0
but	0
not	0
TFE3	9
or	0
Ets-1	9
bends	0
mu	1
enhancer	2
DNA	2
toward	0
the	0
major	0
groove	0
.	0

We	0
propose	0
that	0
the	0
requirement	0
for	0
precise	0
spacing	0
of	0
the	0
muA	1
and	2
muB	2
elements	2
is	0
due	0
in	0
part	0
to	0
a	0
directed	0
DNA	0
bend	0
induced	0
by	0
PU.1	9
.	0

[	0
Cortisone-resistant	0
bronchial	0
asthma	0
]	0

There	0
is	0
general	0
agreement	0
on	0
the	0
inflammatory	0
pathogenesis	0
of	0
bronchial	0
asthma	0
:	0
an	0
accumulation	0
of	0
activated	7
eosinophils	8
,	0
degranulated	7
mast	8
cells	8
,	0
T	7
lymphocytes	8
and	0
in	0
very	0
severe	0
forms	0
,	0
granulocytes	7
has	0
constantly	0
been	0
found	0
in	0
the	0
bronchial	0
mucosa	0
.	0

In	0
allergic	0
bronchial	0
asthma	0
,	0
inflammation	0
seems	0
to	0
be	0
orchestrated	0
predominantly	0
by	0
a	0
subset	0
of	0
T	7
lymphocytes	8
,	0
with	0
a	0
phenotype	0
similar	0
to	0
the	0
Th2	7
subset	8
able	0
to	0
produce	0
IL-4	9
and	0
IL-5	9
.	0

Although	0
corticosteroids	0
are	0
the	0
most	0
potent	0
therapeutic	0
agents	0
used	0
for	0
this	0
disease	0
,	0
their	0
anti-inflammatory	0
effect	0
differs	0
from	0
patient	0
to	0
patient	0
.	0

Some	0
criteria	0
which	0
can	0
be	0
used	0
to	0
define	0
steroid-resistant	0
bronchial	0
asthma	0
are	0
listed	0
here	0
.	0

This	0
review	0
analyzes	0
various	0
molecular	0
alterations	0
responsible	0
for	0
the	0
deficient	0
response	0
to	0
corticosteroid	0
treatment	0
observed	0
in	0
steroid-resistant	0
bronchial	0
asthmatic	0
subjects	0
.	0

New	0
knowledge	0
on	0
the	0
mechanism	0
of	0
steroid	0
resistance	0
may	0
have	0
important	0
implications	0
for	0
the	0
treatment	0
of	0
chronic	0
asthma	0
and	0
other	0
diseases	0
.	0

Mechanisms	0
of	0
transactivation	0
by	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells-1	10
.	0

Nuclear	9
factor	10
of	10
activated	10
T	10
cells-family	10
proteins	10
(	0
NFAT1/NFATp	9
,	0
NFATc	9
,	0
NFAT3	9
,	0
and	0
NFAT4/NFATx/NFATc3	9
)	0
play	0
a	0
key	0
role	0
in	0
the	0
transcription	0
of	0
cytokine	1
genes	2
and	0
other	0
genes	0
during	0
the	0
immune	0
response	0
.	0

We	0
have	0
defined	0
the	0
mechanisms	0
of	0
transactivation	0
by	0
NFAT1	9
.	0

NFAT1	9
possesses	0
two	0
transactivation	1
domains	2
whose	0
sequences	0
are	0
not	0
conserved	0
in	0
the	0
other	0
NFAT-family	9
proteins	10
,	0
and	0
a	0
conserved	0
DNA-binding	1
domain	2
that	0
mediates	0
the	0
recruitment	0
of	0
cooperating	0
nuclear	9
transcription	10
factors	10
even	0
when	0
it	0
is	0
expressed	0
in	0
the	0
absence	0
of	0
other	0
regions	0
of	0
the	0
protein	0
.	0

The	0
activity	0
of	0
the	0
NH2-terminal	9
transactivation	10
domain	10
is	0
modulated	0
by	0
an	0
adjacent	0
regulatory	9
region	10
that	0
contains	0
several	0
conserved	1
sequence	2
motifs	2
represented	0
only	0
in	0
the	0
NFAT	9
family	10
.	0

Our	0
results	0
emphasize	0
the	0
multiple	0
levels	0
at	0
which	0
NFAT-dependent	0
transactivation	0
is	0
regulated	0
,	0
and	0
predict	0
significant	0
differences	0
in	0
the	0
architecture	0
of	0
cooperative	0
transcription	9
complexes	10
containing	0
different	0
NFAT-family	9
proteins	10
.	0

Induction	0
of	0
activator	9
protein	10
(	10
AP	10
)	10
-1	10
and	0
nuclear	9
factor-kappaB	10
by	0
CD28	9
stimulation	0
involves	0
both	0
phosphatidylinositol	9
3-kinase	10
and	0
acidic	9
sphingomyelinase	10
signals	0
.	0

A	0
major	0
obstacle	0
in	0
understanding	0
the	0
signaling	0
events	0
that	0
follow	0
CD28	9
receptor	0
ligation	0
arises	0
from	0
the	0
fact	0
that	0
CD28	9
acts	0
as	0
a	0
costimulus	0
to	0
TCR	9
engagement	0
,	0
making	0
it	0
difficult	0
to	0
assess	0
the	0
relative	0
contribution	0
of	0
CD28	9
signals	0
as	0
distinct	0
from	0
those	0
of	0
the	0
TCR	9
.	0

To	0
overcome	0
this	0
problem	0
,	0
we	0
have	0
exploited	0
the	0
observation	0
that	0
activated	0
human	7
T	8
cell	8
blasts	8
can	0
be	0
stimulated	0
via	0
the	0
CD28	9
surface	10
molecule	10
in	0
the	0
absence	0
of	0
antigenic	0
challenge	0
;	0
thus	0
,	0
we	0
have	0
been	0
able	0
to	0
observe	0
the	0
response	0
of	0
normal	7
T	8
cells	8
to	0
CD28	9
activation	0
in	0
isolation	0
.	0

Using	0
this	0
system	0
,	0
we	0
observed	0
that	0
CD28	9
stimulation	0
by	0
B7-transfected	5
CHO	6
cells	6
induced	0
a	0
proliferative	0
response	0
in	0
T	7
cells	8
that	0
was	0
not	0
accompanied	0
by	0
measurable	0
IL-2	9
production	0
.	0

However	0
,	0
subsequent	0
analysis	0
of	0
transcription	9
factor	10
generation	0
revealed	0
that	0
B7	0
stimulation	0
induced	0
both	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
and	0
nuclear	9
factor-kappaB	10
(	10
NF-kappaB	10
)	10
complexes	10
,	0
but	0
not	0
NF-AT	9
.	0

In	0
contrast	0
,	0
engagement	0
of	0
the	0
TCR	9
by	0
class	9
II	10
MHC/superantigen	10
,	0
either	0
with	0
or	0
without	0
CD28	9
ligation	0
,	0
resulted	0
in	0
the	0
induction	0
of	0
NF-AT	9
,	0
AP-1	9
,	0
and	0
NF-kappaB	9
as	0
well	0
as	0
IL-2	9
production	0
.	0

Using	0
selective	0
inhibitors	0
,	0
we	0
investigated	0
the	0
signaling	0
pathways	0
involved	0
in	0
the	0
CD28	9
-mediated	0
induction	0
of	0
AP-1	9
and	0
NF-kappaB	9
.	0

This	0
revealed	0
that	0
NF-kappaB	9
generation	0
was	0
sensitive	0
to	0
chloroquine	0
,	0
an	0
inhibitor	0
of	0
acidic	9
sphingomyelinase	10
,	0
but	0
not	0
to	0
the	0
phosphatidylinositol	9
3-kinase	10
inhibitor	0
,	0
wortmannin	0
.	0

In	0
contrast	0
,	0
AP-1	9
generation	0
was	0
inhibited	0
by	0
wortmannin	0
and	0
was	0
also	0
variably	0
sensitive	0
to	0
chloroquine	0
.	0

These	0
data	0
suggest	0
that	0
in	0
activated	0
normal	7
T	8
cells	8
,	0
CD28	9
-derived	0
signals	0
can	0
stimulate	0
proliferation	0
at	0
least	0
in	0
part	0
via	0
NF-kappaB	0
and	0
AP-1	0
generation	0
,	0
and	0
that	0
this	0
response	0
uses	0
both	0
acidic	9
sphingomyelinase	10
and	0
phosphatidylinositol	9
3-kinase	10
-linked	0
pathways	0
.	0

Presence	0
of	0
a	0
variant	0
form	0
of	0
the	0
estrogen	9
receptor	10
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
normal	0
individuals	0
and	0
lupus	0
patients	0
.	0

Estrogen	0
may	0
participate	0
in	0
the	0
pathogenesis	0
of	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
via	0
its	0
intracellular	9
receptor	10
.	0

To	0
investigate	0
the	0
presence	0
of	0
various	0
isoforms	0
of	0
the	0
estrogen	9
receptor	10
(	0
ER	9
)	0
in	0
SLE	0
we	0
isolated	0
RNA	0
from	0
mononuclear	7
cells	8
of	0
lupus	0
patients	0
and	0
normal	0
controls	0
.	0

Using	0
RT-PCR	0
we	0
were	0
able	0
to	0
identify	0
both	0
the	0
full	9
length	10
wild-type	10
form	10
and	0
an	0
isoform	0
of	0
the	0
ER	9
which	0
precisely	0
lacks	0
exon	1
V	2
in	0
both	0
patient	0
and	0
normal	0
individuals	0
.	0

Our	0
results	0
,	0
although	0
limited	0
,	0
suggest	0
that	0
normal	0
individuals	0
can	0
express	0
both	0
the	0
wild-type	0
and	0
truncated	0
version	0
at	0
the	0
same	0
time	0
,	0
whereas	0
lupus	0
patients	0
only	0
express	0
either	0
the	0
wild-type	9
or	10
the	10
truncated	10
ER	10
.	0

This	0
finding	0
may	0
lead	0
to	0
a	0
better	0
understanding	0
of	0
the	0
reasons	0
for	0
the	0
prevalence	0
of	0
lupus	0
in	0
females	0
and	0
of	0
the	0
estrogenic	0
effects	0
on	0
SLE	0
disease	0
activity	0
.	0

Regulation	0
of	0
sialoadhesin	9
expression	0
on	0
rat	7
macrophages	8
.	0

Induction	0
by	0
glucocorticoids	0
and	0
enhancement	0
by	0
IFN-beta	9
,	0
IFN-gamma	9
,	0
IL-4	9
,	0
and	0
lipopolysaccharide	0
.	0

Sialoadhesin	9
is	0
a	0
macrophage-restricted	9
member	10
of	0
the	0
Ig	9
superfamily	10
that	0
mediates	0
adhesion	0
with	0
lymphoid	7
and	8
myeloid	8
cells	8
.	0

It	0
is	0
expressed	0
on	0
a	0
subpopulation	0
of	0
macrophages	7
in	0
lymphoid	0
tissues	0
and	0
in	0
chronic	0
inflammation	0
(	0
e.g.	0
,	0
during	0
autoimmune	0
diseases	0
)	0
.	0

We	0
have	0
studied	0
the	0
regulation	0
of	0
sialoadhesin	9
expression	0
in	0
vitro	0
and	0
show	0
that	0
glucocorticoids	0
(	0
GC	0
)	0
induce	0
sialoadhesin	9
expression	0
on	0
freshly	0
isolated	0
rat	7
macrophages	8
and	0
the	0
rat	5
macrophage	6
cell	6
line	6
R2	6
.	0

The	0
cytokines	9
IFN-beta	9
,	0
IFN-gamma	9
,	0
IL-4	9
,	0
and	0
LPS	0
,	0
although	0
unable	0
to	0
induce	0
sialoadhesin	9
expression	0
by	0
themselves	0
,	0
were	0
able	0
to	0
enhance	0
GC-mediated	0
induction	0
of	0
sialoadhesin	9
.	0

Sialoadhesin	9
expression	0
was	0
functional	0
as	0
shown	0
by	0
cell	0
adhesion	0
assays	0
with	0
human	7
RBCs	8
.	0

Northern	0
blotting	0
experiments	0
indicated	0
that	0
regulation	0
predominantly	0
occurred	0
at	0
the	0
mRNA	0
level	0
.	0

Comparison	0
of	0
the	0
different	0
combinations	0
of	0
GC	0
and	0
cytokines	9
/LPS	0
revealed	0
differences	0
in	0
the	0
level	0
of	0
GC-dependent	0
enhancement	0
of	0
sialoadhesin	9
expression	0
,	0
with	0
IFN-beta	9
and	0
IL-4	9
being	0
more	0
potent	0
than	0
IFN-gamma	9
and	0
LPS	0
.	0

Moreover	0
,	0
the	0
effects	0
of	0
IFN-gamma	9
and	0
LPS	0
could	0
be	0
reproduced	0
by	0
priming	0
,	0
whereas	0
IFN-beta	9
and	0
IL-4	9
were	0
required	0
simultaneously	0
with	0
GC	0
.	0

The	0
regulation	0
of	0
sialoadhesin	9
expression	0
was	0
mediated	0
by	0
the	0
GC	9
receptor	10
,	0
and	0
not	0
by	0
mineralocorticoid	9
receptor	10
,	0
as	0
shown	0
by	0
inhibition	0
experiments	0
with	0
specific	0
antagonists	0
.	0

Finally	0
,	0
it	0
is	0
demonstrated	0
that	0
macrophages	7
in	0
the	0
adrenal	0
gland	0
,	0
the	0
major	0
site	0
of	0
endogenous	0
GC	0
production	0
,	0
express	0
sialoadhesin	9
.	0

This	0
study	0
demonstrates	0
that	0
GC	0
act	0
as	0
a	0
primary	0
inducer	0
of	0
sialoadhesin	9
expression	0
on	0
rat	7
macrophages	8
,	0
and	0
that	0
the	0
response	0
can	0
be	0
enhanced	0
by	0
IFN-beta	9
,	0
T	9
cell-derived	10
cytokines	10
,	0
or	0
LPS	0
.	0

Apoptosis	0
mediated	0
by	0
HIV	9
protease	10
is	0
preceded	0
by	0
cleavage	0
of	0
Bcl-2	9
.	0

Expression	0
of	0
the	0
human	9
immunodeficiency	10
virus	10
type	10
1	10
(	10
HIV	10
)	10
protease	10
in	0
cultured	5
cells	6
leads	0
to	0
apoptosis	0
,	0
preceded	0
by	0
cleavage	0
of	0
bcl-2	9
,	0
a	0
key	0
negative	0
regulator	0
of	0
cell	0
death	0
.	0

In	0
contrast	0
,	0
a	0
high	0
level	0
of	0
bcl-2	9
protects	0
cells	0
in	0
vitro	0
and	0
in	0
vivo	0
from	0
the	0
viral	9
protease	10
and	0
prevents	0
cell	0
death	0
following	0
HIV	0
infection	0
of	0
human	7
lymphocytes	8
,	0
while	0
reducing	0
the	0
yields	0
of	0
viral	9
structural	10
proteins	10
,	0
infectivity	0
,	0
and	0
tumor	9
necrosis	10
factor	10
alpha	10
.	0

We	0
present	0
a	0
model	0
for	0
HIV	0
replication	0
in	0
which	0
the	0
viral	9
protease	10
depletes	0
the	0
infected	0
cells	0
of	0
bcl-2	9
,	0
leading	0
to	0
oxidative	0
stress-dependent	0
activation	0
of	0
NF	9
kappa	10
B	10
,	0
a	0
cellular	9
factor	10
required	0
for	0
HIV	0
transcription	0
,	0
and	0
ultimately	0
to	0
cell	0
death	0
.	0

Purified	0
bcl-2	9
is	0
cleaved	0
by	0
HIV	9
protease	10
between	0
phenylalanine	0
112	0
and	0
alanine	0
113	0
.	0

The	0
results	0
suggest	0
a	0
new	0
option	0
for	0
HIV	0
gene	0
therapy	0
;	0
bcl-2	9
muteins	10
that	0
have	0
noncleavable	9
alterations	10
surrounding	0
the	0
HIV	9
protease	10
cleavage	10
site	10
.	0

Alpha	9
4	10
beta	10
1	10
(	10
CD49d/CD29	10
)	10
integrin	10
costimulation	0
of	0
human	7
T	8
cells	8
enhances	0
transcription	9
factor	10
and	0
cytokine	0
induction	0
in	0
the	0
absence	0
of	0
altered	0
sensitivity	0
to	0
anti-CD3	9
stimulation	0
.	0

The	0
integrin	9
alpha	10
4	10
beta	10
1	10
can	0
provide	0
a	0
costimulus	0
to	0
induce	0
IL-2	9
secretion	0
and	0
IL-2R	9
expression	0
leading	0
to	0
enhanced	0
proliferation	0
of	0
purified	0
,	0
peripheral	7
blood	8
T	8
cells	8
.	0

Similar	0
to	0
expression	0
of	0
IL-2	9
,	0
we	0
demonstrated	0
that	0
recombinant	9
vascular-cell	10
adhesion	10
molecule-1	10
,	0
when	0
co-immobilized	0
with	0
anti-CD3	9
mAb	10
,	0
significantly	0
enhanced	0
the	0
induction	0
of	0
transcription	9
factors	10
NF-AT	9
,	0
AP-1	9
,	0
and	0
NF-kappa	9
B	10
as	0
determined	0
by	0
electromobility	0
shift	0
assays	0
.	0

alpha	9
4	10
beta	10
1	10
ligation	0
alone	0
had	0
no	0
effect	0
on	0
transcription	9
factor	10
binding	0
.	0

The	0
requirements	0
for	0
induction	0
of	0
transcription	9
factors	10
reflected	0
the	0
requirements	0
for	0
the	0
secretion	0
of	0
multiple	0
cytokines	9
,	0
including	0
IL-2	9
,	0
TNF-alpha	9
,	0
IFN-gamma	9
,	0
and	0
granulocyte	9
macrophage-CSF	10
.	0

In	0
contrast	0
to	0
freshly	7
isolated	8
T	8
cells	8
,	0
in	0
vitro-cultured	5
T	6
cells	6
did	0
not	0
require	0
costimulation	0
for	0
cytokine	9
secretion	0
in	0
response	0
to	0
anti-CD3	9
alone	0
.	0

Comparison	0
of	0
the	0
dose	0
response	0
to	0
anti-CD3	9
stimulation	0
demonstrated	0
that	0
half-maximal	0
induction	0
of	0
IL-2	9
was	0
achieved	0
using	0
the	0
same	0
dose	0
of	0
anti-CD3	9
for	0
both	0
freshly	7
isolated	8
and	0
cultured	5
T	6
cells	6
.	0

Furthermore	0
,	0
the	0
dose	0
of	0
OKT3	9
required	0
to	0
achieve	0
half-maximal	0
activation	0
was	0
the	0
same	0
using	0
PMA	0
or	0
different	0
concentrations	0
of	0
alpha	9
4	10
beta	10
1	10
ligands	0
.	0

Therefore	0
,	0
costimulation	0
by	0
alpha	9
4	10
beta	10
1	10
ligands	0
was	0
not	0
due	0
to	0
stabilization	0
of	0
the	0
interaction	0
of	0
the	0
cells	0
with	0
its	0
substrate	0
.	0

We	0
conclude	0
,	0
rather	0
,	0
that	0
alpha	9
4	10
beta	10
1	10
in	0
freshly	7
isolated	8
T	8
cells	8
delivers	0
a	0
distinct	0
signal	0
that	0
synergizes	0
early	0
with	0
signals	0
initiated	0
by	0
TCR/CD3	9
ligation	0
to	0
induce	0
DNA	0
binding	0
of	0
multiple	0
transcription	9
factors	10
required	0
for	0
cytokine	1
gene	2
induction	0
.	0

Inhibition	0
of	0
T	7
lymphocyte	8
activation	0
by	0
cAMP	0
is	0
associated	0
with	0
down-regulation	0
of	0
two	0
parallel	0
mitogen-activated	0
protein	9
kinase	10
pathways	0
,	0
the	0
extracellular	9
signal-related	10
kinase	10
and	0
c-Jun	9
N-terminal	10
kinase	10
.	0

The	0
induction	0
of	0
T	0
cell	0
proliferation	0
requires	0
signals	0
from	0
the	0
TCR	9
and	0
a	0
co-receptor	9
molecule	10
,	0
such	0
as	0
CD28	9
,	0
that	0
activate	0
parallel	0
and	0
partially	0
cross-reactive	0
signaling	0
pathways	0
.	0

These	0
pathways	0
are	0
disrupted	0
by	0
agonists	0
that	0
utilize	0
adenylate	9
cyclase	10
and	0
cAMP-dependent	9
protein	10
kinase	10
A	10
(	0
PKA	9
)	0
.	0

We	0
found	0
that	0
the	0
adenylate	9
cyclase	10
activator	0
,	0
forskolin	0
,	0
inhibits	0
anti-CD3	9
-induced	0
shift	0
in	0
Lck	9
electrophoretic	0
mobility	0
,	0
suggesting	0
an	0
intervention	0
at	0
the	0
TCR	9
-coupled	0
phosphoinositide	0
turnover	0
that	0
precedes	0
the	0
activation	0
of	0
PKC	9
.	0

The	0
shift	0
of	0
Lck	9
following	0
direct	0
PKC	9
activation	0
by	0
12-O-tetradecanoyl	0
phorbol	0
13-acetate	0
,	0
which	0
bypasses	0
early	0
receptor-triggered	0
biochemical	0
events	0
,	0
is	0
insensitive	0
to	0
forskolin	0
.	0

Nevertheless	0
,	0
forskolin	0
also	0
inhibits	0
PKC	9
downstream	0
events	0
,	0
such	0
as	0
c-jun	1
expression	0
,	0
which	0
is	0
critical	0
for	0
the	0
activation	0
process	0
of	0
T	7
cells	8
.	0

To	0
further	0
analyze	0
potential	0
cross	0
points	0
between	0
positively	0
and	0
negatively	0
regulating	0
signaling	0
pathways	0
in	0
T	7
cells	8
,	0
we	0
tested	0
the	0
effects	0
of	0
activators	0
of	0
the	0
adenylate	9
cyclase	10
or	0
PKA	9
on	0
two	0
parallel	0
mitogen-activated	0
protein	0
kinase	0
signaling	0
pathways	0
mediated	0
by	0
extracellular	9
signal-regulated	10
kinase	10
(	0
ERK	9
)	0
and	0
c-Jun	9
N-terminal	10
kinase	10
.	0

Using	0
a	0
PKC	9
-specific	0
inhibitor	0
,	0
GF109203X	0
,	0
or	0
PKC-depleted	5
T	6
cells	6
,	0
we	0
found	0
that	0
a	0
large	0
part	0
of	0
the	0
anti-CD3	9
-induced	0
ERK	9
activation	0
is	0
PKC	9
dependent	0
.	0

Both	0
PKC-	0
dependent	0
and	0
-independent	0
activation	0
of	0
ERK	9
were	0
sensitive	0
to	0
inhibition	0
by	0
forskolin	0
or	0
a	0
cell-permeable	0
cAMP	0
analogue	0
,	0
dbcAMP	0
.	0

Furthermore	0
,	0
the	0
effect	0
of	0
12-O-tetradecanoyl	0
phorbol	0
13-acetate	0
and	0
ionomycin	0
,	0
which	0
synergized	0
to	0
fully	0
activate	0
c-Jun	9
N-terminal	10
kinase	10
,	0
was	0
also	0
sensitive	0
to	0
inhibition	0
by	0
forskolin	0
.	0

Our	0
results	0
suggest	0
that	0
PKA	9
inhibits	0
T	0
cell	0
activation	0
by	0
interfering	0
with	0
multiple	0
events	0
along	0
the	0
two	0
signaling	0
pathways	0
operating	0
downstream	0
of	0
the	0
TCR	9
and	0
the	0
CD28	9
co-receptor	10
molecules	10
.	0

Transcriptional	0
and	0
posttranscriptional	0
regulation	0
of	0
erythroid	1
gene	2
expression	0
in	0
anthracycline-induced	0
differentiation	0
of	0
human	7
erythroleukemic	8
cells	8
.	0

Aclacinomycin	0
(	0
ACLA	0
)	0
and	0
doxorubicin	0
(	0
DOX	0
)	0
were	0
used	0
at	0
subtoxic	0
concentrations	0
to	0
induce	0
erythroid	0
differentiation	0
in	0
the	0
human	5
leukemic	6
cell	6
line	6
K562	6
.	0

Cell	0
hemoglobinization	0
was	0
accompanied	0
by	0
the	0
increased	0
expression	0
of	0
genes	1
encoding	0
gamma-globin	9
and	10
porphobilinogen	10
deaminase	10
(	0
PBGD	9
)	0
,	0
an	0
enzyme	0
of	0
heme	0
synthesis	0
.	0

By	0
using	0
run-on	0
assays	0
,	0
ACLA	0
was	0
shown	0
to	0
induce	0
an	0
enhancement	0
of	0
the	0
transcription	0
of	0
erythroid	1
genes	2
,	0
including	0
gamma-globin	9
,	0
PBGD	9
,	0
erythropoietin	9
receptor	10
,	0
and	0
GATA-1	9
transcription	9
factor	10
.	0

In	0
contrast	0
,	0
in	0
DOX-treated	5
cells	6
,	0
the	0
transcription	0
rate	0
of	0
these	0
genes	1
was	0
unchanged	0
in	0
comparison	0
with	0
control	7
cells	8
.	0

In	0
addition	0
,	0
inhibition	0
of	0
mRNA	3
synthesis	0
with	0
actinomycin	0
D	0
indicated	0
that	0
DOX	0
induced	0
an	0
increased	0
stability	0
of	0
PBGD	3
and	4
GATA-1	4
mRNAs	4
,	0
whereas	0
ACLA	0
did	0
not	0
affect	0
the	0
half-lives	0
of	0
these	0
mRNAs	3
.	0

Because	0
the	0
increase	0
in	0
erythroid	3
mRNA	4
steady-state	0
level	0
in	0
anthracycline-treated	7
cells	8
was	0
inhibited	0
by	0
cycloheximide	0
,	0
this	0
suggests	0
that	0
transcriptional	0
activation	0
in	0
ACLA-treated	5
cells	6
and	0
mRNA	0
stabilization	0
in	0
DOX-treated	7
cells	8
were	0
dependent	0
on	0
de	0
novo	0
protein	0
synthesis	0
.	0

Finally	0
,	0
GATA-1	9
protein	0
level	0
was	0
shown	0
to	0
be	0
increased	0
in	0
ACLA-treated	5
but	6
not	6
in	6
DOX-treated	6
cells	6
.	0

These	0
two	0
anthracyclines	0
,	0
although	0
closely	0
related	0
in	0
their	0
structures	0
,	0
appeared	0
to	0
act	0
as	0
differentiation	0
inducers	0
by	0
distinct	0
mechanisms	0
.	0

Indeed	0
,	0
erythroid	1
gene	2
expression	0
was	0
demonstrated	0
to	0
be	0
regulated	0
transcriptionally	0
by	0
ACLA	0
and	0
mainly	0
posttranscriptionally	0
by	0
DOX	0
.	0

Interleukin-7	9
signaling	0
in	0
human	5
B	6
cell	6
precursor	6
acute	6
lymphoblastic	6
leukemia	6
cells	6
and	0
murine	5
BAF3	6
cells	6
involves	0
activation	0
of	0
STAT1	9
and	0
STAT5	9
mediated	0
via	0
the	0
interleukin-7	9
receptor	10
alpha	10
chain	10
.	0

Interleukin-7	9
(	0
IL-7	9
)	0
stimulates	0
the	0
proliferation	0
of	0
normal	7
and	8
leukemic	8
B	8
and	8
T	8
cell	8
precursors	8
and	8
T	8
lymphocytes	8
.	0

Activation	0
of	0
the	0
JAK	9
/STAT	9
pathway	0
has	0
been	0
implicated	0
in	0
IL-7R	9
signaling	0
.	0

We	0
investigated	0
which	0
STAT	9
complexes	10
are	0
formed	0
upon	0
stimulation	0
of	0
B	5
cell	6
precursor	6
acute	6
lymphoblastic	6
leukemia	6
(	6
BCP-ALL	6
)	6
cells	6
with	0
IL-7	9
.	0

Gel	0
retardation	0
assays	0
with	0
STAT-binding	0
oligonucleotides	0
showed	0
that	0
IL-7	9
induces	0
the	0
formation	0
of	0
two	0
major	0
STAT	9
complexes	10
in	0
BCP-ALL	5
cells	6
.	0

Supershifts	0
with	0
anti-STAT	0
antibodies	0
identified	0
these	0
as	0
STAT1	9
and	0
STAT5	9
complexes	10
.	0

This	0
pattern	0
of	0
STAT	9
activation	0
was	0
seen	0
in	0
all	0
BCP-ALL	0
cases	0
that	0
respond	0
to	0
IL-7	9
in	0
proliferation	0
assays	0
.	0

IL-7	9
also	0
induced	0
STAT	9
/DNA	0
binding	0
in	0
BCP-ALL	0
cases	0
that	0
failed	0
to	0
proliferate	0
in	0
response	0
to	0
IL-7	9
,	0
suggesting	0
that	0
the	0
ability	0
of	0
IL-7R	9
to	0
activate	0
the	0
JAK	9
/STAT	9
pathway	0
per	0
se	0
is	0
not	0
sufficient	0
for	0
proliferation	0
induction	0
.	0

To	0
determine	0
the	0
contribution	0
of	0
the	0
cytoplasmic	9
domain	10
of	0
the	0
IL-7	9
receptor	10
alpha	10
chain	10
(	0
IL-7R	9
alpha	10
)	0
to	0
activation	0
of	0
STAT	9
proteins	10
,	0
transfectants	0
of	0
the	0
murine	5
pro-B	6
cell	6
line	6
BAF3	6
were	0
made	0
that	0
express	0
chimeric	9
receptors	10
consisting	0
of	0
the	0
extracellular	9
domain	10
of	0
human	9
granulocyte	10
colony-stimulating	10
factor	10
receptor	10
(	0
G-CSF-R	9
)	0
and	0
the	0
transmembrane	9
and	10
intracellular	10
domains	10
of	0
human	9
IL-7R	10
alpha	10
.	0

Activation	0
of	0
the	0
chimeric	9
G-CSF-R/IL-7R	10
alpha	10
with	0
G-CSF	9
resulted	0
in	0
a	0
full	0
proliferative	0
response	0
and	0
induced	0
the	0
phosphorylation	0
of	0
JAK1	9
but	0
not	0
JAK2	9
.	0

Major	0
STAT	9
complexes	10
activated	0
by	0
G-CSF-R/IL-7R	9
alpha	10
contained	0
STAT1	9
or	0
STAT5	9
,	0
while	0
some	0
formation	0
of	0
STAT3-containing	9
complexes	10
was	0
also	0
seen	0
.	0

These	0
findings	0
establish	0
that	0
STAT1	9
and	0
STAT5	9
,	0
and	0
possibly	0
STAT3	9
,	0
are	0
activated	0
upon	0
stimulation	0
of	0
precursor	7
B	8
cells	8
with	0
IL-7	9
.	0

The	0
data	0
further	0
indicate	0
that	0
the	0
IL-7R	9
alpha	10
chains	10
are	0
directly	0
involved	0
in	0
the	0
activation	0
of	0
JAKs	9
and	0
STATs	9
and	0
have	0
a	0
major	0
role	0
in	0
proliferative	0
signaling	0
in	0
precursor	7
B	8
cells	8
.	0

Stimulation	0
of	0
human	0
lymphocyte	0
proliferation	0
and	0
CD40	9
antigen	0
expression	0
by	0
phosphorothioate	0
oligonucleotides	0
complementary	0
to	0
hepatitis	1
B	2
virus	2
genome	2
.	0

We	0
have	0
studied	0
the	0
proliferation	0
and	0
CD40	9
antigen	0
expression	0
of	0
lymphocytes	7
,	0
and	0
the	0
cytotoxicity	0
to	0
monocytes	7
,	0
of	0
antisense	0
phosphorothioate	0
oligodeoxynucleotides	0
complementary	0
to	0
the	0
SP	1
II	2
promoter	2
of	0
HBV	3
mRNA	4
(	0
sequence	0
I	0
)	0
and	0
the	0
X	1
gene	2
(	0
sequence	0
II	0
)	0
in	0
patients	0
with	0
chronic	0
hepatitis	0
B	0
.	0

The	0
oligo	0
sequence	0
I	0
stimulated	0
proliferation	0
of	0
both	0
T	7
and	8
,	8
to	8
a	8
lesser	8
extent	8
,	8
B	8
cells	8
.	0

The	0
percentage	0
of	0
cells	0
expressing	0
CD40	9
in	0
T	5
and	6
B	6
cell	6
co-cultures	6
increased	0
from	0
4.2	0
%	0
to	0
13.8	0
%	0
after	0
oligo	0
stimulation	0
in	0
patients	0
,	0
while	0
it	0
increased	0
form	0
4.7	0
%	0
to	0
48.6	0
%	0
in	0
healthy	0
controls	0
.	0

The	0
sense	0
sequence	0
(	0
sequence	0
III	0
)	0
of	0
the	0
X	1
gene	2
also	0
enhanced	0
the	0
expression	0
of	0
CD40	9
antigen	10
in	0
patients	0
with	0
hepatitis	0
B	0
.	0

The	0
proportion	0
of	0
CD40	5
cells	6
(	0
26	0
%	0
)	0
in	0
a	0
resting	5
B-cell	6
preparation	6
from	0
hepatitis	0
B	0
patients	0
decreased	0
to	0
zero	0
after	0
a	0
5-day	0
culture	0
with	0
sequence	0
I	0
,	0
but	0
IgG	0
levels	0
in	0
the	0
culture	0
supernatant	0
increased	0
.	0

The	0
cytotoxic	0
properties	0
of	0
monocytes	7
were	0
not	0
influenced	0
by	0
the	0
oligos	0
.	0

These	0
findings	0
indicate	0
that	0
antisense	0
oligos	0
against	0
hepatitis	0
B	0
virus	0
(	0
HBV	0
)	0
have	0
mitogenic	0
effects	0
on	0
the	0
proliferation	0
of	0
human	7
lymphocytes	8
in	0
a	0
non-specific	0
manner	0
and	0
may	0
activate	0
T	7
cells	8
to	0
express	0
CD40	9
antigen	10
.	0

Activation	9
protein	10
1	10
-dependent	0
transcriptional	0
activation	0
of	0
interleukin	1
2	2
gene	2
by	0
Ca2+/calmodulin	9
kinase	10
type	10
IV/Gr	10
.	0

The	0
Ca2+/calmodulin-dependent	9
protein	10
kinase	10
(	10
CaMK	10
)	10
type	10
IV/Gr	10
is	0
selectively	0
expressed	0
in	0
T	7
lymphocytes	8
and	0
is	0
activated	0
after	0
signaling	0
via	0
the	0
T	9
cell	10
antigen	10
receptor	10
(	0
TCR	9
)	0
,	0
indicating	0
that	0
it	0
mediates	0
some	0
of	0
the	0
Ca	0
(	0
2+	0
)	0
-dependent	0
transcriptional	0
events	0
that	0
follow	0
TCR	9
engagement	0
.	0

Here	0
we	0
show	0
that	0
CaMKIV/Gr	9
induces	0
the	0
transcription	9
factor	10
activation	10
protein	10
1	10
(	0
AP-1	9
)	0
alone	0
or	0
in	0
synergy	0
with	0
T	9
cell	10
mitogens	10
and	0
with	0
the	0
p21ras	9
oncoprotein	10
.	0

CaMKIV/	9
Gr	10
signaling	0
is	0
associated	0
with	0
transcriptional	0
activation	0
of	0
c-fos	1
but	0
is	0
independent	0
of	0
p21ras	1
or	0
calcineurin	9
.	0

AP-1	9
is	0
an	0
integral	0
component	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	10
NFAT	10
)	10
transcriptional	10
complex	10
,	0
which	0
is	0
required	0
for	0
interleukin	1
2	2
gene	2
expression	0
in	0
T	7
cells	8
.	0

We	0
demonstrate	0
that	0
CaMKIV/Gr	9
reconstitutes	0
the	0
capacity	0
of	0
the	0
cytosolic	0
component	0
of	0
NFAT	9
to	0
direct	0
transcription	0
from	0
NFAT	1
sites	2
in	0
non-	0
T	7
cells	8
.	0

These	0
results	0
reveal	0
a	0
central	0
role	0
for	0
CaMKIV/Gr	9
as	0
a	0
Ca	0
(	0
2+	0
)	0
-regulated	0
activator	0
of	0
gene	0
transcription	0
in	0
T	7
lymphocytes	8
.	0

IL-12	9
-induced	0
activation	0
of	0
NK	7
and	8
T	8
cells	8
occurs	0
in	0
the	0
absence	0
of	0
immediate-early	1
activation	2
gene	2
expression	0
.	0

The	0
responses	0
of	0
lymphocytes	7
to	0
IL-2	9
and	0
IL-12	9
,	0
involving	0
proliferation	0
,	0
differentiation	0
,	0
and	0
cytokine	9
production	0
,	0
are	0
only	0
partially	0
overlapping	0
,	0
and	0
may	0
depend	0
on	0
induced	0
differential	0
expression	0
of	0
specific	0
sets	0
of	0
genes	9
.	0

Using	0
reverse-transcription	0
PCR	0
differential	0
display	0
,	0
we	0
isolated	0
an	0
mRNA	3
species	4
expressed	0
in	0
IL-2	7
-but	8
not	8
IL-12-stimulated	8
NK	8
cells	8
.	0

This	0
was	0
identified	0
as	0
the	0
mRNA	3
encoding	0
the	0
transcription	9
factor	10
egr-1	9
,	0
which	0
is	0
expressed	0
with	0
fast	0
kinetics	0
in	0
T	7
and	8
NK	8
cells	8
upon	0
IL-2	9
,	0
but	0
not	0
IL-12	9
,	0
stimulation	0
.	0

Analysis	0
of	0
the	0
accumulation	0
of	0
mRNA-encoding	9
members	10
of	0
the	0
AP-1	9
transcription	10
factor	10
family	10
demonstrated	0
that	0
c-fos	1
and	0
junB	1
are	0
also	0
expressed	0
upon	0
stimulation	0
of	0
NK	7
and	8
T	8
cells	8
with	0
IL-2	9
,	0
but	0
not	0
IL-12	9
,	0
whereas	0
expression	0
of	0
c-jun	1
and	0
junD	1
is	0
not	0
modified	0
by	0
either	0
cytokine	9
.	0

Accordingly	0
,	0
increased	0
AP-1	9
DNA-binding	0
activity	0
and	0
AP-1	9
-dependent	0
transcriptional	0
activity	0
were	0
detected	0
exclusively	0
in	0
IL-2-stimulated	5
cells	6
.	0

Analysis	0
of	0
the	0
expression	0
of	0
genes	9
reported	0
to	0
regulate	0
cytokine	9
-induced	0
proliferation	0
demonstrated	0
that	0
both	0
IL-2	9
and	0
IL-12	9
induce	0
c-myc	3
mRNA	4
accumulation	0
in	0
NK	7
and	8
T	8
cells	8
,	0
whereas	0
only	0
IL-2	9
induces	0
bcl-2	1
expression	0
.	0

Our	0
data	0
provide	0
the	0
first	0
demonstration	0
that	0
IL-12	9
-mediated	0
activation	0
of	0
T	7
and	8
NK	8
cells	8
does	0
not	0
involve	0
expression	0
of	0
members	0
of	0
the	0
immediate-early	1
activation	2
genes	2
family	2
(	0
egr-1	1
,	0
c-fos	1
,	0
and	0
junB	1
)	0
,	0
AP-1	9
transcriptional	0
activity	0
,	0
or	0
bcl-2	1
expression	0
.	0

This	0
indicates	0
that	0
functional	0
differences	0
observed	0
in	0
IL-2-	5
and	6
IL-12-stimulated	6
cells	6
may	0
depend	0
,	0
at	0
least	0
in	0
part	0
,	0
on	0
differential	0
gene	0
regulation	0
.	0

Active	0
suppression	0
of	0
the	0
class	1
II	2
transactivator-encoding	2
AIR-1	2
locus	2
is	0
responsible	0
for	0
the	0
lack	0
of	0
major	1
histocompatibility	2
complex	2
class	2
II	2
gene	2
expression	0
observed	0
during	0
differentiation	0
from	0
B	7
cells	8
to	0
plasma	7
cells	8
.	0

In	0
this	0
study	0
the	0
genetic	0
control	0
of	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
gene	2
expression	0
during	0
the	0
transition	0
from	0
B	7
cell	8
to	0
plasma	7
cell	8
has	0
been	0
analyzed	0
.	0

Class	9
II	10
molecules	10
are	0
not	0
expressed	0
in	0
plasma	7
cells	8
because	0
of	0
an	0
active	0
suppression	0
resulting	0
in	0
the	0
abrogation	0
of	0
class	1
II	2
gene	2
transcription	0
.	0

We	0
show	0
here	0
that	0
the	0
plasma	0
cell-specific	0
repressor	0
function	0
,	0
designated	0
SIR	1
(	0
suppressor	1
of	2
immune	2
response	2
genes	2
)	0
,	0
does	0
not	0
act	0
directly	0
on	0
the	0
transcription	0
of	0
class	1
II	2
genes	2
,	0
but	0
instead	0
on	0
the	0
transcription	0
of	0
the	0
AIR-1	1
gene	2
,	0
whose	0
product	0
,	0
the	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
,	0
is	0
fundamental	0
for	0
the	0
regulation	0
of	0
the	0
constitutive	0
and	0
inducible	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
.	0

This	0
was	0
unambiguously	0
demonstrated	0
by	0
the	0
fact	0
that	0
plasmacytoma	5
x	6
B	6
cell	6
hybrids	6
carrying	0
an	0
AIR-1	1
locus	2
derived	0
from	0
CIITA-expressing	5
cells	6
do	0
not	0
express	0
CIITA-specific	3
transcripts	4
.	0

Transfection	0
of	0
a	0
cDNA	0
containing	0
the	0
human	1
CIITA	2
coding	2
sequence	2
under	0
the	0
control	0
of	0
an	0
heterologous	1
promoter	2
restores	0
expression	0
of	0
human	1
MHC	2
class	2
II	2
genes	2
in	0
the	0
hybrids	0
and	0
is	0
responsible	0
for	0
de	0
novo	0
expression	0
of	0
mouse	1
MHC	2
class	2
II	2
genes	2
in	0
both	0
the	0
mouse	5
plasmacytoma	6
cell	6
line	6
and	0
the	0
hybrids	5
.	0

These	0
results	0
confirm	0
and	0
extend	0
the	0
notion	0
of	0
the	0
functional	0
conservation	0
of	0
the	0
AIR-1	9
gene	10
product	10
across	0
species	0
barriers	0
.	0

Interestingly	0
,	0
in	0
CIITA-transfected	5
cell	6
hybrids	6
,	0
cell	0
surface	0
expression	0
of	0
the	0
human	9
HLA-DQ	10
heterodimer	10
was	0
not	0
observed	0
.	0

This	0
result	0
was	0
not	0
attributable	0
to	0
lack	0
of	0
HLA-DQ	0
alpha	0
or	0
-DQ	0
beta	0
transcription	0
,	0
because	0
both	0
transcripts	0
were	0
present	0
in	0
the	0
CIITA-transfected	5
hybrids	6
,	0
although	0
at	0
reduced	0
levels	0
.	0

These	0
findings	0
further	0
support	0
our	0
previous	0
observations	0
on	0
the	0
distinct	0
regulation	0
of	0
expression	0
of	0
the	0
human	1
HLA-DQ	2
class	2
II	2
subset	2
,	0
which	0
may	0
be	0
thus	0
controlled	0
at	0
the	0
posttranscriptional	0
level	0
by	0
a	0
CIITA	9
-independent	0
mechanism	0
.	0

Requirements	0
for	0
induction	0
of	0
vitamin	0
D-mediated	0
gene	0
regulation	0
in	0
normal	7
human	8
B	8
lymphocytes	8
.	0

Mature	0
human	7
lymphocytes	8
are	0
unique	0
targets	0
of	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
alpha	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
)	0
in	0
that	0
vitamin	9
D	10
receptors	10
(	0
VDR	9
)	0
are	0
not	0
constitutively	0
expressed	0
,	0
and	0
specific	0
cellular	0
activation	0
signals	0
are	0
required	0
for	0
both	0
the	0
up-regulation	0
of	0
VDR	9
and	0
establishment	0
of	0
reactivity	0
to	0
the	0
lipophilic	0
ligand	0
.	0

Treatment	0
of	0
B	7
lymphocytes	8
with	0
the	0
cytokine	9
IL-4	9
(	0
IL-4	9
)	0
,	0
in	0
the	0
absence	0
of	0
prior	0
activation	0
,	0
induces	0
a	0
weak	0
up-regulation	0
of	0
VDR	9
expression	0
but	0
fails	0
to	0
generate	0
vitamin	9
D-responsive	10
element	10
(	10
VDRE	10
)	10
-reactive	10
nuclear	10
protein	10
complexes	10
or	0
to	0
initiate	0
the	0
genomic	0
transcription	0
of	0
25-hydroxyvitamin	9
D3	10
24-hydroxylase	10
.	0

Stimulation	0
of	0
B	7
lymphocytes	8
by	0
either	0
ligation	0
of	0
CD40	9
Ag	10
or	0
cross-linking	0
the	0
Ig	9
receptor	10
is	0
also	0
insufficient	0
to	0
render	0
B	7
lymphocytes	8
responsive	0
to	0
1	0
alpha	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

However	0
,	0
this	0
apparent	0
lack	0
of	0
response	0
to	0
the	0
secosterol	0
can	0
be	0
overcome	0
by	0
stimulation	0
of	0
B	7
lymphocytes	8
with	0
a	0
combination	0
of	0
these	0
cellular	0
activation	0
signals	0
,	0
which	0
are	0
sufficient	0
to	0
lead	0
to	0
G1	0
cell	0
cycle	0
progression	0
.	0

In	0
the	0
presence	0
of	0
1	0
alpha	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
cellular	0
activation	0
associated	0
with	0
stimulation	0
of	0
such	0
a	0
progression	0
appears	0
to	0
be	0
sufficient	0
for	0
the	0
up-regulation	0
of	0
VDR	9
message	0
and	0
protein	0
and	0
necessary	0
for	0
the	0
establishment	0
of	0
VDRE	9
binding	10
complexes	10
and	0
the	0
induction	0
of	0
24-hydroxylase	9
message	0
.	0

Furthermore	0
,	0
biologic	0
functions	0
are	0
modulated	0
,	0
in	0
that	0
the	0
hormone	0
inhibits	0
proliferation	0
in	0
a	0
subset	0
of	0
the	0
activated	0
B	7
cells	8
.	0

These	0
observations	0
suggest	0
that	0
reactivity	0
to	0
1	0
alpha	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
is	0
tightly	0
regulated	0
in	0
B	7
lymphocytes	8
,	0
requiring	0
specific	0
signals	0
for	0
its	0
initiation	0
.	0

Cross	0
talk	0
between	0
cell	0
death	0
and	0
cell	0
cycle	0
progression	0
:	0
BCL-2	9
regulates	0
NFAT	9
-mediated	0
activation	0
.	0

BCL-2-deficient	5
T	6
cells	6
demonstrate	0
accelerated	0
cell	0
cycle	0
progression	0
and	0
increased	0
apoptosis	0
following	0
activation	0
.	0

Increasing	0
the	0
levels	0
of	0
BCL-2	9
retarded	0
the	0
G0	0
--	0
>	0
S	0
transition	0
,	0
sustained	0
the	0
levels	0
of	0
cyclin-dependent	9
kinase	10
inhibitor	0
p27Kip1	0
,	0
and	0
repressed	0
postactivation	0
death	0
.	0

Proximal	0
signal	0
transduction	0
events	0
and	0
immediate	1
early	2
gene	2
transcription	0
were	0
unaffected	0
.	0

However	0
,	0
the	0
transcription	0
and	0
synthesis	0
of	0
interleukin	9
2	10
and	0
other	0
delayed	0
early	0
cytokines	9
were	0
markedly	0
attenuated	0
by	0
BCL-2	9
.	0

In	0
contrast	0
,	0
a	0
cysteine	0
protease	0
inhibitor	0
that	0
also	0
blocks	0
apoptosis	0
had	0
no	0
substantial	0
affect	0
upon	0
cytokine	9
production	0
.	0

InterleUkin	9
2	10
expression	0
requires	0
several	0
transcription	9
factors	10
of	0
which	0
nuclear	0
translocation	0
of	0
NFAT	9
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
)	0
and	0
NFAT	9
-mediated	0
transactivation	0
were	0
impaired	0
by	0
BCL-2	9
.	0

Thus	0
,	0
select	0
genetic	0
aberrations	0
in	0
the	0
apoptotic	0
pathway	0
reveal	0
a	0
cell	0
autonomous	0
coregulation	0
of	0
activation	0
.	0

Interaction	0
of	0
the	0
human	9
T-cell	10
lymphotropic	10
virus	10
type	10
1	10
tax	10
transactivator	10
with	0
transcription	9
factor	10
IIA	10
.	0

The	0
Tax	9
protein	10
of	0
human	0
T-cell	0
lymphotropic	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
is	0
a	0
40-kDa	9
transcriptional	10
activator	10
which	0
is	0
critical	0
for	0
HTLV-1	0
gene	0
regulation	0
and	0
virus-induced	0
cellular	0
transformation	0
.	0

Tax	9
is	0
localized	0
to	0
the	0
DNA	0
through	0
its	0
interaction	0
with	0
the	0
site-specific	9
activators	10
cyclic	9
AMP-responsive	10
element-binding	10
protein	10
,	0
NF-kappaB	9
,	0
and	0
serum	9
response	10
factor	10
.	0

It	0
has	0
been	0
suggested	0
that	0
the	0
recruitment	0
of	0
Tax	9
to	0
the	0
DNA	0
positions	0
Tax	9
for	0
interaction	0
with	0
the	0
basal	0
transcriptional	0
machinery	0
.	0

On	0
the	0
basis	0
of	0
several	0
independent	0
assays	0
,	0
we	0
now	0
report	0
a	0
physical	0
and	0
functional	0
interaction	0
between	0
Tax	9
and	0
the	0
transcription	9
factor	10
,	0
TFIIA	9
.	0

First	0
,	0
Tax	9
was	0
found	0
to	0
interact	0
with	0
the	0
35-kDa	9
(	10
alpha	10
)	10
subunit	10
of	0
TFIIA	9
in	0
the	0
yeast	0
two-hybrid	0
interaction	0
system	0
.	0

Importantly	0
,	0
two	0
previously	0
characterized	0
mutants	9
with	0
point	0
mutations	0
in	0
Tax	9
,	0
M32	9
(	0
Y196A	0
,	0
K197S	0
)	0
and	0
M41	9
(	0
H287A	0
,	0
P288S	0
)	0
,	0
which	0
were	0
shown	0
to	0
be	0
defective	0
in	0
Tax	9
-activated	0
transcription	0
were	0
unable	0
to	0
interact	0
with	0
TFIIA	9
in	0
this	0
assay	0
.	0

Second	0
,	0
a	0
glutathione-S-transferase	0
(	0
GST	9
)	0
affinity-binding	0
assay	0
showed	0
that	0
the	0
interaction	0
of	0
holo-	0
TFIIA	9
with	0
GST-Tax	9
was	0
20-fold	0
higher	0
than	0
that	0
observed	0
with	0
either	0
the	0
GST-Tax	9
M32	10
activation	10
mutant	10
or	0
the	0
GST	0
control	0
.	0

Third	0
,	0
a	0
coimmunoprecipitation	0
assay	0
showed	0
that	0
in	0
HTLV-1-infected	5
human	6
T	6
lymphocytes	6
,	0
Tax	9
and	0
TFIIA	9
were	0
associated	0
.	0

Finally	0
,	0
TFIIA	9
facilitates	0
Tax	9
transactivation	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

In	0
vitro	0
transcription	0
studies	0
showed	0
reduced	0
levels	0
of	0
Tax	9
-activated	0
transcription	0
in	0
cell	0
extracts	0
depleted	0
of	0
TFIIA	9
.	0

In	0
addition	0
,	0
transfection	0
of	0
human	7
T	8
lymphocytes	8
with	0
TFIIA	1
expression	2
vectors	2
enhanced	0
Tax	9
-activated	0
transcription	0
of	0
an	0
HTLV-1	1
long	2
terminal	2
repeat-chloramphenicol	2
acetyltransferase	2
reporter	2
construct	2
.	0

Our	0
study	0
suggests	0
that	0
the	0
interaction	0
of	0
Tax	9
with	0
the	0
transcription	9
factor	10
TFIIA	9
may	0
play	0
a	0
role	0
in	0
Tax	9
-mediated	0
transcriptional	0
activation	0
.	0

Inhibition	0
of	0
transcription	9
factor	10
Stat1	9
activity	0
in	0
mononuclear	5
cell	6
cultures	6
and	0
T	7
cells	8
by	0
the	0
cyclic	0
AMP	0
signaling	0
pathway	0
.	0

Activation	0
of	0
T	7
cells	8
results	0
in	0
a	0
cascade	0
of	0
gene	0
activation	0
and	0
subsequent	0
proliferation	0
and	0
differentiation	0
into	0
effector	0
phenotypes	0
.	0

The	0
regulation	0
of	0
transcription	9
factors	10
belonging	0
to	0
the	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
family	10
was	0
analyzed	0
in	0
PHA-activated	5
mononuclear	6
cells	6
and	0
in	0
purified	5
T	6
cells	6
activated	0
by	0
cross-linking	0
cell	9
surface	10
CD3	10
.	0

Cell	0
activation	0
resulted	0
in	0
a	0
delayed	0
induction	0
of	0
STAT	9
DNA-binding	0
activity	0
,	0
which	0
was	0
sustained	0
for	0
several	0
days	0
,	0
was	0
composed	0
predominantly	0
of	0
Stat1	9
and	0
Stat3	9
,	0
and	0
was	0
blocked	0
by	0
cycloheximide	0
and	0
actinomycin	0
D	0
.	0

Increased	0
Stat1	0
and	0
Stat3	0
mRNA	0
and	0
protein	0
levels	0
were	0
detected	0
,	0
respectively	0
4	0
and	0
24	0
h	0
after	0
activation	0
.	0

Stimulation	0
of	0
the	0
cAMP	0
signal	0
transduction	0
pathway	0
,	0
which	0
skews	0
cytokine	9
production	0
toward	0
a	0
Th2	0
pattern	0
,	0
resulted	0
in	0
the	0
preferential	0
suppression	0
of	0
Stat1	9
activity	0
.	0

cAMP	0
inhibited	0
the	0
induction	0
of	0
expression	0
of	0
IL-2	9
receptor	10
components	10
,	0
but	0
did	0
not	0
inhibit	0
IL-4	9
receptor	10
alpha-chain	10
and	0
CD69	9
expression	0
or	0
the	0
induction	0
of	0
activator	9
protein	10
1	10
transcription	10
factors	10
.	0

cAMP	0
signaling	0
inhibited	0
Stat1	9
at	0
several	0
different	0
levels	0
,	0
including	0
suppression	0
of	0
DNA	0
binding	0
and	0
down-regulation	0
of	0
Stat1	0
protein	0
and	0
mRNA	0
levels	0
.	0

Our	0
results	0
demonstrate	0
the	0
regulation	0
of	0
STAT	9
activity	0
by	0
a	0
signaling	0
pathway	0
that	0
regulates	0
the	0
T	0
cell	0
functional	0
phenotype	0
and	0
is	0
distinct	0
from	0
the	0
cytokine	9
-activated	0
Janus	9
kinase	10
-STAT	9
signaling	0
pathway	0
.	0

Suppression	0
of	0
c-jun	1
by	0
antisense	0
oligonucleotides	0
inhibits	0
cell	0
adhesion	0
but	0
not	0
respiratory	0
burst	0
during	0
phorbol	0
ester-induced	0
differentiation	0
of	0
U937	5
human	6
monoblastic	6
cells	6
.	0

We	0
studied	0
the	0
role	0
of	0
the	0
immediate	1
early	2
gene	2
c-jun	1
in	0
cell	0
proliferation	0
and	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
-induced	0
differentiation	0
in	0
U937	5
human	6
monoblastic	6
cells	6
,	0
using	0
c-jun	1
-specific	0
antisense	0
(	0
AS	0
)	0
phosphorothioate	0
oligonucleotides	0
.	0

In	0
selecting	0
the	0
most	0
specific	0
and	0
potent	0
oligonucleotide	0
sequence	0
,	0
we	0
performed	0
extensive	0
analyses	0
for	0
the	0
binding	0
specificity	0
between	0
all	0
candidates	0
of	0
c-jun	1
AS	0
oligonucleotides	0
and	0
the	0
whole	0
sequences	0
in	0
GenBank	0
database	0
,	0
using	0
a	0
computer	0
program	0
.	0

Among	0
the	0
20	0
selected	0
oligonucleotides	0
,	0
two	0
potent	0
15-mer	0
AS	0
oligonucleotides	0
(	0
C-JUN	0
AS	0
oligonucleotides	0
)	0
exhibited	0
significant	0
inhibition	0
of	0
cell	0
growth	0
in	0
a	0
dose-dependent	0
manner	0
between	0
2	0
and	0
10	0
microM	0
.	0

Reverse	0
transcription-PCR	0
and	0
Western	0
blot	0
analysis	0
demonstrated	0
that	0
10	0
microM	0
of	0
C-JUN	0
AS	0
oligonucleotides	0
reduced	0
c-jun	1
expression	0
at	0
both	0
the	0
mRNA	3
and	0
protein	0
levels	0
.	0

More	0
importantly	0
,	0
C-JUN	0
AS	0
oligonucleotides	0
showed	0
distinct	0
effects	0
on	0
two	0
markers	0
of	0
PMA-induced	0
differentiation	0
;	0
the	0
C-JUN	0
AS	0
oligonucleotides	0
inhibited	0
cell	0
adhesion	0
,	0
whereas	0
they	0
did	0
not	0
affect	0
another	0
marker	0
of	0
differentiation	0
,	0
respiratory	0
burst	0
(	0
measured	0
by	0
nitro	0
blue	0
tetrazolium	0
reduction	0
assay	0
)	0
.	0

These	0
results	0
suggest	0
a	0
critical	0
role	0
of	0
c-jun	1
in	0
both	0
cell	0
proliferation	0
and	0
PMA-induced	0
cell	0
adhesion	0
but	0
not	0
in	0
PMA-induced	0
respiratory	0
burst	0
in	0
U937	5
cells	6
.	0

Effects	0
of	0
IL-10	9
and	0
IL-4	9
on	0
LPS-induced	0
transcription	9
factors	10
(	0
AP-1	9
,	0
NF-IL6	9
and	0
NF-kappa	9
B	10
)	0
which	0
are	0
involved	0
in	0
IL-6	9
regulation	0
.	0

Interleukin-10	9
(	0
IL-10	9
)	0
,	0
like	0
IL-4	9
,	0
is	0
known	0
to	0
inhibit	0
cytokine	9
expression	0
in	0
activated	7
human	8
monocytes	8
.	0

We	0
showed	0
that	0
both	0
IL-10	9
and	0
IL-4	9
inhibit	0
LPS-induced	3
IL-6	4
mRNA	4
and	0
protein	0
expression	0
by	0
inhibiting	0
the	0
transcription	0
rate	0
of	0
the	0
IL-6	1
gene	2
.	0

The	0
strong	0
inhibition	0
of	0
the	0
IL-6	9
transcription	0
rate	0
prompted	0
us	0
to	0
study	0
the	0
effect	0
of	0
IL-10	9
and	0
IL-4	9
on	0
the	0
expression	0
of	0
transcription	9
factors	10
.	0

We	0
questioned	0
whether	0
or	0
not	0
IL-10	9
and	0
IL-4	9
affected	0
the	0
expression	0
of	0
transcription	9
factors	10
that	0
are	0
known	0
to	0
be	0
involved	0
in	0
the	0
control	0
of	0
the	0
IL-6	9
transcription	0
rate	0
,	0
namely	0
activator	0
protein-1	0
(	0
AP-1	9
)	0
,	0
nuclear	9
factor	10
IL-6	9
(	0
NF-IL6	9
)	0
,	0
and	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappaB	9
)	0
.	0

In	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
we	0
showed	0
that	0
IL-10	9
and	0
IL-4	9
inhibited	0
LPS-induced	0
AP-1	9
binding	0
activity	0
.	0

The	0
inhibiting	0
effect	0
of	0
IL-4	9
was	0
slightly	0
more	0
pronounced	0
than	0
that	0
of	0
IL-10	9
.	0

Downregulation	0
of	0
LPS-induced	9
AP-1	10
was	0
accompanied	0
,	0
and	0
thus	0
possibly	0
explained	0
,	0
by	0
a	0
reduced	0
expression	0
at	0
mRNA	3
level	0
of	0
the	0
two	0
major	0
components	0
of	0
the	0
AP-1	9
complex	10
,	0
namely	0
c-fos	1
and	0
c-jun	1
as	0
determined	0
by	0
Northern	0
experiments	0
.	0

Binding	0
activity	0
of	0
NF-IL6	9
was	0
also	0
strongly	0
inhibited	0
by	0
IL-4	9
whereas	0
IL-10	9
showed	0
no	0
effect	0
.	0

NF-IL6	3
mRNA	4
levels	0
were	0
not	0
affected	0
by	0
IL-10	9
or	0
IL-4	9
,	0
suggesting	0
that	0
IL-4	9
affects	0
binding	0
activity	0
of	0
preexisting	0
NF-IL6	9
.	0

Neither	0
IL-10	9
nor	0
IL-4	9
inhibited	0
LPS-induced	0
NF-kappa	9
B	10
binding	0
activity	0
.	0

In	0
agreement	0
with	0
this	0
finding	0
,	0
Northern	0
experiments	0
where	0
p65	0
and	0
p105	0
mRNA	0
levels	0
were	0
determined	0
,	0
demonstrated	0
that	0
expression	0
of	0
these	0
components	0
of	0
the	0
NF-kappa	9
B	10
transcription	0
factor	0
were	0
not	0
affected	0
by	0
IL-10	9
or	0
IL-4	9
.	0

Furthermore	0
,	0
neither	0
IL-10	9
nor	0
IL-4	9
showed	0
any	0
effect	0
on	0
I-kappa	3
B	4
mRNA	4
expression	0
as	0
determined	0
by	0
Northern	0
experiments	0
.	0

Thus	0
,	0
IL-10	9
and	0
IL-4	9
similarly	0
affect	0
IL-6	9
expression	0
.	0

However	0
,	0
for	0
IL-4	9
this	0
was	0
accompanied	0
with	0
a	0
reduction	0
of	0
AP-1	0
and	0
NF-IL6	0
binding	0
activity	0
whereas	0
IL-10	9
only	0
inhibited	0
AP-1	9
binding	0
activity	0
.	0

Regulation	0
of	0
GM-CSF	1
gene	2
transcription	0
by	0
core-binding	9
factor	10
.	0

GM-CSF	1
gene	2
activation	0
in	0
T	7
cells	8
is	0
known	0
to	0
involve	0
the	0
transcription	9
factors	10
nuclear	9
factor-kappa	10
B	10
,	0
AP-1	9
,	0
NFAT	9
,	0
and	0
Sp1	0
.	0

Here	0
we	0
demonstrate	0
that	0
the	0
human	1
GM-CSF	2
promoter	2
and	2
enhancer	2
also	0
encompass	0
binding	0
sites	0
for	0
core-binding	9
factor	10
(	0
CBF	9
)	0
.	0

Significantly	0
,	0
the	0
CBF	1
sites	2
are	0
in	0
each	0
case	0
contained	0
within	0
the	0
minimum	0
essential	1
core	2
regions	2
required	0
for	0
inducible	0
activation	0
of	0
transcription	0
.	0

Furthermore	0
,	0
these	0
core	0
regions	0
of	0
the	0
enhancer	0
and	0
promoter	0
each	0
encompass	0
closely	1
linked	2
binding	2
sites	2
for	0
CBF	9
,	0
AP-1	9
,	0
and	0
NFATp	9
.	0

The	0
GM-CSF	1
promoter	2
CBF	2
site	2
TGTGGTCA	0
is	0
located	0
51	1
bp	2
upstream	2
of	0
the	0
transcription	1
start	2
site	2
and	0
also	0
overlaps	0
a	0
YY-1	1
binding	2
site	2
.	0

A	0
2-bp	1
mutation	2
within	0
the	0
CBF	9
site	0
resulted	0
in	0
a	0
2-3-fold	0
decrease	0
in	0
the	0
activities	0
of	0
both	0
a	0
69-bp	1
proximal	2
promoter	2
fragment	2
and	0
a	0
627-bp	1
full-length	2
promoter	2
fragment	2
.	0

Stepwise	0
deletions	0
into	0
the	0
proximal	1
promoter	2
also	0
revealed	0
that	0
the	0
CBF	9
site	0
,	0
but	0
not	0
the	0
YY-1	1
site	2
,	0
was	0
required	0
for	0
efficient	0
induction	0
of	0
transcriptional	0
activation	0
.	0

The	0
AML1	1
and	2
CBF	2
beta	2
genes	2
that	0
encode	0
CBF	9
each	0
have	0
the	0
ability	0
to	0
influence	0
cell	0
growth	0
and	0
differentiation	0
and	0
have	0
been	0
implicated	0
as	0
proto-oncogenes	1
in	0
acute	0
myeloid	0
leukemia	0
.	0

This	0
study	0
adds	0
GM-CSF	9
to	0
a	0
growing	0
list	0
of	0
cytokines	9
and	0
receptors	0
that	0
are	0
regulated	0
by	0
CBF	9
and	0
which	0
control	0
the	0
growth	0
,	0
differentiation	0
,	0
and	0
activation	0
of	0
hemopoietic	7
cells	8
.	0

The	0
GM-CSF	1
locus	2
may	0
represent	0
one	0
of	0
several	0
target	0
genes	9
that	0
are	0
dysregulated	0
in	0
acute	0
myeloid	0
leukemia	0
.	0

Sublethal	0
levels	0
of	0
oxidative	0
stress	0
stimulate	0
transcriptional	0
activation	0
of	0
c-jun	1
and	0
suppress	0
IL-2	1
promoter	2
activation	0
in	0
Jurkat	5
T	6
cells	6
.	0

Sublethal	0
levels	0
of	0
oxidative	0
stress	0
are	0
well	0
known	0
to	0
alter	0
T	0
cell	0
functional	0
responses	0
,	0
but	0
the	0
underlying	0
mechanisms	0
are	0
unknown	0
.	0

The	0
current	0
study	0
examined	0
the	0
effects	0
of	0
oxidative	0
stress	0
on	0
transcriptional	0
activities	0
mediated	0
by	0
c-Fos/c-Jun	9
AP-1	9
and	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
.	0

The	0
present	0
results	0
show	0
that	0
Jurkat	5
T	6
cells	6
acutely	0
exposed	0
to	0
micromolar	0
concentrations	0
of	0
H2O2	0
exhibit	0
substantial	0
increases	0
in	0
AP-1	9
binding	0
activity	0
and	0
the	0
expression	0
of	0
c-jun	1
but	0
not	0
c-fos	3
mRNA	4
.	0

The	0
preferential	0
induction	0
of	0
c-jun	1
by	0
H2O2	0
did	0
not	0
represent	0
redox	0
stabilization	0
of	0
mRNA	3
transcripts	4
,	0
and	0
oxidative	0
signals	0
closely	0
resembled	0
PHA/PMA	0
stimulation	0
by	0
effectively	0
transactivating	0
the	0
full	0
length	0
c-jun	1
promoter	0
via	0
the	0
proximal	1
jun1	2
tumor	2
promoter-responsive	2
element	2
(	2
TRE	2
)	2
-like	2
promoter	2
element	2
.	0

Similarly	0
,	0
the	0
complexes	0
binding	0
the	0
consensus	1
AP-1	2
TRE	2
and	0
jun	1
TRE-like	2
motifs	2
in	0
cells	0
exposed	0
to	0
oxidative	0
signals	0
or	0
PHA/PMA	0
were	0
indistinguishable	0
,	0
being	0
composed	0
of	0
c-Fos	9
,	0
c-Jun	9
,	0
and	0
JunD	9
.	0

However	0
,	0
PHA/PMA	0
but	0
not	0
oxidative	0
signals	0
induced	0
the	0
coordinate	0
activation	0
of	0
reporter	1
constructs	2
containing	0
the	0
AP-1-TRE	1
,	2
NF-AT	2
,	2
and	2
IL-2	2
promoter	2
regions	2
along	0
with	0
IL-2	3
mRNA	4
expression	0
.	0

Furthermore	0
,	0
sublethal	0
levels	0
of	0
H2O2	0
actively	0
suppressed	0
the	0
transcriptional	0
activation	0
of	0
NF-AT	9
and	0
IL-2	1
reporters	2
as	0
well	0
as	0
the	0
expression	0
of	0
IL-2	3
mRNA	4
in	0
cells	0
stimulated	0
with	0
PHA/PMA	0
.	0

Gel	0
shift	0
analysis	0
revealed	0
that	0
oxidative	0
suppression	0
of	0
NF-AT	9
represented	0
inhibition	0
in	0
the	0
early	0
generation	0
of	0
NFAT	9
complexes	10
rather	0
than	0
the	0
binding	0
of	0
preformed	0
NF-AT	9
complexes	10
.	0

These	0
results	0
suggest	0
that	0
oxidative	0
signals	0
can	0
positively	0
and	0
negatively	0
regulate	0
T	7
cell	8
transcriptional	0
events	0
and	0
that	0
changes	0
in	0
cellular	0
redox	0
can	0
uncouple	0
AP-1	9
regulation	0
of	0
c-jun	1
from	0
transcriptional	0
up-regulation	0
of	0
IL-2	9
via	0
NF-AT	9
.	0

Inorganic	0
lead	0
activates	0
NF-kappa	9
B	10
in	0
primary	7
human	8
CD4+	8
T	8
lymphocytes	8
.	0

Inorganic	0
lead	0
(	0
Pb	0
)	0
is	0
a	0
ubiquitous	0
environmental	0
contaminant	0
that	0
produces	0
a	0
variety	0
of	0
effects	0
on	0
humoral	0
and	0
cell	0
mediated	0
immune	0
responses	0
.	0

The	0
underlying	0
molecular	0
mechanism	0
for	0
Pb	0
's	0
complex	0
effects	0
on	0
the	0
immune	0
system	0
remain	0
obscure	0
.	0

Many	0
of	0
Pb	0
's	0
effects	0
on	0
the	0
immune	0
system	0
could	0
be	0
explained	0
through	0
activation	0
of	0
the	0
transcription	9
factor	10
,	0
NF-kappa	9
B	10
.	0

NF-kappa	9
B	10
is	0
critical	0
for	0
T	0
lymphocyte	0
function	0
and	0
is	0
a	0
strong	0
inducer	0
of	0
HIV-LTR	1
activation	0
.	0

We	0
demonstrate	0
that	0
Pb	0
at	0
physiologically	0
relevant	0
concentrations	0
activates	0
NF-kappa	9
B	10
in	0
primary	7
human	8
CD4+	8
T	8
lymphocytes	8
.	0

Pb-induced	0
activation	0
of	0
NF-kappa	9
B	10
is	0
blocked	0
by	0
antibodies	9
for	0
p65	9
and	0
p50	9
subunits	0
but	0
not	0
cRel	9
,	0
indicating	0
that	0
the	0
p65	9
:	10
p50	10
heterodimer	10
(	0
NF-kappa	9
B	10
)	0
is	0
involved	0
.	0

Functional	0
activation	0
of	0
gene	0
expression	0
by	0
Pb	0
was	0
confirmed	0
using	0
primary	5
CD4+	6
T	6
cells	6
transfected	0
with	0
an	0
NF-kappa	1
B	2
dependent	2
reporter	2
gene	2
construct	2
.	0

Pb	0
did	0
not	0
activate	0
NF-kappa	9
B	10
in	0
4	0
different	0
T	5
cell	6
lines	6
,	0
suggesting	0
that	0
lymphoid	0
cell	0
lines	0
may	0
not	0
be	0
reliable	0
surrogates	0
for	0
the	0
study	0
of	0
transcriptional	0
activation	0
in	0
human	7
T	8
cells	8
.	0

These	0
data	0
suggest	0
that	0
NF-kappa	9
B	10
may	0
be	0
an	0
important	0
molecular	0
mediator	0
of	0
Pb-induced	0
immunotoxicity	0
.	0

Tyrosine	9
kinase	10
and	0
cAMP-dependent	9
protein	10
kinase	10
activities	0
in	0
CD40-activated	5
human	6
B	6
lymphocytes	6
.	0

In	0
vitro	0
,	0
human	7
B	8
lymphocytes	8
undergo	0
long-term	0
proliferation	0
when	0
activated	0
through	0
CD40	9
,	0
a	0
protein	0
expressed	0
on	0
their	0
cell	0
surface	0
.	0

The	0
nature	0
of	0
CD40	9
-dependent	0
signals	0
in	0
proliferating	0
fresh	0
human	5
Epstein-Barr	6
virus-negative	6
B	6
lymphocytes	6
is	0
currently	0
unknown	0
.	0

In	0
this	0
study	0
,	0
a	0
CD40	9
-dependent	0
B	0
cell	0
culture	0
system	0
was	0
used	0
to	0
examine	0
the	0
role	0
of	0
different	0
signal	1
transduction	2
elements	2
.	0

Protein	0
kinase	0
C	0
(	0
PKC	9
)	0
depletion	0
generated	0
by	0
a	0
long-term	0
phorbol	0
12	0
myristate	0
13-acetate	0
treatment	0
had	0
weak	0
effects	0
on	0
proliferation	0
.	0

Rather	0
,	0
tyrosine	0
phosphorylation	0
was	0
shown	0
to	0
be	0
directly	0
involved	0
in	0
mediating	0
CD40	9
-dependent	0
signals	0
.	0

The	0
use	0
of	0
the	0
protein	9
tyrosine	10
kinase	10
(	0
PTK	9
)	0
-specific	0
inhibitor	0
herbimycin	0
A	0
dramatically	0
decreased	0
cellular	0
proliferation	0
without	0
altering	0
the	0
activity	0
of	0
the	0
human	1
immunodeficiency	2
virus-1	2
long	2
terminal	2
repeat	2
(	0
HIV-1	1
LTR	2
)	0
,	0
a	0
promoter	1
largely	0
dependent	0
on	0
the	0
binding	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-	9
kappa	10
B	10
)	0
.	0

In	0
contrast	0
,	0
the	0
cAMP-dependent	9
protein	10
kinase	10
specific	0
inhibitor	0
H-89	0
totally	0
inhibited	0
HIV-1	1
LTR	2
activity	0
at	0
a	0
concentration	0
as	0
low	0
as	0
100	0
nM	0
without	0
affecting	0
cellular	0
proliferation	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
and	0
supershift	0
assay	0
using	0
an	0
NF-kappa	1
B	2
binding	2
sequence	2
from	0
the	0
kappa	9
light	10
chain	10
as	0
a	0
probe	0
,	0
revealed	0
that	0
both	0
p65	9
(	0
RelA	9
)	0
and	0
c-Rel	9
were	0
present	0
in	0
CD40-stimulated	7
B	8
cells	8
.	0

While	0
PKC	9
depletion	0
did	0
not	0
alter	0
the	0
NF-kappa	9
B	10
level	0
,	0
treatment	0
of	0
B	7
lymphocytes	8
with	0
H-89	0
or	0
herbimycin	0
A	0
provoked	0
a	0
decrease	0
in	0
the	0
NF-kappa	9
B	10
level	0
.	0

These	0
observations	0
establish	0
the	0
importance	0
of	0
different	0
signal	0
transducing	0
pathways	0
leading	0
to	0
CD40	9
activation	0
of	0
B	7
lymphocytes	8
.	0

Interferons	9
induce	0
normal	0
and	0
aberrant	0
retinoic-acid	9
receptors	10
type	10
alpha	10
in	0
acute	7
promyelocytic	8
leukemia	8
cells	8
:	0
potentiation	0
of	0
the	0
induction	0
of	0
retinoid-dependent	0
differentiation	9
markers	10
.	0

Treatment	0
of	0
the	0
acute	5
promyelocytic	6
(	6
APL	6
)	6
cell	6
line	6
NB4	5
with	0
interferon	9
alpha	10
(	0
IFN	9
(	10
alpha	10
)	10
)	0
,	0
as	0
well	0
as	0
IFN	9
(	10
beta	10
)	10
and	10
gamma	10
,	0
results	0
in	0
an	0
increased	0
expression	0
of	0
the	0
transcripts	0
coding	0
for	0
retinoic-acid	9
receptor	10
type	10
alpha	10
(	0
RAR	9
(	10
alpha	10
)	10
)	0
and	0
the	0
leukemia-specific	9
retinoic	10
acid	10
receptor	10
PML-RAR	9
.	0

Transcriptional	0
induction	0
of	0
the	0
RAR	3
(	4
alpha	4
)	4
and	4
PML-RAR	4
mRNAs	4
is	0
rapid	0
and	0
it	0
is	0
parallelled	0
by	0
an	0
increase	0
in	0
the	0
corresponding	0
proteins	0
.	0

Up-regulation	0
of	0
RAR	9
(	10
alpha	10
)	10
and	0
PML-RAR	9
gene	0
expression	0
by	0
IFN	9
(	10
alpha	10
)	10
is	0
accompanied	0
by	0
a	0
strong	0
potentiation	0
in	0
the	0
induction	0
of	0
2	0
retinoid-dependent	9
granulocytic	10
markers	10
,	0
i.e.	0
,	0
granulocyte-colony-stimulating	3
factor	4
receptor	4
mRNA	4
and	0
leukocyte	9
alkaline	10
phosphatase	10
.	0

However	0
,	0
IFN	9
(	10
alpha	10
)	10
does	0
not	0
have	0
any	0
effects	0
on	0
the	0
retinoid-dependent	0
regulation	0
of	0
the	0
myeloid	9
surface	10
markers	10
CD11b	9
and	0
CD33	9
.	0

The	0
IFN	9
-dependent	0
increase	0
in	0
RAR	9
(	10
alpha	10
)	10
levels	0
and	0
the	0
enhancing	0
effect	0
of	0
the	0
cytokine	9
on	0
retinoid-dependent	9
granulocytic	10
markers	10
expression	0
may	0
be	0
a	0
characteristic	0
of	0
PML-RAR	5
positive	6
cells	6
,	0
since	0
the	0
phenomena	0
are	0
not	0
observed	0
in	0
HL-60	5
promyelocytes	6
.	0

Interferons	9
as	0
well	0
as	0
retinoids	0
inhibit	0
the	0
growth	0
of	0
NB4	5
cells	6
,	0
although	0
the	0
2	0
classes	0
of	0
compounds	0
do	0
not	0
significantly	0
interact	0
in	0
terms	0
of	0
anti-proliferative	0
activity	0
.	0

These	0
results	0
suggest	0
the	0
possible	0
use	0
of	0
combinations	0
between	0
IFNs	9
and	0
retinoic	0
acid	0
in	0
the	0
cyto-differentiating	0
treatment	0
of	0
APL	0
patients	0
.	0

Modulatory	0
effects	0
of	0
glucocorticoids	0
and	0
catecholamines	0
on	0
human	0
interleukin	9
-12	0
and	0
interleukin	9
-10	0
production	0
:	0
clinical	0
implications	0
.	0

Interleukin-12	9
(	0
IL-12	9
)	0
is	0
a	0
key	0
inducer	0
of	0
differentiation	0
of	0
uncommitted	7
T	8
helper	8
(	8
TH	8
)	8
cells	8
toward	0
the	0
TH1	0
phenotype	0
,	0
which	0
regulates	0
cellular	0
immunity	0
,	0
whereas	0
IL-10	9
inhibits	0
TH1	0
functions	0
and	0
potentiates	0
TH2-regulated	0
responses	0
(	0
i.e.	0
,	0
humoral	0
immunity	0
)	0
.	0

To	0
examine	0
the	0
potential	0
effects	0
of	0
stress	0
on	0
TH1/TH2	0
balance	0
,	0
we	0
studied	0
the	0
ability	0
of	0
three	0
prototype	0
stress	0
hormones-dexamethasone	0
(	0
a	0
synthetic	0
glucocorticoid	0
)	0
and	0
the	0
catecholamines	0
norepinephrine	0
and	0
epinephrine-to	0
alter	0
the	0
production	0
of	0
IL-12	9
(	0
p70	9
)	0
and	0
IL-10	9
induced	0
by	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
in	0
human	0
whole	0
blood	0
.	0

Dexamethasone	0
inhibited	0
LPS-induced	0
bioactive	0
IL-12	9
production	0
in	0
a	0
dose-dependent	0
fashion	0
and	0
at	0
physiologically	0
relevant	0
concentrations	0
;	0
it	0
had	0
no	0
effect	0
on	0
IL-10	9
secretion	0
.	0

The	0
glucocorticoid-induced	0
reduction	0
of	0
IL-12	9
production	0
was	0
antagonized	0
by	0
RU	0
486	0
,	0
a	0
glucocorticoid-receptor	0
antagonist	0
,	0
suggesting	0
that	0
it	0
was	0
mediated	0
by	0
the	0
glucocorticoid	0
receptor	0
.	0

Norepinephrine	0
and	0
epinephrine	0
also	0
suppressed	0
IL-12	9
production	0
in	0
a	0
dose-dependent	0
fashion	0
and	0
at	0
physiological	0
concentrations	0
;	0
both	0
catecholamines	0
,	0
however	0
,	0
dose-dependently	0
increased	0
the	0
production	0
of	0
IL-10	9
.	0

The	0
effects	0
of	0
either	0
catecholamine	0
on	0
IL-12	9
or	0
IL-10	9
secretion	0
were	0
blocked	0
completely	0
by	0
propranolol	0
,	0
a	0
beta-adrenoreceptor	0
antagonist	0
,	0
indicating	0
that	0
they	0
were	0
mediated	0
by	0
the	0
beta-adrenergic	9
receptor	10
.	0

These	0
findings	0
suggest	0
that	0
the	0
central	0
nervous	0
system	0
may	0
regulate	0
IL-12	0
and	0
IL-10	0
secretion	0
and	0
,	0
hence	0
,	0
TH1/TH2	0
balance	0
via	0
the	0
peripheral	0
end-effectors	0
of	0
the	0
stress	0
system	0
.	0

Thus	0
,	0
stress	0
may	0
cause	0
a	0
selective	0
suppression	0
of	0
TH1	0
functions	0
and	0
a	0
shift	0
toward	0
a	0
TH2	9
cytokine	10
pattern	0
rather	0
than	0
generalized	0
TH	0
suppression	0
.	0

The	0
TH1-to-TH2	0
shift	0
may	0
be	0
responsible	0
for	0
the	0
stress-induced	0
susceptibility	0
of	0
the	0
organism	0
to	0
certain	0
infections	0
.	0

Through	0
the	0
same	0
or	0
a	0
reciprocal	0
mechanism	0
,	0
states	0
associated	0
with	0
chronic	0
hyperactivity	0
or	0
hypoactivity	0
of	0
the	0
stress	0
system	0
might	0
influence	0
the	0
susceptibility	0
of	0
an	0
individual	0
to	0
certain	0
autoimmune	0
,	0
allergic	0
,	0
infectious	0
,	0
or	0
neoplastic	0
diseases	0
.	0

Activation	0
of	0
human	7
monocytic	8
cells	8
by	0
Treponema	9
pallidum	10
and	10
Borrelia	10
burgdorferi	10
lipoproteins	10
and	0
synthetic	0
lipopeptides	0
proceeds	0
via	0
a	0
pathway	0
distinct	0
from	0
that	0
of	0
lipopolysaccharide	0
but	0
involves	0
the	0
transcriptional	0
activator	0
NF-kappa	9
B	10
.	0

There	0
is	0
increasing	0
evidence	0
that	0
lipoproteins	9
of	0
Treponema	0
pallidum	0
and	0
Borrelia	0
burgdorferi	0
are	0
key	0
inflammatory	0
mediators	0
during	0
syphilis	0
and	0
Lyme	0
disease	0
.	0

A	0
principal	0
objective	0
of	0
the	0
present	0
study	0
was	0
to	0
identify	0
more	0
precisely	0
similarities	0
and	0
divergences	0
among	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-	0
and	0
lipoprotein-lipopeptide-induced	0
immune	0
cell	0
signaling	0
events	0
.	0

Like	0
LPS	0
,	0
purified	9
native	10
B.	10
burgdorferi	10
OspA	10
and	0
synthetic	0
analogs	0
of	0
OspA	9
,	0
OspB	9
,	0
and	0
two	0
T.	9
pallidum	10
lipoproteins	10
(	0
Tpp47	9
and	0
Tpp17	9
)	0
all	0
induced	0
NF-kappa	9
B	10
translocation	0
in	0
THP-1	7
human	8
monocytoid	8
cells	8
.	0

Acylation	0
of	0
OspA	9
and	0
the	0
synthetic	0
peptides	0
was	0
requisite	0
for	0
cell	0
activation	0
.	0

Polymyxin	0
B	0
abrogated	0
only	0
the	0
response	0
to	0
LPS	0
.	0

By	0
using	0
70Z/3-derived	5
pre-B-cell	6
lines	6
either	0
lacking	0
or	0
expressing	0
human	9
CD14	10
(	0
the	0
LPS	9
receptor	10
)	0
,	0
it	0
was	0
observed	0
that	0
expression	0
of	0
human	9
CD14	10
imparted	0
responsiveness	0
to	0
LPS	0
but	0
not	0
to	0
OspA	9
or	0
spirochetal	9
lipopeptides	10
(	0
assessed	0
by	0
induction	0
of	0
NF-kappa	9
B	10
and	0
expression	0
of	0
surface	9
immunoglobulin	10
M	10
)	0
.	0

Finally	0
,	0
the	0
biological	0
relevance	0
of	0
the	0
observation	0
that	0
T.	9
pallidum	10
lipoproteins	10
-lipopeptides	0
induce	0
both	0
NF-kappa	9
B	10
and	0
cytokine	9
production	0
in	0
monocytes	7
was	0
supported	0
by	0
the	0
ability	0
of	0
the	0
synthetic	0
analogs	0
to	0
promote	0
human	0
immunodeficiency	0
virus	0
replication	0
in	0
chronically	0
infected	0
U1	0
monocytoid	0
cells	0
;	0
these	0
observations	0
also	0
suggest	0
a	0
potential	0
mechanism	0
whereby	0
a	0
syphilitic	0
chancre	0
can	0
serve	0
as	0
a	0
cofactor	0
for	0
human	0
immunodeficiency	0
virus	0
transmission	0
.	0

The	0
combined	0
data	0
lend	0
additional	0
support	0
to	0
the	0
proposal	0
that	0
spirochetal	9
lipoproteins	10
and	0
LPS	0
initiate	0
monocyte	0
activation	0
via	0
different	0
cell	0
surface	0
events	0
but	0
that	0
the	0
signaling	0
pathways	0
ultimately	0
converge	0
to	0
produce	0
qualitatively	0
similar	0
cellular	0
responses	0
.	0

LYSP100	9
-associated	0
nuclear	0
domains	0
(	0
LANDs	0
)	0
:	0
description	0
of	0
a	0
new	0
class	0
of	0
subnuclear	0
structures	0
and	0
their	0
relationship	0
to	0
PML	0
nuclear	0
bodies	0
.	0

The	0
PML	1
gene	2
is	0
fused	0
to	0
the	0
retinoic	1
acid	2
receptor	2
alpha	2
(	2
RAR	2
alpha	2
)	2
gene	2
in	0
t	0
(	0
15	0
;	0
17	0
)	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
,	0
creating	0
a	0
PML-RAR	9
alpha	10
fusion	10
oncoprotein	10
.	0

The	0
PML	9
gene	10
product	10
has	0
been	0
localized	0
to	0
subnuclear	5
dot-like	6
structures	6
variously	0
termed	0
PODs	0
,	0
ND10s	0
,	0
Kr	0
bodies	0
,	0
or	0
PML	0
nuclear	0
bodies	0
(	0
PML	0
NBs	0
)	0
.	0

The	0
present	0
study	0
describes	0
the	0
cloning	0
of	0
a	0
lymphoid-restricted	1
gene	2
,	0
LYSP100	1
,	0
that	0
is	0
homologous	0
to	0
another	0
protein	0
that	0
localizes	0
to	0
PML	0
NBs	0
,	0
SP100	9
.	0

In	0
addition	0
to	0
SP100	1
homology	2
regions	2
,	0
one	0
LYSP100	1
cDNA	2
isoform	2
contains	0
a	0
bromodomain	9
and	0
a	0
PHD/TTC	9
domain	10
,	0
which	0
are	0
present	0
in	0
a	0
variety	0
of	0
transcriptional	9
regulatory	10
proteins	10
.	0

By	0
immunofluorescence	0
,	0
LYSP100	1
was	0
localized	0
to	0
nuclear	0
dots	0
that	0
were	0
surprisingly	0
largely	0
nonoverlapping	0
with	0
PML	0
NBs	0
.	0

However	0
,	0
a	0
minority	0
of	0
LYSP100	1
nuclear	0
dots	0
exactly	0
colocalized	0
with	0
PML	7
and	0
SP100	9
.	0

We	0
term	0
the	0
LYSP100	1
structures	0
``	0
LANDs	0
,	0
''	0
for	0
LYSP100	1
-associated	0
nuclear	0
domains	0
.	0

Although	0
LYSP100	1
is	0
expressed	0
only	0
in	0
lymphoid	7
cells	8
,	0
LANDs	0
could	0
be	0
visualized	0
in	0
HeLa	5
cells	6
by	0
transfection	0
of	0
a	0
LYSP100	1
cDNA	2
.	0

Immunoelectron	0
microscopy	0
revealed	0
LANDs	0
to	0
be	0
globular	0
,	0
electron-dense	0
structures	0
morphologically	0
distinct	0
from	0
the	0
annular	0
structures	0
characteristic	0
of	0
PML	0
NBs	0
.	0

LANDs	0
were	0
most	0
often	0
found	0
in	0
the	0
nucleoplasm	0
,	0
but	0
were	0
also	0
found	0
at	0
the	0
nuclear	0
membrane	0
and	0
in	0
the	0
cytoplasm	0
,	0
suggesting	0
that	0
these	0
structures	0
may	0
traffic	0
between	0
the	0
cytoplasm	0
and	0
the	0
nucleus	0
.	0

By	0
double-immunogold	0
labeling	0
of	0
PML	7
and	0
LYSP100	1
,	0
some	0
LANDs	0
were	0
shown	0
to	0
contain	0
both	0
PML	7
and	0
LYSP100	1
.	0

Thus	0
,	0
PML	7
is	0
localized	0
to	0
a	0
second	0
subnuclear	0
domain	0
that	0
is	0
morphologically	0
and	0
biochemically	0
distinct	0
from	0
PML	7
NBs	0
.	0

Transcriptional	0
control	0
of	0
steroid-regulated	0
apoptosis	0
in	0
murine	7
thymoma	8
cells	8
.	0

Early	0
studies	0
in	0
murine	0
T	5
cell	6
lines	6
indicated	0
that	0
transcriptional	0
transactivation	0
functions	0
encoded	0
in	0
the	0
glucocorticoid	9
receptor	10
(	10
GR	10
)	10
N-terminal	10
domain	10
are	0
required	0
for	0
glucocorticoid-mediated	0
apoptosis	0
.	0

However	0
,	0
more	0
recent	0
studies	0
in	0
human	5
T	6
cell	6
lines	6
have	0
suggested	0
that	0
the	0
N-terminal	9
domain	10
is	0
not	0
necessary	0
for	0
steroid-regulated	0
apoptosis	0
and	0
that	0
GR	9
-mediated	0
transrepression	0
may	0
be	0
the	0
more	0
critical	0
mechanism	0
.	0

To	0
better	0
understand	0
the	0
contribution	0
of	0
the	0
GR	9
N-terminal	10
transactivation	10
domain	10
in	0
mediating	0
murine	0
thymocyte	0
apoptosis	0
,	0
we	0
stably	0
transfected	0
GR	9
,	0
GR	9
variants	10
,	0
and	0
the	0
androgen	9
receptor	10
(	0
AR	9
)	0
into	0
receptor-negative	5
S49	6
murine	6
thymoma	6
cells	6
.	0

GR	9
expression	0
levels	0
were	0
shown	0
to	0
be	0
rate-limiting	0
for	0
initiating	0
the	0
apoptotic	0
pathway	0
,	0
and	0
a	0
positive	0
correlation	0
between	0
steroid	0
sensitivity	0
and	0
GR	9
-mediated	0
induction	0
of	0
an	0
integrated	0
mouse	1
mammary	2
tumor	2
virus	2
(	2
MMTV	2
)	2
LTR	2
reporter	2
gene	2
was	0
observed	0
.	0

Analysis	0
of	0
GR	9
chimeric	10
receptors	10
containing	0
the	0
potent	0
VP16	1
and	2
E1A	2
viral	2
transactivation	2
domains	2
in	0
place	0
of	0
the	0
GR	9
N	10
terminus	10
revealed	0
that	0
even	0
low	0
level	0
expression	0
of	0
these	0
receptors	0
resulted	0
in	0
both	0
enhanced	0
steroid	0
sensitivity	0
and	0
MMTV	0
induction	0
,	0
thus	0
supporting	0
a	0
role	0
for	0
transactivation	0
in	0
apoptosis	0
.	0

In	0
contrast	0
,	0
we	0
found	0
that	0
AR	9
can	0
initiate	0
apoptosis	0
in	0
S49	5
cells	6
after	0
treatment	0
with	0
5	0
alpha-dihydrotestosterone	0
,	0
despite	0
its	0
relative	0
inability	0
to	0
induce	0
high	0
level	0
expression	0
of	0
MMTV	0
.	0

To	0
investigate	0
this	0
further	0
,	0
we	0
examined	0
the	0
steroid-regulated	0
expression	0
of	0
an	0
endogenous	0
thymocyte-specific	1
gene	2
called	0
GIG18	1
.	0

We	0
found	0
that	0
GIG18	1
was	0
rapidly	0
induced	0
to	0
comparable	0
levels	0
by	0
both	0
AR	9
and	0
GR	9
,	0
demonstrating	0
that	0
AR	9
can	0
indeed	0
function	0
as	0
a	0
transcriptional	0
activator	0
in	0
S49	5
cells	6
and	0
,	0
moreover	0
,	0
that	0
GIG18	1
induction	0
may	0
be	0
a	0
marker	0
of	0
early	0
apoptotic	0
events	0
in	0
steroid-treated	0
cells	0
.	0

Taken	0
together	0
,	0
these	0
results	0
support	0
our	0
conclusion	0
that	0
transcriptional	0
transactivation	0
is	0
a	0
necessary	0
signaling	0
component	0
of	0
S49	0
cell	0
apoptosis	0
,	0
although	0
an	0
additional	0
role	0
for	0
GR	9
-mediated	0
transrepression	0
can	0
not	0
be	0
excluded	0
.	0

Multiple	0
p21ras	9
effector	0
pathways	0
regulate	0
nuclear	0
factor	0
of	0
activated	7
T	8
cells	8
.	0

The	0
transcription	9
factor	10
,	0
Nuclear	9
Factor	10
of	10
Activated	10
T	10
cells	10
(	0
NFAT	9
)	0
is	0
a	0
major	0
target	0
for	0
p21ras	9
and	0
calcium	0
signalling	0
pathways	0
in	0
the	0
IL-2	1
gene	2
and	0
is	0
induced	0
by	0
p21ras	9
signals	0
acting	0
in	0
synergy	0
with	0
calcium	0
/calcineurin	9
signals	0
.	0

One	0
p21ras	9
effector	0
pathway	0
involves	0
the	0
MAP	9
kinase	10
ERK-2	9
,	0
and	0
we	0
have	0
examined	0
its	0
role	0
in	0
NFAT	9
regulation	0
.	0

Expression	0
of	0
dominant	9
negative	10
MAPKK-1	10
prevents	0
NFAT	9
induction	0
.	0

Constitutively	0
active	0
MAPKK-1	9
fully	0
activates	0
ERK-2	9
and	0
the	0
transcription	9
factor	10
Elk-1	9
,	0
but	0
does	0
not	0
substitute	0
for	0
activated	0
p21ras	9
and	0
synergize	0
with	0
calcium	0
/calcineurin	9
signals	0
to	0
induce	0
NFAT	9
.	0

Expression	0
of	0
dominant	9
negative	10
N17Rac	10
also	0
prevents	0
TCR	9
and	0
p21ras	9
activation	0
of	0
NFAT	9
,	0
but	0
without	0
interfering	0
with	0
the	0
ERK-2	9
pathway	0
.	0

The	0
transcriptional	0
activity	0
of	0
the	0
NFAT	1
binding	2
site	2
is	0
mediated	0
by	0
a	0
complex	0
comprising	0
a	0
member	0
of	0
the	0
NFAT	9
group	0
and	0
AP-1	9
family	10
proteins	10
.	0

The	0
induction	0
of	0
AP-1	9
by	0
p21ras	9
also	0
requires	0
Rac-1	9
function	0
.	0

Activated	9
Rac-1	10
could	0
mimic	0
activated	9
p21ras	10
to	0
induce	0
AP-1	9
but	0
not	0
to	0
induce	0
NFAT	9
.	0

Moreover	0
,	0
the	0
combination	0
of	0
activated	0
MAPKK-1	9
and	0
Rac-1	9
could	0
not	0
substitute	0
for	0
activated	0
p21ras	9
and	0
synergize	0
with	0
calcium	0
signals	0
to	0
induce	0
NFAT	9
.	0

Thus	0
,	0
p21ras	9
regulation	0
of	0
NFAT	9
in	0
T	7
cells	8
requires	0
the	0
activity	0
of	0
multiple	0
effector	0
pathways	0
including	0
those	0
regulated	0
by	0
MAPKK-1	9
/ERK-2	9
and	0
Rac-1	9
.	0

Retinoid	0
differentiation	0
therapy	0
in	0
promyelocytic	0
leukemia	0
.	0

Acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
is	0
a	0
specific	0
type	0
of	0
acute	0
myeloid	0
leukemia	0
characterized	0
by	0
the	0
morphology	0
of	0
the	0
blast	7
cells	8
,	0
a	0
specific	0
t	0
(	0
15	0
;	0
17	0
)	0
translocation	0
,	0
and	0
risks	0
of	0
definite	0
coagulopathy	0
.	0

Recently	0
this	0
leukemia	0
was	0
further	0
characterized	0
by	0
an	0
exquisite	0
sensitivity	0
to	0
all-trans	0
retinoic	0
acid	0
's	0
differentiation	0
effect	0
and	0
the	0
production	0
of	0
a	0
fusion	1
gene	2
altering	0
the	0
gene	0
of	0
RARalpha	9
and	0
a	0
novel	1
gene	2
PML	2
.	0

In	0
vivo	0
differentiation	0
therapy	0
with	0
retinoids	0
in	0
APL	0
patients	0
follows	0
strict	0
guidelines	0
related	0
both	0
to	0
the	0
APL	0
cell	0
and	0
the	0
biodisposal	0
of	0
all-trans	0
retinoic	0
acid	0
.	0

Differential	0
utilization	0
of	0
Janus	9
kinase	10
-signal	0
transducer	0
activator	0
of	0
transcription	0
signaling	0
pathways	0
in	0
the	0
stimulation	0
of	0
human	7
natural	8
killer	8
cells	8
by	0
IL-2	9
,	0
IL-12	9
,	0
and	0
IFN-alpha	9
.	0

IL-2-	0
,	0
IL-12-	0
,	0
and	0
IFN-alpha-mediated	0
signaling	0
pathways	0
were	0
analyzed	0
in	0
primary	7
NK	8
cells	8
and	0
in	0
the	0
NK3.3	5
cell	6
line	6
.	0

Gel	0
mobility	0
shift	0
and	0
immunoprecipitation	0
analyses	0
revealed	0
that	0
in	0
addition	0
to	0
activating	0
STAT3	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription-3	10
)	0
and	0
STAT5	9
,	0
IL-2	9
induced	0
tyrosine	0
and	0
serine	0
phosphorylation	0
of	0
STAT1	9
alpha	10
,	0
which	0
formed	0
IFN-gamma-activated	9
sequence-binding	10
complexes	10
by	0
itself	0
and	0
with	0
STAT3	9
.	0

Although	0
IL-2	9
and	0
IFN-alpha	9
activated	0
STAT1	9
alpha	10
and	0
STAT5	9
,	0
IL-2	9
predominantly	0
activated	0
STAT5	9
,	0
while	0
IFN-alpha	9
predominantly	0
activated	0
STAT1	9
alpha	10
.	0

IL-2	9
induced	0
less	0
STAT1	9
alpha	10
activation	0
and	0
IFN-alpha	9
induced	0
greater	0
STAT5	9
activation	0
in	0
NK3.3	5
cells	6
compared	0
with	0
preactivated	5
primary	6
NK	6
cells	6
.	0

In	0
NK3.3	5
cells	6
,	0
IL-2	9
induced	0
comparable	0
formation	0
of	0
c-fos	9
promoter	10
sis-inducible	10
element	10
IFN-gamma-activated	10
sequence-binding	10
complexes	10
containing	0
STAT3	9
alone	0
with	0
complexes	0
containing	0
STAT3	9
and	0
STAT1	9
alpha	10
,	0
while	0
in	0
preactivated	5
primary	6
NK	6
cells	6
,	0
it	0
preferentially	0
induced	0
complexes	0
containing	0
STAT3	9
and	0
STAT1	9
alpha	10
.	0

Thus	0
,	0
signaling	0
in	0
NK3.3	5
cells	6
is	0
not	0
always	0
identical	0
with	0
that	0
in	0
primary	7
NK	8
cells	8
.	0

In	0
contrast	0
to	0
IL-2	9
and	0
IFN-alpha	9
,	0
IL-12	9
induced	0
strong	0
tyrosine	0
phosphorylation	0
of	0
STAT4	9
and	0
variable	0
weak	0
phosphorylation	0
of	0
STAT3	9
.	0

However	0
,	0
supershift	0
analyses	0
using	0
the	0
c-fos	1
promoter	2
sis-inducible	2
element	2
probe	2
showed	0
that	0
IL-12	9
activated	0
STAT4	9
,	0
STAT1	9
alpha	10
,	0
and	0
STAT3	9
,	0
and	0
induced	0
complexes	0
containing	0
STAT4	9
only	0
,	0
STAT4	9
with	0
STAT1	9
alpha	10
,	0
STAT3	9
with	0
STAT1	9
alpha	10
,	0
or	0
STAT1	9
alpha	10
only	0
in	0
preactivated	5
primary	6
NK	6
cells	6
.	0

STAT1	9
alpha	10
activation	0
by	0
IL-12	9
correlated	0
with	0
increased	0
phosphorylation	0
of	0
serine	0
,	0
but	0
not	0
tyrosine	0
.	0

Finally	0
,	0
IL-2	9
induced	0
tyrosine	0
phosphorylation	0
of	0
JAK1	9
and	0
JAK3	9
,	0
while	0
IL-12	9
induced	0
phosphorylation	0
of	0
JAK2	9
and	0
TYK2	9
in	0
both	0
preactivated	5
primary	6
NK	6
and	6
NK3.3	6
cells	6
.	0

Differential	0
phosphorylation	0
and	0
consequent	0
differential	0
activation	0
of	0
both	0
separate	0
and	0
overlapping	0
STAT	9
proteins	10
by	0
IL-2	9
,	0
IL-12	9
,	0
and	0
IFN-alpha	9
may	0
provide	0
a	0
molecular	0
basis	0
for	0
the	0
similarities	0
and	0
differences	0
in	0
the	0
actions	0
of	0
these	0
cytokines	9
on	0
NK	7
cells	8
.	0

The	0
suppression	0
of	0
T	7
cell	8
function	0
and	0
NF	9
(	10
kappa	10
)	10
B	10
expression	0
by	0
serine	0
protease	0
inhibitors	0
is	0
blocked	0
by	0
N-acetylcysteine	0
.	0

Direct	0
evidence	0
that	0
N-acetylcysteine	0
(	0
NAC	0
)	0
enhances	0
the	0
immune	0
response	0
of	0
peripheral	7
blood	8
T	8
cells	8
at	0
the	0
level	0
of	0
NF	9
(	10
kappa	10
)	10
B	10
is	0
presented	0
.	0

In	0
addition	0
,	0
NAC	0
blocks	0
the	0
suppression	0
of	0
T	0
cell	0
mitogenesis	0
and	0
cytokine	9
production	0
by	0
protease	0
inhibitors	0
such	0
as	0
N-tosylphenylalanine	0
chloromethyl	0
ketone	0
(	0
TPCK	0
)	0
.	0

The	0
proliferative	0
responses	0
of	0
purified	7
CD4+	8
or	8
CD8+	8
T	8
cells	8
are	0
suppressed	0
more	0
strongly	0
by	0
TPCK	0
when	0
anti-CD28	9
rather	0
than	0
the	0
phorbol	0
ester	0
PMA	0
is	0
used	0
as	0
the	0
mitogenic	0
coactivator	9
.	0

Cytokine	9
(	0
IL-2	9
,	0
IL-6	9
,	0
INF-gamma	9
)	0
production	0
is	0
inhibited	0
95-100	0
%	0
by	0
concentrations	0
of	0
TPCK	0
that	0
totally	0
suppress	0
the	0
mitogenesis	0
of	0
CD4+	7
or	8
CD8+	8
cells	8
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
we	0
find	0
that	0
TPCK	0
virtually	0
abolishes	0
(	0
to	0
less	0
than	0
1	0
%	0
)	0
the	0
levels	0
of	0
NF	9
(	10
kappa	10
)	10
B	10
(	0
but	0
not	0
Oct-1	9
)	0
found	0
in	0
nuclear	0
and	0
whole	0
cell	0
extracts	0
of	0
activated	7
T	8
cells	8
.	0

Strikingly	0
,	0
the	0
immunosuppressive	0
effects	0
of	0
TPCK	0
are	0
blocked	0
when	0
T	7
cells	8
are	0
pretreated	0
for	0
15	0
min	0
with	0
5	0
mM	0
NAC	0
.	0

NAC	0
not	0
only	0
blocks	0
the	0
effect	0
of	0
TPCK	0
but	0
enhances	0
mitogenesis	0
and	0
cytokine	9
production	0
(	0
>	0
2.5-fold	0
in	0
some	0
cases	0
)	0
upon	0
activation	0
of	0
unsuppressed	7
T	8
cells	8
.	0

Our	0
data	0
support	0
the	0
notion	0
that	0
NF	9
(	10
kappa	10
)	10
B	10
and	0
I	9
(	10
kappa	10
)	10
B	10
proteases	10
play	0
obligate	0
roles	0
in	0
T	0
cell	0
activation	0
and	0
mitogenesis	0
,	0
roles	0
that	0
are	0
enhanced	0
significantly	0
by	0
NAC	0
.	0

Signaling	0
by	0
IL-2	9
and	0
related	0
cytokines	9
:	0
JAKs	9
,	0
STATs	9
,	0
and	0
relationship	0
to	0
immunodeficiency	0
.	0

Cytokines	9
that	0
bind	0
to	0
the	0
interleukin-2	9
(	10
IL-2	10
)	10
receptor	10
common	10
gamma	10
chain	10
(	0
gamma	9
c	10
)	0
,	0
including	0
IL-2	9
,	0
IL-4	9
,	0
IL-7	9
,	0
IL-9	9
,	0
and	0
IL-15	9
,	0
are	0
important	0
for	0
the	0
growth	0
and	0
differentiation	0
of	0
T	7
and	8
B	8
lymphocytes	8
,	0
natural	7
killer	8
cells	8
,	0
macrophages	7
,	0
and	0
monoctyes	7
.	0

These	0
cytokines	9
have	0
overlapping	0
biological	0
effects	0
that	0
in	0
part	0
result	0
from	0
the	0
use	0
of	0
the	0
shared	9
receptor	10
subunit	10
gamma	10
c	10
.	0

Recently	0
it	0
has	0
become	0
clear	0
that	0
these	0
cytokines	9
activate	0
a	0
number	0
of	0
important	0
intracellular	9
signaling	10
molecules	10
,	0
including	0
the	0
Janus	9
kinases	10
JAK1	9
and	0
JAK3	9
and	0
members	0
of	0
the	0
transcription	9
factor	10
family	10
of	0
signal	9
transducers	10
and	0
activators	9
of	10
transcription	10
(	0
STATs	9
)	0
.	0

The	0
discovery	0
of	0
these	0
signaling	0
pathways	0
has	0
led	0
to	0
important	0
new	0
insights	0
into	0
their	0
role	0
in	0
lymphocyte	0
maturation	0
,	0
as	0
it	0
has	0
emerged	0
that	0
mutations	0
in	0
the	0
genes	0
encoding	0
both	0
gamma	9
c	10
and	0
JAK3	9
result	0
in	0
similar	0
forms	0
of	0
severe	0
combined	0
immunodeficiency	0
(	0
SCID	0
)	0
.	0

In	0
this	0
review	0
we	0
examine	0
the	0
structure	0
and	0
function	0
of	0
cytokine	9
receptors	10
and	0
the	0
signaling	0
pathways	0
involved	0
in	0
their	0
regulation	0
of	0
gene	0
expression	0
.	0

Furthermore	0
,	0
we	0
discuss	0
recent	0
advances	0
that	0
have	0
led	0
to	0
a	0
better	0
understanding	0
of	0
how	0
cytokines	9
elicit	0
intracellular	0
responses	0
,	0
as	0
well	0
as	0
their	0
role	0
in	0
normal	0
lymphoid	0
development	0
.	0

Cytomegalovirus	0
modulates	0
interleukin-6	1
gene	2
expression	0
.	0

Complications	0
after	0
lung	0
transplantation	0
include	0
the	0
development	0
of	0
rejection	0
and	0
an	0
increased	0
incidence	0
of	0
infection	0
,	0
particularly	0
with	0
cytomegalovirus	0
(	0
CMV	0
)	0
.	0

Several	0
recent	0
studies	0
have	0
suggested	0
that	0
interleukin	0
(	0
IL	0
)	0
-6	0
may	0
be	0
used	0
to	0
detect	0
both	0
infection	0
and	0
rejection	0
after	0
lung	0
transplantation	0
.	0

In	0
addition	0
,	0
IL-6	9
may	0
play	0
a	0
role	0
in	0
the	0
development	0
of	0
bronchiolitis	0
obliterans	0
after	0
transplantation	0
.	0

Because	0
CMV	0
is	0
also	0
associated	0
with	0
the	0
development	0
of	0
bronchiolitis	0
obliterans	0
after	0
transplantation	0
,	0
we	0
determined	0
whether	0
CMV	0
induces	0
IL-6	9
gene	0
expression	0
.	0

We	0
demonstrated	0
that	0
CMV	0
infection	0
increased	0
both	0
IL-6	9
protein	10
and	0
mRNA	3
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
.	0

We	0
also	0
demonstrated	0
that	0
the	0
CMV	9
immediate	10
early	10
1	10
gene	10
product	10
increased	0
expression	0
of	0
the	0
IL-6	1
promoter	2
.	0

This	0
effect	0
of	0
the	0
CMV	9
immediate	10
early	10
1	10
gene	10
product	10
was	0
dependent	0
upon	0
the	0
presence	0
of	0
specific	0
transcription	1
factor	2
binding	2
sites	2
in	0
the	0
IL-6	1
promoter	2
.	0

These	0
studies	0
demonstrate	0
that	0
CMV	0
may	0
be	0
an	0
important	0
cofactor	0
in	0
the	0
development	0
of	0
rejection	0
and	0
infection	0
after	0
transplantation	0
through	0
its	0
effects	0
on	0
IL-6	9
.	0

Vitamin	0
D3-	0
and	0
retinoic	0
acid-induced	0
monocytic	0
differentiation	0
:	0
interactions	0
between	0
the	0
endogenous	9
vitamin	10
D3	10
receptor	10
,	0
retinoic	9
acid	10
receptors	10
,	0
and	0
retinoid	9
X	10
receptors	10
in	0
U-937	5
cells	6
.	0

Retinoic	0
acid	0
(	0
RA	0
)	0
and	0
1	0
,	0
25	0
alpha-dihydroxycholecalciferol	0
(	0
VitD3	0
)	0
are	0
potent	0
regulators	0
of	0
hematopoletic	0
differentiation	0
.	0

Yet	0
,	0
little	0
is	0
known	0
as	0
to	0
how	0
the	0
RA	9
and	10
VitD3	10
receptor	10
network	10
operates	0
in	0
hematopoietic	7
cells	8
,	0
and	0
whether	0
receptor	0
interactions	0
can	0
explain	0
the	0
interplay	0
between	0
the	0
RA	0
-and	0
VitD3-signaling	0
pathways	0
during	0
differentiation	0
.	0

Therefore	0
,	0
we	0
analyzed	0
the	0
expression	0
,	0
DNA	0
binding	0
,	0
and	0
transcriptional	0
activity	0
of	0
the	0
endogenous	9
RA	10
and	10
VitD3	10
receptors	10
[	0
retinoic	9
acid	10
receptors	10
(	0
RARs	9
)	0
,	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
)	0
,	0
and	0
VitD3	9
receptor	10
(	0
VDR	9
)	0
]	0
in	0
the	0
U-937	5
cell	6
line	6
,	0
in	0
which	0
RA	0
and	0
VitD3	0
induce	0
distinct	0
monocytic	0
differentiation	0
pathways	0
.	0

VitD3	0
induction	0
resulted	0
in	0
the	0
formation	0
of	0
VDR/RXR	9
DNA-binding	10
complexes	10
on	0
both	0
VitD3	1
response	2
elements	2
and	0
RA	1
response	2
elements	2
(	0
RAREs	1
)	0
.	0

However	0
,	0
transcriptional	0
activation	0
was	0
only	0
observed	0
from	0
a	0
VitD3	1
response	2
element-driven	2
reporter	2
construct	2
.	0

Several	0
DNA-binding	9
complexes	10
were	0
detected	0
on	0
RAREs	1
in	0
undifferentiated	7
cells	8
.	0

Stimulation	0
by	0
RA	0
resulted	0
in	0
increased	0
RAR	9
beta	10
/RXR	9
DNA	0
binding	0
,	0
activated	0
RARE	1
-dependent	0
transcription	0
,	0
and	0
increased	0
expression	0
of	0
RAR-beta	9
.	0

Concomitant	0
stimulation	0
by	0
VitD3	0
inhibited	0
the	0
RA-stimulated	0
formation	0
of	0
RAR	9
beta/RXR	10
heterodimers	10
,	0
favoring	0
VDR	9
/RXR	9
binding	0
to	0
the	0
RARE	1
.	0

Also	0
,	0
VitD3	0
inhibited	0
the	0
expression	0
of	0
CD23	9
and	0
CD49f	9
,	0
characteristic	0
markers	0
of	0
retinoid-induced	0
U-937	5
cell	6
differentiation	0
.	0

In	0
contrast	0
,	0
neither	0
the	0
RA-stimulated	0
,	0
RARE	1
-mediated	0
transcription	0
nor	0
the	0
induced	0
RAR-beta	9
expression	0
was	0
suppressed	0
by	0
VitD3	0
,	0
suggesting	0
that	0
VitD3	0
selectively	0
inhibited	0
the	0
retinoid-induced	0
differentiation	0
program	0
but	0
not	0
the	0
RARE	1
-mediated	0
signal	0
.	0

These	0
results	0
demonstrate	0
a	0
complex	0
role	0
for	0
VitD3	0
in	0
modifying	0
the	0
retinoid	0
differentiation	0
pathway	0
and	0
may	0
have	0
implications	0
for	0
differentiation-inducing	0
therapy	0
of	0
hematopoietic	0
tumors	0
.	0

The	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
posttranscriptional	10
trans-activator	10
Rex	9
contains	0
a	0
nuclear	9
export	10
signal	10
.	0

The	0
Rex	9
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
is	0
required	0
for	0
the	0
nuclear	0
export	0
of	0
unspliced	3
viral	4
mRNA	4
and	0
,	0
therefore	0
,	0
for	0
virus	0
replication	0
.	0

In	0
this	0
manuscript	0
,	0
we	0
demonstrate	0
that	0
Rex	9
shuttles	0
between	0
the	0
nucleus	0
and	0
the	0
cytoplasm	0
and	0
that	0
its	0
activation	9
domain	10
constitutes	0
a	0
nuclear	9
export	10
signal	10
that	0
specifies	0
efficient	0
transport	0
to	0
the	0
cytoplasm	0
.	0

These	0
findings	0
are	0
consistent	0
with	0
a	0
model	0
for	0
Rex	9
-mediated	0
trans-activation	0
in	0
which	0
Rex-viral	9
mRNA	10
complexes	10
are	0
targeted	0
for	0
nuclear	0
export	0
by	0
the	0
direct	0
action	0
of	0
the	0
activation	9
domain	10
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
preferentially	0
activates	0
the	0
94-kD	9
STAT5A	10
and	0
an	0
80-kD	9
STAT5A	10
isoform	10
in	0
human	0
peripheral	0
blood	0
monocytes	0
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
induces	0
immediate	0
effects	0
in	0
monocytes	0
by	0
activation	0
of	0
the	0
Janus	9
kinase	10
(	0
JAK2	9
)	0
and	0
STAT	9
transcription	10
factor	10
(	0
STAT5	9
)	0
pathway	0
.	0

Recent	0
studies	0
have	0
identified	0
homologues	0
of	0
STAT5	9
,	0
STAT5A	9
,	0
and	0
STAT5B	9
,	0
as	0
well	0
as	0
lower	0
molecular	0
weight	0
variants	0
of	0
STAT5	9
.	0

To	0
define	0
the	0
activation	0
of	0
the	0
STAT5	9
homologues	10
and	0
lower	0
molecular	0
weight	0
variant	0
in	0
human	7
monocytes	8
and	0
monocytes	7
differentiated	0
into	0
macrophages	7
by	0
culture	0
in	0
macrophage-CSF	9
(	0
M-CSF	9
)	0
,	0
we	0
measured	0
the	0
GM-CSF	9
induced	0
tyrosine	0
phosphorylation	0
of	0
STAT5A	9
,	0
STAT5B	9
,	0
and	0
any	0
lower	0
molecular	0
weight	0
STAT5	9
isoforms	10
.	0

Freshly	0
isolated	0
monocytes	0
expressed	0
94-kD	9
STAT5A	10
,	0
92-kD	0
STAT5B	9
,	0
and	0
an	0
80-kD	9
STAT5A	10
molecule	10
.	0

Whereas	0
94-kD	9
STAT5A	10
was	0
clearly	0
tyrosine	0
phosphorylated	0
and	0
bound	0
to	0
the	0
enhancer	1
element	2
,	0
the	0
gamma	1
response	2
region	2
(	0
GRR	1
)	0
,	0
of	0
the	0
Fc	1
gamma	2
RI	2
gene	2
,	0
substantially	0
less	0
tyrosine	0
phosphorylated	0
STAT5B	9
bound	0
to	0
the	0
immobilized	0
GRR	1
element	2
.	0

Macrophages	0
lost	0
their	0
ability	0
to	0
express	0
the	0
80-kD	9
STAT5A	10
protein	10
,	0
but	0
retained	0
their	0
ability	0
to	0
activate	0
STAT5A	9
.	0

STAT5A-STAT5A	9
homodimers	10
and	0
STAT5A-STAT5B	9
heterodimers	10
formed	0
in	0
response	0
to	0
GM-CSF	9
.	0

Therefore	0
,	0
activation	0
of	0
STAT5A	9
predominates	0
compared	0
to	0
STAT5B	9
when	0
assayed	0
by	0
direct	0
immunoprecipitation	0
and	0
by	0
evaluation	0
of	0
bound	0
STATs	9
to	0
immobilized	0
GRR	1
.	0

Selective	0
activation	0
of	0
STAT5	9
homologues	10
in	0
addition	0
to	0
generation	0
of	0
lower	0
molecular	0
isoforms	0
may	0
provide	0
specificity	0
and	0
control	0
to	0
genes	0
expressed	0
in	0
response	0
to	0
cytokines	9
such	0
as	0
GM-CSF	9
.	0

Translocation	1
(	2
3	2
;	2
14	2
)	2
(	2
q27	2
;	2
q11	2
)	2
:	0
a	0
new	0
variant	0
translocation	0
in	0
a	0
patient	0
with	0
non-Hodgkin	0
's	0
lymphoma	0
of	0
B-cell	0
type	0
with	0
BCL6	1
rearrangement	0
.	0

We	0
report	0
a	0
65-year-old	0
woman	0
with	0
non-Hodgkin	0
's	0
lymphoma	0
(	0
NHL	0
)	0
carrying	0
a	0
t	1
(	2
3	2
;	2
14	2
)	2
(	2
q27	2
;	2
q11	2
)	2
and	0
BCL6	1
rearrangement	0
in	0
the	0
affected	7
cells	8
.	0

She	0
had	0
generalized	0
lymphadenopathy	0
and	0
the	0
bone	0
marrow	0
was	0
infiltrated	0
by	0
lymphoma	7
cells	8
at	0
presentation	0
.	0

Histological	0
diagnosis	0
was	0
``	0
malignant	0
lymphoma	0
,	0
diffuse	0
,	0
large	0
cell	0
''	0
type	0
according	0
to	0
an	0
International	0
Working	0
Formulation	0
.	0

Chromosome	0
analysis	0
revealed	0
a	0
t	1
(	2
3	2
;	2
14	2
)	2
(	2
q27	2
;	2
q11	2
)	2
,	0
which	0
is	0
a	0
new	0
variant	0
translocation	0
of	0
t	1
(	2
3	2
;	2
14	2
)	2
(	2
q27	2
;	2
q32	2
)	2
.	0

Southern	0
blot	0
analysis	0
showed	0
rearrangement	0
of	0
BCL6	1
,	0
JH	1
,	0
and	0
TCR	1
beta	2
but	0
not	0
of	0
TCR	1
delta	2
.	0

Cosmid	1
probe	2
of	0
BCL6	1
hybridized	0
to	0
14q11	1
and	0
3q27	1
by	0
fluorescence	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
.	0

Although	0
the	0
band	1
14q11	2
is	0
a	0
locus	0
of	0
T-cell	9
receptor	10
alpha-	10
and	10
delta-chains	10
(	0
TCR	9
alpha/delta	10
)	0
,	0
lymphoma	7
cells	8
expressed	0
B-cell	7
,	8
IgGk	8
phenotype	8
.	0

The	0
findings	0
suggest	0
that	0
a	0
novel	1
proto-oncogene	2
in	0
the	0
vicinity	0
of	0
TCR	1
alpha/delta	2
is	0
involved	0
in	0
this	0
translocation	0
.	0

Transgenic	0
expression	0
of	0
PML/RARalpha	9
impairs	0
myelopoiesis	0
.	0

The	0
translocation	0
found	0
in	0
acute	0
promyelocytic	0
leukemia	0
rearranges	0
the	0
promyelocytic	1
leukemia	2
gene	2
(	0
PML	1
)	0
on	0
chromosome	1
15	2
with	0
the	0
retinoic	1
acid	2
receptor	2
alpha	2
(	0
RARalpha	9
)	0
on	0
chromosome	1
17	2
.	0

This	0
yields	0
a	0
fusion	0
transcript	0
,	0
PML/RARalpha	9
,	0
a	0
transcription	9
factor	10
with	0
reported	0
dominant	0
negative	0
functions	0
in	0
the	0
absence	0
of	0
hormone	0
.	0

Clinical	0
remissions	0
induced	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
treatment	0
in	0
acute	0
promyelocytic	0
leukemia	0
are	0
linked	0
to	0
PML/RARalpha	9
expression	0
in	0
leukemic	7
cells	8
.	0

To	0
evaluate	0
the	0
PML/RARalpha	9
role	0
in	0
myelopoiesis	0
,	0
transgenic	0
mice	0
expressing	0
PML/RARalpha	9
were	0
engineered	0
.	0

A	0
full-length	0
PML/RARalpha	1
cDNA	2
driven	0
by	0
the	0
CD11b	1
promoter	2
was	0
expressed	0
in	0
transgenic	0
mice	0
.	0

Expression	0
was	0
confirmed	0
in	0
the	0
bone	0
marrow	0
with	0
a	0
reverse	0
transcription	0
PCR	0
assay	0
.	0

Basal	0
total	0
white	0
blood	0
cell	0
and	0
granulocyte	0
counts	0
did	0
not	0
appreciably	0
differ	0
between	0
PML/RARalpha	9
transgenic	0
and	0
control	0
mice	0
.	0

Cell	0
sorter	0
analysis	0
of	0
CD11b+	7
bone	8
marrow	8
cells	8
revealed	0
similar	0
CD11b+	7
populations	8
in	0
transgenic	0
and	0
control	0
mice	0
.	0

However	0
,	0
in	0
vitro	0
clonal	0
growth	0
assays	0
performed	0
on	0
peripheral	0
blood	0
from	0
transgenic	0
versus	0
control	0
mice	0
revealed	0
a	0
marked	0
reduction	0
of	0
myeloid	7
progenitors	8
,	0
especially	0
in	0
those	0
responding	0
to	0
granulocyte/	9
macrophage	10
colony-stimulating	10
factor	10
.	0

Granulocyte/macrophage	9
colony-stimulating	10
factor	10
and	0
kit	0
ligand	0
cotreatment	0
did	0
not	0
overcome	0
this	0
inhibition	0
.	0

Impaired	0
myelopoiesis	0
in	0
vivo	0
was	0
shown	0
by	0
stressing	0
these	0
mice	0
with	0
sublethal	0
irradiation	0
.	0

Following	0
irradiation	0
,	0
PML/RARalpha	9
transgenic	0
mice	0
,	0
as	0
compared	0
with	0
controls	0
,	0
more	0
rapidly	0
depressed	0
peripheral	0
white	0
blood	0
cell	0
and	0
granulocyte	0
counts	0
.	0

As	0
expected	0
,	0
nearly	0
all	0
control	0
mice	0
(	0
94.4	0
%	0
)	0
survived	0
irradiation	0
,	0
yet	0
this	0
irradiation	0
was	0
lethal	0
to	0
45.8	0
%	0
of	0
PML/RARalpha	9
transgenic	0
mice	0
.	0

Lethality	0
was	0
associated	0
with	0
more	0
severe	0
leukopenia	0
in	0
transgenic	0
versus	0
control	0
mice	0
.	0

Retinoic	0
acid	0
treatment	0
of	0
irradiated	0
PML/RARalpha	9
mice	0
enhanced	0
granulocyte	7
recovery	0
.	0

These	0
data	0
suggest	0
that	0
abnormal	0
myelopoiesis	0
due	0
to	0
PML/RARalpha	9
expression	0
is	0
an	0
early	0
event	0
in	0
oncogenic	0
transformation	0
.	0

C/EBP	9
activators	10
are	0
required	0
for	0
HIV-1	0
replication	0
and	0
proviral	0
induction	0
in	0
monocytic	5
cell	6
lines	6
.	0

Previous	0
work	0
has	0
shown	0
that	0
C/EBP	1
sites	2
and	0
C/EBP	9
transcriptional	10
activators	10
are	0
necessary	0
for	0
HIV-1	1
LTR	2
activity	0
in	0
monocytes/macrophages	7
.	0

We	0
have	0
investigated	0
the	0
role	0
that	0
C/EBP	9
proteins	10
play	0
in	0
induction	0
and	0
replication	0
of	0
HIV-1	0
.	0

Ectopic	0
expression	0
of	0
the	0
dominant	0
negative	0
C/EBP	9
protein	10
LIP	10
inhibited	0
HIV-1	0
mRNA	0
and	0
virus	0
production	0
in	0
activated	5
U1	6
cells	6
,	0
demonstrating	0
that	0
C/EBP	9
proteins	10
are	0
required	0
for	0
provirus	0
induction	0
.	0

U1	5
lines	6
overexpressing	0
C/EBP	9
activator	10
NF-IL-6	9
produced	0
more	0
viral	3
mRNA	4
and	0
virus	0
particles	0
following	0
cellular	0
activation	0
than	0
control	5
lines	6
,	0
demonstrating	0
that	0
C/EBP	9
proteins	10
are	0
limiting	0
for	0
virus	0
transcription	0
.	0

HIV-1	0
harboring	0
mutations	0
within	0
two	0
C/EBP	1
sites	2
were	0
crippled	0
in	0
their	0
ability	0
to	0
replicate	0
in	0
U937	5
promonocytic	6
cells	6
,	0
indicating	0
that	0
these	0
sites	0
are	0
required	0
for	0
replication	0
.	0

These	0
data	0
identify	0
C/EBP	9
proteins	10
as	0
regulators	0
of	0
HIV-1	0
expression	0
in	0
monocytes/macrophages	7
.	0

Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
and	0
latent	9
membrane	10
protein	10
independently	0
transactivate	0
p53	9
through	0
induction	0
of	0
NF-kappaB	9
activity	0
.	0

B-cell	7
immortalization	0
by	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
dependent	0
on	0
permanent	0
control	0
of	0
the	0
cellular	0
processes	0
which	0
normally	0
regulate	0
cell	0
division	0
and	0
apoptosis	0
,	0
functions	0
possessed	0
by	0
p53	9
in	0
a	0
number	0
of	0
normal	0
cell	0
types	0
.	0

In	0
studies	0
initiated	0
to	0
evaluate	0
relationships	0
between	0
EBV	1
latent	2
genes	2
and	0
p53	9
,	0
p53	9
levels	0
were	0
found	0
to	0
increase	0
approximately	0
10-fold	0
4	0
to	0
5	0
days	0
after	0
EBV	0
infection	0
of	0
purified	0
resting	7
human	8
B	8
cells	8
;	0
the	0
induced	0
p53	9
was	0
transcriptionally	0
active	0
.	0

Latent	9
membrane	10
protein	10
1	10
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
EBV	9
nuclear	10
antigen	10
2	10
mediated	0
the	0
increase	0
in	0
p53	9
levels	0
via	0
activation	0
of	0
the	0
NF-kappaB	9
transcription	9
factor	10
.	0

Cooperation	0
between	0
core	9
binding	10
factor	10
and	0
adjacent	1
promoter	2
elements	2
contributes	0
to	0
the	0
tissue-specific	0
expression	0
of	0
interleukin-3	9
.	0

Tissue-specific	0
expression	0
of	0
interleukin-3	9
(	0
IL-3	9
)	0
is	0
mediated	0
via	0
cis-acting	1
elements	2
located	0
within	0
315	0
base	0
pairs	0
of	0
the	0
transcription	1
start	2
.	0

This	0
is	0
achieved	0
in	0
part	0
through	0
the	0
positive	0
activities	0
of	0
the	0
AP-1	1
and	2
Elf-1	2
sites	2
in	0
the	0
IL-3	1
promoter	2
.	0

The	0
contribution	0
to	0
T	0
cell-specific	0
expression	0
by	0
other	0
promoter	1
sites	2
was	0
assessed	0
in	0
a	0
transient	0
expression	0
assay	0
with	0
IL-3	1
promoter	2
constructs	2
linked	0
to	0
a	0
luciferase	1
gene	2
,	0
focusing	0
initially	0
on	0
the	0
core	1
binding	2
factor	2
(	2
CBF	2
)	2
site	2
,	0
which	0
is	0
footprinted	0
in	0
vivo	0
upon	0
T	0
cell	0
activation	0
.	0

Activity	0
of	0
the	0
CBF	1
site	2
is	0
shown	0
to	0
be	0
critically	0
dependent	0
on	0
the	0
adjacent	1
activator	2
site	2
Act-1	2
.	0

Together	0
the	0
Act-1	1
and	0
CBF	1
sites	2
form	0
a	0
functional	1
unit	2
(	0
AC	1
unit	2
)	0
with	0
dual	0
activity	0
.	0

The	0
AC	1
unit	2
is	0
demonstrated	0
to	0
enhance	0
basal	0
activity	0
of	0
promoters	0
both	0
in	0
fibroblasts	7
and	0
T	7
cells	8
.	0

This	0
activity	0
is	0
further	0
inducible	0
in	0
activated	0
T	7
cells	8
,	0
but	0
not	0
in	0
fibroblasts	7
.	0

In	0
addition	0
to	0
the	0
already	0
identified	0
NIP	1
repressor	2
site	2
,	0
evidence	0
is	0
presented	0
for	0
a	0
second	1
repressor	2
region	2
that	0
restricts	0
promoter	0
activity	0
in	0
fibroblasts	7
.	0

Finally	0
,	0
a	0
novel	0
positive	1
regulatory	2
element	2
has	0
been	0
mapped	0
in	0
the	0
IL-3	1
promoter	2
between	0
nucleotide	0
-180	0
and	0
-210	0
that	0
leads	0
to	0
increased	0
expression	0
in	0
T	7
cells	8
.	0

Together	0
these	0
results	0
demonstrate	0
that	0
T	0
cell	0
expression	0
of	0
IL-3	9
is	0
not	0
specified	0
by	0
the	0
activity	0
of	0
a	0
single	0
tissue-specific	1
element	2
,	0
but	0
instead	0
involves	0
multiple	0
interacting	1
elements	2
that	0
provide	0
both	0
specific	0
positive	0
regulation	0
in	0
T	7
cells	8
and	0
specific	0
negative	0
regulation	0
in	0
fibroblasts	7
.	0

Modulation	0
of	0
the	0
expression	0
of	0
the	0
IFN-gamma	9
receptor	10
beta-chain	10
controls	0
responsiveness	0
to	0
IFN-gamma	9
in	0
human	7
peripheral	8
blood	8
T	8
cells	8
.	0

IFN-gamma	9
has	0
potent	0
antiproliferative	0
and	0
apoptotic	0
effects	0
in	0
T	7
cells	8
that	0
are	0
important	0
in	0
determining	0
T	0
cell	0
development	0
and	0
polarized	0
differentiation	0
.	0

Therefore	0
,	0
any	0
event	0
that	0
enables	0
T	7
cells	8
to	0
become	0
less	0
responsive	0
to	0
IFN-	9
gamma	10
may	0
potentially	0
alter	0
immune	0
responsiveness	0
to	0
Ag	9
.	0

In	0
this	0
work	0
,	0
we	0
show	0
that	0
human	7
peripheral	8
blood	8
T	8
cells	8
that	0
are	0
stimulated	0
through	0
the	0
TCR	9
and	0
expanded	0
with	0
IL-2	9
are	0
unresponsive	0
to	0
IFN-gamma	9
,	0
as	0
determined	0
by	0
a	0
lack	0
of	0
activation	0
of	0
jak	9
kinases	10
and	0
the	0
transcription	9
factor	10
,	0
STAT1	9
(	10
alpha	10
)	10
,	0
a	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
.	0

This	0
nonresponsiveness	0
occurs	0
because	0
of	0
a	0
lack	0
of	0
expression	0
of	0
the	0
beta-	9
chain	10
(	0
accessory	0
factor	0
)	0
of	0
the	0
IFN-gamma	9
receptor	10
,	0
while	0
at	0
the	0
same	0
time	0
maintaining	0
IFN-gamma	9
receptor	10
alpha-chain	10
expression	0
.	0

Expression	0
of	0
the	0
beta-chain	9
can	0
be	0
restored	0
by	0
secondary	0
TCR	9
ligation	0
or	0
PMA	0
treatment	0
.	0

T	7
cell	8
blasts	8
treated	0
with	0
PMA	0
are	0
now	0
responsive	0
to	0
IFN-gamma	9
.	0

When	0
freshly	0
isolated	0
,	0
highly	0
enriched	0
(	0
>	0
98	0
%	0
)	0
T	7
cells	8
are	0
examined	0
for	0
IFN-gamma	9
responsiveness	0
;	0
these	0
cells	0
can	0
respond	0
to	0
IFN-gamma	9
and	0
express	0
beta-chain	9
.	0

Therefore	0
,	0
as	0
T	7
cells	8
progress	0
from	0
primary	0
TCR	9
activation	0
through	0
IL-2	9
-dependent	0
proliferation	0
,	0
followed	0
by	0
secondary	0
TCR	9
stimulation	0
,	0
their	0
responsiveness	0
to	0
IFN-gamma	9
varies	0
,	0
and	0
this	0
may	0
affect	0
their	0
ability	0
to	0
participate	0
in	0
an	0
ongoing	0
immune	0
response	0
.	0

Age-related	0
decreases	0
in	0
IL-2	9
production	0
by	0
human	7
T	8
cells	8
are	0
associated	0
with	0
impaired	0
activation	0
of	0
nuclear	9
transcriptional	10
factors	10
AP-1	9
and	0
NF-AT	9
.	0

Although	0
transcriptional	9
factors	10
AP-1	9
and	0
nuclear	0
factor	0
of	0
activated	0
T	0
cells	0
(	0
NF-AT	9
)	0
are	0
important	0
for	0
the	0
normal	0
induction	0
of	0
IL-2	9
,	0
it	0
is	0
unknown	0
if	0
the	0
age-related	0
decline	0
in	0
IL-2	9
production	0
by	0
activated	0
human	7
T	8
cells	8
may	0
be	0
associated	0
with	0
aberrancies	0
in	0
transcriptional	9
regulatory	10
proteins	10
.	0

In	0
the	0
current	0
studies	0
,	0
IL-2	9
production	0
by	0
T	7
cells	8
from	0
elderly	0
(	0
mean	0
78	0
years	0
)	0
and	0
young	0
(	0
mean	0
37	0
years	0
)	0
humans	0
was	0
measured	0
in	0
cultures	0
stimulated	0
with	0
PHA	9
,	0
PHA	9
plus	0
PMA	0
,	0
crosslinked	0
anti-CD3	0
mAB	0
OKT3	0
plus	0
PMA	0
,	0
or	0
PMA	0
plus	0
ionomycin	0
.	0

Substantial	0
decreases	0
of	0
IL-2	9
production	0
were	0
observed	0
for	0
cell	0
cultures	0
from	0
7	0
of	0
12	0
elderly	0
individuals	0
in	0
response	0
to	0
the	0
different	0
stimuli	0
,	0
whereas	0
the	0
levels	0
of	0
IL-2	9
produced	0
by	0
stimulated	0
T	7
cells	8
from	0
other	0
elderly	0
individuals	0
were	0
equivalent	0
to	0
those	0
observed	0
for	0
stimulated	0
T	0
cells	0
of	0
young	0
subjects	0
.	0

Analyses	0
of	0
nuclear	0
extracts	0
by	0
electrophoretic	0
DNA	0
mobility	0
shift	0
assays	0
showed	0
that	0
decreased	0
IL-2	9
production	0
by	0
stimulated	7
T	8
cells	8
of	0
elderly	0
individuals	0
was	0
closely	0
associated	0
with	0
impairments	0
in	0
the	0
activation	0
of	0
both	0
AP-1	9
and	0
NF-AT	9
.	0

By	0
contrast	0
,	0
T	7
cells	8
from	0
elderly	0
subjects	0
with	0
normal	0
levels	0
of	0
IL-2	9
production	0
exhibited	0
normal	0
activation	0
of	0
AP-1	9
and	0
NF-AT	9
.	0

In	0
addition	0
,	0
the	0
results	0
of	0
competition	0
experiments	0
analyzing	0
the	0
normal	0
components	0
of	0
NF-AT	9
showed	0
that	0
the	0
age-related	0
reductions	0
in	0
stimulus-dependent	0
NF-AT	9
complexes	10
corresponded	0
to	0
the	0
slow	0
migrating	0
complexes	0
that	0
were	0
composed	0
of	0
c-Fos/c-Jun	9
AP-1	9
.	0

The	0
resting	0
and	0
stimulated	0
levels	0
of	0
NF	9
kappa	10
B	10
were	0
reduced	0
in	0
T	7
cells	8
from	0
certain	0
elderly	0
individuals	0
;	0
however	0
,	0
alterations	0
of	0
NF	9
kappa	10
B	10
did	0
not	0
correlate	0
with	0
changes	0
in	0
IL-2	9
expression	0
.	0

Thus	0
,	0
these	0
results	0
show	0
that	0
age-related	0
impairments	0
in	0
the	0
activation	0
of	0
AP-1	9
and	0
NF-AT	9
are	0
closely	0
associated	0
with	0
decreased	0
expression	0
of	0
IL-2	9
and	0
further	0
suggest	0
that	0
aberrancies	0
in	0
the	0
signaling	0
pathways	0
important	0
for	0
the	0
induction	0
of	0
transcriptionally	0
active	0
c-Fos/c-Jun	9
AP-1	9
may	0
contribute	0
to	0
the	0
impaired	0
activation	0
of	0
NF-AT	9
.	0

IL-13	9
induces	0
phosphorylation	0
and	0
activation	0
of	0
JAK2	9
Janus	10
kinase	10
in	0
human	5
colon	6
carcinoma	6
cell	6
lines	6
:	0
similarities	0
between	0
IL-4	9
and	0
IL-13	9
signaling	0
.	0

We	0
have	0
recently	0
reported	0
that	0
IL-13R	9
may	0
share	0
a	0
component	0
with	0
IL-4R	9
.	0
Here	0
we	0
report	0
that	0
both	0
IL-4	9
and	0
IL-13	9
share	0
signaling	0
events	0
in	0
human	5
colon	6
carcinoma	6
cell	6
lines	6
(	0
HT-29	5
and	0
WiDr	5
)	0
.	0

IL-13	9
caused	0
rapid	0
phosphorylation	0
of	0
the	0
three	0
out	0
of	0
four	0
members	0
of	0
the	0
known	0
Janus	9
family	10
of	10
kinases	10
(	0
JAKs	9
)	0
.	0

We	0
show	0
that	0
JAK2	9
kinase	10
is	0
rapidly	0
phosphorylated	0
and	0
activated	0
in	0
response	0
to	0
IL-13	9
.	0

Within	0
1	0
min	0
of	0
activation	0
,	0
JAK2	9
was	0
phosphorylated	0
,	0
and	0
peaked	0
in	0
10	0
min	0
.	0

In	0
addition	0
,	0
IL-13	9
phosphorylated	0
insulin	9
response	10
substrate-1	10
,	0
IL-4R	9
p140	10
,	0
JAK1	9
,	0
and	0
Tyk2	9
,	0
but	0
not	0
JAK3	9
kinase	10
.	0

IL-4	9
also	0
stimulated	0
all	0
three	0
kinases	9
and	0
substrates	0
,	0
but	0
unlike	0
in	0
immune	7
cells	8
,	0
IL-4	9
did	0
not	0
involve	0
JAK3	9
activation	0
for	0
its	0
signaling	0
in	0
colon	5
cancer	6
cell	6
lines	6
.	0

Furthermore	0
,	0
JAK2	9
associated	0
with	0
the	0
IL-4R	9
p140	10
before	0
and	0
after	0
stimulation	0
with	0
IL-13	9
.	0

Both	0
IL-13	9
and	0
IL-4	9
induced	0
phosphorylation	0
of	0
IL-4	9
STAT	10
(	0
STAT6	9
)	0
but	0
not	0
STAT1	9
,	0
STAT3	9
,	0
or	0
STAT5	9
.	0

125I-IL-13	9
did	0
not	0
bind	0
to	0
colon	5
cancer	6
cell	6
lines	6
,	0
but	0
unlabeled	0
IL-13	9
competed	0
for	0
the	0
binding	0
of	0
125I-IL-4	9
.	0

Our	0
data	0
suggest	0
that	0
IL-13	9
utilizes	0
IL-4R	9
and	0
its	0
signaling	0
pathway	0
,	0
and	0
JAK2	9
may	0
play	0
an	0
important	0
role	0
in	0
the	0
function	0
of	0
IL-4R	9
and	0
IL-13R	9
in	0
colon	7
cancer	8
cells	8
.	0

Differential	0
regulation	0
of	0
IL-6	1
gene	2
transcription	0
and	0
expression	0
by	0
IL-4	9
and	0
IL-10	9
in	0
human	5
monocytic	6
cell	6
lines	6
.	0

IL-4	9
and	0
IL-10	9
inhibit	0
the	0
cytokine	9
production	0
and	0
mRNA	0
expression	0
by	0
monocytes/macrophages	7
.	0

To	0
investigate	0
the	0
molecular	0
mechanism	0
of	0
the	0
inhibitory	0
effect	0
on	0
transcriptional	0
or	0
post-transcriptional	0
regulation	0
of	0
IL-6	1
gene	2
expression	0
by	0
IL-4	9
and	0
IL-10	9
,	0
we	0
studied	0
IL-6	9
production	0
,	0
expression	0
level	0
of	0
IL-6	3
mRNA	4
,	0
IL-6	9
promoter	0
activity	0
,	0
transcriptional	0
activity	0
of	0
NF-kappaB	9
and	0
NF-IL-6	9
,	0
and	0
IL-6	3
mRNA	4
stability	0
in	0
human	5
monocytic	6
cell	6
lines	6
,	0
THP-1	5
and	0
U937	5
,	0
stimulated	0
by	0
PMA	0
and	0
LPS	0
in	0
the	0
absence	0
or	0
the	0
presence	0
of	0
IL-4	9
or	0
IL-10	9
.	0

Both	0
IL-4	9
and	0
IL-10	9
were	0
seen	0
to	0
inhibit	0
IL-6	9
production	0
and	0
the	0
expression	0
of	0
IL-6	3
mRNA	4
in	0
both	0
monocytic	5
cell	6
lines	6
studied	0
.	0

In	0
chloramphenicol	9
acetyltransferase	10
assays	0
,	0
utilizing	0
the	0
transient	0
transfection	0
of	0
a	0
chloramphenicol	1
acetyltransferase	2
reporter	2
plasmid	2
containing	0
the	0
IL-6	1
gene	2
promoter	2
,	0
IL-4	9
,	0
but	0
not	0
IL-10	9
,	0
suppressed	0
the	0
transcriptional	0
activity	0
of	0
the	0
IL-6	0
gene	0
promoter	0
stimulated	0
by	0
PMA	0
and	0
LPS	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
showed	0
that	0
IL-4	9
,	0
but	0
not	0
IL-10	9
,	0
inhibited	0
nuclear	0
NF-kappaB	9
activity	0
,	0
and	0
that	0
IL-4	9
and	0
IL-10	9
did	0
not	0
affect	0
NF-	0
IL-6	9
activity	0
.	0

On	0
the	0
other	0
hand	0
,	0
IL-10	9
enhanced	0
the	0
degradation	0
of	0
IL-6	3
mRNA	4
in	0
a	0
mRNA	0
stability	0
assay	0
.	0

These	0
results	0
suggest	0
that	0
IL-4	9
may	0
inhibit	0
the	0
transcription	0
of	0
the	0
IL-6	1
gene	2
by	0
affecting	0
NF-kappaB	9
binding	0
activity	0
,	0
while	0
IL-10	9
may	0
inhibit	0
the	0
IL-6	3
mRNA	4
levels	0
post-transcriptionally	0
,	0
without	0
suppressing	0
promoter	0
activity	0
.	0

Therefore	0
,	0
we	0
conclude	0
that	0
IL-4	9
and	0
IL-10	9
inhibit	0
IL-6	9
production	0
by	0
different	0
mechanisms	0
in	0
human	5
monocytic	6
cell	6
lines	6
.	0

Activation	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
in	0
a	0
cyclosporin	0
A-resistant	0
pathway	0
.	0

The	0
mechanism	0
of	0
action	0
of	0
the	0
immunosuppressive	0
drug	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
is	0
the	0
inactivation	0
of	0
the	0
Ca2+/calmodulin-dependent	9
serine-threonine	10
phosphatase	10
calcineurin	9
by	0
the	0
drug-immunophilin	9
complex	10
.	0

Inactive	0
calcineurin	9
is	0
unable	0
to	0
activate	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
,	0
a	0
transcription	9
factor	10
required	0
for	0
expression	0
of	0
the	0
interleukin	1
2	2
(	2
IL-2	2
)	2
gene	2
.	0

IL-2	9
production	0
by	0
CsA-treated	5
cells	6
is	0
therefore	0
dramatically	0
reduced	0
.	0

We	0
demonstrate	0
here	0
,	0
however	0
,	0
that	0
NFAT	9
can	0
be	0
activated	0
,	0
and	0
significant	0
levels	0
of	0
IL-2	9
can	0
be	0
produced	0
by	0
the	0
CsA-resistant	0
CD28	9
-signaling	0
pathway	0
.	0

In	0
transient	0
transfection	0
assays	0
,	0
both	0
multicopy	0
NFAT	9
-and	0
IL-2	1
promoter-beta-galactosidase	2
reporter	2
gene	2
constructs	2
could	0
be	0
activated	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
/alpha-	0
CD28	9
stimulation	0
,	0
and	0
this	0
activation	0
was	0
resistant	0
to	0
CsA	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
showed	0
the	0
induction	0
of	0
a	0
CsA-resistant	9
NFAT	10
complex	10
in	0
the	0
nuclear	0
extracts	0
of	0
peripheral	7
blood	8
T	8
cells	8
stimulated	0
with	0
PMA	0
plus	0
alphaCD28	9
.	0

Peripheral	7
blood	8
T	8
cells	8
stimulated	0
with	0
PMA	0
/alphaCD28	9
produced	0
IL-2	9
in	0
the	0
presence	0
of	0
CsA	0
.	0

Collectively	0
,	0
these	0
data	0
suggest	0
that	0
NFAT	9
can	0
be	0
activated	0
and	0
IL-2	9
can	0
be	0
produced	0
in	0
a	0
calcineurin	9
independent	0
manner	0
.	0

Effects	0
of	0
interleukin-10	9
on	0
human	7
peripheral	8
blood	8
mononuclear	8
cell	8
responses	0
to	0
Cryptococcus	0
neoformans	0
,	0
Candida	0
albicans	0
,	0
and	0
lipopolysaccharide	0
.	0

Deactivation	0
of	0
mononuclear	7
phagocytes	8
is	0
critical	0
to	0
limit	0
the	0
inflammatory	0
response	0
but	0
can	0
be	0
detrimental	0
in	0
the	0
face	0
of	0
progressive	0
infection	0
.	0

We	0
compared	0
the	0
effects	0
of	0
the	0
deactivating	9
cytokine	10
interleukin	9
10	10
(	0
IL-10	9
)	0
on	0
human	7
peripheral	8
blood	8
mononuclear	8
cell	8
(	0
PBMC	7
)	0
responses	0
to	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
Cryptococcus	0
neoformans	0
,	0
and	0
Candida	0
albicans	0
.	0

IL-10	9
effected	0
dose-dependent	0
inhibition	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
release	0
in	0
PBMC	7
stimulated	0
by	0
LPS	0
and	0
C.	0
neoformans	0
,	0
with	0
significant	0
inhibition	0
seen	0
with	0
0.1	0
U/ml	0
and	0
greater	0
than	0
90	0
%	0
inhibition	0
noted	0
with	0
10	0
U/ml	0
.	0

In	0
contrast	0
,	0
even	0
at	0
doses	0
as	0
high	0
as	0
100	0
U/ml	0
,	0
IL-10	9
inhibited	0
TNF-alpha	9
release	0
in	0
response	0
to	0
C.	0
albicans	0
by	0
only	0
50	0
%	0
.	0

IL-10	9
profoundly	0
inhibited	0
release	0
of	0
IL-1beta	9
from	0
PBMC	7
stimulated	0
by	0
all	0
three	0
stimuli	0
.	0

TNF-alpha	3
mRNA	4
and	0
release	0
was	0
inhibited	0
even	0
if	0
IL-10	9
was	0
added	0
up	0
to	0
8	0
h	0
after	0
cryptococcal	0
stimulation	0
.	0

In	0
contrast	0
,	0
inhibition	0
of	0
IL-1	3
beta	4
mRNA	4
was	0
of	0
lesser	0
magnitude	0
and	0
occurred	0
only	0
when	0
IL-10	9
was	0
added	0
within	0
2	0
h	0
of	0
cryptococcal	0
stimulation	0
.	0

IL-10	9
inhibited	0
translocation	0
of	0
NF-kappaB	9
in	0
response	0
to	0
LPS	0
but	0
not	0
the	0
fungal	0
stimuli	0
.	0

All	0
three	0
stimuli	0
induced	0
IL-10	9
production	0
in	0
PBMC	7
,	0
although	0
over	0
10-fold	0
less	0
IL-10	9
was	0
released	0
in	0
response	0
to	0
C.	0
neoformans	0
compared	0
with	0
LPS	0
and	0
C.	0
albicans	0
.	0

Thus	0
,	0
while	0
IL-10	9
has	0
deactivating	0
effects	0
on	0
PBMC	7
responses	0
to	0
all	0
three	0
stimuli	0
,	0
disparate	0
stimulus-	0
and	0
response-specific	0
patterns	0
of	0
deactivation	0
are	0
seen	0
.	0

Inhibition	0
by	0
IL-10	9
of	0
proinflammatory	9
cytokine	10
release	0
appears	0
to	0
occur	0
at	0
the	0
level	0
of	0
gene	0
transcription	0
for	0
TNF-alpha	9
and	0
both	0
transcriptionally	0
and	0
posttranscriptionally	0
for	0
IL-1beta	9
.	0

Characterization	0
and	0
purification	0
of	0
a	0
protein	9
kinase	10
C	10
substrate	10
in	0
human	7
B	8
cells	8
.	0

Identification	0
as	0
lymphocyte-specific	9
protein	10
1	10
(	0
LSP1	9
)	0
.	0

Incubation	0
of	0
B-chronic	5
lymphocytic	6
leukemia	6
(	6
B-CLL	6
)	6
cells	6
with	0
phorbol	0
esters	0
resulted	0
in	0
the	0
phosphorylation	0
of	0
two	0
major	0
PKC	9
substrates	10
,	0
MARCKS	9
(	0
myristoylated	9
,	10
alanine-rich	10
C	10
kinase	10
substrate	10
)	0
and	0
MRP	9
(	0
MARCKS-related	9
protein	10
)	0
,	0
and	0
of	0
a	0
third	0
protein	0
,	0
with	0
an	0
apparent	0
m.w.	0
of	0
60	0
,	0
000	0
that	0
was	0
the	0
most	0
prominent	0
protein	9
kinase	10
C	10
substrate	10
in	0
these	0
cells	0
.	0

p60	9
phosphorylation	0
was	0
time	0
and	0
PMA	0
dose	0
dependent	0
,	0
and	0
was	0
induced	0
by	0
cell-permeable	0
diacylglycerol	0
,	0
but	0
not	0
by	0
inactive	0
phorbol	0
esters	0
.	0

Two-dimensional	0
electrophoretic	0
analysis	0
of	0
the	0
protein	0
phosphorylation	0
pattern	0
from	0
the	0
B	5
cell	6
line	6
CESS	6
demonstrated	0
the	0
identity	0
between	0
the	0
p60	9
protein	10
expressed	0
in	0
this	0
cell	0
line	0
and	0
that	0
expressed	0
in	0
B-CLL	5
cells	6
.	0

p60	9
was	0
purified	0
from	0
CESS	5
cells	6
and	0
peptide	0
microsequencing	0
of	0
this	0
protein	0
revealed	0
that	0
it	0
was	0
lymphocyte-specific	9
protein	10
1	10
(	0
LSP1	9
)	0
,	0
that	0
is	0
here	0
characterized	0
as	0
the	0
most	0
prominent	0
protein	9
kinase	10
C	10
substrate	10
in	0
B	7
cells	8
.	0

Transcription	9
factors	10
of	0
T	7
and	8
B	8
lymphocytes	8
--	0
basic	0
research	0
and	0
clinical	0
perspectives	0
for	0
gastroenterology	0
.	0

Tissue	0
specific	0
regulation	0
of	0
gene	0
expression	0
by	0
transcription	9
factors	10
is	0
a	0
fascinating	0
new	0
field	0
in	0
molecular	0
immunology	0
.	0

This	0
review	0
summarizes	0
data	0
on	0
specific	0
regulation	0
of	0
promoters	1
and	0
enhancers	1
by	0
nuclear	9
trans-acting	10
factors	10
in	0
lymphocytes	7
.	0

The	0
structural	0
classes	0
of	0
transcription	9
factors	10
are	0
described	0
and	0
basic	0
methods	0
for	0
detection	0
and	0
analysis	0
of	0
transcription	9
factors	10
are	0
detailed	0
.	0

Furthermore	0
,	0
the	0
most	0
important	0
trans-acting	9
factors	10
of	0
T	7
and	8
B	8
lymphocytes	8
(	0
e.g	0
.	0
NF-kB	9
,	0
NF-AT	9
and	0
STAT	9
families	10
)	0
and	0
their	0
functional	0
importance	0
are	0
described	0
.	0

Several	0
methods	0
for	0
specific	0
down-regulation	0
of	0
transcription	9
factors	10
are	0
shown	0
that	0
may	0
be	0
relevant	0
to	0
treatment	0
of	0
human	0
disease	0
.	0

The	0
data	0
are	0
discussed	0
with	0
regard	0
to	0
their	0
potential	0
clinical	0
relevance	0
for	0
gastroenterology	0
.	0

Selective	0
effects	0
of	0
DNA	0
damaging	0
agents	0
on	0
HIV	1
long	2
terminal	2
repeat	2
activation	0
and	0
virus	0
replication	0
in	0
vitro	0
.	0

Much	0
attention	0
has	0
recently	0
focused	0
on	0
the	0
observation	0
that	0
UV	0
light	0
can	0
activate	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
.	0

Although	0
the	0
mechanism	0
of	0
LTR	1
activation	0
remains	0
obscure	0
,	0
several	0
lines	0
of	0
investigation	0
have	0
suggested	0
that	0
it	0
is	0
a	0
result	0
of	0
activation	0
of	0
the	0
NF-kappa	9
B	10
transcription	9
factor	10
(	0
s	0
)	0
following	0
signaling	0
events	0
related	0
to	0
generalized	0
DNA	0
damage	0
.	0

In	0
this	0
report	0
,	0
we	0
present	0
data	0
demonstrating	0
that	0
HIV	0
LTR	1
activation	0
is	0
not	0
a	0
general	0
consequence	0
of	0
cellular	1
DNA	2
damage	0
,	0
but	0
rather	0
a	0
process	0
unique	0
to	0
specific	0
genotoxic	0
stimuli	0
,	0
and	0
that	0
it	0
does	0
not	0
necessarily	0
depend	0
on	0
activation	0
of	0
NF-kappa	9
B	10
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
several	0
of	0
these	0
agents	0
can	0
significantly	0
increase	0
HIV	0
replication	0
and	0
accelerate	0
CD4	9
-positive	0
lymphocyte	0
cytotoxicity	0
in	0
vitro	0
.	0

These	0
findings	0
,	0
therefore	0
,	0
could	0
have	0
clinical	0
significance	0
to	0
AIDS	0
patients	0
with	0
malignancies	0
who	0
are	0
undergoing	0
radiotherapy	0
and	0
chemotherapy	0
.	0

Receptors	0
for	0
interleukin	9
(	10
IL	10
)	10
-10	10
and	10
IL-6-type	10
cytokines	10
use	0
similar	0
signaling	0
mechanisms	0
for	0
inducing	0
transcription	0
through	0
IL-6	1
response	2
elements	2
.	0

The	0
cytoplasmic	9
domain	10
of	0
the	0
receptor	0
for	0
interleukin	9
10	10
(	0
IL-10R	9
)	0
contains	0
two	0
box	9
3	10
sequence	10
motifs	10
that	0
have	0
been	0
identified	0
in	0
the	0
signal-transducing	9
receptor	10
subunits	10
for	0
IL-6-type	9
cytokines	10
and	0
noted	0
to	0
be	0
required	0
for	0
activating	0
STAT3	9
and	0
inducing	0
transcription	0
through	0
IL-6-responsive	1
elements	2
.	0

To	0
determine	0
whether	0
the	0
IL-10R	9
has	0
signaling	0
functions	0
similar	0
to	0
IL-6R	9
in	0
cells	0
normally	0
expressing	0
these	0
receptors	0
,	0
leukocytes	7
of	0
the	0
B-	7
,	8
T-	8
,	8
and	8
NK-cell	8
lineages	8
were	0
treated	0
with	0
either	0
cytokine	0
.	0

Both	0
cytokines	9
activated	0
factors	0
that	0
bound	0
to	0
the	0
sis-inducible	1
element	2
and	0
included	0
STAT1	9
and	0
STAT3	9
.	0

The	0
cell	0
response	0
to	0
IL-10	9
characteristically	0
differed	0
from	0
that	0
to	0
IL-2/IL-15	9
,	0
IL-4	9
,	0
and	0
interferon	9
gamma	10
.	0

The	0
signaling	0
capabilities	0
of	0
the	0
IL-10R	9
for	0
activating	0
specific	0
STAT	9
proteins	10
and	0
inducing	0
gene	0
transcription	0
were	0
defined	0
by	0
reconstitution	0
of	0
receptor	0
functions	0
in	0
transfected	5
tissue	6
culture	6
cells	6
.	0

COS-1	5
cells	6
,	0
co-expressing	0
the	0
human	0
IL-10R	9
and	0
individual	0
STAT	9
proteins	10
,	0
confirmed	0
a	0
preference	0
of	0
the	0
IL-10R	9
for	0
STAT3	9
and	0
STAT1	9
.	0

Unlike	0
many	0
hematopoietin	9
receptors	10
,	0
the	0
IL-10R	9
did	0
not	0
detectably	0
activate	0
STAT5	9
.	0

The	0
IL-10R	9
,	0
together	0
with	0
reporter	0
gene	0
constructs	0
containing	0
different	0
IL-6-responsive	1
gene	2
elements	2
,	0
reconstituted	0
in	0
hepatoma	7
cells	8
an	0
induction	0
of	0
transcription	0
by	0
IL-10	9
that	0
was	0
comparable	0
to	0
that	0
by	0
IL-6	9
.	0

This	0
regulation	0
could	0
not	0
be	0
appreciably	0
modified	0
by	0
enhanced	0
expression	0
of	0
STAT	9
proteins	10
.	0

The	0
similar	0
actions	0
of	0
IL-10R	9
and	0
IL-6R	9
on	0
the	0
induction	0
of	0
endogenous	0
IL-6-responsive	1
genes	2
were	0
demonstrated	0
in	0
hepatoma	7
cells	8
stably	0
expressing	0
the	0
IL-10R	9
.	0

These	0
receptor	0
functions	0
required	0
the	0
presence	0
of	0
the	0
box	9
3	10
motifs	10
,	0
as	0
shown	0
by	0
the	0
analysis	0
of	0
the	0
mouse	0
IL-10R	9
constructs	0
containing	0
progressively	9
truncated	10
cytoplasmic	10
domains	10
.	0

The	0
data	0
demonstrate	0
that	0
the	0
IL-10R	9
,	0
unlike	0
other	0
members	0
of	0
the	0
interferon	0
receptor	0
family	0
,	0
is	0
highly	0
effective	0
in	0
recruiting	0
the	0
signaling	0
pathways	0
of	0
IL-6-type	9
cytokine	10
receptors	10
.	0

Induction	0
of	0
CIITA	9
and	0
modification	0
of	0
in	0
vivo	0
HLA-DR	1
promoter	2
occupancy	0
in	0
normal	7
thymic	8
epithelial	8
cells	8
treated	0
with	0
IFN-gamma	9
:	0
similarities	0
and	0
distinctions	0
with	0
respect	0
to	0
HLA-DR-constitutive	7
B	8
cells	8
.	0

In	0
this	0
study	0
,	0
the	0
IFN-gamma	9
induction	0
of	0
MHC	1
class	2
II	2
gene	2
expression	0
in	0
primary	0
cultures	0
of	0
thymic	5
epithelial	6
cells	6
(	0
TEC	5
)	0
was	0
analyzed	0
.	0

This	0
cellular	0
system	0
offers	0
the	0
advantage	0
that	0
MHC	9
class	10
II	10
induction	0
is	0
studied	0
in	0
a	0
``	7
physiologic	8
''	8
cell	8
lineage	8
that	0
,	0
as	0
a	0
result	0
of	0
this	0
expression	0
within	0
the	0
thymus	0
,	0
is	0
thought	0
to	0
participate	0
to	0
the	0
selection	0
and	0
maturation	0
of	0
the	0
T	7
cells	8
.	0

It	0
was	0
found	0
that	0
the	0
MHC	1
class	2
II	2
gene	2
expression	0
was	0
associated	0
with	0
the	0
de	0
novo	0
transcription	0
of	0
the	0
gene	0
encoding	0
the	0
CIITA	9
trans-activator	10
,	0
a	0
crucial	0
MHC	9
class	10
II	10
gene	10
regulatory	10
factor	10
.	0

Furthermore	0
,	0
the	0
anatomy	0
of	0
interaction	0
between	0
the	0
MHC	1
class	2
II	2
DRA	2
promoter	2
and	0
corresponding	0
binding	9
factors	10
was	0
analyzed	0
by	0
in	0
vivo	0
DNAse	9
I	10
footprint	0
.	0

It	0
was	0
found	0
that	0
treatment	0
with	0
IFN-gamma	9
induces	0
changes	0
in	0
the	0
occupancy	0
of	0
the	0
DRA	1
gene	2
regulatory	2
sequences	2
by	0
nuclear	9
factors	10
.	0

The	0
resulting	0
occupancy	0
displays	0
strong	0
similarities	0
with	0
the	0
one	0
observed	0
in	0
the	0
MHC	7
class	8
II-constitutive	8
B	8
cells	8
,	0
represented	0
by	0
both	0
the	0
Burkitt	5
lymphoma	6
line	6
Raji	6
and	0
normal	7
tonsil-	8
derived	8
B	8
cells	8
.	0

However	0
,	0
some	0
peculiar	0
differences	0
were	0
observed	0
between	0
the	0
TEC	5
,	0
either	0
IFN-gamma	9
-induced	0
or	0
not	0
,	0
and	0
the	0
constitutive	0
B	5
cells	6
.	0

These	0
results	0
suggest	0
that	0
both	0
common	0
mechanisms	0
,	0
such	0
as	0
the	0
one	0
mediated	0
by	0
the	0
CIITA	9
trans-activator	10
,	0
and	0
distinct	0
tissue-specific	0
constraints	0
contribute	0
to	0
the	0
transcriptional	0
control	0
of	0
constitutive	0
and	0
IFN-gamma	9
-induced	0
MHC	1
class	2
II	2
gene	2
expression	0
.	0

Inhibitory	0
effect	0
of	0
E3330	0
,	0
a	0
novel	0
quinone	0
derivative	0
able	0
to	0
suppress	0
tumor	9
necrosis	10
factor-alpha	10
generation	0
,	0
on	0
activation	0
of	0
nuclear	9
factor-kappa	10
B	10
.	0

(	0
2E	0
)	0
-3-	0
[	0
5-	0
(	0
2	0
,	0
3-Dimethoxy-6-methyl-1	0
,	0
4-benzoquinoyl	0
)	0
]	0
-2-nonyl-2-	0
propenoic	0
acid	0
(	0
E3330	0
)	0
,	0
is	0
a	0
novel	0
agent	0
with	0
hepatoprotective	0
activity	0
.	0

We	0
report	0
the	0
effect	0
of	0
E3330	0
on	0
transcriptional	0
activation	0
of	0
tumor	1
necrosis	2
factor	2
(	2
TNF	2
)	2
-alpha	2
gene	2
and	0
on	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
activation	0
.	0

Nuclear	0
run-on	0
experiments	0
showed	0
that	0
E3330	0
decreases	0
transcriptional	0
activation	0
of	0
TNF-alpha	1
gene	2
induced	0
by	0
lipopolysaccharide	0
(	0
LPS	0
)	0
stimulation	0
in	0
human	7
peripheral	8
monocytes	8
.	0

To	0
investigate	0
the	0
inhibitory	0
mechanisms	0
,	0
we	0
constructed	0
a	0
secreted-type	1
placental	2
alkaline	2
phosphatase	2
(	2
PLAP	2
)	2
reporter	2
gene	2
whose	0
transcription	0
is	0
controlled	0
by	0
a	0
1.4-kb	1
human	2
TNF-alpha	2
promoter	2
.	0

A	0
stable	0
transformant	0
of	0
the	0
PLAP	1
reporter	2
gene	2
derived	0
from	0
human	5
monocytic	6
cell	6
line	6
showed	0
very	0
little	0
activity	0
on	0
the	0
promoter	0
before	0
stimulation	0
,	0
whereas	0
LPS	0
stimulation	0
led	0
to	0
a	0
dramatic	0
increase	0
in	0
PLAP	9
activity	0
.	0

E3330	0
inhibited	0
this	0
induced	0
promoter	0
activity	0
in	0
a	0
dose-dependent	0
manner	0
.	0

There	0
are	0
four	0
putative	0
NF-kappa	1
B	2
binding	2
sites	2
(	0
kappa	1
B-1	2
,	0
kappa	1
B-2	2
,	0
kappa	1
B-3	2
,	0
kappa	1
B-4	2
)	0
in	0
human	1
TNF-alpha	2
promoter	2
.	0

By	0
using	0
mutated	1
promoter-PLAP	2
plasmids	2
,	0
we	0
established	0
that	0
these	0
NF-kappa	1
B	2
sites	2
were	0
necessary	0
for	0
induction	0
of	0
TNF-alpha	9
transcription	0
on	0
stimulation	0
with	0
LPS	0
.	0

A	0
gel	0
retardation	0
experiment	0
with	0
synthetic	0
double-stranded	0
oligonucleotides	0
showed	0
that	0
activated	0
NF-kappa	9
B	10
consisting	0
of	0
p50/p65	9
heterodimer	10
bound	0
to	0
all	0
four	0
putative	0
NF-kappa	1
B	2
DNA	2
probes	2
,	0
suggesting	0
that	0
all	0
four	0
putative	0
NF-kappa	1
B	2
recognition	2
sites	2
play	0
an	0
important	0
role	0
in	0
inducible	0
TNF-alpha	9
expression	0
.	0

E3330	0
decreased	0
activated	0
NF-kappa	9
B	10
in	0
nuclei	0
,	0
suggesting	0
that	0
E3330	0
inhibits	0
NF-kappa	9
B	10
activation	0
and/or	0
translocation	0
of	0
the	0
nuclei	0
.	0

Western	0
blotting	0
analysis	0
with	0
anti-I	9
kappa	10
B-alpha	10
antibody	10
indicated	0
that	0
E3330	0
inhibited	0
degradation	0
of	0
I	9
kappa	10
B-alpha	10
,	0
which	0
is	0
an	0
inhibitory	9
protein	10
of	0
NF-kappa	9
B	10
,	0
in	0
LPS-stimulated	5
monocytes	6
.	0

E3330	0
may	0
suppress	0
the	0
production	0
of	0
active	0
oxygen	0
species	0
serving	0
as	0
common	0
messengers	0
to	0
activate	0
NF-kappa	9
B	10
.	0

C-terminal	9
activating	10
and	10
inhibitory	10
domains	10
determine	0
the	0
transactivation	0
potential	0
of	0
BSAP	9
(	0
Pax-5	1
)	0
,	0
Pax-2	1
and	0
Pax-8	1
.	0

Pax-5	1
encodes	0
the	0
transcription	9
factor	10
BSAP	9
which	0
plays	0
an	0
essential	0
role	0
in	0
early	0
B	0
cell	0
development	0
and	0
midbrain	0
patterning	0
.	0

In	0
this	0
study	0
we	0
have	0
analysed	0
the	0
structural	0
requirements	0
for	0
transcriptional	0
activation	0
by	0
BSAP	9
.	0

In	0
vitro	0
mutagenesis	0
and	0
transient	0
transfection	0
experiments	0
indicate	0
that	0
the	0
C-terminal	9
serine/threonine/proline-rich	10
region	10
of	0
BSAP	9
contains	0
a	0
potent	0
transactivation	9
domain	10
of	0
55	0
amino	0
acids	0
which	0
is	0
active	0
from	0
promoter	1
and	2
enhancer	2
positions	2
.	0

This	0
transactivation	9
domain	10
was	0
found	0
to	0
be	0
inactivated	0
by	0
a	0
naturally	0
occurring	0
frameshift	0
mutation	0
in	0
one	0
PAX-5	1
allele	2
of	0
the	0
acute	5
lymphoblastic	6
leukemia	6
cell	6
line	6
REH	6
.	0

The	0
function	0
of	0
the	0
transactivation	9
domain	10
is	0
negatively	0
regulated	0
by	0
adjacent	0
sequences	0
from	0
the	0
extreme	9
C-terminus	10
.	0

The	0
activating	0
and	0
inhibitory	0
domains	0
function	0
together	0
as	0
an	0
independent	0
regulatory	0
module	0
in	0
different	0
cell	0
types	0
as	0
shown	0
by	0
fusion	0
to	0
the	0
GAL4	9
DNA	10
binding	10
domain	10
.	0

The	0
same	0
arrangement	0
of	0
positively	1
and	2
negatively	2
acting	2
sequences	2
has	0
been	0
conserved	0
in	0
the	0
mammalian	1
Pax-2	2
and	0
Pax-8	1
,	0
the	0
zebrafish	1
Pax-b	2
as	0
well	0
as	0
the	0
sea	9
urchin	10
Pax-258	10
proteins	10
.	0

These	0
data	0
demonstrate	0
that	0
the	0
transcriptional	0
competence	0
of	0
a	0
subfamily	0
of	0
Pax	9
proteins	10
is	0
determined	0
by	0
a	0
C-terminal	9
regulatory	10
module	10
composed	0
of	0
activating	1
and	2
inhibitory	2
sequences	2
.	0

Second	0
messenger	0
up-regulation	0
of	0
androgen	1
receptor	2
gene	2
transcription	0
is	0
absent	0
in	0
androgen	5
insensitive	6
human	6
prostatic	6
carcinoma	6
cell	6
lines	6
,	0
PC-3	5
and	0
DU-145	5
.	0

A	0
theoretical	0
pathway	0
of	0
transcriptional	0
regulation	0
of	0
the	0
androgen	1
receptor	2
(	2
AR	2
)	2
gene	2
is	0
via	0
a	0
cAMP	1
response	2
element	2
(	0
CRE	1
)	0
present	0
in	0
its	0
promoter	1
region	2
(	0
-508	0
to	0
-501	0
)	0
.	0

After	0
20	0
h	0
of	0
stimulation	0
with	0
8-bromo-cAMP	0
,	0
AR	3
mRNA	4
was	0
upregulated	0
in	0
LNCaP	5
but	0
not	0
in	0
either	0
PC-3	5
or	0
DU-145	5
cell	6
lines	6
.	0

We	0
have	0
demonstrated	0
that	0
the	0
level	0
of	0
CRE	9
binding	10
protein	10
(	0
CREB	9
)	0
was	0
the	0
same	0
in	0
all	0
cell	0
lines	0
and	0
that	0
the	0
putative	0
AR-CRE	9
forms	0
specific	0
and	0
compatible	0
protein	0
interactions	0
with	0
CREB	9
.	0

The	0
ability	0
to	0
regulate	0
AR	1
gene	2
transcription	0
via	0
the	0
second	0
messenger	0
pathway	0
is	0
lost	0
in	0
the	0
PC-3	5
and	6
DU-145	6
cell	6
lines	6
.	0

This	0
may	0
be	0
an	0
important	0
primary	0
mechanism	0
of	0
androgen	0
insensitivity	0
in	0
prostate	0
cancer	0
.	0

Structural	0
and	0
functional	0
characterization	0
of	0
the	0
human	1
CD36	2
gene	2
promoter	2
:	0
identification	0
of	0
a	0
proximal	0
PEBP2/CBF	1
site	2
.	0

CD36	9
is	0
a	0
cell	0
surface	0
glycoprotein	9
composed	0
of	0
a	0
single	0
polypeptide	0
chain	0
,	0
which	0
interacts	0
with	0
thrombospondin	9
,	0
collagens	9
type	10
I	10
and	10
IV	10
,	0
oxidized	0
low	9
density	10
lipoprotein	10
,	0
fatty	0
acids	0
,	0
anionic	0
phospholipids	0
,	0
and	0
erythrocytes	7
parasitized	0
with	0
Plasmodium	0
falciparum	0
.	0

Its	0
expression	0
is	0
restricted	0
to	0
a	0
few	0
cell	0
types	0
,	0
including	0
monocyte/macrophages	7
.	0

In	0
these	0
cells	0
,	0
CD36	9
is	0
involved	0
in	0
phagocytosis	0
of	0
apoptotic	7
cells	8
,	0
and	0
foam	0
cell	0
formation	0
by	0
uptake	0
of	0
oxidized	9
low	10
density	10
lipoprotein	10
.	0

To	0
study	0
the	0
molecular	0
mechanisms	0
that	0
control	0
the	0
transcription	0
of	0
the	0
CD36	9
gene	0
in	0
monocytic	0
cells	0
we	0
have	0
isolated	0
and	0
analyzed	0
the	0
CD36	1
promoter	2
.	0

Transient	0
expression	0
experiments	0
of	0
5'-deletion	1
fragments	2
of	0
the	0
CD36	1
promoter	2
coupled	0
to	0
luciferase	9
demonstrated	0
that	0
as	0
few	0
as	0
158	1
base	2
pairs	2
upstream	2
from	0
the	0
transcription	1
initiation	2
site	2
were	0
sufficient	0
to	0
direct	0
the	0
monocyte-specific	0
transcription	0
of	0
the	0
reporter	1
gene	2
.	0

Within	0
the	0
above	0
region	0
,	0
the	0
fragment	0
spanning	0
nucleotides	1
-158	2
to	2
-90	2
was	0
required	0
for	0
optimal	0
transcription	0
in	0
monocytic	7
cells	8
.	0

Biochemical	0
analysis	0
of	0
the	0
region	0
-158/-90	1
revealed	0
a	0
binding	0
site	0
for	0
transcription	9
factors	10
of	0
the	0
polyomavirus	9
enhancer-binding	10
protein	10
2/core-binding	10
factor	10
(	10
PEBP2/CBF	10
)	10
family	10
at	0
position	1
-103	2
.	0

Disruption	0
of	0
the	0
PEBP2/CBF	1
site	2
markedly	0
diminished	0
the	0
role	0
of	0
the	0
PEBP2/CBF	9
factors	10
in	0
the	0
constitutive	0
transcription	0
of	0
the	0
CD36	1
gene	2
.	0

The	0
involvement	0
of	0
members	0
of	0
the	0
PEBP2/CBF	9
family	10
in	0
chromosome	0
translocations	0
associated	0
with	0
acute	0
myeloid	0
leukemia	0
,	0
and	0
in	0
the	0
transcriptional	0
regulation	0
of	0
the	0
myeloid-specific	1
genes	2
encoding	0
for	0
myeloperoxidase	9
,	0
elastase	9
,	0
and	0
the	0
colony-stimulating	9
factor	10
receptor	10
,	0
highlights	0
the	0
relevance	0
of	0
the	0
regulation	0
of	0
the	0
CD36	1
gene	2
promoter	2
in	0
monocytic	7
cells	8
by	0
members	0
of	0
the	0
PEBP2/CBF	9
family	10
.	0

HLA-DQB1	1
codon	2
57	2
is	0
critical	0
for	0
peptide	0
binding	0
and	0
recognition	0
.	0

The	0
association	0
of	0
specific	0
HLA-DQ	1
alleles	2
with	0
autoimmunity	0
is	0
correlated	0
with	0
discrete	0
polymorphisms	0
in	0
the	0
HLA-DQ	1
sequence	2
that	0
are	0
localized	0
within	0
sites	0
suitable	0
for	0
peptide	0
recognition	0
.	0

The	0
polymorphism	0
at	0
residue	0
57	0
of	0
the	0
DQB1	0
polypeptide	0
is	0
of	0
particular	0
interest	0
since	0
it	0
may	0
play	0
a	0
major	0
structural	0
role	0
in	0
the	0
formation	0
of	0
a	0
salt	9
bridge	10
structure	10
at	0
one	0
end	0
of	0
the	0
peptide-binding	9
cleft	10
of	0
the	0
DQ	0
molecules	0
.	0

This	0
polymorphism	0
at	0
residue	0
57	0
is	0
a	0
recurrent	0
feature	0
of	0
HLA-DQ	0
evolution	0
,	0
occurring	0
in	0
multiple	0
distinct	0
allelic	0
families	0
,	0
which	0
implies	0
a	0
functional	0
selection	0
for	0
maintaining	0
variation	0
at	0
this	0
position	0
in	0
the	0
class	9
II	10
molecule	10
.	0

We	0
directly	0
tested	0
the	0
amino	0
acid	0
polymorphism	0
at	0
this	0
site	0
as	0
a	0
determinant	0
for	0
peptide	0
binding	0
and	0
for	0
antigen-specific	0
T	0
cell	0
stimulation	0
.	0

We	0
found	0
that	0
a	0
single	0
Ala	0
--	0
>	0
Asp	0
amino	0
acid	0
57	0
substitution	0
in	0
an	0
HLA-DQ3.2	0
molecule	0
regulated	0
binding	0
of	0
an	0
HSV-2	0
VP-16-derived	0
peptide	0
.	0

A	0
complementary	0
single-residue	0
substitution	0
in	0
the	0
peptide	0
abolished	0
its	0
binding	0
to	0
DQ3.2	0
and	0
converted	0
it	0
to	0
a	0
peptide	0
that	0
can	0
bind	0
to	0
DQ3.1	0
and	0
DQ3.3	9
Asp-57-positive	10
MHC	10
molecules	10
.	0

These	0
binding	0
studies	0
were	0
paralleled	0
by	0
specific	0
T	0
cell	0
recognition	0
of	0
the	0
class	9
II-peptide	10
complex	10
,	0
in	0
which	0
the	0
substituted	0
peptide	0
abolished	0
T	0
cell	0
reactivity	0
,	0
which	0
was	0
directed	0
to	0
the	0
DQ3.2-peptide	9
complex	10
,	0
whereas	0
the	0
same	0
T	5
cell	6
clone	6
recognized	0
the	0
substituted	0
peptide	0
presented	0
by	0
DQ3.3	0
,	0
a	0
class	0
II	0
restriction	0
element	0
differing	0
from	0
DQ3.2	0
only	0
at	0
residue	0
57	0
.	0

This	0
structural	0
and	0
functional	0
complementarity	0
for	0
residue	0
57	0
and	0
a	0
specific	0
peptide	0
residue	0
identifies	0
this	0
interaction	0
as	0
a	0
key	0
controlling	0
determinant	0
of	0
restricted	0
recognition	0
in	0
HLA-DQ-specific	0
immune	0
response	0
.	0

Autocrine	0
activation	0
by	0
interferon-gamma	9
of	0
STAT	9
factors	10
following	0
T	0
cell	0
activation	0
.	0

The	0
activation	0
of	0
T	7
cells	8
requires	0
engagement	0
of	0
the	0
T	9
cell	10
receptor/CD3	10
complex	10
and	0
co-stimulatory	9
molecules	10
,	0
and	0
results	0
in	0
the	0
triggering	0
of	0
several	0
signaling	0
pathways	0
which	0
lead	0
rapidly	0
to	0
the	0
nuclear	0
translocation	0
of	0
several	0
transcription	9
factors	10
,	0
such	0
as	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
and	0
NF-AT	9
.	0

A	0
result	0
of	0
this	0
activation	0
process	0
is	0
the	0
induction	0
of	0
a	0
number	0
of	0
genes	0
,	0
including	0
those	0
encoding	0
cytokines	9
such	0
as	0
interleukin-2	9
,	0
tumor	9
necrosis	10
factor-alpha	10
,	0
and	0
interferon	9
(	10
IFN	10
)	10
-gamma	10
which	0
have	0
important	0
immunoregulatory	9
effects	0
.	0

We	0
report	0
here	0
that	0
a	0
DNA-binding	9
factor	10
containing	0
STAT1	9
also	0
becomes	0
activated	0
in	0
human	7
peripheral	8
blood	8
T	8
lymphocytes	8
or	0
Jurkat	5
cells	6
,	0
although	0
not	0
until	0
1-2	0
h	0
after	0
stimulation	0
.	0

Activation	0
is	0
delayed	0
a	0
further	0
1-2	0
hr	0
when	0
mononuclear	5
cell	6
cultures	6
are	0
stimulated	0
by	0
an	0
antigen	0
which	0
requires	0
processing	0
.	0

Appearance	0
of	0
the	0
STAT1	9
factor	0
is	0
significantly	0
reduced	0
in	0
the	0
presence	0
of	0
cyclosporin	0
A	0
,	0
and	0
blocked	0
by	0
cycloheximide	0
,	0
indicating	0
that	0
its	0
activation	0
is	0
dependent	0
upon	0
a	0
protein	0
(	0
s	0
)	0
synthesized	0
in	0
response	0
to	0
initial	0
signaling	0
events	0
.	0

Neutralizing	0
antiserum	0
against	0
IFN-gamma	9
,	0
but	0
not	0
other	0
cytokines	9
tested	0
,	0
blocked	0
activation	0
of	0
the	0
factor	0
almost	0
completely	0
,	0
and	0
IFN-gamma	9
was	0
found	0
in	0
the	0
culture	0
supernatants	0
of	0
stimulated	5
cells	6
at	0
levels	0
at	0
which	0
recombinant	0
IFN-gamma	9
could	0
activate	0
the	0
factor	0
in	0
naive	7
cells	8
.	0

Therefore	0
,	0
a	0
STAT1	9
transcription	9
factor	10
is	0
activated	0
by	0
IFN-gamma	9
synthesized	0
and	0
released	0
upon	0
stimulation	0
of	0
T	7
lymphocyte	8
populations	8
.	0

While	0
Jurkat	5
cells	6
both	0
secrete	0
and	0
respond	0
to	0
IFN-gamma	9
in	0
an	0
autocrine	0
loop	0
,	0
it	0
seems	0
likely	0
that	0
the	0
responding	0
cells	0
may	0
differ	0
from	0
those	0
synthesizing	0
this	0
cytokine	9
in	0
the	0
mononuclear	5
cell	6
cultures	6
in	0
the	0
light	0
of	0
the	0
recent	0
report	0
that	0
Th1	5
cells	6
lack	0
the	0
IFN-gamma	9
receptor	0
chain	0
necessary	0
for	0
activation	0
of	0
STAT1	9
(	0
Pernis	0
,	0
A.	0
,	0
Gupta	0
,	0
S.	0
,	0
Gollob	0
,	0
K.J.	0
,	0
Garfein	0
,	0
E.	0
,	0
Coffman	0
,	0
R.L.	0
,	0
Schindler	0
,	0
C.	0
,	0
and	0
Rothman	0
,	0
P.	0
,	0
Science	0
1995.	0
269	0
:	0
245	0
)	0
.	0

Absence	0
of	0
T-cell-	9
and	10
B-cell-specific	10
transcription	10
factors	10
TCF-1	9
,	0
GATA-3	9
,	0
and	0
BSAP	9
in	0
Hodgkin	5
's	6
Reed-Sternberg	6
cells	6
.	0

Based	0
on	0
the	0
presence	0
of	0
T	1
cell	2
receptor-beta	2
(	2
TcR-beta	2
)	2
gene	2
rearrangements	2
in	0
L428	5
and	6
HDLM-1	6
cells	6
,	0
the	0
expression	0
of	0
CD2	9
in	0
HDLM-1	5
cells	6
,	0
and	0
the	0
presence	0
of	0
immunoglobulin	1
heavy-chain	2
(	2
IgH	2
)	2
gene	2
rearrangement	2
in	0
KM-H2	5
cells	6
,	0
some	0
researchers	0
have	0
concluded	0
that	0
these	0
long-term	5
cell	6
lines	6
derived	0
from	0
patients	0
with	0
Hodgkin	0
's	0
disease	0
are	0
lymphoid	0
in	0
nature	0
.	0

The	0
information	0
obtained	0
from	0
these	0
cell	5
lines	6
has	0
also	0
been	0
used	0
in	0
arguments	0
for	0
a	0
lymphoid	0
origin	0
of	0
H-RS	5
cells	6
in	0
tissue	0
despite	0
the	0
frequent	0
absence	0
of	0
lymphoid	9
markers	10
and	0
Ig/TcR	1
gene	2
rearrangements	2
in	0
these	0
cells	0
.	0

We	0
questioned	0
whether	0
one	0
can	0
use	0
the	0
limited	0
expression	0
of	0
lymphoid	9
markers	10
or	0
the	0
limited	0
gene	0
rearrangement	0
to	0
conclude	0
that	0
H-RS	5
cells	6
have	0
a	0
lymphoid	0
origin	0
,	0
because	0
these	0
markers	0
may	0
be	0
aberrant	0
in	0
tumor	7
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
expression	0
of	0
two	0
T-cell-specific	9
transcription	10
factors	10
(	0
TCF-1	9
and	0
GATA-3	9
)	0
and	0
one	0
B-cell-specific	9
transcription	10
factor	10
(	0
BSAP	9
)	0
in	0
cultured	5
H-RS	6
cells	6
by	0
using	0
a	0
gel	0
mobility	0
shift	0
assay	0
.	0

The	0
sensitivity	0
and	0
specificity	0
of	0
this	0
assay	0
for	0
determination	0
of	0
cell	5
lineage	6
have	0
been	0
established	0
in	0
a	0
large	0
number	0
of	0
cultured	5
human	6
and	6
murine	6
cell	6
lines	6
.	0

All	0
three	0
types	0
of	0
H-RS	5
cell	6
lines	6
were	0
consistently	0
negative	0
for	0
BSAP	9
,	0
TCF-1	9
,	0
and	0
GATA-3	9
.	0

The	0
absence	0
of	0
GATA-3	9
was	0
confirmed	0
in	0
H-RS	5
cells	6
in	0
tissues	0
by	0
an	0
in	0
situ	0
hybridization	0
technique	0
.	0

Virtually	0
all	0
B-cell	5
lines	6
,	0
with	0
the	0
exception	0
of	0
some	0
myeloma	5
cell	6
lines	6
,	0
are	0
positive	0
for	0
BSAP	9
,	0
which	0
is	0
the	0
transcription	9
factor	10
for	0
promoters	1
for	0
several	0
B-cell	9
markers	10
,	0
including	0
VpreB1	9
,	0
lambda	9
5	10
,	0
CD19	9
,	0
and	0
CD20	9
.	0

All	0
T-cell	5
lines	6
tested	0
were	0
positive	0
for	0
TCF-1	9
and	0
GATA-3	9
,	0
which	0
are	0
the	0
transcription	9
factors	10
for	0
promoters	0
for	0
several	0
T-cell-restricted	9
markers	10
,	0
including	0
CD2	9
,	0
CD3	9
,	0
TcR	9
,	0
and	0
lck	9
.	0

The	0
absence	0
of	0
BSAP	9
,	0
TCF-1	9
,	0
and	0
GATA-3	9
clearly	0
indicates	0
an	0
underlying	0
difference	0
between	0
H-RS	5
cells	6
and	0
lymphoid	7
cells	8
.	0

MEK1	9
and	0
the	0
extracellular	9
signal-regulated	10
kinases	10
are	0
required	0
for	0
the	0
stimulation	0
of	0
IL-2	1
gene	2
transcription	0
in	0
T	7
cells	8
.	0

TCR	9
engagement	0
stimulates	0
the	0
activation	0
of	0
the	0
protein	9
kinase	10
Raf-1	9
.	0

Active	0
Raf-1	9
phosphorylates	0
and	0
activates	0
the	0
mitogen-activated	9
protein	10
(	10
MAP	10
)	10
kinase/extracellular	10
signal-regulated	10
kinase	10
kinase	10
1	10
(	0
MEK1	9
)	0
,	0
which	0
in	0
turn	0
phosphorylates	0
and	0
activates	0
the	0
MAP	9
kinases/extracellular	10
signal	10
regulated	10
kinases	10
,	0
ERK1	9
and	0
ERK2	9
.	0

Raf-1	9
activity	0
promotes	0
IL-2	0
production	0
in	0
activated	0
T	7
lymphocytes	8
.	0

Therefore	0
,	0
we	0
sought	0
to	0
determine	0
whether	0
MEK1	9
and	0
ERK	9
activities	0
also	0
stimulate	0
IL-2	1
gene	2
transcription	0
.	0

Expression	0
of	0
constitutively	0
active	0
Raf-1	9
or	0
MEK1	9
in	0
Jurkat	5
T	6
cells	6
enhanced	0
the	0
stimulation	0
of	0
IL-2	1
promoter	2
-driven	0
transcription	0
stimulated	0
by	0
a	0
calcium	0
ionophore	0
and	0
PMA	0
,	0
and	0
together	0
with	0
a	0
calcium	0
ionophore	0
the	0
expression	0
of	0
each	0
protein	0
was	0
sufficient	0
to	0
stimulate	0
NF-AT	9
activity	0
.	0

Expression	0
of	0
MEK1-interfering	9
mutants	10
inhibited	0
the	0
stimulation	0
of	0
IL-2	1
promoter	2
-driven	0
transcription	0
and	0
blocked	0
the	0
ability	0
of	0
constitutively	0
active	0
Ras	9
and	0
Raf-1	9
to	0
costimulate	0
NF-AT	9
activity	0
with	0
a	0
calcium	0
ionophore	0
.	0

Expression	0
of	0
the	0
MAP	9
kinase-specific	10
phosphatase	10
,	0
MKP-1	9
,	0
which	0
blocks	0
ERK	9
activation	0
,	0
inhibited	0
IL-2	1
promoter	2
and	0
NF-AT	9
-driven	0
transcription	0
stimulated	0
by	0
a	0
calcium	0
ionophore	0
and	0
PMA	0
,	0
and	0
in	0
addition	0
,	0
MKP-1	9
neutralized	0
the	0
transcriptional	0
enhancement	0
caused	0
by	0
active	0
Raf-1	0
and	0
MEK1	0
expression	0
.	0

We	0
conclude	0
that	0
the	0
MAP	9
kinase	10
signal	0
transduction	0
pathway	0
consisting	0
of	0
Raf-1	9
,	0
MEK1	9
,	0
and	0
ERK1	9
and	0
ERK2	9
functions	0
in	0
the	0
stimulation	0
IL-2	1
gene	2
transcription	0
in	0
activated	0
T	7
lymphocytes	8
.	0

Multiple	0
transcription	9
factors	10
are	0
required	0
for	0
activation	0
of	0
human	1
interleukin	2
9	2
gene	2
in	0
T	7
cells	8
.	0

The	0
genetic	0
elements	0
and	0
regulatory	0
mechanisms	0
responsible	0
for	0
human	1
interleukin	2
9	2
(	2
IL-9	2
)	2
gene	2
expression	0
in	0
a	0
human	5
T	6
cell	6
leukemia	6
virus	6
type	6
I-transformed	6
human	6
T	6
cell	6
line	6
,	0
C5MJ2	5
,	0
were	0
investigated	0
.	0

We	0
demonstrated	0
that	0
IL-9	1
gene	2
expression	0
is	0
controlled	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
transcriptional	0
activation	0
.	0

Transient	0
expression	0
of	0
the	0
luciferase	1
reporter	2
gene	2
linked	0
to	0
serially	0
deleted	0
sequences	0
of	0
the	0
5'-flanking	1
region	2
of	0
the	0
IL-9	1
gene	2
has	0
revealed	0
several	0
positive	0
and	0
negative	1
regulatory	2
elements	2
involved	0
in	0
the	0
basal	0
and	0
inducible	0
expression	0
of	0
the	0
IL-9	1
gene	2
in	0
C5MJ2	5
cells	6
.	0

An	0
AP-1	0
site	0
at	0
-146	0
to	0
-140	0
was	0
shown	0
to	0
be	0
involved	0
in	0
the	0
expression	0
of	0
the	0
IL-9	1
gene	2
.	0

A	0
proximal	1
region	2
between	0
-46	1
and	2
-80	2
was	0
identified	0
as	0
the	0
minimum	0
sequence	0
for	0
the	0
basal	0
and	0
inducible	0
expression	0
of	0
the	0
IL-9	1
gene	2
in	0
C5MJ2	5
cells	6
.	0

Within	0
this	0
region	0
,	0
an	0
NF-kappaB	1
site	2
at	0
-59	1
to	2
-50	2
and	0
its	0
adjacent	0
20-base	1
pair	2
upstream	2
sequence	2
were	0
demonstrated	0
to	0
play	0
a	0
critical	0
role	0
for	0
the	0
IL-9	1
promoter	2
activity	0
.	0

DNA-protein	0
binding	0
studies	0
indicated	0
that	0
NF-kappaB	9
,	0
c-Jun	9
,	0
and	0
potentially	0
novel	9
proteins	10
(	0
around	0
35	9
kDa	10
)	0
can	0
bind	0
to	0
this	0
important	0
sequence	0
.	0

Mutations	0
at	0
different	0
sites	0
within	0
this	0
proximal	1
promoter	2
region	2
abolished	0
the	0
promoter	0
activity	0
as	0
well	0
as	0
the	0
DNA	0
binding	0
.	0

Taken	0
together	0
,	0
these	0
results	0
suggest	0
that	0
the	0
cooperation	0
of	0
different	0
transcription	9
factors	10
is	0
essential	0
for	0
IL-9	1
gene	2
expression	0
in	0
T	7
cells	8
.	0

DNA	0
triplex	0
formation	0
selectively	0
inhibits	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
gene	2
expression	0
in	0
human	0
T	0
cells	0
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
is	0
a	0
hemopoietic	0
growth	0
factor	0
that	0
is	0
expressed	0
in	0
activated	0
T	0
cells	0
,	0
fibroblasts	0
,	0
macrophages	0
,	0
and	0
endothelial	0
cells	0
.	0

Although	0
GM-CSF	9
does	0
not	0
appear	0
to	0
be	0
essential	0
for	0
normal	0
hemopoiesis	0
,	0
overexpression	0
of	0
GM-CSF	0
has	0
been	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
some	0
diseases	0
such	0
as	0
myeloid	0
leukemia	0
and	0
chronic	0
inflammation	0
.	0

An	0
NF-kappaB	9
/Rel	0
binding	0
site	0
within	0
the	0
GM-CSF	1
promoter	2
,	0
termed	0
the	0
kappaB	0
element	0
appears	0
to	0
be	0
important	0
for	0
controlling	0
expression	0
in	0
reporter	1
gene	2
assays	0
in	0
response	0
to	0
a	0
number	0
of	0
stimuli	0
in	0
T	7
cells	8
.	0

We	0
investigated	0
oligonucleotide-directed	0
triple	0
helix	0
formation	0
across	0
this	0
regulatory	1
sequence	2
as	0
a	0
potential	0
tool	0
to	0
inhibit	0
GM-CSF	9
gene	0
transcription	0
.	0

A	0
15-base	0
oligonucleotide	0
,	0
GM3	0
,	0
was	0
targeted	0
to	0
a	0
purine-rich	1
region	2
in	0
the	0
GM-CSF	1
proximal	2
promoter	2
,	0
which	0
overlaps	0
the	0
kappaB	1
element	2
.	0

Gel	0
mobility	0
shift	0
assays	0
and	0
DNase	9
I	10
footprinting	0
demonstrated	0
that	0
GM3	0
formed	0
a	0
sequence-specific	0
collinear	0
triplex	0
with	0
its	0
double-stranded	1
DNA	2
target	2
.	0

Triplex	0
formation	0
by	0
GM3	0
blocked	0
recombinant	9
and	10
nuclear	10
NF-kappaB	10
proteins	10
binding	0
to	0
the	0
GM-CSF	1
element	2
.	0

GM3	0
also	0
caused	0
selective	0
inhibition	0
of	0
the	0
human	9
T-cell	10
lymphotrophic	10
virus-1	10
Tax	10
transactivator-induced	0
luciferase	9
activity	0
from	0
a	0
reporter	0
construct	0
driven	0
by	0
the	0
GM-CSF	1
promoter	2
in	0
Jurkat	5
T	6
cells	6
.	0

Finally	0
,	0
GM3	0
greatly	0
reduced	0
the	0
concentration	0
of	0
endogenous	0
GM-CSF	3
mRNA	4
induced	0
by	0
different	0
stimuli	0
in	0
Jurkat	5
T	6
cells	6
but	0
did	0
not	0
affect	0
interleukin	3
3	4
mRNA	4
levels	0
in	0
the	0
same	0
cells	0
.	0

We	0
conclude	0
that	0
the	0
kappaB	1
element	2
in	0
the	0
GM-CSF	1
promoter	2
plays	0
a	0
central	0
role	0
in	0
the	0
transcriptional	0
activation	0
of	0
the	0
endogenous	0
GM-CSF	1
gene	2
.	0

Colinear	0
triplex	0
formation	0
acts	0
as	0
a	0
selective	0
transcriptional	0
repressor	0
of	0
the	0
GM-CSF	1
gene	2
and	0
may	0
have	0
potential	0
therapeutic	0
application	0
in	0
cases	0
of	0
undesirable	0
overexpression	0
of	0
this	0
protein	0
.	0

Reversible	0
differentiation	0
of	0
human	5
monoblastic	6
leukemia	6
U937	6
cells	6
by	0
ML-9	0
,	0
an	0
inhibitor	0
of	0
myosin	9
light	10
chain	10
kinase	10
.	0

Human	5
monoblastic	6
leukemia	6
U937	6
cells	6
are	0
induced	0
to	0
differentiate	0
into	0
monocytes	7
and	0
macrophages	7
by	0
various	0
agents	0
.	0

We	0
have	0
shown	0
that	0
1-	0
(	0
5-chloronaphthalene-1-sulfonyl	0
)	0
-1H-hexahydro-1	0
,	0
4-diazepine	0
hydrochloride	0
(	0
ML-9	0
)	0
,	0
an	0
inhibitor	0
of	0
myosin	9
light	10
chain	10
kinase	10
,	0
induces	0
differentiation	0
of	0
monocytoid	5
leukemia	6
cell	6
lines	6
U937	5
and	0
THP-1	5
but	0
not	0
of	0
myeloblastic	5
leukemic	6
ML-1	6
cell	6
or	0
erythroleukemia	5
K562	6
cells	6
.	0

In	0
the	0
present	0
study	0
,	0
we	0
further	0
analyzed	0
the	0
effect	0
of	0
ML-9	0
in	0
comparison	0
with	0
that	0
of	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
VD3	0
)	0
a	0
typical	0
inducer	0
of	0
monocytic	0
differentiation	0
.	0

ML-9	0
induced	0
nitroblue	0
tetrazolium	0
(	0
NBT	0
)	0
-reducing	0
activity	0
of	0
U937	5
cell	6
more	0
rapidly	0
than	0
VD3	0
:	0
This	0
differentiation	0
marker	0
was	0
induced	0
significantly	0
after	0
incubation	0
with	0
ML-9	0
and	0
VD3	0
for	0
4	0
hours	0
and	0
1	0
day	0
,	0
respectively	0
.	0

ML-9	0
also	0
induced	0
alpha-naphthyl	9
acetate	10
esterase	10
(	0
ANAE	9
)	0
activity	0
,	0
another	0
monocytic	0
differentiation	0
marker	0
,	0
more	0
rapidly	0
than	0
VD3	0
.	0

The	0
maximum	0
levels	0
of	0
these	0
markers	0
induced	0
by	0
ML-9	0
were	0
comparable	0
to	0
those	0
induced	0
by	0
VD3	0
,	0
but	0
after	0
removal	0
of	0
ML-9	0
from	0
the	0
medium	0
by	0
washing	0
the	0
cells	0
,	0
the	0
expressions	0
of	0
theses	0
markers	0
decreased	0
within	0
4	0
hours	0
and	0
reached	0
basal	0
levels	0
in	0
1	0
day	0
,	0
indicating	0
that	0
ML-9	0
's	0
induction	0
of	0
expression	0
of	0
differentiation-associated	0
phenotypes	0
was	0
reversible	0
.	0

The	0
growth	0
inhibition	0
of	0
U937	5
cells	6
by	0
ML-9	0
was	0
also	0
reversible	0
.	0

Similar	0
effects	0
were	0
observed	0
in	0
another	0
line	0
of	0
human	5
monoblastic	6
cells	6
,	0
THP-1	5
.	0

ML-9	0
had	0
little	0
or	0
no	0
effect	0
on	0
the	0
morphology	0
of	0
U937	5
cells	6
but	0
increased	0
the	0
expression	0
of	0
monocyte-macrophage	9
lineage-associated	10
surface	10
antigen	10
,	0
CD14	9
,	0
to	0
some	0
extent	0
.	0

Irreversible	0
terminal	0
differentiation	0
induced	0
by	0
VD3	0
is	0
associated	0
with	0
down	0
regulation	0
of	0
the	0
expression	0
of	0
c-myc	0
and	0
upregulation	0
of	0
the	0
expression	0
of	0
c-fos	0
and	0
c-jun	0
,	0
but	0
ML-9	0
did	0
not	0
affect	0
the	0
expression	0
of	0
these	0
oncogenes	0
appreciably	0
.	0

ML-9-induced	0
differentiation	0
was	0
also	0
reversible	0
when	0
the	0
cells	0
were	0
cultured	0
with	0
cultured	0
with	0
ML-9	0
plus	0
an	0
anti-cancer	0
drug	0
such	0
as	0
1-beta-D-arabino-furanosylcytosine	0
or	0
daunomycin	0
.	0

it	0
became	0
irreversible	0
,	0
however	0
,	0
upon	0
simultaneous	0
treatment	0
with	0
dexamethasone	0
and	0
transforming	9
growth	10
factor-beta	10
1	10
(	0
TGF-beta	9
1	10
)	0
,	0
which	0
did	0
not	0
induce	0
differentiation	0
of	0
U937	5
cells	6
but	0
caused	0
growth	0
arrest	0
of	0
the	0
cells	0
in	0
the	0
G0/G1	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

These	0
results	0
suggest	0
that	0
ML-9	0
should	0
be	0
useful	0
for	0
studying	0
the	0
mechanisms	0
of	0
monocytic	0
differentiation	0
.	0

Modulation	0
of	0
endogenous	0
IL-1	9
beta	10
and	0
IL-1	9
receptor	10
antagonist	0
results	0
in	0
opposing	0
effects	0
on	0
HIV	0
expression	0
in	0
chronically	5
infected	6
monocytic	6
cells	6
.	0

A	0
proportion	0
of	0
HIV-infected	0
individuals	0
experience	0
episodes	0
of	0
localized	0
or	0
systemic	0
bacterial	0
infections	0
caused	0
by	0
Gram-negative	0
bacteria	0
.	0

Many	0
of	0
the	0
clinical	0
side	0
effects	0
of	0
these	0
infections	0
are	0
associated	0
with	0
the	0
production	0
of	0
proinflammatory	9
cytokines	10
,	0
which	0
are	0
induced	0
primarily	0
by	0
LPS	0
,	0
a	0
constituent	0
of	0
the	0
bacterial	0
cell	0
wall	0
of	0
Gram-negative	0
bacteria	0
.	0

The	0
present	0
study	0
examines	0
the	0
mechanisms	0
involved	0
in	0
LPS-mediated	0
induction	0
of	0
HIV	0
expression	0
in	0
U1	5
cells	6
,	0
a	0
promonocytic	5
cell	6
line	6
chronically	0
infected	0
with	0
HIV	0
.	0

Stimulation	0
of	0
U1	5
cells	6
by	0
LPS	0
alone	0
induced	0
minimal	0
levels	0
of	0
HIV	0
expression	0
,	0
which	0
was	0
significantly	0
enhanced	0
by	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
.	0

Costimulation	0
of	0
U1	5
cells	6
with	0
LPS	0
plus	0
GM-CSF	9
resulted	0
in	0
the	0
accumulation	0
of	0
steady-state	0
levels	0
of	0
HIV	3
RNA	4
;	0
however	0
,	0
only	0
a	0
weak	0
induction	0
of	0
HIV	1
long	2
terminal	2
repeat	2
-driven	0
transcription	0
,	0
which	0
was	0
not	0
associated	0
with	0
the	0
activation	0
of	0
the	0
cellular	9
transcription	10
factor	10
nuclear	9
factor-kappa	10
B	10
,	0
was	0
noted	0
.	0

Costimulation	0
of	0
cells	0
with	0
LPS	0
plus	0
GM-CSF	9
induced	0
the	0
production	0
of	0
proinflammatory	9
cytokines	10
,	0
IL-8	9
,	0
IL-1	9
beta	10
and	0
IL-6	9
,	0
but	0
not	0
TNF-alpha	9
.	0

IL-1	9
receptor	10
antagonist	0
(	0
ra	0
)	0
inhibited	0
LPS	0
enhancement	0
of	0
HIV	0
expression	0
in	0
GM-CSF-stimulated	5
cells	6
,	0
suggesting	0
that	0
endogenous	9
IL-1	10
was	0
involved	0
in	0
LPS-mediated	0
viral	0
production	0
.	0

In	0
this	0
regard	0
,	0
anti-inflammatory	9
cytokines	10
inhibited	0
LPS	0
plus	0
GM-CSF	9
-stimulated	0
HIV	0
expression	0
,	0
and	0
this	0
effect	0
closely	0
correlated	0
with	0
inhibition	0
of	0
IL-1	9
beta	10
release	0
and	0
,	0
in	0
particular	0
,	0
with	0
up-regulation	0
of	0
endogenous	0
IL-1ra	0
production	0
.	0

Thus	0
,	0
the	0
balance	0
between	0
an	0
endogenously	9
produced	10
viral	10
inducer	10
(	0
IL-1	9
beta	10
)	0
and	0
an	0
inhibitor	0
(	0
IL-1ra	9
)	0
may	0
represent	0
an	0
important	0
pathway	0
leading	0
to	0
modulation	0
of	0
HIV	0
expression	0
from	0
monocytic	7
cells	8
.	0

Herpesvirus	5
saimiri	6
immortalized	6
gamma	6
delta	6
T	6
cell	6
line	6
activated	0
by	0
IL-12	9
.	0

IL-12	9
is	0
a	0
novel	0
heterodimeric	9
cytokine	10
important	0
for	0
the	0
regulation	0
and	0
differentiation	0
of	0
lymphocytes	0
and	0
NK	0
cells	0
.	0

Like	0
other	0
cytokines	0
,	0
IL-12	9
mediates	0
its	0
biologic	0
activity	0
through	0
high-affinity	0
receptors	0
expressed	0
on	0
responsive	7
cells	8
.	0

To	0
date	0
,	0
a	0
large	0
number	0
of	0
receptors	0
for	0
IL-12	9
have	0
been	0
found	0
only	0
on	0
PBMC	7
following	0
activation	0
with	0
PHA	9
or	0
IL-2	9
.	0

To	0
gain	0
further	0
knowledge	0
of	0
the	0
IL-12R	9
complex	10
and	0
the	0
IL-12	9
signal	0
transduction	0
pathway	0
in	0
cytotoxic	7
T	8
cells	8
,	0
we	0
studied	0
a	0
number	0
of	0
human	5
T	6
cell	6
lines	6
that	0
had	0
been	0
transformed	0
to	0
permanent	0
growth	0
with	0
Herpesvirus	0
saimiri	0
,	0
an	0
oncogenic	0
virus	0
of	0
nonhuman	0
primates	0
.	0

This	0
paper	0
reports	0
the	0
expression	0
of	0
IL-12R	9
on	0
a	0
human	5
gamma	6
delta	6
T	6
cell	6
line	6
that	0
responds	0
to	0
IL-12	9
with	0
enhanced	0
cytolytic	0
activity	0
and	0
increased	0
expression	0
of	0
cytolytic	9
effector	10
molecules	10
granzyme	9
B	10
and	0
perforin	9
.	0

Using	0
these	0
T	7
cells	8
as	0
a	0
model	0
of	0
IL-12	9
signal	0
transduction	0
,	0
we	0
confirmed	0
that	0
these	0
events	0
involve	0
members	0
of	0
the	0
Janus	9
kinase	10
family	10
of	0
nonreceptor	9
tyrosine	10
kinases	10
JAK2	9
,	0
TYK2	9
,	0
and	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
4	10
.	0

Regulation	0
of	0
gene	0
expression	0
at	0
early	0
stages	0
of	0
B-cell	0
and	0
T-cell	0
differentiation	0
.	0

The	0
expression	0
of	0
distinct	0
sets	0
of	0
genes	0
at	0
different	0
stages	0
of	0
B-lymphocyte	0
and	0
T-lymphocyte	0
differentiation	0
is	0
controlled	0
at	0
the	0
level	0
of	0
transcription	0
.	0

A	0
number	0
of	0
recent	0
studies	0
have	0
described	0
interactions	0
between	0
transcription	9
factors	10
in	0
lymphocytes	0
that	0
provide	0
new	0
insights	0
into	0
mechanisms	0
regulating	0
gene	0
expression	0
.	0

These	0
mechanisms	0
include	0
the	0
assembly	0
of	0
higher	9
order	10
nucleoprotein	10
complexes	10
and	0
other	0
protein-protein	0
interactions	0
that	0
enhance	0
the	0
functional	0
specificity	0
of	0
transcriptional	9
regulators	10
in	0
lymphocytes	0
.	0

Identification	0
of	0
a	0
human	1
LIM-Hox	2
gene	2
,	0
hLH-2	1
,	0
aberrantly	0
expressed	0
in	0
chronic	0
myelogenous	0
leukaemia	0
and	0
located	0
on	0
9q33-34.1	1
.	0

We	0
describe	0
the	0
isolation	0
of	0
human	9
LH-2	10
,	0
a	0
putative	9
transcription	10
factor	10
containing	0
two	0
cysteine-rich	9
regions	10
(	0
LIM	9
domains	10
)	0
and	0
a	0
homeobox	9
(	10
Hox	10
)	10
DNA-binding	10
domain	10
.	0

High	0
levels	0
of	0
hLH-2	1
expression	0
were	0
observed	0
in	0
all	0
cases	0
of	0
chronic	0
myelogenous	0
leukaemia	0
(	0
CML	0
)	0
tested	0
,	0
regardless	0
of	0
disease	0
status	0
.	0

hLH-2	1
was	0
mapped	0
to	0
chromosome	1
9Q33-34.1	2
,	0
in	0
the	0
same	0
region	0
as	0
the	0
reciprocal	0
translocation	0
that	0
creates	0
the	0
BCR-ABL	9
chimera	10
of	0
the	0
Philadelphia	0
chromosome	0
(	0
Ph	0
'	0
)	0
,	0
the	0
hallmark	0
of	0
CML	0
;	0
hLH-2	1
was	0
retained	0
on	0
the	0
derivative	1
9	2
chromosome	2
and	0
is	0
therefore	0
centromeric	0
of	0
c-ABL	1
.	0

The	0
proximity	0
of	0
hLH-2	1
to	0
the	0
breakpoint	0
on	0
chromosome	1
9	2
raises	0
the	0
possibility	0
of	0
cis-activation	0
by	0
the	0
t	1
(	2
9	2
;	2
22	2
)	2
(	2
q34	2
;	2
q11	2
)	2
translocation	2
.	0

In	0
addition	0
to	0
finding	0
hLH-2	1
expression	0
in	0
all	0
cases	0
of	0
CML	0
,	0
expression	0
was	0
observed	0
in	0
lymphoid	0
malignancies	0
and	0
myeloid	5
cell	6
lines	6
,	0
but	0
not	0
in	0
primary	0
cases	0
of	0
acute	0
myelogenous	0
leukaemia	0
.	0

The	0
role	0
of	0
hLH-2	1
in	0
the	0
development	0
or	0
progression	0
of	0
leukaemia	0
is	0
not	0
known	0
.	0

However	0
,	0
hLH-2	1
may	0
prove	0
useful	0
as	0
a	0
marker	0
of	0
CML	0
for	0
monitoring	0
residual	0
disease	0
.	0

Lymphoid	0
cell	0
resistance	0
to	0
glucocorticoids	0
in	0
HIV	0
infection	0
.	0

In	0
humans	0
infected	0
with	0
the	0
HIV-1	0
virus	0
there	0
may	0
be	0
a	0
disproportionate	0
severity	0
of	0
signs	0
and	0
symptoms	0
of	0
illness	0
compared	0
to	0
the	0
fraction	0
of	0
CD4+	5
infected	6
T-lymphoid	6
cells	6
.	0

In	0
part	0
,	0
this	0
may	0
be	0
due	0
to	0
altered	0
intercellular	0
signalling	0
systems	0
and	0
intracellular	0
signal	0
transduction	0
.	0

Glucocorticoids	0
are	0
well	0
known	0
for	0
their	0
effects	0
on	0
the	0
vitality	0
and	0
function	0
of	0
lymphoid	7
cells	8
.	0

Patients	0
with	0
HIV	0
infections	0
often	0
show	0
elevated	0
circulating	0
levels	0
of	0
cortisol	0
,	0
suggesting	0
some	0
misfunction	0
in	0
the	0
regulatory	0
systems	0
that	0
maintain	0
the	0
levels	0
of	0
this	0
critical	0
hormone	0
.	0

At	0
the	0
cellular	0
level	0
,	0
it	0
is	0
known	0
that	0
both	0
acute	0
HIV	0
infection	0
and	0
glucocorticoids	0
can	0
cause	0
apoptotic	0
cell	0
death	0
in	0
thymic	7
lymphocytes	8
.	0

However	0
,	0
chronically	7
HIV-infected	8
cells	8
appear	0
to	0
be	0
resistant	0
to	0
glucocorticoid-evoked	0
cell	0
death	0
.	0

Glucocorticoid	9
receptor	10
-ligand	0
binding	0
studies	0
on	0
patients	0
'	0
cells	0
have	0
shown	0
reduced	0
affinity	0
between	0
the	0
receptor	9
binding	10
sites	10
and	0
test	0
steroids	0
.	0

In	0
vitro	0
,	0
chronically	5
HIV-infected	6
cells	6
of	0
the	0
lymphoid	5
CEM	6
line	6
displayed	0
resistance	0
to	0
glucocorticoid-induced	0
apoptosis	0
.	0

These	0
cells	0
showed	0
reduced	0
numbers	0
of	0
binding	9
sites	10
with	0
little	0
alteration	0
in	0
apparent	0
affinity	0
between	0
ligand	0
and	0
receptor	0
.	0

Thus	0
it	0
appears	0
that	0
there	0
may	0
often	0
be	0
malfunction	0
of	0
the	0
normal	0
glucocorticoid	0
response	0
in	0
HIV-infected	7
cells	8
probably	0
due	0
to	0
altered	0
interactions	0
between	0
the	0
glucocorticoid	9
receptor	10
and	0
its	0
hormone	0
.	0

Such	0
alterations	0
may	0
have	0
clinical	0
consequences	0
,	0
including	0
the	0
possibility	0
of	0
a	0
relatively	0
longer	0
life	0
span	0
of	0
infected	7
CD4+	8
T-lymphocytes	8
,	0
as	0
well	0
as	0
systemic	0
effects	0
of	0
chronically	0
elevated	0
cortisol	0
level	0
.	0

Abundant	0
expression	0
of	0
erythroid	3
transcription	4
factor	4
P45	4
NF-E2	4
mRNA	4
in	0
human	7
peripheral	8
granurocytes	8
.	0

Transcription	9
factor	10
NF-E2	10
is	0
crucial	0
for	0
regulation	0
of	0
erythroid-specific	0
gene	0
expression	0
.	0

p45	9
subunit	10
of	0
NF-E2	9
contains	0
a	0
basic-leucine	9
zipper	10
domain	10
and	0
dimerizes	0
with	0
the	0
small	9
Maf	10
family	10
protein	10
to	0
form	0
functional	0
NF-E2	9
complex	10
.	0

While	0
p45	9
expression	0
was	0
shown	0
to	0
be	0
restricted	0
to	0
erythroid	7
cells	8
,	0
megakaryocytes	7
and	0
mast	7
cells	8
in	0
hematopoietic	0
lineage	0
,	0
we	0
found	0
in	0
this	0
study	0
that	0
p45	3
mRNA	4
is	0
abundantly	0
transcribed	0
in	0
the	0
granulocyte	7
fraction	8
of	0
human	7
peripheral	8
blood	8
cells	8
.	0

As	0
neutrophils	7
occupy	0
approximately	0
92	0
%	0
of	0
the	0
cells	0
in	0
granulocyte	7
fraction	8
of	0
human	7
peripheral	8
blood	8
cells	8
.	0

As	0
neutrophils	7
occupy	0
approximately	0
92	0
%	0
of	0
the	0
cells	0
in	0
this	0
fraction	0
,	0
the	0
cells	0
expressing	0
p45	9
is	0
most	0
likely	0
to	0
be	0
neutrophils	7
.	0

p45	3
mRNA	4
is	0
also	0
expressed	0
in	0
HL-60	5
promyelocytes	6
,	0
albeit	0
the	0
expression	0
level	0
is	0
much	0
lower	0
than	0
that	0
of	0
the	0
granulocyte	7
fraction	8
.	0

HL-60	5
cells	6
were	0
found	0
to	0
express	0
mafK	3
mRNA	4
,	0
indicating	0
the	0
presence	0
of	0
genuine	0
NF-E2	9
complex	10
in	0
the	0
cells	0
.	0

Although	0
p45	3
mRNA	4
is	0
transcribed	0
from	0
two	0
different	0
promoters	0
,	0
aNF-E2	1
promoter	2
and	0
fNF-E2	1
promoter	2
,	0
in	0
erythroid	7
and	8
megakaryocytic	8
lineage	8
cells	8
,	0
p45	3
mRNA	4
is	0
transcribed	0
only	0
from	0
aNF-E2	1
promoter	2
.	0

The	0
expression	0
of	0
p45	9
megakaryocytic	7
lineage	8
cells	8
,	0
p45	3
mRNA	4
is	0
transcribed	0
only	0
from	0
aNF-E2	1
promoter	2
.	0

The	0
expression	0
of	0
p45	3
mRNA	4
in	0
the	0
neutrophils	7
declined	0
rapidly	0
after	0
transfer	0
of	0
the	0
cells	0
to	0
in	0
vitro	0
culture	0
and	0
G-CSF	9
could	0
not	0
sustain	0
the	0
expression	0
from	0
the	0
down-regulation	0
,	0
suggesting	0
the	0
E2	9
may	0
also	0
participate	0
in	0
the	0
regulation	0
of	0
neutrophil-specific	0
gene	0
expression	0
.	0

Expression	0
of	0
c-fos	9
and	10
c-jun	10
proteins	10
and	0
AP-1	9
binding	0
activity	0
during	0
cell	0
cycle	0
progression	0
of	0
HL60	5
cells	6
and	0
phytohemagglutinin-stimulated	5
lymphocytes	6
.	0

The	0
protein	0
products	0
of	0
the	0
c-fos	1
(	0
p62c-fos	9
)	0
and	0
c-jun	1
(	0
p39c-jun	9
)	0
genes	0
are	0
members	0
of	0
the	0
AP-1	9
transcription	10
factor	10
family	10
and	0
are	0
thought	0
to	0
play	0
important	0
roles	0
in	0
the	0
regulation	0
of	0
gene	0
expression	0
during	0
the	0
cell	0
cycle	0
.	0

Most	0
studies	0
on	0
the	0
expression	0
of	0
these	0
proteins	0
in	0
relation	0
to	0
the	0
cell	0
cycle	0
have	0
been	0
performed	0
at	0
the	0
mRNA	0
level	0
,	0
and	0
therefore	0
do	0
not	0
give	0
direct	0
information	0
about	0
the	0
presence	0
of	0
the	0
proteins	0
during	0
the	0
cell	0
cycle	0
.	0

We	0
have	0
used	0
Western	0
blotting	0
to	0
investigate	0
the	0
presence	0
of	0
these	0
proteins	0
during	0
the	0
cell	0
cycles	0
of	0
two	0
different	0
cellular	5
systems	6
:	0
a	0
continuously	5
growing	6
myeloid	6
leukemic	6
cell	6
line	6
,	0
HL60	5
,	0
and	0
normal	7
cells	8
stimulated	0
into	0
cycle	0
,	0
phyto-	5
hemagglutinin	6
(	6
PHA	6
)	6
-stimulated	6
normal	6
human	6
peripheral	6
blood	6
lymphocytes	6
(	0
PBL	7
)	0
.	0

The	0
binding	0
activity	0
of	0
transcription	0
factor	0
AP-1	9
,	0
which	0
consists	0
of	0
dimers	0
of	0
Fos	9
and	10
Jun	10
family	10
proteins	10
,	0
was	0
also	0
studied	0
using	0
a	0
gel	0
shift	0
assay	0
.	0

We	0
found	0
nuclear	0
p62c-fos	9
,	0
p39c-jun	9
,	0
and	0
AP-1	9
binding	0
activity	0
throughout	0
the	0
cell	0
cycle	0
both	0
in	0
HL60	5
cells	6
and	0
in	0
PHA-stimulated	5
PBL	6
,	0
and	0
we	0
postulate	0
that	0
these	0
proteins	0
are	0
required	0
throughout	0
the	0
cell	0
cycle	0
and	0
not	0
transiently	0
in	0
the	0
G0	0
to	0
G1	0
transition	0
as	0
previous	0
mRNA	0
studies	0
have	0
indicated	0
.	0

We	0
demonstrated	0
an	0
uncoupling	0
of	0
AP-1	9
binding	0
activity	0
from	0
p62c-fos	9
,	0
and	0
p39c-jun	9
AP-1	9
activity	0
was	0
expressed	0
more	0
strongly	0
in	0
the	0
G1-	0
and	0
G2/M-phase	0
enriched	0
samples	0
than	0
in	0
the	0
S-phase	0
enriched	0
samples	0
of	0
HL60	5
cells	6
,	0
while	0
levels	0
of	0
nuclear	9
p62c-fos	10
and	10
p39c-jun	10
were	0
constant	0
.	0

Nuclei	0
of	0
unstimulated	7
PBL	8
from	0
different	0
donors	0
expressed	0
p62c-fos	9
and	0
p39c-jun	9
,	0
but	0
AP-1	9
was	0
not	0
detected	0
in	0
the	0
majority	0
of	0
samples	0
.	0

Following	0
PHA	9
stimulation	0
of	0
PBL	7
,	0
the	0
increase	0
in	0
AP-1	9
activity	0
was	0
delayed	0
with	0
respect	0
to	0
the	0
augmentation	0
of	0
p39c-jun	9
expression	0
.	0

We	0
also	0
observed	0
that	0
cytoplasmic	9
p62c-fos	10
and	10
p39c-jun	10
were	0
present	0
in	0
HL60	5
cells	6
and	0
PHA-stimulated	5
PBL	6
.	0

However	0
,	0
no	0
cytoplasmic	9
p62c-fos	10
was	0
detected	0
in	0
unstimulated	7
PBL	8
,	0
although	0
in	0
some	0
cases	0
cytoplasmic	9
p39c-jun	10
was	0
detected	0
,	0
suggesting	0
that	0
subcellular	0
compartmentalization	0
of	0
these	0
proteins	9
may	0
occur	0
under	0
certain	0
circumstances	0
.	0

Octamer	9
binding	10
factors	10
and	0
their	0
coactivator	9
can	0
activate	0
the	0
murine	1
PU.1	2
(	2
spi-1	2
)	2
promoter	2
.	0

PU.1	9
(	0
spi-1	9
)	0
,	0
a	0
member	0
of	0
the	0
Ets	9
transcription	10
factor	10
family	10
,	0
is	0
predominantly	0
expressed	0
in	0
myeloid	7
and	8
B	8
cells	8
,	0
activates	0
many	0
B	1
cell	2
and	2
myeloid	2
genes	2
,	0
and	0
is	0
critical	0
for	0
development	0
of	0
both	0
of	0
these	0
lineages	0
.	0

Our	0
previous	0
studies	0
(	0
Chen	0
,	0
H.M.	0
,	0
Ray-Gallet	0
,	0
D.	0
,	0
Zhang	0
,	0
P.	0
,	0
Hetherington	0
,	0
C.J.	0
,	0
Gonzalez	0
,	0
D.A.	0
,	0
Zhang	0
,	0
D.-E.	0
,	0
Moreau-Gachelin	0
,	0
F.	0
,	0
and	0
Tenen	0
,	0
D.G.	0
(	0
1995	0
)	0
Oncogene	0
11	0
,	0
1549-1560	0
)	0
demonstrate	0
that	0
the	0
PU.1	1
promoter	2
directs	0
cell	1
type-specific	2
reporter	2
gene	2
expression	0
in	0
myeloid	0
cell	0
lines	0
,	0
and	0
that	0
PU.1	9
activates	0
its	0
own	0
promoter	0
in	0
an	0
autoregulatory	0
loop	0
.	0

Here	0
we	0
show	0
that	0
the	0
murine	1
PU.1	2
promoter	2
is	0
also	0
specifically	0
and	0
highly	0
functional	0
in	0
B	5
cell	6
lines	6
as	0
well	0
.	0

Oct-1	9
and	0
Oct-2	9
can	0
bind	0
specifically	0
to	0
a	0
site	0
at	0
base	0
pair	0
-55	0
in	0
vitro	0
,	0
and	0
this	0
site	0
is	0
specifically	0
protected	0
in	0
B	7
cells	8
in	0
vivo	0
.	0

We	0
also	0
demonstrate	0
that	0
two	0
other	0
sites	0
contribute	0
to	0
promoter	0
activity	0
in	0
B	7
cells	8
;	0
an	0
Sp1	1
binding	2
site	2
adjacent	0
to	0
the	0
octamer	1
site	2
,	0
and	0
the	0
PU.1	1
autoregulatory	2
site	2
.	0

Finally	0
,	0
we	0
show	0
that	0
the	0
B	0
cell	0
coactivator	9
OBF-1/Bob1/OCA-B	9
is	0
only	0
expressed	0
in	0
B	7
cells	8
and	0
not	0
in	0
myeloid	7
cells	8
,	0
and	0
that	0
OBF-1/Bob1/OCA-B	9
can	0
transactivate	0
the	0
PU.1	1
promoter	2
in	0
HeLa	5
and	0
myeloid	7
cells	8
.	0

This	0
B	9
cell	10
restricted	10
coactivator	10
may	0
be	0
responsible	0
for	0
the	0
B	0
cell	0
specific	0
expression	0
of	0
PU.1	9
mediated	0
by	0
the	0
octamer	1
site	2
.	0

Inhibition	0
of	0
p105	9
processing	0
by	0
NF-kappaB	9
proteins	10
in	0
transiently	5
transfected	6
cells	6
.	0

Regulation	0
of	0
the	0
transcription	0
factor	0
NF-kappaB	9
involves	0
proteasome-mediated	0
processing	0
of	0
the	0
NF-kappaB1	9
p105	10
precursor	10
protein	10
,	0
which	0
generates	0
the	0
p50	9
subunit	10
of	0
NF-kappaB	9
.	0

The	0
processing	0
of	0
p105	9
occurs	0
constitutively	0
in	0
vivo	0
but	0
can	0
be	0
markedly	0
enhanced	0
by	0
various	0
cellular	0
activation	0
agents	0
,	0
although	0
the	0
underlying	0
regulatory	0
mechanism	0
is	0
not	0
yet	0
clear	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
demonstrate	0
that	0
signal-mediated	0
induction	0
of	0
p105	9
processing	0
in	0
human	7
T	8
cells	8
is	0
associated	0
with	0
de	0
novo	0
synthesis	0
of	0
this	0
precursor	9
protein	10
.	0

Transient	0
transfection	0
studies	0
performed	0
in	0
COS7	5
cells	6
revealed	0
that	0
the	0
newly	0
synthesized	0
p105	9
protein	0
appears	0
to	0
be	0
more	0
rapidly	0
processed	0
compared	0
to	0
its	0
accumulated	0
form	0
that	0
is	0
already	0
associated	0
with	0
the	0
processed	0
product	0
p50	9
.	0

Interestingly	0
,	0
the	0
processing	0
rate	0
of	0
p105	9
is	0
markedly	0
inhibited	0
in	0
cells	0
co-transfected	0
with	0
p50	9
or	0
other	0
NF-kappaB	9
subunits	10
,	0
including	0
RelA	9
and	0
c-Rel	9
,	0
that	0
physically	0
interact	0
with	0
p105	9
.	0

These	0
findings	0
suggest	0
that	0
the	0
processing	0
of	0
p105	9
is	0
subject	0
to	0
negative	0
regulation	0
by	0
the	0
various	0
NF-kappaB	9
subunits	10
.	0

We	0
further	0
demonstrate	0
that	0
p105	9
undergoes	0
degradation	0
in	0
lipopolysaccharide-stimulated	5
human	6
monocytic	6
cells	6
.	0

However	0
,	0
the	0
inducible	0
degradation	0
of	0
p105	9
is	0
not	0
coupled	0
with	0
the	0
generation	0
of	0
p50	9
.	0

Together	0
,	0
these	0
studies	0
demonstrate	0
that	0
the	0
processing	0
and	0
inducible	0
degradation	0
of	0
p105	9
are	0
differentially	0
regulated	0
.	0

Identification	0
of	0
an	0
inducible	9
regulator	10
of	0
c-myb	1
expression	0
during	0
T-cell	7
activation	0
.	0

Resting	7
T	8
cells	8
express	0
very	0
low	0
levels	0
of	0
c-Myb	9
protein	10
.	0

During	0
T-cell	0
activation	0
,	0
c-myb	1
expression	0
is	0
induced	0
and	0
much	0
of	0
the	0
increase	0
in	0
expression	0
occurs	0
at	0
the	0
transcriptional	0
level	0
.	0

We	0
identified	0
a	0
region	0
of	0
the	0
c-myb	1
5	2
'	2
flanking	2
sequence	2
that	0
increased	0
c-myb	1
expression	0
during	0
T-cell	0
activation	0
.	0

In	0
vivo	0
footprinting	0
by	0
ligation-mediated	0
PCR	0
was	0
performed	0
to	0
correlate	0
in	0
vivo	0
protein	0
binding	0
with	0
functional	0
activity	0
.	0

A	0
protein	0
footprint	0
was	0
visible	0
over	0
this	0
region	0
of	0
the	0
c-myb	1
5	2
'	2
flanking	2
sequence	2
in	0
activated	7
T	8
cells	8
but	0
not	0
in	0
unactivated	7
T	8
cells	8
.	0

An	0
electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
with	0
nuclear	0
extract	0
from	0
activated	7
T	8
cells	8
and	0
an	0
oligonucleotide	0
of	0
this	0
binding	0
site	0
demonstrated	0
a	0
new	0
protein-DNA	9
complex	10
,	0
referred	0
to	0
as	0
CMAT	9
for	0
c-myb	9
in	10
activated	10
T	10
cells	10
;	0
this	0
complex	0
was	0
not	0
present	0
in	0
unactivated	7
T	8
cells	8
.	0

Because	0
the	0
binding	1
site	2
showed	0
some	0
sequence	0
similarity	0
with	0
the	0
nuclear	1
factor	2
of	2
activated	2
T	2
cells	2
(	2
NFAT	2
)	2
binding	2
site	2
,	0
we	0
compared	0
the	0
kinetics	0
of	0
induction	0
of	0
the	0
two	0
binding	0
complexes	0
and	0
the	0
molecular	0
masses	0
of	0
the	0
two	0
proteins	0
.	0

Studies	0
of	0
the	0
kinetics	0
of	0
induction	0
showed	0
that	0
the	0
NFAT	9
EMSA	10
binding	10
complex	10
appeared	0
earlier	0
than	0
the	0
CMAT	9
complex	10
.	0

The	0
NFAT	9
protein	0
migrated	0
more	0
slowly	0
in	0
a	0
sodium	0
dodecyl	0
sulfate-polyacrylamide	0
gel	0
than	0
the	0
CMAT	9
protein	10
did	0
.	0

In	0
addition	0
,	0
an	0
antibody	0
against	0
NFAT	9
did	0
not	0
cross-react	0
with	0
the	0
CMAT	9
protein	10
.	0

The	0
appearance	0
of	0
the	0
CMAT	9
binding	10
complex	10
was	0
inhibited	0
by	0
both	0
cyclosporin	0
A	0
and	0
rapamycin	0
.	0

The	0
CMAT	9
protein	0
appears	0
to	0
be	0
a	0
novel	0
inducible	0
protein	0
involved	0
in	0
the	0
regulation	0
of	0
c-myb	1
expression	0
during	0
T-cell	0
activation	0
.	0

CNI-1493	0
inhibits	0
monocyte/macrophage	9
tumor	10
necrosis	10
factor	10
by	0
suppression	0
of	0
translation	0
efficiency	0
.	0

Tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
mediates	0
a	0
wide	0
variety	0
of	0
disease	0
states	0
including	0
septic	0
shock	0
,	0
acute	0
and	0
chronic	0
inflammation	0
,	0
and	0
cachexia	0
.	0

Recently	0
,	0
a	0
multivalent	0
guanylhydrazone	0
(	0
CNI-1493	0
)	0
developed	0
as	0
an	0
inhibitor	0
of	0
macrophage	0
activation	0
was	0
shown	0
to	0
suppress	0
TNF	9
production	0
and	0
protect	0
against	0
tissue	0
inflammation	0
and	0
endotoxin	0
lethality	0
[	0
Bianchi	0
,	0
M.	0
,	0
Ulrich	0
,	0
P.	0
,	0
Bloom	0
,	0
O.	0
,	0
Meistrell	0
,	0
M.	0
,	0
Zimmerman	0
,	0
G.A.	0
,	0
Schmidtmayerova	0
,	0
H.	0
,	0
Bukrinsky	0
,	0
M.	0
,	0
Donnelley	0
,	0
T.	0
,	0
Bucala	0
,	0
R.	0
,	0
Sherry	0
,	0
B.	0
,	0
Manogue	0
,	0
K.R.	0
,	0
Tortolani	0
,	0
A.J.	0
,	0
Cerami	0
,	0
A.	0
&	0
Tracey	0
,	0
K.J.	0
(	0
1995	0
)	0
Mol.Med.1	0
,	0
254-266	0
,	0
and	0
Bianchi	0
,	0
M.	0
,	0
Bloom	0
,	0
O.	0
,	0
Raabe	0
,	0
T.	0
,	0
Cohen	0
,	0
P.	0
S.	0
,	0
Chesney	0
,	0
J.	0
,	0
Sherry	0
,	0
B.	0
,	0
Schmidtmayerova	0
,	0
H.	0
,	0
Zhang	0
,	0
X.	0
,	0
Bukrinsky	0
,	0
M.	0
,	0
Ulrich	0
,	0
P.	0
,	0
Cerami	0
,	0
A.	0
&	0
Tracey	0
,	0
J.	0
(	0
1996	0
)	0
J.Exp.Med.	0
,	0
in	0
press	0
]	0
.	0

We	0
have	0
now	0
elucidated	0
the	0
mechanism	0
by	0
which	0
CNI-1493	0
inhibits	0
macrophage	0
TNF	9
synthesis	0
and	0
show	0
here	0
that	0
it	0
acts	0
through	0
suppression	0
of	0
TNF	9
translation	0
efficiency	0
.	0

CNI-1493	0
blocked	0
neither	0
the	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-induced	0
increases	0
in	0
the	0
expression	0
of	0
TNF	3
mRNA	4
nor	0
the	0
translocation	0
of	0
nuclear	9
factor	10
NF-kappa	10
B	10
to	0
the	0
nucleus	0
in	0
macrophages	7
activated	0
by	0
15	0
min	0
of	0
LPS	0
stimulation	0
,	0
indicating	0
that	0
CNI-1493	0
does	0
not	0
interfere	0
with	0
early	0
NF-kappa	9
B	10
-mediated	0
transcriptional	0
regulation	0
of	0
TNF	9
.	0

However	0
,	0
synthesis	0
of	0
the	0
26-kDa	9
membrane	10
form	10
of	0
TNF	9
was	0
effectively	0
blocked	0
by	0
CNI-1493	0
.	0

Further	0
evidence	0
for	0
the	0
translational	0
suppression	0
of	0
TNF	9
is	0
given	0
by	0
experiments	0
using	0
chloram-phenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
constructs	2
containing	0
elements	0
of	0
the	0
TNF	1
gene	2
that	0
are	0
involved	0
in	0
TNF	9
translational	0
regulation	0
.	0

Both	0
the	0
5	1
'	2
and	2
3	2
'	2
untranslated	2
regions	2
of	0
the	0
TNF	1
gene	2
were	0
required	0
to	0
elicit	0
maximal	0
translational	0
suppression	0
by	0
CNI-1493	0
.	0

Identification	0
of	0
the	0
molecular	0
target	0
through	0
which	0
CNI-	0
1493	0
inhibits	0
TNF	9
translation	0
should	0
provide	0
insight	0
into	0
the	0
regulation	0
of	0
macrophage	0
activation	0
and	0
mechanisms	0
of	0
inflammation	0
.	0

Soluble	9
tumor	10
necrosis	10
factor	10
receptors	10
inhibit	0
phorbol	0
myristate	0
acetate	0
and	0
cytokine-induced	0
HIV-1	0
expression	0
chronically	0
infected	7
U1	8
cells	8
.	0

Recombinant	9
human	10
tumor	10
necrosis	10
factor	10
(	10
TNF	10
)	10
binding	10
protein-1	10
(	0
r-h	9
TBP-1	10
)	0
and	0
recombinant	9
human	10
soluble	10
dimeric	10
TNF	10
receptor	10
(	0
rhu	9
TNFR	10
:	10
Fc	10
)	0
were	0
used	0
to	0
determine	0
the	0
relative	0
contributions	0
of	0
TNF	9
to	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
and	0
cytokine-induced	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replication	0
in	0
chronically	0
infected	0
cell	0
lines	0
.	0

Treatment	0
of	0
HIV-1-infected	7
promonocytic	8
U1	8
cells	8
with	0
r-h-TBP-1	9
or	0
rhu	9
TNFR	10
:	10
Fc	10
reduced	0
PMA-induced	0
HIV-1	9
p24	10
antigen	10
production	0
in	0
a	0
concentration-dependent	0
manner	0
,	0
with	0
a	0
maximal	0
inhibition	0
of	0
approximately	0
90	0
%	0
.	0

Maximal	0
inhibition	0
of	0
p24	9
antigen	10
production	0
in	0
T-lymphocytic	5
ACH-2	6
cells	6
was	0
47	0
%	0
with	0
r-hTBP-1	9
and	0
42	0
%	0
with	0
rhu	9
TNFR	10
:	10
Fc	10
.	0

r-hTBP-1	9
and	0
rhu	9
TNFR	10
:	10
Fc	10
also	0
decreased	0
p24	9
antigen	10
synthesized	0
by	0
U1	5
cells	6
in	0
response	0
to	0
other	0
stimuli	0
,	0
including	0
phytohemagglutinin	9
(	10
PHA	10
)	10
-induced	10
supernatant	10
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
,	0
interleukin-6	9
,	0
and	0
TNF	9
.	0

Addition	0
of	0
r-hTBP-1	9
to	0
U1	5
cells	6
during	0
the	0
last	0
4	0
h	0
of	0
a	0
24	0
h	0
incubation	0
with	0
PMA	0
still	0
inhibited	0
p24	9
antigen	10
production	0
by	0
15	0
%	0
.	0

U1	5
cells	6
stimulated	0
with	0
10	0
(	0
-7	0
)	0
M	0
PMA	0
released	0
approximately	0
1	0
ng/ml	0
endogenous	9
TBP-1	10
with	0
an	0
initial	0
peak	0
observed	0
at	0
1	0
h	0
and	0
a	0
second	0
peak	0
at	0
24	0
h	0
after	0
PMA	0
stimulation	0
.	0

r-hTBP-1	9
also	0
partially	0
reversed	0
inhibition	0
of	0
U1	0
cellular	0
proliferation	0
caused	0
by	0
PMA	0
.	0

Both	0
r-hTBP-1	9
and	0
rhu	9
TNFR	10
:	10
Fc	10
blocked	0
PMA	0
induction	0
of	0
nuclear	9
factor	10
(	10
NK	10
)	10
-	10
kappa	10
B	10
DNA-binding	0
activity	0
in	0
U1	5
cells	6
in	0
association	0
with	0
decreases	0
in	0
HIV-1	0
replication	0
.	0

We	0
conclude	0
that	0
soluble	0
TNF	0
receptors	0
can	0
inhibit	0
stimuli-induced	0
HIV-1	0
expression	0
and	0
NK-	9
kappa	10
B	10
DNA-binding	0
activity	0
in	0
chronically	0
infected	7
U1	8
cells	8
.	0

Transcriptional	0
activation	0
of	0
RNA	1
polymerase	2
III-dependent	2
genes	2
by	0
the	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
tax	10
protein	10
.	0

The	0
human	9
T-cell	10
leukemia	10
virus-encoded	10
tax	10
protein	10
is	0
a	0
potent	0
activator	0
of	0
many	0
viral	1
and	2
cellular	2
genes	2
transcribed	0
by	0
RNA	9
polymerase	10
II	10
.	0

We	0
find	0
that	0
both	0
chromatin	1
and	0
cell	0
extracts	0
derived	0
from	0
human	5
T-cell	6
leukemia	6
virus	6
type	6
1-infected	6
human	6
T	6
lymphocytes	6
support	0
higher	0
levels	0
of	0
5S	0
rRNA	0
and	0
tRNA	0
gene	0
transcription	0
than	0
chromatin	1
or	0
extracts	0
from	0
uninfected	7
T	8
lymphocytes	8
.	0

The	0
viral	9
protein	10
Tax	10
was	0
likely	0
responsible	0
for	0
this	0
higher	0
level	0
of	0
class	1
II	2
gene	2
transcription	0
,	0
as	0
purified	9
Tax	10
was	0
found	0
to	0
stimulate	0
both	0
genes	0
when	0
added	0
to	0
the	0
uninfected	0
cell	0
extract	0
or	0
in	0
reconstituted	0
systems	0
.	0

Both	0
limiting-component	0
transcription	0
assays	0
and	0
DNA	0
binding	0
assays	0
identified	0
the	0
class	9
III	10
gene	10
transcription	10
factor	10
TFIIIB	9
as	0
the	0
principle	0
target	0
of	0
Tax	9
activity	0
.	0

Surprisingly	0
,	0
we	0
find	0
that	0
Tax	9
increases	0
the	0
effective	0
concentration	0
of	0
active	9
TFIIIB	10
molecules	10
.	0

These	0
data	0
suggest	0
that	0
Tax	9
stimulates	0
RNA	1
polymerase	2
III-dependent	2
gene	2
expression	0
by	0
accelerating	0
the	0
rate	0
and/or	0
extent	0
of	0
transcription	9
initiation	10
complex	10
assembly	0
.	0

Expression	0
of	0
Retinoid	9
X	10
Receptor	10
alpha	10
is	0
increased	0
upon	0
monocytic	0
cell	0
differentiation	0
.	0

1	0
alpha	0
,	0
25-Dihydroxyvitamin	0
D3	0
(	0
VD	0
)	0
is	0
a	0
potent	0
inducer	0
of	0
monocytic	0
differentiation	0
of	0
both	0
normal	7
and	8
leukemic	8
cells	8
.	0

Its	0
effects	0
are	0
mediated	0
by	0
its	0
nuclear	9
receptor	10
(	0
VDR	9
)	0
.	0

Efficient	0
gene	0
activation	0
requires	0
the	0
heterodimerization	0
of	0
VDR	9
with	0
Retinoid	9
X	10
Receptors	10
(	0
RXR	9
)	0
.	0

In	0
the	0
present	0
study	0
using	0
specific	9
antibodies	10
,	0
we	0
analyzed	0
the	0
expression	0
of	0
the	0
RXR	9
alpha	10
protein	10
in	0
blood	7
mononuclear	8
cells	8
from	0
acute	0
myeloid	0
patients	0
(	0
AML	0
)	0
(	0
10	0
cases	0
)	0
and	0
from	0
myelomonocytic	5
cell	6
lines	6
arrested	0
at	0
different	0
stages	0
of	0
differentiation	0
.	0

We	0
observed	0
that	0
the	0
RXR	9
alpha	10
expression	0
increased	0
during	0
myelomonocytic	0
differentiation	0
,	0
since	0
the	0
highest	0
levels	0
were	0
found	0
in	0
AML	0
samples	0
and	0
in	0
myelomonocytic	5
cell	6
lines	6
having	0
the	0
highest	0
amounts	0
of	0
monocytic	7
precursors	8
.	0

We	0
also	0
demonstrated	0
that	0
fresh	0
leukemic	7
cells	8
,	0
whatever	0
their	0
stage	0
of	0
differentiation	0
,	0
as	0
well	0
as	0
myelomonocytic	5
cell	6
lines	6
,	0
respond	0
to	0
VD	0
by	0
an	0
increase	0
in	0
RXR	9
alpha	10
levels	0
.	0

Combinations	0
of	0
all-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
and	0
VD	0
,	0
in	0
some	0
cases	0
,	0
increased	0
this	0
effect	0
.	0

This	0
response	0
suggests	0
the	0
involvement	0
of	0
RXR	9
alpha	10
in	0
monocytic	0
differentiation	0
upon	0
VD	0
treatment	0
.	0

Expression	0
of	0
p13MTCP1	9
is	0
restricted	0
to	0
mature	0
T-cell	0
proliferations	0
with	0
t	0
(	0
X	0
;	0
14	0
)	0
translocations	0
.	0

T-cell	0
prolymphocytic	0
leukemia	0
(	0
T-PLL	0
)	0
,	0
a	0
rare	0
form	0
of	0
mature	0
T-cell	0
leukemias	0
,	0
and	0
ataxia	0
telangiectasia	0
clonal	0
proliferation	0
,	0
a	0
related	0
condition	0
occurring	0
in	0
patients	0
suffering	0
from	0
ataxia	0
telangiectasia	0
,	0
have	0
been	0
associated	0
to	0
translocations	0
involving	0
the	0
14q32.1	1
or	0
Xq28	1
regions	2
,	0
where	0
are	0
located	0
the	0
TCL1	1
and	2
MTCP1	2
putative	2
oncogenes	2
,	0
respectively	0
.	0

The	0
MTCP1	1
gene	2
is	0
involved	0
in	0
the	0
t	1
(	2
X	2
;	2
14	2
)	2
(	2
q28	2
;	2
q11	2
)	2
translocation	2
associated	0
with	0
these	0
T-cell	0
proliferations	0
.	0

Alternative	0
splicing	0
generates	0
type	3
A	4
and	4
B	4
transcripts	4
that	0
potentially	0
encode	0
two	0
entirely	0
distinct	0
proteins	0
;	0
type	0
A	3
transcripts	4
code	0
for	0
a	0
small	0
mitochondrial	9
protein	10
,	0
p8MTCP1	9
,	0
and	0
type	3
B	4
transcripts	4
,	0
containing	0
an	0
additional	0
open	1
reading	2
frame	2
,	0
may	0
code	0
for	0
107	9
amino-acid	10
protein	10
,	0
p13MTCP1	9
.	0

The	0
recently	0
cloned	0
TCL1	1
gene	2
,	0
also	0
involved	0
in	0
translocations	0
and	0
inversions	0
associated	0
with	0
T-cell	0
proliferations	0
,	0
codes	0
for	0
a	0
14-kD	9
protein	10
that	0
displays	0
significant	0
homology	0
with	0
p13MTCP1	9
.	0

We	0
have	0
generated	0
rabbit	0
antisera	0
against	0
this	0
putative	0
p13MTCP1	9
protein	10
and	0
screened	0
for	0
expression	0
of	0
p13MTCP1	9
normal	0
lymphoid	0
tissues	0
and	0
33	0
cases	0
of	0
immature	7
and	8
mature	8
lymphoid	8
T-cell	8
proliferations	8
using	0
a	0
sensitive	0
Western	0
blot	0
assay	0
.	0

We	0
also	0
investigated	0
the	0
MTCP1	1
locus	2
configuration	0
by	0
Southern	0
blot	0
analysis	0
.	0

The	0
p13MTCP1	9
protein	10
was	0
detected	0
in	0
the	0
three	0
T-cell	0
proliferations	0
with	0
MTCP1	1
rearrangements	2
because	0
of	0
t	0
(	0
X	0
;	0
14	0
)	0
translocations	0
,	0
but	0
neither	0
in	0
normal	0
resting	0
and	0
activated	7
lymphocytes	8
nor	0
in	0
the	0
other	0
T-cell	7
leukemias	0
.	0

Our	0
data	0
support	0
the	0
hypothesis	0
that	0
p13MTCP1	9
and	0
p14TCL1	9
form	0
a	0
new	0
protein	9
family	10
that	0
plays	0
a	0
key	0
role	0
in	0
the	0
pathogenesis	0
of	0
T-PLL	0
and	0
related	0
conditions	0
.	0

Preassociation	0
of	0
STAT1	9
with	0
STAT2	9
and	0
STAT3	9
in	0
separate	0
signalling	9
complexes	10
prior	0
to	0
cytokine	9
stimulation	0
.	0

A	0
variety	0
of	0
cytokines	9
and	0
growth	9
factors	10
act	0
through	0
an	0
induction	0
of	0
gene	0
expression	0
mediated	0
by	0
a	0
family	0
of	0
latent	9
transcription	10
factors	10
called	0
STAT	9
(	10
signal	10
transducers	10
and	10
activators	10
of	10
transcription	10
)	10
proteins	10
.	0

Ligand-induced	0
tyrosine	0
phosphorylation	0
of	0
the	0
STATs	9
promotes	0
their	0
homodimer	0
and	0
heterodimer	0
formation	0
and	0
subsequent	0
nuclear	0
translocation	0
.	0

We	0
demonstrate	0
here	0
that	0
STAT	9
protein	10
heterocomplexes	10
exist	0
prior	0
to	0
cytokine	9
treatment	0
.	0

When	0
unstimulated	5
HeLa	6
cells	6
are	0
ruptured	0
in	0
hypotonic	0
buffer	0
without	0
salt	0
or	0
detergent	0
,	0
immunoadsorption	0
of	0
either	0
STAT1	9
or	0
STAT2	9
from	0
the	0
resulting	0
cytosol	0
yields	0
coimmunoadsorption	0
of	0
the	0
other	0
STAT	9
protein	10
.	0

Similarly	0
,	0
STAT1	9
-STAT3	9
heterocomplexes	0
are	0
coimmunoadsorbed	0
from	0
hypotonic	0
cytosol	0
.	0

STAT1	9
and	0
STAT2	9
or	0
STAT1	9
and	0
STAT3	9
translated	0
in	0
reticulocyte	0
lysate	0
spontaneously	0
form	0
heterocomplexes	0
when	0
the	0
translation	0
lysates	0
are	0
mixed	0
at	0
0	0
degrees	0
C	0
.	0

Our	0
data	0
suggest	0
that	0
interferon-alpha	9
/beta-induced	0
tyrosine	0
phosphorylation	0
increases	0
the	0
stability	0
of	0
a	0
preexisting	0
,	0
latent	0
,	0
STAT1	9
-	0
STAT2	9
signaling	10
complex	10
.	0

Newly	0
translated	0
STAT1	9
binds	0
in	0
equilibrium	0
fashion	0
to	0
STAT2	9
and	0
STAT3	9
,	0
but	0
we	0
show	0
that	0
STAT2	9
and	0
STAT3	9
exist	0
in	0
separate	0
heterocomplexes	9
with	0
STAT1	9
,	0
consistent	0
with	0
a	0
model	0
in	0
which	0
STAT1	9
contains	0
a	0
common	0
binding	0
site	0
for	0
other	0
STAT	9
proteins	10
.	0

Interferon-gamma	9
modulates	0
the	0
lipopolysaccharide-induced	0
expression	0
of	0
AP-1	9
and	0
NF-kappa	9
B	10
at	0
the	0
mRNA	0
and	0
protein	0
level	0
in	0
human	7
monocytes	8
.	0

Interferon-gamma	9
(	0
IFN-gamma	9
)	0
modulates	0
the	0
expression	0
of	0
several	0
cytokines	9
by	0
human	7
monocytes	8
at	0
the	0
transcriptional	0
level	0
.	0

In	0
view	0
of	0
these	0
findings	0
,	0
we	0
analyzed	0
the	0
effects	0
of	0
IFN-gamma	9
on	0
the	0
expression	0
of	0
different	0
transcription	9
factors	10
in	0
activated	0
human	7
monocytes	8
.	0

Priming	0
of	0
human	7
monocytes	8
with	0
IFN-gamma	9
resulted	0
in	0
the	0
down	0
regulation	0
of	0
c-fos	3
and	4
c-jun	4
mRNA	4
in	0
response	0
to	0
stimulation	0
with	0
lipopolysaccharide	0
(	0
LPS	0
)	0
compared	0
to	0
the	0
effects	0
of	0
LPS	0
alone	0
.	0

Not	0
only	0
was	0
this	0
effect	0
observed	0
at	0
the	0
mRNA	0
level	0
,	0
but	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
DNA	0
binding	0
capacity	0
was	0
affected	0
as	0
well	0
,	0
A	0
strong	0
reduction	0
was	0
observed	0
in	0
the	0
LPS-induced	0
DNA-binding	0
activity	0
of	0
AP-1	9
in	0
the	0
presence	0
of	0
IFN-gamma	9
.	0

LPS-stimulated	7
monocytes	8
showed	0
an	0
increased	0
expression	0
of	0
p105	3
mRNA	4
,	0
the	0
precursor	0
of	0
the	0
p50	9
subunit	10
of	0
the	0
transcription	9
factor	10
nuclear	10
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
while	0
no	0
effect	0
was	0
noticed	0
on	0
the	0
expression	0
of	0
p65	3
mRNA	4
.	0

In	0
contrast	0
,	0
IFN-gamma	9
priming	0
did	0
not	0
affect	0
the	0
expression	0
of	0
p105	3
transcripts	4
but	0
enhanced	0
the	0
expression	0
of	0
p65	3
mRNA	4
(	0
two-fold	0
)	0
.	0

Priming	0
with	0
IFN-gamma	9
followed	0
by	0
LPS	0
stimulation	0
resulted	0
in	0
a	0
further	0
increase	0
in	0
the	0
expression	0
of	0
p65	3
mRNA	4
.	0

This	0
was	0
due	0
to	0
an	0
increase	0
in	0
the	0
half-life	0
of	0
p65	3
mRNA	4
(	0
75	0
vs	0
150	0
minutes	0
)	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
demonstrated	0
that	0
unstimulated	0
monocytes	0
predominantly	0
expressed	0
p50	9
NF-kappa	9
B	10
.	0

Stimulation	0
with	0
LPS	0
or	0
IFN-gamma	9
resulted	0
in	0
the	0
expression	0
of	0
p50	9
and	0
p65	9
subunits	10
,	0
while	0
the	0
combination	0
of	0
IFN-gamma	9
plus	0
LPS	0
caused	0
a	0
further	0
increase	0
in	0
the	0
expression	0
of	0
NF-kappa	9
B	10
.	0

With	0
Western	0
blotting	0
,	0
it	0
was	0
shown	0
that	0
nuclear	0
extracts	0
from	0
monocytes	7
contained	0
p50	9
and	0
p65	9
protein	10
in	0
response	0
to	0
LPS	0
and	0
IFN-gamma	9
stimulation	0
.	0

However	0
,	0
the	0
combined	0
stimulation	0
did	0
not	0
result	0
in	0
enhanced	0
p50	9
and	0
p65	9
protein	10
expression	0
.	0

The	0
effects	0
of	0
IFN-gamma	9
on	0
the	0
transcription	9
factors	10
were	0
specific	0
,	0
since	0
no	0
change	0
was	0
observed	0
in	0
the	0
expression	0
of	0
NF-IL-6	9
or	0
I	9
kappa	10
B	10
alpha	10
,	0
the	0
inhibitor	0
of	0
NF-kappa	9
B	10
.	0

We	0
conclude	0
that	0
the	0
effects	0
of	0
IFN-gamma	9
on	0
the	0
expression	0
of	0
the	0
transcription	9
factors	10
AP-1	9
and	0
NF-kappa	9
B	10
may	0
be	0
important	0
for	0
the	0
modulatory	0
effects	0
of	0
IFN-gamma	9
on	0
the	0
cytokine	9
expression	0
in	0
activated	0
human	7
monocytes	8
.	0

HIV-1	9
tat	10
induces	0
the	0
expression	0
of	0
a	0
new	0
hematopoietic	9
cell-specific	10
transcription	10
factor	10
and	0
downregulates	0
MIP-1	1
alpha	2
gene	2
expression	0
in	0
activated	7
T-cells	8
.	0

MIP-1	9
alpha	10
is	0
a	0
secreted	0
chemokine	9
which	0
can	0
inhibit	0
hematopoietic	7
stem	8
cells	8
and	0
modulate	0
inflammatory	0
responses	0
.	0

It	0
is	0
also	0
an	0
inhibitor	0
of	0
HIV	0
replication	0
in	0
CD8+	7
T-cells	8
.	0

The	0
expression	0
of	0
MIP-1	9
alpha	10
is	0
induced	0
during	0
cellular	0
activation	0
of	0
CD4+	7
T-cells	8
and	0
monocytes	7
.	0

It	0
is	0
also	0
expressed	0
in	0
transformed	5
B-cells	6
.	0

We	0
have	0
previously	0
identified	0
a	0
new	0
transcription	9
factor	10
family	10
(	0
the	0
MNP	9
family	10
)	0
whose	0
expression	0
is	0
crucial	0
for	0
the	0
induction	0
of	0
MIP-1	9
alpha	10
transcription	0
during	0
cellular	0
activation	0
and	0
in	0
transformed	5
B	6
cells	6
.	0

Monocytes	0
and	0
transformed	5
B-cells	6
normally	0
express	0
MNP-1	9
strongly	0
and	0
MNP-2	9
weakly	0
,	0
while	0
T-cells	0
strongly	0
express	0
only	0
MNP-2	9
.	0

Recently	0
,	0
we	0
reported	0
that	0
HIV-1	9
tat	10
downregulates	0
MIP-1	9
alpha	10
expression	0
in	0
Jurkat	5
T-cells	6
.	0

In	0
this	0
report	0
we	0
show	0
induction	0
of	0
MNP-1	9
in	0
Jurkat	5
T-cells	6
expressing	0
HIV-1	9
tat	10
.	0

Expression	0
of	0
neither	0
HTLV-1	9
tax	10
in	0
Jurkat	5
T-cells	6
nor	0
EBV	0
in	0
B-cells	7
had	0
any	0
effect	0
on	0
MNP-1	9
or	0
MNP-2	9
expression	0
,	0
showing	0
that	0
the	0
effect	0
is	0
specific	0
for	0
HIV-1	9
tat	10
.	0

We	0
propose	0
that	0
HIV-1	9
tat	10
may	0
inhibit	0
MIP-1	9
alpha	10
expression	0
by	0
inducing	0
MNP-1	9
expression	0
in	0
T-cells	7
,	0
probably	0
by	0
either	0
competing	0
with	0
MNP-2	9
for	0
binding	0
to	0
the	0
MIP-1	1
alpha	2
promoter	2
or	0
by	0
sequestering	0
it	0
into	0
inactive	0
forms	0
.	0

Differentiation	0
of	0
T-helper	7
lymphocytes	8
:	0
selective	0
regulation	0
by	0
members	0
of	0
the	0
STAT	9
family	10
of	0
transcription	9
factors	10
.	0

Interleukin-4	9
(	0
IL-4	9
)	0
and	0
interleukin-12	9
(	0
IL-12	9
)	0
control	0
the	0
differentiation	0
of	0
T-helper	7
cells	8
.	0

Here	0
we	0
summarize	0
studies	0
which	0
investigate	0
the	0
mechanism	0
by	0
which	0
these	0
cytokines	9
selectively	0
reprogramme	0
gene	0
expression	0
in	0
T-lymphocytes	7
.	0

Cytokine	9
stimulation	0
leads	0
to	0
the	0
phosphorylation	0
of	0
specific	0
tyrosine	0
residues	0
within	0
the	0
intracellular	9
domain	10
of	0
the	0
corresponding	0
cytokine	9
receptor	10
.	0

These	0
phosphotyrosines	0
serve	0
as	0
docking	9
sites	10
for	0
latent	0
,	0
cytoplasmic	9
transcription	10
factors	10
known	0
as	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
Stat	10
)	10
proteins	10
.	0

Receptor/Stat	0
interaction	0
is	0
mediated	0
by	0
the	0
src	9
homology	10
2	10
(	10
SH2	10
)	10
domain	10
of	0
the	0
corresponding	0
Stat	9
protein	10
.	0

Although	0
Stat	0
binding	0
to	0
the	0
intracellular	9
domain	10
of	0
the	0
cytokine	9
receptor	10
strongly	0
depends	0
on	0
the	0
phosphotyrosine	0
residue	0
,	0
the	0
recruitment	0
of	0
a	0
specific	0
Stat	9
protein	10
is	0
dictated	0
by	0
amino	0
acid	0
residues	0
C-terminal	0
to	0
the	0
phosphotyrosine	0
.	0

Specific	0
docking	9
sites	10
within	0
individual	0
cytokine	9
receptors	10
have	0
been	0
identified	0
for	0
almost	0
all	0
Stat	9
proteins	10
.	0

The	0
direct	0
coupling	0
between	0
cytokine	9
receptor	10
and	0
transcription	9
factor	10
helps	0
to	0
explain	0
how	0
different	0
cytokines	9
elicit	0
distinct	0
patterns	0
of	0
gene	0
expression	0
.	0

Role	0
of	0
EGR1	9
in	0
regulation	0
of	0
stimulus-dependent	0
CD44	9
transcription	0
in	0
B	0
lymphocytes	0
.	0

The	0
immediate-early	1
gene	2
egr-1	1
encodes	0
a	0
transcription	9
factor	10
(	0
EGR1	9
)	0
that	0
links	0
B-cell	9
antigen	10
receptor	10
(	0
BCR	9
)	0
signals	0
to	0
downstream	0
activation	0
events	0
through	0
the	0
regulation	0
of	0
previously	0
unidentified	0
target	1
genes	2
.	0

Here	0
we	0
identify	0
the	0
gene	0
encoding	0
the	0
lymphocyte	9
homing	10
and	10
migration	10
protein	10
CD44	9
as	0
a	0
target	0
of	0
EGR1	9
regulation	0
in	0
B	7
cells	8
.	0

BCR	9
-induced	0
increases	0
in	0
CD44	3
mRNA	4
expression	0
and	0
transcription	0
levels	0
are	0
shown	0
to	0
occur	0
in	0
EGR1-expressing	5
but	6
not	6
in	6
nonexpressing	6
subclones	6
of	0
the	0
B-cell	5
line	6
WEHI-231	5
.	0

Kinetics	0
of	0
egr-1	1
transcription	0
and	0
the	0
appearance	0
of	0
nuclear	0
EGR1	9
protein	10
precede	0
CD44	9
induction	0
and	0
occur	0
within	0
30	0
min	0
after	0
stimulation	0
in	0
the	0
EGR1-expressing	5
subclone	6
.	0

A	0
single	0
EGR1	9
binding	0
motif	0
is	0
demonstrated	0
at	0
bp	0
-301	0
of	0
the	0
human	1
CD44	2
promoter	2
.	0

Cotransfection	0
of	0
a	0
CD44	1
promoter-chloramphenicol	2
acetyltransferase	2
reporter	2
construct	2
with	0
an	0
egr-1	1
expression	2
vector	2
resulted	0
in	0
a	0
6.5-	0
to	0
8.5-fold	0
induction	0
of	0
transcriptional	0
activity	0
relative	0
to	0
an	0
empty	1
expression	2
vector	2
.	0

The	0
EGR1	1
binding	2
motif	2
was	0
shown	0
to	0
be	0
necessary	0
for	0
stimulus-induced	0
expression	0
of	0
a	0
CD44	9
promoter-chloramphenicol	1
acetyltransferase	2
reporter	2
construct	2
in	0
nontransformed	7
B	8
lymphocytes	8
and	0
was	0
required	0
for	0
transactivation	0
by	0
an	0
EGR1	1
expression	2
vector	2
in	0
a	0
B-cell	5
line	6
.	0

These	0
studies	0
identify	0
EGR1	9
as	0
an	0
intermediary	0
linking	0
BCR	9
-derived	0
signals	0
to	0
the	0
induction	0
of	0
CD44	9
.	0

The	0
relevance	0
of	0
these	0
molecular	0
events	0
to	0
BCR	9
signal	0
transduction	0
and	0
antigen-stimulated	0
B-cell-mediated	0
immune	0
responses	0
is	0
discussed	0
.	0

Involvement	0
of	0
intracellular	0
Ca2+	0
in	0
oxidant-induced	0
NF-kappa	9
B	10
activation	0
.	0

In	0
human	5
Jurkat	6
T	6
cells	6
and	0
its	0
subclone	0
Wurzburg	5
cells	6
oxidant	0
challenge	0
elevated	0
[	0
Ca2+	0
]	0
i	0
by	0
mobilizing	0
Ca2+	0
from	0
intracellular	0
stores	0
.	0

In	0
Jurkat	5
cells	6
this	0
effect	0
was	0
rapid	0
and	0
transient	0
,	0
but	0
in	0
Wurzburg	5
cells	6
the	0
response	0
was	0
slow	0
and	0
sustained	0
.	0

H2O2-induced	0
NF-kappaB	9
activation	0
in	0
Wurzburg	5
cells	6
was	0
not	0
influenced	0
by	0
the	0
presence	0
of	0
extracellular	0
EGTA	0
but	0
was	0
totally	0
inhibited	0
in	0
cells	0
that	0
were	0
loaded	0
with	0
esterified	0
EGTA	0
.	0

In	0
Jurkat	5
cells	6
that	0
are	0
not	0
sensitive	0
to	0
H2O2-induced	0
NF-kappaB	9
activation	0
,	0
H2O2	0
potentiated	0
NF-kappaB	9
activation	0
in	0
the	0
presence	0
of	0
sustained	0
high	0
[	0
Ca2+	0
]	0
i	0
following	0
thapsigargin	0
treatment	0
.	0

NF-kappaB	9
regulatory	0
effect	0
of	0
alpha-lipoate	0
and	0
N-acetylcysteine	0
appeared	0
to	0
be	0
,	0
at	0
least	0
in	0
part	0
,	0
due	0
to	0
their	0
ability	0
to	0
stabilize	0
elevation	0
of	0
[	0
Ca2+	0
]	0
i	0
following	0
oxidant	0
challenge	0
.	0

Results	0
of	0
this	0
study	0
indicate	0
that	0
a	0
sustained	0
elevated	0
[	0
Ca2+	0
]	0
i	0
is	0
a	0
significant	0
factor	0
in	0
oxidant-induced	0
NF-kappaB	9
activation	0
.	0

Transactivation	0
of	0
the	0
interleukin-1alpha	1
promoter	2
by	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
I	10
and	10
type	10
II	10
Tax	10
proteins	10
.	0

Human	5
T-cell	6
leukemia	6
virus	6
type	6
I	6
(	6
HTLV-I	6
)	6
-infected	6
T-cell	6
lines	6
constitutively	0
produce	0
high	0
levels	0
of	0
interleukin-1alpha	9
(	0
IL-1alpha	9
)	0
.	0

To	0
analyze	0
the	0
mechanisms	0
that	0
lead	0
to	0
the	0
expression	0
of	0
IL-1alpha	9
in	0
HTLV-I-infected	5
cell	6
lines	6
,	0
we	0
studied	0
regulatory	0
regions	0
of	0
the	0
human	0
IL-1alpha	1
promoter	2
involved	0
in	0
activation	0
of	0
the	0
IL-1alpha	1
gene	2
.	0

IL-1alpha	1
promoter	2
constructs	2
drive	0
transcription	0
of	0
the	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
reporter	2
gene	2
in	0
HTLV-I-positive	5
MT-2	6
cells	6
,	0
which	0
constitutively	0
produce	0
IL-1alpha	9
.	0

In	0
a	0
cotransfection	0
assay	0
,	0
the	0
Tax	9
protein	10
of	0
both	0
HTLV-I	0
and	0
HTLV-II	0
specifically	0
activated	0
transcription	0
from	0
the	0
IL-1alpha	1
promoter	2
in	0
an	0
uninfected	5
Jurkat	6
cell	6
line	6
.	0

A	0
mutant	0
Tax	9
protein	10
deficient	0
in	0
transactivation	0
of	0
genes	0
by	0
the	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
pathway	0
was	0
unable	0
to	0
induce	0
transcriptional	0
activity	0
of	0
IL-1alpha	1
promoter-CAT	2
constructs	2
,	0
but	0
was	0
rescued	0
by	0
exogenous	0
provision	0
of	0
p65/p50	9
NF-kappaB	9
.	0

We	0
found	0
that	0
two	0
IL-1alpha	1
kappaB-like	2
sites	2
(	0
positions	0
-1	1
,	2
065	2
to	2
-1	2
,	2
056	2
and	0
+646	1
to	2
+655	2
)	0
specifically	0
formed	0
a	0
complex	0
with	0
NF-kappaB	9
-containing	0
nuclear	0
extract	0
from	0
MT-2	5
cells	6
and	0
that	0
NF-kappaB	9
bound	0
with	0
higher	0
affinity	0
to	0
the	0
3	1
'	2
NF-kappaB	2
binding	2
site	2
than	0
to	0
the	0
5	1
'	2
NF-kappaB	2
site	2
.	0

Moreover	0
,	0
deletion	0
of	0
either	0
5	1
'	2
or	2
3	2
'	2
NF-kappaB	2
sites	2
reduced	0
IL-1alpha	1
promoter	2
activity	0
in	0
MT-2	5
cells	6
and	0
transactivation	0
of	0
the	0
IL-1alpha	1
promoter	2
by	0
exogenous	0
NF-kappaB	9
and	0
Tax	9
in	0
Jurkat	5
cells	6
.	0

These	0
data	0
suggest	0
a	0
general	0
role	0
for	0
Tax	9
induction	0
of	0
IL-1alpha	1
gene	2
transcription	0
by	0
the	0
NF-kappaB	9
pathway	0
.	0

Expression	0
of	0
IL-1alpha	9
by	0
HTLV-I	0
productively	0
infected	7
cells	8
may	0
be	0
important	0
in	0
the	0
hypercalcemia	0
,	0
osteolytic	0
bone	0
lesions	0
,	0
neutrophilia	0
,	0
elevation	0
of	0
C-reactive	9
protein	10
,	0
and	0
fever	0
frequently	0
seen	0
in	0
patients	0
with	0
HTLV-I-induced	0
adult	0
T-cell	0
leukemia/lymphoma	0
.	0

The	0
myeloid-cell-specific	1
c-fes	2
promoter	2
is	0
regulated	0
by	0
Sp1	9
,	0
PU.1	9
,	0
and	0
a	0
novel	0
transcription	9
factor	10
.	0

The	0
protein	0
product	0
of	0
the	0
c-fps/fes	1
(	2
c-fes	2
)	2
proto-oncogene	2
has	0
been	0
implicated	0
in	0
the	0
normal	0
development	0
of	0
myeloid	7
cells	8
(	0
macrophages	7
and	0
neutrophils	7
)	0
.	0

mRNA	0
for	0
c-fes	0
has	0
been	0
detected	0
exclusively	0
in	0
myeloid	7
cells	8
and	0
vascular	7
endothelial	8
cells	8
in	0
adult	0
mammals	0
.	0

Although	0
a	0
13-kilobase-pair	1
(	2
kb	2
)	2
human	2
c-fes	2
transgene	2
exhibits	0
high	0
levels	0
of	0
expression	0
in	0
mice	0
,	0
the	0
sequences	0
that	0
confer	0
myeloid-cell-specific	0
expression	0
of	0
the	0
human	1
c-fes	2
gene	2
have	0
not	0
been	0
defined	0
.	0

Transient-transfection	0
experiments	0
demonstrated	0
that	0
plasmids	1
containing	0
446	0
bp	0
of	0
c-fes	1
5'-flanking	2
sequences	2
linked	0
to	0
a	0
luciferase	0
reporter	0
gene	0
were	0
active	0
exclusively	0
in	0
myeloid	7
cells	8
.	0

No	0
other	0
DNA	0
element	0
within	0
the	0
13-kb	1
human	2
c-fes	2
locus	2
contained	0
positive	1
cis-acting	2
elements	2
,	0
with	0
the	0
exception	0
of	0
a	0
weakly	0
active	0
region	0
within	0
the	0
3'-flanking	1
sequences	2
.	0

DNase	0
I	0
footprinting	0
assays	0
revealed	0
four	0
distinct	0
sites	0
that	0
bind	0
myeloid	9
nuclear	10
proteins	10
(	0
-408	1
to	2
-386	2
,	0
-293	1
to	2
-254	2
,	0
-76	1
to	2
-65	2
,	0
and	0
-34	1
to	2
+3	2
)	0
.	0

However	0
,	0
the	0
first	0
two	0
footprints	0
resided	0
in	0
sequences	0
that	0
were	0
largely	0
dispensable	0
for	0
transient	0
activity	0
.	0

Plasmids	0
containing	0
151	1
bp	2
of	0
5'-flanking	1
sequences	2
confer	0
myeloid-cell-specific	0
gene	0
expression	0
.	0

Electrophoretic	0
mobility	0
shift	0
analyses	0
demonstrated	0
that	0
the	0
151-bp	1
region	2
contains	0
nuclear	1
protein	2
binding	2
sites	2
for	0
Sp1	9
,	0
PU.1	9
,	0
and/or	0
Elf-1	9
,	0
and	0
a	0
novel	9
factor	10
.	0

This	0
unidentified	0
factor	0
binds	0
immediately	0
3	0
'	0
of	0
the	0
PU.1/Elf-1	1
sites	2
and	0
appears	0
to	0
be	0
myeloid	0
cell	0
specific	0
.	0

Mutation	0
of	0
the	0
PU.1	9
/Elf-1	9
site	0
or	0
the	0
3	1
'	2
site	2
(	0
FP4-3	1
'	2
)	0
within	0
the	0
context	0
of	0
the	0
c-fes	1
promoter	2
resulted	0
in	0
substantially	0
reduced	0
activity	0
in	0
transient	0
transfections	0
.	0

Furthermore	0
,	0
transient-cotransfection	0
assay	0
demonstrated	0
that	0
PU.1	9
(	0
and	0
not	0
Elf-1	9
)	0
can	0
transactivate	0
the	0
c-fes	1
promoter	2
in	0
nonmyeloid	5
cell	6
lines	6
.	0

We	0
conclude	0
that	0
the	0
human	1
c-fes	2
gene	2
contains	0
a	0
strong	0
myeloid-cell-specific	1
promoter	2
that	0
is	0
regulated	0
by	0
Sp1	9
,	0
PU.1	9
,	0
and	0
a	0
novel	0
transcription	9
factor	10
.	0

IL-10	9
inhibits	0
nuclear	9
factor-kappa	10
B/Rel	10
nuclear	0
activity	0
in	0
CD3-stimulated	5
human	6
peripheral	6
T	6
lymphocytes	6
.	0

IL-10	9
markedly	0
reduces	0
nuclear	0
factor	0
(	9
NF	10
)	10
-kappa	10
B/Rel	10
nuclear	0
activity	0
induced	0
in	0
PBMC	7
by	0
stimulation	0
with	0
the	0
anti-CD3	9
mAb	10
OKT3	9
.	0

The	0
inhibition	0
is	0
exerted	0
specifically	0
on	0
the	0
NF-kappa	9
B/Rel	10
activation	0
induced	0
by	0
mAb	9
OKT3	10
,	0
and	0
not	0
that	0
produced	0
by	0
PMA	0
.	0

As	0
judged	0
by	0
supershifting	0
the	0
DNA-protein	9
complexes	10
with	0
Abs	9
recognizing	0
specific	0
components	0
of	0
the	0
NF-kappa	9
B/Rel	10
protein	10
family	10
,	0
the	0
p50/p65	9
(	0
Rel	9
A	10
)	0
heterodimeric	0
form	0
of	0
NF-kappa	9
B	10
is	0
primarily	0
affected	0
.	0

The	0
maximal	0
effect	0
is	0
observed	0
at	0
the	0
IL-10	9
concentration	0
of	0
20	0
U/ml	0
.	0

IL-10	9
inhibitory	0
activity	0
is	0
exerted	0
on	0
T	7
lymphocytes	8
and	0
is	0
mediated	0
by	0
monocytes	7
.	0

Indeed	0
,	0
monocytes	7
pretreated	0
with	0
IL-10	9
are	0
able	0
so	0
inhibit	0
NF-kappa	9
B	10
nuclear	0
activity	0
in	0
purified	0
T	7
lymphocytes	8
stimulated	0
with	0
OKT3	9
.	0

Soluble	0
factors	0
do	0
not	0
appear	0
to	0
be	0
involved	0
in	0
the	0
mechanism	0
of	0
inhibition	0
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
up-regulation	0
of	0
CD80	9
Ag	10
,	0
found	0
on	0
monocytes	7
obtained	0
from	0
PBMC	7
incubated	0
with	0
OKT3	9
,	0
is	0
not	0
detected	0
after	0
addition	0
of	0
IL-10	9
,	0
and	0
the	0
anti-CD28	9
mAb	10
CLB-CD28/1	9
restores	0
the	0
NF-kappa	9
B/Rel	10
nuclear	0
activity	0
in	0
IL-10-inhibited	5
lymphocytes	6
.	0

Therefore	0
,	0
the	0
NF-kappa	9
B/Rel	10
inhibition	0
might	0
be	0
ascribed	0
to	0
a	0
lack	0
of	0
cooperation	0
between	0
accessory	0
cells	0
and	0
T	7
lymphocytes	8
,	0
resulting	0
from	0
down-regulation	0
of	0
a	0
costimulatory	0
molecule	0
,	0
such	0
as	0
CD80	9
,	0
produced	0
by	0
IL-10	9
on	0
activated	0
monocytes	7
.	0

Our	0
results	0
demonstrate	0
that	0
IL-10	9
can	0
inhibit	0
the	0
induction	0
of	0
NF-kappa	9
B/Rel	10
nuclear	0
activity	0
in	0
CD3-stimulated	5
T	6
lymphocytes	6
.	0

Since	0
inappropriate	0
activation	0
of	0
kappa	1
B-driven	2
genes	2
has	0
a	0
physiopathologic	0
role	0
in	0
a	0
number	0
of	0
diseases	0
,	0
such	0
as	0
HIV	0
infection	0
,	0
our	0
findings	0
support	0
the	0
possibility	0
of	0
using	0
this	0
cytokine	0
to	0
suppress	0
an	0
undesirable	0
activation	0
of	0
these	0
transcription	9
factors	10
.	0

Expression	0
of	0
A-myb	1
,	0
but	0
not	0
c-myb	1
and	0
B-myb	1
,	0
is	0
restricted	0
to	0
Burkitt	0
's	0
lymphoma	0
,	0
sIg+	0
B-acute	0
lymphoblastic	0
leukemia	0
,	0
and	0
a	0
subset	0
of	0
chronic	0
lymphocytic	0
leukemias	0
.	0

The	0
A-myb	1
gene	2
encodes	0
a	0
transcription	9
factor	10
that	0
is	0
related	0
both	0
functionally	0
and	0
structurally	0
to	0
the	0
v-myb	1
oncogene	2
.	0

Following	0
our	0
observations	0
that	0
A-myb	1
is	0
expressed	0
in	0
a	0
restricted	0
subset	0
of	0
normal	0
mature	7
human	8
B	8
lymphocytes	8
,	0
with	0
the	0
phenotype	0
CD38+	0
,	0
CD39-	0
,	0
slgM-	0
,	0
we	0
have	0
now	0
investigated	0
the	0
pattern	0
of	0
A-myb	1
expression	0
in	0
neoplastic	0
B	7
cells	8
representating	0
the	0
whole	0
spectrum	0
of	0
B-cell	0
differentiation	0
and	0
compared	0
it	0
to	0
that	0
of	0
c-myb	1
and	0
B-myb	1
.	0

In	0
a	0
panel	0
of	0
32	0
B-cell	5
lines	6
,	0
A-myb	1
was	0
very	0
strongly	0
expressed	0
in	0
most	0
Burkitt	0
's	0
lymphoma	0
(	0
BL	0
)	0
cell	0
lines	0
,	0
but	0
weak	0
or	0
negative	0
in	0
2	0
pre-B	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
,	0
4	0
non-Hodgkin	0
's	0
lymphoma	0
(	0
NHL	0
)	0
,	0
6	0
Epstein-Barr	5
virus-immortalized	6
lymphoblastoid	6
cell	6
lines	6
,	0
and	0
6	0
myeloma	5
lines	6
.	0

Protein	0
expression	0
paralleled	0
that	0
of	0
the	0
RNA	0
.	0

We	0
have	0
also	0
investigated	0
A-myb	1
expression	0
in	0
49	0
fresh	0
cases	0
of	0
B	0
leukemias	0
.	0

Among	0
24	0
ALL	0
,	0
6	0
were	0
of	0
the	0
null	0
and	0
11	0
of	0
the	0
common	0
type	0
and	0
all	0
these	0
were	0
negative	0
for	0
A-myb	9
expression	0
;	0
on	0
the	0
other	0
hand	0
,	0
all	0
7	0
B-ALL	0
cases	0
(	0
slg+	0
)	0
,	0
as	0
well	0
as	0
one	0
fresh	0
BL	0
case	0
with	0
bone	0
marrow	0
infiltration	0
,	0
expressed	0
A-myb	1
.	0

A-myb	1
was	0
undetectable	0
in	0
4	0
prolymphocytic	0
leukemias	0
(	0
PLL	0
)	0
but	0
was	0
strongly	0
expressed	0
in	0
5/20	0
(	0
25	0
%	0
)	0
of	0
chronic	0
lymphocytic	0
leukemia	0
(	0
CLL	0
)	0
samples	0
.	0

In	0
the	0
latter	0
A-myb	1
did	0
not	0
correlate	0
with	0
phenotype	0
or	0
clinical	0
stage	0
.	0

Finally	0
,	0
we	0
have	0
studied	0
the	0
progression	0
of	0
one	0
case	0
of	0
CLL	0
into	0
Richter	0
's	0
syndrome	0
and	0
have	0
found	0
that	0
the	0
Richter	5
's	6
cells	6
expressed	0
about	0
25-fold	0
less	0
A-myb	3
RNA	4
than	0
the	0
CLL	5
cells	6
from	0
the	0
same	0
patient.	0
The	0
pattern	0
of	0
c-myb	1
and	0
B-myb	1
was	0
clearly	0
distinct	0
from	0
that	0
of	0
A-myb	1
.	0

C-myb	0
and	0
B-myb	1
were	0
expressed	0
in	0
all	0
neoplastic	0
groups	0
,	0
except	0
in	0
CLL	5
cells	6
.	0

Thus	0
,	0
A-myb	1
expression	0
,	0
unlike	0
that	0
of	0
c-myb	1
and	0
B-myb	1
,	0
is	0
restricted	0
to	0
a	0
subset	0
of	0
B-cell	0
neoplasias	0
(	0
in	0
particular	0
BL	0
and	0
slg+B-ALL	0
)	0
representative	0
of	0
a	0
specific	0
stage	0
of	0
B-cell	0
differentiation	0
.	0

This	0
expression	0
may	0
in	0
part	0
reflect	0
expression	0
of	0
A-myb	1
by	0
the	0
normal	0
germinal	0
center	0
B	7
cells	8
that	0
are	0
the	0
normal	0
counterpart	0
of	0
these	0
transformed	5
B	6
cells	6
.	0

The	0
data	0
presented	0
strongly	0
support	0
a	0
role	0
for	0
this	0
transcription	9
factor	10
in	0
B-cell	0
differentiation	0
and	0
perhaps	0
in	0
B-cell	0
transformation	0
in	0
some	0
neoplasias	0
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
stimulates	0
JAK2	9
signaling	0
pathway	0
and	0
rapidly	0
activates	0
p93fes	9
,	0
STAT1	9
p91	10
,	0
and	0
STAT3	9
p92	10
in	0
polymorphonuclear	7
leukocytes	8
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
,	0
supports	0
proliferation	0
,	0
differentiation	0
,	0
and	0
functional	0
activation	0
of	0
hemopoietic	0
cells	0
by	0
its	0
interaction	0
with	0
a	0
heterodimeric	0
receptor	0
.	0

Although	0
GM-CSF	9
receptor	0
is	0
devoid	0
of	0
tyrosine	9
kinase	10
enzymatic	0
activity	0
,	0
GM-CSF-induced	5
peripheral	6
blood	6
polymorphonuclear	6
leukocytes	6
(	0
PMN	7
)	0
functional	0
activation	0
is	0
mediated	0
by	0
the	0
phosphorylation	0
of	0
a	0
large	0
number	0
of	0
intracellular	9
signaling	10
molecules	10
.	0

We	0
have	0
previously	0
shown	0
that	0
JAK2	9
becomes	0
tyrosine-phosphorylated	0
in	0
response	0
to	0
GM-CSF	9
in	0
PMN	7
.	0

In	0
the	0
present	0
study	0
we	0
demonstrate	0
that	0
also	0
the	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
family	10
members	10
STAT1	9
p91	10
and	0
STAT3	9
p92	10
and	0
the	0
product	0
of	0
the	0
c-fps/fes	1
protooncogene	2
become	0
tyrosine-phosphorylated	0
upon	0
GM-CSF	9
stimulation	0
and	0
physically	0
associated	0
with	0
both	0
GM-CSF	9
receptor	0
beta	0
common	0
subunit	0
and	0
JAK2	9
.	0

Moreover	0
GM-CSF	9
was	0
able	0
to	0
induce	0
JAK2	9
and	0
p93fes	9
catalytic	0
activity	0
.	0

We	0
also	0
demonstrate	0
that	0
the	0
association	0
of	0
the	0
GM-CSF	9
receptor	10
beta	10
common	10
subunit	10
with	0
JAK2	9
is	0
ligand-dependent	0
.	0

Finally	0
we	0
demonstrate	0
that	0
GM-CSF	9
induces	0
a	0
DNA-binding	9
complex	10
that	0
contains	0
both	0
p91	9
and	0
p92	9
.	0

These	0
results	0
identify	0
a	0
new	0
signal	0
transduction	0
pathway	0
activated	0
by	0
GM-CSF	9
and	0
provide	0
a	0
mechanism	0
for	0
rapid	0
activation	0
of	0
gene	0
expression	0
in	0
GM-CSF-stimulated	7
PMN	8
.	0

Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
(	10
EBNA2	10
)	10
-oestrogen	10
receptor	10
fusion	10
proteins	10
complement	0
the	0
EBNA2-deficient	0
Epstein-Barr	0
virus	0
strain	0
P3HR1	0
in	0
transformation	0
of	0
primary	7
B	8
cells	8
but	0
suppress	0
growth	0
of	0
human	5
B	6
cell	6
lymphoma	6
lines	6
.	0

To	0
develop	0
a	0
transformation	0
system	0
with	0
a	0
conditional	0
Epstein-Barr	1
virus	2
nuclear	2
antigen	2
2	2
(	2
EBNA2	2
)	2
gene	2
,	0
we	0
fused	0
the	0
hormone	9
binding	10
domain	10
of	0
the	0
oestrogen	0
receptor	0
to	0
the	0
N	9
or	10
C	10
terminus	10
of	0
EBNA2	9
.	0

In	0
promoter	0
transactivation	0
as	0
well	0
as	0
primary	0
B	0
cell	0
transformation	0
assays	0
these	0
chimeric	0
EBNA2	9
proteins	0
are	0
able	0
to	0
substitute	0
for	0
wild-type	9
EBNA2	10
in	0
the	0
presence	0
of	0
oestrogen	0
.	0

Here	0
we	0
provide	0
evidence	0
that	0
this	0
transformation	0
is	0
the	0
result	0
of	0
double	0
infection	0
of	0
a	0
cell	0
with	0
two	0
virions	0
,	0
the	0
P3HR1	1
virus	2
genome	2
and	0
a	0
mini-EBV	1
plasmid	2
carrying	0
the	0
chimeric	0
EBNA2	1
gene	2
.	0

Unexpectedly	0
,	0
expression	0
of	0
the	0
same	0
EBNA2	9
-oestrogen	0
receptor	0
fusion	0
protein	0
in	0
established	5
human	6
B	6
cell	6
lymphoma	6
lines	6
resulted	0
in	0
growth	0
retardation	0
or	0
growth	0
arrest	0
upon	0
the	0
addition	0
of	0
oestrogen	0
.	0

By	0
titrating	0
the	0
oestrogen	0
concentration	0
in	0
these	0
stably	5
transfected	6
cells	6
,	0
the	0
growth	0
retarding	0
and	0
the	0
transactivating	0
function	0
of	0
the	0
chimeric	9
proteins	10
could	0
not	0
be	0
dissociated	0
.	0

We	0
propose	0
that	0
growth	0
inhibition	0
of	0
established	0
B	5
cell	6
lymphoma	6
lines	6
is	0
a	0
novel	0
function	0
of	0
EBNA2	9
which	0
has	0
not	0
been	0
detected	0
in	0
the	0
absence	0
of	0
an	0
inducible	0
system	0
.	0

It	0
remains	0
open	0
whether	0
the	0
growth	0
retarding	0
property	0
of	0
the	0
EBNA2-oestrogen	9
receptor	10
fusion	10
protein	10
in	0
B	5
cell	6
lymphoma	6
lines	6
is	0
due	0
to	0
unphysiologically	0
high	0
expression	0
of	0
the	0
chimeric	9
protein	10
or	0
to	0
interference	0
with	0
a	0
cellular	0
programme	0
driving	0
proliferation	0
in	0
these	0
cell	5
lines	6
.	0

Tissue-specific	0
activity	0
of	0
the	0
gammac	1
chain	2
gene	2
promoter	2
depends	0
upon	0
an	0
Ets	1
binding	2
site	2
and	0
is	0
regulated	0
by	0
GA-binding	9
protein	10
.	0

The	0
gammac	9
chain	10
is	0
a	0
subunit	0
of	0
multiple	0
cytokine	9
receptors	10
(	0
interleukin	9
(	10
IL	10
)	10
-2	10
,	0
IL-4	9
,	0
IL-7	9
,	0
IL-9	9
,	0
and	0
IL-15	9
)	0
,	0
the	0
expression	0
of	0
which	0
is	0
restricted	0
to	0
hematopoietic	7
lineages	8
.	0

A	0
defect	0
in	0
gammac	0
leads	0
to	0
the	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
characterized	0
by	0
a	0
block	0
in	0
T	0
cell	0
differentiation	0
.	0

In	0
order	0
to	0
better	0
characterize	0
the	0
human	1
gammac	2
promoter	2
and	0
define	0
the	0
minimal	1
tissue-specific	2
promoter	2
region	2
,	0
progressive	0
5'-deletion	1
constructs	2
of	0
a	0
segment	0
extending	0
1053	1
base	2
pairs	2
upstream	2
of	0
the	0
major	1
transcription	2
start	2
site	2
were	0
generated	0
and	0
tested	0
for	0
promoter	0
activity	0
in	0
various	0
hematopoietic	7
and	8
nonhematopoietic	8
cell	8
types	8
.	0

The	0
-1053/+34	1
construct	2
allowed	0
promoter	0
activity	0
only	0
in	0
cells	0
of	0
hematopoietic	7
origin	8
,	0
and	0
tissue	0
specificity	0
was	0
conserved	0
in	0
all	0
other	0
constructs	0
tested	0
.	0

The	0
region	0
downstream	0
of	0
-90	0
appeared	0
critical	0
for	0
basal	0
promoter	0
activity	0
.	0

It	0
contains	0
two	0
potential	0
Ets	1
binding	2
sites	2
conserved	0
in	0
the	0
murine	1
gammac	2
promoter	2
gene	2
,	0
one	0
of	0
which	0
was	0
found	0
essential	0
for	0
functional	0
promoter	0
activity	0
as	0
determined	0
by	0
mutational	0
analysis	0
.	0

The	0
functional	0
Ets	1
binding	2
site	2
was	0
found	0
to	0
bind	0
Ets	9
family	10
proteins	10
,	0
principally	0
GA-binding	9
protein	10
and	0
Elf-1	9
and	0
could	0
be	0
transactivated	0
by	0
GABPalpha	9
and	0
-beta	9
synergistically	0
.	0

These	0
results	0
indicate	0
that	0
,	0
as	0
already	0
reported	0
for	0
the	0
IL2Rbeta	1
promoter	2
,	0
GA-binding	9
protein	10
is	0
an	0
essential	0
component	0
of	0
gammac	0
basal	0
promoter	0
activity	0
.	0

Although	0
GABP	9
expression	0
is	0
not	0
restricted	0
to	0
the	0
hematopoietic	7
lineage	8
,	0
its	0
interaction	0
with	0
other	0
specific	9
factors	10
may	0
contribute	0
to	0
the	0
tissue-specific	0
expression	0
of	0
the	0
gammac	1
gene	2
.	0

Detection	0
of	0
intracellular	9
signal	10
transduction	10
molecules	10
in	0
PBMC	7
from	0
rhesus	0
macaques	0
and	0
sooty	0
mangabeys	0
.	0

One	0
of	0
the	0
manifestations	0
of	0
human	0
HIV-1	0
and	0
nonhuman	0
primate	0
SIV	0
infection	0
that	0
lead	0
to	0
disease	0
is	0
reasoned	0
to	0
be	0
secondary	0
to	0
generalized	0
T-cell	0
dysfunction	0
.	0

The	0
molecular	0
mechanisms	0
associated	0
with	0
the	0
T-cell	0
dysfunction	0
remain	0
to	0
be	0
elucidated	0
.	0

To	0
address	0
this	0
issue	0
,	0
we	0
sought	0
to	0
utilize	0
the	0
nonhuman	0
primate	0
model	0
to	0
study	0
intracellular	0
signaling	0
events	0
in	0
cells	0
from	0
disease-susceptible	0
rhesus	0
macaques	0
and	0
disease-resistant	0
sooty	0
mangabeys	0
.	0

Because	0
relatively	0
little	0
is	0
known	0
about	0
these	0
events	0
in	0
nonhuman	0
primates	0
,	0
our	0
laboratory	0
defined	0
optimal	0
conditions	0
,	0
reagents	0
,	0
and	0
assays	0
for	0
the	0
study	0
of	0
signal	0
transduction	0
events	0
in	0
cells	0
from	0
nonhuman	0
primates	0
.	0

The	0
protein	0
phosphorylation	0
patterns	0
in	0
the	0
two	0
monkeys	0
exhibited	0
quantitative	0
,	0
qualitative	0
,	0
and	0
kinetic	0
differences	0
.	0

Antibodies	0
to	0
Stat6	9
detected	0
a	0
unique	0
band	0
in	0
macaque	0
cell	0
lysates	0
.	0

This	0
band	0
is	0
markedly	0
decreased	0
human	0
cell	0
lysates	0
and	0
never	0
seen	0
in	0
mangabey	0
cell	0
lysates	0
.	0

Detection	0
of	0
various	0
other	0
intracellular	9
signaling	10
proteins	10
is	0
also	0
described	0
.	0

Genetic	0
characterization	0
of	0
transactivation	0
of	0
the	0
human	1
T-cell	2
leukemia	2
virus	2
type	2
1	2
promoter	2
:	0
Binding	0
of	0
Tax	9
to	0
Tax-responsive	1
element	2
1	2
is	0
mediated	0
by	0
the	0
cyclic	9
AMP-responsive	10
members	10
of	0
the	0
CREB/ATF	9
family	10
of	0
transcription	0
factors	0
.	0

To	0
achieve	0
a	0
better	0
understanding	0
of	0
the	0
mechanism	0
of	0
transactivation	0
by	0
Tax	9
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
Tax-responsive	1
element	2
1	2
(	0
TRE-1	1
)	0
,	0
we	0
developed	0
a	0
genetic	0
approach	0
with	0
Saccharomyces	0
cerevisiae	0
.	0

We	0
constructed	0
a	0
yeast	0
reporter	0
strain	0
containing	0
the	0
lacZ	1
gene	2
under	0
the	0
control	0
of	0
the	0
CYC1	1
promoter	2
associated	0
with	0
three	0
copies	0
of	0
TRE-1	1
.	0

Expression	0
of	0
either	0
the	0
cyclic	9
AMP	10
response	10
element-binding	10
protein	10
(	0
CREB	9
)	0
or	0
CREB	9
fused	0
to	0
the	0
GAL4	9
activation	10
domain	10
(	0
GAD	9
)	0
in	0
this	0
strain	0
did	0
not	0
modify	0
the	0
expression	0
of	0
the	0
reporter	1
gene	2
.	0

Tax	9
alone	0
was	0
also	0
inactive	0
.	0

However	0
,	0
expression	0
of	0
the	0
reporter	1
gene	2
was	0
induced	0
by	0
coexpression	0
of	0
Tax	9
and	0
CREB	9
.	0

This	0
effect	0
was	0
stronger	0
with	0
the	0
GAD-CREB	9
fusion	10
protein	10
.	0

Analysis	0
of	0
different	0
CREB	9
mutants	10
with	0
this	0
genetic	0
system	0
indicated	0
that	0
the	0
C-terminal	9
92	10
amino	10
acid	10
residues	10
,	0
which	0
include	0
the	0
basic	9
domain	10
and	0
the	0
leucine	9
zipper	10
,	0
are	0
necessary	0
and	0
sufficient	0
to	0
mediate	0
transactivation	0
by	0
Tax	9
.	0

To	0
identify	0
cellular	9
proteins	10
binding	0
to	0
TRE-1	1
in	0
a	0
Tax	9
-dependent	0
manner	0
,	0
this	0
strain	0
was	0
also	0
used	0
to	0
screen	0
a	0
library	0
of	0
human	1
cDNAs	2
fused	0
to	0
GAD	9
.	0

Of	0
five	0
positive	0
clones	0
isolated	0
from	0
0.75	0
x	0
10	0
(	0
6	0
)	0
yeast	0
colonies	0
,	0
four	0
were	0
members	0
of	0
the	0
CREB/activating	9
transcription	10
factor	10
(	10
ATF	10
)	10
family	10
:	0
CREB	9
,	0
two	9
isoforms	10
of	10
the	10
cyclic	10
AMP-responsive	10
element	10
modulator	10
(	0
CREM	9
)	0
,	0
and	0
ATF-1	9
.	0

Interestingly	0
,	0
these	0
three	0
proteins	0
can	0
be	0
phosphorylated	0
by	0
protein	9
kinase	10
A	10
and	0
thus	0
form	0
a	0
particular	0
subgroup	0
within	0
the	0
CREB/ATF	9
family	10
.	0

Expression	0
of	0
ATF-2	9
in	0
S.	0
cerevisiae	0
did	0
not	0
activate	0
TRE-1	1
in	0
the	0
presence	0
of	0
Tax	9
.	0

This	0
shows	0
that	0
in	0
a	0
eukaryotic	0
nucleus	0
,	0
Tax	9
specifically	0
interacts	0
with	0
the	0
basic	9
domain-leucine	10
zipper	10
region	10
of	0
ATF-1	9
,	0
CREB	9
,	0
and	0
CREM	9
.	0

The	0
fifth	0
clone	0
identified	0
in	0
this	0
screening	0
corresponded	0
to	0
the	0
Ku	9
autoantigen	10
p70	10
subunit	10
.	0

When	0
fused	0
to	0
GAD	9
,	0
the	0
C-terminal	9
region	10
of	0
Ku	9
was	0
able	0
to	0
activate	0
transcription	0
via	0
TRE-1	1
but	0
this	0
activation	0
was	0
not	0
dependent	0
on	0
Tax	9
.	0

A	0
mammalian	9
histone	10
deacetylase	10
related	0
to	0
the	0
yeast	9
transcriptional	10
regulator	10
Rpd3p	9
[	0
see	0
comments	0
]	0

Trapoxin	0
is	0
a	0
microbially	0
derived	0
cyclotetrapeptide	0
that	0
inhibits	0
histone	9
deacetylation	0
in	0
vivo	0
and	0
causes	0
mammalian	0
cells	0
to	0
arrest	0
in	0
the	0
cell	0
cycle	0
.	0

A	0
trapoxin	0
affinity	0
matrix	0
was	0
used	0
to	0
isolate	0
two	0
nuclear	0
proteins	0
that	0
copurified	0
with	0
histone	9
deacetylase	10
activity	0
.	0

Both	0
proteins	0
were	0
identified	0
by	0
peptide	0
microsequencing	0
,	0
and	0
a	0
complementary	1
DNA	2
encoding	0
the	0
histone	9
deacetylase	10
catalytic	10
subunit	10
(	0
HD1	9
)	0
was	0
cloned	0
from	0
a	0
human	0
Jurkat	0
T	0
cell	0
library	0
.	0

As	0
the	0
predicted	0
protein	0
is	0
very	0
similar	0
to	0
the	0
yeast	9
transcriptional	10
regulator	10
Rpd3p	9
,	0
these	0
results	0
support	0
a	0
role	0
for	0
histone	9
deacetylase	10
as	0
a	0
key	0
regulator	0
of	0
eukaryotic	0
transcription	0
.	0

Coexpression	0
of	0
the	0
interleukin-13	1
and	2
interleukin-4	2
genes	2
correlates	0
with	0
their	0
physical	0
linkage	0
in	0
the	0
cytokine	1
gene	2
cluster	2
on	0
human	1
chromosome	2
5q23-31	2
.	0

Interleukin-13	9
(	0
IL-13	9
)	0
and	0
IL-4	9
are	0
cytokines	0
produced	0
by	0
T	0
cells	0
that	0
are	0
encoded	0
by	0
the	0
q23-31	0
region	0
of	0
human	0
chromosome	0
5	0
.	0

To	0
investigate	0
the	0
regulation	0
of	0
IL-13	1
gene	2
expression	0
by	0
T	7
cells	8
,	0
we	0
isolated	0
and	0
sequenced	0
the	0
human	0
IL-13	1
gene	2
,	0
analyzed	0
its	0
5'-flanking	1
region	2
for	0
potential	0
transcriptional	1
activation	2
elements	2
,	0
and	0
examined	0
its	0
expression	0
in	0
nontransformed	5
T-lineage	6
cell	6
populations	6
.	0

The	0
human	1
IL-13	2
gene	2
was	0
located	0
12.5-kb	1
upstream	2
of	0
the	0
IL-4	1
gene	2
and	0
2-kb	1
downstream	2
of	0
a	0
CpG	1
island	2
.	0

The	0
IL-13	1
gene	2
5	2
'	2
flank	2
region	2
included	0
a	0
segment	0
with	0
sequence	0
homology	0
to	0
P	1
elements	2
of	0
the	0
IL-4	1
promoter	2
involved	0
in	0
transcriptional	0
activation	0
in	0
T	7
cells	8
.	0

Mutation	0
of	0
the	0
IL-13	1
P	2
element	2
site	2
significantly	0
reduced	0
IL-13	9
promoter	0
activity	0
in	0
response	0
to	0
T-cell	0
activation	0
.	0

Oligonucleotides	0
containing	0
the	0
IL-13	9
or	0
IL-4	1
P	2
element	2
sites	2
specifically	0
bound	0
the	0
transcriptional	9
activator	10
protein	10
,	0
nuclear	9
factor-activated	10
T	10
cells	10
,	0
preformed	0
(	0
NF-ATp	9
)	0
,	0
when	0
incubated	0
with	0
nuclear	0
protein	0
extracts	0
from	0
activated	7
T	8
cells	8
.	0

Similar	0
to	0
IL-4	9
,	0
IL-13	3
mRNA	4
expression	0
was	0
highest	0
in	0
T-cell	5
populations	6
enriched	0
for	0
cells	0
that	0
had	0
previously	0
been	0
primed	0
in	0
vivo	0
or	0
in	0
vitro	0
,	0
indicating	0
that	0
priming	0
increases	0
the	0
expression	0
of	0
the	0
IL-13	1
and	2
IL-4	2
genes	2
in	0
a	0
coordinate	0
manner	0
.	0

Because	0
the	0
primed	5
T	6
cells	6
contain	0
higher	0
levels	0
of	0
nuclear	9
NF-ATp	10
,	0
capable	0
of	0
binding	0
to	0
P	1
elements	2
of	0
the	0
IL-4	1
and	2
IL-13	2
promoters	2
,	0
than	0
do	0
freshly-isolated	7
T	8
cells	8
,	0
the	0
NF-AT-binding	1
P	2
elements	2
are	0
attractive	0
candidates	0
to	0
mediate	0
the	0
coordinate	0
expression	0
of	0
these	0
two	0
cytokine	1
genes	2
.	0

Inhibition	0
of	0
alpha	9
interferon	10
but	0
not	0
gamma	9
interferon	10
signal	0
transduction	0
by	0
phorbol	0
esters	0
is	0
mediated	0
by	0
a	0
tyrosine	9
phosphatase	10
.	0

Previous	0
studies	0
have	0
indicated	0
that	0
the	0
expression	0
of	0
viral	0
oncoproteins	0
,	0
cell	0
transformation	0
,	0
or	0
phorbol	0
ester	0
treatment	0
of	0
cells	0
can	0
inhibit	0
alpha/beta	0
interferon	0
(	0
IFN-alpha/beta	0
)	0
-induced	0
gene	0
expression	0
.	0

The	0
mechanisms	0
by	0
which	0
these	0
promoters	0
of	0
cell	0
growth	0
exert	0
their	0
inhibitory	0
effects	0
vary	0
,	0
but	0
in	0
most	0
instances	0
they	0
involve	0
a	0
disruption	0
of	0
the	0
IFN-alpha/beta-induced	0
transcription	0
complex	0
ISGF3	0
such	0
that	0
the	0
DNA-binding	0
component	0
of	0
this	0
complex	0
(	0
the	0
48-kDa	0
ISGF3gamma	0
protein	0
)	0
does	0
not	0
bind	0
to	0
the	0
interferon-stimulated	0
response	0
element	0
(	0
ISRE	0
)	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrated	0
that	0
phorbol	0
ester	0
treatment	0
of	0
human	0
peripheral	0
blood	0
monocytes	0
dramatically	0
inhibits	0
activation	0
of	0
IFN-alpha/B-stimulated	0
early	0
response	0
genes	0
but	0
by	0
a	0
mechanism	0
which	0
does	0
not	0
involve	0
abrogation	0
of	0
the	0
ISRE	0
binding	0
of	0
ISGF3gamma	0
.	0

Phorbol	0
ester	0
treatment	0
of	0
monocytes	0
inhibited	0
IFN	0
alpha-stimulated	0
tyrosine	0
phosphorylation	0
of	0
the	0
transcription	9
factors	10
Stat1alpha	9
,	0
Stat2	9
,	0
and	0
Stat3	9
and	0
of	0
the	0
tyrosine	9
kinase	10
Tyk2	9
but	0
had	0
no	0
effect	0
on	0
IFN-gamma	9
activation	0
of	0
Stat1alpha	9
.	0

IFNalpha-stimulated	0
tyrosine	0
phosphorylation	0
of	0
Jak1	9
and	0
the	0
alpha	9
subunit	10
of	0
the	0
IFN-alpha	9
receptor	10
were	0
unaffected	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
.	0

Moreover	0
,	0
PMA	0
caused	0
the	0
dephosphorylation	0
of	0
Tyk2	9
but	0
not	0
of	0
Jak1	9
,	0
which	0
was	0
activated	0
by	0
IFN	9
.	0

Pretreatment	0
of	0
cells	0
with	0
vanadate	0
prevented	0
the	0
effects	0
of	0
PMA	0
with	0
regard	0
to	0
PMA-induced	0
Tyk2	9
dephosphorylation	0
.	0

These	0
observations	0
suggest	0
that	0
PMA	0
exerts	0
its	0
inhibitory	0
effects	0
by	0
activation	0
of	0
a	0
tyrosine	9
phosphatase	10
which	0
selectively	0
regulates	0
Tyk2	9
but	0
not	0
Jak1	9
activity	0
.	0

Transcriptional	0
regulation	0
of	0
the	0
interleukin-2	1
gene	2
in	0
normal	0
human	7
peripheral	8
blood	8
T	8
cells	8
.	0

Convergence	0
of	0
costimulatory	0
signals	0
and	0
differences	0
from	0
transformed	7
T	8
cells	8
.	0

To	0
study	0
transcriptional	0
regulation	0
in	0
normal	7
human	8
T	8
cells	8
,	0
we	0
have	0
optimized	0
conditions	0
for	0
transient	0
transfection	0
.	0

Interleukin-2	1
(	2
IL-2	2
)	2
promoter	2
-reporter	1
gene	2
behavior	0
closely	0
parallels	0
the	0
endogenous	1
gene	2
in	0
response	0
to	0
T	9
cell	10
receptor	10
and	0
costimulatory	0
signals	0
.	0

As	0
assessed	0
with	0
mutagenized	1
promoters	2
,	0
the	0
most	0
important	0
IL-2	1
cis-regulatory	2
elements	2
in	0
normal	7
T	8
cells	8
are	0
the	0
proximal	1
AP-1	2
site	2
and	0
the	0
NF-	1
kappaB	2
site	2
.	0

Both	0
primary	0
activation	0
,	0
with	0
phytohemagglutinin	9
or	0
antibodies	9
to	10
CD3	10
,	0
and	0
costimulation	0
,	0
provided	0
by	0
pairs	0
of	0
CD2	9
antibodies	10
or	0
B7-positive	7
(	8
B	8
cells	8
)	8
or	0
B7-negative	7
(	8
endothelial	8
)	8
accessory	8
cells	8
,	8
are	0
mediated	0
through	0
the	0
same	0
cis-elements	1
.	0

Interestingly	0
,	0
the	0
nuclear	1
factor	2
of	2
activated	2
T	2
cell	2
sites	2
are	0
much	0
less	0
important	0
in	0
normal	7
T	8
cells	8
than	0
in	0
Jurkat	5
T	6
cells	6
.	0

We	0
conclude	0
that	0
IL-2	9
transcriptional	0
regulation	0
differs	0
in	0
tumor	5
cell	6
lines	6
compared	0
with	0
normal	7
T	8
cells	8
and	0
that	0
different	0
costimulatory	0
signals	0
converge	0
on	0
the	0
same	0
cis-elements	1
in	0
the	0
IL-2	1
promoter	2
.	0

The	0
RAR-RXR	9
as	0
well	0
as	0
the	0
RXR-RXR	9
pathway	0
is	0
involved	0
in	0
signaling	0
growth	0
inhibition	0
of	0
human	5
CD34+	6
erythroid	6
progenitor	6
cells	6
.	0

Previous	0
studies	0
have	0
shown	0
that	0
retinoic	0
acid	0
(	0
RA	0
)	0
,	0
similar	0
to	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
,	0
can	0
act	0
as	0
a	0
bifunctional	0
regulator	0
of	0
the	0
growth	0
of	0
bone	7
marrow	8
progenitors	8
,	0
in	0
that	0
it	0
can	0
stimulate	0
granulocyte-macrophage	0
colony-stimulating	0
factor	0
(	0
GM-CSF	0
)	0
-	0
or	0
interleukin-3	0
(	0
IL-3	0
)	0
-induced	0
GM	0
colony	0
formation	0
,	0
but	0
potently	0
inhibit	0
G-CSF	9
-induced	0
growth	0
.	0

The	0
present	0
study	0
,	0
using	0
highly	0
enriched	0
human	9
CD34+	10
as	0
well	0
as	0
Lin-	5
murine	6
bone	6
marrow	6
progenitor	6
cells	6
,	0
demonstrates	0
a	0
potent	0
inhibitory	0
effect	0
of	0
9-cis-RA	0
on	0
burst-forming	0
unit-erythroid	0
(	0
BFU-E	0
)	0
colony	0
formation	0
regardless	0
of	0
the	0
cytokine	9
stimulating	0
growth	0
.	0

Specifically	0
,	0
9-cis-RA	0
potently	0
inhibited	0
the	0
growth	0
of	0
BFU-E	0
response	0
to	0
erythropoietin	9
(	0
Epo	9
)	0
(	0
100	0
%	0
)	0
,	0
stem	9
cell	10
factor	10
(	0
SCF	9
)	0
+	0
Epo	9
(	0
92	0
%	0
)	0
,	0
IL-3	9
+	0
Epo	9
(	0
97	0
%	0
)	0
,	0
IL-4	9
+	0
Epo	9
(	0
88	0
%	0
)	0
,	0
and	0
IL-9	9
+	0
Epo	9
(	0
100	0
%	0
)	0
.	0

Erythroid	0
colony	0
growth	0
was	0
also	0
inhibited	0
when	0
CD34+	7
progenitors	8
were	0
seeded	0
at	0
one	0
cell	0
per	0
well	0
,	0
suggesting	0
a	0
direct	0
action	0
of	0
RA	0
.	0

Using	0
synthetic	0
ligands	0
to	0
retinoic	9
acid	10
receptors	10
(	0
RARs	9
)	0
and	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
)	0
that	0
selectively	0
bind	0
and	0
activate	0
RAR-RXR	9
or	0
RXR-RXR	9
dimers	0
,	0
respectively	0
,	0
we	0
dissected	0
the	0
involvement	0
of	0
the	0
two	0
retinoid	0
response	0
pathways	0
in	0
the	0
regulation	0
of	0
normal	0
myeloid	0
and	0
erythroid	0
progenitor	0
cell	0
growth	0
.	0

Transactivation	0
studies	0
showed	0
that	0
both	0
the	0
RAR	9
(	0
Ro	0
13-7410	0
)	0
and	0
RXR	9
(	0
Ro	0
25-6603	0
and	0
Ro	0
25-7386	0
)	0
ligands	0
were	0
highly	0
selective	0
at	0
100	0
nmol/L	0
.	0

At	0
this	0
concentration	0
,	0
Ro	0
13-7410	0
potently	0
inhibited	0
G-CSF	9
-stimulated	0
myeloid	0
as	0
well	0
as	0
SCF	9
+	0
Epo	9
-induced	0
erythroid	0
colony	0
growth	0
.	0

At	0
the	0
same	0
concentration	0
,	0
Ro	0
25-6603	0
and	0
Ro	0
25-7386	0
had	0
little	0
or	0
no	0
effect	0
on	0
G-CSF	9
-induced	0
colony	0
formation	0
,	0
whereas	0
they	0
inhibited	0
75	0
%	0
and	0
53	0
%	0
,	0
respectively	0
,	0
of	0
SCF	9
+	0
Epo	9
-stimulated	0
BFU-E	0
colony	0
growth	0
.	0

Thus	0
,	0
the	0
RAR-RXR	9
response	0
pathway	0
can	0
signal	0
growth	0
inhibition	0
of	0
normal	7
bone	8
marrow	8
myeloid	8
and	8
erythroid	8
progenitor	8
cells	8
.	0

In	0
addition	0
,	0
we	0
demonstrate	0
a	0
unique	0
involvement	0
of	0
the	0
RXR-RXR	9
pathway	0
in	0
mediating	0
growth	0
inhibition	0
of	0
erythroid	7
but	0
not	0
myeloid	7
progenitor	8
cells	8
.	0

AM580	0
,	0
a	0
stable	0
benzoic	0
derivative	0
of	0
retinoic	0
acid	0
,	0
has	0
powerful	0
and	0
selective	0
cyto-differentiating	0
effects	0
on	0
acute	5
promyelocytic	6
leukemia	6
cells	6
.	0

All-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
is	0
successfully	0
used	0
in	0
the	0
cyto-differentiating	0
treatment	0
of	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
.	0

Paradoxically	0
,	0
APL	5
cells	6
express	0
PML-RAR	9
,	0
an	0
aberrant	0
form	0
of	0
the	0
retinoic	9
acid	10
receptor	10
type	10
alpha	10
(	0
RAR	9
alpha	10
)	0
derived	0
from	0
the	0
leukemia-specific	1
t	2
(	2
15	2
;	2
17	2
)	2
chromosomal	2
translocation	2
.	0

We	0
show	0
here	0
that	0
AM580	0
,	0
a	0
stable	0
retinobenzoic	0
derivative	0
originally	0
synthesized	0
as	0
a	0
RAR	9
alpha	10
agonist	0
,	0
is	0
a	0
powerful	0
inducer	0
of	0
granulocytic	0
maturation	0
in	0
NB4	5
,	0
an	0
APL-derived	5
cell	6
line	6
,	0
and	0
in	0
freshly	7
isolated	8
APL	8
blasts	8
.	0

After	0
treatment	0
of	0
APL	5
cells	6
with	0
AM580	0
either	0
alone	0
or	0
in	0
combination	0
with	0
granulocyte	9
colony-stimulating	10
factor	10
(	0
G-CSF	9
)	0
,	0
the	0
compound	0
induces	0
granulocytic	0
maturation	0
,	0
as	0
assessed	0
by	0
determination	0
of	0
the	0
levels	0
of	0
leukocyte	3
alkaline	4
phosphatase	4
,	4
CD11b	4
,	4
CD33	4
,	4
and	4
G-CSF	4
receptor	4
mRNA	4
,	0
at	0
concentrations	0
that	0
are	0
10-	0
to	0
100-fold	0
lower	0
than	0
those	0
of	0
ATRA	0
necessary	0
to	0
produce	0
similar	0
effects	0
.	0

By	0
contrast	0
,	0
AM580	0
is	0
not	0
effective	0
as	0
ATRA	0
in	0
modulating	0
the	0
expression	0
of	0
these	0
differentiation	9
markers	10
in	0
the	0
HL-60	5
cell	6
line	6
and	0
in	0
freshly	7
isolated	8
granulocytes	8
obtained	0
from	0
the	0
peripheral	0
blood	0
of	0
chronic	0
myelogenous	0
leukemia	0
patients	0
during	0
the	0
stable	0
phase	0
of	0
the	0
disease	0
.	0

In	0
NB4	5
cells	6
,	0
two	0
other	0
synthetic	0
nonselective	0
RAR	0
ligands	0
are	0
capable	0
of	0
inducing	0
LAP	9
as	0
much	0
as	0
AM580	0
,	0
whereas	0
RAR	0
beta-	0
or	0
RAR	0
gamma-specific	0
ligands	0
are	0
totally	0
ineffective	0
.	0

These	0
results	0
show	0
that	0
AM580	0
is	0
more	0
powerful	0
than	0
ATRA	0
in	0
modulating	0
the	0
expression	0
of	0
differentiation	0
antigens	0
only	0
in	0
cells	0
in	0
which	0
PML-RAR	9
is	0
present	0
.	0

Binding	0
experiments	0
,	0
using	0
COS-7	5
cells	6
transiently	0
transfected	0
with	0
PML-RAR	9
and	0
the	0
normal	0
RAR	9
alpha	10
,	0
show	0
that	0
AM580	0
has	0
a	0
lower	0
affinity	0
than	0
ATRA	0
for	0
both	0
receptors	0
.	0

However	0
,	0
in	0
the	0
presence	0
of	0
PML-RAR	9
,	0
the	0
synthetic	0
retinoid	0
is	0
a	0
much	0
better	0
transactivator	0
of	0
retinoic	1
acid-responsive	2
element-containing	2
promoters	2
than	0
the	0
natural	0
retinoid	0
,	0
whereas	0
,	0
in	0
the	0
presence	0
of	0
RAR	9
alpha	10
,	0
AM580	0
and	0
ATRA	0
have	0
similar	0
activity	0
.	0

This	0
may	0
explain	0
the	0
strong	0
cyto-differentiating	0
potential	0
of	0
AM580	0
in	0
PML-RAR-containing	7
leukemic	8
cells	8
.	0

Inhibition	0
of	0
vitamin	9
D	10
receptor-retinoid	10
X	10
receptor-vitamin	10
D	10
response	10
element	10
complex	10
formation	0
by	0
nuclear	0
extracts	0
of	0
vitamin	7
D-resistant	8
New	8
World	8
primate	8
cells	8
.	0

Most	0
New	0
World	0
primate	0
(	0
NWP	0
)	0
genera	0
evolved	0
to	0
require	0
high	0
circulating	0
levels	0
of	0
steroid	0
hormones	0
and	0
vitamin	0
D	0
.	0

We	0
hypothesized	0
that	0
an	0
intracellular	9
vitamin	10
D	10
binding	10
protein	10
(	0
IDBP	9
)	0
,	0
present	0
in	0
both	0
nuclear	0
and	0
cytoplasmic	0
fractions	0
of	0
NWP	5
cells	6
,	0
or	0
another	0
protein	0
(	0
s	0
)	0
may	0
cause	0
or	0
contribute	0
to	0
the	0
steroid	0
hormone-resistant	0
state	0
in	0
NWP	5
by	0
disruption	0
of	0
the	0
receptor	0
dimerization	0
process	0
and/or	0
by	0
interference	0
of	0
receptor	9
complex	10
binding	0
to	0
the	0
consensus	1
response	2
elements	2
present	0
in	0
the	0
enhancer	1
regions	2
of	0
steroid-responsive	1
genes	2
.	0

We	0
employed	0
electromobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
to	0
screen	0
for	0
the	0
presence	0
of	0
proteins	0
capable	0
of	0
binding	0
to	0
the	0
vitamin	1
D	2
response	2
element	2
(	0
VDRE	1
)	0
.	0

Nuclear	0
and	0
post-nuclear	0
extracts	0
were	0
prepared	0
from	0
two	0
B-lymphoblastoid	5
cell	6
lines	6
known	0
to	0
be	0
representative	0
of	0
the	0
vitamin	5
D-resistant	6
and	0
wild	5
type	6
phenotypes	6
,	0
respectively	0
.	0

The	0
extracts	0
were	0
compared	0
for	0
their	0
ability	0
to	0
retard	0
the	0
migration	0
of	0
radiolabeled	0
double	0
stranded	0
oligomers	0
representative	0
of	0
the	0
VDREs	1
of	0
the	0
human	1
osteocalcin	2
and	2
the	2
mouse	2
osteopontin	2
gene	2
promoters	2
.	0

A	0
specific	0
,	0
retarded	0
band	0
containing	0
VDR-RXR	9
was	0
identified	0
when	0
wild	0
type	0
cell	0
but	0
not	0
when	0
vitamin	0
D-resistant	0
cell	0
nuclear	0
extract	0
was	0
used	0
in	0
the	0
binding	0
reaction	0
with	0
either	0
probe	0
.	0

In	0
addition	0
,	0
vitamin	0
D-resistant	0
cell	0
nuclear	0
extract	0
contained	0
a	0
protein	0
(	0
s	0
)	0
which	0
was	0
bound	0
specifically	0
to	0
the	0
VDRE	1
and	0
was	0
capable	0
of	0
completely	0
inhibiting	0
VDR-RXR-VDRE	9
complex	10
formation	0
;	0
these	0
effects	0
were	0
not	0
demonstrated	0
with	0
nuclear	0
extract	0
from	0
the	0
wild	5
type	6
cell	6
line	6
or	0
with	0
the	0
post-nuclear	0
extract	0
of	0
the	0
vitamin	5
D-resistant	6
cell	6
line	6
.	0

We	0
conclude	0
that	0
a	0
VDRE-binding	9
protein	10
(	0
s	0
)	0
,	0
distinct	0
from	0
IDBP	9
and	0
present	0
in	0
nuclear	0
extract	0
of	0
cells	0
from	0
a	0
prototypical	5
vitamin	6
D-resistant	6
NWP	6
,	0
is	0
capable	0
of	0
inhibiting	0
normal	0
VDR-RXR	9
heterodimer	0
binding	0
to	0
the	0
VDRE	1
.	0

BCL-6	9
expression	0
during	0
B-cell	0
activation	0
.	0

Translocations	0
involving	0
the	0
BCL-6	1
gene	2
are	0
common	0
in	0
the	0
diffuse	0
large	0
cell	0
subtype	0
of	0
non-Hodgkin	0
's	0
lymphoma	0
.	0

Invariably	0
,	0
the	0
BCL-6	9
coding	0
region	0
is	0
intact	0
,	0
but	0
its	0
5	1
'	2
untranslated	2
region	2
is	0
replaced	0
with	0
sequences	0
from	0
the	0
translocation	1
partner	2
.	0

The	0
present	0
study	0
shows	0
that	0
BCL-6	9
expression	0
is	0
regulated	0
in	0
lymphocytes	7
during	0
mitogenic	0
stimulation	0
.	0

Resting	7
B	8
and	8
T	8
lymphocytes	8
contain	0
high	0
levels	0
of	0
BCL-6	3
mRNA	4
.	0

Stimulation	0
of	0
mouse	7
B	8
cells	8
with	0
anti-IgM	9
or	10
IgD	10
antibodies	10
,	0
bacterial	0
lipopolysaccharide	0
,	0
phorbol	0
12-myristate	0
13-acetate	0
plus	0
ionomycin	0
,	0
or	0
CD40	9
ligand	10
led	0
to	0
a	0
five-fold	0
to	0
35-fold	0
decrease	0
in	0
BCL-6	3
mRNA	4
levels	0
.	0

Similar	0
downregulation	0
of	0
BCL-6	3
mRNA	4
was	0
seen	0
in	0
human	7
B	8
cells	8
stimulated	0
with	0
Staphylococcus	0
aureus	0
plus	0
interleukin-2	9
or	0
anti-IgM	9
antibodies	10
and	0
in	0
human	7
T	8
lymphocytes	8
stimulated	0
with	0
phytohemagglutinin	9
.	0

BCL-6	3
mRNA	4
levels	0
began	0
to	0
decrease	0
8	0
to	0
16	0
hours	0
after	0
stimulation	0
,	0
before	0
cells	0
entered	0
S	0
phase	0
.	0

Although	0
polyclonal	0
activation	0
of	0
B	7
cells	8
in	0
vitro	0
invariably	0
decreased	0
BCL-6	9
MRNA	0
expression	0
,	0
activated	7
B	8
cells	8
from	0
human	0
germinal	0
centers	0
expressed	0
BCL-6	0
mRNA	0
at	0
levels	0
comparable	0
to	0
the	0
levels	0
in	0
resting	0
B	0
cells	0
.	0

Despite	0
these	0
similar	0
mRNA	0
levels	0
,	0
BCL-6	9
protein	0
expression	0
was	0
threefold	0
to	0
34-fold	0
higher	0
in	0
germinal	7
center	8
B	8
cells	8
than	0
in	0
resting	7
B	8
cells	8
,	0
suggesting	0
that	0
BCL-6	9
protein	0
levels	0
are	0
controlled	0
by	0
translational	0
or	0
posttranslational	0
mechanisms	0
.	0

These	0
observations	0
suggest	0
that	0
the	0
germinal	0
center	0
reaction	0
provides	0
unique	0
activation	0
signals	0
to	0
B	7
cells	8
that	0
allow	0
for	0
continued	0
,	0
high-level	0
BCL-6	9
expression	0
.	0

DNA-binding	9
phosphoproteins	10
induced	0
after	0
T	0
cell	0
activation	0
:	0
effects	0
of	0
cyclosporin	0
A	0
.	0

To	0
define	0
novel	9
proteins	10
involved	0
in	0
the	0
early	0
transcriptional	0
response	0
during	0
the	0
activation	0
of	0
human	7
T	8
lymphocytes	8
,	0
we	0
used	0
a	0
high-resolution	0
,	0
two-dimensional	0
gel	0
electrophoresis	0
system	0
to	0
identify	0
nuclear	9
,	10
deoxyribonucleic	10
acid	10
(	10
DNA	10
)	10
binding	10
proteins	10
exhibiting	0
rapid	0
changes	0
in	0
phosphorylation	0
following	0
cell	0
stimulation	0
.	0

We	0
identified	0
18	0
nuclear	9
proteins	10
whose	0
phosphorylation	0
level	0
changed	0
more	0
than	0
5-fold	0
upon	0
activation	0
.	0

Of	0
these	0
,	0
11	0
were	0
found	0
to	0
possess	0
DNA-binding	0
properties	0
.	0

The	0
11	0
phosphoproteins	9
with	0
DNA-binding	0
activity	0
,	0
along	0
with	0
4	0
others	0
,	0
were	0
analyzed	0
further	0
.	0

Phosphoamino	0
acid	0
analysis	0
revealed	0
several	0
sets	0
of	0
proteins	0
with	0
different	0
phosphorylated	0
residues	0
Kinetic	0
analysis	0
of	0
the	0
phosphorylation	0
of	0
the	0
selected	0
proteins	0
was	0
performed	0
and	0
revealed	0
a	0
complex	0
group	0
of	0
transient	0
and	0
sustained	0
responses	0
to	0
cell	0
activation	0
.	0

Finally	0
,	0
the	0
activation-induced	0
changes	0
in	0
one	0
set	0
of	0
phosphoproteins	9
were	0
dramatically	0
inhibited	0
by	0
cyclosporin	0
A	0
.	0

We	0
suggest	0
that	0
these	0
phosphoproteins	9
may	0
be	0
directly	0
involved	0
in	0
regulating	0
the	0
transcriptional	0
response	0
to	0
cellular	0
activation	0
by	0
external	0
stimuli	0
.	0

Inactivation	0
of	0
IkappaBbeta	9
by	0
the	0
tax	9
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
:	0
a	0
potential	0
mechanism	0
for	0
constitutive	0
induction	0
of	0
NF-kappaB	9
.	0

In	0
resting	7
T	8
lymphocytes	8
,	0
the	0
transcription	9
factor	10
NF-kappaB	9
is	0
sequestered	0
in	0
the	0
cytoplasm	0
via	0
interactions	0
with	0
members	0
of	0
the	0
I	9
kappa	10
B	10
family	10
of	0
inhibitors	0
,	0
including	0
IkappaBalpha	9
and	0
IkappaBbeta	9
.	0

During	0
normal	0
T-cell	0
activation	0
,	0
IkappaBalpha	9
is	0
rapidly	0
phosphorylated	0
,	0
ubiquitinated	0
,	0
and	0
degraded	0
by	0
the	0
26S	9
proteasome	10
,	0
thus	0
permitting	0
the	0
release	0
of	0
functional	0
NF-kappaB	9
.	0

In	0
contrast	0
to	0
its	0
transient	0
pattern	0
of	0
nuclear	0
induction	0
during	0
an	0
immune	0
response	0
,	0
NF-kappaB	9
is	0
constitutively	0
activated	0
in	0
cells	0
expressing	0
the	0
Tax	9
transforming	10
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-1	0
)	0
.	0

Recent	0
studies	0
indicate	0
that	0
HTLV-1	0
Tax	9
targets	0
IkappaBalpha	9
to	0
the	0
ubiquitin-proteasome	0
pathway	0
.	0

However	0
,	0
it	0
remains	0
unclear	0
how	0
this	0
viral	9
protein	10
induces	0
a	0
persistent	0
rather	0
than	0
transient	0
NF-kappaB	9
response	0
.	0

In	0
this	0
report	0
,	0
we	0
provide	0
evidence	0
that	0
in	0
addition	0
to	0
acting	0
on	0
IkappaBalpha	9
,	0
Tax	9
stimulates	0
the	0
turnover	0
Of	0
IkappaBbeta	9
via	0
a	0
related	0
targeting	0
mechanism	0
.	0

Like	0
IkappaBalpha	9
,	0
Tax	9
-mediated	0
breakdown	0
of	0
IkappaBbeta	9
in	0
transfected	5
T	6
lymphocytes	6
is	0
blocked	0
either	0
by	0
cell-permeable	0
proteasome	0
inhibitors	0
or	0
by	0
mutation	0
Of	0
IkappaBbeta	9
at	0
two	0
serine	0
residues	0
present	0
within	0
its	0
N-terminal	9
region	10
.	0

Despite	0
the	0
dual	0
specificity	0
of	0
HTLV-1	0
Tax	9
for	0
IkappaBalpha	9
and	0
IkappaBbeta	9
at	0
the	0
protein	0
level	0
,	0
Tax	9
selectively	0
stimulates	0
NF-kappaB	9
-directed	0
transcription	0
of	0
the	0
IkappaBalpha	1
gene	2
.	0

Consequently	0
,	0
IkappaBbeta	9
protein	0
expression	0
is	0
chronically	0
downregulated	0
in	0
HTLV-1-infected	7
T	8
lymphocytes	8
.	0

These	0
findings	0
with	0
IkappaBbeta	9
provide	0
a	0
potential	0
mechanism	0
for	0
the	0
constitutive	0
activation	0
of	0
NF-kappaB	9
in	0
Tax-expressing	5
cells	6
.	0

The	0
role	0
of	0
p16	9
in	0
the	0
E2F-dependent	9
thymidine	10
kinase	10
regulation	0
.	0

The	0
role	0
of	0
alterations	0
of	0
the	0
MTS1	1
tumor	2
suppressor	2
gene	2
on	0
chromosome	1
9p21	2
,	0
which	0
encodes	0
p16	9
,	0
the	0
inhibitor	0
of	0
cyclin-dependent-kinase-4	9
and	10
6	10
,	0
in	0
tumorigenesis	0
is	0
not	0
yet	0
clear	0
.	0

Phosphorylation	0
of	0
the	0
retinoblastoma	9
protein	10
by	0
cyclin-dependent	9
kinases	10
4	10
and	10
6	10
prevents	0
its	0
interaction	0
with	0
the	0
transcription	9
factor	10
E2F	9
,	0
which	0
subsequently	0
promotes	0
the	0
expression	0
of	0
S	1
phase	2
regulated	2
genes	2
,	0
such	0
as	0
thymidine	9
kinase	10
.	0

Although	0
a	0
role	0
of	0
p16	9
in	0
this	0
regulation	0
has	0
been	0
presumed	0
,	0
there	0
is	0
no	0
proof	0
so	0
far	0
that	0
loss	0
of	0
this	0
tumor	1
suppressor	2
gene	2
really	0
affects	0
E2F	9
-mediated	0
regulations	0
.	0

We	0
investigated	0
the	0
regulation	0
of	0
thymidine	9
kinase	10
in	0
phytohemagglutinin-stimulated	5
normal	6
human	6
lymphocytes	6
and	0
in	0
the	0
p16-negative	5
human	6
acute	6
lymphoblastic	6
leukemia	6
cell	6
lines	6
,	0
MOLT-4	5
and	0
CEM	5
.	0

Compared	0
to	0
normal	7
lymphocytes	8
,	0
MOLT-4	5
and	6
CEM	6
cells	6
exhibited	0
an	0
altered	0
cell	0
cycle	0
regulation	0
of	0
thymidine	9
kinase	10
,	0
a	0
much	0
higher	0
intracellular	0
activity	0
of	0
this	0
enzyme	9
,	0
and	0
higher	0
thymidine	3
kinase	4
mRNA	4
expression	0
.	0

Transient	0
expression	0
of	0
p16	9
in	0
normal	0
human	0
lymphocytes	0
caused	0
arrest	0
in	0
G1	0
,	0
but	0
was	0
without	0
effect	0
on	0
the	0
cell	0
growth	0
of	0
MOLT-4	5
and	6
CEM	6
cells	6
,	0
although	0
all	0
of	0
them	0
express	0
functional	0
retinoblastoma	9
protein	10
.	0

Nevertheless	0
,	0
in	0
the	0
two	0
leukemia	5
cell	6
lines	6
transient	0
overexpression	0
of	0
p16	9
reestablished	0
the	0
normal	0
regulation	0
of	0
thymidine	9
kinase	10
,	0
paralleled	0
by	0
an	0
increase	0
of	0
the	0
underphosphorylated	0
form	0
of	0
retinoblastoma	9
protein	10
and	0
decrease	0
of	0
free	0
E2F	9
bound	0
to	0
its	0
motif	0
in	0
the	0
thymidine	1
kinase	2
promoter	2
.	0

We	0
demonstrate	0
that	0
loss	0
of	0
p16	9
causes	0
upregulation	0
of	0
this	0
DNA	0
precursor	0
pathway	0
enzyme	9
via	0
activation	0
of	0
E2F	9
by	0
a	0
mechanism	0
involving	0
retinoblastoma	9
protein	10
.	0

Interactions	0
of	0
a	0
transcriptional	1
activator	2
in	0
the	0
env	1
gene	2
of	0
the	0
mouse	0
mammary	0
tumor	0
virus	0
with	0
activation-dependent	9
,	10
T	10
cell-specific	10
transacting	10
factors	10
.	0

The	0
mouse	0
mammary	0
tumor	0
virus	0
env	1
gene	2
contains	0
a	0
transcriptional	1
activator	2
(	0
META	1
)	0
that	0
can	0
control	0
transcription	0
of	0
the	0
adjacent	0
long	1
terminal	2
repeat	2
region	2
.	0

Transcriptional	0
control	0
by	0
META	1
parallels	0
that	0
of	0
several	0
lymphokine	1
genes	2
,	0
being	0
specific	0
to	0
T	7
cells	8
,	0
dependent	0
on	0
their	0
activation	0
,	0
and	0
inhibited	0
by	0
the	0
immunosuppressive	0
drug	0
cyclosporine	0
(	0
CsA	0
)	0
.	0

DNase	9
I	10
footprinting	0
indicated	0
that	0
nuclear	9
factors	10
from	0
activated	7
T	8
lymphocytes	8
bound	0
a	0
promoter-proximal	1
site	2
,	0
META	1
(	2
P	2
)	2
,	0
and	0
a	0
promoter-distal	1
site	2
,	0
META	1
(	2
D+	2
)	2
,	0
within	0
the	0
400-base	1
pair	2
META	2
region	2
.	0

Nuclear	9
factors	10
from	0
unstimulated	0
,	0
but	0
not	0
from	0
activated	0
cells	0
,	0
bound	0
a	0
site	0
,	0
META	1
(	2
D-	2
)	2
,	0
adjacent	0
to	0
META	1
(	2
D+	2
)	2
.	0

META	1
(	2
D+	2
)	2
directed	0
transcription	0
of	0
a	0
linked	0
luciferase	1
gene	2
,	0
and	0
gel	0
shift	0
analysis	0
revealed	0
binding	0
of	0
inducible	0
,	0
CsA-sensitive	9
T	10
cell	10
factors	10
,	0
in	0
parallel	0
with	0
transfection	0
results	0
.	0

Authentic	0
NFAT	1
and	2
NF-kappaB	2
targets	2
did	0
not	0
compete	0
for	0
the	0
META	9
(	10
D+	10
)	10
binding	10
factor	10
(	0
s	0
)	0
.	0

The	0
SV40	1
core	2
sequence	2
competed	0
for	0
META	9
(	10
D+	10
)	10
binding	10
factors	10
,	0
but	0
META	1
(	2
D+	2
)	2
failed	0
to	0
compete	0
for	0
the	0
complexes	0
obtained	0
with	0
the	0
SV40	0
probe	0
.	0

Our	0
results	0
,	0
taken	0
together	0
,	0
indicate	0
that	0
META	1
(	2
D+	2
)	2
is	0
a	0
novel	0
transcriptional	1
enhancer	2
element	2
that	0
is	0
similar	0
in	0
its	0
cell-type	0
specificity	0
,	0
activation	0
dependence	0
,	0
and	0
CsA	0
sensitivity	0
to	0
the	0
NFAT	1
element	2
.	0

It	0
may	0
be	0
relevant	0
to	0
the	0
role	0
of	0
MMTV	0
in	0
expression	0
of	0
Mls	9
antigens	10
or	0
the	0
induction	0
of	0
T	0
cell	0
lymphomas	0
.	0

A	0
novel	0
interferon	9
regulatory	10
factor	10
family	10
transcription	10
factor	10
,	0
ICSAT/Pip/LSIRF	9
,	0
that	0
negatively	0
regulates	0
the	0
activity	0
of	0
interferon-regulated	1
genes	2
.	0

We	0
have	0
isolated	0
a	0
novel	1
cDNA	2
clone	2
encoding	0
interferon	9
(	10
IFN	10
)	10
consensus	10
sequence-binding	10
protein	10
in	0
adult	5
T-cell	6
leukemia	6
cell	6
line	6
or	0
activated	0
T	7
cells	8
(	0
ICSAT	9
)	0
;	0
this	0
protein	0
is	0
the	0
human	0
homolog	0
of	0
the	0
recently	0
cloned	0
Pip/LSIRF	9
.	0

ICSAT	9
is	0
structurally	0
most	0
closely	0
related	0
to	0
the	0
previously	0
cloned	0
ICSBP	9
,	0
a	0
member	0
of	0
the	0
IFN	9
regulatory	10
factor	10
(	10
IRF	10
)	10
family	10
of	0
proteins	0
that	0
binds	0
to	0
interferon	1
consensus	2
sequences	2
(	0
ICSs	1
)	0
found	0
in	0
many	0
promoters	0
of	0
the	0
IFN-regulated	1
genes	2
.	0

Among	0
T-cell	5
lines	6
investigated	0
,	0
ICSAT	9
was	0
abundantly	0
expressed	0
in	0
human	5
T-cell	6
leukemia	6
virus	6
type	6
1	6
(	6
HTLV-1	6
)	6
-infected	6
T	6
cells	6
.	0

When	0
the	0
HTLV-1	1
tax	2
gene	2
was	0
expressed	0
or	0
phorbol	0
myristake	0
acetate-A23187	0
stimulation	0
was	0
used	0
,	0
ICSAT	9
expression	0
was	0
induced	0
in	0
Jurkat	5
cells	6
which	0
otherwise	0
do	0
not	0
express	0
ICSAT	9
.	0

When	0
the	0
binding	0
of	0
ICSAT	9
to	0
four	0
different	0
ICSs	1
was	0
tested	0
,	0
the	0
relative	0
differences	0
in	0
binding	0
affinities	0
for	0
those	0
ICSs	1
were	0
determined	0
.	0

To	0
study	0
the	0
functional	0
role	0
of	0
ICSAT	9
,	0
we	0
performed	0
cotransfection	0
experiments	0
with	0
the	0
human	5
embryonal	6
carcinoma	6
cell	6
line	6
N-Tera2	6
.	0

ICSAT	9
was	0
demonstrated	0
to	0
possess	0
repressive	0
function	0
over	0
the	0
gene	0
activation	0
induced	0
by	0
IFN	9
stimulation	0
or	0
by	0
IRF-1	9
cotransfection	0
.	0

Such	0
repressive	0
function	0
is	0
similar	0
to	0
that	0
seen	0
in	0
IRF-2	9
or	0
ICSBP	9
.	0

However	0
,	0
we	0
have	0
found	0
that	0
ICSAT	9
has	0
a	0
different	0
repressive	0
effect	0
from	0
that	0
of	0
IRF-2	9
or	0
ICSBP	9
in	0
some	0
IFN-responsive	1
reporter	2
constructs	2
.	0

These	0
results	0
suggest	0
that	0
a	0
novel	0
mechanism	0
of	0
gene	0
regulation	0
by	0
``	0
differential	0
repression	0
''	0
is	0
used	0
by	0
multiple	0
members	0
of	0
repressor	9
proteins	10
with	0
different	0
repressive	0
effects	0
on	0
the	0
IFN-responsive	1
genes	2
.	0

Regulation	0
of	0
[	0
Ca2+	0
]	0
i	0
rise	0
activated	0
by	0
doxepin-sensitive	9
H1-histamine	10
receptors	10
in	0
Jurkat	5
cells	6
,	0
cloned	5
human	6
T	6
lymphocytes	6
.	0

To	0
clarify	0
the	0
presence	0
of	0
histamine	9
receptor	10
and	0
its	0
transmembrane	0
mechanism	0
in	0
human	7
T	8
lymphocytes	8
,	0
we	0
investigated	0
the	0
effects	0
of	0
agonists	0
or	0
antagonists	0
of	0
histamine	9
receptor	10
subtypes	0
and	0
bacterial	0
toxins	0
on	0
intracellular	0
concentration	0
of	0
Ca2+	0
[	0
Ca2+	0
]	0
i	0
)	0
,	0
[	0
3H	0
]	0
pyrilamine	0
binding	0
and	0
c-fos	3
mRNA	4
expression	0
in	0
Jurkat	5
cells	6
,	0
cloned	0
human	7
T	8
lymphocytes	8
.	0

H1-agonists	0
(	0
histamine	0
and	0
2-methylhistamine	0
)	0
caused	0
a	0
transient	0
rise	0
of	0
[	0
Ca2+	0
]	0
,	0
and	0
H1-antagonists	0
(	0
pyrilamine	0
and	0
doxepin	0
)	0
inhibited	0
the	0
histamine-induced	0
[	0
Ca2+	0
]	0
i	0
rise	0
more	0
potently	0
than	0
the	0
H2-antagonist	0
(	0
cimetidine	0
)	0
on	0
the	0
H3-antagonist	0
(	0
impromidine	0
)	0
.	0

Binding	0
parameters	0
of	0
[	0
3H	0
]	0
pyrilamine	0
binding	0
were	0
Kd	0
=	0
5.53	0
nM	0
and	0
Bmax	0
=	0
2	0
,	0
647	0
sites/cell	0
.	0

Pretreatment	0
with	0
B.pertussis	0
,	0
V.cholera.	0
or	0
C.botulinum	0
toxin	0
did	0
not	0
influence	0
histamine-induced	0
[	0
Ca2+	0
]	0
i	0
rise	0
.	0

Western	0
Blot	0
analysis	0
using	0
antibodies	0
against	0
subunits	0
of	0
GTP-binding	9
proteins	10
indicated	0
that	0
Gq/G11	9
richly	0
existed	0
in	0
Jurkat	5
cells	6
.	0

Histamine	0
induced	0
mRNA	3
expression	0
of	0
an	0
immediate	1
early	2
gene	2
c-fos	1
.	0

Pretreatment	0
with	0
a	0
protein	9
kinase	10
C	10
activator	0
,	0
phorbol	0
12-myristate	0
13-acetate	0
,	0
caused	0
almost	0
complete	0
inhibition	0
of	0
histamine-induced	0
[	0
Ca2+	0
]	0
i	0
rise	0
,	0
but	0
did	0
not	0
do	0
so	0
by	0
activators	0
of	0
cAMP-	9
and	10
cGMP-dependent	10
protein	10
kinases	10
.	0

STAT-related	0
transcription	9
factors	10
are	0
constitutively	0
activated	0
in	0
peripheral	7
blood	8
cells	8
from	0
acute	0
leukemia	0
patients	0
.	0

A	0
signal	0
transduction	0
pathway	0
activated	0
by	0
many	0
cytokines	9
has	0
recently	0
been	0
elaborated	0
.	0

The	0
JAK	9
kinases	10
and	0
the	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
factors	10
have	0
been	0
found	0
to	0
be	0
essential	0
components	0
.	0

In	0
this	0
report	0
,	0
we	0
describe	0
the	0
presence	0
of	0
constitutively	0
activated	0
STAT	9
factors	10
in	0
peripheral	7
blood	8
cells	8
from	0
patients	0
with	0
acute	0
leukemia	0
.	0

We	0
used	0
oligonucleotide	0
probes	0
from	0
the	0
beta-casein	1
and	2
IRF-1	2
gene	2
promoters	2
and	0
the	0
ISRE	0
probe	0
to	0
detect	0
STAT	9
proteins	10
in	0
nuclear	0
extracts	0
from	0
acute	7
leukemia	8
cells	8
in	0
bandshift	0
assays	0
.	0

Specific	0
DNA	0
protein	9
complex	10
formation	0
was	0
observed	0
with	0
the	0
probes	0
from	0
the	0
beta-casein	0
and	0
IRF-1	1
gene	2
promoters	2
,	0
but	0
not	0
with	0
the	0
ISRE	0
oligonucleotide	0
probe	0
,	0
when	0
cell	0
extracts	0
from	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
and	0
acute	0
myeloid	0
leukemia	0
(	0
AML	0
)	0
were	0
investigated	0
.	0

We	0
used	0
nonradioactive	0
oligonucleotides	0
as	0
competitors	0
to	0
show	0
the	0
specificity	0
of	0
the	0
complex	0
formation	0
.	0

Specific	0
antibodies	9
directed	0
against	0
the	0
individual	0
STAT	9
proteins	10
were	0
used	0
in	0
supershift	0
experiments	0
.	0

STAT5-	9
and	10
STAT1-related	10
factors	10
were	0
detected	0
in	0
ALL	0
and	0
STAT1-	9
,	10
STAT3-	10
,	10
and	10
STAT5-related	10
proteins	10
were	0
present	0
in	0
nuclear	0
cell	0
extracts	0
from	0
AML	0
.	0

Since	0
the	0
cells	0
were	0
not	0
treated	0
with	0
cytokines	9
before	0
the	0
nuclear	9
proteins	10
were	0
extracted	0
,	0
we	0
conclude	0
that	0
these	0
factors	0
are	0
constitutively	0
activated	0
in	0
vivo	0
.	0

It	0
is	0
likely	0
that	0
the	0
constitutive	0
activation	0
of	0
STAT	9
proteins	10
is	0
a	0
part	0
of	0
the	0
events	0
of	0
leukemogenesis	0
.	0

An	0
element	1
upstream	0
from	0
the	0
human	1
delta-globin-encoding	2
gene	2
specifically	0
enhances	0
beta-globin	1
reporter	2
gene	2
expression	0
in	0
murine	7
erythroleukemia	8
cells	8
.	0

We	0
have	0
previously	0
shown	0
that	0
a	0
DNA-binding	9
factor	10
specific	0
to	0
adult	7
hematopoietic	8
cells	8
(	0
polypryrimidine-binding	9
factor	10
,	0
PYBF	9
)	0
binds	0
to	0
a	0
pyrimidine-rich	1
region	2
1	1
kb	2
upstream	2
from	0
the	0
human	1
delta-globin-encoding	2
gene	2
(	0
HBD	1
)	0
.	0

The	0
developmental	0
stage-specificity	0
of	0
PYBF	9
and	0
the	0
location	0
of	0
its	0
binding	0
site	0
between	0
the	0
fetal	1
and	2
adult	2
beta-globin	2
(	2
HBB	2
)	2
-like	2
genes	2
suggest	0
that	0
PBYF	9
and	0
its	0
binding	0
site	0
may	0
function	0
in	0
fetal-to-adult	0
globin	1
gene	2
switching	0
.	0

Here	0
,	0
we	0
describe	0
the	0
effect	0
of	0
383-bp	1
(	2
delta383	2
)	2
and	2
99-bp	2
(	2
delta99	2
)	2
sequences	2
containing	0
the	0
PYBF-binding	1
site	2
on	0
transcription	0
from	0
various	0
globin	0
and	0
non-globin	0
promoters	0
,	0
using	0
a	0
transient	0
assay	0
with	0
the	0
cat	1
reporter	2
gene	2
in	0
murine	5
erythroleukemia	6
(	6
MEL	6
)	6
cells	6
,	0
a	0
cell	0
line	0
with	0
abundant	0
PYBF	9
activity	0
.	0

We	0
show	0
that	0
both	0
delta383	1
and	0
delta99	1
specifically	0
enhance	0
expression	0
of	0
cat	9
for	0
plasmids	1
containing	0
a	0
human	1
adult	2
globin	2
(	2
HBB	2
)	2
promoter	2
,	0
whereas	0
expression	0
of	0
similar	0
constructs	0
using	0
human	1
fetal	2
(	2
A	2
gamma-	2
)	2
globin	2
(	2
HBG1	2
)	2
or	2
simian	2
virus	2
40	2
(	2
SV40	2
)	2
promoters	2
is	0
not	0
enhanced	0
.	0

The	0
results	0
suggest	0
that	0
PYBF	9
and	0
the	0
pyrimidine-rich	1
region	2
upstream	0
from	0
HBD	1
can	0
specifically	0
enhance	0
HBB	1
transcription	0
in	0
adult	7
erythroid	8
cells	8
.	0

Translocation	1
breakpoints	2
in	0
three	0
patients	0
with	0
campomelic	0
dysplasia	0
and	0
autosomal	0
sex	0
reversal	0
map	0
more	0
than	0
130	0
kb	0
from	0
SOX9	1
.	0

Campomelic	0
dysplasia	0
(	0
CMPD1	0
)	0
and	0
autosomal	0
XY	0
sex	0
reversal	0
(	0
SRA1	0
)	0
are	0
caused	0
by	0
mutations	0
in	0
the	0
SRY-related	1
gene	2
SOX9	1
on	0
17q	1
.	0

Unexpectedly	0
,	0
the	0
17q	1
breakpoints	2
in	0
four	0
CMPD1	0
translocation	0
cases	0
previously	0
analyzed	0
by	0
us	0
and	0
others	0
map	0
50	0
kb	0
or	0
more	0
from	0
SOX9	1
.	0

Here	0
,	0
we	0
present	0
clinical	0
,	0
cytogenetic	0
,	0
and	0
molecular	0
data	0
from	0
a	0
new	0
CMPD1/SRA1	0
patient	0
with	0
t	1
(	2
6	2
;	2
17	2
)	2
(	2
q14	2
;	2
q24	2
)	2
.	0

Fluorescence	0
in	0
situ	0
hybridization	0
has	0
shown	0
that	0
the	0
17q	1
breakpoint	2
in	0
this	0
case	0
maps	0
to	0
the	0
same	0
region	0
as	0
the	0
breakpoints	0
in	0
the	0
other	0
translocation	0
cases	0
,	0
at	0
least	0
130	0
kb	0
from	0
SOX9	1
.	0

Likewise	0
,	0
the	0
breakpoints	0
in	0
two	0
of	0
the	0
previously	0
described	0
cases	0
also	0
map	0
more	0
than	0
130	0
kb	0
and	0
,	0
as	0
shown	0
by	0
pulsed	0
field	0
gel	0
electrophoresis	0
analysis	0
,	0
at	0
most	0
400	0
kb	0
or	0
690	0
kb	0
from	0
SOX9	1
.	0

By	0
using	0
a	0
SOX9	1
coding	2
sequence	2
polymorphism	2
,	0
expression	0
of	0
both	0
SOX9	1
alleles	0
has	0
been	0
demonstrated	0
by	0
the	0
reverse	9
transcriptase	10
polymerase	0
chain	0
reaction	0
in	0
lymphoblastoid	7
cells	8
from	0
one	0
of	0
the	0
translocation	0
cases	0
.	0

An	0
alternatively	0
spliced	0
isoform	0
of	0
the	0
Spi-B	9
transcription	9
factor	10
.	0

Spi-B	9
is	0
an	0
Ets	9
transcription	10
factor	10
related	0
to	0
the	0
oncoprotein	9
Spi-1/PU.1	9
and	0
highly	0
expressed	0
in	0
B	7
lymphoid	8
cells	8
.	0

The	0
Ets	9
proteins	10
share	0
a	0
conserved	0
Ets	9
domain	10
that	0
mediates	0
specific	0
DNA	0
binding	0
.	0

Spi-B	9
binds	0
DNA	1
sequences	2
containing	0
a	0
core	0
5'-GGAA-3	0
'	0
and	0
activates	0
transcription	0
through	0
this	0
motif	0
.	0

Up	0
to	0
date	0
,	0
the	0
biological	0
function	0
of	0
Spi-B	9
remains	0
unknown	0
.	0

Here	0
,	0
we	0
describe	0
the	0
characterization	0
of	0
an	0
alternatively	0
spliced	0
variant	0
of	0
Spi-B	9
,	0
named	0
deltaSpi-B	9
,	0
which	0
has	0
lost	0
the	0
Ets	9
domain	10
.	0

In	0
B	7
lymphoid	8
cells	8
,	0
deltaspi-B	3
and	4
spi-B	4
mRNAs	4
were	0
present	0
simultaneously	0
in	0
a	0
ratio	0
of	0
around	0
10	0
%	0
.	0

DeltaSpi-B	9
product	0
was	0
not	0
able	0
to	0
bind	0
DNA	0
and	0
was	0
recovered	0
in	0
cytoplasmic	0
cellular	0
extracts	0
.	0

We	0
raise	0
the	0
hypothesis	0
that	0
delta	9
Spi-B	10
might	0
affect	0
Spi-B	9
function	0
by	0
recruiting	0
factors	0
involved	0
in	0
Spi-B	9
activity	0
.	0

Binding	0
and	0
cooperative	0
interactions	0
between	0
two	0
B	9
cell-specific	10
transcriptional	10
coactivators	10
.	0

The	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
and	0
B	9
cell	10
octamer-binding	10
protein	10
1/octamer-binding	10
factor	10
1/Oct	10
coactivator	10
from	0
B	7
cells	8
(	0
Bob1/OBF-1/OCA-B	9
)	0
represent	0
two	0
B	9
cell-specific	10
transcriptional	10
coactivators	10
.	0

CIITA	9
and	0
Bob1	9
interact	0
with	0
proteins	0
that	0
bind	0
to	0
conserved	1
upstream	2
sequences	2
in	0
promoters	1
of	0
class	1
II	2
major	2
histocompatibility	2
genes	2
and	0
octamer-binding	9
transcription	10
factors	10
Oct-1	9
and	0
Oct-2	9
,	0
respectively	0
.	0

Both	0
CIITA	9
and	0
Bob1	9
increase	0
the	0
expression	0
from	0
the	0
DRA	1
promoter	2
,	0
which	0
is	0
a	0
prototypic	0
class	1
II	2
promoter	2
.	0

Moreover	0
,	0
in	0
the	0
presence	0
of	0
CIITA	9
,	0
interactions	0
between	0
class	1
II	2
promoters	2
and	0
Bob1	9
are	0
independent	0
of	0
the	0
octamer-binding	3
site	4
.	0

Using	0
in	0
vivo	0
and	0
in	0
vitro	0
binding	0
assays	0
,	0
we	0
confirm	0
that	0
Bob1	9
binds	0
to	0
CIITA	9
.	0

Thus	0
,	0
CIITA	9
not	0
only	0
activates	0
the	0
expression	0
of	0
class	1
II	2
genes	2
but	0
recruits	0
another	0
B	0
cell-specific	0
coactivator	0
to	0
increase	0
transcriptional	0
activity	0
of	0
class	1
II	2
promoters	2
in	0
B	7
cells	8
.	0

Efficient	0
transcription	0
and	0
replication	0
of	0
simian	0
immunodeficiency	0
virus	0
in	0
the	0
absence	0
of	0
NF-kappaB	1
and	2
Sp1	2
binding	2
elements	2
.	0

Ten	0
mutants	0
of	0
the	0
simian	0
immunodeficiency	0
virus	0
(	0
SIV	0
)	0
SIVmac239	0
bearing	0
deletions	0
(	0
delta	0
)	0
or	0
substitutions	0
(	0
subst	0
)	0
in	0
the	0
NF-kappaB	1
and/or	0
Sp1	1
binding	2
elements	2
were	0
created	0
,	0
and	0
the	0
replicative	0
capacities	0
of	0
the	0
mutants	0
were	0
analyzed	0
.	0

All	0
mutants	0
,	0
including	0
one	0
extensively	0
mutagenized	0
strain	0
entirely	0
missing	0
the	0
NF-kappaB	1
and	2
four	2
Spl	2
binding	2
elements	2
,	0
replicated	0
with	0
wild-type	0
kinetics	0
and	0
to	0
a	0
wild-type	0
level	0
in	0
peripheral	5
blood	6
mononuclear	6
cell	6
cultures	6
in	0
50	0
to	0
100	0
%	0
of	0
the	0
experiments	0
.	0

One	0
group	0
of	0
mutants	0
replicated	0
very	0
similarly	0
to	0
SIVmac239	0
in	0
kinetics	0
and	0
yield	0
in	0
CEMxl74	5
cells	6
(	0
2x	0
NFKappaB	9
>	0
or	0
=	0
SlVmac239	9
approximately	0
deltaNFkappaB	9
approximately	0
deltaSpl234	9
approximately	0
substNFkappaB	9
approximately	0
substSpl2	9
approximately	0
substSp23	9
)	0
,	0
while	0
a	0
second	0
group	0
replicated	0
with	0
delayed	0
or	0
slightly	0
delayed	0
kinetics	0
in	0
CEMxl74	5
cells	6
(	0
SIVmac239	0
>	0
substSp34	9
>	0
deltaNFkappaBdeltaSpl234	9
approximately	0
deltaNFkappaBdeltaSp1	9
>	0
substSpl234	9
)	0
.	0

Reversions	0
or	0
additional	0
mutations	0
were	0
not	0
detected	0
in	0
the	0
U3	1
and	2
R	2
regions	2
of	0
proviral	1
DNA	2
from	0
CEMxl74	5
cells	6
infected	0
with	0
the	0
SIVmac239	0
mutants	0
.	0

Similar	0
results	0
were	0
obtained	0
when	0
mutants	0
of	0
SIVmacMER	0
(	0
a	0
macrophage-competent	0
derivative	0
of	0
SIVmac239	0
)	0
were	0
tested	0
in	0
peripheral	7
blood	8
mononuclear	8
cell	8
and	0
CEMx174	5
cultures	6
.	0

However	0
,	0
the	0
growth	0
of	0
most	0
mutated	0
viruses	0
was	0
suppressed	0
in	0
primary	7
rhesus	8
monkey	8
alveolar	8
macrophages	8
(	0
SIVmacMER	0
approximately	0
2xNFkappaB	9
approximately	0
substNFkappaB	9
>	0
deltaNFkappaB	9
>	0
deltaNFkappaB	9
deltaSpl234	9
approximately	0
deltaNFkappaBdeltaSpl	9
>	0
deltaSpl234	9
approximately	0
substSpl2	9
>	0
substSp23	9
approximately	0
substSp34	9
approximately	0
substSpl234	9
>	0
or	0
=	0
SIVmac239	0
)	0
.	0

Thus	0
,	0
changes	0
in	0
the	0
Sp1	1
binding	2
sites	2
had	0
the	0
most	0
dramatic	0
effects	0
on	0
SIVmac	0
replication	0
in	0
primary	5
macrophage	6
cultures	6
.	0

Analysis	0
of	0
long	1
terminal	2
repeat	2
-driven	0
secreted	0
alkaline	9
phosphatase	10
activity	0
in	0
transient	0
assays	0
showed	0
that	0
,	0
unlike	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
,	0
the	0
SIV	1
long	2
terminal	2
repeat	2
possesses	0
an	0
enhancer	1
region	2
just	0
upstream	0
of	0
the	0
NF-kappaB	1
element	2
which	0
maintains	0
significant	0
levels	0
of	0
basal	0
transcription	0
in	0
the	0
absence	0
of	0
NF-kappaB	1
and	2
Sp1	2
sites	2
.	0

This	0
region	0
is	0
responsive	0
to	0
transactivation	0
by	0
Tat	9
.	0

In	0
addition	0
,	0
the	0
SIV	1
TATA	2
box	2
was	0
shown	0
to	0
be	0
stronger	0
than	0
that	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
.	0

Therefore	0
,	0
the	0
surprisingly	0
high	0
replicative	0
capacity	0
of	0
NF-kappaB	0
and	0
Sp1	0
binding	0
site	0
mutants	0
of	0
SIVmac	0
is	0
due	0
to	0
unique	0
features	0
or	0
the	0
enhancer/promoter	1
region	2
.	0

cAMP	0
inducibility	0
of	0
transcriptional	9
repressor	10
ICER	9
in	0
developing	0
and	0
mature	7
human	8
T	8
lymphocytes	8
[	0
published	0
erratum	0
appears	0
in	0
Proc	0
Natl	0
Acad	0
Sci	0
U	0
S	0
A	0
1996	0
Jul	0
23	0
;	0
93	0
(	0
15	0
)	0
:	0
8154	0
]	0

Stimulation	0
of	0
the	0
cAMP-dependent	0
signaling	0
pathway	0
exerts	0
an	0
inhibitory	0
effect	0
on	0
the	0
proliferation	0
and	0
effector	0
functions	0
of	0
T	7
cells	8
.	0

The	0
ability	0
of	0
T	7
cells	8
to	0
form	0
high	0
intracellular	0
levels	0
of	0
cAMP	0
is	0
acquired	0
during	0
development	0
in	0
the	0
human	0
thymus	0
and	0
is	0
retained	0
by	0
the	0
majority	0
of	0
mature	0
peripheral	7
T	8
lymphocytes	8
.	0

Here	0
we	0
show	0
that	0
elevated	0
cAMP	0
levels	0
in	0
T	7
cells	8
correlate	0
with	0
the	0
expression	0
of	0
the	0
potent	9
transcriptional	10
repressor	10
ICER	9
(	0
inducible	9
cAMP	10
early	10
repressor	10
)	0
previously	0
described	0
in	0
the	0
hypothalamic-pituitary-gonadal	0
axis	0
.	0

Further	0
,	0
in	0
transcriptional	0
assays	0
in	0
vivo	0
,	0
ICER	9
inhibits	0
calcineurin	9
-mediated	0
expression	0
of	0
the	0
interleukin	1
2	2
promoter	2
as	0
well	0
as	0
Tax	9
-mediated	0
transactivation	0
of	0
the	0
human	1
T-lymphotropic	2
virus	2
type	2
I	2
(	2
HTLV-I	2
)	2
promoter	2
.	0

Thus	0
,	0
the	0
induction	0
of	0
ICER	9
in	0
T	7
cells	8
may	0
play	0
an	0
important	0
role	0
in	0
the	0
cAMP-induced	0
quiescence	0
and	0
the	0
persistent	0
latency	0
of	0
HTLV-I	0
.	0

A	0
hydrophobic	0
domain	0
of	0
Ca2+-modulating	9
cyclophilin	10
ligand	10
modulates	0
calcium	0
influx	0
signaling	0
in	0
T	0
lymphocytes	0
.	0

Ca2+-modulating	9
cyclophilin	10
ligand	10
(	0
CAML	9
)	0
was	0
originally	0
described	0
as	0
a	0
cyclophilin	9
B-binding	10
protein	10
whose	0
overexpression	0
in	0
T	7
cells	8
causes	0
a	0
rise	0
in	0
intracellular	0
calcium	0
,	0
thus	0
activating	0
transcription	9
factors	10
responsible	0
for	0
the	0
early	0
immune	0
response	0
.	0

As	0
reported	0
here	0
,	0
structure-function	0
analysis	0
of	0
the	0
CAML	1
gene	2
in	0
Jurkat	5
T	6
cells	6
indicates	0
that	0
two	0
of	0
CAML	9
's	0
putative	9
membrane-spanning	10
domains	10
are	0
necessary	0
and	0
sufficient	0
for	0
the	0
modulation	0
of	0
intracellular	0
calcium	0
.	0

We	0
propose	0
that	0
the	0
hydrophobic	9
C-terminal	10
tail	10
of	0
CAML	9
forms	0
its	0
effector	0
domain	0
,	0
thus	0
implicating	0
the	0
N-terminal	9
hydrophilic	10
domain	10
in	0
a	0
regulatory	0
role	0
.	0

These	0
findings	0
define	0
a	0
novel	9
protein	10
motif	10
that	0
functions	0
in	0
intracellular	0
calcium	0
signaling	0
.	0

The	0
Epstein-Barr	9
virus-encoded	10
nuclear	10
antigen	10
EBNA-5	10
accumulates	0
in	0
PML-containing	0
bodies	0
.	0

EBNA-5	9
is	0
one	0
of	0
the	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
-encoded	10
nuclear	10
proteins	10
required	0
for	0
immortalization	0
of	0
human	7
B	8
lymphocytes	8
.	0

In	0
the	0
nuclei	0
of	0
EBV-transformed	5
lymphoblastoid	6
cell	6
lines	6
EBNA-5	9
is	0
preferentially	0
targetted	0
to	0
distinct	0
nuclear	0
foci	0
.	0

Previously	0
we	0
have	0
shown	0
(	0
W.Q.	0
Jiang	0
,	0
L.Szekely	0
,	0
V.Wendel-Hansen	0
,	0
N.Ringertz	0
,	0
G.Klein	0
,	0
and	0
A.	0
Rosen	0
,	0
Exp.Cell	0
Res	0
.	0

A	0
new	0
variant	0
translocation	0
in	0
acute	0
promyelocytic	0
leukaemia	0
:	0
molecular	0
characterization	0
and	0
clinical	0
correlation	0
.	0

Translocation	1
t	2
(	2
15	2
;	2
17	2
)	2
(	2
q22	2
;	2
q21	2
)	0
is	0
an	0
acquired	0
clonal	0
cytogenetic	0
change	0
present	0
in	0
almost	0
all	0
cases	0
of	0
acute	0
promelocytic	0
leukemia	0
(	0
APL	0
)	0
.	0

The	0
molecular	0
genetic	0
basis	0
of	0
the	0
translocation	0
supports	0
its	0
integral	0
role	0
in	0
pathogenesis	0
.	0

We	0
describe	0
a	0
patient	0
with	0
APL	0
in	0
whom	0
the	0
leukaemic	0
clone	0
was	0
characterized	0
by	0
a	0
true	0
variant	0
of	0
the	0
classical	1
t	2
(	2
15	2
;	2
17	2
)	2
.	0

The	0
patient	0
whose	0
disease	0
had	0
numerous	0
atypical	0
clinical	0
features	0
,	0
had	0
t	1
(	2
11	2
;	2
17	2
)	2
(	2
q13	2
;	2
121	2
)	2
.	0

The	0
chromosome	1
17	2
breakpoint	2
was	0
localized	0
to	0
intron	1
2	2
of	0
RARA	1
by	0
Southern	0
blotting	0
,	0
and	0
there	0
was	0
no	0
evidence	0
at	0
the	0
molecular	0
level	0
for	0
rearrangement	0
at	0
PML	1
locus	2
.	0

These	0
data	0
,	0
along	0
with	0
previous	0
reports	0
of	0
rare	0
variant	0
translocations	0
in	0
APL	0
,	0
indicate	0
that	0
while	0
dysregulation	0
of	0
RARA	1
by	0
gene	0
fusion	0
may	0
be	0
essential	0
for	0
the	0
APL	0
phenotype	0
,	0
the	0
particular	0
fusion	0
partner	0
may	0
determine	0
clinicopathological	0
aspects	0
,	0
including	0
presentation	0
,	0
response	0
to	0
treatment	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
,	0
and	0
prognosis	0
.	0

This	0
heterogeneity	0
suggests	0
that	0
the	0
variant	0
fusion	9
partners	10
of	0
RARA	1
in	0
APL	0
encode	0
factors	9
with	0
properties	0
both	0
common	0
to	0
and	0
distinct	0
from	0
those	0
of	0
PML	7
.	0

Investigation	0
of	0
these	0
factors	0
promises	0
to	0
shed	0
light	0
on	0
the	0
complex	0
development	0
pathways	0
involved	0
in	0
the	0
regulation	0
of	0
haematopoiesis	0
.	0

A	0
model	0
of	0
latent	0
adenovirus	0
5	0
infection	0
in	0
the	0
guinea	0
pig	0
(	0
Cavia	0
porcellus	0
)	0
.	0

A	0
model	0
of	0
adenovirus	0
5	0
(	0
Ad5	0
)	0
infection	0
was	0
developed	0
in	0
guinea	0
pigs	0
to	0
begin	0
to	0
study	0
its	0
role	0
in	0
the	0
pathogenesis	0
of	0
peripheral	0
lung	0
inflammation	0
.	0

Forty	0
animals	0
were	0
inoculated	0
intranasally	0
with	0
10	0
(	0
7.0	0
)	0
pfu	0
of	0
Ad5/animal	0
,	0
and	0
15	0
animals	0
inoculated	0
with	0
sterile	0
culture	0
media	0
served	0
as	0
controls	0
.	0

Viral	0
titres	0
were	0
10	0
(	0
4.4	0
)	0
,	0
10	0
(	0
6.1	0
)	0
,	0
10	0
(	0
5.2	0
)	0
,	0
and	0
10	0
(	0
2.9	0
)	0
pfu/animal	0
,	0
on	0
days	0
1	0
,	0
3	0
,	0
4	0
,	0
and	0
7	0
after	0
infection	0
,	0
respectively	0
.	0

In	0
situ	0
hybridization	0
to	0
viral	1
DNA	2
and	0
immunocytochemistry	0
for	0
Ad5	0
E1A	9
protein	10
localized	0
the	0
virus	0
to	0
airway	0
and	0
alveolar	7
epithelial	8
cells	8
.	0

Histologic	0
examination	0
showed	0
an	0
extensive	0
inflammatory	0
cell	0
infiltration	0
around	0
the	0
airways	0
,	0
with	0
epithelial	0
necrosis	0
and	0
an	0
alveolar	0
exudate	0
that	0
caused	0
localized	0
alveolar	0
collapse	0
in	0
the	0
infected	0
areas	0
.	0

Immunocytochemistry	0
identified	0
the	0
cells	0
in	0
the	0
infiltrate	0
as	0
cytotoxic	7
T	8
cells	8
.	0

Although	0
all	0
animals	0
20	0
and	0
47	0
days	0
after	0
infection	0
had	0
seroconverted	0
to	0
Ad5	0
,	0
virus	0
was	0
not	0
detected	0
in	0
these	0
groups	0
either	0
by	0
viral	0
plaque	0
assay	0
or	0
in	0
situ	0
hybridization	0
.	0

Ad5	1
E1A	2
DNA	2
was	0
detected	0
by	0
polymerase	0
chain	0
reaction	0
in	0
five	0
of	0
six	0
animals	0
20	0
days	0
after	0
infection	0
and	0
in	0
five	0
of	0
five	0
animals	0
47	0
days	0
after	0
infection	0
.	0

In	0
these	0
same	0
animals	0
,	0
E1A	9
protein	10
was	0
detected	0
20	0
days	0
after	0
infection	0
in	0
two	0
and	0
47	0
days	0
after	0
infection	0
in	0
one	0
while	0
persistent	0
bronchiolitis	0
was	0
observed	0
in	0
four	0
and	0
three	0
animals	0
20	0
and	0
47	0
days	0
after	0
infection	0
,	0
respectively	0
.	0

These	0
results	0
demonstrate	0
that	0
the	0
guinea	0
pig	0
provides	0
a	0
useful	0
model	0
to	0
study	0
the	0
role	0
of	0
Ad5	0
infection	0
in	0
chronic	0
airway	0
inflammation	0
.	0

Cyclic	0
AMP	0
-responsive	1
element	2
-dependent	0
activation	0
of	0
Epstein-Barr	0
virus	0
zebra	1
promoter	2
by	0
human	0
herpesvirus	0
6	0
.	0

We	0
have	0
recently	0
shown	0
that	0
infection	0
of	0
Epstein-Barr	5
virus	6
(	6
EBV	6
)	6
genome-positive	6
B	6
cells	6
by	0
human	0
herpesvirus	0
6	0
(	0
HHV-6	0
)	0
results	0
in	0
the	0
expression	0
of	0
the	0
immediate-early	1
EBV	2
Zebra	2
gene	2
,	0
followed	0
by	0
virus	0
replication	0
(	0
L.Flamand	0
,	0
I.Stefanescu	0
,	0
D.V.Ablashi	0
,	0
and	0
J.Menezes	0
,	0
J.Virol.67	0
:	0
6768-6777	0
,	0
1993	0
)	0
.	0

Here	0
we	0
show	0
that	0
HHV-6	0
upregulates	0
Zebra	1
gene	2
transcription	0
through	0
a	0
cyclic	1
AMP-responsive	2
element	2
(	0
CRE	1
)	0
located	0
within	0
the	0
Zebra	1
promoter	2
(	0
Zp	1
)	0
.	0

Using	0
human	5
B-	6
or	6
T-cell	6
lines	6
transfected	0
with	0
ZpCat	1
reporter	2
gene	2
constructs	2
,	0
we	0
demonstrate	0
that	0
a	0
region	0
designated	0
the	0
ZII	1
domain	2
of	0
Zp	1
is	0
the	0
target	0
of	0
HHV-6	0
transactivation	0
.	0

Mutation	0
of	0
the	0
consensus	1
AP-1/CRE	2
site	2
within	0
ZII	1
abolished	0
the	0
inducibility	0
of	0
Zp	1
by	0
HHV-6	0
,	0
whereas	0
positioning	0
of	0
the	0
ZII	1
domain	2
upstream	0
of	0
the	0
beta-globin	1
minimal	2
promoter	2
conferred	0
responsiveness	0
following	0
HHV-6	0
infection	0
.	0

Binding	0
of	0
these	0
factors	0
to	0
ZII	1
was	0
prevented	0
by	0
oligonucleotides	0
containing	0
CRE	1
but	0
not	0
by	0
AP-1	1
consensus	2
sequences	2
.	0

Antibodies	0
against	0
CRE-binding	9
(	10
CREB	10
)	10
protein	10
but	0
not	0
against	0
c-Fos	9
or	0
c-Jun	9
were	0
able	0
to	0
supershift	0
the	0
DNA-protein	9
complex	10
,	0
identifying	0
the	0
nature	0
of	0
the	0
transcription	9
factor	10
which	0
binds	0
to	0
ZII	1
as	0
a	0
member	0
of	0
the	0
CREB	9
family	10
of	10
proteins	10
.	0

Finally	0
,	0
transfection	0
of	0
CREB	9
protein	10
and	0
protein	1
kinase	2
A	2
expression	2
vectors	2
were	0
found	0
to	0
activate	0
Zp	1
in	0
Jurkat	7
cells	8
,	0
suggesting	0
that	0
phosphorylated	0
form	0
of	0
CREB	9
protein	10
can	0
play	0
a	0
determining	0
role	0
in	0
the	0
EBV	0
reactivation	0
process	0
.	0

Regulation	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
in	0
stably	0
transfected	0
Jurkat	5
cell	6
clones	6
.	0

Two	0
Jurkat	5
cell	6
clones	6
have	0
been	0
stably	0
transfected	0
with	0
a	0
reporter	1
vector	2
for	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
.	0

Upon	0
stimulation	0
,	0
they	0
express	0
high	0
levels	0
of	0
secreted	0
heat	0
stable	0
placental	9
alkaline	10
phosphatase	10
.	0

With	0
these	0
clones	0
,	0
we	0
demonstrated	0
that	0
NFAT	9
activation	0
induced	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
ionomycin	0
was	0
inhibited	0
by	0
both	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
(	0
IC50	0
=	0
8	0
nM	0
)	0
and	0
FK506	0
(	0
IC50	0
=	0
160	0
pM	0
)	0
,	0
presumably	0
by	0
inhibition	0
of	0
calcineurin	9
activity	0
.	0

Selective	0
phosphatase	0
inhibitors	0
for	0
protein	9
phosphatase	10
1	10
(	0
PP1	9
)	0
and	0
2A	9
(	0
PP2A	9
)	0
that	0
do	0
not	0
inhibit	0
calcineurin	9
,	0
such	0
as	0
okadaic	0
acid	0
and	0
calyculin	0
A	0
,	0
also	0
inhibited	0
NFAT	9
activation	0
with	0
IC50s	0
of	0
87	0
nM	0
and	0
4	0
nM	0
,	0
respectively	0
,	0
suggesting	0
that	0
okadaic	0
acid	0
and	0
related	0
inhibitors	0
may	0
block	0
NFAT	9
activation	0
through	0
the	0
inhibition	0
of	0
PP1	9
,	0
instead	0
of	0
PP2A	9
.	0

NFAT	9
activation	0
was	0
also	0
inhibited	0
by	0
agents	0
that	0
increase	0
cAMP	0
concentrations	0
such	0
as	0
dibutyryl	0
cAMP	0
,	0
forskolin	0
and	0
prostaglandin	0
E2	0
.	0

These	0
stable	0
Jurkat	5
cell	6
clones	6
provide	0
a	0
convenient	0
and	0
sensitive	0
tool	0
to	0
study	0
NFAT	9
regulation	0
.	0

Glucocorticoids	0
induced	0
down-regulation	0
of	0
glucocorticoid	9
receptor	10
mRNA	0
expression	0
in	0
asthma	0
.	0

Although	0
their	0
precise	0
mechanism	0
of	0
action	0
remains	0
to	0
be	0
elucidated	0
,	0
glucocorticoids	0
represent	0
the	0
most	0
effective	0
therapy	0
in	0
the	0
treatment	0
of	0
asthma	0
.	0

Interactions	0
between	0
the	0
glucocorticoid	9
receptor	10
and	0
the	0
AP-1	9
complex	10
have	0
been	0
shown	0
to	0
regulate	0
the	0
transcription	0
of	0
some	0
genes	0
,	0
including	0
glucocorticoid	9
receptor	10
itself	0
.	0

The	0
aim	0
of	0
the	0
present	0
study	0
was	0
to	0
compare	0
the	0
expression	0
of	0
mRNA	3
for	0
glucocorticoid	9
receptor	10
in	0
human	7
blood	8
monocytes	8
obtained	0
from	0
seven	0
unstable	0
untreated	0
asthmatic	0
patients	0
who	0
were	0
subsequently	0
treated	0
with	0
high	0
doses	0
of	0
parenteral	0
corticosteroid	0
(	0
methyl	0
prednisolone	0
120	0
mg/day	0
)	0
for	0
10	0
days	0
.	0

mRNA	3
expression	0
was	0
identified	0
after	0
RNA	0
extraction	0
using	0
RNAzol	0
and	0
analysed	0
after	0
reverse	9
transcriptase	10
,	0
by	0
polymerase	0
chain	0
reaction	0
using	0
a	0
semiquantitative	0
competitive	0
hybridization	0
assay	0
.	0

All	0
asthmatic	0
patients	0
showed	0
an	0
improvement	0
in	0
their	0
FEV1	0
values	0
after	0
corticosteroid	0
treatment	0
(	0
per	0
cent	0
of	0
predicted	0
value	0
68.28	0
+/-	0
4.93	0
versus	0
95.57	0
+/-	0
6.41	0
,	0
P	0
<	0
0.02	0
)	0
,	0
and	0
a	0
significant	0
decrease	0
for	0
glucocorticoid	9
receptor	10
mRNA	3
expression	0
(	0
P	0
<	0
0.02	0
)	0
was	0
observed	0
in	0
their	0
monocytes	0
.	0

This	0
is	0
the	0
first	0
report	0
of	0
an	0
ex	0
vivo	0
down-regulation	0
for	0
the	0
glucocorticoid	9
receptor	10
mRNA	3
expression	0
,	0
following	0
corticosteroid	0
treatment	0
.	0

Mapping	0
of	0
the	0
transcriptional	9
repression	10
domain	10
of	0
the	0
lymphoid-specific	9
transcription	10
factor	10
oct-2A	9
.	0

The	0
lymphoid-specific	9
transcription	10
factor	10
Oct-2a	9
is	0
implicated	0
in	0
B	0
cell-specific	0
transcriptional	0
activity	0
via	0
the	0
octamer	0
motif	0
.	0

Structure/function	0
analysis	0
of	0
various	0
Oct-2a	9
effector	10
regions	10
in	0
the	0
context	0
of	0
the	0
GAL4	9
DNA-binding	10
domain	10
revealed	0
that	0
Oct-2a	9
contains	0
two	0
functionally	0
different	0
activation	9
domains	10
at	0
the	0
N	9
and	10
the	10
C	10
termini	10
.	0

The	0
transcriptional	0
activity	0
of	0
both	0
domains	0
is	0
strongly	0
potentiated	0
by	0
interactions	0
with	0
distinct	0
B	9
cell-specific	10
coactivators	10
.	0

Recently	0
,	0
we	0
have	0
identified	0
a	0
repression	9
domain	10
located	0
within	0
the	0
N	9
terminus	10
of	0
Oct-2a	9
(	0
amino	9
acids	10
2-99	10
)	0
.	0

When	0
this	0
domain	0
was	0
transferred	0
to	0
a	0
potent	0
activator	0
,	0
transcription	0
was	0
strongly	0
inhibited	0
.	0

In	0
this	0
study	0
we	0
present	0
a	0
deletion	0
analysis	0
of	0
the	0
N-terminal	9
region	10
of	0
Oct-2a	9
to	0
determine	0
the	0
minimal	9
repression	10
domain	10
.	0

We	0
identified	0
a	0
stretch	0
of	0
23	0
amino	0
acids	0
,	0
rich	0
in	0
serine	0
and	0
threonine	0
residues	0
,	0
which	0
was	0
responsible	0
for	0
most	0
of	0
the	0
repression	0
activity	0
.	0

We	0
show	0
that	0
repression	0
is	0
strongly	0
dependent	0
on	0
the	0
type	0
of	0
enhancer	1
present	0
in	0
the	0
reporter	1
plasmid	2
as	0
well	0
as	0
on	0
the	0
cell	5
line	6
tested	0
.	0

The	0
possibility	0
that	0
Oct-2a	9
can	0
act	0
as	0
an	0
activator	0
and/or	0
a	0
repressor	0
may	0
have	0
important	0
consequences	0
for	0
the	0
function	0
of	0
Oct-2a	9
in	0
B	0
cell	0
differentiation	0
and	0
other	0
developmental	0
processes	0
.	0

Opposing	0
effects	0
of	0
glucocorticoids	0
on	0
the	0
rate	0
of	0
apoptosis	0
in	0
neutrophilic	7
and	8
eosinophilic	8
granulocytes	8
.	0

Eosinophils	7
and	0
neutrophils	7
are	0
closely	0
related	0
,	0
terminally	7
differentiated	8
cells	8
that	0
in	0
vitro	0
undergo	0
constitutive	0
cell	0
death	0
by	0
apoptosis	0
.	0

The	0
onset	0
of	0
apoptosis	0
in	0
both	0
cell	0
types	0
can	0
be	0
delayed	0
by	0
hemopoietins	9
and	0
inflammatory	9
mediators	10
.	0

Although	0
there	0
have	0
been	0
a	0
number	0
of	0
reports	0
demonstrating	0
that	0
glucocorticoids	0
(	0
in	0
particular	0
dexamethasone	0
)	0
antagonize	0
the	0
eosinophil	0
life-prolonging	0
effects	0
of	0
hemopoietins	9
,	0
direct	0
effects	0
of	0
dexamethasone	0
on	0
eosinophil	0
apoptosis	0
have	0
not	0
been	0
documented	0
.	0

In	0
this	0
study	0
we	0
examined	0
the	0
direct	0
effects	0
of	0
glucocorticoids	0
on	0
eosinophil	7
and	0
neutrophil	7
apoptosis	0
in	0
light	0
of	0
their	0
common	0
therapeutic	0
use	0
as	0
anti-inflammatory	0
and	0
anti-allergic/hypereosinophilic	0
agents	0
.	0

We	0
found	0
that	0
treatment	0
with	0
dexamethasone	0
induced	0
eosinophil	7
apoptosis	0
.	0

In	0
contrast	0
,	0
dexamethasone	0
was	0
a	0
potent	0
inhibitor	0
of	0
neutrophil	7
apoptosis	0
.	0

The	0
effect	0
of	0
dexamethasone	0
on	0
both	0
cell	0
types	0
was	0
mediated	0
through	0
the	0
glucocorticoid	9
receptor	10
,	0
i.e.	0
,	0
it	0
was	0
abolished	0
by	0
the	0
glucocorticoid	9
receptor	10
antagonist	0
RU38486	0
.	0

This	0
is	0
the	0
first	0
description	0
of	0
an	0
agent	0
that	0
promotes	0
eosinophil	7
apoptosis	0
while	0
inhibiting	0
neutrophil	7
apoptosis	0
,	0
and	0
thus	0
presents	0
a	0
novel	0
approach	0
to	0
the	0
study	0
of	0
control	0
of	0
apoptosis	0
in	0
these	0
closely	0
related	0
cell	0
types	0
as	0
well	0
as	0
increases	0
our	0
understanding	0
of	0
the	0
clinical	0
action	0
of	0
glucocorticoids	0
in	0
inflammation	0
.	0

Permanent	0
occupancy	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
enhancer	2
by	0
NF-kappa	9
B	10
is	0
needed	0
for	0
persistent	0
viral	0
replication	0
in	0
monocytes	7
.	0

This	0
work	0
aimed	0
to	0
ascertain	0
the	0
role	0
of	0
kappaB-responsive	1
elements	2
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
(	2
HIV-1	2
)	2
enhancer	2
not	0
only	0
in	0
early	0
initiation	0
but	0
also	0
in	0
long-term	0
maintenance	0
of	0
proviral	0
transcription	0
in	0
cells	0
of	0
the	0
monocytic	7
lineage	8
.	0

For	0
this	0
purpose	0
,	0
we	0
used	0
three	0
main	0
approaches	0
.	0

The	0
first	0
was	0
to	0
abruptly	0
terminate	0
tumor	0
necrosis	0
factor-induced	0
NF-kappaB	9
binding	0
to	0
the	0
enhancer	0
sequences	0
in	0
U1	0
monocytic	0
cells	0
,	0
using	0
a	0
short	0
pulse	0
of	0
exogenous	9
tumor	10
necrosis	10
factor	10
.	0

This	0
resulted	0
in	0
concomitant	0
decrease	0
in	0
nuclear	0
NF-kappaB	9
DNA-binding	0
activity	0
and	0
endogenous	1
long	2
terminal	2
repeat	2
transcriptional	0
activity	0
.	0

The	0
second	0
was	0
to	0
suppress	0
the	0
permanent	0
NF-kappaB	9
translocation	0
induced	0
by	0
HIV-1	0
replication	0
itself	0
in	0
chronically	5
infected	6
U937	6
cells	6
,	0
using	0
a	0
specific	0
proteasome	0
inhibitor	0
(	0
Z-LLL-H	0
)	0
.	0

As	0
early	0
as	0
2	0
h	0
after	0
addition	0
of	0
the	0
inhibitor	0
to	0
the	0
culture	0
medium	0
,	0
there	0
was	0
an	0
inhibition	0
of	0
both	0
constitutive	0
activation	0
of	0
NF-kappaB	9
and	0
HIV-1	0
genome	0
expression	0
.	0

The	0
third	0
approach	0
was	0
to	0
monitor	0
the	0
replication	0
competence	0
in	0
U937	5
cells	6
of	0
an	0
infectious	0
HIV-1	0
provirus	0
carrying	0
point	0
mutations	0
in	0
the	0
kappaB-responsive	1
elements	2
of	0
both	0
long	1
terminal	2
repeats	2
.	0

Compared	0
with	0
its	0
wild-type	0
counterpart	0
,	0
this	0
mutated	0
provirus	0
showed	0
a	0
profoundly	0
decreased	0
,	0
Z-LLL-H-insensitive	0
transcriptional	0
and	0
replicative	0
activity	0
in	0
U937	5
monocytes	6
.	0

Together	0
,	0
our	0
results	0
indicate	0
that	0
occupancy	0
of	0
the	0
viral	1
enhancer	2
by	0
NF-kappaB	9
(	10
p50/p65	10
)	10
heterodimers	10
is	0
required	0
for	0
ongoing	0
transcription	0
of	0
integrated	0
HIV	0
provirus	0
in	0
monocytes	7
,	0
even	0
in	0
cells	0
chronically	0
infected	0
and	0
permanently	0
producing	0
functional	0
HIV	9
Tat	10
protein	10
.	0

Thus	0
,	0
the	0
ability	0
of	0
HIV-1	0
replication	0
to	0
activate	0
NF-kappaB	9
is	0
crucial	0
to	0
the	0
intense	0
self-perpetuated	0
viral	0
transcription	0
observed	0
in	0
cells	0
of	0
the	0
monocytic	7
lineage	8
.	0

Rel-deficient	7
T	8
cells	8
exhibit	0
defects	0
in	0
production	0
of	0
interleukin	9
3	10
and	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
.	0

The	0
c-rel	1
protooncogene	2
encodes	0
a	0
subunit	0
of	0
the	0
NF-kappa	9
B-like	10
family	10
of	10
transcription	10
factors	10
.	0

Mice	0
lacking	0
Rel	9
are	0
defective	0
in	0
mitogenic	0
activation	0
of	0
B	7
and	8
T	8
lymphocytes	8
and	0
display	0
impaired	0
humoral	0
immunity	0
.	0

In	0
an	0
attempt	0
to	0
identify	0
changes	0
in	0
gene	0
expression	0
that	0
accompany	0
the	0
T-cell	0
stimulation	0
defects	0
associated	0
with	0
the	0
loss	0
of	0
Rel	9
,	0
we	0
have	0
examined	0
the	0
expression	0
of	0
cell	9
surface	10
activation	10
markers	10
and	0
cytokine	0
production	0
in	0
mitogen-stimulated	0
Rel-/-	7
T	8
cells	8
.	0

The	0
expression	0
of	0
cell	0
surface	0
markers	0
including	0
the	0
interleukin	9
2	10
receptor	10
alpha	10
(	10
IL-2R	10
alpha	10
)	10
chain	10
(	0
CD25	9
)	0
,	0
CD69	9
and	0
L-selectin	9
(	0
CD62	9
)	0
is	0
normal	0
in	0
mitogen-activated	5
Rel-/-	6
T	6
cells	6
,	0
but	0
cytokine	9
production	0
is	0
impaired	0
.	0

In	0
Rel-/-	5
splenic	6
T	6
cell	6
cultures	6
stimulated	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
ionomycin	0
,	0
the	0
levels	0
of	0
IL-3	0
,	0
IL-5	0
,	0
granulocyte-	9
macrophage	10
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
,	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
,	0
and	0
gamma	9
interferon	10
(	0
IFN-gamma	9
)	0
were	0
only	0
2-	0
to	0
3-fold	0
lower	0
compared	0
with	0
normal	0
T	0
cells	0
.	0

In	0
contrast	0
,	0
anti-CD3	9
and	0
anti-CD28	9
stimulated	0
Rel-/-	5
T	6
cells	6
,	0
which	0
fail	0
to	0
proliferate	0
,	0
make	0
little	0
or	0
no	0
detectable	0
cytokines	9
.	0

Exogenous	0
IL-2	9
,	0
which	0
restitutes	0
the	0
proliferative	0
response	0
of	0
the	0
anti-CD3-	5
and	6
anti-CD28-treated	6
Rel-/-	6
T	6
cells	6
,	0
restores	0
production	0
of	0
IL-5	0
,	0
TNF-alpha	9
,	0
and	0
IFN-gamma	9
,	0
but	0
not	0
IL-3	9
and	0
GM-CSF	9
expression	0
to	0
approximately	0
normal	0
levels	0
.	0

In	0
contrast	0
to	0
mitogen-activated	5
Rel-/-	6
T	6
cells	6
,	0
lipopolysaccharide-stimulated	0
Rel-/-	5
macrophages	6
produce	0
higher	0
than	0
normal	0
levels	0
of	0
GM-CSF	9
.	0

These	0
findings	0
establish	0
that	0
Rel	9
can	0
function	0
as	0
an	0
activator	0
or	0
repressor	0
of	0
gene	0
expression	0
and	0
is	0
required	0
by	0
T	7
lymphocytes	8
for	0
production	0
of	0
IL-3	9
and	0
GM-CSF	9
.	0

Nuclear	0
appearance	0
of	0
a	0
factor	0
that	0
binds	0
the	0
CD28	1
response	2
element	2
within	0
the	0
interleukin-2	1
enhancer	2
correlates	0
with	0
interleukin-2	9
production	0
.	0

Activation	0
of	0
T	7
lymphocytes	8
requires	0
the	0
combined	0
signaling	0
of	0
the	0
T	9
cell	10
receptor	10
and	0
costimulatory	9
molecules	10
such	0
as	0
CD28	9
.	0

The	0
ability	0
of	0
T	7
cells	8
to	0
produce	0
interleukin-2	9
(	0
IL-2	9
)	0
is	0
a	0
critical	0
control	0
point	0
in	0
T	0
lymphocyte	0
activation	0
.	0

The	0
IL-2	9
enhancer	0
contains	0
a	0
functional	0
motif	0
named	0
CD28	1
response	2
element	2
(	0
CD28RE	1
)	0
that	0
serves	0
a	0
role	0
as	0
a	0
target	0
for	0
mitogenic	0
T	0
cell	0
activation	0
signals	0
.	0

The	0
CD28RE	1
sequence	0
reveals	0
similarity	0
to	0
the	0
consensus	1
kappaB	2
binding	2
motif	2
.	0

Here	0
we	0
demonstrate	0
that	0
CD28RE	1
binds	0
an	0
inducible	0
protein	0
with	0
a	0
molecular	0
mass	0
of	0
approximately	0
35	0
kDa	0
called	0
nuclear	9
factor	10
of	10
mitogenic-activated	10
T	10
cells	10
(	0
NF-MATp35	9
)	0
that	0
is	0
clearly	0
different	0
from	0
the	0
known	0
NF-	9
kappaB/Rel	10
family	10
members	10
.	0

Induction	0
of	0
NF-MATp35	9
was	0
shown	0
to	0
depend	0
on	0
de	0
novo	0
protein	0
synthesis	0
and	0
was	0
restricted	0
to	0
T	7
cells	8
that	0
received	0
a	0
mitogenic	0
combination	0
of	0
T	0
cell	0
stimuli	0
,	0
not	0
necessarily	0
including	0
CD28	9
signaling	0
.	0

Nonmitogenic	0
T	0
cell	0
stimulation	0
did	0
not	0
result	0
in	0
appearance	0
of	0
NF-MATp35	9
.	0

These	0
results	0
indicate	0
that	0
mitogenic	0
combinations	0
of	0
T	0
cell	0
activation	0
signals	0
are	0
integrated	0
at	0
the	0
level	0
of	0
NF-MATp35	9
induction	0
.	0

Similar	0
to	0
its	0
effect	0
on	0
IL-2	9
production	0
,	0
cyclosporin	0
A	0
inhibited	0
the	0
induction	0
of	0
NF-MATp35	9
.	0

Taken	0
together	0
,	0
these	0
data	0
demonstrate	0
that	0
the	0
nuclear	0
appearance	0
of	0
NF-MATp35	9
shows	0
excellent	0
correlation	0
with	0
IL-2	9
production	0
,	0
which	0
is	0
a	0
unique	0
characteristic	0
among	0
nuclear	0
factors	0
implicated	0
in	0
the	0
control	0
of	0
IL-2	9
gene	0
expression	0
.	0

Transcriptional	0
basis	0
for	0
hyporesponsiveness	0
of	0
the	0
human	1
inducible	2
nitric	2
oxide	2
synthase	2
gene	2
to	0
lipopolysaccharide/interferon-gamma	0
.	0

The	0
work	0
reported	0
here	0
resolves	0
,	0
at	0
the	0
level	0
of	0
gene	0
regulation	0
,	0
the	0
controversy	0
as	0
to	0
whether	0
or	0
not	0
human	7
monocytes/macrophages	8
can	0
produce	0
nitric	0
oxide	0
(	0
NO	0
)	0
when	0
stimulated	0
with	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
with	0
or	0
without	0
co-stimulation	0
by	0
interferon-gamma	0
(	0
IFN-gamma	9
)	0
.	0

Studies	0
included	0
structural	0
comparison	0
of	0
the	0
promoters	0
for	0
human	0
and	0
mouse	0
inducible	1
NO	2
synthase	2
(	2
iNOS	2
)	2
genes	2
,	0
transfection	0
and	0
assay	0
of	0
human	0
and	0
mouse	0
iNOS	1
promoter	2
regions	2
in	0
response	0
to	0
LPS	0
+/-	0
IFN-gamma	9
,	0
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
of	0
kappa	1
B	2
response	2
elements	2
.	0

Two	0
explanations	0
for	0
hyporesponsiveness	0
of	0
the	0
human	1
iNOS	2
promoter	2
to	0
LPS	0
+/-	0
IFN-gamma	9
were	0
found	0
:	0
(	0
1	0
)	0
multiple	0
inactivating	0
nucleotide	0
substitutions	0
in	0
the	0
human	0
counterpart	0
of	0
the	0
enhancer	1
element	2
that	0
has	0
been	0
shown	0
to	0
regulate	0
LPS/	0
IFN-gamma	9
induced	0
expression	0
of	0
the	0
mouse	1
iNOS	2
gene	2
;	0
and	0
(	0
2	0
)	0
and	0
absence	0
of	0
one	0
or	0
more	0
nuclear	9
factors	10
in	0
human	7
macrophages	8
(	0
e.g.	0
,	0
an	0
LPS-inducible	9
nuclear	10
factor-kappa	10
B/Rel	10
complex	10
)	0
,	0
that	0
is	0
(	0
are	0
)	0
required	0
for	0
maximal	0
expression	0
of	0
the	0
gene	0
.	0

The	0
importance	0
of	0
resolution	0
of	0
this	0
controversy	0
is	0
that	0
future	0
research	0
in	0
this	0
area	0
should	0
be	0
directed	0
toward	0
the	0
understanding	0
of	0
alternative	0
mechanisms	0
that	0
can	0
result	0
in	0
the	0
successful	0
production	0
of	0
NO	0
.	0

X	0
inactivation	0
analysis	0
in	0
a	0
female	0
with	0
hypomelanosis	0
of	0
Ito	0
associated	0
with	0
a	0
balanced	1
X	2
;	2
17	2
translocation	2
:	0
evidence	0
for	0
functional	0
disomy	0
of	0
Xp	0
.	0

X	0
inactivation	0
analysis	0
was	0
performed	0
on	0
normal	0
and	0
hypopigmented	0
skin	0
samples	0
obtained	0
from	0
a	0
female	0
with	0
hypomelanosis	0
of	0
Ito	0
associated	0
with	0
a	0
balanced	1
whole	2
arm	2
X	2
;	2
17	2
translocation	2
.	0

Severe	0
skewing	0
of	0
X	0
inactivation	0
resulting	0
in	0
inactivity	0
of	0
the	0
intact	0
X	1
was	0
found	0
in	0
blood	0
and	0
cultures	0
of	0
both	0
types	0
of	0
skin	0
,	0
but	0
analysis	0
of	0
DNA	0
prepared	0
directly	0
from	0
hypopigmented	0
skin	0
showed	0
significant	0
inactivation	0
of	0
the	0
translocated	0
X	1
,	0
inconsistent	0
with	0
the	0
usual	0
mechanism	0
of	0
phenotypic	0
expression	0
in	0
X	1
;	2
autosome	2
translocations	2
.	0

In	0
addition	0
,	0
dual	0
colour	0
FISH	0
analysis	0
using	0
centromere	0
specific	0
probes	0
for	0
chromosomes	0
X	1
and	0
17	1
showed	0
that	0
the	0
breakpoints	0
on	0
both	0
chromosomes	1
lie	0
within	0
the	0
alphoid	0
arrays	0
,	0
making	0
interruption	0
of	0
a	0
locus	0
on	0
either	0
chromosome	0
unlikely	0
.	0

While	0
partial	0
variable	0
monosomy	0
of	0
loci	0
on	0
chromosome	1
17p	2
can	0
not	0
be	0
excluded	0
as	0
contributing	0
to	0
the	0
phenotype	0
in	0
this	0
patient	0
,	0
it	0
is	0
argued	0
that	0
the	0
major	0
likely	0
factor	0
is	0
partial	0
functional	0
disomy	0
of	0
sequences	0
on	0
Xp	1
in	0
cell	0
lineages	0
that	0
have	0
failed	0
to	0
inactivate	0
the	0
intact	0
X	1
chromosome	2
.	0

Identification	0
of	0
a	0
herpesvirus	1
Saimiri	2
cis-acting	2
DNA	2
fragment	2
that	0
permits	0
stable	0
replication	0
of	0
episomes	0
in	0
transformed	0
T	7
cells	8
.	0

Herpesvirus	0
saimiri	0
is	0
a	0
lymphotropic	0
herpesvirus	0
capable	0
of	0
immortalizing	0
and	0
transforming	0
T	7
cells	8
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Immortalized	0
and	0
transformed	0
T	7
cells	8
harbor	0
several	0
copies	0
of	0
the	0
viral	1
genome	2
as	0
a	0
persisting	1
genome	2
.	0

The	0
mapping	0
of	0
the	0
cis-acting	1
genetic	2
cis-acting	2
segment	2
(	0
oriP	1
)	0
required	0
for	0
viral	0
episomal	0
maintenance	0
is	0
reported	0
here	0
.	0

Viral	1
DNA	2
fragments	2
that	0
potentially	0
contain	0
oriP	1
were	0
cloned	0
into	0
a	0
plasmid	1
that	0
contains	0
the	0
hygromycin	1
resistance	2
gene	2
.	0

After	0
several	0
round	0
of	0
subcloning	0
followed	0
by	0
transfection	0
,	0
oriP	1
was	0
mapped	0
to	0
a	0
1.955-kb	1
viral	2
segment	2
.	0

This	0
viral	0
fragment	0
permits	0
stable	0
plasmid	1
replication	0
without	0
deletion	0
or	0
rearrangement	0
as	0
well	0
as	0
episomal	0
maintenance	0
without	0
integration	0
or	0
recombination	0
.	0

The	0
function	0
of	0
oriP	1
depends	0
on	0
a	0
trans-acting	9
factor	10
(	0
s	0
)	0
encoded	0
by	0
the	0
viral	1
genome	2
.	0

The	0
1.955-kb	1
viral	2
segment	2
includes	0
a	0
dyad	0
symmetry	0
region	0
located	0
between	0
two	0
small	1
nuclear	2
RNA	2
genes	2
and	0
is	0
located	0
upstream	0
of	0
the	0
dihydrofolate	1
reductase	2
gene	2
homolog	2
.	0

Therefore	0
,	0
this	0
oriP	1
contains	0
novel	0
elements	0
distinct	0
from	0
those	0
of	0
other	0
DNA	0
viruses	0
.	0

In	0
vivo	0
anergized	5
CD4+	6
T	6
cells	6
express	0
perturbed	0
AP-1	0
and	0
NF-kappa	9
B	10
transcription	9
factors	10
.	0

Anergy	0
is	0
a	0
major	0
mechanism	0
to	0
ensure	0
antigen-specific	0
tolerance	0
in	0
T	7
lymphocytes	8
in	0
the	0
adult	0
.	0

In	0
vivo	0
,	0
anergy	0
has	0
mainly	0
been	0
studied	0
at	0
the	0
cellular	0
level	0
.	0

In	0
this	0
study	0
,	0
we	0
used	0
the	0
T-cell-activating	9
superantigen	10
staphylococcal	9
enterotoxin	10
A	10
(	0
SEA	9
)	0
to	0
investigate	0
molecular	0
mechanisms	0
of	0
T-lymphocyte	0
anergy	0
in	0
vivo	0
.	0

Injection	0
of	0
SEA	9
to	0
adult	0
mice	0
activates	0
CD4+	7
T	8
cells	8
expressing	0
certain	0
T-cell	9
receptor	10
(	10
TCR	10
)	10
variable	10
region	10
beta-chain	10
families	10
and	0
induces	0
strong	0
and	0
rapid	0
production	0
of	0
interleukin	0
2	0
(	0
IL-2	9
)	0
.	0

In	0
contrast	0
,	0
repeated	0
injections	0
of	0
SEA	9
cause	0
CD4+	7
T-cell	8
deletion	0
and	0
anergy	0
in	0
the	0
remaining	0
CD4+	0
T	7
cells	8
,	0
characterized	0
by	0
reduced	0
expression	0
of	0
IL-2	9
at	0
mRNA	0
and	0
protein	0
levels	0
.	0

We	0
analyzed	0
expression	0
of	0
AP-1	9
,	0
NF-kappa	9
B	10
,	0
NF-AT	9
,	0
and	0
octamer	9
binding	10
transcription	10
factors	10
,	0
which	0
are	0
known	0
to	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
IL-2	9
gene	0
promoter	0
activity	0
.	0

Large	0
amounts	0
of	0
AP-1	9
and	0
NF-kappa	9
B	10
and	0
significant	0
quantities	0
of	0
NF-AT	9
were	0
induced	0
in	0
SEA-activated	5
CD4+	6
spleen	6
T	6
cells	6
,	0
whereas	0
Oct-1	0
and	0
Oct-2	0
DNA	0
binding	0
activity	0
was	0
similar	0
in	0
both	0
resting	0
and	0
activated	7
T	8
cells	8
.	0

In	0
contrast	0
,	0
anergic	7
CD4+	8
T	8
cells	8
contained	0
severely	0
reduced	0
levels	0
of	0
AP-1	9
and	0
Fos/Jun-containing	9
NF-AT	10
complexes	10
but	0
expressed	0
significant	0
amounts	0
of	0
NF-kappa	9
B	10
and	0
Oct	9
binding	10
proteins	10
after	0
SEA	9
stimulation	0
.	0

Resolution	0
of	0
the	0
NF-kappa	9
B	10
complex	10
demonstrated	0
predominant	0
expression	0
of	0
p50-p65	9
heterodimers	10
in	0
activated	7
CD4+	8
T	8
cells	8
,	0
while	0
anergic	0
cells	0
mainly	0
expressed	0
the	0
transcriptionally	0
inactive	0
p50	9
homodimer	10
.	0

These	0
alterations	0
of	0
transcription	9
factors	10
are	0
likely	0
to	0
be	0
responsible	0
for	0
repression	0
of	0
IL-2	9
in	0
anergic	7
T	8
cells	8
.	0

Fas	9
ligation	0
induces	0
apoptosis	0
and	0
Jun	9
kinase	10
activation	0
independently	0
of	0
CD45	9
and	0
Lck	9
in	0
human	7
T	8
cells	8
.	0

Stimulation	0
through	0
the	0
Fas/APO-1	9
receptor	10
results	0
in	0
apoptosis	0
through	0
an	0
incompletely	0
characterized	0
signaling	0
pathway	0
.	0

More	0
is	0
known	0
regarding	0
signal	0
transduction	0
events	0
that	0
occur	0
after	0
ligation	0
of	0
the	0
T-cell	9
antigen	10
receptor	10
(	0
TCR	9
)	0
.	0

It	0
has	0
been	0
shown	0
that	0
TCR	9
stimulation	0
requires	0
both	0
the	0
membrane	9
tyrosine	10
phosphatase	10
,	0
CD45	9
,	0
and	0
the	0
Src-family	9
kinase	10
,	0
Lck	9
,	0
to	0
result	0
in	0
cellular	0
activation	0
.	0

Although	0
prior	0
studies	0
suggest	0
a	0
role	0
for	0
protein	9
tyrosine	10
kinases	10
and	0
phosphatases	0
in	0
Fas	9
signaling	0
,	0
we	0
report	0
here	0
that	0
Fas	0
ligation	0
induces	0
apoptosis	0
in	0
T	7
cells	8
deficient	0
in	0
either	0
CD45	9
or	0
Lck	9
.	0

Further	0
,	0
in	0
normal	0
and	0
CD45-	5
or	6
Lck-deficient	6
cell	6
lines	6
,	0
Fas	0
stimulation	0
results	0
in	0
activation	0
of	0
Jun	9
kinase	10
(	0
JNK	9
)	0
,	0
a	0
proposed	0
mediator	0
of	0
stress	0
activation	0
pathways	0
.	0

Previous	0
studies	0
have	0
also	0
demonstrated	0
a	0
role	0
for	0
endogenous	0
ceramide	0
release	0
in	0
Fas-mediated	0
apoptosis	0
.	0

We	0
show	0
that	0
stimulation	0
with	0
a	0
synthetic	0
ceramide	0
analog	0
results	0
in	0
JNK	9
activation	0
as	0
well	0
as	0
apoptosis	0
,	0
suggesting	0
ceramide	0
release	0
occurs	0
proximal	0
to	0
JNK	9
activation	0
in	0
Fas	9
signaling	0
.	0

Our	0
data	0
suggest	0
that	0
although	0
CD45	9
and	0
Lck	9
are	0
not	0
required	0
for	0
Fas	9
signaling	0
,	0
JNK	9
activation	0
may	0
play	0
an	0
important	0
role	0
transducing	0
distal	0
signals	0
that	0
lead	0
to	0
apoptosis	0
after	0
Fas	9
ligation	0
.	0

Globin	0
gene	0
switching	0
.	0

In	0
vivo	0
protein-DNA	0
interactions	0
of	0
the	0
human	1
beta-globin	2
locus	2
in	0
erythroid	7
cells	8
expressing	0
the	0
fetal	0
or	0
the	0
adult	0
globin	1
gene	2
program	0
.	0

To	0
characterize	0
the	0
protein-DNA	0
interactions	0
important	0
for	0
the	0
developmental	0
control	0
of	0
the	0
human	1
beta-globin	2
locus	2
,	0
we	0
analyzed	0
by	0
in	0
vivo	0
dimethyl	0
sulfate	0
footprinting	0
erythroid	7
cells	8
expressing	0
either	0
the	0
fetal	0
or	0
the	0
adult	0
globin	0
developmental	0
program	0
.	0

In	0
the	0
locus	1
control	2
region	2
(	0
LCR	1
)	0
of	0
the	0
beta-globin	1
locus	2
,	0
in	0
vivo	0
footprints	0
on	0
NF-E2	9
(	0
or	0
AP-1	9
)	0
and	0
GATA-1	1
motifs	2
remained	0
the	0
same	0
regardless	0
of	0
whether	0
the	0
fetal	0
or	0
the	0
adult	1
globin	2
genes	2
are	0
expressed	0
.	0

In	0
contrast	0
,	0
in	0
vivo	0
footprints	0
on	0
GT	1
(	2
CACCC	2
)	2
motifs	2
differed	0
between	0
the	0
cells	0
expressing	0
the	0
fetal	0
or	0
the	0
adult	0
globin	0
program	0
.	0

In	0
promoter	1
regions	2
,	0
the	0
actively	1
transcribed	2
genes	2
demonstrated	0
extensive	0
and	0
consistent	0
footprints	0
over	0
the	0
canonical	0
elements	0
,	0
such	0
as	0
CACCC	1
and	2
CCAAT	2
motifs	2
.	0

The	0
adult	7
globin	8
expressing	8
cells	8
displayed	0
more	0
extensive	0
footprints	0
than	0
the	0
fetal	7
globin	8
expressing	8
cells	8
in	0
the	0
3	1
'	2
regulatory	2
sequences	2
of	0
both	0
the	0
Agamma-	1
and	2
the	2
beta-globin	2
genes	2
,	0
suggesting	0
a	0
role	0
of	0
these	0
3	1
'	2
elements	2
in	0
beta-globin	1
gene	2
expression	0
.	0

Our	0
results	0
suggest	0
that	0
the	0
bulk	0
of	0
protein-DNA	0
interactions	0
that	0
underlies	0
the	0
developmental	0
control	0
of	0
globin	1
genes	2
takes	0
place	0
in	0
the	0
gamma-	1
and	2
beta-globin	2
gene	2
promoters	2
,	0
and	0
that	0
GT	1
motifs	2
of	0
the	0
beta-globin	1
locus	2
LCR	1
may	0
play	0
a	0
role	0
in	0
the	0
developmental	0
regulation	0
of	0
human	0
beta-globin	1
gene	2
expression	0
,	0
perhaps	0
by	0
increasing	0
the	0
probability	0
of	0
interaction	0
of	0
the	0
LCR	9
holocomplex	10
with	0
the	0
fetal	1
or	2
the	2
adult	2
globin	2
gene	2
.	0

Antisense	0
inhibition	0
of	0
vitamin	9
D	10
receptor	10
expression	0
induces	0
apoptosis	0
in	0
monoblastoid	5
U937	6
cells	6
.	0

The	0
active	0
vitamin	0
D3	0
metabolite	0
1	0
,	0
25-dihydroxycholecalciferol	0
(	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
)	0
acts	0
as	0
an	0
antiproliferative	0
and	0
differentiating	0
agent	0
for	0
the	0
monoblastoid	5
cell	6
line	6
U937	6
and	0
as	0
an	0
important	0
immunologic	0
mediator	0
implicated	0
particularly	0
in	0
the	0
function	0
of	0
cells	0
belonging	0
to	0
the	0
monocyte/macrophage	7
lineage	8
.	0

These	0
effects	0
are	0
controlled	0
by	0
the	0
vitamin	9
D	10
receptor	10
(	0
VDR	9
)	0
,	0
a	0
member	0
of	0
the	0
steroid	9
hormone	10
receptor	10
family	10
.	0

The	0
objective	0
of	0
this	0
study	0
was	0
to	0
develop	0
U937	5
transfectants	0
expressing	0
antisense	0
VDR	3
mRNA	4
,	0
and	0
to	0
use	0
these	0
to	0
examine	0
the	0
role	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
-VDR	9
interaction	0
in	0
this	0
lineage	0
.	0

A	0
2-kb	1
VDR	2
cDNA	2
insert	2
(	0
including	0
the	0
complete	0
VDR	1
coding	2
region	2
)	0
was	0
cloned	0
in	0
an	0
antisense	0
orientation	0
into	0
the	0
EBV	0
episomal	0
vector	0
pMEP4	0
under	0
the	0
control	0
of	0
an	0
inducible	1
promoter	2
and	0
transfected	0
into	0
U937	5
.	0

The	0
resultant	5
cell	6
line	6
,	0
DH42	5
,	0
was	0
hygromycin	0
resistant	0
,	0
contained	0
VDR	1
cDNA	2
,	0
expressed	0
fewer	0
VDRs	9
than	0
controls	0
,	0
and	0
showed	0
a	0
substantial	0
decrease	0
in	0
antiproliferative	0
response	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

However	0
,	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
increased	0
the	0
number	0
of	0
cells	0
expressing	0
macrophage	9
cell	10
surface	10
Ags	10
,	0
including	0
CD14	9
and	0
CD11b	9
.	0

A	0
subpopulation	0
of	0
smaller	0
cells	0
did	0
not	0
express	0
the	0
differentiation	0
markers	0
after	0
cadmium	0
stimulation	0
.	0

Cell	0
cycle	0
analysis	0
showed	0
shifts	0
in	0
the	0
distribution	0
of	0
cells	0
from	0
G1	0
to	0
S	0
phase	0
,	0
which	0
were	0
more	0
pronounced	0
after	0
cadmium	0
treatment	0
.	0

A	0
considerable	0
proportion	0
of	0
cells	0
were	0
outside	0
the	0
cycle	0
and	0
DNA	0
fragmentation	0
confirmed	0
apoptosis	0
.	0

Thus	0
,	0
the	0
functional	0
outcome	0
of	0
the	0
VDR	9
antisense	0
transfection	0
suggests	0
that	0
in	0
the	0
myelomonocytic	7
lineage	8
,	0
VDR	9
expression	0
may	0
act	0
as	0
a	0
protective	0
mechanism	0
against	0
programmed	0
cell	0
death	0
.	0

Human	0
T	0
lymphotropic	0
virus-I	0
infection	0
of	0
human	7
T	8
lymphocytes	8
induces	0
expression	0
of	0
the	0
beta-galactoside-binding	9
lectin	10
,	0
galectin-3	9
.	0

Animal	0
lectins	9
play	0
important	0
roles	0
in	0
a	0
variety	0
of	0
biological	0
processes	0
via	0
their	0
recognition	0
of	0
glycoconjugates	0
.	0

Galectin-3	0
is	0
a	0
beta-galactoside-binding	9
lectin	10
previously	0
designated	0
as	0
epsilon	9
BP	10
(	0
IgE-binding	9
protein	10
)	0
,	0
CBP35	9
,	0
Mac-2	9
,	0
L-29	9
,	0
and	0
L-34	9
,	0
and	0
its	0
expression	0
has	0
been	0
associated	0
with	0
various	0
physiological	0
and	0
pathological	0
processes	0
,	0
including	0
cell	0
growth	0
,	0
tumor	0
transformation	0
,	0
and	0
metastasis	0
.	0

Galectin-3	9
is	0
widely	0
distributed	0
in	0
various	0
tissues	0
and	0
cell	0
types	0
and	0
is	0
expressed	0
in	0
many	0
leukocytes	7
,	0
with	0
the	0
notable	0
exception	0
of	0
B	7
and	8
T	8
lymphocytes	8
.	0

We	0
now	0
report	0
that	0
galectin-3	9
is	0
abundantly	0
expressed	0
in	0
a	0
number	0
of	0
human	5
T	6
lymphotropic	6
virus	6
(	6
HTLV	6
)	6
-I-infected	6
human	6
T	6
cell	6
lines	6
,	0
including	0
F6T	5
,	0
HUT	5
102	6
,	0
K3T	5
,	0
MT-2	5
,	0
and	0
SLB-I	5
,	0
but	0
is	0
not	0
expressed	0
in	0
non-HTLV-I-infected	5
T	6
cell	6
lines	6
such	0
as	0
Jurkat	5
,	0
CEM	5
,	0
and	0
MOLT-4	5
.	0

In	0
addition	0
,	0
the	0
galectin-3	9
level	0
was	0
markedly	0
increased	0
in	0
human	7
thymocytes	8
after	0
infection	0
with	0
HTLV-I	0
as	0
compared	0
with	0
uninfected	7
thymocytes	8
.	0

The	0
up-regulation	0
of	0
galectin-3	9
expression	0
appeared	0
to	0
correlate	0
well	0
with	0
HTLV-I	0
gene	0
expression	0
,	0
as	0
undetectable	0
or	0
very	0
low	0
levels	0
of	0
galectin-3	9
were	0
found	0
in	0
the	0
S1T	5
and	6
ATL-1K	6
cell	6
lines	6
,	0
which	0
are	0
nonproductively	0
infected	0
with	0
HTLV-I	0
.	0

In	0
co-transfection	0
experiments	0
,	0
the	0
galectin-3	1
promoter	2
was	0
significantly	0
up-regulated	0
by	0
expression	1
vectors	2
encoding	0
the	0
40-kd	9
Tax	10
protein	10
,	0
a	0
potent	0
transactivator	0
in	0
HTLV-I	0
.	0

Analysis	0
of	0
various	0
Tax	9
mutants	10
suggested	0
that	0
galectin-3	1
promoter	2
induction	0
is	0
dependent	0
on	0
activation	0
of	0
the	0
cyclic-AMP-responsive	9
element	10
binding	10
protein/activation	10
transcription	10
factor	10
family	10
of	0
transcription	9
factors	10
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
nuclear	9
factor-kappa	10
B/Rel	10
induction	0
.	0

Transfection	0
of	0
human	5
promonocytic	6
U-937	6
cells	6
with	0
an	0
HTLV-I	0
Tax	0
expression	0
vector	0
induced	0
galectin-3	9
expression	0
in	0
this	0
cell	0
line	0
.	0

Functionally	0
,	0
galectin-3	9
was	0
shown	0
to	0
activate	0
interleukin-2	9
production	0
in	0
Jurkat	7
T	8
cells	8
.	0

Together	0
,	0
these	0
findings	0
raise	0
the	0
possibility	0
that	0
HTLV-I	0
Tax	9
production	0
induces	0
the	0
transcription	0
and	0
subsequent	0
synthesis	0
and	0
secretion	0
of	0
galectin-3	9
,	0
which	0
in	0
turn	0
may	0
further	0
activate	0
these	0
T	7
cells	8
and	0
contribute	0
to	0
the	0
altered	0
properties	0
of	0
cell	0
growth	0
found	0
in	0
adult	0
T	0
cell	0
leukemia	0
induced	0
by	0
HTLV-I	0
.	0

Monocytic	0
cell	0
type-specific	0
transcriptional	0
induction	0
of	0
collagenase	9
.	0

Interstitial	0
collagenase	9
(	0
MMP-1	9
)	0
,	0
a	0
metalloproteinase	9
produced	0
by	0
resident	7
and	8
inflammatory	8
cells	8
during	0
connective	0
tissue	0
turnover	0
,	0
cleaves	0
type	9
I	10
collagen	10
fibrils	10
.	0

This	0
catalytic	0
event	0
is	0
rate	0
limiting	0
in	0
remodeling	0
of	0
tissues	0
rich	0
in	0
fibrillar	9
collagen	10
such	0
as	0
the	0
skin	0
and	0
lungs	0
.	0

The	0
regulation	0
of	0
collagenase	9
expression	0
is	0
cell-type	0
specific	0
;	0
bacterial	0
LPS	0
and	0
zymosan	0
,	0
a	0
yeast	0
cell	0
wall	0
derivative	0
,	0
are	0
potent	0
inducers	0
of	0
collagenase	9
expression	0
in	0
macrophages	7
,	0
but	0
do	0
not	0
alter	0
fibroblast	7
collagenase	9
expression	0
.	0

Since	0
promoter	0
elements	0
controlling	0
collagenase	9
transcription	0
in	0
monocytic	0
cells	0
have	0
not	0
been	0
previously	0
defined	0
,	0
we	0
sought	0
to	0
delineate	0
responsive	0
cis-acting	1
elements	2
of	0
the	0
collagenase	1
promoter	2
in	0
transiently	0
transfected	0
human	5
(	6
U937	6
)	6
and	6
murine	6
(	6
J774	6
)	6
monocytic	6
cell	6
lines	6
.	0

Deletion	0
constructs	0
containing	0
as	0
little	0
as	0
72	0
bp	0
of	0
5	1
'	2
-flanking	2
sequence	2
of	0
the	0
collagenase	1
promoter	2
were	0
sufficient	0
for	0
LPS-	0
or	0
zymosan-mediated	0
transcriptional	0
induction	0
,	0
whereas	0
phorbol	0
inducibility	0
exhibited	0
an	0
absolute	0
requirement	0
for	0
upstream	0
elements	0
including	0
the	0
polyoma	1
enhancer	2
A-binding	2
protein-3	2
site	2
(	0
-83	1
to	2
-91	2
)	0
and	0
TTCA	1
sequence	2
(	0
-102	1
to	2
-105	2
)	0
in	0
both	0
monocytic	7
cells	8
and	0
fibroblasts	7
.	0

Mutagenesis	0
of	0
the	0
activator	1
protein-1	2
[	2
AP-1	2
]	2
site	2
at	0
-72	1
abolished	0
basal	1
promoter	2
activity	0
and	0
LPS/zymosan	0
inducibility	0
,	0
while	0
mutagenesis	0
of	0
an	0
NF-kappaB-like	1
site	2
at	0
-20	0
to	0
-10	0
had	0
no	0
effect	0
.	0

Nuclear	0
extracts	0
from	0
LPS	0
-and	0
zymosan-treated	7
cells	8
showed	0
strong	0
AP-1	9
activity	0
by	0
gel-shift	0
analysis	0
,	0
and	0
supershift	0
analysis	0
showed	0
the	0
AP-1	9
complexes	10
contained	0
specific	0
members	0
of	0
both	0
the	0
jun	1
and	2
fos	2
gene	2
families	2
.	0

These	0
data	0
indicate	0
that	0
,	0
in	0
contrast	0
to	0
most	0
LPS	0
effects	0
,	0
AP-1	9
,	0
but	0
not	0
nuclear	9
factor-kappaB	10
,	0
mediates	0
LPS	0
induction	0
of	0
collagenase	9
transcription	0
in	0
macrophagelike	7
cells	8
.	0

Furthermore	0
,	0
as	0
compared	0
to	0
regulation	0
by	0
phorbol	0
ester	0
,	0
collagenase	9
induction	0
in	0
monocytic	7
cells	8
by	0
cell	0
wall	0
derivatives	0
of	0
bacteria	0
or	0
yeast	0
is	0
largely	0
independent	0
of	0
upstream	1
promoter	2
sequences	2
.	0

Activation	0
of	0
c-Jun	9
N-terminal	10
kinase	10
in	0
bacterial	7
lipopolysaccharide-stimulated	8
macrophages	8
.	0

Activation	0
of	0
macrophages	7
by	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
induces	0
transcription	0
of	0
genes	0
that	0
encode	0
for	0
proinflammatory	9
regulators	10
of	0
the	0
immune	0
response	0
.	0

Previous	0
work	0
has	0
suggested	0
that	0
activation	0
of	0
the	0
transcription	9
factor	10
activator	10
protein	10
1	10
(	0
AP-1	9
)	0
is	0
one	0
LPS-induced	0
event	0
that	0
mediates	0
this	0
response	0
.	0

Consistent	0
with	0
this	0
notion	0
,	0
we	0
found	0
that	0
LPS	0
stimulated	0
AP-1	9
-mediated	0
transcription	0
of	0
a	0
transfected	1
reporter	2
gene	2
in	0
the	0
murine	5
macrophage	6
cell	6
line	6
RAW	6
264.7	6
.	0

As	0
AP-1	9
activity	0
is	0
regulated	0
in	0
part	0
by	0
activation	0
of	0
the	0
c-Jun	9
N-terminal	10
kinase	10
(	0
JNK	9
)	0
,	0
which	0
phosphorylates	0
and	0
subsequently	0
increases	0
the	0
transcriptional	0
activity	0
of	0
c-Jun	0
,	0
we	0
examined	0
whether	0
LPS	0
treatment	0
of	0
macrophages	7
resulted	0
in	0
activation	0
of	0
this	0
kinase	9
.	0

LPS	0
treatment	0
of	0
RAW	5
264.7	6
cells	6
,	0
murine	7
bone	8
marrow-derived	8
macrophages	8
,	0
and	0
the	0
human	5
monocyte	6
cell	6
line	6
THP-1	6
resulted	0
in	0
rapid	0
activation	0
of	0
the	0
p46	9
and	10
p54	10
isoforms	10
of	0
JNK	9
.	0

Treatment	0
with	0
wild-type	0
and	0
rough	0
mutant	0
forms	0
of	0
LPS	0
and	0
synthetic	0
lipid	0
A	0
resulted	0
in	0
JNK	9
activation	0
,	0
while	0
pretreatment	0
with	0
the	0
tyrosine	9
kinase	10
inhibitor	0
herbimycin	0
A	0
inhibited	0
this	0
response	0
.	0

Binding	0
of	0
LPS-	0
LPS	9
binding	10
protein	10
(	10
LBP	10
)	10
complexes	10
to	0
CD14	9
,	0
a	0
surface	9
receptor	10
that	0
mediates	0
many	0
LPS	0
responses	0
,	0
was	0
found	0
to	0
be	0
crucial	0
,	0
as	0
pretreatment	0
of	0
THP-1	5
cells	6
with	0
the	0
monoclonal	9
antibody	10
60b	10
,	0
which	0
blocks	0
this	0
binding	0
,	0
inhibited	0
JNK	9
activation	0
.	0

These	0
results	0
suggest	0
that	0
LPS	0
activation	0
of	0
JNK	9
in	0
monocyte/macrophage	7
cells	8
is	0
a	0
CD14-	0
and	0
protein	0
tyrosine	0
phosphorylation-dependent	0
event	0
that	0
may	0
mediate	0
the	0
early	0
activation	0
of	0
AP-1	9
in	0
regulating	0
LPS-triggered	0
gene	0
induction	0
.	0

Surfactant	0
suppresses	0
NF-kappa	9
B	10
activation	0
in	0
human	0
monocytic	7
cells	8
.	0

In	0
addition	0
to	0
biophysical	0
properties	0
,	0
pulmonary	0
surfactant	0
has	0
immunomodulatory	0
activity	0
.	0

We	0
previously	0
demonstrated	0
that	0
both	0
synthetic	0
(	0
Exosurf	0
)	0
and	0
modified	0
natural	0
surfactant	0
(	0
Survanta	0
)	0
downregulated	0
endotoxin-stimulated	0
inflammatory	3
c	4
ytokine	4
mRNA	4
levels	0
and	0
protein	9
products	10
(	0
tumor	9
necrosis	10
factor-alpha	10
[	0
TNF	0
]	0
,	0
interleukin-1-beta	9
[	0
IL-1	9
]	0
,	0
interleukin-6	9
[	0
IL-6	9
]	0
)	0
in	0
human	7
alveolar	8
macrophages	8
.	0

In	0
this	0
study	0
,	0
we	0
report	0
that	0
both	0
Exosurf	0
and	0
Survanta	0
suppress	0
TNF	3
mRNA	4
and	0
secretion	0
(	0
85	0
+/-	0
4	0
%	0
mean	0
percent	0
inhibition	0
+/-	0
SEM	0
by	0
Exosurf	0
;	0
71	0
+/-	0
6	0
%	0
by	0
Survanta	0
)	0
by	0
endotoxin-stimulated	5
THP-1	6
,	0
a	0
human	5
monocytic	6
cell	6
line	6
.	0

Because	0
surfactant	0
downregulated	0
inflammatory	9
cytokine	10
production	0
similarly	0
in	0
both	0
normal	7
human	8
alveolar	8
macrophages	8
and	0
the	0
THP-1	5
cell	6
line	6
,	0
we	0
used	0
this	0
cell	5
line	6
to	0
investigate	0
whether	0
surfactant	0
affected	0
transcriptional	0
mechanisms	0
.	0

Specifically	0
,	0
we	0
examined	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
because	0
it	0
is	0
crucial	0
in	0
transcriptional	0
regulation	0
of	0
many	0
inflammatory	1
cytokine	2
genes	2
including	0
TNF	1
,	0
IL-1	1
,	0
and	0
IL-6	1
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
showed	0
that	0
both	0
surfactants	0
decreased	0
activation	0
of	0
NF-kappa	9
B	10
.	0

The	0
presence	0
of	0
both	0
p65	9
and	0
p50	9
NF-kappa	9
B	10
components	10
in	0
LPS-activated	0
THP-1	5
cells	6
was	0
confirmed	0
by	0
specific	0
antibody	0
induction	0
of	0
supershifts	0
in	0
mobility	0
assays	0
.	0

These	0
results	0
are	0
the	0
first	0
to	0
suggest	0
that	0
surfactant	0
's	0
suppressive	0
effects	0
on	0
inflammatory	9
cytokine	10
production	0
may	0
involve	0
transcriptional	0
regulation	0
through	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
.	0

A	0
cell	1
type-specific	2
enhancer	2
in	0
the	0
human	1
B7.1	2
gene	2
regulated	0
by	0
NF-kappaB	9
.	0

The	0
costimulatory	9
molecule	10
B7.1	10
provides	0
a	0
second	0
signal	0
critical	0
for	0
T	0
cell	0
activation	0
.	0

The	0
distribution	0
of	0
this	0
integral	9
membrane	10
protein	10
is	0
restricted	0
to	0
certain	0
tissues	0
where	0
its	0
level	0
of	0
expression	0
is	0
modulated	0
by	0
multiple	0
exogenous	0
stimuli	0
.	0

To	0
identify	0
the	0
molecular	0
basis	0
for	0
specificity	0
and	0
inducibility	0
,	0
the	0
chromatin	1
configuration	0
of	0
the	0
human	1
B7.1	2
gene	2
was	0
examined	0
in	0
intact	0
nuclei	0
from	0
various	0
cell	0
types	0
.	0

The	0
identification	0
of	0
a	0
tissue-specific	0
deoxyribonuclease	1
I	2
hypersensitive	2
site	2
approximately	0
3kb	1
upstream	2
of	0
the	0
transcription	1
start	2
site	2
led	0
to	0
the	0
characterization	0
of	0
a	0
cell	1
type-specific	2
enhancer	2
region	2
.	0

This	0
183-bp	1
region	2
was	0
both	0
cell	0
type	0
specific	0
and	0
responsive	0
to	0
two	0
distinct	0
stimuli	0
,	0
lipopolysaccharide	0
and	0
dibutyryl	0
cAMP	0
,	0
known	0
to	0
regulate	0
B7.1	9
expression	0
.	0

Deletional	0
and	0
site-directed	0
mutagenesis	0
revealed	0
the	0
presence	0
of	0
multiple	0
functionally	0
critical	0
cis	1
elements	2
within	0
this	0
region	0
,	0
one	0
of	0
which	0
was	0
a	0
nuclear	1
factor	2
(	2
NF	2
)	2
-kappaB	2
consensus	2
sequence	2
.	0

In	0
B7.1-positive	7
B	8
cells	8
,	0
this	0
element	0
bound	0
several	0
members	0
of	0
the	0
NF-kappaB	9
family	10
,	0
transcription	9
factors	10
already	0
implicated	0
in	0
signal	0
transduction	0
pathways	0
relevant	0
to	0
B7.1	9
expression	0
.	0

This	0
is	0
the	0
first	0
description	0
,	0
to	0
our	0
knowledge	0
,	0
of	0
regulatory	1
elements	2
that	0
control	0
expression	0
of	0
a	0
gene	0
encoding	0
a	0
B7	9
costimulatory	10
molecule	10
.	0

Ubiquitinylation	0
of	0
transcription	9
factors	10
c-Jun	9
and	0
c-Fos	9
using	0
reconstituted	9
ubiquitinylating	10
enzymes	10
.	0

Recombinant	0
c-Jun	9
and	0
c-Fos	9
were	0
ubiquitinylated	0
by	0
the	0
ubiquitin	9
carrier	10
enzymes	10
E214K	9
,	0
E220K	9
,	0
or	0
E232K	9
in	0
the	0
presence	0
of	0
the	0
ubiquitin-activating	9
enzyme	10
,	0
E1	9
.	0

Addition	0
of	0
ubiquitin	9
protein	10
ligase	10
E3	10
substantially	0
enhanced	0
the	0
E214K	9
-mediated	0
ubiquitinylation	0
of	0
c-Jun	9
and	0
c-Fos	9
.	0

Truncated	9
c-Jun	10
and	10
c-Fos	10
mutant	10
proteins	10
including	0
wbJun	9
and	0
wbFos	9
were	0
also	0
ubiquitinylated	0
under	0
the	0
same	0
conditions	0
,	0
suggesting	0
the	0
sites	0
of	0
ubiquitinylation	0
are	0
located	0
within	0
the	0
dimerization	9
and	10
DNA	10
binding	10
domains	10
of	0
c-Jun	9
and	0
c-Fos	9
.	0

The	0
E3-dependent	0
ubiquitinylation	0
of	0
c-Jun	9
was	0
inhibited	0
upon	0
the	0
heterodimerization	0
of	0
c-Jun	9
with	0
c-Fos	9
.	0

Further	0
addition	0
of	0
E220K	9
significantly	0
enhanced	0
ubiquitinylation	0
of	0
c-Jun	9
in	0
the	0
heterodimer	0
suggesting	0
a	0
regulatory	0
role	0
of	0
E220K	9
.	0

Polyubiquitinylated	0
c-Jun	9
,	0
wbFos	9
,	0
and	0
wbJun	9
,	0
but	0
not	0
E220K-ubiquitinylated	9
c-Jun	10
,	0
were	0
readily	0
degraded	0
by	0
the	0
ATP-dependent	9
26	10
S	10
multicatalytic	10
proteases	10
.	0

These	0
results	0
suggest	0
that	0
the	0
temporal	0
control	0
of	0
c-Jun	9
and	0
c-Fos	9
may	0
be	0
regulated	0
through	0
the	0
ubiquitinylation	0
pathways	0
,	0
and	0
the	0
ubiquitinylation	0
of	0
c-Jun	9
and	0
c-Fos	9
may	0
in	0
turn	0
be	0
regulated	0
in	0
response	0
to	0
the	0
heterodimerization	0
between	0
them	0
and	0
the	0
cooperation	0
between	0
E220K	9
and	0
E3	0
mediated	0
polyubiquitinylation	0
.	0

Cloning	0
and	0
characterization	0
of	0
the	0
murine	9
B-cell	10
specific	10
transcriptional	10
coactivator	10
Bob1	9
.	0

From	0
a	0
murine	1
B-cell	2
cDNA-library	2
we	0
have	0
cloned	0
a	0
cDNA	1
encoding	0
the	0
murine	9
B-cell	10
specific	10
coactivator	10
mBob1	9
.	0

The	0
protein	0
is	0
the	0
murine	0
homologue	0
to	0
the	0
recently	0
described	0
human	9
coactivator	10
Bob1	10
(	0
hBob1	9
)	0
,	0
also	0
referred	0
to	0
as	0
OBF-1	9
or	0
OCA-B	9
.	0

We	0
have	0
also	0
characterized	0
the	0
genomic	9
mBob1	10
clone	10
.	0

Analysis	0
of	0
its	0
intron-exon	0
structure	0
has	0
allowed	0
identification	0
of	0
a	0
C-terminal	9
splice	10
variant	10
.	0

mBob1	9
is	0
B-cell	0
restricted	0
,	0
and	0
is	0
found	0
in	0
all	0
B-cell	5
lines	6
representing	0
different	0
stages	0
of	0
B-cell	0
differentiation	0
.	0

mBob1	9
interacts	0
with	0
the	0
octamer	9
transcription	10
factors	10
Oct-1	9
and	0
Oct-2	9
and	0
stimulates	0
transcription	0
mediated	0
by	0
these	0
factors	0
.	0

HIV	9
glycoprotein	10
120	10
enhances	0
intercellular	9
adhesion	10
molecule-1	10
gene	0
expression	0
in	0
glial	7
cells	8
.	0

Involvement	0
of	0
Janus	9
kinase	10
/signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
and	0
protein	9
kinase	10
C	10
signaling	0
pathways	0
.	0

It	0
is	0
well	0
established	0
that	0
the	0
two	0
major	0
glial	7
cells	8
in	0
the	0
central	0
nervous	0
system	0
(	0
CNS	0
)	0
,	0
astrocytes	7
and	0
microglia	7
,	0
are	0
key	0
participants	0
in	0
mediating	0
the	0
neurologic	0
dysfunction	0
associated	0
with	0
HIV	0
infection	0
of	0
the	0
CNS	0
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
ability	0
of	0
the	0
major	9
envelope	10
glycoprotein	10
of	0
HIV	0
,	0
glycoprotein	9
120	10
(	0
gp120	9
)	0
,	0
to	0
regulate	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
expression	0
in	0
glial	7
cells	8
,	0
because	0
ICAM-1	9
is	0
important	0
in	0
mediating	0
immune	0
responsiveness	0
in	0
the	0
CNS	0
,	0
facilitating	0
entry	0
of	0
HIV-infected	7
cells	8
into	0
the	0
CNS	0
,	0
and	0
promoting	0
syncytia	0
formation	0
.	0

Our	0
results	0
indicate	0
that	0
gp120	9
enhances	0
ICAM-1	9
gene	0
expression	0
in	0
primary	7
rat	8
astrocytes	8
,	0
primary	7
human	8
astrocytes	8
,	0
a	0
human	5
astroglioma	6
cell	6
line	6
CRT	6
,	0
and	0
primary	7
rat	8
microglia	8
.	0

The	0
signal	0
transduction	0
events	0
involved	0
in	0
gp120	9
-mediated	0
enhancement	0
of	0
ICAM-1	9
appear	0
to	0
involve	0
activation	0
of	0
both	0
protein	9
kinase	10
C	10
and	0
tyrosine	9
kinase	10
,	0
because	0
inhibitors	0
of	0
protein	9
kinase	10
C	10
and	0
tyrosine	9
kinase	10
abrogate	0
gp120	9
-mediated	0
ICAM-1	9
expression	0
in	0
both	0
astrocytes	7
and	0
microglia	7
.	0

Moreover	0
,	0
gp120	9
induces	0
tyrosine	0
phosphorylation	0
of	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	0
STAT-1	9
alpha	10
)	0
as	0
well	0
as	0
the	0
Janus	9
kinase	10
(	0
JAK2	9
)	0
in	0
glial	7
cells	8
.	0

We	0
also	0
demonstrate	0
that	0
gp120	9
-mediated	0
ICAM-1	9
expression	0
has	0
functional	0
significance	0
,	0
as	0
it	0
enhances	0
the	0
ability	0
of	0
monocytic	7
cells	8
to	0
bind	0
to	0
gp120-stimulated	7
human	8
astrocytes	8
in	0
an	0
ICAM-1	9
/beta	0
2	0
integrin	9
-dependent	0
fashion	0
.	0

These	0
results	0
provide	0
new	0
insights	0
into	0
how	0
gp120	9
can	0
influence	0
the	0
involvement	0
of	0
glial	7
cells	8
in	0
the	0
pathogenesis	0
of	0
AIDS	0
dementia	0
complex	0
.	0

IL-10	9
cooperates	0
with	0
TNF-alpha	9
to	0
activate	0
HIV-1	0
from	0
latently	7
and	8
acutely	8
infected	8
cells	8
of	0
monocyte/macrophage	7
lineage	8
.	0

IL-10	9
is	0
elevated	0
in	0
HIV-1-infected	0
individuals	0
and	0
has	0
been	0
implicated	0
in	0
disease	0
progression	0
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
effects	0
of	0
IL-10	9
on	0
the	0
activation	0
of	0
HIV-1	0
from	0
infected	7
monocytes	8
and	0
macrophages	7
.	0

Although	0
IL-10	9
alone	0
did	0
not	0
induce	0
HIV-1	0
replication	0
,	0
in	0
the	0
presence	0
of	0
TNF-alpha	9
,	0
IL-10	9
markedly	0
enhanced	0
virion	0
production	0
from	0
a	0
chronically	0
infected	0
promonocytic	5
cell	6
line	6
(	0
U1	5
)	0
and	0
in	0
acutely	0
infected	0
monocyte-derived	7
macrophages	8
.	0

Neutralizing	0
mAbs	9
to	0
IL-10	9
and	0
TNF-alpha	9
indicated	0
that	0
both	0
cytokines	9
were	0
essential	0
for	0
the	0
induction	0
and	0
were	0
required	0
to	0
generate	0
a	0
synergistic	0
increase	0
in	0
virus	0
expression	0
.	0

The	0
effects	0
of	0
the	0
two	0
cytokines	9
were	0
distinguishable	0
functionally	0
since	0
pretreatment	0
with	0
TNF-alpha	9
attenuated	0
the	0
cytokine	9
cooperativity	0
,	0
while	0
pretreatment	0
with	0
IL-10	9
potentiated	0
their	0
cooperativity	0
,	0
suggesting	0
that	0
IL-10	9
and	0
TNF-alpha	9
play	0
different	0
roles	0
in	0
the	0
activation	0
of	0
virus	0
.	0

Northern	0
blot	0
analysis	0
as	0
well	0
as	0
Ab	0
blocking	0
and	0
cytokine	9
secretion	0
studies	0
indicated	0
that	0
the	0
induction	0
of	0
either	0
endogenous	9
TNF-alpha	10
or	0
IL-10	9
was	0
not	0
involved	0
in	0
the	0
cooperativity	0
,	0
nor	0
was	0
an	0
up-regulation	0
of	0
TNF-alpha	9
receptors	10
.	0

In	0
combination	0
with	0
TNF-alpha	9
,	0
IL-10	9
stimulated	0
activating	9
protein-1	10
(	0
AP-1	9
)	0
and	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
binding	0
activities	0
and	0
cooperated	0
to	0
increase	0
HIV-1	0
steady-state	0
mRNA	0
levels	0
and	0
enhance	0
long	1
terminal	2
repeat	2
-directed	0
transcription	0
through	0
activation	0
of	0
the	0
NF-kappa	1
B	2
binding	2
sites	2
,	0
suggesting	0
the	0
IL-10	9
effect	0
occurs	0
at	0
least	0
in	0
part	0
at	0
the	0
transcriptional	0
level	0
.	0

These	0
results	0
indicate	0
that	0
IL-10	9
,	0
in	0
addition	0
to	0
down-regulating	0
the	0
cellular	0
immune	0
response	0
to	0
HIV-1	0
,	0
may	0
also	0
play	0
a	0
role	0
in	0
TNF-alpha	9
-mediated	0
activation	0
of	0
HIV-1	0
replication	0
in	0
the	0
monocyte/macrophage	7
lineage	8
.	0

Interaction	0
of	0
HTLV-I	9
Tax	10
with	0
the	0
human	9
proteasome	10
:	0
implications	0
for	0
NF-kappa	9
B	10
induction	0
.	0

The	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
has	0
been	0
etiologically	0
associated	0
with	0
the	0
development	0
of	0
the	0
adult	0
T-cell	0
leukemia	0
(	0
ATL	0
)	0
as	0
well	0
as	0
degenerative	0
neurologic	0
syndrome	0
termed	0
tropical	0
spastic	0
paraparesis	0
(	0
TSP	0
)	0
.	0

HTLV-I	0
encodes	0
a	0
potent	0
transactivator	9
protein	0
termed	0
Tax	9
that	0
appears	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
process	0
of	0
T-cell	0
immortalization	0
.	0

Even	0
though	0
the	0
mechanisms	0
by	0
which	0
Tax	9
induces	0
transformation	0
are	0
still	0
unknown	0
,	0
it	0
seems	0
likely	0
that	0
the	0
ability	0
of	0
Tax	9
to	0
alter	0
the	0
expression	0
of	0
many	0
cellular	1
genes	2
plays	0
an	0
important	0
part	0
in	0
this	0
process	0
.	0

Tax	9
does	0
not	0
bind	0
directly	0
to	0
DNA	0
but	0
rather	0
deregulates	0
the	0
activity	0
of	0
cellular	9
transcription	10
factors	10
.	0

One	0
family	0
of	0
host	9
transcription	10
factors	10
whose	0
activity	0
is	0
altered	0
by	0
Tax	9
includes	0
NF-kappa	9
B/Rel	10
.	0

These	0
transcription	9
factors	10
are	0
post-transcriptionally	0
regulated	0
by	0
their	0
assembly	0
with	0
a	0
second	0
family	0
of	0
inhibitory	9
proteins	10
termed	0
I	9
kappa	10
B	10
that	0
serve	0
to	0
sequester	0
the	0
NF-kappa	9
B/Rel	10
complexes	10
in	0
the	0
cytoplasm	0
.	0

Upon	0
cellular	0
activation	0
,	0
I	9
kappa	10
B	10
alpha	10
is	0
phosphorylated	0
,	0
polyubiquitinated	0
,	0
and	0
degraded	0
in	0
the	0
proteasome	9
.	0

This	0
proteolytic	0
event	0
liberates	0
NF-kappa	9
B	10
,	0
permitting	0
its	0
rapid	0
translocation	0
into	0
the	0
nucleus	0
where	0
it	0
binds	0
to	0
its	0
cognate	1
enhancer	2
elements	2
.	0

Similarly	0
,	0
the	0
p105	9
precursor	10
of	0
the	0
NF-kappa	9
B	10
p50	9
subunit	10
is	0
also	0
post-translationally	0
processed	0
in	0
the	0
proteasome	9
.	0

The	0
mechanisms	0
by	0
which	0
Tax	9
activates	0
NF-kappa	9
B	10
remain	0
unclear	0
,	0
and	0
findings	0
presented	0
in	0
the	0
literature	0
are	0
often	0
controversial	0
.	0

We	0
identified	0
a	0
physical	0
interaction	0
between	0
Tax	9
and	0
the	0
HsN3	9
subunit	10
of	0
the	0
human	9
proteasome	10
.	0

This	0
raises	0
the	0
intriguing	0
possibility	0
that	0
physical	0
association	0
of	0
the	0
HsN3	9
proteasome	10
subunit	10
with	0
HTLV-I	9
Tax	10
coupled	0
with	0
the	0
independent	0
interaction	0
of	0
Tax	9
with	0
either	0
p100	0
or	0
p65-	0
I	9
kappa	10
B	10
alpha	10
targets	0
these	0
cytoplasmic	9
NF-kappa	10
B/Rel	10
complexes	10
to	0
the	0
proteasome	9
for	0
processing	0
.	0

Immunophenotype	0
of	0
intraductal	0
carcinoma	0
.	0

OBJECTIVE	0
--	0
Mammography	0
and	0
breast-conserving	0
therapy	0
have	0
focused	0
attention	0
on	0
the	0
classification	0
of	0
intraductal	0
carcinoma	0
(	0
IDC	0
)	0
and	0
emphasized	0
the	0
prognostic	0
importance	0
of	0
comedo	0
versus	0
noncomedo	0
variants	0
.	0

We	0
used	0
histochemical	0
markers	0
to	0
define	0
the	0
immunophenotype	0
of	0
43	0
IDCs	0
with	0
respect	0
to	0
comedo	0
versus	0
noncomedo	0
status	0
and	0
patterns	0
of	0
angiogenesis	0
.	0

RESULTS	0
--	0
Reactions	0
in	0
comedo	0
carcinomas	0
were	0
significantly	0
negative	0
for	0
estrogen	9
receptor	10
and	0
progesterone	9
receptor	10
,	0
and	0
positive	0
for	0
p53	9
and	0
HER-2/neu	9
more	0
often	0
than	0
the	0
noncomedo	0
variant	0
.	0

All	0
seven	0
IDCs	0
associated	0
with	0
Paget	0
's	0
disease	0
showed	0
positive	0
reactions	0
for	0
HER-2/neu	9
.	0

Basement	0
membrane	0
immunoreactivity	0
for	0
type	9
IV	10
collagen	10
and	0
laminin	9
was	0
discontinuous	0
in	0
most	0
examples	0
of	0
IDC	0
regardless	0
of	0
type	0
,	0
with	0
a	0
trend	0
toward	0
more	0
intense	0
staining	0
in	0
comedo	0
than	0
in	0
noncomedo	0
carcinomas	0
.	0

Periductal	0
angiogenesis	0
was	0
not	0
significantly	0
related	0
to	0
the	0
type	0
of	0
IDC	0
but	0
was	0
more	0
pronounced	0
with	0
comedo	0
carcinomas	0
.	0

CONCLUSIONS	0
--	0
These	0
observations	0
indicate	0
that	0
there	0
are	0
immunophenotypic	0
correlates	0
to	0
the	0
current	0
structural	0
classification	0
of	0
IDC	0
.	0

The	0
immunophenotype	0
of	0
IDC	0
is	0
helpful	0
in	0
subclassifying	0
an	0
IDC	0
and	0
could	0
prove	0
useful	0
as	0
a	0
prognostic	0
indicator	0
for	0
local	0
control	0
in	0
patients	0
treated	0
by	0
breast-conserving	0
therapy	0
.	0

Inhibition	0
of	0
protein	9
phosphatase	10
2A	10
induces	0
serine/threonine	0
phosphorylation	0
,	0
subcellular	0
redistribution	0
,	0
and	0
functional	0
inhibition	0
of	0
STAT3	9
.	0

Signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
STATs	9
)	0
are	0
rapidly	0
phosphorylated	0
on	0
tyrosine	0
residues	0
in	0
response	0
to	0
cytokine	9
and	0
growth	9
factor	10
stimulation	0
of	0
cell	9
surface	10
receptors	10
.	0

STATs	9
hereafter	0
are	0
translocated	0
to	0
the	0
nucleus	0
where	0
they	0
act	0
as	0
transcription	9
factors	10
.	0

Recent	0
reports	0
suggest	0
that	0
serine	0
phosphorylation	0
of	0
STATs	9
also	0
is	0
involved	0
in	0
the	0
regulation	0
of	0
STAT	9
-mediated	0
gene	0
transcription	0
.	0

Here	0
,	0
we	0
studied	0
the	0
role	0
of	0
serine/threonine	9
phosphatases	10
in	0
STAT3	9
signaling	0
in	0
human	5
antigen-specific	6
CD4	6
(	6
+	6
)	6
T	6
cell	6
lines	6
and	0
cutaneous	5
T	6
cell	6
lymphoma	6
lines	6
,	0
expressing	0
a	0
constitutively	0
activated	0
STAT3	9
.	0

We	0
show	0
that	0
an	0
inhibitor	0
of	0
protein	9
phosphatases	10
(	0
PPs	9
)	0
PP1/PP2A	9
,	0
calyculin	9
A	10
,	0
induces	0
(	0
i	0
)	0
phosphorylation	0
of	0
STAT3	9
on	0
serine	0
and	0
threonine	0
residues	0
,	0
(	0
ii	0
)	0
inhibition	0
of	0
STAT3	9
tyrosine	0
phosphorylation	0
and	0
DNA	0
binding	0
activity	0
,	0
and	0
(	0
iii	0
)	0
relocation	0
of	0
STAT3	9
from	0
the	0
nucleus	0
to	0
the	0
cytoplasm	0
.	0

Similar	0
results	0
were	0
obtained	0
with	0
other	0
PP2A	0
inhibitors	0
(	0
okadaic	0
acid	0
,	0
endothall	0
thioanhydride	0
)	0
but	0
not	0
with	0
inhibitors	0
of	0
PP1	9
(	0
tautomycin	0
)	0
or	0
PP2B	9
(	0
cyclosporine	0
A	0
)	0
.	0

Pretreatment	0
with	0
the	0
broad	0
serine/threonine	0
kinase	0
inhibitor	0
staurosporine	0
partly	0
blocked	0
the	0
calyculin	9
A	10
-induced	0
STAT3	9
phosphorylation	0
,	0
whereas	0
inhibitors	0
of	0
serine/threonine	9
kinases	10
,	0
such	0
as	0
mitogen-activated	9
protein	10
kinase-1	10
extracellular-regulated	10
kinase-kinase	10
,	0
mitogen-activated	9
protein	10
p38	10
kinase	10
,	0
and	0
phosphatidylinositol	9
3-kinase	10
,	0
did	0
not	0
.	0

In	0
conclusion	0
,	0
we	0
provide	0
evidence	0
that	0
PP2A	9
plays	0
a	0
crucial	0
role	0
in	0
the	0
regulation	0
of	0
STAT3	9
phosphorylation	0
and	0
subcellular	0
distribution	0
in	0
T	7
cells	8
.	0

Moreover	0
,	0
our	0
findings	0
suggest	0
that	0
the	0
level	0
of	0
STAT3	9
phosphorylation	0
is	0
balanced	0
between	0
a	0
staurosporine-sensitive	9
kinase	10
(	0
s	0
)	0
and	0
PP2A	9
.	0

Polyamines	0
in	0
human	0
breast	0
cancer	0
and	0
its	0
relations	0
to	0
classical	0
prognostic	0
features	0
:	0
clinical	0
implications	0
.	0

Experimental	0
evidence	0
suggest	0
an	0
important	0
role	0
of	0
polyamines	0
in	0
breast	0
cancer	0
development	0
.	0

Polyamines	0
have	0
been	0
determined	0
in	0
tissue	0
and	0
erythrocyte	0
samples	0
from	0
100	0
patients	0
with	0
primary	0
invasive	0
breast	0
cancer	0
and	0
30	0
patients	0
with	0
fibroadenomas	0
.	0

Statistical	0
analysis	0
was	0
performed	0
in	0
order	0
to	0
determine	0
the	0
prognostic	0
value	0
of	0
the	0
polyamine	0
patterns	0
of	0
tumor	0
tissues	0
and	0
erythrocytes	0
in	0
comparison	0
with	0
clinical	0
and	0
histological	0
prognostic	0
factors	0
.	0

In	0
malignant	0
tissues	0
,	0
polyamine	0
levels	0
were	0
significantly	0
higher	0
than	0
in	0
benign	0
tissues	0
.	0

They	0
correlated	0
with	0
markers	0
of	0
tumor	0
aggressivity	0
(	0
axillary	0
node	0
involvement	0
and	0
especially	0
with	0
markers	0
of	0
high	0
mitotic	0
rate	0
as	0
Ki-67	0
staining	0
,	0
histological	0
grade	0
)	0
.	0

No	0
correlation	0
was	0
found	0
between	0
estrogen	0
and	0
progesterone	0
status	0
,	0
tumor	0
size	0
and	0
polyamine	0
concentrations	0
.	0

Erythrocyte	0
polyamines	0
levels	0
were	0
identical	0
between	0
cancer	0
patients	0
and	0
controls	0
.	0

The	0
knowledge	0
of	0
the	0
polyamine	0
pattern	0
in	0
breast	0
cancer	0
could	0
become	0
useful	0
in	0
clinical	0
practice	0
particularly	0
if	0
polyamine	0
metabolism	0
is	0
targeted	0
as	0
a	0
therapeutic	0
approach	0
.	0

Signal	0
transduction	0
pathways	0
triggered	0
by	0
the	0
FcepsilonRIIb	9
receptor	10
(	0
CD23	9
)	0
in	0
human	7
monocytes	8
lead	0
to	0
nuclear	9
factor-kappaB	10
activation	0
.	0

BACKGROUND	0
:	0
Alveolar	7
macrophages	8
play	0
a	0
key	0
role	0
in	0
the	0
initiation	0
of	0
the	0
inflammatory	0
reaction	0
of	0
allergic	0
asthma	0
.	0

Alveolar	7
macrophages	8
and	0
peripheral	7
blood	8
monocytes	8
are	0
activated	0
when	0
IgE/allergen	9
immune	10
complexes	10
bind	0
to	0
the	0
CD23	9
receptor	10
,	0
which	0
leads	0
to	0
the	0
production	0
of	0
inflammatory	9
cytokines	10
.	0

OBJECTIVE	0
:	0
We	0
sought	0
to	0
investigate	0
the	0
molecular	0
mechanisms	0
regulating	0
this	0
early	0
inflammatory	0
response	0
.	0

We	0
have	0
focused	0
on	0
the	0
study	0
of	0
the	0
signal	0
transduction	0
pathways	0
triggered	0
by	0
CD23	9
in	0
human	7
monocytes	8
and	0
the	0
promonocytic	5
cell	6
line	6
U937	6
.	0

METHODS	0
:	0
CD23	9
was	0
cross-linked	0
in	0
human	7
monocytes	8
and	0
U937	5
cells	6
with	0
IgE	9
immune	10
complexes	10
.	0

Surface	0
expression	0
of	0
CD23	9
was	0
determined	0
by	0
FACS	0
analysis	0
.	0

Transcription	9
factor	10
activation	0
and	0
gene	0
transcription	0
were	0
studied	0
by	0
gel-shift	0
assays	0
and	0
Northern	0
blot	0
analysis	0
,	0
respectively	0
.	0

IkappaBalpha	9
phosphorylation	0
and	0
degradation	0
was	0
analyzed	0
by	0
Western	0
blot	0
.	0

RESULTS	0
:	0
Nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
is	0
the	0
main	0
transcription	0
factor	0
involved	0
in	0
the	0
gene	0
activation	0
that	0
follows	0
CD23	9
cross-linking	0
in	0
monocytes	7
.	0

CD23-induced	9
NF-kappaB	10
is	0
a	0
heterodimer	0
composed	0
of	0
p65/p50	9
subunits	10
.	0

NF-kappaB	0
nuclear	0
translocation	0
is	0
secondary	0
to	0
the	0
phosphorylation	0
and	0
subsequent	0
degradation	0
of	0
the	0
NF-kappaB	9
inhibitory	10
molecule	10
IkappaBalpha	9
.	0

Tyrosine	9
kinase	10
-dependent	0
,	0
and	0
not	0
protein	9
kinase	10
C	10
-dependent	0
,	0
pathways	0
mediate	0
CD23	9
-triggered	0
NF-kappaB	9
activation	0
but	0
do	0
not	0
participate	0
in	0
the	0
direct	0
phosphorylation	0
of	0
IkappaBalpha	9
.	0

IkappaBalpha	9
degradation	0
and	0
NF-kappaB	9
nuclear	0
translocation	0
correlate	0
with	0
transcriptional	0
activation	0
of	0
the	0
inflammatory	9
cytokines	10
TNF-alpha	9
and	0
IL-1beta	0
.	0

CONCLUSIONS	0
:	0
NF-kappaB	9
is	0
the	0
main	0
transcription	0
factor	0
involved	0
in	0
the	0
signal	0
transduction	0
pathway	0
of	0
CD23	9
in	0
monocytes	7
.	0

Suppression	0
of	0
TNFalpha	9
-mediated	0
NFkappaB	9
activity	0
by	0
myricetin	0
and	0
other	0
flavonoids	0
through	0
downregulating	0
the	0
activity	0
of	0
IKK	9
in	0
ECV304	5
cells	6
.	0

Flavonoids	0
are	0
a	0
group	0
of	0
naturally-occurring	0
phenolic	0
compounds	0
in	0
the	0
plant	0
kingdom	0
,	0
and	0
many	0
flavonoids	0
are	0
found	0
with	0
vascular	0
protective	0
properties	0
.	0

Nevertheless	0
how	0
the	0
protective	0
response	0
is	0
exerted	0
by	0
flavonoids	0
is	0
not	0
well	0
characterized	0
.	0

In	0
view	0
of	0
the	0
nuclear	9
factor-kappaB	10
(	0
NFkappaB	9
)	0
may	0
play	0
a	0
central	0
role	0
in	0
the	0
initiation	0
of	0
atherosclerosis	0
,	0
prevention	0
of	0
the	0
activation	0
of	0
NFkappaB	9
represents	0
an	0
important	0
role	0
in	0
protecting	0
vascular	0
injury	0
.	0

In	0
this	0
study	0
,	0
the	0
effects	0
of	0
flavonoids	0
on	0
NFkappaB	9
/inhibitor-kappaB	0
(	0
IkappaB	9
)	0
system	0
in	0
ECV304	5
cells	6
activated	0
with	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNFalpha	9
)	0
were	0
examined	0
.	0

We	0
investigated	0
the	0
inhibitory	0
action	0
of	0
six	0
flavonoids	0
on	0
IkappaB	9
kinase	10
(	0
IKK	9
)	0
activity	0
,	0
an	0
enzyme	0
recently	0
found	0
to	0
phosphorylate	0
critical	0
serine	0
residues	0
of	0
IkappaB	0
for	0
degradation	0
.	0

Of	0
six	0
flavonoids	0
tested	0
,	0
myricetin	0
was	0
found	0
to	0
strongly	0
inhibit	0
IKK	9
kinase	0
activity	0
,	0
and	0
prevent	0
the	0
degradation	0
of	0
IkappaBalpha	9
and	0
IkappaBbeta	9
in	0
activated	0
endothelial	0
cells	0
.	0

Furthermore	0
,	0
myricetin	0
was	0
also	0
found	0
to	0
inhibit	0
NFkappaB	9
activity	0
correlated	0
with	0
suppression	0
of	0
monocyte	0
adhesion	0
to	0
ECV304	5
cells	6
.	0

Therefore	0
we	0
conclude	0
that	0
flavonoids	0
may	0
be	0
of	0
therapeutic	0
value	0
for	0
vascular	0
disease	0
through	0
down	0
regulation	0
of	0
NFkappaB	9
/IkappaB	9
system	0
.	0

Copyright	0
1999	0
Wiley-Liss	0
,	0
Inc	0
.	0

Bcl-2	9
-mediated	0
drug	0
resistance	0
:	0
inhibition	0
of	0
apoptosis	0
by	0
blocking	0
nuclear	9
factor	10
of	10
activated	10
T	10
lymphocytes	10
(	0
NFAT	9
)	0
-induced	0
Fas	9
ligand	0
transcription	0
.	0

Bcl-2	9
inhibits	0
apoptosis	0
induced	0
by	0
a	0
variety	0
of	0
stimuli	0
,	0
including	0
chemotherapy	0
drugs	0
and	0
glucocorticoids	0
.	0

It	0
is	0
generally	0
accepted	0
that	0
Bcl-2	9
exerts	0
its	0
antiapoptotic	0
effects	0
mainly	0
by	0
dimerizing	0
with	0
proapoptotic	0
members	0
of	0
the	0
Bcl-2	9
family	10
such	0
as	0
Bax	9
and	0
Bad	9
.	0

However	0
,	0
the	0
mechanism	0
of	0
the	0
antiapoptotic	0
effects	0
is	0
unclear	0
.	0

Paclitaxel	0
and	0
other	0
drugs	0
that	0
disturb	0
microtubule	9
dynamics	0
kill	0
cells	0
in	0
a	0
Fas	9
/Fas	9
ligand	10
(	0
FasL	9
)	0
-dependent	0
manner	0
;	0
antibody	0
to	0
FasL	9
inhibits	0
paclitaxel-induced	0
apoptosis	0
.	0

We	0
have	0
found	0
that	0
Bcl-2	9
overexpression	0
leads	0
to	0
the	0
prevention	0
of	0
chemotherapy	0
(	0
paclitaxel	0
)	0
-induced	0
expression	0
of	0
FasL	9
and	0
blocks	0
paclitaxel-induced	0
apoptosis	0
.	0

The	0
mechanism	0
of	0
this	0
effect	0
is	0
that	0
Bcl-2	9
prevents	0
the	0
nuclear	0
translocation	0
of	0
NFAT	9
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
lymphocytes	10
,	0
a	0
transcription	9
factor	10
activated	0
by	0
microtubule	9
damage	0
)	0
by	0
binding	0
and	0
sequestering	0
calcineurin	0
,	0
a	0
calcium-dependent	0
phosphatase	0
that	0
must	0
dephosphorylate	0
NFAT	9
to	0
move	0
to	0
the	0
nucleus	0
.	0

Without	0
NFAT	9
nuclear	0
translocation	0
,	0
the	0
FasL	9
gene	0
is	0
not	0
transcribed	0
.	0

Thus	0
,	0
it	0
appears	0
that	0
paclitaxel	0
and	0
other	0
drugs	0
that	0
disturb	0
microtubule	9
function	0
kill	0
cells	0
at	0
least	0
in	0
part	0
through	0
the	0
induction	0
of	0
FasL	9
.	0

Furthermore	0
,	0
Bcl-2	9
antagonizes	0
drug-induced	0
apoptosis	0
by	0
inhibiting	0
calcineurin	9
activation	0
,	0
blocking	0
NFAT	9
nuclear	0
translocation	0
,	0
and	0
preventing	0
FasL	9
expression	0
.	0

The	0
effects	0
of	0
Bcl-2	9
can	0
be	0
overcome	0
,	0
at	0
least	0
partially	0
,	0
through	0
phosphorylation	0
of	0
Bcl-2	9
.	0

Phosphorylated	0
Bcl-2	9
can	0
not	0
bind	0
calcineurin	9
,	0
and	0
NFAT	9
activation	0
,	0
FasL	9
expression	0
,	0
and	0
apoptosis	0
can	0
occur	0
after	0
Bcl-2	9
phosphorylation	0
.	0

MHC-peptide	0
ligand	0
interactions	0
establish	0
a	0
functional	0
threshold	0
for	0
antigen-specific	0
T	0
cell	0
recognition	0
.	0

Antigen-specific	0
T	0
cell	0
recognition	0
is	0
dependent	0
on	0
the	0
functional	0
density	0
of	0
the	0
TCR	9
-ligand	0
,	0
which	0
consists	0
of	0
specific	0
MHC	9
molecules	10
and	0
a	0
specifically	0
bound	0
peptide	0
.	0

We	0
have	0
examined	0
the	0
influence	0
of	0
the	0
affinity	0
and	0
concentration	0
of	0
exogenous	0
peptide	0
and	0
the	0
density	0
of	0
specific	0
MHC	9
molecules	10
on	0
the	0
proliferation	0
of	0
a	0
CD4+	5
,	6
DQA1*0501/DQB1*0201	6
(	6
DQ2.1	6
)	6
-restricted	6
,	6
HSV-2-specific	6
T	6
cell	6
clone	6
.	0

Using	0
antigen	0
peptide	0
analogs	0
with	0
different	0
mutations	0
of	0
known	0
DQ2-anchor	0
residues	0
,	0
T	0
cell	0
response	0
was	0
reduced	0
in	0
an	0
peptide-affinity	0
and	0
-	0
concentration	0
specific	0
manner	0
.	0

The	0
decrease	0
using	0
weaker	0
binding	0
peptides	0
was	0
gradual	0
as	0
stimulation	0
with	0
a	0
peptide	0
with	0
intermediate	0
affinity	0
yielded	0
intermediate	0
T	7
cell	8
proliferation	0
and	0
the	0
poorest	0
binding	0
peptide	0
induced	0
an	0
even	0
weaker	0
T	7
cell	8
response	0
.	0

MHC	9
class	10
II	10
density	0
on	0
the	0
APC	7
was	0
modified	0
using	0
DQ2	5
homo	6
-and	6
heterozygous	6
B-LCLs	6
as	0
APCs	7
,	0
however	0
this	0
variation	0
of	0
MHC	0
concentration	0
had	0
no	0
effect	0
on	0
T	7
cell	8
proliferation	0
.	0

We	0
interpret	0
this	0
as	0
a	0
reflection	0
of	0
a	0
low	0
threshold	0
for	0
activation	0
of	0
the	0
T	5
cell	6
clone	6
,	0
in	0
which	0
peptide-	0
MHC	9
avidity	0
is	0
the	0
over-riding	0
determinant	0
of	0
the	0
strength	0
of	0
ligand	0
signal	0
.	0

Regulatory	0
effects	0
of	0
interleukin-11	9
during	0
acute	0
lung	0
inflammatory	0
injury	0
.	0

The	0
role	0
of	0
interleukin-11	9
(	0
IL-11	9
)	0
was	0
evaluated	0
in	0
the	0
IgG	9
immune	10
complex	10
model	0
of	0
acute	0
lung	0
injury	0
in	0
rats	0
.	0

IL-11	3
mRNA	4
and	0
protein	0
were	0
both	0
up-regulated	0
during	0
the	0
course	0
of	0
this	0
inflammatory	0
response	0
.	0

Exogenously	0
administered	0
IL-11	9
substantially	0
reduced	0
,	0
in	0
a	0
dose-dependent	0
manner	0
,	0
the	0
intrapulmonary	0
accumulation	0
of	0
neutrophils	7
and	0
the	0
lung	0
vascular	0
leak	0
of	0
albumin	9
.	0

These	0
in	0
vivo	0
anti-inflammatory	0
effects	0
of	0
IL-11	9
were	0
associated	0
with	0
reduced	0
NF-kappaB	9
activation	0
in	0
lung	0
,	0
reduced	0
levels	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
in	0
bronchoalveolar	0
lavage	0
(	0
BAL	0
)	0
fluids	0
,	0
and	0
diminished	0
up-regulation	0
of	0
lung	9
vascular	10
ICAM-1	10
.	0

It	0
is	0
interesting	0
that	0
IL-11	9
did	0
not	0
affect	0
BAL	0
fluid	0
content	0
of	0
the	0
CXC	9
chemokines	10
,	0
macrophage	9
inflammatory	10
protein-2	10
(	0
MIP-2	9
)	0
and	0
cytokine-inducible	9
neutrophil	10
chemoattractant	10
(	0
CINC	9
)	0
;	0
the	0
presence	0
of	0
IL-11	9
did	0
not	0
affect	0
these	0
chemokines	9
.	0

However	0
,	0
BAL	0
content	0
of	0
C5a	0
was	0
reduced	0
by	0
IL-11	9
.	0

These	0
data	0
indicate	0
that	0
IL-11	9
is	0
a	0
regulatory	9
cytokine	10
in	0
the	0
lung	0
and	0
that	0
,	0
like	0
other	0
members	0
of	0
this	0
family	0
,	0
its	0
anti-inflammatory	0
properties	0
appear	0
to	0
be	0
linked	0
to	0
its	0
suppression	0
of	0
NF-kappaB	9
activation	0
,	0
diminished	0
production	0
of	0
TNF-alpha	9
,	0
and	0
reduced	0
up-regulation	0
of	0
lung	9
vascular	10
ICAM-1	10
.	0

Thrombopoietin	9
induces	0
tyrosine	0
phosphorylation	0
of	0
Stat3	9
and	0
Stat5	9
in	0
human	7
blood	8
platelets	8
.	0

Thrombopoietin	9
is	0
known	0
to	0
be	0
essential	0
for	0
megakaryocytopoiesis	0
and	0
thrombopoiesis	0
.	0

Recently	0
,	0
we	0
and	0
others	0
have	0
shown	0
that	0
thrombopoietin	9
induces	0
rapid	0
tyrosine	0
phosphorylation	0
of	0
Jak2	9
and	0
other	0
proteins	0
in	0
human	7
platelets	8
and	0
BaF3	5
cells	6
,	0
genetically	0
engineered	0
to	0
express	0
c-Mpl	9
,	0
a	0
receptor	0
for	0
thrombopoietin	9
.	0

The	0
Jak	0
family	0
of	0
tyrosine	9
kinases	10
are	0
known	0
to	0
mediate	0
some	0
of	0
the	0
effects	0
of	0
cytokines	9
or	0
hematopoietic	9
growth	10
factors	10
by	0
recruitment	0
and	0
tyrosine	0
phosphorylation	0
of	0
a	0
variety	0
of	0
Stat	9
(	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
)	0
proteins	0
.	0

Hence	0
,	0
we	0
have	0
investigated	0
whether	0
Stat	9
proteins	10
are	0
present	0
in	0
platelets	7
and	0
,	0
if	0
so	0
,	0
whether	0
they	0
become	0
tyrosine	0
phosphorylated	0
in	0
response	0
to	0
thrombopoietin	9
.	0

We	0
immunologically	0
identified	0
Stat1	9
,	0
Stat2	9
,	0
Stat3	9
,	0
and	0
Stat5	9
in	0
human	0
platelet	0
lysates	0
.	0

Thrombopoietin	9
induced	0
tyrosine	0
phosphorylation	0
of	0
Stat3	9
and	0
Stat5	9
in	0
these	0
cells	0
.	0

Thrombopoietin	9
also	0
induced	0
tyrosine	0
phosphorylation	0
of	0
Stat3	9
and	0
Stat5	9
in	0
FDCP-2	5
cells	6
genetically	0
engineered	0
to	0
constitutively	0
express	0
human	9
c-Mpl	10
.	0

Thus	0
,	0
our	0
data	0
indicate	0
that	0
Stat3	9
and	0
Stat5	9
may	0
be	0
involved	0
in	0
signal	0
transduction	0
after	0
ligand	0
binding	0
to	0
c-Mpl	9
and	0
that	0
this	0
event	0
may	0
have	0
a	0
role	0
in	0
megakaryopoiesis/thrombopoiesis	0
or	0
possibly	0
a	0
mature	0
platelet	0
function	0
such	0
as	0
aggregation	0
.	0

Mechanisms	0
that	0
contribute	0
to	0
the	0
development	0
of	0
lymphoid	0
malignancies	0
:	0
roles	0
for	0
genetic	0
alterations	0
and	0
cytokine	9
production	0
.	0

Recent	0
studies	0
have	0
defined	0
genetic	0
alterations	0
commonly	0
associated	0
with	0
transformed	5
lymphocytes	6
.	0

This	0
review	0
suggests	0
roles	0
for	0
these	0
alterations	0
in	0
the	0
development	0
of	0
lymphoid	0
neoplasms	0
.	0

Damage	0
to	0
the	0
genes	0
encoding	0
proteins	0
that	0
function	0
in	0
intracellular	0
signaling	0
,	0
transcription	0
,	0
or	0
regulation	0
of	0
the	0
cell	0
cycle	0
has	0
been	0
identified	0
and	0
linked	0
at	0
varying	0
degrees	0
to	0
the	0
progression	0
of	0
certain	0
lymphoid	0
malignancies	0
.	0

An	0
understanding	0
of	0
the	0
mechanistic	0
consequences	0
following	0
such	0
genetic	0
alterations	0
is	0
essential	0
to	0
an	0
understanding	0
of	0
the	0
development	0
of	0
these	0
lymphoid	0
neoplasms	0
.	0

In	0
contrast	0
,	0
it	0
is	0
also	0
becoming	0
clear	0
that	0
the	0
dysregulated	0
expression	0
of	0
proteins	0
that	0
are	0
not	0
genetically	0
altered	0
can	0
also	0
contribute	0
to	0
the	0
progression	0
of	0
lymphoid	0
malignancies	0
.	0

One	0
such	0
example	0
is	0
the	0
excessive	0
expression	0
of	0
``	9
normal	10
''	10
lymphokines	10
of	0
cytokines	9
which	0
accompanies	0
many	0
lymphoproliferative	0
diseases	0
.	0

The	0
dysregulated	0
expression	0
of	0
cytokines	9
during	0
malignancy	0
can	0
result	0
in	0
the	0
augmentation	0
of	0
growth	0
of	0
transformed	5
lymphocytes	6
,	0
as	0
well	0
as	0
an	0
alteration	0
of	0
the	0
anti-tumor	0
immune	0
response	0
.	0

The	0
latter	0
mechanism	0
is	0
especially	0
important	0
because	0
evasion	0
of	0
the	0
impending	0
immune	0
response	0
is	0
a	0
prerequisite	0
for	0
the	0
progression	0
of	0
lymphoproliferative	0
diseases	0
.	0

Taken	0
together	0
,	0
this	0
review	0
supports	0
the	0
notion	0
that	0
the	0
development	0
of	0
lymphoid	0
malignancies	0
is	0
multifactorial	0
,	0
involving	0
genetic	0
alterations	0
as	0
well	0
as	0
dysregulated	0
cytokine	9
expression	0
.	0

Dehydroepiandrosterone	0
modulation	0
of	0
lipopolysaccharide-stimulated	0
monocyte	0
cytotoxicity	0
.	0

Dehydroepiandrosterone	0
(	0
DHEA	0
)	0
,	0
the	0
predominant	0
androgen	0
secreted	0
by	0
the	0
adrenal	0
cortex	0
,	0
can	0
be	0
converted	0
to	0
both	0
potent	0
androgens	0
and	0
estrogens	0
.	0

In	0
addition	0
to	0
its	0
role	0
as	0
a	0
precursor	0
for	0
other	0
steroid	0
hormones	0
,	0
DHEA	0
has	0
been	0
proposed	0
to	0
play	0
an	0
important	0
role	0
in	0
immunity	0
.	0

This	0
study	0
has	0
investigated	0
DHEA	0
modulation	0
of	0
LPS-induced	0
monocyte	0
cytotoxicity	0
.	0

Cytotoxicity	9
markers	10
assessed	0
include	0
tumor	0
cell	0
killing	0
,	0
IL-1	9
secretion	0
,	0
reactive	0
oxygen	0
intermediate	0
release	0
,	0
nitric	9
oxide	10
synthetase	10
activity	0
as	0
measured	0
by	0
the	0
release	0
of	0
reactive	0
nitrogen	0
intermediates	0
,	0
complement	9
receptor-1	10
cell	10
surface	10
protein	10
,	0
and	0
TNF-alpha	9
protein	10
presence	0
.	0

Monocytes	7
stimulated	0
with	0
LPS	0
concentrations	0
of	0
1.0	0
micrograms/ml	0
displayed	0
the	0
above	0
cytotoxic	0
markers	0
,	0
whereas	0
monocytes	7
stimulated	0
with	0
DHEA	0
alone	0
or	0
with	0
LPS	0
at	0
a	0
lower	0
concentration	0
of	0
0.2	0
ng/ml	0
did	0
not	0
.	0

However	0
,	0
when	0
used	0
simultaneously	0
,	0
DHEA	0
and	0
LPS	0
0.2	0
ng/ml	0
displayed	0
a	0
synergistic	0
effect	0
on	0
monocyte	0
cytotoxicity	0
against	0
cancerous	5
cell	6
lines	6
,	0
IL-1	9
secretion	0
,	0
reactive	0
nitrogen	0
intermediate	0
release	0
,	0
complement	9
receptor-1	10
cell-surface	10
protein	10
,	0
and	0
TNF-alpha	9
protein	10
to	0
levels	0
comparable	0
with	0
levels	0
obtained	0
using	0
LPS	0
1.0	0
microgram/ml	0
.	0

Finally	0
,	0
Scatchard	0
plot	0
analysis	0
demonstrated	0
the	0
presence	0
of	0
a	0
DHEA	0
receptor	0
in	0
monocytes	7
,	0
suggesting	0
that	0
DHEA	0
effects	0
on	0
LPS-stimulated	5
monocytes	6
are	0
mediated	0
through	0
a	0
receptor-dependent	0
process	0
.	0

Interferons	0
inhibit	0
activation	0
of	0
STAT6	9
by	0
interleukin	9
4	10
in	0
human	7
monocytes	8
by	0
inducing	0
SOCS-1	1
gene	2
expression	0
.	0

Interferons	9
(	0
IFNs	9
)	0
inhibit	0
induction	0
by	0
IL-4	9
of	0
multiple	0
genes	0
in	0
human	7
monocytes	8
.	0

However	0
,	0
the	0
mechanism	0
by	0
which	0
IFNs	9
mediate	0
this	0
inhibition	0
has	0
not	0
been	0
defined	0
.	0

IL-4	9
activates	0
gene	0
expression	0
by	0
inducing	0
tyrosine	0
phosphorylation	0
,	0
homodimerization	0
,	0
and	0
nuclear	0
translocation	0
of	0
the	0
latent	9
transcription	10
factor	10
,	0
STAT6	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription-6	10
)	0
.	0

STAT6	9
-responsive	0
elements	0
are	0
characteristically	0
present	0
in	0
the	0
promoters	1
of	0
IL-4-inducible	1
genes	2
.	0

Because	0
STAT6	9
activation	0
is	0
essential	0
for	0
IL-4	9
-induced	0
gene	0
expression	0
,	0
we	0
examined	0
the	0
ability	0
of	0
type	0
I	0
and	0
type	0
II	0
IFNs	9
to	0
regulate	0
activation	0
of	0
STAT6	9
by	0
IL-4	9
in	0
primary	7
human	8
monocytes	8
.	0

Pretreatment	0
of	0
monocytes	7
with	0
IFN-beta	9
or	0
IFN-gamma	9
,	0
but	0
not	0
IL-1	9
,	0
IL-2	9
,	0
macrophage	9
colony-stimulating	10
factor	10
,	0
granulocyte/macrophage	9
colony-stimulating	10
factor	10
,	0
IL-6	9
,	0
or	0
transforming	0
growth	0
factor	0
beta	0
suppressed	0
activation	0
of	0
STAT6	9
by	0
IL-4	9
.	0

This	0
inhibition	0
was	0
associated	0
with	0
decreased	0
tyrosine	0
phosphorylation	0
and	0
nuclear	0
translocation	0
of	0
STAT6	9
and	0
was	0
not	0
evident	0
unless	0
the	0
cells	0
were	0
preincubated	0
with	0
IFN	9
for	0
at	0
least	0
1	0
hr	0
before	0
IL-4	9
stimulation	0
.	0

Furthermore	0
,	0
inhibition	0
by	0
IFN	9
could	0
be	0
blocked	0
by	0
cotreatment	0
with	0
actinomycin	0
D	0
and	0
correlated	0
temporally	0
with	0
induction	0
of	0
the	0
JAK/STAT	1
inhibitory	2
gene	2
,	0
SOCS-1	1
.	0

Forced	0
expression	0
of	0
SOCS-1	1
in	0
a	0
macrophage	5
cell	6
line	6
,	0
RAW264	5
,	0
markedly	0
suppressed	0
trans-activation	0
of	0
an	0
IL-4-inducible	1
reporter	2
as	0
well	0
as	0
IL-6-	0
and	0
IFN-gamma-induced	0
reporter	0
gene	0
activity	0
.	0

These	0
findings	0
demonstrate	0
that	0
IFNs	9
inhibit	0
IL-4	9
-induced	0
activation	0
of	0
STAT6	9
and	0
STAT6	9
-dependent	0
gene	0
expression	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
inducing	0
expression	0
of	0
SOCS-1	1
.	0

An	0
activation-responsive	0
element	0
in	0
single	0
C	1
motif-1/lymphotactin	2
promoter	2
is	0
a	0
site	0
of	0
constitutive	0
and	0
inducible	0
DNA-protein	0
interactions	0
involving	0
nuclear	9
factor	10
of	10
activated	10
T	10
cell	10
.	0

Single	9
C	10
motif-1	10
(	10
SCM-1	10
)	10
/lymphotactin	10
is	0
a	0
C-type	9
chemokine	10
whose	0
expression	0
is	0
activation	0
dependent	0
,	0
cyclosporin	0
A	0
sensitive	0
and	0
restricted	0
to	0
CD8+	7
T	8
cells	8
,	0
double-negative	7
thymocytes	8
,	0
gammadelta-type	7
T	8
cells	8
,	0
and	0
NK	7
cells	8
.	0

In	0
humans	0
,	0
there	0
are	0
two	0
highly	0
homologous	1
genes	2
encoding	0
SCM-1alpha	9
and	0
SCM-1beta	9
.	0

Here	0
we	0
examined	0
the	0
regulatory	0
mechanism	0
of	0
the	0
SCM-1	1
genes	2
.	0

The	0
luciferase	1
reporter	2
gene	2
under	0
the	0
control	0
of	0
the	0
5	1
'	2
flanking	2
region	2
of	0
0.7	0
kb	0
was	0
strongly	0
induced	0
upon	0
activation	0
with	0
anti-CD3	9
or	0
PHA	9
plus	0
PMA	0
only	0
in	0
SCM-1-producer	5
T	6
cell	6
lines	6
through	0
a	0
cyclosporin	0
A-sensitive	0
mechanism	0
.	0

An	0
element	0
termed	0
E1	1
located	0
at	0
-108	1
to	2
-95	2
nt	2
relative	0
to	0
the	0
major	0
transcription	0
start	0
site	0
was	0
found	0
to	0
be	0
critical	0
for	0
the	0
promoter	0
activity	0
.	0

In	0
electrophoretic	0
mobility	0
shift	0
assays	0
using	0
the	0
E1	1
oligonucleotide	0
as	0
probe	0
,	0
nuclear	0
extracts	0
from	0
unstimulated	0
T	0
and	0
B	5
cell	6
lines	6
formed	0
a	0
constitutive	9
complex	10
termed	0
complex	9
I	10
,	0
while	0
nuclear	0
extracts	0
from	0
stimulated	0
SCM-1-producer	5
T	6
cell	6
lines	6
formed	0
a	0
higher	9
mobility	10
complex	10
termed	0
complex	9
II	10
with	0
a	0
concomitant	0
decrease	0
in	0
complex	9
I	10
.	0

The	0
shift	0
from	0
complex	9
I	10
to	0
complex	9
II	10
seen	0
only	0
in	0
SCM-1-producer	5
T	6
cell	6
lines	6
upon	0
activation	0
was	0
completely	0
suppressed	0
by	0
cyclosporin	0
A	0
.	0

Both	0
complexes	0
were	0
critically	0
dependent	0
on	0
the	0
NF-AT	1
core	2
sequence	2
TTTCC	0
in	0
the	0
E1	1
element	2
and	0
were	0
partially	0
supershifted	0
by	0
anti-NF-ATp	9
.	0

One-hybrid	0
assays	0
in	0
yeast	9
isolated	10
NF-ATp	10
as	0
an	0
E1	9
binding	10
protein	10
,	0
and	0
transfection	0
of	0
NF-ATp	9
into	0
T	5
and	6
B	6
cell	6
lines	6
strongly	0
enhanced	0
the	0
activation-dependent	9
SCM-1	10
promoter	0
activity	0
.	0

Collectively	0
,	0
a	0
unique	0
mechanism	0
involving	0
NF-ATp	9
appears	0
to	0
regulate	0
the	0
cell	0
type-specific	0
and	0
activation-dependent	0
expression	0
of	0
the	0
SCM-1	1
genes	2
.	0

Dopamine	0
stimulates	0
expression	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
via	0
NF-kappaB	9
in	0
cells	0
of	0
the	0
immune	0
system	0
.	0

Recent	0
studies	0
have	0
reported	0
that	0
lymphocytes	7
produce	0
,	0
transport	0
and	0
bind	0
dopamine	0
present	0
in	0
plasma	0
.	0

However	0
,	0
the	0
action	0
of	0
dopamine	0
on	0
HIV-1	0
gene	0
expression	0
in	0
cells	0
of	0
the	0
immune	0
system	0
has	0
not	0
yet	0
been	0
examined	0
.	0

Here	0
,	0
we	0
have	0
investigated	0
the	0
regulation	0
of	0
HIV-1	0
expression	0
by	0
dopamine	0
in	0
Jurkat	5
T	6
cells	6
and	0
in	0
primary	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

HIV-1	0
replication	0
was	0
increased	0
by	0
dopamine	0
,	0
which	0
correlated	0
with	0
the	0
increased	0
levels	0
of	0
HIV-1	0
transactivation	0
.	0

Our	0
transient	0
expression	0
data	0
revealed	0
that	0
dopamine	0
stimulated	0
transcription	0
through	0
the	0
NF-kappaB	1
element	2
present	0
in	0
the	0
long	1
terminal	2
repeat	2
.	0

The	0
importance	0
of	0
NF-kappaB	1
sites	2
was	0
confirmed	0
by	0
using	0
vectors	0
containing	0
wild-type	1
or	2
mutant	2
kappaB	2
sites	2
in	0
a	0
heterologous	1
promoter	2
.	0

Consistent	0
with	0
the	0
role	0
of	0
NF-kappaB	9
in	0
mediating	0
dopamine	0
responsiveness	0
,	0
the	0
proteasome	0
inhibitor	0
MG132	0
abolished	0
dopamine-induced	0
transcriptional	0
activation	0
.	0

We	0
further	0
explored	0
the	0
effect	0
of	0
dopamine	0
in	0
the	0
presence	0
of	0
phorbol	0
esters	0
or	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
known	0
to	0
activate	0
NF-kappaB	9
.	0

The	0
combination	0
of	0
dopamine	0
and	0
TNF-alpha	9
led	0
to	0
a	0
stimulation	0
of	0
HIV-1	0
transcription	0
and	0
replication	0
.	0

However	0
,	0
in	0
contrast	0
with	0
TNF-alpha	9
,	0
dopamine	0
treatment	0
did	0
not	0
affect	0
NF-kappaB	9
DNA	0
binding	0
activity	0
nor	0
the	0
concentrations	0
of	0
p50	9
,	0
p65	9
and	0
IkappaB-alpha	9
proteins	10
,	0
which	0
suggests	0
a	0
distinct	0
NF-kappaB	9
activation	0
mechanism	0
.	0

These	0
results	0
reveal	0
a	0
new	0
link	0
between	0
the	0
dopamine	0
system	0
,	0
cytokine	9
signaling	0
pathway	0
and	0
regulation	0
of	0
gene	0
expression	0
via	0
the	0
involvement	0
of	0
NF-kappaB	9
in	0
T	7
cells	8
and	0
PBMC	7
.	0

[	0
Hormonal	0
metabolic	0
status	0
in	0
breast	0
cancer	0
patients	0
after	0
conservative	0
surgery	0
:	0
comparison	0
with	0
known	0
prognostic	0
criteria	0
]	0

Body	0
weight	0
,	0
body	0
mass	0
index	0
,	0
body	0
fat	0
,	0
lean	0
body	0
mass	0
,	0
blood-glucose	0
,	0
cholesterol	0
,	0
HDL-cholesterol	9
,	0
triglyceride	0
,	0
beta-lipoproteins	9
,	0
insulin	0
,	0
gonadotropin	0
,	0
estradiol	0
,	0
testosterone	0
,	0
SHBG	9
,	0
T3	9
,	0
T4	9
and	0
TSH	0
levels	0
as	0
well	0
as	0
estradiol	0
and	0
progesterone	0
receptor	0
levels	0
in	0
excised	0
tumor	0
were	0
studied	0
in	0
40	0
patients	0
with	0
breast	0
cancer	0
prior	0
to	0
conservative	0
treatment	0
.	0

Said	0
anthropometric	0
,	0
metabolic	0
and	0
hormonal	0
parameters	0
were	0
compared	0
with	0
the	0
index	0
of	0
lymphocytic	0
infiltration	0
of	0
tumor	0
selected	0
as	0
a	0
prognostic	0
factor	0
.	0

A	0
significant	0
correlation	0
between	0
high	0
lymphocytic	0
infiltration	0
(	0
2.5	0
points	0
)	0
,	0
low	0
body	0
mass	0
and	0
fat	0
was	0
identified	0
.	0

Also	0
,	0
smoking	0
contributed	0
to	0
loss	0
of	0
body	0
mass	0
and	0
fat	0
;	0
however	0
,	0
it	0
caused	0
lymphocytic	0
infiltration	0
to	0
rise	0
.	0

Moderate	0
body	0
mass	0
,	0
relatively	0
low	0
fat	0
level	0
and	0
positive	0
receptor	0
status	0
are	0
among	0
factors	0
of	0
good	0
prognosis	0
in	0
breast	0
cancer	0
of	0
early	0
stages	0
.	0

Selective	0
DNA-binding	0
activity	0
of	0
interleukin-10-stimulated	9
STAT	10
molecules	10
in	0
human	7
monocytes	8
.	0

It	0
has	0
been	0
demonstrated	0
that	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
and	0
interleukin-10	9
(	0
IL-10	9
)	0
have	0
various	0
reverse	0
effects	0
on	0
macrophages	7
;	0
however	0
,	0
the	0
molecular	0
mechanism	0
of	0
this	0
difference	0
has	0
not	0
been	0
fully	0
understood	0
.	0

In	0
this	0
study	0
,	0
we	0
analyzed	0
the	0
binding	0
activity	0
of	0
IL-10-	9
and	10
IFN-gamma-activated	10
STAT	10
molecules	10
to	0
two	0
kinds	0
of	0
GAS	1
-motif	0
sequences	0
.	0

IL-10-activated	9
STAT1	10
could	0
bind	0
to	0
the	0
GAS-motif	1
sequence	2
in	0
the	0
promoter	0
region	0
of	0
the	0
Fcgamma	9
receptor	10
,	0
but	0
not	0
to	0
that	0
in	0
the	0
promoter	1
region	2
of	0
the	0
COX-2	1
gene	2
,	0
whereas	0
IFN-gamma-activated	9
STAT1	10
and	0
STAT5	9
could	0
bind	0
to	0
both	0
sequences	0
.	0

IL-10	9
inhibited	0
IFN-gamma	9
-induced	0
STAT	9
activation	0
without	0
newly	9
synthesized	10
protein	10
.	0

We	0
further	0
demonstrated	0
that	0
aspirin	0
,	0
but	0
not	0
dexamethasone	0
,	0
suppressed	0
IFN-gamma	9
-induced	0
STAT	9
activation	0
.	0

Taken	0
together	0
,	0
these	0
results	0
suggest	0
that	0
IL-10-activated	9
STAT1	10
has	0
a	0
specificity	0
in	0
binding	0
to	0
the	0
GAS-motif	1
sequences	2
,	0
whereas	0
IFN-gamma-activated	9
STAT1	10
and	0
STAT5	9
have	0
a	0
broader	0
spectrum	0
in	0
binding	0
to	0
the	0
GAS-motif	1
sequences	2
.	0

This	0
may	0
explain	0
the	0
difference	0
between	0
IL-10	9
and	0
IFN-gamma	9
in	0
biological	0
activity	0
,	0
and	0
the	0
inhibitory	0
effect	0
of	0
IL-10	9
on	0
IFN-gamma	9
activities	0
.	0

Peptide	0
binding	0
affinity	0
and	0
pH	0
variation	0
establish	0
functional	0
thresholds	0
for	0
activation	0
of	0
HLA-DQ	1
-restricted	0
T	0
cell	0
recognition	0
.	0

Peptides	0
derived	0
from	0
the	0
HSV-2	9
VP16	10
protein	10
were	0
utilized	0
for	0
studies	0
of	0
peptide	0
binding	0
to	0
DQ0302	0
molecules	0
and	0
T	0
cell	0
activation	0
at	0
both	0
neutral	0
and	0
acidic	0
pH	0
.	0

The	0
native	0
peptide	0
VP16	0
430-444	0
contains	0
an	0
Asp	0
at	0
position	9
442	10
,	0
binds	0
to	0
DQ0302	0
strongly	0
,	0
with	0
a	0
Kd	0
value	0
of	0
50nM	0
at	0
acidic	0
pH	0
and	0
very	0
weakly	0
,	0
with	0
a	0
Kd	0
value	0
of	0
greater	0
than	0
10	0
microM	0
at	0
neutral	0
pH	0
.	0

A	0
truncated	0
version	0
of	0
430-444	0
,	0
i.e.	0
,	0
VP16	0
433-442	0
,	0
binds	0
with	0
an	0
affinity	0
10-fold	0
lower	0
compared	0
to	0
430-444	0
at	0
acidic	0
pH	0
,	0
and	0
binding	0
at	0
neutral	0
pH	0
was	0
barely	0
detectable	0
.	0

The	0
homologous	0
peptide	0
430-444	0
,	0
442A	0
has	0
an	0
Asp	0
to	0
Ala	0
substitution	0
at	0
position	0
442	0
and	0
binds	0
to	0
DQ0302	0
with	0
a	0
Kd	0
similar	0
to	0
433-442	0
.	0

The	0
short	0
truncated	0
analog	0
433-442A	0
binds	0
very	0
poorly	0
at	0
both	0
acidic	0
and	0
neutral	0
pH	0
.	0

Both	0
the	0
wild	0
type	0
430-444	0
and	0
433-442	0
peptides	0
stimulated	0
a	0
HSV-specific	0
T	0
cell	0
clone	0
after	0
a	0
brief	0
incubation	0
with	0
antigen	7
presenting	8
cells	8
(	0
APC	7
)	0
expressing	0
DQ0302	0
at	0
acidic	0
pH	0
.	0

Much	0
higher	0
concentrations	0
of	0
wild	0
type	0
peptides	0
were	0
needed	0
to	0
activate	0
T	7
cells	8
at	0
neutral	0
pH	0
.	0

In	0
contrast	0
,	0
APC	7
pulsed	0
with	0
Ala-substituted	0
peptides	0
430-444	0
,	0
442A	0
or	0
433-442A	0
at	0
neutral	0
pH	0
failed	0
to	0
stimulate	0
the	0
T	5
cell	6
clone	6
,	0
while	0
APC	7
pulsed	0
at	0
acidic	0
pH	0
and	0
subsequently	0
washed	0
led	0
to	0
successful	0
T	0
cell	0
activation	0
.	0

The	0
Ala-substituted	0
peptide	0
was	0
recognized	0
by	0
the	0
T	5
cell	6
clone	6
at	0
neutral	0
pH	0
only	0
when	0
it	0
was	0
present	0
in	0
the	0
APC	5
culture	6
throughout	0
the	0
stimulation	0
process	0
.	0

While	0
the	0
MHC-peptide	9
complexes	10
formed	0
with	0
the	0
native	0
peptide	0
are	0
stable	0
,	0
complexes	0
formed	0
with	0
the	0
Ala-substituted	0
peptide	0
had	0
a	0
functional	0
t1/2	0
of	0
less	0
than	0
4	0
hr	0
at	0
neutral	0
pH	0
.	0

ETS	9
transcription	10
factors	10
regulate	0
an	0
enhancer	0
activity	0
in	0
the	0
third	1
intron	2
of	0
TNF-alpha	9
.	0

We	0
describe	0
an	0
enhancer	0
site	0
in	0
the	0
third	1
intron	2
of	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
.	0

A	0
reporter	1
construct	2
containing	0
the	0
5'-flanking	1
region	2
of	0
the	0
mouse	0
TNF-alpha	1
gene	2
displayed	0
weak	0
activity	0
when	0
transfected	0
into	0
RAW264.7	5
macrophage-like	6
cells	6
.	0

The	0
addition	0
of	0
the	0
third	1
intron	2
of	0
TNF-alpha	9
to	0
this	0
construct	0
resulted	0
in	0
an	0
enhancement	0
of	0
CAT	9
protein	10
.	0

This	0
enhancement	0
was	0
eliminated	0
if	0
a	0
conserved	1
20-bp	2
sequence	2
was	0
removed	0
from	0
the	0
intron	1
or	0
if	0
a	0
dominant-negative	9
ets-binding	10
factor	10
was	0
co-transfected	0
with	0
the	0
reporter	1
gene	2
.	0

Mutations	0
of	0
this	0
site	0
that	0
destroyed	0
potential	0
ets	1
transcription	2
factor	2
binding	2
sites	2
had	0
reduced	0
transcriptional	0
activity	0
.	0

The	0
major	0
transcription	0
factor	0
that	0
bound	0
to	0
the	0
oligonucleotide	0
was	0
confirmed	0
to	0
be	0
GABP	9
by	0
supershift	0
and	0
competition	0
analysis	0
.	0

In	0
RAW264.7	5
cells	6
,	0
the	0
binding	0
was	0
constitutive	0
,	0
however	0
,	0
in	0
bone	5
marrow-derived	6
macrophages	6
binding	0
activity	0
was	0
shown	0
to	0
be	0
interferon-gamma	9
inducible	0
.	0

This	0
may	0
imply	0
a	0
role	0
for	0
ets	9
transcription	10
factors	10
in	0
the	0
production	0
of	0
TNF-alpha	9
.	0

E2F-1	9
blocks	0
terminal	0
differentiation	0
and	0
causes	0
proliferation	0
in	0
transgenic	7
megakaryocytes	8
.	0

The	0
transcription	9
factor	10
E2F-1	9
plays	0
a	0
central	0
role	0
in	0
the	0
cell	0
cycle	0
through	0
its	0
ability	0
to	0
activate	1
genes	2
involved	0
in	0
cell	0
division	0
.	0

E2F-1	9
activity	0
is	0
regulated	0
by	0
a	0
number	0
of	0
proteins	0
,	0
including	0
the	0
retinoblastoma	0
susceptibility	1
gene	2
product	0
,	0
cyclin-dependent	9
kinases	10
,	0
and	0
their	0
inhibitors	0
,	0
proteins	0
that	0
have	0
been	0
implicated	0
in	0
the	0
control	0
of	0
certain	0
developmental	0
processes	0
.	0

To	0
investigate	0
a	0
potential	0
role	0
of	0
E2F-1	9
in	0
differentiation	0
,	0
we	0
assayed	0
the	0
ability	0
of	0
megakaryocytes	7
to	0
form	0
platelets	7
in	0
an	0
in	0
vivo	0
transgenic	0
model	0
.	0

E2F-1	9
expression	0
in	0
megakaryocytes	7
blocked	0
differentiation	0
during	0
maturation	0
,	0
resulting	0
in	0
severe	0
thrombocytopenia	0
.	0

Ultrastructural	0
analysis	0
of	0
megakaryocytes	7
revealed	0
abnormal	0
development	0
characterized	0
by	0
hyperdemarcation	0
of	0
cytoplasmic	0
membranes	0
and	0
reduced	0
numbers	0
of	0
alpha	0
granules	0
.	0

Administration	0
of	0
megakaryocyte	9
growth	10
and	10
development	10
factor	10
or	0
interleukin	9
6	10
could	0
not	0
overcome	0
the	0
differentiation	0
block	0
.	0

Additionally	0
,	0
E2F-1	9
caused	0
massive	0
megakaryocyte	7
accumulation	0
in	0
both	0
normal	0
and	0
ectopic	0
sites	0
,	0
first	0
evident	0
in	0
E15	0
embryonic	0
liver	0
.	0

Furthermore	0
,	0
significant	0
apoptosis	0
was	0
observed	0
in	0
transgenic	7
megakaryocytes	8
.	0

These	0
data	0
indicate	0
that	0
E2F-1	9
can	0
prevent	0
terminal	0
differentiation	0
,	0
probably	0
through	0
its	0
cell	0
cycle-stimulatory	0
activity	0
.	0

Polymorphic	0
nucleotides	0
within	0
the	0
human	1
IL-4	2
promoter	2
that	0
mediate	0
overexpression	0
of	0
the	0
gene	0
.	0

Atopy	0
,	0
which	0
predisposes	0
individuals	0
to	0
develop	0
asthma	0
,	0
severe	0
systemic	0
anaphylaxis	0
,	0
and	0
atopic	0
dermatitis	0
,	0
is	0
usually	0
associated	0
with	0
dramatically	0
elevated	0
total	0
serum	0
IgE	9
levels	0
and	0
is	0
thought	0
to	0
be	0
controlled	0
by	0
a	0
major	0
susceptibility	1
gene	2
and	0
multiple	0
minor	0
susceptibility	1
genes	2
.	0

A	0
recent	0
sib-pair	0
analysis	0
revealed	0
a	0
tight	0
linkage	0
between	0
markers	0
on	0
5q31.1	1
and	0
a	0
major	1
susceptibility	2
gene	2
controlling	0
total	0
serum	0
IgE	9
levels	0
.	0

Due	0
to	0
its	0
location	0
within	0
this	0
cluster	0
and	0
its	0
biologic	0
role	0
in	0
Ig	0
class	0
switching	0
and	0
Th2	5
cell	6
differentiation	0
,	0
the	0
IL-4	1
gene	2
has	0
emerged	0
as	0
one	0
major	0
candidate	0
for	0
the	0
atopy	1
gene	2
.	0

In	0
one	0
model	0
,	0
polymorphisms	0
within	0
IL-4	1
regulatory	2
elements	2
might	0
result	0
in	0
overexpression	0
of	0
the	0
gene	0
,	0
amplifying	0
Th2	5
cell	6
differentiation	0
and	0
class	0
switching	0
to	0
IgE	9
.	0

In	0
support	0
of	0
this	0
model	0
,	0
we	0
report	0
that	0
the	0
human	1
IL-4	2
promoter	2
exists	0
in	0
multiple	0
allelic	0
forms	0
that	0
exhibit	0
distinct	0
transcriptional	0
activities	0
in	0
IL-4-positive	7
T	8
cells	8
.	0

A	0
particular	0
allele	0
has	0
an	0
unusually	0
high	0
transcriptional	0
activity	0
.	0

A	0
nucleotide	0
substitution	0
within	0
a	0
recently	0
described	0
OAP40	1
element	2
located	0
just	0
upstream	0
of	0
an	0
NF-AT	1
site	2
(	0
P	1
sequence	2
)	0
appears	0
to	0
be	0
largely	0
responsible	0
for	0
the	0
increased	0
promotor	0
strength	0
of	0
this	0
particular	0
allelic	0
form	0
of	0
the	0
IL-4	1
promoter	2
.	0

In	0
EMSAs	0
,	0
this	0
substitution	0
results	0
in	0
a	0
markedly	0
enhanced	0
affinity	0
for	0
sequence-specific	0
complexes	0
exhibiting	0
an	0
AP-1	9
specificity	0
.	0

The	0
identification	0
of	0
allelic	0
nucleotides	0
,	0
which	0
results	0
in	0
overexpression	0
of	0
the	0
IL-4	1
gene	2
,	0
provides	0
specific	0
targets	0
for	0
a	0
comprehensive	0
screening	0
of	0
atopic	0
and	0
nonatopic	0
individuals	0
and	0
may	0
provide	0
a	0
clue	0
for	0
genetic	0
predisposition	0
for	0
atopy	0
.	0

Evidence	0
for	0
lowered	0
induction	0
of	0
nuclear	9
factor	10
kappa	10
B	10
in	0
activated	7
human	8
T	8
lymphocytes	8
during	0
aging	0
.	0

Transcription	0
factor	0
NF	9
kappa	10
B	10
(	0
nuclear	9
factor	10
kappa	10
B	10
)	0
is	0
induced	0
in	0
T	7
lymphocytes	8
from	0
young	0
individuals	0
following	0
activation	0
with	0
a	0
variety	0
of	0
stimuli	0
including	0
anti-CD3	9
,	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
,	0
and	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

In	0
contrast	0
,	0
activated	0
T	7
lymphocytes	8
from	0
older	0
individuals	0
show	0
a	0
significant	0
reduction	0
in	0
the	0
induction	0
of	0
NF	9
kappa	10
B	10
in	0
response	0
to	0
the	0
same	0
stimuli	0
.	0

The	0
age-related	0
decline	0
in	0
induction	0
of	0
NF	9
kappa	10
B	10
could	0
not	0
be	0
attributed	0
to	0
alteration	0
in	0
the	0
composition	0
of	0
subunits	0
,	0
p50	9
and	0
p65	9
were	0
found	0
to	0
be	0
the	0
predominant	0
subunits	0
of	0
induced	0
NF	9
kappa	10
B	10
in	0
T	7
cells	8
from	0
young	0
as	0
well	0
as	0
elderly	0
donors	0
.	0

Furthermore	0
,	0
similar	0
levels	0
of	0
NF	9
kappa	10
B	10
were	0
found	0
in	0
the	0
cytosols	0
of	0
unactivated	0
T	7
cells	8
from	0
both	0
young	0
and	0
elderly	0
donors	0
suggesting	0
that	0
precursor	0
levels	0
of	0
NF	9
kappa	10
B	10
remain	0
unaltered	0
during	0
aging	0
.	0

These	0
results	0
suggest	0
that	0
an	0
age-associated	0
decline	0
in	0
the	0
induction	0
of	0
NF	9
kappa	10
B	10
in	0
activated	0
T	7
cells	8
from	0
elderly	0
individuals	0
may	0
be	0
attributable	0
to	0
altered	0
regulation	0
of	0
the	0
inhibitor	0
,	0
I	9
kappa	10
B	10
,	0
and	0
may	0
play	0
an	0
important	0
role	0
in	0
immune	0
dysregulation	0
accompanying	0
aging	0
.	0

Inhibition	0
of	0
lipopolysaccharide-induced	0
monocyte	9
interleukin-1	10
receptor	10
antagonist	0
synthesis	0
by	0
cortisol	0
:	0
involvement	0
of	0
the	0
mineralocorticoid	9
receptor	10
.	0

Glucocorticoids	0
,	0
as	0
a	0
part	0
of	0
their	0
physiological	0
role	0
in	0
the	0
control	0
of	0
inflammatory	0
and	0
immune	0
processes	0
,	0
suppress	0
the	0
expression	0
of	0
interleukin-1	9
(	0
IL-1	9
)	0
and	0
other	0
cytokines	9
.	0

Human	3
monocyte	4
IL-1	4
receptor	4
antagonist	4
(	4
IL-1ra	4
)	4
messenger	4
ribonucleic	4
acid	4
(	0
mRNA	0
)	0
expression	0
and	0
protein	0
secretion	0
are	0
inhibited	0
by	0
dexamethasone	0
.	0

We	0
have	0
now	0
further	0
studied	0
the	0
regulation	0
of	0
IL-1ra	9
by	0
the	0
major	0
physiological	0
human	0
glucocorticoid	0
,	0
cortisol	0
.	0

We	0
found	0
that	0
cortisol	0
incubation	0
induced	0
a	0
decrease	0
in	0
IL-1ra	3
mRNA	4
expression	0
and	0
a	0
significant	0
inhibition	0
of	0
IL-1ra	9
protein	10
secretion	0
in	0
cell	0
cultures	0
of	0
human	7
peripheral	8
monocytes	8
stimulated	0
with	0
the	0
bacterial	0
endotoxin	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

Oral	0
administration	0
of	0
276	0
mumol	0
cortisol	0
to	0
normal	0
subjects	0
also	0
decreased	0
LPS-induced	0
IL-1ra	9
synthesis	0
in	0
cultured	5
monocytes	6
.	0

By	0
coincubating	0
the	0
monocytes	7
with	0
either	0
the	0
mineralocorticoid	0
antagonist	0
spironolactone	0
or	0
the	0
glucocorticoid	9
receptor	10
antagonist	0
RU	0
38486	0
,	0
the	0
in	0
vitro	0
cortisol-induced	0
inhibition	0
of	0
LPS-stimulated	0
IL-1ra	9
secretion	0
was	0
partially	0
reversed	0
.	0

The	0
mineralocorticoid	0
aldosterone	0
exerted	0
a	0
significant	0
decrease	0
in	0
LPS-induced	0
monocyte	0
IL-1ra	9
secretion	0
in	0
vitro	0
,	0
which	0
was	0
blocked	0
by	0
coincubation	0
with	0
spironolactone	0
.	0

In	0
addition	0
,	0
the	0
expression	0
of	0
mineralocorticoid	3
receptor	4
mRNA	4
in	0
human	0
monocytes	7
was	0
observed	0
by	0
PCR	0
of	0
reversed	3
transcribed	4
RNA	4
.	0

Our	0
results	0
further	0
indicate	0
that	0
corticosteroids	0
physiologically	0
control	0
the	0
IL-1/	0
IL-1ra	9
system	0
during	0
inflammatory	0
or	0
immune	0
processes	0
.	0

Moreover	0
,	0
we	0
provide	0
evidence	0
that	0
,	0
in	0
addition	0
to	0
a	0
glucocorticoid	9
receptor	10
-mediated	0
effect	0
,	0
the	0
mineralocorticoid	9
receptor	10
is	0
involved	0
in	0
the	0
inhibition	0
of	0
monocyte	0
IL-1ra	9
secretion	0
by	0
cortisol	0
.	0

Target	0
structures	0
of	0
the	0
CD8	0
(	0
+	0
)	0
-T-cell	0
response	0
to	0
human	0
cytomegalovirus	0
:	0
the	0
72-kilodalton	9
major	10
immediate-early	10
protein	10
revisited	0
.	0

Cell-mediated	0
immunity	0
plays	0
an	0
essential	0
role	0
in	0
the	0
control	0
of	0
infection	0
with	0
the	0
human	0
cytomegalovirus	0
(	0
HCMV	0
)	0
.	0

However	0
,	0
only	0
a	0
few	0
CD8	9
(	10
+	10
)	10
-T-cell	10
epitopes	10
are	0
known	0
,	0
with	0
the	0
majority	0
being	0
contained	0
in	0
the	0
pp65	9
phosphoprotein	10
,	0
which	0
is	0
believed	0
to	0
dominate	0
the	0
CD8	0
(	0
+	0
)	0
-T-cell	0
response	0
to	0
HCMV	0
.	0

Here	0
,	0
we	0
have	0
readdressed	0
the	0
issue	0
of	0
CD8	7
(	8
+	8
)	8
T	8
cells	8
specific	0
for	0
the	0
72-kDa	9
major	10
immediate-early	10
protein	10
(	0
IE-1	9
)	0
,	0
which	0
is	0
nonstructural	0
but	0
is	0
found	0
very	0
early	0
and	0
throughout	0
the	0
replicative	0
cycle	0
.	0

Using	0
a	0
novel	0
flow-cytometric	0
assay	0
,	0
we	0
were	0
able	0
to	0
identify	0
CD8	9
(	10
+	10
)	10
-T-cell	10
epitopes	10
(	0
by	0
IE-1	9
peptide-specific	0
induction	0
of	0
cytokine	9
synthesis	0
)	0
and	0
simultaneously	0
measure	0
the	0
frequency	0
of	0
cells	0
directed	0
against	0
them	0
.	0

For	0
this	0
purpose	0
,	0
81	0
pentadecamer	0
peptides	0
covering	0
the	0
complete	0
491-amino-acid	9
sequence	10
of	0
IE-1	9
were	0
tested	0
on	0
peripheral	7
blood	8
mononuclear	8
cells	8
of	0
anti-HCMV	0
immunoglobulin	0
G-seropositive	0
donors	0
.	0

At	0
least	0
10	0
new	0
epitopes	9
were	0
identified	0
,	0
and	0
the	0
fine	0
specificity	0
and	0
presenting	0
HLA	9
molecule	10
of	0
the	0
first	0
of	0
them	0
was	0
determined	0
.	0

The	0
frequencies	0
of	0
CD8	7
(	8
+	8
)	8
T	8
cells	8
directed	0
against	0
IE-1	9
were	0
similar	0
to	0
those	0
directed	0
against	0
pp65	9
in	0
donors	0
tested	0
with	0
known	0
pp65	9
-derived	0
peptides	0
.	0

Importantly	0
,	0
additional	0
testing	0
of	0
a	0
corresponding	0
set	0
of	0
peptides	0
covering	0
the	0
complete	0
sequence	0
of	0
pp65	9
on	0
10	0
of	0
these	0
donors	0
identified	0
individuals	0
whose	0
CD8	7
(	8
+	8
)	8
T	8
cells	8
recognized	0
IE-1	9
but	0
not	0
pp65	9
and	0
vice	0
versa	0
,	0
clearly	0
illustrating	0
that	0
either	0
protein	0
may	0
be	0
a	0
major	0
target	0
.	0

In	0
summary	0
,	0
our	0
results	0
suggest	0
that	0
IE-1	9
is	0
far	0
more	0
important	0
as	0
a	0
CD8	0
(	0
+	0
)	0
-T-cell	0
target	0
than	0
current	0
opinion	0
suggests	0
.	0

E1A	1
oncogene	2
induction	0
of	0
cellular	0
susceptibility	0
to	0
killing	0
by	0
cytolytic	7
lymphocytes	8
through	0
target	0
cell	0
sensitization	0
to	0
apoptotic	0
injury	0
.	0

E1A	1
oncogene	2
expression	0
increases	0
mammalian	0
cell	0
susceptibility	0
to	0
lysis	0
by	0
cytolytic	7
lymphocytes	8
(	0
CLs	7
)	0
at	0
a	0
stage	0
in	0
this	0
intercellular	0
interaction	0
that	0
is	0
independent	0
of	0
cell	0
surface	0
recognition	0
events	0
.	0

Since	0
CLs	7
can	0
induce	0
either	0
apoptotic	0
or	0
necrotic	0
cell	0
death	0
,	0
we	0
asked	0
whether	0
E1A	9
sensitization	0
to	0
injury-induced	0
apoptosis	0
is	0
sufficient	0
to	0
explain	0
E1A	9
-induced	0
cytolytic	0
susceptibility	0
.	0

Mouse	7
,	8
rat	8
,	8
hamster	8
,	8
and	8
human	8
cells	8
that	0
were	0
rendered	0
cytolytic	0
susceptible	0
by	0
E1A	9
were	0
also	0
sensitized	0
to	0
CL-induced	0
and	0
chemically	0
induced	0
apoptosis	0
.	0

In	0
contrast	0
,	0
E1A-positive	7
cells	8
were	0
no	0
more	0
susceptible	0
to	0
injury-induced	0
necrosis	0
than	0
E1A-negative	7
cells	8
.	0

Similar	0
to	0
induction	0
of	0
cytolytic	0
susceptibility	0
and	0
in	0
contrast	0
to	0
other	0
E1A	9
activities	0
,	0
cellular	0
sensitization	0
to	0
chemically	0
induced	0
apoptosis	0
depended	0
on	0
high-level	0
E1A	9
oncoprotein	9
expression	0
.	0

Loss	0
of	0
both	0
cytolytic	0
susceptibility	0
and	0
sensitization	0
to	0
chemically	0
induced	0
apoptosis	0
was	0
coselected	0
during	0
in	0
vivo	0
selection	0
of	0
E1A-positive	7
sarcoma	8
cells	8
for	0
increased	0
tumorigenicity	0
.	0

Furthermore	0
,	0
E1A	9
mutant	9
proteins	10
that	0
can	0
not	0
bind	0
the	0
cellular	9
transcriptional	10
coactivator	10
,	0
p300	9
,	0
and	0
that	0
fail	0
to	0
induce	0
cytolytic	0
susceptibility	0
also	0
failed	0
to	0
sensitize	0
cells	0
to	0
injury-induced	0
apoptosis	0
.	0

These	0
data	0
indicate	0
that	0
E1A	9
induces	0
susceptibility	0
to	0
killer	0
cell-induced	0
lysis	0
through	0
sensitization	0
of	0
cells	0
to	0
injury-induced	0
apoptosis	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

TCL1	1
oncogene	2
expression	0
in	0
AIDS-related	0
lymphomas	0
and	0
lymphoid	0
tissues	0
.	0

AIDS-related	0
non-Hodgkin	0
's	0
lymphoma	0
(	0
AIDS	0
NHL	0
)	0
comprises	0
a	0
diverse	0
and	0
heterogeneous	0
group	0
of	0
high-grade	0
B	0
cell	0
tumors	0
.	0

Certain	0
classes	0
of	0
AIDS	0
NHL	0
are	0
associated	0
with	0
alterations	0
in	0
oncogenes	1
or	0
tumor-suppressor	1
genes	2
or	0
infections	0
by	0
oncogenic	0
herpesviruses	0
.	0

However	0
,	0
the	0
clinically	0
significant	0
class	0
of	0
AIDS	0
NHL	0
designated	0
immunoblastic	0
lymphoma	0
plasmacytoid	0
(	0
AIDS	0
IBLP	0
)	0
lacks	0
any	0
consistent	0
genetic	0
alterations	0
.	0

We	0
identified	0
the	0
TCL1	1
oncogene	2
from	0
a	0
set	0
of	0
AIDS	1
IBLP-associated	2
cDNA	2
fragments	2
generated	0
by	0
subtractive	0
hybridization	0
with	0
non-AIDS	0
IBLP	0
.	0

Aberrant	0
TCL1	9
expression	0
has	0
been	0
implicated	0
in	0
T	0
cell	0
leukemia/lymphoma	0
development	0
,	0
and	0
its	0
expression	0
also	0
has	0
been	0
seen	0
in	0
many	0
established	0
B	5
cell	6
tumor	6
lines	6
.	0

However	0
,	0
TCL1	9
expression	0
has	0
not	0
been	0
reported	0
in	0
AIDS	0
NHL	0
.	0

We	0
find	0
that	0
TCL1	9
is	0
expressed	0
in	0
the	0
majority	0
of	0
AIDS	0
IBLP	0
tumors	0
examined	0
.	0

TCL1	9
protein	0
expression	0
is	0
restricted	0
to	0
tumor	0
cells	0
in	0
AIDS	0
IBLP	0
tissue	0
samples	0
analyzed	0
with	0
immunohistochemical	0
staining	0
.	0

Hyperplastic	0
lymph	0
node	0
and	0
tonsil	0
also	0
exhibit	0
strong	0
TCL1	9
protein	0
expression	0
in	0
mantle	7
zone	8
B	8
cells	8
and	0
in	0
rare	0
interfollicular	7
zone	8
cells	8
,	0
whereas	0
follicle-center	7
B	8
cells	8
(	0
centroblasts	7
and	0
centrocytes	7
)	0
show	0
weaker	0
expression	0
.	0

These	0
results	0
establish	0
TCL1	9
as	0
the	0
most	0
prevalent	0
of	0
all	0
of	0
the	0
surveyed	0
oncogenes	1
associated	0
with	0
AIDS	0
IBLP	0
.	0

They	0
also	0
indicate	0
that	0
abundant	0
TCL1	9
expression	0
in	0
quiescent	7
mantle	8
zone	8
B	8
cells	8
is	0
down-regulated	0
in	0
activated	0
germinal	7
center	8
follicular	8
B	8
cells	8
in	0
parallel	0
to	0
the	0
known	0
expression	0
pattern	0
of	0
BCL-2	9
.	0

High-level	0
expression	0
in	0
nonproliferating	7
B	8
cells	8
suggests	0
that	0
TCL1	9
may	0
function	0
in	0
protecting	0
naive	7
preactivated	8
B	8
cells	8
from	0
apoptosis	0
.	0

IL-2	9
-independent	0
activation	0
and	0
proliferation	0
in	0
human	7
T	8
cells	8
induced	0
by	0
CD28	9
.	0

Although	0
the	0
role	0
of	0
CD28	9
in	0
T	0
cell	0
costimulation	0
is	0
firmly	0
established	0
,	0
the	0
mechanisms	0
by	0
which	0
it	0
exerts	0
its	0
costimulatory	0
actions	0
are	0
less	0
clear	0
.	0

In	0
many	0
circumstances	0
it	0
is	0
difficult	0
to	0
distinguish	0
the	0
effects	0
of	0
CD28	9
from	0
subsequent	0
actions	0
of	0
cytokines	9
,	0
such	0
as	0
IL-2	9
,	0
on	0
T	0
cell	0
proliferation	0
.	0

Here	0
,	0
we	0
report	0
a	0
model	0
of	0
CD28	9
costimulation	0
using	0
PMA	0
plus	0
the	0
natural	9
ligand	10
CD80	10
that	0
resulted	0
in	0
very	0
limited	0
stimulation	0
of	0
IL-2	9
,	0
as	0
evidenced	0
by	0
both	0
cytokine	9
production	0
and	0
IL-2	1
promoter	2
stimulation	0
.	0

Promoter	0
assays	0
revealed	0
CD28	9
-dependent	0
effects	0
on	0
both	0
NF-kappaB	9
and	0
AP-1	9
,	0
but	0
not	0
on	0
NF-AT	9
or	0
the	0
intact	0
IL-2	1
promoter	2
.	0

In	0
addition	0
,	0
T	0
cell	0
proliferation	0
was	0
completely	0
resistant	0
to	0
the	0
actions	0
of	0
the	0
immunosuppressant	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
.	0

Moreover	0
T	0
cell	0
proliferation	0
was	0
unaffected	0
by	0
the	0
addition	0
of	0
blocking	0
Abs	9
to	0
both	0
IL-2	9
and	0
the	0
IL-2	9
receptor	10
,	0
demonstrating	0
that	0
this	0
form	0
of	0
costimulation	0
by	0
CD28	9
was	0
independent	0
of	0
IL-2	9
.	0

We	0
also	0
investigated	0
the	0
effects	0
of	0
stimulating	0
T	7
cell	8
blasts	8
with	0
CD80	9
alone	0
and	0
found	0
that	0
there	0
was	0
a	0
limited	0
requirement	0
for	0
IL-2	9
in	0
this	0
system	0
.	0

We	0
conclude	0
that	0
CD28	9
costimulation	0
can	0
cause	0
substantial	0
T	0
cell	0
proliferation	0
in	0
the	0
absence	0
of	0
IL-2	9
,	0
which	0
is	0
driven	0
by	0
a	0
soluble	9
factor	10
independent	0
of	0
NF-AT	9
transactivation	0
.	0

The	0
Epstein-Barr	1
virus	2
latency	2
BamHI-Q	2
promoter	2
is	0
positively	0
regulated	0
by	0
STATs	9
and	0
Zta	9
interference	0
with	0
JAK	9
/STAT	9
activation	0
leads	0
to	0
loss	0
of	0
BamHI-Q	1
promoter	2
activity	0
.	0

In	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
-associated	0
tumors	0
in	0
nonimmunocompromised	0
patients	0
,	0
EBV	0
gene	0
expression	0
is	0
highly	0
restricted	0
.	0

EBV-encoded	9
nuclear	10
antigen	10
(	10
EBNA	10
)	10
-1	10
is	0
expressed	0
,	0
whereas	0
the	0
immunogenic	0
and	0
proliferative	0
EBNAs	9
are	0
not	0
.	0

This	0
pattern	0
of	0
EBNA	9
expression	0
is	0
generated	0
by	0
usage	0
of	0
the	0
BamHI-Q	1
promoter	2
(	0
Qp	1
)	0
.	0

We	0
have	0
determined	0
that	0
the	0
JAK	9
/STAT	9
pathway	0
positively	0
regulates	0
Qp	1
activity	0
.	0

In	0
transient-transfection	0
assays	0
,	0
a	0
Qp-CAT	1
reporter	2
was	0
activated	0
by	0
cotransfected	0
JAK-1	9
and	0
by	0
treatment	0
of	0
cells	0
with	0
the	0
cytokine	9
IL-6	9
.	0

The	0
ability	0
of	0
Qp	1
to	0
bind	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
proteins	10
was	0
directly	0
demonstrated	0
by	0
electrophoretic	0
mobility-shift	0
assay	0
,	0
and	0
mutation	0
of	0
potential	0
STAT-binding	1
sites	2
reduced	0
Qp	1
responsiveness	0
to	0
Janus	9
kinase	10
(	10
JAK	10
)	10
-1	10
.	0

Consistent	0
with	0
a	0
role	0
for	0
STATs	9
in	0
Qp	1
function	0
,	0
Qp	1
using	0
Burkitt	5
's	6
lymphoma	6
Rael	6
cells	6
and	0
cultured	7
nasopharyngeal	8
carcinoma	8
(	8
NPC	8
)	8
cells	8
contained	0
nuclear	0
STAT	9
protein	10
.	0

We	0
investigated	0
whether	0
the	0
inability	0
to	0
maintain	0
EBV-positive	5
NPC	6
cell	6
lines	6
in	0
culture	0
was	0
related	0
to	0
Qp	1
activity	0
.	0

Passaging	0
of	0
the	0
NPC	5
cell	6
line	6
HK666	6
led	0
to	0
activation	0
of	0
expression	0
of	0
BZLF1	1
,	0
which	0
encodes	0
Zta	9
and	0
loss	0
of	0
Qp	1
function	0
.	0

Transient	0
expression	0
assays	0
linked	0
Zta	9
expression	0
to	0
the	0
down-regulation	0
of	0
Qp	1
.	0

Cotransfection	0
of	0
Zta	9
reduced	0
Qp	1
activity	0
in	0
reporter	0
assays	0
.	0

This	0
negative	0
regulation	0
required	0
Zta	9
DNA-binding	0
activity	0
.	0

We	0
provide	0
evidence	0
that	0
Zta	9
up-regulation	0
of	0
p53	9
leads	0
to	0
p53	9
-mediated	0
interference	0
with	0
JAK	9
/STAT	9
activation	0
of	0
Qp	1
.	0

The	0
data	0
imply	0
that	0
JAK	9
/STAT	9
signaling	0
has	0
a	0
role	0
in	0
EBV-associated	0
malignancies	0
.	0

Reactive	0
oxygen	0
intermediate-release	0
of	0
fibre-exposed	5
monocytes	6
increases	0
inflammatory	0
cytokine-mRNA	3
level	0
,	0
protein	9
tyrosine	10
kinase	10
and	0
NF-kappaB	9
activity	0
in	0
co-cultured	5
bronchial	6
epithelial	6
cells	6
(	0
BEAS-2B	5
)	0
.	0

Some	0
pulmonary	0
diseases	0
like	0
bronchitis	0
or	0
asthma	0
bronchiale	0
are	0
mediated	0
by	0
inflammatory	0
mechanisms	0
in	0
bronchial	7
epithelial	8
cells	8
.	0

Alveolar	7
macrophages	8
are	0
located	0
directly	0
in	0
the	0
surrounding	0
of	0
these	0
cells	0
,	0
so	0
that	0
we	0
suppose	0
an	0
interaction	0
between	0
epithelial	7
cells	8
and	0
macrophages	7
regarding	0
to	0
the	0
release	0
of	0
inflammatory	9
mediators	10
.	0

For	0
measuring	0
the	0
contribution	0
of	0
macrophages	7
to	0
the	0
release	0
of	0
inflammatory	9
mediators	10
by	0
bronchial	7
epithelial	8
cells	8
,	0
we	0
established	0
an	0
in	0
vitro	0
model	0
of	0
co-cultured	7
blood	8
monocytes	8
(	0
BM	7
)	0
and	0
BEAS-2B	5
cells	6
in	0
a	0
transwell	0
system	0
(	0
Costar	0
)	0
.	0

BM	7
were	0
exposed	0
to	0
Chrysotile	0
B	0
and	0
soot	0
particle	0
FR	0
101	0
in	0
a	0
concentration	0
of	0
100	0
microg/10	0
(	0
6	0
)	0
cells	0
.	0

After	0
up	0
to	0
90	0
min	0
exposure	0
time	0
ELISA	0
,	0
EMSA	0
(	0
electromobility	0
shift	0
assay	0
)	0
and	0
RT-PCR	0
were	0
used	0
to	0
measure	0
protein	9
tyrosine	10
kinase	10
activity	0
,	0
protein	0
activity	0
of	0
NF-kappaB	9
and	0
cytokine	9
(	0
IL-1beta	9
,	0
IL-6	9
,	0
TNF-alpha	9
)	0
specific	0
mRNA	3
levels	0
in	0
BEAS-2B	7
cells	8
.	0

We	0
observed	0
an	0
increase	0
in	0
protein	9
tyrosine	10
kinase	10
activity	0
(	0
up	0
to	0
1.8	0
+/-	0
0.5-fold	0
)	0
and	0
NF-kappaB	9
protein	0
activity	0
in	0
BEAS-2B	7
cells	8
after	0
particle	0
or	0
fibre	0
exposure	0
of	0
co-cultured	5
BM	6
.	0

Consecutive	0
IL-1beta-	3
,	4
IL-6-	4
and	4
TNF-alpha-mRNA	4
were	0
elevated	0
(	0
up	0
to	0
1.9	0
+/-	0
0.58-fold	0
)	0
.	0

Protein	9
tyrosine	10
kinase	10
activity	0
,	0
NF-kappaB	9
activity	0
,	0
and	0
the	0
synthesis	0
of	0
cytokine-specific	3
mRNA	4
were	0
inhibited	0
by	0
antioxidants	0
.	0

These	0
data	0
suggest	0
a	0
ROI-dependent	0
NF-kappaB	9
mediated	0
transcription	0
of	0
inflammatory	9
cytokines	10
in	0
bronchial	7
epithelial	8
cells	8
.	0

Suppression	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
long	2
terminal	2
repeat	2
by	0
CD8+	7
T	8
cells	8
is	0
dependent	0
on	0
the	0
NFAT-1	1
element	2
.	0

CD8+	7
T	8
lymphocytes	8
of	0
HIV-1	0
infected	0
individuals	0
produce	0
a	0
soluble	9
factor	10
that	0
efficiently	0
suppresses	0
HIV-1	0
replication	0
at	0
the	0
transcriptional	0
level	0
.	0

We	0
show	0
here	0
that	0
the	0
response	0
of	0
the	0
HIV-1	0
long	0
terminal	0
repeat	0
(	0
LTR	1
)	0
to	0
mitogenic	0
or	0
Tat	9
-mediated	0
activation	0
is	0
sensitive	0
to	0
the	0
suppressive	0
action	0
of	0
a	0
Herpesvirus	5
saimiri	6
(	6
HVS	6
)	6
-transformed	6
CD8+	6
T	6
cell	6
clone	6
from	0
an	0
HIV-infected	0
individual	0
and	0
supernatants	0
from	0
CD8+	7
T	8
cells	8
of	0
HIV-1-infected	0
asymptomatic	0
subjects	0
(	0
CD4+	9
>	0
350/microliters	0
)	0
.	0

Mutagenesis	0
of	0
NF	1
kappa	2
B	2
or	2
Sp-1	2
elements	2
within	0
the	0
LTR	1
resulted	0
in	0
no	0
change	0
in	0
the	0
ability	0
of	0
CD8+	7
T	8
cell	8
supernatants	0
to	0
inhibit	0
Tat-	0
or	0
mitogen-mediated	0
LTR	0
transcription	0
.	0

However	0
,	0
the	0
response	0
to	0
HIV-1	9
Tat	10
by	0
a	0
LTR	1
in	0
which	0
the	0
interleukin	1
(	2
IL	2
)	2
-2	2
homology	2
NFAT-1	2
region	2
was	0
mutated	0
resulted	0
in	0
almost	0
complete	0
elimination	0
of	0
suppression	0
by	0
CD8+	7
T	8
cells	8
.	0

This	0
was	0
not	0
observed	0
when	0
the	0
NFAT-1	1
mutant	2
LTR	2
was	0
activated	0
by	0
mitogen	9
.	0

We	0
have	0
previously	0
shown	0
that	0
gene	0
expression	0
directed	0
by	0
the	0
HIV-1	0
NF	1
kappa	2
B	2
elements	2
is	0
inhibited	0
by	0
CD8	9
+	0
cell-derived	0
supernatants	0
(	0
Copeland	0
et	0
al.	0
,	0
AIDS	0
Res	0
Hum	0
Retroviruses	0
,	0
1995	0
;	0
11	0
:	0
1321-1326	0
)	0
.	0

Taken	0
together	0
,	0
these	0
observations	0
suggest	0
that	0
mitogenic	0
activation	0
,	0
mediated	0
primarily	0
through	0
the	0
NF	1
kappa	2
B	2
enhancer	2
,	0
is	0
susceptible	0
to	0
CD8	9
-mediated	0
inhibition	0
,	0
however	0
,	0
inhibition	0
of	0
Tat	9
-mediated	0
activation	0
may	0
rely	0
upon	0
a	0
different	0
pathway	0
that	0
is	0
NFAT-1	9
dependent	0
.	0

Inhibition	0
of	0
NF-kappa	9
B	10
activation	0
in	0
human	5
T-cell	6
lines	6
by	0
anetholdithiolthione	0
.	0

Nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
is	0
a	0
redox	9
sensitive	10
cytosolic	10
transcription	10
factor	10
.	0

Redox	0
regulation	0
of	0
NF-kappa	9
B	10
has	0
been	0
implicated	0
in	0
the	0
activation	0
of	0
the	0
human	0
immuno-deficiency	0
virus	0
(	0
HIV	0
)	0
.	0

Therefore	0
,	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
may	0
be	0
an	0
effective	0
strategy	0
for	0
acquired	0
immunodeficiency	0
syndrome	0
therapy	0
.	0

Anetholdithiolthione	0
(	0
ADT	0
,	0
5-	0
[	0
p-methoxyphenyl	0
]	0
-3H-1	0
,	0
2-dithiol-3-thione	0
)	0
is	0
an	0
antioxidant	0
which	0
has	0
been	0
used	0
to	0
protect	0
against	0
acetaminophen-	0
and	0
CCl4-induced	0
hepatotoxicity	0
,	0
lipid	0
peroxidation	0
,	0
radiation	0
injury	0
,	0
and	0
also	0
has	0
been	0
used	0
clinically	0
as	0
an	0
anti-choleretic	0
agent	0
.	0

The	0
present	0
study	0
examined	0
the	0
effect	0
of	0
ADT	0
pretreatment	0
on	0
NF-kappa	9
B	10
activation	0
in	0
response	0
to	0
a	0
variety	0
of	0
stimuli	0
such	0
as	0
H2O2	0
,	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
or	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
.	0

PMA	0
and	0
TNF	9
alpha	10
induced	0
activation	0
of	0
(	9
NF	10
)	10
-kappa	10
B	10
in	0
human	0
Jurkat	5
T-cells	6
was	0
partially	0
inhibited	0
by	0
ADT	0
(	0
0.1	0
mM	0
)	0
pretreatment	0
.	0

ADT	0
(	0
0.1	0
mM	0
)	0
also	0
inhibited	0
H2O2	0
induced	0
activation	0
of	0
the	0
transcription	9
factor	10
in	0
the	0
peroxide	5
sensitive	6
human	6
Wurzburg	6
T-cells	6
.	0

Furthermore	0
,	0
ADT	0
treated	0
Wurzburg	5
cells	6
had	0
significantly	0
higher	0
glutathione	0
levels	0
as	0
compared	0
with	0
untreated	7
cells	8
.	0

H2O2	0
induced	0
lipid	0
peroxidation	0
in	0
Wurzburg	5
cells	6
was	0
remarkably	0
inhibited	0
by	0
ADT	0
pretreatment	0
.	0

ADT	0
,	0
a	0
pro-glutathione	0
antioxidant	0
,	0
was	0
observed	0
to	0
be	0
capable	0
of	0
modulating	0
NF-kappa	9
B	10
activation	0
.	0

Involvement	0
of	0
tyrosine	0
phosphorylation	0
in	0
endothelial	9
adhesion	10
molecule	10
induction	0
.	0

Induction	0
of	0
endothelial	9
adhesion	10
molecules	10
by	0
the	0
cytokine	9
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF	9
)	0
can	0
occur	0
independently	0
of	0
protein	9
kinase	10
C	10
and	0
activation	0
of	0
a	0
protein	9
tyrosine	10
kinase	10
(	0
PTK	9
)	0
has	0
recently	0
been	0
implicated	0
in	0
the	0
upregulation	0
of	0
vascular	9
cell	10
adhesion	10
molecule	10
1	10
(	0
VCAM-1	9
)	0
by	0
interleukin-4	9
(	0
IL-4	9
)	0
on	0
endothelial	7
cells	8
.	0

We	0
demonstrate	0
that	0
the	0
PTK	9
inhibitors	0
herbimycin	0
A	0
or	0
genistein	0
suppress	0
induction	0
of	0
endothelial	0
VCAM-1	9
and	0
E-selectin	9
,	0
as	0
well	0
as	0
subsequent	0
monocytic	0
cell	0
adhesion	0
to	0
endothelial	7
cells	8
stimulated	0
by	0
TNF	9
.	0

Inhibition	0
studies	0
indicate	0
that	0
specific	0
tyrosine	0
phosphorylation	0
following	0
PTK	9
activation	0
is	0
involved	0
in	0
the	0
mobilization	0
of	0
the	0
transcription	9
factor	10
,	0
nuclear	9
factor	10
kappa	10
B	10
,	0
and	0
VCAM-1	3
mRNA	4
expression	0
.	0

This	0
may	0
have	0
implications	0
for	0
pathophysiological	0
conditions	0
that	0
involve	0
the	0
upregulation	0
of	0
these	0
molecules	0
(	0
e.g.	0
inflammation	0
and	0
atherosclerosis	0
)	0
.	0

Protein	9
kinase	10
C-zeta	10
mediates	0
NF-kappa	9
B	10
activation	0
in	0
human	7
immunodeficiency	8
virus-infected	8
monocytes	8
.	0

The	0
molecular	0
mechanisms	0
regulating	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
persistence	0
in	0
a	0
major	0
cell	0
reservoir	0
such	0
as	0
the	0
macrophage	7
remain	0
unknown	0
.	0

NF-kappa	9
B	10
is	0
a	0
transcription	9
factor	10
involved	0
in	0
the	0
regulation	0
of	0
the	0
HIV	1
long	2
terminal	2
repeat	2
and	0
is	0
selectively	0
activated	0
following	0
HIV	0
infection	0
of	0
human	7
macrophages	8
.	0

Although	0
little	0
information	0
as	0
to	0
what	0
signal	0
transduction	0
pathways	0
mediate	0
NF-kappa	9
B	10
activation	0
in	0
monocytes-macrophages	7
is	0
available	0
,	0
our	0
previous	0
work	0
indicated	0
that	0
classical	0
protein	9
kinase	10
C	10
(	10
PKC	10
)	10
isoenzymes	10
were	0
not	0
involved	0
in	0
the	0
HIV-mediated	0
NF-kappa	9
B	10
activation	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
focused	0
on	0
atypical	0
PKC	9
isoenzymes	10
.	0

PKC-zeta	9
belongs	0
to	0
this	0
family	0
and	0
is	0
known	0
to	0
be	0
an	0
important	0
step	0
in	0
NF-kappa	9
B	10
activation	0
in	0
other	0
cell	0
systems	0
.	0

Immunoblotting	0
experiments	0
with	0
U937	5
cells	6
demonstrate	0
that	0
PKC-zeta	9
is	0
present	0
in	0
these	0
cells	0
,	0
and	0
its	0
expression	0
can	0
be	0
downmodulated	0
by	0
antisense	0
oligonucleotides	0
(	0
AO	0
)	0
.	0

The	0
HIV-mediated	0
NF-kappa	9
B	10
activation	0
is	0
selectively	0
reduced	0
by	0
AO	0
to	0
PKC-zeta	9
.	0

In	0
addition	0
,	0
cotransfection	0
of	0
a	0
negative	0
dominant	0
molecule	0
of	0
PKC-zeta	9
(	0
PKC-zeta	9
mut	10
)	0
with	0
NF-kappa	9
B	10
-dependent	0
reporter	0
genes	0
selectively	0
inhibits	0
the	0
HIV	0
-but	0
not	0
phorbol	0
myristate	0
acetate-	0
or	0
lipopolysaccharide-mediated	0
activation	0
of	0
NF-kappa	9
B	10
.	0

That	0
PKC-zeta	9
is	0
specific	0
in	0
regulating	0
NF-kappa	9
B	10
is	0
concluded	0
from	0
the	0
inability	0
of	0
PKC-zeta	9
(	10
mut	10
)	10
to	0
interfere	0
with	0
the	0
basal	0
or	0
phorbol	0
myristate	0
acetate-inducible	0
CREB	9
-or	0
AP1	9
-dependent	0
transcriptional	0
activity	0
.	0

Lastly	0
,	0
we	0
demonstrate	0
a	0
selective	0
inhibition	0
of	0
p24	9
production	0
by	0
HIV-infected	7
human	8
macrophages	8
when	0
treated	0
with	0
AO	0
to	0
PKC-zeta	9
.	0

Altogether	0
,	0
these	0
results	0
suggest	0
that	0
atypical	9
PKC	10
isoenzymes	10
,	0
including	0
PKC-zeta	9
,	0
participate	0
in	0
the	0
signal	0
transduction	0
pathways	0
by	0
which	0
HIV	0
infection	0
results	0
in	0
the	0
activation	0
of	0
NF-kappa	9
B	10
in	0
human	7
monocytic	8
cells	8
and	0
macrophages	7
.	0

Induction	0
of	0
Bcl-x	9
(	10
L	10
)	10
expression	0
by	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
Tax	10
through	0
NF-kappaB	9
in	0
apoptosis-resistant	5
T-cell	6
transfectants	6
with	0
Tax	9
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
Tax	9
is	0
thought	0
to	0
play	0
a	0
pivotal	0
role	0
in	0
immortalization	0
of	0
T	7
cells	8
.	0

We	0
have	0
recently	0
shown	0
that	0
the	0
expression	0
of	0
Tax	9
protected	0
the	0
mouse	5
T-cell	6
line	6
CTLL-2	6
against	0
apoptosis	0
induced	0
by	0
interleukin-2	9
(	0
IL-2	9
)	0
deprivation	0
and	0
converted	0
its	0
growth	0
from	0
being	0
IL-2	9
dependent	0
to	0
being	0
IL-2	9
independent	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
constitutive	0
expression	0
of	0
bcl-xl	9
but	0
not	0
bcl-2	9
,	0
bcl-xs	9
,	0
bak	9
,	0
bad	9
,	0
or	0
bax	9
was	0
associated	0
with	0
apoptosis	0
resistance	0
after	0
IL-2	9
deprivation	0
in	0
CTLL-2	5
cells	6
that	0
expressed	0
Tax	9
.	0

Transient-transfection	0
assays	0
showed	0
that	0
bcl-x	1
promoter	2
was	0
transactivated	0
by	0
wild-type	9
Tax	10
.	0

Similar	0
effects	0
were	0
observed	0
in	0
mutant	0
Tax	9
retaining	0
transactivating	0
ability	0
through	0
NF-kappaB	9
.	0

Deletion	0
or	0
substitution	0
of	0
a	0
putative	9
NF-kappaB	10
binding	10
site	10
identified	0
in	0
the	0
bcl-x	1
promoter	2
significantly	0
decreased	0
Tax	9
-induced	0
transactivation	0
.	0

This	0
NF-kappaB-like	1
element	2
was	0
able	0
to	0
form	0
a	0
complex	0
with	0
NF-kappaB	9
family	10
proteins	10
in	0
vitro	0
.	0

Furthermore	0
,	0
Tax	9
-induced	0
transactivation	0
of	0
the	0
bcl-x	1
promoter	2
was	0
also	0
diminished	0
by	0
the	0
mutant	9
IkappaBalpha	10
,	0
which	0
specifically	0
inhibits	0
NF-kappaB	9
activity	0
.	0

Our	0
findings	0
suggest	0
that	0
constitutive	0
expression	0
of	0
Bcl-x	9
(	10
L	10
)	10
induced	0
by	0
Tax	9
through	0
the	0
NF-kappaB	9
pathway	0
contributes	0
to	0
the	0
inhibition	0
of	0
apoptosis	0
in	0
CTLL-2	5
cells	6
after	0
IL-2	9
deprivation	0
.	0

The	0
beta-globin	1
promoter	2
is	0
important	0
for	0
recruitment	0
of	0
erythroid	9
Kruppel-like	10
factor	10
to	0
the	0
locus	1
control	2
region	2
in	0
erythroid	7
cells	8
.	0

Erythroid	9
Kruppel-like	10
factor	10
(	0
EKLF	9
)	0
,	0
which	0
binds	0
to	0
the	0
CACCC	0
box	0
in	0
the	0
beta-globin	1
promoter	2
,	0
is	0
required	0
for	0
the	0
expression	0
of	0
the	0
beta-globin	1
gene	2
in	0
adult	7
erythroid	8
cells	8
.	0

It	0
was	0
recently	0
demonstrated	0
that	0
EKLF	9
is	0
also	0
required	0
for	0
the	0
activity	0
of	0
the	0
beta-globin	1
locus	2
control	2
region	2
(	0
LCR	1
)	0
5'HS3	1
.	0

Some	0
evidence	0
suggests	0
that	0
the	0
LCR	1
and	0
the	0
beta-globin	1
promoter	2
interact	0
in	0
adult	7
erythroid	8
cells	8
,	0
and	0
the	0
network	0
of	0
protein-protein	0
interactions	0
that	0
exists	0
between	0
these	0
two	0
elements	0
may	0
regulate	0
how	0
EKLF	9
is	0
recruited	0
to	0
the	0
LCR	1
.	0

In	0
this	0
report	0
,	0
we	0
use	0
the	0
PIN*POINT	0
assay	0
to	0
study	0
the	0
role	0
of	0
the	0
promoter	0
on	0
the	0
recruitment	0
of	0
EKLF	9
to	0
5'HS2	1
and	0
5'HS3	1
of	0
the	0
LCR	1
.	0

We	0
find	0
that	0
recruitment	0
of	0
EKLF	9
to	0
5'HS2	1
requires	0
the	0
TATA	1
box	2
,	0
but	0
recruitment	0
to	0
5'HS3	1
depends	0
on	0
the	0
CACCC	0
and	0
TATA	1
boxes	2
of	0
the	0
beta-globin	1
promoter	2
.	0

Furthermore	0
,	0
recruitment	0
of	0
EKLF	9
to	0
5'HS3	1
only	0
occurred	0
in	0
beta-globin-expressing	7
murine	8
erythroid	8
leukemia	8
cells	8
,	0
whereas	0
recruitment	0
of	0
EKLF	9
to	0
5'HS2	1
occurred	0
in	0
both	0
gamma-globin-expressing	5
K562	6
cells	6
and	0
murine	7
erythroid	8
leukemia	8
cells	8
.	0

Unlike	0
EKLF	9
,	0
Sp1	9
,	0
which	0
also	0
binds	0
to	0
CACCC	0
boxes	0
,	0
is	0
not	0
recruited	0
to	0
5'HS3	1
.	0

We	0
have	0
also	0
examined	0
how	0
one	0
5'HS	1
affects	0
the	0
recruitment	0
of	0
EKLF	9
to	0
another	0
5'HS	1
.	0

We	0
have	0
found	0
that	0
the	0
recruitment	0
of	0
EKLF	9
to	0
5'HS3	1
depends	0
on	0
the	0
presence	0
of	0
5'HS2	1
in	0
cis	0
,	0
but	0
the	0
recruitment	0
to	0
5'HS2	1
does	0
not	0
depend	0
on	0
5'HS3	1
.	0

Based	0
on	0
these	0
results	0
,	0
we	0
present	0
a	0
model	0
that	0
illustrates	0
how	0
EKLF	9
may	0
be	0
recruited	0
to	0
the	0
beta-globin	1
locus	2
.	0

Estrogen	0
decreases	0
TNF	9
gene	0
expression	0
by	0
blocking	0
JNK	9
activity	0
and	0
the	0
resulting	0
production	0
of	0
c-Jun	9
and	0
JunD	9
.	0

Central	0
to	0
the	0
bone-sparing	0
effect	0
of	0
estrogen	0
(	0
E	0
(	0
2	0
)	0
)	0
is	0
its	0
ability	0
to	0
block	0
the	0
monocytic	0
production	0
of	0
the	0
osteoclastogenic	9
cytokine	10
TNF-alpha	10
(	0
TNF	9
)	0
.	0

However	0
,	0
the	0
mechanism	0
by	0
which	0
E	0
(	0
2	0
)	0
downregulates	0
TNF	9
production	0
is	0
presently	0
unknown	0
.	0

Transient	0
transfection	0
studies	0
in	0
HeLa	5
cells	6
,	0
an	0
E	0
(	0
2	0
)	0
receptor-negative	0
line	0
,	0
suggest	0
that	0
E	0
(	0
2	0
)	0
inhibits	0
TNF	9
gene	0
expression	0
through	0
an	0
effect	0
mediated	0
by	0
estrogen	9
receptor	10
beta	10
(	0
ERbeta	9
)	0
.	0

We	0
also	0
report	0
that	0
in	0
RAW	5
264.7	6
cells	6
,	0
an	0
E	0
(	0
2	0
)	0
receptor-positive	0
murine	0
monocytic	0
line	0
,	0
E	0
(	0
2	0
)	0
downregulates	0
cytokine-induced	0
TNF	9
gene	0
expression	0
by	0
decreasing	0
the	0
activity	0
of	0
the	0
Jun	9
NH	10
(	10
2	10
)	10
-terminal	10
kinase	10
(	0
JNK	9
)	0
.	0

The	0
resulting	0
diminished	0
phosphorylation	0
of	0
c-Jun	9
and	0
JunD	9
at	0
their	0
NH	9
(	10
2	10
)	10
-termini	10
decreases	0
the	0
ability	0
of	0
these	0
nuclear	0
proteins	0
to	0
autostimulate	0
the	0
expression	0
of	0
the	0
c-Jun	1
and	2
JunD	2
genes	2
,	0
thus	0
leading	0
to	0
lower	0
production	0
of	0
c-Jun	9
and	0
JunD	9
.	0

The	0
consequent	0
decrease	0
in	0
the	0
nuclear	0
levels	0
of	0
c-Jun	9
and	0
JunD	9
leads	0
to	0
diminished	0
binding	0
of	0
c-Jun/c-Fos	9
and	0
JunD/c-Fos	9
heterodimers	10
to	0
the	0
AP-1	1
consensus	2
sequence	2
in	0
the	0
TNF	1
promoter	2
and	0
,	0
thus	0
,	0
to	0
decreased	0
transactivation	0
of	0
the	0
TNF	1
gene	2
.	0

Cutting	0
edge	0
:	0
TCR	9
stimulation	0
by	0
antibody	0
and	0
bacterial	0
superantigen	0
induces	0
Stat3	9
activation	0
in	0
human	7
T	8
cells	8
.	0

Recent	0
data	0
show	0
that	0
TCR/CD3	9
stimulation	0
induces	0
activation	0
of	0
Stat5	9
in	0
murine	7
T	8
cells	8
.	0

Here	0
,	0
we	0
show	0
that	0
CD3	0
ligation	0
by	0
mAb	0
and	0
Staphylococcal	0
enterotoxin	0
(	0
SE	0
)	0
induce	0
a	0
rapid	0
,	0
gradually	0
accumulating	0
,	0
long-lasting	0
tyrosine	0
,	0
and	0
serine	0
phosphorylation	0
of	0
Stat3	9
(	0
but	0
not	0
Stat5	9
)	0
in	0
allogen-specific	5
human	6
CD4+	6
T	6
cell	6
lines	6
.	0

In	0
contrast	0
,	0
IL-2	9
induces	0
a	0
rapid	0
and	0
transient	0
tyrosine	0
and	0
serine	0
phosphorylation	0
of	0
Stat3	9
.	0

Compared	0
with	0
IL-2	9
,	0
CD3	9
ligation	0
induces	0
a	0
delayed	0
Stat3	9
binding	0
to	0
oligonucleotide	0
probes	0
from	0
the	0
ICAM-1	9
and	0
IL-2R	1
alpha	2
promoter	2
.	0

CD3	9
-mediated	0
activation	0
of	0
Stat3	9
is	0
almost	0
completely	0
inhibited	0
by	0
a	0
Src	9
kinase	10
inhibitor	10
(	0
PP1	9
)	0
,	0
whereas	0
IL-2	9
-induced	0
Stat3	9
activation	0
is	0
unaffected	0
.	0

In	0
conclusion	0
,	0
we	0
show	0
that	0
CD3	9
ligation	0
by	0
mAb	9
and	0
SE	0
triggers	0
a	0
rapid	0
,	0
PP1	9
-sensitive	0
tyrosine	0
and	0
serine	0
phosphorylation	0
of	0
Stat3	9
in	0
human	7
CD4+	8
T	8
cells	8
.	0

Moreover	0
,	0
we	0
provide	0
evidence	0
that	0
TCR/CD3	9
and	0
IL-2	9
induce	0
Stat3	9
activation	0
via	0
distinct	0
signaling	0
pathways	0
.	0

Distinctive	0
gene	0
expression	0
patterns	0
in	0
human	7
mammary	8
epithelial	8
cells	8
and	0
breast	0
cancers	0
.	0

cDNA	1
microarrays	2
and	0
a	0
clustering	0
algorithm	0
were	0
used	0
to	0
identify	0
patterns	0
of	0
gene	0
expression	0
in	0
human	7
mammary	8
epithelial	8
cells	8
growing	0
in	0
culture	0
and	0
in	0
primary	0
human	0
breast	0
tumors	0
.	0

Clusters	0
of	0
coexpressed	1
genes	2
identified	0
through	0
manipulations	0
of	0
mammary	7
epithelial	8
cells	8
in	0
vitro	0
also	0
showed	0
consistent	0
patterns	0
of	0
variation	0
in	0
expression	0
among	0
breast	0
tumor	0
samples	0
.	0

By	0
using	0
immunohistochemistry	0
with	0
antibodies	0
against	0
proteins	0
encoded	0
by	0
a	0
particular	0
gene	0
in	0
a	0
cluster	0
,	0
the	0
identity	0
of	0
the	0
cell	0
type	0
within	0
the	0
tumor	0
specimen	0
that	0
contributed	0
the	0
observed	0
gene	0
expression	0
pattern	0
could	0
be	0
determined	0
.	0

Clusters	0
of	0
genes	1
with	0
coherent	0
expression	0
patterns	0
in	0
cultured	7
cells	8
and	0
in	0
the	0
breast	0
tumors	0
samples	0
could	0
be	0
related	0
to	0
specific	0
features	0
of	0
biological	0
variation	0
among	0
the	0
samples	0
.	0

Two	0
such	0
clusters	0
were	0
found	0
to	0
have	0
patterns	0
that	0
correlated	0
with	0
variation	0
in	0
cell	0
proliferation	0
rates	0
and	0
with	0
activation	0
of	0
the	0
IFN	9
-regulated	0
signal	0
transduction	0
pathway	0
,	0
respectively	0
.	0

Clusters	0
of	0
genes	1
expressed	0
by	0
stromal	7
cells	8
and	0
lymphocytes	7
in	0
the	0
breast	0
tumors	0
also	0
were	0
identified	0
in	0
this	0
analysis	0
.	0

These	0
results	0
support	0
the	0
feasibility	0
and	0
usefulness	0
of	0
this	0
systematic	0
approach	0
to	0
studying	0
variation	0
in	0
gene	0
expression	0
patterns	0
in	0
human	0
cancers	0
as	0
a	0
means	0
to	0
dissect	0
and	0
classify	0
solid	0
tumors	0
.	0

PPARgamma	9
activation	0
induces	0
the	0
expression	0
of	0
the	0
adipocyte	1
fatty	2
acid	2
binding	2
protein	2
gene	2
in	0
human	7
monocytes	8
.	0

The	0
peroxisome-proliferator	9
activated	10
receptor	10
gamma	10
(	0
PPARgamma	9
)	0
,	0
a	0
member	0
of	0
the	0
nuclear	9
receptor	10
superfamily	10
of	0
ligand	9
activated	10
transcription	10
factors	10
,	0
plays	0
a	0
key	0
role	0
in	0
the	0
anti-diabetic	0
actions	0
of	0
the	0
thiazolidinediones	0
(	0
TZDs	0
)	0
.	0

PPARgamma	9
induces	0
the	0
expression	0
of	0
many	0
genes	1
involved	0
in	0
lipid	0
anabolism	0
,	0
including	0
the	0
adipocyte	9
fatty	10
acid	10
binding	10
protein	10
(	0
aP2	9
)	0
,	0
and	0
is	0
a	0
key	0
regulator	0
of	0
adipocyte	7
differentiation	0
.	0

PPARgamma	9
is	0
also	0
expressed	0
in	0
hematopoietic	7
cells	8
and	0
is	0
up-regulated	0
in	0
activated	0
monocytes/macrophages	7
.	0

Activation	0
of	0
PPARgamma	9
may	0
play	0
a	0
role	0
in	0
the	0
induction	0
of	0
differentiation	0
of	0
macrophages	7
to	0
foam	7
cells	8
that	0
are	0
associated	0
with	0
atherosclerotic	0
lesions	0
.	0

We	0
report	0
that	0
both	0
natural	0
and	0
synthetic	0
PPARgamma	0
agonists	0
induce	0
time-	0
and	0
dose-dependent	0
increases	0
in	0
aP2	3
mRNA	4
in	0
both	0
primary	7
human	8
monocytes	8
and	0
the	0
monocytic	5
cell	6
line	6
,	0
THP-1	5
.	0

These	0
data	0
suggest	0
that	0
PPARgamma	9
activation	0
may	0
play	0
a	0
role	0
in	0
monocyte	7
differentiation	0
and	0
function	0
analogous	0
to	0
its	0
well-characterized	0
role	0
in	0
adipocytes	7
.	8

Identification	0
of	0
a	0
physical	0
interaction	0
between	0
calcineurin	9
and	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFATp	9
)	0
.	0

In	0
T	7
lymphocytes	8
,	0
the	0
calcium/calmodulin-dependent	9
serine/threonine	10
phosphatase	10
,	0
calcineurin	9
,	0
plays	0
a	0
pivotal	0
role	0
in	0
transducing	0
membrane-associated	0
signals	0
to	0
the	0
nucleus	0
.	0

One	0
of	0
the	0
putative	0
targets	0
of	0
calcineurin	9
is	0
the	0
pre-existing	0
,	0
cytosolic	9
component	10
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFATp	9
;	0
also	0
referred	0
to	0
as	0
NFAT1	9
)	0
,	0
which	0
is	0
one	0
of	0
several	0
transcription	9
factors	10
required	0
for	0
the	0
expression	0
of	0
interleukin	9
2	10
.	0

Inhibition	0
of	0
calcineurin	9
by	0
the	0
immunosuppressive	0
drugs	0
cyclosporin	0
A	0
and	0
FK506	0
prevents	0
dephosphorylation	0
of	0
NFATp	9
and	0
its	0
translocation	0
to	0
the	0
nucleus	0
.	0

However	0
,	0
a	0
physical	0
interaction	0
between	0
calcineurin	9
and	0
NFATp	9
has	0
not	0
been	0
demonstrated	0
.	0

Here	0
we	0
demonstrate	0
the	0
binding	0
of	0
NFATp	9
from	0
lysates	0
of	0
T	7
cells	8
to	0
immobilized	0
calcineurin	9
.	0

Stimulation	0
of	0
T	7
cells	8
with	0
calcium	0
ionophore	0
induced	0
a	0
shift	0
in	0
the	0
molecular	0
weight	0
of	0
NFATp	9
that	0
is	0
due	0
to	0
its	0
dephosphorylation	0
.	0

This	0
dephosphorylation	0
was	0
inhibited	0
by	0
treatment	0
of	0
T	7
cells	8
with	0
cyclosporin	0
A	0
or	0
FK506	0
prior	0
to	0
stimulation	0
.	0

Of	0
note	0
,	0
both	0
the	0
phosphorylated	0
and	0
the	0
dephosphorylated	0
form	0
of	0
NFATp	9
bound	0
to	0
calcineurin	9
.	0

Furthermore	0
,	0
the	0
binding	0
of	0
both	0
forms	0
of	0
NFATp	9
to	0
calcineurin	9
was	0
inhibited	0
by	0
pretreatment	0
of	0
calcineurin	9
with	0
a	0
complex	0
of	0
FK506	0
and	0
its	0
ligand	0
FKBP12	0
.	0

Taken	0
together	0
these	0
data	0
strongly	0
suggest	0
a	0
direct	0
interaction	0
of	0
calcineurin	9
with	0
NFATp	9
and	0
that	0
this	0
interaction	0
does	0
not	0
depend	0
upon	0
the	0
phosphorylation	1
sites	2
of	0
NFATp	9
affected	0
by	0
activation	0
.	0

Cross-linking	0
CD40	9
on	0
B	7
cells	8
preferentially	0
induces	0
stress-activated	9
protein	10
kinases	10
rather	0
than	0
mitogen-activated	9
protein	10
kinases	10
.	0

The	0
B	9
cell-associated	10
surface	10
molecule	10
CD40	9
plays	0
a	0
key	0
role	0
in	0
T	0
cell-dependent	0
B	0
cell	0
maturation	0
,	0
as	0
individuals	0
with	0
defects	0
in	0
either	0
CD40	9
or	0
its	0
ligand	0
are	0
impaired	0
in	0
immunoglobulin	9
isotype	0
class	0
switching	0
and	0
germinal	0
center	0
formation	0
.	0

CD40	9
signaling	0
activates	0
downstream	9
effectors	10
,	0
including	0
the	0
tyrosine	9
protein	10
kinase	10
,	0
Lyn	9
,	0
the	0
phosphatidylinositol-3-kinase	9
(	0
PI-3	9
kinase	10
)	0
,	0
and	0
the	0
transcription	0
factor	0
,	0
NF-kappa	9
B	10
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
stress-activated	9
protein	10
kinases	10
(	0
SAPK	9
)	0
are	0
activated	0
after	0
CD40	9
cross-linking	0
on	0
various	0
B	5
cell	6
lines	6
or	0
human	7
tonsillar	8
B	8
cells	8
.	0

The	0
activation	0
is	0
rapid	0
and	0
transient	0
and	0
is	0
mediated	0
through	0
a	0
cyclosporin	0
A-insensitive	0
pathway	0
.	0

Furthermore	0
,	0
this	0
signaling	0
pathway	0
appears	0
not	0
to	0
rely	0
on	0
protein	9
kinase	10
C	10
.	0

While	0
CD40	9
ligation	0
strongly	0
activates	0
the	0
SAPKs	9
(	0
up	0
to	0
25-fold	0
)	0
,	0
it	0
does	0
not	0
affect	0
members	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
family	10
(	0
MAPK	9
;	0
ERK1	9
and	0
ERK2	9
)	0
.	0

Consistent	0
with	0
these	0
data	0
,	0
CD40	9
signals	0
up-regulate	0
c-jun	3
but	4
not	4
c-fos	4
mRNA	4
and	0
alter	0
the	0
transcription	9
factor	10
ATF2	9
but	0
not	0
the	0
Raf-1	9
protein	10
.	0

In	0
summary	0
,	0
CD40	9
signaling	0
preferentially	0
induces	0
SAPK	9
but	0
not	0
MAPK	9
.	0

Stimulation	0
of	0
the	0
T-cell	9
antigen	10
receptor-CD3	10
complex	10
signaling	0
pathway	0
by	0
the	0
tyrosine	9
phosphatase	10
inhibitor	0
pervanadate	0
is	0
mediated	0
by	0
inhibition	0
of	0
CD45	9
:	0
evidence	0
for	0
two	0
interconnected	0
Lck/Fyn-	0
or	0
zap-70-dependent	0
signaling	0
pathways	0
.	0

The	0
tyrosine	9
phosphatase	10
specific	0
inhibitor	0
pervanadate	0
is	0
a	0
potent	0
activator	0
of	0
T	7
lymphocytes	8
through	0
induction	0
of	0
tyrosine	9
phosphorylation	10
and	0
downstream	0
events	0
of	0
the	0
activation	0
cascade	0
.	0

Using	0
CD45-	5
or	6
CD3-negative	6
variants	6
of	0
the	0
Jurkat	5
leukemic	6
T-cell	6
line	6
we	0
show	0
that	0
the	0
different	0
biochemical	0
events	0
induced	0
by	0
pervanadate	0
appeared	0
to	0
be	0
dependent	0
on	0
the	0
presence	0
at	0
the	0
cell	0
surface	0
of	0
either	0
CD45	9
or	0
CD3	9
.	0

CD45	9
-dependent	0
events	0
such	0
as	0
tyrosine	9
phosphorylation	10
of	0
Shc	9
,	0
activation	0
of	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
,	0
transcription	9
factors	10
,	0
and	0
stimulation	0
of	0
interleukin-2	1
(	2
IL-2	2
)	2
promoter	2
and	0
of	0
CD69	9
and	0
CD25	9
surface	0
expression	0
paralleled	0
activation	0
of	0
the	0
tyrosine	9
kinases	10
lck	9
and	0
fyn	9
.	0

By	0
contrast	0
,	0
stimulation	0
of	0
calcium	0
influx	0
,	0
a	0
CD3	9
-dependent	0
event	0
,	0
paralleled	0
zap-70	9
activation	0
.	0

The	0
data	0
demonstrate	0
that	0
the	0
T-cell	0
antigen	0
receptor	0
-CD3	9
(	10
TcR-CD3	10
)	10
complex	10
is	0
functionally	0
linked	0
to	0
two	0
different	0
protein	9
tyrosine	10
kinase	10
(	0
PTK	9
)	0
modules	0
with	0
separate	0
specific	0
functions	0
and	0
that	0
CD45	9
may	0
be	0
an	0
important	0
regulator	0
of	0
this	0
coupling	0
.	0

Vitamin	0
D	0
analogs	0
,	0
20-Epi-22-oxa-24a	0
,	0
26a	0
,	0
27a	0
,	0
-trihomo-1alpha	0
,	0
25	0
(	0
OH	0
)	0
2-vitamin	0
D3	0
,	0
1	0
,	0
24	0
(	0
OH	0
)	0
2-22-ene-24-cyclopropyl-vitamin	0
D3	0
and	0
1alpha	0
,	0
25	0
(	0
OH	0
)	0
2-lumisterol3	0
prime	0
NB4	5
leukemia	6
cells	6
for	0
monocytic	0
differentiation	0
via	0
nongenomic	0
signaling	0
pathways	0
,	0
involving	0
calcium	0
and	0
calpain	0
.	0

Side-chain	0
modified	0
vitamin	0
D	0
analogs	0
including	0
20-Epi-22-oxa-24a	0
,	0
26a	0
,	0
27a-trihomo-1alpha	0
,	0
2	0
5-dihydroxyvitamin	0
D3	0
(	0
KH1060	0
)	0
,	0
and	0
1	0
,	0
24-dihydroxy-22-ene-24-cyclopropyl-vitamin	0
D3	0
(	0
MC903	0
)	0
were	0
originally	0
designed	0
to	0
aid	0
in	0
the	0
treatment	0
of	0
hyperproliferative	0
disorders	0
including	0
psoriasis	0
and	0
cancer	0
.	0

Here	0
we	0
demonstrate	0
that	0
these	0
analogs	0
,	0
as	0
well	0
as	0
the	0
6-cis-locked	0
conformer	0
,	0
1alpha	5
,	6
25-dihydroxy-lumisterol3	6
(	6
JN	6
)	6
prime	6
NB4	6
cells	6
for	0
monocytic	0
differentiation	0
.	0

Previously	0
,	0
the	0
action	0
of	0
MC903	0
and	0
KH1060	0
was	0
presumed	0
to	0
be	0
mediated	0
by	0
the	0
nuclear	9
vitamin	10
D	10
receptor	10
(	0
VDRnuc	9
)	0
.	0

Differentiation	0
in	0
response	0
to	0
all	0
analogs	0
was	0
shown	0
to	0
be	0
inhibited	0
by	0
1beta	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
HL	0
)	0
,	0
the	0
antagonist	0
to	0
the	0
nongenomic	0
activities	0
of	0
1	0
,	0
25D3	0
.	0

These	0
data	0
suggest	0
that	0
although	0
MC903	0
and	0
KH1060	0
may	0
bind	0
the	0
VDRnuc	9
,	0
that	0
the	0
differentiative	0
activities	0
of	0
these	0
agents	0
requires	0
nongenomic	0
signaling	0
pathways	0
.	0

Here	0
we	0
show	0
that	0
1alpha	0
,	0
25	0
(	0
OH	0
)	0
2-d5-previtamin	0
D3	0
(	0
HF	0
)	0
,	0
JN	0
,	0
KH1060	0
,	0
and	0
MC903	0
induce	0
expression	0
of	0
PKC	9
alpha	10
and	0
PKC	9
delta	10
and	0
translocation	0
of	0
both	0
isoforms	0
to	0
the	0
particulate	0
fraction	0
,	0
and	0
PKC	9
alpha	10
to	0
the	0
nuclear	0
fraction	0
.	0

The	0
full	0
differentiation	0
response	0
with	0
combinations	0
of	0
analogs	0
and	0
TPA	0
was	0
inhibited	0
50	0
%	0
by	0
the	0
membrane	0
permeable	0
Ca2+	0
chelator	0
,	0
1	0
,	0
2-bis	0
(	0
o-aminophenoxy	0
)	0
-ethane-N	0
,	0
N	0
,	0
N	0
'	0
,	0
N'-tetraacetic	0
acid	0
(	0
BAPTA-AM	0
)	0
or	0
calpain	9
inhibitor	0
I	0
.	0

These	0
data	0
demonstrate	0
that	0
intracellular	0
free	0
calcium	0
and	0
the	0
calcium-dependent	9
protease	10
,	0
calpain	9
play	0
critical	0
roles	0
in	0
monocytic	0
differentiation	0
.	0

Intracellular	0
calcium	0
appears	0
to	0
be	0
most	0
critical	0
in	0
the	0
1	0
,	0
25D3-priming	0
stage	0
of	0
differentiation	0
,	0
while	0
calpain	9
is	0
essential	0
in	0
the	0
TPA	0
maturation	0
response	0
.	0

Neutrophil	7
maturation	0
and	0
the	0
role	0
of	0
retinoic	0
acid	0
.	0

Neutrophil	7
maturation	0
occurs	0
in	0
well	0
defined	0
morphological	0
stages	0
that	0
correlate	0
with	0
the	0
acquisition	0
of	0
molecular	9
markers	10
associated	0
with	0
neutrophil	0
function	0
.	0

A	0
variety	0
of	0
factors	0
are	0
known	0
to	0
play	0
a	0
role	0
in	0
terminal	0
neutrophil	7
maturation	0
,	0
including	0
the	0
vitamin	0
A	0
derivative	0
,	0
retinoic	0
acid	0
.	0

Retinoic	0
acid	0
can	0
directly	0
modulate	0
gene	0
expression	0
via	0
binding	0
to	0
its	0
nuclear	9
receptors	10
,	0
which	0
can	0
,	0
in	0
turn	0
,	0
activate	0
transcription	0
of	0
target	1
genes	2
.	0

A	0
role	0
for	0
retinoic	0
acid	0
during	0
neutrophil	7
maturation	0
has	0
been	0
suggested	0
from	0
a	0
variety	0
of	0
sources.	0
Here	0
we	0
present	0
a	0
review	0
of	0
the	0
mechanism	0
of	0
retinoic	9
acid	10
receptor	10
action	0
and	0
the	0
major	0
evidence	0
showing	0
that	0
normal	0
retinoid	0
signaling	0
is	0
required	0
for	0
neutrophil	7
maturation	0
.	0

Human	1
T-cell	2
lymphotrophic	2
virus	2
type-I	2
tax	2
gene	2
induces	0
secretion	0
of	0
human	9
macrophage	10
inflammatory	10
protein-1alpha	10
.	0

Human	0
T-cell	0
lymphotropic	0
virus	0
I	0
(	0
HTLV-I	0
)	0
encodes	0
for	0
a	0
40-kDa	9
protein	10
,	0
Tax	9
,	0
which	0
is	0
important	0
for	0
the	0
immortalization	0
of	0
T	7
cells	8
.	0

Tax	9
has	0
been	0
shown	0
to	0
transactivate	0
several	0
cellular	1
genes	2
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
MIP-1alpha	9
is	0
selectively	0
expressed	0
and	0
secreted	0
in	0
the	0
tax	5
transfected	6
Jurkat	6
cell	6
line	6
upon	0
mitogen	9
stimulation	0
.	0

Expression	0
of	0
MIP-1alpha-R	3
mRNA	4
in	0
these	0
cells	0
suggests	0
an	0
autocrine	0
role	0
for	0
this	0
chemokine	9
in	0
HTLV-I	7
infected	8
T-cells	8
.	0

Induced	0
MIP-1alpha	9
expression	0
and	0
secretion	0
in	0
PMA/PHA	5
stimulated	6
tax	6
transfected	6
cells	6
correlate	0
with	0
the	0
noninduction	0
of	0
MNP-1	9
transcription	9
factor	10
,	0
which	0
is	0
intimately	0
involved	0
in	0
downmodulating	0
the	0
MIP-1alpha	1
gene	2
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Dendritic	7
cells	8
and	0
the	0
pathogenesis	0
of	0
rheumatoid	0
arthritis	0
.	0

Rheumatoid	0
arthritis	0
(	0
RA	0
)	0
is	0
a	0
chronic	0
autoimmune	0
inflammatory	0
disease	0
in	0
which	0
unknown	0
arthrogenic	9
autoantigen	10
is	0
presented	0
to	0
CD4+	7
T	8
cells	8
.	0

The	0
strong	0
association	0
of	0
the	0
disease	0
with	0
an	0
epitope	9
within	0
the	0
HLA-DR	9
chain	10
shared	0
between	0
various	0
alleles	0
of	0
HLA-DR4	9
and	0
DR1	9
emphasizes	0
the	0
importance	0
of	0
antigen	0
presentation	0
.	0

This	0
immune	0
response	0
predominantly	0
occurs	0
in	0
the	0
synovial	0
tissue	0
and	0
fluid	0
of	0
the	0
joints	0
and	0
autoreactive	7
T	8
cells	8
are	0
readily	0
demonstrable	0
in	0
both	0
the	0
synovial	0
compartment	0
and	0
blood	0
.	0

Circulating	7
dendritic	8
cells	8
(	0
DC	7
)	0
are	0
phenotypically	0
and	0
functionally	0
identical	0
with	0
normal	7
peripheral	8
blood	8
(	8
PB	8
)	8
DC	8
.	0

In	0
the	0
synovial	0
tissue	0
,	0
fully	0
differentiated	0
perivascular	7
DC	8
are	0
found	0
in	0
close	0
association	0
with	0
T	7
cells	8
and	0
with	0
B	7
cell	8
follicles	8
,	0
sometimes	0
containing	0
follicular	7
DC	8
.	0

These	0
perivascular	7
DC	8
migrate	0
across	0
the	0
activated	0
endothelium	0
from	0
blood	0
and	0
receive	0
differentiative	0
signals	0
within	0
the	0
joint	0
from	0
monocyte-derived	9
cytokines	10
and	0
CD40-ligand+	7
T	8
cells	8
.	0

In	0
the	0
SF	0
,	0
DC	7
manifest	0
an	0
intermediate	0
phenotype	0
,	0
similar	0
to	0
that	0
of	0
monocyte-derived	7
DC	8
in	0
vitro	0
.	0

Like	0
a	0
delayed-type	0
hypersensitivity	0
response	0
,	0
the	0
rheumatoid	0
synovium	0
represents	0
an	0
effector	0
site	0
.	0

DC	0
at	0
many	0
effector	0
sites	0
have	0
a	0
characteristic	0
pattern	0
of	0
infiltration	0
and	0
differentiation	0
.	0

It	0
is	0
important	0
to	0
note	0
that	0
the	0
effector	0
response	0
is	0
not	0
self-limiting	0
in	0
RA	0
autoimmune	0
inflammation	0
.	0

In	0
this	0
article	0
,	0
we	0
argue	0
that	0
the	0
presentation	0
of	0
self-antigen	9
by	0
DC	7
and	0
by	0
autoantibody-producing	7
B	8
cells	8
is	0
critical	0
for	0
the	0
perpetuation	0
of	0
the	0
autoimmune	0
response	0
.	0

Permanently	0
arresting	0
this	0
ongoing	0
immune	0
response	0
with	0
either	0
pharmaceutical	0
agents	0
or	0
immunotherapy	0
is	0
a	0
major	0
challenge	0
for	0
immunology	0
.	0

Thymocyte-thymic	0
epithelial	7
cell	8
interaction	0
leads	0
to	0
high-level	0
replication	0
of	0
human	0
immunodeficiency	0
virus	0
exclusively	0
in	0
mature	7
CD4	8
(	8
+	8
)	8
CD8	8
(	8
-	8
)	8
CD3	8
(	8
+	8
)	8
thymocytes	8
:	0
a	0
critical	0
role	0
for	0
tumor	9
necrosis	10
factor	10
and	0
interleukin-7	9
.	0

This	0
work	0
aims	0
at	0
identifying	0
the	0
thymocyte	0
subpopulation	0
able	0
to	0
support	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
replication	0
under	0
the	0
biological	0
stimuli	0
of	0
the	0
thymic	0
microenvironment	0
.	0

In	0
this	0
report	0
we	0
demonstrate	0
that	0
interaction	0
with	0
thymic	7
epithelial	8
cells	8
(	0
TEC	7
)	0
induces	0
a	0
high-level	0
replication	0
of	0
the	0
T-tropic	9
primary	10
isolate	10
HIV-1	10
(	0
B-LAIp	9
)	0
exclusively	0
in	0
the	0
mature	0
CD4	7
(	8
+	8
)	8
CD8	8
(	8
-	8
)	8
CD3	8
(	8
+	8
)	8
thymocytes	8
.	0

Tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
and	0
interleukin-7	9
(	0
IL-7	9
)	0
,	0
secreted	0
during	0
this	0
interaction	0
,	0
are	0
critical	0
cytokines	0
for	0
HIV	1
long	2
terminal	2
repeat	2
transactivation	0
through	0
NF-kappaB	9
-dependent	0
activation	0
.	0

TNF	9
is	0
the	0
major	0
inducer	0
of	0
NF-kappaB	9
and	0
particularly	0
of	0
the	0
p50-p65	9
complex	10
,	0
whereas	0
IL-7	9
acts	0
as	0
a	0
cofactor	0
by	0
sustaining	0
the	0
expression	0
of	0
the	0
p75	9
TNF	10
receptor	10
.	0

The	0
requirement	0
for	0
TNF	9
is	0
further	0
confirmed	0
by	0
the	0
observation	0
that	0
the	0
inability	0
of	0
the	0
intermediate	7
CD4	8
(	8
+	8
)	8
CD8	8
(	8
-	8
)	8
CD3	8
(	8
-	8
)	8
thymocytes	8
to	0
replicate	0
the	0
virus	0
is	0
associated	0
with	0
a	0
defect	0
in	0
TNF	9
production	0
during	0
their	0
interaction	0
with	0
TEC	7
and	0
correlates	0
with	0
the	0
absence	0
of	0
nuclear	0
NF-kappaB	9
activity	0
in	0
these	0
freshly	7
isolated	8
thymocytes	8
.	0

Addition	0
of	0
exogenous	0
TNF	9
to	0
the	0
intermediate	5
thymocyte	6
cultures	6
induces	0
NF-kappaB	9
activity	0
and	0
is	0
sufficient	0
to	0
promote	0
HIV	0
replication	0
in	0
the	0
cocultures	0
with	0
TEC	7
.	0

The	0
other	0
major	0
subpopulation	0
expressing	0
the	0
CD4	9
receptor	10
,	0
namely	0
,	0
the	0
double-positive	7
(	8
DP	8
)	8
CD4	8
(	8
+	8
)	8
CD8	8
(	8
+	8
)	8
CD3	8
(	8
+/-	8
)	8
thymocytes	8
,	0
despite	0
the	0
entry	0
of	0
the	0
virus	0
,	0
do	0
not	0
produce	0
a	0
significant	0
level	0
of	0
virus	0
,	0
presumably	0
because	0
they	0
are	0
unresponsive	0
to	0
TNF	9
and	0
IL-7	9
.	0

Together	0
,	0
these	0
data	0
suggest	0
that	0
in	0
vivo	0
,	0
despite	0
an	0
efficient	0
entry	0
of	0
the	0
virus	0
in	0
all	0
the	0
CD4	7
(	8
+	8
)	8
subpopulations	8
,	0
a	0
high	0
viral	0
load	0
may	0
be	0
generated	0
exclusively	0
within	0
the	0
mature	7
CD4	8
(	8
+	8
)	8
CD8	8
(	8
-	8
)	8
CD3	8
(	8
+	8
)	8
subset	8
of	8
thymocytes	8
.	0

However	0
,	0
under	0
conditions	0
of	0
inflammatory	0
response	0
after	0
infection	0
,	0
TNF	9
might	0
also	0
be	0
present	0
in	0
the	0
intermediate	7
thymocyte	8
compartment	8
,	0
leading	0
to	0
efficient	0
HIV	0
replication	0
in	0
these	0
cells	0
.	0

NF-kappaB-mediated	7
up-regulation	8
of	0
Bcl-x	9
and	0
Bfl-1/A1	9
is	0
required	0
for	0
CD40	9
survival	0
signaling	0
in	0
B	7
lymphocytes	8
.	0

Activation	0
of	0
CD40	9
is	0
essential	0
for	0
thymus-dependent	0
humoral	0
immune	0
responses	0
and	0
rescuing	0
B	7
cells	8
from	0
apoptosis	0
.	0

Many	0
of	0
the	0
effects	0
of	0
CD40	9
are	0
believed	0
to	0
be	0
achieved	0
through	0
altered	0
gene	0
expression	0
.	0

In	0
addition	0
to	0
Bcl-x	9
,	0
a	0
known	0
CD40-regulated	9
antiapoptotic	10
molecule	10
,	0
we	0
identified	0
a	0
related	0
antiapoptotic	9
molecule	10
,	0
A1/Bfl-1	9
,	0
as	0
a	0
CD40-inducible	1
gene	2
.	0

Inhibition	0
of	0
the	0
NF-kappaB	9
pathway	0
by	0
overexpression	0
of	0
a	0
dominant-active	0
inhibitor	0
of	0
NF-kappaB	9
abolished	0
CD40	9
-induced	0
up-regulation	0
of	0
both	0
the	0
Bfl-1	9
and	0
Bcl-x	9
genes	0
and	0
also	0
eliminated	0
the	0
ability	0
of	0
CD40	9
to	0
rescue	0
Fas	9
-induced	0
cell	0
death	0
.	0

Within	0
the	0
upstream	1
promoter	2
region	2
of	0
Bcl-x	9
,	0
a	0
potential	0
NF-kappaB-binding	1
sequence	2
was	0
found	0
to	0
support	0
NF-kappaB	9
-dependent	0
transcriptional	0
activation	0
.	0

Furthermore	0
,	0
expression	0
of	0
physiological	0
levels	0
of	0
Bcl-x	7
protected	8
B	8
cells	8
from	0
Fas-mediated	0
apoptosis	0
in	0
the	0
absence	0
of	0
NF-kappaB	9
signaling	0
.	0

Thus	0
,	0
our	0
results	0
suggest	0
that	0
CD40	9
-mediated	0
cell	0
survival	0
proceeds	0
through	0
NF-kappaB	9
-dependent	0
up-regulation	0
of	0
Bcl-2	9
family	10
members	10
.	0

Stimulation	0
of	0
neutrophil	7
interleukin-8	9
production	0
by	0
eosinophil	9
granule	10
major	10
basic	10
protein	10
.	0

We	0
evaluated	0
the	0
ability	0
of	0
eosinophil	9
granule	10
major	10
basic	10
protein	10
(	0
MBP	9
)	0
to	0
stimulate	0
interleukin	9
(	10
IL	10
)	10
-8	10
production	0
by	0
neutrophils	7
.	0

MBP	9
over	0
the	0
concentration	0
range	0
of	0
0.1	0
to	0
10	0
microM	0
stimulated	0
the	0
release	0
of	0
up	0
to	0
approximately	0
8	0
ng/ml	0
IL-8	9
.	0

Incubation	0
with	0
2	0
microM	0
MBP	9
showed	0
that	0
,	0
after	0
a	0
1	0
h	0
lag	0
,	0
the	0
level	0
of	0
IL-8	9
release	0
increased	0
with	0
time	0
for	0
approximately	0
10	0
h	0
.	0

At	0
the	0
2	0
microM	0
concentration	0
,	0
eosinophil	9
cationic	10
protein	10
,	0
eosinophil-derived	0
neurotoxin	0
,	0
and	0
eosinophil	9
peroxidase	10
did	0
not	0
stimulate	0
significant	0
levels	0
of	0
IL-8	9
production	0
.	0

MBP	9
stimulated	0
2-fold	0
increases	0
in	0
IL-8	3
messenger	4
RNA	4
(	0
mRNA	3
)	0
after	0
1	0
and	0
3	0
h	0
of	0
incubation	0
,	0
which	0
were	0
blocked	0
by	0
pretreatment	0
with	0
actinomycin	0
D	0
.	0

However	0
,	0
stimulation	0
with	0
MBP	9
did	0
not	0
produce	0
an	0
increase	0
in	0
the	0
binding	0
activity	0
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
or	0
activator	9
protein-1	10
.	0

No	0
NF-IL-6	9
binding	0
activity	0
was	0
detected	0
in	0
the	0
same	0
nuclear	0
extracts	0
.	0

In	0
addition	0
,	0
stimulation	0
with	0
MBP	9
prolonged	0
the	0
stability	0
of	0
IL-8	3
mRNA	4
.	0

MBP	9
also	0
induced	0
transient	0
increases	0
in	0
mRNA	3
for	0
macrophage	9
inflammatory	10
protein	10
(	10
MIP	10
)	10
-1alpha	10
and	0
MIP-1beta	9
,	0
but	0
did	0
not	0
stimulate	0
the	0
release	0
of	0
either	0
chemokine	9
.	0

These	0
findings	0
indicate	0
that	0
MBP	9
is	0
selective	0
among	0
the	0
eosinophil	9
granule	10
proteins	10
as	0
a	0
stimulus	0
for	0
neutrophil	7
IL-8	9
release	0
and	0
,	0
further	0
,	0
that	0
stimulation	0
of	0
neutrophil	7
IL-8	9
release	0
by	0
MBP	9
involves	0
both	0
transcriptional	0
and	0
posttranscriptional	0
regulation	0
.	0

We	0
postulate	0
that	0
MBP	9
-induced	0
release	0
of	0
IL-8	9
by	0
neutrophils	7
may	0
contribute	0
to	0
the	0
pathophysiology	0
of	0
acute	0
asthma	0
and	0
other	0
inflammatory	0
lung	0
diseases	0
.	0

Expression	0
of	0
either	0
the	0
TCL1	1
oncogene	2
,	0
or	0
transcripts	0
from	0
its	0
homologue	0
MTCP1/c6.1B	1
,	0
in	0
leukaemic	0
and	0
non-leukaemic	7
T	8
cells	8
from	0
ataxia	0
telangiectasia	0
patients	0
.	0

Patients	0
with	0
the	0
recessively	0
inherited	0
disorder	0
ataxia	0
telangiectasia	0
(	0
A-T	0
)	0
have	0
a	0
high	0
level	0
of	0
specific	0
chromosome	1
translocations	2
which	0
can	0
be	0
easily	0
observed	0
in	0
peripheral	7
T	8
cells	8
and	0
show	0
a	0
greatly	0
increased	0
predisposition	0
to	0
leukaemia/lymphoma	0
,	0
mainly	0
of	0
T	7
cell	8
origin	0
.	0

Some	0
translocation	7
cells	8
proliferate	0
into	0
a	0
large	0
clone	0
and	0
may	0
develop	0
into	0
T	0
cell	0
prolymphocytic	0
leukaemia	0
(	0
T-PLL	0
)	0
.	0

By	0
the	0
time	0
of	0
diagnosis	0
of	0
T-PLL	0
,	0
the	0
clone	0
contains	0
many	0
more	0
genetic	0
changes	0
in	0
the	0
form	0
of	0
additional	0
translocations	0
.	0

T-PLL	0
is	0
also	0
seen	0
in	0
non-A-T	0
individuals	0
where	0
expression	0
of	0
either	0
TCL1	9
(	0
at	0
14q32	1
)	0
or	0
the	0
c6.1B/MTCP1	9
A1	10
transcript	10
(	0
at-Xq28	1
)	0
has	0
been	0
demonstrated	0
in	0
just	0
a	0
few	0
instances	0
.	0

We	0
show	0
here	0
,	0
that	0
expression	0
of	0
TCL1	9
occurs	0
in	0
leukaemic	7
T	8
cells	8
from	0
A-T	0
patients	0
with	0
chromosome	1
14	2
rearrangements	0
.	0

Expression	0
of	0
TCL1	9
also	0
occurs	0
in	0
the	0
preleukaemic	7
clone	8
cells	8
of	0
A-T	0
patients	0
containing	0
the	0
primary	0
translocation	0
alone	0
.	0

Some	0
expression	0
of	0
TCL1	9
could	0
also	0
be	0
detected	0
in	0
randomly	0
selected	0
A-T	0
patients	0
without	0
large	0
cytogenetic	0
clones	0
and	0
without	0
any	0
evidence	0
of	0
leukaemic	0
change	0
.	0

We	0
also	0
show	0
that	0
expression	0
of	0
the	0
B1	3
transcript	4
from	0
a	0
second	0
gene	0
,	0
MTCP1	1
,	0
occurred	0
at	0
a	0
relatively	0
high	0
level	0
only	0
in	0
two	0
T-PLL	0
tumours	0
from	0
A-T	0
patients	0
with	0
t	0
(	0
X	0
;	0
14	0
)	0
translocations	0
whereas	0
the	0
MTCP1/A1	3
transcript	4
is	0
much	0
more	0
widely	0
expressed	0
in	0
both	0
tumour	7
and	8
non	8
tumour	8
cells	8
of	0
A-T	0
and	0
non-A-T	0
individuals	0
.	0

[	0
Correlation	0
of	0
lymphocytic	0
infiltration	0
of	0
tumor	0
tissue	0
with	0
the	0
hormonal	0
and	0
metabolic	0
state	0
in	0
patients	0
with	0
breast	0
cancer	0
]	0

Lymphocyte	0
infiltration	0
of	0
tumor	0
was	0
studied	0
vis-a-vis	0
hormone	0
metabolic	0
status	0
,	0
tumor	0
tissue	0
hormone	0
sensitivity	0
and	0
tobacco	0
smoking	0
,	0
in	0
113	0
breast	0
cancer	0
patients	0
,	0
aged	0
25-77	0
.	0

On	0
the	0
average	0
,	0
no	0
correlation	0
was	0
established	0
between	0
degree	0
of	0
lymphocyte	0
infiltration	0
in	0
breast	0
tumor	0
and	0
age	0
and	0
menopause	0
onset	0
.	0

In	0
smoking	0
menopausal	0
patients	0
,	0
lymphocyte	0
infiltration	0
was	0
found	0
to	0
be	0
higher	0
than	0
in	0
non-smokers	0
(	0
p	0
<	0
0.05	0
)	0
.	0

There	0
was	0
a	0
direct	0
correlation	0
between	0
the	0
rate	0
of	0
lymphocyte	0
infiltration	0
and	0
the	0
level	0
of	0
progesterone	9
receptors	10
in	0
tumor	0
.	0

Some	0
subgroups	0
displayed	0
a	0
direct	0
correlation	0
between	0
infiltration	0
and	0
sex-binding	9
globulin	10
,	0
cholesterol	0
,	0
luteinizing	0
hormone	0
in	0
blood	0
,	0
and	0
lean	0
body	0
mass	0
.	0

It	0
was	0
matched	0
by	0
an	0
inverse	0
correlation	0
between	0
lymphocyte	0
infiltration	0
and	0
blood-thyroid	0
hormone	0
concentration	0
,	0
urine	0
catecholamines	0
and	0
free	0
cortisol	0
excretion	0
and	0
fat/lean	0
body	0
mass	0
ratio	0
.	0

Considering	0
the	0
abovesaid	0
as	0
well	0
as	0
the	0
lymphocyte	0
ability	0
to	0
perform	0
the	0
dual	0
function	0
of	0
immunocytes	7
and	0
hormonocytes	7
,	0
it	0
is	0
suggested	0
that	0
the	0
results	0
may	0
be	0
used	0
in	0
both	0
the	0
study	0
of	0
lymphocyte	0
infiltration	0
and	0
research	0
in	0
means	0
of	0
its	0
control	0
.	0

Gene	0
transcription	0
through	0
activation	0
of	0
G-protein-coupled	9
chemoattractant	10
receptors	10
.	0

Receptors	0
for	0
leukocyte	9
chemoattractants	10
,	0
including	0
chemokines	9
,	0
are	0
traditionally	0
considered	0
to	0
be	0
responsible	0
for	0
the	0
activation	0
of	0
special	0
leukocyte	0
functions	0
such	0
as	0
chemotaxis	0
,	0
degranulation	0
,	0
and	0
the	0
release	0
of	0
superoxide	0
anions	0
.	0

Recently	0
,	0
these	0
G-protein-coupled	9
serpentine	10
receptors	10
have	0
been	0
found	0
to	0
transduce	0
signals	0
leading	0
to	0
gene	0
transcription	0
and	0
translation	0
in	0
leukocytes	7
.	0

Transcription	9
factors	10
,	0
such	0
as	0
NF	9
kappa	10
B	10
and	0
AP-1	9
,	0
are	0
activated	0
upon	0
stimulation	0
of	0
the	0
cells	0
with	0
several	0
chemoattractants	0
at	0
physiologically	0
relevant	0
concentrations	0
.	0

Activation	0
of	0
transcription	0
factors	0
through	0
these	0
receptors	0
involves	0
G-protein	9
coupling	0
and	0
the	0
activation	0
of	0
protein	9
kinases	10
.	0

The	0
underlying	0
signaling	0
pathways	0
appear	0
to	0
be	0
different	0
from	0
those	0
utilized	0
by	0
TNF-alpha	9
,	0
a	0
better	0
characterized	0
cytokine	0
that	0
induces	0
the	0
transcription	0
of	0
immediate-early	1
genes	2
.	0

Chemoattractants	0
stimulate	0
the	0
expression	0
of	0
several	0
inflammatory	9
cytokines	10
and	0
chemokines	9
,	0
which	0
in	0
turn	0
may	0
activate	0
their	0
respective	0
receptors	0
and	0
initiate	0
an	0
autocrine	0
regulatory	0
mechanism	0
for	0
persistent	0
cytokine	9
and	0
chemokine	9
gene	0
expression	0
.	0

Affinity-driven	0
peptide	0
selection	0
of	0
an	0
NFAT	0
inhibitor	0
more	0
selective	0
than	0
cyclosporin	0
A	0
[	0
see	0
comments	0
]	0

The	0
flow	0
of	0
information	0
from	0
calcium-mobilizing	9
receptors	10
to	0
nuclear	1
factor	2
of	2
activated	2
T	2
cells	2
(	2
NFAT	2
)	2
-dependent	2
genes	2
is	0
critically	0
dependent	0
on	0
interaction	0
between	0
the	0
phosphatase	9
calcineurin	9
and	0
the	0
transcription	9
factor	10
NFAT	9
.	0

A	0
high-affinity	0
calcineurin	9
-binding	0
peptide	0
was	0
selected	0
from	0
combinatorial	0
peptide	0
libraries	0
based	0
on	0
the	0
calcineurin	9
docking	10
motif	10
of	0
NFAT	9
.	0

This	0
peptide	0
potently	0
inhibited	0
NFAT	9
activation	0
and	0
NFAT	9
-dependent	0
expression	0
of	0
endogenous	1
cytokine	2
genes	2
in	0
T	7
cells	8
,	0
without	0
affecting	0
the	0
expression	0
of	0
other	0
cytokines	9
that	0
require	0
calcineurin	9
but	0
not	0
NFAT	9
.	0

Substitution	0
of	0
the	0
optimized	0
peptide	0
sequence	0
into	0
the	0
natural	0
calcineurin	9
docking	10
site	10
increased	0
the	0
calcineurin	9
responsiveness	0
of	0
NFAT	9
.	0

Compounds	0
that	0
interfere	0
selectively	0
with	0
the	0
calcineurin	9
-NFAT	9
interaction	0
without	0
affecting	0
calcineurin	9
phosphatase	9
activity	0
may	0
be	0
useful	0
as	0
therapeutic	0
agents	0
that	0
are	0
less	0
toxic	0
than	0
current	0
drugs	0
.	0

9-cis	0
retinoic	0
acid	0
induces	0
monocyte	9
chemoattractant	10
protein-1	10
secretion	0
in	0
human	7
monocytic	8
THP-1	8
cells	8
.	0

Monocyte	0
migration	0
and	0
activation	0
are	0
regulated	0
by	0
monocyte	9
chemoattractant	10
protein-1	10
(	0
MCP-1	9
)	0
.	0

Prior	0
studies	0
have	0
shown	0
MCP-1	9
expression	0
is	0
modulated	0
by	0
a	0
variety	0
of	0
ligands	0
that	0
act	0
through	0
extracellular	9
receptors	10
.	0

In	0
the	0
current	0
study	0
,	0
we	0
show	0
9-cis	0
retinoic	0
acid	0
(	0
RA	0
)	0
,	0
a	0
ligand	0
for	0
the	0
nuclear	9
hormone	10
receptor	10
retinoid	10
X	10
receptor	10
(	0
RXR	9
)	0
and	0
retinoic	9
acid	10
receptor	10
(	0
RAR	9
)	0
,	0
markedly	0
induces	0
the	0
expression	0
of	0
MCP-1	9
.	0

In	0
human	5
THP-1	6
monocytic	6
leukemia	6
cells	6
cultured	0
with	0
RA	0
(	0
0.05	0
to	0
500	0
nmol/L	0
)	0
,	0
MCP-1	9
expression	0
was	0
induced	0
rapidly	0
,	0
significantly	0
,	0
and	0
dose-dependently	0
by	0
as	0
much	0
as	0
165-fold	0
.	0

MCP-1	3
RNA	4
level	0
was	0
also	0
increased	0
in	0
RA-treated	0
cells	0
.	0

Expression	0
of	0
PPARgamma	9
,	0
a	0
heterodimer	0
partner	0
of	0
RXR	9
,	0
is	0
also	0
markedly	0
induced	0
by	0
RA	0
in	0
THP-1	7
cells	8
.	0

However	0
,	0
BRL49653	0
,	0
a	0
PPARgamma	9
ligand	0
,	0
failed	0
to	0
induce	0
MCP-1	9
secretion	0
either	0
alone	0
or	0
to	0
modify	0
the	0
expression	0
level	0
induced	0
by	0
RA	0
.	0

In	0
contrast	0
,	0
BRL49653	0
significantly	0
increased	0
MCP-1	9
(	0
biotinylated	9
MCP-1	10
)	0
binding	0
to	0
THP-1	7
cells	8
,	0
whereas	0
RA	0
had	0
no	0
effect	0
.	0

Other	0
peroxisome	9
proliferator	10
activated	10
receptor	10
(	0
PPAR	9
)	0
ligands	0
,	0
15d-PGJ	0
(	0
2	0
)	0
and	0
troglitazone	0
(	0
PPARgamma	9
)	0
,	0
Wy14	0
,	0
643	0
(	0
PPARalpha	9
)	0
,	0
and	0
PD195599	0
(	0
PPARbeta	9
)	0
inhibited	0
the	0
induction	0
of	0
MCP-1	9
by	0
RA	0
.	0

RA	0
's	0
effect	0
on	0
MCP-1	9
expression	0
in	0
human	0
elutriated	0
monocytes	0
were	0
similar	0
to	0
that	0
observed	0
in	0
the	0
THP-1	5
cells	6
.	0

These	0
studies	0
identify	0
RA	0
as	0
a	0
nuclear	0
signal	0
for	0
MCP-1	9
induction	0
in	0
undifferentiated	7
human	8
monocytic	8
cells	8
.	0

These	0
studies	0
also	0
suggest	0
monocyte	0
MCP-1	9
expression	0
induced	0
through	0
RA	0
may	0
modulate	0
cell	0
migration	0
.	0

Classification	0
of	0
IVS1-10T	0
--	0
>	0
C	0
as	0
a	0
polymorphism	0
of	0
BRCA1	1
.	0

Mutations	0
inactivating	0
the	0
tumor	1
suppressor	2
gene	2
BRCA1	1
may	0
be	0
responsible	0
for	0
disease	0
for	0
up	0
to	0
80	0
%	0
of	0
familial	0
ovarian	0
cancer	0
cases	0
.	0

In	0
this	0
syndrome	0
,	0
tumorigenesis	0
classically	0
initiates	0
from	0
an	0
inherited	0
mutation	0
in	0
one	0
allele	1
followed	0
by	0
somatic	0
deletion	0
of	0
the	0
normal	1
allele	2
.	0

Sequencing	0
of	0
BRCA1	1
amplified	0
from	0
genomic	1
DNA	2
of	0
lymphocytes	7
and	0
microdissected	7
ovarian	8
tumor	8
cells	8
of	0
a	0
familial	0
ovarian	0
cancer	0
patient	0
revealed	0
three	0
,	0
rare	0
heterozygous	0
DNA	0
variations	0
(	0
2418delA	0
,	0
233G	0
--	0
>	0
A	0
,	0
and	0
IVS1-10T	0
--	0
>	0
C	0
)	0
in	0
both	0
tumor	1
and	2
constitutional	2
(	2
lymphocyte	2
)	2
DNA	2
.	0

Thus	0
,	0
both	0
copies	0
of	0
BRCA1	1
were	0
retained	0
in	0
tumor	0
.	0

Haplotype	0
analysis	0
of	0
the	0
patient	0
and	0
four	0
siblings	0
assigned	0
2418delA	0
to	0
one	0
copy	0
of	0
BRCA1	1
and	0
233G	0
--	0
>	0
A	0
and	0
IVS1-10T	0
--	0
>	0
C	0
to	0
the	0
other	0
.	0

The	0
DNA	0
change	0
,	0
2418delA	0
,	0
is	0
considered	0
a	0
mutation	0
that	0
inactivated	0
one	0
BRCA1	1
allele	0
because	0
it	0
caused	0
a	0
frameshift	0
and	0
generation	0
of	0
a	0
premature	1
stop	2
codon	2
,	0
resulting	0
in	0
synthesis	0
of	0
a	0
truncated	0
peptide	0
as	0
evidenced	0
by	0
an	0
in	0
vitro	0
protein	0
truncation	0
test	0
.	0

The	0
DNA	0
variation	0
,	0
233G	0
--	0
>	0
A	0
,	0
does	0
not	0
result	0
in	0
an	0
amino	0
acid	0
change	0
,	0
and	0
is	0
considered	0
a	0
benign	0
polymorphism	0
.	0

IVS1-10T	0
--	0
>	0
C	0
is	0
a	0
unique	0
BRCA1	1
change	0
that	0
occurs	0
in	0
the	0
last	0
nucleotide	0
of	0
a	0
consensus	1
sequence	2
for	0
a	0
branch	1
site	2
critical	0
for	0
RNA	0
splicing	0
.	0

Therefore	0
,	0
we	0
investigated	0
whether	0
IVS1-10T	0
--	0
>	0
C	0
deleteriously	0
affected	0
BRCA1	1
splicing	0
or	0
expression	0
,	0
and	0
thereby	0
inactivated	0
the	0
other	0
BRCA1	1
allele	2
.	0

Using	0
the	0
technique	0
of	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
with	0
RNA	0
isolated	0
from	0
lymphoid	5
cell	6
lines	6
of	0
the	0
patient	0
and	0
of	0
controls	0
,	0
no	0
evidence	0
was	0
found	0
that	0
IVS1-10TC	0
abnormally	0
disrupted	0
mRNA	3
splicing	0
or	0
caused	0
the	0
absence	0
of	0
BRCA1	3
mRNA	4
.	0

Thus	0
,	0
IVS1-10T	0
--	0
>	0
C	0
is	0
not	0
harmful	0
to	0
BRCA1	1
function	0
,	0
and	0
is	0
classified	0
a	0
benign	0
polymorphism	0
.	0

Retention	0
of	0
the	0
normal	0
BRCA1	1
allele	2
in	0
the	0
tumor	0
with	0
the	0
heterozygous	0
germline	0
BRCA1	1
mutation	0
,	0
2418delA	0
,	0
indicated	0
that	0
mutational	0
inactivation	0
of	0
both	0
BRCA1	1
alleles	2
was	0
not	0
required	0
for	0
tumorigenesis	0
.	0

It	0
is	0
possible	0
that	0
the	0
normal	1
allele	2
may	0
be	0
functionally	0
inactivated	0
by	0
a	0
nonmutational	0
mechanism	0
.	0

Myb-transformed	7
hematopoietic	8
cells	8
as	0
a	0
model	0
for	0
monocyte	0
differentiation	0
into	0
dendritic	7
cells	8
and	0
macrophages	7
.	0

Immune	0
induction	0
is	0
effected	0
through	0
the	0
interaction	0
of	0
antigen-presenting	7
cells	8
with	0
specific	0
receptors	9
on	0
the	0
surface	0
of	0
thymus-derived	7
lymphocytes	8
.	0

Cells	0
most	0
able	0
to	0
ingest	0
,	0
process	0
,	0
and	0
present	0
antigen	0
appear	0
to	0
be	0
related	0
to	0
the	0
mononuclear	7
phagocyte/neutrophil	8
series	8
.	0

For	0
example	0
dendritic	7
cells	8
(	0
DC	7
)	0
can	0
be	0
found	0
in	0
colonies	0
of	0
GM-CSF-responsive	7
bone	8
marrow	8
cells	8
,	0
and	0
under	0
experimental	0
conditions	0
are	0
routinely	0
expanded	0
as	0
a	0
population	0
in	0
vitro	0
from	0
GM-CSF-responsive	7
progenitor	8
cells	8
.	0

To	0
address	0
the	0
question	0
of	0
DC	7
lineage	8
and	0
to	0
determine	0
what	0
genes	0
are	0
involved	0
in	0
lineage	0
commitment	0
,	0
we	0
have	0
generated	0
a	0
series	0
of	0
GM-CSF-responsive	5
cell	6
lines	6
that	0
can	0
be	0
induced	0
to	0
differentiate	0
in	0
a	0
homogeneous	0
manner	0
in	0
vitro	0
.	0

The	0
cloned	5
cell	6
lines	6
are	0
derived	0
from	0
12-day	0
fetal	0
liver	0
and	0
are	0
transformed	0
with	0
a	0
truncated	0
form	0
of	0
c-myb	1
,	0
which	0
lacks	0
the	0
normal	0
autoregulatory	1
sequences	2
.	0

As	0
far	0
as	0
we	0
know	0
,	0
these	0
myb-transformed	5
hemopoi-etic	6
cells	6
(	0
MTHC	5
)	0
differ	0
from	0
normal	0
only	0
in	0
the	0
unregulated	0
expression	0
of	0
myb	0
,	0
a	0
gene	0
whose	0
expression	0
is	0
obligatory	0
for	0
proliferation	0
of	0
hemopoietic	0
cells	0
.	0

MTHC	5
in	0
the	0
presence	0
of	0
TNF-alpha	9
and	0
IL-4	9
will	0
differentiate	0
into	0
cells	0
that	0
have	0
many	0
of	0
the	0
properties	0
of	0
macrophages	7
.	0

When	0
the	0
same	0
MTHC	5
lines	6
are	0
exposed	0
to	0
TNF-alpha	9
in	0
combination	0
with	0
IFN-gamma	9
,	0
the	0
cells	0
instead	0
become	0
DC	7
.	0

The	0
differentiated	0
DC	7
are	0
potent	0
presenters	0
of	0
antigen	0
in	0
mixed	0
lymphocyte	0
reactions	0
and	0
of	0
soluble	0
antigen	0
to	0
specific	0
T	5
cell	6
lines	6
.	0

Thus	0
,	0
cells	0
with	0
the	0
properties	0
of	0
both	0
macrophages	7
and	0
DC	7
can	0
be	0
derived	0
from	0
a	0
single	0
type	0
of	0
GM-CSF-responsive	7
progenitor	8
cell	8
.	0

We	0
have	0
used	0
this	0
MTHC	5
system	6
to	0
analyze	0
differences	0
in	0
gene	0
expression	0
as	0
the	0
cells	0
mature	0
along	0
the	0
DC	7
and	0
macrophage	7
pathways	8
.	0

A	0
distinctive	0
pattern	0
of	0
differentially	0
expressed	0
cDNAs	1
is	0
evident	0
where	0
macrophage-specific	1
cDNAs	2
are	0
homologous	0
to	0
genes	0
encoding	0
cytoskeletal	9
and	10
cell-surface	10
proteins	10
,	0
whereas	0
the	0
DC	7
-specific	0
cDNAs	1
are	0
homologous	0
to	0
signaling	1
,	2
chemokine	2
,	2
and	2
IFN-gamma-inducible	2
genes	2
.	0

We	0
discuss	0
the	0
utility	0
of	0
MTHC	5
in	0
analyzing	0
the	0
relationships	0
between	0
DC	7
and	0
macrophages	7
,	0
and	0
suggest	0
that	0
DC	7
and	0
macrophages	7
represent	0
extreme	0
phenotypes	0
in	0
a	0
spectrum	0
of	0
antigen	7
handling	8
cells	8
that	0
are	0
somewhat	0
interchangeable	0
,	0
depending	0
on	0
their	0
immediate	0
environment	0
.	0

The	0
Legionella	0
pneumophila	0
rpoS	1
gene	2
is	0
required	0
for	0
growth	0
within	0
Acanthamoeba	0
castellanii	0
.	0

To	0
investigate	0
regulatory	0
networks	0
in	0
Legionella	0
pneumophila	0
,	0
the	0
gene	0
encoding	0
the	0
homolog	0
of	0
the	0
Escherichia	9
coli	10
stress	10
and	10
stationary-phase	10
sigma	10
factor	10
RpoS	9
was	0
identified	0
by	0
complementation	0
of	0
an	0
E.	0
coli	0
rpoS	1
mutation	0
.	0

An	0
open	1
reading	2
frame	2
that	0
is	0
approximately	0
60	0
%	0
identical	0
to	0
the	0
E.	1
coli	2
rpoS	2
gene	2
was	0
identified	0
.	0

Western	0
blot	0
analysis	0
showed	0
that	0
the	0
level	0
of	0
L.	0
pneumophila	0
RpoS	9
increased	0
in	0
stationary	0
phase	0
.	0

An	0
insertion	0
mutation	0
was	0
constructed	0
in	0
the	0
rpoS	1
gene	2
on	0
the	0
chromosome	0
of	0
L.	0
pneumophila	0
,	0
and	0
the	0
ability	0
of	0
this	0
mutant	0
strain	0
to	0
survive	0
various	0
stress	0
conditions	0
was	0
assayed	0
and	0
compared	0
with	0
results	0
for	0
the	0
wild-type	0
strain	0
.	0

Both	0
the	0
mutant	0
and	0
wild-type	0
strains	0
were	0
more	0
resistant	0
to	0
stress	0
when	0
in	0
stationary	0
phase	0
than	0
when	0
in	0
the	0
logarithmic	0
phase	0
of	0
growth	0
.	0

This	0
finding	0
indicates	0
that	0
L.	0
pneumophila	0
RpoS	9
is	0
not	0
required	0
for	0
a	0
stationary-phase-dependent	0
resistance	0
to	0
stress	0
.	0

Although	0
the	0
mutant	0
strain	0
was	0
able	0
to	0
kill	0
HL-60-	7
and	8
THP-1-derived	8
macrophages	8
,	0
it	0
could	0
not	0
replicate	0
within	0
a	0
protozoan	0
host	0
,	0
Acanthamoeba	0
castellanii	0
.	0

These	0
data	0
suggest	0
that	0
L.	0
pneumophila	0
possesses	0
a	0
growth	0
phase-dependent	0
resistance	0
to	0
stress	0
that	0
is	0
independent	0
of	0
RpoS	9
control	0
and	0
that	0
RpoS	9
likely	0
regulates	0
genes	0
that	0
enable	0
it	0
to	0
survive	0
in	0
the	0
environment	0
within	0
protozoa	0
.	0

Our	0
data	0
indicate	0
that	0
the	0
role	0
of	0
rpoS	1
in	0
L.	0
pneumophila	0
is	0
very	0
different	0
from	0
what	0
has	0
previously	0
been	0
reported	0
for	0
E.	0
coli	0
rpoS	1
.	0

Monoallelic	0
expression	0
of	0
Pax5	9
:	0
a	0
paradigm	0
for	0
the	0
haploinsufficiency	0
of	0
mammalian	1
Pax	2
genes	2
?	0

It	0
is	0
generally	0
assumed	0
that	0
most	0
mammalian	1
genes	2
are	0
transcribed	0
from	0
both	0
alleles	1
.	0

Hence	0
,	0
the	0
diploid	0
state	0
of	0
the	0
genome	0
offers	0
the	0
advantage	0
that	0
a	0
loss-of-function	0
mutation	0
in	0
one	0
allele	1
can	0
be	0
compensated	0
for	0
by	0
the	0
remaining	0
wild-type	1
allele	2
of	0
the	0
same	0
gene	0
.	0

Indeed	0
,	0
the	0
vast	0
majority	0
of	0
human	0
disease	0
syndromes	0
and	0
engineered	0
mutations	0
in	0
the	0
mouse	1
genome	2
are	0
recessive	0
,	0
indicating	0
that	0
recessiveness	0
is	0
the	0
'default	0
'	0
state	0
.	0

However	0
,	0
a	0
minority	0
of	0
genes	0
are	0
semi-dominant	0
,	0
as	0
heterozygous	0
loss-of-function	0
mutation	0
in	0
these	0
genes	0
leads	0
to	0
phenotypic	0
abnormalities	0
.	0

This	0
condition	0
,	0
known	0
as	0
haploinsufficiency	0
,	0
has	0
been	0
described	0
for	0
five	0
of	0
the	0
nine	0
mammalian	1
Pax	2
genes	2
,	0
which	0
are	0
associated	0
with	0
mouse	0
developmental	0
mutants	0
and	0
human	0
disease	0
syndromes	0
.	0

Recently	0
we	0
have	0
reported	0
that	0
the	0
Pax5	1
gene	2
is	0
subject	0
to	0
allele	1
-specific	0
regulation	0
during	0
B	0
cell	0
development	0
.	0

Pax5	9
is	0
predominantly	0
transcribed	0
from	0
only	0
one	0
of	0
its	0
two	0
alleles	1
in	0
early	7
B-lymphoid	8
progenitors	8
and	0
mature	7
B	8
cells	8
,	0
while	0
it	0
transiently	0
switches	0
to	0
a	0
biallelic	0
mode	0
of	0
transcription	0
in	0
pre-B	7
and	8
immature	8
B	8
cells	8
.	0

As	0
a	0
consequence	0
,	0
B-lymphoid	0
tissues	0
are	0
mosaic	0
with	0
regard	0
to	0
the	0
transcribed	0
allele	1
,	0
and	0
heterozygous	0
mutation	0
of	0
Pax5	9
therefore	0
results	0
in	0
deletion	0
of	0
B	7
lymphocytes	8
expressing	0
only	0
the	0
mutant	1
allele	2
.	0

The	0
allele	1
-specific	0
regulation	0
of	0
Pax5	9
raises	0
the	0
intriguing	0
possibility	0
that	0
monoallelic	0
expression	0
may	0
also	0
be	0
the	0
mechanism	0
causing	0
the	0
haploinsufficiency	0
of	0
other	0
Pax	1
genes	2
.	0

In	0
this	0
review	0
,	0
we	0
discuss	0
different	0
models	0
accounting	0
for	0
the	0
haploinsufficiency	0
of	0
mammalian	1
Pax	2
genes	2
,	0
provide	0
further	0
evidence	0
in	0
support	0
of	0
the	0
allele	1
-specific	0
regulation	0
of	0
Pax5	9
and	0
discuss	0
the	0
implication	0
of	0
these	0
findings	0
in	0
the	0
context	0
of	0
the	0
recent	0
literature	0
describing	0
the	0
stochastic	0
and	0
monoallelic	0
activation	0
of	0
other	0
hematopoietic	1
genes	2
.	0

Activation	0
of	0
STAT5	9
by	0
IL-4	9
relies	0
on	0
Janus	9
kinase	10
function	0
but	0
not	0
on	0
receptor	0
tyrosine	0
phosphorylation	0
,	0
and	0
can	0
contribute	0
to	0
both	0
cell	0
proliferation	0
and	0
gene	0
regulation	0
.	0

We	0
have	0
investigated	0
mechanisms	0
and	0
consequences	0
of	0
STAT5	9
activation	0
through	0
the	0
human	9
IL-4	10
receptor	10
(	0
IL-4R	9
)	0
.	0

By	0
functionally	0
expressing	0
receptor	9
mutants	10
in	0
the	0
murine	5
pro-B	6
cell	6
line	6
Ba/F3	5
,	0
we	0
could	0
show	0
that	0
phosphorylated	0
tyrosine	0
residues	0
within	0
the	0
IL-4R	9
alpha	10
chain	10
are	0
dispensable	0
for	0
IL-4	9
-induced	0
STAT5	9
activity	0
.	0

However	0
,	0
disruption	0
of	0
a	0
membrane-proximal	9
proline-rich	10
sequence	10
motif	10
(	0
'	0
box1	9
'	0
)	0
in	0
either	0
subunit	0
of	0
the	0
bipartite	9
IL-4R	10
abolished	0
not	0
only	0
ligand-induced	0
tyrosine	0
phosphorylation	0
of	0
Janus	9
kinases	10
JAK1	9
and	0
JAK3	9
,	0
but	0
also	0
IL-4	9
-triggered	0
activation	0
of	0
STAT5	9
and	0
concomitant	0
cell	0
proliferation	0
.	0

A	0
dominant-negative	9
version	10
of	0
STAT5b	9
,	0
but	0
not	0
of	0
STAT5a	9
,	0
interfered	0
with	0
IL-4	9
-induced	0
DNA	0
synthesis	0
in	0
Ba/F3	5
cells	6
,	0
suggesting	0
an	0
involvement	0
of	0
STAT5b	9
in	0
the	0
control	0
of	0
cell	0
proliferation	0
through	0
IL-4R	9
.	0

Reporter	0
gene	0
experiments	0
finally	0
showed	0
that	0
transcription	0
from	0
promoters	0
of	0
STAT5	9
target	0
genes	0
can	0
be	0
specifically	0
induced	0
by	0
challenging	0
cells	0
with	0
IL-4	9
,	0
and	0
that	0
both	0
STAT5a	9
and	0
STAT5b	9
can	0
contribute	0
to	0
IL-4	9
-triggered	0
transcriptional	0
control	0
.	0

Inhibition	0
of	0
NF-AT	9
signal	0
transduction	0
events	0
by	0
a	0
dominant-negative	0
form	0
of	0
calcineurin	9
.	0

An	0
inhibitory	0
,	0
``	0
dominant-negative	0
,	0
''	0
form	0
of	0
the	0
calcineurin	9
catalytic	10
(	10
A	10
)	10
subunit	10
was	0
prepared	0
,	0
which	0
lacks	0
the	0
calmodulin-binding	9
domain	10
,	0
autoinhibitory	9
domain	10
and	0
most	0
of	0
its	0
catalytic	0
core	0
but	0
possesses	0
the	0
regulatory	9
(	10
B	10
)	10
subunit	10
binding	0
domain	0
.	0

When	0
tested	0
for	0
its	0
ability	0
to	0
block	0
calcineurin	9
-dependent	0
signaling	0
in	0
Jurkat	0
cells	0
,	0
expression	0
of	0
this	0
``	1
B-subunit	2
knock-out	2
''	2
(	2
BKO	2
)	2
construct	2
suppressed	0
reporter	1
gene	2
activity	0
driven	0
by	0
NF-AT	9
,	0
the	0
pivotal	0
promoter	1
element	2
for	0
interleukin	1
(	2
IL	2
)	2
-2	2
gene	2
induction	0
.	0

Immunoprecipitation	0
of	0
epitope-labeled	9
BKO	10
demonstrated	0
for	0
the	0
formation	0
of	0
a	0
tight	0
complex	0
with	0
endogenous	9
B	10
subunit	10
in	0
Jurkat	5
cells	6
,	0
consistent	0
with	0
an	0
inhibitory	0
mechanism	0
that	0
involves	0
the	0
sequestration	0
of	0
the	0
B	9
subunit	10
.	0

Furthermore	0
,	0
the	0
sharply	0
reduced	0
NF-AT	9
activity	0
produced	0
by	0
co-transfecting	1
BKO	2
could	0
be	0
``	0
rescued	0
''	0
by	0
overexpression	0
of	0
transfected	0
B	9
subunit	10
,	0
suggesting	0
that	0
depletion	0
of	0
this	0
subunit	0
was	0
responsible	0
for	0
the	0
inhibition	0
.	0

These	0
data	0
suggest	0
the	0
potential	0
utility	0
of	0
agents	0
that	0
disrupt	0
calcineurin	9
-mediated	0
signal	0
transduction	0
pathways	0
by	0
blocking	0
formation	0
of	0
the	0
catalytically	9
active	10
dimer	10
of	0
calcineurin	9
A	10
and	10
B	10
subunits	10
.	0

Evaluation	0
of	0
monoclonal	0
anti-D	0
reagents	0
using	0
D	5
variant	6
cells	6
.	0

Monoclonal	9
anti-D	10
antibodies	10
submitted	0
to	0
the	0
Third	0
Monoclonal	0
International	0
Workshop	0
were	0
evaluated	0
against	0
a	0
number	0
of	0
D	5
variant	6
cells	6
using	0
standard	0
serological	0
techniques	0
.	0

The	0
monoclonal	9
antibodies	10
were	0
able	0
to	0
discriminate	0
between	0
the	0
cells	0
of	0
Categories	5
Va	6
,	6
VI	6
and	6
DFR	6
but	6
not	6
Category	6
III	6
cells	6
.	0

Cells	0
within	0
each	0
category	0
did	0
not	0
give	0
any	0
aberrant	0
results	0
.	0

The	0
Rh	5
:	6
33	6
cells	6
behaved	0
as	0
normal	7
Rh	8
(	8
D	8
)	8
positive	8
cells	8
.	0

Interleukin	9
10	10
induced	0
c-fos	1
expression	0
in	0
human	7
B	8
cells	8
by	0
activation	0
of	0
divergent	9
protein	10
kinases	10
.	0

IL-10	9
is	0
a	0
potent	0
mediator	0
of	0
human	7
B	8
cell	8
growth	0
and	0
plasma	0
cell	0
formation	0
.	0

However	0
,	0
signal	0
transduction	0
of	0
IL-10	9
in	0
B	7
cells	8
is	0
poorly	0
understood	0
.	0

In	0
this	0
study	0
the	0
effect	0
of	0
IL-10	9
on	0
the	0
expression	0
of	0
the	0
protooncogene	1
c-fos	2
was	0
investigated	0
,	0
because	0
Fos	0
plays	0
a	0
potential	0
role	0
in	0
the	0
regulation	0
of	0
B	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

B	7
cells	8
were	0
purified	0
from	0
buffy	0
coat	0
preparations	0
of	0
healthy	0
blood	0
donors	0
by	0
positive	0
selection	0
using	0
an	0
anti	9
CD20	10
monoclonal	10
antibody	10
and	0
a	0
MiniMACS	0
separation	0
unit	0
.	0

B	7
cells	8
were	0
prestimulated	0
with	0
SAC	0
for	0
48	0
hrs	0
.	0

Then	0
,	0
cells	0
were	0
incubated	0
with	0
medium	0
or	0
IL-10	9
(	0
100	0
ng/ml	0
)	0
for	0
10	0
to	0
120	0
min	0
.	0

RNA	3
was	0
extracted	0
by	0
phenol/chloroform	0
and	0
c-fos	1
expression	0
was	0
analyzed	0
by	0
PCR	0
assisted	0
mRNA	0
assay	0
.	0

A	0
significant	0
2-4	0
fold	0
increase	0
of	0
c-fos	1
expression	0
was	0
observed	0
within	0
30	0
min	0
of	0
stimulation	0
with	0
IL-10	9
(	0
p	0
<	0
0.01	0
)	0
.	0

After	0
2	0
hrs	0
c-fos	1
expression	0
declined	0
to	0
basal	0
levels	0
.	0

The	0
effect	0
of	0
IL-10	9
was	0
dose-dependent	0
with	0
a	0
maximum	0
stimulation	0
using	0
100	0
ng/ml	0
of	0
IL-10	9
.	0

The	0
IL-10	9
effect	0
on	0
c-fos	1
expression	0
was	0
not	0
blocked	0
by	0
polymyxin	0
B	0
.	0

Using	0
the	0
tyrosine	0
kinase	0
inhibitor	0
genistein	0
(	0
10	0
microM	0
)	0
a	0
complete	0
inhibition	0
of	0
IL-10	9
induced	0
c-fos	1
expression	0
was	0
observed	0
.	0

In	0
addition	0
,	0
H-7	0
(	0
10	0
microM	0
)	0
,	0
a	0
specific	0
inhibitor	0
of	0
serine/threonine	9
kinases	10
,	0
significantly	0
blocked	0
IL-10	9
mediated	0
c-fos	1
expression	0
(	0
p	0
<	0
0.05	0
)	0
.	0

In	0
conclusion	0
,	0
these	0
data	0
show	0
that	0
IL-10	9
induces	0
c-fos	1
expression	0
in	0
human	7
B-cells	8
by	0
activation	0
of	0
tyrosine	0
and	0
serine/threonine	9
kinases	10
.	0

Since	0
this	0
is	0
the	0
first	0
report	0
on	0
IL-10	9
induced	0
signal	0
transduction	0
,	0
these	0
data	0
may	0
help	0
to	0
identify	0
the	0
intracellular	0
mechanisms	0
by	0
which	0
IL-10	9
stimulates	0
human	7
B-cells	8
.	0

Immunocytochemical	0
analysis	0
of	0
MNDA	9
in	0
tissue	0
sections	0
and	0
sorted	0
normal	0
bone	0
marrow	0
cells	0
documents	0
expression	0
only	0
in	0
maturing	0
normal	0
and	0
neoplastic	0
myelomonocytic	0
cells	0
and	0
a	0
subset	0
of	0
normal	0
and	0
neoplastic	0
B	0
lymphocytes	0
.	0

The	0
human	0
myeloid	0
cell	0
nuclear	0
differentiation	0
antigen	0
(	0
MNDA	9
)	0
is	0
a	0
nuclear	0
antigen	0
known	0
to	0
be	0
expressed	0
in	0
mature	0
myelomonocytic	0
cell	0
lines	0
.	0

An	0
extensive	0
immunocytochemical	0
evaluation	0
of	0
fixed	0
tissues	0
confirmed	0
MNDA	9
expression	0
in	0
normal	7
maturing	8
granulocytes	8
and	0
monocytes	7
and	0
in	0
acute	0
nonlymphocytic	0
leukemias	0
and	0
chronic	0
myelogenous	0
leukemia	0
.	0

MNDA	9
was	0
not	0
detected	0
in	0
normal	0
tissue	0
histiocytes	0
but	0
was	0
found	0
in	0
activated	7
macrophages	8
and	0
foreign	7
body	8
giant	8
cells	8
associated	0
with	0
inflammation	0
.	0

Flow	0
cytometric	0
cell	0
sorting	0
of	0
normal	0
bone	0
marrow	0
established	0
that	0
MNDA	9
is	0
initially	0
expressed	0
in	0
myeloid	7
blast	8
cells	8
.	0

Examination	0
of	0
lymphoid	0
tissues	0
showed	0
a	0
low	0
level	0
of	0
expression	0
in	0
a	0
population	0
of	0
normal	0
mande	5
B	6
lymphocytes	6
but	0
not	0
in	0
germinal	7
center	8
cells	8
or	0
plasma	7
cells	8
.	0

A	0
subset	0
of	0
B	7
cell	8
neoplasms	8
expressing	0
MNDA	9
included	0
hairy	0
cell	0
leukemia	0
,	0
parafollicular	0
(	0
monocytoid	0
)	0
B	0
cell	0
lymphoma	0
,	0
mantle	0
cell	0
lymphoma	0
,	0
and	0
small	0
lymphocytic	0
lymphoma	0
.	0

Cell	0
sorting	0
of	0
normal	0
bone	0
marrow	0
showed	0
MNDA	9
expression	0
in	0
CD20	9
+/CD10-/CD5-	0
B	7
cells	8
.	0

MNDA	9
was	0
not	0
detected	0
in	0
other	0
normal	0
bone	0
marrow	0
or	0
all	0
other	0
nonhematopoietic	7
cells	8
.	0

The	0
hematopoietic	0
cell-specific	0
pattern	0
of	0
MNDA	9
expression	0
was	0
elucidated	0
through	0
a	0
comprehensive	0
analysis	0
of	0
normal	0
and	0
neoplastic	0
tissues	0
,	0
and	0
the	0
results	0
provide	0
further	0
evidence	0
of	0
the	0
coexpression	0
of	0
B-	9
and	10
myeloid	10
cell	10
markers	10
in	0
neoplastic	7
B	8
cells	8
and	0
identify	0
a	0
normal	7
B	8
cell	8
population	8
that	0
might	0
be	0
related	0
to	0
the	0
cell	0
of	0
origin	0
of	0
a	0
subset	0
of	0
B	7
cell	8
neoplasms	8
.	0

Peroxisome	9
proliferator-activated	10
receptor	10
activators	10
target	0
human	7
endothelial	8
cells	8
to	0
inhibit	0
leukocyte	7
-endothelial	7
cell	8
interaction	0
.	0

An	0
early	0
event	0
in	0
acute	0
and	0
chronic	0
inflammation	0
and	0
associated	0
diseases	0
such	0
as	0
atherosclerosis	0
and	0
rheumatoid	0
arthritis	0
is	0
the	0
induced	0
expression	0
of	0
specific	0
adhesion	9
molecules	10
on	0
the	0
surface	0
of	0
endothelial	7
cells	8
(	0
ECs	7
)	0
,	0
which	0
subsequently	0
bind	0
leukocytes	7
.	0

Peroxisome	9
proliferator-activated	10
receptors	10
(	0
PPARs	9
)	0
,	0
members	0
of	0
the	0
nuclear	9
receptor	10
superfamily	10
of	0
transcription	9
factors	10
,	0
are	0
activated	0
by	0
fatty	0
acid	0
metabolites	0
,	0
peroxisome	0
proliferators	0
,	0
and	0
thiazolidinediones	0
and	0
are	0
now	0
recognized	0
as	0
important	0
mediators	0
in	0
the	0
inflammatory	0
response	0
.	0

Whether	0
PPAR	0
activators	0
influence	0
the	0
inflammatory	0
responses	0
of	0
ECs	7
is	0
unknown	0
.	0

We	0
show	0
that	0
the	0
PPAR	0
activators	0
15-deoxy-Delta	0
(	0
12	0
,	0
14	0
)	0
-prostaglandin	0
J	0
(	0
2	0
)	0
(	0
15d-PGJ	0
(	0
2	0
)	0
)	0
,	0
Wyeth	0
14643	0
,	0
ciglitazone	0
,	0
and	0
troglitazone	0
,	0
but	0
not	0
BRL	0
49653	0
,	0
partially	0
inhibit	0
the	0
induced	0
expression	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
,	0
as	0
measured	0
by	0
ELISA	0
,	0
and	0
monocyte	0
binding	0
to	0
human	7
aortic	8
endothelial	8
cells	8
(	0
HAECs	7
)	0
activated	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
or	0
lipopolysaccharide	0
.	0

The	0
``	0
natural	0
''	0
PPAR	0
activator	0
15d-PGJ	0
(	0
2	0
)	0
had	0
the	0
greatest	0
potency	0
and	0
was	0
the	0
only	0
tested	0
molecule	0
capable	0
of	0
partially	0
inhibiting	0
the	0
induced	0
expression	0
of	0
E-selectin	9
and	0
neutrophil-like	0
HL60	5
cell	6
binding	0
to	0
PMA-activated	0
HAECs	7
.	0

Intracellular	0
adhesion	0
molecule-1	0
induction	0
by	0
PMA	0
was	0
unaffected	0
by	0
any	0
of	0
the	0
molecules	0
tested	0
.	0

Both	0
PPAR-alpha	3
and	4
PPAR-gamma	4
mRNAs	4
were	0
detected	0
in	0
HAECs	7
by	0
using	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
and	0
a	0
ribonuclease	9
protection	0
assay	0
;	0
however	0
,	0
we	0
have	0
yet	0
to	0
determine	0
which	0
,	0
if	0
any	0
,	0
of	0
the	0
PPARs	9
are	0
mediating	0
this	0
process	0
.	0

These	0
results	0
suggest	0
that	0
certain	0
PPAR	0
activators	0
may	0
help	0
limit	0
chronic	0
inflammation	0
mediated	0
by	0
VCAM-1	9
and	0
monocytes	7
without	0
affecting	0
acute	0
inflammation	0
mediated	0
by	0
E-selectin	9
and	0
neutrophil	7
binding	0
.	0

Dephosphorylation	0
of	0
ZAP-70	9
and	0
inhibition	0
of	0
T	0
cell	0
activation	0
by	0
activated	9
SHP1	10
.	0

Studies	0
with	0
motheaten	0
mice	0
,	0
which	0
lack	0
the	0
SHP1	9
protein	10
tyrosine	9
phosphatase	10
,	0
indicate	0
that	0
this	0
enzyme	0
plays	0
an	0
important	0
negative	0
role	0
in	0
T	9
cell	10
antigen	10
receptor	10
(	0
TCR	9
)	0
signaling	0
.	0

The	0
physiological	0
substrates	0
for	0
SHP1	9
in	0
T	7
lymphocytes	8
,	0
however	0
,	0
have	0
remained	0
unclear	0
or	0
controversial	0
.	0

To	0
define	0
these	0
targets	0
for	0
SHP1	9
we	0
have	0
compared	0
the	0
effects	0
of	0
constitutively	0
active	0
and	0
inactive	0
mutants	0
of	0
SHP1	9
on	0
TCR	9
signaling	0
.	0

Expression	0
of	0
wild-type	9
SHP1	10
had	0
a	0
very	0
small	0
effect	0
on	0
the	0
TCR-induced	0
tyrosine	0
phosphorylation	0
of	0
ZAP-70	9
and	0
Syk	9
,	0
even	0
when	0
SHP1	9
was	0
overexpressed	0
20	0
-	0
100-fold	0
over	0
endogenous	9
SHP1	10
.	0

Inactive	9
SHP1-D421A	10
and	0
wild-type	9
SHP2	10
were	0
without	0
effects	0
.	0

Constitutively	9
active	10
SHP1-DeltaSH2	10
had	0
a	0
more	0
pronounced	0
effect	0
on	0
ZAP-70	9
and	0
Syk	9
,	0
even	0
when	0
expressed	0
at	0
near	0
physiological	0
levels	0
.	0

SHP1-DeltaSH2	9
also	0
inhibited	0
events	0
downstream	0
of	0
ZAP-70	9
and	0
Syk	9
,	0
such	0
as	0
activation	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
Erk2	9
and	0
the	0
transcriptional	0
activation	0
of	0
the	0
interleukin-2	1
gene	2
.	0

In	0
contrast	0
,	0
a	0
constitutively	0
active	0
SHP2-DeltaSH2	9
had	0
no	0
statistically	0
significant	0
effect	0
(	0
although	0
it	0
caused	0
a	0
slight	0
augmentation	0
in	0
some	0
individual	0
experiments	0
)	0
.	0

None	0
of	0
the	0
constructs	0
influenced	0
the	0
anti-CD3-induced	0
tyrosine	0
phosphorylation	0
of	0
the	0
TCR	9
zeta-chain	10
or	0
phospholipase	9
Cgamma1	10
,	0
indicating	0
that	0
Src	9
family	10
kinase	10
function	0
was	0
intact	0
.	0

Taken	0
together	0
,	0
our	0
findings	0
support	0
the	0
notion	0
that	0
ZAP-70	9
and	0
Syk	9
can	0
be	0
direct	0
substrates	0
for	0
SHP1	9
in	0
intact	0
cells	0
.	0

However	0
,	0
the	0
two	0
SH2	9
domains	10
of	0
SHP1	9
did	0
not	0
facilitate	0
its	0
recognition	0
of	0
ZAP-70	9
and	0
Syk	9
as	0
substrates	0
in	0
intact	0
cells	0
.	0

Therefore	0
,	0
we	0
suggest	0
that	0
SHP1	9
is	0
not	0
actively	0
recruited	0
to	0
inhibit	0
TCR	9
signaling	0
induced	0
by	0
ligation	0
of	0
this	0
receptor	0
alone	0
.	0

Instead	0
,	0
we	0
propose	0
that	0
ligation	0
of	0
a	0
distinct	0
inhibitory	9
receptor	10
leads	0
to	0
the	0
recruitment	0
of	0
SHP1	9
via	0
its	0
SH2	9
domains	10
,	0
activation	0
of	0
SHP1	9
and	0
subsequently	0
inhibition	0
of	0
TCR	9
signals	0
if	0
the	0
inhibitory	9
receptor	10
is	0
juxtaposed	0
to	0
the	0
TCR	9
.	0

Immune	0
responses	0
to	0
adenoviruses	0
:	0
viral	0
evasion	0
mechanisms	0
and	0
their	0
implications	0
for	0
the	0
clinic	0
.	0

Adenoviruses	0
encode	0
proteins	0
that	0
block	0
responses	0
to	0
interferons	9
,	0
intrinsic	0
cellular	0
apoptosis	0
,	0
killing	0
by	0
CD8	7
(	8
+	8
)	8
cytotoxic	8
T	8
lymphocytes	8
and	0
killing	0
by	0
the	0
death	9
ligands	10
TNF	9
,	0
Fas	9
ligand	10
and	0
TRAIL	9
.	0

The	0
viral	9
proteins	10
are	0
believed	0
to	0
prolong	0
acute	0
and	0
persistent	0
adenovirus	0
infections	0
.	0

The	0
proteins	0
may	0
prove	0
useful	0
in	0
protecting	0
adenovirus	1
gene	2
therapy	2
vectors	2
and	0
transplanted	5
cells	6
from	0
the	0
immune	0
system	0
.	0

C/EBPbeta	9
and	0
GATA-1	9
synergistically	0
regulate	0
activity	0
of	0
the	0
eosinophil	1
granule	2
major	2
basic	2
protein	2
promoter	2
:	0
implication	0
for	0
C/EBPbeta	9
activity	0
in	0
eosinophil	0
gene	0
expression	0
.	0

Eosinophil	9
granule	10
major	10
basic	10
protein	10
(	0
MBP	9
)	0
is	0
expressed	0
exclusively	0
in	0
eosinophils	7
and	0
basophils	7
in	0
hematopoietic	7
cells	8
.	0

In	0
our	0
previous	0
study	0
,	0
we	0
demonstrated	0
a	0
major	0
positive	0
regulatory	0
role	0
for	0
GATA-1	9
and	0
a	0
negative	0
regulatory	0
role	0
for	0
GATA-2	9
in	0
MBP	9
gene	0
transcription	0
.	0

Further	0
analysis	0
of	0
the	0
MBP	1
promoter	2
region	2
identified	0
a	0
C/EBP	1
(	2
CCAAT/enhancer-binding	2
protein	2
)	2
consensus	2
binding	2
site	2
6	0
bp	0
upstream	0
of	0
the	0
functional	0
GATA-binding	1
site	2
in	0
the	0
MBP	1
gene	2
.	0

In	0
the	0
cell	5
line	6
HT93A	6
,	0
which	0
is	0
capable	0
of	0
differentiating	0
towards	0
both	0
the	0
eosinophil	7
and	0
neutrophil	0
lineages	0
in	0
response	0
to	0
retinoic	0
acid	0
(	0
RA	0
)	0
,	0
C/EBPalpha	3
mRNA	4
expression	0
decreased	0
significantly	0
concomitant	0
with	0
eosinophilic	0
and	0
neutrophilic	0
differentiation	0
,	0
whereas	0
C/EBPbeta	9
expression	0
was	0
markedly	0
increased	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
showed	0
that	0
recombinant	0
C/EBPbeta	9
protein	0
could	0
bind	0
to	0
the	0
potential	0
C/EBP-binding	1
site	2
(	0
bp	1
-90	2
to	2
-82	2
)	0
in	0
the	0
MBP	9
promoter	0
.	0

Furthermore	0
,	0
we	0
have	0
demonstrated	0
that	0
both	0
C/EBPbeta	9
and	0
GATA-1	9
can	0
bind	0
simultaneously	0
to	0
the	0
C/EBP-	0
and	0
GATA-binding	1
sites	2
in	0
the	0
MBP	1
promoter	2
.	0

To	0
determine	0
the	0
functionality	0
of	0
both	0
the	0
C/EBP-	1
and	2
GATA-	2
binding	2
sites	2
,	0
we	0
analyzed	0
whether	0
C/EBPbeta	9
and	0
GATA-1	9
can	0
stimulate	0
the	0
MBP	1
promoter	2
in	0
the	0
C/EBPbeta	5
and	6
GATA-1	6
negative	6
Jurkat	6
T-cell	6
line	6
.	0

Cotransfection	0
with	0
C/EBPbeta	1
and	2
GATA-1	2
expression	2
vectors	2
produced	0
a	0
5-fold	0
increase	0
compared	0
with	0
cotransfection	0
with	0
the	0
C/EBPbeta	9
or	0
GATA-1	1
expression	2
vectors	2
individually	0
.	0

In	0
addition	0
,	0
GST	9
pull-down	0
experiments	0
demonstrated	0
a	0
physical	0
interaction	0
between	0
human	0
GATA-1	9
and	0
C/EBPbeta	9
.	0

Expression	0
of	0
FOG	9
(	0
riend	9
ATA	10
)	0
,	0
which	0
binds	0
to	0
GATA-1	9
and	0
acts	0
as	0
a	0
cofactor	0
for	0
GATA-binding	9
proteins	10
,	0
decreased	0
transactivation	0
activity	0
of	0
GATA-1	9
for	0
the	0
MBP	1
promoter	2
in	0
a	0
dose-dependent	0
manner	0
.	0

Our	0
results	0
provide	0
the	0
first	0
evidence	0
that	0
both	0
GATA-1	9
and	0
C/EBPbeta	9
synergistically	0
transactivate	0
the	0
promoter	1
of	0
an	0
eosinophil-specific	1
granule	2
protein	2
gene	2
and	0
that	0
FOG	9
may	0
act	0
as	0
a	0
negative	0
cofactor	0
for	0
the	0
eosinophil	7
lineage	8
,	0
unlike	0
its	0
positively	0
regulatory	0
function	0
for	0
the	0
erythroid	7
and	8
megakaryocyte	8
lineages	8
.	0

Tissue-specific	0
regulation	0
of	0
the	0
ecto-5'-nucleotidase	1
promoter	2
.	0

Role	0
of	0
the	0
camp	1
response	2
element	2
site	2
in	0
mediating	0
repression	0
by	0
the	0
upstream	1
regulatory	2
region	2
.	0

We	0
have	0
isolated	0
the	0
5	1
'	2
region	2
of	0
the	0
ecto-5'-nucleotidase	1
(	2
low	2
K	2
(	2
m	2
)	2
5'-NT	2
)	2
gene	2
and	0
established	0
that	0
a	0
969-base	1
pair	2
(	2
bp	2
)	2
fragment	2
confers	0
cell-specific	0
expression	0
of	0
a	0
CAT	1
reporter	2
gene	2
that	0
correlates	0
with	0
the	0
expression	0
of	0
endogenous	3
ecto-5'-NT	4
mRNA	4
and	0
enzymatic	0
activity	0
.	0

A	0
768-bp	1
upstream	2
negative	2
regulatory	2
region	2
has	0
been	0
identified	0
that	0
conferred	0
lymphocyte-specific	0
negative	0
regulation	0
in	0
a	0
heterologous	0
system	0
with	0
a	0
244-bp	1
deoxycytidine	2
kinase	2
core	2
promoter	2
.	0

DNase	9
I	10
footprinting	0
identified	0
several	0
protected	0
areas	0
including	0
Sp1	1
,	2
Sp1/AP-2	2
,	2
and	2
cAMP	2
response	2
element	2
(	2
CRE	2
)	2
binding	2
sites	2
within	0
the	0
201-bp	0
core	0
promoter	0
region	0
and	0
Sp1	1
,	2
NRE-2a	2
,	2
TCF-1/LEF-1	2
,	2
and	2
Sp1/NF-AT	2
binding	2
sites	2
in	0
the	0
upstream	1
regulatory	2
region	2
.	0

Whereas	0
the	0
CRE	1
site	2
was	0
essential	0
in	0
mediating	0
the	0
negative	0
activity	0
of	0
the	0
upstream	1
regulatory	2
region	2
in	0
Jurkat	5
but	0
not	0
in	0
HeLa	5
cells	6
,	0
mutation	0
of	0
the	0
Sp1/AP-2	1
site	2
decreased	0
promoter	0
activity	0
in	0
both	0
cell	0
lines	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
analysis	0
of	0
proteins	0
binding	0
to	0
the	0
CRE	1
site	2
identified	0
both	0
ATF-1	9
and	0
ATF-2	9
in	0
Jurkat	5
cells	6
.	0

Finally	0
,	0
phorbol	0
12-myristate	0
13-acetate	0
increased	0
the	0
activity	0
of	0
both	0
the	0
core	0
and	0
the	0
969-bp	1
promoter	2
fragments	2
,	0
and	0
this	0
increase	0
was	0
abrogated	0
by	0
mutations	0
at	0
the	0
CRE	1
site	2
.	0

In	0
summary	0
,	0
we	0
have	0
identified	0
a	0
tissue-specific	1
regulatory	2
region	2
5	0
'	0
of	0
the	0
ecto-5'-NT	1
core	2
promoter	2
that	0
requires	0
the	0
presence	0
of	0
a	0
functional	0
CRE	1
site	2
within	0
the	0
basal	1
promoter	2
for	0
its	0
suppressive	0
activity	0
.	0

Extracellular	0
signal-regulated	0
protein	0
kinase	0
(	0
ERK	0
)	0
-dependent	0
and	0
ERK-independent	0
pathways	0
target	0
STAT3	9
on	0
serine-727	0
in	0
human	0
neutrophils	0
stimulated	0
by	0
chemotactic	9
factors	10
and	0
cytokines	9
.	0

STAT3	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
3	10
)	0
is	0
a	0
latent	0
transcription	0
factor	0
that	0
is	0
activated	0
by	0
tyrosine	0
phosphorylation	0
(	0
Tyr-705	0
)	0
in	0
cells	0
stimulated	0
with	0
cytokines	9
or	0
growth	9
factors	10
.	0

Recent	0
studies	0
suggest	0
that	0
one	0
or	0
more	0
cytoplasmic	9
serine	10
kinases	10
also	0
phosphorylate	0
STAT3	9
and	0
are	0
necessary	0
for	0
maximal	0
gene	0
activation	0
.	0

Here	0
we	0
demonstrate	0
,	0
with	0
a	0
site-specific	0
antibody	0
,	0
that	0
STAT3	9
is	0
phosphorylated	0
on	0
Ser-727	0
in	0
human	7
neutrophils	8
stimulated	0
with	0
chemotactic	9
factors	10
(	0
N-formyl-methionyl-leucyl-phenylalanine	0
and	0
complement	0
C5a	0
)	0
,	0
cytokines	9
[	0
granulocyte/macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
and	0
granulocyte	9
colony-stimulating	10
factor	10
(	0
G-CSF	9
)	0
]	0
,	0
or	0
a	0
protein	9
kinase	10
C	10
activator	0
(	0
PMA	0
)	0
.	0

(	0
2-Amino-3'-methoxyphenyl	0
)	0
oxanaphthalen-4-one	0
(	0
PD	0
98059	0
)	0
,	0
an	0
inhibitor	0
of	0
extracellular	0
signal-regulated	9
protein	10
kinase	10
(	0
ERK	9
)	0
activation	0
,	0
blocked	0
the	0
serine	0
phosphorylation	0
of	0
STAT3	9
induced	0
by	0
chemotactic	9
factors	10
or	0
PMA	0
.	0

The	0
drug	0
was	0
less	0
effective	0
on	0
cytokines	9
:	0
it	0
virtually	0
abolished	0
the	0
response	0
to	0
GM-CSF	9
that	0
occurred	0
5	0
min	0
after	0
stimulation	0
but	0
only	0
partly	0
decreased	0
those	0
at	0
15-30	0
min	0
and	0
did	0
not	0
appreciably	0
alter	0
responses	0
to	0
G-CSF	9
regardless	0
of	0
incubation	0
time	0
.	0

1-	0
(	0
5-Isoquinolinylsulphonyl	0
)	0
-2-methylpiperazine	0
dihydrochloride	0
(	0
H7	0
)	0
,	0
an	0
inhibitor	0
of	0
a	0
putative	0
STAT3	9
serine	10
kinase	10
,	0
and	0
4-	0
(	0
4-fluorophenyl	0
)	0
-2-	0
(	0
4-methylsulphinylphenyl	0
)	0
-5-	0
(	0
4-pyridyl	0
)	0
1H-imidazole	0
(	0
SB	0
203580	0
)	0
,	0
an	0
inhibitor	0
of	0
p38	9
mitogen-activated	10
protein	10
(	10
MAP	10
)	10
kinase	10
,	0
did	0
not	0
dampen	0
any	0
of	0
these	0
serine	0
phosphorylation	0
responses	0
.	0

We	0
propose	0
that	0
neutrophils	7
use	0
both	0
ERK-dependent	0
and	0
ERK-independent	0
pathways	0
to	0
phosphorylate	0
Ser-727	0
on	0
STAT3	9
.	0

The	0
former	0
pathway	0
is	0
recruited	0
by	0
all	0
ERK	9
-activating	0
stimuli	0
,	0
whereas	0
the	0
latter	0
pathway	0
uses	0
an	0
undefined	0
serine	9
kinase	10
and	0
is	0
recruited	0
selectively	0
by	0
cytokines	9
.	0

GATA	9
transcription	10
factors	10
associate	0
with	0
a	0
novel	0
class	0
of	0
nuclear	0
bodies	0
in	0
erythroblasts	7
and	0
megakaryocytes	7
.	0

The	0
nuclear	0
distribution	0
of	0
GATA	9
transcription	10
factors	10
in	0
murine	7
haemopoietic	8
cells	8
was	0
examined	0
by	0
indirect	0
immunofluorescence	0
.	0

Specific	0
bright	0
foci	0
of	0
GATA-1	9
fluorescence	0
were	0
observed	0
in	0
erythroleukaemia	7
cells	8
and	0
primary	7
murine	8
erythroblasts	8
and	0
megakaryocytes	7
,	0
in	0
addition	0
to	0
diffuse	0
nucleoplasmic	0
localization	0
.	0

These	0
foci	0
,	0
which	0
were	0
preferentially	0
found	0
adjacent	0
to	0
nucleoli	0
or	0
at	0
the	0
nuclear	0
periphery	0
,	0
did	0
not	0
represent	0
sites	0
of	0
active	0
transcription	0
or	0
binding	0
of	0
GATA-1	9
to	0
consensus	1
sites	2
in	0
the	0
beta-globin	1
loci	2
.	0

Immunoelectron	0
microscopy	0
demonstrated	0
the	0
presence	0
of	0
intensely	0
labelled	0
structures	0
likely	0
to	0
represent	0
the	0
GATA-1	9
foci	0
seen	0
by	0
immunofluorescence	0
.	0

The	0
GATA-1	9
nuclear	0
bodies	0
differed	0
from	0
previously	0
described	0
nuclear	0
structures	0
and	0
there	0
was	0
no	0
co-localization	0
with	0
nuclear	9
antigens	10
involved	0
in	0
RNA	0
processing	0
or	0
other	0
ubiquitous	9
(	10
Spl	10
,	10
c-Jun	10
and	10
TBP	10
)	10
or	10
haemopoietic	10
(	10
NF-E2	10
)	10
transcription	10
factors	10
.	0

Interestingly	0
,	0
GATA-2	9
and	0
GATA-3	9
proteins	10
also	0
localized	0
to	0
the	0
same	0
nuclear	0
bodies	0
in	0
cell	0
lines	0
co-expressing	0
GATA-1	9
and	10
-2	10
or	10
GATA-1	10
and	10
-3	10
gene	10
products	10
.	0

This	0
pattern	0
of	0
distribution	0
is	0
,	0
thus	0
far	0
,	0
unique	0
to	0
the	0
GATA	9
transcription	10
factors	10
and	0
suggests	0
a	0
protein-protein	0
interaction	0
with	0
other	0
components	0
of	0
the	0
nuclear	0
bodies	0
via	0
the	0
GATA	9
zinc	10
finger	10
domain	10
.	0

Energy	0
substrates	0
,	0
hormone	0
responses	0
and	0
glucocorticoid	0
binding	0
in	0
lymphocytes	7
during	0
intense	0
physical	0
exercise	0
in	0
humans	0
following	0
phosphocreatine	0
administration	0
.	0

Eight	0
healthy	0
untrained	0
male	0
volunteers	0
pedalled	0
a	0
cycle	0
ergometer	0
according	0
to	0
two	0
exercise	0
protocols	0
:	0
the	0
first	0
involved	0
step-wise	0
increasing	0
physical	0
exercise	0
to	0
maximal	0
(	0
MPE	0
)	0
;	0
the	0
second	0
involved	0
prolonged	0
(	0
35	0
min	0
)	0
submaximal	0
physical	0
exercise	0
(	0
PPE	0
)	0
at	0
70	0
%	0
of	0
the	0
individual	0
's	0
maximal	0
oxygen	0
uptake	0
.	0

Each	0
volunteer	0
performed	0
these	0
exercise	0
twice	0
,	0
following	0
either	0
an	0
intravenous	0
injection	0
of	0
phosphocreatine	0
(	0
PCr	0
)	0
or	0
a	0
placebo	0
of	0
an	0
isotonic	0
NaCl	0
solution	0
.	0

Anaerobic	0
threshold	0
(	0
AT	0
)	0
was	0
determined	0
from	0
the	0
point	0
of	0
departure	0
of	0
the	0
ventilatory	0
response	0
from	0
linearity	0
and	0
from	0
the	0
sudden	0
increase	0
in	0
venous	0
blood	0
lactate	0
concentrations	0
during	0
MPE	0
.	0

After	0
exercise	0
following	0
placebo	0
administration	0
we	0
observed	0
increases	0
in	0
concentrations	0
of	0
blood	0
substrates	0
,	0
plasma	9
adrenocorticotropin	10
(	0
ACTH	9
)	0
,	0
growth	0
hormone	0
and	0
cortisol	0
and	0
in	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
without	0
changes	0
in	0
the	0
dissociation	0
constant	0
.	0

Intravenous	0
administration	0
of	0
PCr	0
(	0
starting	0
1	0
day	0
before	0
exercise	0
)	0
led	0
to	0
an	0
increase	0
in	0
the	0
total	0
workload	0
(	0
on	0
average	0
by	0
5.8	0
%	0
)	0
and	0
in	0
AT	0
(	0
on	0
average	0
by	0
6.8	0
%	0
)	0
during	0
MPE	0
and	0
to	0
a	0
better	0
tolerance	0
of	0
exercise	0
during	0
PPE	0
.	0

Following	0
PCr	0
administration	0
we	0
observed	0
lower	0
blood	0
lactate	0
concentrations	0
and	0
different	0
patterns	0
of	0
some	0
enzyme	0
activities	0
,	0
less	0
pronounced	0
changes	0
in	0
plasma	9
ACTH	10
and	0
cortisol	0
concentrations	0
and	0
in	0
glucocorticoid	0
binding	0
in	0
lymphocytes	7
,	0
but	0
no	0
changes	0
in	0
plasma	0
growth	0
hormone	0
concentrations	0
compared	0
to	0
the	0
placebo	0
.	0

The	0
results	0
showed	0
that	0
intense	0
physical	0
exercise	0
led	0
not	0
only	0
to	0
increases	0
in	0
blood	0
hormone	0
concentrations	0
but	0
also	0
to	0
an	0
increase	0
in	0
the	0
density	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
.	0

Intravenous	0
PCr	0
injection	0
led	0
to	0
smaller	0
changes	0
in	0
ACTH	9
and	0
cortisol	0
concentrations	0
as	0
well	0
as	0
to	0
a	0
lower	0
activation	0
of	0
glucocorticoid	0
binding	0
in	0
lymphocytes	7
.	0

Putative	9
steroid	10
binding	10
domain	10
of	0
the	0
human	9
mineralocorticoid	10
receptor	10
,	0
expressed	0
in	0
E.	0
coli	0
in	0
the	0
presence	0
of	0
heat	9
shock	10
proteins	10
shows	0
typical	0
native	0
receptor	0
characteristics	0
.	0

Domain	9
E	10
,	0
considered	0
as	0
the	0
putative	9
hormone	10
binding	10
domain	10
(	0
HBD	9
)	0
of	0
the	0
human	9
mineralocorticoid	10
receptor	10
(	0
hMR	9
)	0
was	0
expressed	0
in	0
Escherichia	0
coli	0
as	0
a	0
fusion	0
protein	0
with	0
either	0
maltose	9
binding	10
protein	10
(	0
MBP	9
)	0
or	0
glutathione	9
S-transferase	10
(	0
GST	9
)	0
.	0

These	0
bacterially-produced	1
MR	2
constructs	2
had	0
no	0
steroid	0
binding	0
activity	0
per	0
se	0
.	0

In	0
fact	0
,	0
heat	9
shock	10
protein	10
association	0
(	0
hsp	9
)	0
is	0
required	0
for	0
high	0
affinity	0
ligand-binding	0
of	0
the	0
MR	9
.	0

After	0
incubation	0
of	0
purified	0
MBP-	9
or	10
GST-HBD	10
with	0
rabbit	0
reticulocyte	0
lysate	0
,	0
known	0
to	0
be	0
rich	0
in	0
heat	9
shock	10
proteins	10
,	0
we	0
obtained	0
saturable	0
binding	0
of	0
[	0
3H	0
]	0
aldosterone	0
.	0

The	0
Kd	0
value	0
for	0
aldosterone	0
was	0
0.3	0
nM	0
and	0
the	0
Bmax	0
=	0
32	0
pmol/mg	0
.	0

Hormone	0
binding	0
specificity	0
was	0
assessed	0
by	0
competition	0
studies	0
with	0
various	0
steroid	0
ligands	0
.	0

Sucrose	0
gradient	0
assays	0
performed	0
with	0
[	9
3H	10
]	10
aldosterone-MBP-HBD	10
revealed	0
complex	0
sedimenting	0
at	0
8.3S	0
and	0
4.9S	0
with	0
[	9
3H	10
]	10
progesterone-MBP-HBD	10
.	0

Western-blot	0
analysis	0
of	0
the	0
sedimentation	0
peak	0
showed	0
the	0
concomitant	0
presence	0
of	0
MBP-HBD	9
by	0
a	0
monoclonal	9
anti-MBP	10
antibody	10
,	0
and	0
hsp90	9
by	0
a	0
monoclonal	9
anti-hsp	10
antibody	10
.	0

Moreover	0
,	0
following	0
incubation	0
with	0
the	0
anti-rabbit	9
hsp90	10
monoclonal	10
antibody	10
the	0
sedimenting	0
gradient	0
showed	0
a	0
10.4S	9
sedimenting	10
complex	10
.	0

These	0
analyses	0
demonstrated	0
that	0
the	0
[	0
3H	0
]	0
aldosterone-	0
MBP-HBD	9
complex	10
is	0
at	0
least	0
associated	0
with	0
hsp90	9
in	0
reticulocyte	0
lysate	0
and	0
that	0
the	0
HBD	9
of	0
hMR	9
is	0
sufficient	0
to	0
bind	0
hsp90	9
.	0

Deletions	0
of	0
a	0
relatively	0
short	0
amino-	9
(	10
729-766	10
)	10
or	10
carboxy-	10
terminal	10
(	10
940-984	10
)	10
region	10
of	0
the	0
HBD	9
fragment	10
eliminated	0
all	0
steroid-binding	0
properties	0
.	0

Overall	0
,	0
these	0
results	0
indicate	0
that	0
the	0
integrity	0
of	0
domain	9
E	10
is	0
necessary	0
and	0
sufficient	0
to	0
bind	0
steroid	0
ligands	0
,	0
agonists	0
or	0
antagonists	0
,	0
with	0
characteristics	0
similar	0
to	0
the	0
entire	0
native	0
MR	9
.	0

Renal	0
cell	0
carcinoma-derived	0
gangliosides	0
suppress	0
nuclear	9
factor-kappaB	10
activation	0
in	0
T	7
cells	8
.	0

Activation	0
of	0
the	0
transcription	9
factor	10
nuclear	10
factor-kappaB	10
(	0
NFkappaB	9
)	0
is	0
impaired	0
in	0
T	7
cells	8
from	0
patients	0
with	0
renal	0
cell	0
carcinomas	0
(	0
RCCs	0
)	0
.	0

In	0
circulating	0
T	7
cells	8
from	0
a	0
subset	0
of	0
patients	0
with	0
RCCs	0
,	0
the	0
suppression	0
of	0
NFkappaB	9
binding	0
activity	0
is	0
downstream	0
from	0
the	0
stimulus-induced	0
degradation	0
of	0
the	0
cytoplasmic	9
factor	10
IkappaBalpha	9
.	0

Tumor-derived	9
soluble	10
products	10
from	0
cultured	0
RCC	0
explants	0
inhibit	0
NFkappaB	9
activity	0
in	0
T	7
cells	8
from	0
healthy	0
volunteers	0
,	0
despite	0
a	0
normal	0
level	0
of	0
stimulus-induced	0
IkappaBalpha	9
degradation	0
in	0
these	0
cells	0
.	0

The	0
inhibitory	0
agent	0
has	0
several	0
features	0
characteristic	0
of	0
a	0
ganglioside	0
,	0
including	0
sensitivity	0
to	0
neuraminidase	9
but	0
not	0
protease	9
treatment	0
;	0
hydrophobicity	0
;	0
and	0
molecular	0
weight	0
less	0
than	0
3	0
kDa	0
.	0

Indeed	0
,	0
we	0
detected	0
gangliosides	0
in	0
supernatants	0
from	0
RCC	7
explants	8
and	0
not	0
from	0
adjacent	0
normal	0
kidney	0
tissue	0
.	0

Gangliosides	0
prepared	0
from	0
RCC	0
supernatants	0
,	0
as	0
well	0
as	0
the	0
purified	0
bovine	0
gangliosides	0
G	0
(	0
m1	0
)	0
and	0
G	0
(	0
d1a	0
)	0
,	0
suppressed	0
NFkappaB	9
binding	0
activity	0
in	0
T	7
cells	8
and	0
reduced	0
expression	0
of	0
the	0
cytokines	9
IL-2	9
and	0
IFN-gamma	9
.	0

Taken	0
together	0
,	0
our	0
findings	0
suggest	0
that	0
tumor-derived	0
gangliosides	0
may	0
blunt	0
antitumor	0
immune	0
responses	0
in	0
patients	0
with	0
RCCs	0
.	0

Nuclear	9
factor-kappaB	10
-dependent	0
induction	0
of	0
interleukin-8	9
gene	0
expression	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
:	0
evidence	0
for	0
an	0
antioxidant	0
sensitive	0
activating	0
pathway	0
distinct	0
from	0
nuclear	0
translocation	0
.	0

Tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNFalpha	9
)	0
is	0
a	0
pluripotent	0
activator	0
of	0
inflammation	0
by	0
inducing	0
a	0
proinflammatory	9
cytokine	10
cascade	0
.	0

This	0
phenomenon	0
is	0
mediated	0
,	0
in	0
part	0
,	0
through	0
inducible	0
expression	0
of	0
the	0
CXC	9
chemokine	10
,	0
interleukin-8	9
(	0
IL-8	0
)	0
.	0

In	0
this	0
study	0
,	0
we	0
investigate	0
the	0
role	0
of	0
TNFalpha	9
-inducible	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
in	0
IL-8	9
expression	0
by	0
``	0
monocyte-like	0
''	0
U937	5
histiocytic	6
lymphoma	6
cells	6
.	0

TNFalpha	9
is	0
a	0
rapid	0
activator	0
of	0
IL-8	1
gene	2
expression	0
by	0
U937	5
,	0
producing	0
a	0
50-fold	0
induction	0
of	0
mRNA	3
within	0
1	0
hour	0
of	0
treatment	0
.	0

In	0
gene	0
transfection	0
assays	0
,	0
the	0
effect	0
of	0
TNFalpha	9
requires	0
the	0
presence	0
of	0
an	0
inducible	1
nuclear	2
factor-kappaB	2
(	2
NF-kappaB	2
)	2
(	2
Rel	2
A	2
)	2
binding	2
site	2
in	0
the	0
IL-8	1
promoter	2
.	0

TNFalpha	9
treatment	0
induces	0
a	0
rapid	0
translocation	0
of	0
the	0
65	9
kD	10
transcriptional	10
activator	10
NF-kappaB	9
subunit	10
,	0
Rel	9
A	10
,	0
whose	0
binding	0
in	0
the	0
nucleus	0
occurs	0
before	0
changes	0
in	0
intracellular	0
ROS	0
.	0

Pretreatment	0
(	0
or	0
up	0
to	0
15	0
minutes	0
posttreatment	0
)	0
relative	0
to	0
TNFalpha	9
with	0
the	0
antioxidant	0
dimethyl	0
sulfoxide	0
(	0
DMSO	0
)	0
(	0
2	0
%	0
[	0
vol/vol	0
]	0
)	0
blocks	0
80	0
%	0
of	0
NF-kappaB	9
-dependent	0
transcription	0
.	0

Surprisingly	0
,	0
however	0
,	0
DMSO	0
has	0
no	0
effect	0
on	0
inducible	0
Rel	9
A	10
binding	0
.	0

Similar	0
selective	0
effects	0
on	0
NF-kappaB	9
transcription	0
are	0
seen	0
with	0
the	0
unrelated	0
antioxidants	0
,	0
N-acetylcysteine	0
(	0
NAC	0
)	0
and	0
vitamin	0
C	0
.	0

These	0
data	0
indicate	0
that	0
TNFalpha	9
induces	0
a	0
delayed	0
ROS-dependent	0
signalling	0
pathway	0
that	0
is	0
required	0
for	0
NF-kappaB	9
transcriptional	0
activation	0
and	0
is	0
separable	0
from	0
that	0
required	0
for	0
its	0
nuclear	0
translocation	0
.	0

Further	0
definition	0
of	0
this	0
pathway	0
will	0
yield	0
new	0
insights	0
into	0
inflammation	0
initiated	0
by	0
TNFalpha	9
signalling	0
.	0

Gender	0
and	0
vascular	0
reactivity	0
.	0

Estrogen	9
receptors	10
are	0
found	0
on	0
vascular	7
endothelial	8
and	8
smooth	8
muscle	8
cells	8
;	0
their	0
expression	0
is	0
influenced	0
by	0
exposure	0
to	0
the	0
hormone	0
.	0

Estrogen	9
receptors	10
influence	0
non-genomic	0
events	0
,	0
which	0
are	0
rapid	0
in	0
onset	0
and	0
genomic	0
events	0
,	0
which	0
are	0
longer	0
acting	0
responses	0
.	0

Estrogens	0
affect	0
vascular	0
tone	0
indirectly	0
by	0
modulating	0
release	0
of	0
endothelium-derived	9
vasoactive	10
factors	10
and	0
directly	0
by	0
modulating	0
intracellular	0
calcium	0
in	0
vascular	7
smooth	8
muscle	8
cells	8
.	0

Estrogens	0
indirectly	0
affect	0
thrombotic	0
events	0
and	0
inflammation	0
by	0
altering	0
platelet	7
aggregation	0
and	0
leukocyte	7
adherence	0
and	0
migration	0
,	0
respectively	0
.	0

Estrogens	0
also	0
influence	0
production	0
of	0
mitogens	0
which	0
,	0
when	0
released	0
at	0
sites	0
of	0
vascular	0
injury	0
,	0
affect	0
vascular	0
remodeling	0
.	0

Although	0
estrogens	0
initiate	0
vascular	0
responses	0
,	0
genomic	0
sex	0
may	0
influence	0
and/or	0
limit	0
expression	0
of	0
estrogen	0
receptors	0
and	0
therefore	0
actions	0
of	0
sex	0
steroid	0
hormones	0
throughout	0
the	0
vasculature	0
.	0

Induction	0
of	0
a	0
functional	0
vitamin	9
D	10
receptor	10
in	0
all-trans-retinoic	0
acid-induced	0
monocytic	0
differentiation	0
of	0
M2-type	5
leukemic	6
blast	6
cells	6
.	0

Different	0
types	0
of	0
acute	7
myeloid	8
leukemia	8
blast	8
cells	8
were	0
induced	0
to	0
differentiate	0
in	0
vitro	0
with	0
all-trans-retinoic	0
acid	0
(	0
ATRA	0
)	0
and	0
vitamin	0
D3	0
(	0
VD	0
)	0
.	0

M0/M1	5
leukemic	6
cells	6
are	0
not	0
sensitive	0
to	0
differentiating	0
agents	0
,	0
whereas	0
M3	5
leukemic	6
cells	6
are	0
induced	0
to	0
undergo	0
granulocytic	0
differentiation	0
after	0
ATRA	0
treatment	0
but	0
are	0
not	0
sensitive	0
to	0
VD	0
.	0

M2	5
leukemic	6
blast	6
cells	6
behave	0
differently	0
because	0
they	0
undergo	0
monocytic	0
differentiation	0
with	0
both	0
the	0
differentiation	0
inducers	0
.	0

To	0
gain	0
some	0
insight	0
into	0
the	0
maturation	0
of	0
M2-type	7
leukemic	8
cells	8
,	0
we	0
studied	0
the	0
molecular	0
mechanisms	0
underlying	0
monocytic	0
differentiation	0
induced	0
by	0
ATRA	0
and	0
VD	0
in	0
spontaneous	0
M2	5
blast	6
cells	6
as	0
well	0
as	0
in	0
Kasumi-1	5
cells	6
(	0
an	0
acute	5
myeloid	6
leukemia	6
M2-type	6
cell	6
line	6
)	0
.	0

Our	0
results	0
indicate	0
that	0
ATRA	0
as	0
well	0
as	0
VD	0
efficiently	0
increases	0
the	0
nuclear	0
abundance	0
of	0
VD	9
receptor	10
(	0
VDR	9
)	0
and	0
promotes	0
monocytic	0
differentiation	0
.	0

VDR	9
is	0
functionally	0
active	0
in	0
ATRA-treated	0
Kasumi-1	5
cells	6
because	0
it	0
efficiently	0
heterodimerizes	0
with	0
retinoid	9
X	10
receptor	10
,	0
binds	0
to	0
a	0
DR3-type	1
vitamin	2
D-responsive	2
element	2
,	0
and	0
activates	0
the	0
transcription	0
of	0
a	0
vitamin	1
D-responsive	2
element-regulated	2
reporter	2
gene	2
.	0

Consistent	0
with	0
these	0
findings	0
,	0
VD-responsive	1
genes	2
are	0
induced	0
by	0
ATRA	0
treatment	0
of	0
Kasumi-1	5
cells	6
,	0
suggesting	0
that	0
the	0
genetic	0
program	0
underlying	0
monocytic	0
differentiation	0
is	0
activated	0
.	0

The	0
molecular	0
mechanism	0
by	0
which	0
ATRA	0
increases	0
the	0
nuclear	0
abundance	0
of	0
a	0
functional	0
VDR	9
is	0
still	0
unknown	0
,	0
but	0
our	0
data	0
clearly	0
indicate	0
that	0
the	0
M2	5
leukemic	6
cell	6
context	0
is	0
only	0
permissive	0
of	0
monocytic	0
differentiation	0
.	0

Protein	9
kinase	10
C	10
and	0
calcineurin	9
synergize	0
to	0
activate	0
IkappaB	9
kinase	10
and	0
NF-kappaB	9
in	0
T	7
lymphocytes	8
.	0

The	0
nuclear	0
factor	0
of	0
kappaB	0
(	0
NF-kappaB	9
)	0
is	0
a	0
ubiquitous	9
transcription	10
factor	10
that	0
is	0
key	0
in	0
the	0
regulation	0
of	0
the	0
immune	0
response	0
and	0
inflammation	0
.	0

T	9
cell	10
receptor	10
(	0
TCR	9
)	0
cross-linking	0
is	0
in	0
part	0
required	0
for	0
activation	0
of	0
NF-kappaB	9
,	0
which	0
is	0
dependent	0
on	0
the	0
phosphorylation	0
and	0
degradation	0
of	0
IkappaBalpha	9
.	0

By	0
using	0
Jurkat	5
and	0
primary	7
human	8
T	8
lymphocytes	8
,	0
we	0
demonstrate	0
that	0
the	0
simultaneous	0
activation	0
of	0
two	0
second	0
messengers	0
of	0
the	0
TCR	9
-initiated	0
signal	0
transduction	0
,	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
and	0
calcineurin	9
,	0
results	0
in	0
the	0
synergistic	0
activation	0
of	0
the	0
IkappaBalpha	9
kinase	10
(	10
IKK	10
)	10
complex	10
but	0
not	0
of	0
another	0
putative	9
IkappaBalpha	10
kinase	10
,	0
p90	9
(	10
rsk	10
)	10
.	0

We	0
also	0
demonstrate	0
that	0
the	0
IKK	9
complex	10
,	0
but	0
not	0
p90	9
(	10
rsk	10
)	10
,	0
is	0
responsible	0
for	0
the	0
in	0
vivo	0
phosphorylation	0
of	0
IkappaBalpha	9
mediated	0
by	0
the	0
co-activation	0
of	0
PKC	9
and	0
calcineurin	9
.	0

Each	0
second	0
messenger	0
is	0
necessary	0
,	0
as	0
inhibition	0
of	0
either	0
one	0
reverses	0
the	0
activation	0
of	0
the	0
IKK	9
complex	10
and	0
IkappaBalpha	9
phosphorylation	0
in	0
vivo	0
.	0

Overexpression	0
of	0
dominant	0
negative	0
forms	0
of	0
IKKalpha	9
and	10
-beta	10
demonstrates	0
that	0
only	0
IKKbeta	9
is	0
the	0
target	0
for	0
PKC	9
and	0
calcineurin	9
.	0

These	0
results	0
indicate	0
that	0
within	0
the	0
TCR	9
/CD3	9
signal	0
transduction	0
pathway	0
both	0
PKC	9
and	0
calcineurin	9
are	0
required	0
for	0
the	0
effective	0
activation	0
of	0
the	0
IKK	9
complex	10
and	0
NF-kappaB	9
in	0
T	7
lymphocytes	8
.	0

Diminished	0
responses	0
to	0
IL-13	9
by	0
human	0
monocytes	0
differentiated	0
in	0
vitro	0
:	0
role	0
of	0
the	0
IL-13Ralpha1	9
chain	10
and	0
STAT6	9
.	0

The	0
primary	0
IL-13	9
receptor	10
complex	10
on	0
human	7
monocytes	8
is	0
believed	0
to	0
be	0
a	0
heterodimer	0
comprised	0
of	0
the	0
IL-4R	9
alpha	10
chain	10
and	0
the	0
IL-2R	9
gamma	10
chain	10
(	9
gamma	10
(	10
c	10
)	10
)	10
-like	10
molecule	10
,	0
IL-13R	9
alpha1	10
.	0

mRNA	3
levels	0
for	0
IL-13R	9
alpha1	10
,	0
but	0
not	0
IL-4R	9
alpha	10
,	0
were	0
markedly	0
decreased	0
in	0
in	5
vitro	6
monocyte-derived	6
macrophages	6
(	0
MDMac	5
)	0
,	0
and	0
with	0
increasing	0
time	0
of	0
monocytes	7
in	0
culture	0
correlated	0
with	0
the	0
loss	0
of	0
IL-13	9
regulation	0
of	0
lipopolysaccharide-induced	0
TNF-alpha	9
production	0
.	0

Analysis	0
of	0
cell	5
lines	6
Daudi	5
and	0
THP-1	5
that	0
differentially	0
express	0
gamma	9
(	10
c	10
)	10
and	0
IL-13R	9
alpha1	10
showed	0
that	0
IL-13	9
can	0
activate	0
STAT6	9
in	0
IL-13R	5
alpha1-positive	6
THP-1	6
cells	6
but	0
not	0
in	0
gamma	5
(	6
c	6
)	6
-positive	6
,	6
IL-13R	6
alpha1-negative	6
Daudi	6
cells	6
.	0

IL-13	9
activation	0
of	0
STAT6	9
was	0
reduced	0
in	0
MDMac	5
which	0
was	0
associated	0
with	0
diminished	0
IL-13	9
-induced	0
expression	0
of	0
CD23	9
and	0
MHC	9
class	10
II	10
.	0

However	0
,	0
with	0
reduced	0
IL-13R	9
alpha1	10
expression	0
and	0
low	0
nuclear	0
STAT6	9
activity	0
,	0
some	0
IL-13	9
-induced	0
responses	0
were	0
unaltered	0
in	0
magnitude	0
in	0
MDMac	5
.	0

In	0
the	0
absence	0
of	0
functional	0
IL-13R	9
alpha1	10
and	0
gamma	9
(	10
c	10
)	10
,	0
IL-13	9
must	0
signal	0
through	0
an	0
alternative	0
receptor	9
complex	10
on	0
MDMac	5
.	0

Experiments	0
with	0
a	0
blocking	0
antibody	0
to	0
IL-4R	9
alpha	10
showed	0
that	0
this	0
chain	0
remains	0
an	0
essential	0
component	0
of	0
the	0
IL-13	9
receptor	10
complex	10
on	0
MDMac	5
.	0

The	0
p53	9
paradox	0
in	0
the	0
pathogenesis	0
of	0
tumor	0
progression	0
.	0

Recent	0
evidence	0
suggests	0
that	0
the	0
p53	9
molecule	10
appears	0
in	0
two	0
different	0
forms	0
:	0
the	0
mutant	9
p53	10
that	0
stimulates	0
tumor	0
progression	0
,	0
and	0
wild	9
type	10
p53	10
that	0
inhibits	0
tumor	0
progression	0
.	0

In	0
addition	0
,	0
it	0
has	0
been	0
established	0
that	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
can	0
activate	0
the	0
expression	0
of	0
wild	9
type	10
p53	10
in	0
concert	0
with	0
the	0
nuclear	9
transcription	10
factor	10
,	0
NF-kappa	9
B	10
.	0

Both	0
TNF-alpha	9
and	0
NF-kappa	9
B	10
are	0
also	0
involved	0
in	0
the	0
stimulation	0
of	0
the	0
pathway	0
that	0
leads	0
to	0
the	0
expression	0
of	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
I	10
molecules	10
and	0
,	0
hence	0
,	0
antigen	0
presentation	0
to	0
the	0
T	7
cells	8
.	0

In	0
this	0
paper	0
we	0
shall	0
advance	0
the	0
hypothesis	0
that	0
:	0
(	0
i	0
)	0
TNF-alpha	9
indirectly	0
controls	0
immune	0
surveillance	0
;	0
and	0
(	0
ii	0
)	0
TNF-alpha	9
controls	0
DNA	0
repair	0
and	0
tumor	0
suppression	0
through	0
the	0
regulation	0
of	0
wild	9
type	10
p53	10
.	0

Thus	0
,	0
it	0
is	0
hypothesized	0
that	0
elevated	0
TNF-alpha	9
is	0
primarily	0
responsible	0
for	0
promoting	0
tumor	0
progression	0
.	0

The	0
promoter	1
and	0
5	1
'	2
flanking	2
sequences	2
controlling	0
human	0
B29	1
gene	2
expression	0
.	0

The	0
product	0
of	0
the	0
B-cell-specific	1
B29	2
gene	2
(	0
B29	9
,	0
Ig	9
beta	10
,	0
CD79b	9
)	0
is	0
essential	0
for	0
Ig-mediated	0
B-cell	0
activation	0
via	0
the	0
B-cell	9
antigen	10
receptor	10
complex	10
(	0
BCR	9
)	0
on	0
human	7
and	8
murine	8
B	8
lymphocytes	8
.	0

To	0
better	0
understand	0
the	0
regulation	0
of	0
this	0
pivotal	0
gene	0
,	0
we	0
have	0
analyzed	0
the	0
human	1
genomic	2
DNA	2
sequence	2
upstream	0
of	0
the	0
B29	9
ATG	1
start	2
codon	2
for	0
transcriptional	0
control	0
activity	0
.	0

The	0
human	0
B29	1
gene	2
lacks	0
either	0
a	0
TATA	1
or	2
a	2
CAAT	2
box	2
and	0
transcription	0
is	0
initiated	0
at	0
multiple	1
sites	2
.	0

The	0
minimal	0
promoter	0
of	0
the	0
human	1
B29	2
gene	2
is	0
contained	0
within	0
a	0
193-bp	1
region	2
5	0
'	0
of	0
these	0
multiple	1
start	2
sites	2
.	0

This	0
minimal	1
promoter	2
exhibits	0
B-cell-specific	0
activity	0
and	0
contains	0
SP1	1
,	2
ETS	2
,	2
OCT	2
,	2
and	2
IKAROS/LYF-1	2
transcription	2
factor	2
motifs	2
.	0

All	0
these	0
motifs	0
are	0
strikingly	0
conserved	0
in	0
sequence	0
and	0
placement	0
relative	0
to	0
the	0
previously	0
characterized	0
murine	1
B29	2
promoter	2
.	0

Additional	0
upstream	0
gene	0
segments	0
dramatically	0
affected	0
B29	9
minimal	1
promoter	2
activity	0
.	0

A	0
newly	0
identified	0
motif	0
called	0
the	0
B29	1
conserved	2
sequence	2
(	0
BCS	1
)	0
,	0
found	0
upstream	0
of	0
both	0
human	1
and	2
murine	2
B29	2
promoters	2
,	0
appears	0
to	0
stimulate	0
B29	9
transcription	0
through	0
a	0
novel	0
mechanism	0
.	0

A	0
single	0
BCS	1
had	0
little	0
effect	0
either	0
on	0
the	0
minimal	0
B29	1
promoter	2
or	0
on	0
a	0
heterologous	0
promoter	0
.	0

Instead	0
,	0
the	0
BCS	1
stimulated	0
transcription	0
by	0
counteracting	0
5	1
'	2
negative	2
regulatory	2
DNA	2
sequences	2
that	0
block	0
the	0
activity	0
of	0
the	0
B29	9
minimal	1
promoter	2
in	0
its	0
absence	0
.	0

These	0
findings	0
indicate	0
that	0
B29	1
gene	2
expression	0
is	0
controlled	0
by	0
the	0
complex	0
interplay	0
of	0
positive	0
and	0
negative	1
regulatory	2
elements	2
.	0

A	0
novel	0
immunosuppressive	9
factor	10
in	0
bovine	0
colostrum	0
blocks	0
activation	0
of	0
the	0
interleukin	1
2	2
gene	2
enhancer	2
at	0
the	0
NFAT	1
site	2
.	0

A	0
factor	0
in	0
bovine	0
colostrum	0
(	0
colostrum	9
inhibitory	10
factor	10
,	0
CIF	9
)	0
inhibits	0
interleukin	9
2	10
(	0
IL2	9
)	0
production	0
in	0
activated	0
T	7
helper	8
cells	8
by	0
blocking	0
the	0
accumulation	0
of	0
IL2	3
mRNA	4
.	0

To	0
determine	0
whether	0
CIF	9
blocks	0
at	0
the	0
level	0
of	0
IL2	9
transcription	0
,	0
we	0
introduced	0
reporter	0
plasmids	0
into	0
the	0
human	5
T	6
leukemia	6
cell	6
line	6
Jurkat	6
by	0
transient	0
transfection	0
.	0

These	0
contained	0
the	0
luciferase	1
gene	2
under	0
the	0
control	0
of	0
either	0
the	0
human	1
IL2	2
upstream	2
enhancer	2
region	0
(	0
segments	0
-326	0
to	0
+45	0
)	0
or	0
three	0
repeats	0
of	0
the	0
NFAT	1
element	2
contained	0
within	0
it	0
(	0
segments	0
-255	0
to	0
-285	0
)	0
.	0

Expression	0
of	0
luciferase	9
in	0
these	0
cells	0
was	0
induced	0
by	0
phorbol	0
myristate	0
acetate	0
plus	0
a	0
calcium	0
ionophore	0
.	0

CIF	9
inhibited	0
induction	0
of	0
either	0
construct	0
as	0
did	0
cyclosporine	0
,	0
which	0
is	0
known	0
to	0
block	0
activation	0
of	0
the	0
NFAT	9
element	10
.	0

CIF	9
failed	0
to	0
inhibit	0
several	0
other	0
enhancer	1
elements	2
.	0

The	0
NFAT-controlled	1
luciferase	2
gene	2
system	2
distinguishes	0
CIF	9
from	0
other	0
T	0
cell	0
inhibitory	0
activities	0
present	0
in	0
colostrum	0
,	0
in	0
particular	0
,	0
TGF	9
beta	10
1	10
and	0
TGF	9
beta	10
2	10
and	0
the	0
glucocorticoids	0
.	0

Stably	0
transfected	0
Jurkat	0
cells	0
behaved	0
similarly	0
to	0
the	0
transiently	0
transfected	0
ones	0
with	0
respect	0
to	0
inhibition	0
by	0
CIF	9
and	0
cyclosporine	0
.	0

The	0
NFAT	9
-luc	0
assay	0
is	0
a	0
useful	0
technique	0
for	0
the	0
rapid	0
,	0
sensitive	0
measurement	0
of	0
CIF	9
or	0
other	0
immunosuppressants	0
with	0
a	0
similar	0
mode	0
of	0
action	0
.	0

Heat	0
shock	0
induces	0
HIV-1	0
replication	0
in	0
chronically	0
infected	0
promyelocyte	5
cell	6
line	6
OM10.1	6
.	0

A	0
long	0
period	0
of	0
clinical	0
latency	0
before	0
development	0
of	0
symptoms	0
is	0
characteristic	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
.	0

OM10.1	5
,	0
a	0
promyelocyte	5
cell	6
line	6
latently	0
infected	0
with	0
HIV-1	0
,	0
has	0
been	0
developed	0
as	0
a	0
model	0
for	0
studying	0
the	0
mechanism	0
of	0
viral	0
latency	0
and	0
the	0
activation	0
of	0
virus	0
expression	0
.	0

We	0
found	0
that	0
this	0
latently	0
infected	0
cell	0
line	0
with	0
heat	0
shock	0
at	0
42	0
degrees	0
C	0
for	0
2	0
h	0
resulted	0
in	0
a	0
high	0
level	0
of	0
HIV-1	0
production	0
without	0
addition	0
of	0
any	0
cytokines	9
.	0

The	0
mechanism	0
of	0
activation	0
was	0
analyzed	0
by	0
using	0
anti-TNF-alpha	9
antibody	10
and	0
various	0
inhibitors	0
.	0

Although	0
the	0
TNF-alpha	9
level	0
in	0
culture	0
supernatants	0
was	0
below	0
the	0
sensitivity	0
of	0
an	0
ELISA	0
assay	0
system	0
,	0
addition	0
of	0
anti-	0
TNF-alpha	9
antibody	0
in	0
culture	0
medium	0
could	0
partially	0
suppress	0
the	0
heat	0
shock	0
induced	0
HIV-1	0
production	0
.	0

Staurosporine	0
(	0
PKC	0
inhibitor	0
)	0
,	0
pentoxifylline	0
(	0
NF-kappa	0
B	0
inhibitor	0
)	0
,	0
and	0
Ro5-3335	0
(	0
HIV-1	0
Tat	9
inhibitor	0
)	0
also	0
inhibited	0
significantly	0
the	0
heat	0
shock	0
induced	0
virus	0
activation	0
.	0

In	0
particular	0
,	0
staurosporine	0
achieved	0
approximately	0
90	0
%	0
inhibition	0
of	0
the	0
HIV-1	0
antigen	0
expression	0
in	0
heat	5
shock-treated	6
OM10.1	6
at	0
a	0
non-toxic	0
concentration	0
.	0

Although	0
the	0
mechanism	0
of	0
HIV-1	0
activation	0
with	0
heat	0
shock	0
has	0
not	0
been	0
fully	0
elucidated	0
yet	0
,	0
it	0
is	0
presumed	0
PKC	9
plays	0
an	0
important	0
role	0
in	0
HIV-1	0
activation	0
.	0

Thus	0
,	0
the	0
present	0
observations	0
will	0
provide	0
a	0
further	0
insight	0
into	0
the	0
pathogenesis	0
of	0
HIV-1	0
infections	0
.	0

Activation	0
of	0
the	0
CDC42	9
effector	10
N-WASP	9
by	0
the	0
Shigella	9
flexneri	10
IcsA	10
protein	10
promotes	0
actin	9
nucleation	0
by	0
Arp2/3	9
complex	10
and	0
bacterial	0
actin	9
-based	0
motility	0
.	0

To	0
propel	0
itself	0
in	0
infected	7
cells	8
,	0
the	0
pathogen	0
Shigella	0
flexneri	0
subverts	0
the	0
Cdc42	9
-controlled	0
machinery	0
responsible	0
for	0
actin	9
assembly	0
during	0
filopodia	0
formation	0
.	0

Using	0
a	0
combination	0
of	0
bacterial	0
motility	0
assays	0
in	0
platelet	0
extracts	0
with	0
Escherichia	0
coli	0
expressing	0
the	0
Shigella	9
IcsA	10
protein	10
and	0
in	0
vitro	0
analysis	0
of	0
reconstituted	0
systems	0
from	0
purified	9
proteins	10
,	0
we	0
show	0
here	0
that	0
the	0
bacterial	9
protein	10
IcsA	10
binds	0
N-WASP	9
and	0
activates	0
it	0
in	0
a	0
Cdc42	9
-like	0
fashion	0
.	0

Dramatic	0
stimulation	0
of	0
actin	9
assembly	0
is	0
linked	0
to	0
the	0
formation	0
of	0
a	0
ternary	0
IcsA-N-WASP-Arp2/3	9
complex	10
,	0
which	0
nucleates	0
actin	9
polymerization	0
.	0

The	0
Arp2/3	9
complex	10
is	0
essential	0
in	0
initiation	0
of	0
actin	9
assembly	0
and	0
Shigella	0
movement	0
,	0
as	0
previously	0
observed	0
for	0
Listeria	0
monocytogenes	0
.	0

Activation	0
of	0
N-WASP	9
by	0
IcsA	9
unmasks	0
two	0
domains	0
acting	0
together	0
in	0
insertional	0
actin	9
polymerization	0
.	0

The	0
isolated	0
COOH-terminal	9
domain	10
of	0
N-WASP	9
containing	0
a	0
verprolin-homology	9
region	10
,	0
a	0
cofilin-homology	0
sequence	0
,	0
and	0
an	0
acidic	9
terminal	10
segment	10
(	0
VCA	9
)	0
interacts	0
with	0
G-actin	9
in	0
a	0
unique	0
profilin-like	0
functional	0
fashion	0
.	0

Hence	0
,	0
when	0
N-WASP	9
is	0
activated	0
,	0
its	0
COOH-terminal	9
domain	10
feeds	0
barbed	0
end	0
growth	0
of	0
filaments	0
and	0
lowers	0
the	0
critical	0
concentration	0
at	0
the	0
bacterial	0
surface	0
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
NH	9
(	10
2	10
)	10
-terminal	10
domain	10
of	0
N-WASP	9
interacts	0
with	0
F-actin	9
,	0
mediating	0
the	0
attachment	0
of	0
the	0
actin	9
tail	10
to	0
the	0
bacterium	0
surface	0
.	0

VASP	0
is	0
not	0
involved	0
in	0
Shigella	0
movement	0
,	0
and	0
the	0
function	0
of	0
profilin	9
does	0
not	0
require	0
its	0
binding	0
to	0
proline-rich	9
regions	10
.	0

c-Maf	9
induces	0
monocytic	0
differentiation	0
and	0
apoptosis	0
in	0
bipotent	7
myeloid	8
progenitors	8
.	0

The	0
transcriptional	0
mechanisms	0
that	0
drive	0
colony-forming	5
unit	6
granulocyte-macrophage	6
(	6
CFU-GM	6
)	6
myeloid	6
progenitors	6
to	0
differentiate	0
into	0
cells	0
of	0
either	0
the	0
granulocytic	7
or	8
monocytic	8
lineage	8
are	0
not	0
fully	0
understood	0
.	0

We	0
have	0
shown	0
that	0
the	0
c-Maf	9
and	0
c-Myb	9
transcription	10
factors	10
physically	0
interact	0
in	0
myeloid	0
cells	0
to	0
form	0
inhibitory	0
complexes	0
that	0
hinder	0
transactivation	0
of	0
c-Myb	1
target	2
genes	2
through	0
direct	0
binding	0
to	0
Myb	1
consensus	2
sites	2
.	0

These	0
complexes	0
arise	0
in	0
a	0
developmentally	0
regulated	0
pattern	0
,	0
peaking	0
at	0
the	0
promyelocyte	7
stage	8
,	0
or	0
in	0
cell	5
model	6
systems	6
,	0
appearing	0
soon	0
after	0
the	0
induction	0
of	0
monocytic	0
differentiation	0
.	0

We	0
wished	0
to	0
determine	0
if	0
this	0
developmentally	0
related	0
interaction	0
is	0
a	0
consequence	0
of	0
myeloid	0
differentiation	0
or	0
an	0
intrinsic	0
differentiating	0
stimulus	0
.	0

Because	0
the	0
elevated	0
Myb	9
:	10
Maf	10
status	0
seen	0
in	0
differentiating	7
cells	8
can	0
be	0
recapitulated	0
by	0
overexpression	0
of	0
c-Maf	9
in	0
myeloid	0
cell	0
lines	0
,	0
we	0
inducibly	0
expressed	0
the	0
c-Maf	1
cDNA	2
in	0
2	0
bipotent	0
human	7
myeloid	8
progenitor	8
cells	8
.	0

Elevated	0
levels	0
of	0
c-Maf	9
protein	10
led	0
to	0
marked	0
increases	0
in	0
Myb	9
:	10
Maf	10
complexes	10
and	0
the	0
accumulation	0
of	0
monocyte/macrophage	7
cells	8
,	0
followed	0
by	0
eventual	0
programmed	0
cell	0
death	0
.	0

Analysis	0
of	0
targets	0
that	0
could	0
mediate	0
these	0
phenotypic	0
changes	0
indicated	0
that	0
c-Maf	9
likely	0
plays	0
a	0
key	0
role	0
in	0
myeloid	0
cell	0
development	0
through	0
dual	0
mechanisms	0
;	0
inhibition	0
of	0
a	0
select	0
set	0
of	0
c-Myb	9
regulated	0
targets	0
,	0
such	0
as	0
Bcl-2	9
and	0
CD13/APN	9
,	0
coupled	0
with	0
the	0
activation	0
of	0
as	0
yet	0
undefined	0
differentiation-promoting	1
genes	2
.	0

AML1	9
(	10
CBFalpha2	10
)	10
cooperates	0
with	0
B	9
cell-specific	10
activating	10
protein	10
(	10
BSAP/PAX5	10
)	10
in	0
activation	0
of	0
the	0
B	1
cell-specific	2
BLK	2
gene	2
promoter	2
.	0

AML1	9
plays	0
a	0
critical	0
role	0
during	0
hematopoiesis	0
and	0
chromosomal	0
translocations	0
involving	0
AML1	9
are	0
commonly	0
associated	0
with	0
different	0
forms	0
of	0
leukemia	0
,	0
including	0
pre-B	0
acute	0
lymphoblastic	0
leukemia	0
.	0

To	0
understand	0
the	0
function	0
of	0
AML1	9
during	0
B	7
cell	8
differentiation	0
,	0
we	0
analyzed	0
regulatory	1
regions	2
of	0
B	1
cell-specific	2
genes	2
for	0
potential	0
AML1-binding	1
sites	2
and	0
have	0
identified	0
a	0
putative	0
AML1-binding	1
site	2
in	0
the	0
promoter	0
of	0
the	0
B	1
cell-specific	2
tyrosine	2
kinase	2
gene	2
,	2
blk	2
.	0

Gel	0
mobility	0
shift	0
assays	0
and	0
transient	0
transfection	0
assays	0
demonstrate	0
that	0
AML1	9
binds	0
specifically	0
to	0
this	0
site	0
in	0
the	0
blk	1
promoter	2
and	0
this	0
binding	0
site	0
is	0
important	0
for	0
blk	1
promoter	0
activity	0
.	0

Furthermore	0
,	0
in	0
vitro	0
binding	0
analysis	0
revealed	0
that	0
the	0
AML1	1
runt	2
DNA-binding	2
domain	2
physically	0
interacts	0
with	0
the	0
paired	1
DNA-binding	2
domain	2
of	0
BSAP	9
,	0
a	0
B	9
cell-specific	10
transcription	10
factor	10
.	0

BSAP	9
has	0
been	0
shown	0
previously	0
to	0
be	0
important	0
for	0
B	0
cell-specific	0
regulation	0
of	0
the	0
blk	1
gene	0
.	0

Physical	0
interaction	0
of	0
AML1	9
with	0
BSAP	9
correlates	0
with	0
functional	0
cooperativity	0
in	0
transfection	0
studies	0
where	0
AML1	9
and	0
BSAP	9
synergistically	0
activate	0
blk	1
promoter	0
transcription	0
by	0
more	0
than	0
50-fold	0
.	0

These	0
results	0
demonstrate	0
physical	0
and	0
functional	0
interactions	0
between	0
AML1	9
and	0
BSAP	9
and	0
suggest	0
that	0
AML1	9
is	0
an	0
important	0
factor	0
for	0
regulating	0
a	0
critical	0
B	1
cell-specific	2
gene	2
,	0
blk	1
.	0

Transcriptional	0
inhibition	0
by	0
interleukin-6	9
of	0
the	0
class	9
A	10
macrophage	10
scavenger	10
receptor	10
in	0
macrophages	7
derived	0
from	0
human	7
peripheral	8
monocytes	8
and	0
the	0
THP-1	5
monocytic	6
cell	6
line	6
.	0

Expression	0
of	0
the	0
class	9
A	10
macrophage	10
scavenger	10
receptor	10
(	10
MSR	10
)	10
contributes	0
to	0
the	0
uptake	0
of	0
modified	9
low	10
density	10
lipoproteins	10
(	10
LDL	10
)	10
by	0
macrophages	7
and	0
transformation	0
of	0
these	0
cells	0
into	0
lipid-laden	7
foam	8
cells	8
,	0
which	0
characterize	0
atherosclerosis	0
.	0

Many	0
environmental	0
factors	0
,	0
in	0
particular	0
,	0
proinflammatory	9
cytokines	10
and	0
growth	9
factors	10
,	0
can	0
exert	0
regulatory	0
effects	0
on	0
MSR	9
expression	0
,	0
whereas	0
intracellular	0
accumulation	0
of	0
cholesterol	0
itself	0
does	0
not	0
influence	0
MSR	9
levels	0
to	0
any	0
considerable	0
extent	0
.	0

In	0
the	0
present	0
study	0
,	0
by	0
using	0
an	0
in	0
vitro	0
model	0
,	0
we	0
examined	0
whether	0
stimulation	0
with	0
interleukin-6	9
(	10
IL-6	10
)	10
,	0
an	0
immunoregulatory	9
,	0
multipotential	9
cytokine	10
,	0
modulates	0
the	0
expression	0
and	0
activities	0
of	0
the	0
MSR	9
in	0
macrophages	7
.	0

When	0
treated	0
with	0
IL-6	9
,	0
macrophages	7
derived	0
from	0
peripheral	7
monocytes	8
and	0
phorbol	5
12-myristate	6
13-acetate	6
(	6
PMA	6
)	6
-differentiated	6
THP-1	6
monocytic	6
cells	6
showed	0
significantly	0
reduced	0
uptake	0
and/or	0
binding	0
of	0
the	0
MSR	9
ligand	0
,	0
acetylated	9
LDL	10
.	0

This	0
effect	0
was	0
paralleled	0
by	0
a	0
reduction	0
in	0
the	0
expression	0
of	0
MSR	9
protein	0
and	0
mRNA	3
.	0

Analysis	0
of	0
MSR	1
promoter	2
activity	0
in	0
THP-1	5
cells	6
transfected	0
with	0
an	0
MSR	1
promoter-reporter	2
gene	2
construct	2
demonstrated	0
decreased	0
activity	0
of	0
the	0
MSR	1
promoter	2
in	0
IL-6	9
-treated	0
THP-1	5
macrophages	7
.	0

Electrophoretic	0
mobility	0
gel	0
shift	0
assay	0
also	0
showed	0
a	0
reduction	0
in	0
the	0
binding	0
of	0
a	0
transcription	9
factor	10
to	0
the	0
MSR	1
promoter	2
AP-1/ets	2
elements	2
in	0
IL-6	9
-treated	0
cells	0
.	0

Thus	0
,	0
exposure	0
to	0
IL-6	9
may	0
inhibit	0
expression	0
of	0
the	0
class	9
A	10
MSR	10
in	0
differentiated	0
macrophages	7
at	0
transcriptional	0
levels	0
.	0

This	0
result	0
suggests	0
that	0
this	0
cytokine	9
may	0
modulate	0
foam	0
cell	0
formation	0
during	0
atherogenesis	0
.	0

Retinoblastoma	0
protein	0
expression	0
leads	0
to	0
reduced	0
Oct-1	9
DNA	0
binding	0
activity	0
and	0
enhances	0
interleukin-8	9
expression	0
.	0

Tumor	0
cell	0
lines	0
with	0
a	0
defective	0
retinoblastoma	1
gene	2
are	0
unable	0
to	0
transcribe	0
the	0
HLA	1
class	2
II	2
genes	2
in	0
response	0
to	0
IFN-gamma	9
treatment	0
,	0
and	0
reconstitution	0
of	0
functional	0
Rb	9
rescues	0
IFN-gamma-induced	0
class	1
II	2
gene	2
expression	0
.	0

However	0
,	0
the	0
molecular	0
mechanism	0
of	0
Rb	9
rescue	0
of	0
the	0
class	1
II	2
genes	2
is	0
unknown	0
.	0

We	0
have	0
examined	0
the	0
effect	0
of	0
Rb	9
expression	0
on	0
the	0
activation	0
of	0
the	0
promoter	0
for	0
HLA-DRA	1
,	0
the	0
prototype	1
class	2
II	2
gene	2
.	0

Oct-1	9
,	0
a	0
POU	9
domain	10
transcription	10
factor	10
,	0
was	0
identified	0
as	0
a	0
repressor	0
of	0
HLA-DRA	1
promoter	0
activity	0
in	0
the	0
Rb-defective	7
cells	8
.	0

Rb	9
expression	0
led	0
to	0
phosphorylation	0
of	0
Oct-1	9
,	0
thus	0
relieving	0
its	0
repressive	0
effect	0
.	0

Oct-1	9
has	0
also	0
been	0
shown	0
to	0
repress	0
interleukin	9
8	10
promoter	0
activity	0
.	0

Consistent	0
with	0
reduced	0
levels	0
of	0
Oct-1	9
DNA	0
binding	0
activity	0
in	0
the	0
Rb-transformed	5
cell	6
lines	6
,	0
interleukin	9
8	10
expression	0
is	0
higher	0
in	0
these	0
cell	0
lines	0
.	0

Cell	0
activation	0
and	0
apoptosis	0
by	0
bacterial	9
lipoproteins	10
through	0
toll-like	9
receptor-2	10
.	0

Apoptosis	0
is	0
implicated	0
in	0
the	0
generation	0
and	0
resolution	0
of	0
inflammation	0
in	0
response	0
to	0
bacterial	0
pathogens	0
.	0

All	0
bacterial	0
pathogens	0
produce	0
lipoproteins	9
(	10
BLPs	10
)	10
,	0
which	0
trigger	0
the	0
innate	0
immune	0
response	0
.	0

BLPs	9
were	0
found	0
to	0
induce	0
apoptosis	0
in	0
THP-1	5
monocytic	6
cells	6
through	0
human	9
Toll-like	10
receptor-2	10
(	10
hTLR2	10
)	10
.	0

BLPs	9
also	0
initiated	0
apoptosis	0
in	0
an	0
epithelial	5
cell	6
line	6
transfected	0
with	0
hTLR2	9
.	0

In	0
addition	0
,	0
BLPs	9
stimulated	0
nuclear	9
factor-kappaB	10
,	0
a	0
transcriptional	9
activator	10
of	0
multiple	1
host	2
defense	2
genes	2
,	0
and	0
activated	0
the	0
respiratory	0
burst	0
through	0
hTLR2	9
.	0

Thus	0
,	0
hTLR2	9
is	0
a	0
molecular	0
link	0
between	0
microbial	0
products	0
,	0
apoptosis	0
,	0
and	0
host	0
defense	0
mechanisms	0
.	0

Possible	0
differences	0
in	0
the	0
mechanism	0
(	0
s	0
)	0
of	0
action	0
of	0
different	0
glucocorticoid	0
hormone	0
compounds	0
.	0

Different	0
glucocorticoid	0
hormones	0
(	0
GCH	0
)	0
show	0
differences	0
in	0
the	0
intensity	0
and	0
in	0
the	0
kinetics	0
of	0
their	0
immunomodulating	0
activity	0
.	0

The	0
mechanism	0
(	0
s	0
)	0
of	0
action	0
of	0
GCH	0
is	0
under	0
investigation	0
,	0
but	0
is	0
has	0
been	0
noted	0
that	0
they	0
exert	0
immune	0
activity	0
via	0
the	0
genomic	0
pathway	0
.	0

We	0
have	0
studied	0
the	0
effects	0
of	0
prednisone	0
(	0
PDN	0
)	0
,	0
deflazacort	0
(	0
DFC	0
)	0
,	0
and	0
dexamethasone	0
(	0
DXM	0
)	0
on	0
the	0
production	0
of	0
cytokines	9
(	0
IL-2	9
,	0
IL-6	9
,	0
TNF-alpha	9
,	0
IL-10	9
)	0
by	0
peripheral	7
T	8
lymphocytes	8
,	0
and	0
the	0
effects	0
on	0
the	0
inhibition	0
of	0
NF-kB	9
DNA	0
binding	0
activity	0
by	0
activated	5
Jurkat	6
cell	6
line	6
.	0

The	0
data	0
obtained	0
show	0
that	0
the	0
three	0
GCH	0
molecules	0
exert	0
an	0
immunosuppression	0
on	0
cytokine	9
production	0
by	0
T	7
lymphocytes	8
and	0
a	0
strong	0
decrease	0
in	0
the	0
nuclear	0
translocation	0
of	0
NF-kB	9
in	0
Jurkat	5
cells	6
;	0
moreover	0
,	0
(	0
a	0
)	0
not	0
all	0
the	0
cytokines	9
investigated	0
were	0
affected	0
,	0
and	0
not	0
with	0
the	0
same	0
intensity	0
,	0
by	0
the	0
three	0
GCH	0
and	0
(	0
b	0
)	0
DXM	0
inhibited	0
the	0
binding	0
activity	0
of	0
NF-kB	9
less	0
than	0
that	0
of	0
DFC	0
and	0
PDN	0
.	0

These	0
data	0
are	0
in	0
agreement	0
with	0
the	0
concept	0
that	0
different	0
GCH	0
compounds	0
might	0
differ	0
in	0
their	0
binding	0
and	0
affinity	0
properties	0
,	0
tissue-specific	0
metabolism	0
,	0
and	0
interaction	0
with	0
transcription	9
factor	10
.	0

Distinctive	0
expression	0
pattern	0
of	0
the	0
BCL-6	9
protein	10
in	0
nodular	0
lymphocyte	0
predominance	0
Hodgkin	0
's	0
disease	0
.	0

The	0
BCL-6	3
gene	4
encoding	0
a	0
nuclear-located	9
Kruppel-type	10
zinc	10
finger	10
protein	10
is	0
rearranged	0
in	0
about	0
30	0
%	0
diffuse	0
large	0
B-cell	7
lymphomas	8
and	0
is	0
expressed	0
predominantly	0
in	0
normal	0
germinal	7
center	8
B	8
cells	8
and	0
related	0
lymphomas	0
.	0

These	0
findings	0
suggest	0
that	0
BCL-6	9
may	0
play	0
a	0
role	0
in	0
regulating	0
differentiation	0
of	0
normal	0
germinal	7
center	8
B	8
cells	8
and	0
that	0
its	0
deregulated	0
expression	0
caused	0
by	0
rearrangements	0
may	0
contribute	0
to	0
lymphomagenesis	0
.	0

This	0
prompted	0
us	0
to	0
investigate	0
the	0
expression	0
of	0
the	0
BCL-6	9
protein	10
in	0
Hodgkin	0
's	0
disease	0
(	0
HD	0
)	0
,	0
focusing	0
on	0
the	0
nodular	0
lymphocyte	0
predominance	0
subtype	0
(	0
NLPHD	0
)	0
,	0
which	0
differs	0
from	0
classical	0
HD	0
by	0
virtue	0
of	0
the	0
B-cell	0
nature	0
of	0
the	0
malignant	7
cell	8
population	8
(	0
so-called	0
L	7
&	8
H	8
cells	8
)	0
and	0
its	0
relationship	0
with	0
germinal	0
centers	0
.	0

Forty-one	0
HD	0
samples	0
(	0
19	0
NLPHD	0
,	0
12	0
nodular	0
sclerosis	0
,	0
and	0
10	0
mixed	0
cellularity	0
)	0
were	0
immunostained	0
with	0
the	0
monoclonal	9
antibodies	10
PG-B6	9
and	0
PG-B6p	9
that	0
react	0
with	0
a	0
fixative-sensitive	0
and	0
a	0
formalin-resistant	9
epitope	10
on	0
the	0
aminoterminal	9
region	10
of	0
the	0
BCL-6	9
gene	10
product	10
,	0
respectively	0
.	0

Strong	0
nuclear	0
positivity	0
for	0
the	0
BCL-6	9
protein	10
was	0
detected	0
in	0
tumor	7
(	8
L	8
&	8
H	8
)	8
cells	8
in	0
all	0
cases	0
of	0
NLPHD	0
.	0

In	0
contrast	0
,	0
BCL-6	9
was	0
expressed	0
only	0
in	0
a	0
small	0
percentage	0
of	0
Hodgkin	5
and	6
Reed-Sternberg	6
cells	6
in	0
about	0
30	0
%	0
of	0
classical	0
HD	0
cases	0
.	0

Notably	0
,	0
the	0
nuclei	0
of	0
reactive	7
CD3+/CD4+	8
T	8
cells	8
nearby	0
to	0
and	0
rosetting	0
around	0
L	7
&	8
H	8
cells	8
in	0
NLPHD	0
were	0
also	0
strongly	0
BCL-6	9
+	0
,	0
but	0
lacked	0
CD40	9
ligand	10
(	0
CD40L	9
)	0
expression	0
.	0

This	0
staining	0
pattern	0
clearly	0
differed	0
from	0
that	0
of	0
classical	0
HD	0
,	0
whose	0
cellular	0
background	0
was	0
made	0
up	0
of	0
CD3+/CD4+	7
T	8
cells	8
showing	0
the	0
BCL-6	9
-/	0
CD40L	9
+	0
phenotype	0
.	0

These	0
results	0
further	0
support	0
the	0
concept	0
that	0
NLPHD	0
is	0
an	0
histogenetically	0
distinct	0
,	0
B-cell-derived	0
subtype	0
of	0
HD	0
and	0
suggest	0
a	0
role	0
for	0
BCL-6	9
in	0
its	0
development	0
.	0

Selenium-mediated	0
inhibition	0
of	0
transcription	9
factor	10
NF-kappa	10
B	10
and	0
HIV-1	1
LTR	2
promoter	2
activity	0
.	0

The	0
eukaryotic	9
transcription	10
factor	10
NF-kappa	10
B	10
is	0
involved	0
in	0
the	0
inducible	0
expression	0
of	0
various	0
inflammatory	1
genes	2
as	0
well	0
as	0
in	0
HIV-1	0
replication	0
.	0

Activation	0
of	0
NF-kappa	9
B	10
is	0
induced	0
by	0
prooxidants	0
and	0
several	0
stimuli	0
eliciting	0
oxidative	0
stress	0
,	0
such	0
as	0
cytokines	9
,	0
lipopolysaccharide	0
,	0
UV	0
irradiation	0
and	0
other	0
mediators	0
.	0

Various	0
antioxidants	0
inhibit	0
NF-kappa	9
B	10
activation	0
in	0
response	0
to	0
these	0
stimuli	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
investigated	0
the	0
effects	0
of	0
selenium	0
,	0
an	0
integral	0
component	0
of	0
glutathione	9
peroxidase	10
(	0
GPX	9
)	0
,	0
on	0
NF-kappa	9
B	10
activation	0
.	0

In	0
selenium-deprived	5
Jurkat	6
and	0
ESb-L	5
T	6
lymphocytes	6
,	0
supplementation	0
of	0
selenium	0
led	0
to	0
a	0
substantial	0
increase	0
of	0
GPX	9
activity	0
.	0

Analysis	0
of	0
DNA	0
binding	0
revealed	0
that	0
NF-kappa	9
B	10
activation	0
in	0
response	0
to	0
TNF	9
was	0
significantly	0
inhibited	0
under	0
these	0
conditions	0
.	0

Likewise	0
,	0
reporter	0
gene	0
assays	0
using	0
luciferase	0
constructs	0
driven	0
by	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
showed	0
a	0
dose-dependent	0
inhibition	0
of	0
NF-kappa	9
B	10
controlled	0
gene	0
expression	0
by	0
selenium	0
.	0

The	0
effects	0
of	0
selenium	0
were	0
specific	0
for	0
NF-kappa	9
B	10
,	0
since	0
the	0
activity	0
of	0
the	0
transcription	0
factor	0
AP-1	9
was	0
not	0
suppressed	0
.	0

These	0
data	0
suggest	0
that	0
selenium	0
supplementation	0
may	0
be	0
used	0
to	0
modulate	0
the	0
expression	0
of	0
NF-kappa	1
B	2
target	2
genes	2
and	0
HIV-1	0
.	0

The	0
involvement	0
of	0
p23	9
,	0
hsp90	9
,	0
and	0
immunophilins	9
in	0
the	0
assembly	0
of	0
progesterone	9
receptor	10
complexes	10
.	0

To	0
better	0
understand	0
the	0
assembly	0
mechanism	0
for	0
the	0
progesterone	9
receptor	10
(	0
PR	9
)	0
,	0
we	0
have	0
developed	0
cell-free	0
systems	0
for	0
studying	0
interactions	0
of	0
PR	9
,	0
hsp90	9
,	0
and	0
other	0
associated	9
proteins	10
.	0

When	0
PR	9
is	0
incubated	0
in	0
rabbit	0
reticulocyte	0
lysate	0
,	0
its	0
association	0
with	0
hsp90	9
,	0
hsp70	9
,	0
the	0
three	0
immunophilins	9
FKBP54	9
,	0
FKBP52	9
and	0
CyP-40	9
,	0
and	0
with	0
p23	9
is	0
observed	0
.	0

These	0
interactions	0
require	0
ATP/Mg2+	0
and	0
when	0
ATP	0
is	0
limiting	0
the	0
PR	9
complex	0
is	0
altered	0
to	0
one	0
containing	0
the	0
proteins	0
p60	9
and	0
p48	9
,	0
but	0
lacking	0
immunophilins	9
and	0
p23	9
.	0

We	0
have	0
studied	0
two	0
pre-formed	9
hsp90	10
complexes	10
that	0
may	0
participate	0
in	0
the	0
assembly	0
of	0
PR	9
complexes	10
.	0

One	0
contains	0
hsp90	9
bound	0
to	0
hsp70	9
and	0
p60	9
and	0
this	0
complex	0
forms	0
spontaneously	0
in	0
the	0
absence	0
of	0
ATP	0
.	0

A	0
second	0
complex	0
contains	0
hsp90	9
bound	0
to	0
p23	9
plus	0
the	0
three	0
immunophilins	9
and	0
some	0
hsp70	9
.	0

The	0
formation	0
of	0
this	0
complex	0
requires	0
ATP	0
.	0

In	0
further	0
studies	0
we	0
have	0
shown	0
that	0
purified	0
hsp90	9
can	0
bind	0
to	0
purified	0
p23	9
and	0
this	0
interaction	0
requires	0
both	0
ATP	0
and	0
molybdate	0
.	0

This	0
explains	0
,	0
in	0
part	0
,	0
the	0
known	0
effects	0
of	0
ATP	0
and	0
molybdate	0
on	0
assembly	0
of	0
PR	9
complexes	10
.	0

Increased	0
IkappaB	9
expression	0
and	0
diminished	0
nuclear	9
NF-kappaB	10
in	0
human	7
mononuclear	8
cells	8
following	0
hydrocortisone	0
injection	0
.	0

We	0
have	0
recently	0
demonstrated	0
that	0
hydrocortisone	0
and	0
other	0
glucocorticoids	0
inhibit	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
generation	0
by	0
mononuclear	7
(	8
MNC	8
)	8
and	8
polymorphonuclear	8
leucocytes	8
(	0
PMNL	7
)	0
.	0

Since	0
NF-kappaB/	0
IkappaB	9
system	0
regulates	0
the	0
transcription	0
of	0
proinflammatory	9
genes	10
,	0
including	0
those	0
responsible	0
for	0
ROS	0
generation	0
,	0
we	0
tested	0
the	0
hypothesis	0
that	0
hydrocortisone	0
may	0
stimulate	0
IkappaB	9
production	0
thus	0
inhibiting	0
NF-kappaB	9
translocation	0
from	0
the	0
cytosol	0
into	0
the	0
nucleus	0
in	0
MNC	7
,	0
in	0
vivo	0
.	0

One	0
hundred	0
milligram	0
of	0
hydrocortisone	0
was	0
injected	0
intravenously	0
into	0
4	0
normal	0
subjects	0
.	0

Blood	0
samples	0
were	0
obtained	0
prior	0
to	0
the	0
injection	0
and	0
at	0
1	0
,	0
2	0
,	0
4	0
,	0
8	0
and	0
24	0
hr	0
after	0
the	0
injection	0
.	0

Nuclear	0
extracts	0
and	0
total	0
cell	0
lysates	0
were	0
prepared	0
from	0
MNC	7
by	0
standard	0
techniques	0
.	0

IkappaB	9
levels	0
in	0
MNC	7
homogenates	0
increased	0
at	0
1	0
hr	0
,	0
peaked	0
at	0
2-4	0
hr	0
,	0
started	0
to	0
decrease	0
at	0
8	0
hr	0
,	0
and	0
returned	0
to	0
baseline	0
levels	0
at	0
24	0
hr	0
.	0

NF-kappaB	9
in	0
MNC	7
nuclear	0
extracts	0
decreased	0
at	0
1	0
hr	0
,	0
reached	0
a	0
nadir	0
at	0
4	0
hr	0
,	0
gradually	0
increased	0
at	0
8	0
hr	0
and	0
returned	0
back	0
to	0
baseline	0
levels	0
at	0
24	0
hr	0
.	0

The	0
total	0
protein	0
content	0
of	0
NF-kappaB	9
subunit	10
(	0
P65	9
)	0
in	0
MNC	7
lysates	0
also	0
showed	0
a	0
decrease	0
following	0
hydrocortisone	0
injection	0
.	0

This	0
decrease	0
was	0
observed	0
at	0
2	0
hr	0
,	0
reached	0
a	0
nadir	0
at	0
4	0
hr	0
,	0
and	0
returned	0
to	0
baseline	0
levels	0
at	0
24	0
hr	0
.	0

ROS	0
generation	0
inhibition	0
paralleled	0
NF-kappaB	9
levels	0
in	0
the	0
nucleus	0
.	0

It	0
was	0
inhibited	0
at	0
1	0
hr	0
,	0
reached	0
a	0
nadir	0
at	0
2-4	0
hr	0
,	0
started	0
to	0
increase	0
at	0
8	0
hr	0
,	0
and	0
returned	0
to	0
basal	0
levels	0
at	0
24	0
hr	0
.	0

Our	0
data	0
demonstrate	0
that	0
hydrocortisone	0
induces	0
IkappaB	9
and	0
suppresses	0
NF-kappaB	9
expression	0
in	0
MNC	7
in	0
parallel	0
.	0

IkappaB	9
further	0
reduces	0
the	0
translocation	0
of	0
NF-kappaB	9
into	0
the	0
nucleus	0
thus	0
preventing	0
the	0
expression	0
of	0
proinflammatory	1
genes	2
.	0

Glucocorticoids	0
induce	0
apoptosis	0
in	0
human	7
monocytes	8
:	0
potential	0
role	0
of	0
IL-1	9
beta	10
.	0

Glucocorticoids	0
(	0
GC	0
)	0
are	0
potent	0
anti-inflammatory	0
and	0
immunosuppressive	0
agents	0
that	0
act	0
on	0
a	0
variety	0
of	0
immune	7
cells	8
,	0
including	0
monocytes	7
and	0
macrophages	7
.	0

However	0
,	0
the	0
exact	0
cellular	0
mechanisms	0
underlying	0
this	0
anti-inflammatory	0
capacity	0
are	0
still	0
unknown	0
.	0

In	0
our	0
study	0
,	0
we	0
determined	0
the	0
induction	0
of	0
apoptosis	0
by	0
GC	0
in	0
human	7
monocytes	8
.	0

Peripheral	7
blood	8
monocytes	8
were	0
isolated	0
by	0
density	0
centrifugation	0
methods	0
with	0
a	0
purity	0
of	0
>	0
90	0
%	0
and	0
were	0
cultured	0
in	0
RPMI	0
1640	0
medium	0
.	0

Monocyte	0
apoptosis	0
was	0
determined	0
by	0
four	0
independent	0
methods	0
,	0
including	0
annexin-V	0
staining	0
,	0
TUNEL	0
,	0
DNA-laddering	0
,	0
and	0
typical	0
morphology	0
by	0
means	0
of	0
transmission	0
electron	0
microscopy	0
.	0

TNF-alpha	9
and	0
IL-1beta	9
were	0
measured	0
by	0
ELISA	0
.	0

GC	9
receptor	10
was	0
blocked	0
with	0
mifepristone	0
.	0

Caspase	0
3	0
was	0
inhibited	0
with	0
caspase-3	0
inhibitor	0
(	0
DEVD-CHO	0
)	0
.	0

Stimulation	0
with	0
different	0
GC	0
at	0
therapeutic	0
concentrations	0
resulted	0
in	0
monocyte	0
apoptosis	0
in	0
a	0
time-	0
and	0
dose-dependent	0
manner	0
.	0

Necrosis	0
was	0
excluded	0
by	0
propidium	0
iodide	0
staining	0
.	0

Proinflammatory	9
cytokines	10
such	0
as	0
IL-1beta	9
and	0
TNF-alpha	9
were	0
down-regulated	0
by	0
GC	0
treatment	0
.	0

Continuous	0
treatment	0
of	0
monocytes	7
with	0
IL-1beta	9
,	0
but	0
not	0
with	0
TNF-alpha	9
,	0
could	0
almost	0
completely	0
prevent	0
GC-induced	0
cell	0
death	0
.	0

The	0
addition	0
of	0
mifepristone	0
or	0
caspase-3	0
inhibitor	0
could	0
partially	0
abrogate	0
GC-induced	0
apoptosis	0
as	0
well	0
as	0
GC-induced	0
inhibition	0
of	0
IL-1beta	9
.	0

This	0
is	0
the	0
first	0
study	0
to	0
demonstrate	0
induction	0
of	0
apoptosis	0
by	0
GC	0
in	0
human	7
monocytes	8
.	0

GC-induced	0
monocyte	0
apoptosis	0
may	0
be	0
partially	0
mediated	0
through	0
effects	0
on	0
IL-1beta	9
production	0
.	0

It	0
is	0
conceivable	0
that	0
GC	0
exert	0
their	0
anti-inflammatory	0
capacity	0
in	0
various	0
diseases	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
the	0
induction	0
of	0
apoptosis	0
in	0
monocytes	7
.	0

Differential	0
effects	0
of	0
lipopolysaccharide	0
and	0
tumor	9
necrosis	10
factor	10
on	0
monocytic	9
IkappaB	10
kinase	10
signalsome	0
activation	0
and	0
IkappaB	9
proteolysis	0
.	0

The	0
inflammatory	0
mediators	0
lipopolysaccharide	0
(	0
LPS	0
)	0
and	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
are	0
potent	0
activators	0
of	0
NF-kappaB	9
.	0

This	0
study	0
compared	0
the	0
effect	0
of	0
these	0
stimuli	0
on	0
endogenous	0
IkappaB	9
kinase	10
(	0
IKK	9
)	0
signalsome	0
activation	0
and	0
IkappaB	9
phosphorylation/proteolysis	0
in	0
human	7
monocytic	8
cells	8
and	0
investigated	0
the	0
role	0
of	0
the	0
signalsome	9
proteins	10
IKK-alpha	9
,	0
IKK-beta	9
,	0
NF-kappaB-inducing	9
kinase	10
(	0
NIK	9
)	0
,	0
IKK-gamma	9
(	0
NF-kappaB	9
essential	0
modulator	0
)	0
,	0
and	0
IKK	9
complex-associated	10
protein	10
.	0

Kinase	0
assays	0
showed	0
that	0
TNF	9
elicited	0
a	0
rapid	0
but	0
short-lived	0
induction	0
of	0
IKK	9
activity	0
with	0
a	0
3-fold	0
greater	0
effect	0
on	0
IKK-alpha	9
than	0
on	0
IKK-beta	9
,	0
peaking	0
at	0
5	0
min	0
.	0

In	0
contrast	0
,	0
LPS	0
predominantly	0
stimulated	0
IKK-beta	9
activity	0
,	0
which	0
slowly	0
increased	0
,	0
peaking	0
at	0
30	0
min	0
.	0

A	0
second	0
peak	0
was	0
observed	0
at	0
a	0
later	0
time	0
point	0
following	0
LPS	0
stimulation	0
,	0
which	0
consisted	0
of	0
both	0
IKK-alpha	0
and	0
-beta	0
activity	0
.	0

The	0
endogenous	0
levels	0
of	0
the	0
signalsome	0
components	0
were	0
unaffected	0
by	0
stimulation	0
.	0

Furthermore	0
,	0
our	0
studies	0
showed	0
association	0
of	0
the	0
IKK-alpha/beta	9
heterodimer	10
with	0
NIK	9
,	0
IkappaB-alpha	9
and	0
-epsilon	9
in	0
unstimulated	7
cells	8
.	0

Exposure	0
to	0
LPS	0
or	0
TNF	9
led	0
to	0
differential	0
patterns	0
of	0
IkappaB-alpha	9
and	0
IkappaB-epsilon	9
disappearance	0
from	0
and	0
reassembly	0
with	0
the	0
signalsome	0
,	0
whereas	0
IKK-alpha	9
,	0
IKK-beta	9
,	0
and	0
NIK	9
remained	0
complex-associated	0
.	0

NIK	9
can	0
not	0
phosphorylate	0
IkappaB-alpha	9
directly	0
,	0
but	0
it	0
appears	0
to	0
be	0
a	0
functionally	0
important	0
subunit	0
,	0
because	0
mutated	0
NIK	9
inhibited	0
stimulus-induced	0
kappaB	9
-dependent	0
transcription	0
more	0
effectively	0
than	0
mutated	0
IKK-alpha	9
or	0
-beta	9
.	0

Overexpression	0
of	0
IKK	9
complex-associated	10
protein	10
inhibited	0
stimulus-mediated	0
transcription	0
,	0
whereas	0
NF-kappaB	9
essential	0
modulator	0
enhanced	0
it	0
.	0

The	0
understanding	0
of	0
LPS-	0
and	0
TNF-induced	0
signaling	0
may	0
allow	0
the	0
development	0
of	0
specific	0
strategies	0
to	0
treat	0
sepsis-associated	0
disease	0
.	0

Tumor	9
necrosis	10
factor	10
alpha	10
decreases	0
,	0
and	0
interleukin-10	9
increases	0
,	0
the	0
sensitivity	0
of	0
human	7
monocytes	8
to	0
dexamethasone	0
:	0
potential	0
regulation	0
of	0
the	0
glucocorticoid	9
receptor	10
.	0

Resistance	0
to	0
glucocorticoid	0
therapy	0
has	0
been	0
observed	0
in	0
patients	0
with	0
autoimmune/inflammatory	0
diseases	0
and	0
may	0
be	0
related	0
to	0
the	0
inflammatory	0
process	0
itself	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
examine	0
the	0
ability	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNFalpha	9
,	0
a	0
proinflammatory	9
cytokine	10
)	0
and	0
interleukin	9
(	10
IL	10
)	10
-10	10
(	0
an	0
anti-inflammatory	9
cytokine	10
)	0
to	0
differentially	0
regulate	0
the	0
sensitivity	0
of	0
human	7
monocytes	8
/macrophages	7
to	0
glucocorticoids	0
.	0

To	0
accomplish	0
this	0
,	0
we	0
first	0
analyzed	0
the	0
pattern	0
of	0
TNFalpha	9
and	0
IL-10	0
inhibition	0
by	0
dexamethasone	0
in	0
LPS-stimulated	5
whole-blood	6
cell	6
cultures	6
.	0

Second	0
,	0
we	0
studied	0
the	0
modulation	0
of	0
the	0
sensitivity	0
of	0
these	0
cells	0
to	0
dexamethasone	0
by	0
preincubation	0
with	0
TNFalpha	9
or	0
IL-10	9
and	0
measurement	0
of	0
LPS-stimulated	0
IL-6	9
secretion	0
.	0

In	0
addition	0
,	0
we	0
evaluated	0
the	0
effect	0
of	0
dexamethasone	0
on	0
phorbolmyristate-acetate-stimulated	0
IL-1	9
receptor	10
antagonist	0
secretion	0
by	0
the	0
human	5
monocytic	6
cell	6
line	6
U937	6
.	0

Finally	0
,	0
we	0
investigated	0
whether	0
the	0
modulation	0
of	0
corticosensitivity	0
in	0
TNFalpha-	5
and	6
IL-10-pretreated	6
U937	6
cells	6
was	0
related	0
to	0
a	0
change	0
of	0
the	0
glucocorticoid	9
receptor	10
concentration	0
and	0
affinity	0
.	0

Dexamethasone	0
had	0
different	0
effects	0
on	0
LPS-induced	0
TNFalpha	9
and	0
IL-10	9
secretion	0
;	0
whereas	0
it	0
suppressed	0
TNFalpha	9
in	0
a	0
dose-dependent	0
fashion	0
,	0
its	0
effect	0
on	0
IL-10	9
secretion	0
was	0
biphasic	0
,	0
producing	0
stimulation	0
at	0
lower	0
,	0
and	0
inhibition	0
at	0
higher	0
doses	0
.	0

The	0
concentration	0
of	0
LPS	0
employed	0
influenced	0
the	0
effect	0
of	0
dexamethasone	0
on	0
IL-10	9
secretion	0
(	0
P	0
<	0
0.001	0
)	0
.	0

Pretreatment	0
with	0
TNFalpha	9
diminished	0
,	0
and	0
with	0
IL-10	9
improved	0
,	0
the	0
ability	0
of	0
dexamethasone	0
to	0
suppress	0
IL-6	9
secretion	0
in	0
whole-blood	7
cell	8
cultures	8
(	0
P	0
<	0
0.01	0
for	0
both	0
)	0
and	0
to	0
enhance	0
IL-1	9
receptor	0
antagonist	0
secretion	0
by	0
U937	0
cells	0
(	0
P	0
<	0
0.05	0
for	0
both	0
)	0
.	0

TNFalpha	9
decreased	0
(	0
P	0
<	0
0.001	0
)	0
,	0
while	0
IL-10	9
increased	0
(	0
P	0
<	0
0.001	0
)	0
,	0
the	0
concentration	0
of	0
dexamethasone	0
binding	0
sites	0
in	0
these	0
cells	0
,	0
with	0
no	0
discernible	0
effect	0
on	0
their	0
binding	0
affinity	0
.	0

We	0
conclude	0
that	0
glucocorticoids	0
differentially	0
modulate	0
TNFalpha	9
and	0
IL-10	9
secretion	0
by	0
human	7
monocytes	8
in	0
a	0
LPS	0
dose-dependent	0
fashion	0
and	0
that	0
the	0
sensitivity	0
of	0
these	0
cells	0
to	0
glucocorticoids	0
is	0
altered	0
by	0
TNFalpha	9
or	0
IL-10	9
pretreatment	0
;	0
TNFalpha	9
blocks	0
their	0
effects	0
,	0
whereas	0
IL-10	9
acts	0
synergistically	0
with	0
glucocorticoids	0
.	0

This	0
is	0
accompanied	0
by	0
opposite	0
glucocorticoid	9
receptor	10
changes	0
,	0
respectively	0
opposing	0
and	0
favoring	0
glucocorticoid	0
actions	0
.	0

This	0
study	0
suggests	0
that	0
the	0
pattern	0
of	0
pro-/antiinflammatory	0
cytokine	9
secretion	0
may	0
alter	0
the	0
response	0
of	0
patients	0
to	0
glucocorticoid	0
therapy	0
.	0

Block	0
of	0
granulocytic	0
differentiation	0
of	0
32Dcl3	5
cells	6
by	0
AML1/ETO	1
(	2
MTG8	2
)	2
but	0
not	0
by	0
highly	0
expressed	0
Bcl-2	9
.	0

The	0
chimeric	1
gene	2
,	2
AML1/ETO	1
(	2
MTG8	2
)	2
,	0
generated	0
in	0
t	1
(	2
8	2
;	2
21	2
)	2
acute	0
myeloid	0
leukemia	0
enhances	0
the	0
expression	0
of	0
Bcl-2	9
.	0

To	0
evaluate	0
whether	0
this	0
enhancement	0
is	0
the	0
primary	0
role	0
of	0
AML1/ETO	1
in	0
leukemogenesis	0
,	0
effects	0
of	0
over-expression	0
of	0
Bcl-2	9
in	0
the	0
murine	5
myeloid	6
precursor	6
cell	6
line	6
,	0
32Dcl3	5
,	0
were	0
examined	0
.	0

When	0
32Dcl3	5
cells	6
expressing	0
exogenous	0
Bcl-2	9
were	0
induced	0
to	0
differentiate	0
,	0
the	0
onset	0
of	0
morphological	0
differentiation	0
was	0
delayed	0
.	0

However	0
,	0
even	0
the	0
cells	0
expressing	0
very	0
high	0
levels	0
of	0
exogenous	0
Bcl-2	9
eventually	0
underwent	0
differentiation	0
without	0
a	0
significant	0
decrease	0
in	0
the	0
synthesis	0
of	0
Bcl-2	9
.	0

On	0
the	0
contrary	0
,	0
32Dcl3	5
cells	6
stably	0
expressing	0
AML1/ETO	1
were	0
completely	0
resistant	0
to	0
differentiation	0
and	0
continued	0
to	0
grow	0
in	0
the	0
presence	0
of	0
G-CSF	9
.	0

These	0
results	0
are	0
consistent	0
with	0
the	0
interpretation	0
that	0
stimulation	0
of	0
Bcl-2	9
expression	0
is	0
not	0
the	0
primary	0
target	0
of	0
AML1/ETO	1
.	0

Host	0
defense	0
mechanisms	0
triggered	0
by	0
microbial	9
lipoproteins	10
through	0
toll-like	9
receptors	10
.	0

The	0
generation	0
of	0
cell-mediated	0
immunity	0
against	0
many	0
infectious	0
pathogens	0
involves	0
the	0
production	0
of	0
interleukin-12	9
(	0
IL-12	9
)	0
,	0
a	0
key	0
signal	0
of	0
the	0
innate	0
immune	0
system	0
.	0

Yet	0
,	0
for	0
many	0
pathogens	0
,	0
the	0
molecules	0
that	0
induce	0
IL-12	9
production	0
by	0
macrophages	7
and	0
the	0
mechanisms	0
by	0
which	0
they	0
do	0
so	0
remain	0
undefined	0
.	0

Here	0
it	0
is	0
shown	0
that	0
microbial	9
lipoproteins	10
are	0
potent	0
stimulators	0
of	0
IL-12	9
production	0
by	0
human	0
macrophages	7
,	0
and	0
that	0
induction	0
is	0
mediated	0
by	0
Toll-like	9
receptors	10
(	0
TLRs	9
)	0
.	0

Several	0
lipoproteins	0
stimulated	0
TLR-dependent	0
transcription	0
of	0
inducible	0
nitric	9
oxide	10
synthase	10
and	0
the	0
production	0
of	0
nitric	0
oxide	0
,	0
a	0
powerful	0
microbicidal	0
pathway	0
.	0

Activation	0
of	0
TLRs	9
by	0
microbial	9
lipoproteins	10
may	0
initiate	0
innate	0
defense	0
mechanisms	0
against	0
infectious	0
pathogens	0
.	0

Abnormal	0
NF-kappa	9
B	10
activity	0
in	0
T	7
lymphocytes	8
from	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
is	0
associated	0
with	0
decreased	0
p65-RelA	9
protein	0
expression	0
.	0

Numerous	0
cellular	0
and	0
biochemical	0
abnormalities	0
in	0
immune	0
regulation	0
have	0
been	0
described	0
in	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
,	0
including	0
surface	0
Ag	9
receptor	10
-initiated	0
signaling	0
events	0
and	0
lymphokine	9
production	0
.	0

Because	0
NF-kappa	9
B	10
contributes	0
to	0
the	0
transcription	0
of	0
numerous	0
inflammatory	1
genes	2
and	0
has	0
been	0
shown	0
to	0
be	0
a	0
molecular	0
target	0
of	0
antiinflammatory	0
drugs	0
,	0
we	0
sought	0
to	0
characterize	0
the	0
functional	0
role	0
of	0
the	0
NF-kappa	9
B	10
protein	10
complex	10
in	0
lupus	7
T	8
cells	8
.	0

Freshly	0
isolated	0
T	7
cells	8
from	0
lupus	0
patients	0
,	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
patients	0
,	0
and	0
normal	0
individuals	0
were	0
activated	0
physiologically	0
via	0
the	0
TCR	9
with	0
anti-CD3	9
and	0
anti-CD28	9
Abs	10
to	0
assess	0
proximal	0
membrane	0
signaling	0
,	0
and	0
with	0
PMA	0
and	0
a	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
to	0
bypass	0
membrane-mediated	0
signaling	0
events	0
.	0

We	0
measured	0
the	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
nuclear	0
extracts	0
by	0
gel	0
shift	0
analysis	0
.	0

When	0
compared	0
with	0
normal	7
cells	8
,	0
the	0
activation	0
of	0
NF-kappa	9
B	10
activity	0
in	0
SLE	0
patients	0
was	0
significantly	0
decreased	0
in	0
SLE	0
,	0
but	0
not	0
in	0
RA	0
,	0
patients	0
.	0

NF-kappa	9
B	10
binding	0
activity	0
was	0
absent	0
in	0
several	0
SLE	0
patients	0
who	0
were	0
not	0
receiving	0
any	0
medication	0
,	0
including	0
corticosteroids	0
.	0

Also	0
,	0
NF-kappa	9
B	10
activity	0
remained	0
absent	0
in	0
follow-up	0
studies	0
.	0

In	0
supershift	0
experiments	0
using	0
specific	0
Abs	9
,	0
we	0
showed	0
that	0
,	0
in	0
the	0
group	0
of	0
SLE	0
patients	0
who	0
displayed	0
undetectable	0
NF-kappa	9
B	10
activity	0
,	0
p65	9
complexes	10
were	0
not	0
formed	0
.	0

Finally	0
,	0
immunoblot	0
analysis	0
of	0
nuclear	0
extracts	0
showed	0
decreased	0
or	0
absent	0
p65	9
protein	10
levels	0
.	0

As	0
p65	9
complexes	10
are	0
transcriptionally	0
active	0
in	0
comparison	0
to	0
the	0
p50	0
homodimer	0
,	0
this	0
novel	0
finding	0
may	0
provide	0
insight	0
on	0
the	0
origin	0
of	0
abnormal	9
cytokine	10
or	0
other	0
gene	0
transcription	0
in	0
SLE	0
patients	0
.	0

Signaling	0
events	0
induced	0
by	0
lipopolysaccharide-activated	9
toll-like	10
receptor	10
2	10
.	0

Human	9
Toll-like	10
receptor	10
2	10
(	10
TLR2	10
)	10
is	0
a	0
signaling	9
receptor	10
that	0
responds	0
to	0
LPS	0
and	0
activates	0
NF-kappaB	9
.	0

Here	0
,	0
we	0
investigate	0
further	0
the	0
events	0
triggered	0
by	0
TLR2	9
in	0
response	0
to	0
LPS	0
.	0

We	0
show	0
that	0
TLR2	9
associates	0
with	0
the	0
high-affinity	9
LPS	10
binding	10
protein	10
membrane	0
CD14	9
to	0
serve	0
as	0
an	0
LPS	9
receptor	10
complex	10
,	0
and	0
that	0
LPS	0
treatment	0
enhances	0
the	0
oligomerization	0
of	0
TLR2	9
.	0

Concomitant	0
with	0
receptor	0
oligomerization	0
,	0
the	0
IL-1R-associated	9
kinase	10
(	10
IRAK	10
)	10
is	0
recruited	0
to	0
the	0
TLR2	9
complex	0
.	0

Intracellular	0
deletion	0
variants	0
of	0
TLR2	9
lacking	0
C-terminal	0
13	0
or	0
141	0
aa	0
fail	0
to	0
recruit	0
IRAK	9
,	0
which	0
is	0
consistent	0
with	0
the	0
inability	0
of	0
these	0
mutants	0
to	0
transmit	0
LPS	0
cellular	0
signaling	0
.	0

Moreover	0
,	0
both	0
deletion	0
mutants	0
could	0
still	0
form	0
complexes	0
with	0
wild-type	9
TLR2	10
and	0
act	0
in	0
a	0
dominant-negative	0
(	0
DN	0
)	0
fashion	0
to	0
block	0
TLR2	9
-mediated	0
signal	0
transduction	0
.	0

DN	0
constructs	0
of	0
myeloid	9
differentiation	10
protein	10
,	0
IRAK	9
,	0
TNF	9
receptor-associated	10
factor	10
6	10
,	0
and	0
NF-kappaB-inducing	9
kinase	10
,	0
when	0
coexpressed	0
with	0
TLR2	9
,	0
abrogate	0
TLR2	9
-mediated	0
NF-kappaB	9
activation	0
.	0

These	0
results	0
reveal	0
a	0
conserved	0
signaling	0
pathway	0
for	0
TLR2	9
and	0
IL-1Rs	9
and	0
suggest	0
a	0
molecular	0
mechanism	0
for	0
the	0
inhibition	0
of	0
TLR2	9
by	0
DN	0
variants	0
.	0

Tyrphostin	0
AG-490	0
inhibits	0
cytokine-mediated	0
JAK3	9
/STAT5a/b	9
signal	0
transduction	0
and	0
cellular	0
proliferation	0
of	0
antigen-activated	0
human	0
T	7
cells	8
.	0

Janus	9
kinase	10
3	10
(	10
JAK3	10
)	10
is	0
a	0
cytoplasmic	9
tyrosine	10
kinase	10
required	0
for	0
T	7
cell	8
development	0
and	0
activated	0
by	0
cytokines	9
that	0
utilize	0
the	0
interleukin-2	9
(	10
IL-2	10
)	10
receptor	10
common	10
gamma	10
chain	10
(	10
gamma	10
(	10
c	10
)	10
)	10
.	0

Genetic	0
inactivation	0
of	0
JAK3	9
is	0
manifested	0
as	0
severe	0
combined	0
immunodeficiency	0
disease	0
(	0
SCID	0
)	0
in	0
humans	0
and	0
mice	0
.	0

These	0
findings	0
have	0
suggested	0
that	0
JAK3	9
represents	0
a	0
pharmacological	0
target	0
to	0
control	0
certain	0
lymphoid-derived	0
diseases	0
.	0

Here	0
we	0
provide	0
novel	0
evidence	0
that	0
AG-490	0
potently	0
inhibits	0
the	0
autokinase	0
activity	0
of	0
JAK3	9
and	0
tyrosine	0
phosphorylation	0
and	0
DNA	0
binding	0
of	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
5a	10
and	10
5b	10
(	10
STAT5a/b	10
)	10
.	0

Similar	0
inhibitory	0
effects	0
were	0
observed	0
with	0
other	0
cytokines	9
that	0
use	0
gamma	9
(	10
c	10
)	10
.	0

AG-490	0
also	0
inhibited	0
IL-2	9
-mediated	0
proliferative	0
growth	0
in	0
human	0
T	7
cells	8
with	0
an	0
IC50	0
)	0
=	0
25	0
microM	0
that	0
was	0
partially	0
recoverable	0
.	0

Moreover	0
,	0
we	0
demonstrate	0
that	0
this	0
inhibitor	0
prevented	0
tetanus	0
toxoid	0
antigen-specific	0
T	0
cell	0
proliferation	0
and	0
expansion	0
but	0
failed	0
to	0
block	0
activation	0
of	0
Zap70	9
or	0
p56Lck	9
after	0
anti-CD3	9
stimulation	0
of	0
human	0
T	7
cells	8
.	0

Taken	0
together	0
,	0
these	0
findings	0
suggest	0
that	0
AG-490	0
inhibits	0
the	0
JAK3	9
-mediated	0
Type	0
II	0
signaling	0
pathway	0
but	0
not	0
the	0
T	7
cell	8
receptor-derived	0
Type	0
I	0
pathway	0
and	0
possesses	0
therapeutic	0
potential	0
for	0
T	7
cell	8
-derived	0
pathologies	0
such	0
as	0
graft-versus-host	0
disease	0
,	0
allergy	0
,	0
and	0
autoimmune	0
disorders	0
.	0

C/EBP	9
beta	10
in	0
rheumatoid	0
arthritis	0
:	0
correlation	0
with	0
inflammation	0
,	0
not	0
disease	0
specificity	0
.	0

Rheumatoid	0
arthritis	0
synovial	0
tissue	0
was	0
examined	0
and	0
compared	0
with	0
osteoarthritis	0
tissue	0
for	0
the	0
presence	0
of	0
the	0
nuclear	9
transcription	10
factor	10
C/EBP	10
beta	10
(	10
NF-IL-6	10
)	10
.	0

The	0
region	0
(	0
lining	0
or	0
sublining	0
)	0
,	0
cell	0
type	0
,	0
and	0
subcellular	0
distribution	0
(	0
cytoplasmic	0
or	0
nuclear	0
)	0
of	0
the	0
expression	0
of	0
C/EBP	9
beta	10
was	0
characterized	0
.	0

Rheumatoid	0
arthritis	0
synovial	0
fluid	0
and	0
blood	0
and	0
normal	0
peripheral	0
blood	0
were	0
also	0
examined	0
.	0

C/EBP	9
beta	10
was	0
detected	0
in	0
the	0
synovial	0
lining	0
and	0
in	0
sublining	7
cells	8
of	8
synovial	8
tissue	8
from	0
patients	0
with	0
both	0
rheumatoid	0
and	0
osteoarthritis	0
.	0

A	0
significant	0
(	0
P	0
<	0
0.001	0
and	0
<	0
0.05	0
,	0
respectively	0
)	0
increase	0
in	0
the	0
percentage	0
of	0
cells	0
with	0
nuclear	0
staining	0
was	0
seen	0
in	0
the	0
lining	0
layer	0
,	0
compared	0
to	0
cells	0
in	0
the	0
sublining	0
region	0
,	0
in	0
rheumatoid	0
and	0
osteoarthritis	0
.	0

In	0
both	0
diseases	0
a	0
strong	0
correlation	0
(	0
r	0
=	0
0.79	0
,	0
P	0
<	0
0.001	0
)	0
was	0
observed	0
between	0
the	0
percentage	0
of	0
cells	0
in	0
the	0
synovial	0
lining	0
that	0
were	0
positive	0
for	0
nuclear	9
C/EBP	10
beta	10
and	0
lining	0
cell	0
depth	0
.	0

Two-color	0
immunohistochemistry	0
demonstrated	0
that	0
both	0
macrophages	7
and	0
fibroblast-like	7
synoviocytes	8
were	0
positive	0
for	0
nuclear	0
C/EBP	9
beta	10
.	0

The	0
presence	0
of	0
C/EBP	9
beta	10
was	0
confirmed	0
by	0
immunohistochemistry	0
and	0
Western	0
blot	0
analysis	0
with	0
isolated	0
synovial	7
fibroblasts	8
.	0

Nuclear	0
C/EBP	9
beta	10
was	0
also	0
detected	0
in	0
rheumatoid	7
synovial	8
fluid	8
monocytes/macrophages	8
,	8
but	8
not	8
in	8
lymphocytes	8
or	8
neutrophils	8
.	0

Western	0
blot	0
analysis	0
confirmed	0
the	0
presence	0
of	0
C/EBP	9
beta	10
in	0
these	0
cells	0
.	0

The	0
intensity	0
of	0
C/EBP	9
beta	10
staining	0
was	0
greater	0
(	0
P	0
<	0
0.001	0
)	0
in	0
synovial	7
fluid	8
monocytes	8
than	0
in	0
those	0
from	0
normal	7
or	8
rheumatoid	8
peripheral	8
blood	8
.	0

In	0
conclusion	0
,	0
the	0
enhanced	0
nuclear	0
staining	0
for	0
C/EBP	9
beta	10
in	0
the	0
synovial	0
lining	0
,	0
compared	0
to	0
the	0
sublining	0
,	0
suggesting	0
activation	0
in	0
the	0
lining	0
,	0
and	0
the	0
positive	0
correlation	0
of	0
lining	0
layer	0
depth	0
with	0
the	0
percentage	0
of	0
cells	0
in	0
the	0
lining	0
positive	0
for	0
nuclear	0
C/EBP	9
beta	10
,	0
suggest	0
a	0
potential	0
role	0
for	0
C/EBP	9
beta	10
in	0
chronic	0
inflammation	0
.	0

The	0
regulation	0
of	0
the	0
production	0
or	0
activity	0
of	0
C/EBP	9
beta	10
,	0
to	0
inhibit	0
inflammatory	0
mediator	0
expression	0
by	0
synovial	7
macrophages	8
and	0
fibroblasts	7
,	0
offers	0
a	0
novel	0
approach	0
to	0
therapeutic	0
intervention	0
.	0

Direct	0
interaction	0
of	0
hematopoietic	9
transcription	10
factors	10
PU.1	10
and	10
GATA-1	10
:	0
functional	0
antagonism	0
in	0
erythroid	7
cells	8
.	0

Malignant	0
transformation	0
usually	0
inhibits	0
terminal	0
cell	0
differentiation	0
but	0
the	0
precise	0
mechanisms	0
involved	0
are	0
not	0
understood	0
.	0

PU.1	9
is	0
a	0
hematopoietic-specific	9
Ets	10
family	10
transcription	10
factor	10
that	0
is	0
required	0
for	0
development	0
of	0
some	0
lymphoid	7
and	8
myeloid	8
lineages	8
.	0

PU.1	9
can	0
also	0
act	0
as	0
an	0
oncoprotein	9
as	0
activation	0
of	0
its	0
expression	0
in	0
erythroid	0
precursors	0
by	0
proviral	0
insertion	0
or	0
transgenesis	0
causes	0
erythroleukemias	0
in	0
mice	0
.	0

Restoration	0
of	0
terminal	0
differentiation	0
in	0
the	0
mouse	5
erythroleukemia	6
(	6
MEL	6
)	6
cells	6
requires	0
a	0
decline	0
in	0
the	0
level	0
of	0
PU.1	9
,	0
indicating	0
that	0
PU.1	9
can	0
block	0
erythroid	0
differentiation	0
.	0

Here	0
we	0
investigate	0
the	0
mechanism	0
by	0
which	0
PU.1	9
interferes	0
with	0
erythroid	0
differentiation	0
.	0

We	0
find	0
that	0
PU.1	9
interacts	0
directly	0
with	0
GATA-1	9
,	0
a	0
zinc	9
finger	10
transcription	10
factor	10
required	0
for	0
erythroid	0
differentiation	0
.	0

Interaction	0
between	0
PU.1	9
and	0
GATA-1	9
requires	0
intact	0
DNA-binding	9
domains	10
in	0
both	0
proteins	0
.	0

PU.1	9
represses	0
GATA-1	9
-mediated	0
transcriptional	0
activation	0
.	0

Both	0
the	0
DNA	9
binding	10
and	0
transactivation	9
domains	10
of	0
PU.1	9
are	0
required	0
for	0
repression	0
and	0
both	0
domains	0
are	0
also	0
needed	0
to	0
block	0
terminal	0
differentiation	0
in	0
MEL	5
cells	6
.	0

We	0
also	0
show	0
that	0
ectopic	0
expression	0
of	0
PU.1	9
in	0
Xenopus	0
embryos	0
is	0
sufficient	0
to	0
block	0
erythropoiesis	0
during	0
normal	0
development	0
.	0

Furthermore	0
,	0
introduction	0
of	0
exogenous	0
GATA-1	9
in	0
both	0
MEL	5
cells	6
and	0
Xenopus	0
embryos	0
and	0
explants	0
relieves	0
the	0
block	0
to	0
erythroid	0
differentiation	0
imposed	0
by	0
PU.1	9
.	0

Our	0
results	0
indicate	0
that	0
the	0
stoichiometry	0
of	0
directly	0
interacting	0
but	0
opposing	0
transcription	9
factors	10
may	0
be	0
a	0
crucial	0
determinant	0
governing	0
processes	0
of	0
normal	0
differentiation	0
and	0
malignant	0
transformation	0
.	0

IL-12	9
induces	0
IFN	9
regulating	10
factor-1	10
(	10
IRF-1	10
)	10
gene	0
expression	0
in	0
human	0
NK	7
and	0
T	7
cells	8
.	0

IL-12	9
is	0
a	0
critical	9
immunoregulatory	10
cytokine	10
that	0
promotes	0
cell-mediated	0
immune	0
responses	0
and	0
the	0
differentiation	0
of	0
naive	0
CD4+	7
cells	8
to	0
Th1	7
cells	8
;	0
however	0
,	0
relatively	0
few	0
IL-12	9
target	0
genes	0
have	0
been	0
identified	0
.	0

To	0
better	0
clarify	0
the	0
molecular	0
basis	0
of	0
IL-12	9
action	0
,	0
we	0
set	0
out	0
to	0
characterize	0
genes	0
up-regulated	0
by	0
IL-12	9
,	0
first	0
by	0
contrasting	0
IL-12	1
-and	0
IFN-alpha-inducible	1
genes	2
.	0

We	0
identified	0
several	0
genes	0
up-regulated	0
by	0
IL-12	9
,	0
namely	0
,	0
MIP-1alpha	9
,	0
MIP-1beta	9
,	0
IL-1RA	9
,	0
and	0
IFN	9
regulatory	10
factor-1	10
(	10
IRF-1	10
)	10
.	0

IRF-1	9
is	0
a	0
transcription	9
factor	10
regulated	0
by	0
IFNs	9
that	0
is	0
also	0
essential	0
for	0
Th1	7
responses	0
.	0

We	0
demonstrated	0
that	0
IL-12	9
directly	0
up-regulates	0
IRF-1	9
to	0
the	0
same	0
extent	0
as	0
IFN-alpha	9
in	0
normal	0
human	0
T	7
cells	8
and	0
in	0
NK	7
cells	8
.	0

We	0
showed	0
that	0
IL-12	9
had	0
a	0
direct	0
effect	0
on	0
IRF-1	9
,	0
an	0
effect	0
not	0
mediated	0
indirectly	0
by	0
the	0
induction	0
of	0
IFN-gamma	9
production	0
.	0

Furthermore	0
,	0
IL-2	9
and	0
IL-12	9
synergistically	0
induced	0
IRF-1	9
,	0
whereas	0
IFN-alpha	9
and	0
IL-12	9
did	0
not	0
.	0

The	0
participation	0
of	0
STAT4	9
in	0
the	0
regulation	0
of	0
IRF-1	9
was	0
demonstrated	0
in	0
two	0
ways	0
.	0

First	0
,	0
STAT4	9
was	0
required	0
for	0
the	0
IL-12	9
-dependent	0
transactivation	0
of	0
an	0
IRF-1	1
reporter	2
construct	2
,	0
and	0
second	0
,	0
STAT4	9
binding	0
to	0
the	0
IRF-1	1
promoter	2
was	0
shown	0
using	0
EMSA	0
.	0

In	0
contrast	0
to	0
IL-12	9
,	0
no	0
up-regulation	0
of	0
IRF-1	9
was	0
found	0
in	0
IL-4-stimulated	5
cells	6
,	0
and	0
IL-4	9
did	0
not	0
block	0
IL-12	9
-dependent	0
up-regulation	0
of	0
IRF-1	9
.	0

Therefore	0
,	0
IRF-1	9
may	0
be	0
an	0
important	0
contributor	0
to	0
IL-12	9
signaling	0
,	0
and	0
we	0
speculate	0
that	0
the	0
defective	0
IL-12	9
responses	0
seen	0
in	0
IRF	9
-1-/-	0
mice	0
might	0
be	0
attributable	0
,	0
in	0
part	0
,	0
to	0
the	0
absence	0
of	0
this	0
transcription	9
factor	10
.	0

Targeted	0
remodeling	0
of	0
human	0
beta-globin	0
promoter	0
chromatin	0
structure	0
produces	0
increased	0
expression	0
and	0
decreased	0
silencing	0
.	0

The	0
chromatin	0
structure	0
of	0
the	0
human	1
beta-globin	2
gene	2
locus	2
assumes	0
a	0
transcriptionally-active	0
conformation	0
in	0
erythroid	7
cells	8
.	0

One	0
feature	0
of	0
this	0
chromatin	0
reorganization	0
is	0
the	0
formation	0
of	0
DNase	1
1	2
hypersensitive	2
sites	2
in	0
the	0
regions	0
of	0
active	1
globin	2
gene	2
promoters	2
.	0

This	0
reorganization	0
requires	0
the	0
globin	1
locus	2
control	2
region	2
and	0
is	0
associated	0
with	0
normal	0
expression	0
of	0
the	0
beta-like	1
globin	2
genes	2
.	0

To	0
determine	0
whether	0
it	0
is	0
possible	0
to	0
artificially	0
enhance	0
the	0
opening	0
of	0
the	0
chromatin	0
structure	0
of	0
a	0
minimal	1
beta-globin	2
promoter	2
,	0
we	0
placed	0
a	0
101bp	0
,	0
erythroid-specific	1
DNase	2
1	2
hypersensitive	2
site-forming	2
element	2
(	0
HSFE	1
)	0
immediately	0
upstream	0
of	0
the	0
beta-globin	1
promoter	2
and	2
gene	2
.	0

This	0
element	0
includes	0
binding	0
sites	0
for	0
NF-E2	9
,	0
AP-1	9
,	0
GATA-1	9
and	0
Sp-1	9
.	0

Constructs	0
were	0
stably	0
transfected	0
into	0
murine	7
erythroleukemia	8
cells	8
and	0
promoter	0
chromatin	0
structure	0
and	0
gene	0
expression	0
were	0
analyzed	0
.	0

The	0
HSFE	1
induced	0
an	0
area	0
of	0
enhanced	0
DNase	9
1	10
hypersensitivity	0
extending	0
from	0
the	0
transcriptional	0
start	0
site	0
to	0
-300bp	0
of	0
the	0
artificial	1
promoter	2
and	0
significantly	0
increased	0
the	0
proportion	0
of	0
beta-globin	1
promoters	2
in	0
an	0
open	0
chromatin	0
configuration	0
.	0

This	0
remodeling	0
of	0
promoter	0
chromatin	0
structure	0
resulted	0
in	0
3-fold	0
increases	0
in	0
beta-globin	1
gene	2
transcription	0
and	0
induction	0
,	0
and	0
inhibited	0
long-term	0
beta-globin	1
gene	2
silencing	0
.	0

These	0
results	0
indicate	0
that	0
a	0
relatively	0
small	0
cis-acting	1
element	2
is	0
able	0
to	0
enhance	0
remodeling	0
of	0
promoter	0
chromatin	0
structure	0
resulting	0
in	0
increased	0
beta-globin	1
gene	2
expression	0
.	0

Regulation	0
of	0
low	0
shear	0
flow-induced	0
HAEC	5
VCAM-1	9
expression	0
and	0
monocyte	0
adhesion	0
.	0

We	0
recently	0
reported	0
that	0
prolonged	0
exposure	0
of	0
human	7
aortic	8
endothelial	8
cells	8
(	0
HAEC	5
)	0
to	0
low	0
shear	0
stress	0
flow	0
patterns	0
is	0
associated	0
with	0
a	0
sustained	0
increase	0
in	0
the	0
activated	0
form	0
of	0
the	0
transcriptional	0
regulator	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
.	0

Here	0
we	0
investigate	0
the	0
hypothesis	0
that	0
low	0
shear-induced	0
activation	0
of	0
NF-kappaB	9
is	0
responsible	0
for	0
enhanced	0
expression	0
of	0
vascular	9
cell	10
adhesion	10
molecule	10
(	0
VCAM-1	9
)	0
resulting	0
in	0
augmented	0
endothelial	0
cell-monocyte	0
(	0
EC-Mn	0
)	0
adhesion	0
and	0
that	0
this	0
activation	0
is	0
dependent	0
on	0
intracellular	0
oxidant	0
activity	0
.	0

Before	0
exposure	0
to	0
low	0
shear	0
(	0
2	0
dyn/cm2	0
)	0
for	0
6	0
h	0
,	0
HAEC	5
were	0
preincubated	0
with	0
or	0
without	0
the	0
antioxidants	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
or	0
N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
.	0

PDTC	0
strongly	0
inhibited	0
low	0
shear-induced	0
activation	0
of	0
NF-kappaB	9
,	0
expression	0
of	0
VCAM-1	9
,	0
and	0
EC-Mn	0
adhesion	0
.	0

Paradoxically	0
,	0
NAC	0
exerted	0
a	0
positive	0
effect	0
on	0
low	0
shear-induced	0
VCAM-1	9
expression	0
and	0
EC-Mn	0
adhesion	0
and	0
only	0
slightly	0
downregulated	0
NF-kappaB	9
activation	0
.	0

However	0
,	0
cytokine-induced	0
NF-kappaB	9
activation	0
and	0
VCAM-1	9
expression	0
are	0
blocked	0
by	0
both	0
PDTC	0
and	0
NAC	0
.	0

These	0
data	0
suggest	0
that	0
NF-kappaB	9
plays	0
a	0
key	0
role	0
in	0
low	0
shear-induced	0
VCAM-1	9
expression	0
and	0
that	0
pathways	0
mediating	0
low	0
shear-	0
and	0
cytokine-induced	0
EC-Mn	0
adhesion	0
may	0
be	0
differentially	0
regulated	0
.	0

Nuclear	9
factor-90	10
of	0
activated	7
T-cells	8
:	0
A	0
double-stranded	3
RNA	4
-binding	0
protein	0
and	0
substrate	0
for	0
the	0
double-stranded	9
RNA-dependent	10
protein	10
kinase	10
,	0
PKR	9
.	0

NFAT	0
transcription	0
factors	0
play	0
a	0
central	0
role	0
in	0
initiating	0
T-cell	0
activation	0
through	0
the	0
induction	0
of	0
immediate-early	0
T-cell	0
specific	0
genes	0
including	0
interleukin-2	0
(	0
IL-2	9
)	0
.	0

NFAT	0
transcription	0
factors	0
bind	0
to	0
a	0
sequence	0
in	0
the	0
IL-2	1
enhancer	2
known	0
as	0
the	0
antigen	1
receptor	2
response	2
element	2
2	2
(	0
ARRE-2	1
)	0
.	0

Multiple	0
proteins	0
exhibiting	0
ARRE-2	1
binding	0
activity	0
have	0
been	0
isolated	0
,	0
including	0
a	0
heterodimer	9
from	0
stimulated	0
T-cell	0
nuclear	0
extracts	0
consisting	0
of	0
Mr	0
=	0
90	0
000	0
(	0
NF90	9
)	0
and	0
Mr	0
=	0
45	0
000	0
(	0
NF45	9
)	0
subunits	0
.	0

The	0
subunits	0
of	0
this	0
heterodimer	9
have	0
been	0
cloned	0
,	0
and	0
NF90	9
was	0
found	0
to	0
encode	0
a	0
protein	0
containing	0
two	0
domains	0
that	0
are	0
predicted	0
to	0
form	0
motifs	0
capable	0
of	0
binding	0
to	0
double-stranded	3
RNA	4
.	0

Using	0
in	0
vitro	0
translated	0
polypeptides	0
,	0
we	0
have	0
demonstrated	0
that	0
NF90	9
specifically	0
binds	0
to	0
double-stranded	3
RNA	4
.	0

Furthermore	0
,	0
NF90	9
was	0
phosphorylated	0
in	0
a	0
double-stranded	3
RNA	4
-dependent	0
manner	0
likely	0
by	0
the	0
interferon-induced	0
,	0
double-stranded	9
RNA-dependent	10
protein	10
kinase	10
,	0
PKR	9
.	0

The	0
NF90	9
protein	0
was	0
found	0
to	0
be	0
expressed	0
not	0
only	0
in	0
T-cells	7
,	0
but	0
also	0
in	0
nonimmune	5
HeLa	6
cells	6
.	0

In	0
HeLa	5
cells	6
,	0
the	0
protein	0
was	0
almost	0
exclusively	0
localized	0
to	0
the	0
ribosome	0
salt	0
wash	0
fraction	0
of	0
cell	0
lysates	0
.	0

NF-kappaB	9
activation	0
is	0
required	0
for	0
C5a-induced	1
interleukin-8	2
gene	2
expression	0
in	0
mononuclear	7
cells	8
.	0

C5a	0
,	0
a	0
potent	0
peptide	0
chemoattractant	0
,	0
stimulates	0
interleukin-8	9
(	0
IL-8	9
)	0
secretion	0
from	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

Experiments	0
were	0
conducted	0
to	0
understand	0
the	0
mechanisms	0
for	0
C5a-induced	0
IL-8	9
production	0
,	0
which	0
was	0
14-fold	0
greater	0
than	0
that	0
in	0
unstimulated	7
cells	8
by	0
2	0
hours	0
.	0

IL-8	9
secretion	0
was	0
accompanied	0
by	0
accumulation	0
of	0
IL-8	3
mRNA	4
in	0
the	0
cytosol	0
and	0
by	0
nuclear	0
expression	0
of	0
a	0
kappaB	9
DNA	0
binding	0
activity	0
within	0
30	0
minutes	0
.	0

AP-1	9
but	0
not	0
NF-IL-6	9
DNA	0
binding	0
activity	0
was	0
also	0
detected	0
in	0
C5a-stimulated	5
PBMC	6
;	0
however	0
,	0
its	0
delayed	0
expression	0
(	0
maximal	0
at	0
4	0
hours	0
)	0
suggested	0
a	0
less	0
important	0
role	0
in	0
the	0
rapid	0
production	0
of	0
IL-8	9
.	0

The	0
correlation	0
between	0
C5a-induced	0
kappaB	9
binding	0
activity	0
and	0
IL-8	9
gene	0
expression	0
was	0
examined	0
in	0
the	0
RAW264.7	5
macrophage	6
cells	6
using	0
reporter	0
genes	0
directed	0
by	0
the	0
kappaB	1
sequence	2
from	0
IkappaBalpha	9
and	0
IL-8	1
promoter	2
regions	2
.	0

C5a-induced	0
reporter	1
gene	2
expression	0
was	0
abolished	0
by	0
introducing	0
mutations	0
into	0
the	0
kappaB	1
sites	2
and	0
by	0
coexpression	0
of	0
a	0
dominant	1
negative	2
IkappaBalpha	2
construct	2
resistant	0
to	0
agonist-induced	0
phosphorylation	0
.	0

Pertussis	0
toxin	0
,	0
which	0
ADP-ribosylates	0
the	0
Gi	9
proteins	10
known	0
to	0
couple	0
to	0
the	0
C5a	9
receptor	10
,	0
produced	0
minimal	0
inhibition	0
of	0
C5a-induced	0
IL-8	9
expression	0
and	0
had	0
little	0
effect	0
on	0
C5a-induced	0
calcium	0
mobilization	0
in	0
RAW264.7	5
cells	6
.	0

These	0
results	0
suggest	0
that	0
NF-kappaB	9
activation	0
is	0
required	0
for	0
C5a-induced	0
IL-8	9
gene	0
expression	0
and	0
that	0
this	0
response	0
is	0
mediated	0
primarily	0
through	0
a	0
pertussis	0
toxin-insensitive	0
pathway	0
.	0

Increased	0
glucocorticoid	9
receptor	10
beta	10
in	0
airway	7
cells	8
of	0
glucocorticoid-insensitive	0
asthma	0
.	0

Glucocorticoid	0
(	0
GC	0
)	0
-insensitive	0
asthma	0
is	0
a	0
challenging	0
clinical	0
problem	0
that	0
can	0
be	0
associated	0
with	0
life-threatening	0
disease	0
progression	0
.	0

The	0
molecular	0
basis	0
of	0
GC	0
insensitivity	0
is	0
unknown	0
.	0

Alternative	0
splicing	0
of	0
the	0
GC	3
receptor	4
(	4
GCR	4
)	4
pre-mRNA	4
generates	0
a	0
second	0
GCR	9
,	0
termed	0
GCRbeta	9
,	0
which	0
does	0
not	0
bind	0
GC	0
but	0
antagonizes	0
the	0
transactivating	0
activity	0
of	0
the	0
classic	0
GCR	9
.	0

Thus	0
increased	0
expression	0
of	0
GCRbeta	9
could	0
account	0
for	0
glucocorticoid	0
insensitivity	0
.	0

Bronchoalveolar	7
lavage	8
(	8
BAL	8
)	8
cells	8
and	0
peripheral	0
blood	0
mononuclear	7
cells	8
(	0
PBMC	7
)	0
were	0
examined	0
for	0
GCRbeta	9
immunoreactivity	0
using	0
a	0
GCRbeta-specific	9
antibody	10
by	0
immunohistochemical	0
staining	0
.	0

Cell	0
localization	0
of	0
GCRbeta	9
expression	0
was	0
performed	0
using	0
a	0
double	0
immunostaining	0
technique	0
.	0

Patients	0
with	0
GC-insensitive	0
asthma	0
expressed	0
a	0
significantly	0
higher	0
number	0
of	0
GCRbeta-immunoreactive	7
cells	8
in	0
their	0
BAL	0
and	0
peripheral	0
blood	0
than	0
GC-sensitive	0
asthmatics	0
or	0
normal	0
control	0
subjects	0
.	0

Furthermore	0
,	0
GCRbeta	9
expression	0
in	0
GC-insensitive	0
asthma	0
was	0
particularly	0
high	0
in	0
airway	0
T	7
cells	8
,	0
which	0
are	0
thought	0
to	0
play	0
a	0
major	0
role	0
in	0
the	0
pathogenesis	0
of	0
asthma	0
.	0

We	0
also	0
examined	0
the	0
expression	0
of	0
GCRbeta	9
in	0
specimens	0
from	0
the	0
airways	0
of	0
patients	0
with	0
chronic	0
bronchitis	0
.	0

In	0
chronic	0
bronchitis	0
,	0
few	0
cells	0
were	0
GCRbeta-positive	7
and	0
their	0
numbers	0
did	0
not	0
differ	0
significantly	0
from	0
normal	0
control	0
subjects	0
.	0

We	0
conclude	0
that	0
GC-insensitive	0
asthma	0
is	0
associated	0
with	0
increased	0
expression	0
of	0
GCRbeta	9
in	0
airway	0
T	7
cells	8
.	0

Activation	0
of	0
the	0
Janus	9
kinase	10
3	10
-STAT5a	9
pathway	0
after	0
CD40	9
triggering	0
of	0
human	7
monocytes	8
but	0
not	0
of	0
resting	7
B	8
cells	8
.	0

CD40	9
/CD40	9
ligand	0
interactions	0
play	0
a	0
key	0
role	0
in	0
the	0
immune	0
responses	0
of	0
B	7
lymphocytes	8
,	0
monocytes	7
,	0
and	0
dendritic	7
cells	8
.	0

The	0
signal	0
transduction	0
events	0
triggered	0
by	0
cross-linking	0
of	0
the	0
CD40	9
receptor	10
have	0
been	0
widely	0
studied	0
in	0
B	5
cell	6
lines	6
,	0
but	0
little	0
is	0
known	0
about	0
signaling	0
following	0
CD40	9
stimulation	0
of	0
monocytes	7
and	0
resting	5
tonsillar	6
B	6
cells	6
.	0

Therefore	0
,	0
we	0
studied	0
the	0
CD40	9
pathway	0
in	0
highly	0
purified	0
human	7
monocytes	8
and	0
resting	7
B	8
cells	8
.	0

After	0
CD40	9
triggering	0
,	0
a	0
similar	0
activation	0
of	0
the	0
NF-kappaB	9
(	0
but	0
not	0
of	0
the	0
AP-1	9
)	0
transcription	9
factor	10
complex	10
occurred	0
in	0
both	0
cell	0
preparations	0
.	0

However	0
,	0
the	0
components	0
of	0
the	0
NF-kappaB	9
complexes	10
were	0
different	0
in	0
monocytes	7
and	0
B	0
cells	0
,	0
because	0
p50	9
is	0
part	0
of	0
the	0
NF-kappaB	9
complex	10
induced	0
by	0
CD40	9
triggering	0
in	0
both	0
monocytes	7
and	0
B	7
cells	8
,	0
whereas	0
p65	9
was	0
only	0
induced	0
in	0
B	7
cells	8
.	0
In	0
contrast	0
,	0
although	0
the	0
Janus	9
kinase	10
3	10
tyrosine	10
kinase	10
was	0
associated	0
with	0
CD40	9
molecules	0
in	0
both	0
monocytes	7
and	0
resting	7
B	8
cells	8
,	0
Janus	9
kinase	10
3	10
phosphorylation	0
induction	0
was	0
observed	0
only	0
in	0
CD40-activated	5
monocytes	6
,	0
with	0
subsequent	0
induction	0
of	0
STAT5a	9
DNA	0
binding	0
activity	0
in	0
the	0
nucleus	0
.	0

These	0
results	0
suggest	0
that	0
the	0
activation	0
signals	0
in	0
human	7
B	8
cells	8
and	0
monocytes	7
differ	0
following	0
CD40	9
stimulation	0
.	0

This	0
observation	0
is	0
consistent	0
with	0
the	0
detection	0
of	0
normal	0
CD40	9
-induced	0
monocyte	0
activation	0
in	0
patients	0
with	0
CD40	9
ligand+	0
hyper	0
IgM	9
syndrome	0
in	0
whom	0
a	0
defect	0
in	0
CD40	9
-induced	0
B	0
cell	0
activation	0
has	0
been	0
reported	0
.	0

Genetic	0
evidence	0
for	0
an	0
additional	0
factor	0
required	0
for	0
erythropoietin	9
-induced	0
signal	0
transduction	0
.	0

Erythropoietin	9
(	0
EPO	9
)	0
and	0
its	0
receptor	0
(	0
EPOR	9
)	0
are	0
required	0
for	0
the	0
development	0
of	0
mature	0
erythrocytes	0
.	0

After	0
binding	0
of	0
ligand	0
,	0
the	0
EPOR	9
activates	0
a	0
variety	0
of	0
signaling	0
pathways	0
that	0
ultimately	0
control	0
cellular	0
proliferation	0
,	0
survival	0
,	0
and	0
specific	0
gene	0
expression	0
.	0

Although	0
erythroid	7
progenitors	8
appear	0
to	0
be	0
the	0
principal	0
EPO-responsive	7
cell	8
type	8
in	0
vivo	0
due	0
to	0
the	0
restricted	0
expression	0
of	0
the	0
EPOR	9
,	0
many	0
growth	5
factor-dependent	6
cell	6
lines	6
expressing	0
the	0
EPOR	9
can	0
respond	0
to	0
EPO	9
by	0
activating	0
many	0
or	0
all	0
of	0
these	0
pathways	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
have	0
identified	0
a	0
cellular	0
context	0
(	0
the	0
interleukin-2	5
[	6
IL-2	6
]	6
-dependent	6
HT-2	6
line	6
)	0
in	0
which	0
the	0
EPO	9
stimulation	0
of	0
the	0
EPOR	9
fails	0
to	0
support	0
cellular	0
proliferation	0
,	0
STAT-5	9
induction	0
,	0
or	0
MAPK	9
activation	0
,	0
despite	0
efficient	0
phosphorylation	0
of	0
the	0
EPOR	9
and	0
JAK2	9
and	0
inhibition	0
of	0
apoptosis	0
after	0
withdrawal	0
of	0
IL-2	9
.	0

Interestingly	0
,	0
when	0
we	0
fused	0
HT-2	5
cells	6
expressing	0
the	0
EPOR	9
with	0
Ba/F3	5
cells	6
in	0
a	0
complementation	0
assay	0
,	0
the	0
resulting	0
hybridomas	5
proliferated	0
and	0
potently	0
activated	0
STAT-5	9
and	0
MAPK	9
in	0
response	0
to	0
EPO	9
.	0

These	0
data	0
indicate	0
that	0
an	0
unidentified	9
cellular	10
factor	10
is	0
needed	0
to	0
mediate	0
signaling	0
by	0
the	0
EPOR	9
.	0

Moreover	0
,	0
Ba/F3	5
cells	6
apparently	0
express	0
this	0
factor	0
(	0
s	0
)	0
and	0
somatic	0
fusions	0
can	0
,	0
therefore	0
,	0
confer	0
EPO	9
-responsiveness	0
to	0
HT-2	5
cells	6
that	0
lack	0
this	0
factor	0
.	0

Novel	0
therapies	0
for	0
inflammatory	0
bowel	0
disease	0
.	0

Looking	0
back	0
at	0
successes	0
and	0
failures	0
in	0
newer	0
approaches	0
to	0
treating	0
IBD	0
,	0
it	0
is	0
tempting	0
--	0
although	0
still	0
difficult	0
--	0
to	0
draw	0
conclusions	0
about	0
pathogenesis	0
.	0

When	0
a	0
therapy	0
proves	0
effective	0
,	0
do	0
clinicians	0
truly	0
know	0
how	0
it	0
works	0
?	0
Even	0
with	0
a	0
therapy	0
as	0
specific	0
as	0
anti-TNF	9
antibody	10
,	0
it	0
is	0
not	0
clear	0
if	0
the	0
benefit	0
is	0
attributable	0
to	0
simple	0
binding	0
and	0
clearance	0
of	0
TNF-alpha	9
or	0
to	0
binding	0
on	0
the	0
cell	0
surface	0
and	0
subsequent	0
deletion	0
of	0
the	0
activated	7
macrophage	8
.	0

When	0
a	0
drug	0
appears	0
to	0
be	0
less	0
effective	0
than	0
preclinical	0
models	0
suggest	0
,	0
can	0
failures	0
in	0
effectiveness	0
from	0
delivery	0
or	0
dosing	0
be	0
differentiated	0
?	0
The	0
disappointing	0
results	0
of	0
clinical	0
trials	0
with	0
IL-10	9
--	0
so	0
at	0
odds	0
with	0
the	0
prediction	0
of	0
benefit	0
from	0
animal	0
models	0
--	0
bring	0
into	0
question	0
the	0
validity	0
of	0
those	0
models	0
as	0
well	0
as	0
the	0
soundness	0
of	0
design	0
of	0
the	0
clinical	0
trials	0
on	0
which	0
efficacy	0
of	0
IL-10	9
is	0
judged	0
.	0

The	0
variability	0
of	0
response	0
even	0
to	0
the	0
most	0
narrowly	0
targeted	0
agents	0
suggests	0
that	0
these	0
diseases	0
are	0
far	0
more	0
heterogeneous	0
in	0
humans	0
than	0
in	0
their	0
murine	0
counterparts	0
.	0

Clinicians	0
are	0
only	0
just	0
beginning	0
to	0
recognize	0
subclinical	0
markers	0
of	0
response	0
,	0
and	0
it	0
may	0
soon	0
be	0
possible	0
to	0
predict	0
response	0
on	0
the	0
basis	0
of	0
genetic	0
composition	0
.	0

For	0
the	0
moment	0
,	0
however	0
,	0
the	0
field	0
of	0
pharmacogenetics	0
is	0
embryonic	0
.	0

Challenges	0
in	0
developing	0
new	0
therapeutic	0
strategies	0
include	0
not	0
only	0
identifying	0
novel	0
agents	0
,	0
but	0
also	0
improving	0
the	0
definitions	0
of	0
clinical	0
endpoints	0
and	0
defining	0
efficacy	0
at	0
the	0
biologic	0
level	0
.	0

Only	0
through	0
considered	0
evaluation	0
of	0
clinical	0
evidence	0
may	0
clinicians	0
determine	0
which	0
therapies	0
should	0
remain	0
novelties	0
and	0
which	0
should	0
become	0
an	0
accepted	0
part	0
of	0
the	0
armamentarium	0
.	0

Potent	0
and	0
stable	0
attenuation	0
of	0
live-HIV-1	0
by	0
gain	0
of	0
a	0
proteolysis-resistant	9
inhibitor	10
of	0
NF-kappaB	9
(	0
IkappaB-alphaS32/36A	9
)	0
and	0
the	0
implications	0
for	0
vaccine	0
development	0
.	0

Live-attenuated	0
human	0
immunodeficiency	0
viruses	0
(	0
HIVs	0
)	0
are	0
candidates	0
for	0
Acquired	0
Immunodeficiency	0
Syndrome	0
(	0
AIDS	0
)	0
vaccine	0
.	0

Based	0
on	0
the	0
simian	0
immunodeficiency	0
virus	0
(	0
SIV	0
)	0
model	0
for	0
AIDS	0
,	0
loss-of-function	0
(	0
e.g.	0
deletion	0
of	0
accessory	0
genes	0
such	0
as	0
nef	1
)	0
has	0
been	0
forwarded	0
as	0
a	0
primary	0
approach	0
for	0
creating	0
enfeebled	0
,	0
but	0
replication-competent	0
,	0
HIV-1/SIV	0
.	0

Regrettably	0
,	0
recent	0
evidence	0
suggests	0
that	0
loss-of-function	0
alone	0
is	0
not	0
always	0
sufficient	0
to	0
prevent	0
the	0
emergence	0
of	0
virulent	0
mutants	0
.	0

New	0
strategies	0
that	0
attenuate	0
via	0
mechanisms	0
distinct	0
from	0
loss-of-function	0
are	0
needed	0
for	0
enhancing	0
the	0
safety	0
phenotype	0
of	0
viral	1
genome	2
.	0

Here	0
,	0
we	0
propose	0
gain-of-function	0
to	0
be	0
used	0
simultaneously	0
with	0
loss-of-function	0
as	0
a	0
novel	0
approach	0
for	0
attenuating	0
HIV-1	0
.	0

We	0
have	0
constructed	0
an	0
HIV-1	1
genome	2
carrying	0
the	0
cDNA	1
of	0
a	0
proteolysis-resistant	9
nuclear	10
factor-kappaB	10
inhibitor	10
(	0
IkappaB-alphaS32/36A	9
)	0
in	0
the	0
nef	1
region	2
.	0

HIV-1	0
expressing	0
IkappaB-alphaS32/36A	9
down-regulates	0
viral	0
expression	0
and	0
is	0
highly	0
attenuated	0
in	0
both	0
Jurkat	5
and	0
peripheral	7
blood	8
mononuclear	8
cells	8
.	0

We	0
provide	0
formal	0
proof	0
that	0
the	0
phenotypic	0
and	0
attenuating	0
characteristics	0
of	0
IkappaB-alphaS32/36A	9
permit	0
its	0
stable	0
maintenance	0
in	0
a	0
live	0
,	0
replicating	0
HIV-1	0
despite	0
180	0
days	0
of	0
forced	0
ex	0
vivo	0
passaging	0
in	0
tissue	0
culture	0
.	0

As	0
compared	0
with	0
other	0
open-reading	1
frames	2
embedded	0
into	0
HIV/SIV	1
genome	2
,	0
this	0
degree	0
of	0
stability	0
is	0
unprecedented	0
.	0

Thus	0
,	0
IkappaB-alphaS32/36A	9
offers	0
proof-of-principle	0
that	0
artifactually	0
gained	0
functions	0
,	0
when	0
used	0
to	0
attenuate	0
the	0
replication	0
of	0
live	0
HIV-1	0
,	0
can	0
be	0
stable	0
.	0

These	0
findings	0
illustrate	0
gain-of-function	0
as	0
a	0
feasible	0
strategy	0
for	0
developing	0
safer	0
live-attenuated	0
HIVs	0
to	0
be	0
tested	0
as	0
candidates	0
for	0
AIDS	0
vaccine	0
.	0

Multiple	0
NF-ATc	9
isoforms	10
with	0
individual	0
transcriptional	0
properties	0
are	0
synthesized	0
in	0
T	7
lymphocytes	8
.	0

The	0
transcription	9
factor	10
NF-ATc	9
that	0
controls	0
gene	0
expression	0
in	0
T	7
lymphocytes	8
and	0
embryonic	7
cardiac	8
cells	8
is	0
expressed	0
in	0
three	0
prominent	0
isoforms	0
.	0

This	0
is	0
due	0
to	0
alternative	0
splice/polyadenylation	0
events	0
that	0
lead	0
to	0
the	0
predominant	0
synthesis	0
of	0
two	0
long	0
isoforms	0
in	0
naive	7
T	8
cells	8
and	0
a	0
shorter	0
NF-ATc	9
isoform	10
in	0
effector	7
T	8
cells	8
.	0

Whereas	0
the	0
previously	0
described	0
isoform	9
NF-ATc/A	10
contains	0
a	0
relatively	0
short	0
C	9
terminus	10
,	0
the	0
longer	0
isoforms	0
,	0
B	9
and	0
C	9
,	0
span	0
extra	0
C-terminal	0
peptides	0
of	0
128	0
and	0
246	0
aa	0
,	0
respectively	0
.	0

We	0
show	0
here	0
that	0
in	0
addition	0
to	0
the	0
strong	9
N-terminal	10
trans-activation	10
domain	10
,	0
TAD-A	9
,	0
which	0
is	0
common	0
to	0
all	0
three	0
NF-ATc	9
isoforms	10
,	0
NF-ATc/C	9
contains	0
a	0
second	0
trans-activation	9
domain	10
,	0
TAD-B	9
,	0
in	0
its	0
C-terminal	0
peptide	0
.	0

Various	0
stimuli	0
of	0
T	7
cells	8
that	0
induce	0
the	0
activity	0
of	0
TAD-A	9
also	0
enhance	0
the	0
activity	0
of	0
TAD-B	9
,	0
but	0
,	0
unlike	0
TAD-A	9
,	0
TAD-B	9
remains	0
unphosphorylated	0
by	0
protein	0
from	0
12-O-tetradecanoyl	5
12-phorbol	6
13-acetate-stimulated	6
T	6
cells	6
.	0

The	0
shorter	0
C-terminal	0
peptide	0
of	0
isoform	0
NF-ATc/B	9
exerts	0
a	0
suppressive	0
transcriptional	0
effect	0
.	0

These	0
properties	0
of	0
NF-ATc/B	9
and	10
-C	10
might	0
be	0
of	0
importance	0
for	0
gene	0
regulation	0
in	0
naive	7
T	8
lymphocytes	8
in	0
which	0
NF-ATc/B	9
and	10
-C	10
are	0
predominantly	0
synthesized	0
.	0

Selection	0
and	0
long-term	0
persistence	0
of	0
reactive	0
CTL	5
clones	6
during	0
an	0
EBV	0
chronic	0
response	0
are	0
determined	0
by	0
avidity	0
,	0
CD8	9
variable	0
contribution	0
compensating	0
for	0
differences	0
in	0
TCR	9
affinities	0
.	0

Recent	0
studies	0
have	0
suggested	0
that	0
the	0
diversity	0
of	0
TCR	9
repertoire	0
after	0
primary	0
immunization	0
is	0
conserved	0
in	0
memory	7
T	8
cells	8
and	0
that	0
a	0
progressive	0
narrowing	0
of	0
this	0
repertoire	0
may	0
take	0
place	0
during	0
recall	0
infections	0
.	0

It	0
now	0
remains	0
to	0
be	0
investigated	0
which	0
parameters	0
determine	0
the	0
repertoire	0
of	0
the	0
memory	0
response	0
and	0
possibly	0
restrict	0
its	0
diversity	0
after	0
subsequent	0
antigenic	0
challenges	0
.	0

To	0
address	0
this	0
question	0
,	0
we	0
took	0
advantage	0
of	0
a	0
panel	0
of	0
CD8+	5
T	6
cell	6
clones	6
from	0
the	0
joint	0
of	0
a	0
rheumatoid	0
arthritis	0
patient	0
and	0
selected	0
for	0
their	0
reactivity	0
against	0
a	0
single	9
MHC/peptide	10
complex	10
.	0

Characterization	0
of	0
both	0
TCR	9
chains	10
documented	0
a	0
great	0
diversity	0
among	0
those	0
clones	0
and	0
the	0
persistence	0
of	0
clonotypes	0
over	0
a	0
2-yr	0
period	0
.	0

Strikingly	0
,	0
despite	0
the	0
observed	0
repertoire	0
heterogeneity	0
,	0
all	0
clones	0
displayed	0
a	0
narrow	0
range	0
of	0
MHC	9
/peptide	0
density	0
requirements	0
in	0
cytotoxicity	0
assays	0
(	0
ED50	0
between	0
9	0
and	0
36	0
nM	0
)	0
.	0

TCR	9
affinities	0
were	0
then	0
indirectly	0
estimated	0
by	0
blocking	0
CD8	9
interaction	0
with	0
an	0
anti-CD8	9
mAb	10
.	0

We	0
found	0
a	0
wide	0
range	0
of	0
TCR	9
affinities	0
among	0
the	0
different	0
clonotypes	0
that	0
segregated	0
with	0
Vbeta	0
usage	0
.	0

We	0
thus	0
propose	0
that	0
during	0
an	0
in	0
vivo	0
chronic	0
response	0
,	0
a	0
narrow	0
range	0
of	0
avidity	0
of	0
the	0
TCR-CD8	9
complex	10
conditions	0
long-term	0
clonotype	0
persistence	0
,	0
and	0
that	0
the	0
level	0
of	0
CD8	9
contribution	0
is	0
adjusted	0
to	0
keep	0
clonotypes	0
with	0
variable	0
TCR	9
affinities	0
within	0
this	0
avidity	0
window	0
.	0

Nuclear	0
localization	0
and	0
formation	0
of	0
beta-catenin-lymphoid	9
enhancer	10
factor	10
1	10
complexes	10
are	0
not	0
sufficient	0
for	0
activation	0
of	0
gene	0
expression	0
.	0

In	0
response	0
to	0
activation	0
of	0
the	0
Wnt	0
signaling	0
pathway	0
,	0
beta-catenin	9
accumulates	0
in	0
the	0
nucleus	0
,	0
where	0
it	0
cooperates	0
with	0
LEF/TCF	9
(	0
for	0
lymphoid	9
enhancer	10
factor	10
and	10
T-cell	10
factor	10
)	0
transcription	9
factors	10
to	0
activate	0
gene	0
expression	0
.	0

The	0
mechanisms	0
by	0
which	0
beta-catenin	9
undergoes	0
this	0
shift	0
in	0
location	0
and	0
participates	0
in	0
activation	0
of	0
gene	0
transcription	0
are	0
unknown	0
.	0

We	0
demonstrate	0
here	0
that	0
beta-catenin	9
can	0
be	0
imported	0
into	0
the	0
nucleus	0
independently	0
of	0
LEF/TCF	9
binding	0
,	0
and	0
it	0
may	0
also	0
be	0
exported	0
from	0
nuclei	0
.	0

We	0
have	0
introduced	0
a	0
small	0
deletion	0
within	0
beta-catenin	9
(	0
Delta19	1
)	0
that	0
disrupts	0
binding	0
to	0
LEF-1	9
,	0
E-cadherin	9
,	0
and	0
APC	9
but	0
not	0
axin	9
.	0

This	0
Delta19	9
beta-catenin	10
mutant	10
localizes	0
to	0
the	0
nucleus	0
because	0
it	0
may	0
not	0
be	0
efficiently	0
sequestered	0
in	0
the	0
cytoplasm	0
.	0

The	0
nuclear	0
localization	0
of	0
Delta19	1
definitively	0
demonstrates	0
that	0
the	0
mechanisms	0
by	0
which	0
beta-catenin	9
localizes	0
in	0
the	0
nucleus	0
are	0
completely	0
independent	0
of	0
LEF/TCF	9
factors	10
.	0

beta-Catenin	9
and	0
LEF-1	9
complexes	10
can	0
activate	0
reporter	0
gene	0
expression	0
in	0
a	0
transformed	5
T-lymphocyte	6
cell	6
line	6
(	0
Jurkat	5
)	0
but	0
not	0
in	0
normal	7
T	8
lymphocytes	8
,	0
even	0
though	0
both	0
factors	0
are	0
nuclear	0
.	0

Thus	0
,	0
localization	0
of	0
both	0
factors	0
to	0
the	0
nucleus	0
is	0
not	0
sufficient	0
for	0
activation	0
of	0
gene	0
expression	0
.	0

Excess	0
beta-catenin	9
can	0
squelch	0
reporter	0
gene	0
activation	0
by	0
LEF-1-beta-catenin	9
complexes	10
but	0
not	0
activation	0
by	0
the	0
transcription	9
factor	10
VP16	9
.	0

Taken	0
together	0
,	0
these	0
data	0
suggest	0
that	0
a	0
third	0
component	0
is	0
necessary	0
for	0
gene	0
activation	0
and	0
that	0
this	0
third	0
component	0
may	0
vary	0
with	0
cell	0
type	0
.	0

Control	0
of	0
lymphocyte	0
development	0
by	0
the	0
Ikaros	1
gene	2
family	2
.	0

Lymphoid	0
cell	0
differentiation	0
relies	0
on	0
precisely	0
orchestrated	0
gene	0
activation	0
and	0
repression	0
events	0
.	0

Gene	0
targeting	0
studies	0
have	0
demonstrated	0
crucial	0
roles	0
for	0
the	0
transcription	9
factors	10
Ikaros	9
and	0
Aiolos	9
in	0
regulating	0
multiple	0
stages	0
of	0
B	0
and	0
T	0
cell	0
development	0
.	0

Recent	0
experiments	0
suggest	0
that	0
Ikaros	9
and	0
Aiolos	9
set	0
B	0
cell	0
antigen-receptor	0
(	0
BCR	0
)	0
-	0
and	0
TCR-mediated	0
signaling	0
thresholds	0
and	0
that	0
the	0
molecules	0
exist	0
within	0
T	7
cells	8
in	0
nuclear	9
complexes	10
that	0
contain	0
nucleosome	0
remodeling	0
and	0
histone	9
deacetylase	10
activities	0
.	0

Transcriptional	0
targeting	0
of	0
retroviral	0
vectors	0
to	0
the	0
erythroblastic	7
progeny	8
of	0
transduced	5
hematopoietic	6
stem	6
cells	6
.	0

Targeted	0
expression	0
to	0
specific	0
tissues	0
or	0
cell	0
lineages	0
is	0
a	0
necessary	0
feature	0
of	0
a	0
gene	0
therapy	0
vector	0
for	0
many	0
clinical	0
applications	0
,	0
such	0
as	0
correction	0
of	0
hemoglobinopathies	0
or	0
thalassemias	0
by	0
transplantation	0
of	0
genetically	7
modified	8
hematopoietic	8
stem	8
cells	8
.	0

We	0
developed	0
retroviral	0
vectors	0
in	0
which	0
the	0
constitutive	1
viral	2
enhancer	2
in	0
the	0
U3	1
region	2
of	0
the	0
3	1
'	2
LTR	2
is	0
replaced	0
by	0
an	0
autoregulatory	1
enhancer	2
of	0
the	0
erythroid-specific	1
GATA-1	2
transcription	2
factor	2
gene	2
.	0

The	0
replaced	1
enhancer	2
is	0
propagated	0
to	0
the	0
5	1
'	2
LTR	2
upon	0
integration	0
into	0
the	0
target	1
cell	2
genome	2
.	0

The	0
modified	0
vectors	0
were	0
used	0
to	0
transduce	0
human	5
hematopoietic	6
cell	6
lines	6
,	0
cord	7
blood-derived	8
CD34	8
(	8
+	8
)	8
stem/progenitor	8
cells	8
,	0
and	0
murine	5
bone	6
marrow	6
repopulating	6
stem	6
cells	6
.	0

The	0
expression	0
of	0
appropriate	0
reporter	1
genes	2
(	0
triangle	1
upLNGFR	2
,	0
EGFP	1
)	0
was	0
analyzed	0
in	0
the	0
differentiated	0
progeny	0
of	0
transduced	5
stem	6
cells	6
in	0
vitro	0
,	0
in	0
liquid	0
culture	0
as	0
well	0
as	0
in	0
clonogenic	0
assay	0
,	0
and	0
in	0
vivo	0
,	0
after	0
bone	0
marrow	0
transplantation	0
in	0
lethally	0
irradiated	0
mice	0
.	0

The	0
GATA-1	1
autoregulatory	2
enhancer	2
effectively	0
restricts	0
the	0
expression	0
of	0
the	0
LTR-driven	1
proviral	2
transcription	2
unit	2
to	0
the	0
erythroblastic	7
progeny	8
of	0
both	0
human	7
progenitors	8
and	0
mouse-repopulating	5
stem	6
cells	6
.	0

Packaging	0
of	0
viral	0
particles	0
,	0
integration	0
into	0
the	0
target	0
genome	0
,	0
and	0
stability	0
of	0
the	0
integrated	0
provirus	0
are	0
not	0
affected	0
by	0
the	0
LTR	1
modification	0
.	0

Enhancer	0
replacement	0
is	0
therefore	0
an	0
effective	0
strategy	0
to	0
target	0
expression	0
of	0
a	0
retroviral	1
transgene	2
to	0
a	0
specific	0
progeny	0
of	0
transduced	5
hematopoietic	6
stem	6
cells	6
.	0

Regulation	0
of	0
Fas	9
ligand	10
expression	0
and	0
cell	0
death	0
by	0
apoptosis-linked	1
gene	2
4	2
.	0

Programmed	0
cell	0
death	0
is	0
a	0
process	0
required	0
for	0
the	0
normal	0
development	0
of	0
an	0
organism	0
.	0

One	0
of	0
the	0
best	0
understood	0
apoptotic	0
pathways	0
occurs	0
in	0
T	7
lymphocytes	8
and	0
is	0
mediated	0
by	0
Fas	9
/Fas	9
ligand	10
(	0
FasL	9
)	0
interaction	0
.	0

During	0
studies	0
of	0
apoptosis	0
induced	0
by	0
T	0
cell-receptor	0
engagement	0
,	0
we	0
identified	0
ALG-4F	9
,	0
a	0
truncated	9
transcript	10
that	0
prevents	0
T	0
cell-receptor-induced	0
FasL	9
upregulation	0
and	0
cell	0
death	0
.	0

Overexpression	0
of	0
full-length	9
ALG-4	10
induced	0
transcription	0
of	0
FasL	9
and	0
,	0
consequently	0
,	0
apoptosis	0
.	0

These	0
results	0
indicate	0
that	0
ALG-4	9
is	0
necessary	0
and	0
sufficient	0
for	0
FasL	9
expression	0
.	0

Fas/	0
FasL	9
interaction	0
initiates	0
cell	0
death	0
in	0
many	0
other	0
systems	0
,	0
and	0
its	0
dysregulation	0
is	0
a	0
mechanism	0
by	0
which	0
several	0
pathologic	0
conditions	0
arise	0
.	0

Understanding	0
the	0
molecular	0
mechanisms	0
of	0
FasL	9
regulation	0
could	0
be	0
very	0
useful	0
in	0
elucidating	0
how	0
these	0
diseases	0
develop	0
and	0
in	0
identifying	0
potential	0
therapeutic	0
targets	0
.	0

The	0
Epstein-Barr	9
virus	10
oncoprotein	10
latent	10
membrane	10
protein	10
1	10
engages	0
the	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
proteins	10
TRADD	9
and	0
receptor-interacting	9
protein	10
(	0
RIP	9
)	0
but	0
does	0
not	0
induce	0
apoptosis	0
or	0
require	0
RIP	9
for	0
NF-kappaB	9
activation	0
.	0

A	0
site	0
in	0
the	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
transforming	10
protein	10
LMP1	9
that	0
constitutively	0
associates	0
with	0
the	0
tumor	9
necrosis	10
factor	10
receptor	10
1	10
(	10
TNFR1	10
)	10
-associated	10
death	10
domain	10
protein	10
TRADD	9
to	0
mediate	0
NF-kappaB	9
and	0
c-Jun	9
N-terminal	10
kinase	10
activation	0
is	0
critical	0
for	0
long-term	0
lymphoblastoid	0
cell	0
proliferation	0
.	0

We	0
now	0
find	0
that	0
LMP1	9
signaling	0
through	0
TRADD	9
differs	0
from	0
TNFR1	9
signaling	0
through	0
TRADD	9
.	0

LMP1	9
needs	0
only	0
11	0
amino	0
acids	0
to	0
activate	0
NF-kappaB	9
or	0
synergize	0
with	0
TRADD	9
in	0
NF-kappaB	9
activation	0
,	0
while	0
TNFR1	9
requires	0
approximately	0
70	0
residues	0
.	0

Further	0
,	0
LMP1	9
does	0
not	0
require	0
TRADD	9
residues	0
294	0
to	0
312	0
for	0
NF-kappaB	9
activation	0
,	0
while	0
TNFR1	9
requires	0
TRADD	9
residues	0
296	0
to	0
302	0
.	0

LMP1	9
is	0
partially	0
blocked	0
for	0
NF-kappaB	9
activation	0
by	0
a	0
TRADD	9
mutant	0
consisting	0
of	0
residues	9
122	10
to	10
293	10
.	0

Unlike	0
TNFR1	9
,	0
LMP1	9
can	0
interact	0
directly	0
with	0
receptor-interacting	9
protein	10
(	0
RIP	9
)	0
and	0
stably	0
associates	0
with	0
RIP	9
in	0
EBV-transformed	5
lymphoblastoid	6
cell	6
lines	6
.	0

Surprisingly	0
,	0
LMP1	9
does	0
not	0
require	0
RIP	9
for	0
NF-kappaB	9
activation	0
.	0

Despite	0
constitutive	0
association	0
with	0
TRADD	9
or	0
RIP	9
,	0
LMP1	9
does	0
not	0
induce	0
apoptosis	0
in	0
EBV-negative	5
Burkitt	6
lymphoma	6
or	6
human	6
embryonic	6
kidney	6
293	6
cells	6
.	0

These	0
results	0
add	0
a	0
different	0
perspective	0
to	0
the	0
molecular	0
interactions	0
through	0
which	0
LMP1	9
,	0
TRADD	9
,	0
and	0
RIP	9
participate	0
in	0
B-lymphocyte	0
activation	0
and	0
growth	0
.	0

Inhibition	0
of	0
NF-kappa	9
B	10
activity	0
in	0
human	0
T	0
lymphocytes	0
induces	0
caspase-dependent	0
apoptosis	0
without	0
detectable	0
activation	0
of	0
caspase-1	9
and	10
-3	10
.	0

NF-kappa	9
B	10
is	0
involved	0
in	0
the	0
transcriptional	0
control	0
of	0
various	1
genes	2
that	0
act	0
as	0
extrinsic	0
and	0
intrinsic	0
survival	0
factors	0
for	0
T	7
cells	8
.	0

Our	0
findings	0
show	0
that	0
suppression	0
of	0
NF-kappa	9
B	10
activity	0
with	0
cell-permeable	0
SN50	0
peptide	0
,	0
which	0
masks	0
the	0
nuclear	0
localization	0
sequence	0
of	0
NF-kappa	9
B1	10
dimers	10
and	0
prevents	0
their	0
nuclear	0
localization	0
,	0
induces	0
apoptosis	0
in	0
resting	7
normal	8
human	8
PBL	8
.	0

Inhibition	0
of	0
NF-kappa	9
B	10
resulted	0
in	0
the	0
externalization	0
of	0
phosphatidylserine	0
,	0
induction	0
of	0
DNA	0
breaks	0
,	0
and	0
morphological	0
changes	0
consistent	0
with	0
apoptosis	0
.	0

DNA	0
fragmentation	0
was	0
efficiently	0
blocked	0
by	0
the	0
caspase	9
inhibitor	10
Z-VAD-fmk	9
and	0
partially	0
blocked	0
by	0
Ac-DEVD-fmk	9
,	0
suggesting	0
that	0
SN50-mediated	0
apoptosis	0
is	0
caspase	9
-dependent	0
.	0

Interestingly	0
,	0
apoptosis	0
induced	0
by	0
NF-kappa	9
B	10
suppression	0
,	0
in	0
contrast	0
to	0
that	0
induced	0
by	0
TPEN	0
(	0
N	0
,	0
N	0
,	0
N	0
'	0
,	0
N'-tetrakis	0
[	0
2-pyridylmethyl	0
]	0
ethylenediamine	0
)	0
or	0
soluble	9
Fas	10
ligand	10
(	0
CD95	9
)	0
,	0
was	0
observed	0
in	0
the	0
absence	0
of	0
active	9
death	10
effector	10
proteases	10
caspase-1	9
-like	0
(	0
IL-1	9
converting	10
enzyme	10
)	0
,	0
caspase-3	9
-like	0
(	0
CPP32/Yama/apopain	9
)	0
,	0
and	0
caspase-6	9
-like	0
and	0
without	0
cleavage	0
of	0
caspase-3	9
substrates	10
poly	9
(	10
ADP-ribose	10
)	10
polymerase	10
and	0
DNA	9
fragmentation	10
factor-45	10
.	0

These	0
findings	0
suggest	0
either	0
low	0
level	0
of	0
activation	0
is	0
required	0
or	0
that	0
different	0
caspases	9
are	0
involved	0
.	0

Preactivation	0
of	0
T	7
cells	8
resulting	0
in	0
NF-kappa	9
B	10
nuclear	0
translocation	0
protected	0
cells	0
from	0
SN50-induced	0
apoptosis	0
.	0

Our	0
findings	0
demonstrate	0
an	0
essential	0
role	0
of	0
NF-kappa	9
B	10
in	0
survival	0
of	0
naive	7
PBL	8
.	0

Signal	0
transduction	0
pathways	0
in	0
normal	7
human	8
monocytes	8
stimulated	0
by	0
cytokines	9
and	0
mediators	0
:	0
comparative	0
study	0
with	0
normal	7
human	8
neutrophils	8
or	0
transformed	5
cells	6
and	0
the	0
putative	0
roles	0
in	0
functionality	0
and	0
cell	0
biology	0
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
and	0
interleukin	9
(	10
IL	10
)	10
-3	10
induced	0
tyrosine	0
phosphorylation	0
of	0
92-kDa	9
protein	10
in	0
normal	7
human	8
monocytes	8
.	0

We	0
identified	0
this	0
92-kDa	9
protein	10
as	0
STAT5	9
,	0
but	0
not	0
as	0
STATs1	9
,	10
3	10
,	10
and	10
6	10
nor	0
c-fes	9
and	0
vav	9
protooncogene	10
products	10
,	0
and	0
demonstrated	0
its	0
translocation	0
to	0
the	0
nucleus	0
,	0
enhancement	0
of	0
specific	0
DNA	0
binding	0
capacity	0
,	0
and	0
potentiation	0
of	0
trancriptional	0
activity	0
by	0
GM-CSF	9
.	0

N-formyl-methionyl-leucyl-phenylalanine	0
(	0
FMLP	0
)	0
and	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
induced	0
tyrosine	0
phosphorylation	0
of	0
42-	9
and	10
44-kDa	10
proteins	10
,	0
which	0
were	0
identified	0
as	0
extracellular	9
signal-regulated	10
kinase	10
(	0
ERK	9
)	0
,	0
in	0
human	7
monocytes	8
.	0

In	0
marked	0
contrast	0
to	0
neutrophils	7
and	0
MO7e	7
cells	8
,	0
GM-CSF	9
did	0
not	0
induce	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
ERK	9
in	0
monocytes	7
.	0

Among	0
upstream	9
signaling	10
molecules	10
of	0
ERK	9
,	0
Shc	9
was	0
constitutively	0
associated	0
with	0
Grb2	0
and	0
was	0
not	0
tyrosine-phosphorylated	0
by	0
GM-CSF	9
and	0
FMLP	0
,	0
and	0
Sos1	9
and	0
c-Raf-1	9
were	0
not	0
phosphorylated	0
by	0
GM-CSF	9
,	0
IL-3	0
,	0
TNF	0
,	0
and	0
FMLP	0
in	0
monocytes	7
,	0
whereas	0
all	0
these	0
signaling	0
molecules	0
were	0
affected	0
and/or	0
utilized	0
by	0
GM-CSF	9
in	0
MO7e	7
cells	8
.	0

In	0
contrast	0
to	0
neutrophils	7
,	0
p38	9
was	0
constitutively	0
phosphorylated	0
and	0
agonist-dependent	0
phosphorylation	0
and	0
activation	0
was	0
not	0
detected	0
in	0
human	7
monocytes	8
.	0

Superoxide	0
release	0
stimulated	0
by	0
FMLP	0
was	0
inhibited	0
partially	0
by	0
PD98059	0
or	0
SB203580	0
,	0
a	0
specific	0
inhibitor	0
of	0
ERK	0
or	0
p38	0
pathway	0
,	0
and	0
was	0
almost	0
completely	0
inhibited	0
by	0
the	0
combination	0
of	0
both	0
inhibitors	0
,	0
whereas	0
PMA-induced	0
superoxide	0
release	0
was	0
resistant	0
to	0
these	0
two	0
inhibitors	0
in	0
monocytes	7
.	0

PD98059	0
inhibited	0
GM-CSF	9
-dependent	0
proliferation	0
of	0
MO7e	7
cells	8
.	0

Present	0
results	0
indicate	0
trancriptional	0
roles	0
of	0
STAT5	9
and	0
functional	0
roles	0
of	0
ERK	9
and/or	0
p38	9
in	0
normal	7
human	8
monocytes	8
stimulated	0
by	0
physiological	0
receptor-mediated	0
agonists	0
GM-CSF	9
and	0
FMLP	0
.	0

Possible	0
roles	0
of	0
ERK	9
in	0
proliferation	0
of	0
transformed	5
cells	6
were	0
also	0
suggested	0
.	0

Aiolos	9
transcription	9
factor	10
controls	0
cell	0
death	0
in	0
T	7
cells	8
by	0
regulating	0
Bcl-2	9
expression	0
and	0
its	0
cellular	0
localization	0
.	0

We	0
searched	0
for	0
proteins	0
that	0
interact	0
with	0
Ras	9
in	0
interleukin	5
(	6
IL	6
)	6
-2-stimulated	6
or	6
IL-2-deprived	6
cells	6
,	0
and	0
found	0
that	0
the	0
transcription	9
factor	10
Aiolos	9
interacts	0
with	0
Ras	9
.	0

The	0
Ras	9
-Aiolos	9
interaction	0
was	0
confirmed	0
in	0
vitro	0
and	0
in	0
vivo	0
by	0
co-immunoprecipitation	0
.	0

Indirect	0
immunofluorescence	0
shows	0
that	0
IL-2	9
controls	0
the	0
cellular	0
distribution	0
of	0
Aiolos	9
and	0
induces	0
its	0
tyrosine	0
phosphorylation	0
,	0
required	0
for	0
dissociation	0
from	0
Ras	9
.	0

We	0
also	0
identified	0
functional	0
Aiolos-binding	1
sites	2
in	0
the	0
Bcl-2	1
promoter	2
,	0
which	0
are	0
able	0
to	0
activate	0
the	0
luciferase	1
reporter	2
gene	2
.	0

Mutation	0
of	0
Aiolos-binding	1
sites	2
within	0
the	0
Bcl-2	1
promoter	2
inhibits	0
transactivation	0
of	0
the	0
reporter	1
gene	2
luciferase	2
,	0
suggesting	0
direct	0
control	0
of	0
Bcl-2	9
expression	0
by	0
Aiolos	9
.	0

Co-transfection	0
experiments	0
confirm	0
that	0
Aiolos	9
induces	0
Bcl-2	9
expression	0
and	0
prevents	0
apoptosis	0
in	0
IL-2-deprived	5
cells	6
.	0

We	0
propose	0
a	0
model	0
for	0
the	0
regulation	0
of	0
Bcl-2	9
expression	0
via	0
Aiolos	9
.	0

Binding	0
of	0
YY1	9
and	0
Oct1	9
to	0
a	0
novel	0
element	0
that	0
downregulates	0
expression	0
of	0
IL-5	9
in	0
human	0
T	7
cells	8
.	0

BACKGROUND	0
:	0
IL-5	9
controls	0
development	0
of	0
eosinophilia	0
and	0
has	0
been	0
shown	0
to	0
be	0
involved	0
in	0
the	0
pathogenesis	0
of	0
allergic	0
diseases	0
.	0

In	0
both	0
atopic	0
and	0
nonatopic	0
asthma	0
,	0
elevated	0
IL-5	9
has	0
been	0
detected	0
in	0
peripheral	0
blood	0
and	0
the	0
airways	0
.	0

IL-5	9
is	0
produced	0
mainly	0
by	0
activated	0
T	7
cells	8
,	0
and	0
its	0
expression	0
is	0
regulated	0
at	0
the	0
transcriptional	0
level	0
.	0

OBJECTIVE	0
:	0
This	0
study	0
focuses	0
on	0
the	0
functional	0
analysis	0
of	0
the	0
human	1
IL-5	2
(	2
hIL-5	2
)	2
promoter	2
and	0
characterization	0
of	0
cis	0
-regulatory	0
elements	0
and	0
transcription	0
factors	0
involved	0
in	0
the	0
suppression	0
of	0
IL-5	9
transcription	0
in	0
T	7
cells	8
.	0

METHODS	0
:	0
Methods	0
used	0
in	0
this	0
study	0
include	0
DNase	9
I	10
footprint	0
assays	0
,	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
and	0
functional	0
analysis	0
by	0
mammalian	0
cell	0
transfection	0
involving	0
deletion	0
analysis	0
and	0
site-directed	0
mutagenesis	0
.	0

RESULTS	0
:	0
We	0
identified	0
5	0
protein	1
binding	2
regions	2
(	0
BRs	1
)	0
located	0
within	0
the	0
proximal	1
hIL-5	2
promoter	2
.	0

Functional	0
analysis	0
indicates	0
that	0
the	0
BRs	1
are	0
involved	0
in	0
control	0
of	0
hIL-5	1
promoter	2
activity	0
.	0

Two	0
of	0
these	0
regions	0
,	0
BR3	1
and	0
BR4	1
located	0
at	0
positions	0
-102	0
to	0
-73	0
,	0
have	0
not	0
previously	0
been	0
described	0
as	0
regulators	0
of	0
IL-5	9
expression	0
in	0
T	7
cells	8
.	0

We	0
show	0
that	0
the	0
BR3	1
sequence	0
contains	0
a	0
novel	0
negative	1
regulatory	2
element	2
located	0
at	0
positions	0
-90	0
to	0
-79	0
of	0
the	0
hIL-5	1
promoter	2
,	0
which	0
binds	0
Oct1	9
,	0
octamer-like	9
,	0
and	0
YY1	9
nuclear	10
factors	10
.	0

Substitution	0
mutations	0
,	0
which	0
abolished	0
binding	0
of	0
these	0
proteins	0
to	0
the	0
BR3	1
sequence	2
,	0
significantly	0
increased	0
hIL-5	1
promoter	2
activity	0
in	0
activated	7
T	8
cells	8
.	0

CONCLUSION	0
:	0
We	0
suggest	0
that	0
Oct1	9
,	0
YY1	9
,	0
and	0
octamer-like	9
factors	10
binding	0
to	0
the	0
-90/-79	1
sequence	2
within	0
the	0
proximal	1
IL-5	2
promoter	2
are	0
involved	0
in	0
suppression	0
of	0
IL-5	9
transcription	0
in	0
T	7
cells	8
.	0

New	0
immunosuppressive	0
drug	0
PNU156804	0
blocks	0
IL-2	9
-dependent	0
proliferation	0
and	0
NF-kappa	0
B	0
and	0
AP-1	0
activation	0
.	0

We	0
had	0
previously	0
shown	0
that	0
the	0
drug	0
undecylprodigiosin	0
(	0
UP	0
)	0
blocks	0
human	7
lymphocyte	8
proliferation	0
in	0
vitro	0
.	0

We	0
have	0
now	0
investigated	0
the	0
mechanism	0
of	0
action	0
of	0
a	0
new	0
analogue	0
of	0
UP	0
,	0
PNU156804	0
,	0
which	0
shows	0
a	0
more	0
favorable	0
activity	0
profile	0
than	0
UP	0
in	0
mice	0
.	0

We	0
demonstrate	0
here	0
that	0
the	0
biological	0
effect	0
of	0
PNU156804	0
in	0
vitro	0
is	0
indistinguishable	0
from	0
UP	0
:	0
PNU156804	0
blocks	0
human	7
T	8
cell	8
proliferation	0
in	0
mid-late	0
G1	0
,	0
as	0
determined	0
by	0
cell	0
cycle	0
analysis	0
,	0
expression	0
of	0
cyclins	9
,	0
and	0
cyclin-dependent	9
kinases	10
and	0
retinoblastoma	0
phosphorylation	0
.	0

In	0
addition	0
,	0
we	0
show	0
that	0
PNU156804	0
does	0
not	0
block	0
significantly	0
the	0
induction	0
of	0
either	0
IL-2	9
or	0
IL-2R	9
alpha-	10
and	10
gamma-chains	10
but	0
inhibits	0
IL-2	9
-dependent	0
T	0
cell	0
proliferation	0
.	0

We	0
have	0
investigated	0
several	0
molecular	0
pathways	0
that	0
are	0
known	0
to	0
be	0
activated	0
by	0
IL-2	9
in	0
T	7
cells	8
.	0

We	0
show	0
that	0
PNU156804	0
does	0
not	0
inhibit	0
c-myc	0
and	0
bcl-2	0
mRNA	0
induction	0
.	0

On	0
the	0
other	0
hand	0
,	0
PNU156804	0
efficiently	0
inhibits	0
the	0
activation	0
of	0
the	0
NF-kappa	9
B	10
and	0
AP-1	9
transcription	0
factors	0
.	0

PNU156804	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
is	0
due	0
to	0
the	0
inhibition	0
of	0
the	0
degradation	0
of	0
I	9
kappa	10
B-alpha	10
and	0
I	9
kappa	10
B-beta	10
.	0

PNU156804	0
action	0
is	0
restricted	0
to	0
some	0
signaling	0
pathways	0
;	0
it	0
does	0
not	0
affect	0
NF-kappa	9
B	10
activation	0
by	0
PMA	0
in	0
T	7
cells	8
but	0
blocks	0
that	0
induced	0
by	0
CD40	9
cross-linking	0
in	0
B	7
lymphocytes	8
.	0

We	0
conclude	0
that	0
the	0
prodigiosin	0
family	0
of	0
immunosuppressants	0
is	0
a	0
new	0
family	0
of	0
molecules	0
that	0
show	0
a	0
novel	0
target	0
specificity	0
clearly	0
distinct	0
from	0
that	0
of	0
other	0
immunosuppressive	0
drugs	0
such	0
as	0
cyclosporin	0
A	0
,	0
FK506	0
,	0
and	0
rapamycin	0
.	0

Human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
Tax	10
protein	10
induces	0
the	0
expression	0
of	0
STAT1	1
and	2
STAT5	2
genes	2
in	0
T-cells	7
.	0

Human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
(	10
HTLV-1	10
)	10
Tax	10
transforms	0
normal	0
T-cells	7
in	0
the	0
presence	0
of	0
interleukin	9
(	10
IL	10
)	10
-2	10
in	0
vitro	0
.	0

STAT	9
is	0
a	0
family	0
of	0
transcription	9
factors	10
that	0
play	0
a	0
pivotal	0
role	0
in	0
cytokine-induced	0
functions	0
of	0
a	0
various	0
type	0
of	0
cells	0
.	0

We	0
investigated	0
the	0
involvement	0
of	0
STATs	9
in	0
the	0
transformation	0
of	0
T-cells	7
by	0
HTLV-1	0
.	0

HTLV-1-transformed	5
T-cell	6
lines	6
expressed	0
higher	0
amounts	0
of	0
STAT1	3
,	4
STAT3	4
and	4
STAT5	4
RNA	4
and	0
proteins	0
than	0
virus-negative	7
T	8
cells	8
.	0

The	0
expression	0
of	0
STAT1	9
and	0
STAT5	9
in	0
a	0
human	5
T-cell	6
line	6
was	0
induced	0
by	0
Tax	9
.	0

IL-2	9
induced	0
the	0
DNA	0
binding	0
activity	0
of	0
STAT3	9
and	0
STAT5	9
of	0
a	0
HTLV-1-transformed	0
cell	0
line	0
and	0
then	0
stimulated	0
its	0
proliferation	0
.	0

In	0
contrast	0
,	0
IL-2	9
did	0
neither	0
in	0
a	0
cell	0
line	0
lacking	0
STAT3	9
and	0
STAT5	9
.	0

The	0
expression	0
of	0
STAT1	3
,	4
STAT3	4
and	4
STAT5	4
mRNAs	4
were	0
also	0
induced	0
by	0
a	0
T-cell	9
mitogen	10
in	0
normal	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

Our	0
results	0
suggest	0
that	0
the	0
induction	0
of	0
STAT1	9
and	0
STAT5	9
by	0
Tax	9
enhances	0
cytokine	9
-induced	0
functions	0
of	0
virus-infected	0
T-cells	7
,	0
hence	0
the	0
induction	0
may	0
play	0
a	0
role	0
in	0
IL-2	9
-dependent	0
transformation	0
steps	0
of	0
T-cells	7
by	0
HTLV-1	0
.	0

Transcriptional	0
control	0
of	0
the	0
IL-5	9
gene	0
by	0
human	7
helper	8
T	8
cells	8
:	0
IL-5	9
synthesis	0
is	0
regulated	0
independently	0
from	0
IL-2	9
or	0
IL-4	9
synthesis	0
.	0

BACKGROUND	0
:	0
IL-5	9
is	0
fundamentally	0
involved	0
in	0
eosinophilic	0
inflammation	0
.	0

Control	0
of	0
IL-5	9
production	0
may	0
be	0
effective	0
for	0
the	0
management	0
of	0
allergic	0
diseases	0
.	0

OBJECTIVE	0
:	0
We	0
aimed	0
to	0
find	0
the	0
transcriptional	0
mechanisms	0
that	0
regulate	0
the	0
IL-5	9
gene	0
to	0
selectively	0
control	0
IL-5	9
synthesis	0
.	0

METHODS	0
:	0
Allergen-specific	5
T-cell	6
clones	6
and	0
T-cell	5
hybridomas	6
were	0
established	0
from	0
the	0
peripheral	7
blood	8
lymphocytes	8
of	0
patients	0
with	0
asthma	0
,	0
and	0
the	0
transcriptional	0
regulation	0
of	0
the	0
IL-5	1
gene	2
was	0
investigated	0
with	0
transient	0
transfection	0
and	0
electrophoretic	0
mobility	0
shift	0
analysis	0
.	0

RESULTS	0
:	0
A	0
human	0
IL-5	1
promoter/enhancer-luciferase	2
gene	2
construct	2
,	0
pIL-5	1
(	2
-511	2
)	2
Luc	2
,	0
was	0
transcribed	0
on	0
activation	0
of	0
IL-5-producing	5
T-cell	6
clones	6
,	0
but	0
not	0
IL-5-nonproducing	5
clones	6
.	0

pIL-5	1
(	2
-511	2
)	2
Luc	2
was	0
transcribed	0
by	0
T-cell	5
hybridomas	6
derived	0
from	0
fusion	0
between	0
IL-5-producing	5
T-cell	6
clones	6
and	0
an	0
IL-5	5
gene-nonexpressing	6
T-cell	6
line	6
,	0
but	0
not	0
by	0
hybridomas	5
derived	0
from	0
IL-5-nonproducing	5
T-cell	6
clones	6
.	0

IL-5	9
synthesis	0
was	0
not	0
only	0
induced	0
by	0
T-cell	0
receptor	0
stimulation	0
but	0
also	0
by	0
IL-2	9
receptor	0
stimulation	0
.	0

Binding	0
of	0
NF-AT	9
,	0
NF-kappaB	9
,	0
and	0
AP-1	9
was	0
induced	0
by	0
T-cell	9
receptor	10
(	0
TcR	9
)	0
stimulation	0
,	0
although	0
there	0
was	0
no	0
significant	0
upregulation	0
of	0
binding	0
by	0
IL-2	9
stimulation	0
.	0

CONCLUSION	0
:	0
IL-5	9
synthesis	0
by	0
human	7
helper	8
T	8
cells	8
is	0
regulated	0
at	0
the	0
transcriptional	0
level	0
.	0

A	0
unique	0
transcriptional	0
mechanism	0
distinct	0
from	0
those	0
regulating	0
the	0
IL-2	1
or	2
IL-4	2
genes	2
seems	0
to	0
control	0
the	0
IL-5	1
gene	2
.	0

Selective	0
regulation	0
of	0
IL-5	9
gene	0
transcription	0
may	0
be	0
useful	0
for	0
treating	0
eosinophlic	0
inflammation	0
.	0

Defining	0
therapeutic	0
targets	0
by	0
using	0
adenovirus	0
:	0
blocking	0
NF-kappaB	9
inhibits	0
both	0
inflammatory	0
and	0
destructive	0
mechanisms	0
in	0
rheumatoid	0
synovium	0
but	0
spares	0
anti-inflammatory	9
mediators	10
.	0

The	0
role	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
in	0
the	0
pathogenesis	0
of	0
rheumatoid	0
arthritis	0
has	0
long	0
been	0
a	0
subject	0
of	0
controversy	0
.	0

We	0
used	0
an	0
adenoviral	0
technique	0
of	0
blocking	0
NF-kappaB	9
through	0
overexpression	0
of	0
the	0
inhibitory	9
subunit	10
IkappaBalpha	9
,	0
which	0
has	0
the	0
advantage	0
that	0
it	0
can	0
be	0
used	0
in	0
the	0
diseased	0
tissue	0
itself	0
,	0
with	0
>	0
90	0
%	0
of	0
the	0
synovial	7
macrophages	8
,	0
fibroblasts	7
,	0
and	0
T	7
cells	8
infected	0
.	0

We	0
found	0
that	0
the	0
spontaneous	0
production	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
and	0
other	0
pro-inflammatory	9
cytokines	10
is	0
NF-kappaB	9
-dependent	0
in	0
rheumatoid	0
synovial	0
tissue	0
,	0
in	0
contrast	0
to	0
the	0
main	0
anti-inflammatory	9
mediators	10
,	0
like	0
IL-10	9
and	10
-11	10
,	0
and	0
the	0
IL-1	9
receptor	10
antagonist	10
.	0

Of	0
even	0
more	0
interest	0
,	0
IkappaBalpha	9
overexpression	0
inhibited	0
the	0
production	0
of	0
matrix	9
metalloproteinases	10
1	10
and	10
3	10
while	0
not	0
affecting	0
their	0
tissue	0
inhibitor	0
.	0

Blocking	0
NF-kappaB	9
in	0
the	0
rheumatoid	0
joint	0
thus	0
has	0
a	0
very	0
beneficial	0
profile	0
,	0
reducing	0
both	0
the	0
inflammatory	0
response	0
and	0
the	0
tissue	0
destruction	0
.	0

The	0
adenoviral	0
technique	0
described	0
here	0
has	0
widespread	0
applicability	0
,	0
allowing	0
rapid	0
testing	0
of	0
the	0
effects	0
of	0
blocking	0
a	0
potential	0
therapeutic	0
target	0
in	0
either	0
cultures	0
of	0
normal	7
cells	8
or	0
in	0
the	0
diseased	0
tissue	0
itself	0
.	0

Resistance	0
to	0
tumor	9
necrosis	10
factor	10
induced	0
apoptosis	0
in	0
vitro	0
correlates	0
with	0
high	0
metastatic	0
capacity	0
of	0
cells	0
in	0
vivo	0
.	0

TNF	9
is	0
one	0
of	0
the	0
cytokines	9
secreted	0
by	0
the	0
cells	0
of	0
the	0
immune	0
system	0
.	0

Our	0
data	0
demonstrate	0
that	0
those	0
cell	5
lines	6
lacking	0
capability	0
to	0
form	0
metastatic	0
tumors	0
in	0
vivo	0
are	0
susceptible	0
to	0
TNF	9
induced	0
apoptosis	0
in	0
vitro	0
.	0

However	0
,	0
cell	5
lines	6
with	0
high	0
metastatic	0
potential	0
are	0
resistant	0
to	0
TNF	9
in	0
vitro	0
.	0

Furthermore	0
,	0
the	0
same	0
cell	5
lines	6
were	0
resistant	0
to	0
cytolytic	0
action	0
of	0
other	0
cytotoxic	9
proteins	10
secreted	0
by	0
LAK	5
cells	6
.	0

Our	0
data	0
showed	0
that	0
TNF	9
resistance	0
in	0
vitro	0
correlates	0
with	0
the	0
increased	0
level	0
of	0
transcription	9
factor	10
NF-kappaB	9
.	0

This	0
finding	0
may	0
provide	0
a	0
tool	0
to	0
improve	0
current	0
protocols	0
of	0
immunotherapy	0
and	0
insights	0
to	0
how	0
tumor	7
cells	8
are	0
or	0
are	0
not	0
killed	0
by	0
LAK	5
cells	6
.	0

Clonality	0
analysis	0
of	0
granulocytes	7
and	0
T	7
lymphocytes	8
in	0
healthy	0
females	0
by	0
the	0
PCR-based	0
HUMARA	1
method	0
.	0

Clonality	0
analysis	0
utilizing	0
X-chromosome	1
inactivation	0
has	0
been	0
used	0
in	0
the	0
study	0
of	0
various	0
diseases	0
,	0
including	0
hematological	0
malignancies	0
.	0

The	0
human	1
androgen	2
receptor	2
gene	2
(	0
HUMARA	1
)	0
assay	0
is	0
the	0
newest	0
of	0
such	0
methods	0
,	0
and	0
the	0
majority	0
of	0
the	0
female	0
population	0
can	0
be	0
assessed	0
by	0
this	0
relatively	0
simple	0
procedure	0
.	0

One	0
problem	0
in	0
using	0
these	0
clonality	0
analysis	0
methods	0
,	0
however	0
,	0
is	0
that	0
there	0
may	0
be	0
significant	0
variation	0
in	0
Lyonization	0
in	0
blood	7
cells	8
in	0
normal	0
individuals	0
.	0

To	0
determine	0
the	0
diversity	0
in	0
X-chromosome	1
methylation	0
patterns	0
,	0
which	0
reflect	0
Lyonization	0
,	0
assessed	0
by	0
the	0
HUMARA	1
assay	0
in	0
the	0
supposedly	0
normal	0
population	0
,	0
we	0
analyzed	0
granulocytes	7
and	0
T	5
cells	6
from	0
97	0
relatively	0
young	0
(	0
18-	0
to	0
35-year-old	0
)	0
healthy	0
female	0
volunteers	0
.	0

We	0
found	0
that	0
the	0
methylation	0
patterns	0
in	0
the	0
two	0
HUMARA	1
alleles	2
were	0
distributed	0
even	0
more	0
widely	0
,	0
both	0
in	0
granuloctyes	7
and	0
in	0
T	5
cells	6
,	0
than	0
previously	0
reported	0
with	0
other	0
methods	0
.	0

We	0
also	0
found	0
that	0
the	0
deviation	0
of	0
methylation	0
in	0
granulocytes	7
and	0
T	5
cells	6
was	0
well	0
correlated	0
.	0

Thus	0
,	0
we	0
conclude	0
that	0
appropriate	0
controls	0
from	0
the	0
same	0
individuals	0
,	0
such	0
as	0
T	5
cells	6
in	0
the	0
case	0
of	0
stem	0
cell	0
disorders	0
,	0
should	0
always	0
be	0
employed	0
to	0
conclusively	0
determine	0
whether	0
certain	0
cells	0
of	0
hematopoietic	0
origin	0
are	0
clonal	0
.	0

Functional	0
B-cell	0
response	0
in	0
intrahepatic	0
lymphoid	0
follicles	0
in	0
chronic	0
hepatitis	0
C	0
.	0

Intrahepatic	0
lymphoid	0
follicle	0
(	0
ILF	0
)	0
formation	0
is	0
one	0
of	0
the	0
most	0
characteristic	0
and	0
commonly	0
observed	0
histological	0
features	0
in	0
patients	0
with	0
chronic	0
hepatitis	0
C	0
.	0

However	0
,	0
little	0
is	0
known	0
regarding	0
whether	0
follicles	0
in	0
the	0
liver	0
belong	0
to	0
functional	0
lymphoid	0
tissues	0
,	0
where	0
B	0
cells	0
are	0
activated	0
,	0
differentiated	0
,	0
and	0
proliferated	0
,	0
or	0
if	0
the	0
lymphocytes	0
are	0
merely	0
infiltrated	0
after	0
recruitment	0
from	0
the	0
secondary	0
lymphoid	0
organs	0
.	0

To	0
ascertain	0
this	0
possibility	0
,	0
we	0
examined	0
the	0
expression	0
of	0
markers	0
for	0
B-cell	0
activation	0
,	0
differentiation	0
,	0
and	0
proliferation	0
in	0
ILFs	0
in	0
patients	0
with	0
chronic	0
hepatitis	0
C	0
using	0
surgically	0
resected	0
specimens	0
,	0
and	0
compared	0
them	0
with	0
specimens	0
of	0
perihepatic	0
lymph	0
nodes	0
by	0
an	0
immunohistochemical	0
technique	0
.	0

Germinal	0
center	0
(	0
GC	0
)	0
formation	0
in	0
the	0
ILFs	0
was	0
frequently	0
found	0
in	0
HCV-positive	0
cases	0
.	0

The	0
distribution	0
of	0
immunoglobulin	0
M	0
(	0
IgM	0
)	0
-	0
,	0
IgD-	0
,	0
and	0
IgG-positive	0
cells	0
and	0
the	0
expression	0
patterns	0
of	0
Ki-67	0
,	0
CD23	0
,	0
or	0
bcl-2	0
and	0
bcl-6	0
gene	0
products	0
in	0
the	0
follicles	0
with	0
GC	0
formation	0
in	0
the	0
liver	0
of	0
patients	0
with	0
chronic	0
hepatitis	0
C	0
were	0
similar	0
to	0
those	0
of	0
lymph	0
nodes	0
,	0
indicating	0
that	0
B	7
cells	8
are	0
activated	0
,	0
proliferated	0
,	0
and	0
differentiated	0
in	0
the	0
ILFs	0
with	0
GC	0
formation	0
in	0
patients	0
with	0
chronic	0
hepatitis	0
C	0
.	0

Oligoclonal	0
expansion	0
of	0
B	7
cells	8
in	0
the	0
livers	0
with	0
ILFs	0
was	0
confirmed	0
by	0
an	0
analysis	0
of	0
immunoglobulin	1
heavy	2
chain	2
(	2
IgH	2
)	2
gene	2
rearrangement	0
determined	0
by	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
.	0

These	0
data	0
strongly	0
suggest	0
that	0
ILFs	0
with	0
GC	0
formation	0
,	0
which	0
are	0
frequently	0
found	0
in	0
patients	0
with	0
chronic	0
hepatitis	0
C	0
,	0
may	0
functionally	0
be	0
the	0
same	0
as	0
those	0
found	0
in	0
lymph	0
nodes	0
with	0
respect	0
to	0
B-cell	0
expansion	0
and	0
maturation	0
.	0

Downregulation	0
of	0
Wilms	1
'	2
tumor	2
gene	2
(	0
WT1	1
)	0
is	0
not	0
a	0
prerequisite	0
for	0
erythroid	0
or	0
megakaryocytic	0
differentiation	0
of	0
the	0
leukemic	5
cell	6
line	6
K562	6
.	0

The	0
Wilms	1
'	2
tumor	2
gene	2
(	0
WT1	1
)	0
encodes	0
a	0
transcription	9
factor	10
of	0
the	0
zinc	9
finger	10
type	10
.	0

A	0
high	0
expression	0
of	0
WT1	1
has	0
been	0
detected	0
in	0
a	0
range	0
of	0
acute	0
leukemias	0
,	0
and	0
WT1	1
is	0
downregulated	0
during	0
induced	0
differentiation	0
of	0
some	0
leukemic	5
cell	6
lines	6
.	0

Overexpression	0
of	0
WT1	1
in	0
some	0
myeloid	5
cell	6
lines	6
confers	0
resistance	0
to	0
differentiation	0
induction	0
.	0

These	0
observations	0
suggest	0
that	0
a	0
high	0
WT1	1
expression	0
in	0
hematopoietic	7
cells	8
is	0
incompatible	0
with	0
differentiation	0
.	0

In	0
this	0
study	0
,	0
each	0
of	0
the	0
four	0
different	0
isoforms	0
of	0
WT1	1
was	0
constitutively	0
overexpressed	0
in	0
the	0
leukemic	5
cell	6
line	6
K562	6
.	0

K562	5
cells	6
express	0
endogenous	0
WT1	1
,	0
which	0
is	0
downregulated	0
as	0
a	0
response	0
to	0
induced	0
differentiation	0
along	0
the	0
erythroid	0
and	0
megakaryocytic	0
pathways	0
.	0

We	0
now	0
demonstrate	0
that	0
a	0
forced	0
exogenous	0
expression	0
of	0
the	0
four	0
different	0
isoforms	0
of	0
WT1	1
in	0
K562	5
does	0
not	0
affect	0
the	0
differentiation	0
response	0
,	0
as	0
judged	0
by	0
accumulation	0
of	0
hemoglobin	9
in	0
response	0
to	0
hemin	9
or	0
the	0
expression	0
of	0
megakaryocytic	9
cell	10
surface	10
markers	10
in	0
response	0
to	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
.	0

We	0
conclude	0
that	0
downregulation	0
of	0
WT1	1
during	0
induced	0
differentiation	0
of	0
K562	5
cells	6
is	0
not	0
a	0
prerequisite	0
for	0
erythroid	0
or	0
megakaryocytic	0
differentiation	0
of	0
these	0
cells	0
.	0

Association	0
of	0
the	0
interleukin-4	9
receptor	10
alpha	10
chain	10
with	0
p47phox	0
,	0
an	0
activator	0
of	0
the	0
phagocyte	9
NADPH	10
oxidase	10
in	0
B	7
cells	8
.	0

Interleukin	9
(	10
IL	10
)	10
-4	10
plays	0
an	0
important	0
role	0
in	0
IgE	9
synthesis	0
in	0
B	7
cells	8
and	0
in	0
Th2	0
differentiation	0
in	0
T	5
cells	6
.	0

IL-4	9
conducts	0
its	0
biological	0
activities	0
through	0
binding	0
to	0
the	0
IL-4	9
receptor	10
(	0
IL-4R	9
)	0
on	0
the	0
surface	0
of	0
target	7
cells	8
.	0

IL-4R	9
are	0
thought	0
to	0
be	0
composed	0
of	0
the	0
IL-4R	9
alpha	10
chain	10
(	0
IL-4R	9
alpha	10
)	0
and	0
either	0
the	0
IL-2R	9
gamma	10
chain	10
or	0
the	0
IL-13R	9
alpha	10
chain	10
.	0

We	0
have	0
previously	0
shown	0
that	0
the	0
membrane-proximal	9
portion	10
in	0
the	0
cytoplasmic	9
domain	10
of	0
the	0
human	9
IL-4R	10
alpha	10
(	0
hIL-4R	9
alpha	10
)	0
is	0
critical	0
for	0
proliferation	0
,	0
generation	0
of	0
germline	0
epsilon	0
transcript	0
,	0
and	0
activation	0
of	0
STAT6	9
,	0
based	0
on	0
analyses	0
of	0
truncated	9
hIL-4R	10
alphas	10
.	0

In	0
this	0
study	0
,	0
we	0
found	0
that	0
p47phox	0
,	0
an	0
activator	0
of	0
the	0
phagocyte	9
NADPH	10
oxidase	10
,	0
binds	0
to	0
this	0
portion	0
by	0
the	0
two-hybrid	0
system	0
.	0

Furthermore	0
,	0
we	0
observed	0
the	0
association	0
of	0
p47phox	0
with	0
the	0
hIL-4R	9
alpha	10
in	0
B	7
cells	8
derived	0
from	0
a	0
normal	0
donor	0
.	0

These	0
results	0
suggest	0
that	0
p47phox	0
is	0
involved	0
in	0
the	0
signal	0
transduction	0
of	0
IL-4	9
in	0
B	7
cells	8
.	0

However	0
,	0
activation	0
of	0
STAT6	9
,	0
CD23	9
expression	0
,	0
and	0
IgE	9
synthesis	0
induced	0
by	0
IL-4	9
were	0
not	0
affected	0
in	0
p47phox-deficient	0
patients	0
,	0
which	0
raises	0
the	0
possibility	0
that	0
p47phox	0
may	0
be	0
important	0
in	0
other	0
signaling	0
activities	0
as	0
well	0
in	0
B	7
cells	8
.	0

Effects	0
of	0
diesel	0
organic	0
extracts	0
on	0
chemokine	9
production	0
by	0
peripheral	7
blood	8
mononuclear	8
cells	8
.	0

BACKGROUND	0
:	0
Polyaromatic	0
hydrocarbons	0
(	0
PAHs	0
)	0
associated	0
with	0
diesel	0
exhaust	0
particles	0
(	0
DEPs	0
)	0
are	0
found	0
in	0
the	0
atmospheric	0
urban	0
pollution	0
.	0

Such	0
compounds	0
have	0
been	0
shown	0
to	0
favor	0
IgE	9
production	0
,	0
bronchial	0
hyperresponsiveness	0
,	0
and	0
airway	0
inflammation	0
.	0

Chemokines	0
are	0
a	0
group	0
of	0
chemotactic	9
cytokines	10
involved	0
in	0
the	0
recruitment	0
of	0
inflammatory	7
cells	8
.	0

OBJECTIVE	0
:	0
We	0
investigated	0
the	0
effect	0
of	0
DEP-PAHs	0
on	0
the	0
release	0
and	0
mRNA	3
expression	0
of	0
IL-8	9
,	0
MCP-1	9
,	0
and	0
RANTES	9
by	0
PBMCs	7
obtained	0
from	0
healthy	0
subjects	0
.	0

METHODS	0
:	0
Protein	0
production	0
in	0
supernatants	0
was	0
assessed	0
by	0
ELISA	0
,	0
and	0
mRNA	3
expression	0
was	0
evaluated	0
by	0
semiquantitative	0
RT-PCR	0
.	0

RESULTS	0
:	0
Secretion	0
of	0
IL-8	9
and	0
RANTES	9
increased	0
in	0
a	0
dose-dependent	0
manner	0
with	0
increasing	0
concentrations	0
of	0
DEP-PAHs	0
(	0
range	0
,	0
0.5	0
ng	0
to	0
50	0
ng/mL	0
)	0
.	0

On	0
the	0
contrary	0
,	0
the	0
release	0
of	0
MCP-1	9
was	0
significantly	0
inhibited	0
,	0
also	0
in	0
a	0
dose-dependent	0
manner	0
.	0

Messenger	3
RNA	4
production	0
coding	0
for	0
IL-8	9
,	0
RANTES	9
,	0
and	0
MCP-1	9
showed	0
parallel	0
variations	0
to	0
the	0
production	0
of	0
the	0
correspondent	9
proteins	10
.	0

Effects	0
of	0
DEP-PAHs	0
became	0
significant	0
at	0
7	0
hours	0
and	0
up	0
to	0
48	0
hours	0
time	0
culture	0
for	0
MCP-1	9
,	0
and	0
up	0
to	0
24	0
hours	0
time	0
culture	0
for	0
IL-8	9
and	0
RANTES	9
.	0

Moreover	0
,	0
supernatants	0
from	0
DEP-PAH-activated	7
cells	8
,	0
compared	0
with	0
those	0
of	0
controls	0
,	0
exhibited	0
a	0
significantly	0
enhanced	0
chemotactic	0
activity	0
for	0
neutrophils	7
and	0
eosinophils	7
,	0
which	0
was	0
significantly	0
inhibited	0
by	0
pretreatment	0
with	0
anti-IL-8	9
and	0
anti-RANTES	9
neutralizing	0
antibodies	0
,	0
respectively	0
.	0

CONCLUSION	0
:	0
These	0
findings	0
suggest	0
that	0
the	0
chemokine	9
pathways	0
are	0
modulated	0
by	0
DEP-PAHs	0
at	0
the	0
transcriptional	0
level	0
,	0
reinforcing	0
the	0
idea	0
that	0
the	0
development	0
of	0
inflammatory	0
reactions	0
might	0
be	0
affected	0
by	0
diesel	0
exhaust	0
emission	0
.	0

20-Epi	0
analogues	0
of	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
are	0
highly	0
potent	0
inducers	0
of	0
DRIP	9
coactivator	10
complex	10
binding	0
to	0
the	0
vitamin	9
D3	10
receptor	10
.	0

1	0
,	0
25-Dihydroxyvitamin	0
D3	0
(	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
)	0
plays	0
a	0
major	0
role	0
in	0
the	0
stimulation	0
of	0
bone	0
growth	0
,	0
mineralization	0
,	0
and	0
intestinal	0
calcium	0
and	0
phosphate	0
absorption	0
;	0
it	0
also	0
acts	0
as	0
a	0
general	0
inhibitor	0
of	0
cellular	0
proliferation	0
.	0

Several	0
new	0
,	0
clinically	0
relevant	0
compounds	0
dissociate	0
antiproliferative	0
and	0
calcemic	0
activities	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
but	0
the	0
molecular	0
basis	0
for	0
this	0
has	0
not	0
been	0
clearly	0
elucidated	0
.	0

Here	0
,	0
we	0
tested	0
whether	0
the	0
potency	0
of	0
one	0
class	0
of	0
compounds	0
,	0
20-epi	0
analogues	0
,	0
to	0
induce	0
myeloid	0
cell	0
differentiation	0
,	0
is	0
because	0
of	0
direct	0
molecular	0
effects	0
on	0
vitamin	9
D	10
receptor	10
(	0
VDR	9
)	0
.	0

We	0
report	0
that	0
two	0
20-epi	0
analogues	0
,	0
MC1627	0
and	0
MC1288	0
,	0
induced	0
differentiation	0
and	0
transcription	0
of	0
p21	1
(	0
Waf1	1
,	0
Cip1	1
)	0
,	0
a	0
key	0
VDR	1
target	2
gene	2
involved	0
in	0
growth	0
inhibition	0
,	0
at	0
a	0
concentration	0
100-fold	0
lower	0
than	0
that	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

We	0
compared	0
this	0
sensitivity	0
to	0
analogue	0
effects	0
on	0
VDR	9
interacting	0
proteins	0
:	0
RXR	9
,	0
GRIP-1	9
,	0
and	0
DRIP205	9
,	0
a	0
subunit	0
of	0
the	0
DRIP	9
coactivator	10
complex	10
.	0

Compared	0
with	0
the	0
interaction	0
of	0
VDR	9
with	0
RXR	9
or	0
GRIP-1	9
,	0
the	0
differentiation	0
dose-response	0
most	0
closely	0
correlated	0
to	0
the	0
ligand-dependent	0
recruitment	0
of	0
the	0
DRIP	9
coactivator	10
complex	10
to	0
VDR	9
and	0
to	0
the	0
ability	0
of	0
the	0
receptor	0
to	0
activate	0
transcription	0
in	0
a	0
cell-free	0
system	0
.	0

These	0
results	0
provide	0
compelling	0
links	0
between	0
the	0
efficiency	0
of	0
the	0
20-epi	0
analogue	0
in	0
inducing	0
VDR	9
/DRIP	0
interactions	0
,	0
transactivation	0
in	0
vitro	0
,	0
and	0
its	0
enhanced	0
ability	0
to	0
induce	0
cellular	0
differentiation	0
.	0

SLP-76	9
and	0
Vav	9
function	0
in	0
separate	0
,	0
but	0
overlapping	0
pathways	0
to	0
augment	0
interleukin-2	1
promoter	2
activity	0
.	0

SLP-76	9
and	0
Vav	9
,	0
two	0
hematopoietic	9
cell	10
specific	10
molecules	10
,	0
are	0
critical	0
for	0
T	0
cell	0
development	0
and	0
activation	0
.	0

Following	0
T	9
cell	10
antigen	10
receptor	10
stimulation	0
,	0
SLP-76	9
and	0
Vav	9
both	0
undergo	0
tyrosine	0
phosphorylation	0
and	0
associate	0
with	0
each	0
other	0
via	0
the	0
SH2	0
domain	0
of	0
Vav	9
and	0
phosphorylated	0
tyrosines	0
of	0
SLP-76	9
.	0

Furthermore	0
,	0
SLP-76	9
and	0
Vav	9
have	0
a	0
synergistic	0
effect	0
on	0
interleukin	1
(	2
IL	2
)	2
-2	2
promoter	2
activity	0
in	0
T	5
cells	6
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
two	0
tyrosines	0
,	0
Tyr-113	0
and	0
Tyr-128	0
,	0
of	0
SLP-76	9
are	0
required	0
for	0
its	0
binding	0
to	0
Vav	9
,	0
both	0
in	0
vitro	0
and	0
in	0
intact	7
cells	8
.	0

Surprisingly	0
,	0
we	0
find	0
also	0
that	0
the	0
interaction	0
between	0
SLP-76	9
and	0
Vav	9
is	0
not	0
required	0
for	0
their	0
cooperation	0
in	0
augmenting	0
IL-2	1
promoter	2
activity	0
,	0
as	0
the	0
two	0
molecules	0
appear	0
to	0
function	0
in	0
different	0
signaling	0
pathways	0
upstream	0
of	0
IL-2	1
gene	2
expression	0
.	0

Overexpression	0
of	0
SLP-76	9
in	0
the	0
Jurkat	5
T	6
cell	6
line	6
potentiates	0
the	0
activities	0
of	0
both	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
and	0
AP-1	9
transcription	10
factors	10
.	0

In	0
contrast	0
,	0
overexpression	0
of	0
Vav	9
leads	0
to	0
enhanced	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
activity	0
without	0
affecting	0
AP-1	9
.	0

Additionally	0
,	0
overexpression	0
of	0
Vav	9
,	0
but	0
not	0
SLP-76	9
,	0
augments	0
CD28-induced	0
IL-2	1
promoter	2
activity	0
.	0

These	0
findings	0
suggest	0
that	0
the	0
synergy	0
between	0
SLP-76	9
and	0
Vav	9
in	0
regulating	0
IL-2	1
gene	2
expression	0
reflects	0
the	0
cooperation	0
between	0
different	0
signaling	0
pathways	0
.	0

Rel/NF-kappaB	9
can	0
trigger	0
the	0
Notch	0
signaling	0
pathway	0
by	0
inducing	0
the	0
expression	0
of	0
Jagged1	9
,	0
a	0
ligand	0
for	0
Notch	9
receptors	10
.	0

Jagged1	9
belongs	0
to	0
the	0
DSL	9
family	10
of	10
ligands	10
for	0
Notch	9
receptors	10
that	0
control	0
the	0
proliferation	0
and	0
differentiation	0
of	0
various	0
cell	7
lineages	8
.	0

However	0
,	0
little	0
is	0
known	0
about	0
the	0
transcription	9
factors	10
that	0
regulate	0
its	0
expression	0
.	0

Here	0
,	0
we	0
show	0
that	0
Jagged1	9
is	0
a	0
Rel/NF-kappaB-responsive	1
gene	2
.	0

Both	0
c-Rel	9
and	0
RelA	9
induced	0
jagged1	0
gene	0
expression	0
,	0
whereas	0
a	0
mutant	0
defective	0
for	0
transactivation	0
did	0
not	0
.	0

Importantly	0
,	0
jagged1	9
transcripts	10
were	0
also	0
upregulated	0
by	0
endogenous	0
NF-kappaB	9
activation	0
and	0
this	0
effect	0
was	0
inhibited	0
by	0
a	0
dominant	0
mutant	0
of	0
IkappaBalpha	9
,	0
a	0
physiological	0
inhibitor	0
of	0
NF-kappaB	9
.	0

Cell	0
surface	0
expression	0
of	0
Jagged1	9
in	0
c-Rel-expressing	5
cell	6
monolayers	6
led	0
to	0
a	0
functional	0
interaction	0
with	0
lymphocytes	7
expressing	0
the	0
Notch1/TAN-1	9
receptor	10
.	0

This	0
correlated	0
with	0
the	0
initiation	0
of	0
signaling	0
downstream	0
of	0
Notch	0
,	0
as	0
evidenced	0
by	0
increased	0
levels	0
of	0
HES-1	3
transcripts	4
in	0
co-cultivated	5
T	6
cells	6
and	0
of	0
CD23	3
transcripts	4
in	0
co-cultivated	0
B	7
cells	8
.	0

Consistent	0
with	0
its	0
Rel/NF-kappaB	9
-dependent	0
induction	0
,	0
Jagged1	9
was	0
found	0
to	0
be	0
highly	0
expressed	0
in	0
splenic	7
B	8
cells	8
where	0
c-Rel	9
is	0
expressed	0
constitutively	0
.	0

These	0
results	0
demonstrate	0
that	0
c-Rel	9
can	0
trigger	0
the	0
Notch	0
signaling	0
pathway	0
in	0
neighboring	0
cells	0
by	0
inducing	0
jagged1	0
gene	0
expression	0
,	0
and	0
suggest	0
a	0
role	0
for	0
Jagged1	9
in	0
B-cell	0
activation	0
,	0
differentiation	0
or	0
function	0
.	0

These	0
findings	0
also	0
highlight	0
the	0
potential	0
for	0
an	0
interplay	0
between	0
the	0
Notch	0
and	0
NF-kappaB	0
signaling	0
pathways	0
in	0
the	0
immune	0
system	0
.	0

Bacterial	0
peptidoglycan	0
induces	0
CD14	9
-dependent	0
activation	0
of	0
transcription	9
factors	10
CREB/ATF	9
and	0
AP-1	9
.	0

Peptidoglycan	0
(	0
PGN	0
)	0
,	0
the	0
major	0
cell	0
wall	0
component	0
of	0
Gram-positive	0
bacteria	0
,	0
induces	0
secretion	0
of	0
cytokines	9
in	0
macrophages	7
through	0
CD14	9
,	0
the	0
pattern	0
recognition	0
receptor	0
that	0
binds	0
lipopolysaccharide	0
and	0
other	0
microbial	0
products	0
.	0

To	0
begin	0
to	0
elucidate	0
the	0
mechanisms	0
that	0
regulate	0
the	0
transcription	0
of	0
cytokine	1
genes	2
,	0
we	0
wanted	0
to	0
determine	0
which	0
transcription	9
factors	10
are	0
activated	0
by	0
PGN	0
in	0
mouse	5
RAW264.7	6
and	0
human	5
THP-1	6
macrophage	6
cells	6
.	0

Our	0
results	0
demonstrated	0
that	0
:	0
(	0
i	0
)	0
PGN	0
induced	0
phosphorylation	0
of	0
the	0
transcription	9
factors	10
ATF-1	9
and	0
CREB	9
;	0
(	0
ii	0
)	0
ATF-1	9
and	0
CREB	9
bound	0
DNA	0
as	0
a	0
dimer	0
and	0
induced	0
transcriptional	0
activation	0
of	0
a	0
CRE	1
reporter	2
plasmid	2
,	0
which	0
was	0
inhibited	0
by	0
dominant	0
negative	0
CREB	9
and	0
ATF-1	9
;	0
(	0
iii	0
)	0
PGN	0
induced	0
phosphorylation	0
of	0
c-Jun	9
,	0
protein	0
synthesis	0
of	0
JunB	9
and	0
c-Fos	9
,	0
and	0
transcriptional	0
activation	0
of	0
the	0
AP-1	1
reporter	2
plasmid	2
,	0
which	0
was	0
inhibited	0
by	0
dominant	0
negative	0
c-Fos	9
;	0
and	0
(	0
iv	0
)	0
PGN-induced	0
activation	0
of	0
CREB/ATF	9
and	0
AP-1	9
was	0
mediated	0
through	0
CD14	9
.	0

This	0
is	0
the	0
first	0
study	0
to	0
demonstrate	0
activation	0
of	0
CREB/ATF	9
and	0
AP-1	9
transcription	10
factors	10
by	0
PGN	0
or	0
by	0
any	0
other	0
component	0
of	0
Gram-positive	0
bacteria	0
.	0

Glucocorticoid	9
receptors	10
are	0
down-regulated	0
in	0
inflamed	0
colonic	0
mucosa	0
but	0
not	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
patients	0
with	0
inflammatory	0
bowel	0
disease	0
[	0
see	0
comments	0
]	0

BACKGROUND	0
:	0
Growing	0
evidence	0
indicates	0
that	0
the	0
immune	0
system	0
and	0
the	0
hypothalamic-pituitary-adrenal	0
system	0
are	0
linked	0
by	0
several	0
mechanisms	0
,	0
for	0
example	0
intracellular	0
glucocorticoid	9
receptors	10
(	0
hGR	9
)	0
.	0

Glucocorticoids	0
are	0
the	0
standard	0
treatment	0
of	0
acute	0
attacks	0
of	0
inflammatory	0
bowel	0
disease	0
(	0
IBD	0
)	0
.	0

Binding	0
of	0
glucocorticoids	0
to	0
hGR	9
down-regulates	0
the	0
transcription	0
of	0
inflammatory	1
genes	2
that	0
can	0
propagate	0
IBD	0
.	0

PATIENTS	0
AND	0
METHODS	0
:	0
IBD	0
patients	0
were	0
either	0
treated	0
with	0
5-60	0
mg	0
of	0
prednisolone	0
for	0
more	0
than	0
1	0
week	0
or	0
were	0
without	0
glucocorticoid	0
treatment	0
for	0
more	0
than	0
4	0
weeks	0
.	0

hGR	9
levels	0
were	0
determined	0
from	0
isolated	0
cytosol	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
or	0
mucosal	0
biopsies	0
using	0
a	0
radioassay	0
with	0
[	0
3H	0
]	0
-dexamethasone	0
.	0

Interleukin	0
(	0
IL	0
)	0
6	0
levels	0
were	0
determined	0
by	0
enzyme-linked	0
immunosorbent	0
assay	0
(	0
ELISA	0
)	0
.	0

RESULTS	0
:	0
The	0
systemic	0
(	0
PBMC	0
)	0
hGR	9
levels	0
of	0
corticosteroid-treated	0
IBD	0
patients	0
were	0
significantly	0
lower	0
than	0
those	0
of	0
control	0
subjects	0
(	0
59.6	0
+/-	0
57.1	0
dpm	0
mg-1	0
cytosol	9
protein	10
vs	0
.	0

227.0	0
+/-	0
90.8	0
dpm	0
mg-1	0
cytosol	9
protein	10
,	0
P	0
=	0
0.007	0
)	0
and	0
IBD	0
patients	0
not	0
receiving	0
glucocorticoid	0
treatment	0
(	0
179.7	0
+/-	0
171.3	0
dpm	0
mg-1	0
cytosol	9
protein	10
,	0
P	0
=	0
0.002	0
)	0
.	0

Systemic	0
hGR	9
levels	0
in	0
untreated	0
IBD	0
patients	0
did	0
not	0
differ	0
significantly	0
from	0
those	0
in	0
control	0
subjects	0
.	0

In	0
patients	0
with	0
connective	0
tissue	0
diseases	0
,	0
systemic	0
hGR	9
levels	0
were	0
also	0
found	0
to	0
be	0
decreased	0
in	0
the	0
absence	0
of	0
glucocorticoid	0
treatment	0
.	0

Systemic	0
hGR	9
levels	0
in	0
patients	0
with	0
Crohn	0
's	0
disease	0
(	0
CD	0
)	0
treated	0
with	0
steroids	0
(	0
66.6	0
+/-	0
61.0	0
dpm	0
mg-1	0
cytosol	9
protein	10
)	0
were	0
not	0
different	0
from	0
those	0
in	0
patients	0
with	0
ulcerative	0
colitis	0
(	0
UC	0
)	0
(	0
56.1	0
+/-	0
51.6	0
dpm	0
mg-1	0
cytosol	9
protein	10
)	0
.	0

In	0
contrast	0
to	0
these	0
findings	0
,	0
mucosal	0
hGR	9
levels	0
were	0
significantly	0
decreased	0
in	0
both	0
steroid-treated	0
(	0
18.0	0
+/-	0
15.5	0
)	0
and	0
not	0
steroid-treated	0
(	0
37.8	0
+/-	0
30.5	0
)	0
patients	0
compared	0
with	0
control	0
subjects	0
(	0
125.6	0
+/-	0
97.1	0
;	0
P	0
=	0
0.00009	0
and	0
P	0
=	0
0.0008	0
respectively	0
)	0
.	0

IL-6	0
levels	0
in	0
all	0
IBD	0
groups	0
with	0
and	0
without	0
steroids	0
were	0
significantly	0
different	0
from	0
those	0
in	0
control	0
subjects	0
.	0

CONCLUSION	0
:	0
In	0
IBD	0
there	0
is	0
no	0
difference	0
in	0
systemic	0
hGR	9
levels	0
between	0
not	0
steroid-treated	0
patients	0
and	0
control	0
subjects	0
,	0
in	0
spite	0
of	0
inflammatory	0
activity	0
(	0
IL-6	9
)	0
.	0

Mucosal	0
hGR	9
levels	0
were	0
decreased	0
independently	0
of	0
treatment	0
,	0
probably	0
leading	0
to	0
a	0
decreased	0
protection	0
against	0
NF-kappaB	9
action	0
in	0
the	0
intestinal	0
mucosa	0
.	0

ICSAT	9
overexpression	0
is	0
not	0
sufficient	0
to	0
cause	0
adult	0
T-cell	0
leukemia	0
or	0
multiple	0
myeloma	0
.	0

ICSAT	9
(	0
Interferon	9
Consensus	10
Sequence	10
binding	10
protein	10
for	10
Activated	10
T	10
cells	10
)	0
is	0
a	0
lymphocyte-specific	0
member	0
of	0
the	0
interferon	9
regulatory	10
factor	10
(	10
IRF	10
)	10
family	10
of	0
transcription	0
factors	0
,	0
originally	0
identified	0
through	0
Southwestern	0
screening	0
of	0
the	0
ATL	1
(	2
Adult	2
T-cell	2
leukemia	2
)	2
-16T	2
expression	2
library	2
.	0

In	0
this	0
study	0
,	0
we	0
created	0
transgenic	0
mice	0
overexpressing	0
ICSAT	9
in	0
lymphocytes	7
.	0

Although	0
spontaneous	0
tumorigenesis	0
was	0
not	0
observed	0
,	0
IL-2	9
production	0
with	0
Concanavalin	0
A	0
stimulation	0
was	0
significantly	0
increased	0
in	0
transgenic	0
mice	0
overexpressing	0
ICSAT	9
.	0

ICSAT	9
overexpression	0
in	0
lymphocytes	7
seems	0
insufficient	0
for	0
the	0
leukemogenesis	0
of	0
ATL	0
or	0
multiple	0
myeloma	0
(	0
MM	0
)	0
,	0
however	0
,	0
it	0
may	0
regulate	0
T	0
cell	0
activation	0
and	0
its	0
overexpression	0
may	0
lead	0
to	0
leukemogenesis	0
via	0
controlling	0
IL-2	9
production	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Altered	0
memory	7
T	8
cell	8
differentiation	0
in	0
patients	0
with	0
early	0
rheumatoid	0
arthritis	0
.	0

The	0
chronic	0
immune	0
response	0
in	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
might	0
be	0
driven	0
by	0
activated	0
Th1	0
cells	0
without	0
sufficient	0
Th2	0
cell	0
differentiation	0
to	0
down-modulate	0
inflammation	0
.	0

To	0
test	0
whether	0
disordered	0
memory	7
T	8
cell	8
differentiation	0
contributes	0
to	0
the	0
typical	0
Th1-dominated	0
chronic	0
inflammation	0
in	0
RA	0
we	0
investigated	0
differentiation	0
of	0
resting	7
CD4+	8
memory	8
T	8
cells	8
in	0
patients	0
with	0
early	0
(	0
6	0
wk	0
to	0
12	0
mo	0
)	0
untreated	0
RA	0
and	0
in	0
age-	0
and	0
sex-matched	0
healthy	0
controls	0
in	0
vitro	0
.	0

No	0
difference	0
in	0
cytokine	9
secretion	0
profiles	0
of	0
freshly	7
isolated	8
memory	8
T	8
cells	8
was	0
detected	0
between	0
patients	0
and	0
controls	0
.	0

A	0
cell	5
culture	6
system	6
was	0
then	0
employed	0
that	0
permitted	0
the	0
differentiation	0
of	0
Th	9
effectors	10
from	0
resting	7
memory	8
T	8
cells	8
by	0
short	0
term	0
priming	0
.	0

Marked	0
differences	0
were	0
found	0
in	0
response	0
to	0
priming	0
.	0

Th2	5
cells	6
could	0
be	0
induced	0
in	0
all	0
healthy	0
controls	0
by	0
priming	0
with	0
anti-CD28	9
in	0
the	0
absence	0
of	0
TCR	9
ligation	0
.	0

By	0
contrast	0
,	0
priming	0
under	0
those	0
conditions	0
resulted	0
in	0
Th2	0
differentiation	0
in	0
only	0
9	0
of	0
24	0
RA	0
patients	0
.	0

Exogenous	0
IL-4	9
could	0
overcome	0
the	0
apparent	0
Th2	0
differentiation	0
defect	0
in	0
seven	0
patients	0
but	0
was	0
without	0
effect	0
in	0
the	0
remaining	0
eight	0
patients	0
.	0

In	0
all	0
patients	0
a	0
marked	0
decrease	0
in	0
IL-2-producing	7
cells	8
and	0
a	0
significant	0
increase	0
in	0
well-differentiated	0
Th1	7
cells	8
that	0
produced	0
IFN-gamma	9
but	0
not	0
IL-2	9
were	0
evident	0
after	0
priming	0
with	0
anti-CD3	9
and	0
anti-CD28	9
.	0

The	0
data	0
suggest	0
that	0
CD4+	7
memory	8
T	8
cells	8
from	0
patients	0
with	0
early	0
untreated	0
RA	0
manifest	0
an	0
intrinsic	0
abnormality	0
in	0
their	0
ability	0
to	0
differentiate	0
into	0
specific	0
cytokine-producing	7
effector	8
cells	8
that	0
might	0
contribute	0
to	0
the	0
characteristic	0
Th1-dominated	0
chronic	0
(	0
auto	0
)	0
immune	0
inflammation	0
in	0
RA	0
.	0

The	0
intracellular	0
parasite	0
Theileria	0
parva	0
protects	0
infected	7
T	8
cells	8
from	0
apoptosis	0
.	0

Parasites	0
have	0
evolved	0
a	0
plethora	0
of	0
strategies	0
to	0
ensure	0
their	0
survival	0
.	0

The	0
intracellular	0
parasite	0
Theileria	0
parva	0
secures	0
its	0
propagation	0
and	0
spreads	0
through	0
the	0
infected	0
animal	0
by	0
infecting	0
and	0
transforming	0
T	7
cells	8
,	0
inducing	0
their	0
continuous	0
proliferation	0
and	0
rendering	0
them	0
metastatic	0
.	0

In	0
previous	0
work	0
,	0
we	0
have	0
shown	0
that	0
the	0
parasite	0
induces	0
constitutive	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
,	0
by	0
inducing	0
the	0
constitutive	0
degradation	0
of	0
its	0
cytoplasmic	9
inhibitors	10
.	0

The	0
biological	0
significance	0
of	0
NF-kappaB	9
activation	0
in	0
T.	7
parva-infected	8
cells	8
,	0
however	0
,	0
has	0
not	0
yet	0
been	0
defined	0
.	0

Cells	0
that	0
have	0
been	0
transformed	0
by	0
viruses	0
or	0
oncogenes	1
can	0
persist	0
only	0
if	0
they	0
manage	0
to	0
avoid	0
destruction	0
by	0
the	0
apoptotic	0
mechanisms	0
that	0
are	0
activated	0
on	0
transformation	0
and	0
that	0
contribute	0
to	0
maintain	0
cellular	0
homeostasis	0
.	0

We	0
now	0
demonstrate	0
that	0
parasite-induced	0
NF-kappaB	9
activation	0
plays	0
a	0
crucial	0
role	0
in	0
the	0
survival	0
of	0
T.	7
parva-transformed	8
T	8
cells	8
by	0
conveying	0
protection	0
against	0
an	0
apoptotic	0
signal	0
that	0
accompanies	0
parasite-mediated	0
transformation	0
.	0

Consequently	0
,	0
inhibition	0
of	0
NF-kappaB	9
nuclear	0
translocation	0
and	0
the	0
expression	0
of	0
dominant	9
negative	10
mutant	10
forms	0
of	0
components	0
of	0
the	0
NF-kappaB	9
activation	0
pathway	0
,	0
such	0
as	0
IkappaBalpha	9
or	0
p65	9
,	0
prompt	0
rapid	0
apoptosis	0
of	0
T.	7
parva-transformed	8
T	8
cells	8
.	0

Our	0
findings	0
offer	0
important	0
insights	0
into	0
parasite	0
survival	0
strategies	0
and	0
demonstrate	0
that	0
parasite-induced	0
constitutive	0
NF-kappaB	9
activation	0
is	0
an	0
essential	0
step	0
in	0
maintaining	0
the	0
transformed	0
phenotype	0
of	0
the	0
infected	7
cells	8
.	0

A	0
polymorphism	0
that	0
affects	0
OCT-1	9
binding	0
to	0
the	0
TNF	1
promoter	2
region	2
is	0
associated	0
with	0
severe	0
malaria	0
[	0
see	0
comments	0
]	0

Genetic	0
variation	0
in	0
cytokine	1
promoter	2
regions	2
is	0
postulated	0
to	0
influence	0
susceptibility	0
to	0
infection	0
,	0
but	0
the	0
molecular	0
mechanisms	0
by	0
which	0
such	0
polymorphisms	0
might	0
affect	0
gene	0
regulation	0
are	0
unknown	0
.	0

Through	0
systematic	0
DNA	0
footprinting	0
of	0
the	0
TNF	0
(	0
encoding	0
tumour	0
necrosis	0
factor	0
,	0
TNF	0
)	0
promoter	0
region	0
,	0
we	0
have	0
identified	0
a	0
single	0
nucleotide	0
polymorphism	0
(	0
SNP	0
)	0
that	0
causes	0
the	0
helix-turn-helix	0
transcription	9
factor	10
OCT-1	0
to	0
bind	0
to	0
a	0
novel	0
region	0
of	0
complex	0
protein-DNA	0
interactions	0
and	0
alters	0
gene	0
expression	0
in	0
human	7
monocytes	8
.	0

The	0
OCT-1-binding	0
genotype	0
,	0
found	0
in	0
approximately	0
5	0
%	0
of	0
Africans	0
,	0
is	0
associated	0
with	0
fourfold	0
increased	0
susceptibility	0
to	0
cerebral	0
malaria	0
in	0
large	0
case-control	0
studies	0
of	0
West	0
African	0
and	0
East	0
African	0
populations	0
,	0
after	0
correction	0
for	0
other	0
known	0
TNF	0
polymorphisms	0
and	0
linked	0
HLA	1
alleles	2
.	0

UV-induced	0
CYP1A1	9
gene	0
expression	0
in	0
human	0
cells	0
is	0
mediated	0
by	0
tryptophan	0
.	0

Induction	0
of	0
cytochrome	9
P-4501A1	10
(	0
CYP1A1	9
)	0
activity	0
by	0
UV	0
has	0
been	0
observed	0
earlier	0
in	0
animal	0
studies	0
via	0
a	0
mechanism	0
that	0
has	0
not	0
yet	0
been	0
resolved	0
.	0

Our	0
previous	0
data	0
have	0
indicated	0
that	0
formylated	0
indolocarbazoles	0
which	0
are	0
formed	0
by	0
UV	0
irradiation	0
of	0
tryptophan	0
solutions	0
are	0
very	0
potent	0
Ah-receptor	0
agonists	0
.	0

To	0
evaluate	0
the	0
effect	0
of	0
UV	0
light	0
on	0
cytochrome	9
P4501A1	10
gene	0
expression	0
,	0
we	0
studied	0
the	0
induction	0
of	0
CYP1A1	3
mRNA	4
by	0
UV	0
irradiation	0
of	0
cultured	5
human	6
keratinocytes	6
(	0
HaCaT	5
cell	6
line	6
)	0
,	0
primary	7
human	8
blood	8
lymphocytes	8
and	0
mouse	5
Hepa-1	6
cells	6
.	0

The	0
cells	0
were	0
exposed	0
to	0
UV	0
light	0
delivered	0
by	0
a	0
bank	0
of	0
6	0
Philips	0
TL20/12RS	0
sun	0
lamps	0
emitting	0
primarily	0
in	0
the	0
UVB	0
range	0
in	0
the	0
absence	0
and	0
presence	0
of	0
tryptophan	0
.	0

A	0
semiquantitative	0
reverse	9
transcriptase	10
-linked	0
polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
was	0
used	0
for	0
analysis	0
of	0
gene	0
expression	0
in	0
the	0
treated	7
cells	8
.	0

The	0
results	0
show	0
that	0
the	0
CYP1A1	3
mRNA	4
level	0
induced	0
by	0
UV	0
in	0
the	0
presence	0
of	0
tryptophan	0
was	0
higher	0
than	0
that	0
induced	0
by	0
UV	0
alone	0
in	0
both	0
HaCaT	5
cells	6
and	0
lymphocytes	7
after	0
3	0
h	0
of	0
incubation	0
post-UV	0
irradiation	0
.	0

To	0
find	0
out	0
if	0
the	0
induction	0
by	0
UV	0
light	0
is	0
caused	0
by	0
the	0
formation	0
of	0
an	0
Ah	0
receptor	0
ligand	0
,	0
Hepa-1	5
wild-type	6
and	6
Ah	6
receptor	6
deficient	6
c12	6
cell	6
lines	6
were	0
applied	0
.	0

Wild-type	5
(	6
wt	6
)	6
cells	6
were	0
inducible	0
either	0
by	0
the	0
tryptophan	0
photoproduct	0
6-formylindolo	0
[	0
3	0
,	0
2-b	0
]	0
carbazole	0
(	0
FICZ	0
)	0
or	0
by	0
UV-irradiation	0
but	0
very	0
low	0
or	0
undetectable	0
levels	0
were	0
observed	0
in	0
the	0
c12	7
cells	8
.	0

This	0
shows	0
that	0
the	0
induction	0
of	0
gene	0
expression	0
by	0
FICZ	0
and	0
UV	0
is	0
Ah	9
receptor	10
dependent	0
.	0

Together	0
,	0
these	0
results	0
indicate	0
that	0
UV-induced	0
CYP1A1	9
gene	0
expression	0
in	0
mammalian	7
cells	8
is	0
mediated	0
by	0
an	0
Ah	9
receptor	10
ligand	0
formed	0
from	0
tryptophan	0
.	0

Thus	0
,	0
the	0
photoproducts	0
of	0
tryptophan	0
are	0
suggested	0
to	0
be	0
mediators	0
of	0
light	0
via	0
binding	0
to	0
the	0
Ah	9
receptor	10
and	0
as	0
such	0
also	0
could	0
have	0
a	0
role	0
in	0
light-regulated	0
biological	0
rhythms	0
.	0

Repression	0
by	0
Ikaros	9
and	0
Aiolos	9
is	0
mediated	0
through	0
histone	9
deacetylase	10
complexes	10
.	0

Here	0
we	0
show	0
that	0
the	0
lymphoid	9
lineage-determining	10
factors	10
Ikaros	9
and	0
Aiolos	9
can	0
function	0
as	0
strong	9
transcriptional	10
repressors	10
.	0

This	0
function	0
is	0
mediated	0
through	0
two	0
repression	9
domains	10
and	0
is	0
dependent	0
upon	0
the	0
promoter	0
context	0
and	0
cell	0
type	0
.	0

Repression	0
by	0
Ikaros	9
proteins	10
correlates	0
with	0
hypo-acetylation	0
of	0
core	9
histones	10
at	0
promoter	1
sites	2
and	0
is	0
relieved	0
by	0
histone	9
deacetylase	10
inhibitors	0
.	0

Consistent	0
with	0
these	0
findings	0
,	0
Ikaros	9
and	0
its	0
repression	9
domains	10
can	0
interact	0
in	0
vivo	0
and	0
in	0
vitro	0
with	0
the	0
mSin3	9
family	10
of	0
co-repressors	0
which	0
bind	0
to	0
histone	9
deacetylases	10
.	0

Based	0
on	0
these	0
and	0
our	0
recent	0
findings	0
of	0
associations	0
between	0
Ikaros	9
and	0
Mi-2-HDAC	9
,	0
we	0
propose	0
that	0
Ikaros	9
family	10
members	10
modulate	0
gene	0
expression	0
during	0
lymphocyte	0
development	0
by	0
recruiting	0
distinct	0
histone	9
deacetylase	10
complexes	10
to	0
specific	1
promoters	2
.	0

Protein	9
kinase	10
B	10
(	0
c-Akt	9
)	0
,	0
phosphatidylinositol	9
3-kinase	10
,	0
and	0
STAT5	9
are	0
activated	0
by	0
erythropoietin	9
(	0
EPO	9
)	0
in	0
HCD57	5
erythroid	6
cells	6
but	0
are	0
constitutively	0
active	0
in	0
an	0
EPO-independent	5
,	6
apoptosis-resistant	6
subclone	6
(	0
HCD57-SREI	5
cells	6
)	0
.	0

We	0
found	0
that	0
erythropoietin	9
(	0
EPO	9
)	0
and	0
stem	9
cell	10
factor	10
(	0
SCF	9
)	0
activated	9
protein	10
kinase	10
B	10
(	0
PKB/Akt	9
)	0
in	0
EPO-dependent	5
HCD57	6
erythroid	6
cells	6
.	0

To	0
better	0
understand	0
signals	0
controlling	0
proliferation	0
and	0
viability	0
,	0
erythroid	0
cells	0
that	0
resist	0
apoptosis	0
in	0
the	0
absence	0
of	0
EPO	9
were	0
subcloned	0
and	0
characterized	0
(	0
HCD57-SREI	5
cells	6
)	0
.	0

Constitutive	0
activations	0
of	0
PKB/Akt	9
,	0
STAT5a	9
,	0
and	0
STAT5b	9
were	0
noted	0
in	0
these	0
EPO-independent	5
cells	6
.	0

PI3-kinase	9
activity	0
was	0
an	0
upstream	0
activator	0
of	0
PKB/Akt	9
because	0
the	0
PI3-kinase	9
inhibitor	0
LY294002	0
blocked	0
both	0
constitutive	0
PKB/Akt	9
and	0
factor-dependent	0
PKB/Akt	9
activity	0
.	0

The	0
LY294002	0
study	0
showed	0
that	0
proliferation	0
and	0
viability	0
of	0
both	0
HCD57-SREI	5
and	0
HCD57	5
cells	6
correlated	0
with	0
the	0
activity	0
of	0
PKB/Akt	9
;	0
however	0
,	0
PKB/Akt	9
activity	0
alone	0
did	0
not	0
protect	0
these	0
cells	0
from	0
apoptosis	0
.	0

Treatment	0
of	0
HCD57	5
cells	6
with	0
SCF	9
also	0
activated	0
PKB/Akt	9
,	0
but	0
did	0
not	0
protect	0
from	0
apoptosis	0
.	0

This	0
result	0
suggested	0
that	0
PKB/PI3-kinase	9
activity	0
is	0
necessary	0
but	0
not	0
sufficient	0
to	0
promote	0
viability	0
and/or	0
proliferation	0
.	0

Constitutive	0
STAT5	9
activity	0
,	0
activated	0
through	0
an	0
unknown	0
pathway	0
not	0
including	0
JAK2	9
or	0
EPOR	9
,	0
may	0
act	0
in	0
concert	0
with	0
the	0
constitutive	0
PI3-kinase	9
/PKB/Akt	9
pathway	0
to	0
protect	0
the	0
EPO-independent	5
HCD57-SREI	6
cells	6
from	0
apoptosis	0
and	0
promote	0
limited	0
proliferation	0
.	0

Disruption	0
of	0
alpha	0
beta	0
but	0
not	0
of	0
gamma	0
delta	0
T	0
cell	0
development	0
by	0
overexpression	0
of	0
the	0
helix-loop-helix	9
protein	10
Id3	9
in	0
committed	7
T	8
cell	8
progenitors	8
.	0

Enforced	0
expression	0
of	0
Id3	9
,	0
which	0
has	0
the	0
capacity	0
to	0
inhibit	0
many	0
basic	9
helix-loop-helix	10
(	10
bHLH	10
)	10
transcription	10
factors	10
,	0
in	0
human	7
CD34	8
(	8
+	8
)	8
hematopoietic	8
progenitor	8
cells	8
that	0
have	0
not	0
undergone	0
T	1
cell	2
receptor	2
(	2
TCR	2
)	2
gene	2
rearrangements	2
inhibits	0
development	0
of	0
the	0
transduced	7
cells	8
into	0
TCRalpha	5
beta	6
and	6
gamma	6
delta	6
cells	6
in	0
a	0
fetal	5
thymic	6
organ	6
culture	6
(	0
FTOC	5
)	0
.	0

Here	0
we	0
document	0
that	0
overexpression	0
of	0
Id3	9
,	0
in	0
progenitors	7
that	0
have	0
initiated	0
TCR	1
gene	2
rearrangements	2
(	0
pre-T	7
cells	8
)	0
,	0
inhibits	0
development	0
into	0
TCRalpha	5
beta	6
but	0
not	0
into	0
TCRgamma	5
delta	6
T	6
cells	6
.	0

Furthermore	0
,	0
Id3	9
impedes	0
expression	0
of	0
recombination	0
activating	0
genes	0
and	0
downregulates	0
pre-Talpha	3
mRNA	4
.	0

These	0
observations	0
suggest	0
possible	0
mechanisms	0
by	0
which	0
Id3	9
overexpression	0
can	0
differentially	0
affect	0
development	0
of	0
pre-T	7
cells	8
into	0
TCRalpha	5
beta	6
and	6
gamma	6
delta	6
cells	6
.	0

We	0
also	0
observed	0
that	0
cell	7
surface	8
CD4	8
(	8
-	8
)	8
CD8	8
(	8
-	8
)	8
CD3	8
(	8
-	8
)	8
cells	8
with	0
rearranged	1
TCR	2
genes	2
developed	0
from	0
Id3-transduced	5
but	0
not	0
from	0
control-transduced	5
pre-T	6
cells	6
in	0
an	0
FTOC	5
.	0

These	0
cells	0
had	0
properties	0
of	0
both	0
natural	7
killer	8
(	0
NK	7
)	0
and	0
pre-T	7
cells	8
.	0

These	0
findings	0
suggest	0
that	0
bHLH	9
factors	10
are	0
required	0
to	0
control	0
T	0
cell	0
development	0
after	0
the	0
T/NK	0
developmental	0
checkpoint	0
.	0

HIV-1	0
reactivation	0
in	0
resting	7
peripheral	8
blood	8
mononuclear	8
cells	8
of	0
infected	0
adults	0
upon	0
in	0
vitro	0
CD4	9
cross-linking	0
by	0
ligands	0
of	0
the	0
CDR2-loop	9
in	0
extracellular	9
domain	10
1	10
.	0

HIV-1	0
infects	0
resting	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
but	0
remains	0
inactive	0
state	0
until	0
subsequent	0
cell	0
activation	0
.	0

We	0
have	0
demonstrated	0
that	0
the	0
cross-linking	0
of	0
cell	9
surface	10
CD4	10
by	0
gp120-anti-gp120	9
immune	10
complexes	10
or	0
heat-inactivated	0
HIV-1	0
(	0
iHIV-1	0
)	0
is	0
sufficient	0
to	0
trigger	0
activation	0
signals	0
leading	0
to	0
virus	0
reactivation	0
(	0
9	0
)	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
NF-kappaB	9
nuclear	0
translocation	0
and	0
stimulation	0
of	0
virus	0
production	0
by	0
iHIV-1	0
were	0
strictly	0
linked	0
to	0
the	0
concentrations	0
of	0
viral	9
proteins	10
used	0
as	0
exogenous	0
stimuli	0
.	0

Moreover	0
,	0
we	0
further	0
investigated	0
the	0
physiologic	0
relevance	0
of	0
these	0
observations	0
.	0

When	0
submitted	0
to	0
an	0
in	0
vitro	0
CD4	9
cross-linking	0
by	0
iHIV-1	0
,	0
PBMCs	7
from	0
HIV-1-infected	0
patients	0
were	0
found	0
to	0
produce	0
virus	0
.	0

This	0
viral	0
reactivation	0
was	0
associated	0
with	0
increased	0
NF-kappaB	9
nuclear	0
translocation	0
in	0
patients	0
'	0
PBMCs	7
.	0

Additionally	0
,	0
virus	0
reactivation	0
in	0
resting	7
PBMCs	8
infected	0
in	0
vitro	0
with	0
HIV-1	0
was	0
found	0
to	0
be	0
specifically	0
induced	0
by	0
ligands	0
of	0
the	0
CDR2-loop	9
in	0
domain	9
1	10
(	0
D1	9
)	0
of	0
CD4	9
(	0
virus	9
envelope	10
and	10
anti-CD4	10
monoclonal	10
antibodies	10
)	0
.	0

In	0
contrast	0
,	0
virus	0
reactivation	0
was	0
not	0
observed	0
following	0
CD4	9
oligomerization	0
by	0
antibodies	9
that	0
bind	0
other	0
epitopes	0
in	0
D1	9
,	0
including	0
the	0
D1/CDR3-loop	9
.	0

Finally	0
,	0
soluble	9
CD4	10
(	0
sCD4	9
)	0
prevented	0
virus	0
reactivation	0
by	0
D1/CDR2-loop	9
ligands	10
.	0

Our	0
results	0
indicate	0
that	0
the	0
signaling	0
events	0
initiated	0
in	0
PBMCs	7
by	0
oligomerization	0
of	0
CD4	9
at	0
the	0
D1/CDR2-loop	9
can	0
trigger	0
HIV-1	0
upregulation	0
in	0
infected	0
individuals	0
.	0

Signaling	0
through	0
the	0
lymphotoxin-beta	9
receptor	10
stimulates	0
HIV-1	0
replication	0
alone	0
and	0
in	0
cooperation	0
with	0
soluble	0
or	0
membrane-bound	9
TNF-alpha	10
.	0

The	0
level	0
of	0
ongoing	0
HIV-1	0
replication	0
within	0
an	0
individual	0
is	0
critical	0
to	0
HIV-1	0
pathogenesis	0
.	0

Among	0
host	0
immune	0
factors	0
,	0
the	0
cytokine	9
TNF-alpha	9
has	0
previously	0
been	0
shown	0
to	0
increase	0
HIV-1	0
replication	0
in	0
various	0
monocyte	0
and	0
T	0
cell	0
model	0
systems	0
.	0

Here	0
,	0
we	0
demonstrate	0
that	0
signaling	0
through	0
the	0
TNF	9
receptor	0
family	0
member	0
,	0
the	0
lymphotoxin-beta	9
(	10
LT-beta	10
)	10
receptor	10
(	0
LT-betaR	9
)	0
,	0
also	0
regulates	0
HIV-1	0
replication	0
.	0

Furthermore	0
,	0
HIV-1	0
replication	0
is	0
cooperatively	0
stimulated	0
when	0
the	0
distinct	0
LT-betaR	9
and	0
TNF	9
receptor	10
systems	10
are	0
simultaneously	0
engaged	0
by	0
their	0
specific	0
ligands	0
.	0

Moreover	0
,	0
in	0
a	0
physiological	0
coculture	0
cellular	0
assay	0
system	0
,	0
we	0
show	0
that	0
membrane-bound	9
TNF-alpha	10
and	0
LT-alpha1beta2	9
act	0
virtually	0
identically	0
to	0
their	0
soluble	0
forms	0
in	0
the	0
regulation	0
of	0
HIV-1	0
replication	0
.	0

Thus	0
,	0
cosignaling	0
via	0
the	0
LT-beta	9
and	10
TNF-alpha	10
receptors	10
is	0
probably	0
involved	0
in	0
the	0
modulation	0
of	0
HIV-1	0
replication	0
and	0
the	0
subsequent	0
determination	0
of	0
HIV-1	0
viral	0
burden	0
in	0
monocytes	7
.	0

Intriguingly	0
,	0
surface	0
expression	0
of	0
LT-alpha1beta2	9
is	0
up-regulated	0
on	0
a	0
T	5
cell	6
line	6
acutely	0
infected	0
with	0
HIV-1	0
,	0
suggesting	0
a	0
positive	0
feedback	0
loop	0
between	0
HIV-1	0
infection	0
,	0
LT-alpha1beta2	9
expression	0
,	0
and	0
HIV-1	0
replication	0
.	0

Given	0
the	0
critical	0
role	0
that	0
LT-alpha1beta2	9
plays	0
in	0
lymphoid	0
architecture	0
,	0
we	0
speculate	0
that	0
LT-alpha1beta2	9
may	0
be	0
involved	0
in	0
HIV-associated	0
abnormalities	0
of	0
the	0
lymphoid	0
organs	0
.	0

Monoclonal	9
anti-endothelial	10
cell	10
antibodies	10
from	0
a	0
patient	0
with	0
Takayasu	0
arteritis	0
activate	0
endothelial	0
cells	0
from	0
large	0
vessels	0
.	0

OBJECTIVE	0
:	0
To	0
create	0
monoclonal	9
anti-endothelial	10
cell	10
antibodies	10
(	0
mAECA	9
)	0
from	0
a	0
patient	0
with	0
Takayasu	0
arteritis	0
to	0
evaluate	0
their	0
ability	0
to	0
activate	0
human	5
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVEC	5
)	0
,	0
and	0
to	0
characterize	0
the	0
mechanism	0
of	0
EC	0
activation	0
.	0

METHODS	0
:	0
A	0
panel	0
of	0
mAECA	9
was	0
generated	0
from	0
peripheral	7
blood	8
lymphocytes	8
of	0
a	0
patient	0
with	0
Takayasu	0
arteritis	0
,	0
using	0
Epstein-Barr	0
virus	0
transformation	0
.	0

Activity	0
against	0
macrovascular	5
EC	6
(	0
HUVEC	5
)	0
and	0
microvascular	5
EC	6
(	0
human	5
bone	6
marrow	6
EC	6
immortalized	6
by	6
SV40	6
)	0
antigens	0
was	0
detected	0
by	0
enzyme-linked	0
immunosorbent	0
assay	0
.	0

Inhibition	0
studies	0
were	0
used	0
to	0
select	0
the	0
monoclonal	9
antibodies	10
(	0
mAECA	9
)	0
which	0
share	0
the	0
same	0
EC	0
epitope	0
binding	0
specificity	0
as	0
the	0
total	9
IgG-AECA	10
from	0
the	0
Takayasu	0
arteritis	0
patient	0
.	0

The	0
binding	0
of	0
the	0
mAECA	9
to	0
human	7
aortic	8
EC	8
was	0
studied	0
by	0
immunohistochemistry	0
.	0

The	0
secretion	0
levels	0
of	0
interleukin-6	9
(	0
IL-6	9
)	0
and	0
von	0
Willebrand	0
factor	0
(	0
vWF	0
)	0
were	0
determined	0
,	0
to	0
serve	0
as	0
markers	0
for	0
EC	0
activation	0
.	0

The	0
activated	5
EC	6
were	0
examined	0
for	0
the	0
adherence	0
of	0
a	0
monocytic	5
cell	6
line	6
(	0
U937	5
)	0
,	0
as	0
well	0
as	0
for	0
expression	0
of	0
vascular	9
cell	10
adhesion	10
molecule	10
1	10
,	0
intercellular	0
adhesion	0
molecule	0
1	0
,	0
and	0
E-selectin	9
.	0

In	0
addition	0
,	0
nuclear	0
extracts	0
of	0
the	0
mAECA-treated	5
EC	6
were	0
analyzed	0
for	0
the	0
induction	0
of	0
translocation	0
of	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
,	0
using	0
a	0
specific	0
NF-kappaB	9
oligoprobe	0
in	0
an	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

RESULTS	0
:	0
Six	0
mAECA	9
were	0
selected	0
,	0
the	0
mixture	0
of	0
which	0
produced	0
100	0
%	0
inhibition	0
of	0
binding	0
of	0
the	0
original	0
IgG	9
(	0
from	0
the	0
patient	0
with	0
Takayasu	0
arteritis	0
)	0
to	0
HUVEC	5
.	0

All	0
mAECA	9
possessed	0
high	0
activity	0
against	0
macrovascular	5
EC	6
,	0
but	0
none	0
had	0
significant	0
antimicrovascular	0
EC	0
activity	0
.	0

The	0
mAECA	9
,	0
but	0
not	0
normal	9
human	10
IgG	10
,	0
had	0
anti-human	0
aortic	0
EC	0
activity	0
.	0

Four	0
of	0
the	0
6	0
mAECA	9
activated	5
EC	6
,	0
manifested	0
by	0
increased	0
IL-6	9
and	0
vWF	0
secretion	0
.	0

The	0
4	0
mAECA	9
induced	0
EC	0
expression	0
of	0
adhesion	9
molecules	10
and	0
increased	0
adhesion	0
of	0
U937	7
monocytic	8
cells	8
to	0
EC	7
.	0

In	0
addition	0
,	0
these	0
mAECA	9
stimulated	0
the	0
nuclear	0
translocation	0
of	0
the	0
NF-kappaB	9
transcription	10
factor	10
.	0

CONCLUSION	0
:	0
Our	0
findings	0
suggest	0
that	0
AECA	9
may	0
directly	0
stimulate	0
EC	7
in	0
Takayasu	0
arteritis	0
through	0
elevation	0
of	0
adhesion	9
molecule	10
expression	0
associated	0
with	0
NF-kappaB	9
activation	0
and	0
adhesion	0
of	0
monocytes	7
,	0
and	0
may	0
therefore	0
play	0
a	0
pathogenic	0
role	0
in	0
the	0
development	0
of	0
the	0
vasculopathy	0
in	0
Takayasu	0
arteritis	0
.	0

Cutting	0
edge	0
:	0
expression	0
of	0
the	0
NF	9
of	10
activated	10
T	10
cells	10
in	0
eosinophils	7
:	0
regulation	0
by	0
IL-4	9
and	0
IL-5	9
.	0

We	0
report	0
that	0
NF-AT1	9
and	0
NF-AT4	9
are	0
expressed	0
cytoplasmically	0
in	0
resting	7
eosinophils	8
,	0
whereas	0
NF-AT2	9
and	0
NF-AT3	9
have	0
not	0
been	0
seen	0
.	0

Likewise	0
,	0
NF-AT1	3
mRNA	4
and	0
NF-AT4	3
mRNA	4
have	0
been	0
detected	0
in	0
resting	7
eosinophils	8
,	0
and	0
their	0
levels	0
can	0
be	0
significantly	0
up-regulated	0
by	0
the	0
Th2-associated	9
cytokines	10
IL-4	9
and	0
IL-5	9
.	0

There	0
is	0
no	0
detectable	0
NF-AT	9
protein	0
expression	0
in	0
the	0
nuclei	0
of	0
resting	7
eosinophils	8
.	0

However	0
NF-ATs	9
appear	0
in	0
the	0
nuclei	0
of	0
IL-4-	5
,	6
IL-5-	6
,	6
or	6
ionomycin-stimulated	6
eosinophils	6
.	0

Only	0
NF-AT1	9
and	0
NF-AT4	9
,	0
but	0
not	0
NF-AT2	9
and	0
NF-AT3	9
,	0
have	0
translocated	0
into	0
the	0
nuclei	0
in	0
IL-4-	5
or	6
IL-5-stimulated	6
eosinophils	6
.	0

These	0
findings	0
delineate	0
a	0
novel	0
pathway	0
in	0
the	0
cytokine	0
network	0
in	0
which	0
Th2	5
lymphocytes	6
``	0
control	0
''	0
eosinophils	7
via	0
the	0
release	0
of	0
IL-4	9
and	0
IL-5	9
,	0
and	0
activation	0
of	0
NF-AT	9
in	0
eosinophils	7
.	0

The	0
findings	0
also	0
suggest	0
that	0
a	0
later	0
feedback	0
``	0
talking	0
''	0
may	0
exist	0
between	0
eosinophils	7
and	0
Th2	5
lymphocytes	6
.	0

PPARalpha	0
activators	0
inhibit	0
cytokine-induced	0
vascular	9
cell	10
adhesion	10
molecule-1	10
expression	0
in	0
human	7
endothelial	8
cells	8
.	0

BACKGROUND	0
:	0
Adhesion	0
molecule	0
expression	0
on	0
the	0
endothelial	0
cell	0
(	0
EC	0
)	0
surface	0
is	0
critical	0
for	0
leukocyte	0
recruitment	0
to	0
atherosclerotic	0
lesions	0
.	0

Better	0
understanding	0
of	0
transcriptional	0
regulation	0
of	0
adhesion	9
molecules	10
in	0
ECs	7
may	0
provide	0
important	0
insight	0
into	0
plaque	0
formation	0
.	0

Peroxisome	9
proliferator-activated	10
receptor-alpha	10
(	0
PPARalpha	9
)	0
,	0
a	0
member	0
of	0
the	0
nuclear	9
receptor	10
family	10
,	0
regulates	0
gene	0
expression	0
in	0
response	0
to	0
certain	0
fatty	0
acids	0
and	0
fibric	0
acid	0
derivatives	0
.	0

The	0
present	0
study	0
investigated	0
PPARalpha	9
expression	0
in	0
human	7
ECs	8
and	0
their	0
regulation	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
Immunohistochemistry	0
revealed	0
that	0
human	7
carotid	8
artery	8
ECs	8
express	0
PPARalpha	9
.	0

Pretreatment	0
of	0
cultured	7
human	8
ECs	8
with	0
the	0
PPARalpha	9
activators	0
fenofibrate	0
or	0
WY14643	0
inhibited	0
TNF-alpha-induced	9
VCAM-1	10
in	0
a	0
time-	0
and	0
concentration-dependent	0
manner	0
,	0
an	0
effect	0
not	0
seen	0
with	0
PPARgamma	9
activators	0
.	0

Both	0
PPARalpha	9
activators	0
decreased	0
cytokine-induced	0
VCAM-1	9
mRNA	0
expression	0
without	0
altering	0
its	0
mRNA	0
half-life	0
.	0

Transient	0
transfection	0
of	0
deletional	0
VCAM-1	1
promoter	2
constructs	2
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
suggest	0
that	0
fenofibrate	0
inhibits	0
VCAM-1	9
transcription	0
in	0
part	0
by	0
inhibiting	0
NF-kappaB	9
.	0

Finally	0
,	0
PPARalpha	9
activators	0
significantly	0
reduced	0
adhesion	0
of	0
U937	5
cells	6
to	0
cultured	7
human	8
ECs	8
.	0

CONCLUSIONS	0
:	0
Human	7
ECs	8
express	0
PPARalpha	9
,	0
a	0
potentially	0
important	0
regulator	0
of	0
atherogenesis	0
through	0
its	0
transcriptional	0
control	0
of	0
VCAM-1	9
gene	0
expression	0
.	0

Such	0
findings	0
also	0
have	0
implications	0
regarding	0
the	0
clinical	0
use	0
of	0
lipid-lowering	0
agents	0
,	0
like	0
fibric	0
acids	0
,	0
which	0
can	0
activate	0
PPARalpha	9
.	0

CBP/p300	9
integrates	0
Raf	9
/	0
Rac	9
-signaling	0
pathways	0
in	0
the	0
transcriptional	0
induction	0
of	0
NF-ATc	9
during	0
T	0
cell	0
activation	0
.	0

NF-ATc	9
,	0
an	0
inducibly	0
expressed	0
transcription	9
factor	10
,	0
controls	0
gene	0
expression	0
in	0
T	7
lymphocytes	8
and	0
cardiomyocytes	7
.	0

We	0
show	0
here	0
that	0
the	0
transcriptional	9
co-activators	10
CBP/p300	9
bind	0
to	0
and	0
control	0
the	0
activity	0
of	0
the	0
inducible	9
N-terminal	10
transactivation	10
domain	10
of	0
NF-ATc	9
,	0
TAD-A	9
.	0

Similar	0
to	0
the	0
N	9
terminal	10
transactivation	10
domain	10
of	0
c-Jun	9
,	0
TAD-A	9
is	0
inducibly	0
phosphorylated	0
,	0
but	0
this	0
phosphorylation	0
is	0
dispensable	0
for	0
the	0
interaction	0
with	0
CBP/p300	9
.	0

Constitutive	0
active	0
versions	0
of	0
c-Raf	9
and	0
Rac	9
synergistically	0
enhance	0
the	0
CBP/p300	9
-mediated	0
increase	0
of	0
TAD-A	9
activity	0
,	0
indicating	0
the	0
important	0
role	0
CBP/p300	9
plays	0
in	0
the	0
integration	0
of	0
T	0
cell	0
activation	0
signals	0
.	0

Since	0
a	0
mutation	0
of	0
CBP	9
abolishing	0
HAT	0
activity	0
is	0
almost	0
as	0
active	0
as	0
wild-type	9
CBP	10
in	0
T	7
cells	8
,	0
functions	0
of	0
CBP/p300	9
other	0
than	0
histone	0
acetylation	0
appear	0
to	0
control	0
the	0
NF-AT	9
-dependent	0
transcription	0
in	0
T	7
cells	8
.	0

Immune	0
functions	0
,	0
clinical	0
parameters	0
and	0
hormone	0
receptor	0
status	0
in	0
breast	0
cancer	0
patients	0
.	0

We	0
have	0
carried	0
out	0
a	0
detailed	0
analysis	0
of	0
the	0
cellular	0
immune	0
functions	0
of	0
breast	0
cancer	0
patients	0
in	0
comparison	0
with	0
healthy	0
controls	0
.	0

A	0
possible	0
correlation	0
between	0
immune	0
and	0
clinical	0
parameters	0
was	0
analysed	0
in	0
50	0
breast	0
cancer	0
patients	0
.	0

Immune	0
parameters	0
,	0
natural	7
killer	8
cell	8
and	0
T	0
lymphocyte	0
functions	0
and	0
the	0
numbers	0
of	0
circulating	7
T	8
lymphocytes	8
were	0
analysed	0
against	0
the	0
clinical	0
parameters	0
comprising	0
the	0
tumour	0
burden	0
,	0
the	0
stage	0
of	0
the	0
disease	0
and	0
the	0
expression	0
of	0
hormone	9
receptors	10
on	0
the	0
tumour	0
.	0

In	0
order	0
to	0
analyse	0
the	0
immune	0
function	0
data	0
effectively	0
,	0
low	0
responders	0
were	0
identified	0
with	0
stringent	0
cut-off	0
values	0
.	0

Considerably	0
higher	0
proportions	0
of	0
low	0
responders	0
were	0
found	0
among	0
the	0
patient	0
population	0
.	0

Elevated	0
numbers	0
of	0
circulating	7
T	8
lymphocytes	8
and	0
CD3	9
-directed	0
cytolysis	0
correlated	0
with	0
the	0
expression	0
of	0
oestrogen	9
receptors	10
independently	0
of	0
the	0
clinical/histological	0
parameters	0
.	0

Latent	9
membrane	10
protein	10
1	10
of	0
Epstein-Barr	0
virus	0
interacts	0
with	0
JAK3	9
and	0
activates	0
STAT	9
proteins	10
.	0

Latent	9
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
acts	0
like	0
a	0
permanently	9
activated	10
receptor	10
of	0
the	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-receptor	10
superfamily	10
and	0
is	0
absolutely	0
required	0
for	0
B	0
cell	0
immortalization	0
by	0
Epstein-Barr	0
virus	0
.	0

Molecular	0
and	0
biochemical	0
approaches	0
demonstrated	0
that	0
LMP1	9
usurps	0
cellular	0
signaling	0
pathways	0
resulting	0
in	0
the	0
induction	0
of	0
NF-kappaB	9
and	0
AP-1	9
via	0
two	0
C-terminal	9
activating	10
regions	10
.	0

We	0
demonstrate	0
here	0
that	0
a	0
third	0
region	0
encompassing	0
a	0
proline	9
rich	10
sequence	10
within	0
the	0
33	0
bp	0
repetitive	0
stretch	0
of	0
LMP1	9
's	0
C-terminus	9
is	0
required	0
for	0
the	0
activation	0
of	0
Janus	9
kinase	10
3	10
(	0
JAK3	9
)	0
.	0

The	0
interaction	0
of	0
LMP1	9
and	0
JAK3	9
leads	0
to	0
the	0
enhanced	0
tyrosine	0
auto/transphosphorylation	0
of	0
JAK3	9
within	0
minutes	0
after	0
crosslinking	0
of	0
a	0
conditional	0
NGF-R	9
:	10
LMP1	10
chimera	10
and	0
is	0
a	0
prerequisite	0
for	0
the	0
activation	0
of	0
STAT	9
transcription	10
factors	10
.	0

These	0
results	0
reveal	0
a	0
novel	0
activating	0
region	0
in	0
the	0
LMP1	9
C-terminus	9
and	0
identify	0
the	0
JAK	9
/STAT	9
pathway	0
as	0
a	0
target	0
of	0
this	0
viral	9
integral	10
membrane	10
protein	10
in	0
B	7
cells	8
.	0

Monocyte	0
arrest	0
and	0
transmigration	0
on	0
inflamed	0
endothelium	0
in	0
shear	0
flow	0
is	0
inhibited	0
by	0
adenovirus-mediated	0
gene	0
transfer	0
of	0
IkappaB-alpha	9
.	0

Mobilization	0
of	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
activates	0
transcription	0
of	0
genes	0
encoding	0
endothelial	9
adhesion	10
molecules	10
and	0
chemokines	0
that	0
contribute	0
to	0
monocyte	0
infiltration	0
critical	0
in	0
atherogenesis	0
.	0

Inhibition	0
of	0
NF-kappaB	9
has	0
been	0
achieved	0
by	0
pharmacological	0
and	0
genetic	0
approaches	0
;	0
however	0
,	0
monocyte	0
interactions	0
with	0
activated	0
endothelium	0
in	0
shear	0
flow	0
following	0
gene	0
transfer	0
of	0
the	0
NF-kappaB	9
inhibitor	0
IkappaB-alpha	9
have	0
not	0
been	0
studied	0
.	0

We	0
found	0
that	0
overexpression	0
of	0
IkappaB-alpha	9
in	0
endothelial	7
cells	8
using	0
a	0
recombinant	0
adenovirus	0
prevented	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
-induced	0
degradation	0
of	0
IkappaB-alpha	9
and	0
suppressed	0
the	0
upregulation	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
,	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
,	0
and	0
E-selectin	3
mRNA	4
and	0
surface	0
protein	0
expression	0
and	0
the	0
upregulation	0
of	0
transcripts	0
for	0
the	0
chemokines	9
monocyte	9
chemoattractant	10
protein	10
1	10
(	0
MCP-1	9
)	0
and	0
growth-related	9
activity-alpha	10
(	0
GRO-alpha	9
)	0
by	0
TNF-alpha	9
.	0

This	0
was	0
associated	0
with	0
a	0
reduction	0
in	0
endothelial	0
MCP-1	9
secretion	0
and	0
GRO-alpha	9
immobilization	0
.	0

Adhesion	0
assays	0
under	0
physiological	0
shear	0
flow	0
conditions	0
showed	0
that	0
firm	0
arrest	0
,	0
spreading	0
,	0
and	0
transmigration	0
of	0
monocytes	7
on	0
TNF-alpha	9
-activated	0
endothelium	0
was	0
markedly	0
inhibited	0
by	0
IkappaB-alpha	9
overexpression	0
.	0

Inhibition	0
with	0
monoclonal	9
antibodies	10
and	0
peptide	0
antagonists	0
inferred	0
that	0
this	0
was	0
due	0
to	0
reduced	0
expression	0
of	0
Ig	0
integrin	0
ligand	0
as	0
well	0
as	0
of	0
chemokines	9
specifically	0
involved	0
in	0
these	0
events	0
.	0

In	0
contrast	0
,	0
rolling	0
of	0
monocytes	7
was	0
increased	0
by	0
IkappaB-alpha	9
transfer	0
and	0
was	0
partly	0
mediated	0
by	0
P-selectin	9
;	0
however	0
,	0
it	0
appeared	0
to	0
be	0
unaffected	0
by	0
the	0
inhibition	0
of	0
E-selectin	9
induction	0
.	0

Thus	0
,	0
our	0
data	0
provide	0
novel	0
evidence	0
that	0
selective	0
modulation	0
of	0
NF-kappaB	9
by	0
adenoviral	0
transfer	0
of	0
IkappaB-alpha	9
impairs	0
the	0
expression	0
of	0
multiple	0
endothelial	9
gene	10
products	10
required	0
for	0
subsequent	0
monocyte	0
arrest	0
and	0
emigration	0
in	0
shear	0
flow	0
and	0
thus	0
for	0
monocyte	0
infiltration	0
in	0
atherosclerotic	0
plaques	0
.	0

Recognition	0
of	0
NFATp/AP-1	1
composite	2
elements	2
within	0
genes	0
induced	0
upon	0
the	0
activation	0
of	0
immune	7
cells	8
.	0

Composite	1
elements	2
are	0
regulatory	1
modules	2
of	0
promoters	1
or	0
enhancers	1
that	0
consist	0
of	0
binding	0
sites	0
of	0
two	0
different	0
but	0
synergizing	0
transcription	9
factors	10
.	0

A	0
well-studied	0
example	0
is	0
nuclear	1
factors	2
of	2
activated	2
T-cell	2
(	2
NFAT	2
)	2
sites	2
which	0
are	0
composite	0
elements	0
of	0
a	0
NFATp/c	1
and	2
an	2
activating	2
protein	2
1	2
(	2
AP-1	2
)	2
binding	2
site	2
.	0

We	0
have	0
developed	0
a	0
computational	0
approach	0
to	0
identify	0
potential	0
NFAT	1
target	2
genes	2
which	0
(	0
a	0
)	0
comprises	0
an	0
improved	0
method	0
to	0
scan	0
for	0
individual	0
NFAT	1
composite	2
elements	2
;	0
(	0
b	0
)	0
considers	0
positional	0
effects	0
relative	0
to	0
transcription	1
start	2
sites	2
;	0
and	0
(	0
c	0
)	0
involves	0
cluster	0
analysis	0
of	0
potential	0
NFAT	1
composite	2
elements	2
.	0

All	0
three	0
steps	0
progressively	0
helpX	0
?	0
ed	0
to	0
discriminate	0
T-cell-specific	1
promoter	2
sequences	2
against	0
other	0
functional	1
regions	2
(	0
coding	1
and	2
intronic	2
sequences	2
)	0
of	0
the	0
same	0
genes	0
,	0
against	0
promoters	1
of	0
muscle-specific	1
genes	2
or	0
against	0
random	1
sequences	2
.	0

Using	0
this	0
approach	0
,	0
we	0
identified	0
potential	0
NFAT	1
composite	2
elements	2
in	0
promoters	1
of	0
cytokine	1
genes	2
and	0
their	0
receptors	0
as	0
well	0
as	0
in	0
promoters	1
of	0
genes	0
for	0
AP-1	9
family	10
members	10
,	0
Ca2+-binding	9
proteins	10
and	0
some	0
other	0
components	0
of	0
the	0
regulatory	0
network	0
operating	0
in	0
activated	7
T-cells	8
and	0
other	0
immune	7
cells	8
.	0

The	0
method	0
developed	0
can	0
be	0
adapted	0
to	0
characterize	0
and	0
identify	0
other	0
composite	1
elements	2
as	0
well	0
.	0

The	0
program	0
for	0
recognition	0
NFAT	1
composite	2
elements	2
is	0
available	0
through	0
the	0
World	0
Wide	0
Web	0
(	0
http	0
:	0
//compel.bionet.nsc.ru/FunSite/CompelScan.html	0
and	0
http	0
:	0
//transfac.gbf.de/dbsearch/funsitep/s_comp.html	0
)	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

The	0
oestrogen	9
receptor	10
codon	1
10	2
polymorphism	0
detected	0
in	0
breast	0
cancer	0
is	0
also	0
present	0
in	0
non-malignant	7
cells	8
.	0

The	0
effect	0
of	0
oestrogens	0
on	0
oestrogen-receptive	0
organs	0
and	0
cells	0
is	0
mediated	0
via	0
intracellular	9
receptors	10
(	0
ERalpha	9
and	0
ERbeta	9
)	0
.	0

Oestrogen	9
receptor	10
gene	0
polymorphisms	0
in	0
the	0
region	0
encoding	0
the	0
N-terminal	9
portion	10
of	0
the	0
protein	0
are	0
reportedly	0
associated	0
with	0
pathological	0
conditions	0
including	0
breast	0
cancer	0
,	0
hypertension	0
,	0
spontaneous	0
abortion	0
and	0
coronary	0
heart	0
disease	0
.	0

A	0
silent	0
mutation	0
in	0
codon	1
10	2
of	0
exon	1
1	2
,	0
detected	0
in	0
ER-negative	5
and	6
ER-positive	6
human	6
breast	6
cancer	6
cell	6
lines	6
,	0
in	0
breast	0
tumors	0
and	0
blood	1
DNA	2
from	0
breast	0
cancer	0
patients	0
,	0
has	0
been	0
recognized	0
as	0
a	0
polymorphic	1
site	2
.	0

In	0
this	0
study	0
we	0
examined	0
,	0
by	0
denaturing	0
gradient-gel	0
electrophoresis	0
and	0
DNA	1
sequence	2
analysis	0
,	0
the	0
possible	0
presence	0
of	0
a	0
codon	1
10	2
polymorphic	2
site	2
in	0
normal	0
oestrogen	0
target	0
organs	0
and	0
cells	0
such	0
as	0
the	0
uterus	0
(	0
myometrium	0
and	0
endometrium	0
)	0
,	0
in	0
the	0
placenta	0
and	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
in	0
a	0
benign	0
uterus	0
tumour	0
(	0
leiomyoma	0
)	0
.	0

We	0
have	0
detected	0
ER	1
codon	2
10	2
polymorphism	0
in	0
these	0
samples	0
and	0
have	0
compared	0
them	0
to	0
those	0
observed	0
in	0
breast	0
cancer	0
samples	0
.	0

All	0
tissues	0
and	0
cells	0
studied	0
were	0
homozygous	0
for	0
the	0
wild-type	1
gene	2
,	0
and	0
were	0
heterozygous	0
as	0
well	0
as	0
homozygous	0
for	0
the	0
codon-10-variant	1
type	2
.	0

These	0
results	0
indicate	0
that	0
the	0
presence	0
of	0
the	0
codon-10-variant	1
type	2
is	0
not	0
a	0
characteristic	0
of	0
breast	0
cancer	0
.	0

Out	0
current	0
findings	0
suggest	0
that	0
further	0
investigations	0
are	0
warranted	0
to	0
elucidate	0
the	0
possible	0
linkage	0
of	0
ER	1
codon	2
10	2
polymorphism	0
to	0
physiological	0
and	0
pathological	0
conditions	0
.	0

USF/c-Myc	9
enhances	0
,	0
while	0
Yin-Yang	9
1	10
suppresses	0
,	0
the	0
promoter	0
activity	0
of	0
CXCR4	9
,	0
a	0
coreceptor	9
for	0
HIV-1	0
entry	0
.	0

Transcription	9
factors	10
USF1	9
and	0
USF2	9
up-regulate	0
gene	0
expression	0
(	0
i.e.	0
,	0
HIV-1	1
long	2
terminal	2
repeats	2
)	0
via	0
interaction	0
with	0
an	0
E	1
box	2
on	0
their	0
target	0
promoters	0
,	0
which	0
is	0
also	0
a	0
binding	1
site	2
for	0
c-Myc	9
.	0

The	0
c-Myc	9
oncoprotein	10
is	0
important	0
in	0
control	0
of	0
cellular	0
proliferation	0
and	0
differentiation	0
,	0
while	0
Yin-Yang	9
1	10
(	0
YY1	9
)	0
has	0
been	0
shown	0
to	0
control	0
the	0
expression	0
of	0
a	0
number	0
of	0
cellular	1
and	2
viral	2
genes	2
.	0

These	0
two	0
proteins	0
physically	0
interact	0
with	0
each	0
other	0
and	0
mutually	0
inhibit	0
their	0
respective	0
biological	0
functions	0
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
USF/c-Myc	9
up-regulates	0
,	0
while	0
YY1	9
down-regulates	0
the	0
promoter	0
activity	0
of	0
CXCR4	9
,	0
a	0
coreceptor	0
for	0
T	0
cell-tropic	0
HIV-1	0
entry	0
.	0

We	0
have	0
identified	0
an	0
E	1
box	2
around	0
-260	1
and	0
a	0
YY1	1
binding	2
site	2
around	0
-300	1
relative	0
to	0
the	0
transcription	1
start	2
site	2
.	0

Mutation	0
of	0
the	0
E	1
box	2
abolished	0
USF/c-Myc	9
-mediated	0
up-regulation	0
of	0
CXCR4	9
promoter	0
activity	0
,	0
and	0
mutation	0
of	0
the	0
YY1	1
binding	2
site	2
was	0
associated	0
with	0
unresponsiveness	0
to	0
YY1	9
-mediated	0
inhibition	0
.	0

These	0
data	0
suggest	0
that	0
USF/c-Myc	9
and	0
YY1	9
may	0
play	0
an	0
important	0
role	0
in	0
the	0
HIV-1-replicative	0
cycle	0
,	0
by	0
modulating	0
both	0
the	0
viral	0
fusion/entry	0
process	0
and	0
viral	0
expression	0
.	0

Suppression	0
of	0
NF-kappaB	9
activation	0
in	0
normal	7
T	8
cells	8
by	0
supernatant	0
fluid	0
from	0
human	0
renal	0
cell	0
carcinomas	0
.	0

T	7
lymphocytes	8
from	0
patients	0
with	0
renal	0
cell	0
carcinoma	0
(	0
RCC	0
)	0
show	0
reduced	0
immune	0
function	0
and	0
impaired	0
activation	0
of	0
the	0
transcription	9
factor	10
,	0
NF-kappaB	9
.	0

We	0
determined	0
the	0
mechanism	0
of	0
NF-kappaB	9
suppression	0
in	0
T	7
cells	8
of	0
RCC	0
patient	0
and	0
determined	0
whether	0
supernatant	0
fluid	0
from	0
RCC	0
explants	0
(	0
RCC-S	0
)	0
induced	0
the	0
same	0
phenotype	0
of	0
NF-kappaB	9
suppression	0
in	0
normal	7
T	8
cells	8
that	0
is	0
observed	0
in	0
patient	0
T	7
cells	8
.	0

The	0
pattern	0
of	0
kappaB	9
-binding	0
activity	0
in	0
T	7
cells	8
of	0
RCC	0
patient	0
was	0
altered	0
as	0
compared	0
to	0
that	0
seen	0
in	0
T	7
cells	8
obtained	0
from	0
normal	0
volunteers	0
.	0

In	0
some	0
patients	0
,	0
no	0
activation	0
of	0
RelA/NFkappaB1	9
-binding	0
activity	0
was	0
detectable	0
,	0
while	0
in	0
others	0
kappaB	9
-binding	0
activity	0
was	0
modestly	0
induced	0
but	0
the	0
duration	0
was	0
reduced	0
.	0

IkappaBalpha	9
was	0
degraded	0
normally	0
following	0
stimulation	0
in	0
both	0
normal	0
controls	0
and	0
T	7
cells	8
from	0
RCC	0
patients	0
.	0

RCC-S	0
did	0
not	0
alter	0
the	0
cytoplasmic	0
levels	0
of	0
RelA	9
and	0
NF-kappaB1	9
but	0
did	0
suppress	0
their	0
nuclear	0
localization	0
and	0
inhibited	0
the	0
activation	0
of	0
RelA/NF-kappaB1	9
binding	10
complexes	10
.	0

These	0
results	0
show	0
that	0
RCC-S	0
can	0
induce	0
in	0
normal	7
T	8
cells	8
the	0
same	0
phenotype	0
of	0
impaired	0
NF-kappaB	9
activation	0
that	0
is	0
detected	0
in	0
T	7
cells	8
of	0
RCC	0
patient	0
.	0

It	0
also	0
appears	0
that	0
NF-kappaB	9
suppression	0
by	0
RCC-S	0
may	0
contribute	0
to	0
the	0
immunosuppression	0
of	0
host	0
immunity	0
.	0

STAT1	9
activation	0
during	0
monocyte	0
to	0
macrophage	0
maturation	0
:	0
role	0
of	0
adhesion	9
molecules	10
.	0

Human	7
monocytes	8
isolated	0
from	0
peripheral	0
blood	0
of	0
healthy	0
donors	0
show	0
a	0
time-dependent	0
differentiation	0
into	0
macrophages	7
upon	0
in	0
vitro	0
cultivation	0
,	0
closely	0
mimicking	0
their	0
in	0
vivo	0
migration	0
and	0
maturation	0
into	0
extravascular	0
tissues	0
.	0

The	0
mediator	0
(	0
s	0
)	0
of	0
this	0
maturation	0
process	0
has	0
not	0
been	0
yet	0
defined	0
.	0

We	0
investigated	0
the	0
involvement	0
of	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
factors	10
in	0
this	0
phenomenon	0
and	0
reported	0
the	0
specific	0
,	0
time-dependent	0
,	0
activation	0
of	0
STAT1	9
protein	0
starting	0
at	0
day	0
0/1	0
of	0
cultivation	0
and	0
maximally	0
expressed	0
at	0
day	0
5	0
.	0

STAT1	9
activity	0
was	0
evident	0
on	0
the	0
STAT	1
binding	2
sequences	2
(	0
SBE	1
)	0
present	0
in	0
the	0
promoters	1
of	0
genes	0
which	0
are	0
up-regulated	0
during	0
monocyte	0
to	0
macrophage	0
maturation	0
such	0
as	0
FcgammaRI	1
and	0
ICAM-1	1
,	0
and	0
in	0
the	0
promoter	0
of	0
the	0
transcription	1
factor	2
IFN	2
regulatory	2
factor-1	2
.	0

Moreover	0
,	0
the	0
effect	0
of	0
cell	0
adhesion	0
to	0
fibronectin	0
or	0
laminin	0
was	0
studied	0
to	0
investigate	0
mechanisms	0
involved	0
in	0
STAT1	9
activation	0
.	0

Compared	0
with	0
monocytes	7
adherent	0
on	0
plastic	0
surfaces	0
,	0
freshly	0
isolated	0
cells	0
allowed	0
to	0
adhere	0
either	0
to	0
fibronectin-	0
or	0
laminin-coated	0
flasks	0
exhibited	0
an	0
increased	0
STAT1	9
binding	0
activity	0
both	0
in	0
control	0
and	0
in	0
IFN-gamma-treated	5
cells	6
.	0

The	0
molecular	0
events	0
leading	0
to	0
enhanced	0
STAT1	9
activation	0
and	0
cytokine	9
responsiveness	0
concerned	0
both	0
Y701	9
and	0
S727	9
STAT1	10
phosphorylation	0
.	0

Exogenous	0
addition	0
of	0
transforming	9
growth	10
factor-beta	10
,	0
which	0
exerts	0
an	0
inhibitory	0
effect	0
on	0
some	0
monocytic	9
differentiation	10
markers	10
,	0
inhibited	0
macrophage	0
maturation	0
,	0
integrin	0
expression	0
and	0
STAT1	9
binding	0
activity	0
.	0

Taken	0
together	0
these	0
results	0
indicate	0
that	0
STAT1	9
plays	0
a	0
pivotal	0
role	0
in	0
the	0
differentiation/maturation	0
process	0
of	0
monocytes	7
as	0
an	0
early	0
transcription	9
factor	10
initially	0
activated	0
by	0
adherence	0
and	0
then	0
able	0
to	0
modulate	0
the	0
expression	0
of	0
functional	1
genes	2
,	0
such	0
as	0
ICAM-1	9
and	0
FcgammaRI	9
.	0

Expression	0
and	0
role	0
of	0
PML	1
gene	2
in	0
normal	0
adult	0
hematopoiesis	0
:	0
functional	0
interaction	0
between	0
PML	9
and	10
Rb	10
proteins	10
in	0
erythropoiesis	0
.	0

The	0
expression	0
of	0
the	0
PML	1
gene	2
was	0
investigated	0
in	0
purified	0
early	0
hematopoietic	7
progenitor	8
cells	8
(	0
HPCs	7
)	0
induced	0
to	0
unilineage	0
erythroid	0
or	0
granulocytic	0
differentiation	0
.	0

PML	3
mRNA	4
and	0
protein	9
,	0
while	0
barely	0
detectable	0
in	0
quiescent	0
HPCs	7
,	0
are	0
consistently	0
induced	0
by	0
growth	9
factor	10
stimulation	0
through	0
the	0
erythroid	0
or	0
granulocytic	0
lineage	0
.	0

Thereafter	0
,	0
PML	9
is	0
downmodulated	0
in	0
late	0
granulocytic	0
maturation	0
,	0
whereas	0
it	0
is	0
sustainably	0
expressed	0
through	0
the	0
erythroid	0
pathway	0
.	0

In	0
functional	0
studies	0
,	0
PML	9
expression	0
was	0
inhibited	0
by	0
addition	0
of	0
antisense	0
oligomers	0
targeting	0
PML	3
mRNA	4
(	0
alpha-PML	9
)	0
.	0

Interestingly	0
,	0
early	0
treatment	0
(	0
day	0
0	0
HPCs	7
)	0
with	0
alpha-PML	9
reduced	0
the	0
number	0
of	0
both	0
erythroid	5
and	6
granulocytic	6
colonies	6
,	0
whereas	0
late	0
treatment	0
(	0
day	0
5	0
culture	0
)	0
reduced	0
erythroid	0
,	0
but	0
not	0
granulocytic	0
,	0
clonogenesis	0
.	0

These	0
findings	0
suggest	0
that	0
PML	9
is	0
required	0
for	0
early	0
hematopoiesis	0
and	0
erythroid	0
,	0
but	0
not	0
granulocytic	0
maturation	0
.	0

The	0
pattern	0
of	0
PML	9
expression	0
in	0
normal	0
hematopoiesis	0
mimics	0
that	0
of	0
retinoblastoma	7
pRb	9
105	10
.	0

Combined	0
treatment	0
of	0
HPCs	7
with	0
alpha-PML	9
and	0
alpha-Rb	0
oligomers	0
inhibited	0
both	0
PML	0
and	0
Rb	0
protein	0
expression	0
and	0
completely	0
blocked	0
erythroid	0
colony	0
development	0
.	0

Furthermore	0
,	0
PML	9
and	0
pRb	9
105	10
were	0
co-immunoprecipitated	0
in	0
cellular	0
lysates	0
derived	0
from	0
erythroid	7
precursors	8
indicating	0
that	0
this	0
functional	0
interaction	0
may	0
have	0
a	0
biochemical	0
basis	0
.	0

These	0
results	0
suggest	0
a	0
key	0
functional	0
role	0
of	0
PML	9
in	0
early	0
hematopoiesis	0
and	0
late	0
erythropoiesis	0
:	0
the	0
latter	0
phenomenon	0
may	0
be	0
related	0
to	0
the	0
molecular	0
and	0
functional	0
interaction	0
of	0
PML	9
with	0
pRb	9
105	10
.	0

Binding	0
characteristics	0
of	0
the	0
glucocorticoid	9
receptor	10
in	0
peripheral	7
blood	8
lymphocytes	8
in	0
multiple	0
sclerosis	0
.	0

Although	0
the	0
exact	0
etiology	0
of	0
multiple	0
sclerosis	0
(	0
MS	0
)	0
remains	0
unresolved	0
,	0
immune	0
reactions	0
are	0
believed	0
to	0
be	0
the	0
central	0
pathogenic	0
mechanisms	0
.	0

Endogenous	0
and	0
therapeutic	0
steroid	0
hormones	0
affect	0
the	0
immune	0
system	0
,	0
and	0
inflammatory	0
diseases	0
are	0
associated	0
with	0
activation	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
axis	0
,	0
providing	0
evidence	0
of	0
an	0
immune-endocrine	0
interplay	0
.	0

Function	0
tests	0
in	0
MS	0
have	0
revealed	0
dysregulation	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
system	0
in	0
a	0
substantial	0
proportion	0
of	0
patients	0
.	0

We	0
characterized	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
binding	0
in	0
peripheral	7
blood	8
lymphocytes	8
from	0
39	0
MS	0
patients	0
and	0
14	0
age-	0
and	0
sex-matched	0
controls	0
with	0
respect	0
to	0
dissociation	0
constant	0
and	0
binding	0
capacity	0
,	0
using	0
a	0
whole-cell	0
binding	0
assay	0
with	0
[	0
3H	0
]	0
dexamethasone	0
as	0
the	0
ligand	0
.	0

GR	9
binding	0
parameters	0
did	0
not	0
differ	0
significantly	0
between	0
patients	0
(	0
Kd	0
8.98	0
+/-	0
1.07	0
nM	0
,	0
Bmax	0
183	0
+/-	0
29.8	0
fmol/mg	0
)	0
and	0
controls	0
(	0
Kd	0
9.36	0
+/-	0
1.17	0
nM	0
,	0
Bmax	0
158	0
+/-	0
16	0
fmol/mg	0
)	0
.	0

No	0
effect	0
of	0
age	0
,	0
sex	0
,	0
course	0
,	0
duration	0
or	0
severity	0
of	0
disease	0
,	0
or	0
prior	0
steroid	0
treatments	0
was	0
detected	0
.	0

GR	9
binding	0
parameters	0
were	0
analyzed	0
in	0
relation	0
to	0
the	0
results	0
of	0
the	0
combined	0
dexamethasone	0
-CRH	9
test	0
,	0
which	0
reflects	0
corticosteroid	0
receptor	0
function	0
at	0
the	0
hypothalamus	0
,	0
in	0
30	0
patients	0
and	0
9	0
controls	0
.	0

While	0
controls	0
showed	0
a	0
moderate	0
correlation	0
between	0
binding	0
affinity	0
of	0
the	0
GR	9
in	0
lymphocytes	0
and	0
regulatory	0
function	0
at	0
the	0
hypothalamic	0
level	0
,	0
the	0
patients	0
did	0
not	0
.	0

These	0
data	0
suggest	0
that	0
the	0
physiological	0
relationship	0
between	0
binding	0
and	0
function	0
of	0
the	0
glucocorticoid	9
receptor	10
is	0
disturbed	0
in	0
MS	0
.	0

Phorbol	0
ester-induced	0
mononuclear	0
cell	0
differentiation	0
is	0
blocked	0
by	0
the	0
mitogen-activated	9
protein	10
kinase	10
kinase	10
(	0
MEK	9
)	0
inhibitor	0
PD98059	0
.	0

The	0
purpose	0
of	0
this	0
study	0
was	0
to	0
evaluate	0
whether	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
signaling	0
pathway	0
contributes	0
to	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
-induced	0
mononuclear	0
differentiation	0
in	0
the	0
human	5
myeloblastic	6
leukemia	6
ML-1	6
cells	6
.	0

Upon	0
TPA	0
treatment	0
,	0
the	0
activity	0
of	0
ERK1	9
and	0
ERK2	9
rapidly	0
increased	0
,	0
with	0
maximal	0
induction	0
between	0
1	0
and	0
3	0
h	0
,	0
while	0
ERK2	9
protein	0
levels	0
remained	0
constant	0
.	0

The	0
activity	0
of	0
JNK1	9
was	0
also	0
significantly	0
induced	0
,	0
with	0
JNK1	9
protein	0
levels	0
increasing	0
moderately	0
during	0
exposure	0
to	0
TPA	0
.	0

Treatment	0
of	0
cells	0
with	0
PD98059	0
,	0
a	0
specific	0
inhibitor	0
of	0
mitogen-activated	9
protein	10
kinase	10
kinase	10
(	0
MEK	9
)	0
,	0
inhibited	0
TPA-induced	0
ERK2	9
activity	0
.	0

Furthermore	0
,	0
PD98059	0
completely	0
blocked	0
the	0
TPA-induced	0
differentiation	0
of	0
ML-1	5
cells	6
,	0
as	0
assessed	0
by	0
a	0
number	0
of	0
features	0
associated	0
with	0
mononuclear	0
differentiation	0
including	0
changes	0
in	0
morphology	0
,	0
nonspecific	0
esterase	9
activity	0
,	0
phagocytic	0
ability	0
,	0
NADPH	9
oxidase	10
activity	0
,	0
mitochondrial	0
respiration	0
,	0
and	0
c-jun	3
mRNA	4
inducibility	0
.	0

We	0
conclude	0
that	0
activation	0
of	0
the	0
MEK	9
/ERK	0
signaling	0
pathway	0
is	0
necessary	0
for	0
TPA-induced	0
mononuclear	0
cell	0
differentiation	0
.	0

Glucocorticoid	9
receptors	10
in	0
anorexia	0
nervosa	0
and	0
Cushing	0
's	0
disease	0
.	0

BACKGROUND	0
:	0
Patients	0
with	0
anorexia	0
nervosa	0
do	0
not	0
display	0
cushingoid	0
features	0
in	0
spite	0
of	0
elevated	0
cortisol	0
plasma	0
levels	0
.	0

Whether	0
a	0
cortisol	0
resistance	0
or	0
a	0
reduced	0
availability	0
of	0
the	0
metabolic	0
substrates	0
necessary	0
to	0
develop	0
the	0
effect	0
of	0
glucocorticoids	0
is	0
responsible	0
for	0
this	0
has	0
not	0
been	0
established	0
.	0

METHODS	0
:	0
Twenty-two	0
patients	0
with	0
severe	0
restrictive	0
anorexia	0
nervosa	0
,	0
10	0
patients	0
with	0
active	0
Cushing	0
's	0
disease	0
,	0
and	0
24	0
healthy	0
volunteers	0
without	0
psychiatric	0
disorders	0
or	0
mood	0
alterations	0
were	0
investigated	0
.	0

Glucocorticoid	0
receptor	0
characteristics	0
were	0
examined	0
on	0
mononuclear	7
leukocytes	8
by	0
measuring	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
and	0
the	0
effect	0
of	0
dexamethasone	0
on	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
,	0
which	0
represents	0
an	0
index	0
of	0
DNA	0
synthesis	0
.	0

RESULTS	0
:	0
The	0
number	0
of	0
glucocorticoid	9
receptors	10
on	0
mononuclear	7
leukocytes	8
(	0
MNL	7
)	0
was	0
comparable	0
in	0
patients	0
with	0
anorexia	0
nervosa	0
,	0
patients	0
with	0
active	0
Cushing	0
's	0
disease	0
,	0
and	0
normal	0
subjects	0
(	0
binding	0
capacity	0
3.3	0
+/-	0
0.23	0
vs.	0
3.7	0
+/-	0
0.30	0
and	0
3.5	0
+/-	0
0.20	0
fmol/10	0
(	0
6	0
)	0
cells	0
)	0
.	0

Conversely	0
,	0
glucocorticoid	9
receptor	10
affinity	0
was	0
significantly	0
decreased	0
in	0
anorexia	0
nervosa	0
as	0
well	0
as	0
in	0
Cushing	0
's	0
patients	0
compared	0
to	0
control	0
subjects	0
(	0
dissociation	0
constant	0
4.0	0
+/-	0
0.31	0
and	0
4.1	0
+/-	0
0.34	0
vs.	0
2.9	0
+/-	0
0.29	0
nmol/L	0
,	0
p	0
<	0
.001	0
)	0
and	0
inversely	0
correlated	0
with	0
the	0
levels	0
of	0
urinary	0
free	0
cortisol	0
in	0
both	0
groups	0
of	0
patients	0
.	0

Basal	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
in	0
MNL	7
was	0
significantly	0
reduced	0
in	0
anorexia	0
nervosa	0
as	0
well	0
as	0
in	0
Cushing	0
's	0
patients	0
compared	0
to	0
control	0
subjects	0
(	0
p	0
<	0
.001	0
)	0
and	0
was	0
diminished	0
by	0
dexamethasone	0
to	0
an	0
extent	0
similar	0
to	0
control	0
subjects	0
in	0
patients	0
with	0
anorexia	0
nervosa	0
,	0
but	0
significantly	0
(	0
p	0
<	0
.001	0
)	0
less	0
in	0
those	0
with	0
Cushing	0
's	0
disease	0
.	0

In	0
patients	0
with	0
anorexia	0
nervosa	0
,	0
the	0
incorporation	0
of	0
[	0
3H	0
]	0
thymidine	0
into	0
the	0
MNL	7
was	0
inversely	0
correlated	0
with	0
urinary	0
free	0
cortisol	0
levels	0
.	0

CONCLUSIONS	0
:	0
These	0
data	0
indicate	0
that	0
the	0
lack	0
of	0
cushingoid	0
features	0
in	0
patients	0
with	0
anorexia	0
nervosa	0
is	0
not	0
ascribable	0
to	0
a	0
reduced	0
sensitivity	0
to	0
glucocorticoids	0
but	0
is	0
more	0
likely	0
due	0
to	0
the	0
paucity	0
of	0
metabolic	0
substrates	0
.	0

Different	0
sequence	0
requirements	0
for	0
expression	0
in	0
erythroid	7
and	8
megakaryocytic	8
cells	8
within	0
a	0
regulatory	1
element	2
upstream	0
of	0
the	0
GATA-1	1
gene	2
.	0

The	0
lineage-restricted	9
transcription	10
factor	10
GATA-1	9
is	0
required	0
for	0
differentiation	0
of	0
erythroid	7
and	8
megakaryocytic	8
cells	8
.	0

We	0
have	0
localized	0
a	0
317	0
base	0
pair	0
cis-acting	1
regulatory	2
element	2
,	0
HS	1
I	2
,	0
associated	0
with	0
a	0
hematopoietic-specific	1
DNase	2
I	2
hypersensitive	2
site	2
,	0
which	0
lies	0
approx	0
.	0

3.7	0
kilobases	0
upstream	0
of	0
the	0
murine	1
hematopoietic-specific	2
GATA-1	2
IE	2
promoter	2
.	0

HS	1
I	2
directs	0
high-level	0
expression	0
of	0
reporter	0
GATA-1/lacZ	1
genes	2
to	0
primitive	7
and	8
definitive	8
erythroid	8
cells	8
and	0
megakaryocytes	7
in	0
transgenic	0
mice	0
.	0

Comparative	0
sequence	0
analysis	0
of	0
HS	1
I	2
between	0
human	0
and	0
mouse	0
shows	0
approx	0
.	0

63	0
%	0
nucleotide	0
identity	0
with	0
a	0
more	0
conserved	0
core	0
of	0
169	1
base	2
pairs	2
(	0
86	0
%	0
identity	0
)	0
.	0

This	0
core	0
contains	0
a	0
GATA	1
site	2
separated	0
by	0
10	0
base	0
pairs	0
from	0
an	0
E-box	1
motif	2
.	0

The	0
composite	1
motif	2
binds	0
a	0
multi-protein	9
hematopoietic-specific	10
transcription	10
factor	10
complex	10
which	0
includes	0
GATA-1	9
,	0
SCL/tal-1	9
,	10
E2A	9
,	0
Lmo2	9
and	0
Ldb-1	9
.	0

Point	0
mutations	0
of	0
the	0
GATA	1
site	2
abolishes	0
HS	1
I	2
function	0
,	0
whereas	0
mutation	0
of	0
the	0
E-box	1
motif	2
still	0
allows	0
reporter	0
gene	0
expression	0
in	0
both	0
lineages	0
.	0

Strict	0
dependence	0
of	0
HS	1
I	2
activity	0
on	0
a	0
GATA	1
site	2
implies	0
that	0
assembly	0
of	0
a	0
protein	0
complex	0
containing	0
a	0
GATA-factor	9
,	0
presumably	0
GATA-1	9
or	0
GATA-2	9
,	0
is	0
critical	0
to	0
activating	0
or	0
maintaining	0
its	0
function	0
.	0

Further	0
dissection	0
of	0
the	0
317	1
base	2
pair	2
region	2
demonstrates	0
that	0
,	0
whereas	0
all	0
317	1
base	2
pairs	2
are	0
required	0
for	0
expression	0
in	0
megakaryocytes	7
,	0
only	0
the	0
5	1
'	2
62	2
base	2
pairs	2
are	0
needed	0
for	0
erythroid-specific	0
reporter	0
expression	0
.	0

These	0
findings	0
demonstrate	0
differential	0
lineage	0
requirements	0
for	0
expression	0
within	0
the	0
HS	1
I	2
element	2
.	0

Non-steroidal	0
anti-inflammatory	0
drugs	0
inhibit	0
the	0
expression	0
of	0
cytokines	9
and	0
induce	0
HSP70	9
in	0
human	7
monocytes	8
.	0

Recent	0
studies	0
have	0
shown	0
that	0
the	0
non-steroidal	0
anti-inflammatory	0
drugs	0
(	0
NSAIDs	0
)	0
activate	0
heat	9
shock	10
transcription	10
factor	10
(	0
HSF1	9
)	0
from	0
a	0
latent	9
cytoplasmic	10
form	10
to	0
a	0
nuclear	9
,	10
DNA	10
binding	10
state	10
.	0

As	0
HSF1	9
can	0
function	0
as	0
both	0
an	0
activator	0
of	0
heat	1
shock	2
genes	2
and	0
a	0
repressor	0
of	0
non-heat	1
shock	2
genes	2
such	0
as	0
IL1B	0
and	0
c-	0
fos	0
,	0
we	0
have	0
examined	0
the	0
potential	0
role	0
of	0
HSF1	9
in	0
the	0
effects	0
of	0
NSAIDs	0
on	0
gene	0
expression	0
in	0
a	0
human	0
monocytic	5
cell	6
line	6
THP-1	6
.	0

We	0
found	0
that	0
two	0
members	0
of	0
the	0
NSAIDs	0
,	0
sodium	0
salicylate	0
and	0
sulindac	0
repress	0
the	0
IL1B	1
promoter	2
to	0
similar	0
degree	0
to	0
heat	0
shock	0
or	0
HSF1	9
overexpression	0
.	0

In	0
addition	0
,	0
sodium	0
salicylate	0
and	0
additional	0
NSAIDs	0
used	0
at	0
concentrations	0
that	0
activate	0
HSF1	9
also	0
inhibited	0
the	0
expression	0
of	0
other	0
monocytic	1
genes	2
(	0
TNF-alpha	1
,	0
IL-1beta	1
,	0
IL-6	1
,	0
IL-8	1
,	0
IL-10	1
,	0
ICAM-1	1
)	0
activated	0
by	0
exposure	0
to	0
a	0
pro-inflammatory	0
stimulus	0
(	0
lipopolysaccharide	0
,	0
LPS	0
)	0
.	0

At	0
least	0
in	0
the	0
case	0
of	0
the	0
IL1B	1
promoter	2
,	0
repression	0
did	0
not	0
seem	0
to	0
involve	0
another	0
factor	0
whose	0
activity	0
is	0
affected	0
by	0
the	0
NSAIDs	0
,	0
NFkappaB	9
as	0
the	0
IL1B	1
promoter	2
fragment	2
used	0
in	0
our	0
studies	0
is	0
not	0
NFkappaB	9
responsive	0
and	0
binds	0
specifically	0
to	0
HSF1	9
.	0

Exposure	0
to	0
NSAIDs	0
had	0
a	0
complex	0
effect	0
on	0
HSP	0
gene	0
expression	0
and	0
while	0
sulindac	0
activated	0
the	0
stress	0
responsive	0
HSP70B	1
promoter	2
,	0
sodium	0
salicylate	0
did	0
not	0
.	0

In	0
addition	0
,	0
only	0
a	0
subset	0
of	0
the	0
NSAIDs	0
induced	0
HSP70	3
mRNA	4
species	4
.	0

These	0
findings	0
reflect	0
the	0
properties	0
of	0
HSF1	9
which	0
can	0
be	0
activated	0
to	0
at	0
least	0
two	0
DNA	9
binding	10
forms	10
only	0
one	0
of	0
which	0
activates	0
heat	1
shock	2
promoters	2
and	0
suggest	0
that	0
individual	0
NSAID	0
family	0
members	0
may	0
differentially	0
induce	0
one	0
or	0
other	0
of	0
these	0
forms	0
.	0

Overall	0
therefore	0
,	0
exposure	0
to	0
NSAIDs	0
leads	0
to	0
a	0
profound	0
switch	0
in	0
gene	0
expression	0
in	0
monocytic	7
cells	8
,	0
with	0
suppression	0
of	0
genes	0
involved	0
in	0
macrophage	0
activation	0
and	0
induction	0
of	0
stress	1
genes	2
and	0
HSF1	9
appears	0
to	0
play	0
a	0
regulatory	0
role	0
in	0
these	0
effects	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Immortalization	0
of	0
CD4	7
(	8
+	8
)	8
and	8
CD8	8
(	8
+	8
)	8
T	8
lymphocytes	8
by	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
Tax	9
mutants	10
expressed	0
in	0
a	0
functional	5
molecular	6
clone	6
.	0

The	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
(	10
HTLV-1	10
)	10
transcriptional	10
trans-activator	10
Tax	9
has	0
been	0
demonstrated	0
to	0
have	0
transforming	0
activity	0
in	0
multiple	5
cell	6
culture	6
and	0
transgenic-mouse	0
models	0
.	0

In	0
addition	0
to	0
activating	0
transcription	0
from	0
the	0
viral	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
through	0
the	0
cyclic	9
AMP	10
response	10
element	10
binding	10
protein/activating	10
transcription	10
factor	10
(	10
CREB/ATF	10
)	10
family	10
of	0
transcription	9
factors	10
,	0
Tax	9
activates	0
the	0
expression	0
of	0
multiple	1
cellular	2
promoters	2
through	0
the	0
NF-kappaB	9
pathway	0
of	0
transcriptional	0
activation	0
.	0

The	0
Tax	9
mutants	10
M22	9
and	0
M47	9
have	0
previously	0
been	0
demonstrated	0
to	0
selectively	0
abrogate	0
the	0
ability	0
of	0
Tax	9
to	0
activate	0
transcription	0
through	0
the	0
NF-kappaB	0
or	0
CREB/ATF	0
pathway	0
,	0
respectively	0
.	0

These	0
mutations	0
were	0
introduced	0
in	0
the	0
tax	1
gene	2
of	0
the	0
ACH	1
functional	2
molecular	2
clone	2
of	0
HTLV-1	0
,	0
and	0
virus	0
produced	0
from	0
the	0
mutant	1
ACH	2
clones	2
was	0
examined	0
for	0
the	0
ability	0
to	0
replicate	0
and	0
immortalize	0
primary	7
human	8
lymphocytes	8
.	0

While	0
virus	0
derived	0
from	0
the	0
clone	0
containing	0
the	0
M47	9
mutation	0
retained	0
the	0
ability	0
to	0
immortalize	0
T	7
lymphocytes	8
,	0
the	0
M22	9
mutant	0
lost	0
the	0
ability	0
to	0
immortalize	0
infected	7
cells	8
.	0

These	0
results	0
indicate	0
that	0
activation	0
of	0
the	0
CREB/ATF	9
pathway	0
by	0
Tax	9
is	0
dispensable	0
for	0
the	0
immortalization	0
of	0
T	7
cells	8
by	0
HTLV-1	0
,	0
whereas	0
activation	0
of	0
the	0
NF-kappaB	9
pathway	0
may	0
be	0
critical	0
.	0

Fibroblast	9
growth	10
factor-1	10
(	0
FGF-1	9
)	0
enhances	0
IL-2	9
production	0
and	0
nuclear	0
translocation	0
of	0
NF-kappaB	9
in	0
FGF	5
receptor-bearing	6
Jurkat	6
T	6
cells	6
.	0

Fibroblast	9
growth	10
factors	10
(	0
FGFs	9
)	0
are	0
heparin-binding	9
proteins	10
crucial	0
to	0
embryogenesis	0
,	0
angiogenesis	0
,	0
and	0
wound	0
healing	0
.	0

FGF-1	9
is	0
abundantly	0
expressed	0
in	0
the	0
synovium	0
in	0
rheumatoid	0
arthritis	0
and	0
in	0
rejecting	0
allografts	0
,	0
sites	0
of	0
chronic	0
immune-mediated	0
inflammation	0
.	0

The	0
frequency	0
of	0
FGF-1	9
-responsive	0
T	7
cells	8
is	0
increased	0
in	0
the	0
peripheral	0
blood	0
of	0
these	0
disorders	0
,	0
and	0
a	0
high	0
percentage	0
of	0
infiltrating	7
T	8
cells	8
in	0
rheumatoid	0
arthritis	0
synovium	0
express	0
receptors	0
for	0
FGF-1	9
.	0

To	0
understand	0
the	0
action	0
of	0
FGF-1	9
in	0
T	7
cells	8
,	0
studies	0
were	0
initiated	0
in	0
Jurkat	5
T	6
cells	6
that	0
express	0
the	0
signaling	0
isoform	0
of	0
FGF	9
receptor-1	10
.	0

These	0
experiments	0
show	0
that	0
FGF-1	9
stimulation	0
of	0
Jurkat	5
T	6
cells	6
provides	0
a	0
second	0
signal	0
that	0
augments	0
TCR-mediated	0
IL-2	9
production	0
.	0

Analogous	0
to	0
costimulation	0
via	0
CD28	9
,	0
this	0
activity	0
is	0
mediated	0
through	0
activation	0
of	0
Rel/kappaB	9
,	0
a	0
family	0
of	0
transcription	9
factors	10
known	0
to	0
regulate	0
IL-2	9
and	0
other	0
activation-inducible	9
proteins	10
.	0

FGF-1	9
alone	0
induces	0
modest	0
nuclear	0
translocation	0
of	0
kappaB-binding	9
proteins	10
,	0
and	0
this	0
translocation	0
is	0
enhanced	0
by	0
the	0
combination	0
of	0
anti-CD3	9
and	0
FGF-1	9
.	0

This	0
NF-kappaB	9
binding	10
complex	10
is	0
composed	0
of	0
transcriptionally	9
active	10
p65	10
(	10
RelA	10
)	10
/p50	10
heterodimers	10
and	0
results	0
primarily	0
from	0
the	0
targeted	0
degradation	0
of	0
IkappaB-alpha	9
,	0
an	0
inhibitor	0
that	0
sequesters	0
Rel/kappaB	9
in	0
the	0
cytoplasm	0
.	0

These	0
data	0
are	0
the	0
first	0
to	0
show	0
a	0
connection	0
between	0
FGF-1	9
signaling	0
and	0
NF-kappaB	9
activation	0
outside	0
of	0
embryonic	0
development	0
.	0

The	0
signaling	0
events	0
that	0
link	0
FGF	9
receptor-1	10
engagement	0
and	0
NF-kappaB	9
activation	0
in	0
Jurkat	5
are	0
probably	0
distinct	0
from	0
the	0
CD28	9
costimulation	0
pathway	0
,	0
since	0
FGF-1	9
-induced	0
Rel/kappaB	9
binding	10
proteins	10
do	0
not	0
contain	0
significant	0
levels	0
of	0
c-Rel	9
and	0
are	0
not	0
identical	0
with	0
the	0
CD28	9
response	10
complex	10
.	0

Escape	0
of	0
human	0
cytomegalovirus	0
from	0
HLA-DR	9
-restricted	0
CD4	0
(	0
+	0
)	0
T-cell	0
response	0
is	0
mediated	0
by	0
repression	0
of	0
gamma	9
interferon	10
-induced	0
class	9
II	10
transactivator	10
expression	0
.	0

Human	0
cytomegalovirus	0
(	0
HCMV	0
)	0
,	0
a	0
betaherpesvirus	0
,	0
is	0
a	0
pathogen	0
which	0
escapes	0
immune	0
recognition	0
through	0
various	0
mechanisms	0
.	0

In	0
this	0
paper	0
,	0
we	0
show	0
that	0
HCMV	0
down	0
regulates	0
gamma	0
interferon	0
(	0
IFN-gamma	9
)	0
-induced	0
HLA-DR	9
expression	0
in	0
U373	5
MG	6
astrocytoma	6
cells	6
due	0
to	0
a	0
defect	0
downstream	0
of	0
STAT1	9
phosphorylation	0
and	0
nuclear	0
translocation	0
.	0

Repression	0
of	0
class	0
II	0
transactivator	0
(	0
CIITA	1
)	0
mRNA	0
expression	0
is	0
detected	0
within	0
the	0
first	0
hours	0
of	0
IFN-gamma	9
-HCMV	0
coincubation	0
and	0
results	0
in	0
the	0
absence	0
of	0
HLA-DR	9
synthesis	0
.	0

This	0
defect	0
leads	0
to	0
the	0
absence	0
of	0
presentation	0
of	0
the	0
major	9
immediate-early	10
protein	10
IE1	9
to	0
specific	0
CD4	5
(	6
+	6
)	6
T-cell	6
clones	6
when	0
U373	5
MG	6
cells	6
,	0
used	0
as	0
antigen-presenting	7
cells	8
,	0
are	0
treated	0
with	0
IFN-gamma	9
plus	0
HCMV	0
.	0

However	0
,	0
presentation	0
of	0
endogenously	0
synthesized	0
IE1	9
can	0
be	0
restored	0
when	0
U373	5
MG	6
cells	6
are	0
transfected	0
with	0
CIITA	1
prior	0
to	0
infection	0
with	0
HCMV	0
.	0

Altogether	0
,	0
the	0
data	0
indicate	0
that	0
the	0
defect	0
induced	0
by	0
HCMV	0
resides	0
in	0
the	0
activation	0
of	0
the	0
IFN-gamma-responsive	1
promoter	2
of	0
CIITA	1
.	0

This	0
is	0
the	0
first	0
demonstration	0
of	0
a	0
viral	0
inhibition	0
of	0
CIITA	1
expression	0
.	0

3-deazaadenosine	0
,	0
a	0
S-adenosylhomocysteine	9
hydrolase	10
inhibitor	0
,	0
has	0
dual	0
effects	0
on	0
NF-kappaB	9
regulation	0
.	0

Inhibition	0
of	0
NF-kappaB	9
transcriptional	0
activity	0
and	0
promotion	0
of	0
IkappaBalpha	9
degradation	0
.	0

Previously	0
we	0
reported	0
that	0
3-deazaadenosine	0
(	0
DZA	0
)	0
,	0
a	0
potent	0
inhibitor	0
and	0
substrate	0
for	0
S-adenosylhomocysteine	9
hydrolase	10
inhibits	0
bacterial	0
lipopolysaccharide-induced	0
transcription	0
of	0
tumor	9
necrosis	10
factor-alpha	10
and	0
interleukin-1beta	9
in	0
mouse	5
macrophage	6
RAW	6
264.7	6
cells	6
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
the	0
effects	0
of	0
DZA	0
on	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
regulation	0
.	0

DZA	0
inhibits	0
the	0
transcriptional	0
activity	0
of	0
NF-kappaB	9
through	0
the	0
hindrance	0
of	0
p65	9
(	0
Rel-A	9
)	0
phosphorylation	0
without	0
reduction	0
of	0
its	0
nuclear	0
translocation	0
and	0
DNA	0
binding	0
activity	0
.	0

The	0
inhibitory	0
effect	0
of	0
DZA	0
on	0
NF-kappaB	9
transcriptional	0
activity	0
is	0
potentiated	0
by	0
the	0
addition	0
of	0
homocysteine	0
.	0

Taken	0
together	0
,	0
DZA	0
promotes	0
the	0
proteolytic	0
degradation	0
of	0
IkappaBalpha	9
,	0
but	0
not	0
IkappaBbeta	9
,	0
resulting	0
in	0
an	0
increase	0
of	0
DNA	0
binding	0
activity	0
of	0
NF-kappaB	9
in	0
the	0
nucleus	0
in	0
the	0
absence	0
of	0
its	0
transcriptional	0
activity	0
in	0
RAW	5
264.7	6
cells	6
.	0

The	0
reduction	0
of	0
IkappaBalpha	9
by	0
DZA	0
is	0
neither	0
involved	0
in	0
IkappaB	9
kinase	10
complex	10
activation	0
nor	0
modulated	0
by	0
the	0
addition	0
of	0
homocysteine	0
.	0

This	0
study	0
strongly	0
suggests	0
that	0
DZA	0
may	0
be	0
a	0
potent	0
drug	0
for	0
the	0
treatment	0
of	0
diseases	0
in	0
which	0
NF-kappaB	9
plays	0
a	0
central	0
pathogenic	0
role	0
,	0
as	0
well	0
as	0
a	0
useful	0
tool	0
for	0
studying	0
the	0
regulation	0
and	0
physiological	0
functions	0
of	0
NF-kappaB	9
.	0

The	0
role	0
of	0
gamma/delta	7
T	8
cell	8
receptor	8
positive	8
cells	8
in	0
pregnancy	0
.	0

PROBLEM	0
:	0
Due	0
to	0
the	0
lack	0
of	0
classical	9
HLA	10
antigens	10
on	0
the	0
trophoblast	0
,	0
fetal	9
antigens	10
are	0
possibly	0
presented	0
in	0
a	0
non	0
major	9
histocompatibility	10
complex	10
(	0
MHC	9
)	0
restricted	0
way	0
.	0

Decidual	7
gammadelta	8
T	8
cells	8
,	0
which	0
significantly	0
increase	0
in	0
number	0
during	0
pregnancy	0
,	0
might	0
play	0
a	0
role	0
in	0
recognition	0
of	0
fetal	9
antigens	10
and	0
also	0
in	0
determining	0
the	0
quality	0
of	0
the	0
response	0
to	0
these	0
antigens	9
.	0

Our	0
study	0
was	0
aimed	0
at	0
investigating	0
the	0
role	0
of	0
this	0
cell	0
population	0
in	0
progesterone-dependent	0
immunomodulation	0
.	0

METHOD	0
OF	0
STUDY	0
:	0
Peripheral	7
lymphocytes	8
from	0
healthy	0
pregnant	0
women	0
and	0
from	0
habitual	0
aborters	0
were	0
tested	0
by	0
immunocytochemistry	0
for	0
the	0
presence	0
of	0
gamma/delta	0
T	0
cell	0
receptor	0
(	0
TCR	0
)	0
and	0
progesterone	0
receptor	0
.	0

To	0
investigate	0
the	0
effect	0
of	0
treatment	0
with	0
a	0
pan	0
anti	9
gamma/delta	10
antibody	10
,	0
lymphocytes	7
were	0
incubated	0
for	0
3	0
hr	0
with	0
the	0
antibody	0
,	0
and	0
then	0
interleukin	9
(	10
IL	10
)	10
-10	10
,	0
IL-12	9
and	0
progesterone-induced	9
blocking	10
factor	10
(	0
PIBF	9
)	0
expression	0
(	0
by	0
immuno-cytochemistry	0
)	0
as	0
well	0
as	0
natural	7
killer	8
(	8
NK	8
)	8
cell	8
activity	0
were	0
determined	0
.	0

RESULTS	0
:	0
In	0
peripheral	0
blood	0
of	0
healthy	0
pregnant	0
women	0
the	0
percentage	0
of	0
gamma/delta	7
TCR+	8
cells	8
was	0
significantly	0
higher	0
(	0
P	0
<	0
0.001	0
)	0
than	0
in	0
that	0
of	0
recurrent	0
aborters	0
or	0
of	0
non-pregnant	0
individuals	0
.	0

Ninety-seven	0
percent	0
of	0
gamma/delta	7
TCR+	8
pregnancy	8
lymphocytes	8
expressed	0
progesterone	9
receptor	10
.	0

Binding	0
of	0
a	0
specific	0
antibody	0
to	0
the	0
gamma/delta	0
TCR	0
inhibited	0
PIBF	0
-as	0
well	0
as	0
IL-10	0
production	0
,	0
whereas	0
it	0
increased	0
NK	0
activity	0
and	0
IL-12	9
expression	0
.	0

CONCLUSIONS	0
:	0
These	0
data	0
suggest	0
the	0
role	0
of	0
gamma/delta	7
TCR-bearing	8
lymphocytes	8
in	0
progesterone-dependent	0
immunomodulation	0
.	0

Monocyte	0
adhesion	0
and	0
spreading	0
on	0
human	7
endothelial	8
cells	8
is	0
dependent	0
on	0
Rho	9
-regulated	0
receptor	0
clustering	0
.	0

The	0
GTPase	9
Rho	9
is	0
known	0
to	0
mediate	0
the	0
assembly	0
of	0
integrin-containing	0
focal	0
adhesions	0
and	0
actin	0
stress	0
fibers	0
.	0

Here	0
,	0
we	0
investigate	0
the	0
role	0
of	0
Rho	9
in	0
regulating	0
the	0
distribution	0
of	0
the	0
monocyte-binding	9
receptors	10
E-selectin	9
,	0
ICAM-1	9
,	0
and	0
VCAM-1	9
in	0
human	7
endothelial	8
cells	8
.	0

Inhibition	0
of	0
Rho	9
activity	0
with	0
C3	9
transferase	10
or	0
N19RhoA	9
,	0
a	0
dominant	0
negative	0
RhoA	9
mutant	10
,	0
reduced	0
the	0
adhesion	0
of	0
monocytes	7
to	0
activated	0
endothelial	7
cells	8
and	0
inhibited	0
their	0
spreading	0
.	0

Similar	0
effects	0
were	0
observed	0
after	0
pretreatment	0
of	0
endothelial	7
cells	8
with	0
cytochalasin	0
D	0
.	0

In	0
contrast	0
,	0
dominant	9
negative	10
Rac	10
and	10
Cdc42	10
proteins	10
did	0
not	0
affect	0
monocyte	0
adhesion	0
or	0
spreading	0
.	0

C3	0
transferase	0
and	0
cytochalasin	0
D	0
did	0
not	0
alter	0
the	0
expression	0
levels	0
of	0
monocyte-binding	9
receptors	10
on	0
endothelial	7
cells	8
,	0
but	0
did	0
inhibit	0
clustering	0
of	0
E-selectin	9
,	0
ICAM-1	9
,	0
and	0
VCAM-1	9
on	0
the	0
cell	0
surface	0
induced	0
by	0
monocyte	0
adhesion	0
or	0
cross-linking	9
antibodies	10
.	0

Similarly	0
,	0
N19RhoA	9
inhibited	0
receptor	0
clustering	0
.	0

Monocyte	0
adhesion	0
and	0
receptor	0
cross-linking	0
induced	0
stress	0
fiber	0
assembly	0
,	0
and	0
inhibitors	0
of	0
myosin	9
light	10
chain	10
kinase	10
prevented	0
this	0
response	0
but	0
did	0
not	0
affect	0
receptor	0
clustering	0
.	0

Finally	0
,	0
receptor	0
clusters	0
colocalized	0
with	0
ezrin/moesin/radixin	9
proteins	10
.	0

These	0
results	0
suggest	0
that	0
Rho	9
is	0
required	0
in	0
endothelial	7
cells	8
for	0
the	0
assembly	0
of	0
stable	0
adhesions	0
with	0
monocytes	7
via	0
the	0
clustering	0
of	0
monocyte-binding	9
receptors	10
and	0
their	0
association	0
with	0
the	0
actin	0
cytoskeleton	0
,	0
independent	0
of	0
stress	0
fiber	0
formation	0
.	0

Selection	0
of	0
the	0
T	0
cell	0
repertoire	0
.	0

Advances	0
in	0
gene	0
technology	0
have	0
allowed	0
the	0
manipulation	0
of	0
molecular	0
interactions	0
that	0
shape	0
the	0
T	0
cell	0
repertoire	0
.	0

Although	0
recognized	0
as	0
fundamental	0
aspects	0
of	0
T	7
lymphocyte	8
development	0
,	0
only	0
recently	0
have	0
the	0
mechanisms	0
governing	0
positive	0
and	0
negative	0
selection	0
been	0
examined	0
at	0
a	0
molecular	0
level	0
.	0

Positive	0
selection	0
refers	0
to	0
the	0
active	0
process	0
of	0
rescuing	0
MHC-restricted	7
thymocytes	8
from	0
programmed	0
cell	0
death	0
.	0

Negative	0
selection	0
refers	0
to	0
the	0
deletion	0
or	0
inactivation	0
of	0
potentially	0
autoreactive	7
thymocytes	8
.	0

This	0
review	0
focuses	0
on	0
interactions	0
during	0
thymocyte	7
maturation	0
that	0
define	0
the	0
T	0
cell	0
repertoire	0
,	0
with	0
an	0
emphasis	0
placed	0
on	0
current	0
literature	0
within	0
this	0
field	0
.	0

CD28	9
costimulation	0
augments	0
IL-2	9
secretion	0
of	0
activated	0
lamina	0
propria	0
T	0
cells	0
by	0
increasing	0
mRNA	0
stability	0
without	0
enhancing	0
IL-2	9
gene	0
transactivation	0
.	0

The	0
pathways	0
leading	0
to	0
activation	0
in	0
lamina	7
propria	8
(	8
LP	8
)	8
T	8
cells	8
are	0
different	0
from	0
peripheral	7
T	8
cells	8
.	0

LP	7
T	8
cells	8
exhibit	0
enhanced	0
IL-2	9
secretion	0
when	0
activated	0
through	0
the	0
CD2	9
pathway	0
.	0

Coligation	0
of	0
CD28	9
leads	0
to	0
synergistic	0
enhancement	0
of	0
IL-2	9
secretion	0
.	0

Previous	0
studies	0
have	0
characterized	0
the	0
CD28	9
augmentation	0
of	0
TCR	9
-mediated	0
signaling	0
in	0
peripheral	7
blood	8
T	8
cells	8
through	0
transcriptional	0
activation	0
of	0
an	0
IL-2	9
promoter	0
CD28	1
response	2
element	2
(	0
CD28RE	1
)	0
,	0
along	0
with	0
enhanced	0
mRNA	0
stability	0
.	0

This	0
study	0
characterized	0
molecular	0
events	0
involved	0
in	0
CD28	9
costimulation	0
of	0
IL-2	9
production	0
in	0
LP	7
mononuclear	8
cells	8
(	8
LPMC	8
)	8
.	0

LPMC	7
exhibited	0
increased	0
IL-2	9
production	0
in	0
response	0
to	0
CD28	9
costimulation	0
,	0
compared	0
with	0
cells	0
activated	0
through	0
CD2	9
alone	0
.	0

IL-2	9
secretion	0
was	0
paralleled	0
by	0
increased	0
expression	0
of	0
IL-2	3
mRNA	4
,	0
resulting	0
from	0
enhanced	0
IL-2	3
mRNA	4
stability	0
.	0

In	0
contrast	0
to	0
transcriptional	0
activation	0
in	0
PBMC	7
,	0
EMSA	0
revealed	0
that	0
CD28	9
coligation	0
of	0
CD2-activated	7
LPMC	8
does	0
not	0
result	0
in	0
increased	0
binding	0
of	0
trans-factors	0
to	0
the	0
CD28RE	1
,	0
nor	0
did	0
Western	0
blots	0
detect	0
changes	0
in	0
I-kappaBalpha	9
or	0
I-kappaBbeta	9
levels	0
following	0
CD28	9
coligation	0
.	0

Furthermore	0
,	0
CD28	9
coligation	0
fails	0
to	0
enhance	0
IL-2	1
promoter-reporter	2
or	0
RE/AP	9
construct	0
expression	0
in	0
CD2-activated	7
LPMC	8
.	0

The	0
results	0
reported	0
herein	0
indicate	0
that	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
CD28	9
cosignaling	0
and	0
regulation	0
of	0
IL-2	9
secretion	0
in	0
LP	7
T	8
cells	8
are	0
unique	0
to	0
that	0
compartment	0
and	0
differ	0
from	0
those	0
seen	0
in	0
peripheral	7
blood	8
T	8
cells	8
.	0

These	0
observations	0
suggest	0
a	0
biological	0
significance	0
for	0
different	0
mechanisms	0
of	0
IL-2	9
activation	0
in	0
initiation	0
and	0
maintenance	0
of	0
the	0
cytokine	9
repertoire	10
found	0
in	0
the	0
mucosa	0
.	0

Expression	0
of	0
Th1	9
and	10
Th2	10
type	10
cytokines	10
responding	0
to	0
HBsAg	9
and	0
HBxAg	9
in	0
chronic	0
hepatitis	0
B	0
patients	0
.	0

The	0
cytokine	9
pattern	10
on	0
viral	0
antigen	0
recognition	0
is	0
believed	0
to	0
exert	0
a	0
profound	0
influence	0
on	0
the	0
resolution	0
of	0
viral	0
infections	0
and	0
viral	0
clearance	0
.	0

This	0
study	0
was	0
initiated	0
to	0
investigate	0
whether	0
a	0
cytokine	9
imbalance	0
oriented	0
toward	0
Th2	0
type	0
response	0
plays	0
a	0
role	0
in	0
chronic	0
hepatitis	0
B	0
.	0

Cytokine	9
profiles	10
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
associated	0
with	0
chronic	0
hepatitis	0
B	0
were	0
analysed	0
by	0
RT-PCR	0
.	0

Upon	0
HBsAg	9
stimulation	0
,	0
expression	0
of	0
IFN-gamma	9
,	0
IL-2	9
,	0
IL-4	9
,	0
and	0
IL-10	9
was	0
detected	0
in	0
41	0
%	0
,	0
8	0
%	0
,	0
41	0
%	0
,	0
and	0
50	0
%	0
of	0
the	0
patients	0
,	0
respectively	0
.	0

Among	0
these	0
cytokines	9
,	0
the	0
expression	0
of	0
IFN-gamma	9
was	0
associated	0
with	0
high	0
levels	0
of	0
serum	9
AST/ALT	10
.	0

However	0
,	0
we	0
could	0
not	0
prove	0
that	0
Th2	9
type	10
cytokines	10
had	0
a	0
protective	0
effect	0
on	0
hepatocytes	7
.	0

Upon	0
HBxAg	9
stimulation	0
,	0
there	0
was	0
no	0
recognizable	0
association	0
of	0
cytokine	9
patterns	10
with	0
AST/ALT	0
levels	0
.	0

In	0
conclusion	0
,	0
production	0
of	0
a	0
Th1	9
cytokine	10
,	0
IFN-gamma	9
,	0
by	0
HBsAg	9
-reactive	0
cells	0
was	0
associated	0
with	0
hepatocyte	0
damage	0
in	0
chronic	0
hepatitis	0
B	0
,	0
while	0
no	0
counteracting	0
effect	0
of	0
Th2	9
cytokines	10
produced	0
by	0
those	0
cells	0
was	0
observed	0
.	0

Apoptosis	0
and	0
growth	0
inhibition	0
in	0
malignant	7
lymphocytes	8
after	0
treatment	0
with	0
arsenic	0
trioxide	0
at	0
clinically	0
achievable	0
concentrations	0
[	0
see	0
comments	0
]	0

BACKGROUND	0
:	0
Arsenic	0
trioxide	0
(	0
As2O3	0
)	0
can	0
induce	0
clinical	0
remission	0
in	0
patients	0
with	0
acute	0
promyelocytic	0
leukemia	0
via	0
induction	0
of	0
differentiation	0
and	0
programmed	0
cell	0
death	0
(	0
apoptosis	0
)	0
.	0

We	0
investigated	0
the	0
effects	0
of	0
As2O3	0
on	0
a	0
panel	0
of	0
malignant	7
lymphocytes	8
to	0
determine	0
whether	0
growth-inhibitory	0
and	0
apoptotic	0
effects	0
of	0
As2O3	0
can	0
be	0
observed	0
in	0
these	0
cells	0
at	0
clinically	0
achievable	0
concentrations	0
.	0

METHODS	0
:	0
Eight	0
malignant	5
lymphocytic	6
cell	6
lines	6
and	0
primary	5
cultures	6
of	0
lymphocytic	7
leukemia	8
and	8
lymphoma	8
cells	8
were	0
treated	0
with	0
As2O3	0
,	0
with	0
or	0
without	0
dithiothreitol	0
(	0
DTT	0
)	0
or	0
buthionine	0
sulfoximine	0
(	0
BSO	0
)	0
(	0
an	0
inhibitor	0
of	0
glutathione	0
synthesis	0
)	0
.	0

Apoptosis	0
was	0
assessed	0
by	0
cell	0
morphology	0
,	0
flow	0
cytometry	0
,	0
annexin	0
V	0
protein	0
level	0
,	0
and	0
terminal	9
deoxynucleotidyl	10
transferase	10
labeling	0
of	0
DNA	1
fragments	2
.	0

Cellular	0
proliferation	0
was	0
determined	0
by	0
5-bromo-2'-deoxyuridine	0
incorporation	0
into	0
DNA	0
and	0
flow	0
cytometry	0
and	0
by	0
use	0
of	0
a	0
mitotic	0
arrest	0
assay	0
.	0

Mitochondrial	0
transmembrane	0
potential	0
(	0
delta	0
psi	0
(	0
m	0
)	0
)	0
was	0
measured	0
by	0
means	0
of	0
rhodamine	0
123	0
staining	0
and	0
flow	0
cytometry	0
.	0

Protein	0
expression	0
was	0
assessed	0
by	0
western	0
blot	0
analysis	0
or	0
immunofluorescence	0
.	0

RESULTS	0
:	0
Therapeutic	0
concentrations	0
of	0
As2O3	0
(	0
1-2	0
microM	0
)	0
had	0
dual	0
effects	0
on	0
malignant	7
lymphocytes	8
:	0
1	0
)	0
inhibition	0
of	0
growth	0
through	0
adenosine	0
triphosphate	0
(	0
ATP	0
)	0
depletion	0
and	0
prolongation	0
of	0
cell	0
cycle	0
time	0
and	0
2	0
)	0
induction	0
of	0
apoptosis	0
.	0

As2O3-induced	0
apoptosis	0
was	0
preceded	0
by	0
delta	0
psi	0
(	0
m	0
)	0
collapse	0
.	0

DTT	0
antagonized	0
and	0
BSO	0
enhanced	0
As2O3-induced	0
ATP	0
depletion	0
,	0
delta	0
psi	0
(	0
m	0
)	0
collapse	0
,	0
and	0
apoptosis	0
.	0

Caspase-3	9
activation	0
,	0
usually	0
resulting	0
from	0
delta	0
psi	0
(	0
m	0
)	0
collapse	0
,	0
was	0
not	0
always	0
associated	0
with	0
As2O3-induced	0
apoptosis	0
.	0

As2O3	0
induced	0
PML	0
(	0
promyelocytic	0
leukemia	0
)	0
protein	0
degradation	0
but	0
did	0
not	0
modulate	0
expression	0
of	0
cell	9
cycle-related	10
proteins	10
,	0
including	0
c-myc	9
,	0
retinoblastoma	9
protein	10
,	0
cyclin-dependent	9
kinase	10
4	10
,	0
cyclin	9
D1	10
,	0
and	0
p53	9
,	0
or	0
expression	0
of	0
differentiation-related	9
antigens	10
.	0

CONCLUSIONS	0
:	0
Substantial	0
growth	0
inhibition	0
and	0
apoptosis	0
without	0
evidence	0
of	0
differentiation	0
were	0
induced	0
in	0
most	0
malignant	7
lymphocytic	8
cells	8
treated	0
with	0
1-2	0
microM	0
As2O3	0
.	0

As2O3	0
may	0
prove	0
useful	0
in	0
the	0
treatment	0
of	0
malignant	0
lymphoproliferative	0
disorders	0
.	0

Control	0
of	0
cell	0
cycle	0
entry	0
and	0
apoptosis	0
in	0
B	7
lymphocytes	8
infected	0
by	0
Epstein-Barr	0
virus	0
.	0

Infection	0
of	0
human	7
B	8
cells	8
with	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
results	0
in	0
activation	0
of	0
the	0
cell	0
cycle	0
and	0
cell	0
growth	0
.	0

To	0
interpret	0
the	0
mechanisms	0
by	0
which	0
EBV	0
activates	0
the	0
cell	0
,	0
we	0
have	0
assayed	0
many	0
proteins	0
involved	0
in	0
control	0
of	0
the	0
G0	0
and	0
G1	0
phases	0
of	0
the	0
cell	0
cycle	0
and	0
regulation	0
of	0
apoptosis	0
.	0

In	0
EBV	0
infection	0
most	0
of	0
the	0
changes	0
,	0
including	0
the	0
early	0
induction	0
of	0
cyclin	9
D2	10
,	0
are	0
dependent	0
on	0
expression	0
of	0
EBV	1
genes	2
,	0
but	0
an	0
alteration	0
in	0
the	0
E2F-4	9
profile	0
was	0
partly	0
independent	0
of	0
viral	0
gene	0
expression	0
,	0
presumably	0
occurring	0
in	0
response	0
to	0
signal	0
transduction	0
activated	0
when	0
the	0
virus	0
binds	0
to	0
its	0
receptor	0
,	0
CD21	9
.	0

By	0
comparing	0
the	0
expression	0
of	0
genes	0
controlling	0
apoptosis	0
,	0
including	0
those	0
encoding	0
several	0
members	0
of	0
the	0
BCL-2	9
family	10
of	0
proteins	0
,	0
the	0
known	0
relative	0
resistance	0
of	0
EBV-immortalized	5
B-cell	6
lines	6
to	0
apoptosis	0
induced	0
by	0
low	0
serum	0
was	0
found	0
to	0
correlate	0
with	0
expression	0
of	0
both	0
BCL-2	9
and	0
A20	9
.	0

A20	0
can	0
be	0
regulated	0
by	0
the	0
NF-kappaB	9
transcription	9
factor	10
,	0
which	0
is	0
known	0
to	0
be	0
activated	0
by	0
the	0
EBV	9
LMP-1	10
protein	10
.	0

Quantitative	0
assays	0
demonstrated	0
a	0
direct	0
temporal	0
relationship	0
between	0
LMP-1	9
protein	10
levels	0
and	0
active	0
NF-kappaB	9
during	0
the	0
time	0
course	0
of	0
infection	0
.	0

CTLA-4	9
-Mediated	0
inhibition	0
of	0
early	0
events	0
of	0
T	0
cell	0
proliferation	0
.	0

CTLA-4	9
engagement	0
by	0
mAbs	9
inhibits	0
,	0
while	0
CD28	9
enhances	0
,	0
IL-2	9
production	0
and	0
proliferation	0
upon	0
T	0
cell	0
activation	0
.	0

Here	0
,	0
we	0
have	0
analyzed	0
the	0
mechanisms	0
involved	0
in	0
CTLA-4	9
-mediated	0
inhibition	0
of	0
T	0
cell	0
activation	0
of	0
naive	0
CD4+	7
T	8
cells	8
using	0
Ab	0
cross-linking	0
.	0

CTLA-4	9
ligation	0
inhibited	0
CD3/	0
CD28	9
-induced	0
IL-2	3
mRNA	4
accumulation	0
by	0
inhibiting	0
IL-2	9
transcription	0
,	0
which	0
appears	0
to	0
be	0
mediated	0
in	0
part	0
through	0
decreasing	0
NF-AT	9
accumulation	0
in	0
the	0
nuclei	0
.	0

However	0
,	0
CTLA-4	9
ligation	0
did	0
not	0
appear	0
to	0
affect	0
the	0
CD28	9
-mediated	0
stabilization	0
of	0
IL-2	3
mRNA	4
.	0

Further	0
,	0
CTLA-4	9
engagement	0
inhibited	0
progression	0
through	0
the	0
cell	0
cycle	0
by	0
inhibiting	0
the	0
production	0
of	0
cyclin	9
D3	10
,	0
cyclin-dependent	9
kinase	10
(	9
cdk	10
)	10
4	10
,	0
and	0
cdk6	9
when	0
the	0
T	7
cells	8
were	0
stimulated	0
with	0
anti-CD3/CD28	9
and	0
with	0
anti-CD3	9
alone	0
.	0

These	0
results	0
indicate	0
that	0
CTLA-4	9
signaling	0
inhibits	0
events	0
early	0
in	0
T	0
cell	0
activation	0
both	0
at	0
IL-2	9
transcription	0
and	0
at	0
the	0
level	0
of	0
IL-2	9
-independent	0
events	0
of	0
the	0
cell	0
cycle	0
,	0
and	0
does	0
not	0
simply	0
oppose	0
CD28	9
-mediated	0
costimulation	0
.	0

The	0
glucocorticoid	9
receptor	10
cooperates	0
with	0
the	0
erythropoietin	9
receptor	10
and	0
c-Kit	9
to	0
enhance	0
and	0
sustain	0
proliferation	0
of	0
erythroid	7
progenitors	8
in	0
vitro	0
.	0

Although	0
erythropoietin	9
(	0
Epo	9
)	0
is	0
essential	0
for	0
the	0
production	0
of	0
mature	7
red	8
blood	8
cells	8
,	0
the	0
cooperation	0
with	0
other	0
factors	0
is	0
required	0
for	0
a	0
proper	0
balance	0
between	0
progenitor	0
proliferation	0
and	0
differentiation	0
.	0

In	0
avian	0
erythroid	7
progenitors	8
,	0
steroid	0
hormones	0
cooperate	0
with	0
tyrosine	9
kinase	10
receptors	10
to	0
induce	0
renewal	0
of	0
erythroid	7
progenitors	8
.	0

We	0
examined	0
the	0
role	0
of	0
corticosteroids	0
in	0
the	0
in	0
vitro	0
expansion	0
of	0
primary	7
human	8
erythroid	8
cells	8
in	0
liquid	0
cultures	0
and	0
colony	0
assays	0
.	0

Dexamethasone	0
(	0
Dex	0
)	0
,	0
a	0
synthetic	0
glucocorticoid	0
hormone	0
,	0
cooperated	0
with	0
Epo	9
and	0
stem	9
cell	10
factor	10
to	0
induce	0
erythroid	7
progenitors	8
to	0
undergo	0
15	0
to	0
22	0
cell	0
divisions	0
,	0
corresponding	0
to	0
a	0
10	0
(	0
5	0
)	0
-	0
to	0
10	0
(	0
6	0
)	0
-fold	0
amplification	0
of	0
erythroid	7
cells	8
.	0

Dex	0
acted	0
directly	0
on	0
erythroid	7
progenitors	8
and	0
maintained	0
the	0
colony-forming	0
capacity	0
of	0
the	0
progenitor	7
cells	8
expanded	0
in	0
liquid	5
cultures	6
.	0

The	0
hormone	0
delayed	0
terminal	0
differentiation	0
into	0
erythrocytes	7
,	0
which	0
was	0
assayed	0
by	0
morphology	0
,	0
hemoglobin	9
accumulation	0
,	0
and	0
the	0
expression	0
of	0
genes	0
characteristic	0
for	0
immature	7
cells	8
.	0

Sustained	0
proliferation	0
of	0
erythroid	7
progenitors	8
could	0
be	0
induced	0
equally	0
well	0
from	0
purified	5
erythroid	6
burst-forming	6
units	6
(	0
BFU-E	5
)	0
,	0
from	0
CD34	7
(	8
+	8
)	8
blast	8
cells	8
,	0
and	0
from	0
bone	0
marrow	0
depleted	0
from	0
CD34	7
(	8
+	8
)	8
cells	8
.	0

NF-kappaB	9
functions	0
as	0
both	0
a	0
proapoptotic	9
and	10
antiapoptotic	10
regulatory	10
factor	10
within	0
a	0
single	0
cell	0
type	0
.	0

Recently	0
NF-kappaB	9
has	0
been	0
shown	0
to	0
have	0
both	0
proapoptotic	0
and	0
antiapoptotic	0
functions	0
.	0

In	0
T	5
cell	6
hybridomas	6
,	0
both	0
T	0
cell	0
activators	0
and	0
glucocorticoids	0
induce	0
apoptosis	0
.	0

Here	0
we	0
show	0
that	0
blockade	0
of	0
NF-kappaB	9
activity	0
,	0
using	0
a	0
dominant	9
negative	10
IkappaBalpha	10
,	0
has	0
opposite	0
effects	0
on	0
these	0
two	0
apoptotic	0
signals	0
.	0

Treatment	0
with	0
PMA	0
plus	0
ionomycin	0
(	0
P/I	0
)	0
results	0
in	0
the	0
upregulation	0
of	0
Fas	9
Ligand	10
(	0
FasL	9
)	0
and	0
induction	0
of	0
apoptosis	0
.	0

Inhibition	0
of	0
NF-kappaB	9
activity	0
inhibits	0
the	0
P/I	0
mediated	0
induction	0
of	0
FasL	3
mRNA	4
and	0
decreases	0
the	0
level	0
of	0
apoptosis	0
in	0
these	0
cultures	0
,	0
thus	0
establishing	0
NF-kappaB	9
as	0
a	0
proapoptotic	9
factor	10
in	0
this	0
context	0
.	0

Conversely	0
,	0
inhibition	0
of	0
NF-kappaB	9
confers	0
a	0
tenfold	0
increase	0
in	0
glucocorticoid	0
mediated	0
apoptosis	0
,	0
establishing	0
that	0
NF-kappaB	9
also	0
functions	0
as	0
an	0
antiapoptotic	0
factor	0
.	0

We	0
conclude	0
that	0
NF-kappaB	9
is	0
a	0
context-dependent	0
apoptosis	0
regulator	0
.	0

Our	0
data	0
suggests	0
that	0
NF-kappaB	9
may	0
function	0
as	0
an	0
antiapoptotic	0
factor	0
in	0
thymocytes	7
while	0
functioning	0
as	0
a	0
proapoptotic	0
factor	0
in	0
mature	7
peripheral	8
T	8
cells	8
.	0

SOCS-3	9
is	0
tyrosine	0
phosphorylated	0
in	0
response	0
to	0
interleukin-2	9
and	0
suppresses	0
STAT5	9
phosphorylation	0
and	0
lymphocyte	0
proliferation	0
.	0

Members	0
of	0
the	0
recently	0
discovered	0
SOCS/CIS/SSI	9
family	10
have	0
been	0
proposed	0
as	0
regulators	0
of	0
cytokine	9
signaling	0
,	0
and	0
while	0
targets	0
and	0
mechanisms	0
have	0
been	0
suggested	0
for	0
some	0
family	0
members	0
,	0
the	0
precise	0
role	0
of	0
these	0
proteins	0
remains	0
to	0
be	0
defined	0
.	0

To	0
date	0
no	0
SOCS	9
proteins	10
have	0
been	0
specifically	0
implicated	0
in	0
interleukin-2	9
(	0
IL-2	9
)	0
signaling	0
in	0
T	7
cells	8
.	0

Here	0
we	0
report	0
SOCS-3	9
expression	0
in	0
response	0
to	0
IL-2	9
in	0
both	0
T-cell	5
lines	6
and	0
human	7
peripheral	8
blood	8
lymphocytes	8
.	0

SOCS-3	9
protein	0
was	0
detectable	0
as	0
early	0
as	0
30	0
min	0
following	0
IL-2	9
stimulation	0
,	0
while	0
CIS	9
was	0
seen	0
only	0
at	0
low	0
levels	0
after	0
2	0
h	0
.	0

Unlike	0
CIS	9
,	0
SOCS-3	9
was	0
rapidly	0
tyrosine	0
phosphorylated	0
in	0
response	0
to	0
IL-2	9
.	0

Tyrosine	0
phosphorylation	0
of	0
SOCS-3	9
was	0
observed	0
upon	0
coexpression	0
with	0
Jak1	9
and	0
Jak2	9
but	0
only	0
weakly	0
with	0
Jak3	9
.	0

In	0
these	0
experiments	0
,	0
SOCS-3	9
associated	0
with	0
Jak1	9
and	0
inhibited	0
Jak1	9
phosphorylation	0
,	0
and	0
this	0
inhibition	0
was	0
markedly	0
enhanced	0
by	0
the	0
presence	0
of	0
IL-2	9
receptor	10
beta	10
chain	10
(	0
IL-2Rbeta	9
)	0
.	0

Moreover	0
,	0
following	0
IL-2	9
stimulation	0
of	0
T	7
cells	8
,	0
SOCS-3	9
was	0
able	0
to	0
interact	0
with	0
the	0
IL-2	9
receptor	10
complex	10
,	0
and	0
in	0
particular	0
tyrosine	9
phosphorylated	10
Jak1	10
and	0
IL-2Rbeta	9
.	0

Additionally	0
,	0
in	0
lymphocytes	7
expressing	0
SOCS-3	9
but	0
not	0
CIS	9
,	0
IL-2	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
STAT5b	9
was	0
markedly	0
reduced	0
,	0
while	0
there	0
was	0
only	0
a	0
weak	0
effect	0
on	0
IL-3-mediated	9
STAT5b	10
tyrosine	0
phosphorylation	0
.	0

Finally	0
,	0
proliferation	0
induced	0
by	0
both	0
IL-2	9
-and	0
IL-3	9
was	0
significantly	0
inhibited	0
in	0
the	0
presence	0
of	0
SOCS-3	9
.	0

The	0
findings	0
suggest	0
that	0
when	0
SOCS-3	9
is	0
rapidly	0
induced	0
by	0
IL-2	9
in	0
T	7
cells	8
,	0
it	0
acts	0
to	0
inhibit	0
IL-2	9
responses	0
in	0
a	0
classical	0
negative	0
feedback	0
loop	0
.	0

Human	7
alveolar	8
macrophages	8
are	0
markedly	0
deficient	0
in	0
REF-1	9
and	0
AP-1	9
DNA	0
binding	0
activity	0
.	0

Although	0
many	0
functions	0
of	0
human	7
alveolar	8
macrophages	8
are	0
altered	0
compared	0
with	0
their	0
precursor	7
cell	8
,	0
the	0
blood	7
monocyte	8
(	0
monocyte	7
)	0
,	0
the	0
reason	0
(	0
s	0
)	0
for	0
these	0
functional	0
changes	0
have	0
not	0
been	0
determined	0
.	0

We	0
recently	0
reported	0
that	0
human	7
alveolar	8
macrophages	8
do	0
not	0
express	0
AP-1	9
DNA	0
binding	0
activity	0
(	0
Monick	0
,	0
M.	0
M.	0
,	0
Carter	0
,	0
A.	0
B.	0
,	0
Gudmundsson	0
,	0
G.	0
,	0
Geist	0
,	0
L.	0
J.	0
,	0
and	0
Hunninghake	0
,	0
G.	0
W.	0
(	0
1998	0
)	0
Am.	0
J.	0
Physiol.	0
275	0
,	0
L389-L397	0
)	0
.	0

To	0
determine	0
why	0
alveolar	7
macrophages	8
do	0
not	0
express	0
AP-1	9
DNA	0
binding	0
activity	0
,	0
we	0
first	0
showed	0
that	0
there	0
was	0
not	0
a	0
decrease	0
in	0
expression	0
of	0
the	0
FOS	9
and	10
JUN	10
proteins	10
that	0
make	0
up	0
the	0
AP-1	9
complex	0
.	0

There	0
was	0
,	0
however	0
,	0
a	0
significant	0
difference	0
in	0
the	0
amounts	0
of	0
the	0
nuclear	9
protein	10
,	0
REF-1	9
(	0
which	0
regulates	0
AP-1	9
DNA	0
binding	0
by	0
altering	0
the	0
redox	0
status	0
of	0
FOS	9
and	0
JUN	9
proteins	10
)	0
,	0
in	0
alveolar	7
macrophages	8
compared	0
with	0
monocytes	7
.	0

In	0
addition	0
,	0
in	0
vitro	0
differentiation	0
of	0
monocytes	7
to	0
a	0
macrophage-like	7
cell	8
resulted	0
in	0
decreased	0
amounts	0
of	0
REF-1	9
.	0

Finally	0
,	0
addition	0
of	0
REF-1	9
from	0
activated	7
monocytes	8
to	0
alveolar	0
macrophage	0
nuclear	0
proteins	0
resulted	0
in	0
a	0
marked	0
increase	0
in	0
AP-1	9
DNA	0
binding	0
.	0

These	0
studies	0
strongly	0
suggest	0
that	0
the	0
process	0
of	0
differentiation	0
of	0
monocytes	7
into	0
alveolar	7
macrophages	8
is	0
associated	0
with	0
a	0
loss	0
of	0
REF-1	9
and	0
AP-1	9
activity	0
.	0

This	0
observation	0
may	0
explain	0
,	0
in	0
part	0
,	0
some	0
of	0
the	0
functional	0
differences	0
observed	0
for	0
alveolar	7
macrophages	8
compared	0
with	0
monocytes	7
.	0

Development	0
and	0
maturation	0
of	0
secondary	0
lymphoid	0
tissues	0
.	0

The	0
secondary	0
lymphoid	0
tissues	0
are	0
located	0
at	0
strategic	0
sites	0
where	0
foreign	9
antigens	10
can	0
be	0
efficiently	0
brought	0
together	0
with	0
immune	7
system	8
regulatory	8
and	8
effector	8
cells	8
.	0

The	0
organized	0
structure	0
of	0
the	0
secondary	0
lymphoid	0
tissues	0
is	0
thought	0
to	0
enhance	0
the	0
sensitivity	0
of	0
antigen	0
recognition	0
and	0
to	0
support	0
proper	0
regulation	0
of	0
the	0
activation	0
and	0
maturation	0
of	0
the	0
antigen-responsive	7
lymphoid	8
cells	8
.	0

Although	0
a	0
substantial	0
amount	0
is	0
known	0
about	0
the	0
cellular	1
elements	2
that	0
compose	0
the	0
lymphoid	0
and	0
nonlymphoid	0
components	0
of	0
the	0
secondary	0
lymphoid	0
tissues	0
,	0
information	0
concerning	0
the	0
signals	0
that	0
control	0
the	0
development	0
of	0
the	0
tissues	0
and	0
that	0
maintain	0
the	0
organized	0
tissue	0
microenvironment	0
remain	0
undefined	0
.	0

Studies	0
over	0
the	0
past	0
few	0
years	0
have	0
identified	0
lymphotoxin	0
as	0
a	0
critical	0
signaling	0
molecule	0
not	0
only	0
for	0
the	0
organogenesis	0
of	0
secondary	0
lymphoid	0
tissues	0
but	0
for	0
the	0
maintenance	0
of	0
aspects	0
of	0
their	0
microarchitecture	0
as	0
well	0
.	0

Additional	0
signaling	0
molecules	0
that	0
contribute	0
to	0
the	0
formation	0
of	0
normal	0
lymphoid	0
tissue	0
structure	0
are	0
being	0
identified	0
at	0
an	0
accelerating	0
pace	0
.	0

Analyses	0
of	0
mouse	0
strains	0
with	0
congenital	0
defects	0
in	0
different	0
aspects	0
of	0
secondary	0
lymphoid	0
tissue	0
development	0
are	0
beginning	0
to	0
clarify	0
the	0
role	0
of	0
these	0
tissues	0
in	0
immune	0
responses	0
and	0
host	0
defense	0
.	0

This	0
review	0
focuses	0
on	0
studies	0
defining	0
recently	0
identified	0
crucial	0
signals	0
for	0
the	0
biogenesis	0
of	0
secondary	0
lymphoid	0
organs	0
and	0
for	0
the	0
maintenance	0
of	0
their	0
proper	0
microarchitecture	0
.	0

It	0
also	0
discusses	0
new	0
insights	0
into	0
how	0
the	0
structure	0
of	0
these	0
tissues	0
supports	0
effective	0
immune	0
responses	0
.	0

Modulation	0
of	0
CD28	9
expression	0
:	0
distinct	0
regulatory	0
pathways	0
during	0
activation	0
and	0
replicative	0
senescence	0
.	0

The	0
costimulatory	9
molecule	10
CD28	9
has	0
a	0
restricted	0
tissue	0
distribution	0
and	0
is	0
expressed	0
on	0
T	7
cells	8
and	0
some	0
plasmacytoma	7
cells	8
.	0

Although	0
CD28	9
is	0
constitutively	0
expressed	0
,	0
its	0
expression	0
is	0
transiently	0
down-regulated	0
following	0
T	0
cell	0
activation	0
and	0
declines	0
progressively	0
with	0
in	0
vitro	0
senescence	0
.	0

In	0
vivo	0
,	0
CD8+	7
T	8
cells	8
and	0
,	0
less	0
frequently	0
,	0
CD4+	7
T	8
cells	8
may	0
completely	0
lose	0
CD28	9
surface	0
expression	0
during	0
chronic	0
infections	0
and	0
with	0
aging	0
.	0

This	0
correlates	0
with	0
changes	0
of	0
nuclear	0
protein-binding	0
activities	0
to	0
two	0
motifs	0
,	0
site	9
alpha	10
and	10
beta	10
,	0
within	0
the	0
CD28	1
minimal	2
promoter	2
.	0

Both	0
alpha-	0
and	0
beta-bound	0
complexes	0
are	0
found	0
only	0
in	0
lymphoid	0
tissues	0
,	0
in	0
CD28+	7
T	8
cells	8
,	0
and	0
in	0
some	0
transformed	5
B	6
cells	6
.	0

These	0
complexes	0
are	0
coordinately	0
expressed	0
except	0
during	0
replicative	0
senescence	0
,	0
which	0
is	0
characterized	0
by	0
the	0
down-modulation	0
of	0
site	9
beta	10
-but	0
not	0
site	9
alpha	10
-binding	0
activities	0
.	0

In	0
contrast	0
,	0
T	0
cell	0
activation	0
induces	0
a	0
parallel	0
decline	0
in	0
both	0
site	0
alpha-	0
and	0
beta-binding	0
activities	0
.	0

CD4+	0
and	0
CD8+	7
T	8
cells	8
differ	0
in	0
their	0
beta-binding	0
profiles	0
,	0
which	0
may	0
explain	0
the	0
more	0
pronounced	0
down-regulation	0
of	0
CD28	9
in	0
senescent	0
CD8+	7
T	8
cells	8
.	0

In	0
vivo	0
expanded	0
CD4+CD28null	5
and	6
CD8+CD28null	6
T	6
cells	6
uniformly	0
lack	0
alpha-	9
and	10
beta-	10
bound	10
complexes	10
,	0
resembling	0
the	0
pattern	0
seen	0
in	0
chronically	7
activated	8
cells	8
and	0
not	0
of	0
senescent	7
cells	8
.	0

A	0
role	0
for	0
RanBP1	9
in	0
the	0
release	0
of	0
CRM1	9
from	0
the	0
nuclear	9
pore	10
complex	10
in	0
a	0
terminal	0
step	0
of	0
nuclear	0
export	0
.	0

We	0
recently	0
developed	0
an	0
assay	0
in	0
which	0
nuclear	0
export	0
of	0
the	0
shuttling	0
transcription	9
factor	10
NFAT	10
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
)	0
can	0
be	0
reconstituted	0
in	0
permeabilized	0
cells	0
with	0
the	0
GTPase	9
Ran	9
and	0
the	0
nuclear	0
export	0
receptor	0
CRM1	9
.	0

We	0
have	0
now	0
used	0
this	0
assay	0
to	0
identify	0
another	0
export	0
factor	0
.	0

After	0
preincubation	0
of	0
permeabilized	5
cells	6
with	0
a	0
Ran	9
mutant	10
that	0
can	0
not	0
hydrolyze	0
GTP	0
(	0
RanQ69L	9
)	0
,	0
cytosol	0
supports	0
NFAT	9
export	0
,	0
but	0
CRM1	9
and	0
Ran	9
alone	0
do	0
not	0
.	0

The	0
RanQ69L	9
preincubation	0
leads	0
to	0
accumulation	0
of	0
CRM1	9
at	0
the	0
cytoplasmic	0
periphery	0
of	0
the	0
nuclear	9
pore	10
complex	10
(	0
NPC	9
)	0
in	0
association	0
with	0
the	0
p62	9
complex	10
and	0
Can/Nup214	0
.	0

Ran	9
GTP-dependent	0
association	0
of	0
CRM1	9
with	0
these	0
nucleoporins	9
was	0
reconstituted	0
in	0
vitro	0
.	0

By	0
biochemical	0
fractionation	0
and	0
reconstitution	0
,	0
we	0
showed	0
that	0
RanBP1	9
restores	0
nuclear	0
export	0
after	0
the	0
RanQ69L	9
preincubation	0
.	0

It	0
also	0
stimulates	0
nuclear	0
export	0
in	0
cells	0
that	0
have	0
not	0
been	0
preincubated	0
with	0
RanQ69L	9
.	0

RanBP1	9
as	0
well	0
as	0
Ran-binding	9
domains	10
of	0
the	0
cytoplasmic	9
nucleoporin	10
RanBP2	9
promote	0
the	0
release	0
of	0
CRM1	9
from	0
the	0
NPC	9
.	0

Taken	0
together	0
,	0
our	0
results	0
indicate	0
that	0
Ran	9
GTP	0
is	0
important	0
for	0
the	0
targeting	0
of	0
export	0
complexes	0
to	0
the	0
cytoplasmic	0
side	0
of	0
the	0
NPC	9
and	0
that	0
RanBP1	9
and	0
probably	0
RanBP2	9
are	0
involved	0
in	0
the	0
dissociation	0
of	0
nuclear	9
export	10
complexes	10
from	0
the	0
NPC	9
in	0
a	0
terminal	0
step	0
of	0
transport	0
.	0

c-Myc	9
and	0
E1A	9
induced	0
cellular	0
sensitivity	0
to	0
activated	7
NK	8
cells	8
involves	0
cytotoxic	0
granules	0
as	0
death	0
effectors	0
.	0

The	0
contact	0
of	0
natural	7
killer	8
(	8
NK	8
)	8
cells	8
with	0
foreign	7
cells	8
and	0
with	0
certain	0
virus-infected	7
or	8
tumor	8
cells	8
triggers	0
the	0
cytolytic	0
machinery	0
of	0
NK	7
cells	8
.	0

This	0
triggering	0
leads	0
to	0
exocytosis	0
of	0
the	0
cytotoxic	7
NK	8
cell	8
granules	8
.	0

The	0
oncoproteins	9
c-Myc	9
and	0
E1A	9
render	0
cells	0
vulnerable	0
to	0
NK	0
cell	0
mediated	0
cytolysis	0
yet	0
the	0
mechanisms	0
of	0
sensitization	0
are	0
not	0
well	0
understood	0
.	0

In	0
a	0
model	0
where	0
foreign	7
cells	8
(	0
rat	7
fibroblasts	8
)	0
were	0
cocultured	0
with	0
human	7
IL-2	8
activated	8
NK	8
cells	8
,	0
we	0
observed	0
that	0
NK	7
cells	8
were	0
capable	0
of	0
efficiently	0
killing	0
their	0
targets	0
only	0
if	0
the	0
cells	0
overexpressed	0
the	0
oncogene	0
c-Myc	9
or	0
E1A	9
.	0

Both	0
the	0
parental	0
and	0
the	0
oncogene	7
expressing	8
fibroblasts	8
similarly	0
triggered	0
phosphoinositide	0
hydrolysis	0
in	0
the	0
bound	0
NK	7
cells	8
,	0
demonstrating	0
that	0
NK	7
cells	8
were	0
cytolytically	0
activated	0
in	0
contact	0
with	0
both	0
resistant	0
parental	0
and	0
oncogene	7
expressing	8
sensitive	8
target	8
fibroblasts	8
.	0

The	0
cell	0
death	0
was	0
independent	0
of	0
wild-type	9
p53	10
and	0
was	0
not	0
inhibited	0
by	0
an	0
anti-apoptotic	9
protein	10
EIB19K	10
.	0

These	0
results	0
provided	0
evidence	0
that	0
c-Myc	9
and	0
E1A	9
activated	0
the	0
NK	0
cell	0
induced	0
cytolysis	0
at	0
a	0
post-triggering	0
stage	0
of	0
NK	0
cell-target	0
cell	0
interaction	0
.	0

In	0
consistence	0
,	0
the	0
c-Myc	9
and	0
E1A	9
overexpressing	0
fibroblasts	7
were	0
more	0
sensitive	0
to	0
the	0
cytolytic	0
effects	0
of	0
isolated	0
NK	0
cell-derived	0
granules	0
than	0
parental	7
cells	8
.	0

The	0
data	0
indicate	0
that	0
oncogenes	1
activate	0
the	0
cytotoxicity	0
of	0
NK	0
cell	0
granules	0
.	0

This	0
mechanism	0
can	0
have	0
a	0
role	0
in	0
directing	0
the	0
cytolytic	0
action	0
of	0
NK	7
cells	8
towards	0
the	0
virus-infected	7
and	8
cancer	8
cells	8
.	0

Unicellular-unilineage	5
erythropoietic	6
cultures	6
:	0
molecular	0
analysis	0
of	0
regulatory	0
gene	0
expression	0
at	0
sibling	0
cell	0
level	0
.	0

In	0
vitro	0
studies	0
on	0
hematopoietic	0
control	0
mechanisms	0
have	0
been	0
hampered	0
by	0
the	0
heterogeneity	0
of	0
the	0
analyzed	0
cell	0
populations	0
,	0
ie	0
,	0
lack	0
of	0
lineage	0
specificity	0
and	0
developmental	0
stage	0
homogeneity	0
of	0
progenitor/precursor	7
cells	8
growing	0
in	0
culture	0
.	0

We	0
developed	0
unicellular	0
culture	0
systems	0
for	0
unilineage	0
differentiation	0
of	0
purified	7
hematopoietic	8
progenitor	8
cells	8
followed	0
by	0
daughter	0
cell	0
analysis	0
at	0
cellular	0
and	0
molecular	0
level	0
.	0

In	0
the	0
culture	0
system	0
reported	0
here	0
,	0
(	0
1	0
)	0
the	0
growth	9
factor	10
(	0
GF	9
)	0
stimulus	0
induces	0
cord	7
blood	8
(	8
CB	8
)	8
progenitor	8
cells	8
to	0
proliferate	0
and	0
differentiate/mature	0
exclusively	0
along	0
the	0
erythroid	7
lineage	8
;	0
(	0
2	0
)	0
this	0
erythropoietic	0
wave	0
is	0
characterized	0
by	0
less	0
than	0
4	0
%	0
apoptotic	0
cells	0
;	0
(	0
3	0
)	0
asymmetric	0
divisions	0
are	0
virtually	0
absent	0
,	0
ie	0
,	0
nonresponsive	0
hematopoietic	7
progenitors	8
with	0
no	0
erythropoietic	0
potential	0
are	0
forced	0
into	0
apoptosis	0
;	0
(	0
4	0
)	0
the	0
system	0
is	0
cell	0
division	0
controlled	0
(	0
cdc	0
)	0
,	0
ie	0
,	0
the	0
number	0
of	0
divisions	0
performed	0
by	0
each	0
cell	0
is	0
monitored	0
.	0

Single-cell	0
reverse	9
transcriptase	10
-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
analysis	0
was	0
applied	0
to	0
this	0
culture	0
system	0
to	0
investigate	0
gene	0
expression	0
of	0
diverse	0
receptors	9
,	0
markers	9
of	10
differentiation	10
,	0
and	0
transcription	9
factors	10
(	0
EKLF	9
,	0
GATA-1	9
,	0
GATA-2	9
,	0
p45	9
NF-E2	10
,	0
PU.1	9
,	0
and	0
SCL/Tal1	9
)	0
at	0
discrete	0
stages	0
of	0
erythropoietic	0
development	0
.	0

Freshly	0
isolated	0
CD34	7
(	8
+	8
)	8
cells	8
expressed	0
CD34	9
,	0
c-kit	9
,	0
PU.1	9
,	0
and	0
GATA-2	9
but	0
did	0
not	0
express	0
CD36	9
,	0
erythropoietin	9
receptor	10
(	0
EpoR	9
)	0
,	0
SCL/Tal1	9
,	0
EKLF	9
,	0
NF-E2	0
,	0
GATA-1	9
,	0
or	0
glyocophorin	9
A	10
(	0
GPA	9
)	0
.	0

In	0
early	0
to	0
intermediate	0
stages	0
of	0
erythroid	0
differentiation	0
we	0
monitored	0
the	0
induction	0
of	0
CD36	9
,	0
Tal1	9
,	0
EKLF	9
,	0
NF-E2	9
,	0
and	0
GATA-1	9
that	0
preceeded	0
expression	0
of	0
EpoR	9
.	0

In	0
late	0
stages	0
of	0
erythroid	0
maturation	0
,	0
GPA	9
was	0
upregulated	0
,	0
whereas	0
CD34	9
,	0
c-kit	9
,	0
PU.1	9
,	0
and	0
GATA-2	9
were	0
barely	0
or	0
not	0
detected	0
.	0

In	0
addition	0
,	0
competitive	0
single-cell	0
RT-PCR	0
was	0
used	0
to	0
assay	0
CD34	3
mRNA	4
transcripts	4
in	0
sibling	5
CD34	6
(	6
+	6
)	6
CD38	6
(	6
-	6
)	6
cells	6
differentiating	0
in	0
unilineage	5
erythroid	6
cultures	6
:	0
this	0
analysis	0
allowed	0
us	0
to	0
semiquantitate	0
the	0
gradual	0
downmodulation	0
of	0
CD34	3
mRNA	4
from	0
progenitor	7
cells	8
through	0
their	0
differentiating	5
erythroid	6
progeny	6
.	0

It	0
is	0
concluded	0
that	0
this	0
novel	0
culture	0
system	0
,	0
coupled	0
with	0
single-cell	0
RT-PCR	0
analysis	0
,	0
may	0
eliminate	0
the	0
ambiguities	0
intrinsic	0
to	0
molecular	0
studies	0
on	0
heterogeneous	0
populations	0
of	0
hematopoietic	7
progenitors/precursors	8
growing	0
in	0
culture	0
,	0
particularly	0
in	0
the	0
initial	0
stages	0
of	0
development	0
.	0

Differences	0
in	0
phosphorylation	0
of	0
the	0
IL-2R	9
associated	10
JAK/STAT	10
proteins	10
between	0
HTLV-I	5
(	6
+	6
)	6
,	6
IL-2-independent	6
and	6
IL-2-dependent	6
cell	6
lines	6
and	0
uncultured	7
leukemic	8
cells	8
from	0
patients	0
with	0
adult	0
T-cell	0
lymphoma/leukemia	0
.	0

To	0
determine	0
activation	0
status	0
of	0
the	0
IL-2R	9
-associated	0
(	0
Jak/STAT	9
)	0
pathway	0
in	0
the	0
HTLV-I	5
infected	6
cells	6
,	0
we	0
examined	0
tyrosine	0
phosphorylation	0
of	0
Jak3	9
,	0
STAT3	9
,	0
and	0
STAT5	9
in	0
several	0
HTLV-I	5
(	6
+	6
)	6
T-cell	6
lines	6
and	0
in	0
uncultured	7
leukemic	8
T	8
cells	8
isolated	0
from	0
patients	0
with	0
adult	0
T-cell	0
lymphoma/leukemia	0
(	0
ATLL	0
)	0
.	0

Constitutive	0
basal	0
phosphorylation	0
of	0
Jak3	9
and	0
,	0
usually	0
,	0
STAT3	9
and	0
STAT5	9
was	0
detected	0
in	0
all	0
four	0
IL-2-independent	5
cell	6
lines	6
tested	0
,	0
but	0
in	0
none	0
of	0
the	0
three	0
IL-2-dependent	5
cell	6
lines	6
.	0

Similarly	0
,	0
there	0
was	0
no	0
detectable	0
basal	0
phosphorylation	0
of	0
Jak3	9
and	0
STAT5	9
in	0
the	0
leukemic	7
cells	8
from	0
ATLL	0
patients	0
(	0
0/8	0
and	0
0/3	0
,	0
respectively	0
)	0
.	0

However	0
,	0
stimulation	0
with	0
IL-2	9
resulted	0
in	0
Jak3	9
and	0
STAT5	9
phosphorylation	0
in	0
both	0
leukemic	7
ATLL	8
cells	8
and	0
IL-2-dependent	5
lines	6
.	0

Furthermore	0
,	0
expression	0
of	0
SHP-1	9
phosphatase	10
which	0
is	0
a	0
negative	0
regulator	0
of	0
cytokine	9
receptor	10
signaling	0
,	0
was	0
lost	0
in	0
most	0
IL-2	5
independent	6
cell	6
lines	6
(	0
3/4	0
)	0
but	0
not	0
in	0
the	0
leukemic	0
ATLL	7
cells	8
(	0
0/3	0
)	0
.	0

Finally	0
,	0
the	0
HTLV-I	5
(	6
+	6
)	6
T-cell	6
lines	6
(	0
313	0
)	0
but	0
not	0
the	0
control	0
,	0
HTLV-I	5
(	6
-	6
)	6
T-cell	6
lines	6
were	0
resistant	0
to	0
rapamycin	0
and	0
its	0
novel	0
analog	0
RAD	0
.	0

We	0
conclude	0
that	0
(	0
1	0
)	0
HTLV-I	0
infection	0
per	0
se	0
does	0
not	0
result	0
in	0
a	0
constitutive	0
phosphorylation	0
of	0
the	0
Jak3	9
,	0
STAT3	9
,	0
and	0
STAT5	9
proteins	0
;	0
(	0
2	0
)	0
malignant	0
transformation	0
in	0
at	0
least	0
some	0
cases	0
of	0
ATLL	0
does	0
not	0
require	0
the	0
constitutive	0
,	0
but	0
may	0
require	0
IL-2	9
-induced	0
,	0
activation	0
of	0
the	0
IL-2R	9
Jak/STAT	9
pathway	0
;	0
and	0
(	0
3	0
)	0
there	0
are	0
major	0
differences	0
in	0
T-cell	0
immortalization	0
mechanism	0
(	0
s	0
)	0
which	0
appear	0
to	0
involve	0
SHP-1	9
and	0
target	0
molecules	0
for	0
rapamycin	0
and	0
RAD	0
.	0

Clonality	0
analysis	0
using	0
X-chromosome	1
inactivation	0
at	0
the	0
human	1
androgen	2
receptor	2
gene	2
(	0
Humara	1
)	0
.	0

Evaluation	0
of	0
large	0
cohorts	0
of	0
patients	0
with	0
chronic	0
myeloproliferative	0
diseases	0
,	0
secondary	0
neutrophilia	0
,	0
and	0
reactive	0
thrombocytosis	0
.	0

Chronic	0
myeloproliferative	0
diseases	0
(	0
MPDs	0
)	0
are	0
not	0
associated	0
with	0
consistent	0
cytogenetic	0
or	0
molecular	0
abnormalities	0
.	0

Demonstration	0
of	0
clonal	0
cell	0
growth	0
by	0
analysis	0
of	0
X-chromosome	1
inactivation	0
(	0
XCI	0
)	0
patterns	0
in	0
females	0
provides	0
a	0
promising	0
tool	0
for	0
diagnosis	0
.	0

However	0
,	0
this	0
technique	0
can	0
be	0
complicated	0
by	0
excessive	0
lyonization	0
of	0
normal	0
cells	0
mimicking	0
clonal	0
cell	0
growth	0
:	0
We	0
analyzed	0
XCI	0
patterns	0
at	0
the	0
human	1
androgen	2
receptor	2
(	2
HUMARA	2
)	2
locus	2
in	0
146	0
healthy	0
females	0
,	0
65	0
women	0
with	0
secondary	0
neutrophilia	0
,	0
31	0
women	0
with	0
reactive	0
thrombocytosis	0
,	0
and	0
86	0
women	0
with	0
chronic	0
MPDs	0
.	0

A	0
skewed	0
XCI	0
pattern	0
with	0
greater	0
than	0
75	0
%	0
amplification	0
of	0
1	0
allele	1
(	0
allele	1
ratio	0
>	0
3	0
:	0
1	0
)	0
was	0
found	0
in	0
22	0
(	0
9.1	0
%	0
)	0
of	0
242	0
control	0
subjects	0
.	0

The	0
incidence	0
of	0
skewing	0
was	0
statistically	0
significantly	0
lower	0
in	0
women	0
younger	0
than	0
30	0
years	0
(	0
2/73	0
)	0
compared	0
with	0
women	0
older	0
than	0
60	0
years	0
(	0
10/53	0
)	0
.	0

Of	0
86	0
patients	0
with	0
a	0
chronic	0
MPD	0
,	0
71	0
(	0
82	0
%	0
)	0
exhibited	0
an	0
allele	1
ratio	0
greater	0
than	0
3	0
:	0
1	0
,	0
whereas	0
only	0
10	0
(	0
12	0
%	0
)	0
of	0
86	0
age-matched	0
control	0
subjects	0
showed	0
a	0
skewed	0
XCI	0
pattern	0
.	0

Although	0
statistical	0
evaluation	0
of	0
the	0
data	0
showed	0
a	0
significant	0
difference	0
between	0
patients	0
with	0
a	0
chronic	0
MPD	0
and	0
control	0
subjects	0
,	0
proof	0
of	0
clonality	0
in	0
individual	0
,	0
especially	0
elderly	0
,	0
patients	0
is	0
difficult	0
.	0

GATA-1	9
and	0
erythropoietin	9
cooperate	0
to	0
promote	0
erythroid	0
cell	0
survival	0
by	0
regulating	0
bcl-xL	9
expression	0
.	0

The	0
transcription	9
factor	10
GATA-1	9
is	0
essential	0
for	0
normal	0
erythropoiesis	0
.	0

By	0
examining	0
in	0
vitro-differentiated	5
embryonic	6
stem	6
cells	6
,	0
we	0
showed	0
previously	0
that	0
in	0
the	0
absence	0
of	0
GATA-1	9
,	0
committed	5
erythroid	6
precursors	6
fail	0
to	0
complete	0
maturation	0
and	0
instead	0
undergo	0
apoptosis	0
.	0

The	0
mechanisms	0
by	0
which	0
GATA-1	9
controls	0
cell	0
survival	0
are	0
unknown	0
.	0

Here	0
we	0
report	0
that	0
in	0
erythroid	7
cells	8
,	0
GATA-1	9
strongly	0
induces	0
the	0
expression	0
of	0
the	0
anti-apoptotic	9
protein	10
bcl-xL	9
,	0
but	0
not	0
the	0
related	0
proteins	0
bcl-2	9
and	0
mcl-1	9
.	0

Consistent	0
with	0
a	0
role	0
for	0
bcl-xL	9
in	0
mediating	0
GATA-1	9
-induced	0
erythroid	0
cell	0
survival	0
,	0
in	0
vitro-differentiated	5
bcl-xL-/-	6
embryonic	6
stem	6
cells	6
fail	0
to	0
generate	0
viable	0
mature	0
definitive	0
erythroid	7
cells	8
,	0
a	0
phenotype	0
resembling	0
that	0
of	0
GATA-1	1
gene	2
disruption	0
.	0

In	0
addition	0
,	0
we	0
show	0
that	0
erythropoietin	9
,	0
which	0
is	0
also	0
required	0
for	0
erythroid	0
cell	0
survival	0
,	0
cooperates	0
with	0
GATA-1	9
to	0
stimulate	0
bcl-xL	9
gene	0
expression	0
and	0
to	0
maintain	0
erythroid	0
cell	0
viability	0
during	0
terminal	0
maturation	0
.	0

Together	0
,	0
our	0
data	0
show	0
that	0
bcl-xL	9
is	0
essential	0
for	0
normal	0
erythroid	0
development	0
and	0
suggest	0
a	0
regulatory	0
hierarchy	0
in	0
which	0
bcl-xL	9
is	0
a	0
critical	0
downstream	0
effector	0
of	0
GATA-1	9
and	0
erythropoietin	9
-mediated	0
signals	0
.	0

p70	9
(	10
s6k	10
)	10
integrates	0
phosphatidylinositol	9
3-kinase	10
and	0
rapamycin-regulated	0
signals	0
for	0
E2F	9
regulation	0
in	0
T	7
lymphocytes	8
.	0

In	0
T	7
lymphocytes	8
,	0
the	0
hematopoietic	9
cytokine	10
interleukin-2	9
(	0
IL-2	9
)	0
uses	0
phosphatidylinositol	9
3-kinase	10
(	0
PI	9
3-kinase	10
)	0
-induced	0
signaling	0
pathways	0
to	0
regulate	0
E2F	9
transcriptional	0
activity	0
,	0
a	0
critical	0
cell	0
cycle	0
checkpoint	0
.	0

PI	9
3-kinase	10
also	0
regulates	0
the	0
activity	0
of	0
p70	9
(	10
s6k	10
)	10
,	0
the	0
40S	9
ribosomal	10
protein	10
S6	10
kinase	10
,	0
a	0
response	0
that	0
is	0
abrogated	0
by	0
the	0
macrolide	0
rapamycin	0
.	0

This	0
immunosuppressive	0
drug	0
is	0
known	0
to	0
prevent	0
T-cell	0
proliferation	0
,	0
but	0
the	0
precise	0
point	0
at	0
which	0
rapamycin	0
regulates	0
T-cell	0
cycle	0
progression	0
has	0
yet	0
to	0
be	0
elucidated	0
.	0

Moreover	0
,	0
the	0
effects	0
of	0
rapamycin	0
on	0
,	0
and	0
the	0
role	0
of	0
p70	9
(	10
s6k	10
)	10
in	0
,	0
IL-2	9
and	0
PI	9
3-kinase	10
activation	0
of	0
E2Fs	9
have	0
not	0
been	0
characterized	0
.	0

Our	0
present	0
results	0
show	0
that	0
IL-2	9
-and	0
PI	9
3-kinase	10
-induced	0
pathways	0
for	0
the	0
regulation	0
of	0
E2F	9
transcriptional	0
activity	0
include	0
both	0
rapamycin-resistant	0
and	0
rapamycin-sensitive	0
components	0
.	0

Expression	0
of	0
a	0
rapamycin-resistant	9
mutant	10
of	0
p70	9
(	10
s6k	10
)	10
in	0
T	7
cells	8
could	0
restore	0
rapamycin-suppressed	0
E2F	9
responses	0
.	0

Thus	0
,	0
the	0
rapamycin-controlled	0
processes	0
involved	0
in	0
E2F	9
regulation	0
appear	0
to	0
be	0
mediated	0
by	0
p70	9
(	10
s6k	10
)	10
.	0

However	0
,	0
the	0
rapamycin-resistant	9
p70	10
(	10
s6k	10
)	10
could	0
not	0
rescue	0
rapamycin	0
inhibition	0
of	0
T-cell	0
cycle	0
entry	0
,	0
consistent	0
with	0
the	0
involvement	0
of	0
additional	0
,	0
rapamycin-sensitive	0
pathways	0
in	0
the	0
control	0
of	0
T-cell	0
cycle	0
progression	0
.	0

The	0
present	0
results	0
thus	0
show	0
that	0
p70	9
(	10
s6k	10
)	10
is	0
able	0
to	0
regulate	0
E2F	9
transcriptional	0
activity	0
and	0
provide	0
direct	0
evidence	0
for	0
the	0
first	0
time	0
for	0
a	0
link	0
between	0
IL-2	9
receptors	0
,	0
PI	9
3-kinase	10
,	0
and	0
p70	9
(	10
s6k	10
)	10
that	0
regulates	0
a	0
crucial	0
G1	0
checkpoint	0
in	0
T	7
lymphocytes	8
.	0

Oxidative	0
stress	0
triggers	0
STAT3	9
tyrosine	0
phosphorylation	0
and	0
nuclear	0
translocation	0
in	0
human	7
lymphocytes	8
.	0

Oxidizing	0
agents	0
are	0
powerful	0
activators	0
of	0
factors	0
responsible	0
for	0
the	0
transcriptional	0
activation	0
of	0
cytokine-encoding	1
genes	2
involved	0
in	0
tissue	0
injury	0
.	0

In	0
this	0
study	0
we	0
show	0
evidence	0
that	0
STAT3	9
is	0
a	0
transcription	9
factor	10
whose	0
activity	0
is	0
modulated	0
by	0
H2O2	0
in	0
human	7
lymphocytes	8
,	0
in	0
which	0
endogenous	0
catalase	9
had	0
previously	0
been	0
inhibited	0
.	0

H2O2-induced	0
nuclear	0
translocation	0
of	0
STAT3	9
to	0
form	0
sequence-specific	9
DNA-bound	10
complexes	10
was	0
evidenced	0
by	0
immunoblotting	0
of	0
nuclear	0
fractions	0
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
and	0
vanadate	0
was	0
found	0
to	0
strongly	0
synergize	0
with	0
H2O2	0
.	0

Moreover	0
,	0
anti-	0
STAT3	9
antibodies	10
specifically	0
precipitated	0
a	0
protein	0
of	0
92	9
kDa	10
that	0
becomes	0
phosphorylated	0
on	0
tyrosine	0
upon	0
lymphocyte	0
treatment	0
with	0
H2O2	0
.	0

Phenylarsine	0
oxide	0
,	0
a	0
tyrosine	0
phosphatase	0
inhibitor	0
,	0
and	0
genistein	0
,	0
a	0
tyrosine	0
kinase	0
inhibitor	0
,	0
cooperated	0
and	0
cancelled	0
,	0
respectively	0
,	0
the	0
H2O2-promoted	0
STAT3	9
nuclear	0
translocation	0
.	0

Evidence	0
is	0
also	0
presented	0
,	0
using	0
Fe2+/Cu2+	0
ions	0
,	0
that.OH	0
generated	0
from	0
H2O2	0
through	0
Fenton	0
reactions	0
could	0
be	0
a	0
candidate	0
oxygen	0
reactive	0
species	0
to	0
directly	0
activate	0
STAT3	9
.	0

Present	0
data	0
suggest	0
that	0
H2O2	0
and	0
vanadate	0
are	0
likely	0
to	0
inhibit	0
the	0
activity	0
of	0
intracellular	9
tyrosine	10
phosphatase	10
(	0
s	0
)	0
,	0
leading	0
to	0
enhanced	0
STAT3	9
tyrosine	0
phosphorylation	0
and	0
hence	0
its	0
translocation	0
to	0
the	0
nucleus	0
.	0

These	0
results	0
demonstrate	0
that	0
the	0
DNA	0
binding	0
activity	0
of	0
STAT3	9
can	0
be	0
modulated	0
by	0
oxidizing	0
agents	0
and	0
provide	0
a	0
framework	0
to	0
understand	0
the	0
effects	0
of	0
oxidative	0
stress	0
on	0
the	0
JAK	9
-STAT	9
signaling	0
pathway	0
.	0

Transcriptional	0
regulation	0
of	0
T	0
lymphocyte	0
development	0
and	0
function	0
.	0

The	0
development	0
and	0
function	0
of	0
T	7
lymphocytes	8
are	0
regulated	0
tightly	0
by	0
signal	0
transduction	0
pathways	0
that	0
include	0
specific	0
cell-surface	9
receptors	10
,	0
intracellular	9
signaling	10
molecules	10
,	0
and	0
nuclear	9
transcription	10
factors	10
.	0

Since	0
1988	0
,	0
several	0
families	0
of	0
functionally	0
important	0
T	9
cell	10
transcription	10
factors	10
have	0
been	0
identified	0
.	0

These	0
include	0
the	0
Ikaros	9
,	0
LKLF	9
,	0
and	0
GATA3	9
zinc-finger	10
proteins	10
;	0
the	0
Ets	9
,	0
CREB/ATF	9
,	0
and	0
NF-kappa	9
B/Rel/NFAT	10
transcription	10
factors	10
;	0
the	0
Stat	9
proteins	10
;	0
and	0
HMG	9
box	10
transcription	10
factors	10
such	0
as	0
LEF1	9
,	0
TCF1	9
,	0
and	0
Sox4	9
.	0

In	0
this	0
review	0
,	0
we	0
summarize	0
our	0
current	0
understanding	0
of	0
the	0
transcriptional	0
regulation	0
of	0
T	0
cell	0
development	0
and	0
function	0
with	0
particular	0
emphasis	0
on	0
the	0
results	0
of	0
recent	0
gene	0
targeting	0
and	0
transgenic	0
experiments	0
.	0

In	0
addition	0
to	0
increasing	0
our	0
understanding	0
of	0
the	0
molecular	0
pathways	0
that	0
regulate	0
T	0
cell	0
development	0
and	0
function	0
,	0
these	0
results	0
have	0
suggested	0
novel	0
targets	0
for	0
genetic	0
and	0
pharmacological	0
manipulation	0
of	0
T	0
cell	0
immunity	0
.	0

In	0
vivo	0
inhibition	0
of	0
NF-kappa	9
B	10
in	0
T-lineage	7
cells	8
leads	0
to	0
a	0
dramatic	0
decrease	0
in	0
cell	0
proliferation	0
and	0
cytokine	9
production	0
and	0
to	0
increased	0
cell	0
apoptosis	0
in	0
response	0
to	0
mitogenic	0
stimuli	0
,	0
but	0
not	0
to	0
abnormal	0
thymopoiesis	0
.	0

To	0
understand	0
the	0
role	0
of	0
NF-kappa	9
B	10
complexes	0
in	0
T	0
cell	0
development	0
and	0
activation	0
,	0
we	0
have	0
generated	0
transgenic	0
mice	0
in	0
which	0
RelA	9
and	0
c-Rel	9
complexes	10
were	0
selectively	0
inhibited	0
in	0
the	0
T-lineage	7
cells	8
by	0
specific	0
expression	0
of	0
a	0
trans-dominant	0
form	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

Transgene	0
expression	0
did	0
not	0
affect	0
the	0
thymic	0
development	0
,	0
but	0
led	0
to	0
lowered	0
numbers	0
of	0
splenic	0
T	7
cells	8
and	0
to	0
a	0
dramatic	0
decrease	0
in	0
the	0
ex	0
vivo	0
proliferative	0
response	0
of	0
splenic	7
T	8
lymphocytes	8
.	0

Analysis	0
of	0
IL-2	9
and	0
IL-2R	9
alpha	10
expression	0
demonstrated	0
that	0
the	0
perturbation	0
of	0
the	0
proliferation	0
response	0
was	0
not	0
attributable	0
to	0
an	0
abnormal	0
expression	0
of	0
these	0
genes	0
.	0

In	0
contrast	0
,	0
expression	0
of	0
IL-4	9
,	0
IL-10	9
,	0
and	0
IFN-gamma	9
was	0
strongly	0
inhibited	0
in	0
the	0
transgenic	7
T	8
cells	8
.	0

The	0
proliferative	0
deficiency	0
of	0
the	0
transgenic	7
T	8
cells	8
was	0
associated	0
with	0
an	0
increased	0
apoptosis	0
.	0

These	0
results	0
point	0
out	0
the	0
involvement	0
of	0
NF-kappa	9
B/Rel	10
family	10
proteins	10
in	0
growth	0
signaling	0
pathways	0
by	0
either	0
regulating	9
proteins	10
involved	0
in	0
the	0
IL-2	9
signaling	0
or	0
by	0
functionally	0
interfering	0
with	0
the	0
cell	0
cycle	0
progression	0
.	0

Paradoxical	0
priming	0
effects	0
of	0
IL-10	9
on	0
cytokine	9
production	0
.	0

IL-10	9
is	0
a	0
well-known	0
immunosuppressive	9
and/or	10
anti-inflammatory	10
cytokine	10
.	0

However	0
,	0
we	0
report	0
in	0
vitro	0
experimental	0
studies	0
in	0
which	0
IL-10	5
primed	6
leukocytes	6
and	0
led	0
to	0
an	0
enhanced	0
production	0
of	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
upon	0
further	0
stimulation	0
by	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

Monocytes	7
and	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
prepared	0
from	0
whole	0
blood	0
maintained	0
for	0
20	0
h	0
at	0
37	0
degrees	0
C	0
in	0
the	0
presence	0
of	0
recombinant	9
human	10
IL-10	10
had	0
an	0
enhanced	0
capacity	0
to	0
produce	0
TNF	9
in	0
response	0
to	0
LPS	0
.	0

In	0
addition	0
to	0
TNF	9
,	0
LPS-induced	0
IL-6	0
and	0
spontaneous	0
IL-1ra	0
production	0
were	0
also	0
enhanced	0
.	0

When	0
isolated	0
PBMC	7
were	0
first	0
cultured	0
for	0
20	0
h	0
in	0
the	0
presence	0
of	0
IL-10	9
on	0
Teflon	0
to	0
prevent	0
adherence	0
,	0
washed	0
to	0
remove	0
IL-10	9
and	0
then	0
further	0
cultured	0
in	0
plastic	0
dishes	0
for	0
an	0
additional	0
20	0
h	0
in	0
the	0
presence	0
of	0
LPS	0
or	0
IL-1beta	9
,	0
an	0
enhanced	0
release	0
of	0
TNF	9
was	0
observed	0
.	0

This	0
was	0
not	0
the	0
case	0
when	0
PBMC	7
were	0
pre-cultured	0
in	0
plastic	0
multidishes	0
in	0
the	0
presence	0
of	0
IL-10	9
.	0

TNF	3
mRNA	4
expression	0
induced	0
by	0
LPS	0
was	0
decreased	0
when	0
the	0
pre-treatment	0
of	0
PBMC	7
with	0
IL-10	9
was	0
performed	0
on	0
plastic	0
,	0
whereas	0
this	0
was	0
not	0
the	0
case	0
when	0
cells	0
were	0
pre-cultured	0
with	0
IL-10	9
on	0
Teflon	0
.	0

Furthermore	0
,	0
NFkappaB	0
translocation	0
following	0
LPS	0
activation	0
was	0
higher	0
after	0
IL-10	9
pre-treatment	0
on	0
Teflon	0
than	0
on	0
plastic	0
.	0

Interestingly	0
,	0
an	0
enhanced	0
frequency	0
of	0
CD16	9
and	0
CD68	0
(	0
+	0
)	0
cells	0
among	0
the	0
CD14	0
(	0
+	0
)	0
cells	0
was	0
observed	0
in	0
the	0
presence	0
of	0
IL-10	9
,	0
independently	0
of	0
the	0
pre-culture	0
conditions	0
of	0
the	0
PBMC	7
.	0

Altogether	0
,	0
these	0
results	0
indicate	0
that	0
the	0
IL-10	9
-induced	0
up-regulation	0
of	0
cytokine	9
production	0
depends	0
on	0
the	0
prevention	0
of	0
monocyte	0
adherence	0
by	0
red	7
cells	8
in	0
the	0
whole	0
blood	0
assays	0
or	0
by	0
cultures	0
of	0
PBMC	7
on	0
Teflon	0
.	0

In	0
contrast	0
,	0
the	0
adherence	0
parameter	0
has	0
no	0
effect	0
on	0
the	0
IL-10	9
-induced	0
modulation	0
of	0
some	0
monocyte	9
surface	10
markers	10
.	0

Cell	0
growth-regulated	0
expression	0
of	0
mammalian	1
MCM5	2
and	2
MCM6	2
genes	2
mediated	0
by	0
the	0
transcription	9
factor	10
E2F	9
.	0

Initiation	0
of	0
DNA	0
replication	0
requires	0
the	0
function	0
of	0
MCM	9
gene	10
products	10
,	0
which	0
participate	0
in	0
ensuring	0
that	0
DNA	0
replication	0
occurs	0
only	0
once	0
in	0
the	0
cell	0
cycle	0
.	0

Expression	0
of	0
all	0
mammalian	1
genes	2
of	0
the	0
MCM	1
family	2
is	0
induced	0
by	0
growth	0
stimulation	0
,	0
unlike	0
yeast	0
,	0
and	0
the	0
mRNA	0
levels	0
peak	0
at	0
G1/S	0
boundary	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
transcriptional	0
activities	0
of	0
isolated	1
human	2
MCM	2
gene	2
promoters	2
.	0

Human	1
MCM5	2
and	2
MCM6	2
promoters	2
with	0
mutation	0
in	0
the	0
E2F	1
sites	2
failed	0
in	0
promoter	0
regulation	0
following	0
serum	0
stimulation	0
and	0
exogenous	0
E2F	9
expression	0
.	0

In	0
addition	0
,	0
we	0
identified	0
a	0
novel	0
E2F-like	1
sequence	2
in	0
human	1
MCM6	2
promoter	2
which	0
cooperates	0
with	0
the	0
authentic	0
E2F	1
sites	2
in	0
E2F	9
-dependent	0
regulation	0
.	0

Forced	0
expression	0
of	0
E2F1	9
could	0
induce	0
expression	0
of	0
all	0
members	0
of	0
the	0
endogenous	1
MCM	2
genes	2
in	0
rat	5
embryonal	6
fibroblast	6
REF52	6
cells	6
.	0

Our	0
results	0
demonstrated	0
that	0
the	0
growth-regulated	0
expression	0
of	0
mammalian	1
MCM5	2
and	2
MCM6	2
genes	2
,	0
and	0
presumably	0
other	0
MCM	0
members	0
,	0
is	0
primarily	0
regulated	0
by	0
E2F	9
through	0
binding	0
to	0
multiple	1
E2F	2
sites	2
in	0
the	0
promoters	1
.	0

An	0
essential	0
role	0
for	0
NF-kappaB	9
in	0
human	7
CD34	8
(	8
+	8
)	8
bone	8
marrow	8
cell	8
survival	0
.	0

The	0
transcription	9
factor	10
,	0
NF-kappaB	9
,	0
is	0
important	0
for	0
T-cell	0
activation	0
,	0
B-cell	0
maturation	0
,	0
and	0
human	0
immunodeficiency	0
virus	0
transcription	0
and	0
plays	0
a	0
role	0
in	0
alternatively	0
mediating	0
and	0
protecting	0
against	0
apoptosis	0
in	0
a	0
variety	0
of	0
cell	0
types	0
.	0

However	0
,	0
a	0
role	0
for	0
NF-kappaB	9
in	0
human	7
CD34	8
(	8
+	8
)	8
bone	8
marrow	8
cells	8
has	0
not	0
been	0
described	0
.	0

We	0
provide	0
evidence	0
here	0
that	0
virtually	0
all	0
human	7
CD34	8
(	8
+	8
)	8
bone	8
marrow	8
cells	8
express	0
NF-kappaB	9
that	0
can	0
be	0
activated	0
by	0
exposure	0
to	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
a	0
variety	0
of	0
cytokines	9
,	0
eg	0
,	0
tumor	9
necrosis	10
factor	10
alpha	10
,	0
interleukin-3	9
,	0
and	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
.	0

In	0
addition	0
,	0
we	0
demonstrate	0
that	0
NF-kappaB	9
may	0
be	0
required	0
for	0
human	0
CD34	7
(	8
+	8
)	8
bone	8
marrow	8
cell	8
clonogenic	0
function	0
and	0
survival	0
.	0

These	0
results	0
offer	0
insight	0
into	0
a	0
new	0
role	0
for	0
NF-kappaB	9
in	0
maintaining	0
survival	0
and	0
function	0
in	0
hematopoietic	7
stem	8
and	8
progenitor	8
cells	8
and	0
suggest	0
that	0
proposed	0
strategies	0
involving	0
inhibition	0
of	0
NF-kappaB	9
activation	0
as	0
an	0
adjunct	0
to	0
cancer	0
chemotherapy	0
should	0
be	0
approached	0
with	0
caution	0
.	0

High	0
molecular	0
weight	0
dextran	0
sulfate	0
increases	0
the	0
activity	0
of	0
NF-kappaB-regulated	1
promoter	2
in	0
monocyte-derived	7
macrophages	8
.	0

It	0
is	0
known	0
that	0
sulfated	0
polysaccharides	0
can	0
mimic	0
the	0
action	0
of	0
common	9
T-cell	10
mitogens	10
.	0

To	0
investigate	0
the	0
molecular	0
basis	0
of	0
the	0
mitogenic	0
effect	0
of	0
high	0
molecular	0
weight	0
dextran	0
sulfate	0
(	0
HMDS	0
)	0
,	0
monocyte-derived	7
macrophages	8
were	0
transfected	0
with	0
recombinant	1
plasmid	2
containing	0
chloramphenicol	1
acetyl	2
transferase	2
(	2
CAT	2
)	2
reporter	2
gene	2
under	0
the	0
control	0
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
(	2
LTR	2
)	2
promoter	2
,	0
which	0
is	0
regulated	0
by	0
transcription	9
factor	10
NF-kappaB	9
.	0

We	0
observed	0
that	0
HMDS	0
,	0
similar	0
to	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
increases	0
the	0
expression	0
of	0
CAT	1
reporter	2
gene	2
suggesting	0
increased	0
activity	0
of	0
NF-kappaB	9
.	0

The	0
activation	0
of	0
NF-kappaB	9
correlated	0
with	0
the	0
increased	0
expression	0
of	0
B7.1	9
molecules	10
.	0

It	0
was	0
postulated	0
that	0
this	0
NF-kappaB-regulated	1
promoter	2
might	0
play	0
a	0
role	0
in	0
the	0
activation	0
of	0
the	0
accessory	0
cells	0
as	0
well	0
as	0
the	0
rate	0
of	0
replication	0
of	0
HIV-1	0
in	0
monocyte-derived	7
macrophages	8
.	0

Transcription	9
factors	10
Sp1	9
and	0
AP-2	9
mediate	0
induction	0
of	0
acid	9
sphingomyelinase	10
during	0
monocytic	0
differentiation	0
.	0

Cells	0
from	0
the	0
human	5
monocytic	6
leukemia	6
cell	6
line	6
THP-1	5
differentiate	0
towards	0
a	0
macrophage-like	0
phenotype	0
when	0
stimulated	0
with	0
phorbol	0
12-myristate	0
-13-	0
acetate	0
(	0
PMA	0
)	0
,	0
1	0
,	0
25-dihydroxy-vitamin	0
D3	0
,	0
and	0
various	0
other	0
agents	0
.	0

We	0
demonstrate	0
here	0
that	0
the	0
expression	0
of	0
the	0
lysosomal	9
enzyme	10
acid	9
sphingomyelinase	10
(	0
ASM	0
;	0
E.C.3.1.4.12	0
)	0
is	0
induced	0
during	0
this	0
process	0
and	0
is	0
strongly	0
elevated	0
in	0
differentiated	0
THP-1	5
cells	6
,	0
as	0
well	0
as	0
in	0
differentiated	0
human	7
mononuclear	8
phagocytes	8
.	0

Using	0
Northern	0
blotting	0
,	0
RNase	9
protection	0
assay	0
,	0
and	0
nuclear	0
run-on	0
analyses	0
,	0
we	0
show	0
that	0
the	0
up-regulation	0
of	0
ASM	0
expression	0
is	0
regulated	0
mainly	0
at	0
the	0
level	0
of	0
transcription	0
and	0
that	0
new	0
protein	0
synthesis	0
is	0
required	0
for	0
enhanced	0
ASM	0
activity	0
.	0

This	0
cell-type	0
specific	0
induction	0
by	0
PMA	0
treatment	0
was	0
further	0
investigated	0
with	0
respect	0
to	0
transcriptional	0
control	0
.	0

A	0
series	0
of	0
5	1
'	2
deletion	2
derivatives	2
of	0
the	0
upstream	1
regulatory	2
region	2
were	0
used	0
in	0
transient	0
transfection	0
assays	0
to	0
identify	0
promoter	1
elements	2
required	0
for	0
basal	0
and	0
inducible	0
gene	0
expression	0
.	0

A	0
PMA	1
responsive	2
element	2
was	0
localized	0
to	0
a	0
region	0
between	0
-319	1
and	2
-219	2
bp	2
upstream	2
of	0
the	0
initiation	0
codon	0
and	0
co-transfections	0
with	0
transcription	1
factor	2
expression	2
plasmids	2
for	0
AP-2	9
and	0
Sp1	9
resulted	0
in	0
augmented	0
ASM	0
promoter	0
activity	0
,	0
which	0
was	0
abolished	0
when	0
the	0
binding	1
sites	2
for	0
these	0
two	0
factors	0
were	0
deleted	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
and	0
supershift	0
assays	0
we	0
demonstrate	0
that	0
this	0
region	0
is	0
specifically	0
bound	0
by	0
Sp1	9
and	0
AP-2	9
.	0

These	0
factors	0
are	0
present	0
in	0
nuclear	0
extracts	0
prepared	0
from	0
both	0
induced	0
and	0
uninduced	0
THP-1	5
cells	6
.	0

However	0
,	0
the	0
intensity	0
of	0
the	0
complex	0
formed	0
appeared	0
to	0
increase	0
when	0
nuclear	0
extracts	0
from	0
PMA-treated	5
cells	6
were	0
used	0
.	0

From	0
these	0
studies	0
,	0
we	0
conclude	0
that	0
a	0
concerted	0
action	0
of	0
the	0
transcription	9
factors	10
AP-2	9
and	0
Sp1	9
is	0
essential	0
for	0
the	0
up	0
-regulation	0
of	0
ASM	0
expression	0
during	0
the	0
process	0
of	0
macrophage	0
differentiation	0
.	0

LPS-Induced	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
release	0
in	0
human	7
monocytes	8
are	0
protein	9
tyrosine	10
kinase	10
dependent	0
and	0
protein	9
kinase	10
C	10
independent	0
.	0

BACKGROUND	0
:	0
Tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
is	0
an	0
important	0
mediator	0
of	0
septic	0
shock	0
.	0

Endotoxin	0
(	0
LPS	0
)	0
signal	0
transduction	0
in	0
human	7
monocytes	8
leads	0
to	0
activation	0
of	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappaB	9
)	0
and	0
TNF-alpha	9
release	0
.	0

Previous	0
studies	0
have	0
implicated	0
activation	0
of	0
both	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
and	0
protein	9
tyrosine	10
kinases	10
(	0
PTK	9
)	0
in	0
LPS-induced	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
production	0
.	0

We	0
hypothesized	0
that	0
inhibition	0
of	0
either	0
PKC	9
or	0
PTK	9
would	0
decrease	0
LPS-induced	0
NF-kappaB	9
DNA	0
binding	0
and	0
TNF-alpha	9
release	0
in	0
human	7
monocytes	8
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
Human	7
monocytes	8
were	0
stimulated	0
with	0
PMA	0
(	0
50	0
ng/ml	0
)	0
alone	0
or	0
LPS	0
(	0
100	0
ng/ml	0
)	0
with	0
and	0
without	0
a	0
nonspecific	0
serine/threonine	9
protein	10
kinase	10
inhibitor	0
staurosporine	0
(	0
Stauro	0
)	0
,	0
a	0
specific	0
pan-	0
PKC	9
inhibitor	0
bisindolylmaleimide	0
(	0
Bis	0
)	0
,	0
or	0
an	0
inhibitor	0
of	0
PTK	9
genistein	0
(	0
Gen	0
)	0
.	0

TNF-alpha	9
release	0
in	0
culture	0
supernatants	0
was	0
measured	0
by	0
an	0
ELISA	0
.	0

NF-kappaB	9
DNA	0
binding	0
was	0
evaluated	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

RESULTS	0
:	0
LPS	0
increased	0
NF-kappaB	9
DNA	0
binding	0
and	0
TNF-alpha	9
release	0
in	0
human	7
monocytes	8
.	0

Nonspecific	0
protein	9
kinase	10
inhibition	0
inhibited	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
release	0
,	0
while	0
specific	0
PKC	9
inhibition	0
with	0
Bis	0
had	0
no	0
effect	0
on	0
LPS-induced	0
NF-kappaB	9
DNA	0
binding	0
or	0
TNF-alpha	9
release	0
.	0

PTK	9
inhibition	0
with	0
Gen	0
attenuated	0
both	0
LPS-induced	0
NF-kappaB	9
DNA	0
binding	0
and	0
TNF-alpha	9
production	0
in	0
human	7
monocytes	8
.	0

Direct	0
activation	0
of	0
PKC	9
with	0
PMA	0
induced	0
both	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
production	0
by	0
human	7
monocytes	8
.	0

CONCLUSIONS	0
:	0
These	0
results	0
suggest	0
that	0
LPS-induced	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
release	0
in	0
human	7
monocytes	8
are	0
independent	0
of	0
PKC	9
activity	0
.	0

Furthermore	0
,	0
our	0
results	0
provide	0
evidence	0
that	0
PTK	9
plays	0
a	0
role	0
in	0
LPS-induced	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
release	0
in	0
human	7
monocytes	8
and	0
thus	0
could	0
be	0
a	0
potential	0
therapeutic	0
target	0
in	0
inflammatory	0
states	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Amelioration	0
of	0
rat	0
cerulein	0
pancreatitis	0
by	0
guamerin-derived	0
peptide	0
,	0
a	0
novel	0
elastase	9
inhibitor	0
.	0

Increased	0
activity	0
of	0
various	0
proteases	9
is	0
observed	0
in	0
both	0
human	0
and	0
experimental	0
pancreatitis	0
;	0
however	0
,	0
the	0
information	0
on	0
the	0
effects	0
of	0
specific	0
protease	0
inhibitors	0
on	0
the	0
disease	0
is	0
limited	0
.	0

In	0
this	0
study	0
we	0
show	0
that	0
a	0
novel	0
elastase	0
inhibitor	0
,	0
guamerin-derived	0
synthetic	0
peptide	0
(	0
GDSP	0
)	0
,	0
improves	0
the	0
parameters	0
of	0
cerulein-induced	0
acute	0
pancreatitis	0
in	0
the	0
rat	0
.	0

The	0
effects	0
of	0
GDSP	0
on	0
pancreatic	0
weight	0
,	0
serum	9
amylase	10
and	10
lipase	10
,	0
morphologic	0
changes	0
in	0
the	0
pancreas	0
,	0
neutrophil	0
infiltration	0
,	0
and	0
nuclear	9
factor	10
KB	10
(	0
NF-KB	9
)	0
activation	0
were	0
measured	0
in	0
rats	0
infused	0
with	0
supramaximal	0
dose	0
of	0
cerulein	0
(	0
5	0
(	0
g/kg/h	0
)	0
for	0
6	0
h	0
.	0

The	0
effects	0
of	0
GDSP	0
were	0
also	0
measured	0
on	0
superoxide	0
formation	0
by	0
activated	7
human	8
neutrophils	8
.	0

The	0
effects	0
of	0
GDSP	0
were	0
compared	0
with	0
those	0
of	0
another	0
elastase	0
inhibitor	0
,	0
elastatinal	0
.	0

GDSP	0
significantly	0
inhibited	0
edema	0
formation	0
,	0
neutrophil	0
infiltration	0
,	0
acinar	0
cell	0
damage	0
,	0
and	0
plasma	9
lipase	10
and	0
amylase	9
increases	0
caused	0
by	0
cerulein	0
.	0

GDSP	0
also	0
completely	0
inhibited	0
superoxide	0
formation	0
in	0
the	0
human	7
neutrophils	8
stimulated	0
by	0
N-formyl-methionine-leucine-phenyl-alanine	0
(	0
fMLP	0
)	0
or	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
.	0

Elastatinal	0
had	0
some	0
of	0
the	0
same	0
effects	0
as	0
GDSP	0
but	0
was	0
less	0
potent	0
and	0
effective	0
.	0

These	0
results	0
demonstrate	0
a	0
beneficial	0
effect	0
of	0
GDSP	0
,	0
a	0
novel	0
specific	0
elastase	0
inhibitor	0
,	0
on	0
the	0
development	0
of	0
rat	0
cerulein	0
pancreatitis	0
.	0

A	0
novel	0
lipopolysaccharide-induced	9
transcription	10
factor	10
regulating	0
tumor	9
necrosis	10
factor	10
alpha	10
gene	0
expression	0
:	0
molecular	0
cloning	0
,	0
sequencing	0
,	0
characterization	0
,	0
and	0
chromosomal	0
assignment	0
.	0

Lipopolysaccharide	0
(	0
LPS	0
)	0
is	0
a	0
potent	0
stimulator	0
of	0
monocytes	7
and	0
macrophages	7
,	0
causing	0
secretion	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
and	0
other	0
inflammatory	0
mediators	0
.	0

Given	0
the	0
deleterious	0
effects	0
to	0
the	0
host	0
of	0
TNF-alpha	9
,	0
it	0
has	0
been	0
postulated	0
that	0
TNF-alpha	9
gene	0
expression	0
must	0
be	0
tightly	0
regulated	0
.	0

The	0
nature	0
of	0
the	0
nuclear	9
factor	10
(	0
s	0
)	0
that	0
control	0
TNF-alpha	9
gene	0
transcription	0
in	0
humans	0
remains	0
obscure	0
,	0
although	0
NF-kappaB	9
has	0
been	0
suggested	0
.	0

Our	0
previous	0
studies	0
pertaining	0
to	0
macrophage	0
response	0
to	0
LPS	0
identified	0
a	0
novel	0
DNA-binding	9
domain	10
located	0
from	0
-550	0
to	0
-487	0
in	0
the	0
human	1
TNF-alpha	2
promoter	2
that	0
contains	0
transcriptional	0
activity	0
,	0
but	0
lacks	0
any	0
known	0
NF-kappaB	9
-binding	1
sites	2
.	0

We	0
have	0
used	0
this	0
DNA	0
fragment	0
to	0
isolate	0
and	0
purify	0
a	0
60-kDa	9
protein	10
binding	0
to	0
this	0
fragment	0
and	0
obtained	0
its	0
amino-terminal	9
sequence	10
,	0
which	0
was	0
used	0
to	0
design	0
degenerate	1
probes	2
to	0
screen	0
a	0
cDNA	0
library	0
from	0
THP-1	5
cells	6
.	0

A	0
novel	0
cDNA	1
clone	2
(	0
1.8	0
kb	0
)	0
was	0
isolated	0
and	0
fully	0
sequenced	0
.	0

Characterization	0
of	0
this	0
cDNA	1
clone	2
revealed	0
that	0
its	0
induction	0
was	0
dependent	0
on	0
LPS	0
activation	0
of	0
THP-1	5
cells	6
;	0
hence	0
,	0
the	0
name	0
LPS-induced	9
TNF-alpha	10
factor	10
(	0
LITAF	9
)	0
.	0

Inhibition	0
of	0
LITAF	3
mRNA	4
expression	0
in	0
THP-1	5
cells	6
resulted	0
in	0
a	0
reduction	0
of	0
TNF-alpha	9
transcripts	0
.	0

In	0
addition	0
,	0
high	0
level	0
of	0
expression	0
of	0
LITAF	3
mRNA	4
was	0
observed	0
predominantly	0
in	0
the	0
placenta	0
,	0
peripheral	7
blood	8
leukocytes	8
,	0
lymph	0
nodes	0
,	0
and	0
the	0
spleen	0
.	0

Finally	0
,	0
chromosomal	0
localization	0
using	0
fluorescence	0
in	0
situ	0
hybridization	0
revealed	0
that	0
LITAF	9
mapped	0
to	0
chromosome	1
16p12-16p13.3	2
.	0

Together	0
,	0
these	0
findings	0
suggest	0
that	0
LITAF	9
plays	0
an	0
important	0
role	0
in	0
the	0
activation	0
of	0
the	0
human	1
TNF-alpha	2
gene	2
and	0
proposes	0
a	0
new	0
mechanism	0
to	0
control	0
TNF-alpha	9
gene	0
expression	0
.	0

A	0
human	1
IFNGR1	2
small	2
deletion	2
hotspot	2
associated	0
with	0
dominant	0
susceptibility	0
to	0
mycobacterial	0
infection	0
[	0
see	0
comments	0
]	0

The	0
immunogenetic	0
basis	0
of	0
severe	0
infections	0
caused	0
by	0
bacille	0
Calmette-Guerin	0
vaccine	0
and	0
environmental	0
mycobacteria	0
in	0
humans	0
remains	0
largely	0
unknown	0
.	0

We	0
describe	0
18	0
patients	0
from	0
several	0
generations	0
of	0
12	0
unrelated	0
families	0
who	0
were	0
heterozygous	0
for	0
1	0
to	0
5	0
overlapping	1
IFNGR1	2
frameshift	2
small	2
deletions	2
and	0
a	0
wild-type	1
IFNGR1	2
allele	2
.	0

There	0
were	0
12	0
independent	0
mutation	0
events	0
at	0
a	0
single	1
mutation	2
site	2
,	0
defining	0
a	0
small	1
deletion	2
hotspot	2
.	0

Neighbouring	0
sequence	0
analysis	0
favours	0
a	0
small	0
deletion	0
model	0
of	0
slipped	0
mispairing	0
events	0
during	0
replication	0
.	0

The	0
mutant	0
alleles	0
encode	0
cell-surface	9
IFNgamma	10
receptors	10
that	0
lack	0
the	0
intra-cytoplasmic	9
domain	10
,	0
which	0
,	0
through	0
a	0
combination	0
of	0
impaired	0
recycling	0
,	0
abrogated	0
signalling	0
and	0
normal	0
binding	0
to	0
IFNgamma	9
exert	0
a	0
dominant-negative	0
effect	0
.	0

We	0
thus	0
report	0
a	0
hotspot	0
for	0
human	1
IFNGR1	2
small	2
deletions	2
that	0
confer	0
dominant	0
susceptibility	0
to	0
infections	0
caused	0
by	0
poorly	0
virulent	0
mycobacteria	0
.	0

Characterization	0
of	0
expression	0
of	0
the	0
gene	0
for	0
human	9
pterin	10
carbinolamine	10
dehydratase/dimerization	10
cofactor	10
of	0
HNF1	9
.	0

Pterin	9
carbinolamine	10
dehydratase/dimerization	10
cofactor	10
of	0
HNF1	9
(	0
PCD/DCoH	9
)	0
is	0
a	0
dual-function	9
protein	10
.	0

In	0
the	0
cytoplasm	0
it	0
acts	0
as	0
a	0
dehydratase	9
in	0
the	0
regeneration	0
of	0
tetrahydrobiopterin	9
,	0
the	0
cofactor	0
for	0
aromatic	9
amino	10
acid	10
hydroxylases	10
.	0

In	0
the	0
nucleus	0
,	0
it	0
functions	0
as	0
a	0
dimerization	9
cofactor	10
of	0
HNF1	9
and	0
increases	0
the	0
transcriptional	0
activity	0
of	0
HNF1	9
.	0

To	0
deepen	0
our	0
understanding	0
of	0
this	0
protein	0
,	0
we	0
characterized	0
its	0
expression	0
in	0
human	0
tissues	0
and	0
cells	0
.	0

Human	0
PCD/DCoH	9
was	0
present	0
predominantly	0
in	0
liver	0
and	0
kidney	0
,	0
with	0
significant	0
amounts	0
in	0
testis	0
and	0
ovary	0
,	0
trace	0
amounts	0
in	0
lung	0
,	0
and	0
undetectable	0
levels	0
in	0
whole	0
brain	0
,	0
heart	0
,	0
and	0
spleen	0
.	0

It	0
was	0
expressed	0
in	0
all	0
of	0
the	0
cells	0
that	0
were	0
examined	0
.	0

Importantly	0
,	0
it	0
was	0
also	0
present	0
in	0
the	0
nucleus	0
of	0
HeLa	5
cells	6
,	0
which	0
lack	0
HNF1	9
,	0
and	0
in	0
the	0
cytoplasm	0
of	0
fibroblasts	7
that	0
have	0
little	0
or	0
no	0
tetrahydrobiopterin	9
.	0

The	0
expression	0
of	0
human	9
PCD/DCoH	10
in	0
the	0
liver	0
and	0
nonhepatic	7
cells	8
was	0
compared	0
at	0
both	0
the	0
mRNA	0
and	0
protein	0
levels	0
.	0

Although	0
the	0
mRNA	0
level	0
in	0
liver	0
was	0
only	0
fourfold	0
higher	0
than	0
that	0
in	0
keratinocytes	7
and	0
fibroblasts	7
,	0
the	0
hepatic	9
PCD/DCoH	10
protein	10
level	0
was	0
20-fold	0
higher	0
than	0
that	0
in	0
normal	7
human	8
epidermal	8
keratinocytes	8
and	0
dermal	7
fibroblasts	8
.	0

Cloning	0
of	0
the	0
5	1
'	2
and	2
3	2
'	2
untranslated	2
region	2
(	0
UTR	1
)	0
of	0
human	9
keratinocyte	10
PCD/DCoH	10
revealed	0
that	0
it	0
has	0
53	0
bp	0
more	0
of	0
GC-rich	1
5	2
'	2
untranslated	2
sequence	2
than	0
the	0
published	0
liver	9
PCD/DCoH	10
.	0

In	0
vitro	0
transcription	0
and	0
translation	0
analysis	0
showed	0
that	0
the	0
longer	0
5	1
'	2
UTR	2
resulted	0
in	0
about	0
a	0
35	0
%	0
decrease	0
in	0
translation	0
efficiency	0
.	0

These	0
data	0
show	0
that	0
human	9
PCD/DCoH	10
is	0
not	0
only	0
present	0
in	0
cells	0
where	0
tetrahydrobiopterin	9
is	0
synthesized	0
or	0
HNF1	9
is	0
present	0
but	0
is	0
a	0
widely	0
distributed	0
protein	0
.	0

Its	0
differential	0
expression	0
in	0
different	0
tissues	0
and	0
cells	0
is	0
regulated	0
not	0
only	0
at	0
the	0
transcriptional	0
level	0
but	0
also	0
at	0
the	0
translational	0
level	0
.	0

NF-kappaB	9
regulates	0
Fas/APO-1/CD95-	0
and	0
TCR-	0
mediated	0
apoptosis	0
of	0
T	7
lymphocytes	8
.	0

The	0
maintenance	0
of	0
lymphocyte	0
homeostasis	0
by	0
apoptosis	0
is	0
a	0
critical	0
regulatory	0
mechanism	0
in	0
the	0
normal	0
immune	0
system	0
.	0

The	0
transcription	9
factor	10
NF-kappaB	9
has	0
been	0
shown	0
to	0
play	0
a	0
role	0
in	0
protecting	0
cells	0
against	0
death	0
mediated	0
by	0
TNF	9
We	0
show	0
here	0
that	0
NF-kappaB	9
also	0
has	0
a	0
role	0
in	0
regulating	0
Fas	9
/	0
APO-1	9
/	0
CD95	9
-mediated	0
death	0
,	0
a	0
major	0
pathway	0
of	0
peripheral	7
T	8
cell	8
death	0
.	0

Transfection	0
of	0
Jurkat	5
cells	6
with	0
the	0
NF-kappaB	9
subunits	10
p50	9
and	0
p65	9
confers	0
resistance	0
against	0
Fas-mediated	0
apoptosis	0
.	0

Reciprocally	0
,	0
inhibition	0
of	0
NF-kappaB	9
activation	0
by	0
a	0
soluble	0
peptide	0
inhibitor	0
or	0
a	0
dominant	0
form	0
of	0
the	0
NF-kappaB	9
inhibitor	0
,	0
IkappaB	9
,	0
makes	0
the	0
cells	0
more	0
susceptible	0
to	0
Fas-mediated	0
apoptosis	0
.	0

Furthermore	0
,	0
inhibition	0
of	0
NF-kappaB	9
activation	0
by	0
a	0
soluble	0
peptide	0
inhibitor	0
rendered	0
a	0
T	5
cell	6
hybridoma	6
more	0
susceptible	0
to	0
TCR-mediated	0
apoptosis	0
.	0

Correspondingly	0
,	0
transfection	0
of	0
p50	9
and	0
p65	9
provided	0
considerable	0
protection	0
from	0
TCR-mediated	0
apoptosis	0
.	0

These	0
observations	0
were	0
corroborated	0
by	0
studies	0
on	0
Fas	9
-mediated	0
death	0
in	0
primary	7
T	8
cells	8
.	0

Concanavalin	0
A-activated	0
cycling	5
T	6
cell	6
blasts	6
from	0
mice	0
that	0
are	0
transgenic	0
for	0
the	0
dominant	9
IkappaB	10
molecule	10
have	0
increased	0
sensitivity	0
to	0
Fas-mediated	0
apoptosis	0
,	0
associated	0
with	0
a	0
down-regulation	0
of	0
NF-kappaB	9
complexes	10
in	0
the	0
nucleus	0
.	0

In	0
addition	0
,	0
blocking	0
TNF	9
,	0
itself	0
a	0
positive	0
regulator	0
of	0
NF-kappaB	9
,	0
with	0
neutralizing	9
antibodies	10
renders	0
the	0
cells	0
more	0
susceptible	0
to	0
anti-Fas-mediated	0
apoptosis	0
.	0

In	0
summary	0
,	0
our	0
results	0
provide	0
compelling	0
evidence	0
that	0
NF-kappaB	9
protects	0
against	0
Fas	9
-mediated	0
death	0
and	0
is	0
likely	0
to	0
be	0
an	0
important	0
regulator	0
of	0
T	0
cell	0
homeostasis	0
and	0
tolerance	0
.	0

T	0
helper	0
differentiation	0
proceeds	0
through	0
Stat1-dependent	0
,	0
Stat4-dependent	0
and	0
Stat4-independent	0
phases	0
.	0

Much	0
of	0
our	0
focus	0
in	0
understanding	0
Th1/Th2	0
development	0
has	0
been	0
on	0
the	0
signals	0
delivered	0
by	0
IL-12	9
and	0
IL-4	9
as	0
final	0
determinants	0
of	0
terminal	0
T	0
cell	0
differentiation	0
.	0

Because	0
extinction	0
of	0
IL-12	9
signaling	0
in	0
early	0
Th2	0
development	0
could	0
potentially	0
be	0
important	0
in	0
imprinting	0
a	0
more	0
permanent	0
Th2	0
phenotype	0
on	0
a	0
population	0
of	0
T	7
cells	8
,	0
we	0
have	0
also	0
examined	0
various	0
parameters	0
regulating	0
the	0
IL-12	9
signaling	0
pathway	0
.	0

Whereas	0
IL-4	9
appears	0
to	0
repress	0
functional	0
IL-12	9
signaling	0
through	0
inhibition	0
of	0
IL-12R	9
beta	10
2	10
expression	0
,	0
IFN-gamma	9
in	0
the	0
mouse	0
,	0
and	0
IFN-alpha	9
in	0
the	0
human	0
appear	0
to	0
induce	0
IL-12R	9
beta	10
2	10
expression	0
and	0
promote	0
IL-12	9
responsiveness	0
.	0

We	0
propose	0
that	0
Th1	0
development	0
can	0
be	0
considered	0
in	0
two	0
stages	0
,	0
capacitance	0
and	0
development	0
.	0

Capacitance	0
would	0
simply	0
involve	0
expression	0
of	0
IL-12R	9
beta	10
1	10
and	10
beta	10
2	10
subunits	10
,	0
regulated	0
by	0
TCR	0
,	0
IL-4	9
and	0
IFNs	9
.	0

The	0
second	0
stage	0
,	0
development	0
,	0
we	0
propose	0
is	0
the	0
true	0
IL-12	9
induced	0
developmental	0
stage	0
,	0
involving	0
expression	0
of	0
Stat4	9
inducible	10
proteins	10
.	0

In	0
the	0
human	0
,	0
this	0
may	0
also	0
occur	0
via	0
IFN-alpha	9
,	0
which	0
is	0
able	0
to	0
activate	0
Stat4	9
.	0

It	0
is	0
perhaps	0
possible	0
that	0
all	0
of	0
Stat4	9
actions	0
on	0
Th1	0
development	0
may	0
be	0
exert	0
directly	0
by	0
Stat4	9
at	0
the	0
IFN-gamma	1
gene	2
,	0
however	0
we	0
suggest	0
that	0
,	0
more	0
likely	0
,	0
Stat4	9
may	0
act	0
to	0
induce	0
Th1	0
development	0
through	0
the	0
induction	0
of	0
other	0
non-cytokine	1
genes	2
,	0
whose	0
stable	0
expression	0
maintains	0
the	0
transcriptional	0
state	0
of	0
a	0
Th1	7
cell	8
.	0

Lineage-specific	0
activation	0
of	0
STAT3	9
by	0
interferon-gamma	9
in	0
human	7
neutrophils	8
.	0

Binding	0
of	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
to	0
its	0
heterodimeric	0
receptor	0
induces	0
activation	0
of	0
the	0
tyrosine	9
kinases	10
JAK1	9
and	0
JAK2	9
followed	0
by	0
tyrosine	0
phosphorylation	0
of	0
STAT1alpha	9
.	0

Selective	0
activation	0
of	0
STAT1alpha	9
at	0
the	0
IFN-gamma	9
receptor	10
is	0
achieved	0
by	0
specific	0
interaction	0
between	0
a	0
cytosolic	9
tyrosine	10
motif	10
including	0
Y440	9
in	0
the	0
IFN-gamma	9
receptor	10
alpha-chain	10
and	0
the	0
SH2	9
domain	10
of	0
STAT1alpha	9
.	0

We	0
demonstrate	0
that	0
,	0
in	0
addition	0
to	0
STAT1alpha	9
,	0
STAT3	9
is	0
also	0
activated	0
by	0
IFN-gamma	9
in	0
human	7
neutrophils	8
.	0

The	0
activation	0
of	0
STAT3	9
was	0
not	0
found	0
in	0
human	7
eosinophils	8
,	0
monocytes	7
,	0
and	0
HL-60	5
cells	6
,	0
although	0
the	0
STAT3	9
protein	10
was	0
expressed	0
in	0
these	0
cells	0
.	0

The	0
cell	0
type-specific	0
activation	0
of	0
STAT3	9
by	0
IFN-gamma	9
was	0
also	0
observed	0
in	0
neutrophils	7
that	0
are	0
differentiated	0
in	0
vitro	0
from	0
human	7
CD34+	8
hematopoietic	8
stem	8
cells	8
.	0

These	0
results	0
indicate	0
that	0
a	0
single	0
cytokine	9
receptor	10
can	0
activate	0
different	0
STAT	9
family	10
members	10
in	0
a	0
cell-specific	0
manner	0
,	0
which	0
might	0
result	0
in	0
cell-specific	0
gene	0
transcription	0
.	0

Alternative	0
polyadenylation	0
events	0
contribute	0
to	0
the	0
induction	0
of	0
NF-ATc	9
in	0
effector	7
T	8
cells	8
.	0

The	0
transcription	9
factor	10
NF-ATc	9
is	0
synthesized	0
in	0
three	0
prominent	0
isoforms	9
.	0

These	0
differ	0
in	0
the	0
length	0
of	0
their	0
C	0
terminal	0
peptides	0
and	0
mode	0
of	0
synthesis	0
.	0

Due	0
to	0
a	0
switch	0
from	0
the	0
use	0
of	0
a	0
3	1
'	2
polyA	2
site	2
to	0
a	0
more	0
proximal	1
polyA	2
site	2
,	0
NF-ATc	9
expression	0
switches	0
from	0
the	0
synthesis	0
of	0
the	0
two	0
longer	0
isoforms	0
in	0
naive	7
T	8
cells	8
to	0
that	0
of	0
short	0
isoform	9
A	10
in	0
T	7
effector	8
cells	8
.	0

The	0
relative	0
low	0
binding	0
affinity	0
of	0
cleavage	9
stimulation	10
factor	10
CstF-64	9
to	0
the	0
proximal	1
polyA	2
site	2
seems	0
to	0
contribute	0
to	0
its	0
neglect	0
in	0
naive	7
T	8
cells	8
.	0

These	0
alternative	0
polyadenylation	0
events	0
ensure	0
the	0
rapid	0
accumulation	0
of	0
high	0
concentrations	0
of	0
NF-ATc	9
necessary	0
to	0
exceed	0
critical	0
threshold	0
levels	0
of	0
NF-ATc	9
for	0
gene	0
induction	0
in	0
effector	7
T	8
cells	8
.	0

Estrogen	0
and	0
progesterone	0
induction	0
of	0
survival	0
of	0
monoblastoid	7
cells	8
undergoing	0
TNF-alpha	9
-induced	0
apoptosis	0
.	0

Induction	0
of	0
apoptosis	0
of	0
mononucleated	7
cells	8
is	0
a	0
physiological	0
process	0
for	0
regulating	0
the	0
intensity	0
of	0
the	0
immune	0
response	0
.	0

The	0
female	0
steroid	0
hormones	0
estrogen	0
(	0
E2	0
)	0
and	0
progesterone	0
(	0
Prog	0
)	0
are	0
known	0
to	0
modulate	0
the	0
reactivity	0
of	0
the	0
immune	0
system	0
;	0
recently	0
it	0
has	0
been	0
demonstrated	0
that	0
they	0
can	0
regulate	0
induction	0
of	0
apoptosis	0
of	0
endothelial	7
cells	8
and	0
osteoblasts	7
.	0

TNF-alpha	9
-mediated	0
induction	0
of	0
apoptosis	0
has	0
been	0
well	0
characterized	0
in	0
myeloid	7
cells	8
.	0

We	0
investigated	0
whether	0
E2	0
and	0
Prog	0
could	0
interfere	0
with	0
TNF-alpha	9
-induced	0
apoptosis	0
of	0
the	0
monoblastoid	5
U937	6
cell	6
line	6
.	0

Treatment	0
with	0
E2	0
or	0
Prog	0
increased	0
survival	0
and	0
prevented	0
apoptosis	0
induced	0
by	0
TNF-alpha	9
in	0
both	0
undifferentiated	0
and	0
macrophage-like	0
PMA-differentiated	5
U937	6
cells	6
,	0
as	0
assessed	0
by	0
trypan	0
blue	0
exclusion	0
cell	0
counting	0
,	0
thymidine	0
incorporation	0
,	0
AnnexinV	0
labeling	0
,	0
followed	0
by	0
flow	0
cytometry	0
and	0
DNA	0
fragmentation	0
studies	0
.	0

This	0
effect	0
can	0
be	0
associated	0
with	0
the	0
activation	0
of	0
specific	0
hormone	0
receptors	0
,	0
since	0
we	0
observed	0
the	0
expression	0
of	0
the	0
estrogen	3
receptor	4
alpha	4
(	4
ER-alpha	4
)	4
,	4
ER-beta	4
,	4
and	4
progesterone	4
receptor	4
(	4
PR	4
)	4
mRNAs	4
;	0
the	0
ER-alpha	9
protein	0
expression	0
was	0
confirmed	0
by	0
immunocytochemical	0
analysis	0
.	0

In	0
addition	0
,	0
hormone-mediated	0
survival	0
against	0
apoptosis	0
was	0
concentration	0
dependent	0
,	0
reaching	0
the	0
half-maximal	0
effect	0
at	0
10	0
nM	0
and	0
blocked	0
by	0
the	0
ER	0
antagonist	0
ICI	0
182	0
,	0
780	0
in	0
undifferentiated	7
cells	8
,	0
further	0
supporting	0
a	0
receptor-mediated	0
mechanism	0
of	0
cell	0
survival	0
.	0

Other	0
steroid	0
receptor	0
drugs	0
such	0
as	0
Raloxifene	0
,	0
RU486	0
,	0
or	0
the	0
ICI	0
182	0
,	0
780	0
in	0
PMA-differentiated	5
cells	6
displayed	0
agonist	0
activity	0
by	0
preventing	0
TNF-alpha	9
-induced	0
apoptosis	0
as	0
efficiently	0
as	0
the	0
hormones	0
alone	0
,	0
providing	0
further	0
evidence	0
to	0
the	0
notion	0
that	0
steroid	0
receptor	0
drugs	0
may	0
manifest	0
agonist	0
or	0
antagonist	0
activities	0
depending	0
on	0
the	0
cellular	0
context	0
in	0
which	0
they	0
are	0
studied	0
.	0

Treatment	0
with	0
E2	0
was	0
also	0
associated	0
with	0
a	0
time-dependent	0
decrease	0
in	0
the	0
mRNA	0
level	0
of	0
the	0
proapoptotic	9
Nip-2	10
protein	10
,	0
supporting	0
the	0
hypothesis	0
that	0
hormone	0
responsiveness	0
of	0
U937	5
cells	6
is	0
mediated	0
by	0
target	0
gene	0
transcription	0
.	0

Together	0
,	0
these	0
results	0
demonstrate	0
that	0
ER	9
and	0
PR	9
can	0
be	0
activated	0
by	0
endogenous	0
or	0
exogenous	0
ligands	0
to	0
induce	0
a	0
genetic	0
response	0
that	0
impairs	0
TNF-alpha	9
-induced	0
apoptosis	0
in	0
U937	5
cells	6
.	0

The	0
data	0
presented	0
here	0
suggest	0
that	0
the	0
female	9
steroid	10
receptors	10
play	0
a	0
role	0
in	0
regulation	0
of	0
the	0
immune	0
response	0
by	0
preventing	0
apoptosis	0
of	0
monoblastoid	7
cells	8
;	0
this	0
effect	0
might	0
have	0
important	0
consequences	0
in	0
the	0
clinical	0
use	0
of	0
steroid	0
receptor	0
drugs	0
.	0

--	0
Vegeto	0
,	0
E.	0
,	0
Pollio	0
,	0
G.	0
,	0
Pellicciari	0
,	0
C.	0
,	0
Maggi	0
,	0
A	0
.	0

Estrogen	0
and	0
progesterone	0
induction	0
of	0
survival	0
of	0
monoblastoid	7
cells	8
undergoing	0
TNF-alpha	9
-inuced	0
apoptosis	0
.	0

Dicarba-closo-dodecaboranes	0
as	0
a	0
pharmacophore	0
.	0

Retinoidal	0
antagonists	0
and	0
potential	0
agonists	0
.	0

Synthesis	0
and	0
biological	0
evaluation	0
of	0
the	0
first	0
dicarba-closo-dodecaborane	0
(	0
carborane	0
)	0
derivatives	0
of	0
retinoids	0
are	0
described	0
.	0

Their	0
retinoidal	0
activity	0
were	0
examined	0
in	0
terms	0
of	0
the	0
differentiation-inducing	0
ability	0
toward	0
human	5
promyelocytic	6
leukemia	6
HL-60	6
cells	6
.	0

High	0
retinoidal	0
activity	0
(	0
agonist	0
or	0
antagonist	0
for	0
retinoic	9
acid	10
receptor	10
(	0
RAR	9
)	0
requires	0
a	0
carboxylic	0
acid	0
moiety	0
and	0
an	0
appropriate	0
hydrophobic	0
group	0
located	0
at	0
a	0
suitable	0
position	0
on	0
the	0
molecule	0
.	0

The	0
4-carboranyl-substituted	0
compounds	0
(	0
7	0
,	0
11	0
)	0
showed	0
antagonistic	0
activity	0
but	0
no	0
agonistic	0
activity	0
even	0
in	0
the	0
presence	0
of	0
the	0
potent	0
synergist	0
HX630	0
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
3-carboranyl-substituted	0
compounds	0
(	0
8	0
,	0
12	0
)	0
showed	0
potential	0
agonistic	0
activity	0
,	0
but	0
no	0
antagonistic	0
activity	0
.	0

The	0
results	0
indicates	0
that	0
carboranes	0
are	0
applicable	0
as	0
the	0
hydrophobic	0
moiety	0
of	0
biologically	0
active	0
molecules	0
.	0

Inhibition	0
of	0
T	0
cell	0
signaling	0
by	0
mitogen-activated	9
protein	10
kinase-targeted	10
hematopoietic	10
tyrosine	10
phosphatase	10
(	0
HePTP	9
)	0
.	0

Activation	0
of	0
T	7
lymphocytes	8
to	0
produce	0
cytokines	9
is	0
regulated	0
by	0
the	0
counterbalance	0
of	0
protein-tyrosine	9
kinases	10
and	0
protein-tyrosine	0
phosphatases	0
,	0
many	0
of	0
which	0
have	0
a	0
high	0
degree	0
of	0
substrate	0
specificity	0
because	0
of	0
physical	0
association	0
with	0
their	0
targets	0
.	0

Overexpression	0
of	0
hematopoietic	9
protein-tyrosine	10
phosphatase	10
(	0
HePTP	9
)	0
results	0
in	0
suppression	0
of	0
T	0
lymphocyte	0
activation	0
as	0
measured	0
by	0
T	9
cell	10
antigen	10
receptor	10
-induced	0
activation	0
of	0
transcription	9
factors	10
binding	0
to	0
the	0
5	1
'	2
promoter	2
of	0
the	0
interleukin-2	1
gene	2
.	0

Efforts	0
to	0
pinpoint	0
the	0
exact	0
site	0
of	0
action	0
and	0
specificity	0
of	0
HePTP	9
in	0
the	0
signaling	0
cascade	0
revealed	0
that	0
HePTP	9
acts	0
directly	0
on	0
the	0
mitogen-activated	9
protein	10
(	10
MAP	10
)	10
kinases	10
Erk1	9
and	10
2	10
and	0
consequently	0
reduces	0
the	0
magnitude	0
and	0
duration	0
of	0
their	0
catalytic	0
activation	0
in	0
intact	7
T	8
cells	8
.	0

In	0
contrast	0
,	0
HePTP	9
had	0
no	0
effects	0
on	0
N-terminal	9
c-Jun	10
kinase	10
or	0
on	0
events	0
upstream	0
of	0
the	0
MAP	0
kinases	0
.	0

The	0
specificity	0
of	0
HePTP	9
correlated	0
with	0
its	0
physical	0
association	0
through	0
its	0
noncatalytic	0
N	9
terminus	10
with	0
Erk	9
and	0
another	0
MAP	9
kinase	10
,	0
p38	9
,	0
but	0
not	0
Jnk	9
or	0
other	0
proteins	0
.	0

We	0
propose	0
that	0
HePTP	9
plays	0
a	0
negative	0
role	0
in	0
antigen	0
receptor	0
signaling	0
by	0
specifically	0
regulating	0
MAP	9
kinases	10
in	0
the	0
cytosol	0
and	0
at	0
early	0
time	0
points	0
of	0
T	0
cell	0
activation	0
before	0
the	0
activation-induced	0
expression	0
of	0
nuclear	9
dual-specific	10
MAP	10
kinase	10
phosphatases	10
.	0

p38	9
mitogen-activated	10
protein	10
kinase	10
mediates	0
signal	0
integration	0
of	0
TCR	9
/CD28	9
costimulation	0
in	0
primary	7
murine	8
T	8
cells	8
.	0

Optimal	0
T	0
cell	0
activation	0
requires	0
two	0
signals	0
,	0
one	0
generated	0
by	0
TCR	9
and	0
another	0
by	0
the	0
CD28	9
costimulatory	10
receptor	10
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
regulation	0
of	0
costimulation-induced	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
activation	0
in	0
primary	7
mouse	8
T	8
cells	8
.	0

In	0
contrast	0
to	0
that	0
reported	0
for	0
human	7
Jurkat	8
T	8
cells	8
,	0
we	0
found	0
that	0
p38	9
MAPK	10
,	0
but	0
not	0
Jun	9
NH2-terminal	10
kinase	10
(	0
JNK	9
)	0
,	0
is	0
weakly	0
activated	0
upon	0
stimulation	0
with	0
either	0
anti-CD3	9
or	0
anti-CD28	9
in	0
murine	7
thymocytes	8
and	0
splenic	7
T	8
cells	8
.	0

However	0
,	0
p38	9
MAPK	10
is	0
activated	0
strongly	0
and	0
synergistically	0
by	0
either	0
CD3/CD28	9
coligation	0
or	0
PMA/Ca2+	0
ionophore	0
stimulation	0
,	0
which	0
mimics	0
TCR	9
-	0
CD3/CD28	9
-mediated	0
signaling	0
.	0

Activation	0
of	0
p38	9
MAPK	10
correlates	0
closely	0
with	0
the	0
stimulation	0
of	0
T	0
cell	0
proliferation	0
.	0

In	0
contrast	0
,	0
PMA-induced	0
JNK	9
activation	0
is	0
inhibited	0
by	0
Ca2+	0
ionophore	0
.	0

T	0
cell	0
proliferation	0
and	0
production	0
of	0
IL-2	9
,	0
IL-4	9
,	0
and	0
IFN-gamma	9
induced	0
by	0
both	0
CD3	9
and	0
CD3	9
/CD28	9
ligation	0
and	0
the	0
nuclear	0
expression	0
of	0
the	0
c-Jun	9
and	10
ATF-2	10
proteins	10
are	0
each	0
blocked	0
by	0
the	0
p38	9
MAPK	10
inhibitor	0
SB203580	0
.	0

Our	0
findings	0
demonstrate	0
that	0
p38	9
MAPK	10
1	0
)	0
plays	0
an	0
important	0
role	0
in	0
signal	0
integration	0
during	0
costimulation	0
of	0
primary	7
mouse	8
T	8
cells	8
,	0
2	0
)	0
may	0
be	0
involved	0
in	0
the	0
induction	0
of	0
c-Jun	9
activation	0
and	0
augmentation	0
of	0
AP-1	9
transcriptional	0
activity	0
,	0
and	0
3	0
)	0
regulates	0
whether	0
T	7
cells	8
enter	0
a	0
state	0
of	0
functional	0
unresponsiveness	0
.	0

Erythroid	0
gene	0
expression	0
is	0
differentially	0
regulated	0
by	0
erythropoietin	9
,	0
haemin	0
and	0
delta-aminolaevulinic	0
acid	0
in	0
UT-7	5
cells	6
.	0

Erythropoietin	0
(	0
Epo	0
)	0
is	0
essential	0
for	0
the	0
later	0
stages	0
of	0
erythropoiesis	0
,	0
acting	0
to	0
promote	0
cell	0
survival	0
and	0
proliferation	0
,	0
but	0
its	0
role	0
in	0
differentiation	0
remains	0
to	0
be	0
defined	0
.	0

The	0
UT-7	5
cell	6
line	6
exhibits	0
both	0
erythroid	0
and	0
megakaryocytic	0
characteristics	0
and	0
can	0
be	0
induced	0
to	0
differentiate	0
along	0
the	0
erythroid	0
pathway	0
by	0
Epo	9
or	0
the	0
megakaryocytic	0
pathway	0
by	0
phorbol	0
myristic	0
acetate	0
.	0

We	0
have	0
compared	0
the	0
effects	0
of	0
Epo	9
and	0
the	0
chemical	0
inducers	0
,	0
delta-aminolaevulinic	0
acid	0
(	0
delta-ALA	0
)	0
and	0
haemin	0
on	0
the	0
differentiation	0
capacity	0
of	0
UT-7	5
cells	6
.	0

Epo	9
alone	0
promoted	0
relatively	0
early	0
events	0
in	0
erythroid	0
maturation	0
,	0
without	0
significant	0
changes	0
in	0
haemoglobin	0
production	0
or	0
morphology	0
.	0

GATA-2	9
and	0
c-myb	9
were	0
down-regulated	0
by	0
Epo	9
,	0
and	0
GATA-2	9
was	0
further	0
down-modulated	0
by	0
the	0
inducers	0
.	0

Conversely	0
,	0
SCL	9
expression	0
was	0
up-regulated	0
by	0
Epo	9
and	0
further	0
increased	0
by	0
haemin	0
and	0
delta-ALA	0
.	0

Epo	9
caused	0
an	0
increase	0
in	0
the	0
proportion	0
of	0
cells	0
expressing	0
cell	0
surface	0
glycophorin	9
A	10
(	0
GPA	9
)	0
and	0
up-regulated	0
beta-	9
and	10
gamma-globin	10
by	0
several	0
fold	0
.	0

Both	0
haemin	0
and	0
delta-ALA	0
caused	0
a	0
de	0
novo	0
increase	0
in	0
alpha-globin	9
expression	0
as	0
well	0
as	0
enhancing	0
Epo	9
-induced	0
beta-globin	9
expression	0
,	0
leading	0
to	0
a	0
marked	0
increase	0
in	0
haemoglobin	0
production	0
.	0

These	0
results	0
suggest	0
that	0
haemoglobin	0
production	0
in	0
UT-7	5
cells	6
is	0
limited	0
by	0
a	0
deficiency	0
of	0
erythroid-specific	9
aminolaevulinic	10
acid	10
synthase	10
(	0
ALAS-E	9
)	0
activity	0
or	0
globin	0
synthesis	0
as	0
a	0
consequence	0
of	0
their	0
immaturity	0
as	0
a	0
multipotential	5
cell	6
line	6
.	0

Essential	0
role	0
of	0
alveolar	7
macrophages	8
in	0
intrapulmonary	0
activation	0
of	0
NF-kappaB	9
.	0

Acute	0
inflammatory	0
injury	0
in	0
rat	0
lung	0
induced	0
by	0
deposition	0
of	0
immunoglobulin	9
G	10
immune	10
complexes	10
requires	0
expression	0
of	0
cytokines	9
and	0
chemokines	9
as	0
well	0
as	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
.	0

There	0
is	0
little	0
direct	0
evidence	0
regarding	0
the	0
role	0
of	0
alveolar	7
macrophages	8
in	0
these	0
activation	0
events	0
.	0

In	0
the	0
present	0
studies	0
,	0
rat	0
lungs	0
were	0
depleted	0
of	0
alveolar	7
macrophages	8
by	0
airway	0
instillation	0
of	0
liposome-encapsulated	0
dichloromethylene	0
diphosphonate	0
.	0

These	0
procedures	0
,	0
which	0
greatly	0
reduced	0
the	0
number	0
of	0
retrievable	0
alveolar	7
macrophages	8
,	0
suppressed	0
activation	0
of	0
lung	9
NF-kappaB	10
in	0
the	0
inflammatory	0
model	0
.	0

In	0
addition	0
,	0
bronchoalveolar	0
lavage	0
levels	0
of	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
and	0
the	0
CXC	9
chemokine	10
,	0
macrophage	9
inflammatory	10
protein-2	10
,	0
were	0
substantially	0
reduced	0
.	0

In	0
parallel	0
,	0
upregulation	0
of	0
the	0
lung	9
vascular	10
adhesion	10
molecule	10
,	0
intercellular	9
adhesion	10
molecule-1	10
,	0
was	0
greatly	0
reduced	0
by	0
intrapulmonary	0
instillation	0
of	0
phosphonate-containing	0
liposomes	0
.	0

Neutrophil	0
accumulation	0
and	0
development	0
of	0
lung	0
injury	0
were	0
also	0
substantially	0
diminished	0
.	0

Lung	0
instillation	0
of	0
TNF-alpha	9
in	0
alveolar	0
macrophage-depleted	0
rats	0
restored	0
the	0
NF-kappaB	9
activation	0
response	0
in	0
whole	0
lung	0
.	0

These	0
data	0
suggest	0
that	0
,	0
in	0
this	0
inflammatory	0
model	0
,	0
initial	0
activation	0
of	0
NF-kappaB	9
occurs	0
in	0
alveolar	7
macrophages	8
and	0
the	0
ensuing	0
production	0
of	0
TNF-alpha	9
may	0
propagate	0
NF-kappaB	9
activation	0
to	0
other	0
cell	0
types	0
in	0
the	0
lung	0
.	0

Interferon-beta	9
mediates	0
stromal	0
cell	0
rescue	0
of	0
T	7
cells	8
from	0
apoptosis	0
.	0

The	0
resolution	0
of	0
immune	0
responses	0
is	0
characterized	0
by	0
extensive	0
apoptosis	0
of	0
activated	0
T	7
cells	8
.	0

However	0
,	0
to	0
generate	0
and	0
maintain	0
immunological	0
memory	0
,	0
some	0
antigen-specific	7
T	8
cells	8
must	0
survive	0
and	0
revert	0
to	0
a	0
resting	0
G0/G1	0
state	0
.	0

Cytokines	9
that	0
bind	0
to	0
the	0
common	0
gamma	9
chain	10
of	0
the	0
IL-2	9
receptor	0
promote	0
the	0
survival	0
of	0
T	7
cell	8
blasts	8
,	0
but	0
also	0
induce	0
proliferation	0
.	0

In	0
contrast	0
,	0
soluble	9
factors	10
secreted	0
by	0
stromal	7
cells	8
induce	0
Tcell	0
survival	0
in	0
a	0
resting	0
G0/G1	0
state	0
.	0

We	0
now	0
report	0
that	0
interferon-beta	0
is	0
the	0
principal	0
mediator	0
of	0
stromal	0
cell-mediated	0
Tcell	0
rescue	0
from	0
apoptosis	0
.	0

Interferon-alpha	9
and	10
-beta	10
promote	0
the	0
reversion	0
of	0
blast	7
Tcells	8
to	0
a	0
resting	0
G0/G1	0
configuration	0
with	0
all	0
the	0
characteristic	0
features	0
of	0
stromal	0
cell	0
rescue	0
;	0
such	0
as	0
high	0
Bcl-XL	9
expression	0
and	0
low	0
Bcl-2	9
.	0

Type	9
I	10
interferons	10
and	0
stromal	7
cells	8
stimulate	0
apparently	0
identical	0
signaling	0
pathways	0
,	0
leading	0
to	0
STAT-1	9
activation	0
.	0

We	0
also	0
show	0
that	0
this	0
mechanism	0
may	0
play	0
a	0
fundamental	0
role	0
in	0
the	0
persistence	0
of	0
T	7
cells	8
at	0
sites	0
of	0
chronic	0
inflammation	0
;	0
suggesting	0
that	0
chronic	0
inflammation	0
is	0
an	0
aberrant	0
consequence	0
of	0
immunological	0
memory	0
.	0

Reduction	0
of	0
tumour	9
necrosis	10
factor	10
alpha	10
expression	0
and	0
signalling	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
patients	0
with	0
thalassaemia	0
or	0
sickle	0
cell	0
anaemia	0
upon	0
treatment	0
with	0
desferrioxamine	0
.	0

Recent	0
evidence	0
indicates	0
that	0
the	0
rate	0
of	0
progression	0
of	0
the	0
HIV-1	0
disease	0
is	0
significantly	0
reduced	0
in	0
thalassaemia	0
major	0
patients	0
upon	0
treatment	0
with	0
high	0
doses	0
of	0
desferrioxamine	0
(	0
DFX	0
)	0
.	0

The	0
authors	0
have	0
previously	0
demonstrated	0
that	0
in	0
vitro	0
exposure	0
of	0
mononuclear	7
cells	8
to	0
DFX	0
decreases	0
the	0
bioavailability	0
of	0
tumour	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
which	0
has	0
a	0
stimulatory	0
effect	0
on	0
HIV-1	0
replication	0
.	0

In	0
this	0
study	0
,	0
therefore	0
,	0
TNF-alpha	9
bioavailability	0
from	0
mononuclear	7
cells	8
isolated	0
from	0
10	0
patients	0
with	0
thalassaemia	0
or	0
sickle	0
cell	0
anaemia	0
given	0
DFX	0
as	0
compared	0
to	0
10	0
untreated	0
subjects	0
has	0
been	0
evaluated	0
.	0

Evidence	0
is	0
presented	0
showing	0
that	0
DFX	0
treatment	0
reduces	0
TNF-alpha	9
bioavailability	0
(	0
P	0
<	0
0.05	0
)	0
by	0
inhibiting	0
its	0
steady	0
state	0
(	0
P	0
<	0
0.05	0
)	0
and	0
by	0
enhancing	0
its	0
inactivation	0
through	0
binding	0
to	0
soluble	0
TNF-alpha	9
receptor	0
type	0
II	0
(	0
P	0
<	0
0.05	0
)	0
.	0

We	0
also	0
show	0
that	0
DFX	0
treatment	0
limits	0
the	0
in	0
vivo	0
activation	0
of	0
NF-kappaB	9
,	0
a	0
transcription	9
factor	10
involved	0
in	0
both	0
TNF-alpha	9
gene	0
transcription	0
and	0
TNF-alpha	9
signalling	0
(	0
P	0
<	0
0.005	0
)	0
.	0

We	0
conclude	0
that	0
TNF-alpha	9
bioavailability	0
and	0
signalling	0
are	0
impaired	0
in	0
patients	0
upon	0
DFX	0
treatment	0
.	0

This	0
mechanism	0
may	0
contribute	0
to	0
delayed	0
progression	0
of	0
the	0
HIV-1	0
infection	0
in	0
vivo	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Involvement	0
of	0
NF-kappaB	9
p50/p65	10
heterodimer	10
in	0
activation	0
of	0
the	0
human	1
pro-interleukin-1beta	2
gene	2
at	0
two	0
subregions	0
of	0
the	0
upstream	1
enhancer	2
element	2
.	0

A	0
region	0
between-3134	0
and	0
-2729	0
bp	0
upstream	0
from	0
the	0
transcription	1
site	2
of	0
the	0
human	1
pro-interleukin	2
1beta	2
(	2
proIL-1beta	2
)	2
gene	2
was	0
identified	0
as	0
an	0
LPS-responsive	1
enhancer	2
element	2
.	0

In	0
this	0
study	0
,	0
the	0
influence	0
of	0
the	0
sequences	0
located	0
between	1
-3134	2
and	2
-2987	2
on	0
the	0
transcriptional	0
activity	0
of	0
the	0
proIL-1beta	1
gene	2
in	0
LPS-stimulated	5
Raw	6
264.7	6
cells	6
was	0
examined	0
in	0
detail	0
.	0

The	0
results	0
obtained	0
by	0
transient	0
transfection	0
of	0
fos	0
-CAT	1
constructs	2
that	0
contained	0
serial	1
5'-deletion	2
mutations	2
showed	0
that	0
the	0
region	0
between	0
-3134	0
and	0
-3059	0
appears	0
to	0
be	0
required	0
for	0
the	0
induction	0
of	0
transcription	0
by	0
LPS	0
.	0

Gel	0
shift	0
assay	0
studies	0
with	0
synthetic	1
oligonucleotides	2
corresponding	0
to	0
partial	0
sequences	0
of	0
the	0
latter	0
region	0
and	0
nuclear	0
extracts	0
from	0
stimulated	0
cells	0
revealed	0
specific	0
protein	1
binding	2
sites	2
between	0
-3110	0
and	0
-3090	0
and	0
between	0
-3079	0
and	0
-3059	0
.	0

These	0
specific	0
bindings	0
were	0
time	0
and	0
LPS	0
dose	0
dependent	0
.	0

The	0
results	0
of	0
supershift	0
analysis	0
using	0
specific	0
antibodies	0
against	0
transcription	9
factors	10
suggested	0
that	0
both	0
binding	0
complexes	0
contained	0
the	0
NF-kappaB	9
components	10
p50	9
and	0
p65	9
,	0
and	0
did	0
not	0
contain	0
other	0
NF-kappaB	9
proteins	10
(	0
p52	9
,	0
c-Rel	9
,	0
Rel	9
B	10
)	0
,	0
AP-1	9
proteins	10
(	0
c-Fos	9
,	0
C-Jun	9
)	0
,	0
CREB	9
or	0
C/EBPbeta	9
(	0
NF-IL6	9
)	0
.	0

Mutation	0
of	0
either	0
of	0
the	0
putative	0
NF-kappaB-binding	1
sites	2
in	0
the	0
enhancer	0
element	0
decreased	0
the	0
LPS-stimulated	0
transcriptional	0
activity	0
.	0

These	0
data	0
indicated	0
that	0
two	0
NF-kappaB-binding	1
sites	2
,	0
which	0
are	0
located	0
between	0
-3134	1
and	2
-3059	2
,	0
are	0
critical	0
for	0
the	0
activation	0
of	0
proIL-1beta	1
gene	2
transcription	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

N-acetyl-L-cysteine	0
inhibits	0
primary	0
human	0
T	0
cell	0
responses	0
at	0
the	0
dendritic	0
cell	0
level	0
:	0
association	0
with	0
NF-kappaB	9
inhibition	0
.	0

N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
is	0
an	0
antioxidant	0
molecule	0
endowed	0
with	0
immunomodulatory	0
properties	0
.	0

To	0
investigate	0
the	0
effect	0
of	0
NAC	0
on	0
the	0
induction	0
phase	0
of	0
T	0
cell	0
responses	0
,	0
we	0
analyzed	0
its	0
action	0
on	0
human	0
dendritic	0
cells	0
(	0
DC	0
)	0
derived	0
from	0
adherent	0
PBMC	0
cultured	0
with	0
IL-4	9
and	0
granulocyte-macrophage	9
CSF	10
.	0

We	0
first	0
found	0
that	0
NAC	0
inhibited	0
the	0
constitutive	0
as	0
well	0
as	0
the	0
LPS-induced	0
activity	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
.	0

In	0
parallel	0
,	0
NAC	0
was	0
shown	0
to	0
down-regulate	0
the	0
production	0
of	0
cytokines	9
by	0
DC	7
as	0
well	0
as	0
their	0
surface	0
expression	0
of	0
HLA-DR	9
,	0
CD86	9
(	0
B7-2	9
)	0
,	0
and	0
CD40	9
molecules	10
both	0
at	0
the	0
basal	0
state	0
and	0
upon	0
LPS	0
activation	0
.	0

NAC	0
also	0
inhibited	0
DC	0
responses	0
induced	0
by	0
CD40	9
engagement	0
.	0

The	0
inhibitory	0
effects	0
of	0
NAC	0
were	0
not	0
due	0
to	0
nonspecific	0
toxicity	0
as	0
neither	0
the	0
viability	0
of	0
DC	7
nor	0
their	0
mannose	0
receptor-mediated	0
endocytosis	0
were	0
modified	0
by	0
NAC	0
.	0

Finally	0
,	0
we	0
found	0
that	0
the	0
addition	0
of	0
NAC	0
to	0
MLR	0
between	0
naive	7
T	8
cells	8
and	0
allogeneic	0
DC	7
resulted	0
in	0
a	0
profound	0
inhibition	0
of	0
alloreactive	0
responses	0
,	0
which	0
could	0
be	0
attributed	0
to	0
a	0
defect	0
of	0
DC	7
as	0
APC-independent	0
T	0
cell	0
responses	0
were	0
not	0
inhibited	0
by	0
NAC	0
.	0

Altogether	0
,	0
our	0
results	0
suggest	0
that	0
NAC	0
might	0
impair	0
the	0
generation	0
of	0
primary	0
immune	0
responses	0
in	0
humans	0
through	0
its	0
inhibitory	0
action	0
on	0
DC	7
.	0

Thrombin-induced	9
p65	10
homodimer	10
binding	0
to	0
downstream	0
NF-kappa	1
B	2
site	2
of	0
the	0
promoter	0
mediates	0
endothelial	0
ICAM-1	9
expression	0
and	0
neutrophil	7
adhesion	0
.	0

We	0
investigated	0
the	0
mechanisms	0
by	0
which	0
proinflammatory	9
mediator	10
,	0
thrombin	9
,	0
released	0
during	0
intravascular	0
coagulation	0
and	0
tissue	0
injury	0
,	0
induces	0
ICAM-1	9
(	0
CD54	9
)	0
expression	0
in	0
endothelial	7
cells	8
.	0

Stimulation	0
of	0
HUVEC	5
with	0
thrombin	9
resulted	0
in	0
dose-	0
and	0
time-dependent	0
increases	0
in	0
ICAM-1	3
mRNA	4
and	0
cell	0
surface	0
expression	0
and	0
in	0
ICAM-1	9
-dependent	0
endothelial	0
adhesivity	0
toward	0
polymorphonuclear	7
leukocytes	8
.	0

Transient	0
transfection	0
of	0
endothelial	7
cells	8
with	0
ICAM-1	1
promoter	2
luciferase	2
reporter	2
gene	2
(	2
ICAM-1LUC	2
)	2
constructs	2
indicated	0
that	0
deletion	0
of	0
upstream	0
NF-kappa	1
B	2
site	2
(	0
-533	1
bases	2
from	0
translation	1
start	2
site	2
)	0
had	0
no	0
effect	0
on	0
thrombin	9
responsiveness	0
,	0
whereas	0
mutation/deletion	0
of	0
downstream	0
NF-kappa	1
B	2
site	2
(	0
-223	1
bases	2
from	0
the	0
translation	1
start	2
site	2
)	0
prevented	0
the	0
activation	0
of	0
ICAM-1	1
promoter	2
,	0
indicating	0
that	0
the	0
downstream	0
NF-kappa	1
B	2
site	2
is	0
critical	0
for	0
thrombin	9
inducibility	0
.	0

NF-kappa	9
B	10
-directed	0
luciferase	9
activity	0
increased	0
approximately	0
3-fold	0
when	0
cells	0
transfected	0
with	0
the	0
plasmid	1
pNF-kappa	2
BLUC	2
containing	0
five	0
copies	0
of	0
consensus	1
NF-kappa	2
B	2
site	2
linked	0
to	0
a	0
minimal	0
adenovirus	1
E1B	2
promoter-luciferase	2
gene	2
were	0
exposed	0
to	0
thrombin	9
,	0
indicating	0
that	0
activation	0
of	0
NF-kappa	9
B	10
was	0
essential	0
for	0
thrombin	9
response	0
.	0

Gel	0
supershift	0
assays	0
demonstrated	0
that	0
thrombin	9
induced	0
binding	0
of	0
NF-kappa	9
Bp65	10
(	0
Rel	9
A	10
)	0
to	0
downstream	0
NF-kappa	1
B	2
site	2
of	0
the	0
ICAM-1	1
promoter	2
.	0

Thrombin	9
receptor	0
activation	0
peptide	0
,	0
a	0
14-amino-acid	0
peptide	0
representing	0
the	0
new	0
NH2	9
terminus	10
of	0
proteolytically	0
activated	0
receptor-1	9
,	0
mimicked	0
thrombin	9
's	0
action	0
in	0
inducing	0
ICAM-1	9
expression	0
.	0

These	0
data	0
indicate	0
that	0
thrombin	9
activates	0
endothelial	0
ICAM-1	9
expression	0
and	0
polymorphonuclear	7
leukocyte	8
adhesion	0
by	0
NF-kappa	9
Bp65	10
binding	0
to	0
the	0
downstream	0
NF-kappa	1
B	2
site	2
of	0
ICAM-1	1
promoter	2
after	0
proteolytically	0
activated	0
receptor-1	0
activation	0
.	0

Differential	0
inhibition	0
of	0
Smad6	9
and	0
Smad7	9
on	0
bone	0
morphogenetic	0
protein-	0
and	0
activin-mediated	0
growth	0
arrest	0
and	0
apoptosis	0
in	0
B	7
cells	8
.	0

Smad6	9
and	0
Smad7	9
prevent	0
ligand-induced	0
activation	0
of	0
signal-transducing	9
Smad	10
proteins	10
in	0
the	0
transforming	9
growth	10
factor-beta	10
family	10
.	0

Here	0
we	0
demonstrate	0
that	0
both	0
Smad6	9
and	0
Smad7	9
are	0
human	9
bone	10
morphogenetic	10
protein-2	10
(	0
hBMP-2	9
)	0
-inducible	0
antagonists	0
of	0
hBMP-2	9
-induced	0
growth	0
arrest	0
and	0
apoptosis	0
in	0
mouse	5
B	6
cell	6
hybridoma	6
HS-72	5
cells	6
.	0

Moreover	0
,	0
we	0
confirmed	0
that	0
the	0
ectopic	0
expressions	0
of	0
Smad6	9
and	0
Smad7	9
inhibited	0
the	0
hBMP-2	9
-induced	0
Smad1/Smad5	9
phosphorylation	0
.	0

We	0
previously	0
reported	0
that	0
Smad7	9
is	0
an	0
activin	0
A-inducible	0
antagonist	0
of	0
activin	0
A-induced	0
growth	0
arrest	0
and	0
apoptosis	0
in	0
HS-72	5
cells	6
.	0

Interestingly	0
,	0
although	0
mRNA	0
expression	0
of	0
Smad6	9
was	0
induced	0
by	0
activin	0
A	0
in	0
HS-72	5
cells	6
,	0
Smad6	9
showed	0
no	0
antagonistic	0
effect	0
on	0
activin	0
A-induced	0
growth	0
arrest	0
and	0
apoptosis	0
.	0

Moreover	0
,	0
we	0
found	0
that	0
the	0
ectopic	0
expression	0
of	0
Smad7	9
,	0
but	0
not	0
Smad6	9
,	0
inhibited	0
the	0
activin	0
A-induced	0
Smad2	0
phosphorylation	0
in	0
HS-72	5
cells	6
.	0

Thus	0
,	0
Smad6	9
and	0
Smad7	9
exhibit	0
differential	0
inhibitory	0
effects	0
in	0
bone	0
morphogenetic	0
protein-2-	0
and	0
activin	0
A-mediated	0
signaling	0
in	0
B	7
lineage	8
cells	8
.	0

Retinoic	0
acid	0
induces	0
apoptosis	0
of	0
human	7
CD34+	8
hematopoietic	8
progenitor	8
cells	8
:	0
involvement	0
of	0
retinoic	9
acid	10
receptors	10
and	0
retinoid	9
X	10
receptors	10
depends	0
on	0
lineage	0
commitment	0
of	0
the	0
hematopoietic	7
progenitor	8
cells	8
.	0

Retinoids	0
are	0
bifunctional	0
regulators	0
of	0
growth	0
and	0
differentiation	0
of	0
hematopoietic	7
cells	8
.	0

In	0
this	0
study	0
we	0
explored	0
the	0
effects	0
of	0
retinoic	0
acid	0
(	0
RA	0
)	0
on	0
apoptosis	0
of	0
human	7
CD34+	8
hematopoietic	8
progenitor	8
cells	8
isolated	0
from	0
normal	0
bone	0
marrow	0
.	0

RA	0
(	0
100	0
nM	0
)	0
induced	0
an	0
increase	0
in	0
the	0
percentage	0
of	0
dead	7
cells	8
from	0
24	0
%	0
to	0
44	0
%	0
at	0
day	0
6	0
(	0
p	0
<	0
0.05	0
,	0
n	0
=	0
6	0
)	0
as	0
compared	0
to	0
control	7
cells	8
cultured	0
in	0
medium	0
alone	0
.	0

The	0
effect	0
was	0
dose	0
dependent	0
and	0
appeared	0
relatively	0
late	0
.	0

Significant	0
differences	0
were	0
observed	0
from	0
day	0
4	0
onward	0
.	0

Apoptosis	0
,	0
or	0
programmed	0
cell	0
death	0
,	0
was	0
demonstrated	0
as	0
the	0
mode	0
of	0
cell	0
death	0
by	0
using	0
the	0
TUNEL	0
assay	0
,	0
which	0
detects	0
single	0
strand	0
nicks	0
in	0
DNA	0
,	0
or	0
by	0
the	0
Nicoletti	0
technique	0
demonstrating	0
a	0
subdiploid	0
population	0
by	0
DNA	0
staining	0
.	0

RA	0
previously	0
was	0
found	0
to	0
inhibit	0
granulocyte	9
colony-stimulating	10
factor	10
--	0
and	0
not	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
--	0
stimulated	0
proliferation	0
of	0
CD34+	7
cells	8
.	0

However	0
,	0
we	0
found	0
that	0
RA	0
opposed	0
anti-apoptotic	0
effects	0
of	0
G-CSF	9
and	0
GM-CSF	9
on	0
CD34+	7
cells	8
(	0
G-CSF	9
:	0
8	0
%	0
dead	7
cells	8
at	0
day	0
6	0
;	0
G-CSF	9
+	0
RA	0
:	0
20	0
%	0
;	0
GM-CSF	9
:	0
12	0
%	0
;	0
GM-CSF	9
+	0
RA	0
:	0
27	0
%	0
)	0
.	0

Moreover	0
,	0
RA	0
induced	0
apoptosis	0
of	0
CD34+	7
cells	8
and	0
CD34+CD71+	7
cells	8
stimulated	0
with	0
erythropoietin	9
.	0

To	0
explore	0
the	0
receptor	0
signaling	0
pathways	0
involved	0
in	0
RA-induced	0
apoptosis	0
,	0
we	0
used	0
selective	0
ligands	0
for	0
retinoic	9
acid	10
receptors	10
(	0
RARs	0
;	0
RO13-7410	0
)	0
and	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
;	0
RO	0
25-6603	0
)	0
.	0

We	0
found	0
that	0
RARs	9
were	0
involved	0
in	0
RA-mediated	0
apoptosis	0
of	0
myeloid	0
progenitor	0
cells	0
,	0
whereas	0
RARs	9
as	0
well	0
as	0
RXRs	9
were	0
involved	0
in	0
RA-mediated	0
apoptosis	0
of	0
erythroid	7
progenitor	8
cells	8
.	0

Suppressive	0
effects	0
of	0
anti-inflammatory	0
agents	0
on	0
human	7
endothelial	8
cell	8
activation	0
and	0
induction	0
of	0
heat	9
shock	10
proteins	10
.	0

BACKGROUND	0
:	0
Studies	0
from	0
our	0
laboratory	0
have	0
shown	0
that	0
the	0
earliest	0
stages	0
of	0
atherosclerosis	0
may	0
be	0
mediated	0
by	0
an	0
autoimmune	0
reaction	0
against	0
heat	9
shock	10
protein	10
60	10
(	0
Hsp60	9
)	0
.	0

The	0
interactions	0
of	0
Hsp60-specific	5
T	6
cells	6
with	0
arterial	0
endothelial	7
cells	8
(	0
EC	7
)	0
require	0
expression	0
of	0
both	0
Hsp60	9
and	0
certain	0
adhesion	9
molecules	10
shown	0
to	0
be	0
induced	0
simultaneously	0
in	0
EC	7
by	0
mechanical	0
and	0
other	0
types	0
of	0
stress	0
.	0

Recently	0
,	0
it	0
was	0
shown	0
that	0
suppression	0
of	0
T	0
cell-mediated	0
immune	0
responses	0
by	0
cyclosporin	0
A	0
(	0
CyA	0
)	0
enhanced	0
atherosclerotic	0
lesion	0
formation	0
in	0
mice	0
.	0

In	0
contrast	0
,	0
aspirin	0
was	0
found	0
to	0
lower	0
the	0
risk	0
of	0
myocardial	0
infarction	0
in	0
men	0
.	0

These	0
conflicting	0
observations	0
may	0
be	0
due	0
to	0
different	0
effects	0
of	0
anti-inflammatory	0
agents	0
on	0
adhesion	0
molecule	0
and	0
Hsp	0
expression	0
in	0
EC	7
,	0
respectively	0
.	0

MATERIAL	0
AND	0
METHODS	0
:	0
In	0
the	0
present	0
study	0
,	0
we	0
analyzed	0
the	0
effects	0
of	0
CyA	0
,	0
aspirin	0
,	0
and	0
indomethacin	0
on	0
T	0
cell	0
proliferation	0
using	0
a	0
proliferation	0
assay	0
.	0

To	0
explore	0
the	0
expression	0
of	0
adhesion	9
molecules	10
,	0
monocyte	9
chemoattractant	10
protein-1	10
(	0
MCP-1	9
)	0
,	0
and	0
Hsp60	9
in	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
(	0
HUVECs	7
)	0
,	0
Northern	0
blot	0
analyses	0
were	0
used	0
.	0

To	0
examine	0
the	0
activation	0
status	0
of	0
the	0
transcription	9
factors	10
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
and	0
heat	9
shock	10
factor-1	10
(	0
HSF-1	9
)	0
,	0
electrophoretic	0
mobility	0
shift	0
assays	0
were	0
performed	0
.	0

RESULTS	0
:	0
With	0
the	0
exception	0
of	0
indomethacin	0
,	0
the	0
used	0
immunosuppressive	0
and	0
anti-inflammatory	0
agents	0
significantly	0
inhibited	0
T	0
cell	0
proliferation	0
in	0
response	0
to	0
influenza	9
virus	10
antigen	10
in	0
a	0
dose-dependent	0
manner	0
.	0

Interestingly	0
,	0
CyA	0
and	0
indomethacin	0
did	0
not	0
suppress	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
-induced	0
adhesion	0
molecule	0
expression	0
on	0
HUVECs	7
,	0
whereas	0
aspirin	0
had	0
an	0
inhibitory	0
effect	0
.	0

These	0
observations	0
correlated	0
with	0
the	0
modulation	0
of	0
NF-kappaB	9
activity	0
in	0
EC	7
.	0

All	0
agents	0
tested	0
induced	0
expression	0
of	0
Hsp60	9
6	0
hr	0
after	0
application	0
.	0

In	0
addition	0
,	0
aspirin	0
and	0
indomethacin	0
,	0
but	0
not	0
CyA	0
,	0
induced	0
Hsp70	9
expression	0
in	0
HUVECs	7
that	0
correlated	0
with	0
induction	0
of	0
HSF-1	9
activity	0
.	0

CONCLUSION	0
:	0
Our	0
results	0
show	0
that	0
the	0
tested	0
agents	0
(	0
except	0
indomethacin	0
)	0
are	0
inhibitors	0
of	0
the	0
T	0
cell-mediated	0
immune	0
response	0
,	0
as	0
expected	0
,	0
that	0
aspirin	0
is	0
an	0
effective	0
suppressor	0
of	0
adhesion	9
molecule	10
expression	0
,	0
and	0
that	0
all	0
three	0
agents	0
can	0
induce	0
Hsp60	9
in	0
HUVECs	7
.	0

These	0
data	0
provide	0
the	0
molecular	0
basis	0
for	0
the	0
notion	0
that	0
(	0
1	0
)	0
part	0
of	0
the	0
anti-atherogenic	0
effect	0
of	0
aspirin	0
may	0
be	0
due	0
to	0
the	0
prevention	0
of	0
the	0
adhesion	0
of	0
sensitized	7
T	8
cells	8
to	0
stressed	0
EC	7
;	0
(	0
2	0
)	0
that	0
part	0
of	0
the	0
atherosclerosis-promoting	0
effect	0
of	0
CyA	0
may	0
be	0
due	0
to	0
its	0
potential	0
as	0
an	0
inducer	0
of	0
Hsp60	9
expression	0
and	0
its	0
inability	0
to	0
down-regulate	0
adhesion	9
molecule	10
expression	0
on	0
EC	7
;	0
and	0
(	0
3	0
)	0
that	0
down-regulation	0
of	0
MCP-1	9
expression	0
by	0
aspirin	0
may	0
result	0
in	0
decreased	0
recruitment	0
of	0
monocytes	7
into	0
the	0
arterial	0
intima	0
beneath	0
stressed	0
EC	7
.	0

In	0
vivo	0
modulation	0
of	0
glucocorticoid	3
receptor	4
mRNA	4
by	0
inhaled	0
fluticasone	0
propionate	0
in	0
bronchial	0
mucosa	0
and	0
blood	7
lymphocytes	8
in	0
subjects	0
with	0
mild	0
asthma	0
.	0

BACKGROUND	0
:	0
In	0
vivo	0
regulation	0
of	0
the	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
by	0
glucocorticoids	0
provides	0
a	0
means	0
of	0
modulating	0
sensitivity	0
of	0
targeted	0
cells	0
.	0

OBJECTIVE	0
:	0
We	0
sought	0
to	0
determine	0
the	0
in	0
vivo	0
modulation	0
of	0
GR	3
mRNA	4
expression	0
by	0
fluticasone	0
propionate	0
(	0
FP	0
)	0
in	0
subjects	0
with	0
mild	0
asthma	0
.	0

METHODS	0
:	0
Ten	0
atopic	0
asthmatic	0
subjects	0
were	0
treated	0
with	0
FP	0
250	0
microg	0
twice	0
daily	0
for	0
4	0
weeks	0
.	0

Before	0
and	0
after	0
treatment	0
,	0
the	0
patients	0
underwent	0
fiberoptic	0
bronchoscopy	0
with	0
endobronchial	0
biopsy	0
and	0
sampling	0
of	0
venous	0
blood	0
for	0
measurements	0
of	0
GR	3
mRNA	4
levels	0
.	0

A	0
solution	0
hybridization	0
assay	0
was	0
used	0
for	0
quantitative	0
analysis	0
of	0
GR	3
mRNA	4
.	0

In	0
addition	0
,	0
a	0
24-hour	0
urinary	0
cortisol	0
excretion	0
and	0
an	0
adrenocorticotropic	0
hormone	0
test	0
before	0
and	0
after	0
treatment	0
with	0
FP	0
were	0
performed	0
.	0

RESULTS	0
:	0
A	0
high	0
interindividual	0
variation	0
in	0
GR	3
mRNA	4
expression	0
was	0
seen	0
.	0

However	0
,	0
we	0
detected	0
a	0
significant	0
reduction	0
of	0
the	0
GR	3
mRNA	4
levels	0
in	0
the	0
endobronchial	0
biopsy	0
specimens	0
after	0
FP	0
treatment	0
(	0
36.6	0
+/-	0
23.1	0
and	0
25.0	0
+/-	0
10.9	0
amol	0
GR	3
mRNA	4
/microg	0
RNA	0
,	0
respectively	0
;	0
P	0
<	0
.01	0
)	0
.	0

In	0
the	0
peripheral	0
blood	7
lymphocytes	8
an	0
even	0
more	0
striking	0
downregulation	0
of	0
the	0
GR	0
by	0
its	0
cognate	0
ligand	0
was	0
documented	0
(	0
30.3	0
+/-	0
26.5	0
and	0
8.8	0
+/-	0
5	0
amol	0
GR	3
mRNA	4
/microg	0
RNA	0
,	0
respectively	0
;	0
P	0
<	0
.001	0
)	0
,	0
possibly	0
reflecting	0
differences	0
in	0
glucocorticoid	0
sensitivity	0
between	0
tissues	0
.	0

A	0
small	0
but	0
significant	0
reduction	0
of	0
the	0
24-hour	0
urinary	0
cortisol	0
excretion	0
was	0
observed	0
(	0
233	0
+/-	0
109	0
and	0
157	0
+/-	0
66	0
nmol/L	0
,	0
respectively	0
;	0
P	0
<	0
.01	0
)	0
,	0
whereas	0
the	0
feedback	0
regulation	0
of	0
glucocorticoid	0
synthesis	0
by	0
means	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
axis	0
as	0
assessed	0
by	0
the	0
adrenocorticotropic	0
hormone	0
test	0
remained	0
normal	0
after	0
treatment	0
with	0
FP	0
.	0

CONCLUSION	0
:	0
The	0
results	0
in	0
this	0
study	0
confirm	0
the	0
potency	0
of	0
the	0
inhaled	0
corticosteroid	0
FP	0
and	0
provide	0
evidence	0
for	0
a	0
considerable	0
tissue-specific	0
interindividual	0
variation	0
in	0
the	0
expression	0
of	0
the	0
GR	9
.	0

[	0
Corticoids	0
and	0
allergy	0
]	0

Inflammation	0
is	0
constantly	0
observed	0
in	0
allergic	0
reactions	0
.	0

Corticosteroids	0
are	0
most	0
effective	0
in	0
preventing	0
the	0
late	0
phase	0
of	0
allergic	0
reaction	0
.	0

The	0
action	0
of	0
glucocorticosteroids	0
is	0
mediated	0
through	0
glucocorticoid	9
receptors	10
present	0
in	0
the	0
cellular	0
cytoplasm	0
.	0

When	0
activated	0
,	0
glucocorticoid	9
receptors	10
form	0
a	0
dimer	9
and	0
bind	0
to	0
DNA	0
after	0
migration	0
into	0
the	0
nucleus	0
.	0

Interaction	0
to	0
DNA	0
induces	0
changes	0
in	0
the	0
transcription	0
rate	0
,	0
leading	0
to	0
either	0
gene	0
induction	0
or	0
gene	0
repression	0
.	0

Glucocorticoid	0
receptors	0
are	0
also	0
able	0
to	0
interact	0
with	0
transcriptional	0
factors	0
such	0
as	0
AP-1	9
(	0
activator	9
protein-1	10
)	0
of	0
NF-kappa	9
B	10
(	0
nuclear	9
factor-kappa	10
B	10
)	0
.	0

Through	0
these	0
actions	0
glucocorticosteroids	0
are	0
susceptible	0
to	0
modify	0
functions	0
of	0
cells	0
involved	0
in	0
the	0
allergic	0
inflammatory	0
response	0
.	0

They	0
are	0
in	0
particular	0
able	0
to	0
inhibit	0
most	0
of	0
the	0
pro-inflammatory	0
functions	0
of	0
the	0
eosinophils	7
.	0

Jeg-3	0
human	0
choriocarcinoma-induced	0
immunosuppression	0
:	0
downregulation	0
of	0
interleukin-2	9
,	0
interleukin-2	9
receptor	10
alpha-chain	10
,	0
and	0
its	0
Jak/Stat	9
signaling	0
pathway	0
.	0

PROBLEM	0
:	0
The	0
mechanisms	0
of	0
the	0
immunosuppressive	0
and	0
immunosuppression-inducing	0
capacities	0
of	0
Jeg-3	5
human	6
choriocarcinoma	6
cell	6
line	6
supernatants	0
(	0
HCSs	0
)	0
are	0
not	0
yet	0
completely	0
understood	0
.	0

The	0
influence	0
on	0
interleukin	9
(	10
IL	10
)	10
-2	10
,	0
IL-4	9
and	0
interferon	9
(	10
IFN	10
)	10
-gamma	10
production	0
;	0
IL-2	9
receptor	10
(	10
IL-2R	10
)	10
alpha	10
-	0
,	0
beta	9
-	0
,	0
and	0
gamma-chain	9
;	0
and	0
the	0
signaling	9
pathway	10
molecules	10
Janus	9
kinase	10
(	9
Jak	10
)	10
1	10
,	0
Jak3	9
,	0
signal	0
transducers	0
and	0
activators	9
of	10
transcription	10
(	9
Stat	10
)	10
1	10
,	0
Stat3	9
,	0
and	0
Stat5	9
should	0
be	0
investigated	0
.	0

METHOD	0
OF	0
STUDY	0
:	0
For	0
assessment	0
of	0
IL	0
production	0
,	0
whole	0
peripheral	0
venous	0
blood	0
from	0
healthy	0
donors	0
was	0
stimulated	0
with	0
phorbol-myristate-acetate	0
and	0
ionomycine	0
.	0

Secretion	0
of	0
ILs	9
was	0
blocked	0
with	0
monensine	0
.	0

Intracellular	0
ILs	9
were	0
analyzed	0
by	0
flow	0
cytometry	0
.	0

For	0
IL-2R	9
and	0
signaling	0
pathway	0
molecule	0
analysis	0
,	0
peripheral	0
blood	7
lymphocytes	8
were	0
stimulated	0
with	0
phytohemagglutinin	9
(	0
PHA	9
)	0
.	0

IL-2R	0
chains	0
were	0
measured	0
by	0
flow	0
cytometry	0
,	0
and	0
Jaks/Stats	9
by	0
sodium	0
dodecyl	0
sulfate	0
polyacrylamide	0
gel	0
electrophoresis	0
(	0
SDS-PAGE	0
)	0
and	0
Western	0
blot	0
.	0

RESULTS	0
:	0
Phorbol-myristate-acetate	0
and	0
ionomycine	0
strongly	0
increase	0
the	0
percent-age	0
of	0
IL-2+	5
cells	6
;	0
an	0
additional	0
50	0
%	0
HCSs	0
significantly	0
suppresses	0
the	0
percentage	0
to	0
,	0
or	0
below	0
the	0
level	0
of	0
unstimulated	7
cells	8
.	0

IFN-gamma	0
production	0
is	0
strongly	0
decreased	0
by	0
HCSs	0
in	0
some	0
cases	0
,	0
but	0
not	0
in	0
others	0
.	0

PHA	9
stimulates	0
IL-2R	0
alpha-	0
,	0
beta-	0
,	0
and	0
gamma-chain	0
expression	0
and	0
their	0
signaling	9
pathway	10
molecules	10
Jak1	9
,	0
Jak3	9
,	0
Stat1	0
,	0
Stat3	9
,	0
and	0
Stat5	9
.	0

50	0
%	0
HCS	0
downregulates	0
the	0
alpha-chain	9
and	0
slightly	0
upregulates	0
the	0
beta-chain	9
.	0

Jak1	0
,	0
Jak3	0
,	0
Stat1	0
,	0
Stat3	0
,	0
and	0
Stat5	0
expression	0
is	0
suppressed	0
approximately	0
to	0
,	0
or	0
below	0
the	0
level	0
of	0
unstimulated	7
cells	8
.	0

CONCLUSIONS	0
:	0
HCS	0
forcefully	0
blocks	0
the	0
production	0
of	0
IL-2	9
;	0
the	0
IL-2R	9
alpha-chain	10
;	0
and	0
Jak1	0
,	0
Jak3	0
,	0
Stat1	0
,	0
Stat3	0
,	0
and	0
Stat5	0
expression	0
.	0

The	0
observed	0
phenomena	0
might	0
be	0
caused	0
by	0
downregulation	0
of	0
an	0
IL-2R	1
regulation	2
gene	2
,	0
and	0
might	0
play	0
a	0
key	0
role	0
in	0
the	0
expansion	0
of	0
choriocarcinoma	0
,	0
and	0
possibly	0
in	0
the	0
survival	0
of	0
the	0
fetal	0
allograft	0
.	0

Apoptosis-resistant	5
T	6
cells	6
have	0
a	0
deficiency	0
in	0
NF-kappaB	9
-mediated	0
induction	0
of	0
Fas	9
ligand	10
transcription	0
.	0

Apoptosis	0
induced	0
through	0
the	0
TCR	9
in	0
CD4+	7
T	8
cells	8
is	0
mostly	0
mediated	0
by	0
the	0
inducible	0
expression	0
of	0
Fas	9
ligand	10
(	0
FasL	9
)	0
as	0
a	0
primary	0
event	0
leading	0
to	0
the	0
commitment	0
to	0
death	0
.	0

To	0
gain	0
a	0
better	0
understanding	0
of	0
the	0
transcriptional	0
events	0
that	0
regulate	0
this	0
expression	0
,	0
we	0
took	0
advantage	0
of	0
our	0
previously	0
described	0
mutant	5
Jurkat	6
cells	6
.	0

These	0
cells	0
are	0
deficient	0
in	0
FasL	9
expression	0
and	0
apoptosis	0
induced	0
upon	0
TCR	9
triggering	0
,	0
although	0
their	0
cytokine	0
(	0
IL-2	9
and	0
IFN-gamma	9
)	0
production	0
is	0
normal	0
.	0

Here	0
we	0
show	0
that	0
both	0
a	0
FasL-	1
and	2
a	2
consensus	2
NF-kappaB-	2
reporter	2
construct	2
are	0
inefficiently	0
induced	0
in	0
these	0
cells	0
compared	0
to	0
wild-type	7
cells	8
.	0

In	0
addition	0
,	0
we	0
demonstrate	0
that	0
the	0
inducible	0
transcriptional	0
activity	0
of	0
the	0
FasL	1
reporter	2
is	0
abolished	0
by	0
specific	0
inhibitors	0
of	0
NF-kappaB	9
activation	0
.	0

Thus	0
,	0
we	0
could	0
trace	0
the	0
deficit	0
of	0
the	0
mutant	7
cells	8
to	0
an	0
inefficient	0
NF-kappaB	9
activation	0
,	0
evidencing	0
a	0
relevant	0
role	0
for	0
NF-kappaB	9
in	0
the	0
regulation	0
of	0
FasL	9
expression	0
in	0
activated	7
T	8
cells	8
.	0

Furthermore	0
,	0
our	0
results	0
suggest	0
that	0
the	0
induction	0
of	0
FasL	9
versus	0
cytokine	1
gene	2
expression	0
is	0
differentially	0
sensitive	0
to	0
NF-kappaB	9
deprivation	0
.	0

Decreased	0
proteasome	9
-mediated	0
degradation	0
in	0
T	7
cells	8
from	0
the	0
elderly	0
:	0
A	0
role	0
in	0
immune	0
senescence	0
.	0

Induction	0
of	0
NFkappaB	9
is	0
a	0
highly	0
regulated	0
process	0
requiring	0
phosphorylation	0
,	0
ubiquitination	0
,	0
and	0
proteasome	9
-mediated	0
degradation	0
of	0
the	0
cytosolic	9
inhibitor	10
IkappaBalpha	9
.	0

Analyses	0
of	0
the	0
regulation	0
of	0
IkappaBalpha	9
in	0
TNF-alpha-treated	7
T	8
lymphocytes	8
from	0
young	0
and	0
elderly	0
donors	0
revealed	0
severely	0
compromised	0
degradation	0
of	0
IkappaBalpha	9
in	0
T	7
cells	8
from	0
the	0
elderly	0
.	0

Examination	0
of	0
activation-induced	0
phosphorylation	0
and	0
ubiquitination	0
of	0
IkappaBalpha	9
did	0
not	0
demonstrate	0
any	0
significant	0
age-related	0
alterations	0
.	0

However	0
,	0
examination	0
of	0
proteasome	9
activity	0
in	0
these	0
T	7
cells	8
using	0
fluorogenic	0
peptide	0
assays	0
revealed	0
a	0
significant	0
age-related	0
decline	0
in	0
chymotryptic	0
activity	0
.	0

These	0
results	0
suggest	0
that	0
a	0
decline	0
in	0
proteasome	9
activity	0
results	0
in	0
a	0
failure	0
to	0
fully	0
degrade	0
IkappaBalpha	9
in	0
the	0
elderly	0
.	0

This	0
failure	0
to	0
degrade	0
IkappaBalpha	9
may	0
underlie	0
both	0
the	0
observed	0
decrease	0
in	0
NFkappaB	9
induction	0
and	0
the	0
IL-2	9
receptor	0
expression	0
in	0
TNF-treated	5
T	6
cells	6
during	0
aging	0
.	0

Thus	0
,	0
decreased	0
proteasome	9
-mediated	0
degradation	0
may	0
be	0
central	0
to	0
immune	0
dysfunction	0
that	0
accompanies	0
aging	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Inhibition	0
of	0
IL-4	9
-inducible	0
gene	0
expression	0
in	0
human	7
monocytes	8
by	0
type	9
I	10
and	10
type	10
II	10
interferons	10
.	0

The	0
Th2-type	9
cytokines	10
,	0
interleukin-4	9
(	0
IL-4	9
)	0
and	0
interleukin-13	9
(	0
IL-13	9
)	0
,	0
induce	0
expression	0
of	0
a	0
distinct	0
subset	0
of	0
genes	0
in	0
human	7
monocytes	8
,	0
including	0
FcepsilonRIIb	9
(	0
CD23	9
)	0
,	0
15-lipoxygenase	9
,	0
IL-1	9
receptor	10
antagonist	10
(	0
IL-1ra	9
)	0
,	0
and	0
type	9
I	10
and	10
type	10
II	10
IL-1	10
receptors	10
(	0
IL-1R	9
)	0
.	0

Type	9
I	10
interferons	10
(	0
IFN-alpha	9
and	0
IFN-beta	9
)	0
and	0
type	9
II	10
interferon	10
(	0
IFN-gamma	9
)	0
inhibit	0
induction	0
of	0
these	0
genes	0
by	0
IL-4	9
and	0
IL-13	9
.	0

However	0
,	0
the	0
mechanism	0
by	0
which	0
IFNs	9
mediate	0
this	0
inhibition	0
has	0
not	0
been	0
defined	0
.	0

In	0
this	0
overview	0
,	0
we	0
discuss	0
the	0
role	0
of	0
the	0
transcription	9
factor	10
,	0
STAT6	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription-6	10
)	0
in	0
mediating	0
IL-4-	0
and	0
IL-13-induced	0
gene	0
expression	0
in	0
monocytes	7
.	0

We	0
also	0
discuss	0
our	0
recent	0
findings	0
that	0
type	9
I	10
and	10
type	10
II	10
IFNs	10
suppress	0
IL-4	9
/	0
IL-13	9
-inducible	0
gene	0
expression	0
by	0
inhibiting	0
tyrosine	0
phosphorylation	0
and	0
nuclear	0
translocation	0
of	0
STAT6	9
.	0

The	0
ability	0
of	0
type	9
I	10
and	10
type	10
II	10
IFNs	10
to	0
inhibit	0
IL-4	9
/	0
IL-13	9
-induced	0
STAT6	9
activity	0
is	0
dose-	0
and	0
time-dependent	0
,	0
and	0
is	0
not	0
unique	0
to	0
monocytes	7
because	0
IFNs	9
induce	0
the	0
same	0
effects	0
in	0
fibroblasts	7
.	0

Inhibition	0
of	0
STAT6	9
activity	0
is	0
not	0
evident	0
unless	0
cells	0
are	0
preincubated	0
with	0
IFN	9
for	0
at	0
least	0
1	0
h	0
before	0
IL-4	9
stimulation	0
.	0

Furthermore	0
,	0
inhibition	0
can	0
be	0
blocked	0
by	0
actinomycin	0
D	0
,	0
indicating	0
a	0
requirement	0
for	0
de	0
novo	0
transcription	0
.	0

We	0
propose	0
a	0
model	0
in	0
which	0
stimulation	0
of	0
monocytes	7
by	0
IFN	9
activates	0
de	0
novo	0
synthesis	0
of	0
an	0
inhibitory	9
factor	10
,	0
possibly	0
one	0
or	0
more	0
members	0
of	0
the	0
SOCS/	9
SSI/CIS	10
gene	10
family	10
,	0
capable	0
of	0
suppressing	0
activation	0
of	0
STAT6	9
by	0
IL-4	9
and	0
IL-13	9
.	0

Because	0
STAT6	9
activation	0
plays	0
an	0
essential	0
role	0
in	0
IL-4	9
/	0
IL-13	9
-induced	0
gene	0
expression	0
,	0
the	0
ability	0
of	0
IFN-beta	9
and	0
IFN-gamma	9
to	0
inhibit	0
STAT6	9
activity	0
provides	0
an	0
explanation	0
for	0
how	0
IFNs	9
can	0
suppress	0
IL-4	9
/	0
IL-13	9
-inducible	0
gene	0
expression	0
.	0

HLA	9
class	10
I	10
-mediated	0
induction	0
of	0
cell	0
proliferation	0
involves	0
cyclin	1
E	2
-mediated	0
inactivation	0
of	0
Rb	0
function	0
and	0
induction	0
of	0
E2F	9
activity	0
.	0

Chronic	0
rejection	0
of	0
transplanted	0
organs	0
is	0
manifested	0
as	0
atherosclerosis	0
of	0
the	0
blood	0
vessels	0
of	0
the	0
allograft	0
.	0

HLA	9
class	10
I	10
Ags	10
have	0
been	0
implicated	0
to	0
play	0
a	0
major	0
role	0
in	0
this	0
process	0
,	0
since	0
signaling	0
via	0
HLA	9
class	10
I	10
molecules	10
can	0
induce	0
the	0
proliferation	0
of	0
aortic	7
endothelial	8
as	0
well	0
as	0
smooth	7
muscle	8
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
HLA	9
class	10
I	10
-mediated	0
induction	0
of	0
cell	0
proliferation	0
correlates	0
with	0
inactivation	0
of	0
the	0
Rb	9
protein	10
in	0
the	0
T	5
cell	6
line	6
Jurkat	6
as	0
well	0
as	0
human	7
aortic	8
endothelial	8
cells	8
.	0

HLA	9
class	10
I	10
-mediated	0
inactivation	0
of	0
Rb	9
can	0
be	0
inhibited	0
specifically	0
by	0
neutralizing	9
Abs	10
to	0
basic	9
fibroblast	10
growth	10
factor	10
(	0
bFGF	9
)	0
,	0
suggesting	0
a	0
role	0
for	0
FGF	9
receptors	10
in	0
the	0
signaling	0
process	0
.	0

Signaling	0
through	0
HLA	9
class	10
I	10
molecules	10
induced	0
cyclin	1
E	2
-associated	0
kinase	0
activity	0
within	0
4	0
h	0
in	0
quiescent	7
endothelial	8
cells	8
,	0
and	0
appeared	0
to	0
mediate	0
the	0
inactivation	0
of	0
Rb	9
.	0

A	0
cdk2	0
inhibitor	0
,	0
Olomoucine	0
,	0
as	0
well	0
as	0
a	0
dominant-negative	1
cdk2	2
construct	2
prevented	0
HLA	9
class	10
I	10
-mediated	0
inactivation	0
of	0
Rb	9
;	0
in	0
contrast	0
,	0
dominant-negative	1
cdk4	2
and	2
cdk6	2
constructs	2
had	0
no	0
effect	0
.	0

Furthermore	0
,	0
there	0
was	0
no	0
increase	0
in	0
cyclin	9
D-associated	10
kinase	10
activity	0
upon	0
HLA	9
class	10
I	10
ligation	0
,	0
suggesting	0
that	0
cyclin	9
E-dependent	10
kinase	10
activity	0
mediates	0
Rb	9
inactivation	0
,	0
leading	0
to	0
E2F	9
activation	0
and	0
cell	0
proliferation	0
.	0

Immunosuppressant	0
PG490	0
(	0
triptolide	0
)	0
inhibits	0
T-cell	9
interleukin-2	10
expression	0
at	0
the	0
level	0
of	0
purine-box/nuclear	9
factor	10
of	0
activated	7
T-cells	8
and	0
NF-kappaB	9
transcriptional	0
activation	0
.	0

PG490	0
(	0
triptolide	0
)	0
is	0
a	0
diterpene	0
triepoxide	0
with	0
potent	0
immunosuppressive	0
and	0
antiinflammatory	0
properties	0
.	0

PG490	0
inhibits	0
interleukin	9
(	10
IL	10
)	10
-2	10
expression	0
by	0
normal	7
human	8
peripheral	8
blood	8
lymphocytes	8
stimulated	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
antibody	0
to	0
CD3	9
(	0
IC50	0
of	0
10	0
ng/ml	0
)	0
,	0
and	0
with	0
PMA	0
and	0
ionomycin	0
(	0
Iono	0
,	0
IC50	0
of	0
40	0
ng/ml	0
)	0
.	0

In	0
Jurkat	5
T-cells	6
,	0
PG490	0
inhibits	0
PMA/Iono-stimulated	0
IL-2	9
transcription	0
.	0

PG490	0
inhibits	0
the	0
induction	0
of	0
DNA	0
binding	0
activity	0
at	0
the	0
purine-box/antigen	1
receptor	2
response	2
element	2
(	2
ARRE	2
)	2
/nuclear	2
factor	2
of	2
activated	2
T-cells	2
(	2
NF-AT	2
)	2
target	2
sequence	2
but	0
not	0
at	0
the	0
NF-kappaB	1
site	2
.	0

PG490	0
can	0
completely	0
inhibit	0
transcriptional	0
activation	0
at	0
the	0
purine-box/ARRE/NF-AT	1
and	2
NF-kappaB	2
target	2
DNA	2
sequences	2
triggered	0
by	0
all	0
stimuli	0
examined	0
(	0
PMA	0
,	0
PMA/Iono	0
,	0
tumor	9
necrosis	10
factor-alpha	10
)	0
.	0

PG490	0
also	0
inhibits	0
PMA-stimulated	0
activation	0
of	0
a	0
chimeric	9
transcription	10
factor	10
in	0
which	0
the	0
C-terminal	9
TA1	10
transactivation	10
domain	10
of	0
NF-kappaB	9
p65	10
is	0
fused	0
to	0
the	0
DNA	9
binding	10
domain	10
of	0
GAL4	9
.	0

In	0
16HBE	7
human	8
bronchial	8
epithelial	8
cells	8
,	0
IL-8	9
expression	0
is	0
regulated	0
predominantly	0
by	0
NF-kappaB	9
,	0
and	0
PG490	0
but	0
not	0
cyclosporin	0
A	0
can	0
completely	0
inhibit	0
expression	0
of	0
IL-8	9
.	0

The	0
mechanism	0
of	0
PG490	0
inhibition	0
of	0
cytokine	1
gene	2
expression	0
differs	0
from	0
cyclosporin	0
A	0
and	0
involves	0
nuclear	0
inhibition	0
of	0
transcriptional	0
activation	0
of	0
NF-kappaB	9
and	0
the	0
purine-box	1
regulator	2
operating	0
at	0
the	0
ARRE/NF-AT	1
site	2
at	0
a	0
step	0
after	0
specific	0
DNA	0
binding	0
.	0

Unexpected	0
and	0
coordinated	0
expression	0
of	0
Spi-1	9
,	0
Fli-1	9
,	0
and	0
megakaryocytic	1
genes	2
in	0
four	0
Epo-dependent	5
cell	6
lines	6
established	0
from	0
transgenic	0
mice	0
displaying	0
erythroid-specific	0
expression	0
of	0
a	0
thermosensitive	9
SV40	10
T	10
antigen	10
.	0

Most	0
erythroleukemic	5
cell	6
lines	6
established	0
in	0
vitro	0
coexpress	0
erythrocytic	9
and	10
megakaryocytic	10
markers	10
that	0
often	0
are	0
associated	0
with	0
expression	0
of	0
Spi-1	9
and/or	0
Fli-1	9
transcription	10
factors	10
known	0
as	0
transactivators	9
of	10
megakaryocyte-specific	10
promoters	10
.	0

In	0
the	0
present	0
study	0
,	0
we	0
examined	0
the	0
possibility	0
of	0
establishing	0
new	5
cell	6
lines	6
keeping	0
strictly	0
erythroid-specific	0
properties	0
in	0
vitro	0
through	0
the	0
targeted	0
and	0
conditional	0
immortalization	0
of	0
erythrocytic	7
progenitors	8
.	0

For	0
that	0
purpose	0
,	0
we	0
established	0
several	0
lines	0
of	0
transgenic	0
mice	0
displaying	0
erythroid-specific	0
expression	0
of	0
a	0
thermosensitive	9
SV40	10
T	10
antigen	10
.	0

As	0
expected	0
,	0
these	0
transgenic	0
mice	0
developed	0
splenomegaly	0
due	0
to	0
the	0
massive	0
amplification	0
of	0
Ter	5
119	6
positive	6
erythroid	6
nucleated	6
cells	6
expressing	0
T	9
antigen	10
.	0

Despite	0
this	0
drastic	0
effect	0
in	0
vivo	0
,	0
the	0
in	0
vitro	0
immortalization	0
of	0
erythropoietin-dependent	7
erythroid	8
progenitors	8
unexpectedly	0
occurred	0
at	0
low	0
frequency	0
,	0
and	0
all	0
four	0
cell	5
lines	6
established	0
expressed	0
both	0
erythrocytic	9
(	10
globins	10
)	10
and	10
megakaryocytic	10
markers	10
(	0
glycoprotein	9
IIb	10
,	0
platelet	9
factor	10
4	10
)	0
as	0
well	0
as	0
Spi-1	9
and	0
Fli-1	9
transcripts	10
at	0
permissive	0
temperature	0
.	0

Switching	0
the	0
cells	0
to	0
the	0
nonpermissive	0
temperature	0
led	0
to	0
a	0
marked	0
increase	0
in	0
globin	1
gene	2
expression	0
and	0
concomitant	0
decrease	0
in	0
expression	0
of	0
Spi-1	9
,	0
Fli-1	9
,	0
and	0
megakaryocytic	1
genes	2
in	0
an	0
erythropoietin	9
-dependent	0
manner	0
.	0

Interestingly	0
,	0
enhanced	0
expression	0
of	0
Spi-1	1
and	2
Fli-1	2
genes	2
already	0
was	0
detected	0
in	0
the	0
Ter	5
119	6
positive	6
cell	6
population	6
of	0
transgenic	0
mice	0
spleen	0
in	0
vivo	0
.	0

However	0
,	0
like	0
normal	5
Ter	6
119	6
erythroid	6
cells	6
,	0
these	0
Ter	5
119	6
positive	6
cells	6
from	0
transgenic	0
mice	0
still	0
expressed	0
high	0
levels	0
of	0
beta-globin	9
and	0
very	0
low	0
or	0
undetectable	0
glycoprotein	9
IIb	10
and	0
platelet	9
factor	10
4	10
megakaryocytic	10
transcripts	10
.	0

Taken	0
together	0
,	0
these	0
data	0
indicate	0
that	0
the	0
unexpected	0
expression	0
of	0
megakaryocytic	1
genes	2
is	0
a	0
specific	0
property	0
of	0
immortalized	5
cells	6
that	0
can	0
not	0
be	0
explained	0
only	0
by	0
enhanced	0
expression	0
of	0
Spi-1	1
and/or	2
Fli-1	2
genes	2
.	0

Fludarabine-induced	0
immunosuppression	0
is	0
associated	0
with	0
inhibition	0
of	0
STAT1	9
signaling	0
.	0

Fludarabine	0
is	0
a	0
nucleoside	0
analog	0
used	0
in	0
the	0
treatment	0
of	0
hematologic	0
malignancies	0
that	0
can	0
induce	0
severe	0
and	0
prolonged	0
immunosuppression	0
.	0

Although	0
it	0
can	0
be	0
incorporated	0
into	0
the	0
DNA	0
of	0
dividing	0
cells	0
,	0
fludarabine	0
is	0
also	0
a	0
potent	0
inhibitor	0
of	0
cells	0
with	0
a	0
low	0
growth	0
fraction	0
,	0
thus	0
it	0
must	0
have	0
other	0
mechanisms	0
of	0
action	0
.	0

STAT1	9
,	0
which	0
is	0
activated	0
in	0
response	0
to	0
many	0
lymphocyte-activating	9
cytokines	10
including	0
the	0
interferons	9
,	0
is	0
essential	0
for	0
cell-mediated	0
immunity	0
,	0
as	0
the	0
absence	0
of	0
this	0
protein	0
is	0
associated	0
with	0
prominent	0
defects	0
in	0
the	0
ability	0
to	0
control	0
viral	0
infections	0
.	0

Here	0
we	0
show	0
that	0
fludarabine	0
,	0
but	0
not	0
the	0
immunosuppressant	0
cyclosporine	0
A	0
,	0
inhibits	0
the	0
cytokine	9
-induced	0
activation	0
of	0
STAT1	9
and	0
STAT1	9
-dependent	0
gene	0
transcription	0
in	0
normal	7
resting	8
or	8
activated	8
lymphocytes	8
.	0

Fludarabine	0
caused	0
a	0
specific	0
depletion	0
of	0
STAT1	9
protein	10
(	0
and	0
mRNA	0
)	0
but	0
not	0
of	0
other	0
STATs	9
.	0

This	0
loss	0
of	0
STAT1	9
was	0
also	0
seen	0
in	0
cells	0
from	0
patients	0
treated	0
with	0
fludarabine	0
in	0
vivo	0
.	0

Brief	0
exposure	0
to	0
fludarabine	0
led	0
to	0
a	0
sustained	0
loss	0
of	0
STAT1	9
,	0
analogous	0
to	0
the	0
prolonged	0
period	0
of	0
immunosuppression	0
induced	0
by	0
exposure	0
to	0
the	0
drug	0
in	0
vivo	0
.	0

Thus	0
,	0
STAT1	9
may	0
be	0
a	0
useful	0
target	0
in	0
the	0
development	0
of	0
new	0
immunosuppressive	0
and	0
antineoplastic	0
agents	0
.	0

Studies	0
into	0
the	0
effect	0
of	0
tyrosine	9
phosphatase	10
inhibitor	0
phenylarsine	0
oxide	0
on	0
NFkappaB	9
activation	0
in	0
T	7
lymphocytes	8
during	0
aging	0
:	0
evidence	0
for	0
altered	0
IkappaB-alpha	9
phosphorylation	0
and	0
degradation	0
.	0

Nuclear	9
Factor	10
kappa	10
B	10
(	0
NFkappaB	9
)	0
is	0
a	0
critical	0
regulator	0
of	0
several	0
genes	0
involved	0
in	0
immune	0
and	0
inflammatory	0
responses	0
.	0

Treatment	0
of	0
T	7
cells	8
with	0
a	0
variety	0
of	0
stimuli	0
,	0
including	0
TNF-alpha	9
,	0
leads	0
to	0
the	0
translocation	0
of	0
the	0
active	0
p65-50	9
heterodimer	10
to	0
the	0
nucleus	0
,	0
albeit	0
at	0
a	0
lower	0
level	0
in	0
T	7
cells	8
from	0
the	0
elderly	0
.	0

We	0
demonstrate	0
here	0
that	0
pretreatment	0
with	0
PAO	0
results	0
in	0
the	0
inhibition	0
of	0
NFkappaB	9
induction	0
in	0
TNF-alpha	9
treated	0
T	7
cells	8
,	0
suggesting	0
a	0
role	0
for	0
PAO-sensitive	9
phosphatase	10
in	0
the	0
activation	0
of	0
the	0
NFkappaB	9
via	0
this	0
pathway	0
in	0
human	7
T	8
cells	8
.	0

Furthermore	0
,	0
it	0
demonstrates	0
that	0
aging	0
does	0
not	0
influence	0
the	0
sensitivity	0
of	0
this	0
phosphatase	9
.	0

Treatment	0
with	0
DMP	0
prior	0
to	0
treatment	0
with	0
PAO	0
and	0
TNF	9
abolishes	0
the	0
inhibition	0
induced	0
by	0
PAO	0
,	0
in	0
T	7
cells	8
from	0
both	0
young	0
and	0
old	0
donors	0
,	0
alike	0
.	0

Finally	0
,	0
we	0
demonstrate	0
that	0
a	0
failure	0
to	0
degrade	0
IkappaB-alpha	9
in	0
cytosols	0
of	0
TNF-treated	7
T	8
cells	8
pretreated	0
with	0
PAO	0
is	0
due	0
to	0
its	0
interference	0
with	0
the	0
phosphorylation	0
of	0
IkappaB-alpha	9
and	0
not	0
due	0
to	0
its	0
inhibitory	0
effect	0
on	0
proteasomal	0
degradation	0
.	0

These	0
data	0
collectively	0
suggest	0
that	0
PAO	0
interferes	0
with	0
the	0
phosphorylation	0
and	0
the	0
regulated	0
degradation	0
of	0
IkappaB-alpha	9
,	0
induced	0
by	0
TNF	9
,	0
without	0
affecting	0
the	0
chymotryptic	0
activity	0
of	0
the	0
proteasome	9
,	0
independent	0
of	0
age	0
.	0

Spi-C	9
,	0
a	0
novel	0
Ets	9
protein	10
that	0
is	0
temporally	0
regulated	0
during	0
B	0
lymphocyte	0
development	0
.	0

A	0
novel	0
Ets	9
protein	10
was	0
isolated	0
by	0
yeast	0
one-hybrid	0
screening	0
of	0
a	0
cDNA	1
library	2
made	0
from	0
lipopolysaccharide-stimulated	5
mouse	6
splenic	6
B	6
cells	6
,	0
using	0
the	0
SP6	1
kappa	2
promoter	2
kappaY	2
element	2
as	0
a	0
bait	0
.	0

The	0
novel	0
Ets	9
protein	10
was	0
most	0
closely	0
related	0
to	0
PU.1	9
and	0
Spi-B	9
within	0
the	0
DNA	1
binding	2
Ets	2
domain	2
and	0
was	0
therefore	0
named	0
Spi-C	9
.	0

However	0
,	0
Spi-C	9
may	0
represent	0
a	0
novel	0
subgroup	0
within	0
the	0
Ets	9
protein	10
family	10
,	0
as	0
it	0
differed	0
significantly	0
from	0
Spi-B	9
and	0
PU.1	9
within	0
helix	9
1	10
of	0
the	0
Ets	9
domain	10
.	0

Spi-C	9
was	0
encoded	0
by	0
a	0
single-copy	1
gene	2
that	0
was	0
mapped	0
to	0
chromosome	1
10	2
,	0
region	1
C	2
.	0

Spi-C	9
interacted	0
with	0
DNA	0
similarly	0
to	0
PU.1	9
as	0
judged	0
by	0
methylation	0
interference	0
,	0
band-shift	0
and	0
site	0
selection	0
analysis	0
,	0
and	0
activated	0
transcription	0
of	0
a	0
kappaY	1
element	2
reporter	2
gene	2
upon	0
co-transfection	0
of	0
HeLa	5
cells	6
.	0

Spi-C	3
RNA	4
was	0
expressed	0
in	0
mature	7
B	8
lymphocytes	8
and	0
at	0
lower	0
levels	0
in	0
macrophages	7
.	0

Furthermore	0
,	0
pre-B	5
cell	6
and	6
plasma	6
cell	6
lines	6
were	0
Spi-C	9
-negative	0
,	0
suggesting	0
that	0
Spi-C	9
might	0
be	0
a	0
regulatory	9
molecule	10
during	0
a	0
specific	0
phase	0
of	0
B	0
lymphoid	0
development	0
.	0

Glucocorticoid-induced	0
cell	0
death	0
requires	0
autoinduction	0
of	0
glucocorticoid	9
receptor	10
expression	0
in	0
human	7
leukemic	8
T	8
cells	8
.	0

In	0
contrast	0
to	0
the	0
negative	0
autoregulation	0
of	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
expression	0
seen	0
in	0
most	0
cells	0
and	0
tissues	0
,	0
GR	9
expression	0
is	0
positively	0
autoregulated	0
in	0
human	7
leukemic	8
T	8
cells	8
and	0
in	0
other	0
cells	0
sensitive	0
to	0
glucocorticoid-induced	0
cell	0
death	0
.	0

To	0
determine	0
whether	0
positive	0
autoregulation	0
is	0
a	0
necessary	0
component	0
of	0
glucocorticoid-induced	0
cell	0
death	0
,	0
a	0
wild-type	1
GR	2
gene	2
under	0
the	0
control	0
of	0
a	0
tetracycline-regulated	1
promoter	2
was	0
stably	0
transfected	0
into	0
glucocorticoid-resistant	5
cells	6
lacking	0
endogenous	0
functional	0
receptor	0
.	0

Transfectants	5
grown	0
in	0
the	0
presence	0
of	0
tetracycline	0
contained	0
about	0
15	0
,	0
000	0
receptors/cell	0
,	0
a	0
value	0
approximately	0
equal	0
to	0
basal	0
level	0
GR	9
expression	0
in	0
glucocorticoid-sensitive	5
6TG1.1	6
cells	6
before	0
steroid	0
treatment	0
.	0

Under	0
these	0
conditions	0
,	0
dexamethasone	0
had	0
a	0
minimal	0
effect	0
on	0
cell	0
growth	0
,	0
elicited	0
little	0
internucleosomal	0
DNA	0
fragmentation	0
,	0
and	0
induced	0
no	0
cell	0
cycle	0
perturbation	0
.	0

In	0
the	0
absence	0
of	0
tetracycline	0
,	0
GR	3
mRNA	4
and	0
protein	0
expression	0
increased	0
2-3-fold	0
,	0
and	0
cells	0
expressed	0
48	0
,	0
000	0
receptors	0
,	0
a	0
level	0
nearly	0
equivalent	0
to	0
that	0
present	0
in	0
6TG1.1	5
cells	6
after	0
18	0
h	0
of	0
autoinduction	0
.	0

Under	0
these	0
conditions	0
,	0
dexamethasone	0
markedly	0
inhibited	0
cell	0
growth	0
,	0
caused	0
G1	0
arrest	0
,	0
and	0
induced	0
significant	0
internucleosomal	0
DNA	0
fragmentation	0
.	0

These	0
studies	0
therefore	0
suggest	0
that	0
basal	0
level	0
GR	9
expression	0
is	0
inadequate	0
to	0
mediate	0
glucocorticoid-induced	0
apoptosis	0
in	0
glucocorticoid-sensitive	5
T	6
cells	6
and	0
that	0
positive	0
autoregulation	0
is	0
a	0
necessary	0
component	0
of	0
this	0
process	0
.	0

Constitutive	0
activation	0
of	0
NF-kappaB	9
in	0
primary	7
adult	8
T-cell	8
leukemia	8
cells	8
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
is	0
an	0
etiologic	0
agent	0
of	0
adult	0
T-cell	0
leukemia	0
(	0
ATL	0
)	0
.	0

The	0
viral	9
protein	10
Tax	9
induces	0
the	0
activation	0
and	0
nuclear	0
translocalization	0
of	0
transcription	9
factor	10
NF-kappaB	9
,	0
which	0
is	0
proposed	0
to	0
play	0
a	0
crucial	0
role	0
in	0
the	0
transformation	0
of	0
T	7
cells	8
by	0
HTLV-I	0
.	0

However	0
,	0
the	0
HTLV-I	1
genes	2
including	0
Tax	9
are	0
not	0
expressed	0
significantly	0
in	0
primary	7
leukemic	8
cells	8
from	0
ATL	0
patients	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
basis	0
for	0
NF-kappaB	9
activation	0
in	0
freshly	7
isolated	8
leukemic	8
cells	8
from	0
ATL	0
patients	0
.	0

We	0
found	0
that	0
leukemic	7
cells	8
from	0
ATL	0
patients	0
,	0
like	0
HTLV-I-infected	5
T-cell	6
lines	6
,	0
display	0
constitutive	0
NF-kappaB	9
DNA	0
binding	0
activity	0
and	0
increased	0
degradation	0
of	0
IkappaBalpha	9
(	0
an	0
inhibitor	0
of	0
NF-kappaB	9
)	0
.	0

Whereas	0
the	0
NF-kappaB	9
binding	0
activity	0
in	0
Tax-expressing	5
T-cell	6
lines	6
consisted	0
mostly	0
of	0
p50/c-Rel	9
,	0
fresh	0
ATL	0
samples	0
contained	0
p50/p50	9
and	10
p50/p65	10
heterodimers	10
.	0

One	0
T-cell	5
line	6
derived	0
from	0
ATL	0
leukemic	7
cells	8
,	0
TL-Om1	0
,	0
displayed	0
constitutive	0
NF-kappaB	9
activity	0
,	0
as	0
well	0
as	0
enhanced	0
degradation	0
of	0
IkappaBalpha	9
,	0
despite	0
the	0
lack	0
of	0
detectable	0
Tax	9
expression	0
.	0

Interestingly	0
,	0
the	0
NF-kappaB	9
in	0
TL-Om1	0
consists	0
of	0
p50/p50	9
and	0
p50/p65	9
like	0
that	0
in	0
fresh	0
primary	7
leukemic	8
cells	8
.	0

Our	0
results	0
suggest	0
that	0
activation	0
of	0
NF-kappaB	9
occurs	0
through	0
a	0
Tax	9
-independent	0
mechanism	0
in	0
leukemic	7
cells	8
of	0
ATL	0
patients	0
,	0
possibly	0
due	0
to	0
differential	0
NF-kappaB	9
subunit	0
activation	0
.	0

Interferon-alpha	9
induction	0
of	0
STATs1	9
,	10
-3	10
DNA	0
binding	0
and	0
growth	0
arrest	0
is	0
independent	0
of	0
Lck	9
and	0
active	0
mitogen-activated	9
kinase	10
in	0
T	7
cells	8
.	0

Type	0
I	0
interferons	9
(	0
IFNs	9
)	0
are	0
a	0
family	0
of	0
cytokines	9
that	0
have	0
antiviral	0
and	0
antiproliferative	0
effects	0
.	0

Data	0
regarding	0
the	0
processes	0
by	0
which	0
these	0
cytokines	9
transduce	0
signals	0
from	0
the	0
cell	0
membrane	0
to	0
the	0
nucleus	0
are	0
becoming	0
increasingly	0
complex	0
.	0

The	0
most	0
characterized	0
pathway	0
is	0
via	0
JAK	9
-STAT	9
signaling	0
.	0

Previous	0
studies	0
established	0
a	0
potential	0
role	0
for	0
the	0
Src-family	9
kinase	10
Lck	9
in	0
JAK	9
-STAT	9
signaling	0
.	0

Therefore	0
,	0
this	0
study	0
was	0
designed	0
to	0
analyze	0
the	0
role	0
of	0
Lck	9
in	0
IFN-alpha	9
signaling	0
by	0
using	0
the	0
Jurkat	0
,	0
JCam	0
(	0
an	0
Lck-defective	5
cell	6
line	6
derived	0
from	0
Jurkat	5
)	0
,	0
and	0
JCam/Lck	5
(	0
JCam	5
cells	6
with	0
Lck	9
restored	0
)	0
.	0

The	0
results	0
show	0
that	0
IFN-alpha	9
can	0
induce	0
MAPK	9
activity	0
,	0
but	0
only	0
in	0
cells	0
containing	0
Lck	9
.	0

Furthermore	0
,	0
STATs1	9
and	10
-3	10
are	0
effectively	0
phosphorylated	0
and	0
activated	0
to	0
bind	0
DNA	0
in	0
the	0
absence	0
of	0
Lck	9
expression	0
in	0
IFN-alpha-treated	5
cells	6
.	0

Finally	0
,	0
the	0
results	0
demonstrate	0
that	0
IFN-alpha	9
exerts	0
an	0
antiproliferative	0
effect	0
in	0
all	0
three	0
cell	0
lines	0
.	0

These	0
data	0
indicate	0
that	0
Lck	9
and	0
active	0
MAPK	9
do	0
not	0
affect	0
IFN-alpha	9
-induced	0
growth	0
arrest	0
or	0
induction	0
of	0
STAT1s1	0
and	0
-3	0
DNA	0
binding	0
ability	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Selective	0
activation	0
and	0
functional	0
significance	0
of	0
p38alpha	9
mitogen-activated	10
protein	10
kinase	10
in	0
lipopolysaccharide-stimulated	5
neutrophils	6
.	0

Activation	0
of	0
leukocytes	7
by	0
proinflammatory	0
stimuli	0
selectively	0
initiates	0
intracellular	0
signal	0
transduction	0
via	0
sequential	0
phosphorylation	0
of	0
kinases	9
.	0

Lipopolysaccharide	0
(	0
LPS	0
)	0
stimulation	0
of	0
human	7
neutrophils	8
is	0
known	0
to	0
result	0
in	0
activation	0
of	0
p38	9
mitogen-activated	10
protein	10
kinase	10
(	0
MAPk	9
)	0
;	0
however	0
,	0
the	0
upstream	9
activator	10
(	0
s	0
)	0
of	0
p38	9
MAPk	10
is	0
unknown	0
,	0
and	0
consequences	0
of	0
p38	9
MAPk	10
activation	0
remain	0
largely	0
undefined	0
.	0

We	0
investigated	0
the	0
MAPk	9
kinase	10
(	0
MKK	9
)	0
that	0
activates	0
p38	9
MAPk	10
in	0
response	0
to	0
LPS	0
,	0
the	0
p38	9
MAPk	10
isoforms	10
that	0
are	0
activated	0
as	0
part	0
of	0
this	0
pathway	0
,	0
and	0
the	0
functional	0
responses	0
affected	0
by	0
p38	9
MAPk	10
activation	0
.	0

Although	0
MKK3	9
,	0
MKK4	9
,	0
and	0
MKK6	9
all	0
activated	0
p38	9
MAPk	10
in	0
experimental	0
models	0
,	0
only	0
MKK3	9
was	0
found	0
to	0
activate	0
recombinant	0
p38	9
MAPk	10
in	0
LPS-treated	0
neutrophils	0
.	0

Of	0
p38	9
MAPk	10
isoforms	10
studied	0
,	0
only	0
p38alpha	9
and	0
p38delta	9
were	0
detected	0
in	0
neutrophils	7
.	0

LPS	0
stimulation	0
selectively	0
activated	0
p38alpha	9
.	0

Specific	0
inhibitors	0
of	0
p38alpha	9
MAPk	10
blocked	0
LPS-induced	0
adhesion	0
,	0
nuclear	0
factor-kappa	0
B	0
(	0
NF-kappaB	9
)	0
activation	0
,	0
and	0
synthesis	0
of	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

Inhibition	0
of	0
p38alpha	9
MAPk	10
resulted	0
in	0
a	0
transient	0
decrease	0
in	0
TNF-alpha	3
mRNA	4
accumulation	0
but	0
persistent	0
loss	0
of	0
TNF-alpha	9
synthesis	0
.	0

These	0
findings	0
support	0
a	0
pathway	0
by	0
which	0
LPS	0
stimulation	0
of	0
neutrophils	7
results	0
in	0
activation	0
of	0
MKK3	9
,	0
which	0
in	0
turn	0
activates	0
p38alpha	9
MAPk	10
,	0
ultimately	0
regulating	0
adhesion	0
,	0
NF-kappaB	9
activation	0
,	0
enhanced	0
gene	0
expression	0
of	0
TNF-alpha	9
,	0
and	0
regulation	0
of	0
TNF-alpha	9
synthesis	0
.	0

The	0
evolutionarily	1
conserved	2
sequence	2
upstream	0
of	0
the	0
human	9
Ig	10
heavy	10
chain	10
S	10
gamma	10
3	10
region	10
is	0
an	0
inducible	1
promoter	2
:	0
synergistic	0
activation	0
by	0
CD40	9
ligand	10
and	0
IL-4	9
via	0
cooperative	0
NF-kappa	1
B	2
and	2
STAT-6	2
binding	2
sites	2
.	0

Germline	0
C	0
gamma	0
gene	0
transcription	0
is	0
a	0
crucial	0
event	0
in	0
the	0
process	0
that	0
leads	0
to	0
switch	0
DNA	0
recombination	0
to	0
IgG	9
,	0
but	0
its	0
regulation	0
in	0
the	0
human	0
is	0
poorly	0
understood	0
.	0

We	0
took	0
advantage	0
of	0
our	0
monoclonal	0
model	0
of	0
germinal	7
center	8
B	8
cell	8
differentiation	0
,	0
IgM+	5
IgD+	6
CL-01	6
cells	6
,	0
to	0
define	0
the	0
role	0
of	0
the	0
I	9
gamma	10
3	10
evolutionarily	1
conserved	2
sequence	2
(	0
ECS	1
)	0
in	0
the	0
germline	1
transcriptional	0
activation	0
of	0
the	0
human	1
C	2
gamma	2
3	2
gene	2
.	0

The	0
I	9
gamma	10
3	10
ECS	1
lies	0
upstream	0
of	0
the	0
major	1
I	2
gamma	2
3	2
transcription	2
initiation	2
site	2
and	0
displays	0
more	0
than	0
90	0
%	0
identity	0
with	0
the	0
corresponding	0
human	1
I	2
gamma	2
1	2
,	0
I	1
gamma	2
2	2
,	0
and	0
I	1
gamma	2
4	2
regions	0
.	0

Reporter	1
luciferase	2
gene	2
vectors	2
containing	0
the	0
human	1
gamma	2
3	2
ECS	2
were	0
used	0
to	0
transfect	0
CL-01	5
cells	6
,	0
which	0
have	0
been	0
shown	0
to	0
undergo	0
Smu	0
--	0
>	0
S	0
gamma	0
3	0
DNA	0
recombination	0
,	0
upon	0
engagement	0
of	0
CD40	9
by	0
CD40	9
ligand	10
(	0
CD40L	9
)	0
and	0
exposure	0
to	0
IL-4	9
.	0

In	0
these	0
transfected	0
CL-01	5
cells	6
,	0
CD40	0
:	0
CD40L	9
engagement	0
and	0
exposure	0
to	0
IL-4	9
synergistically	0
induced	0
gamma	0
3	0
ECS-dependent	0
luciferase	1
reporter	2
gene	2
activation	0
.	0

Targeted	0
mutational	0
analysis	0
demonstrated	0
that	0
a	0
tandem	0
NF-kappa	1
B/Rel	2
binding	2
motif	2
is	0
critical	0
for	0
the	0
gamma	1
3	2
ECS	2
responsiveness	0
to	0
both	0
CD40L	9
and	0
IL-4	9
,	0
while	0
a	0
STAT-6-binding	1
site	2
is	0
additionally	0
required	0
for	0
IL-4	9
inducibility	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
showed	0
that	0
p50/p65/c-Rel	9
and	0
STAT-6	9
are	0
effectively	0
induced	0
by	0
CD40L	9
and	0
IL-4	9
,	0
respectively	0
,	0
and	0
bind	0
to	0
specific	0
DNA	1
motifs	2
within	0
the	0
ECS	1
.	0

These	0
partially	0
overlapping	0
CD40L	1
and	2
IL-4	2
responsive	2
elements	2
are	0
functionally	0
cooperative	0
as	0
the	0
disruption	0
of	0
one	0
of	0
them	0
prevents	0
synergistic	0
promoter	0
activation	0
.	0

Thus	0
,	0
the	0
gamma	1
3	2
ECS	2
is	0
an	0
inducible	0
promoter	0
containing	0
cis	1
elements	2
that	0
critically	0
mediate	0
CD40L	9
and	0
IL-4	9
-triggered	0
transcriptional	0
activation	0
of	0
the	0
human	1
C	2
gamma	2
3	2
gene	2
.	0

CIITA	9
-induced	0
occupation	0
of	0
MHC	1
class	2
II	2
promoters	2
is	0
independent	0
of	0
the	0
cooperative	0
stabilization	0
of	0
the	0
promoter-bound	9
multi-protein	10
complexes	10
.	0

Precise	0
regulation	0
of	0
MHC	7
class	8
II	8
expression	0
plays	0
a	0
crucial	0
role	0
in	0
the	0
control	0
of	0
the	0
immune	0
response	0
.	0

The	0
transactivator	9
CIITA	9
behaves	0
as	0
a	0
master	0
controller	0
of	0
constitutive	0
and	0
inducible	0
MHC	1
class	2
II	2
gene	2
activation	0
,	0
but	0
its	0
exact	0
mechanism	0
of	0
action	0
is	0
not	0
known	0
.	0

Activation	0
of	0
MHC	1
class	2
II	2
promoters	2
requires	0
binding	0
of	0
at	0
least	0
three	0
distinct	0
multi-protein	9
complexes	10
(	0
RFX	9
,	0
X2BP	9
and	0
NF-Y	9
)	0
.	0

It	0
is	0
known	0
that	0
the	0
stability	0
of	0
this	0
binding	0
results	0
from	0
cooperative	0
interactions	0
between	0
these	0
proteins	0
.	0

We	0
show	0
here	0
that	0
expression	0
of	0
CIITA	9
in	0
MHC	5
class	6
II	6
-cells	6
triggers	0
occupation	0
of	0
the	0
promoters	0
by	0
these	0
complexes	0
.	0

This	0
observation	0
raised	0
the	0
possibility	0
that	0
the	0
effect	0
of	0
CIITA	9
on	0
promoter	0
occupation	0
is	0
mediated	0
by	0
an	0
effect	0
on	0
the	0
cooperative	0
stabilization	0
of	0
the	0
DNA-bound	9
multi-protein	10
complexes	10
.	0

We	0
show	0
,	0
however	0
,	0
that	0
the	0
presence	0
of	0
CIITA	9
does	0
not	0
affect	0
the	0
stability	0
of	0
the	0
higher-order	0
protein	0
complex	0
formed	0
on	0
DNA	0
by	0
RFX	9
,	0
X2BP	9
and	0
NF-Y	9
.	0

This	0
suggests	0
other	0
mechanisms	0
for	0
CIITA	9
-induced	0
promoter	0
occupancy	0
,	0
such	0
as	0
an	0
effect	0
on	0
chromatin	1
structure	0
leading	0
to	0
increased	0
accessibility	0
of	0
MHC	1
class	2
II	2
promoters	2
.	0

This	0
ability	0
of	0
CIITA	9
to	0
facilitate	0
promoter	0
occupation	0
is	0
undissociable	0
from	0
its	0
transactivation	0
potential	0
.	0

Finally	0
,	0
we	0
conclude	0
that	0
this	0
effect	0
of	0
CIITA	9
is	0
cell-type	0
specific	0
,	0
since	0
expression	0
of	0
CIITA	9
is	0
not	0
required	0
for	0
normal	0
occupation	0
of	0
MHC	1
class	2
II	2
promoters	2
in	0
B	7
lymphocytes	8
.	0

GrpL	9
,	0
a	0
Grb2	9
-related	0
adaptor	9
protein	10
,	0
interacts	0
with	0
SLP-76	9
to	0
regulate	0
nuclear	9
factor	10
of	10
activated	10
T	10
cell	10
activation	0
.	0

Propagation	0
of	0
signals	0
from	0
the	0
T	9
cell	10
antigen	10
receptor	10
(	0
TCR	9
)	0
involves	0
a	0
number	0
of	0
adaptor	0
molecules	0
.	0

SH2	9
domain-containing	10
protein	10
76	10
(	0
SLP-76	9
)	0
interacts	0
with	0
the	0
guanine	9
nucleotide	10
exchange	10
factor	10
Vav	9
to	0
activate	0
the	0
nuclear	9
factor	10
of	10
activated	10
cells	10
(	0
NF-AT	9
)	0
,	0
and	0
its	0
expression	0
is	0
required	0
for	0
normal	0
T	7
cell	8
development	0
.	0

We	0
report	0
the	0
cloning	0
and	0
characterization	0
of	0
a	0
novel	0
Grb2-like	9
adaptor	10
molecule	10
designated	0
as	0
Grb2-related	9
protein	10
of	10
the	10
lymphoid	10
system	10
(	0
GrpL	9
)	0
.	0

Expression	0
of	0
GrpL	9
is	0
restricted	0
to	0
hematopoietic	0
tissues	0
,	0
and	0
it	0
is	0
distinguished	0
from	0
Grb2	9
by	0
having	0
a	0
proline-rich	9
region	10
.	0

GrpL	9
can	0
be	0
coimmunoprecipitated	0
with	0
SLP-76	9
but	0
not	0
with	0
Sos1	9
or	0
Sos2	9
from	0
Jurkat	5
cell	6
lysates	0
.	0

In	0
contrast	0
,	0
Grb2	9
can	0
be	0
coimmunoprecipitated	0
with	0
Sos1	9
and	0
Sos2	9
but	0
not	0
with	0
SLP-76	9
.	0

Moreover	0
,	0
tyrosine-phosphorylated	9
LAT/pp36/38	10
in	0
detergent	0
lysates	0
prepared	0
from	0
anti-CD3	7
stimulated	8
T	8
cells	8
associated	0
with	0
Grb2	9
but	0
not	0
GrpL	9
.	0

These	0
data	0
reveal	0
the	0
presence	0
of	0
distinct	0
complexes	0
involving	0
GrpL	9
and	0
Grb2	9
in	0
T	7
cells	8
.	0

A	0
functional	0
role	0
of	0
the	0
GrpL-SLP-76	9
complex	10
is	0
suggested	0
by	0
the	0
ability	0
of	0
GrpL	9
to	0
act	0
alone	0
or	0
in	0
concert	0
with	0
SLP-76	9
to	0
augment	0
NF-AT	9
activation	0
in	0
Jurkat	5
T	7
cells	8
.	0

Differential	0
induction	0
of	0
interferon	9
(	10
IFN	10
)	10
-inducible	10
protein	10
10	10
following	0
differentiation	0
of	0
a	0
monocyte	7
,	0
macrophage	7
cell	8
lineage	0
is	0
related	0
to	0
the	0
changes	0
of	0
nuclear	9
proteins	10
bound	0
to	0
IFN	1
stimulus	2
response	2
element	2
and	0
kappaB	1
sites	2
.	0

We	0
examined	0
chemokine	9
gene	0
expression	0
following	0
the	0
differentiation	0
of	0
a	0
monocyte	7
,	0
macrophage	5
cell	6
lineage	6
.	0

The	0
human	5
monoblastic	6
cell	6
line	6
,	0
U937	5
was	0
differentiated	0
to	0
macrophages	7
by	0
the	0
treatment	0
with	0
either	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
,	0
retinoic	0
acid	0
(	0
RA	0
)	0
,	0
or	0
vitamin	0
D3	0
(	0
VitD3	0
)	0
.	0

The	0
gene	0
expression	0
of	0
interferon	9
(	10
IFN	10
)	10
-inducible	10
protein	10
10	10
(	0
IP-10	9
)	0
(	0
a	0
CXC	9
chemokine	10
)	0
was	0
markedly	0
augmented	0
by	0
the	0
IFNgamma	9
treatment	0
in	0
PMA	0
-or	0
RA-differentiated	0
U937	5
cells	6
,	0
but	0
only	0
marginally	0
in	0
undifferentiated	0
or	0
VitD3-treated	5
cells	6
.	0

In	0
contrast	0
,	0
another	0
inducible	0
gene	0
expression	0
of	0
monocyte	9
chemotactic	10
protein-1	10
(	0
a	0
CC	9
chemokine	10
)	0
and	0
the	0
activation	0
of	0
the	0
transcriptional	9
factor	10
(	0
FcRFgamma	9
)	0
bound	0
to	0
the	0
gamma	1
response	2
region	2
were	0
similarly	0
or	0
less	0
abundantly	0
induced	0
by	0
IFNgamma	9
treatment	0
in	0
PMA	0
-or	0
RA-differentiated	0
U937	5
cells	6
,	0
indicating	0
that	0
increased	0
IP-10	3
mRNA	4
induction	0
was	0
not	0
due	0
to	0
the	0
augmented	0
ability	0
of	0
the	0
cells	0
to	0
respond	0
to	0
the	0
presence	0
of	0
IFNgamma	9
.	0

Increased	0
expression	0
of	0
IFNgamma	9
-induced	0
IP-10	3
mRNA	4
following	0
the	0
differentiation	0
of	0
U937	5
cells	6
was	0
mediated	0
largely	0
by	0
augmented	0
transcriptional	0
activity	0
of	0
the	0
gene	0
and	0
was	0
related	0
to	0
differentiation-dependent	0
changes	0
of	0
the	0
proteins	0
bound	0
to	0
IFN	1
stimulus	2
response	2
element	2
(	2
ISRE	2
)	2
and	0
kB	1
sites	2
,	0
suggesting	0
that	0
these	0
nuclear	9
proteins	10
may	0
determine	0
the	0
IP-10	3
mRNA	4
inducibility	0
by	0
IFNgamma	9
.	0

Role	0
of	0
cellular	9
tumor	10
necrosis	10
factor	10
receptor-associated	10
factors	10
in	0
NF-kappaB	9
activation	0
and	0
lymphocyte	7
transformation	0
by	0
herpesvirus	0
Saimiri	0
STP	9
.	0

The	0
STP	9
oncoproteins	10
of	0
the	0
herpesvirus	0
saimiri	0
(	0
HVS	0
)	0
subgroup	0
A	0
strain	0
11	0
and	0
subgroup	0
C	0
strain	0
488	0
are	0
now	0
found	0
to	0
be	0
stably	0
associated	0
with	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
factor	10
(	10
TRAF	10
)	10
1	10
,	10
2	10
,	10
or	10
3	10
.	0

Mutational	0
analyses	0
identified	0
residues	0
of	0
PXQXT/S	9
in	0
STP-A11	9
as	0
critical	0
for	0
TRAF	9
association	0
.	0

In	0
addition	0
,	0
a	0
somewhat	0
divergent	0
region	0
of	0
STP-C488	9
is	0
critical	0
for	0
TRAF	9
association	0
.	0

Mutational	0
analysis	0
also	0
revealed	0
that	0
STP-C488	9
induced	0
NF-kappaB	9
activation	0
that	0
was	0
correlated	0
with	0
its	0
ability	0
to	0
associate	0
with	0
TRAFs	9
.	0

The	0
HVS	0
STP-C488	9
P10	0
--	0
>	0
R	0
mutant	0
was	0
deficient	0
in	0
human	0
T-lymphocyte	0
transformation	0
to	0
interleukin-2-independent	0
growth	0
but	0
showed	0
wild-type	0
phenotype	0
for	0
marmoset	0
T-lymphocyte	0
transformation	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

The	0
STP-C488	9
P10	10
--	10
>	10
R	10
mutant	10
was	0
also	0
defective	0
in	0
Rat-1	0
fibroblast	0
transformation	0
,	0
and	0
fibroblast	0
cell	0
transformation	0
was	0
blocked	0
by	0
a	0
TRAF2	9
dominant-negative	0
mutant	0
.	0

These	0
data	0
implicate	0
TRAFs	9
in	0
STP-C488	9
-mediated	0
transformation	0
of	0
human	7
lymphocytes	8
and	0
rodent	0
fibroblasts	7
.	0

Other	0
factors	0
are	0
implicated	0
in	0
immortalization	0
of	0
common	7
marmoset	8
T	8
lymphocytes	8
and	0
may	0
also	0
be	0
critical	0
in	0
the	0
transformation	0
of	0
human	7
lymphocytes	8
and	0
rodent	7
fibroblasts	8
.	0

Cleavage	0
of	0
transcription	9
factor	10
SP1	9
by	0
caspases	9
during	0
anti-IgM-induced	0
B-cell	7
apoptosis	0
.	0

Apoptosis	0
is	0
instrumental	0
in	0
the	0
processes	0
generating	0
the	0
diversity	0
of	0
the	0
B-cell	0
repertoire	0
.	0

Autoreactive	7
B-cells	8
are	0
eliminated	0
by	0
anti-IgM	9
crosslinking	0
after	0
encountering	0
self-antigens	9
,	0
but	0
precise	0
mechanisms	0
leading	0
to	0
B-cell	7
apoptosis	0
are	0
still	0
not	0
well	0
understood	0
.	0

We	0
report	0
here	0
the	0
cleavage	0
of	0
the	0
transcription	9
factor	10
SP1	9
in	0
the	0
human	5
Burkitt	6
lymphoma	6
cell	6
line	6
BL60	6
during	0
anti-IgM	9
-induced	0
apoptosis	0
.	0

Western	0
blot	0
analysis	0
revealed	0
two	0
cleavage	0
products	0
of	0
approximately	0
68	9
kDa	10
and	0
45	9
kDa	10
after	0
induction	0
of	0
apoptosis	0
.	0

Cleavage	0
could	0
be	0
completely	0
inhibited	0
by	0
zDEVD-fmk	0
,	0
an	0
inhibitor	0
specific	0
for	0
caspase	9
3-like	10
proteases	10
.	0

In-vitro	0
cleavage	0
of	0
recombinant	9
SP1	10
by	0
recombinant	9
caspase	10
3	10
(	0
CPP32	9
)	0
or	0
caspase	9
7	10
(	0
Mch	9
3	10
)	0
results	0
in	0
similar	0
cleavage	0
products	0
as	0
those	0
observed	0
in	0
vivo	0
.	0

Recombinant	9
caspase	10
6	10
(	0
Mch	9
2	10
)	0
primarily	0
generates	0
a	0
68-kDa	0
cleavage	0
product	0
,	0
as	0
observed	0
after	0
calcium	0
ionophore	0
(	0
CaI	0
)	0
induced	0
B-cell	7
apoptosis	0
.	0

In	0
contrast	0
,	0
caspase	0
1	0
(	0
ICE	0
)	0
did	0
not	0
cleave	0
SP1	9
in	0
vitro	0
.	0

The	0
time	0
course	0
of	0
SP1	9
cleavage	0
during	0
anti-IgM-induced	0
apoptosis	0
is	0
paralleled	0
by	0
an	0
increase	0
of	0
caspase	0
activity	0
measured	0
by	0
DEVD-p-nitroanilide	0
(	0
DEVD-pNA	0
)	0
cleavage	0
.	0

DNA	0
band-shift	0
assays	0
revealed	0
a	0
decrease	0
in	0
the	0
intensity	0
of	0
the	0
full	0
length	0
SP1	9
/DNA	0
complex	0
and	0
an	0
increase	0
in	0
the	0
intensity	0
of	0
a	0
smaller	0
complex	0
due	0
to	0
the	0
binding	0
of	0
one	0
SP1	9
cleavage	0
product	0
.	0

By	0
Edman	0
sequencing	0
we	0
could	0
identify	0
a	0
caspase	0
3	0
cleavage	0
site	0
after	0
Asp584	0
(	0
D584AQPQAGR	0
)	0
,	0
generating	0
a	0
22-kDa	0
C-terminal	0
SP1	9
protein	0
fragment	0
which	0
still	0
contains	0
the	0
DNA	0
binding	0
site	0
.	0

Our	0
results	0
show	0
the	0
cleavage	0
of	0
the	0
human	0
transcription	9
factor	10
SP1	9
in	0
vivo	0
and	0
in	0
vitro	0
,	0
underlining	0
the	0
central	0
role	0
of	0
caspase	9
3-like	10
proteases	10
during	0
the	0
process	0
of	0
anti-IgM-induced	0
apoptosis	0
.	0

Stimulation	0
of	0
CD40	9
on	0
immunogenic	0
human	0
malignant	0
melanomas	0
augments	0
their	0
cytotoxic	7
T	8
lymphocyte	8
-mediated	0
lysis	0
and	0
induces	0
apoptosis	0
.	0

Here	0
,	0
we	0
report	0
the	0
functional	0
expression	0
of	0
CD40	9
on	0
human	0
malignant	0
melanomas	0
(	0
MMs	0
)	0
.	0

Comparison	0
of	0
tumor	0
specimen	0
from	0
MM	0
precursor	0
lesions	0
,	0
primary	0
tumors	0
,	0
and	0
metastases	0
revealed	0
that	0
CD40	9
surface	0
expression	0
is	0
down-regulated	0
during	0
tumor	0
progression	0
.	0

CD40	9
expression	0
was	0
confirmed	0
in	0
7	0
human	5
MM	6
cell	6
lines	6
established	0
from	0
immunogenic	0
primary	0
tumors	0
or	0
metastases	0
,	0
whereas	0
11	0
cell	5
lines	6
established	0
from	0
advanced	0
stages	0
were	0
CD40	9
negative	0
.	0

CD40	9
expression	0
could	0
be	0
enhanced	0
in	0
CD40	9
-positive	0
MM	0
by	0
stimulation	0
with	0
IFN-gamma	9
and	0
tumor	9
necrosis	10
factor-alpha	10
but	0
not	0
by	0
interleukin	9
(	10
IL	10
)	10
-1beta	10
or	0
CD40	9
triggering	0
.	0

CD40	9
ligation	0
on	0
MM	0
by	0
CD40L-transfected	5
murine	6
L-cells	6
or	0
by	0
a	0
soluble	0
CD40L	9
fusion	10
protein	10
up-regulated	0
their	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
and	0
MHC	9
class	10
I	10
and	10
class	10
II	10
molecules	10
and	0
their	0
secretion	0
of	0
IL-6	9
,	0
IL-8	9
,	0
tumor	9
necrosis	10
factor-a	10
,	0
and	0
granulocyte	9
macrophage	10
colony-stimulating	10
factor	10
and	0
also	0
induced	0
a	0
rapid	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor	10
kappaB	10
.	0

Furthermore	0
,	0
CD40	9
ligation	0
of	0
a	0
HLA-A2+	5
,	6
MelanA/MART1+	6
MM	6
cell	6
line	6
enhanced	0
its	0
susceptibility	0
to	0
specific	0
lysis	0
by	0
a	0
HLA-A2-restricted	5
,	6
MelanA/MART-1-specific	6
CTL	6
clone	6
.	0

Finally	0
,	0
CD40	9
ligation	0
induced	0
growth	0
inhibition	0
and	0
apoptosis	0
in	0
MM	0
.	0

These	0
results	0
indicate	0
that	0
CD40	9
-CD40L	9
interactions	0
may	0
play	0
an	0
important	0
role	0
in	0
augmenting	0
antitumor	0
immunity	0
and	0
inducing	0
apoptosis	0
in	0
some	0
CD40	9
-positive	0
immunogenic	0
human	0
MMs	0
.	0

Human	0
immunodeficiency	0
virus-associated	0
Hodgkin	0
's	0
disease	0
derives	0
from	0
post-germinal	7
center	8
B	8
cells	8
.	0

Human	0
immunodeficiency	0
virus-associated	0
Hodgkin	0
's	0
disease	0
(	0
HIV-HD	0
)	0
displays	0
several	0
peculiarities	0
when	0
compared	0
with	0
HD	0
of	0
the	0
general	0
population	0
.	0

These	0
include	0
overrepresentation	0
of	0
clinically	0
aggressive	0
histologic	0
types	0
and	0
frequent	0
infection	0
of	0
Reed-Sternberg	5
(	6
RS	6
)	6
cells	6
by	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
.	0

Recently	0
,	0
we	0
have	0
reported	0
that	0
the	0
histogenesis	0
of	0
HD	0
of	0
the	0
general	0
population	0
may	0
be	0
assessed	0
by	0
monitoring	0
the	0
expression	0
pattern	0
of	0
BCL-6	9
,	0
a	0
transcription	9
factor	10
expressed	0
in	0
germinal	5
center	6
(	6
GC	6
)	6
B	6
cells	6
,	0
and	0
of	0
CD138/syndecan-1	9
(	0
syn-1	9
)	0
,	0
a	0
proteoglycan	0
associated	0
with	0
post-GC	0
,	0
terminal	0
B-cell	7
differentiation	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
applied	0
these	0
two	0
markers	0
to	0
the	0
study	0
of	0
HIV-HD	0
histogenesis	0
and	0
correlated	0
their	0
expression	0
status	0
to	0
the	0
virologic	0
features	0
of	0
this	0
disease	0
.	0

We	0
have	0
found	0
that	0
RS	5
cells	6
of	0
all	0
histologic	0
categories	0
of	0
HIV-HD	0
consistently	0
display	0
the	0
BCL-6	9
(	0
-	0
)	0
/syn-1	0
(	0
+	0
)	0
phenotype	0
and	0
thus	0
reflect	0
post-GC	5
B	6
cells	6
.	0

Although	0
BCL-6	9
(	0
-	0
)	0
/syn-1	0
(	0
+	0
)	0
RS	5
cells	6
of	0
HIV-HD	0
express	0
CD40	9
,	0
they	0
are	0
not	0
surrounded	0
by	0
CD40	7
ligand-positive	8
(	8
CD40L+	8
)	8
reactive	8
T	8
lymphocytes	8
,	0
which	0
,	0
in	0
HD	0
of	0
the	0
general	0
population	0
,	0
are	0
thought	0
to	0
regulate	0
the	0
disease	0
phenotype	0
through	0
CD40	9
/CD40L	9
interactions	0
.	0

Conversely	0
,	0
RS	5
cells	6
of	0
virtually	0
all	0
HIV-HD	0
express	0
the	0
EBV-encoded	9
latent	10
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
,	0
which	0
,	0
being	0
functionally	0
homologous	0
to	0
CD40	9
,	0
may	0
contribute	0
,	0
at	0
least	0
in	0
part	0
,	0
to	0
the	0
modulation	0
of	0
the	0
HIV-HD	0
phenotype	0
.	0

MDS1/EVI1	1
enhances	0
TGF-beta1	9
signaling	0
and	0
strengthens	0
its	0
growth-inhibitory	0
effect	0
but	0
the	0
leukemia-associated	9
fusion	10
protein	10
AML1/MDS1/EVI1	9
,	0
product	0
of	0
the	0
t	0
(	0
3	0
;	0
21	0
)	0
,	0
abrogates	0
growth-inhibition	0
in	0
response	0
to	0
TGF-beta1	9
.	0

MDS1/EVI1	1
,	0
located	0
on	0
chromosome	1
3	2
band	2
q26	2
,	0
encodes	0
a	0
zinc-finger	9
DNA-binding	10
transcription	10
activator	10
not	0
detected	0
in	0
normal	7
hematopoietic	8
cells	8
but	0
expressed	0
in	0
several	0
normal	0
tissues	0
.	0

MDS1/EVI1	1
is	0
inappropriately	0
activated	0
in	0
myeloid	7
leukemias	8
following	0
chromosomal	0
rearrangements	0
involving	0
band	9
3q26	10
.	0

The	0
rearrangements	0
lead	0
either	0
to	0
gene	0
truncation	0
,	0
and	0
to	0
expression	0
of	0
the	0
transcription	9
repressor	10
EVI1	10
,	0
as	0
seen	0
in	0
the	0
t	1
(	2
3	2
;	2
3	2
)	2
(	2
q21	2
;	2
q26	2
)	2
and	0
inv	1
(	2
3	2
)	2
(	2
q21q26	2
)	2
,	0
or	0
to	0
gene	0
fusion	0
,	0
as	0
seen	0
in	0
the	0
t	1
(	2
3	2
;	2
21	2
)	2
(	2
q26	2
;	2
q22	2
)	2
which	0
results	0
in	0
the	0
fusion	0
protein	0
AML1/MDS1/EVI1	9
.	0

This	0
fusion	0
protein	0
contains	0
the	0
DNA-binding	9
domain	10
of	0
the	0
transcription	9
factor	10
AML1	9
fused	0
in-frame	0
to	0
the	0
entire	0
MDS1/EVI1	1
with	0
the	0
exclusion	0
of	0
its	0
first	0
12	0
amino	0
acids	0
.	0

In	0
this	0
report	0
,	0
we	0
have	0
analyzed	0
the	0
response	0
of	0
the	0
hematopoietic	5
precursor	6
cell	6
line	6
32Dcl3	6
,	0
expressing	0
either	0
the	0
normal	9
protein	10
MDS1/EVI1	10
or	0
the	0
fusion	9
protein	10
AML1/MDS1/EVI1	10
,	0
to	0
factors	0
that	0
control	0
cell	0
differentiation	0
or	0
cell	0
replication	0
.	0

The	0
32Dcl3	5
cells	6
are	0
IL-3	9
-dependent	0
for	0
growth	0
and	0
they	0
differentiate	0
into	0
granulocytes	0
when	0
exposed	0
to	0
G-CSF	9
.	0

They	0
are	0
growth-inhibited	0
by	0
TGF-beta1	9
.	0

We	0
show	0
that	0
whereas	0
the	0
expression	0
of	0
MDS1/EVI1	1
has	0
no	0
effect	0
on	0
granulocytic	0
differentiation	0
induced	0
by	0
G-CSF	9
,	0
expression	0
of	0
AML1/MDS1/EVI1	9
blocks	0
differentiation	0
resulting	0
in	0
cell	0
death	0
.	0

This	0
effect	0
is	0
similar	0
to	0
that	0
previously	0
described	0
by	0
others	0
for	0
32Dcl3	5
cells	6
that	0
express	0
transgenic	9
Evil	10
.	0

Furthermore	0
,	0
we	0
show	0
that	0
whereas	0
the	0
expression	0
of	0
the	0
fusion	0
protein	0
AML1/MDS1/EVI1	9
completely	0
abrogates	0
the	0
growth-inhibitory	0
effect	0
of	0
TGF-beta1	9
and	0
allows	0
32Dcl3	5
cells	6
to	0
proliferate	0
,	0
expression	0
of	0
the	0
normal	0
protein	0
MDS1/EVI1	1
has	0
the	0
opposite	0
effect	0
,	0
and	0
it	0
strengthens	0
the	0
response	0
of	0
cells	0
to	0
the	0
growth-inhibitory	0
effect	0
of	0
TGF-beta1	9
.	0

By	0
using	0
the	0
yeast	0
two-hybrid	0
system	0
,	0
we	0
also	0
show	0
that	0
EVI1	9
(	0
contained	0
in	0
its	0
entirety	0
in	0
MDS1/EVI1	1
and	0
AML1/MDS1/EVI1	9
)	0
physically	0
interacts	0
with	0
SMAD3	9
,	0
which	0
is	0
an	0
intracellular	0
mediator	0
of	0
TGF-beta1	9
signaling	0
.	0

Finally	0
,	0
we	0
have	0
correlated	0
the	0
response	0
of	0
the	0
cells	0
to	0
G-CSF	9
or	0
TGF-beta1	9
with	0
the	0
ability	0
of	0
the	0
normal	0
and	0
fusion	9
proteins	10
to	0
activate	0
or	0
repress	0
promoters	0
which	0
they	0
can	0
directly	0
regulate	0
by	0
binding	0
to	0
the	0
promoter	1
site	2
.	0

We	0
propose	0
that	0
mutations	0
of	0
MDS1/EVI1	1
either	0
by	0
gene	0
truncation	0
resulting	0
in	0
the	0
transcription	9
repressor	10
EVI1	10
or	0
by	0
gene	0
fusion	0
to	0
AML1	9
lead	0
to	0
an	0
altered	0
cellular	0
response	0
to	0
growth	0
and	0
differentiation	9
factors	10
that	0
could	0
result	0
in	0
leukemic	0
transformation	0
.	0

The	0
different	0
response	0
of	0
myeloid	0
cells	0
ectopically	0
expressing	0
the	0
normal	0
or	0
the	0
fusion	9
protein	10
to	0
G-CSF	9
and	0
TGF-beta1	9
could	0
depend	0
on	0
the	0
different	0
transactivation	0
properties	0
of	0
these	0
proteins	0
resulting	0
in	0
divergent	0
expression	0
of	0
downstream	1
genes	2
regulated	0
by	0
the	0
two	0
proteins	0
.	0

Abnormalities	0
of	0
cyclic	0
adenosine	0
monophosphate	0
signaling	0
in	0
platelets	7
from	0
untreated	0
patients	0
with	0
bipolar	0
disorder	0
.	0

BACKGROUND	0
:	0
Abnormalities	0
in	0
the	0
cyclic	0
adenosine	0
monophosphate	0
(	0
cAMP	0
)	0
-dependent	0
phosphorylation	0
system	0
have	0
been	0
recently	0
reported	0
in	0
patients	0
with	0
bipolar	0
disorder	0
.	0

We	0
evaluated	0
the	0
immunoreactivity	0
of	0
the	0
regulatory	9
and	10
catalytic	10
subunits	10
of	0
cAMP-dependent	9
protein	10
kinase	10
(	0
protein	9
kinase	10
A	10
)	0
and	0
1	0
of	0
its	0
substrates	0
,	0
Rap1	9
,	0
in	0
platelets	7
from	0
untreated	0
euthymic	0
,	0
manic	0
,	0
and	0
depressed	0
patients	0
with	0
bipolar	0
disorder	0
and	0
healthy	0
subjects	0
.	0

METHODS	0
:	0
Platelets	7
were	0
collected	0
from	0
112	0
drug-free	0
patients	0
with	0
bipolar	0
disorder	0
(	0
52	0
euthymic	0
,	0
29	0
depressed	0
,	0
and	0
31	0
manic	0
)	0
and	0
62	0
healthy	0
subjects	0
.	0

The	0
levels	0
of	0
cAMP-dependent	9
protein	10
kinase	10
and	0
Rap1	9
were	0
assessed	0
by	0
Western	0
blot	0
analysis	0
,	0
immunostaining	0
,	0
and	0
computer-assisted	0
imaging	0
.	0

RESULTS	0
:	0
The	0
immunolabeling	0
of	0
the	0
catalytic	9
subunit	10
of	0
cAMP-dependent	9
protein	10
kinase	10
was	0
significantly	0
different	0
among	0
groups	0
(	0
P	0
<	0
.001	0
)	0
,	0
with	0
higher	0
values	0
in	0
untreated	0
depressed	0
and	0
manic	0
patients	0
with	0
bipolar	0
disorder	0
compared	0
with	0
untreated	0
euthymic	0
patients	0
with	0
bipolar	0
disorder	0
and	0
healthy	0
subjects	0
.	0

No	0
significant	0
differences	0
were	0
found	0
in	0
the	0
immunolabeling	0
of	0
the	0
regulatory	9
subunits	10
(	0
type	0
I	0
and	0
type	0
II	0
)	0
of	0
cAMP-dependent	9
protein	10
kinase	10
.	0

The	0
immunolabeling	0
of	0
Rap1	9
was	0
significantly	0
higher	0
(	0
P	0
<	0
.001	0
)	0
in	0
untreated	0
euthymic	0
,	0
depressed	0
,	0
and	0
manic	0
patients	0
than	0
in	0
healthy	0
persons	0
.	0

CONCLUSIONS	0
:	0
Levels	0
of	0
Rap1	9
and	0
the	0
catalytic	9
subunit	10
of	0
cAMP-dependent	9
protein	10
kinase	10
are	0
altered	0
in	0
the	0
platelets	7
of	0
bipolar	0
patients	0
.	0

These	0
findings	0
may	0
provide	0
clues	0
toward	0
understanding	0
the	0
involvement	0
of	0
cAMP	0
signaling	0
in	0
the	0
pathogenesis	0
of	0
bipolar	0
disorder	0
.	0

Molecular	0
regulation	0
of	0
cytokine	1
gene	2
expression	0
during	0
the	0
immune	0
response	0
.	0

Cytokine	9
expression	0
by	0
immune	0
system	0
cells	0
plays	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
the	0
immune	0
response	0
.	0

On	0
first	0
encounter	0
with	0
antigen	0
,	0
naive	7
CD4+	8
T	8
helper	8
(	8
Th	8
)	8
cells	8
differentiate	0
into	0
cytokine-producing	5
effector	6
cells	6
.	0

Two	0
types	0
of	0
effector	0
cells	0
characterized	0
by	0
their	0
distinct	0
expression	0
of	0
cytokine	9
profiles	0
have	0
been	0
described	0
.	0

Th1	0
cells	0
produce	0
IL-2	9
and	0
IFN-gamma	9
,	0
whereas	0
Th2	5
cells	6
produce	0
IL-4	9
,	0
IL-5	9
,	0
IL-6	9
,	0
IL-10	9
,	0
and	0
IL-13	9
.	0

In	0
many	0
pathological	0
situations	0
,	0
the	0
balance	0
between	0
Th1	0
and	0
Th2	0
immune	0
responses	0
determines	0
the	0
outcome	0
of	0
diverse	0
immunologically	0
mediated	0
clinical	0
syndromes	0
including	0
infectious	0
,	0
autoimmune	0
,	0
and	0
allergic	0
diseases	0
.	0

However	0
,	0
the	0
molecular	0
basis	0
for	0
the	0
tissue-specific	0
expression	0
of	0
Th1/Th2-like	9
cytokines	10
has	0
remained	0
elusive	0
.	0

In	0
this	0
review	0
we	0
evaluate	0
the	0
possible	0
in	0
vivo	0
role	0
of	0
different	0
transcription	0
factors	0
and	0
transcriptional	0
mechanisms	0
in	0
T	0
cell	0
differentiation	0
and	0
the	0
immune	0
response	0
.	0

Tcf-1	9
-mediated	0
transcription	0
in	0
T	7
lymphocytes	8
:	0
differential	0
role	0
for	0
glycogen	9
synthase	10
kinase-3	10
in	0
fibroblasts	7
and	0
T	7
cells	8
.	0

Beta-catenin	0
is	0
the	0
vertebrate	0
homolog	0
of	0
the	0
Drosophila	1
segment	2
polarity	2
gene	2
Armadillo	1
and	0
plays	0
roles	0
in	0
both	0
cell-cell	0
adhesion	0
and	0
transduction	0
of	0
the	0
Wnt	0
signaling	0
cascade	0
.	0

Recently	0
,	0
members	0
of	0
the	0
Lef/Tcf	9
transcription	10
factor	10
family	10
have	0
been	0
identified	0
as	0
protein	0
partners	0
of	0
beta-catenin	9
,	0
explaining	0
how	0
beta-catenin	9
alters	0
gene	0
expression	0
.	0

Here	0
we	0
report	0
that	0
in	0
T	7
cells	8
,	0
Tcf-1	9
also	0
becomes	0
transcriptionally	0
active	0
through	0
interaction	0
with	0
beta-catenin	9
,	0
suggesting	0
that	0
the	0
Wnt	0
signal	0
transduction	0
pathway	0
is	0
operational	0
in	0
T	7
lymphocytes	8
as	0
well	0
.	0

However	0
,	0
although	0
Wnt	0
signals	0
are	0
known	0
to	0
inhibit	0
the	0
activity	0
of	0
the	0
negative	9
regulatory	10
protein	10
kinase	10
glycogen	9
synthase	10
kinase-3beta	10
(	0
GSK-3beta	9
)	0
,	0
resulting	0
in	0
increased	0
levels	0
of	0
beta-catenin	9
,	0
we	0
find	0
no	0
evidence	0
for	0
involvement	0
of	0
GSK-3beta	9
in	0
Tcf-mediated	0
transcription	0
in	0
T	7
cells	8
.	0

That	0
is	0
,	0
a	0
dominant	9
negative	10
GSK-3beta	10
does	0
not	0
specifically	0
activate	0
Tcf	0
transcription	0
and	0
stimuli	0
(	0
lithium	0
or	0
phytohemagglutinin	9
)	0
that	0
inhibit	0
GSK-3beta	9
activity	0
also	0
do	0
not	0
activate	0
Tcf	1
reporter	2
genes	2
.	0

Thus	0
,	0
inhibition	0
of	0
GSK-3beta	9
is	0
insufficient	0
to	0
activate	0
Tcf-dependent	0
transcription	0
in	0
T	7
lymphocytes	8
.	0

In	0
contrast	0
,	0
in	0
C57MG	5
fibroblast	6
cells	6
,	0
lithium	0
inactivates	0
GSK-3beta	9
and	0
induces	0
Tcf-controlled	0
transcription	0
.	0

This	0
is	0
the	0
first	0
demonstration	0
that	0
lithium	0
can	0
alter	0
gene	0
expression	0
of	0
Tcf-responsive	1
genes	2
,	0
and	0
points	0
to	0
a	0
difference	0
in	0
regulation	0
of	0
Wnt	0
signaling	0
between	0
fibroblasts	7
and	0
lymphocytes	7
.	0

SHP2-interacting	9
transmembrane	10
adaptor	10
protein	10
(	0
SIT	9
)	0
,	0
a	0
novel	0
disulfide-linked	9
dimer	10
regulating	0
human	0
T	0
cell	0
activation	0
.	0

T	7
lymphocytes	8
express	0
several	0
low	9
molecular	10
weight	10
transmembrane	10
adaptor	10
proteins	10
that	0
recruit	0
src	9
homology	10
(	10
SH	10
)	10
2	10
domain-containing	10
intracellular	10
molecules	10
to	0
the	0
cell	0
membrane	0
via	0
tyrosine-based	0
signaling	0
motifs	0
.	0

We	0
describe	0
here	0
a	0
novel	0
molecule	0
of	0
this	0
group	0
termed	0
SIT	9
(	0
SHP2	9
interacting	10
transmembrane	10
adaptor	10
protein	10
)	0
.	0

SIT	9
is	0
a	0
disulfide-linked	9
homodimeric	10
glycoprotein	10
that	0
is	0
expressed	0
in	0
lymphocytes	7
.	0

After	0
tyrosine	0
phosphorylation	0
by	0
src	9
and	0
possibly	0
syk	9
protein	9
tyrosine	10
kinases	10
SIT	9
recruits	0
the	0
SH2	9
domain-containing	10
tyrosine	10
phosphatase	10
SHP2	9
via	0
an	0
immunoreceptor	0
tyrosine-based	0
inhibition	0
motif	0
.	0

Overexpression	0
of	0
SIT	9
in	0
Jurkat	5
cells	6
downmodulates	0
T	0
cell	0
receptor-	0
and	0
phytohemagglutinin-mediated	0
activation	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
by	0
interfering	0
with	0
signaling	0
processes	0
that	0
are	0
probably	0
located	0
upstream	0
of	0
activation	0
of	0
phospholipase	9
C	10
.	0

However	0
,	0
binding	0
of	0
SHP2	9
to	0
SIT	9
is	0
not	0
required	0
for	0
inhibition	0
of	0
NF-AT	9
induction	0
,	0
suggesting	0
that	0
SIT	9
not	0
only	0
regulates	0
NF-AT	9
activity	0
but	0
also	0
controls	0
NF-AT	9
unrelated	0
pathways	0
of	0
T	0
cell	0
activation	0
involving	0
SHP2	9
.	0

Extracellular-regulated	9
kinase	10
1/2	10
,	0
Jun	9
N-terminal	10
kinase	10
,	0
and	0
c-Jun	9
are	0
involved	0
in	0
NF-kappa	9
B	10
-dependent	0
IL-6	9
expression	0
in	0
human	0
monocytes	0
.	0

In	0
the	0
present	0
study	0
we	0
investigated	0
the	0
possible	0
involvement	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
family	10
members	0
extracellular-regulated	9
kinase	10
1/2	10
(	0
ERK1/2	9
)	0
and	0
c-	0
Jun	9
N-terminal	10
kinase	10
(	0
JNK	9
)	0
in	0
mediating	0
IL-6	9
gene	0
expression	0
in	0
human	7
monocytes	8
,	0
in	0
particular	0
their	0
role	0
in	0
enhancing	0
NF-kappa	9
B	10
activity	0
.	0

Freshly	0
isolated	0
monocytes	0
treated	0
with	0
the	0
protein	0
phosphatase	0
inhibitor	0
okadaic	0
acid	0
secreted	0
high	0
levels	0
of	0
IL-6	9
protein	10
,	0
which	0
coincided	0
with	0
enhanced	0
binding	0
activity	0
of	0
NF-kappa	9
B	10
as	0
well	0
as	0
with	0
phosphorylation	0
and	0
activation	0
of	0
the	0
ERK1/2	9
and	10
JNK	10
proteins	10
.	0

The	0
ERK	0
pathway-specific	0
inhibitor	0
PD98059	0
inhibited	0
IL-6	9
secretion	0
from	0
monocytes	7
.	0

Transient	0
overexpression	0
of	0
inactive	0
mutants	0
of	0
either	0
Raf-1	9
or	0
JNK1	9
showed	0
that	0
both	0
pathways	0
were	0
involved	0
in	0
kappa	0
B-dependent	0
IL-6	9
promoter	0
activity	0
.	0

By	0
using	0
PD98059	0
,	0
we	0
demonstrated	0
that	0
the	0
Raf1/MEK1/	0
ERK1/2	9
pathway	0
did	0
not	0
affect	0
the	0
DNA	0
binding	0
of	0
NF-kappa	9
B	10
but	0
,	0
rather	0
,	0
acted	0
at	0
the	0
level	0
of	0
transcriptional	0
activity	0
of	0
NF-kappa	9
B	10
.	0

Interestingly	0
,	0
it	0
was	0
shown	0
that	0
NF-kappa	9
B	10
-mediated	0
gene	0
transcription	0
,	0
both	0
in	0
the	0
context	0
of	0
the	0
IL-6	1
promoter	2
as	0
well	0
as	0
on	0
its	0
own	0
,	0
was	0
dependent	0
on	0
both	0
serine	0
kinase	0
activity	0
and	0
interaction	0
with	0
c-Jun	9
protein	10
.	0

We	0
conclude	0
that	0
okadaic	0
acid-induced	0
IL-6	9
gene	0
expression	0
is	0
at	0
least	0
partly	0
mediated	0
through	0
the	0
ERK1/2	9
and	0
JNK	9
pathway-dependent	0
activation	0
of	0
NF-kappa	9
B	10
transcriptional	0
capacity	0
.	0

Our	0
results	0
suggest	0
that	0
the	0
JNK	9
pathway	0
may	0
regulate	0
NF-kappa	9
B	10
-mediated	0
gene	0
transcription	0
through	0
its	0
phosphorylation	0
and	0
activation	0
of	0
c-Jun	9
.	0

The	0
Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
(	0
EBNA2	9
)	0
,	0
a	0
protein	0
required	0
for	0
B	7
lymphocyte	8
immortalization	0
,	0
induces	0
the	0
synthesis	0
of	0
type	9
I	10
interferon	10
in	0
Burkitt	5
's	6
lymphoma	6
cell	6
lines	6
.	0

Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
(	0
EBNA2	9
)	0
,	0
a	0
protein	0
involved	0
in	0
cell	0
transformation	0
,	0
interferes	0
with	0
the	0
cellular	0
response	0
to	0
type	9
I	10
interferons	10
(	0
IFN-alpha/beta	9
)	0
.	0

We	0
investigated	0
the	0
function	0
of	0
conditionally	0
expressed	0
EBNA2	9
in	0
the	0
context	0
of	0
the	0
IFN	9
response	0
in	0
Burkitt	5
's	6
lymphoma	6
cell	6
lines	6
.	0

Expression	0
of	0
EBNA2	9
led	0
to	0
the	0
transcriptional	0
activation	0
of	0
both	0
endogenous	0
or	0
transfected	0
IFN-stimulated	1
genes	2
(	0
ISGs	1
)	0
,	0
genes	0
which	0
contain	0
within	0
their	0
promoters	1
either	0
the	0
interferon-stimulated	1
response	2
element	2
(	0
ISRE	1
)	0
or	0
the	0
gamma	1
interferon	2
activation	2
site	2
(	0
GAS	1
)	0
.	0

In	0
search	0
of	0
a	0
molecular	0
mechanism	0
for	0
the	0
transcriptional	0
induction	0
of	0
ISGs	1
,	0
we	0
observed	0
an	0
EBNA2	9
-dependent	0
synthesis	0
of	0
IFN-beta	0
mRNA	0
at	0
low	0
levels	0
and	0
the	0
secretion	0
of	0
low	0
amounts	0
of	0
IFN	0
.	0

A	0
transfected	0
IFN-beta	0
promoter	0
responded	0
to	0
EBNA2	9
activation	0
,	0
and	0
a	0
sequence	0
closely	0
resembling	0
a	0
RBP-Jkappa	1
binding	2
site	2
was	0
pinpointed	0
as	0
a	0
potential	0
target	0
of	0
EBNA2	9
activity	0
.	0

EBNA2	9
-dependent	0
transcriptional	0
induction	0
of	0
the	0
IFN-beta	1
promoter	2
occurred	0
in	0
EBV-negative	5
Burkitt	6
's	6
lymphoma	6
cells	6
,	0
indicating	0
that	0
other	0
EBV	1
genes	2
were	0
not	0
required	0
for	0
the	0
induction	0
of	0
IFN-beta	9
synthesis	0
.	0

PGG-glucan	0
,	0
a	0
soluble	0
beta-	0
(	0
1	0
,	0
3	0
)	0
-glucan	0
,	0
enhances	0
the	0
oxidative	0
burst	0
response	0
,	0
microbicidal	0
activity	0
,	0
and	0
activates	0
an	0
NF-kappa	9
B-like	10
factor	10
in	0
human	7
PMN	8
:	0
evidence	0
for	0
a	0
glycosphingolipid	9
beta-	10
(	10
1	10
,	10
3	10
)	10
-glucan	10
receptor	10
.	0

PGG-Glucan	0
,	0
a	0
soluble	0
beta-	0
(	0
1	0
,	0
6	0
)	0
-branched	0
beta-	0
(	0
1	0
,	0
3	0
)	0
-linked	0
glucose	0
homopolymer	0
derived	0
from	0
the	0
cell	0
wall	0
of	0
the	0
yeast	0
Saccharomyces	0
cerevisiae	0
,	0
is	0
an	0
immunomodulator	0
which	0
enhances	0
leukocyte	0
anti-infective	0
activity	0
and	0
enhances	0
myeloid	0
and	0
megakaryocyte	0
progenitor	0
proliferation	0
.	0

Incubation	0
of	0
human	0
whole	0
blood	0
with	0
PGG-Glucan	0
significantly	0
enhanced	0
the	0
oxidative	0
burst	0
response	0
of	0
subsequently	7
isolated	8
blood	8
leukocytes	8
to	0
both	0
soluble	0
and	0
particulate	0
activators	0
in	0
a	0
dose-dependent	0
manner	0
,	0
and	0
increased	0
leukocyte	0
microbicidal	0
activity	0
.	0

No	0
evidence	0
for	0
inflammatory	0
cytokine	9
production	0
was	0
obtained	0
under	0
these	0
conditions	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
demonstrated	0
that	0
PGG-Glucan	0
induced	0
the	0
activation	0
of	0
an	0
NF-kappaB-like	9
nuclear	10
transcription	10
factor	10
in	0
purified	7
human	8
neutrophils	8
.	0

The	0
binding	0
of	0
3H-PGG-Glucan	0
to	0
human	0
leukocyte	0
membranes	0
was	0
specific	0
,	0
concentration-dependent	0
,	0
saturable	0
,	0
and	0
high	0
affinity	0
(	0
Kd	0
approximately	0
6	0
nM	0
)	0
.	0

A	0
monoclonal	9
antibody	10
specific	0
to	0
the	0
glycosphingolipid	0
lactosylceramide	0
was	0
able	0
to	0
inhibit	0
activation	0
of	0
the	0
NF-kappaB-like	9
factor	10
by	0
PGG-Glucan	0
,	0
and	0
ligand	0
binding	0
data	0
,	0
including	0
polysaccharide	0
specificity	0
,	0
suggested	0
that	0
the	0
PGG-Glucan	0
binding	0
moiety	0
was	0
lactosylceramide	0
.	0

These	0
results	0
indicate	0
that	0
PGG-Glucan	0
enhances	0
neutrophil	0
anti-microbial	0
functions	0
and	0
that	0
interaction	0
between	0
this	0
beta-glucan	0
and	0
human	7
neutrophils	8
is	0
mediated	0
by	0
the	0
glycosphingolipid	0
lactosylceramide	0
present	0
at	0
the	0
cell	0
surface	0
.	0

Glucocorticoids	0
promote	0
nonphlogistic	0
phagocytosis	0
of	0
apoptotic	7
leukocytes	8
.	0

Phagocyte	0
recognition	0
,	0
uptake	0
,	0
and	0
nonphlogistic	0
degradation	0
of	0
neutrophils	7
and	0
other	0
leukocytes	7
undergoing	0
apoptosis	0
promote	0
the	0
resolution	0
of	0
inflammation	0
.	0

This	0
study	0
assessed	0
the	0
effects	0
of	0
anti-inflammatory	0
glucocorticoids	0
on	0
this	0
leukocyte	0
clearance	0
mechanism	0
.	0

Pretreatment	0
of	0
``	0
semimature	0
''	0
5-day	0
human	7
monocyte-derived	8
macrophages	8
(	0
M	0
phi	0
)	0
for	0
24	0
h	0
with	0
methylprednisolone	0
,	0
dexamethasone	0
,	0
and	0
hydrocortisone	0
,	0
but	0
not	0
the	0
nonglucocorticoid	0
steroids	0
aldosterone	0
,	0
estradiol	0
,	0
and	0
progesterone	0
,	0
potentiated	0
phagocytosis	0
of	0
apoptotic	7
neutrophils	8
.	0

These	0
effects	0
were	0
specific	0
in	0
that	0
the	0
potentiated	0
phagocytosis	0
of	0
apoptotic	7
neutrophils	8
was	0
completely	0
blocked	0
by	0
the	0
glucocorticoid	9
receptor	10
antagonist	0
RU38486	0
,	0
and	0
glucocorticoids	0
did	0
not	0
promote	0
5-day	0
M	0
phi	0
ingestion	0
of	0
opsonized	7
erythrocytes	8
.	0

Similar	0
glucocorticoid-mediated	0
potentiation	0
was	0
observed	0
with	0
5-day	0
M	0
phi	0
uptake	0
of	0
alternative	0
apoptotic	0
``	0
targets	0
''	0
(	0
eosinophils	7
and	0
Jurkat	5
T	6
cells	6
)	0
and	0
in	0
uptake	0
of	0
apoptotic	7
neutrophils	8
by	0
alternative	0
phagocytes	7
(	0
human	7
glomerular	8
mesangial	8
cells	8
and	0
murine	5
M	6
phi	6
elicited	0
into	0
the	0
peritoneum	0
or	0
derived	0
from	0
bone	0
marrow	0
)	0
.	0

Importantly	0
,	0
methylprednisolone-mediated	0
enhancement	0
of	0
the	0
uptake	0
of	0
apoptotic	7
neutrophils	8
did	0
not	0
trigger	0
the	0
release	0
of	0
the	0
chemokines	9
IL-8	9
and	0
monocyte	9
chemoattractant	10
protein-1	10
.	0

Furthermore	0
,	0
longer-term	0
potentiation	0
by	0
methylprednisolone	0
was	0
observed	0
in	0
maturing	5
human	6
monocyte-derived	6
M	6
phi	6
,	0
with	0
greater	0
increases	0
in	0
5-day	0
M	5
phi	6
uptake	0
of	0
apoptotic	7
cells	8
being	0
observed	0
the	0
earlier	0
glucocorticoids	0
were	0
added	0
during	0
monocyte	0
maturation	0
into	0
M	5
phi	6
.	0

We	0
conclude	0
that	0
potentiation	0
of	0
nonphlogistic	0
clearance	0
of	0
apoptotic	7
leukocytes	8
by	0
phagocytes	7
is	0
a	0
hitherto	0
unrecognized	0
property	0
of	0
glucocorticoids	0
that	0
has	0
potential	0
implications	0
for	0
therapies	0
aimed	0
at	0
promoting	0
the	0
resolution	0
of	0
inflammatory	0
diseases	0
.	0

1	0
,	0
25-Dihydroxyvitamin	0
D3	0
induces	0
differentiation	0
of	0
a	0
retinoic	5
acid-resistant	6
acute	6
promyelocytic	6
leukemia	6
cell	6
line	6
(	0
UF-1	5
)	0
associated	0
with	0
expression	0
of	0
p21	9
(	10
WAF1/CIP1	10
)	10
and	0
p27	9
(	10
KIP1	10
)	10
.	0

Retinoic	0
acid	0
(	0
RA	0
)	0
resistance	0
is	0
a	0
serious	0
problem	0
for	0
patients	0
with	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
who	0
are	0
receiving	0
all-trans	0
RA	0
.	0

However	0
,	0
the	0
mechanisms	0
and	0
strategies	0
to	0
overcome	0
RA	0
resistance	0
by	0
APL	7
cells	8
are	0
still	0
unclear	0
.	0

The	0
biologic	0
effects	0
of	0
RA	0
are	0
mediated	0
by	0
two	0
distinct	0
families	0
of	0
transcriptional	9
factors	10
:	0
RA	9
receptors	10
(	0
RARs	9
)	0
and	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
)	0
.	0

RXRs	9
heterodimerize	0
with	0
1	9
,	10
25-dihydroxyvitamin	10
D3	10
[	10
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
]	10
receptor	10
(	0
VDR	9
)	0
,	0
enabling	0
their	0
efficient	0
transcriptional	0
activation	0
.	0

The	0
cyclin-dependent	9
kinase	10
(	10
cdk	10
)	10
inhibitor	10
p21	9
(	10
WAF1/CIP1	10
)	10
has	0
a	0
vitamin	1
D3-responsive	2
element	2
(	0
VDRE	1
)	0
in	0
its	0
promoter	1
,	0
and	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
enhances	0
the	0
expression	0
of	0
p21	9
(	10
WAF1/CIP1	10
)	10
and	0
induces	0
differentiation	0
of	0
selected	0
myeloid	5
leukemic	6
cell	6
lines	6
.	0

We	0
have	0
recently	0
established	0
a	0
novel	0
APL	5
cell	6
line	6
(	0
UF-1	5
)	0
with	0
features	0
of	0
RA	0
resistance	0
.	0

1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
can	0
induce	0
growth	0
inhibition	0
and	0
G1	0
arrest	0
of	0
UF-1	5
cells	6
,	0
resulting	0
in	0
differentiation	0
of	0
these	0
cells	0
toward	0
granulocytes	7
.	0

This	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3-induced	0
G1	0
arrest	0
is	0
enhanced	0
by	0
all-trans	0
RA	0
.	0

Also	0
,	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
(	0
10	0
(	0
-10	0
)	0
to	0
10	0
(	0
-7	0
)	0
mol/L	0
)	0
in	0
combination	0
with	0
RA	0
markedly	0
inhibits	0
cellular	0
proliferation	0
in	0
a	0
dose-	0
and	0
time-dependent	0
manner	0
.	0

Associated	0
with	0
these	0
findings	0
,	0
the	0
levels	0
of	0
p21	9
(	10
WAF1/CIP1	10
)	10
and	0
p27	3
(	4
KIP1	4
)	4
mRNA	4
and	0
protein	0
increased	0
in	0
these	0
cells	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
p21	3
(	4
WAF1/CIP1	4
)	4
and	4
p27	4
(	4
KIP1	4
)	4
mRNA	4
and	0
protein	0
increased	0
in	0
these	0
cells	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
p21	9
(	10
WAF1/CIP1	10
)	10
and	0
p27	9
(	10
KIP1	10
)	10
transcripts	0
were	0
induced	0
after	0
6	0
hours	0
'	0
exposure	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
and	0
then	0
decreased	0
to	0
basal	0
levels	0
over	0
48	0
hours	0
.	0

Western	0
blot	0
experiments	0
showed	0
that	0
p21	9
(	10
WAF1/CIP1	10
)	10
protein	0
levels	0
increased	0
and	0
became	0
detectable	0
after	0
12	0
hours	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
treatment	0
and	0
induction	0
of	0
p27	9
(	10
KIP1	10
)	10
protein	0
was	0
much	0
more	0
gradual	0
and	0
sustained	0
in	0
UF-1	5
cells	6
.	0

Interestingly	0
,	0
the	0
combination	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
and	0
RA	0
markedly	0
enhanced	0
the	0
levels	0
of	0
p27	9
(	10
KIP1	10
)	10
transcript	0
and	0
protein	0
as	0
compared	0
with	0
levels	0
induced	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
alone	0
.	0

In	0
addition	0
,	0
exogenous	0
p27	9
(	10
KIP1	10
)	10
expression	0
can	0
enhance	0
the	0
level	0
of	0
CD11b	9
antigen	10
in	0
myeloid	7
leukemic	8
cells	8
.	0

In	0
contrast	0
,	0
RA	0
alone	0
can	0
induce	0
G1	0
arrest	0
of	0
UF-1	5
cells	6
;	0
however	0
,	0
it	0
did	0
not	0
result	0
in	0
an	0
increase	0
of	0
p21	9
(	10
WAF1/CIP1	10
)	10
and	0
p27	9
(	10
KIP1	10
)	10
transcript	0
and	0
protein	0
expression	0
in	0
RA-resistant	0
cells	0
.	0

Taken	0
together	0
,	0
we	0
conclude	0
that	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
induces	0
increased	0
expression	0
of	0
cdk	9
inhibitors	10
,	0
which	0
mediates	0
a	0
G1	0
arrest	0
,	0
and	0
this	0
may	0
be	0
associated	0
with	0
differentiation	0
of	0
RA-resistant	0
UF-1	5
cells	6
toward	0
mature	0
granulocytes	7
.	0

Molecular	0
mechanisms	0
of	0
neutrophil-endothelial	0
cell	0
adhesion	0
induced	0
by	0
redox	0
imbalance	0
.	0

Previous	0
studies	0
have	0
implicated	0
a	0
role	0
for	0
intracellular	0
thiols	0
in	0
the	0
activation	0
of	0
nuclear	9
factor-kappaB	10
and	0
transcriptional	0
regulation	0
of	0
endothelial	9
cell	10
adhesion	10
molecules	10
.	0

This	0
study	0
was	0
designed	0
to	0
determine	0
whether	0
changes	0
in	0
endothelial	0
cell	0
glutathione	0
(	0
GSH	0
)	0
or	0
oxidized	0
glutathione	0
(	0
GSSG	0
)	0
can	0
alter	0
neutrophil	0
adhesivity	0
and	0
to	0
define	0
the	0
molecular	0
mechanism	0
that	0
underlies	0
this	0
GSSG/GSH-induced	0
adhesion	0
response	0
.	0

Treatment	0
of	0
human	5
umbilical	6
vein	6
endothelial	6
cell	6
(	6
HUVEC	6
)	6
monolayers	6
for	0
6	0
hours	0
with	0
0.2	0
mmol/L	0
diamide	0
and	0
1	0
mmol/L	0
buthionine	0
sulfoximine	0
(	0
BSO	0
)	0
decreased	0
GSH	0
levels	0
and	0
increased	0
the	0
ratio	0
of	0
GSSG	0
to	0
GSH	0
without	0
cell	0
toxicity	0
.	0

These	0
redox	0
changes	0
are	0
similar	0
to	0
those	0
observed	0
with	0
anoxia/reoxygenation	0
.	0

Diamide	0
plus	0
BSO-induced	0
thiol/disulfide	0
imbalance	0
was	0
associated	0
with	0
a	0
biphasic	0
increase	0
in	0
neutrophil	7
adhesion	0
to	0
HUVECs	5
with	0
peak	0
responses	0
observed	0
at	0
15	0
minutes	0
(	0
phase	0
1	0
)	0
and	0
240	0
minutes	0
(	0
phase	0
2	0
)	0
.	0

N-Acetylcysteine	0
treatment	0
attenuated	0
neutrophil	7
adhesion	0
in	0
both	0
phases	0
,	0
which	0
indicated	0
a	0
role	0
for	0
GSH	0
in	0
the	0
adhesion	0
responses	0
.	0

Interestingly	0
,	0
phase	0
1	0
adhesion	0
was	0
inversely	0
correlated	0
with	0
GSH	0
levels	0
but	0
not	0
with	0
the	0
GSSG/GSH	0
ratio	0
,	0
whereas	0
phase	0
2	0
neutrophil	7
adhesion	0
was	0
positively	0
correlated	0
with	0
GSSG/GSH	0
ratio	0
but	0
not	0
with	0
GSH	0
levels	0
.	0

Intercellular	9
adhesion	10
molecule-1	10
and	0
P-selectin-specific	9
monoclonal	10
antibodies	10
attenuated	0
the	0
increased	0
neutrophil	7
adhesion	0
during	0
both	0
phases	0
,	0
whereas	0
an	0
anti-E-selectin	9
monoclonal	10
antibody	10
also	0
attenuated	0
the	0
phase	0
2	0
response	0
.	0

Pretreatment	0
with	0
actinomycin	0
D	0
and	0
cycloheximide	0
or	0
with	0
competing	0
ds-oligonucleotides	0
that	0
contained	0
nuclear	9
factor-kappaB	10
or	0
activator	9
protein-1	10
cognate	0
DNA	0
sequences	0
significantly	0
attenuated	0
the	0
phase	0
2	0
response	0
,	0
which	0
implicated	0
a	0
role	0
for	0
de	0
novo	0
protein	0
synthesis	0
.	0

Surface	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
,	0
P-selectin	9
,	0
and	0
E-selectin	9
on	0
HUVECs	5
correlated	0
with	0
the	0
phase	0
1	0
and	0
2	0
neutrophil	7
adhesion	0
responses	0
.	0

This	0
study	0
demonstrates	0
that	0
changes	0
in	0
endothelial	0
cell	0
GSSG/GSH	0
cause	0
transcription-independent	0
and	0
transcription-dependent	0
surface	0
expression	0
of	0
different	0
endothelial	9
cell	10
adhesion	10
molecules	10
,	0
which	0
leads	0
to	0
a	0
2-phase	0
neutrophil	7
-endothelial	0
adhesion	0
response	0
.	0

Glucocorticoid	0
hormone	0
suppression	0
of	0
human	0
neutrophil	7
-mediated	0
tumor	0
cell	0
cytostasis	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
have	0
investigated	0
the	0
effect	0
of	0
glucocorticoid	0
hormones	0
on	0
neutrophil	7
-mediated	0
tumor	0
cell	0
cytostasis	0
and	0
found	0
that	0
hydrocortisone	0
and	0
a	0
synthetic	0
hormone	0
,	0
dexamethasone	0
(	0
Dex	0
)	0
,	0
inhibited	0
cytostasis	0
in	0
the	0
presence	0
or	0
absence	0
of	0
tumor	9
necrosis	10
factor-alpha	10
.	0

The	0
effect	0
of	0
Dex	0
was	0
completely	0
reversed	0
by	0
a	0
glucocorticoid	9
receptor	10
antagonist	0
,	0
RU38486	0
.	0

To	0
clarify	0
the	0
underlying	0
mechanisms	0
,	0
we	0
examined	0
effects	0
of	0
Dex	0
on	0
the	0
binding	0
avidity	0
of	0
beta2	9
integrin	10
on	0
the	0
neutrophil	7
surface	0
and	0
how	0
these	0
might	0
in	0
turn	0
affect	0
neutrophil	7
-to-tumor	0
cell	0
binding	0
.	0

Dex	0
was	0
found	0
to	0
inhibit	0
these	0
neutrophil	7
properties	0
,	0
and	0
RU38486	0
completely	0
suppressed	0
both	0
forms	0
of	0
Dex	0
inhibition	0
.	0

Taken	0
together	0
,	0
our	0
findings	0
suggest	0
that	0
glucocorticoid	0
hormone	0
inhibition	0
of	0
neutrophil	7
-mediated	0
tumor	0
cell	0
cytostasis	0
is	0
at	0
least	0
partially	0
due	0
to	0
a	0
lowering	0
of	0
the	0
ligand	0
binding	0
avidity	0
of	0
beta2	9
integrin	10
on	0
the	0
neutrophil	7
surface	0
.	0

Constitutive	0
activation	0
of	0
an	0
epithelial	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
(	0
STAT	9
)	0
pathway	0
in	0
asthma	0
.	0

Cytokine	9
effects	0
on	0
immunity	0
and	0
inflammation	0
often	0
depend	0
on	0
the	0
transcription	9
factors	10
termed	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
STATs	9
)	0
,	0
so	0
STAT	9
signaling	0
pathways	0
are	0
candidates	0
for	0
influencing	0
inflammatory	0
disease	0
.	0

We	0
reasoned	0
that	0
selective	0
IFN	9
responsiveness	0
of	0
the	0
first	0
STAT	9
family	10
member	10
(	0
Stat1	9
)	0
and	0
Stat1-dependent	1
immune-response	2
genes	2
such	0
as	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
,	0
IFN	9
regulatory	10
factor-1	10
(	0
IRF-1	9
)	0
,	0
and	0
Stat1	9
itself	0
in	0
airway	7
epithelial	8
cells	8
provides	0
a	0
basis	0
for	0
detecting	0
cytokine	9
signaling	0
abnormalities	0
in	0
inflammatory	0
airway	0
disease	0
.	0

On	0
the	0
basis	0
of	0
nuclear	0
localization	0
and	0
phosphorylation	0
,	0
we	0
found	0
that	0
epithelial	9
Stat1	10
(	0
but	0
not	0
other	0
control	0
transcription	9
factors	10
)	0
was	0
invariably	0
activated	0
in	0
asthmatic	0
compared	0
with	0
normal	0
control	0
or	0
chronic	0
bronchitis	0
subjects	0
.	0

Furthermore	0
,	0
epithelial	0
levels	0
of	0
activated	0
Stat1	9
correlated	0
with	0
levels	0
of	0
expression	0
for	0
epithelial	9
ICAM-1	10
,	0
IRF-1	9
,	0
and	0
Stat1	9
,	0
and	0
in	0
turn	0
,	0
ICAM-1	9
levels	0
correlated	0
with	0
T-cell	0
accumulation	0
in	0
tissue	0
.	0

However	0
,	0
only	0
low	0
levels	0
of	0
IFN-gamma	9
or	0
IFN-gamma-producing	7
cells	8
were	0
detected	0
in	0
airway	0
tissue	0
in	0
all	0
subjects	0
.	0

The	0
results	0
therefore	0
provide	0
initial	0
evidence	0
linking	0
abnormal	0
behavior	0
of	0
STAT	9
pathways	0
for	0
cytokine	9
signaling	0
to	0
the	0
development	0
of	0
an	0
inflammatory	0
disease	0
.	0

In	0
that	0
context	0
,	0
the	0
results	0
also	0
change	0
the	0
current	0
scheme	0
for	0
asthma	0
pathogenesis	0
to	0
one	0
that	0
must	0
include	0
a	0
localized	0
gain	0
in	0
transcriptional	0
signal	0
ordinarily	0
used	0
for	0
a	0
T	9
helper	10
1-type	10
cytokine	10
(	0
IFN-gamma	9
)	0
in	0
combination	0
with	0
allergy-driven	0
overproduction	0
of	0
T	9
helper	10
2-type	10
cytokines	10
.	0

Leukocyte	7
populations	8
,	0
hormone	9
receptors	10
and	0
apoptosis	0
in	0
eutopic	0
and	0
ectopic	0
first	0
trimester	0
human	0
pregnancies	0
.	0

The	0
implantation	0
of	0
trophoblast	7
cells	8
at	0
extrauterine	0
sites	0
still	0
results	0
in	0
decidualization	0
.	0

The	0
objective	0
of	0
the	0
present	0
study	0
was	0
to	0
compare	0
decidualization	0
at	0
eutopic	0
and	0
ectopic	0
implantation	0
sites	0
.	0

Tissues	0
from	0
women	0
undergoing	0
elective	0
termination	0
of	0
uterine	0
pregnancy	0
and	0
from	0
women	0
with	0
ectopic	0
pregnancy	0
were	0
used	0
to	0
detect	0
the	0
presence	0
of	0
cells	0
important	0
for	0
the	0
maintenance	0
of	0
pregnancy	0
,	0
such	0
as	0
BCL-2+	7
,	8
CD56+	8
,	8
CD3+	8
,	8
CD8+	8
and	8
CD68+	8
cells	8
,	0
and	0
the	0
presence	0
of	0
oestrogen	9
(	10
ER	10
)	10
and	10
progesterone	10
receptors	10
(	0
PR	9
)	0
by	0
immunohistochemistry	0
.	0

In-situ	0
detection	0
of	0
fragmented	0
DNA	0
was	0
performed	0
to	0
identify	0
apoptotic	7
cells	8
.	0

The	0
percentage	0
of	0
CD3+	7
cells	8
among	0
all	0
immunocompetent	7
cells	8
in	0
the	0
tubal	0
epithelium	0
was	0
46.6	0
%	0
(	0
39.9	0
%	0
of	0
CD3+	7
were	0
also	0
CD8+	7
)	0
;	0
the	0
other	0
53.4	0
%	0
were	0
CD68+	7
cells	8
.	0

CD56+	7
cells	8
were	0
undetectable	0
in	0
ectopic	0
decidua	0
at	0
the	0
feto-maternal	0
interface	0
in	0
ectopic	0
tissue	0
.	0

In	0
uterine	0
decidua	0
,	0
we	0
found	0
29.9	0
%	0
CD3+	7
cells	8
(	0
2.2	0
%	0
of	0
CD3+	0
were	0
CD8+	0
)	0
,	0
51.6	0
%	0
CD56+	7
cells	8
and	0
18.5	0
%	0
CD68+	7
cells	8
.	0

The	0
ratio	0
of	0
BCL2+	7
to	0
CD3+	7
cells	8
in	0
ectopic	0
pregnancy	0
was	0
0.41	0
.	0

In	0
uterine	0
pregnancy	0
,	0
the	0
ratio	0
of	0
BCL-2	9
to	0
CD3	0
was	0
0.44	0
and	0
0.39	0
for	0
CD56	0
.	0

Tissues	0
from	0
both	0
ectopic	0
and	0
uterine	0
pregnancies	0
were	0
positive	0
for	0
PR	9
.	0

Fewer	0
apoptotic	7
cell	8
bodies	8
were	0
present	0
in	0
ectopic	0
pregnancy	0
.	0

The	0
use	0
of	0
tissue	0
obtained	0
from	0
ectopic	0
pregnancy	0
may	0
become	0
an	0
excellent	0
model	0
to	0
identify	0
the	0
mechanism	0
of	0
trophoblast	0
invasion	0
in	0
eutopic	0
pregnancies	0
.	0

Angiotensin	9
II	10
activates	0
the	0
proinflammatory	9
transcription	10
factor	10
nuclear	9
factor-kappaB	10
in	0
human	7
monocytes	8
.	0

The	0
renin	9
-angiotensin	0
system	0
may	0
contribute	0
to	0
the	0
pathogenesis	0
of	0
atherosclerosis	0
.	0

A	0
common	0
feature	0
of	0
all	0
stages	0
of	0
atherosclerosis	0
is	0
inflammation	0
of	0
the	0
vessel	0
wall	0
.	0

The	0
transcription	0
factor	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
participates	0
in	0
most	0
signaling	0
pathways	0
involved	0
in	0
inflammation	0
.	0

This	0
study	0
therefore	0
examined	0
the	0
effect	0
of	0
angiotensin	9
(	10
ANG	10
)	10
II	10
on	0
NF-kappaB	9
activation	0
in	0
monocytic	7
cells	8
,	0
a	0
major	0
cellular	0
component	0
of	0
human	0
atheroma	0
,	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

ANG	9
II	10
,	0
like	0
TNFalpha	9
,	0
caused	0
rapid	0
activation	0
of	0
NF-kappaB	9
in	0
human	7
mononuclear	8
cells	8
isolated	0
from	0
peripheral	0
blood	0
by	0
Ficoll	0
density	0
gradient	0
.	0

This	0
ANG	9
II	10
effect	0
was	0
blocked	0
by	0
the	0
angiotensin	0
AT1	0
receptor	0
antagonist	0
losartan	0
.	0

Specificity	0
of	0
ANG	9
II	10
-induced	0
NF-kappaB	9
activation	0
was	0
ascertained	0
by	0
supershift	0
and	0
competition	0
experiments	0
.	0

Moreover	0
,	0
ANG	9
II	10
stimulated	0
NF-kappaB	9
activation	0
in	0
human	7
monocytes	8
,	0
but	0
not	0
in	0
lymphocytes	7
from	0
the	0
same	0
preparation	0
.	0

Together	0
,	0
the	0
data	0
demonstrate	0
the	0
ability	0
of	0
the	0
vasoactive	0
peptide	0
ANG	9
II	10
to	0
activate	0
inflammatory	0
pathways	0
in	0
human	7
monocytes	8
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Signal	0
transduction	0
pathways	0
activated	0
in	0
endothelial	7
cells	8
following	0
infection	0
with	0
Chlamydia	0
pneumoniae	0
.	0

Chlamydia	0
pneumoniae	0
is	0
an	0
important	0
respiratory	0
pathogen	0
.	0

Recently	0
,	0
its	0
presence	0
has	0
been	0
demonstrated	0
in	0
atherosclerotic	0
lesions	0
.	0

In	0
this	0
study	0
,	0
we	0
characterized	0
C.	0
pneumoniae-mediated	0
activation	0
of	0
endothelial	7
cells	8
and	0
demonstrated	0
an	0
enhanced	0
expression	0
of	0
endothelial	9
adhesion	10
molecules	10
followed	0
by	0
subsequent	0
rolling	0
,	0
adhesion	0
,	0
and	0
transmigration	0
of	0
leukocytes	7
(	0
monocytes	7
,	0
granulocytes	7
)	0
.	0

These	0
effects	0
were	0
blocked	0
by	0
mAbs	9
against	0
endothelial	9
and/or	10
leukocyte	10
adhesion	10
molecules	10
(	0
beta1	9
and	10
beta2	10
integrins	10
)	0
.	0

Additionally	0
,	0
activation	0
of	0
different	0
signal	0
transduction	0
pathways	0
in	0
C.	7
pneumoniae-infected	8
endothelial	8
cells	8
was	0
shown	0
:	0
protein	0
tyrosine	0
phosphorylation	0
,	0
up-regulation	0
of	0
phosphorylated	0
p42/p44	9
mitogen-activated	10
protein	10
kinase	10
,	0
and	0
NF-kappaB	9
activation/translocation	0
occurred	0
within	0
10-15	0
min	0
.	0

Increased	0
mRNA	3
and	0
surface	0
expression	0
of	0
E-selectin	9
,	0
ICAM-1	9
,	0
and	0
VCAM-1	9
were	0
noted	0
within	0
hours	0
.	0

Thus	0
,	0
C.	0
pneumoniae	0
triggers	0
a	0
cascade	0
of	0
events	0
that	0
could	0
lead	0
to	0
endothelial	0
activation	0
,	0
inflammation	0
,	0
and	0
thrombosis	0
,	0
which	0
in	0
turn	0
may	0
result	0
in	0
or	0
may	0
promote	0
atherosclerosis	0
.	0

Transient	0
pseudo-hypoaldosteronism	0
following	0
resection	0
of	0
the	0
ileum	0
:	0
normal	0
level	0
of	0
lymphocytic	9
aldosterone	10
receptors	10
outside	0
the	0
acute	0
phase	0
.	0

Pseudo-hypoaldosteronism	0
(	0
PHA	0
)	0
is	0
due	0
to	0
mineralocorticoid	0
resistance	0
and	0
manifests	0
as	0
hyponatremia	0
and	0
hyperkalemia	0
with	0
increased	0
plasma	0
aldosterone	0
levels	0
.	0

It	0
may	0
be	0
familial	0
or	0
secondary	0
to	0
abnormal	0
renal	0
sodium	0
handling	0
.	0

We	0
report	0
the	0
case	0
of	0
a	0
54-year-old	0
woman	0
with	0
multifocal	0
cancer	0
of	0
the	0
colon	0
,	0
who	0
developed	0
PHA	0
after	0
subtotal	0
colectomy	0
,	0
ileal	0
resection	0
and	0
jejunostomy	0
.	0

She	0
was	0
treated	0
with	0
6	0
g	0
of	0
salt	0
daily	0
to	0
prevent	0
dehydration	0
,	0
which	0
she	0
stopped	0
herself	0
because	0
of	0
reduced	0
fecal	0
losses	0
.	0

One	0
month	0
later	0
she	0
was	0
admitted	0
with	0
signs	0
of	0
acute	0
adrenal	0
failure	0
,	0
i.e.	0
fatigue	0
,	0
severe	0
nausea	0
,	0
blood	0
pressure	0
of	0
80/60	0
mmHg	0
,	0
extracellular	0
dehydration	0
,	0
hyponatremia	0
(	0
118	0
mmol/l	0
)	0
;	0
hyperkalemia	0
(	0
7.6	0
mmol/l	0
)	0
,	0
increased	0
blood	0
urea	0
nitrogen	0
(	0
BUN	0
)	0
(	0
200	0
mg/dl	0
)	0
and	0
creatininemia	0
(	0
2.5	0
mg/dl	0
)	0
,	0
and	0
decreased	0
plasma	0
bicarbonates	0
level	0
(	0
HCO3-	0
:	0
16	0
mmol/l	0
;	0
N	0
:	0
27-30	0
)	0
.	0

However	0
,	0
the	0
plasma	0
cortisol	0
was	0
high	0
(	0
66	0
microg/100	0
ml	0
at	0
10	0
:	0
00	0
h	0
;	0
N	0
:	0
8-15	0
)	0
and	0
the	0
ACTH	0
was	0
normal	0
(	0
13	0
pg/ml	0
,	0
N	0
:	0
10-60	0
)	0
;	0
there	0
was	0
a	0
marked	0
increase	0
in	0
plasma	0
renin	0
activity	0
(	0
>	0
37	0
ng/ml/h	0
;	0
N	0
supine	0
<	0
3	0
)	0
,	0
active	0
renin	0
(	0
869	0
pg/ml	0
;	0
N	0
supine	0
:	0
1.120	0
)	0
,	0
aldosterone	0
(	0
>	0
2000	0
pg/ml	0
;	0
N	0
supine	0
<	0
150	0
)	0
and	0
plasma	0
AVP	0
(	0
20	0
pmol/l	0
;	0
N	0
:	0
0.5-2.5	0
)	0
.	0

The	0
plasma	0
ANH	0
level	0
was	0
38	0
pmol/l	0
(	0
N	0
supine	0
:	0
5-25	0
)	0
.	0

A	0
urinary	0
steroidogram	0
resulted	0
in	0
highly	0
elevated	0
tetrahydrocortisol	0
(	0
THF	0
:	0
13.3	0
mg/24h	0
;	0
N	0
:	0
1.4+/-0.8	0
)	0
with	0
no	0
increase	0
in	0
tetrahydrocortisone	0
(	0
THE	0
:	0
3.16	0
mg/24h	0
;	0
N	0
:	0
2.7+/-2.0	0
)	0
excretion	0
,	0
and	0
with	0
low	0
THE/THF	0
(	0
0.24	0
;	0
N	0
:	0
1.87+/-0.36	0
)	0
and	0
alpha	0
THF/THF	0
(	0
0.35	0
;	0
N	0
:	0
0.92+/-0.42	0
)	0
ratios	0
.	0

The	0
number	0
of	0
mineralocorticoid	9
receptors	10
in	0
mononuclear	7
leukocytes	8
was	0
in	0
the	0
lower	0
normal	0
range	0
for	0
age	0
,	0
while	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
was	0
reduced	0
.	0

Small-bowel	0
resection	0
in	0
ileostomized	0
patients	0
causes	0
excessive	0
fecal	0
sodium	0
losses	0
and	0
results	0
in	0
chronic	0
sodium	0
depletion	0
with	0
contraction	0
of	0
the	0
plasma	0
volume	0
and	0
severe	0
secondary	0
hyperaldosteronism	0
.	0

Nevertheless	0
,	0
this	0
hyperaldosteronism	0
may	0
be	0
associated	0
with	0
hyponatremia	0
and	0
hyperkalemia	0
suggesting	0
PHA	0
related	0
to	0
the	0
major	0
importance	0
of	0
the	0
colon	0
for	0
the	0
absorption	0
of	0
sodium	0
.	0

In	0
conclusion	0
,	0
this	0
case	0
report	0
emphasizes	0
1	0
)	0
the	0
possibility	0
of	0
a	0
syndrome	0
of	0
acquired	0
PHA	0
with	0
severe	0
hyperkalemia	0
after	0
resection	0
of	0
the	0
ileum	0
and	0
colon	0
responding	0
to	0
oral	0
salt	0
supplementation	0
;	0
2	0
)	0
the	0
major	0
increase	0
in	0
AVP	0
and	0
the	0
small	0
increase	0
in	0
ANH	0
;	0
3	0
)	0
the	0
strong	0
increase	0
in	0
urinary	0
THF	0
with	0
low	0
THE/THF	0
and	0
alpha	0
THF/THF	0
ratios	0
;	0
4	0
)	0
the	0
normal	0
number	0
of	0
lymphocytic	9
mineralocorticoid	10
receptors	10
outside	0
the	0
acute	0
episode	0
.	0

Modulation	0
of	0
the	0
immune	0
response	0
by	0
progesterone-induced	9
lymphocyte	10
factors	10
.	0

Rat	0
spleen	0
and	0
peripheral	7
blood	8
lymphocytes	8
express	0
progesterone	9
receptors	10
whose	0
concentration	0
is	0
increased	0
greatly	0
during	0
the	0
early	0
phase	0
of	0
pregnancy	0
.	0

After	0
stimulation	0
of	0
progesterone	0
the	0
expression	0
of	0
receptors	0
was	0
augmented	0
2-3	0
times	0
.	0

When	0
cells	0
were	0
cultured	0
in	0
the	0
presence	0
of	0
progesterone	0
they	0
released	0
a	0
soluble	9
factor	10
that	0
inhibited	0
cellular	0
immunoreactions	0
(	0
MLR	0
,	0
CRC	0
)	0
and	0
cellular	0
proliferation	0
as	0
measured	0
by	0
thymidine	0
incorporation	0
by	0
spleen-cell	5
culture	6
.	0

This	0
factor	0
also	0
inhibited	0
the	0
synthesis	0
of	0
anti-DNP	9
antibodies	10
by	0
a	0
mouse	5
hybridoma	6
and	0
diminished	0
the	0
proportion	0
of	0
cells	0
in	0
phase	0
S	0
.	0

However	0
,	0
the	0
percentage	0
of	0
asymmetric	9
molecules	10
produced	0
by	0
the	0
hybridoma	5
remained	0
unaltered	0
.	0

These	0
results	0
support	0
the	0
hypothesis	0
that	0
soluble	9
factors	10
released	0
by	0
rat	7
lymphocytes	8
modulate	0
the	0
immune	0
response	0
of	0
the	0
mother	0
and	0
participate	0
in	0
the	0
mechanism	0
that	0
protects	0
the	0
fetus	0
against	0
antipaternal	9
antibodies	10
.	0

Differential	0
regulation	0
of	0
4E-BP1	9
and	0
4E-BP2	9
,	0
two	0
repressors	0
of	0
translation	0
initiation	0
,	0
during	0
human	7
myeloid	8
cell	8
differentiation	0
.	0

Human	0
myeloid	0
differentiation	0
is	0
accompanied	0
by	0
a	0
decrease	0
in	0
cell	0
proliferation	0
.	0

Because	0
the	0
translation	0
rate	0
is	0
an	0
important	0
determinant	0
of	0
cell	0
proliferation	0
,	0
we	0
have	0
investigated	0
translation	0
initiation	0
during	0
human	7
myeloid	8
cell	8
differentiation	0
using	0
the	0
HL-60	5
promyelocytic	6
leukemia	6
cell	6
line	6
and	0
the	0
U-937	5
monoblastic	6
cell	6
line	6
.	0

A	0
decrease	0
in	0
the	0
translation	0
rate	0
is	0
observed	0
when	0
the	0
cells	0
are	0
induced	0
to	0
differentiate	0
along	0
the	0
monocytic/macrophage	0
pathway	0
or	0
along	0
the	0
granulocytic	0
pathway	0
.	0

The	0
inhibition	0
in	0
protein	0
synthesis	0
correlates	0
with	0
specific	0
regulation	0
of	0
two	0
repressors	0
of	0
translation	0
initiation	0
,	0
4E-BP1	9
and	0
4E-BP2	9
.	0

Induction	0
of	0
HL-60	5
and	0
U-937	5
cell	0
differentiation	0
into	0
monocytes/macrophages	7
by	0
IFN-gamma	9
or	0
PMA	0
results	0
in	0
a	0
dephosphorylation	0
and	0
consequent	0
activation	0
of	0
4E-BP1	9
.	0

Dephosphorylation	0
of	0
4E-BP1	9
was	0
also	0
observed	0
when	0
U-937	5
cells	6
were	0
induced	0
to	0
differentiate	0
into	0
monocytes/macrophages	7
following	0
treatment	0
with	0
retinoic	0
acid	0
or	0
DMSO	0
.	0

In	0
contrast	0
,	0
treatment	0
of	0
HL-60	5
cells	6
with	0
retinoic	0
acid	0
or	0
DMSO	0
,	0
which	0
results	0
in	0
a	0
granulocytic	0
differentiation	0
of	0
these	0
cells	0
,	0
decreases	0
4E-BP1	9
amount	0
without	0
affecting	0
its	0
phosphorylation	0
and	0
strongly	0
increases	0
4E-BP2	9
amount	0
.	0

Taken	0
together	0
,	0
these	0
data	0
provide	0
evidence	0
for	0
differential	0
regulation	0
of	0
the	0
translational	0
machinery	0
during	0
human	0
myeloid	0
differentiation	0
,	0
specific	0
to	0
the	0
monocytic/macrophage	0
pathway	0
or	0
to	0
the	0
granulocytic	0
pathway	0
.	0

Nonimmunoglobulin	0
gene	0
hypermutation	0
in	0
germinal	7
center	8
B	8
cells	8
.	0

Somatic	0
hypermutation	0
is	0
the	0
most	0
critical	0
mechanism	0
underlying	0
the	0
diversification	0
of	0
Ig	1
genes	2
.	0

Although	0
mutation	0
occurs	0
specifically	0
in	0
B	7
cells	8
during	0
the	0
germinal	0
center	0
reaction	0
,	0
it	0
remains	0
a	0
matter	0
of	0
debate	0
whether	0
the	0
mutation	0
machinery	0
also	0
targets	0
non-Ig	1
genes	2
.	0

We	0
have	0
studied	0
mutations	0
in	0
the	0
5	1
'	2
noncoding	2
region	2
of	0
the	0
Bcl6	1
gene	2
in	0
different	0
subtypes	0
of	0
lymphomas	0
.	0

We	0
found	0
frequent	0
hypermutation	0
in	0
follicular	0
lymphoma	0
(	0
25	0
of	0
59	0
=	0
42	0
%	0
)	0
(	0
germinal	0
center	0
cell	0
origin	0
)	0
and	0
mucosa-associated	0
lymphoid	0
tissue	0
(	0
MALT	0
)	0
lymphoma	0
(	0
19	0
of	0
45	0
=	0
42	0
%	0
)	0
(	0
postgerminal	0
center	0
)	0
,	0
but	0
only	0
occasionally	0
in	0
mantle	0
cell	0
lymphoma	0
(	0
1	0
of	0
21	0
=	0
4.8	0
%	0
)	0
(	0
pregerminal	0
center	0
)	0
.	0

Most	0
mutations	0
were	0
outside	0
the	0
motifs	0
potentially	0
important	0
for	0
transcription	0
,	0
suggesting	0
they	0
were	0
not	0
important	0
in	0
lymphomagenesis	0
but	0
may	0
,	0
like	0
Ig	0
mutation	0
,	0
represent	0
an	0
inherent	0
feature	0
of	0
the	0
lymphoma	7
precursor	8
cells	8
.	0

Therefore	0
,	0
we	0
investigated	0
their	0
normal	0
cell	0
counterparts	0
microdissected	0
from	0
a	0
reactive	0
tonsil	0
.	0

Bcl6	0
mutation	0
was	0
found	0
in	0
13	0
of	0
24	0
(	0
54	0
%	0
)	0
clones	0
from	0
the	0
germinal	0
centre	0
but	0
only	0
in	0
1	0
of	0
24	0
(	0
4	0
%	0
)	0
clones	0
from	0
the	0
naive	7
B	8
cells	8
of	0
the	0
mantle	0
zone	0
.	0

The	0
frequency	0
,	0
distribution	0
,	0
and	0
nature	0
of	0
these	0
mutations	0
were	0
similar	0
to	0
those	0
resulting	0
from	0
the	0
Ig	0
hypermutation	0
process	0
.	0

The	0
results	0
show	0
unequivocal	0
evidence	0
of	0
non-	0
Ig	1
gene	2
hypermutation	0
in	0
germinal	7
center	8
B	8
cells	8
and	0
provide	0
fresh	0
insights	0
into	0
the	0
process	0
of	0
hypermutation	0
and	0
lymphomagenesis	0
.	0

Impaired	0
binding	0
of	0
a	0
DQ2	9
and	0
DQ8	9
-binding	0
HSV	0
VP16	0
peptide	0
to	0
a	0
DQA1*0501/DQB1*0302	9
trans	10
class	10
II	10
heterodimer	10
.	0

DQalpha	9
and	10
DQbeta	10
trans	10
heterodimeric	10
HLA-DQ	10
molecules	10
form	0
in	0
individuals	0
heterozygous	0
for	0
the	0
DQ2	9
and	0
DQ8	9
specificities	0
.	0

Unique	0
functions	0
and	0
disease	0
associations	0
have	0
been	0
postulated	0
for	0
such	0
trans-dimers	9
,	0
which	0
may	0
be	0
different	0
from	0
cis-encoded	9
DQ	10
molecules	10
encoded	0
by	0
the	0
corresponding	0
haplotypes	0
.	0

We	0
analyzed	0
the	0
ability	0
of	0
the	0
trans-dimer	0
encoded	0
by	0
HLA-DQA1*0501/DQB1*0302	9
to	0
bind	0
a	0
peptide	0
antigen	0
which	0
interacts	0
with	0
DQ	9
molecules	10
encoded	0
by	0
both	0
parental	0
haplotypes	0
.	0

Markedly	0
impaired	0
binding	0
was	0
observed	0
,	0
consistent	0
with	0
both	0
the	0
use	0
of	0
different	0
anchor	0
residues	0
and	0
with	0
changes	0
in	0
levels	0
of	0
DQ	0
cis-	0
dimer	9
availability	0
for	0
peptide	0
binding	0
interactions	0
.	0

Detection	0
of	0
intracellular	9
phosphorylated	10
STAT-1	10
by	0
flow	0
cytometry	0
.	0

We	0
have	0
applied	0
flow	0
cytometry	0
to	0
the	0
investigation	0
of	0
interferon-gamma	9
activation	0
of	0
human	7
monocytes	8
.	0

This	0
approach	0
uses	0
monoclonal	9
antibodies	10
that	0
distinguish	0
between	0
the	0
native	0
and	0
phosphorylated	0
forms	0
of	0
STAT-1	9
.	0

It	0
enables	0
rapid	0
and	0
quantitative	0
assessment	0
of	0
STAT-1	9
phosphorylation	0
on	0
a	0
discrete	0
cell	0
basis	0
and	0
is	0
both	0
more	0
sensitive	0
and	0
less	0
time	0
consuming	0
than	0
immunoblotting	0
.	0

Furthermore	0
,	0
it	0
allows	0
for	0
discrimination	0
between	0
a	0
mixture	0
of	0
cells	0
that	0
differ	0
in	0
their	0
response	0
to	0
interferon-gamma	9
.	0

This	0
approach	0
should	0
allow	0
for	0
the	0
evaluation	0
of	0
different	0
intracellular	0
signaling	0
pathways	0
using	0
a	0
combination	0
of	0
monoclonal	0
reagents	0
that	0
are	0
specific	0
for	0
native	0
and	0
activation	9
modified	10
proteins	10
.	0

Application	0
of	0
this	0
form	0
of	0
testing	0
should	0
prove	0
valuable	0
in	0
screening	0
for	0
signaling	0
defects	0
in	0
selected	0
patients	0
with	0
recurrent	0
infections	0
.	0

In	0
addition	0
,	0
this	0
technique	0
should	0
permit	0
dissection	0
of	0
a	0
full	0
range	0
of	0
cellular	0
signaling	0
pathways	0
at	0
the	0
protein	0
level	0
.	0

Activation	0
of	0
nuclear	9
factor-kappaB	10
by	0
lipopolysaccharide	0
in	0
mononuclear	7
leukocytes	8
is	0
prevented	0
by	0
inhibitors	0
of	0
cytosolic	9
phospholipase	10
A2	10
.	0

In	0
monocytes	7
,	0
lipopolysaccharide	0
induces	0
synthesis	0
and	0
activity	0
of	0
the	0
85-kDa	0
cytosolic	9
phospholipase	10
A2	10
.	0

This	0
enzyme	0
releases	0
arachidonic	0
acid	0
and	0
lyso-phospholipids	0
from	0
membranes	0
which	0
are	0
metabolized	0
to	0
eicosanoids	0
and	0
platelet-activating-factor	0
.	0

These	0
lipid	0
mediators	0
increase	0
activity	0
of	0
transcription	9
factors	10
and	0
expression	0
of	0
cytokine	1
genes	2
indicating	0
a	0
function	0
for	0
cytosolic	9
phospholipase	10
A2	10
in	0
signal	0
transduction	0
and	0
inflammation	0
.	0

We	0
have	0
shown	0
previously	0
that	0
trifluoromethylketone	0
inhibitors	0
of	0
cytosolic	9
phospholipase	10
A2	10
suppressed	0
interleukin-1beta	0
protein	0
and	0
steady-state	0
mRNA	0
levels	0
in	0
human	0
lipopolysaccharide-stimulated	7
peripheral	8
blood	8
mononuclear	8
leukocytes	8
.	0

In	0
this	0
study	0
,	0
the	0
subcellular	0
mechanisms	0
were	0
analyzed	0
by	0
which	0
trifluoromethylketones	0
interfere	0
with	0
gene	0
expression	0
.	0

We	0
found	0
that	0
they	0
reduced	0
the	0
initial	0
interleukin-1beta	3
mRNA	4
transcription	0
rate	0
through	0
prevention	0
of	0
degradation	0
of	0
inhibitor-kappaB	9
alpha	10
.	0

Consequently	0
,	0
cytosolic	0
activation	0
,	0
nuclear	0
translocation	0
and	0
DNA-binding	0
of	0
nuclear	9
factor-kappaB	10
were	0
decreased	0
.	0

Trifluoromethylketones	0
ameliorate	0
chronic	0
inflammation	0
in	0
vivo	0
.	0

Thus	0
,	0
this	0
therapeutic	0
potency	0
may	0
reside	0
in	0
retention	0
of	0
inactive	0
nuclear	9
factor-kappaB	10
in	0
the	0
cytosol	7
thereby	0
abrogating	0
interleukin-1beta	9
gene	0
transcription	0
.	0

Cellular	0
disposition	0
of	0
sulphamethoxazole	0
and	0
its	0
metabolites	0
:	0
implications	0
for	0
hypersensitivity	0
.	0

1.	0
Bioactivation	0
of	0
sulphamethoxazole	0
(	0
SMX	0
)	0
to	0
chemically-reactive	0
metabolites	0
and	0
subsequent	0
protein	0
conjugation	0
is	0
thought	0
to	0
be	0
involved	0
in	0
SMX	0
hypersensitivity	0
.	0

We	0
have	0
therefore	0
examined	0
the	0
cellular	0
metabolism	0
,	0
disposition	0
and	0
conjugation	0
of	0
SMX	0
and	0
its	0
metabolites	0
in	0
vitro	0
.	0

2.	0
Flow	0
cytometry	0
revealed	0
binding	0
of	0
N-hydroxy	0
(	0
SMX-NHOH	0
)	0
and	0
nitroso	0
(	0
SMX-NO	0
)	0
metabolites	0
of	0
SMX	0
,	0
but	0
not	0
of	0
SMX	0
itself	0
,	0
to	0
the	0
surface	0
of	0
viable	0
white	7
blood	8
cells	8
.	0

Cellular	0
haptenation	0
by	0
SMX-NO	0
was	0
reduced	0
by	0
exogenous	0
glutathione	0
(	0
GSH	0
)	0
.	0

3.	0
SMX-NHOH	0
and	0
SMX-NO	0
were	0
rapidly	0
reduced	0
back	0
to	0
the	0
parent	0
compound	0
by	0
cysteine	0
(	0
CYS	0
)	0
,	0
GSH	0
,	0
human	7
peripheral	8
blood	8
cells	8
and	0
plasma	0
,	0
suggesting	0
that	0
this	0
is	0
an	0
important	0
and	0
ubiquitous	9
bioinactivation	0
mechanism	0
.	0

4.	0
Fluorescence	0
HPLC	0
showed	0
that	0
SMX-NHOH	0
and	0
SMX-NO	0
depleted	0
CYS	0
and	0
GSH	0
in	0
buffer	0
,	0
and	0
to	0
a	0
lesser	0
extent	0
,	0
in	0
cells	0
and	0
plasma	0
.	0

5.	0
Neutrophil	0
apoptosis	0
and	0
inhibition	0
of	0
neutrophil	0
function	0
were	0
induced	0
at	0
lower	0
concentrations	0
of	0
SMX-NHOH	0
and	0
SMX-NO	0
than	0
those	0
inducing	0
loss	0
of	0
membrane	0
viability	0
,	0
with	0
SMX	0
having	0
no	0
effect	0
.	0

Lymphocytes	7
were	0
significantly	0
(	0
P	0
<	0
0.05	0
)	0
more	0
sensitive	0
to	0
the	0
direct	0
cytotoxic	0
effects	0
of	0
SMX-NO	0
than	0
neutrophils	7
.	0

6.	0
Partitioning	0
of	0
SMX-NHOH	0
into	0
red	7
blood	8
cells	8
was	0
significantly	0
(	0
P	0
<	0
0.05	0
)	0
lower	0
than	0
with	0
the	0
hydroxylamine	0
of	0
dapsone	0
.	0

7.	0
Our	0
results	0
suggest	0
that	0
the	0
balance	0
between	0
oxidation	0
of	0
SMX	0
to	0
its	0
toxic	0
metabolites	0
and	0
their	0
reduction	0
is	0
an	0
important	0
protective	0
cellular	0
mechanism	0
.	0

If	0
an	0
imbalance	0
exists	0
,	0
haptenation	0
of	0
the	0
toxic	0
metabolites	0
to	0
bodily	0
proteins	0
including	0
the	0
surface	0
of	0
viable	0
cells	0
can	0
occur	0
,	0
and	0
may	0
result	0
in	0
drug	0
hypersensitivity	0
.	0

Bcl-6	9
expression	0
in	0
reactive	0
follicular	0
hyperplasia	0
,	0
follicular	0
lymphoma	0
,	0
and	0
angioimmunoblastic	0
T-cell	0
lymphoma	0
with	0
hyperplastic	0
germinal	0
centers	0
:	0
heterogeneity	0
of	0
intrafollicular	7
T-cells	8
and	0
their	0
altered	0
distribution	0
in	0
the	0
pathogenesis	0
of	0
angioimmunoblastic	0
T-cell	0
lymphoma	0
.	0

BACKGROUND	0
:	0
The	0
Bcl-6	9
gene	10
product	10
,	0
a	0
nuclear	9
phosphoprotein	10
,	0
is	0
expressed	0
independently	0
of	0
Bcl-6	9
gene	0
rearrangement	0
.	0

In	0
lymph	0
nodes	0
,	0
expression	0
of	0
Bcl-6	9
protein	0
is	0
restricted	0
to	0
germinal	7
center	8
(	8
GC	8
)	8
B-cells	8
and	0
10	0
%	0
to	0
15	0
%	0
of	0
CD3/CD4+	7
intrafollicular	8
T	8
cells	8
.	0

Interfollicular	0
cells	0
are	0
negative	0
for	0
Bcl-6	9
protein	10
,	0
except	0
for	0
rare	0
CD3+/CD4+	7
T	8
cells	8
.	0

Recently	0
,	0
we	0
reported	0
cases	0
of	0
angioimmunoblastic	0
T-cell	0
lymphoma	0
(	0
AITL	0
)	0
with	0
hyperplastic	0
GCs	0
(	0
AITL/GC	0
)	0
,	0
and	0
observed	0
that	0
borders	0
of	0
enlarged	0
GCs	0
were	0
ill	0
defined	0
,	0
with	0
features	0
suggestive	0
of	0
an	0
outward	0
migration	0
of	0
GC	7
cells	8
to	0
surrounding	0
interfollicular	0
zones	0
.	0

This	0
prompted	0
a	0
study	0
of	0
follicular	0
borders	0
with	0
Bcl-6	9
staining	0
in	0
reactive	0
follicular	0
hyperplasias	0
and	0
follicular	0
lymphomas	0
to	0
compare	0
with	0
AITL/GC	0
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
Formalin-fixed	0
paraffin	0
sections	0
were	0
used	0
for	0
immunostaining	0
of	0
Bcl-6	9
.	0

Six	0
cases	0
of	0
AITL/GC	0
,	0
12	0
nonspecific	0
reactive	0
follicular	0
hyperplasia	0
(	0
FH	0
)	0
,	0
7	0
HIV	0
adenopathy	0
,	0
10	0
follicular	0
lymphoma	0
(	0
FL	0
)	0
,	0
and	0
8	0
typical	0
AITL	0
(	0
ie	0
,	0
AITL	0
without	0
GC	0
)	0
were	0
studied	0
.	0

Double	0
staining	0
for	0
Bcl-6/CD20	9
,	0
Bcl-6/CD3	9
,	0
and	0
Bcl-6/CD57	9
was	0
performed	0
in	0
selected	0
cases	0
.	0

RESULTS	0
:	0
In	0
FH	0
and	0
HIV	0
adenopathy	0
,	0
staining	0
for	0
Bcl-6	9
revealed	0
densely	0
populated	0
GCs	0
with	0
well-defined	0
and	0
regular	0
GC	0
borders	0
,	0
whereas	0
Bcl-6+	7
cells	8
were	0
rare	0
in	0
the	0
interfollicular	0
areas	0
.	0

An	0
occasional	0
GC	0
with	0
an	0
ill-defined	0
border	0
was	0
invariably	0
surrounded	0
by	0
a	0
broad	0
mantle	0
zone	0
;	0
those	0
with	0
indistinct	0
mantle	0
zones	0
had	0
well-defined	0
,	0
regular	0
borders	0
.	0

In	0
FL	0
,	0
follicles	0
were	0
densely	0
populated	0
,	0
and	0
their	0
borders	0
were	0
irregular	0
,	0
with	0
some	0
Bcl-6+	7
cells	8
in	0
the	0
interfollicular	0
zones	0
.	0

In	0
AITL/GC	0
,	0
GCs	0
were	0
less	0
dense	0
,	0
GC	0
borders	0
were	0
ill	0
defined	0
and	0
irregular	0
,	0
and	0
the	0
number	0
of	0
interfollicular	7
Bcl-6+	8
cells	8
was	0
markedly	0
increased	0
.	0

Double	0
staining	0
revealed	0
that	0
these	0
interfollicular	7
Bcl-6+	8
cells	8
in	0
AITL/GC	0
were	0
Bcl6+/CD3+/CD20-/CD57-	7
T	8
cells	8
.	0

Moreover	0
,	0
CD3+	7
intrafollicular	8
T	8
cells	8
were	0
depleted	0
in	0
AITL/GC	0
,	0
whereas	0
they	0
were	0
abundant	0
in	0
FH	0
.	0

Intrafollicular	0
CD57+	7
cells	8
did	0
not	0
stain	0
for	0
Bcl-6	9
,	0
and	0
were	0
also	0
depleted	0
in	0
AITL/GC	0
.	0

In	0
typical	0
AITL	0
,	0
some	0
neoplastic	0
cells	0
were	0
positive	0
for	0
Bcl-6	9
,	0
showing	0
variable	0
degrees	0
of	0
staining	0
.	0

CONCLUSIONS	0
:	0
(	0
1	0
)	0
GCs	0
of	0
AITL/GC	0
differed	0
from	0
those	0
of	0
other	0
reactive	0
follicular	0
hyperplasias	0
and	0
follicular	0
lymphomas	0
,	0
and	0
staining	0
for	0
Bcl-6	9
was	0
useful	0
to	0
discern	0
them	0
.	0

(	0
2	0
)	0
Intrafollicular	7
CD3+	8
T	8
cells	8
,	0
many	0
of	0
which	0
were	0
also	0
positive	0
for	0
Bcl-6	9
,	0
were	0
markedly	0
depleted	0
in	0
AITL/GC	0
,	0
with	0
increased	0
interfollicular	0
Bcl-6+/CD3+	7
cells	8
,	0
suggesting	0
an	0
outward	0
migration	0
of	0
intrafollicular	7
T	8
cells	8
in	0
this	0
condition	0
.	0

(	0
3	0
)	0
Interfollicular	7
Bcl-6+/CD3+	8
cells	8
in	0
AITL/GC	0
were	0
too	0
numerous	0
to	0
be	0
accounted	0
for	0
by	0
migration	0
alone	0
,	0
suggesting	0
local	0
proliferation	0
.	0

(	0
4	0
)	0
Intrafollicular	7
CD57+	8
cells	8
were	0
negative	0
for	0
Bcl-6	9
,	0
indicating	0
heterogeneity	0
of	0
the	0
intrafollicular	7
T-cell	8
population	8
.	0

(	0
5	0
)	0
Some	0
neoplastic	0
cells	0
in	0
AITL	0
stained	0
for	0
Bcl-6	9
,	0
suggesting	0
up-regulation	0
of	0
Bcl-6	9
expression	0
in	0
this	0
tumor	0
.	0

Human	0
cytomegalovirus	0
binding	0
to	0
human	7
monocytes	8
induces	0
immunoregulatory	0
gene	0
expression	0
.	0

To	0
continue	0
our	0
investigation	0
of	0
the	0
cellular	0
events	0
that	0
occur	0
following	0
human	0
CMV	0
(	0
HCMV	0
)	0
infection	0
,	0
we	0
focused	0
on	0
the	0
regulation	0
of	0
cellular	0
activation	0
following	0
viral	0
binding	0
to	0
human	7
monocytes	8
.	0

First	0
,	0
we	0
showed	0
that	0
viral	0
binding	0
induced	0
a	0
number	0
of	0
immunoregulatory	7
genes	8
(	0
IL-1beta	9
,	0
A20	9
,	0
NF-kappaB-p105/p50	9
,	0
and	0
IkappaBalpha	9
)	0
in	0
unactivated	0
monocytes	7
and	0
that	0
neutralizing	9
Abs	10
to	0
the	0
major	0
HCMV	9
glycoproteins	10
,	0
gB	9
(	0
UL55	9
)	0
and	0
gH	9
(	0
UL75	9
)	0
,	0
inhibited	0
the	0
induction	0
of	0
these	0
genes	0
.	0

Next	0
,	0
we	0
demonstrated	0
that	0
these	0
viral	0
ligands	0
directly	0
up-regulated	0
monocyte	0
gene	0
expression	0
upon	0
their	0
binding	0
to	0
their	0
appropriate	0
cellular	0
receptors	0
.	0

We	0
then	0
investigated	0
if	0
HCMV	0
binding	0
also	0
resulted	0
in	0
the	0
translation	0
and	0
secretion	0
of	0
cytokines	9
.	0

Our	0
results	0
showed	0
that	0
HCMV	0
binding	0
to	0
monocytes	7
resulted	0
in	0
the	0
production	0
and	0
release	0
of	0
IL-1beta	9
protein	10
.	0

Because	0
these	0
induced	0
gene	0
products	0
have	0
NF-kappaB	1
sites	2
in	0
their	0
promoter	1
regions	2
,	0
we	0
next	0
examined	0
whether	0
there	0
was	0
an	0
up-regulation	0
of	0
nuclear	0
NF-kappaB	9
levels	0
.	0

These	0
experiments	0
showed	0
that	0
,	0
in	0
fact	0
,	0
NF-kappaB	9
was	0
translocated	0
to	0
the	0
nucleus	0
following	0
viral	0
binding	0
or	0
purified	0
viral	0
ligand	0
binding	0
.	0

Changes	0
in	0
IkappaBalpha	9
levels	0
correlated	0
with	0
the	0
changes	0
in	0
NF-kappaB	9
translocation	0
.	0

Lastly	0
,	0
we	0
demonstrated	0
that	0
p38	9
kinase	0
activity	0
played	0
a	0
central	0
role	0
in	0
IL-1beta	9
production	0
and	0
that	0
it	0
was	0
rapidly	0
up-regulated	0
following	0
infection	0
.	0

These	0
results	0
support	0
our	0
hypothesis	0
that	0
HCMV	0
initiates	0
a	0
signal	0
transduction	0
pathway	0
that	0
leads	0
to	0
monocyte	0
activation	0
and	0
pinpoints	0
a	0
potential	0
mechanism	0
whereby	0
HCMV	0
infection	0
of	0
monocytes	7
can	0
result	0
in	0
profound	0
pathogenesis	0
,	0
especially	0
in	0
chronic	0
inflammatory-type	0
conditions	0
.	0

Regulation	0
of	0
the	0
megakaryocytic	1
glycoprotein	2
IX	2
promoter	2
by	0
the	0
oncogenic	9
Ets	10
transcription	10
factor	10
Fli-1	9
.	0

Glycoprotein	9
(	10
GP	10
)	10
IX	10
is	0
a	0
subunit	0
of	0
the	0
von	9
Willebrand	10
receptor	10
,	0
GPIb-V-IX	9
,	0
which	0
mediates	0
adhesion	0
of	0
platelets	7
to	0
the	0
subendothelium	0
of	0
damaged	0
blood	0
vessels	0
.	0

Previous	0
characterization	0
of	0
the	0
GPIX	1
promoter	2
identified	0
a	0
functional	0
Ets	0
site	0
that	0
,	0
when	0
disrupted	0
,	0
reduced	0
promoter	0
activity	0
.	0

However	0
,	0
the	0
Ets	9
protein	10
(	0
s	0
)	0
that	0
regulated	0
GPIX	1
promoter	2
expression	0
was	0
unknown	0
.	0

In	0
this	0
study	0
,	0
transient	0
cotransfection	0
of	0
several	0
GPIX	1
promoter/reporter	2
constructs	2
into	0
293T	5
kidney	6
fibroblasts	6
with	0
a	0
Fli-1	1
expression	2
vector	2
shows	0
that	0
the	0
oncogenic	0
protein	0
Fli-1	9
can	0
transactivate	0
the	0
GPIX	1
promoter	2
when	0
an	0
intact	0
GPIX	1
Ets	2
site	2
is	0
present	0
.	0

In	0
addition	0
,	0
Fli-1	9
binding	0
of	0
the	0
GPIX	1
Ets	2
site	2
was	0
identified	0
in	0
antibody	0
supershift	0
experiments	0
in	0
nuclear	0
extracts	0
derived	0
from	0
hematopoietic	7
human	8
erythroleukemia	8
cells	8
.	0

Comparative	0
studies	0
showed	0
that	0
Fli-1	9
was	0
also	0
able	0
to	0
transactivate	0
the	0
GPIbalpha	1
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
the	0
GPIIb	1
promoter	2
.	0

Immunoblot	0
analysis	0
identified	0
Fli-1	9
protein	10
in	0
lysates	0
derived	0
from	0
platelets	7
.	0

In	0
addition	0
,	0
expression	0
of	0
Fli-1	9
was	0
identified	0
immunohistochemically	0
in	0
megakaryocytes	7
derived	0
from	0
CD34	7
(	8
+	8
)	8
cells	8
treated	0
with	0
the	0
megakaryocyte	9
differentiation	10
and	10
proliferation	10
factor	10
,	0
thrombopoietin	9
.	0

These	0
results	0
suggest	0
that	0
Fli-1	9
is	0
likely	0
to	0
regulate	0
lineage-specific	1
genes	2
during	0
megakaryocytopoiesis	0
.	0

Expression	0
of	0
IkappaBalpha	9
in	0
the	0
nucleus	0
of	0
human	7
peripheral	8
blood	8
T	8
lymphocytes	8
.	0

According	0
to	0
current	0
models	0
the	0
inhibitory	0
capacity	0
of	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
would	0
be	0
mediated	0
through	0
the	0
retention	0
of	0
Rel/NF-kappaB	9
proteins	10
in	0
the	0
cytosol	7
.	0

However	0
,	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
has	0
also	0
been	0
detected	0
in	0
the	0
nucleus	0
of	0
cell	0
lines	0
and	0
when	0
overexpressed	0
by	0
transient	0
transfection	0
.	0

To	0
gain	0
better	0
insight	0
into	0
the	0
potential	0
role	0
of	0
nuclear	9
I	10
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
in	0
a	0
physiological	0
context	0
we	0
have	0
analysed	0
its	0
presence	0
in	0
the	0
nucleus	0
of	0
human	7
peripheral	8
blood	8
T	8
lymphocytes	8
(	0
PBL	7
)	0
.	0

We	0
demonstrate	0
the	0
nuclear	0
localization	0
of	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
in	0
PBL	7
by	0
different	0
techniques	0
:	0
Western	0
blot	0
,	0
indirect	0
immunofluorescence	0
and	0
electron	0
microscopy	0
.	0

Low	0
levels	0
of	0
nuclear	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
were	0
detected	0
in	0
resting	0
cells	0
whereas	0
a	0
superinduction	0
was	0
obtained	0
after	0
PMA	0
activation	0
.	0

The	0
nuclear	0
pool	0
of	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
showed	0
a	0
higher	0
stability	0
than	0
cytosolic	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
and	0
was	0
partially	0
independent	0
of	0
the	0
resynthesis	0
of	0
the	0
protein	0
.	0

Unexpectedly	0
,	0
the	0
presence	0
of	0
nuclear	9
I	10
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
did	0
not	0
inhibit	0
NF-kappaB	9
binding	0
to	0
DNA	0
and	0
this	0
phenomenon	0
was	0
not	0
due	0
to	0
the	0
presence	0
of	0
IkappaBbeta	9
at	0
the	0
nuclear	0
level	0
.	0

Immunoprecipitation	0
experiments	0
failed	0
to	0
demonstrate	0
an	0
association	0
between	0
nuclear	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
and	0
NF-kappaB	9
proteins	0
.	0

Our	0
results	0
demonstrate	0
that	0
in	0
resting	0
and	0
PMA-activated	7
human	8
PBL	8
,	0
I	9
(	10
kappa	10
)	10
B	10
(	10
alpha	10
)	10
is	0
present	0
in	0
the	0
nucleus	0
in	0
an	0
apparently	0
inactive	0
form	0
unable	0
to	0
disrupt	0
NF-kappaB	9
binding	0
from	0
DNA	0
.	0

Impaired	0
fetal	7
thymocyte	8
development	0
after	0
efficient	0
adenovirus-mediated	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
.	0

We	0
introduce	0
a	0
new	0
experimental	0
system	0
combining	0
adenovirus-mediated	0
gene	0
transfer	0
and	0
fetal	0
thymic	0
organ	0
culture	0
(	0
FTOC	0
)	0
.	0

This	0
system	0
allowed	0
us	0
to	0
efficiently	0
express	0
in	0
developing	0
thymocytes	0
a	0
mutant	0
form	0
of	0
the	0
NF-kappa	9
B	10
inhibitor	0
I	9
kappa	10
B	10
alpha	10
(	0
mut-I	9
kappa	10
B	10
)	0
and	0
to	0
study	0
the	0
maturation	0
defects	0
occurring	0
when	0
NF-kappa	9
B	10
activation	0
is	0
inhibited	0
during	0
fetal	0
development	0
.	0

Fetal	7
thymocytes	8
infected	0
with	0
adenovirus	0
containing	0
mut-I	9
kappa	10
B	10
were	0
found	0
to	0
develop	0
normally	0
until	0
the	0
CD44	9
-CD25+	0
,	0
CD4	9
-	0
CD8	9
-	0
double-negative	0
stage	0
,	0
while	0
production	0
of	0
more	0
mature	0
double-positive	0
and	0
single-positive	0
populations	0
was	0
strongly	0
decreased	0
.	0

Proliferation	0
,	0
as	0
measured	0
by	0
the	0
percentage	0
of	0
cells	0
in	0
cycle	0
appeared	0
normal	0
,	0
as	0
did	0
rearrangement	0
and	0
expression	0
of	0
the	0
TCR	9
beta-chain	10
.	0

However	0
,	0
apoptosis	0
was	0
much	0
higher	0
in	0
FTOC	0
infected	0
with	0
adenovirus	0
containing	0
mut-I	9
kappa	10
B	10
than	0
in	0
FTOC	0
infected	0
with	0
a	0
control	0
virus	0
.	0

Taken	0
together	0
,	0
these	0
results	0
suggest	0
that	0
NF-kappa	9
B	10
plays	0
a	0
crucial	0
role	0
in	0
ensuring	0
the	0
differentiation	0
and	0
survival	0
of	0
thymocytes	7
in	0
the	0
early	0
stages	0
of	0
their	0
development	0
.	0

The	0
relationship	0
between	0
Ca2+-ATPase	9
and	0
freely	0
exchangeable	0
Ca2+	0
in	0
the	0
dense	0
tubules	0
:	0
a	0
study	0
in	0
platelets	7
from	0
women	0
.	0

The	0
main	0
aims	0
of	0
this	0
work	0
were	0
to	0
examine	0
in	0
women	0
:	0
the	0
relationship	0
between	0
the	0
freely	0
exchangeable	0
Ca2+	0
(	0
FECa2+	0
)	0
in	0
the	0
dense	0
tubules	0
and	0
the	0
activity	0
of	0
the	0
sarco	9
(	10
endo	10
)	10
plasmic	10
reticulum	10
(	10
SER	10
)	10
Ca2+-ATPase	10
(	10
SERCA	10
)	10
in	0
platelets	7
,	0
and	0
the	0
relationship	0
of	0
these	0
parameters	0
with	0
blood	0
pressure	0
and	0
serum	9
lipoproteins	10
.	0

Platelets	0
from	0
14	0
white	0
and	0
13	0
black	0
women	0
in	0
good	0
health	0
were	0
studied	0
.	0

The	0
FECa2+	0
was	0
measured	0
as	0
the	0
ionomycin-evoked	0
Ca2+	0
release	0
(	0
in	0
the	0
presence	0
of	0
thapsigargin	0
)	0
in	0
Ca2+-free	0
medium	0
.	0

SERCA	9
activity	0
was	0
measured	0
as	0
the	0
thapsigargin	0
sensitive	0
,	0
Ca2+	0
dependent	0
and	0
ouabain	0
resistant	0
,	0
ATP	0
hydrolyses	0
in	0
platelet	0
membranes	0
.	0

Relative	0
expressions	0
of	0
SERCA	9
2	0
and	0
3	0
isoforms	0
and	0
Ras-related	9
protein	10
(	10
Rap	10
)	10
1	10
in	0
platelet	0
membranes	0
were	0
determined	0
by	0
Western	0
immunoblots	0
.	0

Highly	0
significant	0
correlations	0
were	0
observed	0
for	0
FECa2+	0
in	0
the	0
dense	0
tubules	0
with	0
:	0
1	0
)	0
the	0
maximal	0
reaction	0
velocity	0
(	0
Vmax	0
)	0
of	0
the	0
SERCA	9
(	0
r	0
=	0
0.592	0
,	0
P	0
=	0
.0014	0
)	0
,	0
and	0
2	0
)	0
Rapl	9
(	0
r	0
=	0
0.551	0
,	0
P	0
=	0
.0035	0
)	0
.	0

In	0
addition	0
,	0
negative	0
correlations	0
were	0
observed	0
between	0
FECa2+	0
in	0
the	0
dense	0
tubules	0
and	0
age	0
.	0

No	0
correlations	0
were	0
observed	0
for	0
these	0
variables	0
with	0
blood	0
pressure	0
or	0
serum	9
lipoproteins	10
.	0

We	0
conclude	0
the	0
FECa2+	0
and	0
the	0
Vmax	0
of	0
the	0
SERCA	9
are	0
reliable	0
indicators	0
of	0
Ca2+	0
load	0
in	0
platelets	7
from	0
women	0
.	0

However	0
,	0
in	0
women	0
,	0
unlike	0
previous	0
observations	0
in	0
men	0
,	0
these	0
platelet	0
parameters	0
are	0
not	0
correlated	0
with	0
blood	0
pressure	0
and	0
serum	9
lipoproteins	10
.	0

Cobalt	0
chloride-induced	0
signaling	0
in	0
endothelium	0
leading	0
to	0
the	0
augmented	0
adherence	0
of	0
sickle	7
red	8
blood	8
cells	8
and	0
transendothelial	0
migration	0
of	0
monocyte-like	5
HL-60	6
cells	6
is	0
blocked	0
by	0
PAF-receptor	0
antagonist	0
.	0

In	0
response	0
to	0
hypoxia	0
,	0
sickle	7
red	8
blood	8
cells	8
(	0
SS	7
RBC	8
)	0
and	0
leukocytes	7
exhibit	0
increased	0
adherence	0
to	0
the	0
vascular	0
endothelium	0
,	0
while	0
diapedesis	0
of	0
leukocytes	7
through	0
the	0
blood	0
vessel	0
increases	0
.	0

However	0
,	0
the	0
cellular	0
signaling	0
pathway	0
(	0
s	0
)	0
caused	0
by	0
hypoxia	0
is	0
poorly	0
understood	0
.	0

We	0
utilized	0
CoCl2	0
as	0
a	0
mimetic	0
molecule	0
for	0
hypoxia	0
to	0
study	0
cellular	0
signaling	0
pathways	0
.	0

We	0
found	0
that	0
in	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
(	0
HUVEC	7
)	0
,	0
CoCl2	0
at	0
2	0
mM	0
concentration	0
induced	0
the	0
surface	0
expression	0
of	0
a	0
subset	0
of	0
CAMs	9
(	0
VCAM-1	9
)	0
and	0
activation	0
of	0
transcription	9
factor	10
NF-kappaB	9
in	0
the	0
nuclear	0
extracts	0
of	0
HUVEC	7
.	0

Furthermore	0
,	0
CoCl2	0
also	0
caused	0
time-dependent	0
tyrosine	0
phosphorylation	0
of	0
mitogen-activated	9
protein	10
(	10
MAP	10
)	10
kinase	10
isoform	0
ERK2	9
without	0
significantly	0
affecting	0
ERK1	9
,	0
indicating	0
ERK2	9
is	0
the	0
preferred	0
substrate	0
for	0
upstream	9
kinase	10
of	0
the	0
MAPK	9
pathway	0
.	0

Inhibitors	0
of	0
MAP	9
kinase	10
(	0
PD98059	0
)	0
or	0
platelet-activating	0
factor	0
(	0
PAF	0
)	0
-	0
receptor	0
antagonist	0
(	0
CV3988	0
)	0
inhibited	0
the	0
CoCl2-induced	0
NF-kappaB	9
activation	0
and	0
VCAM-1	9
expression	0
.	0

Augmented	0
expression	0
of	0
VCAM-1	9
led	0
to	0
increased	0
SS	7
RBC	8
adhesion	0
,	0
inhibitable	0
by	0
a	0
VCAM-1	9
antibody	10
.	0

Additionally	0
,	0
CoCl2	0
caused	0
a	0
two-	0
to	0
threefold	0
increase	0
in	0
the	0
rate	0
of	0
transendothelial	0
migration	0
of	0
monocyte-like	5
HL-60	6
cells	6
and	0
a	0
twentyfold	0
increase	0
in	0
phosphorylation	0
of	0
platelet	9
endothelial	10
cell	10
adhesion	10
molecules	10
(	0
PECAM-1	9
)	0
.	0

The	0
transendothelial	0
migration	0
of	0
monocytes	7
was	0
inhibited	0
by	0
an	0
antibody	0
to	0
PECAM-1	9
.	0

Both	0
phosphorylation	0
of	0
PECAM-1	9
and	0
transendothelial	0
migration	0
of	0
monocytes	7
in	0
response	0
to	0
CoCl2	0
were	0
inhibited	0
by	0
protein	0
kinase	0
inhibitor	0
(	0
GF109203X	0
)	0
and	0
augmented	0
by	0
protein	0
phosphatase	0
inhibitor	0
(	0
Calyculin	0
A	0
)	0
.	0

Our	0
data	0
suggests	0
that	0
CoCl2-induced	0
cellular	0
signals	0
directing	0
increased	0
expression	0
of	0
VCAM-1	9
in	0
HUVEC	7
involve	0
downstream	0
activation	0
of	0
MAP	9
kinase	10
and	0
NF-kappaB	9
,	0
while	0
the	0
phosphorylation	0
of	0
PECAM-1	9
occurs	0
as	0
a	0
result	0
of	0
activation	0
of	0
PKC	9
.	0

We	0
conclude	0
that	0
PAF-receptor	0
antagonist	0
inhibits	0
the	0
CoCl2	0
-or	0
hypoxia-induced	0
increase	0
in	0
the	0
adhesion	0
of	0
SS	7
RBC	8
,	0
PECAM-1	9
phosphorylation	0
,	0
and	0
the	0
concomitant	0
transendothelial	0
migration	0
of	0
monocytes	7
.	0

Bacterial	0
lipopolysaccharide	0
activates	0
nuclear	9
factor-kappaB	10
through	0
interleukin-1	9
signaling	10
mediators	10
in	0
cultured	5
human	6
dermal	6
endothelial	6
cells	6
and	0
mononuclear	7
phagocytes	8
.	0

Bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-mediated	0
immune	0
responses	0
,	0
including	0
activation	0
of	0
monocytes	7
,	0
macrophages	7
,	0
and	0
endothelial	7
cells	8
,	0
play	0
an	0
important	0
role	0
in	0
the	0
pathogenesis	0
of	0
Gram-negative	0
bacteria-induced	0
sepsis	0
syndrome	0
.	0

Activation	0
of	0
NF-kappaB	9
is	0
thought	0
to	0
be	0
required	0
for	0
cytokine	0
release	0
from	0
LPS-responsive	7
cells	8
,	0
a	0
critical	0
step	0
for	0
endotoxic	0
effects	0
.	0

Here	0
we	0
investigated	0
the	0
role	0
and	0
involvement	0
of	0
interleukin-1	9
(	0
IL-1	9
)	0
and	0
tumor	9
necrosis	10
factor	10
(	0
TNF-alpha	9
)	0
signal	9
transducer	10
molecules	10
in	0
LPS	0
signaling	0
in	0
human	7
dermal	8
microvessel	8
endothelial	8
cells	8
(	0
HDMEC	7
)	0
and	0
THP-1	5
monocytic	6
cells	6
.	0

LPS	0
stimulation	0
of	0
HDMEC	7
and	0
THP-1	5
cells	6
initiated	0
an	0
IL-1	9
receptor	10
-like	0
NF-kappaB	9
signaling	0
cascade	0
.	0

In	0
transient	0
cotransfection	0
experiments	0
,	0
dominant	0
negative	0
mutants	0
of	0
the	0
IL-1	9
signaling	0
pathway	0
,	0
including	0
MyD88	9
,	0
IRAK	9
,	0
IRAK2	9
,	0
and	0
TRAF6	9
inhibited	0
both	0
IL-1	9
-and	0
LPS-induced	0
NF-kappaB	9
-luciferase	9
activity	0
.	0

LPS-induced	0
NF-kappaB	9
activation	0
was	0
not	0
inhibited	0
by	0
a	0
dominant	0
negative	0
mutant	0
of	0
TRAF2	9
that	0
is	0
involved	0
in	0
TNF	9
signaling	0
.	0

LPS-induced	0
activation	0
of	0
NF-kappaB-responsive	1
reporter	2
gene	2
was	0
not	0
inhibited	0
by	0
IL-1	9
receptor	0
antagonist	0
.	0

TLR2	9
and	0
TLR4	9
were	0
expressed	0
on	0
the	0
cell	0
surface	0
of	0
HDMEC	7
and	0
THP-1	5
cells	6
.	0

These	0
findings	0
suggest	0
that	0
a	0
signal	9
transduction	10
molecule	10
in	0
the	0
LPS	0
receptor	0
complex	0
may	0
belong	0
to	0
the	0
IL-1	9
receptor/toll-like	0
receptor	0
(	0
TLR	0
)	0
super	0
family	0
,	0
and	0
the	0
LPS	0
signaling	0
cascade	0
uses	0
an	0
analogous	0
molecular	0
framework	0
for	0
signaling	0
as	0
IL-1	9
in	0
mononuclear	7
phagocytes	8
and	0
endothelial	7
cells	8
.	0

Signal	0
transduction	0
through	0
interferon-gamma	9
receptor	10
on	0
human	7
eosinophils	8
.	0

BACKGROUND	0
:	0
We	0
reported	0
on	0
the	0
constitutive	0
interferon-gamma	9
receptor	10
(	0
IFN-gammaR	9
)	0
expression	0
on	0
eosinophils	7
.	0

But	0
signal	0
transduction	0
through	0
IFN-gammaR	9
on	0
eosinophils	7
remains	0
to	0
be	0
elucidated	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
involvement	0
of	0
the	0
Jak/Stat	9
pathway	0
in	0
the	0
signaling	0
of	0
eosinophils	7
after	0
IFN-gammaR	9
conjugation	0
by	0
the	0
ligand	0
binding	0
.	0

METHODS	0
:	0
Purified	7
peripheral	8
eosinophils	8
were	0
stimulated	0
with	0
IFN-gamma	9
at	0
37	0
degrees	0
C	0
for	0
1-60	0
min	0
.	0

Tyrosine	0
phosphorylation	0
of	0
IFN-gammaR	9
,	0
Jak1	9
,	0
Jak2	9
,	0
and	0
Stat1alpha	9
was	0
examined	0
by	0
immunoblotting	0
.	0

Gel-shift	0
assay	0
was	0
also	0
examined	0
to	0
show	0
the	0
formation	0
of	0
Stat1alpha-DNA	9
complexes	10
.	0

RESULTS	0
:	0
We	0
show	0
that	0
binding	0
of	0
IFN-gamma	9
to	0
human	7
eosinophils	8
initiated	0
a	0
series	0
of	0
events	0
that	0
resulted	0
in	0
the	0
rapid	0
tyrosine	0
phosphorylation	0
of	0
not	0
only	0
the	0
IFN-gammaRalpha	9
chain	10
but	0
also	0
Jak1	9
,	0
Jak2	9
,	0
and	0
Stat1alpha	9
.	0

In	0
addition	0
,	0
IFN-gamma	9
enhanced	0
the	0
DNA-binding	0
activity	0
of	0
Stat1alpha	9
.	0

CONCLUSION	0
:	0
These	0
data	0
indicate	0
that	0
IFN-gamma	9
affects	0
eosinophils	7
through	0
its	0
specific	0
receptor	0
and	0
utilizes	0
the	0
Jak/Stat	9
pathway	0
as	0
its	0
mode	0
of	0
signaling	0
.	0

Expression	0
of	0
E2A-HLF	9
chimeric	10
protein	10
induced	0
T-cell	0
apoptosis	0
,	0
B-cell	0
maturation	0
arrest	0
,	0
and	0
development	0
of	0
acute	0
lymphoblastic	0
leukemia	0
.	0

The	0
E2A-HLF	1
fusion	2
gene	2
,	0
generated	0
by	0
t	1
(	2
17	2
;	2
19	2
)	2
(	2
q22	2
;	2
p13	2
)	2
in	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
,	0
encodes	0
a	0
chimeric	9
transcription	10
factor	10
in	0
which	0
the	0
trans-activating	9
domains	10
of	0
E2A	9
are	0
fused	0
to	0
the	0
DNA-	9
binding	10
and	10
dimerization	10
domains	10
of	0
hepatic	9
leukemic	10
factor	10
(	0
HLF	9
)	0
.	0

To	0
investigate	0
its	0
biological	0
role	0
,	0
we	0
generated	0
transgenic	0
mice	0
expressing	0
E2A-HLF	9
using	0
Ig	1
enhancer	2
and	2
promoter	2
,	0
which	0
direct	0
transgene	0
expression	0
in	0
cells	0
committed	0
to	0
the	0
lymphoid	0
lineage	0
.	0

The	0
transgenic	0
mice	0
exhibited	0
abnormal	0
development	0
in	0
the	0
thymus	0
and	0
spleen	0
and	0
were	0
susceptible	0
to	0
infection	0
.	0

The	0
thymus	0
contained	0
small	0
numbers	0
of	0
thymocytes	7
,	0
and	0
TUNEL	0
staining	0
showed	0
that	0
higher	0
population	0
of	0
thymocytes	7
were	0
undergoing	0
apoptosis	0
.	0

The	0
spleen	0
exhibited	0
a	0
marked	0
reduction	0
in	0
splenic	7
lymphocytes	8
and	0
the	0
flow	0
cytometric	0
analyses	0
and	0
the	0
in	0
vitro	0
colony	0
formation	0
assays	0
showed	0
that	0
the	0
B-cell	0
maturation	0
was	0
blocked	0
at	0
a	0
very	0
early	0
developmental	0
stage	0
.	0

These	0
findings	0
indicated	0
that	0
the	0
expression	0
of	0
E2A-HLF	9
induced	0
T-cell	0
apoptosis	0
and	0
B-cell	0
maturation	0
arrest	0
in	0
vivo	0
and	0
that	0
the	0
susceptibility	0
of	0
the	0
transgenic	0
mice	0
to	0
infection	0
was	0
due	0
to	0
immunodeficiency	0
.	0

Moreover	0
,	0
several	0
transgenic	0
mice	0
developed	0
acute	0
leukemia	0
,	0
classified	0
as	0
T-ALL	0
based	0
on	0
the	0
surface	0
marker	0
analysis	0
and	0
DNA	0
rearrangements	0
,	0
suggesting	0
that	0
an	0
additional	0
event	0
is	0
required	0
for	0
malignant	0
transformation	0
of	0
lymphoid	7
cells	8
expressing	0
E2A-HLF	9
.	0

Our	0
findings	0
provide	0
insight	0
into	0
the	0
biological	0
function	0
of	0
E2A-HLF	9
in	0
lymphoid	0
development	0
and	0
also	0
its	0
role	0
in	0
leukemogenesis	0
.	0

Retinoid	9
X	10
receptor	10
(	0
RXR	9
)	0
agonist-induced	0
activation	0
of	0
dominant-negative	0
RXR	9
-retinoic	0
acid	0
receptor	0
alpha403	0
heterodimers	0
is	0
developmentally	0
regulated	0
during	0
myeloid	0
differentiation	0
.	0

The	0
multiple	0
biologic	0
activities	0
of	0
retinoic	0
acid	0
(	0
RA	0
)	0
are	0
mediated	0
through	0
RAR	9
and	0
retinoid	9
X	10
receptor	10
(	10
RXR	10
)	10
nuclear	10
receptors	10
that	0
interact	0
with	0
specific	0
DNA	1
target	2
sequences	2
as	0
heterodimers	9
(	0
RXR-RAR	9
)	0
or	0
homodimers	9
(	0
RXR-RXR	9
)	0
.	0

RA	0
receptor	0
activation	0
appears	0
critical	0
to	0
regulating	0
important	0
aspects	0
of	0
hematopoiesis	0
,	0
since	0
transducing	0
a	0
COOH-terminally	9
truncated	10
RARalpha	10
exhibiting	0
dominant-negative	0
activity	0
(	0
RARalpha403	9
)	0
into	0
normal	0
mouse	0
bone	0
marrow	0
generates	0
hematopoietic	5
growth	6
factor-dependent	6
cell	6
lines	6
frozen	0
at	0
the	0
multipotent	0
progenitor	0
(	0
EML	0
)	0
or	0
committed	0
promyelocyte	0
(	0
MPRO	0
)	0
stages	0
.	0

Nevertheless	0
,	0
relatively	0
high	0
,	0
pharmacological	0
concentrations	0
of	0
RA	0
(	0
1	0
to	0
10	0
&	0
mgr	0
;	0
M	0
)	0
overcome	0
these	0
differentiation	0
blocks	0
and	0
induce	0
terminal	0
granulocytic	0
differentiation	0
of	0
the	0
MPRO	7
promyelocytes	8
while	0
potentiating	0
interleukin-3	9
(	0
IL-3	9
)	0
-induced	0
commitment	0
of	0
EML	7
cells	8
to	0
the	0
granulocyte/monocyte	0
lineage	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
utilized	0
RXR	9
-and	0
RAR	9
-specific	0
agonists	0
and	0
antagonists	0
to	0
determine	0
how	0
RA	0
overcomes	0
the	0
dominant-negative	0
activity	0
of	0
the	0
truncated	9
RARalpha	10
in	0
these	0
different	0
myeloid	0
developmental	0
stages	0
.	0

Unexpectedly	0
,	0
we	0
observed	0
that	0
an	0
RXR	9
-specific	0
,	0
rather	0
than	0
an	0
RAR	9
-specific	0
,	0
agonist	0
induces	0
terminal	0
granulocytic	0
differentiation	0
of	0
MPRO	7
promyelocytes	8
,	0
and	0
this	0
differentiation	0
is	0
associated	0
with	0
activation	0
of	0
DNA	1
response	2
elements	2
corresponding	0
to	0
RAR-RXR	9
heterodimers	10
rather	0
than	0
RXR-RXR	9
homodimers	10
.	0

This	0
RXR	9
agonist	0
activity	0
is	0
blocked	0
by	0
RAR	9
-specific	0
antagonists	0
,	0
suggesting	0
extensive	0
cross-talk	0
between	0
the	0
partners	0
of	0
the	0
RXR	9
-RARalpha403	10
heterodimer	10
.	0

In	0
contrast	0
,	0
in	0
the	0
more	0
immature	0
,	0
multipotent	0
EML	7
cells	8
we	0
observed	0
that	0
this	0
RXR	9
-specific	0
agonist	0
is	0
inactive	0
either	0
in	0
potentiating	0
IL-3	9
-mediated	0
commitment	0
of	0
EML	7
cells	8
to	0
the	0
granulocyte	7
lineage	8
or	0
in	0
transactivating	0
RAR-RXR	1
response	2
elements	2
.	0

RA	0
-triggered	0
GALdbd-	0
RARalpha	9
hybrid	0
activity	0
in	0
these	0
cells	0
indicates	0
that	0
the	0
multipotent	0
EML	7
cells	8
harbor	0
substantial	0
nuclear	0
hormone	0
receptor	0
coactivator	9
activity	0
.	0

However	0
,	0
the	0
histone	9
deacetylase	10
(	10
HDAC	10
)	10
inhibitor	10
trichostatin	0
A	0
readily	0
activates	0
an	0
RXR-RAR	1
reporter	2
construct	2
in	0
the	0
multipotent	0
EML	7
cells	8
but	0
not	0
in	0
the	0
committed	0
MPRO	7
promyelocytes	8
,	0
indicating	0
that	0
differences	0
in	0
HDAC-containing	9
repressor	10
complexes	10
in	0
these	0
two	0
closely	0
related	0
but	0
distinct	0
hematopoietic	7
lineages	8
might	0
account	0
for	0
the	0
differential	0
activation	0
of	0
the	0
RXR-RARalpha403	9
heterodimers	10
that	0
we	0
observed	0
at	0
these	0
different	0
stages	0
of	0
myeloid	0
development	0
.	0

The	0
functional	0
synergy	0
between	0
IL-12	9
and	0
IL-2	9
involves	0
p38	9
mitogen-activated	10
protein	10
kinase	10
and	0
is	0
associated	0
with	0
the	0
augmentation	0
of	0
STAT	0
serine	0
phosphorylation	0
.	0

IL-12	9
and	0
IL-2	9
can	0
stimulate	0
mitogen-	7
or	8
CD3-activated	8
T	8
cells	8
to	0
proliferate	0
,	0
produce	0
IFN-gamma	9
,	0
and	0
kill	0
tumor	7
cells	8
.	0

The	0
magnitude	0
of	0
these	0
functional	0
responses	0
is	0
greatly	0
augmented	0
when	0
T	7
cells	8
are	0
activated	0
by	0
the	0
combination	0
of	0
IL-12	9
and	0
IL-2	9
.	0

Although	0
peripheral	0
blood	0
T	7
cells	8
are	0
largely	0
unresponsive	0
to	0
these	0
cytokines	9
without	0
prior	0
activation	0
,	0
a	0
small	0
subset	0
of	0
CD8+	7
T	8
cells	8
(	0
CD8+CD18bright	7
)	0
is	0
strongly	0
activated	0
by	0
the	0
combination	0
of	0
IL-12	9
and	0
IL-2	9
.	0

In	0
this	0
report	0
we	0
show	0
that	0
the	0
functional	0
synergy	0
between	0
IL-12	9
and	0
IL-2	9
in	0
CD8+CD18bright	7
T	8
cells	8
correlates	0
with	0
the	0
activation	0
of	0
the	0
stress	9
kinases	10
,	0
p38	9
mitogen-activated	10
protein	10
(	10
MAP	10
)	10
kinase	10
and	0
stress-activated	9
protein	10
kinase	10
(	10
SAPK	10
)	10
/Jun	10
N-terminal	10
kinase	10
,	0
but	0
not	0
with	0
the	0
activation	0
of	0
the	0
extracellular	9
signal-regulated	10
kinases	10
.	0

The	0
functional	0
synergy	0
between	0
IL-2	9
and	0
IL-12	9
is	0
also	0
associated	0
with	0
a	0
prominent	0
increase	0
in	0
STAT1	9
and	0
STAT3	9
serine	0
phosphorylation	0
over	0
that	0
observed	0
with	0
IL-12	9
or	0
IL-2	9
alone	0
.	0

By	0
contrast	0
,	0
STAT	9
tyrosine	0
phosphorylation	0
is	0
not	0
augmented	0
over	0
that	0
seen	0
with	0
either	0
cytokine	0
alone	0
.	0

A	0
specific	0
inhibitor	0
of	0
p38	0
MAP	0
kinase	0
completely	0
inhibits	0
the	0
serine	0
phosphorylation	0
of	0
STAT1	9
and	0
STAT3	9
induced	0
by	0
IL-12	9
and	0
IL-2	9
and	0
abrogates	0
the	0
functional	0
synergy	0
between	0
IL-12	9
and	0
IL-2	9
without	0
affecting	0
STAT	0
tyrosine	0
phosphorylation	0
.	0

This	0
suggests	0
that	0
p38	0
MAP	0
kinase	0
may	0
play	0
an	0
important	0
role	0
in	0
regulating	0
STAT	0
serine	0
phosphorylation	0
in	0
response	0
to	0
the	0
combination	0
of	0
IL-12	9
and	0
IL-2	9
.	0

Furthermore	0
,	0
these	0
findings	0
indicate	0
that	0
the	0
optimal	0
activation	0
of	0
T	7
cells	8
by	0
IL-12	9
and	0
IL-2	9
may	0
depend	0
on	0
an	0
interaction	0
between	0
the	0
p38	9
MAP	10
kinase	10
and	0
Janus	9
kinase/STAT	10
signaling	0
pathways	0
.	0

Activation	0
of	0
NF-kappaB	9
in	0
Mycobacterium	0
tuberculosis	0
-induced	0
interleukin-2	9
receptor	10
expression	0
in	0
mononuclear	7
phagocytes	8
.	0

Soluble	0
interleukin-2	9
receptor-alpha	10
(	0
IL-2Ralpha	9
)	0
has	0
been	0
reported	0
to	0
be	0
increased	0
in	0
the	0
sera	0
of	0
patients	0
with	0
advanced	0
tuberculosis	0
,	0
and	0
levels	0
decline	0
after	0
therapy	0
in	0
accordance	0
with	0
improvement	0
of	0
radiologic	0
findings	0
.	0

We	0
investigated	0
expression	0
of	0
the	0
IL-2Ralpha	9
in	0
bronchoalveolar	7
lavage	8
(	8
BAL	8
)	8
cells	8
in	0
active	0
pulmonary	0
tuberculosis	0
,	0
and	0
evaluated	0
the	0
mechanism	0
Mycobacterium	0
tuberculosis	0
induces	0
in	0
the	0
IL-2Ralpha	9
using	0
the	0
THP-1	5
mononuclear	6
phagocyte	6
cell	6
line	6
.	0

We	0
found	0
IL-2Ralpha	9
expression	0
to	0
be	0
increased	0
in	0
BAL	0
cells	0
from	0
involved	0
sites	0
of	0
active	0
pulmonary	0
tuberculosis	0
.	0

Expression	0
of	0
the	0
alpha-chain	9
of	0
IL-2Ralpha	9
on	0
peripheral	7
blood	8
monocytes	8
(	0
PBM	7
)	0
was	0
induced	0
by	0
M.	0
tuberculosis	0
by	0
flow	0
cytometry	0
evaluation	0
.	0

Northern	0
analysis	0
demonstrated	0
increased	0
IL-2Ralpha	9
gene	0
expression	0
after	0
stimulation	0
with	0
M.	0
tuberculosis	0
which	0
was	0
further	0
induced	0
by	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
.	0

The	0
IL-2Ralpha	1
promoter	2
containing	0
the	0
nuclear	1
factor	2
kappa	2
B	2
(	2
NF-kappaB	2
)	2
site	2
was	0
transcriptionally	0
induced	0
by	0
M.	0
tuberculosis	0
and	0
this	0
NF-kappaB	9
site	0
could	0
confer	0
inducibility	0
to	0
a	0
heterologous	1
herpes	2
thymidine	2
kinase	2
(	2
TK	2
)	2
promoter	2
by	0
M.	0
tuberculosis	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
revealed	0
specific	0
binding	0
of	0
nuclear	0
protein	0
to	0
the	0
NF-kappaB	1
site	2
upon	0
induction	0
with	0
M.	0
tuberculosis	0
.	0

Using	0
antibodies	0
against	0
the	0
p50	9
and	0
p65	9
subunits	10
of	0
NF-kappaB	9
in	0
EMSAs	0
,	0
the	0
involvement	0
of	0
both	0
p50	9
and	0
p65	9
proteins	10
was	0
further	0
demonstrated	0
.	0

Functional	0
expression	0
of	0
the	0
IL-2Ralpha	9
on	0
mononuclear	7
phagocytes	8
in	0
M.	0
tuberculosis	0
infection	0
may	0
play	0
an	0
important	0
immunomodulatory	0
role	0
in	0
the	0
host	0
response	0
.	0

Vitamin	9
D	10
receptor	10
3'-untranslated	1
region	2
polymorphisms	0
:	0
lack	0
of	0
effect	0
on	0
mRNA	0
stability	0
.	0

Allelic	0
variation	0
at	0
the	0
3'-end	0
of	0
the	0
vitamin	1
D	2
receptor	2
(	2
VDR	2
)	2
gene	2
has	0
been	0
associated	0
with	0
a	0
3-5-fold	0
increased	0
risk	0
of	0
developing	0
prostate	0
cancer	0
and	0
with	0
differences	0
in	0
bone	0
mineralization	0
.	0

This	0
genetic	0
diversity	0
does	0
not	0
alter	0
the	0
VDR	9
protein	10
structurally	0
,	0
but	0
instead	0
may	0
be	0
a	0
marker	0
(	0
s	0
)	0
of	0
other	0
,	0
nearby	0
polymorphisms	0
that	0
influence	0
message	0
stability	0
or	0
translation	0
.	0

The	0
work	0
reported	0
here	0
was	0
instigated	0
to	0
identify	0
additional	0
VDR	9
3'-UTR	1
polymorphisms	0
that	0
may	0
have	0
functional	0
significance	0
and	0
to	0
then	0
test	0
whether	0
these	0
genetic	0
variants	0
alter	0
message	0
stability	0
.	0

Initially	0
,	0
four	0
novel	0
,	0
frequently	0
occurring	0
sequence	1
variants	2
were	0
identified	0
that	0
associated	0
with	0
two	0
common	0
haplotypes	0
that	0
were	0
described	0
previously	0
.	0

These	0
common	0
sequence	0
variants	0
were	0
not	0
found	0
within	0
three	0
message-destabilizing	1
elements	2
that	0
we	0
mapped	0
within	0
the	0
3'-UTR	1
of	0
the	0
vitamin	3
D	4
receptor	4
mRNA	4
.	0

Furthermore	0
,	0
the	0
two	0
VDR	1
3'-UTR	2
haplotypes	0
conferred	0
an	0
identical	0
half-life	0
on	0
a	0
heterologous	1
beta-globin	2
reporter	2
gene	2
,	0
in	0
an	0
in	0
vitro	0
assay	0
.	0

We	0
therefore	0
conclude	0
that	0
common	0
polymorphisms	0
within	0
the	0
VDR	1
3'-UTR	2
do	0
not	0
influence	0
message	0
stability	0
.	0

IL-2	9
-mediated	0
cell	0
cycle	0
progression	0
and	0
inhibition	0
of	0
apoptosis	0
does	0
not	0
require	0
NF-kappa	9
B	10
or	0
activating	0
protein-1	0
activation	0
in	0
primary	0
human	0
T	0
cells	0
.	0

The	0
IL-2	9
growth	0
hormone	0
is	0
the	0
major	0
growth	0
factor	0
of	0
activated	0
T	7
lymphocytes	8
during	0
a	0
developing	0
immune	0
response	0
.	0

IL-2	9
is	0
required	0
not	0
only	0
for	0
cell	0
cycle	0
progression	0
but	0
also	0
to	0
protect	0
Ag-activated	7
T	8
cells	8
from	0
programmed	0
cell	0
death	0
.	0

In	0
several	0
cell	0
types	0
,	0
activation	0
of	0
NF-kappa	9
B	10
and/or	0
activating	9
protein-1	10
(	0
AP-1	9
)	0
has	0
been	0
demonstrated	0
to	0
be	0
extremely	0
important	0
in	0
blocking	0
apoptosis	0
.	0

To	0
determine	0
whether	0
either	0
or	0
both	0
of	0
these	0
transcription	9
factors	10
are	0
involved	0
in	0
cell	0
survival	0
or	0
cell	0
cycle	0
progression	0
in	0
response	0
to	0
IL-2	9
,	0
primary	7
human	8
T	8
cells	8
responsive	0
to	0
the	0
growth	0
factor	0
were	0
analyzed	0
for	0
NF-kappa	0
B	0
and	0
AP-1	0
activation	0
.	0

The	0
current	0
study	0
clearly	0
demonstrates	0
that	0
IL-2	9
does	0
not	0
induce	0
I	9
kappa	10
B	10
alpha	0
degradation	0
or	0
NF-kappa	9
B	10
activation	0
in	0
primary	7
human	8
T	8
cells	8
that	0
respond	0
to	0
IL-2	9
by	0
entering	0
the	0
cell	0
cycle	0
and	0
avoiding	0
apoptosis	0
.	0

Similarly	0
,	0
IL-2	9
neither	0
activates	0
JNK	9
nor	0
increases	0
AP-1	9
binding	0
activity	0
to	0
a	0
consensus	0
o-tetradecanoylphorbol	1
13-acetate	2
(	2
TPA	2
)	2
response	2
element	2
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
growth	9
factor	10
does	0
induce	0
the	0
activation	0
of	0
STAT3	9
and	0
STAT5	9
in	0
these	0
cells	0
,	0
as	0
has	0
been	0
previously	0
demonstrated	0
.	0

These	0
data	0
show	0
that	0
neither	0
NF-kappa	9
B	10
nor	0
AP-1	9
activation	0
is	0
required	0
for	0
IL-2	9
-mediated	0
survival	0
or	0
cell	0
cycle	0
progression	0
in	0
activated	0
primary	7
human	8
T	8
cells	8
.	0

Estrone	0
potentiates	0
myeloid	0
cell	0
differentiation	0
:	0
a	0
role	0
for	0
17	9
beta-hydroxysteroid	10
dehydrogenase	10
in	0
modulating	0
hemopoiesis	0
.	0

Hormones	0
such	0
as	0
1	0
alpha	0
,	0
25-dihydroxy	0
vitamin	0
D3	0
(	0
D3	0
)	0
,	0
all-trans	0
retinoic	0
acid	0
,	0
and	0
9-cis	0
retinoic	0
acid	0
stimulate	0
differentiation	0
of	0
myeloid	7
progenitor	8
cells	8
via	0
their	0
interaction	0
with	0
specific	0
hormone	9
receptors	10
.	0

However	0
,	0
the	0
sensitivity	0
of	0
cells	0
to	0
these	0
agents	0
is	0
not	0
merely	0
governed	0
by	0
the	0
expression	0
of	0
their	0
receptors	0
and	0
the	0
availability	0
of	0
ligand	0
to	0
bind	0
them	0
.	0

Recent	0
studies	0
from	0
our	0
group	0
suggested	0
that	0
the	0
actions	0
of	0
D3	0
and	0
retinoids	0
on	0
myelopoiesis	0
also	0
are	0
influenced	0
by	0
endogenous	0
mechanisms	0
involving	0
other	0
steroid	0
hormones	0
.	0

In	0
this	0
study	0
we	0
examined	0
the	0
influence	0
of	0
local	0
estrogen	0
metabolism	0
on	0
the	0
differentiation	0
of	0
HL60	5
cells	6
and	0
normal	0
primitive	0
myeloid	7
progenitor	8
cells	8
.	0

Quantitative	0
thin-layer	0
chromatography	0
(	0
TLC	0
)	0
analyses	0
showed	0
that	0
HL60	5
and	0
normal	7
cells	8
are	0
able	0
to	0
generate	0
estrone	0
(	0
E1	0
)	0
from	0
estradiol	0
(	0
E2	0
)	0
.	0

Neither	0
cell	0
population	0
generated	0
significant	0
amounts	0
of	0
E2	0
from	0
E1	0
.	0

Reverse	0
transcriptase	0
polymerase	0
chain	0
reaction	0
and	0
Northern	0
analyses	0
confirmed	0
that	0
normal	0
and	0
leukemic	0
myeloid	7
progenitor	8
cells	8
expressed	0
mRNA	3
for	0
the	0
type	0
I	0
and	0
IV	0
isoforms	0
of	0
17	9
beta-hydroxysteroid	10
dehydrogenase	10
.	0

Conversion	0
of	0
E2	0
to	0
E1	0
was	0
upregulated	0
within	0
24	0
hours	0
when	0
HL60	5
cells	6
were	0
treated	0
with	0
either	0
all-trans	0
retinoic	0
acid	0
or	0
D3	0
at	0
doses	0
that	0
induce	0
their	0
differentiation	0
toward	0
neutrophils	7
or	0
monocytes	7
,	0
respectively	0
.	0

Similarly	0
,	0
D3-induced	0
monocyte	0
differentiation	0
of	0
normal	0
myeloid	7
progenitor	8
cells	8
was	0
associated	0
with	0
increased	0
capacity	0
to	0
generate	0
E1	0
from	0
E2	0
.	0

When	0
HL60	5
cells	6
or	0
normal	0
myeloid	7
progenitor	8
cells	8
were	0
exposed	0
to	0
exogenous	0
E1	0
they	0
became	0
more	0
sensitive	0
to	0
the	0
differentiation-inducing	0
effects	0
of	0
D3	0
.	0

Data	0
presented	0
provide	0
further	0
evidence	0
for	0
the	0
local	0
modulation	0
of	0
myelopoiesis	0
by	0
intracrine	0
mechanisms	0
.	0

In	0
particular	0
,	0
our	0
findings	0
suggest	0
that	0
local	0
metabolism	0
of	0
steroids	0
by	0
normal	0
as	0
well	0
as	0
leukemic	7
myeloid	8
cells	8
influences	0
their	0
responsiveness	0
to	0
D3	0
and	0
retinoids	0
.	0

Phosphorylation	0
of	0
TRAF2	9
inhibits	0
binding	0
to	0
the	0
CD40	9
cytoplasmic	10
domain	10
.	0

TRAF2	9
is	0
a	0
signal	9
transducing	10
adaptor	10
molecule	10
which	0
binds	0
to	0
the	0
CD40	9
cytoplasmic	10
domain	10
.	0

We	0
have	0
found	0
that	0
it	0
is	0
phosphorylated	0
,	0
predominantly	0
on	0
serine	0
residues	0
,	0
when	0
transiently	0
overexpressed	0
in	0
293	5
cells	6
.	0

The	0
phosphorylation	0
appears	0
to	0
be	0
related	0
to	0
the	0
signaling	0
events	0
that	0
are	0
activated	0
by	0
TRAF2	9
under	0
these	0
circumstances	0
,	0
since	0
two	0
nonfunctional	0
mutants	0
were	0
found	0
to	0
be	0
phosphorylated	0
significantly	0
less	0
than	0
the	0
wild-type	9
protein	10
.	0

Furthermore	0
,	0
the	0
phosphorylation	0
status	0
of	0
TRAF2	9
had	0
significant	0
effects	0
on	0
the	0
ability	0
of	0
the	0
protein	0
to	0
bind	0
to	0
CD40	9
,	0
as	0
evidenced	0
by	0
our	0
observations	0
that	0
the	0
CD40	9
cytoplasmic	10
domain	10
interacted	0
preferentially	0
with	0
underphosphorylated	0
TRAF2	9
and	0
that	0
phosphatase	9
treatment	0
significantly	0
enhanced	0
the	0
binding	0
of	0
TRAF2	9
to	0
CD40	9
.	0

We	0
conclude	0
from	0
these	0
studies	0
that	0
the	0
phosphorylation	0
of	0
TRAF2	9
is	0
likely	0
to	0
play	0
an	0
important	0
role	0
in	0
regulating	0
signaling	0
by	0
virtue	0
of	0
its	0
ability	0
to	0
influence	0
the	0
CD40	9
-TRAF2	9
interaction	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

A	0
direct	0
interaction	0
between	0
the	0
adaptor	9
protein	10
Cbl-b	9
and	0
the	0
kinase	9
zap-70	9
induces	0
a	0
positive	0
signal	0
in	0
T	7
cells	8
.	0

Engagement	0
of	0
the	0
T-cell	9
receptor	10
(	10
TCR	10
)	10
-CD3	10
complex	10
induces	0
a	0
rapid	0
increase	0
in	0
the	0
activities	0
of	0
Src-family	9
and	0
Syk/Zap-70-family	9
kinases	10
[	0
1	0
]	0
[	0
2	0
]	0
.	0

These	0
activated	9
kinases	10
then	0
induce	0
the	0
tyrosine	0
phosphorylation	0
of	0
multiple	9
intracellular	10
proteins	10
,	0
eventually	0
leading	0
to	0
T-cell	0
activation	0
.	0

One	0
of	0
the	0
prominent	0
substrates	0
for	0
these	0
kinases	9
is	0
the	0
adaptor	9
protein	10
Cbl	0
[	0
3	0
]	0
and	0
recent	0
studies	0
suggest	0
that	0
Cbl	9
negatively	0
regulates	0
upstream	9
kinases	10
such	0
as	0
Syk	9
and	0
Zap-70	9
[	0
4	0
]	0
[	0
5	0
]	0
.	0

Cbl-b	9
,	0
a	0
homologue	0
of	0
Cbl	9
,	0
is	0
widely	0
expressed	0
in	0
many	0
tissues	0
and	0
cells	0
including	0
hematopoietic	7
cells	8
[	0
6	0
]	0
[	0
7	0
]	0
.	0

Cbl-b	9
undergoes	0
rapid	0
tyrosine	0
phosphorylation	0
upon	0
stimulation	0
of	0
the	0
TCR	9
and	0
cytokine	0
receptors	0
[	0
8	0
]	0
[	0
9	0
]	0
.	0

The	0
role	0
of	0
Cbl-b	9
is	0
unclear	0
,	0
however	0
.	0

Here	0
,	0
we	0
show	0
that	0
overexpression	0
of	0
Cbl-b	9
in	0
T	7
cells	8
induced	0
the	0
constitutive	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	10
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
.	0

A	0
loss-of-function	0
mutation	0
in	0
Cbl-b	9
disrupted	0
the	0
interaction	0
between	0
Cbl-b	9
and	0
Zap-70	9
and	0
nearly	0
completely	0
abrogated	0
the	0
Cbl-b	9
-mediated	0
activation	0
of	0
NFAT	9
.	0

Unlike	0
the	0
proposed	0
role	0
of	0
Cbl	9
as	0
a	0
negative	0
regulator	0
,	0
our	0
results	0
suggest	0
that	0
the	0
Cbl	9
homologue	0
Cbl-b	9
has	0
a	0
positive	0
role	0
in	0
T-cell	0
signaling	0
,	0
most	0
likely	0
via	0
a	0
direct	0
interaction	0
with	0
the	0
upstream	9
kinase	10
Zap-70	9
.	0

Grf40	9
,	0
A	0
novel	0
Grb2	9
family	10
member	10
,	0
is	0
involved	0
in	0
T	0
cell	0
signaling	0
through	0
interaction	0
with	0
SLP-76	9
and	0
LAT	9
.	0

We	0
molecularly	0
cloned	0
a	0
new	0
Grb2	9
family	10
member	10
,	0
named	0
Grf40	9
,	0
containing	0
the	0
common	0
SH3-SH2-SH3	9
motif	10
.	0

Expression	0
of	0
Grf40	9
is	0
predominant	0
in	0
hematopoietic	7
cells	8
,	0
particularly	0
T	7
cells	8
.	0

Grf40	9
binds	0
to	0
the	0
SH2	9
domain-containing	10
leukocyte	10
protein	10
of	0
76	0
kD	0
(	0
SLP-76	9
)	0
via	0
its	0
SH3	0
domain	0
more	0
tightly	0
than	0
Grb2	9
.	0

Incidentally	0
,	0
Grf40	9
binds	0
to	0
linker	9
for	10
activation	10
of	10
T	10
cells	10
(	0
LAT	9
)	0
possibly	0
via	0
its	0
SH2	9
domain	10
.	0

Overexpression	0
of	0
wild-type	9
Grf40	10
in	0
Jurkat	5
cells	6
induced	0
a	0
significant	0
increase	0
of	0
SLP-76-dependent	1
interleukin	2
(	2
IL	2
)	2
-2	2
promoter	2
and	0
nuclear	9
factor	10
of	10
activated	10
T	10
cell	10
(	0
NF-AT	9
)	0
activation	0
upon	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
stimulation	0
,	0
whereas	0
the	0
COOH-terminal	9
SH3-deleted	10
Grf40	10
mutant	10
lacked	0
any	0
recognizable	0
increase	0
in	0
IL-2	1
promoter	2
activity	0
.	0

Furthermore	0
,	0
the	0
SH2-deleted	9
Grf40	10
mutant	10
led	0
to	0
a	0
marked	0
inhibition	0
of	0
these	0
regulatory	0
activities	0
,	0
the	0
effect	0
of	0
which	0
is	0
apparently	0
stronger	0
than	0
that	0
of	0
the	0
SH2-deleted	9
Grb2	10
mutant	10
.	0

Our	0
data	0
suggest	0
that	0
Grf40	9
is	0
an	0
adaptor	9
molecule	10
involved	0
in	0
TCR	9
-mediated	0
signaling	0
through	0
a	0
more	0
efficient	0
interaction	0
than	0
Grb2	9
with	0
SLP-76	9
and	0
LAT	9
.	0

Modulation	0
of	0
the	0
immune	0
response	0
and	0
tumor	0
growth	0
by	0
activated	0
Ras	9
.	0

As	0
a	0
result	0
of	0
its	0
transforming	0
abilities	0
,	0
activated	9
Ras	10
is	0
expressed	0
in	0
a	0
great	0
number	0
of	0
cancers	0
.	0

The	0
ras	0
mutation	0
frequency	0
varies	0
between	0
95	0
%	0
in	0
pancreatic	0
cancer	0
and	0
5	0
%	0
in	0
breast	0
cancer	0
.	0

In	0
leukemia	0
,	0
the	0
highest	0
frequency	0
(	0
30	0
%	0
)	0
is	0
found	0
in	0
acute	0
myeloid	0
leukemia	0
.	0

The	0
presence	0
of	0
ras	0
mutations	0
has	0
been	0
correlated	0
with	0
a	0
poor	0
prognosis	0
and	0
negative	0
clinical	0
outcome	0
.	0

This	0
suggests	0
that	0
mutated	9
Ras	10
activates	0
mechanisms	0
,	0
which	0
favor	0
tumor	0
growth	0
,	0
enhance	0
the	0
metastatic	0
capacity	0
of	0
tumors	0
or	0
modulate	0
tumor-specific	0
immune	0
responses	0
.	0

Several	0
new	0
functions	0
of	0
Ras	9
,	0
such	0
as	0
downregulation	0
of	0
major	9
histocompatibility	10
complex	10
molecules	10
,	0
upregulation	0
of	0
certain	0
cytokines	9
,	0
growth	9
factors	10
and	0
degradative	9
enzymes	10
have	0
been	0
uncovered	0
in	0
the	0
last	0
decade	0
.	0

Additionally	0
,	0
mutated	9
Ras	10
can	0
also	0
serve	0
as	0
a	0
primary	0
target	0
for	0
the	0
development	0
of	0
immunotherapy	0
or	0
drug	0
therapy	0
.	0

This	0
review	0
will	0
discuss	0
the	0
mechanisms	0
by	0
which	0
Ras	9
expressing	0
tumors	0
are	0
able	0
to	0
evade	0
destruction	0
by	0
the	0
immune	0
system	0
and	0
enhance	0
their	0
growth	0
and	0
metastatic	0
potential	0
.	0

It	0
will	0
further	0
elaborate	0
on	0
the	0
attempts	0
to	0
develop	0
successful	0
immunotherapy	0
and	0
drug	0
therapy	0
targeting	0
Ras	9
expressing	0
tumors	0
.	0

Modulation	0
of	0
E2F	9
complexes	10
during	0
G0	0
to	0
S	0
phase	0
transition	0
in	0
human	7
primary	8
B-lymphocytes	8
.	0

The	0
pocket	9
protein-E2F	10
complexes	10
are	0
convergence	0
points	0
for	0
cell	0
cycle	0
signaling	0
.	0

In	0
the	0
present	0
report	0
,	0
we	0
identified	0
and	0
monitored	0
the	0
pocket	9
protein-E2F	10
complexes	10
in	0
human	7
primary	8
B-lymphocytes	8
after	0
activation	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
.	0

Consistent	0
with	0
previous	0
data	0
from	0
human	7
and	8
mouse	8
fibroblasts	8
and	0
T-lymphocytes	7
,	0
E2F4	9
and	0
DP1	9
form	0
the	0
predominant	0
E2F	9
heterodimers	10
both	0
in	0
G0	0
and	0
G1	0
phases	0
of	0
the	0
human	0
B-lymphocyte	0
cell	0
cycle	0
,	0
whereas	0
E2F1	9
and	10
-3	10
are	0
first	0
detected	0
in	0
late	0
G1	0
,	0
and	0
their	0
expression	0
levels	0
increase	0
towards	0
S	0
phase	0
.	0

Intriguingly	0
,	0
the	0
major	9
E2F	10
complex	10
that	0
we	0
detected	0
in	0
quiescent	7
human	8
B-lymphocytes	8
is	0
consisted	0
of	0
pRB	9
,	0
E2F4	9
,	0
and	0
DP1	9
.	0

Though	0
the	0
levels	0
of	0
DP1	9
and	10
-2	10
increase	0
when	0
cells	0
progress	0
from	0
G0	0
to	0
S	0
,	0
the	0
proportion	0
of	0
DP1	9
to	0
DP2	9
remains	0
relatively	0
constant	0
during	0
the	0
cell	0
cycle	0
.	0

We	0
also	0
observed	0
an	0
increase	0
in	0
electrophoretic	0
mobility	0
of	0
the	0
predominant	0
E2F	9
components	10
,	0
DP1	9
and	0
E2F4	9
,	0
as	0
B-lymphocytes	7
progressed	0
from	0
G0	0
into	0
early	0
G1	0
.	0

This	0
increase	0
in	0
mobility	0
was	0
attributable	0
to	0
dephosphorylation	0
,	0
as	0
lambda	0
phosphatase	0
treatment	0
could	0
convert	0
the	0
slower	9
migrating	10
forms	10
into	0
the	0
corresponding	9
faster	10
mobility	10
forms	10
.	0

We	0
further	0
demonstrated	0
that	0
this	0
change	0
in	0
phosphorylation	0
status	0
correlates	0
with	0
a	0
decrease	0
in	0
DNA	0
binding	0
activity	0
.	0

This	0
modulation	0
of	0
DNA	0
binding	0
activity	0
mediated	0
through	0
the	0
dephosphorylation	0
of	0
DP1	9
and	0
E2F4	9
could	0
help	0
to	0
explain	0
the	0
lack	0
of	0
in	0
vivo	0
DNA	0
footprinting	0
in	0
late	0
G1	0
and	0
S	0
phases	0
of	0
gene	1
promoters	2
negatively	0
regulated	0
through	0
E2F	1
sites	2
and	0
suggests	0
a	0
novel	0
mechanism	0
for	0
controlling	0
E2F	9
transcriptional	0
activity	0
during	0
the	0
transition	0
from	0
quiescence	0
to	0
proliferation	0
.	0

Engagement	0
of	0
natural	0
cytotoxicity	0
programs	0
regulates	0
AP-1	9
expression	0
in	0
the	0
NKL	5
human	6
NK	6
cell	6
line	6
.	0

NK	0
cell	0
cytotoxicity	0
is	0
a	0
fast	0
and	0
efficient	0
mechanism	0
of	0
target	0
cell	0
lysis	0
.	0

Using	0
transcription	0
analysis	0
,	0
such	0
as	0
multiplex	0
messenger	0
assays	0
,	0
we	0
show	0
here	0
that	0
natural	0
cytotoxicity	0
exerted	0
by	0
the	0
human	5
NKL	6
cell	6
line	6
correlates	0
with	0
mRNA	0
accumulation	0
of	0
very	9
early	10
activator	10
protein	10
(	10
AP	10
)	10
-1	10
transcription	1
factor	2
genes	2
such	0
as	0
JunB	1
,	0
FosB	1
and	0
c-Fos	1
.	0

In	0
addition	0
,	0
DNA-binding	0
activities	0
of	0
Jun-Fos	9
heterodimers	10
were	0
observed	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
during	0
the	0
course	0
of	0
natural	0
cytotoxicity	0
.	0

Interaction	0
between	0
immunoglobulin-like	9
transcript-2/leukocyte	10
Ig-like	10
receptor	10
1	10
on	0
NKL	7
cells	8
and	0
HLA-B27	9
on	0
target	7
cells	8
leads	0
to	0
an	0
impairment	0
of	0
NKL	0
natural	0
cytotoxicity	0
,	0
which	0
correlates	0
with	0
an	0
absence	0
of	0
JunB	0
,	0
FosB	0
,	0
and	0
c-Fos	0
transcription	0
,	0
as	0
well	0
as	0
an	0
absence	0
of	0
their	0
DNA-binding	0
activity	0
.	0

Our	0
studies	0
thus	0
indicate	0
that	0
,	0
despite	0
the	0
rapidity	0
of	0
NK	0
cell-mediated	0
lysis	0
,	0
AP-1	9
transcription	10
factor	10
is	0
activated	0
during	0
the	0
early	0
stage	0
of	0
NK	0
cell	0
cytolytic	0
programs	0
and	0
that	0
engagement	0
of	0
NK	9
cell	10
inhibitory	10
receptors	10
for	0
MHC	9
class	10
I	10
molecules	10
impairs	0
the	0
very	0
early	0
activation	0
of	0
AP-1	9
.	0

Evidence	0
for	0
a	0
polyclonal	0
etiology	0
of	0
palmar	0
fibromatosis	0
.	0

X	1
chromosome	2
inactivation	0
patterns	0
at	0
the	0
androgen	0
receptor	0
locus	0
were	0
evaluated	0
to	0
determine	0
clonality	0
in	0
microdissected	0
lesional	0
tissue	0
and	0
in	0
leukocytes	7
from	0
2	0
women	0
with	0
Dupuytren	0
's	0
disease	0
.	0

The	0
tissue	0
from	0
both	0
patients	0
generated	0
a	0
polyclonal	0
pattern	0
of	0
X	1
chromosome	2
inactivation	0
of	0
the	0
human	1
androgen	2
receptor	2
gene	2
.	0

This	0
finding	0
supports	0
a	0
polyclonal	0
reactive	0
process	0
as	0
the	0
underlying	0
etiology	0
for	0
palmar	0
fibromatosis	0
.	0

Inhibition	0
of	0
cyclooxygenase-2	9
expression	0
by	0
4-trifluoromethyl	0
derivatives	0
of	0
salicylate	0
,	0
triflusal	0
,	0
and	0
its	0
deacetylated	0
metabolite	0
,	0
2-hydroxy-4-trifluoromethylbenzoic	0
acid	0
.	0

The	0
therapeutic	0
potential	0
of	0
drugs	0
that	0
block	0
the	0
induction	0
of	0
cyclooxygenase-2	9
has	0
been	0
emphasized	0
.	0

When	0
two	0
4-trifluoromethyl	0
salicylate	0
derivatives	0
[	0
2-acetoxy-4-trifluoromethyl-benzoic	0
acid	0
(	0
triflusal	0
)	0
and	0
its	0
deacetylated	0
metabolite	0
2-hydroxy-4-trifluoromethylbenzoic	0
acid	0
(	0
HTB	0
)	0
]	0
were	0
compared	0
with	0
aspirin	0
and	0
sodium	0
salicylate	0
as	0
cyclooxygenase-2	9
(	0
COX-2	0
)	0
inhibitors	0
,	0
we	0
observed	0
that	0
in	0
bacterial	0
lipopolysaccharide-activated	0
human	0
blood	0
,	0
triflusal	0
,	0
aspirin	0
,	0
and	0
HTB	0
,	0
but	0
not	0
sodium	0
salicylate	0
,	0
inhibited	0
COX-2-mediated	0
prostaglandin	0
E2	0
(	0
PGE2	0
)	0
production	0
(	0
IC50	0
=	0
0.16	0
,	0
0.18	0
,	0
0.39	0
,	0
and	0
>	0
10	0
mM	0
,	0
respectively	0
)	0
.	0

However	0
,	0
only	0
triflusal	0
and	0
aspirin	0
inhibited	0
purified	9
COX-2	10
enzyme	10
.	0

To	0
test	0
this	0
apparent	0
discrepancy	0
,	0
we	0
realized	0
that	0
HTB	0
and	0
triflusal	0
(	0
but	0
neither	0
aspirin	0
nor	0
salicylate	0
)	0
produced	0
a	0
concentration-dependent	0
inhibition	0
of	0
COX-2	9
protein	0
expression	0
in	0
peripheral	7
human	8
mononuclear	8
cells	8
.	0

This	0
observation	0
was	0
further	0
confirmed	0
in	0
a	0
rat	0
air	0
pouch	0
model	0
in	0
vivo	0
,	0
in	0
which	0
both	0
aspirin	0
and	0
triflusal	0
inhibited	0
PGE2	0
production	0
(	0
ID50	0
=	0
18.9	0
and	0
11.4	0
mg/kg	0
p.o.	0
,	0
respectively	0
)	0
but	0
only	0
triflusal-treated	0
animals	0
showed	0
a	0
decrease	0
in	0
COX-2	9
expression	0
.	0

This	0
different	0
behavior	0
may	0
be	0
,	0
at	0
least	0
in	0
part	0
,	0
due	0
to	0
the	0
ability	0
of	0
HTB	0
and	0
triflusal	0
to	0
block	0
the	0
activation	0
of	0
the	0
transcription	0
factor	0
nuclear	9
factor-kappaB	10
to	0
a	0
higher	0
extent	0
than	0
aspirin	0
and	0
sodium	0
salicylate	0
.	0

Thus	0
,	0
in	0
addition	0
to	0
inhibiting	0
the	0
COX-2	0
activity	0
at	0
therapeutic	0
concentrations	0
,	0
triflusal	0
is	0
able	0
to	0
block	0
through	0
its	0
metabolite	0
HTB	0
the	0
expression	0
of	0
new	0
enzyme	0
,	0
and	0
hence	0
the	0
resumption	0
of	0
PGE2	0
synthesis	0
.	0

Triflusal	0
and	0
HTB	0
may	0
exert	0
beneficial	0
effects	0
in	0
processes	0
in	0
which	0
de	0
novo	0
COX-2	9
expression	0
is	0
involved	0
and	0
,	0
in	0
a	0
broader	0
sense	0
,	0
in	0
pathological	0
situations	0
in	0
which	0
genes	0
under	0
nuclear	9
factor-kappaB	10
control	0
are	0
up-regulated	0
.	0

Evidence	0
for	0
distinct	0
intracellular	0
signaling	0
pathways	0
in	0
CD34+	7
progenitor	8
to	0
dendritic	0
cell	0
differentiation	0
from	0
a	0
human	0
cell	0
line	0
model	0
.	0

Intracellular	0
signals	0
that	0
mediate	0
differentiation	0
of	0
pluripotent	7
hemopoietic	8
progenitors	8
to	0
dendritic	7
cells	8
(	0
DC	7
)	0
are	0
largely	0
undefined	0
.	0

We	0
have	0
previously	0
shown	0
that	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
activation	0
(	0
with	0
phorbol	0
ester	0
(	0
PMA	0
)	0
alone	0
)	0
specifically	0
induces	0
differentiation	0
of	0
primary	5
human	6
CD34+	6
hemopoietic	6
progenitor	6
cells	6
(	0
HPC	5
)	0
to	0
mature	7
DC	8
.	0

We	0
now	0
find	0
that	0
cytokine-driven	0
(	0
granulocyte-macrophage	0
CSF	0
and	0
TNF-alpha	0
)	0
CD34+	0
HPC	5
--	0
>	0
DC	0
differentiation	0
is	0
preferentially	0
blocked	0
by	0
inhibitors	0
of	0
PKC	9
activation	0
.	0

To	0
further	0
identify	0
intracellular	0
signals	0
and	0
downstream	0
events	0
important	0
in	0
CD34+	5
HPC	6
--	0
>	0
DC	7
differentiation	0
we	0
have	0
characterized	0
a	0
human	0
leukemic	0
cell	0
line	0
model	0
of	0
this	0
process	0
.	0

The	0
CD34+	5
myelomonocytic	6
cell	6
line	6
KG1	5
differentiates	0
into	0
dendritic-like	0
cells	0
in	0
response	0
to	0
granulocyte-macrophage	9
CSF	10
plus	0
TNF-alpha	9
,	0
or	0
PMA	0
(	0
with	0
or	0
without	0
the	0
calcium	0
ionophore	0
ionomycin	0
,	0
or	0
TNF-alpha	9
)	0
,	0
with	0
different	0
stimuli	0
mediating	0
different	0
aspects	0
of	0
the	0
process	0
.	0

Phenotypic	0
DC	7
characteristics	0
of	0
KG1	5
dendritic-like	6
cells	6
include	0
morphology	0
(	0
loosely	7
adherent	8
cells	8
with	0
long	0
neurite	0
processes	0
)	0
,	0
MHC	9
I+/	0
MHC	9
IIbright/CD83+/CD86+/	0
CD14	9
-	0
surface	0
Ag	0
expression	0
,	0
and	0
RelB	9
and	0
DC	7
-CK1	0
gene	0
expression	0
.	0

Functional	0
DC	7
characteristics	0
include	0
fluid	0
phase	0
macromolecule	0
uptake	0
(	0
FITC-dextran	0
)	0
and	0
activation	0
of	0
resting	7
T	8
cells	8
.	0

Comparison	0
of	0
KG1	5
to	0
the	0
PMA-unresponsive	5
subline	6
KG1a	6
reveals	0
differences	0
in	0
expression	0
of	0
TNF	9
receptors	10
1	10
and	10
2	10
;	0
PKC	9
isoforms	10
alpha	10
,	10
beta	10
I	10
,	10
beta	10
II	10
,	10
and	10
mu	10
;	0
and	0
RelB	9
,	0
suggesting	0
that	0
these	0
components/pathways	0
are	0
important	0
for	0
DC	7
differentiation	0
.	0

Together	0
,	0
these	0
findings	0
demonstrate	0
that	0
cytokine	0
or	0
phorbol	0
ester	0
stimulation	0
of	0
KG1	5
is	0
a	0
model	0
of	0
human	5
CD34+	6
HPC	6
to	0
DC	7
differentiation	0
and	0
suggest	0
that	0
specific	0
intracellular	0
signaling	0
pathways	0
mediate	0
specific	0
events	0
in	0
DC	7
lineage	0
commitment	0
.	0

Involvement	0
of	0
adenylate	9
cyclase	10
and	0
p70	9
(	10
S6	10
)	10
-kinase	10
activation	0
in	0
IL-10	9
up-regulation	0
in	0
human	7
monocytes	8
by	0
gp41	9
envelope	10
protein	10
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
.	0

Our	0
previous	0
results	0
show	0
that	0
recombinant	9
gp41	10
(	0
aa565-647	9
)	0
,	0
the	0
extracellular	9
domain	10
of	0
HIV-1	9
transmembrane	10
glycoprotein	10
,	0
stimulates	0
interleukin-10	9
(	0
IL-10	9
)	0
production	0
in	0
human	7
monocytes	8
.	0

The	0
signal	0
cascade	0
transducing	0
this	0
effect	0
is	0
not	0
yet	0
clear	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
whether	0
gp41	9
-induced	0
IL-10	9
up-regulation	0
is	0
mediated	0
by	0
the	0
previously	0
described	0
synergistic	0
activation	0
of	0
cAMP	0
and	0
NF-kappaB	9
pathways	0
.	0

gp41	9
induced	0
cAMP	0
accumulation	0
in	0
monocytes	7
in	0
a	0
time-	0
and	0
concentration-dependent	0
manner	0
and	0
the	0
adenylate	9
cyclase	10
inhibitor	0
SQ	0
22536	0
suppressed	0
gp41	9
-induced	0
IL-10	9
production	0
in	0
monocytes	7
.	0

In	0
contrast	0
,	0
gp41	9
failed	0
to	0
stimulate	0
NF-kappaB	9
binding	0
activity	0
in	0
as	0
much	0
as	0
no	0
NF-kappaB	9
bound	0
to	0
the	0
main	1
NF-kappaB-binding	2
site	2
2	0
of	0
the	0
IL-10	1
promoter	2
after	0
addition	0
of	0
gp41	9
.	0

We	0
also	0
examined	0
the	0
involvement	0
of	0
other	0
signal	0
transduction	0
pathways	0
.	0

Specific	0
inhibitors	0
of	0
p70	9
(	10
S6	10
)	10
-kinase	10
(	0
rapamycin	0
)	0
,	0
and	0
Gi	9
protein	10
(	0
pertussis	9
toxin	10
)	0
,	0
prevented	0
induction	0
of	0
IL-10	9
production	0
by	0
gp41	9
in	0
monocytes	7
,	0
while	0
inhibitors	0
of	0
the	0
phosphatidylinositol	9
3-kinase	10
(	0
PI	9
3-kinase	10
)	0
(	0
wortmannin	0
)	0
and	0
mitogen-activated	0
protein	0
kinase	0
(	0
MAPK	9
)	0
pathway	0
(	0
PD	0
98059	0
)	0
did	0
not	0
.	0

Thus	0
HIV-1	0
gp41	9
-induced	0
IL-10	9
up-regulation	0
in	0
monocytes	7
may	0
not	0
involve	0
NF-kappaB	9
,	0
MAPK	9
,	0
or	0
PI	9
3-kinase	10
activation	0
,	0
but	0
rather	0
may	0
operate	0
through	0
activation	0
of	0
adenylate	9
cyclase	10
and	0
pertussis-toxin-sensitive	9
Gi/Go	10
protein	10
to	0
effect	0
p70	9
(	10
S6	10
)	10
-kinase	10
activation	0
.	0

Analysis	0
of	0
the	0
modulation	0
of	0
transcriptional	0
activity	0
in	0
myelopoiesis	0
and	0
leukemogenesis	0
.	0

Acute	0
myeloid	0
leukemia	0
(	0
AML	0
)	0
is	0
still	0
associated	0
with	0
a	0
mortality	0
of	0
60	0
to	0
80	0
%	0
.	0

AML	0
is	0
characterized	0
by	0
a	0
block	0
in	0
myeloid	0
differentiation	0
.	0

The	0
transcription	9
factors	10
PU.1	9
and	0
C/EBPalpha	9
are	0
responsible	0
for	0
normal	0
myeloid	0
differentiation	0
from	0
stem	7
cells	8
to	0
monocytes	7
or	0
granulocytes	0
.	0

In	0
particular	0
,	0
PU.1	9
induces	0
expression	0
of	0
the	0
macrophage	9
colony-stimulating	10
factor	10
(	10
M-CSF	10
)	10
receptor	10
and	0
the	0
development	0
of	0
monocytes	7
,	0
whereas	0
C/EBPalpha	9
increases	0
the	0
expression	0
of	0
the	0
granulocyte	9
colony-stimulating	10
factor	10
(	10
G-CSF	10
)	10
receptor	10
and	0
leads	0
to	0
mature	0
granulocytes	7
.	0

In	0
AML	0
,	0
chromosomal	0
aberrations	0
result	0
in	0
oncoproteins	9
such	0
as	0
AML1/ETO	9
,	0
PML/RARalpha	9
,	0
or	0
activated	9
Ras	10
,	0
which	0
can	0
deregulate	0
genes	0
important	0
for	0
normal	0
myelopoiesis	0
.	0

Thus	0
,	0
AML1/ETO	9
can	0
bind	0
to	0
the	0
transcription	9
factor	10
C/EBPalpha	9
,	0
inhibit	0
C/EBPalpha	9
-dependent	0
transcription	0
,	0
and	0
block	0
granulocytic	0
differentiation	0
.	0

However	0
,	0
AML1/ETO	9
can	0
also	0
synergize	0
with	0
the	0
transcription	9
factor	10
AML1	9
to	0
enhance	0
the	0
activity	0
of	0
the	0
M-CSF	1
receptor	2
promoter	2
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
PML/RARalpha	9
fusion	10
protein	10
causes	0
transcriptional	0
repression	0
by	0
recruiting	0
the	0
nuclear	9
corepressor	10
(	10
N-CoR	10
)	10
histone	10
deacetylase	10
complex	10
to	0
the	0
DNA	0
,	0
which	0
results	0
in	0
decreased	0
histone	9
acetylation	0
and	0
a	0
repressive	0
chromatin	1
organization	0
.	0

Here	0
we	0
describe	0
methods	0
to	0
investigate	0
whether	0
and	0
how	0
signaling	0
agonists	0
induce	0
myeloid	0
differentiation	0
and	0
how	0
oncoproteins	9
might	0
cause	0
AML	0
by	0
modulating	0
the	0
activity	0
of	0
transcription	9
factors	10
that	0
are	0
pivotal	0
for	0
normal	0
myeloid	0
development	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

NF-ATc	9
isoforms	10
are	0
differentially	0
expressed	0
and	0
regulated	0
in	0
murine	7
T	8
and	8
mast	8
cells	8
.	0

NF	9
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
denotes	0
a	0
family	0
of	0
transcription	9
factors	10
that	0
regulate	0
the	0
activation-dependent	0
expression	0
of	0
many	0
immunologically	9
important	10
proteins	10
.	0

At	0
least	0
four	0
distinct	0
genes	0
encode	0
the	0
various	0
family	0
members	0
,	0
and	0
several	0
isoforms	0
of	0
these	0
have	0
been	0
identified	0
as	0
well	0
.	0

The	0
overlapping	0
expression	0
patterns	0
and	0
similar	0
in	0
vitro	0
binding	0
and	0
trans-activation	0
activities	0
on	0
various	0
promoter	1
elements	2
of	0
NF-AT-regulated	1
genes	2
suggest	0
some	0
redundancy	0
in	0
the	0
function	0
of	0
these	0
proteins	0
.	0

However	0
,	0
the	0
phenotypic	0
analysis	0
of	0
NF-AT	9
-deficient	0
mice	0
supports	0
the	0
idea	0
that	0
there	0
are	0
tissue-	0
and	0
gene-	0
specific	0
functions	0
as	0
well	0
.	0

In	0
this	0
study	0
we	0
have	0
characterized	0
the	0
expression	0
of	0
NF-AT	1
cDNAs	2
in	0
murine	0
mast	7
cells	8
.	0

The	0
majority	0
of	0
clones	0
identified	0
correspond	0
to	0
two	0
NF-ATc	9
isoforms	10
that	0
differ	0
only	0
in	0
their	0
amino-terminal	9
sequence	10
.	0

Despite	0
minimal	0
discrepancies	0
in	0
the	0
coding	1
region	2
,	0
there	0
are	0
striking	0
tissue-	0
and	0
cell	0
type-specific	0
differences	0
in	0
isoform	0
expression	0
patterns	0
.	0

Detection	0
of	0
NF-ATc.alpha	3
mRNA	4
is	0
strictly	0
dependent	0
on	0
cell	0
activation	0
signals	0
in	0
both	0
T	5
and	6
mast	6
cell	6
lines	6
.	0

In	0
contrast	0
,	0
the	0
beta	9
isoform	10
is	0
expressed	0
at	0
very	0
low	0
constitutive	0
levels	0
in	0
both	0
cell	0
types	0
but	0
is	0
only	0
up-regulated	0
in	0
response	0
to	0
mast	0
cell	0
activation	0
signals	0
delivered	0
through	0
the	0
FcepsilonRI	9
or	0
via	0
calcium	0
ionophores	0
.	0

These	0
results	0
demonstrate	0
another	0
level	0
of	0
regulation	0
within	0
the	0
NF-AT	9
family	10
that	0
can	0
contribute	0
to	0
cell	0
type-specific	0
gene	0
expression	0
.	0

Crossreactive	0
recognition	0
of	0
viral	0
,	0
self	0
,	0
and	0
bacterial	0
peptide	0
ligands	0
by	0
human	7
class	8
I-restricted	8
cytotoxic	8
T	8
lymphocyte	8
clonotypes	8
:	8
implications	0
for	0
molecular	0
mimicry	0
in	0
autoimmune	0
disease	0
.	0

The	0
immunodominant	0
,	0
CD8	7
(	8
+	8
)	8
cytotoxic	8
T	8
lymphocyte	8
(	0
CTL	0
)	0
response	0
to	0
the	0
HLA-B8-restricted	0
peptide	0
,	0
RAKFKQLL	0
,	0
located	0
in	0
the	0
Epstein-Barr	9
virus	10
immediate-early	10
antigen	10
,	0
BZLF1	9
,	0
is	0
characterized	0
by	0
a	0
diverse	0
T	9
cell	10
receptor	10
(	10
TCR	10
)	10
repertoire	10
.	0

Here	0
,	0
we	0
show	0
that	0
this	0
diversity	0
can	0
be	0
partitioned	0
on	0
the	0
basis	0
of	0
crossreactive	0
cytotoxicity	0
patterns	0
involving	0
the	0
recognition	0
of	0
a	0
self	0
peptide-RSKFRQIV-located	0
in	0
a	0
serine/threonine	9
kinase	10
and	0
a	0
bacterial	0
peptide-RRKYKQII-located	0
in	0
Staphylococcus	9
aureus	10
replication	10
initiation	10
protein	10
.	0

Thus	0
CTL	5
clones	6
that	0
recognized	0
the	0
viral	0
,	0
self	0
,	0
and	0
bacterial	0
peptides	0
expressed	0
a	0
highly	0
restricted	0
alphabeta	0
TCR	9
phenotype	0
.	0

The	0
CTL	5
clones	6
that	0
recognized	0
viral	0
and	0
self	0
peptides	0
were	0
more	0
oligoclonal	0
,	0
whereas	0
clones	0
that	0
strictly	0
recognized	0
the	0
viral	0
peptide	0
displayed	0
a	0
diverse	0
TCR	9
profile	0
.	0

Interestingly	0
,	0
the	0
self	0
and	0
bacterial	0
peptides	0
equally	0
were	0
substantially	0
less	0
effective	0
than	0
the	0
cognate	0
viral	0
peptide	0
in	0
sensitizing	0
target	0
cell	0
lysis	0
,	0
and	0
also	0
resulted	0
only	0
in	0
a	0
weak	0
reactivation	0
of	0
memory	7
CTLs	8
in	0
limiting	0
dilution	0
assays	0
,	0
whereas	0
the	0
cognate	0
peptide	0
was	0
highly	0
immunogenic	0
.	0

The	0
described	0
crossreactions	0
show	0
that	0
human	0
antiviral	0
,	0
CD8	0
(	0
+	0
)	0
CTL	0
responses	0
can	0
be	0
shaped	0
by	0
peptide	0
ligands	0
derived	0
from	0
autoantigens	0
and	0
environmental	0
bacterial	0
antigens	0
,	0
thereby	0
providing	0
a	0
firm	0
structural	0
basis	0
for	0
molecular	0
mimicry	0
involving	0
class	0
I-restricted	5
CTLs	6
in	0
the	0
pathogenesis	0
of	0
autoimmune	0
disease	0
.	0

RFLAT-1	9
:	0
a	0
new	0
zinc	9
finger	10
transcription	10
factor	10
that	0
activates	0
RANTES	1
gene	2
expression	0
in	0
T	7
lymphocytes	8
.	0

RANTES	9
(	0
Regulated	9
upon	10
Activation	10
,	10
Normal	10
T	10
cell	10
Expressed	10
and	10
Secreted	10
)	0
is	0
a	0
chemoattractant	9
cytokine	10
(	0
chemokine	9
)	0
important	0
in	0
the	0
generation	0
of	0
inflammatory	0
infiltrate	0
and	0
human	0
immunodeficiency	0
virus	0
entry	0
into	0
immune	7
cells	8
.	0

RANTES	9
is	0
expressed	0
late	0
(	0
3-5	0
days	0
)	0
after	0
activation	0
in	0
T	7
lymphocytes	8
.	0

Using	0
expression	0
cloning	0
,	0
we	0
identified	0
the	0
first	0
``	0
late	0
''	0
T	9
lymphocyte	10
associated	10
transcription	10
factor	10
and	0
named	0
it	0
``	0
RANTES	9
Factor	10
of	10
Late	10
Activated	10
T	10
Lymphocytes-1	10
``	0
(	0
RFLAT-1	9
)	0
.	0

RFLAT-1	9
is	0
a	0
novel	0
,	0
phosphorylated	0
,	0
zinc	9
finger	10
transcription	10
factor	10
that	0
is	0
expressed	0
in	0
T	7
cells	8
3	0
days	0
after	0
activation	0
,	0
coincident	0
with	0
RANTES	9
expression	0
.	0

While	0
Rel	9
proteins	10
play	0
the	0
dominant	0
role	0
in	0
RANTES	1
gene	2
expression	0
in	0
fibroblasts	0
,	0
RFLAT-1	9
is	0
a	0
strong	0
transactivator	0
for	0
RANTES	9
in	0
T	7
cells	8
.	0

Fas	9
ligand	10
induction	0
in	0
human	7
NK	8
cells	8
is	0
regulated	0
by	0
redox	0
through	0
a	0
calcineurin-nuclear	9
factors	10
of	0
activated	0
T	0
cell-dependent	0
pathway	0
.	0

Fas	9
ligand	10
(	0
FasL	9
)	0
on	0
cytotoxic	0
lymphocytes	0
is	0
important	0
for	0
mediating	0
apoptosis	0
of	0
activated	0
lymphocytes	0
and	0
other	0
target	0
cells	0
.	0

We	0
have	0
reported	0
that	0
NK	0
cell	0
functions	0
,	0
such	0
as	0
proliferation	0
,	0
cell	0
death	0
,	0
and	0
killing	0
activity	0
,	0
are	0
subject	0
to	0
regulation	0
by	0
cellular	0
redox	0
status	0
.	0

Here	0
,	0
we	0
report	0
that	0
expression	0
of	0
FasL	9
protein	10
and	0
mRNA	3
in	0
activated	7
NK	8
cells	8
is	0
also	0
regulated	0
by	0
redox	0
.	0

Ligation	0
of	0
CD16	9
on	0
IL-2-preactivated	7
NK	8
cells	8
resulted	0
in	0
reduction	0
of	0
intracellular	0
peroxide	0
level	0
as	0
well	0
as	0
induction	0
of	0
FasL	9
expression	0
.	0

This	0
CD16	9
-induced	0
FasL	9
expression	0
was	0
suppressed	0
by	0
oxidative	0
stress	0
,	0
including	0
thiol	0
deprivation	0
or	0
treatment	0
with	0
hydrogen	0
peroxide	0
(	0
H2O2	0
)	0
.	0

Addition	0
of	0
thiol-reducing	0
compounds	0
,	0
such	0
as	0
L-cystine	0
,	0
2-ME	0
,	0
or	0
N-acetyl	0
cysteine	0
,	0
restored	0
FasL	9
expression	0
.	0

These	0
data	0
suggest	0
that	0
CD16	9
stimulation	0
requires	0
cellular	0
reducing	0
status	0
for	0
FasL	9
induction	0
in	0
NK	7
cells	8
.	0

Because	0
FasL	0
gene	0
activation	0
following	0
CD16	9
cross-linking	0
is	0
regulated	0
by	0
the	0
NF	9
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
,	0
we	0
examined	0
the	0
effect	0
of	0
oxidative	0
stresses	0
on	0
NFAT	9
activation	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
revealed	0
that	0
both	0
thiol	0
insufficiency	0
and	0
H2O2	0
treatment	0
suppressed	0
DNA-binding	0
activity	0
of	0
NFAT	9
and	0
that	0
addition	0
of	0
thiol-reducing	0
compounds	0
reversed	0
or	0
even	0
enhanced	0
it	0
.	0

Furthermore	0
,	0
these	0
oxidative	0
stresses	0
inhibited	0
activity	0
of	0
calcineurin	0
,	0
a	0
serine/	0
threonine	9
phosphatase	10
that	0
regulates	0
NFAT	9
activation	0
.	0

These	0
results	0
suggest	0
that	0
suppression	0
of	0
calcineurin	9
and	0
NFAT	9
activation	0
is	0
a	0
mechanism	0
by	0
which	0
oxidative	0
stress	0
inhibits	0
FasL	9
induction	0
in	0
activated	7
NK	8
cells	8
and	0
further	0
support	0
the	0
hypothesis	0
that	0
thiol-reducing	0
compounds	0
might	0
be	0
required	0
for	0
maintenance	0
of	0
optimal	0
NK	0
functions	0
under	0
physiologic	0
oxidative	0
conditions	0
.	0

Heterogeneity	0
of	0
clonal	0
development	0
in	0
chronic	1
myeloproliferative	2
disorders	2
.	0

Recent	0
reports	0
have	0
suggested	0
a	0
previously	0
unexpected	0
variability	0
in	0
the	0
expression	0
of	0
the	0
dominant	5
neoplastic	6
clone	6
in	0
myeloproliferative	0
disorders	0
(	0
MPD	0
)	0
.	0

We	0
evaluated	0
49	0
female	0
patients	0
with	0
MPD	0
and	0
informative	0
at	0
the	0
X-linked	1
androgen	2
receptor	2
(	2
AR	2
)	2
locus	2
to	0
establish	0
the	0
X	1
chromosome	2
inactivation	0
pattern	0
of	0
hemopoietic	7
cells	8
.	0

Whereas	0
in	0
chronic	0
myelogenous	0
leukemia	0
(	0
CML	0
)	0
the	0
granulocytes	7
(	0
PMN	7
)	0
were	0
uniformly	0
of	0
monoclonal	0
origin	0
,	0
a	0
striking	0
heterogeneity	0
of	0
clonal	0
development	0
was	0
found	0
in	0
PMN	7
from	0
patients	0
with	0
other	0
MPD	0
,	0
with	0
up	0
to	0
50	0
%	0
of	0
them	0
expressing	0
a	0
polyclonal	0
pattern	0
of	0
X	0
inactivation	0
.	0

CD80	9
and	0
CD86	9
are	0
not	0
equivalent	0
in	0
their	0
ability	0
to	0
induce	0
the	0
tyrosine	0
phosphorylation	0
of	0
CD28	9
.	0

Ligation	0
of	0
either	0
CD80	9
(	0
B7-1	9
)	0
or	0
CD86	9
(	0
B7-2	9
)	0
,	0
two	0
principal	0
ligands	0
for	0
CD28	9
,	0
is	0
thought	0
to	0
skew	0
the	0
immune	0
response	0
toward	0
Th1	0
or	0
Th2	0
differentiation	0
.	0

We	0
have	0
examined	0
early	0
signal	0
transduction	0
pathways	0
recruited	0
following	0
T	0
cell	0
stimulation	0
with	0
either	0
CD80	9
or	0
CD86	9
.	0

Purified	5
human	6
peripheral	6
T	6
cells	6
or	0
Jurkat	5
T	6
cells	6
were	0
stimulated	0
with	0
Chinese	0
hamster	0
ovary	0
(	0
CHO	0
)	0
cells	0
expressing	0
either	0
human	9
CD80	10
(	0
CHO-CD80	9
)	0
or	0
human	9
CD86	10
(	0
CHO-CD86	9
)	0
or	0
with	0
anti-CD28	9
monoclonal	10
antibody	10
(	0
mAb	0
)	0
.	0

In	0
the	0
presence	0
of	0
phorbol	0
12-myristate	0
13-acetate	0
,	0
both	0
CHO-CD80	9
and	0
CHO-CD86	9
,	0
like	0
anti-CD28	9
mAb	10
,	0
were	0
capable	0
of	0
stimulating	0
cytokine	9
production	0
from	0
both	0
human	7
peripheral	8
T	8
cells	8
and	0
Jurkat	5
T	6
cells	6
.	0

Both	0
CHO-CD80	9
and	0
CHO-CD86	9
,	0
in	0
the	0
presence	0
of	0
anti-CD3	9
mAb	10
,	0
costimulated	0
NFAT	9
-dependent	0
transcriptional	0
activation	0
.	0

Several	0
intracellular	0
signaling	9
proteins	10
,	0
such	0
as	0
CBL	9
and	0
VAV	9
,	0
were	0
phosphorylated	0
on	0
tyrosine	0
in	0
response	0
to	0
CD80	9
,	0
CD86	9
,	0
and	0
anti-CD28	9
mAb	10
.	0

Surprisingly	0
,	0
although	0
stimulation	0
of	0
Jurkat	5
T	6
cells	6
with	0
either	0
CHO-CD80	9
or	0
anti-CD28	9
mAb	10
resulted	0
in	0
robust	0
tyrosine	0
phosphorylation	0
of	0
CD28	9
itself	0
,	0
ligation	0
with	0
CHO-CD86	9
was	0
unable	0
to	0
induce	0
detectable	0
CD28	9
tyrosyl	0
phosphorylation	0
over	0
a	0
range	0
of	0
stimulation	0
conditions	0
.	0

In	0
addition	0
,	0
the	0
association	0
of	0
phosphoinositide	9
3-kinase	10
with	0
CD28	9
and	0
enhanced	0
tyrosine	0
phosphorylation	0
of	0
phospholipase	0
Cgamma	0
were	0
seen	0
after	0
anti-CD28	0
mAb	0
and	0
CHO-CD80	0
stimulation	0
but	0
to	0
a	0
much	0
lesser	0
extent	0
after	0
CHO-CD86	9
stimulation	0
.	0

Thus	0
,	0
ligation	0
of	0
CD28	9
with	0
either	0
CD80	9
or	0
CD86	9
leads	0
to	0
shared	0
early	0
signal	0
transduction	0
events	0
such	0
as	0
the	0
tyrosine	0
phosphorylation	0
of	0
CBL	9
and	0
VAV	9
,	0
to	0
NFAT	9
-mediated	0
transcriptional	0
activation	0
,	0
and	0
to	0
the	0
costimulation	0
of	0
interleukin-2	9
and	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
production	0
.	0

However	0
,	0
CD80	9
and	0
CD86	9
also	0
induce	0
distinct	0
signal	0
transduction	0
pathways	0
including	0
the	0
tyrosine	0
phosphorylation	0
of	0
CD28	9
and	0
phospholipase	9
Cgamma1	10
and	0
the	0
SH2	9
-dependent	0
association	0
of	0
phosphoinositide	9
3-kinase	10
with	0
CD28	9
.	0

These	0
quantitative	0
,	0
if	0
not	0
qualitative	0
,	0
differences	0
between	0
signaling	0
initiated	0
by	0
these	0
two	0
ligands	0
for	0
CD28	9
may	0
contribute	0
to	0
functional	0
differences	0
(	0
e.g.	0
Th1	0
or	0
Th2	0
differentiation	0
)	0
in	0
T	0
cell	0
responses	0
.	0

Binding	0
of	0
HMG-I	9
(	10
Y	10
)	10
elicits	0
structural	0
changes	0
in	0
a	0
silencer	0
of	0
the	0
human	1
beta-globin	2
gene	2
.	0

Proteins	0
involved	0
in	0
repression	0
of	0
the	0
human	1
beta-globin	2
gene	2
may	0
be	0
useful	0
in	0
the	0
treatment	0
of	0
sickle	0
cell	0
anemia	0
,	0
in	0
conjunction	0
with	0
therapy	0
to	0
reactivate	0
fetal	1
globin	2
genes	2
.	0

If	0
there	0
is	0
a	0
reciprocal	0
elevation	0
of	0
gamma-globin	9
expression	0
upon	0
repression	0
,	0
this	0
approach	0
could	0
be	0
useful	0
in	0
additional	0
hemoglobinopathies	0
.	0

We	0
previously	0
showed	0
that	0
repression	0
of	0
the	0
beta-globin	0
gene	0
appears	0
to	0
be	0
mediated	0
through	0
two	0
DNA	1
sequences	2
,	0
silencers	1
I	2
and	2
II	2
,	0
and	0
identified	0
a	0
protein	0
termed	0
BP1	9
which	0
binds	0
to	0
both	0
silencer	0
sequences	0
.	0

In	0
this	0
study	0
,	0
we	0
cloned	0
two	0
cDNAs	1
encoding	0
proteins	0
which	0
bind	0
to	0
an	0
oligonucleotide	0
in	0
silencer	1
I	2
containing	0
a	0
BP1	9
binding	0
site	0
.	0

These	0
cDNAs	1
correspond	0
to	0
HMG-I	9
and	0
HMG-Y	9
,	0
isoforms	0
regarded	0
as	0
architectural	9
proteins	10
.	0

We	0
demonstrate	0
that	0
binding	0
of	0
HMG-I	9
(	10
Y	10
)	10
to	0
this	0
oligonucleotide	0
causes	0
bending/flexure	0
of	0
the	0
DNA	0
.	0

HMG-I	9
(	10
Y	10
)	10
also	0
binds	0
to	0
a	0
second	0
oligonucleotide	0
containing	0
a	0
BP1	1
binding	2
site	2
located	0
in	0
a	0
negative	1
control	2
region	2
upstream	0
of	0
the	0
delta-globin	1
gene	2
,	0
suggesting	0
a	0
role	0
for	0
HMG-I	9
(	10
Y	10
)	10
in	0
repression	0
of	0
adult	0
globin	0
genes	0
.	0

Expression	0
studies	0
revealed	0
that	0
HMG-I	9
(	10
Y	10
)	10
is	0
ubiquitously	0
expressed	0
in	0
human	0
tissues	0
that	0
do	0
not	0
express	0
beta-globin	9
,	0
being	0
present	0
in	0
48	0
of	0
50	0
tissues	0
and	0
six	0
hematopoietic	5
cell	6
lines	6
examined	0
.	0

Furthermore	0
,	0
HMG-I	9
(	10
Y	10
)	10
expression	0
is	0
down-regulated	0
during	0
differentiation	0
of	0
primary	7
erythroid	8
cells	8
.	0

We	0
present	0
a	0
model	0
in	0
which	0
HMG-I	9
(	10
Y	10
)	10
alters	0
DNA	0
conformation	0
to	0
allow	0
binding	0
of	0
repressor	9
proteins	10
,	0
and	0
in	0
which	0
the	0
relative	0
amount	0
of	0
HMG-I	0
(	0
Y	0
)	0
helps	0
to	0
determine	0
the	0
repressive	0
state	0
of	0
the	0
beta-globin	1
gene	2
.	0

Interactions	0
between	0
the	0
class	9
II	10
transactivator	10
and	0
CREB	9
binding	10
protein	10
increase	0
transcription	0
of	0
major	1
histocompatibility	2
complex	2
class	2
II	2
genes	2
.	0

Class	1
II	2
major	2
histocompatibility	2
(	2
class	2
II	2
)	2
genes	2
are	0
regulated	0
in	0
a	0
B-cell-specific	0
and	0
gamma	0
interferon-inducible	0
fashion	0
.	0

The	0
master	0
switch	0
for	0
the	0
expression	0
of	0
these	0
genes	0
is	0
the	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
one	0
of	0
the	0
functions	0
of	0
CIITA	9
is	0
to	0
recruit	0
the	0
CREB	9
binding	10
protein	10
(	0
CBP	9
)	0
to	0
class	1
II	2
promoters	2
.	0

Not	0
only	0
functional	0
but	0
also	0
specific	0
binding	0
interactions	0
between	0
CIITA	9
and	0
CBP	9
were	0
demonstrated	0
.	0

Moreover	0
,	0
a	0
dominant	0
negative	0
form	0
of	0
CBP	9
decreased	0
the	0
activity	0
of	0
class	1
II	2
promoters	2
and	0
levels	0
of	0
class	9
II	10
determinants	10
on	0
the	0
surface	0
of	0
cells	0
.	0

Finally	0
,	0
the	0
inhibition	0
of	0
class	1
II	2
gene	2
expression	0
by	0
the	0
glucocorticoid	0
hormone	0
could	0
be	0
attributed	0
to	0
the	0
squelching	0
of	0
CBP	9
by	0
the	0
glucocorticoid	9
receptor	10
.	0

We	0
conclude	0
that	0
CBP	9
,	0
a	0
histone	9
acetyltransferase	10
,	0
plays	0
an	0
important	0
role	0
in	0
the	0
transcription	0
of	0
class	1
II	2
genes	2
.	0

Role	0
of	0
cyclic	9
AMP	10
response	10
element-binding	10
protein	10
in	0
cyclic	0
AMP	0
inhibition	0
of	0
NF-kappaB	9
-mediated	0
transcription	0
.	0

The	0
NF-kappaB	9
family	0
of	0
transcription	0
factors	0
regulates	0
the	0
inducible	0
expression	0
of	0
a	0
variety	0
of	0
genes	0
.	0

Recently	0
,	0
we	0
showed	0
that	0
elevation	0
of	0
intracellular	0
cyclic	0
AMP	0
inhibits	0
NF-kappaB	9
-mediated	0
transcription	0
in	0
human	7
monocytes	8
and	0
endothelial	7
cells	8
without	0
preventing	0
nuclear	0
translocation	0
of	0
NF-kappaB	9
complexes	10
.	0

The	0
present	0
study	0
examined	0
the	0
molecular	0
mechanism	0
of	0
this	0
inhibition	0
.	0

We	0
hypothesized	0
that	0
activation	0
of	0
the	0
protein	9
kinase	10
A	10
signaling	0
pathway	0
may	0
inhibit	0
NF-kappaB	9
-mediated	0
transcription	0
by	0
phosphorylating	0
proteins	0
,	0
such	0
as	0
cAMP	9
response	10
element-binding	10
protein	10
(	0
CREB	9
)	0
,	0
which	0
compete	0
for	0
limiting	0
amounts	0
of	0
the	0
coactivator	0
CBP	9
.	0

Here	0
,	0
we	0
show	0
that	0
the	0
amino-terminal	9
region	10
(	0
amino	9
acids	10
1-450	10
)	0
of	0
CBP	9
specifically	0
interacts	0
with	0
the	0
carboxyl-terminal	9
region	10
(	0
amino	9
acids	10
286-551	10
)	0
of	0
NF-kappaB	9
p65	9
(	0
RelA	9
)	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Functional	0
studies	0
using	0
human	0
endothelial	7
cells	8
demonstrated	0
that	0
overexpression	0
of	0
CBP	9
rescued	0
cAMP	0
inhibition	0
of	0
NF-kappaB	9
-mediated	0
transcription	0
and	0
transcription	0
mediated	0
by	0
a	0
chimeric	9
protein	10
,	0
GAL4-p65	9
(	10
286-551	10
)	10
,	0
which	0
contained	0
the	0
GAL4	9
DNA	10
binding	10
domain	10
fused	0
to	0
the	0
carboxyl-terminal	9
region	10
of	0
p65	9
(	0
amino	9
acids	10
286-551	10
)	0
.	0

In	0
contrast	0
,	0
overexpression	0
of	0
CREB	9
inhibited	0
GAL4	9
-p65	0
(	0
286-551	0
)	0
-mediated	0
transcription	0
.	0

These	0
results	0
suggest	0
that	0
activation	0
of	0
the	0
protein	9
kinase	10
A	10
pathway	0
inhibits	0
NF-kappaB	9
transcription	0
by	0
phosphorylating	0
CREB	9
,	0
which	0
competes	0
with	0
p65	9
for	0
limiting	0
amounts	0
of	0
CBP	9
.	0

Glucocorticoid	9
receptors	10
in	0
cord	7
blood	8
lymphocytes	8
of	0
healthy	0
neonates	0
and	0
of	0
preterms	0
suffering	0
from	0
respiratory	0
distress	0
syndrome	0
.	0

We	0
measured	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
cord	7
blood	8
lymphocytes	8
and	0
the	0
binding	0
affinity	0
(	0
Kd	0
)	0
in	0
15	0
term	0
and	0
in	0
20	0
preterm	0
babies	0
.	0

Thirteen	0
preterms	0
of	0
the	0
latter	0
group	0
received	0
prenatal	0
steroid	0
treatment	0
.	0

Seven	0
preterms	0
developed	0
neonatal	0
respiratory	0
distress	0
syndrome	0
(	0
NRDS	0
)	0
.	0

The	0
number	0
of	0
GR	9
and	0
the	0
Kd	0
were	0
similar	0
in	0
the	0
term	0
and	0
preterm	0
(	0
with	0
and	0
without	0
NRDS	0
)	0
babies	0
.	0

The	0
maximum	0
(	0
3H	0
)	0
-thymidine	0
incorporation	0
into	0
DNA	0
of	0
cord	7
blood	8
lymphocytes	8
from	0
all	0
preterms	0
,	0
with	0
or	0
without	0
NRDS	0
was	0
suppressed	0
when	0
compared	0
to	0
that	0
from	0
term	0
babies	0
or	0
adults	0
.	0

This	0
could	0
partly	0
be	0
explained	0
by	0
the	0
antenatal	0
steroid	0
treatment	0
.	0

Sensitivity	0
(	0
ID50	0
)	0
of	0
the	0
lymphocytes	7
for	0
the	0
inhibitory	0
effect	0
of	0
dexamethasone	0
was	0
the	0
same	0
in	0
all	0
groups	0
.	0

In	0
this	0
study	0
on	0
the	0
number	0
and	0
function	0
of	0
GR	9
in	0
lymphocytes	7
,	0
we	0
were	0
unable	0
to	0
find	0
a	0
relation	0
between	0
the	0
functionality	0
of	0
the	0
GR	9
and	0
the	0
development	0
of	0
NRDS	0
.	0

Inefficient	0
termination	0
of	0
antigen	0
responses	0
in	0
NF-ATp	9
-deficient	0
mice	0
.	0

In	0
order	0
to	0
elucidate	0
the	0
role	0
of	0
NF-ATp	9
,	0
one	0
of	0
the	0
most	0
prominent	0
members	0
of	0
family	0
of	0
NF-AT	9
transcription	10
factors	10
in	0
peripheral	7
T	8
lymphocytes	8
,	0
in	0
T	0
cell	0
activation	0
and	0
differentiation	0
we	0
created	0
NF-ATp	9
-deficient	0
mice	0
by	0
gene	0
targeting	0
.	0

Such	0
NF-ATp	9
-/-	0
mice	0
are	0
born	0
and	0
appear	0
to	0
develop	0
a	0
normal	0
immune	0
system	0
.	0

Apart	0
from	0
clear-cut	0
defects	0
in	0
the	0
synthesis	0
of	0
mRNAs	3
for	0
Th2-type	9
lymphokines	10
,	0
such	0
as	0
IL-4	9
,	0
IL-5	9
,	0
IL-10	9
and	0
IL-13	9
,	0
in	0
primary	0
and	0
secondary	0
stimulations	0
of	0
spleen	7
cells	8
in	0
vitro	0
,	0
of	0
a	0
distinct	0
impaired	0
deletion	0
of	0
V	5
beta	6
11+/CD4+	6
T	6
lymphocytes	6
from	0
these	0
mice	0
was	0
detected	0
after	0
superantigen	0
injection	0
.	0

Moreover	0
,	0
NF-ATp	9
-/-	0
mice	0
older	0
than	0
6	0
weeks	0
show	0
an	0
2-5	0
fold	0
increase	0
in	0
number	0
of	0
lymphocytes	7
.	0

This	0
is	0
correlated	0
with	0
an	0
increased	0
expression	0
of	0
activation	9
markers	10
CD44	9
and	0
CD69	9
and	0
decreased	0
expression	0
of	0
CD62	9
.	0

AML	9
and	10
Ets	10
proteins	10
regulate	0
the	0
I	1
alpha1	2
germ-line	2
promoter	2
.	0

The	0
immunoglobulin	9
heavy	10
chain	10
(	0
IgH	9
)	0
class	0
switch	0
recombination	0
of	0
B	7
lymphocytes	8
preferentially	0
targets	0
unrearranged	0
IgH	1
genes	2
that	0
have	0
already	0
been	0
rendered	0
transcriptionally	0
active	0
.	0

Transcription	0
of	0
the	0
germ-line	1
IgH	2
genes	2
is	0
controlled	0
by	0
intervening	1
(	2
I	2
)	2
regions	2
upstream	0
of	0
their	0
switch	0
regions	0
.	0

The	0
I	0
alpha1	0
promoter	0
activates	0
transcription	0
of	0
the	0
human	1
germ-line	2
C	2
alpha1	2
gene	2
for	0
IgA1	9
and	0
mediates	0
the	0
transforming	9
growth	10
factor	10
(	10
TGF	10
)	10
-beta1	10
responsiveness	0
of	0
this	0
locus	0
.	0

Here	0
we	0
show	0
that	0
the	0
I	0
alpha1	0
promoter	0
contains	0
several	0
binding	0
sites	0
for	0
the	0
AML/PEBP2/CBF	9
family	10
of	10
transcription	10
factors	10
and	0
that	0
AML	9
and	10
Ets	10
proteins	10
are	0
major	0
regulators	0
of	0
the	0
basal	0
and	0
TGF-beta-inducible	0
promoter	0
activity	0
.	0

Our	0
data	0
constitute	0
a	0
starting	0
point	0
for	0
studies	0
to	0
elucidate	0
the	0
molecular	0
mechanism	0
by	0
which	0
TGF-beta	9
regulates	0
IgA	9
production	0
.	0

Daidzein	0
and	0
genistein	0
glucuronides	0
in	0
vitro	0
are	0
weakly	0
estrogenic	0
and	0
activate	0
human	7
natural	8
killer	8
cells	8
at	0
nutritionally	0
relevant	0
concentrations	0
.	0

Daidzein	0
and	0
genistein	0
glucuronides	0
(	0
DG	0
and	0
GG	0
)	0
,	0
major	0
isoflavone	0
metabolites	0
,	0
may	0
be	0
partly	0
responsible	0
for	0
biological	0
effects	0
of	0
isoflavones	0
,	0
such	0
as	0
estrogen	0
receptor	0
binding	0
and	0
natural	7
killer	8
cell	8
(	0
NK	0
)	0
activation	0
or	0
inhibition	0
.	0

DG	0
and	0
GG	0
were	0
synthesized	0
using	0
3-methylcholanthrene-induced	0
rat	0
liver	0
microsomes	0
.	0

The	0
Km	0
and	0
Vmax	0
for	0
daidzein	0
and	0
genistein	0
were	0
9.0	0
and	0
7.7	0
micromol/L	0
,	0
and	0
0.7	0
and	0
1.6	0
micromol/	0
(	0
mg	0
protein.	0
min	0
)	0
,	0
respectively	0
.	0

The	0
absence	0
of	0
ultraviolet	0
absorbance	0
maxima	0
shifts	0
in	0
the	0
presence	0
of	0
sodium	0
acetate	0
confirmed	0
that	0
the	0
synthesized	0
products	0
were	0
7-O-glucuronides	0
.	0

DG	0
and	0
GG	0
were	0
further	0
purified	0
by	0
a	0
Sephadex	0
LH-20	0
column	0
.	0

DG	0
and	0
GG	0
competed	0
with	0
the	0
binding	0
of	0
17beta-	0
(	0
3H	0
)	0
estradiol	0
to	0
estrogen	9
receptors	10
of	0
B6D2F1	0
mouse	0
uterine	0
cytosol	0
.	0

The	0
concentrations	0
required	0
for	0
50	0
%	0
displacement	0
of	0
17beta-	0
(	0
3H	0
)	0
estradiol	0
(	0
CB50	0
)	0
were	0
:	0
17beta-estradiol	0
,	0
1.34	0
nmol/L	0
;	0
diethylstilbestrol	0
,	0
1.46	0
nmol/L	0
;	0
daidzein	0
,	0
1.6	0
micromol/L	0
;	0
DG	0
,	0
14.7	0
micromol/L	0
;	0
genistein	0
,	0
0.154	0
micromol/L	0
;	0
GG	0
,	0
7.27	0
micromol/L	0
.	0

In	0
human	7
peripheral	8
blood	8
NK	8
cells	8
,	0
genistein	0
at	0
<	0
0.5	0
micromol/L	0
and	0
DG	0
and	0
GG	0
at	0
0.1-10	0
micromol/L	0
enhanced	0
NK	0
cell-mediated	0
K562	5
cancer	6
cell	6
killing	0
significantly	0
(	0
P	0
<	0
0.05	0
)	0
.	0

At	0
>	0
0.5	0
micromol/L	0
,	0
genistein	0
inhibited	0
NK	0
cytotoxicity	0
significantly	0
(	0
P	0
<	0
0.05	0
)	0
.	0

The	0
glucuronides	0
only	0
inhibited	0
NK	0
cytotoxicity	0
at	0
50	0
micromol/L	0
.	0

Isoflavones	0
,	0
and	0
especially	0
the	0
isoflavone	0
glucuronides	0
,	0
enhanced	0
activation	0
of	0
NK	7
cells	8
by	0
interleukin-2	9
(	0
IL-2	9
)	0
,	0
additively	0
.	0

At	0
physiological	0
concentrations	0
,	0
DG	0
and	0
GG	0
were	0
weakly	0
estrogenic	0
,	0
and	0
they	0
activated	0
human	7
NK	8
cells	8
in	0
nutritionally	0
relevant	0
concentrations	0
in	0
vitro	0
,	0
probably	0
at	0
a	0
site	0
different	0
from	0
IL-2	9
action	0
.	0

Cross-linking	0
of	0
CD44	9
on	0
rheumatoid	7
synovial	8
cells	8
up-regulates	0
VCAM-1	9
.	0

CD44	0
is	0
a	0
ubiquitous	0
molecule	0
also	0
known	0
as	0
hyaluronic	0
acid	0
or	0
homing	0
receptor	0
.	0

However	0
,	0
the	0
cellular	0
functions	0
and	0
its	0
role	0
in	0
inflammation	0
,	0
for	0
example	0
,	0
rheumatoid	0
synovitis	0
,	0
are	0
currently	0
unknown	0
.	0

In	0
this	0
study	0
,	0
we	0
propose	0
a	0
novel	0
function	0
for	0
CD44	0
.	0

Using	0
synovial	0
cells	0
from	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
patients	0
,	0
we	0
demonstrated	0
that	0
CD44	0
cross-linking	0
and	0
binding	0
to	0
hyaluronan	0
augmented	0
VCAM-1	9
expression	0
and	0
subsequently	0
VCAM-1	9
-mediated	0
cell	0
adhesion	0
.	0

Briefly	0
,	0
we	0
found	0
that	0
1	0
)	0
rheumatoid	7
synovial	8
cells	8
highly	0
expressed	0
CD44	9
;	0
2	0
)	0
cross-linking	0
of	0
CD44	9
markedly	0
but	0
transiently	0
augmented	0
VCAM-1	9
expression	0
and	0
its	0
mRNA	0
transcription	0
much	0
more	0
than	0
did	0
IL-1beta	9
and	0
TNF-alpha	0
;	0
3	0
)	0
hyaluronan	0
,	0
especially	0
when	0
fragmented	0
,	0
also	0
up-regulated	0
VCAM-1	9
;	0
4	0
)	0
CD44	9
activated	0
the	0
transcription	0
factor	0
AP-1	0
;	0
and	0
5	0
)	0
the	0
integrin	9
-dependent	0
adhesive	0
function	0
of	0
RA	7
synovial	8
cells	8
to	0
T	7
cells	8
was	0
also	0
amplified	0
by	0
CD44	9
cross-linking	0
.	0

These	0
results	0
indicate	0
that	0
the	0
adhesion	0
of	0
RA	7
synovial	8
cells	8
to	0
matrices	0
such	0
as	0
hyaluronic	0
acid	0
through	0
CD44	9
could	0
up-regulate	0
VCAM-1	9
expression	0
and	0
VCAM-1	9
-mediated	0
adhesion	0
to	0
T	7
cells	8
,	0
which	0
might	0
in	0
turn	0
cause	0
activation	0
of	0
T	7
cells	8
and	0
synovial	7
cells	8
in	0
RA	0
synovitis	0
.	0

We	0
therefore	0
propose	0
that	0
such	0
cross-talking	0
among	0
distinct	0
adhesion	0
molecules	0
may	0
be	0
involved	0
in	0
the	0
pathogenesis	0
of	0
inflammation	0
,	0
including	0
RA	0
synovitis	0
.	0

NF-kappaB	9
activation	0
is	0
a	0
critical	0
regulator	0
of	0
human	0
granulocyte	0
apoptosis	0
in	0
vitro	0
.	0

During	0
beneficial	0
inflammation	0
,	0
potentially	0
tissue-damaging	7
granulocytes	8
undergo	0
apoptosis	0
before	0
being	0
cleared	0
by	0
phagocytes	0
in	0
a	0
non-phlogistic	0
manner	0
.	0

Here	0
we	0
show	0
that	0
the	0
rate	0
of	0
constitutive	0
apoptosis	0
in	0
human	7
neutrophils	8
and	0
eosinophils	7
is	0
greatly	0
accelerated	0
in	0
both	0
a	0
rapid	0
and	0
concentration-dependent	0
manner	0
by	0
the	0
fungal	0
metabolite	0
gliotoxin	0
,	0
but	0
not	0
by	0
its	0
inactive	0
analog	0
methylthiogliotoxin	0
.	0

This	0
induction	0
of	0
apoptosis	0
was	0
abolished	0
by	0
the	0
caspase	0
inhibitor	0
zVAD-fmk	0
,	0
correlated	0
with	0
the	0
inhibition	0
of	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappaB	9
)	0
,	0
and	0
was	0
mimicked	0
by	0
a	0
cell	0
permeable	0
inhibitory	0
peptide	0
of	0
NF-kappaB	9
,	0
SN-50	0
;	0
other	0
NF-kappaB	9
inhibitors	0
,	0
curcumin	0
and	0
pyrrolidine	0
dithiocarbamate	0
;	0
and	0
the	0
proteasome	0
inhibitor	0
,	0
MG-132	0
.	0

Gliotoxin	0
also	0
augmented	0
dramatically	0
the	0
early	0
(	0
2-6	0
h	0
)	0
pro-apoptotic	0
effects	0
of	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
in	0
neutrophils	7
and	0
unmasked	0
the	0
ability	0
of	0
TNF-alpha	9
to	0
induce	0
eosinophil	7
apoptosis	0
.	0

In	0
neutrophils	7
,	0
TNF-alpha	9
caused	0
a	0
gliotoxin-inhibitable	0
activation	0
of	0
an	0
inducible	0
form	0
of	0
NF-kappaB	9
,	0
a	0
response	0
that	0
may	0
underlie	0
the	0
ability	0
of	0
TNF-alpha	9
to	0
delay	0
apoptosis	0
at	0
later	0
times	0
(	0
12-24	0
h	0
)	0
and	0
limit	0
its	0
early	0
killing	0
effect	0
.	0

Furthermore	0
,	0
cycloheximide	0
displayed	0
a	0
similar	0
capacity	0
to	0
enhance	0
TNF-alpha	9
induced	0
neutrophil	0
apoptosis	0
even	0
at	0
time	0
points	0
when	0
cycloheximide	0
alone	0
had	0
no	0
pro-apoptotic	0
effect	0
,	0
suggesting	0
that	0
NF-kappaB	9
may	0
regulate	0
the	0
production	0
of	0
protein	0
(	0
s	0
)	0
which	0
protect	0
neutrophils	7
from	0
the	0
cytotoxic	0
effects	0
of	0
TNF-alpha	9
.	0

These	0
data	0
shed	0
light	0
on	0
the	0
biochemical	0
and	0
molecular	0
mechanisms	0
regulating	0
human	0
granulocyte	0
apoptosis	0
and	0
,	0
in	0
particular	0
,	0
indicate	0
that	0
the	0
transcription	9
factor	10
NF-kappaB	9
plays	0
a	0
crucial	0
role	0
in	0
regulating	0
the	0
physiological	0
cell	0
death	0
pathway	0
in	0
granulocytes	7
.	0

Role	0
of	0
Egr-2	9
in	0
up-regulation	0
of	0
Fas	9
ligand	10
in	0
normal	0
T	7
cells	8
and	0
aberrant	7
double-negative	8
lpr	8
and	8
gld	8
T	8
cells	8
.	0

We	0
previously	0
identified	0
a	0
Fas	1
ligand	2
regulatory	2
element	2
(	0
FLRE	1
)	0
in	0
the	0
Fas	1
ligand	2
(	2
fasL	2
)	2
promoter	2
that	0
binds	0
Egr	9
family	10
proteins	10
and	0
demonstrated	0
that	0
Egr-3	9
(	0
PILOT	9
)	0
but	0
not	0
Egr-1	9
(	0
NGFI-A	9
,	0
Krox-24	9
,	0
Tis-8	9
,	0
and	0
Zif-268	9
)	0
induces	0
transcription	0
of	0
fasL	9
.	0

The	0
aberrant	7
CD4	8
(	8
-	8
)	8
CD8	8
(	8
-	8
)	8
T	8
cells	8
from	0
lpr/lpr	0
and	0
gld/gld	0
mice	0
,	0
which	0
have	0
mutations	0
in	0
the	0
genes	0
encoding	0
Fas	9
and	0
FasL	9
,	0
respectively	0
,	0
have	0
an	0
activated	0
phenotype	0
and	0
constitutively	0
express	0
high	0
levels	0
of	0
fasL	3
mRNA	4
,	0
prompting	0
us	0
to	0
ask	0
what	0
role	0
if	0
any	0
the	0
FLRE	1
and	0
Egr	9
family	10
proteins	10
have	0
in	0
this	0
aberrant	0
expression	0
of	0
fasL	9
.	0

Unstimulated	0
MRL-lpr/lpr	5
and	6
C3H-gld/gld	6
CD4	6
(	6
-	6
)	6
CD8	6
(	6
-	6
)	6
T	6
cells	6
constitutively	0
contained	0
high	0
levels	0
of	0
two	0
proteins	0
that	0
bound	0
to	0
the	0
FLRE	1
.	0

Supershift	0
analysis	0
revealed	0
these	0
proteins	0
to	0
be	0
Egr-1	9
and	0
Egr-2	9
(	0
Krox-20	0
)	0
;	0
Egr-3	9
was	0
not	0
detected	0
.	0

Activation	0
of	0
normal	7
lymph	8
node	8
cells	8
resulted	0
in	0
increased	0
expression	0
of	0
Egr-1	9
,	10
-2	10
,	10
and	10
-3	10
.	0

As	0
with	0
egr-3	1
,	0
expression	0
of	0
egr-2	1
was	0
blocked	0
by	0
cyclosporin	0
A	0
.	0

Although	0
overexpressed	0
Egr-1	9
was	0
ineffective	0
,	0
overexpressed	0
Egr-2	9
was	0
as	0
potent	0
as	0
Egr-3	9
in	0
inducing	0
fasL	1
promoter-dependent	2
reporter	2
constructs	2
in	0
T	0
cell	0
hybridomas	0
and	0
HeLa	0
cells	0
,	0
and	0
both	0
up-regulated	0
endogenous	0
fasL	3
mRNA	4
in	0
HeLa	5
cells	6
.	0

FasL-dependent	1
reporter	2
constructs	2
in	0
MRL-lpr/lpr	5
and	6
C3H-gld/gld	6
CD4	6
(	6
-	6
)	6
CD8	6
(	6
-	6
)	6
T	6
cells	6
were	0
constitutively	0
active	0
,	0
and	0
this	0
activity	0
was	0
largely	0
prevented	0
by	0
mutation	0
of	0
the	0
critical	0
Egr	1
family	2
binding	2
element	2
.	0

Thus	0
,	0
Egr-2	9
,	0
in	0
addition	0
to	0
Egr-3	9
,	0
regulates	0
FasL	9
expression	0
in	0
activated	0
normal	0
T	7
cells	8
,	0
and	0
Egr-2	9
is	0
likely	0
to	0
play	0
a	0
direct	0
role	0
in	0
aberrant	0
fasL	9
up-regulation	0
in	0
lpr/lpr	5
and	6
gld/gld	6
CD4	6
(	6
-	6
)	6
CD8	6
(	6
-	6
)	6
T	6
cells	6
.	0

The	0
activity	0
of	0
the	0
CCAAT-box	9
binding	10
factor	10
NF-Y	10
is	0
modulated	0
through	0
the	0
regulated	0
expression	0
of	0
its	0
A	9
subunit	10
during	0
monocyte	0
to	0
macrophage	0
differentiation	0
:	0
regulation	0
of	0
tissue-specific	1
genes	2
through	0
a	0
ubiquitous	0
transcription	9
factor	10
.	0

In	0
this	0
study	0
,	0
we	0
analyzed	0
the	0
regulation	0
of	0
NF-Y	9
expression	0
during	0
human	0
monocyte	0
to	0
macrophage	0
maturation	0
.	0

NF-Y	9
is	0
a	0
ubiquitous	0
and	0
evolutionarily	0
conserved	0
transcription	9
factor	10
that	0
binds	0
specifically	0
to	0
the	0
CCAAT	1
motif	2
present	0
in	0
the	0
5	1
'	2
promoter	2
region	2
of	0
a	0
wide	0
variety	0
of	0
genes	0
.	0

We	0
show	0
here	0
that	0
in	0
circulating	7
monocytes	8
,	0
NF-Y	9
binding	0
activity	0
is	0
not	0
detected	0
on	0
the	0
CCAAT	1
motif	2
present	0
in	0
the	0
promoters	1
of	2
genes	2
such	0
as	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
,	0
gp91-phox	1
,	0
mig	1
,	0
and	0
fibronectin	0
,	0
whereas	0
during	0
macrophage	0
differentiation	0
,	0
a	0
progressive	0
increase	0
in	0
NF-Y	9
binding	0
activity	0
is	0
observed	0
on	0
these	0
promoters	0
.	0

Analysis	0
of	0
NF-Y	9
subunit	0
expression	0
indicates	0
that	0
the	0
absence	0
of	0
NF-Y	9
activity	0
in	0
circulating	7
monocytes	8
is	0
caused	0
by	0
a	0
lack	0
of	0
the	0
A	9
subunit	10
.	0

Furthermore	0
,	0
addition	0
of	0
the	0
recombinant	0
NF-Y	9
A	9
subunit	10
restores	0
NF-Y	9
binding	0
.	0

We	0
show	0
that	0
the	0
lack	0
of	0
NF-YA	9
protein	10
is	0
due	0
to	0
posttranscriptional	0
regulation	0
and	0
not	0
to	0
a	0
specific	0
proteolytic	0
activity	0
.	0

In	0
fact	0
,	0
NF-YA	3
mRNA	4
is	0
present	0
at	0
the	0
same	0
level	0
at	0
all	0
days	0
of	0
monocyte	0
cultivation	0
,	0
whereas	0
the	0
protein	0
is	0
absent	0
in	0
freshly	7
isolated	8
monocytes	8
but	0
is	0
progressively	0
synthesized	0
during	0
the	0
maturation	0
process	0
.	0

We	0
thus	0
conclude	0
that	0
the	0
NF-Y	9
A	9
subunit	10
plays	0
a	0
relevant	0
role	0
in	0
activating	0
transcription	0
of	0
genes	0
highly	0
expressed	0
in	0
mature	7
monocytes	8
.	0

In	0
line	0
with	0
this	0
conclusion	0
,	0
we	0
show	0
that	0
the	0
cut/CDP	9
protein	10
,	0
a	0
transcriptional	0
repressor	0
that	0
inhibits	0
gpc91-phox	1
gene	2
expression	0
by	0
preventing	0
NF-Y	9
binding	0
to	0
the	0
CAAT	1
box	2
,	0
is	0
absent	0
in	0
monocytes	7
.	0

Interdomain	9
B	10
in	0
ZAP-70	9
regulates	0
but	0
is	0
not	0
required	0
for	0
ZAP-70	9
signaling	0
function	0
in	0
lymphocytes	7
.	0

The	0
protein	0
tyrosine	0
kinase	0
ZAP-70	9
plays	0
an	0
important	0
role	0
in	0
T-cell	0
activation	0
and	0
development	0
.	0

After	0
T-cell	9
receptor	10
stimulation	0
,	0
ZAP-70	9
associates	0
with	0
the	0
receptor	0
and	0
is	0
phosphorylated	0
on	0
many	0
tyrosines	0
,	0
including	0
Y292	0
,	0
Y315	0
,	0
and	0
Y319	0
within	0
interdomain	0
B	0
.	0

Previously	0
,	0
we	0
demonstrated	0
that	0
Y292	0
negatively	0
regulates	0
ZAP-70	9
function	0
and	0
that	0
Y315	0
positively	0
regulates	0
ZAP-70	9
function	0
by	0
interacting	0
with	0
Vav	9
.	0

Recent	0
studies	0
have	0
suggested	0
that	0
Y319	0
also	0
positively	0
regulate	0
ZAP-70	9
function	0
.	0

Paradoxically	0
,	0
removal	0
of	0
interdomain	9
B	10
(	0
to	0
create	0
the	0
construct	0
designated	0
Delta	9
)	0
,	0
containing	0
the	0
Y292	0
,	0
Y315	0
,	0
and	0
Y319	0
sites	0
,	0
did	0
not	0
eliminate	0
the	0
ability	0
of	0
ZAP-70	9
to	0
induce	0
multiple	1
gene	2
reporters	2
in	0
Syk-deficient	5
DT-40	6
B	6
cells	6
and	0
ZAP-70/Syk-deficient	5
Jurkat	6
cells	6
.	0

Here	0
we	0
show	0
that	0
Delta	9
still	0
utilizes	0
the	0
same	0
pathways	0
as	0
wild-type	0
ZAP-70	9
to	0
mediate	0
NF-AT	9
induction	0
.	0

This	0
is	0
manifested	0
by	0
the	0
ability	0
of	0
Delta	9
to	0
restore	0
induction	0
of	0
calcium	0
fluxes	0
and	0
mitogen-activated	9
protein	10
kinase	10
activation	0
and	0
by	0
the	0
ability	0
of	0
dominant	0
negative	0
Ras	9
and	0
FK506	9
to	0
block	0
the	0
induction	0
of	0
NF-AT	9
activity	0
mediated	0
by	0
Delta	9
.	0

Biochemically	0
we	0
show	0
that	0
the	0
stimulated	0
tyrosine	0
phosphorylation	0
of	0
Vav	9
,	0
Shc	9
,	0
and	0
ZAP-70	9
itself	0
is	0
diminished	0
,	0
whereas	0
that	0
of	0
Slp-76	9
is	0
increased	0
in	0
cells	0
reconstituted	0
with	0
Delta	9
.	0

Deletion	0
of	0
interdomain	9
B	10
did	0
not	0
affect	0
the	0
ability	0
of	0
ZAP-70	9
to	0
bind	0
to	0
the	0
receptor	0
.	0

The	0
in	0
vitro	0
kinase	0
activity	0
of	0
ZAP-70	9
lacking	0
interdomain	9
B	10
was	0
markedly	0
reduced	0
,	0
but	0
the	0
kinase	0
activity	0
was	0
still	0
required	0
for	0
the	0
protein	0
's	0
in	0
vivo	0
activity	0
.	0

Based	0
on	0
these	0
data	0
,	0
we	0
concluded	0
that	0
interdomain	9
B	10
regulates	0
but	0
is	0
not	0
required	0
for	0
ZAP-70	9
signaling	0
function	0
leading	0
to	0
cellular	0
responses	0
.	0

Differential	0
induction	0
of	0
DNA-binding	9
activities	10
following	0
CD19	9
cross-linking	0
in	0
human	7
B	8
lineage	8
cells	8
.	0

The	0
B	9
cell-specific	10
cell	10
surface	10
molecule	10
CD19	9
is	0
expressed	0
at	0
all	0
stages	0
of	0
B	0
cell	0
development	0
,	0
including	0
normal	0
plasma	0
cells	0
,	0
and	0
mediates	0
signal	0
transduction	0
via	0
interaction	0
with	0
cytoplasmic	9
effector	10
proteins	10
.	0

Cross-linking	0
CD19	9
on	0
early	0
human	7
B	8
lineage	8
cells	8
induces	0
the	0
formation	0
of	0
a	0
CD19/Vav/phosphatidylinositol-3	9
kinase	10
complex	10
,	0
tyrosine	0
phosphorylation	0
of	0
CD19	9
and	0
Vav	9
,	0
and	0
activation	0
of	0
the	0
Ras	9
pathway	0
.	0

To	0
further	0
explore	0
the	0
ramifications	0
of	0
CD19	9
signaling	0
,	0
the	0
current	0
study	0
examined	0
whether	0
phosphorylation	0
of	0
Elk-1	9
,	0
activation	0
of	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
,	0
or	0
activation	0
of	0
nuclear	0
factor-kappaB	0
(	0
NF-kappaB	9
)	0
transcription	9
factors	10
occurred	0
following	0
CD19	9
cross-linking	0
.	0

The	0
cells	0
used	0
were	0
the	0
BLIN-1	5
pre-B	6
cell	6
line	6
expressing	0
low	0
levels	0
of	0
cell	9
surface	10
mu	10
heavy	10
chain	10
associated	0
with	0
surrogate	9
light	10
chain	10
and	0
the	0
1E8	0
immature	0
B	0
cell	0
line	0
expressing	0
cell	9
surface	10
mu/kappa	10
.	0

Lysates	0
from	0
CD19	9
cross-linked	0
1E8	5
cells	6
induced	0
robust	0
phosphorylation	0
of	0
an	0
Elk-1	9
fusion	10
protein	10
in	0
vitro	0
,	0
whereas	0
no	0
phosphorylation	0
of	0
Elk-1	9
fusion	10
protein	10
occurred	0
using	0
lysates	0
from	0
CD19	5
cross-linked	6
BLIN-1	6
cells	6
.	0

An	0
electrophoretic	0
mobility	0
shift	0
assay	0
employing	0
AP-1	9
and	0
NF-kappaB	9
consensus	0
oligonucleotides	0
was	0
used	0
to	0
demonstrate	0
that	0
AP-1	9
-binding	0
activity	0
increased	0
,	0
while	0
constitutive	0
NF-kappaB	9
-binding	0
activity	0
was	0
not	0
enhanced	0
,	0
following	0
2	0
h	0
of	0
CD19	9
cross-linking	0
in	0
1E8	5
cells	6
.	0
Supershift	0
experiments	0
revealed	0
that	0
JunD	9
and	0
c-Fos	9
proteins	10
mediated	0
anti-	0
CD19	9
induced	0
AP-1	9
-binding	0
activity	0
in	0
1E8	5
cells	6
.	0

In	0
contrast	0
,	0
CD19	9
cross-linking	0
in	0
BLIN-1	5
cells	6
resulted	0
in	0
the	0
induction	0
of	0
NF-kappaB	9
,	0
but	0
had	0
no	0
apparent	0
effect	0
on	0
AP-1	9
-binding	0
activity	0
.	0

These	0
data	0
suggest	0
that	0
CD19	9
-mediated	0
signal	0
transduction	0
activates	0
different	0
transcription	9
factors	10
at	0
juxtaposed	0
stages	0
of	0
B	0
cell	0
development	0
that	0
may	0
culminate	0
in	0
the	0
activation	0
or	0
suppression	0
of	0
distinct	0
sets	0
of	0
genes	1
.	0

Oxidants	0
,	0
transcription	9
factors	10
,	0
and	0
intestinal	0
inflammation	0
.	0

It	0
is	0
now	0
well	0
appreciated	0
that	0
chronic	0
gut	0
inflammation	0
is	0
characterized	0
by	0
enhanced	0
production	0
of	0
reactive	0
metabolites	0
of	0
oxygen	0
and	0
nitrogen	0
.	0

Some	0
of	0
these	0
oxidants	0
are	0
known	0
to	0
modulate	0
the	0
expression	0
of	0
a	0
variety	0
of	0
genes	0
that	0
are	0
involved	0
in	0
the	0
immune	0
and	0
inflammatory	0
responses	0
.	0

For	0
example	0
,	0
certain	0
oxidants	0
are	0
known	0
to	0
activate	0
the	0
nuclear	9
transcription	10
factor	10
kappa	10
B	10
,	0
which	0
regulates	0
the	0
expression	0
of	0
a	0
variety	0
of	0
different	0
adhesion	9
molecules	10
,	0
cytokines	9
,	0
and	0
enzymes	9
.	0

Oxidants	0
are	0
also	0
known	0
to	0
activate	0
another	0
transcription	9
factor	10
,	0
activator	9
protein-1	10
.	0

This	0
transcription	9
factor	10
is	0
composed	0
of	0
products	0
from	0
the	0
fos	9
and	10
jun	10
proto-oncogene	10
family	10
and	0
is	0
believed	0
to	0
be	0
important	0
in	0
regulating	0
cell	0
growth	0
and	0
proliferation	0
.	0

Finally	0
,	0
oxidants	0
are	0
believed	0
to	0
promote	0
intestinal	7
epithelial	8
cell	8
apoptosis	0
,	0
and	0
the	0
B-cell	9
lymphoma/leukemia-2	10
gene	10
product	10
is	0
believed	0
to	0
inhibit	0
this	0
phenomenon	0
in	0
an	0
antioxidant-dependent	0
manner	0
.	0

Taken	0
together	0
,	0
these	0
observations	0
suggest	0
that	0
nontoxic	0
concentrations	0
of	0
reactive	0
metabolites	0
of	0
oxygen	0
and	0
nitrogen	0
play	0
an	0
important	0
role	0
in	0
regulating	0
the	0
expression	0
of	0
genes	0
involved	0
in	0
the	0
inflammatory	0
response	0
and	0
in	0
modulating	0
apoptosis	0
.	0

Identification	0
of	0
target	1
genes	2
of	0
the	0
lymphoid-specific	9
transcription	10
factor	10
Oct2	10
.	0

The	0
Oct2	9
transcription	9
factor	10
is	0
expressed	0
predominantly	0
in	0
B	7
lymphocytes	8
and	0
plays	0
an	0
essential	0
role	0
during	0
the	0
terminal	0
phase	0
of	0
B	0
cell	0
differentiation	0
.	0

The	0
regulatory	1
regions	2
of	0
several	0
genes	0
specifically	0
expressed	0
in	0
B	7
cells	8
contain	0
functional	1
binding	2
sites	2
for	0
Oct2	9
.	0

Nevertheless	0
,	0
none	0
of	0
the	0
genes	0
originally	0
thought	0
to	0
be	0
regulated	0
by	0
Oct2	9
were	0
affected	0
in	0
their	0
expression	0
in	0
Oct2-deficient	5
B	6
cells	6
.	0

In	0
an	0
attempt	0
to	0
find	0
such	0
elusive	0
Oct2	9
target	1
genes	2
and	0
to	0
understand	0
the	0
molecular	0
function	0
of	0
Oct2	9
in	0
B	0
cell	0
development	0
,	0
we	0
isolated	0
cDNAs	1
for	0
Oct2	9
target	1
genes	2
.	0

So	0
far	0
,	0
we	0
have	0
identified	0
five	0
potential	0
targets	0
for	0
Oct2	9
:	0
the	0
membrane	9
glycoprotein	10
CD36	9
,	0
the	0
cysteine-rich	9
secreted	10
protein	10
3	10
(	0
CRISP-3	9
)	0
,	0
a	0
mouse	0
homolog	0
of	0
the	0
human	9
monocyte/neutrophil	10
elastase	10
inhibitor	10
(	0
mEI	9
)	0
and	0
two	0
unknown	0
cDNA	1
sequences	2
Nov1	1
and	0
Nov2	1
.	0

These	0
target	1
genes	2
show	0
quite	0
distinct	0
expression	0
patterns	0
demonstrating	0
that	0
transcription	9
factors	10
in	0
addition	0
to	0
Oct2	9
are	0
involved	0
in	0
their	0
regulation	0
.	0

Whereas	0
CD36	9
and	0
mEI	9
were	0
expressed	0
in	0
all	0
hematopoetic	5
cell	6
lines	6
containing	0
Oct2	9
,	0
.	0

CRISP-3	9
is	0
pre-B	0
cell-specific	0
,	0
Nov1	1
is	0
plasma	0
B	0
cell-specific	0
and	0
Nov2	1
is	0
B	0
cell-specifically	0
expressed	0
.	0

RFX-B	1
is	0
the	0
gene	0
responsible	0
for	0
the	0
most	0
common	0
cause	0
of	0
the	0
bare	0
lymphocyte	0
syndrome	0
,	0
an	0
MHC	9
class	10
II	10
immunodeficiency	0
[	0
published	0
erratum	0
appears	0
in	0
Immunity	0
1999	0
Mar	0
;	0
10	0
(	0
3	0
)	0
:	0
399	0
]	0

The	0
bare	0
lymphocyte	0
syndrome	0
(	0
BLS	0
)	0
is	0
characterized	0
by	0
the	0
absence	0
of	0
MHC	9
class	10
II	10
transcription	0
and	0
humoral-	0
and	0
cellular-mediated	0
immune	0
responses	0
to	0
foreign	0
antigens	0
.	0

Three	0
of	0
the	0
four	0
BLS	0
genetic	0
complementation	0
groups	0
have	0
defects	0
in	0
the	0
activity	0
of	0
the	0
MHC	9
class	10
II	10
transcription	10
factor	10
RFX	9
.	0

We	0
have	0
purified	0
the	0
RFX	9
complex	10
and	0
sequenced	0
its	0
three	0
subunits	0
.	0

The	0
sequence	0
of	0
the	0
smallest	0
subunit	0
describes	0
a	0
novel	0
gene	0
,	0
termed	0
RFX-B	1
.	0

RFX-B	1
complements	0
the	0
predominant	0
BLS	9
complementation	10
group	10
(	0
group	9
B	10
)	0
and	0
was	0
found	0
to	0
be	0
mutant	0
in	0
cell	5
lines	6
from	0
this	0
BLS	0
group	0
.	0

The	0
protein	0
has	0
no	0
known	0
DNA-binding	9
domain	10
but	0
does	0
contain	0
three	0
ankyrin	0
repeats	0
that	0
are	0
likely	0
to	0
be	0
important	0
in	0
protein-protein	0
interactions	0
.	0

Binding	0
of	0
c-Rel	9
to	0
STAT5	1
target	2
sequences	2
in	0
HTLV-I-transformed	7
T	8
cells	8
.	0

The	0
type	0
I	0
human	0
T-cell	0
leukemia	0
virus	0
(	0
HTLV-I	0
)	0
induces	0
abnormal	0
growth	0
and	0
subsequent	0
transformation	0
of	0
T	7
cells	8
,	0
which	0
is	0
associated	0
with	0
the	0
development	0
of	0
an	0
acute	0
T-cell	0
malignancy	0
termed	0
adult	0
T-cell	0
leukemia	0
.	0

A	0
characteristic	0
of	0
HTLV-I-transformed	7
T	8
cells	8
is	0
the	0
constitutive	0
nuclear	0
expression	0
of	0
NF-kappaB/Rel	9
family	10
of	0
transcription	0
factors	0
,	0
which	0
appears	0
to	0
be	0
essential	0
for	0
the	0
growth	0
of	0
these	0
transformed	7
cells	8
.	0

Although	0
NF-kappaB/Rel	9
factors	10
are	0
known	0
to	0
induce	0
the	0
expression	0
of	0
T-cell	9
growth	10
factor	10
interleukin	10
(	10
IL	10
)	10
-2	10
,	0
it	0
is	0
unclear	0
how	0
they	0
participate	0
in	0
the	0
IL-2	9
-independent	0
growth	0
of	0
HTLV-I-transformed	5
cells	6
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
certain	0
NF-kappaB/Rel	9
members	10
,	0
predominantly	0
c-Rel	9
,	0
interact	0
with	0
enhancer	0
sequences	0
for	0
STAT5	9
,	0
a	0
key	0
transcription	0
factor	0
mediating	0
IL-2	9
-induced	0
T-cell	0
proliferation	0
.	0

Reporter	0
gene	0
assays	0
reveal	0
that	0
the	0
binding	0
of	0
c-Rel	9
to	0
the	0
STAT5	9
site	0
present	0
in	0
the	0
Fc	1
gammaR1	2
gene	2
leads	0
to	0
potent	0
transactivation	0
of	0
this	0
enhancer	0
.	0

Binding	0
of	0
c-Rel	9
to	0
the	0
Fc	1
gammaR1	2
STAT	2
site	2
also	0
occurs	0
in	0
human	0
peripheral	7
blood	8
T	8
cells	8
immortalized	0
with	0
HTLV-I	0
in	0
vitro	0
and	0
is	0
correlated	0
with	0
enhanced	0
levels	0
of	0
proliferation	0
of	0
these	0
cells	0
.	0

These	0
results	0
raise	0
the	0
possibility	0
that	0
NF-kappaB/Rel	9
may	0
participate	0
in	0
the	0
growth	0
control	0
of	0
HTLV-I-transformed	5
T	6
cells	6
by	0
regulating	0
genes	0
driven	0
by	0
both	0
kappaB	1
and	0
certain	0
STAT	1
enhancers	2
.	0

Activation-dependent	0
transcriptional	0
regulation	0
of	0
the	0
human	1
Fas	2
promoter	2
requires	0
NF-kappaB	9
p50-p65	10
recruitment	0
.	0

Fas	9
(	0
CD95	9
)	0
and	0
Fas	9
ligand	10
(	0
CD95L	9
)	0
are	0
an	0
interacting	0
receptor-ligand	0
pair	0
required	0
for	0
immune	0
homeostasis	0
.	0

Lymphocyte	0
activation	0
results	0
in	0
the	0
upregulation	0
of	0
Fas	9
expression	0
and	0
the	0
acquisition	0
of	0
sensitivity	0
to	0
FasL	9
-mediated	0
apoptosis	0
.	0

Although	0
Fas	0
upregulation	0
is	0
central	0
to	0
the	0
preservation	0
of	0
immunologic	0
tolerance	0
,	0
little	0
is	0
known	0
about	0
the	0
molecular	0
machinery	0
underlying	0
this	0
process	0
.	0

To	0
investigate	0
the	0
events	0
involved	0
in	0
activation-induced	0
Fas	9
upregulation	0
,	0
we	0
have	0
examined	0
mRNA	0
accumulation	0
,	0
fas	0
promoter	0
activity	0
,	0
and	0
protein	0
expression	0
in	0
the	0
Jurkat	5
T-cell	6
line	6
treated	0
with	0
phorbol	0
myristate	0
acetate	0
and	0
ionomycin	0
(	0
P/I	0
)	0
,	0
pharmacological	0
mimics	0
of	0
T-cell	9
receptor	10
activation	0
.	0

Although	0
resting	5
Jurkat	6
cells	6
express	0
Fas	9
,	0
Fas	3
mRNA	4
was	0
induced	0
approximately	0
10-fold	0
in	0
2	0
h	0
upon	0
P/I	0
stimulation	0
.	0

Using	0
sequential	1
deletion	2
mutants	2
of	0
the	0
human	1
fas	2
promoter	2
in	0
transient	0
transfection	0
assays	0
,	0
we	0
identified	0
a	0
47-bp	1
sequence	2
(	0
positions	1
-306	2
to	2
-260	2
relative	0
to	0
the	0
ATG	0
)	0
required	0
for	0
activation-driven	0
fas	0
upregulation	0
.	0

Sequence	0
analysis	0
revealed	0
the	0
presence	0
of	0
a	0
previously	0
unrecognized	1
composite	2
binding	2
site	2
for	0
both	0
the	0
Sp1	9
and	0
NF-kappaB	9
transcription	9
factors	10
at	0
positions	1
-295	2
to	2
-286	2
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
and	0
supershift	0
analyses	0
of	0
this	0
region	0
documented	0
constitutive	0
binding	0
of	0
Sp1	9
in	0
unactivated	0
nuclear	0
extracts	0
and	0
inducible	0
binding	0
of	0
p50-p65	9
NF-kappaB	10
heterodimers	10
after	0
P/I	0
activation	0
.	0

Sp1	9
and	0
NF-kappaB	9
transcription	0
factor	0
binding	0
was	0
shown	0
to	0
be	0
mutually	0
exclusive	0
by	0
EMSA	0
displacement	0
studies	0
with	0
purified	0
recombinant	0
Sp1	9
and	0
recombinant	0
p50	9
.	0

The	0
functional	0
contribution	0
of	0
the	0
kappaB-Sp1	1
composite	2
site	2
in	0
P/I-inducible	1
fas	2
promoter	2
activation	0
was	0
verified	0
by	0
using	0
kappaB-	0
Sp1	9
concatamers	0
(	0
-295	1
to	2
-286	2
)	0
in	0
a	0
thymidine	1
kinase	2
promoter-driven	2
reporter	2
construct	2
and	0
native	1
promoter	2
constructs	2
in	0
Jurkat	5
cells	6
overexpressing	0
IkappaB-alpha	9
.	0

Site-directed	0
mutagenesis	0
of	0
the	0
critical	0
guanine	0
nucleotides	0
in	0
the	0
kappaB-Sp1	1
element	2
documented	0
the	0
essential	0
role	0
of	0
this	0
site	0
in	0
activation-dependent	0
fas	0
promoter	0
induction	0
.	0

Evidence	0
for	0
repression	0
of	0
IL-2	1
gene	2
activation	0
in	0
anergic	7
T	8
cells	8
.	0

The	0
induction	0
of	0
clonal	0
anergy	0
in	0
a	0
T	0
cell	0
inhibits	0
IL-2	9
secretion	0
because	0
of	0
the	0
development	0
of	0
a	0
proximal	0
signal	0
transduction	0
defect	0
.	0

Fusion	0
of	0
anergic	7
murine	8
T	8
cells	8
to	0
human	7
Jurkat	8
T	8
leukemia	8
cells	8
and	0
formation	0
of	0
heterokaryons	5
failed	0
to	0
result	0
in	0
a	0
complementation	0
of	0
this	0
signaling	0
defect	0
and	0
restoration	0
of	0
murine	3
IL-2	4
mRNA	4
inducibility	0
.	0

Instead	0
,	0
signal	0
transduction	0
to	0
the	0
human	0
IL-2	1
gene	2
became	0
disrupted	0
.	0

Heterokaryons	5
formed	0
by	0
the	0
fusion	0
of	0
anergic	7
murine	8
T	8
cells	8
to	0
normal	7
murine	8
T	8
cells	8
also	0
failed	0
to	0
accumulate	0
intracellular	9
IL-2	10
protein	10
in	0
response	0
to	0
stimulation	0
either	0
with	0
the	0
combination	0
of	0
CD3	9
and	0
CD28	9
mAbs	10
or	0
with	0
ionomycin	0
plus	0
a	0
protein	9
kinase	10
C	10
-activating	0
phorbol	0
ester	0
.	0

The	0
results	0
argue	0
against	0
a	0
loss-of-function	0
signaling	0
defect	0
as	0
the	0
sole	0
basis	0
for	0
clonal	0
anergy	0
induction	0
and	0
document	0
the	0
presence	0
of	0
a	0
dominant-acting	9
repressor	10
molecule	10
that	0
inhibits	0
signal	0
transduction	0
to	0
the	0
IL-2	1
gene	2
within	0
viable	0
anergic	7
T	8
cells	8
.	0

Comparison	0
of	0
HTLV-I	0
basal	0
transcription	0
and	0
expression	0
of	0
CREB/ATF-1/CREM	9
family	10
members	10
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
Jurkat	5
T	6
cells	6
.	0

HTLV-I	0
is	0
the	0
etiologic	0
agent	0
of	0
adult	0
T-cell	0
leukemia/lymphoma	0
and	0
is	0
associated	0
with	0
tropical	0
spastic	0
paraparesis/HTLV-I-associated	0
myelopathy	0
.	0

Following	0
integration	0
into	0
the	0
host	0
cell	0
genome	0
,	0
HTLV-I	0
replication	0
is	0
regulated	0
by	0
both	0
host	0
and	0
viral	0
mechanisms	0
that	0
control	0
transcription	0
.	0

Low	0
levels	0
of	0
viral	0
transcription	0
(	0
basal	0
transcription	0
)	0
occur	0
before	0
expression	0
of	0
the	0
virally	9
encoded	10
Tax	10
protein	10
(	0
Tax	9
-mediated	0
transcription	0
)	0
.	0

Members	0
of	0
the	0
cyclic	9
adenosine	10
monophosphate	10
(	10
cAMP	10
)	10
response	10
element	10
binding	10
(	10
CREB	10
)	10
/activating	10
transcription	10
factor	10
1	10
(	10
ATF-1	10
)	10
family	10
of	0
transcription	9
factors	10
bind	0
three	0
21-bp	1
repeats	2
(	0
Tax-responsive	1
element-1	2
,	0
or	0
TRE-1	1
)	0
within	0
the	0
viral	1
promoter	2
and	0
are	0
important	0
for	0
basal	0
and	0
Tax-mediated	0
transcription	0
.	0

Using	0
mitogen	0
stimulated	0
and	0
quiescent	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
and	0
Jurkat	5
cells	6
,	0
we	0
compared	0
differences	0
in	0
basal	0
transcription	0
and	0
amounts	0
and	0
binding	0
of	0
transcription	9
factors	10
with	0
TRE-1	1
.	0

We	0
demonstrate	0
that	0
amounts	0
of	0
transcriptionally	0
active	0
phosphorylated	9
CREB	10
protein	10
(	0
P-CREB	9
)	0
differ	0
between	0
activated	0
PBMC	7
and	0
Jurkat	5
cells	6
.	0

Following	0
stimulation	0
,	0
P-CREB	9
levels	0
remain	0
elevated	0
in	0
PBMC	7
for	0
up	0
to	0
24	0
hours	0
whereas	0
CREB	0
is	0
dephosphorylated	0
in	0
Jurkat	5
cells	6
within	0
4	0
hours	0
following	0
stimulation	0
.	0

The	0
differences	0
in	0
P-CREB	9
levels	0
between	0
PBMC	7
and	0
Jurkat	5
cells	6
were	0
directly	0
correlated	0
with	0
basal	0
transcription	0
of	0
HTLV-I	0
in	0
the	0
two	0
cell	0
types	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
we	0
determined	0
that	0
the	0
pattern	0
of	0
band	0
migration	0
differed	0
between	0
the	0
two	0
cell	0
types	0
.	0

These	0
data	0
demonstrate	0
that	0
PBMC	7
differentially	0
regulate	0
basal	0
HTLV-I	0
transcription	0
compared	0
with	0
Jurkat	5
T	6
cells	6
,	0
and	0
this	0
differential	0
regulation	0
is	0
due	0
,	0
in	0
part	0
to	0
differential	0
phosphorylation	0
and	0
binding	0
of	0
CREB/ATF-1	9
to	0
TRE-1	1
in	0
the	0
HTLV-I	0
promoter	0
.	0

We	0
demonstrate	0
the	0
utility	0
of	0
using	0
primary	0
lymphocyte	0
models	0
to	0
study	0
HTLV-I	0
transcription	0
in	0
the	0
context	0
of	0
cell	0
signaling	0
and	0
suggest	0
that	0
activated	0
PBMC	7
maintain	0
elevated	0
levels	0
of	0
P-CREB	9
,	0
which	0
promote	0
basal	0
HTLV-I	0
transcription	0
and	0
enhance	0
viral	0
persistence	0
in	0
vivo	0
.	0

Anoxia/reoxygenation-induced	0
tolerance	0
with	0
respect	0
to	0
polymorphonuclear	0
leukocyte	0
adhesion	0
to	0
cultured	5
endothelial	6
cells	6
.	0

A	0
nuclear	9
factor-kappaB	10
-mediated	0
phenomenon	0
.	0

Exposing	0
human	5
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVECs	5
)	0
to	0
anoxia/reoxygenation	0
(	0
A/R	0
)	0
results	0
in	0
an	0
increase	0
in	0
polymorphonuclear	0
leukocyte	0
(	0
PMN	7
)	0
adhesion	0
to	0
HUVECs	5
.	0

This	0
A/R-induced	0
hyperadhesion	0
is	0
completely	0
prevented	0
by	0
a	0
previous	0
(	0
24	0
hours	0
earlier	0
)	0
exposure	0
of	0
HUVECs	5
to	0
A/R	0
.	0

This	0
phenomenon	0
has	0
been	0
termed	0
``	0
A/R	0
tolerance.	0
''	0

Exposing	0
HUVECs	5
to	0
A/R	0
induces	0
an	0
increase	0
in	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
in	0
HUVEC	0
nuclei	0
within	0
4	0
hours	0
.	0

Interfering	0
with	0
either	0
NF-kappaB	9
activation	0
(	0
proteasome	9
inhibitor	0
)	0
or	0
translocation	0
(	0
double-stranded	0
oligonucleotides	0
containing	0
NF-kappaB	1
binding	2
sequence	2
)	0
prevents	0
the	0
development	0
of	0
A/R	0
tolerance	0
(	0
ie	0
,	0
the	0
increase	0
in	0
A/R-induced	0
PMN	0
adhesion	0
to	0
HUVECs	5
is	0
the	0
same	0
after	0
the	0
first	0
and	0
second	0
A/R	0
challenges	0
)	0
.	0

NO	0
production	0
by	0
HUVECs	5
is	0
increased	0
after	0
the	0
second	0
A/R	0
challenge	0
,	0
but	0
not	0
after	0
the	0
first	0
A/R	0
challenge	0
.	0

Inhibition	0
of	0
NO	9
synthase	10
(	0
NOS	9
)	0
during	0
the	0
second	0
A/R	0
challenge	0
prevents	0
the	0
development	0
of	0
A/R	0
tolerance	0
with	0
respect	0
to	0
PMN	0
adhesion	0
.	0

However	0
,	0
while	0
HUVECs	5
contained	0
endothelial	0
NOS	9
protein	10
,	0
no	0
inducible	0
NOS	9
was	0
detected	0
in	0
either	0
tolerant	0
or	0
nontolerant	7
cells	8
.	0

Further	0
studies	0
indicated	0
that	0
inhibition	0
of	0
GTP-cyclohydrolase	9
I	10
(	0
an	0
enzyme	0
involved	0
in	0
de	0
novo	0
synthesis	0
of	0
an	0
important	0
cofactor	0
for	0
NOS	9
activity	0
,	0
tetrahydrobiopterin	0
)	0
prevented	0
the	0
generation	0
of	0
NO	0
in	0
A/R-tolerant	5
cells	6
.	0

Extracellular	0
generation	0
of	0
NO	0
(	0
NO	0
donor	0
)	0
did	0
not	0
effect	0
the	0
hyperadhesion	0
response	0
induced	0
by	0
the	0
initial	0
A/R	0
challenge	0
.	0

A/R	0
also	0
induced	0
an	0
oxidant	0
stress	0
in	0
naive	0
HUVECs	5
,	0
but	0
not	0
in	0
A/R-tolerant	5
HUVECs	6
.	0

Inhibition	0
of	0
NOS	9
during	0
the	0
second	0
A/R	0
insult	0
results	0
in	0
the	0
generation	0
of	0
an	0
oxidant	0
stress	0
similar	0
to	0
that	0
observed	0
after	0
the	0
first	0
A/R	0
challenge	0
.	0

Taken	0
together	0
,	0
the	0
findings	0
of	0
the	0
present	0
study	0
are	0
consistent	0
with	0
a	0
role	0
for	0
NF-kappaB	9
in	0
the	0
development	0
of	0
A/R	0
tolerance	0
(	0
with	0
respect	0
to	0
PMN	7
adhesion	0
)	0
,	0
perhaps	0
by	0
transcriptional	0
regulation	0
of	0
GTP-cyclohydrolase	9
.	0

The	0
increased	0
NO	0
production	0
during	0
the	0
second	0
A/R	0
insult	0
reduces	0
PMN	0
adhesion	0
most	0
likely	0
by	0
reducing	0
the	0
intracellular	0
oxidant	0
stress	0
induced	0
by	0
A/R	0
.	0

Mildly	0
oxidized	0
low-density	9
lipoproteins	10
decrease	0
early	0
production	0
of	0
interleukin	9
2	10
and	0
nuclear	9
factor	10
kappaB	10
binding	0
to	0
DNA	0
in	0
activated	7
T-lymphocytes	8
.	0

Activated	0
T-lymphocytes	0
are	0
found	0
early	0
in	0
atherosclerosis	0
lesions	0
,	0
but	0
little	0
is	0
known	0
about	0
their	0
role	0
.	0

Oxidized	0
low-density	9
lipoproteins	10
(	0
oxLDLs	9
)	0
are	0
considered	0
to	0
be	0
involved	0
in	0
the	0
pathogenesis	0
of	0
the	0
lesions	0
,	0
and	0
we	0
have	0
previously	0
demonstrated	0
that	0
oxLDLs	9
inhibit	0
not	0
only	0
interleukin	9
(	10
IL	10
)	10
-2-receptor	10
expression	0
on	0
the	0
surface	0
of	0
in	0
vitro-activated	0
T-lymphocytes	0
but	0
also	0
their	0
proliferation	0
.	0

We	0
have	0
now	0
investigated	0
the	0
effect	0
of	0
oxLDLs	9
on	0
blast	0
differentiation	0
,	0
on	0
IL-2	9
synthesis	0
and	0
on	0
the	0
activation	0
of	0
the	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
system	0
in	0
activated	0
lymphocytes	0
.	0

Mildly	0
oxLDLs	9
(	0
50	0
and	0
100	0
microgram/ml	0
)	0
decreased	0
the	0
number	0
of	0
lymphoblasts	7
and	0
the	0
level	0
of	0
IL-2	0
concentration	0
in	0
the	0
culture	0
supernatants	0
after	0
activation	0
of	0
lymphocytes	7
by	0
phytohaemagglutinin	9
and	0
PMA+ionomycin	0
.	0

The	0
inhibition	0
of	0
IL-2	9
production	0
was	0
observed	0
in	0
the	0
CD3	9
(	0
+	0
)	0
T-lymphocyte	0
cytoplasm	0
as	0
early	0
as	0
4	0
h	0
after	0
activation	0
by	0
PMA+ionomycin	0
.	0

The	0
study	0
of	0
NF-kappaB	9
showed	0
that	0
oxLDLs	9
led	0
to	0
a	0
decrease	0
of	0
activation-induced	9
p65/p50	10
NF-kappaB	9
heterodimer	0
binding	0
to	0
DNA	0
,	0
whereas	0
the	0
presence	0
of	0
the	0
constitutive	0
nuclear	0
form	0
of	0
p50	9
dimer	10
was	0
unchanged	0
.	0

This	0
was	0
correlated	0
with	0
an	0
unchanged	0
level	0
of	0
the	0
active	0
form	0
of	0
the	0
cytosolic	9
inhibitor	10
protein	10
IkappaB-alpha	9
.	0

Taken	0
together	0
,	0
these	0
observations	0
suggest	0
that	0
the	0
immunosuppressive	0
effect	0
of	0
oxLDLs	9
might	0
operate	0
via	0
a	0
dysregulation	0
of	0
the	0
T-lymphocyte	7
activation	0
mechanisms	0
.	0

The	0
B29	1
(	2
immunoglobulin	2
beta-chain	2
)	2
gene	2
is	0
a	0
genetic	0
target	0
for	0
early	9
B-cell	10
factor	10
.	0

Early	9
B-cell	10
factor	10
(	0
EBF	9
)	0
is	0
a	0
transcription	9
factor	10
suggested	0
as	0
essential	0
for	0
early	0
B-lymphocyte	7
development	0
by	0
findings	0
in	0
mice	0
where	0
the	0
coding	0
gene	0
has	0
been	0
inactivated	0
by	0
homologous	0
disruption	0
.	0

This	0
makes	0
the	0
identification	0
of	0
genetic	0
targets	0
for	0
this	0
transcription	9
factor	10
pertinent	0
for	0
the	0
understanding	0
of	0
early	0
B-cell	0
development	0
.	0

The	0
lack	0
of	0
B29	3
transcripts	4
,	0
coding	0
for	0
the	0
beta	9
subunit	10
of	0
the	0
B-cell	0
receptor	0
complex	0
,	0
in	0
pro-B	7
cells	8
from	0
EBF	9
-deficient	0
mice	0
suggested	0
that	0
B29	0
might	0
be	0
a	0
genetic	0
target	0
for	0
EBF	9
.	0

We	0
here	0
present	0
data	0
suggesting	0
that	0
EBF	9
interacts	0
with	0
three	0
independent	0
sites	0
within	0
the	0
mouse	1
B29	2
promoter	2
.	0

Furthermore	0
,	0
ectopic	0
expression	0
of	0
EBF	9
in	0
HeLa	5
cells	6
activated	0
a	0
B29	1
promoter-controlled	2
reporter	2
construct	2
13-fold	0
and	0
induced	0
a	0
low	0
level	0
of	0
expression	0
from	0
the	0
endogenous	1
B29	2
gene	2
.	0

Finally	0
,	0
mutations	0
in	0
the	0
EBF	9
binding	0
sites	0
diminished	0
B29	1
promoter	2
activity	0
in	0
pre-B	7
cells	8
while	0
the	0
same	0
mutations	0
did	0
not	0
have	0
as	0
striking	0
an	0
effect	0
on	0
the	0
promoter	0
function	0
in	0
B-cell	5
lines	6
of	0
later	0
differentiation	0
stages	0
.	0

These	0
data	0
suggest	0
that	0
the	0
B29	1
gene	2
is	0
a	0
genetic	0
target	0
for	0
EBF	9
in	0
early	0
B-cell	0
development	0
.	0

Delta-opioid	0
receptors	0
expressed	0
by	0
Jurkat	5
T	6
cells	6
enhance	0
IL-2	9
secretion	0
by	0
increasing	0
AP-1	9
complexes	10
and	0
activity	0
of	0
the	0
NF-AT/AP-1-binding	1
promoter	2
element	2
.	0

Recent	0
molecular	0
evidence	0
points	0
to	0
transient	0
and/or	0
stage-specific	0
expression	0
of	0
delta-	9
and	10
kappa-opioid	10
receptors	10
by	0
thymic	7
and	8
peripheral	8
T	8
lymphocytes	8
.	0

Since	0
medical	0
treatments	0
or	0
stress	0
commonly	0
increase	0
opioid	0
levels	0
,	0
it	0
is	0
important	0
to	0
understand	0
the	0
mechanisms	0
by	0
which	0
opioids	0
affect	0
T	0
lymphocyte	0
functions	0
.	0

We	0
therefore	0
created	0
and	0
studied	0
a	0
T	5
cell	6
line	6
expressing	0
the	0
cloned	9
delta-opioid	10
receptor	10
(	0
DOR1	9
)	0
.	0

DOR1	9
ligation	0
by	0
a	0
specific	0
DOR1	9
agonist	0
,	0
deltorphin	0
,	0
augmented	0
IL-2	9
secretion	0
by	0
synergizing	0
with	0
signals	0
from	0
TCR-CD3	9
and	0
CD28	9
.	0

Reporter	0
gene	0
constructs	0
were	0
used	0
to	0
map	0
this	0
effect	0
of	0
deltorphin	0
to	0
the	0
AP-1-	1
and	2
NF-AT/AP-1-binding	2
sites	2
of	0
the	0
IL-2	1
promoter	2
.	0

Although	0
DOR1	9
signaling	0
increased	0
[	0
Ca2+	0
]	0
i	0
,	0
deltorphin	0
enhanced	0
transcriptional	0
activity	0
of	0
the	0
NF-AT/AP-1-binding	1
site	2
via	0
a	0
mechanism	0
independent	0
of	0
calcineurin	9
and	0
distinct	0
from	0
the	0
effects	0
of	0
elevated	0
[	0
Ca2+	0
]	0
i	0
.	0

Deltorphin	0
also	0
increased	0
accumulation	0
of	0
AP-1	9
transcription	10
factor	10
complexes	10
,	0
suggesting	0
that	0
DOR1	9
augments	0
IL-2	9
secretion	0
by	0
increasing	0
the	0
AP-1	9
component	10
of	0
the	0
NF-AT/AP-1	9
transcription	10
factor	10
.	0

These	0
results	0
advance	0
the	0
molecular	0
understanding	0
of	0
opioid	0
effects	0
on	0
lymphocytes	7
,	0
and	0
in	0
addition	0
,	0
demonstrate	0
regulation	0
of	0
IL-2	9
synthesis	0
and	0
secretion	0
by	0
the	0
novel	0
mechanism	0
of	0
receptor-mediated	0
AP-1	9
induction	0
.	0

Induction	0
of	0
interleukin-12	9
p40	3
transcript	4
by	0
CD40	9
ligation	0
via	0
activation	0
of	0
nuclear	9
factor-kappaB	10
.	0

Interleukin-12	9
is	0
produced	0
in	0
response	0
to	0
infection	0
with	0
bacteria	0
or	0
parasites	0
or	0
to	0
bacterial	0
constituents	0
such	0
as	0
LPS	0
in	0
monocytes/macrophages	7
and	0
dendritic	7
cells	8
,	0
and	0
also	0
generated	0
by	0
the	0
interaction	0
between	0
activated	7
T	8
cells	8
and	0
antigen-presenting	7
cells	8
via	0
CD40-CD40	9
ligand	10
(	0
CD40L	9
)	0
.	0

So	0
far	0
,	0
transcriptional	0
analyses	0
of	0
p40	9
have	0
been	0
carried	0
out	0
only	0
using	0
bacterial	0
constituents	0
such	0
as	0
LPS	0
as	0
stimuli	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
have	0
characterized	0
the	0
transcriptional	0
induction	0
of	0
p40	9
by	0
CD40	9
ligation	0
in	0
a	0
human	5
B	6
lymphoblastoid	6
cell	6
line	6
,	0
Daudi	5
,	0
and	0
a	0
human	5
acute	6
monocytic	6
leukemia	6
cell	6
line	6
,	0
THP-1	5
.	0

These	0
cells	0
,	0
stimulated	0
by	0
an	0
agonistic	0
monoclonal	0
antibody	0
against	0
CD40	9
or	0
by	0
transfection	0
with	0
a	0
CD40L	1
expression	2
vector	2
,	0
secreted	0
p40	9
and	0
showed	0
enhanced	0
p40	3
mRNA	4
expression	0
.	0

Sequence	0
analysis	0
of	0
the	0
p40	1
promoter	2
region	2
identified	0
two	0
potential	1
nuclear	2
factor	2
(	2
NF	2
)	2
-kappaB	2
binding	2
sites	2
conserved	0
between	0
mouse	0
and	0
human	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
revealed	0
that	0
the	0
potential	0
NF-kappaB	1
binding	2
sequence	2
which	0
is	0
located	0
around	0
120	1
bp	2
upstream	2
of	0
the	0
transcription	1
initiation	2
site	2
in	0
murine	1
and	2
human	2
p40	2
genes	2
formed	0
an	0
NF-kappaB	9
complex	10
with	0
nuclear	0
extract	0
from	0
Daudi	5
cells	6
stimulated	0
by	0
CD40	9
ligation	0
.	0

Moreover	0
,	0
transfection	0
of	0
Daudi	5
cells	6
with	0
the	0
polymerized	0
NF-kappaB	1
binding	2
sequence	2
ligated	0
to	0
a	0
thymidine	1
kinase/chloramphenicol	2
acetyltransferase	2
(	2
CAT	2
)	2
reporter	2
plasmid	2
greatly	0
induced	0
CAT	9
activity	0
,	0
but	0
transfection	0
with	0
the	0
polymerized	1
mutated	2
NF-kappaB	2
binding	2
sequence	2
did	0
not	0
.	0

These	0
results	0
suggest	0
that	0
the	0
NF-kappaB	1
binding	2
site	2
located	0
around	0
120	0
bp	0
upstream	0
of	0
the	0
transcription	1
initiation	2
site	2
in	0
murine	1
and	2
human	2
p40	2
promoter	2
regions	2
could	0
be	0
important	0
for	0
the	0
p40	9
induction	0
by	0
CD40	9
ligation	0
via	0
activation	0
of	0
NF-kappaB	9
.	0

High	0
frequency	0
of	0
germ-line	0
BRCA2	1
mutations	0
among	0
Hungarian	0
male	0
breast	0
cancer	0
patients	0
without	0
family	0
history	0
.	0

To	0
determine	0
the	0
contribution	0
of	0
BRCA1	1
and	0
BRCA2	1
mutations	0
to	0
the	0
pathogenesis	0
of	0
male	0
breast	0
cancer	0
in	0
Hungary	0
,	0
the	0
country	0
with	0
the	0
highest	0
male	0
breast	0
cancer	0
mortality	0
rates	0
in	0
continental	0
Europe	0
,	0
a	0
series	0
of	0
18	0
male	0
breast	0
cancer	0
patients	0
and	0
three	0
patients	0
with	0
gynecomastia	0
was	0
analyzed	0
for	0
germ-line	0
mutations	0
in	0
both	0
BRCA1	1
and	0
BRCA2	1
.	0

Although	0
no	0
germ-line	0
BRCA1	1
mutation	0
was	0
observed	0
,	0
6	0
of	0
the	0
18	0
male	0
breast	0
cancer	0
cases	0
(	0
33	0
%	0
)	0
carried	0
truncating	0
mutations	0
in	0
the	0
BRCA2	1
gene	0
.	0

Unexpectedly	0
,	0
none	0
of	0
them	0
reported	0
a	0
family	0
history	0
for	0
breast/ovarian	0
cancer	0
.	0

Four	0
of	0
six	0
truncating	0
mutations	0
were	0
novel	0
,	0
and	0
two	0
mutations	0
were	0
recurrent	0
.	0

Four	0
patients	0
(	0
22	0
%	0
)	0
had	0
a	0
family	0
history	0
of	0
breast/ovarian	0
cancer	0
in	0
at	0
least	0
one	0
first-	0
or	0
second-degree	0
relative	0
;	0
however	0
,	0
no	0
BRCA2	1
mutation	0
was	0
identified	0
among	0
them	0
.	0

No	0
mutation	0
was	0
identified	0
in	0
either	0
of	0
the	0
genes	0
in	0
the	0
gynecomastias	0
.	0

These	0
results	0
provide	0
evidence	0
for	0
a	0
strong	0
genetic	0
component	0
of	0
male	0
breast	0
cancer	0
in	0
Hungary	0
.	0

T-cell	0
expression	0
of	0
the	0
human	1
GATA-3	2
gene	2
is	0
regulated	0
by	0
a	0
non-lineage-specific	1
silencer	2
.	0

The	0
GATA-3	9
transcription	10
factor	10
is	0
required	0
for	0
development	0
of	0
the	0
T-cell	5
lineage	6
and	0
Th2	1
cytokine	2
gene	2
expression	0
in	0
CD4	7
T-cells	8
.	0

We	0
have	0
mapped	0
the	0
DNase-I-hypersensitive	1
(	2
HS	2
)	2
regions	2
of	0
the	0
human	1
GATA-3	2
gene	2
in	0
T-cells	7
and	0
non-T-cells	7
and	0
studied	0
their	0
transcriptional	0
activities	0
.	0

HS	1
I-III	2
,	0
located	0
5	0
'	0
from	0
the	0
transcriptional	1
initiation	2
site	2
,	0
were	0
found	0
in	0
hematopoietic	7
and	8
non-hematopoietic	8
cells	8
,	0
whereas	0
HS	1
IV-VII	2
,	0
located	0
3	0
'	0
from	0
the	0
transcriptional	1
start	2
site	2
,	0
were	0
exclusively	0
observed	0
in	0
T-cells	7
.	0

Among	0
these	0
hypersensitive	1
sites	2
,	0
two	0
transcriptional	1
control	2
elements	2
were	0
found	0
,	0
one	0
in	0
the	0
first	1
intron	2
of	0
the	0
GATA-3	1
gene	2
and	0
the	0
other	0
between	1
8.3	2
and	2
5.9	2
kilobases	2
5	0
'	0
from	0
the	0
GATA-3	1
transcriptional	2
initiation	2
site	2
.	0

The	0
first	1
intron	2
acted	0
as	0
a	0
strong	0
transcriptional	0
activator	0
in	0
a	0
position-dependent	0
manner	0
and	0
with	0
no	0
cell-type	0
specificity	0
.	0

The	0
upstream	1
regulatory	2
element	2
could	0
confer	0
T-cell	0
specificity	0
to	0
the	0
GATA-3	1
promoter	2
activity	0
,	0
and	0
analysis	0
of	0
this	0
region	0
revealed	0
a	0
707-base	1
pair	2
silencer	2
that	0
drastically	0
inhibited	0
GATA-3	1
promoter	2
activity	0
in	0
non-T-cells	7
.	0

Two	0
CAGGTG	0
E-boxes	0
,	0
located	0
at	0
the	0
5'-	1
and	2
3'-ends	2
of	0
the	0
silencer	0
,	0
were	0
necessary	0
for	0
this	0
silencer	0
activity	0
.	0

The	0
3'-CAGGTG	1
E-box	2
could	0
bind	0
USF	9
proteins	10
,	0
the	0
ubiquitous	9
repressor	10
ZEB	9
,	0
or	0
the	0
basic	9
helix-loop-helix	10
proteins	10
E2A	9
and	0
HEB	9
,	0
and	0
we	0
showed	0
that	0
a	0
competition	0
between	0
ZEB	9
and	0
E2A/HEB	9
proteins	10
is	0
involved	0
in	0
the	0
silencer	0
activity	0
.	0

Reactive	0
oxygen	0
intermediate-dependent	0
NF-kappaB	9
activation	0
by	0
interleukin-1beta	9
requires	0
5-lipoxygenase	9
or	0
NADPH	0
oxidase	0
activity	0
.	0

We	0
previously	0
reported	0
that	0
the	0
role	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROIs	0
)	0
in	0
NF-kappaB	9
activation	0
by	0
proinflammatory	9
cytokines	10
was	0
cell	0
specific	0
.	0

However	0
,	0
the	0
sources	0
for	0
ROIs	0
in	0
various	0
cell	0
types	0
are	0
yet	0
to	0
be	0
determined	0
and	0
might	0
include	0
5-lipoxygenase	9
(	0
5-LOX	9
)	0
and	0
NADPH	0
oxidase	0
.	0

5-LOX	9
and	0
5-LOX	9
activating	10
protein	10
(	0
FLAP	9
)	0
are	0
coexpressed	0
in	0
lymphoid	7
cells	8
but	0
not	0
in	0
monocytic	7
or	8
epithelial	8
cells	8
.	0

Stimulation	0
of	0
lymphoid	7
cells	8
with	0
interleukin-1beta	9
(	0
IL-1beta	9
)	0
led	0
to	0
ROI	0
production	0
and	0
NF-kappaB	9
activation	0
,	0
which	0
could	0
both	0
be	0
blocked	0
by	0
antioxidants	0
or	0
FLAP	9
inhibitors	0
,	0
confirming	0
that	0
5-LOX	9
was	0
the	0
source	0
of	0
ROIs	0
and	0
was	0
required	0
for	0
NF-kappaB	9
activation	0
in	0
these	0
cells	0
.	0

IL-1beta	9
stimulation	0
of	0
epithelial	7
cells	8
did	0
not	0
generate	0
any	0
ROIs	0
and	0
NF-kappaB	9
induction	0
was	0
not	0
influenced	0
by	0
5-LOX	9
inhibitors	0
.	0

However	0
,	0
reintroduction	0
of	0
a	0
functional	0
5-LOX	9
system	0
in	0
these	0
cells	0
allowed	0
ROI	0
production	0
and	0
5-LOX	9
-dependent	0
NF-kappaB	9
activation	0
.	0

In	0
monocytic	7
cells	8
,	0
IL-1beta	9
treatment	0
led	0
to	0
a	0
production	0
of	0
ROIs	0
which	0
is	0
independent	0
of	0
the	0
5-LOX	9
enzyme	10
but	0
requires	0
the	0
NADPH	0
oxidase	0
activity	0
.	0

This	0
pathway	0
involves	0
the	0
Rac1	9
and	0
Cdc42	9
GTPases	9
,	0
two	0
enzymes	0
which	0
are	0
not	0
required	0
for	0
NF-kappaB	9
activation	0
by	0
IL-1beta	9
in	0
epithelial	7
cells	8
.	0

In	0
conclusion	0
,	0
three	0
different	0
cell-specific	0
pathways	0
lead	0
to	0
NF-kappaB	9
activation	0
by	0
IL-1beta	9
:	0
a	0
pathway	0
dependent	0
on	0
ROI	0
production	0
by	0
5-LOX	9
in	0
lymphoid	7
cells	8
,	0
an	0
ROI-	0
and	0
5-LOX	9
-independent	0
pathway	0
in	0
epithelial	7
cells	8
,	0
and	0
a	0
pathway	0
requiring	0
ROI	0
production	0
by	0
NADPH	9
oxidase	10
in	0
monocytic	7
cells	8
.	0

Cutting	0
edge	0
:	0
dominant	0
effect	0
of	0
Ile50Val	9
variant	10
of	0
the	0
human	9
IL-4	10
receptor	10
alpha-chain	10
in	0
IgE	9
synthesis	0
.	0

Two	0
variants	0
of	0
the	0
IL-4R	1
alpha-chain	2
(	2
IL-4Ralpha	2
)	2
gene	2
have	0
been	0
recently	0
identified	0
in	0
association	0
with	0
different	0
atopic	0
disorders	0
.	0

To	0
clarify	0
the	0
etiological	0
relationship	0
between	0
the	0
two	0
variants	0
,	0
we	0
analyzed	0
responsiveness	0
to	0
IL-4	9
of	0
transfectants	0
with	0
four	0
kinds	0
of	0
IL-4Ralpha	9
carrying	0
either	0
Val	0
or	0
Ile	0
at	0
50	9
and	0
either	0
Gln	0
or	0
Arg	0
at	0
551	9
.	0

The	0
substitution	0
of	0
Ile	0
for	0
Val	0
augmented	0
STAT6	9
activation	0
,	0
proliferation	0
,	0
and	0
transcription	0
activity	0
of	0
the	0
Iepsilon	1
promoter	2
by	0
IL-4	9
,	0
whereas	0
that	0
of	0
Arg	0
for	0
Gln	0
did	0
not	0
change	0
these	0
IL-4	9
signals	0
.	0

Arg551	0
was	0
not	0
associated	0
with	0
atopic	0
asthma	0
in	0
the	0
Japanese	0
population	0
.	0

CD23	9
expression	0
and	0
IgE	9
synthesis	0
by	0
IL-4	9
were	0
augmented	0
in	0
Ile50-bearing	5
PBMC	6
,	0
compared	0
with	0
those	0
bearing	0
Val50	0
.	0

Taken	0
together	0
,	0
substitution	0
of	0
Arg551	0
does	0
not	0
enhance	0
the	0
IL-4	9
signal	0
for	0
generation	0
of	0
germline	0
epsilon	0
transcript	0
,	0
whereas	0
the	0
substitution	0
of	0
Ile50	0
contributes	0
to	0
enhancement	0
of	0
IgE	9
synthesis	0
.	0

A	0
novel	0
growth-factor-dependent	5
myeloid	6
cell	6
line	6
derived	0
from	0
mouse	7
bone	8
marrow	8
cells	8
contains	0
progenitors	0
endowed	0
with	0
high	0
proliferative	0
potential	0
.	0

Constitutive	0
expression	0
of	0
human	9
colony-stimulating	10
factor-1	10
receptor	10
(	0
CSF-1R	9
)	0
confers	0
long-lasting	0
CSF-1	9
-dependent	0
proliferation	0
to	0
mouse	5
myeloid	6
cell	6
lines	6
.	0

We	0
developed	0
mice	0
transgenic	0
for	0
human	0
CSF-1R	9
because	0
mouse	0
CSF-1	9
can	0
not	0
activate	0
human	0
CSF-1R	9
.	0

Then	0
bone	7
marrow	8
cells	8
from	0
transgenic	0
mice	0
were	0
plated	0
onto	0
MS-5	0
stromal	0
cells	0
expressing	0
the	0
membrane	9
form	10
of	0
human	9
CSF-1	10
(	0
2M-1	5
cells	6
)	0
in	0
order	0
to	0
combine	0
the	0
hematopoietic	0
supporting	0
properties	0
of	0
stromal	7
cells	8
and	0
the	0
proliferative	0
effects	0
of	0
CSF-1	9
.	0

Thus	0
,	0
we	0
were	0
able	0
to	0
derive	0
a	0
hematopoietic	5
cell	6
line	6
,	0
called	0
47.10	5
,	0
that	0
grew	0
indefinitely	0
under	0
these	0
conditions	0
,	0
whereas	0
no	0
cell	0
line	0
could	0
be	0
developed	0
from	0
nontransgenic	0
mice	0
.	0

Proliferation	0
of	0
47.10	5
cells	6
is	0
severely	0
affected	0
by	0
neutralizing	0
anti-CSF-1R	9
monoclonal	10
antibodies	10
.	0

Morphologic	0
and	0
cytofluorometry	0
analysis	0
established	0
that	0
most	0
47.10	5
cells	6
are	0
immature	7
myelomonocytic	8
cells	8
.	0

Consistent	0
with	0
this	0
phenotype	0
,	0
the	0
myeloid	9
transcription	10
factor	10
PU.1	10
,	0
but	0
not	0
the	0
erythroid	9
transcription	10
factor	10
GATA-1	10
,	0
is	0
expressed	0
in	0
47.10	5
cells	6
.	0

A	0
few	0
47.10	5
cells	6
(	0
3-5	0
%	0
)	0
do	0
not	0
express	0
lineage	0
specific	0
markers	0
;	0
they	0
differentiate	0
spontaneously	0
to	0
lineage-positive	5
cells	6
after	0
replating	0
on	0
2M-1	5
cells	6
.	0

In	0
agar	0
cultures	0
,	0
47.10	5
cells	6
form	0
7-	0
and	0
14-day	0
colonies	0
in	0
response	0
to	0
a	0
cocktail	0
of	0
granulocyte/macrophage	9
colony-stimulating	10
factor	10
(	0
2.5	0
ng/mL	0
)	0
,	0
interleukin-3	9
(	0
1	0
ng/mL	0
)	0
,	0
and	0
mouse	0
CSF-1	9
(	0
10	0
ng/mL	0
)	0
.	0

Under	0
these	0
conditions	0
,	0
about	0
0.5	0
%	0
of	0
47.10	5
cells	6
formed	0
large	0
14-day	0
colonies	0
(	0
>	0
1	0
mm	0
)	0
composed	0
of	0
mature	7
monocytes	8
and	0
granulocytes	7
,	0
reflecting	0
the	0
presence	0
of	0
progenitors	0
endowed	0
with	0
high	0
proliferative	0
potential	0
(	0
HPP-47.10	5
cells	6
)	0
.	0

In	0
conclusion	0
,	0
we	0
have	0
characterized	0
a	0
novel	0
continuous	5
myeloid	6
cell	6
line	6
presenting	0
a	0
hierarchical	0
structure	0
similar	0
to	0
that	0
of	0
the	0
bone	5
marrow	6
progenitor	6
cell	6
compartment	6
.	0

Regulation	0
of	0
IL-4	9
expression	0
by	0
the	0
transcription	9
factor	10
JunB	9
during	0
T	0
helper	0
cell	0
differentiation	0
.	0

The	0
molecular	0
basis	0
for	0
restricted	0
cytokine	9
expression	0
by	0
T	7
helper	8
1	8
(	8
Th1	8
)	8
and	8
T	8
helper	8
2	8
(	8
Th2	8
)	8
cells	8
is	0
unclear	0
.	0

Previous	0
studies	0
found	0
that	0
P1	1
,	0
an	0
element	0
of	0
the	0
interleukin	1
4	2
(	2
IL-4	2
)	2
promoter	2
that	0
binds	0
AP-1	0
,	0
is	0
important	0
for	0
Th2-restricted	0
IL-4	9
expression	0
.	0

Here	0
we	0
show	0
that	0
JunB	9
,	0
but	0
not	0
the	0
other	0
Jun	9
family	10
members	10
,	0
was	0
selectively	0
induced	0
in	0
Th2	7
cells	8
and	0
not	0
in	0
Th1	7
cells	8
during	0
differentiation	0
.	0

JunB	9
has	0
previously	0
been	0
considered	0
to	0
be	0
a	0
negative	0
regulator	0
of	0
transcription	0
.	0

However	0
,	0
we	0
show	0
that	0
JunB	9
binds	0
directly	0
to	0
the	0
P1	1
site	2
and	0
synergizes	0
with	0
c-Maf	9
to	0
activate	0
an	0
IL-4	1
luciferase	2
reporter	2
gene	2
.	0

JunB	9
-control	0
of	0
IL-4	9
expression	0
is	0
mediated	0
by	0
the	0
phosphorylation	0
of	0
JunB	9
at	0
Thr102	0
and-	0
104	0
by	0
JNK	9
MAP	10
kinase	10
.	0

The	0
synergy	0
between	0
c-Maf	9
and	0
JunB	9
can	0
be	0
attributed	0
to	0
cooperative	0
DNA	0
binding	0
,	0
which	0
is	0
facilitated	0
by	0
JunB	9
phosphorylation	0
.	0

In	0
transgenic	0
mice	0
,	0
elevated	0
JunB	9
levels	0
caused	0
increased	0
expression	0
of	0
several	0
Th2	9
cytokines	10
in	0
developing	0
Th1	7
cells	8
.	0

JunB	9
also	0
upregulated	0
IL-4	9
expression	0
in	0
response	0
to	0
immunization	0
.	0

Thus	0
,	0
the	0
early	0
increase	0
of	0
JunB	9
protein	0
in	0
Th2	7
cells	8
can	0
provide	0
the	0
specificity	0
for	0
c-Maf	9
in	0
IL-4	9
expression	0
during	0
T	0
cell	0
development	0
and	0
directs	0
thereby	0
Th2	0
differentiation	0
.	0

Human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
tax	10
protein	10
abrogates	0
interleukin-2	9
dependence	0
in	0
a	0
mouse	5
T-cell	6
line	6
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
is	0
the	0
etiologic	0
agent	0
of	0
adult	0
T-cell	0
leukemia	0
.	0

Tax	9
,	0
the	0
viral	9
protein	10
,	0
is	0
thought	0
to	0
be	0
crucial	0
in	0
the	0
development	0
of	0
the	0
disease	0
,	0
since	0
it	0
transforms	0
healthy	7
T	8
cells	8
in	0
vitro	0
and	0
induces	0
tumors	0
in	0
transgenic	0
animals	0
.	0

We	0
examined	0
the	0
effect	0
of	0
Tax	9
activity	0
on	0
the	0
growth	0
of	0
the	0
interleukin-2	5
(	6
IL-2	6
)	6
-dependent	6
T-cell	6
line	6
CTLL-2	5
.	0

Stable	0
expression	0
of	0
Tax	9
in	0
CTLL-2	5
transformed	0
cell	0
growth	0
from	0
being	0
IL-2	9
dependent	0
to	0
IL-2	9
independent	0
.	0

Tax	9
stimulated	0
transcription	0
through	0
NF-kappaB	9
and	0
the	0
cyclic	1
AMP-responsive	2
element-like	2
sequence	2
in	0
the	0
HTLV-1	0
promoter	0
.	0

The	0
finding	0
of	0
Tax	9
mutants	0
segregating	0
these	0
two	0
pathways	0
suggested	0
that	0
the	0
NF-kappaB	9
pathway	0
was	0
essential	0
for	0
IL-2	9
-independent	0
growth	0
of	0
CTLL-2	7
cells	8
while	0
the	0
CRE	1
pathway	0
was	0
unnecessary	0
.	0

However	0
,	0
both	0
pathways	0
were	0
necessary	0
for	0
another	0
transformation-related	0
activity	0
(	0
colony	0
formation	0
in	0
soft	0
agar	0
)	0
of	0
CTLL-2/Tax	9
.	0

Our	0
results	0
show	0
that	0
Tax	9
has	0
at	0
least	0
two	0
distinct	0
activities	0
on	0
T	7
cells	8
,	0
and	0
suggest	0
that	0
Tax	9
plays	0
a	0
crucial	0
role	0
in	0
IL-2	9
-independent	0
T-cell	0
transformation	0
induced	0
by	0
HTLV-1	0
,	0
in	0
addition	0
to	0
its	0
well-known	0
IL-2	9
-dependent	0
cell	0
transformation	0
.	0

Accessing	0
Epstein-Barr	0
virus-specific	0
T-cell	0
memory	0
with	0
peptide-loaded	5
dendritic	6
cells	6
.	0

The	0
conventional	0
means	0
of	0
studying	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
-induced	0
cytotoxic	7
T-lymphocyte	8
(	0
CTL	0
)	0
memory	0
,	0
by	0
in	0
vitro	0
stimulation	0
with	0
the	0
latently	0
infected	0
autologous	0
lymphoblastoid	5
cell	6
line	6
(	0
LCL	5
)	0
,	0
has	0
important	0
limitations	0
.	0

First	0
,	0
it	0
gives	0
no	0
information	0
on	0
memory	0
to	0
lytic	9
cycle	10
antigens	10
;	0
second	0
,	0
it	0
preferentially	0
amplifies	0
the	0
dominant	0
components	0
of	0
latent	0
antigen-specific	0
memory	0
at	0
the	0
expense	0
of	0
key	0
subdominant	0
reactivities	0
.	0

Here	0
we	0
describe	0
an	0
alternative	0
approach	0
,	0
based	0
on	0
in	0
vitro	0
stimulation	0
with	0
epitope	5
peptide-loaded	6
dendritic	6
cells	6
(	0
DCs	5
)	0
,	0
which	0
allows	0
one	0
to	0
probe	0
the	0
CTL	0
repertoire	0
for	0
any	0
individual	0
reactivity	0
of	0
choice	0
;	0
this	0
method	0
proved	0
significantly	0
more	0
efficient	0
than	0
stimulation	0
with	0
peptide	0
alone	0
.	0

Using	0
this	0
approach	0
we	0
first	0
show	0
that	0
reactivities	0
to	0
the	0
immunodominant	0
and	0
subdominant	0
lytic	9
cycle	10
epitopes	10
identified	0
by	0
T	7
cells	8
during	0
primary	0
EBV	0
infection	0
are	0
regularly	0
detectable	0
in	0
the	0
CTL	0
memory	0
of	0
virus	0
carriers	0
;	0
this	0
implies	0
that	0
in	0
such	0
carriers	0
chronic	0
virus	0
replication	0
remains	0
under	0
direct	0
T-cell	0
control	0
.	0

We	0
further	0
show	0
that	0
subdominant	0
latent	0
cycle	0
reactivities	0
to	0
epitopes	0
in	0
the	0
latent	9
membrane	10
protein	10
LMP2	10
,	0
though	0
rarely	0
undetectable	0
in	0
LCL	5
-stimulated	0
populations	0
,	0
can	0
be	0
reactivated	0
by	0
DC	0
stimulation	0
and	0
selectively	0
expanded	0
as	0
polyclonal	0
CTL	5
lines	6
;	0
the	0
adoptive	0
transfer	0
of	0
such	0
preparations	0
may	0
be	0
of	0
value	0
in	0
targeting	0
certain	0
EBV-positive	0
malignancies	0
.	0

Regulation	0
of	0
the	0
human	1
interleukin-2	2
gene	2
by	0
the	0
alpha	9
and	10
beta	10
isoforms	10
of	0
the	0
glucocorticoid	9
receptor	10
.	0

The	0
immunosuppressive	0
effects	0
of	0
glucocorticoids	0
are	0
largely	0
due	0
to	0
transcriptional	0
inhibition	0
of	0
immunologically	1
relevant	2
genes	2
,	0
such	0
as	0
the	0
interleukin-2	1
(	2
IL-2	2
)	2
gene	2
.	0

These	0
effects	0
are	0
mediated	0
by	0
the	0
intracellular	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
.	0

In	0
humans	0
,	0
alternative	0
splicing	0
of	0
the	0
GR	3
precursor	4
mRNA	4
gives	0
rise	0
to	0
two	0
receptor	0
isoforms	0
,	0
termed	0
GRalpha	9
and	0
GRbeta	9
.	0

We	0
previously	0
demonstrated	0
that	0
GRbeta	9
could	0
antagonize	0
GRalpha	9
-mediated	0
transactivation	0
of	0
a	0
glucocorticoid-responsive	1
element	2
(	2
GRE	2
)	2
-driven	2
reporter	2
gene	2
in	0
COS-7	5
cells	6
.	0

The	0
present	0
study	0
was	0
designed	0
to	0
analyze	0
the	0
roles	0
of	0
the	0
two	0
GR	9
isoforms	10
on	0
glucocorticoid-mediated	0
transrepression	0
of	0
the	0
IL-2	1
gene	2
.	0

Using	0
a	0
recently	0
developed	0
transfection	0
technique	0
,	0
we	0
demonstrate	0
that	0
in	0
primary	7
human	8
lymphocytes	8
,	0
stimulation	0
of	0
a	0
548	1
bp	2
IL-2	2
promoter-luciferase	2
reporter	2
construct	2
by	0
phorbol	0
ester	0
and	0
calcium	0
ionophore	0
is	0
reversed	0
by	0
dexamethasone	0
to	0
a	0
similar	0
extent	0
as	0
in	0
Jurkat	0
T	0
lymphoma	0
cells	0
transfected	0
with	0
a	0
GRalpha	9
expression	0
vector	0
.	0

Transfection	0
of	0
a	0
GRbeta	9
expression	0
vector	0
alone	0
did	0
not	0
result	0
in	0
IL-2	1
promoter	2
repression	0
in	0
response	0
to	0
glucocorticoids	0
.	0

Furthermore	0
,	0
GRbeta	9
did	0
not	0
antagonize	0
the	0
repressive	0
effects	0
of	0
GRalpha	9
on	0
IL-2	1
promoter	2
activity	0
.	0

Surprisingly	0
,	0
overexpression	0
of	0
GRbeta	9
in	0
Jurkat	5
cells	6
did	0
not	0
cause	0
significant	0
inhibition	0
of	0
GRalpha	9
-induced	0
transactivation	0
of	0
a	0
GRE-dependent	1
luciferase	2
reporter	2
gene	2
either	0
.	0

We	0
conclude	0
that	0
the	0
transrepressive	0
effect	0
of	0
glucocorticoids	0
on	0
IL-2	1
gene	2
transcription	0
is	0
exclusively	0
mediated	0
by	0
GRalpha	9
.	0

GRbeta	9
can	0
neither	0
antagonize	0
GRalpha	9
-mediated	0
transactivation	0
nor	0
transrepression	0
in	0
Jurkat	5
cells	6
,	0
indicating	0
a	0
cell	0
type-specific	0
pattern	0
of	0
GRbeta	9
-mediated	0
antiglucocorticoid	0
activity	0
.	0

Extinction	0
of	0
immunoglobulin	1
gene	2
expression	0
in	0
B	7
cells	8
upon	0
fusion	0
with	0
HeLa	5
cells	6
is	0
preceded	0
by	0
rapid	0
nuclear	0
depletion	0
of	0
essential	9
transcription	10
factors	10
and	0
is	0
accompanied	0
by	0
widespread	0
inactivation	0
of	0
genes	0
expressed	0
in	0
a	0
B	0
cell-specific	0
manner	0
.	0

When	0
immunoglobulin	7
(	8
Ig	8
)	8
expressing	8
B	8
cells	8
are	0
fused	0
with	0
non-B	7
cells	8
,	0
Ig	0
expression	0
is	0
rapidly	0
suppressed	0
at	0
the	0
level	0
of	0
transcription	0
,	0
a	0
phenomenon	0
termed	0
extinction	0
.	0

Here	0
we	0
demonstrate	0
that	0
fusion	0
of	0
HeLa	5
cells	6
with	0
either	0
diploid	7
or	8
tetraploid	8
B	8
cells	8
(	0
Daudi	5
)	0
results	0
in	0
widespread	0
extinction	0
of	0
several	0
other	0
B	1
cell-encoded	2
genes	2
that	0
are	0
expressed	0
in	0
a	0
B	0
cell-specific	0
manner	0
.	0

In	0
contrast	0
,	0
expression	0
of	0
B	1
cell-expressed	2
genes	2
that	0
are	0
not	0
dependent	0
on	0
cell-specific	0
controls	0
is	0
unaffected	0
.	0

We	0
show	0
that	0
the	0
molecular	0
mechanism	0
(	0
s	0
)	0
underlying	0
Ig	1
gene	2
extinction	0
can	0
be	0
explained	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
a	0
lack	0
of	0
transcription	9
factors	10
that	0
are	0
essential	0
for	0
Ig	1
gene	2
transcription	0
.	0

These	0
transcription	9
factors	10
are	0
either	0
not	0
produced	0
due	0
to	0
block	0
of	0
transcription	0
of	0
their	0
respective	0
genes	0
(	0
Oct-2	1
,	0
OBF-1	1
,	0
PU.1	9
)	0
,	0
or	0
are	0
rendered	0
inactive	0
posttranslationally	0
(	0
NF-kappa	9
B	10
,	0
E47	1
)	0
.	0

By	0
isolating	0
Daudi	5
x	6
HeLa	6
heterokaryons	6
a	0
few	0
hours	0
after	0
fusion	0
,	0
we	0
have	0
studied	0
the	0
initial	0
fate	0
of	0
two	0
B	9
cell-specific	10
transcription	10
factors	10
involved	0
in	0
Ig	1
gene	2
transcription	0
,	0
Oct-2	1
and	0
NF-kappa	9
B	10
.	0

This	0
report	0
provides	0
the	0
first	0
demonstration	0
that	0
upon	0
fusion	0
with	0
HeLa	5
cells	6
,	0
the	0
nuclear	0
contents	0
of	0
B	9
cell-expressed	10
transcription	10
factors	10
are	0
depleted	0
within	0
a	0
few	0
hours	0
with	0
kinetics	0
that	0
are	0
as	0
fast	0
or	0
faster	0
than	0
that	0
of	0
Ig	1
gene	2
extinction	0
.	0

Thus	0
,	0
the	0
extinguishing	0
mechanism	0
is	0
effective	0
very	0
early	0
after	0
fusion	0
.	0

We	0
suggest	0
that	0
extinction	0
of	0
Ig	1
genes	2
is	0
part	0
of	0
a	0
global	0
mechanism	0
that	0
suppresses	0
the	0
differentiation	0
program	0
foreign	0
to	0
the	0
HeLa	5
phenotype	6
.	0

Evidence	0
for	0
suppressed	0
activity	0
of	0
the	0
transcription	9
factor	10
NFAT1	9
at	0
its	0
proximal	1
binding	2
element	2
P0	1
in	0
the	0
IL-4	1
promoter	2
associated	0
with	0
enhanced	0
IL-4	1
gene	2
transcription	0
in	0
T	7
cells	8
of	0
atopic	0
patients	0
.	0

Allergen-specific	0
T	7
cells	8
in	0
atopic	0
patients	0
are	0
polarized	0
IL-4-producing	5
Th2	6
cells	6
,	0
promoting	0
IgE	9
synthesis	0
by	0
B	7
cells	8
.	0

The	0
molecular	0
basis	0
for	0
increased	0
IL-4	1
gene	2
expression	0
in	0
atopy	0
is	0
not	0
fully	0
understood	0
.	0

IL-4	1
gene	2
regulation	0
in	0
general	0
involves	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	10
NFAT	10
)	10
family	10
of	0
transcription	9
factors	10
,	0
of	0
which	0
NFAT1	9
and	0
NFAT2	9
are	0
most	0
prominent	0
in	0
peripheral	7
T	8
cells	8
.	0

Recently	0
,	0
a	0
unique	0
inhibitory	0
role	0
of	0
NFAT1	9
in	0
IL-4	1
gene	2
control	0
was	0
shown	0
in	0
the	0
mouse	0
.	0

In	0
a	0
series	0
of	0
electrophoretic	0
mobility	0
shift	0
assays	0
with	0
protein	0
extracts	0
of	0
highly	5
polarized	6
Th2	6
clones	6
from	0
atopics	0
and	0
Th1	5
clones	6
from	0
controls	0
we	0
compared	0
DNA-binding	0
activities	0
at	0
the	0
two	0
NFAT-binding	1
elements	2
P0	1
and	0
P1	1
of	0
the	0
crucial	0
proximal	0
human	0
IL-4	1
promoter	2
.	0

At	0
the	0
most	0
proximal	0
P0	1
site	0
,	0
NFAT-containing	0
complexes	0
devoid	0
of	0
NFAT2	9
were	0
readily	0
inducible	0
in	0
the	0
Th1	5
clones	6
,	0
but	0
hardly	0
or	0
not	0
in	0
the	0
Th2	5
clones	6
.	0

In	0
contrast	0
,	0
both	0
in	0
Th1	5
and	6
Th2	6
clones	6
NFAT-containing	0
complexes	0
were	0
strongly	0
inducible	0
at	0
the	0
P1	1
site	2
,	0
consisting	0
of	0
NFAT2	9
and	0
a	0
P0	1
-compatible	0
NFAT	9
activity	0
,	0
without	0
apparent	0
differences	0
between	0
Th1	5
and	6
Th2	6
clones	6
.	0

Like	0
in	0
Th2	5
clones	6
,	0
suppressed	0
NFAT-	0
P0	1
complex	0
formation	0
was	0
observed	0
also	0
at	0
the	0
polyclonal	0
level	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
of	0
three	0
of	0
five	0
severe	0
atopic	0
dermatitis	0
patients	0
with	0
strongly	0
elevated	0
serum	0
IgE	9
levels	0
,	0
but	0
not	0
in	0
control	0
PBMC	7
.	0

These	0
findings	0
suggest	0
that	0
high-level	0
IL-4	9
production	0
in	0
atopic	7
Th2	8
cells	8
is	0
associated	0
with	0
selective	0
reduction	0
of	0
suppressive	0
NFAT1	9
activity	0
at	0
the	0
IL-4	1
P0	2
element	2
and	0
that	0
some	0
patients	0
with	0
this	0
multifactorial	0
disease	0
may	0
have	0
a	0
putative	0
systemic	0
disorder	0
at	0
this	0
level	0
.	0

Differential	0
expression	0
and	0
phosphorylation	0
of	0
CTCF	9
,	0
a	0
c-myc	0
transcriptional	0
regulator	0
,	0
during	0
differentiation	0
of	0
human	0
myeloid	0
cells	0
.	0

CTCF	9
is	0
a	0
transcriptional	0
repressor	0
of	0
the	0
c-myc	0
gene	0
.	0

Although	0
CTCF	9
has	0
been	0
characterized	0
in	0
some	0
detail	0
,	0
there	0
is	0
very	0
little	0
information	0
about	0
the	0
regulation	0
of	0
CTCF	9
activity	0
.	0

Therefore	0
we	0
investigated	0
CTCF	9
expression	0
and	0
phosphorylation	0
during	0
induced	0
differentiation	0
of	0
human	7
myeloid	8
leukemia	8
cells	8
.	0

We	0
found	0
that	0
:	0
(	0
i	0
)	0
both	0
CTCF	3
mRNA	4
and	0
protein	0
are	0
down-regulated	0
during	0
terminal	0
differentiation	0
in	0
most	0
cell	0
lines	0
tested	0
;	0
(	0
ii	0
)	0
CTCF	9
down-regulation	0
is	0
retarded	0
and	0
less	0
pronounced	0
than	0
that	0
of	0
c-myc	1
;	0
(	0
iii	0
)	0
CTCF	9
protein	10
is	0
differentially	0
phosphorylated	0
and	0
the	0
phosphorylation	0
profiles	0
depend	0
on	0
the	0
differentiation	0
pathway	0
.	0

We	0
concluded	0
that	0
CTCF	9
expression	0
and	0
activity	0
is	0
controlled	0
at	0
transcriptional	0
and	0
post-transcriptional	0
levels	0
.	0

Glucocorticoid	0
resistance	0
in	0
the	0
squirrel	0
monkey	0
is	0
associated	0
with	0
overexpression	0
of	0
the	0
immunophilin	9
FKBP51	10
.	0

Squirrel	0
monkeys	0
are	0
neotropical	0
primates	0
that	0
have	0
high	0
circulating	0
cortisol	0
to	0
compensate	0
for	0
expression	0
of	0
glucocorticoid	9
receptors	10
(	0
GRs	9
)	0
with	0
reduced	0
affinity	0
.	0

The	0
low	0
binding	0
affinity	0
of	0
squirrel	0
monkey	0
GR	9
does	0
not	0
result	0
from	0
substitutions	0
in	0
the	0
receptor	0
,	0
because	0
squirrel	9
monkey	10
GR	10
expressed	0
in	0
vitro	0
exhibits	0
high	0
affinity	0
.	0

Rather	0
,	0
squirrel	0
monkeys	0
express	0
a	0
soluble	0
factor	0
that	0
,	0
in	0
mixing	0
studies	0
of	0
cytosol	0
from	0
squirrel	7
monkey	8
lymphocytes	8
(	0
SML	7
)	0
and	0
mouse	0
L929	0
cells	0
,	0
reduced	0
GR	0
binding	0
affinity	0
by	0
11-fold	0
.	0

In	0
an	0
effort	0
to	0
identify	0
this	0
factor	0
,	0
the	0
cellular	0
levels	0
of	0
components	0
of	0
the	0
GR	9
heterocomplex	10
in	0
SML	7
and	0
human	7
lymphocytes	8
(	0
HL	7
)	0
were	0
compared	0
.	0

The	0
immunophilin	9
FKBP51	10
was	0
13-fold	0
higher	0
in	0
SML	7
than	0
in	0
HL	0
cytosol	0
;	0
FKBP52	9
in	0
SML	7
was	0
42	0
%	0
of	0
that	0
in	0
HL	0
cytosol	0
.	0

A	0
role	0
for	0
changes	0
in	0
immunophilins	9
,	0
causing	0
glucocorticoid	0
resistance	0
in	0
neotropical	0
primates	0
,	0
is	0
supported	0
by	0
the	0
following	0
:	0
the	0
changes	0
in	0
FKBP51	9
and	0
FKBP52	9
were	0
observed	0
in	0
cells	0
from	0
other	0
neotropical	0
primates	0
with	0
glucocorticoid	0
resistance	0
;	0
the	0
elevated	0
level	0
of	0
FKBP51	9
was	0
reflected	0
in	0
an	0
abundance	0
of	0
FKBP51	9
in	0
heat	9
shock	10
protein	10
90	10
complexes	10
in	0
SML	7
;	0
when	0
cytosols	0
of	0
SML	7
and	0
L929	5
cells	6
were	0
mixed	0
,	0
the	0
decrease	0
in	0
GR	0
binding	0
was	0
associated	0
with	0
incorporation	0
of	0
FKBP51	9
into	0
GR	9
heterocomplexes	10
;	0
the	0
effect	0
of	0
SML	7
cytosol	0
on	0
GR	0
binding	0
was	0
reproduced	0
with	0
cytosol	0
from	0
COS	5
cells	6
expressing	0
squirrel	0
monkey	0
FKBP51	9
;	0
and	0
both	0
the	0
effect	0
of	0
SML	7
cytosol	0
on	0
GR	0
binding	0
and	0
the	0
incorporation	0
of	0
FKBP51	9
into	0
GR	9
heterocomplexes	10
were	0
blocked	0
by	0
FK506	0
.	0

Regulation	0
of	0
GR	0
binding	0
by	0
FKBP51	9
represents	0
a	0
previously	0
unrecognized	0
mechanism	0
for	0
regulating	0
glucocorticoid	0
sensitivity	0
.	0

High-level	0
replication	0
of	0
human	0
immunodeficiency	0
virus	0
in	0
thymocytes	7
requires	0
NF-kappaB	9
activation	0
through	0
interaction	0
with	0
thymic	7
epithelial	8
cells	8
.	0

We	0
have	0
previously	0
demonstrated	0
that	0
interaction	0
of	0
infected	0
thymocytes	7
with	0
autologous	0
thymic	7
epithelial	8
cells	8
(	0
TEC	7
)	0
is	0
a	0
prerequisite	0
for	0
a	0
high	0
level	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replication	0
in	0
thymocytes	7
(	0
M.Rothe	0
,	0
L.Chene	0
,	0
M.Nugeyre	0
,	0
F.Barre-Sinoussi	0
,	0
and	0
N.Israel	0
,	0
J.Virol.72	0
:	0
5852-5861	0
,	0
1998	0
)	0
.	0

We	0
report	0
here	0
that	0
this	0
activation	0
of	0
HIV	0
replication	0
takes	0
place	0
at	0
the	0
transcriptional	0
level	0
through	0
activation	0
of	0
the	0
Rel/NF-kappaB	9
transcription	9
factors	10
.	0

We	0
first	0
demonstrate	0
that	0
an	0
HIV-1	0
provirus	0
(	0
SF-2	0
strain	0
)	0
very	0
effectively	0
replicates	0
in	0
thymocytes	7
cocultured	0
with	0
TEC	7
whereas	0
this	0
provirus	0
,	0
with	0
kappaB	1
sites	2
deleted	0
,	0
fails	0
to	0
replicate	0
.	0

We	0
provide	0
evidence	0
that	0
several	0
NF-kappaB	9
complexes	10
are	0
constitutively	0
found	0
in	0
the	0
nuclei	0
of	0
thymocytes	7
either	0
freshly	0
isolated	0
from	0
the	0
thymus	0
or	0
maintained	0
in	0
coculture	0
with	0
autologous	0
or	0
heterologous	0
TEC	7
.	0

The	0
prevalent	0
complex	0
is	0
the	0
heterodimer	9
p50-p65	10
.	0

NF-kappaB	9
activity	0
is	0
tightly	0
correlated	0
with	0
the	0
transcriptional	0
activity	0
of	0
a	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
HIV-1	0
transfected	0
in	0
thymocytes	7
.	0

The	0
cotransfection	0
of	0
this	0
LTR	1
with	0
a	0
mutated	0
IkappaBalpha	9
molecule	10
formally	0
demonstrates	0
that	0
LTR	1
transactivation	0
is	0
regulated	0
by	0
members	0
of	0
the	0
Rel/NF-kappaB	9
family	10
in	0
thymocytes	7
.	0

We	0
also	0
showed	0
that	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
and	0
to	0
a	0
lesser	0
extent	0
interleukin-1	9
(	0
IL-1	9
)	0
,	0
secreted	0
within	0
the	0
coculture	0
,	0
induce	0
NF-kappaB	9
activity	0
and	0
a	0
correlative	0
LTR	1
transactivation	0
.	0

However	0
IL-7	9
,	0
a	0
crucial	0
factor	0
for	0
thymopoiesis	0
that	0
is	0
secreted	0
mainly	0
by	0
TEC	7
,	0
is	0
a	0
necessary	0
cofactor	0
for	0
NF-kappaB	9
activation	0
elicited	0
by	0
TNF	9
or	0
IL-1	9
.	0

Together	0
,	0
these	0
data	0
indicate	0
that	0
NF-kappaB	9
activation	0
,	0
required	0
for	0
a	0
high	0
level	0
of	0
HIV	0
replication	0
in	0
thymocytes	7
,	0
is	0
regulated	0
in	0
a	0
specific	0
manner	0
in	0
the	0
thymic	0
microenvironment	0
which	0
provides	0
the	0
necessary	0
cytokines	0
:	0
TNF	9
,	0
IL-1	9
,	0
and	0
IL-7	9
.	0

Imbalanced	0
expression	0
of	0
the	0
glucocorticoid	9
receptor	10
isoforms	10
in	0
cultured	7
lymphocytes	8
from	0
a	0
patient	0
with	0
systemic	0
glucocorticoid	0
resistance	0
and	0
chronic	0
lymphocytic	0
leukemia	0
.	0

The	0
human	9
glucocorticoid	10
receptor	10
(	0
GR	9
)	0
is	0
expressed	0
as	0
two	0
alternatively	0
spliced	0
isoforms	0
,	0
GRalpha	9
and	0
GRbeta	9
.	0

Whereas	0
GRalpha	9
is	0
a	0
hormone-activated	0
transcription	9
factor	10
,	0
GRbeta	9
does	0
not	0
bind	0
glucocorticoids	0
(	0
GCs	0
)	0
,	0
is	0
transcriptionally	0
inactive	0
,	0
and	0
is	0
a	0
potential	0
inhibitor	0
of	0
activated	0
GRalpha	9
.	0

Differential	0
expression	0
of	0
GR	9
isoforms	10
may	0
play	0
a	0
role	0
in	0
generalized	0
or	0
tissue-specific	0
GC	0
resistance	0
.	0

GCs	0
induce	0
apoptosis	0
in	0
neoplastic	7
lymphoid	8
cells	8
;	0
and	0
,	0
defective	0
apoptosis	0
is	0
implicated	0
in	0
the	0
genesis	0
of	0
chronic	0
lymphocytic	0
leukemia	0
(	0
CLL	0
)	0
.	0

We	0
studied	0
a	0
patient	0
with	0
generalized	0
GC	0
resistance	0
and	0
CLL	0
.	0

GR	0
number	0
in	0
the	0
patient	0
's	0
transformed	5
lymphocytes	6
was	0
approximately	0
one	0
half	0
that	0
of	0
control	0
cells	0
with	0
a	0
approximately	0
10-fold	0
reduction	0
in	0
binding	0
affinity	0
for	0
dexamethasone	0
.	0

In	0
vitro	0
apoptosis	0
induction	0
in	0
CLL	5
cells	6
was	0
delayed	0
in	0
response	0
to	0
GCs	0
,	0
but	0
not	0
to	0
other	0
apoptosis	0
inducers	0
.	0

Sequencing	0
of	0
the	0
GR	1
cDNA	2
and	0
gene	0
including	0
the	0
2.3-kb	0
coding	0
region	0
,	0
the	0
intron/exon	0
junctions	0
,	0
the	0
known	0
5'-regulatory	1
region	2
,	0
and	0
approximately	0
300	0
bp	0
of	0
the	0
3'-region	1
revealed	0
no	0
alterations	0
.	0

Western	0
blot	0
with	0
an	0
N-terminal	0
antibody	0
showed	0
normal	0
levels	0
of	0
immunoreactive	9
GR	10
,	0
but	0
quantitative	0
analysis	0
with	0
isoform-specific	0
C-terminal	9
antibodies	10
revealed	0
a	0
markedly	0
reduced	0
GRalpha	9
expression	0
,	0
and	0
high	0
GRbeta	9
expression	0
.	0

These	0
findings	0
indicate	0
that	0
imbalanced	0
expression	0
of	0
the	0
GR	9
isoforms	10
may	0
be	0
a	0
mechanism	0
of	0
GC	0
resistance	0
,	0
and	0
may	0
have	0
implications	0
for	0
tumorigenesis	0
by	0
enhancing	0
cell	0
survival	0
.	0

Copyright	0
1999	0
Academic	0
Press	0
.	0

Intranuclear	0
targeted	0
delivery	0
of	0
functional	0
NF-kappaB	9
by	0
70	9
kDa	10
heat	10
shock	10
protein	10
.	0

The	0
70	9
kDa	10
heat	10
shock	10
protein	10
(	0
Hsp70	9
)	0
is	0
a	0
highly	0
conserved	0
,	0
ubiquitous	9
protein	10
involved	0
in	0
chaperoning	9
proteins	10
to	0
various	0
cellular	0
organelles	0
.	0

Here	0
we	0
show	0
that	0
when	0
added	0
exogenously	0
to	0
cells	0
,	0
Hsp70	9
is	0
readily	0
imported	0
into	0
both	0
cytoplasmic	0
and	0
nuclear	0
compartments	0
in	0
a	0
cell-type-specific	0
fashion	0
.	0

We	0
exploited	0
this	0
ability	0
of	0
Hsp70	9
to	0
deliver	0
NF-kappaB	9
,	0
a	0
key	0
transcriptional	0
regulator	0
of	0
inflammatory	0
responses	0
.	0

We	0
demonstrate	0
that	0
a	0
fusion	0
protein	0
composed	0
of	0
a	0
C-terminal	0
Hsp70	9
peptide	0
and	0
the	0
p50	9
subunit	10
of	0
NF-kappaB	9
was	0
directed	0
into	0
the	0
nucleus	0
of	0
cells	0
,	0
could	0
bind	0
DNA	0
specifically	0
,	0
and	0
activated	0
Igkappa	9
expression	0
and	0
TNFalpha	9
production	0
.	0

We	0
therefore	0
propose	0
that	0
Hsp70	9
can	0
be	0
used	0
as	0
a	0
vehicle	0
for	0
intracytoplasmic	0
and	0
intranuclear	0
delivery	0
of	0
proteins	0
or	0
DNA	0
to	0
modulate	0
gene	0
expression	0
and	0
thereby	0
control	0
immune	0
responses	0
.	0

Characterization	0
of	0
the	0
human	1
elk-1	2
promoter	2
.	0

Potential	0
role	0
of	0
a	0
downstream	1
intronic	2
sequence	2
for	0
elk-1	1
gene	2
expression	0
in	0
monocytes	7
.	0

To	0
characterize	0
the	0
human	1
elk-1	2
promoter	2
,	0
we	0
mapped	0
the	0
transcriptional	1
start	2
site	2
and	0
isolated	0
elk-1-specific	5
genomic	6
phage	6
clones	6
that	0
contained	0
extensive	0
upstream	1
and	2
downstream	2
sequences	2
.	0

A	0
TATA-like	1
motif	2
was	0
identified	0
immediately	0
upstream	0
of	0
the	0
transcriptional	1
start	2
site	2
.	0

Functional	0
analyses	0
of	0
DNA	1
fragments	2
containing	0
the	0
TATA	1
element	2
and	0
the	0
identification	0
of	0
a	0
DNase	1
I-hypersensitive	2
chromatin	2
site	2
(	0
HS	1
1	2
)	0
in	0
close	0
proximity	0
to	0
the	0
TATA	1
box	2
suggest	0
that	0
the	0
identified	0
TATA	1
motif	2
is	0
important	0
for	0
elk-1	1
transcription	0
in	0
vivo	0
.	0

Sequences	0
upstream	0
and	0
downstream	0
from	0
the	0
TATA	1
box	2
were	0
found	0
to	0
contribute	0
to	0
elk-1	1
promoter	0
activity	0
.	0

A	0
second	0
hypersensitive	0
site	0
(	0
HS	0
2	0
)	0
was	0
identified	0
within	0
the	0
first	0
intron	0
in	0
pre-monocytic	0
cells	0
,	0
which	0
express	0
Elk-1	0
only	0
when	0
differentiating	0
to	0
monocytes	7
.	0

In	0
a	0
variety	0
of	0
other	0
cell	0
types	0
,	0
which	0
display	0
a	0
constitutive	0
Elk-1	9
expression	0
,	0
HS	0
2	0
did	0
not	0
exist	0
,	0
suggesting	0
that	0
inducibility	0
of	0
elk-1	1
expression	0
is	0
associated	0
with	0
the	0
presence	0
of	0
HS	0
2	0
.	0

Egr-1	0
and	0
the	0
serum	0
response	0
factor	0
were	0
found	0
to	0
interact	0
specifically	0
with	0
the	0
intronic	1
sequence	2
at	0
+265	0
and	0
+448	0
,	0
respectively	0
.	0

Because	0
Egr-1	3
mRNA	4
and	0
protein	0
levels	0
were	0
observed	0
to	0
increase	0
significantly	0
before	0
induction	0
of	0
elk-1	1
expression	0
,	0
we	0
propose	0
that	0
Egr-1	9
is	0
important	0
for	0
the	0
regulation	0
of	0
elk-1	1
transcription	0
in	0
differentiating	0
monocytes	7
.	0

Immunohistochemical	0
study	0
of	0
c-fos-positive	9
lymphocytes	10
infiltrated	0
into	0
human	0
squamous	0
cell	0
carcinomas	0
of	0
the	0
head	0
and	0
neck	0
during	0
radiation	0
therapy	0
and	0
its	0
clinical	0
significance	0
.	0

C-fos	1
has	0
been	0
reported	0
to	0
be	0
one	0
of	0
the	0
immediate	1
early	2
genes	2
in	0
signal	0
transduction	0
systems	0
after	0
many	0
kinds	0
of	0
stresses	0
,	0
including	0
ionizing	0
radiation	0
.	0

Changes	0
in	0
c-fos	1
expression	0
induced	0
by	0
radiation	0
therapy	0
in	0
tumor	0
tissues	0
have	0
not	0
yet	0
been	0
reported	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
attempted	0
to	0
determine	0
whether	0
c-fos	1
expression	0
is	0
induced	0
by	0
radiotherapy	0
in	0
human	0
squamous	0
cell	0
carcinomas	0
of	0
the	0
head	0
and	0
neck	0
and	0
to	0
establish	0
a	0
possible	0
correlation	0
between	0
c-fos	1
expression	0
and	0
the	0
therapeutic	0
effects	0
of	0
radiation	0
therapy	0
.	0

Twenty-seven	0
patients	0
with	0
tumors	0
of	0
the	0
oral	0
cavity	0
,	0
oropharynx	0
,	0
and	0
maxillary	0
sinus	0
were	0
examined	0
,	0
all	0
of	0
which	0
were	0
confirmed	0
as	0
squamous	0
cell	0
carcinomas	0
.	0

After	0
obtaining	0
the	0
patients	0
'	0
informed	0
consent	0
,	0
biopsies	0
were	0
performed	0
before	0
treatment	0
and	0
at	0
doses	0
of	0
4	0
,	0
10	0
,	0
and	0
20	0
Gy	0
of	0
radiotherapy	0
,	0
and	0
the	0
specimens	0
were	0
preserved	0
in	0
liquid	0
nitrogen	0
for	0
further	0
examination	0
.	0

Serial	0
sectioning	0
of	0
6	0
micrometer	0
was	0
performed	0
using	0
a	0
cryostat	0
,	0
and	0
samples	0
were	0
immunohistochemically	0
stained	0
using	0
the	0
streptoavidin	9
-biotin	9
peroxidase	10
method	0
and	0
a	0
monoclonal	0
antibody	0
against	0
c-fos	0
.	0

Three	0
of	0
the	0
27	0
patients	0
with	0
squamous	0
cell	0
carcinoma	0
showed	0
slight	0
expression	0
of	0
c-fos	0
in	0
their	0
tumor	0
cells	0
before	0
and/or	0
at	0
4	0
or	0
10	0
Gy	0
of	0
radiotherapy	0
.	0

The	0
tumors	0
showed	0
high	0
radiosensitivity	0
.	0

Concerning	0
tumor-infiltrating	7
lymphocytes	8
,	0
the	0
rate	0
of	0
moderate	0
or	0
remarkable	0
grades	0
of	0
c-fos-positive	9
lymphocytes	10
before	0
radiotherapy	0
and	0
at	0
radiation	0
doses	0
of	0
4	0
,	0
10	0
,	0
and	0
20	0
Gy	0
was	0
8.0	0
,	0
29.2	0
,	0
4.8	0
,	0
and	0
0	0
%	0
,	0
respectively	0
.	0

The	0
relationship	0
between	0
the	0
immunohistochemical	0
findings	0
and	0
the	0
antitumor	0
effect	0
at	0
a	0
radiation	0
dose	0
of	0
20	0
Gy	0
was	0
examined	0
on	0
the	0
corresponding	0
H	0
&	0
E-stained	0
sections	0
.	0

In	0
patients	0
whose	0
infiltration	0
of	0
c-fos-positive	9
lymphocytes	10
into	0
tumor	0
tissues	0
were	0
moderate	0
or	0
remarkable	0
at	0
4	0
Gy	0
of	0
radiotherapy	0
,	0
the	0
tumors	0
responded	0
significantly	0
well	0
to	0
radiation	0
therapy	0
(	0
P	0
<	0
0.025	0
,	0
chi2	0
test	0
)	0
,	0
and	0
the	0
patients	0
took	0
a	0
significantly	0
favorable	0
clinical	0
course	0
(	0
P	0
<	0
0.05	0
,	0
chi2	0
test	0
)	0
.	0

In	0
a	0
sample	0
from	0
one	0
of	0
the	0
patients	0
,	0
c-fos-positive	9
lymphocytes	10
were	0
identified	0
as	0
CD4	0
positive	0
and	0
CD8	0
negative	0
.	0

Therefore	0
,	0
the	0
high	0
radiosensitivity	0
of	0
squamous	0
cell	0
carcinomas	0
in	0
our	0
samples	0
could	0
be	0
explained	0
by	0
an	0
overexpression	0
of	0
c-fos	9
in	0
the	0
tumor-infiltrating	7
lymphocytes	8
induced	0
by	0
small	0
doses	0
of	0
radiation	0
therapy	0
,	0
and	0
these	0
activated	7
lymphocytes	8
exerted	0
a	0
cytotoxic	0
effect	0
against	0
the	0
cancer	7
cells	8
.	0

Paternal	0
expression	0
of	0
WT1	9
in	0
human	7
fibroblasts	8
and	0
lymphocytes	7
.	0

The	0
Wilms	1
'	2
tumor	2
suppressor	2
gene	2
(	0
WT1	9
)	0
was	0
previously	0
identified	0
as	0
being	0
imprinted	0
,	0
with	0
frequent	0
maternal	0
expression	0
in	0
human	0
placentae	0
and	0
fetal	0
brains	0
.	0

We	0
examined	0
the	0
allele-specific	0
expression	0
of	0
WT1	9
in	0
cultured	0
human	7
fibroblasts	8
from	0
15	0
individuals	0
.	0

Seven	0
of	0
15	0
fibroblast	5
lines	6
were	0
heterozygous	0
for	0
polymorphic	1
alleles	2
,	0
and	0
the	0
expression	0
patterns	0
were	0
variable	0
,	0
i.e.	0
,	0
equal	0
,	0
unequal	0
or	0
monoallelic	0
paternal	0
expression	0
in	0
three	0
,	0
two	0
and	0
two	0
cases	0
,	0
respectively	0
.	0

Exclusive	0
paternal	0
expression	0
of	0
WT1	9
was	0
also	0
shown	0
in	0
non-cultured	7
peripheral	8
lymphocytes	8
from	0
the	0
latter	0
two	0
individuals	0
.	0

The	0
allele-specific	0
expression	0
profiles	0
of	0
other	0
imprinted	1
genes	2
,	0
IGF2	1
and	0
H19	1
,	0
on	0
human	1
chromosome	2
11	2
were	0
constant	0
and	0
consistent	0
with	0
those	0
in	0
other	0
tissues	0
.	0

Our	0
unexpected	0
observations	0
of	0
paternal	0
or	0
biallelic	0
expression	0
of	0
WT1	9
in	0
fibroblasts	7
and	0
lymphocytes	7
,	0
together	0
with	0
the	0
previous	0
findings	0
of	0
maternal	0
or	0
biallelic	0
expression	0
in	0
placentae	0
and	0
brains	0
,	0
suggest	0
that	0
the	0
allele-specific	0
regulatory	0
system	0
of	0
WT1	9
is	0
unique	0
and	0
may	0
be	0
controlled	0
by	0
a	0
putative	0
tissue-	0
and	0
individual-specific	0
modifier	0
.	0

T	0
cell	0
reactivity	0
to	0
Sjogren	0
's	0
syndrome	0
related	0
antigen	0
La	9
(	10
SSB	10
)	10
.	0

OBJECTIVE	0
.	0

Many	0
patients	0
with	0
primary	0
Sjogren	0
's	0
syndrome	0
(	0
SS	0
)	0
make	0
high	0
titer	0
IgG	9
autoantibodies	10
to	0
the	0
La	9
(	10
SSB	10
)	10
antigen	0
,	0
suggesting	0
antigen	0
specific	0
T	0
cell-B	0
cell	0
interactions	0
.	0

T	0
cell	0
responses	0
to	0
some	0
nuclear	0
antigens	0
,	0
particularly	0
U1RNP	9
,	0
have	0
been	0
detected	0
in	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
and	0
in	0
healthy	0
subjects	0
.	0

We	0
investigated	0
T	0
cell	0
reactivity	0
to	0
the	0
autoantigen	9
SSB	10
in	0
patients	0
with	0
SS	0
and	0
healthy	0
controls	0
.	0

METHODS	0
.	0

Using	0
the	0
[	0
3H	0
]	0
thymidine	0
proliferation	0
assay	0
,	0
we	0
determined	0
reactivity	0
to	0
purified	9
recombinant	10
SSB	10
(	0
rSSB	9
)	0
in	0
20	0
patients	0
with	0
SS	0
and	0
19	0
controls	0
.	0

Specificity	0
was	0
determined	0
using	0
tetanus	0
toxoid	0
,	0
endotoxin	0
,	0
and	0
3	0
other	0
autoantigens	9
(	0
PBC.M2	9
,	0
Sc170	9
,	0
and	0
GAD	9
)	0
.	0

Precursor	0
frequency	0
was	0
calculated	0
by	0
limiting	0
dilution	0
analysis	0
.	0

HLA	0
Class	0
II	0
dependency	0
was	0
investigated	0
using	0
anti-Class	9
II	10
monoclonal	10
antibodies	10
.	0

HLA-DR	0
typing	0
was	0
by	0
polymerase	0
chain	0
reaction	0
and	0
sequence	0
specific	0
oligonucleotide	0
typing	0
.	0

RESULTS	0
.	0

Six	0
of	0
20	0
patients	0
with	0
SS	0
and	0
10/19	0
controls	0
proliferated	0
to	0
La	0
(	0
rSSB	9
)	0
.	0

Precursor	0
frequency	0
of	0
anti-SSB	5
T	6
cells	6
was	0
1	0
:	0
77	0
,	0
040	0
and	0
1	0
:	0
115	0
,	0
000	0
in	0
2	0
healthy	0
subjects	0
and	0
1	0
:	0
230	0
,	0
250	0
and	0
1	0
:	0
103	0
,	0
034	0
in	0
two	0
patients	0
with	0
SS	0
.	0

Anti-	0
HLA-DR	9
abrogated	0
proliferation	0
to	0
SSB	9
and	0
tetanus	0
toxoid	0
.	0

Thirteen	0
of	0
15	0
patients	0
with	0
SS	0
and	0
4/17	0
controls	0
were	0
HLA-DR3	9
positive	0
,	0
with	0
no	0
apparent	0
association	0
of	0
HLA-DR3	9
with	0
SSB	9
reactivity	0
in	0
controls	0
.	0

CONCLUSION	0
.	0

Anti-La	5
(	6
SSB	6
)	6
specific	6
T	6
cells	6
occur	0
in	0
a	0
significant	0
proportion	0
of	0
controls	0
and	0
in	0
some	0
patients	0
with	0
SS	0
.	0

The	0
function	0
of	0
SSB	5
T	6
cells	6
in	0
controls	0
remains	0
to	0
be	0
defined	0
.	0

They	0
may	0
represent	0
immunoregulatory	7
cells	8
,	0
and	0
further	0
analysis	0
of	0
these	0
cells	0
,	0
and	0
a	0
comparison	0
to	0
those	0
found	0
in	0
patients	0
with	0
SS	0
,	0
may	0
elucidate	0
normal	0
immunoregulation	0
and	0
the	0
derangements	0
that	0
lead	0
to	0
Sjogren	0
's	0
syndrome	0
.	0

Anti-rheumatic	0
compound	0
aurothioglucose	0
inhibits	0
tumor	9
necrosis	10
factor-alpha	10
-induced	0
HIV-1	0
replication	0
in	0
latently	0
infected	0
OM10.1	5
and	6
Ach2	6
cells	6
.	0

NF-kappaB	9
is	0
a	0
potent	0
cellular	0
activator	0
of	0
HIV-1	0
gene	0
expression	0
.	0

Down-regulation	0
of	0
NF-kappaB	9
activation	0
is	0
known	0
to	0
inhibit	0
HIV	0
replication	0
from	0
the	0
latently	7
infected	8
cells	8
.	0

Gold	0
compounds	0
have	0
been	0
effectively	0
used	0
for	0
many	0
decades	0
in	0
the	0
treatment	0
of	0
rheumatoid	0
arthritis	0
.	0

We	0
previously	0
reported	0
that	0
gold	0
compounds	0
,	0
especially	0
aurothioglucose	0
(	0
AuTG	0
)	0
containing	0
monovalent	0
gold	0
ion	0
,	0
inhibited	0
the	0
DNA-binding	0
of	0
NF-kappaB	9
in	0
vitro	0
.	0

In	0
this	0
report	0
we	0
have	0
examined	0
the	0
efficacy	0
of	0
the	0
gold	0
compound	0
AuTG	0
as	0
an	0
inhibitor	0
of	0
HIV	0
replication	0
in	0
latently	0
infected	0
OM10.1	5
and	6
Ach2	6
cells	6
.	0

Tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
-induced	0
HIV-1	0
replication	0
in	0
OM10.1	5
or	0
Ach2	5
cells	6
was	0
significantly	0
inhibited	0
by	0
non-cytotoxic	0
doses	0
of	0
AuTG	0
(	0
>	0
10	0
microM	0
in	0
OM10.1	0
cells	0
and	0
>	0
25	0
F.M	0
in	0
Ach2	5
cells	6
)	0
,	0
while	0
25	0
microM	0
of	0
the	0
counter-anion	9
thioglucose	10
(	0
TG	9
)	0
or	0
gold	0
compound	0
containing	0
divalent	0
gold	0
ion	0
,	0
HAuCl3	0
,	0
had	0
no	0
effect	0
.	0

The	0
effect	0
of	0
AuTG	0
on	0
NF-kappaB	9
-dependent	0
gene	0
expression	0
was	0
confirmed	0
by	0
a	0
transient	0
CAT	9
assay	0
.	0

Specific	0
staining	0
as	0
well	0
as	0
electron	0
microscopic	0
examinations	0
revealed	0
the	0
accumulation	0
of	0
metal	0
gold	0
in	0
the	0
cells	0
,	0
supporting	0
our	0
previous	0
hypothesis	0
that	0
gold	0
ions	0
could	0
block	0
NF-kappaB	9
-DNA	0
binding	0
by	0
a	0
redox	0
mechanism	0
.	0

These	0
observations	0
indicate	0
that	0
the	0
monovalent	0
gold	0
compound	0
AuTG	0
is	0
a	0
potentially	0
useful	0
drug	0
for	0
the	0
treatment	0
of	0
patients	0
infected	0
with	0
HIV	0
.	0

Clonality	0
of	0
isolated	7
eosinophils	8
in	0
the	0
hypereosinophilic	0
syndrome	0
.	0

The	0
idiopathic	0
hypereosinophilic	0
syndrome	0
(	0
IHES	0
)	0
is	0
a	0
rare	0
disorder	0
characterized	0
by	0
unexplained	0
,	0
persistent	0
eosinophilia	0
associated	0
with	0
multiple	0
organ	0
dysfunction	0
due	0
to	0
eosinophilic	0
tissue	0
infiltration	0
.	0

In	0
the	0
absence	0
of	0
karyotypic	0
abnormalities	0
,	0
there	0
is	0
no	0
specific	0
test	0
to	0
detect	0
clonal	0
eosinophilia	0
in	0
IHES	0
.	0

Analysis	0
of	0
X-chromosome	1
inactivation	0
patterns	0
can	0
be	0
used	0
to	0
determine	0
whether	0
proliferative	0
disorders	0
are	0
clonal	0
in	0
origin	0
.	0

Methylation	0
of	0
HpaII	1
and	2
Hha	2
I	2
sites	2
near	0
the	0
polymorphic	1
trinucleotide	2
repeat	2
of	0
the	0
human	1
androgen	2
receptor	2
gene	2
(	0
HUMARA	1
)	0
has	0
been	0
shown	0
to	0
correlate	0
with	0
X-inactivation	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
used	0
the	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
with	0
nested	0
primers	0
to	0
analyze	0
X-inactivation	0
patterns	0
of	0
the	0
HUMARA	1
loci	2
in	0
purified	7
eosinophils	8
from	0
female	0
patients	0
with	0
eosinophilia	0
.	0

Peripheral	7
blood	8
eosinophils	8
were	0
isolated	0
by	0
their	0
autofluoresence	0
using	0
flow	0
cytometric	0
sorting	0
.	0

Eosinophils	7
purified	0
from	0
a	0
female	0
patient	0
presenting	0
with	0
IHES	0
were	0
found	0
to	0
show	0
a	0
clonal	0
pattern	0
of	0
X-inactivation	0
.	0

Eosinophil-depleted	7
leukocytes	8
from	0
this	0
patient	0
were	0
polyclonal	0
by	0
HUMARA	1
analysis	0
,	0
thus	0
excluding	0
skewedness	0
of	0
random	0
X-inactivation	0
.	0

After	0
corticosteroid	0
suppression	0
of	0
her	0
blood	0
eosinophilia	0
,	0
a	0
clonal	0
population	0
of	0
eosinophils	7
could	0
no	0
longer	0
be	0
detected	0
in	0
purified	7
eosinophils	8
.	0

In	0
contrast	0
,	0
eosinophils	7
purified	0
from	0
a	0
patient	0
with	0
Churg-Strauss	0
syndrome	0
and	0
from	0
six	0
patients	0
with	0
reactive	0
eosinophilias	0
attributed	0
to	0
allergy	0
,	0
parasitic	0
infection	0
,	0
or	0
drug	0
reaction	0
showed	0
a	0
polyclonal	0
pattern	0
of	0
X-inactivation	0
by	0
HUMARA	1
analysis	0
.	0

The	0
finding	0
of	0
clonal	0
eosinophilia	0
in	0
a	0
patient	0
presenting	0
with	0
IHES	0
indicates	0
that	0
such	0
patients	0
may	0
have	0
,	0
in	0
reality	0
,	0
a	0
low-grade	0
clonal	0
disorder	0
that	0
can	0
be	0
distinguished	0
from	0
reactive	0
eosinophilias	0
by	0
HUMARA	1
analysis	0
.	0

Further	0
,	0
the	0
method	0
described	0
can	0
be	0
used	0
to	0
monitor	0
disease	0
progression	0
.	0

GA-binding	9
protein	10
factors	10
,	0
in	0
concert	0
with	0
the	0
coactivator	9
CREB	10
binding	10
protein/p300	10
,	0
control	0
the	0
induction	0
of	0
the	0
interleukin	1
16	2
promoter	2
in	0
T	7
lymphocytes	8
.	0

Interleukin	9
16	10
(	0
IL-16	9
)	0
is	0
a	0
chemotactic	9
cytokine	10
that	0
binds	0
to	0
the	0
CD4	9
receptor	10
and	0
affects	0
the	0
activation	0
of	0
T	7
cells	8
and	0
replication	0
of	0
HIV	0
.	0

It	0
is	0
expressed	0
as	0
a	0
large	0
67-kDa	9
precursor	10
protein	10
(	0
pro-IL-16	9
)	0
in	0
lymphocytes	7
,	0
macrophages	7
,	0
and	0
mast	7
cells	8
,	0
as	0
well	0
as	0
in	0
airway	7
epithelial	8
cells	8
from	0
asthmatics	0
after	0
challenge	0
with	0
allergen	0
.	0

This	0
pro-IL-16	9
is	0
subsequently	0
processed	0
to	0
the	0
mature	0
cytokine	0
of	0
13	9
kDa	10
.	0

To	0
study	0
the	0
expression	0
of	0
IL-16	9
at	0
the	0
transcriptional	0
level	0
,	0
we	0
cloned	0
the	0
human	1
chromosomal	2
IL-16	2
gene	2
and	0
analyzed	0
its	0
promoter	0
.	0

The	0
human	1
IL-16	2
gene	2
consists	0
of	0
seven	0
exons	1
and	0
six	0
introns	1
.	0

The	0
5	1
'	2
sequences	2
up	0
to	0
nucleotide	0
-120	0
of	0
the	0
human	0
and	0
murine	0
IL-16	9
genes	0
share	0
>	0
84	0
%	0
sequence	0
homology	0
and	0
harbor	1
promoter	2
elements	2
for	0
constitutive	0
and	0
inducible	0
transcription	0
in	0
T	7
cells	8
.	0

Although	0
both	0
promoters	0
lack	0
any	0
TATA	1
box	2
,	0
they	0
contain	0
two	0
CAAT	1
box-like	2
motifs	2
and	0
three	0
binding	1
sites	2
of	0
GA-binding	9
protein	10
(	10
GABP	10
)	10
transcription	10
factors	10
.	0

Two	0
of	0
these	0
motifs	0
are	0
part	0
of	0
a	0
highly	0
conserved	0
and	0
inducible	0
dyad	1
symmetry	2
element	2
shown	0
previously	0
to	0
control	0
a	0
remote	0
IL-2	1
enhancer	2
and	0
the	0
CD18	1
promoter	2
.	0

In	0
concert	0
with	0
the	0
coactivator	9
CREB	10
binding	10
protein/p300	10
,	0
which	0
interacts	0
with	0
GABPalpha	9
,	0
the	0
binding	0
of	0
GABPalpha	9
and	0
-beta	9
to	0
the	0
dyad	1
symmetry	2
element	2
controls	0
the	0
induction	0
of	0
IL-16	1
promoter	2
in	0
T	7
cells	8
.	0

Supplementing	0
the	0
data	0
on	0
the	0
processing	0
of	0
pro-IL-16	9
,	0
our	0
results	0
indicate	0
the	0
complexity	0
of	0
IL-16	9
expression	0
,	0
which	0
is	0
tightly	0
controlled	0
at	0
the	0
transcriptional	0
and	0
posttranslational	0
levels	0
in	0
T	7
lymphocytes	8
.	0

Tuberculosis	0
and	0
chronic	0
hepatitis	0
B	0
virus	0
infection	0
in	0
Africans	0
and	0
variation	0
in	0
the	0
vitamin	1
D	2
receptor	2
gene	2
.	0

The	0
active	0
metabolite	0
of	0
vitamin	0
D	0
,	0
1	0
,	0
25	0
dihydroxyvitamin	0
D3	0
,	0
is	0
an	0
important	0
immunoregulatory	0
hormone	0
[	0
1	0
]	0
.	0

Its	0
effects	0
are	0
exerted	0
by	0
interaction	0
with	0
the	0
vitamin	9
D	10
receptor	10
,	0
which	0
is	0
present	0
on	0
human	7
monocytes	8
and	0
activated	7
T	8
and	8
B	8
lymphocytes	8
.	0

Variation	0
in	0
the	0
vitamin	1
D	2
receptor	2
gene	2
was	0
typed	0
in	0
2015	0
subjects	0
from	0
large	0
case-control	0
studies	0
of	0
three	0
major	0
infectious	0
diseases	0
:	0
tuberculosis	0
,	0
malaria	0
,	0
and	0
hepatitis	0
B	0
virus	0
.	0

Homozygotes	0
for	0
a	0
polymorphism	0
at	0
codon	1
352	2
(	0
genotype	0
tt	0
)	0
were	0
significantly	0
underrepresented	0
among	0
those	0
with	0
tuberculosis	0
(	0
chi2=6.22	0
,	0
1	0
df	0
,	0
P=.01	0
)	0
and	0
persistent	0
hepatitis	0
B	0
infection	0
(	0
chi2=6.25	0
,	0
1	0
df	0
,	0
P=.01	0
)	0
but	0
not	0
in	0
subjects	0
with	0
clinical	0
malaria	0
compared	0
with	0
the	0
other	0
genotypes	0
.	0

Therefore	0
,	0
this	0
genetic	0
variant	0
,	0
which	0
predisposes	0
to	0
low	0
bone	0
mineral	0
density	0
in	0
many	0
populations	0
,	0
may	0
confer	0
resistance	0
to	0
certain	0
infectious	0
diseases	0
.	0

Inhibition	0
of	0
NF-kappa	9
B	10
activation	0
in	0
vitro	0
and	0
in	0
vivo	0
:	0
role	0
of	0
26S	9
proteasome	10
.	0

It	0
is	0
becoming	0
increasingly	0
apparent	0
that	0
NF-kappa	9
B	10
plays	0
a	0
critical	0
role	0
in	0
regulating	0
the	0
inflammatory	0
response	0
.	0

Data	0
obtained	0
from	0
studies	0
in	0
our	0
laboratories	0
demonstrate	0
that	0
the	0
proteasome	0
plays	0
an	0
important	0
role	0
in	0
the	0
inflammatory	0
cascade	0
by	0
regulating	0
the	0
activation	0
of	0
NF-kappa	9
B	10
.	0

Indeed	0
,	0
the	0
availability	0
of	0
selective	0
and	0
orally	0
active	0
proteasome	0
inhibitors	0
should	0
prove	0
useful	0
in	0
delineating	0
the	0
roles	0
of	0
the	0
proteasome	0
and	0
NF-kappa	9
B	10
in	0
other	0
pathophysiological	0
conditions	0
such	0
as	0
cancer	0
and	0
heart	0
disease	0
.	0

Tissue	0
factor	0
expression	0
of	0
human	7
monocytes	8
is	0
suppressed	0
by	0
lysophosphatidylcholine	0
.	0

The	0
expression	0
of	0
tissue	9
factor	10
(	0
TF	9
)	0
,	0
the	0
principal	0
initiator	0
of	0
coagulation	0
,	0
is	0
increased	0
during	0
inflammation	0
and	0
atherosclerosis	0
.	0

Both	0
conditions	0
are	0
promoted	0
by	0
lysophosphatidylcholine	0
(	0
lysoPC	0
)	0
.	0

We	0
observed	0
in	0
the	0
present	0
study	0
that	0
lysoPC	0
(	0
1	0
to	0
10	0
micromol/L	0
)	0
dose-dependently	0
reduced	0
TF	9
activity	0
in	0
human	7
monocytes	8
,	0
as	0
elicited	0
by	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

Lysophosphatidylethanolamine	0
(	0
lysoPE	0
)	0
and	0
other	0
lysophospholipids	0
did	0
not	0
affect	0
LPS-induced	0
TF	0
activity	0
of	0
human	7
monocytes	8
.	0

TF	0
antigen	0
expression	0
as	0
elicited	0
by	0
LPS	0
was	0
also	0
lowered	0
by	0
lysoPC	0
.	0

Phospholipid	0
analyses	0
indicated	0
a	0
selective	0
increase	0
in	0
the	0
lysoPC	0
content	0
of	0
the	0
monocytes	7
after	0
preincubation	0
with	0
the	0
lysophospholipid	0
.	0

LysoPC	0
inhibited	0
the	0
TF	0
activity	0
of	0
Mono	5
Mac-6	6
cells	6
to	0
a	0
similar	0
extent	0
as	0
in	0
the	0
monocytes	7
.	0

LPS	0
binding	0
to	0
plasma	0
membrane	0
receptors	0
and	0
internalization	0
of	0
LPS	0
into	0
monocytes	7
were	0
not	0
affected	0
by	0
lysoPC	0
.	0

In	0
contrast	0
,	0
LPS-mediated	0
nuclear	0
binding	0
of	0
nuclear	9
factor-kappaB/Rel	10
to	0
a	0
TF-specific	1
kappaB	2
site	2
was	0
inhibited	0
by	0
lysoPC	0
.	0

Induction	0
of	0
TF	3
mRNA	4
expression	0
by	0
LPS	0
tended	0
to	0
be	0
partially	0
reduced	0
by	0
the	0
lysophospholipid	0
.	0

Preincubation	0
with	0
lysoPC	0
increased	0
monocytic	0
cAMP	0
levels	0
.	0

Inhibition	0
of	0
adenylyl	9
cyclase	10
by	0
pretreatment	0
with	0
2'-deoxy-3'-adenosine	9
monophosphate	10
partially	0
reversed	0
the	0
inhibition	0
of	0
TF	0
activity	0
promoted	0
by	0
lysoPC	0
.	0

In	0
conclusion	0
,	0
lysoPC	0
markedly	0
decreases	0
LPS-mediated	0
TF	0
expression	0
of	0
human	7
monocytes	8
,	0
the	0
effect	0
probably	0
being	0
mediated	0
by	0
both	0
transcriptional	0
and	0
posttranscriptional	0
mechanisms	0
.	0

LysoPC	0
may	0
thus	0
attenuate	0
activation	0
of	0
coagulation	0
during	0
inflammation	0
and	0
atherosclerosis	0
.	0

Regulation	0
of	0
fas-ligand	0
expression	0
during	0
activation-induced	0
cell	0
death	0
in	0
T	7
lymphocytes	8
via	0
nuclear	9
factor	10
kappaB	10
.	0

T	0
cell	0
receptor	0
engagement	0
activates	0
transcription	9
factors	10
important	0
for	0
cytokine	1
gene	2
regulation	0
.	0

Additionally	0
,	0
this	0
signaling	0
pathway	0
also	0
leads	0
to	0
activation-induced	0
apoptosis	0
in	0
T	7
lymphocytes	8
that	0
is	0
dependent	0
on	0
FasL	0
transcription	0
and	0
expression	0
.	0

Here	0
we	0
demonstrate	0
that	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
,	0
which	0
is	0
involved	0
in	0
the	0
transcriptional	0
regulation	0
of	0
many	0
cytokine	1
genes	2
expressed	0
in	0
activated	7
lymphocytes	8
,	0
also	0
plays	0
a	0
role	0
in	0
T	0
cell	0
activation-induced	0
FasL	9
expression	0
.	0

Inhibition	0
of	0
NF-kappaB	9
activity	0
in	0
a	0
T	5
cell	6
hybridoma	6
leads	0
to	0
decreased	0
FasL	9
expression	0
and	0
apoptosis	0
upon	0
T	9
cell	10
receptor	10
stimulation	0
.	0

We	0
identified	0
the	0
NF-kappaB	1
site	2
in	0
the	0
FasL	1
promoter	2
that	0
contributes	0
to	0
such	0
regulation	0
.	0

Co-expression	0
of	0
p65	9
(	10
Rel	10
A	10
)	10
with	0
the	0
FasL	1
promoter	2
enhanced	0
its	0
activity	0
,	0
and	0
co-expression	0
of	0
IkappaB	9
dramatically	0
inhibited	0
the	0
inducible	1
promoter	2
activity	0
.	0

In	0
contrast	0
,	0
the	0
transcription	9
factor	10
AP-1	10
is	0
not	0
required	0
for	0
activation-induced	0
FasL	9
promoter	0
activity	0
.	0

These	0
results	0
define	0
a	0
role	0
for	0
NF-kappaB	9
in	0
mediating	0
FasL	9
expression	0
during	0
T	0
cell	0
activation	0
.	0

Promoter	1
sequence	2
,	0
exon	0
:	0
intron	0
structure	0
,	0
and	0
synteny	0
of	0
genetic	0
location	0
show	0
that	0
a	0
chicken	9
cytokine	10
with	0
T-cell	0
proliferative	0
activity	0
is	0
IL2	9
and	0
not	0
IL15	9
.	0

The	0
gene	0
encoding	0
a	0
chicken	9
cytokine	10
with	0
T-cell	0
proliferative	0
activity	0
was	0
cloned	0
,	0
sequenced	0
,	0
and	0
mapped	0
.	0

The	0
results	0
show	0
that	0
this	0
cytokine	9
is	0
chicken	0
IL2	9
and	0
not	0
IL15	9
.	0

The	0
exon	0
:	0
intron	0
structure	0
of	0
chicken	9
IL2	10
corresponds	0
almost	0
exactly	0
to	0
those	0
of	0
mammalian	0
IL2s	9
with	0
the	0
exceptions	0
of	0
exon	1
2	2
and	0
introns	1
2	0
and	0
3	0
which	0
are	0
shorter	0
.	0

Chicken	0
IL2	9
contains	0
five	0
repeats	0
of	0
the	0
``	0
instability	0
''	0
motif	0
ATTTA	0
in	0
the	0
3'untranslated	1
region	2
in	0
exon	1
4	2
.	0

It	0
is	0
a	0
single-copy	1
gene	2
,	0
with	0
neither	0
structural	0
(	0
amino	0
acid	0
)	0
nor	0
promoter	0
sequence	0
polymorphisms	0
identified	0
.	0

Analysis	0
of	0
the	0
predicted	0
amino	0
acid	0
sequence	0
suggests	0
that	0
overall	0
protein	9
structure	10
is	0
conserved	0
,	0
but	0
the	0
receptor	0
binding	0
sites	0
are	0
not	0
.	0

A	0
number	0
of	0
potential	1
regulatory	2
sequences	2
similar	0
to	0
those	0
found	0
in	0
mammals	0
have	0
been	0
identified	0
in	0
the	0
promoter	1
.	0

These	0
include	0
(	0
5'-3	0
'	0
)	0
a	0
composite	0
NF-AT/	1
``	2
AP-1	2
''	2
element	2
,	0
a	0
CD28	1
response	2
element	2
,	0
an	0
AP-1	1
element	2
,	0
an	0
NF-AT	1
element	2
,	0
and	0
the	0
AP-1	1
part	2
of	2
an	2
AP-1/octamer	2
composite	2
element	2
.	0

The	0
mammalian	9
NF-kappaB	10
and	0
octamer	1
binding	2
sites	2
seem	0
to	0
be	0
absent	0
,	0
although	0
there	0
are	0
alternative	0
potential	0
NF-kappaB	9
and	0
octamer-binding	1
elements	2
in	0
the	0
chicken	1
IL2	2
promoter	2
,	0
in	0
close	0
proximity	0
to	0
their	0
mammalian	1
homologues	2
.	0

Sequence	0
comparisons	0
also	0
predict	0
other	0
potential	0
transcription	0
factor	0
binding	0
sites	0
as	0
yet	0
undescribed	0
in	0
mammalian	1
IL2	2
promoters	2
.	0

A	0
Taq	1
I	2
polymorphism	2
was	0
identified	0
which	0
enabled	0
chicken	0
IL2	9
to	0
be	0
mapped	0
to	0
chromosome	1
4	2
,	0
linked	0
to	0
ANX5	1
,	0
with	0
synteny	0
with	0
mouse	1
chromosome	2
3	2
and	0
human	1
chromosome	2
4	2
.	0

This	0
is	0
the	0
first	0
non-mammalian	1
cytokine	2
gene	2
to	0
be	0
mapped	0
.	0

Endothelial	0
production	0
of	0
MCP-1	9
:	0
modulation	0
by	0
heparin	0
and	0
consequences	0
for	0
mononuclear	0
cell	0
activation	0
.	0

Heparin	0
is	0
a	0
polyanionic	0
glycosaminoglycan	0
(	0
GAG	0
)	0
that	0
can	0
bind	0
with	0
high	0
affinity	0
to	0
a	0
range	0
of	0
cytokines	9
including	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
and	0
members	0
of	0
the	0
chemokine	9
superfamily	10
.	0

This	0
GAG	0
also	0
possesses	0
immunomodulatory	0
activity	0
in	0
vivo	0
and	0
can	0
antagonize	0
the	0
capacity	0
of	0
IFN-gamma	9
to	0
induce	0
class	9
II	10
MHC	10
antigen	10
expression	0
,	0
and	0
to	0
up-regulate	0
intercellular	9
adhesion	10
molecule-1	10
,	0
by	0
cultured	5
endothelial	6
cells	6
.	0

Previous	0
studies	0
have	0
shown	0
that	0
binding	0
to	0
cell-surface	0
heparan	0
sulphate	0
is	0
essential	0
for	0
optimal	0
activity	0
of	0
IFN-gamma	9
and	0
that	0
free	0
heparin	0
competitively	0
inhibits	0
this	0
sequestration	0
process	0
.	0

The	0
present	0
study	0
was	0
performed	0
to	0
increase	0
our	0
understanding	0
of	0
the	0
immunosuppressive	0
activity	0
of	0
heparin	0
by	0
investigation	0
of	0
potential	0
antagonism	0
of	0
the	0
production	0
and	0
function	0
of	0
monocyte	9
chemotactic	10
peptide-1	10
(	0
MCP-1	9
)	0
,	0
a	0
chemokine	9
important	0
for	0
mononuclear	0
leucocyte	0
recruitment	0
across	0
vascular	0
endothelium	0
.	0

It	0
was	0
found	0
that	0
mixture	0
of	0
heparin	0
with	0
IFN-gamma	9
inhibited	0
up-regulation	0
of	0
the	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
protein	0
,	0
STAT-1	9
produced	0
normally	0
by	0
treatment	0
of	0
endothelial	7
cells	8
with	0
IFN-gamma	9
.	0

An	0
inhibition	0
of	0
MCP-1	9
production	0
was	0
observed	0
that	0
was	0
specifically	0
caused	0
by	0
mixture	0
of	0
IFN-gamma	9
with	0
heparin-like	0
,	0
and	0
therefore	0
cytokine-binding	0
,	0
GAGs	0
.	0

It	0
was	0
also	0
shown	0
that	0
mixture	0
of	0
heparin-like	0
GAGs	0
with	0
MCP-1	9
inhibited	0
the	0
rapid	0
tyrosine	0
phosphorylation	0
of	0
phosphatidylinositol	9
3-kinase	10
which	0
is	0
normally	0
produced	0
by	0
treatment	0
of	0
mononuclear	7
leucocytes	8
with	0
this	0
chemokine	9
.	0

Blockade	0
of	0
this	0
intracellular	0
signalling	0
event	0
was	0
associated	0
with	0
a	0
reduction	0
in	0
the	0
normal	0
transendothelial	0
migration	0
response	0
towards	0
MCP-1	9
.	0

Results	0
from	0
this	0
study	0
indicate	0
that	0
soluble	0
,	0
heparin-like	0
GAGs	0
can	0
block	0
IFN-gamma	9
-dependent	0
up-regulation	0
of	0
MCP-1	9
production	0
by	0
cultured	5
endothelial	6
cells	6
,	0
and	0
can	0
also	0
antagonize	0
the	0
leucocyte-activating	0
and	0
migration-promoting	0
properties	0
of	0
pre-existing	0
MCP-1	9
.	0

These	0
activities	0
may	0
contribute	0
to	0
the	0
immunomodulatory	0
properties	0
of	0
heparin	0
.	0

[	0
Molecular-biologic	0
aspects	0
of	0
interaction	0
between	0
nervous	0
and	0
immune	0
systems	0
]	0

The	0
problem	0
of	0
the	0
neuro-immuno	0
interactions	0
on	0
the	0
level	0
of	0
the	0
protein	9
trans-factors	10
,	0
stimulating	0
interleukin-2	1
(	2
IL-2	2
)	2
gene	2
expression	0
was	0
discussed	0
.	0

The	0
physico-chemical	0
and	0
functional	0
parameters	0
of	0
the	0
low	9
molecular	10
nuclear	10
proteins	10
(	0
SP	9
and	0
BP-	9
14	10
,	10
18	10
,	10
19	10
kDs	10
)	0
isolated	0
from	0
splenic	7
and	8
brain	8
cells	8
of	0
immunized	0
rats	0
were	0
studied	0
.	0

The	0
binding	0
of	0
these	0
proteins	0
to	0
the	0
regulatory	0
region	0
of	0
IL-2	1
gene	2
in	0
vitro	0
and	0
stimulation	0
of	0
the	0
IL-2mRNA	3
synthesis	0
in	0
splenic	5
T-lymphocytes	6
culture	6
in	0
normal	0
conditions	0
were	0
shown	0
.	0

The	0
protective	0
effect	0
of	0
SP	9
and	0
BP	9
on	0
the	0
IL-2mRNA	3
synthesis	0
in	0
stressful	0
conditions	0
and	0
by	0
the	0
T-cells	7
treatment	0
with	0
the	0
CsA	0
was	0
demonstrated	0
.	0

Interferon-alpha	9
activates	0
multiple	0
STAT	9
proteins	10
and	0
upregulates	0
proliferation-associated	0
IL-2Ralpha	9
,	0
c-myc	1
,	2
and	2
pim-1	2
genes	2
in	0
human	7
T	8
cells	8
.	0

Interferon-alpha	9
(	0
IFN-alpha	9
)	0
is	0
a	0
pleiotropic	9
cytokine	10
that	0
has	0
antiviral	0
,	0
antiproliferative	0
,	0
and	0
immunoregulatory	9
functions	0
.	0

There	0
is	0
increasing	0
evidence	0
that	0
IFN-alpha	9
has	0
an	0
important	0
role	0
in	0
T-cell	0
biology	0
.	0

We	0
have	0
analyzed	0
the	0
expression	0
of	0
IL-2Ralpha	9
,	0
c-myc	1
,	0
and	0
pim-1	1
genes	2
in	0
anti-CD3-activated	7
human	8
T	8
lymphocytes	8
.	0

The	0
induction	0
of	0
these	0
genes	0
is	0
associated	0
with	0
interleukin-2	9
(	0
IL-2	9
)	0
-induced	0
T-cell	0
proliferation	0
.	0

Treatment	0
of	0
T	7
lymphocytes	8
with	0
IFN-alpha	9
,	0
IL-2	9
,	0
IL-12	9
,	0
and	0
IL-15	9
upregulated	0
IL-2Ralpha	9
,	0
c-myc	1
,	0
and	0
pim-1	1
gene	2
expression	0
.	0

IFN-alpha	9
also	0
sensitized	5
T	6
cells	6
to	0
IL-2	9
-induced	0
proliferation	0
,	0
further	0
suggesting	0
that	0
IFN-alpha	9
may	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
T-cell	0
mitogenesis	0
.	0

When	0
we	0
analyzed	0
the	0
nature	0
of	0
STAT	9
proteins	10
capable	0
of	0
binding	0
to	0
IL-2Ralpha	9
,	0
pim-1	1
,	2
and	2
IRF-1	2
GAS	2
elements	2
after	0
cytokine	9
stimulation	0
,	0
we	0
observed	0
IFN-alpha	9
-induced	0
binding	0
of	0
STAT1	9
,	0
STAT3	9
,	0
and	0
STAT4	9
,	0
but	0
not	0
STAT5	9
to	0
all	0
of	0
these	0
elements	0
.	0

Yet	0
,	0
IFN-alpha	9
was	0
able	0
to	0
activate	0
binding	0
of	0
STAT5	9
to	0
the	0
high-affinity	0
IFP53	0
GAS	0
site	0
.	0

IFN-alpha	9
enhanced	0
tyrosine	0
phosphorylation	0
of	0
STAT1	0
,	0
STAT3	9
,	0
STAT4	9
,	0
STAT5a	9
,	0
and	0
STAT5b	9
.	0

IL-12	9
induced	0
STAT4	9
and	0
IL-2	9
and	0
IL-15	9
induced	0
STAT5	9
binding	0
to	0
the	0
GAS	1
elements	2
.	0

Taken	0
together	0
,	0
our	0
results	0
suggest	0
that	0
IFN-alpha	9
,	0
IL-2	9
,	0
IL-12	9
,	0
and	0
IL-15	9
have	0
overlapping	0
activities	0
on	0
human	7
T	8
cells	8
.	0

These	0
findings	0
thus	0
emphasize	0
the	0
importance	0
of	0
IFN-alpha	9
as	0
a	0
T-cell	9
regulatory	10
cytokine	10
.	0

The	0
Megakaryocyte/Platelet-specific	1
enhancer	2
of	0
the	0
alpha2beta1	1
integrin	2
gene	2
:	0
two	0
tandem	0
AP1	1
sites	2
and	0
the	0
mitogen-activated	9
protein	10
kinase	10
signaling	0
cascade	0
.	0

The	0
alpha2beta1	9
integrin	10
,	0
a	0
collagen	0
receptor	0
on	0
platelets	7
and	0
megakaryocytes	7
,	0
is	0
required	0
for	0
normal	0
platelet	0
function	0
.	0

Transcriptional	0
regulation	0
of	0
the	0
alpha2	1
integrin	2
gene	2
in	0
cells	0
undergoing	0
megakaryocytic	0
differentiation	0
requires	0
a	0
core	1
promoter	2
between	0
bp	0
-30	0
and	0
-92	0
,	0
a	0
silencer	1
between	0
bp	0
-92	0
and	0
-351	0
,	0
and	0
megakaryocytic	1
enhancers	2
in	0
the	0
distal	1
5	2
'	2
flank	2
.	0

We	0
have	0
now	0
identified	0
a	0
229-bp	1
region	2
of	0
the	0
distal	1
5	2
'	2
flank	2
of	0
the	0
alpha2	1
integrin	2
gene	2
required	0
for	0
high-level	7
enhancer	8
activity	8
in	8
cells	8
with	0
megakaryocytic	0
features	0
.	0

Two	0
tandem	0
AP1	1
binding	2
sites	2
with	0
dyad	0
symmetry	0
are	0
required	0
for	0
enhancer	0
activity	0
and	0
for	0
DNA-protein	9
complex	10
formation	0
with	0
members	0
of	0
the	0
c-fos/c-jun	9
family	10
.	0

The	0
requirement	0
for	0
AP1	9
activation	0
suggested	0
a	0
role	0
for	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
signaling	0
pathway	0
in	0
regulating	0
alpha2	1
integrin	2
gene	2
expression	0
.	0

Inhibition	0
of	0
the	0
MAP	9
kinase	10
cascade	0
with	0
PD98059	0
,	0
a	0
specific	0
inhibitor	0
of	0
MAPK	9
kinase	10
1	10
,	0
prevented	0
the	0
expression	0
of	0
the	0
alpha2	9
integrin	10
subunit	10
in	0
cells	0
induced	0
to	0
become	0
megakaryocytic	0
.	0

We	0
provide	0
a	0
model	0
of	0
megakaryocytic	0
differentiation	0
in	0
which	0
expression	0
of	0
the	0
alpha2	1
integrin	2
gene	2
requires	0
signaling	0
via	0
the	0
MAP	9
kinase	10
pathway	0
to	0
activate	0
two	0
tandem	0
AP1	1
binding	2
sites	2
in	0
the	0
alpha2	1
integrin	2
enhancer	2
.	0

Functional	0
association	0
of	0
Nmi	9
with	0
Stat5	9
and	0
Stat1	9
in	0
IL-2	9
-and	0
IFNgamma	9
-mediated	0
signaling	0
.	0

Using	0
the	0
coiled-coil	0
region	0
of	0
Stat5b	9
as	0
the	0
bait	0
in	0
a	0
yeast	0
two-hybrid	0
screen	0
,	0
we	0
identified	0
the	0
association	0
of	0
Nmi	9
,	0
a	0
protein	0
of	0
unknown	0
function	0
previously	0
reported	0
as	0
an	0
N-Myc	9
interactor	0
.	0

We	0
further	0
show	0
that	0
Nmi	9
interacts	0
with	0
all	0
STATs	9
except	0
Stat2	9
.	0

We	0
evaluated	0
two	0
cytokine	0
systems	0
,	0
IL-2	9
and	0
IFNgamma	9
,	0
and	0
demonstrate	0
that	0
Nmi	9
augments	0
STAT	9
-mediated	0
transcription	0
in	0
response	0
to	0
these	0
cytokines	9
.	0

Interestingly	0
,	0
Nmi	9
lacks	0
an	0
intrinsic	0
transcriptional	9
activation	10
domain	10
;	0
instead	0
,	0
Nmi	9
enhances	0
the	0
association	0
of	0
CBP/p300	9
coactivator	10
proteins	10
with	0
Stat1	9
and	0
Stat5	9
,	0
and	0
together	0
with	0
CBP/p300	9
can	0
augment	0
IL-2-	0
and	0
IFNgamma-dependent	0
transcription	0
.	0

Therefore	0
,	0
our	0
data	0
not	0
only	0
reveal	0
that	0
Nmi	9
can	0
potentiate	0
STAT	9
-dependent	0
transcription	0
,	0
but	0
also	0
suggest	0
that	0
it	0
can	0
augment	0
coactivator	0
protein	0
recruitment	0
to	0
at	0
least	0
some	0
members	0
of	0
a	0
group	0
of	0
sequence-specific	9
transcription	10
factors	10
.	0

Lactobacilli	0
and	0
vaginal	0
host	0
defense	0
:	0
activation	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
,	0
cytokine	9
production	0
,	0
and	0
NF-kappaB	9
.	0

Lactobacilli	0
,	0
a	0
component	0
of	0
the	0
normal	0
vaginal	0
flora	0
,	0
can	0
activate	0
the	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
-1	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
in	0
the	0
Jurkat	5
T	6
lymphocyte	6
and	0
THP-1	5
macrophage	6
cell	6
lines	6
.	0

Activation	0
of	0
the	0
LTR	1
in	0
Jurkat	5
cells	6
was	0
strongly	0
enhanced	0
by	0
vanadate	0
and	0
inhibited	0
by	0
catalase	9
,	0
implicating	0
H2O2	0
.	0

In	0
contrast	0
,	0
activation	0
in	0
THP-1	9
cells	10
occurred	0
in	0
the	0
absence	0
of	0
vanadate	0
and	0
was	0
unaffected	0
by	0
catalase	9
.	0

The	0
active	0
material	0
partitioned	0
into	0
the	0
phenol	0
layer	0
on	0
hot	0
aqueous	0
phenol	0
extraction	0
.	0

Lactobacilli	0
also	0
increased	0
tumor	9
necrosis	10
factor	10
-alphaand	0
interleukin	9
-1betaproduction	0
and	0
activated	0
NF-kappaB	9
in	0
THP-1	9
cells	10
and	0
increased	0
tumor	9
necrosis	10
factor	10
-alphaproduction	0
by	0
human	7
monocytes	8
.	0

Human	0
vaginal	0
fluid	0
specimens	0
had	0
comparable	0
properties	0
,	0
which	0
correlated	0
with	0
their	0
bacterial	0
content	0
.	0

These	0
findings	0
suggest	0
the	0
presence	0
in	0
vaginal	0
fluid	0
of	0
agent	0
(	0
s	0
)	0
derived	0
from	0
indigenous	0
bacteria	0
that	0
can	0
activate	0
the	0
HIV-1	1
LTR	2
,	0
cytokine	9
production	0
,	0
and	0
NF-kappaB	9
in	0
cells	0
of	0
macrophage	7
lineage	8
,	0
with	0
possible	0
influence	0
on	0
vaginal	0
physiology	0
and	0
host	0
defense	0
.	0

T	0
cell	0
priming	0
enhances	0
IL-4	1
gene	2
expression	0
by	0
increasing	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

The	0
repetitive	0
activation	0
of	0
T	7
cells	8
(	0
priming	0
)	0
enhances	0
the	0
expression	0
of	0
many	0
cytokines	9
,	0
such	0
as	0
IL-4	0
,	0
but	0
not	0
others	0
,	0
such	0
as	0
IL-2	9
.	0

Molecular	0
mechanisms	0
underlying	0
selective	0
expression	0
of	0
cytokines	9
by	0
T	7
cells	8
remain	0
poorly	0
understood	0
.	0

Here	0
we	0
show	0
that	0
priming	0
of	0
CD4	7
T	8
cells	8
selectively	0
enhances	0
IL-4	9
expression	0
relative	0
to	0
IL-2	9
expression	0
by	0
a	0
transcriptional	0
mechanism	0
involving	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	10
NFAT	10
)	10
proteins	10
.	0

As	0
detected	0
by	0
in	0
vivo	0
footprinting	0
,	0
priming	0
markedly	0
increases	0
the	0
activation-dependent	0
engagement	0
of	0
the	0
P0	1
and	0
P1	1
NFAT-binding	1
elements	2
of	0
the	0
IL-4	1
promoter	2
.	0

Moreover	0
,	0
each	0
proximal	1
P	2
element	2
is	0
essential	0
for	0
optimal	0
IL-4	1
promoter	2
activity	0
.	0

Activated	0
primed	0
CD4	7
T	8
cells	8
contain	0
more	0
NFAT1	9
and	0
support	0
greater	0
NFAT	9
-directed	0
transcription	0
than	0
unprimed	0
CD4	7
T	8
cells	8
,	0
while	0
activator	9
protein	10
1	10
binding	0
and	0
activator	9
protein	10
1	10
-mediated	0
transcription	0
by	0
both	0
cell	0
types	0
is	0
similar	0
.	0

Increased	0
expression	0
of	0
wild-type	0
NFAT1	9
substantially	0
increases	0
IL-4	1
promoter	2
activity	0
in	0
unprimed	0
CD4	7
T	8
cells	8
,	0
suggesting	0
NFAT1	9
may	0
be	0
limiting	0
for	0
IL-4	9
gene	0
expression	0
in	0
this	0
cell	0
type	0
.	0

Furthermore	0
,	0
a	0
truncated	0
form	0
of	0
NFAT1	9
acts	0
as	0
a	0
dominant-negative	0
,	0
reducing	0
IL-4	1
promoter	2
activity	0
in	0
primed	0
CD4	7
T	8
cells	8
and	0
confirming	0
the	0
importance	0
of	0
endogenous	9
NFAT	10
to	0
increased	0
IL-4	9
gene	0
expression	0
by	0
effector	0
T	0
cells	0
.	0

NFAT1	9
appears	0
to	0
be	0
the	0
major	0
NFAT	9
family	10
member	10
responsible	0
for	0
the	0
initial	0
increased	0
expression	0
of	0
IL-4	9
by	0
primed	0
CD4	7
T	8
cells	8
.	0

Differential	0
monocyte	0
adhesion	0
and	0
adhesion	9
molecule	10
expression	0
in	0
venous	0
and	0
arterial	0
endothelial	0
cells	0
.	0

We	0
compared	0
U-937	5
cell	6
adhesion	0
and	0
adhesion	9
molecule	10
expression	0
in	0
human	7
umbilical	8
venous	8
(	0
HUVECs	7
)	0
and	0
arterial	7
(	8
HUAECs	8
)	8
endothelial	8
cells	8
exposed	0
to	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
,	0
interleukin-1	9
,	0
and	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

TNF	9
and	0
LPS	0
stimulated	0
vascular	9
cell	10
adhesion	10
molecule	10
(	0
VCAM	9
)	0
-1	0
surface	0
expression	0
and	0
adhesion	0
of	0
U-937	5
monocyte-like	6
cells	6
to	0
HUVECs	7
but	0
not	0
to	0
HUAECs	7
.	0

Antibody	0
studies	0
demonstrated	0
that	0
in	0
HUVECs	7
at	0
least	0
75	0
%	0
of	0
the	0
adhesion	0
response	0
is	0
VCAM-1	9
mediated	0
.	0

Interleukin-1	9
stimulated	0
U-937	5
cell	6
adhesion	0
to	0
and	0
VCAM-1	9
surface	0
expression	0
in	0
both	0
HUVECs	7
and	0
HUAECs	7
.	0

Pyrrolidinedithiocarbamate	0
and	0
the	0
proteasome	0
inhibitor	0
MG-132	0
blocked	0
TNF	9
-and	0
LPS-stimulated	0
U-937	5
cell	6
adhesion	0
to	0
HUVECs	7
.	0

These	0
agents	0
also	0
significantly	0
decreased	0
TNF	9
-and	0
LPS-stimulated	0
increases	0
in	0
HUVEC	9
surface	10
VCAM-1	10
.	0

TNF	9
increased	0
VCAM-1	9
protein	0
and	0
mRNA	3
in	0
HUVECs	7
that	0
was	0
blocked	0
by	0
pyrrolidinedithiocarbamate	0
.	0

However	0
,	0
neither	0
TNF	9
or	0
LPS	0
stimulated	0
VCAM-1	9
expression	0
in	0
HUAECs	7
.	0

TNF	9
stimulated	0
expression	0
of	0
both	0
intercellular	9
adhesion	10
molecule-1	10
and	0
E-selectin	9
in	0
HUVECs	7
,	0
but	0
in	0
HUAECs	7
,	0
only	0
intercellular	9
adhesion	10
molecule-1	10
was	0
increased	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
demonstrated	0
no	0
difference	0
in	0
the	0
pattern	0
of	0
TNF	9
-stimulated	0
nuclear	9
factor-kappaB	10
activation	0
between	0
HUVECs	7
and	0
HUAECs	7
.	0

These	0
studies	0
demonstrate	0
a	0
novel	0
and	0
striking	0
insensitivity	0
of	0
arterial	0
endothelium	0
to	0
the	0
effects	0
of	0
TNF	9
and	0
LPS	0
and	0
indicate	0
a	0
dissociation	0
between	0
the	0
ability	0
of	0
HUAECs	7
to	0
upregulate	0
nuclear	9
factor-kappaB	10
and	0
VCAM-1	9
.	0

Functional	0
testosterone	9
receptors	10
in	0
plasma	0
membranes	0
of	0
T	7
cells	8
.	0

T	7
cells	8
are	0
considered	0
to	0
be	0
unresponsive	0
to	0
testosterone	0
due	0
to	0
the	0
absence	0
of	0
androgen	9
receptors	10
(	0
AR	9
)	0
.	0

Here	0
,	0
we	0
demonstrate	0
the	0
testosterone	0
responsiveness	0
of	0
murine	7
splenic	8
T	8
cells	8
in	0
vitro	0
as	0
well	0
as	0
the	0
presence	0
of	0
unconventional	9
cell	10
surface	10
receptors	10
for	0
testosterone	0
and	0
classical	9
intracellular	10
AR	10
.	0

Binding	0
sites	0
for	0
testosterone	0
on	0
the	0
surface	0
of	0
both	0
CD4	7
(	8
+	8
)	8
and	8
CD8	8
(	8
+	8
)	8
subsets	8
of	0
T	7
cells	8
are	0
directly	0
revealed	0
with	0
the	0
impeded	0
ligand	0
testosterone-BSA-FITC	0
by	0
confocal	0
laser	0
scanning	0
microscopy	0
(	0
CLSM	0
)	0
and	0
flow	0
cytometry	0
,	0
respectively	0
.	0

Binding	0
of	0
the	0
plasma	0
membrane	0
impermeable	0
testosterone-BSA	9
conjugate	10
induces	0
a	0
rapid	0
rise	0
(	0
<	0
5	0
s	0
)	0
in	0
[	0
Ca2+	0
]	0
i	0
of	0
Fura-2-loaded	7
T	8
cells	8
.	0

This	0
rise	0
reflects	0
influx	0
of	0
extracellular	0
Ca2+	0
through	0
non-voltage-gated	0
and	0
Ni2+-blockable	9
Ca2+	10
channels	10
of	0
the	0
plasma	0
membrane	0
.	0

The	0
testosterone-BSA-induced	0
Ca2+	0
import	0
is	0
not	0
affected	0
by	0
cyproterone	0
,	0
a	0
blocker	0
of	0
the	0
AR	9
.	0

In	0
addition	0
,	0
AR	9
are	0
not	0
detectable	0
on	0
the	0
surface	0
of	0
intact	7
T	8
cells	8
when	0
using	0
anti-AR	9
antibodies	10
directed	0
against	0
the	0
amino	9
and	10
carboxy	10
terminus	10
of	0
the	0
AR	9
,	0
although	0
T	7
cells	8
contain	0
AR	9
,	0
as	0
revealed	0
by	0
reverse	0
transcription-polymerase	0
chain	0
reactions	0
and	0
Western	0
blotting	0
.	0

AR	9
can	0
be	0
visualized	0
with	0
the	0
anti-AR	9
antibodies	10
in	0
the	0
cytoplasm	0
of	0
permeabilized	7
T	8
cells	8
by	0
using	0
CLSM	0
,	0
though	0
AR	9
are	0
not	0
detectable	0
in	0
cytosol	0
fractions	0
when	0
using	0
the	0
charcoal	0
binding	0
assay	0
with	0
3H-R1881	0
as	0
ligand	0
.	0

Cytoplasmic	9
AR	10
do	0
not	0
translocate	0
to	0
the	0
nucleus	0
of	0
T	7
cells	8
in	0
the	0
presence	0
of	0
testosterone	0
,	0
in	0
contrast	0
to	0
cytoplasmic	9
AR	10
in	0
human	5
cancer	6
LNCaP	6
cells	6
.	0

These	0
findings	0
suggest	0
that	0
the	0
classical	9
AR	10
present	0
in	0
splenic	7
T	8
cells	8
are	0
not	0
active	0
in	0
the	0
genomic	0
pathway	0
.	0

By	0
contrast	0
,	0
the	0
cell	9
surface	10
receptors	10
for	0
testosterone	0
are	0
in	0
a	0
functionally	0
active	0
state	0
,	0
enabling	0
T	7
cells	8
a	0
nongenomic	0
response	0
to	0
testosterone	0
.	0

Limited	0
proteolysis	0
for	0
assaying	0
ligand	0
binding	0
affinities	0
of	0
nuclear	9
receptors	10
.	0

The	0
binding	0
of	0
natural	0
or	0
synthetic	0
ligands	0
to	0
nuclear	9
receptors	10
is	0
the	0
triggering	0
event	0
leading	0
to	0
gene	0
transcription	0
activation	0
or	0
repression	0
.	0

Ligand	0
binding	0
to	0
the	0
ligand	9
binding	10
domain	10
of	0
these	0
receptors	9
induces	0
conformational	0
changes	0
that	0
are	0
evidenced	0
by	0
an	0
increased	0
resistance	0
of	0
this	0
domain	0
to	0
proteases	9
.	0

In	9
vitro	10
labeled	10
receptors	10
were	0
incubated	0
with	0
various	0
synthetic	0
or	0
natural	0
agonists	0
or	0
antagonists	0
and	0
submitted	0
to	0
trypsin	9
digestion	0
.	0

Proteolysis	0
products	0
were	0
separated	0
by	0
SDS-PAGE	0
and	0
quantified	0
.	0

The	0
amount	0
of	0
trypsin	9
-resistant	0
fragments	0
was	0
proportional	0
to	0
receptor	0
occupancy	0
by	0
the	0
ligand	0
,	0
and	0
allowed	0
the	0
determination	0
of	0
dissociation	0
constants	0
(	0
kDa	0
)	0
.	0

Using	0
the	0
wild-type	9
or	10
mutated	10
human	10
retinoic	10
acid	10
receptor	10
alpha	10
as	0
a	0
model	0
,	0
kDa	0
values	0
determined	0
by	0
classical	0
competition	0
binding	0
assays	0
using	0
tritiated	0
ligands	0
are	0
in	0
agreement	0
with	0
those	0
measured	0
by	0
the	0
proteolytic	0
assay	0
.	0

This	0
method	0
was	0
successfully	0
extended	0
to	0
human	9
retinoic	10
X	10
receptor	10
alpha	10
,	0
glucocorticoid	9
receptor	10
,	0
and	0
progesterone	9
receptor	10
,	0
thus	0
providing	0
a	0
basis	0
for	0
a	0
new	0
,	0
faster	0
assay	0
to	0
determine	0
simultaneously	0
the	0
affinity	0
and	0
conformation	0
of	0
receptors	0
when	0
bound	0
to	0
a	0
given	0
ligand	0
.	0

Genes	0
that	0
regulate	0
interleukin-4	9
expression	0
in	0
T	7
cells	8
.	0

Interleukin-4	9
is	0
an	0
immunomodulatory	9
cytokine	10
which	0
plays	0
a	0
central	0
role	0
in	0
the	0
regulation	0
of	0
allergic	0
and	0
atopic	0
immune	0
responses	0
.	0

Significant	0
progress	0
has	0
been	0
made	0
in	0
gaining	0
a	0
detailed	0
understanding	0
of	0
the	0
transcriptional	0
regulation	0
of	0
the	0
interleukin-4	1
gene	2
.	0

The	0
recent	0
identification	0
and	0
characterization	0
of	0
several	0
key	0
transcription	9
factors	10
has	0
helped	0
to	0
elucidate	0
the	0
molecular	0
mechanisms	0
of	0
T	1
helper	2
cell	2
cytokine	2
gene	2
expression	0
.	0

B	7
lymphocytes	8
from	0
patients	0
with	0
chronic	0
lymphocytic	0
leukemia	0
contain	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
1	10
and	0
STAT3	9
constitutively	0
phosphorylated	0
on	0
serine	0
residues	0
.	0

To	0
explore	0
the	0
pathogenesis	0
of	0
chronic	0
lymphocytic	0
leukemia	0
(	0
CLL	0
)	0
,	0
we	0
examined	0
whether	0
phosphorylation	0
of	0
one	0
or	0
more	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
factors	10
was	0
abnormal	0
in	0
cells	0
from	0
CLL	0
patients	0
.	0

No	0
constitutive	0
tyrosine	0
phosphorylation	0
was	0
detected	0
on	0
any	0
STAT	9
in	0
CLL	5
cells	6
.	0

To	0
assess	0
the	0
phosphorylation	0
of	0
serine	0
residues	0
of	0
STAT1	9
and	0
STAT3	9
in	0
CLL	5
cells	6
,	0
we	0
raised	0
antibodies	0
that	0
specifically	0
recognize	0
the	0
form	0
of	0
STAT1	9
phosphorylated	0
on	0
ser-727	0
and	0
the	0
form	0
of	0
STAT3	9
phosphorylated	0
on	0
ser-727	0
.	0

We	0
found	0
that	0
in	0
100	0
%	0
of	0
patients	0
with	0
CLL	0
(	0
n	0
=	0
32	0
)	0
,	0
STAT1	9
and	0
STAT3	9
were	0
constitutively	0
phosphorylated	0
on	0
serine	0
.	0

This	0
was	0
in	0
contrast	0
to	0
normal	0
peripheral	0
blood	0
B	7
lymphocytes	8
or	0
CD5+	7
)	8
B	8
cells	8
isolated	0
from	0
tonsils	0
,	0
in	0
which	0
this	0
phosphorylation	0
was	0
absent	0
.	0

Serine	0
phosphorylation	0
of	0
STAT1	9
and	0
STAT3	9
was	0
seen	0
occasionally	0
in	0
other	0
leukemias	0
,	0
but	0
it	0
was	0
a	0
universal	0
finding	0
only	0
in	0
CLL	0
.	0

The	0
serine	0
phosphorylation	0
of	0
these	0
STATs	9
was	0
a	0
continuous	0
process	0
,	0
as	0
incubation	0
of	0
CLL	5
cells	6
with	0
the	0
kinase	9
inhibitor	10
H7	10
led	0
to	0
the	0
dephosphorylation	0
of	0
these	0
serine	0
residues	0
.	0

The	0
STAT	0
serine	0
kinase	0
in	0
CLL	0
cells	0
has	0
not	0
been	0
identified	0
,	0
and	0
appears	0
to	0
be	0
neither	0
mitogen-activated	9
protein	10
kinase	10
nor	0
pp70	9
(	10
s6k	10
)	10
.	0

In	0
summary	0
,	0
the	0
constitutive	0
serine	0
phosphorylation	0
of	0
STAT1	9
and	0
STAT3	9
is	0
present	0
in	0
all	0
CLL	0
samples	0
tested	0
to	0
date	0
,	0
although	0
the	0
physiologic	0
significance	0
of	0
this	0
modification	0
remains	0
to	0
be	0
determined	0
.	0

Activation	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
expression	0
by	0
Gardnerella	0
vaginalis	0
.	0

Bacterial	0
vaginosis	0
(	0
BV	0
)	0
is	0
associated	0
with	0
an	0
increased	0
rate	0
of	0
sexual	0
transmission	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
type	0
1	0
,	0
and	0
Gardnerella	0
vaginalis	0
is	0
frequently	0
isolated	0
from	0
the	0
genital	0
tracts	0
of	0
women	0
with	0
BV	0
.	0

G.	0
vaginalis	0
lysates	0
were	0
found	0
to	0
significantly	0
stimulate	0
HIV	0
expression	0
in	0
monocytoid	7
cells	8
.	0

Stimulation	0
was	0
significantly	0
higher	0
when	0
lysates	0
were	0
heated	0
at	0
100	0
degrees	0
C	0
for	0
5	0
min	0
but	0
was	0
reduced	0
by	0
treatment	0
with	0
lysozyme	9
or	0
protease	9
.	0

G.	0
vaginalis	0
lysates	0
also	0
activated	0
HIV	0
expression	0
in	0
certain	0
T	5
cell	6
lines	6
.	0

G.	0
vaginalis	0
lysates	0
activated	0
HIV	0
long-terminal	0
repeat	0
transcription	0
in	0
HIV-infected	7
cells	8
and	0
increased	0
NF-kappaB	9
binding	0
activity	0
,	0
indicating	0
an	0
effect	0
by	0
G.	0
vaginalis	0
on	0
HIV	0
transcription	0
.	0

The	0
activation	0
of	0
HIV	0
production	0
by	0
G.	0
vaginalis	0
suggests	0
that	0
genital	0
tract	0
infection	0
with	0
G.	0
vaginalis	0
increases	0
the	0
risk	0
of	0
HIV	0
transmission	0
by	0
increasing	0
HIV	0
expression	0
in	0
the	0
genital	0
tract	0
.	0

This	0
may	0
explain	0
,	0
at	0
least	0
in	0
part	0
,	0
the	0
increased	0
rate	0
of	0
HIV	0
transmission	0
in	0
women	0
with	0
BV	0
.	0

Interleukin-10	9
inhibits	0
expression	0
of	0
both	0
interferon	1
alpha-	2
and	2
interferon	2
gamma-	2
induced	2
genes	2
by	0
suppressing	0
tyrosine	0
phosphorylation	0
of	0
STAT1	9
.	0

Interleukin-10	9
(	0
IL-10	9
)	0
helps	0
maintain	0
polarized	7
T-helper	8
cells	8
in	0
a	0
T-helper	7
lymphocyte	8
2	8
(	8
Th2	8
)	8
phenotype	8
.	0

Part	0
of	0
this	0
process	0
involves	0
the	0
prevention	0
of	0
the	0
development	0
of	0
Th1	7
cells	8
,	0
which	0
are	0
a	0
primary	0
source	0
of	0
interferon	9
gamma	10
(	0
IFNgamma	9
)	0
,	0
a	0
potent	0
activator	0
of	0
monocytes	7
and	0
an	0
inhibitor	0
of	0
Th2	0
proliferation	0
.	0

Because	0
monocytes	7
and	0
macrophages	0
are	0
important	0
mediators	0
of	0
Th1-type	0
responses	0
,	0
such	0
as	0
delayed-type	0
hypersensitivity	0
,	0
we	0
sought	0
to	0
determine	0
if	0
IL-10	9
could	0
directly	0
mediate	0
inhibition	0
of	0
IFNgamma-	0
and	0
IFNalpha-induced	0
gene	0
expression	0
in	0
these	0
cells	0
.	0

Highly	0
purified	0
monocytes	7
were	0
incubated	0
with	0
IL-10	9
for	0
60	0
to	0
90	0
minutes	0
before	0
the	0
addition	0
of	0
IFNgamma	9
or	0
IFNalpha	9
.	0

IL-10	9
preincubation	0
resulted	0
in	0
the	0
inhibition	0
of	0
gene	0
expression	0
for	0
several	0
IFN-induced	1
genes	2
,	0
such	0
as	0
IP-10	9
,	0
ISG54	9
,	0
and	0
intercellular	9
adhesion	10
molecule-1	10
.	0

The	0
reduction	0
in	0
gene	0
expression	0
resulted	0
from	0
the	0
ability	0
of	0
IL-10	9
to	0
suppress	0
IFN	9
-induced	0
assembly	0
of	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
factors	10
to	0
specific	1
promoter	2
motifs	2
on	0
IFNalpha-	1
and	2
IFNgamma-inducible	2
genes	2
.	0

This	0
was	0
accomplished	0
by	0
preventing	0
the	0
IFN-induced	0
tyrosine	0
phosphorylation	0
of	0
STAT1	9
,	0
a	0
component	0
of	0
both	0
IFNalpha-	9
and	10
IFNgamma-induced	10
DNA	10
binding	10
complexes	10
.	0

Therefore	0
,	0
IL-10	9
can	0
directly	0
inhibit	0
STAT-dependent	1
early	2
response	2
gene	2
expression	0
induced	0
by	0
both	0
IFNalpha	9
and	0
IFNgamma	9
in	0
monocytes	7
by	0
suppressing	0
the	0
tyrosine	0
phosphorylation	0
of	0
STAT1	9
.	0

This	0
may	0
occur	0
through	0
the	0
ability	0
of	0
IL-10	9
to	0
induce	0
expression	0
of	0
the	0
gene	0
,	0
suppressor	0
of	0
cytokine	9
signaling	10
3	10
(	0
SOCS3	9
)	0
.	0

Clonality	0
analysis	0
of	0
refractory	0
anemia	0
with	0
ring	7
sideroblasts	8
:	0
simultaneous	0
study	0
of	0
clonality	0
and	0
cytochemistry	0
of	0
bone	7
marrow	8
progenitors	8
.	0

X	0
chromosome	0
inactivation	0
and	0
polymorphism	0
of	0
the	0
human	1
androgen	2
receptor	2
(	2
HUMARA	2
)	2
gene	2
has	0
been	0
applied	0
for	0
analyzing	0
the	0
clonality	0
of	0
blood	7
cells	8
.	0

In	0
the	0
present	0
study	0
,	0
the	0
clonal	0
relationship	0
was	0
investigated	0
between	0
peripheral	7
blood	8
polymorphonuclear	8
cells	8
(	0
PMNCs	7
)	0
and	0
marrow	7
progenitor	8
cells	8
and	0
the	0
origin	0
of	0
ringed	7
sideroblasts	8
in	0
patients	0
with	0
refractory	0
anemia	0
with	0
ring	7
sideroblasts	8
(	0
RARS	7
)	0
by	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
of	0
HUMARA	1
gene	2
.	0

The	0
X-inactivation	0
patterns	0
of	0
circulating	0
PMNCs	7
and	0
T	7
lymphocytes	8
as	0
well	0
as	0
individual	0
granulocyte	5
colonies	6
grown	0
in	0
vitro	0
from	0
bone	0
marrow	0
cells	0
were	0
analyzed	0
.	0

The	0
development	0
of	0
ringed	7
sideroblasts	8
in	0
erythroid	5
colonies	6
by	0
iron	0
staining	0
and	0
their	0
X-inactivation	0
pattern	0
were	0
also	0
examined	0
.	0

All	0
three	0
RARS	7
patients	0
showed	0
monoclonal	0
PMNCs	7
.	0

In	0
granulocyte	5
colonies	6
,	0
however	0
,	0
two	0
different	0
X-inactivation	0
patterns	0
were	0
observed	0
in	0
all	0
patients	0
,	0
indicating	0
that	0
non-clonal	7
progenitor	8
cells	8
remained	0
in	0
the	0
bone	0
marrow	0
.	0

All	0
erythroid	5
colonies	6
consisted	0
of	0
ringed	7
sideroblasts	8
exclusively	0
showed	0
one	0
pattern	0
dominant	0
in	0
those	0
of	0
PMNCs	7
.	0

Our	0
findings	0
suggest	0
that	0
non-clonal	7
progenitor	8
cells	8
persist	0
in	0
some	0
RARS	7
cases	0
,	0
that	0
erythroid	7
progenitors	8
show	0
mosaicism	0
,	0
and	0
that	0
ringed	7
sideroblasts	8
may	0
be	0
derived	0
from	0
an	0
abnormal	0
clone	0
involved	0
in	0
the	0
pathogenesis	0
of	0
this	0
disease	0
.	0

Granulosa	0
cell	0
tumor	0
of	0
the	0
ovary	0
.	0

Immunohistochemical	0
evidence	0
of	0
low	0
proliferative	0
activity	0
and	0
virtual	0
absence	0
of	0
mutation	0
of	0
the	0
p53	1
tumor-suppressor	2
gene	2
.	0

BACKGROUND	0
AND	0
METHODS	0
:	0
Because	0
the	0
use	0
of	0
immunohistochemistry	0
in	0
the	0
diagnosis	0
of	0
granulosa	0
cell	0
tumor	0
(	0
GCT	0
)	0
has	0
not	0
been	0
fully	0
explored	0
,	0
routinely	0
processed	0
(	0
formalin-fixed	0
,	0
paraffin-embedded	0
)	0
tissue	0
from	0
11	0
GCT	0
,	0
adult	0
type	0
,	0
was	0
investigated	0
immunohistochemically	0
(	0
ABC	0
method	0
)	0
with	0
a	0
broad	0
spectrum	0
of	0
antibodies	0
against	0
various	0
markers	0
,	0
including	0
p53	9
and	0
Ki-67	9
.	0

All	0
of	0
the	0
tumors	0
exhibited	0
typical	0
morphology	0
,	0
were	0
limited	0
to	0
the	0
ovary	0
(	0
stage	0
I	0
)	0
,	0
and	0
7	0
cases	0
followed	0
a	0
benign	0
clinical	0
course	0
.	0

RESULTS	0
:	0
All	0
the	0
tumors	0
exhibited	0
strong	0
expression	0
of	0
vimentin	9
,	0
but	0
most	0
other	0
antigens	0
(	0
including	0
smooth	9
muscle	10
actin	10
)	0
were	0
expressed	0
infrequently	0
by	0
a	0
minority	0
of	0
tumor	7
cells	8
or	0
not	0
at	0
all	0
.	0

Tumor	0
cells	0
in	0
9	0
GCT	0
expressed	0
inhibin	0
A	0
.	0

All	0
the	0
tumors	0
exhibited	0
very	0
low	0
proliferative	0
activity	0
,	0
fewer	0
than	0
10	0
%	0
of	0
the	0
tumor	0
cell	0
nuclei	0
being	0
stained	0
by	0
the	0
antibody	9
MIB-1	10
(	0
Ki-67	9
antigen	10
)	0
.	0

The	0
antibody	9
D07	10
revealed	0
marked	0
overexpression	0
of	0
p53	9
protein	10
in	0
only	0
one	0
tumor	0
.	0

Clinical	0
outcome	0
was	0
not	0
found	0
to	0
be	0
related	0
to	0
immunophenotypic	0
differences	0
.	0

CONCLUSIONS	0
:	0
The	0
diagnosis	0
of	0
GCT	0
should	0
be	0
based	0
primarily	0
on	0
the	0
typical	0
morphology	0
revealed	0
by	0
conventional	0
stains	0
,	0
but	0
additional	0
immunohistochemical	0
staining	0
with	0
a	0
small	0
panel	0
of	0
selected	0
antibodies	0
(	0
for	0
example	0
,	0
against	0
keratin	9
,	0
vimentin	9
,	0
and	0
inhibin	9
A	10
)	0
may	0
be	0
helpful	0
in	0
a	0
few	0
cases	0
.	0

The	0
very	0
low	0
proliferative	0
activity	0
and	0
the	0
lack	0
of	0
overexpression	0
of	0
p53	9
protein	10
are	0
consistent	0
with	0
the	0
benign	0
clinical	0
behavior	0
of	0
the	0
majority	0
of	0
GCT	0
.	0

Protective	0
effects	0
of	0
notch-1	9
on	0
TCR	9
-induced	0
apoptosis	0
.	0

The	0
Notch	9
receptor	10
protein	10
was	0
originally	0
identified	0
in	0
Drosophila	0
and	0
is	0
known	0
to	0
mediate	0
cell	0
to	0
cell	0
communication	0
and	0
influence	0
cell	0
fate	0
decisions	0
.	0

Members	0
of	0
this	0
family	0
have	0
been	0
isolated	0
from	0
invertebrates	0
as	0
well	0
as	0
vertebrates	0
.	0

We	0
isolated	0
mouse	9
Notch-1	10
in	0
a	0
yeast	0
two-hybrid	0
screen	0
with	0
Nur77	9
,	0
which	0
is	0
a	0
protein	0
that	0
has	0
been	0
shown	0
previously	0
to	0
be	0
required	0
for	0
apoptosis	0
in	0
T	5
cell	6
lines	6
.	0

The	0
data	0
presented	0
below	0
indicate	0
that	0
Notch-1	9
expression	0
provides	0
significant	0
protection	0
to	0
T	5
cell	6
lines	6
from	0
TCR	9
-mediated	0
apoptosis	0
.	0

These	0
data	0
demonstrate	0
a	0
new	0
antiapoptotic	0
role	0
for	0
Notch-1	9
,	0
providing	0
evidence	0
that	0
,	0
in	0
addition	0
to	0
regulating	0
cell	0
fate	0
decisions	0
,	0
Notch-1	9
can	0
play	0
a	0
critical	0
role	0
in	0
controlling	0
levels	0
of	0
cell	0
death	0
in	0
T	7
cells	8
.	0

Comparison	0
of	0
primary	0
sensitization	0
of	0
naive	7
human	8
T	8
cells	8
to	0
varicella-zoster	0
virus	0
peptides	0
by	0
dendritic	7
cells	8
in	0
vitro	0
with	0
responses	0
elicited	0
in	0
vivo	0
by	0
varicella	0
vaccination	0
.	0

Dendritic	7
cells	8
(	0
DC	7
)	0
are	0
potent	0
APC	7
during	0
primary	0
and	0
secondary	0
immune	0
responses	0
.	0

The	0
first	0
objective	0
of	0
this	0
study	0
was	0
to	0
determine	0
whether	0
human	7
DC	8
mediate	0
in	0
vitro	0
sensitization	0
of	0
naive	7
CD4+	8
T	8
cells	8
to	0
epitopes	9
of	0
the	0
immediate	9
early	10
62	10
(	10
IE62	10
)	10
protein	10
of	0
varicella	0
zoster	0
virus	0
(	0
VZV	0
)	0
.	0

The	0
induction	0
of	0
CD4+	9
T	0
cell	0
proliferative	0
responses	0
to	0
eight	0
synthetic	0
peptides	0
representing	0
amino	0
acid	0
sequences	0
of	0
the	0
VZV	9
IE62	10
protein	10
was	0
assessed	0
using	0
T	7
cells	8
and	0
DC	7
from	0
VZV-susceptible	0
donors	0
.	0

The	0
second	0
objective	0
was	0
to	0
compare	0
in	0
vitro	0
responses	0
of	0
naive	7
T	8
cells	8
with	0
responses	0
to	0
VZV	0
peptides	0
induced	0
in	0
vivo	0
after	0
immunization	0
with	0
varicella	0
vaccine	0
.	0

T	0
cell	0
proliferation	0
was	0
induced	0
by	0
three	0
peptides	0
,	0
P1	0
,	0
P4	0
,	0
and	0
P7	0
,	0
in	0
71-100	0
%	0
of	0
the	0
donors	0
tested	0
before	0
and	0
after	0
vaccination	0
using	0
DC	7
as	0
APC	7
.	0

Monocytes	7
were	0
effective	0
APC	7
for	0
VZV	0
peptides	0
only	0
after	0
immunization	0
.	0

Two	0
peptides	0
,	0
P2	0
and	0
P8	0
,	0
induced	0
naive	0
T	0
cell	0
proliferation	0
less	0
effectively	0
and	0
were	0
also	0
less	0
immunogenic	0
for	0
T	7
cells	8
from	0
vaccinated	0
or	0
naturally	0
immune	0
donors	0
.	0

T	0
cell	0
recognition	0
of	0
specific	0
peptides	0
was	0
concordant	0
between	0
naive	0
,	0
DC	7
-mediated	0
responses	0
,	0
and	0
postvaccine	0
responses	0
using	0
monocytes	7
as	0
APC	7
in	0
69	0
%	0
of	0
comparisons	0
(	0
p	0
=	0
0.05	0
;	0
chi2	0
)	0
;	0
the	0
predictive	0
value	0
of	0
a	0
positive	0
response	0
to	0
an	0
IE62	0
peptide	0
before	0
immunization	0
for	0
T	0
cell	0
sensitization	0
in	0
vivo	0
was	0
82	0
%	0
.	0

These	0
observations	0
indicate	0
that	0
primary	0
T	0
cell	0
responses	0
detected	0
in	0
vitro	0
using	0
DC	7
as	0
APC	7
may	0
be	0
useful	0
to	0
characterize	0
the	0
potential	0
immunogenicity	0
of	0
viral	0
protein	0
epitopes	0
in	0
vivo	0
.	0

Mechanism	0
of	0
interleukin-10	9
inhibition	0
of	0
T-helper	0
cell	0
activation	0
by	0
superantigen	9
at	0
the	0
level	0
of	0
the	0
cell	0
cycle	0
.	0

We	0
have	0
analyzed	0
the	0
effects	0
of	0
interleukin-10	9
(	0
IL-10	9
)	0
on	0
the	0
entry	0
of	0
quiescent	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
into	0
the	0
cell	0
cycle	0
upon	0
stimulation	0
with	0
the	0
superantigen	9
staphylococcal	9
enterotoxin	10
B	10
(	0
SEB	9
)	0
.	0

IL-10	9
arrested	0
cells	0
at	0
G0/G1	0
.	0

IL-10	9
treatment	0
prevented	0
the	0
downregulation	0
of	0
p27	9
(	10
Kip1	10
)	0
,	0
an	0
inhibitory	9
protein	10
that	0
controls	0
progression	0
out	0
of	0
the	0
G0	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

IL-10	9
also	0
prevented	0
the	0
upregulation	0
of	0
the	0
G1	9
cyclins	10
D2	9
and	0
D3	9
,	0
proteins	0
necessary	0
for	0
entry	0
and	0
progression	0
through	0
the	0
G1	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

Associated	0
with	0
the	0
inhibition	0
of	0
the	0
cell	0
cycle	0
,	0
IL-10	9
suppressed	0
SEB	9
induction	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
.	0

Addition	0
of	0
exogenous	0
IL-2	9
to	0
IL-10-treated	5
cells	6
significantly	0
reversed	0
the	0
antiproliferative	0
effects	0
of	0
IL-10	9
.	0

Moreover	0
,	0
IL-10	9
effects	0
on	0
the	0
early	9
G1	10
proteins	10
p27	9
(	10
Kip1	10
)	10
and	0
cyclin	9
D2	10
were	0
similarly	0
reversed	0
by	0
exogenous	0
IL-2	9
.	0

Although	0
this	0
reversal	0
by	0
IL-2	9
was	0
pronounced	0
,	0
it	0
was	0
not	0
complete	0
,	0
suggesting	0
that	0
IL-10	9
may	0
have	0
some	0
effects	0
not	0
directly	0
related	0
to	0
the	0
suppression	0
of	0
IL-2	9
production	0
.	0

Cell	0
separation	0
experiments	0
suggest	0
that	0
IL-10	9
can	0
effect	0
purified	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
directly	0
,	0
providing	0
functional	0
evidence	0
for	0
the	0
presence	0
of	0
IL-10	9
receptors	0
on	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
.	0

IL-10	9
also	0
inhibited	0
expression	0
of	0
IL-2	9
transcriptional	10
regulators	10
c-fos	9
and	0
c-jun	9
,	0
which	0
also	0
inhibit	0
other	0
cell	0
functions	0
.	0

Our	0
studies	0
show	0
that	0
the	0
mechanism	0
of	0
IL-10	9
regulation	0
of	0
quiescent	0
CD4	0
(	0
+	0
)	0
T-cell	0
activation	0
is	0
mainly	0
by	0
blocking	0
induction	0
of	0
IL-2	9
that	0
is	0
critical	0
to	0
downregulation	0
of	0
p27	9
(	10
Kip1	10
)	10
and	0
upregulation	0
of	0
D	9
cyclins	10
in	0
T-cell	0
activation	0
and	0
entry	0
into	0
the	0
cell	0
cycle	0
.	0

IFN-gamma	9
and	0
IL-10	9
inhibit	0
induction	0
of	0
IL-1	0
receptor	0
type	0
I	0
and	0
type	0
II	0
gene	0
expression	0
by	0
IL-4	9
and	0
IL-13	9
in	0
human	0
monocytes	7
.	0

The	0
Th2-type	9
cytokines	10
IL-4	9
and	0
IL-13	9
induce	0
expression	0
of	0
a	0
distinct	0
subset	0
of	0
genes	0
in	0
human	7
monocytes	8
.	0

These	0
include	0
Fc	9
epsilonRII	10
(	0
CD23	9
)	0
,	0
15-lipoxygenase	9
,	0
IL-1	9
receptor	10
antagonist	10
(	0
IL-1ra	9
)	0
,	0
and	0
type	9
I	10
and	10
type	10
II	10
IL-1	10
receptors	10
(	0
IL-1R	9
)	0
.	0

IFN-gamma	9
has	0
been	0
shown	0
to	0
inhibit	0
induction	0
of	0
CD23	9
and	0
15-lipoxygenase	9
in	0
monocytes	7
;	0
however	0
,	0
the	0
effects	0
of	0
IFN-gamma	9
on	0
type	0
I	0
and	0
type	0
II	0
IL-1R	0
gene	0
expression	0
have	0
not	0
been	0
defined	0
.	0

We	0
examined	0
the	0
effects	0
of	0
IFN-gamma	9
on	0
both	0
basal	0
and	0
IL-4	9
/	0
IL-13	9
-induced	0
IL-1R	1
gene	2
expression	0
in	0
primary	7
monocytes	8
.	0

IL-4	9
and	0
IL-13	9
induced	0
dose-	0
and	0
time-dependent	0
increases	0
in	0
IL-1RI	0
and	0
IL-1RII	0
mRNA	0
levels	0
.	0

IFN-gamma	9
decreased	0
basal	0
expression	0
as	0
well	0
as	0
the	0
induction	0
of	0
these	0
genes	0
by	0
IL-4	9
and	0
IL-13	9
.	0

Inhibition	0
of	0
IL-1RI	9
and	0
IL-1RII	0
mRNA	0
levels	0
by	0
IFN-gamma	9
was	0
transcriptionally	0
mediated	0
,	0
and	0
correlated	0
directly	0
with	0
decreased	0
production	0
of	0
soluble	0
IL-1RII	9
.	0

Furthermore	0
,	0
the	0
ability	0
to	0
suppress	0
IL-1RI	0
and	0
IL-1RII	9
mRNA	0
levels	0
was	0
not	0
unique	0
to	0
IFN-gamma	9
because	0
IL-10	9
also	0
inhibited	0
expression	0
of	0
these	0
genes	0
in	0
IL-4/IL-13-stimulated	5
monocytes	6
.	0

Inhibition	0
of	0
IL-1R	1
gene	2
expression	0
by	0
IFN-gamma	9
and	0
IL-10	9
was	0
not	0
due	0
to	0
down-regulation	0
of	0
surface	9
IL-4R	10
because	0
pretreatment	0
with	0
these	0
cytokines	0
did	0
not	0
decrease	0
the	0
number	0
of	0
IL-4	9
binding	0
sites	0
per	0
cell	0
.	0

However	0
,	0
suppression	0
of	0
IL-1R	1
gene	2
expression	0
by	0
IFN-gamma	9
and	0
IL-10	9
was	0
associated	0
with	0
decreased	0
tyrosine	0
phosphorylation	0
and	0
nuclear	0
translocation	0
of	0
the	0
IL-4/IL-13-inducible	9
transcription	10
factor	10
,	0
Stat6	9
,	0
suggesting	0
a	0
potential	0
mechanism	0
by	0
which	0
IFN-gamma	9
and	0
IL-10	9
may	0
mediate	0
their	0
suppressive	0
effects	0
.	0

These	0
findings	0
demonstrate	0
that	0
certain	0
cytokines	0
,	0
including	0
IFN-gamma	9
and	0
IL-10	9
,	0
antagonize	0
the	0
ability	0
of	0
IL-4	9
and	0
IL-13	9
to	0
induce	0
increased	0
expression	0
of	0
the	0
IL-1RI	0
and	0
IL-1RII	1
genes	2
in	0
monocytes	7
.	0

Cytokine	9
rescue	0
from	0
glucocorticoid	0
induced	0
apoptosis	0
in	0
T	7
cells	8
is	0
mediated	0
through	0
inhibition	0
of	0
IkappaBalpha	9
.	0

We	0
previously	0
reported	0
that	0
dexamethasone	0
(	0
DEX	0
)	0
,	0
a	0
synthetic	0
glucocorticoid	0
,	0
causes	0
apoptosis	0
in	0
mature	5
Th	6
cell	6
lines	6
,	0
and	0
that	0
this	0
induction	0
of	0
cell	0
death	0
is	0
prevented	0
by	0
specific	0
cytokines	9
,	0
namely	0
,	0
by	0
IL-2	9
in	0
Th1	7
cells	8
and	0
by	0
IL-4	9
in	0
Th2	7
cells	8
.	0

We	0
now	0
show	0
that	0
this	0
differential	0
rescue	0
by	0
specific	0
cytokines	9
in	0
Th	7
cells	8
correlates	0
with	0
the	0
level	0
of	0
IkappaBalpha	9
that	0
is	0
regulated	0
by	0
DEX	0
and	0
cytokines	9
.	0

In	0
both	0
cell	0
types	0
the	0
cellular	0
levels	0
of	0
IkappaBalpha	3
mRNA	4
and	0
protein	0
were	0
evaluated	0
by	0
DEX	0
treatment	0
.	0

Interestingly	0
,	0
the	0
DEX-mediated	0
IkappaBalpha	9
induction	0
was	0
completely	0
inhibited	0
by	0
IL-2	9
,	0
but	0
not	0
IL-4	9
,	0
in	0
Th1	7
cells	8
,	0
while	0
the	0
reverse	0
profile	0
was	0
seen	0
in	0
Th2	7
cells	8
.	0

In	0
both	0
cell	0
types	0
,	0
the	0
cytokine	9
that	0
inhibits	0
the	0
induction	0
of	0
IkappaBalpha	9
by	0
DEX	0
,	0
also	0
rescues	0
these	0
cells	0
from	0
DEX-induced	0
apoptosis	0
,	0
although	0
the	0
rescue	0
cytokine	0
is	0
different	0
in	0
Th1	7
and	8
Th2	8
cells	8
.	0

Our	0
results	0
imply	0
that	0
T	7
cells	8
need	0
to	0
maintain	0
a	0
certain	0
level	0
of	0
NF-kappaB	9
transcriptional	0
activity	0
in	0
order	0
to	0
survive	0
;	0
up-	0
or	0
down-regulation	0
of	0
nuclear	9
NF	10
kappaB	10
through	0
modulation	0
of	0
IkappaBalpha	9
expression	0
by	0
cytokines	9
or	0
DEX	0
may	0
lead	0
to	0
cell	0
survival	0
or	0
cell	0
death	0
,	0
respectively	0
.	0

Expression	0
of	0
transcription	1
factor	2
genes	2
after	0
influenza	0
A	0
virus	0
infection	0
.	0

Infection	0
of	0
human	0
monocytes	7
with	0
influenza	0
A	0
virus	0
induces	0
a	0
broad	0
range	0
of	0
proinflammatory	9
cytokines	10
and	0
mononuclear	0
cell	0
attracting	0
chemokines	9
before	0
the	0
infected	7
cells	8
undergo	0
apoptosis	0
.	0

The	0
underlying	0
mechanisms	0
by	0
which	0
the	0
corresponding	0
genes	0
are	0
transcriptionally	0
initiated	0
after	0
virus	0
infection	0
are	0
still	0
poorly	0
understood	0
.	0

Activation	0
of	0
NF-kappa	9
B	10
seems	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
many	0
proinflammatory	1
cytokine	2
genes	2
,	0
but	0
can	0
not	0
be	0
the	0
only	0
mechanism	0
,	0
since	0
several	0
cytokine	1
genes	2
lack	0
respective	0
binding	1
sites	2
in	0
their	0
promoter	1
regions	2
.	0

Therefore	0
,	0
we	0
additionally	0
investigated	0
other	0
transcription	9
factors	10
of	0
possible	0
importance	0
such	0
as	0
CREB	9
,	0
CTF	9
,	0
OTF-1	9
,	0
and	0
OTF-2	9
.	0

To	0
explore	0
long-term	0
regulatory	0
mechanisms	0
,	0
we	0
investigated	0
the	0
induction	0
of	0
transcription	9
factors	10
on	0
the	0
gene	0
expression	0
level	0
which	0
may	0
be	0
important	0
to	0
substitute	0
for	0
metabolized	9
transcription	10
factor	10
proteins	10
after	0
their	0
activation	0
.	0

We	0
identified	0
a	0
cell-type-specific	0
differential	0
response	0
:	0
CREB	1
,	2
CTF	2
,	2
OTF-1	2
,	2
OFT-2	2
,	2
and	2
NF-kappa	2
B	2
genes	2
were	0
strongly	0
induced	0
1	0
to	0
4	0
hours	0
after	0
influenza	0
A	0
virus	0
infection	0
in	0
the	0
monocytic	5
cell	6
line	6
Mono	5
Mac	6
6	6
,	0
while	0
in	0
freshly	0
prepared	0
human	0
monocytes	7
no	0
significant	0
changes	0
were	0
detected	0
.	0

In	0
infected	0
monocytes	7
,	0
which	0
die	0
by	0
apoptosis	0
,	0
the	0
expression	0
of	0
CREB	9
,	0
CTF	9
,	0
and	0
OTF-2	9
was	0
rather	0
suppressed	0
8	0
hours	0
after	0
infection	0
.	0

In	0
conclusion	0
,	0
the	0
long-term	0
regulation	0
of	0
transcription	9
factor	10
gene	0
expression	0
in	0
non-proliferating	7
cells	8
seems	0
to	0
be	0
of	0
minor	0
importance	0
after	0
influenza	0
infection	0
since	0
in	0
apoptosisprone	7
cells	8
an	0
immediate	0
availability	0
of	0
transcription	9
factor	10
proteins	10
is	0
required	0
.	0

Peripheral	7
blood	8
mononuclear	8
cells	8
isolated	0
from	0
patients	0
with	0
diabetic	0
nephropathy	0
show	0
increased	0
activation	0
of	0
the	0
oxidative-stress	9
sensitive	10
transcription	10
factor	10
NF-kappaB	9
.	0

Increased	0
oxidative	0
stress	0
and	0
subsequent	0
activation	0
of	0
the	0
transcription	0
factor	0
NF-kappaB	9
has	0
been	0
linked	0
to	0
the	0
development	0
of	0
late	0
diabetic	0
complications	0
.	0

To	0
determine	0
whether	0
oxidative	0
stress	0
dependent	0
NF-kappaB	9
activation	0
is	0
evident	0
in	0
patients	0
with	0
diabetic	0
nephropathy	0
we	0
used	0
an	0
Electrophoretic	0
Mobility	0
Shift	0
Assay	0
based	0
semiquantitative	0
detection	0
system	0
which	0
enabled	0
us	0
to	0
determine	0
NF-kappaB	9
activation	0
in	0
ex	0
vivo	0
isolated	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

We	0
examined	0
33	0
patients	0
with	0
diabetes	0
mellitus	0
(	0
Type	0
I	0
and	0
Type	0
II	0
)	0
.	0

Patients	0
with	0
diabetic	0
nephropathy	0
showed	0
higher	0
NF-kappaB	9
binding	0
activity	0
in	0
Electrophoretic	0
Mobility	0
Shift	0
Assays	0
and	0
stronger	0
immunohistological	0
staining	0
for	0
activated	0
NF-kappaBp65	9
than	0
patients	0
without	0
renal	0
complications	0
.	0

NF-kappaB	9
binding	0
activity	0
correlated	0
with	0
the	0
degree	0
of	0
albuminuria	0
(	0
r	0
=	0
0.316	0
)	0
and	0
with	0
thrombomodulin	9
plasma	0
concentrations	0
(	0
r	0
=	0
0.33	0
)	0
,	0
indicative	0
for	0
albuminuria	0
associated	0
endothelial	0
dysfunction	0
.	0

In	0
a	0
3	0
day	0
intervention	0
study	0
in	0
which	0
600	0
mg	0
of	0
the	0
antioxidant	0
thioctic	0
acid	0
(	0
alpha-lipoic	0
acid	0
)	0
per	0
day	0
were	0
given	0
to	0
nine	0
patients	0
with	0
diabetic	0
nephropathy	0
oxidative	0
stress	0
in	0
plasma	0
samples	0
was	0
decreased	0
by	0
48	0
%	0
and	0
NF-kappaB	9
binding	0
activity	0
in	0
ex	0
vivo	0
isolated	7
peripheral	8
blood	8
mononuclear	8
cells	8
by	0
38	0
%	0
.	0

In	0
conclusion	0
,	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
in	0
ex	0
vivo	0
isolated	7
peripheral	8
blood	8
mononuclear	8
cells	8
of	0
patients	0
with	0
diabetes	0
mellitus	0
correlates	0
with	0
the	0
degree	0
of	0
diabetic	0
nephropathy	0
.	0

NF-kappaB	9
activation	0
is	0
at	0
least	0
in	0
part	0
dependent	0
on	0
oxidative	0
stress	0
since	0
thioctic	0
acid	0
(	0
alpha-lipoic	0
acid	0
)	0
reduced	0
NF-kappaB	9
binding	0
activity	0
.	0

Osteoclast	9
markers	10
accumulate	0
on	0
cells	0
developing	0
from	0
human	7
peripheral	8
blood	8
mononuclear	8
precursors	8
.	0

Recent	0
studies	0
show	0
that	0
human	7
osteoclasts	8
develop	0
in	0
vitro	0
from	0
hematopoietic	7
cells	8
;	0
however	0
,	0
special	0
cultures	0
conditions	0
and/or	0
cytokine	0
mobilized	0
peripheral	0
blood	0
are	0
apparently	0
required	0
.	0

Here	0
,	0
we	0
report	0
that	0
cells	0
expressing	0
osteoclast	9
markers	10
differentiate	0
from	0
precursors	0
present	0
in	0
nonmobilized	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
,	0
without	0
the	0
addition	0
of	0
stromal	7
cells	8
,	0
growth	9
factors	10
,	0
cytokines	0
or	0
steroids	0
;	0
and	0
characterize	0
their	0
phenotype	0
.	0

Three	0
days	0
after	0
establishing	0
high-density	0
PBMC	7
cultures	0
(	0
1.5	0
x	0
10	0
(	0
6	0
)	0
cells/cm2	0
)	0
,	0
in	0
serum-containing	0
medium	0
,	0
small	0
adherent	5
colonies	6
of	0
tartrate	5
resistant	6
acid	6
phosphatase	6
positive	6
(	6
TRAP+	6
)	6
cells	6
emerge	0
,	0
amidst	0
massive	0
monocyte	0
cell	0
death	0
.	0

These	0
adherent	7
cells	8
have	0
an	0
eccentrically	0
placed	0
,	0
round	0
nucleus	0
,	0
and	0
express	0
low	0
levels	0
of	0
TRAP	9
and	0
sodium	9
fluoride-resistant-	10
alpha-naphthyl-acetate-esterase	10
(	0
NaF-R-NSE	9
)	0
.	0

Over	0
the	0
next	0
week	0
,	0
this	0
cell	0
population	0
accumulates	0
phenotypic	0
markers	0
of	0
osteoclasts	7
(	0
vitronectin	9
receptor	10
[	0
VR	9
]	0
,	0
calcitonin	9
receptor	10
,	0
TRAP	9
,	0
cathepsin	9
K	10
protein	10
,	0
and	0
mRNA	3
)	0
with	0
increased	0
nuclearity	0
,	0
covering	0
the	0
entire	0
surface	0
by	0
15	0
days	0
.	0

When	0
cultured	0
on	0
bone	0
,	0
VR+	5
,	6
TRAP+	6
cells	6
of	0
low	0
multinuclearity	0
appear	0
and	0
cover	0
up	0
to	0
50	0
%	0
of	0
the	0
surface	0
.	0

Resorption	0
lacunae	0
can	0
be	0
observed	0
by	0
day	0
22	0
.	0

Although	0
these	0
pits	0
are	0
not	0
nearly	0
as	0
numerous	0
as	0
the	0
cells	0
of	0
preosteoclast	7
phenotype	8
,	0
they	0
do	0
represent	0
the	0
activity	0
of	0
a	0
subset	0
of	0
osteoclast-like	7
cells	8
that	0
has	0
achieved	0
osteoclastic	0
maturity	0
under	0
these	0
culture	0
conditions	0
.	0

Transcripts	0
for	0
osteoprotegerin	9
ligand	10
(	0
OPGL	9
)	0
,	0
an	0
osteoclast	9
differentiation	10
factor	10
(	0
also	0
known	0
as	0
RANKL	9
and	0
TRANCE	9
)	0
are	0
expressed	0
,	0
likely	0
by	0
adherent	7
cells	8
.	0

Thus	0
,	0
an	0
adherent	0
population	0
of	0
cells	0
,	0
with	0
preosteoclast/	0
osteoclast	7
phenotypic	0
properties	0
,	0
arises	0
selectively	0
under	0
simple	0
culture	0
conditions	0
from	0
normal	0
PBMC	7
.	0

Further	0
characterization	0
of	0
these	0
cells	0
should	0
identify	0
factors	0
involved	0
in	0
the	0
growth	0
,	0
terminal	0
differentiation	0
and	0
activation	0
of	0
osteoclasts	7
.	0

Oleic	0
acid	0
inhibits	0
endothelial	0
activation	0
:	0
A	0
direct	0
vascular	0
antiatherogenic	0
mechanism	0
of	0
a	0
nutritional	0
component	0
in	0
the	0
mediterranean	0
diet	0
.	0

Because	0
oleic	0
acid	0
is	0
implicated	0
in	0
the	0
antiatherogenic	0
effects	0
attributed	0
to	0
the	0
Mediterranean	0
diet	0
,	0
we	0
investigated	0
whether	0
this	0
fatty	0
acid	0
can	0
modulate	0
endothelial	0
activation	0
,	0
ie	0
,	0
the	0
concerted	0
expression	0
of	0
gene	9
products	10
involved	0
in	0
leukocyte	0
recruitment	0
and	0
early	0
atherogenesis	0
.	0

We	0
incubated	0
sodium	0
oleate	0
with	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
for	0
0	0
to	0
72	0
hours	0
,	0
followed	0
by	0
coincubation	0
of	0
oleate	0
with	0
human	9
recombinant	10
tumor	10
necrosis	10
factor	10
,	0
interleukin	9
(	10
IL	10
)	10
-1alpha	10
,	0
IL-1beta	9
,	0
IL-4	9
,	0
Escherichia	0
coli	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
or	0
phorbol	0
12-myristate	0
13-acetate	0
for	0
a	0
further	0
6	0
to	0
24	0
hours	0
.	0

The	0
endothelial	0
expression	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
,	0
E-selectin	9
,	0
and	0
intercellular	9
adhesion	10
molecule-1	10
was	0
monitored	0
by	0
cell	0
surface	0
enzyme	0
immunoassays	0
or	0
flow	0
cytometry	0
,	0
and	0
steady-state	0
levels	0
of	0
VCAM-1	3
mRNA	4
were	0
assessed	0
by	0
Northern	0
blot	0
analysis	0
.	0

At	0
10	0
to	0
100	0
micromol/L	0
for	0
>	0
24	0
hours	0
,	0
oleate	0
inhibited	0
the	0
expression	0
of	0
all	0
adhesion	9
molecules	10
tested	0
.	0

After	0
a	0
72-hour	0
incubation	0
with	0
oleate	0
and	0
a	0
further	0
16-hour	0
incubation	0
with	0
oleate	0
plus	0
1	0
microg/mL	0
LPS	0
,	0
VCAM-1	9
expression	0
was	0
reduced	0
by	0
>	0
40	0
%	0
compared	0
with	0
control	0
.	0

Adhesion	0
of	0
monocytoid	5
U937	6
cells	6
to	0
LPS-treated	0
endothelial	0
cells	0
was	0
reduced	0
concomitantly	0
.	0

Oleate	0
also	0
produced	0
a	0
quantitatively	0
similar	0
reduction	0
of	0
VCAM-1	3
mRNA	4
levels	0
on	0
Northern	0
blot	0
analysis	0
and	0
inhibited	0
nuclear	9
factor-kappaB	10
activation	0
on	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

Incubation	0
of	0
endothelial	7
cells	8
with	0
oleate	0
for	0
72	0
hours	0
decreased	0
the	0
relative	0
proportions	0
of	0
saturated	0
(	0
palmitic	0
and	0
stearic	0
)	0
acids	0
in	0
total	0
cell	0
lipids	0
and	0
increased	0
the	0
proportions	0
of	0
oleate	0
in	0
total	0
cell	0
lipids	0
without	0
significantly	0
changing	0
the	0
relative	0
proportions	0
of	0
polyunsaturated	0
fatty	0
acids	0
.	0

Although	0
less	0
potent	0
than	0
polyunsaturated	0
fatty	0
acids	0
in	0
inhibiting	0
endothelial	0
activation	0
,	0
oleic	0
acid	0
may	0
contribute	0
to	0
the	0
prevention	0
of	0
atherogenesis	0
through	0
selective	0
displacement	0
of	0
saturated	0
fatty	0
acids	0
in	0
cell	0
membrane	0
phospholipids	0
and	0
a	0
consequent	0
modulation	0
of	0
gene	0
expression	0
for	0
molecules	0
involved	0
in	0
monocyte	0
recruitment	0
.	0

Both	0
Stat3	9
-activation	0
and	0
Stat3	9
-independent	0
BCL2	9
downregulation	0
are	0
important	0
for	0
interleukin-6	9
-induced	0
apoptosis	0
of	0
1A9-M	5
cells	6
.	0

A	0
unique	0
subclone	0
of	0
a	0
bone	5
marrow-derived	6
stromal	6
cell	6
line	6
,	0
BMS2.4	5
,	0
produces	0
soluble	9
factors	10
that	0
inhibit	0
proliferation	0
of	0
several	0
types	0
of	0
hematopoietic	5
cell	6
lines	6
.	0

An	0
understanding	0
of	0
these	0
molecules	0
may	0
be	0
informative	0
about	0
negative	0
regulatory	0
circuits	0
that	0
can	0
potentially	0
limit	0
blood	0
cell	0
formation	0
.	0

We	0
used	0
expression	0
cloning	0
to	0
identify	0
interleukin-6	9
(	0
IL-6	9
)	0
as	0
one	0
factor	0
that	0
suppressed	0
growth	0
of	0
a	0
pre-B-cell	5
variant	6
line	6
,	0
1A9-M	5
.	0

Moreover	0
,	0
IL-6	9
induced	0
macrophage-differentiation	0
and	0
apoptosis	0
of	0
1A9-M	5
cells	6
.	0

During	0
this	0
process	0
,	0
IL-6	9
downregulated	0
expression	0
of	0
BCL2	9
in	0
1A9-M	5
cells	6
and	0
stimulated	0
BCL-XL	0
expression	0
,	0
but	0
had	0
no	0
effect	0
on	0
p53	0
,	0
Bax	0
,	0
or	0
Bak	0
gene	0
expression	0
.	0

Mechanisms	0
for	0
transduction	0
of	0
IL-6	9
-induced	0
signals	0
were	0
then	0
evaluated	0
in	0
IL-6-stimulated	5
1A9-M	6
cells	6
.	0

Whereas	0
the	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
3	10
(	0
Stat3	9
)	0
was	0
phosphorylated	0
and	0
activated	0
,	0
there	0
was	0
no	0
effect	0
on	0
either	0
Stat1	9
or	0
Stat5	9
.	0

The	0
importance	0
of	0
BCL2	9
and	0
Stat3	9
on	0
IL-6	9
-induced	0
macrophage-differentiation	0
and	0
apoptosis	0
was	0
studied	0
with	0
1A9-M	5
cells	6
expressing	0
human	9
BCL2	10
or	0
a	0
dominant-negative	0
form	0
of	0
Stat3	9
,	0
respectively	0
.	0

IL-6	9
-induced	0
apoptosis	0
,	0
but	0
not	0
macrophage-differentiation	0
,	0
was	0
blocked	0
by	0
continuously	0
expressed	0
BCL2	9
.	0

A	0
dominant-negative	9
form	10
of	10
Stat3	10
inhibited	0
both	0
macrophage-differentiation	0
and	0
apoptosis	0
induced	0
by	0
IL-6	9
.	0

However	0
,	0
diminished	0
Stat3	9
activity	0
did	0
not	0
prevent	0
IL-6	9
-induced	0
downregulation	0
of	0
the	0
BCL2	1
gene	2
.	0

Therefore	0
,	0
activation	0
of	0
Stat3	9
is	0
essential	0
for	0
IL-6	9
-induced	0
macrophage-differentiation	0
and	0
programmed	0
cell	0
death	0
in	0
this	0
model	0
.	0

Whereas	0
overexpression	0
of	0
BCL2	9
abrogates	0
the	0
apoptotic	0
response	0
,	0
Stat3	9
-independent	0
signals	0
appear	0
to	0
downregulate	0
expression	0
of	0
the	0
BCL2	1
gene	2
.	0

Involvement	0
of	0
mitogen-activated	9
protein	10
kinase	10
pathways	0
in	0
interleukin-8	9
production	0
by	0
human	7
monocytes	8
and	0
polymorphonuclear	7
cells	8
stimulated	0
with	0
lipopolysaccharide	0
or	0
Mycoplasma	9
fermentans	10
membrane	10
lipoproteins	10
.	0

Interleukin-8	9
(	0
IL-8	9
)	0
is	0
a	0
chemokine	9
that	0
belongs	0
to	0
the	0
alpha-chemokine	9
or	0
CXC	9
subfamily	10
and	0
is	0
produced	0
by	0
a	0
wide	0
variety	0
of	0
human	0
cells	0
,	0
including	0
monocytes	7
and	0
polymorphonuclear	7
cells	8
(	0
PMN	7
)	0
.	0

IL-8	9
is	0
secreted	0
in	0
response	0
to	0
inflammatory	0
stimuli	0
,	0
notably	0
bacterial	0
products	0
such	0
as	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
but	0
little	0
is	0
known	0
about	0
the	0
mechanisms	0
by	0
which	0
these	0
agents	0
mediate	0
IL-8	9
induction	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
Mycoplasma	9
fermentans	10
lipid-associated	10
membrane	10
proteins	10
(	0
LAMPf	9
)	0
induce	0
the	0
production	0
of	0
high	0
levels	0
of	0
IL-8	9
by	0
THP-1	5
(	6
human	6
monocyte	6
)	6
cells	6
and	0
PMN	7
at	0
the	0
same	0
extent	0
as	0
LPS	0
.	0

It	0
was	0
previously	0
demonstrated	0
that	0
stimulation	0
of	0
monocytic	0
cells	0
with	0
either	0
LPS	0
or	0
LAMPf	9
led	0
to	0
a	0
series	0
of	0
common	0
downstream	0
signaling	0
events	0
,	0
including	0
the	0
activation	0
of	0
protein	9
tyrosine	10
kinase	10
and	0
of	0
mitogen-activated	9
protein	10
kinase	10
cascades	0
.	0

By	0
using	0
PD-98059	0
and	0
SB203580	0
,	0
two	0
potent	0
and	0
selective	0
inhibitors	0
of	0
MEK1	9
(	0
a	0
kinase	9
upstream	0
of	0
ERK1/2	9
)	0
and	0
p38	9
,	0
respectively	0
,	0
we	0
have	0
demonstrated	0
that	0
both	0
ERK1/2	0
and	0
p38	0
cascades	0
play	0
a	0
key	0
role	0
in	0
the	0
production	0
of	0
IL-8	9
by	0
monocytes	7
and	0
PMN	7
stimulated	0
with	0
bacterial	0
fractions	0
.	0

Regulation	0
of	0
IL-6	9
synthesis	0
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
by	0
C3a	9
and	0
C3a	9
(	10
desArg	10
)	10
.	0

The	0
anaphylatoxin	9
C3a	9
has	0
been	0
reported	0
to	0
have	0
immunomodulatory	0
effects	0
on	0
a	0
number	0
of	0
different	0
cell	0
types	0
.	0

In	0
this	0
study	0
we	0
investigated	0
the	0
effects	0
of	0
C3a	9
and	0
C3a	9
(	10
desArg	10
)	10
on	0
gene	0
expression	0
and	0
protein	0
secretion	0
of	0
IL-6	9
in	0
human	0
PBMCs	7
,	0
either	0
alone	0
or	0
in	0
combination	0
with	0
LPS	0
or	0
IL-1beta	9
.	0

C3a	9
or	0
C3a	9
(	10
desArg	10
)	10
alone	0
exhibited	0
no	0
effect	0
on	0
the	0
expression	0
or	0
secretion	0
of	0
IL-6	9
.	0

However	0
,	0
when	0
PBMC	7
were	0
stimulated	0
with	0
LPS	0
or	0
IL-1beta	9
,	0
both	0
C3a	9
and	0
C3a	9
(	10
desArg	10
)	10
were	0
found	0
to	0
enhance	0
IL-6	9
release	0
by	0
PBMC	7
in	0
a	0
dose-dependent	0
manner	0
.	0

Since	0
C3a	9
has	0
been	0
shown	0
to	0
induce	0
PGE2	0
production	0
by	0
monocytes	7
,	0
and	0
PGE2	0
has	0
been	0
shown	0
to	0
influence	0
cytokine	0
production	0
,	0
we	0
investigated	0
the	0
potential	0
role	0
of	0
PGE2	0
in	0
C3a	9
-mediated	0
enhancement	0
of	0
LPS-	0
and	0
IL-1beta-induced	0
IL-6	0
production	0
.	0

Indomethacin	0
blocked	0
PGE2	0
release	0
,	0
but	0
had	0
no	0
influence	0
on	0
the	0
observed	0
effects	0
of	0
C3a	9
,	0
suggesting	0
that	0
the	0
effects	0
of	0
C3a	9
on	0
IL-6	9
production	0
are	0
independent	0
of	0
PGE2	0
formation	0
by	0
monocytes	7
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
C3a	9
as	0
well	0
as	0
C3a	9
(	10
desArg	10
)	10
enhanced	0
LPS	0
-induced	3
mRNA	4
levels	0
for	0
IL-6	9
.	0

Pretreatment	0
of	0
PBMCs	7
with	0
pertussis	9
toxin	10
blocked	0
the	0
functions	0
of	0
C3a	9
and	0
C3a	9
(	10
desArg	10
)	10
,	0
indicating	0
that	0
the	0
actions	0
of	0
these	0
two	0
molecules	0
are	0
mediated	0
by	0
a	0
G	9
protein	10
-coupled	0
pathway	0
.	0

Furthermore	0
,	0
we	0
investigated	0
the	0
effects	0
of	0
C3a	9
and	0
C3a	9
(	10
desArg	10
)	10
on	0
induction	0
of	0
NF-kappaB	9
and	0
activating	9
protein-1	10
binding	0
.	0

Both	0
molecules	0
enhanced	0
LPS-induced	0
NF-kappaB	9
and	0
activating	9
protein-1	10
binding	0
activity	0
.	0

These	0
results	0
demonstrate	0
the	0
capacity	0
of	0
intact	0
C3a	9
and	0
its	0
circulating	0
des-Arg	9
form	10
to	0
exert	0
immunmodulatory	0
effects	0
in	0
vitro	0
.	0

Phenylarsine	0
oxide	0
inhibits	0
ex	0
vivo	0
HIV-1	0
expression	0
.	0

Phenylarsine	0
oxide	0
(	0
PAO	0
)	0
,	0
which	0
is	0
described	0
as	0
an	0
inhibitor	0
of	0
tyrosine	9
phosphatase	10
activity	0
,	0
inhibits	0
H2O2	0
release	0
from	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
as	0
measured	0
by	0
electrochemistry	0
.	0

Since	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replication	0
is	0
known	0
to	0
be	0
favored	0
under	0
oxidative	0
stress	0
conditions	0
,	0
ex	0
vivo	0
experiments	0
using	0
uninfected	0
PBMCs	7
,	0
primary	7
monocytes	8
or	0
a	0
latently	0
infected	0
promonocytic	5
U1	6
cell	6
line	6
show	0
that	0
HIV-1	0
replication	0
and	0
reactivation	0
,	0
monitored	0
by	0
p24	9
antigen	10
measurement	0
,	0
are	0
inhibited	0
by	0
PAO	0
in	0
a	0
time-	0
and	0
concentration-dependent	0
manner	0
.	0

These	0
observations	0
can	0
be	0
linked	0
with	0
the	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
when	0
uninfected	0
monocytes	0
are	0
induced	0
by	0
either	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
or	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

Pharmacological	0
control	0
of	0
antigen	0
responsiveness	0
in	0
genetically	5
modified	6
T	6
lymphocytes	6
.	0

A	0
chimeric	1
TCR	2
gene	2
,	0
comprising	0
an	0
anti-hapten	9
single-chain	10
Ab	10
variable	10
fragment	10
fused	0
to	0
the	0
transmembrane	9
and	10
cytoplasmic	10
regions	10
of	0
the	0
human	9
TCR	10
zeta-chain	10
,	0
was	0
used	0
to	0
determine	0
whether	0
the	0
tetracycline-regulatable	0
system	0
could	0
be	0
used	0
to	0
regulate	0
gene	0
expression	0
in	0
T	7
cells	8
.	0

Jurkat	5
T	6
cells	6
were	0
stably	0
transfected	0
with	0
a	0
single	0
vector	0
encoding	0
the	0
tetracycline	9
trans-activator	10
protein	10
,	0
controlled	0
by	0
a	0
constitutive	1
promoter	2
,	0
and	0
the	0
chimeric	9
TCR	10
,	0
under	0
the	0
control	0
of	0
a	0
trans-activator	1
protein-responsive	2
promoter	2
.	0

In	0
the	0
absence	0
of	0
tetracyclines	0
,	0
the	0
transfected	0
T	7
cells	8
were	0
shown	0
to	0
express	0
the	0
chimeric	9
receptor	10
on	0
the	0
cell	0
surface	0
and	0
could	0
be	0
activated	0
by	0
its	0
cognate	9
Ag	10
,	0
leading	0
to	0
the	0
secretion	0
of	0
IL-2	9
.	0

When	0
the	0
cells	0
were	0
exposed	0
to	0
increasing	0
concentrations	0
of	0
tetracyclines	0
,	0
surface	0
expression	0
of	0
the	0
chimeric	9
receptor	10
was	0
suppressed	0
in	0
a	0
dose-dependent	0
manner	0
,	0
and	0
this	0
suppression	0
was	0
sufficient	0
to	0
result	0
in	0
complete	0
loss	0
of	0
responsiveness	0
to	0
the	0
targeted	9
Ag	10
.	0

Prolonged	0
suppression	0
of	0
trans-gene	0
expression	0
for	0
up	0
to	0
7	0
days	0
was	0
observed	0
after	0
doxycycline	0
was	0
removed	0
from	0
the	0
cultures	0
,	0
but	0
eventual	0
recovery	0
of	0
surface	0
expression	0
was	0
complete	0
,	0
and	0
the	0
absolute	0
time	0
to	0
recovery	0
was	0
directly	0
proportional	0
to	0
the	0
initial	0
concentration	0
of	0
the	0
drug	0
.	0

Pharmacologic	0
control	0
of	0
trans-gene	0
expression	0
in	0
gene-modified	5
T	6
cells	6
will	0
not	0
only	0
facilitate	0
new	0
approaches	0
to	0
the	0
study	0
of	0
different	0
aspects	0
of	0
T	0
cell	0
biology	0
,	0
but	0
will	0
also	0
provide	0
the	0
basis	0
for	0
new	0
gene	0
therapy	0
strategies	0
.	0

Glucocorticoid	9
receptors	10
,	0
fibromyalgia	0
and	0
low	0
back	0
pain	0
.	0

Recently	0
,	0
fibromyalgia	0
(	0
FMS	0
)	0
was	0
shown	0
to	0
be	0
a	0
disorder	0
associated	0
with	0
an	0
altered	0
functioning	0
of	0
the	0
stress	0
response	0
system	0
.	0

FMS	0
patients	0
display	0
a	0
hyperreactive	0
pituitary	0
adrenocorticotropic	0
hormone	0
(	0
ACTH	0
)	0
release	0
in	0
response	0
to	0
corticotropin-releasing	0
hormone	0
(	0
CRH	0
)	0
and	0
to	0
insulin-induced	0
hypoglycemia	0
.	0

We	0
suggested	0
that	0
negative	0
feedback	0
of	0
cortisol	0
could	0
be	0
deranged	0
.	0

Therefore	0
we	0
investigated	0
the	0
properties	0
and	0
function	0
of	0
the	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
FMS	0
patients	0
and	0
compared	0
the	0
results	0
with	0
those	0
of	0
healthy	0
persons	0
and	0
patients	0
with	0
chronic	0
low	0
back	0
pain	0
(	0
LBP	0
a	0
localized	0
pain	0
condition	0
)	0
.	0

Forty	0
primary	0
FMS	0
patients	0
(	0
F	0
:	0
M	0
=	0
36	0
:	0
4	0
)	0
,	0
28	0
LBP	0
patients	0
(	0
25	0
:	0
3	0
)	0
and	0
14	0
(	0
12	0
:	0
2	0
)	0
healthy	0
,	0
sedentary	0
control	0
persons	0
were	0
recruited	0
for	0
the	0
study	0
.	0

Urinary	0
free	0
cortisol	0
excretion	0
in	0
FMS	0
and	0
LBP	0
patients	0
was	0
lower	0
compared	0
to	0
controls	0
.	0

Only	0
FMS	0
patients	0
displayed	0
lower	0
CBG	0
and	0
basal	0
serum	0
cortisol	0
concentrations	0
when	0
compared	0
to	0
controls	0
.	0

However	0
,	0
plasma	0
free	0
cortisol	0
concentrations	0
were	0
similar	0
in	0
the	0
three	0
groups	0
.	0

There	0
was	0
no	0
difference	0
in	0
the	0
number	0
of	0
GR	9
per	0
cell	0
among	0
the	0
three	0
groups	0
(	0
FMS	0
:	0
6498	0
+/-	0
252	0
,	0
LBP	0
:	0
6625	0
+/-	0
284	0
,	0
controls	0
:	0
6576	0
+/-	0
304	0
)	0
,	0
but	0
the	0
dissociation	0
constant	0
(	0
Kd	0
)	0
of	0
the	0
FMS	0
(	0
14.5	0
+/-	0
0.9	0
nmol/l	0
)	0
and	0
LBP	0
(	0
14.7	0
+/-	0
1.3	0
nmol/l	0
)	0
subjects	0
was	0
significantly	0
higher	0
than	0
that	0
of	0
the	0
controls	0
(	0
10.9	0
+/-	0
0.8	0
nmol/l	0
)	0
(	0
p	0
<	0
.05	0
)	0
.	0

The	0
maximal	0
stimulation	0
of	0
the	0
lymphocytes	7
,	0
as	0
measured	0
by	0
the	0
maximal	0
thymidine	0
incorporation	0
(	0
in	0
the	0
absence	0
of	0
cortisol	0
)	0
in	0
the	0
FMS	0
group	0
was	0
approximately	0
1.5	0
times	0
higher	0
(	0
p	0
<	0
.05	0
)	0
than	0
in	0
the	0
control	0
or	0
LBP	0
group	0
.	0

The	0
ED50	0
(	0
the	0
cortisol	0
concentration	0
giving	0
50	0
%	0
inhibition	0
of	0
the	0
thymidine	0
incorporation	0
)	0
,	0
however	0
,	0
was	0
identical	0
in	0
all	0
three	0
groups	0
.	0

We	0
conclude	0
that	0
FMS	0
patients	0
have	0
a	0
mild	0
hypocortisolemia	0
,	0
increased	0
cortisol	0
feedback	0
resistance	0
in	0
combination	0
probably	0
with	0
a	0
reduced	0
CRH	0
synthesis	0
or	0
release	0
in	0
the	0
hypothalamus	0
.	0

The	0
role	0
of	0
the	0
GR	9
and	0
mineralocorticoid	9
receptor	10
(	0
MR	9
)	0
in	0
the	0
CRH	0
regulation	0
in	0
the	0
FMS	0
patients	0
remains	0
to	0
be	0
solved	0
.	0

Temporal	0
control	0
of	0
IgH	1
gene	2
expression	0
in	0
developing	7
B	8
cells	8
by	0
the	0
3	1
'	2
locus	2
control	2
region	2
.	0

The	0
suggested	0
roles	0
of	0
the	0
downstream	1
3	2
'	2
regions	2
acting	0
as	0
a	0
Locus	1
Control	2
Region	2
(	0
LCR	1
)	0
,	0
have	0
allowed	0
comparisons	0
to	0
be	0
made	0
between	0
the	0
regulation	0
of	0
the	0
IgH	1
locus	2
with	0
other	0
model	0
systems	0
whose	0
gene	0
expression	0
is	0
governed	0
by	0
LCR	1
activity	0
.	0

Here	0
we	0
summarize	0
the	0
importance	0
of	0
the	0
IgH	1
3'LCR	2
and	0
its	0
putative	0
functional	0
role	0
in	0
IgH	1
gene	2
expression	0
and	0
compare	0
it	0
with	0
the	0
5'LCR	1
regulatory	2
region	2
of	0
the	0
human	1
beta-globin	2
locus	2
.	0

HLA	0
binding	0
characteristics	0
and	0
generation	0
of	0
cytotoxic	7
lymphocytes	8
against	0
peptides	0
derived	0
from	0
oncogenic	9
proteins	10
.	0

AIMS	0
AND	0
BACKGROUND	0
:	0
Structurally	0
altered	0
proteins	0
(	0
derived	0
from	0
chromosomal	0
translocations	0
or	0
gene	0
mutations	0
)	0
can	0
be	0
considered	0
tumor	0
specific	0
antigens	0
and	0
represent	0
an	0
attractive	0
target	0
for	0
a	0
T-cell	0
mediated	0
response	0
.	0

T	0
lymphocytes	0
recognize	0
antigens	0
in	0
the	0
form	0
of	0
peptides	0
bound	0
to	0
HLA-molecules	9
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
Peptides	0
derived	0
from	0
oncogenic	9
proteins	10
were	0
screened	0
for	0
the	0
presence	0
of	0
HLA	9
binding	10
motifs	10
;	0
actual	0
binding	0
were	0
evaluated	0
by	0
HLA	0
stabilization	0
experiments	0
using	0
transfectants	0
and	0
specific	0
anti-HLA	9
antibodies	10
.	0

Specific	0
lymphocytes	7
were	0
induced	0
by	0
in	0
vitro	0
peptide	0
sensitization	0
and	0
screened	0
by	0
thymidine	0
uptake	0
or	0
cellular	0
cytotoxic	0
assays	0
.	0

RESULTS	0
:	0
We	0
identified	0
peptides	0
derived	0
from	0
EWS/FLI-1	9
fusion	10
protein	10
and	0
from	0
mutated	9
K-RAS	10
protein	10
(	0
encompassing	0
respectively	0
the	0
fusion	9
point	10
and	0
the	0
mutation	0
at	0
position	9
12	10
)	0
that	0
showed	0
binding	9
motif	10
for	0
HLA-Cw*0702	9
and	0
HLA-A3	9
respectively	0
.	0

The	0
actual	0
binding	0
of	0
these	0
peptides	0
was	0
analysed	0
in	0
a	0
stabilization	0
assay	0
.	0

We	0
detected	0
binding	0
for	0
the	0
EWS/FLI-1	0
peptide	0
and	0
for	0
5	0
RAS	0
peptides	0
(	0
1	0
wild	0
type	0
and	0
4	0
mutated	0
)	0
.	0

The	0
effect	0
of	0
temperature	0
,	0
beta	9
2-microglobulin	10
(	0
beta	9
2-m	10
)	0
and	0
fetal	0
calf	0
serum	0
(	0
FCS	0
)	0
on	0
the	0
binding	0
and	0
the	0
stability	0
of	0
the	0
HLA/peptide	9
complex	10
was	0
studied	0
.	0

A	0
low	0
temperature	0
(	0
26	0
degrees	0
C	0
)	0
increased	0
the	0
binding	0
both	0
in	0
HLA-A3	9
and	0
HLA-Cw*0702	9
,	0
while	0
FCS	0
reduced	0
it	0
.	0

beta	9
2-m	10
increased	0
the	0
binding	0
to	0
the	0
HLA-A3	9
molecule	10
but	0
did	0
not	0
influence	0
the	0
binding	0
to	0
the	0
HLA-Cw*0702	9
.	0

The	0
stability	0
of	0
already	0
formed	0
complexed	0
was	0
somewhat	0
different	0
in	0
the	0
HLA-A3	9
and	0
HLA-Cw*0702	9
system	0
:	0
both	0
were	0
more	0
stable	0
at	0
26	0
degrees	0
C	0
than	0
at	0
37	0
degrees	0
C	0
but	0
while	0
the	0
beta	9
2-m	10
and	0
FCS	0
did	0
not	0
influence	0
the	0
stability	0
of	0
the	0
HLA-A3/peptide	9
complex	10
,	0
they	0
seemed	0
to	0
cause	0
opposite	0
effects	0
in	0
the	0
HLA-Cw*0702	9
system	0
(	0
beta	9
2-m	10
stabilized	0
and	0
FCS	0
destabilized	0
the	0
complex	0
)	0
.	0

Finally	0
,	0
we	0
were	0
able	0
to	0
generate	0
a	0
specific	0
CD8+	5
CTL	6
line	6
against	0
a	0
K-RAS	0
mutated	0
peptide	0
.	0

CONCLUSIONS	0
:	0
Although	0
binding	9
motifs	10
and	0
actual	0
HLA	0
binding	0
can	0
be	0
detected	0
in	0
several	0
cases	0
,	0
the	0
generation	0
of	0
a	0
cellular	0
response	0
is	0
infrequent	0
,	0
confirming	0
that	0
HLA	0
binding	0
is	0
necessary	0
but	0
not	0
sufficient	0
to	0
obtain	0
an	0
in	0
vitro	0
response	0
.	0

Further	0
optimization	0
of	0
culture	0
conditions	0
,	0
type	0
of	0
Antigen	7
Presenting	8
Cells	8
(	0
APC	7
)	0
,	0
peptides	0
,	0
use	0
of	0
stabilizers	0
like	0
beta	9
2-m	10
are	0
still	0
needed	0
.	0

OCA-B	9
is	0
a	0
functional	0
analog	0
of	0
VP16	9
but	0
targets	0
a	0
separate	0
surface	0
of	0
the	0
Oct-1	9
POU	10
domain	10
[	0
published	0
erratum	0
appears	0
in	0
Mol	0
Cell	0
Biol	0
1998	0
Apr	0
;	0
18	0
(	0
4	0
)	0
:	0
2430	0
]	0

OCA-B	9
is	0
a	0
B-cell-specific	9
coregulator	10
of	0
the	0
broadly	0
expressed	0
POU	9
domain	10
transcription	10
factor	10
Oct-1	9
.	0

OCA-B	9
associates	0
with	0
the	0
Oct-1	9
POU	10
domain	10
,	0
a	0
bipartite	0
DNA-binding	0
structure	0
containing	0
a	0
POU-specific	9
(	10
POU	10
[	10
S	10
]	10
)	10
domain	10
joined	0
by	0
a	0
flexible	0
linker	0
to	0
a	0
POU	9
homeodomain	10
(	0
POU	9
[	10
H	10
]	10
)	0
.	0

Here	0
,	0
we	0
show	0
that	0
OCA-B	9
alters	0
the	0
activity	0
of	0
Oct-1	9
in	0
two	0
ways	0
.	0

It	0
provides	0
a	0
transcriptional	0
activation	0
domain	0
which	0
,	0
unlike	0
Oct-1	9
,	0
activates	0
an	0
mRNA-type	1
promoter	2
effectively	0
,	0
and	0
it	0
stabilizes	0
Oct-1	9
on	0
the	0
Oct-1-responsive	1
octamer	2
sequence	2
ATGCAAAT	0
.	0

These	0
properties	0
of	0
OCA-B	9
parallel	0
those	0
displayed	0
by	0
the	0
herpes	9
simplex	10
virus	10
Oct-1	10
coregulator	10
VP16	9
.	0

OCA-B	9
,	0
however	0
,	0
interacts	0
with	0
a	0
different	0
surface	0
of	0
the	0
DNA-bound	0
Oct-1	9
POU	10
domain	10
,	0
interacting	0
with	0
both	0
the	0
POU	9
(	10
S	10
)	10
and	10
POU	10
(	10
H	10
)	10
domains	10
and	0
the	0
center	0
of	0
the	0
ATGCAAAT	1
octamer	2
sequence	2
.	0

The	0
OCA-B	0
and	0
VP16	9
interactions	0
with	0
the	0
Oct-1	9
POU	10
domain	10
are	0
sufficiently	0
different	0
to	0
permit	0
OCA-B	9
and	0
VP16	9
to	0
bind	0
the	0
Oct-1	9
POU	10
domain	10
simultaneously	0
.	0

These	0
results	0
emphasize	0
the	0
structural	0
versatility	0
of	0
the	0
Oct-1	9
POU	10
domain	10
in	0
its	0
interaction	0
with	0
coregulators	0
.	0

Phosphatidylinositol	9
3-kinase	10
couples	0
the	0
interleukin-2	9
receptor	10
to	0
the	0
cell	9
cycle	10
regulator	10
E2F	9
.	0

Cell	0
cycle	0
progression	0
initiated	0
by	0
interleukin-2	9
(	0
IL-2	9
)	0
in	0
T	7
cells	8
is	0
critical	0
for	0
lymphoproliferation	0
and	0
an	0
immune	0
response	0
.	0

Phosphatidyl	9
inositol	10
3-kinase	10
(	0
PI3K	9
)	0
is	0
activated	0
by	0
IL-2	9
.	0

However	0
,	0
nuclear	0
targets	0
for	0
PI3K	9
are	0
not	0
known	0
.	0

Here	0
we	0
identify	0
the	0
cell	9
cycle	10
regulator	10
E2F	9
as	0
an	0
IL-2	9
target	0
in	0
T	0
lymphocytes	7
and	0
PI3K	9
as	0
the	0
critical	0
signaling	0
pathway	0
.	0

We	0
eliminate	0
both	0
Stat5	9
and	0
Raf	9
/MEK	9
pathways	0
from	0
E2F	9
regulation	0
.	0

Protein	9
kinase	10
B	10
(	0
PKB	9
)	0
is	0
activated	0
by	0
IL-2	9
via	0
PI3K	9
.	0

The	0
expression	0
of	0
an	0
active	0
PKB	9
is	0
sufficient	0
to	0
induce	0
E2F	9
activity	0
.	0

Inhibition	0
of	0
PI3K	9
inhibits	0
phosphorylation	0
of	0
Rb	9
,	0
induction	0
of	0
cyclin	9
D3	10
,	0
and	0
degradation	0
of	0
p27kip1	9
.	0

These	0
results	0
establish	0
a	0
crucial	0
PI3K	9
/	0
PKB	9
-mediated	0
link	0
between	0
the	0
IL-2	9
teceptor	10
and	0
the	0
cell	0
cycle	0
machinery	0
.	0

The	0
Epstein-Barr	9
virus	10
oncogene	10
product	10
latent	9
membrane	10
protein	10
1	10
engages	0
the	0
tumor	0
necrosis	0
factor	0
receptor-associated	0
death	0
domain	0
protein	0
to	0
mediate	0
B	0
lymphocyte	0
growth	0
transformation	0
and	0
activate	0
NF-kappaB	0
.	0

The	0
Epstein-Barr	0
virus	0
latent	9
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
is	0
essential	0
for	0
the	0
transformation	0
of	0
B	7
lymphocytes	8
into	0
lymphoblastoid	5
cell	6
lines	6
.	0

Previous	0
data	0
are	0
consistent	0
with	0
a	0
model	0
that	0
LMP1	9
is	0
a	0
constitutively	9
activated	10
receptor	10
that	0
transduces	0
signals	0
for	0
transformation	0
through	0
its	0
carboxyl-terminal	9
cytoplasmic	10
tail	10
.	0

One	0
transformation	9
effector	10
site	10
(	0
TES1	9
)	0
,	0
located	0
within	0
the	0
membrane	9
proximal	10
45	10
residues	10
of	0
the	0
cytoplasmic	0
tail	0
,	0
constitutively	0
engages	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
factors	10
.	0

Signals	0
from	0
TES1	9
are	0
sufficient	0
to	0
drive	0
initial	0
proliferation	0
of	0
infected	0
resting	0
B	0
lymphocytes	7
,	0
but	0
most	0
lymphoblastoid	7
cells	8
infected	0
with	0
a	0
virus	0
that	0
does	0
not	0
express	0
the	0
155	9
residues	10
beyond	0
TES1	9
fail	0
to	0
grow	0
as	0
long-term	5
cell	6
lines	6
.	0

We	0
now	0
find	0
that	0
mutating	0
two	0
tyrosines	0
to	0
an	0
isoleucine	0
at	0
the	0
carboxyl	9
end	10
of	0
the	0
cytoplasmic	9
tail	10
cripples	0
the	0
ability	0
of	0
EBV	0
to	0
cause	0
lymphoblastoid	0
cell	0
outgrowth	0
,	0
thereby	0
marking	0
a	0
second	0
transformation	9
effector	10
site	10
,	0
TES2	9
.	0

A	0
yeast	0
two-hybrid	0
screen	0
identified	0
TES2	9
interacting	10
proteins	10
,	0
including	0
the	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
death	10
domain	10
protein	10
(	0
TRADD	9
)	0
.	0

TRADD	9
was	0
the	0
only	0
protein	0
that	0
interacted	0
with	0
wild-type	9
TES2	10
and	0
not	0
with	0
isoleucine-mutated	9
TES2	10
.	0

TRADD	9
associated	0
with	0
wild-type	9
LMP1	10
but	0
not	0
with	0
isoleucine-mutated	0
LMP1	9
in	0
mammalian	0
cells	0
,	0
and	0
TRADD	9
constitutively	0
associated	0
with	0
LMP1	9
in	0
EBV-transformed	5
cells	6
.	0

In	0
transfection	0
assays	0
,	0
TRADD	9
and	0
TES2	9
synergistically	0
mediated	0
high-level	0
NF-kappaB	9
activation	0
.	0

These	0
results	0
indicate	0
that	0
LMP1	9
appropriates	0
TRADD	9
to	0
enable	0
efficient	0
long-term	0
lymphoblastoid	0
cell	0
outgrowth	0
.	0

High-level	0
NF-kappaB	9
activation	0
also	0
appears	0
to	0
be	0
a	0
critical	0
component	0
of	0
long-term	0
outgrowth	0
.	0

Inhibition	0
of	0
T	7
cell	8
and	0
promotion	0
of	0
natural	0
killer	0
cell	0
development	0
by	0
the	0
dominant	9
negative	10
helix	10
loop	10
helix	10
factor	10
Id3	9
.	0

Bipotential	7
T/natural	8
killer	8
(	8
NK	8
)	8
progenitor	8
cells	8
are	0
present	0
in	0
the	0
human	0
thymus	0
.	0

Despite	0
their	0
bipotential	0
capacity	0
,	0
these	0
progenitors	0
develop	0
predominantly	0
to	0
T	7
cells	8
in	0
the	0
thymus	0
.	0

The	0
mechanisms	0
controlling	0
this	0
developmental	0
choice	0
are	0
unknown	0
.	0

Here	0
we	0
present	0
evidence	0
that	0
a	0
member	0
(	0
s	0
)	0
of	0
the	0
family	0
of	0
basic	9
helix	10
loop	10
helix	10
(	10
bHLH	10
)	10
transcription	10
factors	10
determines	0
lineage	0
specification	0
of	0
NK/T	7
cell	8
progenitors	8
.	0

The	0
natural	0
dominant	9
negative	10
HLH	10
factor	10
Id3	9
,	0
which	0
blocks	0
transcriptional	0
activity	0
of	0
a	0
number	0
of	0
known	0
bHLH	9
factors	10
,	0
was	0
expressed	0
in	0
CD34+	7
progenitor	8
cells	8
by	0
retrovirus-mediated	0
gene	0
transfer	0
.	0

Constitutive	0
expression	0
of	0
Id3	9
completely	0
blocks	0
development	0
of	0
CD34+	7
cells	8
into	0
T	7
cells	8
in	0
a	0
fetal	0
thymic	0
organ	0
culture	0
(	0
FTOC	0
)	0
.	0

In	0
contrast	0
,	0
development	0
into	0
NK	7
cells	8
in	0
an	0
FTOC	0
is	0
enhanced	0
.	0

Thus	0
,	0
the	0
activity	0
of	0
a	0
bHLH	9
transcription	10
factor	10
is	0
necessary	0
for	0
T	0
lineage	0
differentiation	0
of	0
bipotential	7
precursors	8
,	0
in	0
the	0
absence	0
of	0
which	0
a	0
default	0
pathway	0
leading	0
to	0
NK	0
cell	0
development	0
is	0
chosen	0
.	0

Our	0
results	0
identify	0
a	0
molecular	0
switch	0
for	0
lineage	0
specification	0
in	0
early	7
lymphoid	8
precursors	8
of	0
humans	0
.	0

Late	0
gene	0
expression	0
from	0
the	0
Epstein-Barr	0
virus	0
BcLF1	1
and	2
BFRF3	2
promoters	2
does	0
not	0
require	0
DNA	0
replication	0
in	0
cis	0
.	0

Late	0
gene	0
expression	0
follows	0
and	0
is	0
dependent	0
upon	0
lytic	0
replication	0
of	0
the	0
viral	1
genome	2
.	0

Although	0
experimental	0
evidence	0
is	0
lacking	0
,	0
lytic	0
viral	0
DNA	0
replication	0
is	0
believed	0
to	0
remove	0
modifications	0
or	0
binding	9
factors	10
from	0
the	0
genome	0
which	0
serve	0
to	0
repress	0
late	0
gene	0
expression	0
during	0
latency	0
or	0
the	0
early	0
lytic	0
cycle	0
.	0

We	0
have	0
developed	0
a	0
reporter	0
assay	0
to	0
begin	0
characterizing	0
the	0
mechanisms	0
that	0
regulate	0
late	0
gene	0
expression	0
in	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
.	0

In	0
this	0
model	0
system	0
,	0
the	0
activities	0
of	0
late	1
promoter-reporter	2
fusions	2
are	0
measured	0
following	0
transient	0
transfection	0
into	0
tissue	5
culture	6
cells	6
expressing	0
EBV	0
during	0
different	0
stages	0
of	0
the	0
lytic	0
cycle	0
.	0

This	0
system	0
faithfully	0
recapitulates	0
late	0
expression	0
patterns	0
from	0
the	0
endogenous	0
virus	0
,	0
implicating	0
specific	0
cis-active	1
sequences	2
in	0
the	0
control	0
of	0
late	0
gene	0
expression	0
.	0

In	0
addition	0
,	0
these	0
promoters	0
respond	0
only	0
indirectly	0
to	0
the	0
viral	1
immediate-early	2
transactivator	2
,	0
ZEBRA	1
.	0

This	0
indirect	0
response	0
is	0
mediated	0
by	0
other	0
viral	0
or	0
virally	0
induced	0
activities	0
downstream	0
of	0
ZEBRA	1
in	0
the	0
lytic	0
cascade	0
.	0

In	0
this	0
system	0
,	0
late	0
gene	0
expression	0
is	0
sensitive	0
to	0
inhibitors	0
of	0
the	0
viral	9
DNA	10
polymerase	10
such	0
as	0
phosphonoacetic	0
acid	0
,	0
although	0
the	0
reporters	0
lack	0
a	0
eukaryotic	0
origin	0
of	0
replication	0
and	0
are	0
not	0
replicated	0
under	0
the	0
assay	0
conditions	0
.	0

Thus	0
,	0
replication	0
of	0
the	0
transcriptional	1
template	2
is	0
not	0
a	0
prerequisite	0
for	0
expression	0
with	0
late	0
kinetics	0
,	0
a	0
finding	0
inconsistent	0
with	0
the	0
current	0
models	0
which	0
posit	0
a	0
cis-active	0
relationship	0
between	0
lytic	0
EBV	0
DNA	0
replication	0
and	0
late	0
gene	0
expression	0
.	0

Rather	0
,	0
analysis	0
of	0
this	0
system	0
has	0
revealed	0
a	0
trans	0
relationship	0
between	0
late	0
gene	0
expression	0
and	0
viral	0
DNA	0
replication	0
and	0
highlights	0
the	0
indirect	0
and	0
complex	0
link	0
between	0
these	0
two	0
events	0
.	0

Modulation	0
of	0
mRNA	0
expression	0
of	0
a	0
novel	1
human	2
myeloid-selective	2
CCAAT/enhancer	2
binding	2
protein	2
gene	2
(	0
C/EBP	1
epsilon	2
)	0
.	0

Human	0
C/EBP	1
epsilon	2
is	0
a	0
newly	0
cloned	0
gene	0
coding	0
for	0
a	0
CCAAT/enhancer	9
binding	10
protein	10
that	0
may	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
myeloid	0
differentiation	0
.	0

Our	0
studies	0
showed	0
that	0
levels	0
of	0
C/EBP	3
epsilon	4
mRNA	4
were	0
markedly	0
increased	0
in	0
NB4	5
cells	6
(	0
promyelocytic	5
leukemia	6
line	6
)	0
,	0
because	0
they	0
were	0
induced	0
by	0
9-cis	0
retinoic	0
acid	0
(	0
9-cis	0
RA	0
)	0
to	0
differentiate	0
towards	0
granulocytes	7
.	0

Accumulation	0
of	0
C/EBP	3
epsilon	4
mRNA	4
occurred	0
as	0
early	0
as	0
1	0
hour	0
after	0
exposure	0
of	0
NB4	5
cells	6
to	0
9-cis	0
RA	0
(	0
5	0
x	0
10	0
(	0
-7	0
)	0
mol/L	0
)	0
;	0
and	0
at	0
48	0
hours	0
,	0
levels	0
were	0
increased	0
by	0
5.1-fold	0
.	0

Dose-response	0
studies	0
showed	0
that	0
10	0
(	0
-7	0
)	0
to	0
10	0
(	0
-6	0
)	0
mol/L	0
9-cis	0
RA	0
(	0
12	0
hours	0
)	0
resulted	0
in	0
peak	0
levels	0
of	0
C/EBP	3
epsilon	4
mRNA	4
;	0
but	0
even	0
10	0
(	0
-10	0
)	0
mol/L	0
9-cis	0
RA	0
increased	0
levels	0
of	0
these	0
transcripts	0
.	0

NB4	5
cells	6
pulse-exposed	0
(	0
30	0
minutes	0
)	0
to	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
,	0
washed	0
,	0
and	0
cultured	0
(	0
3	0
days	0
)	0
with	0
either	0
dimethylsulfoxide	0
(	0
DMSO	0
)	0
or	0
hexamethylene	0
bisacetamide	0
(	0
HMBA	0
)	0
had	0
a	0
prominent	0
increase	0
in	0
levels	0
of	0
C/EBP	3
epsilon	4
mRNA	4
and	0
an	0
increase	0
in	0
granulocytic	0
differentiation	0
,	0
but	0
exposure	0
to	0
either	0
DMSO	0
or	0
HMBA	0
alone	0
had	0
no	0
effect	0
on	0
base	0
levels	0
of	0
C/EBP	0
epsilon	0
and	0
did	0
not	0
induce	0
differentiation	0
.	0

Macrophage-differentiation	0
of	0
NB4	5
reduced	0
levels	0
of	0
C/EBP	3
epsilon	4
mRNA	4
.	0

Nuclear	0
run-off	0
assays	0
and	0
half-life	0
studies	0
showed	0
that	0
accumulation	0
of	0
C/EBP	3
epsilon	4
mRNA	4
by	0
9-cis	0
RA	0
was	0
due	0
to	0
enhanced	0
transcription	0
.	0

Furthermore	0
,	0
this	0
C/EBP	3
epsilon	4
mRNA	4
accumulation	0
did	0
not	0
require	0
synthesis	0
of	0
new	0
protein	9
factors	10
because	0
9-cis	0
RA	0
induced	0
C/EBP	3
epsilon	4
mRNA	4
accumulation	0
in	0
the	0
absence	0
of	0
new	0
protein	0
synthesis	0
.	0

ATRA	0
also	0
induced	0
expression	0
of	0
C/EBP	9
epsilon	10
protein	10
in	0
NB4	5
cells	6
,	0
as	0
shown	0
by	0
Western	0
blotting	0
.	0

In	0
contrast	0
to	0
the	0
increase	0
of	0
C/EBP	0
epsilon	0
in	0
9-cis	0
RA-mediated	0
granulocytic	0
differentiation	0
,	0
the	0
DMSO-induced	0
differentiation	0
of	0
HL-60	5
cells	6
down	0
the	0
granulocytic	0
pathway	0
was	0
associated	0
with	0
an	0
initial	0
reduction	0
of	0
C/EBP	3
epsilon	4
mRNA	4
levels	0
.	0

In	0
summary	0
,	0
we	0
have	0
discovered	0
that	0
expression	0
of	0
C/EBP	3
epsilon	4
mRNA	4
is	0
markedly	0
enhanced	0
as	0
the	0
NB4	5
promyelocytes	6
are	0
induced	0
by	0
retinoids	0
to	0
differentiate	0
towards	0
granulocytes	7
.	0

This	0
induction	0
of	0
C/EBP	3
epsilon	4
mRNA	4
expression	0
is	0
transcriptionally	0
mediated	0
and	0
occurs	0
in	0
the	0
absence	0
of	0
synthesis	0
of	0
additional	0
protein	9
factors	10
.	0

We	0
suspect	0
that	0
the	0
C/EBP	1
epsilon	2
promoter/enhancer	2
contains	0
a	0
retinoic	1
acid-response	2
element	2
that	0
is	0
directly	0
stimulated	0
by	0
retinoids	0
.	0

Dual	0
effects	0
of	0
LPS	9
antibodies	10
on	0
cellular	0
uptake	0
of	0
LPS	0
and	0
LPS-induced	0
proinflammatory	0
functions	0
.	0

Human	7
phagocytes	8
recognize	0
bacterial	0
LPS	0
(	0
endotoxin	0
)	0
through	0
membrane	9
CD14	10
(	0
mCD14	9
)	0
,	0
a	0
proinflammatory	9
LPS	10
receptor	10
.	0

This	0
study	0
tested	0
the	0
hypothesis	0
that	0
anti-LPS	9
Abs	10
neutralize	0
endotoxin	0
by	0
blocking	0
cellular	0
uptake	0
through	0
mCD14	9
.	0

Ab-associated	0
changes	0
in	0
the	0
uptake	0
and	0
cellular	0
distribution	0
of	0
FITC-LPS	0
were	0
assessed	0
by	0
flow	0
cytometry	0
and	0
laser	0
scanning	0
confocal	0
microscopy	0
in	0
human	5
CD14-transfected	6
Chinese	6
hamster	6
ovary	6
fibroblasts	6
(	0
CHO-CD14	5
cells	6
)	0
and	0
human	7
peripheral	8
blood	8
monocytes	8
.	0

LPS	0
core-	9
and	10
O-side	10
chain-specific	10
mAbs	10
inhibited	0
mCD14	9
-mediated	0
LPS	0
uptake	0
by	0
both	0
cell	0
types	0
in	0
the	0
presence	0
of	0
serum	0
.	0

O-side	9
chain-specific	10
mAb	10
concurrently	0
enhanced	0
complement-dependent	0
LPS	0
uptake	0
by	0
monocytes	0
through	0
complement	9
receptor-1	10
(	0
CR1	9
)	0
and	0
uptake	0
by	0
CHO-CD14	5
cells	6
involving	0
another	0
heat-labile	9
serum	10
factor	10
(	0
s	0
)	0
and	0
cell-associated	9
recognition	10
molecule	10
(	0
s	0
)	0
.	0

Core-specific	9
mAb	10
inhibited	0
mCD14	9
-mediated	0
uptake	0
of	0
homologous	0
and	0
heterologous	0
LPS	0
,	0
while	0
producing	0
less	0
concurrent	0
enhancement	0
of	0
non-	0
mCD14	9
-mediated	0
LPS	0
uptake	0
.	0

The	0
modulation	0
by	0
anti-LPS	9
mAbs	10
of	0
mCD14	9
-mediated	0
LPS	0
uptake	0
was	0
associated	0
with	0
inhibition	0
of	0
LPS-induced	9
nuclear	10
factor-kappaB	10
(	0
NF-kappaB	9
)	0
translocation	0
and	0
TNF-alpha	9
secretion	0
in	0
CHO-CD14	5
cells	6
and	0
monocytes	0
,	0
respectively	0
,	0
while	0
mAb	0
enhancement	0
of	0
non-	0
mCD14	9
-mediated	0
LPS	0
uptake	0
stimulated	0
these	0
activities	0
.	0

LPS-specific	9
Abs	10
thus	0
mediate	0
anti-inflammatory	0
and	0
proinflammatory	0
functions	0
,	0
respectively	0
,	0
by	0
preventing	0
target	0
cell	0
uptake	0
of	0
LPS	0
through	0
mCD14	9
and	0
augmenting	0
uptake	0
through	0
CR1	9
or	0
other	0
cell	9
receptors	10
.	0

Four	0
P-like	1
elements	2
are	0
required	0
for	0
optimal	0
transcription	0
of	0
the	0
mouse	1
IL-4	2
gene	2
:	0
involvement	0
of	0
a	0
distinct	0
set	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
and	0
activator	9
protein-1	10
family	10
proteins	10
.	0

We	0
previously	0
identified	0
the	0
P	1
sequence	2
as	0
a	0
critical	0
regulatory	1
element	2
of	0
the	0
human	1
IL-4	2
promoter	2
.	0

In	0
the	0
mouse	1
IL-4	2
promoter	2
,	0
there	0
are	0
five	0
elements	0
homologous	0
to	0
the	0
human	0
P	1
sequence	2
designated	0
conserved	1
lymphokine	2
element	2
0	2
(	0
CLE0	1
)	0
,	0
P	1
,	0
P2	1
,	0
P3	1
and	0
P4	1
.	0

To	0
characterize	0
the	0
role	0
of	0
these	0
P-like	1
elements	2
and	0
their	0
binding	9
factors	10
in	0
the	0
native	1
promoter	2
,	0
we	0
did	0
transient	0
transfection	0
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
.	0

Transfection	0
of	0
EL-4	5
cells	6
with	0
the	0
IL-4	1
promoter-reporter	2
constructs	2
carrying	0
mutated	1
P-like	2
elements	2
showed	0
that	0
four	0
P-like	1
elements	2
,	0
CLE0	1
,	0
P	1
,	0
P2	1
and	0
P4	1
,	0
but	0
not	0
P3	1
,	0
were	0
required	0
for	0
optimal	0
activation	0
of	0
the	0
IL-4	1
promoter	2
.	0

EMSA	0
showed	0
that	0
both	0
constitutive	0
and	0
inducible	0
complexes	0
bound	0
to	0
CLE0	1
,	0
P	1
,	0
P2	1
and	0
P4	1
,	0
whereas	0
only	0
a	0
constitutive	0
complex	0
bound	0
to	0
P3	1
.	0

In	0
competition	0
and	0
antibody	0
supershift	0
assays	0
in	0
EMSA	0
,	0
complexes	0
formed	0
with	0
P	1
or	0
P2	1
proved	0
to	0
contain	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	10
NFAT	10
)	10
family	10
proteins	10
as	0
major	0
components	0
.	0

Activator	9
protein	10
(	10
AP	10
)	10
-1	10
family	10
proteins	10
interacted	0
with	0
CLE0	1
,	0
P	0
,	0
P2	1
and	0
P4	1
.	0

NFAT/AP-1	9
complex	10
formed	0
only	0
with	0
P	1
and	0
P2	1
.	0

Cross-competition	0
assays	0
among	0
the	0
P-like	1
elements	2
revealed	0
element-specific	9
and	10
common	10
complexes	10
.	0

Six	0
tandem	0
repeats	0
of	0
the	0
P	1
element	2
linked	0
to	0
the	0
SV40	1
promoter	2
responded	0
to	0
phorbol	0
12-myristate	0
13-acetate	0
,	0
while	0
that	0
of	0
other	0
elements	0
did	0
not.	0
It	0
would	0
thus	0
appear	0
that	0
components	0
of	0
each	0
P-like	9
element-binding	10
complexes	10
are	0
not	0
identical	0
and	0
may	0
coordinately	0
contribute	0
to	0
transcriptional	0
activity	0
.	0

Constitutive	0
expression	0
c-fos	3
,	4
c-jun	4
,	4
and	4
NF	4
kappa	4
B	4
mRNA	4
is	0
in	0
nucleated	7
fetal	8
blood	8
cells	8
and	0
up-regulation	0
of	0
c-fos	9
and	0
c-jun	9
with	0
anti-CD3	9
stimulation	0
.	0

Fetal	7
and	8
neonatal	8
lymphocytes	8
are	0
relatively	0
resistant	0
to	0
activation	0
and	0
cytokine	9
production	0
when	0
stimulated	0
either	0
via	0
their	0
T-cell	9
antigen	10
receptors	10
or	0
lectins	9
.	0

The	0
molecular	0
mechanism	0
(	0
s	0
)	0
responsible	0
for	0
this	0
phenomenon	0
have	0
not	0
been	0
clearly	0
elucidated	0
.	0

We	0
have	0
hypothesized	0
that	0
such	0
defects	0
in	0
fetal/neonatal	0
T-cell	0
activation	0
may	0
be	0
due	0
to	0
lack	0
of	0
expression	0
of	0
the	0
transcriptional	9
regulatory	10
elements	10
required	0
for	0
T-cell	0
activation	0
.	0

We	0
used	0
reverse	9
transcriptase	10
-polymerase	0
chain	0
reaction	0
to	0
examine	0
both	0
fetal	0
and	0
term	0
neonatal	0
cord	0
bloods	0
for	0
mRNA	0
expression	0
of	0
three	0
transcription	9
factors	10
implicated	0
in	0
T-cell	0
activation	0
:	0
c-jun	9
,	0
c-fos	9
,	0
and	0
NF	9
kappa	10
B	10
(	0
p50	9
subunit	10
)	0
.	0

We	0
demonstrate	0
that	0
mRNAs	3
for	0
all	0
three	0
of	0
these	0
regulatory	0
factors	0
are	0
expressed	0
in	0
fetal	7
blood	8
cells	8
by	0
the	0
27th	0
week	0
of	0
gestation	0
and	0
in	0
term	0
cord	0
bloods	0
.	0

Activation	0
of	0
term	7
infant	8
cord	8
blood	8
mononuclear	8
cells	8
with	0
anti-CD3	9
monoclonal	10
antibodies	10
resulted	0
in	0
up-regulation	0
of	0
both	0
c-jun	9
and	0
c-fos	0
mRNAs	3
within	0
15	0
min	0
of	0
stimulation	0
.	0

However	0
,	0
secretion	0
of	0
IL-2	9
by	0
anti-CD3-stimulated	5
cord	6
blood	6
mononuclear	6
cells	6
was	0
still	0
blunted	0
compared	0
with	0
control	7
cells	8
from	0
adults	0
.	0

We	0
conclude	0
that	0
fetal	7
nucleated	8
blood	8
cells	8
constitutively	0
express	0
important	0
genes	0
for	0
cytokine	9
regulation	0
and	0
are	0
able	0
to	0
increase	0
intracellular	0
accumulation	0
of	0
the	0
mRNAs	3
for	0
these	0
factors	0
in	0
response	0
to	0
anti-CD3	9
stimulation	0
.	0

Thus	0
,	0
qualitative	0
differences	0
in	0
the	0
capacity	0
to	0
regulate	0
these	0
factors	0
could	0
not	0
be	0
shown	0
in	0
fetal	7
blood	8
cells	8
.	0

Quantitative	0
experiments	0
comparing	0
binding	0
of	0
these	0
transcription	9
factors	10
to	0
the	0
IL-2	1
promoter	2
are	0
currently	0
under	0
investigation	0
.	0

Nuclear	0
accumulation	0
of	0
NFAT4	9
opposed	0
by	0
the	0
JNK	9
signal	0
transduction	0
pathway	0
.	0

The	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	10
NFAT	10
)	10
group	10
of	0
transcription	9
factors	10
is	0
retained	0
in	0
the	0
cytoplasm	0
of	0
quiescent	7
cells	8
.	0

NFAT	9
activation	0
is	0
mediated	0
in	0
part	0
by	0
induced	0
nuclear	0
import	0
.	0

This	0
process	0
requires	0
calcium-dependent	0
dephosphorylation	0
of	0
NFAT	9
caused	0
by	0
the	0
phosphatase	9
calcineurin	9
.	0

The	0
c-Jun	9
amino-terminal	10
kinase	10
(	0
JNK	9
)	0
phosphorylates	0
NFAT4	9
on	0
two	0
sites	0
.	0

Mutational	0
removal	0
of	0
the	0
JNK	9
phosphorylation	10
sites	10
caused	0
constitutive	0
nuclear	0
localization	0
of	0
NFAT4	9
.	0

In	0
contrast	0
,	0
JNK	9
activation	0
in	0
calcineurin-stimulated	5
cells	6
caused	0
nuclear	0
exclusion	0
of	0
NFAT4	9
.	0

These	0
findings	0
show	0
that	0
the	0
nuclear	0
accumulation	0
of	0
NFAT4	9
promoted	0
by	0
calcineurin	9
is	0
opposed	0
by	0
the	0
JNK	9
signal	0
transduction	0
pathway	0
.	0

Thiol	0
modulation	0
inhibits	0
the	0
interleukin	9
(	10
IL	10
)	10
-1	10
-mediated	0
activation	0
of	0
an	0
IL-1	9
receptor-associated	10
protein	10
kinase	10
and	0
NF-kappa	9
B	10
.	0

The	0
interleukin-1	9
receptor	10
type	10
I	10
(	0
IL-1RI	9
)	0
is	0
associated	0
with	0
other	0
proteins	0
thus	0
forming	0
a	0
complex	9
system	10
by	0
which	0
IL-1	9
exerts	0
its	0
various	0
signals	0
.	0

The	0
initiating	0
event	0
is	0
still	0
uncertain	0
,	0
but	0
activation	0
of	0
a	0
recently	0
described	0
receptor-associated	9
protein	10
kinase	10
is	0
one	0
of	0
the	0
earliest	0
events	0
detectable	0
(	0
Martin	0
et	0
al.	0
,	0
Eur.J.Immunol.1994.24	0
:	0
1566	0
)	0
.	0

IL-1	9
signaling	0
is	0
commonly	0
accompanied	0
by	0
oxidative	0
processes	0
and	0
is	0
thought	0
to	0
be	0
subject	0
to	0
redox	0
regulation	0
.	0

We	0
therefore	0
investigated	0
whether	0
the	0
activation	0
of	0
the	0
IL-1RI-associated	9
protein	10
kinase	10
could	0
be	0
a	0
target	0
for	0
redox	0
regulation	0
and	0
whether	0
an	0
altered	0
activity	0
of	0
the	0
kinase	0
could	0
influence	0
IL-1	9
-mediated	0
NF-kappa	9
B	10
activation	0
.	0

A	0
murine	5
T	6
cell	6
line	6
,	0
EL4	5
,	0
was	0
stimulated	0
with	0
IL-1	9
with	0
and	0
without	0
pretreatment	0
with	0
different	0
compounds	0
known	0
to	0
influence	0
the	0
cellular	0
redox	0
status	0
.	0

Thiol	0
modifying	0
agents	0
like	0
diamide	0
,	0
menadione	0
,	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
,	0
diethyl	0
dithiocarbamate	0
or	0
phenylarsine	0
oxide	0
inhibited	0
the	0
IL-1	9
-induced	0
activation	0
of	0
the	0
IL-1RI-associated	9
protein	10
kinase	10
.	0

N-Acetylcysteine	0
,	0
alpha	0
,	0
alpha'-dipyridyl	0
,	0
aminotriazole	0
or	0
nitrofurantoin	0
did	0
not	0
show	0
any	0
effect	0
.	0

The	0
inhibition	0
by	0
PDTC	0
was	0
reversible	0
unless	0
glutathione	0
synthesis	0
was	0
blocked	0
by	0
buthionine	0
sulfoximine	0
.	0

The	0
described	0
conditions	0
which	0
inhibited	0
or	0
prevented	0
the	0
activation	0
of	0
the	0
IL-1RI-associated	9
kinase	10
similarly	0
impaired	0
the	0
activation	0
of	0
NF-kappa	9
B	10
in	0
EL4	5
cells	6
.	0

From	0
these	0
observations	0
we	0
conclude	0
that	0
free	0
thiols	0
in	0
the	0
IL-1RI	9
complex	10
are	0
essential	0
for	0
the	0
activation	0
of	0
the	0
IL-1RI-associated	9
protein	10
kinase	10
and	0
that	0
this	0
process	0
is	0
mandatory	0
for	0
IL-1	9
signaling	0
leading	0
to	0
NF-kappa	9
B	10
activation	0
.	0

Switching	0
gears	0
during	0
T-cell	0
maturation	0
:	0
RANTES	9
and	0
late	0
transcription	0
.	0

Although	0
much	0
is	0
understood	0
about	0
the	0
induction	0
of	0
genes	1
expressed	0
early	0
(	0
within	0
24	0
h	0
)	0
after	0
T-cell	0
activation	0
,	0
little	0
is	0
known	0
about	0
the	0
regulation	0
of	0
expression	0
of	0
genes	1
expressed	0
'late	0
'	0
(	0
three	0
or	0
more	0
days	0
)	0
post-stimulation	0
.	0

A	0
better	0
understanding	0
of	0
transcriptional	0
regulation	0
at	0
this	0
important	0
stage	0
of	0
T-cell	0
maturation	0
may	0
yield	0
new	0
insights	0
into	0
T-cell	0
development	0
and	0
new	0
immunotherapeutic	0
targets	0
.	0

Involvement	0
of	0
different	0
transduction	0
pathways	0
in	0
NF-kappa	9
B	10
activation	0
by	0
several	0
inducers	1
.	0

Double-stimulation	0
was	0
used	0
to	0
demonstrate	0
that	0
,	0
in	0
a	0
T	5
lymphocytic	6
cell	6
line	6
(	0
CEM	5
)	0
,	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
rapidly	0
induced	0
NF-kappa	9
B	10
through	0
a	0
signaling	0
pathway	0
which	0
did	0
not	0
involve	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
and	0
was	0
different	0
from	0
the	0
activation	0
triggered	0
by	0
either	0
H2O2	0
or	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

Since	0
these	0
latter	0
compounds	0
were	0
known	0
to	0
activate	0
NF-kappa	9
B	10
translocation	0
in	0
a	0
redox-sensitive	0
way	0
,	0
we	0
have	0
demonstrated	0
that	0
NF-kappa	9
B	10
activation	0
by	0
PMA	0
was	0
resistant	0
to	0
antioxidant	0
N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
and	0
sensitive	0
to	0
kinase	0
inhibitors	0
staurosporine	0
and	0
H7	0
while	0
activation	0
by	0
H2O2	0
or	0
TNF-alpha	9
were	0
not	0
.	0

Blockade	0
of	0
T-cell	0
activation	0
by	0
dithiocarbamates	0
involves	0
novel	0
mechanisms	0
of	0
inhibition	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

Dithiocarbamates	0
(	0
DTCs	0
)	0
have	0
recently	0
been	0
reported	0
as	0
powerful	0
inhibitors	0
of	0
NF-kappaB	9
activation	0
in	0
a	0
number	0
of	0
cell	0
types	0
.	0

Given	0
the	0
role	0
of	0
this	0
transcription	0
factor	0
in	0
the	0
regulation	0
of	0
gene	0
expression	0
in	0
the	0
inflammatory	0
response	0
,	0
NF-kappaB	9
inhibitors	0
have	0
been	0
suggested	0
as	0
potential	0
therapeutic	0
drugs	0
for	0
inflammatory	0
diseases	0
.	0

We	0
show	0
here	0
that	0
DTCs	0
inhibited	0
both	0
interleukin	9
2	10
(	0
IL-2	9
)	0
synthesis	0
and	0
membrane	0
expression	0
of	0
antigens	9
which	0
are	0
induced	0
during	0
T-cell	0
activation	0
.	0

This	0
inhibition	0
,	0
which	0
occurred	0
with	0
a	0
parallel	0
activation	0
of	0
c-Jun	9
transactivating	0
functions	0
and	0
expression	0
,	0
was	0
reflected	0
by	0
transfection	0
experiments	0
at	0
the	0
IL-2	1
promoter	2
level	0
,	0
and	0
involved	0
not	0
only	0
the	0
inhibition	0
of	0
NF-kappaB	9
-driven	0
reporter	0
activation	0
but	0
also	0
that	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
.	0

Accordingly	0
,	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
indicated	0
that	0
pyrrolidine	0
DTC	0
(	0
PDTC	0
)	0
prevented	0
NF-kappaB	9
,	0
and	0
NFAT	9
DNA-binding	0
activity	0
in	0
T	7
cells	8
stimulated	0
with	0
either	0
phorbol	0
myristate	0
acetate	0
plus	0
ionophore	0
or	0
antibodies	0
against	0
the	0
CD3-T-cell	9
receptor	10
complex	10
and	0
simultaneously	0
activated	0
the	0
binding	0
of	0
AP-1	9
.	0

Furthermore	0
,	0
PDTC	0
differentially	0
targeted	0
both	0
NFATp	9
and	10
NFATc	10
family	10
members	10
,	0
inhibiting	0
the	0
transactivation	0
functions	0
of	0
NFATp	9
and	0
mRNA	0
induction	0
of	0
NFATc	9
.	0

Strikingly	0
,	0
Western	0
blotting	0
and	0
immunocytochemical	0
experiments	0
indicated	0
that	0
PDTC	0
promoted	0
a	0
transient	0
and	0
rapid	0
shuttling	0
of	0
NFATp	9
and	0
NFATc	9
,	0
leading	0
to	0
their	0
accelerated	0
export	0
from	0
the	0
nucleus	0
of	0
activated	7
T	8
cells	8
.	0

We	0
propose	0
that	0
the	0
activation	0
of	0
an	0
NFAT	0
kinase	0
by	0
PDTC	0
could	0
be	0
responsible	0
for	0
the	0
rapid	0
shuttling	0
of	0
the	0
NFAT	9
,	0
therefore	0
transiently	0
converting	0
the	0
sustained	0
transactivation	0
of	0
this	0
transcription	9
factor	10
that	0
occurs	0
during	0
lymphocyte	0
activation	0
,	0
and	0
show	0
that	0
c-Jun	9
NH2-terminal	10
kinase	10
(	0
JNK	9
)	0
can	0
act	0
by	0
directly	0
phosphorylating	0
NFATp	9
.	0

In	0
addition	0
,	0
the	0
combined	0
inhibitory	0
effects	0
on	0
NFAT	9
and	0
NF-KB	9
support	0
a	0
potential	0
use	0
of	0
DTCs	0
as	0
immunosuppressants	0
.	0

Activation	0
of	0
a	0
novel	1
gene	2
in	0
3q21	1
and	0
identification	0
of	0
intergenic	0
fusion	0
transcripts	0
with	0
ecotropic	1
viral	2
insertion	2
site	2
I	2
in	0
leukemia	0
.	0

We	0
have	0
identified	0
a	0
novel	1
gene	2
,	0
GR6	1
,	0
located	0
within	0
the	0
leukemia	0
breakpoint	0
region	0
of	0
3q21	1
,	0
that	0
is	0
normally	0
expressed	0
in	0
early	0
fetal	0
development	0
but	0
not	0
in	0
adult	0
peripheral	0
blood	0
.	0

GR6	1
is	0
activated	0
in	0
the	0
UCSD-AML1	5
cell	6
line	6
and	0
in	0
a	0
leukemic	5
sample	6
,	0
both	0
of	0
which	0
carry	0
a	0
t	1
(	2
3	2
;	2
3	2
)	2
(	2
q21	2
;	2
q26	2
)	2
.	0

In	0
UCSD-AML1	5
,	0
we	0
have	0
also	0
identified	0
fusion	3
transcripts	4
between	0
the	0
ecotropic	1
viral	2
insertion	2
site	2
I	2
(	2
EVI1	2
)	2
gene	2
in	0
3q26	1
and	0
GR6	1
and	0
between	0
EVI1	1
and	0
Ribophorin	1
I	2
that	0
maps	0
30	0
kb	0
telomeric	0
to	0
GR6	1
in	0
3q21	1
.	0

All	0
fusions	0
splice	0
the	0
5	1
'	2
ends	2
of	0
the	0
3q21	1
genes	2
into	0
exon	1
2	2
of	0
the	0
EVI1	1
gene	0
,	0
an	0
event	0
that	0
is	0
similar	0
to	0
the	0
normal	0
intergenic	0
splicing	0
of	0
MDS1-EVI1	1
and	0
to	0
those	0
previously	0
documented	0
in	0
leukemias	0
with	0
t	1
(	2
3	2
;	2
21	2
)	2
and	0
t	1
(	2
3	2
;	2
12	2
)	2
,	0
in	0
which	0
acute	0
myelogenous	1
leukemia	2
1-EVI1	2
fusions	2
and	0
ETV6-EVI1	1
fusions	2
,	0
respectively	0
,	0
occur	0
.	0

The	0
Ribophorin	1
I-EVI1	2
fusion	2
in	0
particular	0
may	0
be	0
a	0
common	0
occurrence	0
in	0
t	1
(	2
3	2
;	2
3	2
)	2
.	0

The	0
A-myb	9
transcription	10
factor	10
in	0
neoplastic	7
and	8
normal	8
B	8
cells	8
.	0

The	0
myb	9
family	10
of	0
transcription	9
factors	10
has	0
been	0
strongly	0
implicated	0
in	0
the	0
regulation	0
of	0
cell	0
growth	0
and	0
differentiation	0
in	0
the	0
haematopoietic	0
system	0
.	0

The	0
v-myb	1
oncogene	2
,	0
carried	0
by	0
avian	0
defective	0
retroviruses	0
,	0
causes	0
leukaemias	0
in	0
the	0
chicken	0
and	0
transforms	0
haematopoietic	7
cells	8
in	0
vitro	0
.	0

Its	0
normal	0
cellular	0
equivalent	0
c-myb	1
,	0
has	0
been	0
shown	0
to	0
promote	0
the	0
proliferation	0
and	0
block	0
the	0
differentiation	0
of	0
haematopoietic	7
cells	8
in	0
several	0
experimental	0
models	0
and	0
is	0
required	0
for	0
fetal	0
haematopoiesis	0
.	0

Two	0
other	0
members	0
of	0
the	0
family	0
have	0
been	0
cloned	0
more	0
recently	0
,	0
A-myb	9
and	0
B-myb	9
,	0
which	0
show	0
sequence	0
homology	0
with	0
c-myb	1
in	0
several	0
domains	0
,	0
of	0
which	0
the	0
DNA	9
binding	10
domain	10
as	0
well	0
as	0
other	0
regulatory	9
domains	10
.	0

Both	0
have	0
been	0
shown	0
to	0
be	0
transcription	9
factors	10
.	0

B-myb	9
is	0
also	0
involved	0
in	0
the	0
control	0
of	0
proliferation	0
and	0
differentiation	0
,	0
but	0
,	0
unlike	0
c-myb	1
,	0
it	0
is	0
expressed	0
in	0
many	0
cell	0
types	0
.	0

The	0
third	0
member	0
of	0
the	0
family	9
,	0
A-myb	9
,	0
shows	0
the	0
most	0
restricted	0
pattern	0
of	0
expression	0
,	0
suggesting	0
a	0
very	0
specific	0
role	0
for	0
this	0
transcription	9
factor	10
.	0

A-myb	9
is	0
expressed	0
in	0
a	0
subpopulation	0
of	0
normal	7
B	8
lymphocytes	8
activated	0
in	0
vivo	0
and	0
localised	0
in	0
the	0
germinal	0
center	0
of	0
peripheral	0
lymphoid	0
organs	0
and	0
is	0
not	0
detected	0
at	0
significant	0
levels	0
in	0
all	0
other	0
mature	0
or	0
immature	7
haematopoietic	8
populations	8
studied	0
,	0
including	0
bone	7
marrow	8
cells	8
,	0
T	7
lymphocytes	8
,	0
granulocytes	7
,	0
monocytes	7
,	0
either	0
at	0
rest	0
or	0
after	0
in	0
vitro	0
activation	0
.	0

These	0
studies	0
indicate	0
that	0
A-myb	9
plays	0
a	0
role	0
during	0
a	0
narrow	0
window	0
of	0
normal	7
B	8
cell	8
differentiation	0
.	0

A-myb	9
expression	0
has	0
also	0
been	0
studied	0
in	0
a	0
wide	0
range	0
of	0
neoplastic	7
B	8
cells	8
,	0
representing	0
the	0
whole	0
spectrum	0
of	0
B	0
cell	0
differentiation	0
.	0

A-myb	9
is	0
strongly	0
expressed	0
in	0
Burkitt	0
's	0
lymphomas	0
(	0
BL	0
)	0
and	0
slg+	0
B-acute	0
lymphoblastic	0
leukaemias	0
(	0
B-ALL	0
)	0
and	0
not	0
in	0
all	0
other	0
leukaemias/lymphomas	0
tested	0
,	0
with	0
the	0
exception	0
of	0
a	0
subset	0
of	0
CLL	0
(	0
about	0
25	0
%	0
of	0
cases	0
)	0
.	0

It	0
is	0
intriguing	0
that	0
the	0
A-myb	1
genome	2
has	0
been	0
localised	0
relatively	0
close	0
to	0
the	0
c-myc	1
gene	2
on	0
chromosome	1
8	2
,	0
suggesting	0
that	0
the	0
c-myc	0
translocation	0
in	0
BL	0
and	0
B-ALL	0
may	0
affect	0
A-myb	9
transcription	0
.	0

Studies	0
are	0
in	0
progress	0
to	0
investigate	0
the	0
functional	0
relationship	0
between	0
A-myb	9
and	0
c-myc	1
,	0
particularly	0
in	0
the	0
context	0
of	0
BL	7
cells	8
and	0
to	0
determine	0
whether	0
A-myb	9
is	0
deregulated	0
in	0
these	0
cells	0
.	0

Expression	0
of	0
bcl-6	9
protein	10
in	0
normal	0
skin	0
and	0
epidermal	0
neoplasms	0
.	0

Bcl-6	9
protein	10
is	0
a	0
recently	0
identified	0
novel	0
transcription	9
factor	10
whose	0
deregulated	0
expression	0
is	0
associated	0
with	0
diffuse	0
large	0
B	0
cell	0
lymphomas	0
.	0

It	0
was	0
recently	0
shown	0
by	0
us	0
that	0
the	0
protein	0
is	0
located	0
in	0
germinal	7
center	8
B	8
cells	8
and	0
their	0
neoplastic	7
counterparts	8
.	0

In	0
the	0
present	0
study	0
,	0
the	0
expression	0
of	0
bcl-6	9
protein	10
on	0
normal	0
epidermis	0
,	0
benign	0
,	0
and	0
malignant	0
tumors	0
originating	0
from	0
epidermal	7
cells	8
,	0
and	0
squamous	5
cell	6
carcinoma	6
(	6
SCC	6
)	6
cell	6
lines	6
are	0
investigated	0
.	0

With	0
the	0
use	0
of	0
immunohistochemistry	0
,	0
bcl-6	9
protein	10
was	0
shown	0
to	0
stain	0
intensely	0
on	0
normal	5
prickle	6
cells	6
,	0
but	0
none	0
to	0
only	0
slightly	0
on	0
epidermal	7
basal	8
cells	8
.	0

Papillomas	0
and	0
keratoacanthomas	0
copied	0
their	0
normal	0
counterparts	0
in	0
the	0
mode	0
of	0
expression	0
.	0

Various	0
levels	0
of	0
expression	0
were	0
found	0
on	0
seborrheic	0
keratoses	0
,	0
while	0
the	0
expression	0
level	0
on	0
basal	0
cell	0
epitheliomas	0
was	0
low	0
.	0

Peculiarly	0
,	0
eccrine	0
poromas	0
and	0
undifferentiated	0
spindle-shaped	0
basal	0
cell	0
epitheliomas	0
were	0
totally	0
unstained	0
.	0

Squamous	0
cell	0
carcinomas	0
showed	0
a	0
variety	0
of	0
expression	0
levels	0
,	0
while	0
two	0
undifferentiated	0
spindle-shaped	0
carcinomas	0
and	0
one	0
undifferentiated	0
SCC	5
cell	6
line	6
remained	0
unstained	0
.	0

These	0
results	0
suggest	0
that	0
the	0
expression	0
of	0
bcl-6	9
protein	10
may	0
be	0
associated	0
with	0
morphological	0
differentiation	0
in	0
normal	0
and	0
neoplastic	7
epidermal	8
cells	8
.	0

Sp3	9
mediates	0
transcriptional	0
activation	0
of	0
the	0
leukocyte	1
integrin	2
genes	2
CD11C	1
and	0
CD11B	1
and	0
cooperates	0
with	0
c-Jun	0
to	0
activate	0
CD11C	1
.	0

The	0
leukocyte	1
integrin	2
genes	2
CD11c	1
and	0
CD11b	1
are	0
expressed	0
predominately	0
in	0
myelomonocytic	0
cells	0
.	0

In	0
previous	0
experiments	0
,	0
the	0
-70	1
to	2
-65	2
and	2
-121	2
to	2
-103	2
regions	2
of	0
the	0
CD11c	1
promoter	2
and	0
the	0
-66	1
to	2
-59	2
region	2
of	0
the	0
CD11b	1
promoter	2
were	0
shown	0
to	0
be	0
essential	0
for	0
Sp1-	9
mediated	0
activation	0
of	0
these	0
genes	0
.	0

In	0
vivo	0
genomic	0
footprinting	0
had	0
also	0
revealed	0
cell-specific	0
binding	0
of	0
protein	0
,	0
presumably	0
Sp1	9
,	0
to	0
these	0
regions	0
.	0

In	0
this	0
study	0
,	0
electrophoretic	0
mobility	0
shift	0
analysis	0
showed	0
that	0
the	0
Sp1-related	9
factor	10
,	0
Sp3	9
,	0
also	0
binds	0
at	0
or	0
near	0
these	0
same	0
regions	0
.	0

Cotransfection	0
of	0
Sp3	9
along	0
with	0
CD11c	1
promoter-luciferase	2
constructs	2
into	0
Sp-deficient	5
Drosophila	6
Schneider	6
2	6
cells	6
showed	0
that	0
Sp3	9
could	0
activate	0
the	0
CD11c	1
promoter	2
.	0

Deletion	0
of	0
both	0
the	0
-70	1
to	2
-65	2
and	2
-121	2
to	2
-103	2
regions	2
of	0
the	0
CD11c	1
promoter	2
resulted	0
in	0
the	0
loss	0
of	0
activation	0
by	0
Sp3	9
.	0

Both	0
sites	0
showed	0
activation	0
by	0
Sp3	9
;	0
however	0
,	0
the	0
-70	1
to	2
-65	2
region	2
was	0
more	0
responsive	0
to	0
Sp3	9
than	0
to	0
Sp1	9
.	0

Similar	0
transfection	0
analysis	0
of	0
the	0
-66	1
to	2
-59	2
region	2
of	0
the	0
CD11b	1
promoter	2
showed	0
Sp3	9
-dependent	0
expression	0
.	0

Further	0
,	0
cotransfection	0
analysis	0
in	0
Drosophila	5
cells	6
showed	0
that	0
Sp3	9
,	0
as	0
was	0
previously	0
shown	0
for	0
Sp1	9
,	0
also	0
synergizes	0
with	0
c-Jun	9
to	0
activate	0
CD11c	1
.	0

Antisense	0
experiments	0
that	0
knocked	0
out	0
endogenous	0
Sp3	9
expression	0
in	0
the	0
myelomocytic	5
cell	6
line	6
,	0
HL60	5
,	0
revealed	0
that	0
Sp3	9
participates	0
in	0
activation	0
of	0
the	0
CD11c	1
and	2
CD11b	2
promoters	2
in	0
vivo	0
.	0

The	0
winged-helix	9
transcription	10
factor	10
Trident	9
is	0
expressed	0
in	0
actively	0
dividing	7
lymphocytes	8
.	0

We	0
recently	0
identified	0
the	0
winged-helix	9
transcription	10
factor	10
Trident	9
and	0
described	0
its	0
expression	0
pattern	0
in	0
synchronized	7
fibroblasts	8
.	0

We	0
have	0
now	0
studied	0
Trident	9
expression	0
in	0
cell	5
lines	6
,	0
differentiating	7
thymocytes	8
and	0
in	0
lymphocytes	0
derived	0
from	0
peripheral	0
blood	0
.	0

During	0
T	0
cell	0
differentiation	0
,	0
expression	0
peaked	0
in	0
the	0
actively	7
dividing	8
immature	8
single	8
positive	8
cells	8
.	0

In	0
peripheral	0
blood	0
lymphocytes	0
,	0
expression	0
of	0
Trident	3
mRNA	4
was	0
absent	0
,	0
but	0
could	0
be	0
induced	0
upon	0
stimulation	0
with	0
mitogens	0
in	0
vitro	0
.	0

These	0
observations	0
imply	0
a	0
function	0
for	0
Trident	9
in	0
dividing	7
lymphocytes	8
.	0

Estrogen	9
receptor	10
diminishes	0
DNA-binding	0
activities	0
of	0
chicken	9
GATA-1	10
and	0
CACCC-binding	9
proteins	10
.	0

The	0
estrogen	9
receptor	10
(	0
ER	9
)	0
repressed	0
erythroid	0
differentiation	0
and	0
erythroid-specific	1
gene	2
expression	0
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
effect	0
of	0
ER	9
alpha	10
(	0
referred	0
to	0
throughout	0
as	0
ER	9
)	0
on	0
DNA-binding	0
activities	0
of	0
transcription	9
factors	10
involved	0
in	0
regulating	0
the	0
expression	0
of	0
erythroid-specific	1
genes	2
,	0
and	0
,	0
in	0
particular	0
,	0
the	0
histone	1
H5	2
gene	2
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
we	0
found	0
that	0
in	0
the	0
presence	0
of	0
rabbit	0
reticulocyte	0
lysate	0
,	0
human	9
ER	10
reduced	0
the	0
binding	0
activities	0
of	0
chicken	9
immature	10
erythrocyte	10
nuclear	10
extracted	10
proteins	10
to	0
GATA	1
and	2
CACCC	2
sites	2
in	0
the	0
H5	1
promoter	2
and	2
enhancer	2
.	0

In	0
contrast	0
,	0
the	0
binding	0
activities	0
of	0
NF1	9
and	0
Sp1	9
were	0
not	0
affected	0
by	0
ER	9
.	0

Binding	0
of	0
ER	9
to	0
an	0
estrogen	1
response	2
element	2
was	0
enhanced	0
by	0
addition	0
of	0
rabbit	0
reticulocyte	0
lysate	0
.	0

This	0
lysate	0
was	0
also	0
necessary	0
for	0
ER	9
to	0
diminish	0
the	0
DNA-binding	0
activity	0
of	0
GATA-1	9
.	0

These	0
results	0
suggest	0
that	0
additional	0
factor	0
(	0
s	0
)	0
are	0
necessary	0
for	0
full	0
ER	9
function	0
.	0

Both	0
GATA-1	9
and	0
CACCC-binding	9
proteins	10
are	0
critical	0
for	0
the	0
developmentally	0
regulated	0
expression	0
of	0
erythroid-specific	1
genes	2
.	0

We	0
hypothesize	0
that	0
interference	0
in	0
DNA-binding	0
activities	0
of	0
GATA-1	9
and	0
CACCC-binding	9
proteins	10
is	0
the	0
mechanism	0
by	0
which	0
the	0
ER	9
inhibits	0
regulation	0
of	0
these	0
genes	0
.	0

Regulation	0
of	0
Id3	9
cell	0
cycle	0
function	0
by	0
Cdk-2-dependent	0
phosphorylation	0
.	0

The	0
functions	0
of	0
basic	9
helix-loop-helix	10
(	10
bHLH	10
)	10
transcription	10
factors	10
in	0
activating	0
differentiation-linked	0
gene	0
expression	0
and	0
in	0
inducing	0
G1	0
cell	0
cycle	0
arrest	0
are	0
negatively	0
regulated	0
by	0
members	0
of	0
the	0
Id	9
family	10
of	10
HLH	10
proteins	10
.	0

These	0
bHLH	9
antagonists	10
are	0
induced	0
during	0
a	0
mitogenic	0
signalling	0
response	0
,	0
and	0
they	0
function	0
by	0
sequestering	0
their	0
bHLH	9
targets	10
in	0
inactive	9
heterodimers	10
that	0
are	0
unable	0
to	0
bind	0
to	0
specific	0
gene	1
regulatory	2
(	2
E	2
box	2
)	2
sequences	2
.	0

Recently	0
,	0
cyclin	0
E-Cdk2-	0
and	0
cyclin	0
A-Cdk2-dependent	0
phosphorylation	0
of	0
a	0
single	0
conserved	0
serine	0
residue	0
(	0
Ser5	0
)	0
in	0
Id2	9
has	0
been	0
shown	0
to	0
occur	0
during	0
late	0
G1-to-S	0
phase	0
transition	0
of	0
the	0
cell	0
cycle	0
,	0
and	0
this	0
neutralizes	0
the	0
function	0
of	0
Id2	9
in	0
abrogating	0
E-box-dependent	9
bHLH	10
homo	0
-or	0
heterodimer	0
complex	0
formation	0
in	0
vitro	0
(	0
E.Hara	0
,	0
M.Hall	0
,	0
and	0
G.Peters	0
,	0
EMBO	0
J.16	0
:	0
332-342	0
,	0
1997	0
)	0
.	0

We	0
now	0
show	0
that	0
an	0
analogous	0
cell-cycle-regulated	0
phosphorylation	0
of	0
Id3	9
alters	0
the	0
specificity	0
of	0
Id3	9
for	0
abrogating	0
both	0
E-box-dependent	9
bHLH	10
homo-	0
or	0
heterodimer	0
complex	0
formation	0
in	0
vitro	0
and	0
E-box-dependent	0
reporter	1
gene	2
function	0
in	0
vivo	0
.	0

Furthermore	0
,	0
compared	0
with	0
wild-type	9
Id3	10
,	0
an	0
Id3	9
Asp5	10
mutant	10
(	0
mimicking	0
phosphorylation	0
)	0
is	0
unable	0
to	0
promote	0
cell	0
cycle	0
S	0
phase	0
entry	0
in	0
transfected	5
fibroblasts	6
,	0
whereas	0
an	0
Id3	9
Ala5	10
mutant	10
(	0
ablating	0
phosphorylation	0
)	0
displays	0
an	0
activity	0
significantly	0
greater	0
than	0
that	0
of	0
wild-type	9
Id3	10
protein	10
.	0

Cdk2-dependent	0
phosphorylation	0
therefore	0
provides	0
a	0
switch	0
during	0
late	0
G1-to-S	0
phase	0
that	0
both	0
nullifies	0
an	0
early	0
G1	0
cell	0
cycle	0
regulatory	0
function	0
of	0
Id3	9
and	0
modulates	0
its	0
target	0
bHLH	9
specificity	0
.	0

These	0
data	0
also	0
demonstrate	0
that	0
the	0
ability	0
of	0
Id3	9
to	0
promote	0
cell	0
cycle	0
S	0
phase	0
entry	0
is	0
not	0
simply	0
a	0
function	0
of	0
its	0
ability	0
to	0
modulate	0
bHLH	9
heterodimer-dependent	0
gene	0
expression	0
and	0
establish	0
a	0
biologically	0
important	0
mechanism	0
through	0
which	0
Cdk2	0
and	0
Id-bHLH	0
functions	0
are	0
integrated	0
in	0
the	0
coordination	0
of	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

Molecular	0
cloning	0
and	0
functional	0
characterization	0
of	0
murine	9
cDNA	10
encoding	10
transcription	10
factor	10
NFATc	9
.	0

Transcription	9
factors	10
of	0
the	0
NFAT	9
(	10
nuclear	10
factor	10
of	10
activated	10
T	10
cells	10
)	10
family	10
play	0
important	0
roles	0
in	0
immune	0
and	0
inflammatory	0
responses	0
by	0
regulating	0
the	0
expression	0
of	0
genes	0
encoding	0
cytokines	9
and	0
immunoregulatory	9
proteins	10
.	0

Here	0
we	0
describe	0
cloning	0
and	0
characterization	0
of	0
full-length	0
cDNA	9
encoding	10
murine	10
(	10
m	10
)	10
NFATc	10
which	0
predicts	0
that	0
the	0
protein	0
has	0
all	0
the	0
conserved	9
structural	10
motifs	10
of	0
NFAT	9
family	10
members	10
,	0
including	0
the	0
rel	0
homology	0
domain	0
,	0
the	0
NFAT	9
homology	10
domain	10
and	0
the	0
nuclear	0
translocation	0
signals	0
.	0

mNFATc	9
complexed	0
with	0
AP-1	9
bound	0
specifically	0
to	0
the	0
murine	9
IL-2	10
NFAT	10
recognition	10
sequence	10
and	0
activated	0
transcription	0
from	0
the	0
co-transfected	1
IL-2	2
promoter	2
in	0
COS-7	5
cells	6
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
the	0
cDNA	1
probe	2
hybridized	0
with	0
a	0
4.5	0
kb	0
transcript	0
which	0
is	0
highly	0
inducible	0
in	0
murine	7
T	8
cells	8
.	0

By	0
Northern	0
and	0
in	0
situ	0
hybridization	0
,	0
mNFATc	3
transcript	4
was	0
detected	0
from	0
the	0
early	0
stage	0
of	0
development	0
.	0

In	0
the	0
mouse	0
embryo	0
,	0
mNFATc	3
transcript	4
was	0
strongly	0
expressed	0
in	0
thymus	0
,	0
lung	0
and	0
submandibular	0
gland	0
and	0
weakly	0
in	0
skeletal	0
muscle	0
and	0
heart	0
suggesting	0
that	0
mNFATc	9
may	0
have	0
a	0
role	0
both	0
in	0
embryogenesis	0
and	0
in	0
mature	7
T	8
cells	8
.	0

TNFalpha	9
cooperates	0
with	0
the	0
protein	9
kinase	10
A	10
pathway	0
to	0
synergistically	0
increase	0
HIV-1	1
LTR	2
transcription	0
via	0
downstream	0
TRE-like	1
cAMP	2
response	2
elements	2
.	0

Activating	9
protein-1	10
(	0
AP-1	9
)	0
binding	0
TPA	1
responsive	2
elements	2
(	0
TRE	1
)	0
are	0
located	0
downstream	0
of	0
the	0
transcription	1
initiation	2
site	2
in	0
the	0
U5	1
region	2
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

These	0
downstream	1
sequence	2
elements	2
,	0
termed	0
DSE	1
,	0
can	0
bind	0
both	0
AP-1	9
and	0
CREB/ATF	9
transcription	9
factors	10
.	0

Recently	0
,	0
we	0
demonstrated	0
that	0
the	0
DSE	1
are	0
also	0
cAMP-responsive	1
elements	2
(	0
CRE	1
)	0
,	0
since	0
they	0
mediated	0
activation	0
signals	0
elicited	0
by	0
cholera	9
toxin	10
(	0
Ctx	9
)	0
,	0
a	0
potent	0
activator	0
of	0
the	0
cAMP-dependent	0
protein	9
kinase	10
A	10
(	0
PKA	9
)	0
signal	0
transduction	0
pathway	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
demonstrate	0
that	0
the	0
HIV-1	1
DSE	2
can	0
mediate	0
the	0
transcriptional	0
synergy	0
elicited	0
by	0
the	0
combination	0
of	0
Ctx	9
and	0
TNFalpha	9
.	0

Ctx	9
combined	0
with	0
TNFalpha	9
or	0
IL-1beta	9
to	0
produce	0
a	0
synergistic	0
increase	0
in	0
p24	9
antigen	10
production	0
in	0
U1	5
promonocytic	6
cells	6
.	0

Transfection	0
studies	0
of	0
LTR	1
reporter	2
constructs	2
indicated	0
that	0
mutation	0
of	0
the	0
DSE	1
sites	2
abrogated	0
the	0
LTR	1
-mediated	0
synergy	0
induced	0
by	0
Ctx	9
and	0
TNFalpha	9
,	0
whereas	0
the	0
synergy	0
induced	0
by	0
Ctx	9
and	0
IL-1beta	9
was	0
unaffected	0
,	0
suggesting	0
TNFalpha	9
and	0
IL-1beta	9
cooperate	0
differently	0
with	0
the	0
cAMP	0
/PKA	9
activation	0
pathway	0
to	0
induce	0
HIV-1	0
expression	0
in	0
U1	5
cells	6
.	0

Because	0
the	0
DSE	1
are	0
also	0
TRE	1
sites	0
,	0
we	0
assessed	0
the	0
effect	0
of	0
the	0
agonist	0
combinations	0
on	0
AP-1	9
-dependent	0
transcription	0
.	0

TNFalpha	9
as	0
well	0
as	0
IL-1beta	9
cooperated	0
with	0
Ctx	9
to	0
produce	0
a	0
synergistic	0
activation	0
of	0
AP-1	9
-mediated	0
transcription	0
.	0

These	0
data	0
indicate	0
that	0
the	0
TRE-like	1
cAMP-responsive	2
DSE	2
sites	2
within	0
the	0
5'-untranslated	1
leader	2
can	0
mediate	0
the	0
transcriptional	0
cooperativity	0
between	0
TNFalpha	9
and	0
the	0
cAMP	0
/PKA	9
pathway	0
.	0

Since	0
the	0
DSE	1
and	0
TRE	1
sites	0
can	0
not	0
bind	0
CREB/ATF	9
homodimers	10
,	0
we	0
propose	0
a	0
mechanism	0
in	0
which	0
the	0
HIV-1	0
DSE	1
bind	0
heterodimers	9
composed	0
of	0
both	0
AP-1	9
and	10
CREB/ATF	10
proteins	10
.	0

Copyright	0
1997	0
Academic	0
Press	0
.	0

Association	0
of	0
glucocorticoid	0
insensitivity	0
with	0
increased	0
expression	0
of	0
glucocorticoid	9
receptor	10
beta	10
.	0

In	0
many	0
chronic	0
inflammatory	0
disorders	0
,	0
glucocorticoid	0
(	0
GC	0
)	0
insensitivity	0
is	0
a	0
challenging	0
clinical	0
problem	0
associated	0
with	0
life-threatening	0
disease	0
progression	0
.	0

The	0
molecular	0
basis	0
of	0
GC	0
insensitivity	0
,	0
however	0
,	0
is	0
unknown	0
.	0

Alternative	0
splicing	0
of	0
the	0
GC	3
receptor	4
(	4
R	4
)	4
pre-messenger	4
RNA	4
generates	0
a	0
second	0
GCR	9
,	0
termed	0
GCR-beta	9
,	0
which	0
does	0
not	0
bind	0
GCs	0
but	0
antagonizes	0
the	0
transactivating	0
activity	0
of	0
the	0
classic	0
GCR	9
,	0
termed	0
GCR-alpha	9
.	0

In	0
the	0
current	0
study	0
,	0
we	0
demonstrate	0
that	0
GC-insensitive	0
asthma	0
is	0
associated	0
with	0
a	0
significantly	0
higher	0
number	0
of	0
GCR-beta-immunoreactive	7
cells	8
in	0
peripheral	0
blood	0
than	0
GC-sensitive	0
asthmatics	0
or	0
normal	0
controls	0
.	0

Furthermore	0
,	0
we	0
show	0
that	0
patients	0
with	0
GC-insensitive	0
asthma	0
have	0
cytokine-induced	0
abnormalities	0
in	0
the	0
DNA	0
binding	0
capability	0
of	0
the	0
GCR	9
.	0

These	0
abnormalities	0
can	0
be	0
reproduced	0
by	0
transfection	0
of	0
cell	5
lines	6
with	0
the	0
GCR-beta	9
gene	0
resulting	0
in	0
significant	0
reduction	0
of	0
their	0
GCR-alpha	9
DNA	0
binding	0
capacity	0
.	0

We	0
conclude	0
that	0
increased	0
expression	0
of	0
GCR-beta	9
is	0
cytokine	9
inducible	0
and	0
may	0
account	0
for	0
GC	0
insensitivity	0
in	0
this	0
common	0
inflammatory	0
condition	0
.	0

Epstein-Barr	0
virus	0
EBNA3C	9
represses	0
Cp	1
,	0
the	0
major	0
promoter	0
for	0
EBNA	9
expression	0
,	0
but	0
has	0
no	0
effect	0
on	0
the	0
promoter	0
of	0
the	0
cell	1
gene	2
CD21	2
.	0

EBNA3C	9
is	0
a	0
potent	0
repressor	0
of	0
transcription	0
when	0
bound	0
to	0
DNA	0
as	0
a	0
fusion	0
with	0
the	0
DNA	9
binding	10
domain	10
(	0
DBD	9
)	0
of	0
GALA	0
.	0

A	0
survey	0
of	0
promoters	0
has	0
revealed	0
that	0
the	0
wild-type	9
,	10
unfused	10
EBNA3C	10
can	0
specifically	0
repress	0
expression	0
from	0
reporter	1
plasmids	2
containing	0
the	0
Epstein-Barr	0
virus	0
Cp	1
latency-associated	2
promoter	2
.	0

Repression	0
of	0
Cp	1
activity	0
required	0
amino	9
acids	10
207	10
to	10
368	10
,	0
which	0
encompasses	0
a	0
region	0
resembling	0
a	0
basic	9
DBD	10
adjacent	0
to	0
a	0
leucine	9
zipper	10
DNA	10
binding	10
motif	10
and	0
a	0
site	0
which	0
binds	0
to	0
the	0
cellular	9
factor	10
CBF1/RBP-Jkappa	10
.	0

However	0
,	0
amino	0
acids	0
207	0
to	0
368	0
are	0
dispensable	0
when	0
the	0
protein	0
is	0
bound	0
to	0
DNA	0
as	0
a	0
fusion	0
with	0
the	0
GAL4	0
DBD	9
,	0
thus	0
implicating	0
this	0
region	0
in	0
DNA	0
binding	0
.	0

Mutation	0
of	0
the	0
CBF1/RBP-Jkappa	9
binding	10
site	10
in	0
EBNA3C	9
abrogated	0
repression	0
,	0
strongly	0
suggesting	0
that	0
CBF1/RBP-Jkappa	9
is	0
necessary	0
for	0
targeting	0
the	0
viral	0
protein	0
to	0
Cp	1
.	0

Consistent	0
with	0
this	0
result	0
,	0
mutation	0
of	0
the	0
EBNA2	1
response	2
element	2
(	0
a	0
CBF1/RBP-Jkappa	1
binding	2
site	2
)	0
in	0
Cp	1
also	0
prevented	0
significant	0
repression	0
.	0

In	0
addition	0
,	0
amino	9
acids	10
346	10
to	10
543	10
,	0
which	0
were	0
previously	0
defined	0
as	0
important	0
for	0
the	0
repressor	0
activity	0
of	0
the	0
GAL4-EBNA3C	9
fusion	10
proteins	10
,	0
also	0
appear	0
to	0
be	0
necessary	0
for	0
the	0
repression	0
of	0
Cp	1
.	0

Since	0
repression	0
by	0
these	0
fusions	0
was	0
not	0
observed	0
in	0
all	0
cell	0
types	0
,	0
it	0
seems	0
likely	0
that	0
EBNA3C	9
either	0
depends	0
on	0
a	0
corepressor	9
which	0
may	0
interact	0
with	0
amino	9
acids	10
346	10
to	10
543	10
or	0
is	0
modified	0
in	0
a	0
cell-specific	0
manner	0
in	0
order	0
to	0
repress	0
.	0

These	0
data	0
are	0
consistent	0
with	0
EBNA3C	9
contributing	0
to	0
the	0
regulation	0
of	0
EBNA	9
expression	0
in	0
latently	7
infected	8
B	8
cells	8
through	0
CBF1/RBP-Jkappa	9
and	0
another	0
factor	0
,	0
but	0
this	0
need	0
not	0
directly	0
involve	0
EBNA2	9
.	0

Finally	0
,	0
although	0
it	0
has	0
been	0
reported	0
that	0
EBNA3C	9
can	0
upregulate	0
CD21	9
in	0
some	0
B	7
cells	8
,	0
we	0
were	0
unable	0
to	0
demonstrate	0
any	0
effect	0
of	0
EBNA3C	9
on	0
reporter	1
plasmids	2
which	0
contain	0
the	0
CD21	1
promoter	2
.	0

Relationship	0
between	0
glucocorticoid	9
receptor	10
and	0
response	0
to	0
glucocorticoid	0
therapy	0
in	0
ulcerative	0
colitis	0
.	0

PURPOSE	0
:	0
To	0
clarify	0
the	0
relationship	0
between	0
the	0
glucocorticoid	9
receptor	10
and	0
the	0
effectiveness	0
of	0
glucocorticoid	0
therapy	0
in	0
patients	0
with	0
ulcerative	0
colitis	0
,	0
we	0
investigated	0
the	0
number	0
and	0
apparent	0
dissociation	0
constant	0
of	0
glucocorticoid	9
receptor	10
in	0
peripheral	7
blood	8
mononuclear	8
leukocytes	8
of	0
patients	0
with	0
ulcerative	0
colitis	0
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
Eleven	0
patients	0
with	0
ulcerative	0
colitis	0
(	0
5	0
who	0
responded	0
to	0
intravenous	0
glucocorticoids	0
and	0
6	0
who	0
did	0
not	0
)	0
and	0
ten	0
control	0
subjects	0
were	0
studied	0
.	0

The	0
number	0
and	0
apparent	0
dissociation	0
constant	0
of	0
glucocorticoid	9
receptor	10
were	0
measured	0
using	0
a	0
whole-cell	0
binding	0
assay	0
.	0

Results	0
were	0
expressed	0
as	0
a	0
median	0
(	0
interquartile	0
range	0
)	0
.	0

RESULTS	0
:	0
The	0
number	0
of	0
glucocorticoid	9
receptors	10
from	0
the	0
six	0
nonresponders	0
,	0
five	0
responders	0
,	0
and	0
ten	0
healthy	0
controls	0
were	0
4922	0
(	0
range	0
,	0
4484-5643	0
)	0
,	0
3413	0
(	0
range	0
,	0
3183-4450	0
)	0
,	0
and	0
3610	0
(	0
range	0
,	0
2594-3979	0
)	0
binding	0
sites/cell	0
,	0
respectively	0
.	0

The	0
apparent	0
dissociation	0
constant	0
of	0
the	0
glucocorticoid	9
receptors	10
from	0
the	0
nonresponders	0
,	0
responders	0
,	0
and	0
healthy	0
controls	0
were	0
7.03	0
(	0
range	0
,	0
5.66-10	0
)	0
,	0
4.27	0
(	0
range	0
,	0
4-5.13	0
)	0
,	0
and	0
6.18	0
(	0
range	0
,	0
5.86-6.74	0
)	0
nM	0
,	0
respectively	0
.	0

Nonresponders	0
had	0
a	0
significant	0
increase	0
both	0
in	0
the	0
number	0
of	0
binding	9
sites	10
and	0
in	0
the	0
apparent	0
dissociation	0
constant	0
compared	0
with	0
responders	0
(	0
P	0
=	0
0.045	0
;	0
P	0
=	0
0.029	0
)	0
.	0

CONCLUSIONS	0
:	0
The	0
increased	0
number	0
and	0
apparent	0
dissociation	0
constant	0
of	0
glucocorticoid	9
receptor	10
are	0
closely	0
associated	0
with	0
the	0
effectiveness	0
of	0
glucocorticoid	0
therapy	0
.	0

The	0
measurement	0
of	0
the	0
number	0
and	0
apparent	0
dissociation	0
constant	0
of	0
glucocorticoid	9
receptor	10
may	0
be	0
useful	0
in	0
predicting	0
response	0
to	0
glucocorticoids	0
.	0

Cooperation	0
of	0
binding	9
sites	10
for	0
STAT6	9
and	0
NF	9
kappa	10
B/rel	10
in	0
the	0
IL-4	9
-induced	0
up-regulation	0
of	0
the	0
human	1
IgE	2
germline	2
promoter	2
.	0

Ig	9
heavy	10
chain	10
class	0
switching	0
is	0
directed	0
by	0
cytokines	9
inducing	0
transcription	0
from	0
unrearranged	0
CH	1
genes	2
.	0

Subsequently	0
,	0
such	0
primed	7
cells	8
can	0
undergo	0
switch	0
recombination	0
to	0
express	0
the	0
selected	0
new	0
isotype	0
.	0

In	0
the	0
case	0
of	0
IgE	9
class	0
switching	0
,	0
IL-4	9
activates	0
the	0
IgE	1
germline	2
promoter	2
by	0
inducing	0
the	0
interaction	0
of	0
the	0
transcription	9
factor	10
STAT6	9
(	0
IL-4STAT	9
)	0
with	0
a	0
responsive	1
DNA	2
element	2
in	0
the	0
proximal	1
region	2
of	0
the	0
promoter	1
.	0

This	0
study	0
describes	0
the	0
characterization	0
of	0
two	0
additional	0
cis-acting	1
elements	2
that	0
interact	0
with	0
members	0
of	0
the	0
NF	9
kappa	10
B/rel	10
transcription	10
factor	10
family	10
in	0
an	0
IL-4	9
-independent	0
fashion	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
show	0
that	0
the	0
nucleoprotein	9
complex	10
formed	0
on	0
the	0
upstream	1
site	2
(	0
NF	9
kappa	10
B1	10
)	0
contains	0
the	0
classical	9
p50/p65	10
heterodimer	10
.	0

The	0
complex	0
on	0
the	0
proximal	1
site	2
(	0
NF	9
kappa	10
B2	10
)	0
appears	0
to	0
be	0
composed	0
of	0
p50	9
and	0
relB	9
.	0

IgE	1
germline	2
promoter	2
reporter	2
gene	2
constructs	2
carrying	0
point	0
mutations	0
in	0
the	0
NF	9
kappa	10
B2	10
site	0
were	0
largely	0
unresponsive	0
to	0
IL-4	9
stimulation	0
in	0
transient	0
transfection	0
experiments	0
,	0
while	0
plasmids	0
with	0
similar	0
mutations	0
in	0
the	0
NF	9
kappa	10
B1	10
site	0
responded	0
to	0
cytokine	9
stimulation	0
better	0
than	0
the	0
wild-type	1
promoter	2
.	0

The	0
NF	9
kappa	10
B2	10
effect	0
was	0
dependent	0
on	0
the	0
presence	0
of	0
the	0
STAT6	1
binding	2
site	2
,	0
demonstrating	0
that	0
the	0
NF	9
kappa	10
B2	10
motif	10
is	0
necessary	0
but	0
not	0
sufficient	0
for	0
mediating	0
cytokine	9
up-regulation	0
.	0

In	0
addition	0
,	0
the	0
combination	0
of	0
a	0
NF	1
kappa	2
B/rel	2
binding	2
site	2
and	0
the	0
STAT6	1
response	2
element	2
conferred	0
IL-4	9
inducibility	0
to	0
a	0
heterologous	1
minimal	2
promoter	2
,	0
while	0
the	0
individual	0
sites	0
had	0
no	0
effect	0
.	0

The	0
available	0
data	0
suggest	0
that	0
the	0
NF	9
kappa	10
B2	10
nucleoprotein	10
complex	10
may	0
cooperate	0
with	0
DNA-bound	9
STAT6	10
to	0
achieve	0
IL-4	9
-dependent	0
activation	0
of	0
the	0
human	1
IgE	2
germline	2
gene	2
.	0

Alcohol-induced	0
regulation	0
of	0
nuclear	9
regulatory	10
factor-kappa	10
beta	10
in	0
human	7
monocytes	8
.	0

Acute	0
ethanol	0
exposure	0
has	0
the	0
capacity	0
to	0
modulate	0
immune	0
functions	0
,	0
particularly	0
,	0
to	0
down	0
regulate	0
monocyte	0
production	0
of	0
inflammatory	9
cytokines	10
.	0

However	0
,	0
the	0
intracellular	0
mechanisms	0
for	0
these	0
effects	0
of	0
ethanol	0
are	0
yet	0
to	0
be	0
understood	0
.	0

Considering	0
that	0
nuclear	9
regulatory	10
factor-kappa	10
beta	10
(	9
NF-kappa	10
B	10
)	10
/Rel	10
is	0
a	0
common	0
regulatory	9
element	10
of	0
the	0
promoter	1
region	2
of	0
the	0
inflammatory	1
cytokine	2
genes	2
,	0
herein	0
,	0
we	0
tested	0
the	0
hypothesis	0
that	0
acute	0
ethanol	0
affects	0
NF-kappa	9
B	10
activation	0
in	0
human	7
monocytes	8
.	0

Adherence-isolated	5
monocytes	6
showed	0
constitutive	0
DNA	0
binding	0
activity	0
of	0
NF-kappa	9
B	10
.	0

A	0
clinically	0
relevant	0
dose	0
(	0
25	0
mM	0
)	0
of	0
acute	0
ethanol	0
treatment	0
in	0
vitro	0
increased	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
monocytes	7
with	0
a	0
preferential	0
induction	0
of	0
the	0
inhibitory	0
,	0
p50/p50	9
,	0
NF-kappa	9
B/Rel	10
homodimer	10
,	0
and	0
resulted	0
in	0
no	0
induction	0
of	0
the	0
p65/p50	9
heterodimer	10
.	0

In	0
contrast	0
,	0
lipopolysaccharide	0
stimulation	0
primarily	0
induced	0
the	0
p65/p50	9
heterodimer	10
that	0
has	0
been	0
shown	0
to	0
result	0
in	0
gene	0
activation	0
.	0

Thus	0
,	0
such	0
unique	0
activation	0
of	0
the	0
inhibitory	9
p50/p50	10
homodimer	10
by	0
acute	0
ethanol	0
treatment	0
may	0
result	0
in	0
inhibition	0
rather	0
than	0
activation	0
of	0
NF-kappa	1
B-regulated	2
inflammatory	2
cytokine	2
genes	2
.	0

Consequently	0
,	0
these	0
results	0
suggest	0
that	0
physiologically	0
relevant	0
concentrations	0
of	0
ethanol	0
may	0
affect	0
production	0
of	0
inflammatory	9
cytokines	10
,	0
such	0
as	0
tumor	9
necrosis	10
factor-alpha	10
,	0
interleukin-1	9
beta	10
,	0
and	0
interleukin-6	9
by	0
disrupting	0
NF-kappa	9
B	10
signaling	0
in	0
monocytes	7
.	0

LPS	0
tolerance	0
in	0
monocytes/macrophages	7
:	0
three	0
3	0
'	0
cytosins	0
are	0
required	0
in	0
the	0
DNA	1
binding	2
motif	2
for	0
detection	0
of	0
upregulated	0
NF-kappa	9
B	10
p50	10
homodimers	10
.	0

When	0
monocytes	7
are	0
stimulated	0
with	0
LPS	0
(	0
lipopolysaccharide	0
)	0
repeatedly	0
then	0
the	0
initially	0
high	0
expression	0
of	0
the	0
TNF	1
(	2
tumor	2
necrosis	2
factor	2
)	2
gene	2
is	0
only	0
very	0
low	0
,	0
i.e.	0
the	0
cells	0
are	0
tolerant	0
to	0
LPS	0
.	0

Tolerant	0
cells	0
still	0
express	0
the	0
CD14	9
receptor	10
and	0
they	0
can	0
still	0
be	0
activated	0
to	0
mobilize	0
NF-kappa	9
B	10
into	0
nucleus	0
.	0

Analysis	0
of	0
the	0
binding	0
proteins	0
employing	0
the	0
-605	0
motif	0
of	0
the	0
human	1
TNF	2
promoter	2
(	0
GGGGCTGTCCC	0
)	0
revealed	0
that	0
in	0
tolerant	0
cells	0
of	0
the	0
human	5
monocytic	6
cell	6
line	6
Mono	5
Mac	6
6	6
there	0
is	0
a	0
predominance	0
of	0
p50p50	9
of	0
NF-kappa	9
B	10
.	0

We	0
now	0
show	0
that	0
a	0
mutant	1
motif	2
that	0
exchanges	0
the	0
terminal	0
3	0
'	0
C	0
for	0
a	0
G	0
fails	0
to	0
bind	0
the	0
p50	9
homodimer	10
that	0
is	0
upregulated	0
in	0
LPS	0
toler	0
ant	0
human	5
Mono	6
Mac	6
6	6
cells	6
.	0

The	0
same	0
is	0
true	0
for	0
nuclear	0
extracts	0
taken	0
from	0
the	0
murine	5
P388D1	6
macrophage	6
cell	6
line	6
when	0
tested	0
with	0
the	0
-516	1
motif	2
of	0
the	0
murine	1
TNF	2
promoter	2
(	0
GGGGGCTTTCCC	0
)	0
.	0

Here	0
the	0
wild	1
type	2
motif	2
gives	0
efficient	0
binding	0
of	0
p50p50	9
that	0
again	0
is	0
upregulated	0
in	0
tolerant	7
cells	8
whereas	0
a	0
mutant	0
with	0
a	0
3	0
'	0
G	0
shows	0
hardly	0
any	0
binding	0
of	0
p50p50	9
.	0

Conversely	0
,	0
the	0
murine	1
kappa	2
light	2
chain	2
enhancer	2
motif	2
(	0
GGGGACTTTCCG	0
)	0
does	0
not	0
efficiently	0
bind	0
the	0
nuclear	0
p50p50	9
from	0
tolerant	5
murine	6
P388	6
macrophages	6
.	0

Binding	0
is	0
,	0
however	0
,	0
readily	0
detected	0
when	0
the	0
3	0
'	0
G	0
is	0
replaced	0
by	0
a	0
C	0
.	0

These	0
data	0
show	0
that	0
the	0
detection	0
of	0
upregulated	0
p50	9
homodimers	10
in	0
LPS	0
tolerant	7
cells	8
is	0
dependent	0
on	0
subtle	0
differences	0
in	0
the	0
sequence	0
of	0
the	0
DNA	1
binding	2
motif	2
.	0

Cyclosporin	0
A	0
inhibits	0
early	0
mRNA	0
expression	0
of	0
G0/G1	1
switch	2
gene	2
2	2
(	0
G0S2	1
)	0
in	0
cultured	5
human	6
blood	6
mononuclear	6
cells	6
.	0

Cyclosporin	0
A	0
(	0
CsA	0
)	0
may	0
achieve	0
its	0
immunosuppressive	0
effects	0
by	0
inhibiting	0
the	0
calcium-	9
and	10
calmodulin-dependent	10
phosphatase	10
calcineurin	9
which	0
is	0
required	0
for	0
activation	0
of	0
target	1
genes	2
by	0
members	0
of	0
the	0
NFAT	9
(	10
nuclear	10
factor	10
of	10
activated	10
T	10
cells	10
)	10
transcription	10
factor	10
family	10
.	0

Among	0
these	0
target	1
genes	2
is	0
the	0
gene	0
encoding	0
interleukin-2	9
(	0
IL2	9
)	0
,	0
a	0
cytokine	9
facilitating	0
progression	0
through	0
the	0
G1	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

However	0
,	0
IL2	9
does	0
not	0
reverse	0
CsA	0
inhibition	0
,	0
suggesting	0
that	0
at	0
least	0
one	0
other	0
NFAT-sensitive	1
gene	2
may	0
be	0
involved	0
.	0

The	0
human	1
G0/G1	2
switch	2
gene	2
,	0
G0S2	1
,	0
has	0
potential	0
NFAT-binding	1
sites	2
in	0
the	0
5	1
'	2
flank	2
and	0
encodes	0
a	0
small	9
basic	10
potential	10
phosphoprotein	10
of	0
unknown	0
function	0
.	0

Using	0
a	0
sensitive	0
,	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
assay	0
,	0
G0S2	1
mRNA	0
levels	0
were	0
assayed	0
in	0
cultured	5
blood	6
mononuclear	6
cells	6
.	0

Freshly	0
isolated	0
cells	0
contain	0
high	0
levels	0
of	0
G0S2	3
mRNA	4
which	0
rapidly	0
decline	0
.	0

This	0
``	0
spontaneous	0
stimulation	0
''	0
is	0
also	0
noted	0
with	0
some	0
other	0
G0S	1
genes	2
and	0
has	0
been	0
attributed	0
to	0
some	0
aspect	0
of	0
the	0
isolation	0
procedure	0
.	0

In	0
cells	0
that	0
have	0
been	0
preincubated	0
to	0
lower	0
mRNA	0
levels	0
,	0
there	0
is	0
a	0
transient	0
increase	0
in	0
G0S2	3
mRNA	4
,	0
peaking	0
between	0
1-2	0
h	0
,	0
in	0
response	0
to	0
Concanavalin-A	0
(	0
ConA	0
)	0
,	0
or	0
to	0
the	0
combination	0
of	0
phorbol	0
ester	0
(	0
TPA	0
)	0
,	0
and	0
the	0
calcium	0
ionophore	0
,	0
ionomycin	0
.	0

Both	0
these	0
responses	0
are	0
inhibited	0
by	0
CsA	0
.	0

Our	0
results	0
suggest	0
that	0
G0S2	1
expression	0
is	0
required	0
to	0
commit	0
cells	0
to	0
enter	0
the	0
G1	0
phase	0
of	0
the	0
cell	0
cycle	0
,	0
and	0
that	0
,	0
while	0
not	0
excluding	0
other	0
possible	0
targets	0
,	0
early	0
inhibition	0
of	0
G0S2	1
expression	0
by	0
CsA	0
may	0
be	0
important	0
in	0
achieving	0
immunosuppression	0
.	0

G0S2	1
may	0
be	0
of	0
value	0
as	0
a	0
reporter	0
gene	0
for	0
analyzing	0
the	0
mechanism	0
of	0
action	0
of	0
CsA	0
and	0
its	0
influence	0
on	0
the	0
positive	0
and	0
negative	0
selection	0
of	0
lymphocytes	7
in	0
response	0
to	0
self	0
and	0
not-self	0
antigens	0
.	0

c-Rel	9
and	10
p65	10
subunits	10
bind	0
to	0
an	0
upstream	1
NF-kappaB	2
site	2
in	0
human	1
granulocyte	2
macrophage-colony	2
stimulating	2
factor	2
promoter	2
involved	0
in	0
phorbol	0
ester	0
response	0
in	0
5637	5
cells	6
.	0

To	0
further	0
clarify	0
the	0
complex	0
transcriptional	0
regulation	0
of	0
the	0
human	1
GM-CSF	2
gene	2
,	0
which	0
was	0
extensively	0
investigated	0
in	0
activated	7
T	8
cells	8
,	0
we	0
have	0
studied	0
the	0
role	0
of	0
an	0
upstream	0
NF-kappaB	1
like	2
site	2
in	0
the	0
5637	5
non-lymphoid	6
cell	6
line	6
,	0
which	0
derives	0
from	0
a	0
bladder	0
carcinoma	0
and	0
constitutively	0
produces	0
GM-CSF	9
.	0

This	0
sequence	0
,	0
named	0
the	0
A	0
element	0
,	0
has	0
an	0
active	0
role	0
on	0
GM-CSF	9
transcription	0
and	0
is	0
responsive	0
to	0
the	0
tumor	1
promoter	2
PMA	2
in	0
transient	0
transfection	0
experiments	0
.	0

We	0
describe	0
here	0
a	0
heterodimeric	9
binding	10
complex	10
of	0
NF-kappaB	9
subunits	10
(	0
c-Rel	9
and	0
p65	9
)	0
which	0
is	0
identical	0
to	0
the	0
one	0
obtained	0
using	0
the	0
HIV-LTR-kappaB	1
site	2
as	0
recognition	0
sequence	0
and	0
different	0
from	0
the	0
one	0
(	0
c-Rel	9
and	0
p50	9
)	0
observed	0
with	0
nuclear	0
extracts	0
from	0
Mo	5
T-lymphoid	6
HTLV-II	6
infected	6
cells	6
.	0

Repression	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
through	0
the	0
novel	0
cooperation	0
of	0
human	9
factors	10
YY1	9
and	0
LSF	9
[	0
published	0
erratum	0
appears	0
in	0
J	0
Virol	0
1998	0
Feb	0
;	0
72	0
(	0
2	0
)	0
:	0
1709	0
]	0

A	0
subpopulation	0
of	0
stably	7
infected	8
CD4+	8
cells	8
capable	0
of	0
producing	0
virus	0
upon	0
stimulation	0
has	0
been	0
identified	0
in	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
-positive	0
individuals	0
(	0
T.-W.Chun	0
,	0
D.Finzi	0
,	0
J.Margolick	0
,	0
K.Chadwick	0
,	0
D.Schwartz	0
,	0
and	0
R.F.Siliciano	0
,	0
Nat.Med.1	0
:	0
1284-1290	0
,	0
1995	0
)	0
.	0

Few	0
host	0
factors	0
that	0
directly	0
limit	0
HIV-1	0
transcription	0
and	0
could	0
support	0
this	0
state	0
of	0
nonproductive	0
HIV-1	0
infection	0
have	0
been	0
described	0
.	0

YY1	9
,	0
a	0
widely	0
distributed	0
human	9
transcription	10
factor	10
,	0
is	0
known	0
to	0
inhibit	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
transcription	0
and	0
virus	0
production	0
.	0

LSF	9
(	0
also	0
known	0
as	0
LBP-1	9
,	0
UBP	9
,	0
and	0
CP-2	9
)	0
has	0
been	0
shown	0
to	0
repress	0
LTR	0
transcription	0
in	0
vitro	0
,	0
but	0
transient	0
expression	0
of	0
LSF	9
has	0
no	0
effect	0
on	0
LTR	1
activity	0
in	0
vivo	0
.	0

We	0
report	0
that	0
both	0
YY1	9
and	0
LSF	9
participate	0
in	0
the	0
formation	0
of	0
a	0
complex	0
that	0
recognizes	0
the	0
initiation	0
region	0
of	0
the	0
HIV-1	1
LTR	2
.	0

Further	0
,	0
we	0
have	0
found	0
that	0
these	0
factors	0
cooperate	0
in	0
the	0
repression	0
of	0
LTR	1
expression	0
and	0
viral	0
replication	0
.	0

This	0
cooperative	0
function	0
may	0
account	0
for	0
the	0
divergent	0
effects	0
of	0
LSF	9
previously	0
observed	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Thus	0
,	0
the	0
cooperation	0
of	0
two	0
general	0
cellular	0
transcription	0
factors	0
may	0
allow	0
for	0
the	0
selective	0
downregulation	0
of	0
HIV	0
transcription	0
.	0

Through	0
this	0
mechanism	0
of	0
gene	0
regulation	0
,	0
YY1	9
and	0
LSF	9
could	0
contribute	0
to	0
the	0
establishment	0
and	0
maintenance	0
of	0
a	0
population	0
of	0
cells	0
stably	0
but	0
nonproductively	0
infected	0
with	0
HIV-1	0
.	0

Analysis	0
of	0
interactions	0
between	0
huGATA-3	9
transcription	0
factor	0
and	0
three	0
GATA	1
regulatory	2
elements	2
of	0
HIV-1	1
long	2
terminal	2
repeat	2
,	0
by	0
surface	0
plasmon	0
resonance	0
.	0

Relative	0
affinities	0
of	0
transcriptional	1
regulatory	2
elements	2
for	0
their	0
respective	0
factor	0
have	0
been	0
essentially	0
studied	0
by	0
bandshift	0
analysis	0
.	0

Here	0
we	0
report	0
a	0
real-time	0
study	0
of	0
factor/DNA	0
interactions	0
using	0
a	0
surface	0
plasmon	0
resonance	0
approach	0
and	0
further	0
characterization	0
of	0
recovered	9
proteins	10
involved	0
in	0
this	0
interaction	0
.	0

For	0
this	0
purpose	0
,	0
human	9
GATA-3	10
,	0
either	0
recombinant	0
or	0
in	0
nuclear	0
extracts	0
,	0
and	0
three	0
natural	1
GATA	2
elements	2
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
sites	1
1	2
,	2
2	2
,	2
and	2
3	2
)	0
were	0
chosen	0
,	0
in	0
which	0
only	0
site	1
2	2
is	0
a	0
noncanonical	0
GATA	1
site	2
.	0

Direct	0
analysis	0
of	0
sensorgrams	0
,	0
with	0
recombinant	9
huGATA-3	10
,	0
allowed	0
the	0
comparison	0
of	0
association	0
and	0
dissociation	0
profiles	0
of	0
the	0
three	0
DNA	1
regions	2
and	0
their	0
ranking	0
according	0
to	0
their	0
relative	0
affinities	0
.	0

This	0
result	0
,	0
confirmed	0
by	0
competitions	0
with	0
each	0
GATA	1
site	2
,	0
demonstrated	0
the	0
higher	0
relative	0
affinity	0
(	0
at	0
least	0
sevenfold	0
)	0
of	0
site	0
3	0
.	0

Interactions	0
between	0
the	0
canonical	0
and	0
unique	0
GATA	1
site	2
3	2
and	0
nuclear	0
extracts	0
were	0
also	0
studied	0
in	0
real	0
time	0
and	0
provided	0
information	0
on	0
its	0
association	0
and	0
dissociation	0
rates	0
for	0
native	0
huGATA-3	9
.	0

Finally	0
,	0
recovered	0
protein	0
was	0
identified	0
as	0
genuine	0
huGATA-3	9
by	0
SDS-PAGE	0
,	0
Western	0
blotting	0
,	0
and	0
bandshift	0
assays	0
.	0

Copyright	0
1997	0
Academic	0
Press	0
.	0

Stable	0
transfection	0
of	0
U937	5
cells	6
with	0
sense	0
or	0
antisense	1
RXR-alpha	2
cDNA	2
suggests	0
a	0
role	0
for	0
RXR-alpha	9
in	0
the	0
control	0
of	0
monoblastic	0
differentiation	0
induced	0
by	0
retinoic	0
acid	0
and	0
vitamin	0
D	0
.	0

Although	0
retinoic	0
acid	0
(	0
RA	0
)	0
has	0
been	0
known	0
for	0
many	0
years	0
to	0
be	0
a	0
modulating	0
agent	0
that	0
plays	0
a	0
role	0
in	0
generating	0
both	0
granulocytes	7
and	0
monocytes	7
,	0
the	0
molecular	0
mechanism	0
underlying	0
this	0
role	0
has	0
not	0
been	0
defined	0
in	0
the	0
monoblast	7
lineage	8
.	0

In	0
particular	0
,	0
the	0
part	0
played	0
by	0
the	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
)	0
,	0
which	0
are	0
members	0
of	0
the	0
steroid/thyroid	9
hormone	10
nuclear	10
receptor	10
family	10
,	0
has	0
not	0
been	0
explored	0
.	0

In	0
this	0
study	0
,	0
therefore	0
,	0
the	0
human	5
monoblastic	6
leukemia	6
cell	6
line	6
U937	6
has	0
been	0
used	0
as	0
a	0
model	0
system	0
to	0
investigate	0
the	0
role	0
of	0
one	0
of	0
the	0
RXRs	9
,	0
RXR-alpha	9
,	0
in	0
monoblast	0
differentiation	0
.	0

RXR-alpha	3
mRNA	4
was	0
present	0
in	0
untreated	0
U937	5
cells	6
,	0
and	0
levels	0
increased	0
after	0
induction	0
of	0
differentiation	0
with	0
phorbol	0
ester	0
.	0

The	0
same	0
was	0
found	0
for	0
RXR-beta	3
mRNA	4
.	0

Using	0
plasmids	0
containing	0
sense	0
or	0
antisense	1
RXR-alpha	2
sequences	2
under	0
the	0
control	0
of	0
an	0
inducible	0
promoter	0
,	0
we	0
generated	0
stably	0
transfected	0
cell	0
lines	0
which	0
expressed	0
either	0
increased	0
or	0
decreased	0
levels	0
of	0
RXR-alpha	9
,	0
respectively	0
.	0

The	0
sense	5
cell	6
lines	6
(	0
U	5
alpha	6
S	6
and	0
its	0
clonal	0
derivative	0
alpha	0
G2S	5
)	0
showed	0
increased	0
sensitivity	0
to	0
RA	0
,	0
while	0
the	0
antisense	5
cell	6
lines	6
(	0
U	5
alpha	6
A	6
and	0
its	0
clonal	0
derivative	0
alpha	0
B5A	5
)	0
showed	0
decreased	0
sensitivity	0
to	0
RA	0
,	0
as	0
demonstrated	0
by	0
growth	0
inhibition	0
and	0
by	0
regulation	0
of	0
an	0
RA-responsive	1
reporter	2
gene	2
.	0

Both	0
U	5
alpha	6
A	6
and	0
alpha	0
B5A	5
also	0
failed	0
to	0
respond	0
to	0
another	0
modulating	0
agent	0
,	0
1	0
alpha	0
,	0
25-dihydroxycholecalciferol	0
(	0
DHCC	0
)	0
,	0
but	0
only	0
U	5
alpha	6
S	6
and	0
not	0
alpha	9
G2S	10
showed	0
an	0
enhanced	0
response	0
to	0
DHCC	0
.	0

The	0
combination	0
of	0
RA	0
and	0
DHCC	0
together	0
inhibited	0
growth	0
of	0
both	0
sense	0
and	0
antisense	5
cell	6
lines	6
.	0

In	0
addition	0
,	0
alpha	9
G2S	10
exhibited	0
increased	0
expression	0
of	0
CD11b	9
and	0
CD54	9
,	0
while	0
alpha	5
B5A	6
cells	6
showed	0
increased	0
expression	0
of	0
CD102	9
,	0
suggesting	0
that	0
RXR-alpha	9
has	0
a	0
role	0
in	0
regulating	0
expression	0
of	0
cell	9
adhesion	10
molecules	10
in	0
U937	5
cells	6
.	0

These	0
results	0
demonstrate	0
that	0
RXR-alpha	9
has	0
a	0
role	0
in	0
mediating	0
growth	0
inhibition	0
and	0
cell	0
adhesion	0
during	0
myelomonocytic	0
differentiation	0
,	0
and	0
suggest	0
that	0
different	0
species	0
of	0
heterodimers	9
involving	0
RXR-alpha	9
may	0
control	0
the	0
acquisition	0
of	0
different	0
features	0
of	0
mature	0
monocyte/macrophage	0
function	0
.	0

Transcriptional	0
activation	0
of	0
the	0
vascular	1
cell	2
adhesion	2
molecule-1	2
gene	2
in	0
T	7
lymphocytes	8
expressing	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
Tax	10
protein	10
.	0

Recruitment	0
and	0
extravasation	0
of	0
T	7
cells	8
through	0
the	0
blood-brain	0
barrier	0
are	0
favored	0
by	0
adhesion	9
molecule	10
-mediated	0
interactions	0
of	0
circulating	7
T	8
cells	8
with	0
endothelial	7
cells	8
.	0

Since	0
a	0
common	0
pathological	0
finding	0
in	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
-associated	0
diseases	0
is	0
the	0
infiltration	0
of	0
HTLV-1-infected	7
T	8
lymphocytes	8
into	0
various	0
organs	0
,	0
we	0
have	0
looked	0
for	0
the	0
profile	0
of	0
adhesion	9
molecules	10
expressed	0
by	0
HTLV-1-transformed	7
T	8
cells	8
.	0

Flow	0
cytometry	0
analysis	0
indicated	0
that	0
these	0
cells	0
were	0
expressing	0
high	0
levels	0
of	0
vascular	9
cell	10
adhesion	10
molecule	10
1	10
(	0
VCAM-1	9
[	0
CD106	9
]	0
)	0
,	0
a	0
110-kDa	0
member	0
of	0
the	0
immunoglobulin	9
gene	10
superfamily	10
,	0
first	0
identified	0
on	0
endothelial	7
cells	8
stimulated	0
with	0
inflammatory	9
cytokines	10
.	0

This	0
adhesion	0
molecule	0
was	0
also	0
expressed	0
by	0
T	7
cells	8
obtained	0
from	0
one	0
patient	0
with	0
HTLV-1-associated	0
myelopathy/tropical	0
spastic	0
paraparesis	0
but	0
not	0
by	0
activated	7
T	8
cells	8
isolated	0
from	0
one	0
normal	0
blood	0
donor	0
.	0

The	0
role	0
of	0
the	0
viral	9
trans-activator	10
Tax	10
protein	10
in	0
the	0
induction	0
of	0
VCAM-1	9
was	0
first	0
indicated	0
by	0
the	0
detection	0
of	0
this	0
adhesion	9
molecule	10
on	0
Jurkat	5
T-cell	6
clones	6
stably	0
expressing	0
the	0
tax	0
gene	0
.	0

The	0
effect	0
of	0
Tax	9
on	0
VCAM-1	9
gene	0
transcription	0
was	0
next	0
confirmed	0
in	0
JPX-9	5
cells	6
,	0
a	0
subclone	0
of	0
Jurkat	5
cells	6
,	0
carrying	0
the	0
tax	1
sequences	2
under	0
the	0
control	0
of	0
an	0
inducible	1
promoter	2
.	0

Furthermore	0
,	0
deletion	0
and	0
mutation	0
analyses	0
of	0
the	0
VCAM-1	1
promoter	2
performed	0
with	0
chloramphenicol	1
acetyltransferase	2
constructs	2
revealed	0
that	0
Tax	9
was	0
trans	0
activating	0
the	0
VCAM-1	1
promoter	2
via	0
two	0
NF-kappaB	1
sites	2
present	0
at	0
bp	0
-72	0
and	0
-57	0
in	0
the	0
VCAM-1	1
gene	2
promoter	2
,	0
with	0
both	0
of	0
them	0
being	0
required	0
for	0
the	0
Tax	9
-induced	0
expression	0
of	0
this	0
adhesion	9
molecule	10
.	0

Finally	0
,	0
gel	0
mobility	0
shift	0
assays	0
demonstrated	0
the	0
nuclear	0
translocation	0
of	0
proteins	0
specifically	0
bound	0
to	0
these	0
two	0
NF-kappaB	1
motifs	2
,	0
confirming	0
that	0
VCAM-1	9
was	0
induced	0
on	0
Tax-expressing	5
cells	6
in	0
a	0
kappaB	9
-dependent	0
manner	0
.	0

Collectively	0
,	0
these	0
results	0
therefore	0
suggest	0
that	0
the	0
exclusive	0
Tax	9
-induced	0
expression	0
of	0
VCAM-1	9
on	0
T	7
cells	8
may	0
represent	0
a	0
pivotal	0
event	0
in	0
the	0
progression	0
of	0
HTLV-1-associated	0
diseases	0
.	0

HIV-1	9
Vpr	10
suppresses	0
immune	0
activation	0
and	0
apoptosis	0
through	0
regulation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
[	0
see	0
comments	0
]	0

The	0
HIV-1	9
accessory	10
gene	10
product	10
Vpr	9
can	0
influence	0
viral	0
pathogenesis	0
by	0
affecting	0
viral	0
replication	0
as	0
well	0
as	0
host	0
cell	0
transcription	0
and	0
proliferation	0
.	0

We	0
have	0
investigated	0
the	0
effects	0
of	0
Vpr	9
on	0
host	0
cell	0
activation	0
and	0
confirm	0
that	0
it	0
influences	0
cellular	0
proliferation	0
.	0

However	0
,	0
we	0
have	0
also	0
found	0
that	0
Vpr	9
modulates	0
T-cell	0
receptor	0
(	0
TCR	9
)	0
-triggered	0
apoptosis	0
in	0
a	0
manner	0
similar	0
to	0
that	0
of	0
glucocorticoids	0
.	0

In	0
the	0
absence	0
of	0
TCR	9
-mediated	0
activation	0
,	0
Vpr	9
induces	0
apoptosis	0
whereas	0
in	0
its	0
presence	0
,	0
Vpr	9
interrupts	0
the	0
expected	0
induction	0
of	0
apoptosis	0
.	0

This	0
regulation	0
of	0
apoptosis	0
is	0
linked	0
to	0
Vpr	9
suppression	0
of	0
NF-kappa	9
B	10
activity	0
via	0
the	0
induction	0
of	0
I	9
kappa	10
B	10
,	0
an	0
inhibitor	0
of	0
NF-kappa	9
B	10
.	0

Further	0
,	0
Vpr	9
suppresses	0
expression	0
of	0
IL-2	9
,	0
IL-10	9
,	0
IL-12	9
,	0
TNF	9
alpha	10
and	0
IL-4	9
,	0
all	0
of	0
which	0
are	0
NF-kappa	9
B	10
-dependent	0
.	0

The	0
effects	0
of	0
Vpr	9
could	0
be	0
reversed	0
by	0
RU486	0
.	0

Our	0
finding	0
that	0
Vpr	9
can	0
regulate	0
NF-kappa	9
B	10
supports	0
the	0
hypothesis	0
that	0
some	0
aspects	0
of	0
viral	0
pathogenesis	0
are	0
the	0
consequence	0
of	0
cell	0
dysregulation	0
by	0
Vpr	9
.	0

Tissue	0
transglutaminase-dependent	0
posttranslational	0
modification	0
of	0
the	0
retinoblastoma	9
gene	10
product	10
in	0
promonocytic	5
cells	6
undergoing	0
apoptosis	0
.	0

The	0
retinoblastoma	9
gene	10
product	10
(	0
pRB	9
)	0
plays	0
an	0
important	0
role	0
in	0
controlling	0
both	0
cell	0
release	0
from	0
the	0
G1	0
phase	0
and	0
apoptosis	0
.	0

We	0
show	0
here	0
that	0
in	0
the	0
early	0
phases	0
of	0
apoptosis	0
,	0
pRB	9
is	0
posttranslationally	0
modified	0
by	0
a	0
tissue	0
transglutaminase	0
(	0
tTG	9
)	0
-catalyzed	0
reaction	0
.	0

In	0
fact	0
,	0
by	0
employing	0
a	0
novel	0
haptenized	0
lysis	0
synthetic	0
substrate	0
which	0
allows	0
the	0
isolation	0
of	0
glutaminyl-tTG	0
substrates	0
in	0
vivo	0
,	0
we	0
identified	0
pRB	9
as	0
a	0
potential	0
tTG	0
substrate	0
in	0
U937	5
cells	6
undergoing	0
apoptosis	0
.	0

In	0
keeping	0
with	0
this	0
finding	0
,	0
we	0
showed	0
that	0
apoptosis	0
of	0
U937	5
cells	6
is	0
characterized	0
by	0
the	0
rapid	0
disappearance	0
of	0
the	0
105	0
,	0
000-	0
to	0
110	0
,	0
000-molecular-weight	0
pRB	9
forms	0
concomitantly	0
with	0
the	0
appearance	0
of	0
a	0
smear	0
of	0
immunoreactive	0
products	0
with	0
a	0
molecular	0
weight	0
of	0
greater	0
than	0
250	0
,	0
000	0
.	0

The	0
shift	0
in	0
pRB	9
molecular	0
weight	0
was	0
reproduced	0
by	0
adding	0
exogenous	0
purified	0
tTG	0
to	0
extracts	0
obtained	0
from	0
viable	0
U937	5
cells	6
and	0
was	0
prevented	0
by	0
dansylcadaverine	0
,	0
a	0
potent	0
enzyme	0
inhibitor	0
.	0

The	0
effect	0
of	0
the	0
pRB	9
posttranslational	0
modification	0
during	0
apoptosis	0
was	0
investigated	0
by	0
determining	0
the	0
E2F-1	9
levels	0
and	0
by	0
isolating	0
and	0
characterizing	0
pRB-null	5
clones	6
from	0
U937	5
cells	6
.	0

Notably	0
,	0
the	0
lack	0
of	0
pRB	9
in	0
these	0
U937-derived	5
clones	6
renders	0
these	0
p53-null	5
cells	6
highly	0
resistant	0
to	0
apoptosis	0
induced	0
by	0
serum	0
withdrawal	0
,	0
calphostin	0
C	0
,	0
and	0
ceramide	0
.	0

Taken	0
together	0
,	0
these	0
data	0
suggest	0
that	0
tTG	9
,	0
acting	0
on	0
the	0
pRB	9
protein	10
,	0
might	0
play	0
an	0
important	0
role	0
in	0
the	0
cell	0
progression	0
through	0
the	0
death	0
program	0
.	0

STAT3	9
is	0
a	0
serine	9
kinase	10
target	10
in	0
T	7
lymphocytes	8
.	0

Interleukin	9
2	10
and	0
T	9
cell	10
antigen	10
receptor	10
signals	0
converge	0
upon	0
serine	0
727	0
.	0

Interleukin	9
2	10
(	0
IL-2	9
)	0
induces	0
tyrosine	0
phosphorylation	0
of	0
STATs	9
3	10
and	10
5	10
(	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
)	0
.	0

We	0
now	0
show	0
that	0
IL-2	9
regulation	0
of	0
STAT3	9
proteins	10
in	0
T	7
cells	8
is	0
a	0
complex	0
response	0
involving	0
activation	0
of	0
two	0
forms	0
of	0
STAT3	9
:	0
90-kDa	0
STAT3alpha	9
and	0
an	0
83-kDa	9
carboxyl-terminal	10
truncated	10
STAT3beta	10
.	0

The	0
phosphorylation	0
of	0
STAT	9
proteins	10
on	0
serine	0
residues	0
is	0
also	0
required	0
for	0
competent	0
STAT	9
transcription	0
.	0

A	0
critical	0
serine	9
phosphorylation	10
site	10
in	0
STAT3alpha	9
is	0
at	0
position	0
727	0
.	0

In	0
this	0
study	0
we	0
have	0
produced	0
an	0
antisera	0
specific	0
for	0
STAT3alpha	9
proteins	10
phosphorylated	0
on	0
serine	0
727	0
and	0
used	0
this	0
to	0
monitor	0
the	0
phosphorylation	0
of	0
this	0
residue	0
during	0
T	0
lymphocyte	0
activation	0
.	0

Our	0
results	0
show	0
that	0
phosphorylation	0
of	0
STAT3alpha	9
on	0
serine	0
727	0
is	0
not	0
constitutive	0
in	0
quiescent	7
T	8
cells	8
but	0
can	0
be	0
induced	0
by	0
the	0
cytokine	9
IL-2	10
.	0

Interestingly	0
,	0
triggering	0
of	0
the	0
T	9
cell	10
antigen	10
receptor	10
complex	10
or	0
activation	0
of	0
protein	9
kinase	10
C	10
with	0
phorbol	0
esters	0
also	0
induces	0
phosphorylation	0
of	0
serine	0
727	0
but	0
without	0
simultaneously	0
inducing	0
STAT3	9
tyrosine	0
phosphorylation	0
or	0
DNA	0
binding	0
.	0

Hence	0
,	0
the	0
present	0
results	0
show	0
that	0
STAT3	9
serine	0
phosphorylation	0
can	0
be	0
regulated	0
independently	0
of	0
the	0
tyrosine	0
phosphorylation	0
of	0
this	0
molecule	0
.	0

IL-2	9
and	0
T	9
cell	10
antigen	10
receptor	10
complex	10
induction	0
of	0
STAT3alpha	9
serine	0
727	0
phosphorylation	0
is	0
dependent	0
on	0
the	0
activity	0
of	0
the	0
MEK	9
/ERK	9
pathway	0
.	0

Previous	0
studies	0
have	0
identified	0
H-7-sensitive	0
kinase	0
pathways	0
that	0
regulate	0
STAT3	9
DNA	0
binding	0
.	0

We	0
show	0
that	0
H-7-sensitive	0
pathways	0
regulate	0
STAT3	9
DNA	0
binding	0
in	0
T	7
cells	8
.	0

Nevertheless	0
,	0
we	0
show	0
that	0
H-7-sensitive	9
kinases	10
do	0
not	0
regulate	0
STAT3	9
tyrosine	0
phosphorylation	0
or	0
phosphorylation	0
of	0
serine	0
727	0
.	0

These	0
results	0
thus	0
show	0
that	0
STAT3	9
proteins	10
are	0
targets	0
for	0
multiple	0
kinase	0
pathways	0
in	0
T	7
cells	8
and	0
can	0
integrate	0
signals	0
from	0
both	0
cytokine	9
receptors	10
and	0
antigen	9
receptors	10
.	0

NF-kappa	9
B/Rel	10
family	10
members	10
regulating	0
the	0
ICAM-1	1
promoter	2
in	0
monocytic	5
THP-1	6
cells	6
.	0

A	0
kappa	1
B-site	2
was	0
identified	0
in	0
the	0
promoter	0
of	0
the	0
intercellular	1
adhesion	2
molecule-1	2
(	2
ICAM-1	2
)	2
gene	2
,	0
which	0
is	0
involved	0
in	0
regulation	0
of	0
ICAM-1	9
expression	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
and	0
glucocorticoids	0
.	0

We	0
now	0
report	0
on	0
the	0
transcription	9
factors	10
which	0
bind	0
and	0
transactivate	0
this	0
enhancer	1
sequence	2
.	0

In	0
vitro	0
,	0
the	0
ICAM-1	1
kappa	2
B	2
site	2
appeared	0
to	0
bind	0
RelA	9
and	0
c-Rel	9
homodimers	10
as	0
well	0
as	0
heterodimers	0
with	0
NF-kappa	9
B1	10
,	0
but	0
weakly	0
NF-kappa	9
B1	10
homodimers	10
.	0

In	0
addition	0
,	0
both	0
RelA	9
and	0
c-Rel	9
,	0
but	0
not	0
NF-kappa	9
B1	10
,	0
were	0
shown	0
to	0
transactivate	0
an	0
ICAM-1	1
kappa	2
B-reporter	2
construct	2
.	0

In	0
monocytic	5
THP-1	6
cells	6
TNF-alpha	9
induced	0
two	0
nuclear	9
complexes	10
which	0
in	0
vitro	0
bound	0
to	0
the	0
ICAM-1	1
kappa	2
B	2
site	2
.	0

Using	0
antibodies	0
in	0
an	0
electrophoretic	0
mobility	0
supershift	0
assay	0
,	0
one	0
of	0
these	0
complexes	0
was	0
shown	0
to	0
contain	0
NF-kappa	9
B1	10
and	0
RelA	9
,	0
and	0
to	0
bind	0
with	0
higher	0
affinity	0
to	0
the	0
consensus	1
kappa	2
B	2
site	2
in	0
the	0
HIV	1
long	2
terminal	2
repeat	2
.	0

The	0
second	0
complex	0
contained	0
RelA	9
,	0
and	0
exhibited	0
higher	0
affinity	0
towards	0
the	0
ICAM-1	1
kappa	2
B	2
than	0
to	0
the	0
HIV	1
kappa	2
B	2
site	2
.	0

The	0
glucocorticoid	9
receptor	10
was	0
shown	0
to	0
repress	0
activity	0
of	0
both	0
the	0
RelA	9
homodimer	10
and	0
the	0
NF-kappa	9
B1/RelA	10
heterodimer	10
.	0

We	0
argue	0
that	0
in	0
vivo	0
RelA	9
homodimers	10
are	0
likely	0
to	0
play	0
a	0
dominant	0
role	0
in	0
TNF-alpha	9
-induced	0
ICAM-1	9
transcription	0
in	0
monocytic	7
cells	8
.	0

Competent	0
transcription	0
initiation	0
by	0
RNA	9
polymerase	10
II	10
in	0
cell-free	7
extracts	8
from	0
xeroderma	0
pigmentosum	0
groups	0
B	0
and	0
D	0
in	0
an	0
optimized	0
RNA	0
transcription	0
assay	0
.	0

The	0
human	0
autosomal	0
recessive	0
disease	0
,	0
xeroderma	0
pigmentosum	0
(	0
XP	0
)	0
,	0
can	0
result	0
from	0
mutations	0
in	0
any	0
one	0
of	0
seven	0
genes	0
,	0
designated	0
XPA	1
through	0
XPG	1
.	0

Of	0
these	0
,	0
the	0
XPB	1
and	2
XPD	2
genes	2
encode	0
proteins	0
that	0
are	0
subunits	0
of	0
a	0
general	9
transcription	10
factor	10
,	0
TFIIH	9
,	0
involved	0
in	0
both	0
nucleotide	0
excision	0
repair	0
(	0
NER	0
)	0
and	0
initiation	0
of	0
mRNA	0
transcription	0
by	0
RNA	9
polymerase	10
II	10
.	0

In	0
humans	0
,	0
mutation	0
of	0
the	0
XPB	1
or	2
XPD	2
gene	2
impairs	0
NER	0
,	0
resulting	0
in	0
hyper-sensitivity	0
to	0
sunlight	0
and	0
greatly	0
increased	0
skin	0
tumor	0
formation	0
.	0

However	0
,	0
no	0
transcription	0
deficiency	0
has	0
been	0
demonstrated	0
in	0
either	0
XP-B	0
or	0
XP-D	0
.	0

We	0
have	0
employed	0
an	0
optimized	0
cell-free	0
RNA	0
transcription	0
assay	0
to	0
analyze	0
transcription	0
activity	0
of	0
XP-B	0
and	0
XP-D	0
.	0

Although	0
the	0
growth	0
rate	0
was	0
normal	0
,	0
the	0
XP-B	5
and	6
XP-D	6
cells	6
contained	0
reduced	0
amounts	0
of	0
TFIIH	9
.	0

Extracts	0
prepared	0
from	0
XP-B	5
and	6
XP-D	6
lymphoblastoid	6
cells	6
exhibited	0
similar	0
transcription	0
activity	0
from	0
the	0
adenovirus	1
major	2
late	2
promoter	2
when	0
compared	0
to	0
that	0
in	0
extracts	0
from	0
normal	0
cells	0
.	0

Thus	0
,	0
we	0
conclude	0
that	0
the	0
XP-B	5
and	6
XP-D	6
lymphoblastoid	6
cells	6
do	0
not	0
have	0
impaired	0
RNA	0
transcription	0
activity	0
.	0

We	0
consider	0
the	0
possible	0
consequences	0
of	0
the	0
reduced	0
cellular	0
content	0
of	0
TFIIH	9
for	0
the	0
clinical	0
symptoms	0
in	0
XP-B	0
or	0
XP-D	0
patients	0
,	0
and	0
discuss	0
a	0
'conditional	0
phenotype	0
'	0
that	0
may	0
involve	0
an	0
impairment	0
of	0
cellular	0
function	0
only	0
under	0
certain	0
growth	0
conditions	0
.	0

A	0
novel	0
form	0
of	0
the	0
myeloid-specific	9
zinc	10
finger	10
protein	10
(	0
MZF-2	9
)	0
.	0

BACKGROUND	0
:	0
Myeloid	0
cell	0
development	0
is	0
controlled	0
by	0
tissue-specific	0
transcription	9
factors	10
.	0

Human	9
myeloid	10
zinc	10
finger	10
protein	10
(	0
MZF-1	9
)	0
is	0
a	0
putative	0
transcription	0
factor	0
containing	0
13	9
zinc	10
fingers	10
,	0
and	0
has	0
been	0
suggested	0
that	0
it	0
regulates	0
the	0
development	0
of	0
neutrophilic	7
granulocytes	8
.	0

RESULTS	0
:	0
Here	0
,	0
we	0
have	0
isolated	0
the	0
murine	1
and	2
human	2
cDNAs	2
which	0
encode	0
a	0
novel	0
form	0
of	0
MZF	9
protein	10
(	0
MZF-2	9
)	0
.	0

Murine	9
and	10
human	10
MZF-2	10
proteins	10
consisted	0
of	0
814	0
and	0
775	0
amino	0
acids	0
,	0
respectively	0
,	0
and	0
have	0
identity	0
of	0
75.3	0
%	0
between	0
them	0
.	0

The	0
C-terminal	9
half	10
of	0
human	9
MZF-2	10
,	0
carrying	0
the	0
zinc	9
finger	10
domains	10
,	0
was	0
completely	0
identical	0
with	0
that	0
of	0
human	9
MZF-1	10
,	0
whereas	0
the	0
N-terminal	9
half	10
of	0
MZF-2	9
was	0
different	0
from	0
the	0
corresponding	0
region	0
of	0
human	0
MZF-1	9
,	0
and	0
was	0
coded	0
by	0
distinct	0
exons	1
.	0

MZF-2	3
mRNA	4
was	0
expressed	0
in	0
myeloid	0
cells	0
,	0
particularly	0
in	0
the	0
cells	0
committed	0
to	0
the	0
neutrophilic	7
lineage	8
,	0
and	0
down-regulated	0
by	0
G-CSF	9
.	0

CONCLUSIONS	0
:	0
MZF-1	3
and	4
MZF-2	4
mRNAs	4
seem	0
to	0
be	0
produced	0
by	0
the	0
alternative	0
use	0
of	0
two	0
different	0
transcription	1
initiation	2
sites	2
.	0

The	0
distinct	0
N-terminal	9
half	10
of	0
MZF-2	9
carries	0
two	0
characteristic	0
domains	0
,	0
a	0
leucine-rich	9
domain	10
called	0
LeR	9
and	0
an	0
acidic	9
domain	10
,	0
which	0
suggests	0
a	0
unique	0
function	0
of	0
MZF-2	9
in	0
neutrophil	0
development	0
.	0

Impaired	0
cortisol	0
binding	0
to	0
glucocorticoid	9
receptors	10
in	0
hypertensive	0
patients	0
.	0

We	0
compared	0
glucocorticoid	0
receptor	0
binding	0
characteristics	0
and	0
glucocorticoid	0
responsiveness	0
of	0
human	7
mononuclear	8
leukocytes	8
(	0
HML	7
)	0
from	0
hypertensive	0
patients	0
and	0
matched	0
normotensive	0
volunteers	0
.	0

We	0
also	0
considered	0
associations	0
of	0
these	0
variables	0
with	0
plasma	0
renin	9
activity	0
,	0
aldosterone	0
,	0
cortisol	0
,	0
corticotropin	0
,	0
and	0
electrolyte	0
concentrations	0
.	0

We	0
calculated	0
binding	0
affinity	0
(	0
Kd	0
;	0
nmol/L	0
)	0
and	0
capacity	0
(	0
Bmax	0
;	0
sites/cell	0
)	0
for	0
dexamethasone	0
and	0
cortisol	0
from	0
homologous	0
and	0
heterologous	0
competition	0
curves	0
for	0
specific	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
sites	0
on	0
HML	7
isolated	0
from	0
the	0
blood	0
of	0
normotensive	0
volunteers	0
and	0
subjects	0
with	0
essential	0
hypertension	0
.	0

Glucocorticoid	0
responsiveness	0
of	0
HML	7
was	0
evaluated	0
as	0
IC50	0
values	0
(	0
nmol/L	0
)	0
for	0
dexamethasone	0
and	0
cortisol	0
for	0
the	0
inhibition	0
of	0
lysozyme	9
release	0
.	0

We	0
measured	0
plasma	0
hormones	0
by	0
radioimmunoassay	0
.	0

Kd	0
values	0
(	0
mean+/-SE	0
)	0
for	0
cortisol	0
in	0
HML	7
of	0
hypertensive	0
patients	0
were	0
higher	0
than	0
in	0
control	0
subjects	0
(	0
24.6+/-2.4	0
versus	0
17.5+/-1.7	0
nmol/L	0
,	0
P	0
<	0
.04	0
)	0
.	0

Binding	0
capacity	0
(	0
4978+/-391	0
versus	0
4131+/-321	0
sites/cell	0
)	0
,	0
Kd	0
values	0
for	0
dexamethasone	0
(	0
6.7+/-0.5	0
versus	0
5.7+/-0.3	0
nmol/L	0
)	0
,	0
and	0
IC50	0
values	0
for	0
dexamethasone	0
(	0
3.4+/-0.3	0
versus	0
3.1+/-0.2	0
nmol/L	0
)	0
and	0
cortisol	0
(	0
12.2+/-1.6	0
versus	0
9.5+/-0.3	0
nmol/L	0
)	0
were	0
not	0
significantly	0
different	0
.	0

Patients	0
with	0
renin	9
values	0
less	0
than	0
0.13	0
ng	0
angiotensin	0
I/L	0
per	0
second	0
were	0
markedly	0
less	0
sensitive	0
to	0
cortisol	0
than	0
those	0
with	0
higher	0
values	0
.	0

Both	0
Kd	0
(	0
30.3+/-2.5	0
versus	0
19.2+/-2.4	0
nmol/L	0
)	0
and	0
IC50	0
values	0
(	0
15.5+/-1.8	0
versus	0
8.9+/-1.2	0
nmol/L	0
)	0
for	0
cortisol	0
were	0
significantly	0
higher	0
in	0
patients	0
with	0
lower	0
renin	9
values	0
(	0
P	0
<	0
.03	0
)	0
.	0

Other	0
variables	0
,	0
including	0
plasma	0
hormone	0
and	0
electrolyte	0
values	0
and	0
binding	0
characteristics	0
for	0
dexamethasone	0
,	0
were	0
not	0
different	0
.	0

These	0
data	0
suggest	0
that	0
cortisol	0
binding	0
to	0
glucocorticoid	9
receptor	10
is	0
slightly	0
impaired	0
in	0
patients	0
with	0
essential	0
hypertension	0
.	0

In	0
vivo	0
,	0
this	0
could	0
lead	0
to	0
inappropriate	0
binding	0
of	0
cortisol	0
to	0
mineralocorticoid	0
receptors	0
.	0

Hence	0
,	0
decreased	0
sensitivity	0
to	0
cortisol	0
is	0
associated	0
with	0
renin	9
suppression	0
.	0

This	0
hypothesis	0
is	0
supported	0
by	0
evidence	0
of	0
hypertension	0
and	0
low	0
renin	9
activity	0
,	0
which	0
others	0
have	0
described	0
in	0
patients	0
with	0
primary	0
glucocorticoid	0
resistance	0
due	0
to	0
mutations	0
of	0
the	0
glucocorticoid	9
receptor	10
.	0

PU.1/Pip	9
and	0
basic	9
helix	10
loop	10
helix	10
zipper	10
transcription	10
factors	10
interact	0
with	0
binding	1
sites	2
in	0
the	0
CD20	1
promoter	2
to	0
help	0
confer	0
lineage-	0
and	0
stage-specific	0
expression	0
of	0
CD20	9
in	0
B	7
lymphocytes	8
.	0

CD20	9
is	0
a	0
B-lineage-specific	1
gene	2
expressed	0
at	0
the	0
pre-B-cell	0
stage	0
of	0
B-cell	0
development	0
that	0
disappears	0
on	0
differentiation	0
to	0
plasma	7
cells	8
.	0

As	0
such	0
,	0
it	0
serves	0
as	0
an	0
excellent	0
paradigm	0
for	0
the	0
study	0
of	0
lineage	0
and	0
developmental	0
stage-specific	0
gene	0
expression	0
.	0

Using	0
in	0
vivo	0
footprinting	0
we	0
identified	0
two	0
sites	0
in	0
the	0
promoter	0
at	0
-45	1
and	2
-160	2
that	0
were	0
occupied	0
only	0
in	0
CD20	9
+	0
B	0
cells	0
.	0

The	0
-45	1
site	2
is	0
an	0
E	1
box	2
that	0
binds	0
basic	9
helix-loop-helix-zipper	10
proteins	10
whereas	0
the	0
-160	1
site	2
is	0
a	0
composite	1
PU.1	2
and	2
Pip	2
binding	2
site	2
.	0

Transfection	0
studies	0
with	0
reporter	1
constructs	2
and	0
various	0
expression	0
vectors	0
verified	0
the	0
importance	0
of	0
these	0
sites	0
.	0

The	0
composite	1
PU.1	2
and	2
Pip	2
site	2
likely	0
accounts	0
for	0
both	0
lineage	0
and	0
stage-specific	0
expression	0
of	0
CD20	9
whereas	0
the	0
CD20	9
E	10
box	10
binding	10
proteins	10
enhance	0
overall	0
promoter	0
activity	0
and	0
may	0
link	0
the	0
promoter	0
to	0
a	0
distant	1
enhancer	2
.	0

Glucocorticoids	0
and	0
the	0
immune	0
function	0
in	0
the	0
human	0
immunodeficiency	0
virus	0
infection	0
:	0
a	0
study	0
in	0
hypercortisolemic	0
and	0
cortisol-resistant	0
patients	0
.	0

Immunological	0
studies	0
in	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
-positive	0
patients	0
suggest	0
that	0
the	0
disease	0
progression	0
is	0
accompanied	0
by	0
a	0
defective	0
production	0
of	0
type	0
1	9
cytokines	10
(	0
interleukin-2	9
(	0
IL-2	9
)	0
and	0
IL-12	9
]	0
,	0
an	0
increased	0
production	0
of	0
type	9
2	10
cytokines	10
(	0
IL-4	9
,	0
IL-6	9
,	0
and	0
IL-10	9
)	0
,	0
and	0
an	0
increased	0
production	0
of	0
IgE	9
.	0

HIV	0
infection	0
is	0
also	0
associated	0
with	0
activation	0
of	0
the	0
hypothalamo-pituitary-adrenal	0
axis	0
function	0
and	0
increased	0
plasma	0
and	0
urinary	0
cortisol	0
concentrations	0
.	0

As	0
cortisol	0
is	0
involved	0
in	0
the	0
physiological	0
regulation	0
of	0
cytokines	9
,	0
a	0
study	0
was	0
conducted	0
to	0
examine	0
cytokine	9
patterns	0
in	0
two	0
groups	0
of	0
hypercortisolemic	0
patients	0
,	0
one	0
with	0
normal	0
sensitivity	0
to	0
glucocorticoids	0
and	0
the	0
other	0
with	0
glucocorticoid	0
resistance	0
.	0

Ten	0
HIV-infected	0
patients	0
with	0
normal	0
receptor	0
affinity	0
to	0
glucocorticoids	0
(	0
AIDS-C	0
)	0
,	0
10	0
HIV-infected	0
patients	0
with	0
low	0
receptor	0
affinity	0
to	0
glucocorticoids	0
(	0
AIDS-GR	0
)	0
,	0
and	0
20	0
healthy	0
subjects	0
were	0
studied	0
.	0

Receptor	0
characteristics	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
were	0
evaluated	0
by	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
.	0

Serum	0
cortisol	0
and	0
urinary	0
free	0
cortisol	0
were	0
measured	0
by	0
RIA	0
.	0

Serum	0
ACTH	0
and	0
IgE	9
were	0
measured	0
by	0
immunoradiometric	0
assay	0
,	0
and	0
IL-2	9
,	0
IL-4	9
,	0
and	0
IL-10	9
cytokines	9
and	0
interferon-gamma	9
were	0
measured	0
by	0
enzyme-linked	0
immunosorbent	0
assay	0
.	0

AIDS-C	0
patients	0
showed	0
low	0
IL-2	9
and	0
high	0
IL-4	9
,	0
IL-10	9
,	0
and	0
IgE	9
concentratios	0
;	0
conversely	0
,	0
AIDS-GR	0
patients	0
showed	0
high	0
IL-2	9
and	0
low	0
IL-4	9
and	0
IgE	9
concentrations	0
.	0

Thus	0
,	0
in	0
HIV	0
infection	0
,	0
elevated	0
cortisol	0
levels	0
suppress	0
cell-mediated	0
immunity	0
and	0
stimulate	0
humoral	0
immunity	0
,	0
whereas	0
this	0
response	0
is	0
not	0
detected	0
in	0
cortisol-resistant	0
patients	0
.	0

These	0
findings	0
indicate	0
that	0
cortisol	0
and	0
its	0
receptors	0
are	0
critically	0
involved	0
in	0
the	0
regulation	0
of	0
immune	0
function	0
in	0
HIV	0
infection	0
.	0

Monocytic	0
differentiation	0
of	0
HL-60	5
promyelocytic	6
leukemia	6
cells	6
correlates	0
with	0
the	0
induction	0
of	0
Bcl-xL	9
.	0

Treatment	0
of	0
human	5
promyelocytic	6
leukemia	6
HL-60	6
cells	6
with	0
phorbol	0
esters	0
ultimately	0
induces	0
the	0
differentiation	0
of	0
these	0
cells	0
along	0
the	0
monocyte/macrophage	7
lineage	8
,	0
whereas	0
treatment	0
with	0
retinoic	0
acid	0
or	0
DMSO	0
induces	0
granulocytic/neutrophillic	0
differentiation	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
the	0
disparate	0
fates	0
of	0
HL-60	5
cells	6
treated	0
with	0
the	0
phorbol	0
ester	0
12	0
,	0
13-phorbol	0
dibutyric	0
acid	0
(	0
PDBu	0
)	0
or	0
DMSO	0
.	0

After	0
DMSO	0
treatment	0
,	0
HL-60	5
cells	6
eventually	0
died	0
via	0
apoptosis	0
,	0
whereas	0
the	0
viability	0
of	0
PDBu-treated	5
cells	6
was	0
not	0
affected	0
during	0
the	0
same	0
interval	0
.	0

The	0
levels	0
of	0
the	0
apoptosis	0
effector	0
proteins	0
Bak	9
and	0
Bad	9
were	0
enhanced	0
,	0
whereas	0
there	0
was	0
a	0
slight	0
down-regulation	0
of	0
the	0
apoptosis	9
suppressor	10
protein	10
Bcl-2	9
after	0
treatment	0
of	0
the	0
cells	0
with	0
PDBu	0
and	0
DMSO	0
.	0

Treatment	0
with	0
DMSO	0
resulted	0
in	0
the	0
elevation	0
of	0
the	0
apoptosis	9
effector	10
Bax	9
,	0
whereas	0
treatment	0
with	0
PDBu	0
did	0
not	0
significantly	0
alter	0
the	0
levels	0
of	0
this	0
protein	0
.	0

However	0
,	0
treatment	0
of	0
HL-60	5
cells	6
with	0
PDBu	0
induced	0
the	0
rapid	0
expression	0
of	0
the	0
apoptosis	9
suppressor	10
protein	10
Bcl-xL	9
,	0
whereas	0
the	0
expression	0
of	0
this	0
protein	0
remained	0
unaltered	0
in	0
DMSO-treated	0
cells	0
.	0

The	0
generality	0
of	0
this	0
finding	0
was	0
confirmed	0
by	0
the	0
induction	0
of	0
Bcl-xL	9
in	0
human	5
myeloid	6
U-937	6
cells	6
,	0
human	7
peripheral	8
blood	8
monocytes	8
exposed	0
to	0
phorbol	0
ester	0
,	0
and	0
mouse	5
thioglycollate-activated	6
and	6
resident	6
peritoneal	6
macrophages	6
.	0

PDBu-treated	5
HL-60	6
cells	6
remained	0
viable	0
for	0
7	0
days	0
and	0
thereafter	0
began	0
to	0
die	0
via	0
apoptosis	0
,	0
with	0
a	0
concomitant	0
down-regulation	0
of	0
Bcl-xL	9
.	0

In	0
conclusion	0
,	0
we	0
propose	0
that	0
Bcl-xL	9
expression	0
is	0
associated	0
with	0
differentiation	0
and	0
survival	0
of	0
hematopoietic	7
cells	8
along	0
the	0
monocyte/macrophage	7
lineage	8
.	0

Monochloramine	0
inhibits	0
phorbol	0
ester-inducible	0
neutrophil	0
respiratory	0
burst	0
activation	0
and	0
T	0
cell	0
interleukin-2	9
receptor	0
expression	0
by	0
inhibiting	0
inducible	0
protein	9
kinase	10
C	10
activity	0
.	0

Monochloramine	0
derivatives	0
are	0
long	0
lived	0
physiological	0
oxidants	0
produced	0
by	0
neutrophils	7
during	0
the	0
respiratory	0
burst	0
.	0

The	0
effects	0
of	0
chemically	0
prepared	0
monochloramine	0
(	0
NH2Cl	0
)	0
on	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
and	0
PKC	9
-mediated	0
cellular	0
responses	0
were	0
studied	0
in	0
elicited	7
rat	8
peritoneal	8
neutrophils	8
and	0
human	5
Jurkat	6
T	6
cells	6
.	0

Neutrophils	0
pretreated	0
with	0
NH2Cl	0
(	0
30-50	0
microM	0
)	0
showed	0
a	0
marked	0
decrease	0
in	0
the	0
respiratory	0
burst	0
activity	0
induced	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
,	0
which	0
is	0
a	0
potent	0
PKC	9
activator	0
.	0

These	0
cells	0
,	0
however	0
,	0
were	0
viable	0
and	0
showed	0
a	0
complete	0
respiratory	0
burst	0
upon	0
arachidonic	0
acid	0
stimulation	0
,	0
which	0
induces	0
the	0
respiratory	0
burst	0
by	0
a	0
PKC	9
-independent	0
mechanism	0
.	0

The	0
NH2Cl-treated	5
neutrophils	6
showed	0
a	0
decrease	0
in	0
both	0
PKC	9
activity	0
and	0
PMA-induced	0
phosphorylation	0
of	0
a	0
47-kDa	9
protein	10
,	0
which	0
corresponds	0
to	0
the	0
cytosolic	9
factor	10
of	0
NADPH	9
oxidase	10
,	0
p47	9
(	10
phox	10
)	10
.	0

Jurkat	5
T	6
cells	6
pretreated	0
with	0
NH2Cl	0
(	0
20-70	0
microM	0
)	0
showed	0
a	0
decrease	0
in	0
the	0
expression	0
of	0
the	0
interleukin-2	9
receptor	9
alpha	10
chain	10
following	0
PMA	0
stimulation	0
.	0

This	0
was	0
also	0
accompanied	0
by	0
a	0
decrease	0
in	0
both	0
PKC	9
activity	0
and	0
nuclear	0
transcription	0
factor-	0
kappaB	9
activation	0
,	0
also	0
without	0
loss	0
of	0
cell	0
viability	0
.	0

These	0
results	0
show	0
that	0
NH2Cl	0
inhibits	0
PKC	9
-mediated	0
cellular	0
responses	0
through	0
inhibition	0
of	0
the	0
inducible	0
PKC	9
activity	0
.	0

Evidence	0
that	0
calcineurin	0
is	0
rate-limiting	0
for	0
primary	0
human	0
lymphocyte	0
activation	0
.	0

Cyclosporine	0
(	0
CsA	0
)	0
is	0
both	0
a	0
clinical	0
immunosuppressive	0
drug	0
and	0
a	0
probe	0
to	0
dissect	0
intracellular	0
signaling	0
pathways	0
.	0

In	0
vitro	0
,	0
CsA	0
inhibits	0
lymphocyte	1
gene	2
activation	0
by	0
inhibiting	0
the	0
phosphatase	9
activity	0
of	0
calcineurin	9
(	0
CN	9
)	0
.	0

In	0
clinical	0
use	0
,	0
CsA	0
treatment	0
inhibits	0
50-75	0
%	0
of	0
CN	9
activity	0
in	0
circulating	7
leukocytes	8
.	0

We	0
modeled	0
this	0
degree	0
of	0
CN	9
inhibition	0
in	0
primary	7
human	8
leukocytes	8
in	0
vitro	0
in	0
order	0
to	0
study	0
the	0
effect	0
of	0
partial	0
CN	9
inhibition	0
on	0
the	0
downstream	0
signaling	0
events	0
that	0
lead	0
to	0
gene	0
activation	0
.	0

In	0
CsA-treated	5
leukocytes	6
stimulated	0
by	0
calcium	0
ionophore	0
,	0
the	0
degree	0
of	0
reduction	0
in	0
CN	9
activity	0
was	0
accompanied	0
by	0
a	0
similar	0
degree	0
of	0
inhibition	0
of	0
each	0
event	0
tested	0
:	0
dephosphorylation	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cell	10
proteins	10
,	0
nuclear	0
DNA	0
binding	0
,	0
activation	0
of	0
a	0
transfected	1
reporter	2
gene	2
construct	2
,	0
IFN-gamma	0
and	0
IL-2	0
mRNA	0
accumulation	0
,	0
and	0
IFN-gamma	9
production	0
.	0

Furthermore	0
,	0
the	0
degree	0
of	0
CN	9
inhibition	0
was	0
reflected	0
by	0
a	0
similar	0
degree	0
of	0
reduction	0
in	0
lymphocyte	0
proliferation	0
and	0
IFN-gamma	9
production	0
in	0
the	0
allogeneic	5
mixed	6
lymphocyte	6
cultures	6
.	0

These	0
data	0
support	0
the	0
conclusion	0
that	0
CN	9
activity	0
is	0
rate-limiting	0
for	0
the	0
activation	0
of	0
primary	7
human	8
T	8
lymphocytes	8
.	0

Thus	0
,	0
the	0
reduction	0
of	0
CN	9
activity	0
observed	0
in	0
CsA-treated	0
patients	0
is	0
accompanied	0
by	0
a	0
similar	0
degree	0
of	0
reduction	0
in	0
lymphocyte	1
gene	2
activation	0
,	0
and	0
accounts	0
for	0
the	0
immunosuppression	0
observed	0
.	0

Selection	0
of	0
down-regulated	1
sequences	2
along	0
the	0
monocytic	0
differentiation	0
of	0
leukemic	5
HL60	6
cells	6
.	0

In	0
order	0
to	0
dissect	0
the	0
molecular	0
mechanisms	0
of	0
monocytic	0
differentiation	0
we	0
have	0
developed	0
a	0
subtractive	0
hybridisation	0
method	0
based	0
on	0
a	0
simplified	0
'representational	0
difference	0
analysis'	0
.	0

We	0
have	0
selected	0
16	1
sequences	2
and	0
confirmed	0
their	0
down-regulation	0
along	0
the	0
TPA-induced	0
monocytic	0
differentiation	0
of	0
HL60	5
cells	6
.	0

Among	0
these	0
sequences	0
we	0
have	0
identified	0
the	0
alpha-tubulin	9
,	0
the	0
TaxREB	9
protein	10
and	0
two	0
ribosomal	1
protein	2
sequences	2
which	0
had	0
not	0
been	0
previously	0
described	0
as	0
differentially	0
expressed	0
.	0

These	0
results	0
add	0
to	0
our	0
knowledge	0
about	0
the	0
molecules	0
implicated	0
along	0
the	0
monocytic	0
differentiation	0
and	0
growth	0
arrest	0
of	0
leukemic	7
cells	8
and	0
provide	0
a	0
first	0
step	0
in	0
the	0
study	0
of	0
their	0
respective	0
roles	0
.	0

Control	0
of	0
NF-kappa	9
B	10
activity	0
by	0
the	0
I	9
kappa	10
B	10
beta	10
inhibitor	10
.	0

The	0
transcription	9
factor	10
NF-kappa	9
B	10
is	0
maintained	0
in	0
an	0
inactive	0
cytoplasmic	0
state	0
by	0
I	9
kappa	10
B	10
inhibitors	10
.	0

In	0
mammalian	7
cells	8
,	0
I	9
kappa	10
B	10
alpha	10
and	0
I	9
kappa	10
B	10
beta	10
proteins	10
have	0
been	0
purified	0
and	0
shown	0
to	0
be	0
the	0
inhibitors	0
of	0
NF-kappa	9
B	10
through	0
their	0
association	0
with	0
the	0
p65	9
or	10
c-Rel	10
subunits	10
.	0

In	0
addition	0
,	0
we	0
have	0
isolated	0
a	0
third	0
NF-kappa	9
B	10
inhibitor	10
,	0
I	9
kappa	10
B	10
epsilon	10
(	0
1	0
)	0
.	0

Upon	0
treatment	0
with	0
a	0
large	0
variety	0
of	0
inducers	0
,	0
I	9
kappa	10
B	10
alpha	10
,	0
I	9
kappa	10
B	10
beta	10
are	0
proteolytically	0
degraded	0
,	0
resulting	0
in	0
NF-kappa	9
B	10
translocation	0
into	0
the	0
nucleus	0
.	0

Here	0
we	0
show	0
that	0
in	0
E29.1	5
T	6
cell	6
hybridoma	6
I	9
kappa	10
B	10
alpha	10
and	0
I	9
kappa	10
B	10
beta	10
are	0
equally	0
associated	0
with	0
p65	9
and	0
that	0
I	9
kappa	10
B	10
beta	10
is	0
degraded	0
in	0
response	0
to	0
TNF	9
alpha	10
in	0
contrast	0
to	0
what	0
has	0
been	0
originally	0
published	0
.	0

Our	0
data	0
also	0
suggest	0
that	0
,	0
unlike	0
I	9
kappa	10
B	10
alpha	10
,	0
I	9
kappa	10
B	10
beta	10
is	0
constitutively	0
phosphorylated	0
and	0
resynthesized	0
as	0
a	0
hypophosphorylated	9
form	10
.	0

The	0
absence	0
of	0
slow	0
migrating	0
forms	0
of	0
I	9
kappa	10
B	10
beta	10
following	0
stimulation	0
suggests	0
that	0
the	0
phosphorylation	0
does	0
not	0
necessarily	0
constitute	0
the	0
signal-induced	0
event	0
which	0
targets	0
the	0
molecule	0
for	0
proteolysis	0
.	0

Agonistic	0
activity	0
of	0
a	0
CD40-specific	9
single-chain	10
Fv	10
constructed	0
from	0
the	0
variable	9
regions	10
of	0
mAb	9
G28-5	10
.	0

A	0
single-chain	9
Fv	10
(	0
sFv	9
)	0
was	0
expressed	0
from	0
the	0
variable	9
regions	10
of	0
the	0
CD40-specific	0
mAb	9
G28-5	10
.	0

The	0
molecule	0
bound	0
CD40	9
with	0
a	0
high	0
affinity	0
(	0
2.2	0
nM	0
)	0
and	0
was	0
a	0
monomer	0
in	0
solution	0
.	0

Surprisingly	0
,	0
G28-5	9
sFv	10
was	0
a	0
potent	0
CD40	9
agonist	10
that	0
rapidly	0
crosslinked	0
CD40	9
on	0
the	0
cell	0
surface	0
but	0
did	0
not	0
crosslink	0
CD40-Ig	9
in	0
solution	0
.	0

G28-5	9
sFv	10
was	0
a	0
more	0
potent	0
agonist	0
than	0
G28-5	9
IgG	10
and	0
was	0
able	0
to	0
stimulate	0
CD40	9
responses	0
by	0
B	7
cells	8
and	0
monocytes	0
.	0

G28-5	9
IgG	10
partially	0
blocked	0
,	0
whereas	0
G28-5	9
sFv	10
augmented	0
CD40	9
responses	0
during	0
stimulation	0
with	0
natural	9
ligand	10
(	0
gp39-CD8	9
fusion	10
protein	10
)	0
.	0

These	0
results	0
indicate	0
that	0
the	0
functional	0
activity	0
of	0
ligands	0
built	0
from	0
the	0
binding	9
site	10
of	0
G28-5	9
is	0
highly	0
dependent	0
upon	0
the	0
size	0
and	0
physical	0
properties	0
of	0
the	0
molecule	0
both	0
in	0
solution	0
and	0
on	0
the	0
cell	0
surfaces	0
.	0

C/EBP	9
activates	0
the	0
human	1
corticotropin-releasing	2
hormone	2
gene	2
promoter	2
.	0

The	0
purpose	0
of	0
these	0
studies	0
was	0
to	0
identify	0
whether	0
transcription	0
factors	0
,	0
associated	0
with	0
cytokine	0
signalling	0
,	0
affected	0
promoter	0
activity	0
of	0
the	0
corticotropin	1
releasing	2
hormone	2
(	2
CRH	2
)	2
gene	2
.	0

Fragments	0
of	0
a	0
3.6	0
kb	0
sequence	0
of	0
the	0
human	1
CRH	2
gene	2
promoter	2
were	0
amplified	0
by	0
PCR	0
and	0
ligated	0
upstream	0
of	0
a	0
CAT	1
reporter	2
.	0

These	0
constructs	0
were	0
transfected	0
into	0
a	0
variety	0
of	0
cell	0
lines	0
,	0
either	0
alone	0
or	0
together	0
,	0
with	0
transcription	9
factor	10
expression	0
vectors	0
.	0

Basal	0
activity	0
of	0
a	0
3070	1
bp	2
CRH	2
promoter	2
fragment	2
was	0
only	0
seen	0
in	0
neuronal	0
and	0
lymphoblastoid	5
cell	6
lines	6
.	0

Promoter	0
activity	0
was	0
increased	0
by	0
the	0
transcription	9
factors	10
C/EBPbeta	9
(	0
NF-IL6	9
)	0
and	0
more	0
strongly	0
,	0
by	0
C/EBPdelta	9
(	0
NF-IL6beta	9
)	0
.	0

Increased	0
CRH	9
promoter	0
activity	0
following	0
phorbol	0
ester	0
treatment	0
was	0
inhibited	0
by	0
a	0
dominant	0
negative	0
NF-IL6	9
mutant	10
,	0
showing	0
that	0
the	0
effects	0
of	0
phorbol	0
ester	0
were	0
principally	0
mediated	0
by	0
C/EBP	9
.	0

Moreover	0
,	0
the	0
inverse	0
changes	0
in	0
the	0
expression	0
of	0
CRH	9
in	0
the	0
hypothalamus	0
and	0
spleens	0
of	0
arthritic	0
rats	0
were	0
paralleled	0
by	0
similar	0
inverse	0
changes	0
in	0
NF-IL6beta	9
expression	0
in	0
these	0
organs	0
.	0

These	0
data	0
show	0
that	0
some	0
transcription	9
factors	10
associated	0
with	0
cytokine	9
signalling	0
can	0
also	0
activate	0
the	0
CRH	1
promoter	2
.	0

Aberrant	0
splicing	0
of	0
the	0
TSG101	1
and	2
FHIT	2
genes	2
occurs	0
frequently	0
in	0
multiple	0
malignancies	0
and	0
in	0
normal	0
tissues	0
and	0
mimics	0
alterations	0
previously	0
described	0
in	0
tumours	0
.	0

Intragenic	0
deletions	0
of	0
TSG101	1
,	0
the	0
human	0
homolog	0
of	0
a	0
mouse	1
gene	2
(	0
tsg101	1
)	0
that	0
acts	0
to	0
suppress	0
malignant	0
cell	0
growth	0
,	0
were	0
reported	0
in	0
human	7
breast	8
tumours	8
.	0

We	0
screened	0
TSG101	1
for	0
somatic	0
mutations	0
in	0
DNA	0
and	0
RNA	0
samples	0
isolated	0
from	0
a	0
variety	0
of	0
common	0
human	0
malignancies	0
,	0
EBV-immortalised	7
B-cells	8
,	0
and	0
normal	0
lung	0
parenchyma	0
.	0

Intragenic	0
TSG101	1
deletions	0
in	0
RNA	3
transcripts	4
were	0
frequently	0
found	0
in	0
all	0
types	0
of	0
samples	0
.	0

Analysis	0
of	0
DNA	0
failed	0
to	0
show	0
genomic	0
rearrangements	0
corresponding	0
to	0
transcripts	0
containing	0
deletions	0
in	0
the	0
same	0
samples	0
.	0

The	0
breakpoints	0
of	0
most	0
transcript	0
deletions	0
coincide	0
with	0
genuine	0
or	0
cryptic	0
splice	1
site	2
sequences	2
,	0
suggesting	0
that	0
they	0
result	0
from	0
alternative	0
or	0
aberrant	0
splicing	0
.	0

A	0
similar	0
spectrum	0
of	0
transcript	0
deletions	0
has	0
previously	0
been	0
described	0
in	0
the	0
putative	1
tumour	2
suppressor	2
gene	2
FHIT	1
.	0

We	0
analysed	0
FHIT	1
in	0
the	0
same	0
series	0
of	0
RNA	3
samples	4
and	0
detected	0
truncated	0
FHIT	3
transcripts	4
frequently	0
in	0
both	0
tumour	0
and	0
normal	0
tissues	0
.	0

In	0
addition	0
,	0
transcripts	0
from	0
TSG101	1
,	0
FHIT	1
and	0
seven	0
other	0
genes	0
were	0
analysed	0
in	0
RNA	0
isolated	0
from	0
normal	7
peripheral	8
blood	8
lymphocytes	8
.	0

Large	0
TSG101	1
and	0
FHIT	1
intragenic	0
transcript	0
deletions	0
were	0
detected	0
and	0
these	0
appeared	0
to	0
be	0
the	0
predominant	0
transcript	0
in	0
'aged	7
'	8
lymphocytes	8
.	0

Similar	0
alterations	0
were	0
not	0
detected	0
in	0
transcripts	0
of	0
the	0
other	0
genes	0
which	0
were	0
analysed	0
.	0

Our	0
findings	0
demonstrate	0
that	0
truncated	3
TSG101	4
and	4
FHIT	4
transcripts	4
are	0
commonly	0
detected	0
in	0
both	0
normal	0
and	0
malignant	0
tissues	0
and	0
that	0
a	0
significant	0
fraction	0
of	0
these	0
are	0
likely	0
to	0
be	0
the	0
result	0
of	0
aberrant	0
splicing	0
.	0

While	0
we	0
can	0
not	0
exclude	0
that	0
alterations	0
in	0
TSG101	1
and	0
FHIT	1
occur	0
during	0
cancer	0
development	0
,	0
our	0
data	0
indicate	0
that	0
in	0
this	0
context	0
the	0
commonly	0
observed	0
transcript	0
abnormalities	0
are	0
misleading	0
.	0

Inhibition	0
of	0
proliferation	0
and	0
apoptosis	0
of	0
human	7
and	8
rat	8
T	8
lymphocytes	8
by	0
curcumin	0
,	0
a	0
curry	0
pigment	0
.	0

Curcumin	0
(	0
diferuoylmethane	0
)	0
,	0
the	0
yellow	0
pigment	0
in	0
the	0
rhizome	0
of	0
tumeric	0
(	0
Curcuma	0
longa	0
)	0
,	0
an	0
ingredient	0
of	0
curry	0
spice	0
,	0
is	0
known	0
to	0
exhibit	0
a	0
variety	0
of	0
pharmacological	0
effects	0
including	0
antitumor	0
,	0
antiinflammatory	0
,	0
and	0
antiinfectious	0
activities	0
.	0

Although	0
its	0
precise	0
mode	0
of	0
action	0
remains	0
elusive	0
,	0
curcumin	0
has	0
been	0
shown	0
to	0
suppress	0
the	0
activity	0
of	0
the	0
AP-1	9
transcription	9
factor	10
in	0
cells	0
stimulated	0
to	0
proliferate	0
.	0

In	0
this	0
study	0
,	0
we	0
observed	0
that	0
curcumin	0
(	0
50	0
microM	0
)	0
inhibited	0
proliferation	0
of	0
rat	7
thymocytes	8
stimulated	0
with	0
concanavalin	0
A	0
(	0
Con	0
A	0
)	0
as	0
well	0
as	0
that	0
of	0
human	7
Jurkat	8
lymphoblastoid	8
cells	8
in	0
the	0
logarithmic	0
growth	0
phase	0
.	0

The	0
pigment	0
also	0
inhibited	0
apoptosis	0
in	0
dexamethasone-treated	5
rat	6
thymocytes	6
and	0
in	0
UV-irradiated	5
Jurkat	6
cells	6
as	0
judged	0
by	0
DNA	0
ladder	0
formation	0
,	0
cellular	0
morphological	0
changes	0
,	0
and	0
flow	0
cytometry	0
analysis	0
.	0

The	0
inhibition	0
of	0
apoptosis	0
by	0
curcumin	0
in	0
rat	7
thymocytes	8
was	0
accompanied	0
by	0
partial	0
suppression	0
of	0
AP-1	9
activity	0
.	0

Complete	0
suppression	0
of	0
AP-1	9
activity	0
was	0
observed	0
in	0
Con	5
A-treated	6
,	6
proliferating	6
thymocytes	6
.	0

The	0
capacity	0
of	0
curcumin	0
to	0
inhibit	0
both	0
cell	0
growth	0
and	0
death	0
strongly	0
implies	0
that	0
these	0
two	0
biological	0
processes	0
share	0
a	0
common	0
pathway	0
at	0
some	0
point	0
and	0
that	0
curcumin	0
affects	0
a	0
common	0
step	0
,	0
presumably	0
involving	0
a	0
modulation	0
of	0
the	0
AP-1	9
transcription	9
factor	10
.	0

Interleukin-7	9
upregulates	0
the	0
interleukin-2-gene	1
expression	0
in	0
activated	7
human	8
T	8
lymphocytes	8
at	0
the	0
transcriptional	0
level	0
by	0
enhancing	0
the	0
DNA	0
binding	0
activities	0
of	0
both	0
nuclear	0
factor	0
of	0
activated	7
T	8
cells	8
and	0
activator	9
protein-1	10
.	0

In	0
the	0
present	0
report	0
,	0
we	0
studied	0
the	0
role	0
of	0
the	0
stromal-derived	9
cytokine	10
interleukin-7	10
(	0
IL-7	9
)	0
in	0
the	0
IL-2-gene	1
regulation	0
in	0
activated	7
T	8
lymphocytes	8
.	0

Production	0
of	0
IL-2	9
requires	0
the	0
formation	0
of	0
transcription	9
factors	10
involved	0
in	0
the	0
IL-2-gene	1
regulation	0
.	0

T-cell	9
receptor	10
(	9
TCR	10
)	10
/CD3	10
engagement	0
results	0
in	0
the	0
activation	0
of	0
nuclear	0
factor	0
of	0
activated	7
T	8
cells	8
(	0
NFAT	9
)	0
,	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
,	0
and	0
nuclear	9
factor	10
kappaB	10
(	0
NFkappaB	9
)	0
,	0
whereas	0
the	0
CD28	9
responsive	10
complex	10
(	0
CD28RC	9
)	0
is	0
activated	0
in	0
response	0
to	0
the	0
CD28	9
signal	0
.	0

Costimulation	0
of	0
phytohemagglutinin/anti-CD28	5
activated	6
T	6
lymphocytes	6
with	0
IL-7	9
induces	0
a	0
fivefold	0
enhanced	0
IL-2	9
-mRNA	0
accumulation	0
and	0
a	0
2.5-fold	0
enhanced	0
protein	0
secretion	0
.	0

The	0
IL-2-gene	1
transcription	0
rate	0
is	0
increased	0
3.4-fold	0
,	0
indicating	0
that	0
the	0
effect	0
of	0
IL-7	9
is	0
in	0
part	0
mediated	0
at	0
the	0
transcriptional	0
level	0
.	0

The	0
molecular	0
mechanisms	0
underlying	0
the	0
IL-7	9
effect	0
involve	0
the	0
upregulation	0
of	0
the	0
DNA	0
binding	0
activity	0
of	0
NFAT	9
(	0
60	0
%	0
)	0
and	0
AP-1	9
(	0
120	0
%	0
)	0
,	0
without	0
affecting	0
the	0
activities	0
of	0
NFkappaB	9
and	0
CD28RC	9
,	0
which	0
was	0
confirmed	0
by	0
transfection	0
assays	0
.	0

We	0
also	0
show	0
that	0
the	0
IL-7	9
-induced	0
enhancement	0
of	0
the	0
AP-1	9
-DNA	0
binding	0
activity	0
is	0
not	0
cyclosporin	0
A-sensitive	0
.	0

Since	0
AP-1	9
is	0
part	0
of	0
the	0
NFAT	9
complex	10
,	0
we	0
conclude	0
that	0
the	0
IL-7	9
-signaling	0
pathway	0
is	0
involved	0
in	0
the	0
activation	0
of	0
the	0
fos	9
and	10
jun	10
proteins	10
of	0
which	0
AP-1	9
consists	0
.	0

The	0
spatial	0
distribution	0
of	0
human	1
immunoglobulin	2
genes	2
within	0
the	0
nucleus	0
:	0
evidence	0
for	0
gene	0
topography	0
independent	0
of	0
cell	0
type	0
and	0
transcriptional	0
activity	0
.	0

The	0
three-dimensional	0
positioning	0
of	0
immunoglobulin	1
(	2
Ig	2
)	2
genes	2
within	0
the	0
nucleus	0
of	0
human	7
cells	8
was	0
investigated	0
using	0
in	0
situ	0
hybridization	0
and	0
confocal	0
microscopy	0
.	0

The	0
visualization	0
of	0
heavy	1
and	2
light	2
chain	2
genes	2
in	0
B-lymphoid	7
cells	8
showed	0
that	0
the	0
three	0
Ig	1
genes	2
are	0
differentially	0
and	0
nonrandomly	0
distributed	0
in	0
different	0
nuclear	0
subvolumes	0
:	0
the	0
kappa	1
genes	2
were	0
found	0
to	0
be	0
preferentially	0
confined	0
to	0
an	0
outer	0
nuclear	0
volume	0
,	0
whereas	0
the	0
gamma	1
and	2
lambda	2
genes	2
consistently	0
occupied	0
more	0
central	0
positions	0
within	0
the	0
nucleus	0
,	0
the	0
lambda	1
genes	2
being	0
more	0
interior	0
when	0
compared	0
with	0
the	0
gamma	1
genes	2
.	0

The	0
data	0
further	0
show	0
that	0
these	0
overall	0
topographical	0
distributions	0
are	0
independent	0
of	0
gene	0
transcriptional	0
activity	0
and	0
are	0
conserved	0
in	0
different	7
cell	8
types	8
.	0

Although	0
subtle	0
gene	0
movements	0
within	0
those	0
defined	0
topographical	0
regions	0
can	0
not	0
be	0
excluded	0
by	0
this	0
study	0
,	0
the	0
results	0
indicate	0
that	0
tissue	0
specificity	0
of	0
gene	0
expression	0
is	0
not	0
accompanied	0
by	0
drastic	0
changes	0
in	0
gene	0
nuclear	0
topography	0
,	0
rather	0
suggesting	0
that	0
gene	0
organization	0
within	0
the	0
nucleus	0
may	0
be	0
primarily	0
dependent	0
on	0
structural	0
constraints	0
imposed	0
on	0
the	0
respective	0
chromosomes	1
.	0

Dominant	0
cytotoxic	7
T	8
lymphocyte	8
response	0
to	0
the	0
immediate-early	9
trans-activator	10
protein	10
,	0
BZLF1	9
,	0
in	0
persistent	0
type	0
A	0
or	0
B	0
Epstein-Barr	0
virus	0
infection	0
.	0

Five	0
healthy	0
human	0
leukocyte	0
antigen-B8	0
(	0
HLA-B8	0
)	0
-positive	0
virus	0
carriers	0
were	0
studied	0
to	0
investigate	0
the	0
CD8+	7
cytotoxic	8
T	8
lymphocyte	8
(	0
CTL	0
)	0
response	0
to	0
an	0
HLA-B8-restricted	0
peptide	0
,	0
RAKFKQLLQ	0
,	0
located	0
in	0
the	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
immediate-early	10
trans-activator	10
protein	10
,	0
BZLF1	9
.	0

Of	0
the	0
5	0
virus	0
carriers	0
,	0
4	0
were	0
infected	0
with	0
type	0
A	0
and	0
1	0
with	0
type	0
B	0
EBV	0
.	0

Using	0
limiting-dilution	0
analysis	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
,	0
a	0
high	0
RAKFKQLLQ-specific	0
CTL	0
precursor	0
frequency	0
was	0
demonstrated	0
after	0
specific	0
peptide	0
or	0
autologous	0
lymphoblastoid	0
cell	0
line	0
stimulation	0
in	0
both	0
type	0
A	0
and	0
type	0
B	0
EBV	0
carriers	0
.	0

The	0
RAKFKQLLQ-specific	0
CTL	0
precursor	0
frequencies	0
in	0
all	0
5	0
persons	0
were	0
at	0
least	0
as	0
dominant	0
as	0
those	0
observed	0
with	0
two	0
other	0
EBV-associated	9
,	10
HLA-B8-restricted	10
latent	10
epitopes	10
,	0
FLRGRAYGL	0
and	0
QAKWRLQTL	0
.	0

These	0
findings	0
show	0
that	0
healthy	0
virus	0
carriers	0
maintain	0
a	0
high	0
frequency	0
of	0
BZLF1-specific	7
memory	8
T	8
cells	8
,	0
potentially	0
to	0
control	0
virus	0
spread	0
from	0
lytically	7
infected	8
cells	8
.	0

The	0
DNA	9
binding	10
domain	10
of	0
the	0
A-MYB	9
transcription	9
factor	10
is	0
responsible	0
for	0
its	0
B	0
cell-specific	0
activity	0
and	0
binds	0
to	0
a	0
B	9
cell	10
110-kDa	10
nuclear	10
protein	10
.	0

Expression	0
studies	0
as	0
well	0
as	0
the	0
use	0
of	0
transgenic	0
animals	0
have	0
demonstrated	0
that	0
the	0
A-MYB	9
transcription	9
factor	10
plays	0
central	0
and	0
specific	0
role	0
in	0
the	0
regulation	0
of	0
mature	7
B	8
cell	8
proliferation	0
and/or	0
differentiation	0
.	0

Furthermore	0
,	0
it	0
is	0
highly	0
expressed	0
in	0
Burkitt	5
's	6
lymphoma	6
cells	6
and	0
may	0
participate	0
in	0
the	0
pathogenesis	0
of	0
this	0
disease	0
.	0

We	0
have	0
therefore	0
investigated	0
the	0
transcriptional	0
activity	0
of	0
A-MYB	9
and	0
its	0
regulation	0
in	0
several	0
human	5
lymphoid	6
cell	6
lines	6
using	0
co-transfection	0
assays	0
and	0
show	0
that	0
A-MYB	9
is	0
transcriptionally	0
active	0
in	0
all	0
the	0
B	5
cell	6
lines	6
studied	0
,	0
but	0
not	0
in	0
T	7
cells	8
.	0

In	0
particular	0
the	0
best	0
responder	5
cell	6
line	6
was	0
the	0
Burkitt	5
's	6
cell	6
line	6
Namalwa	6
.	0

The	0
activity	0
of	0
A-MYB	9
in	0
B	7
and	8
not	8
T	8
cells	8
was	0
observed	0
when	0
either	0
an	0
artificial	0
construct	0
or	0
the	0
c-MYC	1
promoter	2
was	0
used	0
as	0
a	0
reporter	0
.	0

Furthermore	0
,	0
the	0
functional	9
domains	10
responsible	0
for	0
DNA	0
binding	0
,	0
transactivation	0
,	0
and	0
negative	0
regulation	0
,	0
previously	0
characterized	0
in	0
a	0
fibroblast	0
context	0
,	0
were	0
found	0
to	0
have	0
similar	0
activity	0
in	0
B	7
cells	8
.	0

The	0
region	0
of	0
A-MYB	9
responsible	0
for	0
the	0
B	0
cell	0
specific	0
activity	0
was	0
defined	0
to	0
be	0
the	0
N-terminal	9
218	10
amino	10
acids	10
containing	0
the	0
DNA	9
binding	10
domain	10
.	0

Finally	0
,	0
a	0
110-kDa	9
protein	10
has	0
been	0
identified	0
in	0
the	0
nuclei	0
of	0
all	0
the	0
B	5
,	6
but	6
not	6
T	6
,	6
cell	6
lines	6
that	0
specifically	0
binds	0
to	0
this	0
A-MYB	9
N-terminal	10
domain	10
.	0

We	0
hypothesize	0
that	0
this	0
110-kDa	9
protein	10
may	0
be	0
a	0
functionally	0
important	0
B	9
cell-specific	10
co-activator	10
of	0
A-MYB	9
.	0

Transcription	0
factor	0
Egr-1	9
activity	0
down-regulates	0
Fas	0
and	0
CD23	0
expression	0
in	0
B	7
cells	8
.	0

Activation	0
of	0
mature	0
B	7
cells	8
via	0
Ag	9
receptor	10
cross-linking	0
induces	0
transient	0
expression	0
of	0
the	0
transcription	9
factor	10
Egr-1	9
.	0

Although	0
the	0
activating	0
signals	0
leading	0
to	0
Egr-1	9
induction	0
have	0
been	0
studied	0
extensively	0
,	0
little	0
is	0
known	0
about	0
the	0
genes	0
that	0
are	0
placed	0
further	0
downstream	0
within	0
this	0
activation	0
cascade	0
and	0
that	0
are	0
transcriptionally	0
regulated	0
by	0
Egr-1	9
.	0

To	0
identify	0
such	0
target	1
genes	2
,	0
we	0
established	0
Egr-1-overexpressing	5
transfectants	6
from	0
the	0
murine	5
B	6
cell	6
line	6
K46	6
and	0
from	0
human	5
Ramos	6
B	6
cells	6
.	0

All	0
clones	0
derived	0
from	0
K46	5
B	6
cells	6
showed	0
increased	0
expression	0
of	0
CD44	9
.	0

Most	0
interestingly	0
,	0
expression	0
of	0
CD95	9
(	0
Fas/Apo-1	9
)	0
and	0
of	0
CD23	9
was	0
down-regulated	0
in	0
all	0
K46	5
transfectants	6
.	0

As	0
a	0
consequence	0
,	0
they	0
became	0
resistant	0
to	0
apoptosis	0
induced	0
by	0
anti-CD95	9
Ab	10
treatment	0
.	0

Similarly	0
,	0
the	0
Egr-1-expressing	5
Ramos	6
cells	6
showed	0
reduced	0
levels	0
of	0
CD95	9
expression	0
.	0

Thus	0
,	0
Egr-1	9
seems	0
to	0
control	0
the	0
expression	0
of	0
downstream	1
target	2
genes	2
not	0
only	0
as	0
a	0
transcriptional	0
activator	0
,	0
but	0
also	0
as	0
a	0
repressor	9
molecule	10
.	0

In	0
B	7
cells	8
,	0
Egr-1	9
therefore	0
plays	0
a	0
critical	0
role	0
in	0
integrating	0
the	0
short-lived	0
signal	0
delivered	0
by	0
triggering	0
of	0
the	0
Ag	9
receptor	10
into	0
phenotypic	0
changes	0
,	0
including	0
repression	0
of	0
CD95	9
and	0
CD23	9
transcription	0
.	0

Regulation	0
of	0
NF-kappa	9
B	10
activity	0
by	0
I	0
kappa	0
B	0
alpha	0
and	0
I	0
kappa	0
B	0
beta	0
stability	0
.	0

Transcription	9
factor	10
NF-kappa	9
B	10
must	0
be	0
released	0
from	0
cytoplasmic	9
inhibitory	10
molecules	10
(	0
I	9
kappa	10
Bs	10
)	0
in	0
order	0
to	0
move	0
to	0
the	0
nucleus	0
and	0
to	0
activate	0
its	0
target	1
genes	2
.	0

Little	0
is	0
known	0
about	0
the	0
mechanisms	0
regulating	0
the	0
maintenance	0
of	0
constitutive	9
nuclear	10
NF-kappa	10
B	10
in	0
some	0
cell-types	0
and	0
of	0
sustained	0
nuclear	0
NF-kappa	9
B	10
activity	0
after	0
stimulation	0
.	0

Increased	0
turnover	0
has	0
been	0
implicated	0
in	0
the	0
regulation	0
of	0
constitutive	0
NF-kappa	9
B	10
activity	0
in	0
mature	7
B	8
cells	8
.	0

We	0
therefore	0
compared	0
the	0
turnover	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
I	9
kappa	10
B	10
beta	10
in	0
mature	7
B	8
cells	8
and	0
HeLa	5
cells	6
.	0

Both	0
proteins	0
display	0
a	0
high	0
turnover	0
in	0
B	7
cells	8
although	0
I	9
kappa	10
B	10
beta	10
is	0
considerably	0
more	0
stable	0
than	0
I	9
kappa	10
B	10
alpha	10
.	0

The	0
half-life	0
of	0
both	0
inhibitors	0
is	0
increased	0
in	0
HeLa	5
cells	6
.	0

In	0
contrast	0
,	0
all	0
other	0
NF-kappa	9
B	10
/I	0
kappa	0
B	0
molecules	0
tested	0
are	0
relatively	0
stable	0
in	0
both	0
cell-types	0
.	0

The	0
elevated	0
turnover	0
of	0
endogenous	0
I	9
kappa	10
B	10
alpha	10
in	0
Namalwa	7
cells	8
is	0
inhibited	0
by	0
a	0
proteasome	0
inhibitor	0
and	0
thus	0
seems	0
to	0
be	0
driven	0
by	0
the	0
same	0
degradation	0
machinery	0
as	0
the	0
slower	0
turnover	0
in	0
non-B	7
cells	8
.	0

Furthermore	0
,	0
we	0
investigated	0
the	0
processes	0
involved	0
in	0
persistent	0
activation	0
of	0
NF-kappa	9
B	10
.	0

TNF-alpha	0
signaling	0
leads	0
to	0
a	0
rapid	0
depletion	0
of	0
cellular	0
I	9
kappa	10
B	10
beta	10
pools	0
.	0

I	9
kappa	10
B	10
alpha	10
is	0
efficiently	0
resynthesized	0
whereas	0
I	9
kappa	10
B	10
beta	10
levels	0
stay	0
low	0
for	0
a	0
prolonged	0
time	0
.	0

NF-kappa	9
B	10
binding	0
activity	0
can	0
be	0
detected	0
for	0
several	0
hours	0
after	0
stimulation	0
.	0

We	0
found	0
that	0
removal	0
of	0
the	0
TNF-alpha	9
containing	0
medium	0
causes	0
a	0
rapid	0
decrease	0
in	0
nuclear	9
NF-kappa	10
B	10
.	0

A	0
phosphoform	0
of	0
newly	0
synthesized	0
I	9
kappa	10
B	10
alpha	10
is	0
visible	0
when	0
degradation	0
by	0
the	0
proteasome	9
is	0
inhibited	0
and	0
new	0
I	9
kappa	10
B	10
alpha	10
displays	0
the	0
same	0
properties	0
regarding	0
phosphorylation	0
and	0
degradation	0
in	0
response	0
to	0
a	0
second	0
inducer	0
.	0

There	0
is	0
no	0
significant	0
difference	0
in	0
the	0
turnover	0
of	0
pre-	0
and	0
post-inductive	0
I	9
kappa	10
B	10
alpha	10
.	0

These	0
observations	0
suggest	0
that	0
resynthesis	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
removal	0
of	0
the	0
stimulus	0
are	0
obligatory	0
steps	0
for	0
the	0
inactivation	0
of	0
nuclear	9
NF	10
kappa	10
B	10
.	0

Selection	0
of	0
a	0
diverse	0
TCR	9
repertoire	10
in	0
response	0
to	0
an	0
Epstein-Barr	9
virus-encoded	10
transactivator	10
protein	10
BZLF1	9
by	0
CD8+	7
cytotoxic	8
T	8
lymphocytes	8
during	0
primary	0
and	0
persistent	0
infection	0
.	0

We	0
investigated	0
the	0
CD8+	9
cytotoxic	10
T	10
lymphocyte	10
(	10
CTL	10
)	10
repertoire	10
to	0
an	0
HLA	0
B8-restricted	0
peptide	0
,	0
RAKFKQLLQ	0
,	0
located	0
in	0
the	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
immediate-early	10
protein	10
,	0
BZLF1	9
.	0

Repertoire	0
selection	0
was	0
monitored	0
by	0
determining	0
the	0
TCR	9
beta	10
chain	10
sequences	10
of	0
RAKFKQLLQ-specific	5
CTL	6
established	0
from	0
primary	0
infected	0
and	0
healthy	0
virus	0
carriers	0
.	0

PCR	0
analysis	0
of	0
spontaneous	5
EBV-transformed	6
lymphoblastoid	6
cell	6
lines	6
(	0
LCL	5
)	0
from	0
three	0
individuals	0
with	0
primary	0
infection	0
showed	0
that	0
two	0
were	0
infected	0
with	0
type	0
A	0
and	0
one	0
with	0
type	0
B	0
EBV	0
.	0

Polyclonal	5
and	6
clonal	6
CTL	6
that	0
were	0
generated	0
by	0
stimulating	0
peripheral	7
blood	8
mononuclear	8
cells	8
with	0
an	0
HLA	5
B8+	6
homozygous	6
LCL	6
lysed	6
T	6
cell	6
blasts	6
pulsed	0
with	0
the	0
peptide	0
,	0
RAKFKQLLQ	0
;	0
lysis	0
of	0
certain	0
HLA	0
B8+	0
LCL	0
targets	0
was	0
associated	0
with	0
the	0
abundance	0
of	0
BZLF1	3
transcripts	4
.	0

TCR	1
beta	2
analysis	0
showed	0
that	0
while	0
there	0
was	0
loop	0
length	0
restriction	0
in	0
the	0
putative	0
peptide	0
contact	0
site	0
of	0
all	0
responding	0
beta	9
chains	10
,	0
diverse	0
and	0
unique	5
(	6
non-recurrent	6
)	6
TCR	6
beta	6
clonotypes	6
were	0
selected	0
in	0
individuals	0
during	0
primary	0
infection	0
and	0
continued	0
to	0
emerge	0
after	0
long-term	0
virus	0
exposure	0
.	0

TCR	9
-contact	0
site	0
heterogeneity	0
was	0
excluded	0
as	0
the	0
selective	0
force	0
in	0
diversity	0
generation	0
since	0
the	0
epitope-encoded	0
sequences	0
were	0
found	0
to	0
be	0
identical	0
within	0
endogenous	0
virus	0
isolates	0
.	0

In	0
this	0
first	0
study	0
of	0
TCR	9
repertoire	10
selection	0
for	0
an	0
EBV	9
lytic	10
antigen	10
,	0
a	0
BZLF1	9
-reactive	0
component	0
of	0
diverse	0
clonotypes	0
was	0
identified	0
in	0
primary	0
type	0
A	0
or	0
type	0
B	0
EBV	0
infection	0
which	0
was	0
sustained	0
in	0
the	0
EBV-specific	0
memory	0
response	0
throughout	0
life-long	0
infection	0
.	0

This	0
diversity	0
selection	0
is	0
likely	0
to	0
play	0
a	0
critical	0
role	0
in	0
maintaining	0
a	0
balanced	0
viral	0
load	0
throughout	0
EBV	0
persistence	0
.	0

Molecular	0
mechanisms	0
of	0
anoxia/reoxygenation-induced	0
neutrophil	0
adherence	0
to	0
cultured	5
endothelial	6
cells	6
.	0

The	0
objectives	0
of	0
this	0
study	0
were	0
to	0
(	0
1	0
)	0
determine	0
the	0
time	0
course	0
of	0
neutrophil	0
adhesion	0
to	0
monolayers	0
of	0
human	5
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVECs	5
)	0
that	0
were	0
exposed	0
to	0
60	0
minutes	0
of	0
anoxia	0
followed	0
by	0
30	0
to	0
600	0
minutes	0
of	0
reoxygenation	0
and	0
(	0
2	0
)	0
define	0
the	0
mechanisms	0
responsible	0
for	0
both	0
the	0
early	0
(	0
minutes	0
)	0
and	0
late	0
(	0
hours	0
)	0
hyperadhesivity	0
of	0
postanoxic	5
HUVECs	6
to	0
human	7
neutrophils	8
.	0

The	0
results	0
clearly	0
demonstrate	0
that	0
anoxia/reoxygenation	0
(	0
A/R	0
)	0
leads	0
to	0
a	0
biphasic	0
increase	0
in	0
neutrophil	0
adhesion	0
to	0
HUVECs	5
,	0
with	0
peak	0
responses	0
occurring	0
at	0
30	0
minutes	0
(	0
phase	0
1	0
)	0
and	0
240	0
minutes	0
(	0
phase	0
2	0
)	0
after	0
reoxygenation	0
.	0

Oxypurinol	0
and	0
catalase	9
inhibited	0
phase-1	0
adhesion	0
,	0
suggesting	0
a	0
role	0
for	0
xanthine	9
oxidase	10
and	0
H2O2	0
.	0

In	0
comparison	0
,	0
platelet	9
activating	10
factor	10
(	0
PAF	9
)	0
contributed	0
to	0
both	0
phases	0
of	0
neutrophil	0
adhesion	0
.	0

Anti-intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
and	0
anti-P-selectin	9
antibodies	10
(	0
monoclonal	9
antibodies	10
[	0
mAbs	9
]	0
)	0
attenuated	0
phase-1	0
neutrophil	0
adhesion	0
,	0
consistent	0
with	0
roles	0
for	0
constitutively	0
expressed	0
ICAM-1	9
and	0
enhanced	0
surface	0
expression	0
of	0
preformed	0
P-selectin	9
.	0

Phase-2	0
neutrophil	0
adhesion	0
was	0
attenuated	0
by	0
an	0
anti-E-selectin	9
mAb	10
,	0
indicating	0
a	0
dominant	0
role	0
of	0
this	0
adhesion	0
molecule	0
in	0
the	0
late	0
phase	0
response	0
.	0

Pretreatment	0
with	0
actinomycin	0
D	0
and	0
cycloheximide	0
or	0
with	0
competing	0
ds-oligonucleotides	0
containing	0
the	0
nuclear	9
factor-kappa	10
B	10
or	0
activator	9
protein-1	10
cognate	1
DNA	2
sequences	2
significantly	0
attenuated	0
phase-2	0
response	0
,	0
suggesting	0
a	0
role	0
for	0
de	0
novo	0
macromolecule	0
synthesis	0
.	0

Surface	0
expression	0
of	0
ICAM-1	9
,	0
P-selectin	9
,	0
and	0
E-selectin	9
on	0
HUVECs	5
correlated	0
with	0
the	0
phase-1	0
and	0
-2	0
neutrophil	0
adhesion	0
responses	0
.	0

Collectively	0
,	0
these	0
findings	0
indicate	0
that	0
A/R	0
elicits	0
a	0
two-phase	0
neutrophil-endothelial	0
cell	0
adhesion	0
response	0
that	0
involves	0
transcription-independent	0
and	0
transcription-dependent	0
surface	0
expression	0
of	0
different	0
endothelial	9
cell	10
adhesion	10
molecules	10
.	0

Characterization	0
of	0
CD40	9
signaling	0
determinants	0
regulating	0
nuclear	9
factor-kappa	10
B	10
activation	0
in	0
B	7
lymphocytes	8
.	0

CD40	9
signaling	0
to	0
B	7
cells	8
is	0
important	0
for	0
generating	0
an	0
effective	0
humoral	0
immune	0
response	0
.	0

CD40	9
ligation	0
leads	0
to	0
B	0
cell	0
activation	0
events	0
such	0
as	0
proliferation	0
,	0
Ig	0
secretion	0
,	0
isotype	0
switching	0
,	0
and	0
up-regulation	0
of	0
cell	9
surface	10
molecules	10
,	0
as	0
well	0
as	0
the	0
generation	0
of	0
memory	7
B	8
cells	8
.	0

Many	0
of	0
these	0
events	0
are	0
dependent	0
upon	0
the	0
ability	0
of	0
CD40	9
to	0
activate	0
the	0
transcription	0
factor	0
NF-kappa	9
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

To	0
define	0
the	0
CD40	9
signaling	0
components	0
upstream	0
of	0
NF-kappa	9
B	10
activation	0
and	0
the	0
functional	0
consequences	0
downstream	0
of	0
NF-kappa	9
B	10
activation	0
,	0
we	0
examined	0
mouse	5
B	6
cell	6
transfectants	6
expressing	0
wild-type	9
or	10
mutant	10
human	10
CD40	10
.	0

Analysis	0
of	0
CD40	9
cytoplasmic	10
domain	10
truncation	0
and	0
point	0
mutants	0
defined	0
a	0
10-amino	9
acid	10
CD40	10
cytoplasmic	10
signaling	10
determinant	10
required	0
for	0
NF-kappa	9
B	10
activation	0
.	0

A	0
threonine	0
residue	0
at	0
position	9
234	10
,	0
previously	0
shown	0
to	0
be	0
important	0
for	0
CD40	9
association	0
with	0
TNF	9
receptor-associated	10
factor	10
2	10
(	0
TRAF2	9
)	0
,	0
TRAF3	9
,	0
and	0
TRAF5	9
,	0
was	0
not	0
required	0
for	0
NF-kappa	9
B	10
activation	0
.	0

This	0
suggests	0
that	0
in	0
B	7
cells	8
,	0
CD40	9
-induced	0
NF-kappa	9
B	10
activation	0
can	0
occur	0
independently	0
of	0
TRAF2	9
and	0
TRAF5	9
association	0
.	0

NF-kappa	9
B	10
activation	0
was	0
independent	0
of	0
the	0
transmembrane	9
domain	10
of	0
CD40	9
,	0
suggesting	0
that	0
it	0
is	0
independent	0
of	0
p23	9
,	0
a	0
molecule	0
that	0
associates	0
with	0
CD40	9
in	0
a	0
region	0
other	0
than	0
the	0
cytoplasmic	9
domain	10
.	0

Proteasome-dependent	0
inhibitory	0
kappa	0
B	0
alpha	0
(	0
I	9
kappa	10
B	10
alpha	10
)	0
and	0
I	9
kappa	10
B	10
beta	10
degradation	0
occurred	0
downstream	0
of	0
CD40	9
ligation	0
and	0
preceded	0
CD40	9
-mediated	0
NF-kappa	9
B	10
nuclear	0
translocation	0
.	0

CD40-	0
or	0
pervanadate-mediated	0
I	0
kappa	0
B	0
tyrosine	0
phosphorylation	0
was	0
not	0
detected	0
.	0

NF-kappa	9
B	10
activation	0
correlated	0
with	0
the	0
ability	0
of	0
CD40	9
to	0
induce	0
Ab	0
secretion	0
and	0
the	0
up-regulation	0
of	0
ICAM-1	9
and	0
LFA-1	9
.	0

However	0
,	0
NF-kappa	9
B	10
activation	0
was	0
insufficient	0
for	0
CD40	9
-mediated	0
up-regulation	0
of	0
B7-1	9
,	0
Fas	9
,	0
and	0
CD23	9
.	0

CD30	9
-dependent	0
degradation	0
of	0
TRAF2	9
:	0
implications	0
for	0
negative	0
regulation	0
of	0
TRAF	9
signaling	0
and	0
the	0
control	0
of	0
cell	0
survival	0
.	0

CD30	9
is	0
a	0
cell-surface	9
receptor	10
that	0
can	0
augment	0
lymphocyte	0
activation	0
and	0
survival	0
through	0
its	0
ability	0
to	0
induce	0
the	0
transcription	9
factor	10
NF-kappaB	9
.	0

CD30	9
,	0
however	0
,	0
has	0
also	0
been	0
implicated	0
in	0
the	0
induction	0
of	0
apoptotic	0
cell	0
death	0
of	0
lymphocytes	7
.	0

Here	0
we	0
show	0
that	0
one	0
of	0
the	0
effects	0
of	0
CD30	9
signal	0
transduction	0
is	0
to	0
render	0
cells	0
sensitive	0
to	0
apoptosis	0
induced	0
by	0
the	0
type	9
1	10
tumor	10
necrosis	10
factor	10
receptor	10
(	0
TNFR1	9
)	0
.	0

This	0
sensitization	0
is	0
dependent	0
on	0
the	0
TRAF-binding	9
sites	10
within	0
the	0
CD30	9
cytoplasmic	9
domain	10
.	0

One	0
of	0
the	0
proteins	0
that	0
binds	0
to	0
these	0
sites	0
is	0
TRAF2	9
,	0
a	0
signal	9
transduction	10
molecule	10
that	0
is	0
also	0
utilized	0
by	0
TNFR1	9
to	0
mediate	0
the	0
activation	0
of	0
several	0
downstream	0
kinases	9
and	0
transcription	9
factors	10
.	0

During	0
CD30	9
signal	0
transduction	0
,	0
we	0
found	0
that	0
binding	0
of	0
TRAF2	9
to	0
the	0
cytoplasmic	9
domain	10
of	0
CD30	9
results	0
in	0
the	0
rapid	0
depletion	0
of	0
TRAF2	9
and	0
the	0
associated	0
protein	0
TRAF1	9
by	0
proteolysis	0
.	0

These	0
data	0
suggest	0
a	0
model	0
in	0
which	0
CD30	9
limits	0
its	0
own	0
ability	0
to	0
transduce	0
cell	0
survival	0
signals	0
through	0
signal-coupled	0
depletion	0
of	0
TRAF2	9
.	0

Depletion	0
of	0
intracellular	0
TRAF2	9
and	0
its	0
coassociated	9
proteins	10
also	0
increased	0
the	0
sensitivity	0
of	0
the	0
cell	0
to	0
undergoing	0
apoptosis	0
during	0
activation	0
of	0
death-inducing	9
receptors	10
such	0
as	0
TNFR1	9
.	0

Consistent	0
with	0
this	0
hypothesis	0
,	0
expression	0
of	0
a	0
dominant-negative	9
form	10
of	0
TRAF2	9
was	0
found	0
to	0
potentiate	0
TNFR1	9
-mediated	0
death	0
.	0

These	0
studies	0
provide	0
a	0
potential	0
mechanism	0
through	0
which	0
CD30	9
,	0
as	0
well	0
as	0
other	0
TRAF-binding	9
members	10
of	0
the	0
TNFR	9
superfamily	10
,	0
can	0
negatively	0
regulate	0
cell	0
survival	0
.	0

Analysis	0
of	0
myeloid-associated	1
genes	2
in	0
human	7
hematopoietic	8
progenitor	8
cells	8
.	0

The	0
distribution	0
of	0
myeloid	9
lineage-associated	10
cytokine	10
receptors	10
and	0
lysosomal	9
proteins	10
was	0
analyzed	0
in	0
human	5
CD34+	6
cord	6
blood	6
cell	6
(	6
CB	6
)	6
subsets	6
at	0
different	0
stages	0
of	0
myeloid	0
commitment	0
by	0
reverse-transcriptase	0
polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
.	0

The	0
highly	0
specific	0
granulomonocyte-associated	9
lysosomal	10
proteins	10
myeloperoxidase	9
(	0
MPO	9
)	0
and	0
lysozyme	9
(	0
LZ	9
)	0
,	0
as	0
well	0
as	0
the	0
transcription	9
factor	10
PU.1	9
,	0
were	0
already	0
detectable	0
in	0
the	0
most	0
immature	0
CD34+Thy-1+	5
subset	6
.	0

Messenger	3
RNA	4
(	0
mRNA	3
)	0
levels	0
for	0
the	0
granulocyte-colony	9
stimulating	10
factor	10
(	10
G-CSF	10
)	10
receptor	10
,	0
granulocyte-macrophage	9
(	10
GM	10
)	10
-CSF	10
receptor	10
alpha	10
subunit	10
and	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
receptors	10
I	10
(	10
p55	10
)	10
and	10
II	10
(	10
p75	10
)	10
were	0
also	0
detected	0
in	0
this	0
subset	0
in	0
addition	0
to	0
c-kit	9
and	0
flt-3	9
,	0
receptors	0
known	0
to	0
be	0
expressed	0
on	0
progenitor	7
cells	8
.	0

By	0
contrast	0
,	0
the	0
monocyte-macrophage	9
colony	10
stimulating	10
factor	10
(	10
M-CSF	10
)	10
receptor	10
was	0
largely	0
absent	0
at	0
this	0
stage	0
and	0
in	0
the	0
CD34+Thy-1-CD45RA-	5
subsets	6
.	0

The	0
M-CSF	9
receptor	10
was	0
first	0
detectable	0
in	0
the	0
myeloid-committed	5
CD34+Thy-l-CD45RA+	6
subset	6
.	0

All	0
other	0
molecules	0
studied	0
were	0
found	0
to	0
be	0
expressed	0
at	0
this	0
stage	0
of	0
differentiation	0
.	0

Different	0
cocktails	0
of	0
the	0
identified	0
ligands	0
were	0
added	0
to	0
sorted	5
CD34+Thy-1+	6
single	6
cells	6
.	0

Low	0
proliferative	0
capacity	0
was	0
observed	0
after	0
1	0
week	0
in	0
culture	0
in	0
the	0
presence	0
of	0
stem	9
cell	10
factor	10
(	0
SCF	9
)	0
+	0
Flt-3	9
ligand	10
(	0
FL	9
)	0
+	0
G-CSF	9
.	0

Addition	0
of	0
GM-CSF	9
to	0
this	0
basic	0
cocktail	0
consistently	0
increased	0
the	0
clonogenic	0
capacity	0
of	0
single	5
CD34+Thy-1+	6
cells	6
,	0
and	0
this	0
effect	0
was	0
further	0
enhanced	0
(	0
up	0
to	0
72.3	0
+/-	0
4.3	0
%	0
on	0
day	0
7	0
)	0
by	0
the	0
inclusion	0
of	0
TNF-alpha	9
.	0

In	0
conclusion	0
,	0
the	0
presence	0
of	0
myeloid-associated	3
growth	4
factor	4
receptor	4
transcripts	4
in	0
CD34+	5
CB	6
subsets	6
does	0
not	0
discriminate	0
the	0
various	0
stages	0
of	0
differentiation	0
,	0
with	0
the	0
exception	0
of	0
the	0
M-CSF	9
receptor	10
.	0

In	0
addition	0
,	0
we	0
show	0
that	0
TNF-alpha	9
is	0
a	0
potent	0
costimulatory	0
factor	0
of	0
the	0
very	0
immature	5
CD34+Thy-1+	6
CB	6
subset	6
.	0

Induction	0
of	0
endothelial	9
cell	10
surface	10
adhesion	10
molecules	10
by	0
tumor	9
necrosis	10
factor	10
is	0
blocked	0
by	0
protein	0
tyrosine	0
phosphatase	0
inhibitors	0
:	0
role	0
of	0
the	0
nuclear	9
transcription	10
factor	10
NF-kappa	10
B	10
.	0

Recent	0
studies	0
from	0
our	0
laboratory	0
have	0
indicated	0
that	0
protein	9
tyrosine	10
phosphatase	10
(	0
PTPase	9
)	0
inhibitors	0
can	0
down-modulate	0
the	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
-mediated	0
activation	0
of	0
the	0
nuclear	9
transcription	10
factor	10
NF-kappa	10
B	10
in	0
ML-1a	5
,	0
a	0
monocytic	5
cell	6
line	6
(	0
Singh	0
and	0
Aggarwal	0
,	0
J.	0
Biol.	0
Chem.	0
1995	0
:	0
270	0
:	0
10631	0
)	0
.	0

Since	0
TNF	9
is	0
one	0
of	0
the	0
major	0
inducers	0
of	0
various	0
adhesion	9
molecules	10
in	0
human	0
endothelial	0
cells	0
and	0
their	0
expression	0
is	0
known	0
to	0
require	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
we	0
examined	0
the	0
effect	0
of	0
PTPase	9
inhibitors	0
on	0
the	0
TNF	9
-mediated	0
induction	0
of	0
intracellular	9
adhesion	10
molecule	10
(	10
ICAM	10
)	10
-1	10
,	0
vascular	9
cell	10
adhesion	10
molecule	10
(	10
VCAM	10
)	10
-1	10
and	0
endothelial	9
leukocyte	10
adhesion	10
molecule	10
(	10
ELAM	10
)	10
-1	10
.	0

Like	0
ML-1a	5
,	0
human	5
dermal	6
microvessel	6
endothelial	6
cells	6
(	0
MVEC	5
)	0
treated	0
with	0
TNF	9
rapidly	0
activated	0
(	0
within	0
30	0
min	0
)	0
NF-kappa	9
B	10
;	0
this	0
effect	0
was	0
completely	0
abolished	0
by	0
co-treatment	0
with	0
phenylarsine	0
oxide	0
(	0
PAO	0
)	0
,	0
a	0
specific	0
inhibitor	0
of	0
PTPase	9
.	0

The	0
induction	0
of	0
ICAM-1	9
,	0
VCAM-1	9
,	0
and	0
ELAM-1	9
by	0
TNF	9
in	0
MVEC	5
occurred	0
within	0
6	0
h	0
and	0
was	0
also	0
completely	0
down-regulated	0
by	0
PAO	0
in	0
a	0
dose-dependent	0
manner	0
.	0

PAO	0
was	0
found	0
to	0
be	0
effective	0
even	0
when	0
added	0
3	0
h	0
after	0
TNF	9
,	0
suggesting	0
a	0
rapid	0
mode	0
of	0
action	0
of	0
this	0
inhibitor	0
.	0

Besides	0
PAO	0
,	0
other	0
inhibitors	0
of	0
PTPase	9
,	0
including	0
pervanadate	0
and	0
diamide	0
,	0
also	0
blocked	0
TNF	9
-dependent	0
NF-kappa	9
B	10
activation	0
and	0
induction	0
of	0
all	0
the	0
three	0
adhesion	9
proteins	10
.	0

Consistent	0
with	0
these	0
results	0
,	0
the	0
attachment	0
of	0
monocytes	0
to	0
MVEC	5
was	0
also	0
blocked	0
by	0
the	0
PTPase	9
inhibitors	0
.	0

Thus	0
,	0
overall	0
,	0
our	0
results	0
demonstrate	0
that	0
a	0
PTPase	9
is	0
involved	0
either	0
directly	0
or	0
indirectly	0
in	0
the	0
pathway	0
leading	0
to	0
the	0
induction	0
of	0
endothelial	9
cell	10
adhesion	10
molecules	10
by	0
TNF	9
.	0

Because	0
of	0
their	0
role	0
in	0
cell	0
adhesion	0
,	0
PTPase	9
may	0
provide	0
a	0
novel	0
target	0
of	0
drug	0
development	0
for	0
treatment	0
of	0
inflammation	0
,	0
atherogenesis	0
,	0
and	0
tumor	0
metastasis	0
.	0

Regulation	0
of	0
nuclear	9
factor-kappa	10
B	10
and	0
its	0
inhibitor	0
I	9
kappa	10
B-alpha/MAD-3	10
in	0
monocytes	7
by	0
Mycobacterium	0
tuberculosis	0
and	0
during	0
human	0
tuberculosis	0
.	0

Blood	7
monocytes	8
from	0
patients	0
with	0
active	0
tuberculosis	0
are	0
activated	0
in	0
vivo	0
,	0
as	0
evidenced	0
by	0
an	0
increase	0
in	0
the	0
stimulated	0
release	0
of	0
proinflammatory	9
cytokines	10
,	0
such	0
as	0
TNF-alpha	9
,	0
and	0
the	0
spontaneous	0
expression	0
of	0
IL-2R	9
.	0

Further	0
,	0
monocytes	7
from	0
patients	0
demonstrate	0
an	0
augmented	0
susceptibility	0
to	0
a	0
productive	0
infection	0
with	0
HIV-1	0
in	0
vitro	0
.	0

Mycobacterium	0
tuberculosis	0
and	0
its	0
components	0
are	0
strong	0
signals	0
to	0
activate	0
monocytes	7
to	0
production	0
of	0
cytokines	9
.	0

In	0
this	0
study	0
we	0
examined	0
the	0
basis	0
of	0
activation	0
of	0
monocytes	7
during	0
active	0
tuberculosis	0
and	0
by	0
M.	0
tuberculosis	0
.	0

We	0
found	0
a	0
constitutive	0
degradation	0
of	0
I	9
kappa	10
B-alpha	10
,	0
the	0
major	0
cytoplasmic	9
inhibitor	10
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
in	0
freshly	0
isolated	0
PBMC	7
and	0
monocytes	7
from	0
patients	0
with	0
tuberculosis	0
.	0

In	0
contrast	0
,	0
I	9
kappa	10
B-alpha	10
levels	0
in	0
PBMC	7
and	0
monocytes	7
from	0
healthy	0
subjects	0
or	0
from	0
patients	0
with	0
nontuberculous	0
pulmonary	0
conditions	0
were	0
intact	0
.	0

Further	0
,	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
NF-kappa	9
B	10
was	0
activated	0
in	0
monocytes	7
from	0
tuberculous	0
patients	0
.	0

The	0
expression	0
of	0
I	9
kappa	10
B-alpha	10
gene	0
,	0
which	0
is	0
responsive	0
to	0
activation	0
by	0
NF-kappa	9
B	10
,	0
was	0
up-regulated	0
in	0
PBMC	7
and	0
monocytes	7
from	0
patients	0
,	0
but	0
not	0
in	0
mononuclear	7
cells	8
from	0
healthy	0
subjects	0
or	0
those	0
with	0
nontuberculous	0
lung	0
diseases	0
.	0

By	0
contrast	0
,	0
the	0
expression	0
of	0
other	0
adherence-associated	1
early	2
genes	2
,	0
such	0
as	0
IL-8	9
and	0
IL-1	9
beta	10
,	0
was	0
not	0
up-regulated	0
in	0
PBMC	7
of	0
tuberculous	0
patients	0
.	0

Further	0
,	0
M.	0
tuberculosis	0
and	0
its	0
tuberculin	9
,	0
purified	9
protein	10
derivative	10
,	0
induced	0
the	0
degradation	0
of	0
I	9
kappa	10
B-alpha	10
and	0
the	0
expression	0
of	0
I	3
kappa	4
B-alpha	4
mRNA	4
,	0
and	0
purified	0
protein	0
derivative	0
induced	0
the	0
activation	0
of	0
NF-kappa	9
B	10
in	0
monocytes	7
.	0

Cooperation	0
of	0
Spi-1/PU.1	9
with	0
an	0
activated	9
erythropoietin	10
receptor	10
inhibits	0
apoptosis	0
and	0
Epo	9
-dependent	0
differentiation	0
in	0
primary	7
erythroblasts	8
and	0
induces	0
their	0
Kit	0
ligand-dependent	0
proliferation	0
.	0

Spi-1/PU.1	9
is	0
a	0
myeloid-	9
and	10
B-cell	10
specific	10
transcription	10
factor	10
which	0
is	0
also	0
involved	0
in	0
Friend	0
virus-induced	0
murine	0
erythroleukemia	0
.	0

The	0
pre-leukemic	0
phase	0
of	0
Friend	0
erythroleukemia	0
results	0
from	0
activation	0
of	0
the	0
erythropoietin	9
receptor	10
(	0
EpoR	9
)	0
by	0
the	0
spleen	9
focus	10
forming	10
virus	10
(	10
SFFV	10
)	10
envelope	10
glycoprotein	10
,	0
followed	0
by	0
the	0
emergence	0
of	0
leukemic	0
clones	0
characterized	0
by	0
overexpression	0
of	0
Spi-1	9
and	0
mutation	0
of	0
the	0
p53	1
tumor	2
suppressor	2
gene	2
.	0

We	0
developed	0
a	0
heterologous	0
system	0
to	0
analyze	0
the	0
contribution	0
of	0
these	0
alterations	0
to	0
the	0
induction	0
of	0
primary	0
erythroblast	0
transformation	0
.	0

Avian	7
erythroblasts	8
expressing	0
the	0
activated	9
mouse	10
EpoR	10
(	10
R129C	10
)	10
differentiated	0
into	0
erythrocytes	7
in	0
response	0
to	0
hEpo	9
.	0

Expression	0
of	0
Spi-1	9
in	0
these	0
cells	0
inhibited	0
this	0
ability	0
to	0
differentiate	0
and	0
rescued	0
the	0
cells	0
from	0
the	0
apoptotic	0
cell	0
death	0
program	0
normally	0
induced	0
upon	0
hEpo	9
withdrawal	0
.	0

Although	0
devoid	0
of	0
any	0
effect	0
by	0
itself	0
,	0
a	0
mutant	9
p53	10
cooperated	0
with	0
Spi-1	9
and	0
EpoR	9
(	10
R129C	10
)	10
to	0
reinforce	0
both	0
phenotypes	0
.	0

Analysis	0
of	0
erythroblasts	0
co-expressing	0
Spi-1	9
and	0
the	0
wild-type	9
mouse	10
EpoR	10
showed	0
that	0
differentiation	0
arrest	0
and	0
inhibition	0
of	0
apoptosis	0
depended	0
on	0
specific	0
cooperation	0
between	0
Spi-1	9
and	0
EpoR	9
(	10
R129C	10
)	10
.	0

This	0
cooperation	0
was	0
also	0
required	0
to	0
induce	0
the	0
sustained	0
proliferation	0
of	0
differentiation-blocked	5
erythroblasts	6
in	0
response	0
to	0
ligand	0
activation	0
of	0
the	0
endogenous	9
tyrosine	10
kinase	10
receptor	10
c-Kit	9
.	0

These	0
results	0
show	0
that	0
Spi-1/	0
PU.1	9
requires	0
signals	0
emanating	0
from	0
specific	0
cytokine	0
and	0
growth	0
factor	0
receptors	0
to	0
affect	0
the	0
survival	0
,	0
proliferation	0
and	0
differentiation	0
control	0
of	0
primary	7
erythroblasts	8
.	0

They	0
also	0
suggest	0
that	0
the	0
function	0
of	0
Spi-1/PU.1	9
in	0
the	0
late	0
phase	0
of	0
Friend	0
leukemia	0
requires	0
specific	0
signaling	0
from	0
the	0
gp55-modified	9
EpoR	10
generated	0
during	0
the	0
early	0
phase	0
of	0
the	0
disease	0
.	0

The	0
role	0
of	0
Rel/NF-kappa	9
B	10
proteins	10
in	0
viral	0
oncogenesis	0
and	0
the	0
regulation	0
of	0
viral	0
transcription	0
.	0

Rel/NF-kappa	9
B	10
is	0
a	0
ubiquitous	9
transcription	10
factor	10
that	0
consists	0
of	0
multiple	9
polypeptide	10
subunits	10
,	0
and	0
is	0
subject	0
to	0
complex	0
regulatory	0
mechanisms	0
that	0
involve	0
protein-protein	0
interactions	0
,	0
phosphorylation	0
,	0
ubiquitination	0
,	0
proteolytic	0
degradation	0
,	0
and	0
nucleocytoplasmic	0
translocation	0
.	0

The	0
sophisticated	0
control	0
of	0
Rel/NF-kappa	9
B	10
activity	0
is	0
not	0
surprising	0
since	0
this	0
transcription	9
factor	10
is	0
involved	0
in	0
a	0
wide	0
array	0
of	0
cellular	0
responses	0
to	0
extracellular	0
cues	0
,	0
associated	0
with	0
growth	0
,	0
development	0
,	0
apoptosis	0
,	0
and	0
pathogen	0
invasion	0
.	0

Thus	0
,	0
it	0
is	0
not	0
unexpected	0
that	0
this	0
versatile	0
cellular	0
homeostatic	0
switch	0
would	0
be	0
affected	0
by	0
a	0
variety	0
of	0
viral	0
pathogens	0
,	0
which	0
have	0
evolved	0
mechanisms	0
to	0
utilize	0
various	0
aspects	0
of	0
Rel/NF-kappa	9
B	10
activity	0
to	0
facilitate	0
their	0
replication	0
,	0
cell	0
survival	0
and	0
possibly	0
evasion	0
of	0
immune	0
responses	0
.	0

This	0
review	0
will	0
cover	0
the	0
molecular	0
mechanisms	0
that	0
are	0
utilized	0
by	0
mammalian	0
oncogenic	0
viruses	0
to	0
affect	0
the	0
activity	0
of	0
Rel/NF-kappa	9
B	10
transcription	9
factors	10
and	0
the	0
role	0
of	0
Rel/NF-kappa	9
B	10
in	0
the	0
regulation	0
of	0
viral	0
gene	0
expression	0
and	0
replication	0
.	0

Cellular	0
and	0
molecular	0
mechanisms	0
of	0
IL-5	9
synthesis	0
in	0
atopic	0
diseases	0
:	0
a	0
study	0
with	0
allergen-specific	5
human	6
helper	6
T	6
cells	6
.	0

BACKGROUND	0
:	0
Cytokines	9
produced	0
by	0
helper	7
T	8
cells	8
are	0
intimately	0
involved	0
in	0
chronic	0
allergic	0
diseases	0
associated	0
with	0
eosinophilic	0
inflammation	0
.	0

OBJECTIVE	0
:	0
We	0
investigated	0
the	0
production	0
of	0
IL-5	9
,	0
a	0
potent	0
growth	0
factor	0
and	0
chemotactic	0
factor	0
for	0
eosinophils	7
,	0
by	0
CD4+	7
T	8
lymphocytes	8
in	0
patients	0
with	0
asthma	0
.	0

METHODS	0
:	0
Allergen-specific	5
T	6
cell	6
clones	6
and	0
T	5
cell	6
hybridomas	6
were	0
established	0
from	0
the	0
peripheral	7
blood	8
lymphocytes	8
of	0
patients	0
with	0
asthma	0
,	0
and	0
the	0
responses	0
to	0
various	0
stimuli	0
were	0
determined	0
.	0

RESULTS	0
:	0
After	0
nonspecific	0
stimulation	0
,	0
IL-5	9
production	0
by	0
CD4+	7
T	8
cells	8
from	0
both	0
atopic	0
and	0
nonatopic	0
subjects	0
with	0
asthma	0
was	0
significantly	0
enhanced	0
compared	0
with	0
that	0
by	0
cells	0
from	0
healthy	0
controls	0
.	0

Peripheral	7
blood	8
mononuclear	8
cells	8
from	0
atopic	0
asthma	0
patients	0
both	0
proliferated	0
and	0
produced	0
IL-5	9
after	0
incubation	0
with	0
mite	0
allergen	0
,	0
suggesting	0
that	0
mite-specific	7
helper	8
T	8
cells	8
were	0
involved	0
in	0
the	0
eosinophilic	0
inflammation	0
of	0
atopic	0
asthma	0
.	0

A	0
human	0
IL-5	1
promoter/enhancer	2
luciferase	2
gene	2
construct	2
transfected	0
into	0
IL-5-producing	5
T	6
cell	6
clones	6
was	0
clearly	0
transcribed	0
after	0
stimulation	0
,	0
indicating	0
that	0
the	0
515	0
base	0
pair	0
IL-5	1
gene	2
segment	2
upstream	0
of	0
the	0
coding	0
region	0
was	0
sufficient	0
to	0
respond	0
to	0
activating	0
signals	0
in	0
human	0
helper	7
T	8
cells	8
.	0

The	0
same	0
gene	0
segment	0
was	0
not	0
transcribed	0
in	0
IL-5-nonproducing	5
T	6
cell	6
clones	6
,	0
suggesting	0
that	0
human	0
T	0
cell	0
IL-5	9
synthesis	0
is	0
regulated	0
at	0
the	0
transcriptional	0
level	0
.	0

Experiments	0
with	0
T	5
cell	6
hybridomas	6
confirmed	0
these	0
findings	0
and	0
suggested	0
that	0
a	0
unique	9
transcription	10
factor	10
may	0
be	0
essential	0
for	0
human	0
IL-5	9
gene	0
transcription	0
.	0

CONCLUSION	0
:	0
Enhanced	0
IL-5	9
production	0
by	0
helper	7
T	8
cells	8
seems	0
to	0
cause	0
the	0
eosinophilic	0
inflammation	0
of	0
both	0
atopic	0
and	0
nonatopic	0
asthma	0
.	0

Elucidation	0
of	0
IL-5	9
-specific	0
regulatory	0
mechanisms	0
may	0
facilitate	0
the	0
development	0
of	0
novel	0
treatments	0
for	0
allergic	0
diseases	0
associated	0
with	0
eosinophilic	0
inflammation	0
.	0

Cyclosporin	0
A	0
inhibits	0
monocyte	0
tissue	9
factor	10
activation	0
in	0
cardiac	0
transplant	0
recipients	0
.	0

BACKGROUND	0
:	0
Fibrin	0
deposition	0
and	0
thrombosis	0
have	0
been	0
implicated	0
in	0
both	0
allograft	0
rejection	0
and	0
vasculopathy	0
after	0
cardiac	0
transplantation	0
.	0

Because	0
monocytes	7
play	0
a	0
pivotal	0
role	0
in	0
the	0
pathophysiology	0
of	0
intravascular	0
coagulation	0
activation	0
through	0
their	0
ability	0
to	0
synthesize	0
tissue	9
factor	10
(	0
TF	9
)	0
,	0
we	0
asked	0
(	0
1	0
)	0
whether	0
monocyte	0
TF	9
activation	0
occurs	0
in	0
cardiac	0
transplant	0
recipients	0
and	0
(	0
2	0
)	0
whether	0
monocyte	0
TF	9
expression	0
is	0
affected	0
by	0
treatment	0
with	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
We	0
measured	0
levels	0
of	0
TF	9
activity	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
highly	7
purified	8
monocytes/macrophages	8
from	0
10	0
consecutive	0
cardiac	0
transplant	0
recipients	0
and	0
10	0
healthy	0
control	0
subjects	0
.	0

TF	9
activity	0
generated	0
by	0
both	0
unstimulated	5
and	0
endotoxin-stimulated	5
cells	6
was	0
significantly	0
higher	0
in	0
transplant	0
recipients	0
than	0
in	0
control	0
subjects	0
(	0
P	0
<	0
.05	0
)	0
.	0

Increased	0
monocyte	0
TF	9
expression	0
in	0
transplant	0
recipients	0
was	0
shown	0
to	0
be	0
adversely	0
affected	0
by	0
treatment	0
with	0
CsA	0
:	0
TF	9
induction	0
was	0
markedly	0
reduced	0
by	0
CsA	0
serum	0
concentrations	0
reaching	0
peak	0
CsA	0
drug	0
levels	0
.	0

Inhibition	0
of	0
TF	9
induction	0
in	0
the	0
presence	0
of	0
high	0
CsA	0
blood	0
concentrations	0
was	0
also	0
observed	0
when	0
stimulation	0
of	0
cells	0
was	0
performed	0
with	0
interferon-gamma	9
or	0
interleukin-1beta	9
.	0

As	0
shown	0
by	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
and	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
respectively	0
,	0
treatment	0
with	0
CsA	0
leads	0
to	0
decreased	0
TF	3
mRNA	4
expression	0
and	0
reduced	0
activation	0
of	0
the	0
NF-kappaB	9
transcription	10
factor	10
,	0
which	0
is	0
known	0
to	0
contribute	0
to	0
the	0
induction	0
of	0
the	0
TF	1
promotor	2
in	0
human	7
monocytes	8
.	0

CONCLUSIONS	0
:	0
This	0
study	0
demonstrates	0
that	0
TF	9
activation	0
,	0
occurring	0
in	0
mononuclear	7
cells	8
of	0
cardiac	0
transplant	0
recipients	0
,	0
is	0
inhibited	0
by	0
treatment	0
with	0
CsA	0
.	0

Inhibition	0
of	0
monocyte	0
TF	9
induction	0
by	0
CsA	0
may	0
contribute	0
to	0
its	0
successful	0
use	0
in	0
cardiac	0
transplant	0
medicine	0
and	0
might	0
be	0
useful	0
in	0
managing	0
further	0
settings	0
of	0
vascular	0
pathology	0
also	0
known	0
to	0
involve	0
TF	9
expression	0
and	0
NF-kappaB	9
activation	0
.	0

IL-2	9
and	0
IL-7	9
induce	0
heterodimerization	0
of	0
STAT5	9
isoforms	10
in	0
human	7
peripheral	8
blood	8
T	8
lymphoblasts	8
.	0

Despite	0
differences	0
in	0
T	0
cell	0
responses	0
induced	0
by	0
interleukin	9
(	10
IL	10
)	10
-2	10
and	0
IL-7	9
,	0
both	0
cytokines	9
modulate	0
T	0
cell	0
functions	0
by	0
activation	0
of	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
proteins	10
.	0

We	0
examined	0
the	0
contribution	0
of	0
the	0
two	0
isoforms	0
of	0
STAT5	9
,	0
STAT5A	9
and	0
STAT5B	9
,	0
to	0
IL-2-	0
and	0
IL-7-induced	0
activation	0
of	0
human	7
peripheral	8
blood	8
T	8
lymphoblasts	8
.	0

Both	0
cytokines	9
induced	0
assembly	0
of	0
STAT5A	9
and	0
STAT5B	9
containing	0
complexes	0
capable	0
of	0
binding	0
to	0
the	0
interferon-gamma	1
activation	2
sequence	2
(	0
GAS	1
)	0
,	0
and	0
these	0
complexes	0
rapidly	0
translocated	0
(	0
within	0
1	0
min	0
)	0
into	0
the	0
nucleus	0
of	0
IL-2-	5
or	6
IL-7-treated	6
cells	6
.	0

The	0
kinetics	0
of	0
this	0
translocation	0
were	0
delayed	0
in	0
IL-7-treated	5
as	0
compared	0
to	0
IL-2-treated	5
cells	6
.	0

IL-2	9
and	0
IL-7	9
were	0
equivalent	0
in	0
their	0
ability	0
to	0
induce	0
tyrosine	0
phosphorylation	0
of	0
STAT5A	9
and	0
STAT5B	9
and	0
to	0
facilitate	0
binding	0
of	0
these	0
STATs	9
to	0
an	0
immobilized	1
GAS	2
element	2
.	0

Both	0
IL-2	9
and	0
IL-7	9
induced	0
substantial	0
amounts	0
of	0
STAT5A	9
/STAT5B	9
heterodimerization	0
.	0

Moreover	0
,	0
we	0
observed	0
constitutive	0
association	0
of	0
STAT3	9
with	0
each	0
STAT5	9
isomer	10
.	0

These	0
data	0
suggest	0
that	0
IL-2	9
and	0
IL-7	9
induce	0
assembly	0
of	0
STAT	9
heterodimers	10
in	0
a	0
similar	0
manner	0
and	0
that	0
subsequent	0
cellular	0
responses	0
may	0
be	0
driven	0
by	0
induction	0
of	0
similar	0
sets	0
of	0
genes	1
.	0

Transcription	9
factor	10
NF-kappaB	9
regulates	0
inducible	0
Oct-2	1
gene	2
expression	0
in	0
precursor	7
B	8
lymphocytes	8
.	0

The	0
POU	9
transcription	10
factors	10
Oct-1	9
and	0
Oct-2	9
regulate	0
the	0
activity	0
of	0
octamer-dependent	1
promoters	2
,	0
including	0
those	0
that	0
direct	0
transcription	0
from	0
rearranged	0
immunoglobulin	9
genes	10
.	0

Unlike	0
Oct-1	9
,	0
which	0
is	0
constitutively	0
expressed	0
in	0
many	0
cell	0
types	0
,	0
Oct-2	9
expression	0
is	0
restricted	0
primarily	0
to	0
B	7
lymphocytes	8
and	0
can	0
be	0
induced	0
in	0
precursor	7
B	8
cells	8
by	0
stimulation	0
with	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

However	0
,	0
the	0
precise	0
factors	0
that	0
mediate	0
this	0
induction	0
mechanism	0
remain	0
unknown	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
monitored	0
Oct-2	9
expression	0
in	0
cells	0
arrested	0
for	0
the	0
activation	0
of	0
NF-kappaB	9
,	0
an	0
LPS-responsive	9
member	10
of	0
the	0
Rel	9
transcription	10
factor	10
family	10
.	0

Despite	0
stimulation	0
with	0
LPS	0
,	0
disruption	0
of	0
the	0
NF-kappaB	9
signaling	0
pathway	0
in	0
precursor	7
B	8
cells	8
led	0
to	0
the	0
loss	0
of	0
inducible	0
Oct-2	9
DNA	0
binding	0
activity	0
in	0
vitro	0
and	0
the	0
suppression	0
of	0
Oct-2	9
-directed	0
transcription	0
in	0
vivo	0
.	0

This	0
biochemical	0
defect	0
correlated	0
with	0
a	0
specific	0
block	0
to	0
Oct-2	1
gene	2
expression	0
at	0
the	0
level	0
of	0
transcription	0
,	0
whereas	0
the	0
expression	0
of	0
Oct-1	9
was	0
unaffected	0
.	0

The	0
finding	0
that	0
Oct-2	9
is	0
under	0
NF-kappaB	9
control	0
highlights	0
an	0
important	0
cross-talk	0
mechanism	0
involving	0
two	0
distinct	0
transcription	9
factor	10
families	10
that	0
regulate	0
B	7
lymphocyte	8
function	0
.	0

Suppression	0
of	0
MHC	9
class	10
II	10
expression	0
by	0
human	1
class	2
II	2
trans-activator	2
constructs	2
lacking	0
the	0
N-terminal	9
domain	10
.	0

The	0
class	9
II	10
trans-activator	10
(	0
CIITA	9
)	0
is	0
a	0
bi-	9
or	10
multi-functional	10
domain	10
protein	10
which	0
plays	0
a	0
critical	0
role	0
in	0
the	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
.	0

We	0
report	0
that	0
removal	0
of	0
the	0
N-terminal	9
151	10
amino	10
acids	10
,	0
encompassing	0
all	0
of	0
the	0
acidic	9
domain	10
but	0
leaving	0
intact	0
the	0
proline/serine/threonine-rich	9
domain	10
,	0
results	0
in	0
a	0
mutant	0
protein	0
with	0
potent	0
suppressive	0
properties	0
for	0
MHC	9
class	10
II	10
expression	0
.	0

HeLa	5
cells	6
stably	0
or	0
transiently	0
transfected	0
with	0
mutant	1
CIITA	2
constructs	2
showed	0
up	0
to	0
99	0
%	0
suppression	0
of	0
MHC	9
class	10
II	10
antigen	0
induction	0
by	0
IFN-gamma	9
and	0
marked	0
suppression	0
of	0
HLA-DRA	3
mRNA	4
expression	0
.	0

Transient	0
transfection	0
of	0
a	0
B	0
lymphoma	0
line	0
resulted	0
in	0
up	0
to	0
89	0
%	0
reduction	0
of	0
constitutive	0
MHC	9
class	10
II	10
expression	0
within	0
5	0
days	0
and	0
suppression	0
of	0
HLA-DRA	3
mRNA	4
synthesis	0
.	0

Helenalin	0
,	0
an	0
anti-inflammatory	0
sesquiterpene	0
lactone	0
from	0
Arnica	0
,	0
selectively	0
inhibits	0
transcription	9
factor	10
NF-kappaB	9
[	0
see	0
comments	0
]	0

Alcoholic	0
extracts	0
prepared	0
form	0
Arnicae	0
flos	0
,	0
the	0
collective	0
name	0
for	0
flowerheads	0
from	0
Arnica	0
montana	0
and	0
A.	0
chamissonis	0
ssp.	0
foliosa	0
,	0
are	0
used	0
therapeutically	0
as	0
anti-inflammatory	0
remedies	0
.	0

The	0
active	0
ingredients	0
mediating	0
the	0
pharmacological	0
effect	0
are	0
mainly	0
sesquiterpene	0
lactones	0
,	0
such	0
as	0
helenalin	0
,	0
11alpha	0
,	0
13-dihydrohelenalin	0
,	0
chamissonolid	0
and	0
their	0
ester	0
derivatives	0
.	0

While	0
these	0
compounds	0
affect	0
various	0
cellular	0
processes	0
,	0
current	0
data	0
do	0
not	0
fully	0
explain	0
how	0
sesquiterpene	0
lactones	0
exert	0
their	0
anti-inflammatory	0
effect	0
.	0

We	0
show	0
here	0
that	0
helenalin	0
,	0
and	0
,	0
to	0
a	0
much	0
lesser	0
degree	0
,	0
11alpha	0
,	0
13-dihydrohelenalin	0
and	0
chamissonolid	0
,	0
inhibit	0
activation	0
of	0
transcription	9
factor	10
NF-kappaB	9
.	0

This	0
difference	0
in	0
efficacy	0
,	0
which	0
correlates	0
with	0
the	0
compounds	0
'	0
anti-inflammatory	0
potency	0
in	0
vivo	0
,	0
may	0
be	0
explained	0
by	0
differences	0
in	0
structure	0
and	0
conformation	0
.	0

NF-kappaB	9
,	0
which	0
resides	0
in	0
an	0
inactive	0
,	0
cytoplasmic	9
complex	10
in	0
unstimulated	5
cells	6
,	0
is	0
activated	0
by	0
phosphorylation	0
and	0
degradation	0
of	0
its	0
inhibitory	9
subunit	10
,	0
IkappaB	9
.	0

Helenalin	0
inhibits	0
NF-kappaB	9
activation	0
in	0
response	0
to	0
four	0
different	0
stimuli	0
in	0
T-cells	7
,	0
B-cells	7
and	0
epithelial	7
cells	8
and	0
abrogates	0
kappaB	9
-driven	0
gene	0
expression	0
.	0

This	0
inhibition	0
is	0
selective	0
,	0
as	0
the	0
activity	0
of	0
four	0
other	0
transcription	9
factors	10
,	0
Oct-1	9
,	0
TBP	9
,	0
Sp1	9
and	0
STAT	9
5	10
was	0
not	0
affected	0
.	0

We	0
show	0
that	0
inhibition	0
is	0
not	0
due	0
to	0
a	0
direct	0
modification	0
of	0
the	0
active	0
NF-kappaB	9
heterodimer	10
.	0

Rather	0
,	0
helenalin	0
modifies	0
the	0
NF-kappaB/IkappaB	9
complex	10
,	0
preventing	0
the	0
release	0
of	0
IkappaB	9
.	0

These	0
data	0
suggest	0
a	0
molecular	0
mechanism	0
for	0
the	0
anti-inflammatory	0
effect	0
of	0
sesquiterpene	0
lactones	0
,	0
which	0
differs	0
from	0
that	0
of	0
other	0
nonsteroidal	0
anti-inflammatory	0
drugs	0
(	0
NSAIDs	0
)	0
,	0
indomethacin	0
and	0
acetyl	0
salicylic	0
acid	0
.	0

The	0
tax	9
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
mediates	0
the	0
transactivation	0
of	0
the	0
c-sis/platelet-derived	1
growth	2
factor-B	2
promoter	2
through	0
interactions	0
with	0
the	0
zinc	9
finger	10
transcription	10
factors	10
Sp1	9
and	0
NGFI-A/Egr-1	9
.	0

Transcriptional	0
up-regulation	0
of	0
the	0
c-sis/platelet-derived	1
growth	2
factor-B	2
(	2
PDGF-B	2
)	2
proto-oncogene	2
by	0
the	0
Tax	9
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
has	0
been	0
implicated	0
as	0
one	0
possible	0
mechanism	0
of	0
cellular	0
transformation	0
by	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
.	0

In	0
previous	0
work	0
,	0
we	0
identified	0
an	0
essential	0
site	0
in	0
the	0
c-sis/PDGF-B	1
promoter	2
,	0
Tax-responsive	1
element	2
1	2
(	0
TRE1	1
)	0
,	0
necessary	0
for	0
transactivation	0
by	0
Tax	9
.	0

We	0
also	0
identified	0
Sp1	9
,	0
Sp3	0
,	0
and	0
NGFI-A/Egr-1	9
as	0
the	0
primary	9
nuclear	10
transcription	10
factors	10
binding	0
to	0
TRE1	1
which	0
mediate	0
Tax	9
responsiveness	0
.	0

In	0
the	0
present	0
work	0
,	0
we	0
have	0
investigated	0
the	0
mechanism	0
(	0
s	0
)	0
whereby	0
Tax	9
transactivates	0
the	0
c-sis/PDGF-B	1
proto-oncogene	2
.	0

In	0
vitro	0
transcription	0
assays	0
showed	0
that	0
Tax	9
was	0
able	0
to	0
significantly	0
increase	0
the	0
transcriptional	0
activity	0
of	0
a	0
template	0
containing	0
the	0
-257	1
to	2
+74	2
region	2
of	0
the	0
c-sis/PDGF-B	1
promoter	2
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
analysis	0
showed	0
that	0
Tax	9
increased	0
the	0
DNA	0
binding	0
activity	0
of	0
both	0
Sp1	9
and	0
NGFI-A/Egr-1	9
using	0
a	0
TRE1	1
probe	2
.	0

Analysis	0
of	0
Tax	9
mutants	10
showed	0
that	0
two	0
mutants	0
,	0
IEXC29S	9
and	0
IEXL320G	9
,	0
were	0
unable	0
to	0
significantly	0
transactivate	0
the	0
c-sis/PDGF-B	1
promoter	2
.	0

Finally	0
,	0
co-immunoprecipitation	0
analysis	0
revealed	0
that	0
Tax	9
is	0
able	0
to	0
stably	0
bind	0
to	0
both	0
Sp1	9
and	0
NGFI-A/Egr-1	9
.	0

Interestingly	0
,	0
co-immunoprecipitation	0
analysis	0
also	0
revealed	0
that	0
Tax	9
mutant	0
IEXC29S	9
is	0
unable	0
to	0
interact	0
with	0
NGFI-A/Egr-1	9
,	0
whereas	0
Tax	9
mutant	0
IEXL320G	9
is	0
able	0
to	0
interact	0
with	0
NGFI-A/Egr-1	9
.	0

Nuclear	0
localization	0
of	0
RelB	9
is	0
associated	0
with	0
effective	0
antigen-presenting	0
cell	0
function	0
.	0

Dendritic	7
cells	8
(	0
DC	7
)	0
are	0
potent	0
APCs	7
that	0
enter	0
resting	0
tissues	0
as	0
precursors	0
and	0
,	0
after	0
Ag	0
exposure	0
,	0
differentiate	0
and	0
migrate	0
to	0
draining	0
lymph	0
nodes	0
.	0

The	0
phenotype	0
of	0
RelB	9
knockout	0
mice	0
implicates	0
this	0
member	0
of	0
the	0
NF	9
kappa	10
B/Rel	10
family	10
in	0
DC	7
differentiation	0
.	0

To	0
further	0
elucidate	0
the	0
role	0
of	0
RelB	9
in	0
DC	7
differentiation	0
,	0
mRNA	3
,	0
intracellular	0
protein	0
expression	0
,	0
and	0
DNA	0
binding	0
activity	0
of	0
RelB	9
were	0
examined	0
in	0
immature	0
and	0
differentiated	0
human	7
DC	8
,	0
as	0
well	0
as	0
other	0
PB	7
mononuclear	8
cell	8
populations	8
.	0

RelB	9
protein	0
and	0
mRNA	3
were	0
detected	0
constitutively	0
in	0
lymphocytes	7
and	0
in	0
activated	7
monocytes	8
,	0
differentiated	7
DC	8
,	0
and	0
monocyte-derived	5
DC	6
.	0

Immunohistochemical	0
staining	0
demonstrated	0
RelB	9
within	0
the	0
differentiated	7
lymph	8
node	8
interdigitating	8
DC	8
and	0
follicular	7
DC	8
,	0
but	0
not	0
undifferentiated	7
DC	8
in	0
normal	0
skin	0
.	0

Active	0
nuclear	0
RelB	9
was	0
detected	0
by	0
supershift	0
assay	0
only	0
in	0
differentiated	0
DC	7
derived	0
from	0
either	0
PB	7
precursors	8
or	0
monocytes	7
and	0
in	0
activated	7
B	8
cells	8
.	0

These	0
RelB+	7
APC	8
were	0
potent	0
stimulators	0
of	0
the	0
MLR	9
.	0

The	0
data	0
indicate	0
that	0
RelB	9
expression	0
is	0
regulated	0
both	0
transcriptionally	0
and	0
post-translationally	0
in	0
myeloid	7
cells	8
.	0

Within	0
the	0
nucleus	0
,	0
RelB	9
may	0
specifically	0
transactivate	0
genes	0
that	0
are	0
critical	0
for	0
APC	7
function	0
.	0

NF-AT	9
activation	0
induced	0
by	0
a	0
CAML	9
-interacting	0
member	0
of	0
the	0
tumor	9
necrosis	10
factor	10
receptor	10
superfamily	10
.	0

Activation	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
transcription	9
factor	10
(	0
NF-AT	9
)	0
is	0
a	0
key	0
event	0
underlying	0
lymphocyte	0
action	0
.	0

The	0
CAML	9
(	10
calcium-modulator	10
and	10
cyclophilin	10
ligand	10
)	10
protein	10
is	0
a	0
coinducer	0
of	0
NF-AT	9
activation	0
when	0
overexpressed	0
in	0
Jurkat	5
T	6
cells	6
.	0

A	0
member	0
of	0
the	0
tumor	9
necrosis	10
factor	10
receptor	10
superfamily	10
was	0
isolated	0
by	0
virtue	0
of	0
its	0
affinity	0
for	0
CAML	9
.	0

Cross-linking	0
of	0
this	0
lymphocyte-specific	9
protein	10
,	0
designated	0
TACI	9
(	0
transmembrane	9
activator	10
and	10
CAML-interactor	10
)	0
,	0
on	0
the	0
surface	0
of	0
transfected	5
Jurkat	6
cells	6
with	0
TACI-specific	9
antibodies	10
led	0
to	0
activation	0
of	0
the	0
transcription	9
factors	10
NF-AT	9
,	0
AP-1	9
,	0
and	0
NFkappaB	9
.	0

TACI	9
-induced	0
activation	0
of	0
NF-AT	9
was	0
specifically	0
blocked	0
by	0
a	0
dominant-negative	9
CAML	10
mutant	10
,	0
thus	0
implicating	0
CAML	9
as	0
a	0
signaling	0
intermediate	0
.	0

Rel/NF-kappa	9
B	10
transcription	9
factors	10
and	0
the	0
control	0
of	0
apoptosis	0
.	0

The	0
process	0
of	0
apoptosis	0
is	0
used	0
to	0
eliminate	0
unwanted	7
cells	8
from	0
a	0
wide	0
variety	0
of	0
organisms	0
.	0

Various	0
extracellular	0
signals	0
,	0
often	0
converging	0
in	0
common	0
intracellular	0
pathways	0
,	0
can	0
induce	0
apoptosis	0
in	0
a	0
cell-type-specific	0
fashion	0
.	0

Recent	0
work	0
from	0
several	0
laboratories	0
has	0
demonstrated	0
that	0
Rel/NF-kappa	9
B	10
transcription	9
factors	10
regulate	0
apoptosis	0
in	0
many	0
cell	0
types	0
.	0

In	0
most	0
cells	0
,	0
Rel/NF-kappa	9
B	10
transcription	9
factors	10
appear	0
to	0
mediate	0
survival	0
signals	0
that	0
protect	0
cells	0
from	0
apoptosis	0
;	0
however	0
,	0
under	0
some	0
circumstances	0
,	0
activation	0
of	0
these	0
factors	0
may	0
also	0
promote	0
apoptosis	0
.	0

A	0
thiol	0
antioxidant	0
regulates	0
IgE	9
isotype	10
switching	0
by	0
inhibiting	0
activation	0
of	0
nuclear	9
factor-kappaB	10
.	0

The	0
binding	1
site	2
for	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
is	0
present	0
at	0
the	0
promoter	1
region	2
of	0
the	0
germline	1
Cepsilon	2
gene	2
,	0
but	0
there	0
is	0
little	0
information	0
on	0
whether	0
this	0
factor	0
is	0
involved	0
in	0
regulating	0
IgE	9
synthesis	0
by	0
human	7
B	8
cells	8
.	0

Accordingly	0
,	0
we	0
studied	0
the	0
role	0
of	0
NF-kappaB	9
in	0
germline	1
Cepsilon	0
transcription	0
by	0
using	0
two	0
human	5
Burkitt	6
's	6
lymphoma	6
B	6
cell	6
lines	6
,	0
DND39	5
and	0
DG75	5
.	0

In	0
both	0
cell	5
lines	6
,	0
n-acetyl-L-cysteine	0
(	0
NAC	0
)	0
,	0
a	0
potent	0
thiol	0
antioxidant	0
,	0
inhibited	0
the	0
triggering	0
of	0
the	0
nuclear	0
expression	0
of	0
NF-kappaB	9
by	0
IL-4	9
and	0
by	0
anti-CD40	9
monoclonal	10
antibody	10
.	0

Although	0
IL-4	9
activated	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
6	10
in	0
addition	0
to	0
NF-kappaB	9
,	0
NAC	0
treatment	0
or	0
the	0
transfection	0
of	0
decoy	0
oligodeoxynucleotides	0
for	0
NF-kappaB	9
or	0
STAT6	9
only	0
partly	0
blocked	0
IL-4	9
-induced	0
germline	1
Cepsilon	0
transcription	0
.	0

However	0
,	0
these	0
two	0
decoy	0
oligodeoxynucleotides	0
together	0
almost	0
completely	0
abrogated	0
IL-4	9
-induced	0
germline	1
Cepsilon	0
transcription	0
.	0

Of	0
note	0
,	0
CD40	9
-mediated	0
enhancement	0
of	0
IL-4	9
-driven	0
germline	1
Cepsilon	0
transcription	0
was	0
markedly	0
decreased	0
by	0
NAC	0
or	0
by	0
a	0
decoy	0
oligodeoxynucleotide	0
for	0
NF-kappaB	9
.	0

The	0
effect	0
of	0
NAC	0
was	0
also	0
examined	0
on	0
deletional	0
switch	0
recombination	0
underlying	0
the	0
isotype	0
switch	0
to	0
IgE	9
.	0

NAC	0
inhibited	0
the	0
generation	0
of	0
Smu/Sepsilon	9
switch	10
fragments	10
in	0
normal	0
human	7
B	8
cells	8
costimulated	0
with	0
IL-4	9
and	0
anti-CD40	9
monoclonal	10
antibody	10
.	0

It	0
also	0
abolished	0
IL-4	9
-induced	0
upregulation	0
of	0
CD40	9
but	0
promoted	0
upregulation	0
of	0
CD23	0
.	0

These	0
results	0
suggest	0
that	0
coordination	0
of	0
NF-kappaB	9
and	0
STAT6	9
may	0
be	0
required	0
for	0
induction	0
of	0
germline	1
Cepsilon	0
transcription	0
by	0
IL-4	9
,	0
and	0
that	0
CD40	9
-mediated	0
NF-kappaB	9
activation	0
may	0
be	0
important	0
in	0
regulating	0
both	0
enhancement	0
of	0
germline	1
Cepsilon	0
transcription	0
and	0
class	0
switching	0
to	0
IgE	9
.	0

Pathogenesis	0
.	0

There	0
are	0
many	0
hypotheses	0
concerning	0
the	0
pathogenesis	0
of	0
endometriosis	0
,	0
though	0
no	0
single	0
theory	0
can	0
explain	0
all	0
cases	0
.	0

It	0
is	0
likely	0
that	0
several	0
mechanisms	0
are	0
involved	0
.	0

Early	0
studies	0
concentrated	0
on	0
the	0
histogenesis	0
of	0
the	0
endometriotic	0
lesion	0
.	0

Recent	0
evidence	0
has	0
implicated	0
components	0
of	0
the	0
immune	0
system	0
in	0
the	0
pathogenesis	0
of	0
endometriosis	0
.	0

This	0
review	0
considers	0
the	0
evidence	0
for	0
different	0
theories	0
of	0
the	0
histogenesis	0
of	0
endometriosis	0
and	0
discusses	0
possible	0
immune	0
factors	0
that	0
may	0
be	0
involved	0
in	0
the	0
pathophysiology	0
of	0
the	0
disease	0
.	0

ATF1	9
and	0
CREB	9
trans-activate	0
a	0
cell	1
cycle	2
regulated	2
histone	2
H4	2
gene	2
at	0
a	0
distal	1
nuclear	2
matrix	2
associated	2
promoter	2
element	2
.	0

Proteins	0
of	0
the	0
ATF/	0
CREB	9
class	0
of	0
transcription	9
factors	10
stimulate	0
gene	0
expression	0
of	0
several	0
cell	1
growth-related	2
genes	2
through	0
protein	1
kinase	2
A-related	2
cAMP	2
response	2
elements	2
.	0

The	0
promoter	0
activity	0
of	0
cell	1
cycle	2
regulated	2
histone	2
H4	2
genes	2
is	0
regulated	0
by	0
at	0
least	0
four	0
principal	1
cis-acting	2
elements	2
which	0
mediate	0
G1/S	0
phase	0
control	0
and/or	0
enhancement	0
of	0
transcription	0
during	0
the	0
cell	0
cycle	0
.	0

Using	0
protein-DNA	0
interaction	0
assays	0
we	0
show	0
that	0
the	0
H4	1
promoter	2
contains	0
two	0
ATF/	0
CREB	9
recognition	0
motifs	0
which	0
interact	0
with	0
CREB	9
,	0
ATF1	9
,	0
and	0
ATF2	9
but	0
not	0
with	0
ATF4/CREB2	9
.	0

One	0
ATF/CRE	1
motif	2
is	0
located	0
in	0
the	0
distal	1
promoter	2
at	0
the	0
nuclear	1
matrix-associated	2
Site	2
IV	2
,	0
and	0
the	0
second	0
motif	0
is	0
present	0
in	0
the	0
proximal	1
promoter	2
at	0
Site	1
I	2
.	0

Both	0
ATF/CRE	1
motifs	2
overlap	0
binding	1
sequences	2
for	0
the	0
multifunctional	9
YY1	10
transcription	10
factor	10
,	0
which	0
has	0
previously	0
been	0
shown	0
to	0
be	0
nuclear	0
matrix	0
associated	0
.	0

Subnuclear	0
fractionation	0
reveals	0
that	0
there	0
are	0
two	0
ATF1	9
isoforms	10
which	0
appear	0
to	0
differ	0
with	0
respect	0
to	0
DNA	0
binding	0
activity	0
and	0
partition	0
selectively	0
between	0
nuclear	0
matrix	0
and	0
nonmatrix	0
compartments	0
,	0
consistent	0
with	0
the	0
role	0
of	0
the	0
nuclear	0
matrix	0
in	0
regulating	0
gene	0
expression	0
.	0

Site-directed	0
mutational	0
studies	0
demonstrate	0
that	0
Site	1
I	2
and	0
Site	1
IV	2
together	0
support	0
ATF1-	0
and	0
CREB-induced	0
trans-activation	0
of	0
the	0
H4	1
promoter	2
.	0

Thus	0
,	0
our	0
data	0
establish	0
that	0
ATF/CREB	9
factors	10
functionally	0
modulate	0
histone	1
H4	2
gene	2
transcription	0
at	0
distal	1
and	2
proximal	2
promoter	2
elements	2
.	0

Is	0
celiac	0
disease	0
due	0
to	0
molecular	0
mimicry	0
between	0
gliadin	0
peptide	0
-HLA	9
class	10
II	10
molecule	10
-T	0
cell	0
interactions	0
and	0
those	0
of	0
some	0
unidentified	9
superantigen	10
?	0

This	0
paper	0
presents	0
a	0
new	0
hypothesis	0
for	0
the	0
etiology	0
and	0
pathogenesis	0
of	0
celiac	0
disease	0
(	0
CD	0
)	0
.	0

It	0
is	0
our	0
contention	0
that	0
CD	0
is	0
triggered	0
by	0
the	0
binding	0
of	0
one	0
or	0
more	0
gliadin	0
peptides	0
to	0
CD-associated	9
HLA	10
class	10
II	10
molecules	10
.	0

Furthermore	0
,	0
we	0
propose	0
that	0
these	0
putative	0
CD	0
peptides	0
bind	0
to	0
oligosaccharide	0
residues	0
on	0
HLA	9
class	10
II	10
molecules	10
distal	0
to	0
the	0
peptide-binding	9
groove	10
invoking	0
recognition	0
and	0
binding	0
by	0
specialized	0
subsets	0
of	0
gamma	7
delta	8
T	8
cell	8
receptor-bearing	8
lymphocytes	8
.	0

The	0
binding	0
of	0
these	0
gamma	7
delta	8
T	8
cells	8
serves	0
as	0
a	0
signal	0
for	0
abrogation	0
of	0
oral	0
tolerance	0
to	0
ingested	9
proteins	10
setting	0
in	0
motion	0
a	0
series	0
of	0
immune	0
responses	0
directed	0
against	0
the	0
small	0
intestinal	0
epithelium	0
of	0
CD	0
patients	0
.	0

CD	0
patients	0
are	0
victimized	0
by	0
this	0
self-distructed	0
immune	0
response	0
because	0
of	0
inheritance	0
of	0
certain	0
combinations	0
of	0
HLA-DQ	0
and	0
DR	0
haplotypes	0
.	0

Dimers	0
encoded	0
by	0
HLA-DR	9
haplotypes	0
may	0
be	0
the	0
primary	1
restriction	2
elements	2
for	0
lectin-like	0
,	0
gliadin	0
peptides	0
while	0
the	0
degree	0
of	0
immune	0
suppression	0
(	0
or	0
lack	0
thereof	0
)	0
to	0
ingested	0
gliadins	0
is	0
governed	0
by	0
inherited	0
HLA-DQ	1
haplotypes	0
.	0

Finally	0
,	0
we	0
speculate	0
that	0
molecular	0
mimicry	0
between	0
one	0
or	0
more	0
gliadin	0
peptides	0
and	0
some	0
,	0
as	0
yet	0
unidentified	0
,	0
bacterial	9
or	10
viral	10
superantigen	10
plays	0
a	0
role	0
in	0
disease	0
pathogenesis	0
.	0

Epstein-Barr	0
virus	0
latent	9
membrane	10
protein-1	10
triggers	0
AP-1	9
activity	0
via	0
the	0
c-Jun	9
N-terminal	0
kinase	0
cascade	0
.	0

The	0
Epstein-Barr	0
virus	0
latent	9
membrane	10
protein-1	10
(	0
LMP-1	9
)	0
is	0
an	0
integral	9
membrane	10
protein	10
which	0
transforms	0
fibroblasts	7
and	0
is	0
essential	0
for	0
EBV-mediated	0
B-cell	0
immortalization	0
.	0

LMP-1	9
has	0
been	0
shown	0
to	0
trigger	0
cellular	0
NF-kappa	9
B	10
activity	0
which	0
,	0
however	0
,	0
can	0
not	0
fully	0
explain	0
the	0
oncogenic	0
potential	0
of	0
LMP-1	9
.	0

Here	0
we	0
show	0
that	0
LMP-1	9
induces	0
the	0
activity	0
of	0
the	0
AP-1	9
transcription	10
factor	10
,	0
a	0
dimer	0
of	0
Jun/Jun	9
or	10
Jun/Fos	10
proteins	10
.	0

LMP-1	9
effects	0
on	0
AP-1	9
are	0
mediated	0
through	0
activation	0
of	0
the	0
c-Jun	9
N-terminal	0
kinase	0
(	0
JNK	9
)	0
cascade	0
,	0
but	0
not	0
the	0
extracellular	9
signal-regulated	10
kinase	10
(	0
Erk	9
)	0
pathway	0
.	0

Consequently	0
,	0
LMP-1	9
triggers	0
the	0
activity	0
of	0
the	0
c-Jun	9
N-terminal	10
transactivation	10
domain	10
which	0
is	0
known	0
to	0
be	0
activated	0
upon	0
JNK	9
-mediated	0
phosphorylation	0
.	0

Deletion	0
analysis	0
indicates	0
that	0
the	0
55	0
C-terminal	9
amino	10
acids	10
of	0
the	0
LMP-1	9
molecule	10
,	0
but	0
not	0
its	0
TRAF	9
interaction	10
domain	10
,	0
are	0
essential	0
for	0
AP-1	9
activation	0
.	0

JNK	9
-mediated	0
transcriptional	0
activation	0
of	0
AP-1	9
is	0
the	0
direct	0
output	0
of	0
LMP	9
-1-triggered	0
signaling	0
,	0
as	0
shown	0
by	0
an	0
inducible	0
LMP-1	9
mutant	10
.	0

Using	0
a	0
tetracycline-regulated	1
LMP-1	2
allele	2
,	0
we	0
demonstrate	0
that	0
JNK	9
is	0
also	0
an	0
effector	0
of	0
non-cytotoxic	0
LMP-1	9
signaling	0
in	0
B	7
cells	8
,	0
the	0
physiological	0
target	0
cells	0
of	0
EBV	0
.	0

In	0
summary	0
,	0
our	0
data	0
reveal	0
a	0
novel	0
effector	0
of	0
LMP-1	9
,	0
the	0
SEK/	0
JNK	9
/	0
c-Jun	9
/	0
AP-1	9
pathway	0
,	0
which	0
contributes	0
to	0
our	0
understanding	0
of	0
the	0
immortalizing	0
and	0
transforming	0
potential	0
of	0
LMP-1	9
.	0

Abnormal	0
apoptosis	0
and	0
cell	0
cycle	0
progression	0
in	0
humans	0
exposed	0
to	0
methyl	0
tertiary-butyl	0
ether	0
and	0
benzene	0
contaminating	0
water	0
.	0

1.	0
In	0
this	0
study	0
we	0
hypothesized	0
that	0
in	0
individuals	0
with	0
certain	0
genetic	0
makeup	0
,	0
MTBE	0
,	0
benzene	0
or	0
their	0
metabolites	0
act	0
as	0
adducts	0
and	0
may	0
induce	0
programmed	0
cell	0
death	0
.	0

2.	0
Our	0
study	0
involved	0
a	0
group	0
of	0
60	0
male	0
and	0
female	0
subjects	0
who	0
were	0
exposed	0
to	0
MTBE	0
and	0
benzene-contaminated	0
water	0
concentrations	0
up	0
to	0
76	0
PPB	0
for	0
MTBE	0
and	0
14	0
PPB	0
for	0
benzene	0
,	0
for	0
a	0
period	0
of	0
5	0
to	0
8	0
years	0
.	0

For	0
comparison	0
,	0
we	0
recruited	0
a	0
control	0
group	0
consisting	0
of	0
32	0
healthy	0
males	0
and	0
females	0
with	0
similar	0
age	0
distribution	0
and	0
without	0
a	0
history	0
of	0
exposure	0
to	0
MTBE	0
or	0
benzene	0
.	0

3	0
.	0
Peripheral	7
blood	8
lymphocytes	8
(	0
PBL	7
)	0
of	0
both	0
groups	0
were	0
tested	0
for	0
the	0
percentage	0
of	0
apoptotic	7
cells	8
and	0
cell	0
cycle	0
progression	0
using	0
flow	0
cytometry	0
.	0

4.	0
When	0
apoptotic	7
lymphocytes	8
from	0
exposed	0
individuals	0
were	0
compared	0
to	0
apoptotic	7
lymphocytes	8
from	0
the	0
control	0
group	0
,	0
statistically-significant	0
differences	0
between	0
each	0
mean	0
group	0
were	0
detected	0
(	0
26.4	0
+/-	0
1.8	0
and	0
12.1	0
+/-	0
1.3	0
,	0
respectively	0
)	0
,	0
indicating	0
an	0
increased	0
rate	0
of	0
apoptosis	0
in	0
80.5	0
%	0
of	0
exposed	0
individuals	0
(	0
P	0
<	0
0.0001	0
,	0
Mann-Whitney	0
U-Test	0
)	0
.	0

MTBE	0
and	0
benzene-induced	0
apoptosis	0
is	0
attributed	0
to	0
a	0
discrete	0
block	0
within	0
the	0
cell	0
cycle	0
progression	0
.	0

Because	0
cell	0
cycle	0
analysis	0
showed	0
that	0
in	0
PBL	7
from	0
chemically-exposed	0
individuals	0
,	0
between	0
20-50	0
%	0
of	0
cells	0
were	0
accumulated	0
at	0
the	0
S-G2/M	0
boundaries	0
.	0

5.	0
One	0
of	0
the	0
signaling	9
molecules	10
which	0
mediates	0
programmed	0
cell	0
death	0
is	0
nuclear	9
factor	10
Kappa-B	10
(	0
NF-kappa	9
B	10
)	0
.	0

NF-kappa	9
B	10
was	0
examined	0
as	0
one	0
of	0
the	0
many	0
molecular	0
mechanisms	0
for	0
mediating	0
cell	0
death	0
by	0
MTBE	0
and	0
benzene	0
.	0

Indeed	0
,	0
addition	0
of	0
inhibitors	0
of	0
NF-kappa	9
B	10
activation	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
,	0
to	0
the	0
lymphocytes	7
of	0
the	0
chemically-exposed	0
group	0
was	0
capable	0
of	0
inhibiting	0
programmed	0
cell	0
death	0
by	0
40	0
%	0
.	0

This	0
reversal	0
of	0
apoptosis	0
almost	0
to	0
the	0
control	0
level	0
by	0
inhibitor	0
of	0
NF-kappa	9
B	10
activation	0
may	0
indicate	0
involvement	0
of	0
this	0
signaling	9
molecule	10
in	0
MTBE	0
and	0
benzene	0
induction	0
of	0
programmed	0
cell	0
death	0
.	0

Purification	0
and	0
characterization	0
of	0
the	0
human	9
SR	10
31747A-binding	10
protein	10
.	0

A	0
nuclear	9
membrane	10
protein	10
related	0
to	0
yeast	9
sterol	10
isomerase	10
.	0

SR	0
31747A	0
,	0
defined	0
as	0
a	0
sigma	0
ligand	0
,	0
is	0
a	0
novel	0
immunosuppressive	0
agent	0
that	0
blocks	0
proliferation	0
of	0
human	7
and	8
mouse	8
lymphocytes	8
.	0

Using	0
a	0
radiolabeled	0
chemical	0
probe	0
,	0
we	0
here	0
purified	0
a	0
target	0
of	0
SR	0
31747A	0
and	0
called	0
it	0
SR	9
31747A-binding	10
protein	10
(	0
SR-BP	9
)	0
.	0

Purified	9
SR-BP	10
retained	0
its	0
binding	0
properties	0
and	0
migrated	0
on	0
SDS-polyacrylamide	0
gel	0
as	0
a	0
Mr	9
28	10
,	10
000	10
protein	10
.	0

Cloning	0
of	0
the	0
cDNA	1
encoding	0
human	9
SR-BP	10
shows	0
an	0
open	1
reading	2
frame	2
for	0
a	0
223-amino	9
acid	10
protein	10
,	0
which	0
is	0
homologous	0
to	0
the	0
recently	0
cloned	0
sigma	9
1	10
receptor	10
.	0

Interestingly	0
,	0
the	0
deduced	0
amino	0
acid	0
sequence	0
was	0
found	0
to	0
be	0
related	0
to	0
fungal	9
C8-C7	10
sterol	10
isomerase	10
,	0
encoded	0
by	0
the	0
ERG2	1
gene	2
.	0

The	0
ERG2	9
gene	10
product	10
has	0
been	0
identified	0
recently	0
as	0
the	0
molecular	0
target	0
of	0
SR	0
31747A	0
that	0
mediates	0
antiproliferative	0
effects	0
of	0
the	0
drug	0
in	0
yeast	0
.	0

Northern	0
blot	0
analysis	0
of	0
SR-BP	9
gene	0
expression	0
revealed	0
a	0
single	0
transcript	0
of	0
2	3
kilobases	4
which	0
was	0
widely	0
expressed	0
among	0
organs	0
,	0
with	0
the	0
highest	0
abundance	0
in	0
liver	0
and	0
the	0
lowest	0
abundance	0
in	0
brain	0
.	0

Subcellular	0
localization	0
analysis	0
in	0
various	0
cells	0
,	0
using	0
a	0
specific	9
monoclonal	10
antibody	10
raised	0
against	0
SR-BP	9
,	0
demonstrated	0
that	0
this	0
protein	0
was	0
associated	0
with	0
the	0
nuclear	0
envelope	0
.	0

When	0
studying	0
the	0
binding	0
of	0
SR	0
31747A	0
on	0
membranes	0
from	0
yeast	0
expressing	0
SR-BP	9
,	0
we	0
found	0
a	0
pharmacological	0
profile	0
of	0
sigma	9
1	10
receptors	10
;	0
binding	0
was	0
displaced	0
by	0
(	0
+	0
)	0
-pentazocine	0
,	0
haloperidol	0
,	0
and	0
(	0
+	0
)	0
-SKF	0
10	0
,	0
047	0
,	0
with	0
(	0
+	0
)	0
-SKF	0
10	0
,	0
047	0
being	0
a	0
more	0
potent	0
competitor	0
than	0
(	0
-	0
)	0
-SKF	0
10	0
,	0
047	0
.	0

Scatchard	0
plot	0
analysis	0
revealed	0
Kd	0
values	0
of	0
7.1	0
nM	0
and	0
0.15	0
nM	0
for	0
(	0
+	0
)	0
-pentazocine	0
and	0
SR	0
31747A	0
,	0
respectively	0
,	0
indicating	0
an	0
affinity	0
of	0
SR-BP	9
50-fold	0
higher	0
for	0
SR	0
31747A	0
than	0
for	0
pentazocine	0
.	0

Additionally	0
,	0
we	0
showed	0
that	0
pentazocine	0
,	0
a	0
competitive	0
inhibitor	0
of	0
SR	0
31747A	0
binding	0
,	0
also	0
prevents	0
the	0
immunosuppressive	0
effect	0
of	0
SR	0
31747A	0
.	0

Taken	0
together	0
,	0
these	0
findings	0
strongly	0
suggest	0
that	0
SR-BP	9
represents	0
the	0
molecular	0
target	0
for	0
SR	0
31747A	0
in	0
mammalian	0
tissues	0
,	0
which	0
could	0
be	0
critical	0
for	0
T	0
cell	0
proliferation	0
.	0

Phospholipase	9
C	10
gamma	10
1	10
overexpression	0
and	0
activation	0
induced	0
by	0
interferon	9
beta	10
in	0
human	7
T	8
lymphocytes	8
:	0
an	0
ISGF3	9
-independent	0
response	0
.	0

Interferons	9
exert	0
their	0
antiviral	0
,	0
antiproliferative	0
and	0
immunoregulatory	9
activities	0
by	0
stimulating	0
the	0
expression	0
of	0
several	0
genes	0
.	0

Such	0
genes	0
disclose	0
a	0
common	0
element	0
within	0
their	0
promoters	1
,	0
defined	0
Interferon	1
Stimulated	2
Response	2
Element	2
(	0
ISRE	1
)	0
,	0
which	0
binds	0
a	0
nuclear	9
factor	10
(	0
s	0
)	0
translocated	0
from	0
the	0
cytoplasm	0
to	0
the	0
nucleus	0
(	0
ISGF3	9
)	0
after	0
the	0
binding	0
of	0
interferon	9
(	0
IFN	9
)	0
to	0
the	0
specific	0
receptor	0
.	0

Here	0
we	0
report	0
the	0
induction	0
of	0
the	0
synthesis	0
and	0
of	0
the	0
hydrolytic	0
activity	0
of	0
phospholipase	9
C	10
gamma	10
1	10
(	0
PLC	9
gamma	10
1	10
)	0
in	0
human	7
T	8
lymphocytes	8
by	0
IFN-beta	9
.	0

The	0
increased	0
level	0
of	0
PLC	9
gamma	10
1	10
becomes	0
evident	0
after	0
90	0
min	0
of	0
IFN-beta	9
treatment	0
and	0
is	0
still	0
detectable	0
after	0
24	0
h	0
.	0

Neither	0
the	0
PLC	9
gamma	10
1	10
overexpression	0
induced	0
by	0
IFN	9
nor	0
the	0
increased	0
hydrolytic	0
activity	0
of	0
the	0
enzyme	9
appear	0
to	0
be	0
affected	0
by	0
pretreatment	0
of	0
the	0
cells	0
with	0
the	0
protein	0
tyrosine	9
kinase	10
inhibitor	0
genistein	0
,	0
which	0
is	0
known	0
to	0
prevent	0
the	0
association	0
of	0
ISGF3	9
components	0
.	0

These	0
results	0
suggest	0
that	0
in	0
human	7
T	8
lymphocytes	8
IFN-beta	9
can	0
activate	0
other	0
transcription	9
factor	10
(	0
s	0
)	0
distinct	0
from	0
ISGF3	9
to	0
regulate	0
PLC	9
gamma	10
1	10
expression	0
.	0

In	0
addition	0
,	0
the	0
ability	0
of	0
this	0
enzyme	9
to	0
hydrolyse	0
PIP2	0
,	0
also	0
in	0
the	0
presence	0
of	0
genistein	0
,	0
implies	0
the	0
possibility	0
that	0
this	0
enzyme	0
can	0
exert	0
its	0
hydrolytic	0
activity	0
independently	0
of	0
protein	9
tyrosine	10
kinase	10
activation	0
.	0

Negative	0
regulation	0
by	0
HLA-DO	9
of	0
MHC	9
class	10
II	10
-restricted	0
antigen	0
processing	0
.	0

HLA-DM	9
is	0
a	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
II-like	10
molecule	10
that	0
facilitates	0
antigen	0
processing	0
by	0
catalyzing	0
the	0
exchange	0
of	0
invariant	0
chain-derived	0
peptides	0
(	0
CLIP	0
)	0
from	0
class	9
II	10
molecules	10
for	0
antigenic	0
peptides	0
.	0

HLA-DO	9
is	0
a	0
second	0
class	9
II-like	10
molecule	10
that	0
physically	0
associates	0
with	0
HLA-DM	9
in	0
B	7
cells	8
.	0

HLA-DO	9
was	0
shown	0
to	0
block	0
HLA-DM	9
function	0
.	0

Purified	0
HLA-DM-DO	9
complexes	10
could	0
not	0
promote	0
peptide	0
exchange	0
in	0
vitro	0
.	0

Expression	0
of	0
HLA-DO	9
in	0
a	0
class	5
II+	6
and	6
DM+	6
,	6
DO-	6
human	6
T	6
cell	6
line	6
caused	0
the	0
accumulation	0
of	0
class	9
II-CLIP	10
complexes	10
,	0
indicating	0
that	0
HLA-DO	9
blocked	0
DM	0
function	0
in	0
vivo	0
and	0
suggesting	0
that	0
HLA-DO	9
is	0
an	0
important	0
modulator	0
of	0
class	0
II-restricted	0
antigen	0
processing	0
.	0

Vitamin	9
D	10
receptor	10
:	0
no	0
evidence	0
for	0
allele-specific	0
mRNA	0
stability	0
in	0
cells	0
which	0
are	0
heterozygous	0
for	0
the	0
Taq	9
I	10
restriction	10
enzyme	10
polymorphism	0
.	0

Allelic	0
variations	0
of	0
the	0
vitamin	1
D	2
receptor	2
(	2
VDR	2
)	2
gene	2
have	0
been	0
associated	0
with	0
the	0
risk	0
of	0
developing	0
prostate	0
cancer	0
in	0
men	0
and	0
osteoporosis	0
in	0
postmenopausal	0
women	0
.	0

Three	0
RFLPs	1
(	0
TaqI	1
,	0
ApaI	1
,	0
BsmI	1
)	0
define	0
two	0
common	0
haplotypes	0
:	0
BAt	0
and	0
baT	0
.	0

None	0
of	0
these	0
polymorphisms	1
change	0
the	0
translated	9
protein	10
.	0

Since	0
sequence	1
variations	2
in	0
the	0
3	1
'	2
UTR	2
of	0
VDR	9
have	0
been	0
linked	0
to	0
the	0
different	0
haplotypes	0
,	0
investigators	0
have	0
proposed	0
that	0
the	0
stability	0
of	0
VDR	3
mRNA	4
is	0
influenced	0
by	0
allelic	0
variations	0
.	0

Indirect	0
evidence	0
suggested	0
that	0
allele	1
T	2
is	0
less	0
stable	0
than	0
allele	1
t	2
.	0

In	0
this	0
study	0
,	0
we	0
used	0
a	0
RT-PCR	0
based	0
approach	0
to	0
compare	0
the	0
stability	0
of	0
the	0
big	1
T	2
and	2
small	2
t	2
allele	2
in	0
normal	7
heterozygous	8
lymphocytes	8
and	0
the	0
heterozygous	5
cell	6
lines	6
NB4	5
(	0
myeloid	0
leukemia	0
)	0
and	0
PC-3	5
and	0
DU	5
145	6
(	0
prostate	0
cancers	0
)	0
.	0

In	0
all	0
three	0
cases	0
,	0
we	0
did	0
not	0
find	0
a	0
significant	0
difference	0
in	0
stability	0
.	0

Interestingly	0
,	0
we	0
consistently	0
observed	0
30	0
%	0
less	0
RT-PCR	1
product	2
derived	0
from	0
the	0
small	3
t	4
allele	4
mRNA	4
in	0
steady	0
state	0
,	0
a	0
finding	0
which	0
also	0
speaks	0
against	0
a	0
higher	0
stability	0
of	0
the	0
small	3
t	4
allele	4
mRNA	4
.	0

These	0
results	0
indicate	0
a	0
variation	0
in	0
transcriptional	0
regulation	0
rather	0
than	0
mRNA	0
stability	0
between	0
the	0
alleles	1
.	0

We	0
hypothesize	0
that	0
an	0
unknown	0
gene	0
or	0
genes	0
in	0
linkage	0
with	0
the	0
polymorphisms	1
is	0
(	0
are	0
)	0
responsible	0
for	0
the	0
relationship	0
between	0
risk	0
of	0
prostate	0
cancer	0
and	0
VDR	9
polymorphisms	1
.	0

Replication	0
of	0
human	0
immunodeficiency	0
virus-1	0
in	0
primary	7
human	8
T	8
cells	8
is	0
dependent	0
on	0
the	0
autocrine	0
secretion	0
of	0
tumor	9
necrosis	10
factor	10
through	0
the	0
control	0
of	0
nuclear	9
factor-kappa	10
B	10
activation	0
.	0

Tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
controls	0
T-cell	0
activation	0
and	0
is	0
a	0
major	0
inducer	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
-1	0
replication	0
in	0
chronically	7
infected	8
cells	8
.	0

Therefore	0
,	0
we	0
have	0
investigated	0
its	0
role	0
in	0
primary	0
cultures	0
of	0
HIV-infected	7
human	8
T	8
lymphocytes	8
by	0
using	0
neutralizing	0
anti-TNF-alpha	9
antibodies	10
or	0
TNF-alpha	9
.	0

Primary	0
resting	0
T	0
lymphocytes	0
produced	0
TNF-alpha	9
and	0
supported	0
HIV	0
replication	0
after	0
T-cell	0
receptor	0
activation	0
.	0

Addition	0
of	0
neutralizing	0
anti-TNF-alpha	9
antibodies	10
drastically	0
reduced	0
p24	9
antigen	10
release	0
and	0
prevented	0
CD4+	9
cell	0
depletion	0
associated	0
with	0
infection	0
.	0

Anti-TNF-alpha	9
also	0
prevented	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
,	0
and	0
a	0
good	0
correlation	0
between	0
this	0
inhibition	0
and	0
inhibition	0
of	0
HIV	0
replication	0
was	0
observed	0
.	0

Moreover	0
,	0
supplementing	0
the	0
cultures	0
with	0
high	0
doses	0
of	0
IL-2	0
reverted	0
anti-	0
TNF-alpha	9
inhibition	0
of	0
cell	0
proliferation	0
but	0
did	0
not	0
affect	0
the	0
inhibition	0
of	0
HIV	0
p24	9
antigen	10
release	0
or	0
NF-kappa	9
B	10
activation	0
in	0
the	0
same	0
cultures	0
.	0

Moreover	0
,	0
anti-TNF-alpha	9
inhibited	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
-driven	0
transcription	0
of	0
a	0
reporter	1
gene	2
in	0
primary	7
T	8
cells	8
in	0
response	0
to	0
activation	0
,	0
either	0
in	0
the	0
presence	0
or	0
the	0
absence	0
of	0
HIV-1	9
Tat	10
.	0

Our	0
results	0
support	0
an	0
important	0
role	0
for	0
autocrine	0
TNF-alpha	9
secretion	0
in	0
controlling	0
HIV	0
replication	0
in	0
primary	7
T	8
cells	8
because	0
of	0
its	0
ability	0
to	0
maintain	0
NF-kappa	9
B	10
elevated	0
in	0
the	0
nucleus	0
of	0
T	7
cells	8
.	0

Hypoxia	0
enhances	0
induction	0
of	0
endothelial	9
ICAM-1	10
:	0
role	0
for	0
metabolic	0
acidosis	0
and	0
proteasomes	9
.	0

Intercellular	9
adhesion	10
molecule	10
1	10
(	0
ICAM-1	9
)	0
is	0
an	0
important	0
molecule	0
in	0
promotion	0
of	0
polymorphonuclear	0
neutrophil	0
transendothelial	0
migration	0
during	0
inflammation	0
.	0

Coincident	0
with	0
many	0
inflammatory	0
diseases	0
is	0
tissue	0
hypoxia	0
.	0

Thus	0
we	0
hypothesized	0
that	0
combinations	0
of	0
hypoxia	0
and	0
inflammatory	0
stimuli	0
may	0
differentially	0
regulate	0
expression	0
of	0
endothelial	9
ICAM-1	10
.	0

Human	7
endothelial	8
cells	8
were	0
exposed	0
to	0
hypoxia	0
in	0
the	0
presence	0
or	0
absence	0
of	0
added	0
lipopolysaccharide	0
(	0
LPS	0
)	0
and	0
examined	0
for	0
expression	0
of	0
functional	0
ICAM-1	9
.	0

Although	0
hypoxia	0
alone	0
did	0
not	0
induce	0
ICAM-1	9
,	0
the	0
combination	0
of	0
LPS	0
and	0
hypoxia	0
enhanced	0
(	0
3	0
+/-	0
0.4-fold	0
over	0
normoxia	0
)	0
ICAM-1	9
expression	0
.	0

Combinations	0
of	0
hypoxia	0
and	0
LPS	0
significantly	0
increased	0
lymphocyte	0
binding	0
,	0
and	0
such	0
increases	0
were	0
inhibited	0
by	0
addition	0
of	0
anti-ICAM-1	9
antibodies	10
or	0
antisense	0
oligonucleotides	0
.	0

Hypoxic	0
endothelia	0
showed	0
a	0
>	0
10-fold	0
increase	0
in	0
sensitivity	0
to	0
inhibitors	0
of	0
proteasome	9
activation	0
,	0
and	0
combinations	0
of	0
hypoxia	0
and	0
LPS	0
enhanced	0
proteasome	9
-dependent	0
cytoplasmic-to-nuclear	0
localization	0
of	0
the	0
nuclear	9
transcription	10
factor-kappa	10
B	10
p65	10
(	10
Rel	10
A	10
)	10
subunit	10
.	0

Such	0
proteasome	9
activation	0
correlated	0
with	0
hypoxia-evoked	0
decreases	0
in	0
both	0
extracellular	0
and	0
intracellular	0
pH	0
.	0

We	0
conclude	0
from	0
these	0
studies	0
that	0
endothelial	0
hypoxia	0
provides	0
a	0
novel	0
,	0
proteasome	9
-dependent	0
stimulus	0
for	0
ICAM-1	9
induction	0
.	0

Differanisole	0
A	0
,	0
a	0
novel	0
antitumor	0
antibiotic	0
,	0
enhances	0
growth	0
inhibition	0
and	0
differentiation	0
of	0
human	7
myeloid	8
leukemia	8
cells	8
induced	0
by	0
9-cis	0
retinoic	0
acid	0
.	0

Differanisole	0
A	0
,	0
3	0
,	0
5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic	0
acid	0
,	0
inhibited	0
growth	0
of	0
human	7
myeloid	8
leukemia	8
cells	8
.	0

The	0
compound	0
induced	0
G1	0
arrest	0
and	0
granulocytic	0
differentiation	0
of	0
HL-60	5
cells	6
,	0
although	0
the	0
differentiation-inducing	0
effect	0
was	0
modest	0
.	0

Differanisole	0
A	0
and	0
9-cis	0
retinoic	0
acid	0
(	0
9cisRA	0
)	0
synergistically	0
inhibited	0
the	0
growth	0
and	0
induced	0
functional	0
and	0
morphologic	0
differentiation	0
of	0
HL-60	5
and	6
NB4	6
cells	6
,	0
whereas	0
the	0
combined	0
treatment	0
with	0
differanisole	0
A	0
and	0
all-trans	0
retinoic	0
acid	0
or	0
1alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
was	0
less	0
effective	0
.	0

Similar	0
results	0
were	0
obtained	0
in	0
primary	0
culture	0
of	0
leukemia	7
cells	8
from	0
a	0
patient	0
with	0
acute	0
promyelocytic	0
leukemia	0
.	0

The	0
synergistic	0
effect	0
on	0
growth	0
inhibition	0
and	0
induction	0
of	0
differentiation	0
required	0
simultaneous	0
treatment	0
with	0
differanisole	0
A	0
and	0
9cisRA	0
.	0

Differanisole	0
A	0
and	0
an	0
RXR-specific	0
ligand	0
(	0
Ro47-5944	0
)	0
cooperatively	0
inhibited	0
the	0
cell	0
growth	0
,	0
while	0
the	0
combined	0
effect	0
of	0
differanisole	0
A	0
and	0
an	0
RAR-specific	0
ligand	0
Am80	0
was	0
just	0
additive	0
.	0

Differanisole	0
A	0
in	0
combination	0
with	0
9cisRA	0
may	0
have	0
implications	0
for	0
therapy	0
of	0
acute	0
promyelocytic	0
leukemia	0
patients	0
.	0

The	0
activation	0
of	0
the	0
JAK2	9
/STAT5	9
pathway	0
is	0
commonly	0
involved	0
in	0
signaling	0
through	0
the	0
human	9
IL-5	10
receptor	10
.	0

The	0
JAK	9
(	10
Janus	10
kinase	10
)	10
family	10
of	0
protein	9
tyrosine	10
kinases	10
and	0
the	0
STATs	9
(	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
)	0
have	0
been	0
shown	0
to	0
be	0
activated	0
in	0
response	0
to	0
a	0
number	0
of	0
cytokines	9
and	0
growth	9
factors	10
.	0

In	0
this	0
study	0
,	0
we	0
evaluated	0
the	0
activation	0
of	0
JAK	9
/STAT	9
pathway	0
upon	0
human	9
interleukin-5	10
(	0
hIL-5	9
)	0
stimulation	0
of	0
two	0
different	0
hIL-5-responsive	5
cell	6
lines	6
,	0
hIL-5	5
receptor	6
alpha-subunit	6
(	6
hIL-5R	6
alpha	6
)	6
cDNA-transfected	6
TF-1	6
(	0
TF-h5R	5
alpha	6
)	0
and	0
butyric-acid-treated	5
YY-1	6
(	0
YY-Bu	5
)	0
,	0
and	0
peripheral	5
eosinophils	6
.	0

Immunoprecipitation	0
and	0
electrophoretic	0
mobility	0
shift	0
analysis	0
revealed	0
that	0
tyrosine	0
phosphorylation	0
of	0
JAK2	9
and	0
activation	0
of	0
STAT5	9
were	0
induced	0
upon	0
stimulation	0
with	0
hIL-5	9
in	0
all	0
three	0
cell	0
types	0
,	0
while	0
STAT1	9
activation	0
was	0
only	0
observed	0
in	0
eosinophils	7
.	0

These	0
results	0
indicate	0
that	0
JAK2	9
/STAT5	9
activation	0
is	0
a	0
common	0
JAK	9
/STAT	9
pathway	0
for	0
hIL-5	9
-mediated	0
signal	0
in	0
these	0
cells	0
.	0

Dysregulation	0
of	0
monocytic	9
nuclear	10
factor-kappa	10
B	10
by	0
oxidized	0
low-density	9
lipoprotein	10
.	0

Nuclear	9
factor-kappa	10
B	10
(	10
NF-kappa	10
B	10
)	10
/Rel	10
transcription	10
factors	10
may	0
be	0
involved	0
in	0
atherosclerosis	0
,	0
as	0
is	0
suggested	0
by	0
the	0
presence	0
of	0
activated	0
NF-kappa	9
B	10
in	0
human	0
atherosclerotic	0
lesions	0
.	0

The	0
aim	0
of	0
the	0
present	0
study	0
was	0
to	0
investigate	0
the	0
effects	0
of	0
oxidized	9
LDL	10
(	0
oxLDL	9
)	0
on	0
the	0
NF-kappa	9
B	10
system	0
in	0
human	0
THP-1	5
monocytic	6
cells	6
as	0
well	0
as	0
adherent	7
monocytes	8
.	0

Our	0
results	0
demonstrate	0
that	0
short-term	0
incubation	0
of	0
these	0
cells	0
with	0
oxLDL	9
activated	10
p50/p65	10
containing	0
NF-kappa	9
B	10
dimers	10
and	0
induced	0
the	0
expression	0
of	0
the	0
target	1
gene	2
IL-8	2
.	0

This	0
activation	0
of	0
NF-kappa	9
B	10
was	0
inhibited	0
by	0
the	0
antioxidant	0
and	0
H2O2	0
scavenger	0
pyrrolidine	0
dithiocarbamate	0
and	0
the	0
proteasome	9
inhibitor	0
PSI	0
.	0

The	0
oxLDL	9
-induced	0
NF-kappa	9
B	10
activation	0
was	0
accompanied	0
by	0
an	0
initial	0
depletion	0
of	0
I	9
kappa	10
B-alpha	10
followed	0
by	0
a	0
slight	0
transient	0
increase	0
in	0
the	0
level	0
of	0
this	0
inhibitor	0
protein	0
.	0

In	0
contrast	0
,	0
long-term	0
treatment	0
with	0
oxLDL	9
prevented	0
the	0
lipopolysaccharide-induced	0
depletion	0
of	0
I	9
kappa	10
B-alpha	10
,	0
accompanied	0
by	0
an	0
inhibition	0
of	0
both	0
NF-kappa	9
B	10
activation	0
and	0
the	0
expression	0
of	0
tumor	1
necrosis	2
factor-alpha	2
and	2
interleukin-1	2
beta	2
genes	2
.	0

These	0
observations	0
provide	0
additional	0
evidence	0
that	0
oxLDL	9
is	0
a	0
potent	0
modulator	0
of	0
gene	0
expression	0
and	0
suggest	0
that	0
(	0
dys	0
)	0
regulation	0
of	0
NF-kappa	9
B/Rel	10
is	0
likely	0
to	0
play	0
an	0
important	0
role	0
in	0
atherogenesis	0
.	0

Suppression	0
of	0
nuclear	9
factor	10
kappa	10
B	10
and	0
CD18	9
-mediated	0
leukocyte	0
adhesion	0
to	0
the	0
corneal	0
endothelium	0
by	0
dexamethasone	0
.	0

PURPOSE	0
:	0
To	0
demonstrate	0
that	0
leukocyte	0
adhesion	0
to	0
cultured	5
corneal	6
endothelial	6
cells	6
is	0
mediated	0
by	0
the	0
CD18	9
antigen	10
,	0
and	0
to	0
determine	0
whether	0
dexamethasone	0
directly	0
suppresses	0
adhesion	0
by	0
inhibiting	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NFkappaB	9
)	0
.	0

METHODS	0
:	0
Cultured	0
bovine	0
corneal	0
endothelium	0
was	0
stimulated	0
for	0
6	0
hours	0
by	0
40	0
micron/ml	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNFalpha	9
)	0
.	0

Dexamethasone	0
was	0
added	0
1	0
hour	0
before	0
TNFalpha	9
stimulation	0
in	0
the	0
dexamethasone	0
group	0
.	0

After	0
stimulation	0
,	0
neutrophils	0
separated	0
from	0
a	0
healthy	0
human	0
volunteer	0
were	0
added	0
with	0
or	0
without	0
anti-CD18	9
antibody	10
.	0

The	0
culture	0
plate	0
was	0
settled	0
for	0
15	0
minutes	0
at	0
37	0
degrees	0
C	0
,	0
and	0
then	0
neutrophils	7
were	0
activated	0
by	0
N-formyl-methionyl-leucyl-phenylalanine	0
for	0
5	0
minutes	0
.	0

Nonadherent	0
neutrophils	7
were	0
removed	0
by	0
sealing	0
and	0
inverting	0
the	0
culture	0
well	0
.	0

The	0
intracellular	0
localization	0
of	0
NFkappaB	9
after	0
TNFalpha	9
simulation	0
was	0
determined	0
by	0
confocal	0
immunocytochemistry	0
using	0
an	0
anti-p65	9
antibody	10
.	0

RESULTS	0
:	0
Neutrophil	0
adhesion	0
to	0
cultured	5
corneal	6
endothelial	6
cells	6
increased	0
significantly	0
on	0
exposure	0
to	0
TNFalpha	9
(	0
451.4+/-45.4	0
cells/mm2	0
,	0
n	0
=	0
16	0
)	0
compared	0
to	0
control	0
(	0
156.7+/-27.3	0
cells/mm2	0
,	0
n	0
=	0
16	0
,	0
P	0
<	0
0.01	0
)	0
.	0

This	0
increased	0
adhesion	0
was	0
suppressed	0
by	0
the	0
addition	0
of	0
anti-CD18	9
antibody	10
(	0
157.6+/-25.1	0
cells/mm2	0
,	0
n	0
=	0
8	0
,	0
P	0
<	0
0.01	0
)	0
and	0
by	0
pretreatment	0
with	0
10	0
(	0
-7	0
)	0
M	0
dexamethasone	0
(	0
207.9+/-31.5	0
cells/mm2	0
,	0
n	0
=	0
10	0
,	0
P	0
<	0
0.01	0
)	0
.	0

Immunocytochemistry	0
60	0
minutes	0
after	0
stimulation	0
revealed	0
that	0
NFkappaB	9
was	0
located	0
in	0
the	0
cytoplasm	0
in	0
unstimulated	7
cells	8
;	0
however	0
,	0
the	0
addition	0
of	0
TNFalpha	9
caused	0
NFkappaB	9
to	0
translocate	0
into	0
the	0
nucleus	0
.	0

Pretreatment	0
with	0
dexamethasone	0
tapered	0
NFkappaB	9
translocation	0
into	0
the	0
nucleus	0
.	0

CONCLUSIONS	0
:	0
Leukocyte	0
adhesion	0
to	0
the	0
corneal	0
endothelium	0
was	0
shown	0
to	0
be	0
mediated	0
by	0
CD18	9
expressed	0
on	0
activated	7
leukocytes	8
.	0

Pretreatment	0
of	0
the	0
endothelium	0
with	0
dexamethasone	0
inhibited	0
leukocyte	0
adhesion	0
;	0
this	0
may	0
be	0
due	0
in	0
part	0
to	0
the	0
suppression	0
of	0
NFkappaB	9
entry	0
into	0
the	0
nucleus	0
.	0

Molecular	0
characterization	0
and	0
pattern	0
of	0
tissue	0
expression	0
of	0
the	0
gene	0
for	0
neutrophil	9
gelatinase-associated	10
lipocalin	10
from	0
humans	0
.	0

Neutrophil	9
gelatinase-associated	10
lipocalin	10
(	0
NGAL	9
)	0
is	0
a	0
25-kDa	9
lipocalin	10
first	0
identified	0
as	0
a	0
protein	0
stored	0
in	0
specific	0
granules	0
of	0
the	0
human	7
neutrophil	8
.	0

The	0
protein	0
is	0
believed	0
to	0
bind	0
small	0
lipophilic	0
substances	0
such	0
as	0
bacterial	0
derived	0
formylpeptides	0
and	0
lipopolysaccharides	0
(	0
LPS	0
)	0
and	0
might	0
function	0
as	0
a	0
modulator	0
of	0
inflammation	0
.	0

To	0
characterize	0
the	0
regulation	0
of	0
NGAL	9
further	0
,	0
we	0
have	0
cloned	0
and	0
sequenced	0
a	0
5869-bp	1
region	2
of	0
the	0
NGAL	1
gene	2
including	0
1695	0
bp	0
of	0
the	0
5	1
'	2
nontranscribed	2
region	2
and	0
a	0
3696-bp	1
coding	2
region	2
encompassing	0
seven	1
exons	2
and	2
six	2
introns	2
.	0

The	0
transcriptional	1
start	2
sites	2
were	0
identified	0
by	0
an	0
RNase	9
protection	0
assay	0
.	0

The	0
NGAL	9
gene	0
is	0
highly	0
homologous	0
to	0
the	0
mouse	1
gene	2
24p3	2
.	0

NGAL	9
was	0
expressed	0
in	0
bone	0
marrow	0
and	0
in	0
tissues	0
that	0
are	0
prone	0
to	0
exposure	0
to	0
microorganisms	0
.	0

Potential	0
cis-acting	1
elements	2
were	0
identified	0
in	0
the	0
promoter	1
region	2
of	0
the	0
NGAL	1
gene	2
by	0
computer	0
analysis	0
and	0
include	0
binding	1
sites	2
for	0
CTF/CBP	9
,	0
the	0
hematopoietic	9
transcription	10
factors	10
GATA-1	9
and	0
PU.1	9
,	0
and	0
the	0
LPS-inducible	9
factor	10
NF-kappa	10
B	10
.	0

Human	7
neutrophils	8
express	0
GH-N	3
gene	4
transcripts	4
and	0
the	0
pituitary	9
transcription	10
factor	10
Pit-1b	9
.	0

Since	0
GH	9
stimulates	0
the	0
development	0
and	0
function	0
of	0
granulocytes	7
,	0
we	0
investigated	0
the	0
expression	0
of	0
GH	9
in	0
granulocyte	7
subsets	8
.	0

By	0
immunocytochemistry	0
,	0
25	0
+/-	0
7	0
%	0
of	0
the	0
human	7
neutrophils	8
were	0
shown	0
to	0
express	0
immunoreactive	9
GH	10
,	0
whereas	0
eosinophils	7
were	0
negative	0
.	0

Reversed	0
transcription	0
(	0
RT	0
)	0
-PCR	0
analysis	0
demonstrated	0
GH	3
mRNA	4
in	0
neutrophils	7
.	0

Restriction	0
analysis	0
revealed	0
that	0
neutrophils	7
express	0
the	0
GH-N	1
gene	2
but	0
not	0
the	0
GH-V	1
gene	2
.	0

Furthermore	0
,	0
we	0
demonstrated	0
by	0
western	0
blot	0
analysis	0
that	0
neutrophils	7
express	0
an	0
alternatively	0
spliced	0
variant	0
of	0
the	0
pituitary	9
transcription	10
factor	10
Pit-1	9
,	0
designated	0
Pit-1b	9
.	0

The	0
ability	0
of	0
BHRF1	9
to	0
inhibit	0
apoptosis	0
is	0
dependent	0
on	0
stimulus	0
and	0
cell	0
type	0
.	0

The	0
development	0
of	0
resistance	0
to	0
host	0
defense	0
mechanisms	0
such	0
as	0
tumor	0
necrosis	0
factor	0
(	0
TNF	0
)	0
-	0
and	0
Fas-mediated	0
apoptosis	0
of	0
transformed	7
or	0
virus-infected	7
cells	8
may	0
be	0
a	0
critical	0
component	0
in	0
the	0
development	0
of	0
disease	0
.	0

To	0
find	0
genes	0
that	0
protect	0
cells	0
from	0
apoptosis	0
,	0
we	0
used	0
an	0
expression	0
cloning	0
strategy	0
and	0
identified	0
BHRF1	9
,	0
an	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
early-lytic-cycle	10
protein	10
with	0
distant	0
homology	0
to	0
Bcl-2	9
,	0
as	0
an	0
anti-apoptosis	9
protein	10
.	0

Expression	0
of	0
BHRF1	9
in	0
MCF-Fas	5
cells	6
conferred	0
nearly	0
complete	0
resistance	0
against	0
both	0
anti-Fas	9
antibody	10
and	0
TNF-mediated	0
apoptosis	0
.	0

In	0
addition	0
,	0
BHRF1	9
protected	0
these	0
cells	0
from	0
monocyte-mediated	0
killing	0
but	0
failed	0
to	0
protect	0
them	0
from	0
killing	0
mediated	0
by	0
lymphokine-activated	7
killer	8
cells	8
.	0

The	0
ability	0
of	0
BHRF1	9
to	0
protect	0
MCF-Fas	5
cells	6
from	0
apoptosis	0
induced	0
by	0
various	0
stimuli	0
was	0
identical	0
to	0
that	0
of	0
Bcl-2	9
and	0
Bcl-xL	9
.	0

Moreover	0
,	0
the	0
mechanism	0
of	0
action	0
of	0
BHRF1	9
resembled	0
that	0
of	0
Bcl-2	9
and	0
Bcl-xL	9
as	0
it	0
inhibited	0
TNF-	0
and	0
anti-Fas-induced	0
activation	0
of	0
two	0
enzymes	0
participating	0
in	0
the	0
apoptosis	0
pathway	0
,	0
cytosolic	9
phospholipase	10
A2	10
and	0
caspase-3/CPP32	9
,	0
but	0
did	0
not	0
interfere	0
with	0
the	0
activation	0
of	0
NF-kappaB-like	9
transcription	10
factors	10
.	0

A	0
putative	0
function	0
of	0
BHRF1	9
in	0
EBV-infected	7
epithelial	8
cells	8
may	0
be	0
to	0
protect	0
virus-infected	0
cells	0
from	0
TNF-	0
and/or	0
anti-Fas-	0
induced	0
cell	0
death	0
in	0
order	0
to	0
maximize	0
virus	0
production	0
.	0

Surprisingly	0
,	0
expression	0
of	0
neither	0
BHRF1	9
nor	0
Bcl-2	9
in	0
a	0
B-cell	5
line	6
,	0
BJAB	5
,	0
protected	0
the	0
cells	0
from	0
anti-Fas-mediated	0
apoptosis	0
even	0
though	0
they	0
increased	0
the	0
survival	0
of	0
serum-starved	7
cells	8
.	0

Thus	0
,	0
the	0
protective	0
role	0
of	0
BHRF1	9
against	0
apoptosis	0
resembles	0
that	0
of	0
Bcl-2	9
in	0
being	0
cell	0
type	0
specific	0
and	0
dependent	0
on	0
the	0
apoptotic	0
stimulus	0
.	0

Genomic	0
organization	0
,	0
sequence	0
,	0
and	0
transcriptional	0
regulation	0
of	0
the	0
human	1
eotaxin	2
gene	2
.	0

Eotaxin	9
is	0
an	0
eosinophil	9
specific	10
beta-chemokine	10
assumed	0
to	0
be	0
involved	0
in	0
eosinophilic	0
inflammatory	0
diseases	0
such	0
as	0
atopic	0
dermatitis	0
,	0
allergic	0
rhinitis	0
,	0
asthma	0
and	0
parasitic	0
infections	0
.	0

Its	0
expression	0
is	0
stimulus-	0
and	0
cell-specific	0
.	0

We	0
here	0
describe	0
the	0
genomic	0
organisation	0
(	0
3	0
exons	1
of	0
132	0
,	0
112	0
and	0
542	0
bp	0
and	0
2	0
introns	1
of	0
1211	0
and	0
378	0
bp	0
)	0
and	0
sequence	0
including	0
3	0
kb	0
of	0
DNA	0
from	0
the	0
immediate	0
5	1
'	2
upstream	2
region	2
of	0
the	0
human	1
eotaxin	2
gene	2
.	0

Among	0
the	0
regulatory	1
promoter	2
elements	2
potentially	0
regulating	0
eotaxin	1
gene	2
expression	0
and/or	0
mediating	0
the	0
effects	0
of	0
anti-inflammatory	0
drugs	0
we	0
identified	0
consensus	1
sequences	2
known	0
to	0
interact	0
with	0
nuclear	9
factors	10
like	0
NF-IL6	9
,	0
AP-1	9
,	0
a	0
NF-kappa-B	1
like	2
consensus	2
sequence	2
and	0
gamma-interferon-	1
as	2
well	2
as	2
glucocorticoid	2
response	2
elements	2
.	0

Differential	0
interaction	0
of	0
nuclear	9
factors	10
with	0
the	0
leukocyte-specific	1
pp52	2
promoter	2
in	0
B	7
and	8
T	8
cells	8
.	0

The	0
leukocyte-specific	0
,	0
cytoskeleton-binding	0
pp52	0
(	0
LSP-1	0
,	0
WP-34	0
)	0
protein	0
is	0
widely	0
expressed	0
in	0
multiple	0
leukocyte	0
lineages	0
,	0
including	0
B	7
and	8
T	8
lymphocytes	8
,	0
granulocytes	7
,	0
and	0
macrophages	7
.	0

We	0
previously	0
detected	0
a	0
tissue-specific	1
promoter	2
preceding	0
the	0
exon	0
encoding	0
the	0
N	9
terminus	10
of	0
the	0
pp52	9
leukocyte	10
protein	10
.	0

Here	0
we	0
describe	0
the	0
functional	0
characterization	0
of	0
this	0
promoter	0
and	0
identification	0
of	0
the	0
factors	0
in	0
B	7
and	8
T	8
cells	8
that	0
regulate	0
its	0
activity	0
.	0

The	0
pp52	1
promoter	2
contains	0
an	0
initiator	0
specifying	0
the	0
unique	0
5	1
'	2
terminus	2
of	0
pp52	3
mRNA	4
,	0
tandem	0
pairs	0
of	0
Ets	1
and	2
SP1	2
motifs	2
,	0
and	0
a	0
lone	1
C/EBP	2
motif	2
.	0

All	0
these	0
motifs	0
are	0
essential	0
and	0
collectively	0
control	0
transcriptional	0
activity	0
.	0

DNA	0
binding	0
studies	0
and	0
Ab	0
supershift	0
assays	0
revealed	0
that	0
different	0
combinations	0
of	0
factors	0
interact	0
with	0
these	0
motifs	0
in	0
B	7
cells	8
vs	0
T	7
cells	8
.	0

The	0
Ets	1
motifs	2
are	0
preferentially	0
bound	0
by	0
PU-1	9
in	0
B	0
cell	0
extracts	0
from	0
all	0
stages	0
of	0
development	0
,	0
whereas	0
a	0
different	0
Ets	9
family	10
member	10
reacts	0
with	0
these	0
motifs	0
in	0
T	0
cell	0
extracts	0
.	0

The	0
C/EBP	1
motif	2
is	0
bound	0
by	0
Ig/EBP-1	9
in	0
pre-B	0
cell	0
and	0
T	0
cell	0
extracts	0
,	0
but	0
is	0
replaced	0
by	0
nuclear	9
factor-IL-6beta	10
or	0
a	0
nuclear	9
factor-IL-6beta-Ig/EBP-1	10
heterodimer	10
in	0
plasmacytoma	0
cell	0
extracts	0
.	0

Despite	0
its	0
reported	0
role	0
as	0
a	0
negative	0
regulator	0
of	0
transcription	0
,	0
Ig/EBP-1	9
appears	0
to	0
exert	0
a	0
stimulatory	0
effect	0
on	0
this	0
promoter	1
.	0

These	0
findings	0
reveal	0
the	0
features	0
controlling	0
the	0
pp52	1
promoter	2
in	0
B	7
and	8
T	8
cells	8
and	0
provide	0
the	0
foundation	0
for	0
determining	0
the	0
regulation	0
of	0
this	0
promoter	1
in	0
other	0
leukocyte	7
lineages	8
.	0

Regulation	0
of	0
B-cell	0
commitment	0
to	0
plasma	7
cells	8
or	0
to	0
memory	7
B	8
cells	8
.	0

During	0
humoral	0
immune	0
responses	0
,	0
B-lymphocyte	0
activation	0
is	0
followed	0
by	0
differentiation	0
along	0
either	0
the	0
plasma	0
cell	0
pathway	0
or	0
the	0
memory	0
B-cell	0
pathway	0
.	0

Recent	0
studies	0
suggest	0
that	0
CD40-CD40	9
ligand	10
,	0
OX-OX40	9
ligand	10
,	0
a	0
group	0
of	0
cytokines	9
and	0
intracellular	0
transcriptional	0
factors	0
may	0
all	0
contribute	0
to	0
B-lymphocyte	0
differentiation	0
control	0
.	0

Transcription	9
factor	10
binding	0
sites	0
downstream	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
transcription	2
start	2
site	2
are	0
important	0
for	0
virus	0
infectivity	0
.	0

When	0
transcriptionally	0
active	0
,	0
the	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
promoter	1
contains	0
a	0
nucleosome-free	0
region	0
encompassing	0
both	0
the	0
promoter/enhancer	1
region	2
and	0
a	0
large	0
region	0
(	0
255	1
nucleotides	2
[	0
nt	0
]	0
)	0
downstream	0
of	0
the	0
transcription	1
start	2
site	2
.	0

We	0
have	0
previously	0
identified	0
new	0
binding	0
sites	0
for	0
transcription	9
factors	10
downstream	0
of	0
the	0
transcription	1
start	2
site	2
(	0
nt	1
465	2
to	2
720	2
)	0
:	0
three	0
AP-1	1
sites	2
(	0
I	0
,	0
II	0
,	0
and	0
III	0
)	0
,	0
an	0
AP3-like	1
motif	2
(	0
AP3-L	1
)	0
,	0
a	0
downstream	1
binding	2
factor	2
(	2
DBF	2
)	2
site	2
,	0
and	0
juxtaposed	1
Sp1	2
sites	2
.	0

Here	0
,	0
we	0
show	0
that	0
the	0
DBF	1
site	2
is	0
an	0
interferon-responsive	1
factor	2
(	2
IRF	2
)	2
binding	2
site	2
and	0
that	0
the	0
AP3-L	1
motif	2
binds	0
the	0
T-cell-specific	9
factor	10
NF-AT	9
.	0

Mutations	0
that	0
abolish	0
the	0
binding	0
of	0
each	0
factor	0
to	0
its	0
cognate	0
site	0
are	0
introduced	0
in	0
an	0
infectious	0
HIV-1	0
molecular	0
clone	0
to	0
study	0
their	0
effect	0
on	0
HIV-1	0
transcription	0
and	0
replication	0
.	0

Individual	0
mutation	0
of	0
the	0
DBF	0
or	0
AP3-L	1
site	0
as	0
well	0
as	0
the	0
double	0
mutation	1
AP-1	2
(	2
III	2
)	2
/AP3-L	2
did	0
not	0
affect	0
HIV-1	0
replication	0
compared	0
to	0
that	0
of	0
the	0
wild-type	0
virus	0
.	0

In	0
contrast	0
,	0
proviruses	0
carrying	0
mutations	0
in	0
the	0
Sp1	1
sites	2
were	0
totally	0
defective	0
in	0
terms	0
of	0
replication	0
.	0

Virus	0
production	0
occurred	0
with	0
slightly	0
delayed	0
kinetics	0
for	0
viruses	0
containing	0
combined	0
mutations	0
in	0
the	0
AP-1	1
(	2
III	2
)	2
,	0
AP3-L	1
,	0
and	0
DBF	1
sites	2
and	0
in	0
the	0
AP3-L	1
and	0
DBF-sites	1
,	0
whereas	0
viruses	0
mutated	0
in	0
the	0
AP-1	1
(	2
I	2
,	2
II	2
,	2
III	2
)	2
and	0
AP3-L	1
sites	2
and	0
in	0
the	0
AP-1	0
(	0
I	0
,	0
II	0
,	0
III	0
)	0
,	0
AP3-L	1
,	0
and	0
DBF	1
sites	2
exhibited	0
a	0
severely	0
defective	0
replicative	0
phenotype	0
.	0

No	0
RNA-packaging	0
defect	0
could	0
be	0
measured	0
for	0
any	0
of	0
the	0
mutant	0
viruses	0
as	0
determined	0
by	0
quantification	0
of	0
their	0
HIV	3
genomic	4
RNA	4
.	0

Measurement	0
of	0
the	0
transcriptional	0
activity	0
of	0
the	0
HIV-1	1
promoter	2
after	0
transient	0
transfection	0
of	0
the	0
HIV-1	1
provirus	2
DNA	2
or	0
of	0
long	1
terminal	2
repeat-luciferase	2
constructs	2
showed	0
a	0
positive	0
correlation	0
between	0
the	0
transcriptional	0
and	0
the	0
replication	0
defects	0
for	0
most	0
mutants	0
.	0

Glucocorticoid	9
receptor	10
regulates	0
expression	0
of	0
L-selectin	9
and	0
CD11/CD18	9
on	0
human	7
neutrophils	8
[	0
see	0
comments	0
]	0

BACKGROUND	0
:	0
Recent	0
studies	0
have	0
raised	0
the	0
hypothesis	0
that	0
glucocorticoids	0
could	0
diminish	0
the	0
ability	0
of	0
endothelial	7
cells	8
to	0
direct	0
leukocyte	0
traffic	0
into	0
inflamed	0
tissues	0
by	0
inhibiting	0
expression	0
of	0
the	0
adhesion	9
molecules	10
endothelial-leukocyte	9
adhesion	10
molecule-1	10
and	0
intercellular	9
adhesion	10
molecule-1	10
.	0

The	0
aim	0
of	0
the	0
present	0
study	0
was	0
to	0
investigate	0
whether	0
glucocorticoids	0
also	0
regulate	0
the	0
expression	0
of	0
L-selectin	9
and	0
CD11/CD18	9
integrins	9
on	0
human	7
neutrophil	8
granulocytes	8
.	0

METHODS	0
AND	0
RESULTS	0
:	0
Incubation	0
of	0
human	0
whole	0
blood	0
with	0
platelet-activating	9
factor	10
(	0
PAF	9
,	0
1	0
mumol/L	0
)	0
evoked	0
downregulation	0
of	0
L-selectin	9
and	0
upregulation	0
of	0
CD11/CD18	9
adhesion	9
receptors	10
on	0
neutrophils	0
as	0
measured	0
by	0
flow	0
cytometry	0
.	0

While	0
dexamethasone	0
(	0
0.1	0
nmol/L	0
to	0
100	0
mumol/L	0
)	0
did	0
not	0
affect	0
expression	0
of	0
adhesion	9
molecules	10
on	0
resting	7
neutrophils	8
,	0
it	0
attenuated	0
the	0
PAF	9
-induced	0
changes	0
in	0
L-selectin	9
and	0
CD18	9
expression	0
in	0
a	0
time-	0
and	0
concentration-dependent	0
fashion	0
with	0
IC50	0
values	0
of	0
31	0
and	0
13	0
nmol/L	0
,	0
respectively	0
.	0

These	0
effects	0
of	0
dexamethasone	0
were	0
completely	0
aborted	0
by	0
RU-486	0
(	0
10	0
mumol/L	0
)	0
,	0
which	0
blocks	0
transcriptional	0
activation	0
of	0
the	0
glucocorticoid	9
receptor	10
,	0
and	0
by	0
the	0
protein	0
synthesis	0
inhibitor	0
cycloheximide	0
(	0
35.5	0
mumol/L	0
)	0
.	0

Dexamethasone	0
,	0
up	0
to	0
a	0
concentration	0
of	0
1	0
mumol/L	0
,	0
neither	0
affected	0
significantly	0
the	0
release	0
of	0
granule	9
enzymes	10
nor	0
interfered	0
with	0
PAF	9
binding	0
to	0
its	0
membrane	9
receptors	10
.	0

CONCLUSIONS	0
:	0
Our	0
results	0
show	0
that	0
glucocorticoids	0
at	0
clinically	0
relevant	0
concentrations	0
exert	0
specific	0
actions	0
on	0
expression	0
of	0
adhesion	9
molecules	10
on	0
activated	7
neutrophils	8
,	0
which	0
are	0
mediated	0
through	0
ligation	0
of	0
glucocorticoid	9
receptors	10
and	0
induction	0
of	0
protein	0
synthesis	0
,	0
and	0
suggest	0
a	0
novel	0
mechanism	0
by	0
which	0
anti-inflammatory	0
corticosteroids	0
may	0
inhibit	0
leukocyte	0
accumulation	0
.	0

The	0
immediate-early	0
gene	0
product	0
Egr-1	9
regulates	0
the	0
human	1
interleukin-2	2
receptor	2
beta-chain	2
promoter	2
through	0
noncanonical	1
Egr	2
and	2
Sp1	2
binding	2
sites	2
.	0

The	0
interleukin-2	9
IL-2	10
receptor	10
beta-chain	10
(	0
IL-2Rbeta	9
)	0
is	0
an	0
essential	0
component	0
of	0
the	0
receptors	0
for	0
IL-2	9
and	0
IL-15	9
.	0

Although	0
IL-2Rbeta	9
is	0
constitutively	0
expressed	0
by	0
lymphocytes	0
,	0
its	0
expression	0
can	0
be	0
further	0
induced	0
by	0
a	0
number	0
of	0
stimuli	0
,	0
including	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
.	0

We	0
have	0
now	0
characterized	0
factors	0
that	0
bind	0
to	0
an	0
enhancer	0
region	0
located	0
between	0
nucleotides	1
-170	2
and	2
-139	2
of	0
the	0
human	0
IL-2Rbeta	1
promoter	2
.	0

Both	0
Sp1	9
and	0
Sp3	9
bound	0
to	0
the	0
5	1
'	2
portion	2
of	0
this	0
region	0
,	0
whereas	0
a	0
PMA-inducible	9
factor	10
(	0
PIF	9
)	0
mainly	0
bound	0
to	0
its	0
3	1
'	2
portion	2
and	0
bound	0
to	0
the	0
Sp	1
binding	2
motifs	2
as	0
well	0
.	0

In	0
Jurkat	5
T	6
cells	6
,	0
induction	0
of	0
PIF	9
DNA	0
binding	0
activity	0
was	0
rapidly	0
induced	0
,	0
required	0
de	0
novo	0
protein	0
synthesis	0
,	0
and	0
was	0
sustained	0
at	0
a	0
high	0
level	0
for	0
at	0
least	0
23	0
h	0
.	0

Interestingly	0
,	0
PIF	9
was	0
constitutively	0
activated	0
in	0
human	5
T-cell	6
leukemia	6
virus	6
type	6
1-transformed	6
MT-2	6
cells	6
.	0

In	0
this	0
paper	0
,	0
we	0
demonstrate	0
that	0
PIF	9
is	0
Egr-1	9
based	0
on	0
its	0
recognition	0
by	0
anti-	0
Egr-1	9
antisera	0
in	0
gel	0
mobility	0
shift	0
assays	0
,	0
even	0
though	0
the	0
IL-2Rbeta	1
DNA	2
binding	2
motif	2
differed	0
substantially	0
from	0
the	0
canonical	0
Egr-1	1
binding	2
site	2
.	0

In	0
addition	0
,	0
Egr-1	9
bound	0
to	0
the	0
Sp	1
binding	2
site	2
.	0

In	0
Jurkat	5
cells	6
,	0
both	0
sites	0
were	0
required	0
for	0
maximal	0
IL-2Rbeta	9
promoter	0
activity	0
,	0
and	0
in	0
HeLaS3	0
cells	0
,	0
transfection	0
of	0
Egr-1	9
could	0
drive	0
activity	0
of	0
a	0
reporter	0
construct	0
containing	0
both	0
sites	0
.	0

Moreover	0
,	0
Sp1	9
and	0
Egr-1	9
could	0
form	0
a	0
complex	0
with	0
kinetics	0
that	0
correlated	0
with	0
the	0
production	0
of	0
Egr-1	9
in	0
Jurkat	5
cells	6
upon	0
PMA	0
stimulation	0
.	0

Thus	0
,	0
Sp1	9
and	0
Egr-1	9
physically	0
and	0
functionally	0
cooperate	0
to	0
mediate	0
maximal	0
IL-2Rbeta	1
promoter	2
activity	0
.	0

Overexpression	0
of	0
HSF2-beta	9
inhibits	0
hemin	9
-induced	0
heat	0
shock	0
gene	0
expression	0
and	0
erythroid	0
differentiation	0
in	0
K562	5
cells	6
.	0

Acquisition	0
of	0
heat	0
shock	0
factor	0
2	0
(	0
HSF2	0
)	0
DNA	0
binding	0
activity	0
is	0
accompanied	0
by	0
induced	0
transcription	0
of	0
heat	1
shock	2
genes	2
in	0
hemin-treated	0
K562	5
cells	6
undergoing	0
erythroid	0
differentiation	0
.	0

Previous	0
studies	0
revealed	0
that	0
HSF2	9
consists	0
of	0
two	0
alternatively	0
spliced	0
isoforms	0
,	0
HSF2-alpha	9
and	0
HSF2-beta	9
,	0
whose	0
relative	0
abundance	0
is	0
developmentally	0
regulated	0
and	0
varies	0
between	0
different	0
tissues	0
.	0

To	0
investigate	0
whether	0
the	0
molar	0
ratio	0
of	0
HSF2-alpha	9
and	0
HSF2-beta	9
isoforms	0
is	0
crucial	0
for	0
the	0
activation	0
of	0
HSF2	9
and	0
whether	0
the	0
HSF2	9
isoforms	0
play	0
functionally	0
distinct	0
roles	0
during	0
the	0
hemin-mediated	0
erythroid	0
differentiation	0
,	0
we	0
generated	0
cell	0
clones	0
expressing	0
different	0
levels	0
of	0
HSF2-alpha	9
and	0
HSF2-beta	9
.	0

We	0
show	0
that	0
in	0
parental	0
K562	5
cells	6
,	0
the	0
HSF2-alpha	9
isoform	10
is	0
predominantly	0
expressed	0
and	0
HSF2	9
can	0
be	0
activated	0
upon	0
hemin	0
treatment	0
.	0

In	0
contrast	0
,	0
when	0
HSF2-beta	9
is	0
expressed	0
at	0
levels	0
exceeding	0
those	0
of	0
endogenous	9
HSF2-alpha	10
,	0
the	0
hemin-induced	0
DNA	0
binding	0
activity	0
and	0
transcription	0
of	0
heat	1
shock	2
genes	2
are	0
repressed	0
,	0
whereas	0
overexpression	0
of	0
HSF2-alpha	9
results	0
in	0
an	0
enhanced	0
hemin	9
response	0
.	0

Furthermore	0
,	0
the	0
hemin	9
-induced	0
accumulation	0
of	0
globin	9
,	0
known	0
as	0
a	0
marker	0
of	0
erythroid	0
differentiation	0
,	0
is	0
decreased	0
in	0
cells	0
overexpressing	0
HSF2-beta	9
.	0

We	0
suggest	0
that	0
HSF2-beta	9
acts	0
as	0
a	0
negative	0
regulator	0
of	0
HSF2	9
activity	0
during	0
hemin-mediated	0
erythroid	0
differentiation	0
of	0
K562	5
cells	6
.	0

Sequential	0
development	0
of	0
structural	0
and	0
functional	0
alterations	0
in	0
T	7
cells	8
from	0
tumor-bearing	0
mice	0
.	0

The	0
TCR	9
alpha	10
beta	10
or	10
-gamma	10
delta	10
chains	10
bind	0
the	0
peptide	0
ligand	0
,	0
whereas	0
the	0
associated	0
CD3	9
delta	10
epsilon	10
gamma	10
and	0
TCR	9
zeta	10
subunits	10
couple	0
the	0
TCR	9
to	0
intracellular	0
signal	0
transduction	0
components	0
.	0

Recently	0
,	0
several	0
groups	0
have	0
described	0
marked	0
alterations	0
in	0
signal	0
transduction	0
elements	0
in	0
T	7
cells	8
from	0
cancer	0
patients	0
or	0
in	0
mice	0
bearing	0
tumor	0
for	0
a	0
few	0
weeks	0
(	0
>	0
26	0
days	0
)	0
.	0

The	0
sequence	0
in	0
which	0
these	0
alterations	0
develop	0
is	0
unknown	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
explore	0
the	0
kinetics	0
of	0
the	0
development	0
of	0
alterations	0
in	0
signal	0
transduction	0
molecules	0
(	0
TCR	9
zeta	10
chain	10
,	0
NF	9
kappaB	10
family	10
proteins	10
,	0
and	0
tyrosine	9
kinase	10
p56	10
(	10
lck	10
)	10
)	0
in	0
mice	0
bearing	0
MC38	0
colon	0
adenocarcinoma	0
.	0

The	0
results	0
demonstrate	0
that	0
alterations	0
in	0
NF	9
kappaB	10
family	10
proteins	10
,	0
specifically	0
the	0
failure	0
of	0
p65	9
translocation	0
to	0
the	0
nucleus	0
,	0
occur	0
earlier	0
and	0
more	0
frequently	0
than	0
the	0
decrease	0
in	0
zeta-chain	9
.	0

These	0
defects	0
are	0
paralleled	0
by	0
an	0
impaired	0
ability	0
to	0
produce	0
Th1	9
cytokines	10
(	0
IL-2	9
and	0
IFN-gamma	9
)	0
.	0

These	0
initial	0
changes	0
are	0
followed	0
by	0
the	0
eventual	0
loss	0
of	0
TCR	9
zeta	10
chain	10
and	0
p56	9
(	10
lck	10
)	10
and	0
a	0
marked	0
decrease	0
in	0
cytotoxic	0
function	0
.	0

An	0
increased	0
rate	0
of	0
lysosomal	0
degradation	0
is	0
one	0
of	0
the	0
mechanisms	0
responsible	0
for	0
the	0
loss	0
of	0
zeta-chain	9
.	0

HLA-DMA	0
and	0
HLA-DMB	0
gene	0
expression	0
functions	0
through	0
the	0
conserved	0
S-X-Y	1
region	2
.	0

The	0
MHC	9
class	10
II	10
homologous	10
proteins	10
HLA-DMA	9
and	0
HLA-DMB	9
function	0
in	0
the	0
loading	0
of	0
peptides	0
onto	0
class	9
II	10
molecules	10
.	0

Like	0
the	0
class	1
II	2
genes	2
,	0
the	0
HLA-DM	1
genes	2
contain	0
upstream	0
regulatory	0
sequences	0
similar	0
to	0
the	0
S-X-Y	1
regulatory	2
region	2
as	0
well	0
as	0
additional	0
putative	0
regulatory	0
sites	0
.	0

To	0
determine	0
whether	0
the	0
DM	1
genes	2
are	0
regulated	0
in	0
a	0
similar	0
manner	0
as	0
class	1
II	2
genes	2
,	0
a	0
series	0
of	0
in	0
vivo	0
and	0
in	0
vitro	0
analyses	0
was	0
performed	0
.	0

Deletion	0
analysis	0
showed	0
that	0
expression	0
from	0
the	0
DM	1
promoters	2
is	0
dependent	0
on	0
the	0
conserved	0
S-X-Y	1
region	2
.	0

The	0
class	9
II-specific	10
transcription	10
factors	10
RFX	9
and	0
CIITA	9
are	0
also	0
required	0
for	0
expression	0
,	0
as	0
cell	0
lines	0
deficient	0
in	0
these	0
factors	0
failed	0
to	0
allow	0
transcription	0
from	0
the	0
DM	1
promoters	2
.	0

In	0
addition	0
,	0
in	0
vivo	0
footprint	0
analysis	0
showed	0
the	0
putative	0
X	1
and	2
Y	2
boxes	2
to	0
be	0
occupied	0
by	0
transcription	9
factors	10
in	0
wild-type	7
B	8
cells	8
,	0
but	0
not	0
in	0
RFX-deficient	5
B	6
cells	6
.	0

In	0
astrocytes	7
,	0
IFN-gamma	9
treatment	0
induced	0
increased	0
occupancy	0
of	0
these	0
sites	0
.	0

None	0
of	0
the	0
other	0
putative	0
regulatory	0
sites	0
was	0
occupied	0
in	0
vivo	0
,	0
indicating	0
that	0
they	0
may	0
not	0
be	0
functional	0
.	0

Finally	0
,	0
gel	0
shift	0
analysis	0
showed	0
synergistic	0
complex	0
formation	0
between	0
proteins	0
that	0
bind	0
to	0
the	0
putative	0
X	1
boxes	2
of	0
the	0
DM	0
genes	0
,	0
as	0
is	0
found	0
for	0
the	0
DRA	1
gene	2
.	0

Therefore	0
,	0
the	0
DM	1
genes	2
share	0
a	0
common	0
mechanism	0
of	0
regulation	0
with	0
the	0
class	1
II	2
genes	2
.	0

Effect	0
of	0
adenovirus	0
2	0
on	0
cellular	0
gene	0
activation	0
in	0
blood-derived	7
monocytes	8
and	0
macrophages	7
.	0

We	0
have	0
investigated	0
the	0
effect	0
of	0
adenovirus	0
2	0
(	0
Ad2	0
)	0
infection	0
on	0
human	7
monocytes	8
and	0
monocyte-derived	7
macrophages	8
with	0
regard	0
to	0
expression	0
of	0
TNF-alpha	9
and	0
IL-1	9
beta	10
.	0

In	0
monocytes	0
,	0
the	0
virus	0
was	0
bound	0
to	0
the	0
surface	0
without	0
being	0
internalized	0
.	0

On	0
the	0
other	0
hand	0
,	0
Ad2	0
was	0
internalized	0
by	0
macrophages	7
.	0

No	0
virus	0
replication	0
and	0
no	0
transcription	0
of	0
the	0
Ad2	1
early	2
genes	2
was	0
observed	0
in	0
either	0
of	0
the	0
cells	0
.	0

Ad2	0
infection	0
induced	0
transient	0
increase	0
in	0
the	0
mRNA	3
levels	0
for	0
TNF-alpha	9
and	0
IL-1	9
beta	10
in	0
both	0
monocytes	7
and	0
in	0
macrophages	7
,	0
although	0
the	0
kinetics	0
of	0
the	0
transcription	0
was	0
slightly	0
different	0
.	0

The	0
production	0
of	0
both	0
cytokines	9
,	0
measured	0
by	0
ELISA	0
tests	0
,	0
was	0
enhanced	0
in	0
monocytes	7
.	0

In	0
macrophages	7
,	0
a	0
slight	0
enhancement	0
of	0
TNF-alpha	9
production	0
was	0
seen	0
,	0
whereas	0
IL-1	9
beta	10
was	0
not	0
detected	0
.	0

The	0
data	0
indicate	0
that	0
cellular	1
genes	2
might	0
be	0
activated	0
by	0
Ad2	0
virus	0
infection	0
in	0
nonpermissive	0
cells	0
where	0
no	0
viral	9
gene	10
products	10
could	0
be	0
detected	0
.	0

Structure	0
and	0
function	0
analysis	0
of	0
the	0
human	1
myeloid	2
cell	2
nuclear	2
differentiation	2
antigen	2
promoter	2
:	0
evidence	0
for	0
the	0
role	0
of	0
Sp1	9
and	0
not	0
of	0
c-Myb	9
or	0
PU.1	9
in	0
myelomonocytic	0
lineage-specific	0
expression	0
.	0

The	0
human	9
myeloid	10
nuclear	10
differentiation	10
antigen	10
(	0
MNDA	9
)	0
is	0
expressed	0
specifically	0
in	0
maturing	7
cells	8
of	0
the	0
myelomonocytic	0
lineage	0
and	0
in	0
monocytes	7
and	0
granulocytes	7
.	0

Epitope	0
enhancement	0
was	0
used	0
to	0
confirm	0
the	0
strict	0
lineage-	0
and	0
stage-specific	0
expression	0
of	0
MNDA	9
in	0
bone	0
marrow	0
as	0
well	0
as	0
in	0
other	0
paraffin-embedded	0
fixed	0
tissues	0
.	0

A	0
1-kb	1
region	2
of	0
the	0
gene	0
that	0
includes	0
5	1
'	2
flanking	2
sequence	2
was	0
reported	0
earlier	0
to	0
contain	0
functional	0
promoter	0
activity	0
and	0
was	0
specifically	0
demethylated	0
in	0
expressing	7
cells	8
in	0
contrast	0
to	0
null	7
cells	8
.	0

Further	0
analysis	0
has	0
revealed	0
that	0
this	0
1-kb	1
fragment	2
promotes	0
higher	0
reporter	0
gene	0
activity	0
in	0
MNDA	9
-expressing	7
cells	8
than	0
non-expressing	7
cells	8
,	0
indicating	0
cell-specific	0
differences	0
in	0
transactivation	0
.	0

This	0
sequence	0
contains	0
consensus	1
elements	2
consistent	0
with	0
myeloid-specific	0
gene	0
expression	0
,	0
including	0
a	0
PU.1	1
consensus	2
site	2
near	0
the	0
major	0
transcription	1
start	2
site	2
and	0
a	0
cluster	0
of	0
c-Myb	1
sites	2
located	0
several	0
hundred	0
bases	0
upstream	0
of	0
this	0
region	0
.	0

However	0
,	0
analysis	0
of	0
deletion	1
mutants	2
localized	0
nearly	0
all	0
of	0
the	0
promoter	0
activity	0
to	0
a	0
short	0
region	0
(	0
-73	1
to	2
-16	2
)	0
that	0
did	0
not	0
include	0
the	0
cluster	0
of	0
c-Myb	1
sites	2
.	0

A	0
4-bp	0
mutation	0
of	0
the	0
core	1
Sp1	2
consensus	2
element	2
(	0
GC	1
box	2
)	0
(	0
-20	0
)	0
reduced	0
overall	0
promoter	0
activity	0
of	0
the	0
1-kb	1
fragment	2
.	0

Mutation	0
of	0
the	0
PU.1	1
site	2
did	0
not	0
significantly	0
affect	0
promoter	0
activity	0
.	0

Only	0
a	0
small	0
region	0
(	0
-35	0
to	0
+22	0
)	0
including	0
the	0
Sp1	1
element	2
and	0
transcription	1
start	2
site	2
,	0
but	0
not	0
the	0
PU.1	1
site	2
was	0
footprinted	0
.	0

The	0
4-bp	0
mutation	0
of	0
the	0
core	0
Sp1	1
consensus	2
element	2
abolished	0
footprinting	0
at	0
the	0
site	0
and	0
an	0
antibody	0
super-shift	0
reaction	0
showed	0
that	0
Sp1	9
is	0
one	0
of	0
the	0
factors	0
binding	0
the	0
consensus	1
site	2
.	0

The	0
Sp1	1
site	2
also	0
co-localizes	0
with	0
a	0
DNase	1
I	2
hypersensitive	2
site	2
.	0

The	0
results	0
indicate	0
that	0
DNA	0
methylation	0
,	0
chromatin	1
structure	0
,	0
and	0
transactivation	0
at	0
an	0
Sp1	1
site	2
contribute	0
to	0
the	0
highly	0
restricted	0
expression	0
of	0
this	0
myelomonocytic	1
lineage	2
specific	2
gene	2
.	0

Critical	0
cytoplasmic	9
domains	10
of	0
human	9
interleukin-9	10
receptor	10
alpha	10
chain	10
in	0
interleukin	9
-9-mediated	0
cell	0
proliferation	0
and	0
signal	0
transduction	0
.	0

Interleukin-9	9
receptor	10
(	10
IL-9R	10
)	10
complex	10
consists	0
of	0
a	0
ligand-specific	9
alpha	10
chain	10
and	0
IL-2R	9
gamma	10
chain	10
.	0

In	0
this	0
study	0
,	0
two	0
regions	0
in	0
the	0
cytoplasmic	9
domain	10
of	0
human	9
IL-9Ralpha	10
were	0
found	0
to	0
be	0
important	0
for	0
IL-9	9
-mediated	0
cell	0
growth	0
.	0

A	0
membrane-proximal	9
region	10
that	0
contains	0
the	0
BOX1	9
consensus	10
sequence	10
is	0
required	0
for	0
IL-9	9
-induced	0
cell	0
proliferation	0
and	0
tyrosine	0
phosphorylation	0
of	0
Janus	9
kinases	10
(	0
JAKs	9
)	0
.	0

Deletion	0
of	0
this	0
region	0
or	0
internal	0
deletion	0
of	0
the	0
BOX1	9
motif	10
abrogated	0
IL-9	9
-induced	0
cell	0
proliferation	0
and	0
signal	0
transduction	0
.	0

However	0
,	0
substitution	0
of	0
the	0
Pro-X-Pro	9
in	0
the	0
BOX1	9
motif	10
with	0
Ala-X-Ala	9
failed	0
to	0
abolish	0
IL-9	9
-induced	0
cell	0
proliferation	0
but	0
decreased	0
IL-9	9
-mediated	0
tyrosine	0
phosphorylation	0
of	0
JAK	9
kinases	10
,	0
insulin	9
receptor	10
substrate-2	10
,	0
and	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
3	10
(	0
STAT3	9
)	0
and	0
expression	0
of	0
c-myc	1
and	0
junB	1
.	0

Another	0
important	0
region	0
is	0
downstream	0
of	0
the	0
BOX1	9
motif	10
and	0
contains	0
a	0
STAT3	1
binding	2
motif	2
YLPQ	1
.	0

Deletion	0
of	0
this	0
region	0
significantly	0
impaired	0
IL-9	9
-induced	0
cell	0
growth	0
,	0
activation	0
of	0
JAK	9
kinases	10
,	0
insulin	9
receptor	10
substrate-2	10
,	0
and	0
STAT3	9
and	0
expression	0
of	0
early	1
response	2
genes	2
.	0

A	0
point	0
mutation	0
changing	0
YLPQ	1
into	0
YLPA	1
greatly	0
reduced	0
IL-9	9
-induced	0
activation	0
of	0
STAT3	9
and	0
expression	0
of	0
c-myc	1
but	0
did	0
not	0
affect	0
cell	0
proliferation	0
.	0

These	0
results	0
suggest	0
that	0
cooperation	0
or	0
cross-talk	0
of	0
signaling	0
molecules	0
associated	0
with	0
different	0
domains	0
of	0
IL-9Ralpha	9
other	0
than	0
STAT3	9
is	0
essential	0
for	0
IL-9	9
-mediated	0
cell	0
growth	0
.	0

Bcl-2	9
protein	10
inhibits	0
bufalin-induced	0
apoptosis	0
through	0
inhibition	0
of	0
mitogen-activated	9
protein	10
kinase	10
activation	0
in	0
human	5
leukemia	6
U937	6
cells	6
.	0

In	0
a	0
previous	0
study	0
,	0
we	0
demonstrated	0
that	0
bufalin	0
,	0
which	0
is	0
an	0
active	0
principle	0
of	0
Chinese	0
medicine	0
,	0
chan'su	0
,	0
caused	0
apoptosis	0
in	0
human	5
leukemia	6
U937	6
cells	6
by	0
anomalous	0
activation	0
of	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
via	0
the	0
signaling	0
pathway	0
of	0
Ras	9
,	0
Raf-1	9
,	0
and	0
MAPK	9
kinase-1	10
.	0

Here	0
,	0
we	0
report	0
the	0
effect	0
of	0
overexpression	0
of	0
bcl-2	9
in	0
U937	5
cells	6
on	0
the	0
signaling	0
pathway	0
of	0
apoptosis	0
that	0
is	0
induced	0
by	0
bufalin	0
.	0

The	0
results	0
indicated	0
that	0
the	0
apoptosis	0
induced	0
by	0
bufalin	0
in	0
U937	5
cells	6
was	0
significantly	0
inhibited	0
by	0
overexpression	0
of	0
the	0
Bcl-2	9
protein	10
.	0

No	0
significant	0
difference	0
was	0
detected	0
in	0
the	0
activation	0
of	0
MAPK	9
kinase-1	10
that	0
is	0
induced	0
by	0
bufalin	0
in	0
wild-type	0
or	0
Bcl-2-overexpressed	7
U937	8
cells	8
;	0
however	0
,	0
the	0
activation	0
of	0
MAPK	9
by	0
bufalin	0
was	0
significantly	0
attenuated	0
in	0
the	0
cells	0
overexpressing	0
Bcl-2	9
.	0

Bufalin	0
treatment	0
activated	9
activator	10
protein-1	10
transcriptional	0
activity	0
;	0
however	0
,	0
this	0
activation	0
was	0
decreased	0
to	0
40	0
%	0
in	0
bcl-2	9
-overexpressed	0
U937	5
cells	6
.	0

These	0
results	0
indicate	0
that	0
Bcl-2	9
acts	0
downstream	0
of	0
MAPK	9
kinase-1	10
but	0
upstream	0
of	0
MAPK	9
and	0
suggest	0
that	0
,	0
in	0
the	0
signaling	0
pathway	0
of	0
the	0
apoptotic	0
process	0
induced	0
by	0
bufalin	0
,	0
the	0
transcriptional	0
activity	0
of	0
activator	9
protein-1	10
may	0
be	0
down-regulated	0
through	0
the	0
inhibition	0
of	0
MAPK	9
activity	0
by	0
Bcl-2	9
.	0

Pancreatic	0
islet	0
expression	0
studies	0
and	0
polymorphic	0
DNA	0
markers	0
in	0
the	0
genes	0
encoding	0
hepatocyte	9
nuclear	10
factor-3alpha	10
,	10
-3beta	10
,	10
-3gamma	10
,	10
-4gamma	10
,	10
and	10
-6	10
.	0

The	0
genes	0
encoding	0
the	0
functionally	0
related	0
hepatocyte	9
nuclear	10
factors	10
HNF-1alpha	9
and	0
HNF-4alpha	9
play	0
a	0
critical	0
role	0
in	0
normal	0
pancreatic	0
beta-cell	0
function	0
.	0

Mutations	0
in	0
these	0
liver-enriched	9
transcription	10
factors	10
result	0
in	0
two	0
forms	0
of	0
early-onset	0
type	0
2	0
diabetes	0
(	0
maturity-onset	0
diabetes	0
of	0
the	0
young	0
[	0
MODY	0
]	0
)	0
,	0
MODY3	0
and	0
MODY1	0
,	0
which	0
are	0
characterized	0
by	0
impaired	0
glucose-stimulated	0
insulin	0
secretion	0
,	0
early	0
disease	0
onset	0
,	0
and	0
autosomal	0
dominant	0
inheritance	0
.	0

The	0
transcriptional	0
hierarchy	0
of	0
HNFs	0
suggests	0
that	0
other	0
proteins	0
of	0
the	0
regulatory	0
cascade	0
might	0
be	0
responsible	0
for	0
other	0
forms	0
of	0
MODY	0
and/or	0
late-onset	0
type	0
2	0
diabetes	0
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
HNF-3alpha	9
,	10
-3beta	10
,	10
-3gamma	10
,	10
-4gamma	10
,	10
and	10
-6	10
are	0
expressed	0
in	0
pancreatic	7
beta-cells	8
.	0

We	0
report	0
the	0
identification	0
and	0
characterization	0
of	0
simple	1
tandem	2
repeat	2
DNA	2
polymorphisms	2
in	0
the	0
genes	0
encoding	0
HNF-3alpha	9
,	0
-3beta	9
,	0
-3gamma	9
,	0
-4gamma	9
,	0
and	0
-6	9
and	0
the	0
mapping	0
of	0
HNF-6	9
to	0
chromosome	1
bands	2
15q21.1-21.2	1
by	0
fluorescence	0
in	0
situ	0
hybridization	0
.	0

These	0
markers	0
will	0
be	0
useful	0
to	0
study	0
the	0
role	0
of	0
genetic	0
variation	0
in	0
these	0
genes	0
in	0
the	0
pathogenesis	0
of	0
type	0
2	0
diabetes	0
.	0

Induction	0
of	0
nuclear	9
factor	10
kappa	10
B/Rel	10
nuclear	0
activity	0
in	0
human	7
peripheral	8
blood	8
T	8
lymphocytes	8
by	0
anti-HLA	9
class	10
I	10
monoclonal	10
antibodies	10
.	0

Monoclonal	0
antibodies	0
against	0
either	0
monomorphic	0
or	0
polymorphic	0
determinants	0
of	0
class	9
I	10
antigen	10
induced	0
in	0
PBMC	7
and	0
highly	0
purified	7
T	8
lymphocytes	8
the	0
nuclear	0
activity	0
of	0
NF-kappa	9
B/Rel	10
complexes	10
.	0

These	0
included	0
both	0
p50/p50	9
and	0
p50/p65	9
dimers	10
,	0
recognized	0
by	0
specific	9
antibodies	10
in	0
EMSA	0
.	0

The	0
induced	0
complexes	9
were	0
detectable	0
in	0
extracts	0
of	0
cells	0
incubated	0
with	0
anti-class	9
I	10
monoclonal	10
antibody	10
(	0
mAb	9
)	0
for	0
1.5	0
h	0
;	0
the	0
induction	0
was	0
maximal	0
at	0
5	0
h	0
,	0
persistent	0
at	0
16	0
h	0
and	0
no	0
longer	0
observed	0
at	0
40	0
h	0
.	0

The	0
mAb	9
failed	0
to	0
induce	0
NF-kappa	9
B/Rel	10
nuclear	0
activity	0
in	0
cells	0
incubated	0
in	0
the	0
presence	0
of	0
3	0
,	0
4-dichloroisocoumarin	0
,	0
an	0
inhibitor	0
of	0
I	9
kappa	10
B-alpha	10
degradation	0
.	0

Together	0
,	0
these	0
results	0
suggest	0
that	0
class	0
I	0
triggering	0
can	0
induce	0
the	0
activity	0
of	0
NF-kappa	9
B/Rel	10
nuclear	0
activity	0
in	0
peripheral	7
blood	8
T	8
lymphocytes	8
,	0
thereby	0
modulating	0
the	0
expression	0
of	0
genes	0
regulated	0
by	0
these	0
transcription	9
factors	10
.	0

Anti-Ehrlichia	9
chaffeensis	10
antibody	10
complexed	0
with	0
E.	0
chaffeensis	0
induces	0
potent	0
proinflammatory	3
cytokine	4
mRNA	4
expression	0
in	0
human	7
monocytes	8
through	0
sustained	0
reduction	0
of	0
IkappaB-alpha	9
and	0
activation	0
of	0
NF-kappaB	9
.	0

Ehrlichia	0
chaffeensis	0
is	0
an	0
obligatory	0
intracellular	0
bacterium	0
that	0
infects	0
monocytes	7
and	0
macrophages	7
and	0
is	0
the	0
etiologic	0
agent	0
of	0
human	0
ehrlichiosis	0
in	0
the	0
United	0
States	0
.	0

Our	0
previous	0
studies	0
showed	0
that	0
the	0
exposure	0
of	0
human	7
monocytes	8
to	0
E.	0
chaffeensis	0
induces	0
the	0
expression	0
of	0
interleukin-1beta	9
(	0
IL-1beta	9
)	0
,	0
IL-8	9
,	0
and	0
IL-10	1
genes	2
in	0
vitro	0
but	0
not	0
the	0
expression	0
of	0
tumor	3
necrosis	4
factor	4
alpha	4
(	4
TNF-alpha	4
)	4
and	4
IL-6	4
mRNAs	4
.	0

In	0
this	0
study	0
,	0
the	0
effect	0
of	0
anti-E.	9
chaffeensis	10
antibody	10
complexed	0
with	0
E.	0
chaffeensis	0
on	0
the	0
expression	0
of	0
major	9
proinflammatory	10
cytokines	10
in	0
human	7
monocytes	8
was	0
examined	0
.	0

Human	5
monocytic	6
cell	6
line	6
THP-1	6
was	0
treated	0
with	0
E.	0
chaffeensis	0
which	0
had	0
been	0
preincubated	0
with	0
human	0
anti-E.	0
chaffeensis	0
serum	0
for	0
2	0
h	0
,	0
and	0
the	0
levels	0
of	0
cytokine	3
mRNAs	4
were	0
evaluated	0
by	0
competitive	0
reverse	0
transcription-PCR	0
.	0

Anti-E.	9
chaffeensis	10
antibody	10
complexed	0
with	0
E.	0
chaffeensis	0
significantly	0
enhanced	0
mRNA	0
expression	0
of	0
IL-1beta	9
in	0
THP-1	5
cells	6
.	0

The	0
expression	0
of	0
TNF-alpha	3
and	4
IL-6	4
mRNAs	4
was	0
also	0
induced	0
.	0

The	0
levels	0
of	0
secreted	0
IL-1beta	9
,	0
TNF-alpha	9
,	0
and	0
IL-6	9
during	0
24	0
h	0
of	0
stimulation	0
were	0
comparable	0
to	0
those	0
induced	0
by	0
Escherichia	0
coli	0
lipopolysaccharide	0
at	0
1	0
microg/ml	0
.	0

Fab	0
fragment	0
of	0
anti-E.	9
chaffeensis	10
immunoglobulin	10
G	10
complexed	0
with	0
E.	0
chaffeensis	0
did	0
not	0
induce	0
any	0
of	0
these	0
three	0
cytokines	0
,	0
indicating	0
that	0
ehrlichial	0
binding	0
is	0
required	0
for	0
IL-1beta	3
mRNA	4
expression	0
and	0
that	0
binding	0
of	0
the	0
immune	9
complex	10
to	0
the	0
Fc	9
gamma	10
receptor	10
is	0
required	0
for	0
TNF-alpha	9
and	0
IL-6	3
mRNA	4
expression	0
and	0
enhanced	0
IL-1beta	3
mRNA	4
expression	0
.	0

Furthermore	0
,	0
prolonged	0
degradation	0
of	0
IkappaB-alpha	9
and	0
activation	0
of	0
NF-kappaB	9
were	0
demonstrated	0
in	0
THP-1	5
cells	6
exposed	0
to	0
anti-E.	0
chaffeensis	0
serum	0
and	0
E.	0
chaffeensis	0
.	0

This	0
result	0
implies	0
that	0
development	0
of	0
anti-E.	9
chaffeensis	10
antibody	10
in	0
patients	0
can	0
result	0
in	0
the	0
production	0
of	0
major	9
proinflammatory	10
cytokines	10
,	0
which	0
may	0
play	0
an	0
important	0
role	0
in	0
the	0
pathophysiology	0
of	0
ehrlichiosis	0
and	0
immune	0
responses	0
to	0
it	0
.	0

The	0
class	9
II	10
trans-activator	10
CIITA	10
interacts	0
with	0
the	0
TBP-associated	9
factor	10
TAFII32	10
.	0

The	0
class	9
II	10
trans-	10
activator	10
(	0
CIITA	9
)	0
is	0
the	0
main	0
transcriptional	0
co-activator	0
for	0
the	0
expression	0
of	0
MHC	9
class	10
II	10
proteins	10
.	0

Its	0
N-terminal	9
125	10
amino	10
acids	10
function	0
as	0
an	0
independent	9
transcriptional	10
activation	10
domain	10
.	0

Analyses	0
of	0
the	0
primary	9
amino	10
acid	10
sequence	10
of	0
the	0
activation	9
domain	10
predict	0
the	0
presence	0
of	0
three	0
alpha-helices	9
,	0
each	0
with	0
a	0
high	0
proportion	0
of	0
acidic	0
residues	0
.	0

Using	0
site-directed	0
mutagenesis	0
,	0
we	0
found	0
that	0
two	0
of	0
these	0
predicted	0
alpha-helices	9
are	0
required	0
for	0
full	0
transcriptional	0
activation	0
by	0
CIITA	9
.	0

Moreover	0
,	0
a	0
CIITA	9
protein	10
in	0
which	0
both	0
functional	0
alpha-helices	9
have	0
been	0
deleted	0
displays	0
a	0
dominant	0
negative	0
phenotype	0
.	0

This	0
activation	9
domain	10
of	0
CIITA	9
interacts	0
with	0
the	0
32	9
kDa	10
subunit	10
of	0
the	0
general	9
transcription	10
complex	10
TFIID	9
,	0
TAFII32	9
.	0

Decreased	0
transcriptional	0
activation	0
by	0
N-terminal	9
deletions	10
of	0
CIITA	9
is	0
correlated	0
directly	0
with	0
their	0
reduced	0
binding	0
to	0
TAFII32	9
.	0

We	0
conclude	0
that	0
interactions	0
between	0
TAFII32	9
and	0
CIITA	9
are	0
responsible	0
for	0
activation	0
of	0
class	1
II	2
genes	2
.	0

Characterization	0
of	0
interleukin-10	9
receptor	10
expression	0
on	0
B-cell	5
chronic	6
lymphocytic	6
leukemia	6
cells	6
.	0

B-cell	5
chronic	6
lymphocytic	6
leukemia	6
(	6
B-CLL	6
)	6
cells	6
accumulate	0
in	0
vivo	0
in	0
the	0
G0/G1	0
phase	0
of	0
the	0
cell	0
cycle	0
,	0
suggesting	0
that	0
their	0
malignant	0
expansion	0
is	0
due	0
,	0
at	0
least	0
in	0
part	0
,	0
to	0
a	0
delay	0
in	0
cell	0
death	0
.	0

However	0
,	0
the	0
cellular	0
or	0
molecular	9
factors	10
responsible	0
for	0
a	0
delay	0
in	0
B-CLL	0
cell	0
death	0
are	0
unknown	0
.	0

B-CLL	0
cells	0
do	0
express	0
receptors	0
for	0
interferon-alpha	9
(	0
IFN-alpha	9
)	0
and	0
IFN-gamma	9
,	0
and	0
activation	0
of	0
both	0
has	0
been	0
shown	0
to	0
promote	0
B-CLL	0
survival	0
in	0
vitro	0
by	0
preventing	0
apoptosis	0
.	0

The	0
interleukin-10	9
(	10
IL-10	10
)	10
receptor	10
is	0
another	0
member	0
of	0
the	0
IFN	9
receptor	10
family	10
,	0
but	0
its	0
ligand	0
,	0
IL-10	9
,	0
has	0
been	0
reported	0
to	0
induce	0
apoptosis	0
in	0
B-CLL	5
cells	6
.	0

In	0
the	0
current	0
study	0
,	0
we	0
undertook	0
a	0
biochemical	0
analysis	0
of	0
IL-10	9
receptor	10
expression	0
on	0
freshly	0
isolated	0
B-CLL	5
cells	6
and	0
characterized	0
the	0
functional	0
responsiveness	0
of	0
IL-10	9
binding	0
to	0
its	0
constitutively	9
expressed	10
receptor	10
.	0

We	0
show	0
that	0
B-CLL	5
cells	6
bind	0
IL-10	9
with	0
significant	0
specificity	0
and	0
express	0
between	0
47	0
and	0
127	0
IL-10	9
receptor	10
sites	0
per	0
cell	0
,	0
with	0
a	0
dissociation	0
constant	0
in	0
the	0
range	0
of	0
168	0
to	0
426	0
x	0
10	0
(	0
-12	0
)	0
mol/L	0
.	0

Ligand	0
binding	0
and	0
activation	0
of	0
the	0
IL-10	9
receptor	10
expressed	0
on	0
B-CLL	5
cells	6
results	0
in	0
the	0
phosphorylation	0
of	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
1	10
(	0
STAT1	9
)	0
and	0
STAT3	9
proteins	0
.	0

This	0
pattern	0
of	0
STAT	9
protein	10
phosphorylation	0
is	0
identical	0
to	0
IL-10	9
receptor	10
activation	0
on	0
normal	7
cells	8
and	0
similar	0
to	0
IFN-alpha	9
(	0
STAT1	9
and	0
STAT3	9
)	0
and	0
IFN-gamma	9
(	0
STAT1	9
)	0
receptor	0
activation	0
in	0
CLL	5
.	0

Further	0
,	0
in	0
consecutive	0
samples	0
of	0
fresh	0
blood	0
obtained	0
from	0
patients	0
with	0
B-CLL	5
cells	6
,	0
the	0
addition	0
of	0
IL-10	9
inhibited	0
B-CLL	5
proliferation	0
,	0
enhanced	0
B-CLL	5
differentiation	0
,	0
but	0
did	0
not	0
induce	0
apoptosis	0
.	0

Indeed	0
,	0
IL-10	9
,	0
like	0
IFN-gamma	9
,	0
was	0
able	0
to	0
significantly	0
reduce	0
the	0
amount	0
of	0
B-CLL	0
cell	0
death	0
caused	0
by	0
hydrocortisone-induced	0
apoptosis	0
.	0

We	0
conclude	0
that	0
cytokines	9
,	0
which	0
signal	0
through	0
the	0
interferon	9
family	10
of	0
receptors	0
,	0
have	0
comparable	0
functional	0
effects	0
on	0
B-CLL	5
cells	6
.	0

Involvement	0
of	0
the	0
N-terminal	9
region	10
of	0
the	0
human	9
mineralocorticoid	10
receptor	10
hormone-binding	10
domain	10
in	0
agonist	0
and	0
antagonist	0
binding	0
as	0
revealed	0
by	0
a	0
new	9
monoclonal	10
antibody	10
.	0

To	0
gain	0
a	0
better	0
understanding	0
of	0
the	0
mechanism	0
of	0
binding	0
to	0
the	0
human	9
mineralocorticoid	10
receptor	10
(	0
hMR	9
)	0
,	0
we	0
developed	0
a	0
new	0
monoclonal	9
antibody	10
(	0
mAb	9
)	0
raised	0
against	0
the	0
hormone-binding	9
domain	10
(	0
HBD	9
)	0
.	0

For	0
this	0
purpose	0
,	0
mice	0
were	0
immunized	0
with	0
a	0
fusion	9
protein	10
including	0
the	0
sequence	0
Thr729-Lys984	9
of	0
hMR	9
.	0

After	0
ELISA	0
screening	0
,	0
mAb	9
18C7	10
was	0
selected	0
for	0
its	0
specificity	0
towards	0
the	0
HBD	9
.	0

This	0
antibody	0
recognized	0
both	0
the	0
denatured	0
and	0
native	9
MR	10
forms	10
,	0
as	0
well	0
as	0
the	0
hetero-oligomeric	9
MR	10
form	10
and	0
the	0
transformed	9
MR	10
state	10
.	0

By	0
using	0
several	0
HBD	9
subfragments	10
,	0
the	0
mAb	9
18C7	10
epitope	10
was	0
located	0
in	0
the	0
N-terminal	9
region	10
of	0
the	0
HBD	9
from	0
Thr729	9
to	10
Leu765	10
.	0

We	0
then	0
studied	0
the	0
effect	0
of	0
the	0
antibody	0
on	0
aldosterone	0
and	0
progesterone	0
binding	0
to	0
the	0
hMR	9
.	0

When	0
18C7	9
was	0
incubated	0
with	0
liganded	9
MR	10
,	0
it	0
was	0
able	0
to	0
partly	0
displace	0
(	0
20	0
%	0
)	0
the	0
hormone	0
from	0
its	0
binding	0
site	0
.	0

When	0
18C7	9
was	0
incubated	0
with	0
MR	9
before	0
aldosterone	0
or	0
progesterone	0
,	0
the	0
antibody	0
inhibited	0
75-80	0
%	0
of	0
the	0
binding	0
.	0

The	0
effect	0
of	0
18C7	9
on	0
the	0
binding	0
was	0
similar	0
with	0
both	0
hormones	0
.	0

A	0
sucrose	0
gradient	0
analysis	0
indicated	0
the	0
simultaneous	0
presence	0
of	0
two	0
kinds	0
of	0
receptor	0
complexes	0
:	0
the	0
steroid-MR	9
complex	10
and	0
the	0
antibody-MR	9
complex	10
.	0

After	0
its	0
associated	0
proteins	0
,	0
especially	0
the	0
heat-shock	9
protein	10
hsp90	10
,	0
had	0
been	0
cross-linked	0
with	0
the	0
hMR	9
by	0
dimethylpimelimidate	0
,	0
18C7	9
was	0
still	0
able	0
to	0
react	0
with	0
the	0
receptor	0
.	0

Our	0
results	0
indicated	0
that	0
the	0
epitope	9
recognized	0
by	0
18C7	9
was	0
directly	0
implicated	0
in	0
hormone	0
binding	0
.	0

The	0
lack	0
of	0
steroid	0
binding	0
of	0
HBD	9
mutants	0
with	0
the	0
Thr729-Leu765	9
sequence	10
deleted	0
[	0
Jalaguier	0
,	0
Mesnier	0
,	0
Leger	0
and	0
Auzou	0
(	0
1996	0
)	0
J.Steroid	0
Biochem.Mol.Biol.57	0
,	0
43-50	0
]	0
supports	0
this	0
hypothesis	0
.	0

Because	0
of	0
the	0
similar	0
behaviours	0
of	0
aldosterone	0
and	0
progesterone	0
,	0
we	0
conclude	0
that	0
the	0
N-terminal	9
Thr729-Leu765	10
region	10
of	0
the	0
HBD	9
is	0
similarly	0
involved	0
in	0
the	0
binding	0
of	0
both	0
hormones	0
.	0

Molecular	0
cloning	0
of	0
SLAP-130	9
,	0
an	0
SLP-76-associated	9
substrate	10
of	0
the	0
T	9
cell	10
antigen	10
receptor-stimulated	10
protein	10
tyrosine	10
kinases	10
.	0

Previous	0
work	0
has	0
demonstrated	0
that	0
SLP-76	9
,	0
a	0
Grb2-associated	9
tyrosine-phosphorylated	10
protein	10
,	0
augments	0
Interleukin-2	1
promoter	2
activity	0
when	0
overexpressed	0
in	0
the	0
Jurkat	5
T	6
cell	6
line	6
.	0

This	0
activity	0
requires	0
regions	0
of	0
SLP-76	9
that	0
mediate	0
protein-protein	0
interactions	0
with	0
other	0
molecules	0
in	0
T	7
cells	8
,	0
suggesting	0
that	0
SLP-76	9
-associated	0
proteins	0
also	0
function	0
to	0
regulate	0
signal	0
transduction	0
.	0

Here	0
we	0
describe	0
the	0
molecular	0
cloning	0
of	0
SLAP-130	9
,	0
a	0
SLP-76-associated	9
phosphoprotein	10
of	0
130	0
kDa	0
.	0

We	0
demonstrate	0
that	0
SLAP-130	9
is	0
hematopoietic	0
cell-specific	0
and	0
associates	0
with	0
the	0
SH2	9
domain	10
of	0
SLP-76	9
.	0

Additionally	0
,	0
we	0
show	0
that	0
SLAP-130	9
is	0
a	0
substrate	0
of	0
the	0
T	9
cell	10
antigen	10
receptor-induced	10
protein	10
tyrosine	9
kinases	10
.	0

Interestingly	0
,	0
we	0
find	0
that	0
in	0
contrast	0
to	0
SLP-76	9
,	0
overexpression	0
of	0
SLAP-130	9
diminishes	0
T	9
cell	10
antigen	10
receptor	10
-induced	0
activation	0
of	0
the	0
interleukin-2	1
promoter	2
in	0
Jurkat	5
T	6
cells	6
and	0
interferes	0
with	0
the	0
augmentation	0
of	0
interleukin-2	1
promoter	2
activity	0
seen	0
when	0
SLP-76	9
is	0
overexpressed	0
in	0
these	0
cells	0
.	0

These	0
data	0
suggest	0
that	0
SLP-76	9
recruits	0
a	0
negative	0
regulator	0
,	0
SLAP-130	9
,	0
as	0
well	0
as	0
positive	0
regulators	0
of	0
signal	0
transduction	0
in	0
T	7
cells	8
.	0

Molecular	0
actions	0
of	0
prolactin	0
in	0
the	0
immune	0
system	0
.	0

The	0
immunoregulatory	9
properties	0
of	0
prolactin	0
,	0
a	0
pituitary	0
peptide	0
hormone	0
,	0
have	0
received	0
renewed	0
attention	0
.	0

The	0
prolactin	9
receptor	10
,	0
a	0
member	0
of	0
the	0
hematopoietin/cytokine	9
receptor	10
superfamily	10
,	0
is	0
ubiquitously	0
expressed	0
by	0
cells	0
in	0
the	0
immune	0
system	0
.	0

Certain	0
subpopulations	0
of	0
lymphocytes	7
synthesize	0
and	0
secrete	0
biologically	0
active	0
prolactin	0
,	0
which	0
suggests	0
that	0
prolactin	0
can	0
act	0
as	0
an	0
autocrine	0
and/or	0
paracrine	0
factor	0
to	0
modulate	0
the	0
activities	0
of	0
cells	0
of	0
the	0
immune	0
system	0
.	0

This	0
review	0
focuses	0
on	0
the	0
molecular	0
actions	0
of	0
prolactin	0
in	0
the	0
immune	0
system	0
.	0

Emphasis	0
is	0
given	0
to	0
recent	0
information	0
about	0
the	0
molecular	0
mechanisms	0
of	0
prolactin	0
receptor	0
signal	0
transduction	0
,	0
and	0
the	0
signaling	9
molecules	10
and	0
prolactin-inducible	1
target	2
genes	2
that	0
participate	0
in	0
these	0
responses	0
.	0

In	0
particular	0
,	0
the	0
prolactin-inducible	1
interferon	2
regulatory	2
factor-1	2
gene	2
and	0
its	0
roles	0
in	0
mediating	0
diverse	0
immune	0
responses	0
.	0

Transcriptional	0
regulation	0
during	0
myelopoiesis	0
.	0

The	0
coordinated	0
production	0
of	0
all	0
blood	7
cells	8
from	0
a	0
common	7
stem	8
cell	8
is	0
a	0
highly	0
regulated	0
process	0
involving	0
successive	0
stages	0
of	0
commitment	0
and	0
differentiation	0
.	0

From	0
analyses	0
of	0
mice	0
deficient	0
in	0
transcription	1
factor	2
genes	2
and	0
from	0
the	0
characterizations	0
of	0
chromosome	1
breakpoints	2
in	0
human	0
leukemias	0
,	0
it	0
has	0
become	0
evident	0
that	0
transcription	9
factors	10
are	0
important	0
regulators	0
of	0
hematopoiesis	0
.	0

During	0
myelopoiesis	0
,	0
which	0
includes	0
the	0
development	0
of	0
granulocytic	7
and	8
monocytic	8
lineages	8
,	0
transcription	9
factors	10
from	0
several	0
families	0
are	0
active	0
,	0
including	0
AML1/CBF	1
beta	2
,	0
C/EBP	1
,	0
Ets	1
,	0
c-Myb	1
,	0
HOX	1
,	0
and	0
MZF-1	1
.	0

Few	0
of	0
these	0
factors	0
are	0
expressed	0
exclusively	0
in	0
myeloid	7
cells	8
;	0
instead	0
it	0
appears	0
that	0
they	0
cooperatively	0
regulate	0
transcription	0
of	0
myeloid-specific	1
genes	2
.	0

Here	0
we	0
discuss	0
recent	0
advances	0
in	0
transcriptional	0
regulation	0
during	0
myelopoiesis	0
.	0

Activation	0
of	0
transcription	0
factor	0
NF-kappa	9
B	10
by	0
phagocytic	0
stimuli	0
in	0
human	0
neutrophils	0
.	0

Phagocytosis	0
represents	0
an	0
important	0
physiological	0
trigger	0
for	0
the	0
inducible	0
expression	0
of	0
several	0
genes	0
in	0
human	7
neutrophils	8
.	0

Here	0
,	0
we	0
report	0
that	0
a	0
DNA-binding	0
activity	0
primarily	0
consisting	0
of	0
the	0
classical	0
NF-kappa	9
B	10
heterodimer	10
,	0
p50/RelA	9
,	0
is	0
induced	0
in	0
phagocytosing	7
neutrophils	8
.	0

Under	0
these	0
conditions	0
,	0
NF-kappa	9
B	10
activation	0
was	0
found	0
to	0
be	0
a	0
rapid	0
and	0
transient	0
response	0
,	0
reaching	0
a	0
maximum	0
by	0
10-15	0
min	0
,	0
and	0
returning	0
to	0
near-basal	0
levels	0
by	0
30	0
min	0
.	0

In	0
neutrophils	0
undergoing	0
the	0
phagocytosis	0
of	0
opsonized	0
yeasts	0
,	0
the	0
onset	0
of	0
NF-kappa	9
B	10
activation	0
was	0
paralleled	0
by	0
a	0
decline	0
in	0
immunoreactive	0
I	9
kappa	10
B-alpha	10
protein	0
levels	0
,	0
and	0
the	0
cellular	0
I	9
kappa	10
B	10
-alpha	0
pool	0
was	0
replenished	0
by	0
30	0
min	0
,	0
in	0
agreement	0
with	0
our	0
gel	0
shift	0
data	0
.	0

We	0
conclude	0
that	0
NF-kappa	9
B	10
activation	0
could	0
constitute	0
one	0
of	0
the	0
mechanisms	0
whereby	0
the	0
expression	0
of	0
kappa	1
B-responsive	2
genes	2
is	0
enhanced	0
in	0
phagocytosing	7
neutrophils	8
.	0

To	0
our	0
knowledge	0
,	0
this	0
represents	0
the	0
first	0
demonstration	0
that	0
phagocytic	0
stimuli	0
can	0
induce	0
NF-kappa	9
B	10
activation	0
in	0
human	7
neutrophils	8
.	0

Induction	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
expression	0
in	0
monocytic	7
cells	8
by	0
Cryptococcus	0
neoformans	0
and	0
Candida	0
albicans	0
.	0

Because	0
candidiasis	0
and	0
cryptococcosis	0
are	0
common	0
in	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
-infected	0
persons	0
,	0
the	0
effect	0
of	0
Cryptococcus	0
neoformans	0
and	0
Candida	0
albicans	0
on	0
HIV	0
expression	0
in	0
monocytic	7
cells	8
was	0
examined	0
.	0

Stimulation	0
of	0
the	0
latently	0
HIV-infected	5
myelomonocytic	6
cell	6
line	6
OM-10.1	0
with	0
C.	0
neoformans	0
and	0
C.	0
albicans	0
in	0
the	0
presence	0
of	0
pooled	0
human	0
serum	0
caused	0
a	0
ratio-dependent	0
increase	0
in	0
HIV	0
production	0
.	0

Induction	0
of	0
HIV	0
by	0
C.	0
neoformans	0
was	0
enhanced	0
by	0
anti-capsular	9
antibody	10
,	0
while	0
induction	0
by	0
both	0
organisms	0
was	0
inhibited	0
by	0
anti-TNF-alpha	9
antibody	10
.	0

In	0
THP-1	0
cells	0
transfected	0
with	0
HIV	1
plasmid	2
constructs	2
,	0
both	0
organisms	0
induced	0
transcription	0
from	0
the	0
HIV	1
long	2
terminal	2
repeat	2
that	0
was	0
dependent	0
on	0
intact	0
NF-kappaB	1
binding	2
sequences	2
.	0

Thus	0
,	0
C.	0
neoformans	0
and	0
C.	0
albicans	0
enhance	0
HIV	0
expression	0
in	0
monocytic	7
cells	8
through	0
a	0
TNF-alpha-	0
and	0
NF-kappaB-dependent	0
mechanism	0
.	0

In	0
HIV-infected	0
patients	0
,	0
such	0
enhancement	0
may	0
further	0
impair	0
host	0
immunity	0
and	0
could	0
accelerate	0
the	0
course	0
of	0
HIV	0
disease	0
.	0

Nuclear	0
levels	0
of	0
NF-kappaB	9
correlate	0
with	0
syncytium-forming	0
capacity	0
of	0
8e51	5
cells	6
,	0
expressing	0
a	0
defective	0
HIV	0
virus	0
.	0

The	0
double	1
NF-kappaB	2
site	2
identified	0
in	0
the	0
LTR	1
of	0
the	0
human	0
immunodeficiency	0
virus-1	0
(	0
HIV-1	0
)	0
has	0
been	0
demonstrated	0
to	0
be	0
necessary	0
for	0
efficient	0
viral	0
transcription	0
.	0

In	0
this	0
report	0
we	0
present	0
the	0
characterisation	0
of	0
NF-kappaB	9
subunits	10
engaged	0
in	0
complexes	0
binding	0
to	0
the	0
HIV-1	1
NF-kappaB	2
site	2
in	0
human	5
8e51	6
T-cells	6
,	0
that	0
harbour	0
a	0
defective	0
HIV-1	0
.	0

At	0
least	0
four	0
different	0
specific	0
NF-kappaB	9
complexes	10
are	0
present	0
in	0
the	0
nucleus	0
of	0
these	0
cells	0
.	0

With	0
the	0
use	0
of	0
specific	9
antibodies	10
we	0
have	0
determined	0
the	0
composition	0
of	0
each	0
complex	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

The	0
results	0
show	0
the	0
presence	0
of	0
several	0
NF-kappaB	9
family	10
members	10
,	10
with	0
the	0
transactivating	0
RelA	9
being	0
engaged	0
in	0
multiple	0
complexes	0
.	0

The	0
importance	0
of	0
NF-kappaB	9
complexes	10
in	0
viral	0
functions	0
has	0
been	0
established	0
comparing	0
the	0
level	0
of	0
NF-kappaB	0
DNA-binding	0
complexes	0
with	0
syncytia-forming	0
activity	0
of	0
8e51	5
cells	6
.	0

In	0
fact	0
,	0
8e51	5
cells	6
that	0
had	0
almost	0
lost	0
their	0
syncytia-forming	0
capacity	0
were	0
found	0
to	0
contain	0
at	0
least	0
10	0
times	0
less	0
active	0
NF-kappaB	9
DNA-binding	10
complex	10
than	0
the	0
actively	7
fusing	8
cells	8
.	0

The	0
correlation	0
is	0
specific	0
as	0
the	0
level	0
of	0
at	0
least	0
three	0
other	0
transcription	9
factors	10
did	0
not	0
change	0
.	0

c-Myb	1
and	0
Ets	9
proteins	10
synergize	0
to	0
overcome	0
transcriptional	0
repression	0
by	0
ZEB	9
.	0

The	0
Zfh	9
family	10
of	0
zinc	9
finger/homeodomain	10
proteins	10
was	0
first	0
identified	0
in	0
Drosophila	0
where	0
it	0
is	0
required	0
for	0
differentiation	0
of	0
tissues	0
such	0
as	0
the	0
central	0
nervous	0
system	0
and	0
muscle	0
.	0

ZEB	9
,	0
a	0
vertebrate	0
homolog	0
of	0
Zfh-1	9
,	0
binds	0
a	0
subset	0
of	0
E	1
boxes	2
and	0
blocks	0
myogenesis	0
through	0
transcriptional	0
repression	0
of	0
muscle	1
genes	2
.	0

We	0
present	0
evidence	0
here	0
that	0
ZEB	9
also	0
has	0
an	0
important	0
role	0
in	0
controlling	0
hematopoietic	1
gene	2
transcription	0
.	0

Two	0
families	0
of	0
transcription	9
factors	10
that	0
are	0
required	0
for	0
normal	0
hematopoiesis	0
are	0
c-Myb	9
and	0
Ets	9
.	0

These	0
factors	0
act	0
synergistically	0
to	0
activate	0
transcription	0
,	0
and	0
this	0
synergy	0
is	0
required	0
for	0
transcription	0
of	0
at	0
least	0
several	0
important	0
hematopoietic	1
genes	2
.	0

ZEB	9
blocks	0
the	0
activity	0
of	0
c-Myb	9
and	0
Ets	9
individually	0
,	0
but	0
together	0
the	0
factors	0
synergize	0
to	0
resist	0
this	0
repression	0
.	0

Such	0
repression	0
imposes	0
a	0
requirement	0
for	0
both	0
c-Myb	9
and	0
Ets	9
for	0
transcriptional	0
activity	0
,	0
providing	0
one	0
explanation	0
for	0
why	0
synergy	0
between	0
these	0
factors	0
is	0
important	0
.	0

The	0
balance	0
between	0
repression	0
by	0
ZEB	9
and	0
transcriptional	0
activation	0
by	0
c-Myb	9
/Ets	9
provides	0
a	0
flexible	0
regulatory	0
mechanism	0
for	0
controlling	0
gene	0
expression	0
in	0
hematopoietic	7
cells	8
.	0

We	0
demonstrate	0
that	0
one	0
target	0
of	0
this	0
positive/negative	0
regulation	0
in	0
vivo	0
is	0
the	0
alpha4	9
integrin	10
,	0
which	0
play	0
a	0
key	0
role	0
in	0
normal	0
hematopoiesis	0
and	0
function	0
of	0
mature	7
leukocytes	8
.	0

Comparison	0
of	0
the	0
transactivation	9
domains	10
of	0
Stat5	9
and	0
Stat6	9
in	0
lymphoid	7
cells	8
and	0
mammary	7
epithelial	8
cells	8
.	0

Stat	9
(	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
)	0
and	0
Jak	9
(	0
Janus	9
kinases	10
)	0
proteins	0
are	0
central	0
components	0
in	0
the	0
signal	0
transduction	0
events	0
in	0
hematopoietic	7
and	8
epithelial	8
cells	8
.	0

They	0
are	0
rapidly	0
activated	0
by	0
various	0
cytokines	9
,	0
hormones	0
,	0
and	0
growth	0
factors	0
.	0

Upon	0
ligand	0
binding	0
and	0
cytokine	9
receptor	10
dimerization	0
,	0
Stat	9
proteins	10
are	0
phosphorylated	0
on	0
tyrosine	0
residues	0
by	0
Jak	9
kinases	10
.	0

Activated	0
Stat	9
proteins	10
form	0
homo-	0
or	0
heterodimers	0
,	0
translocate	0
to	0
the	0
nucleus	0
,	0
and	0
induce	0
transcription	0
from	0
responsive	0
genes	0
.	0

Stat5	9
and	0
Stat6	9
are	0
transcription	9
factors	10
active	0
in	0
mammary	7
epithelial	8
cells	8
and	0
immune	0
cells	0
.	0

Prolactin	0
activates	0
Stat5	9
,	0
and	0
interleukin-4	9
(	0
IL-4	9
)	0
activates	0
Stat6	9
.	0

Both	0
cytokines	9
are	0
able	0
to	0
stimulate	0
cell	0
proliferation	0
,	0
differentiation	0
,	0
and	0
survival	0
.	0

We	0
investigated	0
the	0
transactivation	0
potential	0
of	0
Stat6	9
and	0
found	0
that	0
it	0
is	0
not	0
restricted	0
to	0
lymphocytes	0
.	0

IL-4	9
-dependent	0
activation	0
of	0
Stat6	9
was	0
also	0
observed	0
in	0
HC11	5
mammary	6
epithelial	6
cells	6
.	0

In	0
these	0
cells	0
,	0
Stat6	9
activation	0
led	0
to	0
the	0
induction	0
of	0
the	0
beta-casein	1
gene	2
promoter	2
.	0

The	0
induction	0
of	0
this	0
promoter	0
was	0
confirmed	0
in	0
COS7	5
cells	6
.	0

The	0
glucocorticoid	9
receptor	10
was	0
able	0
to	0
further	0
enhance	0
IL-4	9
-induced	0
gene	0
transcription	0
through	0
the	0
action	0
of	0
Stat6	9
.	0

Deletion	0
analysis	0
of	0
the	0
carboxyl-terminal	9
region	10
of	0
Stat6	9
and	0
recombination	0
of	0
this	0
region	0
with	0
a	0
heterologous	9
DNA	10
binding	10
domain	10
allowed	0
the	0
delimitation	0
and	0
characterization	0
of	0
the	0
transactivation	0
domain	0
of	0
Stat6	9
.	0

The	0
potencies	0
of	0
the	0
transactivation	9
domains	10
of	0
Stat5	9
,	0
Stat6	9
,	0
and	0
viral	9
protein	10
VP16	10
were	0
compared	0
.	0

Stat6	9
had	0
a	0
transactivation	0
domain	0
which	0
was	0
about	0
10-fold	0
stronger	0
than	0
that	0
of	0
Stat5	9
.	0

In	0
pre-B	7
cells	8
(	0
Ba/F3	0
)	0
,	0
the	0
transactivation	0
domain	0
of	0
Stat6	9
was	0
IL-4	9
regulated	0
,	0
independently	0
from	0
its	0
DNA	0
binding	0
function	0
.	0

ETS1	9
,	0
NFkappaB	9
and	0
AP1	9
synergistically	0
transactivate	0
the	0
human	1
GM-CSF	2
promoter	2
.	0

Activation	0
of	0
helper	7
T	8
cells	8
results	0
in	0
coordinate	0
expression	0
of	0
a	0
number	0
of	0
cytokines	9
involved	0
in	0
differentiation	0
,	0
proliferation	0
and	0
activation	0
of	0
the	0
haematopoietic	0
system	0
.	0

Granulocyte-macrophage	9
colony	10
stimulating	10
factor	10
(	0
GM-CSF	9
)	0
is	0
one	0
such	0
cytokine	9
,	0
whose	0
increased	0
expression	0
results	0
mostly	0
from	0
increases	0
in	0
transcription	0
.	0

Cis-acting	1
elements	2
with	0
NFkappaB	1
,	2
AP1	2
and	2
ETS-like	2
binding	2
motifs	2
have	0
been	0
identified	0
in	0
the	0
promoter	0
region	0
of	0
the	0
GM-CSF	1
gene	2
,	0
and	0
are	0
important	0
or	0
essential	0
for	0
transcriptional	0
activity	0
following	0
T	0
cell	0
activation	0
.	0

ETS1	9
is	0
a	0
transcription	9
factor	10
of	0
the	0
ETS	9
family	10
that	0
is	0
expressed	0
in	0
T	7
cells	8
.	0

We	0
have	0
previously	0
shown	0
that	0
ETS1	9
can	0
transactivate	0
GM-CSF	9
in	0
Jurkat	5
T	6
cells	6
,	0
but	0
only	0
after	0
the	0
cells	0
have	0
been	0
stimulated	0
by	0
treatment	0
with	0
PMA	0
and	0
ionomycin	0
,	0
agents	0
that	0
mimic	0
T	0
cell	0
activation	0
.	0

Thus	0
we	0
proposed	0
that	0
ETS1	9
,	0
which	0
is	0
expressed	0
constitutively	0
in	0
Jurkat	5
cells	6
,	0
may	0
act	0
in	0
concert	0
with	0
PMA/ionomycin	9
inducible	10
factors	10
.	0

Here	0
we	0
show	0
that	0
ETS1	9
can	0
transactivate	0
a	0
GM-CSF	1
reporter	2
construct	2
in	0
unstimulated	0
Jurkat	5
cells	6
,	0
providing	0
that	0
either	0
NFkappaB	9
or	0
AP1	9
transcription	9
factors	10
are	0
supplied	0
by	0
co-transfection	0
.	0

We	0
confirm	0
that	0
binding	0
of	0
endogenous	0
NFkappaB	9
and	0
AP1	9
is	0
induced	0
following	0
PMA/ionomycin	0
treatment	0
of	0
T	7
cells	8
.	0

Transactivation	0
by	0
ETS1	9
,	0
NFkappaB	9
and	0
AP1	9
is	0
synergistic	0
,	0
and	0
mutation	0
of	0
the	0
individual	0
binding	0
sites	0
reveals	0
that	0
the	0
transcriptional	0
activities	0
of	0
these	0
factors	0
are	0
interdependent	0
.	0

Our	0
results	0
suggest	0
that	0
constitutive	0
ETS1	9
,	0
and	0
inducible	0
NFkappaB	9
and	0
AP1	9
,	0
cooperate	0
as	0
part	0
of	0
a	0
higher	0
order	0
transcriptional	9
complex	10
in	0
activated	0
T	7
cells	8
.	0

Abnormal	0
T	7
lymphocyte	8
development	0
induced	0
by	0
targeted	0
overexpression	0
of	0
IkappaB	9
alpha	10
.	0

A	0
role	0
in	0
thymic	0
maturation	0
for	0
factors	0
of	0
the	0
NF-kappaB	9
family	10
has	0
long	0
been	0
suspected	0
,	0
but	0
not	0
yet	0
proven	0
.	0

Transgenic	0
mice	0
with	0
a	0
lymphocyte-specific	0
defect	0
in	0
NF-kappaB	9
activation	0
were	0
produced	0
by	0
targeted	0
expression	0
of	0
human	0
IkappaB	9
alpha	10
.	0

The	0
thymic	0
cellularity	0
of	0
these	0
mice	0
was	0
significantly	0
decreased	0
.	0

The	0
proportion	0
of	0
mature	0
,	0
TCRhigh	7
thymocytes	8
of	0
the	0
alphabeta	7
lineage	8
was	0
reduced	0
,	0
and	0
the	0
remaining	0
TCRhigh	7
population	8
contained	0
an	0
unusually	0
high	0
proportion	0
of	0
double-positive	5
cells	6
.	0

This	0
defect	0
in	0
maturation	0
resulted	0
in	0
a	0
transgene	0
dose-dependent	0
reduction	0
in	0
peripheral	7
T	8
lymphocytes	8
,	0
with	0
the	0
CD8	7
lineage	8
being	0
more	0
severely	0
affected	0
.	0

These	0
data	0
provide	0
direct	0
evidence	0
for	0
the	0
involvement	0
of	0
NF-kappaB/Rel	9
family	10
proteins	10
in	0
late	0
stages	0
of	0
T	7
lymphocyte	8
development	0
,	0
coincident	0
with	0
positive	0
and	0
negative	0
selection	0
.	0

CD40	9
is	0
a	0
functional	0
activation	9
antigen	10
and	0
B7-independent	9
T	10
cell	10
costimulatory	10
molecule	10
on	0
normal	0
human	7
lung	8
fibroblasts	8
.	0

CD40	9
is	0
an	0
important	0
signaling	0
and	0
activation	0
Ag	0
found	0
on	0
certain	0
bone	7
marrow-derived	8
cells	8
.	0

Recently	0
,	0
CD40	9
also	0
has	0
been	0
shown	0
to	0
be	0
expressed	0
by	0
mesenchymal	7
cells	8
,	0
including	0
human	7
fibroblasts	8
.	0

Little	0
is	0
known	0
about	0
the	0
role	0
of	0
CD40	9
in	0
fibroblasts	7
.	0

The	0
current	0
study	0
investigates	0
the	0
hypothesis	0
that	0
CD40	9
expressed	0
on	0
lung	7
fibroblasts	8
is	0
an	0
activation	0
structure	0
and	0
mechanism	0
for	0
interaction	0
with	0
hemopoietic	7
cells	8
.	0

Communication	0
between	0
resident	0
tissue	0
fibroblasts	7
and	0
T	7
cells	8
is	0
necessary	0
for	0
normal	0
wound	0
healing	0
,	0
and	0
can	0
be	0
pathologic	0
,	0
resulting	0
in	0
tissue	0
fibrosis	0
.	0

Signaling	0
through	0
CD40	9
with	0
soluble	0
CD40	9
ligand	0
stimulated	0
fibroblast	0
activation	0
,	0
as	0
evidenced	0
by	0
mobilization	0
of	0
nuclear	0
factor-kappaB	0
and	0
by	0
induction	0
of	0
the	0
proinflammatory	0
and	0
chemoattractant	0
cytokines	9
IL-6	9
and	0
IL-8	9
.	0

IFN-gamma-primed	5
lung	6
fibroblasts	6
costimulate	0
T	0
lymphocyte	0
proliferation	0
utilizing	0
CD40	9
,	0
but	0
not	0
the	0
well-studied	0
costimulatory	9
molecules	10
B7-1	9
and	0
B7-2	9
.	0

Data	0
reported	0
herein	0
support	0
the	0
hypothesis	0
that	0
cognate	0
interactions	0
between	0
tissue	7
fibroblasts	8
and	0
infiltrating	0
T	0
lymphocytes	0
,	0
via	0
the	0
CD40	9
/CD40L	9
pathway	0
,	0
augment	0
inflammation	0
and	0
may	0
promote	0
fibrogenesis	0
by	0
activating	0
both	0
cell	0
types	0
.	0

Biphasic	0
control	0
of	0
NF-kappa	9
B	10
activation	0
induced	0
by	0
the	0
triggering	0
of	0
HLA-DR	9
antigens	10
expressed	0
on	0
B	7
cells	8
.	0

The	0
regulation	0
of	0
NF-kappa	9
B	10
activation	0
following	0
the	0
triggering	0
of	0
HLA-DR	9
antigens	10
by	0
mAb	9
L243	10
has	0
been	0
studied	0
at	0
various	0
times	0
in	0
Raji	5
cells	6
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
demonstrated	0
a	0
strong	0
increase	0
of	0
NF-kappa	9
B	10
DNA	0
binding	0
after	0
triggering	0
of	0
HLA-DR	9
antigens	10
.	0

Using	0
TNF-alpha-activity	9
neutralizing	10
antibodies	10
,	0
the	0
authors	0
demonstrated	0
that	0
the	0
upregulation	0
of	0
NF-kappa	9
B	10
was	0
found	0
to	0
depend	0
,	0
at	0
later	0
time	0
point	0
,	0
on	0
an	0
autocrine	0
effect	0
of	0
TNF-alpha	9
secreted	0
following	0
triggering	0
of	0
HLA-DR	9
antigens	10
.	0

In	0
contrast	0
,	0
it	0
was	0
found	0
to	0
be	0
TNF-alpha	9
independent	0
in	0
the	0
early	0
time	0
point	0
.	0

Moreover	0
,	0
the	0
upregulation	0
of	0
NF-kappa	9
B	10
binding	0
activity	0
is	0
regulated	0
by	0
the	0
triggering	0
of	0
selected	0
epitopes	9
of	0
HLA-DR	9
antigens	10
.	0

In	0
fact	0
,	0
mAb	9
L243	10
but	0
not	0
the	0
staphylococcal	9
superantigens	10
,	0
staphylococcal	9
exotoxin	10
toxic	10
shock	10
syndrome	10
toxin-I	10
or	0
staphylococcal	9
enterotoxin	10
B	10
,	0
regulate	0
the	0
NF-kappa	9
B	10
binding	0
activity	0
.	0

Regulation	0
of	0
inosine-5'-monophosphate	9
dehydrogenase	10
type	10
II	10
gene	0
expression	0
in	0
human	7
T	8
cells	8
.	0

Role	0
for	0
a	0
novel	0
5	1
'	2
palindromic	2
octamer	2
sequence	2
.	0

Expression	0
of	0
the	0
gene	0
encoding	0
human	9
inosine-	10
5'-monophosphate	10
dehydrogenase	10
(	10
IMPDH	10
)	10
type	10
II	10
,	0
an	0
enzyme	9
catalyzing	0
the	0
rate-limiting	0
step	0
in	0
the	0
generation	0
of	0
guanine	0
nucleotides	0
,	0
is	0
increased	0
more	0
than	0
10-fold	0
in	0
activated	7
peripheral	8
blood	8
T	8
lymphocytes	8
and	0
is	0
required	0
for	0
T	0
cell	0
activation	0
.	0

We	0
have	0
examined	0
the	0
5'-regulatory	1
sequences	2
that	0
are	0
important	0
for	0
the	0
transcriptional	0
regulation	0
of	0
this	0
gene	0
in	0
T	7
cells	8
.	0

DNase	9
I	10
mapping	0
of	0
genomic	1
DNA	2
identified	0
a	0
hypersensitive	1
element	2
near	0
the	0
transcription	1
initiation	2
site	2
.	0

Fine	0
mapping	0
by	0
in	0
vivo	0
footprinting	0
demonstrated	0
five	0
transcription	0
factor	0
binding	0
sites	0
that	0
are	0
occupied	0
in	0
both	0
resting	0
and	0
activated	7
peripheral	8
blood	8
T	8
lymphocytes	8
;	0
these	0
are	0
tandem	1
CRE	2
motifs	2
,	0
a	0
Sp1	1
site	2
,	0
an	0
overlapping	0
Egr-1/Sp1	1
site	2
,	0
and	0
a	0
novel	0
palindromic	1
octamer	2
sequence	2
(	0
POS	1
)	0
.	0

The	0
tandem	0
CRE	1
and	2
POS	2
sites	2
are	0
of	0
major	0
functional	0
importance	0
as	0
judged	0
by	0
mutational	0
and	0
electrophoretic	0
mobility	0
shift	0
analyses	0
.	0

These	0
data	0
provide	0
evidence	0
that	0
expression	0
of	0
the	0
human	1
IMPDH	2
type	2
II	2
gene	2
is	0
predominantly	0
regulated	0
by	0
the	0
nuclear	9
factors	10
ATF-2	9
and	0
an	0
as	0
yet	0
unidentified	0
POS-binding	9
protein	10
.	0

Additional	0
major	0
protein-DNA	0
interactions	0
do	0
not	0
occur	0
within	0
the	0
promoter	0
region	0
after	0
T	0
lymphocyte	0
activation	0
,	0
indicating	0
a	0
requirement	0
for	0
additional	0
protein-protein	0
interactions	0
and/or	0
post-translational	0
modifications	0
of	0
pre-bound	9
transcription	10
factors	10
to	0
account	0
for	0
the	0
observed	0
increase	0
in	0
IMPDH	0
type	0
II	0
gene	0
expression	0
.	0

Distinct	0
mechanisms	0
for	0
N-acetylcysteine	0
inhibition	0
of	0
cytokine-induced	9
E-selectin	10
and	0
VCAM-1	9
expression	0
.	0

We	0
have	0
examined	0
the	0
effects	0
of	0
N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
,	0
a	0
well-characterized	0
,	0
thiol-containing	0
antioxidant	0
,	0
on	0
agonist-induced	0
monocytic	0
cell	0
adhesion	0
to	0
endothelial	7
cells	8
(	0
EC	7
)	0
.	0

NAC	0
inhibited	0
interleukin-1	9
(	0
IL-1	9
beta	10
)	0
-induced	0
,	0
but	0
not	0
basal	0
,	0
adhesion	0
with	0
50	0
%	0
inhibition	0
at	0
approximately	0
20	0
mM	0
.	0

Monocytic	0
cell	0
adhesion	0
to	0
EC	7
in	0
response	0
to	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
,	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
alpha-thrombin	9
,	0
or	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
was	0
similarly	0
inhibited	0
by	0
NAC	0
.	0

Unlike	0
published	0
studies	0
with	0
pyrrolidinedithiocarbamate	0
,	0
which	0
specifically	0
inhibited	0
vascular	9
cell	10
adhesion	10
molecule	10
1	10
(	0
VCAM-1	9
)	0
,	0
NAC	0
inhibited	0
IL-1	3
beta-induced	4
mRNA	4
and	0
cell	0
surface	0
expression	0
of	0
both	0
E-selectin	9
and	0
VCAM-1	9
.	0

NAC	0
had	0
no	0
effect	0
on	0
the	0
half-life	0
of	0
E-selectin	3
or	4
VCAM-1	4
mRNA	4
.	0

Although	0
NAC	0
reduced	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
in	0
EC	7
as	0
measured	0
by	0
gel-shift	0
assays	0
using	0
an	0
oligonucleotide	1
probe	2
corresponding	0
to	0
the	0
consensus	0
NF-kappa	1
B	2
binding	2
sites	2
of	0
the	0
VCAM-1	1
gene	2
(	0
VCAM-NF-kappa	9
B	10
)	0
,	0
the	0
antioxidant	0
had	0
no	0
appreciable	0
effect	0
when	0
an	0
oligomer	0
corresponding	0
to	0
the	0
consensus	1
NF-kappa	2
B	2
binding	2
site	2
of	0
the	0
E-selectin	1
gene	2
(	0
E-selectin	9
-NF-kappa	9
B	10
)	0
was	0
used	0
.	0

Because	0
NF-kappa	9
B	10
has	0
been	0
reported	0
to	0
be	0
redox	0
sensitive	0
,	0
we	0
studied	0
the	0
effects	0
of	0
NAC	0
on	0
the	0
EC	7
redox	0
environment	0
.	0

NAC	0
caused	0
an	0
expected	0
dramatic	0
increase	0
in	0
the	0
reduced	0
glutathione	0
(	0
GSH	0
)	0
levels	0
in	0
EC	7
.	0

In	0
vitro	0
studies	0
demonstrated	0
that	0
whereas	0
the	0
binding	0
affinity	0
of	0
NF-kappa	9
B	10
to	0
the	0
VCAM-NF-kappa	1
B	2
oligomer	2
peaked	0
at	0
a	0
GSH-to-oxidized	0
glutathione	0
(	0
GSSG	0
)	0
ratio	0
of	0
approximately	0
200	0
and	0
decreased	0
at	0
higher	0
ratios	0
,	0
the	0
binding	0
to	0
the	0
E-selectin-NF-kappa	1
B	2
oligomer	2
appeared	0
relatively	0
unaffected	0
even	0
at	0
ratios	0
>	0
400	0
,	0
i.e.	0
,	0
those	0
achieved	0
in	0
EC	7
treated	0
with	0
40	0
mM	0
NAC	0
.	0

These	0
results	0
suggest	0
that	0
NF-kappa	9
B	10
binding	0
to	0
its	0
consensus	0
sequences	0
in	0
the	0
VCAM-1	9
and	0
E-selectin	1
gene	2
exhibits	0
marked	0
differences	0
in	0
redox	0
sensitivity	0
,	0
allowing	0
for	0
differential	0
gene	0
expression	0
regulated	0
by	0
the	0
same	0
transcription	0
factor	0
.	0

Our	0
data	0
also	0
demonstrate	0
that	0
NAC	0
increases	0
the	0
GSH-to-GSSG	0
ratio	0
within	0
the	0
EC	7
suggesting	0
one	0
possible	0
mechanism	0
through	0
which	0
this	0
antioxidant	0
inhibits	0
agonist-induced	0
monocyte	0
adhesion	0
to	0
EC	7
.	0

Opposite	0
effects	0
of	0
the	0
acute	9
promyelocytic	10
leukemia	10
PML-retinoic	10
acid	10
receptor	10
alpha	10
(	0
RAR	9
alpha	10
)	0
and	0
PLZF-RAR	9
alpha	10
fusion	10
proteins	10
on	0
retinoic	0
acid	0
signalling	0
.	0

Fusion	0
proteins	0
involving	0
the	0
retinoic	0
acid	0
receptor	9
alpha	10
(	0
RAR	9
alpha	10
)	0
and	0
the	0
PML	9
or	0
PLZF	9
nuclear	10
protein	10
are	0
the	0
genetic	0
markers	0
of	0
acute	0
promyelocytic	0
leukemias	0
(	0
APLs	0
)	0
.	0

APLs	0
with	0
the	0
PML-RAR	9
alpha	10
or	0
the	0
PLZF-RAR	9
alpha	10
fusion	10
protein	10
are	0
phenotypically	0
indistinguishable	0
except	0
that	0
they	0
differ	0
in	0
their	0
sensitivity	0
to	0
retinoic	0
acid	0
(	0
RA	0
)	0
-induced	0
differentiation	0
:	0
PML-RAR	9
alpha	10
blasts	0
are	0
sensitive	0
to	0
RA	0
and	0
patients	0
enter	0
disease	0
remission	0
after	0
RA	0
treatment	0
,	0
while	0
patients	0
with	0
PLZF-RAR	9
alpha	10
do	0
not	0
.	0

We	0
here	0
report	0
that	0
(	0
i	0
)	0
like	0
PML-RAR	9
alpha	10
expression	0
,	0
PLZF-RAR	9
alpha	10
expression	0
blocks	0
terminal	0
differentiation	0
of	0
hematopoietic	0
precursor	0
cell	0
lines	0
(	0
U937	5
and	0
HL-60	5
)	0
in	0
response	0
to	0
different	0
stimuli	0
(	0
vitamin	0
D3	0
,	0
transforming	0
growth	0
factor	0
beta1	0
,	0
and	0
dimethyl	0
sulfoxide	0
)	0
;	0
(	0
ii	0
)	0
PML-RAR	9
alpha	10
,	0
but	0
not	0
PLZF-RAR	9
alpha	10
,	0
increases	0
RA	0
sensitivity	0
of	0
hematopoietic	7
precursor	8
cells	8
and	0
restores	0
RA	0
sensitivity	0
of	0
RA-resistant	7
hematopoietic	8
cells	8
;	0
(	0
iii	0
)	0
PML-RAR	9
alpha	10
and	0
PLZF-RAR	9
alpha	10
have	0
similar	0
RA	0
binding	0
affinities	0
;	0
and	0
(	0
iv	0
)	0
PML-RAR	9
alpha	10
enhances	0
the	0
RA	0
response	0
of	0
RA	1
target	2
genes	2
(	0
those	0
for	0
RAR	9
beta	10
,	0
RAR	9
gamma	10
,	0
and	0
transglutaminase	9
type	10
II	10
[	0
TGase	9
]	0
)	0
in	0
vivo	0
,	0
while	0
PLZF-RAR	9
alpha	10
expression	0
has	0
either	0
no	0
effect	0
(	0
RAR	9
beta	10
)	0
or	0
an	0
inhibitory	0
activity	0
(	0
RAR	9
gamma	10
and	0
type	9
II	10
TGase	10
)	0
.	0

These	0
data	0
demonstrate	0
that	0
PML-RAR	9
alpha	10
and	0
PLZF-RAR	9
alpha	10
have	0
similar	0
(	0
inhibitory	0
)	0
effects	0
on	0
RA-independent	0
differentiation	0
and	0
opposite	0
(	0
stimulatory	0
or	0
inhibitory	0
)	0
effects	0
on	0
RA-dependent	0
differentiation	0
and	0
that	0
they	0
behave	0
in	0
vivo	0
as	0
RA-dependent	1
enhancers	2
or	0
inhibitors	0
of	0
RA-responsive	1
genes	2
,	0
respectively	0
.	0

Their	0
different	0
activities	0
on	0
the	0
RA	0
signalling	0
pathway	0
might	0
underlie	0
the	0
different	0
responses	0
of	0
PML-RAR	9
alpha	10
and	0
PLZF-RAR	9
alpha	10
APLs	0
to	0
RA	0
treatment	0
.	0

The	0
PLZF-RAR	9
alpha	10
fusion	10
protein	10
contains	0
an	0
approximately	0
120-amino-acid	9
N-terminal	10
motif	10
(	0
called	0
the	0
POZ	9
domain	10
)	0
,	0
which	0
is	0
also	0
found	0
in	0
a	0
variety	0
of	0
zinc	0
finger	0
proteins	0
and	0
a	0
group	0
of	0
poxvirus	9
proteins	10
and	0
which	0
mediates	0
protein-protein	0
interactions	0
.	0

Deletion	0
of	0
the	0
PLZF	9
POZ	10
domain	10
partially	0
abrogated	0
the	0
inhibitory	0
effect	0
of	0
PLZF-RAR	9
alpha	10
on	0
RA-induced	0
differentiation	0
and	0
on	0
RA-mediated	0
type	9
II	10
TGase	10
up-regulation	0
,	0
suggesting	0
that	0
POZ-mediated	0
protein	0
interactions	0
might	0
be	0
responsible	0
for	0
the	0
inhibitory	0
transcriptional	0
activities	0
of	0
PLZF-RAR	9
alpha	10
.	0

A	0
human	0
homologue	0
of	0
the	0
Drosophila	9
Toll	10
protein	10
signals	0
activation	0
of	0
adaptive	0
immunity	0
[	0
see	0
comments	0
]	0

Induction	0
of	0
the	0
adaptive	0
immune	0
response	0
depends	0
on	0
the	0
expression	0
of	0
co-stimulatory	9
molecules	10
and	0
cytokines	9
by	0
antigen-presenting	7
cells	8
.	0

The	0
mechanisms	0
that	0
control	0
the	0
initial	0
induction	0
of	0
these	0
signals	0
upon	0
infection	0
are	0
poorly	0
understood	0
.	0

It	0
has	0
been	0
proposed	0
that	0
their	0
expression	0
is	0
controlled	0
by	0
the	0
non-clonal	0
,	0
or	0
innate	0
,	0
component	0
of	0
immunity	0
that	0
preceded	0
in	0
evolution	0
the	0
development	0
of	0
an	0
adaptive	0
immune	0
system	0
in	0
vertebrates	0
.	0

We	0
report	0
here	0
the	0
cloning	0
and	0
characterization	0
of	0
a	0
human	9
homologue	10
of	0
the	0
Drosophila	9
toll	10
protein	10
(	0
Toll	9
)	0
which	0
has	0
been	0
shown	0
to	0
induce	0
the	0
innate	0
immune	0
response	0
in	0
adult	0
Drosophila	0
.	0

Like	0
Drosophila	0
Toll	9
,	0
human	9
Toll	10
is	0
a	0
type	0
I	0
transmembrane	0
protein	0
with	0
an	0
extracellular	0
domain	0
consisting	0
of	0
a	0
leucine-rich	9
repeat	10
(	10
LRR	10
)	10
domain	10
,	0
and	0
a	0
cytoplasmic	0
domain	0
homologous	0
to	0
the	0
cytoplasmic	9
domain	10
of	0
the	0
human	9
interleukin	10
(	10
IL	10
)	10
-1	10
receptor	10
.	0

Both	0
Drosophila	0
Toll	9
and	0
the	0
IL-1	0
receptor	0
are	0
known	0
to	0
signal	0
through	0
the	0
NF-kappaB	9
pathway	0
.	0

We	0
show	0
that	0
a	0
constitutively	0
active	0
mutant	0
of	0
human	9
Toll	10
transfected	0
into	0
human	0
cell	0
lines	0
can	0
induce	0
the	0
activation	0
of	0
NF-kappaB	9
and	0
the	0
expression	0
of	0
NF-kappaB-controlled	1
genes	2
for	0
the	0
inflammatory	9
cytokines	10
IL-1	9
,	0
IL-6	9
and	0
IL-8	9
,	0
as	0
well	0
as	0
the	0
expression	0
of	0
the	0
co-stimulatory	9
molecule	10
B7.1	9
,	0
which	0
is	0
required	0
for	0
the	0
activation	0
of	0
naive	7
T	8
cells	8
.	0

Role	0
of	0
ascorbate	0
in	0
the	0
activation	0
of	0
NF-kappaB	9
by	0
tumour	9
necrosis	10
factor-alpha	10
in	0
T-cells	7
.	0

The	0
first	0
product	0
of	0
ascorbate	0
oxidation	0
,	0
the	0
ascorbate	0
free	0
radical	0
(	0
AFR	0
)	0
,	0
acts	0
in	0
biological	0
systems	0
mainly	0
as	0
an	0
oxidant	0
,	0
and	0
through	0
its	0
role	0
in	0
the	0
plasma	0
membrane	0
redox	0
system	0
exerts	0
different	0
effects	0
on	0
the	0
cell	0
.	0

We	0
have	0
investigated	0
the	0
role	0
of	0
ascorbate	0
,	0
AFR	0
and	0
dehydroascorbate	0
(	0
DHA	0
)	0
in	0
the	0
activation	0
of	0
the	0
NF-kappaB	9
transcription	10
factor	10
in	0
Jurkat	5
T-cells	6
stimulated	0
by	0
tumour	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

Here	0
we	0
show	0
,	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
that	0
ascorbate	0
increases	0
the	0
binding	0
of	0
NF-kappaB	9
to	0
DNA	0
in	0
TNF-alpha-stimulated	5
Jurkat	6
cells	6
.	0

The	0
ability	0
of	0
ascorbate	0
to	0
enhance	0
cytoplasmic	0
inhibitory	0
IkBalpha	9
protein	10
degradation	0
correlates	0
completely	0
with	0
its	0
capacity	0
to	0
induce	0
NF-kappaB	9
binding	0
to	0
DNA	0
and	0
to	0
potentiate	0
NF-kappaB	9
-mediated	0
transactivation	0
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
promoter	2
in	0
TNF-alpha-stimulated	5
Jurkat	6
cells	6
but	0
not	0
in	0
cells	0
stimulated	0
with	0
PMA	0
plus	0
ionomycin	0
.	0

AFR	0
behaves	0
like	0
ascorbate	0
,	0
while	0
DHA	0
and	0
ascorbate	0
phosphate	0
do	0
not	0
affect	0
TNF-alpha	9
-mediated	0
NF-kappaB	9
activation	0
.	0

These	0
results	0
provide	0
new	0
evidence	0
for	0
a	0
possible	0
relationship	0
between	0
the	0
activation	0
of	0
the	0
electron-transport	0
system	0
at	0
the	0
plasma	0
membrane	0
by	0
ascorbate	0
or	0
its	0
free	0
radical	0
and	0
redox-dependent	0
gene	0
transcription	0
in	0
T-cells	7
.	0

Human	0
cytomegalovirus	0
induces	0
interleukin-8	9
production	0
by	0
a	0
human	5
monocytic	6
cell	6
line	6
,	0
THP-1	5
,	0
through	0
acting	0
concurrently	0
on	0
AP-1-	1
and	2
NF-kappaB-binding	2
sites	2
of	0
the	0
interleukin-8	1
gene	2
.	0

Cytomegalovirus	0
(	0
CMV	0
)	0
infection	0
induced	0
interleukin-8	9
(	0
IL-8	9
)	0
gene	0
transcription	0
in	0
a	0
human	5
monocytic	6
cell	6
line	6
,	0
THP-1	5
cells	6
,	0
leading	0
to	0
IL-8	9
secretion	0
.	0

The	0
functional	0
analysis	0
of	0
the	0
IL-8	1
gene	2
revealed	0
that	0
both	0
AP-1-	1
and	2
NF-kappaB	2
factor-binding	2
elements	2
were	0
involved	0
in	0
conferring	0
the	0
responsiveness	0
to	0
CMV	0
.	0

Moreover	0
,	0
electrophoretic	0
mobility	0
shift	0
assays	0
demonstrated	0
that	0
CMV	0
induced	0
the	0
formation	0
of	0
NF-kappaB	9
and	0
AP-1	9
complexes	10
.	0

These	0
results	0
suggest	0
that	0
CMV	0
activates	0
these	0
transcriptional	9
factors	10
,	0
resulting	0
in	0
IL-8	9
gene	0
expression	0
.	0

Construction	0
and	0
biological	0
characterization	0
of	0
an	0
interleukin-12	9
fusion	10
protein	10
(	0
Flexi-12	9
)	0
:	0
delivery	0
to	0
acute	7
myeloid	8
leukemic	8
blasts	8
using	0
adeno-associated	0
virus	0
.	0

Interleukin-12	9
(	0
IL-12	9
)	0
is	0
a	0
cytokine	9
that	0
exhibits	0
pleiotropic	0
effects	0
on	0
lymphocytes	7
and	0
natural	7
killer	8
cells	8
and	0
has	0
been	0
shown	0
to	0
have	0
promise	0
for	0
the	0
immunotherapy	0
of	0
cancer	0
.	0

The	0
combination	0
of	0
the	0
immune	9
costimulatory	10
molecule	10
B7.1	9
and	0
IL-12	9
has	0
been	0
shown	0
to	0
be	0
synergistic	0
for	0
T	0
cell	0
activation	0
.	0

By	0
transfecting	0
tumor	0
cells	0
with	0
both	0
IL-12	1
and	2
B7.1	2
cDNAs	2
,	0
it	0
may	0
be	0
possible	0
to	0
use	0
these	0
modified	0
targets	0
as	0
vaccines	0
.	0

A	0
major	0
obstacle	0
in	0
designing	0
a	0
vector	0
to	0
deliver	0
these	0
genes	0
results	0
from	0
the	0
structure	0
of	0
IL-12	9
.	0

Functional	0
IL-12	9
is	0
a	0
heterodimer	9
composed	0
of	0
two	0
distinct	0
subunits	0
that	0
are	0
encoded	0
by	0
separate	0
genes	0
on	0
different	0
chromosomes	0
.	0

Production	0
of	0
functional	9
IL-12	10
requires	0
the	0
coordinated	0
expression	0
of	0
both	0
genes	0
.	0

This	0
presents	0
several	0
problems	0
in	0
vectors	0
,	0
particularly	0
those	0
in	0
which	0
additional	0
genes	0
,	0
either	0
a	0
co-stimulatory	1
gene	2
or	0
a	0
selectable	0
marker	0
,	0
are	0
inserted	0
.	0

Therefore	0
,	0
we	0
have	0
constructed	0
a	0
single	0
cDNA	1
that	0
encodes	0
a	0
single-chain	9
protein	10
,	0
called	0
Flexi-12	9
,	0
which	0
retains	0
all	0
of	0
the	0
biological	0
characteristics	0
of	0
recombinant	0
IL-12	9
(	0
rIL-12	9
)	0
.	0

The	0
monomeric	0
polypeptide	0
Flexi-12	9
is	0
able	0
to	0
induce	0
the	0
proliferation	0
of	0
phytohemagglutinin	5
(	6
PHA	6
)	6
blasts	6
,	0
induce	0
PHA	5
blasts	6
to	0
secrete	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
and	0
additionally	0
,	0
by	0
preincubation	0
,	0
enhance	0
the	0
killing	0
of	0
K562	0
targets	0
by	0
PBLs	7
.	0

These	0
phenomena	0
are	0
in	0
a	0
dose-dependent	0
manner	0
comparable	0
to	0
that	0
seen	0
with	0
rIL-12	9
.	0

We	0
have	0
also	0
shown	0
that	0
tyrosine	0
phosphorylation	0
of	0
the	0
STAT	9
4	10
transcription	10
factor	10
,	0
which	0
has	0
been	0
shown	0
to	0
be	0
unique	0
to	0
the	0
IL-12	9
signaling	0
pathway	0
,	0
occurs	0
with	0
Flexi-12	9
at	0
levels	0
similar	0
to	0
those	0
seen	0
with	0
rIL-12	9
.	0

We	0
have	0
packaged	0
Flexi-12	9
into	0
a	0
recombinant	0
adeno-associated	0
virus	0
(	0
AAV	0
)	0
and	0
used	0
this	0
vector	0
to	0
infect	0
acute	7
myeloid	8
leukemic	8
(	8
AML	8
)	8
blasts	8
.	0

Infected	0
AML	7
blasts	8
produced	0
between	0
2	0
and	0
6	0
ng	0
of	0
IL-12/10	0
(	0
6	0
)	0
cells	0
per	0
ml	0
per	0
48	0
hr	0
.	0

These	0
studies	0
also	0
confirm	0
that	0
AAV	0
is	0
an	0
efficient	0
delivery	0
vehicle	0
for	0
cytokines	9
to	0
leukemic	0
cells	0
.	0

Direct	0
analysis	0
of	0
these	0
modified	0
cells	0
acting	0
as	0
tumor	0
vaccines	0
is	0
underway	0
.	0

Plasma	0
sialyltransferase	9
levels	0
in	0
psychiatric	0
disorders	0
as	0
a	0
possible	0
indicator	0
of	0
HPA	0
axis	0
function	0
.	0

A	0
dysfunction	0
in	0
the	0
regulation	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
(	0
HPA	0
)	0
axis	0
,	0
possibly	0
attributed	0
to	0
a	0
change	0
in	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
functionality	0
,	0
has	0
been	0
implicated	0
in	0
depression	0
.	0

We	0
have	0
measured	0
both	0
lymphocyte	9
GR	10
receptor	0
binding	0
parameters	0
and	0
plasma	0
sialyltransferase	9
activity	0
,	0
as	0
a	0
biochemical	0
marker	0
of	0
GR	9
function	0
,	0
in	0
two	0
groups	0
of	0
patients	0
suffering	0
from	0
depression	0
or	0
schizophrenia	0
and	0
in	0
a	0
group	0
of	0
age-	0
and	0
sex-matched	0
controls	0
.	0

While	0
there	0
was	0
a	0
significant	0
increase	0
in	0
plasma	0
cortisol	0
levels	0
in	0
the	0
depressed	0
group	0
,	0
there	0
were	0
no	0
changes	0
in	0
the	0
lymphocyte	0
GR	9
binding	0
parameters	0
(	0
K	0
(	0
m	0
)	0
and	0
Bmax	0
)	0
.	0

There	0
was	0
,	0
however	0
,	0
a	0
significant	0
decrease	0
in	0
the	0
plasma	9
sialyltransferase	10
:	10
cortisol	0
ratio	0
in	0
the	0
depressed	0
group	0
suggesting	0
an	0
inability	0
of	0
the	0
raised	0
cortisol	0
levels	0
to	0
induce	0
enzyme	0
expression	0
and	0
this	0
ratio	0
may	0
provide	0
a	0
useful	0
biochemical	0
marker	0
of	0
cortisol	0
receptor	0
function	0
.	0

Although	0
there	0
was	0
an	0
increase	0
in	0
the	0
plasma	0
activity	0
of	0
the	0
alpha	9
2	10
,	10
6	10
sialyltransferase	10
isozyme	10
in	0
the	0
schizophrenic	0
group	0
,	0
no	0
other	0
changes	0
were	0
determined	0
.	0

Therefore	0
,	0
while	0
the	0
total	0
plasma	9
sialyltransferase	10
:	0
cortisol	0
ratio	0
reflects	0
HPA	0
axis	0
function	0
,	0
alterations	0
in	0
specific	0
isozyme	0
activity	0
may	0
also	0
be	0
associated	0
with	0
other	0
CNS	0
disease	0
states	0
.	0

Regulation	0
of	0
CD95	9
(	10
Fas	10
)	10
ligand	10
expression	0
by	0
TCR	9
-mediated	0
signaling	0
events	0
.	0

Stimulation	0
of	0
mature	7
peripheral	8
T	8
cells	8
by	0
TCR	9
engagement	0
results	0
in	0
activation	0
of	0
signals	0
that	0
drive	0
induction	0
of	0
cytokine	9
gene	0
expression	0
and	0
clonal	0
expansion	0
.	0

However	0
,	0
under	0
some	0
conditions	0
,	0
engagement	0
of	0
the	0
TCR	9
leads	0
instead	0
to	0
apoptosis	0
.	0

Recent	0
studies	0
demonstrate	0
that	0
TCR	9
-stimulated	0
apoptosis	0
requires	0
expression	0
of	0
CD95	9
ligand	10
on	0
activated	7
T	8
cells	8
followed	0
by	0
an	0
interaction	0
between	0
CD95	9
ligand	10
and	0
the	0
CD95	9
receptor	10
also	0
expressed	0
on	0
this	0
population	0
.	0

The	0
experiments	0
reported	0
in	0
this	0
study	0
were	0
designed	0
to	0
address	0
the	0
signaling	0
events	0
triggered	0
by	0
TCR	9
engagement	0
that	0
are	0
important	0
for	0
regulating	0
CD95	9
ligand	10
gene	0
expression	0
.	0

To	0
approach	0
this	0
,	0
we	0
generated	0
a	0
luciferase	1
reporter	2
construct	2
containing	0
elements	0
of	0
the	0
CD95	9
ligand	10
promoter	0
.	0

Using	0
a	0
previously	0
described	0
mutant	0
of	0
the	0
Jurkat	5
T	6
cell	6
line	6
,	0
we	0
show	0
that	0
proximal	0
signaling	0
events	0
dependent	0
on	0
the	0
presence	0
of	0
the	0
CD45	9
tyrosine	10
phosphatase	10
are	0
required	0
for	0
TCR	9
-stimulated	0
CD95	9
ligand	10
expression	0
.	0

Transient	0
transfection	0
studies	0
demonstrate	0
further	0
that	0
TCR	9
-stimulated	0
activation	0
of	0
the	0
Ras	9
signaling	0
pathway	0
is	0
required	0
for	0
optimal	0
activation	0
of	0
CD95	9
ligand	10
.	0

Next	0
,	0
in	0
an	0
effort	0
to	0
determine	0
critical	0
transcription	9
factors	10
that	0
regulate	0
CD95	9
ligand	10
expression	0
,	0
we	0
demonstrate	0
a	0
cyclosporin	1
A-sensitive	2
nuclear	2
factor-AT	2
response	2
element	2
in	0
the	0
promoter	1
region	2
of	0
this	0
gene	0
that	0
is	0
critical	0
for	0
optimal	0
CD95	9
ligand	10
reporter	0
activity	0
in	0
stimulated	7
T	8
cells	8
.	0

Together	0
,	0
these	0
studies	0
begin	0
a	0
dissection	0
of	0
the	0
biochemical	0
events	0
that	0
lead	0
to	0
expression	0
of	0
CD95	9
ligand	10
,	0
a	0
required	0
step	0
for	0
TCR	9
-induced	0
apoptosis	0
.	0

Reactive	0
oxygen	0
species	0
and	0
antioxidants	0
in	0
inflammatory	0
diseases	0
.	0

This	0
paper	0
aims	0
to	0
review	0
the	0
role	0
of	0
free	0
radical-induced	0
tissue	0
damage	0
and	0
antioxidant	0
defence	0
mechanisms	0
in	0
inflammatory	0
diseases	0
that	0
involve	0
pathogenic	0
processes	0
similar	0
to	0
the	0
periodontal	0
diseases	0
.	0

There	0
is	0
a	0
clearly	0
defined	0
and	0
substantial	0
role	0
for	0
free	0
radicals	0
or	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
in	0
periodontitis	0
,	0
but	0
little	0
research	0
has	0
been	0
performed	0
in	0
this	0
area	0
.	0

This	0
paper	0
reviews	0
the	0
considerable	0
data	0
available	0
relating	0
ROS	0
activity	0
and	0
antioxidant	0
defence	0
to	0
inflammatory	0
diseases	0
and	0
attempts	0
to	0
draw	0
parallels	0
with	0
periodontitis	0
,	0
in	0
an	0
effort	0
to	0
stimulate	0
more	0
periodontal	0
research	0
in	0
this	0
important	0
area	0
.	0

The	0
recent	0
discovery	0
of	0
the	0
transcription	9
factor	10
nuclear	10
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
reviewed	0
and	0
several	0
potential	0
pathways	0
for	0
cytokine	9
-induced	0
periodontal	0
tissue	0
damage	0
,	0
mediated	0
by	0
NF-kappa	9
B1	10
are	0
discussed	0
.	0

Emphasis	0
is	0
placed	0
on	0
cytokines	9
that	0
have	0
been	0
studied	0
in	0
periodontitis	0
,	0
principally	0
TNF-alpha	9
,	0
IL-1	9
,	0
IL-6	9
,	0
IL-8	9
and	0
beta-interferon	9
.	0

The	0
link	0
between	0
cellular	0
production	0
of	0
such	0
important	0
mediators	0
of	0
inflammation	0
and	0
the	0
antioxidant	0
(	0
AO	0
)	0
thiols	0
,	0
cysteine	0
and	0
reduced	0
glutathione	0
(	0
GSH	0
)	0
,	0
is	0
discussed	0
and	0
it	0
is	0
hypothesised	0
that	0
NF-kappa	9
B	10
antagonists	0
may	0
offer	0
important	0
therapeutic	0
benefits	0
.	0

Mutations	0
in	0
the	0
TSC2	1
gene	2
:	0
analysis	0
of	0
the	0
complete	0
coding	0
sequence	0
using	0
the	0
protein	0
truncation	0
test	0
(	0
PTT	0
)	0
.	0

Mutations	0
in	0
the	0
TSC2	1
gene	2
on	0
chromosome	1
16p13.3	2
are	0
responsible	0
for	0
approximately	0
50	0
%	0
of	0
familial	0
tuberous	0
sclerosis	0
(	0
TSC	0
)	0
.	0

The	0
gene	0
has	0
41	1
small	2
exons	2
spanning	0
45	1
kb	2
of	0
genomic	1
DNA	2
and	0
encoding	0
a	0
5.5	3
kb	4
mRNA	4
.	0

Large	0
germline	0
deletions	0
of	0
TSC2	1
occur	0
in	0
<	0
5	0
%	0
of	0
cases	0
,	0
and	0
a	0
number	0
of	0
small	0
intragenic	0
mutations	0
have	0
been	0
described	0
.	0

We	0
analysed	0
mRNA	0
from	0
18	0
unrelated	0
cases	0
of	0
TSC	0
for	0
TSC2	1
mutations	2
using	0
the	0
protein	0
truncation	0
test	0
(	0
PTT	0
)	0
.	0

Three	0
cases	0
were	0
predicted	0
to	0
be	0
TSC2	1
mutations	2
on	0
the	0
basis	0
of	0
linkage	0
analysis	0
or	0
because	0
a	0
hamartoma	0
from	0
the	0
patient	0
showed	0
loss	0
of	0
heterozygosity	0
for	0
16p13.3	1
markers	2
.	0

Three	0
overlapping	0
PCR	1
products	2
,	0
covering	0
the	0
complete	0
coding	0
sequence	0
of	0
mRNA	3
,	0
were	0
generated	0
from	0
lymphoblastoid	5
cell	6
lines	6
,	0
translated	0
into	0
35S-methionine	9
labelled	10
protein	10
,	0
and	0
analysed	0
by	0
SDS-PAGE	0
.	0

PCR	1
products	2
showing	0
PTT	0
shifts	0
were	0
directly	0
sequenced	0
,	0
and	0
mutations	0
confirmed	0
by	0
restriction	0
enzyme	0
digestion	0
where	0
possible	0
.	0

Six	0
PTT	0
shifts	0
were	0
identified	0
.	0

Five	0
of	0
these	0
were	0
caused	0
by	0
mutations	0
predicted	0
to	0
produce	0
a	0
truncated	9
protein	10
:	0
(	0
i	0
)	0
a	0
sporadic	0
case	0
showed	0
a	0
32	1
bp	2
deletion	2
in	0
exon	3
11	4
,	0
and	0
a	0
mutant	3
mRNA	4
without	0
exon	3
11	4
was	0
produced	0
;	0
the	0
normal	0
exon	0
10	0
was	0
also	0
spliced	0
out	0
;	0
(	0
ii	0
)	0
a	0
sporadic	0
case	0
had	0
a	0
1	1
bp	2
deletion	2
in	0
exon	3
12	4
(	0
1634delT	3
)	0
;	0
(	0
iii	0
)	0
a	0
TSC2-linked	3
mother	4
and	4
daughter	4
pair	4
had	0
a	0
G	0
--	0
>	0
T	0
transversion	0
in	0
exon	3
23	4
(	0
G2715T	3
)	0
introducing	0
a	0
cryptic	0
splice	0
site	0
causing	0
a	0
29	0
bp	0
truncation	0
of	0
mRNA	0
from	0
exon	3
23	4
;	0
(	0
iv	0
)	0
a	0
sporadic	0
case	0
showed	0
a	0
2	1
bp	2
deletion	2
in	0
exon	3
36	4
;	0
(	0
v	0
)	0
a	0
sporadic	0
case	0
showed	0
a	0
1	1
bp	2
insertion	2
disrupting	0
the	0
donor	0
splice	0
site	0
of	0
exon	3
37	4
(	0
5007+2insA	3
)	0
,	0
resulting	0
in	0
the	0
use	0
of	0
an	0
upstream	3
exonic	4
cryptic	4
splice	4
site	4
to	0
cause	0
a	0
29	3
bp	4
truncation	4
of	0
mRNA	3
from	0
exon	3
37	4
.	0

In	0
one	0
case	0
,	0
the	0
PTT	0
shift	0
was	0
explained	0
by	0
in-frame	0
splicing	0
out	0
of	0
exon	3
10	4
,	0
in	0
the	0
presence	0
of	0
a	0
normal	1
exon	2
10	2
genomic	2
sequence	2
.	0

Alternative	0
splicing	0
of	0
exon	3
10	4
of	0
the	0
TSC2	1
gene	2
may	0
be	0
a	0
normal	0
variant	0
.	0

Three	0
3rd	0
base	0
substitution	0
polymorphisms	0
were	0
also	0
detected	0
during	0
direct	0
sequencing	0
of	0
PCR	1
products	2
.	0

Confirmed	0
mutations	0
were	0
identified	0
in	0
28	0
%	0
of	0
the	0
families	0
studied	0
and	0
on	0
the	0
assumption	0
that	0
half	0
of	0
the	0
sporadic	0
cases	0
should	0
have	0
TSC2	1
mutations	2
,	0
a	0
crude	0
estimate	0
of	0
the	0
detection	0
rate	0
would	0
be	0
60	0
%	0
.	0

This	0
compares	0
favourably	0
with	0
other	0
screening	0
methods	0
used	0
for	0
TSC2	1
,	0
notably	0
SSCP	0
,	0
and	0
since	0
PTT	0
involves	0
much	0
less	0
work	0
it	0
may	0
be	0
the	0
method	0
of	0
choice	0
.	0

alpha-Tocopheryl	0
succinate	0
inhibits	0
monocytic	0
cell	0
adhesion	0
to	0
endothelial	7
cells	8
by	0
suppressing	0
NF-kappa	9
B	10
mobilization	0
.	0

The	0
adherence	0
of	0
monocytes	7
to	0
activated	0
endothelium	0
is	0
an	0
early	0
event	0
in	0
atherogenesis	0
.	0

Because	0
antioxidants	0
have	0
been	0
considered	0
to	0
be	0
of	0
antiatherosclerotic	0
potential	0
,	0
we	0
investigated	0
the	0
effects	0
of	0
alpha-tocopherol	0
(	0
TCP	0
)	0
and	0
its	0
acetate	0
and	0
succinate	0
esters	0
on	0
monocyte	0
adhesion	0
to	0
cytokine-stimulated	5
human	6
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVEC	5
)	0
.	0

Endothelial	7
cells	8
were	0
treated	0
with	0
TCP	0
,	0
alpha-tocopherol	0
acetate	0
(	0
TCP	0
acetate	0
)	0
,	0
or	0
alpha-tocopheryl	0
succinate	0
(	0
TCP	0
succinate	0
)	0
before	0
stimulation	0
with	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
;	0
10	0
U/ml	0
,	0
6	0
h	0
)	0
or	0
interleukin-1	9
beta	10
(	0
IL-1	9
beta	10
;	0
10	0
U/ml	0
,	0
6	0
h	0
)	0
.	0

Cytokine-stimulated	0
cell	0
surface	0
expression	0
of	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
,	0
CD106	9
)	0
and	0
E-selectin	9
(	0
ELAM-1	9
,	0
CD62E	9
)	0
,	0
but	0
not	0
of	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
,	0
CD54	9
)	0
,	0
was	0
time-	0
and	0
dose-dependently	0
inhibited	0
by	0
TCP	0
succinate	0
but	0
not	0
by	0
TCP	0
or	0
TCP	0
acetate	0
.	0

TCP	0
succinate	0
(	0
200	0
microM	0
,	0
24	0
h	0
)	0
reduced	0
TNF-induced	9
VCAM-1	10
and	0
E-selectin	9
expression	0
from	0
a	0
specific	0
mean	0
fluorescence	0
intensity	0
of	0
151	0
+/-	0
28	0
to	0
12	0
+/-	0
4	0
channels	0
and	0
from	0
225	0
+/-	0
38	0
to	0
79	0
+/-	0
21	0
channels	0
,	0
respectively	0
.	0

Succinate	0
alone	0
had	0
no	0
effect	0
.	0

Decreased	0
adhesion	9
molecule	10
expression	0
was	0
associated	0
with	0
a	0
reduction	0
of	0
monocytic	0
cell	0
adhesion	0
.	0

TCP	0
succinate	0
(	0
20	0
microM	0
,	0
72	0
h	0
)	0
,	0
but	0
not	0
TCP	0
(	0
200	0
microM	0
,	0
72	0
h	0
)	0
,	0
reduced	0
U-937	5
cell	6
adhesion	0
to	0
TNF-alpha-stimulated	5
(	6
10	6
U/ml	6
,	6
6	6
h	6
)	6
HUVEC	6
by	0
30	0
%	0
(	0
P	0
<	0
0.025	0
)	0
and	0
to	0
IL-1	5
beta-stimulated	6
HUVEC	6
by	0
56	0
%	0
(	0
P	0
<	0
0.010	0
)	0
.	0

Electrophoretic	0
mobility-shift	0
assays	0
of	0
HUVEC	5
nuclear	9
proteins	10
revealed	0
a	0
decrease	0
in	0
TNF-alpha-stimulated	9
nuclear	10
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
after	0
pretreatment	0
of	0
HUVEC	5
with	0
TCP	0
succinate	0
but	0
not	0
with	0
TCP	0
,	0
TCP	0
acetate	0
,	0
or	0
succinate	0
alone	0
.	0

In	0
conclusion	0
,	0
we	0
demonstrate	0
that	0
the	0
vitamin	0
E	0
derivative	0
TCP	0
succinate	0
prevents	0
monocytic	0
cell	0
adhesion	0
to	0
cytokine-stimulated	0
endothelial	7
cells	8
by	0
inhibiting	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
further	0
emphasizing	0
the	0
antiatherosclerotic	0
potential	0
of	0
lipid	0
soluble	0
antioxidants	0
.	0

The	0
product	0
of	0
the	0
murine	1
homolog	2
of	0
the	0
Drosophila	1
extra	2
sex	2
combs	2
gene	2
displays	0
transcriptional	9
repressor	10
activity	0
.	0

The	0
heterogeneous	9
nuclear	10
ribonucleoprotein	10
K	10
protein	10
represents	0
a	0
novel	0
class	0
of	0
proteins	0
that	0
may	0
act	0
as	0
docking	0
platforms	0
that	0
orchestrate	0
cross-talk	0
among	0
molecules	0
involved	0
in	0
signal	0
transduction	0
and	0
gene	0
expression	0
.	0

Using	0
a	0
fragment	0
of	0
K	9
protein	10
as	0
bait	0
in	0
the	0
yeast	0
two-hybrid	0
screen	0
,	0
we	0
isolated	0
a	0
cDNA	1
that	0
encodes	0
a	0
protein	0
whose	0
primary	0
structure	0
has	0
extensive	0
similarity	0
to	0
the	0
Drosophila	9
melanogaster	10
extra	10
sex	10
combs	10
(	10
esc	10
)	10
gene	10
product	10
,	0
Esc	9
,	0
a	0
putative	0
silencer	0
of	0
homeotic	1
genes	2
.	0

The	0
cDNA	1
that	0
we	0
isolated	0
is	0
identical	0
to	0
the	0
cDNA	1
of	0
the	0
recently	0
positionally	0
cloned	0
mouse	1
embryonic	2
ectoderm	2
development	2
gene	2
,	0
eed	0
.	0

Like	0
Esc	9
,	0
Eed	9
contains	0
six	0
WD-40	9
repeats	10
in	0
the	0
C-terminal	9
half	10
of	0
the	0
protein	0
and	0
is	0
thought	0
to	0
repress	0
homeotic	0
gene	0
expression	0
during	0
mouse	0
embryogenesis	0
.	0

Eed	9
binds	0
to	0
K	9
protein	10
through	0
a	0
domain	0
in	0
its	0
N	9
terminus	10
,	0
but	0
interestingly	0
,	0
this	0
domain	0
is	0
not	0
found	0
in	0
the	0
Drosophila	0
Esc	9
.	0

Gal4-Eed	9
fusion	10
protein	10
represses	0
transcription	0
of	0
a	0
reporter	0
gene	0
driven	0
by	0
a	0
promoter	0
that	0
contains	0
Gal4-binding	1
DNA	2
elements	2
.	0

Eed	9
also	0
represses	0
transcription	0
when	0
recruited	0
to	0
a	0
target	0
promoter	0
by	0
Gal4-K	9
protein	10
.	0

Point	0
mutations	0
within	0
the	0
eed	0
gene	0
that	0
are	0
responsible	0
for	0
severe	0
embryonic	0
development	0
abnormalities	0
abolished	0
the	0
transcriptional	9
repressor	10
activity	0
of	0
Eed	9
.	0

Results	0
of	0
this	0
study	0
suggest	0
that	0
Eed	9
-restricted	0
homeotic	0
gene	0
expression	0
during	0
embryogenesis	0
reflects	0
the	0
action	0
of	0
Eed	9
as	0
a	0
transcriptional	9
repressor	10
.	0

The	0
Eed	9
-mediated	0
transcriptional	0
effects	0
are	0
likely	0
to	0
reflect	0
the	0
interaction	0
of	0
Eed	9
with	0
multiple	0
molecular	0
partners	0
,	0
including	0
K	9
protein	10
.	0

Interferons	9
up-regulate	0
STAT1	9
,	0
STAT2	9
,	0
and	0
IRF	9
family	0
transcription	0
factor	0
gene	0
expression	0
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
and	0
macrophages	7
.	0

IFN	9
signaling	0
is	0
mediated	0
by	0
binding	0
of	0
IFNs	9
to	0
their	0
receptors	0
and	0
subsequent	0
activation	0
of	0
Janus	0
tyrosine	0
kinase	0
(	0
JAK	9
)	0
-	0
STAT	9
signaling	0
pathway	0
.	0

Stimulation	0
of	0
cells	0
with	0
IFN-alpha	9
leads	0
to	0
the	0
assembly	0
of	0
IFN-stimulated	9
gene	10
factor	10
3	10
transcription	10
factor	10
complex	10
formed	0
by	0
STAT1	9
,	0
STAT2	9
,	0
and	0
p48	9
protein	10
.	0

IFN-gamma	9
signaling	0
is	0
mediated	0
by	0
homodimeric	9
STAT1	10
protein	10
.	0

Although	0
these	0
signaling	0
molecules	0
are	0
expressed	0
constitutively	0
,	0
there	0
is	0
also	0
evidence	0
of	0
transcriptional	0
regulation	0
by	0
IFNs	9
.	0

We	0
have	0
characterized	0
the	0
expression	0
of	0
STAT	9
and	10
IFN	10
regulatory	10
factor	10
(	10
IRF	10
)	10
family	10
transcription	10
factors	10
in	0
primary	7
human	8
blood	8
mononuclear	8
cells	8
and	0
macrophages	7
in	0
response	0
to	0
IFN-alpha	0
and	0
IFN-gamma	0
stimulation	0
.	0

We	0
show	0
that	0
IFN-alpha	9
and	0
IFN-gamma	9
rapidly	0
and	0
efficiently	0
enhanced	0
STAT1	9
,	0
STAT2	9
,	0
p48	9
,	0
and	0
IRF-1	1
gene	2
expression	0
.	0

IFN-gamma	9
induced	0
IRF-1	1
gene	2
expression	0
more	0
strongly	0
than	0
IFN-alpha	9
.	0

Stimulation	0
experiments	0
in	0
the	0
presence	0
of	0
protein	0
synthesis	0
inhibitor	0
,	0
cycloheximide	0
,	0
suggested	0
that	0
these	0
genes	0
were	0
activated	0
directly	0
by	0
IFNs	9
.	0

IRF-2	1
gene	2
was	0
apparently	0
only	0
weakly	0
responsive	0
to	0
IFNs	9
in	0
these	0
cells	0
.	0

When	0
macrophages	7
were	0
pretreated	0
with	0
low	0
doses	0
of	0
IFN-gamma	9
and	0
then	0
stimulated	0
with	0
IFN-alpha	9
,	0
clearly	0
enhanced	0
formation	0
of	0
specific	0
transcription	9
factor	10
complexes	0
was	0
detected	0
.	0

This	0
suggests	0
that	0
higher	0
intracellular	0
levels	0
of	0
STAT1	9
,	0
STAT2	9
,	0
and	0
p48	9
protein	10
may	0
result	0
in	0
enhanced	0
signal	0
transduction	0
for	0
cytokines	9
utilizing	0
these	0
transcription	9
factors	10
.	0

The	0
role	0
of	0
nuclear	9
factor-kappa	10
B	10
in	0
cytokine	1
gene	2
regulation	0
.	0

Transcription	9
factors	10
are	0
DNA-binding	9
proteins	10
that	0
regulate	0
gene	0
expression	0
.	0

Nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
a	0
critical	0
transcription	9
factor	10
for	0
maximal	0
expression	0
of	0
many	0
cytokines	9
that	0
are	0
involved	0
in	0
the	0
pathogenesis	0
of	0
inflammatory	0
diseases	0
,	0
such	0
as	0
adult	0
respiratory	0
distress	0
syndrome	0
(	0
ARDS	0
)	0
and	0
sepsis	0
syndrome	0
.	0

Activation	0
and	0
regulation	0
of	0
NF-kappa	9
B	10
are	0
tightly	0
controlled	0
by	0
a	0
group	0
of	0
inhibitory	9
proteins	10
(	0
I	9
kappa	10
B	10
)	0
that	0
sequester	0
NF-kappa	9
B	10
in	0
the	0
cytoplasm	0
of	0
immune/inflammatory	7
effector	8
cells	8
.	0

NF-kappa	9
B	10
activation	0
involves	0
signaled	0
phosphorylation	0
,	0
ubiquitination	0
,	0
and	0
proteolysis	0
of	0
I	9
kappa	10
B	10
.	0

Liberated	0
NF-kappa	9
B	10
migrates	0
to	0
the	0
nucleus	0
,	0
where	0
it	0
binds	0
to	0
specific	1
promoter	2
sites	2
and	0
activates	0
gene	0
transcription	0
.	0

The	0
activation	0
of	0
NF-kappa	9
B	10
initiates	0
both	0
extracellular	0
and	0
intracellular	0
regulatory	0
events	0
that	0
result	0
in	0
autoregulation	0
of	0
the	0
inflammatory	0
cascade	0
through	0
modulation	0
of	0
NF-kappa	9
B	10
activation	0
.	0

Recently	0
,	0
activation	0
of	0
NF-kappa	9
B	10
has	0
been	0
linked	0
to	0
ARDS	0
and	0
has	0
been	0
shown	0
to	0
be	0
a	0
critical	0
proximal	0
step	0
in	0
the	0
initiation	0
of	0
neutrophilic	0
inflammation	0
in	0
animal	0
models	0
.	0

Activation	0
of	0
NF-kappa	9
B	10
can	0
be	0
inhibited	0
in	0
vivo	0
by	0
treatment	0
with	0
antioxidants	0
,	0
corticosteroids	0
,	0
and	0
the	0
induction	0
of	0
endotoxin	9
tolerance	0
.	0

Identification	0
of	0
more	0
specific	0
and	0
efficacious	0
inhibitors	0
of	0
NF-kappa	9
B	10
activation	0
might	0
prove	0
beneficial	0
for	0
the	0
treatment	0
of	0
cytokine-mediated	0
inflammatory	0
diseases	0
.	0

Chimeric	9
oncoprotein	10
E2a-Pbx1	9
induces	0
apoptosis	0
of	0
hematopoietic	7
cells	8
by	0
a	0
p53	9
-independent	0
mechanism	0
that	0
is	0
suppressed	0
by	0
Bcl-2	9
.	0

The	0
chimeric	9
oncoprotein	10
E2a-Pbx1	9
results	0
from	0
fusion	0
of	0
the	0
E2A	1
and	2
PBX1	2
genes	2
following	0
t	1
(	2
1	2
;	2
19	2
)	2
chromosomal	2
translocations	2
in	0
B	0
cell	0
precursor	0
acute	0
leukemias	0
.	0

Experimentally	0
B	7
cell	8
progenitors	8
do	0
not	0
tolerate	0
constitutive	0
expression	0
of	0
E2a-Pbx1	9
which	0
contrasts	0
with	0
transformation	0
of	0
several	0
other	0
cell	0
types	0
following	0
its	0
stable	0
expression	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

To	0
further	0
investigate	0
the	0
effects	0
of	0
E2a-Pbx1	9
on	0
the	0
B	7
cell	8
progenitors	8
,	0
we	0
conditionally	0
expressed	0
E2a-Pbx1	9
under	0
control	0
of	0
a	0
metal	0
response	0
element	0
in	0
hematopoietic	5
precursor	6
cell	6
lines	6
in	0
vitro	0
.	0

Inducible	0
expression	0
of	0
E2a-Pbx1	9
resulted	0
in	0
cell	0
death	0
with	0
the	0
morphologic	0
and	0
molecular	0
features	0
of	0
apoptosis	0
.	0

A	0
structure-function	0
analysis	0
demonstrated	0
that	0
induction	0
of	0
apoptosis	0
was	0
not	0
a	0
dominant-negative	0
effect	0
of	0
the	0
E2a	9
moiety	10
but	0
,	0
rather	0
,	0
required	0
the	0
DNA-binding	9
homeodomain	10
of	0
Pbx1	9
.	0

E2a-	0
Pbx1	9
-induced	0
apoptosis	0
proceeded	0
through	0
a	0
BCL2	9
-responsive	0
checkpoint	0
eventuating	0
in	0
PARP	9
inactivation	0
but	0
did	0
require	0
p53	9
.	0

Constitutive	0
expression	0
of	0
E2a-Pbx1	9
did	0
not	0
induce	0
apoptosis	0
or	0
continued	0
cycling	0
of	0
Rat-1	5
fibroblasts	6
in	0
low	0
serum	0
conditions	0
.	0

These	0
studies	0
demonstrate	0
that	0
E2a-Pbx1	9
initiates	0
programmed	0
cell	0
death	0
of	0
hematopoietic	7
precursers	8
by	0
a	0
mechanism	0
that	0
requires	0
its	0
chimeric	0
transcriptional	0
properties	0
,	0
but	0
,	0
unlike	0
other	0
nuclear	9
oncoproteins	10
,	0
is	0
independent	0
of	0
p53	9
.	0

CCAAT/enhancer	9
binding	10
protein	10
epsilon	10
is	0
preferentially	0
up-regulated	0
during	0
granulocytic	0
differentiation	0
and	0
its	0
functional	0
versatility	0
is	0
determined	0
by	0
alternative	0
use	0
of	0
promoters	1
and	0
differential	0
splicing	0
.	0

CCAAT/enhancer	9
binding	10
protein	10
(	10
C/EBP	10
)	10
epsilon	10
is	0
a	0
recently	0
cloned	0
member	0
of	0
the	0
C/EBP	9
family	10
of	0
transcription	9
factors	10
and	0
is	0
expressed	0
exclusively	0
in	0
cells	0
of	0
hematopoietic	0
origin	0
.	0

The	0
human	1
C/EBPepsilon	2
gene	2
is	0
transcribed	0
by	0
two	0
alternative	0
promoters	1
,	0
Palpha	1
and	0
Pbeta	1
.	0

A	0
combination	0
of	0
differential	0
splicing	0
and	0
alternative	0
use	0
of	0
promoters	1
generates	0
four	0
mRNA	3
isoforms	4
,	0
of	0
2.6	0
kb	0
and	0
1.3-1.5	0
kb	0
in	0
size	0
.	0

These	0
transcripts	0
can	0
encode	0
three	0
proteins	0
of	0
calculated	0
molecular	0
mass	0
32.2	3
kDa	4
,	0
27.8	3
kDa	4
,	0
and	0
14.3	3
kDa	4
.	0

Accordingly	0
,	0
Western	0
blots	0
with	0
antibodies	9
specific	0
for	0
the	0
DNA-binding	0
domain	0
,	0
that	0
is	0
common	0
to	0
all	0
forms	0
,	0
identify	0
multiple	0
proteins	0
.	0

C/EBPepsilon	3
mRNA	4
was	0
greatly	0
induced	0
during	0
in	0
vitro	0
granulocytic	0
differentiation	0
of	0
human	7
primary	8
CD34	8
(	8
+	8
)	8
cells	8
.	0

Retinoic	0
acid	0
treatment	0
of	0
HL60	5
promyelocytic	6
leukemia	6
cells	6
for	0
24	0
hr	0
induced	0
C/EBPepsilon	3
mRNA	4
levels	0
by	0
4-fold	0
,	0
while	0
prolonged	0
treatment	0
gradually	0
reduced	0
mRNA	0
expression	0
to	0
pretreatment	0
levels	0
.	0

Transient	0
transfection	0
experiments	0
with	0
expression	0
vectors	0
for	0
two	0
of	0
the	0
isoforms	0
demonstrated	0
that	0
the	0
32.2-kDa	9
protein	10
is	0
an	0
activator	0
of	0
transcription	0
of	0
granulocyte	1
colony-stimulating	2
factor	2
receptor	2
promoter	2
,	0
while	0
the	0
14.3-kDa	9
protein	10
is	0
not	0
.	0

Thus	0
,	0
C/EBPepsilon	9
is	0
regulated	0
in	0
a	0
complex	0
fashion	0
and	0
may	0
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
genes	0
involved	0
in	0
myeloid	0
differentiation	0
.	0

Effects	0
of	0
TPA	9
,	0
bryostatin	9
1	10
,	0
and	0
retinoic	0
acid	0
on	0
PO-B	9
,	0
AP-1	9
,	0
and	0
AP-2	9
DNA	0
binding	0
during	0
HL-60	0
differentiation	0
.	0

PO-B	9
was	0
originally	0
characterized	0
as	0
a	0
transcriptional	9
regulatory	10
factor	10
of	0
the	0
pro-opiomelanocortin	1
(	2
POMC	2
)	2
gene	2
;	0
however	0
,	0
it	0
has	0
become	0
increasingly	0
clear	0
that	0
this	0
protein	0
may	0
be	0
active	0
in	0
tissues	0
outside	0
the	0
pituitary	0
,	0
since	0
it	0
is	0
present	0
in	0
diverse	0
cell	0
types	0
,	0
including	0
differentiated	0
HL-60	7
promyelocytic	8
leukemia	8
cells	8
.	0

We	0
previously	0
showed	0
that	0
PO-B	9
DNA-binding	0
is	0
progressively	0
induced	0
during	0
differentiation	0
of	0
promyelomonocytic	5
leukemic	6
HL-60	6
cells	6
to	0
the	0
macrophage-like	7
lineage	8
(	0
with	0
phorbol	0
esters	0
)	0
.	0

We	0
now	0
report	0
that	0
PO-B	9
DNA-binding	0
in	0
HL-60	5
cells	6
is	0
similarly	0
induced	0
during	0
differentiation	0
to	0
the	0
granulocytic	7
lineage	8
(	0
with	0
either	0
retinoic	0
acid	0
or	0
dimethylsulfoxide	0
)	0
.	0

Either	0
a	0
genetic	0
or	0
pharmacologic	0
blockade	0
of	0
HL-60	0
differentiation	0
prohibited	0
these	0
inductive	0
effects	0
.	0

These	0
studies	0
have	0
prompted	0
our	0
interest	0
in	0
the	0
dynamics	0
of	0
other	0
transcription	9
factor	10
changes	0
during	0
HL-60	0
differentiation	0
.	0

Of	0
these	0
,	0
we	0
observed	0
that	0
another	0
transcription	9
factor	10
(	0
AP-1	9
)	0
is	0
also	0
robustly	0
induced	0
at	0
the	0
DNA-binding	0
level	0
during	0
macrophage-like	0
HL-60	0
differentiation	0
,	0
but	0
not	0
during	0
granulocytic	0
differentiation	0
.	0

Conversely	0
,	0
the	0
DNA-binding	0
of	0
the	0
transcription	9
factor	10
AP-2	9
was	0
slightly	0
reduced	0
by	0
TPA	9
-induced	0
HL-60	0
differentiation	0
but	0
unchanged	0
during	0
granulocyte	0
differentiation	0
.	0

From	0
these	0
data	0
,	0
we	0
conclude	0
that	0
the	0
induction	0
of	0
PO-B	9
DNA	0
binding	0
is	0
a	0
general	0
marker	0
of	0
HL-60	0
myelomonocytic	0
differentiation	0
,	0
but	0
that	0
qualitative	0
aspects	0
of	0
the	0
induction	0
of	0
additional	0
distinct	0
transcription	9
factors	10
,	0
such	0
as	0
AP-1	9
,	0
may	0
contribute	0
to	0
lineage-specific	0
determinants	0
of	0
cell	0
fate	0
.	0

A	0
novel	0
genetic	0
system	0
to	0
isolate	0
a	0
dominant	9
negative	10
effector	10
on	0
DNA-binding	0
activity	0
of	0
Oct-2	9
.	0

Recent	0
studies	0
have	0
revealed	0
that	0
interactions	0
between	0
transcription	9
factors	10
play	0
an	0
important	0
role	0
in	0
regulation	0
of	0
gene	0
expression	0
in	0
eukaryotic	7
cells	8
.	0

To	0
isolate	0
cDNA	0
clones	0
that	0
dominantly	0
inhibit	0
the	0
DNA-binding	0
activity	0
of	0
Oct-2	9
,	0
chosen	0
as	0
a	0
representative	0
factor	0
,	0
we	0
have	0
developed	0
a	0
novel	0
screening	0
system	0
.	0

This	0
employs	0
an	0
Escherichia	0
coli	0
tester	0
strain	0
carrying	0
a	0
modified	1
lac	2
operon	2
as	0
a	0
reporter	1
gene	2
,	0
with	0
the	0
lac	0
operator	0
sequence	0
replaced	0
by	0
an	0
octamer	1
sequence	2
.	0

Oct-2	9
expressed	0
in	0
this	0
tester	0
strain	0
represses	0
the	0
expression	0
of	0
the	0
reporter	0
gene	0
and	0
changes	0
the	0
phenotype	0
of	0
the	0
cell	0
from	0
Lac+to	0
Lac-	0
.	0

Introduction	0
of	0
a	0
cDNA	0
expression	0
library	0
prepared	0
from	0
a	0
human	5
T-cell	6
line	6
into	0
the	0
Oct-2	9
-harboring	0
tester	0
strain	0
allowed	0
selection	0
of	0
three	0
Lac+clones	0
out	0
of	0
1	0
x	0
10	0
(	0
5	0
)	0
transformants	0
.	0

One	0
of	0
them	0
,	0
hT86	0
,	0
encoding	0
a	0
putative	9
zinc	10
finger	10
protein	10
was	0
found	0
to	0
derepress	0
beta-galactosidase	9
activity	0
in	0
the	0
Oct-2	9
-harboring	0
tester	0
strain	0
at	0
the	0
transcriptional	0
level	0
.	0

In	0
gel	0
mobility	0
shift	0
assays	0
,	0
hT86	0
attenuated	0
the	0
intensity	0
of	0
the	0
retarded	0
band	0
composed	0
of	0
the	0
octamer	1
probe	2
and	0
Oct-2	9
,	0
suggesting	0
a	0
dominant	0
negative	0
effect	0
on	0
the	0
DNA-binding	0
activity	0
of	0
Oct-2	9
.	0

The	0
strategy	0
described	0
here	0
provides	0
a	0
new	0
approach	0
for	0
studying	0
protein-protein	0
interactions	0
that	0
govern	0
the	0
complex	0
regulation	0
of	0
gene	0
expression	0
.	0

Tap	9
:	0
a	0
novel	0
cellular	9
protein	10
that	0
interacts	0
with	0
tip	0
of	0
herpesvirus	0
saimiri	0
and	0
induces	0
lymphocyte	7
aggregation	0
.	0

Tip	0
of	0
herpesvirus	0
saimiri	0
associates	0
with	0
Lck	9
and	0
down-regulates	0
Lck	9
-mediated	0
activation	0
.	0

We	0
identified	0
a	0
novel	0
cellular	0
Tip-associated	9
protein	10
(	0
Tap	9
)	0
by	0
a	0
yeast	0
two-hybrid	0
screen	0
.	0

Tap	9
associated	0
with	0
Tip	9
following	0
transient	0
expression	0
in	0
COS-1	5
cells	6
and	0
stable	0
expression	0
in	0
human	5
Jurkat-T	6
cells	6
.	0

Expression	0
of	0
Tip	9
and	0
Tap	9
in	0
Jurkat-T	5
cells	6
induced	0
dramatic	0
cell	0
aggregation	0
.	0

Aggregation	0
was	0
likely	0
caused	0
by	0
the	0
up-regulated	0
surface	0
expression	0
of	0
adhesion	9
molecules	10
including	0
integrin	9
alpha	10
,	0
L-selectin	9
,	0
ICAM-3	9
,	0
and	0
H-CAM	9
.	0

Furthermore	0
,	0
NF-kappaB	9
transcriptional	10
factor	10
of	0
aggregated	0
cells	0
had	0
approximately	0
40-fold	0
higher	0
activity	0
than	0
that	0
of	0
parental	7
cells	8
.	0

Thus	0
,	0
Tap	9
is	0
likely	0
to	0
be	0
an	0
important	0
cellular	0
mediator	0
of	0
Tip	9
function	0
in	0
T	0
cell	0
transformation	0
by	0
herpesvirus	0
saimiri	0
.	0

Human	7
monocyte	8
binding	0
to	0
fibronectin	9
enhances	0
IFN-gamma	9
-induced	0
early	0
signaling	0
events	0
.	0

Leukocyte	9
integrins	10
are	0
fundamentally	0
important	0
in	0
modulating	0
adhesion	0
to	0
extracellular	0
matrix	0
components	0
and	0
to	0
other	0
cells	0
.	0

This	0
integrin-mediated	0
adhesion	0
controls	0
leukocyte	0
arrest	0
and	0
extravasation	0
during	0
the	0
onset	0
of	0
inflammatory	0
responses	0
.	0

Moreover	0
,	0
integrin	9
-ligand	0
interactions	0
trigger	0
signaling	0
pathways	0
that	0
may	0
influence	0
leukocyte	0
phenotype	0
and	0
function	0
at	0
sites	0
of	0
inflammation	0
.	0

In	0
the	0
current	0
studies	0
,	0
we	0
evaluated	0
the	0
combinatorial	0
effects	0
of	0
monocyte	0
adhesion	0
and	0
IFN-gamma	9
on	0
intracellular	0
signaling	0
pathways	0
.	0

IFN-gamma	9
triggers	0
a	0
well-defined	0
signal	0
transduction	0
pathway	0
,	0
which	0
although	0
not	0
directly	0
stimulated	0
by	0
monocyte	0
adherence	0
to	0
fibronectin	9
or	0
arginine-glycine-aspartate	9
(	10
RGD	10
)	10
-coated	10
substrata	10
,	0
was	0
enhanced	0
significantly	0
in	0
these	0
matrix-adherent	7
cells	8
.	0

Compared	0
with	0
monocytes	0
in	0
suspension	0
or	0
adherent	0
on	0
plastic	0
surfaces	0
,	0
monocytes	0
adherent	0
to	0
fibronectin	9
or	0
RGD	0
exhibited	0
a	0
greater	0
than	0
threefold	0
increase	0
in	0
steady	0
state	0
levels	0
of	0
IFN-gamma-induced	3
mRNA	4
for	0
the	0
high	9
affinity	10
Fc	10
gammaRI	10
receptor	10
.	0

By	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
this	0
increase	0
in	0
mRNA	3
was	0
associated	0
with	0
a	0
5-	0
to	0
10-fold	0
increase	0
in	0
the	0
STAT1-containing	9
DNA-binding	10
complex	10
that	0
binds	0
to	0
Fc	1
gammaRI	2
promoter	2
elements	2
.	0

Furthermore	0
,	0
the	0
tyrosine	0
phosphorylation	0
of	0
STAT1	9
and	0
the	0
tyrosine	9
kinases	10
JAK1	9
and	0
JAK2	9
was	0
enhanced	0
significantly	0
in	0
RGD-adherent	7
monocytes	8
compared	0
with	0
control	7
cells	8
.	0

These	0
results	0
suggest	0
a	0
novel	0
mechanism	0
by	0
which	0
integrin	9
-mediated	0
cell	0
adhesion	0
can	0
modulate	0
the	0
magnitude	0
of	0
cytokine	9
-induced	0
signal	0
transduction	0
pathways	0
,	0
thereby	0
amplifying	0
cellular	0
events	0
leading	0
to	0
monocyte	0
activation	0
and	0
inflammation	0
.	0

Surfactant	9
protein	10
A	10
activates	0
NF-kappa	9
B	10
in	0
the	0
THP-1	5
monocytic	6
cell	6
line	6
.	0

The	0
expression	0
of	0
many	0
genes	0
for	0
which	0
products	0
are	0
involved	0
in	0
inflammation	0
is	0
controlled	0
by	0
the	0
transcriptional	9
regulator	10
nuclear	10
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
.	0

Because	0
surfactant	9
protein	10
(	10
SP	10
)	10
A	10
is	0
involved	0
in	0
local	0
host	0
defense	0
in	0
the	0
lung	0
and	0
alters	0
immune	0
cell	0
function	0
by	0
modulating	0
the	0
expression	0
of	0
proinflammatory	9
cytokines	10
as	0
well	0
as	0
surface	9
proteins	10
involved	0
in	0
inflammation	0
,	0
we	0
hypothesized	0
that	0
SP-A	9
exerts	0
its	0
action	0
,	0
at	0
least	0
in	0
part	0
,	0
via	0
activation	0
of	0
NF-kappa	9
B	10
.	0

We	0
used	0
gel	0
shift	0
assays	0
to	0
determine	0
whether	0
SP-A	9
activated	0
NF-kappa	9
B	10
in	0
the	0
THP-1	5
cell	6
line	6
,	0
a	0
human	5
monocytic	6
cell	6
line	6
.	0

Activation	0
of	0
NF-kappa	9
B	10
in	0
THP-1	5
cells	6
by	0
SP-A	9
doses	0
as	0
low	0
as	0
1	0
microgram/ml	0
occurred	0
within	0
30	0
min	0
of	0
SP-A	9
treatment	0
,	0
peaked	0
at	0
60	0
min	0
,	0
and	0
then	0
declined	0
.	0

This	0
activation	0
is	0
inhibited	0
by	0
known	0
inhibitors	0
of	0
NF-kappa	9
B	10
or	0
by	0
simultaneous	0
treatment	0
of	0
the	0
cells	0
with	0
surfactant	0
lipids	0
.	0

Moreover	0
,	0
the	0
NF-kappa	9
B	10
inhibitors	10
blocked	0
SP-A	9
-dependent	0
increases	0
in	0
tumor	3
necrosis	4
factor-alpha	4
mRNA	4
levels	0
.	0

These	0
observations	0
suggest	0
a	0
mechanism	0
by	0
which	0
SP-A	9
plays	0
a	0
role	0
in	0
the	0
pathogenesis	0
of	0
some	0
lung	0
conditions	0
and	0
point	0
to	0
potential	0
therapeutic	0
measures	0
that	0
could	0
be	0
used	0
to	0
prevent	0
SP-A	9
induced	0
inflammation	0
in	0
the	0
lung	0
.	0

GABP	9
factors	10
bind	0
to	0
a	0
distal	1
interleukin	2
2	2
(	2
IL-2	2
)	2
enhancer	2
and	0
contribute	0
to	0
c-Raf	9
-mediated	0
increase	0
in	0
IL-2	9
induction	0
.	0

Triggering	0
of	0
the	0
T-cell	9
receptor-CD3	10
complex	10
activates	0
two	0
major	0
signal	0
cascades	0
in	0
T	7
lymphocytes	8
,	0
(	0
i	0
)	0
Ca2+-dependent	0
signal	0
cascades	0
and	0
(	0
ii	0
)	0
protein	9
kinase	10
cascades	0
.	0

Both	0
signal	0
cascades	0
contribute	0
to	0
the	0
induction	0
of	0
the	0
interleukin	1
2	2
(	2
IL-2	2
)	2
gene	2
during	0
T-cell	0
activation	0
.	0

Prominent	0
protein	9
kinase	10
cascades	0
are	0
those	0
that	0
activate	0
mitogen-activated	9
protein	10
(	10
MAP	10
)	10
kinases	10
.	0

We	0
show	0
here	0
that	0
c-Raf	9
,	0
which	0
is	0
at	0
the	0
helm	0
of	0
the	0
classic	0
MAP-	0
Erk	9
cascade	0
,	0
contributes	0
to	0
IL-2	9
induction	0
through	0
a	0
distal	1
enhancer	2
element	2
spanning	0
the	0
nucleotides	0
from	0
positions	0
-502	0
to	0
-413	0
in	0
front	0
of	0
the	0
transcriptional	0
start	0
site	0
of	0
the	0
IL-2	1
gene	2
.	0

Induction	0
of	0
this	0
distal	1
IL-2	2
enhancer	2
differs	0
from	0
induction	0
of	0
the	0
proximal	1
IL-2	2
promoter-enhancer	2
,	0
since	0
it	0
is	0
induced	0
by	0
phorbol	0
esters	0
alone	0
and	0
independent	0
from	0
Ca2+	0
signals	0
.	0

In	0
DNA-protein	0
binding	0
studies	0
,	0
we	0
detected	0
the	0
binding	0
of	0
transcription	9
factors	10
GABP	9
alpha	10
and	10
-beta	10
to	0
a	0
dyad	1
symmetry	2
element	2
(	0
DSE	1
)	0
of	0
the	0
distal	1
enhancer	2
,	0
which	0
is	0
formed	0
by	0
palindromic	1
binding	2
sites	2
of	0
Ets-like	9
factors	10
.	0

Introduction	0
of	0
point	0
mutations	0
suppressing	0
GABP	0
binding	0
to	0
the	0
DSE	1
interfered	0
with	0
the	0
induction	0
of	0
the	0
distal	1
enhancer	2
and	0
the	0
entire	0
IL-2	1
promoter-enhancer	2
,	0
while	0
overexpression	0
of	0
both	0
GABP	9
factors	10
enhanced	0
the	0
IL-2	1
promoter-enhancer	2
induction	0
.	0

Overexpression	0
of	0
BXB	9
,	0
a	0
constitutive	0
active	0
version	0
of	0
c-Raf	9
,	0
and	0
of	0
further	0
members	0
of	0
the	0
Ras	9
-	0
Raf	9
-	0
Erk	9
signal	0
cascade	0
exerted	0
an	0
increase	0
of	0
GABP	9
-mediated	0
promoter-enhancer	0
induction	0
.	0

In	0
conjunction	0
with	0
previously	0
published	0
data	0
on	0
c-Raf	9
-induced	0
phosphorylation	0
of	0
GABP	9
factors	10
(	0
E.Flory	0
,	0
A.	0
Hoffmeyer	0
,	0
U.Smola	0
,	0
U.R.Rapp	0
,	0
and	0
J.T.Bruder	0
,	0
J.Virol.70	0
:	0
2260-	0
2268	0
,	0
1996	0
)	0
,	0
these	0
results	0
indicate	0
a	0
contribution	0
of	0
GABP	9
factors	10
to	0
the	0
Raf	9
-mediated	0
enhancement	0
of	0
IL-2	9
induction	0
during	0
T-cell	0
activation	0
.	0

Lipopolysaccharide	0
induction	0
of	0
the	0
tumor	1
necrosis	2
factor-alpha	2
promoter	2
in	0
human	7
monocytic	8
cells	8
.	0

Regulation	0
by	0
Egr-1	9
,	0
c-Jun	9
,	0
and	0
NF-kappaB	9
transcription	9
factors	10
.	0

Biosynthesis	0
of	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
is	0
predominantly	0
by	0
cells	0
of	0
the	0
monocytic	7
lineage	8
.	0

This	0
study	0
examined	0
the	0
role	0
of	0
various	0
cis-acting	1
regulatory	2
elements	2
in	0
the	0
lipopolysaccharide	0
(	0
LPS	0
)	0
induction	0
of	0
the	0
human	1
TNF-alpha	2
promoter	2
in	0
cells	0
of	0
monocytic	7
lineage	8
.	0

Functional	0
analysis	0
of	0
monocytic	5
THP-1	6
cells	6
transfected	0
with	0
plasmids	1
containing	0
various	0
lengths	0
of	0
TNF-alpha	1
promoter	2
localized	0
enhancer	1
elements	2
in	0
a	0
region	0
(	0
-182	1
to	2
-37	2
base	2
pairs	2
(	0
bp	0
)	0
)	0
that	0
were	0
required	0
for	0
optimal	0
transcription	0
of	0
the	0
TNF-alpha	1
gene	2
in	0
response	0
to	0
LPS	0
.	0

Two	0
regions	0
were	0
identified	0
:	0
region	1
I	2
(	0
-182	1
to	2
-162	2
bp	2
)	0
contained	0
an	0
overlapping	0
Sp1/Egr-1	1
site	2
,	0
and	0
region	1
II	2
(	0
-119	1
to	2
-88	2
)	0
contained	0
CRE	1
and	0
NF-kappaB	1
(	2
designated	2
kappaB3	2
)	2
sites	2
.	0

In	0
unstimulated	0
THP-1	5
,	0
CRE-binding	9
protein	10
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
c-Jun	9
complexes	10
were	0
found	0
to	0
bind	0
to	0
the	0
CRE	1
site	2
.	0

LPS	0
stimulation	0
increased	0
the	0
binding	0
of	0
c-Jun-containing	9
complexes	10
.	0

In	0
addition	0
,	0
LPS	0
stimulation	0
induced	0
the	0
binding	0
of	0
cognate	0
nuclear	9
factors	10
to	0
the	0
Egr-1	1
and	2
kappaB3	2
sites	2
,	0
which	0
were	0
identified	0
as	0
Egr-1	9
and	0
p50/p65	9
,	0
respectively	0
.	0

The	0
CRE	1
and	2
kappaB3	2
sites	2
in	0
region	1
II	2
together	0
conferred	0
strong	0
LPS	0
responsiveness	0
to	0
a	0
heterologous	1
promoter	2
,	0
whereas	0
individually	0
they	0
failed	0
to	0
provide	0
transcriptional	0
activation	0
.	0

Furthermore	0
,	0
increasing	0
the	0
spacing	0
between	0
the	0
CRE	1
and	2
the	2
kappaB3	2
sites	2
completely	0
abolished	0
LPS	0
induction	0
,	0
suggesting	0
a	0
cooperative	0
interaction	0
between	0
c-Jun	9
complexes	10
and	0
p50/p65	9
.	0

These	0
studies	0
indicate	0
that	0
maximal	0
LPS	0
induction	0
of	0
the	0
TNF-alpha	1
promoter	2
is	0
mediated	0
by	0
concerted	0
participation	0
of	0
at	0
least	0
two	0
separate	0
cis-acting	1
regulatory	2
elements	2
.	0

Rescue	0
by	0
cytokines	9
of	0
apoptotic	0
cell	0
death	0
induced	0
by	0
IL-2	9
deprivation	0
of	0
human	5
antigen-specific	6
T	6
cell	6
clones	6
.	0

The	0
control	0
of	0
cell	0
survival	0
and	0
cell	0
death	0
is	0
of	0
central	0
importance	0
in	0
tissues	0
with	0
high	0
cell	0
turnover	0
such	0
as	0
the	0
lymphoid	0
system	0
.	0

We	0
have	0
examined	0
the	0
effect	0
of	0
cytokines	9
on	0
IL-2	9
deprivation-induced	0
apoptosis	0
of	0
human	5
antigen-specific	6
T	6
helper	6
clones	6
with	0
different	0
cytokine	9
production	0
profiles	0
.	0

We	0
found	0
that	0
IL-2	9
,	0
interferon-alpha	9
(	0
IFN-alpha	9
)	0
,	0
and	0
IFN-beta	9
inhibited	0
IL-2	9
deprivation	0
apoptosis	0
in	0
Th0	5
,	6
Th1	6
,	6
and	6
Th2	6
clones	6
.	0

We	0
also	0
found	0
that	0
IL-2	9
protects	0
T	5
cell	6
clones	6
from	0
IL-2	9
deprivation	0
apoptosis	0
accompanying	0
active	0
proliferation	0
and	0
enhanced	0
expression	0
of	0
P53	9
,	0
Rb	9
and	0
Bcl-xL	9
proteins	10
.	0

In	0
contrast	0
,	0
IFN-alpha/beta	9
rescued	0
T	5
cell	6
clones	6
from	0
apoptosis	0
without	0
active	0
proliferation	0
,	0
and	0
expression	0
of	0
apoptosis-associated	9
proteins	10
tested	0
so	0
far	0
was	0
unaffected	0
.	0

This	0
may	0
be	0
due	0
to	0
the	0
fact	0
that	0
T	7
cells	8
treated	0
with	0
IL-2	9
contained	0
those	0
located	0
in	0
S	0
+	0
G2/M	0
phases	0
of	0
the	0
cell	0
cycle	0
,	0
whereas	0
the	0
vast	0
majority	0
of	0
T	7
cells	8
treated	0
with	0
IFN-alpha/beta	9
were	0
located	0
in	0
G0/G1	0
phase	0
.	0

IFN-alpha/beta	9
specifically	0
induced	0
tyrosine	0
phosphorylation	0
and	0
translocation	0
into	0
nucleus	0
of	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
2	10
protein	10
in	0
the	0
T	5
cell	6
clones	6
.	0

In	0
addition	0
,	0
over-expression	0
of	0
STAT2	9
by	0
transfection	0
of	0
the	0
cDNA	0
prevented	0
apoptosis	0
of	0
the	0
T	5
cell	6
clones	6
.	0

Our	0
present	0
study	0
shows	0
that	0
IFN-alpha	9
and	10
-beta	10
mediate	0
anti-apoptotic	0
effect	0
through	0
other	0
pathways	0
than	0
that	0
of	0
IL-2	9
in	0
growth	0
factor	0
deprivation	0
apoptosis	0
.	0

Interleukin-10	9
inhibits	0
interferon-gamma-induced	0
intercellular	1
adhesion	2
molecule-1	2
gene	2
transcription	0
in	0
human	7
monocytes	8
.	0

Interleukin-10	9
(	0
IL-10	9
)	0
is	0
a	0
potent	0
monocyte	9
regulatory	10
cytokine	10
that	0
inhibits	0
gene	0
expression	0
of	0
proinflammatory	9
mediators	10
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
mechanism	0
by	0
which	0
IL-10	9
downregulates	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
on	0
the	0
cell	0
surface	0
of	0
normal	7
human	8
monocytes	8
activated	0
with	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
.	0

IL-10	9
inhibition	0
of	0
IFN-gamma	9
-induced	0
ICAM-1	9
expression	0
was	0
apparent	0
as	0
early	0
as	0
3	0
hours	0
and	0
was	0
blocked	0
by	0
an	0
anti-IL-10	9
antibody	10
but	0
not	0
by	0
an	0
isotype-matched	9
control	10
antibody	10
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
IL-10	9
reduced	0
the	0
accumulation	0
of	0
ICAM-1	3
mRNA	4
in	0
IFN-gamma-stimulated	5
monocytes	6
.	0

IL-10	9
inhibition	0
of	0
ICAM-1	3
steady-state	4
mRNA	4
was	0
detected	0
at	0
3	0
hours	0
and	0
remained	0
at	0
24	0
hours	0
.	0

Nuclear	0
run-on	0
transcription	0
assays	0
showed	0
that	0
IL-10	9
inhibited	0
the	0
rate	0
of	0
IFN-gamma	9
-induced	0
transcription	0
of	0
the	0
ICAM-1	1
gene	2
,	0
and	0
mRNA	0
stability	0
studies	0
showed	0
that	0
IL-10	9
did	0
not	0
alter	0
the	0
half-life	0
of	0
IFN-gamma-induced	3
ICAM-1	4
message	4
.	0

Thus	0
,	0
IL-10	9
inhibits	0
IFN-gamma	9
-induced	0
ICAM-1	9
expression	0
in	0
monocytes	7
primarily	0
at	0
the	0
level	0
of	0
gene	0
transcription	0
.	0

Activation	0
of	0
IFN-gamma-responsive	1
genes	2
requires	0
tyrosine	0
phosphorylation	0
of	0
the	0
transcriptional	0
factor	0
STAT-1alpha	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription-1alpha	10
)	0
.	0

However	0
,	0
IL-10	9
did	0
not	0
affect	0
IFN-gamma	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
STAT-1alpha	9
or	0
alter	0
STAT-1alpha	9
binding	0
to	0
the	0
IFN-gamma	1
response	2
element	2
(	0
IRE	1
)	0
in	0
the	0
ICAM-1	1
promoter	2
.	0

Instead	0
,	0
IL-10	9
prevented	0
IFN-gamma	9
-induced	0
binding	0
activity	0
at	0
the	0
NF-kappaB	9
site	0
of	0
the	0
tumor	1
necrosis	2
factor	2
alpha	2
(	2
TNF-alpha	2
)	2
-responsive	2
NF-kappaB/C-EBP	2
composite	2
element	2
in	0
the	0
ICAM-1	1
promoter	2
.	0

These	0
data	0
indicate	0
that	0
IL-10	9
inhibits	0
IFN-gamma	9
-induced	0
transcription	0
of	0
the	0
ICAM-1	1
gene	2
by	0
a	0
regulatory	0
mechanism	0
that	0
may	0
involve	0
NF-kappaB	9
.	0

Specific	0
complex	0
formation	0
between	0
the	0
type	9
II	10
bare	10
lymphocyte	10
syndrome-associated	10
transactivators	10
CIITA	9
and	0
RFX5	9
.	0

Two	0
of	0
the	0
genes	0
defective	0
in	0
the	0
five	0
complementation	0
groups	0
identified	0
in	0
the	0
class	0
II-negative	0
bare	0
lymphocyte	0
syndrome	0
or	0
corresponding	0
laboratory	0
mutants	0
have	0
been	0
cloned	0
.	0

One	0
gene	0
encodes	0
a	0
protein	0
,	0
RFX5	9
,	0
that	0
is	0
a	0
member	0
of	0
the	0
RFX	9
family	10
of	10
DNA	10
binding	10
proteins	10
.	0

The	0
other	0
,	0
CIITA	9
,	0
encodes	0
a	0
large	0
protein	0
with	0
a	0
defined	0
acidic	9
transcriptional	10
activation	10
domain	10
;	0
this	0
protein	0
does	0
not	0
interact	0
with	0
DNA	0
.	0

Expression	1
plasmids	2
encoding	0
regions	0
of	0
RFX5	9
fused	0
to	0
the	0
GAL4	9
DNA	10
binding	10
domain	10
activated	0
transcription	0
from	0
a	0
reporter	0
construct	0
containing	0
GAL4	1
sites	2
in	0
a	0
cotransfection	0
assay	0
in	0
the	0
Raji	5
human	6
B	6
cell	6
line	6
.	0

However	0
,	0
these	0
plasmids	1
produced	0
transcriptional	0
activity	0
in	0
HeLa	5
cells	6
only	0
in	0
conjunction	0
with	0
interferon	9
gamma	10
stimulation	0
,	0
a	0
condition	0
in	0
which	0
expression	0
of	0
both	0
CIITA	9
and	0
class	9
II	10
major	10
histocompatibility	10
complex	10
surface	10
proteins	10
are	0
induced	0
.	0

Furthermore	0
,	0
these	0
plasmids	1
were	0
not	0
active	0
in	0
RJ2.2.5	5
,	0
an	0
in	0
vitro	0
mutagenized	0
derivative	0
of	0
Raji	5
in	0
which	0
both	0
copies	0
of	0
CIITA	9
are	0
defective	0
.	0

Transcriptional	0
activation	0
by	0
the	0
RFX5	9
fusion	10
protein	10
could	0
be	0
restored	0
in	0
RJ2.2.5	5
by	0
cotransfection	0
with	0
a	0
CIITA	1
expression	2
plasmid	2
.	0

Finally	0
,	0
a	0
direct	0
interaction	0
between	0
RFX5	9
and	0
CIITA	9
was	0
detected	0
with	0
the	0
yeast	0
two-hybrid	0
and	0
far-Western	0
blot	0
assays	0
.	0

Thus	0
,	0
RFX5	9
can	0
activate	0
transcription	0
only	0
in	0
cooperation	0
with	0
CIITA	9
.	0

RFX5	9
and	0
CIITA	9
associate	0
to	0
form	0
a	0
complex	0
capable	0
of	0
activating	0
transcription	0
from	0
class	1
II	2
major	2
histocompatibility	2
complex	2
promoters	2
.	0

In	0
this	0
complex	0
,	0
promoter	0
specificity	0
is	0
determined	0
by	0
the	0
DNA	0
binding	0
domain	0
of	0
RFX5	9
and	0
the	0
general	0
transcription	0
apparatus	0
is	0
recruited	0
by	0
the	0
acidic	9
activation	10
domain	10
of	0
CIITA	9
.	0

Involvement	0
of	0
phosphatidylinositol	9
3-kinase	10
in	0
NFAT	9
activation	0
in	0
T	7
cells	8
.	0

Phosphatidylinositol	9
3-kinase	10
(	0
PI3-K	9
)	0
has	0
been	0
implicated	0
in	0
the	0
regulation	0
of	0
cell	0
proliferation	0
in	0
many	0
cell	0
types	0
.	0

We	0
have	0
previously	0
shown	0
that	0
in	0
T	7
cells	8
the	0
PI3-K	9
inhibitor	0
,	0
wortmannin	0
,	0
interferes	0
with	0
activation	0
of	0
the	0
mitogen-activated	9
kinase	10
,	0
Erk2	9
,	0
after	0
T	9
cell	10
receptor	10
(	0
TcR	9
)	0
stimulation	0
.	0

To	0
further	0
explore	0
the	0
involvement	0
of	0
PI3-K	9
in	0
T	0
cell	0
activation	0
,	0
we	0
created	0
a	0
set	0
of	0
potentially	0
dominant	1
negative	2
PI3-K	2
constructs	2
comprising	0
individual	0
or	0
tandem	1
domains	2
of	0
the	0
regulatory	9
p85	10
subunit	10
and	0
tested	0
their	0
effect	0
on	0
downstream	0
signaling	0
events	0
like	0
Erk2	9
activation	0
and	0
transcription	0
from	0
an	0
NFAT	1
(	2
nuclear	2
factor	2
of	2
activated	2
T	2
cells	2
)	2
element	2
taken	0
from	0
the	0
interleukin-2	1
promoter	2
.	0

Following	0
TcR	9
stimulation	0
,	0
activation	0
of	0
Erk2	9
was	0
only	0
inhibited	0
by	0
a	0
previously	0
described	0
truncated	9
form	10
of	10
p85	10
that	0
can	0
not	0
bind	0
the	0
catalytic	9
subunit	10
,	0
but	0
not	0
by	0
other	0
constructs	0
of	0
p85	9
.	0

In	0
contrast	0
,	0
several	0
mutant	0
p85	9
alleles	0
had	0
dramatic	0
effects	0
on	0
NFAT	9
activation	0
.	0

Most	0
interestingly	0
,	0
the	0
N-terminal	9
SH2	10
domain	10
had	0
an	0
inhibitory	0
effect	0
,	0
whereas	0
a	0
mutant	9
p85	10
containing	0
only	0
the	0
two	9
SH2	10
domains	10
enhanced	0
basal	0
NFAT	9
activity	0
in	0
a	0
Ras	9
-dependent	0
manner	0
.	0

Ionomycin	0
induced	0
synergistic	0
activation	0
of	0
NFAT	9
in	0
cells	0
expressing	0
p85	9
mutants	10
that	0
contained	0
the	0
C-terminal	9
SH2	10
domain	10
.	0

Analysis	0
of	0
phosphotyrosine-containing	9
proteins	10
bound	0
to	0
truncated	0
p85	9
constructs	10
revealed	0
cooperative	0
binding	0
of	0
the	0
two	9
SH2	10
domains	10
but	0
no	0
apparent	0
differences	0
between	0
the	0
N-	9
and	10
C-	10
terminal	10
SH2	10
domains	10
.	0

Wortmannin	0
did	0
not	0
interfere	0
with	0
NFAT	9
activation	0
,	0
although	0
it	0
inhibited	0
PI3-K	9
and	0
Erk2	9
activation	0
in	0
the	0
same	0
experiment	0
.	0

These	0
results	0
suggest	0
that	0
PI3-K	9
is	0
involved	0
in	0
NFAT	9
activation	0
through	0
a	0
complex	0
adaptor	0
function	0
of	0
its	0
regulatory	9
subunit	10
and	0
that	0
its	0
lipid	9
kinase	10
activity	0
is	0
dispensable	0
for	0
this	0
effect	0
.	0

Acute	0
leukemia	0
with	0
promyelocytic	0
features	0
in	0
PML/RARalpha	0
transgenic	0
mice	0
.	0

Acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
is	0
associated	0
with	0
reciprocal	0
chromosomal	0
translocations	0
involving	0
the	0
retinoic	1
acid	2
receptor	2
alpha	2
(	2
RARalpha	2
)	2
locus	2
on	0
chromosome	1
17	2
.	0

In	0
the	0
majority	0
of	0
cases	0
,	0
RARalpha	9
translocates	0
and	0
fuses	0
with	0
the	0
promyelocytic	1
leukemia	2
(	2
PML	2
)	2
gene	2
located	0
on	0
chromosome	1
15	2
.	0

The	0
resulting	0
fusion	1
genes	2
encode	0
the	0
two	0
structurally	0
unique	0
PML/RARalpha	9
and	0
RARalpha/PML	9
fusion	10
proteins	10
as	0
well	0
as	0
aberrant	9
PML	10
gene	10
products	10
,	0
the	0
respective	0
pathogenetic	0
roles	0
of	0
which	0
have	0
not	0
been	0
elucidated	0
.	0

We	0
have	0
generated	0
transgenic	0
mice	0
in	0
which	0
the	0
PML/RARalpha	9
fusion	10
protein	10
is	0
specifically	0
expressed	0
in	0
the	0
myeloid-promyelocytic	7
lineage	8
.	0

During	0
their	0
first	0
year	0
of	0
life	0
,	0
all	0
the	0
PML/	0
RARalpha	9
transgenic	0
mice	0
have	0
an	0
abnormal	0
hematopoiesis	0
that	0
can	0
best	0
be	0
described	0
as	0
a	0
myeloproliferative	0
disorder	0
.	0

Between	0
12	0
and	0
14	0
months	0
of	0
age	0
,	0
10	0
%	0
of	0
them	0
develop	0
a	0
form	0
of	0
acute	0
leukemia	0
with	0
a	0
differentiation	0
block	0
at	0
the	0
promyelocytic	0
stage	0
that	0
closely	0
mimics	0
human	0
APL	0
even	0
in	0
its	0
response	0
to	0
retinoic	0
acid	0
.	0

Our	0
results	0
are	0
conclusive	0
in	0
vivo	0
evidence	0
that	0
PML/RARalpha	9
plays	0
a	0
crucial	0
role	0
in	0
the	0
pathogenesis	0
of	0
APL	0
.	0

Constitutive	0
and	0
inducible	0
protein/DNA	0
interactions	0
of	0
the	0
interferon-gamma	1
promoter	2
in	0
vivo	0
in	0
[	0
corrected	0
]	0
CD45RA	7
and	8
CD45R0	8
T	8
helper	8
subsets	8
[	0
published	0
erratum	0
appears	0
in	0
Eur	0
J	0
Immunol	0
1997	0
Jul	0
;	0
27	0
(	0
7	0
)	0
:	0
1830	0
]	0

Interferon-gamma	0
(	0
IFN-gamma	9
)	0
is	0
a	0
key	0
cytokine	0
of	0
T	7
lymphocytes	8
with	0
major	0
regulatory	0
functions	0
in	0
the	0
immune	0
system	0
.	0

To	0
determine	0
and	0
compare	0
protein/DNA	0
interactions	0
at	0
the	0
native	0
IFN-gamma	9
locus	0
in	0
T	7
cells	8
,	0
we	0
analyzed	0
the	0
human	1
IFN-gamma	2
promoter	2
by	0
ligation-mediated	0
polymerase	0
chain	0
reaction	0
(	0
LM-PCR	0
)	0
techniques	0
.	0

Accordingly	0
,	0
Jurkat	5
T	6
cells	6
and	0
primary	7
CD45RA	8
and	8
CD45R0	8
CD4+	8
T	8
cell	8
subsets	8
isolated	0
from	0
peripheral	0
blood	0
using	0
immunomagnetic	0
beads	0
were	0
cultured	0
and	0
analyzed	0
by	0
LM-PCR	0
.	0

Constitutive	0
and	0
inducible	0
protein/DNA	0
interactions	0
of	0
the	0
IFN-gamma	1
promoter	2
in	0
vivo	0
were	0
detected	0
in	0
all	0
T	7
cells	8
tested	0
.	0

Interestingly	0
,	0
an	0
inducible	0
footprint	0
between	0
-183	1
and	2
-196	2
was	0
consistently	0
observed	0
in	0
Jurkat	5
T	6
cells	6
and	0
CD45RA	7
and	8
CD45R0	8
T	8
helper	8
subsets	8
upon	0
stimulation	0
with	0
phorbol	0
12-myristate	0
13-acetate+	0
phytohemagglutinin	9
(	0
PMA+	0
PHA	9
)	0
that	0
was	0
highly	0
sensitive	0
to	0
treatment	0
with	0
corticosteroids	0
.	0

This	0
novel	1
target	2
site	2
,	0
denoted	0
the	0
C-site	1
,	0
was	0
shown	0
by	0
several	0
criteria	0
,	0
including	0
cell	0
distribution	0
studies	0
,	0
stimulation	0
experiments	0
,	0
supershift	0
assays	0
,	0
and	0
cross-competition	0
electrophoretic	0
mobility	0
shift	0
assays	0
to	0
bind	0
the	0
transcription	9
factor	10
AP-1	10
.	0

Mutation	0
of	0
the	0
C-site	1
that	0
prevented	0
AP-1	9
binding	0
to	0
this	0
site	0
was	0
sufficient	0
strikingly	0
to	0
reduce	0
inducible	0
promoter	0
activity	0
in	0
primary	7
CD45R0	8
T	8
cells	8
.	0

In	0
summary	0
,	0
the	0
data	0
demonstrate	0
that	0
IFN-gamma	9
gene	0
transcription	0
in	0
primary	7
T	8
cells	8
is	0
regulated	0
in	0
vivo	0
at	0
the	0
level	0
of	0
constitutive	0
and	0
inducible	0
protein/DNA	0
interactions	0
.	0

We	0
propose	0
a	0
model	0
where	0
basal	0
transcription	0
is	0
maintained	0
by	0
binding	0
of	0
various	0
transcription	9
factors	10
to	0
the	0
IFN-gamma	1
promoter	2
,	0
whereas	0
PMA+	0
PHA	9
-inducible	0
IFN-gamma	9
transcription	0
in	0
CD45R0	7
T	8
cells	8
is	0
associated	0
with	0
binding	0
of	0
AP-1	9
to	0
the	0
C-site	1
.	0

Activation	0
domain	0
requirements	0
for	0
disruption	0
of	0
Epstein-Barr	0
virus	0
latency	0
by	0
ZEBRA	9
.	0

Latent	0
infection	0
of	0
B	7
lymphocytes	8
by	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
can	0
be	0
disrupted	0
by	0
expression	0
of	0
the	0
EBV	9
ZEBRA	10
protein	10
.	0

ZEBRA	9
,	0
a	0
transcriptional	0
activator	0
,	0
initiates	0
the	0
EBV	0
lytic	0
cascade	0
by	0
activating	0
viral	0
gene	0
expression	0
.	0

ZEBRA	9
is	0
also	0
indispensable	0
for	0
viral	0
replication	0
and	0
binds	0
directly	0
to	0
the	0
EBV	0
lytic	0
origin	0
of	0
replication	0
.	0

The	0
studies	0
described	0
herein	0
demonstrate	0
that	0
the	0
activation	0
domain	0
.	0

ZEBRA	9
activation	0
can	0
be	0
replaced	0
by	0
a	0
heterologous	9
acidic	10
,	10
proline-rich	10
,	10
or	10
glutamine-rich	10
activation	10
domain	10
.	0

ZEBRA	9
activation	0
domain	0
swap	0
constructs	0
retain	0
ZEBRA	9
's	0
native	0
abilities	0
to	0
activate	0
specific	0
EBV	1
promoters	2
,	0
to	0
disrupt	0
EBV	0
latency	0
,	0
and	0
to	0
stimulate	0
replication	0
at	0
the	0
EBV	1
lytic	2
origin	2
.	0

Additional	0
work	0
,	0
employing	0
sequential	0
and	0
internal	0
deletions	0
of	0
ZEBRA	9
's	0
N-terminal	9
activation	10
domain	10
,	0
indicates	0
that	0
its	0
separate	0
activities	0
are	0
not	0
attributable	0
to	0
specific	0
subdomains	9
but	0
are	0
spread	0
throughout	0
its	0
N	9
terminus	10
and	0
therefore	0
can	0
not	0
be	0
inactivated	0
by	0
deleting	0
localized	0
regions	0
.	0

CholecystokininB	9
receptor	10
from	0
human	5
Jurkat	6
lymphoblastic	6
T	6
cells	6
is	0
involved	0
in	0
activator	9
protein-1	10
-responsive	0
gene	0
activation	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
analyze	0
the	0
role	0
of	0
cholecystokinin	9
(	10
CCK	10
(	10
B	10
)	10
)	10
receptor	10
in	0
human	5
lymphoblastic	6
Jurkat	6
T	6
cells	6
.	0

We	0
investigated	0
the	0
trophic	0
effect	0
resulting	0
from	0
activation	0
of	0
such	0
a	0
receptor	0
by	0
using	0
the	0
reporter	1
gene	2
strategy	0
.	0

For	0
this	0
purpose	0
,	0
we	0
transiently	0
transfected	0
Jurkat	5
T	6
cells	6
with	0
the	0
reporter	1
plasmid	2
p	2
[	2
(	2
TRE	2
)	2
3-tk-Luc	2
]	2
and	0
found	0
that	0
CCK-8	0
was	0
able	0
to	0
dose-dependently	0
induce	0
luciferase	9
expression	0
related	0
to	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
activation	0
with	0
a	0
maximal	0
response	0
identical	0
to	0
that	0
obtained	0
with	0
compounds	0
known	0
to	0
activate	0
AP-1	9
complex	10
(	0
quantitatively	0
,	0
the	0
same	0
level	0
of	0
induction	0
was	0
obtained	0
with	0
1	0
nM	0
12-O-tetradecanoylphorbol-13-acetate	0
,	0
100	0
microM	0
diacylglycerol	0
,	0
or	0
4	0
nM	0
epidermal	0
growth	0
factor	0
)	0
.	0

The	0
involvement	0
of	0
the	0
CCK	9
(	10
B	10
)	10
receptor	10
in	0
such	0
a	0
stimulation	0
was	0
demonstrated	0
by	0
the	0
inhibiting	0
effect	0
of	0
the	0
selective	0
CCK	9
(	10
B	10
)	10
receptor	10
antagonist	0
PD-135	0
,	0
158	0
.	0

This	0
effect	0
was	0
confirmed	0
in	0
COS-7	0
cells	0
transfected	0
with	0
the	0
cDNA	0
of	0
CCK	9
(	10
B	10
)	10
receptor	10
cloned	0
from	0
Jurkat	5
T	6
cells	6
.	0

To	0
better	0
understand	0
the	0
AP-1	9
-dependent	0
luciferase	9
expression	0
in	0
Jurkat	5
T	6
cells	6
,	0
we	0
tested	0
two	0
specific	0
inhibitors	0
of	0
serine/threonine	9
phosphatases-1	10
and	10
-2A	10
:	0
okadaic	0
acid	0
and	0
calyculin	0
A	0
.	0

These	0
compounds	0
strongly	0
increased	0
the	0
phorbol-12-myristate-13-acetate	0
response	0
,	0
whereas	0
we	0
have	0
not	0
observed	0
a	0
contribution	0
of	0
phosphatase	0
inhibitors	0
on	0
a	0
CCK-8-induced	0
luciferase	9
activity	0
.	0

To	0
confirm	0
that	0
CCK	9
(	10
B	10
)	10
receptors	10
are	0
involved	0
in	0
AP-1	9
response	0
,	0
we	0
investigated	0
the	0
CCK-8	0
effect	0
on	0
interleukin-2	9
expression	0
,	0
a	0
natural	0
endogenous	1
gene	2
regulated	0
by	0
several	0
factors	0
,	0
including	0
AP-1	9
.	0

In	0
Jurkat	5
T	6
cells	6
activated	0
by	0
phorbol-12-myristate-13-acetate	0
and	0
phytohemagglutinin	9
,	0
CCK-8	0
induced	0
IL-2	0
expression	0
.	0

This	0
induction	0
was	0
abolished	0
by	0
PD-135	0
,	0
158	0
.	0

Our	0
results	0
indicate	0
that	0
CCK-8	0
exerts	0
a	0
trophic	0
effect	0
in	0
Jurkat	5
T	6
cells	6
through	0
stimulation	0
of	0
CCK	9
(	10
B	10
)	10
receptors	10
by	0
modulation	0
of	0
expression	0
of	0
AP-1-regulated	1
genes	2
.	0

A	0
conserved	0
tissue-specific	0
structure	0
at	0
a	0
human	1
T-cell	2
receptor	2
beta-chain	2
core	2
promoter	2
.	0

The	0
T-cell	1
receptor	2
(	2
TCR	2
)	2
beta-chain	2
promoters	2
have	0
been	0
characterized	0
as	0
nonstructured	1
basal	2
promoters	2
that	0
carry	0
a	0
single	0
conserved	0
ubiquitous	1
cyclic	2
AMP-responsive	2
element	2
.	0

Our	0
investigation	0
of	0
the	0
human	1
TCR	2
beta	2
gene	2
uncovers	0
a	0
surprisingly	0
complex	0
and	0
tissue-specific	0
structure	0
at	0
the	0
TCR	1
Vbeta	2
8.1	2
promoter	2
.	0

The	0
core	0
of	0
the	0
promoter	1
(	0
positions	1
-42	2
to	2
+11	2
)	0
is	0
recognized	0
by	0
the	0
lymphoid	9
cell-specific	10
transcription	10
factors	10
Ets-1	9
,	0
LEF1	9
,	0
and	0
AML1	9
as	0
well	0
as	0
by	0
CREB/ATF-1	9
,	0
as	0
is	0
demonstrated	0
in	0
gel	0
shift	0
and	0
footprinting	0
experiments	0
.	0

With	0
the	0
exception	0
of	0
LEF1	9
,	0
these	0
factors	0
activate	0
transcription	0
in	0
T	7
cells	8
.	0

Binding	1
sites	2
at	0
the	0
core	0
region	0
show	0
little	0
conservation	0
with	0
consensus	1
sites	2
.	0

Nonetheless	0
,	0
CREB	9
,	0
Ets-1	9
,	0
and	0
AML1	9
bind	0
and	0
activate	0
cooperatively	0
and	0
very	0
efficiently	0
through	0
the	0
nonconsensus	1
binding	2
sites	2
at	0
the	0
core	1
promoter	2
region	2
.	0

Moderate	0
ubiquitous	0
activation	0
is	0
further	0
induced	0
by	0
CREB/ATF	9
and	10
Sp1	10
factors	10
through	0
proximal	1
upstream	2
elements	2
.	0

The	0
tissue-specific	1
core	2
promoter	2
structure	2
is	0
apparently	0
conserved	0
in	0
other	0
T-cell-specifically	1
expressed	2
genes	2
such	0
as	0
the	0
CD4	1
gene	2
.	0

Our	0
observations	0
suggest	0
that	0
both	0
the	0
enhancer	1
and	0
the	0
promoter	1
have	0
a	0
complex	0
tissue-specific	0
structure	0
whose	0
functional	0
interplay	0
potentiates	0
T-cell-specific	0
transcription	0
.	0

The	0
cytoplasmic	9
domain	10
of	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	10
GM-CSF	10
)	10
receptor	10
alpha	10
subunit	10
is	0
essential	0
for	0
both	0
GM-CSF	9
-mediated	0
growth	0
and	0
differentiation	0
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
regulates	0
differentiation	0
,	0
survival	0
,	0
and	0
proliferation	0
of	0
colony-forming	5
unit-granulocyte-macrophage	6
progenitor	6
cells	6
.	0

The	0
biologic	0
actions	0
of	0
GM-CSF	9
are	0
mediated	0
by	0
binding	0
to	0
a	0
specific	0
receptor	0
consisting	0
of	0
two	0
chains	0
designated	0
as	0
alpha	9
and	10
beta	10
subunits	10
.	0

We	0
have	0
demonstrated	0
that	0
the	0
murine	5
FDC-P1-derived	6
cell	6
line	6
WT-19	5
transfected	0
with	0
the	0
human	9
GM-CSF	10
receptor	10
alpha	10
and	10
beta	10
subunits	10
(	0
GM-CSFRalpha	9
and	10
beta	10
)	0
can	0
be	0
induced	0
to	0
differentiate	0
by	0
the	0
addition	0
of	0
human	9
GM-CSF	10
(	0
hGM-CSF	9
)	0
.	0

By	0
expressing	0
a	0
series	0
of	0
GM-CSFRalpha	9
mutants	10
in	0
WT19	5
cells	6
,	0
we	0
have	0
determined	0
the	0
amino	9
acid	10
domains	10
of	0
the	0
GM-CSFRalpha	9
cytoplasmic	9
domain	10
that	0
regulate	0
cell	0
differentiation	0
,	0
proliferation	0
,	0
and	0
survival	0
.	0

We	0
found	0
that	0
the	0
membrane	9
proximal	10
proline-rich	10
domain	10
and	0
adjacent	9
16	10
residues	10
are	0
essential	0
for	0
both	0
hGM-CSF	9
-dependent	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

In	0
contrast	0
,	0
the	0
C-terminal	9
region	10
of	0
the	0
GM-CSFRalpha	9
cytoplasmic	10
domain	10
was	0
not	0
necessary	0
for	0
cell	0
differentiation	0
mediated	0
by	0
hGM-CSF	9
,	0
but	0
the	0
removal	0
of	0
this	0
region	0
severely	0
impaired	0
the	0
ability	0
of	0
hGM-CSF	9
to	0
support	0
cell	0
survival	0
.	0

While	0
the	0
activation	0
of	0
JAK2	9
,	0
Shc	9
,	0
Erk	9
,	0
and	0
STAT5	9
proteins	10
correlated	0
with	0
hGM-CSF	9
-mediated	0
cell	0
growth	0
,	0
cellular	0
differentiation	0
occurred	0
in	0
the	0
absence	0
of	0
activation	0
of	0
these	0
signal	0
transduction	0
pathways	0
.	0

gamma-Interferon	9
-induced	0
resistance	0
to	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2	0
D3	0
in	0
human	7
monocytes	8
and	0
macrophages	7
:	0
a	0
mechanism	0
for	0
the	0
hypercalcemia	0
of	0
various	0
granulomatoses	0
.	0

The	0
hypercalcemia	0
of	0
various	0
granulomatoses	0
is	0
caused	0
by	0
endogenous	0
1	0
,	0
25-dihydroxyvitamin	0
D	0
[	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
]	0
overproduction	0
by	0
disease-activated	0
macrophages	7
.	0

The	0
inability	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
to	0
suppress	0
its	0
synthesis	0
in	0
macrophages	7
contrasts	0
with	0
the	0
tight	0
control	0
of	0
its	0
production	0
in	0
macrophage	0
precursors	0
,	0
peripheral	7
blood	8
monocytes	8
(	0
PBM	7
)	0
.	0

We	0
examined	0
whether	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
resistance	0
develops	0
as	0
PBM	7
differentiate	0
to	0
macrophages	7
or	0
with	0
macrophage	0
activation	0
.	0

Normal	0
human	7
pulmonary	8
alveolar	8
macrophages	8
(	0
PAM	7
)	0
are	0
less	0
sensitive	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
than	0
PBM	7
,	0
despite	0
similar	0
vitamin	9
D	10
receptor	10
content	0
;	0
however	0
,	0
both	0
PBM	7
and	0
PAM	7
respond	0
to	0
exogenous	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
by	0
inhibiting	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
synthesis	0
and	0
inducing	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
degradation	0
through	0
enhancement	0
of	0
24-hydroxylase	9
mRNA	0
levels	0
and	0
activity	0
.	0

The	0
human	5
monocytic	6
cell	6
line	6
THP-1	5
mimics	0
PAM	7
in	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
synthesis	0
and	0
sensitivity	0
to	0
exogenous	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

We	0
utilized	0
THP-1	5
cells	6
to	0
examine	0
the	0
response	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
with	0
macrophage	0
activation	0
.	0

Activation	0
of	0
THP-1	5
cells	6
with	0
gamma-interferon	9
(	0
gamma-IFN	9
)	0
enhances	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
synthesis	0
30-fold	0
,	0
blocks	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
suppression	0
of	0
its	0
synthesis	0
,	0
and	0
reduces	0
by	0
42.2	0
%	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
induction	0
of	0
its	0
degradation	0
.	0

The	0
antagonistic	0
effects	0
of	0
gamma-IFN	9
are	0
not	0
merely	0
restricted	0
to	0
enzymatic	0
activities	0
.	0

In	0
THP-1	5
cells	6
and	0
in	0
normal	0
PBM	7
,	0
gamma-IFN	9
inhibits	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
induction	0
of	0
24-hydroxylase	9
mRNA	0
levels	0
without	0
reducing	0
mRNA	0
stability	0
,	0
suggesting	0
gamma-IFN	9
inhibition	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
transactivating	0
function	0
.	0

These	0
results	0
explain	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
overproduction	0
in	0
granulomatoses	0
and	0
demonstrate	0
potent	0
inhibition	0
by	0
gamma-IFN	9
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
action	0
in	0
immune	7
cells	8
.	0

Molecular	0
cloning	0
and	0
characterization	0
of	0
a	0
cDNA	1
,	0
CHEMR1	1
,	0
encoding	0
a	0
chemokine	9
receptor	10
with	0
a	0
homology	0
to	0
the	0
human	9
C-C	10
chemokine	10
receptor	10
,	0
CCR-4	9
.	0

Chemokines	9
refer	0
to	0
a	0
rapidly	0
expanding	0
family	0
of	0
small	0
cytokines	9
whose	0
primary	0
function	0
is	0
recruitment	0
of	0
leukocytes	0
to	0
inflammatory	0
sites	0
.	0

These	0
are	0
known	0
to	0
bind	0
to	0
seven-transmembrane-domain	9
containing	10
receptors	10
.	0

A	0
cDNA	1
clone	2
,	0
CHEMR1	1
,	0
resembling	0
the	0
typical	0
G	9
protein-coupled	10
receptor	10
,	0
was	0
isolated	0
from	0
a	0
mouse	1
cytotoxic	2
T-lymphocyte	2
(	2
CTL	2
)	2
library	2
.	0

Northern	0
blot	0
analysis	0
in	0
mouse	0
cell	0
lines	0
suggests	0
that	0
its	0
expression	0
is	0
found	0
in	0
a	0
variety	0
of	0
cells	0
,	0
including	0
T	7
cells	8
,	0
B	7
cells	8
,	0
and	0
macrophages	7
.	0

The	0
CHEMR1	1
gene	2
Scya3r2	1
is	0
a	0
single-copy	1
gene	2
whose	0
open	0
reading	0
frame	0
may	0
be	0
in	0
a	0
single	0
exon	0
and	0
maps	0
to	0
the	0
distal	0
region	0
of	0
mouse	1
Chr	2
9	2
where	0
the	0
mouse	1
macrophage	2
inflammatory	2
protein-1alpha	2
(	2
MIP-1alpha	2
)	2
receptor	2
gene	2
Scya3r	1
and	0
two	0
related	0
C-C	1
chemokine	2
receptor-like	2
genes	2
reside	0
.	0

Amino	0
acid	0
sequence	0
comparison	0
shows	0
that	0
CHEMR1	1
is	0
84	0
%	0
identical	0
to	0
human	9
CCR-4	10
,	0
indicating	0
that	0
CHEMR1	1
is	0
likely	0
to	0
be	0
a	0
mouse	9
CCR-4	10
.	0

Binding	0
assays	0
using	0
125I-labeled	9
C-C	10
chemokines	10
in	0
mammalian	7
cells	8
indicated	0
that	0
CHEMR1	1
did	0
not	0
bind	0
MIP-1alpha	0
,	0
RANTES	0
,	0
or	0
MIP-1beta	0
,	0
whereas	0
CCR-1	9
binds	0
MIP-1alpha	9
and	0
RANTES	9
.	0

Our	0
result	0
is	0
different	0
from	0
the	0
reported	0
properties	0
of	0
human	9
CCR-4	10
.	0

This	0
suggests	0
that	0
CHEMR1	1
may	0
be	0
a	0
receptor	0
for	0
unidentified	0
C-C	9
chemokine	10
or	0
a	0
low-affinity	0
receptor	0
for	0
MIP-1alpha	9
.	0

Transactivation	0
by	0
CIITA	9
,	0
the	0
type	9
II	10
bare	10
lymphocyte	10
syndrome-associated	10
factor	10
,	0
requires	0
participation	0
of	0
multiple	0
regions	0
of	0
the	0
TATA	9
box	10
binding	10
protein	10
.	0

CIITA	9
is	0
a	0
positive	0
regulator	0
of	0
class	1
II	2
major	2
histocompatibility	2
complex	2
gene	2
transcription	0
that	0
has	0
been	0
found	0
to	0
be	0
defective	0
in	0
one	0
of	0
the	0
five	0
complementation	0
groups	0
of	0
class	5
II	6
major	6
histocompatibility	6
complex-negative	6
cell	6
lines	6
.	0

Its	0
N-terminal	9
region	10
is	0
capable	0
of	0
activating	0
transcription	0
from	0
a	0
reporter	0
gene	0
when	0
fused	0
to	0
a	0
DNA	9
binding	10
domain	10
.	0

We	0
have	0
investigated	0
the	0
mechanism	0
of	0
transactivation	0
mediated	0
by	0
the	0
CIITA	9
activation	10
domain	10
by	0
studying	0
its	0
role	0
in	0
the	0
process	0
of	0
transcription	0
initiation	0
and	0
elongation	0
.	0

Specifically	0
the	0
altered	0
specificity	0
TBP	0
(	0
TATA	9
box	10
binding	10
protein	10
)	0
assay	0
has	0
been	0
used	0
to	0
analyze	0
the	0
response	0
of	0
the	0
CIITA	9
activation	10
domain	10
to	0
mutations	0
in	0
TBP	9
known	0
to	0
disrupt	0
its	0
interaction	0
with	0
its	0
associated	9
general	10
factors	10
.	0

Transactivation	0
by	0
CIITA	9
was	0
extremely	0
sensitive	0
to	0
a	0
mutation	0
in	0
TBP	9
that	0
in	0
yeast	0
is	0
known	0
to	0
abolish	0
VP16	9
-mediated	0
transcription	0
but	0
leaves	0
basal	0
transcription	0
unaffected	0
.	0

A	0
TBP	0
mutant	0
defective	0
in	0
interaction	0
with	0
TBP-associated	9
factor	10
TAFII250	9
also	0
failed	0
to	0
mediate	0
transactivation	0
through	0
the	0
CIITA	9
activation	10
domain	10
.	0

Certain	0
interactions	0
between	0
TBP	9
and	0
general	9
factors	10
that	0
are	0
specifically	0
required	0
for	0
acidic	9
activation	10
domains	10
were	0
also	0
required	0
for	0
CIITA	9
-mediated	0
transactivation	0
to	0
reach	0
its	0
full	0
potential	0
.	0

Finally	0
,	0
like	0
VP16	0
,	0
CIITA	9
was	0
able	0
to	0
stimulate	0
elongation	0
of	0
transcription	0
.	0

Overall	0
the	0
mechanism	0
of	0
transactivation	0
by	0
the	0
human	9
B-cell-specific	10
CIITA	10
is	0
very	0
similar	0
to	0
that	0
mediated	0
by	0
the	0
herpes	9
virus	10
transactivator	10
VP16	9
in	0
the	0
ways	0
that	0
have	0
been	0
tested	0
.	0

Relief	0
of	0
cyclin	9
A	10
gene	0
transcriptional	0
inhibition	0
during	0
activation	0
of	0
human	7
primary	8
T	8
lymphocytes	8
via	0
CD2	9
and	0
CD28	9
adhesion	9
molecules	10
.	0

Cyclin	9
A	10
transcription	0
is	0
cell	0
cycle	0
regulated	0
and	0
induced	0
by	0
cell	0
proliferative	0
signals	0
.	0

To	0
understand	0
the	0
mechanisms	0
underlined	0
in	0
this	0
regulation	0
in	0
normal	0
human	0
cells	0
,	0
we	0
have	0
analysed	0
in	0
vivo	0
protein-DNA	0
interactions	0
at	0
the	0
Cyclin	9
A	10
locus	0
in	0
primary	7
T	8
lymphocytes	8
.	0

Stimulation	0
of	0
purified	0
T	0
lymphocytes	0
by	0
a	0
combination	0
of	0
monoclonal	9
antibodies	10
directed	0
at	0
CD2	9
and	0
CD28	9
adhesion	9
molecules	10
gives	0
rise	0
to	0
a	0
long	0
lasting	0
proliferation	0
in	0
the	0
absence	0
of	0
accessory	7
cells	8
.	0

Cyclin	9
A	10
was	0
observed	0
after	0
4	0
days	0
of	0
costimulation	0
with	0
anti	9
CD2	10
+	0
CD28	9
whereas	0
stimulation	0
by	0
anti	9
CD2	10
or	0
anti	9
CD28	10
alone	0
was	0
not	0
effective	0
.	0

In	0
vivo	0
genomic	0
DMS	0
footprinting	0
revealed	0
upstream	0
of	0
the	0
major	0
transcription	1
initiation	2
sites	2
,	0
the	0
presence	0
of	0
at	0
least	0
three	0
protein	1
binding	2
sites	2
,	0
two	0
of	0
which	0
were	0
constitutively	0
occupied	0
.	0

They	0
bind	0
in	0
vitro	0
respectively	0
ATF-1	9
and	0
NF-Y	9
proteins	10
.	0

The	0
third	0
site	0
was	0
occupied	0
in	0
quiescent	0
cells	0
or	0
in	0
cells	0
stimulated	0
by	0
anti	9
CD2	10
or	0
anti	9
CD28	10
alone	0
.	0

The	0
mitogenic	0
combination	0
of	0
anti	9
CD2	10
+	0
anti	9
CD28	10
released	0
the	0
footprint	0
as	0
cells	0
were	0
committed	0
to	0
proliferation	0
.	0

Consistent	0
with	0
theses	0
results	0
,	0
nuclear	0
extracts	0
prepared	0
from	0
quiescent	0
cells	0
formed	0
a	0
specific	0
complex	0
with	0
this	0
element	0
,	0
whereas	0
extracts	0
prepared	0
from	0
cells	0
treated	0
with	0
anti	9
CD2	10
+	0
anti	9
CD28	10
failed	0
to	0
do	0
so	0
after	0
cells	0
entered	0
a	0
proliferative	0
state	0
.	0

An	0
enhancer-blocking	1
element	2
between	0
alpha	1
and	2
delta	2
gene	2
segments	2
within	0
the	0
human	1
T	2
cell	2
receptor	2
alpha/delta	2
locus	2
.	0

T	9
cell	10
receptor	10
(	10
TCR	10
)	10
alpha	10
and	0
delta	0
gene	0
segments	0
are	0
organized	0
within	0
a	0
single	0
genetic	0
locus	0
but	0
are	0
differentially	0
regulated	0
during	0
T	0
cell	0
development	0
.	0

An	0
enhancer-blocking	1
element	2
(	0
BEAD-1	1
,	0
for	0
blocking	0
element	1
alpha/delta	2
1	2
)	0
was	0
localized	0
to	0
a	0
2.0-kb	1
region	2
3	0
'	0
of	0
TCR	1
delta	2
gene	2
segments	2
and	0
5	0
'	0
of	0
TCR	1
alpha	2
joining	2
gene	2
segments	2
within	0
this	0
locus	0
.	0

BEAD-1	1
blocked	0
the	0
ability	0
of	0
the	0
TCR	1
delta	2
enhancer	2
(	0
Edelta	1
)	0
to	0
activate	0
a	0
promoter	0
when	0
located	0
between	0
the	0
two	0
in	0
a	0
chromatin-integrated	1
construct	2
.	0

We	0
propose	0
that	0
BEAD-1	1
functions	0
as	0
a	0
boundary	0
that	0
separates	0
the	0
TCR	1
alpha/delta	2
locus	2
into	0
distinct	0
regulatory	1
domains	2
controlled	0
by	0
Edelta	1
and	0
the	0
TCR	1
alpha	2
enhancer	2
,	0
and	0
that	0
it	0
prevents	0
Edelta	1
from	0
opening	0
the	0
chromatin	1
of	0
the	0
TCR	1
alpha	2
joining	0
gene	0
segments	0
for	0
VDJ	0
recombination	0
at	0
an	0
early	0
stage	0
of	0
T	0
cell	0
development	0
.	0

Uncoupling	0
of	0
cell	0
cycle	0
arrest	0
from	0
the	0
expression	0
of	0
monocytic	0
differentiation	0
markers	0
in	0
HL60	5
cell	6
variants	6
.	0

Differentiation	0
generally	0
leads	0
to	0
cell	0
cycle	0
arrest	0
.	0

Human	5
leukemia	6
HL60	6
cells	6
respond	0
to	0
the	0
presence	0
of	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
,	0
25D3	0
)	0
by	0
expressing	0
a	0
number	0
of	0
markers	0
of	0
the	0
monocyte/macrophage	0
phenotype	0
and	0
become	0
arrested	0
predominantly	0
in	0
the	0
G1	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

We	0
have	0
recently	0
reported	0
a	0
series	0
(	0
A	0
)	0
of	0
1	0
,	0
25D3-resistant	0
variants	0
of	0
HL60	5
cells	6
which	0
proliferate	0
in	0
the	0
presence	0
of	0
1	0
,	0
25D3	0
and	0
do	0
not	0
express	0
differentiation	0
markers	0
(	0
Exp.	0
Cell	0
Res.	0
224	0
,	0
312	0
,	0
1996	0
)	0
.	0

We	0
now	0
describe	0
another	0
series	0
(	0
B	0
)	0
of	0
such	0
variants	0
,	0
which	0
differ	0
from	0
A	0
series	0
cells	0
grown	0
in	0
similar	0
concentrations	0
of	0
1	0
,	0
25D3	0
in	0
that	0
they	0
express	0
the	0
CD14	9
antigen	10
and	0
nonspecific	0
esterase	9
,	0
characteristic	0
of	0
the	0
monocyte	0
,	0
while	0
continuing	0
to	0
proliferate	0
and	0
they	0
develop	0
hypotetraploid	0
DNA	0
(	0
4C	0
)	0
content	0
at	0
higher	0
concentrations	0
of	0
ambient	0
1	0
,	0
25D3	0
than	0
the	0
A	0
series	0
cells	0
.	0

Cells	0
in	0
the	0
B	0
series	0
with	0
4C	0
DNA	0
content	0
(	0
100B	0
and	0
200B	0
)	0
also	0
differed	0
from	0
the	0
A	5
series	6
4C	6
cells	6
by	0
the	0
absence	0
of	0
DNA	0
binding	0
by	0
the	0
full-length	0
Sp1	9
transcription	9
factor	10
.	0

However	0
,	0
B	0
series	0
cells	0
resembled	0
the	0
A	0
series	0
cells	0
in	0
exhibiting	0
faster	0
growth	0
rates	0
than	0
the	0
parental	0
HL60	5
cells	6
and	0
showed	0
high	0
levels	0
of	0
vitamin	9
D	10
receptor	10
and	0
retinoid	9
receptor	10
X	10
proteins	10
.	0

These	0
results	0
show	0
that	0
the	0
initial	0
steps	0
in	0
the	0
1	0
,	0
25D3	0
signaling	0
pathway	0
are	0
intact	0
in	0
B	0
series	0
resistant	0
cells	0
and	0
lead	0
to	0
the	0
appearance	0
of	0
early	0
markers	0
of	0
monocytic	0
differentiation	0
.	0

However	0
,	0
the	0
progression	0
to	0
subsequent	0
events	0
which	0
comprise	0
terminal	0
differentiation	0
and	0
cell	0
cycle	0
arrest	0
is	0
halted	0
during	0
the	0
adaptation	0
to	0
the	0
presence	0
of	0
1	0
,	0
25D3	0
in	0
these	0
cells	0
.	0

Thus	0
,	0
the	0
availability	0
of	0
these	0
variant	0
cells	0
should	0
provide	0
a	0
system	0
for	0
studying	0
the	0
link	0
between	0
differentiation	0
and	0
cell	0
cycle	0
arrest	0
.	0

Inhibition	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
replication	0
in	0
vitro	0
by	0
a	0
novel	0
combination	0
of	0
anti-Tat	9
single-chain	10
intrabodies	10
and	0
NF-kappa	0
B	0
antagonists	0
.	0

Human	9
immunodeficiency	10
virus	10
type	10
1	10
(	10
HIV-1	10
)	10
Tat	10
,	0
an	0
early	0
regulatory	9
protein	10
that	0
is	0
critical	0
for	0
viral	0
gene	0
expression	0
and	0
replication	0
,	0
transactivates	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
via	0
its	0
binding	0
to	0
the	0
transactivation	1
response	2
element	2
(	0
TAR	1
)	0
and	0
,	0
along	0
with	0
other	0
cellular	0
factors	0
,	0
increases	0
viral	0
transcription	0
initiation	0
and	0
elongation	0
.	0

Tat	0
also	0
superactivates	0
the	0
HIV-1	1
promoter	2
through	0
a	0
TAR	1
-independent	0
mechanism	0
,	0
including	0
tumor	0
necrosis	0
factor	0
alpha-induced	0
and	0
protein	0
kinase	0
C	0
(	0
PKC	9
)	0
-dependent	0
activation	0
of	0
NF-kappa	9
B	10
,	0
and	0
inhibitors	0
of	0
Tat	9
and	0
NF-kappa	9
B	10
cooperatively	0
down-regulate	0
this	0
Tat	9
-mediated	0
LTR	1
superactivation	0
.	0

In	0
this	0
study	0
,	0
a	0
combined	0
pharmacologic	0
and	0
genetic	0
strategy	0
using	0
two	0
PKC	9
(	0
NF-kappa	9
B	10
)	0
inhibitors	0
,	0
pentoxifylline	0
(	0
PTX	0
)	0
and	0
Go-6976	0
,	0
and	0
a	0
stably	0
expressed	0
anti-Tat	9
single-chain	10
intracellular	10
antibody	10
(	0
sFv	9
intrabody	10
)	0
was	0
employed	0
to	0
obtain	0
cooperative	0
inhibition	0
of	0
both	0
HIV-1	0
LTR	1
-driven	0
gene	0
expression	0
and	0
HIV-1	0
replication	0
.	0

Treatment	0
of	0
cells	0
with	0
PTX	0
and	0
Go-6976	0
resulted	0
in	0
cooperative	0
inhibition	0
of	0
both	0
HIV-1	1
LTR	2
-driven	0
gene	0
expression	0
and	0
HIV-1	0
replication	0
.	0

In	0
addition	0
,	0
the	0
combined	0
use	0
of	0
anti-Tat	9
sFv	10
intrabodies	10
and	0
the	0
two	0
NF-kappa	9
B	10
inhibitors	0
retained	0
the	0
virus	0
in	0
the	0
latent	0
state	0
for	0
as	0
long	0
as	0
45	0
days	0
.	0

The	0
combined	0
treatment	0
resulted	0
in	0
more	0
durable	0
inhibition	0
of	0
HIV-1	0
replication	0
than	0
was	0
seen	0
with	0
the	0
NF-kappa	9
B	10
inhibitors	0
alone	0
or	0
the	0
anti-	0
Tat	9
sFv	10
intrabodies	10
alone	0
.	0

Together	0
,	0
these	0
results	0
suggest	0
that	0
in	0
future	0
clinical	0
gene	0
therapy	0
trials	0
,	0
a	0
combined	0
pharmacologic	0
and	0
genetic	0
strategy	0
like	0
the	0
one	0
reported	0
here	0
may	0
improve	0
the	0
survival	0
of	0
transduced	5
cells	6
and	0
prolong	0
clinical	0
benefit	0
.	0

Transcription	9
factors	10
in	0
immune-mediated	0
disease	0
.	0

A	0
large	0
amount	0
of	0
detailed	0
information	0
about	0
the	0
intracellular	9
proteins	10
regulating	0
NF-kappa	9
B	10
activation	0
and	0
the	0
cellular	0
response	0
to	0
NF-kappa	9
B	10
activation	0
has	0
emerged	0
recently	0
.	0

Several	0
small	0
molecules	0
,	0
an	0
antisense	1
oligonucleotide	2
,	0
and	0
gene	0
therapeutic	0
agents	0
that	0
inhibit	0
NF-kappa	9
b	10
activation	0
have	0
been	0
described	0
.	0

Despite	0
this	0
,	0
there	0
are	0
still	0
significant	0
gaps	0
in	0
our	0
understanding	0
of	0
this	0
process	0
and	0
its	0
consequences	0
.	0

In	0
contrast	0
,	0
the	0
characterization	0
of	0
transcription	9
factors	10
selectively	0
regulating	0
cytokine	0
production	0
by	0
CD4+	7
T	8
cell	8
subsets	8
is	0
at	0
a	0
very	0
early	0
stage	0
.	0

Three	0
interacting	9
proteins	10
have	0
recently	0
been	0
shown	0
to	0
contribute	0
to	0
subset-restricted	0
expression	0
of	0
the	0
IL-4	1
gene	2
.	0

There	0
are	0
other	0
elements	0
regulating	0
IL-4	1
gene	2
expression	0
,	0
however	0
,	0
and	0
the	0
relative	0
importance	0
of	0
these	0
recently	0
identified	0
proteins	0
has	0
yet	0
to	0
be	0
determined	0
.	0

Involvement	0
of	0
Rel	9
,	10
Fos	10
,	10
and	10
Jun	10
proteins	10
in	0
binding	0
activity	0
to	0
the	0
IL-2	1
promoter	2
CD28	2
response	2
element/AP-1	2
sequence	2
in	0
human	7
T	8
cells	8
.	0

CD28	9
is	0
an	0
important	0
costimulatory	9
molecule	10
in	0
the	0
activation	0
of	0
human	7
T	8
cells	8
.	0

Costimulation	0
of	0
T	7
cells	8
through	0
both	0
the	0
Ag	0
receptor	0
and	0
CD28	9
leads	0
to	0
high	0
level	0
IL-2	9
production	0
,	0
which	0
is	0
vital	0
to	0
the	0
development	0
of	0
an	0
immune	0
response	0
in	0
vivo	0
.	0

Previous	0
reports	0
have	0
suggested	0
the	0
CD28	9
stimulation	0
contributes	0
to	0
the	0
activation	0
of	0
the	0
IL-2	1
promoter	2
by	0
up-regulating	0
the	0
activity	0
of	0
several	0
transcription	9
factors	10
,	0
including	0
AP-1	9
and	0
nuclear	9
factor-kappaB	10
(	10
NF-kappaB	10
)	10
/Rel	10
family	10
members	10
as	0
well	0
as	0
an	0
uncharacterized	9
transcription	10
factor	10
called	0
CD28	9
response	0
complex	0
.	0

While	0
several	0
lines	0
of	0
investigation	0
have	0
suggested	0
that	0
NF-kappaB/Rel	9
family	10
members	10
make	0
up	0
the	0
CD28	9
response	0
complex	0
transcription	9
factor	10
,	0
other	0
work	0
has	0
not	0
supported	0
this	0
conclusion	0
.	0

Recent	0
studies	0
suggest	0
that	0
the	0
CD28	1
response	2
element	2
(	0
CD28RE	1
)	0
does	0
not	0
function	0
independently	0
but	0
works	0
instead	0
in	0
conjunction	0
with	0
the	0
adjacent	1
promoter	2
proximal	2
AP-1-binding	2
site	2
and	0
this	0
hypothesis	0
is	0
confirmed	0
here	0
.	0

Also	0
in	0
the	0
current	0
study	0
,	0
binding	0
activity	0
to	0
the	0
CD28RE/AP-1	1
sequence	2
of	0
the	0
IL-2	1
promoter	2
is	0
evaluated	0
.	0

Although	0
four	0
specific	0
complexes	0
can	0
be	0
detected	0
binding	0
to	0
this	0
sequence	0
,	0
only	0
one	0
of	0
these	0
complexes	0
is	0
specific	0
for	0
both	0
the	0
CD28RE	1
and	0
the	0
adjacent	1
AP-1	2
site	2
.	0

Of	0
the	0
NF-kappaB/Rel	9
family	10
members	10
tested	0
,	0
this	0
CD28RE/AP-1-specific	9
complex	10
contains	0
predominantly	0
c-Rel	9
,	0
despite	0
the	0
fact	0
that	0
both	0
p50	9
and	0
RelA	9
can	0
efficiently	0
bind	0
to	0
the	0
CD28RE	1
.	0

c-Fos	9
and	0
c-Jun	9
are	0
also	0
found	0
in	0
this	0
CD28RE/AP-1-specific	9
complex	10
.	0

These	0
data	0
indicate	0
that	0
functional	0
complexes	0
encompassing	0
both	0
the	0
CD28RE	1
and	0
the	0
AP-1-binding	1
sites	2
influence	0
IL-2	1
promoter	2
activity	0
in	0
CD28	9
-costimulated	0
T	7
cells	8
.	0

Inducible	0
expression	0
and	0
phosphorylation	0
of	0
coactivator	9
BOB.1/OBF.1	10
in	0
T	7
cells	8
[	0
see	0
comments	0
]	0

BOB.1/OBF.1	9
is	0
a	0
transcriptional	9
coactivator	10
that	0
is	0
constitutively	0
expressed	0
in	0
B	7
cells	8
and	0
interacts	0
with	0
the	0
Oct1	0
and	0
Oct2	0
transcription	9
factors	10
.	0

Upon	0
activation	0
of	0
Jurkat	5
T	6
cells	6
and	0
primary	7
murine	8
thymocytes	8
with	0
phorbol	0
esters	0
and	0
ionomycin	0
,	0
BOB.1/OBF.1	9
expression	0
and	0
transactivation	0
function	0
were	0
induced	0
.	0

BOB.1/OBF.1	9
was	0
phosphorylated	0
at	0
Ser184	0
both	0
in	0
vivo	0
and	0
in	0
vitro	0
,	0
and	0
this	0
modification	0
was	0
required	0
for	0
inducible	0
activation	0
.	0

Mutation	0
of	0
Ser184	0
also	0
diminished	0
transactivation	0
function	0
in	0
B	7
cells	8
,	0
suggesting	0
that	0
the	0
activating	0
phosphorylation	0
that	0
is	0
inducible	0
in	0
T	7
cells	8
is	0
constitutively	0
present	0
in	0
B	7
cells	8
.	0

Thus	0
,	0
BOB.1/OBF.1	9
is	0
a	0
transcriptional	9
coactivator	10
that	0
is	0
critically	0
regulated	0
by	0
posttranslational	0
modifications	0
to	0
mediate	0
cell	0
type-specific	0
gene	0
expression	0
.	0

Increased	0
expression	0
of	0
Gs	9
(	10
alpha	10
)	10
enhances	0
activation	0
of	0
the	0
adenylyl	9
cyclase	10
signal	0
transduction	0
cascade	0
.	0

Expression	0
of	0
the	0
stimulatory	0
G	9
protein	10
,	0
G	9
(	10
S	10
)	10
alpha	10
,	0
can	0
vary	0
over	0
a	0
3-fold	0
range	0
in	0
human	0
tissues	0
and	0
in	0
rodent	0
central	0
nervous	0
system	0
.	0

In	0
fact	0
,	0
the	0
offspring	0
of	0
alcoholics	0
have	0
higher	0
levels	0
of	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
in	0
certain	0
tissues	0
compared	0
with	0
the	0
offspring	0
of	0
nonalcoholics	0
.	0

The	0
aim	0
of	0
this	0
research	0
was	0
to	0
test	0
the	0
hypothesis	0
that	0
a	0
causal	0
relationship	0
exists	0
between	0
the	0
level	0
of	0
expression	0
of	0
G	9
(	10
S	10
)	10
alpha	10
and	0
induction	0
of	0
the	0
adenylyl	9
cyclase	10
(	0
AC	0
)	0
cascade	0
.	0

The	0
methodology	0
employed	0
transient	0
transfection	0
of	0
HEK	5
293	6
cells	6
with	0
a	0
cDNA	0
for	0
the	0
52-kDa	0
form	0
of	0
G	9
(	10
S	10
)	10
alpha	10
under	0
regulation	0
by	0
inducible	1
metallothionein	2
promoters	2
.	0

Transfectants	0
were	0
exposed	0
to	0
varying	0
concentrations	0
(	0
0-125	0
microM	0
)	0
of	0
zinc	0
sulfate	0
that	0
produced	0
a	0
3-fold	0
range	0
of	0
membrane	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
.	0

The	0
range	0
of	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
produced	0
was	0
found	0
to	0
mimic	0
a	0
physiologically	0
relevant	0
spectrum	0
of	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
in	0
membranes	0
derived	0
from	0
human	0
tissues	0
and	0
rat	0
brain	0
.	0

It	0
was	0
observed	0
that	0
induction	0
of	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
increased	0
constitutive	0
as	0
well	0
as	0
stimulated	0
cAMP	0
accumulation	0
.	0

Moreover	0
,	0
induction	0
of	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
increased	0
events	0
distal	0
to	0
the	0
accumulation	0
of	0
cAMP	0
including	0
the	0
phosphorylation	0
of	0
the	0
transcription	0
factor	0
,	0
cAMP	9
response	10
element	10
binding	10
protein	10
and	0
transcriptional	0
activation	0
of	0
cAMP-dependent	1
reporter	2
genes	2
.	0

In	0
summary	0
,	0
these	0
studies	0
show	0
that	0
the	0
amount	0
of	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
has	0
a	0
marked	0
impact	0
on	0
the	0
level	0
of	0
activity	0
of	0
the	0
AC	0
cascade	0
from	0
the	0
membrane	0
through	0
to	0
the	0
nucleus	0
.	0

It	0
is	0
hypothesized	0
that	0
individuals	0
who	0
differ	0
in	0
G	9
(	10
S	10
)	10
alpha	10
expression	0
may	0
also	0
differ	0
in	0
the	0
expression	0
of	0
certain	0
cAMP-dependent	1
genes	2
.	0

Thrombin	9
generation	0
by	0
apoptotic	7
vascular	8
smooth	8
muscle	8
cells	8
.	0

Thrombin	9
activation	0
requires	0
assembly	0
of	0
a	0
prothrombinase	9
complex	10
of	0
activated	0
coagulation	9
factors	10
on	0
an	0
anionic	0
phospholipid	0
surface	0
,	0
classically	0
provided	0
by	0
activated	7
platelets	8
.	0

We	0
have	0
previously	0
shown	0
that	0
anionic	0
phosphatidylserine	0
is	0
exposed	0
by	0
rat	7
vascular	8
smooth	8
muscle	8
cells	8
(	0
VSMCs	7
)	0
undergoing	0
apoptosis	0
after	0
serum	0
withdrawal	0
.	0

In	0
this	0
study	0
,	0
using	0
a	0
chromogenic	0
assay	0
,	0
we	0
have	0
shown	0
thrombin	9
generation	0
by	0
apoptotic	7
VSMCs	8
expressing	0
c-myc	9
(	0
VSMC-myc	5
)	0
with	0
an	0
area	0
under	0
the	0
thrombin	9
-generation	0
curve	0
(	0
AUC	0
)	0
of	0
305	0
+/-	0
17	0
nmol	0
x	0
min/L	0
and	0
a	0
peak	0
thrombin	9
(	0
PT	0
)	0
of	0
154	0
+/-	0
9	0
nmol/L	0
.	0

The	0
thrombin	9
-generating	0
potential	0
of	0
the	0
apoptotic	5
VSMC-myc	6
cells	6
was	0
greater	0
than	0
that	0
of	0
unactivated	7
platelets	8
(	0
P	0
=	0
.003	0
for	0
AUC	0
;	0
P	0
=	0
.0002	0
for	0
PT	0
)	0
and	0
similar	0
to	0
calcium-ionophore	0
activated	7
platelets	8
(	0
AUC	0
of	0
332	0
+/-	0
15	0
nmol	0
x	0
min/L	0
,	0
P	0
=	0
.3	0
;	0
PT	0
of	0
172	0
+/-	0
8	0
nmol/L	0
,	0
P	0
=	0
.2	0
)	0
.	0

Thrombin	9
activation	0
was	0
also	0
seen	0
with	0
apoptotic	7
human	8
VSMCs	8
(	0
AUC	0
of	0
211	0
+/-	0
8	0
nmol	0
x	0
min/L	0
;	0
PT	0
of	0
103	0
+/-	0
4	0
nmol/L	0
)	0
and	0
was	0
inhibited	0
by	0
annexin	0
V	0
(	0
P	0
<	0
.0001	0
for	0
AUC	0
and	0
PT	0
)	0
.	0

VSMC-myc	5
cells	6
maintained	0
in	0
serum	0
generated	0
less	0
thrombin	9
than	0
after	0
serum	0
withdrawal	0
(	0
P	0
=	0
.0002	0
for	0
AUC	0
and	0
PT	0
)	0
.	0

VSMCs	7
derived	0
from	0
human	0
coronary	0
atherosclerotic	0
plaques	0
that	0
apoptose	0
even	0
in	0
serum	0
also	0
generated	0
thrombin	9
(	0
AUC	0
of	0
260	0
+/-	0
2	0
nmol	0
x	0
min/L	0
;	0
PT	0
of	0
128	0
+/-	0
4	0
nmol/L	0
)	0
.	0

We	0
conclude	0
that	0
apoptotic	7
VSMCs	8
possess	0
a	0
significant	0
thrombin	9
-generating	0
capacity	0
secondary	0
to	0
phosphatidylserine	0
exposure	0
.	0

Apoptotic	0
cells	0
within	0
atherosclerotic	0
plaques	0
may	0
allow	0
local	0
thrombin	9
activation	0
,	0
thereby	0
contributing	0
to	0
disease	0
progression	0
.	0

An	0
isotype-specific	0
activator	0
of	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
genes	2
that	0
is	0
independent	0
of	0
class	9
II	10
transactivator	10
.	0

Patients	0
with	0
one	0
type	0
of	0
major	9
histocompatibility	10
complex	10
class	10
II	10
combined	0
immunodeficiency	0
have	0
mutations	0
in	0
a	0
gene	0
termed	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
,	0
which	0
coordinately	0
controls	0
the	0
transcription	0
of	0
the	0
three	0
major	0
human	1
class	2
II	2
genes	2
,	0
HLA-DR	1
,	2
-DQ	2
,	2
and	2
-DP	2
.	0

However	0
,	0
the	0
experimentally	0
derived	0
B-lymphoblastoid	5
cell	6
line	6
,	0
clone	5
13	6
,	0
expresses	0
high	0
levels	0
of	0
HLADQ	9
in	0
the	0
absence	0
of	0
HLA-DR	1
and	0
HLA-DP	1
,	0
despite	0
its	0
mapping	0
by	0
complementation	0
analysis	0
to	0
this	0
group	0
.	0

It	0
was	0
possible	0
that	0
one	0
of	0
the	0
clone	1
13	2
CIITA	2
alleles	2
bore	0
a	0
mutation	0
that	0
allowed	0
HLA-DQ	1
,	0
but	0
not	0
HLA-DR	0
or	0
-DP	0
transcription	0
.	0

Alternatively	0
,	0
another	0
factor	0
,	0
distinct	0
from	0
CIITA	9
,	0
might	0
control	0
HLA-DQ	1
expression	0
.	0

We	0
report	0
here	0
that	0
ectopic	0
expression	0
of	0
CIITA	1
cDNAs	2
derived	0
by	0
reverse	0
transcriptase	0
polymerase	0
chain	0
reaction	0
from	0
clone	5
13	6
do	0
not	0
restore	0
expression	0
of	0
HLA-DQ	1
in	0
another	0
CIITA-deficient	5
cell	6
line	6
,	0
RJ2.2.5	5
.	0

In	0
addition	0
,	0
no	0
CIITA	9
protein	0
is	0
detectable	0
in	0
clone	5
13	6
nuclear	0
extracts	0
.	0

In	0
contrast	0
,	0
somatic	0
cell	0
fusion	0
between	0
clone	5
13	6
and	0
RJ2.2.5	5
restored	0
expression	0
of	0
the	0
HLA-DQ	1
haplotype	0
encoded	0
by	0
the	0
RJ2.2.5	1
DQB	2
gene	2
.	0

Taken	0
together	0
,	0
these	0
data	0
demonstrate	0
the	0
existence	0
of	0
an	0
HLA-DQ	9
isotype-specific	10
trans-acting	10
factor	10
,	0
which	0
functions	0
independently	0
of	0
CIITA	9
.	0

Homodimerization	0
of	0
the	0
human	9
interleukin	10
4	10
receptor	10
alpha	10
chain	10
induces	0
Cepsilon	3
germline	4
transcripts	4
in	0
B	7
cells	8
in	0
the	0
absence	0
of	0
the	0
interleukin	9
2	10
receptor	10
gamma	10
chain	10
.	0

The	0
cytokines	9
interleukin	9
(	10
IL	10
)	10
-4	10
and	0
IL-13	9
play	0
a	0
critical	0
role	0
in	0
inducing	0
Cepsilon	3
germline	4
transcripts	4
and	0
IgE	9
isotype	10
switching	0
in	0
human	7
B	8
cells	8
.	0

The	0
IL-4	9
receptor	10
(	0
IL-4R	9
)	0
in	0
B	7
cells	8
is	0
composed	0
of	0
two	0
chains	0
,	0
the	0
IL-4-binding	9
IL-4Ralpha	10
chain	10
,	0
which	0
is	0
shared	0
with	0
the	0
IL-13R	9
,	0
and	0
the	0
IL-2Rgamma	9
(	10
gammac	10
)	10
chain	10
,	0
which	0
is	0
shared	0
with	0
IL-7R	9
,	0
IL-9R	9
,	0
and	0
IL-15R	9
.	0

IL-4	9
induces	0
Cepsilon	3
germline	4
transcripts	4
and	0
IgE	9
isotype	10
switching	0
in	0
B	7
cells	8
from	0
patients	0
with	0
gammac	9
chain	10
deficiency	0
.	0

Induction	0
of	0
Cepsilon	3
germline	4
transcripts	4
by	0
IL-4	9
in	0
B	7
cells	8
that	0
lack	0
the	0
gammac	9
chain	10
may	0
involve	0
signaling	0
via	0
the	0
IL-13R	9
.	0

Alternatively	0
,	0
the	0
IL-4Ralpha	9
chain	10
may	0
transduce	0
intracellular	0
signals	0
that	0
lead	0
to	0
Cepsilon	1
gene	2
transcription	0
independently	0
of	0
its	0
association	0
with	0
other	0
chains	0
.	0

We	0
show	0
that	0
ligand-induced	0
homodimerization	0
of	0
chimeric	9
surface	10
receptors	10
consisting	0
of	0
the	0
extracellular	9
and	10
transmembrane	10
domains	10
of	0
the	0
erythropoietin	9
receptor	10
and	0
of	0
the	0
intracellular	9
domain	10
of	0
IL-4Ralpha	9
induces	0
Janus	9
kinase	10
1	10
(	0
Jak1	9
)	0
activation	0
,	0
STAT6	9
activation	0
,	0
and	0
Cepsilon	3
germline	4
transcripts	4
in	0
human	5
B	6
cell	6
line	6
BJAB	6
.	0

Disruption	0
of	0
the	0
Jak1-binding	9
proline-rich	10
Box1	10
region	10
of	0
IL-4Ralpha	9
abolished	0
signaling	0
by	0
this	0
chimeric	9
receptor	10
.	0

Furthermore	0
,	0
B	7
cells	8
transfected	0
with	0
a	0
chimeric	9
CD8alpha/IL-4Ralpha	10
receptor	10
,	0
which	0
is	0
expressed	0
on	0
the	0
cell	0
surface	0
as	0
a	0
homodimer	9
,	0
constitutively	0
expressed	0
Cepsilon	3
germline	4
transcripts	4
.	0

These	0
results	0
suggest	0
that	0
homodimerization	0
of	0
the	0
IL-4Ralpha	9
chain	10
is	0
sufficient	0
to	0
transduce	0
Jak1	9
-dependent	0
intracellular	0
signals	0
that	0
lead	0
to	0
IgE	9
isotype	10
switching	0
.	0

Transcriptional	0
activity	0
and	0
constitutive	0
nuclear	0
localization	0
of	0
the	0
ETS	9
protein	10
Elf-1	9
.	0

Elf-1	9
is	0
a	0
lymphoid-specific	9
transcription	10
factor	10
that	0
belongs	0
to	0
the	0
ETS	9
protein	10
family	10
.	0

It	0
can	0
bind	0
to	0
DNA	0
target	0
sequences	0
within	0
a	0
variety	0
of	0
cytokine	1
genes	2
.	0

We	0
demonstrate	0
that	0
Elf-1	9
is	0
constitutively	0
localized	0
in	0
the	0
nucleus	0
which	0
is	0
dependent	0
on	0
the	0
presence	0
of	0
amino	9
acids	10
86-265	10
.	0

Analysis	0
of	0
Gal4-Elf-1	9
fusion	10
proteins	10
revealed	0
that	0
the	0
N-terminal	0
86	0
amino	0
acids	0
of	0
Elf-1	9
contain	0
a	0
transcriptional	9
activation	10
domain	10
,	0
the	0
activity	0
of	0
which	0
is	0
attenuated	0
by	0
an	0
internal	9
repression	10
domain	10
.	0

Furthermore	0
,	0
Elf-1	9
interacts	0
specifically	0
with	0
the	0
E74	1
target	2
sequence	2
and	0
can	0
stimulate	0
transcription	0
driven	0
by	0
the	0
E74	1
site	2
independent	0
of	0
mitogenic	0
signaling	0
.	0

Thus	0
,	0
Elf-1	9
is	0
able	0
to	0
stimulate	0
gene	0
transcription	0
which	0
may	0
be	0
required	0
for	0
the	0
development	0
and	0
activity	0
of	0
lymphocytes	7
.	0

Characterization	0
of	0
peripheral	7
blood	8
T-lymphocytes	8
transduced	0
with	0
HTLV-I	9
Tax	10
mutants	10
with	0
different	0
trans-activating	0
phenotypes	0
.	0

Tax1	9
,	0
a	0
transcriptional	9
trans-activator	10
of	0
the	0
Human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
,	0
induces	0
the	0
expression	0
of	0
many	0
cellular	0
genes	0
through	0
interaction	0
with	0
at	0
least	0
three	0
distinct	0
cellular	9
transcription	10
factors	10
;	0
CREB/ATF	9
,	0
NF-kappaB	9
,	0
and	0
SRF	9
.	0

This	0
Tax1	9
-induced	0
activation	0
of	0
cellular	1
genes	2
is	0
considered	0
to	0
be	0
a	0
critical	0
event	0
in	0
T-cell	0
transformation	0
by	0
HTLV-I	0
.	0

To	0
elucidate	0
the	0
role	0
of	0
each	0
Tax1	9
-inducible	0
transcriptional	0
pathway	0
in	0
T-cell	0
transformation	0
,	0
we	0
introduced	0
Tax1	9
mutants	10
with	0
different	0
trans-activating	0
phenotypes	0
into	0
peripheral	7
blood	8
lymphocytes	8
(	0
PBL	7
)	0
by	0
retroviral	0
vectors	0
.	0

Analysis	0
of	0
these	0
PBLs	7
revealed	0
that	0
activation	0
of	0
the	0
NF-kappaB	9
pathway	0
is	0
sufficient	0
to	0
promote	0
the	0
growth	0
response	0
to	0
IL-2	9
.	0

However	0
,	0
for	0
the	0
clonal	0
expansion	0
of	0
CD4+	7
T-cells	8
,	0
which	0
is	0
a	0
characteristic	0
result	0
of	0
HTLV-I	0
infection	0
,	0
activation	0
of	0
the	0
CREB/ATF	0
and	0
SRF	0
pathways	0
is	0
also	0
required	0
.	0

Epstein-Barr	0
virus	0
binding	0
to	0
CD21	9
activates	0
the	0
initial	0
viral	1
promoter	2
via	0
NF-kappaB	9
induction	0
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
,	0
an	0
oncogenic	0
human	0
herpesvirus	0
,	0
binds	0
to	0
and	0
infects	0
normal	7
human	8
B	8
lymphocytes	8
via	0
CD21	9
,	0
the	0
CR2	9
complement	10
receptor	10
.	0

Studies	0
of	0
the	0
mechanisms	0
that	0
enable	0
EBV	0
to	0
infect	0
nonactivated	0
,	0
noncycling	7
B	8
cells	8
provide	0
compelling	0
evidence	0
for	0
a	0
sequence	0
of	0
events	0
in	0
which	0
EBV	0
binding	0
to	0
CD21	9
on	0
purified	0
resting	7
human	8
B	8
cells	8
rapidly	0
activates	0
the	0
NF-kappaB	9
transcription	9
factor	10
,	0
which	0
,	0
in	0
turn	0
,	0
binds	0
to	0
and	0
mediates	0
transcriptional	0
activation	0
of	0
Wp	0
,	0
the	0
initial	0
viral	1
latent	2
gene	2
promoter	2
.	0

Thus	0
,	0
EBV	0
binding	0
to	0
its	0
cellular	0
receptor	0
on	0
resting	0
B	0
cells	0
triggers	0
an	0
NF-kappaB	9
-dependent	0
intracellular	0
signaling	0
pathway	0
which	0
is	0
required	0
for	0
infection	0
.	0

Synthetic	0
glucocorticoids	0
that	0
dissociate	0
transactivation	0
and	0
AP-1	9
transrepression	0
exhibit	0
antiinflammatory	0
activity	0
in	0
vivo	0
.	0

Some	0
of	0
the	0
most	0
potent	0
antiinflammatory	0
and	0
immunosuppressive	0
agents	0
are	0
synthetic	0
glucocorticoids	0
.	0

However	0
,	0
major	0
side	0
effects	0
severely	0
limit	0
their	0
therapeutic	0
use	0
.	0

The	0
development	0
of	0
improved	0
glucocorticoid-based	0
drugs	0
will	0
require	0
the	0
separation	0
of	0
beneficial	0
from	0
deleterious	0
effects	0
.	0

One	0
possibility	0
toward	0
this	0
goal	0
is	0
to	0
try	0
to	0
dissociate	0
two	0
main	0
activities	0
of	0
glucocorticoids	0
,	0
i.e.	0
transactivation	0
and	0
transrepression	0
.	0

Screening	0
of	0
a	0
library	0
of	0
compounds	0
using	0
transactivation	0
and	0
AP-1	9
transrepression	0
models	0
in	0
transiently	0
transfected	0
cells	0
identified	0
dissociated	0
glucocorticoids	0
,	0
which	0
exert	0
strong	0
AP-1	9
inhibition	0
but	0
little	0
or	0
no	0
transactivation	0
.	0

Importantly	0
,	0
despite	0
high	0
ligand	0
binding	0
affinity	0
,	0
the	0
prototypic	0
dissociated	0
compound	0
,	0
RU24858	0
,	0
acted	0
as	0
a	0
weak	0
agonist	0
and	0
did	0
not	0
efficiently	0
antagonize	0
dexamethasone-induced	0
transcription	0
in	0
transfected	7
cells	8
.	0

Similar	0
results	0
were	0
obtained	0
in	0
hepatic	5
HTC	6
cells	6
for	0
the	0
transactivation	0
of	0
the	0
endogenous	1
tyrosine	2
amino	2
transferase	2
gene	2
(	0
TAT	1
)	0
,	0
which	0
encodes	0
one	0
of	0
the	0
enzymes	0
involved	0
in	0
the	0
glucocorticoid-dependent	0
stimulation	0
of	0
neoglucogenesis	0
.	0

To	0
investigate	0
whether	0
dissociated	0
glucocorticoids	0
retained	0
the	0
antiinflammatory	0
and	0
immunosuppressive	0
potential	0
of	0
classic	0
glucocorticoids	0
,	0
several	0
in	0
vitro	0
and	0
in	0
vivo	0
models	0
were	0
used	0
.	0

Indeed	0
,	0
secretion	0
of	0
the	0
proinflammatory	9
lymphokine	10
interleukin-1beta	10
was	0
severely	0
inhibited	0
by	0
dissociated	0
glucocorticoids	0
in	0
human	5
monocytic	6
THP	6
1	6
cells	6
.	0

Moreover	0
,	0
in	0
two	0
in	0
vivo	0
models	0
,	0
these	0
compounds	0
exerted	0
an	0
antiinflammatory	0
and	0
immunosuppressive	0
activity	0
as	0
potent	0
as	0
that	0
of	0
the	0
classic	0
glucocorticoid	0
prednisolone	0
.	0

These	0
results	0
may	0
lead	0
to	0
an	0
improvement	0
of	0
antiinflammatory	0
and	0
immunosuppressive	0
therapies	0
and	0
provide	0
a	0
novel	0
concept	0
for	0
drug	0
discovery	0
.	0

In	0
vivo	0
footprinting	0
and	0
mutational	0
analysis	0
of	0
the	0
proximal	1
CD19	2
promoter	2
reveal	0
important	0
roles	0
for	0
an	0
SP1/Egr-1	1
binding	2
site	2
and	0
a	0
novel	0
site	0
termed	0
the	0
PyG	1
box	2
.	0

CD19	9
expression	0
begins	0
at	0
the	0
pro-B	0
cell	0
stage	0
of	0
B	0
cell	0
development	0
.	0

As	0
such	0
it	0
serves	0
as	0
a	0
good	0
prototype	0
for	0
B	1
cell-specific	2
genes	2
whose	0
expression	0
begins	0
shortly	0
after	0
lineage	0
commitment	0
.	0

To	0
understand	0
the	0
molecular	0
mechanisms	0
controlling	0
CD19	9
gene	0
expression	0
,	0
we	0
isolated	0
and	0
functionally	0
characterized	0
the	0
CD19	1
promoter	2
using	0
in	0
vivo	0
footprinting	0
,	0
gel	0
shift	0
assays	0
,	0
and	0
transfection	0
studies	0
.	0

Reporter	0
constructs	0
spanning	0
portions	0
of	0
the	0
promoter	0
identified	0
a	0
region	1
between	2
-85	2
and	2
-200	2
that	0
produced	0
high	0
levels	0
of	0
reporter	0
gene	0
activity	0
in	0
lymphoid	7
cells	8
.	0

In	0
vivo	0
footprinting	0
identified	0
protected	0
regions	0
over	0
the	0
known	0
high	0
affinity	0
B	1
cell	2
lineage-specific	2
activator	2
protein	2
(	2
BSAP	2
)	2
site	2
,	0
the	0
low	1
affinity	2
BSAP	2
site	2
,	0
a	0
SP1/Egr-1	1
site	2
termed	0
the	0
CD19	1
GC	2
box	2
,	0
and	0
two	0
novel	0
sites	0
named	0
the	0
AT	1
box	2
and	0
PyG	1
box	2
.	0

Phorbol	0
ester	0
treatment	0
of	0
a	0
pre-B	5
cell	6
line	6
up-regulated	0
CD19	9
expression	0
,	0
induced	0
Egr-1	9
,	0
and	0
enhanced	0
the	0
footprint	0
over	0
the	0
GC	0
box	0
.	0

Gel	0
shift	0
assays	0
demonstrated	0
SP1	0
and	0
Egr-1	9
binding	0
to	0
the	0
CD19	1
GC	2
box	2
,	0
while	0
unknown	0
nuclear	0
proteins	0
bound	0
the	0
PyG	1
and	2
AT	2
boxes	2
.	0

Mutations	0
in	0
the	0
AT	1
box	2
or	0
in	0
the	0
BSAP	1
sites	2
did	0
not	0
affect	0
CD19	9
reporter	1
construct	2
activity	0
,	0
while	0
a	0
mutation	0
of	0
the	0
GC	1
box	2
reduced	0
it	0
modestly	0
,	0
and	0
a	0
PyG	1
box	2
mutation	0
reduced	0
it	0
dramatically	0
.	0

BSAP	9
failed	0
to	0
trans-activate	0
CD19	1
promoter	2
constructs	2
in	0
B	7
cells	8
or	0
non-B	7
cells	8
,	0
suggesting	0
that	0
cis	0
elements	0
such	0
as	0
the	0
PyG	1
and	2
GC	2
boxes	2
are	0
also	0
necessary	0
for	0
high	0
level	0
CD19	1
promoter	2
expression	0
.	0

EBF	9
and	0
E47	9
collaborate	0
to	0
induce	0
expression	0
of	0
the	0
endogenous	1
immunoglobulin	2
surrogate	2
light	2
chain	2
genes	2
.	0

Early	9
B	10
cell	10
factor	10
(	0
EBF	9
)	0
and	0
E47	9
participate	0
in	0
the	0
transcriptional	0
control	0
of	0
early	0
B	0
lymphocyte	0
differentiation	0
.	0

With	0
the	0
aim	0
of	0
identifying	0
genetic	0
targets	0
for	0
these	0
transcription	0
factors	0
,	0
we	0
stably	0
transfected	1
cDNAs	2
encoding	0
EBF	9
or	0
a	0
covalent	0
homodimer	0
of	0
E47	9
,	0
individually	0
or	0
together	0
,	0
into	0
immature	5
hematopoietic	6
Ba/F3	6
cells	6
,	0
which	0
lack	0
both	0
factors	0
.	0

In	0
combination	0
,	0
EBF	9
and	0
E47	9
induce	0
efficient	0
expression	0
of	0
the	0
endogenous	1
immunoglobulin	2
surrogate	2
light	2
chain	2
genes	2
,	0
lambda5	1
and	0
VpreB	1
,	0
whereas	0
other	0
pre-B	1
cell-specific	2
genes	2
remain	0
silent	0
.	0

Multiple	0
functionally	0
important	0
EBF	1
and	2
E47	2
binding	2
sites	2
were	0
identified	0
in	0
the	0
lambda5	1
promoter/enhancer	2
region	2
,	0
indicating	0
that	0
lambda5	1
is	0
a	0
direct	0
genetic	0
target	0
for	0
these	0
transcription	9
factors	10
.	0

Taken	0
together	0
,	0
these	0
data	0
suggest	0
that	0
EBF	9
and	0
E47	9
synergize	0
to	0
activate	0
expression	0
of	0
a	0
subset	0
of	0
genes	0
that	0
define	0
an	0
early	0
stage	0
of	0
the	0
B	7
cell	8
lineage	8
.	0

Cytokines	9
:	0
shared	0
receptors	9
,	0
distinct	0
functions	0
.	0

That	0
the	0
signal	0
transduction	0
pathways	0
used	0
by	0
the	0
cytokines	9
IL-2	9
and	0
IL-15	9
are	0
identical	0
would	0
suggest	0
that	0
these	0
cytokines	9
have	0
redundant	0
roles	0
in	0
lymphoid	0
development	0
;	0
instead	0
,	0
IL-2	9
is	0
the	0
guardian	0
of	0
thymus-derived	0
T-cell	0
homeostasis	0
,	0
while	0
interleukin-15	9
promotes	0
extrathymic	0
development	0
of	0
T	7
and	8
NK	8
cells	8
.	0

The	0
IL-4	9
receptor	10
alpha-chain	10
cytoplasmic	10
domain	10
is	0
sufficient	0
for	0
activation	0
of	0
JAK-1	9
and	0
STAT6	9
and	0
the	0
induction	0
of	0
IL-4	9
-specific	0
gene	0
expression	0
.	0

The	0
common	9
gamma-chain	10
(	0
gamma	9
(	10
c	10
)	10
)	0
is	0
a	0
functional	0
component	0
of	0
the	0
IL-4R	9
,	0
yet	0
cells	0
lacking	0
gamma	9
(	10
c	10
)	10
are	0
able	0
to	0
respond	0
to	0
IL-4	9
.	0

This	0
has	0
led	0
to	0
the	0
suggestion	0
that	0
a	0
surrogate	9
gamma'-chain	10
,	0
which	0
can	0
interact	0
with	0
the	0
IL-4R	9
alpha	10
chain	10
to	0
mediate	0
signaling	0
,	0
is	0
expressed	0
on	0
cells	0
lacking	0
gamma	9
(	10
c	10
)	10
.	0

An	0
alternative	0
possibility	0
is	0
that	0
in	0
the	0
absence	0
of	0
gamma	9
(	10
c	10
)	10
,	0
the	0
IL-4R	9
alpha	10
chain	10
is	0
able	0
to	0
transduce	0
signals	0
by	0
homodimerization	0
.	0

To	0
test	0
this	0
latter	0
possibility	0
,	0
a	0
chimeric	9
receptor	10
containing	0
the	0
extracellular	9
domain	10
of	0
c-kit	9
(	0
the	0
stem	9
cell	10
factor	10
(	10
SCF	10
)	10
receptor	10
)	0
and	0
the	0
cytoplasmic	9
and	10
transmembrane	10
domains	10
of	0
the	0
IL-4R	9
alpha	10
chain	10
was	0
generated	0
.	0

Treatment	0
of	0
cells	0
expressing	0
the	0
chimeric	9
receptor	10
kit/IL-4R	9
alpha	10
with	0
SCF	9
induces	0
activation	0
of	0
the	0
IL-4R	9
alpha-associated	10
kinase	10
JAK-1	9
and	0
the	0
transcription	9
factor	10
STAT6	9
.	0

However	0
,	0
tyrosine	0
phosphorylation	0
of	0
JAK-3	9
,	0
which	0
associates	0
with	0
gamma	9
(	10
c	10
)	10
,	0
is	0
not	0
induced	0
by	0
SCF	9
in	0
these	0
cells	0
.	0

SCF	9
-mediated	0
ligation	0
of	0
kit/IL-4R	9
alpha	10
is	0
sufficient	0
to	0
elicit	0
IL-4	9
-specific	0
gene	0
expression	0
,	0
including	0
up-regulation	0
of	0
CD23	9
and	0
synthesis	0
of	0
germ-line	3
epsilon	4
transcripts	4
.	0

In	0
the	0
T	5
cell	6
line	6
CTLL2	6
,	0
ligation	0
of	0
kit/IL-4R	9
alpha	10
induces	0
cellular	0
proliferation	0
.	0

Finally	0
,	0
in	0
JAK-1-deficient	5
HeLa	6
cells	6
,	0
STAT6	9
activation	0
by	0
IL-4	9
is	0
completely	0
abolished	0
.	0

Together	0
,	0
these	0
data	0
demonstrate	0
that	0
the	0
IL-4R	9
alpha	10
cytoplasmic	10
domain	10
is	0
sufficient	0
to	0
activate	0
JAK-1	9
and	0
STAT6	9
and	0
to	0
induce	0
expression	0
of	0
IL-4	1
target	2
genes	2
,	0
thus	0
identifying	0
a	0
mechanism	0
by	0
which	0
IL-4	9
signaling	0
can	0
proceed	0
in	0
the	0
absence	0
of	0
JAK-3	9
and	0
gamma	9
(	10
c	10
)	10
.	0

Histamine	0
modulates	0
the	0
expression	0
of	0
c-fos	1
through	0
cyclic	0
AMP	0
production	0
via	0
the	0
H2	9
receptor	10
in	0
the	0
human	5
promonocytic	6
cell	6
line	6
U937	6
.	0

We	0
examined	0
the	0
effects	0
of	0
histamine	0
and	0
its	0
agonists	0
on	0
the	0
expression	0
of	0
the	0
c-fos	1
and	2
c-myc	2
proto-oncogenes	2
at	0
the	0
transcriptional	0
and	0
translational	0
levels	0
in	0
the	0
human	5
promonocytic	6
U937	6
cell	6
line	6
.	0

Histamine	0
transiently	0
increased	0
cAMP	0
and	0
c-fos	1
expression	0
through	0
H2	9
receptors	10
.	0

Dibutyryl	0
cAMP	0
also	0
increased	0
c-fos	3
mRNA	4
and	0
protein	9
,	0
and	0
levels	0
remained	0
elevated	0
even	0
after	0
12	0
hr	0
of	0
treatment	0
.	0

Dose-dependence	0
studies	0
using	0
histamine	0
and	0
dimaprit	0
showed	0
that	0
the	0
EC50	0
values	0
for	0
cAMP	0
production	0
and	0
c-fos	1
increase	0
were	0
similar	0
,	0
suggesting	0
that	0
cAMP	0
might	0
be	0
involved	0
in	0
c-fos	1
induction	0
via	0
H2	9
receptors	10
.	0

Furthermore	0
,	0
studies	0
carried	0
out	0
using	0
H7	9
,	0
a	0
protein	9
kinase	10
A/protein	10
kinase	10
C	10
inhibitor	10
,	0
blocked	0
c-fos	1
induction	0
,	0
whereas	0
no	0
effect	0
was	0
observed	0
with	0
bisindolylmaleimide	0
,	0
a	0
specific	0
protein	9
kinase	10
C	10
inhibitor	0
.	0

No	0
modification	0
of	0
c-myc	1
expression	0
could	0
be	0
detected	0
on	0
treatment	0
with	0
histamine	0
or	0
its	0
analogues	0
.	0

Nevertheless	0
,	0
dibutyryl	0
cAMP	0
induced	0
a	0
down-regulation	0
of	0
the	0
levels	0
of	0
this	0
proto-oncogene	1
.	0

In	0
addition	0
,	0
dibutyryl	0
cAMP	0
inhibited	0
cell	0
growth	0
in	0
a	0
dose-dependent	0
manner	0
,	0
whereas	0
histamine	0
failed	0
to	0
affect	0
proliferation	0
and	0
differentiation	0
of	0
U937	5
cells	6
.	0

Cells	0
pretreated	0
with	0
dimaprit	0
showed	0
a	0
decrease	0
in	0
the	0
cAMP	0
response	0
to	0
subsequent	0
addition	0
of	0
H2	0
agonists	0
,	0
whereas	0
the	0
cAMP	0
response	0
to	0
prostaglandin	0
E2	0
remained	0
unaltered	0
.	0

This	0
homologous	0
mechanism	0
of	0
H2	9
receptor	10
desensitization	0
was	0
time	0
dependent	0
.	0

These	0
results	0
indicate	0
that	0
histamine	0
activates	0
several	0
mechanisms	0
involved	0
in	0
the	0
induction	0
of	0
differentiation	0
,	0
such	0
as	0
cAMP	0
and	0
c-fos	1
production	0
,	0
but	0
fails	0
to	0
promote	0
differentiation	0
of	0
U937	5
cells	6
,	0
apparently	0
due	0
to	0
the	0
rapid	0
desensitization	0
of	0
H2	9
receptors	10
.	0

Induction	0
of	0
cytokine	9
expression	0
in	0
leukocytes	7
by	0
binding	0
of	0
thrombin-stimulated	7
platelets	8
.	0

BACKGROUND	0
:	0
Activated	7
platelets	8
tether	0
and	0
activate	0
myeloid	7
leukocytes	8
.	0

To	0
investigate	0
the	0
potential	0
relevance	0
of	0
this	0
mechanism	0
in	0
acute	0
myocardial	0
infarction	0
(	0
AMI	0
)	0
,	0
we	0
examined	0
cytokine	9
induction	0
by	0
leukocyte-platelet	0
adhesion	0
and	0
the	0
occurrence	0
of	0
leukocyte-platelet	0
conjugates	0
in	0
patients	0
with	0
AMI	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
We	0
obtained	0
peripheral	0
venous	0
blood	0
samples	0
in	0
20	0
patients	0
with	0
AMI	0
before	0
and	0
daily	0
for	0
5	0
days	0
after	0
direct	0
percutaneous	0
transluminal	0
coronary	0
angioplasty	0
(	0
PTCA	0
)	0
and	0
in	0
20	0
patients	0
undergoing	0
elective	0
PTCA	0
.	0

Throughout	0
the	0
study	0
period	0
,	0
CD41	0
immunofluorescence	0
of	0
leukocytes	7
(	0
flow	0
cytometry	0
)	0
revealed	0
increased	0
leukocyte-platelet	0
adhesion	0
in	0
patients	0
with	0
AMI	0
compared	0
with	0
control	0
patients	0
(	0
mean	0
+/-	0
SE	0
of	0
fluorescence	0
[	0
channels	0
]	0
before	0
PTCA	0
:	0
77	0
+/-	0
16	0
versus	0
35	0
+/-	0
9	0
;	0
P	0
=	0
.003	0
)	0
.	0

In	0
vitro	0
,	0
thrombin-stimulated	7
fixed	8
platelets	8
bound	0
to	0
neutrophils	7
and	0
monocytes	7
.	0

Within	0
2	0
hours	0
,	0
this	0
resulted	0
in	0
increased	0
mRNA	0
for	0
interleukin	9
(	10
IL	10
)	10
,	10
1	10
beta	10
,	0
IL-8	9
,	0
and	0
monocyte	9
chemoattractant	10
protein	10
(	10
MCP	10
)	10
-1	10
in	0
unfractionated	0
leukocytes	7
.	0

After	0
4	0
hours	0
,	0
IL-1	9
beta	10
and	0
IL-8	9
concentration	0
of	0
the	0
cell-free	0
supernatant	0
had	0
increased	0
by	0
268	0
+/-	0
36	0
%	0
and	0
210	0
+/-	0
7	0
%	0
,	0
respectively	0
,	0
and	0
cellular	0
MCP-1	9
content	0
had	0
increased	0
by	0
170	0
+/-	0
8	0
%	0
.	0

Addition	0
of	0
activated	7
platelets	8
to	0
adherent	0
monocytes	7
had	0
a	0
similar	0
effect	0
and	0
was	0
associated	0
with	0
nuclear	9
factor-kappa	10
B	10
activation	0
.	0

Inhibition	0
of	0
binding	0
by	0
anti-P	9
selectin	10
antibodies	10
reduced	0
the	0
effect	0
of	0
activated	7
platelets	8
on	0
cytokine	9
production	0
.	0

CONCLUSIONS	0
:	0
In	0
patients	0
with	0
AMI	0
,	0
leukocyte-platelet	0
adhesion	0
is	0
increased	0
.	0

Binding	0
of	0
activated	7
platelets	8
induces	0
IL-1	9
beta	10
,	0
IL-8	9
,	0
and	0
MCP-1	9
in	0
leukocytes	7
.	0

Our	0
findings	0
suggest	0
that	0
leukocyte-platelet	0
adhesion	0
contributes	0
to	0
the	0
regulation	0
of	0
inflammatory	0
responses	0
in	0
AMI	0
.	0

Immediate	0
early	0
and	0
early	9
lytic	10
cycle	10
proteins	10
are	0
frequent	0
targets	0
of	0
the	0
Epstein-Barr	0
virus-induced	0
cytotoxic	0
T	0
cell	0
response	0
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
,	0
a	0
human	0
gamma-herpesvirus	0
,	0
can	0
establish	0
both	0
nonproductive	0
(	0
latent	0
)	0
and	0
productive	0
(	0
lytic	0
)	0
infections	0
.	0

Although	0
the	0
CD8+	0
cytotoxic	0
T	0
lymphocyte	0
(	0
CTL	0
)	0
response	0
to	0
latently	7
infected	8
cells	8
is	0
well	0
characterized	0
,	0
very	0
little	0
is	0
known	0
about	0
T	0
cell	0
controls	0
over	0
lytic	0
infection	0
;	0
this	0
imbalance	0
in	0
our	0
understanding	0
belies	0
the	0
importance	0
of	0
virus-replicative	0
lesions	0
in	0
several	0
aspects	0
of	0
EBV	0
disease	0
pathogenesis	0
.	0

The	0
present	0
work	0
shows	0
that	0
the	0
primary	0
CD8+	0
CTL	0
response	0
to	0
EBV	0
in	0
infectious	0
mononucleosis	0
patients	0
contains	0
multiple	0
lytic	0
antigen-specific	0
reactivities	0
at	0
levels	0
at	0
least	0
as	0
high	0
as	0
those	0
seen	0
against	0
latent	9
antigens	10
;	0
similar	0
reactivities	0
are	0
also	0
detectable	0
in	0
CTL	0
memory	0
.	0

Clonal	0
analysis	0
revealed	0
individual	0
responses	0
to	0
the	0
two	0
immediate	9
early	10
proteins	10
BZLF1	9
and	0
BRLF1	9
,	0
and	0
to	0
three	0
(	0
BMLF1	9
,	0
BMRF1	9
,	0
and	0
BALF2	9
)	0
of	0
the	0
six	0
early	9
proteins	10
tested	0
.	0

In	0
several	0
cases	0
,	0
the	0
peptide	0
epitope	0
and	0
HLA-restricting	0
determinant	0
recognized	0
by	0
these	0
CTLs	7
has	0
been	0
defined	0
,	0
one	0
unusual	0
feature	0
being	0
the	0
number	0
of	0
responses	0
restricted	0
through	0
HLA-C	1
alleles	2
.	0

The	0
work	0
strongly	0
suggests	0
that	0
EBV-replicative	0
lesions	0
are	0
subject	0
to	0
direct	0
CTL	0
control	0
in	0
vivo	0
and	0
that	0
immediate	9
early	10
and	10
early	10
proteins	10
are	0
frequently	0
the	0
immunodominant	0
targets	0
.	0

This	0
contrasts	0
with	0
findings	0
in	0
alpha-	0
and	0
beta-	0
herpesvirus	0
systems	0
(	0
herpes	0
simplex	0
,	0
cytomegalovirus	0
)	0
where	0
viral	0
interference	0
with	0
the	0
antigen-processing	0
pathway	0
during	0
lytic	0
infection	0
renders	0
immediate	9
early	10
and	10
early	10
proteins	10
much	0
less	0
immunogenic	0
.	0

The	0
unique	0
capacity	0
of	0
gamma-herpesvirus	0
to	0
amplify	0
the	0
viral	0
load	0
in	0
vivo	0
through	0
a	0
latent	0
growth-transforming	0
infection	0
may	0
have	0
rendered	0
these	0
agents	0
less	0
dependent	0
upon	0
viral	0
replication	0
as	0
a	0
means	0
of	0
successfully	0
colonizing	0
their	0
hosts	0
.	0

Triggering	0
of	0
HLA-DR	9
antigens	10
differentially	0
modulates	0
tumor	9
necrosis	10
factor	10
alpha	10
release	0
by	0
B	7
cells	8
at	0
distinct	0
stage	0
of	0
maturation	0
.	0

Triggering	0
of	0
HLA	9
class	10
II	10
antigens	10
by	0
the	0
anti-HLA-DR	9
monoclonal	10
antibody	10
(	10
mAb	10
)	10
L243	10
significantly	0
(	0
P	0
<	0
0.05	0
)	0
and	0
differentially	0
enhanced	0
the	0
release	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
by	0
the	0
non-Hodgkin	7
's	8
lymphoma	8
cells	8
Ri-I	5
,	0
Ci-I	5
,	0
and	0
Sc-I	5
,	0
which	0
are	0
at	0
a	0
distinct	0
stage	0
of	0
B-cell	0
differentiation	0
,	0
and	0
by	0
the	0
more	0
mature	0
Burkitt	5
lymphoma	6
cell	6
Raji	6
;	0
in	0
contrast	0
,	0
it	0
did	0
not	0
induce	0
TNF-alpha	9
release	0
by	0
the	0
pre-B	7
leukemia	8
cells	8
Nalm-6	5
and	0
BV173	5
.	0

TNF-alpha	9
release	0
peaked	0
at	0
24	0
h	0
and	0
decreased	0
thereafter	0
,	0
and	0
it	0
was	0
dose	0
dependent	0
and	0
preceded	0
by	0
an	0
increase	0
of	0
TNF-alpha	3
mRNA	4
detectable	0
after	0
3	0
h	0
of	0
stimulation	0
with	0
mAb	9
L243	10
.	0

Secreted	0
TNF-alpha	9
mediated	0
the	0
enhancement	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
and	0
activator	0
protein-1	0
(	0
AP-1	9
)	0
binding	0
activity	0
;	0
in	0
fact	0
,	0
the	0
triggering	0
of	0
HLA-DR	9
antigens	10
in	0
the	0
presence	0
of	0
antihuman	9
TNF-alpha-neutralizing	10
antibodies	10
did	0
not	0
upregulate	0
NF-kappa	9
B	10
and	0
AP-1	9
.	0

In	0
contrast	0
,	0
released	0
TNF-alpha	9
was	0
not	0
responsible	0
for	0
the	0
homotypic	0
aggregation	0
of	0
Ri-I	5
,	0
Ci-I	5
,	0
Sc-I	5
,	0
and	0
Raji	5
cells	6
induced	0
by	0
mAb	9
L243	10
,	0
and	0
it	0
did	0
not	0
affect	0
the	0
proliferation	0
of	0
B	7
cells	8
investigated	0
.	0

Altogether	0
,	0
our	0
data	0
demonstrate	0
that	0
:	0
(	0
a	0
)	0
the	0
ability	0
of	0
B	7
cells	8
to	0
release	0
TNF-alpha	9
after	0
triggering	0
of	0
HLA-DR	9
antigens	10
depends	0
on	0
their	0
stage	0
of	0
differentiation	0
;	0
(	0
b	0
)	0
levels	0
of	0
released	0
TNF-alpha	9
seem	0
to	0
correlate	0
with	0
the	0
stage	0
of	0
B-cell	0
maturation	0
but	0
do	0
not	0
correlate	0
with	0
the	0
amounts	0
of	0
cell	9
surface	10
HLA-DR	10
antigens	10
;	0
(	0
c	0
)	0
secreted	0
TNF-alpha	9
regulates	0
the	0
levels	0
of	0
expression	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
by	0
an	0
autocrine	0
loop	0
;	0
and	0
(	0
d	0
)	0
intracellular	0
signals	0
mediating	0
TNF-alpha	9
release	0
by	0
B	7
cells	8
are	0
distinct	0
from	0
those	0
regulating	0
homotypic	0
aggregation	0
and	0
proliferation	0
.	0

Transcription	9
factor	10
GATA-3	10
is	0
differentially	0
expressed	0
in	0
murine	5
Th1	6
and	6
Th2	6
cells	6
and	0
controls	0
Th2-specific	0
expression	0
of	0
the	0
interleukin-5	1
gene	2
.	0

Interleukin-5	9
(	0
IL-5	9
)	0
,	0
which	0
is	0
produced	0
by	0
CD4	7
(	8
+	8
)	8
T	8
helper	8
2	8
(	8
Th2	8
)	8
cells	8
,	0
but	0
not	0
by	0
Th1	7
cells	8
,	0
plays	0
a	0
key	0
role	0
in	0
the	0
development	0
of	0
eosinophilia	0
in	0
asthma	0
.	0

Despite	0
increasing	0
evidence	0
that	0
the	0
outcome	0
of	0
many	0
diseases	0
is	0
determined	0
by	0
the	0
ratio	0
of	0
the	0
two	0
subsets	0
of	0
CD4	7
(	8
+	8
)	8
T	8
helper	8
cells	8
,	0
Th1	7
and	0
Th2	7
,	0
the	0
molecular	0
basis	0
for	0
Th1-	0
and	0
Th2-	0
specific	0
gene	0
expression	0
remains	0
to	0
be	0
elucidated	0
.	0

We	0
previously	0
established	0
a	0
critical	0
role	0
for	0
the	0
transcription	9
factor	10
GATA-3	9
in	0
IL-5	1
promoter	2
activation	0
in	0
EL-4	5
cells	6
,	0
which	0
express	0
both	0
Th1-	9
and	10
Th2-type	10
cytokines	10
.	0

Our	0
studies	0
reported	0
here	0
demonstrate	0
that	0
GATA-3	9
is	0
critical	0
for	0
expression	0
of	0
the	0
IL-5	9
gene	0
in	0
bona	7
fide	8
Th2	8
cells	8
.	0

Whereas	0
mutations	0
in	0
the	0
GATA-3	9
site	0
abolished	0
antigen-	0
or	0
cAMP-	0
stimulated	0
IL-5	0
promoter	0
activation	0
in	0
Th2	0
cells	0
,	0
ectopic	0
expression	0
of	0
GATA-3	9
in	0
Th1	7
cells	8
or	0
in	0
a	0
non-lymphoid	5
,	6
non-IL-5-producing	6
cell	6
line	6
activated	0
the	0
IL-5	1
promoter	2
.	0

During	0
the	0
differentiation	0
of	0
naive	7
CD4	8
(	8
+	8
)	8
T	8
cells	8
isolated	0
from	0
T	0
cell	0
receptor	0
transgenic	0
mice	0
,	0
GATA-3	9
gene	0
expression	0
was	0
up-regulated	0
in	0
developing	0
Th2	7
cells	8
,	0
but	0
was	0
down-regulated	0
in	0
Th1	7
cells	8
,	0
and	0
antigen-	7
or	8
cAMP-activated	8
Th2	8
cells	8
(	0
but	0
not	0
Th1	7
cells	8
)	0
expressed	0
the	0
GATA-3	9
protein	10
.	0

Thus	0
,	0
GATA-3	9
may	0
play	0
an	0
important	0
role	0
in	0
the	0
balance	0
between	0
Th1	7
and	0
Th2	7
subsets	8
in	0
immune	0
responses	0
.	0

Inhibition	0
of	0
GATA-3	9
activity	0
has	0
therapeutic	0
potential	0
in	0
the	0
treatment	0
of	0
asthma	0
and	0
other	0
hypereosinophilic	0
diseases	0
.	0

A	0
shortened	0
life	0
span	0
of	0
EKLF-/-	7
adult	8
erythrocytes	8
,	0
due	0
to	0
a	0
deficiency	0
of	0
beta-globin	9
chains	10
,	0
is	0
ameliorated	0
by	0
human	9
gamma-globin	10
chains	10
.	0

Using	0
homologous	0
recombination	0
,	0
both	0
EKLF	1
alleles	2
in	0
murine	5
embryonic	6
stem	6
(	6
ES	6
)	6
cells	6
were	0
inactivated	0
.	0

These	0
EKLF-/-	5
ES	6
cells	6
were	0
capable	0
of	0
undergoing	0
in	0
vitro	0
differentiation	0
to	0
form	0
definitive	0
erythroid	0
colonies	0
that	0
were	0
similar	0
in	0
size	0
and	0
number	0
to	0
those	0
formed	0
by	0
wild-type	7
ES	8
cells	8
.	0

However	0
,	0
the	0
EKLF-/-	5
colonies	6
were	0
poorly	0
hemoglobinized	0
and	0
enucleated	7
erythrocytes	8
in	0
these	0
colonies	0
contained	0
numerous	0
Heinz	0
bodies	0
.	0

Reverse	0
transcriptase-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
analyses	0
revealed	0
that	0
adult	0
and	0
embryonic	1
globin	2
genes	2
were	0
appropriately	0
regulated	0
,	0
with	0
the	0
exception	0
of	0
beta	9
h1-globin	10
,	0
which	0
continued	0
to	0
be	0
expressed	0
at	0
a	0
very	0
low	0
level	0
.	0

The	0
ratio	0
of	0
adult	3
beta-globin/alpha-globin	4
mRNA	4
in	0
the	0
mutant	5
ES	6
cells	6
was	0
1/15	0
of	0
that	0
in	0
wild-type	7
ES	8
cells	8
.	0

When	0
the	0
EKLF-/-	5
cells	6
were	0
injected	0
into	0
blastocysts	0
,	0
they	0
did	0
not	0
contribute	0
at	0
a	0
detectable	0
level	0
to	0
the	0
mature	0
erythrocyte	0
compartment	0
of	0
the	0
chimeric	0
animals	0
,	0
based	0
on	0
analysis	0
of	0
glucose	9
phosphate	10
isomerase-1	10
(	10
GPI-1	10
)	10
isozymes	10
and	0
hemoglobins	0
that	0
distinguish	0
ES	7
cell-derived	8
erythrocytes	8
from	0
host	0
blastocyst-derived	7
erythrocytes	8
.	0

In	0
contrast	0
,	0
semiquantitative	0
RT-PCR	0
analysis	0
of	0
RNA	0
from	0
reticulocytes	7
of	0
the	0
same	0
chimeric	0
animals	0
suggested	0
that	0
the	0
ES	7
cell-derived	8
reticulocytes	8
were	0
present	0
at	0
a	0
level	0
of	0
6	0
%	0
to	0
8	0
%	0
.	0

This	0
indicated	0
that	0
the	0
EKLF-/-	5
erythrocytes	6
in	0
adult	0
animals	0
must	0
be	0
short-lived	0
,	0
apparently	0
due	0
to	0
the	0
imbalance	0
of	0
beta-	9
versus	10
alpha-globin	10
chains	10
,	0
leading	0
to	0
the	0
precipitation	0
of	0
excess	0
alpha-globin	9
chains	10
to	0
form	0
Heinz	0
bodies	0
.	0

Consistent	0
with	0
this	0
hypothesis	0
,	0
the	0
short	0
life	0
span	0
was	0
ameliorated	0
by	0
introduction	0
into	0
the	0
EKLF-/-	5
ES	6
cells	6
of	0
a	0
human	1
LCR/gamma-globin	2
gene	2
,	0
as	0
evidenced	0
by	0
the	0
presence	0
of	0
ES	7
cell-derived	8
reticulocytes	8
as	0
well	0
as	0
mature	7
erythrocytes	8
in	0
the	0
blood	0
of	0
the	0
chimeric	0
animals	0
.	0

RP1	1
,	0
a	0
new	0
member	0
of	0
the	0
adenomatous	1
polyposis	2
coli-binding	2
EB1-like	2
gene	2
family	2
,	0
is	0
differentially	0
expressed	0
in	0
activated	7
T	8
cells	8
.	0

Cross-linking	0
of	0
the	0
CD3	9
and	10
CD28	10
molecules	10
on	0
T	7
lymphocytes	8
represents	0
one	0
of	0
the	0
most	0
effective	0
signals	0
for	0
T	7
lymphocyte	8
activation	0
and	0
triggering	0
of	0
their	0
cytotoxic	0
effector	0
function	0
.	0

To	0
identify	0
genes	0
that	0
are	0
expressed	0
in	0
T	7
cells	8
after	0
stimulation	0
,	0
mRNA	0
from	0
T	7
lymphocytes	8
that	0
had	0
been	0
activated	0
by	0
the	0
simultaneous	0
stimulation	0
of	0
the	0
CD3	9
and	0
CD28	9
trigger	0
molecules	0
was	0
transcribed	0
for	0
a	0
differential	0
mRNA	0
display	0
analysis	0
into	0
cDNA	0
and	0
was	0
compared	0
with	0
cDNA	0
from	0
CD28	9
-or	0
CD3	9
-activated	0
or	0
resting	0
lymphocytes	7
.	0

Differential	0
expression	0
was	0
confirmed	0
subsequently	0
by	0
Northern	0
blot	0
analysis	0
.	0

One	0
of	0
the	0
cDNA	1
fragments	2
expressed	0
specifically	0
in	0
CD3	9
-and	0
CD28	9
-activated	7
T	8
cells	8
was	0
designated	0
RP1	1
.	0

The	0
predictive	1
protein-coding	2
region	2
of	0
RP1	1
had	0
a	0
significant	0
homology	0
to	0
members	0
of	0
the	0
recently	0
found	0
adenomatous	1
polyposis	2
coli	2
(	2
APC	2
)	2
protein-binding	2
EB1	2
gene	2
family	2
,	0
which	0
codes	0
for	0
yet	0
unknown	0
protein	0
(	0
s	0
)	0
.	0

Bacterially	0
expressed	0
RP1	9
protein	10
revealed	0
specific	0
binding	0
to	0
wild-type	9
but	0
not	0
to	0
mutated	9
APC	10
protein	10
.	0

The	0
rapid	0
up-regulation	0
of	0
RP1	3
mRNA	4
in	0
properly	0
activated	7
T	8
cells	8
suggests	0
that	0
this	0
gene	0
might	0
belong	0
to	0
the	0
immediate/early	1
gene	2
family	2
,	0
which	0
controls	0
the	0
signal	0
transduction	0
cascade	0
downstream	0
of	0
the	0
TCR	9
.	0

As	0
the	0
expression	0
level	0
of	0
the	0
RP1	1
gene	2
in	0
activated	7
T	8
cells	8
and	0
a	0
spectrum	0
of	0
tumor-derived	5
cell	6
lines	6
correlates	0
with	0
the	0
proliferative	0
status	0
of	0
the	0
cells	0
,	0
members	0
of	0
the	0
EB1-like	1
gene	2
family	2
may	0
not	0
only	0
be	0
involved	0
in	0
the	0
tumorigenesis	0
of	0
colorectal	0
cancers	0
but	0
may	0
also	0
play	0
a	0
role	0
in	0
the	0
proliferative	0
control	0
of	0
normal	7
cells	8
.	0

Cyclosporin	0
A	0
interferes	0
with	0
the	0
inducible	0
degradation	0
of	0
NF-kappa	9
B	10
inhibitors	0
,	0
but	0
not	0
with	0
the	0
processing	0
of	0
p105/	0
NF-kappa	9
B1	10
in	0
T	7
cells	8
.	0

The	0
transcription	9
factor	10
NF-kappa	9
B	10
controls	0
the	0
induction	0
of	0
numerous	0
cytokine	1
promoters	2
during	0
the	0
activation	0
of	0
T	7
lymphocytes	8
.	0

Inhibition	0
of	0
T	0
cell	0
activation	0
by	0
the	0
immunosuppressants	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
exerts	0
a	0
suppressive	0
effect	0
on	0
the	0
induction	0
of	0
these	0
NF-kappa	1
B-controlled	2
cytokine	2
promoters	2
.	0

We	0
show	0
for	0
human	5
Jurkat	6
T	6
leukemia	6
cells	6
,	0
as	0
well	0
as	0
human	7
and	8
mouse	8
primary	8
T	8
lymphocytes	8
,	0
that	0
this	0
inhibitory	0
effect	0
is	0
accompanied	0
by	0
an	0
impaired	0
nuclear	0
translocation	0
of	0
the	0
Rel	9
proteins	10
c-Rel	9
,	0
RelA/p65	9
and	0
NF-kappa	9
B1/p50	10
,	0
whereas	0
the	0
nuclear	0
appearance	0
of	0
RelB	9
remains	0
unaffected	0
.	0

CsA	0
does	0
not	0
interfere	0
with	0
the	0
synthesis	0
of	0
Rel	9
proteins	10
,	0
but	0
prevents	0
the	0
inducible	0
degradation	0
of	0
cytosolic	9
NF-kappa	10
B	10
inhibitors	10
I	9
kappa	10
B	10
alpha	10
and	0
I	9
kappa	10
B	10
beta	10
upon	0
T	0
cell	0
activation	0
.	0

CsA	0
neither	0
inhibits	0
the	0
processing	0
of	0
the	0
NF-kappa	9
B1	10
precursor	10
p105	9
to	0
p50	9
,	0
nor	0
does	0
it	0
``	0
stabilize	0
''	0
the	0
C-terminal	0
portion	0
of	0
p105	9
,	0
I	9
kappa	10
B	10
gamma	10
,	0
which	0
is	0
degraded	0
during	0
p105	9
processing	0
to	0
mature	9
p50	10
.	0

These	0
results	0
indicate	0
that	0
CsA	0
interferes	0
with	0
a	0
specific	0
event	0
in	0
the	0
signal-induced	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
I	9
kappa	10
B	10
beta	10
,	0
but	0
does	0
not	0
affect	0
the	0
processing	0
of	0
NF-kappa	9
B1/p105	10
to	0
p50	9
.	0

Activation	0
of	0
nuclear	9
factor-kappa	10
B	10
by	0
beta-amyloid	0
peptides	0
and	0
interferon-gamma	9
in	0
murine	0
microglia	0
.	0

An	0
increasing	0
body	0
of	0
evidence	0
suggests	0
that	0
amyloid-beta	0
(	0
A	0
beta	0
)	0
peptides	0
and	0
microglia	7
are	0
crucially	0
involved	0
in	0
the	0
pathogenesis	0
of	0
Alzheimer	0
's	0
disease	0
.	0

In	0
an	0
effort	0
to	0
further	0
elucidate	0
the	0
biological	0
effects	0
of	0
A	0
beta	0
towards	0
microglia	7
,	0
we	0
investigated	0
the	0
ability	0
of	0
A	0
beta	0
peptides	0
to	0
activate	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
in	0
the	0
N9	5
murine	6
microglial	6
cell	6
line	6
.	0

Co-stimulation	0
of	0
microglia	7
with	0
suboptimal	0
concentrations	0
of	0
A	0
beta	0
(	0
25-35	0
)	0
and	0
100	0
U/ml	0
IFN	9
gamma	10
resulted	0
in	0
the	0
detection	0
of	0
a	0
specific	0
NF-kappa	9
B	10
DNA-binding	0
activity	0
in	0
nuclear	0
extracts	0
,	0
as	0
determined	0
in	0
gel	0
mobility	0
shift	0
assays	0
.	0

This	0
response	0
required	0
at	0
least	0
120	0
min	0
to	0
be	0
evident	0
and	0
supershift	0
experiments	0
revealed	0
that	0
the	0
NF-kappa	9
B	10
complex	10
contains	0
both	0
RelA	9
and	0
p50	9
.	0

Accordingly	0
,	0
immunoblot	0
experiments	0
showed	0
that	0
amongst	0
NF-kappa	9
B	10
/Rel	9
proteins	10
,	0
RelA	9
and	0
p50	9
are	0
mobilized	0
to	0
the	0
nucleus	0
following	0
microglial	0
cell	0
stimulation	0
with	0
A	0
beta	0
(	0
25-35	0
)	0
plus	0
IFN	9
gamma	10
.	0

Higher	0
concentrations	0
of	0
A	0
beta	0
(	0
25-35	0
)	0
were	0
effective	0
by	0
themselves	0
in	0
inducing	0
NF-kappa	9
B	10
activation	0
,	0
both	0
in	0
the	0
N9	5
microglial	6
cell	6
line	6
and	0
in	0
rat	5
primary	6
microglia	6
,	0
as	0
well	0
as	0
in	0
human	7
monocytes	8
.	0

For	0
purposes	0
of	0
comparison	0
,	0
microglia	7
were	0
also	0
stimulated	0
with	0
bacterial	0
LPS	0
,	0
a	0
known	0
NF-kappa	9
B	10
inducer	0
.	0

As	0
expected	0
,	0
LPS	0
strongly	0
induced	0
the	0
formation	0
of	0
two	0
NF-kappa	9
B	10
DNA-binding	0
activities	0
,	0
one	0
of	0
which	0
was	0
identified	0
as	0
RelA/p50	9
.	0

The	0
LPS	0
response	0
was	0
also	0
more	0
rapid	0
,	0
as	0
it	0
was	0
already	0
evident	0
by	0
40	0
min	0
and	0
remained	0
sustained	0
for	0
up	0
to	0
3	0
h	0
.	0

Collectively	0
,	0
these	0
findings	0
indicate	0
that	0
NF-kappa	9
B	10
activation	0
might	0
constitute	0
one	0
of	0
the	0
mechanisms	0
underlying	0
the	0
inducible	0
expression	0
of	0
kappa	1
B-dependent	2
genes	2
in	0
microglia	7
stimulated	0
by	0
A	0
beta	0
peptides	0
and	0
IFN	9
gamma	10
,	0
or	0
by	0
LPS	0
.	0

Glucocorticoid-mediated	0
repression	0
of	0
cytokine	1
gene	2
transcription	0
in	0
human	0
arteritis-SCID	9
chimeras	10
.	0

Giant	0
cell	0
arteritis	0
(	0
GCA	0
)	0
is	0
a	0
vasculitic	0
syndrome	0
that	0
preferentially	0
affects	0
medium	0
and	0
large-sized	0
arteries	0
.	0

Glucocorticoid	0
therapy	0
resolves	0
clinical	0
symptoms	0
within	0
hours	0
to	0
days	0
,	0
but	0
therapy	0
has	0
to	0
be	0
continued	0
over	0
several	0
years	0
to	0
prevent	0
disease	0
relapses	0
.	0

It	0
is	0
not	0
known	0
whether	0
and	0
how	0
glucocorticoids	0
affect	0
the	0
function	0
of	0
the	0
inflammatory	0
infiltrate	0
or	0
why	0
the	0
disease	0
persists	0
subclinically	0
despite	0
chronic	0
treatment	0
.	0

GCA	0
is	0
self-sustained	0
in	0
temporal	0
arteries	0
engrafted	0
into	0
SCID	0
mice	0
,	0
providing	0
a	0
model	0
in	0
which	0
the	0
mechanisms	0
of	0
action	0
and	0
limitations	0
of	0
glucocorticoid	0
therapy	0
can	0
be	0
examined	0
in	0
vivo	0
.	0

Administration	0
of	0
dexamethasone	0
to	0
temporal	5
artery-SCID	6
chimeras	6
for	0
1	0
wk	0
induced	0
a	0
partial	0
suppression	0
of	0
T	0
cell	0
and	0
macrophage	0
function	0
as	0
indicated	0
by	0
the	0
reduced	0
tissue	0
concentrations	0
of	0
IL-2	3
,	4
IL-1beta	4
,	4
and	4
IL-6	4
mRNA	4
,	0
and	0
by	0
the	0
diminished	0
expression	0
of	0
inducible	0
NO	9
synthase	10
.	0

In	0
contrast	0
,	0
synthesis	0
of	0
IFN-gamma	3
mRNA	4
was	0
only	0
slightly	0
decreased	0
,	0
and	0
expression	0
of	0
TGF-beta1	9
was	0
unaffected	0
.	0

These	0
findings	0
correlated	0
with	0
activation	0
of	0
the	0
IkappaBalpha	1
gene	2
and	0
blockade	0
of	0
the	0
nuclear	0
translocation	0
of	0
NFkappaB	9
in	0
the	0
xenotransplanted	0
tissue	0
.	0

Dose-response	0
experiments	0
suggested	0
that	0
steroid	0
doses	0
currently	0
used	0
in	0
clinical	0
medicine	0
are	0
suboptimal	0
in	0
repressing	0
NFkappaB	9
-mediated	0
cytokine	9
production	0
in	0
the	0
inflammatory	0
lesions	0
.	0

Chronic	0
steroid	0
therapy	0
was	0
able	0
to	0
deplete	0
the	0
T	9
cell	10
products	10
IL-2	9
and	0
IFN-gamma	9
,	0
whereas	0
the	0
activation	0
of	0
tissue-infiltrating	7
macrophages	8
was	0
only	0
partially	0
affected	0
.	0

IL-1beta	9
transcription	0
was	0
abrogated	0
;	0
in	0
contrast	0
,	0
TGF-beta1	3
mRNA	4
synthesis	0
was	0
steroid	0
resistant	0
.	0

The	0
persistence	0
of	0
TGF-beta1-transcribing	7
macrophages	8
,	0
despite	0
paralysis	0
of	0
T	0
cell	0
function	0
,	0
may	0
provide	0
an	0
explanation	0
for	0
the	0
chronicity	0
of	0
the	0
disease	0
,	0
and	0
may	0
identify	0
a	0
novel	0
therapeutic	0
target	0
in	0
this	0
inflammatory	0
vasculopathy	0
.	0

Defective	0
survival	0
and	0
activation	0
of	0
thymocytes	7
in	0
transgenic	0
mice	0
expressing	0
a	0
catalytically	9
inactive	10
form	10
of	0
Ca2+/calmodulin-dependent	9
protein	10
kinase	10
IV	10
.	0

We	0
have	0
generated	0
transgenic	0
mice	0
that	0
express	0
a	0
catalytically	9
inactive	10
form	10
of	0
Ca2+/calmodulin-dependent	9
protein	10
kinase	10
IV	10
(	0
CaMKIV	9
)	0
specifically	0
in	0
thymic	7
T	8
cells	8
.	0

The	0
presence	0
of	0
this	0
protein	0
results	0
in	0
a	0
markedly	0
reduced	0
thymic	0
cellularity	0
,	0
although	0
the	0
distribution	0
of	0
the	0
remaining	0
cells	0
is	0
normal	0
based	0
on	0
evaluation	0
of	0
the	0
CD4	9
and	0
CD8	9
cell	9
surface	10
antigens	10
that	0
are	0
used	0
to	0
gauge	0
T	0
cell	0
development	0
.	0

Isolated	0
thymic	7
T	8
cells	8
from	0
the	0
transgenic	0
mice	0
also	0
show	0
a	0
dramatically	0
decreased	0
survival	0
rate	0
when	0
evaluated	0
in	0
culture	0
under	0
conditions	0
that	0
do	0
not	0
favor	0
activation	0
.	0

When	0
challenged	0
with	0
an	0
activating	0
stimulus	0
such	0
as	0
alpha-CD3	9
or	0
a	0
combination	0
of	0
phorbol	0
ester	0
plus	0
ionophore	0
,	0
the	0
cells	0
are	0
severely	0
compromised	0
in	0
their	0
ability	0
to	0
produce	0
the	0
cytokine	9
interleukin-2	9
(	0
IL-2	9
)	0
.	0

Reduction	0
of	0
IL-2	9
production	0
is	0
secondary	0
to	0
the	0
inability	0
to	0
phosphorylate	0
the	0
cAMP	9
response	10
element	10
binding	10
protein	10
,	0
CREB	9
,	0
and	0
induce	0
expression	0
of	0
the	0
immediate	1
early	2
genes	2
such	0
as	0
Fos	1
B	2
that	0
are	0
required	0
to	0
transactivate	0
the	0
IL-2	1
promoter	2
.	0

Because	0
transgene	0
expression	0
was	0
regulated	0
by	0
the	0
proximal	1
promoter	2
of	0
the	0
murine	1
lck	2
gene	2
and	0
this	0
promoter	0
is	0
inactivated	0
in	0
T	7
cells	8
that	0
exit	0
the	0
thymus	0
,	0
the	0
mutant	9
hCaMKIV	10
is	0
not	0
present	0
in	0
peripheral	7
T	8
cells	8
.	0

Consequently	0
,	0
T	7
lymphocytes	8
present	0
in	0
the	0
spleen	0
can	0
be	0
activated	0
normally	0
in	0
response	0
to	0
either	0
stimulus	0
mentioned	0
above	0
,	0
demonstrating	0
that	0
the	0
effects	0
of	0
the	0
inactive	9
CaMKIV	10
on	0
activation	0
are	0
reversible	0
.	0

Our	0
results	0
suggest	0
that	0
CaMKIV	9
may	0
represent	0
a	0
physiologically	0
relevant	0
CREB	9
kinase	10
in	0
T	7
cells	8
and	0
that	0
the	0
enzyme	0
is	0
also	0
required	0
to	0
ensure	0
normal	0
expansion	0
of	0
T	7
cells	8
in	0
the	0
thymus	0
.	0

Whereas	0
the	0
pathway	0
responsible	0
for	0
this	0
latter	0
role	0
is	0
yet	0
to	0
be	0
elucidated	0
,	0
it	0
is	0
unlikely	0
to	0
include	0
CREB	9
phosphorylation	0
.	0

A	0
new	0
mouse	1
gene	2
,	0
SRG3	1
,	0
related	0
to	0
the	0
SWI3	1
of	0
Saccharomyces	0
cerevisiae	0
,	0
is	0
required	0
for	0
apoptosis	0
induced	0
by	0
glucocorticoids	0
in	0
a	0
thymoma	5
cell	6
line	6
.	0

We	0
isolated	0
a	0
new	0
mouse	1
gene	2
that	0
is	0
highly	0
expressed	0
in	0
thymocytes	7
,	0
testis	0
,	0
and	0
brain	0
.	0

This	0
gene	0
,	0
SRG3	1
,	0
showed	0
a	0
significant	0
sequence	0
homology	0
to	0
SWI3	1
,	0
a	0
yeast	1
transcriptional	2
activator	2
,	0
and	0
its	0
human	1
homolog	2
BAF155	2
.	0

SRG3	1
encodes	0
1	0
,	0
100	0
amino	0
acids	0
and	0
has	0
33-47	0
%	0
identity	0
with	0
SWI3	9
protein	10
over	0
three	0
regions	0
.	0

The	0
SRG3	9
protein	10
contains	0
an	0
acidic	9
NH2	10
terminus	10
,	0
a	0
myb-like	9
DNA	10
binding	10
domain	10
,	0
a	0
leucine-zipper	9
motif	10
,	0
and	0
a	0
proline-	9
and	10
glutamine-rich	10
region	10
at	0
its	0
COOH	9
terminus	10
.	0

Rabbit	0
antiserum	0
raised	0
against	0
a	0
COOH-terminal	0
polypeptide	0
of	0
the	0
SRG3	1
recognized	0
a	0
protein	0
with	0
an	0
apparent	0
molecular	0
mass	0
of	0
155	0
kD	0
.	0

The	0
serum	0
also	0
detected	0
a	0
170-kD	9
protein	10
that	0
seems	0
to	0
be	0
a	0
mouse	0
homologue	0
of	0
human	9
BAF170	10
.	0

Immunoprecipitation	0
of	0
cell	0
extract	0
with	0
the	0
antiserum	0
against	0
the	0
mouse	9
SRG3	10
also	0
brought	0
down	0
a	0
195-kD	9
protein	10
that	0
could	0
be	0
recognized	0
by	0
an	0
antiserum	0
raised	0
against	0
human	9
SWI2	10
protein	10
.	0

The	0
results	0
suggest	0
that	0
the	0
SRG3	9
protein	10
associates	0
with	0
a	0
mouse	9
SWI2	10
.	0

The	0
SRG3	9
protein	10
is	0
expressed	0
about	0
three	0
times	0
higher	0
in	0
thymocytes	7
than	0
in	0
peripheral	7
lymphocytes	8
.	0

The	0
expression	0
of	0
anti-sense	9
RNA	10
to	0
SRG3	3
mRNA	4
in	0
a	0
thymoma	5
cell	6
line	6
,	0
S49.1	5
,	0
reduced	0
the	0
expression	0
level	0
of	0
the	0
SRG3	9
protein	10
,	0
and	0
decreased	0
the	0
apoptotic	0
cell	0
death	0
induced	0
by	0
glucocorticoids	0
.	0

These	0
results	0
suggest	0
that	0
the	0
SRG3	9
protein	10
is	0
involved	0
in	0
the	0
glucocorticoid-induced	0
apoptosis	0
in	0
the	0
thymoma	5
cell	6
line	6
.	0

This	0
implicates	0
that	0
the	0
SRG3	1
may	0
play	0
an	0
important	0
regulatory	0
role	0
during	0
T	0
cell	0
development	0
in	0
thymus	0
.	0

Transcriptional	0
induction	0
of	0
collagenase-1	9
in	0
differentiated	5
monocyte-like	6
(	6
U937	6
)	6
cells	6
is	0
regulated	0
by	0
AP-1	9
and	0
an	0
upstream	1
C/EBP-beta	2
site	2
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
the	0
AP-1	9
site	0
and	0
a	0
distal	1
promoter	2
element	2
regulate	0
transcriptional	0
induction	0
of	0
collagenase-1	9
during	0
monocytic	0
differentiation	0
.	0

Chloramphenicol	1
acetyltransferase	2
expression	2
constructs	2
containing	0
regions	0
of	0
the	0
human	1
collagenase-1	2
promoter	2
were	0
stably	0
or	0
transiently	0
transfected	0
into	0
U937	5
cells	6
,	0
and	0
reporter	0
activity	0
was	0
assessed	0
at	0
various	0
times	0
after	0
the	0
onset	0
of	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
-mediated	0
differentiation	0
.	0

Rapid	0
and	0
strong	0
induction	0
of	0
promoter	0
activity	0
was	0
lost	0
in	0
constructs	0
with	0
a	0
mutant	1
AP-1	2
element	2
;	0
however	0
,	0
at	0
16-96	0
h	0
post-PMA	0
,	0
the	0
mutant	1
collagenase-1	2
promoter	2
displayed	0
AP-1	9
independent	0
PMA-mediated	0
transactivation	0
.	0

The	0
AP-1	1
mutant	2
constructs	2
also	0
showed	0
delayed	0
transcriptional	0
activation	0
in	0
PMA-treated	5
fibroblasts	6
.	0

Western	0
and	0
supershift	0
analyses	0
indicated	0
that	0
functional	9
Jun	10
and	10
Fos	10
proteins	10
were	0
present	0
in	0
nuclear	0
extracts	0
of	0
PMA-differentiated	5
U937	6
cells	6
.	0

Promoter	0
deletion	0
constructs	0
demonstrated	0
the	0
potential	0
role	0
of	0
distal	1
promoter	2
sequences	2
in	0
regulating	0
collagenase-1	9
transcription	0
.	0

In	0
particular	0
,	0
Western	0
,	0
supershift	0
,	0
and	0
promoter	0
deletion	0
analyses	0
suggested	0
a	0
role	0
for	0
CCAAT/enhancer-binding	1
protein-beta	2
(	2
C/EBP-beta	2
)	2
binding	2
site	2
between	0
-2010	1
and	2
-1954	2
in	0
regulating	0
transcription	0
of	0
collagenase-1	9
in	0
monocytic	7
cells	8
.	0

Our	0
findings	0
suggest	0
that	0
distinct	0
regulatory	1
elements	2
,	0
acting	0
somewhat	0
independently	0
of	0
each	0
other	0
,	0
control	0
expression	0
of	0
collagenase-1	9
.	0

In	0
addition	0
,	0
our	0
data	0
suggests	0
that	0
the	0
rapid	0
PMA-mediated	0
induction	0
of	0
collagenase-1	9
transcription	0
is	0
controlled	0
by	0
a	0
mechanism	0
distinct	0
from	0
that	0
regulating	0
the	0
sustained	0
expression	0
of	0
this	0
proteinase	9
in	0
activated	7
macrophages	8
.	0

Quantification	0
of	0
vitamin	3
D	4
receptor	4
mRNA	4
by	0
competitive	0
polymerase	0
chain	0
reaction	0
in	0
PBMC	7
:	0
lack	0
of	0
correspondence	0
with	0
common	1
allelic	2
variants	2
.	0

It	0
has	0
been	0
recently	0
claimed	0
that	0
polymorphism	0
for	0
the	0
vitamin	9
D	10
receptor	10
(	0
VDR	9
)	0
influences	0
several	0
aspects	0
of	0
calcium	0
and	0
bone	0
metabolism	0
.	0

To	0
evaluate	0
the	0
physiologic	0
plausibility	0
of	0
these	0
claims	0
,	0
we	0
compared	0
the	0
abundance	0
of	0
the	0
VDR	3
mRNA	4
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
between	0
different	0
VDR	9
genotypes	10
using	0
a	0
quantitative	0
reverse	0
transcribed	0
polymerase	0
chain	0
reaction-based	0
method	0
.	0

The	0
method	0
is	0
based	0
on	0
the	0
coamplification	0
of	0
VDR	1
cDNA	2
and	0
an	0
internal	0
standard	0
consisting	0
of	0
known	0
concentrations	0
of	0
a	0
human	1
VDR	2
CDNA	2
mutated	0
at	0
a	0
BglII	1
restriction	2
site	2
;	0
the	0
interassay	0
coefficient	0
of	0
variation	0
is	0
11	0
%	0
.	0

To	0
validate	0
the	0
method	0
,	0
we	0
made	0
use	0
of	0
earlier	0
receptor	0
binding	0
studies	0
indicating	0
that	0
normal	7
human	8
monocytes	8
and	0
activated	0
,	0
but	0
not	0
resting	0
,	0
lymphocytes	7
expressed	0
the	0
VDR	9
.	0

The	0
concentration	0
of	0
the	0
VDR	3
mRNA	4
was	0
10	0
(	0
-8	0
)	0
to	0
10	0
(	0
-7	0
)	0
g/g	0
of	0
total	0
RNA	0
in	0
cell-sorted	7
monocytes	8
and	0
in	0
in	7
vitro	8
activated	8
lymphocytes	8
,	0
but	0
only	0
10	0
(	0
-12	0
)	0
g/g	0
of	0
total	0
mRNA	0
in	0
resting	0
lymphocytes	7
,	0
establishing	0
that	0
the	0
VDR	3
mRNA	4
determined	0
by	0
our	0
method	0
in	0
PBMCs	7
is	0
due	0
to	0
constitutive	0
expression	0
in	0
monocytes	7
.	0

Following	0
an	0
initial	0
genotype	0
screening	0
of	0
85	0
normal	0
volunteers	0
by	0
polymerase	0
chain	0
reaction	0
or	0
restriction	1
fragment	2
length	2
polymorphism	2
analysis	0
,	0
14	0
individuals	0
with	0
the	0
Bb	0
genotype	0
,	0
12	0
with	0
the	0
bb	0
genotype	0
,	0
and	0
12	0
with	0
the	0
BB	0
genotype	0
were	0
selected	0
.	0

The	0
concentration	0
of	0
the	0
VDR	3
mRNA	4
,	0
corrected	0
for	0
the	0
number	0
of	0
monocytes	7
,	0
was	0
similar	0
among	0
the	0
three	0
genotype	0
groups	0
,	0
as	0
were	0
the	0
other	0
variables	0
examined	0
:	0
serum	9
calcitriol	10
,	0
serum	9
osteocalcin	10
,	0
and	0
vertebral	0
and	0
hip	0
bone	0
density	0
.	0

We	0
conclude	0
that	0
VDR	9
polymorphism	0
does	0
not	0
affect	0
the	0
abundance	0
of	0
the	0
VDR	3
mRNA	4
.	0

Oncogenic	0
forms	0
of	0
NOTCH1	9
lacking	0
either	0
the	0
primary	1
binding	2
site	2
for	0
RBP-Jkappa	9
or	0
nuclear	9
localization	10
sequences	10
retain	0
the	0
ability	0
to	0
associate	0
with	0
RBP-Jkappa	9
and	0
activate	0
transcription	0
.	0

Truncated	0
forms	0
of	0
the	0
NOTCH1	9
transmembrane	10
receptor	10
engineered	0
to	0
resemble	0
mutant	0
forms	0
of	0
NOTCH1	9
found	0
in	0
certain	0
cases	0
of	0
human	0
T	0
cell	0
leukemia/lymphoma	0
(	0
T-ALL	0
)	0
efficiently	0
induce	0
T-ALL	0
when	0
expressed	0
in	0
the	0
bone	0
marrow	0
of	0
mice	0
.	0

Unlike	0
full-sized	0
NOTCH1	9
,	0
two	0
such	0
truncated	0
forms	0
of	0
the	0
protein	0
either	0
lacking	0
a	0
major	0
portion	0
of	0
the	0
extracellular	9
domain	10
(	0
DeltaE	9
)	0
or	0
consisting	0
only	0
of	0
the	0
intracellular	9
domain	10
(	0
ICN	9
)	0
were	0
found	0
to	0
activate	0
transcription	0
in	0
cultured	0
cells	0
,	0
presumably	0
through	0
RBP-Jkappa	9
response	0
elements	0
within	0
DNA	0
.	0

Both	0
truncated	0
forms	0
also	0
bound	0
to	0
the	0
transcription	9
factor	10
RBP-Jkappa	10
in	0
extracts	0
prepared	0
from	0
human	5
and	6
murine	6
T-ALL	6
cell	6
lines	6
.	0

Transcriptional	0
activation	0
required	0
the	0
presence	0
of	0
a	0
weak	0
RBP-Jkappa-binding	9
site	10
within	0
the	0
NOTCH1	9
ankyrin	10
repeat	10
region	10
of	0
the	0
intracellular	9
domain	10
.	0

Unexpectedly	0
,	0
a	0
second	0
,	0
stronger	0
RBP-Jkappa-binding	9
site	10
,	0
which	0
lies	0
within	0
the	0
intracellular	9
domain	10
close	0
to	0
the	0
transmembrane	0
region	0
and	0
significantly	0
augments	0
association	0
with	0
RBP-Jkappa	9
,	0
was	0
not	0
needed	0
for	0
oncogenesis	0
or	0
for	0
transcriptional	0
activation	0
.	0

While	0
ICN	9
appeared	0
primarily	0
in	0
the	0
nucleus	0
,	0
DeltaE	9
localized	0
to	0
cytoplasmic	0
and	0
nuclear	0
membranes	0
,	0
suggesting	0
that	0
intranuclear	0
localization	0
is	0
not	0
essential	0
for	0
oncogenesis	0
or	0
transcriptional	0
activation	0
.	0

In	0
support	0
of	0
this	0
interpretation	0
,	0
mutation	0
of	0
putative	0
nuclear	9
localization	10
sequences	10
decreased	0
nuclear	0
localization	0
and	0
increased	0
transcriptional	0
activation	0
by	0
membrane-bound	9
DeltaE	10
.	0

Transcriptional	0
activation	0
by	0
this	0
mutant	0
form	0
of	0
membrane-bound	9
DeltaE	10
was	0
approximately	0
equivalent	0
to	0
that	0
produced	0
by	0
intranuclear	9
ICN	10
.	0

These	0
data	0
are	0
most	0
consistent	0
with	0
NOTCH1	9
oncogenesis	0
and	0
transcriptional	0
activation	0
being	0
independent	0
of	0
association	0
with	0
RBP-Jkappa	9
at	0
promoter	1
sites	2
.	0

Sp	9
family	10
members	10
preferentially	0
interact	0
with	0
the	0
promoter	1
proximal	2
repeat	2
within	0
the	0
HTLV-I	1
enhancer	2
.	0

Human	0
T	0
cell	0
lymphotropic	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
encodes	0
the	0
transactivator	9
protein	10
,	0
Tax	9
,	0
which	0
facilitates	0
viral	0
transcription	0
from	0
three	0
21	1
bp	2
repeated	2
elements	2
within	0
the	0
U3	1
region	2
of	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

Examination	0
of	0
the	0
basal	9
factors	10
interacting	0
with	0
the	0
21	1
bp	2
repeat	2
elements	2
through	0
electrophoretic	0
mobility	0
shift	0
(	0
EMS	0
)	0
analyses	0
has	0
demonstrated	0
the	0
formation	0
of	0
DNA-protein	9
complexes	10
common	0
to	0
each	0
of	0
the	0
21	1
bp	2
repeats	2
(	0
C1-C3	1
)	0
as	0
well	0
as	0
three	0
DNA-protein	9
complexes	10
specific	0
to	0
the	0
promoter	1
proximal	2
(	2
pp	2
)	2
repeat	2
(	0
U1	1
(	0
U1A/U1B	1
)	0
and	0
U2	1
;	0
1-4	0
)	0
.	0

These	0
studies	0
have	0
indicated	0
that	0
the	0
individual	0
repeats	0
are	0
not	0
identical	0
with	0
respect	0
to	0
the	0
cellular	9
factors	10
with	0
which	0
they	0
interact	0
.	0

EMS	0
analyses	0
utilizing	0
a	0
series	0
of	0
mutated	1
pp	2
repeat	2
elements	2
demonstrate	0
that	0
the	0
nucleotide	0
sequence	0
requirements	0
for	0
U1	1
(	0
U1A/U1B	1
)	0
and	0
U2	1
formation	0
are	0
separable	0
from	0
those	0
required	0
for	0
C1-C3	1
formation	0
.	0

Competition	0
EMS	0
analyses	0
utilizing	0
Sp1	0
and	0
CREB	0
binding	0
site	0
oligonucleotides	0
demonstrate	0
that	0
Sp	9
family	10
members	10
are	0
critical	0
components	0
of	0
U1	1
(	0
U1A/U1B	1
)	0
and	0
U2	1
and	0
that	0
ATF/CREB	9
family	10
members	10
are	0
critical	0
components	0
of	0
C1-C3	1
.	0

EMS	0
supershift	0
analyses	0
have	0
demonstrated	0
that	0
Sp1	9
is	0
involved	0
in	0
U1A	0
formation	0
while	0
Sp3	9
is	0
involved	0
in	0
U1B	0
and	0
U2	0
formation	0
.	0

EMS	0
analyses	0
performed	0
with	0
nuclear	0
extracts	0
from	0
Tax-expressing	5
Jurkat	6
cells	6
and	0
HTLV-I-transformed	7
peripheral	8
blood	8
mononuclear	8
cells	8
demonstrate	0
that	0
Tax	9
prevents	0
the	0
formation	0
of	0
U1	1
(	0
U1A/U1B	1
)	0
and	0
U2	1
DNA-protein	9
complexes	10
.	0

Therefore	0
,	0
Tax	9
appears	0
to	0
inhibit	0
the	0
interaction	0
of	0
Sp	9
family	10
members	10
with	0
the	0
pp	1
repeat	2
.	0

Based	0
on	0
these	0
observations	0
,	0
it	0
is	0
possible	0
that	0
the	0
interaction	0
of	0
Sp	9
and	0
ATF/CREB	9
family	10
members	10
with	0
the	0
pp	1
repeat	2
during	0
basal	0
and	0
Tax	9
-mediated	0
transcription	0
may	0
play	0
a	0
critical	0
role	0
in	0
viral	0
gene	0
expression	0
during	0
the	0
initial	0
stages	0
of	0
virus	0
infection	0
or	0
during	0
activation	0
of	0
a	0
latent	0
infection	0
.	0

Lineage-	0
and	0
stage-specific	0
expression	0
of	0
runt	9
box	10
polypeptides	10
in	0
primitive	0
and	0
definitive	0
hematopoiesis	0
.	0

Translocations	0
involving	0
the	0
human	1
CBFA2	2
locus	2
have	0
been	0
associated	0
with	0
leukemia	0
.	0

This	0
gene	0
,	0
originally	0
named	0
AML1	1
,	0
is	0
a	0
human	0
homologue	0
of	0
the	0
Drosophila	1
gene	2
runt	2
that	0
controls	0
early	0
events	0
in	0
fly	0
embryogenesis	0
.	0

To	0
clarify	0
the	0
role	0
of	0
mammalian	9
runt	10
products	10
in	0
normal	0
and	0
leukemic	0
hematopoiesis	0
,	0
we	0
have	0
studied	0
their	0
pattern	0
of	0
expression	0
in	0
mouse	0
hematopoietic	0
tissues	0
in	0
the	0
adult	0
and	0
during	0
ontogeny	0
using	0
an	0
anti-runt	0
box	0
antiserum	0
.	0

In	0
the	0
adult	0
bone	0
marrow	0
,	0
we	0
found	0
expression	0
of	0
runt	0
polypeptides	0
in	0
differentiating	7
myeloid	8
cells	8
and	0
in	0
B	7
lymphocytes	8
.	0

Within	0
the	0
erythroid	7
lineage	8
,	0
runt	0
expression	0
is	0
biphasic	0
,	0
clearly	0
present	0
in	0
the	0
erythroblasts	7
of	0
early	0
blood	0
islands	0
and	0
of	0
the	0
fetal	0
liver	0
,	0
but	0
absent	0
in	0
the	0
adult	0
.	0

Biochemical	0
analysis	0
by	0
Western	0
blotting	0
of	0
fetal	7
and	8
adult	8
hematopoietic	8
populations	8
shows	0
several	0
runt	9
isoforms	10
.	0

At	0
least	0
one	0
of	0
them	0
appears	0
to	0
be	0
myeloid	0
specific	0
.	0

Signal	9
transducer	10
and	10
activator	10
of	10
transcription-3	10
(	0
STAT3	9
)	0
is	0
constitutively	0
activated	0
in	0
normal	0
,	0
self-renewing	7
B-1	8
cells	8
but	0
only	0
inducibly	0
expressed	0
in	0
conventional	0
B	7
lymphocytes	8
[	0
see	0
comments	0
]	0

Cytokine	9
and	0
growth	9
factor	10
receptor	10
engagement	0
leads	0
to	0
the	0
rapid	0
phosphorylation	0
and	0
activation	0
of	0
latent	0
,	0
cytosolic	9
signal	10
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
STAT	10
)	10
proteins	10
,	0
which	0
then	0
translocate	0
to	0
the	0
nucleus	0
where	0
they	0
regulate	0
transcriptional	0
events	0
from	0
specific	1
promoter	2
sequences	2
.	0

STAT3	9
expression	0
in	0
particular	0
has	0
been	0
associated	0
with	0
Abl	9
,	0
Src	9
,	0
and	0
HTLV-1	0
transformation	0
of	0
normal	7
cells	8
.	0

B-1	7
lymphocytes	8
are	0
self-renewing	0
,	0
CD5+	7
B	8
cells	8
that	0
display	0
a	0
propensity	0
for	0
malignant	0
transformation	0
and	0
are	0
the	0
normal	0
counterpart	0
to	0
human	0
chronic	0
lymphocytic	0
leukemias	0
.	0

Further	0
,	0
B-1	7
cells	8
are	0
characterized	0
by	0
aberrant	0
intracellular	0
signaling	0
,	0
including	0
hyperresponsiveness	0
to	0
phorbol	0
ester	0
PKC	0
agonists	0
.	0

Here	0
we	0
demonstrate	0
that	0
B-1	7
lymphocytes	8
constitutively	0
express	0
nuclear	9
activated	10
STAT3	10
,	0
which	0
is	0
not	0
expressed	0
by	0
unmanipulated	7
conventional	8
(	8
B-2	8
)	8
lymphocytes	8
.	0

In	0
contrast	0
,	0
STAT3	9
activation	0
is	0
induced	0
in	0
B-2	7
cells	8
after	0
antigen	0
receptor	0
engagement	0
in	0
a	0
delayed	0
fashion	0
(	0
after	0
3	0
h	0
)	0
.	0

Induction	0
of	0
STAT3	9
is	0
inhibited	0
by	0
both	0
the	0
serine/threonine	0
protein	0
kinase	0
inhibitor	0
H-7	0
and	0
the	0
immunosuppressive	0
drug	0
rapamycin	0
and	0
requires	0
de	0
novo	0
protein	0
synthesis	0
,	0
demonstrating	0
novel	0
coupling	0
between	0
sIg	9
and	0
STAT	9
proteins	10
that	0
differs	0
from	0
the	0
classical	0
paradigm	0
for	0
STAT	9
induction	0
by	0
cytokine	9
receptors	10
.	0

The	0
inability	0
of	0
prolonged	0
stimulation	0
of	0
conventional	0
B-2	7
cells	8
with	0
anti-Ig	9
,	0
a	0
treatment	0
sufficient	0
to	0
induce	0
CD5	9
expression	0
,	0
to	0
result	0
in	0
sustained	0
STAT3	9
activation	0
suggests	0
that	0
STAT3	9
is	0
a	0
specific	0
nuclear	0
marker	0
for	0
B-1	7
cells	8
.	0

Thus	0
,	0
STAT3	9
may	0
play	0
a	0
role	0
in	0
B	0
cell	0
antigen-specific	0
signaling	0
responses	0
,	0
and	0
its	0
constitutive	0
activation	0
is	0
associated	0
with	0
a	0
normal	0
cell	0
population	0
exhibiting	0
intrinsic	0
proliferative	0
behavior	0
.	0

Significance	0
of	0
quantitative	0
analysis	0
of	0
AML1/ETO	3
transcripts	4
in	0
peripheral	7
blood	8
stem	8
cells	8
from	0
t	0
(	0
8	0
;	0
21	0
)	0
acute	0
myelogenous	0
leukemia	0
.	0

Autologous	0
peripheral	7
blood	8
stem	8
cell	8
transplantation	0
(	0
PBSCT	0
)	0
is	0
replacing	0
autologous	0
bone	0
marrow	0
transplantation	0
(	0
BMT	0
)	0
in	0
the	0
treatment	0
of	0
leukemia	0
.	0

One	0
of	0
the	0
potential	0
advantages	0
of	0
autologous	0
PBSCT	0
is	0
the	0
possibility	0
that	0
peripheral	7
blood	8
stem	8
cells	8
(	0
PBSC	7
)	0
are	0
less	0
likely	0
to	0
be	0
contaminated	0
by	0
leukemic	7
cells	8
than	0
bone	0
marrow	0
grafts	0
.	0

However	0
,	0
the	0
major	0
problem	0
still	0
remains	0
the	0
high	0
incidence	0
of	0
leukemic	0
relapse	0
following	0
autologous	0
PBSCT	0
,	0
which	0
may	0
be	0
caused	0
by	0
the	0
reinfusion	0
of	0
PBSC	7
contaminated	0
by	0
leukemic	7
cells	8
.	0

Recently	0
,	0
we	0
have	0
developed	0
a	0
quantitative	0
assay	0
using	0
competitive	0
reverse	9
transcriptase	10
polymerase	10
chain	0
reaction	0
that	0
estimates	0
the	0
number	0
of	0
AML1/ETO	3
transcripts	4
in	0
t	0
(	0
8	0
;	0
21	0
)	0
acute	0
myelogenous	0
leukemia	0
(	0
AML	0
)	0
,	0
in	0
order	0
to	0
determine	0
the	0
degree	0
of	0
leukemic	0
cell	0
contamination	0
in	0
PBSC	7
harvests	0
,	0
and	0
to	0
monitor	0
minimal	0
residual	0
disease	0
(	0
MRD	0
)	0
quantitatively	0
in	0
patients	0
with	0
t	0
(	0
8	0
;	0
21	0
)	0
AML	0
.	0

Our	0
data	0
indicate	0
that	0
although	0
PBSC	7
harvests	0
collected	0
after	0
consolidation	0
chemotherapy	0
are	0
contaminated	0
by	0
leukemic	7
cells	8
,	0
the	0
degree	0
of	0
leukemic	0
cell	0
contamination	0
decreases	0
with	0
repeated	0
cycles	0
of	0
chemotherapy	0
.	0

Furthermore	0
,	0
the	0
MRD	0
in	0
PBSC	7
harvests	0
is	0
less	0
than	0
in	0
the	0
corresponding	0
bone	0
marrow	0
obtained	0
on	0
the	0
day	0
of	0
the	0
PBSC	7
collection	0
.	0

There	0
appears	0
to	0
be	0
no	0
relationship	0
between	0
the	0
number	0
of	0
AML1/ETO	3
transcripts	4
found	0
in	0
the	0
infused	0
PBSC	7
harvests	0
and	0
the	0
incidence	0
of	0
leukemic	0
relapse	0
following	0
autologous	0
PBSCT	0
in	0
our	0
study	0
.	0

However	0
,	0
a	0
substantial	0
decrease	0
of	0
AML1/ETO	3
transcripts	4
was	0
seen	0
following	0
autologous	0
PBSCT	0
.	0

Thus	0
,	0
the	0
quantitative	0
analysis	0
of	0
AML1/ETO	3
transcripts	4
may	0
be	0
clinically	0
useful	0
in	0
patients	0
with	0
t	0
(	0
8	0
;	0
21	0
)	0
AML	0
.	0

Upregulation	0
of	0
c-Fos	9
in	0
activated	7
T	8
lymphoid	8
and	8
monocytic	8
cells	8
by	0
human	9
immunodeficiency	10
virus-1	10
Tat	10
protein	10
.	0

The	0
regulatory	9
Tat	10
protein	10
of	0
the	0
human	0
immunodeficiency	0
virus	0
type-1	0
(	0
HIV-1	0
)	0
is	0
essential	0
for	0
viral	0
replication	0
and	0
also	0
shows	0
pleiotropic	0
activities	0
on	0
various	0
cell	0
functions	0
.	0

To	0
get	0
further	0
insights	0
into	0
the	0
molecular	0
mechanisms	0
underlying	0
the	0
biological	0
activity	0
of	0
Tat	9
,	0
we	0
investigated	0
the	0
effect	0
of	0
endogenous	0
and	0
exogenous	0
Tat	9
protein	10
on	0
c-fos	0
gene	0
expression	0
in	0
T	5
lymphoblastoid	6
(	6
Jurkat	6
)	6
and	6
monocytic	6
(	6
U937	6
)	6
cell	6
lines	6
,	0
as	0
well	0
as	0
in	0
primary	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

Transient	0
cotransfection	0
of	0
tat	1
cDNA	2
in	0
sense	0
orientation	0
(	0
tat/S	1
)	0
,	0
together	0
with	0
a	0
plasmid	1
containing	0
the	0
c-fos	1
promoter	2
(	0
FC3	1
,	0
from-	0
711	1
to	2
+42	2
)	0
in	0
front	0
of	0
the	0
bacterial	1
chloramphenicol	2
acetyltransferase	2
(	2
CAT	2
)	2
gene	2
significantly	0
enhanced	0
CAT	9
activity	0
in	0
Jurkat	5
cells	6
activated	0
by	0
the	0
addition	0
of	0
15	0
%	0
fetal	0
calf	0
serum	0
(	0
FCS	0
)	0
or	0
5	0
micrograms/mL	0
phytohemagglutinin	9
plus	0
10	0
(	0
-7	0
)	0
mol/L	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
and	0
U937	5
cells	6
activated	0
by	0
15	0
%	0
FCS	0
or	0
10	0
(	0
-7	0
)	0
mol/L	0
PMA	0
.	0

This	0
effect	0
was	0
specifically	0
due	0
to	0
Tat	9
,	0
since	0
Jurkat	5
and	0
U937	5
cells	6
cotransfected	0
either	0
with	0
tat	1
cDNA	2
in	0
antisense	0
orientation	0
(	0
tat/AS	1
)	0
,	0
tat	1
carrying	0
a	0
mutation	0
in	0
the	0
aminoacid	9
cys22-gly22	10
(	0
tat	1
22/S	2
)	0
or	0
with	0
the	0
backbone	1
vector	2
alone	2
(	0
pRPneo-SL3	1
)	0
did	0
not	0
show	0
any	0
significant	0
difference	0
in	0
c-fos	1
promoter	2
activity	0
as	0
compared	0
to	0
cells	0
transfected	0
with	0
FC3	1
plasmid	2
alone	0
.	0

By	0
using	0
deletion	0
mutants	0
of	0
the	0
c-fos	1
promoter	2
,	0
we	0
found	0
that	0
the	0
minimal	1
DNA	2
sequence	2
required	0
for	0
Tat	9
activity	0
was	0
located	0
between	0
nucleotides	1
-404/-220	2
and	0
that	0
the	0
serum	1
responsive	2
element	2
(	0
SRE	1
,	0
-317/-288	1
)	0
,	0
present	0
within	0
this	0
region	0
,	0
was	0
still	0
responsive	0
to	0
Tat	9
.	0

A	0
single	1
point	2
mutation	2
in	0
the	0
SRE	1
completely	0
abrogated	0
the	0
responsiveness	0
to	0
tat/S	1
.	0

Exogenous	0
recombinant	9
Tat	10
protein	10
was	0
also	0
able	0
to	0
upregulate	0
c-fos	1
promoter	2
activity	0
in	0
serum-activated	0
Jurkat	0
and	0
U937	5
cells	6
,	0
as	0
well	0
as	0
endogenous	0
c-fos	3
mRNA	4
expression	0
and	0
c-Fos	9
protein	0
synthesis	0
in	0
both	0
serum-activated	5
cell	6
lines	6
and	0
primary	7
PBMC	8
.	0

c-Fos	9
protein	0
was	0
shown	0
essential	0
for	0
an	0
optimal	0
transactivation	0
of	0
the	0
HIV-1	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
by	0
Tat	9
:	0
incubation	0
of	0
Jurkat	5
cells	6
with	0
antisense	0
,	0
but	0
not	0
sense	0
,	0
c-fos	0
oligonucleotides	0
significantly	0
reduced	0
either	0
the	0
Tat	9
-enhanced	0
expression	0
of	0
an	0
LTR-CAT	1
reporter	2
construct	2
or	0
the	0
levels	0
of	0
gag	9
p24	10
in	0
the	0
culture	0
supernatants	0
of	0
Jurkat	5
cells	6
and	0
PBMC	7
acutely	0
infected	0
with	0
HIV-1	0
.	0

Our	0
data	0
suggest	0
that	0
the	0
c-fos	1
upregulation	0
mediated	0
by	0
Tat	9
might	0
play	0
a	0
significant	0
role	0
in	0
the	0
control	0
of	0
viral	0
gene	0
transactivation	0
.	0

Cytokine	9
signal	10
networks	10
and	0
a	0
new	0
era	0
in	0
biomedical	0
research	0
.	0

Elucidation	0
of	0
the	0
biochemical	0
nature	0
of	0
the	0
signal	0
transduction	0
pathway	0
that	0
regulate	0
transcription	0
and	0
replication	0
is	0
the	0
focus	0
of	0
attention	0
in	0
molecular	0
biology	0
.	0

This	0
research	0
may	0
make	0
feasible	0
manipulation	0
of	0
growth	0
and	0
differentiation	0
of	0
mammalian	7
cells	8
,	0
which	0
in	0
turn	0
would	0
have	0
profound	0
implication	0
in	0
biomedical	0
research	0
on	0
cell	0
and	0
gene	0
therapy	0
,	0
and	0
development	0
of	0
pharmaceutical	0
products	0
.	0

Cytokines	9
control	0
growth	0
,	0
differentiation	0
,	0
death	0
,	0
and	0
function	0
of	0
cells	0
of	0
lymphocytic	7
,	8
hemopoietic	8
systems	8
,	0
and	0
together	0
with	0
nerve	7
cells	8
provide	0
a	0
pertinent	0
model	0
to	0
study	0
intercellular	0
communications	0
and	0
intercellular	0
signal	0
networks	0
.	0

This	0
review	0
outlines	0
general	0
features	0
of	0
signal	0
transduction	0
and	0
several	0
aspects	0
of	0
cytokine	9
networks	10
are	0
discussed	0
with	0
emphasis	0
on	0
:	0
transcriptional	0
regulation	0
of	0
Th1	0
and	0
Th2-specific	0
cytokine	1
genes	2
in	0
T	7
cells	8
,	0
the	0
roles	0
of	0
cytokines	9
and	0
their	0
receptors	0
in	0
growth	0
and	0
differentiation	0
of	0
hemopoietic	7
cells	8
,	0
and	0
the	0
manipulation	0
of	0
cytokine	9
networks	10
.	0

Regulation	0
of	0
the	0
tissue	1
factor	2
gene	2
in	0
human	7
monocytic	8
cells	8
.	0

Role	0
of	0
AP-1	9
,	0
NF-kappa	9
B/Rel	10
,	0
and	0
Sp1	9
proteins	0
in	0
uninduced	0
and	0
lipopolysaccharide-induced	0
expression	0
.	0

Tissue	9
factor	10
(	0
TF	0
)	0
expression	0
by	0
peripheral	7
blood	8
monocytes	8
during	0
sepsis	0
initiates	0
intravascular	0
thrombosis	0
.	0

Bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
rapidly	0
induces	0
TF	1
gene	2
transcription	0
in	0
monocytes	7
.	0

The	0
human	1
TF	2
promoter	2
contains	0
binding	0
sites	0
for	0
the	0
transcription	0
factors	0
AP-1	9
,	0
c-Rel/p65	9
,	0
Egr-1	9
,	0
and	0
Sp1	9
.	0

NF-kappa	9
B/Rel	10
proteins	10
have	0
been	0
shown	0
to	0
physically	0
interact	0
with	0
both	0
AP-1	9
and	10
Sp1	10
proteins	10
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
role	0
of	0
these	0
transcription	9
factors	10
in	0
uninduced	0
and	0
LPS-induced	0
TF	1
gene	2
expression	0
in	0
human	7
monocytic	8
THP-1	8
cells	8
.	0

Deletional	0
analysis	0
indicated	0
that	0
five	0
Sp1	1
sites	2
mediated	0
basal	0
expression	0
in	0
uninduced	7
cells	8
.	0

The	0
two	0
AP-1	1
sites	2
bound	0
c-Fos/c-Jun	9
heterodimers	10
in	0
both	0
unstimulated	7
and	8
LPS-stimulated	8
cells	8
.	0

Maximal	0
LPS	0
induction	0
of	0
the	0
TF	1
promoter	2
required	0
the	0
two	0
AP-1	9
sites	0
and	0
the	0
kappa	1
B	2
site	2
within	0
the	0
LPS	1
response	2
element	2
.	0

Disruption	0
of	0
the	0
conserved	0
spacing	0
between	0
the	0
proximal	1
AP-1	2
site	2
and	0
the	0
kappa	1
B	2
site	2
abolished	0
LPS	0
induction	0
.	0

Replacement	0
of	0
the	0
two	0
AP-1	1
sites	2
with	0
intrinsically	0
bent	0
DNA	0
partially	0
restored	0
LPS	0
induction	0
,	0
suggesting	0
an	0
additional	0
structural	0
role	0
for	0
the	0
AP-1	1
sites	2
.	0

Synergistic	0
transactivation	0
of	0
the	0
LPS	1
response	2
element	2
in	0
Drosophila	5
Schneider	6
cells	6
by	0
coexpression	0
of	0
c-Fos	9
,	0
c-Jun	9
,	0
c-Rel	9
,	0
and	0
p65	9
or	0
c-Jun	9
and	0
p65	9
required	0
the	0
transactivation	9
domains	10
of	0
c-Jun	9
and	0
p65	9
.	0

These	0
data	0
indicated	0
that	0
c-Fos	9
/c-Jun	9
,	0
c-Rel	9
/p65	9
,	0
and	0
Sp1	9
regulate	0
TF	1
gene	2
expression	0
in	0
human	7
monocytic	8
cells	8
.	0

Inhibitory	0
effect	0
of	0
growth	0
hormone	0
on	0
TNF-alpha	9
secretion	0
and	0
nuclear	9
factor-kappaB	10
translocation	0
in	0
lipopolysaccharide-stimulated	7
human	8
monocytes	8
.	0

Several	0
studies	0
have	0
pointed	0
to	0
a	0
link	0
between	0
immune	0
and	0
endocrine	0
systems	0
,	0
including	0
a	0
regulatory	0
function	0
of	0
GH	0
on	0
monocyte	0
activation	0
.	0

The	0
present	0
study	0
demonstrates	0
that	0
human	0
THP-1	5
promonocytic	6
cells	6
,	0
engineered	0
by	0
gene	0
transfer	0
to	0
constitutively	0
produce	0
human	0
growth	0
hormone	0
(	0
hGH	0
)	0
,	0
secreted	0
depressed	0
amounts	0
of	0
TNF-alpha	9
in	0
response	0
to	0
challenge	0
by	0
LPS	0
.	0

The	0
effect	0
of	0
GH	0
appears	0
to	0
occur	0
in	0
an	0
autocrine	0
fashion	0
,	0
since	0
the	0
inhibitory	0
effect	0
on	0
TNF-alpha	9
secretion	0
by	0
constitutive	0
GH	0
production	0
could	0
be	0
abolished	0
in	0
the	0
presence	0
of	0
anti-hGH	9
mAb	10
.	0

The	0
GH-induced	0
inhibitory	0
effect	0
was	0
also	0
observed	0
using	0
normal	7
human	8
monocytes	8
and	0
monocyte-derived	7
macrophages	8
.	0

Inhibition	0
of	0
TNF-alpha	9
production	0
by	0
THP-1-hGH-transfected	5
cells	6
cultured	0
in	0
the	0
presence	0
of	0
LPS	0
is	0
dependent	0
on	0
a	0
selective	0
pathway	0
,	0
since	0
no	0
inhibition	0
of	0
TNF-alpha	9
production	0
was	0
observed	0
when	0
cells	0
were	0
cultured	0
in	0
the	0
presence	0
of	0
PMA	0
.	0

Inhibition	0
of	0
TNF-alpha	9
secretion	0
by	0
LPS-stimulated	5
THP-1-hGH	6
cells	6
was	0
associated	0
with	0
a	0
decrease	0
in	0
nuclear	0
translocation	0
of	0
nuclear	9
factor-kappaB	10
.	0

The	0
capacity	0
of	0
GH	0
to	0
inhibit	0
LPS-induced	0
TNF-alpha	9
production	0
by	0
monocytes	7
without	0
altering	0
other	0
pathways	0
leading	0
to	0
TNF-alpha	9
production	0
may	0
be	0
of	0
potential	0
relevance	0
in	0
septic	0
shock	0
,	0
since	0
GH	0
is	0
available	0
for	0
clinical	0
use	0
.	0

Nuclear	9
factor-kappaB	10
activation	0
in	0
human	7
monocytes	8
stimulated	0
with	0
lipopolysaccharide	0
is	0
inhibited	0
by	0
fibroblast	0
conditioned	0
medium	0
and	0
exogenous	0
PGE2	0
.	0

The	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
is	0
thought	0
to	0
be	0
crucially	0
involved	0
in	0
the	0
gene	0
activation	0
of	0
several	0
cytokines	9
,	0
including	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
)	0
.	0

Previously	0
,	0
we	0
showed	0
that	0
fibroblast	0
conditioned	0
medium	0
(	0
FCM	0
)	0
is	0
able	0
to	0
inhibit	0
both	0
TNF	3
mRNA	4
accumulation	0
and	0
protein	0
release	0
in	0
peripheral	5
blood-derived	6
human	6
monocytes	6
(	0
PBM	5
)	0
stimulated	0
with	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

In	0
this	0
study	0
we	0
have	0
investigated	0
the	0
effect	0
of	0
FCM	0
on	0
the	0
LPS-induced	0
DNA-binding	0
activity	0
of	0
NF-kappaB	9
,	0
by	0
means	0
of	0
electrophoretic	0
shift	0
assay	0
(	0
EMSA	0
)	0
.	0

We	0
provide	0
evidence	0
that	0
FCM	0
strongly	0
inhibits	0
the	0
LPS-induced	0
NF-kappaB	9
activation	0
in	0
PBM	5
.	0

Furthermore	0
,	0
we	0
show	0
that	0
exogenous	0
PGE2	0
mimics	0
the	0
NF-kappaB	9
inhibitory	0
effect	0
of	0
FCM	0
.	0

On	0
the	0
other	0
hand	0
,	0
FCM	0
produced	0
in	0
the	0
presence	0
of	0
indomethacin	0
does	0
not	0
inhibit	0
NF-kappaB	9
activation	0
by	0
LPS	0
.	0

Our	0
results	0
lend	0
further	0
support	0
to	0
the	0
hypothesis	0
that	0
inflammatory	0
and	0
immune	0
responses	0
of	0
monocytes/macrophages	7
may	0
be	0
modulated	0
at	0
the	0
molecular	0
level	0
by	0
signals	0
originating	0
from	0
tissue	7
structural	8
cells	8
such	0
as	0
fibroblasts	7
.	0

Human	9
neutrophil	10
elastase	10
proteolytically	0
activates	0
the	0
platelet	9
integrin	10
alphaIIbbeta3	9
through	0
cleavage	0
of	0
the	0
carboxyl	9
terminus	10
of	0
the	0
alphaIIb	9
subunit	10
heavy	10
chain	10
.	0

Involvement	0
in	0
the	0
potentiation	0
of	0
platelet	0
aggregation	0
.	0

Neutrophil	9
elastase	10
(	0
NE	9
)	0
and	0
cathepsin	9
G	10
are	0
two	0
serine	9
proteinases	10
released	0
concomitantly	0
by	0
stimulated	0
polymorphonuclear	7
neutrophils	8
.	0

We	0
previously	0
demonstrated	0
that	0
while	0
NE	9
by	0
itself	0
does	0
not	0
activate	0
human	7
platelets	8
,	0
it	0
strongly	0
enhances	0
the	0
weak	0
aggregation	0
induced	0
by	0
a	0
threshold	0
concentration	0
of	0
cathepsin	9
G	10
(	0
threshold	0
of	0
cathepsin	9
G	10
)	0
(	0
Renesto	0
,	0
P.	0
,	0
and	0
Chignard	0
,	0
M.	0
(	0
1993	0
)	0
Blood	0
82	0
,	0
139-144	0
)	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
delineate	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
this	0
potentiation	0
process	0
.	0

Two	0
main	0
pieces	0
of	0
data	0
prompted	0
us	0
to	0
focus	0
on	0
the	0
activation	0
of	0
the	0
platelet	9
fibrinogen	10
receptor	10
,	0
the	0
alphaIIbbeta3	9
integrin	10
.	0

First	0
,	0
previous	0
studies	0
have	0
shown	0
this	0
integrin	9
to	0
be	0
particularly	0
prone	0
to	0
proteolytic	0
regulation	0
of	0
its	0
function	0
.	0

Second	0
,	0
we	0
found	0
that	0
the	0
potentiating	0
activity	0
of	0
NE	9
on	0
the	0
threshold	0
of	0
cathepsin	9
G	10
-induced	0
platelet	0
aggregation	0
was	0
strictly	0
dependent	0
on	0
the	0
presence	0
of	0
exogenous	9
fibrinogen	10
.	0

Using	0
flow	0
cytometry	0
analysis	0
,	0
NE	9
was	0
shown	0
to	0
trigger	0
a	0
time-dependent	0
binding	0
of	0
PAC-1	9
and	0
AP-5	9
,	0
two	0
monoclonal	9
antibodies	10
specific	0
for	0
the	0
activated	0
and	0
ligand-occupied	0
conformers	0
of	0
alphaIIbbeta3	9
.	0

Furthermore	0
,	0
the	0
potentiated	0
aggregation	0
was	0
shown	0
to	0
result	0
from	0
an	0
increased	0
capacity	0
of	0
platelets	0
to	0
bind	0
fibrinogen	0
.	0

Indeed	0
,	0
the	0
combination	0
of	0
NE	9
and	0
threshold	0
of	0
cathepsin	9
G	10
increased	0
the	0
binding	0
of	0
PAC-1	9
approximately	0
5.5-fold	0
over	0
basal	0
values	0
measured	0
on	0
nontreated	7
platelets	8
,	0
whereas	0
this	0
binding	0
raised	0
only	0
by	0
approximately	0
3-fold	0
in	0
threshold	0
of	0
cathepsin	7
G-stimulated	8
platelets	8
(	0
p	0
<	0
0.05	0
)	0
.	0

By	0
contrast	0
,	0
phosphatidic	0
acid	0
accumulation	0
,	0
pleckstrin	0
phosphorylation	0
,	0
and	0
calcium	0
mobilization	0
produced	0
by	0
the	0
combination	0
of	0
NE	9
and	0
threshold	0
of	0
cathepsin	9
G	10
were	0
not	0
significantly	0
different	0
from	0
those	0
measured	0
with	0
threshold	0
of	0
cathepsin	9
G	10
alone	0
(	0
p	0
>	0
0.05	0
)	0
,	0
indicating	0
that	0
the	0
phospholipase	9
C	10
/protein	9
kinase	10
C	10
pathway	0
is	0
not	0
involved	0
in	0
the	0
potentiation	0
of	0
aggregation	0
.	0

The	0
foregoing	0
data	0
,	0
as	0
well	0
as	0
the	0
requirement	0
of	0
catalytically	0
active	0
NE	9
to	0
trigger	0
alphaIIbbeta3	9
activation	0
and	0
potentiate	0
threshold	0
of	0
cathepsin	9
G	10
-initiated	0
platelet	0
aggregation	0
,	0
led	0
us	0
to	0
examine	0
whether	0
the	0
structure	0
of	0
this	0
integrin	9
was	0
affected	0
by	0
NE	9
.	0

Immunoblot	0
and	0
flow	0
cytometry	0
analysis	0
revealed	0
a	0
limited	0
proteolysis	0
of	0
the	0
carboxyl	9
terminus	10
of	0
the	0
alphaIIb	9
subunit	10
heavy	10
chain	10
(	0
alphaIIbH	9
)	0
,	0
as	0
judged	0
by	0
the	0
disappearance	0
of	0
the	0
epitope	0
for	0
the	0
monoclonal	9
antibody	10
PMI-1	10
.	0

Mass	0
spectrometry	0
studies	0
performed	0
on	0
a	0
synthetic	0
peptide	0
mapping	0
over	0
the	0
cleavage	9
domain	10
of	0
alphaIIbH	9
predicted	0
the	0
site	0
of	0
proteolysis	0
as	0
located	0
between	0
Val837	0
and	0
Asp838	0
.	0

Treatment	0
by	0
NE	9
of	0
ATP-depleted	7
platelets	8
or	0
Chinese	5
hamster	6
ovary	6
cells	6
expressing	0
human	9
recombinant	10
alphaIIbbeta3	10
clearly	0
established	0
that	0
activation	0
of	0
the	0
integrin	9
was	0
independent	0
of	0
signal	0
transduction	0
events	0
and	0
was	0
concomitant	0
with	0
the	0
proteolysis	0
of	0
alphaIIbH	9
.	0

AP-1	9
derived	0
from	0
mature	7
monocytes	8
and	0
astrocytes	7
preferentially	0
interacts	0
with	0
the	0
HTLV-I	1
promoter	2
central	0
21	1
bp	2
repeat	2
.	0

Characterization	0
of	0
the	0
cellular	0
transcription	9
factors	10
interacting	0
with	0
the	0
human	1
T	2
cell	2
lymphotropic	2
virus	2
type	2
I	2
(	2
HTLV-I	2
)	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
is	0
essential	0
to	0
dissecting	0
the	0
mechanisms	0
involved	0
in	0
viral	0
transcription	0
that	0
may	0
be	0
pertinent	0
to	0
the	0
oncogenic	0
and	0
neuropathogenic	0
processes	0
associated	0
with	0
HTLV-I	0
infection	0
in	0
both	0
the	0
immune	0
and	0
nervous	0
systems	0
.	0

Electrophoretic	0
mobility	0
shift	0
(	0
EMS	0
)	0
analyses	0
utilizing	0
oligonucleotides	0
homologous	0
to	0
each	0
of	0
the	0
21	1
bp	2
repeat	2
elements	2
reacted	0
with	0
nuclear	0
extracts	0
derived	0
from	0
cell	5
lines	6
of	0
lymphocytic	7
,	8
monocytic	8
,	8
neuronal	8
,	8
and	8
glial	8
cell	8
origin	8
have	0
demonstrated	0
differential	0
binding	0
of	0
cellular	9
factors	10
to	0
the	0
three	0
21	1
bp	2
repeats	2
(	0
1-4	0
)	0
.	0

ATF/CREB	9
and	0
Sp	9
family	10
members	10
interacted	0
with	0
the	0
21	1
bp	2
repeats	2
to	0
form	0
DNA-protein	9
complexes	10
common	0
to	0
all	0
cell	0
types	0
examined	0
.	0

However	0
,	0
a	0
unique	0
DNA-protein	9
complex	10
was	0
detected	0
when	0
the	0
promoter	0
central	0
21	1
bp	2
repeat	2
was	0
reacted	0
with	0
nuclear	0
extracts	0
derived	0
from	0
either	0
the	0
U-373	5
MG	6
glioblastoma	6
cell	6
line	6
or	0
the	0
THP-1	5
mature	6
monocytic	6
cell	6
line	6
.	0

Based	0
on	0
nucleotide	0
sequence	0
requirements	0
and	0
immunoreactivity	0
,	0
we	0
demonstrate	0
that	0
this	0
DNA-protein	9
complex	10
is	0
comprised	0
of	0
the	0
AP-1	9
components	0
,	0
Fos	9
and	0
Jun	9
.	0

HIV	0
does	0
not	0
replicate	0
in	0
naive	7
CD4	8
T	8
cells	8
stimulated	0
with	0
CD3/CD28	9
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
the	0
T	0
cell	0
tropic	0
strain	0
of	0
HIV	0
,	0
LAI	0
,	0
does	0
not	0
replicate	0
in	0
naive	7
CD4	8
T	8
cells	8
stimulated	0
by	0
cross-linking	0
CD3	9
and	0
CD28	9
.	0

In	0
contrast	0
,	0
LAI	0
replicates	0
well	0
in	0
memory	7
CD4	8
T	8
cells	8
stimulated	0
in	0
the	0
same	0
way	0
.	0

Unlike	0
this	0
physiologically	0
relevant	0
stimulation	0
,	0
PHA	9
stimulates	0
productive	0
LAI	0
replication	0
in	0
both	0
naive	7
and	8
memory	8
T	8
cells	8
.	0

These	0
studies	0
were	0
conducted	0
with	0
highly	0
purified	0
(	0
FACS-isolated	0
)	0
subsets	0
of	0
CD4	7
T	8
cells	8
identified	0
by	0
expression	0
of	0
both	0
CD45RA	9
and	0
CD62L	9
.	0

Remixing	0
of	0
purified	7
T	8
cells	8
showed	0
that	0
naive	7
T	8
cells	8
do	0
not	0
suppress	0
LAI	0
replication	0
in	0
memory	7
T	8
cells	8
and	0
that	0
memory	7
T	8
cells	8
do	0
not	0
restore	0
LAI	0
expression	0
in	0
naive	7
T	8
cells	8
.	0

The	0
suppression	0
of	0
productive	0
LAI	0
replication	0
in	0
naive	7
T	8
cells	8
is	0
not	0
due	0
to	0
differential	0
expression	0
of	0
viral	9
coreceptors	10
,	0
nor	0
is	0
it	0
due	0
to	0
inhibition	0
of	0
activation	0
of	0
the	0
important	0
HIV	0
transcription	9
factors	10
,	0
nuclear	9
factor-kappaB	10
and	0
activator	9
protein-1	10
.	0

The	0
inherent	0
resistance	0
of	0
naive	7
T	8
cells	8
to	0
productive	0
HIV	0
infection	0
,	0
coupled	0
with	0
their	0
proliferative	0
advantage	0
as	0
demonstrated	0
here	0
,	0
provides	0
a	0
sound	0
basis	0
for	0
proposed	0
clinical	0
therapies	0
using	0
ex	0
vivo	0
expansion	0
and	0
reinfusion	0
of	0
CD4	7
T	8
cells	8
from	0
HIV-infected	0
adults	0
.	0

A	0
PMLRARalpha	1
transgene	2
initiates	0
murine	0
acute	0
promyelocytic	0
leukemia	0
.	0

The	0
malignant	7
cells	8
of	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
contain	0
a	0
reciprocal	0
chromosomal	0
translocation	0
that	0
fuses	0
the	0
promyelocytic	1
leukemia	2
gene	2
(	0
PML	0
)	0
with	0
the	0
retinoic	1
acid	2
receptor	2
alpha	2
gene	2
(	0
RAR	9
alpha	10
)	0
.	0

To	0
test	0
the	0
hypothesis	0
that	0
the	0
chimera	9
PMLRAR	10
alpha	10
plays	0
a	0
role	0
in	0
leukemogenesis	0
,	0
we	0
expressed	0
a	0
PMLRAR	1
alpha	2
cDNA	2
in	0
myeloid	7
cells	8
of	0
transgenic	0
mice	0
.	0

PMLRAR	0
alpha	0
transgenic	0
mice	0
exhibited	0
impaired	0
neutrophil	0
maturation	0
early	0
in	0
life	0
,	0
which	0
progressed	0
at	0
a	0
low	0
frequency	0
over	0
the	0
course	0
of	0
several	0
months	0
to	0
overt	0
APL	0
.	0

Both	0
the	0
preleukemic	0
state	0
and	0
the	0
leukemia	0
could	0
be	0
transplanted	0
to	0
nontransgenic	0
mice	0
,	0
and	0
the	0
transplanted	0
preleukemia	0
could	0
progress	0
to	0
APL	0
.	0

The	0
APL	0
recapitulated	0
features	0
of	0
the	0
human	0
disease	0
,	0
including	0
a	0
response	0
to	0
retinoic	0
acid	0
.	0

Retinoic	0
acid	0
caused	0
the	0
leukemic	7
cells	8
to	0
differentiate	0
in	0
vitro	0
and	0
in	0
vivo	0
,	0
eliciting	0
remissions	0
of	0
both	0
the	0
preleukemic	0
state	0
and	0
APL	0
in	0
mice	0
.	0

Our	0
results	0
demonstrate	0
that	0
PMLRAR	9
alpha	10
impairs	0
neutrophil	0
differentiation	0
and	0
initiates	0
the	0
development	0
of	0
APL	0
.	0

The	0
transgenic	0
mice	0
described	0
here	0
provide	0
an	0
apparently	0
accurate	0
model	0
for	0
human	0
APL	0
that	0
includes	0
clear	0
evidence	0
of	0
tumor	0
progression	0
.	0

The	0
model	0
should	0
be	0
useful	0
for	0
exploring	0
the	0
molecular	0
pathogenesis	0
of	0
APL	0
and	0
the	0
mechanisms	0
of	0
the	0
therapeutic	0
response	0
to	0
retinoic	0
acid	0
,	0
as	0
well	0
as	0
for	0
preclinical	0
studies	0
of	0
therapeutic	0
regimens	0
.	0

DNA	0
methylation	0
changes	0
in	0
hematologic	0
malignancies	0
:	0
biologic	0
and	0
clinical	0
implications	0
.	0

DNA	0
methylation	0
changes	0
are	0
among	0
the	0
most	0
common	0
detectable	0
abnormalities	0
in	0
human	0
neoplasia	0
.	0

Hypermethylation	0
within	0
the	0
promoters	1
of	0
selected	0
genes	0
appears	0
to	0
be	0
especially	0
common	0
in	0
all	0
types	0
of	0
human	7
hematopoietic	8
neoplasms	8
,	0
and	0
is	0
usually	0
associated	0
with	0
inactivation	0
of	0
the	0
involved	0
gene	0
(	0
s	0
)	0
.	0

Such	0
hypermethylation-associated	0
silencing	0
of	0
gene	0
expression	0
has	0
been	0
shown	0
for	0
several	0
genes	0
regulating	0
the	0
growth	0
and	0
differentiation	0
of	0
hematopoietic	7
cells	8
,	0
including	0
the	0
estrogen	1
receptor	2
(	2
ER	2
)	2
gene	2
,	0
P15	0
,	0
P16	0
and	0
others	0
.	0

Hypermethylation	0
within	0
the	0
promoters	1
of	0
some	0
genes	0
appear	0
to	0
be	0
an	0
early	0
event	0
in	0
the	0
pathogenesis	0
of	0
neoplasia	0
(	0
ER	1
,	0
P15	1
)	0
,	0
while	0
other	0
genes	0
seem	0
to	0
become	0
methylated	0
during	0
the	0
progression	0
of	0
leukemias	0
(	0
HIC1	0
,	0
c-abl	0
)	0
.	0

The	0
high	0
prevalence	0
of	0
promoter	0
methylation	0
suggests	0
that	0
this	0
molecular	0
abnormality	0
can	0
be	0
used	0
to	0
monitor	0
disease	0
activity	0
during	0
therapy	0
.	0

In	0
addition	0
,	0
new	0
technology	0
allows	0
the	0
sensitive	0
identification	0
of	0
gene	0
hypermethylation	0
in	0
a	0
background	0
of	0
normal	7
cells	8
,	0
suggesting	0
possible	0
new	0
strategies	0
for	0
the	0
detection	0
of	0
minimal	0
residual	0
disease	0
.	0

Finally	0
,	0
reactivation	0
of	0
tumor-suppressor	0
gene	0
expression	0
through	0
pharmacologic	0
inhibition	0
of	0
DNA	9
methyltransferase	10
and	0
resultant	0
DNA	0
demethylation	0
appears	0
to	0
be	0
a	0
promising	0
new	0
avenue	0
of	0
therapy	0
in	0
acute	0
leukemia	0
.	0

Redox	0
regulation	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
pathway	0
during	0
lymphocyte	0
activation	0
.	0

We	0
have	0
previously	0
demonstrated	0
an	0
obligatory	0
requirement	0
for	0
intracellular	0
reactive	0
oxygen	0
species	0
generation	0
during	0
T	0
lymphocyte	0
activation	0
,	0
and	0
have	0
proposed	0
that	0
intracellular	0
reactive	0
oxygen	0
species	0
may	0
act	0
as	0
signalling	0
agents	0
in	0
the	0
regulation	0
of	0
certain	0
cellular	0
processes	0
,	0
for	0
example	0
,	0
during	0
cell	0
cycle	0
entry	0
.	0

To	0
test	0
this	0
hypothesis	0
,	0
we	0
have	0
been	0
interested	0
to	0
determine	0
which	0
,	0
if	0
any	0
,	0
cell	0
cycle	0
entry	0
events	0
are	0
affected	0
by	0
oxidative	0
signalling	0
.	0

In	0
earlier	0
studies	0
,	0
we	0
have	0
identified	0
the	0
transcription	9
factors	10
NF-kappa	9
B	10
and	0
AP-1	9
as	0
molecular	0
targets	0
for	0
oxidative	0
signalling	0
processes	0
during	0
cell	0
cycle	0
entry	0
,	0
and	0
have	0
shown	0
that	0
oxidative	0
signalling	0
is	0
involved	0
in	0
the	0
regulation	0
of	0
early	0
changes	0
in	0
gene	0
expression	0
during	0
the	0
G0	0
to	0
G1	0
phase	0
transition	0
.	0

To	0
extend	0
these	0
initial	0
observations	0
,	0
we	0
have	0
examined	0
the	0
effect	0
of	0
antioxidant	0
treatment	0
on	0
the	0
activity	0
of	0
the	0
mitogen-activated	9
protein	10
kinases	10
erk1	9
and	0
erk2	9
,	0
as	0
members	0
of	0
a	0
signal	0
transduction	0
pathway	0
known	0
to	0
directly	0
regulate	0
transcription	0
factor	0
function	0
.	0

Using	0
as	0
a	0
probe	0
cysteamine	0
,	0
an	0
aminothiol	0
compound	0
with	0
both	0
antioxidant	0
and	0
antiproliferative	0
activity	0
,	0
we	0
have	0
identified	0
erk2	9
,	0
a	0
key	0
element	0
of	0
the	0
MAP	0
kinase	0
pathway	0
,	0
as	0
being	0
responsive	0
to	0
oxidative	0
signalling	0
during	0
lymphocyte	0
activation	0
.	0

These	0
observations	0
provide	0
further	0
evidence	0
to	0
suggest	0
a	0
role	0
for	0
intracellular	0
oxidant	0
generation	0
as	0
a	0
regulatory	0
mechanism	0
during	0
cell	0
cycle	0
entry	0
,	0
and	0
establish	0
a	0
link	0
between	0
oxidative	0
signalling	0
and	0
other	0
aspects	0
of	0
the	0
intracellular	0
signalling	0
network	0
that	0
is	0
activated	0
in	0
response	0
to	0
mitogenic	0
stimulation	0
.	0

Physical	0
and	0
functional	0
interaction	0
between	0
the	0
human	9
T-cell	10
lymphotropic	10
virus	10
type	10
1	10
Tax1	10
protein	10
and	0
the	0
CCAAT	9
binding	10
protein	10
NF-Y	9
.	0

Tax1	9
,	0
a	0
potent	0
activator	0
of	0
human	0
T-cell	0
lymphotropic	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
transcription	0
,	0
has	0
been	0
shown	0
to	0
modulate	0
expression	0
of	0
many	0
cellular	1
genes	2
.	0

Tax1	9
does	0
not	0
bind	0
DNA	0
directly	0
but	0
regulates	0
transcription	0
through	0
protein-protein	0
interactions	0
with	0
sequence-specific	9
transcription	10
factors	10
.	0

Using	0
the	0
yeast	0
two-hybrid	0
system	0
to	0
screen	0
for	0
proteins	0
which	0
interact	0
with	0
Tax1	9
,	0
we	0
isolated	0
the	0
B	9
subunit	10
of	0
the	0
CCAAT	9
binding	10
protein	10
NF-Y	9
from	0
a	0
HeLa	1
cDNA	2
library	2
.	0

The	0
interaction	0
of	0
Tax1	9
with	0
NF-YB	9
was	0
specific	0
in	0
that	0
NF-YB	9
did	0
not	0
interact	0
with	0
a	0
variety	0
of	0
other	0
transcription	9
factors	10
,	0
including	0
human	9
immunodeficiency	10
virus	10
Tat	10
,	0
human	9
papillomavirus	10
E6	10
,	0
and	0
Bicoid	9
,	0
or	0
with	0
the	0
M7	9
(	10
amino	10
acids	10
29CP-AS	10
)	10
Tax1	10
mutant	10
.	0

However	0
,	0
NF-YB	9
did	0
interact	0
with	0
the	0
C-terminal	9
Tax1	10
mutants	10
M22	9
(	0
130TL-AS	9
)	0
and	0
M47	9
(	0
319LL-RS	9
)	0
.	0

We	0
also	0
show	0
that	0
in	0
vitro-translated	0
NF-YB	9
specifically	0
bound	0
to	0
a	0
glutathione	9
S-transferase-Tax1	10
fusion	10
protein	10
.	0

Further	0
,	0
Tax1	9
coimmunoprecipitated	0
with	0
NF-Y	9
from	0
nuclear	0
extracts	0
of	0
HTLV-1-transformed	7
cells	8
,	0
providing	0
evidence	0
for	0
in	0
vivo	0
interaction	0
of	0
Tax1	9
and	0
NF-YB	9
.	0

We	0
further	0
demonstrate	0
that	0
Tax1	9
specifically	0
activated	0
the	0
NF-Y-responsive	1
DQbeta	2
promoter	2
,	0
as	0
well	0
as	0
a	0
minimal	1
promoter	2
which	0
contains	0
only	0
the	0
Y-box	1
element	2
.	0

In	0
addition	0
,	0
mutation	0
of	0
the	0
Y-box	1
element	2
alone	0
abrogated	0
Tax1	9
-mediated	0
activation	0
.	0

Taken	0
together	0
,	0
these	0
data	0
indicate	0
that	0
Tax1	9
interacts	0
with	0
NF-Y	9
through	0
the	0
B	9
subunit	10
and	0
that	0
this	0
interaction	0
results	0
in	0
activation	0
of	0
the	0
major	1
histocompatibility	2
complex	2
class	2
II	2
promoter	2
.	0

Through	0
activation	0
of	0
this	0
and	0
other	0
NF-Y	9
driven	0
promoters	1
,	0
the	0
Tax1	9
-NF-Y	9
interaction	0
may	0
play	0
a	0
critical	0
role	0
in	0
causing	0
cellular	0
transformation	0
and	0
HTLV-1	0
pathogenesis	0
.	0

High	0
levels	0
of	0
the	0
DNA-binding	0
activity	0
of	0
E2F	9
in	0
adult	0
T-cell	0
leukemia	0
and	0
human	7
T-cell	8
leukemia	8
virus	8
type	8
I-infected	8
cells	8
:	0
possible	0
enhancement	0
of	0
DNA-binding	0
of	0
E2F	9
by	0
the	0
human	9
T-cell	10
leukemia	10
virus	10
I	10
transactivating	10
protein	10
,	0
Tax	9
.	0

Transcription	9
factor	10
E2F	9
binds	0
to	0
cellular	1
promoters	2
of	0
certain	0
growth-	1
and	2
cell	2
cycle-controlling	2
genes	2
and	0
forms	0
distinct	0
heteromeric	9
complexes	10
with	0
other	0
nuclear	9
proteins	10
.	0

It	0
has	0
therefore	0
been	0
proposed	0
that	0
E2F	9
is	0
involved	0
in	0
cellular	0
proliferation	0
control	0
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
is	0
an	0
etiological	0
agent	0
of	0
adult	0
T-cell	0
leukemia	0
(	0
ATL	0
)	0
.	0

We	0
show	0
here	0
by	0
mobility-shift	0
assay	0
that	0
E2F-containing	9
DNA-binding	10
complexes	10
were	0
detected	0
in	0
HTLV-I-infected	5
T-cell	6
lines	6
and	0
leukemic	7
cells	8
obtained	0
from	0
ATL	0
patients	0
but	0
not	0
in	0
an	0
uninfected	5
T-cell	6
line	6
,	0
Jurkat	5
,	0
and	0
normal	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

The	0
Tax	9
protein	10
,	0
encoded	0
by	0
HTLV-I	0
,	0
is	0
a	0
potent	0
transcription	0
activator	0
of	0
viral	0
and	0
several	0
cellular	1
genes	2
.	0

We	0
demonstrate	0
that	0
expression	0
of	0
Tax	9
can	0
induce	0
the	0
E2F-containing	9
DNA-binding	10
complexes	10
in	0
Jurkat	5
T	6
cells	6
.	0

Thus	0
,	0
Tax	9
,	0
through	0
enhancement	0
of	0
the	0
DNA-binding	0
activity	0
of	0
E2F	9
,	0
may	0
be	0
capable	0
of	0
regulating	0
cellular	0
gene	0
expression	0
implicated	0
in	0
the	0
proliferation	0
and	0
transformation	0
of	0
T	7
cells	8
in	0
ATL	0
.	0

This	0
activity	0
may	0
be	0
relevant	0
to	0
the	0
mechanisms	0
whereby	0
HTLV-I	0
which	0
does	0
not	0
contain	0
oncogenes	1
induces	0
neoplasia	0
.	0

Dissociation	0
of	0
the	0
Jak	9
kinase	10
pathway	0
from	0
G-CSF	9
receptor	10
signaling	0
in	0
neutrophils	0
.	0

Activation	0
of	0
the	0
granulocyte	9
colony-stimulating	10
factor	10
receptor	10
(	0
G-CSFR	9
)	0
induces	0
rapid	0
tyrosine	0
phosphorylation	0
of	0
multiple	0
intracellular	9
substrates	10
in	0
proliferating	7
cells	8
and	0
nonproliferating	7
,	8
terminally	8
differentiated	8
neutrophils	8
.	0

The	0
kinases	0
that	0
couple	0
ligand	0
binding	0
to	0
tyrosine	0
phosphorylation	0
of	0
cellular	9
substrates	10
by	0
the	0
G-CSFR	0
with	0
activation	0
of	0
specific	0
functional	0
programs	0
are	0
largely	0
unknown	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
early	0
signaling	0
events	0
in	0
proliferating	7
and	0
terminally	7
differentiated	8
cells	8
following	0
G-CSF	9
stimulation	0
to	0
determine	0
whether	0
identical	0
signaling	0
cascades	0
are	0
activated	0
.	0

In	0
murine	5
Ba/F3	6
cells	6
transfected	0
with	0
the	0
human	9
G-CSFR	10
and	0
NFS-60	5
cells	6
constitutively	0
expressing	0
the	0
murine	9
G-CSFR	10
,	0
G-CSF	9
induced	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
Jak1	9
,	0
Jak2	9
,	0
and	0
Tyk2	9
.	0

Tyrosine	0
phosphorylation	0
of	0
Stat3	9
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
Stat1	9
was	0
also	0
detected	0
following	0
G-CSF	9
stimulation	0
.	0

Using	0
a	0
mitogenically	9
incompetent	10
human	10
G-CSFR	10
mutant	10
in	0
which	0
Pro639	0
and	0
Pro641	0
were	0
substituted	0
by	0
alanine	0
,	0
the	0
box	9
1	10
PDP	10
motif	10
was	0
found	0
to	0
be	0
required	0
for	0
activation	0
of	0
Jak	9
kinases	10
,	0
tyrosine	0
phosphorylation	0
of	0
the	0
G-CSFR	9
,	0
and	0
recruitment	0
of	0
Stat	9
proteins	10
.	0

Notably	0
,	0
no	0
activation	0
of	0
Jak1	9
,	0
Jak2	9
,	0
Tyk2	9
,	0
Stat1	9
,	0
or	0
Stat3	9
was	0
observed	0
in	0
neutrophils	7
following	0
G-CSF	9
stimulation	0
.	0

In	0
addition	0
,	0
there	0
was	0
no	0
detectable	0
activation	0
in	0
neutrophils	7
of	0
the	0
recently	0
cloned	0
Jak3	9
kinase	10
,	0
which	0
has	0
been	0
reported	0
to	0
be	0
expressed	0
at	0
high	0
levels	0
as	0
myeloid	7
cells	8
undergo	0
terminal	0
neutrophilic	0
maturation	0
.	0

These	0
results	0
indicate	0
a	0
lack	0
of	0
involvement	0
of	0
Jak	9
kinases	10
in	0
signaling	0
by	0
the	0
G-CSFR	9
in	0
neutrophils	7
,	0
and	0
suggest	0
utilization	0
of	0
alternative	0
signal	0
transduction	0
pathways	0
distinct	0
from	0
those	0
in	0
proliferating	7
cells	8
.	0

Activation	0
of	0
the	0
Jak	9
-Stat	9
pathway	0
correlates	0
with	0
proliferative	0
signaling	0
by	0
the	0
G-CSFR	9
and	0
requires	0
the	0
membrane-proximal	9
box	10
1	10
PXP	10
motif	10
,	0
which	0
is	0
conserved	0
in	0
members	0
of	0
the	0
cytokine	9
receptor	10
superfamily	10
.	0

Impaired	0
induction	0
of	0
c-fos/c-jun	1
genes	2
and	0
of	0
transcriptional	9
regulatory	10
proteins	10
binding	0
distinct	0
c-fos/c-jun	1
promoter	2
elements	2
in	0
activated	7
human	8
T	8
cells	8
during	0
aging	0
.	0

The	0
activation	0
of	0
transcriptional	9
factor	10
c-Fos/c-Jun	0
AP-1	9
is	0
essential	0
for	0
normal	0
T	7
cell	8
responsiveness	0
and	0
is	0
often	0
impaired	0
in	0
T	7
cells	8
during	0
aging	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
investigated	0
whether	0
aberrancies	0
in	0
the	0
regulation	0
of	0
c-fos/c-jun	1
at	0
the	0
mRNA	0
or	0
protein	0
level	0
might	0
underlie	0
the	0
age-associated	0
impairments	0
of	0
AP-1	9
in	0
human	7
T	8
cells	8
.	0

Whereas	0
T	7
cells	8
from	0
young	0
subjects	0
stimulated	0
with	0
cross-linked	9
anti-CD3epsilon	10
mAb	10
OKT3	9
plus	0
PMA	0
or	0
with	0
the	0
lectin	9
PHA	9
plus	0
PMA	0
demonstrated	0
considerable	0
increases	0
in	0
c-Fos	9
protein	0
expression	0
,	0
the	0
expression	0
of	0
c-Fos	9
but	0
not	0
c-Jun	9
was	0
markedly	0
reduced	0
in	0
stimulated	0
T	7
cells	8
from	0
certain	0
elderly	0
subjects	0
.	0

In	0
addition	0
,	0
RNase	9
protection	0
assays	0
revealed	0
that	0
anti-CD3/	0
PMA-stimulated	7
T	8
cells	8
from	0
a	0
substantial	0
proportion	0
of	0
elderly	0
subjects	0
exhibited	0
decreased	0
levels	0
of	0
c-fos	3
and/or	4
c-jun	4
mRNA	4
compared	0
to	0
T	7
cells	8
from	0
young	0
subjects	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
the	0
levels	0
of	0
nuclear	9
regulatory	10
proteins	10
recognizing	0
the	0
AP-1	1
consensus	2
TRE	2
motif	2
,	0
the	0
proximal	1
c-jun	2
TRE-like	2
promoter	2
element	2
,	0
and	0
the	0
c-fos	1
serum	2
response	2
element	2
(	0
SRE	1
)	0
were	0
determined	0
in	0
resting	7
and	8
stimulated	8
T	8
cells	8
.	0

Although	0
the	0
stimulation	0
of	0
T	7
cells	8
from	0
young	0
subjects	0
resulted	0
in	0
coordinated	0
increases	0
of	0
nuclear	9
protein	10
complexes	10
binding	0
the	0
AP-1	1
TRE	2
,	0
c-jun	1
TRE	2
,	0
and	0
c-fos	1
SRE	2
DNA	2
sequence	2
motifs	2
,	0
age-related	0
reductions	0
in	0
the	0
activation	0
of	0
AP-1	9
were	0
accompanied	0
by	0
decreased	0
levels	0
of	0
c-jun	9
TRE	10
and	10
c-fos	10
SRE	10
binding	10
complexes	10
.	0

Furthermore	0
,	0
the	0
nuclear	9
protein	10
complexes	10
binding	0
the	0
SRE	1
motif	2
induced	0
in	0
activated	7
T	8
cells	8
of	0
young	0
and	0
elderly	0
subjects	0
contained	0
serum	9
response	10
factor	10
and	0
Elk-1	9
pointing	0
toward	0
age-related	0
defects	0
in	0
the	0
activation	0
of	0
transcriptional	9
regulatory	10
proteins	10
distinct	0
from	0
c-jun/AP-1	9
.	0

These	0
results	0
suggest	0
that	0
underlying	0
aberrancies	0
in	0
the	0
induction	0
of	0
c-fos/c-jun	1
as	0
well	0
as	0
their	0
nuclear	9
regulatory	10
proteins	10
may	0
contribute	0
to	0
the	0
age-related	0
impairments	0
of	0
AP-1	9
activation	0
in	0
human	7
T	8
cells	8
.	0

Retinoic	0
acid-induced	0
modulation	0
of	0
IL-2	3
mRNA	4
production	0
and	0
IL-2	9
receptor	0
expression	0
on	0
T	7
cells	8
.	0

BACKGROUND	0
:	0
Retinoic	0
acid	0
(	0
RA	0
)	0
has	0
important	0
immune-modulating	0
effects	0
on	0
both	0
T	0
and	0
B	0
cell	0
function	0
.	0

Our	0
laboratory	0
has	0
shown	0
that	0
RA	0
can	0
enhance	0
in	0
vitro	0
polyclonal	0
B	0
cell	0
immunoglobulin	9
(	0
Ig	0
)	0
response	0
.	0

Investigating	0
cytokines	9
known	0
to	0
affect	0
B	0
cell	0
differentiation	0
,	0
we	0
have	0
recently	0
shown	0
that	0
IL-6	9
production	0
is	0
augmented	0
by	0
RA	0
.	0

In	0
the	0
present	0
study	0
we	0
have	0
examined	0
the	0
immune	0
modulating	0
effects	0
of	0
RA	0
on	0
IL-2	3
mRNA	4
,	0
another	0
important	0
cytokine	9
for	0
B	0
cell	0
immunoglobulin	9
production	0
,	0
the	0
expression	0
of	0
IL-2	9
receptors	10
on	0
T	7
cells	8
,	0
and	0
the	0
RA	9
nuclear	10
receptors	10
.	0

METHODS	0
:	0
Purified	0
T	7
cells	8
were	0
obtained	0
from	0
adenoidal	0
tissues	0
,	0
and	0
incubated	0
with	0
RA	0
(	0
10	0
(	0
-7	0
)	0
M	0
)	0
or	0
DMSO	0
solvent/media	0
control	0
for	0
0	0
,	0
6-8	0
,	0
and	0
24	0
h	0
.	0

Total	0
mRNA	3
was	0
extracted	0
from	0
T	7
cells	8
,	0
and	0
using	0
RT-PCR	0
,	0
changes	0
in	0
the	0
production	0
of	0
IL-2	9
and	0
RA	9
receptors	10
(	0
RAR	9
)	0
-	0
alpha	3
,	0
beta	3
,	0
gamma	3
mRNA	4
were	0
determined	0
.	0

The	0
effects	0
of	0
RA	0
on	0
IL-2-alpha	0
receptor	0
expression	0
was	0
determined	0
by	0
flow	0
cytometry	0
on	0
T	7
cells	8
.	0

CONCLUSION	0
:	0
These	0
studies	0
suggest	0
that	0
RA	0
can	0
augment	0
IL-2	3
mRNA	4
production	0
by	0
T	7
cells	8
with	0
a	0
possible	0
paracrine	0
effect	0
on	0
IL-2R-alpha	9
expression	0
.	0

These	0
changes	0
appear	0
to	0
be	0
mediated	0
by	0
RAR-alpha	9
.	0

Thus	0
,	0
IL-2	9
may	0
be	0
another	0
important	0
cytokine	9
modulated	0
by	0
RA	0
in	0
the	0
immune	0
response	0
.	0

Involvement	0
of	0
an	0
SAF-like	9
transcription	10
factor	10
in	0
the	0
activation	0
of	0
serum	1
amyloid	2
A	2
gene	2
in	0
monocyte/macrophage	7
cells	8
by	0
lipopolysaccharide	0
.	0

Serum	9
amyloid	10
A	10
(	0
SAA	9
)	0
has	0
been	0
linked	0
to	0
atherosclerosis	0
because	0
of	0
its	0
ability	0
to	0
remodel	0
high-density	0
lipoprotein	0
by	0
the	0
depletion	0
of	0
apolipoprotein	0
A1	0
,	0
its	0
ability	0
to	0
bind	0
cholesterol	0
,	0
and	0
its	0
presence	0
in	0
the	0
atherosclerotic	0
plaques	0
of	0
coronary	0
and	0
carotid	0
arteries	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
investigated	0
the	0
induction	0
mechanism	0
of	0
SAA	1
gene	2
in	0
THP-1	5
monocyte/macrophage	6
cells	6
which	0
play	0
a	0
critical	0
role	0
in	0
the	0
development	0
of	0
atherosclerotic	0
fatty	0
streak	0
and	0
plaque	0
formation	0
.	0

We	0
and	0
others	0
have	0
shown	0
that	0
SAA	9
gene	0
is	0
induced	0
in	0
monocyte/macrophage	7
cells	8
by	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

By	0
promoter	0
function	0
analysis	0
,	0
we	0
show	0
that	0
the	0
SAA	1
promoter	2
sequence	2
between	0
-280	0
and	0
-226	0
can	0
confer	0
LPS	0
responsiveness	0
.	0

Gel	0
electrophoretic	0
mobility	0
shift	0
assay	0
detected	0
an	0
induced	0
DNA-binding	0
activity	0
in	0
these	0
cells	0
in	0
response	0
to	0
LPS	0
.	0

Characterization	0
of	0
the	0
DNA-binding	9
protein	10
by	0
UV	0
cross-linking	0
,	0
Southwestern	0
blot	0
,	0
and	0
antibody	0
ablation/supershift	0
assays	0
revealed	0
that	0
it	0
is	0
similar	0
to	0
a	0
recently	0
reported	0
nuclear	9
factor	10
designated	0
SAF	9
.	0

These	0
results	0
demonstrated	0
that	0
LPS-mediated	0
SAA	9
gene	0
induction	0
in	0
monocyte/macrophage	7
cells	8
is	0
primarily	0
due	0
to	0
the	0
induction	0
of	0
SAF	9
activity	0
.	0

Cytomegalovirus	1
immediate	2
early	2
genes	2
upregulate	0
interleukin-6	9
gene	0
expression	0
.	0

BACKGROUND	0
:	0
The	0
immediate	1
early	2
genes	2
(	0
IE	1
)	0
of	0
human	0
cytomegalovirus	0
(	0
CMV	0
)	0
can	0
be	0
expressed	0
in	0
monocytic	7
cells	8
and	0
are	0
known	0
to	0
regulate	0
viral	1
and	2
cellular	2
genes	2
.	0

Interleukin-6	9
(	0
IL-6	9
)	0
plays	0
a	0
central	0
role	0
in	0
numerous	0
inflammatory	0
and	0
immune	0
processes	0
.	0

Interleukin-6	9
levels	0
are	0
increased	0
in	0
lung	0
transplant	0
patients	0
clinically	0
diagnosed	0
with	0
CMV	0
pneumonitis	0
.	0

The	0
regulation	0
of	0
IL-6	9
is	0
dependent	0
on	0
various	0
stimuli	0
that	0
include	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
viruses	0
,	0
and	0
other	0
cytokines	9
.	0

These	0
studies	0
examined	0
the	0
ability	0
of	0
CMV	0
IE	0
gene	0
products	0
to	0
modulate	0
IL-6	9
production	0
.	0

METHODS	0
:	0
THP-1	5
cells	6
,	0
a	0
monocytic	5
cell	6
line	6
,	0
were	0
transfected	0
with	0
the	0
CMV	1
IE	2
genes	2
.	0

Interleukin-6	9
protein	0
and	0
IL-6	3
mRNA	4
were	0
measured	0
in	0
control	0
and	0
CMV	7
immediate	8
early	8
transfected	8
cells	8
.	0

Cotransfection	0
of	0
CMV	1
IE	2
genes	2
and	0
IL-6	1
chloramphenicol	2
acetyl	2
transferase	2
(	2
CAT	2
)	2
or	2
IL-6	2
luciferase	2
constructs	2
were	0
used	0
to	0
study	0
IL-6	9
promoter	0
activity	0
.	0

RESULTS	0
:	0
Interleukin-6	9
protein	10
and	0
mRNA	0
production	0
were	0
significantly	0
increased	0
in	0
cells	0
transfected	0
with	0
the	0
CMV	1
IE	2
genes	2
and	0
stimulated	0
with	0
LPS	0
compared	0
to	0
LPS-stimulated	5
control	6
cells	6
.	0

Cytomegalovirus	9
IE	10
gene	10
products	10
significantly	0
enhanced	0
LPS	0
stimulation	0
of	0
IL-6	1
promoter	2
activity	0
in	0
both	0
IL-6	9
CAT	0
and	0
IL-6	0
luciferase	0
assays	0
.	0

A	0
deletion	0
construct	0
that	0
contains	0
a	0
NF-kappa	1
B	2
site	2
but	0
is	0
missing	0
the	0
multiple	0
response	0
region	0
demonstrated	0
a	0
continued	0
increase	0
in	0
IL-6	9
luciferase	9
activity	0
in	0
LPS-stimulated	5
CMV	6
transfected	6
cells	6
.	0

CONCLUSION	0
:	0
Cytomegalovirus	9
immediate	10
early	10
gene	10
products	10
significantly	0
enhanced	0
expression	0
of	0
IL-6	9
in	0
LPS-stimulated	0
cells	0
.	0

The	0
increase	0
in	0
IL-6	9
luciferase	9
activity	0
occurs	0
in	0
the	0
absence	0
of	0
the	0
multiple	0
response	0
region	0
,	0
the	0
area	0
of	0
the	0
IL-6	1
promoter	2
responsive	0
to	0
IL-1	9
,	0
TNF	9
alpha	10
,	0
cyclic	0
amp	0
,	0
and	0
phorbol	0
12-myristate	0
13-acetate	0
.	0

The	0
ability	0
of	0
CMV	9
IE	10
gene	10
products	10
to	0
enhance	0
IL-6	9
production	0
may	0
play	0
an	0
important	0
role	0
in	0
immune	0
inflammatory	0
states	0
associated	0
with	0
CMV	0
infection	0
.	0

Induction	0
of	0
relA	9
(	10
p65	10
)	10
and	0
I	9
kappa	10
B	10
alpha	10
subunit	10
expression	0
during	0
differentiation	0
of	0
human	7
peripheral	8
blood	8
monocytes	8
to	0
macrophages	7
.	0

We	0
evaluated	0
the	0
expression	0
and	0
DNA	0
binding	0
activity	0
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
subunits	10
in	0
human	7
peripheral	8
blood	8
monocytes	8
and	0
in	0
monocyte-derived	7
macrophages	8
(	0
MDMs	7
)	0
.	0

Constitutive	0
DNA	0
binding	0
activity	0
consisting	0
of	0
p50	9
homodimers	10
was	0
detected	0
in	0
nuclear	0
extracts	0
from	0
both	0
cell	0
types	0
.	0

An	0
additional	0
complex	0
composed	0
of	0
p50/RelA	9
(	10
p65	10
)	10
heterodimers	10
appeared	0
only	0
in	0
nuclear	0
extracts	0
from	0
7-day	0
MDMs	7
.	0

Immunoblot	0
analysis	0
showed	0
that	0
the	0
p50	0
subunit	0
was	0
constitutively	0
expressed	0
in	0
monocytes	7
and	0
MDMs	7
.	0

In	0
contrast	0
,	0
the	0
RelA	9
(	10
p65	10
)	10
subunit	10
was	0
barely	0
detectable	0
in	0
monocytes	7
,	0
but	0
its	0
level	0
increased	0
markedly	0
in	0
MDMs	7
.	0

Analysis	0
of	0
RelA	3
(	4
p65	4
)	4
mRNA	4
revealed	0
that	0
the	0
stability	0
of	0
RelA	3
(	4
p65	4
)	4
mRNA	4
was	0
significantly	0
higher	0
in	0
MDMs	7
,	0
compared	0
with	0
monocytes	7
.	0

In	0
MDMs	7
,	0
an	0
upregulation	0
of	0
I	9
kappa	10
B	10
alpha	10
synthesis	0
as	0
well	0
as	0
the	0
appearance	0
of	0
a	0
novel	0
M	0
(	0
r	0
)	0
40	0
,	0
000	0
form	0
of	0
I	9
kappa	10
B	10
alpha	10
were	0
also	0
observed	0
.	0

These	0
results	0
suggest	0
that	0
macrophage	0
differentiation	0
results	0
in	0
the	0
expression	0
of	0
active	0
p50/RelA	9
(	10
p65	10
)	10
heterodimers	10
with	0
the	0
capacity	0
to	0
activate	0
target	0
gene	0
expression	0
.	0

The	0
parallel	0
induction	0
of	0
I	9
kappa	10
B	10
alpha	10
synthesis	0
may	0
allow	0
for	0
the	0
continuous	0
presence	0
of	0
a	0
cytoplasmic	0
reservoir	0
of	0
p50/RelA	9
(	10
p65	10
)	10
complexes	10
that	0
are	0
readily	0
available	0
for	0
inducer-mediated	0
stimulation	0
.	0

Nuclear	9
Rel-A	10
and	10
c-Rel	10
protein	10
complexes	10
are	0
differentially	0
distributed	0
within	0
human	7
thymocytes	8
.	0

Nuclear	9
factor-kappa	10
B	10
(	10
NF-kappa	10
B	10
)	10
/Rel	10
proteins	10
are	0
inducible	0
transcriptional	9
regulators	10
of	0
numerous	0
cellular	1
genes	2
.	0

They	0
are	0
particularly	0
abundant	0
in	0
lymphoid	0
tissues	0
and	0
are	0
thought	0
to	0
be	0
critical	0
for	0
the	0
transcription	0
of	0
genes	0
involved	0
in	0
immune	0
and	0
inflammatory	0
responses	0
.	0

We	0
have	0
reported	0
previously	0
that	0
a	0
nuclear	0
NF-kappa	9
B	10
activity	0
was	0
present	0
in	0
freshly	0
extracted	0
human	7
thymocytes	8
in	0
the	0
absence	0
of	0
in	0
vitro	0
treatment	0
of	0
these	0
cells	0
.	0

In	0
the	0
present	0
report	0
,	0
we	0
identified	0
NF-kappa	9
B	10
proteins	10
extracted	0
from	0
human	0
thymocyte	0
nuclei	0
as	0
being	0
p50/p65	9
and	10
p50/c-Rel	10
complexes	10
.	0

Immunochemical	0
and	0
immunofluorescent	0
staining	0
of	0
thymus	0
sections	0
using	0
specific	9
Abs	10
allowed	0
visualization	0
of	0
nuclear	9
NF-kappa	10
B	10
proteins	10
in	0
both	0
thymocytes	7
and	0
nonthymocyte	7
cells	8
.	0

This	0
detection	0
suggested	0
a	0
preferential	0
activation	0
of	0
p50/c-Rel	9
in	0
medullary	7
thymocytes	8
,	0
whereas	0
p50/p65	9
was	0
present	0
in	0
both	0
cortical	0
and	0
medullary	0
regions	0
of	0
human	0
thymus	0
lobules	0
.	0

However	0
,	0
the	0
intensity	0
of	0
p65	9
labeling	0
was	0
much	0
higher	0
in	0
several	0
thymocytes	7
from	0
the	0
medulla	0
.	0

p65	0
,	0
p50	0
,	0
and	0
c-Rel	0
activities	0
were	0
found	0
in	0
both	0
CD4-	7
and	8
CD8-positive	8
thymocytes	8
.	0

These	0
observations	0
suggest	0
that	0
p65	9
and	10
c-Rel	10
complexes	10
play	0
distinct	0
roles	0
in	0
gene	0
expression	0
and	0
that	0
both	0
forms	0
of	0
NF-kappa	9
B	10
play	0
critical	0
roles	0
during	0
late	0
stages	0
of	0
the	0
intrathymic	0
maturation	0
of	0
T	7
cells	8
.	0

ALY	9
,	0
a	0
context-dependent	9
coactivator	10
of	0
LEF-1	9
and	0
AML-1	9
,	0
is	0
required	0
for	0
TCRalpha	1
enhancer	2
function	0
.	0

LEF-1	9
is	0
a	0
transcription	0
factor	0
that	0
participates	0
in	0
the	0
regulation	0
of	0
the	0
T-cell	1
receptor	2
alpha	2
(	2
TCR	2
alpha	2
)	2
enhancer	2
by	0
facilitating	0
the	0
assembly	0
of	0
multiple	9
proteins	10
into	0
a	0
higher	0
order	0
nucleoprotein	9
complex	10
.	0

The	0
function	0
of	0
LEF-1	9
is	0
dependent	0
,	0
in	0
part	0
,	0
on	0
the	0
HMG	9
domain	10
that	0
induces	0
a	0
sharp	0
bend	0
in	0
the	0
DNA	0
helix	0
,	0
and	0
on	0
an	0
activation	9
domain	10
that	0
stimulates	0
transcription	0
only	0
in	0
a	0
specific	0
context	0
of	0
other	0
enhancer-binding	9
proteins	10
.	0

With	0
the	0
aim	0
of	0
gaining	0
insight	0
into	0
the	0
function	0
of	0
context-dependent	9
activation	10
domains	10
,	0
we	0
cloned	0
ALY	9
,	0
a	0
novel	0
LEF-1-interacting	9
protein	10
.	0

ALY	9
is	0
a	0
ubiquitously	0
expressed	0
,	0
nuclear	0
protein	0
that	0
specifically	0
associates	0
with	0
the	0
activation	9
domains	10
of	0
LEF-1	9
and	0
AML-1	9
(	0
CBF	9
alpha2	10
,	0
PEBP2	9
alpha	10
(	0
B	0
)	0
,	0
which	0
is	0
another	0
protein	0
component	0
of	0
the	0
TCR	9
alpha	10
enhancer	10
complex	10
.	0

In	0
addition	0
,	0
ALY	9
can	0
increase	0
DNA	0
binding	0
by	0
both	0
LEF-1	9
and	0
AML	9
proteins	10
.	0

Overexpression	0
of	0
ALY	9
stimulates	0
the	0
activity	0
of	0
the	0
TCR	9
alpha	10
enhancer	10
complex	10
reconstituted	0
in	0
transfected	5
nonlymphoid	6
HeLa	6
cells	6
,	0
whereas	0
down-regulation	0
of	0
ALY	9
by	0
anti-sense	0
oligonucleotides	0
virtually	0
eliminates	0
TCR	1
alpha	2
enhancer	2
activity	0
in	0
T	7
cells	8
.	0

Similar	0
to	0
LEF-1	9
,	0
ALY	9
can	0
stimulate	0
transcription	0
in	0
the	0
context	0
of	0
the	0
TCR	1
alpha	2
enhancer	2
but	0
apparently	0
not	0
when	0
tethered	0
to	0
DNA	0
through	0
an	0
heterologous	9
DNA-binding	10
domain	10
.	0

We	0
propose	0
that	0
ALY	9
mediates	0
context-dependent	0
transcriptional	0
activation	0
by	0
facilitating	0
the	0
functional	0
collaboration	0
of	0
multiple	9
proteins	10
in	0
the	0
TCR	9
alpha	10
enhancer	10
complex	10
.	0

AML1a	9
but	0
not	0
AML1b	9
inhibits	0
erythroid	0
differentiation	0
induced	0
by	0
sodium	0
butyrate	0
and	0
enhances	0
the	0
megakaryocytic	0
differentiation	0
of	0
K562	7
leukemia	8
cells	8
.	0

AML1	9
may	0
play	0
a	0
role	0
in	0
growth	0
and	0
differentiation	0
of	0
cells	0
along	0
erythroid	7
and/or	8
megakaryocytic	8
lineages	8
,	0
because	0
a	0
significant	0
level	0
of	0
the	0
AML1	9
gene	0
is	0
expressed	0
in	0
these	0
cells	0
.	0

We	0
overexpressed	0
AML1a	9
(	0
without	0
the	0
transcription-activating	9
domain	10
)	0
and	0
AML1b	9
(	0
with	0
the	0
domain	0
)	0
proteins	0
in	0
K562	7
leukemia	8
cells	8
,	0
which	0
can	0
be	0
induced	0
to	0
differentiate	0
into	0
hemoglobin-producing	7
cells	8
and	0
megakaryocytes	7
.	0

The	0
AML1a-transfected	5
K562	6
cells	6
had	0
a	0
reduced	0
capacity	0
to	0
differentiate	0
in	0
the	0
presence	0
of	0
sodium	0
n-butyrate	0
but	0
not	0
in	0
the	0
presence	0
of	0
other	0
inducers	0
,	0
such	0
as	0
hemin	0
,	0
1-beta-D-arabinofuranosylcytosine	0
,	0
and	0
herbimycin	0
A	0
.	0

The	0
AML1	9
antisense	0
oligodeoxynucleotide	0
but	0
not	0
the	0
sense	0
oligomer	0
recovered	0
its	0
differentiation-inducing	0
capacity	0
in	0
the	0
presence	0
of	0
butyrate	0
.	0

On	0
the	0
other	0
hand	0
,	0
AML1b	9
conferred	0
a	0
similar	0
differentiation-inducing	0
capacity	0
upon	0
K562	5
cells	6
transfected	0
with	0
vector	0
alone	0
.	0

AML1a	9
expression	0
was	0
associated	0
with	0
enhanced	0
sensitivity	0
to	0
megakaryocytic	0
differentiation	0
induced	0
by	0
phorbol	0
ester	0
.	0

These	0
results	0
provide	0
evidence	0
that	0
AML1	9
proteins	0
play	0
a	0
role	0
in	0
erythroid	0
and	0
megakaryocytic	0
differentiation	0
.	0

Identification	0
of	0
sequence	0
alterations	0
in	0
the	0
upstream	1
regulatory	2
region	2
of	0
the	0
estrogen	1
receptor	2
gene	2
in	0
an	0
ER-negative	5
breast	6
cancer	6
cell	6
line	6
.	0

Given	0
the	0
important	0
role	0
of	0
the	0
estrogen	9
receptor	10
(	0
ER	9
)	0
in	0
the	0
development	0
and	0
physiology	0
of	0
the	0
breast	0
,	0
it	0
is	0
essential	0
to	0
delineate	0
the	0
mechanisms	0
responsible	0
for	0
its	0
failed	0
expression	0
in	0
some	0
breast	0
tumors	0
.	0

We	0
have	0
cloned	0
and	0
sequenced	0
a	0
portion	0
of	0
the	0
ER	9
upstream	1
regulatory	2
region	2
from	0
the	0
ER-positive	5
MCF-7	6
and	0
the	0
ER-negative	5
MDA-MB-231	6
breast	6
cancer	6
cell	6
lines	6
to	0
determine	0
if	0
sequence	0
alterations	0
in	0
this	0
region	0
account	0
for	0
the	0
ER	9
-negative	0
phenotype	0
of	0
some	0
tumors	0
.	0

From	0
this	0
,	0
we	0
identified	0
a	0
number	0
of	0
variations	0
between	0
the	0
sequences	0
,	0
two	0
of	0
which	0
were	0
determined	0
to	0
be	0
associated	0
with	0
a	0
50	0
%	0
decrease	0
in	0
CAT	9
activity	0
.	0

Suppression	0
by	0
azelastine	0
hydrochloride	0
of	0
NF-kappa	9
B	10
activation	0
involved	0
in	0
generation	0
of	0
cytokines	9
and	0
nitric	0
oxide	0
.	0

The	0
influence	0
of	0
the	0
anti-allergy	0
agent	0
azelastine	0
hydrochloride	0
(	0
Azeptin	0
)	0
on	0
NF-kappa	9
B	10
activation	0
associated	0
with	0
the	0
generation	0
of	0
cytokines	9
and	0
nitric	0
oxide	0
(	0
NO	0
)	0
was	0
investigated	0
in	0
various	0
kinds	0
of	0
human	7
and	8
mouse	8
cells	8
.	0

Azeptin	0
dose-dependently	0
suppressed	0
both	0
DNA	0
and	0
protein	0
synthesis	0
in	0
human	7
gingival	8
fibroblasts	8
(	0
HF	7
)	0
and	0
also	0
suppressed	0
blastogenesis	0
of	0
human	7
peripheral	8
blood	8
lymphocytes	8
(	0
PBL	7
)	0
.	0
Generation	0
of	0
tumor	9
necrosis	10
factor-alpha	10
,	0
interleukin	9
1-beta	10
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
and	0
interleukin-6	9
from	0
10	0
(	0
-5	0
)	0
M	0
Azeptin-treated	0
PBL	7
and	0
human	7
monocytes	8
(	0
HM	7
)	0
was	0
decreased	0
to	0
approximately	0
1/3	0
to	0
2/3	0
of	0
the	0
control	0
levels	0
.	0

In	0
parallel	0
with	0
the	0
decreased	0
cytokine	9
generation	0
,	0
each	0
cytokine	3
mRNA	4
was	0
less	0
expressed	0
in	0
the	0
presence	0
of	0
10	0
(	0
-5	0
)	0
M	0
Azeptin	0
.	0

In	0
addition	0
,	0
both	0
inducible	0
nitric	9
oxide	10
synthase	10
-mRNA	0
level	0
and	0
NO	0
generation	0
in	0
mouse	7
peritoneal	8
macrophages	8
were	0
suppressed	0
by	0
10	0
(	0
-5	0
)	0
M	0
Azeptin	0
.	0

Being	0
compatible	0
with	0
those	0
results	0
,	0
Azeptin	0
(	0
10	0
(	0
-5	0
)	0
M	0
)	0
suppressed	0
activation	0
of	0
NF-kappa	9
B	10
in	0
PBL	7
,	0
HM	0
and	0
HF	7
.	0

These	0
results	0
appear	0
to	0
indicate	0
that	0
suppression	0
of	0
cytokine	9
and	0
NO	0
generation	0
by	0
Azeptin	0
results	0
at	0
least	0
partially	0
from	0
the	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
.	0

Differential	0
interaction	0
of	0
nuclear	0
factors	0
with	0
the	0
PRE-I	1
enhancer	2
element	2
of	0
the	0
human	1
IL-4	2
promoter	2
in	0
different	0
T	7
cell	8
subsets	8
.	0

The	0
immunomodulatory	0
cytokine	9
IL-4	9
affects	0
cells	0
of	0
most	0
hemopoietic	7
lineages	8
.	0

IL-4	9
is	0
secreted	0
by	0
activated	0
Th2	7
but	0
not	0
Th1	7
cells	8
and	0
plays	0
a	0
major	0
role	0
in	0
the	0
immune	0
response	0
by	0
modulating	0
the	0
differentiation	0
of	0
naive	7
Th	8
cells	8
toward	0
the	0
Th2	7
phenotype	8
.	0

We	0
have	0
previously	0
identified	0
an	0
enhancer	1
element	2
,	0
PRE-I	1
,	0
that	0
is	0
essential	0
for	0
the	0
function	0
of	0
the	0
human	1
IL-4	2
promoter	2
.	0

To	0
investigate	0
the	0
mechanisms	0
responsible	0
for	0
tissue-specific	0
expression	0
of	0
the	0
IL-4	9
gene	0
,	0
we	0
analyzed	0
nuclear	9
factors	10
binding	0
to	0
the	0
PRE-I	1
site	2
and	0
compared	0
the	0
binding	0
activities	0
of	0
these	0
factors	0
to	0
the	0
IL-4	9
promoter	0
of	0
Th1	7
and	8
Th2	8
cells	8
.	0

We	0
show	0
that	0
PRE-I	1
interacts	0
with	0
PMA	0
-and	0
PMA/ionomycin-inducible	0
,	0
cyclosporin	0
A-sensitive	0
nuclear	9
factors	10
.	0

Using	0
anti-C/EBPbeta	9
(	0
NF-IL6	9
)	0
,	0
anti-C/EBPdelta	9
(	0
NF-IL6beta	9
)	0
,	0
anti-NF-ATc	9
,	0
anti-NF-ATp	9
,	0
anti-Fos	9
,	0
and	0
anti-Jun	9
Abs	10
we	0
demonstrate	0
that	0
the	0
previously	0
identified	0
PRE-I	9
binding	10
factor	10
POS-1	9
is	0
composed	0
of	0
different	0
transcription	9
factors	10
in	0
different	0
Th	0
cell	0
subsets	0
.	0

In	0
the	0
IL-4-producing	5
Th0-like	6
human	6
Jurkat	6
and	0
mouse	5
EL-4	6
cells	6
,	0
POS-1	9
(	0
designated	0
POS-1a	9
)	0
contains	0
NF-IL6beta	9
and	0
Jun	9
.	0

In	0
the	0
mouse	5
Th2	6
D10	6
cells	6
and	0
in	0
the	0
human	5
Th2	6
clones	6
,	0
POS-1	9
(	0
designated	0
POS-1b	9
)	0
contains	0
NF-IL6beta	9
,	0
Jun	9
,	0
and	0
NF-ATc/p	9
.	0

In	0
contrast	0
,	0
POS-1	9
was	0
not	0
found	0
in	0
nuclear	0
extracts	0
of	0
human	5
Th1	6
clones	6
.	0

These	0
findings	0
suggest	0
that	0
PRE-I	1
may	0
play	0
a	0
role	0
in	0
the	0
differential	0
regulation	0
of	0
IL-4	1
gene	2
expression	0
levels	0
.	0

Regulation	0
of	0
human	0
epsilon	0
germline	1
transcription	0
:	0
role	0
of	0
B-cell-specific	9
activator	10
protein	10
.	0

Germline	9
transcripts	10
initiate	0
from	0
promoters	1
upstream	0
of	0
the	0
immunoglobulin	1
switch	2
region	2
,	0
and	0
are	0
necessary	0
to	0
target	0
the	0
appropriate	0
switch	0
region	0
for	0
recombination	0
and	0
switching	0
.	0

Different	0
cytokines	9
activate	0
transcription	0
at	0
the	0
appropriate	0
germline	1
promoter	2
.	0

Because	0
binding	1
sites	2
for	0
B-cell-specific	9
activator	10
protein	10
(	0
BSAP	9
)	0
are	0
located	0
upstream	0
of	0
several	0
switch	0
regions	0
in	0
the	0
immunoglobulin	1
heavy	2
chain	2
gene	2
cluster	2
,	0
BSAP	9
might	0
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
germline	1
transcription	0
and	0
isotype	0
switching	0
.	0

We	0
investigated	0
whether	0
BSAP	9
plays	0
a	0
role	0
in	0
the	0
transcriptional	0
regulation	0
of	0
the	0
epsilon	0
germline	1
promoter	2
in	0
human	7
B	8
cells	8
.	0

Our	0
results	0
showed	0
that	0
BSAP	9
plays	0
a	0
role	0
in	0
both	0
IL-4	9
-dependent	0
induction	0
and	0
CD40	9
-mediated	0
upregulation	0
of	0
human	0
epsilon	0
germline	1
transcription	0
.	0

BSAP	9
is	0
unique	0
among	0
the	0
transcription	9
factors	10
that	0
regulate	0
epsilon	0
germline	1
expression	0
,	0
because	0
it	0
is	0
B	0
cell	0
specific	0
,	0
and	0
is	0
at	0
the	0
merging	0
point	0
of	0
two	0
signalling	0
pathways	0
that	0
are	0
critical	0
for	0
IgE	9
switching	0
.	0

Experimental	0
expression	0
in	0
mice	0
and	0
spontaneous	0
expression	0
in	0
human	0
SLE	0
of	0
polyomavirus	9
T-antigen	10
.	0

A	0
molecular	0
basis	0
for	0
induction	0
of	0
antibodies	9
to	0
DNA	0
and	0
eukaryotic	9
transcription	10
factors	10
.	0

We	0
have	0
previously	0
demonstrated	0
that	0
experimental	0
expression	0
of	0
the	0
polyomavirus	9
transcription	10
factor	10
T-antigen	10
has	0
the	0
potential	0
to	0
induce	0
anti-DNA	9
antibodies	10
in	0
mice	0
.	0

Two	0
sets	0
of	0
independent	0
evidences	0
are	0
presented	0
here	0
that	0
demonstrate	0
a	0
biological	0
relevance	0
for	0
this	0
model	0
.	0

First	0
,	0
we	0
describe	0
results	0
demonstrating	0
that	0
mice	0
inoculated	0
with	0
T-antigen-expressing	1
plasmids	2
produced	0
antibodies	9
,	0
not	0
only	0
to	0
T-antigen	9
and	0
DNA	0
,	0
but	0
also	0
to	0
the	0
DNA-binding	9
eukaryotic	10
transcription	10
factors	10
TATA-binding	9
protein	10
(	0
TBP	9
)	0
,	0
and	0
to	0
the	0
cAMP-response-element-binding	9
protein	10
(	0
CREB	9
)	0
.	0

Secondly	0
,	0
we	0
investigated	0
whether	0
polyomavirus	0
reactivation	0
occurs	0
in	0
SLE	0
patients	0
,	0
and	0
whether	0
antibodies	9
to	0
T-antigen	9
,	0
DNA	0
,	0
and	0
to	0
TBP	9
and	0
CREB	9
are	0
linked	0
to	0
such	0
events	0
.	0

Both	0
within	0
and	0
among	0
these	0
SLE	0
patients	0
,	0
frequent	0
polyomavirus	0
reactivations	0
were	0
observed	0
that	0
could	0
not	0
be	0
explained	0
by	0
certain	0
rearrangements	0
of	0
the	0
noncoding	0
control	0
regions	0
,	0
nor	0
by	0
corticosteroid	0
treatment	0
.	0

Linked	0
to	0
these	0
events	0
,	0
antibodies	9
to	0
T-antigen	9
,	0
DNA	0
,	0
TBP	9
,	0
and	0
CREB	9
were	0
detected	0
,	0
identical	0
to	0
what	0
we	0
observed	0
in	0
mice	0
.	0

Antibodies	0
recognizing	0
double-stranded	0
DNA	0
were	0
confined	0
to	0
patients	0
with	0
frequent	0
polyomavirus	0
reactivations	0
.	0

The	0
results	0
described	0
here	0
indicate	0
that	0
cognate	0
interaction	0
of	0
B	0
cells	0
recognizing	0
DNA	0
or	0
DNA-associated	9
proteins	10
and	0
T	7
cells	8
recognizing	0
T	9
antigen	10
had	0
taken	0
place	0
as	0
a	0
consequence	0
of	0
complex	0
formation	0
between	0
T	9
ag	10
and	0
DNA	0
in	0
vivo	0
in	0
the	0
context	0
of	0
polyomavirus	0
reactivations	0
.	0

Jak3	9
is	0
associated	0
with	0
CD40	9
and	0
is	0
critical	0
for	0
CD40	9
induction	0
of	0
gene	0
expression	0
in	0
B	7
cells	8
.	0

CD40	9
is	0
a	0
receptor	0
that	0
is	0
critical	0
for	0
the	0
survival	0
,	0
growth	0
,	0
differentiation	0
,	0
and	0
isotype	0
switching	0
of	0
B	7
lymphocytes	8
.	0

Although	0
CD40	9
lacks	0
intrinsic	0
tyrosine	0
kinase	0
activity	0
,	0
its	0
ligation	0
induces	0
protein	0
tyrosine	0
phosphorylation	0
,	0
which	0
is	0
necessary	0
for	0
several	0
CD40	9
-mediated	0
events	0
.	0

We	0
show	0
that	0
engagement	0
of	0
CD40	9
induces	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
Jak3	9
as	0
well	0
as	0
of	0
STAT3	9
.	0

Jak3	9
is	0
constitutively	0
associated	0
with	0
CD40	9
,	0
and	0
this	0
interaction	0
requires	0
a	0
proline-rich	9
sequence	10
in	0
the	0
membrane-proximal	9
region	10
of	0
CD40	9
.	0

Deletion	0
of	0
this	0
sequence	0
abolishes	0
the	0
capacity	0
of	0
CD40	9
to	0
induce	0
expression	0
of	0
CD23	9
,	0
ICAM-1	9
,	0
and	0
lymphotoxin-alpha	1
genes	2
in	0
B	7
cells	8
.	0

These	0
results	0
indicate	0
that	0
signaling	0
through	0
Jak3	9
is	0
activated	0
by	0
CD40	9
and	0
plays	0
an	0
important	0
role	0
in	0
CD40	9
-mediated	0
functions	0
.	0

Transcription	9
factors	10
required	0
for	0
lymphoid	0
lineage	0
commitment	0
.	0

Intimate	0
interactions	0
between	0
multipotential	0
hemopoietic	7
stem	8
cells	8
and	0
their	0
microenvironment	0
work	0
towards	0
redefining	0
the	0
identity	0
and	0
the	0
differentiative	0
fate	0
of	0
these	0
primitive	7
cells	8
.	0

Molecular	0
cues	0
delivered	0
by	0
the	0
microenvironment	0
frequently	0
act	0
in	0
an	0
instructive	0
fashion	0
by	0
initiating	0
intracellular	0
signaling	0
pathways	0
that	0
ultimately	0
target	0
a	0
select	0
group	0
of	0
transcription	9
factors	10
.	0

These	0
transcriptional	0
regulators	0
in	0
turn	0
trigger	0
a	0
cascade	0
of	0
genetic	0
changes	0
that	0
ultimately	0
determine	0
the	0
course	0
of	0
the	0
cells	0
during	0
differentiation	0
.	0

Gene	0
inactivation	0
studies	0
on	0
the	0
PU.1	1
,	2
Ikaros	2
and	2
GATA-3	2
genes	2
have	0
revealed	0
that	0
their	0
encoded	0
factors	0
are	0
essential	0
for	0
the	0
earliest	0
commitment	0
step	0
into	0
the	0
B	7
and	8
T	8
lymphoid	8
lineages	8
.	0

Interleukin-4	9
signaling	0
in	0
B	7
lymphocytes	8
from	0
patients	0
with	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
.	0

Interleukin-4	9
(	0
IL-4	9
)	0
is	0
an	0
important	0
cytokine	0
for	0
B	0
and	0
T	0
lymphocyte	0
function	0
and	0
mediates	0
its	0
effects	0
via	0
a	0
receptor	0
that	0
contains	0
gammac	9
.	0

B	7
cells	8
derived	0
from	0
patients	0
with	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
(	0
X-SCID	0
)	0
are	0
deficient	0
in	0
gammac	0
and	0
provide	0
a	0
useful	0
model	0
in	0
which	0
to	0
dissect	0
the	0
role	0
of	0
this	0
subunit	0
in	0
IL-4	9
-mediated	0
signaling	0
.	0

We	0
found	0
that	0
although	0
IL-4	9
stimulation	0
of	0
X-SCID	7
B	8
cells	8
did	0
not	0
result	0
in	0
Janus	9
tyrosine	10
kinase-3	10
(	0
JAK3	9
)	0
phosphorylation	0
,	0
other	0
IL-4	9
substrates	10
including	0
JAK1	9
and	0
IRS-1	9
were	0
phosphorylated	0
.	0

Additionally	0
,	0
we	0
detected	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
6	10
(	0
STAT6	9
)	0
tyrosine	0
phosphorylation	0
and	0
DNA	0
binding	0
activity	0
in	0
X-SCID	7
B	8
cells	8
with	0
a	0
wide	0
range	0
of	0
gammac	9
mutations	0
.	0

However	0
,	0
reconstitution	0
of	0
these	0
X-SCID	7
B	8
cells	8
with	0
gammac	9
enhanced	0
IL-4	9
-mediated	0
responses	0
including	0
STAT6	9
phosphorylation	0
and	0
DNA	0
binding	0
activity	0
and	0
resulted	0
in	0
increased	0
CD23	9
expression	0
.	0

Thus	0
,	0
gammac	9
is	0
not	0
necessary	0
to	0
trigger	0
IL-4	9
-mediated	0
responses	0
in	0
B	7
cells	8
,	0
but	0
its	0
presence	0
is	0
important	0
for	0
optimal	0
IL-4	9
-signaling	0
.	0

These	0
results	0
suggest	0
that	0
two	0
distinct	0
IL-4	9
signaling	0
pathways	0
exist	0
.	0

Cell-to-cell	0
contact	0
activates	0
the	0
long	1
terminal	2
repeat	2
of	0
human	0
immunodeficiency	0
virus	0
1	0
through	0
its	0
kappaB	1
motif	2
.	0

Cell-to-cell	0
contact	0
between	0
peripheral	7
blood	8
lymphocytes	8
and	0
transfected	5
human	6
colonic	6
carcinoma	6
cell	6
line	6
HT29	6
activates	0
transcription	0
of	0
the	0
long	1
terminal	2
repeats	2
(	0
LTR	1
)	0
of	0
human	0
immunodeficiency	0
virus	0
.	0

HIV-1	1
LTR	2
transcription	0
is	0
controlled	0
by	0
a	0
complex	0
array	0
of	0
virus-encoded	9
and	10
cellular	10
proteins	10
.	0

Using	0
various	0
constructs	0
expressing	0
a	0
lacZ	1
reporter	2
gene	2
under	0
the	0
control	0
of	0
the	0
intact	0
or	0
three	0
deleted	0
forms	0
of	0
HIV-1	1
LTR	2
,	0
we	0
obtained	0
evidence	0
that	0
the	0
kappaB	1
regulatory	2
elements	2
located	0
in	0
the	0
U3	1
region	2
are	0
involved	0
in	0
cell-to-cell	0
activation	0
of	0
HIV-1	1
LTR	2
.	0

Cell-to-cell	0
contact	0
activates	0
in	0
vitro	0
binding	0
of	0
the	0
nuclear	9
factor	10
kappaB	10
(	10
NF-kappaB	10
)	10
p50/p65	10
heterodimer	10
to	0
an	0
HIV-1	0
kappaB	0
oligonucleotide	0
.	0

Cell-to-cell	0
contact	0
activation	0
of	0
NF-kappaB	9
was	0
only	0
partially	0
inhibited	0
by	0
100	0
microM	0
pyrrolidine	0
dithiocarbamate	0
and	0
was	0
not	0
correlated	0
with	0
a	0
significant	0
decrease	0
of	0
cellular	9
inhibitor	10
kappaB	10
alpha	10
.	0

NF-kappaB	9
nuclear	0
activation	0
was	0
not	0
detectable	0
before	0
1	0
h	0
after	0
cell	0
contact	0
and	0
was	0
dependent	0
on	0
protein	0
synthesis	0
.	0

Identification	0
of	0
nucleotide	1
sequences	2
that	0
regulate	0
transcription	0
of	0
the	0
MCF13	0
murine	0
leukemia	0
virus	0
long	1
terminal	2
repeat	2
in	0
activated	0
T	7
cells	8
.	0

The	0
region	0
downstream	0
of	0
the	0
enhancer	1
(	0
DEN	1
)	0
of	0
the	0
long	1
terminal	2
repeat	2
of	0
the	0
mink	0
cell	0
focus-forming	0
murine	0
leukemia	0
virus	0
is	0
important	0
for	0
viral	0
pathogenicity	0
.	0

Another	0
important	0
activity	0
of	0
DEN	1
is	0
its	0
control	0
of	0
transcription	0
in	0
activated	7
T	8
cells	8
,	0
and	0
we	0
have	0
determined	0
that	0
an	0
NF-kappaB	9
site	0
is	0
critical	0
for	0
this	0
activity	0
.	0

Possible	0
role	0
of	0
nuclear	9
factor-kappa	10
B	10
activity	0
in	0
germline	1
C	0
epsilon	0
transcription	0
in	0
a	0
human	5
Burkitt	6
lymphoma	6
B	6
cell	6
line	6
.	0

Nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
plays	0
a	0
broad	0
role	0
in	0
gene	0
regulation	0
,	0
but	0
it	0
is	0
not	0
evident	0
whether	0
NF-kappa	9
B	10
acts	0
as	0
a	0
messenger	0
system	0
for	0
germline	1
C	0
epsilon	0
transcription	0
.	0

We	0
report	0
here	0
that	0
the	0
signaling	0
cascade	0
triggered	0
by	0
interleukin-4	9
(	0
IL-4	9
)	0
or	0
anti-CD40	9
monoclonal	10
antibody	10
(	0
mAb	9
)	0
participates	0
in	0
NF-kappa	9
B	10
activation	0
responsible	0
for	0
germline	1
C	0
epsilon	0
transcription	0
in	0
a	0
human	5
Burkitt	6
lymphoma	6
B	6
cell	6
line	6
,	0
DND39	5
.	0

Both	0
IL-4	9
and	0
anti-	0
CD40	9
mAb	10
induced	0
activation	0
of	0
phosphatidylinositol	9
3-kinase	10
(	0
PI3-kinase	9
)	0
,	0
translocation	0
of	0
a	0
zeta	0
isoform	0
of	0
protein	9
kinase	10
C	10
,	0
and	0
nuclear	0
expression	0
of	0
NF-kappa	9
B	10
.	0

All	0
such	0
events	0
were	0
abrogated	0
by	0
treatment	0
with	0
LY294002	0
,	0
a	0
specific	0
inhibitor	0
of	0
PI3-kinase	9
.	0

In	0
addition	0
,	0
N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
,	0
a	0
potent	0
antioxidant	0
,	0
decreased	0
NF-kappa	9
B	10
activation	0
caused	0
by	0
IL-4	9
,	0
anti-CD40	9
mAb	10
,	0
or	0
their	0
combination	0
.	0

NAC	0
was	0
also	0
effective	0
in	0
diminishing	0
germline	1
C	0
epsilon	0
transcription	0
,	0
and	0
its	0
potency	0
was	0
higher	0
in	0
cultures	0
costimulated	0
with	0
IL-4	9
and	0
anti-CD40	9
mAb	10
than	0
in	0
those	0
stimulated	0
with	0
IL-4	9
alone	0
.	0

These	0
results	0
indicate	0
that	0
IL-4	9
and	0
ligation	0
of	0
CD40	9
induce	0
NF-kappa	9
B	10
expression	0
via	0
at	0
least	0
a	0
mechanism	0
dependent	0
on	0
the	0
PI3-kinase	9
pathway	0
and	0
suggest	0
that	0
NF-kappa	9
B	10
sensitive	0
to	0
NAC	0
may	0
play	0
a	0
role	0
in	0
regulating	0
germline	1
C	0
epsilon	0
transcription	0
.	0

Differentiation	0
of	0
U-937	5
promonocytic	6
cells	6
by	0
etoposide	0
and	0
ICRF-193	0
,	0
two	0
antitumour	0
DNA	9
topoisomerase	10
II	10
inhibitors	0
with	0
different	0
mechanisms	0
of	0
action	0
.	0

We	0
have	0
compared	0
the	0
action	0
on	0
U-937	5
human	6
promonocytic	6
leukemia	6
cells	6
of	0
two	0
DNA	9
topoisomerase	10
II	10
inhibitors	0
,	0
namely	0
the	0
epipodophyllotoxin	0
etoposide	0
and	0
the	0
bisdioxopiperazine	0
ICRF-193	0
.	0

One	0
hour	0
pulse-treatment	0
with	0
3	0
microM	0
etoposide	0
caused	0
topoisomerase	9
associated	0
,	0
primary	0
DNA	0
breakage	0
,	0
which	0
was	0
rapidly	0
followed	0
by	0
apoptosis	0
.	0

By	0
contrast	0
,	0
these	0
effects	0
were	0
not	0
observed	0
upon	0
pulse-treatment	0
with	0
6	0
microM	0
ICRF-193	0
.	0

However	0
,	0
continuous	0
treatments	0
with	0
subcytotoxic	0
concentrations	0
of	0
etoposide	0
(	0
0.15	0
microM	0
)	0
and	0
ICRF-193	0
(	0
0.3	0
microM	0
)	0
produced	0
several	0
similar	0
effects	0
,	0
namely	0
decreased	0
cell	0
proliferation	0
,	0
accumulation	0
of	0
cells	0
at	0
G2	0
,	0
increase	0
in	0
cell	0
mass	0
,	0
and	0
induction	0
of	0
differentiation	0
.	0

Under	0
these	0
conditions	0
,	0
etoposide	0
produced	0
a	0
biphasic	0
activation	0
of	0
protein	9
kinase	10
C	10
,	0
which	0
consisted	0
in	0
an	0
early	0
transient	0
activation	0
(	0
from	0
hours	0
1	0
to	0
6	0
)	0
of	0
the	0
membrane-bound	9
enzyme	10
followed	0
by	0
a	0
later	0
activation	0
(	0
hour	0
48	0
)	0
of	0
the	0
total	0
,	0
membrane-bound	9
and	10
cytosolic	10
enzyme	10
.	0

By	0
contrast	0
,	0
ICRF-193	0
only	0
provoked	0
a	0
late	0
activation	0
(	0
from	0
hours	0
72	0
to	0
96	0
)	0
of	0
the	0
total	0
enzyme	0
.	0

When	0
used	0
at	0
differentiation-inducing	0
concentrations	0
,	0
both	0
topoisomerase	9
inhibitors	0
caused	0
a	0
great	0
stimulation	0
of	0
AP-1	9
binding	0
activity	0
,	0
with	0
maximum	0
value	0
at	0
hour	0
12	0
in	0
etoposide-treated	0
cells	0
and	0
at	0
hour	0
48	0
in	0
ICRF-193-treated	7
cells	8
.	0

By	0
contrast	0
,	0
the	0
binding	0
activity	0
of	0
the	0
NF-kappa	9
(	10
B	10
)	10
and	0
EGR-1	9
transcription	9
factors	10
was	0
little	0
affected	0
.	0

It	0
is	0
concluded	0
that	0
topoisomerase	0
II	0
inhibitors	0
may	0
induce	0
the	0
differentiation	0
of	0
promonocytic	0
cells	0
,	0
independently	0
of	0
their	0
capacity	0
to	0
cause	0
DNA	0
strand	0
breaks	0
.	0

However	0
,	0
there	0
are	0
other	0
effects	0
,	0
such	0
as	0
the	0
early	0
activation	0
of	0
protein	9
kinase	10
C	10
,	0
which	0
are	0
probably	0
derived	0
from	0
the	0
production	0
of	0
primary	0
DNA	0
breakage	0
by	0
some	0
anti-	0
topoisomerase	9
drugs	0
.	0

GATA-1	9
DNA	0
binding	0
activity	0
is	0
down-regulated	0
in	0
late	0
S	0
phase	0
in	0
erythroid	7
cells	8
.	0

We	0
have	0
set	0
out	0
to	0
test	0
a	0
model	0
for	0
tissue-specific	0
gene	0
expression	0
that	0
relies	0
on	0
the	0
early	0
replication	0
of	0
expressed	0
genes	0
to	0
sequester	0
limiting	0
activating	0
transcription	9
factors	10
.	0

Using	0
an	0
erythroid	5
cell	6
line	6
,	0
we	0
have	0
tested	0
the	0
changes	0
in	0
the	0
DNA	0
binding	0
activity	0
of	0
the	0
lineage-restricted	9
transcription	10
factor	10
GATA-1	9
through	0
the	0
cell	0
cycle	0
.	0

We	0
find	0
that	0
GATA-1	9
activity	0
is	0
low	0
in	0
G1	0
,	0
peaks	0
in	0
mid-S	0
phase	0
,	0
and	0
then	0
decreases	0
in	0
G2/M	0
.	0

In	0
contrast	0
,	0
the	0
binding	0
activities	0
of	0
two	0
ubiquitous	0
transcription	9
factors	10
,	0
Oct1	9
and	0
Sp1	9
,	0
remain	0
high	0
in	0
G2/M	0
.	0

GATA-1	9
protein	0
and	0
mRNA	3
vary	0
in	0
a	0
similar	0
manner	0
through	0
the	0
cell	0
cycle	0
,	0
suggesting	0
that	0
the	0
expression	0
of	0
the	0
gene	0
or	0
the	0
stability	0
of	0
its	0
message	0
is	0
regulated	0
.	0

Although	0
a	0
number	0
of	0
transcription	9
factors	10
involved	0
in	0
the	0
control	0
of	0
the	0
cell	0
cycle	0
or	0
DNA	0
replication	0
have	0
been	0
shown	0
to	0
peak	0
in	0
S	0
phase	0
,	0
this	0
is	0
the	0
first	0
example	0
of	0
a	0
lineage-restricted	9
transcription	10
factor	10
displaying	0
S	0
phase-specific	0
DNA	0
binding	0
activity	0
.	0

One	0
interpretation	0
of	0
these	0
data	0
leads	0
to	0
a	0
model	0
in	0
which	0
the	0
peak	0
in	0
GATA-1	9
DNA	0
binding	0
amplifies	0
the	0
effect	0
of	0
early	0
replication	0
on	0
the	0
activation	0
of	0
erythroid-specific	1
genes	2
at	0
the	0
same	0
time	0
as	0
preventing	0
activation	0
of	0
non-erythroid	1
genes	2
containing	0
GATA-responsive	1
elements	2
.	0

These	0
results	0
may	0
also	0
relate	0
to	0
recent	0
data	0
implicating	0
GATA-1	9
function	0
in	0
apoptosis	0
and	0
cell	0
cycle	0
progression	0

Activation	0
of	0
the	0
NF-kappaB	9
pathway	0
by	0
inflammatory	0
stimuli	0
in	0
human	7
neutrophils	8
.	0

Activated	7
neutrophils	8
have	0
the	0
ability	0
to	0
upregulate	0
the	0
expression	0
of	0
many	0
genes	0
,	0
in	0
particular	0
those	0
encoding	0
cytokines	9
and	0
chemokines	9
,	0
and	0
to	0
subsequently	0
release	0
the	0
corresponding	0
proteins	0
.	0

Although	0
little	0
is	0
known	0
to	0
date	0
concerning	0
the	0
regulation	0
of	0
gene	0
transcription	0
in	0
neutrophils	7
,	0
it	0
is	0
noteworthy	0
that	0
many	0
of	0
these	0
genes	0
depend	0
on	0
the	0
activation	0
of	0
transcription	9
factors	10
,	0
such	0
as	0
NF-kappaB	9
,	0
for	0
inducible	0
expression	0
.	0

We	0
therefore	0
investigated	0
whether	0
NF-kappaB/Rel	9
proteins	10
are	0
expressed	0
in	0
human	7
neutrophils	8
,	0
as	0
well	0
as	0
their	0
fate	0
on	0
cell	0
activation	0
.	0

We	0
now	0
report	0
that	0
dimers	0
consisting	0
of	0
p50	9
NFkappaB1	10
,	0
p65	9
RelA	10
,	0
and/or	0
c-Rel	9
are	0
present	0
in	0
neutrophils	7
and	0
that	0
the	0
greater	0
part	0
of	0
these	0
protein	9
complexes	10
is	0
physically	0
associated	0
with	0
cytoplasmic	9
IkappaB-alpha	10
in	0
resting	0
cells	0
.	0

Following	0
neutrophil	0
stimulation	0
with	0
proinflammatory	0
agonists	0
(	0
such	0
as	0
lipopolysaccharide	0
[	0
LPS	0
]	0
,	0
tumor	9
necrosis	10
factor-alpha	10
[	0
TNF-alpha	9
]	0
,	0
and	0
fMet-Leu-Phe	0
)	0
that	0
induce	0
the	0
production	0
of	0
cytokines	9
and	0
chemokines	9
in	0
these	0
cells	0
,	0
NF-kappaB/Rel	9
proteins	10
translocated	0
to	0
nuclear	0
fractions	0
,	0
resulting	0
in	0
a	0
transient	0
induction	0
of	0
NF-kappaB	9
DNA	0
binding	0
activity	0
,	0
as	0
determined	0
in	0
gel	0
mobility	0
shift	0
assays	0
.	0

The	0
onset	0
of	0
both	0
processes	0
was	0
found	0
to	0
be	0
closely	0
paralleled	0
by	0
,	0
and	0
dependent	0
on	0
,	0
IkappaB-alpha	9
degradation	0
.	0

Proinflammatory	7
neutrophil	8
stimuli	0
also	0
promoted	0
the	0
accumulation	0
of	0
IkappaB-alpha	3
mRNA	4
transcripts	4
,	0
resulting	0
in	0
the	0
reexpression	0
of	0
the	0
IkappaB-alpha	9
protein	10
.	0

To	0
our	0
knowledge	0
,	0
this	0
constitutes	0
the	0
first	0
indication	0
that	0
NF-kappaB	9
activation	0
may	0
underlie	0
the	0
action	0
of	0
proinflammatory	0
stimuli	0
towards	0
human	0
neutrophil	0
gene	0
expression	0
and	0
,	0
as	0
such	0
,	0
adds	0
a	0
new	0
facet	0
to	0
our	0
understanding	0
of	0
neutrophil	7
biology	8
.	0

Two	0
distinct	0
pathways	0
of	0
interleukin-5	9
synthesis	0
in	0
allergen-specific	5
human	6
T-cell	6
clones	6
are	0
suppressed	0
by	0
glucocorticoids	0
.	0

Glucocorticoids	0
(	0
GC	0
)	0
have	0
long	0
been	0
used	0
as	0
the	0
most	0
effective	0
agents	0
for	0
the	0
treatment	0
of	0
allergic	0
diseases	0
accompanied	0
by	0
eosinophilia	0
such	0
as	0
chronic	0
asthma	0
and	0
atopic	0
dermatitis	0
.	0

The	0
development	0
of	0
chronic	0
eosinophilic	0
inflammation	0
is	0
dependent	0
on	0
interleukin-5	9
(	0
IL-5	9
)	0
,	0
a	0
selective	9
eosinophil-activating	10
factor	10
,	0
produced	0
by	0
helper	7
T	8
cells	8
.	0

To	0
delineate	0
the	0
regulatory	0
mechanisms	0
of	0
human	0
IL-5	9
synthesis	0
,	0
we	0
established	0
allergen-specific	5
CD4+	6
T-cell	6
clones	6
from	0
asthmatic	0
patients	0
.	0

GC	0
efficiently	0
suppressed	0
IL-5	9
synthesis	0
of	0
T-cell	0
clones	0
activated	0
via	0
either	0
T-cell	9
receptor	10
(	0
TCR	9
)	0
or	0
IL-2	9
receptor	10
(	0
IL-2R	9
)	0
.	0

Induction	0
of	0
IL-5	3
mRNA	4
upon	0
TCR	9
and	0
IL-2R	9
stimulation	0
was	0
totally	0
inhibited	0
by	0
dexamethasone	0
.	0

Human	0
IL-5	9
promoter/enhancer-luciferase	0
gene	0
construct	0
transfected	0
to	0
T-cell	5
clones	6
was	0
transcribed	0
on	0
either	0
TCR	9
or	0
IL-2R	9
stimulation	0
and	0
was	0
clearly	0
downregulated	0
by	0
dexamethasone	0
,	0
indicating	0
that	0
the	0
approximately	0
500-bp	1
human	2
IL-5	2
gene	2
segment	2
located	0
5	1
'	2
upstream	2
of	0
the	0
coding	0
region	0
contains	0
activation-inducible	1
enhancer	2
elements	2
responsible	0
for	0
the	0
regulation	0
by	0
GC	0
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
analysis	0
suggested	0
that	0
AP-1	9
and	0
NF-kappaB	9
are	0
among	0
the	0
possible	0
targets	0
of	0
GC	0
actions	0
on	0
TCR-stimulated	7
T	8
cells	8
.	0

NF-AT	9
and	0
NF-kappaB	9
were	0
not	0
significantly	0
induced	0
by	0
IL-2	9
stimulation	0
.	0

Our	0
results	0
showing	0
that	0
GC	0
suppressed	0
IL-5	9
production	0
by	0
human	7
CD4+	8
T	8
cells	8
activated	0
by	0
two	0
distinct	0
stimuli	0
,	0
TCR	9
and	0
IL-2R	9
stimulation	0
,	0
underscore	0
the	0
efficacy	0
of	0
GC	0
in	0
the	0
treatment	0
of	0
allergic	0
diseases	0
via	0
suppression	0
of	0
T-cell	0
IL-5	9
synthesis	0
.	0

Itk	9
,	0
a	0
T	9
cell-specific	10
tyrosine	10
kinase	10
,	0
is	0
required	0
for	0
CD2-mediated	1
interleukin-2	2
promoter	2
activation	0
in	0
the	0
human	5
T	6
cell	6
line	6
Jurkat	6
.	0

We	0
investigated	0
the	0
functional	0
role	0
of	0
Itk	9
,	0
a	0
member	0
of	0
the	0
cytoplasmic	9
tyrosine	10
kinase	10
Tec	10
family	10
,	0
in	0
T	0
cell	0
activation	0
.	0

Stimulation	0
of	0
either	0
CD2	9
or	0
T	0
cell	0
receptor	0
(	0
TCR	9
)	0
/CD3	0
on	0
Tcells	0
by	0
monoclonal	0
antibody-mediated	0
cross-linking	0
induced	0
tyrosine	0
phosphorylation	0
of	0
Itk	9
,	0
which	0
was	0
maximal	0
as	0
early	0
as	0
1	0
min	0
after	0
stimulation	0
.	0

The	0
tyrosine	0
kinase	0
activity	0
in	0
the	0
anti-	0
Itk	9
immunoprecipitate	0
was	0
significantly	0
activated	0
upon	0
these	0
stimulations	0
.	0

Interleukin-2	0
(	0
IL-2	9
)	0
promoter	0
activity	0
stimulated	0
by	0
cross-linking	0
of	0
CD2	9
,	0
TCR	9
/CD3	0
,	0
and	0
CD28	9
with	0
antibodies	9
was	0
significantly	0
reduced	0
by	0
transient	0
expression	0
of	0
an	0
Itk	9
mutant	10
lacking	0
the	0
kinase	0
activity	0
.	0

The	0
reduction	0
paralleled	0
a	0
decrease	0
in	0
tyrosine	0
phosphorylation	0
of	0
endogenous	9
wild-type	10
Itk	10
.	0

Stimulation	0
of	0
CD2	9
or	0
TCR/CD3	9
induced	0
activation	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
,	0
the	0
binding	1
site	2
of	0
which	0
is	0
included	0
in	0
the	0
IL-2	1
gene	2
promoter	2
.	0

The	0
activation	0
of	0
NFAT	9
was	0
also	0
impaired	0
by	0
expression	0
of	0
the	0
Itk	9
mutant	10
.	0

These	0
results	0
demonstrate	0
that	0
Itk	9
plays	0
a	0
role	0
in	0
IL-2	9
production	0
,	0
indicating	0
a	0
critical	0
involvement	0
of	0
Itk	9
in	0
the	0
initial	0
stage	0
of	0
T	0
cell	0
activation	0
by	0
mediating	0
signals	0
from	0
the	0
TCR/CD3	9
complex	10
,	0
CD2	9
,	0
and	0
CD28	9
.	0

Expression	0
of	0
LAZ3/BCL6	9
in	0
follicular	0
center	0
(	0
FC	0
)	0
B	0
cells	0
of	0
reactive	0
lymph	0
nodes	0
and	0
FC-derived	0
non-Hodgkin	0
lymphomas	0
.	0

Chromosomal	0
translocation	0
resulting	0
in	0
abnormal	0
expression	0
of	0
the	0
LAZ3/BCL6	1
gene	2
in	0
B	7
cells	8
has	0
been	0
implicated	0
in	0
the	0
tumorigenesis	0
of	0
non-Hodgkin	0
lymphoma	0
(	0
NHL	0
)	0
.	0

Therefore	0
we	0
studied	0
the	0
expression	0
pattern	0
of	0
LAZ3/BCL6	9
by	0
in	0
situ	0
hybridization	0
with	0
synthetic	0
oligonucleotide	0
probes	0
in	0
frozen	0
tissue	0
sections	0
from	0
five	0
reactive	0
lymph	0
nodes	0
and	0
38	0
B	0
cell	0
and	0
non-B	0
NHL	0
.	0

In	0
addition	0
,	0
we	0
investigated	0
the	0
expression	0
of	0
LAZ3/BCL6	9
by	0
Northern	0
blot	0
analysis	0
on	0
multiple	0
human	0
tissues	0
.	0

The	0
LAZ3/BCL6	3
transcript	4
was	0
found	0
in	0
a	0
variety	0
of	0
tissues	0
,	0
including	0
skeletal	0
muscle	0
,	0
peripheral	7
blood	8
leukocytes	8
,	0
and	0
weakly	0
in	0
normal	0
lymph	0
nodes	0
.	0

In	0
the	0
tumor	0
samples	0
,	0
expression	0
of	0
LAZ3/BCL6	9
was	0
observed	0
in	0
68	0
%	0
of	0
all	0
B	0
cell	0
NHL	0
and	0
none	0
of	0
the	0
non-B	0
lymphomas	0
.	0

All	0
cases	0
of	0
follicular	0
,	0
mixed	0
small	0
and	0
large	0
cell	0
lymphomas	0
showed	0
LAZ3/BCL6	9
expression	0
confined	0
to	0
the	0
neoplastic	0
follicles	0
.	0

A	0
follicular	0
expression	0
pattern	0
was	0
also	0
found	0
in	0
all	0
non-malignant	0
reactive	0
lymph	0
nodes	0
.	0

Hence	0
,	0
the	0
expression	0
of	0
LAZ3/BCL6	9
does	0
not	0
correlate	0
to	0
malignancy	0
,	0
but	0
reflects	0
the	0
origin	0
of	0
B	7
cells	8
from	0
the	0
germinal	0
centers	0
.	0

Jak1	9
expression	0
is	0
required	0
for	0
mediating	0
interleukin-4-induced	0
tyrosine	0
phosphorylation	0
of	0
insulin	0
receptor	0
substrate	0
and	0
Stat6	9
signaling	9
molecules	10
.	0

The	0
Jak1	9
,	10
Jak2	10
,	10
Jak3	10
,	10
and	10
Fes	10
tyrosine	10
kinases	10
have	0
been	0
demonstrated	0
to	0
undergo	0
tyrosine	0
phosphorylation	0
in	0
response	0
to	0
interleukin	9
(	10
IL	10
)	10
-4	10
stimulation	0
in	0
different	0
cell	0
systems	0
.	0

However	0
,	0
it	0
is	0
not	0
clear	0
which	0
,	0
if	0
any	0
,	0
of	0
these	0
kinases	0
are	0
responsible	0
for	0
initiating	0
IL-4-induced	0
tyrosine	0
phosphorylation	0
of	0
intracellular	9
substrates	10
in	0
vivo	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
have	0
utilized	0
a	0
mutant	5
Jak1-deficient	6
HeLa	6
cell	6
line	6
,	0
E1C3	5
,	0
and	0
its	0
parental	5
Jak1-expressing	6
counterpart	6
,	0
1D4	5
,	0
to	0
analyze	0
the	0
role	0
of	0
Jak1	9
in	0
mediating	0
IL-4-induced	0
tyrosine	0
phosphorylation	0
events	0
.	0

IL-4	0
treatment	0
rapidly	0
induced	0
tyrosine	0
phosphorylation	0
of	0
insulin	9
receptor	10
substrate	10
(	10
IRS	10
)	10
-1	10
and	0
IRS-2	9
in	0
1D4	5
but	0
not	0
in	0
E1C3	5
cells	6
.	0

IL-4	9
-mediated	0
tyrosine	0
phosphorylation	0
of	0
Stat6	9
was	0
pronounced	0
in	0
1D4	5
cells	6
,	0
while	0
no	0
IL-4	9
-induced	0
Stat6	9
phosphorylation	0
was	0
detected	0
in	0
E1C3	5
cells	6
.	0

IL-4	9
also	0
induced	0
Stat6	9
DNA	0
binding	0
activity	0
from	0
lysates	0
of	0
1D4	5
but	0
not	0
E1C3	5
cells	6
utilizing	0
a	0
radiolabeled	1
immunoglobulin	2
heavy	2
chain	2
germline	2
epsilon	2
promotor	2
sequence	2
(	0
Iepsilon	1
)	0
in	0
an	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

Reconstitution	0
of	0
Jak1	9
expression	0
in	0
E1C3	5
cells	6
restored	0
the	0
ability	0
of	0
IL-4	9
to	0
induce	0
IRS	1
and	0
Stat6	9
tyrosine	0
phosphorylation	0
.	0

These	0
results	0
provide	0
evidence	0
that	0
Jak1	9
expression	0
is	0
required	0
for	0
mediating	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
crucial	0
molecules	0
involved	0
in	0
IL-4	9
signal	0
transduction	0
.	0

Oxidant-regulation	0
of	0
gene	0
expression	0
in	0
the	0
chronically	0
inflamed	0
intestine	0
.	0

It	0
is	0
becoming	0
increasingly	0
apparent	0
that	0
the	0
chronic	0
gut	0
inflammation	0
observed	0
in	0
the	0
idiopathic	0
inflammatory	0
bowel	0
diseases	0
(	0
e.g.	0
ulcerative	0
colitis	0
,	0
Crohn	0
's	0
disease	0
)	0
is	0
associated	0
with	0
enhanced	0
production	0
of	0
leukocyte-derived	0
oxidants	0
.	0

Oxidants	0
such	0
as	0
hydrogen	0
peroxide	0
are	0
known	0
to	0
activate	0
certain	0
transcription	9
factors	10
such	0
as	0
nuclear	9
transcription	10
factor	10
kappa	10
beta	10
.	0

Nuclear	9
transcription	10
factor	10
kB	10
(	0
NF-kappa	9
B	10
)	0
is	0
a	0
ubiquitous	9
transcription	10
factor	10
and	0
pleiotropic	9
regulator	10
of	0
numerous	0
genes	0
involved	0
in	0
the	0
immune	0
and	0
inflammatory	0
responses	0
.	0

This	0
transcription	9
factor	10
is	0
activated	0
via	0
the	0
selective	0
phosphorylation	0
,	0
ubiquination	0
and	0
degradation	0
of	0
its	0
inhibitor	9
protein	10
I-kB	10
thereby	0
allowing	0
translocation	0
of	0
NF-kappa	9
B	10
into	0
the	0
nucleus	0
where	0
it	0
upregulates	0
the	0
transcription	0
of	0
a	0
variety	0
of	0
adhesion	9
molecules	10
(	0
e.g	0
.	0
ICAM-1	9
,	0
VCAM-1	9
)	0
,	0
cytokines	9
(	0
TNF	9
,	0
IL-1	9
,	0
IL-6	9
)	0
and	0
enzymes	9
(	0
iNOS	9
)	0
.	0

The	0
proteolytic	0
degradation	0
of	0
the	0
post-translationally	0
modified	0
I-kappa	9
B	10
is	0
known	0
to	0
be	0
mediated	0
by	0
the	0
26S	9
proteasome	10
complex	10
.	0

Based	0
upon	0
work	0
from	0
our	0
laboratory	0
,	0
we	0
propose	0
that	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
produces	0
significant	0
anti	0
inflammatory	0
activity	0
which	0
may	0
be	0
mediated	0
by	0
the	0
inhibition	0
of	0
transcription	0
of	0
certain	0
pro-inflammatory	9
mediators	10
and	0
adhesion	9
molecules	10
.	0

Generation	0
of	0
cytotoxic	7
T	8
lymphocytes	8
against	0
immunorecessive	9
epitopes	10
after	0
multiple	0
immunizations	0
with	0
adenovirus	0
vectors	0
is	0
dependent	0
on	0
haplotype	0
.	0

Currently	0
,	0
adenovirus	0
(	0
Ad	0
)	0
is	0
being	0
considered	0
as	0
a	0
vector	0
for	0
the	0
treatment	0
of	0
cystic	0
fibrosis	0
as	0
well	0
as	0
other	0
diseases	0
.	0

However	0
,	0
the	0
cytotoxic	7
T	8
lymphocyte	8
(	0
CTL	7
)	0
response	0
to	0
Ad	0
could	0
limit	0
the	0
effectiveness	0
of	0
such	0
approaches	0
.	0

Since	0
the	0
CTL	7
response	0
to	0
virus	0
infection	0
is	0
often	0
focused	0
on	0
one	0
or	0
a	0
few	0
immunodominant	9
epitopes	10
,	0
one	0
approach	0
to	0
circumvent	0
this	0
response	0
is	0
to	0
create	0
vectors	0
that	0
lack	0
these	0
immunodominant	9
epitopes	10
.	0

The	0
effectiveness	0
of	0
this	0
approach	0
was	0
tested	0
by	0
immunizing	0
mice	0
with	0
human	0
group	0
C	0
adenoviruses	0
.	0

Three	0
mouse	0
strains	0
(	0
C57BL/10SnJ	0
[	0
H-2b	0
]	0
,	0
C3HeB/FeJ	0
[	0
H-2k	0
]	0
,	0
and	0
BALB/cByJ	0
[	0
H-2d	0
]	0
)	0
were	0
immunized	0
with	0
wild-type	0
Ad	0
or	0
Ad	0
vectors	0
lacking	0
the	0
immunodominant	9
antigen	10
(	0
s	0
)	0
,	0
and	0
the	0
CTL	7
responses	0
were	0
measured	0
.	0

In	0
C57BL/10	0
(	0
B10	0
)	0
mice	0
,	0
a	0
single	0
inoculation	0
intraperitoneally	0
(	0
i.p.	0
)	0
led	0
to	0
the	0
recognition	0
of	0
an	0
immunodominant	9
antigen	10
in	0
E1A	1
.	0

When	0
B10	0
mice	0
were	0
inoculated	0
multiple	0
times	0
either	0
i.p	0
.	0

or	0
intranasally	0
with	0
wild-type	0
Ad	0
or	0
an	0
Ad	0
vector	0
lacking	0
most	0
of	0
the	0
E1	1
region	2
,	0
subdominant	0
epitopes	0
outside	0
this	0
region	0
were	0
recognized	0
.	0

In	0
contrast	0
,	0
C3H	0
mice	0
inoculated	0
with	0
wild-type	0
Ad	0
recognized	0
an	0
epitope	0
mapping	0
within	0
E1B	1
.	0
When	0
inoculated	0
twice	0
with	0
Ad	0
vectors	0
lacking	0
both	0
E1A	1
and	0
E1B	1
,	0
no	0
immunorecessive	9
epitopes	10
were	0
recognized	0
.	0

The	0
immune	0
response	0
to	0
Ad	0
in	0
BALB/c	0
mice	0
was	0
more	0
complex	0
.	0

CTLs	7
from	0
BALB/c	0
mice	0
inoculated	0
i.p.	0
with	0
wild-type	0
Ad	0
recognized	0
E1B	1
in	0
the	0
context	0
of	0
the	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
I	2
Dd	2
allele	2
and	0
a	0
region	0
outside	0
E1	1
associated	0
with	0
the	0
Kd	1
allele	2
.	0

When	0
BALB/c	0
mice	0
were	0
inoculated	0
with	0
E1	1
-deleted	0
Ad	0
vectors	0
,	0
only	0
the	0
immunodominant	9
Kd-restricted	10
epitope	10
was	0
recognized	0
,	0
and	0
Dd-restricted	0
CTLs	7
did	0
not	0
develop	0
.	0

This	0
report	0
indicates	0
that	0
the	0
emergence	0
of	0
CTLs	7
against	0
immunorecessive	9
epitopes	10
following	0
multiple	0
administrations	0
of	0
Ad	0
vectors	0
lacking	0
immunodominant	0
antigens	0
is	0
dependent	0
on	0
haplotype	0
and	0
could	0
present	0
an	0
obstacle	0
to	0
gene	0
therapy	0
in	0
an	0
MHC	9
-diverse	0
human	0
population	0
.	0

Characterization	0
of	0
the	0
human	1
platelet/endothelial	2
cell	2
adhesion	2
molecule-1	2
promoter	2
:	0
identification	0
of	0
a	0
GATA-2	1
binding	2
element	2
required	0
for	0
optimal	0
transcriptional	0
activity	0
.	0

Platelet/endothelial	9
cell	10
adhesion	10
molecule-1	10
(	0
PECAM-1	9
)	0
is	0
a	0
130-kD	9
member	10
of	0
the	0
Ig	1
gene	2
superfamily	2
that	0
is	0
expressed	0
on	0
platelets	7
,	0
endothelial	7
cells	8
,	0
and	0
certain	0
leukocyte	7
subsets	8
.	0

To	0
examine	0
the	0
factors	0
controlling	0
vascular-specific	0
expression	0
of	0
PECAM-1	9
,	0
we	0
cloned	0
the	0
5'-flanking	1
region	2
of	0
the	0
PECAM-1	1
gene	2
and	0
analyzed	0
its	0
transcriptional	0
activity	0
.	0

5'-Rapid	0
amplification	0
of	0
cDNA	1
ends	2
(	0
5'-RACE	1
)	0
analysis	0
showed	0
that	0
transcription	0
initiation	0
occurred	0
at	0
several	0
closely	0
spaced	0
nearby	0
sites	0
originating	0
approximately	0
204	1
bp	2
upstream	2
from	0
the	0
translation	1
start	2
site	2
.	0

Analysis	0
of	0
the	0
sequence	0
immediately	0
upstream	0
from	0
the	0
transcription	1
initiation	2
site	2
(	0
TIS	1
)	0
showed	0
no	0
canonical	0
TATA	1
or	0
CAAT	1
elements	2
,	0
however	0
an	0
initiator	0
element	0
commonly	0
found	0
in	0
TATA-less	1
promoters	2
encompassed	0
the	0
TIS	1
.	0

5'-serially	1
truncated	2
PECAM-1	2
promoter	2
segments	2
cloned	0
in	0
front	0
of	0
a	0
luciferase	1
reporter	2
drove	0
transcription	0
in	0
both	0
a	0
lineage-	0
and	0
orientation-specific	0
manner	0
.	0

Putative	0
cis-acting	1
control	2
elements	2
present	0
within	0
a	0
300-bp	1
core	2
promoter	2
included	0
two	0
ets	1
sites	2
,	0
an	0
Sp1	1
site	2
,	0
tandem	0
E-box	1
domains	2
,	0
two	0
GATA-associated	1
sites	2
(	0
CACCC	0
)	0
,	0
an	0
AP-2	1
binding	2
site	2
,	0
and	0
a	0
GATA	1
element	2
at	0
-24	1
.	0

Mutational	0
analysis	0
showed	0
that	0
optimal	0
transcriptional	0
activity	0
required	0
the	0
GATA	1
sequence	2
at	0
position	0
-24	1
,	0
and	0
gel-shift	0
assays	0
further	0
showed	0
that	0
the	0
GATA-2	9
transcription	10
factor	10
,	0
but	0
not	0
GATA-1	9
,	0
bound	0
to	0
this	0
region	0
of	0
the	0
PECAM-1	1
promoter	2
.	0

Understanding	0
the	0
cis-	9
and	10
transacting	10
factors	10
that	0
regulate	0
the	0
tissue-specific	0
expression	0
of	0
PECAM-1	9
should	0
increase	0
our	0
understanding	0
of	0
the	0
mechanisms	0
by	0
which	0
vascular-specific	0
gene	0
expression	0
is	0
achieved	0
.	0

A	0
negative	0
regulatory	0
region	0
containing	0
a	0
glucocorticosteroid	1
response	2
element	2
(	0
nGRE	1
)	0
in	0
the	0
human	1
interleukin-1beta	2
gene	2
.	0

Interleukin-1	9
beta	10
(	0
IL-1beta	9
)	0
is	0
one	0
of	0
the	0
most	0
important	0
inflammatory	9
mediators	10
in	0
human	0
inflammatory	0
and	0
immunological	0
diseases	0
.	0

The	0
regulation	0
of	0
human	9
IL-1beta	10
gene	0
expression	0
has	0
been	0
studied	0
for	0
several	0
years	0
,	0
and	0
a	0
few	0
regulatory	1
elements	2
have	0
been	0
discovered	0
in	0
the	0
promoter	1
region	2
.	0

However	0
,	0
little	0
is	0
known	0
about	0
negative	0
regulation	0
of	0
IL-1beta	9
expression	0
at	0
the	0
transcriptional	0
level	0
,	0
which	0
may	0
play	0
an	0
important	0
role	0
in	0
anti-inflammatory	0
and	0
immunosuppressive	0
effects	0
.	0

We	0
have	0
identified	0
a	0
negative	1
regulatory	2
element	2
located	0
in	0
the	0
region	0
between	0
-685	1
and	2
-395	2
.	0

Within	0
this	0
region	0
,	0
a	0
19-bp	1
nuclear	2
factor	2
binding	2
site	2
(	0
-570	1
to	2
-552	2
)	0
was	0
characterized	0
by	0
DNase	9
I	10
footprinting	0
and	0
electromobility	0
shift	0
assay	0
.	0

A	0
consensus	1
sequence	2
for	0
a	0
negative	1
glucocorticoid	2
response	2
element	2
(	0
nGRE	1
)	0
and	0
a	0
transcription	1
activator	2
protein-2	2
binding	2
site	2
were	0
noted	0
within	0
this	0
footprint	0
.	0

Functional	0
studies	0
showed	0
a	0
2.5-fold	0
increase	0
in	0
promoter	0
activity	0
when	0
this	0
19-bp	1
binding	2
site	2
was	0
deleted	0
in	0
the	0
reporter	1
constructs	2
IL-1beta	9
/CAT	9
and	0
IL-1beta	9
/SV40	1
promoter	2
/CAT	9
.	0

Dexamethasone	0
(	0
10	0
(	0
-8	0
)	0
M	0
)	0
repressed	0
chloramphenicol	9
acetyltransferase	10
(	0
CAT	9
)	0
production	0
by	0
75	0
%	0
in	0
the	0
wild-type	1
fragment	2
but	0
not	0
in	0
a	0
deletion	1
mutant	2
lacking	0
the	0
19-bp	1
site	2
.	0

A	0
protein	0
of	0
about	0
150	9
kD	10
that	0
bound	0
to	0
this	0
negative	1
regulatory	2
sequence	2
was	0
identified	0
by	0
UV	0
cross-linking	0
.	0

This	0
is	0
the	0
first	0
description	0
of	0
a	0
negative	1
regulatory	2
region	2
responsive	0
to	0
glucocorticoids	0
in	0
a	0
cytokine	1
gene	2
.	0

Interaction	0
of	0
transcription	9
factors	10
RFX1	9
and	0
MIBP1	9
with	0
the	0
gamma	1
motif	2
of	0
the	0
negative	1
regulatory	2
element	2
of	0
the	0
hepatitis	1
B	2
virus	2
core	2
promoter	2
.	0

The	0
negative	1
regulatory	2
element	2
(	0
NRE	1
)	0
of	0
the	0
hepatitis	1
B	2
virus	2
(	2
HBV	2
)	2
core	2
promoter	2
contains	0
three	0
subregions	0
which	0
act	0
synergistically	0
to	0
suppress	0
core	0
promoter	0
activity	0
.	0

One	0
of	0
these	0
subregions	0
,	0
NRE	1
gamma	2
,	0
is	0
active	0
in	0
both	0
HeLa	5
cervical	6
carcinoma	6
cells	6
and	0
Huh7	5
hepatoma	6
cells	6
and	0
was	0
found	0
to	0
be	0
bound	0
by	0
a	0
protein	0
factor	0
present	0
in	0
both	0
cell	0
types	0
.	0

Here	0
we	0
show	0
that	0
the	0
transcription	9
factor	10
RFX1	9
can	0
bind	0
to	0
NRE	1
gamma	2
and	0
transactivate	0
the	0
core	1
promoter	2
through	0
this	0
site	0
.	0

Mutations	0
which	0
abrogated	0
the	0
gene-suppressive	0
activity	0
of	0
NRE	1
gamma	2
prevented	0
RFX1	9
from	0
binding	0
to	0
NRE	1
gamma	2
.	0

In	0
addition	0
,	0
RFX1	9
can	0
bind	0
simultaneously	0
,	0
most	0
likely	0
as	0
a	0
heterodimer	9
,	0
with	0
the	0
transcription	9
factor	10
MIBP1	9
to	0
NRE	1
gamma	2
.	0

In	0
the	0
absence	0
of	0
a	0
cloned	0
MIBP1	1
gene	2
for	0
further	0
studies	0
,	0
we	0
hypothesize	0
that	0
RFX1	9
acts	0
with	0
MIBP1	9
to	0
negatively	0
regulate	0
the	0
core	0
promoter	0
activity	0
through	0
the	0
NRE	1
gamma	2
site	2
.	0

The	0
ability	0
of	0
RFX1	9
to	0
transactivate	0
the	0
core	1
promoter	2
raises	0
the	0
possibility	0
that	0
RFX1	9
may	0
play	0
a	0
dual	0
role	0
in	0
regulating	0
HBV	0
gene	0
expression	0

Use	0
of	0
arsenic	0
trioxide	0
(	0
As2O3	0
)	0
in	0
the	0
treatment	0
of	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
:	0
II	0
.	0

Clinical	0
efficacy	0
and	0
pharmacokinetics	0
in	0
relapsed	0
patients	0
.	0

The	0
therapeutic	0
effect	0
of	0
arsenic	0
trioxide	0
(	0
As2O3	0
)	0
in	0
the	0
treatment	0
of	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
was	0
evaluated	0
among	0
15	0
APL	0
patients	0
at	0
relapse	0
after	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
induced	0
and	0
chemotherapy	0
maintained	0
complete	0
remission	0
(	0
CR	0
)	0
.	0

As2O3	0
was	0
administered	0
intravenously	0
at	0
the	0
dose	0
of	0
10	0
mg/d	0
.	0

Clinical	0
CR	0
was	0
achieved	0
in	0
nine	0
of	0
10	0
(	0
90	0
%	0
)	0
patients	0
treated	0
with	0
As2O3	0
alone	0
and	0
in	0
the	0
remaining	0
five	0
patients	0
treated	0
by	0
the	0
combination	0
of	0
As2O3	0
and	0
low-dose	0
chemotherapeutic	0
drugs	0
or	0
ATRA	0
.	0

During	0
the	0
treatment	0
with	0
As2O3	0
,	0
there	0
was	0
no	0
bone	0
marrow	0
depression	0
and	0
only	0
limited	0
side	0
effects	0
were	0
encountered	0
.	0

Pharmacokinetic	0
studies	0
,	0
which	0
were	0
performed	0
in	0
eight	0
patients	0
,	0
showed	0
that	0
after	0
a	0
peak	0
level	0
of	0
5.54	0
micromol/L	0
to	0
7.30	0
micromol/L	0
,	0
plasma	0
arsenic	0
was	0
rapidly	0
eliminated	0
,	0
and	0
the	0
continuous	0
administration	0
of	0
As2O3	0
did	0
not	0
alter	0
its	0
pharmacokinetic	0
behaviors	0
.	0

In	0
addition	0
,	0
increased	0
amounts	0
of	0
arsenic	0
appeared	0
in	0
the	0
urine	0
,	0
with	0
a	0
daily	0
excretion	0
accounting	0
for	0
approximately	0
1	0
%	0
to	0
8	0
%	0
of	0
the	0
total	0
daily	0
dose	0
administered	0
.	0

Arsenic	0
contents	0
in	0
hair	0
and	0
nail	0
were	0
increased	0
,	0
and	0
the	0
peak	0
content	0
of	0
arsenic	0
could	0
reach	0
2.5	0
to	0
2.7	0
microg/g	0
tissue	0
at	0
CR	0
.	0

On	0
the	0
other	0
hand	0
,	0
a	0
decline	0
of	0
the	0
arsenic	0
content	0
in	0
hair	0
and	0
nail	0
was	0
observed	0
after	0
withdrawal	0
of	0
the	0
drug	0
.	0

We	0
conclude	0
that	0
As2O3	0
treatment	0
is	0
an	0
effective	0
and	0
relatively	0
safe	0
drug	0
in	0
APL	0
patients	0
refractory	0
to	0
ATRA	0
and	0
conventional	0
chemotherapy	0
.	0

Nucleolin	9
is	0
one	0
component	0
of	0
the	0
B	9
cell-specific	10
transcription	10
factor	10
and	0
switch	9
region	10
binding	10
protein	10
,	0
LR1	9
.	0

LR1	9
is	0
a	0
B	0
cell-specific	0
,	0
sequence-specific	0
DNA	0
binding	0
activity	0
that	0
regulates	0
transcription	0
in	0
activated	7
B	8
cells	8
.	0

LR1	9
also	0
binds	0
Ig	9
heavy	10
chain	10
switch	0
region	0
sequences	0
and	0
may	0
function	0
in	0
class	0
switch	0
recombination	0
.	0

LR1	9
contains	0
two	0
polypeptides	0
,	0
of	0
106	0
kDa	0
and	0
45	0
kDa	0
,	0
and	0
here	0
we	0
report	0
that	0
the	0
106-kDa	9
component	10
of	0
LR1	9
is	0
nucleolin	9
.	0

This	0
identification	0
,	0
initially	0
made	0
by	0
microsequence	0
analysis	0
,	0
was	0
verified	0
by	0
showing	0
that	0
(	0
i	0
)	0
LR1	9
-DNA	0
binding	0
activity	0
increased	0
in	0
B	7
cells	8
transfected	0
with	0
a	0
nucleolin	1
cDNA	2
expression	2
construct	2
;	0
(	0
ii	0
)	0
LR1	9
-DNA	0
binding	0
activity	0
was	0
recognized	0
by	0
antibodies	0
raised	0
against	0
recombinant	9
human	10
nucleolin	10
;	0
and	0
(	0
iii	0
)	0
in	0
B	7
cells	8
transfected	0
with	0
epitope-tagged	1
nucleolin	2
expression	2
constructs	2
,	0
the	0
LR1-DNA	9
complex	10
was	0
recognized	0
by	0
the	0
anti-tag	9
antibody	10
.	0

Nucleolin	9
is	0
an	0
abundant	9
nucleolar	10
protein	10
which	0
is	0
believed	0
to	0
play	0
a	0
role	0
in	0
rDNA	1
transcription	0
or	0
organization	0
,	0
or	0
rRNA	3
processing	0
.	0

Homology	0
between	0
nucleolin	9
and	0
histone	9
H1	10
suggests	0
that	0
nucleolin	9
may	0
alter	0
DNA	0
organization	0
in	0
response	0
to	0
cell	0
cycle	0
controls	0
,	0
and	0
the	0
nucleolin	9
component	0
of	0
LR1	9
may	0
therefore	0
function	0
to	0
organize	0
switch	1
regions	2
before	0
,	0
during	0
,	0
or	0
after	0
switch	0
recombination	0
.	0

The	0
demonstration	0
that	0
nucleolin	9
is	0
a	0
component	0
of	0
a	0
B	9
cell-specific	10
complex	10
that	0
binds	0
switch	0
region	0
sequences	0
suggests	0
that	0
the	0
G-rich	1
switch	2
regions	2
may	0
have	0
evolved	0
from	0
rDNA	1
.	0

Glucocorticoid-resistance	0
in	0
peripheral-blood	7
lymphocytes	8
does	0
not	0
correlate	0
with	0
number	0
of	0
affinity	0
of	0
glucocorticoid-receptors	9
in	0
chronic	0
renal	0
failure	0
patients	0
.	0

Glucocorticoid	0
(	0
GC	0
)	0
resistance	0
in	0
patients	0
with	0
chronic	0
renal	0
failure	0
(	0
CRF	0
)	0
seriously	0
impairs	0
successive	0
GC	0
therapy	0
after	0
renal	0
transplantation	0
.	0

We	0
examined	0
the	0
relationship	0
between	0
GC-receptor	0
(	0
GC-R	0
)	0
parameters	0
in	0
peripheral-blood	7
mononuclear	8
cells	8
(	0
PBMC	7
)	0
and	0
PBMC	7
resistance	0
to	0
GC	0
in	0
21	0
CRF	0
patients	0
and	0
18	0
healthy	0
subjects	0
.	0

Each	0
subject	0
group	0
was	0
divided	0
into	0
two	0
subgroups	0
according	0
to	0
PBMC	7
sensitivity	0
to	0
prednisolone	0
in	0
a	0
mitogen	0
assay	0
procedure	0
;	0
i.e.	0
,	0
sensitive	0
(	0
IC50	0
<	0
381	0
ng/mL	0
)	0
and	0
resistant	0
(	0
IC50	0
>	0
381	0
ng/mL	0
)	0
groups	0
.	0

In	0
healthy	0
subjects	0
,	0
the	0
mean	0
GC-R	9
Bmax	0
and	0
Kd	0
in	0
quiescent	0
PBMC	7
of	0
the	0
GC-sensitive	0
group	0
were	0
2.89	0
+/-	0
1.23	0
fmol/10	0
(	0
6	0
)	0
cells	0
and	0
4.00	0
+/-	0
2.24	0
nM	0
,	0
respectively	0
.	0

The	0
Bmax	0
in	0
these	0
subjects	0
significantly	0
increased	0
to	0
6.61	0
+/-	0
2.02	0
(	0
257.7	0
+/-	0
107.8	0
%	0
)	0
after	0
24	0
h	0
stimulation	0
with	0
concanavalin	0
A	0
(	0
p	0
<	0
0.01	0
)	0
,	0
while	0
the	0
Kd	0
change	0
was	0
not	0
significant	0
.	0

The	0
GC-R	9
Bmax	0
and	0
Kd	0
in	0
quiescent	0
PBMC	7
of	0
the	0
GC-resistant	0
group	0
were	0
5.33	0
+/-	0
1.37	0
fmol/10	0
(	0
6	0
)	0
cells	0
and	0
3.20	0
+/-	0
1.39	0
nM	0
,	0
respectively	0
.	0

Both	0
of	0
these	0
parameters	0
,	0
however	0
,	0
did	0
not	0
change	0
significantly	0
after	0
mitogen	9
stimulation	0
.	0

There	0
was	0
a	0
significant	0
negative	0
correlation	0
between	0
IC50S	0
of	0
prednisolone	0
and	0
increase-ratios	0
(	0
post/pre	0
ratio	0
)	0
of	0
Bmax	0
after	0
mitogen	9
stimulation	0
(	0
p	0
<	0
0.05	0
)	0
.	0

In	0
CRF	0
patients	0
,	0
Bmax	0
and	0
Kd	0
in	0
quiescent	0
PBMC	7
of	0
the	0
GC-sensitive	0
group	0
were	0
6.04	0
+/-	0
2.35	0
fmol/10	0
(	0
6	0
)	0
cells	0
and	0
3.49	0
+/-	0
1.72	0
nM	0
,	0
respectively	0
,	0
while	0
those	0
in	0
PBMC	7
of	0
the	0
GC-resistant	0
group	0
were	0
5.13	0
+/-	0
2.31	0
fmol/10	0
(	0
6	0
)	0
cells	0
and	0
4.04	0
+/-	0
1.62	0
nM	0
,	0
respectively	0
.	0

The	0
Bmax	0
and	0
Kd	0
were	0
not	0
significantly	0
changed	0
after	0
mitogen	9
stimulation	0
in	0
both	0
subgroups	0
of	0
CRF	0
.	0

Moreover	0
,	0
in	0
contrast	0
to	0
healthy	0
subjects	0
,	0
there	0
was	0
no	0
correlation	0
between	0
IC50	0
and	0
GC-R	9
parameters	0
in	0
CRF	0
.	0

We	0
concluded	0
that	0
,	0
in	0
healthy	0
subjects	0
,	0
decreased	0
PBMC	7
capacity	0
to	0
amplify	0
GC-R	9
numbers	0
in	0
response	0
to	0
mitogen	9
is	0
correlated	0
with	0
GC	0
resistance	0
,	0
whereas	0
in	0
CRF	0
patients	0
the	0
resistant	0
mechanism	0
is	0
not	0
correlated	0
with	0
GC-R	9
parameters	0
.	0

An	0
unknown	0
event	0
might	0
be	0
involved	0
in	0
GC-resistance	0
of	0
CRF	0
.	0

Alteration	0
of	0
a	0
single	0
serine	0
in	0
the	0
basic	9
domain	10
of	0
the	0
Epstein-Barr	9
virus	10
ZEBRA	10
protein	10
separates	0
its	0
functions	0
of	0
transcriptional	0
activation	0
and	0
disruption	0
of	0
latency	0
.	0

The	0
ZEBRA	9
protein	10
from	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
activates	0
a	0
switch	0
from	0
the	0
latent	0
to	0
the	0
lytic	0
expression	0
program	0
of	0
the	0
virus	0
.	0

ZEBRA	9
,	0
a	0
member	0
of	0
the	0
bZIP	9
family	10
of	0
DNA-binding	9
proteins	10
,	0
is	0
a	0
transcriptional	0
activator	0
capable	0
of	0
inducing	0
expression	0
from	0
viral	1
lytic	2
cycle	2
promoters	2
.	0

It	0
had	0
previously	0
been	0
thought	0
that	0
ZEBRA	9
's	0
capacity	0
to	0
disrupt	0
EBV	0
latency	0
resided	0
primarily	0
in	0
its	0
ability	0
to	0
activate	0
transcription	0
of	0
genes	0
that	0
encode	0
products	0
required	0
for	0
lytic	0
replication	0
.	0

We	0
generated	0
a	0
point	0
mutant	0
of	0
ZEBRA	9
,	0
Z	9
(	10
S186A	10
)	10
,	0
that	0
was	0
not	0
impaired	0
in	0
its	0
ability	0
to	0
activate	0
transcription	0
;	0
however	0
,	0
this	0
mutation	0
abolished	0
its	0
ability	0
to	0
initiate	0
the	0
viral	0
lytic	0
cascade	0
.	0

The	0
mutant	0
,	0
containing	0
a	0
serine-to-alanine	0
substitution	0
in	0
the	0
DNA-binding	9
domain	10
of	0
the	0
protein	0
,	0
bound	0
to	0
several	0
known	0
ZEBRA-binding	1
sites	2
and	0
activated	0
transcription	0
from	0
reporters	0
bearing	0
known	0
ZEBRA-responsive	1
promoters	2
but	0
did	0
not	0
disrupt	0
latency	0
in	0
EBV-infected	5
cell	6
lines	6
.	0

Therefore	0
,	0
initiation	0
of	0
the	0
EBV	0
lytic	0
cycle	0
by	0
the	0
ZEBRA	9
protein	10
requires	0
a	0
function	0
in	0
addition	0
to	0
transcriptional	0
activation	0
;	0
a	0
change	0
of	0
serine	0
186	0
to	0
alanine	0
in	0
the	0
DNA-binding	9
domain	10
of	0
ZEBRA	9
abolished	0
this	0
additional	0
function	0
and	0
uncovered	0
a	0
new	0
role	0
for	0
the	0
ZEBRA	9
protein	10
in	0
disruption	0
of	0
EBV	0
latency	0
.	0

The	0
additional	0
function	0
that	0
is	0
required	0
for	0
initiation	0
of	0
the	0
lytic	0
viral	0
life	0
cycle	0
is	0
likely	0
to	0
require	0
phosphorylation	0
of	0
serine	0
186	0
of	0
the	0
ZEBRA	9
protein	10
,	0
which	0
may	0
influence	0
either	0
DNA	0
recognition	0
or	0
transcriptional	0
activation	0
of	0
lytic	1
viral	2
promoters	2
in	0
a	0
chromatinized	1
viral	2
episome	2
.	0

Immune	0
hyperactivation	0
of	0
HIV-1-infected	7
T	8
cells	8
mediated	0
by	0
Tat	9
and	0
the	0
CD28	9
pathway	0
.	0

Human	0
immunodeficiency	0
virus-type	0
1	0
(	0
HIV-1	0
)	0
infection	0
is	0
characterized	0
by	0
a	0
chronic	0
state	0
of	0
immune	0
hyperactivation	0
in	0
patients	0
.	0

Infection	0
of	0
human	7
peripheral	8
blood	8
lymphocytes	8
with	0
HIV-1	0
in	0
vitro	0
resulted	0
in	0
increased	0
interleukin-2	0
(	0
IL-2	0
)	0
secretion	0
in	0
response	0
to	0
T	0
cell	0
activation	0
via	0
the	0
CD3	9
and	10
CD28	10
receptors	10
.	0

Expression	0
of	0
the	0
HIV-1	9
transactivator	10
Tat	9
recapitulated	0
this	0
phenotype	0
and	0
was	0
associated	0
with	0
increased	0
IL-2	9
secretion	0
in	0
response	0
to	0
costimulation	0
with	0
CD3	9
plus	0
CD28	9
.	0

IL-2	9
superinduction	0
by	0
Tat	9
occurred	0
at	0
the	0
transcriptional	0
level	0
,	0
was	0
mediated	0
by	0
the	0
CD28-responsive	1
element	2
in	0
the	0
IL-2	1
promoter	2
,	0
and	0
was	0
exclusively	0
dependent	0
on	0
the	0
29	9
amino	10
acids	10
encoded	0
by	0
the	0
second	1
exon	2
of	2
Tat	2
.	0

Response	0
to	0
intranasal	0
fluticasone	0
propionate	0
in	0
perennial	0
allergic	0
rhinitis	0
not	0
associated	0
with	0
glucocorticoid	9
receptor	10
characteristics	0
.	0

BACKGROUND	0
:	0
The	0
reduction	0
of	0
symptoms	0
due	0
to	0
treatment	0
with	0
corticosteroids	0
varies	0
among	0
patients	0
with	0
perennial	0
rhinitis	0
.	0

Most	0
patients	0
will	0
respond	0
but	0
a	0
few	0
patients	0
respond	0
less	0
to	0
these	0
drugs	0
.	0

OBJECTIVE	0
:	0
To	0
investigate	0
the	0
association	0
in	0
reduction	0
of	0
symptoms	0
due	0
to	0
glucocorticoids	0
and	0
glucocorticoid	9
receptor	10
characteristics	0
in	0
patients	0
with	0
perennial	0
allergic	0
rhinitis	0
,	0
in	0
vitro	0
glucocorticoid	9
receptor	10
binding	0
studies	0
were	0
performed	0
with	0
peripheral	7
blood	8
mononuclear	8
cells	8
using	0
dexamethasone	0
and	0
in	0
vitro	0
production	0
of	0
mediators	9
were	0
measured	0
.	0

METHODS	0
:	0
During	0
a	0
double-blind	0
placebo-controlled	0
crossover	0
study	0
,	0
200	0
micrograms	0
fluticasone	0
propionate	0
aqueous	0
nasal	0
spray	0
(	0
in	0
the	0
active	0
treatment	0
period	0
)	0
and	0
placebo	0
(	0
in	0
the	0
placebo	0
treatment	0
period	0
)	0
were	0
administered	0
twice	0
daily	0
for	0
2	0
weeks	0
to	0
22	0
patients	0
allergic	0
to	0
house	0
dust	0
mite	0
.	0

At	0
the	0
end	0
of	0
both	0
treatment	0
periods	0
symptoms	0
were	0
scored	0
after	0
allergen	0
provocation	0
(	0
100	0
,	0
1000	0
,	0
10000	0
BU/mL	0
)	0
and	0
during	0
the	0
9.5	0
hours	0
after	0
this	0
challenge	0
.	0

Receptor	0
binding	0
studies	0
with	0
dexamethasone	0
were	0
performed	0
with	0
peripheral	7
blood	8
mononuclear	8
cells	8
.	0

Leukotriene	0
B4	0
produced	0
by	0
monocytes	7
in	0
vitro	0
and	0
soluble	0
interleukin-2	9
receptor	10
released	0
by	0
lymphocytes	7
in	0
vitro	0
and	0
cortisol	0
levels	0
in	0
plasma	0
were	0
determined	0
.	0

RESULTS	0
:	0
No	0
significant	0
partial	0
correlations	0
of	0
the	0
number	0
of	0
the	0
peripheral	9
blood	10
mononuclear	10
cell	10
glucocorticoid	10
receptors	10
(	0
6821	0
+/-	0
5669	0
binding	0
sites	0
per	0
cell	0
)	0
and	0
the	0
affinity	0
(	0
Kd	0
:	0
16.5	0
+/-	0
13.51	0
nmol/L	0
)	0
for	0
the	0
glucocorticoid	9
receptors	10
with	0
the	0
symptom	0
score	0
(	0
placebo	0
:	0
4.3	0
+/-	0
2.45	0
pts	0
;	0
fluticasone	0
:	0
2.4	0
+/-	0
1.55	0
pts	0
)	0
after	0
active	0
treatment	0
were	0
found	0
.	0

Also	0
no	0
significant	0
partial	0
correlations	0
of	0
the	0
levels	0
of	0
leukotriene	0
B4	0
(	0
45.6	0
+/-	0
105.3	0
ng/10	0
(	0
6	0
)	0
cells	0
)	0
produced	0
by	0
monocytes	7
in	0
vitro	0
,	0
soluble	0
interleukin-2	9
receptor	10
(	0
734	0
+/-	0
237	0
ng/10	0
(	0
6	0
)	0
cells	0
)	0
released	0
by	0
lymphocytes	7
in	0
vitro	0
and	0
cortisol	0
levels	0
(	0
571	0
+/-	0
236	0
ng/mL	0
)	0
in	0
plasma	0
with	0
the	0
symptom	0
score	0
after	0
active	0
treatment	0
were	0
found	0
.	0

CONCLUSIONS	0
:	0
The	0
reduction	0
of	0
symptoms	0
due	0
to	0
topical	0
fluticasone	0
propionate	0
in	0
patients	0
with	0
rhinitis	0
and	0
allergy	0
to	0
house	0
dust	0
mite	0
is	0
not	0
correlated	0
with	0
the	0
characteristics	0
of	0
the	0
glucocorticoid	9
receptor	10
.	0

Constitutive	0
expression	0
of	0
p50	9
homodimer	10
in	0
freshly	7
isolated	8
human	8
monocytes	8
decreases	0
with	0
in	0
vitro	0
and	0
in	0
vivo	0
differentiation	0
:	0
a	0
possible	0
mechanism	0
influencing	0
human	0
immunodeficiency	0
virus	0
replication	0
in	0
monocytes	7
and	0
mature	0
macrophages	0
.	0

Human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replicates	0
more	0
efficiently	0
in	0
vitro	0
in	0
differentiated	7
macrophages	8
than	0
in	0
freshly	7
isolated	8
monocytes	8
.	0

We	0
investigated	0
whether	0
this	0
may	0
be	0
partly	0
explained	0
by	0
changes	0
in	0
expression	0
of	0
NF-kappaB	9
with	0
monocyte	0
differentiation	0
.	0

We	0
demonstrated	0
that	0
constitutive	0
expression	0
of	0
NF-kappaB	9
in	0
primary	7
human	8
monocytes	8
changed	0
significantly	0
with	0
differentiation	0
in	0
vitro	0
to	0
monocyte-derived	7
macrophages	8
(	0
MDMs	7
)	0
and	0
differentiation	0
in	0
vivo	0
to	0
alveolar	7
macrophages	8
(	0
AMs	7
)	0
.	0

Freshly	0
isolated	0
monocytes	0
constitutively	0
expressed	0
high	0
levels	0
of	0
transcriptionally	9
inactive	10
p50	10
homodimer	10
which	0
decreased	0
with	0
time	0
in	0
culture	0
in	0
favor	0
of	0
the	0
transcriptionally	0
active	0
p50/p65	9
and	10
p50/RelB	10
heterodimers	10
.	0

As	0
in	0
MDMs	7
,	0
AMs	7
constitutively	0
expressed	0
p50/p65	9
and	0
p50/RelB	9
although	0
at	0
lower	0
levels	0
.	0

HIV	0
infection	0
of	0
fresh	0
monocytes	7
failed	0
to	0
induce	0
p50/p65	9
as	0
seen	0
in	0
MDMs	7
.	0

The	0
replacement	0
of	0
p50	9
homodimers	10
with	0
transcriptionally	0
active	0
heterodimers	0
following	0
time	0
in	0
culture	0
may	0
partially	0
explain	0
the	0
progressive	0
increase	0
in	0
susceptibility	0
of	0
monocytes	7
to	0
HIV	0
infection	0
during	0
in	0
vitro	0
culture	0
.	0

The	0
change	0
in	0
NF-kappaB	9
components	10
with	0
monocyte	0
differentiation	0
in	0
vivo	0
may	0
also	0
explain	0
the	0
different	0
transcriptional	0
activities	0
of	0
these	0
cell	0
populations	0
in	0
HIV-infected	0
individuals	0
.	0

NF-kappa	9
B	10
-independent	0
suppression	0
of	0
HIV	0
expression	0
by	0
ascorbic	0
acid	0
.	0

Ascorbic	0
acid	0
(	0
ascorbate	0
or	0
vitamin	0
C	0
)	0
has	0
been	0
shown	0
to	0
suppress	0
the	0
induction	0
of	0
HIV	0
in	0
latently	7
infected	8
T	8
lymphocytic	8
cells	8
following	0
stimulation	0
with	0
a	0
tumor	0
promoter	0
(	0
PMA	0
)	0
and	0
inflammatory	9
cytokine	10
(	0
TNF-alpha	9
)	0
.	0

To	0
assess	0
whether	0
this	0
inhibition	0
was	0
mediated	0
via	0
modulation	0
of	0
the	0
cellular	9
transcription	10
factor	10
,	0
NF-kappa	9
B	10
,	0
we	0
carried	0
out	0
gel	0
shift	0
analysis	0
on	0
nuclear	0
extracts	0
prepared	0
under	0
different	0
conditions	0
of	0
cell	0
stimulation	0
in	0
the	0
presence	0
or	0
absence	0
of	0
ascorbate	0
,	0
N-acetylcysteine	0
(	0
NAC	0
)	0
,	0
or	0
zidovudine	0
(	0
AZT	0
)	0
.	0

Pretreatment	0
of	0
ACH-2	5
T	6
cells	6
by	0
NAC	0
followed	0
by	0
stimulation	0
with	0
PMA	0
,	0
TNF-alpha	9
,	0
or	0
hydrogen	0
peroxide	0
(	0
H2O2	0
)	0
resulted	0
in	0
strong	0
suppression	0
of	0
NF-kappa	9
B	10
activation	0
.	0

In	0
contrast	0
,	0
neither	0
ascorbate	0
nor	0
AZT	0
affected	0
NF-kappa	9
B	10
activity	0
under	0
all	0
three	0
induction	0
conditions	0
in	0
the	0
ACH-2	5
cell	6
line	6
.	0

Ascorbate	0
and	0
AZT	0
also	0
had	0
no	0
effect	0
on	0
NF-kappa	9
B	10
activation	0
following	0
TNF-alpha-	0
or	0
PMA-induced	0
stimulation	0
of	0
U1	0
promonocytic	0
cells	0
.	0

These	0
results	0
suggest	0
that	0
the	0
molecular	0
mechanism	0
of	0
HIV	0
inhibition	0
by	0
ascorbate	0
is	0
not	0
mediated	0
via	0
NF-kappa	9
B	10
inhibition	0
,	0
unlike	0
that	0
seen	0
with	0
other	0
antioxidants	0
.	0

A	0
T	1
cell-specific	2
enhancer	2
in	0
the	0
interleukin-3	1
locus	2
is	0
activated	0
cooperatively	0
by	0
Oct	1
and	2
NFAT	2
elements	2
within	0
a	0
DNase	1
I-hypersensitive	2
site	2
.	0

Interleukin-3	9
(	0
IL-3	9
)	0
is	0
a	0
cytokine	9
that	0
is	0
expressed	0
primarily	0
in	0
activated	7
T	8
cells	8
.	0

Here	0
we	0
identified	0
an	0
inducible	0
T	1
cell-specific	2
enhancer	2
14	0
kb	0
upstream	0
of	0
the	0
IL-3	1
gene	2
that	0
responded	0
to	0
activation	0
of	0
T	9
cell	10
receptor	10
signaling	0
pathways	0
.	0

The	0
IL-3	9
enhancer	0
spanned	0
an	0
inducible	0
cyclosporin	1
A-sensitive	2
DNase	2
I-hypersensitive	2
site	2
found	0
only	0
in	0
T	7
cells	8
.	0

Four	0
NFAT-like	1
elements	2
exist	0
within	0
the	0
enhancer	0
.	0

The	0
two	0
most	0
active	0
NFAT-like	1
elements	2
were	0
located	0
at	0
the	0
center	0
of	0
the	0
DNase	1
I-hypersensitive	2
site	2
.	0

One	0
of	0
these	0
NFAT-like	1
elements	2
encompassed	0
overlapping	0
Oct-	1
and	2
NFATp/c-binding	2
sites	2
,	0
which	0
functioned	0
in	0
a	0
highly	0
synergistic	0
manner	0
.	0

We	0
suggest	0
that	0
the	0
T	0
cell-specific	0
expression	0
of	0
the	0
IL-3	1
gene	2
is	0
partly	0
controlled	0
through	0
the	0
enhancer	0
by	0
cooperation	0
between	0
Oct	9
and	10
NFAT	10
family	10
proteins	10
.	0

Adenovirus	9
E1B	10
19K	10
protein	10
is	0
required	0
for	0
efficient	0
DNA	0
replication	0
in	0
U937	5
cells	6
.	0

The	0
adenovirus	1
E1B	2
19K	2
gene	2
plays	0
an	0
essential	0
role	0
in	0
transformation	0
of	0
primary	7
rodent	8
cells	8
in	0
cooperation	0
with	0
E1A	9
and	0
in	0
the	0
inhibition	0
of	0
apoptosis	0
during	0
lytic	0
infection	0
.	0

It	0
has	0
been	0
shown	0
that	0
this	0
E1B	9
19K	10
protein	10
is	0
not	0
necessary	0
for	0
viral	0
DNA	0
replication	0
in	0
human	5
cell	6
lines	6
,	0
such	0
as	0
HeLa	5
and	0
KB	5
.	0

We	0
reported	0
here	0
that	0
the	0
E1B	9
19K	10
mutant	0
viruses	0
were	0
unable	0
to	0
replicate	0
efficiently	0
in	0
a	0
monocyte	5
cell	6
line	6
,	0
U937	5
.	0

Viral	0
DNA	0
synthesis	0
and	0
late	0
gene	0
expression	0
were	0
found	0
to	0
be	0
defective	0
in	0
U937	5
cells	6
infected	0
with	0
E1B	9
19K	10
mutants	0
compared	0
with	0
wild-type	0
virus	0
.	0

Early	0
viral	0
RNA	0
splicing	0
patterns	0
also	0
differ	0
between	0
wild-type	5
and	6
dl337-infected	6
cells	6
.	0

Furthermore	0
,	0
the	0
defect	0
in	0
viral	0
replication	0
could	0
be	0
complemented	0
by	0
dl312	0
virus	0
defective	0
in	0
E1A	9
expression	0
4	0
days	0
after	0
infection	0
with	0
E1B	0
mutants	0
,	0
suggesting	0
persistence	0
of	0
the	0
E1B	1
mutant	2
genome	2
in	0
the	0
infected	0
cells	0
despite	0
defective	0
onset	0
of	0
the	0
late	0
phase	0
of	0
replication	0
.	0

These	0
results	0
imply	0
that	0
E1B	9
19K	10
is	0
required	0
for	0
efficient	0
viral	0
DNA	0
replication	0
in	0
U937	5
cells	6
.	0

Inefficient	0
DNA	0
replication	0
is	0
also	0
found	0
in	0
another	0
monocyte	5
cell	6
line	6
,	0
THP-1	5

Activation	0
of	0
Ras	0
and	0
mitogen-activated	9
protein	10
kinase	10
pathway	0
by	0
terminal	9
complement	10
complexes	10
is	0
G	9
protein	10
dependent	0
.	0

Assembly	0
of	0
terminal	9
complement	10
complexes	10
(	0
TCC	9
)	0
C5b-7	9
,	0
C5b-8	9
,	0
and	0
C5b-9	9
on	0
target	0
cells	0
during	0
acute	0
and	0
chronic	0
inflammation	0
induces	0
hydrolysis	0
of	0
plasma	0
membrane	0
phospholipids	0
and	0
heterotrimeric	0
G	9
protein	10
activation	0
.	0

TCC	9
also	0
stimulate	0
a	0
variety	0
of	0
cellular	0
activities	0
,	0
which	0
include	0
cytokine	9
synthesis	0
,	0
proto-oncogene	1
activation	0
,	0
and	0
mitotic	0
signaling	0
.	0

Now	0
we	0
report	0
that	0
sublytic	0
TCC	9
induced	0
Ras	9
,	0
Raf-1	9
,	0
and	0
extracellular	9
signal-regulated	10
kinase	10
(	10
ERK	10
)	10
1	10
activation	0
in	0
JY25	0
B	0
cell	0
line	0
.	0

When	0
cells	0
were	0
exposed	0
to	0
C5b-9	9
,	0
GTP-bound	9
Ras	10
in	0
anti-C5b-9	9
immunoprecipitates	10
was	0
increased	0
3.2-fold	0
at	0
2	0
min	0
,	0
while	0
GTP-bound	9
Ras	10
in	0
anti-Ras	9
immunoprecipitates	10
was	0
increased	0
2-fold	0
at	0
10	0
min	0
.	0

Both	0
C5b-9	9
and	0
C5b-7	9
,	0
but	0
not	0
C5b6	9
,	0
increased	0
Raf-1	9
kinase	0
activity	0
maximum	0
3.3-fold	0
at	0
2	0
min	0
and	0
2.8-fold	0
at	0
5	0
min	0
,	0
respectively	0
.	0

ERK1	9
activity	0
was	0
2-fold	0
increased	0
by	0
C5b-9	9
at	0
2	0
min	0
and	0
by	0
C5b-7	9
at	0
10	0
min	0
,	0
over	0
the	0
C5b6	9
level	0
.	0

The	0
role	0
of	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
pathway	0
on	0
TCC	9
-inducible	0
mitotic	0
signaling	0
was	0
evaluated	0
by	0
assessing	0
DNA	0
synthesis	0
and	0
activator	9
protein	10
1	10
(	0
AP-1	9
)	0
DNA-binding	0
activity	0
.	0

The	0
MAPK/ERK-specific	0
inhibitor	0
PD	0
098	0
,	0
059	0
abolished	0
the	0
C5b-9	9
-induced	0
DNA	0
synthesis	0
.	0

Involvement	0
of	0
G	9
protein	10
in	0
the	0
activation	0
of	0
MAPK	9
pathway	0
by	0
TCC	9
was	0
indicated	0
by	0
inhibition	0
of	0
Raf-1	9
and	0
ERK1	9
kinase	0
activity	0
,	0
as	0
well	0
as	0
the	0
DNA	0
synthesis	0
by	0
pretreatment	0
of	0
cells	0
with	0
pertussis	9
toxin	10
.	0

Overexpression	0
of	0
beta-adrenergic	0
receptor	0
kinase	0
1	0
carboxyl-terminal	0
peptide	0
in	0
JY25	5
cells	6
also	0
inhibited	0
Raf-1	9
and	0
ERK1	9
activity	0
,	0
indicating	0
a	0
direct	0
involvement	0
of	0
G	0
betagamma	0
subunits	0
in	0
the	0
signal	0
transduction	0
generated	0
through	0
activation	0
of	0
MAPK	9
pathway	0
by	0
TCC	9
assembly	0
in	0
the	0
plasma	0
membrane	0
.	0

Spontaneous	0
occurrence	0
of	0
early	0
region	0
1A	0
reiteration	0
mutants	0
of	0
type	0
5	0
adenovirus	0
in	0
persistently	7
infected	8
human	8
T-lymphocytes	8
.	0

Mutants	0
of	0
type	0
5	0
adenovirus	0
(	0
Ad5	0
)	0
with	0
reiterated	1
DNA	2
sequences	2
in	0
the	0
E1a	1
region	2
appeared	0
in	0
a	0
human	5
T-lymphocyte	6
cell	6
line	6
,	0
Molt-4	5
,	0
persistently	0
infected	0
with	0
H5sub304	0
,	0
a	0
deletion/substitution	0
mutant	0
that	0
has	0
a	0
wild-type	0
phenotype	0
in	0
viral	0
replication	0
.	0

Endonuclease	9
analyses	0
and	0
DNA	0
sequencing	0
revealed	0
DNA	0
reiteration	0
in	0
each	0
mutant	0
.	0

In	0
the	0
four	0
representative	0
mutants	0
investigated	0
,	0
the	0
DNA	1
reiterations	2
all	0
started	0
within	0
a	0
six-base-pair	1
consensus	2
sequence	2
,	0
G	0
(	0
or	0
C	0
)	0
CTGTG	0
,	0
located	0
in	0
the	0
second	0
exon	1
of	0
the	0
E1a	1
region	2
(	0
at	0
nt	0
1333	0
,	0
1367	0
,	0
or	0
1419	0
)	0
.	0

There	0
was	0
not	0
any	0
DNA	0
homology	0
between	0
the	0
breakpoints	0
in	0
the	0
second	0
exon	1
and	0
the	0
inserting	1
sequences	2
(	0
starting	0
at	0
nt	0
532	0
,	0
710	0
,	0
or	0
792	0
)	0
.	0

Northern	0
analyses	0
suggested	0
that	0
the	0
reiterated	1
splicing	2
sites	2
of	0
the	0
representative	0
mutants	0
were	0
all	0
used	0
in	0
RNA	0
splicing	0
,	0
and	0
the	0
closest	0
donor	0
and	0
recipient	0
joints	0
were	0
used	0
most	0
frequently	0
.	0

These	0
observations	0
imply	0
that	0
during	0
persistent	0
infection	0
Ad5	0
underwent	0
spontaneous	0
mutations	0
by	0
sequence-specific	0
breakage	0
and	0
nonhomologous	0
end-end	0
joining	0
recombination	0
events	0
.	0

These	0
E1a	0
reiteration	0
mutants	0
could	0
be	0
propagated	0
in	0
HeLa	5
,	0
A549	5
,	0
and	0
KB	5
cells	6
;	0
they	0
were	0
genetically	0
stable	0
;	0
and	0
they	0
killed	0
CREF	5
cells	6
at	0
a	0
strikingly	0
high	0
frequency	0
.	0

Preliminary	0
observations	0
tend	0
to	0
correlate	0
this	0
CREF	0
cell	0
killing	0
with	0
the	0
accumulation	0
of	0
the	0
early	9
viral	10
proteins	10
and/or	0
viral	1
DNA	2
in	0
the	0
infected	7
cells	8
.	0

This	0
degree	0
of	0
cell	0
damage	0
was	0
not	0
observed	0
in	0
Ad5wt	0
or	0
H5sub304	0
infection	0
of	0
CREF	5
cells	6
.	0

The	0
observed	0
E1a	1
reiterations	2
provide	0
a	0
model	0
to	0
gain	0
insight	0
into	0
understanding	0
the	0
evolutionary	0
events	0
of	0
some	0
,	0
if	0
not	0
all	0
,	0
adenovirus	0
types	0
during	0
many	0
years	0
of	0
symbiotic	0
,	0
persistent	0
relationship	0
in	0
human	0
tonsils	0
and	0
adenoids	0
and	0
possibly	0
other	0
lymphoid	0
organs	0
.	0

Preferential	0
presentation	0
of	0
herpes	9
simplex	10
virus	10
T-cell	10
antigen	10
by	0
HLA	9
DQA1*0501/DQB1*0201	10
in	0
comparison	0
to	0
HLA	9
DQA1*0201/DQB1*0201	10
.	0

The	0
HLA	1
DQA1	2
locus	2
is	0
polymorphic	0
.	0

Haplotypes	0
containing	0
HLA	1
DQA1*0501	2
,	0
but	0
not	0
HLA	1
DQA1*0201	2
,	0
together	0
with	0
HLA	1
DQB1*0201	2
are	0
associated	0
with	0
Grave	0
's	0
disease	0
and	0
celiac	0
sprue	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
a	0
functional	0
correlate	0
of	0
DQA1	0
polymorphism	0
.	0

T	7
cells	8
infiltrating	0
a	0
herpes	0
simplex	0
virus	0
(	0
HSV	0
)	0
lesion	0
from	0
a	0
HLA	0
DQ	0
2	0
,	0
7	0
individual	0
yielded	0
a	0
virus-specific	5
CD4+	6
clone	6
restricted	0
by	0
DQ2	9
.	0

Presentation	0
of	0
viral	0
peptide	0
and	0
protein	0
segregated	0
with	0
DQA1	1
allele	2
,	0
because	0
cell	0
lines	0
bearing	0
DQA1*0501/DQB1*0201	9
heterodimers	10
presented	0
antigen	0
in	0
proliferation	0
and	0
cytotoxicity	0
assays	0
much	0
more	0
efficiently	0
than	0
cell	5
lines	6
bearing	0
DQA1*0201/DQB1*0201	9
.	0

Binding	0
of	0
viral	0
peptide	0
to	0
cell	0
lines	0
bearing	0
DQA1*0201	9
,	0
in	0
comparison	0
to	0
DQA1*0501	9
,	0
was	0
only	0
moderately	0
reduced	0
and	0
may	0
not	0
explain	0
this	0
effect	0
.	0

Truncation	0
and	0
substitution	0
analyses	0
of	0
peptide	0
binding	0
and	0
T-cell	0
activation	0
were	0
performed	0
to	0
determine	0
which	0
viral	0
peptide	0
residues	0
contacting	0
TCR	9
might	0
therefore	0
be	0
presented	0
in	0
an	0
altered	0
conformation	0
by	0
DQA1*0201/DQB1*0201	9
.	0

Residues	0
432	0
,	0
435	0
,	0
437	0
,	0
438	0
,	0
and	0
440	0
(	0
position	1
P1	2
,	2
P4	2
,	2
P6	2
,	2
P7	2
,	2
and	2
P9	2
)	0
contributed	0
to	0
DQ2	9
binding	0
,	0
whereas	0
residues	0
431	0
,	0
433	0
,	0
434	0
,	0
and	0
436	0
(	0
positions	1
P	2
1	2
,	2
P2	2
,	2
P3	2
,	2
and	2
P5	2
)	0
contributed	0
to	0
TCR	9
contact	0
.	0

Differential	0
presentation	0
of	0
peptide	0
by	0
HLA	9
DQ2	10
heterodimers	10
varying	0
at	0
the	0
DQA1	1
locus	2
may	0
have	0
relevance	0
to	0
host	0
defense	0
and	0
the	0
pathogenesis	0
of	0
HLA	0
DQ2	9
-associated	0
autoimmune	0
diseases	0
.	0

Inhibitor	0
(	0
IK	0
)	0
of	0
IFN-gamma	9
induced	0
HLA	9
class	10
II	10
antigens	10
expression	0
also	0
inhibits	0
HLA	9
class	10
II	10
constitutive	0
expression	0
in	0
the	0
human	5
Raji	6
B	6
cell	6
line	6
.	0

The	0
expression	0
of	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
II	10
antigens	10
is	0
constitutive	0
in	0
professional	7
antigen	8
presenting	8
cells	8
(	0
APCs	7
)	0
but	0
can	0
also	0
be	0
induced	0
by	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
on	0
the	0
majority	0
of	0
the	0
non	0
professional	7
APCs	8
(	0
e.g	0
.	0
fibroblasts	7
)	0
.	0

We	0
have	0
recently	0
characterised	0
a	0
new	0
factor	0
called	0
IK	9
which	0
is	0
an	0
efficient	0
inhibitor	0
of	0
IFN-gamma	9
induction	0
of	0
MHC	9
class	10
II	10
antigens	10
expression	0
.	0

Here	0
,	0
we	0
demonstrate	0
a	0
novel	0
role	0
for	0
IK	9
in	0
MHC	9
class	10
II	10
expression	0
since	0
over-expression	0
of	0
this	0
protein	0
by	0
stable	0
transfection	0
into	0
human	0
B	0
cells	0
led	0
to	0
a	0
total	0
disappearance	0
of	0
constitutive	0
MHC	3
class	4
II	4
mRNA	4
expression	0
.	0

The	0
class	1
II	2
transactivator	2
(	0
CIITA	1
)	0
is	0
necessary	0
for	0
both	0
constitutive	0
and	0
IFN-gamma	9
induced	0
MHC	9
class	10
II	10
expressions	0
.	0

Examination	0
of	0
CIITA	3
mRNA	4
in	0
IK	9
stably	0
transfected	0
clones	0
revealed	0
a	0
marked	0
reduction	0
of	0
CIITA	3
mRNA	4
transcription	0
.	0

Taken	0
together	0
these	0
results	0
demonstrate	0
that	0
the	0
IK	9
protein	10
plays	0
a	0
key	0
role	0
in	0
the	0
constitutive	0
expression	0
of	0
MHC	9
class	10
II	10
antigens	10
and	0
that	0
inhibition	0
induced	0
by	0
IK	9
is	0
upstream	0
of	0
CIITA	1
in	0
this	0
regulatory	0
pathway	0
.	0

Selective	0
expression	0
of	0
an	0
interleukin-12	9
receptor	10
component	10
by	0
human	7
T	8
helper	8
1	8
cells	8
.	0

Interleukin-12	9
(	0
IL-12	9
)	0
,	0
a	0
heterodimeric	9
cytokine	10
produced	0
by	0
activated	0
monocytes	0
and	0
dendritic	0
cells	0
,	0
plays	0
a	0
crucial	0
role	0
in	0
regulating	0
interferon	9
(	10
IFN	10
)	10
-gamma	10
production	0
and	0
in	0
the	0
generation	0
of	0
IFN-gamma-producing	7
T	8
helper	8
1	8
(	8
Th1	8
)	8
cells	8
.	0

Here	0
we	0
show	0
that	0
the	0
IL-12	9
receptor	10
(	10
IL-12R	10
)	10
beta	10
2	10
subunit	10
,	0
a	0
recently	0
cloned	0
binding	9
and	10
signal	10
transducing	10
component	10
of	0
the	0
IL-12R	9
,	0
is	0
expressed	0
on	0
human	5
Th1	6
but	6
not	6
Th2	6
clones	6
and	0
is	0
induced	0
during	0
differentiation	0
of	0
human	7
naive	8
cells	8
along	0
the	0
Th1	0
but	0
not	0
the	0
Th2	0
pathway	0
.	0

IL-12	9
and	0
type	9
I	10
but	10
not	10
type	10
II	10
interferons	10
induce	0
expression	0
of	0
the	0
IL-12R	9
beta	10
2	10
chain	10
during	0
in	0
vitro	0
T	0
cell	0
differentiation	0
after	0
antigen	0
receptor	0
triggering	0
.	0

The	0
selective	0
expression	0
and	0
regulation	0
of	0
the	0
IL-12R	9
beta	10
2	10
subunit	10
may	0
help	0
to	0
understand	0
the	0
basis	0
of	0
Th1/Th2	0
differentiation	0
and	0
may	0
provide	0
therapeutic	0
options	0
for	0
altering	0
the	0
Th1/Th2	0
balance	0
in	0
several	0
immuno-pathological	0
conditions	0
such	0
as	0
autoimmune	0
diseases	0
and	0
allergies	0
.	0

The	0
T	9
cell	10
activation	10
factor	10
NF-ATc	9
positively	0
regulates	0
HIV-1	0
replication	0
and	0
gene	0
expression	0
in	0
T	7
cells	8
.	0

Clinical	0
deterioration	0
in	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
is	0
associated	0
with	0
increased	0
levels	0
of	0
viral	0
replication	0
and	0
burden	0
in	0
the	0
peripheral	0
blood	0
and	0
lymphoid	0
organs	0
.	0

T	0
cell	0
activation	0
and	0
ensuing	0
cellular	0
gene	0
activation	0
can	0
be	0
critical	0
for	0
HIV-1	0
replication	0
.	0

The	0
hypothesis	0
that	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
may	0
influence	0
HIV-1	0
replication	0
is	0
therefore	0
compelling	0
given	0
the	0
tight	0
correlation	0
of	0
HIV-1	0
transcriptional	0
induction	0
to	0
T	0
cell	0
activation	0
.	0

We	0
report	0
that	0
certain	0
NF-AT	9
(	10
Rel	10
)	10
family	10
members	10
productively	0
bind	0
the	0
kappaB	1
regulatory	2
elements	2
,	0
synergize	0
with	0
NF-kappaB	9
and	0
Tat	9
in	0
transcriptional	0
activation	0
of	0
HIV-1	0
,	0
and	0
enhance	0
HIV-1	0
replication	0
in	0
T	7
cells	8
.	0

These	0
results	0
link	0
regulatory	9
factors	10
critical	0
to	0
T	0
cell	0
commitment	0
directly	0
to	0
HIV-1	0
replication	0
.	0

Transcription	0
mediated	0
by	0
NFAT	9
is	0
highly	0
inducible	0
in	0
effector	0
CD4+	7
T	8
helper	8
2	8
(	8
Th2	8
)	8
cells	8
but	0
not	0
in	0
Th1	7
cells	8
.	0

Transcriptional	9
factors	10
of	0
the	0
NFAT	9
family	10
play	0
an	0
important	0
role	0
in	0
regulating	0
the	0
expression	0
of	0
several	0
cytokine	1
genes	2
during	0
the	0
immune	0
response	0
,	0
such	0
as	0
the	0
genes	0
for	0
interleukin	9
2	10
(	0
IL-2	9
)	0
and	0
IL-4	9
,	0
among	0
others	0
.	0

Upon	0
antigen	0
stimulation	0
,	0
precursor	0
CD4+	7
T	8
helper	8
(	8
pTh	8
)	8
cells	8
proliferate	0
and	0
differentiate	0
into	0
two	0
populations	0
of	0
effector	7
cells	8
(	0
eTh1	7
and	0
eTh2	7
)	0
,	0
each	0
one	0
expressing	0
a	0
specific	0
pattern	0
of	0
cytokines	9
that	0
distinguishes	0
them	0
from	0
their	0
precursors	0
.	0

eTh2	7
cells	8
are	0
the	0
major	0
source	0
of	0
IL-4	9
,	0
while	0
gamma	9
interferon	10
is	0
produced	0
by	0
eTh1	7
cells	8
.	0

Here	0
we	0
have	0
used	0
reporter	0
transgenic	0
mice	0
to	0
show	0
that	0
DNA	0
binding	0
and	0
transcriptional	0
activities	0
of	0
NFAT	9
are	0
transiently	0
induced	0
during	0
the	0
differentiation	0
of	0
pTh	7
cells	8
into	0
either	0
eTh1	7
or	0
eTh2	7
cells	8
to	0
mediate	0
the	0
expression	0
of	0
IL-2	9
as	0
a	0
common	0
growth	0
factor	0
in	0
both	0
pathways	0
.	0

However	0
,	0
although	0
NFAT	9
DNA	0
binding	0
is	0
similarly	0
induced	0
in	0
both	0
eTh1	7
and	0
eTh2	7
cells	8
upon	0
antigen	0
stimulation	0
,	0
only	0
the	0
NFAT	9
complexes	10
present	0
in	0
eTh2	7
cells	8
are	0
able	0
to	0
mediate	0
high-level	0
transcription	0
,	0
and	0
relatively	0
little	0
NFAT	9
transcriptional	0
activity	0
was	0
induced	0
in	0
eTh1	7
cells	8
.	0

In	0
contrast	0
to	0
activated	0
pTh	7
cells	8
,	0
neither	0
eTh1	7
nor	0
eTh2	7
cells	8
produced	0
significant	0
IL-2	9
upon	0
stimulation	0
,	0
but	0
the	0
high	0
levels	0
of	0
NFAT	9
transcriptional	0
activities	0
directly	0
correlate	0
with	0
the	0
IL-4	9
production	0
induced	0
in	0
response	0
to	0
antigen	0
stimulation	0
in	0
eTh2	7
cells	8
.	0

These	0
data	0
suggest	0
that	0
activated	0
NFAT	9
is	0
involved	0
in	0
the	0
effector	0
function	0
of	0
eTh2	7
cells	8
and	0
that	0
the	0
failure	0
of	0
eTh1	7
cells	8
to	0
produce	0
IL-4	9
in	0
response	0
to	0
an	0
antigen	0
is	0
due	0
,	0
at	0
least	0
partially	0
,	0
to	0
a	0
failure	0
to	0
induce	0
high-level	0
transcription	0
of	0
the	0
IL-4	1
gene	2
by	0
NFAT	9
.	0

Regulation	0
of	0
NFAT	9
could	0
be	0
therefore	0
a	0
critical	0
element	0
in	0
the	0
polarization	0
to	0
eTh1	7
or	0
eTh2	7
.	0

Activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
in	0
lipopolysaccharide-stimulated	5
U937	6
cells	6
.	0

During	0
the	0
course	0
of	0
serious	0
bacterial	0
infections	0
,	0
lipopolysaccharide	0
(	0
LPS	0
)	0
interacts	0
with	0
monocyte/macrophage	9
receptors	10
,	0
resulting	0
in	0
the	0
generation	0
of	0
inflammatory	9
cytokines	10
.	0

Transcription	9
factor	10
NF-kappaB	9
is	0
crucial	0
in	0
activating	0
the	0
transcription	0
of	0
genes	0
encoding	0
proinflammatory	9
cytokines	10
.	0

In	0
this	0
paper	0
,	0
we	0
demonstrate	0
that	0
the	0
activation	0
of	0
NF-kappaB	9
by	0
LPS	0
in	0
a	0
promonocytic	5
cell	6
line	6
(	0
U937	5
)	0
followed	0
a	0
rather	0
slow	0
kinetics	0
,	0
depending	0
on	0
the	0
rate	0
of	0
IkappaB-alpha	9
inhibitor	0
hydrolysis	0
.	0

No	0
degradation	0
of	0
p105	9
and	10
p100	10
inhibitors	10
was	0
observed	0
under	0
these	0
conditions	0
.	0

The	0
transduction	0
pathway	0
leading	0
to	0
NF-kappaB	9
activation	0
in	0
U937	5
cells	6
involved	0
the	0
intracellular	0
generation	0
of	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
,	0
as	0
demonstrated	0
by	0
the	0
concomitant	0
inhibitory	0
effects	0
of	0
antioxidants	0
on	0
NF-kappaB	9
activation	0
and	0
the	0
emission	0
of	0
a	0
fluorescent	0
probe	0
reacting	0
intracellularly	0
with	0
hydrogen	0
peroxide	0
.	0

This	0
ROS	0
pathway	0
was	0
also	0
characterized	0
by	0
the	0
use	0
of	0
other	0
inhibitors	0
.	0

This	0
finding	0
indicates	0
that	0
phospholipase	9
A2	10
and	0
5-lipoxygenase	9
are	0
also	0
involved	0
.	0

However	0
,	0
the	0
NF-kappaB	9
activation	0
pathway	0
involving	0
the	0
acidic	9
sphingomyelinase	10
of	0
the	0
endolysosomial	0
membrane	0
did	0
not	0
seem	0
to	0
participate	0
in	0
the	0
LPS-induced	0
NF-kappaB	9
activation	0
in	0
U937	5
cells	6
.	0

c-Rel	9
is	0
a	0
target	0
of	0
pentoxifylline-mediated	0
inhibition	0
of	0
T	0
lymphocyte	0
activation	0
.	0

The	0
possible	0
clinical	0
use	0
of	0
the	0
methyl	0
xanthine	0
derivative	0
,	0
pentoxifylline	0
(	0
PF	0
)	0
,	0
for	0
the	0
treatment	0
of	0
T	0
cell-dependent	0
diseases	0
is	0
being	0
noted	0
with	0
increasing	0
interest	0
.	0

In	0
this	0
paper	0
,	0
we	0
studied	0
the	0
molecular	0
consequences	0
of	0
PF	0
treatment	0
during	0
lymphocyte	0
activation	0
.	0

We	0
found	0
that	0
in	0
T	7
cells	8
,	0
anti-CD3-induced	0
c-Rel	9
expression	0
was	0
blocked	0
by	0
PF	0
,	0
whereas	0
the	0
induction	0
of	0
other	0
NF-kappaB	9
family	10
members	10
was	0
not	0
significantly	0
affected	0
.	0

However	0
,	0
induction	0
of	0
NF-AT	9
,	0
which	0
has	0
the	0
same	0
signaling	0
requirements	0
as	0
c-Rel	9
induction	0
,	0
was	0
not	0
inhibited	0
by	0
PF	0
.	0

Among	0
genes	0
that	0
respond	0
to	0
these	0
transcription	9
factors	10
,	0
IL-2	3
mRNA	4
induction	0
was	0
suppressed	0
by	0
PF	0
,	0
whereas	0
IL-2R	3
(	4
alpha	4
)	4
chain	4
mRNA	4
induction	0
was	0
not	0
affected	0
.	0

These	0
observations	0
implicated	0
c-Rel	9
as	0
an	0
IL-2	9
promoter	10
factor	10
,	0
for	0
which	0
experimental	0
support	0
was	0
obtained	0
from	0
transient	0
transfection	0
experiments	0
.	0

In	0
contrast	0
with	0
the	0
observation	0
in	0
T	7
cells	8
,	0
c-Rel	9
induction	0
was	0
not	0
blocked	0
by	0
PF	0
in	0
B	7
cells	8
.	0

The	0
greater	0
selectivity	0
of	0
PF	0
,	0
compared	0
with	0
FK506	0
,	0
at	0
both	0
the	0
molecular	0
and	0
cellular	0
levels	0
may	0
prove	0
advantageous	0
in	0
manipulating	0
T	0
cell	0
responses	0
in	0
vivo	0
.	0

V3	9
loop	10
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
suppresses	0
interleukin	9
2	10
-induced	0
T	0
cell	0
growth	0
[	0
published	0
erratum	0
appears	0
in	0
AIDS	0
Res	0
Hum	0
Retroviruses	0
1997	0
May	0
1	0
;	0
13	0
(	0
7	0
)	0
:	0
633	0
]	0

We	0
tested	0
the	0
effect	0
of	0
three	0
linear	0
or	0
two	0
loop	0
peptides	0
derived	0
from	0
the	0
V3	9
region	10
of	0
the	0
HTLV-III	0
BH10	0
clone	0
or	0
the	0
SF2	0
strain	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
on	0
IL-2	9
-driven	0
T	0
cell	0
proliferation	0
.	0

V3-BH10	9
,	0
which	0
consists	0
of	0
42	9
amino	10
acids	10
and	0
has	0
a	0
loop	9
structure	10
,	0
suppressed	0
IL-2	9
-driven	0
proliferation	0
of	0
all	0
IL-2-dependent	5
cells	6
[	0
Kit225	5
,	0
ED-40515	5
(	6
+	6
)	6
,	0
KT-3	5
,	0
7-day	5
PHA-blasts	6
,	0
and	0
fresh	7
peripheral	8
blood	8
mononuclear	8
cells	8
]	0
tested	0
,	0
whereas	0
it	0
did	0
not	0
suppress	0
the	0
cell	0
growth	0
of	0
IL-2-independent	5
cell	6
lines	6
(	0
Hut102	5
,	0
Molt-4	5
,	0
and	0
Jurkat	5
)	0
.	0

This	0
suppressive	0
effect	0
was	0
also	0
seen	0
in	0
IL-2	9
-driven	0
cell	0
growth	0
of	0
CD8-positive	7
lymphocytes	8
purified	0
from	0
7-day	7
PHA-blasts	8
,	0
indicating	0
that	0
CD4	9
molecules	10
were	0
not	0
required	0
for	0
the	0
suppression	0
.	0

The	0
treatment	0
with	0
anti-V3	9
loop	10
monoclonal	10
antibody	10
(	0
902	9
antibody	10
)	0
completely	0
abolished	0
the	0
suppressive	0
effect	0
of	0
V3-BH10	9
.	0

In	0
addition	0
,	0
V3-BH10	9
generated	0
the	0
arrest	0
of	0
Kit225	5
cells	6
and	0
also	0
purified	5
CD8-positive	6
lymphocytes	6
in	0
G1	0
phase	0
in	0
the	0
presence	0
of	0
IL-2	9
.	0

Neither	0
chromatin	1
condensation	0
nor	0
DNA	0
fragmentation	0
was	0
detected	0
in	0
Kit225	5
cells	6
cultured	0
with	0
V3-BH10	9
and	0
IL-2	9
.	0

V3-BH10	9
neither	0
blocked	0
radiolabeled	0
IL-2	9
binding	0
to	0
IL-2	9
receptors	10
nor	0
affected	0
tyrosyl	0
phosphorylation	0
of	0
several	0
cellular	9
proteins	10
(	0
p120	9
,	0
p98	9
,	0
p96	9
,	0
p54	9
,	0
and	0
p38	9
)	0
,	0
which	0
is	0
immediately	0
induced	0
by	0
IL-2	9
stimulation	0
.	0

However	0
,	0
V3-BH10	9
enhanced	0
IL-2	9
-induced	3
mRNA	4
expression	0
of	0
c-fos	1
but	0
not	0
c-myc	1
or	0
junB	1
.	0

Thus	0
,	0
the	0
binding	0
of	0
V3	9
loop	10
of	0
gp120	9
to	0
the	0
cell	0
surface	0
molecule	0
(	0
s	0
)	0
appears	0
to	0
affect	0
intracellular	0
IL-2	9
signaling	0
,	0
which	0
leads	0
to	0
the	0
suppression	0
of	0
IL-2	9
-induced	0
T	0
cell	0
growth	0

A	0
negative	0
role	0
for	0
phosphoinositide	9
3-kinase	10
in	0
T-cell	9
antigen	10
receptor	10
function	0
.	0

BACKGROUND	0
:	0
A	0
delicate	0
balance	0
between	0
positive	0
and	0
negative	0
regulatory	0
mechanisms	0
during	0
T-cell	0
activation	0
determines	0
the	0
specificity	0
and	0
magnitude	0
of	0
an	0
immune	0
response	0
.	0

Phosphoinositide	9
3-kinase	10
(	0
PI	9
3-kinase	10
)	0
is	0
activated	0
by	0
a	0
diverse	0
set	0
of	0
receptors	0
that	0
determine	0
T-cell	0
function	0
,	0
including	0
the	0
T-cell	9
antigen	10
receptor	10
(	0
TCR	9
)	0
,	0
the	0
costimulatory	9
receptor	10
CD28	10
,	0
and	0
negative	9
regulators	10
of	0
T-cell	0
activation	0
such	0
as	0
CTLA-4	9
.	0

PI	9
3-kinase	10
is	0
also	0
regulated	0
by	0
the	0
haematopoietic	0
cytokines	0
that	0
determine	0
T-cell	0
differentiation	0
and	0
lymphocyte	7
proliferation	0
.	0

PI	9
3-kinase	10
can	0
thus	0
dynamically	0
influence	0
the	0
outcome	0
of	0
the	0
immune	0
reactions	0
at	0
various	0
stages	0
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
importance	0
of	0
PI	9
3-kinase	10
in	0
TCR	9
-directed	0
T-cell	0
activation	0
using	0
activated	0
or	0
inhibitory	0
versions	0
of	0
PI	9
3-kinase	10
.	0

RESULTS	0
:	0
Certain	0
aspects	0
of	0
TCR	9
responses	0
such	0
as	0
the	0
induction	0
of	0
transcriptional	0
activity	0
of	0
AP1	9
and	0
serum	9
response	10
factor	10
were	0
not	0
affected	0
by	0
expression	0
of	0
the	0
mutant	0
forms	0
of	0
PI	9
3-kinase	10
.	0

We	0
found	0
,	0
however	0
,	0
that	0
PI	9
3-kinase	10
profoundly	0
influenced	0
the	0
transactivation	0
capacity	0
of	0
'	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
'	0
(	0
NF-AT	9
)	0
elicited	0
by	0
the	0
TCR	9
:	0
expression	0
of	0
an	0
activated	0
form	0
of	0
PI	9
3-kinase	10
inhibited	0
TCR	9
-mediated	0
NF-AT	9
responses	0
,	0
whereas	0
expression	0
of	0
a	0
dominant	0
negative	0
mutant	0
of	0
PI	9
3-kinase	10
potently	0
enhanced	0
TCR	9
-controlled	0
NF-AT	9
induction	0
.	0

These	0
effects	0
of	0
PI	9
3-kinase	10
were	0
not	0
mediated	0
by	0
previously	0
identified	0
PI	9
3-kinase	10
effectors	10
,	0
such	0
as	0
protein	9
kinase	10
B	10
,	0
a	0
positive	9
regulator	10
of	0
PI	9
3-kinase	10
,	0
or	0
the	0
GTPase	9
Rac	10
,	0
and	0
are	0
therefore	0
likely	0
to	0
involve	0
a	0
novel	0
,	0
as	0
yet	0
unknown	0
,	0
effector	9
molecule	10
.	0

CONCLUSIONS	0
:	0
Our	0
results	0
establish	0
that	0
PI	9
3-kinase	10
can	0
both	0
positively	0
and	0
negatively	0
regulate	0
T-cell	0
function	0
,	0
and	0
uncover	0
a	0
previously	0
unrecognized	0
function	0
for	0
PI	9
3-kinase	10
in	0
T	7
cells	8
as	0
a	0
selective	0
negative	0
regulator	0
of	0
TCR	9
-signalling	0
events	0
and	0
therefore	0
as	0
a	0
determinant	0
of	0
T-cell	0
homeostasis	0
.	0

The	0
Pax-5	1
gene	2
is	0
alternatively	0
spliced	0
during	0
B-cell	0
development	0
.	0

The	0
transcription	9
factor	10
Pax-5	10
is	0
expressed	0
during	0
the	0
early	0
stages	0
of	0
B-cell	0
differentiation	0
and	0
influences	0
the	0
expression	0
of	0
several	0
B-cell-specific	1
genes	2
.	0

In	0
addition	0
to	0
the	0
existing	0
isoform	0
(	0
Pax-5	9
,	0
which	0
we	0
have	0
named	0
Pax-5a	9
)	0
,	0
we	0
have	0
isolated	0
three	0
new	0
isoforms	0
,	0
Pax-5b	9
,	0
Pax-5d	9
,	0
and	0
Pax-5e	9
,	0
from	0
murine	0
spleen	0
and	0
B-lymphoid	5
cell	6
lines	6
using	0
library	0
screenings	0
and	0
polymerase	0
chain	0
reaction	0
amplification	0
.	0

Isoforms	0
Pax-5b	9
and	0
Pax-5e	9
have	0
spliced	0
out	0
their	0
second	0
exon	0
,	0
resulting	0
in	0
proteins	0
with	0
only	0
a	0
partial	0
DNA-binding	9
domain	10
.	0

Isoforms	0
Pax-5d	0
and	0
Pax-5e	9
have	0
deleted	0
the	0
3'-region	9
,	0
which	0
encodes	0
the	0
transactivating	0
domain	0
,	0
and	0
replaced	0
it	0
with	0
a	0
novel	0
sequence	0
.	0

The	0
existence	0
of	0
alternative	0
Pax-5	3
transcripts	4
was	0
confirmed	0
using	0
RNase	9
protection	0
assays	0
.	0

Furthermore	0
,	0
Pax-5a	9
and	0
Pax-5b	9
proteins	10
were	0
detected	0
using	0
Western	0
blot	0
analysis	0
.	0

Pax-5a	9
was	0
detectable	0
in	0
pro-	5
,	6
pre-	6
,	6
and	6
mature	6
B-cell	6
lines	6
,	0
but	0
not	0
in	0
two	0
plasmacytomas	0
;	0
Pax-5b	9
was	0
shown	0
to	0
be	0
present	0
at	0
low	0
levels	0
in	0
mature	5
B-cell	6
lines	6
and	0
,	0
unexpectedly	0
,	0
in	0
one	0
plasma	0
cell	0
line	0
,	0
but	0
not	0
in	0
pro-B-cell	5
or	6
T-cell	6
lines	6
.	0

Mobility	0
shift	0
assays	0
showed	0
that	0
in	0
vitro	0
translated	0
Pax-5a	9
and	0
Pax-5d	9
,	0
but	0
not	0
Pax-5b	9
or	0
Pax-5e	9
,	0
could	0
interact	0
with	0
a	0
B-cell-specific	1
activator	2
protein-binding	2
site	2
on	0
the	0
blk	1
promoter	2
.	0

Using	0
this	0
assay	0
,	0
we	0
also	0
showed	0
that	0
Pax-5d	9
was	0
present	0
in	0
nuclear	0
extracts	0
of	0
some	0
(	0
but	0
not	0
all	0
)	0
B-lymphoid	5
lines	6
and	0
interacts	0
with	0
the	0
B-cell-specific	1
activator	2
protein-binding	2
site	2
.	0

The	0
pattern	0
of	0
differential	0
expression	0
of	0
alternatively	9
spliced	10
Pax-5	10
isoforms	10
suggests	0
that	0
they	0
may	0
be	0
important	0
regulators	9
of	10
transcription	10
during	0
B-cell	0
maturation	0
.	0

Reconstitution	0
of	0
T	0
cell	0
antigen	0
receptor-induced	0
Erk2	9
kinase	10
activation	0
in	0
Lck-negative	5
JCaM1	6
cells	6
by	0
Syk	9
.	0

The	0
two	0
related	0
protein-tyrosine	9
kinases	10
Syk	9
and	0
Zap	9
are	0
rapidly	0
phosphorylated	0
on	0
tyrosine	0
residues	0
and	0
enzymatically	0
activated	0
upon	0
crosslinking	0
of	0
the	0
T	9
cell	10
antigen	10
receptor	10
.	0

We	0
have	0
previously	0
reported	0
that	0
the	0
activation	0
of	0
Syk	9
is	0
less	0
dependent	0
on	0
the	0
Src	9
family	10
kinase	10
Lck	9
than	0
the	0
activation	0
of	0
Zap	9
.	0

Here	0
we	0
report	0
that	0
overexpression	0
of	0
Syk	9
in	0
the	0
Lck-negative	5
JCaM1	6
cells	6
enabled	0
the	0
T	9
cell	10
antigen	10
receptor/CD3	10
complex	10
to	0
induce	0
a	0
normal	0
activation	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
pathway	0
and	0
expression	0
of	0
a	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
reporter	0
construct	0
.	0

In	0
contrast	0
,	0
Zap	9
and	0
other	0
protein-tyrosine	9
kinases	10
were	0
unable	0
to	0
reconstitute	0
these	0
signaling	0
pathways	0
when	0
expressed	0
at	0
the	0
same	0
levels	0
.	0

In	0
parallel	0
,	0
Syk	9
was	0
phosphorylated	0
on	0
tyrosine	0
,	0
while	0
Zap	9
was	0
not	0
.	0

The	0
Syk	9
-mediated	0
T	9
cell	10
antigen	10
receptor	10
-induced	0
MAPK	9
activation	0
was	0
detectable	0
within	0
1	0
min	0
of	0
receptor	0
stimulation	0
and	0
peaked	0
at	0
3-5	0
min	0
.	0

The	0
capacity	0
of	0
Syk	9
to	0
reconstitute	0
the	0
MAPK	9
response	0
required	0
the	0
catalytic	0
activity	0
of	0
Syk	9
,	0
an	0
intact	0
autophosphorylation	9
site	10
(	0
Y518	0
and	0
Y519	0
)	0
,	0
both	0
Src	9
homology	10
2	10
domains	10
and	0
it	0
was	0
blocked	0
by	0
the	0
inhibitory	9
N17-mutated	10
dominant-negative	10
Ras	10
construct	10
.	0

A	0
Y341	0
--	0
>	0
F	9
mutant	10
of	0
Syk	9
,	0
which	0
is	0
deficient	0
in	0
its	0
interaction	0
with	0
phospholipase	9
Cy1	10
and	0
Vav	9
,	0
was	0
less	0
efficient	0
than	0
wild-type	9
Syk	10
.	0

Our	0
results	0
suggest	0
that	0
Syk	9
,	0
in	0
contrast	0
to	0
Zap	9
,	0
can	0
transduce	0
signals	0
from	0
the	0
T	9
cell	10
antigen	10
receptor	10
independently	0
of	0
Lck	9
.	0

Activation	0
of	0
the	0
transcription	9
factor	10
MEF2C	9
by	0
the	0
MAP	9
kinase	10
p38	10
in	0
inflammation	0
.	0

For	0
cells	0
of	0
the	0
innate	0
immune	0
system	0
to	0
mount	0
a	0
host	0
defence	0
response	0
to	0
infection	0
,	0
they	0
must	0
recognize	0
products	0
of	0
microbial	0
pathogens	0
such	0
as	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
the	0
endotoxin	0
secreted	0
by	0
Gram-negative	0
bacteria	0
.	0

These	0
cellular	0
responses	0
require	0
intracellular	0
signalling	0
pathways	0
,	0
such	0
as	0
the	0
four	0
MAP	9
kinase	10
(	0
MAPK	9
)	0
pathways	0
.	0

In	0
mammalian	0
cells	0
the	0
MAPK	9
p38	10
is	0
thought	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
cellular	0
responses	0
during	0
infection	0
through	0
its	0
effects	0
on	0
the	0
expression	0
of	0
proinflammatory	9
molecules	10
.	0

One	0
means	0
of	0
understanding	0
the	0
role	0
of	0
p38	9
in	0
these	0
responses	0
is	0
to	0
identify	0
proteins	0
with	0
functions	0
regulated	0
by	0
p38	9
-catalysed	0
phosphorylation	0
.	0

Here	0
we	0
demonstrate	0
a	0
link	0
between	0
the	0
p38	9
pathway	0
and	0
a	0
member	0
of	0
the	0
myocyte-enhancer	9
factor	10
2	10
(	10
MEF2	10
)	10
group	10
of	0
transcription	9
factors	10
.	0

We	0
found	0
that	0
in	0
monocytic	7
cells	8
,	0
LPS	0
increases	0
the	0
transactivation	0
activity	0
of	0
MEF2C	9
through	0
p38	9
-catalysed	0
phosphorylation	0
.	0

One	0
consequence	0
of	0
MEF2C	9
activation	0
is	0
increased	0
c-jun	1
gene	2
transcription	0
.	0

Our	0
results	0
show	0
that	0
p38	9
may	0
influence	0
host	0
defence	0
and	0
inflammation	0
by	0
maintaining	0
the	0
balance	0
of	0
c-Jun	9
protein	10
consumed	0
during	0
infection	0
.	0

Cellular	0
redox	0
status	0
influences	0
both	0
cytotoxic	0
and	0
NF-kappa	0
B	0
activation	0
in	0
natural	7
killer	8
cells	8
.	0

The	0
role	0
of	0
cellular	0
redox	0
status	0
in	0
both	0
cytotoxic	0
activity	0
and	0
NF-kappa	9
B	10
activation	0
in	0
natural	7
killer	8
(	8
NK	8
)	8
cells	8
was	0
investigated	0
.	0

The	0
results	0
indicate	0
that	0
stimulation	0
of	0
NK	7
cells	8
,	0
either	0
freshly	0
isolated	0
from	0
peripheral	7
blood	8
lymphocytes	8
(	0
PBL	7
)	0
or	0
long-term	5
cultured	6
NK	6
clones	6
,	0
with	0
specific	0
cell	0
targets	0
results	0
in	0
an	0
increased	0
binding	0
activity	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
transcription	9
factors	10
measured	0
by	0
gel	0
retardation	0
.	0

Pretreatment	0
of	0
NK	7
cells	8
with	0
the	0
antioxidant	0
pyrrolidine	0
dithiocarbarmate	0
(	0
PDTC	0
)	0
leads	0
to	0
the	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
but	0
the	0
AP-1	9
binding	0
to	0
DNA	0
was	0
superinduced	0
.	0

The	0
inhibition	0
of	0
NF-kappa	9
B	10
by	0
PDTC	0
paralleled	0
with	0
an	0
inhibition	0
of	0
spontaneous	0
cytotoxicity	0
mediated	0
by	0
NK	7
cells	8
.	0

Moreover	0
,	0
the	0
inhibitors	0
of	0
serine	9
proteases	10
,	0
N-alpha-tosyl-L-lysine	0
chloromethyl	0
ketone	0
and	0
N-alpha-tosyl-L-phenylalanine	0
chloromethyl	0
ketone	0
,	0
also	0
blocked	0
the	0
cytolytic	0
activity	0
of	0
NK	7
cells	8
against	0
the	0
sensitive	0
target	0
K562	5
.	0

In	0
contrast	0
,	0
NK	0
activity	0
was	0
not	0
affected	0
by	0
pretreatment	0
of	0
the	0
effector	0
cells	0
with	0
the	0
proteasome	9
inhibitor	0
N-acetyl-leu-leu-norleucinal	0
which	0
selectively	0
inhibits	0
NF-kappa	9
B	10
activation	0
.	0

Altogether	0
,	0
these	0
results	0
support	0
the	0
hypothesis	0
that	0
the	0
activation	0
of	0
NK	7
cells	8
involved	0
transcriptional	0
and	0
post-transcriptional	0
events	0
,	0
and	0
that	0
reactive	0
intermediates	0
may	0
play	0
an	0
important	0
role	0
in	0
the	0
molecular	0
processes	0
related	0
with	0
the	0
generation	0
of	0
a	0
cytotoxic	0
response	0
by	0
NK	7
cells	8
.	0

The	0
predominant	0
E2F	9
complex	10
in	0
human	7
primary	8
haemopoietic	8
cells	8
and	0
in	0
AML	7
blasts	8
contains	0
E2F-4	9
,	0
DP-1	9
and	0
p130	9
.	0

The	0
E2F	9
family	10
of	0
transcription	9
factors	10
are	0
thought	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
control	0
of	0
cell	0
cycle	0
progression	0
.	0

There	0
is	0
now	0
also	0
increasing	0
evidence	0
that	0
some	0
family	0
members	0
may	0
act	0
as	0
oncogenes	1
or	0
tumour	1
suppressor	2
genes	2
.	0

The	0
characterization	0
of	0
these	0
proteins	0
in	0
human	7
primary	8
haemopoietic	8
cells	8
and	0
acute	7
myeloid	8
leukaemia	8
(	8
AML	8
)	8
blasts	8
may	0
thus	0
give	0
an	0
insight	0
to	0
the	0
molecular	0
mechanisms	0
governing	0
proliferation	0
and	0
leukaemogenesis	0
in	0
these	0
cells	0
.	0

Therefore	0
we	0
analysed	0
the	0
expression	0
of	0
E2F	9
-DNA	0
binding	0
activity	0
and	0
the	0
constituent	0
proteins	0
found	0
in	0
the	0
complexes	0
in	0
human	7
primary	8
haemopoietic	8
cells	8
of	0
various	0
lineages	0
.	0

We	0
also	0
studied	0
blasts	0
from	0
18	0
patients	0
with	0
acute	0
myeloid	0
leukaemia	0
(	0
AML	0
)	0
.	0

On	0
electromobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
a	0
single	0
E2F-DNA	9
binding	10
complex	10
was	0
detected	0
in	0
T	7
cells	8
,	0
B	7
cells	8
and	0
monocytes	7
which	0
was	0
shown	0
to	0
contain	0
E2F-4	9
,	0
DP-1	9
and	0
p130	9
,	0
indicating	0
that	0
all	0
quiescent	7
haemopoietic	8
cells	8
have	0
the	0
same	0
complex	0
.	0

Examination	0
of	0
18	0
AML	0
samples	0
by	0
EMSA	0
revealed	0
the	0
presence	0
of	0
E2F	9
binding	0
and	0
no	0
gross	0
abnormalities	0
were	0
detected	0
.	0

An	0
E2F-4/p130	9
complex	10
was	0
detected	0
in	0
representative	0
samples	0
of	0
all	0
FAB	9
types	0
analysed	0
.	0

Thus	0
abnormalities	0
of	0
E2F	9
function	0
are	0
unlikely	0
to	0
play	0
a	0
primary	0
pathogenic	0
role	0
in	0
AML	0
.	0

Characterization	0
of	0
a	0
mutant	5
cell	6
line	6
that	0
does	0
not	0
activate	0
NF-kappaB	9
in	0
response	0
to	0
multiple	0
stimuli	0
.	0

Numerous	0
genes	0
required	0
during	0
the	0
immune	0
or	0
inflammation	0
response	0
as	0
well	0
as	0
the	0
adhesion	0
process	0
are	0
regulated	0
by	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
.	0

Associated	0
with	0
its	0
inhibitor	0
,	0
I	9
kappaB	10
,	0
NF-kappaB	9
resides	0
as	0
an	0
inactive	0
form	0
in	0
the	0
cytoplasm	0
.	0

Upon	0
stimulation	0
by	0
various	0
agents	0
,	0
I	9
kappaB	10
is	0
proteolyzed	0
and	0
NF-kappaB	9
translocates	0
to	0
the	0
nucleus	0
,	0
where	0
it	0
activates	0
its	0
target	0
genes	0
.	0

The	0
transduction	0
pathways	0
that	0
lead	0
to	0
I	9
kappaB	10
inactivation	0
remain	0
poorly	0
understood	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
characterized	0
a	0
cellular	0
mutant	0
,	0
the	0
70/Z3-derived	5
1.3E2	6
murine	6
pre-B	6
cell	6
line	6
,	0
that	0
does	0
not	0
activate	0
NF-kappaB	9
in	0
response	0
to	0
several	0
stimuli	0
.	0

We	0
demonstrate	0
that	0
upon	0
stimulation	0
by	0
lipopolysaccharide	0
,	0
Taxol	0
,	0
phorbol	0
myristate	0
acetate	0
,	0
interleukin-1	9
,	0
or	0
double-stranded	3
RNA	4
,	0
I	9
kappaB	10
alpha	10
is	0
not	0
degraded	0
,	0
as	0
a	0
result	0
of	0
an	0
absence	0
of	0
induced	0
phosphorylation	0
on	0
serines	0
32	0
and	0
36	0
.	0

Neither	0
a	0
mutation	0
in	0
I	9
kappaB	10
alpha	10
nor	0
a	0
mutation	0
in	0
p50	9
or	0
relA	9
,	0
the	0
two	0
major	0
subunits	0
of	0
NF-kappaB	9
in	0
this	0
cell	0
line	0
,	0
accounts	0
for	0
this	0
phosphorylation	0
defect	0
.	0

As	0
well	0
as	0
culminating	0
in	0
the	0
inducible	0
phosphorylation	0
of	0
I	9
kappaB	10
alpha	0
on	0
serines	0
32	0
and	0
36	0
,	0
all	0
the	0
stimuli	0
that	0
are	0
inactive	0
on	0
1.3E2	5
cells	6
exhibit	0
a	0
sensitivity	0
to	0
the	0
antioxidant	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
.	0

In	0
contrast	0
,	0
stimuli	0
such	0
as	0
hyperosmotic	0
shock	0
or	0
phosphatase	0
inhibitors	0
,	0
which	0
use	0
PDTC-insensitive	0
pathways	0
,	0
induce	0
I	9
kappaB	10
alpha	0
degradation	0
in	0
1.3E2	5
.	0

Analysis	0
of	0
the	0
redox	0
status	0
of	0
1.3E2	5
does	0
not	0
reveal	0
any	0
difference	0
from	0
wild-type	5
70Z/3	6
.	0

We	0
also	0
report	0
that	0
the	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
1	10
(	10
HTLV-1	10
)	10
-derived	10
Tax	10
trans-activator	10
induces	0
NF-kappaB	9
activity	0
in	0
1.3E2	5
,	0
suggesting	0
that	0
this	0
viral	0
protein	0
does	0
not	0
operate	0
via	0
the	0
defective	0
pathway	0
.	0

Finally	0
,	0
we	0
show	0
that	0
two	0
other	0
I	9
kappaB	10
molecules	10
,	0
I	9
kappaB	10
beta	10
and	0
the	0
recently	0
identified	0
I	9
kappaB	10
epsilon	10
,	0
are	0
not	0
degraded	0
in	0
the	0
1.3E2	5
cell	0
line	0
following	0
stimulation	0
.	0

Our	0
results	0
demonstrate	0
that	0
1.3E2	5
is	0
a	0
cellular	9
transduction	10
mutant	10
exhibiting	0
a	0
defect	0
in	0
a	0
step	0
that	0
is	0
required	0
by	0
several	0
different	0
stimuli	0
to	0
activate	0
NF-kappaB	9
.	0

In	0
addition	0
,	0
this	0
analysis	0
suggests	0
a	0
common	0
step	0
in	0
the	0
signaling	0
pathways	0
that	0
trigger	0
I	9
kappaB	10
alpha	10
,	0
I	9
kappaB	10
beta	10
,	0
and	0
I	9
kappaB	10
epsilon	10
degradation	0
.	0

Involvement	0
of	0
Egr-1	9
/RelA	9
synergy	0
in	0
distinguishing	0
T	0
cell	0
activation	0
from	0
tumor	9
necrosis	10
factor-alpha	10
-induced	0
NF-kappa	9
B1	10
transcription	0
.	0

NF-kappa	9
B	10
is	0
an	0
important	0
transcription	9
factor	10
required	0
for	0
T	0
cell	0
proliferation	0
and	0
other	0
immunological	0
functions	0
.	0

The	0
NF-kappa	1
B1	2
gene	2
encodes	0
a	0
105-kD	9
protein	10
that	0
is	0
the	0
precursor	0
of	0
the	0
p50	9
component	10
of	0
NF-kappa	9
B	10
.	0

Previously	0
,	0
we	0
and	0
others	0
have	0
demonstrated	0
that	0
NF-kappa	9
B	10
regulates	0
the	0
NF-kappa	1
B1	2
gene	2
.	0

In	0
this	0
manuscript	0
we	0
have	0
investigated	0
the	0
molecular	0
mechanisms	0
by	0
which	0
T	5
cell	6
lines	6
stimulated	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
phytohemagglutin	9
(	0
PHA	9
)	0
display	0
significantly	0
higher	0
levels	0
of	0
NF-kappa	9
B1	10
encoding	0
transcripts	3
than	0
cells	0
stimulated	0
with	0
tumor	9
necrosis	10
factor-alpha	10
,	0
despite	0
the	0
fact	0
that	0
both	0
stimuli	0
activate	0
NF-kappa	9
B	10
.	0

Characterization	0
of	0
the	0
NF-kappa	1
B1	2
promoter	2
identified	0
an	0
Egr-1	1
site	2
which	0
was	0
found	0
to	0
be	0
essential	0
for	0
both	0
the	0
PMA/	0
PHA	9
-mediated	0
induction	0
as	0
well	0
as	0
the	0
synergistic	0
activation	0
observed	0
after	0
the	0
expression	0
of	0
the	0
RelA	0
subunit	0
of	0
NF-kappa	9
B	10
and	0
Egr-1	9
.	0

Furthermore	0
,	0
Egr-1	9
induction	0
was	0
required	0
for	0
endogenous	0
NF-kappa	1
B1	2
gene	0
expression	0
,	0
since	0
PMA/	0
PHA-stimulated	5
T	6
cell	6
lines	6
expressing	0
antisense	0
Egr-1	3
RNA	4
were	0
inhibited	0
in	0
their	0
ability	0
to	0
upregulate	0
NF-kappa	0
B1	0
transcription	0
.	0

Our	0
studies	0
indicate	0
that	0
transcriptional	0
synergy	0
mediated	0
by	0
activation	0
of	0
both	0
Egr-1	9
and	0
NF-kappa	9
B	10
may	0
have	0
important	0
ramifications	0
in	0
T	0
cell	0
development	0
by	0
upregulating	0
NF-kappa	1
B1	2
gene	0
expression	0
.	0

The	0
synthesis	0
and	0
immunogenicity	0
of	0
varicella-zoster	9
virus	10
glycoprotein	10
E	10
and	0
immediate-early	9
protein	10
(	0
IE62	9
)	0
expressed	0
in	0
recombinant	0
herpes	0
simplex	0
virus-1	0
.	0

In	0
order	0
to	0
evaluate	0
the	0
conditions	0
for	0
optimal	0
expression	0
and	0
immunogenicity	0
of	0
varicella-zoster	9
virus	10
(	10
VZV	10
)	10
proteins	10
in	0
a	0
herpes	0
simplex	0
virus-1	0
(	0
HSV-1	0
)	0
vector	0
,	0
we	0
selected	0
the	0
VZV	9
glycoprotein	10
E	10
(	0
gE	9
)	0
,	0
encoded	0
by	0
ORF	1
68	2
and	0
the	0
VZV	9
product	10
of	0
ORF	1
62	2
,	0
an	0
immediate-early	9
major	10
tegument	10
protein	10
(	0
IE62	9
)	0
.	0

Three	0
HSV/VZV	1
recombinants	2
were	0
generated	0
:	0
(	0
1	0
)	0
VZV	1
gE	2
protein	2
coding	2
sequences	2
along	0
with	0
the	0
promoter	9
region	10
were	0
inserted	0
into	0
the	0
thymidine	1
kinase	2
(	2
TK	2
)	2
gene	2
of	0
HSV-1	0
strain	0
KOS	0
;	0
(	0
2	0
)	0
VZV	9
gE	10
expressed	0
from	0
the	0
HSV-1	1
ICP4	2
promoter	2
was	0
inserted	0
into	0
the	0
glycoprotein	1
C	2
(	2
gC	2
)	2
gene	2
of	0
HSV-1	0
strain	0
F	0
;	0
and	0
(	0
3	0
)	0
VZV	1
IE62	2
protein	2
coding	2
sequences	2
under	0
the	0
control	0
of	0
the	0
HSV-1	1
ICP4	2
promoter	2
were	0
inserted	0
into	0
the	0
gC	1
gene	2
of	0
HSV-1	0
strain	0
F	0
.	0

Immunoblot	0
analysis	0
and	0
immunoperoxidase	0
staining	0
of	0
infected	0
cell	0
monolayers	0
demonstrated	0
vector	0
expression	0
of	0
VZV	9
proteins	10
.	0

Following	0
intracranial	0
inoculation	0
in	0
mice	0
,	0
both	0
VZV	9
gE-HSV	10
(	0
TK	9
)	0
and	0
VZV	9
IE62-HSV	10
(	0
gC	9
)	0
induced	0
an	0
IgG	9
response	0
against	0
VZV	9
gE	10
or	0
VZV	9
IE62	10
.	0

When	0
tested	0
in	0
cytotoxicity	0
assays	0
using	0
T-lymphocytes	7
from	0
VZV	0
immune	0
human	0
donors	0
,	0
the	0
range	0
of	0
precursor	0
frequencies	0
for	0
T-lymphocytes	7
that	0
recognized	0
VZV	9
gE	10
or	0
VZV	9
IE62	10
was	0
similar	0
whether	0
these	0
proteins	0
were	0
expressed	0
by	0
HSV-1	0
or	0
a	0
vaccinia	0
vector	0
.	0

These	0
experiments	0
demonstrate	0
that	0
HSV-1	0
is	0
a	0
competent	0
vector	0
for	0
expression	0
of	0
these	0
VZV	9
proteins	10
and	0
support	0
the	0
feasibility	0
of	0
engineering	0
a	0
combined	0
vaccine	0
for	0
these	0
closely	0
related	0
alpha-herpesviruses	0
.	0

Constitutive	0
dephosphorylation	0
and	0
activation	0
of	0
a	0
member	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
,	0
NF-AT1	9
,	0
in	0
Tax-expressing	7
and	8
type	8
I	8
human	8
T-cell	8
leukemia	8
virus-infected	8
human	8
T	8
cells	8
.	0

The	0
tax	0
gene	0
product	0
of	0
the	0
type	0
I	0
human	0
T-cell	0
leukemia	0
virus	0
(	0
HTLV-I	0
)	0
transactivates	0
interleukin-2	1
(	2
IL-2	2
)	2
gene	2
through	0
activation	0
of	0
an	0
enhancer	0
termed	0
CD28	1
responsive	2
element	2
(	0
CD28RE	1
)	0
.	0

Tax	9
activation	0
of	0
the	0
CD28RE	1
is	0
partially	0
mediated	0
by	0
a	0
member	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
,	0
NF-AT1	9
.	0

We	0
have	0
previously	0
shown	0
that	0
NF-AT1	9
is	0
constitutively	0
active	0
in	0
Jurkat	5
T	6
cells	6
stably	0
transfected	0
with	0
the	0
Tax	1
cDNA	2
,	0
although	0
the	0
underlying	0
molecular	0
mechanism	0
and	0
physiological	0
relevance	0
of	0
this	0
finding	0
remain	0
unclear	0
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
the	0
active	0
form	0
of	0
NF-AT1	9
is	0
also	0
present	0
in	0
the	0
nuclei	0
of	0
HTLV-I-transformed	7
T	8
cells	8
that	0
express	0
the	0
Tax	9
protein	10
.	0

Interestingly	0
,	0
the	0
constitutive	0
activation	0
of	0
NF-AT1	9
in	0
these	0
T	7
cells	8
is	0
associated	0
with	0
its	0
dephosphorylation	0
.	0

Furthermore	0
,	0
the	0
dephosphorylated	0
NF-AT1	9
can	0
be	0
rapidly	0
rephosphorylated	0
when	0
the	0
cells	0
are	0
incubated	0
with	0
cyclosporin	0
A	0
,	0
an	0
immunosuppressant	0
inhibiting	0
the	0
serine/threonine	9
phosphatase	10
calcineurin	9
.	0

These	0
results	0
suggest	0
that	0
activation	0
of	0
NF-AT1	9
in	0
Tax-expressing	5
and	6
HTLV-I-transformed	6
T	6
cells	6
results	0
from	0
its	0
dephosphorylation	0
,	0
which	0
in	0
turn	0
may	0
be	0
due	0
to	0
deregulation	0
of	0
calcineurin	9

Expression	0
of	0
NFAT-family	9
proteins	10
in	0
normal	7
human	8
T	8
cells	8
.	0

NFAT	9
proteins	10
constitute	0
a	0
family	0
of	0
transcription	9
factors	10
involved	0
in	0
mediating	0
signal	0
transduction	0
.	0

Using	0
a	0
panel	0
of	0
specific	0
antisera	0
in	0
immunoprecipitation	0
assays	0
,	0
we	0
found	0
that	0
NFATp	9
(	0
135	9
kDa	10
)	0
is	0
constitutively	0
expressed	0
in	0
normal	7
human	8
T	8
cells	8
,	0
while	0
synthesis	0
of	0
NFATc	9
(	0
predominant	0
form	0
of	0
86	9
kDa	10
)	0
is	0
induced	0
by	0
ionomycin	0
treatment	0
.	0

NFAT4/x	9
was	0
very	0
weakly	0
expressed	0
in	0
unstimulated	0
cells	0
,	0
and	0
its	0
level	0
did	0
not	0
increase	0
upon	0
treatment	0
with	0
activating	0
agents	0
.	0

NFAT3	9
protein	10
was	0
not	0
observed	0
under	0
any	0
conditions	0
.	0

Higher-molecular-weight	9
species	10
of	0
NFATc	9
(	0
of	0
110	0
and	0
140	0
kDa	0
)	0
were	0
also	0
detected	0
.	0

In	0
addition	0
,	0
translation	0
of	0
NFATc	3
mRNA	4
apparently	0
initiates	0
at	0
two	0
different	0
AUG	1
codons	2
,	0
giving	0
rise	0
to	0
proteins	0
that	0
differ	0
in	0
size	0
by	0
36	0
amino	0
acids	0
.	0

Additional	0
size	0
heterogeneity	0
of	0
both	0
NFATc	9
and	0
NFATp	9
results	0
from	0
phosphorylation	0
.	0

In	0
contrast	0
to	0
ionomycin	0
treatment	0
,	0
exposure	0
of	0
cells	0
to	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
plus	0
anti-CD28	9
did	0
not	0
induce	0
NFATc	9
,	0
indicating	0
that	0
under	0
these	0
conditions	0
,	0
interleukin-2	9
synthesis	0
by	0
these	0
cells	0
is	0
apparently	0
independent	0
of	0
NFATc	9
.	0

In	0
DNA	0
binding	0
assays	0
,	0
both	0
PMA	0
plus	0
anti-CD28	9
and	0
PMA	0
plus	0
ionomycin	0
resulted	0
in	0
nuclear	9
NFAT	10
.	0

Surprisingly	0
,	0
the	0
PMA-ionomycin-induced	0
synthesis	0
of	0
NFATc	9
that	0
was	0
detected	0
by	0
immunoprecipitation	0
was	0
not	0
mirrored	0
in	0
the	0
DNA	0
binding	0
assays	0
:	0
nearly	0
all	0
of	0
the	0
activity	0
was	0
due	0
to	0
NFATp	9
.	0

This	0
is	0
the	0
first	0
study	0
of	0
expression	0
of	0
all	0
family	0
members	0
at	0
the	0
protein	0
level	0
in	0
normal	7
human	8
T	8
cells	8
.	0

Of	0
the	0
GATA-binding	9
proteins	10
,	0
only	0
GATA-4	9
selectively	0
regulates	0
the	0
human	1
IL-5	2
gene	2
promoter	2
in	0
IL-5	7
producing	8
cells	8
which	0
express	0
multiple	9
GATA-binding	10
proteins	10
.	0

Interleukin-5	9
(	0
IL-5	9
)	0
is	0
produced	0
by	0
T	7
lymphocytes	8
and	0
known	0
to	0
support	0
B	0
cell	0
growth	0
and	0
eosinophilic	0
differentiation	0
of	0
the	0
progenitor	7
cells	8
.	0

Using	0
ATL-16T	5
cells	6
which	0
express	0
IL-5	3
mRNA	4
,	0
we	0
have	0
identified	0
a	0
region	0
,	0
within	0
the	0
human	1
IL-5	2
gene	2
promoter	2
,	0
that	0
regulates	0
IL-5	1
gene	2
transcription	0
.	0

This	0
cis-acting	1
sequence	2
contains	0
the	0
core	1
binding	2
motif	2
,	0
(	0
A/T	0
)	0
GATA	0
(	0
A/G	0
)	0
,	0
for	0
GATA-binding	9
family	10
proteins	10
and	0
thus	0
suggests	0
the	0
involvement	0
of	0
these	0
family	0
members	0
.	0

In	0
this	0
report	0
,	0
we	0
describe	0
the	0
cloning	0
of	0
human	9
GATA-4	10
(	0
hGATA-4	9
)	0
and	0
show	0
that	0
hGATA-4	9
selectively	0
interacts	0
with	0
the	0
-70	1
GATA	2
site	2
within	0
the	0
IL-5	1
proximal	2
promoter	2
region	2
.	0

By	0
promoter	0
deletion	0
and	0
mutation	0
analyses	0
,	0
we	0
established	0
this	0
region	0
as	0
a	0
positive	1
regulatory	2
element	2
.	0

Cotransfection	0
experiments	0
revealed	0
that	0
both	0
hGATA-4	9
and	0
PMA/A23187	0
stimulation	0
are	0
necessary	0
for	0
the	0
IL-5	1
promoter	2
activation	0
.	0

The	0
requirement	0
of	0
another	0
regulatory	1
element	2
called	0
CLE0	1
,	0
which	0
lies	0
downstream	0
of	0
the	0
-70	1
GATA	2
site	2
,	0
was	0
also	0
demonstrated	0
.	0

ATL-16T	5
cells	6
express	0
mRNA	3
of	0
three	0
GATA-binding	9
proteins	10
,	0
hGATA-2	9
,	0
hGATA-3	9
and	0
hGATA-4	9
,	0
and	0
each	0
of	0
them	0
has	0
a	0
potential	0
to	0
bind	0
to	0
the	0
consensus	1
(	2
A/T	2
)	2
GATA	2
(	2
G/	2
A	2
)	2
motif	2
.	0

However	0
,	0
using	0
ATL-16T	0
nuclear	0
extract	0
,	0
we	0
demonstrated	0
that	0
GATA-4	9
is	0
the	0
only	0
GATA-binding	9
protein	10
that	0
forms	0
specific	0
DNA-protein	9
complex	10
with	0
the	0
-70	1
GATA	2
site	2
.	0

The	0
electrophoretic	0
mobility	0
shift	0
assay	0
with	0
extracts	0
of	0
COS	5
cells	6
expressing	0
GATA-binding	9
proteins	10
showed	0
that	0
GATA-4	9
has	0
the	0
highest	0
binding	0
affinity	0
to	0
the	0
-70	1
GATA	2
site	2
among	0
the	0
three	0
GATA-binding	9
proteins	10
.	0

When	0
the	0
transactivation	0
ability	0
was	0
compared	0
among	0
the	0
three	0
,	0
GATA-4	9
showed	0
the	0
highest	0
activity	0
.	0

These	0
results	0
demonstrate	0
the	0
selective	0
role	0
of	0
GATA-4	9
in	0
the	0
transcriptional	0
regulation	0
of	0
the	0
IL-5	1
gene	2
in	0
a	0
circumstance	0
where	0
multiple	0
members	0
of	0
the	0
GATA-binding	9
proteins	10
are	0
expressed	0
.	0

Control	0
of	0
NFATx1	9
nuclear	0
translocation	0
by	0
a	0
calcineurin-regulated	9
inhibitory	10
domain	10
.	0

The	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
regulates	0
cytokine	1
gene	2
expression	0
in	0
T	7
cells	8
through	0
cis-acting	1
elements	2
located	0
in	0
the	0
promoters	1
of	0
several	0
cytokine	1
genes	2
.	0

NFATx1	9
,	0
which	0
is	0
preferentially	0
expressed	0
in	0
the	0
thymus	0
and	0
peripheral	7
blood	8
leukocytes	8
,	0
is	0
one	0
of	0
four	0
members	0
of	0
the	0
NFAT	9
family	10
of	0
transcription	9
factors	10
.	0

We	0
have	0
performed	0
domain	0
analysis	0
of	0
NFATx1	9
by	0
examining	0
the	0
effects	0
of	0
deletion	0
mutations	0
.	0

We	0
found	0
that	0
NFATx1	9
DNA	0
binding	0
activity	0
and	0
interaction	0
with	0
AP-1	0
polypeptides	0
were	0
dependent	0
on	0
its	0
central	9
Rel	10
similarity	10
region	10
and	0
that	0
transcriptional	0
activation	0
was	0
reduced	0
by	0
deletions	0
of	0
either	0
its	0
N-terminal	9
domain	10
or	0
its	0
C-terminal	9
domain	10
,	0
suggesting	0
the	0
presence	0
of	0
intrinsic	9
transcriptional	10
activation	10
motifs	10
in	0
both	0
regions	0
.	0

We	0
also	0
identified	0
a	0
potent	0
inhibitory	9
sequence	10
within	0
its	0
N-terminal	9
domain	10
.	0

We	0
show	0
that	0
the	0
inactivation	0
of	0
the	0
inhibition	0
was	0
dependent	0
on	0
the	0
activity	0
of	0
calcineurin	9
,	0
a	0
calcium-calmodulin-dependent	9
phosphatase	10
.	0

We	0
also	0
show	0
that	0
calcineurin	9
associated	0
with	0
the	0
N-terminal	9
domain	10
of	0
NFATx1	9
at	0
multiple	9
docking	10
sites	10
and	0
caused	0
a	0
reduction	0
of	0
size	0
,	0
indicative	0
of	0
dephosphorylation	0
,	0
in	0
NFATx1	9
.	0

We	0
have	0
mapped	0
the	0
inhibitory	0
activity	0
to	0
less	0
than	0
60	9
residues	10
,	0
containing	0
motifs	0
that	0
are	0
conserved	0
in	0
all	0
NFAT	9
proteins	10
.	0

Finally	0
,	0
we	0
demonstrate	0
that	0
deletion	0
in	0
NFATx1	9
of	0
the	0
mapped	0
60	9
residues	10
leads	0
to	0
its	0
nuclear	0
translocation	0
independent	0
of	0
calcium	0
signaling	0
.	0

Our	0
results	0
support	0
the	0
model	0
proposing	0
that	0
the	0
N-terminal	9
domain	10
confers	0
calcium-signaling	0
dependence	0
on	0
NFATx1	9
transactivation	0
activity	0
by	0
regulating	0
its	0
intracellular	0
localization	0
through	0
a	0
protein	0
module	0
that	0
associates	0
with	0
calcineurin	9
and	0
is	0
a	0
target	0
of	0
its	0
phosphatase	9
activity	0
.	0

Neuronal	9
(	10
type	10
I	10
)	10
nitric	10
oxide	10
synthase	10
regulates	0
nuclear	9
factor	10
kappaB	10
activity	0
and	0
immunologic	9
(	10
type	10
II	10
)	10
nitric	10
oxide	10
synthase	10
expression	0
.	0

Nitric	0
oxide	0
subserves	0
diverse	0
physiologic	0
roles	0
in	0
the	0
nervous	0
system	0
.	0

NO	0
is	0
produced	0
from	0
at	0
least	0
three	0
different	0
NO	9
synthase	10
(	10
NOS	10
)	10
isoforms	10
:	0
neuronal	9
NOS	10
(	0
nNOS	9
)	0
,	0
endothelial	9
NOS	10
,	0
and	0
immunologic	9
NOS	10
(	0
iNOS	9
)	0
.	0

We	0
show	0
that	0
nNOS	9
is	0
the	0
predominant	0
isoform	0
constitutively	0
expressed	0
in	0
glia	7
.	0

NO	0
derived	0
from	0
nNOS	9
in	0
glia	7
inhibits	0
the	0
transcription	9
factor	10
nuclear	9
factor	10
kappaB	10
(	0
NF	9
kappaB	10
)	0
as	0
NOS	0
inhibitors	0
enhance	0
basal	0
NF	9
kappaB	10
activation	0
.	0

Pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
is	0
an	0
inhibitor	0
of	0
NF	9
kappaB	10
in	0
most	0
cells	0
;	0
however	0
,	0
we	0
show	0
that	0
PDTC	0
is	0
also	0
a	0
potent	0
scavenger	0
of	0
NO	0
through	0
formation	0
of	0
mononitrosyl	0
iron	0
complexes	0
with	0
PDTC	0
.	0

In	0
Jurkat	5
cells	6
,	0
a	0
human	0
T-cell	5
lymphoma	6
cell	6
line	6
,	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
induces	0
NF	9
kappaB	10
activation	0
that	0
is	0
inhibited	0
by	0
PDTC	0
.	0

Contrary	0
to	0
the	0
results	0
in	0
Jurkat	5
cells	6
,	0
PDTC	0
did	0
not	0
inhibit	0
tumor	9
necrosis	10
factor-alpha	10
-induced	0
NF	9
kappaB	10
activation	0
in	0
astrocytes	7
;	0
instead	0
PDTC	0
itself	0
induces	0
NF	9
kappaB	10
activation	0
in	0
astrocytes	7
,	0
and	0
this	0
may	0
be	0
related	0
to	0
scavenging	0
of	0
endogenously	0
produced	0
NO	0
by	0
the	0
PDTC	0
iron	0
complex	0
.	0

In	0
astrocytes	7
PDTC	0
also	0
dramatically	0
induces	0
the	0
NF	9
kappaB-dependent	10
enzyme	10
,	0
iNOS	9
,	0
supporting	0
the	0
physiologic	0
relevance	0
of	0
endogenous	0
NO	0
regulation	0
of	0
NF	9
kappaB	10
.	0

NF	9
kappaB	10
activation	0
in	0
glia	7
from	0
mice	0
lacking	0
nNOS	9
responds	0
more	0
rapidly	0
to	0
PDTC	0
compared	0
with	0
astrocytes	7
from	0
wild-type	0
mice	0
.	0

Our	0
data	0
suggest	0
that	0
nNOS	9
in	0
astrocytes	7
regulates	0
NF	9
kappaB	10
activity	0
and	0
iNOS	9
expression	0
,	0
and	0
indicate	0
a	0
novel	0
regulatory	0
role	0
for	0
nNOS	9
in	0
tonically	0
suppressing	0
central	0
nervous	0
system	0
,	0
NF	1
kappaB-regulated	2
genes	2
.	0

Involvement	0
of	0
Stat3	9
in	0
interleukin-6	9
-induced	0
IgM	9
production	0
in	0
a	0
human	5
B-cell	6
line	6
.	0

Interleukin-6	9
(	0
IL-6	9
)	0
is	0
an	0
important	0
B-cell	9
growth	10
and	10
differentiation	10
factor	10
.	0

IL-6	9
treatment	0
of	0
the	0
human	5
lymphoblastoid	6
cell	6
line	6
,	0
SKW6.4	5
,	0
leads	0
to	0
increased	0
IgM	9
production	0
.	0

We	0
have	0
previously	0
shown	0
that	0
IL-6	9
induces	0
activation	0
of	0
JAK1	9
and	0
JAK2	9
in	0
human	5
B	6
cell	6
lines	6
.	0

A	0
chimeric	0
IL-6	9
receptor	10
,	0
comprised	0
of	0
the	0
intracellular	9
tail	10
of	0
the	0
IL-6	9
receptor	10
subunit	10
gp130	9
fused	0
to	0
the	0
extracellular	9
domain	10
of	0
the	0
epidermal	9
growth	10
factor	10
(	10
EGF	10
)	10
receptor	10
,	0
was	0
stably	0
transfected	0
into	0
SKW6.4	5
cells	6
.	0

EGF	0
treatment	0
induced	0
IgM	9
production	0
in	0
cells	0
transfected	0
with	0
an	0
intact	0
gp130	9
cytoplasmic	10
tail	10
,	0
but	0
not	0
in	0
untransfected	5
cells	6
or	0
cells	0
transfected	0
with	0
a	0
cytoplasmic	9
tail	10
lacking	0
all	0
four	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	10
Stat	10
)	10
binding	10
sites	10
.	0

Moreover	0
,	0
EGF	0
treatment	0
induced	0
Stat3	9
phosphorylation	0
in	0
cells	0
transfected	0
with	0
the	0
intact	0
chimeric	9
EGF-gp130	10
receptor	10
along	0
with	0
induction	0
of	0
DNA-mobility	0
shift	0
of	0
a	0
classical	1
interferon-gamma-activated	2
site	2
.	0

To	0
define	0
further	0
the	0
relation	0
between	0
Stat3	9
activation	0
and	0
enhanced	0
IgM	9
production	0
,	0
we	0
determined	0
the	0
effect	0
of	0
chimeric	0
gp130	0
on	0
the	0
transcriptional	0
activation	0
of	0
a	0
genetic	0
element	0
linked	0
to	0
immunoglobulin	9
production	0
,	0
namely	0
the	0
immunoglobulin	1
heavy	2
chain	2
enhancer	2
(	0
IgH-enhancer	1
)	0
.	0

Parental	0
as	0
well	0
as	0
transfected	0
SKW6.4	5
cells	6
were	0
transiently	0
transfected	0
with	0
an	0
IgH-enhancer-luciferase	1
construct	2
.	0

The	0
transcriptional	0
activity	0
of	0
the	0
IgH-luciferase	1
construct	2
was	0
induced	0
upon	0
ligation	0
of	0
the	0
full-length	9
chimeric	10
receptor	10
but	0
not	0
by	0
truncated	9
gp130	10
receptors	10
.	0

Moreover	0
,	0
the	0
gp130	9
-induced	0
activity	0
of	0
this	0
reporter	1
gene	2
was	0
abrogated	0
by	0
Stat3EE	9
,	0
a	0
mutant	0
Stat3	9
incapable	0
of	0
binding	0
DNA	0
.	0

These	0
results	0
indicate	0
that	0
IL-6	9
-induced	0
B-cell	0
differentiation	0
,	0
as	0
measured	0
by	0
IgM	9
production	0
,	0
may	0
be	0
controlled	0
by	0
Stat3	9
proteins	10
.	0

T-lymphocytes	7
from	0
individuals	0
with	0
filarial	0
inflammatory	0
disease	0
have	0
increased	0
transendothelial	0
migration	0
in	0
vitro	0
.	0

The	0
in	0
vitro	0
transendothelial	0
migration	0
of	0
circulating	7
filarial	8
antigen-specific	8
T-cells	8
was	0
examined	0
in	0
Wuchereria	0
banerofti	0
infection	0
.	0

Circulating	7
T-cells	8
from	0
individuals	0
with	0
filaria-induced	0
lymphatic	0
pathology	0
(	0
LP	0
)	0
had	0
significantly	0
greater	0
migration	0
through	0
unstimulated	0
HUVEC	7
monolayers	8
than	0
did	0
T-cells	0
from	0
asymptomatic	0
infected	0
(	0
MF	0
)	0
individuals	0
(	0
P	0
=	0
0.04	0
)	0
.	0

In	0
contrast	0
to	0
the	0
MF	0
individuals	0
where	0
no	0
effect	0
was	0
seen	0
,	0
transendothelial	0
migration	0
of	0
48-hr	0
filarial	7
antigen	8
stimulated	8
T-cells	8
from	0
LP	0
individuals	0
was	0
significantly	0
(	0
P	0
=	0
0.01	0
)	0
greater	0
than	0
migration	0
of	0
48-hr	0
media-stimulated	7
T-cells	8
.	0

In	0
six	0
of	0
seven	0
patients	0
examined	0
,	0
inhibition	0
of	0
the	0
VLA-4/	0
VCAM-1	9
pathway	0
resulted	0
in	0
greater	0
than	0
50	0
%	0
inhibition	0
of	0
transendothelial	0
migration	0
of	0
T-cells	7
.	0

Transcriptional	0
regulation	0
of	0
the	0
ferritin	1
heavy-chain	2
gene	2
:	0
the	0
activity	0
of	0
the	0
CCAAT	9
binding	10
factor	10
NF-Y	10
is	0
modulated	0
in	0
heme-treated	5
Friend	6
leukemia	6
cells	6
and	0
during	0
monocyte-to-macrophage	0
differentiation	0
.	0

The	0
ferritin	1
H-chain	2
gene	2
promoter	2
regulation	0
was	0
analyzed	0
in	0
heme-treated	5
Friend	6
leukemia	6
cells	6
(	0
FLCs	5
)	0
and	0
during	0
monocyte-to-macrophage	0
differentiation	0
.	0

In	0
the	0
majority	0
of	0
cell	5
lines	6
studied	0
,	0
the	0
regulation	0
of	0
ferritin	9
expression	0
was	0
exerted	0
mostly	0
at	0
the	0
translational	0
level	0
.	0

However	0
,	0
in	0
differentiating	7
erythroid	8
cells	8
,	0
which	0
must	0
incorporate	0
high	0
levels	0
of	0
iron	0
to	0
sustain	0
hemoglobin	9
synthesis	0
,	0
and	0
in	0
macrophages	7
,	0
which	0
are	0
involved	0
in	0
iron	0
storage	0
,	0
transcriptional	0
regulation	0
seemed	0
to	0
be	0
a	0
relevant	0
mechanism	0
.	0

We	0
show	0
here	0
that	0
the	0
minimum	0
region	0
of	0
the	0
ferritin	1
H-gene	2
promoter	2
that	0
is	0
able	0
to	0
confer	0
transcriptional	0
regulation	0
by	0
heme	0
in	0
FLCs	5
to	0
a	0
reporter	1
gene	2
is	0
77	1
nucleotides	2
upstream	2
of	0
the	0
TATA	1
box	2
.	0

This	0
cis	1
element	2
binds	0
a	0
protein	0
complex	0
referred	0
to	0
as	0
HRF	9
(	0
heme-responsive	9
factor	10
)	0
,	0
which	0
is	0
greatly	0
enhanced	0
both	0
in	0
heme-treated	0
FLCs	5
and	0
during	0
monocyte-to-macrophage	0
differentiation	0
.	0

The	0
CCAAT	1
element	2
present	0
in	0
reverse	0
orientation	0
in	0
this	0
promoter	0
region	0
of	0
the	0
ferritin	1
H-chain	2
gene	2
is	0
necessary	0
for	0
binding	0
and	0
for	0
gene	0
activity	0
,	0
since	0
a	0
single	0
point	0
mutation	0
is	0
able	0
to	0
abolish	0
the	0
binding	0
of	0
HRF	9
and	0
the	0
transcriptional	0
activity	0
in	0
transfected	5
cells	6
.	0

By	0
competition	0
experiments	0
and	0
supershift	0
assays	0
,	0
we	0
identified	0
the	0
induced	0
HRF	9
as	0
containing	0
at	0
least	0
the	0
ubiquitous	0
transcription	9
factor	10
NF-Y	9
.	0

NF-Y	9
is	0
formed	0
by	0
three	0
subunits	9
,	0
A	9
,	0
B	9
,	0
and	0
C	9
,	0
all	0
of	0
which	0
are	0
necessary	0
for	0
DNA	0
binding	0
.	0

Cotransfection	0
with	0
a	0
transdominant	9
negative	10
mutant	10
of	0
the	0
NF-YA	9
subunit	10
abolishes	0
the	0
transcriptional	0
activation	0
by	0
heme	9
,	0
indicating	0
that	0
NF-Y	9
plays	0
an	0
essential	0
role	0
in	0
this	0
activation	0
.	0

We	0
have	0
also	0
observed	0
a	0
differential	0
expression	0
of	0
the	0
NF-YA	9
subunit	10
in	0
heme-treated	0
and	0
control	0
FLCs	5
and	0
during	0
monocyte-to-macrophage	0
differentiation	0
.	0

Concomitant	0
downregulation	0
of	0
IgH	1
3	2
'	2
enhancer	2
activity	0
and	0
c-myc	1
expression	0
in	0
a	0
plasmacytoma	0
x	0
fibroblast	0
environment	0
:	0
implications	0
for	0
dysregulation	0
of	0
translocated	0
c-myc	1
.	0

Regulation	0
of	0
immunoglobulin	1
heavy	2
chain	2
(	2
IgH	2
)	2
gene	2
expression	0
is	0
controlled	0
by	0
a	0
B	1
cell-specific	2
promoter	2
,	0
intronic	1
enhancer	2
and	0
additional	0
B	1
cell-specific	2
enhancer	2
elements	2
identified	0
recently	0
in	0
the	0
3	0
'	0
end	0
of	0
the	0
IgH	1
locus	2
.	0

One	0
of	0
the	0
latter	0
elements	0
,	0
the	0
IgH	1
3	2
'	2
enhancer	2
,	0
is	0
of	0
particular	0
interest	0
:	0
(	0
1	0
)	0
it	0
is	0
B	0
cell-specific	0
and	0
active	0
only	0
in	0
late	0
B	0
cell	0
development	0
;	0
(	0
2	0
)	0
in	0
rodent	0
plasmacytomas	0
and	0
in	0
some	0
human	0
Burkitt	0
's	0
lymphomas	0
it	0
is	0
part	0
of	0
a	0
locus	1
control	2
region	2
(	0
LCR	1
)	0
that	0
is	0
involved	0
in	0
deregulation	0
of	0
the	0
c-myc	1
oncogene	2
as	0
a	0
result	0
of	0
translocation	0
into	0
the	0
IgH	1
locus	2
;	0
and	0
(	0
3	0
)	0
it	0
has	0
been	0
implicated	0
in	0
the	0
mechanisms	0
that	0
control	0
Ig	1
gene	2
class	2
switch	0
recombination	0
.	0

We	0
have	0
used	0
a	0
somatic	0
cell	0
hybridization	0
approach	0
to	0
genetically	0
analyse	0
regulation	0
of	0
the	0
activity	0
of	0
the	0
IgH	1
3	2
'	2
enhancer	2
.	0

When	0
mouse	5
MPC11	6
plasmacytoma	6
cells	6
,	0
in	0
which	0
the	0
IgH	1
3	2
'	2
enhancer	2
is	0
active	0
,	0
are	0
fused	0
with	0
fibroblasts	7
,	0
Ig	0
expression	0
is	0
extinguished	0
at	0
the	0
level	0
of	0
transcription	0
.	0

Here	0
we	0
show	0
that	0
in	0
a	0
MPC11	5
plasmacytoma	6
x	6
fibroblast	6
environment	6
,	0
the	0
IgH	1
3	2
'	2
enhancer	2
is	0
transcriptionally	0
inactive	0
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
binding	0
of	0
several	0
B	9
cell-specific	10
transcription	10
factors	10
,	0
essential	0
for	0
IgH	1
3	2
'	2
enhancer	2
activity	0
,	0
is	0
lacking	0
,	0
which	0
may	0
explain	0
3	0
'	0
enhancer	0
inactivity	0
,	0
although	0
the	0
binding	0
of	0
repressors	0
can	0
not	0
be	0
excluded	0
.	0

Moreover	0
,	0
the	0
high	0
expression	0
level	0
of	0
c-myc	1
,	0
characteristic	0
of	0
the	0
parental	0
MPC11	5
cells	6
carrying	0
the	0
t	1
(	2
12	2
;	2
15	2
)	2
translocation	2
,	0
is	0
down-regulated	0
in	0
the	0
hybrids	0
to	0
that	0
in	0
unfused	0
fibroblasts	7
.	0

Therefore	0
,	0
inactivation	0
of	0
the	0
IgH	1
3	2
'	2
enhancer	2
is	0
a	0
multifactorial	0
process	0
affecting	0
several	0
transcription	9
factors	10
that	0
control	0
the	0
cell-specific	0
and	0
developmental	0
activity	0
of	0
the	0
enhancer	1
.	0

Activation	0
of	0
the	0
NF-kappaB	9
transcription	9
factor	10
in	0
a	0
T-lymphocytic	5
cell	6
line	6
by	0
hypochlorous	0
acid	0
.	0

Reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
such	0
as	0
hydrogen	0
peroxide	0
serve	0
as	0
second	0
messengers	0
in	0
the	0
induction	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
,	0
and	0
hence	0
in	0
the	0
activation	0
and	0
replication	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
in	0
human	7
cells	8
.	0

During	0
inflammatory	0
reactions	0
,	0
many	0
oxidative	0
species	0
are	0
produced	0
,	0
one	0
of	0
which	0
is	0
hypochlorous	0
acid	0
(	0
HOCl	0
)	0
,	0
which	0
is	0
responsible	0
for	0
the	0
microbicidal	0
effects	0
of	0
activated	0
human	7
polymorphonuclear	8
leukocytes	8
.	0

Treatment	0
of	0
a	0
T-lymphocytic	5
cell	6
line	6
with	0
micromolar	0
concentrations	0
of	0
HOCl	0
promoted	0
the	0
appearance	0
of	0
transcription	9
factor	10
NF-kappaB	9
(	0
the	0
heterodimer	9
p50/p65	10
)	0
in	0
the	0
nucleus	0
of	0
the	0
cells	0
,	0
even	0
in	0
the	0
absence	0
of	0
de	0
novo	0
protein	0
synthesis	0
.	0

Western	0
blot	0
analysis	0
of	0
the	0
NF-kappaB	9
inhibitory	10
subunits	10
(	0
IkappaB	9
)	0
demonstrated	0
that	0
both	0
IkappaB	9
-alpha	0
proteolysis	0
and	0
p105	9
processing	0
were	0
induced	0
by	0
the	0
treatment	0
.	0

NF-kappaB	9
activation	0
was	0
very	0
effective	0
when	0
cells	0
were	0
subjected	0
to	0
hyperthermia	0
before	0
being	0
treated	0
with	0
HOCl	0
.	0

Various	0
antioxidants	0
,	0
such	0
as	0
pyrrolidine	0
dithiocarbamate	0
,	0
p-bromophenacyl-bromide	0
and	0
nordihydroguaiaretic	0
acid	0
could	0
strongly	0
reduce	0
NF-kappaB	9
translocation	0
,	0
demonstrating	0
the	0
importance	0
of	0
oxidative	0
species	0
in	0
the	0
transduction	0
mechanism	0
.	0

Moreover	0
,	0
ACH-2	5
cells	6
treated	0
with	0
HOCl	0
or	0
H2O2	0
released	0
tumour	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
in	0
the	0
supernatants	0
.	0

The	0
importance	0
of	0
TNF-alpha	9
release	0
in	0
NF-kappaB	9
induction	0
by	0
HOCl	0
or	0
H2O2	0
was	0
demonstrated	0
by	0
the	0
fact	0
that	0
:	0
(	0
1	0
)	0
the	0
nuclear	0
appearance	0
of	0
NF-kappaB	9
was	0
promoted	0
in	0
untreated	5
cells	6
;	0
and	0
(	0
2	0
)	0
synergism	0
between	0
TNF-alpha	9
and	0
HOCl	0
was	0
detected	0
.	0

Collectively	0
,	0
these	0
results	0
suggest	0
that	0
HOCl	0
should	0
be	0
considered	0
as	0
an	0
oxidative	0
species	0
capable	0
of	0
inducing	0
NF-kappaB	9
in	0
a	0
T-lymphocytic	5
cell	6
line	6
through	0
a	0
transduction	0
mechanism	0
involving	0
ROS	0
,	0
and	0
having	0
a	0
long-distance	0
effect	0
through	0
subsequent	0
TNF-alpha	9
release	0
.	0

Rapid	0
Ca2+-mediated	0
activation	0
of	0
Rap1	9
in	0
human	7
platelets	8
.	0

Rap1	9
is	0
a	0
small	0
,	0
Ras-like	9
GTPase	10
whose	0
function	0
and	0
regulation	0
are	0
still	0
largely	0
unknown	0
.	0

We	0
have	0
developed	0
a	0
novel	0
assay	0
to	0
monitor	0
the	0
active	0
,	0
GTP-bound	9
form	10
of	0
Rap1	9
based	0
on	0
the	0
differential	0
affinity	0
of	0
Rap1GTP	9
and	0
Rap1GDP	9
for	0
the	0
Rap	9
binding	10
domain	10
of	0
RalGDS	9
(	0
RBD	9
)	0
.	0

Stimulation	0
of	0
blood	7
platelets	8
with	0
alpha-thrombin	9
or	0
other	0
platelet	0
activators	0
caused	0
a	0
rapid	0
and	0
strong	0
induction	0
of	0
Rap1	9
that	0
associated	0
with	0
RBD	9
in	0
vitro	0
.	0

Binding	0
to	0
RBD	9
increased	0
from	0
undetectable	0
levels	0
in	0
resting	7
platelets	8
to	0
>	0
50	0
%	0
of	0
total	0
Rap1	9
within	0
30	0
s	0
after	0
stimulation	0
.	0

An	0
increase	0
in	0
the	0
intracellular	0
Ca2+	0
concentration	0
is	0
both	0
necessary	0
and	0
sufficient	0
for	0
Rap1	9
activation	0
since	0
it	0
was	0
induced	0
by	0
agents	0
that	0
increase	0
intracellular	0
Ca2+	0
and	0
inhibited	0
by	0
a	0
Ca2+-chelating	0
agent	0
.	0

Neither	0
inhibition	0
of	0
translocation	0
of	0
Rap1	9
to	0
the	0
cytoskeleton	0
nor	0
inhibition	0
of	0
platelet	0
aggregation	0
affected	0
thrombin	9
-induced	0
activation	0
of	0
Rap1	9
.	0

In	0
contrast	0
,	0
prostaglandin	0
I2	0
(	0
PGI2	0
)	0
,	0
a	0
strong	0
negative	0
regulator	0
of	0
platelet	7
function	0
,	0
inhibited	0
agonist-induced	0
as	0
well	0
as	0
Ca2+-induced	0
activation	0
of	0
Rap1	9
.	0

From	0
our	0
results	0
,	0
we	0
conclude	0
that	0
Rap1	9
activation	0
in	0
platelets	7
is	0
an	0
important	0
common	0
event	0
in	0
early	0
agonist-induced	0
signalling	0
,	0
and	0
that	0
this	0
activation	0
is	0
mediated	0
by	0
an	0
increased	0
intracellular	0
Ca2+	0
concentration	0

Physical	0
interactions	0
between	0
Ets	9
and	10
NF-kappaB/NFAT	10
proteins	10
play	0
an	0
important	0
role	0
in	0
their	0
cooperative	0
activation	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
enhancer	2
in	0
T	7
cells	8
.	0

The	0
transcriptional	1
regulatory	2
elements	2
of	0
many	0
inducible	1
T-cell	2
genes	2
contain	0
adjacent	0
or	0
overlapping	1
binding	2
sites	2
for	0
the	0
Ets	9
and	10
NF-kappaB/NFAT	10
families	10
of	0
transcription	9
factors	10
.	0

Similar	0
arrays	0
of	0
functionally	0
important	0
NF-kappaB/NFAT	1
and	2
Ets	2
binding	2
sites	2
are	0
present	0
in	0
the	0
transcriptional	1
enhancers	2
of	0
human	0
immunodeficiency	0
viruses	0
types	0
1	0
and	0
2	0
(	0
HIV-1	0
and	0
HIV-2	0
)	0
,	0
suggesting	0
that	0
this	0
pattern	0
of	0
nuclear	1
protein	2
binding	2
sites	2
reflects	0
an	0
evolutionarily	0
conserved	0
mechanism	0
for	0
regulating	0
inducible	0
T-cell	0
gene	0
expression	0
that	0
has	0
been	0
co-opted	0
during	0
HIV	0
evolution	0
.	0

Despite	0
these	0
findings	0
,	0
the	0
molecular	0
mechanisms	0
by	0
which	0
Ets	9
and	10
NF-kappaB/NFAT	10
proteins	10
cooperatively	0
regulate	0
inducible	0
T-cell	0
gene	0
expression	0
remained	0
unknown	0
.	0

In	0
the	0
studies	0
described	0
in	0
this	0
report	0
,	0
we	0
demonstrated	0
a	0
physical	0
interaction	0
between	0
multiple	0
Ets	9
and	10
NF-kappaB/NFAT	10
proteins	10
both	0
in	0
vitro	0
and	0
in	0
activated	7
normal	8
human	8
T	8
cells	8
.	0

This	0
interaction	0
is	0
mediated	0
by	0
the	0
Ets	1
domain	2
of	0
Ets	9
proteins	10
and	0
the	0
C-terminal	0
region	0
of	0
the	0
Rel	0
homology	0
domains	0
of	0
NF-kappaB/NFAT	9
proteins	10
.	0

In	0
addition	0
,	0
the	0
Ets	9
-	0
NF-kappaB	9
/	0
NFAT	9
interaction	0
requires	0
the	0
presence	0
of	0
DNA	1
binding	2
sites	2
for	0
both	0
proteins	0
,	0
as	0
it	0
is	0
abolished	0
by	0
the	0
DNA	0
intercalating	0
agents	0
propidium	0
iodide	0
and	0
ethidium	0
bromide	0
and	0
enhanced	0
by	0
the	0
presence	0
of	0
synthetic	0
oligonucleotides	0
containing	0
binding	1
sites	2
for	0
Ets	9
and	0
NF-kappaB	9
proteins	10
.	0

A	0
dominant-negative	0
mutant	0
of	0
NF-kappaB	9
p50	10
that	0
binds	0
DNA	0
but	0
fails	0
to	0
interact	0
with	0
Ets	9
proteins	10
inhibits	0
the	0
synergistic	0
activation	0
of	0
the	0
HIV-1	1
and	2
HIV-2	2
enhancers	2
by	0
NF-kappaB	9
(	0
p50	9
+	0
p65	9
)	0
and	0
Ets-1	9
,	0
suggesting	0
that	0
physical	0
interaction	0
between	0
Ets	9
and	0
NF-kappaB	9
proteins	10
is	0
required	0
for	0
the	0
transcriptional	0
activity	0
of	0
the	0
HIV-1	1
and	2
HIV-2	2
enhancers	2
.	0

Taken	0
together	0
,	0
these	0
findings	0
suggest	0
that	0
evolutionarily	0
conserved	0
physical	0
interactions	0
between	0
Ets	9
and	10
NF-kappaB/NFAT	10
proteins	10
are	0
important	0
in	0
regulating	0
the	0
inducible	0
expression	0
of	0
T-cell	1
genes	2
and	0
viruses	0
.	0

These	0
interactions	0
represent	0
a	0
potential	0
target	0
for	0
the	0
development	0
of	0
novel	0
immunosuppressive	0
and	0
antiviral	0
therapies	0
.	0

An	0
acute	1
myeloid	2
leukemia	2
gene	2
,	0
AML1	1
,	0
regulates	0
transcriptional	0
activation	0
and	0
hemopoietic	0
myeloid	0
cell	0
differentiation	0
antagonistically	0
by	0
two	0
alternative	0
spliced	0
forms	0
.	0

The	0
AML1	1
gene	2
on	0
chromosome	1
21	2
is	0
disrupted	0
in	0
the	0
(	1
8	2
;	2
21	2
)	2
(	2
q22	2
;	2
q22	2
)	2
and	2
(	2
3	2
;	2
21	2
)	2
(	2
q26	2
;	2
q22	2
)	2
translocations	2
associated	0
with	0
myelogenous	0
leukemias	0
and	0
encodes	0
a	0
DNA-binding	9
protein	10
.	0

From	0
AML1	1
gene	2
,	0
two	0
representative	0
forms	0
of	0
proteins	0
,	0
AML1a	9
and	0
AML1b	9
,	0
are	0
produced	0
by	0
an	0
alternative	0
splicing	0
.	0

Both	0
forms	0
have	0
DNA-binding	9
domain	10
,	0
but	0
AML1a	9
lacks	0
a	0
putative	0
transcriptional	0
activation	0
domain	0
which	0
AML1b	9
has	0
.	0

Here	0
we	0
demonstrate	0
that	0
AML1a	9
,	0
which	0
solely	0
has	0
no	0
effects	0
as	0
a	0
transcriptional	0
regulator	0
,	0
dominantly	0
suppresses	0
transcriptional	0
activation	0
by	0
AML1b	9
,	0
and	0
that	0
AML1a	9
exhibits	0
the	0
higher	0
affinity	0
for	0
DNA-binding	0
than	0
AML1b	9
.	0

Furthermore	0
a	0
dominant	9
negative	10
form	10
of	0
AML1	9
,	0
AML1a	9
,	0
totally	0
suppressed	0
granulocytic	0
differentiation	0
otherwise	0
induced	0
by	0
granulocyte	9
colony-stimulating	10
factor	10
when	0
AML1a	9
was	0
overexpressed	0
in	0
32Dc13	7
murine	8
myeloid	8
cells	8
.	0

Such	0
differentiation	0
block	0
by	0
AML1a	9
was	0
canceled	0
by	0
the	0
concomitant	0
overexpression	0
of	0
AML1b	9
.	0

These	0
data	0
strongly	0
suggest	0
that	0
a	0
transcriptionally	0
active	0
form	0
of	0
AML1	9
is	0
essential	0
for	0
the	0
myeloid	0
cell	0
differentiation	0
.	0

In	0
addition	0
,	0
we	0
observed	0
an	0
altered	0
expression	0
level	0
of	0
AML1	9
along	0
with	0
the	0
myeloid	0
differentiation	0
in	0
several	0
hemopoietic	5
cell	6
lines	6
.	0

In	0
these	0
cases	0
,	0
at	0
least	0
,	0
the	0
AML1	9
expression	0
level	0
is	0
a	0
potential	0
regulator	0
for	0
myeloid	0
cell	0
differentiation	0
.	0

Nuclear	9
factor-kappa	10
B	10
potently	0
up-regulates	0
the	0
promoter	0
activity	0
of	0
RANTES	9
,	0
a	0
chemokine	0
that	0
blocks	0
HIV	0
infection	0
.	0

The	0
complex	0
network	0
of	0
cytokines	9
that	0
are	0
involved	0
in	0
inflammatory	0
and	0
immunoregulatory	0
responses	0
plays	0
a	0
critical	0
role	0
in	0
the	0
pathogenesis	0
of	0
HIV	0
infection	0
.	0

RANTES	9
(	0
regulated	9
upon	10
activation	10
,	10
normal	10
T	10
cell	10
expressed	10
and	10
secreted	10
)	0
is	0
a	0
cytokine	9
that	0
belongs	0
to	0
the	0
beta-chemokine	9
family	10
;	0
it	0
is	0
chemoattractant	0
for	0
CD4+/CD45RO	7
T	8
cells	8
,	0
it	0
is	0
produced	0
by	0
various	0
cell	0
types	0
including	0
CD8+	7
and	8
CD4+	8
T	8
cells	8
as	0
well	0
as	0
monocytes/macrophages	7
,	0
and	0
has	0
recently	0
been	0
shown	0
to	0
suppress	0
replication	0
of	0
macrophage-tropic	0
strains	0
of	0
HIV	0
in	0
CD4+	7
T	8
cells	8
.	0

To	0
investigate	0
the	0
molecular	0
mechanisms	0
of	0
RANTES	9
expression	0
,	0
the	0
RANTES	1
promoter	2
region	2
was	0
analyzed	0
by	0
transient	0
expression	0
and	0
gel-mobility	0
shift	0
assays	0
.	0

We	0
demonstrate	0
that	0
:	0
1	0
)	0
RANTES	9
promoter	0
activity	0
is	0
up-regulated	0
by	0
PMA	0
plus	0
ionomycin	0
,	0
coexpression	0
of	0
the	0
p65	9
subunit	10
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
,	0
the	0
proinflammatory	9
cytokines	10
TNF-alpha	9
and	0
IL-1	9
beta	10
,	0
and	0
the	0
CD28	9
costimulatory	0
pathway	0
;	0
2	0
)	0
the	0
RANTES	1
promoter	2
region	2
contains	0
four	0
NF-kappa	1
B	2
binding	2
sites	2
at	0
positions	1
-30	2
,	2
-44	2
,	2
-213	2
,	2
and	2
-579	2
relative	0
to	0
the	0
transcription	1
start	2
site	2
;	0
3	0
)	0
one	0
site	0
(	0
-213	0
)	0
is	0
an	0
NF-AT	1
(	2
nuclear	2
factor	2
of	2
activated	2
T	2
cells	2
)	2
binding	2
site	2
that	0
also	0
has	0
weak	0
affinity	0
to	0
NF-kappa	9
B	10
,	0
and	0
the	0
most	0
distal	0
site	0
(	0
-579	0
)	0
also	0
serves	0
as	0
a	0
CD28-responsive	1
element	2
;	0
and	0
4	0
)	0
mutation	0
on	0
any	0
of	0
those	0
NF-kappa	1
B	2
sites	2
or	0
coexpression	0
of	0
I	9
kappa	10
B	10
alpha	10
(	0
cytoplasmic	9
inhibitor	10
of	10
NF-kappa	10
B	10
)	0
markedly	0
reduced	0
the	0
promoter	0
activity	0
.	0

Thus	0
,	0
NF-kappa	9
B	10
,	0
a	0
potent	0
transcriptional	0
activator	0
of	0
HIV	0
expression	0
,	0
is	0
also	0
involved	0
in	0
the	0
expression	0
of	0
RANTES	9
,	0
a	0
chemokine	9
that	0
blocks	0
infection	0
by	0
macrophage-tropic	0
strains	0
of	0
HIV	0
.	0

Pivotal	0
role	0
for	0
the	0
NFIL3/E4BP4	9
transcription	10
factor	10
in	0
interleukin	9
3	10
-mediated	0
survival	0
of	0
pro-B	7
lymphocytes	8
.	0

The	0
E2A-HLF	9
(	10
hepatic	10
leukemia	10
factor	10
)	10
oncoprotein	10
,	0
generated	0
in	0
pro-B	7
lymphocytes	8
by	0
fusion	0
of	0
the	0
trans-activation	9
domain	10
of	0
E2A	9
to	0
the	0
basic	9
region/leucine	10
zipper	10
(	10
bZIP	10
)	10
domain	10
of	0
HLF	9
,	0
functions	0
as	0
an	0
anti-apoptotic	9
transcription	10
factor	10
in	0
leukemic	0
cell	0
transformation	0
.	0

When	0
introduced	0
into	0
interleukin	9
3	10
(	0
IL-3	9
)	0
-dependent	0
mouse	0
pro-B	7
lymphocytes	8
,	0
E2A-HLF	9
prevents	0
apoptosis	0
induced	0
by	0
growth	9
factor	10
deprivation	0
,	0
suggesting	0
that	0
IL-3	9
mediates	0
cell	0
survival	0
through	0
activation	0
of	0
a	0
transcription	9
factor	10
whose	0
activity	0
can	0
be	0
constitutively	0
replaced	0
by	0
the	0
chimeric	9
oncoprotein	10
.	0

We	0
considered	0
four	0
bZIP	9
transcription	10
factors	10
as	0
candidates	0
for	0
this	0
putative	0
IL-3-regulated	9
factor	10
,	0
each	0
of	0
which	0
binds	0
avidly	0
to	0
the	0
DNA	1
consensus	2
sequence	2
recognized	0
by	0
E2A-HLF	9
and	0
is	0
related	0
to	0
the	0
Caenorhabditis	9
elegans	10
CES-2	10
(	0
cell	9
death	10
specification	10
protein	10
)	0
neuron-specific	9
mediator	10
of	10
cell	10
death	10
.	0

The	0
expression	0
and	0
binding	0
activity	0
of	0
the	0
Nfil3	9
protein	10
(	0
also	0
called	0
E4bp4	9
)	0
,	0
but	0
not	0
of	0
Hlf	9
,	0
Dbp	9
,	0
or	0
Tef	9
,	0
was	0
found	0
to	0
be	0
regulated	0
by	0
IL-3	9
in	0
mouse	5
pro-B	6
cell	6
lines	6
(	0
Baf-3	5
and	0
FL5.12	5
)	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
Nfil3/E4bp4	9
is	0
regulated	0
as	0
a	0
``	1
delayed-early	2
''	2
IL-3-responsive	2
gene	2
,	0
requiring	0
de	0
novo	0
protein	0
synthesis	0
.	0

In	0
the	0
absence	0
of	0
IL-3	9
,	0
enforced	0
expression	0
of	0
the	0
human	1
NFIL3/E4BP4	2
cDNA	2
promoted	0
the	0
survival	0
but	0
not	0
the	0
growth	0
of	0
IL-3-dependent	7
pro-B	8
cells	8
.	0

Our	0
results	0
implicate	0
NFIL3/E4BP4	9
(	0
nuclear	9
factor	10
regulated	10
by	10
IL-3/adenovirus	10
E4	10
promoter	10
binding	10
protein	10
)	0
in	0
a	0
distinct	0
growth	0
factor-regulated	0
signaling	0
pathway	0
that	0
is	0
responsible	0
for	0
the	0
survival	0
of	0
early	7
B-cell	8
progenitors	8
,	0
and	0
whose	0
alteration	0
by	0
E2A-HLF	9
leads	0
to	0
childhood	0
B	0
lineage	0
leukemia	0
.	0

Detection	0
of	0
adenovirus	0
DNA	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
by	0
polymerase	0
chain	0
reaction	0
assay	0
.	0

Adenovirus	0
can	0
establish	0
persistent	0
infections	0
which	0
may	0
reactivate	0
and	0
cause	0
disease	0
in	0
immunocompromised	0
hosts	0
.	0

Lymphocytes	7
have	0
been	0
postulated	0
to	0
serve	0
as	0
a	0
site	0
of	0
adenoviral	0
persistence	0
based	0
upon	0
the	0
ability	0
to	0
isolate	0
adenovirus	0
from	0
tonsils	0
and	0
to	0
detect	0
adenovirus	0
DNA	0
by	0
Southern	0
blot	0
hybridization	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

To	0
test	0
this	0
hypothesis	0
,	0
a	0
more	0
sensitive	0
and	0
specific	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
assay	0
was	0
developed	0
to	0
detect	0
adenovirus	0
DNA	0
.	0

Two	0
sets	0
of	0
nested	0
primers	0
were	0
designed	0
to	0
conserved	0
sequences	0
in	0
the	0
adenovirus	1
E1A	2
and	2
hexon	2
genes	2
.	0

The	0
E1A	1
and	2
hexon	2
primers	2
amplified	0
DNA	0
from	0
representative	0
adenoviral	0
serotypes	0
in	0
all	0
six	0
adenoviral	0
groups	0
(	0
A-F	0
)	0
.	0

Both	0
primers	0
detected	0
a	0
single	0
copy	0
of	0
the	0
adenovirus	1
type	2
2	2
genome	2
but	0
were	0
less	0
sensitive	0
for	0
the	0
group	0
B	0
type	0
35	0
.	0

None	0
of	0
33	0
PBMC	7
specimens	8
from	0
healthy	0
adults	0
and	0
only	0
one	0
of	0
40	0
pediatric	0
samples	0
was	0
positive	0
(	0
at	0
a	0
low	0
level	0
)	0
for	0
adenovirus	0
DNA	0
by	0
nested	0
PCR	0
assay	0
.	0

In	0
comparison	0
,	0
PBMC	7
from	0
two	0
children	0
with	0
fatal	0
adenoviral	0
infection	0
were	0
both	0
strongly	0
positive	0
for	0
adenovirus	0
DNA	0
.	0

It	0
is	0
concluded	0
that	0
,	0
in	0
contrast	0
to	0
a	0
previous	0
study	0
,	0
PBMC	7
are	0
not	0
a	0
common	0
site	0
of	0
persistent	0
group	0
C	0
adenoviral	0
infection	0
.	0

In	0
addition	0
,	0
assay	0
of	0
PBMC	7
by	0
the	0
adenovirus-specific	0
PCR	0
may	0
help	0
detect	0
early	0
invasive	0
disease	0
and	0
warrants	0
further	0
evaluation	0
.	0

Common	0
and	0
distinct	0
intracellular	0
signaling	0
pathways	0
in	0
human	7
neutrophils	8
utilized	0
by	0
platelet	9
activating	10
factor	10
and	0
FMLP	9
.	0

Stimulation	0
of	0
human	7
neutrophils	8
with	0
chemoattractants	9
FMLP	9
or	0
platelet	9
activating	10
factor	10
(	0
PAF	9
)	0
results	0
in	0
different	0
but	0
overlapping	0
functional	0
responses	0
.	0

We	0
questioned	0
whether	0
these	0
differences	0
might	0
reflect	0
patterns	0
of	0
intracellular	0
signal	0
transduction	0
.	0

Stimulation	0
with	0
either	0
PAF	9
or	0
FMLP	9
resulted	0
in	0
equivalent	0
phosphorylation	0
and	0
activation	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	10
MAPk	10
)	10
homologue	10
38-kD	9
murine	10
MAP	10
kinase	10
homologous	0
to	0
HOG-1	9
(	10
p38	10
)	10
MAPk	10
.	0

Neither	0
FMLP	9
nor	0
PAF	9
activated	0
c-jun	9
NH2-terminal	10
MAPk	10
(	0
JNKs	9
)	0
.	0

Under	0
identical	0
conditions	0
,	0
FMLP	9
but	0
not	0
PAF	9
,	0
resulted	0
in	0
significant	0
p42/44	9
(	10
ERK	10
)	10
MAPk	10
activation	0
.	0

Both	0
FMLP	9
and	0
PAF	9
activated	10
MAP	10
kinase	10
kinase-3	10
(	0
MKK3	9
)	0
,	0
a	0
known	0
activator	0
of	0
p38	9
MAPk	10
.	0

Both	0
MAP	9
ERK	10
kinase	10
kinase-1	10
(	0
MEKK1	9
)	0
and	0
Raf	9
are	0
activated	0
strongly	0
by	0
FMLP	9
,	0
but	0
minimally	0
by	0
PAF	9
.	0

Pertussis	9
toxin	10
blocked	0
FMLP	9
-induced	0
activation	0
of	0
the	0
p42/44	9
(	10
ERK	10
)	10
MAPk	10
cascade	0
,	0
but	0
not	0
that	0
of	0
p38	9
MAPk	10
.	0

A	0
specific	0
p38	9
MAPk	10
inhibitor	0
(	0
SK	0
&	0
F	0
86002	0
)	0
blocked	0
superoxide	0
anion	0
production	0
in	0
response	0
to	0
FMLP	9
and	0
reduced	0
adhesion	0
and	0
chemotaxis	0
in	0
response	0
to	0
PAF	9
or	0
FMLP	9
.	0

These	0
results	0
demonstrate	0
distinct	0
patterns	0
of	0
intracellular	0
signaling	0
for	0
two	0
chemoattractants	9
and	0
suggest	0
that	0
selective	0
activation	0
of	0
intracellular	0
signaling	0
cascades	0
may	0
underlie	0
different	0
patterns	0
of	0
functional	0
responses	0
.	0

Cloning	0
of	0
the	0
novel	9
human	10
myeloid-cell-specific	10
C/EBP-epsilon	10
transcription	10
factor	10
.	0

Chicken	9
NF-M	10
transcription	10
factor	10
,	0
in	0
cooperation	0
with	0
either	0
c-Myb	9
or	0
v-Myb	9
,	0
is	0
active	0
in	0
the	0
combinatorial	0
activation	0
of	0
myeloid-cell-specific	1
genes	2
in	0
heterologous	7
cell	8
types	8
,	0
such	0
as	0
embryonic	7
fibroblasts	8
.	0

In	0
humans	0
,	0
similar	0
effects	0
were	0
observed	0
with	0
homologous	0
members	0
of	0
the	0
CCAAT/enhancer-binding	9
protein	10
(	10
C/EBP	10
)	10
family	10
of	0
transcriptional	9
regulators	10
,	0
especially	0
the	0
human	0
homolog	0
of	0
chicken	9
NF-M	10
,	0
C/EBP-beta	9
(	0
NF-IL6	9
)	0
.	0

However	0
,	0
the	0
NF-IL6	1
gene	2
is	0
expressed	0
in	0
a	0
variety	0
of	0
nonmyeloid	0
cell	0
types	0
and	0
is	0
strongly	0
inducible	0
in	0
response	0
to	0
inflammatory	0
stimuli	0
,	0
making	0
it	0
an	0
unlikely	0
candidate	0
to	0
have	0
an	0
exclusive	0
role	0
as	0
a	0
combinatorial	0
differentiation	0
switch	0
during	0
myelopoiesis	0
in	0
human	7
cells	8
.	0

By	0
using	0
a	0
reverse	0
transcription-PCR-based	0
approach	0
and	0
a	0
set	0
of	0
primers	0
specific	0
for	0
the	0
DNA-binding	1
domains	2
of	0
highly	0
homologous	0
members	0
of	0
the	0
C/EBP	9
family	10
of	0
transcriptional	9
regulators	10
,	0
we	0
have	0
cloned	0
a	0
novel	1
human	2
gene	2
encoding	0
a	0
member	0
of	0
the	0
C/EBP	1
gene	2
family	2
,	0
identified	0
as	0
the	0
human	0
homolog	0
of	0
CRP1	9
,	0
C/EBP-epsilon	9
.	0

A	0
1.2-kb	1
cDNA	2
encoding	0
full-length	0
human	1
C/EBP-epsilon	2
was	0
cloned	0
from	0
a	0
promyelocyte-late	1
myeloblast-derived	2
lambda	2
gt11	2
library	2
.	0

Molecular	0
analysis	0
of	0
the	0
cDNA	0
and	0
genomic	0
clones	0
indicated	0
the	0
presence	0
of	0
two	0
exons	1
encoding	0
a	0
protein	0
with	0
an	0
apparent	0
molecular	0
mass	0
of	0
32	0
kDa	0
and	0
a	0
pI	0
of	0
9.5	0
.	0

Primer	0
extension	0
analysis	0
of	0
C/EBP-epsilon	3
mRNA	4
detected	0
a	0
single	0
major	0
transcription	1
start	2
site	2
approximately	0
200	0
bp	0
upstream	0
of	0
the	0
start	1
codon	2
.	0

The	0
putative	0
promoter	0
area	0
is	0
similar	0
to	0
those	0
of	0
several	0
other	0
myeloid-cell-specific	0
genes	0
in	0
that	0
it	0
contains	0
no	0
TATAAA	1
box	2
but	0
has	0
a	0
number	0
of	0
purine-rich	1
stretches	2
with	0
multiple	0
sites	0
for	0
the	0
factors	0
of	0
the	0
Ets	9
family	10
of	0
transcriptional	9
regulators	10
.	0

Northern	0
blot	0
analyses	0
indicated	0
a	0
highly	0
restricted	0
mRNA	0
expression	0
pattern	0
,	0
with	0
the	0
strongest	0
expression	0
occurring	0
in	0
promyelocyte	5
and	6
late-myeloblast-like	6
cell	6
lines	6
.	0

Western	0
blot	0
and	0
immunoprecipitation	0
studies	0
using	0
rabbit	9
anti-C/EBP-epsilon	10
antibodies	10
raised	0
against	0
the	0
N-terminal	9
portion	10
of	0
C/EBP-epsilon	9
(	0
amino	9
acids	10
1	10
to	10
115	10
)	0
showed	0
that	0
C/EBP-epsilon	9
is	0
a	0
32-kDa	9
nuclear	10
phosphoprotein	10
.	0

The	0
human	0
C/EBP-epsilon	9
protein	0
exhibited	0
strong	0
and	0
specific	0
binding	0
to	0
double-stranded	1
DNA	2
containing	2
consensus	2
C/EBP	2
sites	2
.	0

Cotransfection	0
of	0
the	0
C/EBP-epsilon	9
sense	0
and	0
antisense	0
expression	0
constructs	0
together	0
with	0
chloramphenicol	1
acetyltransferase	2
reporter	2
vectors	2
containing	0
myeloid-cell-specific	1
c-mim	2
and	2
human	2
myeloperoxidase	2
promoters	2
suggested	0
a	0
role	0
for	0
C/EBP-epsilon	9
transcription	9
factor	10
in	0
the	0
regulation	0
of	0
a	0
subset	0
of	0
myeloid-cell-specific	1
genes	2
.	0

Transient	0
tranfection	0
of	0
a	0
promyelocyte	5
cell	6
line	6
(	0
NB4	5
)	0
with	0
a	0
C/EBP-epsilon	1
expression	2
plasmid	2
increased	0
cell	0
growth	0
by	0
sevenfold	0
,	0
while	0
antisense	0
C/EBP-epsilon	9
caused	0
a	0
fivefold	0
decrease	0
in	0
clonal	0
growth	0
of	0
these	0
cells	0
.	0

The	0
tumour	9
associated	10
cell	10
surface	10
antigen	10
A6H	9
is	0
costimulatory	0
for	0
human	7
CD4+	8
but	8
not	8
CD8+	8
T	8
cells	8
.	0

The	0
A6H	9
monoclonal	10
antibody	10
(	0
mAb	0
)	0
recognizes	0
a	0
120	9
,	10
000-140	10
,	10
000	10
MW	10
antigen	10
that	0
is	0
expressed	0
at	0
similar	0
densities	0
on	0
85-90	0
%	0
of	0
human	0
CD4+	7
and	8
CD8+	8
T	8
cells	8
and	0
on	0
renal	0
cell	0
carcinomas	0
.	0

The	0
binding	0
of	0
the	0
A6H	9
mAb	10
induced	0
a	0
costimulatory	0
signal	0
in	0
anti-CD3	5
activated	6
T	6
cells	6
.	0

In	0
the	0
present	0
report	0
,	0
we	0
show	0
that	0
A6H	9
costimulated	0
cell	0
proliferation	0
and	0
cytokine	9
production	0
in	0
purified	0
CD4+	7
T	8
cells	8
.	0

Unexpectedly	0
,	0
the	0
CD8+	7
T-cell	8
subpopulation	8
failed	0
to	0
respond	0
.	0

CD4+	7
T	8
cells	8
costimulated	0
with	0
the	0
A6H	9
mAb	10
upregulated	0
CD80	9
,	0
CD86	9
,	0
CD71	9
,	0
interleukin-2	9
(	10
IL-2	10
)	10
R	10
alpha	10
,	0
IL-2R	9
beta	10
and	0
IL-2R	9
gamma	10
,	0
while	0
no	0
corresponding	0
up-regulation	0
of	0
these	0
cell	9
surface	10
molecules	10
was	0
seen	0
in	0
CD8+	7
T	8
cells	8
.	0

In	0
order	0
to	0
investigate	0
the	0
nature	0
of	0
the	0
A6H	9
mAb	10
costimulus	0
at	0
the	0
transcriptional	0
level	0
we	0
have	0
examined	0
induction	0
of	0
the	0
transcription	9
factors	10
OCT-1	9
,	0
AP-1	9
and	0
NF-kappa	9
B	10
which	0
are	0
known	0
to	0
be	0
transcriptional	9
regulators	10
of	0
several	0
cytokine	9
and	0
cytokine	9
receptor	0
genes	0
,	0
including	0
the	0
IL-2	1
and	2
IL-2R	2
genes	2
.	0

Co-ligation	0
of	0
the	0
A6H	9
antigen	0
and	0
the	0
CD3	9
complex	10
induced	0
expression	0
of	0
the	0
transcription	9
factor	10
AP-1	9
in	0
CD4+	7
T	8
cells	8
,	0
whereas	0
no	0
increase	0
in	0
NF-kappa	9
B	10
and	0
octamer-binding	9
(	10
Oct	10
)	10
proteins	10
was	0
seen	0
compared	0
to	0
T	7
cells	8
stimulated	0
with	0
anti-CD3	9
alone	0
.	0

Furthermore	0
,	0
no	0
induction	0
of	0
AP-1	9
was	0
seen	0
in	0
A6H	9
costimulated	0
CD8+	7
T	8
cells	8
.	0

These	0
results	0
suggests	0
that	0
both	0
proximal	0
steps	0
in	0
CD8+	0
T-cell	0
activation	0
as	0
well	0
as	0
the	0
later	0
phases	0
are	0
unresponsive	0
to	0
A6H	9
ligation	0
.	0

Molecular	0
differences	0
of	0
the	0
A6H	9
molecule	10
or	0
distinct	0
regulation	0
of	0
the	0
A6H	9
transduced	0
AP-1	9
activation	0
pathway	0
may	0
exist	0
in	0
CD4+	7
and	8
CD8+	8
T	8
cell	8
subpopulations	8
.	0

Cloning	0
and	0
expression	0
of	0
the	0
glucocorticoid	9
receptor	10
from	0
the	0
squirrel	0
monkey	0
(	0
Saimiri	0
boliviensis	0
boliviensis	0
)	0
,	0
a	0
glucocorticoid-resistant	0
primate	0
.	0

New	0
World	0
primates	0
such	0
as	0
the	0
squirrel	0
monkey	0
have	0
elevated	0
cortisol	0
levels	0
and	0
glucocorticoid	0
resistance	0
.	0

We	0
have	0
shown	0
that	0
the	0
apparent	0
binding	0
affinity	0
of	0
the	0
glucocorticoid	9
receptor	10
in	0
squirrel	7
monkey	8
lymphocytes	8
is	0
5-fold	0
lower	0
than	0
that	0
in	0
human	7
lymphocytes	8
(	0
apparent	0
Kd	0
,	0
20.9	0
+/-	0
1.8	0
and	0
4.3	0
+/-	0
0.2	0
nmol/L	0
,	0
respectively	0
;	0
n	0
=	0
3	0
)	0
,	0
consistent	0
with	0
previous	0
studies	0
in	0
mononuclear	7
leukocytes	8
isolated	0
from	0
the	0
two	0
species	0
.	0

As	0
a	0
first	0
step	0
in	0
understanding	0
the	0
mechanism	0
of	0
decreased	0
binding	0
affinity	0
in	0
New	0
World	0
primates	0
,	0
we	0
used	0
reverse	0
transcription-PCR	0
to	0
clone	0
the	0
glucocorticoid	9
receptor	10
from	0
squirrel	0
monkey	0
liver	0
and	0
have	0
compared	0
the	0
sequence	0
to	0
receptor	0
sequences	0
obtained	0
from	0
owl	0
monkey	0
liver	0
,	0
cotton-top	5
tamarin	6
B95-8	6
cells	6
,	0
and	0
human	7
lymphocytes	8
.	0

The	0
squirrel	0
monkey	0
glucocorticoid	9
receptor	10
is	0
approximately	0
97	0
%	0
identical	0
in	0
nucleotide	0
and	0
amino	0
acid	0
sequence	0
to	0
the	0
human	9
receptor	10
.	0

The	0
ligand-binding	9
domain	10
(	0
amino	9
acids	10
528-777	10
)	0
of	0
the	0
squirrel	0
monkey	0
glucocorticoid	9
receptor	10
contains	0
four	0
amino	0
acid	0
differences	0
(	0
Ser551	0
to	0
Thr	0
,	0
Ser616	0
to	0
Ala	0
,	0
Ala618	0
to	0
Ser	0
,	0
and	0
Ile761	0
to	0
Leu	0
)	0
,	0
all	0
of	0
which	0
are	0
present	0
in	0
owl	9
monkey	10
and	10
cotton-top	10
tamarin	10
receptors	10
.	0

The	0
DNA-binding	9
domain	10
(	0
amino	9
acids	10
421-486	10
)	0
is	0
completely	0
conserved	0
among	0
human	9
,	10
squirrel	10
monkey	10
,	10
owl	10
monkey	10
,	10
and	10
cotton-top	10
tamarin	10
receptors	10
.	0

Twenty-two	0
differences	0
from	0
the	0
human	0
sequence	0
were	0
found	0
in	0
the	0
N-terminal	9
region	10
(	0
amino	9
acids	10
1-421	10
)	0
of	0
the	0
squirrel	0
monkey	0
receptor	0
.	0

None	0
of	0
the	0
substitutions	0
in	0
the	0
ligand-binding	9
domain	10
matched	0
mutations	0
known	0
to	0
influence	0
binding	0
affinity	0
in	0
other	0
species	0
.	0

To	0
determine	0
whether	0
the	0
substitutions	0
per	0
se	0
were	0
responsible	0
for	0
decreased	0
affinity	0
,	0
squirrel	0
monkey	0
and	0
human	9
glucocorticoid	10
receptors	10
were	0
expressed	0
in	0
the	0
TNT	0
Coupled	0
Reticulocyte	0
Lysate	0
System	0
.	0

Expressions	0
of	0
human	0
and	0
squirrel	0
monkey	0
glucocorticoid	9
receptors	10
and	0
a	0
squirrel	9
monkey	10
receptor	10
in	0
which	0
Phe774	0
was	0
mutated	0
to	0
Leu	0
(	0
F774L	0
)	0
were	0
similar	0
.	0

When	0
expressed	0
in	0
the	0
TNT	0
System	0
,	0
squirrel	0
monkey	0
and	0
human	9
glucocorticoid	10
receptors	10
had	0
similar	0
,	0
high	0
affinity	0
binding	0
for	0
dexamethasone	0
(	0
apparent	0
Kd	0
,	0
5.9	0
+/-	0
1.2	0
and	0
4.3	0
+/-	0
0.5	0
nmol/L	0
,	0
respectively	0
;	0
n	0
=	0
3	0
)	0
,	0
whereas	0
the	0
squirrel	9
monkey	10
F774L	10
receptor	10
had	0
lower	0
affinity	0
binding	0
(	0
apparent	0
Kd	0
,	0
20.4	0
+/-	0
2.0	0
nmol/L	0
;	0
n	0
=	0
3	0
)	0
.	0

Thus	0
,	0
substitutions	0
within	0
the	0
ligand-binding	9
domain	10
of	0
the	0
squirrel	0
monkey	0
glucocorticoid	9
receptor	10
can	0
not	0
account	0
for	0
the	0
decreased	0
binding	0
affinity	0
of	0
these	0
receptors	0
in	0
squirrel	7
monkey	8
cells	8
.	0

Rather	0
,	0
the	0
binding	0
affinity	0
is	0
probably	0
influenced	0
by	0
the	0
expression	0
of	0
cytosolic	9
factors	10
that	0
affect	0
glucocorticoid	9
receptor	10
function	0
.	0

Shared	0
gamma	9
(	10
c	10
)	10
subunit	10
within	0
the	0
human	9
interleukin-7	10
receptor	10
complex	10
.	0

A	0
molecular	0
basis	0
for	0
the	0
pathogenesis	0
of	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
.	0

Genetic	0
evidence	0
suggests	0
that	0
mutations	0
in	0
the	0
gamma	9
(	10
c	10
)	10
receptor	10
subunit	10
cause	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
(	0
X-SCID	0
)	0
.	0

The	0
gamma	9
(	10
c	10
)	10
subunit	10
can	0
be	0
employed	0
in	0
receptor	9
complexes	10
for	0
IL-2	9
,	10
-4	10
,	10
-7	10
,	10
-9	10
,	10
and	10
-15	10
,	0
and	0
the	0
multiple	0
signaling	0
defects	0
that	0
would	0
result	0
from	0
a	0
defective	0
gamma	9
(	10
c	10
)	10
chain	10
in	0
these	0
receptors	0
are	0
proposed	0
to	0
cause	0
the	0
severe	0
phenotype	0
of	0
X-SCID	0
patients	0
.	0

Interestingly	0
,	0
gene	0
disruption	0
of	0
either	0
IL-7	9
or	0
the	0
IL-7	9
receptor	10
(	10
IL-7R	10
)	10
alpha	10
subunit	10
in	0
mice	0
leads	0
to	0
immunological	0
defects	0
that	0
are	0
similar	0
to	0
human	0
X-SCID	0
.	0

These	0
observations	0
suggest	0
the	0
functional	0
importance	0
of	0
gamma	9
(	10
c	10
)	10
in	0
the	0
IL-7R	9
complex	10
.	0

In	0
the	0
present	0
study	0
,	0
structure/function	0
analyses	0
of	0
the	0
IL-7R	9
complex	10
using	0
a	0
chimeric	9
receptor	10
system	0
demonstrated	0
that	0
gamma	9
(	10
c	10
)	10
is	0
indeed	0
critical	0
for	0
IL-7R	9
function	0
.	0

Nonetheless	0
,	0
only	0
a	0
limited	0
portion	0
of	0
the	0
cytoplasmic	9
domain	10
of	0
gamma	9
(	10
c	10
)	10
is	0
necessary	0
for	0
IL-7R	9
signal	0
transduction	0
.	0

Furthermore	0
,	0
replacement	0
of	0
the	0
gamma	9
(	10
c	10
)	10
cytoplasmic	9
domain	10
by	0
a	0
severely	9
truncated	10
erythropoeitin	10
receptor	10
does	0
not	0
affect	0
measured	0
IL-7R	9
signaling	0
events	0
.	0

These	0
findings	0
support	0
a	0
model	0
in	0
which	0
gamma	9
(	10
c	10
)	10
serves	0
primarily	0
to	0
activate	0
signal	0
transduction	0
by	0
the	0
IL-7R	9
complex	10
,	0
while	0
IL-7R	9
alpha	10
determines	0
specific	0
signaling	0
events	0
through	0
its	0
association	0
with	0
cytoplasmic	9
signaling	10
molecules	10
.	0

Finally	0
,	0
these	0
studies	0
are	0
consistent	0
with	0
the	0
hypothesis	0
that	0
the	0
molecular	0
pathogenesis	0
of	0
X-SCID	0
is	0
due	0
primarily	0
to	0
gamma	9
(	10
c	10
)	10
-mediated	0
defects	0
in	0
the	0
IL-7	9
/IL-7R	9
system	0

S-allyl	0
cysteine	0
inhibits	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
in	0
human	7
T	8
cells	8
.	0

Reactive	0
oxygen	0
species	0
are	0
involved	0
in	0
signal	0
transduction	0
pathways	0
leading	0
to	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
which	0
has	0
been	0
implicated	0
in	0
the	0
regulation	0
of	0
gene	0
transcription	0
.	0

We	0
recently	0
reported	0
that	0
a	0
garlic	0
compound	0
,	0
S-allyl	0
cysteine	0
(	0
SAC	0
)	0
,	0
protects	0
bovine	7
pulmonary	8
artery	8
endothelial	8
cells	8
from	0
oxidant	0
injury	0
induced	0
by	0
hydrogen	0
peroxide	0
(	0
H2O2	0
)	0
.	0

In	0
this	0
study	0
we	0
determined	0
the	0
effects	0
of	0
SAC	0
on	0
NF-kappa	9
B	10
activation	0
in	0
human	7
T	8
lymphocytes	8
(	0
Jurkat	5
cells	6
)	0
induced	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-	9
alpha	10
)	0
and	0
H2O2	0
.	0

Activated	0
NF-kappa	9
B	10
in	0
nuclear	0
extracts	0
was	0
measured	0
by	0
an	0
electrophoretic	0
mobility	0
shift	0
assay	0
using	0
32P-labeled	1
probe	2
.	0

SAC	0
consistently	0
exhibited	0
a	0
dose-dependent	0
inhibition	0
of	0
NF-kappa	9
B	10
activation	0
induced	0
by	0
both	0
TNF-alpha	9
and	0
H2O2	0
.	0

Supershift	0
with	0
specific	0
antibodies	0
to	0
NF-kappa	9
B	10
subunits	10
confirmed	0
that	0
the	0
inducible	0
retarded	0
bands	0
observed	0
in	0
the	0
EMSA	0
and	0
p65-p50	9
heterodimer	10
of	0
the	0
NF-kappa	9
B/Rel	10
protein	10
.	0

Our	0
data	0
suggest	0
that	0
SAC	0
may	0
act	0
via	0
antioxidant	0
mechanisms	0
to	0
block	0
NF-kappa	9
B	10
activation	0
in	0
Jurkat	5
cells	6
.	0

Elf-2	9
,	0
a	0
rhombotin-2	9
binding	10
ets	10
transcription	10
factor	10
:	0
discovery	0
and	0
potential	0
role	0
in	0
T	0
cell	0
leukemia	0
.	0

Rhombotin-2	1
(	0
RBTN-2	1
)	0
is	0
a	0
proto-oncogene	1
only	0
in	0
the	0
context	0
of	0
T	7
lymphocytes	8
.	0

We	0
postulated	0
that	0
the	0
oncogenic	0
effect	0
of	0
RBTN-2	9
in	0
T	0
cells	0
is	0
likely	0
mediated	0
by	0
binding	9
protein	10
(	0
s	0
)	0
with	0
T	0
cell-specific	0
expression	0
.	0

By	0
screening	0
a	0
T	0
cell	0
cDNA	1
library	2
,	0
we	0
identified	0
a	0
novel	9
ets	10
transcription	10
factor	10
that	0
binds	0
RBTN-2	9
.	0

This	0
protein	0
was	0
named	0
elf-2	9
because	0
its	0
DNA-binding	9
domain	10
is	0
virtually	0
identical	0
to	0
that	0
of	0
ets	9
family	10
member	10
elf-1	9
.	0

Northern	0
analyses	0
showed	0
similar	0
levels	0
of	0
two	0
elf-2	3
transcripts	4
(	0
3.5	0
kb	0
and	0
3.8	0
kb	0
)	0
in	0
all	0
tissues	0
except	0
thymus	0
.	0

Thymocytes	7
expressed	0
four-	0
to	0
10-fold	0
greater	0
amounts	0
of	0
the	0
3.5	3
kb	4
transcript	4
than	0
other	0
tissues	0
.	0

Sequence	0
analyses	0
of	0
cDNA	1
clones	2
indicated	0
that	0
these	0
transcripts	0
encode	0
proteins	0
differing	0
only	0
at	0
their	0
amino	9
termini	10
,	0
and	0
likely	0
represent	0
alternatively	0
spliced	0
isoforms	0
.	0

These	0
isoforms	0
(	0
elf-2a	9
and	0
elf-2b	9
)	0
contain	0
identical	0
RBTN-2	9
binding	10
regions	10
and	0
DNA-binding	9
domains	10
.	0

Elf-2b	9
lacks	0
a	0
putative	9
transactivation	10
domain	10
.	0

The	0
expression	0
patterns	0
suggest	0
that	0
RBTN-2	9
normally	0
interacts	0
equally	0
with	0
elf-2a	9
and	0
elf-2b	9
.	0

In	0
contrast	0
,	0
when	0
RBTN-2	9
is	0
inappropriately	0
expressed	0
in	0
T	7
cells	8
,	0
RBTN-2	9
would	0
interact	0
predominantly	0
with	0
elf-2b	9
;	0
this	0
interaction	0
may	0
lead	0
to	0
T	0
cell	0
proliferation	0
.	0

Transcription	9
factor	10
effects	0
on	0
chromosome	0
constitution	0
of	0
cell	5
hybrids	6
.	0

When	0
immunoglobulin	5
(	6
Ig	6
)	6
-secreting	6
plasmacytomas	6
are	0
fused	0
to	0
a	0
T-cell	7
lymphoma	8
,	0
Ig	1
gene	2
expression	0
ceases	0
in	0
greater	0
than	0
95	0
%	0
of	0
the	0
resulting	0
hybrids	0
.	0

In	0
the	0
rare	0
hybrids	0
that	0
continue	0
to	0
express	0
Ig	0
,	0
all	0
other	0
tested	0
B	1
lymphocyte-specific	2
genes	2
also	0
remain	0
active	0
.	0

The	0
low	0
frequency	0
with	0
which	0
these	0
Ig-expressing	5
hybrids	6
are	0
recovered	0
,	0
along	0
with	0
the	0
fact	0
that	0
cell	0
fusions	0
can	0
lead	0
to	0
chromosome	0
loss	0
,	0
led	0
us	0
to	0
propose	0
that	0
this	0
rare	0
phenotype	0
was	0
due	0
to	0
loss	0
of	0
a	0
T-cell-derived	9
chromosome	10
encoding	10
a	10
factor	10
or	0
factors	0
with	0
gene	0
silencing	0
activity	0
.	0

To	0
identify	0
the	0
relevant	0
chromosome	0
,	0
we	0
have	0
used	0
a	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
-assisted	0
method	0
of	0
chromosome	0
mapping	0
to	0
analyze	0
both	0
Ig-silenced	5
(	6
common	6
)	6
and	6
Ig-expressing	6
(	6
rare	6
)	6
hybrids	6
.	0

Although	0
no	0
single	0
chromosome	0
was	0
found	0
to	0
correlate	0
with	0
Ig	1
gene	2
silencing	0
,	0
we	0
discovered	0
that	0
the	0
two	0
types	0
of	0
hybrids	0
had	0
undergone	0
distinct	0
patterns	0
of	0
chromosome	0
loss	0
.	0

Moreover	0
,	0
we	0
found	0
that	0
ectopic	0
expression	0
of	0
a	0
B-cell-specific	9
transcription	10
factor	10
(	0
Oct-2	9
)	0
dramatically	0
altered	0
both	0
the	0
phenotype	0
and	0
chromosome	0
constitution	0
of	0
hybrids	0
arising	0
in	0
these	0
cell	0
fusions	0
.	0

Reactivation	0
of	0
Kaposi	0
's	0
sarcoma-associated	0
herpesvirus	0
infection	0
from	0
latency	0
by	0
expression	0
of	0
the	0
ORF	9
50	10
transactivator	10
,	0
a	0
homolog	0
of	0
the	0
EBV	9
R	10
protein	10
.	0

Kaposi	0
's	0
sarcoma	0
(	0
KS	0
)	0
-associated	0
herpesvirus	0
(	0
KSHV	0
)	0
,	0
or	0
human	0
herpesvirus	0
8	0
,	0
is	0
a	0
lymphotropic	0
virus	0
strongly	0
linked	0
to	0
several	0
AIDS-related	0
neoplasms	0
.	0

The	0
primary	0
reservoir	0
of	0
infection	0
consists	0
of	0
latently	0
infected	0
B	7
lymphocytes	8
and	0
possibly	0
other	0
mononuclear	7
cells	8
.	0

Viral	0
reactivation	0
from	0
latency	0
and	0
spread	0
from	0
this	0
lymphoid	0
reservoir	0
is	0
presumably	0
required	0
for	0
development	0
of	0
nonlymphoid	0
tumors	0
like	0
KS	0
.	0

Here	0
we	0
show	0
that	0
deregulated	0
expression	0
of	0
a	0
single	0
viral	1
gene	2
,	0
ORF	1
50	2
,	0
which	0
encodes	0
a	0
transactivator	0
able	0
to	0
selectively	0
upregulate	0
delayed-early	1
viral	2
genes	2
,	0
suffices	0
to	0
disrupt	0
latency	0
and	0
induce	0
the	0
lytic	0
gene	0
cascade	0
in	0
latently	7
infected	8
B	8
cells	8
.	0

The	0
identification	0
of	0
this	0
gene	0
opens	0
the	0
way	0
to	0
studies	0
of	0
the	0
physiologic	0
mechanisms	0
controlling	0
reactvation	0
of	0
KSHV	0
from	0
latency	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
and	0
AP-1	9
are	0
insufficient	0
for	0
IL-2	1
promoter	2
activation	0
:	0
requirement	0
for	0
CD28	9
up-regulation	0
of	0
RE/AP	9
.	0

IL-2	9
gene	0
transcription	0
in	0
T	7
cells	8
requires	0
both	0
TCR	0
and	0
costimulatory	0
signals	0
.	0

IL-2	1
promoter	2
activation	0
in	0
Jurkat	5
T	6
cells	6
stimulated	0
with	0
superantigen	0
presented	0
by	0
Raji	5
B	6
cells	6
requires	0
CD28	9
activation	0
.	0

The	0
addition	0
of	0
rCTLA4Ig	0
,	0
which	0
blocks	0
CD28	9
binding	0
to	0
its	0
ligand	0
,	0
to	0
the	0
cultures	0
decreased	0
IL-2	1
promoter	2
activation	0
by	0
>	0
80	0
%	0
.	0

Interestingly	0
,	0
CTLA4Ig	0
did	0
not	0
significantly	0
inhibit	0
the	0
activation	0
of	0
either	0
NF	9
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
or	0
AP-1	1
reporters	2
.	0

Therefore	0
,	0
activation	0
of	0
NFAT	9
and	0
AP-1	9
is	0
insufficient	0
for	0
IL-2	1
promoter	2
activation	0
.	0

In	0
contrast	0
,	0
an	0
RE/AP	9
reporter	0
was	0
blocked	0
by	0
CTLA4Ig	0
by	0
>	0
90	0
%	0
.	0

Thus	0
,	0
the	0
requirement	0
for	0
CD28	9
in	0
IL-2	1
promoter	2
activation	0
appears	0
to	0
be	0
due	0
to	0
RE/AP	9
and	0
not	0
the	0
NFAT	1
or	2
AP-1	2
sites	2
.	0

In	0
addition	0
,	0
these	0
data	0
suggest	0
that	0
transcriptional	0
activation	0
of	0
RE/AP	9
is	0
not	0
mediated	0
by	0
NFAT	9
,	0
because	0
activation	0
of	0
a	0
NFAT	9
reporter	0
is	0
not	0
affected	0
by	0
the	0
addition	0
of	0
CTLA4Ig	0
.	0

The	0
control	0
of	0
lytic	0
replication	0
of	0
Epstein-Barr	0
virus	0
in	0
B	7
lymphocytes	8
(	0
Review	0
)	0
.	0

Uncontrolled	0
replication	0
of	0
a	0
virus	0
,	0
which	0
is	0
harmful	0
to	0
the	0
host	0
is	0
also	0
disadvantageous	0
to	0
the	0
virus	0
.	0

Most	0
viruses	0
can	0
not	0
compete	0
with	0
the	0
various	0
immune	0
mechanisms	0
and	0
become	0
eliminated	0
in	0
the	0
course	0
of	0
infection	0
.	0

Therefore	0
,	0
only	0
the	0
time	0
between	0
infection	0
and	0
eradication	0
remains	0
for	0
these	0
viruses	0
to	0
proliferate	0
.	0

A	0
few	0
viruses	0
,	0
like	0
the	0
Herpesviruses	0
or	0
the	0
papillomaviruses	0
,	0
however	0
,	0
have	0
developed	0
a	0
sophisticated	0
strategy	0
for	0
persisting	0
lifelong	0
,	0
usually	0
asymptomatically	0
in	0
the	0
host	0
,	0
hiding	0
from	0
the	0
immune	0
system	0
and	0
producing	0
infectious	0
progeny	0
at	0
the	0
same	0
time	0
.	0

This	0
strategy	0
depends	0
on	0
a	0
separation	0
of	0
latency	0
and	0
the	0
lytic	0
replication	0
,	0
either	0
by	0
time	0
due	0
to	0
differentiation-dependent	0
mechanisms	0
or	0
by	0
spatial	0
separation	0
as	0
the	0
result	0
of	0
different	0
host	0
cell	0
types	0
.	0

Both	0
are	0
true	0
for	0
the	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
.	0

B	7
cells	8
and	0
epithelial	7
cells	8
have	0
a	0
pivotal	0
role	0
in	0
the	0
life	0
cycle	0
of	0
the	0
virus	0
.	0

The	0
former	0
can	0
become	0
latently	0
infected	0
and	0
are	0
thought	0
to	0
be	0
the	0
virus	0
reservoir	0
in	0
vivo	0
,	0
whereas	0
the	0
latter	0
were	0
shown	0
to	0
be	0
permissive	0
for	0
lytic	0
replication	0
.	0

However	0
,	0
replication	0
of	0
EBV	0
in	0
vivo	0
is	0
controlled	0
primarily	0
by	0
host	0
immune	0
mechanisms	0
selecting	0
for	0
cells	0
that	0
are	0
not	0
permissive	0
for	0
viral	0
replication	0
as	0
the	0
result	0
of	0
a	0
particular	0
set	0
of	0
transcription	9
factors	10
.	0

These	0
factors	0
control	0
the	0
activity	0
of	0
the	0
regulatory	1
immediate-early	2
genes	2
and	0
,	0
in	0
addition	0
,	0
lytic	0
and	0
latent	0
cycle	0
regulatory	0
genes	0
negatively	0
interfere	0
with	0
each	0
other	0
and	0
thus	0
link	0
cellular	0
and	0
viral	1
gene	2
regulatory	0
mechanisms	0
.	0

Disturbance	0
of	0
both	0
the	0
immune	0
surveillance	0
as	0
well	0
as	0
viral	1
gene	2
regulation	0
may	0
result	0
in	0
EBV-associated	0
disease	0
.	0

Adaptor	0
function	0
for	0
the	0
Syk	9
kinases-interacting	10
protein	10
3BP2	9
in	0
IL-2	9
gene	0
activation	0
.	0

Syk-family	9
tyrosine	10
kinases	10
are	0
essential	0
for	0
lymphocyte	0
development	0
and	0
activation	0
.	0

Using	0
a	0
yeast	0
two-hybrid	0
screen	0
to	0
identify	0
Syk	9
kinases-interacting	10
proteins	10
(	0
SKIPs	9
)	0
,	0
we	0
isolated	0
3BP2	9
,	0
an	0
Abl	9
SH3-interacting	10
protein	10
of	0
unknown	0
function	0
.	0

3BP2	9
was	0
selectively	0
expressed	0
in	0
hematopoietic/lymphoid	0
tissues	0
and	0
bound	0
via	0
its	0
SH2	9
domain	10
activated	10
Syk-family	10
kinases	10
in	0
mammalian	7
cells	8
,	0
including	0
in	0
antigen	7
receptor-stimulated	8
T	8
cells	8
.	0

In	0
addition	0
to	0
Zap-70	9
,	0
the	0
3BP2	9
SH2	10
domain	10
associated	0
in	0
vitro	0
with	0
LAT	9
,	0
Grb2	9
,	0
PLCgamma1	9
,	0
and	0
Cbl	9
from	0
activated	0
T	0
cell	0
lysates	0
.	0

Transient	0
3BP2	9
overexpression	0
induced	0
transcriptional	0
activation	0
of	0
the	0
IL-2	1
promoter	2
and	0
its	0
NFAT	1
or	2
AP-1	2
elements	2
.	0

This	0
activity	0
was	0
dependent	0
on	0
the	0
SH2	9
and	0
pleckstrin-homology	9
domains	10
of	0
3BP2	9
,	0
and	0
required	0
functional	0
Syk	9
kinases	10
,	0
Ras	9
,	0
and	0
calcineurin	9
.	0

Thus	0
,	0
3BP2	9
is	0
an	0
important	0
adaptor	0
that	0
may	0
couple	0
activated	0
Zap-70/Syk	9
to	0
a	0
LAT-containing	9
signaling	10
complex	10
involved	0
in	0
TCR-mediated	0
gene	0
transcription	0
.	0

In	0
vitro	0
suppression	0
of	0
programmed	0
cell	0
death	0
of	0
B	7
cells	8
by	0
tissue	0
inhibitor	0
of	0
metalloproteinases-1	9
.	0

Cellular	0
pathways	0
for	0
induction	0
of	0
programmed	0
cell	0
death	0
(	0
PCD	0
)	0
have	0
been	0
identified	0
,	0
but	0
little	0
is	0
known	0
about	0
specific	0
extracellular	0
matrix	0
processes	0
that	0
may	0
affect	0
apoptosis	0
along	0
those	0
pathways	0
.	0

In	0
this	0
study	0
,	0
a	0
series	0
of	0
Burkitt	5
's	6
lymphoma	6
(	6
BL	6
)	6
cell	6
lines	6
were	0
assayed	0
for	0
their	0
expression	0
of	0
tissue	9
inhibitor	10
of	10
metalloproteinases	10
(	10
TIMP	10
)	10
-1	10
.	0

Results	0
indicate	0
that	0
TIMP-1-positive	5
BL	6
lines	6
show	0
resistance	0
to	0
cold-shock-induced	0
apoptosis	0
.	0

Furthermore	0
,	0
recombinant	0
TIMP-1	9
,	0
but	0
not	0
TIMP-2	9
or	0
a	0
synthetic	0
metalloproteinase	0
inhibitor	0
(	0
BB-94	0
)	0
,	0
confers	0
resistance	0
to	0
apoptosis	0
induced	0
by	0
both	0
CD95-dependent	0
and	0
-independent	0
(	0
cold	0
shock	0
,	0
serum	0
deprivation	0
,	0
and	0
gamma-radiation	0
)	0
pathways	0
in	0
TIMP-1-negative	5
BL	6
lines	6
.	0

TIMP-1	9
suppression	0
of	0
PCD	0
is	0
not	0
due	0
to	0
metalloproteinase	9
inhibition	0
,	0
as	0
reduction	0
and	0
alkylation	0
of	0
the	0
TIMP-1	9
did	0
not	0
abolish	0
this	0
activity	0
.	0

Retroviral	0
induction	0
of	0
TIMP-1	9
not	0
only	0
resulted	0
in	0
cell	0
survival	0
but	0
also	0
in	0
continued	0
DNA	0
synthesis	0
for	0
up	0
to	0
5	0
d	0
in	0
the	0
absence	0
of	0
serum	0
,	0
while	0
controls	0
underwent	0
apoptosis	0
.	0

This	0
resistance	0
to	0
apoptosis	0
is	0
reversed	0
by	0
anti-TIMP-1	9
antibodies	10
,	0
demonstrating	0
that	0
secreted	0
TIMP-1	9
is	0
active	0
in	0
blocking	0
apoptosis	0
.	0

Furthermore	0
,	0
TIMP-1	9
upregulation	0
induced	0
expression	0
of	0
Bcl-XL	9
but	0
not	0
Bcl-2	9
as	0
well	0
as	0
decreased	0
NF-kappaB	9
activity	0
as	0
compared	0
with	0
controls	0
.	0

These	0
results	0
demonstrate	0
that	0
TIMP-1	9
suppresses	0
apoptosis	0
in	0
B	7
cells	8
and	0
suggests	0
a	0
novel	0
activity	0
for	0
TIMP-1	9
in	0
tissue	0
homeostasis	0
.	0

Spi-1/PU.1	1
proto-oncogene	1
induces	0
opposite	0
effects	0
on	0
monocytic	0
and	0
erythroid	0
differentiation	0
of	0
K562	5
cells	6
.	0

Spi-1/PU.1	9
is	0
a	0
hematopoietic	9
transcription	10
factor	10
of	0
the	0
Ets	9
family	10
.	0

To	0
analyze	0
the	0
effects	0
of	0
ectopic	0
expression	0
of	0
spi-1	9
on	0
the	0
proliferation/differentiation	0
of	0
human	7
myeloid	8
leukemia	8
cells	8
,	0
K562	5
cells	6
were	0
stably	0
transfected	0
with	0
a	0
spi-1	1
expression	2
vector	2
.	0

The	0
transfected	5
cell	6
lines	6
expressed	0
elevated	0
levels	0
of	0
spi-1	3
mRNA	4
and	0
protein	0
and	0
high	0
Spi-1	9
-DNA	0
binding	0
activity	0
.	0

The	0
spi-1	5
transfected	6
cells	6
showed	0
reduced	0
growth	0
rates	0
and	0
reduced	0
clonogenic	0
cell	0
growth	0
.	0

When	0
the	0
erythroid	0
and	0
monocytic	0
differentiation	0
markers	0
were	0
analyzed	0
,	0
spi-1	9
overexpression	0
resulted	0
in	0
opposite	0
effects	0
:	0
erythroid	0
differentiation	0
was	0
significantly	0
inhibited	0
in	0
spi-1	5
transfectants	6
,	0
while	0
spi-1	9
overexpression	0
increased	0
the	0
monocytic	0
differentiation	0
of	0
cells	0
.	0

These	0
results	0
indicate	0
a	0
differential	0
role	0
of	0
Spi-1	1
on	0
the	0
differentiation	0
of	0
human	5
myeloid	6
leukemia	6
cells	6
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

In	0
vivo	0
function	0
of	0
an	0
interleukin	9
2	10
receptor	10
beta	10
chain	10
(	9
IL-2Rbeta	10
)	10
/IL-4Ralpha	10
cytokine	10
receptor	10
chimera	10
potentiates	0
allergic	0
airway	0
disease	0
.	0

Strength	0
of	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
signaling	0
,	0
coreceptors	9
,	0
costimulation	0
,	0
antigen-presenting	7
cell	8
type	8
,	0
and	0
cytokines	0
all	0
play	0
crucial	0
roles	0
in	0
determining	0
the	0
efficiency	0
with	0
which	0
type	7
2	8
T	8
lymphocytes	8
(	0
Th2	7
,	0
Tc2	7
)	0
develop	0
from	0
uncommitted	9
precursors	10
.	0

To	0
investigate	0
in	0
vivo	0
regulatory	0
mechanisms	0
that	0
control	0
the	0
population	0
of	0
type	7
2	8
T	8
cells	8
and	0
disease	0
susceptibility	0
,	0
we	0
have	0
created	0
lines	0
of	0
transgenic	0
mice	0
in	0
which	0
expression	0
of	0
a	0
chimeric	9
cytokine	10
receptor	10
(	0
the	0
mouse	9
interleukin	10
2	10
receptor	10
beta	10
chain	10
[	10
IL-2Rbeta	10
]	10
extracellular	10
domain	10
fused	0
to	0
the	0
cytoplasmic	9
tail	10
of	0
IL-4Ralpha	9
)	0
is	0
targeted	0
to	0
the	0
T	7
lymphoid	8
lineage	8
using	0
the	0
proximal	1
lck	2
promoter	2
.	0

This	0
chimera	0
transduced	0
IL-4	9
-specific	0
signals	0
in	0
response	0
to	0
IL-2	9
binding	0
and	0
dramatically	0
enhanced	0
type	0
2	0
responses	0
(	0
IL-4	9
,	0
IL-5	9
,	0
and	0
immunoglobulin	9
E	10
production	0
)	0
upon	0
in	0
vitro	0
TCR	9
stimulation	0
or	0
in	0
vivo	0
antigen	0
challenge	0
.	0

Thus	0
,	0
type	0
2	0
effector	0
function	0
was	0
augmented	0
by	0
IL-4	9
signals	0
transduced	0
through	0
a	0
chimeric	9
receptor	10
expressed	0
in	0
a	0
T	0
cell-specific	0
manner	0
.	0

This	0
influence	0
was	0
sufficient	0
for	0
establishment	0
of	0
antigen-induced	0
allergic	0
airway	0
hyperresponsiveness	0
on	0
a	0
disease-resistant	0
background	0

Differentiation-dependent	0
expression	0
of	0
a	0
human	9
carboxylesterase	10
in	0
monocytic	7
cells	8
and	0
transcription	9
factor	10
binding	0
to	0
the	0
promoter	1
.	0

Carboxylesterases	9
play	0
an	0
important	0
role	0
in	0
defense	0
and	0
clearance	0
mechanisms	0
of	0
the	0
monocyte/macrophage	0
system	0
.	0

During	0
the	0
differentiation	0
process	0
of	0
cells	0
from	0
the	0
monocytic	5
cell	6
line	6
THP-1	6
we	0
observed	0
a	0
transient	0
transcriptional	0
upregulation	0
of	0
a	0
human	9
carboxylesterase	10
analyzed	0
by	0
means	0
of	0
Northern	0
blots	0
.	0

In	0
PMA-treated	5
THP-1	6
cells	6
we	0
could	0
detect	0
three	0
major	0
transcription	1
initiation	2
sites	2
as	0
revealed	0
by	0
Nuclease	0
Protection	0
Assay	0
carried	0
out	0
with	0
two	0
overlapping	3
antisense	4
RNA	4
probes	4
.	0

We	0
have	0
recently	0
cloned	0
the	0
carboxylesterase	1
upstream	2
sequence	2
and	0
showed	0
its	0
basal	1
promoter	2
activity	0
in	0
CHO	5
cells	6
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
analysis	0
we	0
demonstrated	0
that	0
the	0
promoter	1
region	2
spanning	0
base	1
pairs	2
-1	2
to	2
-275	2
,	0
which	0
contains	0
several	0
putative	0
binding	0
sites	0
for	0
transcription	9
factors	10
,	0
is	0
bound	0
by	0
nuclear	9
factors	10
Sp1	9
and	0
IRBP	9
but	0
not	0
by	0
C/EBPs	9
.	0

Taken	0
together	0
these	0
data	0
indicate	0
that	0
carboxylesterase	0
gene	0
transcription	0
in	0
THP-1	5
cells	6
starts	0
at	0
multiple	0
initiation	0
sites	0
and	0
that	0
Sp1	9
and	0
IRBP	9
may	0
be	0
critical	0
factors	0
for	0
modulating	0
the	0
differentiation-dependent	0
transcription	0
of	0
this	0
human	1
carboxylesterase	2
gene	2
.	0

The	0
role	0
of	0
the	0
Ikaros	1
gene	2
in	0
lymphocyte	0
development	0
and	0
homeostasis	0
.	0

The	0
Ikaros	1
gene	2
,	0
which	0
encodes	0
a	0
family	0
of	0
hemopoietic-specific	9
zinc	10
finger	10
proteins	10
,	0
is	0
described	0
as	0
a	0
central	0
regulator	0
of	0
lymphocyte	0
differentiation	0
.	0

During	0
fetal	0
development	0
,	0
it	0
is	0
required	0
at	0
the	0
earliest	0
stage	0
of	0
T	0
cell	0
and	0
B	0
cell	0
specification	0
.	0

In	0
the	0
adult	0
,	0
however	0
,	0
lymphoid	7
lineages	8
rely	0
on	0
Ikaros	1
at	0
distinct	0
phases	0
of	0
their	0
development	0
.	0

Its	0
activity	0
is	0
essential	0
for	0
the	0
generation	0
of	0
B	7
cell	8
but	0
not	0
of	0
T	7
cell	8
precursors	8
,	0
although	0
the	0
differentiation	0
of	0
the	0
latter	0
is	0
not	0
normal	0
.	0

A	0
significant	0
increase	0
in	0
CD4	7
thymocytes	8
and	0
their	0
immediate	0
precursors	0
is	0
detected	0
,	0
and	0
because	0
these	0
cells	0
lack	0
markers	0
that	0
correlate	0
with	0
positive	0
selection	0
,	0
a	0
deregulation	0
in	0
their	0
maturation	0
process	0
is	0
suggested	0
.	0

Furthermore	0
,	0
Ikaros-null	7
thymocytes	8
hyperproliferate	0
in	0
response	0
to	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
signaling	0
;	0
within	0
days	0
after	0
their	0
appearance	0
in	0
the	0
thymus	0
,	0
clonally	0
expanding	0
populations	0
are	0
detected	0
.	0

Deregulated	0
TCR	9
-mediated	0
responses	0
and	0
the	0
fast	0
kinetics	0
of	0
tumor	0
development	0
in	0
these	0
mutant	7
thymocytes	8
implicate	0
Ikaros	0
as	0
a	0
central	1
tumor	2
suppressor	2
gene	2
for	0
the	0
T	7
cell	8
lineage	8
.	0

In	0
addition	0
,	0
lack	0
of	0
natural	7
killer	8
cells	8
and	0
selective	0
defects	0
in	0
gamma	7
delta	8
T	8
cells	8
and	0
dendritic	7
antigen-presenting	8
cells	8
point	0
to	0
Ikaros	9
as	0
an	0
essential	0
factor	0
for	0
the	0
establishment	0
of	0
early	0
branchpoints	0
of	0
the	0
T	0
cell	0
pathway	0
.	0

The	0
dominant	0
interference	0
activity	0
of	0
Ikaros	9
isoforms	10
unable	0
to	0
bind	0
DNA	0
and	0
their	0
effects	0
in	0
lymphocyte	0
development	0
suggest	0
that	0
Ikaros	9
works	0
in	0
concert	0
with	0
other	0
factors	0
.	0

The	0
role	0
of	0
Aiolos	1
,	0
a	0
lymphoid-restricted	1
and	2
structurally	2
related	2
gene	2
,	0
in	0
lymphoid	0
differentiation	0
is	0
discussed	0
.	0

A	0
model	0
is	0
proposed	0
that	0
defines	0
Ikaros	9
as	0
the	0
backbone	0
of	0
a	0
complex	9
regulatory	10
protein	10
network	10
that	0
controls	0
cell	0
fate	0
decisions	0
and	0
regulates	0
homeostasis	0
in	0
the	0
hemo-lymphoid	0
system	0
.	0

Changes	0
in	0
this	0
regulatory	0
network	0
may	0
reflect	0
differentiation	0
and	0
proliferation	0
adjustments	0
made	0
in	0
hemo-lymphoid	7
progenitors	8
and	0
precursors	7
as	0
they	0
give	0
rise	0
to	0
the	0
cells	0
of	0
our	0
immune	0
system	0
.	0

STAT1	9
pathway	0
is	0
involved	0
in	0
activation	0
of	0
caprine	0
arthritis-encephalitis	1
virus	2
long	2
terminal	2
repeat	2
in	0
monocytes	7
.	0

The	0
caprine	1
arthritis-encephalitis	2
virus	2
(	2
CAEV	2
)	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
is	0
activated	0
by	0
gamma	9
interferon	10
(	0
IFN-gamma	9
)	0
in	0
promonocytic	7
cells	8
.	0

We	0
have	0
previously	0
shown	0
that	0
a	0
70-bp	1
element	2
is	0
necessary	0
and	0
sufficient	0
for	0
the	0
response	0
of	0
the	0
CAEV	1
LTR	2
to	0
this	0
cytokine	9
.	0

At	0
the	0
5	1
'	2
end	2
,	0
this	0
70-bp	1
IFN-gamma	2
response	2
element	2
contains	0
sequence	0
similarity	0
to	0
the	0
gamma	1
activated	2
site	2
(	0
GAS	1
)	0
.	0

Here	0
we	0
demonstrate	0
that	0
the	0
putative	0
GAS	1
element	2
in	0
the	0
CAEV	1
LTR	2
binds	0
specifically	0
to	0
a	0
cellular	9
factor	10
induced	0
by	0
IFN-gamma	9
in	0
promonocytic	7
cells	8
.	0

Substitution	0
mutations	0
in	0
this	0
consensus	1
sequence	2
eliminate	0
binding	0
of	0
the	0
inducible	9
factor	10
.	0

The	0
GAS	1
element	2
from	0
the	0
70-bp	1
motif	2
is	0
sufficient	0
to	0
confer	0
responsiveness	0
to	0
IFN-gamma	9
using	0
a	0
heterologous	0
minimal	0
promoter	0
.	0

Consistent	0
with	0
the	0
binding	0
data	0
,	0
the	0
same	0
mutations	0
in	0
the	0
GAS	1
element	2
eliminate	0
responsiveness	0
to	0
IFN-gamma	9
in	0
the	0
context	0
of	0
both	0
a	0
functional	0
CAEV	1
LTR	2
and	0
a	0
heterologous	1
promoter	2
.	0

The	0
cellular	0
factor	0
that	0
binds	0
to	0
the	0
GAS	1
element	2
is	0
present	0
from	0
5	0
min	0
to	0
14	0
h	0
after	0
stimulation	0
with	0
IFN-gamma	9
.	0

Binding	0
of	0
the	0
nuclear	0
factor	0
to	0
the	0
GAS	1
element	2
in	0
the	0
CAEV	1
LTR	2
is	0
inhibited	0
by	0
antibody	0
directed	0
against	0
STAT1	9
(	0
p91/84	9
)	0
.	0

Thus	0
,	0
the	0
GAS	0
sequence	0
in	0
the	0
CAEV	1
LTR	2
is	0
essential	0
for	0
the	0
response	0
to	0
IFN-gamma	9
and	0
a	0
STAT1-like	9
factor	10
binds	0
to	0
this	0
site	0
.	0

The	0
STAT-1	0
signaling	0
pathway	0
provides	0
at	0
least	0
one	0
mechanism	0
for	0
activation	0
of	0
the	0
CAEV	1
LTR	2
by	0
IFN-gamma	9
in	0
monocytes	7
.	0

These	0
data	0
are	0
the	0
first	0
demonstration	0
of	0
a	0
role	0
for	0
a	0
STAT	9
family	10
member	10
in	0
the	0
regulation	0
of	0
a	0
viral	1
promoter	2
.	0

1	1
,	2
25-Dihydroxyvitamin	2
D3	2
receptors	2
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
patients	0
with	0
renal	0
insufficiency	0
.	0

A	0
reduced	0
expression	0
of	0
the	0
vitamin	9
D	10
receptor	10
(	0
VDR	0
)	0
in	0
parathyroid	0
glands	0
of	0
uremic	0
animals	0
and	0
humans	0
has	0
been	0
observed	0
.	0

Similar	0
results	0
have	0
been	0
obtained	0
by	0
our	0
own	0
group	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
from	0
patients	0
with	0
secondary	0
hyperparathyroidism	0
to	0
chronic	0
renal	0
failure	0
.	0

However	0
,	0
the	0
reasons	0
for	0
these	0
changes	0
are	0
not	0
clear	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
have	0
investigated	0
the	0
specific	0
uptake	0
of	0
[	0
3H	0
]	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
by	0
PBMC	7
of	0
11	0
women	0
with	0
advanced	0
chronic	0
renal	0
failure	0
(	0
A-CRF	0
)	0
,	0
6	0
women	0
with	0
mild-moderate	0
renal	0
insufficiency	0
(	0
M-CRF	0
)	0
,	0
and	0
23	0
healthy	0
women	0
.	0

The	0
mean	0
dissociation	0
constant	0
(	0
KD	0
)	0
was	0
similar	0
in	0
both	0
groups	0
of	0
patients	0
and	0
in	0
healthy	0
women	0
(	0
A-CRF	0
:	0
0.7	0
+/-	0
0.5	0
x	0
10	0
(	0
-10	0
)	0
M	0
;	0
M-CRF	0
:	0
1.1	0
+/-	0
0.9	0
x	0
10	0
(	0
-10	0
)	0
M	0
;	0
controls	0
:	0
1.0	0
+/-	0
0.6	0
x	0
10	0
(	0
-10	0
)	0
M	0
)	0
.	0

However	0
,	0
VDR	9
concentration	0
was	0
significantly	0
decreased	0
in	0
A-CRF	0
(	0
0.8	0
+/-	0
0.5	0
fmol/10	0
(	0
7	0
)	0
cells	0
vs.	0
2.3	0
+/-	0
0.9	0
fmol/10	0
(	0
7	0
)	0
cells	0
in	0
controls	0
,	0
p	0
<	0
0.001	0
)	0
,	0
whereas	0
no	0
changes	0
were	0
seen	0
in	0
M-CRF	0
(	0
1.7	0
+/-	0
0.7	0
fmol/10	0
(	0
7	0
)	0
cells	0
vs.	0
2.3	0
+/-	0
0.9	0
fmol/10	0
(	0
7	0
)	0
cells	0
in	0
controls	0
)	0
.	0

No	0
correlation	0
was	0
seen	0
between	0
VDR	9
and	0
serum	0
calcitriol	0
or	0
PTH	0
levels	0
,	0
when	0
considering	0
both	0
groups	0
of	0
patients	0
together	0
or	0
separately	0
.	0

Conversely	0
,	0
a	0
significant	0
negative	0
correlation	0
was	0
found	0
between	0
VDR	9
and	0
serum	0
creatinine	0
values	0
when	0
A-CRF	0
and	0
M-CRF	0
were	0
considered	0
altogether	0
(	0
r	0
=	0
-0.63	0
;	0
p	0
<	0
0.01	0
)	0
.	0

Treatment	0
with	0
two	0
different	0
schedules	0
of	0
oral	0
calcitriol	0
(	0
five	0
patients	0
with	0
0.5	0
microgram/day	0
for	0
1	0
month	0
and	0
four	0
patients	0
with	0
2	0
micrograms/day	0
for	0
7	0
days	0
)	0
did	0
not	0
change	0
VDR	9
concentrations	0
.	0

We	0
conclude	0
that	0
the	0
low	0
levels	0
of	0
serum	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
of	0
uremia	0
are	0
not	0
responsible	0
for	0
the	0
decrease	0
in	0
VDR	9
concentration	0
found	0
in	0
these	0
patients	0
.	0

Transcription	9
factor	10
binding	0
to	0
the	0
core	1
promoter	2
of	0
the	0
human	1
monoamine	2
oxidase	2
B	2
gene	2
in	0
the	0
cerebral	0
cortex	0
and	0
in	0
blood	7
cells	8
.	0

Many	0
studies	0
show	0
that	0
monoamine	9
oxidase	10
B	10
in	0
blood	7
cells	8
is	0
a	0
biological	0
marker	0
for	0
personality	0
characteristics	0
such	0
as	0
sensation	0
seeking	0
.	0

The	0
mechanism	0
underlying	0
this	0
association	0
is	0
so	0
far	0
not	0
explored	0
.	0

In	0
the	0
present	0
study	0
we	0
have	0
performed	0
electrophoretic	0
mobility-shift	0
assays	0
to	0
investigate	0
the	0
pattern	0
of	0
protein	0
binding	0
to	0
a	0
150	1
bp	2
fragment	2
of	0
the	0
proximal	1
5'-flanking	2
region	2
of	0
the	0
human	1
monoamine	2
oxidase	2
B	2
gene	2
.	0

We	0
compared	0
the	0
pattern	0
using	0
nuclear	0
extracts	0
from	0
human	0
brain	0
and	0
lymphocytes	7
.	0

Interestingly	0
,	0
a	0
correlation	0
was	0
observed	0
between	0
monoamine	9
oxidase	10
B	10
enzyme	0
activity	0
in	0
blood	7
cells	8
(	0
platelets	7
)	0
and	0
the	0
binding	0
pattern	0
of	0
two	0
uncharacterized	0
transcription	9
factors	10
.	0

These	0
data	0
are	0
well	0
in	0
line	0
with	0
the	0
long-standing	0
notion	0
that	0
interindividual	0
differences	0
in	0
platelet	9
monoamine	10
oxidase	10
may	0
represent	0
differences	0
in	0
expression	0
of	0
the	0
enzyme	0
rather	0
than	0
genotypic	0
variation	0
.	0

Enhanced	0
differentiation	0
of	0
HL-60	5
leukemia	6
cells	6
to	0
macrophages	7
induced	0
by	0
ciprofibrate	0
.	0

Ciprofibrate	0
,	0
an	0
hypolipidaemic	0
peroxisome	0
proliferator	0
,	0
induced	0
differentiation	0
of	0
HL-60	5
cells	6
.	0

The	0
effect	0
was	0
greatly	0
potentiated	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
at	0
a	0
concentration	0
where	0
neither	0
phorbol	0
ester	0
nor	0
ciprofibrate	0
alone	0
had	0
any	0
effect	0
on	0
these	0
cells	0
.	0

As	0
occurs	0
for	0
HL-60	0
cell	0
differentiation	0
induced	0
by	0
high	0
phorbol	0
ester	0
concentration	0
,	0
the	0
ciprofibrate-induced	0
phorbol	0
ester-dependent	0
differentiation	0
of	0
HL-60	5
cells	6
proceeded	0
through	0
the	0
monocytic/macrophage	0
pathway	0
and	0
induced	0
the	0
phosphorylation	0
of	0
proteins	0
with	0
similar	0
molecular	0
weights	0
suggesting	0
that	0
increased	0
protein	9
kinase	10
C	10
activity	0
may	0
be	0
involved	0
in	0
the	0
effect	0
.	0

The	0
peroxisome	0
proliferator-activated	0
receptor	0
(	0
PPARalpha	0
)	0
transcription	9
factor	10
is	0
expressed	0
in	0
HL-60	5
cells	6
,	0
but	0
no	0
changes	0
were	0
observed	0
in	0
its	0
expression	0
upon	0
HL-60	0
cell	0
differentiation	0
.	0

The	0
involvement	0
of	0
multiple	0
tumor	9
necrosis	10
factor	10
receptor	10
(	10
TNFR	10
)	10
-associated	10
factors	10
in	0
the	0
signaling	0
mechanisms	0
of	0
receptor	9
activator	10
of	0
NF-kappaB	9
,	0
a	0
member	0
of	0
the	0
TNFR	9
superfamily	10
.	0

Receptor	9
activator	10
of	10
NF-kappaB	10
(	0
RANK	9
)	0
is	0
a	0
recently	0
identified	0
member	0
of	0
the	0
tumor	9
necrosis	10
factor	10
receptor	10
superfamily	10
and	0
is	0
expressed	0
on	0
activated	7
T	8
cells	8
and	0
dendritic	7
cells	8
.	0

Its	0
cognate	9
ligand	10
(	0
RANKL	9
)	0
plays	0
significant	0
roles	0
in	0
the	0
activation	0
of	0
dendritic	0
cell	0
function	0
and	0
osteoclast	0
differentiation	0
.	0

We	0
demonstrate	0
here	0
the	0
interaction	0
of	0
RANK	9
with	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
factors	10
(	10
TRAFs	10
)	10
1	10
,	10
2	10
,	10
3	10
,	10
5	10
,	10
and	10
6	10
both	0
in	0
vitro	0
and	0
in	0
cells	0
.	0

Mapping	0
of	0
the	0
structural	0
requirements	0
for	0
TRAF	9
/RANK	9
interaction	0
revealed	0
multiple	0
TRAF	9
binding	10
sites	10
clustered	0
in	0
two	0
distinct	0
domains	0
in	0
the	0
RANK	9
cytoplasmic	10
tail	10
.	0

These	0
TRAF	9
binding	10
domains	10
were	0
shown	0
to	0
be	0
functionally	0
important	0
for	0
the	0
RANK	9
-dependent	0
induction	0
of	0
NF-kappaB	9
and	0
c-Jun	9
NH2-terminal	9
kinase	10
activities	0
.	0

Site-directed	0
mutagenesis	0
demonstrated	0
that	0
these	0
TRAF	9
binding	10
sites	10
exhibited	0
selective	0
binding	0
for	0
different	0
TRAF	9
proteins	10
.	0

In	0
particular	0
,	0
TRAF6	9
interacted	0
with	0
membrane-proximal	9
determinants	10
distinct	0
from	0
those	0
binding	0
TRAFs	9
1	10
,	10
2	10
,	10
3	10
,	10
and	10
5	10
.	0

When	0
this	0
membrane-proximal	9
TRAF6	10
interaction	10
domain	10
was	0
deleted	0
,	0
RANK	9
-mediated	0
NF-kappaB	9
signaling	0
was	0
completely	0
inhibited	0
while	0
c-Jun	9
NH2-terminal	10
kinase	10
activation	0
was	0
partially	0
inhibited	0
.	0

An	0
NH2-terminal	9
truncation	10
mutant	10
of	0
TRAF6	9
inhibited	0
RANKL	9
-mediated	0
NF-kappaB	9
activation	0
,	0
but	0
failed	0
to	0
affect	0
constitutive	0
signaling	0
induced	0
by	0
receptor	0
overexpression	0
,	0
revealing	0
a	0
selective	0
role	0
for	0
TRAF6	9
in	0
ligand-induced	0
activation	0
events	0
.	0

Stat6	9
inhibits	0
human	0
interleukin-4	1
promoter	2
activity	0
in	0
T	7
cells	8
.	0

The	0
differentiation	0
of	0
naive	7
T-helper	8
(	8
Th	8
)	8
cells	8
into	0
cytokine-secreting	7
effector	8
Th	8
cells	8
requires	0
exposure	0
to	0
multiple	0
signals	0
,	0
including	0
exogenous	9
cytokines	10
.	0

Interleukin-4	9
(	0
IL-4	9
)	0
plays	0
a	0
major	0
role	0
in	0
this	0
process	0
by	0
promoting	0
the	0
differentiation	0
of	0
IL-4	9
-secreting	0
Th2	0
cells	0
.	0

In	0
Th2	0
cells	0
,	0
IL-4	9
gene	0
expression	0
is	0
tightly	0
controlled	0
at	0
the	0
level	0
of	0
transcription	0
by	0
the	0
coordinated	0
binding	0
of	0
multiple	0
transcription	9
factors	10
to	0
regulatory	0
elements	0
in	0
the	0
proximal	0
promoter	1
region	2
.	0

Nuclear	9
factor	10
of	10
activated	10
T	10
cell	10
(	10
NFAT	10
)	10
family	10
members	10
play	0
a	0
critical	0
role	0
in	0
regulating	0
IL-4	9
transcription	0
and	0
interact	0
with	0
up	0
to	0
five	0
sequences	0
(	0
termed	0
P0	0
through	0
P4	0
)	0
in	0
the	0
IL-4	1
promoter	2
.	0

The	0
molecular	0
mechanisms	0
by	0
which	0
IL-4	9
induces	0
expression	0
of	0
the	0
IL-4	1
gene	2
are	0
not	0
known	0
,	0
although	0
the	0
IL-4-activated	9
transcription	10
factor	10
signal	10
transducer	10
and	10
activator	10
of	10
transcription	10
6	10
(	0
Stat6	9
)	0
is	0
required	0
for	0
this	0
effect	0
.	0

We	0
report	0
here	0
that	0
Stat6	9
interacts	0
with	0
three	0
binding	0
sites	0
in	0
the	0
human	1
IL-4	2
promoter	2
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

These	0
sites	0
overlap	0
the	0
P1	1
,	2
P2	2
,	2
and	2
P4	2
NFAT	2
elements	2
.	0

To	0
investigate	0
the	0
role	0
of	0
Stat6	9
in	0
regulating	0
IL-4	9
transcription	0
,	0
we	0
used	0
Stat6	9
-deficient	0
Jurkat	0
T	7
cells	8
with	0
different	0
intact	0
IL-4	1
promoter	2
constructs	2
in	0
cotransfection	0
assays	0
.	0

We	0
show	0
that	0
,	0
whereas	0
a	0
multimerized	1
response	2
element	2
from	0
the	0
germline	1
IgE	2
promoter	2
was	0
highly	0
induced	0
by	0
IL-4	9
in	0
Stat6-expressing	7
Jurkat	8
cells	8
,	0
the	0
intact	0
human	1
IL-4	2
promoter	2
was	0
repressed	0
under	0
similar	0
conditions	0
.	0

We	0
conclude	0
that	0
the	0
function	0
of	0
Stat6	9
is	0
highly	0
dependent	0
on	0
promoter	0
context	0
and	0
that	0
this	0
factor	0
promotes	0
IL-4	9
gene	0
expression	0
in	0
an	0
indirect	0
manner	0
.	0

Epithelial	0
cell-initiated	0
inflammation	0
plays	0
a	0
crucial	0
role	0
in	0
early	0
tissue	0
damage	0
in	0
amebic	0
infection	0
of	0
human	0
intestine	0
.	0

BACKGROUND	0
&	0
AIMS	0
:	0
Entamoeba	0
histolytica	0
infection	0
of	0
the	0
intestine	0
can	0
induce	0
severe	0
gut	0
inflammation	0
.	0

The	0
aims	0
of	0
this	0
study	0
were	0
to	0
assess	0
the	0
role	0
of	0
the	0
host	0
inflammatory	0
response	0
in	0
the	0
tissue	0
damage	0
observed	0
with	0
amebiasis	0
and	0
the	0
role	0
of	0
the	0
intestinal	7
epithelial	8
cell	8
in	0
initiating	0
that	0
response	0
.	0

METHODS	0
:	0
E.	0
histolytica	0
infection	0
was	0
established	0
in	0
human	0
intestinal	0
xenografts	0
in	0
severe	0
combined	0
immunodeficient	0
(	0
SCID-HU-INT	0
)	0
mice	0
.	0

Human	0
intestinal	7
epithelial	8
cell	8
inflammatory	0
responses	0
to	0
amebic	0
infection	0
were	0
inhibited	0
by	0
the	0
intraluminal	0
administration	0
of	0
an	0
antisense	0
oligonucleotide	0
to	0
the	0
human	9
p65	10
subunit	10
of	0
nuclear	9
factor	10
kappaB	10
,	0
and	0
the	0
role	0
of	0
neutrophils	0
in	0
tissue	0
damage	0
observed	0
with	0
amebiasis	0
was	0
studied	0
by	0
depleting	0
neutrophils	7
from	0
SCID-HU-INT	0
mice	0
.	0

RESULTS	0
:	0
Administration	0
of	0
the	0
antisense	0
oligonucleotide	0
blocked	0
the	0
production	0
of	0
human	9
interleukin	10
1beta	10
and	0
interleukin	9
8	10
by	0
intestinal	7
epithelial	8
cells	8
and	0
inhibited	0
neutrophil	0
influx	0
into	0
the	0
E.	0
histolytica-infected	0
intestinal	0
xenografts	0
.	0

Inhibition	0
of	0
the	0
gut	0
inflammatory	0
response	0
by	0
the	0
antisense	0
oligonucleotide	0
or	0
the	0
depletion	0
of	0
neutrophils	7
from	0
SCID-HU-	0
INT	0
mice	0
blocked	0
the	0
increase	0
in	0
intestinal	0
permeability	0
observed	0
with	0
amebic	0
infection	0
.	0

CONCLUSIONS	0
:	0
Intestinal	7
epithelial	8
cells	8
initiate	0
an	0
inflammatory	0
response	0
with	0
resulting	0
neutrophil-mediated	0
tissue	0
damage	0
in	0
response	0
to	0
E.	0
histolytica	0
infection	0
;	0
this	0
inflammatory	0
cascade	0
can	0
be	0
blocked	0
by	0
inhibiting	0
the	0
transcription	0
of	0
genes	0
regulated	0
by	0
nuclear	9
factor	10
kappaB	10
.	0

Triptolide	0
induces	0
apoptotic	0
death	0
of	0
T	7
lymphocyte	8
.	0

Extract	0
of	0
Tripterygium	0
wilfordii	0
Hook.	0
f	0
(	0
TWHf	0
)	0
has	0
immunosuppressive	0
activity	0
and	0
has	0
been	0
used	0
as	0
anti-inflammatory	0
agent	0
in	0
traditional	0
Chinese	0
medicine	0
for	0
centuries	0
.	0

Recent	0
studies	0
have	0
demonstrated	0
that	0
triptolide	0
is	0
the	0
major	0
active	0
component	0
in	0
the	0
extract	0
that	0
inhibits	0
antigen	0
or	0
mitogen	9
-induced	0
T	0
cell	0
proliferation	0
.	0

In	0
attempting	0
to	0
investigate	0
its	0
effect	0
on	0
activation	0
of	0
T	7
lymphocytes	8
,	0
we	0
found	0
triptolide	0
induces	0
apoptotic	0
death	0
of	0
T	5
cell	6
hybridomas	6
and	0
peripheral	7
T	8
cells	8
but	0
not	0
that	0
of	0
thymocytes	7
.	0

The	0
triptolide-induced	0
apoptosis	0
is	0
accompanied	0
by	0
increase	0
of	0
DEVD-cleavable	0
caspases	9
activity	0
and	0
degradation	0
of	0
caspase	9
substrate	10
poly	10
(	10
ADP-ribose	10
)	10
polymerase	10
(	0
PARP	9
)	0
.	0

A	0
specific	0
inhibitor	0
of	0
caspases	9
,	0
zVAD-FMK	0
,	0
prevents	0
triptolide-induced	0
PARP	9
degradation	0
and	0
DNA	0
fragmentation	0
but	0
not	0
growth	0
arrest	0
.	0

Furthermore	0
,	0
enforced	0
expression	0
of	0
Bcl-2	9
inhibited	0
triptolide-induced	0
degradation	0
of	0
PARP	9
and	0
apoptosis	0
.	0

These	0
results	0
indicate	0
that	0
triptolide	0
induces	0
T	0
cell	0
apoptosis	0
through	0
activating	0
caspases	9
,	0
and	0
suggest	0
the	0
growth	0
arrest	0
and	0
apoptotic	0
effect	0
of	0
triptolide	0
may	0
contribute	0
to	0
the	0
immunosuppressive	0
activity	0
of	0
TWHf	0
extract	0

A	0
novel	0
transcription	9
factor	10
regulates	0
expression	0
of	0
the	0
vacuolar	9
H+-ATPase	10
B2	10
subunit	10
through	0
AP-2	1
sites	2
during	0
monocytic	0
differentiation	0
.	0

During	0
monocyte-to-macrophage	0
differentiation	0
,	0
the	0
cellular	0
content	0
of	0
vacuolar	9
H+-ATPase	10
(	0
V-ATPase	9
)	0
increases	0
more	0
than	0
4-fold	0
.	0

We	0
have	0
shown	0
previously	0
that	0
amplified	0
expression	0
of	0
the	0
B2	9
subunit	10
of	0
the	0
V-ATPase	9
occurs	0
solely	0
by	0
increased	0
transcription	0
,	0
and	0
that	0
the	0
5'-untranslated	1
region	2
of	0
the	0
B2	1
gene	2
,	0
containing	0
multiple	0
consensus	1
binding	2
sites	2
for	0
the	0
transcription	9
factors	10
AP-2	9
and	0
Sp1	9
,	0
is	0
required	0
for	0
this	0
expression	0
.	0

The	0
present	0
study	0
demonstrates	0
that	0
AP-2	1
binding	2
sequences	2
are	0
essential	0
for	0
increased	0
transcription	0
from	0
the	0
B2	1
promoter	2
during	0
monocyte-macrophage	0
differentiation	0
and	0
that	0
AP-2	9
,	0
expressed	0
exogenously	0
in	0
THP-1	5
and	0
other	0
cells	0
,	0
activates	0
transcription	0
from	0
the	0
B2	1
promoter	2
.	0

In	0
mobility	0
shift	0
assays	0
,	0
a	0
nuclear	9
factor	10
from	0
THP-1	5
and	0
U-937	5
cells	6
was	0
identified	0
that	0
binds	0
to	0
several	0
AP-2	1
response	2
elements	2
within	0
the	0
B2	1
promoter	2
,	0
but	0
does	0
not	0
react	0
with	0
AP-2	9
antibodies	10
,	0
and	0
has	0
a	0
DNA	1
sequence	2
binding	0
affinity	0
profile	0
that	0
differs	0
from	0
AP-2	9
.	0

These	0
findings	0
suggest	0
that	0
a	0
novel	0
AP-2-like	9
transcription	10
factor	10
is	0
responsible	0
for	0
V-ATPase	9
B	10
subunit	10
amplification	0
during	0
monocyte	0
differentiation	0
.	0

c-Jun	0
and	0
GST-pi	0
expression	0
in	0
human	7
plasma	8
cells	8
.	0

Bone	0
marrow	0
samples	0
from	0
33	0
patients	0
affected	0
by	0
MM	0
and	0
MGUS	0
,	0
and	0
8	0
patients	0
not	0
affected	0
by	0
lymphoproliferative	0
diseases	0
were	0
studied	0
for	0
expression	0
of	0
c-Jun	9
(	0
a	0
component	0
of	0
the	0
transcription	9
factor	10
AP-1	9
)	0
and	0
glutathione-S-transferase	9
pi	10
(	0
GST-pi	9
)	0
using	0
immunocytochemical	0
methods	0
.	0

A	0
high	0
and	0
frequent	0
expression	0
of	0
these	0
two	0
proteins	0
was	0
found	0
both	0
in	0
MM	0
and	0
MGUS	0
patients	0
(	0
31/33	0
patients	0
positive	0
for	0
c-Jun	9
and	0
29/33	0
patients	0
positive	0
for	0
GST-pi	9
)	0
and	0
in	0
controls	0
not	0
affected	0
by	0
monoclonal	0
gammopathy	0
(	0
7/8	0
patients	0
positive	0
for	0
both	0
c-Jun	9
and	0
GST-pi	9
)	0
.	0

No	0
statistically	0
significant	0
correlation	0
was	0
found	0
between	0
c-Jun-	5
and	6
GST-pi-positive	6
plasma	6
cells	6
.	0

The	0
expression	0
of	0
these	0
two	0
proteins	0
was	0
not	0
related	0
to	0
clinical	0
or	0
laboratory	0
data	0
.	0

Our	0
results	0
seem	0
to	0
confirm	0
a	0
possible	0
role	0
of	0
the	0
transcriptional	9
complex	10
AP-1	9
in	0
activating	0
GST-pi	1
promoter	2
in	0
human	7
plasma	8
cells	8
.	0

Activation	0
of	0
signaling	0
pathways	0
and	0
prevention	0
of	0
apoptosis	0
by	0
cytokines	9
in	0
eosinophils	7
.	0

Inhibition	0
of	0
apoptosis	0
in	0
eosinophils	7
by	0
cytokines	9
such	0
as	0
IL-5	9
and	0
GM-CSF	9
may	0
play	0
an	0
important	0
role	0
in	0
the	0
pathogenesis	0
of	0
allergic	0
and	0
parasitic	0
disorders	0
.	0

Recently	0
,	0
there	0
has	0
been	0
some	0
progress	0
in	0
the	0
understanding	0
of	0
the	0
signal	0
transduction	0
pathways	0
activated	0
by	0
these	0
cytokines	9
in	0
eosinophils	7
.	0

The	0
IL-3	9
,	0
IL-5	9
and	0
GM-CSF	9
receptors	10
share	0
a	0
common	9
signal	10
transducer	10
that	0
possesses	0
no	0
intrinsic	9
kinase	10
domain	10
.	0

It	0
has	0
been	0
shown	0
that	0
eosinophil	0
stimulation	0
by	0
these	0
cytokines	9
is	0
associated	0
with	0
increases	0
in	0
tyrosine	0
phosphorylation	0
of	0
several	0
cellular	0
substrates	0
.	0

In	0
the	0
past	0
few	0
years	0
,	0
there	0
has	0
been	0
some	0
progress	0
in	0
defining	0
the	0
tyrosine	0
kinases	0
that	0
are	0
activated	0
by	0
the	0
IL-3/IL-5/GM-CSF	9
receptor	10
beta-subunit	10
in	0
eosinophils	7
.	0

This	0
review	0
will	0
concentrate	0
on	0
this	0
topic	0
and	0
on	0
its	0
role	0
for	0
the	0
regulation	0
of	0
eosinophil	0
apoptosis	0
.	0

Requirement	0
of	0
GATA-1	9
and	0
p45	9
NF-E2	10
expression	0
in	0
butyric	0
acid-induced	0
erythroid	0
differentiation	0
.	0

Butyric	0
acid	0
(	0
BA	0
)	0
is	0
known	0
to	0
induce	0
overexpression	0
of	0
fetal	9
hemoglobin	10
and	0
then	0
erythroid	0
differentiation	0
.	0

Therefore	0
,	0
BA	0
is	0
currently	0
under	0
clinical	0
investigation	0
as	0
a	0
potential	0
therapy	0
for	0
the	0
treatment	0
of	0
sickle	0
cell	0
disease	0
and	0
cancer	0
.	0

Nevertheless	0
,	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
BA-induced	0
differentiation	0
remain	0
largely	0
unknown	0
.	0

Previous	0
reports	0
have	0
shown	0
that	0
BA-induced	0
overexpression	0
of	0
erythroid	1
genes	2
occurred	0
at	0
the	0
transcriptional	0
level	0
,	0
suggesting	0
the	0
involvement	0
of	0
erythroid	9
transcription	10
factors	10
.	0

Here	0
,	0
we	0
intend	0
to	0
demonstrate	0
the	0
requirement	0
of	0
GATA-1	9
and	0
NF-E2	9
transcription	9
factors	10
in	0
the	0
BA-induced	0
erythroid	0
differentiation	0
of	0
human	5
leukemic	6
K562	6
cells	6
.	0

Time-course	0
experiments	0
showed	0
that	0
nuclear	0
levels	0
of	0
GATA-1	9
and	0
p45	9
NF-E2	10
proteins	0
increased	0
during	0
BA	0
treatment	0
.	0

Moreover	0
,	0
antisense	0
oligodeoxynucleotides	0
targeting	0
either	0
GATA-1	9
or	0
p45	9
NF-E2	10
proteins	0
inhibited	0
both	0
protein	0
expression	0
and	0
BA-induced	0
differentiation	0
.	0

In	0
contrast	0
,	0
BA-induced	0
cell	0
growth	0
inhibition	0
was	0
not	0
affected	0
.	0

These	0
results	0
provide	0
the	0
first	0
direct	0
evidence	0
for	0
the	0
requirement	0
of	0
GATA-1	9
and	0
NF-E2	9
in	0
BA-induced	0
differentiation	0
process	0
.	0

Characterisation	0
of	0
regulatory	0
sequences	0
at	0
the	0
Epstein-Barr	1
virus	2
BamHI	2
W	2
promoter	2
.	0

Epstein-Barr	0
virus	0
,	0
a	0
human	0
gammaherpesvirus	0
,	0
possesses	0
a	0
unique	0
set	0
of	0
latent	1
genes	2
whose	0
constitutive	0
expression	0
in	0
B	7
cells	8
leads	0
to	0
cell	0
growth	0
transformation	0
.	0

The	0
initiation	0
of	0
this	0
growth	0
transforming	0
infection	0
depends	0
on	0
a	0
viral	1
promoter	2
in	0
BamHI	0
W	0
(	0
Wp	0
)	0
whose	0
regulation	0
is	0
poorly	0
understood	0
.	0

Using	0
Wp	1
reporter	2
constructs	2
in	0
in	0
vitro	0
transfection	0
assays	0
,	0
we	0
found	0
that	0
Wp	0
was	0
11-	0
to	0
190-fold	0
more	0
active	0
in	0
B	5
cell	6
than	0
in	0
non-B	5
cell	6
lines	6
and	0
that	0
three	0
regions	0
of	0
the	0
promoter	1
(	0
termed	0
UAS1	1
,	0
UAS2	1
,	0
and	0
UAS3	1
)	0
contributed	0
to	0
transcriptional	0
activation	0
.	0

The	0
upstream	0
regions	0
UAS3	1
(	0
-1168	1
to	2
-440	2
)	0
and	0
UAS2	1
(	0
-352	1
to	2
-264	2
)	0
both	0
functioned	0
in	0
a	0
cell	0
lineage-independent	0
manner	0
and	0
were	0
together	0
responsible	0
for	0
the	0
bulk	0
of	0
Wp	0
activity	0
in	0
non-B	7
cells	8
;	0
mutational	0
analysis	0
indicated	0
the	0
importance	0
of	0
a	0
YY1	1
binding	2
site	2
in	0
UAS2	1
in	0
that	0
context	0
.	0

By	0
contrast	0
,	0
UAS1	1
(	0
-140	1
to	2
-87	2
)	0
was	0
B	0
cell	0
specific	0
and	0
was	0
the	0
key	0
determinant	0
of	0
the	0
promoter	0
's	0
increased	0
activity	0
in	0
B	5
cell	6
lines	6
.	0

Mutational	0
analysis	0
of	0
UAS1	1
sequences	2
combined	0
with	0
in	0
vitro	0
bandshift	0
assays	0
revealed	0
the	0
presence	0
of	0
three	0
binding	1
sites	2
for	0
cellular	9
factors	10
in	0
this	0
region	0
.	0

When	0
mutations	0
that	0
abolished	0
factor	0
binding	0
in	0
bandshift	0
assays	0
were	0
introduced	0
into	0
a	0
Wp	1
reporter	2
construct	2
,	0
the	0
loss	0
of	0
any	0
one	0
of	0
the	0
three	0
UAS1	1
binding	2
sites	2
was	0
sufficient	0
to	0
reduce	0
promoter	0
activity	0
by	0
10-	0
to	0
30-fold	0
in	0
B	7
cells	8
.	0

From	0
sequence	0
analysis	0
,	0
two	0
of	0
these	0
appear	0
to	0
be	0
novel	0
transcription	9
factor	10
binding	1
sites	2
,	0
whereas	0
the	0
third	0
was	0
identified	0
as	0
a	0
cyclic	1
AMP	2
response	2
element	2
(	0
CRE	1
)	0
.	0

Our	0
data	0
indicate	0
that	0
this	0
CRE	1
interacts	0
with	0
CREB	9
and	10
ATF1	10
proteins	10
present	0
in	0
B	0
cell	0
nuclear	0
extracts	0
and	0
that	0
this	0
interaction	0
is	0
important	0
for	0
Wp	0
activity	0
.	0

In	0
situ	0
RT-PCR	0
detection	0
of	0
Epstein-Barr	3
virus	4
immediate-early	4
transcripts	4
in	0
CD4+	7
and	8
CD8+	8
T	8
lymphocytes	8
.	0

AIDS-related	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
-associated	0
T	0
cell	0
lymphomas	0
are	0
emerging	0
as	0
a	0
new	0
,	0
distinct	0
histopathological	0
entity	0
.	0

The	0
pathway	0
whereby	0
EBV	0
infects	0
T	7
cells	8
as	0
well	0
as	0
the	0
initial	0
EBV	0
transcriptional	0
program	0
in	0
T	7
cells	8
has	0
not	0
been	0
established	0
.	0

In	0
order	0
to	0
shed	0
light	0
on	0
the	0
early	0
events	0
of	0
the	0
EBV	0
infection	0
of	0
T	7
cells	8
,	0
we	0
have	0
used	0
in	0
situ	0
reverse	0
transcription	0
based	0
polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
to	0
study	0
the	0
initial	0
EBV	0
transcriptional	0
program	0
in	0
homogeneous	7
CD4+	8
and	8
CD8+	8
lymphocytes	8
.	0

Following	0
EBV	0
infection	0
,	0
Epstein-Barr	0
nuclear	0
antigen	0
(	0
EBNA	9
)	0
expression	0
could	0
be	0
detected	0
in	0
T	7
rosetting	8
CD4+	8
and	8
CD8+	8
T	8
lymphocytes	8
.	0

Only	0
a	0
few	0
cells	0
showed	0
viral	9
capsid	10
antigen	10
(	0
VCA	9
)	0
.	0

EBV	3
immediate-early	4
gene	4
transcripts	4
(	0
BZLF1	3
,	0
BRLF1	3
,	0
and	0
BMLF1	3
)	0
encoded	0
in	0
the	0
BamHI	0
Z	0
,	0
R	0
,	0
and	0
M	0
fragments	0
could	0
be	0
detected	0
by	0
in	0
situ	0
RT-PCR	0
in	0
the	0
EBV	0
producer	0
cell	0
line	0
B95.8	0
.	0

Both	0
BZLF1	3
and	4
BRLF1	4
immediate-early	4
transcripts	4
,	0
but	0
not	0
BMLF1	3
transcript	4
,	0
could	0
be	0
detected	0
in	0
individual	0
CD4+	7
and	8
CD8+	8
T	8
cells	8
infected	0
with	0
EBV	0
.	0

Demonstration	0
of	0
EBV	3
mRNA	4
transcripts	4
encoding	0
immediate-early	9
transcriptional	10
transactivators	10
in	0
EBV-infected	7
T	8
cells	8
provides	0
the	0
first	0
evidence	0
for	0
a	0
possible	0
mechanism	0
whereby	0
EBV	0
could	0
contribute	0
to	0
T	0
cell	0
proliferation	0
and	0
EBV-associated	0
T	0
cell	0
malignancies	0
.	0

The	0
linkage	0
between	0
T-cell	0
and	0
dendritic	0
cell	0
development	0
in	0
the	0
mouse	0
thymus	0
.	0

Thymic	7
dendritic	8
cells	8
(	0
DC	7
)	0
mediate	0
negative	0
selection	0
at	0
a	0
relatively	0
late	0
stage	0
of	0
the	0
T-cell	0
developmental	0
pathway	0
.	0

We	0
present	0
evidence	0
that	0
the	0
development	0
of	0
thymic	7
DC	8
and	0
of	0
T-lineage	7
cells	8
is	0
linked	0
via	0
a	0
common	0
precursor	0
at	0
an	0
early	0
stage	0
of	0
thymocyte	0
development	0
.	0

T-lineage	0
precursor	0
populations	0
from	0
the	0
adult	0
mouse	0
thymus	0
,	0
prior	0
to	0
T-cell	0
receptor	0
gene	0
rearrangement	0
,	0
display	0
a	0
capacity	0
to	0
produce	0
DC	7
as	0
well	0
as	0
T	7
cells	8
in	0
the	0
thymus	0
,	0
and	0
are	0
very	0
efficient	0
precursors	0
of	0
DC	7
in	0
culture	0
.	0

These	0
lymphoid/DC	7
precursors	8
have	0
little	0
capacity	0
to	0
form	0
myeloid	7
cells	8
,	0
indicating	0
that	0
thymic	7
DC	8
are	0
a	0
lymphoid-related	0
rather	0
than	0
myeloid-related	7
lineage	8
.	0

In	0
contrast	0
to	0
myeloid-related	7
DC	8
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
is	0
not	0
required	0
for	0
the	0
development	0
of	0
these	0
lymphoid-related	7
DC	8
in	0
vivo	0
or	0
in	0
vitro	0
.	0

DC	7
can	0
develop	0
in	0
mutant	0
mice	0
lacking	0
mature	7
T	8
cells	8
,	0
provided	0
the	0
common	0
precursors	0
are	0
present	0
.	0

However	0
,	0
in	0
mutant	0
mice	0
lacking	0
functional	0
Ikaros	9
transcription	9
factors	10
,	0
there	0
are	0
deficiencies	0
in	0
lymphoid	7
precursor	8
cells	8
,	0
in	0
mature	7
lymphoid	8
cells	8
and	0
in	0
DC	7
.	0

Host	0
control	0
of	0
HIV-1	0
parasitism	0
in	0
T	7
cells	8
by	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

Post	0
HIV-1	0
entry	0
,	0
productive	0
HIV-1	0
infection	0
of	0
primary	7
T	8
cells	8
requires	0
overcoming	0
several	0
cellular	0
blocks	0
to	0
provirus	0
establishment	0
and	0
replication	0
.	0

Activation	0
of	0
unknown	0
host	0
intracellular	0
events	0
overcomes	0
such	0
inhibitory	0
steps	0
and	0
is	0
concomitant	0
with	0
HIV-1	0
replication	0
.	0

We	0
show	0
that	0
the	0
transcription	9
factor	10
NFATc	9
was	0
sufficient	0
as	0
a	0
cellular	0
factor	0
to	0
induce	0
a	0
highly	0
permissive	0
state	0
for	0
HIV-1	0
replication	0
in	0
primary	7
CD4+	8
T	8
cells	8
.	0

NFATc	9
overcame	0
a	0
blockade	0
at	0
reverse	0
transcription	0
and	0
permitted	0
active	0
HIV-1	0
replication	0
.	0

Pharmacologic	0
blockade	0
of	0
endogenous	9
NFAT	10
activity	0
by	0
FK506	0
or	0
CsA	0
inhibited	0
synthesis	0
of	0
reverse	0
transcription	0
and	0
also	0
potently	0
blocked	0
HIV-1	0
replication	0
.	0

T	7
cells	8
therefore	0
can	0
become	0
competent	0
for	0
HIV-1	0
replication	0
by	0
control	0
of	0
regulated	9
host	10
factors	10
such	0
as	0
the	0
NFATc	9
transcription	9
factor	10
.	0

The	0
host	0
mechanisms	0
regulated	0
by	0
such	0
permissivity	0
factors	0
are	0
potential	0
targets	0
for	0
anti-HIV-1	0
therapy	0
.	0

Regulation	0
of	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
NFAT	9
,	0
and	0
STAT1	9
nuclear	0
import	0
in	0
T	7
lymphocytes	8
by	0
noninvasive	0
delivery	0
of	0
peptide	0
carrying	0
the	0
nuclear	9
localization	10
sequence	10
of	0
NF-kappa	9
B	10
p50	10
.	0

Activation	0
of	0
T	7
lymphocytes	8
by	0
Ags	9
or	0
cytokines	9
results	0
in	0
translocation	0
of	0
the	0
transcription	9
factors	10
NF-kappa	9
B	10
,	0
AP-1	9
,	0
NFAT	9
,	0
and	0
STAT	9
from	0
the	0
cytoplasm	0
into	0
the	0
nucleus	0
.	0

The	0
first	0
step	0
in	0
the	0
nuclear	0
import	0
process	0
is	0
recognition	0
of	0
a	0
nuclear	9
localization	10
sequence	10
(	0
NLS	9
)	0
within	0
the	0
karyophilic	9
protein	10
by	0
a	0
cytoplasmic	9
receptor	10
such	0
as	0
the	0
importin	9
(	10
karyopherin	10
)	10
-alpha	10
subunit	10
.	0

The	0
NLSs	9
of	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
and	0
NFAT	9
differ	0
and	0
the	0
NLS	9
of	0
STAT1	9
has	0
not	0
yet	0
been	0
identified	0
.	0

Herein	0
we	0
demonstrate	0
that	0
the	0
inducible	0
nuclear	0
import	0
of	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
NFAT	9
,	0
and	0
STAT1	9
in	0
Jurkat	5
T	6
lymphocytes	6
is	0
significantly	0
inhibited	0
by	0
a	0
cell-permeable	0
peptide	0
carrying	0
the	0
NLS	9
of	0
the	0
NF-kappa	9
B	10
p50	10
subunit	10
.	0

NLS	9
peptide-mediated	0
disruption	0
of	0
the	0
nuclear	0
import	0
of	0
these	0
transcription	9
factors	10
results	0
in	0
inhibition	0
of	0
I	0
kappa	0
B	0
alpha	0
and	0
IL-2	0
gene	0
expression	0
,	0
processes	0
dependent	0
on	0
NF-kappa	9
B	10
or	0
the	0
combination	0
of	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
and	0
NFAT	9
.	0

Further	0
,	0
we	0
show	0
that	0
inhibitory	0
NLS	9
peptide	0
interacts	0
in	0
vitro	0
with	0
a	0
cytoplasmic	9
NLS	10
receptor	10
complex	10
comprised	0
of	0
the	0
Rch1/importin	9
(	10
karyopherin	10
)	10
-beta	10
heterodimer	10
expressed	0
in	0
Jurkat	5
T	6
cells	6
.	0

Taken	0
together	0
,	0
these	0
data	0
indicate	0
that	0
the	0
inducible	0
nuclear	0
import	0
of	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
NFAT	9
,	0
and	0
STAT1	9
in	0
Jurkat	5
T	6
cells	6
can	0
be	0
regulated	0
by	0
NLS	9
peptide	0
delivered	0
noninvasively	0
to	0
the	0
cytoplasm	0
of	0
Jurkat	5
T	6
cells	6
to	0
target	0
members	0
of	0
the	0
importin	9
(	10
karyopherin	10
)	10
-alpha	10
beta	10
NLS	9
receptor	10
complex	10
.	0

Membrane-associated	9
lymphotoxin	10
on	0
natural	7
killer	8
cells	8
activates	0
endothelial	7
cells	8
via	0
an	0
NF-kappaB	9
-dependent	0
pathway	0
.	0

BACKGROUND	0
:	0
Inhibition	0
of	0
complement	0
in	0
small	0
animal	0
models	0
of	0
xenotransplantation	0
has	0
demonstrated	0
graft	0
infiltration	0
with	0
natural	7
killer	8
(	8
NK	8
)	8
cells	8
and	0
monocytes	0
associated	0
with	0
endothelial	7
cell	8
(	0
EC	7
)	0
activation	0
.	0

We	0
have	0
previously	0
demonstrated	0
that	0
human	7
NK	8
cells	8
activate	0
porcine	0
EC	7
in	0
vitro	0
,	0
which	0
results	0
in	0
adhesion	9
molecule	10
expression	0
and	0
cytokine	9
secretion	0
.	0

In	0
this	0
study	0
,	0
we	0
used	0
the	0
NK	5
cell	6
line	6
NK92	6
to	0
define	0
the	0
molecular	0
and	0
cellular	0
basis	0
of	0
NK	0
cell-mediated	0
EC	7
activation	0
.	0

METHODS	0
:	0
EC	7
were	0
transfected	0
with	0
either	0
reporter	0
constructs	0
containing	0
the	0
luciferase	1
gene	2
driven	0
either	0
by	0
E-selectin	1
or	2
interleukin	2
(	2
IL	2
)	2
-8	2
promoters	2
or	0
a	0
synthetic	0
NF-kappaB-dependent	1
promoter	2
.	0

In	0
addition	0
,	0
a	0
dominant-negative	1
mutant	2
tumor	2
necrosis	2
factor	2
receptor	2
I	2
(	2
TNFRI	2
)	2
expression	2
vector	2
was	0
co-transfected	0
in	0
inhibition	0
studies	0
.	0

Forty-eight	0
hours	0
after	0
transfection	0
,	0
EC	7
were	0
stimulated	0
with	0
NK	7
cells	8
or	0
NK	7
cell	8
membrane	8
extracts	8
for	0
7	0
hr	0
and	0
activation	0
was	0
measured	0
by	0
a	0
luciferase	9
assay	0
.	0

RESULTS	0
:	0
Co-culture	0
of	0
NK	7
cells	8
with	0
transfected	0
EC	7
enhanced	0
E-selectin	9
,	0
IL-8	9
,	0
and	0
NF-kappaB	9
-dependent	0
promoter	0
activity	0
.	0

NK	0
cell	0
membrane	0
extracts	0
retained	0
the	0
capacity	0
to	0
activate	0
EC	7
and	0
induced	0
nuclear	0
translocation	0
of	0
NF-kappaB	9
(	0
p50	9
and	0
p65	9
)	0
.	0

Western	0
blotting	0
of	0
NK	7
cell	8
and	0
membrane	0
extracts	0
detected	0
the	0
presence	0
of	0
Lymphotoxin-alpha	9
(	0
LTalpha	9
)	0
but	0
not	0
tumor	9
necrosis	10
factor-alpha	10
.	0

Furthermore	0
,	0
LTalpha	9
was	0
secreted	0
in	0
NK	5
:	6
EC	6
co-cultures	6
.	0

Co-transfection	0
with	0
dominant-negative	9
mutant	10
TNFRI	10
inhibited	0
EC	7
activation	0
by	0
NK	0
cell	0
membrane	0
extracts	0
and	0
by	0
NK	7
cells	8
by	0
80	0
%	0
and	0
47	0
%	0
,	0
respectively	0
.	0

The	0
same	0
pattern	0
of	0
inhibition	0
was	0
observed	0
using	0
anti-human	0
LT	0
sera	0
.	0

CONCLUSIONS	0
:	0
Human	0
NK	0
cell	0
membrane-bound	0
LT	0
signals	0
across	0
species	0
via	0
TNFRI	9
,	0
leading	0
to	0
NF-kappaB	9
nuclear	0
translocation	0
and	0
transcription	0
of	0
E-selectin	9
and	0
IL-8	9
,	0
which	0
results	0
in	0
EC	7
activation	0
.	0

The	0
discrepancy	0
in	0
the	0
degree	0
of	0
inhibition	0
by	0
membrane	0
extracts	0
and	0
NK	7
cells	8
with	0
mutant	9
TNFRI	10
suggests	0
that	0
additional	0
pathways	0
are	0
utilized	0
by	0
NK	7
cells	8
to	0
activate	0
EC	7

Ras	9
-dependent	0
,	0
Ca2+-stimulated	0
activation	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
by	0
a	0
constitutively	0
active	0
Cbl	9
mutant	10
in	0
T	7
cells	8
.	0

T	9
cell	10
receptor	10
(	0
TCR	9
)	0
stimulation	0
induces	0
rapid	0
tyrosine	0
phosphorylation	0
of	0
cellular	9
proteins	10
,	0
including	0
Cbl	9
,	0
a	0
protooncogene	9
product	10
whose	0
function	0
remains	0
unclear	0
.	0

As	0
a	0
first	0
step	0
toward	0
elucidating	0
the	0
function	0
of	0
Cbl	9
in	0
TCR	9
-initiated	0
signaling	0
,	0
we	0
evaluated	0
the	0
ability	0
of	0
wild-type	9
Cbl	10
or	0
a	0
transforming	0
Cbl	9
mutant	10
(	0
70Z/3	0
)	0
to	0
induce	0
transcriptional	0
activation	0
of	0
a	0
nuclear	1
factor	2
of	2
activated	2
T	2
cells	2
(	2
NFAT	2
)	2
element	2
derived	0
from	0
the	0
interleukin	1
2	2
(	2
IL2	2
)	2
promoter	2
in	0
transiently	0
cotransfected	0
Jurkat-TAg	5
T	6
cells	6
.	0

70Z/3	9
,	0
but	0
not	0
Cbl	9
,	0
caused	0
NFAT	9
activation	0
which	0
was	0
significantly	0
enhanced	0
by	0
stimulation	0
with	0
calcium	0
ionophore	0
,	0
and	0
was	0
drastically	0
reduced	0
by	0
cyclosporin	0
A	0
pretreatment	0
.	0

A	0
point	0
mutation	0
of	0
a	0
potential	0
phosphatidylinositol	1
3-kinase	2
(	2
PI3-K	2
)	2
binding	2
site	2
(	0
Y731EAM	1
to	0
Y731EAC	1
)	0
in	0
70Z/3	9
disrupted	0
the	0
association	0
of	0
PI3-K	9
with	0
70Z/3	9
,	0
but	0
did	0
not	0
reduce	0
the	0
induction	0
of	0
NFAT	9
activity	0
,	0
suggesting	0
that	0
the	0
interaction	0
between	0
Cbl	9
and	0
PI3-K	9
is	0
not	0
required	0
in	0
the	0
70Z/3	9
-mediated	0
induction	0
of	0
NFAT	9
.	0

Additional	0
mapping	0
studies	0
indicated	0
that	0
defined	0
deletions	0
of	0
C-terminal	0
70Z/3	9
sequences	0
affected	0
to	0
a	0
variable	0
degree	0
its	0
ability	0
to	0
stimulate	0
NFAT	9
activity	0
.	0

Strikingly	0
,	0
deletion	0
of	0
346	9
C-terminal	10
residues	10
augmented	0
this	0
activity	0
,	0
whereas	0
removal	0
of	0
20	0
additional	0
residues	0
abolished	0
it	0
.	0

Coexpression	0
of	0
dominant	9
negative	10
Ras	10
abrogated	0
the	0
basal	0
or	0
ionomycin-stimulated	0
,	0
70Z/3	9
-mediated	0
NFAT	9
activation	0
,	0
suggesting	0
a	0
functional	9
Ras	10
is	0
required	0
for	0
this	0
activation	0
.	0

These	0
results	0
implicate	0
Cbl	9
in	0
Ras	9
-dependent	0
signaling	0
pathways	0
which	0
lead	0
to	0
NFAT	9
activation	0
.	0

Requirement	0
of	0
prestimulated	5
THP-1	6
monocytic	6
cells	6
for	0
endothelial	7
cell	8
activation	0
.	0

Involvement	0
of	0
TNF	0
alpha	0
.	0

Blood	7
monocytes	8
spontaneously	0
activate	0
endothelial	7
cells	8
in	0
culture	0
,	0
leading	0
to	0
adhesion	0
of	0
monocytic	7
cells	8
onto	0
the	0
endothelial	0
surface	0
and	0
overproduction	0
of	0
endothelial	0
proteins	0
such	0
as	0
von	9
Willebrand	10
factor	10
(	0
vWf	9
)	0
and	0
plasminogen	9
activator	10
inhibitor	10
type	10
1	10
(	0
PAI-1	9
)	0
.	0

To	0
overcome	0
the	0
difficulty	0
in	0
obtaining	0
quiescent	7
monocytes	8
,	0
we	0
studied	0
the	0
ability	0
of	0
promonocytic	5
THP-1	6
cells	6
to	0
activate	0
endothelial	7
cells	8
.	0

Lipopolysaccharide	0
(	0
LPS	0
)	0
-prestimulated	0
and	0
untreated	0
THP-1	5
cells	6
were	0
cocultured	0
with	0
resting	7
human	8
umbilical	8
vein	8
endothelial	8
cells	8
(	0
HUVEC	7
)	0
for	0
3	0
and	0
24	0
h	0
in	0
the	0
presence	0
of	0
colimycin	0
to	0
neutralize	0
LPS	0
traces	0
.	0

Addition	0
of	0
untreated	0
THP-1	5
cells	6
had	0
little	0
effect	0
on	0
HUVEC	7
adhesiveness	0
.	0

Addition	0
of	0
prestimulated	0
THP-1	5
cells	6
was	0
followed	0
by	0
a	0
noticeable	0
adhesion	0
after	0
3	0
h	0
which	0
reversed	0
to	0
basal	0
values	0
within	0
24	0
h	0
.	0

Under	0
these	0
conditions	0
HUVEC	9
adhesion	10
molecules	10
,	0
E-selectin	9
,	0
VCAM-1	9
and	0
ICAM-1	9
,	0
were	0
increased	0
at	0
3	0
h	0
with	0
only	0
ICAM-1	9
remaining	0
overexpressed	0
at	0
24	0
h	0
.	0

Diffusible	9
endothelial	10
proteins	10
such	0
as	0
soluble	0
E-selectin	9
,	0
PAI-1	9
and	0
vWf	9
to	0
a	0
minimal	0
extent	0
,	0
increased	0
in	0
supernatants	0
from	0
HUVEC	7
cocultured	0
for	0
24	0
h	0
with	0
prestimulated	0
THP-1	5
cells	6
.	0

In	0
those	0
cocultures	0
,	0
TNF	9
alpha	10
concentrations	0
peaked	0
at	0
3	0
h	0
whereas	0
IL-1	0
beta	0
levels	0
progressively	0
rose	0
until	0
24	0
h	0
.	0

Addition	0
of	0
an	0
anti-TNF	9
alpha	10
antibody	10
decreased	0
by	0
40	0
%	0
E-selectin	9
and	0
ICAM-1	9
induction	0
and	0
suppressed	0
PAI-1	9
overproduction	0
with	0
a	0
weak	0
effect	0
on	0
vWf	9
.	0

An	0
anti-IL-1	9
beta	10
antibody	10
had	0
negligible	0
effects	0
on	0
HUVEC	9
adhesion	10
molecules	10
,	0
PAI-1	9
or	0
vWf	9
production	0
.	0

These	0
results	0
provide	0
evidence	0
that	0
promonocytic	5
THP-1	6
cells	6
require	0
prestimulation	0
in	0
order	0
to	0
activate	0
HUVEC	7
and	0
that	0
TNF	9
alpha	10
contributes	0
to	0
this	0
phenomenon	0
.	0

Engagement	0
of	0
the	0
Lewis	0
X	0
antigen	0
(	0
CD15	0
)	0
results	0
in	0
monocyte	0
activation	0
.	0

We	0
previously	0
reported	0
that	0
monocyte	0
adhesion	0
to	0
tumor	5
necrosis	6
factor-alpha	6
(	6
TNF-alpha	6
)	6
-treated	6
endothelial	6
cells	6
increased	0
expression	0
of	0
tissue	0
factor	0
and	0
CD36	9
on	0
monocytes	0
.	0

Using	0
immunological	0
cross-linking	0
to	0
mimic	0
receptor	0
engagement	0
by	0
natural	0
ligands	0
,	0
we	0
now	0
show	0
that	0
CD15	0
(	0
Lewis	0
X	0
)	0
,	0
a	0
monocyte	9
counter-receptor	10
for	0
endothelial	9
selectins	10
may	0
participate	0
in	0
this	0
response	0
.	0

We	0
used	0
cytokine	0
production	0
as	0
a	0
readout	0
for	0
monocyte	0
activation	0
and	0
found	0
that	0
CD15	0
cross-linking	0
induced	0
TNF-alpha	9
release	0
from	0
peripheral	7
blood	8
monocytes	8
and	0
cells	0
from	0
the	0
monocytic	5
cell	6
line	6
MM6	6
.	0

Quantitative	0
reverse	9
transcriptase	10
-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
showed	0
an	0
increase	0
in	0
steady-state	0
TNF-alpha	3
mRNA	4
after	0
3	0
to	0
4	0
hours	0
of	0
cross-linking	0
.	0

CD15	0
cross-linking	0
also	0
concomitantly	0
increased	0
interleukin-1	3
beta	4
(	4
IL-1	4
beta	4
)	4
mRNA	4
,	0
while	0
no	0
apparent	0
change	0
was	0
observed	0
in	0
the	0
levels	0
of	0
beta-actin	3
mRNA	4
,	0
indicating	0
specificity	0
.	0

To	0
examine	0
transcriptional	0
regulation	0
of	0
cytokine	1
genes	2
by	0
CD15	0
engagement	0
,	0
a	0
CAT	0
plasmid	0
reporter	0
construct	0
containing	0
IL-1	1
beta	2
promoter/enhancer	2
sequences	2
was	0
introduced	0
into	0
MM6	5
.	0

Subsequent	0
cross-linking	0
of	0
CD15	0
increased	0
CAT	9
activity	0
.	0

CD15	0
engagement	0
by	0
monoclonal	9
antibody	10
also	0
attenuated	0
IL-1	9
beta	10
transcript	0
degradation	0
,	0
demonstrating	0
that	0
signaling	0
via	0
CD15	0
also	0
had	0
posttranscriptional	0
effects	0
.	0

Nuclear	0
extracts	0
of	0
anti-	0
CD15	7
cross-linked	8
cells	8
demonstrated	0
enhanced	0
levels	0
of	0
the	0
transcriptional	9
factor	10
activator	10
protein-1	10
,	0
minimally	0
changed	0
nuclear	9
factor-kappa	10
B	10
,	0
and	0
did	0
not	0
affect	0
SV40	9
promoter	10
specific	10
protein-1	10
.	0

We	0
conclude	0
that	0
engagement	0
of	0
CD15	0
on	0
monocytes	0
results	0
in	0
monocyte	0
activation	0
.	0

In	0
addition	0
to	0
its	0
well-recognized	0
adhesive	0
role	0
,	0
CD15	0
may	0
function	0
as	0
an	0
important	0
signaling	0
molecule	0
capable	0
of	0
initiating	0
proinflammatory	0
events	0
in	0
monocytes	7
that	0
come	0
into	0
contact	0
with	0
activated	0
endothelium	0
.	0

CD2	9
signalling	0
induces	0
phosphorylation	0
of	0
CREB	9
in	0
primary	7
lymphocytes	8
.	0

Promoter	0
sequences	0
responsive	0
to	0
cyclic	0
AMP	0
(	0
cAMP	0
)	0
are	0
found	0
in	0
a	0
number	0
of	0
cellular	1
genes	2
,	0
and	0
bind	0
transcription	9
factors	10
of	0
the	0
cAMP	9
response	10
element	10
binding	10
protein	10
(	0
CREB	9
)	10
/activating	10
transcription	10
factor-1	10
(	10
ATF-1	10
)	10
family	10
.	0

We	0
have	0
used	0
a	0
human	0
T-lymphotropic	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
model	0
of	0
cAMP	1
response	2
element	2
(	0
CRE	1
)	0
transcription	0
to	0
investigate	0
the	0
influence	0
of	0
lymphocyte	0
activation	0
on	0
transcription	0
from	0
homologous	0
regions	0
in	0
the	0
viral	1
promoter	2
.	0

We	0
previously	0
demonstrated	0
increased	0
HTLV-1	0
transcription	0
following	0
CD2	0
but	0
not	0
CD3	0
receptor	0
cross-linking	0
.	0

We	0
hypothesized	0
that	0
this	0
increased	0
viral	0
transcription	0
was	0
mediated	0
,	0
in	0
part	0
,	0
through	0
the	0
phosphorylation	0
of	0
CREB	9
.	0

Therefore	0
,	0
we	0
investigated	0
CD2	9
and	0
CD3	9
receptor	10
-mediated	0
signalling	0
in	0
primary	7
human	8
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

CD2	9
,	0
but	0
not	0
CD3	9
,	0
cross-linking	0
increased	0
cAMP	0
detected	0
by	0
competitive	0
enzyme-linked	0
immunosorbent	0
assay	0
(	0
ELISA	0
)	0
approximately	0
fourfold	0
.	0

CD2	9
cross-linking	0
concurrently	0
increased	0
phosphorylation	0
of	0
CREB	9
detected	0
by	0
immunoblot	0
assay	0
eightfold	0
.	0

Consistent	0
with	0
post-translational	0
regulation	0
,	0
no	0
change	0
in	0
total	0
level	0
of	0
CREB	9
protein	0
was	0
observed	0
.	0

Phosphorylation	0
of	0
CREB	9
occurred	0
through	0
a	0
herbimycin	0
A	0
and	0
Rp-cAMP-	0
sensitive	0
pathway	0
,	0
suggesting	0
phosphorylation	0
required	0
antecedent	0
activation	0
of	0
both	0
protein	9
tyrosine	10
kinases	10
(	0
PTK	9
)	0
and	0
protein	9
kinase	10
A	10
(	0
PKA	9
)	0
.	0

Both	0
CD2	9
and	0
CD3	9
cross-linking	0
increased	0
binding	0
of	0
nuclear	9
proteins	10
to	0
a	0
radiolabelled	0
CRE	0
oligonucleotide	0
probe	0
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
suggesting	0
that	0
lymphocyte	0
activation	0
enhances	0
binding	0
independently	0
of	0
phosphorylation	0
of	0
CREB	9
at	0
serine	0
133	0
.	0

These	0
data	0
indicate	0
specific	0
modulation	0
of	0
the	0
CREB/ATF-1	9
family	10
of	0
transcription	9
factors	10
by	0
the	0
CD2	9
signalling	0
pathway	0
and	0
suggest	0
CD2	9
receptor	0
modulation	0
of	0
CRE	1
-mediated	0
transcription	0
following	0
ligand	0
engagement	0
(	0
e.g.	0
cell-to-cell	0
contact	0
)	0
.	0

X-rays-induced	0
secretion	0
of	0
cellular	9
factor	10
(	0
s	0
)	0
that	0
enhance	0
(	0
s	0
)	0
HIV-1	1
promoter	2
transcription	0
in	0
various	0
non-irradiated	5
transfected	6
cell	6
lines	6
.	0

Various	0
cellular	0
stress	0
agents	0
like	0
ionizing	0
radiation	0
exposure	0
could	0
activate	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-	0
1	0
)	0
replication	0
or	0
reporter	1
gene	2
expression	0
.	0

In	0
addition	0
,	0
extracellular	9
factor	10
(	0
s	0
)	0
released	0
by	0
X-ray-treated	5
human	6
colonic	6
carcinoma	6
cell	6
line	6
(	0
HT29	5
)	0
might	0
activate	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
HIV-1	0
in	0
non-irradiated	5
HT29	6
cells	6
.	0

In	0
the	0
present	0
report	0
we	0
show	0
that	0
in	0
various	0
transiently	0
or	0
stably	5
transfected	6
cell	6
lines	6
,	0
X-ray	0
irradiation	0
up-regulates	0
HIV-1	1
LTR	2
transcription	0
through	0
the	0
kappaB	9
regulatory	10
elements	10
.	0

A	0
factor	0
(	0
s	0
)	0
,	0
which	0
is	0
processed	0
by	0
and	0
acts	0
upon	0
a	0
variety	0
of	0
cell	0
types	0
,	0
was	0
detected	0
by	0
addition	0
to	0
non-irradiated	7
cells	8
of	0
either	0
X-ray-treated	5
cells	6
or	0
a	0
conditioned	0
medium	0
taken	0
from	0
irradiated	5
cultures	6
.	0

The	0
magnitude	0
of	0
responsiveness	0
is	0
cell	0
type	0
dependent	0
.	0

In	0
addition	0
,	0
X-ray	0
activation	0
of	0
HIV-1	1
LTR	2
in	0
transiently	0
or	0
stably	0
transfected	0
cell	5
lines	6
is	0
inhibited	0
by	0
a	0
potent	0
antioxidant	0
drug	0
,	0
pyrrolidine	0
dithiocarbamate	0
and	0
by	0
another	0
drug	0
,	0
known	0
for	0
its	0
role	0
in	0
the	0
trapping	0
of	0
growth	9
factors	10
,	0
suramin	0
.	0

The	0
importance	0
of	0
these	0
observations	0
in	0
the	0
pathophysiology	0
of	0
patients	0
with	0
AIDS-related	0
cancers	0
treated	0
by	0
radiotherapy	0
remains	0
to	0
be	0
established	0
.	0

Activation	0
of	0
the	0
human	1
delta-globin	2
gene	2
promoter	2
in	0
primary	7
adult	8
erythroid	8
cells	8
.	0

Restoration	0
of	0
the	0
CCAAT	1
box	2
or	0
insertion	0
of	0
an	0
erythroid	1
Kruppel-like	2
factor	2
(	2
EKLF	2
)	2
binding	2
site	2
in	0
the	0
delta	1
promoter	2
activates	0
its	0
expression	0
in	0
several	0
erythroid	5
cell	6
lines	6
.	0

We	0
extended	0
these	0
studies	0
using	0
a	0
novel	0
primary	5
human	6
adult	6
erythroid	6
cell	6
(	6
hAEC	6
)	6
system	6
to	0
investigate	0
these	0
effects	0
at	0
the	0
late	7
erythroblast	8
stage	8
.	0

Restoration	0
of	0
the	0
CCAAT	1
box	2
at	0
-70	1
bp	2
,	0
or	0
insertion	0
of	0
an	0
EKLF	1
binding	2
site	2
at	0
-85	1
bp	2
or	0
-95	1
bp	2
in	0
the	0
promoter	1
significantly	0
increased	0
delta	0
globin	0
gene	0
expression	0
in	0
hAEC	0
.	0

Our	0
results	0
demonstrate	0
that	0
the	0
altered	0
CCAAT	1
box	2
(	0
CCAAC	0
)	0
and	0
the	0
lack	0
of	0
an	0
EKLF	1
binding	2
site	2
in	0
delta-globin	9
contribute	0
to	0
its	0
low	0
level	0
of	0
expression	0
in	0
the	0
hAEC	5
model	6
as	0
well	0
.	0

Constitutive	0
association	0
of	0
JAK1	9
and	0
STAT5	9
in	0
pro-B	7
cells	8
is	0
dissolved	0
by	0
interleukin-4	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
both	0
proteins	0
.	0

The	0
bipartite	9
human	10
interleukin-4	10
(	10
IL-4	10
)	10
receptor	10
was	0
functionally	0
expressed	0
in	0
murine	7
pro-B	8
cells	8
and	0
activated	0
by	0
human	9
IL-4	10
to	0
evoke	0
intracellular	0
signaling	0
.	0

Mutual	0
association	0
of	0
signal	9
transducing	10
proteins	10
within	0
the	0
receptor	0
complex	0
was	0
then	0
studied	0
in	0
dependence	0
of	0
ligand	0
stimulation	0
.	0

Besides	0
ligand-induced	0
receptor	0
heterodimerization	0
and	0
contacts	0
of	0
the	0
two	0
IL-4	9
receptor	10
subunits	10
alpha	10
and	10
gamma	10
with	0
Janus	9
kinases	10
JAK1	9
and	0
JAK3	9
a	0
prominent	0
constitutive	0
binding	0
between	0
JAK1	9
and	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
STAT5	9
was	0
detected	0
.	0

Since	0
both	0
these	0
proteins	0
become	0
phosphorylated	0
in	0
response	0
to	0
IL-4	9
receptor	10
stimulation	0
,	0
the	0
influence	0
of	0
tyrosine	0
phosphorylation	0
on	0
their	0
mutual	0
contact	0
was	0
analyzed	0
.	0

Association	0
of	0
JAK1	9
and	0
STAT5	9
was	0
found	0
to	0
occur	0
exclusively	0
between	0
unphosphorylated	9
proteins	10
.	0

Activation	0
of	0
human	7
macrophages	8
by	0
mechanical	0
ventilation	0
in	0
vitro	0
.	0

Positive-pressure	0
mechanical	0
ventilation	0
supports	0
gas	0
exchange	0
in	0
patients	0
with	0
respiratory	0
failure	0
but	0
is	0
also	0
responsible	0
for	0
significant	0
lung	0
injury	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
developed	0
an	0
in	0
vitro	0
model	0
in	0
which	0
isolated	0
lung	7
cells	8
can	0
be	0
submitted	0
to	0
a	0
prolonged	5
cyclic	6
pressure-stretching	6
strain	6
resembling	0
that	0
of	0
conventional	0
mechanical	0
ventilation	0
.	0

In	0
this	0
model	0
,	0
cells	0
cultured	0
on	0
a	0
Silastic	0
membrane	0
were	0
elongated	0
up	0
to	0
7	0
%	0
of	0
their	0
initial	0
diameter	0
,	0
corresponding	0
to	0
a	0
12	0
%	0
increase	0
in	0
cell	0
surface	0
.	0

The	0
lung	7
macrophage	8
was	0
identified	0
as	0
the	0
main	0
cellular	0
source	0
for	0
critical	0
inflammatory	9
mediators	10
such	0
as	0
tumor	9
necrosis	10
factor-alpha	10
,	0
the	0
chemokines	9
interleukin	9
(	10
IL	10
)	10
-8	10
and	10
-6	10
,	0
and	0
matrix	9
metalloproteinase-9	10
in	0
this	0
model	0
system	0
of	0
mechanical	0
ventilation	0
.	0

These	0
mediators	0
were	0
measured	0
in	0
supernatants	0
from	0
ventilated	7
alveolar	8
macrophages	8
,	0
monocyte-derived	7
macrophages	8
,	0
and	0
promonocytic	5
THP-1	6
cells	6
.	0

Nuclear	9
factor-kappaB	10
was	0
found	0
to	0
be	0
activated	0
in	0
ventilated	7
macrophages	8
.	0

Synergistic	0
proinflammatory	0
effects	0
of	0
mechanical	0
stress	0
and	0
molecules	0
such	0
as	0
bacterial	9
endotoxin	10
were	0
observed	0
,	0
suggesting	0
that	0
mechanical	0
ventilation	0
might	0
be	0
particularly	0
deleterious	0
in	0
preinjured	0
or	0
infected	0
lungs	0
.	0

Dexamethasone	0
prevented	0
IL-8	9
and	0
tumor	9
necrosis	10
factor-alpha	10
secretion	0
in	0
ventilated	7
macrophages	8
.	0

Mechanical	0
ventilation	0
induced	0
low	0
levels	0
of	0
IL-8	9
secretion	0
by	0
alveolar	7
type	8
II-like	8
cells	8
.	0

Other	0
lung	0
cell	0
types	0
such	0
as	0
endothelial	7
cells	8
,	0
bronchial	7
cells	8
,	0
and	0
fibroblasts	7
failed	0
to	0
produce	0
IL-8	9
in	0
response	0
to	0
a	0
prolonged	0
cyclic	0
pressure-stretching	0
load	0
.	0

This	0
model	0
is	0
of	0
particular	0
value	0
for	0
exploring	0
physical	0
stress-induced	0
signaling	0
pathways	0
,	0
as	0
well	0
as	0
for	0
testing	0
the	0
effects	0
of	0
novel	0
ventilatory	0
strategies	0
or	0
adjunctive	0
substances	0
aimed	0
at	0
modulating	0
cell	0
activation	0
induced	0
by	0
mechanical	0
ventilation	0
.	0

Signaling	0
pathways	0
mediated	0
by	0
the	0
TNF-	9
and	10
cytokine-receptor	10
families	0
target	0
a	0
common	0
cis-element	1
of	0
the	0
IFN	1
regulatory	2
factor	2
1	2
promoter	2
.	0

CD40	9
activation	0
of	0
B	7
cells	8
is	0
strongly	0
influenced	0
by	0
the	0
presence	0
of	0
cytokines	9
.	0

However	0
,	0
the	0
molecular	0
basis	0
for	0
the	0
interplay	0
between	0
these	0
distinct	0
stimuli	0
is	0
not	0
clearly	0
delineated	0
.	0

IFN	9
regulatory	10
factor	10
1	10
(	0
IRF-1	9
)	0
is	0
a	0
transcription	9
factor	10
activated	0
by	0
either	0
CD40	9
or	0
cytokines	9
.	0

We	0
have	0
found	0
that	0
these	0
different	0
sets	0
of	0
signals	0
target	0
a	0
common	0
cis-acting	0
element	0
in	0
the	0
promoter	0
of	0
this	0
gene	0
,	0
the	0
IRF-1	1
gamma-activated	2
site	2
(	0
GAS	1
)	0
.	0

Targeting	0
of	0
the	0
IRF-1	1
GAS	2
is	0
not	0
confined	0
to	0
activation	0
via	0
CD40	9
but	0
extends	0
to	0
other	0
stimuli	0
that	0
mimic	0
the	0
CD40	9
signaling	0
cascade	0
,	0
like	0
TNF-alpha	9
and	0
EBV	0
.	0

In	0
contrast	0
to	0
induction	0
of	0
STATs	9
by	0
cytokines	9
,	0
the	0
IRF-1	1
GAS	2
-binding	0
complex	0
activated	0
by	0
CD40	9
,	0
TNF-alpha	9
,	0
or	0
EBV	0
contains	0
Rel	9
proteins	10
,	0
specifically	0
p50	9
and	0
p65	9
.	0

In	0
this	0
system	0
,	0
simultaneous	0
exposure	0
to	0
CD40L	9
together	0
with	0
either	0
IL-4	9
or	0
IFN-gamma	9
does	0
not	0
lead	0
to	0
the	0
activation	0
of	0
novel	0
Rel/STAT	9
complexes	10
.	0

Given	0
the	0
importance	0
of	0
IRF-1	9
in	0
a	0
variety	0
of	0
biologic	0
functions	0
from	0
proliferation	0
to	0
apoptosis	0
,	0
our	0
findings	0
support	0
the	0
notion	0
that	0
modulation	0
of	0
IRF-1	9
levels	0
may	0
be	0
a	0
critical	0
control	0
point	0
in	0
B	0
cell	0
activation	0
.	0

Differential	0
effects	0
of	0
protein	9
kinase	10
C	10
inhibitors	0
on	0
fibronectin	9
-induced	0
interleukin-beta	1
gene	2
transcription	0
,	0
protein	0
synthesis	0
and	0
secretion	0
in	0
human	7
monocytic	8
cells	8
.	0

Human	7
monocytic	8
cells	8
express	0
interleukin-1beta	9
(	0
IL-1beta	9
)	0
when	0
stimulated	0
with	0
the	0
extracellular	9
matrix	10
glycoprotein	10
,	0
fibronectin	9
(	0
FN	9
)	0
.	0

Protein	9
kinase	10
C	10
(	0
PKC	9
)	0
activation	0
is	0
considered	0
important	0
for	0
this	0
process	0
;	0
however	0
,	0
the	0
metabolic	0
steps	0
at	0
which	0
PKC	9
acts	0
upon	0
to	0
mediate	0
the	0
FN	9
-induced	0
IL-1beta	9
response	0
remain	0
unclear	0
.	0

We	0
performed	0
an	0
analysis	0
of	0
the	0
mechanisms	0
by	0
which	0
two	0
PKC	9
inhibitors	0
,	0
Calphostin	0
C	0
and	0
Staurosporine	0
,	0
prevent	0
the	0
FN	9
-induced	0
IL-1beta	9
response	0
.	0

Both	0
inhibitors	0
blocked	0
the	0
secretion	0
of	0
IL-1beta	9
protein	10
into	0
the	0
media	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
exposed	0
to	0
FN	9
.	0

Immunoprecipitation	0
analysis	0
revealed	0
that	0
unde3r	0
these	0
circumstances	0
,	0
Calphostin	0
C	0
inhibited	0
the	0
production	0
of	0
IL-1beta	9
protein	10
,	0
whereas	0
Staurosporine	0
allowed	0
protein	0
production	0
,	0
but	0
inhibited	0
its	0
secretion	0
.	0

To	0
determine	0
the	0
mechanisms	0
responsible	0
for	0
these	0
differences	0
,	0
we	0
turned	0
to	0
human	5
U937	6
promonocytic	6
cells	6
.	0

U937	0
cells	0
transfected	0
with	0
the	0
human	0
full-length	1
IL-1beta	2
promoter	2
connected	0
to	0
a	0
luciferase	1
reporter	2
gene	2
were	0
submitted	0
to	0
transcription	0
assays	0
,	0
Northern	0
blotting	0
,	0
and	0
DNA	0
electrophoresis	0
mobility	0
gel	0
shift	0
assays	0
.	0

These	0
studies	0
revealed	0
that	0
Calphostin	0
C	0
inhibited	0
the	0
nuclear	0
translocation	0
of	0
the	0
transcription	9
factor	10
activator	10
protein-1	10
(	0
AP-1	9
)	0
which	0
is	0
considered	0
necessary	0
for	0
FN	9
induction	0
of	0
IL-1beta	9
gene	0
transcription	0
,	0
and	0
prevented	0
the	0
transcription	0
of	0
the	0
IL-1beta	1
gene	2
.	0

In	0
contrast	0
,	0
Staurosporine	0
alone	0
induced	0
AP-1	9
translocation	0
and	0
stimulation	0
of	0
the	0
gene	0
.	0

Overall	0
,	0
our	0
data	0
indicate	0
that	0
Calphostin	0
C	0
prevents	0
the	0
transcription	0
of	0
the	0
IL-1beta	1
gene	2
thereby	0
inhibiting	0
protein	0
synthesis	0
.	0

Based	0
on	0
the	0
high	0
specificity	0
of	0
this	0
compound	0
for	0
PKC	9
,	0
we	0
conclude	0
that	0
PKC	9
is	0
necessary	0
for	0
FN	9
-induced	0
IL-1beta	9
protein	0
production	0
.	0

In	0
contrast	0
,	0
Staurosporine	0
prevented	0
secretion	0
of	0
IL-1beta	9
by	0
unknown	0
mechanisms	0

The	0
carboxyl-terminal	9
cytoplasmic	10
domain	10
of	0
CD36	9
is	0
required	0
for	0
oxidized	0
low-density	0
lipoprotein	0
modulation	0
of	0
NF-kappaB	9
activity	0
by	0
tumor	9
necrosis	10
factor-alpha	10
.	0

The	0
binding	0
of	0
oxidized	0
low-density	0
lipoprotein	0
(	0
Ox	0
LDL	0
)	0
by	0
monocyte	7
-macrophages	7
causes	0
pleiotropic	0
effects	0
,	0
including	0
changes	0
in	0
gene	0
expression	0
,	0
and	0
is	0
thought	0
to	0
represent	0
an	0
early	0
event	0
in	0
atherogenesis	0
.	0

The	0
integral	0
membrane	0
glycoprotein	9
CD36	10
appears	0
to	0
play	0
a	0
physiological	0
role	0
in	0
binding	0
and	0
uptake	0
of	0
Ox	0
LDL	0
by	0
monocyte-macrophages	7
,	0
although	0
the	0
molecular	0
events	0
associated	0
with	0
CD36	9
-Ox	0
LDL	0
interaction	0
are	0
unknown	0
.	0

To	0
approach	0
this	0
issue	0
,	0
we	0
used	0
CD36	9
transfected	0
Chinese	7
hampster	8
ovary	8
(	8
CHO	8
)	8
cells	8
,	0
exposed	0
them	0
to	0
Ox	0
LDL	0
,	0
and	0
determined	0
changes	0
in	0
the	0
activity	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
.	0

We	0
report	0
here	0
that	0
Ox	0
LDL	0
enhanced	0
DNA	0
binding	0
activity	0
of	0
nuclear	0
extracts	0
to	0
an	0
NF-kappaB	1
sequence	2
following	0
activation	0
of	0
CD36-producing	5
CHO	6
cells	6
with	0
the	0
proinflammatory	9
cytokine	10
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

This	0
enhanced	0
DNA	0
binding	0
activity	0
was	0
inhibited	0
by	0
coincubation	0
of	0
CD36	9
transfected	0
cells	0
with	0
the	0
human	9
CD36-specific	10
antibody	10
OKM5	9
.	0

We	0
also	0
determined	0
that	0
activation	0
of	0
NF-kappaB	9
DNA	0
binding	0
activity	0
required	0
an	0
intact	0
carboxyl-terminal	9
cytoplasmic	10
segment	10
on	0
CD36	9
.	0

Our	0
results	0
support	0
the	0
idea	0
that	0
human	9
CD36	10
mediates	0
signal	0
transduction	0
events	0
in	0
response	0
to	0
Ox	0
LDL	0
.	0

TRAMP	9
,	0
a	0
novel	0
apoptosis-mediating	9
receptor	10
with	0
sequence	0
homology	0
to	0
tumor	9
necrosis	10
factor	10
receptor	10
1	10
and	0
Fas	9
(	0
Apo-1/CD95	9
)	0
.	0

A	0
novel	0
member	0
of	0
the	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
receptor	10
family	10
,	0
designated	0
TRAMP	9
,	0
has	0
been	0
identified	0
.	0

The	0
structural	0
organization	0
of	0
the	0
393	9
amino	10
acid	10
long	10
human	10
TRAMP	10
is	0
most	0
homologous	0
to	0
TNF	9
receptor	10
1	10
.	0

TRAMP	9
is	0
abundantly	0
expressed	0
on	0
thymocytes	7
and	0
lymphocytes	7
.	0

Its	0
extracellular	0
domain	0
is	0
composed	0
of	0
four	0
cysteine-rich	9
domains	10
,	0
and	0
the	0
cytoplasmic	9
region	10
contains	0
a	0
death	9
domain	10
known	0
to	0
signal	0
apoptosis	0
.	0

Overexpression	0
of	0
TRAMP	9
leads	0
to	0
two	0
major	0
responses	0
,	0
NF-kappaB	9
activation	0
and	0
apoptosis	0
.	0

TRAMP	9
-induced	0
cell	0
death	0
is	0
inhibited	0
by	0
an	0
inhibitor	0
of	0
ICE-like	9
proteases	10
,	0
but	0
not	0
by	0
Bcl-2	9
.	0

In	0
addition	0
,	0
TRAMP	9
does	0
not	0
appear	0
to	0
interact	0
with	0
any	0
of	0
the	0
known	0
apoptosis-inducing	9
ligands	10
of	0
the	0
TNF	9
family	10
.	0

The	0
state	0
of	0
maturation	0
of	0
monocytes	7
into	0
macrophages	7
determines	0
the	0
effects	0
of	0
IL-4	9
and	0
IL-13	9
on	0
HIV	0
replication	0
.	0

The	0
molecular	0
mechanisms	0
of	0
the	0
effects	0
of	0
IL-4	9
and	0
IL-13	9
on	0
HIV	0
infection	0
in	0
human	7
monocytes	8
as	0
they	0
matured	0
into	0
monocyte-derived	7
macrophages	8
over	0
7	0
days	0
were	0
investigated	0
using	0
HIV-1	0
(	0
BaL	0
)	0
,	0
and	0
low	0
passage	0
clinical	0
strains	0
.	0

IL-4	9
and	0
IL-13	9
up-regulated	0
the	0
expression	0
of	0
both	0
genomic	0
and	0
spliced	0
HIV	3
mRNA	4
in	0
monocytes	7
cultured	0
on	0
Teflon	0
,	0
as	0
determined	0
by	0
Northern	0
analysis	0
and	0
p24	9
Ag	10
assay	0
.	0

Using	0
a	0
nuclear	0
run-on	0
assay	0
,	0
IL-4	9
stimulation	0
was	0
shown	0
to	0
enhance	0
transcription	0
by	0
two-	0
to	0
threefold	0
.	0

IL-4	9
stimulated	0
nuclear	9
factor-kappaB	10
nuclear	0
translocation	0
and	0
binding	0
before	0
enhancement	0
of	0
HIV	3
RNA	4
expression	0
.	0

Conversely	0
,	0
IL-4	9
and	0
IL-13	9
markedly	0
and	0
significantly	0
inhibited	0
HIV	0
replication	0
at	0
the	0
transcriptional	0
level	0
in	0
monocyte-derived	7
macrophages	8
,	0
and	0
this	0
occurred	0
whether	0
these	0
cytokines	9
were	0
added	0
before	0
or	0
after	0
HIV	0
infection	0
.	0

The	0
reversal	0
from	0
stimulation	0
to	0
inhibition	0
occurred	0
after	0
3	0
to	0
5	0
days	0
of	0
adherence	0
to	0
plastic	0
.	0

IL-4	9
had	0
no	0
significant	0
effect	0
on	0
HIV	0
reverse	0
transcription	0
.	0

The	0
effect	0
of	0
both	0
cytokines	9
on	0
the	0
monocyte	0
maturation/differentiation	0
(	0
CD11b	9
,	0
CD13	9
,	0
and	0
CD26	9
)	0
and	0
other	0
macrophage	9
markers	10
(	0
CD14	9
and	0
CD68	9
)	0
was	0
examined	0
.	0

IL-4	9
enhanced	0
CD11b	9
,	0
but	0
inhibited	0
CD26	9
expression	0
and	0
delayed	0
CD13	9
loss	0
.	0

IL-13	9
had	0
similar	0
effects	0
on	0
CD11b	9
and	0
CD13	9
,	0
but	0
no	0
effect	0
on	0
CD26	9
.	0

Hence	0
,	0
these	0
cytokines	9
do	0
not	0
simply	0
enhance	0
monocyte	0
differentiation	0
,	0
but	0
have	0
complex	0
and	0
slightly	0
divergent	0
effects	0
that	0
impact	0
on	0
HIV	0
replication	0
probably	0
through	0
cell	0
signaling	0
pathways	0
and	0
nuclear	9
factor-kappaB	10
translocation	0
.	0

Mice	0
lacking	0
the	0
transcription	9
factor	10
CIITA	9
--	0
a	0
second	0
look	0
.	0

We	0
have	0
generated	0
a	0
second	0
line	0
of	0
mice	0
lacking	0
a	0
transcription	9
factor	10
thought	0
to	0
be	0
a	0
critical	0
regulator	0
of	0
MHC	1
class	2
II	2
gene	2
expression	0
,	0
CIITA	9
(	0
for	0
class	0
II	0
transactivator	9
)	0
.	0

Our	0
and	0
the	0
previously	0
published	0
lines	0
differ	0
in	0
the	0
deletion	0
that	0
was	0
engineered	0
and	0
by	0
the	0
fact	0
that	0
we	0
removed	0
the	0
neomycin-resistance	1
promoter	2
and	0
structural	1
gene	2
via	0
the	0
cre-loxP	0
recombination	0
system	0
.	0

Characterization	0
of	0
our	0
line	0
led	0
to	0
two	0
new	0
findings	0
.	0

First	0
,	0
a	0
substantial	0
number	0
of	0
cells	0
can	0
express	0
class	9
II	10
molecules	10
in	0
the	0
absence	0
of	0
CIITA	9
,	0
albeit	0
at	0
5-fold	0
reduced	0
levels	0
,	0
most	0
notably	0
dendritic	7
cells	8
in	0
s.c.	0
lymph	0
nodes	0
;	0
therefore	0
,	0
the	0
CIITA	1
gene	2
can	0
not	0
be	0
an	0
absolute	0
'	0
master	1
gene	2
'	0
controlling	0
the	0
expression	0
of	0
class	9
II	10
molecules	10
,	0
as	0
had	0
been	0
thought	0
.	0

Second	0
,	0
in	0
contrast	0
to	0
recent	0
results	0
on	0
human	5
cell	6
lines	6
,	0
CIITA	9
is	0
not	0
critically	0
involved	0
in	0
the	0
IFN-gamma	9
-induced	0
up-regulation	0
of	0
MHC	1
class	2
I	2
genes	2
.	0

Interleukin-10	9
stabilizes	0
inhibitory	0
kappaB-alpha	9
in	0
human	7
monocytes	8
.	0

Interleukin-10	9
(	0
IL-10	9
)	0
protects	0
animals	0
from	0
lethal	0
endotoxemia	0
.	0

This	0
beneficial	0
effect	0
is	0
mediated	0
,	0
in	0
part	0
,	0
by	0
inhibition	0
of	0
inflammatory	9
cytokine	10
production	0
,	0
including	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

Evidence	0
suggests	0
that	0
IL-10	9
may	0
inhibit	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
through	0
an	0
unknown	0
mechanism	0
.	0

NF-kappaB	9
activation	0
in	0
response	0
to	0
inflammatory	0
signals	0
is	0
dependent	0
upon	0
degradation	0
of	0
its	0
associated	0
inhibitory	0
peptide	0
,	0
inhibitory	9
kappaB-alpha	10
(	0
IkappaB-alpha	9
)	0
.	0

We	0
hypothesized	0
that	0
IL-10	9
prevents	0
human	0
monocyte	0
NF-kappaB	9
activation	0
and	0
resultant	0
TNF-alpha	9
production	0
by	0
stabilization	0
of	0
IkappaB-alpha	9
.	0

The	0
purpose	0
of	0
this	0
study	0
was	0
to	0
determine	0
the	0
effect	0
of	0
IL-10	9
on	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-induced	0
human	0
monocyte	0
TNF-alpha	9
production	0
,	0
NF-kappaB	9
activation	0
,	0
and	0
IkappaB-alpha	9
degradation	0
.	0

Monocytes	0
were	0
isolated	0
from	0
human	0
donors	0
.	0

Cells	0
were	0
stimulated	0
with	0
endotoxin	9
(	0
LPS	0
,	0
100	0
ng/mL	0
)	0
with	0
and	0
without	0
human	0
IL-10	9
(	0
10	0
ng/mL	0
)	0
.	0

Following	0
stimulation	0
,	0
TNF-alpha	9
was	0
measured	0
in	0
cell	0
supernatants	0
by	0
ELISA	0
,	0
NF-kappaB	9
activity	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
and	0
IkappaB-alpha	9
levels	0
by	0
Western	0
blot	0
.	0

We	0
observed	0
that	0
after	0
LPS	0
stimulation	0
of	0
human	7
monocytes	8
,	0
TNF-alpha	9
increased	0
to	0
798+/-67	0
pg/mL	0
(	0
p	0
<	0
.001	0
versus	0
control	0
)	0
.	0

IL-10	9
attenuated	0
LPS-stimulated	0
TNF-alpha	9
production	0
(	0
297+/-54	0
;	0
p	0
<	0
.001	0
versus	0
LPS	0
alone	0
)	0
.	0

After	0
LPS	0
stimulation	0
in	0
human	7
monocytes	8
,	0
IkappaB-alpha	9
protein	0
levels	0
decreased	0
,	0
and	0
NF-kappaB	9
DNA	0
binding	0
increased	0
.	0

IL-10	9
pretreatment	0
prevented	0
LPS-induced	0
decreases	0
in	0
IkappaB-alpha	9
protein	0
levels	0
and	0
attenuated	0
NF-kappaB	9
DNA	0
binding	0
.	0

IL-10	9
appears	0
to	0
prevent	0
activation	0
of	0
NF-kappaB	9
by	0
preserving	0
IkappaB-alpha	9
protein	0
levels	0
,	0
leading	0
to	0
a	0
reduction	0
in	0
TNF-alpha	9
release	0
.	0

Down-regulation	0
of	0
human	0
granzyme	9
B	10
expression	0
by	0
glucocorticoids	0
.	0

Dexamethasone	0
inhibits	0
binding	0
to	0
the	0
Ikaros	9
and	0
AP-1	1
regulatory	2
elements	2
of	0
the	0
granzyme	1
B	2
promoter	2
.	0

The	0
serine	9
protease	10
granzyme	10
B	10
is	0
an	0
essential	0
component	0
of	0
the	0
granule	0
exocytosis	0
pathway	0
,	0
a	0
major	0
apoptotic	0
mechanism	0
used	0
by	0
cytotoxic	7
T	8
lymphocytes	8
and	0
natural	7
killer	8
cells	8
to	0
induce	0
target	0
cell	0
apoptosis	0
.	0

Granzyme	0
B	0
gene	0
transcription	0
is	0
induced	0
in	0
activated	0
lymphocytes	7
upon	0
antigenic	0
stimulation	0
,	0
and	0
several	0
regulatory	1
regions	2
including	0
CBF	9
,	0
AP-1	9
,	0
and	0
Ikaros	1
binding	2
sites	2
have	0
been	0
shown	0
to	0
be	0
essential	0
in	0
the	0
control	0
of	0
granzyme	1
B	2
promoter	2
activation	0
.	0

Dexamethasone	0
,	0
a	0
glucocorticoid	0
that	0
is	0
widely	0
used	0
as	0
an	0
immunomodulatory	0
and	0
anti-inflammatory	0
agent	0
,	0
inhibits	0
granzyme	3
B	4
mRNA	4
transcript	4
in	0
phytohemagglutinin-activated	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

Transfection	0
of	0
a	0
reporter	0
construct	0
containing	0
the	0
-148	1
to	2
+60	2
region	2
of	0
the	0
human	0
granzyme	1
B	2
promoter	2
demonstrated	0
that	0
this	0
region	0
was	0
the	0
target	0
for	0
dexamethasone	0
repression	0
.	0

Mutation	0
of	0
Ikaros	9
or	0
AP-1	1
binding	2
sites	2
in	0
the	0
context	0
of	0
the	0
granzyme	1
B	2
promoter	2
demonstrated	0
that	0
both	0
sites	0
participate	0
in	0
dexamethasone-mediated	0
inhibition	0
of	0
the	0
granzyme	1
B	2
promoter	2
activity	0
.	0

Electromobility	0
shift	0
assay	0
revealed	0
that	0
dexamethasone	0
abolished	0
the	0
binding	0
of	0
nuclear	9
transcription	10
factors	10
to	0
the	0
Ikaros	1
binding	2
site	2
and	0
reduced	0
AP-1	9
binding	0
activity	0
.	0

These	0
results	0
indicate	0
that	0
dexamethasone	0
is	0
able	0
to	0
abrogate	0
the	0
transcriptional	0
activity	0
of	0
the	0
human	1
granzyme	2
B	2
gene	2
promoter	2
by	0
inhibiting	0
the	0
binding	0
of	0
nuclear	9
factors	10
at	0
the	0
AP-1	1
and	2
Ikaros	2
sites	2
.	0

Glucocorticoid	9
receptors	10
on	0
mononuclear	7
leukocytes	8
in	0
polycystic	0
ovary	0
syndrome	0
.	0

OBJECTIVE	0
:	0
Many	0
studies	0
have	0
suggested	0
that	0
there	0
is	0
a	0
possible	0
hormonal	0
dysregulation	0
of	0
hypothalamic-pituitary-adrenal	0
(	0
HPA	0
)	0
axis	0
and	0
an	0
increased	0
cortisol	0
clearance	0
in	0
patients	0
with	0
polycystic	0
ovary	0
syndrome	0
(	0
PCOS	0
)	0
.	0

Therefore	0
in	0
this	0
study	0
,	0
we	0
have	0
examined	0
the	0
role	0
of	0
glucocorticoid	9
receptor/s	10
(	0
GR	9
)	0
characteristics	0
in	0
the	0
developing	0
of	0
these	0
abnormalities	0
in	0
patients	0
with	0
PCOS	0
.	0

METHOD	0
:	0
For	0
this	0
purpose	0
,	0
the	0
number	0
and	0
affinity	0
of	0
GR	9
in	0
peripheral	0
mononuclear	7
leukocytes	8
(	0
MNL	0
)	0
of	0
10	0
patients	0
with	0
PCOS	0
and	0
10	0
healthy	0
women	0
(	0
controls	0
)	0
were	0
determined	0
.	0

RESULTS	0
:	0
There	0
were	0
no	0
significant	0
differences	0
in	0
the	0
number	0
(	0
6500+/-1001	0
sites/cell	0
and	0
6352+/-1697	0
sites/cell	0
,	0
respectively	0
;	0
P	0
>	0
0.05	0
)	0
and	0
affinity	0
(	0
3.93+/-0.89	0
nM	0
and	0
4.49+/-0.71	0
nM	0
,	0
respectively	0
;	0
P	0
>	0
0.05	0
)	0
of	0
GR	9
between	0
the	0
PCOS	0
patients	0
and	0
the	0
controls	0
.	0

CONCLUSIONS	0
:	0
These	0
results	0
suggest	0
that	0
the	0
alterations	0
in	0
the	0
HPA	0
axis	0
and	0
in	0
the	0
cortisol	0
metabolism	0
observed	0
in	0
PCOS	0
are	0
not	0
related	0
to	0
GR	9
deficiency	0
.	0

Heterogeneous	0
expression	0
of	0
the	0
lipocalin	9
NGAL	10
in	0
primary	0
breast	0
cancers	0
.	0

We	0
have	0
previously	0
shown	0
that	0
neu	0
oncogene-initiated	0
rat	0
mammary	0
carcinomas	0
uniquely	0
over-express	0
neu-related	9
lipocalin	10
(	0
NRL	9
)	0
,	0
a	0
member	0
of	0
the	0
calycin	9
protein	10
superfamily	10
.	0

Here	0
,	0
we	0
characterize	0
the	0
putative	9
human	10
homolog	10
of	0
NRL	9
,	0
neutrophil	9
gelatinase-associated	10
lipocalin	10
(	0
NGAL	9
)	0
.	0

ngal	0
gene	0
expression	0
was	0
found	0
at	0
moderate	0
levels	0
in	0
only	0
2	0
of	0
17	0
human	0
tissues	0
examined	0
,	0
breast	0
and	0
lung	0
.	0

When	0
breast	0
cancers	0
were	0
examined	0
for	0
NGAL	0
mRNA	0
and	0
protein	0
levels	0
,	0
they	0
were	0
found	0
to	0
exhibit	0
heterogeneous	0
expression	0
.	0

NGAL	9
levels	0
varied	0
in	0
these	0
tumors	0
from	0
undetectable	0
to	0
exceeding	0
those	0
in	0
normal	0
breast	0
parenchyma	0
.	0

Immuno-histochemical	0
analysis	0
confirmed	0
the	0
presence	0
of	0
NGAL	9
within	0
breast	7
carcinoma	8
cells	8
but	0
detected	0
only	0
low	0
levels	0
of	0
this	0
protein	0
in	0
normal	0
ductal	0
epithelium	0
.	0

In	0
contrast	0
,	0
large	0
amounts	0
of	0
the	0
protein	0
were	0
localized	0
to	0
the	0
lumen	0
of	0
normal	0
breast	0
ducts	0
in	0
the	0
vicinity	0
of	0
NGAL	9
-expressing	0
tumors	0
.	0

Interestingly	0
,	0
unlike	0
NRL	9
in	0
rat	0
mammary	0
carcinomas	0
,	0
no	0
significant	0
association	0
between	0
NGAL	9
expression	0
and	0
HER-2/neu	9
activation	0
was	0
found	0
in	0
human	0
breast	0
tumors	0
.	0

In	0
contrast	0
,	0
a	0
significant	0
correlation	0
between	0
NGAL	9
expression	0
in	0
breast	0
cancer	0
was	0
found	0
with	0
several	0
other	0
markers	0
of	0
poor	0
prognosis	0
,	0
including	0
estrogen	0
and	0
progesterone	9
receptor	10
-negative	0
status	0
and	0
high	0
proliferation	0
(	0
S-phase	0
fraction	0
)	0
.	0

NGAL	9
levels	0
were	0
stratified	0
as	0
high	0
or	0
low	0
in	0
breast	0
cancers	0
from	0
a	0
cohort	0
of	0
node-positive	0
patients	0
with	0
known	0
outcome	0
.	0

No	0
significant	0
association	0
between	0
NGAL	9
expression	0
and	0
disease-free	0
or	0
overall	0
survival	0
was	0
observed	0
.	0

BASH	9
,	0
a	0
novel	9
signaling	10
molecule	10
preferentially	0
expressed	0
in	0
B	7
cells	8
of	0
the	0
bursa	0
of	0
Fabricius	0
.	0

The	0
bursa	0
of	0
Fabricius	0
is	0
a	0
gut-associated	0
lymphoid	0
organ	0
that	0
is	0
essential	0
for	0
the	0
generation	0
of	0
a	0
diversified	0
B	7
cell	8
repertoire	8
in	0
the	0
chicken	0
.	0

We	0
describe	0
here	0
a	0
novel	0
gene	0
preferentially	0
expressed	0
in	0
bursal	7
B	8
cells	8
.	0

The	0
gene	0
encodes	0
an	0
85-kDa	9
protein	10
,	0
designated	0
BASH	9
(	0
B	9
cell	10
adaptor	10
containing	10
SH2	10
domain	10
)	0
,	0
that	0
contains	0
N-terminal	9
acidic	10
domains	10
with	0
SH2	9
domain-binding	10
phosphotyrosine-based	10
motifs	10
,	0
a	0
proline-rich	9
domain	10
,	0
and	0
a	0
C-terminal	9
SH2	10
domain	10
.	0

BASH	9
shows	0
a	0
substantial	0
sequence	0
similarity	0
to	0
SLP-76	9
,	0
an	0
adaptor	0
protein	0
functioning	0
in	0
TCR	9
-signal	0
transduction	0
.	0

BASH	9
becomes	0
tyrosine-phosphorylated	0
with	0
the	0
B	9
cell	10
Ag	10
receptor	10
(	0
BCR	9
)	0
cross-link	0
or	0
by	0
coexpression	0
with	0
Syk	9
and	0
Lyn	9
and	0
associates	0
with	0
signaling	9
molecules	10
including	0
Syk	9
and	0
a	0
putative	9
chicken	10
Shc	10
homologue	10
.	0

Overexpression	0
of	0
BASH	9
results	0
in	0
suppression	0
of	0
the	0
NF-AT	9
activation	0
induced	0
by	0
BCR	9
-cross-linking	0
.	0

These	0
findings	0
suggest	0
that	0
BASH	9
is	0
involved	0
in	0
BCR	9
-mediated	0
signal	0
transduction	0
and	0
could	0
play	0
a	0
critical	0
role	0
in	0
B	0
cell	0
development	0
in	0
the	0
bursa	0
.	0

Granulocyte	9
colony-stimulating	10
factor	10
activates	0
a	0
72-kDa	9
isoform	10
of	0
STAT3	9
in	0
human	7
neutrophils	8
.	0

Granulocyte	9
colony-stimulating	10
factor	10
(	0
G-CSF	9
)	0
signaling	0
involves	0
activation	0
of	0
STATs	9
,	0
proteins	0
that	0
serve	0
the	0
dual	0
function	0
of	0
signal	0
transduction	0
and	0
activation	0
of	0
transcription	0
.	0

We	0
previously	0
demonstrated	0
that	0
G-CSF	9
activated	0
a	0
distinct	0
Stat3-like	9
protein	10
in	0
immature	7
and	8
mature	8
normal	8
myeloid	8
cells	8
,	0
StatG	9
.	0

StatG	9
in	0
normal	7
immature	8
human	8
myeloid	8
cells	8
,	0
i.e	0
.	0
adult	7
CD34+	8
bone	8
marrow	8
cells	8
,	0
was	0
composed	0
of	0
Stat3beta	9
.	0

This	0
investigation	0
was	0
undertaken	0
to	0
determine	0
the	0
composition	0
of	0
StatG	9
in	0
mature	7
normal	8
human	8
myeloid	8
cells	8
,	0
i.e	0
.	0
polymorphonuclear	7
neutrophilic	8
granulocytes	8
(	0
PMN	7
)	0
.	0

These	0
studies	0
revealed	0
that	0
the	0
major	9
protein	10
in	0
extracts	0
of	0
PMN	7
activated	0
by	0
G-CSF	9
to	0
bind	0
the	0
high-affinity	1
serum-inducible	2
element	2
(	0
hSIE	1
)	0
is	0
a	0
72-kDa	9
protein	10
that	0
cross-reacts	0
with	0
Stat3	9
monoclonal	10
antibody	10
,	0
which	0
we	0
have	0
designated	0
Stat3gamma	9
.	0

Stat3gamma	9
is	0
derived	0
from	0
Stat3alpha	9
by	0
limited	0
proteolysis	0
and	0
lacks	0
the	0
carboxyl-terminal	9
portion	10
of	0
Stat3alpha	9
.	0

Because	0
this	0
region	0
of	0
Stat3alpha	9
is	0
involved	0
in	0
transcriptional	0
activation	0
,	0
our	0
findings	0
suggest	0
the	0
possibility	0
that	0
Stat3gamma	9
may	0
be	0
transcriptionally	0
inactive	0
and	0
may	0
compete	0
with	0
Stat3alpha	9
for	0
Stat3	1
binding	2
sites	2
in	0
these	0
terminally	7
differentiated	8
myeloid	8
cells	8

Association	0
between	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
and	0
integration	0
of	0
human	0
T-cell-leukemia	0
virus	0
type	0
1	0
in	0
adult	7
T-cell	8
leukemia	8
cells	8
.	0

It	0
is	0
known	0
that	0
the	0
expression	0
levels	0
of	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
in	0
adult	7
T	8
cell	8
leukemia	8
(	8
ATL	8
)	8
cells	8
are	0
high	0
,	0
whereas	0
those	0
in	0
T-lymphoid	7
cells	8
are	0
not	0
.	0

In	0
order	0
to	0
investigate	0
the	0
factors	0
that	0
influence	0
the	0
induction	0
of	0
ICAM-1	9
molecules	0
,	0
Northern	0
blot	0
analysis	0
to	0
measure	0
the	0
expression	0
level	0
of	0
ICAM-1	3
mRNAs	4
and	0
Southern	0
blot	0
hybridization	0
to	0
analyze	0
the	0
integration	0
of	0
human	0
T-cell-leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
provirus	0
were	0
done	0
.	0

The	0
levels	0
of	0
ICAM-1	3
mRNA	4
expression	0
of	0
ATL	5
cells	6
were	0
generally	0
higher	0
than	0
those	0
of	0
T-lymphoid	7
cells	8
.	0

However	0
,	0
ILT-mat	5
cells	6
and	0
ATL16T	5
(	6
-	6
)	6
cells	6
,	0
although	0
they	0
were	0
ATL	5
cells	6
,	0
showed	0
rather	0
low	0
surface	0
ICAM-1	9
expression	0
and	0
ICAM-1	3
mRNA	4
expression	0
.	0

Southern	0
blot	0
hybridization	0
showed	0
that	0
only	0
two	0
and	0
four	0
bands	0
were	0
found	0
in	0
ILT-mat	5
and	0
ATL16T	5
(	6
-	6
)	6
cells	6
,	0
respectively	0
,	0
whereas	0
>	0
10	0
bands	0
were	0
detected	0
in	0
other	0
ATL	5
cells	6
.	0

These	0
results	0
suggest	0
that	0
monoclonal	0
integration	0
of	0
HTLV-1	0
provirus	0
to	0
the	0
genome	0
of	0
T	7
cell	8
,	0
especially	0
the	0
number	0
of	0
integration	0
sites	0
,	0
is	0
one	0
of	0
the	0
factors	0
for	0
induction	0
of	0
ICAM-1	9
molecules	10
.	0

Heat-shock	0
and	0
cadmium	0
chloride	0
increase	0
the	0
vimentin	0
mRNA	0
and	0
protein	0
levels	0
in	0
U-937	5
human	6
promonocytic	6
cells	6
.	0

Heat-shock	0
for	0
2	0
hours	0
at	0
42	0
degrees	0
C	0
,	0
or	0
the	0
administration	0
for	0
3	0
hours	0
of	0
100	0
or	0
150	0
microM	0
cadmium	0
chloride	0
,	0
inhibited	0
the	0
subsequent	5
proliferation	6
activity	6
,	0
induced	0
the	0
expression	0
of	0
functional	0
differentiation	9
markers	10
,	0
and	0
caused	0
an	0
increase	0
in	0
the	0
amount	0
of	0
the	0
stress-responsive	9
HSP70	10
protein	10
in	0
U-937	5
human	6
promonocytic	6
cells	6
.	0

In	0
addition	0
,	0
both	0
heat	0
and	0
cadmium	0
produced	0
an	0
increase	0
in	0
the	0
amount	0
of	0
the	0
intermediate	9
filament	10
protein	10
vimentin	9
,	0
as	0
determined	0
by	0
immunoblot	0
and	0
immunofluorescence	0
assays	0
.	0

By	0
contrast	0
,	0
the	0
amounts	0
of	0
actin	9
and	0
beta-tubulin	9
were	0
not	0
significantly	0
altered	0
.	0

The	0
amount	0
of	0
vimentin	3
mRNA	4
was	0
also	0
increased	0
during	0
recovery	0
from	0
stress	0
,	0
indicating	0
that	0
vimentin	9
expression	0
was	0
not	0
exclusively	0
regulated	0
at	0
the	0
protein	0
level	0
.	0

Although	0
cadmium	0
caused	0
an	0
early	0
,	0
transient	0
stimulation	0
of	0
c-jun	1
and	0
c-fos	1
expression	0
and	0
AP-1	9
binding	0
activity	0
,	0
heat-shock	0
failed	0
to	0
alter	0
both	0
protooncogene	1
expression	0
and	0
transcription	0
factor	0
binding	0
,	0
indicating	0
that	0
the	0
stress-induced	0
vimentin	9
increase	0
was	0
not	0
the	0
result	0
of	0
AP-1	9
-mediated	0
transcriptional	0
activation	0
.	0

Finally	0
,	0
it	0
was	0
observed	0
that	0
the	0
rate	0
of	0
decay	0
of	0
vimentin	3
mRNA	4
upon	0
actinomycin	0
D	0
administration	0
was	0
decreased	0
in	0
heat-	5
and	6
cadmium-pretreated	6
cells	6
in	0
comparison	0
to	0
untreated	7
cells	8
.	0

These	0
results	0
indicate	0
that	0
stress	0
treatments	0
cause	0
an	0
increase	0
in	0
vimentin	9
levels	0
in	0
promonocytic	7
cells	8
,	0
which	0
may	0
be	0
explained	0
at	0
least	0
in	0
part	0
by	0
transcript	0
stabilization	0
.	0

Ovarian	0
and	0
breast	0
cytotoxic	7
T	8
lymphocytes	8
can	0
recognize	0
peptides	0
from	0
the	0
amino	0
enhancer	0
of	0
split	0
protein	0
of	0
the	0
Notch	9
complex	10
.	0

In	0
this	0
study	0
we	0
investigated	0
recognition	0
by	0
ovarian	7
tumor	8
associated	8
lymphocyte	8
(	0
OVTAL	7
)	0
,	0
and	0
breast	7
tumor	8
associated	8
lymphocytes	8
(	0
BRTAL	7
)	0
,	0
of	0
peptides	0
corresponding	0
to	0
the	0
sequence	0
125-135	9
of	10
the	10
Aminoenhancer	10
of	10
split	10
(	10
AES	10
)	10
protein	10
.	0

Three	0
of	0
these	0
peptides	0
designated	0
as	0
G75	0
:	0
AES1/2	0
(	0
128-135	9
)	0
,	0
G60	0
:	0
AES1/2	0
(	0
127-137	9
)	0
and	0
G61	0
:	0
AES1/2	0
(	0
125-133	9
)	0
correspond	0
to	0
the	0
wildtype	1
AES	2
sequence	2
,	0
while	0
the	0
fourth	0
G76	0
:	0
GPLTPLPV	0
,	0
AES1/2	9
(	10
128-135	10
)	10
corresponds	0
to	0
a	0
variant	0
sequence	0
of	0
the	0
peptide	0
G75	0
with	0
the	0
N-terminal	0
Leu	0
substituted	0
to	0
glycine	0
.	0

These	0
sequences	0
were	0
chosen	0
for	0
study	0
because	0
mass-spectrometric	0
analysis	0
(	0
MS	0
)	0
of	0
a	0
CTL	7
active	0
HPLC	0
peptide	0
fraction	0
eluted	0
from	0
immunoaffinity	9
precipitated	10
HLA-A2	10
molecule	10
,	0
revealed	0
:	0
(	0
a	0
)	0
the	0
presence	0
of	0
an	0
ion	0
with	0
a	0
mass-to-charge	0
ratio	0
(	0
m/z	0
)	0
of	0
793	0
which	0
was	0
more	0
abundant	0
than	0
other	0
ions	0
of	0
similar	0
masses	0
;	0
(	0
b	0
)	0
the	0
tentatively	0
reconstituted	0
sequence	0
of	0
the	0
ion	0
793	0
matched	0
the	0
sequence	0
of	0
peptide	0
G76	0
.	0

We	0
found	0
that	0
AES	0
peptides	0
G75	0
(	0
128-135	9
)	0
and	0
G76	0
(	0
128-135	9
)	0
(	0
L128G	0
)	0
reconstituted	0
CTL	0
recognition	0
at	0
concentrations	0
ranging	0
between	0
200-500	0
nM	0
.	0

These	0
concentrations	0
are	0
lower	0
than	0
concentrations	0
reported	0
to	0
activate	0
effector	0
function	0
of	0
CTL	0
recognizing	0
other	0
epithelial	9
tumor	10
Ag	10
.	0

Furthermore	0
,	0
analysis	0
with	0
cloned	0
CD8+	7
T	8
cells	8
indicated	0
that	0
G75	0
and	0
G76	0
were	0
not	0
cross-reactive	0
specificities	0
,	0
suggesting	0
a	0
key	0
role	0
for	0
the	0
N-terminal	9
residues	10
of	0
the	0
variant	0
peptide	0
in	0
dictating	0
specificities	0
.	0

Since	0
the	0
AES	9
proteins	10
are	0
part	0
of	0
a	0
set	0
of	0
transcriptional	0
repressors	0
encoded	0
by	0
the	0
Enhancer	1
of	2
split	2
[	2
E	2
(	2
spl	2
)	2
]	2
genes	2
,	0
and	0
since	0
these	0
repressors	0
are	0
activated	0
to	0
suppress	0
cell	0
differentiation	0
in	0
response	0
to	0
Notch	9
receptors	10
signalling	0
,	0
the	0
AES	0
peptides	0
may	0
represent	0
a	0
novel	0
class	0
of	0
self-antigens	9
that	0
deserve	0
further	0
consideration	0
as	0
tumor	9
Ag	10
in	0
epithelial	0
cancers	0
.	0

Induction	0
of	0
the	0
pro-myelocytic	1
leukaemia	2
gene	2
by	0
type	9
I	10
and	10
type	10
II	10
interferons	10
.	0

The	0
physiological	0
role	0
of	0
the	0
pro-myelocytic	9
leukaemia	10
(	10
PML	10
)	10
gene	10
product	10
is	0
poorly	0
defined	0
.	0

Among	0
other	0
functions	0
,	0
PML	1
is	0
involved	0
in	0
haematopoietic	0
differentiation	0
and	0
in	0
control	0
of	0
cell	0
growth	0
and	0
tumorigenesis	0
.	0

We	0
investigated	0
the	0
regulation	0
of	0
human	0
PML	1
expression	0
by	0
interferons	9
(	0
IFNs	9
)	0
and	0
IL-1	9
in	0
various	0
human	5
haematopoietic	6
lines	6
(	0
U937	5
,	0
THP1	5
,	0
HL60	5
,	0
NB4	5
)	0
,	0
in	0
human	7
diploid	8
fibroblasts	8
and	0
in	0
human	7
peripheral	8
blood	8
leukocytes	8
.	0

Cytokine-induced	0
modulation	0
of	0
PML	1
expression	0
was	0
assessed	0
by	0
Northern	0
blot	0
analyses	0
,	0
flow	0
cytometry	0
studies	0
and	0
in	0
situ	0
immunolabelling	0
.	0

Our	0
data	0
show	0
that	0
IFNs	9
and	0
IL-1	9
upregulate	0
PML	0
transcript	0
and	0
protein	0
expression	0
in	0
a	0
time	0
and	0
dose-dependent	0
manner	0
.	0

In	0
situ	0
immunolabelling	0
revealed	0
that	0
upregulation	0
of	0
protein	0
expression	0
by	0
IFN-alpha	9
is	0
a	0
consequence	0
of	0
a	0
marked	0
increase	0
in	0
both	0
the	0
number	0
and	0
the	0
intensity	0
of	0
the	0
staining	0
of	0
so-called	0
PML	9
nuclear	10
bodies	10
.	0

Our	0
data	0
suggest	0
that	0
stimulation	0
of	0
PML	1
expression	0
by	0
interferons	9
and	0
IL-1	9
may	0
account	0
for	0
upregulation	0
of	0
PML	9
proteins	10
observed	0
in	0
inflammatory	0
tissues	0
and	0
in	0
proliferative	0
states	0
.	0

The	0
position	0
of	0
the	0
ZEBRA	9
activation	10
domain	10
does	0
not	0
influence	0
its	0
biological	0
activity	0
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
a	0
human	0
herpesvirus	0
which	0
latently	0
infects	0
B	7
lymphocytes	8
.	0

EBV	0
encodes	0
a	0
unique	0
transcriptional	0
activator	0
,	0
known	0
as	0
ZEBRA	9
,	0
which	0
can	0
disrupt	0
viral	0
latency	0
in	0
B	7
cells	8
and	0
induce	0
lytic	0
viral	0
replication	0
.	0

Furthermore	0
,	0
ZEBRA	9
has	0
been	0
shown	0
to	0
bind	0
at	0
the	0
EBV	0
origin	0
of	0
lytic	0
replication	0
,	0
and	0
is	0
necessary	0
for	0
viral	0
DNA	0
replication	0
to	0
occur	0
.	0

Previously	0
we	0
demonstrated	0
that	0
heterologous	9
activation	10
domains	10
can	0
fully	0
substitute	0
for	0
the	0
ZEBRA	9
activation	10
domain	10
.	0

Here	0
we	0
extend	0
those	0
results	0
by	0
showing	0
that	0
the	0
position	0
of	0
the	0
ZEBRA	9
activation	10
domain	10
or	0
a	0
heterologous	0
replacement	0
domain	0
does	0
not	0
influence	0
its	0
ability	0
to	0
function	0
in	0
the	0
disruption	0
of	0
EBV	0
latency	0
.	0

In	0
this	0
study	0
three	0
novel	0
clones	0
were	0
constructed	0
in	0
which	0
the	0
ZEBRA	9
activation	10
region	10
was	0
repositioned	0
to	0
the	0
carboxy	9
terminus	10
of	0
the	0
protein	0
.	0

These	0
mutants	0
were	0
used	0
to	0
demonstrate	0
that	0
the	0
ability	0
of	0
ZEBRA	9
's	10
wild	10
type	10
domain	10
to	0
function	0
in	0
the	0
complex	0
biological	0
process	0
of	0
virus	0
activation	0
is	0
not	0
compromised	0
by	0
altering	0
its	0
position	0
within	0
the	0
protein	0
.	0

The	0
modulation	0
of	0
glucocorticoid	9
receptor	10
content	0
by	0
3-O-methyl-D-glucose	0
transport	0
in	0
human	7
mononuclear	8
leukocyte	8
in	0
obesity	0
.	0

Glucocorticoid	9
receptors	10
(	0
GR	9
)	0
and	0
3-O-methyl-D	0
glucose	0
(	0
3-O-MG	0
)	0
transport	0
were	0
determined	0
in	0
mononuclear	7
leukocytes	8
(	0
MNL	7
)	0
from	0
11	0
abdominal	0
obese	0
subjects	0
,	0
10	0
pituitary-dependent	0
Cushing	0
's	0
syndrome	0
(	0
Cushing	0
's	0
disease	0
)	0
and	0
10	0
healthy	0
controls	0
.	0

Using	0
a	0
whole-cell	0
competitive	0
binding	0
assay	0
and	0
3H-dexamethasone	0
as	0
tracer	0
,	0
MNL	7
of	0
abdominal	0
obese	0
subjects	0
were	0
found	0
to	0
have	0
4855	0
+/-	0
1389	0
sites/cell	0
which	0
was	0
significantly	0
lower	0
(	0
p	0
<	0
0.05	0
)	0
than	0
controls	0
(	0
6234	0
+/-	0
1568	0
sites/cell	0
)	0
,	0
although	0
no	0
significant	0
difference	0
was	0
found	0
in	0
the	0
mean	0
serum	0
cortisol	0
level	0
.	0

Their	0
mean	0
Kd	0
(	0
affinity	0
)	0
was	0
also	0
significantly	0
lower	0
than	0
that	0
found	0
in	0
the	0
healthy	0
controls	0
(	0
obese	0
Kd	0
:	0
2.92	0
+/-	0
0.84	0
nmol/l	0
,	0
control	0
Kd	0
:	0
4.55	0
+/-	0
0.67	0
nM	0
,	0
p	0
<	0
0.05	0
)	0
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
receptor	0
characteristics	0
in	0
Cushing	0
's	0
disease	0
patients	0
were	0
within	0
the	0
normal	0
range	0
.	0

At	0
the	0
same	0
time	0
,	0
3-O-MG	0
transport	0
was	0
determined	0
in	0
the	0
same	0
subjects	0
.	0

In	0
Cushing	0
's	0
disease	0
,	0
3-O-MG	0
transport	0
was	0
within	0
the	0
normal	0
range	0
,	0
whereas	0
in	0
abdominal	0
obesity	0
this	0
value	0
was	0
significantly	0
lower	0
than	0
the	0
healthy	0
controls	0
(	0
abdominal	0
obese	0
:	0
31.90	0
+/-	0
8.20	0
;	0
control	0
:	0
46.26	0
+/-	0
12.91	0
fmol/10	0
(	0
6	0
)	0
cell	0
,	0
min	0
,	0
p	0
<	0
0.05	0
)	0
.	0

We	0
also	0
found	0
a	0
positive	0
correlation	0
between	0
3-O-MG	0
transport	0
and	0
GR	9
binding	0
capacity	0
in	0
abdominal	0
subjects	0
(	0
r	0
=	0
0.89	0
,	0
p	0
<	0
0.001	0
)	0
,	0
however	0
we	0
did	0
not	0
find	0
such	0
a	0
correlation	0
in	0
Cushing	0
's	0
disease	0
(	0
r	0
=	0
0.60	0
,	0
p	0
>	0
0.05	0
)	0
.	0

These	0
results	0
indicated	0
that	0
,	0
in	0
abdominal	0
obesity	0
,	0
the	0
GR	9
binding	0
capacity	0
in	0
MNL	7
is	0
influenced	0
by	0
the	0
changes	0
in	0
glucose	0
transport	0
.	0

Interleukin-10	9
and	0
transforming	1
growth	2
factor-beta	2
promoter	2
polymorphisms	2
in	0
allergies	0
and	0
asthma	0
.	0

Interleukin-10	9
(	0
IL-10	9
)	0
and	0
transforming	9
growth	10
factor	10
beta	10
(	0
TGF-beta	9
)	0
are	0
inhibitory	0
for	0
B	7
and	8
T	8
cells	8
,	0
IgE	9
production	0
,	0
and	0
mast	0
cell	0
proliferation	0
,	0
and	0
they	0
induce	0
apoptosis	0
in	0
eosinophils	7
.	0

These	0
cytokines	9
are	0
therefore	0
candidate	0
genes	0
which	0
could	0
contribute	0
to	0
the	0
development	0
of	0
asthma	0
or	0
allergies	0
.	0

We	0
investigated	0
the	0
hypothesis	0
that	0
polymorphic	0
nucleotides	0
within	0
the	0
IL-10	1
and	2
TGF-beta	2
gene	2
promoters	2
would	0
link	0
to	0
the	0
expression	0
of	0
allergies	0
and	0
asthma	0
.	0

DNA	0
taken	0
from	0
families	0
with	0
an	0
asthmatic	0
proband	0
was	0
examined	0
for	0
base	0
exchanges	0
by	0
single-stranded	0
conformational	0
polymorphism	0
(	0
SSCP	0
)	0
.	0

We	0
demonstrated	0
the	0
presence	0
of	0
a	0
polymorphism	0
in	0
the	0
promoter	1
region	2
of	0
the	0
IL-10	1
gene	2
and	0
four	0
in	0
the	0
TGF-beta	1
gene	2
promoters	2
(	0
3	0
in	0
TGF-beta1	1
and	0
1	0
in	0
TGF-beta2	1
)	0
.	0

The	0
IL-10	9
gene	0
polymorphism	0
was	0
a	0
C-to-A	0
exchange	0
571	1
base	2
pairs	2
upstream	2
from	0
the	0
translation	1
start	2
site	2
and	0
was	0
present	0
between	0
consensus	1
binding	2
sequences	2
for	0
Sp1	9
and	0
elevated	0
total	0
serum	0
.	0

This	0
polymorphism	0
was	0
associated	0
with	0
elevated	0
total	9
serum	10
IgE	10
in	0
subjects	0
heterozygotic	0
or	0
homozygotic	0
for	0
this	0
base	0
exchange	0
(	0
p	0
<	0
0.009	0
)	0
.	0

The	0
base	0
exchange	0
at	0
-509	0
(	0
from	0
the	0
transcription	0
initiation	0
site	0
)	0
in	0
the	0
TGF-beta	1
promoter	2
also	0
linked	0
to	0
elevated	0
total	0
IgE	9
(	0
p	0
<	0
0.01	0
)	0
.	0

This	0
polymorphism	0
represented	0
a	0
C-to-T	0
base	0
exchange	0
which	0
induced	0
a	0
YY1	1
consensus	2
sequence	2
and	0
is	0
present	0
in	0
a	0
region	0
of	0
the	0
promoter	0
associated	0
with	0
negative	0
transcription	0
regulation	0
.	0

Tpl-2	9
induces	0
IL-2	9
expression	0
in	0
T-cell	5
lines	6
by	0
triggering	0
multiple	0
signaling	0
pathways	0
that	0
activate	0
NFAT	9
and	0
NF-kappaB	9
.	0

The	0
Tpl-2	9
kinase	10
activates	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
and	0
induces	0
IL-2	9
expression	0
in	0
T-cell	5
lines	6
.	0

Here	0
we	0
show	0
that	0
the	0
activation	0
of	0
the	0
IL-2	1
promoter	2
by	0
Tpl-2	9
is	0
inhibited	0
by	0
mutant	9
signaling	10
molecules	10
that	0
inhibit	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
or	0
the	0
calcineurin	9
/NFAT	9
pathways	0
and	0
is	0
promoted	0
by	0
combinations	0
of	0
signaling	9
molecules	10
that	0
activate	0
these	0
pathways	0
.	0

We	0
,	0
therefore	0
,	0
conclude	0
that	0
signals	0
generated	0
by	0
the	0
convergence	0
of	0
the	0
MAPK	9
and	0
the	0
calcineurin	9
/NFAT	9
pathway	0
are	0
necessary	0
and	0
sufficient	0
for	0
the	0
activation	0
of	0
the	0
IL-2	1
promoter	2
by	0
Tpl-2	9
.	0

The	0
activation	0
of	0
both	0
the	0
IL-2	1
promoter	2
and	0
an	0
NFAT-driven	1
minimal	2
promoter	2
were	0
shown	0
to	0
depend	0
on	0
signals	0
transduced	0
by	0
Raf1	9
.	0

However	0
,	0
it	0
was	0
only	0
the	0
IL-2	1
promoter	2
whose	0
activation	0
by	0
Tpl-2	9
was	0
fully	0
blocked	0
by	0
the	0
dominant	9
negative	10
mutant	10
MEK1S218/222A	10
and	0
the	0
MEK1/MEK2	0
inhibitor	0
PD098059	0
.	0

Since	0
the	0
activation	0
of	0
NFAT	9
is	0
MAPK	9
-dependent	0
these	0
findings	0
suggested	0
that	0
the	0
activation	0
of	0
MAPK	9
by	0
Tpl-2	9
is	0
either	0
independent	0
or	0
only	0
partially	0
dependent	0
on	0
MEK1	9
and	0
MEK2	9
.	0

In	0
addition	0
,	0
they	0
suggested	0
that	0
the	0
activation	0
of	0
the	0
IL-2	1
promoter	2
is	0
under	0
the	0
control	0
of	0
not	0
only	0
NFAT	9
but	0
also	0
a	0
second	0
factor	0
whose	0
activation	0
is	0
MEK	9
-dependent	0
.	0

Experiments	0
in	0
COS-1	5
and	0
EL-4	5
cells	6
confirmed	0
both	0
hypotheses	0
and	0
revealed	0
that	0
the	0
second	0
factor	0
activated	0
by	0
Tpl-2	9
is	0
NF-kappaB	9
.	0

While	0
the	0
activation	0
of	0
the	0
IL-2	1
promoter	2
and	0
an	0
NFAT-driven	1
minimal	2
promoter	2
by	0
Tpl-2	9
was	0
fully	0
blocked	0
by	0
the	0
dominant	9
negative	10
mutant	10
NFAT	9
delta418	10
,	0
it	0
was	0
only	0
partially	0
blocked	0
by	0
the	0
calcineurin	9
inhibitor	0
cyclosporin	0
A	0
suggesting	0
that	0
the	0
Tpl-2	9
-mediated	0
NFAT	9
activation	0
is	0
under	0
the	0
control	0
of	0
a	0
combination	0
of	0
calcineurin-dependent	0
and	0
independent	0
pathways	0
.	0

Both	0
pathways	0
were	0
fully	0
blocked	0
by	0
Bcl-2	9
or	0
Bcl-X	9
(	10
L	10
)	10
.	0

Differential	0
activation	0
of	0
functionally	0
distinct	0
STAT5	9
proteins	10
by	0
IL-5	9
and	0
GM-CSF	9
during	0
eosinophil	0
and	0
neutrophil	0
differentiation	0
from	0
human	5
CD34+	6
hematopoietic	6
stem	6
cells	6
.	0

Interleukin-5	9
(	0
IL-5	9
)	0
and	0
granulocyte	9
macrophage-colony	10
stimulating	10
factor	10
(	0
GM-CSF	9
)	0
are	0
important	0
cytokines	9
for	0
the	0
proliferation	0
,	0
differentiation	0
,	0
and	0
activation	0
of	0
myeloid	7
lineages	8
.	0

The	0
JAK	9
/STAT	9
pathway	0
is	0
one	0
of	0
the	0
signaling	0
pathways	0
implicated	0
in	0
mediating	0
biological	0
responses	0
induced	0
by	0
these	0
cytokines	9
.	0

Previous	0
studies	0
have	0
demonstrated	0
that	0
these	0
cytokines	9
predominantly	0
activate	0
an	0
80	9
kDa	10
STAT5	10
isoform	10
in	0
mature	0
granulocytes	0
.	0

To	0
better	0
understand	0
the	0
role	0
of	0
STAT	0
proteins	0
during	0
growth	0
and	0
differentiation	0
of	0
granulocytes	0
,	0
we	0
evaluated	0
differentiation	0
of	0
human	5
CD34+	6
hematopoietic	6
stem	6
cells	6
ex	0
vivo	0
toward	0
eosinophils	7
and	0
neutrophils	0
.	0

Bandshift	0
experiments	0
showed	0
that	0
in	0
an	0
early	0
stage	0
of	0
both	0
differentiation	0
pathways	0
(	0
14	0
days	0
)	0
,	0
the	0
94	0
kDa	0
STAT5B	9
protein	10
was	0
activated	0
by	0
both	0
IL-5	9
(	0
eosinophil	7
lineage	8
)	0
and	0
GM-CSF	9
(	0
neutrophil	7
lineage	8
)	0
.	0

However	0
,	0
during	0
maturation	0
of	0
both	0
lineages	0
(	0
days	0
21	0
and	0
28	0
)	0
,	0
increased	0
expression	0
of	0
a	0
functionally	0
distinct	0
80	9
kDa	10
STAT5	10
isoform	10
was	0
observed	0
,	0
resulting	0
in	0
heterodimer	9
DNA-binding	10
complexes	10
containing	0
both	0
the	0
94	0
and	0
80	0
kDa	0
STAT5	9
proteins	10
.	0

The	0
finding	0
that	0
functionally	0
distinct	0
isoforms	0
of	0
STAT5	9
are	0
activated	0
during	0
the	0
early	0
and	0
late	0
differentiation	0
stages	0
of	0
granulocytes	0
suggests	0
that	0
they	0
might	0
be	0
involved	0
in	0
regulating	0
different	0
biological	0
functions	0
in	0
these	0
cells	0
.	0

The	0
T-cell	9
oncogenic	10
protein	10
HOX11	10
activates	0
Aldh1	9
expression	0
in	0
NIH	5
3T3	6
cells	6
but	0
represses	0
its	0
expression	0
in	0
mouse	0
spleen	0
development	0
.	0

Hox11	1
is	0
a	0
homeobox	1
gene	2
essential	0
for	0
spleen	0
formation	0
in	0
mice	0
,	0
since	0
atrophy	0
of	0
the	0
anlage	0
of	0
a	0
developing	0
spleen	0
occurs	0
in	0
early	0
embryonic	0
development	0
in	0
Hox11	0
null	0
mice	0
.	0

HOX11	9
is	0
also	0
expressed	0
in	0
a	0
subset	0
of	0
T-cell	0
acute	0
leukemias	0
after	0
specific	0
chromosomal	0
translocations	0
.	0

Since	0
the	0
protein	0
has	0
a	0
homeodomain	1
and	0
can	0
activate	0
transcription	0
,	0
it	0
probably	0
exerts	0
at	0
least	0
some	0
of	0
its	0
effects	0
in	0
vivo	0
by	0
regulation	0
of	0
target	1
genes	2
.	0

Representational	0
difference	0
analysis	0
has	0
been	0
used	0
to	0
isolate	0
cDNA	1
clones	2
corresponding	0
to	0
mRNA	3
species	4
activated	0
following	0
stable	0
expression	0
of	0
HOX11	9
in	0
NIH	5
3T3	6
cells	6
.	0

The	0
gene	0
encoding	0
the	0
retinoic	9
acid-synthesizing	10
enzyme	10
aldehyde	9
dehydrogenase	10
1	10
(	0
Aldh1	9
)	0
,	0
initially	0
called	0
Hdg-1	9
,	0
was	0
found	0
to	0
be	0
ectopically	0
activated	0
by	0
HOX11	9
in	0
this	0
system	0
.	0

Study	0
of	0
Aldh1	9
gene	0
expression	0
during	0
spleen	0
development	0
showed	0
that	0
the	0
presence	0
of	0
Aldh1	3
mRNA	4
inversely	0
correlated	0
with	0
Hox11	9
.	0

Hox11	9
null	0
mouse	0
embryos	0
have	0
elevated	0
Aldh1	3
mRNA	4
in	0
spleen	0
primordia	0
prior	0
to	0
atrophy	0
,	0
while	0
Aldh1	9
seems	0
to	0
be	0
repressed	0
by	0
Hox11	9
during	0
organogenesis	0
of	0
the	0
spleens	0
of	0
wild-type	0
mice	0
.	0

This	0
result	0
suggests	0
that	0
expression	0
of	0
Aldh1	9
protein	10
is	0
negatively	0
regulated	0
by	0
Hox11	9
and	0
that	0
abnormal	0
expression	0
of	0
Aldh1	9
in	0
Hox11	9
null	0
mice	0
may	0
cause	0
loss	0
of	0
splenic	7
precursor	8
cells	8
by	0
aberrant	0
retinoic	0
acid	0
metabolism	0

Role	0
of	0
the	0
X2	1
box	2
in	0
activated	0
transcription	0
from	0
the	0
DRA	1
promoter	2
in	0
B	7
cells	8
.	0

We	0
investigated	0
the	0
function	0
of	0
the	0
evolutionary	0
conserved	0
X2	1
box	2
in	0
the	0
promoter	1
of	0
the	0
HLA-DRA	1
gene	2
from	0
the	0
human	9
major	10
histocompatibility	10
complex	10
(	0
MHC	9
)	0
in	0
resting	0
and	0
activated	0
B	7
cells	8
.	0

NF-X2	1
,	0
which	0
contains	0
members	0
of	0
the	0
AP-1/ATF/CREB	9
families	10
of	0
transcription	9
factors	10
,	0
interacts	0
with	0
the	0
X2	1
box	2
(	0
5'-TGCGTCA-3	0
'	0
)	0
from	0
positions	0
-97	0
to	0
-91	0
in	0
the	0
DRA	1
promoter	2
.	0

In	0
resting	0
Raji	5
cells	6
,	0
little	0
to	0
no	0
binding	0
to	0
the	0
X2	1
box	2
was	0
observed	0
.	0

In	0
sharp	0
contrast	0
,	0
in	0
B	7
cells	8
treated	0
with	0
the	0
phorbol	0
ester	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
,	0
strong	0
interactions	0
between	0
the	0
X2	1
box	2
and	0
NF-X2	1
containing	0
c-Fos	9
were	0
observed	0
.	0

As	0
determined	0
by	0
transient	0
expression	0
and	0
RNA	0
analyses	0
,	0
the	0
activation	0
of	0
protein	0
kinase	0
C	0
(	0
PKC	0
)	0
also	0
increased	0
rates	0
of	0
transcription	0
from	0
the	0
wild-type	0
DRA	1
promoter	2
but	0
not	0
from	0
a	0
DRA	1
promoter	2
bearing	0
clustered	0
point	0
mutations	0
in	0
the	0
X2	1
box	2
.	0

Since	0
the	0
co-expression	0
with	0
a	0
dominant	0
negative	0
c-Fos	9
abolished	0
the	0
responsiveness	0
to	0
TPA	0
,	0
we	0
conclude	0
that	0
activated	0
transcription	0
of	0
the	0
DRA	1
gene	2
depends	0
on	0
interactions	0
between	0
the	0
X2	1
box	2
and	0
NF-X2	1
,	0
which	0
contains	0
c-Fos	9
.	0

Thymocytes	0
control	0
the	0
CD4	1
gene	2
differently	0
from	0
mature	7
T	8
lymphocytes	8
.	0

We	0
analyzed	0
the	0
activity	0
of	0
the	0
enhancer	1
,	0
the	0
promoter	1
and	0
the	0
silencer	1
of	0
the	0
human	1
CD4	2
gene	2
during	0
T	0
cell	0
development	0
using	0
transgenic	0
mice	0
.	0

Immunofluorescence	0
studies	0
on	0
thymic	7
populations	8
of	0
mice	0
carrying	0
transgenes	0
in	0
various	0
combinations	0
of	0
these	0
regulatory	1
DNA	2
elements	2
revealed	0
that	0
thymocytes	7
control	0
the	0
CD4	1
gene	2
in	0
a	0
different	0
manner	0
than	0
mature	0
peripheral	7
T	8
lymphocytes	8
.	0

The	0
5'-positive	1
regulatory	2
unit	2
,	0
consisting	0
of	0
the	0
promoter	1
and	0
the	0
5	1
'	2
enhancer	2
,	0
is	0
already	0
active	0
at	0
the	0
CD4	9
-	0
CD8	9
-double-negative	0
(	0
DN	0
)	0
stage	0
of	0
development	0
.	0

However	0
,	0
its	0
activity	0
becomes	0
lower	0
in	0
the	0
double-positive	0
and	0
a	0
fraction	0
of	0
the	0
CD4+	7
CD8int/-	8
cell	8
population	8
,	0
indicating	0
that	0
an	0
additional	0
enhancer	0
,	0
located	0
in	0
either	0
the	0
first	1
or	2
the	2
third	2
intron	2
of	0
the	0
CD4	1
gene	2
,	0
is	0
required	0
for	0
CD4	1
gene	2
expression	0
in	0
this	0
population	0
.	0

The	0
other	0
studied	0
regulatory	1
element	2
is	0
the	0
minimal	1
CD4	2
silencer	2
which	0
inhibits	0
CD4	1
gene	2
expression	0
in	0
peripheral	7
CD8	8
T	8
lymphocytes	8
.	0

This	0
silencer	0
is	0
inactive	0
in	0
the	0
most	0
immature	7
DN	8
thymocytes	8
,	0
which	0
probably	0
use	0
a	0
distinct	0
silencer	0
mechanism	0
to	0
down-regulate	0
CD4	1
gene	2
expression	0
.	0

Unexpectedly	0
,	0
the	0
CD4	1
silencer	2
is	0
also	0
active	0
in	0
CD4+	7
CD8int/-	8
cells	8
of	0
the	0
thymus	0
,	0
implying	0
that	0
an	0
anti-silencer	0
may	0
be	0
required	0
to	0
resume	0
CD4	9
expression	0
in	0
this	0
cell	0
population	0
.	0

Altogether	0
,	0
the	0
CD4	1
gene	2
is	0
regulated	0
by	0
several	0
positive	0
and	0
negative	0
regulatory	0
mechanisms	0
which	0
come	0
into	0
play	0
in	0
a	0
developmentally	0
coordinated	0
manner	0
.	0

[	0
Induction	0
of	0
apoptosis	0
in	0
lymphocytes	7
by	0
glucocorticoids	0
:	0
between	0
physiology	0
and	0
pharmacology	0
]	0

Glucocorticoids	0
are	0
physiological	0
molecules	0
that	0
are	0
also	0
extensively	0
used	0
in	0
clinics	0
as	0
anti-inflammatory	0
,	0
immunosuppressive	0
or	0
anti-tumoral	0
agents	0
.	0

Glucocorticoids	0
can	0
induce	0
apoptosis	0
on	0
normal	7
lymphoid	8
cells	8
and	0
play	0
a	0
key	0
role	0
in	0
the	0
physiology	0
of	0
thymic	0
selection	0
.	0

In	0
clinics	0
these	0
molecules	0
are	0
also	0
used	0
for	0
their	0
potencies	0
in	0
inducing	0
apoptosis	0
of	0
malignant	7
lymphoid	8
cells	8
.	0

Glucocorticoids	0
are	0
mediating	0
their	0
effects	0
after	0
binding	0
to	0
an	0
intracellular	9
receptor	10
belonging	0
to	0
the	0
steroid	9
receptor	10
superfamily	10
:	0
the	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
.	0

Once	0
activated	0
,	0
the	0
GR	9
,	0
can	0
mediate	0
his	0
effects	0
through	0
direct	0
binding	0
on	0
the	0
DNA	0
or	0
via	0
protein/protein	0
interactions	0
with	0
transcription	9
factors	10
.	0

Depending	0
on	0
the	0
type	0
of	0
lymphocytes	7
,	0
the	0
mechanism	0
of	0
apoptosis	0
induced	0
by	0
glucocorticoids	0
fall	0
roughly	0
in	0
two	0
categories	0
:	0
induction	0
of	0
``	0
death	0
genes	0
''	0
by	0
the	0
activated	0
GR	9
(	0
I	9
kappa	10
B	10
,	0
c-jun	9
)	0
or	0
repression	0
of	0
survival	9
factors	10
(	0
AP-1	9
,	0
c-Myc	9
)	0
.	0

In	0
the	0
case	0
of	0
thymic	0
selection	0
the	0
mechanism	0
is	0
more	0
subtle	0
depending	0
on	0
the	0
mutual	0
repression	0
of	0
Nur77	9
and	0
GR	9
.	0

Direct	0
suppression	0
of	0
Stat1	9
function	0
during	0
adenoviral	0
infection	0
.	0

The	0
action	0
of	0
adenoviral	9
E1A	10
oncoprotein	10
on	0
host	1
immune-response	2
genes	2
has	0
been	0
attributed	0
to	0
interaction	0
with	0
p300/CBP-type	9
transcriptional	10
coactivators	10
in	0
competition	0
with	0
endogenous	9
transcription	10
factors	10
such	0
as	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
proteins	10
.	0

However	0
,	0
we	0
show	0
that	0
mutant	0
forms	0
of	0
E1A	9
that	0
no	0
longer	0
bind	0
p300/CBP	9
can	0
still	0
interact	0
directly	0
with	0
Stat1	9
(	0
via	0
E1A	9
N-terminal	10
and	10
Stat1	10
C-terminal	10
residues	10
)	0
and	0
block	0
IFNgamma-driven	0
,	0
Stat1	9
-dependent	0
gene	0
activation	0
and	0
consequent	0
function	0
during	0
early-phase	0
infection	0
in	0
the	0
natural	7
host	8
cell	8
.	0

The	0
results	0
provide	0
a	0
distinct	0
and	0
more	0
specific	0
mechanism	0
for	0
E1A	9
-mediated	0
immune	0
suppression	0
and	0
an	0
alternative	0
model	0
of	0
IFNgamma	9
-driven	0
enhanceosome	0
formation	0
that	0
may	0
allow	0
for	0
other	0
adaptors	0
(	0
in	0
addition	0
to	0
p300/CBP	9
)	0
to	0
link	0
Stat1	9
to	0
the	0
basal	9
transcription	10
complex	10
.	0

Effect	0
of	0
environmental	0
estrogens	0
on	0
IL-1beta	1
promoter	2
activity	0
in	0
a	0
macrophage	5
cell	6
line	6
.	0

Environmental	0
estrogens	0
or	0
estrogen	0
disrupters	0
have	0
recently	0
received	0
a	0
great	0
deal	0
of	0
attention	0
because	0
of	0
their	0
potential	0
health	0
impact	0
on	0
reproductive	0
tissues	0
.	0

Few	0
,	0
if	0
any	0
,	0
studies	0
have	0
been	0
made	0
on	0
the	0
impact	0
of	0
these	0
compounds	0
on	0
the	0
immune	0
system	0
.	0

We	0
sought	0
to	0
determine	0
the	0
activities	0
of	0
various	0
environmental	0
estrogens	0
on	0
the	0
modulation	0
of	0
the	0
interleukin-1beta	1
(	2
IL-1beta	2
)	2
gene	2
in	0
a	0
model	5
monocytic	6
cell	6
line	6
,	0
hER	5
+	6
IL-1beta-CAT+	6
.	0

This	0
cell	0
line	0
stably	0
transfected	0
with	0
the	0
human	9
estrogen	10
receptor	10
,	0
and	0
an	0
IL-1beta	1
promoter	2
construct	0
fused	0
to	0
the	0
CAT	1
reporter	2
gene	2
allows	0
us	0
to	0
monitor	0
the	0
effect	0
of	0
estrogenic	0
compounds	0
on	0
IL-1beta	1
promoter	2
activity	0
.	0

17beta-estradiol	0
(	0
E2	0
)	0
markedly	0
enhanced	0
lipopolysaccharide	0
-	0
(	0
LPS	0
)	0
induced	0
IL-1beta	1
promoter	2
-driven	0
CAT	9
activity	0
in	0
a	0
dose-dependent	0
manner	0
.	0

The	0
mycotoxins	0
alpha-zearalenol	0
and	0
zearalenone	0
both	0
exhibited	0
full	0
agonist	0
activity	0
,	0
but	0
at	0
lower	0
potencies	0
,	0
with	0
EC50	0
values	0
of	0
1.8	0
and	0
54	0
nM	0
,	0
respectively	0
,	0
compared	0
with	0
E2	0
at	0
0.5	0
nM	0
.	0

In	0
addition	0
,	0
genistein	0
was	0
a	0
very	0
low-potency	0
agonist	0
,	0
having	0
an	0
EC50	0
of	0
1.5	0
microM	0
.	0

Similar	0
to	0
the	0
E2	0
response	0
,	0
the	0
slope	0
factors	0
for	0
alpha-zearalenol	0
,	0
zearalenone	0
,	0
and	0
genistein	0
were	0
close	0
to	0
3.0	0
,	0
suggesting	0
positive	0
cooperativity	0
in	0
the	0
estrogenic	0
response	0
.	0

The	0
activity	0
of	0
the	0
mycotoxins	0
appeared	0
to	0
be	0
mediated	0
through	0
the	0
estrogen	0
receptor	0
,	0
since	0
both	0
the	0
antiestrogens	0
H1285	0
and	0
ICI	0
182	0
,	0
780	0
effectively	0
inhibited	0
their	0
agonist	0
activity	0
in	0
a	0
dose-dependent	0
manner	0
.	0

Representative	0
environmental	0
estrogenic	0
compounds	0
both	0
from	0
plant	0
and	0
industrial	0
sources	0
were	0
also	0
tested	0
.	0

Unlike	0
the	0
mycoestrogens	0
,	0
none	0
of	0
the	0
compounds	0
,	0
with	0
the	0
exception	0
of	0
genistein	0
,	0
synergized	0
with	0
LPS	0
to	0
enhance	0
IL-1beta	1
promoter	2
activity	0
.	0

When	0
tested	0
for	0
antiestrogenic	0
activity	0
,	0
the	0
industrial	0
compound	0
4-octylphenol	0
was	0
able	0
to	0
antagonize	0
the	0
response	0
to	0
E2	0
;	0
however	0
,	0
the	0
response	0
was	0
three	0
orders	0
of	0
magnitude	0
less	0
potent	0
than	0
H	0
1285	0
.	0

Naringenin	0
,	0
a	0
plant	0
flavonoid	0
,	0
showed	0
little	0
or	0
no	0
ability	0
to	0
antagonize	0
the	0
response	0
to	0
E2	0
.	0

Overall	0
,	0
the	0
results	0
show	0
that	0
some	0
environmental	0
estrogens	0
that	0
display	0
agonist	0
activity	0
in	0
reproductive	0
tissue	0
also	0
have	0
an	0
effect	0
on	0
IL-1	1
gene	2
expression	0
in	0
hemopoietic-derived	0
tissue	0
.	0

Isolation	0
and	0
utilization	0
of	0
human	7
dendritic	8
cells	8
from	0
peripheral	0
blood	0
to	0
assay	0
an	0
in	0
vitro	0
primary	0
immune	0
response	0
to	0
varicella-zoster	0
virus	0
peptides	0
.	0

A	0
human	0
dendritic	0
cell-based	0
assay	0
used	0
to	0
monitor	0
a	0
T	0
cell	0
proliferation	0
response	0
to	0
viral	0
peptides	0
in	0
vitro	0
is	0
described	0
.	0

Dendritic	7
cells	8
and	0
autologous	7
CD4+	8
T	8
cells	8
were	0
isolated	0
from	0
peripheral	0
blood	0
by	0
a	0
series	0
of	0
density-gradient	0
centrifugations	0
or	0
magnetic	0
bead	0
separations	0
(	0
or	0
both	0
)	0
.	0

Peptides	0
corresponding	0
to	0
residues	0
of	0
the	0
immediate	9
early	10
protein	10
,	0
IE62	9
,	0
of	0
varicella-zoster	0
virus	0
(	0
VZV	0
)	0
were	0
used	0
as	0
stimulating	9
antigens	10
,	0
and	0
persons	0
with	0
no	0
history	0
of	0
varicella	0
and	0
no	0
humoral	0
or	0
cellular	0
immunity	0
to	0
VZV	0
served	0
as	0
naive	0
donors	0
for	0
the	0
assays	0
.	0

Three	0
VZV-susceptible	0
donors	0
were	0
tested	0
,	0
and	0
all	0
demonstrated	0
an	0
in	0
vitro	0
response	0
to	0
multiple	0
VZV	0
peptides	0
.	0

This	0
assay	0
has	0
potential	0
as	0
a	0
screen	0
to	0
establish	0
the	0
immunogenicity	0
of	0
viral	0
antigens	0
in	0
vitro	0
using	0
T	7
cells	8
from	0
naive	0
donors	0
.	0

Xenogeneic	0
human	0
serum	0
promotes	0
leukocyte	0
adhesion	0
to	0
porcine	0
endothelium	0
under	0
flow	0
conditions	0
,	0
possibly	0
through	0
the	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
.	0

Endothelial	0
cell	0
activation	0
and	0
leukocyte	0
infiltration	0
are	0
a	0
consistent	0
feature	0
of	0
discordant	0
xenograft	0
rejection	0
.	0

Here	0
we	0
evaluated	0
whether	0
xenogeneic	0
serum	0
,	0
as	0
a	0
source	0
of	0
xenoreactive	9
natural	10
antibodies	10
and	0
complement	0
,	0
induced	0
endothelial	0
cell	0
activation	0
with	0
consequent	0
leukocyte	0
adhesion	0
under	0
flow	0
conditions	0
.	0

Porcine	5
aortic	6
endothelial	6
cells	6
(	0
PAEC	5
)	0
were	0
incubated	0
for	0
1	0
hr	0
30	0
min	0
or	0
5	0
hr	0
with	0
10	0
%	0
homologous	0
porcine	0
serum	0
(	0
control	0
)	0
or	0
10	0
%	0
xenogeneic	0
human	0
serum	0
and	0
then	0
perfused	0
with	0
total	0
human	7
leukocytes	8
in	0
a	0
parallel	0
plate	0
flow	0
chamber	0
under	0
laminar	0
flow	0
(	0
1.5	0
dynes/cm2	0
)	0
.	0

Adherent	0
cells	0
were	0
counted	0
by	0
digital	0
image	0
analysis	0
.	0

Xenogeneic	0
human	0
serum	0
significantly	0
(	0
P	0
<	0
0.01	0
)	0
increased	0
the	0
number	0
of	0
adherent	7
leukocytes	8
as	0
compared	0
with	0
porcine	0
serum	0
.	0

A	0
similar	0
adhesive	0
response	0
was	0
elicited	0
by	0
TNF	0
alpha	0
(	0
100	0
U/ml	0
)	0
,	0
one	0
of	0
the	0
most	0
potent	0
inducers	0
of	0
endothelial	7
cell	8
adhesive	0
properties	0
,	0
here	0
used	0
as	0
positive	0
control	0
.	0

In	0
order	0
to	0
elucidate	0
possible	0
mechanisms	0
underlying	0
endothelial	7
cell	8
activation	0
by	0
xenogeneic	0
serum	0
,	0
we	0
focussed	0
on	0
transcription	9
factor	10
NF-kappa	10
B	10
,	0
a	0
central	0
regulator	0
for	0
the	0
induction	0
of	0
different	0
genes	0
,	0
including	0
adhesive	9
molecules	10
and	0
chemoattractants	9
.	0

By	0
confocal	0
fluorescence	0
microscopy	0
,	0
we	0
observed	0
a	0
positive	0
staining	0
for	0
NF-kappa	9
B	10
(	0
p65	9
subunit	10
)	0
in	0
the	0
nuclei	0
of	0
PAEC	5
exposed	0
for	0
1	0
hr	0
30	0
min	0
to	0
human	0
serum	0
,	0
which	0
indicated	0
NF-kappa	9
B	10
activation	0
in	0
this	0
setting	0
.	0

At	0
variance	0
,	0
in	0
PAEC	5
incubated	0
with	0
the	0
homologous	0
serum	0
,	0
NF-kappa	9
B	10
was	0
strictly	0
localized	0
in	0
the	0
cell	0
cytoplasm	0
.	0

Treatment	0
of	0
PAEC	5
exposed	0
to	0
xenogeneic	0
serum	0
with	0
the	0
NF-kappa	9
B	10
inhibitors	0
pyrrolidinedithiocarbamate	0
(	0
PDTC	0
,	0
25	0
microM	0
)	0
and	0
tosyl-phechloromethylketone	0
(	0
TPCK	0
,	0
25	0
microM	0
)	0
significantly	0
(	0
P	0
<	0
0.01	0
)	0
reduced	0
leukocyte	0
adhesion	0
in	0
respect	0
to	0
PAEC	5
treated	0
with	0
human	0
serum	0
alone	0
.	0

Findings	0
that	0
xenogeneic	0
serum	0
promotes	0
leukocyte-endothelium	0
interaction	0
possibly	0
through	0
NF-kappa	9
B	10
activation	0
might	0
be	0
relevant	0
for	0
designing	0
future	0
therapeutic	0
strategies	0
aimed	0
at	0
prolonging	0
xenograft	0
survival	0
.	0

Anaphylatoxins	9
C5a	9
and	0
C3a	9
induce	0
nuclear	9
factor	10
kappaB	10
activation	0
in	0
human	7
peripheral	8
blood	8
monocytes	8
.	0

The	0
anaphylatoxins	9
C5a	9
and	0
C3a	9
are	0
involved	0
in	0
the	0
regulation	0
of	0
cytokine	0
production	0
.	0

In	0
this	0
study	0
the	0
capability	0
of	0
C5a	9
and	0
C3a	9
to	0
induce	0
transcription	0
factor	0
activation	0
was	0
examined	0
.	0

C5a	9
and	0
C3a	9
stimulation	0
of	0
human	7
peripheral	8
blood	8
monocytes	8
resulted	0
in	0
nuclear	0
expression	0
of	0
a	0
DNA	0
binding	0
activity	0
with	0
specificity	0
to	0
the	0
kappaB	1
sequence	2
.	0

The	0
p50	9
and	10
p65	10
proteins	10
,	0
constituents	0
of	0
the	0
prototypic	0
nuclear	9
factor	10
kappaB	10
,	0
were	0
identified	0
as	0
components	0
of	0
the	0
DNA-protein	0
complexes	0
by	0
anti-peptide	9
antibodies	10
in	0
gel	0
supershift	0
assays	0
.	0

C5a	9
induced	0
kappaB	9
binding	0
activity	0
was	0
detected	0
15	0
min	0
after	0
agonist	0
stimulation	0
,	0
peaked	0
at	0
30-40	0
min	0
,	0
and	0
remained	0
detectable	0
at	0
2	0
h	0
.	0

Binding	0
to	0
kappaB	1
sequence	2
was	0
accompanied	0
by	0
an	0
initial	0
decrease	0
and	0
subsequent	0
increase	0
in	0
the	0
cytoplasmic	0
IkappaBalpha	9
levels	0
,	0
as	0
detected	0
by	0
Western	0
blotting	0
using	0
an	0
anti-IkappaBalpha	9
antibody	10
.	0

Pertussis	0
toxin	0
treatment	0
markedly	0
decreased	0
kappaB	9
binding	0
activities	0
induced	0
by	0
both	0
C5a	9
and	0
C3a	9
,	0
whereas	0
cholera	9
toxin	10
displayed	0
no	0
inhibitory	0
effect	0
.	0

Neither	0
of	0
the	0
two	0
toxins	0
affected	0
kappaB	9
binding	0
activity	0
induced	0
by	0
TNFalpha	9
in	0
the	0
same	0
cells	0
.	0

These	0
results	0
imply	0
a	0
potential	0
role	0
of	0
the	0
anaphylatoxins	9
C5a	9
and	0
C3a	9
in	0
regulating	0
leukocytes	0
gene	0
expression	0
through	0
G	0
protein-coupled	0
transcription	0
factor	0
activation	0
.	0

Thrombopoietin	9
and	0
its	0
receptor	0
.	0

Thrombopoietin	9
(	0
TPO	9
)	0
,	0
the	0
primary	0
physiological	0
regulator	0
of	0
platelet	0
production	0
,	0
was	0
initially	0
thought	0
to	0
be	0
a	0
lineage-specific	0
factor	0
acting	0
predominantly	0
on	0
megakaryocytopoiesis	0
.	0

Detailed	0
studies	0
establish	0
that	0
this	0
cytokine	0
mediates	0
biological	0
effects	0
on	0
a	0
broad	0
spectrum	0
of	0
hematopoietic	7
progenitor	8
cells	8
,	0
including	0
stem	7
cells	8
.	0

TPO	9
is	0
a	0
hormone	0
constitutively	0
produced	0
mainly	0
by	0
the	0
liver	0
and	0
kidney	0
.	0

Plasma	0
TPO	9
levels	0
are	0
regulated	0
by	0
the	0
platelet	0
and	0
megakaryocyte	0
mass	0
through	0
Mpl	9
receptor	10
binding	0
,	0
internalization	0
and	0
degradation	0
.	0

The	0
Mpl	9
receptor	10
is	0
a	0
member	0
of	0
the	0
hematopoietin	9
receptor	10
superfamily	10
lacking	0
intrinsic	0
kinase	0
activity	0
.	0

Upon	0
ligand-induced	0
Mpl	0
homodimerization	0
,	0
the	0
major	0
signaling	0
events	0
for	0
proliferation	0
are	0
mediated	0
through	0
the	0
JAK2	9
/STAT5	9
pathway	0
,	0
while	0
differentiation	0
might	0
occur	0
through	0
a	0
prolonged	0
activation	0
of	0
the	0
MAPK	9
pathway	0
.	0

Preclinical	0
and	0
clinical	0
studies	0
demonstrate	0
the	0
potential	0
use	0
of	0
TPO	9
in	0
a	0
variety	0
of	0
contexts	0
,	0
but	0
it	0
is	0
too	0
early	0
to	0
evaluate	0
its	0
benefit	0
in	0
reducing	0
platelet	0
transfusion	0
.	0

TAL1	9
and	0
LIM-only	9
proteins	10
synergistically	0
induce	0
retinaldehyde	9
dehydrogenase	10
2	10
expression	0
in	0
T-cell	0
acute	0
lymphoblastic	0
leukemia	0
by	0
acting	0
as	0
cofactors	0
for	0
GATA3	9
.	0

Previously	0
,	0
we	0
have	0
shown	0
that	0
TAL1	9
and	0
the	0
LIM-only	1
protein	2
gene	2
(	0
LMO	1
)	0
are	0
regularly	0
coactivated	0
in	0
T-cell	0
acute	0
lymphoblastic	0
leukemia	0
(	0
T-ALL	0
)	0
.	0

This	0
observation	0
is	0
likely	0
to	0
relate	0
to	0
the	0
findings	0
that	0
TAL1	9
and	0
LMO	9
are	0
highly	0
synergistic	0
in	0
T-cell	0
tumorigenesis	0
in	0
double-transgenic	0
mice	0
.	0

To	0
understand	0
the	0
molecular	0
mechanisms	0
of	0
functional	0
synergy	0
between	0
TAL1	9
and	0
LMO	9
in	0
tumorigenesis	0
and	0
transcriptional	0
regulation	0
,	0
we	0
tried	0
to	0
identify	0
downstream	1
target	2
genes	2
regulated	0
by	0
TAL1	9
and	0
LMO	9
by	0
a	0
subtractive	0
PCR	0
method	0
.	0

One	0
of	0
the	0
isolated	0
genes	0
,	0
that	0
for	0
retinaldehyde	9
dehydrogenase	10
2	10
(	0
RALDH2	9
)	0
,	0
was	0
regularly	0
expressed	0
in	0
most	0
of	0
the	0
T-ALL	5
cell	6
lines	6
that	0
coexpressed	0
TAL1	9
and	0
LMO	9
.	0

Exogenously	0
transfected	0
TAL1	9
and	0
LMO	9
,	0
but	0
not	0
either	0
alone	0
,	0
induced	0
RALDH2	9
expression	0
in	0
a	0
T-ALL	5
cell	6
line	6
,	0
HPB-ALL	5
,	0
not	0
expressing	0
endogeneous	0
TAL1	9
or	0
LMO	9
.	0

The	0
RALDH2	3
transcripts	4
in	0
T-ALL	0
were	0
,	0
however	0
,	0
mostly	0
initiated	0
within	0
the	0
second	3
intron	4
.	0

Promoter	0
analysis	0
revealed	0
that	0
a	0
GATA	1
site	2
in	0
a	0
cryptic	1
promoter	2
in	0
the	0
second	1
intron	2
was	0
essential	0
and	0
sufficient	0
for	0
the	0
TAL1-	0
and	0
LMO-dependent	0
transcriptional	0
activation	0
,	0
and	0
GATA3	9
binds	0
to	0
this	0
site	0
.	0

In	0
addition	0
,	0
forced	0
expression	0
of	0
GATA3	9
potentiated	0
the	0
induction	0
of	0
RALDH2	9
by	0
TAL1	9
and	0
LMO	9
,	0
and	0
these	0
three	0
factors	0
formed	0
a	0
complex	0
in	0
vivo	0
.	0

Furthermore	0
,	0
a	0
TAL1	9
mutant	0
not	0
binding	0
to	0
DNA	0
also	0
activated	0
the	0
transcription	0
of	0
RALDH2	9
in	0
the	0
presence	0
of	0
LMO	9
and	0
GATA3	9
.	0

Collectively	0
,	0
we	0
have	0
identified	0
the	0
RALDH2	1
gene	2
as	0
a	0
first	0
example	0
of	0
direct	0
transcriptional	1
target	2
genes	2
regulated	0
by	0
TAL1	9
and	0
LMO	9
in	0
T-ALL	0
.	0

In	0
this	0
case	0
,	0
TAL1	9
and	0
LMO	9
act	0
as	0
cofactors	0
for	0
GATA3	9
to	0
activate	0
the	0
transcription	0
of	0
RALDH2	9

Glucocorticoid	9
receptors	10
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
in	0
relation	0
to	0
age	0
and	0
to	0
sport	0
activity	0
.	0

Glucocorticoid	9
receptors	10
(	0
GR	9
)	0
are	0
ubiquitous	0
molecules	0
and	0
are	0
present	0
also	0
in	0
the	0
hippocampus	0
and	0
in	0
several	0
other	0
nervous	0
and	0
immune	0
tissues	0
.	0

Peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
are	0
a	0
good	0
model	0
for	0
studies	0
of	0
GR	9
in	0
humans	0
.	0

Glucocorticoids	0
are	0
important	0
for	0
maintaining	0
cellular	0
and	0
humoral	0
homeostasis	0
and	0
are	0
key	0
mediators	0
of	0
neuroendocrine-immune	0
regulatory	0
interactions	0
.	0

The	0
increase	0
of	0
cortisol	0
is	0
immunosuppressive	0
and	0
reduces	0
GR	9
concentration	0
both	0
in	0
nervous	0
and	0
immune	0
systems	0
.	0

Variation	0
of	0
glucocorticoids	0
in	0
healthy	0
aged	0
subjects	0
and	0
athletes	0
has	0
been	0
shown	0
.	0

Prompted	0
by	0
these	0
results	0
,	0
we	0
have	0
investigated	0
in	0
man	0
a	0
possible	0
relationship	0
between	0
GR	9
binding	0
capacity	0
in	0
the	0
PBMCs	7
and	0
age	0
,	0
in	0
relation	0
also	0
to	0
plasma	0
testosterone	0
and	0
cortisol	0
.	0

The	0
same	0
parameters	0
have	0
been	0
examined	0
in	0
a	0
group	0
of	0
soccer	0
players	0
for	0
comparison	0
with	0
the	0
sedentary	0
group	0
.	0

GR	9
binding	0
capacity	0
was	0
higher	0
in	0
younger	0
subjects	0
than	0
in	0
older	0
ones	0
,	0
and	0
lower	0
in	0
the	0
group	0
of	0
athletes	0
than	0
in	0
the	0
younger	0
and	0
older	0
sedentary	0
subjects	0
.	0

In	0
the	0
sedentary	0
group	0
a	0
negative	0
correlation	0
was	0
present	0
between	0
GR	9
binding	0
capacity	0
and	0
age	0
.	0

Plasma	0
cortisol	0
was	0
higher	0
and	0
testosterone	0
lower	0
in	0
the	0
athletes	0
;	0
they	0
were	0
negatively	0
correlated	0
in	0
athletes	0
and	0
positively	0
correlated	0
in	0
the	0
sedentary	0
subjects	0
.	0

The	0
results	0
for	0
athletes	0
agree	0
with	0
their	0
lower	0
anabolic/catabolic	0
balance	0
.	0

The	0
mechanism	0
of	0
reduced	0
GR	9
levels	0
in	0
relation	0
to	0
age	0
and	0
sport	0
activity	0
could	0
involve	0
a	0
loss	0
or	0
an	0
involution	0
of	0
receptor	0
synthesis	0
.	0

However	0
other	0
possibilities	0
,	0
such	0
as	0
altered	0
distribution	0
of	0
lymphocyte	0
subpopulations	0
with	0
different	0
receptor	0
concentrations	0
and	0
with	0
different	0
cytokine	9
production	0
,	0
can	0
not	0
be	0
excluded	0
.	0

Several	0
neuroendocrine-immune	0
interactions	0
could	0
be	0
responsible	0
for	0
reduced	0
GR	9
levels	0
with	0
age	0
and	0
sport	0
activity	0
in	0
man	0
.	0

Glycation-dependent	0
,	0
reactive	0
oxygen	0
species-mediated	0
suppression	0
of	0
the	0
insulin	0
gene	0
promoter	0
activity	0
in	0
HIT	7
cells	8
.	0

Prolonged	0
poor	0
glycemic	0
control	0
in	0
non-insulin-dependent	0
diabetes	0
mellitus	0
patients	0
often	0
leads	0
to	0
a	0
decline	0
in	0
insulin	0
secretion	0
from	0
pancreatic	7
beta	8
cells	8
,	0
accompanied	0
by	0
a	0
decrease	0
in	0
the	0
insulin	0
content	0
of	0
the	0
cells	0
.	0

As	0
a	0
step	0
toward	0
elucidating	0
the	0
pathophysiological	0
background	0
of	0
the	0
so-called	0
glucose	0
toxicity	0
to	0
pancreatic	7
beta	8
cells	8
,	0
we	0
induced	0
glycation	0
in	0
HIT-T15	7
cells	8
using	0
a	0
sugar	0
with	0
strong	0
deoxidizing	0
activity	0
,	0
D-ribose	0
,	0
and	0
examined	0
the	0
effects	0
on	0
insulin	0
gene	0
transcription	0
.	0

The	0
results	0
of	0
reporter	1
gene	2
analyses	0
revealed	0
that	0
the	0
insulin	1
gene	2
promoter	2
is	0
more	0
sensitive	0
to	0
glycation	0
than	0
the	0
control	0
beta-actin	1
gene	2
promoter	2
;	0
approximately	0
50	0
and	0
80	0
%	0
of	0
the	0
insulin	1
gene	2
promoter	2
activity	0
was	0
lost	0
when	0
the	0
cells	0
were	0
kept	0
for	0
3	0
d	0
in	0
the	0
presence	0
of	0
40	0
and	0
60	0
mM	0
D-ribose	0
,	0
respectively	0
.	0

In	0
agreement	0
with	0
this	0
,	0
decrease	0
in	0
the	0
insulin	3
mRNA	4
and	0
insulin	0
content	0
was	0
observed	0
in	0
the	0
glycation-induced	7
cells	8
.	0

Also	0
,	0
gel	0
mobility	0
shift	0
analyses	0
using	0
specific	0
antiserum	0
revealed	0
decrease	0
in	0
the	0
DNA-binding	0
activity	0
of	0
an	0
insulin	9
gene	10
transcription	10
factor	10
,	0
PDX-1/IPF1/STF-1	9
.	0

These	0
effects	0
of	0
D-ribose	0
seemed	0
almost	0
irreversible	0
but	0
could	0
be	0
prevented	0
by	0
addition	0
of	0
1	0
mM	0
aminoguanidine	0
or	0
10	0
mM	0
N-acetylcysteine	0
,	0
thus	0
suggesting	0
that	0
glycation	0
and	0
reactive	0
oxygen	0
species	0
,	0
generated	0
through	0
the	0
glycation	0
reaction	0
,	0
serve	0
as	0
mediators	0
of	0
the	0
phenomena	0
.	0

These	0
observations	0
suggest	0
that	0
protein	0
glycation	0
in	0
pancreatic	7
beta	8
cells	8
,	0
which	0
occurs	0
in	0
vivo	0
under	0
chronic	0
hyperglycemia	0
,	0
suppresses	0
insulin	0
gene	0
transcription	0
and	0
thus	0
can	0
explain	0
part	0
of	0
the	0
beta	0
cell	0
glucose	0
toxicity	0
.	0

Nuclear	9
factor-kappa	10
B	10
activity	0
in	0
T	7
cells	8
from	0
patients	0
with	0
rheumatic	0
diseases	0
:	0
a	0
preliminary	0
report	0
.	0

OBJECTIVE	0
:	0
The	0
NF-kappa	9
B/Rel	10
family	10
of	0
transcription	9
factors	10
regulates	0
the	0
expression	0
of	0
many	0
genes	0
involved	0
in	0
the	0
immune	0
or	0
inflammatory	0
response	0
at	0
the	0
transcriptional	0
level	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
determine	0
whether	0
distinctive	0
patterns	0
of	0
NF-kappa	9
B	10
activation	0
are	0
seen	0
in	0
different	0
forms	0
of	0
joint	0
disease	0
.	0

METHODS	0
:	0
The	0
DNA	0
binding	0
activity	0
of	0
these	0
nucleoproteins	9
was	0
examined	0
in	0
purified	0
synovial	7
and	8
peripheral	8
T	8
cells	8
from	0
patients	0
with	0
various	0
chronic	0
rheumatic	0
diseases	0
(	0
12	0
:	0
four	0
with	0
rheumatoid	0
arthritis	0
;	0
five	0
with	0
spondyloarthropathies	0
;	0
and	0
three	0
with	0
osteoarthritis	0
)	0
.	0

RESULTS	0
:	0
Electrophoretic	0
mobility	0
shift	0
assays	0
disclosed	0
two	0
specific	0
complexes	0
bound	0
to	0
a	0
NF-kappa	9
B	10
specific	0
32P-labelled	0
oligonucleotide	0
in	0
nucleoproteins	9
extracted	0
from	0
purified	7
T	8
cells	8
isolated	0
from	0
synovial	0
fluid	0
and	0
peripheral	0
blood	0
of	0
patients	0
with	0
rheumatoid	0
arthritis	0
.	0

The	0
complexes	9
consisted	0
of	0
p50/p50	9
homodimers	10
and	0
p50/p65	0
heterodimers	0
.	0

Increased	0
NF-kappa	9
B	10
binding	0
to	0
DNA	0
in	0
synovial	7
T	8
cells	8
was	0
observed	0
relative	0
to	0
peripheral	0
T	0
cells	0
.	0

In	0
non-rheumatoid	0
arthritis	0
,	0
binding	0
of	0
NF-kappa	9
B	10
in	0
synovial	7
T	8
cells	8
was	0
exclusively	0
mediated	0
by	0
p50/p50	9
homodimers	10
.	0

CONCLUSION	0
:	0
Overall	0
,	0
the	0
results	0
suggest	0
that	0
NF-kappa	9
B	10
may	0
play	0
a	0
central	0
part	0
in	0
the	0
activation	0
of	0
infiltrating	7
T	8
cells	8
in	0
chronic	0
rheumatoid	0
arthritis	0
.	0

The	0
activation	0
of	0
this	0
nuclear	0
factor	0
is	0
qualitatively	0
different	0
in	0
rheumatoid	7
synovial	8
T	8
cells	8
to	0
that	0
in	0
other	0
forms	0
of	0
non-rheumatoid	0
arthritis	0
(	0
for	0
example	0
,	0
osteoarthritis	0
,	0
spondyloarthropathies	0
)	0
.	0

X	1
chromosome	2
inactivation	0
patterns	0
in	0
normal	0
females	0
.	0

Since	0
one	0
of	0
the	0
two	0
X	1
chromosomes	2
is	0
randomly	0
inactivated	0
at	0
an	0
early	0
stage	0
of	0
female	0
embryonic	0
development	0
,	0
X-linked	9
markers	10
have	0
been	0
used	0
to	0
study	0
the	0
origin	0
and	0
development	0
of	0
various	0
neoplastic	0
disorders	0
in	0
affected	0
heterozygous	0
women	0
;	0
clonality	0
assays	0
have	0
provided	0
a	0
useful	0
tool	0
to	0
the	0
understanding	0
of	0
the	0
mechanisms	0
underlying	0
the	0
development	0
of	0
neoplasia	0
.	0

Recently	0
,	0
a	0
technique	0
of	0
clonal	0
analysis	0
has	0
been	0
devised	0
that	0
takes	0
advantage	0
of	0
a	0
highly	0
polymorphic	0
short	1
tandem	2
repeat	2
within	0
the	0
X-linked	1
human	2
androgen	2
receptor	2
(	2
AR	2
)	2
gene	2
,	0
resulting	0
in	0
a	0
heterozygosity	0
rate	0
approaching	0
90	0
%	0
.	0

The	0
rapid	0
expansion	0
of	0
the	0
number	0
of	0
women	0
now	0
suitable	0
for	0
X	0
inactivation	0
analysis	0
has	0
however	0
given	0
rise	0
to	0
new	0
controversies	0
,	0
one	0
of	0
the	0
more	0
troublesome	0
being	0
the	0
possibility	0
of	0
a	0
modification	0
of	0
the	0
pattern	0
of	0
X-	1
chromosome	2
inactivation	0
pattern	0
in	0
blood	7
cells	8
of	0
elderly	0
women	0
.	0

In	0
the	0
present	0
study	0
we	0
analyze	0
with	0
the	0
AR	0
assay	0
a	0
group	0
of	0
166	0
healthy	0
females	0
aged	0
between	0
8	0
and	0
94	0
years	0
,	0
with	0
no	0
history	0
of	0
genetic	0
or	0
neoplastic	0
familial	0
disorders	0
.	0

We	0
failed	0
to	0
find	0
any	0
correlation	0
between	0
age	0
and	0
X-	1
chromosome	2
inactivation	0
pattern	0
(	0
r	0
=	0
0.17	0
)	0
,	0
even	0
subdividing	0
the	0
subjects	0
in	0
different	0
age	0
groups	0
according	0
to	0
the	0
criteria	0
used	0
by	0
other	0
researchers	0
,	0
and	0
therefore	0
reaffirm	0
that	0
,	0
when	0
tested	0
for	0
with	0
well-standardized	0
and	0
accurate	0
criteria	0
,	0
extremely	0
unbalanced	0
inactivation	0
of	0
the	0
X	1
chromosome	2
is	0
a	0
truly	0
uncommon	0
phenomenon	0
in	0
normal	0
women	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

The	0
role	0
of	0
Stat4	9
in	0
species-specific	0
regulation	0
of	0
Th	0
cell	0
development	0
by	0
type	9
I	10
IFNs	10
.	0

Type	9
I	10
IFNs	10
(	0
IFN-alpha/beta	9
)	0
,	0
in	0
addition	0
to	0
IL-12	9
,	0
have	0
been	0
shown	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
differentiation	0
of	0
human	0
,	0
but	0
not	0
mouse	0
,	0
Th	7
cells	8
.	0

We	0
show	0
here	0
that	0
IFN-alpha/beta	9
act	0
directly	0
on	0
human	7
T	8
cells	8
to	0
drive	0
Th1	0
development	0
,	0
bypassing	0
the	0
need	0
for	0
IL-12	9
-induced	0
signaling	0
,	0
whereas	0
IFN-alpha	9
can	0
not	0
substitute	0
IL-12	9
for	0
mouse	0
Th1	0
development	0
.	0

The	0
molecular	0
basis	0
for	0
this	0
species	0
specificity	0
is	0
that	0
IFN-alpha/beta	9
activate	0
Stat4	9
in	0
differentiating	0
human	0
,	0
but	0
not	0
mouse	0
,	0
Th	7
cells	8
.	0

Unlike	0
IL-12	9
,	0
which	0
acts	0
only	0
on	0
Th1	7
cells	8
,	0
IFN-alpha/beta	9
can	0
activate	0
Stat4	9
not	0
only	0
in	0
human	7
Th1	8
,	0
but	0
also	0
in	0
Th2	7
cells	8
.	0

However	0
,	0
restimulation	0
of	0
human	5
Th2	6
lines	6
and	0
clones	0
in	0
the	0
presence	0
of	0
IFN-alpha	9
does	0
not	0
induce	0
the	0
production	0
of	0
IFN-gamma	9
.	0

These	0
results	0
suggest	0
that	0
activation	0
of	0
Stat4	9
,	0
which	0
is	0
necessary	0
for	0
the	0
differentiation	0
of	0
naive	7
T	8
cells	8
into	0
polarized	0
Th1	7
cells	8
,	0
is	0
not	0
sufficient	0
to	0
induce	0
phenotype	0
reversal	0
of	0
human	7
Th2	8
cells	8
.	0

Molecular	0
cloning	0
of	0
FKHRL1P2	9
,	0
a	0
member	0
of	0
the	0
developmentally	0
regulated	0
fork	9
head	10
domain	10
transcription	10
factor	10
family	10
.	0

Here	0
we	0
report	0
the	0
expression	0
of	0
a	0
fork	9
head	10
domain	10
protein	10
in	0
human	7
T	8
helper	8
cells	8
.	0

We	0
cloned	0
and	0
characterized	0
a	0
fork	1
head	2
cDNA	2
from	0
human	3
T	4
helper	4
cell	4
mRNA	4
using	0
differential	0
display	0
RT-PCR	0
.	0

The	0
cDNA	0
contains	0
a	0
546-nucleotide	1
(	2
nt	2
)	2
open	2
reading	2
frame	2
(	0
ORF	1
)	0
that	0
codes	0
for	0
the	0
carboxyl-terminal	9
180	10
amino	10
acids	10
(	0
aa	0
)	0
of	0
the	0
recently	0
identified	0
fkhrl1	1
gene	2
.	0

This	0
ORF	1
does	0
not	0
contain	0
the	0
characteristic	0
DNA-binding	1
domain	2
found	0
in	0
members	0
of	0
the	0
forkhead	9
protein	10
family	10
.	0

In-vitro	0
transcription/translation	0
of	0
this	0
cDNA	1
expressed	0
a	0
protein	0
of	0
approximately	0
20	0
kDa	0
.	0

We	0
have	0
generated	0
antibodies	0
that	0
specifically	0
immunoprecipitated	0
the	0
in-vitro-translated	9
20-kDa	10
protein	10
.	0

This	0
antibody	0
also	0
recognizes	0
in	0
human	7
T	8
lymphocytes	8
a	0
70-kDa	0
protein	0
corresponding	0
in	0
size	0
to	0
that	0
predicted	0
for	0
the	0
fkhrl1	1
gene	2
product	0
.	0

The	0
mRNA	0
levels	0
for	0
fkhrl1	1
is	0
elevated	0
in	0
T	7
helper-induced	8
lymphocytes	8
in	0
comparison	0
to	0
PHA-stimulated	5
T	6
lymphocytes	6
.	0

Further	0
characterization	0
of	0
FKHRL1	1
and	0
its	0
related	0
family	0
members	0
should	0
shed	0
light	0
on	0
the	0
transcriptional	0
mechanisms	0
of	0
this	0
fork	1
head	2
gene	2
subfamily	2
and	0
their	0
role	0
in	0
T	0
helper	0
cell	0
differentiation	0
and	0
regulation	0
of	0
cell	0
growth	0
.	0

Inhibition	0
of	0
Th1	0
development	0
mediated	0
by	0
GATA-3	9
through	0
an	0
IL-4-independent	0
mechanism	0
.	0

Recently	0
,	0
the	0
transcription	9
factor	10
GATA-3	9
was	0
shown	0
to	0
be	0
selectively	0
expressed	0
in	0
Th2	0
but	0
not	0
Th1	7
cells	8
and	0
to	0
augment	0
Th2-specific	9
cytokines	10
.	0

Here	0
,	0
we	0
show	0
that	0
loss	0
of	0
GATA-3	9
expression	0
by	0
developing	0
Th1	7
cells	8
requires	0
IL-12	9
signaling	0
through	0
Stat4	9
and	0
does	0
not	0
simply	0
result	0
from	0
an	0
absence	0
of	0
IL-4	9
.	0

Moreover	0
,	0
we	0
demonstrate	0
a	0
novel	0
role	0
for	0
GATA-3	9
in	0
directly	0
repressing	0
Th1	0
development	0
distinct	0
from	0
its	0
positive	0
actions	0
on	0
Th2-specific	9
cytokines	10
.	0

GATA-3	9
inhibits	0
Th1	9
cytokines	10
by	0
a	0
cell-intrinsic	0
mechanism	0
that	0
is	0
not	0
dependent	0
on	0
IL-4	9
and	0
that	0
may	0
involve	0
repression	0
of	0
IL-12	9
signaling	0
.	0

Thus	0
,	0
GATA-3	9
expression	0
and	0
IL-12	9
signaling	0
are	0
mutually	0
antagonistic	0
,	0
which	0
facilitates	0
rapid	0
dominance	0
of	0
one	0
pathway	0
during	0
early	0
Th	0
development	0
,	0
producing	0
a	0
stable	0
divergence	0
in	0
cytokine	9
profiles	0
.	0

Conserved	1
elements	2
containing	0
NF-E2	1
and	2
tandem	2
GATA	2
binding	2
sites	2
are	0
required	0
for	0
erythroid-specific	0
chromatin	0
structure	0
reorganization	0
within	0
the	0
human	1
beta-globin	2
locus	2
control	2
region	2
.	0

Proper	0
expression	0
of	0
the	0
genes	0
of	0
the	0
human	1
beta-globin	2
gene	2
locus	2
requires	0
the	0
associated	0
locus	1
control	2
region	2
(	0
LCR	1
)	0
.	0

Structurally	0
,	0
the	0
LCR	1
is	0
defined	0
by	0
the	0
presence	0
of	0
four	0
domains	0
of	0
erythroid-specific	0
chromatin	0
structure	0
.	0

These	0
domains	0
,	0
which	0
have	0
been	0
characterized	0
as	0
DNase	1
I	2
hypersensitive	2
sites	2
(	0
HSs	1
)	0
,	0
comprise	0
the	0
active	0
elements	0
of	0
the	0
LCR	1
.	0

The	0
major	0
focus	0
of	0
this	0
research	0
is	0
to	0
define	0
the	0
cis	1
-acting	2
elements	2
which	0
are	0
required	0
for	0
the	0
formation	0
of	0
these	0
domains	0
of	0
unique	0
chromatin	0
structure	0
.	0

Our	0
previous	0
investigations	0
on	0
the	0
formation	0
of	0
LCR	1
HS4	2
demonstrated	0
that	0
NF-E2	1
and	2
tandem	2
,	2
inverted	2
GATA	2
binding	2
sites	2
are	0
required	0
for	0
the	0
formation	0
of	0
the	0
native	1
HS	2
.	0

Similarly	0
arranged	0
NF-E2	1
and	2
tandem	2
GATA	2
sites	2
are	0
present	0
within	0
the	0
core	1
regions	2
of	0
the	0
other	0
human	1
LCR	2
HSs	2
and	0
are	0
evolutionarily	0
conserved	0
.	0

Using	0
site-directed	0
mutagenesis	0
of	0
human	1
HSs	2
2	2
and	2
3	2
we	0
have	0
tested	0
the	0
hypothesis	0
that	0
these	0
NF-E2	1
and	2
GATA	2
sites	2
are	0
common	0
requirements	0
for	0
the	0
formation	0
of	0
all	0
LCR	1
HSs	2
.	0

We	0
find	0
that	0
mutation	0
of	0
these	0
elements	0
,	0
and	0
particularly	0
the	0
GATA	1
elements	2
,	0
results	0
in	0
a	0
decrease	0
or	0
complete	0
loss	0
of	0
DNase	9
I	10
hypersensitivity	0
.	0

These	0
data	0
imply	0
the	0
presence	0
of	0
common	0
structural	0
elements	0
within	0
the	0
core	0
of	0
each	0
LCR	1
HS	2
which	0
are	0
required	0
for	0
erythroid-specific	0
chromatin	0
structure	0
reorganization	0
.	0

Cloning	0
of	0
ARE-containing	1
genes	2
by	0
AU-motif-directed	0
display	0
.	0

A	0
procedure	0
suitable	0
for	0
cloning	3
labile	4
mRNAs	4
that	0
contain	0
AU	0
motifs	0
is	0
presented	0
(	0
AU-DD	0
)	0
.	0

These	0
motifs	0
are	0
regulatory	1
sequences	2
within	0
the	0
so-called	0
AU-rich	1
elements	2
(	0
AREs	1
)	0
often	0
found	0
in	0
3	1
'	2
untranslated	2
regions	2
of	0
genes	0
such	0
as	0
cytokines	9
,	0
proto-oncogenes	1
,	0
and	0
transcription	9
factors	10
.	0

AU-DD	1
is	0
an	0
AU-motif-directed	1
differential	2
display	2
that	0
permits	0
the	0
identification	0
of	0
ARE-containing	1
genes	2
differentially	0
expressed	0
after	0
cell	0
activation	0
.	0

It	0
has	0
been	0
applied	0
to	0
peripheral	7
blood	8
monocytes	8
and	0
a	0
T	5
cell	6
clone	6
to	0
isolate	0
59	1
cDNA	2
fragments	2
associated	0
to	0
activation	0
.	0

Fourteen	0
percent	0
of	0
isolated	0
fragments	0
belong	0
to	0
already	0
known	0
genes	0
that	0
certainly	0
are	0
cytokines	9
and	0
transduction/transcription	9
factors	10
.	0

The	0
remaining	0
86	0
%	0
correspond	0
to	0
unknown	0
genes	1
of	0
which	0
92	0
%	0
have	0
been	0
confirmed	0
to	0
be	0
differentially	0
expressed	0
.	0

These	0
data	0
demonstrate	0
the	0
efficiency	0
of	0
the	0
system	0
and	0
support	0
the	0
notion	0
that	0
numerous	0
genes	1
falling	0
into	0
those	0
categories	0
remain	0
unidentified	0
and	0
that	0
they	0
can	0
be	0
cloned	0
by	0
this	0
method	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Transcription	0
factor	0
NF-kappaB	9
regulation	0
of	0
renal	0
fibrosis	0
during	0
ureteral	0
obstruction	0
.	0

Irrespective	0
of	0
the	0
etiology	0
,	0
many	0
kidney	0
diseases	0
result	0
in	0
inflammation	0
and	0
fibrosis	0
of	0
the	0
tubulointerstitium	0
,	0
with	0
the	0
subsequent	0
loss	0
of	0
renal	0
function	0
.	0

To	0
initiate	0
any	0
disease	0
process	0
or	0
for	0
any	0
disease	0
process	0
to	0
progress	0
,	0
there	0
must	0
be	0
changes	0
in	0
the	0
transcription	0
of	0
genes	0
within	0
the	0
affected	0
tissue	0
.	0

The	0
nuclear	9
factor-kappa	10
B	10
(	10
NF-kappaB	10
)	10
family	10
of	0
transcription	9
factors	10
regulates	0
genes	0
involved	0
in	0
inflammation	0
,	0
cell	0
proliferation	0
,	0
and	0
cell	0
differentiation	0
.	0

This	0
review	0
discusses	0
the	0
NF-kappaB	9
transcription	10
factor	10
family	10
in	0
general	0
and	0
the	0
association	0
of	0
NF-kappaB	9
activation	0
with	0
cellular/molecular	0
events	0
of	0
renal	0
inflammation	0
and	0
fibrosis	0

Expression	0
of	0
transcription	9
factors	10
during	0
sodium	0
phenylacetate	0
induced	0
erythroid	0
differentiation	0
in	0
K562	5
cells	6
.	0

During	0
15	0
days	0
of	0
treatment	0
of	0
K562	5
cells	6
with	0
sodium	0
phenylacetate	0
,	0
we	0
observed	0
an	0
increase	0
in	0
the	0
cellular	0
hemoglobin	9
concentration	0
with	0
a	0
similar	0
increase	0
in	0
the	0
expression	0
of	0
gamma-globin	3
mRNA	4
.	0

Morphological	0
studies	0
demonstrated	0
characteristic	0
features	0
of	0
erythroid	0
differentiation	0
and	0
maturation	0
.	0

At	0
the	0
same	0
time	0
there	0
was	0
no	0
change	0
in	0
the	0
level	0
of	0
expression	0
of	0
the	0
cell	9
surface	10
antigenes	10
CD33	9
,	0
CD34	9
,	0
CD45	9
,	0
CD71	9
and	0
glycophorin	9
A	10
.	0

Likewise	0
,	0
the	0
level	0
of	0
expression	0
of	0
the	0
erythroid	9
transcription	10
factors	10
GATA-1	9
,	0
GATA-2	9
,	0
NF-E2	9
,	0
SCL	9
and	0
RBTN2	9
,	0
all	0
expressed	0
in	0
untreated	0
K562	5
cells	6
,	0
did	0
not	0
increase	0
during	0
sodium	0
phenylacetate	0
induced	0
erythroid	0
differentiation	0
.	0

The	0
expression	0
of	0
the	0
nuclear	9
factors	10
Evi-1	9
and	0
c-myb	9
,	0
known	0
to	0
inhibit	0
erythroid	0
differentiation	0
,	0
did	0
not	0
decrease	0
.	0

We	0
conclude	0
that	0
sodium	0
phenylacetate	0
treatment	0
of	0
K562	5
cells	6
increases	0
gamma-globin	3
mRNA	4
and	0
induces	0
cell	0
maturation	0
as	0
judged	0
by	0
morphology	0
without	0
affecting	0
the	0
expression	0
of	0
the	0
erythroid	9
transcription	10
factors	10
,	0
some	0
of	0
which	0
are	0
known	0
to	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
beta-like	1
globin	2
genes	2
.	0

Isolation	0
of	0
a	0
B-cell-specific	1
promoter	2
for	0
the	0
human	9
class	10
II	10
transactivator	10
.	0

The	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
is	0
essential	0
for	0
the	0
expression	0
of	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
II	10
antigens	10
.	0

The	0
tissular	0
patterns	0
of	0
CIITA	0
and	0
MHC	0
class	0
II	0
gene	0
expression	0
are	0
tightly	0
correlated	0
:	0
CIITA	3
mRNA	4
is	0
highly	0
expressed	0
in	0
B	7
cells	8
,	0
and	0
is	0
induced	0
by	0
interferon	9
gamma	10
(	0
IFN-gamma	9
)	0
in	0
macrophage	5
and	6
epithelial	6
cell	6
lines	6
.	0

We	0
first	0
isolated	0
two	0
overlapping	0
cosmids	1
encoding	0
human	9
CIITA	10
which	0
,	0
when	0
co-transfected	0
,	0
are	0
able	0
to	0
restore	0
MHC	9
class	10
II	10
expression	0
in	0
a	0
B-lymphoblastoid	5
cell	6
line	6
(	0
B-LCL	5
)	0
defective	0
for	0
CIITA	9
.	0

Subsequently	0
,	0
a	0
1.8	1
kilobase	2
(	2
kb	2
)	2
fragment	2
of	0
the	0
CIITA	1
promoter	2
was	0
isolated	0
and	0
sequenced	0
.	0

A	0
motif	0
presenting	0
a	0
strong	0
similarity	0
to	0
an	0
initiator	0
was	0
detected	0
,	0
as	0
well	0
as	0
putative	1
binding	2
sites	2
for	0
Sp1	9
,	0
GATA-2	9
,	0
LyF-1	9
,	0
ets-1	9
,	0
AP1	9
,	0
and	0
MZF1	9
transcription	9
factors	10
,	0
and	0
two	0
GAS	1
motifs	2
.	0

When	0
introduced	0
in	0
front	0
of	0
a	0
luciferase	1
reporter	2
gene	2
,	0
this	0
promoter	0
is	0
able	0
to	0
direct	0
a	0
high	0
luciferase	9
activity	0
in	0
a	0
human	5
B-LCL	6
.	0

In	0
contrast	0
,	0
luciferase	9
expression	0
was	0
not	0
stimulated	0
after	0
IFN-gamma	9
treatment	0
when	0
the	0
construct	0
was	0
transfected	0
in	0
macrophage	0
or	0
in	0
epithelial	5
cell	6
lines	6
.	0

However	0
,	0
an	0
induction	0
of	0
the	0
human	1
CIITA	2
gene	2
was	0
observed	0
in	0
mouse	5
macrophage	6
and	6
fibrosarcoma	6
cell	6
lines	6
,	0
when	0
the	0
cells	0
were	0
transfected	0
with	0
a	0
cosmid	1
containing	0
the	0
human	1
CIITA	2
gene	2
,	0
but	0
lacking	0
the	0
1.8	1
kb	2
promoter	2
described	0
above	0
.	0

Taken	0
together	0
,	0
these	0
data	0
suggest	0
the	0
existence	0
of	0
an	0
intragenic	0
promoter	0
driving	0
an	0
IFN-gamma	9
-inducible	0
expression	0
of	0
CIITA	9
.	0

Phenotypic	0
and	0
functional	0
studies	0
of	0
leukocytes	7
in	0
human	0
endometrium	0
and	0
endometriosis	0
.	0

The	0
aetiology	0
of	0
endometriosis	0
,	0
a	0
common	0
and	0
disabling	0
disorder	0
,	0
is	0
presently	0
unknown	0
,	0
although	0
immune	0
dysfunction	0
could	0
allow	0
ectopic	0
endometrial	0
fragments	0
to	0
survive	0
outside	0
the	0
uterine	0
cavity	0
.	0

These	0
studies	0
investigate	0
the	0
relationship	0
between	0
leukocyte	7
populations	8
,	0
steroid	9
hormone	10
receptor	10
expression	0
,	0
proliferative	0
activity	0
,	0
bcl-2	9
expression	0
and	0
apoptosis	0
in	0
eutopic	0
and	0
ectopic	0
endometrium	0
from	0
women	0
with	0
endometriosis	0
or	0
adenomyosis	0
at	0
different	0
phases	0
of	0
the	0
menstrual	0
cycle	0
.	0

Significantly	0
increased	0
oestrogen	9
receptor	10
expression	0
,	0
bcl-2	9
expression	0
and	0
numbers	0
of	0
CD8+	0
leukocytes	7
were	0
found	0
in	0
ectopic	0
compared	0
with	0
eutopic	0
endometrium	0
in	0
endometriosis	0
,	0
and	0
CD56+	0
endometrial	0
granulated	0
lymphocytes	0
(	0
eGLs	0
)	0
were	0
significantly	0
reduced	0
in	0
ectopic	0
endometrium	0
.	0

Apoptotic	7
cells	8
were	0
rarely	0
found	0
in	0
control	0
and	0
subject	0
endometria	0
.	0

In	0
contrast	0
with	0
endometriosis	0
,	0
adenomyotic	0
lesions	0
showed	0
identical	0
steroid	9
hormone	10
receptor	10
expression	0
,	0
proliferative	0
activity	0
,	0
bcl-2	9
expression	0
and	0
leukocyte	0
subpopulations	0
to	0
eutopic	0
endometrium	0
,	0
indicating	0
different	0
aetiologies	0
for	0
these	0
disorders	0
.	0

The	0
unusual	0
CD56+	7
CD16-	8
eGLs	8
present	0
in	0
large	0
numbers	0
in	0
late	0
secretory	0
phase	0
eutopic	0
endometrium	0
were	0
highly	0
purified	0
(	0
>	0
98	0
%	0
)	0
by	0
immunomagnetic	0
separation	0
.	0

Except	0
for	0
a	0
negligible	0
cytotoxic	0
activity	0
of	0
eGLs	7
from	0
early	0
proliferative	0
samples	0
,	0
cytotoxic	0
activity	0
of	0
eGLs	7
from	0
non-pregnant	0
endometrium	0
during	0
the	0
menstrual	0
cycle	0
was	0
comparable	0
with	0
those	0
in	0
peripheral	0
blood	0
,	0
predominantly	0
CD56+	7
CD16+	8
natural	8
killer	8
cells	8
.	0

eGLs	7
from	0
non-pregnant	0
endometrium	0
and	0
early	0
pregnancy	0
showed	0
a	0
variable	0
proliferative	0
response	0
to	0
5	0
and	0
100	0
U/ml	0
interleukin-2	9
over	0
48-h	0
and	0
120-h	0
time	0
courses	0
.	0

eGLs	7
are	0
evidently	0
functionally	0
important	0
in	0
the	0
eutopic	0
endometrium	0
.	0

Their	0
absence	0
in	0
endometriotic	0
lesions	0
together	0
with	0
increased	0
CD+8	7
T-cell	8
numbers	0
and	0
increased	0
oestrogen	9
receptor	10
and	0
bcl-2	9
expression	0
may	0
have	0
significant	0
effects	0
on	0
the	0
development	0
and	0
progression	0
of	0
endometriosis	0
.	0

Regulation	0
of	0
interleukin-1beta	9
transcription	0
by	0
Epstein-Barr	0
virus	0
involves	0
a	0
number	0
of	0
latent	9
proteins	10
via	0
their	0
interaction	0
with	0
RBP	9
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
infects	0
B	7
cells	8
,	0
resulting	0
in	0
the	0
outgrowth	0
of	0
immortalised	5
lymphoblastoid	6
cell	6
lines	6
(	0
LCLs	5
)	0
.	0

Here	0
,	0
we	0
demonstrate	0
through	0
the	0
use	0
of	0
intracellular	0
staining	0
that	0
interleukin-1beta	9
(	0
IL-1beta	9
)	0
is	0
expressed	0
in	0
LCLs	5
and	0
investigate	0
the	0
influence	0
of	0
the	0
individual	0
latent	9
proteins	10
on	0
the	0
expression	0
of	0
IL-1beta	9
.	0

Using	0
RT-PCR	0
,	0
IL-1beta	9
was	0
shown	0
to	0
be	0
up-regulated	0
in	0
EBV-transformed	5
LCLs	6
as	0
well	0
as	0
in	0
group	5
III	6
Burkitt	6
's	6
lymphoma	6
(	6
BL	6
)	6
cell	6
lines	6
,	0
compared	0
with	0
group	5
I	6
BL	6
cell	6
lines	6
.	0

The	0
up-regulation	0
of	0
IL-1beta	9
message	0
could	0
be	0
mediated	0
by	0
the	0
latent	9
membrane	10
protein-1	10
,	0
EBV	1
nuclear	2
proteins	2
2	2
,	2
3	2
,	2
4	2
,	2
and	2
6	2
genes	2
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSAs	0
)	0
demonstrated	0
that	0
the	0
-300	0
region	0
of	0
the	0
IL-1beta	9
promoter	0
,	0
which	0
contains	0
a	0
nuclear	1
factor-kappaB	2
(	2
NF-kappaB	2
)	2
binding	2
site	2
,	0
contained	0
a	0
functional	1
RBP	2
binding	2
site	2
.	0

Binding	0
of	0
RBP	0
to	0
this	0
site	0
could	0
be	0
inhibited	0
by	0
addition	0
of	0
EBV	9
nuclear	10
proteins	10
3	10
and	10
6	10
,	0
suggesting	0
that	0
these	0
proteins	0
displace	0
RBP	9
from	0
its	0
recognition	1
sequence	2
,	0
removing	0
transcriptional	0
repression	0
and	0
allowing	0
gene	0
transcription	0
to	0
occur	0
.	0

In	0
group	5
I	6
BL	6
cells	6
,	0
containing	0
low	0
levels	0
of	0
NF-kappaB	9
,	0
only	0
RBP	9
binding	0
was	0
observed	0
in	0
EMSAs	0
,	0
whereas	0
NF-kappaB	9
binding	0
could	0
be	0
demonstrated	0
in	0
EBV-transformed	5
B	6
cell	6
lines	6
containing	0
high	0
levels	0
of	0
activated	0
NF-kappaB	9
.	0

In	0
addition	0
,	0
the	0
expression	0
of	0
latent	9
membrane	10
protein-1	10
led	0
to	0
activation	0
of	0
NF-kappaB	9
that	0
was	0
capable	0
of	0
binding	0
the	0
IL-1beta	1
promoter	2
.	0

The	0
study	0
demonstrates	0
that	0
EBV	0
can	0
up-regulate	0
IL-1beta	9
expression	0
,	0
possibly	0
by	0
using	0
RBP	9
,	0
NF-kappaB	9
,	0
or	0
both	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

CD27	9
/CD70	0
interaction	0
augments	0
IgE	9
secretion	0
by	0
promoting	0
the	0
differentiation	0
of	0
memory	7
B	8
cells	8
into	0
plasma	7
cells	8
.	0

The	0
induction	0
of	0
IgE	9
switching	0
in	0
B	7
cells	8
requires	0
several	0
signals	0
given	0
by	0
cytokines	9
and	0
cell	0
contact-delivered	0
signals	0
.	0

Here	0
,	0
we	0
investigated	0
the	0
role	0
of	0
CD27	9
/CD70	0
interaction	0
in	0
B	0
cell	0
IgE	9
synthesis	0
.	0

The	0
addition	0
of	0
CD27	0
ligand	0
(	0
CD70	0
)	0
transfectants	0
to	0
B	5
cell	6
cultures	6
increased	0
the	0
IgE	9
synthesis	0
synergistically	0
in	0
the	0
presence	0
of	0
IL-4	9
plus	0
anti-CD40	9
mAb	10
(	0
anti-CD40	9
)	0
.	0

The	0
effect	0
of	0
CD70	5
transfectants	6
was	0
dose	0
dependent	0
and	0
was	0
completely	0
blocked	0
by	0
anti-CD70	9
mAb	10
.	10

CD27+	7
B	8
cells	8
had	0
the	0
ability	0
to	0
produce	0
IgE	9
,	0
which	0
was	0
increased	0
by	0
contact	0
with	0
CD70	0
transfectants	0
,	0
whereas	0
CD27-	0
B	0
cells	0
did	0
not	0
produce	0
IgE	9
.	0

CD27	9
/CD70	0
interaction	0
enhanced	0
B	7
cell	8
proliferation	0
in	0
the	0
presence	0
of	0
IL-4	9
or	0
IL-4	9
plus	0
anti-CD40	9
.	0

The	0
augmentation	0
of	0
B	0
cell	0
proliferation	0
by	0
CD70	0
transfectants	0
was	0
apparent	0
in	0
CD27+	7
B	8
cells	8
,	0
but	0
was	0
mild	0
in	0
CD27-	7
B	8
cells	8
.	0

The	0
helper	0
activity	0
for	0
IgE	9
synthesis	0
by	0
the	0
CD27	9
/CD70	0
interaction	0
did	0
not	0
contribute	0
to	0
the	0
enhancement	0
of	0
germline	3
epsilon	4
transcripts	4
.	0

Flow	0
cytometric	0
and	0
morphological	0
analyses	0
demonstrated	0
that	0
the	0
addition	0
of	0
CD70	0
transfectants	0
to	0
B	5
cell	6
cultures	6
remarkably	0
promoted	0
differentiation	0
into	0
plasma	7
cells	8
in	0
the	0
presence	0
of	0
IL-4	9
and	0
CD40	9
signaling	0
.	0

Finally	0
,	0
CD27	9
cross-linking	0
resulted	0
in	0
the	0
up-regulation	0
of	0
positive	9
regulatory	10
domain	10
I-binding	10
factor-1	10
.	0

Taken	0
together	0
,	0
our	0
findings	0
indicate	0
that	0
signaling	0
via	0
CD27	9
on	0
B	7
cells	8
induces	0
IgE	9
synthesis	0
,	0
in	0
cooperation	0
with	0
IL-4	9
and	0
CD40	9
signaling	0
,	0
by	0
promoting	0
the	0
generation	0
of	0
plasma	7
cells	8
through	0
up-regulation	0
of	0
positive	9
regulatory	10
domain	10
I-binding	10
factor-1	10
.	0

Human	0
immunodeficiency	0
virus	0
type-1	0
transcription	0
:	0
role	0
of	0
the	0
5'-untranslated	0
leader	0
region	0
(	0
review	0
)	0
.	0

Human	0
immunodeficiency	0
virus	0
type-1	0
(	0
HIV-1	0
)	0
transcription	0
is	0
dependent	0
on	0
the	0
interaction	0
of	0
host-cell	9
transcription	10
factors	10
with	0
cis-regulatory	1
DNA	2
elements	2
within	0
the	0
viral	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

Much	0
attention	0
has	0
focused	0
on	0
the	0
series	0
of	0
sequence	0
elements	0
upstream	0
of	0
the	0
transcriptional	1
initiation	2
site	2
in	0
the	0
U3	1
region	2
of	0
the	0
LTR	1
including	0
the	0
Sp1	9
and	0
NF-kappaB	9
binding	1
sites	2
.	0

Recent	0
studies	0
,	0
however	0
,	0
demonstrate	0
that	0
the	0
transcribed	0
5'-untranslated	1
leader	2
region	2
(	0
5'-UTR	1
)	0
also	0
contains	0
important	0
transcriptional	1
elements	2
.	0

These	0
regulatory	1
elements	2
situated	0
downstream	0
of	0
transcription	0
interact	0
with	0
constitutive	0
and	0
inducible	0
transcription	9
factors	10
,	0
mediate	0
transmission	0
of	0
cellular	0
activation	0
signals	0
,	0
and	0
are	0
important	0
for	0
efficient	0
HIV-1	0
transcription	0
and	0
replication	0
.	0

The	0
5'-UTR	1
contains	0
binding	1
sites	2
for	0
the	0
transcription	9
factors	10
AP-1	0
,	0
NF-kappaB	9
,	0
NF-AT	9
,	0
IRF	9
,	0
and	0
Sp1	9
.	0

Mutations	0
in	0
these	0
binding	1
sites	2
can	0
interfere	0
with	0
the	0
viral	0
response	0
to	0
cell	0
activation	0
signals	0
,	0
decrease	0
LTR	1
transcription	0
,	0
and	0
inhibit	0
viral	0
replication	0
.	0

The	0
5'-UTR	1
also	0
interacts	0
with	0
a	0
specific	0
nucleosome	9
that	0
is	0
rapidly	0
displaced	0
during	0
transcriptional	0
activation	0
of	0
the	0
latent	0
provirus	0
.	0

We	0
propose	0
that	0
the	0
inducible	1
transcription	2
factor	2
binding	2
sites	2
in	0
the	0
5'-UTR	1
comprise	0
a	0
downstream	1
enhancer	2
domain	2
that	0
can	0
function	0
independent	0
of	0
,	0
or	0
in	0
concert	0
with	0
,	0
the	0
LTR	1
promoter	2
to	0
rapidly	0
increase	0
latent	0
proviral	0
transcription	0
in	0
response	0
to	0
cell	0
activation	0
signals	0
.	0

In	0
this	0
review	0
,	0
we	0
describe	0
the	0
host-cell	9
transcription	10
factors	10
that	0
interact	0
with	0
the	0
5'-UTR	1
and	0
discuss	0
their	0
role	0
in	0
the	0
transcriptional	0
regulation	0
of	0
HIV-1	0
gene	0
expression	0
.	0

Regulation	0
of	0
PAK	0
activation	0
and	0
the	0
T	0
cell	0
cytoskeleton	0
by	0
the	0
linker	9
protein	10
SLP-76	9
.	0

Tyrosine	0
phosphorylation	0
of	0
linker	9
proteins	10
enables	0
the	0
T	9
cell	10
antigen	10
receptor	10
(	10
TCR	10
)	10
-associated	10
protein	10
tyrosine	10
kinases	10
to	0
phosphorylate	0
and	0
regulate	0
effector	9
molecules	10
that	0
generate	0
second	9
messengers	10
.	0

We	0
demonstrate	0
here	0
that	0
the	0
SLP-76	9
linker	0
protein	0
interacts	0
with	0
both	0
nck	9
,	0
an	0
adaptor	9
protein	10
,	0
and	0
Vav	9
,	0
a	0
guanine	9
nucleotide	10
exchange	10
factor	10
for	0
Rho-family	9
GTPases	10
.	0

The	0
assembly	0
of	0
this	0
tri-molecular	9
complex	10
permits	0
the	0
activated	0
Rho-family	9
GTPases	10
to	0
regulate	0
target	0
effectors	0
that	0
interact	0
through	0
nck	9
.	0

In	0
turn	0
,	0
assembly	0
of	0
this	0
complex	0
mediates	0
the	0
enzymatic	0
activation	0
of	0
the	0
p21-activated	9
protein	10
kinase	10
1	10
and	0
facilitates	0
actin	9
polymerization	0
.	0

Hence	0
,	0
phosphorylation	0
of	0
linker	9
proteins	10
not	0
only	0
bridges	0
the	0
TCR-associated	9
PTK	10
,	0
ZAP-70	9
,	0
with	0
downstream	0
effector	0
proteins	0
,	0
but	0
also	0
provides	0
a	0
scaffold	0
to	0
integrate	0
distinct	0
signaling	9
complexes	10
to	0
regulate	0
T	7
cell	8
function	0
.	0

Interleukin-12	9
expression	0
in	0
B	7
cells	8
by	0
transformation	0
with	0
Epstein-Barr	0
virus	0
.	0

Although	0
interleukin	9
(	10
IL	10
)	10
-12	10
was	0
originally	0
purified	0
from	0
an	0
Epstein-Barr	5
(	6
EBV	6
)	6
-transformed	6
B	6
cell	6
line	6
and	0
the	0
high	0
correlation	0
of	0
EBV	0
infection	0
and	0
IL-12	9
expression	0
has	0
been	0
suggested	0
,	0
no	0
study	0
has	0
reported	0
whether	0
EBV	0
infection	0
is	0
directly	0
linked	0
to	0
IL-12	9
expression	0
.	0

To	0
address	0
this	0
issue	0
,	0
we	0
have	0
investigated	0
IL-12	9
expression	0
in	0
B	7
cells	8
during	0
in	0
vitro	0
transformation	0
with	0
EBV	0
.	0

Human	7
peripheral	8
B	8
cells	8
became	0
capable	0
of	0
constitutively	0
producing	0
p40	0
by	0
in	0
vitro	0
transformation	0
with	0
EBV	0
,	0
coincident	0
with	0
the	0
expression	0
of	0
latent	9
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
of	0
EBV	0
.	0

These	0
B	7
cells	8
expressed	0
p40	3
and	4
p35	4
mRNA	4
,	0
and	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
stimulation	0
strongly	0
enhanced	0
p40	0
and	0
p70	0
production	0
.	0

Furthermore	0
,	0
transfection	0
with	0
LMP1	1
expression	2
vector	2
into	0
a	0
human	5
B	6
lymphoma	6
cell	6
line	6
,	0
Daudi	5
,	0
led	0
to	0
p40	9
production	0
with	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
activation	0
.	0

These	0
results	0
suggest	0
that	0
transformation	0
of	0
primary	7
B	8
cells	8
with	0
EBV	0
induces	0
IL-12	9
expression	0
potentially	0
through	0
LMP1	9
expression	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

The	0
human	1
gene	2
encoding	0
the	0
lectin-type	9
oxidized	10
LDL	10
receptor	10
(	0
OLR1	9
)	0
is	0
a	0
novel	0
member	0
of	0
the	0
natural	9
killer	10
gene	10
complex	10
with	0
a	0
unique	0
expression	0
profile	0
.	0

LOX-1	9
is	0
an	0
endothelial	9
receptor	10
for	0
oxidized	9
low-density	10
lipoprotein	10
that	0
plays	0
essential	0
roles	0
in	0
atherogenesis	0
.	0

LOX-1	9
has	0
the	0
highest	0
homology	0
with	0
C-type	9
lectin	10
receptors	10
expressed	0
on	0
natural	7
killer	8
cells	8
.	0

In	0
the	0
present	0
study	0
,	0
we	0
cloned	0
and	0
characterized	0
the	0
human	1
LOX-1	2
gene	2
(	0
HGMW-approved	9
symbol	10
OLR1	10
)	0
.	0

The	0
gene	0
structure	0
of	0
LOX-1	9
resembles	0
that	0
of	0
the	0
natural	9
killer	10
cell	10
receptors	10
.	0

Fluorescence	0
in	0
situ	0
hybridization	0
and	0
analyses	0
of	0
a	0
yeast	0
artificial	0
chromosome	0
contig	0
revealed	0
that	0
the	0
human	1
LOX-1	2
gene	2
is	0
located	0
in	0
the	0
natural	9
killer	10
gene	10
complex	10
on	0
chromosome	1
12p12-p13	2
,	0
where	0
the	0
genes	0
of	0
the	0
natural	9
killer	10
cell	10
receptors	10
cluster	0
.	0

In	0
contrast	0
,	0
the	0
expression	0
pattern	0
of	0
LOX-1	9
is	0
different	0
from	0
that	0
of	0
the	0
natural	9
killer	10
cell	10
receptors	10
;	0
LOX-1	9
is	0
expressed	0
in	0
vascular-rich	0
organs	0
,	0
but	0
not	0
in	0
lymphocytes	7
.	0

A	0
1753-bp	1
fragment	2
of	0
the	0
5	1
'	2
flanking	2
region	2
of	0
the	0
LOX-1	1
gene	2
had	0
a	0
functional	0
promoter	0
activity	0
.	0

This	0
region	0
contains	0
binding	1
sites	2
for	0
several	0
transcription	9
factors	10
,	0
including	0
the	0
STAT	9
family	10
and	0
NF-IL6	9
,	0
and	0
the	0
expression	0
of	0
LOX-1	9
was	0
upregulated	0
by	0
several	0
cytokines	9
.	0

These	0
results	0
demonstrate	0
that	0
the	0
human	1
LOX-1	2
gene	2
is	0
a	0
new	0
member	0
of	0
the	0
natural	9
killer	10
gene	10
complex	10
with	0
a	0
unique	0
expression	0
profile	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Transcriptional	0
regulation	0
of	0
the	0
beta-casein	1
gene	2
by	0
cytokines	9
:	0
cross-talk	0
between	0
STAT5	9
and	0
other	0
signaling	9
molecules	10
.	0

The	0
beta-casein	1
promoter	2
has	0
been	0
widely	0
used	0
to	0
monitor	0
the	0
activation	0
of	0
STAT	9
(	10
signal	10
transducer	10
and	10
activator	10
of	10
transcription	10
)	10
5	10
since	0
STAT5	9
was	0
originally	0
found	0
as	0
a	0
mediator	0
of	0
PRL-inducible	0
beta-casein	9
expression	0
.	0

However	0
,	0
not	0
only	0
is	0
expression	0
of	0
the	0
beta-casein	1
gene	2
regulated	0
by	0
STAT5	9
but	0
it	0
is	0
also	0
affected	0
by	0
other	0
molecules	0
such	0
as	0
glucocorticoid	0
and	0
Ras	9
.	0

In	0
this	0
report	0
,	0
we	0
describe	0
the	0
transcriptional	0
regulation	0
of	0
the	0
beta-casein	1
gene	2
by	0
cytokines	9
in	0
T	7
cells	8
.	0

We	0
have	0
found	0
that	0
the	0
beta-casein	1
gene	2
is	0
expressed	0
in	0
a	0
cytotoxic	5
T	6
cell	6
line	6
,	0
CTLL-2	5
,	0
in	0
response	0
to	0
interleukin-2	9
(	0
IL-2	9
)	0
,	0
which	0
activates	0
STAT5	9
.	0

While	0
IL-4	9
does	0
not	0
activate	0
STAT5	9
,	0
it	0
induces	0
expression	0
of	0
STAT5-regulated	1
genes	2
in	0
CTLL-2	5
,	0
i.e	0
.	0
beta-casein	9
,	0
a	0
cytokine-inducible	9
SH2-containing	10
protein	10
(	0
CIS	9
)	0
,	0
and	0
oncostatin	9
M	10
(	0
OSM	9
)	0
,	0
suggesting	0
that	0
STAT6	0
activated	0
by	0
IL-4	9
substitutes	0
for	0
the	0
function	0
of	0
STAT5	9
in	0
T	7
cells	8
.	0

IL-2	9
-induced	0
beta-casein	9
expression	0
was	0
enhanced	0
by	0
dexamethasone	0
,	0
and	0
this	0
synergistic	0
effect	0
of	0
Dexamethasone	0
requires	0
the	0
sequence	0
between	0
-155	1
and	2
-193	2
in	0
the	0
beta-casein	1
promoter	2
.	0

Coincidentally	0
,	0
a	0
deletion	0
of	0
this	0
region	0
enhanced	0
the	0
IL-2	9
-induced	0
expression	0
of	0
beta-casein	9
.	0

Expression	0
of	0
an	0
active	0
form	0
of	0
Ras	9
,	0
Ras	9
(	10
G12V	10
)	10
,	0
suppressed	0
the	0
IL-2	9
-induced	0
beta-casein	9
and	0
OSM	9
gene	0
expression	0
,	0
and	0
the	0
negative	0
effect	0
of	0
Ras	9
is	0
mediated	0
by	0
the	0
region	0
between	0
-105	1
and	2
-193	2
in	0
the	0
beta-casein	1
promoter	2
.	0

In	0
apparent	0
contradiction	0
,	0
expression	0
of	0
a	0
dominant	0
negative	0
form	0
of	0
Ras	9
,	0
RasN17	9
,	0
also	0
inhibited	0
IL-2	9
-induced	0
activation	0
of	0
the	0
promoter	0
containing	0
the	0
minimal	0
beta-casein	1
STAT5	2
element	2
as	0
well	0
as	0
the	0
promoters	0
of	0
CIS	9
and	0
OSM	9
.	0

In	0
addition	0
,	0
Ras	9
(	10
G12V	10
)	10
complemented	0
signaling	0
by	0
an	0
erythropoietin	9
receptor	10
mutant	10
defective	0
in	0
Ras	9
activation	0
and	0
augmented	0
the	0
activation	0
of	0
the	0
beta-casein	1
promoter	2
by	0
the	0
mutant	9
erythropoietin	10
receptor	10
signaling	0
,	0
suggesting	0
a	0
possible	0
role	0
of	0
Ras	9
in	0
Stat5	9
-mediated	0
gene	0
expression	0
.	0

These	0
results	0
collectively	0
reveal	0
a	0
complex	0
interaction	0
of	0
STAT5	9
with	0
other	0
signaling	0
pathways	0
and	0
illustrate	0
that	0
regulation	0
of	0
gene	0
expression	0
requires	0
integration	0
of	0
opposing	0
signals	0

GATA-3	9
represses	0
gp91phox	1
gene	2
expression	0
in	0
eosinophil-committed	5
HL-60-C15	6
cells	6
.	0

To	0
study	0
the	0
regulatory	0
mechanism	0
of	0
gp91phox	1
gene	2
expression	0
in	0
eosinophils	0
,	0
we	0
transiently	0
transfected	0
eosinophil-committed	5
HL-60-C15	6
cells	6
with	0
gp91phox	1
promoter	2
constructs	2
,	0
and	0
identified	0
a	0
negative	1
element	2
from	0
bp	0
-267	1
to	2
-246	2
of	0
the	0
gp91phox	1
gene	2
,	0
the	0
deletion	0
of	0
which	0
caused	0
an	0
83	0
%	0
increase	0
in	0
promoter	0
activity	0
.	0

Electrophoresis	0
mobility	0
shift	0
assays	0
demonstrated	0
GATA-3	9
binds	0
to	0
the	0
GATA	1
consensus	2
site	2
from	0
bp	0
-256	1
to	2
-250	2
.	2

An	0
81	0
%	0
increment	0
in	0
promoter	0
activity	0
was	0
obtained	0
when	0
a	0
mutation	0
was	0
introduced	0
in	0
the	0
GATA-3	1
binding	2
site	2
of	0
the	0
bp	1
-267	2
to	2
+12	2
construct	2
,	0
which	0
is	0
comparable	0
to	0
that	0
of	0
the	0
bp	1
-245	2
to	2
+12	2
construct	2
.	0

We	0
therefore	0
conclude	0
that	0
GATA-3	9
specifically	0
binding	0
to	0
the	0
GATA	1
site	2
negatively	0
regulates	0
the	0
expression	0
of	0
the	0
gene	0
in	0
HL-60-C15	5
cells	6
.	0

Uncoupling	0
activation-dependent	0
HS1	9
phosphorylation	0
from	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
transcriptional	0
activation	0
in	0
Jurkat	5
T	6
cells	6
:	0
differential	0
signaling	0
through	0
CD3	9
and	0
the	0
costimulatory	0
receptors	0
CD2	9
and	0
CD28	9
.	0

CD3	9
,	0
CD2	9
,	0
and	0
CD28	9
are	0
functionally	0
distinct	0
receptors	0
on	0
T	7
lymphocytes	8
.	0

Engagement	0
of	0
any	0
of	0
these	0
receptors	0
induces	0
the	0
rapid	0
tyrosine	0
phosphorylation	0
of	0
a	0
shared	0
group	0
of	0
intracellular	9
signaling	10
proteins	10
,	0
including	0
Vav	9
,	0
Cbl	9
,	0
p85	9
phosphoinositide	10
3-kinase	10
,	0
and	0
the	0
Src	9
family	10
kinases	10
Lck	9
and	0
Fyn	9
.	0

Ligation	0
of	0
CD3	9
also	0
induces	0
the	0
tyrosine	0
phosphorylation	0
of	0
HS1	9
,	0
a	0
75-kDa	9
hematopoietic	10
cell-specific	10
intracellular	10
signaling	10
protein	10
of	0
unknown	0
function	0
.	0

We	0
have	0
examined	0
changes	0
in	0
HS1	9
phosphorylation	0
after	0
differential	0
stimulation	0
of	0
CD3	9
,	0
CD2	9
,	0
and	0
CD28	9
to	0
elucidate	0
its	0
role	0
in	0
T	7
cells	8
and	0
to	0
further	0
delineate	0
the	0
signaling	0
pathways	0
recruited	0
by	0
these	0
receptors	0
.	0

Unlike	0
ligation	0
of	0
CD3	9
,	0
stimulation	0
with	0
anti-CD28	9
mAb	10
or	0
CHO	5
cells	6
expressing	0
the	0
CD28	9
ligands	10
CD80	9
or	0
CD86	9
did	0
not	0
lead	0
to	0
tyrosine	0
phosphorylation	0
of	0
HS1	9
in	0
Jurkat	5
T	6
cells	6
.	0

Additionally	0
,	0
no	0
tyrosine	0
phosphorylation	0
of	0
HS1	9
was	0
induced	0
by	0
mitogenic	7
pairs	8
of	0
anti-CD2	9
mAbs	10
capable	0
of	0
activating	0
the	0
transcription	9
factor	10
NFAT	10
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
)	0
.	0

Costimulation	0
through	0
CD28	9
and/or	0
CD2	9
did	0
not	0
modulate	0
the	0
CD3	9
-dependent	0
phosphorylation	0
of	0
HS1	9
.	0

In	0
vivo	0
studies	0
indicated	0
that	0
CD3	9
-induced	0
HSI	9
phosphorylation	0
was	0
dependent	0
upon	0
both	0
the	0
Src	9
family	10
tyrosine	10
kinase	10
Lck	9
and	0
the	0
tyrosine	9
phosphatase	10
CD45	9
,	0
did	0
not	0
require	0
MEK1	9
kinase	0
activity	0
,	0
and	0
was	0
regulated	0
by	0
protein	9
kinase	10
C	10
activation	0
.	0

Thus	0
,	0
although	0
CD3	9
,	0
CD28	9
,	0
and	0
CD2	0
activate	0
many	0
of	0
the	0
same	0
signaling	9
molecules	10
,	0
they	0
differed	0
in	0
their	0
capacity	0
to	0
induce	0
the	0
tyrosine	0
phosphorylation	0
of	0
HSI	9
.	0

Furthermore	0
,	0
activation-dependent	0
tyrosine	0
phosphorylation	0
of	0
HS1	9
was	0
not	0
required	0
for	0
NFAT	9
transcriptional	0
activation	0
.	0

c-fos	0
and	0
c-jun	0
mRNA	0
expression	0
in	0
activated	7
cord	8
and	8
adult	8
lymphocytes	8
:	0
an	0
analysis	0
by	0
Northern	0
hybridization	0
.	0

BACKGROUND	0
AND	0
OBJECTIVES	0
:	0
To	0
further	0
analyze	0
the	0
neonatal	0
immune	0
response	0
to	0
an	0
antigenic	0
challenge	0
such	0
as	0
blood	0
transfusion	0
,	0
c-fos	0
and	0
c-jun	0
mRNA	0
expression	0
were	0
analyzed	0
in	0
twelve	0
in-vitro-stimulated	0
normal	0
cord	0
blood	0
and	0
ten	0
in-vitro-stimulated	7
normal	8
adult	8
peripheral	8
blood	8
lymphocyte	8
samples	8
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
Lymphocyte	7
samples	8
were	0
stimulated	0
by	0
either	0
the	0
mitogen	9
phytohemagglutinin	10
(	0
PHA	9
)	0
or	0
the	0
monoclonal	0
antibody	0
alphaCD3	9
.	0

Proliferation	0
rate	0
and	0
Northern	0
blot	0
hybridization	0
were	0
employed	0
.	0

RESULTS	0
:	0
Cord	0
lymphocytes	0
revealed	0
a	0
greater	0
proliferation	0
rate	0
with	0
PHA	9
and	0
alphaCD3	9
than	0
adult	0
lymphocytes	0
(	0
p	0
=	0
0.0081	0
and	0
0.0023	0
,	0
respectively	0
)	0
.	0

In	0
addition	0
,	0
Northern	0
blot	0
analysis	0
of	0
cord	0
and	0
adult	0
samples	0
revealed	0
similar	0
maximal	0
increases	0
in	0
c-fos	3
(	0
99+/-15	0
and	0
126+/-11	0
%	0
,	0
p	0
=	0
0.0126	0
)	0
and	0
c-jun	3
(	4
123+/-9	4
and	4
185+/-38	4
%	4
,	4
p	4
=	4
0.0291	4
)	4
mRNA	4
expression	0
,	0
respectively	0
,	0
as	0
early	0
as	0
15	0
min	0
post-	0
alphaCD3	9
stimulation	0
.	0

Adult	0
lymphocytes	0
showed	0
an	0
equivalent	0
increase	0
in	0
mRNA	0
expression	0
of	0
c-fos	1
and	0
c-jun	1
(	0
140+/-25	0
and	0
155+/-31	0
%	0
)	0
at	0
30	0
min	0
post-	0
PHA	9
stimulation	0
,	0
while	0
cord	7
lymphocyte	8
maximum	0
c-fos	0
and	0
c-jun	0
expression	0
(	0
82+/-6	0
and	0
142+/-12	0
%	0
)	0
occurred	0
at	0
15	0
min	0
post-	0
PHA	9
stimulation	0
(	0
c-fos	1
,	0
p	0
=	0
0.0354	0
;	0
c-jun	1
,	0
p	0
=	0
0.0112	0
)	0
.	0

CONCLUSION	0
:	0
Although	0
cord	7
lymphocyte	8
proliferation	0
rates	0
were	0
significantly	0
greater	0
than	0
those	0
of	0
adult	0
lymphocytes	0
following	0
stimulation	0
,	0
lymphocyte	0
activation	0
,	0
as	0
analyzed	0
by	0
c-fos	0
and	0
c-jun	0
mRNA	0
expression	0
,	0
appears	0
similar	0
in	0
both	0
cord	0
and	0
adult	0
samples	0
.	0

We	0
conclude	0
that	0
cord	0
lymphocyte	0
activation	0
exhibits	0
an	0
adult-type	0
profile	0
.	0

Fcgamma	9
receptor	10
-mediated	0
mitogen-activated	9
protein	10
kinase	10
activation	0
in	0
monocytes	7
is	0
independent	0
of	0
Ras	9
.	0

Receptors	0
for	0
the	0
Fc	9
portion	10
of	0
immunoglobulin	9
molecules	10
(	0
FcR	9
)	0
present	0
on	0
leukocyte	0
cell	0
membranes	0
mediate	0
a	0
large	0
number	0
of	0
cellular	0
responses	0
that	0
are	0
very	0
important	0
in	0
host	0
defense	0
,	0
including	0
phagocytosis	0
,	0
cell	0
cytotoxicity	0
,	0
production	0
and	0
secretion	0
of	0
inflammatory	9
mediators	10
,	0
and	0
modulation	0
of	0
the	0
immune	0
response	0
.	0

Cross-linking	0
of	0
FcR	9
with	0
immune	9
complexes	10
leads	0
,	0
first	0
to	0
activation	0
of	0
protein-tyrosine	9
kinases	10
.	0

The	0
molecular	0
events	0
that	0
follow	0
and	0
that	0
transduce	0
signals	0
from	0
these	0
receptors	0
to	0
the	0
nucleus	0
are	0
still	0
poorly	0
defined	0
.	0

We	0
have	0
investigated	0
the	0
signal	0
transduction	0
pathway	0
from	0
Fc	9
receptors	10
that	0
leads	0
to	0
gene	0
activation	0
and	0
production	0
of	0
cytokines	9
in	0
monocytes	7
.	0

Cross-linking	0
of	0
FcR	9
,	0
on	0
the	0
THP-1	5
monocytic	6
cell	6
line	6
,	0
by	0
immune	9
complexes	10
resulted	0
in	0
both	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
and	0
interleukin	9
1	10
production	0
.	0

These	0
responses	0
were	0
completely	0
blocked	0
by	0
tyrosine	9
kinase	10
inhibitors	0
.	0

In	0
contrast	0
,	0
expression	0
of	0
dominant	9
negative	10
mutants	10
of	0
Ras	9
and	0
Raf-1	9
,	0
in	0
these	0
cells	0
,	0
did	0
not	0
have	0
any	0
effect	0
on	0
FcR	9
-mediated	0
nuclear	9
factor	10
activation	0
,	0
suggesting	0
that	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
signaling	0
pathway	0
was	0
not	0
used	0
by	0
these	0
receptors	0
.	0

However	0
,	0
MAPK	9
activation	0
was	0
easily	0
detected	0
by	0
in	0
vitro	0
kinase	0
assays	0
,	0
after	0
FcR	9
cross-linking	0
with	0
immune	9
complexes	10
.	0

Using	0
the	0
specific	0
MAPK	9
/extracellular	0
signal-regulated	0
kinase	0
kinase	0
(	0
MAPK	0
kinase	0
)	0
inhibitor	0
PD98059	0
,	0
we	0
found	0
that	0
MAPK	9
activation	0
is	0
necessary	0
for	0
FcR	9
-dependent	0
activation	0
of	0
the	0
nuclear	9
factor	10
NF-kappaB	9
.	0

These	0
results	0
strongly	0
suggest	0
that	0
the	0
signaling	0
pathway	0
from	0
Fc	9
receptors	10
leading	0
to	0
expression	0
of	0
different	0
genes	0
important	0
to	0
leukocyte	0
biology	0
,	0
initiates	0
with	0
tyrosine	9
kinases	10
and	0
requires	0
MAPK	9
activation	0
;	0
but	0
in	0
contrast	0
to	0
other	0
tyrosine	9
kinase	10
receptors	10
,	0
FcR	9
-mediated	0
MAPK	9
activation	0
does	0
not	0
involve	0
Ras	9
and	0
Raf	9
.	0

BCL-6	9
mutations	0
in	0
normal	7
germinal	8
center	8
B	8
cells	8
:	0
evidence	0
of	0
somatic	0
hypermutation	0
acting	0
outside	0
Ig	1
loci	2
.	0

The	0
molecular	0
mechanism	0
involved	0
in	0
the	0
process	0
of	0
antigen-driven	0
somatic	0
hypermutation	0
of	0
Ig	1
genes	2
is	0
unknown	0
,	0
but	0
it	0
is	0
commonly	0
believed	0
that	0
this	0
mechanism	0
is	0
restricted	0
to	0
the	0
Ig	1
loci	2
.	0

B	7
cell	8
lymphomas	8
commonly	0
display	0
multiple	0
somatic	0
mutations	0
clustering	0
in	0
the	0
5'-regulatory	1
region	2
of	0
BCL-6	9
,	0
a	0
proto-oncogene	1
encoding	0
for	0
a	0
POZ/Zinc	9
finger	10
transcriptional	10
repressor	10
expressed	0
in	0
germinal	7
center	8
(	8
GC	8
)	8
B	8
cells	8
and	0
required	0
for	0
GC	0
formation	0
.	0

To	0
determine	0
whether	0
BCL-6	9
mutations	0
represent	0
a	0
tumor-associated	0
phenomenon	0
or	0
reflect	0
a	0
physiologic	0
mechanism	0
,	0
we	0
screened	0
single	0
human	7
tonsillar	8
GC	8
B	8
cells	8
for	0
mutations	0
occurring	0
in	0
the	0
BCL-6	1
5'-noncoding	2
region	2
and	0
in	0
the	0
Ig	1
variable	2
heavy	2
chain	2
sequences	2
.	0

Thirty	0
percent	0
of	0
GC	7
B	8
cells	8
,	0
but	0
not	0
naive	7
B	8
cells	8
,	0
displayed	0
mutations	0
in	0
the	0
742	1
bp	2
region	2
analyzed	0
within	0
the	0
first	0
intron	0
of	0
BCL-6	9
(	0
overall	0
frequency	0
:	0
5	0
x	0
10	0
(	0
-4	0
)	0
/bp	0
)	0
.	0

Accordingly	0
,	0
an	0
expanded	0
survey	0
in	0
lymphoid	0
malignancies	0
showed	0
that	0
BCL-6	9
mutations	0
are	0
restricted	0
to	0
B	0
cell	0
tumors	0
displaying	0
GC	0
or	0
post-GC	0
phenotype	0
and	0
carrying	0
mutated	1
Ig	2
variable	2
heavy	2
chain	2
sequences	2
.	0

These	0
results	0
indicate	0
that	0
the	0
somatic	0
hypermutation	0
mechanism	0
active	0
in	0
GC	7
B	8
cells	8
physiologically	0
targets	0
non-Ig	1
sequences	2
.	0

The	0
AD1	9
and	0
AD2	9
transactivation	0
domains	0
of	0
E2A	9
are	0
essential	0
for	0
the	0
antiapoptotic	0
activity	0
of	0
the	0
chimeric	9
oncoprotein	10
E2A-HLF	9
.	0

The	0
chimeric	9
oncoprotein	10
E2A-HLF	9
,	0
generated	0
by	0
the	0
t	1
(	2
17	2
;	2
19	2
)	2
chromosomal	2
translocation	2
in	0
pro-B-cell	0
acute	0
lymphoblastic	0
leukemia	0
,	0
incorporates	0
the	0
transactivation	9
domains	10
of	0
E2A	9
and	0
the	0
basic	9
leucine	10
zipper	10
(	10
bZIP	10
)	10
DNA-binding	10
and	10
protein	10
dimerization	10
domain	10
of	0
HLF	9
(	0
hepatic	9
leukemic	10
factor	10
)	0
.	0

The	0
ability	0
of	0
E2A-HLF	9
to	0
prolong	0
the	0
survival	0
of	0
interleukin-3	5
(	6
IL-3	6
)	6
-dependent	6
murine	6
pro-B	6
cells	6
after	0
IL-3	9
withdrawal	0
suggests	0
that	0
it	0
disrupts	0
signaling	0
pathways	0
normally	0
responsible	0
for	0
cell	0
suicide	0
,	0
allowing	0
the	0
cells	0
to	0
accumulate	0
as	0
transformed	7
lymphoblasts	8
.	0

To	0
determine	0
the	0
structural	0
motifs	0
that	0
contribute	0
to	0
this	0
antiapoptotic	0
effect	0
,	0
we	0
constructed	0
a	0
panel	0
of	0
E2A-HLF	9
mutants	10
and	0
programmed	0
their	0
expression	0
in	0
IL-3-dependent	5
murine	6
pro-B	6
cells	6
(	0
FL5.12	5
line	6
)	0
,	0
using	0
a	0
zinc-inducible	0
vector	0
.	0

Neither	0
the	0
E12	9
nor	0
the	0
E47	9
product	0
of	0
the	0
E2A	1
gene	2
nor	0
the	0
wild-type	9
HLF	10
protein	10
was	0
able	0
to	0
protect	0
the	0
cells	0
from	0
apoptosis	0
induced	0
by	0
IL-3	9
deprivation	0
.	0

Surprisingly	0
,	0
different	0
combinations	0
of	0
disabling	0
mutations	0
within	0
the	0
HLF	9
bZIP	10
domain	10
had	0
little	0
effect	0
on	0
the	0
antiapoptotic	0
property	0
of	0
the	0
chimeric	9
protein	10
,	0
so	0
long	0
as	0
the	0
amino-terminal	0
portion	0
of	0
E2A	9
remained	0
intact	0
.	0

In	0
the	0
context	0
of	0
a	0
bZIP	9
domain	10
defective	0
in	0
DNA	0
binding	0
,	0
mutants	0
retaining	0
either	0
of	0
the	0
two	0
transactivation	9
domains	10
of	0
E2A	9
were	0
able	0
to	0
extend	0
cell	0
survival	0
after	0
growth	9
factor	10
deprivation	0
.	0

Thus	0
,	0
the	0
block	0
of	0
apoptosis	0
imposed	0
by	0
E2A-HLF	9
in	0
pro-B	7
lymphocytes	8
depends	0
critically	0
on	0
the	0
transactivating	9
regions	10
of	0
E2A	9
.	0

Since	0
neither	0
DNA	0
binding	0
nor	0
protein	0
dimerization	0
through	0
the	0
bZIP	9
domain	10
of	0
HLF	9
is	0
required	0
for	0
this	0
effect	0
,	0
we	0
propose	0
mechanisms	0
whereby	0
protein-protein	0
interactions	0
with	0
the	0
amino-terminal	0
region	0
of	0
E2A	9
allow	0
the	0
chimera	9
to	0
act	0
as	0
a	0
transcriptional	0
cofactor	0
to	0
alter	0
the	0
expression	0
of	0
genes	0
regulating	0
the	0
apoptotic	0
machinery	0
in	0
pro-B	7
cells	8
.	0

Induction	0
of	0
Mn	9
SOD	10
in	0
human	7
monocytes	8
without	0
inflammatory	9
cytokine	10
production	0
by	0
a	0
mutant	9
endotoxin	10
.	0

Endotoxin	9
selectively	0
induces	0
monocyte	9
Mn	10
superoxide	10
dismutase	10
(	0
SOD	9
)	0
without	0
affecting	0
levels	0
of	0
Cu	0
,	0
Zn	9
SOD	10
,	0
catalase	9
,	0
or	0
glutathione	9
peroxidase	10
.	0

However	0
,	0
little	0
is	0
known	0
about	0
the	0
structure-activity	0
relationship	0
and	0
the	0
mechanism	0
by	0
which	0
endotoxin	0
induces	0
Mn	9
SOD	10
.	0

In	0
this	0
study	0
we	0
demonstrated	0
that	0
a	0
mutant	0
Escherichia	0
coli	0
endotoxin	0
lacking	0
myristoyl	0
fatty	0
acid	0
at	0
the	0
3	0
'	0
R-3-hydroxymyristate	0
position	0
of	0
the	0
lipid	0
A	0
moiety	0
retained	0
its	0
full	0
capacity	0
to	0
coagulate	0
Limulus	0
amoebocyte	0
lysate	0
compared	0
with	0
the	0
wild-type	0
E.	0
coli	0
endotoxin	0
and	0
markedly	0
stimulated	0
the	0
activation	0
of	0
human	9
monocyte	10
nuclear	10
factor-kappaB	10
and	0
the	0
induction	0
of	0
Mn	3
SOD	4
mRNA	4
and	0
enzyme	0
activity	0
.	0

However	0
,	0
in	0
contrast	0
to	0
the	0
wild-type	0
endotoxin	0
,	0
it	0
failed	0
to	0
induce	0
significant	0
production	0
of	0
tumor	9
necrosis	10
factor-alpha	10
and	0
macrophage	9
inflammatory	10
protein-1alpha	10
by	0
monocytes	7
and	0
did	0
not	0
induce	0
the	0
phosphorylation	0
and	0
nuclear	0
translocation	0
of	0
mitogen-activated	9
protein	10
kinase	10
.	0

These	0
results	0
suggest	0
that	0
1	0
)	0
lipid	0
A	0
myristoyl	0
fatty	0
acid	0
,	0
although	0
it	0
is	0
important	0
for	0
the	0
induction	0
of	0
inflammatory	9
cytokine	10
production	0
by	0
human	7
monocytes	8
,	0
is	0
not	0
necessary	0
for	0
the	0
induction	0
of	0
Mn	9
SOD	10
,	0
2	0
)	0
endotoxin	9
-mediated	0
induction	0
of	0
Mn	9
SOD	10
and	0
inflammatory	0
cytokines	9
are	0
regulated	0
,	0
at	0
least	0
in	0
part	0
,	0
through	0
different	0
signal	0
transduction	0
pathways	0
,	0
and	0
3	0
)	0
failure	0
of	0
the	0
mutant	9
endotoxin	10
to	0
induce	0
tumor	9
necrosis	10
factor-alpha	10
production	0
is	0
,	0
at	0
least	0
in	0
part	0
,	0
due	0
to	0
its	0
inability	0
to	0
activate	0
mitogen-activated	9
protein	10
kinase	10
.	0

Regulation	0
of	0
the	0
vitellogenin	1
gene	2
B1	2
promoter	2
after	0
transfer	0
into	0
hepatocytes	7
in	0
primary	0
cultures	0
.	0

The	0
estrogen-dependent	0
and	0
tissue-specific	0
regulation	0
of	0
the	0
Xenopus	0
laevis	0
vitellogenin	1
gene	2
B1	2
promoter	2
has	0
been	0
studied	0
by	0
lipid-mediated	0
DNA	0
transfer	0
into	0
Xenopus	7
hepatocytes	8
in	0
primary	0
culture	0
.	0

Hepatocytes	0
achieve	0
an	0
efficient	0
hormonal	0
control	0
of	0
this	0
promoter	0
through	0
a	0
functional	0
interaction	0
between	0
the	0
estrogen	1
responsive	2
elements	2
and	0
a	0
promoter	1
proximal	2
region	2
upstream	0
of	0
the	0
TATA	1
box	2
,	0
which	0
is	0
characterized	0
by	0
a	0
high	0
density	0
of	0
binding	0
sites	0
for	0
the	0
transcription	9
factors	10
CTF/NF-1	9
,	0
C/EBP	9
and	0
HNF3	9
.	0

DNA	0
accessibility	0
to	0
restriction	9
enzymes	10
within	0
the	0
chromosomal	0
copy	0
of	0
the	0
vitellogenin	1
gene	2
B1	2
promoter	2
shows	0
that	0
the	0
estrogen	1
responsive	2
unit	2
and	0
the	0
promoter	1
proximal	2
region	2
are	0
sensitive	0
to	0
digestion	0
in	0
uninduced	0
and	0
estrogen-induced	7
hepatocytes	8
but	0
not	0
in	0
erythrocyte	0
nuclei	0
.	0

Together	0
,	0
these	0
findings	0
support	0
the	0
notion	0
that	0
chromatin	1
configuration	0
as	0
well	0
as	0
the	0
interplay	0
of	0
promoter	1
elements	2
mediate	0
proper	0
hormone-dependent	0
and	0
tissue-specific	0
expression	0
of	0
the	0
B1	1
vitellogenin	2
gene	2
.	0

Characterization	0
of	0
cytokine	9
differential	0
induction	0
of	0
STAT	9
complexes	10
in	0
primary	7
human	8
T	8
and	8
NK	8
cells	8
.	0

Cytokines	9
,	0
IL-2	9
,	0
IL-4	9
,	0
IL-6	9
,	0
IL-7	9
,	0
IL-12	9
,	0
and	0
IL-15	9
are	0
key	0
regulators	0
of	0
human	0
peripheral	0
blood	0
T	0
and	0
NK	0
cell	0
activation	0
and	0
differentiation	0
but	0
the	0
precise	0
mechanisms	0
that	0
give	0
rise	0
to	0
their	0
differential	0
activities	0
within	0
these	0
cells	0
are	0
not	0
clear	0
.	0

Recent	0
studies	0
reveal	0
that	0
a	0
family	0
of	0
transcription	9
factors	10
,	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
STATs	9
)	0
directly	0
mediate	0
many	0
cytokine	9
signals	0
.	0

We	0
analyzed	0
the	0
activation	0
of	0
STATs	9
in	0
primary	7
human	8
T	8
and	8
NK	8
cells	8
by	0
a	0
variety	0
of	0
specific	0
cytokines	9
.	0

We	0
demonstrate	0
that	0
IL-12	9
induces	0
STAT4	9
only	0
in	0
freshly	0
isolated	0
primary	7
NK	8
cells	8
,	0
but	0
not	0
in	0
primary	7
T	8
cells	8
,	0
consistent	0
with	0
the	0
lack	0
of	0
the	0
IL-12	9
receptor	10
in	0
resting	7
T	8
cells	8
.	0

In	0
contrast	0
,	0
IL-4	9
induces	0
different	0
C	9
epsilon	10
GAS	10
DNA-protein	10
binding	10
complexes	10
in	0
both	0
T	0
and	0
NK	7
cells	8
.	0

Moreover	0
,	0
IL-4	9
costimulation	0
with	0
IL-2	9
or	0
IL-12	9
does	0
not	0
alter	0
their	0
own	0
preferential	0
GAS	1
-like	0
DNA	0
binding	0
patterns	0
when	0
C	1
epsilon-	2
,	2
Fc	2
gamma	2
RI-	2
,	2
and	2
SIE	2
GAS	2
motif	2
containing	0
oligonucleotide	0
probes	0
are	0
compared	0
,	0
suggesting	0
that	0
induction	0
of	0
GAS-like	9
DNA-protein	10
binding	10
complexes	10
by	0
IL-2	9
,	0
IL-4	9
,	0
and	0
IL-12	9
is	0
highly	0
selective	0
and	0
represents	0
one	0
important	0
factor	0
in	0
determining	0
specific	0
gene	0
activation	0
.	0

In	0
addition	0
,	0
IL-6	9
and	0
IL-2	9
synergistically	0
induce	0
homo-	0
and	0
heterodimerized	0
STAT1	9
alpha	10
and	0
STAT3	9
in	0
both	0
NK	7
and	8
T	8
cells	8
,	0
consistent	0
with	0
their	0
reported	0
synergism	0
in	0
modulating	0
perforin	1
gene	2
expression	0
.	0

We	0
further	0
demonstrated	0
that	0
IL-2	9
,	10
-7	10
,	10
and	10
-15	10
induce	0
multiple	9
STAT	10
proteins	10
,	0
including	0
STAT5a	9
,	0
STAT5b	9
,	0
STAT1	9
alpha	10
,	0
STAT3	9
,	0
and	0
another	0
unidentified	0
Fc	9
gamma	10
RI	10
GAS	10
DNA-binding	10
protein	10
.	0

Finally	0
,	0
we	0
observed	0
that	0
activated	0
STAT5a	9
and	0
STAT5b	9
proteins	0
form	0
distinct	0
Fc	0
gamma	0
RI	0
GAS	0
binding	0
patterns	0
in	0
T	7
and	8
NK	8
cells	8
,	0
suggesting	0
that	0
they	0
might	0
have	0
different	0
roles	0
in	0
gene	0
regulation	0
.	0

Our	0
data	0
provide	0
evidence	0
that	0
the	0
differential	0
responses	0
in	0
gene	0
expression	0
and	0
cell	0
activation	0
seen	0
in	0
primary	0
NK	7
and	8
T	8
cells	8
on	0
direct	0
stimulation	0
with	0
different	0
cytokines	9
may	0
be	0
a	0
direct	0
result	0
of	0
distinct	0
activation	0
of	0
STAT	9
transcription	10
factors	10
.	0

A	0
regulatory	1
element	2
in	0
the	0
CD95	1
(	2
APO-1/Fas	2
)	2
ligand	2
promoter	2
is	0
essential	0
for	0
responsiveness	0
to	0
TCR	9
-mediated	0
activation	0
.	0

Expression	0
of	0
the	0
CD95	9
(	10
APO-1/Fas	10
)	10
ligand	10
(	0
CD95L	9
)	0
in	0
activated	7
T	8
cells	8
is	0
a	0
major	0
cause	0
of	0
T	0
cell	0
activation-induced	0
apoptosis	0
.	0

To	0
study	0
the	0
molecular	0
mechanisms	0
of	0
transcriptional	0
control	0
of	0
CD95L	9
expression	0
in	0
T	7
cells	8
,	0
we	0
investigated	0
the	0
human	1
CD95L	2
promoter	2
in	0
Jurkat	5
T	6
cells	6
.	0

Deletion	0
studies	0
revealed	0
that	0
the	0
CD95L	1
proximal	2
promoter	2
sequence	2
from	0
-220	1
to	0
the	0
transcription	1
start	2
site	2
is	0
essential	0
for	0
T	0
cell	0
stimulation-induced	0
expression	0
of	0
CD95L	9
.	0

In	0
this	0
study	0
,	0
we	0
discovered	0
a	0
novel	0
regulatory	1
element	2
located	0
at	0
-120	1
of	0
the	0
CD95L	1
promoter	2
which	0
contains	0
DNA	1
binding	2
sites	2
for	0
SP-1	9
and	0
a	0
yet	0
unknown	0
inducible	9
factor	10
.	0

Mutation	0
analysis	0
demonstrated	0
that	0
binding	0
of	0
the	0
inducible	0
factor	0
to	0
the	0
-120	1
region	2
is	0
crucial	0
for	0
the	0
biological	0
function	0
of	0
the	0
CD95L	1
promoter	2
upon	0
T	0
cell	0
stimulation	0
.	0

The	0
DNA	0
sequence	0
at	0
-120	1
also	0
contains	0
two	0
DNA	1
motifs	2
homologous	0
to	0
the	0
binding	0
site	0
for	0
NF-AT	9
.	0

NF-AT	9
does	0
not	0
directly	0
bind	0
to	0
this	0
element	0
.	0

However	0
,	0
cotransfection	0
studies	0
with	0
an	0
NF-AT	1
expression	2
vector	2
showed	0
that	0
NF-AT	9
may	0
confer	0
a	0
strong	0
inducible	0
activity	0
to	0
the	0
CD95L	1
promoter	2
at	0
this	0
regulatory	1
region	2
.	0

Our	0
data	0
also	0
show	0
that	0
the	0
immunosuppressive	0
agent	0
cyclosporin	0
A	0
down-regulates	0
CD95L	9
transcription	0
by	0
inhibiting	0
the	0
function	0
of	0
this	0
positive	0
regulatory	1
element	2

A	0
nongenomic	0
mechanism	0
for	0
progesterone-mediated	0
immunosuppression	0
:	0
inhibition	0
of	0
K+	9
channels	10
,	0
Ca2+	0
signaling	0
,	0
and	0
gene	0
expression	0
in	0
T	7
lymphocytes	8
.	0

The	0
mechanism	0
by	0
which	0
progesterone	0
causes	0
localized	0
suppression	0
of	0
the	0
immune	0
response	0
during	0
pregnancy	0
has	0
remained	0
elusive	0
.	0

Using	0
human	7
T	8
lymphocytes	8
and	0
T	5
cell	6
lines	6
,	0
we	0
show	0
that	0
progesterone	0
,	0
at	0
concentrations	0
found	0
in	0
the	0
placenta	0
,	0
rapidly	0
and	0
reversibly	0
blocks	0
voltage-gated	9
and	10
calcium-activated	10
K+	10
channels	10
(	0
KV	9
and	0
KCa	9
,	0
respectively	0
)	0
,	0
resulting	0
in	0
depolarization	0
of	0
the	0
membrane	0
potential	0
.	0

As	0
a	0
result	0
,	0
Ca2+	0
signaling	0
and	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
-driven	0
gene	0
expression	0
are	0
inhibited	0
.	0

Progesterone	0
acts	0
distally	0
to	0
the	0
initial	0
steps	0
of	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
-mediated	0
signal	0
transduction	0
,	0
since	0
it	0
blocks	0
sustained	0
Ca2+	0
signals	0
after	0
thapsigargin	0
stimulation	0
,	0
as	0
well	0
as	0
oscillatory	0
Ca2+	0
signals	0
,	0
but	0
not	0
the	0
Ca2+	0
transient	0
after	0
TCR	9
stimulation	0
.	0

K+	0
channel	0
blockade	0
by	0
progesterone	0
is	0
specific	0
;	0
other	0
steroid	0
hormones	0
had	0
little	0
or	0
no	0
effect	0
,	0
although	0
the	0
progesterone	0
antagonist	0
RU	0
486	0
also	0
blocked	0
KV	9
and	0
KCa	9
channels	0
.	0

Progesterone	0
effectively	0
blocked	0
a	0
broad	0
spectrum	0
of	0
K+	9
channels	10
,	0
reducing	0
both	0
Kv1.3	9
and	0
charybdotoxin-resistant	9
components	10
of	0
KV	9
current	0
and	0
KCa	9
current	0
in	0
T	7
cells	8
,	0
as	0
well	0
as	0
blocking	0
several	0
cloned	9
KV	10
channels	10
expressed	0
in	0
cell	5
lines	6
.	0

Progesterone	0
had	0
little	0
or	0
no	0
effect	0
on	0
a	0
cloned	9
voltage-gated	10
Na+	10
channel	10
,	0
an	0
inward	0
rectifier	0
K+	9
channel	10
,	0
or	0
on	0
lymphocyte	9
Ca2+	10
and	10
Cl-	10
channels	10
.	0

We	0
propose	0
that	0
direct	0
inhibition	0
of	0
K+	9
channels	10
in	0
T	7
cells	8
by	0
progesterone	0
contributes	0
to	0
progesterone-induced	0
immunosuppression	0
.	0

A	0
mouse	0
carrying	0
genetic	0
defect	0
in	0
the	0
choice	0
between	0
T	7
and	8
B	8
lymphocytes	8
.	0

Transgenic	0
mice	0
with	0
human	1
CD3epsilon	2
gene	2
have	0
been	0
shown	0
to	0
exhibit	0
early	0
arrest	0
of	0
T	0
cell	0
development	0
in	0
the	0
thymus	0
.	0

The	0
present	0
study	0
shows	0
that	0
,	0
instead	0
of	0
T	7
cells	8
,	0
B	7
cells	8
are	0
generated	0
in	0
the	0
thymus	0
of	0
a	0
line	0
,	0
tg	0
epsilon26	0
,	0
of	0
the	0
human	0
CD3epsilon	0
transgenic	0
mice	0
.	0

The	0
accumulation	0
of	0
mature	7
B	8
cells	8
in	0
the	0
thymus	0
was	0
found	0
only	0
in	0
tg	0
epsilon26	0
mice	0
,	0
not	0
in	0
other	0
human	5
CD3epsilon	6
transgenic	6
mouse	6
lines	6
or	0
other	0
T	0
cell-deficient	0
mice	0
,	0
including	0
CD3-epsilon	0
knockout	0
mice	0
and	0
TCR-beta/TCR-delta	0
double	0
knockout	0
mice	0
.	0

Hanging	0
drop-mediated	0
transfer	0
into	0
2-deoxyguanosine-treated	0
thymus	0
lobes	0
showed	0
that	0
lymphoid	7
progenitor	8
cells	8
rather	0
than	0
thymus	0
stromal	0
cells	0
were	0
responsible	0
for	0
abnormal	0
B	0
cell	0
development	0
in	0
tg	9
epsilon26	10
thymus	0
,	0
and	0
that	0
tg	7
epsilon26	8
fetal	8
liver	8
cells	8
were	0
destined	0
to	0
become	0
B	7
cells	8
in	0
normal	0
thymus	0
even	0
in	0
the	0
presence	0
of	0
normal	7
progenitor	8
cells	8
undergoing	0
T	0
cell	0
development	0
.	0

These	0
results	0
indicate	0
that	0
lymphoid	7
progenitor	8
cells	8
in	0
tg	9
epsilon26	10
mice	0
are	0
genetically	0
defective	0
in	0
thymic	0
choice	0
between	0
T	7
cells	8
and	0
B	7
cells	8
,	0
generating	0
B	7
cells	8
even	0
in	0
normal	0
thymus	0
environment	0
.	0

Interestingly	0
,	0
tg	7
epsilon26	8
thymocytes	8
expressed	0
GATA-3	9
and	0
TCF-1	9
,	0
but	0
not	0
LEF-1	9
and	0
PEBP-2alpha	9
,	0
among	0
T	9
cell-specific	10
transcription	10
factors	10
that	0
are	0
involved	0
in	0
early	0
T	0
cell	0
development	0
,	0
indicating	0
that	0
GATA-3	9
and	0
TCF-1	9
expressed	0
during	0
thymocyte	0
development	0
do	0
not	0
necessarily	0
determine	0
the	0
cell	0
fate	0
into	0
T	7
cell	8
lineage	8
.	0

Thus	0
,	0
tg	9
epsilon26	10
mice	0
provide	0
a	0
novel	0
mouse	0
model	0
in	0
that	0
lineage	0
choice	0
between	0
T	7
and	8
B	8
lymphocytes	8
is	0
genetically	0
defective	0
.	0

Downstream	0
activation	0
of	0
a	0
TATA-less	1
promoter	2
by	0
Oct-2	9
,	0
Bob1	0
,	0
and	0
NF-kappaB	9
directs	0
expression	0
of	0
the	0
homing	9
receptor	10
BLR1	10
to	0
mature	7
B	8
cells	8
.	0

The	0
chemokine	9
receptor	10
,	0
BLR1	9
,	0
is	0
a	0
major	0
regulator	0
of	0
the	0
microenvironmental	0
homing	0
of	0
B	7
cells	8
in	0
lymphoid	0
organs	0
.	0

In	0
vitro	0
studies	0
identify	0
three	0
essential	0
elements	0
of	0
the	0
TATA-less	1
blr1	2
core	2
promoter	2
that	0
confer	0
cell	0
type-	0
and	0
differentiation-specific	0
expression	0
in	0
the	0
B	7
cells	8
of	0
both	0
humans	0
and	0
mice	0
,	0
a	0
functional	1
promoter	2
region	2
(	0
-36	0
with	0
respect	0
to	0
the	0
transcription	1
start	2
site	2
)	0
,	0
a	0
NF-kappaB	1
motif	2
(	0
+44	0
)	0
,	0
and	0
a	0
noncanonical	1
octamer	2
motif	2
(	0
+157	0
)	0
.	0

The	0
importance	0
of	0
these	0
sites	0
was	0
confirmed	0
by	0
in	0
vivo	0
studies	0
in	0
gene-targeted	0
mice	0
deficient	0
of	0
either	0
Oct-2	9
,	0
Bob1	9
,	0
or	0
both	0
NF-kappaB	9
subunits	0
p50	0
and	0
p52	0
.	0

In	0
all	0
of	0
these	0
animals	0
,	0
the	0
expression	0
of	0
BLR1	9
was	0
reduced	0
or	0
absent	0
.	0

In	0
mice	0
deficient	0
only	0
of	0
p52/NF-kappaB	9
,	0
BLR1	9
expression	0
was	0
unaffected	0
.	0

Thus	0
our	0
data	0
demonstrate	0
that	0
BLR1	9
is	0
a	0
target	0
gene	0
for	0
Oct-2	9
,	0
Bob1	9
,	0
and	0
members	0
of	0
the	0
NF-kappaB/Rel	9
family	10
and	0
provides	0
a	0
link	0
to	0
the	0
impaired	0
B	0
cell	0
functions	0
in	0
mice	0
deficient	0
for	0
these	0
factors	0
.	0

CD4	1
promoter	2
transactivation	0
by	0
human	0
herpesvirus	0
6	0
.	0

The	0
observation	0
that	0
human	0
herpesvirus	0
6	0
(	0
HHV-6	0
)	0
can	0
induce	0
CD4	1
gene	2
transcription	0
and	0
expression	0
in	0
CD4	5
(	6
-	6
)	6
cells	6
was	0
reported	0
several	0
years	0
ago	0
(	0
P.Lusso	0
,	0
A.De	0
Maria	0
,	0
M.Malnati	0
,	0
F.Lori	0
,	0
S.E.DeRocco	0
,	0
M.	0
Baseler	0
,	0
and	0
R.C.Gallo	0
,	0
Nature	0
349	0
:	0
533-535	0
,	0
1991	0
)	0
and	0
subsequently	0
confirmed	0
(	0
P.Lusso	0
,	0
M.S.Malnati	0
,	0
A.Garzino-Demo	0
,	0
R.W.Crowley	0
,	0
E.	0
O.Long	0
,	0
and	0
R.C.Gallo	0
,	0
Nature	0
362	0
:	0
458-462	0
,	0
1993	0
;	0
G.Furlini	0
,	0
M.	0
Vignoli	0
,	0
E.Ramazzotti	0
,	0
M.C.Re	0
,	0
G.Visani	0
,	0
and	0
M.LaPlaca	0
,	0
Blood	0
87	0
:	0
4737-4745	0
,	0
1996	0
)	0
.	0

Our	0
objective	0
was	0
to	0
identify	0
the	0
mechanisms	0
underlying	0
such	0
phenomena	0
.	0

Using	0
reporter	1
gene	2
constructs	2
driven	0
by	0
the	0
CD4	1
promoter	2
,	0
we	0
report	0
that	0
HHV-6	0
can	0
efficiently	0
transactivate	0
such	0
genetic	1
elements	2
.	0

Activation	0
of	0
the	0
CD4	1
promoter	2
occurs	0
in	0
the	0
presence	0
of	0
the	0
viral	0
DNA	0
polymerase	0
inhibitor	0
phosphonoformic	0
acid	0
,	0
which	0
limits	0
expression	0
to	0
the	0
immediate-early	1
and	2
early	2
classes	2
of	2
viral	2
genes	2
.	0

Using	0
deletion	0
mutants	0
and	0
specific	0
CD4	1
promoter	2
mutants	2
,	0
we	0
identified	0
an	0
ATF/CRE	1
binding	2
site	2
located	0
at	0
nucleotides	1
-67	2
to	2
-60	2
upstream	2
of	0
the	0
CD4	1
gene	2
transcription	2
start	2
site	2
that	0
is	0
important	0
for	0
HHV-6	0
transactivation	0
.	0

The	0
ATF/CRE	1
site	2
is	0
also	0
essential	0
for	0
CD4	1
promoter	2
activation	0
by	0
forskolin	0
,	0
an	0
activator	0
of	0
adenylate	0
cyclase	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
and	0
specific	0
antibodies	0
,	0
we	0
showed	0
that	0
CREB-1	9
binds	0
specifically	0
to	0
the	0
-79	1
to	2
-52	2
region	2
of	0
the	0
CD4	1
promoter	2
.	0

Last	0
,	0
we	0
have	0
identified	0
two	0
open	1
reading	2
frames	2
(	0
ORFs	1
)	0
of	0
HHV-6	0
,	0
U86	1
and	0
U89	1
from	0
the	0
immediate-early	0
locus	0
A	0
,	0
that	0
can	0
transactivate	0
the	0
CD4	1
promoter	2
in	0
HeLa	5
cells	6
.	0

However	0
,	0
transactivation	0
of	0
the	0
CD4	1
promoter	2
by	0
ORFs	1
U86	1
and	0
U89	1
is	0
independent	0
of	0
the	0
CRE	1
element	2
,	0
suggesting	0
that	0
additional	0
HHV-6	1
ORFs	2
are	0
likely	0
to	0
contribute	0
to	0
CD4	1
gene	2
activation	0
.	0

Taken	0
together	0
,	0
our	0
results	0
will	0
help	0
to	0
understand	0
the	0
complex	0
interactions	0
occurring	0
between	0
HHV-6	0
and	0
the	0
CD4	1
promoter	2
and	0
provide	0
additional	0
information	0
regarding	0
the	0
class	0
of	0
transcription	9
factors	10
involved	0
in	0
the	0
control	0
of	0
CD4	1
gene	2
expression	0
.	0

The	0
PEBP2betaMYH11	9
fusion	0
created	0
by	0
Inv	1
(	2
16	2
)	2
(	2
p13	2
;	2
q22	2
)	2
in	0
myeloid	0
leukemia	0
impairs	0
neutrophil	0
maturation	0
and	0
contributes	0
to	0
granulocytic	0
dysplasia	0
.	0

Chromosomal	0
translocations	0
involving	0
the	0
genes	0
encoding	0
the	0
alpha	9
and	10
beta	10
subunits	10
of	0
the	0
Pebp2/Cbf	9
transcription	10
factor	10
have	0
been	0
associated	0
with	0
human	0
acute	0
myeloid	0
leukemia	0
and	0
the	0
preleukemic	0
condition	0
,	0
myelodysplasia	0
.	0

Inv	1
(	2
16	2
)	2
(	2
p13	2
;	2
q22	2
)	2
fuses	0
the	0
gene	0
encoding	0
the	0
beta	9
subunit	10
of	0
Pebp2	9
to	0
the	0
MYH11	1
gene	2
encoding	0
a	0
smooth	9
muscle	10
myosin	10
heavy	10
chain	10
(	0
Smmhc	9
)	0
.	0

To	0
examine	0
the	0
effect	0
of	0
the	0
inv	1
(	2
16	2
)	2
(	2
p13	2
;	2
q22	2
)	2
on	0
myelopoiesis	0
,	0
we	0
used	0
the	0
hMRP8	1
promoter	2
element	2
to	0
generate	0
transgenic	0
mice	0
expressing	0
the	0
Pebp2beta	9
Smmhc	9
chimeric	10
fusion	10
protein	10
in	0
myeloid	7
cells	8
.	0

Neutrophil	0
maturation	0
was	0
impaired	0
in	0
PEBP2betaMYH11	9
transgenic	0
mice	0
.	0

Although	0
the	0
transgenic	0
mice	0
had	0
normal	0
numbers	0
of	0
circulating	7
neutrophils	8
,	0
their	0
bone	0
marrow	0
contained	0
increased	0
numbers	0
of	0
immature	7
neutrophilic	8
cells	8
,	0
which	0
exhibited	0
abnormal	0
characteristics	0
.	0

In	0
addition	0
,	0
PEBP2betaMYH11	9
inhibited	0
neutrophilic	0
differentiation	0
in	0
colonies	0
derived	0
from	0
hematopoietic	7
progenitors	8
.	0

Coexpression	0
of	0
both	0
PEBP2betaMYH11	9
and	0
activated	9
NRAS	10
induced	0
a	0
more	0
severe	0
phenotype	0
characterized	0
by	0
abnormal	0
nuclear	0
morphology	0
indicative	0
of	0
granulocytic	0
dysplasia	0
.	0

These	0
results	0
show	0
that	0
PEBP2betaMYH11	9
can	0
impair	0
neutrophil	0
development	0
and	0
provide	0
evidence	0
that	0
alterations	0
of	0
Pebp2	9
can	0
contribute	0
to	0
the	0
genesis	0
of	0
myelodysplasia	0
.	0

Human	0
T	0
cell	0
leukemia	0
virus-I	0
(	0
HTLV-I	0
)	0
Tax	9
-mediated	0
apoptosis	0
in	0
activated	7
T	8
cells	8
requires	0
an	0
enhanced	0
intracellular	0
prooxidant	0
state	0
.	0

We	0
have	0
shown	0
that	0
an	0
estradiol-dependent	0
activation	0
of	0
human	0
T	0
cell	0
leukemia	0
virus-I	0
Tax	9
leads	0
to	0
the	0
inhibition	0
of	0
cell	0
proliferation	0
and	0
to	0
the	0
induction	0
of	0
apoptosis	0
.	0

The	0
present	0
study	0
demonstrates	0
that	0
a	0
hormone-dependent	0
activation	0
of	0
Tax	9
promotes	0
an	0
enhanced	0
prooxidant	0
state	0
in	0
stably	5
transfected	6
Jurkat	6
cells	6
as	0
measured	0
by	0
changes	0
in	0
the	0
intracellular	0
levels	0
of	0
glutathione	0
and	0
H2O2	0
;	0
these	0
changes	0
are	0
followed	0
by	0
apoptotic	0
cell	0
death	0
.	0

Additional	0
stimulation	0
of	0
the	0
CD3	9
/TCR	9
pathway	0
enhances	0
the	0
oxidative	0
and	0
apoptotic	0
effects	0
.	0

Both	0
Tax	9
-mediated	0
apoptosis	0
and	0
oxidative	0
stress	0
can	0
be	0
potently	0
suppressed	0
by	0
antioxidants	0
,	0
as	0
is	0
seen	0
with	0
the	0
administration	0
of	0
recombinant	9
thioredoxin	10
(	0
adult	9
T	10
cell	10
leukemia-derived	10
factor	10
)	0
or	0
pyrrolidine	0
dithiocarbamate	0
.	0

Hormone-induced	0
Tax	9
activation	0
induces	0
a	0
long-lasting	0
activation	0
of	0
NF-kappaB	9
,	0
which	0
is	0
a	0
major	0
target	0
of	0
reactive	0
oxygen	0
intermediates	0
.	0

The	0
long-term	0
exposure	0
of	0
Jurkat	5
cells	6
to	0
hormone	0
eventually	0
results	0
in	0
a	0
selection	0
of	0
cell	5
clones	6
that	0
have	0
lost	0
Tax	9
activity	0
.	0

A	0
subsequent	0
transfection	0
of	0
these	0
apparently	0
``	5
nonresponsive	6
''	6
clones	6
allows	0
the	0
recovery	0
of	0
Tax	9
responses	0
in	0
these	0
cells	0
.	0

Our	0
observations	0
indicate	0
that	0
changes	0
in	0
the	0
intracellular	0
redox	0
status	0
may	0
be	0
a	0
determining	0
factor	0
in	0
Tax	9
-mediated	0
DNA	0
damage	0
,	0
apoptosis	0
,	0
and	0
selection	0
against	0
the	0
long-term	0
expression	0
of	0
Tax	9
function	0
.	0

An	0
allosteric	0
drug	0
,	0
o	0
,	0
o'-bismyristoyl	0
thiamine	0
disulfide	0
,	0
suppresses	0
HIV-1	0
replication	0
through	0
prevention	0
of	0
nuclear	0
translocation	0
of	0
both	0
HIV-1	9
Tat	10
and	0
NF-kappa	9
B	10
.	0

The	0
efficacy	0
of	0
o	0
,	0
o'-bismyristoyl	0
thiamine	0
disulfide	0
(	0
BMT	0
)	0
was	0
examined	0
in	0
detail	0
against	0
HIV-1	0
laboratory	0
isolates	0
(	0
HTLV-IIIB	0
,	0
JRFL	0
,	0
and	0
MN	0
)	0
,	0
primary	0
isolates	0
(	0
KMT	0
and	0
KMO	0
)	0
,	0
and	0
simian	0
immunodeficiency	0
virus	0
(	0
SIVmac251	0
)	0
in	0
vitro	0
.	0

BMT	0
inhibited	0
the	0
replication	0
of	0
HIV-1	0
in	0
both	0
laboratory	0
and	0
primary	0
isolates	0
in	0
vitro	0
.	0

In	0
addition	0
,	0
BMT	0
exhibited	0
antiviral	0
activity	0
against	0
SIVmac251	0
.	0

Minimizing	0
energy	0
studies	0
of	0
BMT	0
structure	0
reveal	0
that	0
a	0
trans-disulfide	0
of	0
thiamine	0
(	0
holo	0
drug	0
)	0
disulfide	0
(	0
TDS	0
,	0
protodrug	0
)	0
is	0
allosterically	0
transited	0
to	0
the	0
reactive	0
twisted	0
disulfide	0
of	0
BMT	0
(	0
allo	0
drug	0
)	0
by	0
o	0
,	0
o'-bismyristoyl	0
esterification	0
of	0
TDS	0
.	0

BMT	0
inhibits	0
nuclear	0
translocation	0
of	0
both	0
HIV-1	9
transactivator	10
(	0
TAT	9
)	0
and	0
the	0
cellular	9
transcriptional	10
nuclear	10
factor-KB	10
(	0
NF-kappa	9
B	10
)	0
,	0
resulting	0
in	0
the	0
suppression	0
of	0
HIV-1	0
replication	0
.	0

Glucocorticoid-induced	0
apoptosis	0
and	0
regulation	0
of	0
NF-kappaB	9
activity	0
in	0
human	7
leukemic	8
T	8
cells	8
.	0

Glucocorticoid-induced	0
apoptosis	0
was	0
investigated	0
in	0
glucocorticoid-sensitive	5
6TG1.1	6
and	0
resistant	5
ICR27TK.3	6
human	7
leukemic	8
T	8
cells	8
.	0

Following	0
glucocorticoid	0
treatment	0
of	0
6TG1.1	5
cells	6
,	0
chromatin	1
fragmentation	0
was	0
observed	0
after	0
a	0
delay	0
of	0
24	0
h	0
.	0

Fragmentation	0
was	0
not	0
observed	0
in	0
ICR27TK.3	5
cells	6
containing	0
mutant	9
glucocorticoid	10
receptors	10
(	0
L753F	5
)	0
that	0
are	0
activation-deficient	0
but	0
retain	0
the	0
ability	0
to	0
repress	0
AP-1	9
activity	0
.	0

Nor	0
was	0
fragmentation	0
observed	0
after	0
treatment	0
with	0
RU38486	0
,	0
indicating	0
that	0
repression	0
of	0
AP-1	9
activity	0
is	0
not	0
involved	0
.	0

As	0
described	0
in	0
other	0
systems	0
,	0
fragmentation	0
required	0
ongoing	0
protein	0
synthesis	0
.	0

However	0
,	0
inhibition	0
of	0
protein	0
synthesis	0
with	0
cycloheximide	0
anytime	0
during	0
the	0
first	0
18	0
h	0
of	0
steroid	0
treatment	0
was	0
as	0
effective	0
in	0
blocking	0
chromatin	0
fragmentation	0
as	0
inhibition	0
for	0
the	0
entire	0
period	0
,	0
suggesting	0
that	0
synthesis	0
of	0
a	0
component	0
with	0
a	0
rapid	0
turnover	0
rate	0
is	0
required	0
.	0

Dexamethasone	0
treatment	0
completely	0
blocked	0
12-O-tetradecanoylphorbol	0
13-acetate	0
induction	0
of	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
activity	0
and	0
elicited	0
an	0
increase	0
in	0
the	0
amount	0
of	0
immunoreactive	9
IkappaB	10
alpha	10
in	0
sensitive	0
6TG1.1	5
cells	6
but	0
not	0
in	0
resistant	0
ICR27TK.3	5
cells	6
.	0

In	0
addition	0
,	0
mild	0
detergent	0
treatment	0
of	0
cell	0
extracts	0
indicated	0
that	0
a	0
substantial	0
amount	0
of	0
cytoplasmic	9
NF-kappaB	10
is	0
complexed	0
with	0
IkappaB	9
alpha	10
or	0
some	0
other	0
inhibitory	0
factor.	0
These	0
results	0
suggest	0
that	0
induction	0
of	0
a	0
labile	9
inhibitory	10
factor	10
such	0
as	0
IkappaB	9
alpha	10
may	0
contribute	0
to	0
glucocorticoid-induced	0
apoptosis	0
.	0

Inhibition	0
of	0
HIV-1	0
replication	0
by	0
combination	0
of	0
a	0
novel	0
inhibitor	0
of	0
TNF-alpha	9
with	0
AZT	0
.	0

The	0
small	0
molecule	0
S9a	0
was	0
derived	0
from	0
an	0
established	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
inhibitor	0
(	0
Canventol	0
)	0
by	0
replacement	0
of	0
the	0
isopropylidine	0
group	0
with	0
a	0
phenyl	0
ring	0
.	0

S9a	0
at	0
10	0
to	0
100	0
nM	0
inhibited	0
HIV	0
production	0
as	0
potently	0
as	0
3'-azido-3'-deoxythymidine	0
(	0
AZT	0
)	0
,	0
an	0
inhibitor	0
of	0
viral	9
reverse	10
transcriptase	10
.	0

Furthermore	0
,	0
S9a	0
and	0
AZT	0
in	0
combination	0
,	0
at	0
noncytoxic	0
concentrations	0
strongly	0
inhibited	0
HIV-1	0
replication	0
that	0
was	0
more	0
than	0
additive	0
and	0
substantially	0
prolonged	0
the	0
appearance	0
of	0
virus	0
both	0
in	0
acutely	7
infected	8
CD4+	8
lymphocytes	8
(	0
SupT	5
)	0
in	0
culture	0
and	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
infected	0
with	0
a	0
primary	0
HIV-1	0
isolate	0
.	0

S9a	0
inhibited	0
TNF-alpha	9
promoter-driven	0
reporter	1
gene	2
activity	0
.	0

It	0
was	0
proposed	0
that	0
the	0
mechanism	0
of	0
antiviral	0
action	0
of	0
S9a	0
was	0
on	0
the	0
host	0
cell	0
,	0
by	0
blocking	0
TNF-alpha	9
transcription	0
via	0
a	0
Tat	9
-induced	0
tar-independent	0
loop	0
,	0
which	0
decreases	0
downstream	0
NF-kappaB	9
activation	0
of	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

S9a	0
was	0
superior	0
to	0
the	0
first	0
generation	0
compound	0
Canventol	0
,	0
which	0
was	0
superior	0
to	0
the	0
natural	0
compound	0
sarcophytol	0
A	0
,	0
demonstrating	0
that	0
further	0
structure-based	0
enhancement	0
of	0
potency	0
of	0
these	0
compounds	0
is	0
feasible	0
.	0

This	0
study	0
suggests	0
a	0
therapeutic	0
approach	0
against	0
AIDS	0
by	0
application	0
of	0
two	0
drugs	0
,	0
one	0
against	0
a	0
cellular	0
and	0
the	0
other	0
a	0
viral	0
target	0
,	0
which	0
may	0
provide	0
an	0
approach	0
to	0
the	0
problem	0
of	0
frequent	0
emergence	0
of	0
resistant	0
variants	0
to	0
combinations	0
of	0
drugs	0
that	0
target	0
only	0
HIV	1
genes	2
.	0

Highly	0
polarized	0
HLA	9
class	10
II	10
antigen	10
processing	0
and	0
presentation	0
by	0
human	7
intestinal	8
epithelial	8
cells	8
.	0

The	0
high	0
concentration	0
of	0
foreign	9
antigen	10
in	0
the	0
lumen	7
of	0
the	0
gastrointestinal	0
tract	0
is	0
separated	0
from	0
the	0
underlying	0
lymphocytes	7
by	0
a	0
single	0
cell	0
layer	0
of	0
polarized	0
epithelium	0
.	0

Intestinal	7
epithelial	8
cells	8
can	0
express	0
HLA	9
class	10
II	10
antigens	10
and	0
may	0
function	0
as	0
antigen-presenting	7
cells	8
to	8
CD4	8
(	8
+	8
)	8
T	8
cells	8
within	0
the	0
intestinal	0
mucosa	0
.	0

Using	0
tetanus	7
toxoid	8
specific	8
and	8
HLA-DR-restricted	8
T	8
lymphocytes	8
,	0
we	0
show	0
that	0
polarized	7
intestinal	8
epithelial	8
cells	8
directed	0
to	0
express	0
HLA-DR	9
molecules	10
are	0
able	0
to	0
initiate	0
class	0
II	0
processing	0
only	0
after	0
internalization	0
of	0
antigen	0
from	0
their	0
apical	0
surface	0
.	0

Coexpression	0
of	0
the	0
class	9
II	10
transactivator	10
CIITA	10
in	0
these	0
cells	0
,	0
which	0
stimulates	0
highly	0
efficient	0
class	0
II	0
processing	0
without	0
the	0
characteristic	0
decline	0
in	0
barrier	0
function	0
seen	0
in	0
polarized	0
monolayers	0
treated	0
with	0
the	0
proinflammatory	9
cytokine	10
gamma-IFN	10
,	0
facilitates	0
antigen	0
processing	0
from	0
the	0
basolateral	0
surface	0
.	0

In	0
both	0
cases	0
,	0
peptide	0
presentation	0
to	0
T	7
cells	8
via	0
class	9
II	10
molecules	10
was	0
restricted	0
to	0
the	0
basolateral	0
surface	0
.	0

These	0
data	0
indicate	0
a	0
highly	0
polarized	0
functional	0
architecture	0
for	0
antigen	0
processing	0
and	0
presentation	0
by	0
intestinal	7
epithelial	8
cells	8
,	0
and	0
suggest	0
that	0
the	0
functional	0
outcome	0
of	0
antigen	0
processing	0
by	0
the	0
intestinal	0
epithelium	0
is	0
both	0
dependent	0
on	0
the	0
cellular	0
surface	0
at	0
which	0
the	0
foreign	0
antigen	0
is	0
internalized	0
and	0
by	0
the	0
underlying	0
degree	0
of	0
mucosal	0
inflammation	0

Tobacco	0
smoke	0
induces	0
coordinate	0
activation	0
of	0
HSF	9
and	0
inhibition	0
of	0
NFkappaB	9
in	0
human	7
monocytes	8
:	0
effects	0
on	0
TNFalpha	9
release	0
.	0

Tobacco	0
smoke	0
(	0
TS	0
)	0
exposure	0
is	0
a	0
major	0
risk	0
factor	0
for	0
human	0
disease	0
,	0
and	0
macrophages	7
of	0
healthy	0
smokers	0
have	0
a	0
depressed	0
capacity	0
to	0
release	0
cytokines	9
,	0
including	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
alpha	10
.	0

TS	0
induces	0
the	0
synthesis	0
of	0
heat	9
shock	10
(	10
HS	10
)	10
/stress	10
proteins	10
(	0
HSP	9
)	0
,	0
and	0
,	0
in	0
particular	0
,	0
of	0
Hsp70	9
.	0

We	0
determined	0
whether	0
Hsp70	9
induction	0
by	0
TS	0
was	0
mediated	0
by	0
the	0
activation	0
of	0
the	0
HS	9
transcription	10
factor	10
,	0
HSF	9
.	0

HSF	9
activation	0
has	0
been	0
shown	0
to	0
inhibit	0
NFkappaB	9
.	0

Thus	0
,	0
we	0
also	0
determined	0
the	0
effects	0
of	0
TS	0
on	0
NFkappaB	9
.	0

U937	5
cells	6
and	0
human	7
peripheral	8
blood	8
monocytes	8
were	0
exposed	0
to	0
TS	0
,	0
binding	0
activities	0
of	0
the	0
respective	0
transcription	9
factors	10
were	0
analyzed	0
,	0
and	0
Hsp70	9
expression	0
and	0
TNFalpha	9
release	0
were	0
determined	0
in	0
parallel	0
.	0

TS	0
activated	0
HSF	9
,	0
which	0
was	0
associated	0
with	0
Hsp70	9
overexpression	0
and	0
inhibition	0
of	0
NFkappaB	9
binding	0
activity	0
and	0
TNFalpha	9
release	0
.	0

The	0
altered	0
cytokine	9
profile	10
observed	0
in	0
smokers	0
may	0
relate	0
to	0
an	0
HSF	9
/	0
Hsp70	9
-mediated	0
inhibition	0
of	0
NFkappaB	9
activity	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

[	0
Molecular	0
mechanism	0
of	0
cytokine	1
gene	2
expression	0
in	0
Th1	5
and	0
Th2	5
]	0

Upon	0
activation	0
by	0
antigens	9
,	0
helper	7
T	8
cells	8
differentiate	0
into	0
one	0
of	0
several	0
subsets	0
,	0
characterized	0
by	0
their	0
distinct	0
cytokine	9
-production	0
patterns	0
.	0

Among	0
these	0
subsets	0
,	0
Th1	5
cells	6
are	0
known	0
to	0
activate	0
cellular	0
immunity	0
resulting	0
in	0
inflammatory	0
response	0
,	0
whereas	0
Th2	5
cells	6
induce	0
humoral	0
and	0
allergic	0
responses	0
and	0
suppress	0
inflammation	0
.	0

Th1	0
and	0
Th2	0
effector	0
functions	0
and	0
their	0
development	0
are	0
attributable	0
to	0
their	0
distinct	0
cytokine	9
expression	0
patterns	0
.	0

Recent	0
reports	0
have	0
demonstrated	0
that	0
differential	0
expression	0
of	0
cell	0
surface	0
molecules	0
,	0
such	0
as	0
adhesion	9
molecule	10
and	0
chemokine	9
receptor	10
,	0
is	0
involved	0
in	0
their	0
recruitment	0
into	0
target	0
tissues	0
.	0

It	0
is	0
,	0
therefore	0
,	0
suggested	0
that	0
clarification	0
of	0
the	0
mechanisms	0
of	0
differential	0
gene	0
expression	0
in	0
Th1/Th2	5
should	0
lead	0
to	0
rational	0
strategies	0
for	0
manipulating	0
pathological	0
immune	0
responses	0
.	0

Activation	0
of	0
helper	7
T	8
cells	8
mediated	0
by	0
the	0
T	0
cell	0
receptor	0
induces	0
a	0
series	0
of	0
biochemical	0
events	0
.	0

Among	0
them	0
,	0
both	0
the	0
activation	0
of	0
PKC/Ras-	0
and	0
CaM/CN-mediated	0
pathways	0
play	0
a	0
central	0
role	0
in	0
the	0
signal	0
transduction	0
of	0
cytokine	1
gene	2
expression	0
.	0

Closer	0
examination	0
using	0
non-transformed	5
murine	6
Th1	6
and	6
Th2	6
clones	6
suggested	0
that	0
a	0
balance	0
between	0
the	0
activities	0
of	0
the	0
two	0
signaling	0
pathways	0
contributes	0
to	0
cytokine	1
gene	2
expression	0
.	0

We	0
propose	0
that	0
one	0
of	0
the	0
targets	0
of	0
PGE2	0
,	0
whose	0
effect	0
distinguishes	0
Th1	5
from	0
Th2	0
,	0
resides	0
in	0
the	0
downstream	0
PKC/Ras	9
-mediated	0
pathway	0
.	0

Signalling	0
into	0
the	0
T-cell	0
nucleus	0
:	0
NFAT	9
regulation	0
.	0

The	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
plays	0
an	0
important	0
role	0
in	0
T-cell	0
biology	0
.	0

Activation	0
of	0
T	0
cells	0
results	0
in	0
the	0
rapid	0
calcineurin	9
-dependent	0
translocation	0
of	0
NFAT	9
transcription	9
factors	10
from	0
the	0
cytoplasm	0
to	0
the	0
nucleus	0
.	0

This	0
translocation	0
process	0
coupled	0
to	0
the	0
subsequent	0
active	0
maintenance	0
of	0
NFAT	9
in	0
the	0
nucleus	0
compartment	0
is	0
critical	0
for	0
the	0
induction	0
of	0
expression	0
of	0
several	0
genes	0
encoding	0
cytokines	9
and	0
membrane	9
proteins	10
that	0
modulate	0
immune	0
responses	0
.	0

The	0
molecular	0
cloning	0
of	0
the	0
NFAT	9
family	10
of	0
transcription	9
factors	10
has	0
facilitated	0
rapid	0
progress	0
in	0
the	0
understanding	0
of	0
the	0
signalling	0
mechanisms	0
that	0
control	0
the	0
activity	0
of	0
NFAT	9
.	0

Differential	0
RNA	0
display	0
identifies	0
novel	1
genes	2
associated	0
with	0
decreased	0
vitamin	9
D	10
receptor	10
expression	0
.	0

To	0
characterize	0
further	0
the	0
function	0
of	0
the	0
intracellular	9
vitamin	10
D	10
receptor	10
(	0
VDR	9
)	0
,	0
we	0
have	0
developed	0
stable	5
transfectant	6
variants	6
of	0
a	0
vitamin	5
D-responsive	6
cell	6
line	6
(	0
U937	5
)	0
which	0
express	0
either	0
decreased	0
or	0
increased	0
numbers	0
of	0
VDR	9
.	0

In	0
this	0
study	0
we	0
have	0
analyzed	0
changes	0
in	0
gene	0
expression	0
associated	0
with	0
this	0
variable	0
VDR	9
expression	0
.	0

Initial	0
experiments	0
indicated	0
that	0
a	0
50	0
%	0
decrease	0
in	0
VDR	9
levels	0
was	0
associated	0
with	0
a	0
2-fold	0
increase	0
in	0
cell	0
proliferation	0
and	0
a	0
similar	0
rise	0
in	0
c-myc	3
mRNA	4
expression	0
.	0

Further	0
studies	0
were	0
carried	0
out	0
using	0
differential	0
RNA	0
display	0
(	0
DD	0
)	0
.	0

Sequence	0
analysis	0
of	0
DD	9
products	10
revealed	0
two	0
cDNAs	1
with	0
identity	0
to	0
known	9
gene	10
products	10
:	0
the	0
catalytic	9
sub-unit	10
of	10
DNA-protein	10
kinase	10
(	0
DNA-PK	9
(	10
CS	10
)	10
)	0
,	0
and	0
the	0
peroxisomal	9
enzyme	10
17beta-hydroxysteroid	10
dehydrogenase	10
type	10
IV	10
(	0
17beta-HSD	9
IV	10
)	0
.	0

Northern	0
analysis	0
confirmed	0
that	0
expression	0
of	0
both	0
mRNAs	3
was	0
reduced	0
in	0
cells	0
with	0
decreased	0
numbers	0
of	0
VDR	9
.	0

Down-regulation	0
of	0
17beta-HSD	9
IV	10
mRNA	0
expression	0
was	0
associated	0
with	0
enhanced	0
estradiol	0
inactivation	0
by	0
U937	5
cells	6
,	0
suggesting	0
a	0
link	0
between	0
estrogenic	0
pathways	0
and	0
cell	0
proliferation	0
.	0

Further	0
Northern	0
analyses	0
indicated	0
that	0
there	0
was	0
no	0
significant	0
change	0
in	0
17beta-HSD	9
IV	10
or	0
DNA-PK	3
(	4
CS	4
)	4
mRNA	4
levels	0
following	0
treatment	0
with	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
although	0
expression	0
of	0
both	0
genes	0
varied	0
with	0
changes	0
in	0
cell	0
proliferation	0
.	0

These	0
data	0
suggest	0
that	0
,	0
in	0
addition	0
to	0
its	0
established	0
role	0
as	0
a	0
hormone-dependent	9
trans-activator	10
,	0
VDR	9
may	0
influence	0
gene	0
expression	0
by	0
ligand-independent	0
mechanisms	0
.	0

Prostaglandin	0
E2	0
Up-regulates	0
HIV-1	1
long	2
terminal	2
repeat	2
-driven	0
gene	0
activity	0
in	0
T	7
cells	8
via	0
NF-kappaB-dependent	0
and	0
-independent	0
signaling	0
pathways	0
.	0

Replication	0
of	0
human	0
immunodeficiency	0
virus	0
type-1	0
(	0
HIV-1	0
)	0
is	0
highly	0
dependent	0
on	0
the	0
state	0
of	0
activation	0
of	0
the	0
infected	7
cells	8
and	0
is	0
modulated	0
by	0
interactions	0
between	0
viral	9
and	10
host	10
cellular	10
factors	10
.	0

Prostaglandin	0
E2	0
(	0
PGE2	0
)	0
,	0
a	0
pleiotropic	9
immunomodulatory	10
molecule	10
,	0
is	0
observed	0
at	0
elevated	0
levels	0
during	0
HIV-1	0
infection	0
as	0
well	0
as	0
during	0
the	0
course	0
of	0
other	0
pathogenic	0
infections	0
.	0

In	0
1G5	5
,	0
a	0
Jurkat-derived	5
T	6
cell	6
line	6
stably	0
transfected	0
with	0
a	0
luciferase	1
gene	2
driven	0
by	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
,	0
we	0
found	0
that	0
PGE2	0
markedly	0
enhanced	0
HIV-1	1
LTR	2
-mediated	0
reporter	1
gene	2
activity	0
.	0

Experiments	0
have	0
been	0
conducted	0
to	0
identify	0
second	9
messengers	10
involved	0
in	0
this	0
PGE2-dependent	0
up-regulating	0
effect	0
on	0
the	0
regulatory	0
element	0
of	0
HIV-1	0
.	0

In	0
this	0
study	0
,	0
we	0
present	0
evidence	0
indicating	0
that	0
signal	0
transduction	0
pathways	0
induced	0
by	0
PGE2	0
necessitate	0
the	0
participation	0
of	0
cyclic	0
AMP	0
,	0
protein	9
kinase	10
A	10
,	0
and	0
Ca2+	0
.	0

Experiments	0
conducted	0
with	0
different	0
HIV-1	1
LTR-based	2
vectors	2
suggested	0
that	0
PGE2-mediated	0
activation	0
effect	0
on	0
HIV-1	0
transcription	0
was	0
transduced	0
via	0
both	0
NF-kappaB-dependent	0
and	0
-independent	0
signaling	0
pathways	0
.	0

The	0
involvement	0
of	0
NF-kappaB	9
in	0
the	0
PGE2-dependent	0
activating	0
effect	0
on	0
HIV-1	0
transcription	0
was	0
further	0
confirmed	0
using	0
a	0
kappaB-regulated	1
luciferase	2
encoding	2
vector	2
and	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

Results	0
from	0
Northern	0
blot	0
and	0
flow	0
cytometric	0
analyses	0
,	0
as	0
well	0
as	0
the	0
use	0
of	0
a	0
selective	0
antagonist	0
indicated	0
that	0
PGE2	0
modulation	0
of	0
HIV-1	1
LTR	2
-driven	0
reporter	1
gene	2
activity	0
in	0
studied	0
T	7
lymphoid	8
cells	8
is	0
transduced	0
via	0
the	0
EP4	9
receptor	10
subtype	10
.	0

These	0
results	0
suggest	0
that	0
secretion	0
of	0
PGE2	0
by	0
macrophages	7
in	0
response	0
to	0
infection	0
or	0
inflammatory	0
activators	0
could	0
induce	0
signaling	0
events	0
resulting	0
in	0
activation	0
of	0
proviral	0
DNA	0
present	0
into	0
T	7
cells	8
latently	0
infected	0
with	0
HIV-1	0
.	0

Activation	0
of	0
distinct	0
transcription	9
factors	10
in	0
neutrophils	7
by	0
bacterial	0
LPS	0
,	0
interferon-gamma	9
,	0
and	0
GM-CSF	9
and	0
the	0
necessity	0
to	0
overcome	0
the	0
action	0
of	0
endogenous	9
proteases	10
.	0

Human	0
neutrophils	7
can	0
be	0
induced	0
to	0
actively	0
transcribe	0
a	0
number	0
of	0
early-response	1
genes	2
,	0
in	0
particular	0
those	0
encoding	0
cytokines	9
,	0
chemokines	9
,	0
and	0
the	0
high-affinity	0
surface	0
receptor	0
for	0
IgG	9
,	0
FcgammaRI	9
.	0

Although	0
little	0
is	0
known	0
to	0
date	0
about	0
the	0
regulation	0
of	0
gene	0
transcription	0
in	0
neutrophils	7
,	0
several	0
indications	0
point	0
to	0
a	0
role	0
for	0
distinct	0
transcription	9
factors	10
,	0
such	0
as	0
members	0
of	0
the	0
NF-kappaB	9
and	0
STAT	9
families	10
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
whether	0
these	0
transcription	9
factors	10
become	0
activated	0
under	0
stimulatory	0
conditions	0
which	0
are	0
known	0
to	0
induce	0
gene	0
transcription	0
in	0
neutrophils	7
.	0

Unexpectedly	0
,	0
we	0
found	0
that	0
conventional	0
procedures	0
employed	0
to	0
prepare	0
cellular	0
extracts	0
cause	0
the	0
release	0
of	0
proteolytic	0
activities	0
that	0
are	0
normally	0
stored	0
in	0
intracellular	0
granules	0
,	0
resulting	0
in	0
the	0
degradation	0
of	0
various	0
NF-kappaB/Rel	9
and	0
STAT	9
proteins	10
.	0

To	0
circumvent	0
this	0
problem	0
,	0
we	0
developed	0
an	0
alternative	0
procedure	0
which	0
allowed	0
us	0
to	0
show	0
that	0
in	0
neutrophils	7
,	0
LPS	0
and	0
TNFalpha	9
induce	0
a	0
NF-kappaB	9
DNA-binding	0
activity	0
which	0
essentially	0
consists	0
of	0
p50/RelA	9
dimers	10
,	0
and	0
that	0
IFNgamma	9
promotes	0
the	0
binding	0
of	0
STAT1	9
homodimers	10
to	0
the	0
IFNgamma	1
response	2
region	2
of	0
the	0
FcgammaRI	1
promoter	2
.	0

Moreover	0
,	0
we	0
report	0
that	0
neutrophil	0
stimulation	0
with	0
GM-CSF	9
results	0
in	0
the	0
formation	0
of	0
a	0
STAT5	9
-containing	0
DNA-binding	0
activity	0
.	0

Collectively	0
,	0
the	0
current	0
findings	0
open	0
new	0
perspectives	0
about	0
mechanisms	0
that	0
are	0
likely	0
to	0
regulate	0
gene	0
transcription	0
in	0
neutrophils	7
.	0

In	0
addition	0
,	0
the	0
procedure	0
described	0
herein	0
could	0
prove	0
useful	0
in	0
other	0
cell	0
types	0
that	0
express	0
high	0
levels	0
of	0
endogenous	9
proteases	10
.	0

Low	0
CD3+CD28-induced	0
interleukin-2	9
production	0
correlates	0
with	0
decreased	0
reactive	0
oxygen	0
intermediate	0
formation	0
in	0
neonatal	7
T	8
cells	8
.	0

The	0
capacity	0
of	0
neonatal	7
T	8
cells	8
to	0
secrete	0
interleukin-2	9
(	0
IL-2	9
)	0
has	0
been	0
reported	0
to	0
be	0
variable	0
.	0

We	0
analysed	0
IL-2	9
production	0
in	0
purified	0
neonatal	7
and	8
adult	8
T	8
cells	8
using	0
polyclonal	0
activator	0
phorbol	0
ester	0
+	0
calcium	0
ionophore	0
(	0
PDBu	0
+	0
iono	0
)	0
or	0
receptor-mediated	0
anti-CD3	9
/anti-CD3+	0
anti-CD28	9
stimulation	0
.	0

PDBu	0
+	0
iono	0
induced	0
equally	0
high	0
IL-2	9
levels	0
in	0
both	0
groups	0
and	0
,	0
when	0
stimulated	0
with	0
plate-bound	0
anti-CD3	9
monoclonal	10
antibody	10
(	0
mAb	9
)	0
,	0
the	0
IL-2	9
secretion	0
by	0
neonatal	7
cells	8
was	0
undetectable	0
and	0
adult	7
cells	8
produced	0
low	0
amounts	0
of	0
IL-2	9
(	0
mean	0
331	0
+/-	0
86	0
pg/ml	0
)	0
.	0

The	0
addition	0
of	0
anti-CD28	9
mAb	10
to	0
anti-CD3-stimulated	5
cells	6
markedly	0
increased	0
IL-2	9
production	0
in	0
both	0
cell	0
types	0
,	0
but	0
levels	0
of	0
IL-2	9
in	0
neonatal	7
T	8
cells	8
remained	0
clearly	0
lower	0
than	0
those	0
of	0
adult	7
T	8
cells	8
(	0
respective	0
mean	0
values	0
:	0
385	0
+/-	0
109	0
pg/ml	0
and	0
4494	0
+/-	0
1199	0
pg/ml	0
)	0
.	0

As	0
NF-kappa	9
B	10
is	0
a	0
critical	0
transcription	9
factor	10
in	0
the	0
control	0
of	0
IL-2	9
expression	0
,	0
we	0
next	0
analysed	0
its	0
nuclear	0
translocation	0
in	0
neonatal	7
and	8
adult	8
T	8
cells	8
using	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
and	0
,	0
because	0
induction	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROI	0
)	0
is	0
required	0
for	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
we	0
also	0
analysed	0
levels	0
of	0
intracellular	0
ROI	0
in	0
these	0
cells	0
using	0
the	0
ROI-reactive	0
fluorochrome	0
DCFH-DA	0
and	0
flow	0
cytometry	0
.	0

In	0
neonatal	7
T	8
cells	8
NF-kappa	9
B	10
activation	0
and	0
ROI	0
formation	0
after	0
anti-CD3	9
stimulation	0
were	0
low	0
compared	0
with	0
adult	7
T	8
cells	8
and	0
,	0
although	0
addition	0
of	0
anti-CD28	9
mAb	10
increased	0
induction	0
of	0
NF-kappa	9
B	10
and	0
ROI	0
formation	0
,	0
levels	0
similar	0
to	0
those	0
of	0
adults	0
were	0
not	0
achieved	0
.	0

After	0
PDBu	0
+	0
iono	0
stimulation	0
,	0
the	0
cells	0
showed	0
similar	0
ROI	0
formation	0
and	0
IL-2	9
secretion	0
.	0

Our	0
results	0
suggest	0
that	0
reduced	0
IL-2	9
production	0
by	0
neonatal	7
T	8
cells	8
is	0
specific	0
for	0
anti-CD3	9
and	0
anti-CD3	9
+	0
anti-CD28	9
-mediated	0
stimulation	0
and	0
that	0
these	0
activators	0
can	0
not	0
effectively	0
activate	0
the	0
ROI	0
-NF-kappa	9
B	10
signalling	0
pathway	0
in	0
neonatal	7
T	8
cells	8
.	0

CD30	9
is	0
a	0
CD40-inducible	9
molecule	10
that	0
negatively	0
regulates	0
CD40-mediated	9
immunoglobulin	10
class	0
switching	0
in	0
non-antigen-selected	5
human	6
B	6
cells	6
.	0

We	0
used	0
our	0
monoclonal	0
model	0
of	0
germinal	0
center	0
maturation	0
,	0
CL-01	7
B	8
cells	8
,	0
to	0
investigate	0
the	0
role	0
of	0
CD30	9
in	0
human	0
B	0
cell	0
differentiation	0
.	0

CL-01	5
cells	6
are	0
IgM	9
+	0
IgD	9
+	0
CD30	9
+	0
and	0
switch	0
to	0
IgG	9
,	0
IgA	9
,	0
and	0
IgE	9
when	0
exposed	0
to	0
CD40L	9
and	0
IL-4	9
.	0

Switching	0
is	0
hampered	0
by	0
CD30	9
coengagement	0
,	0
possibly	0
through	0
interference	0
with	0
the	0
CD40	9
-mediated	0
NF-kappaB	9
-dependent	0
transcriptional	0
activation	0
of	0
downstream	1
C	2
(	2
H	2
)	2
genes	2
.	0

The	0
physiological	0
relevance	0
of	0
this	0
phenomenon	0
is	0
emphasized	0
by	0
similar	0
CD30	9
-mediated	0
effects	0
in	0
naive	7
B	8
cells	8
.	0

Expression	0
of	0
CD30	9
by	0
these	0
cells	0
is	0
induced	0
by	0
CD40L	9
but	0
is	0
inhibited	0
by	0
B	0
cell	0
receptor	0
coengagement	0
and/or	0
exposure	0
to	0
IL-6	9
and	0
IL-12	9
.	0

Our	0
data	0
suggest	0
that	0
CD30	9
critically	0
regulates	0
the	0
CD40	9
-mediated	0
differentiation	0
of	0
non-antigen-selected	5
human	6
B	6
cells	6
.	0

Calcineurin	9
and	0
the	0
biological	0
effect	0
of	0
cyclosporine	0
and	0
tacrolimus	0
.	0

The	0
mechanism	0
of	0
the	0
immunosuppressive	0
effect	0
of	0
CyA	0
and	0
FK	0
506	0
can	0
be	0
monitored	0
in	0
vivo	0
in	0
humans	0
.	0

The	0
picture	0
emerging	0
is	0
of	0
a	0
close	0
relationship	0
between	0
drug	0
concentrations	0
and	0
CN	0
inhibition	0
.	0

But	0
many	0
puzzles	0
of	0
the	0
drugs	0
remain	0
.	0

What	0
is	0
the	0
role	0
of	0
CyA	0
in	0
the	0
activation	0
of	0
transforming	9
growth	10
factor-beta	10
(	0
TGF-beta	9
)	0
,	0
particularly	0
in	0
relationship	0
to	0
nephrotoxicity	0
and	0
fibrogenesis	0
?	0

How	0
important	0
are	0
the	0
anti-inflammatory	0
(	0
non	0
T	0
)	0
effects	0
of	0
CyA	0
,	0
and	0
which	0
cells	0
do	0
they	0
operate	0
in	0
?	0

Are	0
there	0
effects	0
of	0
CyA	0
and	0
FK	0
506	0
all	0
attributable	0
to	0
CN	0
inhibition	0
,	0
and	0
how	0
much	0
of	0
them	0
are	0
mediated	0
through	0
the	0
NFATC	9
family	10
of	0
transcription	9
factors	10
?	0

Finally	0
,	0
it	0
would	0
be	0
useful	0
to	0
know	0
what	0
the	0
inhibitory	0
effects	0
of	0
CyA	0
are	0
on	0
tolerance	0
and	0
negative	0
regulatory	0
events	0
.	0

Stimulation	0
of	0
B	7
and	8
T	8
cells	8
activates	0
expression	0
of	0
transcription	9
and	10
differentiation	10
factors	10
.	0

During	0
B	0
and	0
T	0
cell	0
differentiation	0
and	0
proliferation	0
many	0
genes	0
are	0
induced	0
or	0
repressed	0
while	0
certain	0
genes	0
are	0
constitutively	0
expressed	0
.	0

To	0
investigate	0
processes	0
related	0
to	0
B	0
and	0
T	0
cell	0
activation	0
,	0
the	0
gene	0
expression	0
of	0
stimulated	0
and	0
nonstimulated	5
Ramos	6
and	6
Jurkat	6
cells	6
was	0
studied	0
using	0
cDNA	0
microarray	0
technology	0
.	0

Simultaneous	0
analysis	0
of	0
close	0
to	0
600	1
genes	2
indicated	0
highest	0
increase	0
in	0
the	0
expression	0
of	0
certain	0
transcription	9
,	10
differentiation	10
and	10
proliferation	10
factors	10
.	0

Many	0
of	0
these	0
genes	0
have	0
not	0
previously	0
been	0
shown	0
to	0
funcion	0
in	0
the	0
stimulated	7
lymphocytes	8
.	0

Also	0
genes	0
encoding	0
proteins	0
involved	0
in	0
DNA	0
replication	0
,	0
binding	0
,	0
transcription	0
and	0
translation	0
were	0
induced	0
.	0

Large	0
part	0
of	0
the	0
activated	1
genes	2
were	0
under	0
very	0
stringent	0
regulation	0
being	0
expressed	0
only	0
after	0
stimulation	0
.	0

The	0
mechanism	0
and	0
function	0
of	0
the	0
expressed	1
genes	2
during	0
lymphocyte	0
differentiation	0
and	0
in	0
disorders	0
is	0
discussed	0
.	0

Interleukin	9
2	10
and	10
15	10
activate	0
Stat3alpha	9
in	0
human	7
T	8
lymphocytes	8
.	0

Signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
3	10
(	0
Stat3	9
)	0
has	0
recently	0
been	0
shown	0
to	0
exist	0
in	0
two	0
alternatively	0
spliced	0
isoforms	0
,	0
a	0
short	0
form	0
,	0
Stat3beta	9
,	0
and	0
a	0
longer	0
form	0
,	0
Stat3alpha	9
,	0
displaying	0
differences	0
in	0
transcriptional	0
activity	0
.	0

It	0
is	0
unknown	0
which	0
Stat3	9
isoform	10
(	0
s	0
)	0
is	0
activated	0
in	0
response	0
to	0
interleukin	9
(	10
IL	10
)	10
-2	10
and	0
IL-15	9
.	0

Here	0
,	0
cytokine	9
-induced	0
activation	0
of	0
Stat3	9
in	0
previously	0
activated	0
CD4	7
(	8
+	8
)	8
human	8
T	8
cells	8
was	0
examined	0
using	0
Stat3	9
antibodies	0
directed	0
against	0
different	0
regions	0
of	0
Stat3	9
.	0

As	0
determined	0
by	0
tyrosine	0
phosphorylation	0
,	0
nuclear	0
translocation	0
and	0
binding	0
to	0
an	0
hSIE-oligonucleotide	0
probe	0
,	0
IL-2	9
and	0
IL-15	9
activated	0
the	0
slowly	0
migrating	0
isoform	0
,	0
Stat3alpha	9
.	0

In	0
contrast	0
,	0
minimal	0
or	0
no	0
activation	0
of	0
Stat3beta	9
was	0
observed	0
,	0
suggesting	0
that	0
IL-2	9
and	0
IL-15	9
predominantly	0
activate	0
Stat3alpha	9
in	0
human	7
CD4	8
(	8
+	8
)	8
T	8
cells	8
.	0

In	0
this	0
way	0
,	0
diversity	0
in	0
the	0
expression	0
and	0
activation	0
of	0
Stat3	9
proteins	10
may	0
provide	0
additional	0
means	0
of	0
regulating	0
cytokine	9
-induced	0
T	0
cell	0
responses	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Transcriptional	0
regulation	0
of	0
lysosomal	9
acid	10
lipase	10
in	0
differentiating	0
monocytes	0
is	0
mediated	0
by	0
transcription	9
factors	10
Sp1	9
and	0
AP-2	9
.	0

Human	0
lysosomal	9
acid	10
lipase	10
(	0
LAL	9
)	0
is	0
a	0
hydrolase	9
required	0
for	0
the	0
cleavage	0
of	0
cholesteryl	0
esters	0
and	0
triglycerides	0
derived	0
from	0
plasma	0
lipoproteins	0
.	0

It	0
is	0
shown	0
here	0
that	0
during	0
monocyte	0
to	0
macrophage	0
differentiation	0
,	0
the	0
expression	0
of	0
LAL-mRNA	3
is	0
induced	0
.	0

This	0
induction	0
is	0
dependent	0
on	0
protein	9
kinase	10
C	10
activity	0
and	0
protein	0
synthesis	0
.	0

The	0
cell	0
type-specific	0
increase	0
in	0
LAL	9
expression	0
is	0
further	0
investigated	0
in	0
the	0
THP-1	5
cell	6
line	6
with	0
respect	0
to	0
transcriptional	0
regulation	0
.	0

The	0
human	5
monocytic	6
leukemia	6
cell	6
line	6
THP-1	5
differentiates	0
into	0
macrophage-like	7
cells	8
when	0
treated	0
with	0
phorbol	0
esters	0
.	0

In	0
order	0
to	0
determine	0
the	0
cis-acting	1
elements	2
necessary	0
for	0
both	0
basal	0
and	0
phorbol	0
12-myristate-13	0
acetate	0
(	0
PMA	0
)	0
-enhanced	0
promoter	0
activity	0
,	0
we	0
performed	0
deletion	0
analysis	0
and	0
reporter	1
gene	2
assays	0
.	0

A	0
PMA	1
responsive	2
element	2
has	0
been	0
identified	0
between	0
-182	1
bp	2
and	0
-107	1
bp	2
upstream	0
of	0
the	0
major	1
transcription	2
start	2
site	2
.	0

Gel	0
mobility	0
shift	0
assays	0
demonstrated	0
that	0
binding	0
of	0
Sp1	9
and	0
AP-2	9
to	0
the	0
LAL	1
promoter	2
is	0
increased	0
by	0
PMA	0
in	0
THP-1	5
cells	6
.	0

Co-transfections	0
with	0
expression	1
plasmids	2
for	0
Sp1	9
and	0
AP-2	9
further	0
emphasized	0
the	0
important	0
role	0
of	0
these	0
transcription	9
factors	10
in	0
both	0
basal	0
and	0
PMA-enhanced	0
LAL	9
expression	0
.	0

Our	0
data	0
suggest	0
that	0
differentiation	0
dependent	0
increase	0
of	0
lysosomal	9
acid	10
lipase	10
(	0
LAL	9
)	0
expression	0
in	0
THP-1	5
cells	6
is	0
mediated	0
by	0
a	0
concerted	0
action	0
of	0
Sp1	9
and	0
AP-2	9
.	0

Relationship	0
between	0
IkappaBalpha	9
constitutive	0
expression	0
,	0
TNFalpha	9
synthesis	0
,	0
and	0
apoptosis	0
in	0
EBV-infected	7
lymphoblastoid	8
cells	8
.	0

In	0
order	0
to	0
understand	0
the	0
role	0
of	0
NF-kappaB	9
in	0
EBV	0
transformation	0
we	0
have	0
established	0
stably	0
transfected	0
IkappaBalpha	9
into	0
lymphoblastoid	7
cells	8
.	0

Two	0
clones	0
were	0
obtained	0
in	0
which	0
the	0
loss	0
of	0
NF-kappaB	9
binding	0
activity	0
correlated	0
with	0
the	0
constitutive	0
expression	0
of	0
the	0
transgenic	0
IkappaBalpha	9
.	0

Protein	0
latency	0
expression	0
was	0
determined	0
by	0
immunocytochemistry	0
.	0

Expression	0
of	0
surface	0
markers	0
,	0
intracytoplasmic	0
content	0
of	0
cytokines	9
cell	0
cycle	0
analysis	0
after	0
BrdU	9
incorporation	0
and	0
DNA	0
staining	0
with	0
propidium	0
iodide	0
were	0
studied	0
by	0
flow	0
cytometry	0
.	0

Percentage	0
of	0
apoptotic	7
cells	8
was	0
determined	0
by	0
in-situ	0
labelling	0
of	0
DNA	0
strand	0
breaks	0
.	0

No	0
significative	0
changes	0
in	0
EBV	0
latency	0
nor	0
in	0
cell	0
surface	0
marker	0
expression	0
was	0
found	0
.	0

In	0
contrast	0
,	0
intracytoplasmic	0
TNFalpha	9
levels	0
were	0
strongly	0
reduced	0
in	0
transfected	5
clones	6
.	0

Furthermore	0
,	0
30	0
%	0
of	0
IkappaBalpha	5
transfected	6
cells	6
were	0
apoptotic	0
after	0
8	0
h	0
of	0
TNFalpha	9
treatment	0
.	0

This	0
correlated	0
with	0
a	0
strong	0
reduction	0
of	0
BrdU	0
incorporation	0
after	0
24	0
h	0
of	0
TNFalpha	9
treatment	0
.	0

No	0
effect	0
was	0
seen	0
with	0
non	0
transfected	5
cells	6
or	0
with	0
cells	0
transfected	0
with	0
a	0
control	0
plasmid	0
.	0

Our	0
results	0
suggest	0
that	0
the	0
TNFalpha	1
gene	2
could	0
be	0
one	0
of	0
the	0
targets	0
of	0
NF-kappaB	9
in	0
EBV	0
infected	0
cells	0
and	0
that	0
NF-kappaB	7
protects	8
EBV-infected	8
cells	8
from	0
apoptosis	0
induced	0
by	0
TNFalpha	9
,	0
which	0
may	0
favour	0
the	0
proliferative	0
effect	0
of	0
this	0
cytokine	9
.	0

Seminoma	0
in	0
a	0
postmenopausal	0
woman	0
with	0
a	0
Y	1
;	2
15	2
translocation	2
in	0
peripheral	7
blood	8
lymphocytes	8
and	0
a	0
t	0
(	0
Y	0
;	0
15	0
)	0
/45	0
,	0
X	0
Turner	0
mosaic	0
pattern	0
in	0
skin	7
fibroblasts	8
.	0

We	0
report	0
an	0
unusual	0
case	0
of	0
a	0
55	0
year	0
old	0
Japanese	0
woman	0
with	0
a	0
seminoma	0
but	0
relatively	0
normal	0
menses	0
.	0

The	0
patient	0
was	0
a	0
phenotypic	0
female	0
with	0
late	0
onset	0
menarche	0
(	0
18	0
years	0
of	0
age	0
)	0
,	0
who	0
was	0
amenorrhoeic	0
for	0
the	0
first	0
year	0
,	0
followed	0
by	0
menses	0
of	0
one	0
to	0
three	0
days	0
'	0
slight	0
flow	0
with	0
dysmenorrhoea	0
,	0
but	0
an	0
otherwise	0
normal	0
menstrual	0
history	0
.	0

A	0
typical	0
seminoma	0
was	0
removed	0
from	0
the	0
left	0
adnexal	0
region	0
and	0
an	0
immature	0
testis	0
was	0
identified	0
separately	0
as	0
an	0
associated	0
right	0
adnexal	0
mass	0
.	0

Repeated	0
karyotypic	0
studies	0
on	0
peripheral	7
blood	8
lymphocyte	8
cultures	8
showed	0
only	0
46	0
,	0
X	0
,	0
-Y	0
,	0
t	0
(	0
Y	0
;	0
15	0
)	0
(	0
q12	0
;	0
p13	0
)	0
.	0

Cytogenetic	0
examination	0
of	0
the	0
patient	0
's	0
younger	0
brother	0
,	0
who	0
had	0
fathered	0
three	0
healthy	0
children	0
,	0
showed	0
an	0
identical	0
karyotype	0
.	0

Mosaicism	0
of	0
46	5
,	6
X	6
,	6
-Y	6
,	6
t	6
(	6
Y	6
;	6
15	6
)	6
(	6
q12	6
;	6
p13	6
)	6
/45	6
,	6
X	6
cell	6
lines	6
was	0
found	0
in	0
skin	0
samples	0
from	0
the	0
patient	0
's	0
elbow	0
and	0
genital	0
regions	0
,	0
although	0
there	0
were	0
no	0
clinical	0
stigmata	0
of	0
Turner	0
syndrome	0
.	0

An	0
androgen	0
receptor	0
binding	0
assay	0
of	0
cultured	5
genital	6
skin	6
fibroblasts	6
was	0
negative	0
.	0

Molecular	0
analysis	0
using	0
Southern	0
blot	0
hybridisation	0
,	0
PCR	0
,	0
and	0
direct	0
DNA	0
sequencing	0
showed	0
that	0
neither	0
the	0
patient	0
nor	0
her	0
brother	0
had	0
a	0
detectable	0
deletion	0
or	0
other	0
abnormalities	0
of	0
Y	0
chromosome	0
sequences	0
,	0
including	0
the	0
SRY	1
(	2
sex	2
determining	2
region	2
of	2
the	2
Y	2
chromosome	2
)	2
gene	2
sequence	2
.	0

These	0
findings	0
suggest	0
that	0
Turner	0
mosaicism	0
of	0
the	0
45	5
,	6
X	6
cell	6
line	6
may	0
have	0
contributed	0
to	0
this	0
atypical	0
presentation	0
in	0
an	0
XY	0
female	0
,	0
although	0
we	0
can	0
not	0
exclude	0
abnormalities	0
of	0
other	0
genes	0
related	0
to	0
sex	0
differentiation	0
.	0

Potent	0
inhibition	0
of	0
HIV	0
type	0
1	0
replication	0
by	0
an	0
antiinflammatory	0
alkaloid	0
,	0
cepharanthine	0
,	0
in	0
chronically	7
infected	8
monocytic	8
cells	8
.	0

Cepharanthine	0
is	0
a	0
biscoclaurine	0
alkaloid	0
isolated	0
from	0
Stephania	0
cepharantha	0
Hayata	0
and	0
has	0
been	0
shown	0
to	0
have	0
antiinflammatory	0
,	0
antiallergic	0
,	0
and	0
immunomodulatory	0
activities	0
in	0
vivo	0
.	0

As	0
several	0
inflammatory	9
cytokines	10
and	0
oxidative	0
stresses	0
are	0
involved	0
in	0
the	0
pathogenesis	0
of	0
HIV-1	0
infection	0
,	0
we	0
investigated	0
the	0
inhibitory	0
effects	0
of	0
cepharanthine	0
on	0
tumor	0
necrosis	0
factor	0
alpha	0
(	0
TNF-alpha	9
)	0
-	0
and	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
-induced	0
HIV-1	0
replication	0
in	0
chronically	5
infected	6
cell	6
lines	6
.	0

Two	0
chronically	5
HIV-1-infected	6
cell	6
lines	6
,	0
U1	5
(	0
monocytic	0
)	0
and	0
ACH-2	5
(	0
T	0
lymphocytic	0
)	0
,	0
were	0
stimulated	0
with	0
TNF-alpha	9
or	0
PMA	0
and	0
cultured	0
in	0
the	0
presence	0
of	0
various	0
concentrations	0
of	0
the	0
compound	0
.	0

HIV-1	0
replication	0
was	0
determined	0
by	0
p24	9
antigen	10
level	0
.	0

The	0
inhibitory	0
effects	0
of	0
cepharanthine	0
on	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
-driven	0
gene	0
expression	0
and	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
activation	0
were	0
also	0
examined	0
.	0

Cepharanthine	0
dose	0
dependently	0
inhibited	0
HIV-1	0
replication	0
in	0
TNF-alpha-	5
and	6
PMA-stimulated	6
U1	6
cells	6
but	0
not	0
in	0
ACH-2	5
cells	6
.	0

Its	0
50	0
%	0
effective	0
and	0
cytotoxic	0
concentrations	0
were	0
0.016	0
and	0
2.2	0
microg/ml	0
in	0
PMA-stimulated	5
U1	6
cells	6
,	0
respectively	0
.	0

Cepharanthine	0
was	0
found	0
to	0
suppress	0
HIV-1	1
LTR	2
-driven	0
gene	0
expression	0
through	0
the	0
inhibition	0
of	0
NF-kappaB	9
activation	0
.	0

These	0
results	0
indicate	0
that	0
cepharanthine	0
is	0
a	0
highly	0
potent	0
inhibitor	0
of	0
HIV-1	0
replication	0
in	0
a	0
chronically	5
infected	6
monocytic	6
cell	6
line	6
.	0

Since	0
biscoclaurine	0
alkaloids	0
,	0
containing	0
cepharanthine	0
as	0
a	0
major	0
component	0
,	0
are	0
widely	0
used	0
for	0
the	0
treatment	0
of	0
patients	0
with	0
various	0
inflammatory	0
diseases	0
in	0
Japan	0
,	0
cepharanthine	0
should	0
be	0
further	0
pursued	0
for	0
its	0
chemotherapeutic	0
potential	0
in	0
HIV-1-infected	0
patients	0
.	0

NF-kappaB	9
only	0
partially	0
mediates	0
Epstein-Barr	9
virus	10
latent	10
membrane	10
protein	10
1	10
activation	0
of	0
B	0
cells	0
.	0

The	0
latent	9
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
required	0
for	0
EBV-induced	0
immortalization	0
of	0
human	7
B	8
cells	8
and	0
causes	0
tumorigenic	0
transformation	0
of	0
cell	5
lines	6
.	0

LMP1	9
expression	0
induces	0
phenotypic	0
changes	0
resembling	0
B	0
cell	0
activation	0
,	0
such	0
as	0
cell	0
size	0
increase	0
and	0
up-regulation	0
of	0
cell	9
surface	10
activation	10
markers	10
.	0

LMP1	9
contains	0
two	0
domains	0
that	0
activate	0
the	0
transcription	9
factor	10
NF-kappaB	9
,	0
one	0
through	0
interactions	0
with	0
TRAF	9
proteins	10
and	0
the	0
other	0
with	0
the	0
TRADD	9
protein	10
.	0

The	0
purpose	0
of	0
the	0
present	0
study	0
was	0
to	0
investigate	0
the	0
importance	0
of	0
NF-kappaB	9
induction	0
in	0
the	0
up-regulation	0
of	0
the	0
B	0
cell	0
activation	0
markers	0
ICAM-1	9
and	0
CD71	9
by	0
LMP1	9
.	0

This	0
study	0
shows	0
that	0
expression	0
of	0
LMP1	9
activates	0
transcription	0
from	0
p50/p65-	1
and	2
c-Rel-	2
responsive	2
promoters	2
,	0
and	0
that	0
this	0
activity	0
can	0
be	0
completely	0
inhibited	0
by	0
expression	0
of	0
a	0
dominant	0
inhibitory	9
IkappaB	10
mutant	10
.	0

ICAM-1	9
and	0
CD71	9
are	0
nevertheless	0
up-regulated	0
by	0
LMP1	9
in	0
primary	7
B	8
cells	8
and	0
cell	0
lines	0
expressing	0
the	0
dominant	9
IkappaB	10
.	0

Furthermore	0
,	0
LMP1	9
-induced	0
cell	0
size	0
increase	0
of	0
primary	7
B	8
cells	8
was	0
unaffected	0
by	0
IkappaB	9
expression	0
.	0

It	0
was	0
concluded	0
that	0
even	0
when	0
LMP1	9
is	0
unable	0
to	0
activate	0
NF-kappaB	9
,	0
it	0
is	0
still	0
capable	0
of	0
inducing	0
certain	0
characteristics	0
of	0
activated	7
B	8
cells	8
,	0
strongly	0
suggesting	0
that	0
LMP1	9
can	0
also	0
activate	0
cells	0
independently	0
of	0
NF-kappaB	9
.	0

Models	0
of	0
lineage	0
switching	0
in	0
hematopoietic	0
development	0
:	0
a	0
new	0
myeloid-committed	5
eosinophil	6
cell	6
line	6
(	0
YJ	5
)	0
demonstrates	0
trilineage	0
potential	0
.	0

A	0
new	0
human	5
leukemia	6
cell	6
line	6
with	0
an	0
eosinophilic	0
phenotype	0
,	0
designated	0
YJ	5
,	0
was	0
established	0
from	0
the	0
peripheral	7
blood	8
cells	8
of	0
a	0
patient	0
with	0
chronic	0
myelomonocytic	0
leukemia	0
(	0
CMMoL	0
)	0
with	0
eosinophilia	0
.	0

When	0
cultured	0
in	0
RPMI	0
1640	0
medium	0
containing	0
10	0
%	0
fetal	0
bovine	0
serum	0
,	0
most	0
YJ	5
cells	6
were	0
myeloblastoid	0
with	0
a	0
small	0
number	0
of	0
the	0
cells	0
having	0
eosinophilic	0
granules	0
.	0

Cell	9
surface	10
markers	10
in	0
the	0
YJ	5
cells	6
were	0
positive	0
for	0
CD33	9
and	0
were	0
negative	0
for	0
CD34	9
,	0
CD16	9
and	0
CD23	9
.	0

The	0
eosinophilic	0
characteristics	0
of	0
YJ	5
cells	6
were	0
confirmed	0
by	0
histochemical	0
staining	0
with	0
Fast-Green/Neutral-Red	0
and	0
by	0
the	0
expression	0
of	0
mRNAs	3
for	0
eosinophil-associated	9
granule	10
proteins	10
,	0
eosinophil	9
cationic	10
protein	10
(	0
ECP	9
)	0
,	0
eosinophil-derived	9
neurotoxin	10
(	0
EDN	9
)	0
,	0
eosinophil	9
peroxidase	10
(	0
EPO	9
)	0
,	0
and	0
major	9
basic	10
protein	10
(	0
MBP	9
)	0
,	0
and	0
for	0
the	0
Charcot-Leyden	9
crystal	10
(	10
CLC	10
)	10
protein	10
.	0

The	0
YJ	5
cells	6
could	0
be	0
induced	0
towards	0
monocytic	0
differentiation	0
by	0
stimulation	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
.	0

The	0
monocytic	0
characteristics	0
of	0
YJ	5
cells	6
treated	0
with	0
PMA	0
were	0
confirmed	0
by	0
morphological	0
analysis	0
with	0
alpha-naphthyl	0
butyrate	0
esterase	0
staining	0
,	0
by	0
CD14	9
expression	0
,	0
and	0
by	0
increased	0
expression	0
of	0
Egr-1	3
mRNA	4
.	0

Furthermore	0
,	0
YJ	5
cells	6
could	0
be	0
differentiated	0
towards	0
the	0
neutrophil	7
lineage	8
by	0
stimulation	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
RA	0
)	0
.	0

YJ	5
cells	6
treated	0
in	0
vitro	0
with	0
2	0
microM	0
RA	0
differentiated	0
into	0
metamyelocytes	7
and	0
band	7
neutrophils	8
,	0
and	0
increased	0
the	0
number	0
of	0
nitroblue	5
tetrazolium	6
(	6
NBT	6
)	6
-positive	6
cells	6
and	0
increased	0
gp91phox	3
mRNA	4
expression	0
.	0

Thus	0
,	0
the	0
YJ	5
cell	6
line	6
exhibited	0
eosinophilic	0
characteristics	0
,	0
but	0
was	0
able	0
to	0
differentiate	0
to	0
the	0
monocytic	7
or	8
neutrophilic	8
lineages	8
in	0
response	0
to	0
PMA	0
or	0
RA	0
,	0
respectively	0
.	0

The	0
expression	0
of	0
genes	0
for	0
transcription	9
factors	10
involved	0
in	0
myeloid	0
differentiation	0
was	0
evaluated	0
by	0
Northern	0
blot	0
analysis	0
.	0

Increased	0
expression	0
of	0
Egr-1	9
was	0
observed	0
with	0
macrophage	0
differentiation	0
.	0

In	0
contrast	0
,	0
increased	0
expressions	0
of	0
C/EBPbeta	9
and	0
MZF-1	3
mRNA	4
occurred	0
with	0
neutrophilic	0
differentiation	0
.	0

The	0
YJ	5
cell	6
line	6
should	0
be	0
useful	0
for	0
elucidating	0
the	0
molecular	0
mechanisms	0
governing	0
lineage	0
switching	0
from	0
the	0
eosinophil	7
to	0
monocytic	7
or	8
neutrophil	8
lineages	8
.	0

Interleukin-6	9
production	0
in	0
hemorrhagic	0
shock	0
is	0
accompanied	0
by	0
neutrophil	0
recruitment	0
and	0
lung	0
injury	0
.	0

Hemorrhagic	0
shock	0
(	0
HS	0
)	0
initiates	0
an	0
inflammatory	0
cascade	0
that	0
includes	0
the	0
production	0
of	0
cytokines	9
and	0
recruitment	0
of	0
neutrophils	7
(	0
PMN	7
)	0
and	0
may	0
progress	0
to	0
organ	0
failure	0
,	0
inducing	0
acute	0
respiratory	0
distress	0
syndrome	0
(	0
ARDS	0
)	0
.	0

To	0
examine	0
the	0
hypothesis	0
that	0
interleukin-6	9
(	0
IL-6	9
)	0
contributes	0
to	0
PMN	0
infiltration	0
and	0
lung	0
damage	0
in	0
HS	0
,	0
we	0
examined	0
the	0
lungs	0
of	0
rats	0
subjected	0
to	0
unresuscitated	0
and	0
resuscitated	0
HS	0
for	0
the	0
production	0
of	0
IL-6	9
and	0
activation	0
of	0
Stat3	9
.	0

Using	0
semiquantitative	0
RT-PCR	0
,	0
we	0
found	0
a	0
striking	0
increase	0
in	0
IL-6	3
mRNA	4
levels	0
only	0
in	0
resuscitated	0
HS	0
,	0
with	0
peak	0
levels	0
observed	0
1	0
h	0
after	0
initiation	0
of	0
resuscitation	0
.	0

Increased	0
IL-6	9
protein	0
expression	0
was	0
localized	0
to	0
bronchial	7
and	8
alveolar	8
cells	8
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
of	0
protein	0
extracts	0
from	0
shock	0
lungs	0
exhibited	0
an	0
increase	0
in	0
Stat3	9
activation	0
with	0
kinetics	0
similar	0
to	0
IL-6	3
mRNA	4
.	0

In	0
situ	0
DNA	0
binding	0
assay	0
determined	0
Stat3	9
activation	0
predominantly	0
within	0
alveoli	0
.	0

Intratracheal	0
instillation	0
of	0
IL-6	9
alone	0
into	0
normal	0
rats	0
resulted	0
in	0
PMN	0
infiltration	0
into	0
lung	0
interstitium	0
and	0
alveoli	0
,	0
marked	0
elevation	0
of	0
bronchoalveolar	0
lavage	0
cellularity	0
,	0
and	0
increased	0
wet-to-dry	0
ratio	0
.	0

These	0
findings	0
indicate	0
that	0
IL-6	9
production	0
and	0
Stat3	9
activation	0
occur	0
early	0
in	0
HS	0
and	0
may	0
contribute	0
to	0
PMN-mediated	0
lung	0
injury	0
,	0
including	0
ARDS	0
after	0
HS	0
.	0

The	0
MHC	9
class	10
II	10
transactivator	10
(	0
CIITA	9
)	0
requires	0
conserved	0
leucine	9
charged	10
domains	10
for	0
interactions	0
with	0
the	0
conserved	0
W	1
box	2
promoter	2
element	2
.	0

The	0
class	9
II	10
transactivator	10
CIITA	9
is	0
required	0
for	0
transcriptional	0
activation	0
of	0
the	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
genes	2
.	0

Aside	0
from	0
an	0
N-terminal	1
acidic	2
transcriptional	2
activation	2
domain	2
,	0
little	0
is	0
known	0
about	0
how	0
this	0
factor	0
functions	0
.	0

Extensive	0
mutagenesis	0
of	0
CIITA	9
was	0
undertaken	0
to	0
identify	0
structural	0
motifs	0
required	0
for	0
function	0
.	0

The	0
ability	0
of	0
mutants	0
to	0
activate	0
a	0
reporter	0
gene	0
under	0
the	0
control	0
of	0
MHC	9
class	10
II	10
conserved	0
W-X-Y	1
or	2
X-Y	2
regulatory	2
elements	2
was	0
determined	0
.	0

Two	0
mutants	0
displayed	0
differential	0
activity	0
between	0
the	0
two	0
promoters	1
,	0
activating	0
transcription	0
with	0
the	0
W-X-Y	1
but	2
not	2
the	2
X-Y	2
elements	2
.	0

All	0
mutants	0
were	0
tested	0
for	0
their	0
ability	0
to	0
interfere	0
with	0
wild-type	0
CIITA	9
activity	0
.	0

Five	0
CIITA	1
mutant	2
constructions	2
were	0
able	0
to	0
down-regulate	0
wild-type	0
CIITA	9
activity	0
.	0

Three	0
of	0
these	0
mutants	0
contained	0
targeted	0
disruptions	0
of	0
potential	0
functional	0
motifs	0
:	0
the	0
acidic	9
activation	10
domain	10
,	0
a	0
putative	0
GTP-binding	9
motif	10
and	0
two	0
leucine	9
charged	10
domains	10
(	0
LCD	9
motifs	10
)	0
.	0

The	0
other	0
two	0
contained	0
mutations	0
in	0
regions	0
that	0
do	0
not	0
have	0
homology	0
to	0
described	0
proteins	0
.	0

The	0
characterization	0
of	0
CIITA	9
mutants	10
that	0
are	0
able	0
to	0
discriminate	0
between	0
promoters	0
with	0
or	0
without	0
the	0
W	1
box	2
strongly	0
suggests	0
that	0
CIITA	9
requires	0
such	0
interactions	0
for	0
function	0
.	0

The	0
identification	0
of	0
LCD	9
motifs	10
required	0
for	0
CIITA	9
function	0
brings	0
to	0
light	0
a	0
previously	0
undefined	0
role	0
of	0
these	0
motifs	0
in	0
CIITA	9
function	0
.	0

The	0
peroxisome	9
proliferator-activated	10
receptor	10
alpha	10
(	0
PPARalpha	9
)	0
ligand	0
WY	0
14	0
,	0
643	0
does	0
not	0
interfere	0
with	0
leukotriene	0
B4	0
induced	0
adhesion	0
of	0
neutrophils	7
to	0
endothelial	7
cells	8
.	0

Peroxisome	9
proliferator-activated	10
receptors	10
(	0
PPAR	9
)	0
control	0
discrete	0
genes	0
involved	0
in	0
fatty	0
acid	0
and	0
lipid	0
metabolism	0
.	0

Recently	0
,	0
it	0
was	0
suggested	0
that	0
activation	0
of	0
the	0
alpha	9
isoform	10
of	0
PPAR	9
by	0
the	0
potent	0
proinflammatory	0
mediator	0
leukotriene	0
B4	0
(	0
LTB4	0
)	0
enhanced	0
degradation	0
of	0
this	0
eicosanoid	0
,	0
offersuggesting	0
a	0
new	0
aspect	0
of	0
down-regulation	0
of	0
inflammation	0
.	0

Here	0
,	0
we	0
studied	0
whether	0
PPARalpha	9
activation	0
(	0
by	0
means	0
of	0
the	0
selective	0
agonist	0
WY	0
14	0
,	0
643	0
)	0
of	0
endothelial	7
cells	8
,	0
pivotal	0
in	0
the	0
regulation	0
of	0
inflammatory	0
responses	0
,	0
interfered	0
with	0
LTB4	0
induced	0
adhesion	0
of	0
PMN	7
neutrophil	8
granulocytes	8
in	0
vitro	0
.	0

When	0
endothelial	7
cells	8
were	0
treated	0
with	0
WY	0
14	0
,	0
643	0
prior	0
to	0
activation	0
with	0
LTB4	0
(	0
or	0
fMLP	9
,	0
IL-1beta	9
or	0
TNFalpha	9
,	0
as	0
controls	0
)	0
we	0
could	0
not	0
document	0
any	0
effect	0
on	0
the	0
number	0
of	0
adhering	7
PMN	8
or	0
duration	0
of	0
the	0
response	0
.	0

Thus	0
,	0
this	0
study	0
provides	0
no	0
evidence	0
indicating	0
a	0
regulatory	0
function	0
of	0
PPARalpha	9
in	0
LTB4	0
induced	0
adhesive	0
interactions	0
between	0
endothelial	7
cells	8
and	0
neutrophils	7

Interaction	0
of	0
sickle	7
erythrocytes	8
with	0
endothelial	7
cells	8
in	0
the	0
presence	0
of	0
endothelial	0
cell	0
conditioned	0
medium	0
induces	0
oxidant	0
stress	0
leading	0
to	0
transendothelial	0
migration	0
of	0
monocytes	7
.	0

The	0
abnormal	0
adherence	0
of	0
sickle	7
red	8
blood	8
cells	8
(	0
SS	7
RBC	8
)	0
to	0
endothelial	7
cells	8
has	0
been	0
thought	0
to	0
contribute	0
to	0
vascular	0
occlusion	0
,	0
a	0
major	0
cause	0
of	0
morbidity	0
in	0
sickle	0
cell	0
disease	0
(	0
SCD	0
)	0
.	0

We	0
determined	0
whether	0
the	0
interaction	0
of	0
SS	7
RBC	8
with	0
cultured	0
endothelial	7
cells	8
induced	0
cellular	0
oxidant	0
stress	0
that	0
would	0
culminate	0
in	0
expression	0
of	0
cell	9
adhesion	10
molecules	10
(	0
CAMs	9
)	0
involved	0
in	0
the	0
adhesion	0
and	0
diapedesis	0
of	0
monocytes	7
and	0
the	0
adherence	0
of	0
SS	7
reticulocytes	8
.	0

We	0
showed	0
that	0
the	0
interaction	0
of	0
SS	7
RBC	8
at	0
2	0
%	0
concentration	0
in	0
the	0
presence	0
of	0
multimers	0
of	0
von	9
Willebrand	10
factor	10
(	0
vWf	9
)	0
,	0
derived	0
from	0
endothelial	0
cell-derived	0
conditioned	0
medium	0
(	0
E-CM	0
)	0
with	0
cultured	5
human	6
umbilical	6
vein	6
endothelial	6
cells	6
(	0
HUVEC	5
)	0
,	0
resulted	0
in	0
a	0
fivefold	0
increased	0
formation	0
of	0
thiobarbituric	0
acid-reactive	0
substances	0
(	0
TBARS	0
)	0
and	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kB	9
,	0
both	0
indicators	0
of	0
cellular	0
oxidant	0
stress	0
.	0

Normal	7
RBC	8
show	0
none	0
of	0
these	0
phenomena	0
.	0

The	0
oxidant	0
stress-induced	0
signaling	0
resulted	0
in	0
an	0
increased	0
surface	0
expression	0
of	0
a	0
subset	0
of	0
CAMs	9
,	0
ICAM-1	9
,	0
E-selectin	9
,	0
and	0
VCAM-1	9
in	0
HUVEC	5
.	0

The	0
addition	0
of	0
oxygen	9
radical	10
scavenger	10
enzymes	10
(	0
catalase	9
,	0
superoxide	9
dismutase	10
)	0
and	0
antioxidant	0
(	0
probucol	0
)	0
inhibited	0
these	0
events	0
.	0

Additionally	0
,	0
preincubation	0
of	0
HUVEC	5
with	0
a	0
synthetic	0
peptide	0
Arg-Gly-Asp	0
(	0
RGD	0
)	0
that	0
prevents	0
vWf	9
-mediated	0
adhesion	0
of	0
SS	7
RBC	8
reduced	0
the	0
surface	0
expression	0
of	0
VCAM-1	9
and	0
NF-kB	9
activation	0
.	0

Furthermore	0
,	0
SS	7
RBC	8
-induced	0
oxidant	0
stress	0
resulted	0
in	0
a	0
twofold	0
increase	0
in	0
the	0
transendothelial	0
migration	0
of	0
both	0
monocyte-like	5
HL-60	6
cells	6
and	0
human	7
peripheral	8
blood	8
monocytes	8
,	0
and	0
approximately	0
a	0
sixfold	0
increase	0
in	0
platelet-endothelial	9
cell	10
adhesion	10
molecule-1	10
(	0
PECAM-1	9
)	0
phosphorylation	0
,	0
each	0
of	0
which	0
was	0
blocked	0
by	0
protein	9
kinase	10
C	10
inhibitor	0
and	0
antioxidants	0
.	0

These	0
results	0
suggest	0
that	0
the	0
adherence/contact	0
of	0
SS	7
RBC	8
to	0
endothelial	7
cells	8
in	0
large	0
vessel	0
can	0
generate	0
enhanced	0
oxidant	0
stress	0
leading	0
to	0
increased	0
adhesion	0
and	0
diapedesis	0
of	0
monocytes	7
,	0
as	0
well	0
as	0
heightened	0
adherence	0
of	0
SS	7
reticulocytes	8
,	0
indicating	0
that	0
injury/activation	0
of	0
endothelium	0
can	0
contribute	0
to	0
vaso-occlusion	0
in	0
SCD	0
.	0

Signal	0
transduction	0
abnormalities	0
in	0
T	7
lymphocytes	8
from	0
patients	0
with	0
advanced	0
renal	0
carcinoma	0
:	0
clinical	0
relevance	0
and	0
effects	0
of	0
cytokine	9
therapy	0
.	0

Studies	0
have	0
demonstrated	0
abnormalities	0
of	0
the	0
CD3/T-cell	9
antigen	10
receptor	10
(	0
TCR	9
)	0
and	0
pathways	0
of	0
signal	0
transduction	0
in	0
T	7
lymphocytes	8
from	0
animals	0
and	0
patients	0
with	0
advanced	0
malignancy	0
.	0

Diminished	0
expression	0
of	0
TCRzeta	9
and	0
p56	9
(	10
lck	10
)	10
that	0
are	0
associated	0
with	0
the	0
TCR	9
and	0
reduced	0
nuclear	0
localization	0
of	0
RelA	9
containing	10
nuclear	10
factor	10
kappaB	10
(	10
NFkappaB	10
)	10
complexes	10
have	0
been	0
noted	0
.	0

These	0
defects	0
have	0
been	0
described	0
in	0
T	7
cells	8
from	0
patients	0
with	0
malignant	0
melanoma	0
,	0
renal	0
cell	0
carcinoma	0
(	0
RCC	0
)	0
,	0
ovarian	0
cancer	0
,	0
and	0
colorectal	0
cancer	0
.	0

Preliminary	0
observations	0
also	0
indicate	0
possible	0
correlation	0
with	0
clinical	0
variables	0
such	0
as	0
stage	0
in	0
selected	0
instances	0
.	0

To	0
further	0
characterize	0
altered	0
expression	0
of	0
TCRzeta	9
,	0
p56	9
(	10
lck	10
)	10
,	0
and	0
impaired	0
activation	0
of	0
NFkappaB	9
,	0
T	7
lymphocytes	8
were	0
obtained	0
from	0
65	0
patients	0
with	0
RCC	0
,	0
the	0
majority	0
of	0
whom	0
were	0
receiving	0
combination	0
cytokine	9
therapy	0
[	0
interleukin	9
(	10
IL	10
)	10
-2	10
,	0
IFN	9
alpha	10
-containing	0
regimens	0
]	0
and	0
37	0
control	0
individuals	0
.	0

In	0
29	0
of	0
these	0
patients	0
,	0
levels	0
of	0
TCRzeta	9
and	0
p56	9
(	10
lck	10
)	10
were	0
determined	0
by	0
Western	0
blots	0
of	0
T-cell	0
lysates	0
and	0
semiquantitated	0
using	0
densitometry	0
.	0

Relative	0
levels	0
were	0
then	0
correlated	0
with	0
a	0
series	0
of	0
clinical	0
variables	0
including	0
response	0
to	0
therapy	0
,	0
performance	0
status	0
,	0
survival	0
,	0
disease	0
sites	0
,	0
age	0
,	0
and	0
others	0
.	0

In	0
another	0
group	0
of	0
28	0
patients	0
(	0
three	0
individuals	0
from	0
the	0
first	0
group	0
)	0
,	0
the	0
frequency	0
of	0
abnormal	0
NFkappaB	9
activation	0
was	0
studied	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
after	0
activation	0
of	0
T	7
cells	8
with	0
phorbol	0
myristate	0
acetate/ionomycin	0
or	0
anti-CD3	9
monoclonal	10
antibody	10
.	0

Changes	0
in	0
these	0
signaling	0
molecules	0
during	0
cytokine	9
treatment	0
were	0
also	0
investigated	0
.	0

TCRzeta	9
and	0
p56	9
(	10
lck	10
)	10
were	0
detected	0
in	0
the	0
peripheral	7
blood	8
T	8
cells	8
in	0
27	0
of	0
29	0
patients	0
,	0
and	0
overall	0
,	0
reduced	0
levels	0
were	0
noted	0
visually	0
in	0
12	0
of	0
29	0
(	0
41	0
%	0
)	0
and	0
13	0
of	0
29	0
(	0
45	0
%	0
)	0
individuals	0
,	0
respectively	0
.	0

When	0
levels	0
were	0
semiquantitated	0
using	0
densitometry	0
,	0
significant	0
decreases	0
of	0
TCRzeta	9
(	0
P	0
=	0
0.029	0
)	0
and	0
p56	9
(	10
lck	10
)	10
(	0
P	0
=	0
0.029	0
)	0
but	0
not	0
CD3epsilon	9
(	0
P	0
=	0
0.131	0
)	0
,	0
compared	0
with	0
control	0
levels	0
,	0
were	0
found	0
.	0

In	0
patients	0
treated	0
with	0
IL-2/	0
IFN	9
alpha	10
-based	0
therapy	0
,	0
relative	0
levels	0
of	0
TCRzeta	9
increased	0
significantly	0
(	0
P	0
=	0
0.002	0
)	0
on	0
day	0
15	0
of	0
cycle	0
one	0
compared	0
with	0
the	0
baseline	0
.	0

Correlations	0
of	0
TCRzeta	9
or	0
p56	9
(	10
lck	10
)	10
levels	0
with	0
response	0
or	0
disease	0
variables	0
,	0
except	0
for	0
lower	0
TCRzeta	9
levels	0
(	0
P	0
<	0
0.001	0
)	0
in	0
the	0
presence	0
of	0
bone	0
metastases	0
,	0
were	0
not	0
found	0
.	0

Abnormal	0
NFkappaB	9
activation	0
after	0
stimulation	0
with	0
phorbol	0
myristate	0
acetate/ionomycin	0
and/or	0
anti-CD3	9
monoclonal	10
antibody	10
was	0
found	0
in	0
59	0
%	0
of	0
patients	0
(	0
17	0
of	0
28	0
)	0
and	0
was	0
not	0
accounted	0
for	0
by	0
the	0
advanced	0
age	0
of	0
the	0
study	0
cohort	0
.	0

Activation	0
of	0
NFkappaB	9
in	0
peripheral	7
blood	8
T	8
cells	8
was	0
inducible	0
during	0
cytokine	9
therapy	0
in	0
four	0
of	0
six	0
individuals	0
who	0
displayed	0
impaired	0
NFkappaB	9
activity	0
prior	0
to	0
therapy	0
.	0

Moreover	0
,	0
impaired	0
activation	0
of	0
NFkappaB	9
does	0
not	0
appear	0
linked	0
to	0
a	0
reduction	0
of	0
TCRzeta	9
expression	0
,	0
because	0
in	0
five	0
patients	0
,	0
normal	0
TCRzeta	9
levels	0
were	0
present	0
although	0
kappaB	9
binding	0
was	0
not	0
inducible	0
.	0

In	0
the	0
majority	0
of	0
patients	0
with	0
advanced	0
RCC	0
,	0
peripheral	7
blood	8
T	8
cells	8
express	0
TCRzeta	9
and	0
p56	9
(	10
lck	10
)	10
,	0
and	0
in	0
a	0
subset	0
,	0
reduced	0
levels	0
of	0
these	0
TCRzeta	9
associated	10
molecules	10
are	0
seen	0
that	0
may	0
increase	0
during	0
cytokine	9
-based	0
therapy	0
.	0

Abnormal	0
activation	0
of	0
NFkappaB	9
is	0
also	0
present	0
in	0
>	0
50	0
%	0
of	0
patients	0
and	0
may	0
also	0
revert	0
to	0
normal	0
during	0
IL-2/	0
IFN	9
alpha	10
-based	0
treatment	0
.	0

This	0
alteration	0
in	0
NFkappaB	9
activation	0
occurred	0
in	0
the	0
presence	0
of	0
normal	0
expression	0
of	0
TCRzeta-associated	1
signaling	2
elements	2
.	0

The	0
clinical	0
significance	0
of	0
these	0
findings	0
remains	0
unclear	0
.	0

Identification	0
of	0
transcription	9
factors	10
expressed	0
during	0
ATRA-induced	0
neutrophil	0
differentiation	0
of	0
HL60	5
cells	6
.	0

A	0
recent	0
clinical	0
therapeutic	0
initiative	0
has	0
been	0
the	0
use	0
of	0
chemical	0
agents	0
which	0
induce	0
the	0
leukaemic	7
cells	8
to	0
overcome	0
their	0
block	0
in	0
differentiation	0
.	0

In	0
order	0
to	0
understand	0
this	0
block	0
the	0
cascade	0
of	0
molecular	0
events	0
needs	0
to	0
be	0
characterized	0
.	0

Haemopoietic	0
differentiation	0
is	0
ultimately	0
controlled	0
at	0
the	0
level	0
of	0
gene	0
transcription	0
which	0
is	0
mediated	0
by	0
an	0
array	0
of	0
transcription	9
factors	10
.	0

Many	0
transcription	9
factors	10
contain	0
similar	0
structural	9
protein	10
sequences	10
,	0
and	0
we	0
have	0
used	0
an	0
RT-PCR-based	0
approach	0
to	0
isolate	0
sequences	0
,	0
from	0
transcription	9
factor	10
gene	0
families	0
which	0
share	0
similar	0
domains	0
.	0

Degenerate	0
primers	0
corresponding	0
to	0
the	0
TFIIIA	1
zinc-finger	2
consensus	2
amino	2
acid	2
sequences	2
and	0
to	0
the	0
POU-homeodomain	9
and	0
POU-specific	9
domain	10
were	0
used	0
to	0
amplify	0
genes	0
on	0
the	0
basis	0
that	0
they	0
contained	0
similarities	0
in	0
structural	0
motifs	0
shared	0
within	0
these	0
families	0
of	0
transcription	9
factors	10
.	0

A	0
serum-independent	5
HL60	6
cell	6
line	6
was	0
induced	0
towards	0
the	0
neutrophil	0
lineage	0
by	0
treatment	0
with	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
for	0
24	0
h	0
.	0

CD38+	7
cells	8
committed	0
towards	0
this	0
lineage	0
were	0
enriched	0
and	0
a	0
population	0
of	0
these	0
cells	0
treated	0
with	0
dihydroxyvitamin	0
D3	0
to	0
induce	0
neutrophil	0
maturation	0
.	0

RNA	0
extracted	0
from	0
uninduced	0
,	0
ATRA-induced	5
CD38+	6
cells	6
,	0
and	0
vitamin	5
D3	6
treated	6
maturing	6
cell	6
cultures	6
were	0
amplified	0
using	0
the	0
degenerate	0
primers	0
.	0

PCR	1
fragments	2
were	0
cloned	0
,	0
sequenced	0
,	0
clustered	0
into	0
homologous	0
groups	0
,	0
and	0
the	0
group	0
sequences	0
searched	0
on	0
the	0
GenBank	0
database	0
.	0

The	0
Oct	0
1	0
transcription	9
factor	10
,	0
and	0
a	0
very	0
close	0
homologue	0
,	0
KIAA0144	1
,	0
was	0
identified	0
using	0
the	0
POU	0
family	0
primers	0
.	0

The	0
zinc-finger	0
primers	0
identified	0
three	0
zinc-finger	0
genes	0
.	0

The	0
pattern	0
of	0
gene	0
expression	0
was	0
suggested	0
from	0
the	0
number	0
of	0
clones	0
in	0
each	0
group	0
at	0
neutrophil	0
commitment	0
and	0
maturation	0
.	0

The	0
differential	0
expression	0
of	0
the	0
genes	0
in	0
the	0
zinc	9
finger	10
and	10
POU	10
families	10
will	0
lead	0
to	0
a	0
better	0
understanding	0
of	0
the	0
cascade	0
of	0
gene	0
expression	0
which	0
occurs	0
following	0
ATRA-induced	0
differentiation	0
.	0

GATA-3	9
-dependent	0
enhancer	0
activity	0
in	0
IL-4	1
gene	2
regulation	0
.	0

Previously	0
,	0
we	0
analyzed	0
the	0
proximal	1
IL-4	2
promoter	2
in	0
directing	0
Th2-specific	0
activity	0
.	0

An	0
800-base	1
pair	2
proximal	2
promoter	2
conferred	0
some	0
Th2-selective	0
expression	0
in	0
transgenic	0
mice	0
.	0

However	0
,	0
this	0
region	0
directed	0
extremely	0
low	0
reporter	0
mRNA	0
levels	0
relative	0
to	0
endogenous	0
IL-4	3
mRNA	4
,	0
suggesting	0
that	0
full	0
gene	0
activity	0
requires	0
additional	0
enhancer	1
elements	2
.	0

Here	0
,	0
we	0
analyzed	0
large	0
genomic	1
IL-4	2
regions	2
for	0
enhancer	0
activity	0
and	0
interaction	0
with	0
transcription	9
factors	10
.	0

The	0
proximal	0
IL-4	1
promoter	2
is	0
only	0
moderately	0
augmented	0
by	0
GATA-3	9
,	0
but	0
certain	0
genomic	1
regions	2
significantly	0
enhanced	0
GATA-3	1
promoter	2
transactivation	0
.	0

Some	0
enhancing	0
regions	0
contained	0
consensus	0
,	0
GATA	1
sites	2
that	0
bound	0
Th2-specific	9
complexes	10
.	0

However	0
,	0
retroviral	0
transduction	0
of	0
GATA-3	9
into	0
developing	7
T	8
cells	8
induced	0
IL-5	9
to	0
full	0
Th2	9
levels	0
,	0
but	0
only	0
partially	0
restored	0
IL-4	9
production	0
.	0

Thus	0
,	0
we	0
propose	0
that	0
GATA-3	9
is	0
permissive	0
,	0
but	0
not	0
sufficient	0
,	0
for	0
full	0
IL-4	9
enhancement	0
and	0
may	0
act	0
through	0
GATA	1
elements	2
surrounding	0
the	0
IL-13/IL-4	1
gene	2
locus	2
.	0

Position	0
effect	0
of	0
translocations	0
involving	0
the	0
inactive	1
X	2
chromosome	2
:	0
physical	0
linkage	0
to	0
XIC/XIST	1
does	0
not	0
lead	0
to	0
long-range	0
de	0
novo	0
inactivation	0
in	0
human	7
differentiated	8
cells	8
.	0

Given	0
the	0
reported	0
long-range	0
cis-inactivating	0
effect	0
of	0
the	0
XIST	1
gene	2
in	0
early	0
embryonic	0
development	0
and	0
the	0
lack	0
of	0
requirement	0
of	0
X-chromosome-specific	1
elements	2
for	0
propagating	0
the	0
inactive	0
state	0
,	0
there	0
exists	0
the	0
possibility	0
of	0
cis	0
inactivation	0
of	0
autosomal	0
material	0
after	0
de	0
novo	0
translocation	0
to	0
an	0
inactive	1
X	2
chromosome	2
(	0
Xi	1
)	0
in	0
differentiated	7
cells	8
.	0

We	0
have	0
analyzed	0
de	0
novo	0
radiation-induced	0
translocations	0
between	0
the	0
Xi	1
and	0
autosomes	1
to	0
study	0
the	0
maintenance	0
and	0
spreading	0
of	0
X-chromosome	1
inactivation	0
(	0
X	0
inactivation	0
)	0
in	0
relation	0
to	0
the	0
position	0
of	0
the	0
X-inactivation	0
center	0
(	1
XIC	2
)	2
/XIST	2
in	0
differentiated	7
cells	8
.	0

Autosome/	0
Xi	1
translocations	0
were	0
detected	0
by	0
fluorescence	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
.	0

The	0
activation	0
status	0
of	0
the	0
chromosomes	1
involved	0
in	0
the	0
translocation	0
was	0
determined	0
by	0
simultaneous	0
immunocytogenetic	0
studies	0
using	0
antibodies	9
against	0
either	0
BrdU	9
incorporated	0
at	0
late	0
S	0
phase	0
or	0
acetylated	9
histone	10
H4	10
.	0

The	0
position	0
of	0
XIC/XIST	1
in	0
the	0
reciprocal	0
products	0
of	0
the	0
translocation	0
was	0
determined	0
by	0
XIST-specific	0
FISH	0
and	0
computer	0
enhancement	0
.	0

In	0
other	0
experiments	0
,	0
the	0
Xq13	1
region	2
carrying	0
XIC/XIST	1
was	0
localized	0
by	0
computer	0
enhancement	0
of	0
the	0
DAPI	0
banding	0
pattern	0
.	0

Our	0
study	0
in	0
differentiated	7
cells	8
provides	0
a	0
visual	0
demonstration	0
that	0
physical	0
separation	0
from	0
XIC/XIST	1
does	0
not	0
result	0
in	0
reactivation	0
of	0
inactive	1
X-chromosome	2
material	0
and	0
that	0
X	0
inactivation	0
is	0
not	0
spread	0
to	0
the	0
translocated	1
autosomes	2
irrespective	0
of	0
the	0
position	0
of	0
XIC/XIST	1
.	0

This	0
observation	0
suggests	0
that	0
physical	0
linkage	0
to	0
XIC/XIST	1
does	0
not	0
lead	0
to	0
de	0
novo	0
inactivation	0
of	0
autosomal	0
material	0
.	0

Interleukin-4	9
and	10
-13	10
induce	0
upregulation	0
of	0
the	0
murine	0
macrophage	0
12/15-lipoxygenase	9
activity	10
:	0
evidence	0
for	0
the	0
involvement	0
of	0
transcription	9
factor	10
STAT6	9
.	0

When	0
human	0
monocytes	7
or	0
alveolar	7
macrophages	8
are	0
cultured	0
in	0
the	0
presence	0
of	0
interleukin	9
(	10
IL	10
)	10
-4	10
or	0
IL-13	9
,	0
the	0
expression	0
of	0
the	0
reticulocyte-type	9
15-lipoxygenase	10
is	0
induced	0
.	0

In	0
mice	0
a	0
15-lipoxygenase	9
is	0
not	0
expressed	0
,	0
but	0
a	0
leukocyte-type	9
12-lipoxygenase	10
is	0
present	0
in	0
peritoneal	7
macrophages	8
.	0

To	0
investigate	0
whether	0
both	0
lipoxygenase	9
isoforms	10
exhibit	0
a	0
similar	0
regulatory	0
response	0
toward	0
cytokine	9
stimulation	0
,	0
we	0
studied	0
the	0
regulation	0
of	0
the	0
leukocyte-type	9
12-lipoxygenase	10
of	0
murine	7
peritoneal	8
macrophages	8
by	0
interleukins	9
and	0
found	0
that	0
the	0
activity	0
of	0
this	0
enzyme	9
is	0
upregulated	0
in	0
a	0
dose-dependent	0
manner	0
when	0
the	0
cells	0
were	0
cultured	0
in	0
the	0
presence	0
of	0
the	0
IL-4	9
or	0
IL-13	9
but	0
not	0
by	0
IL-10	9
.	0

When	0
peripheral	0
murine	0
monocytes	7
that	0
do	0
not	0
express	0
the	0
lipoxygenase	9
were	0
treated	0
with	0
IL-4	9
expression	0
of	0
12/15-lipoxygenase	3
mRNA	4
was	0
induced	0
,	0
suggesting	0
pretranslational	0
control	0
mechanisms	0
.	0

In	0
contrast	0
,	0
no	0
upregulation	0
of	0
the	0
lipoxygenase	9
activity	0
was	0
observed	0
when	0
the	0
macrophages	7
were	0
prepared	0
from	0
homozygous	0
STAT6	9
-deficient	0
mice	0
.	0

Peritoneal	7
macrophages	8
of	0
transgenic	0
mice	0
that	0
systemically	0
overexpress	0
IL-4	9
exhibited	0
a	0
threefold	0
to	0
fourfold	0
higher	0
12-lipoxygenase	9
activity	0
than	0
cells	0
prepared	0
from	0
control	0
animals	0
.	0

A	0
similar	0
upregulation	0
of	0
12-lipoxygenase	9
activity	0
was	0
detected	0
in	0
heart	0
,	0
spleen	0
,	0
and	0
lung	0
of	0
the	0
transgenic	0
animals	0
.	0

Moreover	0
,	0
a	0
strong	0
induction	0
of	0
the	0
enzyme	0
was	0
observed	0
in	0
red	7
cells	8
during	0
experimental	0
anemia	0
in	0
mice	0
.	0

The	0
data	0
presented	0
here	0
indicate	0
that	0
(	0
1	0
)	0
the	0
12-lipoxygenase	9
activity	0
of	0
murine	0
macrophages	0
is	0
upregulated	0
in	0
vitro	0
and	0
in	0
vivo	0
by	0
IL-4	9
and/or	0
IL-13	9
,	0
(	0
2	0
)	0
this	0
upregulation	0
requires	0
expression	0
of	0
the	0
transcription	9
factor	10
STAT6	9
,	0
and	0
(	0
3	0
)	0
the	0
constitutive	0
expression	0
of	0
the	0
enzyme	0
appears	0
to	0
be	0
STAT6	9
independent	0
.	0

The	0
cytokine	9
-dependent	0
upregulation	0
of	0
the	0
murine	9
macrophage	10
12-lipoxygenase	10
and	0
its	0
induction	0
during	0
experimental	0
anemia	0
suggests	0
its	0
close	0
relatedness	0
with	0
the	0
human	9
reticulocyte-type	10
15-lipoxygenase	10
despite	0
their	0
differences	0
in	0
the	0
positional	0
specificity	0
of	0
arachidonic	0
acid	0
oxygenation	0
.	0

Interferon-gamma-induced	9
factor	10
binding	0
to	0
the	0
interleukin-4-responsive	1
element	2
of	0
CD23b	1
promoter	2
in	0
human	7
tonsillar	8
mononuclear	8
cells	8
:	0
role	0
in	0
transient	0
up-regulation	0
of	0
the	0
interleukin-4-induced	3
CD23b	4
mRNA	4
.	0

Stimulation	0
of	0
human	7
tonsillar	8
mononuclear	8
cells	8
with	0
interleukin-4	9
(	0
IL-4	9
)	0
and	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
rapidly	0
induced	0
the	0
activation	0
of	0
distinct	0
nuclear	9
factors	10
with	0
different	0
mobilities	0
,	0
both	0
of	0
which	0
bind	0
the	0
IL-4	1
response	2
element	2
(	0
IL-4RE	1
)	0
of	0
CD23b	1
promoter	2
as	0
examined	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
.	0

Co-treatment	0
of	0
IL-4	9
and	0
IFN-gamma	9
induced	0
,	0
in	0
addition	0
to	0
the	0
two	0
distinct	0
complexes	0
,	0
a	0
new	0
complex	0
with	0
an	0
intermediate	0
mobility	0
.	0

The	0
IL-4-induced	9
complex	10
reacted	0
with	0
anti-STAT	9
(	10
signal	10
transducers	10
and	10
activators	10
of	10
transcription	10
)	10
6	10
,	0
resulting	0
in	0
a	0
supershift	0
whereas	0
the	0
formation	0
of	0
the	0
IFN-gamma-induced	9
complex	10
was	0
inhibited	0
by	0
anti-STAT	9
1	10
.	0

The	0
intermediate	0
complex	0
appeared	0
to	0
react	0
with	0
both	0
anti-STAT	9
6	10
and	0
anti-STAT	9
1	10
.	0

Although	0
IFN-gamma	9
alone	0
did	0
not	0
induce	0
CD23	3
mRNA	4
transcription	0
,	0
Northern	0
blot	0
analysis	0
revealed	0
a	0
transient	0
up-regulation	0
of	0
the	0
IL-4-induced	3
CD23	4
mRNA	4
by	0
IFN-gamma	9
within	0
2	0
h	0
of	0
IFN-gamma	9
treatment	0
in	0
these	0
tonsillar	7
cells	8
.	0

The	0
results	0
suggest	0
that	0
the	0
IL-4RE	1
of	0
the	0
IL-4-inducible	1
gene	2
can	0
accommodate	0
both	0
IL-4-	9
and	10
IFN-gamma-activated	10
factors	10
,	0
such	0
as	0
STAT	9
6	10
and	0
STAT	9
1	10
,	0
either	0
in	0
homodimeric	9
or	10
heterodimeric	10
forms	10
and	0
the	0
binding	0
of	0
these	0
different	0
proteins	0
to	0
the	0
respective	0
promoter	0
may	0
play	0
a	0
potential	0
regulatory	0
role	0
in	0
the	0
IL-4	9
-inducible	0
gene	0
expression	0
.	0

A	0
p56lck	9
-independent	0
pathway	0
of	0
CD2	9
signaling	0
involves	0
Jun	9
kinase	10
.	0

The	0
p56	9
Src	10
family	10
non-receptor	10
tyrosine	10
kinase	10
has	0
been	0
shown	0
to	0
be	0
critical	0
for	0
T	0
lymphocyte	0
differentiation	0
and	0
activation	0
.	0

Hence	0
in	0
the	0
absence	0
of	0
p56	9
,	0
T	9
cell	10
receptor	10
triggered	0
activation	0
does	0
not	0
occur	0
.	0

We	0
now	0
provide	0
evidence	0
for	0
a	0
CD2	9
-based	0
signaling	0
pathway	0
which	0
,	0
in	0
contrast	0
to	0
that	0
of	0
the	0
T	9
cell	10
receptor	10
,	0
is	0
independent	0
of	0
p56	9
.	0

CD2	9
-mediated	0
interleukin-2	9
production	0
occurs	0
via	0
activation	0
of	0
Jun	9
kinase	10
in	0
cell	0
lines	0
lacking	0
p56	9
.	0

Jun	9
kinase	10
then	0
facilitates	0
the	0
binding	0
of	0
c-Jun/c-Fos	9
heterodimers	10
to	0
the	0
AP-1	1
consensus	2
site	2
and	0
the	0
subsequent	0
transcriptional	0
activity	0
of	0
the	0
interleukin-2	1
promoter	2
.	0

These	0
data	0
elucidate	0
differences	0
between	0
TCR	9
and	0
CD2	9
signaling	0
pathways	0
in	0
the	0
same	0
T	7
cells	8
.	0

Activation	0
of	0
E2F	9
-mediated	0
transcription	0
by	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
I	10
Tax	10
protein	10
in	0
a	0
p16	5
(	6
INK4A	6
)	6
-negative	6
T-cell	6
line	6
.	0

The	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
is	0
a	0
causative	0
agent	0
of	0
adult	0
T-cell	0
leukemia	0
.	0

Although	0
the	0
exact	0
mechanism	0
by	0
which	0
HTLV-I	0
contributes	0
to	0
leukemogenesis	0
is	0
still	0
unclear	0
,	0
the	0
Tax	9
protein	10
is	0
thought	0
to	0
play	0
a	0
major	0
role	0
in	0
this	0
process	0
.	0

This	0
40-kDa	0
polypeptide	0
is	0
able	0
to	0
interact	0
with	0
the	0
tumor	9
suppressor	10
p16	9
(	10
INK4A	10
)	10
.	0

Consequently	0
,	0
Tax	9
can	0
activate	0
the	0
signaling	0
pathway	0
that	0
lead	0
to	0
the	0
release	0
of	0
E2F	9
that	0
in	0
turn	0
induces	0
expression	0
of	0
factors	0
required	0
for	0
cell	0
cycle	0
progression	0
.	0

In	0
this	0
paper	0
,	0
we	0
demonstrate	0
that	0
Tax	9
can	0
also	0
activate	0
E2F	9
-mediated	0
transcription	0
independently	0
of	0
p16	9
(	10
INK4A	10
)	10
.	0

Indeed	0
,	0
when	0
Tax	9
is	0
coexpressed	0
with	0
the	0
E2F-1	9
transcription	9
factor	10
in	0
CEM	5
T-cells	6
,	0
which	0
lack	0
expression	0
of	0
p16	9
(	10
INK4A	10
)	10
,	0
it	0
strongly	0
potentiates	0
the	0
E2F	9
-dependent	0
activation	0
of	0
a	0
reporter	0
construct	0
driven	0
by	0
a	0
promoter	0
containing	0
E2F	1
binding	2
sites	2
.	0

This	0
stimulation	0
is	0
abrogated	0
by	0
mutations	0
affecting	0
the	0
E2F-binding	1
sites	2
.	0

In	0
addition	0
,	0
Tax	9
also	0
stimulates	0
the	0
transcription	0
of	0
the	0
E2F-1	1
gene	2
itself	0
.	0

Using	0
Tax	9
mutants	0
that	0
fail	0
to	0
activate	0
either	0
ATF	9
-or	0
NF-kappaB-dependent	1
promoters	2
and	0
different	0
5	1
'	2
truncation	2
mutants	2
of	0
the	0
E2F-1	1
promoter	2
,	0
we	0
show	0
that	0
the	0
Tax	9
-dependent	0
transcriptional	0
control	0
of	0
the	0
E2F1	1
gene	2
involves	0
,	0
at	0
least	0
in	0
part	0
,	0
the	0
ATF	1
binding	2
site	2
located	0
in	0
the	0
E2F-1	1
promoter	2
.	0

Inducible	0
nitric	0
oxide	0
:	0
an	0
autoregulatory	0
feedback	0
inhibitor	0
of	0
vascular	0
inflammation	0
.	0

Inducible	0
nitric	0
oxide	0
(	0
iNO	0
)	0
is	0
produced	0
at	0
sites	0
of	0
vascular	0
inflammation	0
by	0
resident	0
and	0
nonresident	0
vascular	7
wall	8
cells	8
,	0
but	0
its	0
role	0
in	0
the	0
inflammatory	0
process	0
is	0
not	0
known	0
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
a	0
novel	0
function	0
of	0
iNO	0
is	0
to	0
terminate	0
inflammatory	0
processes	0
.	0

We	0
find	0
that	0
iNO	0
produced	0
by	0
murine	5
macrophage-like	6
cells	6
,	0
RAW264.7	5
,	0
can	0
inhibit	0
cytokine	9
-induced	0
endothelial	0
cell	0
activation	0
in	0
a	0
separated	0
and	0
mixed	0
endothelial-RAW264.7	5
coculture	6
system	6
.	0

Both	0
iNO	0
production	0
and	0
endothelial	0
VCAM-1	9
expression	0
were	0
induced	0
simultaneously	0
with	0
bacterial	0
LPS	0
and	0
murine-specific	9
IFN-gamma	10
.	0

Inhibition	0
of	0
iNO	9
synthase	10
(	0
iNOS	9
)	0
activity	0
with	0
N	0
omega-monomethyl-L-arginine	0
in	0
endothelial-RAW264.7	5
cocultures	6
,	0
stimulated	0
with	0
murine-specific	9
IFN-gamma	10
and	0
LPS	0
,	0
decreased	0
iNO	0
production	0
by	0
86	0
%	0
,	0
augmented	0
VCAM-1	9
and	0
iNOS	9
expression	0
in	0
endothelial	0
and	0
RAW264.7	5
cells	6
,	0
respectively	0
,	0
and	0
increased	0
monocyte	0
adhesion	0
to	0
the	0
endothelial	0
cell	0
surface	0
.	0

Transient	0
transfection	0
studies	0
using	0
various	0
VCAM-1	1
promoter	2
constructs	0
demonstrated	0
that	0
inhibitory	0
effects	0
of	0
iNO	0
on	0
VCAM-1	9
gene	0
transcription	0
were	0
mediated	0
,	0
in	0
part	0
,	0
by	0
inhibitory	0
effects	0
of	0
iNO	0
on	0
kappa	1
B	2
cis-acting	2
elements	2
.	0

Immunofluorescence	0
studies	0
using	0
an	0
Ab	0
to	0
the	0
RelA	9
(	10
p65	10
)	10
subunit	10
of	0
nuclear	0
factor-kappa	9
B	10
revealed	0
that	0
iNO	0
inhibited	0
the	0
activation	0
of	0
nuclear	9
factor-kappa	10
B	10
.	0

These	0
studies	0
indicate	0
that	0
iNO	0
attenuates	0
iNOS	9
expression	0
in	0
macrophages	7
and	0
inhibits	0
monocyte	0
adhesion	0
to	0
endothelial	7
cells	8
,	0
and	0
suggest	0
that	0
endogenously	0
derived	0
iNO	0
may	0
be	0
an	0
important	0
autoregulatory	0
inhibitor	0
of	0
vascular	0
inflammation	0

Detection	0
of	0
oestrogen	9
receptor	10
variants	10
in	0
endometrium	0
,	0
myometrium	0
,	0
leiomyoma	0
and	0
peripheral	7
blood	8
mononuclear	8
cells	8
:	0
comparison	0
to	0
variants	0
present	0
in	0
breast	0
cancer	0
.	0

Oestradiol	0
has	0
mitogenic	0
and	0
regulatory	0
effects	0
on	0
various	0
organs	0
and	0
cells	0
,	0
mediated	0
mainly	0
by	0
its	0
nuclear	9
receptor	10
(	0
ER	9
)	0
.	0

The	0
presence	0
of	0
aberrant	0
ER	9
forms	0
in	0
Oestrogen-dependent	0
tumours	0
has	0
been	0
discussed	0
in	0
correlation	0
with	0
tumour	0
progression	0
.	0

ER	9
variants	0
,	0
generated	0
by	0
alternative	0
splicing	0
,	0
have	0
been	0
detected	0
in	0
human	0
breast	0
cancer	0
,	0
but	0
also	0
in	0
normal	0
mammary	0
glands	0
,	0
therefore	0
their	0
role	0
in	0
tumorigenesis	0
has	0
been	0
questioned	0
.	0

We	0
have	0
investigated	0
,	0
by	0
the	0
use	0
of	0
the	0
reverse	0
transcription	0
polymerase	0
chain	0
reaction	0
amplification	0
technique	0
,	0
the	0
possible	0
existence	0
of	0
ER	9
variants	0
in	0
other	0
normal	0
oestrogen	0
target	0
organs	0
and	0
cells	0
,	0
such	0
as	0
uterus	0
(	0
myometrium	0
and	0
endometrium	0
)	0
,	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
in	0
a	0
benign	0
uterus	0
tumour	0
(	0
leiomyoma	0
)	0
.	0

We	0
have	0
detected	0
variant	0
ER	9
in	0
these	0
samples	0
and	0
have	0
compared	0
the	0
variant	0
profile	0
to	0
that	0
observed	0
in	0
breast	0
cancer	0
.	0

All	0
tissues	0
and	0
cells	0
studied	0
expressed	0
both	0
wild-type	9
ER	10
and	0
variant	9
species	10
.	0

Variant	0
forms	0
encompassed	0
ER	9
with	0
deletions	0
of	0
exons	1
2	2
,	2
5	2
and	2
7	2
.	0

Variants	0
with	0
exon	1
5	2
deleted	0
were	0
detected	0
only	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
in	0
breast	0
cancer	0
.	0

Variants	0
with	0
exons	1
2	2
and	2
7	2
deleted	0
were	0
present	0
in	0
all	0
specimens	0
tested	0
.	0

These	0
results	0
corroborate	0
previous	0
findings	0
that	0
the	0
presence	0
of	0
ER	9
variants	0
is	0
not	0
a	0
characteristic	0
of	0
breast	0
cancer	0
.	0

The	0
physiological	0
significance	0
and	0
possible	0
clinical	0
relevance	0
of	0
the	0
variant	0
ER	9
forms	0
remain	0
to	0
be	0
elucidated	0
.	0

p21ras	9
initiates	0
Rac-1	9
but	0
not	0
phosphatidyl	9
inositol	10
3	10
kinase/PKB	10
,	0
mediated	0
signaling	0
pathways	0
in	0
T	7
lymphocytes	8
.	0

p21ras	9
is	0
activated	0
by	0
the	0
T	9
cell	10
antigen	10
receptor	10
(	0
TCR	9
)	0
and	0
then	0
co-ordinates	0
important	0
signaling	0
pathways	0
for	0
T	9
lymphocyte	10
activation	0
.	0

Effector	0
pathways	0
for	0
this	0
guanine	9
nucleotide	10
binding	10
protein	10
in	0
T	7
cells	8
are	0
mediated	0
by	0
the	0
serine/threonine	9
kinase	10
Raf-1	9
and	0
the	0
Ras-related	9
GTPase	10
Rac-1	9
.	0

In	0
fibroblasts	7
,	0
an	0
important	0
effector	0
for	0
the	0
Ras	1
oncogene	2
is	0
Phosphatidylinositol	9
3-kinase	10
(	0
PtdIns	9
3-kinase	10
)	0
.	0

Activation	0
of	0
this	0
lipid	9
kinase	10
is	0
able	0
to	0
induce	0
critical	0
Rac-1	9
signaling	0
pathways	0
and	0
can	0
couple	0
p21ras	9
to	0
cell	0
survival	0
mechanisms	0
via	0
the	0
serine/threonine	9
kinase	10
Akt/PKB	10
.	0

The	0
role	0
of	0
PtdIns	9
3-kinase	10
in	0
Ras	9
signaling	0
in	0
T	7
cells	8
has	0
not	0
been	0
explored	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
examined	0
the	0
ability	0
of	0
PtdIns	9
3-kinase	10
to	0
initiate	0
the	0
Rac-1	9
signaling	0
pathways	0
important	0
for	0
T	0
cell	0
activation	0
.	0

We	0
also	0
examined	0
the	0
possibility	0
that	0
Akt/PKB	9
is	0
regulated	0
by	0
Ras	0
signaling	0
pathways	0
in	0
T	7
lymphocytes	8
.	0

The	0
results	0
show	0
that	0
Ras	9
can	0
initiate	0
a	0
Rac-1	9
mediated	0
pathway	0
that	0
regulates	0
the	0
transcriptional	0
function	0
of	0
AP-1	9
complexes	10
.	0

PtdIns	9
3-kinase	10
signals	0
can	0
not	0
mimic	0
p21ras	9
and	0
induce	0
the	0
Rac	9
mediated	0
responses	0
of	0
AP-1	9
transcriptional	0
activation	0
.	0

Moreover	0
,	0
neither	0
TCR	9
or	0
Ras	9
activation	0
of	0
AP-1	9
is	0
dependent	0
on	0
PtdIns	9
3-kinase	10
.	0

PKB	9
is	0
activated	0
in	0
response	0
to	0
triggering	0
of	0
the	0
T	9
cell	10
antigen	10
receptor	10
;	0
PtdIns	9
3-kinase	10
activity	0
is	0
both	0
required	0
and	0
sufficient	0
for	0
this	0
TCR	9
response	0
.	0

In	0
contrast	0
,	0
p21ras	9
signals	0
are	0
unable	0
to	0
induce	0
Akt/PKB	9
activity	0
in	0
T	7
cell	8
nor	0
is	0
Ras	9
function	0
required	0
for	0
Akt/PKB	9
activation	0
in	0
response	0
to	0
the	0
TCR	9
.	0

The	0
present	0
data	0
thus	0
highlight	0
that	0
PtdIns	9
3-kinase	10
and	0
Akt/PKB	9
are	0
not	0
universal	0
Ras	9
effector	10
molecules	10
.	0

Ras	9
can	0
initiate	0
Rac-1	9
regulated	0
signaling	0
pathways	0
in	0
the	0
context	0
of	0
T	9
cell	10
antigen	10
receptor	10
function	0
independently	0
of	0
PtdIns	9
3-kinase	10
activity	0
.	0

Interleukin	9
1beta	10
mediates	0
the	0
modulatory	0
effects	0
of	0
monocytes	7
on	0
LNCaP	7
human	8
prostate	8
cancer	8
cells	8
.	0

Proliferative	0
and	0
secretory	0
responses	0
in	0
androgen-sensitive	7
prostate	8
cancer	8
LNCaP	8
cells	8
are	0
regulated	0
by	0
steroid	0
and	0
peptide	0
hormones	0
and	0
by	0
differentiation-promoting	0
substances	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
evaluated	0
whether	0
peripheral	7
blood	8
monocytes	8
that	0
exhibit	0
anti-tumour	0
activity	0
in	0
haematopoietic	0
and	0
solid	0
tumours	0
influence	0
growth	0
and	0
secretion	0
in	0
the	0
LNCaP	5
cell	6
line	6
.	0

For	0
this	0
purpose	0
,	0
LNCaP	5
cells	6
were	0
incubated	0
with	0
monocyte-conditioned	0
medium	0
(	0
MCM	0
)	0
,	0
and	0
proliferation	0
as	0
well	0
as	0
expression	0
of	0
androgen	9
receptor	10
(	0
AR	9
)	0
and	0
secretion	0
of	0
prostate-specific	9
antigen	10
(	0
PSA	9
)	0
were	0
assessed	0
.	0

Conditioned	0
medium	0
from	0
monocytes	7
reduced	0
proliferation	0
in	0
a	0
dose-dependent	0
manner	0
.	0

Incubation	0
with	0
40	0
%	0
MCM	0
caused	0
a	0
50	0
%	0
reduction	0
in	0
cell	0
proliferation	0
.	0

AR	9
protein	10
decreased	0
by	0
70	0
%	0
and	0
PSA	9
levels	0
in	0
supernatants	0
from	0
LNCaP	5
cells	6
were	0
reduced	0
by	0
approximately	0
80	0
%	0
following	0
treatment	0
with	0
MCM	0
.	0

We	0
focused	0
on	0
the	0
contribution	0
of	0
two	0
major	0
products	0
of	0
activated	0
monocytes	7
,	0
prostaglandin	0
E2	0
and	0
interleukin	9
1beta	10
(	0
IL-1beta	9
)	0
,	0
to	0
the	0
MCM	0
modulatory	0
action	0
.	0

LNCaP	5
cells	6
treated	0
with	0
prostaglandin	0
E2	0
showed	0
neither	0
a	0
reduction	0
in	0
proliferation	0
nor	0
a	0
down-regulation	0
of	0
AR	9
and	0
PSA	9
levels	0
.	0

The	0
effects	0
of	0
MCM	0
on	0
cellular	0
proliferation	0
,	0
AR	9
protein	10
and	0
PSA	9
secretion	0
were	0
abolished	0
by	0
pretreatment	0
of	0
MCM	0
with	0
a	0
neutralizing	0
anti-IL-1beta	9
antibody	10
.	0

In	0
addition	0
,	0
recombinant	0
IL-1beta	9
was	0
able	0
to	0
replace	0
MCM	0
for	0
the	0
inhibition	0
of	0
proliferation	0
and	0
down-regulation	0
of	0
AR	9
and	0
PSA	9
proteins	0
.	0

LNCaP	5
cells	6
were	0
shown	0
to	0
express	0
the	0
IL-1beta	9
receptor	0
type	0
1	0
,	0
which	0
transduces	0
IL-1beta	9
signal	0
.	0

Our	0
findings	0
reveal	0
that	0
monocyte-derived	9
IL-1beta	10
inhibits	0
the	0
proliferation	0
of	0
androgen-responsive	7
prostate	8
tumour	8
cells	8
and	0
reduces	0
AR	9
and	0
PSA	9
levels	0
.	0

Differential	0
responsiveness	0
of	0
the	0
IL-5	1
and	2
IL-4	2
genes	2
to	0
transcription	9
factor	10
GATA-3	10
.	0

The	0
cytokines	9
IL-4	9
and	0
IL-5	9
are	0
often	0
coordinately	0
produced	0
by	0
Th2	5
cells	6
as	0
in	0
asthma	0
.	0

However	0
,	0
it	0
is	0
unclear	0
whether	0
similar	0
molecular	0
mechanisms	0
underlie	0
transcription	0
of	0
the	0
two	0
genes	1
.	0

We	0
have	0
previously	0
shown	0
that	0
the	0
transcription	9
factor	10
GATA-3	10
is	0
expressed	0
in	0
Th2	5
but	6
not	6
Th1	6
cells	6
and	0
is	0
crucial	0
for	0
activation	0
of	0
the	0
IL-5	1
promoter	2
by	0
different	0
stimuli	0
.	0

In	0
a	0
different	0
study	0
,	0
GATA-3	9
was	0
shown	0
to	0
be	0
sufficient	0
for	0
the	0
expression	0
of	0
IL-4	9
and	0
other	0
Th2	1
cytokine	2
genes	2
.	0

Here	0
,	0
we	0
show	0
that	0
ectopic	0
expression	0
of	0
GATA-3	9
is	0
sufficient	0
to	0
drive	0
IL-5	9
but	0
not	0
IL-4	9
gene	0
expression	0
.	0

Also	0
,	0
in	0
Th2	5
cells	6
,	0
antisense	0
GATA-3	9
RNA	0
inhibits	0
IL-5	9
but	0
not	0
IL-4	9
promoter	0
activation	0
.	0

The	0
induction	0
of	0
IL-5	1
gene	2
expression	0
by	0
GATA-3	9
involves	0
high	0
affinity	0
binding	0
of	0
GATA-3	9
to	0
an	0
inverted	0
GATA	1
repeat	2
in	0
the	0
IL-5	1
promoter	2
.	0

The	0
interleukin	1
2	2
receptor	2
alpha	2
chain/CD25	2
promoter	2
is	0
a	0
target	0
for	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

The	0
expression	0
of	0
the	0
murine	9
interleukin	10
(	10
IL	10
)	10
-2	10
receptor	10
alpha	10
chain/CD25	10
is	0
strongly	0
induced	0
at	0
the	0
transcriptional	0
level	0
after	0
T	0
cell	0
activation	0
.	0

We	0
show	0
here	0
that	0
nuclear	9
factor	10
of	10
activated	10
T	10
cell	10
(	10
NF-AT	10
)	10
factors	10
are	0
involved	0
in	0
the	0
control	0
of	0
CD25	1
promoter	2
induction	0
in	0
T	7
cells	8
.	0

NF-ATp	9
and	0
NF-ATc	9
bind	0
to	0
two	0
sites	0
around	0
positions	1
-585	2
and	2
-650	2
located	0
upstream	0
of	0
the	0
proximal	1
CD25	2
promoter	2
.	0

Immediately	0
3	0
'	0
from	0
these	0
NF-AT	1
motifs	2
,	0
nonconsensus	1
sites	2
are	0
located	0
for	0
the	0
binding	0
of	0
AP-1-like	9
factors	10
.	0

Mutations	0
of	0
sites	0
that	0
suppress	0
NF-AT	9
binding	0
impair	0
the	0
induction	0
and	0
strong	0
NF-ATp	9
-mediated	0
transactivation	0
of	0
the	0
CD25	1
promoter	2
in	0
T	7
cells	8
.	0

In	0
T	7
lymphocytes	8
from	0
NF-ATp	9
-deficient	0
mice	0
,	0
the	0
expression	0
of	0
CD25	9
is	0
severely	0
impaired	0
,	0
leading	0
to	0
a	0
delayed	0
IL-2	9
receptor	10
expression	0
after	0
T	0
cell	0
receptor	0
(	0
TCR	9
)	0
/	0
CD3	9
stimulation	0
.	0

Our	0
data	0
indicate	0
an	0
important	0
role	0
for	0
NF-AT	9
in	0
the	0
faithful	0
expression	0
of	0
high	9
affinity	10
IL-2	10
receptors	10
and	0
a	0
close	0
link	0
between	0
the	0
TCR	9
-mediated	0
induction	0
of	0
IL-2	9
and	0
IL-2	1
receptor	2
alpha	2
chain	2
promoters	2
,	0
both	0
of	0
which	0
are	0
regulated	0
by	0
NF-AT	9
factors	10
.	0

A	0
novel	0
mutation	0
in	0
the	0
coding	0
sequence	0
of	0
the	0
FY*B	1
allele	2
of	0
the	0
Duffy	1
chemokine	2
receptor	2
gene	2
is	0
associated	0
with	0
an	0
altered	0
erythrocyte	0
phenotype	0
.	0

The	0
Duffy	0
blood	0
group	0
system	0
is	0
of	0
clinical	0
and	0
biological	0
significance	0
.	0

Antibodies	9
to	0
Duffy	9
antigens	10
are	0
responsible	0
for	0
some	0
cases	0
of	0
transfusion	0
incompatibility	0
and	0
newborn	0
hemolytic	0
disease	0
.	0

The	0
Duffy	9
protein	10
is	0
a	0
receptor	0
for	0
the	0
Plasmodium	9
vivax	10
erythrocyte-binding	10
protein	10
and	0
is	0
also	0
a	0
receptor	0
for	0
various	0
chemokines	9
(	0
thus	0
renamed	0
Duffy	9
Antigen	10
Receptor	10
for	10
Chemokines	10
[	0
DARC	9
]	0
)	0
.	0

The	0
two	0
Duffy	9
polymorphic	10
antigens	10
,	0
Fya	9
and	0
Fyb	9
(	0
coded	0
by	0
the	0
FY*A	1
and	2
FY*B	2
alleles	2
)	0
,	0
are	0
present	0
on	0
erythrocyte	9
membranes	10
.	0

The	0
Fy	0
(	0
a-b-	0
)	0
phenotype	0
is	0
the	0
predominant	0
one	0
in	0
populations	0
of	0
black	0
people	0
and	0
also	0
occurs	0
in	0
other	0
populations	0
,	0
including	0
some	0
non-Ashkenazi	0
Jewish	0
groups	0
.	0

The	0
Fy	0
(	0
a-b-	0
)	0
phenotype	0
has	0
been	0
associated	0
with	0
a	0
mutation	0
in	0
the	0
FY*B	1
promoter	2
at	0
the	0
GATA	1
box	2
that	0
abolishes	0
the	0
expression	0
of	0
erythrocyte	9
Duffy	10
protein	10
.	0

We	0
describe	0
here	0
a	0
novel	0
mutation	0
,	0
present	0
in	0
the	0
FY*B	1
coding	2
sequence	2
(	0
271C	0
--	0
>	0
T	0
)	0
,	0
that	0
is	0
associated	0
with	0
some	0
Fy	0
(	0
b-	0
)	0
phenotypes	0
among	0
non-Ashkenazi	0
Jews	0
and	0
among	0
Brazilian	0
blacks	0
.	0

The	0
mutation	0
is	0
present	0
in	0
Fy	0
(	0
b-	0
)	0
individuals	0
,	0
who	0
have	0
wild-type	1
FY*B	2
GATA	2
and	0
carry	0
the	0
previously	0
described	0
304G	0
--	0
>	0
A	0
substitution	0
.	0

The	0
271C	0
--	0
>	0
T	0
and	0
304G	0
--	0
>	0
A	0
can	0
be	0
identified	0
by	0
restriction	1
enzyme-generated	2
restriction	2
fragment	2
length	2
polymorphisms	2
.	0

The	0
271C	0
--	0
>	0
T	0
substitution	0
represents	0
a	0
considerable	0
change	0
in	0
chemical	0
nature	0
(	0
Arg91	0
--	0
>	0
Cys	0
)	0
,	0
one	0
which	0
may	0
affect	0
the	0
antigenic	0
determinants	0
of	0
DARC	9
,	0
and	0
thus	0
be	0
of	0
clinical	0
significance	0
.	0

The	0
mutation	0
may	0
have	0
implications	0
for	0
some	0
physiological	0
roles	0
of	0
DARC	9
and	0
be	0
of	0
interest	0
in	0
malaria	0
research	0
and	0
in	0
studies	0
of	0
population	0
genetics	0
.	0

Establishment	0
and	0
characterization	0
of	0
EBV-positive	5
and	6
EBV-negative	6
primary	6
effusion	6
lymphoma	6
cell	6
lines	6
harbouring	0
human	0
herpesvirus	0
type-8	0
.	0

In	0
this	0
study	0
we	0
report	0
on	0
the	0
establishment	0
and	0
characterization	0
of	0
two	0
novel	0
lymphoma	5
cell	6
lines	6
(	0
CRO-AP/3	5
and	0
CRO-AP/5	5
)	0
which	0
carry	0
infection	0
by	0
human	0
herpesvirus	0
type-8	0
(	0
HHV-8	0
)	0
and	0
have	0
derived	0
from	0
AIDS-related	0
primary	0
effusion	0
lymphoma	0
(	0
PEL	5
)	0
.	0

These	0
two	0
cell	5
lines	6
are	0
representative	0
of	0
different	0
virologic	0
subtypes	0
of	0
PEL	5
,	0
i.e	0
.	0
HHV-8+/EBV-	5
PEL	6
in	0
the	0
case	0
of	0
CRO-AP/3	5
and	6
HHV-8+/EBV+	6
PEL	6
in	0
the	0
case	0
of	0
CRO-AP/5	5
.	0

Consistent	0
with	0
the	0
diagnosis	0
of	0
PEL	5
,	0
both	0
CRO-AP/3	5
and	0
CRO-AP/5	5
expressed	0
indeterminate	0
(	0
i.e.	0
non-B	0
,	0
non-T	0
)	0
phenotypes	0
although	0
immunogenotypic	0
studies	0
documented	0
their	0
B-cell	7
origin	8
.	0

Both	0
cell	5
lines	6
are	0
devoid	0
of	0
genetic	0
lesions	0
of	0
c-MYC	9
,	0
BCL-2	9
and	0
p53	9
as	0
well	0
as	0
gross	0
rearrangements	0
of	0
BCL-6	9
.	0

Detailed	0
histogenetic	0
characterization	0
of	0
these	0
novel	0
PEL	5
cell	6
lines	6
suggests	0
that	0
PEL	5
may	0
derive	0
from	0
a	0
post-germinal	5
centre	6
B	6
cell	6
which	0
has	0
undergone	0
pre-terminal	0
differentiation	0
.	0

The	0
CRO-AP/3	5
and	0
CRO-AP/5	5
cell	6
lines	6
may	0
provide	0
a	0
valuable	0
model	0
for	0
clarifying	0
the	0
pathogenesis	0
of	0
PEL	5
.	0

In	0
particular	0
,	0
these	0
cell	5
lines	6
may	0
help	0
understand	0
the	0
relative	0
contribution	0
of	0
HHV-8	0
and	0
EBV	0
to	0
PEL	0
growth	0
and	0
development	0
and	0
may	0
facilitate	0
the	0
identification	0
of	0
recurrent	0
cytogenetic	0
abnormalities	0
highlighting	0
putative	0
novel	0
cancer	0
related	0
loci	0
relevant	0
to	0
PEL	5
.	0

Two-site	0
interaction	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
with	0
activated	0
calcineurin	9
.	0

Transcription	9
factors	10
belonging	0
to	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	10
NFAT	10
)	10
family	10
regulate	0
the	0
expression	0
of	0
cytokine	1
genes	2
and	0
other	0
inducible	0
genes	0
during	0
the	0
immune	0
response	0
.	0

The	0
functions	0
of	0
NFAT	9
proteins	10
are	0
directly	0
controlled	0
by	0
the	0
calcium-	9
and	10
calmodulin-	10
dependent	10
phosphatase	10
calcineurin	9
.	0

Here	0
we	0
show	0
that	0
the	0
binding	0
of	0
calcineurin	9
to	0
NFAT	9
is	0
substantially	0
increased	0
when	0
calcineurin	9
is	0
activated	0
with	0
calmodulin	9
and	0
calcium	0
.	0

FK506.FKBP12	0
drug-immunophilin	0
complexes	0
inhibited	0
the	0
interaction	0
of	0
NFAT	9
with	0
activated	0
calcineurin	9
much	0
more	0
effectively	0
than	0
they	0
inhibited	0
the	0
interaction	0
with	0
inactive	0
calcineurin	9
,	0
suggesting	0
that	0
part	0
of	0
the	0
interaction	0
with	0
activated	0
calcineurin	9
involved	0
the	0
enzyme	1
active	2
site	2
.	0

We	0
have	0
previously	0
shown	0
that	0
NFAT	9
is	0
targeted	0
to	0
inactive	0
calcineurin	9
at	0
a	0
region	0
distinct	0
from	0
the	0
calcineurin	1
active	2
site	2
(	0
Aramburu	0
,	0
J.	0
,	0
Garcia-Cozar	0
,	0
F.	0
J.	0
,	0
Raghavan	0
,	0
A.	0
,	0
Okamura	0
,	0
H.	0
,	0
Rao	0
,	0
A.	0
,	0
and	0
Hogan	0
,	0
P.	0
G.	0
(	0
1998	0
)	0
Mol.	0
Cell	0
1	0
,	0
627-637	0
)	0
;	0
this	0
region	0
is	0
also	0
involved	0
in	0
NFAT	9
binding	0
to	0
activated	0
calcineurin	9
,	0
since	0
binding	0
is	0
inhibited	0
by	0
an	0
NFAT	0
peptide	0
spanning	0
the	0
calcineurin	9
docking	0
site	0
on	0
NFAT	9
.	0

The	0
interacting	0
surfaces	0
are	0
located	0
on	0
the	0
catalytic	9
domain	10
of	0
the	0
calcineurin	9
A	10
chain	10
and	0
on	0
an	0
86-amino	9
acid	10
fragment	10
of	0
the	0
NFAT	9
regulatory	10
domain	10
.	0

NFAT	9
binding	0
to	0
the	0
calcineurin	9
catalytic	10
domain	10
was	0
inhibited	0
by	0
the	0
calcineurin	9
autoinhibitory	10
domain	10
and	0
the	0
RII	0
substrate	0
peptide	0
,	0
which	0
bind	0
in	0
the	0
calcineurin	9
active	10
site	10
,	0
as	0
well	0
as	0
by	0
the	0
NFAT	9
docking	0
site	0
peptide	0
,	0
which	0
binds	0
to	0
a	0
region	0
of	0
calcineurin	9
distinct	0
from	0
the	0
active	9
site	10
.	0

We	0
propose	0
that	0
,	0
in	0
resting	7
cells	8
,	0
NFAT	9
is	0
targeted	0
to	0
a	0
region	0
of	0
the	0
calcineurin	9
catalytic	10
domain	10
that	0
does	0
not	0
overlap	0
the	0
calcineurin	9
active	10
site	10
.	0

Upon	0
cell	0
activation	0
,	0
displacement	0
of	0
the	0
autoinhibitory	9
domain	10
by	0
calmodulin	9
binding	0
allows	0
NFAT	9
to	0
bind	0
additionally	0
to	0
the	0
calcineurin	9
active	10
site	10
,	0
thus	0
positioning	0
NFAT	9
for	0
immediate	0
dephosphorylation	0
at	0
functional	0
phosphoserine	0
residues	0
.	0

Nuclear	9
factor-kappaB	10
induction	0
in	0
CD45RO+	7
and	8
CD45RA+	8
T	8
cell	8
subsets	8
during	0
aging	0
.	0

An	0
increase	0
in	0
the	0
ratio	0
of	0
memory	7
to	8
naive	8
T	8
cells	8
has	0
been	0
postulated	0
to	0
underlie	0
immune	0
hyporesponsiveness	0
accompanying	0
aging	0
.	0

Our	0
analyses	0
of	0
the	0
induction	0
of	0
nuclear	9
factor-kappaB	10
(	0
NFkappaB	9
)	0
in	0
activated	0
memory	7
(	8
CD45RO+	8
)	8
and	8
naive	8
(	8
CD45RA+	8
)	8
T	8
cell	8
subsets	8
from	0
young	0
and	0
elderly	0
donors	0
has	0
demonstrated	0
that	0
,	0
regardless	0
of	0
donor	0
age	0
,	0
memory	7
T	8
cells	8
are	0
not	0
significantly	0
altered	0
in	0
their	0
responsiveness	0
to	0
TNF-alpha	9
-mediated	0
induction	0
of	0
NFkappaB	9
.	0

Although	0
treatment	0
with	0
TNF-alpha	9
induced	0
nuclear	0
localization	0
of	0
NFkappaB	9
in	0
both	0
memory	7
and	8
naive	8
T	8
cell	8
subsets	8
,	0
irrespective	0
of	0
the	0
age	0
of	0
the	0
donor	0
,	0
the	0
levels	0
of	0
induced	0
NFkappaB	9
were	0
significantly	0
lower	0
in	0
both	0
subsets	0
of	0
T	7
cells	8
obtained	0
from	0
the	0
elderly	0
,	0
when	0
compared	0
to	0
those	0
in	0
young	0
.	0

Examination	0
of	0
IkappaB	9
alpha	10
regulation	0
revealed	0
that	0
TNF-alpha	9
-mediated	0
degradation	0
of	0
IkappaB	9
alpha	10
in	0
both	0
memory	7
and	8
naive	8
T	8
cells	8
from	0
the	0
elderly	0
was	0
severely	0
impaired	0
,	0
thus	0
contributing	0
to	0
the	0
lowered	0
induction	0
of	0
the	0
observed	0
NFkappaB	9
.	0

In	0
addition	0
,	0
this	0
age-related	0
decrease	0
in	0
induction	0
of	0
nuclear	9
NFkappaB	10
correlated	0
with	0
decrease	0
in	0
intracellular	0
IL-2	9
receptor	0
expression	0
and	0
anti-CD3	9
-induced	0
proliferation	0
of	0
both	0
memory	7
and	8
naive	8
T	8
cells	8
subsets	8
.	0

Taken	0
together	0
,	0
our	0
results	0
suggest	0
that	0
the	0
age-related	0
hyporesponsiveness	0
can	0
not	0
be	0
attributed	0
to	0
a	0
skewing	0
of	0
the	0
T	0
cell	0
population	0
towards	0
a	0
memory	0
phenotype	0
in	0
the	0
elderly	0
.	0

Cyclosporin	0
A-resistant	0
transactivation	0
of	0
the	0
IL-2	1
promoter	2
requires	0
activity	0
of	0
okadaic	9
acid-sensitive	10
serine/threonine	10
phosphatases	10
.	0

Expression	0
of	0
the	0
IL-2	1
gene	2
requires	0
activation	0
of	0
T	7
cells	8
through	0
stimulation	0
of	0
the	0
TCR	9
and	0
costimulation	0
through	0
accessory	9
receptors	10
.	0

We	0
have	0
found	0
recently	0
that	0
okadaic	9
acid-sensitive	10
Ser/Thr	10
phosphatases	10
are	0
involved	0
in	0
a	0
cyclosporin	0
A-insensitive	0
pathway	0
that	0
selectively	0
transmits	0
costimulatory	0
signals	0
.	0

In	0
this	0
study	0
,	0
we	0
analyzed	0
whether	0
activities	0
of	0
these	0
phosphatases	0
are	0
necessary	0
for	0
the	0
expression	0
of	0
the	0
IL-2	1
gene	2
.	0

In	0
both	0
activated	7
peripheral	8
blood	8
T	8
lymphocytes	8
and	0
activated	5
tumorigenic	6
T	6
cell	6
lines	6
,	0
IL-2	9
gene	0
expression	0
was	0
blocked	0
at	0
the	0
transcriptional	0
level	0
by	0
okadaic	0
acid	0
.	0

The	0
transcription	9
factors	10
active	0
at	0
the	0
IL-2	1
promoter	2
were	0
differentially	0
influenced	0
:	0
upon	0
down-modulation	0
of	0
okadaic	9
acid-sensitive	10
phosphatases	10
,	0
transactivation	0
by	0
octamer	0
,	0
NF-kappa	9
B	10
,	0
and	0
NF	9
of	10
activated	10
T	10
cells	10
proteins	10
was	0
abrogated	0
,	0
while	0
transactivation	0
by	0
AP-1	9
proteins	10
was	10
even	10
enhanced	10
.	10

YM268	0
increases	0
the	0
glucose	0
uptake	0
,	0
cell	0
differentiation	0
,	0
and	0
mRNA	0
expression	0
of	0
glucose	9
transporter	10
in	0
3T3-L1	7
adipocytes	8
.	0

The	0
purpose	0
of	0
this	0
study	0
was	0
to	0
examine	0
the	0
effects	0
of	0
bis	0
[	0
4-	0
[	0
2	0
,	0
4-dioxo-5-thiazolidinyl	0
)	0
methyl	0
]	0
phenyl	0
]	0
methane	0
(	0
YM-268	0
)	0
,	0
a	0
thiazolidinedione	0
derivative	0
,	0
on	0
glucose	0
uptake	0
,	0
adipocyte	7
differentiation	0
through	0
peroxisome	9
proliferator-activated	10
receptor	10
gamma	10
(	0
PPARgamma	9
)	0
,	0
and	0
phosphatidylinositol	9
3-kinase	10
(	0
PI	9
3-kinase	10
)	0
activity	0
in	0
cultured	5
cells	6
.	0

YM268	0
and	0
pioglitazone	0
dose-dependently	0
increased	0
the	0
2-deoxyglucose	0
uptake	0
in	0
3T3-L1	5
cells	6
.	0

YM268	0
facilitated	0
the	0
insulin-stimulated	0
triglyceride	0
accumulation	0
in	0
3T3-L1	7
adipocytes	8
and	0
increased	0
the	0
mRNA	0
expression	0
of	0
fatty	9
acid-binding	10
protein	10
.	0

YM268	0
,	0
with	0
and	0
without	0
insulin	0
,	0
increased	0
the	0
mRNA	0
expression	0
of	0
glucose	9
transporter	10
isoforms	0
such	0
as	0
GLUT1	9
and	0
GLUT4	9
,	0
indicating	0
enhancement	0
of	0
adipocyte	7
differentiation	0
.	0

Additionally	0
,	0
YM268	0
and	0
pioglitazone	0
showed	0
activity	0
of	0
the	0
PPARgamma	9
ligand	10
,	0
a	0
member	0
of	0
the	0
nuclear	9
receptor	10
superfamily	10
responsible	0
for	0
adipogenesis	0
.	0

To	0
examine	0
the	0
possible	0
involvement	0
of	0
the	0
increased	0
activity	0
of	0
PI	9
3-kinase	10
in	0
YM268-stimulated	0
glucose	0
uptake	0
,	0
the	0
enzyme	0
activity	0
was	0
estimated	0
by	0
measuring	0
the	0
phosphatidylinositol-3	0
,	0
4	0
,	0
5-trisphosphate	0
(	0
PI-3	0
,	0
4	0
,	0
5-P3	0
)	0
concentration	0
in	0
human	7
monocytic	8
cells	8
.	0

Insulin	0
dose-dependently	0
increased	0
the	0
PI-3	0
,	0
4	0
,	0
5-P3	0
production	0
but	0
YM268	0
had	0
no	0
significant	0
effect	0
on	0
the	0
insulin-dependent	0
and	0
-independent	0
PI	0
3-kinase	0
activation	0
.	0

These	0
results	0
indicate	0
that	0
the	0
mechanism	0
by	0
which	0
YM268	0
increased	0
glucose	0
uptake	0
,	0
may	0
be	0
accounted	0
for	0
in	0
part	0
by	0
the	0
enhancement	0
of	0
GLUT1	9
and	0
GLUT4	9
expression	0
through	0
PPARgamma	9
activation	0
.	0

The	0
nuclear	9
receptor	10
PPARgamma	9
-	0
bigger	0
than	0
fat	0
.	0

Work	0
reported	0
over	0
the	0
past	0
year	0
has	0
provided	0
insights	0
into	0
the	0
mechanisms	0
whereby	0
ligand	0
activation	0
of	0
the	0
nuclear	9
receptor	10
peroxisome	10
proliferator-activated	10
receptor	10
gamma	10
(	0
PPARgamma	9
)	0
regulates	0
systemic	0
glucose	0
and	0
lipid	0
homeostasis	0
.	0

PPARgamma	9
has	0
also	0
been	0
implicated	0
recently	0
in	0
the	0
biology	0
of	0
monocytes	0
and	0
in	0
cell-cycle	0
regulation	0
and	0
cancer	0
.	0

Polyunsaturated	0
fatty	0
acids	0
and	0
eicosanoids	0
bind	0
and	0
activate	0
PPARgamma	9
,	0
suggesting	0
that	0
these	0
lipids	0
may	0
serve	0
as	0
hormonal	0
regulators	0
of	0
a	0
variety	0
of	0
biological	0
processes	0
.	0

The	0
role	0
of	0
caspases	0
in	0
T	0
cell	0
development	0
and	0
the	0
control	0
of	0
immune	0
responses	0
.	0

Apoptosis	0
is	0
responsible	0
for	0
the	0
removal	0
of	0
potentially	0
autoreactive	0
or	0
useless	0
T	0
cells	0
during	0
thymic	0
selection	0
and	0
activated	7
T	8
cells	8
in	0
the	0
periphery	0
.	0

Specific	0
families	0
of	0
receptors	9
,	0
kinases	9
,	0
transcription	9
factors	10
,	0
and	0
cysteine	9
proteases	10
,	0
termed	9
caspases	10
,	0
are	0
involved	0
in	0
the	0
apoptotic	0
cascade	0
leading	0
to	0
proteolysis	0
of	0
specific	0
substrates	0
and	0
to	0
morphological	0
changes	0
associated	0
with	0
programmed	0
cell	0
death	0
.	0

Although	0
common	0
members	0
of	0
the	0
apoptotic	0
cascade	0
are	0
shared	0
between	0
different	0
cell	0
types	0
,	0
it	0
appears	0
that	0
cell-specific	9
factors	10
can	0
influence	0
the	0
response	0
to	0
a	0
given	0
apoptotic	0
stimuli	0
.	0

Characterization	0
and	0
understanding	0
of	0
the	0
basic	0
mechanisms	0
involved	0
in	0
the	0
different	0
pathways	0
protecting	0
or	0
leading	0
to	0
cell	0
death	0
may	0
provide	0
novel	0
ways	0
to	0
control	0
inappropriate	0
apoptosis	0
involved	0
in	0
several	0
diseases	0
.	0

Cross-priming	0
of	0
CTL	0
responses	0
in	0
vivo	0
does	0
not	0
require	0
antigenic	0
peptides	0
in	0
the	0
endoplasmic	0
reticulum	0
of	0
immunizing	7
cells	8
.	0

It	0
has	0
been	0
proposed	0
that	0
the	0
cross-priming	0
of	0
CTL	0
responses	0
in	0
vivo	0
involves	0
the	0
transfer	0
to	0
host	0
APCs	7
of	0
heat	9
shock	10
protein	10
glycoprotein	10
96	10
-chaperoned	0
antigenic	0
peptides	0
released	0
from	0
the	0
endoplasmic	0
reticulum	0
(	0
ER	0
)	0
of	0
dying	7
or	8
infected	8
cells	8
.	0

We	0
have	0
tested	0
this	0
possibility	0
directly	0
using	0
TAP-deficient	5
cell	6
lines	6
lacking	0
antigenic	0
ER	0
peptides	0
derived	0
from	0
two	0
model	0
Ags	9
,	0
the	0
human	9
adenovirus	10
type	10
5	10
early	10
regions	10
E1A	10
and	10
E1B	10
.	0

Although	0
both	0
proteins	0
were	0
well	0
expressed	0
,	0
the	0
cells	0
were	0
not	0
recognized	0
by	0
E1A-	7
or	8
E1B-specific	8
CTLs	8
unless	0
the	0
relevant	0
epitope	0
was	0
either	0
provided	0
exogenously	0
as	0
a	0
synthetic	0
peptide	0
or	0
targeted	0
to	0
the	0
ER	0
in	0
a	0
TAP-independent	0
fashion	0
.	0

Despite	0
the	0
absence	0
of	0
these	0
ER	0
peptides	0
,	0
the	0
TAP1-/-	7
cells	8
were	0
able	0
to	0
efficiently	0
cross-prime	7
E1A-	8
and	8
E1B-specific	8
CTLs	8
following	0
immunization	0
of	0
syngeneic	0
mice	0
.	0

These	0
results	0
indicate	0
that	0
,	0
although	0
purified	0
peptide/glycoprotein	9
96	10
complexes	10
are	0
potent	0
immunogens	0
,	0
the	0
mechanism	0
of	0
CTL	0
cross-priming	0
in	0
vivo	0
does	0
not	0
depend	0
upon	0
antigenic	0
peptides	0
in	0
the	0
ER	0
of	0
immunizing	7
cells	8
.	0

A	0
critical	0
role	0
of	0
the	0
p75	9
tumor	10
necrosis	10
factor	10
receptor	10
(	0
p75TNF-R	9
)	0
in	0
organ	0
inflammation	0
independent	0
of	0
TNF	9
,	0
lymphotoxin	9
alpha	10
,	0
or	0
the	0
p55TNF-R	9
.	10

Despite	0
overwhelming	0
evidence	0
that	0
enhanced	0
production	0
of	0
the	0
p75	9
tumor	10
necrosis	10
factor	10
receptor	10
(	0
p75TNF-R	9
)	0
accompanies	0
development	0
of	0
specific	0
human	0
inflammatory	0
pathologies	0
such	0
as	0
multi-organ	0
failure	0
during	0
sepsis	0
,	0
inflammatory	0
liver	0
disease	0
,	0
pancreatitis	0
,	0
respiratory	0
distress	0
syndrome	0
,	0
or	0
AIDS	0
,	0
the	0
function	0
of	0
this	0
receptor	0
remains	0
poorly	0
defined	0
in	0
vivo	0
.	0

We	0
show	0
here	0
that	0
at	0
levels	0
relevant	0
to	0
human	0
disease	0
,	0
production	0
of	0
the	0
human	9
p75TNF-R	10
in	0
transgenic	0
mice	0
results	0
in	0
a	0
severe	0
inflammatory	0
syndrome	0
involving	0
mainly	0
the	0
pancreas	0
,	0
liver	0
,	0
kidney	0
,	0
and	0
lung	0
,	0
and	0
characterized	0
by	0
constitutively	0
increased	0
NF-kappaB	9
activity	0
in	0
the	0
peripheral	7
blood	8
mononuclear	8
cell	8
compartment	0
.	0

This	0
process	0
is	0
shown	0
to	0
evolve	0
independently	0
of	0
the	0
presence	0
of	0
TNF	9
,	0
lymphotoxin	9
alpha	10
,	0
or	0
the	0
p55TNF-R	9
,	0
although	0
coexpression	0
of	0
a	0
human	1
TNF	2
transgene	2
accelerated	0
pathology	0
.	0

These	0
results	0
establish	0
an	0
independent	0
role	0
for	0
enhanced	0
p75TNF-R	9
production	0
in	0
the	0
pathogenesis	0
of	0
inflammatory	0
disease	0
and	0
implicate	0
the	0
direct	0
involvement	0
of	0
this	0
receptor	0
in	0
a	0
wide	0
range	0
of	0
human	0
inflammatory	0
pathologies	0
.	0

Expression	0
status	0
of	0
BCL-6	9
and	0
syndecan-1	9
identifies	0
distinct	0
histogenetic	0
subtypes	0
of	0
Hodgkin	0
's	0
disease	0
.	0

The	0
tumor	7
cells	8
in	0
most	0
cases	0
of	0
Hodgkin	0
's	0
disease	0
(	0
HD	0
)	0
have	0
been	0
recently	0
recognized	0
to	0
originate	0
from	0
the	0
B-cell	7
lineage	8
,	0
but	0
their	0
precise	0
differentiation	0
stage	0
is	0
not	0
fully	0
clarified	0
.	0

Recently	0
,	0
we	0
have	0
reported	0
that	0
the	0
histogenesis	0
of	0
B-cell	7
lymphomas	8
may	0
be	0
assessed	0
by	0
monitoring	0
the	0
expression	0
pattern	0
of	0
BCL-6	9
,	0
a	0
transcription	9
factor	10
expressed	0
in	0
germinal	7
center	8
(	8
GC	8
)	8
B	8
cells	8
,	0
and	0
CD138/syndecan-1	9
(	0
syn-1	9
)	0
,	0
a	0
proteoglycan	0
associated	0
with	0
post-GC	0
,	0
terminal	0
B-cell	0
differentiation	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
applied	0
these	0
two	0
markers	0
to	0
the	0
study	0
of	0
HD	0
histogenesis	0
.	0

We	0
have	0
found	0
that	0
in	0
nodular	0
lymphocyte	0
predominance	0
HD	0
(	0
NLPHD	0
)	0
tumor	7
cells	8
consistently	0
display	0
the	0
BCL-6	9
(	0
+	0
)	0
/	0
syn-1	9
(	0
-	0
)	0
phenotype	0
,	0
indicating	0
their	0
derivation	0
from	0
GC	7
B	8
cells	8
.	0

Conversely	0
,	0
classic	0
HD	0
(	0
CHD	0
)	0
is	0
heterogeneous	0
because	0
the	0
tumor	7
cells	8
of	0
a	0
fraction	0
of	0
CHD	0
display	0
the	0
BCL-6	9
(	0
-	0
)	0
/	0
syn-1	9
(	0
+	0
)	0
phenotype	0
of	0
post-GC	0
B-cells	0
,	0
whereas	0
another	0
fraction	0
of	0
CHD	0
is	0
constituted	0
by	0
a	0
mixture	0
of	0
tumor	7
cells	8
reflecting	0
the	0
GC	0
(	0
BCL-6	9
(	0
+	0
)	0
/	0
syn-1	9
(	0
-	0
)	0
)	0
or	0
post-GC	0
(	0
BCL-6	9
(	0
-	0
)	0
/	0
syn-1	9
(	0
+	0
)	0
)	0
phenotypes	0
.	0

BCL-6	5
(	6
-	6
)	6
/syn-1	6
(	6
+	6
)	6
tumor	6
cells	6
of	0
CHD	0
are	0
mostly	0
found	0
surrounded	0
by	0
T	7
cells	8
expressing	0
CD40L	9
,	0
consistent	0
with	0
the	0
observation	0
that	0
CD40	9
signaling	0
downregulates	0
BCL-6	9
expression	0
.	0

These	0
data	0
indicate	0
that	0
tumor	7
cells	8
of	0
NLPHD	0
uniformly	0
display	0
a	0
GC	0
B-cell	0
phenotype	0
,	0
whereas	0
the	0
phenotype	0
of	0
tumor	7
cells	8
of	0
CHD	0
appears	0
to	0
be	0
modulated	0
by	0
the	0
surrounding	0
cellular	0
background	0
,	0
particularly	0
CD40L+	7
reactive	8
T	8
cells	8
.	0

Molecular	0
and	0
cellular	0
analysis	0
of	0
human	0
immunodeficiency	0
virus-induced	0
apoptosis	0
in	0
lymphoblastoid	9
T-cell-line-expressing	10
wild-type	10
and	10
mutated	10
CD4	10
receptors	10
.	0

We	0
have	0
previously	0
shown	0
that	0
the	0
presence	0
of	0
the	0
CD4	9
cytoplasmic	10
tail	10
is	0
critical	0
for	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
-induced	0
apoptosis	0
(	0
J.Corbeil	0
,	0
M.Tremblay	0
,	0
and	0
D.D.Richman	0
,	0
J.Exp.Med.183	0
:	0
39-48	0
,	0
1996	0
)	0
.	0

We	0
have	0
pursued	0
our	0
investigation	0
of	0
the	0
role	0
of	0
the	0
CD4	9
transduction	0
pathway	0
in	0
HIV-induced	0
apoptosis	0
.	0

To	0
do	0
this	0
,	0
wild-type	0
and	0
mutant	0
forms	0
of	0
the	0
CD4	9
cytoplasmic	10
tail	10
were	0
stably	0
expressed	0
in	0
the	0
lymphoblastoid	5
T-cell	6
line	6
A2.01	5
.	0

Apoptosis	0
was	0
prevented	0
when	0
CD4	9
truncated	0
at	0
residue	0
402	0
was	0
expressed	0
;	0
however	0
,	0
cells	0
expressing	0
mutated	0
receptors	0
that	0
do	0
not	0
associate	0
with	0
p56	9
(	10
lck	10
)	10
(	0
mutated	0
at	0
the	0
dicysteine	9
motif	10
and	0
truncated	0
at	0
residue	0
418	0
)	0
but	0
which	0
conserved	0
proximal	0
domains	0
of	0
the	0
cytoplasmic	9
tail	10
underwent	0
apoptosis	0
like	0
wild-	9
type	10
CD4	10
.	0

The	0
differences	0
between	0
wild-type	9
and	10
mutated	10
receptors	10
in	0
the	0
induction	0
of	0
apoptosis	0
were	0
not	0
related	0
to	0
levels	0
of	0
p56	9
(	10
lck	10
)	10
or	0
NF-	9
kappaB	10
activation	0
.	0

Initial	0
signaling	0
through	0
the	0
CD4	9
receptor	10
played	0
a	0
major	0
role	0
in	0
the	0
sensitization	0
of	0
HIV-infected	7
T	8
cells	8
to	0
undergo	0
apoptosis	0
.	0

Incubation	0
of	0
HIV-infected	7
cells	8
with	0
monoclonal	9
antibody	10
(	10
MAb	10
)	10
13B8-2	10
,	0
which	0
binds	0
to	0
CD4	9
in	0
a	0
region	0
critical	0
for	0
dimerization	0
of	0
the	0
receptor	0
,	0
prevented	0
apoptosis	0
without	0
inhibiting	0
HIV	0
replication	0
.	0

Moreover	0
,	0
the	0
apoptotic	0
process	0
was	0
not	0
related	0
to	0
Fas	9
-Fas	9
ligand	10
interaction	0
;	0
however	0
,	0
an	0
antagonistic	0
anti-Fas	0
MAb	0
(	0
ZB-4	0
)	0
enhanced	0
apoptosis	0
in	0
HIV-infected	7
cells	8
without	0
inducing	0
apoptosis	0
in	0
uninfected	7
cells	8
.	0

These	0
observations	0
demonstrate	0
that	0
CD4	9
signaling	0
mediates	0
HIV-induced	0
apoptosis	0
by	0
a	0
mechanism	0
independent	0
of	0
Fas	9
-Fas	9
ligand	10
interaction	0
,	0
does	0
not	0
require	0
p56	9
(	10
lck	10
)	10
signaling	0
,	0
and	0
may	0
involve	0
a	0
critical	0
region	0
for	0
CD4	9
dimerization	0
.	0

p130	9
,	0
p107	9
,	0
and	0
pRb	9
are	0
differentially	0
regulated	0
in	0
proliferating	7
cells	8
and	0
during	0
cell	0
cycle	0
arrest	0
by	0
alpha-interferon	9
.	0

We	0
have	0
determined	0
how	0
the	0
phosphorylation	0
of	0
the	0
retinoblastoma	9
family	10
(	0
pRb	9
,	0
p107	9
,	0
and	0
p130	9
)	0
is	0
governed	0
in	0
individual	0
cell	0
cycle	0
phases	0
of	0
Daudi	5
B-cells	6
during	0
cell	0
cycle	0
exit	0
triggered	0
by	0
alpha-interferon	9
(	0
alpha-IFN	9
)	0
.	0

alpha-IFN	9
causes	0
dephosphorylation	0
of	0
pRb	9
and	0
loss	0
of	0
p130	9
phosphorylated	10
Form	10
3	10
.	0

However	0
,	0
the	0
change	0
in	0
p130	9
phosphorylation	0
in	0
response	0
to	0
alpha-IFN	9
occurs	0
before	0
dephosphorylation	0
of	0
pRb	9
is	0
complete	0
because	0
loss	0
of	0
p130	9
Form	10
3	10
occurs	0
throughout	0
the	0
cell	0
cycle	0
prior	0
to	0
complete	0
arrest	0
in	0
G1	0
,	0
whereas	0
pRb	9
is	0
dephosphorylated	0
only	0
in	0
G1	0
.	0

In	0
contrast	0
,	0
p107	9
is	0
dephosphorylated	0
and	0
is	0
then	0
depleted	0
from	0
cells	0
as	0
they	0
exit	0
the	0
cell	0
cycle	0
.	0

p130	9
,	0
predominantly	0
in	0
Form	0
1	0
,	0
and	0
hypophosphorylated	9
pRb	10
bind	0
an	0
E2F	1
DNA	2
binding	2
site	2
;	0
p130	9
complexes	0
E2F-4	9
,	0
whereas	0
pRb	9
binds	0
both	0
E2F-4	0
and	0
E2F-1	9
.	0

The	0
phosphorylated	0
forms	0
of	0
E2F-4	9
that	0
bind	0
to	0
the	0
E2F	1
DNA	2
site	2
are	0
different	0
from	0
hyperphosphorylated	0
E2F-4	9
,	0
which	0
predominates	0
in	0
primary	7
hemopoietic	8
cells	8
in	0
G0	0
.	0

We	0
conclude	0
that	0
although	0
cell	0
cycle	0
arrest	0
induced	0
by	0
alpha-IFN	9
may	0
be	0
mediated	0
in	0
part	0
by	0
formation	0
of	0
a	0
complex	0
containing	0
p130	9
and	0
E2F-4	9
,	0
alpha-IFN	9
does	0
not	0
induce	0
hyperphosphorylation	0
of	0
E2F-4	9
,	0
which	0
characterizes	0
primary	7
hemopoietic	8
cells	8
in	0
G0	0
.	0

The	0
transcription	9
factors	10
c-myb	9
and	0
C/EBP	9
alpha	10
regulate	0
the	0
monocytic/myeloic	1
gene	2
MRP14	1
.	0

The	0
entry	0
of	0
microorganisms	0
into	0
the	0
body	0
induces	0
inflammatory	0
processes	0
.	0

During	0
this	0
process	0
a	0
sequence	0
of	0
cellular	0
,	0
humoral	0
,	0
non-specific	0
and	0
specific	0
actions	0
are	0
evoked	0
to	0
combat	0
the	0
infection	0
.	0

Macrophages	7
and	0
granulocytes	7
,	0
which	0
are	0
developed	0
from	0
a	0
common	0
progenitor	0
cell	0
,	0
are	0
the	0
cellular	0
components	0
of	0
the	0
specific	0
and	0
non-specific	0
immunoreaction	0
.	0

MRP14	1
(	0
Macrophage	9
migration	10
inhibitory	10
related	10
protein	10
)	0
and	0
MRP8	9
,	0
two	0
S-100	9
proteins	10
contained	0
in	0
high	0
concentrations	0
in	0
these	0
cells	0
are	0
obviously	0
essential	0
for	0
adhesion	0
and	0
migration	0
of	0
monocytes	7
and	0
granulocytes	7
.	0

To	0
investigate	0
the	0
transcriptional	0
regulation	0
of	0
these	0
genes	0
we	0
cotransfected	0
constructs	0
expressing	0
CAT	9
under	0
control	0
of	0
the	0
MRP14	1
promoter	2
and	0
expression	0
constructs	0
of	0
C/EBP	9
alpha	10
and	0
v-myb	9
,	0
two	0
transcription	9
factors	10
involved	0
in	0
myeloid/monocytic	0
differentiation	0
.	0

Transfection	0
with	0
C/EBP	9
alpha	10
revealed	0
a	0
massive	0
enhancement	0
of	0
the	0
MRP14	1
promoter	2
in	0
both	0
,	0
HL	7
60	8
cells	8
(	0
granulocytic	0
differentiated	0
)	0
and	0
L132	7
fibroblasts	8
.	0

In	0
contrast	0
,	0
v-myb	9
reduces	0
MRP14	1
promoter	2
activity	0
.	0

Northern	0
blot	0
analysis	0
of	0
L132	7
cells	8
transfected	0
with	0
the	0
C/EBP	9
alpha	10
expression	0
vector	0
demonstrate	0
that	0
C/EBP	9
alpha	10
is	0
sufficient	0
to	0
enhance	0
MRP14	9
expression	0
in	0
the	0
context	0
of	0
the	0
whole	0
genome	0
.	0

A	0
CD28	9
-associated	0
signaling	0
pathway	0
leading	0
to	0
cytokine	1
gene	2
transcription	0
and	0
T	0
cell	0
proliferation	0
without	0
TCR	9
engagement	0
.	0

Stimulation	0
of	0
resting	7
human	8
T	8
cells	8
with	0
the	0
CD28-specific	9
mAb	10
BW	10
828	10
induces	0
proliferation	0
and	0
cytokine	9
synthesis	0
without	0
further	0
requirement	0
for	0
TCR	9
coengagement	0
.	0

This	0
observation	0
prompted	0
us	0
to	0
postulate	0
that	0
signal	0
2	0
(	0
costimulatory	0
signal	0
)	0
alone	0
without	0
signal	0
1	0
(	0
TCR	9
signal	0
)	0
can	0
activate	0
T	7
cells	8
.	0

To	0
test	0
whether	0
this	0
putative	0
function	0
of	0
CD28	9
is	0
mediated	0
via	0
a	0
particular	0
signaling	0
pathway	0
,	0
we	0
compared	0
early	0
signaling	0
events	0
initiated	0
in	0
resting	0
T	7
cells	8
by	0
the	0
stimulatory	9
mAb	10
BW	10
828	10
with	0
signals	0
triggered	0
by	0
the	0
nonstimulating	9
CD28	10
mAb	10
9.3	10
.	0

Stimulation	0
of	0
T	7
cells	8
with	0
BW	9
828	10
induced	0
an	0
increase	0
in	0
intracellular	0
Ca2+	0
,	0
but	0
did	0
not	0
lead	0
to	0
detectable	0
activation	0
of	0
the	0
protein	9
kinases	10
p56	9
(	10
lck	10
)	10
and	0
c-Raf-1	9
.	0

This	0
pathway	0
resulted	0
in	0
the	0
induction	0
of	0
the	0
transcription	9
factors	10
NF-kappa	9
B	10
,	0
NF-AT	9
,	0
and	0
proteins	0
binding	0
to	0
the	0
CD28	9
response	0
element	0
of	0
the	0
IL-2	1
promoter	2
.	0

On	0
the	0
other	0
hand	0
,	0
stimulation	0
of	0
T	7
cells	8
with	0
mAb	9
9.3	10
increased	0
the	0
level	0
of	0
intracellular	0
Ca2+	0
and	0
triggered	0
the	0
activation	0
of	0
p56	9
(	10
lck	10
)	10
and	0
c-Raf-1	9
,	0
but	0
was	0
unable	0
to	0
induce	0
the	0
binding	0
of	0
transcription	9
factors	10
to	0
the	0
IL-2	1
promoter	2
.	0

In	0
contrast	0
to	0
the	0
differential	0
signaling	0
of	0
BW	9
828	10
and	0
9.3	9
in	0
resting	0
T	0
cells	0
,	0
the	0
two	0
mAbs	0
exhibited	0
a	0
similar	0
pattern	0
of	0
early	0
signaling	0
events	0
in	0
activated	7
T	8
cells	8
and	0
Jurkat	7
cells	8
(	0
p56	9
(	10
lck	10
)	10
activation	0
,	0
association	0
of	0
phosphatidylinositol	9
3-kinase	10
with	0
CD28	9
)	0
,	0
indicating	0
that	0
the	0
signaling	0
capacity	0
of	0
CD28	9
changes	0
with	0
activation	0
.	0

These	0
data	0
support	0
the	0
view	0
that	0
stimulation	0
through	0
CD28	9
can	0
induce	0
some	0
effector	0
functions	0
in	0
T	7
cells	8
and	0
suggest	0
that	0
this	0
capacity	0
is	0
associated	0
with	0
a	0
particular	0
pattern	0
of	0
early	0
signaling	0
events	0

Decreased	0
IL-12	9
production	0
and	0
Th1	0
cell	0
development	0
by	0
acetyl	0
salicylic	0
acid-mediated	0
inhibition	0
of	0
NF-kappaB	9
.	0

IL-12	9
is	0
a	0
75-kDa	9
heterodimeric	10
cytokine	10
composed	0
of	0
two	0
covalently	0
linked	0
p35	9
and	10
p40	10
chains	10
.	0

This	0
pro-inflammatory	9
cytokine	10
plays	0
a	0
prominent	0
role	0
in	0
the	0
development	0
of	0
Th1	0
cell-mediated	0
immune	0
responses	0
.	0

Th1	0
cell-mediated	0
immune	0
responses	0
have	0
been	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
chronic	0
inflammatory	0
autoimmune	0
diseases	0
.	0

Thus	0
,	0
IL-12	9
appears	0
to	0
be	0
a	0
critical	0
factor	0
in	0
the	0
generation	0
and	0
maintenance	0
of	0
chronic	0
inflammatory	0
conditions	0
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
the	0
effects	0
of	0
a	0
commonly	0
prescribed	0
anti-inflammatory	0
drug	0
,	0
acetyl	0
salicylic	0
acid	0
(	0
ASA	0
)	0
,	0
on	0
IL-12	9
production	0
and	0
Th1	0
cell	0
development	0
.	0

ASA	0
was	0
found	0
to	0
inhibit	0
secretion	0
of	0
the	0
IL-12	9
heterodimer	10
as	0
well	0
as	0
p40	9
monomer	10
by	0
human	7
monocytic	8
cells	8
.	0

This	0
was	0
associated	0
with	0
the	0
down-regulation	0
of	0
IL-12p40	3
mRNA	4
expression	0
.	0

Analysis	0
of	0
the	0
regulation	0
of	0
the	0
p40	1
gene	2
promoter	2
revealed	0
that	0
ASA	0
inhibited	0
NF-kappaB	9
activation	0
and	0
binding	0
to	0
the	0
p40-kappaB	1
site	2
in	0
the	0
p40	1
promoter	2
,	0
leading	0
to	0
transcriptional	0
repression	0
of	0
the	0
p40	1
gene	2
.	0

Addition	0
of	0
ASA	0
to	0
an	0
in	0
vitro	0
T	0
helper	0
cell	0
differentiation	0
system	0
,	0
at	0
concentrations	0
compatible	0
with	0
plasma	0
levels	0
reached	0
during	0
anti-inflammatory	0
therapy	0
,	0
resulted	0
in	0
reduced	0
development	0
of	0
Th1	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
the	0
inhibition	0
of	0
NF-kappaB	9
activation	0
by	0
ASA	0
leads	0
to	0
down-regulation	0
of	0
IL-12	9
production	0
and	0
inhibition	0
of	0
Th1	0
cell	0
development	0
.	0

Attenuation	0
of	0
HLA-DR	9
expression	0
by	0
mononuclear	7
phagocytes	8
infected	0
with	0
Mycobacterium	0
tuberculosis	0
is	0
related	0
to	0
intracellular	0
sequestration	0
of	0
immature	9
class	10
II	10
heterodimers	10
.	0

MHC	9
class	10
II	10
expression	0
was	0
examined	0
in	0
macrophages	7
infected	0
with	0
Mycobacterium	0
tuberculosis	0
.	0

IFN-gamma	9
increased	0
the	0
surface	0
expression	0
of	0
class	9
II	10
molecules	10
in	0
THP-1	5
cells	6
and	0
this	0
was	0
markedly	0
reduced	0
in	0
cells	0
infected	0
with	0
M.	0
tuberculosis	0
.	0

Despite	0
this	0
effect	0
,	0
steady	0
state	0
levels	0
of	0
HLA-DRalpha	9
,	0
HLA-DRbeta	9
,	0
and	0
invariant	9
(	10
Ii	10
)	10
chains	10
were	0
equivalent	0
in	0
control	7
and	8
infected	8
cells	8
.	0

Metabolic	0
labeling	0
combined	0
with	0
pulse-chase	0
experiments	0
and	0
biochemical	0
analysis	0
showed	0
that	0
the	0
majority	0
of	0
class	9
II	10
molecules	10
in	0
infected	0
cells	0
became	0
resistant	0
to	0
endoglycosidase	9
H	10
,	0
consistent	0
with	0
normal	0
Golgi	0
processing	0
.	0

However	0
,	0
results	0
of	0
intracellular	0
staining	0
and	0
dual	0
color	0
confocal	0
microscopy	0
revealed	0
a	0
significant	0
defect	0
in	0
transport	0
of	0
newly	0
synthesized	0
class	9
II	10
molecules	10
through	0
the	0
endocytic	0
compartment	0
.	0

Thus	0
,	0
compared	0
with	0
findings	0
in	0
control	0
cells	0
,	0
class	9
II	10
molecules	10
in	0
infected	7
cells	8
colocalized	0
to	0
a	0
minimal	0
extent	0
with	0
a	0
lysosomal-associated	9
membrane	10
protein-1	10
+	0
endosomal	0
compartment	0
.	0

In	0
addition	0
,	0
in	0
contrast	0
to	0
control	7
cells	8
,	0
class	9
II	10
molecules	10
in	0
infected	7
cells	8
failed	0
to	0
colocalize	0
with	0
endocytosed	9
BSA	10
under	0
conditions	0
where	0
this	0
marker	0
is	0
known	0
to	0
label	0
late	0
endosomes	0
,	0
lysosomes	0
,	0
and	0
the	0
MHC	9
class	10
II	10
compartment	0
.	0

Consistent	0
with	0
defective	0
transport	0
along	0
the	0
endocytic	0
pathway	0
,	0
the	0
maturation	0
of	0
SDS-stable	9
class	10
II	10
alphabeta	10
dimers	10
--	0
dependent	0
upon	0
removal	0
of	0
Ii	9
chain	10
and	0
peptide	0
loading	0
of	0
class	9
II	10
dimers	10
in	0
the	0
MHC	9
class	10
II	10
compartment	0
--	0
was	0
markedly	0
impaired	0
in	0
M.	0
tuberculosis	0
-infected	7
cells	8
.	0

These	0
findings	0
indicate	0
that	0
defective	0
transport	0
and	0
processing	0
of	0
class	9
II	10
molecules	10
through	0
the	0
endosomal/lysosomal	0
system	0
is	0
responsible	0
for	0
diminished	0
cell	0
surface	0
expression	0
of	0
MHC	9
class	10
II	10
molecules	10
in	0
cells	0
infected	0
with	0
M.	0
tuberculosis	0
.	0

Identification	0
of	0
upstream	1
regulatory	2
elements	2
that	0
repress	0
expression	0
of	0
adult	1
beta-like	2
globin	2
genes	2
in	0
a	0
primitive	0
erythroid	0
environment	0
.	0

Our	0
investigations	0
have	0
focused	0
on	0
localizing	0
cis-elements	1
responsible	0
for	0
the	0
down	0
regulation	0
of	0
the	0
adult	1
beta-like	2
globin	2
genes	2
(	0
delta	1
and	0
beta	1
)	0
in	0
immature	0
,	0
or	0
primitive	0
erythroid	0
tissues	0
.	0

We	0
studied	0
their	0
activity	0
after	0
transfection	0
into	0
K562	5
cells	6
,	0
an	0
erythroleukemia	5
cell	6
line	6
with	0
an	0
embryonic-fetal	0
phenotype	0
.	0

Analyzed	0
DNA	1
sequences	2
included	0
delta	1
and	2
beta	2
5	2
'	2
flanking	2
regions	2
extending	0
from	0
approximately	0
-500	1
to	2
+50bp	2
(	0
promoter	1
regions	2
)	0
,	0
truncated	0
delta	0
and	0
beta	1
5	2
'	2
flanking	2
regions	2
extending	0
from	0
approximately	0
-250	1
to	2
+50	2
bp	2
,	0
and	0
chimeric	1
promoter	2
constructions	2
,	0
which	0
consisted	0
of	0
a	0
distal	0
delta	1
or	2
beta	2
fragment	2
fused	0
to	0
a	0
proximal	1
beta	2
or	2
delta	2
sequence	2
.	0

In	0
CAT	1
reporter	2
constructions	2
no	0
appreciable	0
level	0
of	0
CAT	9
activity	0
was	0
supported	0
by	0
the	0
beta	1
globin	2
promoter	2
,	0
and	0
only	0
low	0
level	0
activity	0
by	0
the	0
delta	1
promoter	2
.	0

Truncation	0
of	0
the	0
beta	1
globin	2
promoter	2
led	0
to	0
a	0
2-3	0
fold	0
increase	0
in	0
promoter	0
activity	0
.	0

In	0
contrast	0
,	0
deletion	0
of	0
the	0
upstream	1
portion	2
of	0
the	0
delta	1
promoter	2
led	0
to	0
a	0
10	0
fold	0
decrease	0
in	0
expression	0
.	0

Coupling	0
of	0
the	0
upstream	1
beta	2
globin	2
sequence	2
from	0
approximately	0
-500	0
to	0
-250	0
bp	0
to	0
the	0
truncated	0
delta	1
promoter	2
fragment	0
led	0
to	0
complete	0
extinction	0
of	0
transcription	0
activity	0
,	0
consistent	0
with	0
a	0
negative	0
regulatory	0
effect	0
of	0
the	0
beta	1
globin	2
gene	2
upstream	2
element	2
(	0
s	0
)	0
.	0

Fusion	0
of	0
the	0
upstream	1
portion	2
of	0
the	0
delta	1
promoter	2
to	0
the	0
truncated	0
beta	1
globin	2
promoter	2
yielded	0
a	0
modest	0
increase	0
in	0
promoter	0
strength	0
relative	0
to	0
the	0
truncated	1
beta	2
gene	2
promoter	2
,	0
indicating	0
the	0
presence	0
of	0
a	0
positive	1
transcriptional	2
element	2
(	0
s	0
)	0
in	0
the	0
upstream	1
delta	2
globin	2
regulatory	2
region	2
.	0

Site-directed	0
mutagenesis	0
of	0
binding	0
sites	0
for	0
the	0
repressor	9
proteins	10
BP1	10
and	10
BP2	10
in	0
the	0
upstream	1
portion	2
of	0
the	0
beta	1
globin	2
gene	2
flanking	2
region	2
led	0
to	0
a	0
4-6	0
fold	0
increase	0
in	0
promoter	0
activity	0
.	0

DNase	9
I	10
footprinting	0
of	0
the	0
upstream	1
delta-globin	2
region	2
revealed	0
protected	1
sequences	2
corresponding	0
to	0
consensus	1
binding	2
sites	2
for	0
GATA-1	9
and	0
BP2	9
.	0

These	0
results	0
confirm	0
that	0
sequences	0
in	0
the	0
upstream	1
promoter	2
region	2
of	0
the	0
adult	1
beta	2
globin	2
gene	2
contribute	0
to	0
its	0
factor-mediated	0
suppression	0
early	0
in	0
development	0
and	0
then	0
may	0
modulate	0
its	0
expression	0
at	0
a	0
later	0
stage	0
.	0

Analysis	0
of	0
cytokine	9
signaling	0
in	0
patients	0
with	0
extrinsic	0
asthma	0
and	0
hyperimmunoglobulin	0
E	0
.	0

BACKGROUND	0
:	0
Recent	0
data	0
suggest	0
that	0
the	0
regulation	0
of	0
class	0
switching	0
to	0
IgE	9
by	0
cytokines	9
is	0
mediated	0
by	0
STAT	9
transcription	10
factors	10
.	0

The	0
induction	0
of	0
IgE	9
by	0
IL-4	9
and	0
IL-13	9
occurs	0
through	0
the	0
activation	0
of	0
the	0
intracellular	9
signal-transducing	10
protein	10
Stat6	10
,	0
whereas	0
the	0
inhibition	0
of	0
IgE	9
class	0
switching	0
by	0
interferon-y	9
(	0
IFN-gamma	9
)	0
occurs	0
through	0
the	0
activation	0
of	0
Statl	9
.	0

OBJECTIVE	0
:	0
We	0
hypothesized	0
that	0
in	0
extrinsic	0
asthma	0
or	0
in	0
cases	0
of	0
markedly	0
elevated	0
IgE	9
(	0
ie	0
,	0
hyperimmunoglobulin	0
E	0
[	0
HIE	0
]	0
)	0
increased	0
levels	0
of	0
IgE	9
may	0
be	0
associated	0
with	0
alterations	0
in	0
the	0
cytokine	9
levels	0
or	0
the	0
activation	0
of	0
Stat6	9
.	0

METHODS	0
:	0
PBMCs	7
and	0
sera	0
from	0
8	0
patients	0
with	0
extrinsic	0
asthma	0
(	0
mean	0
IgE	9
,	0
285+/-100	0
IU/mL	0
)	0
,	0
3	0
patients	0
with	0
HIE	0
(	0
mean	0
IgE	9
,	0
7050+/-1122	0
IU/mL	0
)	0
,	0
and	0
14	0
nonatopic	0
control	0
subjects	0
(	0
mean	0
IgE	9
,	0
112+/-28	0
IU/mL	0
)	0
were	0
analyzed	0
.	0

RESULTS	0
:	0
The	0
mean	0
IL-4	9
level	0
detected	0
by	0
ELISA	0
was	0
much	0
greater	0
in	0
patients	0
with	0
HIE	0
than	0
control	0
subjects	0
(	0
88.6+/-11.5	0
pg/mL	0
vs	0
11.5+/-7.1	0
pg/mL	0
,	0
P	0
=	0
.005	0
)	0
,	0
and	0
increased	0
IL-4	9
levels	0
among	0
patients	0
with	0
both	0
asthma	0
and	0
HIE	0
correlated	0
with	0
the	0
increased	0
IgE	9
levels	0
.	0

In	0
contrast	0
,	0
IL-13	9
levels	0
were	0
not	0
elevated	0
.	0

Levels	0
of	0
Stat6	9
protein	0
present	0
in	0
PBMCs	7
did	0
not	0
differ	0
in	0
the	0
patients	0
and	0
control	0
subjects	0
.	0

Examination	0
of	0
Stat6	9
DNA-binding	0
activity	0
demonstrated	0
no	0
activation	0
of	0
IL-4	9
signaling	0
in	0
patients	0
with	0
either	0
HIE	0
or	0
acute	0
asthma	0
.	0

Interestingly	0
,	0
evidence	0
for	0
the	0
presence	0
of	0
B	7
cells	8
that	0
have	0
already	0
switched	0
to	0
IgE	9
was	0
seen	0
in	0
PBMCs	7
of	0
several	0
patients	0
with	0
asthma	0
or	0
HIE	0
.	0

CONCLUSION	0
:	0
These	0
results	0
indicate	0
that	0
(	0
1	0
)	0
IgE	9
production	0
in	0
asthma	0
and	0
HIE	0
usually	0
is	0
associated	0
with	0
elevated	0
levels	0
of	0
IL-4	9
,	0
but	0
not	0
IL-13	9
,	0
in	0
the	0
peripheral	0
blood	0
;	0
(	0
2	0
)	0
the	0
increased	0
sera	0
IL-4	9
levels	0
in	0
asthma	0
and	0
HIE	0
are	0
not	0
sufficient	0
to	0
induce	0
Stat6	9
activation	0
in	0
PBMCs	7
;	0
and	0
(	0
3	0
)	0
evidence	0
of	0
switch	0
recombination	0
to	0
epsilon	0
may	0
be	0
detected	0
in	0
isolated	0
cases	0
of	0
elevated	0
IgE	9
.	0

This	0
implies	0
that	0
high	0
levels	0
of	0
IgE	9
in	0
these	0
patients	0
either	0
results	0
from	0
B	7
cells	8
that	0
have	0
already	0
undergone	0
class	0
switching	0
,	0
from	0
Ig	0
class	0
switching	0
that	0
is	0
localized	0
to	0
target	0
tissues	0
,	0
or	0
both	0
.	0

Carboxyl-terminal	9
15-amino	10
acid	10
sequence	10
of	0
NFATx1	9
is	0
possibly	0
created	0
by	0
tissue-specific	0
splicing	0
and	0
is	0
essential	0
for	0
transactivation	0
activity	0
in	0
T	7
cells	8
.	0

NFAT	9
regulates	0
transcription	0
of	0
a	0
number	0
of	0
cytokine	0
and	0
other	0
immunoregulatory	1
genes	2
.	0

We	0
have	0
isolated	0
NFATx	9
,	0
which	0
is	0
one	0
of	0
four	0
members	0
of	0
the	0
NFAT	9
family	10
of	0
transcription	9
factors	10
and	0
is	0
preferentially	0
expressed	0
in	0
the	0
thymus	0
and	0
peripheral	7
blood	8
leukocytes	8
,	0
and	0
an	0
isoform	0
of	0
NFATx	9
,	0
NFATx1	9
.	0

Here	0
we	0
provide	0
evidence	0
showing	0
that	0
15	0
amino	0
acids	0
in	0
the	0
carboxyl-terminal	9
end	10
of	0
NFATx1	9
are	0
required	0
for	0
its	0
maximum	0
transactivation	0
activity	0
in	0
Jurkat	5
T	6
cells	6
.	0

A	0
fusion	0
between	0
these	0
15	0
amino	0
acids	0
and	0
the	0
GAL4	9
DNA	10
binding	10
domain	10
was	0
capable	0
of	0
transactivating	0
reporters	0
driven	0
by	0
the	0
GAL4	1
DNA	2
binding	2
site	2
.	0

Interestingly	0
,	0
this	0
15-amino	9
acid	10
transactivation	10
sequence	10
is	0
well	0
conserved	0
in	0
NFAT	9
family	10
proteins	10
,	0
although	0
the	0
sequences	0
contiguous	0
to	0
the	0
carboxyl-terminal	9
regions	10
of	0
the	0
NFAT	9
family	10
are	0
much	0
less	0
conserved	0
.	0

We	0
also	0
report	0
three	0
additional	0
isoforms	0
of	0
NFATx	9
,	0
designated	0
NFATx2	9
,	0
NFATx3	9
,	0
and	0
NFATx4	9
.	0

This	0
transactivation	0
sequence	0
is	0
altered	0
by	0
tissue-specific	0
alternative	0
splicing	0
in	0
newly	0
isolated	0
NFATx	9
isoforms	10
,	0
resulting	0
in	0
lower	0
transactivation	0
activity	0
in	0
Jurkat	5
T	6
cells	6
.	0

NFATx1	9
is	0
expressed	0
predominantly	0
in	0
the	0
thymus	0
and	0
peripheral	7
blood	8
leukocyte	8
,	0
while	0
the	0
skeletal	0
muscle	0
expressed	0
primarily	0
NFATx2	9
.	0

In	0
Jurkat	5
cells	6
,	0
transcription	0
from	0
the	0
NFAT	1
site	2
of	0
the	0
IL-2	1
promoter	2
is	0
activated	0
strongly	0
by	0
NFATx1	9
but	0
only	0
weakly	0
by	0
NFATx2	9
.	0

These	0
data	0
demonstrate	0
that	0
the	0
15-amino	9
acid	10
sequence	10
of	0
NFATx1	9
is	0
a	0
major	9
transactivation	10
sequence	10
required	0
for	0
induction	0
of	0
genes	0
by	0
NFATx1	9
in	0
T	7
cells	8
and	0
possibly	0
regulates	0
NFAT	9
activity	0
through	0
tissue-specific	0
alternative	0
splicing	0
.	0

Altered	9
DNA-binding	10
specificity	10
mutants	10
of	0
EKLF	9
and	0
Sp1	0
show	0
that	0
EKLF	9
is	0
an	0
activator	0
of	0
the	0
beta-globin	1
locus	2
control	2
region	2
in	0
vivo	0
.	0

The	0
locus	1
control	2
region	2
of	0
the	0
beta-globin	1
cluster	2
contains	0
five	0
DNase	1
I	2
hypersensitive	2
sites	2
(	0
5'HS1-5	1
)	0
required	0
for	0
locus	0
activation	0
.	0

5'HS3	1
contains	0
six	0
G-rich	0
motifs	0
that	0
are	0
essential	0
for	0
its	0
activity	0
.	0

Members	0
of	0
a	0
protein	0
family	0
,	0
characterized	0
by	0
three	0
zinc	9
fingers	10
highly	0
homologous	0
to	0
those	0
found	0
in	0
transcription	9
factor	10
Sp1	10
,	0
interact	0
with	0
these	0
motifs	0
.	0

Because	0
point	0
mutagenesis	0
can	0
not	0
distinguish	0
between	0
family	0
members	0
,	0
it	0
is	0
not	0
known	0
which	0
protein	0
activates	0
5'HS3	1
.	0

We	0
show	0
that	0
the	0
function	0
of	0
such	0
closely	0
related	0
proteins	0
can	0
be	0
distinguished	0
in	0
vivo	0
by	0
matching	0
point	0
mutations	0
in	0
5'HS3	1
with	0
amino	0
acid	0
changes	0
in	0
the	0
zinc	9
fingers	10
of	0
Sp1	9
and	0
EKLF	9
.	0

Testing	0
their	0
activity	0
in	0
transgenic	0
mice	0
shows	0
that	0
EKLF	9
is	0
a	0
direct	0
activator	0
of	0
5'HS3	1
.	0

The	0
Epstein-Barr	9
virus	10
Rta	10
protein	10
activates	0
lytic	1
cycle	2
genes	2
and	0
can	0
disrupt	0
latency	0
in	0
B	7
lymphocytes	8
.	0

The	0
transition	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
from	0
latency	0
into	0
the	0
lytic	0
cycle	0
is	0
associated	0
with	0
the	0
expression	0
of	0
two	0
immediate-early	1
viral	2
genes	2
,	0
BZLF1	1
and	0
BRLF1	1
.	0

Overexpression	0
of	0
ZEBRA	0
,	0
the	0
product	0
of	0
BZLF1	1
,	0
is	0
sufficient	0
to	0
disrupt	0
latency	0
in	0
B	7
lymphocytes	8
and	0
epithelial	7
cells	8
by	0
stimulating	0
expression	0
of	0
lytic	1
cycle	2
genes	2
,	0
including	0
BRLF1	1
.	0

The	0
BRLF1	9
product	10
Rta	10
functions	0
as	0
a	0
transcriptional	0
activator	0
in	0
both	0
B	7
lymphocytes	8
and	0
epithelial	7
cells	8
.	0

However	0
,	0
Rta	9
has	0
recently	0
been	0
reported	0
to	0
disrupt	0
latency	0
in	0
an	0
epithelial	0
specific	0
manner	0
(	0
S.	0
Zalani	0
,	0
E.	0
Holley-Guthrie	0
,	0
and	0
S.	0
Kenney	0
,	0
Proc.	0
Natl.	0
Acad.	0
Sci.	0
USA	0
93	0
:	0
9194-9199	0
,	0
1996	0
)	0
.	0

Here	0
we	0
demonstrate	0
that	0
expression	0
of	0
Rta	9
is	0
also	0
sufficient	0
for	0
disruption	0
of	0
latency	0
in	0
a	0
permissive	5
B-cell	6
line	6
.	0

In	0
HH514-16	5
cells	6
,	0
transfection	0
of	0
Rta	9
leads	0
to	0
synthesis	0
of	0
ZEBRA	9
,	0
viral	0
DNA	0
replication	0
,	0
and	0
late	0
gene	0
expression	0
.	0

However	0
,	0
Rta	9
by	0
itself	0
is	0
less	0
potent	0
than	0
ZEBRA	9
in	0
the	0
ability	0
to	0
activate	0
most	0
early	0
and	0
late	0
lytic	1
cycle	2
genes	2
.	0

In	0
light	0
of	0
previous	0
work	0
implicating	0
ZEBRA	9
in	0
the	0
activation	0
of	0
Rta	9
,	0
we	0
suggest	0
a	0
cooperative	0
model	0
for	0
EBV	0
entry	0
into	0
the	0
lytic	0
cycle	0
.	0

Expression	0
of	0
either	0
BZLF1	1
or	0
BRLF1	1
triggers	0
expression	0
of	0
the	0
other	0
immediate-early	9
factor	10
,	0
and	0
together	0
these	0
activators	0
act	0
individually	0
or	0
in	0
synergy	0
on	0
downstream	1
targets	2
to	0
activate	0
the	0
viral	0
lytic	0
cycle	0
.	0

Transcription	0
of	0
a	0
minimal	1
promoter	2
from	0
the	0
NF-IL6	1
gene	2
is	0
regulated	0
by	0
CREB/ATF	9
and	0
SP1	9
proteins	10
in	0
U937	5
promonocytic	6
cells	6
.	0

NF-IL6	9
is	0
an	0
important	0
transcriptional	0
regulator	0
of	0
genes	0
induced	0
in	0
activated	7
monocytes/macrophages	8
,	0
and	0
NF-IL6	9
is	0
the	0
only	0
CCAAT/enhancer-binding	9
protein	10
(	10
C/EBP	10
)	10
family	10
member	0
whose	0
steady-state	0
mRNA	0
levels	0
increase	0
upon	0
activation	0
of	0
monocytes	7
(	0
1	0
)	0
.	0

We	0
show	0
that	0
increased	0
transcription	0
of	0
the	0
NF-IL6	1
gene	2
is	0
responsible	0
,	0
at	0
least	0
in	0
part	0
,	0
for	0
induction	0
of	0
NF-IL6	3
mRNA	4
following	0
activation	0
of	0
U937	5
promonocytic	6
cells	6
.	0

We	0
have	0
identified	0
a	0
104-bp	1
minimal	2
promoter	2
region	2
of	0
the	0
NF-IL6	1
gene	2
that	0
is	0
sufficient	0
for	0
basal	0
and	0
activation-dependent	0
induction	0
of	0
transcription	0
in	0
U937	5
cells	6
.	0

This	0
region	0
contains	0
binding	0
sites	0
for	0
the	0
cAMP	9
response	10
element-binding	10
protein/activation	10
transcription	10
factor	10
(	0
CREB/ATF	9
)	0
and	0
Sp1	9
families	0
of	0
transcription	9
factors	10
.	0

Each	0
site	0
is	0
functionally	0
important	0
and	0
contributes	0
independently	0
to	0
transcription	0
of	0
the	0
NF-IL6	1
gene	2
in	0
U937	5
cells	6
.	0

CIITA	9
B-cell-specific	1
promoter	2
suppression	0
in	0
MHC	5
class	6
II-silenced	6
cell	6
hybrids	6
.	0

In	0
this	0
study	0
,	0
various	0
sets	0
of	0
somatic	5
cell	6
hybrids	6
,	0
generated	0
by	0
the	0
fusion	0
of	0
epithelial	5
cell	6
lines	6
with	0
B-lymphoblastoid	5
cell	6
lines	6
,	0
were	0
analyzed	0
for	0
the	0
expression	0
of	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
II	10
antigens	10
.	0

We	0
first	0
demonstrate	0
,	0
in	0
human	5
and	6
mouse	6
intraspecies	6
hybrids	6
,	0
the	0
coordinate	0
suppression	0
of	0
MHC	9
class	10
II	10
,	0
Ii	9
(	0
invariant	9
chain	10
)	0
and	0
HLA-DM	1
gene	2
transcription	0
,	0
and	0
the	0
release	0
of	0
the	0
silencing	0
by	0
the	0
addition	0
of	0
interferon	9
gamma	10
.	0

Using	0
interspecies	0
hybrids	0
,	0
the	0
segregation	0
of	0
human	1
chromosomes	2
allowed	0
us	0
to	0
establish	0
that	0
MHC	9
class	10
II	10
extinction	0
is	0
linked	0
to	0
the	0
presence	0
in	0
the	0
hybrids	0
of	0
the	0
chromosomes	1
from	0
the	0
epithelial	7
fusion	8
partner	8
.	0

Moreover	0
,	0
our	0
data	0
provide	0
evidence	0
that	0
the	0
expression	0
pattern	0
of	0
MHC	3
class	4
II	4
mRNA	4
is	0
correlated	0
with	0
that	0
of	0
the	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
,	0
suggesting	0
that	0
CIITA	9
is	0
the	0
actual	0
target	0
of	0
the	0
silencing	0
.	0

To	0
gain	0
further	0
insight	0
into	0
the	0
suppression	0
phenomenon	0
we	0
performed	0
luciferase	0
assays	0
which	0
show	0
that	0
silencing	0
affects	0
the	0
activity	0
of	0
the	0
B-cell-specific	1
promoter	2
of	0
CIITA	9
.	0

These	0
results	0
therefore	0
demonstrate	0
that	0
the	0
MHC	9
class	10
II	10
gene	0
silencing	0
in	0
somatic	5
cell	6
hybrids	6
is	0
due	0
to	0
an	0
active	0
suppression	0
of	0
one	0
of	0
the	0
promoters	1
of	0
the	0
CIITA	1
gene	2
,	0
mediated	0
by	0
the	0
epithelial	7
cell	8
fusion	8
partner	8
.	0

Class	0
II	0
transactivator-independent	0
endothelial	0
cell	0
MHC	9
class	10
II	10
gene	0
activation	0
induced	0
by	0
lymphocyte	0
adhesion	0
.	0

NK	0
cells	0
induce	0
MHC	9
class	10
II	10
molecules	0
on	0
the	0
surface	0
of	0
allogeneic	0
endothelial	0
cells	0
in	0
an	0
adhesion-dependent	0
,	0
IFN-gamma	9
-independent	0
manner	0
.	0

Here	0
,	0
we	0
demonstrate	0
that	0
NK	5
cells	6
induce	0
HLA-DR	9
on	0
the	0
surface	0
of	0
a	0
mutant	5
cell	6
line	6
that	0
is	0
defective	0
in	0
IFN-gamma	9
-induced	0
MHC	9
class	10
II	10
expression	0
.	0

RNA	0
analysis	0
in	0
these	0
cells	0
and	0
in	0
a	0
cell	0
line	0
that	0
is	0
defective	0
in	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
demonstrates	0
that	0
NK	0
cell-induced	0
HLA-DR	3
alpha	4
mRNA	4
expression	0
is	0
also	0
CIITA	9
-independent	0
.	0

The	0
Janus	5
kinase-1-deficient	6
cell	6
line	6
U4A	6
expresses	0
HLA-DR	3
alpha	4
mRNA	4
in	0
response	0
to	0
NK	0
cell	0
activation	0
,	0
and	0
HLA-DR	1
alpha	2
promoter	2
constructs	2
transfected	0
into	0
these	0
cells	0
are	0
induced	0
by	0
NK	5
cells	6
but	0
not	0
IFN-gamma	9
.	0

These	0
data	0
indicate	0
that	0
the	0
IFN-gamma	9
-independent	0
component	0
of	0
the	0
target	0
cell	0
HLA-DR	9
expression	0
induced	0
by	0
lymphocyte	0
adhesion	0
uses	0
a	0
signaling	0
pathway	0
that	0
is	0
distinct	0
from	0
the	0
IFN-gamma	9
-dependent	0
mechanism	0
and	0
also	0
suggest	0
that	0
CIITA	9
is	0
not	0
required	0
.	0

Effects	0
of	0
overexpression	0
of	0
IL-1	9
receptor-associated	10
kinase	10
on	0
NFkappaB	9
activation	0
,	0
IL-2	9
production	0
and	0
stress-activated	0
protein	0
kinases	0
in	0
the	0
murine	5
T	6
cell	6
line	6
EL4	6
.	0

The	0
association	0
and	0
activation	0
of	0
the	0
IL-1	9
receptor-associated	10
protein	10
kinase	10
(	0
IRAK	9
)	0
to	0
the	0
IL-1	9
receptor	10
complex	10
is	0
one	0
of	0
the	0
earliest	0
events	0
detectable	0
in	0
IL-1	9
signal	0
transduction	0
.	0

We	0
generated	0
permanent	0
clones	0
of	0
the	0
murine	5
T	6
cell	6
line	6
EL4	6
6.1	6
overexpressing	0
human	9
(	10
h	10
)	10
IRAK	10
to	0
evaluate	0
the	0
role	0
of	0
this	0
kinase	0
in	0
IL-1	9
signaling	0
.	0

Overexpression	0
of	0
hIRAK	9
enhanced	0
IL-1	9
-stimulated	0
activation	0
of	0
the	0
transcription	9
factor	10
NFkappaB	10
,	0
whereas	0
a	0
truncated	0
form	0
(	0
N-IRAK	9
)	0
specifically	0
inhibited	0
IL-1	9
-dependent	0
NFkappaB	9
activity	0
.	0

In	0
clones	0
stably	0
overexpressing	0
hIRAK	9
a	0
weak	0
constitutive	0
activation	0
of	0
NFkappaB	9
correlated	0
with	0
a	0
low	0
basal	0
IL-2	9
production	0
which	0
was	0
enhanced	0
in	0
an	0
IL-1	9
-dependent	0
manner	0
.	0

Compared	0
to	0
the	0
parental	5
cell	6
line	6
the	0
dose-response	0
curve	0
of	0
IL-1	9
-induced	0
IL-2	9
production	0
was	0
shifted	0
in	0
both	0
potency	0
and	0
efficacy	0
.	0

These	0
results	0
demonstrate	0
that	0
IRAK	9
directly	0
triggers	0
NFkappaB	9
-mediated	0
gene	0
expression	0
in	0
EL4	5
cells	6
.	0

Qualitatively	0
different	0
effects	0
were	0
observed	0
for	0
the	0
IL-1	9
-induced	0
activation	0
of	0
stress-activated	9
protein	10
(	10
SAP	10
)	10
kinases	10
:	0
permanent	0
overexpression	0
of	0
IRAK	9
did	0
not	0
affect	0
the	0
dose	0
dependence	0
but	0
prolonged	0
the	0
kinetics	0
of	0
IL-1	9
-induced	0
activation	0
of	0
SAP	9
kinases	10
,	0
suggesting	0
that	0
this	0
signaling	0
branch	0
may	0
be	0
regulated	0
by	0
distinct	0
mechanisms	0
.	0

The	0
role	0
of	0
protein	9
kinase	10
C	10
signaling	0
in	0
activated	0
DRA	1
transcription	0
.	0

Expression	0
of	0
human	1
MHC	2
HLA-DRA	2
class	2
II	2
gene	2
can	0
be	0
up-regulated	0
in	0
B	7
cells	8
by	0
Ig	0
cross-linking	0
as	0
well	0
as	0
by	0
phorbol	0
esters	0
such	0
as	0
12-O-tetradecanoyl	0
phorbol	0
13-acetate	0
(	0
TPA	0
)	0
.	0

Induced	0
DRA	1
expression	0
involves	0
activation	0
of	0
restricted	9
protein	10
kinase	10
C	10
(	10
PKC	10
)	10
isoforms	10
,	0
resulting	0
in	0
activated	0
activator	0
protein-1	9
-dependent	0
transcription	0
.	0

In	0
this	0
report	0
expression	0
profiles	0
and	0
activation	0
of	0
PKC	9
were	0
analyzed	0
in	0
human	5
Raji	6
B	6
lymphoblastoid	6
cells	6
.	0

Transient	0
transfection	0
analysis	0
with	0
target	1
plasmids	2
containing	0
either	0
DRA	1
promoter	2
(	0
wild-type	0
or	0
mutated	0
)	0
or	0
TPA	1
response	2
elements	2
demonstrated	0
that	0
pretreatment	0
with	0
the	0
selective	0
PKC	9
inhibitor	0
GF	0
109203X	0
repressed	0
TPA-mediated	0
activation	0
.	0

Western	0
analysis	0
performed	0
on	0
cellular	0
fractions	0
of	0
resting	7
cells	8
and	0
of	0
TPA-activated	7
cells	8
revealed	0
abundant	0
expression	0
of	0
classical	9
PKC-alpha	10
(	0
cPKC-alpha	9
)	0
,	0
cPKC-betaII	9
,	0
and	0
atypical	9
PKC-zeta	10
isoforms	10
and	0
identified	0
a	0
sustained	0
translocation	0
of	0
cPKC-alpha	9
and	0
cPKC-betaII	9
from	0
the	0
cytosolic	0
compartment	0
to	0
membranes	0
.	0

As	0
expected	0
,	0
the	0
distribution	0
of	0
atypical	9
PKC-zeta	10
was	0
unaffected	0
by	0
TPA	0
treatment	0
and	0
displayed	0
an	0
even	0
distribution	0
between	0
cytosol	0
and	0
membranes	0
.	0

This	0
finding	0
was	0
confirmed	0
by	0
immunofluorescence	0
microscopy	0
.	0

The	0
TPA-mediated	0
translocation	0
of	0
cPKC-alpha	9
and	0
cPKC-betaII	9
was	0
not	0
influenced	0
by	0
pretreatment	0
with	0
GF	0
109203X	0
.	0

Finally	0
,	0
functional	0
activation	0
and	0
translocation	0
of	0
PKC	9
were	0
investigated	0
with	0
a	0
selective	0
in	0
vitro	0
kinase	0
assay	0
.	0

Together	0
,	0
these	0
results	0
show	0
that	0
activated	0
HLA-DRA	9
expression	0
in	0
response	0
to	0
TPA	0
treatment	0
is	0
strictly	0
dependent	0
on	0
PKC	9
activation	0
acting	0
on	0
the	0
X2	1
box	2
of	0
the	0
DRA	1
promoter	2
and	0
that	0
selective	0
inhibition	0
of	0
PKC	9
enzymatic	0
activity	0
does	0
not	0
influence	0
subcellular	0
localization	0
of	0
expressed	0
PKC	9
isoenzymes	10
.	0

Thus	0
,	0
the	0
translocation	0
event	0
per	0
se	0
occurs	0
independently	0
of	0
PKC	9
activation	0
in	0
these	0
cells	0
.	0

Inhibition	0
of	0
RNA	9
polymerase	10
II	10
transcription	0
in	0
human	7
cells	8
by	0
synthetic	0
DNA-binding	0
ligands	0
[	0
see	0
comments	0
]	0

Sequence-specific	0
DNA-binding	0
small	0
molecules	0
that	0
can	0
permeate	0
human	7
cells	8
potentially	0
could	0
regulate	0
transcription	0
of	0
specific	0
genes	0
.	0

Multiple	0
cellular	9
DNA-binding	10
transcription	10
factors	10
are	0
required	0
by	0
HIV	0
type	0
1	0
for	0
RNA	0
synthesis	0
.	0

Two	0
pyrrole-imidazole	0
polyamides	0
were	0
designed	0
to	0
bind	0
DNA	0
sequences	0
immediately	0
adjacent	0
to	0
binding	0
sites	0
for	0
the	0
transcription	9
factors	10
Ets-1	9
,	0
lymphoid-enhancer	9
binding	10
factor	10
1	10
,	0
and	0
TATA-box	9
binding	10
protein	10
.	0

These	0
synthetic	0
ligands	0
specifically	0
inhibit	0
DNA-binding	0
of	0
each	0
transcription	9
factor	10
and	0
HIV	0
type	0
1	0
transcription	0
in	0
cell-free	0
assays	0
.	0

When	0
used	0
in	0
combination	0
,	0
the	0
polyamides	0
inhibit	0
virus	0
replication	0
by	0
>	0
99	0
%	0
in	0
isolated	7
human	8
peripheral	8
blood	8
lymphocytes	8
,	0
with	0
no	0
detectable	0
cell	0
toxicity	0
.	0

The	0
ability	0
of	0
small	0
molecules	0
to	0
target	0
predetermined	0
DNA	1
sequences	2
located	0
within	0
RNA	1
polymerase	2
II	2
promoters	2
suggests	0
a	0
general	0
approach	0
for	0
regulation	0
of	0
gene	0
expression	0
,	0
as	0
well	0
as	0
a	0
mechanism	0
for	0
the	0
inhibition	0
of	0
viral	0
replication	0
.	0

musculin	1
:	0
a	0
murine	1
basic	2
helix-loop-helix	2
transcription	2
factor	2
gene	2
expressed	0
in	0
embryonic	0
skeletal	0
muscle	0
.	0

We	0
describe	0
the	0
embryonic	0
expression	0
of	0
musculin	9
,	0
a	0
new	0
murine	0
member	0
of	0
the	0
bHLH	9
family	10
of	0
transcription	9
factors	10
.	0

Musculin	0
protein	0
is	0
closely	0
related	0
to	0
human	9
ABF-1	10
,	0
which	0
is	0
expressed	0
in	0
activated	0
B	7
cells	8
,	0
and	0
to	0
epicardin/capsulin/Pod-1	9
,	0
which	0
is	0
expressed	0
in	0
branchial	7
myoblasts	8
,	0
visceral	0
and	0
urogenital	0
mesoderm	0
and	0
epicardium	0
.	0

In	0
situ	0
hybridisation	0
revealed	0
musculin	9
expression	0
in	0
embryos	0
was	0
largely	0
restricted	0
to	0
the	0
embryonic	7
skeletal	8
muscle	8
lineage	8
.	0

While	0
all	0
skeletal	0
muscles	0
expressed	0
the	0
gene	0
,	0
only	0
a	0
subset	0
of	0
myocytes	0
within	0
each	0
muscle	0
were	0
positive	0
,	0
indicating	0
molecular	0
heterogeneity	0
within	0
fetal	0
muscle	0
.	0

Copyright	0
1998	0
Elsevier	0
Science	0
Ireland	0
Ltd	0
.	0

All	0
Rights	0
Reserved	0
.	0

Induction	0
of	0
T	0
cell	0
anergy	0
by	0
high	0
concentrations	0
of	0
immunodominant	0
native	0
peptide	0
is	0
accompanied	0
by	0
IL-10	9
production	0
and	0
a	0
block	0
in	0
JNK	9
activity	0
.	0

The	0
ability	0
to	0
induce	0
anergy	0
in	0
antigen-specific	7
T	8
cells	8
has	0
potential	0
therapeutic	0
value	0
for	0
altering	0
pathologic	0
immune	0
responses	0
.	0

This	0
study	0
was	0
undertaken	0
to	0
further	0
analyze	0
changes	0
in	0
cytokine	9
production	0
and	0
intracellular	0
signaling	0
during	0
anergy	0
induction	0
using	0
high	0
concentrations	0
of	0
native	0
peptide	0
ligand	0
of	0
tetanus	5
toxoid	6
(	6
TT	6
)	6
-	6
and	6
myelin	6
basic	6
protein	6
(	6
MBP	6
)	6
-specific	6
human	6
T	6
cell	6
lines	6
.	0

The	0
TT-selected	5
T	6
cell	6
line	6
could	0
be	0
rendered	0
unresponsive	0
to	0
its	0
dominant	0
epitope	0
in	0
a	0
dose-dependent	0
manner	0
(	0
IC50	0
=	0
0.03	0
microg/ml	0
)	0
.	0

The	0
TT-selected	5
line	6
,	0
as	0
well	0
as	0
three	0
T	0
cell	0
clones	0
established	0
from	0
this	0
line	0
,	0
continued	0
to	0
produce	0
IFN-gamma	9
and	0
significantly	0
increased	0
IL-4	9
and	0
IL-10	9
production	0
when	0
anergy	0
was	0
induced	0
with	0
high	0
concentrations	0
of	0
the	0
immunodominant	0
epitope	0
.	0

JNK	9
enzymatic	0
activity	0
was	0
blocked	0
in	0
anergized	5
T	6
cells	6
.	0

The	0
MBP	9
-selected	0
line	0
could	0
likewise	0
be	0
rendered	0
unresponsive	0
by	0
incubation	0
with	0
supraoptimal	0
concentrations	0
of	0
immunodominant	0
peptide	0
and	0
anergy	0
induction	0
was	0
accompanied	0
by	0
IL-10	9
release	0
.	0

Both	0
T	5
cell	6
lines	6
could	0
be	0
anergized	0
by	0
the	0
autopresentation	0
of	0
native	0
peptide	0
since	0
anergy	0
was	0
induced	0
in	0
cultures	0
lacking	0
fresh	0
antigen-presenting	7
cells	8
.	0

This	0
study	0
shows	0
that	0
the	0
mitogen-activated	9
protein	10
kinase	10
cascade	0
is	0
blocked	0
when	0
anergy	0
is	0
induced	0
to	0
high	0
concentrations	0
of	0
soluble	0
peptide	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Upregulation	0
of	0
interleukin	9
6	10
and	0
granulocyte	9
colony-stimulating	10
factor	10
receptors	10
by	0
transcription	9
factor	10
CCAAT	9
enhancer	10
binding	10
protein	10
alpha	10
(	0
C/EBP	9
alpha	10
)	0
is	0
critical	0
for	0
granulopoiesis	0
.	0

Cytokines	0
stimulate	0
granulopoiesis	0
through	0
signaling	0
via	0
receptors	0
whose	0
expression	0
is	0
controlled	0
by	0
lineage-specific	0
transcription	9
factors	10
.	0

Previously	0
,	0
we	0
demonstrated	0
that	0
granulocyte	3
colony-stimulating	4
factor	4
(	4
G-CSF	4
)	4
receptor	4
mRNA	4
was	0
undetectable	0
and	0
granulocyte	0
maturation	0
blocked	0
in	0
CCAAT	9
enhancer	10
binding	10
protein	10
alpha	10
(	0
C/EBPalpha	9
)	0
-deficient	0
mice	0
.	0

This	0
phenotype	0
is	0
distinct	0
from	0
that	0
of	0
G-CSF	0
receptor-/-	0
mice	0
,	0
suggesting	0
that	0
other	0
genes	0
are	0
likely	0
to	0
be	0
adversely	0
affected	0
by	0
loss	0
of	0
C/EBPalpha	9
.	0

Here	0
we	0
demonstrate	0
loss	0
of	0
interleukin	9
6	10
(	10
IL-6	10
)	10
receptor	10
and	0
IL-6-responsive	9
colony-forming	10
units	10
(	0
CFU-IL6	9
)	0
in	0
C/EBPalpha	9
-/-	0
mice	0
.	0

The	0
observed	0
failure	0
of	0
granulopoiesis	0
could	0
be	0
rescued	0
by	0
the	0
addition	0
of	0
soluble	0
IL-6	9
receptor	10
and	0
IL-6	9
or	0
by	0
retroviral	0
transduction	0
of	0
G-CSF	9
receptors	10
,	0
demonstrating	0
that	0
loss	0
of	0
both	0
of	0
these	0
receptors	0
contributes	0
to	0
the	0
absolute	0
block	0
in	0
granulocyte	0
maturation	0
observed	0
in	0
C/EBPalpha-deficient	7
hematopoietic	8
cells	8
.	0

The	0
results	0
of	0
these	0
and	0
other	0
studies	0
suggest	0
that	0
additional	0
C/EBPalpha	1
target	2
genes	2
,	0
possibly	0
other	0
cytokine	0
receptors	0
,	0
are	0
also	0
important	0
for	0
the	0
block	0
in	0
granulocyte	0
differentiation	0
observed	0
in	0
vivo	0
in	0
C/EBPalpha	9
-deficient	0
mice	0
.	0

Phosphatidylinositides	0
bind	0
to	0
plasma	9
membrane	10
CD14	10
and	0
can	0
prevent	0
monocyte	0
activation	0
by	0
bacterial	0
lipopolysaccharide	0
.	0

Although	0
bacterial	0
lipopolysaccharides	0
(	0
LPS	0
)	0
and	0
several	0
other	0
microbial	0
agonists	0
can	0
bind	0
to	0
mCD14	9
(	0
membrane	9
CD14	10
)	0
,	0
a	0
cell-surface	0
receptor	0
found	0
principally	0
on	0
monocytes	7
and	0
neutrophils	7
,	0
host-derived	0
mCD14	9
ligands	0
are	0
poorly	0
defined	0
.	0

We	0
report	0
here	0
that	0
phosphatidylinositol	0
(	0
PtdIns	0
)	0
,	0
phosphatidylinositol-4-phosphate	0
,	0
and	0
other	0
phosphatidylinositides	0
can	0
bind	0
to	0
mCD14	9
.	0

Phosphatidylserine	0
(	0
PS	0
)	0
,	0
another	0
anionic	0
glycerophospholipid	0
,	0
binds	0
to	0
mCD14	9
with	0
lower	0
apparent	0
affinity	0
than	0
does	0
PtdIns	0
.	0

LPS-binding	9
protein	10
,	0
a	0
lipid	0
transfer	0
protein	0
found	0
in	0
serum	0
,	0
facilitates	0
both	0
PS	0
-and	0
PtdIns-	0
mCD14	9
binding	0
.	0

PtdIns	0
binding	0
to	0
mCD14	9
can	0
be	0
blocked	0
by	0
anti-CD14	9
monoclonal	10
antibodies	10
that	0
inhibit	0
LPS	0
-mCD14	9
binding	0
,	0
and	0
PtdIns	0
can	0
inhibit	0
both	0
LPS	0
-mCD14	9
binding	0
and	0
LPS-induced	0
responses	0
in	0
monocytes	7
.	0

Serum-equilibrated	7
PtdIns	8
also	8
binds	8
to	8
mCD14-expressing	8
cells	8
,	0
raising	0
the	0
possibility	0
that	0
endogenous	0
PtdIns	0
may	0
modulate	0
cellular	0
responses	0
to	0
LPS	0
and	0
other	0
mCD14	9
ligands	0
in	0
vivo	0
.	0

Protein	9
kinase	10
C	10
regulates	0
Fas	9
(	0
CD95/APO-1	9
)	0
expression	0
.	0

Fas	9
(	0
CD95/APO-1	9
)	0
is	0
a	0
transmembrane	9
protein	10
of	0
the	0
TNF/neuron	9
growth	10
factor	10
receptor	10
family	10
.	0

Ligation	0
of	0
Fas	9
by	0
specific	9
Abs	10
or	0
Fas	9
ligand	10
(	0
FasL/CD95	9
ligand	10
)	0
induces	0
rapid	0
apoptotic	0
cell	0
death	0
in	0
a	0
variety	0
of	0
cell	0
types	0
.	0

Despite	0
progress	0
in	0
understanding	0
the	0
death	0
signals	0
transduced	0
from	0
Fas	9
,	0
very	0
little	0
is	0
known	0
with	0
regard	0
to	0
the	0
mechanisms	0
by	0
which	0
Fas	9
expression	0
is	0
regulated	0
.	0

Using	0
our	0
previously	0
established	0
murine	5
T	6
cell	6
hybridoma	6
model	6
A1.1	5
,	0
we	0
show	0
that	0
specific	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
inhibitors	0
could	0
block	0
activation-induced	0
Fas	9
expression	0
and	0
apoptosis	0
.	0

The	0
activation	0
of	0
PKC	9
with	0
PMA	0
or	0
1-oleoyl-2-acetyl-sn-glycerol	0
could	0
mimic	0
the	0
TCR	9
signal	0
by	0
inducing	0
the	0
expression	0
of	0
Fas	9
but	0
not	0
FasL	0
.	0

PKC	9
-dependent	0
Fas	9
expression	0
was	0
also	0
observed	0
in	0
several	0
murine	5
and	6
human	6
tumor	6
cell	6
lines	6
.	0

Since	0
the	0
inhibition	0
of	0
Ca2+	0
redistribution	0
by	0
an	0
inhibitor	0
of	0
intracellular	0
Ca2+	0
mobilization	0
,	0
8-	0
(	0
diethylamino	0
)	0
-octyl-3	0
,	0
4	0
,	0
5-trimethoxybenzoate	0
hydrochloride	0
,	0
inhibited	0
TCR-induced	9
FasL	10
but	0
not	0
Fas	9
,	0
the	0
expression	0
of	0
Fas	9
appears	0
to	0
be	0
independent	0
of	0
Ca2+	0
mobilization	0
.	0

Significantly	0
,	0
expression	0
of	0
the	0
newly	0
identified	0
Fas-regulatory	1
gene	2
,	0
TDAG51	1
,	0
was	0
found	0
to	0
be	0
dependent	0
upon	0
the	0
activity	0
of	0
PKC	9
.	0

PKC	9
activation	0
only	0
induced	0
Fas	9
expression	0
in	0
cells	0
expressing	0
wild-type	0
TDAG51	1
.	0

Thus	0
,	0
Fas	9
expression	0
is	0
likely	0
mediated	0
by	0
PKC	9
through	0
TDAG51	1
.	0

Retinoic	0
acid	0
inhibits	0
CD40	9
+	0
interleukin-4	9
-mediated	0
IgE	9
production	0
in	0
vitro	0
.	0

To	0
elucidate	0
the	0
role	0
of	0
retinoic	0
acid	0
(	0
RA	0
)	0
in	0
anti-CD40	9
+	0
interleukin-4	9
(	0
IL-4	9
)	0
-mediated	0
B-cell	0
activation	0
,	0
the	0
effect	0
of	0
10	0
(	0
-12	0
)	0
to	0
10	0
(	0
-6	0
)	0
mol/L	0
RA	0
was	0
studied	0
in	0
anti-CD40	9
(	0
1	0
microgram/mL	0
)	0
+	0
IL-4	9
(	0
5	0
ng/mL	0
)	0
-mediated	0
proliferation	0
and	0
Ig	0
synthesis	0
by	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
and	0
B	7
cells	8
in	0
healthy	0
donors	0
.	0

Anti-CD40	9
+	0
IL-4	9
-mediated	0
proliferation	0
of	0
PBMC	7
and	0
B	7
cells	8
was	0
inhibited	0
by	0
RA	0
in	0
a	0
dose-dependent	0
manner	0
,	0
with	0
maximal	0
inhibition	0
of	0
62	0
%	0
+/-	0
5	0
%	0
in	0
PBMC	7
and	0
55	0
%	0
+/-	0
4.4	0
%	0
in	0
B	7
cells	8
by	0
all-trans	0
RA	0
,	0
and	0
58	0
%	0
+/-	0
6.7	0
%	0
and	0
51	0
%	0
+/-	0
4.7	0
%	0
,	0
respectively	0
by	0
13-cis	0
RA	0
.	0

IgE	9
synthesis	0
was	0
even	0
more	0
markedly	0
inhibited	0
by	0
RA	0
starting	0
at	0
concentrations	0
of	0
>	0
10	0
(	0
-14	0
)	0
mol/L	0
for	0
B	7
cells	8
and	0
>	0
10	0
(	0
-10	0
)	0
mol/L	0
for	0
PBMC	7
.	0

Maximal	0
inhibition	0
of	0
IgE	9
production	0
for	0
B	7
cells	8
was	0
at	0
10	0
(	0
-8	0
)	0
mol/L	0
for	0
all-trans	0
RA	0
(	0
94	0
%	0
+/-	0
1.8	0
%	0
)	0
and	0
96	0
%	0
+/-	0
3.2	0
%	0
for	0
13-cis	0
RA	0
.	0

Low	0
concentrations	0
of	0
RA	0
inhibiting	0
IgE	9
synthesis	0
(	0
10	0
(	0
-10	0
)	0
mol/L	0
)	0
affected	0
neither	0
B-cell	0
proliferation	0
nor	0
the	0
production	0
of	0
IgA	9
,	0
IgG	9
,	0
and	0
IgM	9
.	0

Elucidation	0
of	0
the	0
mechanism	0
involved	0
in	0
this	0
inhibition	0
of	0
IgE	9
production	0
shows	0
that	0
epsilon	0
germline	1
transcription	0
is	0
decreased	0
by	0
RA	0
,	0
whereas	0
production	0
of	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
was	0
not	0
enhanced	0
in	0
the	0
presence	0
of	0
RA	0
.	0

To	0
differentiate	0
whether	0
the	0
RA	0
effect	0
was	0
mediated	0
by	0
RA	9
receptors	10
alpha	10
,	10
beta	10
,	10
and	10
gamma	10
,	0
the	0
expression	0
of	0
the	0
retinoic	9
acid	10
receptors	10
(	0
RAR	9
)	0
was	0
examined	0
by	0
reverse	9
transcriptase	10
-polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
.	0

The	0
data	0
show	0
that	0
unstimulated	7
human	8
peripheral	8
B	8
cells	8
express	0
mRNA	0
of	0
the	0
RA	9
receptor	10
alpha	10
,	10
beta	10
,	10
and	10
gamma	10
.	0

Using	0
retinoids	0
with	0
different	0
receptor	0
binding	0
specificity	0
(	0
CD336	0
,	0
CD437	0
,	0
CD2019	0
,	0
CD367	0
)	0
,	0
dose-dependent	0
inhibition	0
of	0
IgE	9
synthesis	0
was	0
shown	0
by	0
all	0
four	0
derivates	0
,	0
but	0
was	0
most	0
marked	0
by	0
an	0
RA	0
binding	0
the	0
alpha	9
receptor	10
with	0
high	0
specificity	0
.	0

Taken	0
together	0
,	0
this	0
study	0
shows	0
that	0
RA	0
inhibits	0
IgE	9
production	0
of	0
anti-CD40	5
+	6
IL-4-stimulated	6
B	6
cells	6
in	0
vitro	0
.	0

Copyright	0
1998	0
by	0
The	0
American	0
Society	0
of	0
Hematology	0
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
Tax	9
induction	0
of	0
NF-kappaB	9
involves	0
activation	0
of	0
the	0
IkappaB	9
kinase	10
alpha	10
(	0
IKKalpha	9
)	0
and	0
IKKbeta	9
cellular	9
kinases	10
.	0

Tax	9
corresponds	0
to	0
a	0
40-kDa	9
transforming	10
protein	10
from	0
the	0
pathogenic	0
retrovirus	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
that	0
activates	0
nuclear	0
expression	0
of	0
the	0
NF-kappaB/Rel	9
family	10
of	0
transcription	9
factors	10
by	0
an	0
unknown	0
mechanism	0
.	0

Tax	9
expression	0
promotes	0
N-terminal	0
phosphorylation	0
and	0
degradation	0
of	0
IkappaB	9
alpha	10
,	0
a	0
principal	0
cytoplasmic	0
inhibitor	0
of	0
NF-kappaB	9
.	0

Our	0
studies	0
now	0
demonstrate	0
that	0
HTLV-1	0
Tax	9
activates	0
the	0
recently	0
identified	0
cellular	9
kinases	10
IkappaB	9
kinase	10
alpha	10
(	0
IKKalpha	9
)	0
and	0
IKKbeta	9
,	0
which	0
normally	0
phosphorylate	0
IkappaB	9
alpha	10
on	0
both	0
of	0
its	0
N-terminal	0
regulatory	0
serines	0
in	0
response	0
to	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
and	0
interleukin-1	9
(	0
IL-1	9
)	0
stimulation	0
.	0

In	0
contrast	0
,	0
a	0
mutant	0
of	0
Tax	9
termed	0
M22	9
,	0
which	0
does	0
not	0
induce	0
NF-kappaB	9
,	0
fails	0
to	0
activate	0
either	0
IKKalpha	9
or	0
IKKbeta	9
.	0

Furthermore	0
,	0
endogenous	0
IKK	0
enzymatic	0
activity	0
was	0
significantly	0
elevated	0
in	0
HTLV-1-infected	5
and	6
Tax-expressing	6
T-cell	6
lines	6
.	0

Transfection	0
of	0
kinase-deficient	0
mutants	0
of	0
IKKalpha	9
and	0
IKKbeta	9
into	0
either	0
human	5
Jurkat	6
T	6
or	6
293	6
cells	6
also	0
inhibits	0
NF-kappaB	9
-dependent	0
reporter	1
gene	2
expression	0
induced	0
by	0
Tax	9
.	0

Similarly	0
,	0
a	0
kinase-deficient	9
mutant	10
of	0
NIK	9
(	0
NF-kappaB-inducing	9
kinase	10
)	0
,	0
which	0
represents	0
an	0
upstream	0
kinase	0
in	0
the	0
TNF-alpha	0
and	0
IL-1	0
signaling	0
pathways	0
leading	0
to	0
IKKalpha	9
and	0
IKKbeta	9
activation	0
,	0
blocks	0
Tax	9
induction	0
of	0
NF-kappaB	9
.	0

However	0
,	0
plasma	1
membrane-proximal	2
elements	2
in	0
these	0
proinflammatory	9
cytokine	10
pathways	0
are	0
apparently	0
not	0
involved	0
since	0
dominant	0
negative	0
mutants	0
of	0
the	0
TRAF2	9
and	10
TRAF6	10
adaptors	10
,	0
which	0
effectively	0
block	0
signaling	0
through	0
the	0
cytoplasmic	9
tails	10
of	0
the	0
TNF-alpha	9
and	0
IL-1	9
receptors	0
,	0
respectively	0
,	0
do	0
not	0
inhibit	0
Tax	9
induction	0
of	0
NF-kappaB	9
.	0

Together	0
,	0
these	0
studies	0
demonstrate	0
that	0
HTLV-1	0
Tax	9
exploits	0
a	0
distal	0
part	0
of	0
the	0
proinflammatory	9
cytokine	10
signaling	0
cascade	0
leading	0
to	0
induction	0
of	0
NF-kappaB	9
.	0

The	0
pathological	0
alteration	0
of	0
this	0
cytokine	0
pathway	0
leading	0
to	0
NF-kappaB	9
activation	0
by	0
Tax	9
may	0
play	0
a	0
central	0
role	0
in	0
HTLV-1-mediated	0
transformation	0
of	0
human	7
T	8
cells	8
,	0
clinically	0
manifested	0
as	0
the	0
adult	0
T-cell	0
leukemia	0

Role	0
of	0
IKK1	9
and	0
IKK2	9
in	0
lipopolysaccharide	0
signaling	0
in	0
human	7
monocytic	8
cells	8
.	0

Mononuclear	7
phagocytes	8
play	0
a	0
major	0
role	0
in	0
immune	0
and	0
inflammatory	0
responses	0
.	0

Bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
induces	0
monocytes	7
to	0
express	0
a	0
variety	0
of	0
genes	0
by	0
activating	0
the	0
NF-kappaB/Rel	9
transcription	10
factor	10
family	10
.	0

Recently	0
,	0
we	0
have	0
reported	0
that	0
the	0
tumor	9
necrosis	10
factor	10
and	0
interleukin	9
1	10
signaling	0
pathways	0
activate	0
two	0
kinases	0
,	0
IKK1	9
and	0
IKK2	9
.	0

Phosphorylation	0
of	0
the	0
IkappaB	9
cytoplasmic	10
inhibitors	10
,	0
IkappaBalpha	9
,	0
IkappaBbeta	9
,	0
and	0
IkappaBepsilon	9
,	0
by	0
these	0
kinases	0
triggers	0
proteolytic	0
degradation	0
and	0
the	0
release	0
of	0
NF-kappaB/Rel	9
proteins	10
into	0
the	0
nucleus	0
.	0

At	0
present	0
,	0
the	0
role	0
of	0
the	0
IKKs	0
in	0
LPS	0
signaling	0
has	0
not	0
been	0
investigated	0
.	0

Here	0
,	0
we	0
report	0
that	0
LPS	0
induces	0
IKK	9
activity	0
in	0
human	7
monocytes	8
and	0
THP-1	5
monocytic	6
cells	6
.	0

The	0
kinetics	0
of	0
activation	0
of	0
kinase	0
activity	0
in	0
monocytic	7
cells	8
are	0
relatively	0
slow	0
with	0
maximal	0
activity	0
observed	0
at	0
60	0
min	0
,	0
which	0
coincides	0
with	0
the	0
degradation	0
of	0
IkappaBs	9
and	0
the	0
nuclear	0
translocation	0
of	0
NF-kappaB	9
.	0

In	0
transfection	0
experiments	0
,	0
overexpression	0
of	0
wild	0
type	0
IKK1	9
,	0
a	0
dominant	9
negative	10
mutant	10
IKK1	10
(	0
K44M	9
)	0
,	0
or	0
wild	9
type	10
IKK2	10
did	0
not	0
affect	0
LPS-induced	0
kappaB	9
-dependent	0
transcription	0
in	0
monocytic	7
cells	8
.	0

In	0
contrast	0
,	0
a	0
dominant	0
negative	0
mutant	0
of	0
IKK2	9
inhibited	0
LPS	0
induction	0
of	0
kappaB	9
-dependent	0
transcription	0
in	0
a	0
dose-dependent	0
manner	0
.	0

These	0
results	0
indicate	0
that	0
LPS	0
induction	0
of	0
kappaB-dependent	0
gene	0
expression	0
in	0
human	7
monocytic	8
cells	8
requires	0
activation	0
of	0
IKK2	9
.	0

IL-7	9
reconstitutes	0
multiple	0
aspects	0
of	0
v-Abl	9
-mediated	0
signaling	0
.	0

The	0
mechanism	0
by	0
which	0
early	7
lymphoid	8
cells	8
are	0
selectively	0
transformed	0
by	0
v-Abl	9
is	0
currently	0
unknown	0
.	0

Previous	0
studies	0
have	0
shown	0
constitutive	0
activation	0
of	0
IL-4	9
and	0
IL-7	9
signaling	0
pathways	0
,	0
as	0
measured	0
by	0
activation	0
of	0
Janus	9
protein	10
kinase	10
(	10
JAK	10
)	10
1	10
,	0
JAK3	9
,	0
STAT5	9
,	0
and	0
STAT6	9
,	0
in	0
pre-B	7
cells	8
transformed	0
by	0
v-Abl	9
.	0

To	0
determine	0
whether	0
activation	0
of	0
these	0
cytokine	0
signaling	0
pathways	0
by	0
v-Abl	9
is	0
important	0
in	0
the	0
cellular	0
events	0
induced	0
by	0
the	0
Abelson	0
murine	0
leukemia	0
virus	0
,	0
the	0
effects	0
of	0
IL-4	9
and	0
IL-7	9
on	0
pre-B	7
cells	8
transformed	0
with	0
a	0
temperature-sensitive	9
v-Abl	10
mutant	10
were	0
examined	0
.	0

Whereas	0
IL-4	9
had	0
little	0
or	0
no	0
effect	0
,	0
IL-7	9
delayed	0
both	0
the	0
apoptosis	0
and	0
cell	0
cycle	0
arrest	0
that	0
occur	0
upon	0
v-Abl	9
kinase	0
inactivation	0
.	0

IL-7	9
also	0
delayed	0
the	0
decreases	0
in	0
the	0
levels	0
of	0
c-Myc	9
,	0
Bcl-2	9
,	0
and	0
Bcl-xL	9
that	0
occur	0
upon	0
loss	0
of	0
v-Abl	9
kinase	0
activity	0
.	0

IL-7	9
did	0
not	0
maintain	0
v-Abl	9
-mediated	0
differentiation	0
arrest	0
of	0
the	0
pre-B	7
cells	8
,	0
as	0
activation	0
of	0
NF-kappaB	9
and	0
RAG	1
gene	2
transcription	0
was	0
unaffected	0
by	0
IL-7	9
.	0

These	0
results	0
identify	0
a	0
potential	0
role	0
for	0
IL-7	9
signaling	0
pathways	0
in	0
transformation	0
by	0
v-Abl	9
while	0
demonstrating	0
that	0
a	0
combination	0
of	0
IL-4	9
and	0
IL-7	9
signaling	0
can	0
not	0
substitute	0
for	0
an	0
active	0
v-Abl	9
kinase	0
in	0
transformed	7
pre-B	8
cells	8
.	0

Differential	0
regulation	0
of	0
coproporphyrinogen	1
oxidase	2
gene	2
between	0
erythroid	7
and	8
nonerythroid	8
cells	8
.	0

Coproporphyrinogen	9
oxidase	10
(	0
CPO	9
)	0
catalyzes	0
the	0
sixth	0
step	0
of	0
the	0
heme	9
biosynthetic	0
pathway	0
.	0

To	0
assess	0
the	0
tissue-specific	0
regulation	0
of	0
the	0
CPO	1
gene	2
promoter	2
,	0
mouse	1
genomic	2
DNA	2
clones	2
for	0
CPO	9
were	0
isolated	0
.	0

Structural	0
analysis	0
demonstrated	0
that	0
the	0
mouse	1
CPO	2
gene	2
spans	0
approximately	0
11	0
kb	0
and	0
consists	0
of	0
seven	1
exons	2
,	0
just	0
like	0
its	0
human	0
counterpart	0
.	0

Functional	0
analysis	0
of	0
the	0
promoter	0
by	0
transient	0
transfection	0
assays	0
indicated	0
that	0
synergistic	0
action	0
between	0
an	0
SP-1-like	1
element	2
at	0
-21/-12	0
,	0
a	0
GATA	1
site	2
at	0
-59/-54	0
,	0
and	0
a	0
novel	1
regulatory	2
element	2
,	0
CPRE	1
(	0
-	0
GGACTACAG	1
-	0
)	0
at	0
-49/-41	0
,	0
is	0
essential	0
for	0
the	0
promoter	0
activity	0
in	0
murine	7
erythroleukemia	8
(	8
MEL	8
)	8
cells	8
.	0

In	0
nonerythroid	5
NIH3T3	6
cells	6
,	0
however	0
,	0
the	0
GATA	1
site	2
is	0
not	0
required	0
.	0

Gel	0
mobility	0
shift	0
assays	0
demonstrated	0
that	0
specific	0
DNA-protein	9
complexes	10
can	0
be	0
formed	0
with	0
each	0
element	0
,	0
and	0
that	0
there	0
are	0
cell-specific	0
differences	0
in	0
factors	0
,	0
which	0
bind	0
to	0
the	0
SP-1-like	1
element	2
between	0
MEL	5
and	6
NIH3T3	6
cells	6
.	0

These	0
results	0
provide	0
evidence	0
for	0
differential	0
regulation	0
of	0
the	0
promoter	0
function	0
of	0
CPO	9
gene	0
between	0
erythroid	7
and	8
nonerythroid	8
cells	8
.	0

Copyright	0
1998	0
by	0
The	0
American	0
Society	0
of	0
Hematology	0

Tumor	9
suppressor	10
proteins	10
as	0
regulators	0
of	0
cell	0
differentiation	0
.	0

The	0
products	0
of	0
the	0
tumor	1
suppressor	2
genes	2
are	0
considered	0
to	0
function	0
as	0
specific	0
inhibitors	0
of	0
tumor	0
cell	0
growth	0
.	0

In	0
this	0
communication	0
,	0
we	0
present	0
evidence	0
to	0
show	0
that	0
these	0
proteins	0
inhibit	0
tumor	0
cell	0
proliferation	0
by	0
participating	0
in	0
the	0
activation	0
of	0
tumor	0
cell	0
differentiation	0
.	0

The	0
ML-1	5
human	6
myeloblastic	6
leukemia	6
cells	6
used	0
in	0
this	0
study	0
proliferate	0
when	0
treated	0
with	0
insulin-like	9
growth	10
factor	10
I	10
and	0
transferrin	9
but	0
differentiate	0
to	0
monocytes	7
when	0
exposed	0
to	0
tumor	9
necrosis	10
factor	10
alpha	10
or	0
transforming	9
growth	10
factor	10
beta1	10
,	0
or	0
to	0
macrophage-like	7
cells	8
when	0
treated	0
with	0
both	0
these	0
cytokines	9
.	0

Initiation	0
of	0
proliferation	0
but	0
not	0
of	0
differentiation	0
was	0
followed	0
by	0
a	0
20-	0
to	0
25-fold	0
increase	0
in	0
the	0
nuclear	0
level	0
of	0
the	0
DNA	9
polymerase-associated	10
processivity	10
factor	10
PCNA	10
and	0
of	0
the	0
proliferation-specific	9
transcription	10
factor	10
E2F1	10
.	0

In	0
contrast	0
,	0
induction	0
of	0
differentiation	0
but	0
not	0
of	0
proliferation	0
was	0
followed	0
by	0
a	0
25-	0
to	0
30-fold	0
increase	0
in	0
the	0
nuclear	0
level	0
of	0
the	0
tumor	9
suppressor	10
proteins	10
p53	10
(	0
wild	0
type	0
)	0
,	0
pRb	9
,	0
and	0
p130/Rb2	9
and	0
of	0
the	0
p53-dependent	9
cyclin	10
kinase	10
inhibitor	10
p21/Cip1	9
.	0

p53	9
and	0
p21/Cip1	9
,	0
respectively	0
,	0
inhibit	0
the	0
expression	0
and	0
activation	0
of	0
PCNA	9
,	0
whereas	0
p130	9
and	0
pRb	9
,	0
respectively	0
,	0
inhibit	0
the	0
expression	0
and	0
activation	0
of	0
E2F1	9
.	0

As	0
a	0
result	0
,	0
G1-S-associated	1
DNA	2
and	0
mRNA	0
synthesis	0
is	0
inhibited	0
,	0
growth	0
uncoupled	0
from	0
differentiation	0
,	0
and	0
maturation	0
enabled	0
to	0
proceed	0
.	0

Where	0
this	0
function	0
of	0
the	0
tumor	9
suppressor	10
proteins	10
is	0
impaired	0
,	0
the	0
capacity	0
for	0
differentiation	0
is	0
lost	0
,	0
which	0
leads	0
to	0
the	0
sustained	0
proliferation	0
that	0
is	0
characteristic	0
of	0
the	0
cancer	7
cell	8
.	0

Transcription	9
factor	10
activation	0
in	0
lymphokine	0
activated	0
killer	7
cells	8
and	0
lymphocytes	7
from	0
patients	0
receiving	0
IL-2	9
immunotherapy	0
.	0

Administration	0
of	0
the	0
cytokine	9
interleukin-2	10
(	0
IL-2	9
)	0
can	0
result	0
in	0
therapeutic	0
benefits	0
for	0
individuals	0
with	0
renal	0
cell	0
carcinoma	0
and	0
melanoma	0
.	0

Here	0
we	0
report	0
an	0
analysis	0
of	0
the	0
transcription	0
factor	0
families	0
AP-1	0
,	0
Sp1	0
,	0
NF-kappaB	9
,	0
and	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
STAT	9
)	0
in	0
cancer	7
patients	8
'	8
lymphocytes	8
before	0
and	0
after	0
IL-2	9
immunotherapy	0
,	0
as	0
assessed	0
by	0
a	0
gel-shift	0
assay	0
.	0

An	0
in	0
vitro	0
surrogate	0
of	0
IL-2	9
immunotherapy	0
is	0
the	0
incubation	0
of	0
fresh	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
from	0
healthy	0
individuals	0
in	0
IL-2	9
for	0
several	0
days	0
,	0
resulting	0
in	0
the	0
production	0
of	0
lymphokine	9
-activated	0
killer	0
(	0
LAK	0
)	0
activity	0
in	0
these	0
cultures	0
.	0

One	0
purpose	0
of	0
this	0
study	0
was	0
to	0
describe	0
the	0
profile	0
of	0
transcription	0
factor	0
activation	0
in	0
these	0
different	0
populations	0
,	0
and	0
assess	0
whether	0
the	0
patterns	0
observed	0
correlated	0
with	0
functional	0
differences	0
in	0
these	0
cells	0
.	0

Prior	0
to	0
in	0
vivo	0
IL-2	9
administration	0
,	0
the	0
typical	0
binding	0
pattern	0
of	0
transcription	9
factors	10
in	0
PBMC	7
from	0
patients	0
resembled	0
that	0
seen	0
in	0
fresh	0
PBMC	7
from	0
healthy	0
individuals	0
.	0

Over	0
a	0
3-week	0
course	0
of	0
IL-2	9
therapy	0
,	0
in	0
most	0
patients	0
the	0
binding	0
patterns	0
of	0
AP-1	9
,	0
Sp1	9
,	0
and	0
NF-kappaB	9
proteins	0
changed	0
to	0
resemble	0
those	0
seen	0
in	0
PBMC	7
activated	0
by	0
IL-2	9
in	0
vitro	0
.	0

However	0
,	0
the	0
cells	0
obtained	0
from	0
IL-2	9
-treated	0
patients	0
did	0
not	0
have	0
low-level	0
constitutive	0
expression	0
of	0
STAT	9
binding	10
factors	10
as	0
did	0
LAK	9
cells	10
.	0

When	0
these	0
patient	0
cells	0
were	0
further	0
stimulated	0
by	0
IL-2	9
in	0
vitro	0
,	0
additional	0
differences	0
in	0
STAT	9
induction	0
patterns	0
were	0
noted	0
.	0

These	0
data	0
provide	0
further	0
information	0
on	0
the	0
molecular	0
events	0
occurring	0
in	0
immune	7
cells	8
generated	0
through	0
in	0
vivo	0
and	0
in	0
vitro	0
administration	0
of	0
IL-2	9
,	0
and	0
further	0
document	0
that	0
there	0
is	0
not	0
a	0
precise	0
congruence	0
between	0
PBMC	7
activated	0
in	0
vivo	0
and	0
in	0
vitro	0
by	0
IL-2	9
.	0

Activated	7
platelets	8
induce	0
monocyte	9
chemotactic	10
protein-1	10
secretion	0
and	0
surface	0
expression	0
of	0
intercellular	7
adhesion	8
molecule-1	8
on	0
endothelial	7
cells	8
[	0
see	0
comments	0
]	0

BACKGROUND	0
:	0
Platelet/endothelium	0
interaction	0
plays	0
an	0
important	0
role	0
in	0
the	0
pathophysiology	0
of	0
inflammation	0
and	0
atherosclerosis	0
.	0

The	0
role	0
of	0
platelets	0
for	0
monocyte	9
chemotactic	10
protein-1	10
(	0
MCP-1	9
)	0
secretion	0
and	0
surface	0
expression	0
of	0
intercellular	7
adhesion	8
molecule-1	8
(	0
ICAM-1	9
)	0
on	0
endothelial	7
cells	8
has	0
been	0
assessed	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
Monolayers	0
of	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
were	0
incubated	0
with	0
nonstimulated	0
or	0
ADP-activated	7
platelets	8
for	0
6	0
hours	0
,	0
and	0
secretion	0
of	0
MCP-1	9
and	0
surface	0
expression	0
of	0
ICAM-1	9
were	0
determined	0
by	0
ELISA	0
and	0
flow	0
cytometry	0
,	0
respectively	0
.	0

In	0
the	0
presence	0
of	0
ADP-activated	7
platelets	8
,	0
both	0
MCP-1	9
secretion	0
and	0
ICAM-1	9
surface	0
expression	0
were	0
significantly	0
increased	0
compared	0
with	0
nonstimulated	7
platelets	8
(	0
P	0
<	0
0.02	0
)	0
.	0

Activation	0
of	0
the	0
transcription	9
factor	10
nuclear	10
factor-kappaB	10
(	0
NF-kappaB	9
)	0
determined	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
and	0
kappaB	9
-dependent	0
transcriptional	0
activity	0
was	0
enhanced	0
in	0
the	0
presence	0
of	0
activated	7
platelets	8
.	0

In	0
addition	0
,	0
ADP-activated	7
platelets	8
induced	0
MCP-1	0
and	0
ICAM-1	0
promoter-dependent	0
transcription	0
.	0

Liposomal	0
transfection	0
of	0
a	0
double-stranded	0
kappaB	0
phosphorothioate	0
oligonucleotide	0
,	0
but	0
not	0
of	0
the	0
mutated	0
form	0
,	0
inhibited	0
MCP-1	9
secretion	0
and	0
surface	0
expression	0
of	0
ICAM-1	9
on	0
activated	0
endothelium	0
(	0
P	0
<	0
0.05	0
)	0
.	0

CONCLUSIONS	0
:	0
The	0
present	0
study	0
indicates	0
that	0
activated	7
platelets	8
modulate	0
chemotactic	0
(	0
MCP-1	9
)	0
and	0
adhesive	0
(	0
ICAM-1	9
)	0
properties	0
of	0
endothelial	7
cells	8
via	0
an	0
NF-kappaB	9
-dependent	0
mechanism	0
.	0

Platelet-induced	0
activation	0
of	0
the	0
NF-kappaB	9
system	0
might	0
contribute	0
to	0
early	0
inflammatory	0
events	0
in	0
atherogenesis	0
.	0

Retinoid	9
X	10
receptor	10
and	0
c-cerbA/thyroid	9
hormone	10
receptor	10
regulate	0
erythroid	0
cell	0
growth	0
and	0
differentiation	0
.	0

Nuclear	9
receptors	10
are	0
important	0
regulators	0
of	0
erythroid	0
cell	0
development	0
.	0

Here	0
we	0
investigated	0
the	0
impact	0
of	0
retinoid	9
X	10
receptor	10
(	0
RXR	9
)	0
,	0
retinoic	9
acid	10
receptor	10
(	0
RAR	9
)	0
,	0
and	0
of	0
the	0
c-erbA/thyroid	9
hormone	10
(	10
T3	10
)	10
receptor	10
(	0
c-erbA/TR	9
)	0
on	0
growth	0
and	0
differentiation	0
of	0
erythroid	7
cells	8
using	0
an	0
in	0
vitro	0
culture	0
system	0
of	0
stem	7
cell	8
factor-dependent	8
erythroid	8
progenitors	8
.	0

RXR	9
,	0
RAR	9
,	0
and	0
c-erbA/TR	9
-specific	0
ligands	0
were	0
found	0
to	0
induce	0
erythroid-specific	1
gene	2
expression	0
and	0
to	0
accelerate	0
erythroid	0
differentiation	0
in	0
culture	0
,	0
with	0
T3	0
being	0
most	0
effective	0
.	0

Furthermore	0
,	0
while	0
ligand-activated	0
c-erbA/TR	9
accelerated	0
differentiation	0
,	0
unliganded	0
c-erbA/TR	9
effectively	0
blocked	0
differentiation	0
and	0
supported	0
sustained	0
progenitor	0
growth	0
in	0
culture	0
.	0

Thus	0
,	0
c-erbA/TR	9
appears	0
to	0
act	0
as	0
a	0
binary	0
switch	0
affecting	0
erythroid	7
cell	8
fate	8
:	0
unliganded	0
c-erbA/TR	9
supports	0
growth	0
while	0
ligand-activated	0
c-erbA/TR	9
induces	0
differentiation	0
.	0

Additionally	0
,	0
to	0
determine	0
the	0
impact	0
of	0
RXR	9
for	0
erythroid	0
cell	0
development	0
,	0
dominant	0
interfering	0
mutant	9
RXRs	10
,	0
lacking	0
the	0
transcriptional	0
activator	0
functions	0
AF-1	9
and	0
AF-2	9
,	0
or	0
AF-2	9
only	0
,	0
or	0
the	0
entire	1
DNA-binding	2
domain	2
,	0
were	0
introduced	0
into	0
erythroid	7
progenitor	8
cells	8
via	0
recombinant	0
retrovirus	0
vectors	0
and	0
analyzed	0
for	0
RXR	9
-specific	0
effects	0
.	0

It	0
was	0
found	0
that	0
expression	0
of	0
wild-type	9
RXR	10
and	0
of	0
the	0
RXR	9
mutants	10
devoid	0
of	0
AF-1	9
and/or	0
AF-2	9
supported	0
a	0
transient	0
outgrowth	0
of	0
erythroid	7
cells	8
.	0

In	0
marked	0
contrast	0
,	0
expression	0
of	0
the	0
dominant	9
interfering	10
deltaDNA-binding	10
domain	10
RXR	9
,	0
containing	0
a	0
deletion	0
of	0
the	0
entire	1
DNA-binding	2
domain	2
,	0
was	0
incompatible	0
with	0
erythroid	0
cell	0
growth	0
in	0
vitro	0
,	0
suggesting	0
a	0
pivotal	0
role	0
of	0
RXR	9
for	0
erythroid	0
cell	0
development	0
.	0

Peripheral	7
T	8
lymphocytes	8
from	0
women	0
with	0
breast	0
cancer	0
exhibit	0
abnormal	0
protein	0
expression	0
of	0
several	9
signaling	10
molecules	10
.	0

We	0
examined	0
signaling	0
molecules	0
of	0
peripheral	7
blood	8
T	8
lymphocytes	8
obtained	0
from	0
women	0
with	0
breast	0
cancer	0
.	0

In	0
6	0
of	0
14	0
patients	0
,	0
T	7
lymphocytes	8
displayed	0
an	0
impaired	0
ability	0
to	0
translocate	0
NFeB	9
p65	10
(	0
Rel-A	9
)	0
following	0
activation	0
by	0
anti-CD3	0
and	0
IL-2	9
.	0

This	0
observation	0
was	0
made	0
despite	0
normal	0
cytoplasmic	0
levels	0
of	0
the	0
Rel-A	9
protein	10
.	0

We	0
also	0
detected	0
abnormally	0
low	0
levels	0
of	0
the	0
signaling	9
molecules	10
T-cell	9
receptor	10
(	10
TCR	10
)	10
-zeta	10
,	0
ZAP-70	9
and	0
p56lck	9
in	0
4	0
of	0
14	0
breast	0
cancer	0
patients	0
,	0
i.e.	0
,	0
defects	0
in	0
T-cell	9
signaling	10
molecules	10
.	0

T	7
lymphocytes	8
from	0
6	0
of	0
the	0
14	0
patients	0
also	0
exhibited	0
an	0
increased	0
expression	0
of	0
the	0
dual	0
specificity	9
phosphatase	10
,	0
map	9
kinase	10
phosphatase-1	10
(	0
MKP-1	9
)	0
.	0

MKP-1	9
inactivates	0
MAP	9
kinase	10
and	0
therefore	0
may	0
interfere	0
with	0
the	0
activation	0
of	0
c-jun	1
and	0
c-fos	1
.	0

Abnormalities	0
of	0
I	0
or	0
more	0
signaling	9
molecules	10
were	0
found	0
in	0
9	0
of	0
14	0
patients	0
;	0
however	0
,	0
only	0
3	0
patients	0
had	0
T	7
cells	8
that	0
exhibited	0
all	0
5	0
defects	0
.	0

Our	0
data	0
have	0
implications	0
for	0
the	0
detection	0
of	0
potentially	0
dysfunctional	0
T	7
cells	8
in	0
patients	0
with	0
cancer	0
.	0

For	0
example	0
,	0
the	0
analysis	0
of	0
only	0
1	0
signaling	9
molecule	10
may	0
allow	0
patients	0
with	0
significant	0
defects	0
in	0
T-cell	0
signaling	0
to	0
go	0
unnoticed	0
.	0

Finally	0
,	0
despite	0
impaired	0
Rel-A	9
translocation	0
,	0
T	7
cells	8
were	0
capable	0
of	0
transcribing	0
IL-2	9
.	0

Impairments	0
in	0
the	0
translocation	0
of	0
Rel-B	9
and	0
c-Rel	9
further	0
suggest	0
that	0
the	0
NFKB	9
family	10
members	10
Rel-A	9
,	0
Rel-B	9
and	0
c-Rel	9
are	0
not	0
required	0
for	0
the	0
transcription	0
of	0
IL-2	9
in	0
the	0
peripheral	7
T	8
lymphocytes	8
of	0
patients	0
with	0
breast	0
cancer	0
.	0

Specific	0
glucocorticoid	0
binding	0
at	0
different	0
levels	0
of	0
human	0
motor	0
activity	0
.	0

We	0
studied	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
and	0
dissociation	0
constant	0
in	0
isolated	7
human	8
lymphocytes	8
as	0
well	0
as	0
blood	0
concentrations	0
of	0
hormones	0
produced	0
by	0
the	0
hypothalamic-hypophyseal-adrenocortical	0
system	0
in	0
three	0
experimental	0
series	0
:	0
at	0
normal	0
(	0
17	0
subjects	0
)	0
,	0
decreased	0
(	0
10	0
subjects	0
,	0
a	0
360-d	0
head-down	0
bed	0
rest	0
)	0
and	0
increased	0
(	0
8	0
subjects	0
,	0
physical	0
exercise	0
on	0
bicycle	0
ergometer	0
)	0
levels	0
of	0
motor	0
activity	0
.	0

In	0
the	0
first	0
series	0
we	0
found	0
that	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
and	0
dissociation	0
constant	0
did	0
not	0
depend	0
on	0
the	0
season	0
,	0
on	0
the	0
age	0
of	0
subjects	0
nor	0
on	0
cortisol	0
concentrations	0
in	0
blood	0
.	0

In	0
the	0
second	0
series	0
we	0
observed	0
the	0
following	0
:	0
at	0
the	0
end	0
of	0
the	0
first	0
month	0
of	0
bed	0
rest	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
and	0
receptor	0
affinity	0
significantly	0
increased	0
;	0
at	0
the	0
beginning	0
of	0
the	0
third	0
month	0
of	0
bed	0
rest	0
specific	0
glucocorticoid	0
binding	0
significantly	0
decreased	0
and	0
circadian	0
rhythms	0
of	0
adrenocorticotropin	0
and	0
cortisol	0
in	0
blood	0
varied	0
markedly	0
;	0
at	0
the	0
end	0
of	0
the	0
sixth	0
month	0
of	0
bed	0
rest	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
returned	0
to	0
prebed	0
rest	0
levels	0
and	0
dissociation	0
constant	0
decreased	0
.	0

In	0
the	0
third	0
series	0
physical	0
exercises	0
that	0
induced	0
an	0
activation	0
of	0
the	0
hypothalamic-hypophyseal-adrenocortical	0
system	0
(	0
maximal	0
physical	0
exercises	0
and	0
prolonged	0
submaximal	0
exercises	0
at	0
70	0
%	0
of	0
maximal	0
oxygen	0
uptake	0
)	0
led	0
to	0
a	0
significant	0
increase	0
in	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
without	0
changes	0
of	0
dissociation	0
constant	0
.	0

These	0
results	0
indicate	0
that	0
both	0
a	0
decrease	0
and	0
an	0
increase	0
of	0
human	0
motor	0
activity	0
resulted	0
in	0
significant	0
changes	0
of	0
specific	0
glucocorticoid	0
binding	0
which	0
were	0
not	0
influenced	0
by	0
changes	0
of	0
circulating	0
hormone	0
concentrations	0
in	0
blood	0
but	0
by	0
some	0
other	0
factors	0
affected	0
by	0
physical	0
activity	0
.	0

The	0
small	9
GTP-binding	10
protein	10
Rho	10
potentiates	0
AP-1	9
transcription	0
in	0
T	7
cells	8
.	0

The	0
Rho	9
family	0
of	0
small	9
GTP-binding	10
proteins	10
is	0
involved	0
in	0
the	0
regulation	0
of	0
cytoskeletal	0
structure	0
,	0
gene	0
transcription	0
,	0
specific	0
cell	0
fate	0
development	0
,	0
and	0
transformation	0
.	0

We	0
demonstrate	0
in	0
this	0
report	0
that	0
overexpression	0
of	0
an	0
activated	0
form	0
of	0
Rho	9
enhances	0
AP-1	9
activity	0
in	0
Jurkat	5
T	6
cells	6
in	0
the	0
presence	0
of	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
,	0
but	0
activated	0
Rho	9
(	0
V14Rho	9
)	0
has	0
little	0
or	0
no	0
effect	0
on	0
NFAT	9
,	0
Oct-1	9
,	0
and	0
NF-kappaB	1
enhancer	2
element	2
activities	0
under	0
similar	0
conditions	0
.	0

Overexpression	0
of	0
a	0
V14Rho	1
construct	2
incapable	0
of	0
membrane	0
localization	0
(	0
CAAX	1
deleted	2
)	0
abolishes	0
PMA-induced	0
AP-1	9
transcriptional	0
activation	0
.	0

The	0
effect	0
of	0
Rho	9
on	0
AP-1	9
is	0
independent	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
pathway	0
,	0
as	0
a	0
dominant-negative	9
MEK	10
and	0
a	0
MEK	9
inhibitor	0
(	0
PD98059	0
)	0
did	0
not	0
affect	0
Rho	9
-induced	0
AP-1	9
activity	0
.	0

V14Rho	9
binds	0
strongly	0
to	0
protein	9
kinase	10
Calpha	10
(	0
PKCalpha	9
)	0
in	0
vivo	0
;	0
however	0
,	0
deletion	0
of	0
the	0
CAAX	1
site	2
on	0
V14Rho	9
severely	0
diminished	0
this	0
association	0
.	0

Evidence	0
for	0
a	0
role	0
for	0
PKCalpha	9
as	0
an	0
effector	0
of	0
Rho	9
was	0
obtained	0
by	0
the	0
observation	0
that	0
coexpression	0
of	0
the	0
N-terminal	9
domain	10
of	0
PKCalpha	9
blocked	0
the	0
effects	0
of	0
activated	0
Rho	9
plus	0
PMA	0
on	0
AP-1	9
transcriptional	0
activity	0
.	0

These	0
data	0
suggest	0
that	0
Rho	9
potentiates	0
AP-1	9
transcription	0
during	0
T-cell	0
activation	0

Changes	0
in	0
PKC	9
isoforms	10
in	0
human	7
alveolar	8
macrophages	8
compared	0
with	0
blood	7
monocytes	8
.	0

Alveolar	0
macrophages	0
play	0
an	0
important	0
role	0
in	0
host	0
defense	0
and	0
in	0
other	0
types	0
of	0
inflammatory	0
processes	0
in	0
the	0
lung	0
.	0

These	0
cells	0
exhibit	0
many	0
alterations	0
in	0
function	0
compared	0
with	0
their	0
precursor	7
cells	8
,	0
blood	7
monocytes	8
.	0

To	0
evaluate	0
a	0
potential	0
mechanism	0
for	0
these	0
differences	0
in	0
function	0
,	0
we	0
evaluated	0
expression	0
of	0
protein	9
kinase	10
C	10
(	10
PKC	10
)	10
isoforms	10
.	0

We	0
found	0
an	0
increase	0
in	0
Ca2+-dependent	9
PKC	10
isoforms	10
in	0
monocytes	0
compared	0
with	0
alveolar	0
macrophages	0
.	0

We	0
also	0
found	0
differential	0
expression	0
of	0
the	0
Ca2+-independent	9
isoforms	10
in	0
alveolar	7
macrophages	8
compared	0
with	0
monocytes	7
.	0

One	0
consequence	0
of	0
the	0
activation	0
of	0
PKC	9
can	0
be	0
increased	0
expression	0
of	0
mitogen-activated	9
protein	10
(	10
MAP	10
)	10
kinase	10
pathways	0
.	0

Therefore	0
,	0
we	0
also	0
evaluated	0
activation	0
of	0
the	0
MAP	9
kinase	10
extracellular	10
signal-regulated	10
kinase	10
(	10
ERK	10
)	10
2	10
by	0
the	0
phorbol	0
ester	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
.	0

PMA	0
activated	0
ERK2	9
kinase	10
in	0
both	0
alveolar	7
macrophages	8
and	0
monocytes	7
;	0
however	0
,	0
monocytes	7
consistently	0
showed	0
a	0
significantly	0
greater	0
activation	0
of	0
ERK2	9
kinase	10
by	0
PMA	0
compared	0
with	0
alveolar	7
macrophages	8
.	0

Another	0
known	0
consequence	0
of	0
the	0
activation	0
of	0
PKC	9
and	0
subsequent	0
activation	0
of	0
ERK	9
kinase	10
is	0
activation	0
of	0
the	0
transcription	9
factor	10
activator	10
protein-1	10
(	0
AP-1	9
)	0
.	0

We	0
evaluated	0
the	0
activation	0
of	0
AP-1	9
by	0
PMA	0
in	0
both	0
monocytes	7
and	0
macrophages	0
.	0

We	0
found	0
very	0
little	0
detectable	0
activation	0
of	0
AP-1	9
,	0
as	0
assessed	0
in	0
a	0
gel	0
shift	0
assay	0
,	0
in	0
alveolar	7
macrophages	8
,	0
whereas	0
monocytes	7
showed	0
a	0
substantial	0
activation	0
of	0
AP-1	9
by	0
PMA	0
.	0

These	0
studies	0
show	0
that	0
the	0
differential	0
expression	0
of	0
PKC	9
isoforms	10
in	0
alveolar	7
macrophages	8
and	0
blood	7
monocytes	8
is	0
associated	0
with	0
important	0
functional	0
alterations	0
in	0
the	0
cells	0
.	0

Expression	0
of	0
gamma-IFN	1
responsive	2
genes	2
in	0
scavenger	0
receptor	0
over-expressing	7
monocytes	8
is	0
associated	0
with	0
xanthomatosis	0
.	0

We	0
have	0
recently	0
described	0
an	0
inherited	0
over-expression	0
of	0
the	0
macrophage	9
scavenger	10
receptor	10
(	0
SR	9
)	0
in	0
blood	7
monocytes	8
from	0
members	0
of	0
a	0
kindred	0
,	0
only	0
two	0
of	0
whom	0
displayed	0
extensive	0
xanthomatosis	0
.	0

Using	0
mRNA	0
differential	0
display	0
we	0
demonstrated	0
abnormally	0
high	0
expression	0
of	0
the	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
(	0
STAT1alpha	9
)	0
in	0
monocytes	7
from	0
the	0
proband	5
II-2	6
.	0

Expression	0
of	0
gamma-interferon	9
inducible	10
protein	10
10	10
(	0
IP-10	9
)	0
,	0
a	0
STAT1alpha-responsive	1
gene	2
and	0
mediator	0
of	0
inflammatory	0
response	0
,	0
was	0
also	0
abnormally	0
expressed	0
in	0
the	0
monocytes	7
from	0
II-2	5
.	0

Over-expression	0
of	0
both	0
genes	0
was	0
restricted	0
to	0
monocytes	7
from	0
II-2	5
and	0
was	0
not	0
observed	0
in	0
monocytes	7
from	0
the	0
clinically	0
unaffected	0
family	0
members	0
,	0
unlike	0
that	0
of	0
SR	9
.	0

Gel	0
retardation	0
assays	0
with	0
THP-1	5
cell	6
extracts	0
identified	0
gamma-IFN	9
inducible	0
DNA	0
binding	0
activity	0
to	0
three	0
potential	0
STATI	1
DNA	2
binding	2
elements	2
in	0
the	0
human	1
IP-10	2
promoter	2
region	2
from	0
nucleotides	1
-	2
245	2
to	2
-	2
188	2
.	0

Taken	0
together	0
these	0
results	0
suggest	0
that	0
gamma-interferon	0
mediated	0
cell	0
activation	0
is	0
responsible	0
for	0
STAT1alpha	9
-induced	0
transcription	0
of	0
the	0
IP-10	9
gene	0
in	0
THP-1	5
macrophages	6
as	0
well	0
as	0
in	0
monocytes	7
from	0
II-2	5
.	0

Analysis	0
of	0
monocytes	7
from	0
familial	0
hypercholesterolemic	0
(	0
FH	0
)	0
subjects	0
,	0
who	0
frequently	0
develop	0
xanthomatosis	0
,	0
revealed	0
a	0
significant	0
number	0
of	0
subjects	0
with	0
elevated	0
STAT1alpha	0
and	0
IP-10	0
expression	0
.	0

Our	0
data	0
suggest	0
that	0
the	0
inflammatory	0
effects	0
of	0
gamma-IFN	9
signaling	0
could	0
play	0
a	0
role	0
in	0
foam	0
cell	0
formation	0
and	0
xanthomatosis	0
.	0

Redox	0
signals	0
and	0
NF-kappaB	9
activation	0
in	0
T	7
cells	8
.	0

Accumulating	0
data	0
from	0
a	0
number	0
of	0
laboratories	0
have	0
recently	0
indicated	0
that	0
the	0
response	0
of	0
transcription	9
factor	10
NF-kappaB	9
to	0
alterations	0
in	0
the	0
redox	0
homeostasis	0
of	0
cells	0
may	0
play	0
an	0
important	0
role	0
in	0
modulating	0
immune	0
function	0
.	0

The	0
activation	0
of	0
NF-kappaB	9
has	0
been	0
recognized	0
to	0
regulate	0
a	0
number	0
of	0
genes	0
necessary	0
for	0
normal	0
T	0
cell	0
responses	0
including	0
IL-2	9
,	0
IL-6	9
,	0
IL-8	9
,	0
and	0
several	0
T	9
cell	10
surface	10
receptors	10
.	0

Diminished	0
NF-kappaB	9
activity	0
has	0
been	0
shown	0
to	0
occur	0
in	0
T	7
cells	8
with	0
aging	0
,	0
suggesting	0
that	0
impaired	0
activation	0
of	0
NF-kappaB	9
might	0
occur	0
during	0
cellular	0
senescence	0
.	0

In	0
addition	0
,	0
aberrancies	0
in	0
NF-kappaB	9
activity	0
have	0
been	0
implicated	0
in	0
the	0
immunopathogenesis	0
of	0
diseases	0
involving	0
immune	0
or	0
inflammatory	0
processes	0
such	0
as	0
atherosclerosis	0
and	0
HIV-1	0
infection	0
.	0

The	0
role	0
of	0
H2O2	0
and	0
other	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
as	0
an	0
integratory	0
secondary	0
messenger	0
for	0
divergent	0
T	0
cell	0
signals	0
has	0
been	0
complicated	0
by	0
the	0
fact	0
that	0
various	0
T	5
cell	6
lines	6
and	0
peripheral	7
blood	8
T	8
cells	8
differ	0
markedly	0
in	0
the	0
levels	0
of	0
NF-kappaB	9
activation	0
induced	0
by	0
oxidant	0
stress	0
.	0

Additionally	0
,	0
proposed	0
pathways	0
of	0
NF-kappaB	9
activation	0
have	0
been	0
based	0
on	0
indirect	0
evidence	0
provided	0
by	0
experiments	0
which	0
used	0
antioxidants	0
to	0
inhibit	0
active	0
NF-kappaB	9
formation	0
.	0

Further	0
,	0
complete	0
activation	0
of	0
T	7
cells	8
requires	0
at	0
least	0
two	0
signals	0
,	0
one	0
that	0
stimulates	0
an	0
increase	0
in	0
intracellular	0
calcium	0
and	0
one	0
that	0
stimulates	0
enzymatic	0
processes	0
including	0
kinases	0
.	0

Similarly	0
,	0
substantial	0
evidence	0
indicates	0
that	0
full	0
activation	0
of	0
NF-kappaB	9
requires	0
dual	0
signals	0
.	0

The	0
ability	0
of	0
H2O2	0
or	0
other	0
ROS	0
to	0
induce	0
T	0
cell	0
signals	0
and	0
functional	0
responses	0
by	0
these	0
two	0
mechanisms	0
is	0
reviewed	0
and	0
the	0
specific	0
response	0
of	0
NF-kappaB	9
to	0
redox	0
changes	0
in	0
T	7
cells	8
is	0
examined	0
.	0

Data	0
are	0
also	0
presented	0
to	0
suggest	0
that	0
the	0
redox	0
regulation	0
in	0
NF-kappaB	9
activation	0
may	0
be	0
relevant	0
to	0
immune-related	0
diseases	0
and	0
to	0
aging	0
.	0

Uncoupling	0
of	0
nonreceptor	0
tyrosine	9
kinases	10
from	0
PLC-gamma1	9
in	0
an	0
SLP-76-deficient	0
T	0
cell	0
.	0

Activation	0
of	0
nonreceptor	9
protein	10
tyrosine	10
kinases	10
(	0
PTKs	9
)	0
is	0
essential	0
for	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
responsiveness	0
;	0
however	0
,	0
the	0
function	0
of	0
individual	0
PTK	9
substrates	10
is	0
often	0
uncertain	0
.	0

A	0
mutant	5
T	6
cell	6
line	6
was	0
isolated	0
that	0
lacked	0
expression	0
of	0
SLP-76	9
(	0
SH2	9
domain-containing	10
leukocyte	10
protein	10
of	0
76	0
kilodaltons	0
)	0
,	0
a	0
hematopoietically	9
expressed	10
adaptor	10
protein	10
and	0
PTK	9
substrate	10
.	0

SLP-76	9
was	0
not	0
required	0
for	0
TCR	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
most	0
proteins	0
,	0
but	0
was	0
required	0
for	0
optimal	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
phospholipase	9
C-gamma1	10
(	0
PLC-gamma1	9
)	0
,	0
as	0
well	0
as	0
Ras	9
pathway	0
activation	0
.	0

TCR	9
-inducible	0
gene	0
expression	0
was	0
dependent	0
on	0
SLP-76	9
.	0

Thus	0
,	0
coupling	0
of	0
TCR-regulated	9
PTKs	10
to	0
downstream	0
signaling	0
pathways	0
requires	0
SLP-76	9
.	0

A	0
novel	0
function	0
of	0
Stat1	9
and	0
Stat3	9
proteins	0
in	0
erythropoietin	9
-induced	0
erythroid	0
differentiation	0
of	0
a	0
human	5
leukemia	6
cell	6
line	6
.	0

We	0
recently	0
determined	0
that	0
erythropoietin	9
(	0
EPO	9
)	0
activates	0
3	0
members	0
of	0
the	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
(	0
STAT	0
)	0
family	0
,	0
Stat1alpha	9
,	0
Stat3	9
,	0
and	0
Stat5	9
,	0
in	0
the	0
human	5
EPO-dependent	6
cell	6
lines	6
,	0
UT-7	5
and	0
UT-7/EPO	5
(	0
Kirito	0
et	0
al	0
,	0
J	0
Biol	0
Chem	0
272	0
:	0
16507	0
,	0
1997	0
)	0
.	0

In	0
addition	0
,	0
we	0
have	0
shown	0
that	0
Stat1alpha	9
,	0
but	0
not	0
Stat3	9
,	0
is	0
involved	0
in	0
EPO	9
-induced	0
cellular	0
proliferation	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
roles	0
of	0
Stat1alpha	9
and	0
Stat3	9
in	0
EPO	9
-induced	0
erythroid	0
differentiation	0
.	0

UT-7/GM	5
was	0
used	0
as	0
a	0
model	0
system	0
,	0
because	0
this	0
cell	0
line	0
can	0
differentiate	0
into	0
erythroid-lineage	7
cells	8
with	0
EPO	9
treatment	0
(	0
Komatsu	0
et	0
al	0
,	0
Blood	0
89	0
:	0
4021	0
,	0
1997	0
)	0
.	0

We	0
found	0
that	0
EPO	9
did	0
not	0
activate	0
Stat1alpha	9
or	0
Stat3	9
in	0
UT-7/GM	5
cells	6
.	0

Transfection	0
experiments	0
showed	0
that	0
both	0
Stat1alpha	9
and	0
Stat3	9
inhibited	0
the	0
induction	0
by	0
EPO	9
of	0
gamma-globin	3
and	4
erythroid-specific	4
5-aminolevulinate	4
synthetase	4
transcripts	4
,	0
resulting	0
in	0
a	0
reduction	0
of	0
the	0
percentage	0
of	0
hemoglobin-positive	7
cells	8
.	0

Dominant	0
negative	0
forms	0
of	0
Stat1alpha	9
or	0
Stat3	9
promoted	0
the	0
EPO	9
-induced	0
erythroid	0
differentiation	0
of	0
UT-7/GM	5
cells	6
,	0
even	0
in	0
the	0
presence	0
of	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
,	0
although	0
this	0
cytokine	0
never	0
induced	0
erythroid	0
differentiation	0
of	0
the	0
parent	5
UT-7/GM	6
cells	6
with	0
or	0
without	0
EPO	9
.	0

A	0
cell	0
cycle	0
analysis	0
showed	0
that	0
the	0
constitutive	0
activation	0
of	0
Stat1alpha	9
,	0
but	0
not	0
Stat3	9
,	0
shortened	0
the	0
period	0
of	0
G0/G1	0
prolongation	0
caused	0
by	0
EPO	9
stimulation	0
.	0

Taken	0
together	0
,	0
our	0
data	0
suggest	0
that	0
Stat1alpha	9
and	0
Stat3	9
act	0
as	0
negative	0
regulators	0
in	0
EPO	9
-induced	0
erythroid	0
differentiation	0
.	0

Specifically	0
,	0
Stat1alpha	9
may	0
activate	0
a	0
cell	1
cycle-associated	2
gene	2
(	0
s	0
)	0
,	0
leading	0
to	0
the	0
entry	0
of	0
cells	0
into	0
the	0
cell	0
cycle	0
.	0

Ro	0
09-2210	0
exhibits	0
potent	0
anti-proliferative	0
effects	0
on	0
activated	0
T	7
cells	8
by	0
selectively	0
blocking	0
MKK	9
activity	0
.	0

By	0
using	0
high	0
throughput	0
screening	0
of	0
microbial	0
broths	0
,	0
we	0
have	0
identified	0
a	0
compound	0
,	0
designated	0
Ro	0
09-2210	0
,	0
which	0
is	0
able	0
to	0
block	0
anti-CD3	9
induced	0
peripheral	0
blood	0
T	0
cell	0
activation	0
with	0
an	0
IC50	0
=	0
40	0
nM	0
.	0

Ro	0
09-2210	0
was	0
also	0
able	0
to	0
block	0
antigen-induced	0
IL-2	9
secretion	0
with	0
an	0
IC50	0
=	0
30	0
nM	0
,	0
but	0
was	0
considerably	0
less	0
potent	0
at	0
blocking	0
Ca2+	0
flux	0
stimulated	0
by	0
anti-CD3	9
treatment	0
.	0

To	0
determine	0
the	0
mechanism	0
of	0
action	0
of	0
Ro	0
09-2210	0
,	0
we	0
set	0
up	0
a	0
transient	0
expression	0
system	0
in	0
Jurkat	5
T	6
cells	6
using	0
a	0
variety	0
of	0
reporter	0
gene	0
constructs	0
and	0
showed	0
effective	0
inhibition	0
of	0
phorbol	0
ester/ionomycin-induced	0
NF-AT	9
activation	0
and	0
anti-CD3	0
induced	0
NF-AT	9
with	0
IC50	0
=	0
7.7	0
and	0
10	0
nM	0
,	0
respectively	0
.	0

Ro	0
09-2210	0
was	0
also	0
able	0
to	0
inhibit	0
phorbol	0
ester/ionomycin-induced	0
activation	0
of	0
AP1	9
with	0
IC50	0
=	0
<	0
10	0
nM	0
.	0

We	0
further	0
showed	0
that	0
Ro	0
09-2210	0
was	0
unable	0
to	0
inhibit	0
c-jun	1
induced	0
expression	0
of	0
AP1-dependent	1
reporter	2
constructs	2
(	0
IC50	0
>	0
500	0
nM	0
)	0
,	0
but	0
was	0
able	0
to	0
potently	0
inhibit	0
ras-induced	0
AP1	9
activation	0
(	0
IC50	0
=	0
20	0
nM	0
)	0
.	0

This	0
suggested	0
that	0
Ro	0
09-2210	0
was	0
inhibiting	0
an	0
activator	0
of	0
AP-1	9
which	0
was	0
upstream	0
of	0
c-jun	1
and	0
downstream	0
of	0
ras	9
signaling	0
.	0

To	0
investigate	0
further	0
,	0
we	0
then	0
purified	0
a	0
number	0
of	0
different	0
kinases	0
,	0
including	0
PKC	9
,	0
PhK	9
,	0
ZAP-70	9
,	0
ERK	9
,	0
and	0
MEK	9
1	10
(	0
a	0
MKK	9
)	0
,	0
and	0
showed	0
that	0
Ro	0
09-2210	0
was	0
a	0
selective	0
inhibitor	0
of	0
MEK1	9
in	0
vitro	0
(	0
IC50	0
=	0
59	0
nM	0
)	0
.	0

Coactivation	0
by	0
OCA-B	9
:	0
definition	0
of	0
critical	0
regions	0
and	0
synergism	0
with	0
general	0
cofactors	0
.	0

Molecular	0
dissection	0
of	0
the	0
B-cell-specific	0
transcription	0
coactivator	0
OCA-B	9
has	0
revealed	0
distinct	0
regions	0
important	0
,	0
respectively	0
,	0
for	0
recruitment	0
to	0
immunoglobulin	1
promoters	2
through	0
interaction	0
with	0
octamer-bound	9
Oct-1	10
and	0
for	0
subsequent	0
coactivator	0
function	0
.	0

Further	0
analysis	0
of	0
general	0
coactivator	0
requirements	0
showed	0
that	0
selective	0
removal	0
of	0
PC4	9
from	0
the	0
essential	0
USA	0
fraction	0
severely	0
impairs	0
Oct-1	0
and	0
OCA-B	0
function	0
in	0
a	0
cell-free	0
system	0
reconstituted	0
with	0
partially	0
purified	0
factors	0
.	0

Full	0
activity	0
can	0
be	0
restored	0
by	0
the	0
combined	0
action	0
of	0
recombinant	0
PC4	9
and	0
the	0
PC4	9
-depleted	0
USA	0
fraction	0
,	0
thus	0
suggesting	0
a	0
joint	0
requirement	0
for	0
PC4	9
and	0
another	0
,	0
USA-derived	0
component	0
(	0
s	0
)	0
for	0
optimal	0
function	0
of	0
Oct-1	9
/OCA-B	9
in	0
the	0
reconstituted	0
system	0
.	0

Indeed	0
,	0
USA-derived	9
PC2	10
was	0
found	0
to	0
act	0
synergistically	0
with	0
PC4	9
in	0
reproducing	0
the	0
function	0
of	0
intact	0
USA	0
in	0
the	0
assay	0
system	0
.	0

Consistent	0
with	0
the	0
requirement	0
for	0
PC4	9
in	0
the	0
reconstituted	0
system	0
,	0
OCA-B	9
was	0
found	0
to	0
interact	0
directly	0
with	0
PC4	9
.	0

Surprisingly	0
,	0
however	0
,	0
removal	0
of	0
PC4	9
from	0
the	0
unfractionated	0
nuclear	0
extract	0
has	0
no	0
detrimental	0
effect	0
on	0
OCA-B	9
/	0
Oct-1	9
-dependent	0
transcription	0
.	0

These	0
results	0
lead	0
to	0
a	0
general	0
model	0
for	0
the	0
synergistic	0
function	0
of	0
activation	0
domains	0
in	0
Oct-1	9
and	0
OCA-B	9
(	0
mediated	0
by	0
the	0
combined	0
action	0
of	0
the	0
multiple	0
USA	0
components	0
)	0
and	0
,	0
further	0
,	0
suggest	0
a	0
functional	0
redundancy	0
in	0
general	9
coactivators	10
.	0

Activation	0
of	0
Stat-3	9
is	0
involved	0
in	0
the	0
induction	0
of	0
apoptosis	0
after	0
ligation	0
of	0
major	9
histocompatibility	10
complex	10
class	10
I	10
molecules	10
on	0
human	5
Jurkat	6
T	6
cells	6
.	0

Activation	0
of	0
Janus	9
tyrosine	10
kinases	10
(	0
Jak	9
)	0
and	0
Signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
Stat	9
)	0
after	0
ligation	0
of	0
major	9
histocompatibility	10
complex	10
class	10
I	10
(	0
MHC-I	9
)	0
was	0
explored	0
in	0
Jurkat	5
T	6
cells	6
.	0

Cross-linking	0
of	0
MHC-I	9
mediated	0
tyrosine	0
phosphorylation	0
of	0
Tyk2	9
,	0
but	0
not	0
Jak1	9
,	0
Jak2	9
,	0
and	0
Jak3	9
.	0

In	0
addition	0
,	0
the	0
transcription	9
factor	10
Stat-3	9
was	0
tyrosine	0
phosphorylated	0
in	0
the	0
cytoplasm	0
and	0
subsequently	0
translocated	0
to	0
the	0
cell	0
nucleus	0
.	0

Data	0
obtained	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
suggested	0
that	0
the	0
activated	9
Stat-3	10
protein	10
associates	0
with	0
the	0
human	1
serum-inducible	2
element	2
(	2
hSIE	2
)	2
DNA-probe	2
derived	0
from	0
the	0
interferon-gamma	1
activated	2
site	2
(	0
GAS	1
)	0
in	0
the	0
c-fos	1
promoter	2
,	0
a	0
common	0
DNA	0
sequence	0
for	0
Stat	9
protein	10
binding	0
.	0

An	0
association	0
between	0
hSIE	1
and	0
Stat-3	9
after	0
MHC-I	9
ligation	0
was	0
directly	0
demonstrated	0
by	0
precipitating	0
Stat-3	9
from	0
nuclear	0
extracts	0
with	0
biotinylated	0
hSIE	1
probe	2
and	0
avidin	9
-coupled	0
agarose	0
.	0

To	0
investigate	0
the	0
function	0
of	0
the	0
activated	0
Stat-3	9
,	0
Jurkat	5
T	6
cells	6
were	0
transiently	0
transfected	0
with	0
a	0
Stat-3	9
isoform	10
lacking	0
the	0
transactivating	9
domain	10
.	0

This	0
dominant-negative	9
acting	10
Stat-3	10
isoform	10
significantly	0
inhibited	0
apoptosis	0
induced	0
by	0
ligation	0
of	0
MHC-I	9
.	0

In	0
conclusion	0
,	0
our	0
data	0
suggest	0
the	0
involvement	0
of	0
the	0
Jak/Stat	9
signal	0
pathway	0
in	0
MHC-I	9
-induced	0
signal	0
transduction	0
in	0
T	7
cells	8
.	0

IL-2	9
-induced	0
growth	0
of	0
CD8+	7
T	8
cell	8
prolymphocytic	8
leukemia	8
cells	8
mediated	0
by	0
NF-kappaB	9
induction	0
and	0
IL-2	9
receptor	10
alpha	10
expression	0
.	0

The	0
binding	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
to	0
its	0
receptor	0
on	0
normal	0
T	7
cells	8
induces	0
nuclear	0
expression	0
of	0
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
,	0
activation	0
of	0
the	0
IL-2	1
receptor	2
(	2
IL-2R	2
)	2
alpha	2
chain	2
gene	2
,	0
and	0
cell	0
proliferation	0
.	0

In	0
the	0
present	0
study	0
,	0
the	0
role	0
of	0
IL-2R	9
signaling	0
in	0
the	0
growth	0
of	0
CD8+	5
T	6
cell	6
prolymphocytic	6
leukemia	6
(	6
T-PLL	6
)	6
cells	6
has	0
been	0
investigated	0
.	0

Flow	0
cytometry	0
revealed	0
that	0
primary	7
leukemia	8
cells	8
from	0
a	0
patient	0
with	0
CD8+	0
T-PLL	0
expressed	0
IL-2Ralpha	9
and	10
beta	10
chains	10
,	0
and	0
the	0
cells	0
showed	0
a	0
proliferative	0
response	0
and	0
an	0
increase	0
in	0
IL-2Ralpha	9
expression	0
on	0
culture	0
with	0
exogeneous	0
IL-2	9
.	0

Northern	0
blot	0
analysis	0
failed	0
to	0
detect	0
IL-2	3
mRNA	4
,	0
suggesting	0
that	0
IL-2	9
may	0
act	0
in	0
a	0
paracrine	0
manner	0
in	0
vivo	0
.	0

Electrophoretic	0
mobility-shift	0
assays	0
revealed	0
that	0
recombinant	0
IL-2	9
increased	0
NF-kappaB	9
binding	0
activity	0
in	0
nuclear	0
extracts	0
of	0
the	0
leukemia	7
cells	8
,	0
and	0
Northern	0
blot	0
analysis	0
showed	0
that	0
IL-2	9
increased	0
the	0
abundance	0
of	0
mRNAs	0
encoding	0
the	0
NF-kappaB	9
components	0
c-Rel	9
and	0
KBF1	9
in	0
these	0
cells	0
.	0

IL-2	9
binding	0
analysis	0
demonstrated	0
that	0
IL-2	9
markedly	0
increased	0
the	0
number	0
of	0
low	0
affinity	0
IL-2Rs	9
on	0
the	0
leukemia	7
cells	8
,	0
without	0
an	0
effect	0
on	0
the	0
number	0
of	0
high-affinity	9
IL-2Rs	10
.	0

These	0
results	0
show	0
that	0
IL-2	9
is	0
capable	0
of	0
inducing	0
the	0
nuclear	0
expression	0
of	0
NF-kappaB	9
in	0
primary	5
CD8+	6
T-PLL	6
cells	6
,	0
and	0
that	0
this	0
effect	0
is	0
mediated	0
,	0
at	0
least	0
in	0
part	0
,	0
at	0
a	0
pretranslational	0
level	0

Dimethyldithiocarbamate	0
inhibits	0
in	0
vitro	0
activation	0
of	0
primary	7
human	8
CD4+	8
T	8
lymphocytes	8
.	0

Dithiocarbamates	0
(	0
DTC	0
)	0
,	0
a	0
diverse	0
group	0
of	0
industrial	0
and	0
therapeutic	0
chemicals	0
,	0
have	0
been	0
reported	0
to	0
inhibit	0
,	0
enhance	0
or	0
have	0
no	0
effect	0
on	0
the	0
immune	0
system	0
.	0

These	0
apparent	0
inconsistencies	0
reflect	0
the	0
complexity	0
of	0
the	0
DTCs	0
biological	0
activities	0
and	0
are	0
probably	0
due	0
in	0
part	0
to	0
differences	0
in	0
dose	0
,	0
route	0
of	0
exposure	0
,	0
animal	0
species	0
used	0
and/or	0
specific	0
compound	0
tested	0
.	0

The	0
studies	0
described	0
herein	0
were	0
undertaken	0
to	0
investigate	0
the	0
immunotoxicity	0
of	0
one	0
member	0
of	0
this	0
family	0
,	0
dimethyldithiocarbamate	0
(	0
DMDTC	0
)	0
.	0

We	0
demonstrate	0
that	0
0.1-0.5	0
microM	0
DMDTC	0
inhibits	0
TNF-alpha	9
-induced	0
activation	0
of	0
NF-kappaB	9
in	0
primary	7
human	8
CD4+	8
T	8
cells	8
.	0

This	0
inhibition	0
is	0
not	0
accompanied	0
by	0
a	0
loss	0
in	0
viability	0
,	0
and	0
DMDTC-treated	7
T	8
cells	8
retain	0
other	0
active	0
signaling	0
pathways	0
throughout	0
the	0
exposure	0
duration	0
.	0

The	0
inhibition	0
of	0
NF-kappaB	9
is	0
apparently	0
permanent	0
as	0
DMDTC-treated	7
T	8
cells	8
did	0
not	0
regain	0
normal	0
TNF-alpha	9
activation	0
,	0
even	0
after	0
72	0
h	0
in	0
culture	0
.	0

DMDTC	0
does	0
not	0
appear	0
to	0
alter	0
NF-kappaB	9
directly	0
as	0
pre-incubation	0
of	0
nuclear	0
extracts	0
with	0
DMDTC	0
does	0
not	0
diminish	0
binding	0
activity	0
of	0
this	0
protein	0
.	0

We	0
further	0
demonstrate	0
that	0
0.1-0.5	0
microM	0
DMDTC	0
inhibits	0
intracellular	0
IL-2	9
production	0
and	0
decreases	0
surface	0
expression	0
of	0
CD25	9
(	0
the	0
alpha	9
subunit	10
of	0
the	0
IL-2	9
receptor	10
)	0
in	0
T	7
cells	8
stimulated	0
with	0
phorbol	0
ester	0
.	0

These	0
data	0
demonstrate	0
that	0
DMDTC	0
is	0
a	0
potent	0
immunosuppressive	0
compound	0
in	0
vitro	0
.	0

Human	1
15-lipoxygenase	2
gene	2
promoter	2
:	0
analysis	0
and	0
identification	0
of	0
DNA	1
binding	2
sites	2
for	0
IL-13-induced	9
regulatory	10
factors	10
in	0
monocytes	7
.	0

In	0
order	0
to	0
study	0
the	0
transcriptional	0
control	0
of	0
15-LO	9
expression	0
,	0
we	0
have	0
cloned	0
and	0
sequenced	0
the	0
human	1
15-LO	2
promoter	2
region	2
.	0

The	0
15-LO	9
promoter	0
is	0
associated	0
with	0
a	0
CpG	0
island	0
at	0
the	0
5'-end	1
of	0
the	0
gene	0
,	0
and	0
sequence	0
analysis	0
reveals	0
putative	0
Sp1	1
and	2
Ap2	2
binding	2
site/s	2
and	0
absence	0
of	0
TATA	1
or	2
CAAT	2
motifs	2
.	0

Transcription	0
is	0
initiated	0
at	0
one	0
major	0
site	0
.	0

Using	0
deletion	1
constructs	2
,	0
we	0
have	0
defined	0
an	0
active	1
promoter	2
region	2
of	0
1056	0
bp	0
.	0

Gel-shift	0
assays	0
revealed	0
that	0
transcriptional	9
factor	10
(	0
s	0
)	0
induced	0
only	0
in	0
response	0
to	0
IL-13	9
treatment	0
of	0
human	7
peripheral	8
blood	8
monocytes	8
bind	0
to	0
the	0
15-LO	1
promoter	2
DNA	2
.	0

Two	0
regions	0
,	0
DP1	1
(	0
-140	1
to	2
-92	2
bp	2
)	0
and	0
DP2	1
(	0
-353	1
to	2
-304	2
bp	2
)	0
of	0
the	0
promoter	0
were	0
essential	0
for	0
transcription	0
in	0
HeLa	5
cells	6
and	0
human	7
peripheral	8
monocytes	8
.	0

Hela	0
nuclear	0
extracts	0
contained	0
a	0
specific	9
nuclear	10
factor	10
(	10
s	10
)	10
binding	0
to	0
15-LO	1
promoter	2
DNA	2
which	0
are	0
distinct	0
from	0
those	0
derived	0
from	0
IL-13-treated	5
human	6
peripheral	6
monocyte	6
nuclear	0
extracts	0
.	0

In	0
addition	0
,	0
fluorescent	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
results	0
refined	0
the	0
previous	0
localization	0
of	0
15-LO	9
to	0
human	1
chromosome	2
17p13.3	2
.	0

Ex	0
vivo	0
activation	0
of	0
tumor-draining	7
lymph	8
node	8
T	8
cells	8
reverses	0
defects	0
in	0
signal	9
transduction	10
molecules	10
.	0

The	0
adoptive	0
transfer	0
of	0
tumor-draining	0
lymph	0
node	0
(	0
LN	0
)	0
T	7
cells	8
activated	0
ex	0
vivo	0
with	0
anti-CD3	9
and	0
interleukin	9
2	10
(	0
IL-2	9
)	0
mediates	0
the	0
regression	0
of	0
the	0
poorly	0
immunogenic	0
murine	0
melanoma	0
D5	0
.	0

The	0
efficacy	0
of	0
the	0
activated	7
LN	8
cells	8
is	0
augmented	0
when	0
the	0
sensitizing	0
tumor	0
is	0
a	0
genetically	5
modified	6
variant	6
(	0
designated	0
D5G6	5
)	0
that	0
secretes	0
granulocyte/macrophage-colony-stimulating	9
factor	10
.	0

In	0
contrast	0
to	0
anti-CD3/IL-2-activated	5
LN	6
cells	6
,	0
adoptive	0
transfer	0
of	0
freshly	0
isolated	0
tumor-draining	7
LN	8
T	8
cells	8
has	0
no	0
therapeutic	0
activity	0
.	0

To	0
determine	0
whether	0
the	0
acquisition	0
of	0
antitumor	0
function	0
during	0
ex	0
vivo	0
activation	0
is	0
associated	0
with	0
modifications	0
in	0
signal	0
transduction	0
capacity	0
,	0
the	0
protein	0
tyrosine	9
kinases	10
p56lck	9
and	0
p59fyn	9
and	0
proteins	0
of	0
the	0
NF-kappaB	9
family	10
were	0
analyzed	0
in	0
tumor-draining	7
LN	8
T	8
cells	8
.	0

The	0
levels	0
of	0
p56lck	9
and	0
p59fyn	9
were	0
lower	0
in	0
tumor-draining	0
than	0
in	0
normal	7
LN	8
T	8
cells	8
and	0
production	0
of	0
tyrosine-phosphorylated	9
substrates	10
was	0
markedly	0
depressed	0
following	0
anti-CD3	9
stimulation	0
.	0

After	0
5-day	0
anti-CD3	9
/IL-2	9
activation	0
,	0
levels	0
of	0
p56lck	9
and	0
p59fyn	9
and	0
protein	0
tyrosine	0
kinase	0
activity	0
increased	0
.	0

Interestingly	0
,	0
the	0
levels	0
of	0
p56lck	9
,	0
p59fyn	9
,	0
and	0
tyrosine	0
kinase	0
activity	0
were	0
higher	0
in	0
activated	7
T	8
cells	8
derived	0
from	0
LN	0
that	0
drained	0
D5G6	0
than	0
they	0
were	0
in	0
those	0
from	0
D5	0
tumors	0
.	0

In	0
contrast	0
,	0
the	0
cytoplasmic	0
levels	0
of	0
c-Rel	9
and	0
Rel	9
A	10
were	0
normal	0
in	0
freshly	0
isolated	0
tumor-draining	0
LN	0
,	0
as	0
was	0
nuclear	0
kappaB	9
DNA-binding	0
activity	0
induced	0
by	0
anti-CD3	9
mAb	10
or	0
phorbol	0
myristate	0
acetate	0
.	0

Stimulation	0
of	0
activated	7
LN	8
cells	8
with	0
D5	7
tumor	8
cells	8
induced	0
the	0
nuclear	0
translocation	0
of	0
NF-kappaB	9
.	0

These	0
findings	0
indicate	0
that	0
the	0
recovery	0
of	0
proteins	0
mediating	0
signal	0
transduction	0
through	0
the	0
T	9
cell	10
receptor/CD3	10
complex	10
in	0
LN	7
T	8
cells	8
activated	0
ex	0
vivo	0
was	0
associated	0
with	0
the	0
acquisition	0
of	0
antitumor	0
function	0
.	0

Suppression	0
of	0
human	0
anti-porcine	0
T-cell	0
immune	0
responses	0
by	0
major	1
histocompatibility	2
complex	2
class	2
II	2
transactivator	2
constructs	2
lacking	0
the	0
amino	0
terminal	0
domain	0
.	0

BACKGROUND	0
:	0
The	0
class	9
II	10
transactivator	10
(	0
CIITA	9
)	0
is	0
a	0
bi-	9
or	10
multifunctional	10
domain	10
protein	10
that	0
acts	0
as	0
a	0
transcriptional	9
activator	10
and	0
plays	0
a	0
critical	0
role	0
in	0
the	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
.	0

We	0
have	0
previously	0
demonstrated	0
that	0
a	0
mutated	0
form	0
of	0
the	0
human	1
CIITA	2
gene	2
,	0
coding	0
for	0
a	0
protein	0
lacking	0
the	0
amino	9
terminal	10
151	10
amino	10
acids	10
,	0
acts	0
as	0
a	0
potent	0
dominant-negative	0
suppressor	0
of	0
HLA	9
class	10
II	10
expression	0
.	0

Porcine	9
MHC	10
class	10
II	10
antigens	10
are	0
potent	0
stimulators	0
of	0
direct	0
T-cell	0
recognition	0
by	0
human	7
CD4+	8
T	8
cells	8
and	0
are	0
,	0
therefore	0
,	0
likely	0
to	0
play	0
an	0
important	0
role	0
in	0
the	0
rejection	0
responses	0
to	0
transgenic	0
pig	0
donors	0
in	0
clinical	0
xenotransplantation	0
.	0

We	0
were	0
,	0
therefore	0
,	0
interested	0
in	0
examining	0
mutated	0
CIITA	1
constructs	2
for	0
their	0
effect	0
on	0
porcine	0
MHC	9
class	10
II	10
expression	0
.	0

METHODS	0
:	0
Stable	0
transfectants	0
of	0
the	0
porcine	5
vascular	6
endothelial	6
cell	6
line	6
PIEC	5
with	0
mutated	0
CIITA	1
constructs	2
were	0
tested	0
for	0
SLA-DR	9
and	0
SLA-DQ	9
induction	0
by	0
recombinant	9
porcine	10
interferon-gamma	10
.	0

Transient	0
transfectants	0
of	0
the	0
porcine	5
B-cell	6
line	6
L23	6
with	0
the	0
mutated	0
CIITA	1
constructs	2
were	0
tested	0
for	0
the	0
suppression	0
of	0
constitutive	0
SLA-DR	0
and	0
SLA-DQ	0
expression	0
.	0

T-cell	0
proliferation	0
studies	0
were	0
performed	0
using	0
highly	0
purified	0
human	7
CD4+	8
T	8
cells	8
.	0

RESULTS	0
:	0
In	0
preliminary	0
studies	0
,	0
we	0
demonstrated	0
that	0
transfection	0
of	0
the	0
PIEC	5
line	6
with	0
full-length	0
human	0
CIITA	1
constructs	2
resulted	0
in	0
strong	0
expression	0
of	0
SLA-DR	9
and	0
SLA-DQ	9
antigens	0
,	0
thus	0
establishing	0
the	0
cross-species	0
effectiveness	0
of	0
human	9
CIITA	10
in	0
the	0
pig	0
.	0

The	0
mutated	1
human	2
CIITA	2
constructs	2
were	0
,	0
therefore	0
,	0
tested	0
in	0
the	0
pig	0
.	0

PIEC	5
clones	6
stably	0
transfected	0
with	0
one	0
of	0
these	0
constructs	0
showed	0
up	0
to	0
99	0
%	0
suppression	0
of	0
SLA-DR	9
and	0
SLA-DQ	9
antigen	0
induction	0
and	0
marked	0
suppression	0
of	0
SLA-DRA	3
mRNA	4
induction	0
.	0

Moreover	0
,	0
transient	0
transfection	0
of	0
the	0
porcine	5
B-cell	6
line	6
L23	6
showed	0
up	0
to	0
90	0
%	0
suppression	0
of	0
constitutive	0
SLA-DR	0
and	0
SLA-DQ	0
antigen	0
expression	0
in	0
5-8	0
days	0
.	0

In	0
functional	0
studies	0
,	0
interferon-gamma-stimulated	5
PIEC	6
clones	6
transfected	0
with	0
this	0
mutated	9
CIITA	10
construct	0
failed	0
to	0
stimulate	0
purified	0
human	7
CD4+	8
T	8
lymphocytes	8
.	0

CONCLUSION	0
:	0
Mutated	1
human	2
CIITA	2
constructs	2
are	0
potent	0
suppressors	0
of	0
porcine	0
MHC	9
class	10
II	10
expression	0
.	0

Macrophages	7
in	0
human	0
atheroma	0
contain	0
PPARgamma	9
:	0
differentiation-dependent	9
peroxisomal	10
proliferator-activated	10
receptor	10
gamma	10
(	0
PPARgamma	9
)	0
expression	0
and	0
reduction	0
of	0
MMP-9	9
activity	0
through	0
PPARgamma	9
activation	0
in	0
mononuclear	0
phagocytes	0
in	0
vitro	0
.	0

Mononuclear	7
phagocytes	8
play	0
an	0
important	0
role	0
in	0
atherosclerosis	0
and	0
its	0
sequela	0
plaque	0
rupture	0
in	0
part	0
by	0
their	0
secretion	0
of	0
matrix	9
metalloproteinases	10
(	0
MMPs	9
)	0
,	0
including	0
MMP-9	9
.	0

Peroxisomal	9
proliferator-activated	10
receptor	10
gamma	10
(	0
PPARgamma	9
)	0
,	0
a	0
transcription	9
factor	10
in	0
the	0
nuclear	0
receptor	0
superfamily	0
,	0
regulates	0
gene	0
expression	0
in	0
response	0
to	0
various	0
activators	0
,	0
including	0
15-deoxy-delta12	0
,	0
14-prostaglandin	0
J2	0
and	0
the	0
antidiabetic	0
agent	0
troglitazone	0
.	0

The	0
role	0
of	0
PPARgamma	9
in	0
human	0
atherosclerosis	0
is	0
unexplored	0
.	0

We	0
report	0
here	0
that	0
monocytes/macrophages	7
in	0
human	0
atherosclerotic	0
lesions	0
(	0
n	0
=	0
12	0
)	0
express	0
immunostainable	9
PPARgamma	10
.	0

Normal	0
artery	0
specimens	0
(	0
n	0
=	0
6	0
)	0
reveal	0
minimal	9
immunoreactive	10
PPARgamma	10
.	0

Human	7
monocytes	8
and	0
monocyte-derived	7
macrophages	8
cultured	0
for	0
6	0
days	0
in	0
5	0
%	0
human	0
serum	0
expressed	0
PPARgamma	3
mRNA	4
and	0
protein	0
by	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
and	0
Western	0
blotting	0
,	0
respectively	0
.	0

In	0
addition	0
,	0
PPARgamma	3
mRNA	4
expression	0
in	0
U937	5
cells	6
increased	0
during	0
phorbol	0
12-myristate	0
13	0
acetate-induced	0
differentiation	0
.	0

Stimulation	0
of	0
PPARgamma	9
with	0
troglitazone	0
or	0
15-deoxy-delta12	0
,	0
14-prostaglandin	0
J2	0
in	0
human	0
monocyte-derived	7
macrophages	8
inhibited	0
MMP-9	9
gelatinolytic	0
activity	0
in	0
a	0
concentration-dependent	0
fashion	0
as	0
revealed	0
by	0
zymography	0
.	0

This	0
inhibition	0
correlates	0
with	0
decreased	0
MMP-9	9
secretion	0
as	0
determined	0
by	0
Western	0
blotting	0
.	0

Thus	0
,	0
PPARgamma	9
is	0
present	0
in	0
macrophages	7
in	0
human	0
atherosclerotic	0
lesions	0
and	0
may	0
regulate	0
expression	0
and	0
activity	0
of	0
MMP-9	9
,	0
an	0
enzyme	0
implicated	0
in	0
plaque	0
rupture	0
.	0

PPARgamma	9
is	0
likely	0
to	0
be	0
an	0
important	0
regulator	0
of	0
monocyte/macrophage	0
function	0
with	0
relevance	0
for	0
human	0
atherosclerotic	0
disease	0
.	0

Erythropoietin	9
induces	0
tyrosine	0
phosphorylation	0
of	0
Jak2	9
,	0
STAT5A	9
,	0
and	0
STAT5B	9
in	0
primary	7
cultured	8
human	8
erythroid	8
precursors	8
.	0

We	0
examined	0
signaling	0
by	0
erythropoietin	9
in	0
highly	7
purified	8
human	8
colony	8
forming	8
unit-erythroid	8
cells	8
,	0
generated	0
in	0
vitro	0
from	0
CD34	7
(	8
+	8
)	8
cells	8
.	0

We	0
found	0
that	0
erythropoietin	9
induces	0
tyrosine	0
phosphorylation	0
of	0
Jak2	9
,	0
STAT5A	9
,	0
and	0
STAT5B	9
.	0

Tyrosine	0
phosphorylation	0
of	0
Jak2	9
reaches	0
a	0
peak	0
around	0
10	0
minutes	0
after	0
stimulation	0
and	0
is	0
maximum	0
at	0
5	0
U/mL	0
of	0
erythropoietin	9
.	0

Tyrosine	0
phosphorylation	0
of	0
STAT5	9
is	0
accompanied	0
by	0
the	0
translocation	0
of	0
activated	0
STAT5	9
to	0
the	0
nucleus	0
as	0
shown	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
using	0
32Pi-labeled	0
STAT5	1
binding	2
site	2
in	0
the	0
beta-casein	1
promoter	2
.	0

Tyrosine	0
phosphorylation	0
STAT1	9
or	0
STAT3	9
was	0
not	0
detected	0
in	0
human	7
erythroid	8
precursors	8
after	0
stimulation	0
with	0
erythropoietin	9
.	0

Crkl	9
,	0
an	0
SH2/SH3	9
adapter	10
protein	10
,	0
becomes	0
coimmunoprecipitated	0
specifically	0
with	0
STAT5	9
from	0
erythropoietin-stimulated	7
erythroid	8
cells	8
;	0
although	0
it	0
was	0
shown	0
to	0
become	0
associated	0
with	0
c-Cbl	9
in	0
the	0
studies	0
using	0
cell	5
lines	6
.	0

Thus	0
,	0
human	7
erythroid	8
precursors	8
can	0
be	0
expanded	0
in	0
vitro	0
in	0
sufficient	0
numbers	0
and	0
purity	0
to	0
allow	0
its	0
usage	0
in	0
signal	0
transduction	0
studies	0
.	0

This	0
report	0
sets	0
a	0
basis	0
for	0
further	0
studies	0
on	0
signaling	0
in	0
primary	7
cultured	8
human	8
erythroid	8
precursors	8
,	0
which	0
in	0
turn	0
contribute	0
to	0
our	0
better	0
understanding	0
in	0
the	0
differentiation	0
processes	0
of	0
erythrocytes	7
and	0
their	0
precursors	0
.	0

Oxidative	0
stress	0
suppresses	0
transcription	9
factor	10
activities	0
in	0
stimulated	7
lymphocytes	8
.	0

Effects	0
of	0
oxidative	0
stress	0
on	0
stimulation-dependent	0
signal	0
transduction	0
,	0
leading	0
to	0
IL-2	9
expression	0
,	0
were	0
studied	0
.	0

Purified	7
quiescent	8
human	8
blood	8
T	8
lymphocytes	8
were	0
subjected	0
to	0
:	0
(	0
i	0
)	0
acute	0
exposure	0
to	0
hydrogen	0
peroxide	0
;	0
(	0
ii	0
)	0
chronic	0
exposure	0
to	0
hydrogen	0
peroxide	0
;	0
and	0
(	0
iii	0
)	0
acute	0
exposure	0
to	0
ionizing	0
radiation	0
.	0

The	0
cells	0
were	0
then	0
stimulated	0
for	0
6	0
h	0
.	0

DNA-binding	0
activities	0
(	0
determined	0
by	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
)	0
of	0
three	0
transcription	9
factors	10
:	0
NFkappaB	9
,	0
AP-1	9
and	0
NFAT	9
,	0
were	0
abolished	0
in	0
the	0
lymphocytes	7
by	0
all	0
three	0
modes	0
of	0
oxidative	0
stress	0
.	0

The	0
lymphocytes	7
exhibited	0
lipid	0
peroxidation	0
only	0
upon	0
exposure	0
to	0
the	0
lowest	0
level	0
of	0
hydrogen	0
peroxide	0
used	0
(	0
20	0
microM	0
)	0
.	0

All	0
three	0
modes	0
of	0
oxidative	0
stress	0
induced	0
catalase	9
activity	0
in	0
the	0
lymphocytes	7
.	0

The	0
only	0
exception	0
was	0
hydrogen	0
peroxide	0
at	0
20	0
microM	0
,	0
which	0
did	0
not	0
induce	0
catalase	9
activity	0
.	0

We	0
conclude	0
that	0
:	0
(	0
i	0
)	0
suppression	0
of	0
specific	0
transcription	9
factor	10
functions	0
can	0
potentially	0
serve	0
as	0
a	0
marker	0
of	0
exposure	0
to	0
oxidative	0
stress	0
and	0
its	0
effects	0
on	0
human	7
lymphocytes	8
;	0
(	0
ii	0
)	0
lipid	0
peroxidation	0
is	0
only	0
detectable	0
in	0
human	7
lymphocytes	8
upon	0
exposure	0
to	0
weak	0
oxidative	0
stress	0
which	0
does	0
not	0
induce	0
catalase	9
activity	0
;	0
(	0
iii	0
)	0
therefore	0
,	0
transcription	9
factor	10
DNA-binding	0
activities	0
are	0
more	0
sensitive	0
to	0
oxidative	0
stress	0
than	0
lipid	0
peroxidation	0
.	0

IL-4	9
-dependent	0
regulation	0
of	0
TGF-alpha	0
and	0
TGF-beta1	0
expression	0
in	0
human	7
eosinophils	8
.	0

TGFs	9
play	0
important	0
roles	0
in	0
wound	0
healing	0
and	0
carcinogenesis	0
.	0

We	0
have	0
previously	0
demonstrated	0
that	0
eosinophils	7
infiltrating	0
into	0
different	0
pathologic	0
processes	0
elaborate	0
TGF-alpha	9
and	0
TGF-beta1	9
.	0

Eosinophils	7
infiltrating	0
hamster	0
cutaneous	0
wounds	0
were	0
found	0
to	0
express	0
TGFs	9
sequentially	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
biologic	0
mediators	0
that	0
may	0
regulate	0
the	0
expression	0
of	0
TGF-alpha	9
and	10
-beta1	10
by	0
eosinophils	7
.	0

Eosinophils	7
were	0
isolated	0
from	0
the	0
peripheral	0
blood	0
of	0
healthy	0
donors	0
and	0
cultured	0
in	0
the	0
absence	0
or	0
presence	0
of	0
IL-3	9
,	0
IL-4	9
,	0
and	0
IL-5	9
.	0

Cells	0
were	0
analyzed	0
by	0
in	0
situ	0
hybridization	0
and	0
immunohistochemistry	0
.	0

Supernatants	0
from	0
these	0
cultures	0
were	0
assayed	0
for	0
secreted	0
TGF-alpha	9
and	0
TGF-beta1	9
using	0
TGF	9
-specific	0
ELISAs	0
.	0

IL-3	9
,	0
IL-4	9
,	0
and	0
IL-5	9
independently	0
up-regulated	0
TGF-beta1	3
mRNA	4
and	0
product	0
expression	0
by	0
eosinophils	7
in	0
all	0
donors	0
.	0

Interestingly	0
,	0
TGF-alpha	9
production	0
by	0
eosinophils	7
was	0
up-regulated	0
by	0
IL-3	9
and	0
IL-5	9
but	0
was	0
down-regulated	0
by	0
IL-4	9
.	0

Consistent	0
with	0
the	0
ability	0
of	0
IL-4	9
to	0
regulate	0
eosinophil	0
responses	0
,	0
IL-4	9
signaling	10
molecules	10
are	0
present	0
in	0
human	7
eosinophils	8
.	0

The	0
observation	0
that	0
IL-4	9
can	0
differentially	0
regulate	0
the	0
expression	0
of	0
TGF-alpha	9
and	0
TGF-beta1	9
suggests	0
that	0
IL-4	9
may	0
serve	0
as	0
a	0
physiologic	0
molecular	0
switch	0
of	0
TGF	9
expression	0
by	0
the	0
infiltrating	0
eosinophils	7
in	0
wound	0
healing	0
and	0
carcinogenesis	0
.	0

MLL	0
and	0
CALM	1
are	0
fused	0
to	0
AF10	1
in	0
morphologically	0
distinct	0
subsets	0
of	0
acute	0
leukemia	0
with	0
translocation	1
t	2
(	2
10	2
;	2
11	2
)	2
:	0
both	0
rearrangements	0
are	0
associated	0
with	0
a	0
poor	0
prognosis	0
.	0

The	0
translocation	1
t	2
(	2
10	2
;	2
11	2
)	2
(	2
p13	2
;	2
q14	2
)	2
has	0
been	0
observed	0
in	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
as	0
well	0
as	0
acute	0
myeloid	0
leukemia	0
(	0
AML	0
)	0
.	0

A	0
recent	0
study	0
showed	0
a	0
MLL/AF10	1
fusion	2
in	0
all	0
cases	0
of	0
AML	0
with	0
t	1
(	2
10	2
;	2
11	2
)	2
and	0
various	0
breakpoints	0
on	0
chromosome	1
11	2
ranging	0
from	0
q13	1
to	0
q23	1
.	0

We	0
recently	0
cloned	0
CALM	1
(	0
Clathrin	1
Assembly	2
Lymphoid	2
Myeloid	2
leukemia	2
gene	2
)	0
,	0
the	0
fusion	0
partner	0
of	0
AF10	1
at	0
11q14	1
in	0
the	0
monocytic	5
cell	6
line	6
U937	6
.	0

To	0
further	0
define	0
the	0
role	0
of	0
these	0
genes	0
in	0
acute	0
leukemias	0
,	0
10	0
cases	0
(	0
9	0
AML	0
and	0
1	0
ALL	0
)	0
with	0
cytogenetically	0
proven	0
t	1
(	2
10	2
;	2
11	2
)	2
(	2
p12-14	2
;	2
q13-21	2
)	2
and	0
well-characterized	0
morphology	0
,	0
immunophenotype	0
,	0
and	0
clinical	0
course	0
were	0
analyzed	0
.	0

Interphase	0
fluorescence	0
in	0
situ	0
hybridization	0
(	0
FISH	0
)	0
was	0
performed	0
with	0
2	0
YACs	1
flanking	0
the	0
CALM	1
region	2
,	0
a	0
YAC	1
contig	2
of	0
the	0
MLL	1
region	2
,	0
and	0
a	0
YAC	1
spanning	0
the	0
AF10	1
breakpoint	0
.	0

Rearrangement	0
of	0
at	0
least	0
one	0
of	0
these	0
genes	0
was	0
detected	0
in	0
all	0
cases	0
with	0
balanced	0
t	1
(	2
10	2
;	2
11	2
)	2
.	0

In	0
4	0
cases	0
,	0
including	0
3	0
AML	0
with	0
immature	0
morphology	0
(	0
1	0
AML-M0	0
and	0
2	0
AML-M1	0
)	0
and	0
1	0
ALL	0
,	0
the	0
signals	0
of	0
the	0
CALM	1
YACS	2
were	0
separated	0
in	0
interphase	0
cells	0
,	0
indicating	0
a	0
translocation	0
breakpoint	0
within	0
the	0
CALM	1
region	2
.	0

MLL	0
was	0
rearranged	0
in	0
3	0
AML	0
with	0
myelomonocytic	0
differentiation	0
(	0
2	0
AML-M2	0
and	0
1	0
AML-M5	0
)	0
,	0
including	0
1	0
secondary	0
AML	0
.	0

In	0
all	0
3	0
cases	0
,	0
a	0
characteristic	0
immunophenotype	0
was	0
identified	0
(	0
CD4+	9
,	0
CD13	9
-	0
,	0
CD33+	0
,	0
CD65s+	0
)	0
.	0

AF-10	0
was	0
involved	0
in	0
5	0
of	0
6	0
evaluable	0
cases	0
,	0
including	0
1	0
case	0
without	0
detectable	0
CALM	1
or	0
MLL	0
rearrangement	0
.	0

In	0
2	0
complex	0
translocations	0
,	0
none	0
of	0
the	0
three	0
genes	0
was	0
rearranged	0
.	0

All	0
cases	0
had	0
a	0
remarkably	0
poor	0
prognosis	0
,	0
with	0
a	0
mean	0
survival	0
of	0
9.6	0
+/-	0
6.6	0
months	0
.	0

For	0
the	0
7	0
AML	0
cases	0
that	0
were	0
uniformly	0
treated	0
according	0
to	0
the	0
AMLCG86/92	0
protocols	0
,	0
disease-free	0
and	0
overall	0
survival	0
was	0
significantly	0
worse	0
than	0
for	0
the	0
overall	0
study	0
group	0
(	0
P	0
=	0
.03	0
and	0
P	0
=	0
.01	0
,	0
respectively	0
)	0
.	0

We	0
conclude	0
that	0
the	0
t	1
(	2
10	2
;	2
11	2
)	2
(	2
p13	2
;	2
q14	2
)	2
indicates	0
CALM	1
and	2
MLL	2
rearrangements	2
in	0
morphologically	0
distinct	0
subsets	0
of	0
acute	0
leukemia	0
and	0
may	0
be	0
associated	0
with	0
a	0
poor	0
prognosis	0
.	0

The	0
role	0
of	0
E-proteins	9
in	0
B-	0
and	0
T-lymphocyte	0
development	0
.	0

Department	0
of	0
lymphocytes	7
from	0
hematopoietic	7
stem	8
cells	8
is	0
controlled	0
,	0
in	0
part	0
,	0
by	0
the	0
activity	0
of	0
transcriptional	9
regulatory	10
proteins	10
.	0

In	0
particular	0
,	0
one	0
class	0
of	0
helix-loop-helix	9
proteins	10
,	0
termed	0
E-proteins	9
,	0
have	0
been	0
implicated	0
in	0
the	0
regulation	0
of	0
gene	0
expression	0
during	0
B-cell	0
development	0
.	0

Recent	0
analysis	0
of	0
gene-targeted	0
mice	0
has	0
allowed	0
a	0
direct	0
assessment	0
of	0
the	0
functional	0
roles	0
of	0
several	9
E-protein	10
family	10
members	10
in	0
hematopoiesis	0
.	0

In	0
this	0
review	0
we	0
describe	0
the	0
defects	0
in	0
B-	0
and	0
T-	0
lymphocyte	0
development	0
in	0
mice	0
carrying	0
targeted	0
mutations	0
in	0
the	0
E-protein	1
genes	2
and	0
discuss	0
our	0
current	0
understanding	0
of	0
the	0
role	0
of	0
these	0
proteins	0
in	0
lymphoid	0
development	0

Epstein-Barr	9
virus-transforming	10
protein	10
latent	9
infection	10
membrane	10
protein	10
1	10
activates	0
transcription	9
factor	10
NF-kappaB	10
through	0
a	0
pathway	0
that	0
includes	0
the	0
NF-kappaB-inducing	9
kinase	10
and	0
the	0
IkappaB	9
kinases	10
IKKalpha	9
and	0
IKKbeta	9
.	0

The	0
Epstein-Barr	9
virus	10
oncoprotein	10
latent	9
infection	10
membrane	10
protein	10
1	10
(	0
LMP1	9
)	0
is	0
a	0
constitutively	0
aggregated	0
pseudo-tumor	9
necrosis	10
factor	10
receptor	10
(	0
TNFR	9
)	0
that	0
activates	0
transcription	9
factor	10
NF-kappaB	10
through	0
two	0
sites	0
in	0
its	0
C-terminal	9
cytoplasmic	10
domain	10
.	0

One	0
site	0
is	0
similar	0
to	0
activated	0
TNFRII	9
in	0
associating	0
with	0
TNFR-associated	9
factors	10
TRAF1	9
and	0
TRAF2	9
,	0
and	0
the	0
second	0
site	0
is	0
similar	0
to	0
TNFRI	9
in	0
associating	0
with	0
the	0
TNFRI	9
death	10
domain	10
interacting	10
protein	10
TRADD	9
.	0

TNFRI	9
has	0
been	0
recently	0
shown	0
to	0
activate	0
NF-kappaB	9
through	0
association	0
with	0
TRADD	9
,	0
RIP	9
,	0
and	0
TRAF2	9
;	0
activation	0
of	0
the	0
NF-kappaB-inducing	9
kinase	10
(	0
NIK	9
)	0
;	0
activation	0
of	0
the	0
IkappaB	9
alpha	10
kinases	10
(	0
IKKalpha	9
and	0
IKKbeta	9
)	0
;	0
and	0
phosphorylation	0
of	0
IkappaB	9
alpha	10
.	0

IkappaB	9
alpha	10
phosphorylation	0
on	0
Ser-32	0
and	0
Ser-36	0
is	0
followed	0
by	0
its	0
degradation	0
and	0
NF-kappaB	9
activation	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
NF-kappaB	9
activation	0
by	0
LMP1	9
or	0
by	0
each	0
of	0
its	0
effector	9
sites	10
is	0
mediated	0
by	0
a	0
pathway	0
that	0
includes	0
NIK	9
,	0
IKKalpha	9
,	0
and	0
IKKbeta	9
.	0

Dominant	9
negative	10
mutants	10
of	0
NIK	9
,	0
IKKalpha	9
,	0
or	0
IKKbeta	9
substantially	0
inhibited	0
NF-kappaB	9
activation	0
by	0
LMP1	9
or	0
by	0
each	0
of	0
its	0
effector	9
sites	10
.	0

Targeted	0
disruption	0
of	0
the	0
MyD88	1
gene	2
results	0
in	0
loss	0
of	0
IL-1-	0
and	0
IL-18-mediated	0
function	0
.	0

MyD88	9
,	0
originally	0
isolated	0
as	0
a	0
myeloid	0
differentiation	0
primary	1
response	2
gene	2
,	0
is	0
shown	0
to	0
act	0
as	0
an	0
adaptor	0
in	0
interleukin-1	9
(	0
IL-1	9
)	0
signaling	0
by	0
interacting	0
with	0
both	0
the	0
IL-1	9
receptor	10
complex	10
and	0
IL-1	9
receptor-associated	10
kinase	10
(	0
IRAK	9
)	0
.	0

Mice	0
generated	0
by	0
gene	0
targeting	0
to	0
lack	0
MyD88	9
have	0
defects	0
in	0
T	0
cell	0
proliferation	0
as	0
well	0
as	0
induction	0
of	0
acute	0
phase	0
proteins	0
and	0
cytokines	9
in	0
response	0
to	0
IL-1	9
.	0

Increases	0
in	0
interferon-gamma	9
production	0
and	0
natural	0
killer	0
cell	0
activity	0
in	0
response	0
to	0
IL-18	9
are	0
abrogated	0
.	0

In	0
vivo	0
Th1	0
response	0
is	0
also	0
impaired	0
.	0

Furthermore	0
,	0
IL-18	9
-induced	0
activation	0
of	0
NF-kappaB	9
and	0
c-Jun	9
N-terminal	10
kinase	10
(	0
JNK	9
)	0
is	0
blocked	0
in	0
MyD88-/-	5
Th1-developing	6
cells	6
.	0

Taken	0
together	0
,	0
these	0
results	0
demonstrate	0
that	0
MyD88	9
is	0
a	0
critical	0
component	0
in	0
the	0
signaling	0
cascade	0
that	0
is	0
mediated	0
by	0
IL-1	9
receptor	10
as	0
well	0
as	0
IL-18	9
receptor	10
.	0

Ciprofloxacin	0
induces	0
an	0
immunomodulatory	0
stress	0
response	0
in	0
human	7
T	8
lymphocytes	8
.	0

Exposure	0
of	0
cells	0
to	0
adverse	0
environmental	0
conditions	0
invokes	0
a	0
genetically	0
programmed	0
series	0
of	0
events	0
resulting	0
in	0
the	0
induction	0
of	0
specific	1
genes	2
.	0

The	0
fluoroquinolone	0
antibiotic	0
ciprofloxacin	0
has	0
recently	0
been	0
reported	0
to	0
upregulate	0
interleukin-2	9
(	0
IL-2	9
)	0
gene	0
induction	0
.	0

In	0
the	0
present	0
investigation	0
,	0
the	0
effect	0
of	0
ciprofloxacin	0
at	0
supratherapeutic	0
concentrations	0
on	0
immediate-early	0
(	0
<	0
2	0
h	0
)	0
gene	0
expression	0
in	0
primary	7
human	8
peripheral	8
blood	8
lymphocytes	8
was	0
studied	0
with	0
Northern	0
blots	0
.	0

In	0
addition	0
,	0
transcriptional	0
activity	0
of	0
IL-2	9
and	0
metallothionein	1
enhancer	2
and	2
promoter	2
regions	2
and	0
transcription	9
factors	10
AP-1	9
,	0
NF-kappaB	9
,	0
and	0
NF-AT	9
were	0
analyzed	0
by	0
chloramphenicol	9
acetyltransferase	10
(	0
CAT	9
)	0
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
respectively	0
.	0

The	0
concentration	0
of	0
c-fos	3
,	4
c-jun	4
,	4
c-myc	4
,	4
junB	4
,	4
and	4
fra-1	4
mRNAs	4
was	0
increased	0
in	0
activated	0
peripheral	7
blood	8
lymphocytes	8
incubated	0
with	0
ciprofloxacin	0
compared	0
to	0
that	0
in	0
untreated	0
controls	0
.	0

Ciprofloxacin	0
increased	0
CAT	9
activity	0
in	0
stimulated	0
lymphocytes	0
transfected	0
with	0
plasmids	7
containing	0
either	0
the	0
IL-2	9
or	0
metallothionein	1
enhancer	2
.	0

Furthermore	0
,	0
among	0
the	0
transcription	9
factors	10
tested	0
,	0
AP-1	9
activity	0
was	0
increased	0
in	0
stimulated	7
purified	8
T	8
helper	8
lymphocytes	8
incubated	0
with	0
ciprofloxacin	0
compared	0
to	0
drug-free	7
controls	8
.	0

Taken	0
together	0
,	0
ciprofloxacin	0
increased	0
the	0
levels	0
of	0
immediate-early	3
transcripts	4
,	0
enhanced	0
IL-2	9
and	0
metallothionein	9
promoter	0
induction	0
,	0
and	0
upregulated	0
AP-1	9
concentrations	0
in	0
primary	7
lymphocytes	8
,	0
reflecting	0
a	0
program	0
commonly	0
observed	0
in	0
mammalian	0
stress	0
responses	0
.	0

A	0
novel	0
retinoic	9
acid	10
receptor	10
(	0
RAR	9
)	0
-selective	0
antagonist	0
inhibits	0
differentiation	0
and	0
apoptosis	0
of	0
HL-60	5
cells	6
:	0
implications	0
of	0
RARalpha	9
-mediated	0
signals	0
in	0
myeloid	7
leukemic	8
cells	8
.	0

Retinoic	0
acid	0
(	0
RA	0
)	0
induces	0
HL-60	5
cells	6
to	0
differentiate	0
terminally	0
into	0
mature	7
granulocytes	8
,	0
which	0
subsequently	0
die	0
by	0
apoptosis	0
.	0

The	0
biological	0
effects	0
of	0
RA	0
are	0
mediated	0
by	0
two	0
distinct	0
families	0
of	0
transcription	9
factors	10
:	0
retinoic	9
acid	10
receptors	10
(	0
RARs	9
)	0
and	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
)	0
.	0

RARs	9
and	0
RXRs	9
form	0
heterodimers	9
and	0
regulate	0
retinoid-mediated	0
gene	0
expression	0
.	0

We	0
have	0
recently	0
developed	0
a	0
novel	0
RAR	9
-selective	0
antagonist	0
(	0
ER27191	0
)	0
which	0
prevents	0
RAR	9
activation	0
by	0
retinoids	0
.	0

Using	0
this	0
RAR-selective	0
antagonist	0
,	0
and	0
RXR	9
and	0
RAR	9
agonist	0
,	0
we	0
demonstrate	0
the	0
RAR	9
-mediated	0
signaling	0
pathway	0
is	0
important	0
for	0
differentiation	0
and	0
apoptosis	0
of	0
myeloid	7
leukemic	8
cells	8
.	0

Simple	0
activation	0
of	0
RXRs	9
is	0
not	0
sufficient	0
to	0
induce	0
apoptosis	0
of	0
the	0
cells	0
.	0

Interestingly	0
,	0
the	0
combination	0
of	0
the	0
RAR-selective	0
antagonist	0
and	0
9-cis	0
RA	0
resulted	0
in	0
partial	0
differentiation	0
and	0
apoptosis	0
of	0
HL-60	5
and	6
NB4	6
cells	6
,	0
whereas	0
the	0
RAR	9
antagonist	0
completely	0
blocked	0
all-trans	0
RA-induced	0
differentiation	0
and	0
apoptosis	0
of	0
the	0
cells	0
.	0

Additional	0
experiments	0
showed	0
that	0
levels	0
of	0
BCL-2	9
protein	10
decreased	0
during	0
differentiation	0
of	0
myeloid	7
leukemic	8
cells	8
.	0

Furthermore	0
,	0
HL-60	5
cells	6
transduced	0
with	0
a	0
bcl-2	1
expression	2
vector	2
showed	0
the	0
same	0
differentiation	0
response	0
to	0
retinoids	0
as	0
did	0
parental	5
HL-60	6
cells	6
even	0
though	0
apoptosis	0
was	0
inhibited	0
in	0
these	0
bcl-2-transduced	5
cells	6
,	0
suggesting	0
that	0
differentiation	0
and	0
apoptosis	0
are	0
regulated	0
independently	0
in	0
myeloid	7
leukemic	8
cells	8
.	0

Thrombopoietin	9
supports	0
in	0
vitro	0
erythroid	0
differentiation	0
via	0
its	0
specific	0
receptor	0
c-Mpl	9
in	0
a	0
human	5
leukemia	6
cell	6
line	6
.	0

Thrombopoietin	9
(	0
TPO	9
)	0
acts	0
on	0
megakaryopoiesis	0
and	0
erythropoiesis	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

We	0
isolated	0
a	0
novel	0
subline	0
,	0
UT-7/GMT	5
,	0
from	0
the	0
human	5
leukemia	6
cell	6
line	6
UT-7/GM	6
(	0
N.	0
Komatsu	0
,	0
et	0
al.	0
,	0
Blood	0
,	0
89	0
:	0
4021-4033	0
,	0
1997	0
)	0
.	0

A	0
small	0
population	0
of	0
UT-7/GM	5
cells	6
positively	0
stained	0
for	0
hemoglobin	9
(	0
Hb	9
)	0
after	0
a	0
7-day	0
exposure	0
to	0
TPO	9
.	0

More	0
than	0
50	0
%	0
of	0
TPO-treated	5
UT-7/GMT	6
cells	6
positively	0
stained	0
for	0
Hb	9
.	0

Using	0
UT-7/GMT	5
cells	6
,	0
we	0
examined	0
how	0
TPO	9
promotes	0
hemoglobinization	0
.	0

TPO	9
induced	0
tyrosine	0
phosphorylation	0
of	0
the	0
TPO	9
receptor	0
but	0
not	0
the	0
erythropoietin	9
(	10
EPO	10
)	10
receptor	10
.	0

There	0
was	0
no	0
competition	0
between	0
TPO	9
and	0
EPO	9
for	0
binding	0
to	0
EPO	9
receptor	10
.	0

These	0
findings	0
suggest	0
that	0
TPO	9
has	0
a	0
direct	0
effect	0
on	0
hemoglobinization	0
via	0
a	0
specific	0
receptor	0
on	0
UT-7/GMT	5
cells	6
.	0

Isoelectric	0
focusing	0
demonstrated	0
that	0
TPO	9
induced	0
fetal	0
and	0
adult	0
Hb	0
synthesis	0
,	0
whereas	0
EPO	9
induced	0
embryonic	0
,	0
fetal	0
,	0
and	0
adult	0
Hb	0
synthesis	0
.	0

Thus	0
,	0
our	0
data	0
suggest	0
that	0
TPO	9
has	0
a	0
distinct	0
action	0
on	0
erythropoiesis	0
.	0

Role	0
of	0
GATA-1	9
in	0
proliferation	0
and	0
differentiation	0
of	0
definitive	0
erythroid	7
and	8
megakaryocytic	8
cells	8
in	0
vivo	0
.	0

To	0
elucidate	0
the	0
contributions	0
of	0
GATA-1	9
to	0
definitive	0
hematopoiesis	0
in	0
vivo	0
,	0
we	0
have	0
examined	0
adult	0
mice	0
that	0
were	0
rendered	0
genetically	0
defective	0
in	0
GATA-1	9
synthesis	0
(	0
Takahashi	0
et	0
al	0
,	0
J	0
Biol	0
Chem	0
272	0
:	0
12611	0
,	0
1997	0
)	0
.	0

Because	0
the	0
GATA-1	1
gene	2
is	0
located	0
on	0
the	0
X	1
chromosome	2
,	0
which	0
is	0
randomly	0
inactivated	0
in	0
every	0
cell	0
,	0
heterozygous	0
females	0
can	0
bear	0
either	0
an	0
active	0
wild-type	0
or	0
mutant	0
(	0
referred	0
to	0
as	0
GATA-1.05	1
)	0
GATA-1	9
allele	0
,	0
consequently	0
leading	0
to	0
variable	0
anemic	0
severity	0
.	0

These	0
heterozygous	0
mutant	0
mice	0
usually	0
developed	0
normally	0
,	0
but	0
they	0
began	0
to	0
die	0
after	0
5	0
months	0
.	0

These	0
affected	0
animals	0
displayed	0
marked	0
splenomegaly	0
,	0
anemia	0
,	0
and	0
thrombocytopenia	0
.	0

Proerythroblasts	7
and	0
megakaryocytes	7
massively	0
accumulated	0
in	0
the	0
spleens	0
of	0
the	0
heterozygotes	0
,	0
and	0
we	0
showed	0
that	0
the	0
neomycin	1
resistance	2
gene	2
(	0
which	0
is	0
the	0
positive	0
selection	0
marker	0
in	0
ES	7
cells	8
)	0
was	0
expressed	0
profusely	0
in	0
the	0
abnormally	0
abundant	0
cells	0
generated	0
in	0
the	0
GATA-1.05	9
mutant	0
females	0
.	0

We	0
also	0
observed	0
hematopoiesis	0
outside	0
of	0
the	0
bone	0
marrow	0
in	0
the	0
affected	0
mutant	0
mice	0
.	0

These	0
data	0
suggest	0
that	0
a	0
small	0
number	0
of	0
GATA-1.05	5
mutant	6
hematopoietic	6
progenitor	6
cells	6
begin	0
to	0
proliferate	0
vigorously	0
during	0
early	0
adulthood	0
,	0
but	0
because	0
the	0
cells	0
are	0
unable	0
to	0
terminally	0
differentiate	0
,	0
this	0
leads	0
to	0
progenitor	0
proliferation	0
in	0
the	0
spleen	0
and	0
consequently	0
death	0
.	0

Thus	0
,	0
GATA-1	9
plays	0
important	0
in	0
vivo	0
roles	0
for	0
directing	0
definitive	0
hematopoietic	7
progenitors	8
to	0
differentiate	0
along	0
both	0
the	0
erythroid	0
and	0
megakaryocytic	0
pathways	0
.	0

The	0
GATA-1	9
heterozygous	0
mutant	0
mouse	0
shows	0
a	0
phenotype	0
that	0
is	0
analogous	0
to	0
human	0
myelodysplastic	0
syndrome	0
and	0
thus	0
may	0
serve	0
as	0
a	0
useful	0
model	0
for	0
this	0
disorder	0
.	0

Differential	0
regulation	0
of	0
the	0
Janus	9
kinase	10
-STAT	9
pathway	0
and	0
biologic	0
function	0
of	0
IL-13	9
in	0
primary	7
human	8
NK	8
and	8
T	8
cells	8
:	0
a	0
comparative	0
study	0
with	0
IL-4	9
.	0

IL-13	9
,	0
a	0
cytokine	0
similar	0
to	0
IL-4	9
,	0
is	0
a	0
regulator	0
of	0
human	0
B	0
cell	0
and	0
monocyte	0
functions	0
.	0

Biologic	0
effects	0
of	0
IL-13	9
on	0
primary	7
human	8
NK	8
and	8
T	8
cells	8
have	0
not	0
been	0
well	0
defined	0
.	0

We	0
demonstrate	0
that	0
,	0
in	0
primary	7
NK	8
cells	8
,	0
IL-13	9
,	0
but	0
not	0
IL-4	9
,	0
may	0
induce	0
low	0
levels	0
of	0
IFN-gamma	9
secretion	0
.	0

When	0
NK	7
cells	8
were	0
costimulated	0
with	0
IL-13	9
and	0
IL-2	9
,	0
IL-13	9
generally	0
resulted	0
in	0
two	0
types	0
of	0
reactivity	0
:	0
IL-13	9
synergized	0
with	0
IL-2	9
to	0
stimulate	0
IFN-gamma	9
production	0
or	0
it	0
modestly	0
inhibited	0
IL-2	9
-mediated	0
IFN-gamma	9
production	0
.	0

In	0
both	0
types	0
of	0
donors	0
,	0
the	0
effect	0
of	0
IL-13	9
on	0
IL-2	9
-induced	0
IFN-gamma	9
production	0
was	0
in	0
marked	0
contrast	0
to	0
the	0
strong	0
inhibition	0
seen	0
with	0
IL-4	9
in	0
NK	7
cells	8
.	0

Additionally	0
,	0
IL-13	9
suppresses	0
IL-2-induced	0
NK	0
cytolytic	0
and	0
proliferative	0
activities	0
although	0
less	0
efficiently	0
than	0
IL-4	9
.	0

In	0
T	7
cells	8
,	0
IL-13	9
inhibits	0
anti-CD3	0
mAb/IL-2-	0
or	0
PHA-mediated	0
IFN-gamma	0
production	0
and	0
enhances	0
cytolytic	0
potential	0
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
IL-13	9
,	0
like	0
IL-4	9
,	0
induces	0
distinct	0
STAT6-DNA	9
binding	10
complexes	10
and	0
tyrosine	0
phosphorylation	0
of	0
STAT6	9
and	0
Janus	9
kinase	10
3	10
(	0
JAK3	9
)	0
in	0
NK	0
and	0
T	7
cells	8
.	0

We	0
observed	0
that	0
Abs	0
directed	0
against	0
unique	0
domains	0
of	0
STAT6	9
have	0
differential	0
effects	0
on	0
complexes	0
in	0
T	7
cells	8
but	0
not	0
in	0
NK	7
cells	8
,	0
suggesting	0
different	0
STAT6	9
isoforms	10
.	0

These	0
findings	0
show	0
that	0
IL-13	9
and	0
IL-4	9
have	0
the	0
ability	0
to	0
regulate	0
NK	0
and	0
T	0
cell	0
activation	0
and	0
that	0
IL-13	9
is	0
a	0
potent	0
regulator	0
of	0
STAT6	9
and	0
JAK3	9
in	0
these	0
cell	0
types	0
.	0

The	0
human	0
toll	0
signaling	0
pathway	0
:	0
divergence	0
of	0
nuclear	9
factor	10
kappaB	10
and	0
JNK	9
/SAPK	9
activation	0
upstream	0
of	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
factor	10
6	10
(	0
TRAF6	9
)	0
.	0

The	0
human	0
homologue	0
of	0
Drosophila	9
Toll	10
(	0
hToll	9
)	0
is	0
a	0
recently	0
cloned	0
receptor	0
of	0
the	0
interleukin	9
1	10
receptor	10
(	10
IL-1R	10
)	10
superfamily	10
,	0
and	0
has	0
been	0
implicated	0
in	0
the	0
activation	0
of	0
adaptive	0
immunity	0
.	0

Signaling	0
by	0
hToll	9
is	0
shown	0
to	0
occur	0
through	0
sequential	0
recruitment	0
of	0
the	0
adapter	9
molecule	10
MyD88	9
and	0
the	0
IL-1R-associated	9
kinase	10
.	0

Tumor	9
necrosis	10
factor	10
receptor-activated	10
factor	10
6	10
(	0
TRAF6	9
)	0
and	0
the	0
nuclear	9
factor	10
kappaB	10
(	10
NF-kappaB	10
)	10
-inducing	10
kinase	10
(	0
NIK	9
)	0
are	0
both	0
involved	0
in	0
subsequent	0
steps	0
of	0
NF-kappaB	9
activation	0
.	0

Conversely	0
,	0
a	0
dominant	0
negative	0
version	0
of	0
TRAF6	9
failed	0
to	0
block	0
hToll	9
-induced	0
activation	0
of	0
stress-activated	9
protein	10
kinase/c-Jun	10
NH2-terminal	10
kinases	10
,	0
thus	0
suggesting	0
an	0
early	0
divergence	0
of	0
the	0
two	0
pathways	0
.	0

Inhibition	0
of	0
nuclear	9
factor	10
kappaB	10
activation	0
attenuates	0
apoptosis	0
resistance	0
in	0
lymphoid	7
cells	8
.	0

Death-inducing	9
ligands	10
(	0
DILs	9
)	0
such	0
as	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNFalpha	9
)	0
or	0
the	0
cytotoxic	0
drug	0
doxorubicin	0
have	0
been	0
shown	0
to	0
activate	0
a	0
nuclear	9
factor	10
kappaB	10
(	0
NFkappaB	9
)	0
-dependent	0
program	0
that	0
may	0
rescue	0
cells	0
from	0
apoptosis	0
induction	0
.	0

We	0
demonstrate	0
here	0
that	0
TRAIL	9
(	0
TNF-related	9
apoptosis-inducing	10
ligand	10
)	0
,	0
a	0
recently	0
identified	0
DIL	9
,	0
also	0
activates	0
NFkappaB	9
in	0
lymphoid	0
cell	0
lines	0
in	0
a	0
kinetic	0
similar	0
to	0
TNFalpha	9
.	0

NFkappaB	9
activity	0
is	0
independent	0
from	0
FADD	9
,	0
caspases	9
,	0
and	0
apoptosis	0
induction	0
.	0

To	0
study	0
the	0
influence	0
of	0
NFkappaB	9
activity	0
on	0
apoptosis	0
mediated	0
by	0
TRAIL	9
,	0
CD95	0
,	0
TNFalpha	9
,	0
or	0
doxorubicin	0
,	0
NFkappaB	9
activation	0
was	0
inhibited	0
using	0
the	0
proteasome	9
inhibitor	0
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	0
or	0
transient	0
overexpression	0
of	0
mutant	9
IkappaBalpha	10
.	0

Sensitivity	0
for	0
induction	0
of	0
apoptosis	0
was	0
markedly	0
increased	0
by	0
these	0
treatments	0
in	0
apoptosis	0
sensitive	0
cell	5
lines	6
.	0

Moreover	0
,	0
both	0
in	0
cell	0
lines	0
and	0
in	0
primary	0
leukemia	0
cells	0
that	0
are	0
resistant	0
towards	0
induction	0
of	0
apoptosis	0
by	0
DILs	9
and	0
doxorubicin	0
,	0
antagonization	0
of	0
NFkappaB	9
activity	0
partially	0
restored	0
apoptosis	0
sensitivity	0
.	0

These	0
data	0
suggest	0
that	0
inhibition	0
of	0
NFkappaB	9
activation	0
may	0
provide	0
a	0
molecular	0
approach	0
to	0
increase	0
apoptosis	0
sensitivity	0
in	0
anticancer	0
treatment	0
.	0

Loss-	0
and	0
gain-of-function	0
mutations	0
reveal	0
an	0
important	0
role	0
of	0
BSAP	9
(	0
Pax-5	9
)	0
at	0
the	0
start	0
and	0
end	0
of	0
B	0
cell	0
differentiation	0
.	0

Pax-5	9
codes	0
for	0
the	0
transcription	9
factor	10
BSAP	9
which	0
is	0
expressed	0
throughout	0
B	0
cell	0
development	0
except	0
in	0
terminally	7
differentiated	8
plasma	8
cells	8
.	0

Gene	0
targeting	0
experiments	0
in	0
the	0
mouse	0
revealed	0
a	0
differential	0
dependency	0
of	0
fetal	0
and	0
adult	0
B-lymphopoiesis	0
on	0
this	0
transcription	9
factor	10
.	0

BSAP	9
is	0
required	0
for	0
B-lineage	0
commitment	0
in	0
the	0
fetal	0
liver	0
and	0
for	0
progression	0
beyond	0
an	0
early	0
pro-B	0
cell	0
stage	0
in	0
adult	0
bone	0
marrow	0
.	0

The	0
characterization	0
of	0
Pax-5-deficient	7
pro-B	8
cells	8
demonstrated	0
an	0
important	0
role	0
of	0
BSAP	9
in	0
the	0
regulation	0
of	0
the	0
CD19	9
,	0
mb-1	9
(	0
Ig	9
alpha	10
)	0
and	0
N-myc	1
genes	2
as	0
well	0
as	0
in	0
the	0
developmental	0
pathway	0
controlling	0
VH-to-DHJH	0
recombination	0
at	0
the	0
immunoglobulin	9
heavy-chain	10
(	10
IgH	10
)	10
locus	10
.	0

The	0
human	1
PAX-5	2
gene	2
was	0
recently	0
shown	0
to	0
participate	0
together	0
with	0
the	0
IgH	1
locus	2
in	0
the	0
chromosomal	0
translocation	0
t	1
(	2
9	2
;	2
14	2
)	2
(	2
p13	2
;	2
q32	2
)	2
.	0

This	0
translocation	0
is	0
characteristic	0
of	0
a	0
small	0
subset	0
of	0
non-Hodgkin	0
lymphomas	0
exhibiting	0
plasmacytoid	0
differentiation	0
.	0

The	0
translocated	1
PAX-5	2
gene	2
is	0
deregulated	0
by	0
the	0
insertion	0
of	0
IgH	1
regulatory	2
elements	2
into	0
its	0
5	1
'	2
region	2
,	0
which	0
may	0
contribute	0
to	0
tumorigenesis	0
by	0
interfering	0
with	0
the	0
shut-down	0
of	0
PAX-5	9
transcription	0
and	0
thus	0
with	0
the	0
completion	0
of	0
plasma	7
cell	8
differentiation	0

Acetylation	0
and	0
modulation	0
of	0
erythroid	9
Kruppel-like	10
factor	10
(	0
EKLF	9
)	0
activity	0
by	0
interaction	0
with	0
histone	9
acetyltransferases	10
.	0

Erythroid	9
Kruppel-like	10
factor	10
(	0
EKLF	9
)	0
is	0
a	0
red	9
cell-specific	10
transcriptional	10
activator	10
that	0
is	0
crucial	0
for	0
consolidating	0
the	0
switch	0
to	0
high	0
levels	0
of	0
adult	0
beta-globin	9
expression	0
during	0
erythroid	0
ontogeny	0
.	0

EKLF	9
is	0
required	0
for	0
integrity	0
of	0
the	0
chromatin	0
structure	0
at	0
the	0
beta-like	1
globin	2
locus	2
,	0
and	0
it	0
interacts	0
with	0
a	0
positive-acting	9
factor	10
in	0
vivo	0
.	0

We	0
find	0
that	0
EKLF	9
is	0
an	0
acetylated	9
transcription	10
factor	10
,	0
and	0
that	0
it	0
interacts	0
in	0
vivo	0
with	0
CBP	9
,	0
p300	9
,	0
and	0
P/CAF	9
.	0

However	0
,	0
its	0
interactions	0
with	0
these	0
histone	9
acetyltransferases	10
are	0
not	0
equivalent	0
,	0
as	0
CBP	9
and	0
p300	9
,	0
but	0
not	0
P/CAF	9
,	0
utilize	0
EKLF	9
as	0
a	0
substrate	0
for	0
in	0
vitro	0
acetylation	0
within	0
its	0
trans-	0
activation	9
region	10
.	0

The	0
functional	0
effects	0
of	0
these	0
interactions	0
are	0
that	0
CBP	9
and	0
p300	9
,	0
but	0
not	0
P/CAF	9
,	0
enhance	0
EKLF	9
's	0
transcriptional	0
activation	0
of	0
the	0
beta-globin	1
promoter	2
in	0
erythroid	7
cells	8
.	0

These	0
results	0
establish	0
EKLF	9
as	0
a	0
tissue-specific	9
transcription	10
factor	10
that	0
undergoes	0
post-translational	0
acetylation	0
and	0
suggest	0
a	0
mechanism	0
by	0
which	0
EKLF	9
is	0
able	0
to	0
alter	0
chromatin	1
structure	0
and	0
induce	0
beta-globin	9
expression	0
within	0
the	0
beta-like	1
globin	2
cluster	2
.	0

Recognition	0
of	0
herpes	9
simplex	10
virus	10
type	10
2	10
tegument	10
proteins	10
by	0
CD4	7
T	8
cells	8
infiltrating	0
human	0
genital	0
herpes	0
lesions	0
.	0

The	0
local	0
cellular	0
immune	0
response	0
to	0
herpes	0
simplex	0
virus	0
(	0
HSV	0
)	0
is	0
important	0
in	0
the	0
control	0
of	0
recurrent	0
HSV	0
infection	0
.	0

The	0
antiviral	0
functions	0
of	0
infiltrating	7
CD4-bearing	8
T	8
cells	8
may	0
include	0
cytotoxicity	0
,	0
inhibition	0
of	0
viral	0
growth	0
,	0
lymphokine	9
secretion	0
,	0
and	0
support	0
of	0
humoral	0
and	0
CD8	0
responses	0
.	0

The	0
antigens	0
recognized	0
by	0
many	0
HSV-specific	7
CD4	8
T	8
cells	8
localizing	0
to	0
genital	0
HSV-2	0
lesions	0
are	0
unknown	0
.	0

T	7
cells	8
recognizing	0
antigens	0
encoded	0
within	0
map	0
units	0
0.67	0
to	0
0.73	0
of	0
HSV	1
DNA	2
are	0
frequently	0
recovered	0
from	0
herpetic	0
lesions	0
.	0

Expression	0
cloning	0
with	0
this	0
region	0
of	0
DNA	0
now	0
shows	0
that	0
tegument	9
protein	10
VP22	9
and	0
the	0
viral	9
dUTPase	10
,	0
encoded	0
by	0
genes	1
UL49	2
and	2
UL50	2
,	0
respectively	0
,	0
are	0
T-cell	9
antigens	10
.	0

Separate	0
epitopes	9
in	0
VP22	9
were	0
defined	0
for	0
T-cell	5
clones	6
from	0
each	0
of	0
three	0
patients	0
.	0

Reactivity	0
with	0
the	0
tegument	9
protein	10
encoded	0
by	0
UL21	1
was	0
identified	0
for	0
an	0
additional	0
patient	0
.	0

Three	0
new	0
epitopes	0
were	0
identified	0
in	0
VP16	9
,	0
a	0
tegument	9
protein	10
associated	0
with	0
VP22	9
.	0

Some	0
tegument-specific	5
CD4	6
T-cell	6
clones	6
exhibited	0
cytotoxic	0
activity	0
against	0
HSV-infected	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
herpes	9
simplex	10
tegument	10
proteins	10
are	0
processed	0
for	0
antigen	0
presentation	0
in	0
vivo	0
and	0
are	0
possible	0
candidate	0
compounds	0
for	0
herpes	0
simplex	0
vaccines	0
.	0

Fibrinogen	9
activates	0
NF-kappa	9
B	10
transcription	10
factors	10
in	0
mononuclear	7
phagocytes	8
.	0

Adhesion	0
to	0
extracellular	0
matrices	0
is	0
known	0
to	0
modulate	0
leukocyte	0
activation	0
,	0
although	0
the	0
mechanisms	0
are	0
not	0
fully	0
understood	0
.	0

Mononuclear	7
phagocytes	8
are	0
exposed	0
to	0
fibrinous	0
provisional	0
matrix	0
throughout	0
migration	0
into	0
inflammatory	0
foci	0
,	0
so	0
this	0
study	0
was	0
undertaken	0
to	0
determine	0
whether	0
fibrinogen	0
triggers	0
activation	0
of	0
NF-kappa	9
B	10
transcription	10
factors	10
.	0

U937	5
cells	6
differentiated	0
with	0
PMA	0
in	0
nonadherent	5
culture	6
were	0
shown	0
to	0
express	0
two	0
fibrinogen-binding	9
integrins	10
,	0
predominately	0
CD11b/CD18	9
,	0
and	0
to	0
a	0
lesser	0
extent	0
,	0
CD11c/CD18	9
.	0

Cells	0
stimulated	0
with	0
fibrinogen	9
(	0
10-100	0
microg/ml	0
)	0
/Mn2+	0
(	0
50	0
microM	0
)	0
for	0
2	0
h	0
were	0
examined	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

NF-kappa	9
B	10
activation	0
,	0
minimal	0
in	0
unstimulated	7
cells	8
,	0
was	0
substantially	0
up-regulated	0
by	0
fibrinogen	9
.	0

Fibrinogen	9
also	0
caused	0
activation	0
of	0
AP-1	9
,	0
but	0
not	0
SP1	9
or	0
cAMP	9
response	10
element-binding	10
protein	10
(	10
CREB	10
)	10
factors	10
.	0

Blocking	0
mAbs	9
against	0
CD18	9
and	0
CD11b	9
abrogated	0
fibrinogen	9
-induced	0
NF-kappa	9
B	10
activation	0
.	0

To	0
determine	0
the	0
effects	0
on	0
transcriptional	0
regulation	0
,	0
U937	5
cells	6
were	0
transfected	0
with	0
a	0
plasmid	0
containing	0
the	0
HIV-1	1
enhancer	2
(	0
bearing	0
two	0
NF-kappa	1
B	2
sites	2
)	0
coupled	0
to	0
a	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
reporter	2
.	0

Cells	0
were	0
subsequently	0
stimulated	0
with	0
1	0
)	0
PMA	0
for	0
24	0
h	0
,	0
inducing	0
CAT	9
activity	0
by	0
2.6-fold	0
,	0
2	0
)	0
fibrinogen	9
/Mn2+	0
for	0
2	0
h	0
,	0
inducing	0
CAT	9
activity	0
by	0
3.2-fold	0
,	0
or	0
3	0
)	0
costimulation	0
with	0
fibrinogen	9
and	0
PMA	0
,	0
inducing	0
5.7-fold	0
the	0
CAT	9
activity	0
induced	0
by	0
PMA	0
alone	0
.	0

We	0
conclude	0
that	0
contact	0
with	0
fibrinogen-derived	9
proteins	10
may	0
contribute	0
to	0
mononuclear	0
phagocyte	0
activation	0
by	0
signaling	0
through	0
CD11b/CD18	9
,	0
resulting	0
in	0
selective	0
activation	0
of	0
transcriptional	9
regulatory	10
factors	10
,	0
including	0
NF-kappa	9
B	10
.	0

Peripheral	7
blood	8
T	8
cells	8
and	0
monocytes	7
and	0
B	5
cell	6
lines	6
derived	0
from	0
patients	0
with	0
lupus	0
express	0
estrogen	0
receptor	0
transcripts	0
similar	0
to	0
those	0
of	0
normal	7
cells	8
.	0

OBJECTIVE	0
:	0
To	0
identify	0
and	0
characterize	0
estrogen	3
receptor	4
(	4
ER	4
)	4
transcripts	4
expressed	0
in	0
immune	7
cells	8
of	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
and	0
healthy	0
donors	0
.	0

METHODS	0
:	0
Peripheral	7
blood	8
monocytes	8
and	0
T	7
cells	8
were	0
prepared	0
from	0
patients	0
with	0
SLE	0
(	0
n	0
=	0
6	0
)	0
and	0
healthy	0
donors	0
(	0
n	0
=	0
8	0
)	0
.	0

T	7
cells	8
were	0
separated	0
into	0
CD4	7
and	0
CD8	7
.	0

Some	0
monocytes	7
and	0
T	7
cells	8
were	0
stimulated	0
with	0
estradiol	0
,	0
PMA	0
,	0
and	0
ionomycin	0
.	0

Epstein-Barr	0
virus-transformed	0
B	5
cell	6
lines	6
(	0
n	0
=	0
7	0
)	0
and	0
B	5
cell	6
hybridomas	6
(	0
n	0
=	0
2	0
)	0
established	0
from	0
patients	0
with	0
SLE	0
and	0
a	0
healthy	0
individual	0
were	0
used	0
as	0
a	0
B	0
cell	0
source	0
.	0

These	0
cells	0
were	0
examined	0
for	0
ER	3
mRNA	4
by	0
reverse	0
transcription	0
nested	0
polymerase	0
chain	0
reaction	0
.	0

Amplified	0
cDNA	1
were	0
sequenced	0
by	0
standard	0
methods	0
.	0

RESULTS	0
:	0
In	0
all	0
cells	0
tested	0
,	0
ER	3
mRNA	4
was	0
expressed	0
without	0
prior	0
in	0
vitro	0
stimulation	0
.	0

Partial	0
sequences	0
from	0
exons	1
1-8	2
were	0
nearly	0
identical	0
to	0
the	0
published	0
sequence	0
of	0
the	0
human	3
ER	4
mRNA	4
.	0

There	0
were	0
no	0
notable	0
differences	0
in	0
the	0
ER	3
transcripts	4
between	0
patients	0
and	0
healthy	0
controls	0
.	0

Variant	0
receptor	0
transcripts	0
lacking	0
exon	1
5	2
or	0
exon	1
7	2
,	0
which	0
encodes	0
the	0
hormone	0
binding	0
domain	0
,	0
were	0
identified	0
in	0
the	0
majority	0
of	0
the	0
cells	0
.	0

Precise	0
deletion	0
of	0
the	0
exons	0
suggests	0
that	0
they	0
are	0
alternatively	0
spliced	0
transcripts	0
.	0

Whether	0
the	0
detected	0
transcripts	0
are	0
translated	0
into	0
functional	0
receptor	0
proteins	0
remains	0
to	0
be	0
determined	0
.	0

In	0
vitro	0
stimulation	0
did	0
not	0
affect	0
ER	3
mRNA	4
expression	0
.	0

The	0
presence	0
of	0
variants	0
did	0
not	0
correlate	0
with	0
disease	0
activity	0
or	0
medication	0
.	0

CONCLUSION	0
:	0
Monocytes	7
,	0
T	7
cells	8
,	0
and	0
B	7
cells	8
in	0
patients	0
express	0
transcripts	0
of	0
the	0
normal	0
wild	9
type	10
ER	10
and	0
the	0
hormone	9
binding	10
domain	10
variants	10
in	0
vivo	0
.	0

DNA	0
damaging	0
agents	0
induce	0
expression	0
of	0
Fas	9
ligand	10
and	0
subsequent	0
apoptosis	0
in	0
T	7
lymphocytes	8
via	0
the	0
activation	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
.	0

Apoptosis	0
induced	0
by	0
DNA	0
damage	0
and	0
other	0
stresses	0
can	0
proceed	0
via	0
expression	0
of	0
Fas	9
ligand	10
(	0
FasL	9
)	0
and	0
ligation	0
of	0
its	0
receptor	0
,	0
Fas	0
(	0
CD95	0
)	0
.	0

We	0
report	0
that	0
activation	0
of	0
the	0
two	0
transcription	0
factors	0
NF-kappa	0
B	0
and	0
AP-1	9
is	0
crucially	0
involved	0
in	0
FasL	9
expression	0
induced	0
by	0
etoposide	0
,	0
teniposide	0
,	0
and	0
UV	0
irradiation	0
.	0

A	0
nondegradable	0
mutant	0
of	0
I	9
kappa	10
B	10
blocked	0
both	0
FasL	9
expression	0
and	0
apoptosis	0
induced	0
by	0
DNA	0
damage	0
but	0
not	0
Fas	9
ligation	0
.	0

These	0
stimuli	0
also	0
induced	0
the	0
stress-activated	0
kinase	0
pathway	0
(	0
SAPK	9
/JNK	9
)	0
,	0
which	0
was	0
required	0
for	0
the	0
maximal	0
induction	0
of	0
apoptosis	0
.	0

A	0
1.2	0
kb	0
FasL	1
promoter	2
responded	0
to	0
DNA	0
damage	0
,	0
as	0
well	0
as	0
coexpression	0
with	0
p65	9
Rel	10
or	0
Fos/Jun	9
.	0

Mutations	0
in	0
the	0
relevant	0
NF-kappa	9
B	10
and	0
AP-1	1
binding	2
sites	2
eliminated	0
these	0
responses	0
.	0

Thus	0
,	0
activation	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
contributes	0
to	0
stress-induced	0
apoptosis	0
via	0
the	0
expression	0
of	0
FasL	9
.	0

A	0
small	0
,	0
nonpeptidyl	0
mimic	0
of	0
granulocyte-colony-stimulating	9
factor	10
[	0
see	0
commetns	0
]	0

A	0
nonpeptidyl	0
small	0
molecule	0
SB	0
247464	0
,	0
capable	0
of	0
activating	0
granulocyte-colony-stimulating	9
factor	10
(	0
G-CSF	9
)	0
signal	0
transduction	0
pathways	0
,	0
was	0
identified	0
in	0
a	0
high-throughput	0
assay	0
in	0
cultured	7
cells	8
.	0

Like	0
G-CSF	9
,	0
SB	0
247464	0
induced	0
tyrosine	0
phosphorylation	0
of	0
multiple	9
signaling	10
proteins	10
and	0
stimulated	0
primary	7
murine	8
bone	8
marrow	8
cells	8
to	0
form	0
granulocytic	7
colonies	8
in	0
vitro	0
.	0

It	0
also	0
elevated	0
peripheral	7
blood	8
neutrophil	8
counts	0
in	0
mice	0
.	0

The	0
extracellular	0
domain	0
of	0
the	0
murine	9
G-CSF	10
receptor	10
was	0
required	0
for	0
the	0
activity	0
of	0
SB	0
247464	0
,	0
suggesting	0
that	0
the	0
compound	0
acts	0
by	0
oligomerizing	9
receptor	10
chains	10
.	0

The	0
results	0
indicate	0
that	0
a	0
small	0
molecule	0
can	0
activate	0
a	0
receptor	0
that	0
normally	0
binds	0
a	0
relatively	0
large	0
protein	0
ligand	0
.	0

Minimal	0
residual	0
disease	0
in	0
acute	0
myelogenous	0
leukemia	0
with	0
PML/RAR	3
alpha	4
or	4
AML1/ETO	4
mRNA	4
and	0
phenotypic	0
analysis	0
of	0
possible	7
T	8
and	8
natural	8
killer	8
cells	8
in	0
bone	0
marrow	0
.	0

Here	0
we	0
studied	0
minimal	0
residual	0
disease	0
(	0
MRD	0
)	0
of	0
patients	0
with	0
acute	0
myeloid	0
leukemia	0
(	0
AML	0
)	0
who	0
have	0
PML/RAR	9
alpha	10
or	0
AML1/ETO	9
as	0
well	0
as	0
the	0
phenotypic	0
analysis	0
of	0
lymphocyte	7
subsets	8
involved	0
in	0
antitumor	0
immunity	0
.	0

Eight	0
patients	0
in	0
long-term	0
(	0
LT	0
;	0
3	0
to	0
15	0
years	0
)	0
and	0
15	0
patients	0
in	0
short-term	0
(	0
ST	0
;	0
up	0
to	0
3	0
years	0
)	0
remission	0
were	0
studied	0
.	0

Using	0
the	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
(	0
RT	0
)	0
assay	0
,	0
the	0
limit	0
of	0
detection	0
was	0
10	0
(	0
-5	0
)	0
to	0
10	0
(	0
-6	0
)	0
for	0
PML/RAR	3
alpha	4
transcript	4
and	0
10	0
(	0
-4	0
)	0
to	0
10	0
(	0
-5	0
)	0
for	0
the	0
AML1/ETO	3
transcript	4
.	0

Simultaneously	0
,	0
T	7
lymphocyte	8
subsets	8
and	0
NK	7
cells	8
from	0
the	0
peripheral	0
blood	0
(	0
PB	0
)	0
and	0
bone	0
marrow	0
(	0
BM	0
)	0
were	0
investigated	0
by	0
flow	0
cytometric	0
analysis	0
.	0

Four	0
of	0
the	0
eight	0
patients	0
in	0
LT	0
and	0
7	0
of	0
the	0
15	0
patients	0
in	0
ST	0
remission	0
were	0
MRD-positive	0
.	0

Although	0
all	0
MRD-positive	0
patients	0
in	0
LT	0
remission	0
are	0
still	0
until	0
now	0
event-free	0
,	0
3	0
of	0
the	0
7	0
MRD-positive	0
(	0
MRD+	0
)	0
patients	0
in	0
ST	0
remission	0
soon	0
relapsed	0
.	0

The	0
total	0
populations	0
of	0
CD4	9
+	0
,	0
CD8	9
+	0
and	0
CD56	9
+	0
[	0
possible	0
T-cell	7
and	0
natural	7
killer	8
(	0
T/NK	7
)	0
populations	0
]	0
in	0
the	0
BM	0
of	0
ST	0
patients	0
and	0
MRD+/LT	0
patients	0
were	0
significantly	0
(	0
p	0
<	0
.01	0
)	0
low	0
.	0

The	0
CD8	9
+	0
CD28	9
+	0
population	0
showed	0
the	0
same	0
tendency	0
(	0
p	0
<	0
.01-.02	0
)	0
.	0

The	0
T/NK	7
subsets	8
in	0
the	0
BM	0
of	0
MRD-negative	0
(	0
MRD-	0
)	0
LT	0
(	0
MRD-/LT	0
)	0
patients	0
showed	0
similar	0
numbers	0
of	0
cells	0
as	0
normal	0
volunteers	0
.	0

Basically	0
,	0
the	0
total	0
percentage	0
of	0
the	0
CD4+	7
,	8
CD8+	8
and	8
CD56+	8
cell	8
populations	8
in	0
the	0
BM	0
was	0
increased	0
and	0
in	0
the	0
following	0
order	0
:	0
MRD-/LT	0
patients	0
,	0
normal	0
volunteers	0
,	0
MRD+/LT	0
patients	0
and	0
MRD+	0
or	0
-/ST	0
patients	0
.	0

The	0
percentages	0
of	0
the	0
T/NK-cell	7
subsets	8
in	0
the	0
PB	0
were	0
not	0
significantly	0
different	0
among	0
these	0
groups	0
.	0

Thus	0
,	0
the	0
difference	0
of	0
the	0
possible	0
T/NK-cell	7
phenotype	0
in	0
the	0
BM	0
may	0
strongly	0
influence	0
clinical	0
and	0
molecular	0
remission	0
.	0

These	0
results	0
still	0
remain	0
to	0
be	0
confirmed	0
by	0
further	0
studies	0
of	0
the	0
functional	0
anti-tumor	0
immunity	0
of	0
T/NK	7
cells	8
of	0
AML	0
in	0
remission	0
.	0

Mycobacterium	0
tuberculosis	0
mannose-capped	0
lipoarabinomannan	0
can	0
induce	0
NF-kappaB	9
-dependent	0
activation	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
long	1
terminal	2
repeat	2
in	0
T	7
cells	8
.	0

Tuberculosis	0
has	0
emerged	0
as	0
an	0
epidemic	0
,	0
extended	0
by	0
the	0
large	0
number	0
of	0
individuals	0
infected	0
with	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
.	0

The	0
major	0
goal	0
of	0
this	0
study	0
was	0
to	0
determine	0
whether	0
the	0
mycobacterial	7
cell	8
wall	0
component	0
mannose-capped	0
lipoarabinomannan	0
(	0
ManLAM	0
)	0
of	0
Mycobacterium	0
tuberculosis	0
(	0
M.	0
tuberculosis	0
)	0
could	0
activate	0
transcription	0
of	0
HIV-1	0
in	0
T	7
cells	8
with	0
the	0
use	0
of	0
an	0
in	0
vitro	0
cell	0
culture	0
system	0
.	0

These	0
experiments	0
are	0
of	0
prime	0
importance	0
considering	0
that	0
CD4-expressing	7
T	8
lymphocytes	8
represent	0
the	0
major	0
virus	0
reservoir	0
in	0
the	0
peripheral	0
blood	0
of	0
infected	0
individuals	0
.	0

Using	0
the	0
1G5	5
cell	6
line	6
harbouring	0
the	0
luciferase	1
reporter	2
gene	2
under	0
the	0
control	0
of	0
the	0
HIV-1	1
LTR	2
,	0
it	0
was	0
first	0
found	0
that	0
culture	0
protein	0
filtrates	0
(	0
CFP	0
)	0
from	0
M.	0
tuberculosis	0
or	0
purified	0
ManLAM	0
could	0
activate	0
HIV-1	1
LTR-dependent	2
gene	2
expression	0
unlike	0
similarly	0
prepared	0
CFP	0
extracts	0
devoid	0
of	0
ManLAM	0
.	0

The	0
implication	0
of	0
protein	9
tyrosine	10
kinase	10
(	10
s	10
)	10
,	0
protein	9
kinase	10
A	10
and/or	0
protein	9
kinase	10
C	10
was	0
highlighted	0
by	0
the	0
abrogation	0
of	0
the	0
ManLAM-mediated	0
activation	0
of	0
HIV-1	1
LTR-driven	2
gene	2
expression	0
using	0
herbimycin	0
A	0
and	0
H7	0
.	0

It	0
was	0
also	0
determined	0
,	0
using	0
electrophoresis	0
mobility	0
shift	0
assays	0
,	0
that	0
M.	0
tuberculosis	0
ManLAM	0
led	0
to	0
the	0
nuclear	0
translocation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	10
.	0

M.	0
tuberculosis	0
ManLAM	0
resulted	0
in	0
clear	0
induction	0
of	0
the	0
luciferase	1
gene	2
placed	0
under	0
the	0
control	0
of	0
the	0
wild-type	1
,	2
but	2
not	2
the	2
kappaB-mutated	2
,	2
HIV-1	2
LTR	2
region	2
.	0

Finally	0
,	0
the	0
ManLAM-mediated	0
activation	0
of	0
HIV-1	1
LTR	2
transcription	0
was	0
found	0
to	0
be	0
independent	0
of	0
the	0
autocrine	0
or	0
paracrine	0
action	0
of	0
endogenous	9
TNF-alpha	10
.	0

The	0
results	0
suggest	0
that	0
M.	0
tuberculosis	0
can	0
upregulate	0
HIV-1	0
expression	0
in	0
T	7
cells	8
and	0
could	0
thus	0
have	0
the	0
potential	0
to	0
influence	0
the	0
pathogenesis	0
of	0
HIV-1	0
infection	0
.	0

Human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
quasispecies	2
differ	0
in	0
basal	0
transcription	0
and	0
nuclear	9
factor	10
recruitment	0
in	0
human	7
glial	8
cells	8
and	8
lymphocytes	8
.	0

The	0
generation	0
of	0
genomic	0
diversity	0
during	0
the	0
course	0
of	0
infection	0
has	0
the	0
potential	0
to	0
affect	0
all	0
aspects	0
of	0
HIV-1	0
replication	0
,	0
including	0
expression	0
of	0
the	0
proviral	1
genome	2
.	0

To	0
gain	0
a	0
better	0
understanding	0
of	0
the	0
impact	0
of	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
sequence	0
diversity	0
on	0
LTR-directed	1
gene	2
expression	0
in	0
cells	0
of	0
the	0
central	0
nervous	0
system	0
(	0
CNS	0
)	0
and	0
immune	0
system	0
,	0
we	0
amplified	0
and	0
cloned	0
LTRs	1
from	0
proviral	1
DNA	2
in	0
HIV-1-infected	7
peripheral	8
blood	8
.	0

Sequence	0
analysis	0
of	0
nineteen	0
LTRs	1
cloned	0
from	0
2	0
adult	0
and	0
3	0
pediatric	0
patients	0
revealed	0
an	0
average	0
of	0
33	0
nucleotide	0
changes	0
(	0
with	0
respect	0
to	0
the	0
sequence	0
of	0
the	0
LAI	1
LTR	2
)	0
within	0
the	0
455-bp	1
U3	2
region	2
.	0

Transient	0
expression	0
analyses	0
in	0
cells	0
of	0
neuroglial	0
and	0
lymphocytic	0
origin	0
demonstrated	0
that	0
some	0
of	0
these	0
LTRs	1
had	0
activities	0
which	0
varied	0
significantly	0
from	0
the	0
LAI	1
LTR	2
in	0
U-373	5
MG	6
cells	6
(	0
an	0
astrocytoma	5
cell	6
line	6
)	0
as	0
well	0
as	0
in	0
Jurkat	5
cells	6
(	0
a	0
CD4-positive	5
lymphocyte	6
cell	6
line	6
)	0
.	0

While	0
LTRs	1
which	0
demonstrated	0
the	0
highest	0
activities	0
in	0
U-373	5
MG	6
cells	6
also	0
yielded	0
high	0
activities	0
in	0
Jurkat	0
cells	0
,	0
the	0
LTRs	1
were	0
generally	0
more	0
active	0
in	0
Jurkat	5
cells	6
when	0
compared	0
to	0
the	0
LAI	1
LTR	2
.	0

Differences	0
in	0
LTR	1
sequence	2
also	0
resulted	0
in	0
differences	0
in	0
transcription	0
factor	0
recruitment	0
to	0
cis-acting	1
sites	2
within	0
the	0
U3	1
region	2
of	0
the	0
LTR	1
,	0
as	0
demonstrated	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

In	0
particular	0
,	0
naturally	0
occurring	0
sequence	0
variation	0
impacted	0
transcription	9
factor	10
binding	0
to	0
an	0
activating	1
transcription	2
factor/cAMP	2
response	2
element	2
binding	2
(	2
ATF/CREB	2
)	2
binding	2
site	2
(	0
located	0
between	0
the	0
LEF-1	1
and	2
distal	2
NF-kappaB	2
transcription	2
factor	2
binding	2
sites	2
)	0
that	0
we	0
identified	0
in	0
previous	0
studies	0
of	0
the	0
HIV-1	1
LTR	2
.	0

These	0
findings	0
suggest	0
that	0
LTR	1
sequence	2
changes	0
can	0
significantly	0
affect	0
basal	0
LTR	1
function	0
and	0
transcription	9
factor	10
recruitment	0
,	0
which	0
may	0
,	0
in	0
turn	0
,	0
alter	0
the	0
course	0
of	0
viral	0
replication	0
in	0
cells	0
of	0
CNS	0
and	0
immune	0
system	0
origin	0
.	0

HMG	9
box	10
containing	0
transcription	9
factors	10
in	0
lymphocyte	7
differentiation	0
.	0

The	0
identification	0
of	0
the	0
mammalian	1
sex-determining	2
gene	2
Sry	2
has	0
led	0
to	0
the	0
discovery	0
of	0
a	0
large	0
family	0
of	0
related	0
(	0
'	0
HMG	9
box	10
'	0
)	0
transcription	9
factors	10
that	0
control	0
developmental	0
events	0
in	0
yeast	0
,	0
C.	0
elegans	0
,	0
Drosophila	0
and	0
vertebrates	0
.	0

In	0
lymphocyte	7
differentiation	0
,	0
several	0
HMG	9
box	10
proteins	10
play	0
a	0
decisive	0
role	0
.	0

Sox-4	9
is	0
important	0
for	0
very	0
early	0
B-cell	0
differentiation	0
,	0
while	0
TCF-1/LEF-1	9
play	0
a	0
crucial	0
role	0
in	0
early	0
thymocyte	0
development	0
.	0

TCF/LEF	9
proteins	10
have	0
recently	0
been	0
found	0
to	0
constitute	0
a	0
downstream	0
component	0
of	0
the	0
Wingless/Wnt	0
signal	0
transduction	0
pathway	0
.	0

In	0
flies	0
,	0
this	0
pathway	0
controls	0
segment	0
polarity	0
;	0
in	0
Xenopus	0
it	0
controls	0
the	0
definition	0
of	0
the	0
body	0
axis	0
.	0

Deregulation	0
of	0
the	0
pathway	0
occurs	0
in	0
several	0
human	0
tumors	0
.	0

These	0
insights	0
in	0
the	0
molecular	0
events	0
that	0
are	0
involved	0
in	0
TCF/LEF	9
function	0
in	0
these	0
organisms	0
may	0
eventually	0
lead	0
to	0
the	0
understanding	0
of	0
the	0
function	0
of	0
these	0
HMG	9
box	10
proteins	10
in	0
lymphoid	0
development	0

Single	0
strand	0
conformation	0
polymorphism	0
analysis	0
of	0
androgen	1
receptor	2
gene	2
mutations	0
in	0
patients	0
with	0
androgen	0
insensitivity	0
syndromes	0
:	0
application	0
for	0
diagnosis	0
,	0
genetic	0
counseling	0
,	0
and	0
therapy	0
.	0

Recent	0
studies	0
indicate	0
that	0
mutations	0
in	0
the	0
androgen	1
receptor	2
gene	2
are	0
associated	0
with	0
androgen	0
insensitivity	0
syndromes	0
,	0
a	0
heterogeneous	0
group	0
of	0
related	0
disorders	0
involving	0
defective	0
sexual	0
differentiation	0
in	0
karyotypic	0
males	0
.	0

In	0
this	0
report	0
,	0
we	0
address	0
the	0
possibility	0
of	0
rapid	0
mutational	0
analysis	0
of	0
the	0
androgen	1
receptor	2
gene	2
for	0
initial	0
diagnosis	0
,	0
genetic	0
counseling	0
,	0
and	0
molecular	0
subclassification	0
of	0
affected	0
patients	0
and	0
their	0
families	0
.	0

DNA	0
from	0
peripheral	7
blood	8
leukocytes	8
of	0
six	0
patients	0
from	0
five	0
families	0
with	0
various	0
degrees	0
of	0
androgen	0
insensitivity	0
was	0
studied	0
.	0

Exons	1
2	2
to	2
8	2
of	0
the	0
androgen	1
receptor	2
gene	2
were	0
analyzed	0
using	0
a	0
combination	0
of	0
single	0
strand	0
conformation	0
polymorphism	0
analysis	0
and	0
direct	0
DNA	0
sequencing	0
.	0

Female	0
family	0
members	0
were	0
also	0
studied	0
to	0
identify	0
heterozygote	0
carriers	0
.	0

Point	0
mutations	0
in	0
the	0
AR	1
gene	2
were	0
identified	0
in	0
all	0
six	0
patients	0
,	0
and	0
all	0
mutations	0
caused	0
amino	0
acid	0
substitutions	0
.	0

One	0
patient	0
with	0
incomplete	0
androgen	0
insensitivity	0
was	0
a	0
mosaic	0
for	0
the	0
mutation	0
.	0

Four	0
of	0
the	0
five	0
mothers	0
,	0
as	0
well	0
as	0
a	0
young	0
sister	0
of	0
one	0
patient	0
,	0
were	0
carriers	0
of	0
the	0
mutation	0
present	0
in	0
the	0
affected	0
child	0
.	0

Our	0
data	0
show	0
that	0
new	0
mutations	0
may	0
occur	0
in	0
the	0
androgen	1
receptor	2
gene	2
leading	0
to	0
sporadic	0
androgen	0
insensitivity	0
syndrome	0
.	0

Molecular	0
genetic	0
characterization	0
of	0
the	0
variant	1
allele	2
can	0
serve	0
as	0
a	0
primary	0
tool	0
for	0
diagnosis	0
and	0
subsequent	0
therapy	0
,	0
and	0
can	0
provide	0
a	0
basis	0
for	0
distinguishing	0
heterozygous	0
carriers	0
in	0
familial	0
androgen	0
resistance	0
.	0

The	0
identification	0
of	0
carriers	0
is	0
of	0
substantial	0
clinical	0
importance	0
for	0
genetic	0
counseling	0
.	0

Proliferation	0
index	0
as	0
a	0
prognostic	0
marker	0
in	0
breast	0
cancer	0
.	0

BACKGROUND	0
.	0

The	0
proliferative	0
activity	0
of	0
tumors	0
has	0
been	0
extensively	0
investigated	0
with	0
different	0
approaches	0
,	0
among	0
which	0
the	0
use	0
of	0
the	0
monoclonal	9
antibody	10
Ki-67	10
represents	0
an	0
easy	0
and	0
reliable	0
means	0
of	0
assessing	0
cell	0
proliferation	0
.	0

In	0
this	0
study	0
,	0
the	0
proliferative	0
activity	0
of	0
129	0
primary	0
breast	0
cancers	0
was	0
investigated	0
,	0
and	0
the	0
results	0
were	0
related	0
to	0
prognosis	0
.	0

METHODS	0
.	0

Tumor	0
samples	0
,	0
obtained	0
from	0
129	0
patients	0
who	0
underwent	0
surgery	0
between	0
January	0
1987	0
and	0
December	0
1988	0
,	0
were	0
processed	0
for	0
staining	0
by	0
an	0
immunohistochemical	0
procedure	0
(	0
avidin-biotin	9
complex	10
)	0
.	0

The	0
median	0
time	0
of	0
observation	0
was	0
42	0
months	0
(	0
range	0
,	0
31-55	0
months	0
)	0
.	0

Life-table	0
analysis	0
(	0
Mantel-Cox	0
)	0
was	0
used	0
to	0
assess	0
the	0
probability	0
of	0
disease-free	0
survival	0
(	0
DFS	0
)	0
and	0
overall	0
survival	0
(	0
OS	0
)	0
.	0

RESULTS	0
.	0

Tumors	0
with	0
high	0
Ki-67	9
proliferation	0
indices	0
(	0
>	0
20	0
%	0
)	0
were	0
associated	0
with	0
a	0
higher	0
4-year	0
probability	0
of	0
relapse	0
of	0
disease	0
(	0
55.3	0
%	0
versus	0
79.1	0
%	0
;	0
P	0
=	0
0.003	0
)	0
and	0
death	0
(	0
71	0
%	0
versus	0
95.6	0
%	0
;	0
P	0
=	0
0.00005	0
)	0
when	0
compared	0
with	0
tumors	0
with	0
low	0
Ki-67	9
values	0
.	0

In	0
addition	0
,	0
this	0
proliferative	0
parameter	0
maintained	0
its	0
prognostic	0
significance	0
when	0
the	0
patients	0
were	0
stratified	0
according	0
to	0
lymph	0
node	0
involvement	0
,	0
menopausal	0
status	0
,	0
and	0
nuclear	9
estrogen	10
receptor	10
content	0
.	0

CONCLUSIONS	0
.	0

Tumor	0
proliferative	0
activity	0
as	0
evaluated	0
by	0
the	0
monoclonal	9
antibody	10
Ki-67	10
seems	0
to	0
be	0
an	0
effective	0
indicator	0
of	0
prognosis	0
in	0
breast	0
cancer	0
for	0
DFS	0
and	0
OS	0
.	0

Regulation	0
of	0
the	0
Ets-related	9
transcription	10
factor	10
Elf-1	9
by	0
binding	0
to	0
the	0
retinoblastoma	9
protein	10
.	0

The	0
retinoblastoma	9
gene	10
product	10
(	0
Rb	9
)	0
is	0
a	0
nuclear	9
phosphoprotein	10
that	0
regulates	0
cell	0
cycle	0
progression	0
.	0

Elf-1	9
is	0
a	0
lymphoid-specific	9
Ets	10
transcription	10
factor	10
that	0
regulates	0
inducible	0
gene	0
expression	0
during	0
T	7
cell	8
activation	0
.	0

In	0
this	0
report	0
,	0
it	0
is	0
demonstrated	0
that	0
Elf-1	9
contains	0
a	0
sequence	0
motif	0
that	0
is	0
highly	0
related	0
to	0
the	0
Rb	9
binding	10
sites	10
of	0
several	0
viral	0
oncoproteins	9
and	0
binds	0
to	0
the	0
pocket	0
region	0
of	0
Rb	9
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Elf-1	9
binds	0
exclusively	0
to	0
the	0
underphosphorylated	0
form	0
of	0
Rb	9
and	0
fails	0
to	0
bind	0
to	0
Rb	9
mutants	10
derived	0
from	0
patients	0
with	0
retinoblastoma	0
.	0

Co-immunoprecipitation	0
experiments	0
demonstrated	0
an	0
association	0
between	0
Elf-1	9
and	0
Rb	9
in	0
resting	7
normal	8
human	8
T	8
cells	8
.	0

After	0
T	0
cell	0
activation	0
,	0
the	0
phosphorylation	0
of	0
Rb	9
results	0
in	0
the	0
release	0
of	0
Elf-1	9
,	0
which	0
is	0
correlated	0
temporally	0
with	0
the	0
activation	0
of	0
Elf-1	9
-mediated	0
transcription	0
.	0

Overexpression	0
of	0
a	0
phosphorylation-defective	0
form	0
of	0
Rb	9
inhibited	0
Elf-1	9
-dependent	0
transcription	0
during	0
T	7
cell	8
activation	0
.	0

These	0
results	0
demonstrate	0
that	0
Rb	9
interacts	0
specifically	0
with	0
a	0
lineage-restricted	9
Ets	10
transcription	10
factor	10
.	0

This	0
regulated	0
interaction	0
may	0
be	0
important	0
for	0
the	0
coordination	0
of	0
lineage-specific	0
effector	0
functions	0
such	0
as	0
lymphokine	9
production	0
with	0
cell	0
cycle	0
progression	0
in	0
activated	7
T	8
cells	8
.	0

Human	5
CD3-CD16+	6
natural	6
killer	6
cells	6
express	0
the	0
hGATA-3	9
T	10
cell	10
transcription	10
factor	10
and	0
an	0
unrearranged	0
2.3-kb	9
TcR	10
delta	10
transcript	10
.	0

In	0
this	0
study	0
we	0
analyzed	0
the	0
T	9
cell	10
receptor	10
(	10
TcR	10
)	10
delta	10
transcripts	10
expressed	0
by	0
CD3-CD16+	5
cells	6
and	0
we	0
investigated	0
whether	0
these	0
cells	0
expressed	0
the	0
hGATA-3	9
T	10
cell	10
transcription	10
factor	10
and	0
the	0
recombination-activating	1
gene	2
(	2
RAG	2
)	2
-1	2
.	0

Multiple	0
TcR	9
delta	10
transcripts	10
deriving	0
from	0
an	0
unrearranged	0
TcR	1
delta	2
gene	2
were	0
detected	0
in	0
both	0
polyclonal	5
and	6
clonal	6
CD3-CD16+	6
natural	6
killer	6
(	6
NK	6
)	6
cell	6
lines	6
.	0

Two	0
unrearranged	0
TcR	9
delta	10
transcripts	10
had	0
a	0
size	0
similar	0
to	0
that	0
of	0
the	0
functional	0
TcR	3
delta	4
mRNA	4
(	0
2.3	0
and	0
1.3	0
kb	0
)	0
found	0
in	0
TcR	5
gamma/delta+	6
T	6
lymphocytes	6
.	0

Sequence	0
analysis	0
of	0
nine	0
different	0
2.3-kb	0
cDNA	0
clones	0
obtained	0
from	0
NK-derived	0
polyA+	0
RNA	0
confirmed	0
that	0
they	0
corresponded	0
to	0
an	0
unrearranged	0
TcR	1
delta	2
gene	2
.	0

These	0
cDNA	0
were	0
2343	0
bp	0
long	0
and	0
their	0
transcription	0
initiation	0
site	0
was	0
located	0
814	1
bp	2
upstream	2
from	0
the	0
J	1
delta	2
1	2
segment	2
.	0

The	0
sequence	0
located	0
upstream	0
of	0
the	0
J	1
delta	2
1	2
segment	2
corresponded	0
to	0
the	0
previously	0
reported	0
germ-line	0
sequence	0
.	0

The	0
J	1
delta	2
1	2
segment	2
was	0
correctly	0
spliced	0
to	0
C	1
delta	2
;	0
in	0
addition	0
the	0
four	0
C	0
delta	0
exons	0
were	0
found	0
to	0
be	0
already	0
assembled	0
.	0

Two	0
polyadenylation	0
sites	0
were	0
present	0
in	0
the	0
fourth	1
C	2
delta	2
exon	2
.	0

However	0
,	0
only	0
that	0
located	0
at	0
the	0
3	0
'	0
end	0
appeared	0
to	0
be	0
utilized	0
in	0
the	0
2.3-kb	1
cDNA	2
.	0

The	0
expression	0
of	0
hGATA-3	9
,	0
a	0
T	9
cell-specific	10
factor	10
known	0
to	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
the	0
transcription	0
of	0
TcR	1
delta	2
locus	2
,	0
was	0
analyzed	0
by	0
Northern	0
blot	0
,	0
in	0
cultured	0
NK	5
cell	6
population	6
and	0
clones	0
(	0
but	0
not	0
in	0
freshly	0
derived	0
cell	0
populations	0
)	0
.	0

All	0
NK	5
clones	6
and	0
cell	0
lines	0
studied	0
were	0
found	0
to	0
express	0
hGATA-3-specific	3
mRNA	4
,	0
suggesting	0
that	0
hGATA-3	9
may	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
the	0
unrearranged	0
TcR	1
delta	2
gene	2
expression	0
in	0
NK	7
cells	8
.	0

Finally	0
,	0
no	0
transcription	0
of	0
the	0
RAG-1	1
gene	2
could	0
be	0
detected	0
in	0
all	0
NK	5
cell	6
lines	6
or	0
clones	0
analyzed	0
.	0

Negative	0
transcriptional	0
regulation	0
of	0
human	1
interleukin	2
2	2
(	2
IL-2	2
)	2
gene	2
by	0
glucocorticoids	0
through	0
interference	0
with	0
nuclear	9
transcription	10
factors	10
AP-1	9
and	0
NF-AT	9
.	0

IL-2	1
gene	2
transcription	0
is	0
affected	0
by	0
several	0
nuclear	9
proteins	10
.	0

We	0
asked	0
whether	0
dexamethasone	0
(	0
Dex	0
)	0
and	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
inhibit	0
IL-2	1
gene	2
transcription	0
by	0
interfering	0
with	0
the	0
activity	0
of	0
nuclear	9
proteins	10
that	0
bind	0
to	0
the	0
IL-2	0
promoter	0
.	0

Nuclear	0
extracts	0
from	0
primary	7
human	8
T	8
lymphocytes	8
were	0
analyzed	0
by	0
electrophoretic	0
DNA	0
mobility	0
shift	0
assays	0
.	0

Both	0
Dex	0
and	0
CsA	0
inhibited	0
the	0
binding	0
of	0
transcription	0
factors	0
AP-1	9
and	0
NF-AT	9
,	0
but	0
not	0
of	0
NF-kB	9
and	0
OCT-1/OAF	9
,	0
to	0
their	0
corresponding	0
sites	0
on	0
the	0
IL-2	1
gene	2
promoter	2
.	0

To	0
correlate	0
changes	0
in	0
nuclear	0
factor	0
binding	0
in	0
vitro	0
with	0
transcriptional	0
activity	0
in	0
vivo	0
and	0
define	0
the	0
structural	0
requirements	0
for	0
IL-2	1
promoter	2
repression	0
,	0
we	0
used	0
transient	0
DNA	0
transfections	0
.	0

Jurkat	5
cells	6
were	0
transfected	0
with	0
plasmids	1
containing	0
either	0
the	0
intact	0
IL-2	1
promoter	2
or	0
its	0
AP-1	1
,	2
NF-AT	2
,	2
and	2
NF-kB	2
motifs	2
.	0

Dex	0
inhibited	0
the	0
IL-2	1
promoter	2
and	0
the	0
AP-1	1
,	0
but	0
not	0
the	0
NF-AT	1
and	0
NF-kB	1
plasmids	2
.	0

In	0
contrast	0
,	0
CsA	0
inhibited	0
the	0
IL-2	1
promoter	2
and	0
the	0
NF-AT	1
,	0
but	0
not	0
the	0
AP-1	1
and	0
NF-kB	1
plasmids	2
.	0

These	0
results	0
suggest	0
that	0
in	0
human	7
T	8
lymphocytes	8
both	0
Dex	0
and	0
CsA	0
inhibited	0
IL-2	1
gene	2
transcription	0
through	0
interference	0
with	0
transcription	9
factors	10
AP-1	9
and	0
NF-AT	9
.	0

We	0
propose	0
that	0
,	0
while	0
maximum	0
inhibition	0
may	0
involve	0
interaction	0
with	0
both	0
transcription	9
factors	10
,	0
AP-1	9
is	0
the	0
primary	0
target	0
of	0
Dex	0
.	0

Nuclear	9
factor	10
kappa	10
B	10
,	0
a	0
mediator	0
of	0
lipopolysaccharide	0
effects	0
.	0

Exposure	0
of	0
certain	0
cell	0
types	0
to	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
leads	0
to	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
an	0
inducible	9
transcription	10
factor	10
.	0

One	0
of	0
NF-kappa	9
B	10
's	0
unique	0
properties	0
is	0
its	0
posttranslational	0
activation	0
via	0
release	0
of	0
an	0
inhibitory	9
subunit	10
,	0
called	0
inhibitor	9
of	10
NF-kappa	10
B	10
(	0
I	9
kappa	10
B	10
)	0
,	0
from	0
a	0
sequestered	0
cytoplasmic	0
form	0
.	0

This	0
event	0
is	0
also	0
triggered	0
under	0
various	0
other	0
conditions	0
of	0
biomedical	0
importance	0
.	0

Other	0
bacterial	0
toxins	0
,	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF	9
)	0
,	0
interleukin-1	9
(	0
IL-1	9
)	0
,	0
T	9
cell	10
mitogens	10
,	0
UV	0
light	0
,	0
gamma	0
rays	0
and	0
oxidative	0
stress	0
were	0
reported	0
to	0
induce	0
NF-kappa	9
B	10
.	0

The	0
activated	0
form	0
of	0
NF-kappa	9
B	10
,	0
which	0
is	0
rapidly	0
taken	0
up	0
into	0
nuclei	0
,	0
initiates	0
transcription	0
from	0
immediate	0
early	0
genes	0
in	0
a	0
wide	0
variety	0
of	0
cell	0
types	0
.	0

Most	0
of	0
the	0
target	0
genes	0
for	0
NF-kappa	9
B	10
are	0
of	0
relevance	0
for	0
the	0
immune	0
response	0
and	0
can	0
be	0
grouped	0
into	0
those	0
encoding	0
cytokines	9
,	0
cell	9
surface	10
receptors	10
,	0
acute	9
phase	10
proteins	10
and	0
viral	1
genomes	2
,	0
such	0
as	0
that	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
.	0

We	0
will	0
discuss	0
recent	0
experimental	0
evidences	0
suggesting	0
that	0
LPS	0
might	0
share	0
a	0
pathway	0
of	0
NF-kappa	9
B	10
activation	0
with	0
other	0
inducers	0
of	0
the	0
factor	0
.	0

This	0
common	0
pathway	0
may	0
involve	0
reactive	0
oxygen	0
intermediates	0
(	0
ROI	0
)	0
as	0
messenger	0
molecules	0
.	0

[	0
The	0
trend	0
of	0
molecular	0
biology	0
study	0
on	0
eosinophils	7
]	0

Recently	0
,	0
many	0
investigators	0
have	0
been	0
interested	0
in	0
the	0
study	0
on	0
eosinophil	7
biology	0
since	0
genes	0
association	0
with	0
eosinophils	7
such	0
as	0
interleukin-5	9
or	0
eosinophil	9
granule	10
proteins	10
(	0
EPO	9
,	0
ECP	9
,	0
EDN	9
,	0
MBP	9
,	0
and	0
CLC	9
)	0
,	0
were	0
isolated	0
.	0

However	0
,	0
the	0
molecular	0
basis	0
for	0
the	0
commitment	0
of	0
progenitors	0
to	0
the	0
eosinophil	7
lineage	8
has	0
not	0
been	0
determined	0
.	0

The	0
mechanism	0
by	0
which	0
eosinophil-specific	1
genes	2
encoding	0
primary	0
and	0
secondary	9
granule	10
proteins	10
(	0
e.g	0
.	0
ECP	9
,	0
EDN	9
,	0
EPO	9
,	0
MBP	9
,	0
and	0
CLC	9
)	0
are	0
expressed	0
and	0
regulated	0
during	0
eosinophilopoiesis	0
is	0
also	0
unknown	0
.	0

In	0
this	0
paper	0
,	0
I	0
described	0
the	0
characterization	0
of	0
genes	0
encoding	0
eosinophil	9
granule	10
proteins	10
and	0
the	0
mRNA	0
expression	0
of	0
GATA-1	9
binding	10
transcription	10
factor	10
during	0
eosinophil	0
differentiation	0
.	0

Characterization	0
of	0
the	0
nuclear	0
and	0
cytoplasmic	0
components	0
of	0
the	0
lymphoid-specific	9
nuclear	10
factor	10
of	0
activated	7
T	8
cells	8
(	0
NF-AT	9
)	0
complex	0
.	0

The	0
lymphoid-specific	9
transcription	10
complex	10
,	0
NF-AT	9
,	0
is	0
involved	0
in	0
early	0
gene	0
activation	0
in	0
T	7
cells	8
and	0
is	0
assembled	0
from	0
a	0
pre-existing	0
,	0
T	9
cell	10
restricted	10
cytoplasmic	10
factor	10
and	0
an	0
inducible	0
ubiquitous	9
nuclear	9
component	10
within	0
30	0
min	0
after	0
activation	0
through	0
the	0
antigen	9
receptor	10
.	0

Recent	0
studies	0
have	0
implicated	0
the	0
family	0
of	0
AP1	9
factors	10
as	0
components	0
of	0
the	0
murine	9
NF-AT	10
complex	10
.	0

Evidence	0
is	0
provided	0
here	0
that	0
the	0
nuclear	0
component	0
of	0
human	9
NF-AT	10
contains	0
the	0
phorbol	9
ester-inducible	10
transcription	10
factor	10
AP1	10
(	0
Jun/Fos	9
)	0
.	0

We	0
further	0
characterize	0
which	0
AP1	9
family	10
members	10
can	0
assume	0
this	0
role	0
.	0

Antisera	0
to	0
Fos	9
inhibits	0
NF-AT	9
DNA	0
binding	0
as	0
does	0
an	0
oligonucleotide	0
containing	0
a	0
binding	1
site	2
for	2
AP1	2
.	0

Constitutive	0
expression	0
in	0
vivo	0
of	0
Fos	9
,	0
and	0
to	0
a	0
lesser	0
extent	0
Fra-1	9
,	0
eliminates	0
the	0
requirement	0
for	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
stimulation	0
,	0
leaving	0
NF-AT	9
-directed	0
transcription	0
responsive	0
to	0
calcium	0
ionophore	0
alone	0
.	0

Overexpression	0
of	0
cJun	9
or	0
JunD	9
,	0
but	0
not	0
JunB	9
,	0
also	0
eliminates	0
the	0
requirement	0
for	0
PMA	0
,	0
indicating	0
that	0
many	0
but	0
not	0
all	0
Jun-	9
and	10
Fos-related	10
proteins	10
functionally	0
activate	0
NF-AT	9
-dependent	0
transcription	0
in	0
the	0
presence	0
of	0
the	0
cytoplasmic	0
component	0
.	0

NF-AT	9
DNA	0
binding	0
can	0
be	0
reconstituted	0
in	0
vitro	0
using	0
semi-purified	9
AP1	10
proteins	10
mixed	0
with	0
cytosol	0
from	0
T	7
lymphocytes	8
.	0

Fos	0
proteins	0
are	0
not	0
needed	0
for	0
this	0
reconstitution	0
,	0
and	0
although	0
JunB	9
is	0
not	0
functional	0
,	0
it	0
can	0
participate	0
in	0
the	0
NF-AT	9
DNA	10
binding	10
complex	10
.	0

Finally	0
,	0
we	0
have	0
partially	0
purified	0
the	0
cytoplasmic	0
component	0
of	0
NF-AT	0
and	0
show	0
by	0
elution	0
and	0
renaturation	0
from	0
SDS-polyacrylamide	0
gel	0
electrophoresis	0
gels	0
that	0
it	0
has	0
a	0
molecular	0
mass	0
between	0
94	0
and	0
116	0
kDa	0
and	0
may	0
have	0
multiple	0
differentially	0
modified	0
forms	0
.	0

Glucocorticoid	9
receptors	10
in	0
mononuclear	7
cells	8
of	0
patients	0
with	0
sepsis	0
.	0

Glucocorticoid	9
receptor	10
(	0
GR	9
)	0
hormone-binding	0
activity	0
was	0
studied	0
by	0
a	0
whole-cell	0
method	0
in	0
mononuclear	7
cells	8
(	0
MNC	7
)	0
from	0
peripheral	0
blood	0
of	0
7	0
patients	0
during	0
the	0
hemodynamic	0
compensatory	0
phase	0
of	0
sepsis	0
.	0

4	0
patients	0
were	0
receiving	0
dopamine	0
,	0
which	0
did	0
not	0
affect	0
the	0
GR	9
count	0
.	0

The	0
patients	0
'	0
plasma	0
cortisol	0
concentrations	0
were	0
normal	0
or	0
slightly	0
elevated	0
.	0

Despite	0
a	0
wide	0
range	0
,	0
the	0
mean	0
GR	9
count	0
and	0
affinity	0
in	0
MNC	7
from	0
septic	0
patients	0
did	0
not	0
differ	0
from	0
those	0
in	0
normal	0
controls	0
,	0
suggesting	0
that	0
glucocorticoids	0
could	0
still	0
be	0
effective	0
in	0
the	0
hemodynamic	0
compensatory	0
phase	0
of	0
sepsis	0
.	0

The	0
impaired	0
transcription	9
factor	10
AP-1	10
DNA	0
binding	0
activity	0
in	0
lymphocytes	7
derived	0
from	0
subjects	0
with	0
some	0
symptoms	0
of	0
premature	0
aging	0
.	0

The	0
study	0
of	0
human	0
disorders	0
known	0
as	0
premature	0
aging	0
syndromes	0
may	0
provide	0
insight	0
into	0
the	0
mechanisms	0
of	0
cellular	0
senescence	0
.	0

The	0
main	0
feature	0
of	0
cellular	0
senescence	0
in	0
vitro	0
is	0
cessation	0
of	0
cell	0
proliferation	0
.	0

Down	0
syndrome	0
(	0
DS	0
)	0
and	0
neuronal	0
ceroid-lypofuscinosis	0
(	0
NCL	0
)	0
are	0
clinically	0
characterized	0
by	0
the	0
premature	0
onset	0
of	0
numerous	0
features	0
normally	0
associated	0
with	0
human	0
aging	0
.	0

Phytohemagglutinin	9
stimulated	0
lymphocytes	7
derived	0
from	0
DS	0
subjects	0
showed	0
a	0
statistically	0
significant	0
diminished	0
proliferation	0
capacity	0
in	0
comparison	0
with	0
lymphocytes	7
derived	0
from	0
NCL	0
and	0
healthy	0
individuals	0
.	0

We	0
demonstrated	0
,	0
by	0
applying	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
slightly	0
impaired	0
AP-1	9
DNA	0
binding	0
activity	0
in	0
NCL	7
lymphocytes	8
and	0
strong	0
in	0
DS	7
ones	8
.	0

Our	0
results	0
showed	0
that	0
the	0
same	0
molecular	0
mechanisms	0
of	0
proliferation	0
cessation	0
could	0
exist	0
in	0
fibroblasts	7
characterized	0
by	0
replicative	0
senescence	0
and	0
in	0
lymphocytes	7
derived	0
from	0
individuals	0
with	0
premature	0
aging	0
syndromes	0
(	0
Down	0

Differential	0
contribution	0
of	0
herpes	9
simplex	10
virus	10
type	10
1	10
gene	10
products	10
and	0
cellular	9
factors	10
to	0
the	0
activation	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
provirus	0
.	0

We	0
have	0
previously	0
reported	0
that	0
infection	0
with	0
herpes	0
simplex	0
virus	0
type	0
1	0
(	0
HSV-1	0
)	0
activates	0
expression	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
provirus	0
in	0
T	7
cells	8
.	0

Activation	0
of	0
the	0
HIV-1	0
provirus	0
correlated	0
with	0
the	0
activation	0
of	0
binding	0
of	0
55-	9
and	10
85-kDa	10
proteins	10
to	0
the	0
kappa	1
B	2
enhancer	2
and	0
binding	0
of	0
the	0
50-kDa	9
HLP-1	10
protein	10
to	0
the	0
LBP-1	1
sequences	2
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
.	0

Further	0
examination	0
of	0
this	0
system	0
has	0
shown	0
that	0
the	0
inhibition	0
of	0
HSV-1	0
replication	0
by	0
the	0
antiviral	0
drug	0
acyclovir	0
does	0
not	0
inhibit	0
HSV-1-mediated	0
induction	0
of	0
HIV-1	0
provirus	0
.	0

Surprisingly	0
,	0
the	0
NF-kappa	9
B	10
and	0
HLP-1	0
binding	0
activities	0
were	0
substantially	0
inhibited	0
in	0
acyclovir-treated	5
cells	6
.	0

In	0
the	0
transient-transfection	0
assay	0
,	0
ICP0	9
,	0
but	0
not	0
ICP4	9
,	0
activated	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
promoter	2
region	2
and	0
the	0
effect	0
of	0
ICP0	9
was	0
greatly	0
enhanced	0
in	0
the	0
presence	0
of	0
the	0
NF-kappa	9
B	10
binding	10
proteins	10
,	0
suggesting	0
that	0
induction	0
of	0
the	0
HIV-1	0
provirus	0
involves	0
cooperation	0
between	0
the	0
HSV-1-activated	9
cellular	10
factor	10
,	0
NF-kappa	9
B	10
,	0
and	0
the	0
virus-encoded	9
transactivator	10
,	0
ICP0	9
.	0

Transcriptional	0
activation	0
of	0
the	0
macrophage	1
colony-stimulating	2
factor	2
gene	2
by	0
IL-2	9
is	0
associated	0
with	0
secretion	0
of	0
bioactive	0
macrophage	9
colony-stimulating	10
factor	10
protein	10
by	0
monocytes	7
and	0
involves	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
.	0

Human	7
peripheral	8
blood	8
monocytes	8
(	0
Mo	7
)	0
constitutively	0
display	0
the	0
beta-chain	0
of	0
the	0
receptor	0
for	0
IL-2	9
,	0
whereas	0
expression	0
of	0
the	0
IL-2R	9
alpha-chain	10
is	0
not	0
constitutive	0
but	0
inducible	0
with	0
IL-2	9
.	0

Here	0
we	0
report	0
that	0
binding	0
of	0
human	9
IL-2	10
to	0
its	0
binding	0
site	0
leads	0
to	0
transcriptional	0
activation	0
of	0
the	0
macrophage	1
CSF	2
(	2
M-CSF	2
)	2
gene	2
in	0
Mo	7
resulting	0
in	0
accumulation	0
of	0
M-CSF	3
mRNA	4
and	0
subsequent	0
release	0
of	0
bioactive	0
M-CSF	9
protein	10
as	0
demonstrated	0
by	0
ELISA	0
and	0
inhibition	0
of	0
IL-2	9
induced	0
release	0
of	0
an	0
activity-stimulating	0
growth	0
of	0
monocyte-type	5
colonies	6
by	0
a	0
neutralizing	0
anti-M-CSF	9
antibody	10
.	0

Transcriptional	0
activation	0
of	0
the	0
M-CSF	1
gene	2
by	0
IL-2	9
is	0
preceded	0
by	0
enhanced	0
binding	0
activity	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
to	0
its	0
recognition	0
sequence	0
in	0
the	0
5	0
'	0
regulatory	0
enhancer	0
region	0
of	0
the	0
M-CSF	1
gene	2
.	0

Moreover	0
,	0
using	0
a	0
heterologous	1
promoter	2
(	2
herpes	2
thymidine	2
kinase	2
)	2
construct	2
containing	0
the	0
NF-kappa	1
B	2
consensus	2
sequence	2
,	0
it	0
is	0
shown	0
that	0
NF-kappa	9
B	10
binding	0
by	0
an	0
IL-2-induced	9
monocyte-derived	10
nuclear	10
protein	10
confers	0
reporter	0
gene	0
(	0
human	0
growth	0
hormone	0
)	0
activity	0
.	0

Taken	0
together	0
,	0
our	0
findings	0
indicate	0
that	0
IL-2	9
induces	0
gene	0
expression	0
of	0
M-CSF	9
in	0
human	7
blood-derived	8
Mo	8
and	0
provide	0
evidence	0
for	0
involvement	0
of	0
NF-kappa	9
B	10
in	0
transcriptional	0
regulation	0
of	0
this	0
gene	0
.	0

Regulation	0
of	0
the	0
interleukin-1	1
beta	2
(	2
IL-1	2
beta	2
)	2
gene	2
by	0
mycobacterial	9
components	10
and	0
lipopolysaccharide	0
is	0
mediated	0
by	0
two	0
nuclear	1
factor-IL6	2
motifs	2
.	0

The	0
cytokines	0
interleukin-1	0
beta	0
(	0
IL-1	9
beta	10
)	0
and	0
tumor	0
necrosis	0
factor	0
alpha	0
(	0
TNF-alpha	9
)	0
are	0
released	0
by	0
mononuclear	7
phagocytes	8
in	0
vitro	0
after	0
stimulation	0
with	0
mycobacteria	0
and	0
are	0
considered	0
to	0
mediate	0
pathophysiologic	0
events	0
,	0
including	0
granuloma	0
formation	0
and	0
systemic	0
symptoms	0
.	0

We	0
demonstrated	0
that	0
the	0
Mycobacterium	0
tuberculosis	0
cell	0
wall	0
component	0
lipoarabinomannan	0
(	0
LAM	0
)	0
is	0
a	0
very	0
potent	0
inducer	0
of	0
IL-1	1
beta	2
gene	2
expression	0
in	0
human	7
monocytes	8
and	0
investigated	0
the	0
mechanism	0
of	0
this	0
effect	0
.	0

We	0
localized	0
the	0
LAM-	0
,	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-	0
,	0
and	0
TNF-alpha	9
-inducible	1
promoter	2
activity	0
to	0
a	0
-131/+15	0
(	0
positions	0
-131	0
to	0
+15	0
)	0
DNA	0
fragment	0
of	0
the	0
IL-1	1
beta	2
gene	2
by	0
deletion	0
analysis	0
and	0
chloramphenicol	9
acetyltransferase	10
assay	0
.	0

Within	0
this	0
DNA	0
fragment	0
,	0
there	0
were	0
two	0
novel	0
9-bp	0
motifs	0
(	0
-90/-82	0
and	0
-40/-32	0
)	0
with	0
high	0
homology	0
to	0
the	0
nuclear	1
factor-IL6	2
(	2
NF-IL6	2
)	2
binding	2
site	2
.	0

Site-directed	0
mutagenesis	0
demonstrated	0
that	0
the	0
two	0
NF-IL-6	1
motifs	2
could	0
be	0
independently	0
activated	0
by	0
LAM	0
,	0
LPS	0
,	0
or	0
TNF-alpha	9
and	0
that	0
they	0
acted	0
in	0
an	0
orientation-independent	0
manner	0
.	0

DNA	0
mobility	0
shift	0
assay	0
revealed	0
specific	0
binding	0
of	0
nuclear	9
protein	10
(	0
s	0
)	0
from	0
LAM-	5
,	6
LPS-	6
,	6
or	6
TNF-alpha-	6
stimulated	6
THP-1	6
cells	6
to	0
the	0
NF-IL6	0
motifs	0
.	0

We	0
conclude	0
that	0
the	0
two	0
NF-IL6	1
sites	2
mediate	0
induction	0
of	0
IL-1	9
beta	10
in	0
response	0
to	0
the	0
stimuli	0
LAM	0
,	0
LPS	0
,	0
and	0
TNF-alpha	9
.	0

HIV-1	9
Nef	10
protein	10
inhibits	0
the	0
recruitment	0
of	0
AP-1	9
DNA-binding	0
activity	0
in	0
human	7
T-cells	8
.	0

The	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
,	0
HIV-1-LTR	1
,	0
contains	0
binding	0
sites	0
for	0
several	0
cellular	0
transcription	0
factors	0
which	0
contribute	0
to	0
HIV-1	1
gene	2
expression	0
.	0

Our	0
previous	0
studies	0
on	0
the	0
function	0
of	0
the	0
HIV-1-encoded	9
Nef	10
protein	10
suggested	0
that	0
Nef	9
may	0
be	0
an	0
inhibitor	0
HIV-1	0
transcription	0
.	0

To	0
determine	0
whether	0
Nef	9
affects	0
the	0
binding	0
of	0
cellular	9
factors	10
implicated	0
in	0
HIV-1	0
regulation	0
,	0
32P-labeled	0
oligonucleotides	0
corresponding	0
to	0
the	0
binding	0
sites	0
were	0
incubated	0
with	0
nuclear	0
extracts	0
prepared	0
from	0
Nef-expressing	5
T-cell	6
lines	6
that	0
were	0
not	0
stimulated	0
or	0
were	0
stimulated	0
with	0
T-cell	9
mitogens	10
.	0

We	0
found	0
that	0
Nef	9
inhibited	0
the	0
recruitment	0
of	0
AP-1	9
DNA-binding	0
activity	0
in	0
mitogen-stimulated	0
human	7
T-cells	8
.	0

Additionally	0
,	0
Nef	5
expressing	6
cells	6
were	0
transiently	0
transfected	0
with	0
a	0
plasmid	0
in	0
which	0
HIV-1	1
AP-1	2
DNA	2
recognition	2
sequences	2
were	0
cloned	0
downstream	0
of	0
the	0
chloramphenicol	9
acetyltransferase	10
(	0
CAT	9
)	0
gene	0
.	0

Mitogen-mediated	0
transcriptional	0
activation	0
of	0
the	0
CAT	1
gene	2
in	0
this	0
construct	0
was	0
inhibited	0
in	0
Nef-expressing	5
cells	6
but	0
not	0
in	0
control	0
cells	0
.	0

These	0
studies	0
suggest	0
that	0
,	0
by	0
inhibiting	0
AP-1	9
activation	0
,	0
Nef	9
may	0
play	0
a	0
role	0
in	0
regulating	0
HIV-1	1
gene	2
expression	0
in	0
infected	7
T-cells	8
.	0

Regulation	0
of	0
the	0
beta-globin	1
locus	2
.	0

Transcription	0
of	0
the	0
human	1
beta-globin	2
gene	2
cluster	2
depends	0
upon	0
upstream	1
regulatory	2
sequences	2
,	0
which	0
are	0
collectively	0
termed	0
the	0
locus	1
control	2
region	2
.	0

Recent	0
studies	0
have	0
provided	0
new	0
insights	0
into	0
how	0
the	0
individual	0
genes	0
of	0
the	0
cluster	0
are	0
regulated	0
through	0
development	0
.	0

The	0
crux	0
of	0
transcriptional	0
activation	0
is	0
how	0
the	0
locus	1
control	2
region	2
communicates	0
with	0
the	0
gene-proximal	1
regulatory	2
elements	2
.	0

Enhancing	0
effect	0
of	0
17	0
beta-estradiol	0
on	0
human	0
NK	0
cell	0
activity	0
.	0

The	0
in	0
vitro	0
effect	0
of	0
17	0
beta-estradiol	0
on	0
NK	0
activity	0
was	0
studied	0
.	0

The	0
proliferation	0
and	0
NK	0
activity	0
of	0
YT-N17	5
(	0
a	0
human	5
NK-like	6
cell	6
line	6
)	0
were	0
enhanced	0
by	0
17	0
beta-estradiol	0
(	0
E2	0
)	0
,	0
and	0
the	0
enhancement	0
was	0
blocked	0
by	0
tamoxifen	0
(	0
Tx	0
)	0
,	0
an	0
antagonist	0
of	0
E2	0
.	0

On	0
the	0
contrary	0
,	0
other	0
steroid	0
hormones	0
such	0
as	0
Tx	0
,	0
progesterone	0
,	0
and	0
testosterone	0
had	0
no	0
effect	0
.	0

YT-N17	5
contained	0
11.8	0
fmol/mg	0
protein	0
of	0
estrogen	9
receptor	10
(	0
mean	0
of	0
two	0
independent	0
assays	0
)	0
,	0
a	0
value	0
which	0
was	0
5-10-fold	0
higher	0
than	0
that	0
of	0
other	0
hematopoietic	5
cell	6
lines	6
.	0

An	0
enhancement	0
of	0
NK	0
activity	0
by	0
E2	0
was	0
also	0
seen	0
in	0
large	7
granular	8
lymphocytes	8
obtained	0
from	0
normal	0
subjects	0
,	0
and	0
it	0
was	0
again	0
suppressed	0
by	0
Tx	0
.	0

These	0
data	0
suggest	0
that	0
E2	0
is	0
one	0
of	0
the	0
activating	0
factors	0
for	0
NK/LGL	5
cells	6
.	0

A	0
serum	1
response	2
element	2
and	0
a	0
binding	1
site	2
for	2
NF-Y	2
mediate	0
the	0
serum	0
response	0
of	0
the	0
human	1
thrombospondin	2
1	2
gene	2
.	0

The	0
expression	0
of	0
thrombospondin	9
1	10
(	0
TSP	9
1	10
)	0
,	0
a	0
member	0
of	0
the	0
TSP	1
gene	2
family	2
,	0
is	0
rapidly	0
induced	0
by	0
growth	0
factors	0
.	0

We	0
tested	0
the	0
ability	0
of	0
human	1
TSP	2
1-chloramphenicol	2
acetyltransferase	2
constructs	2
to	0
respond	0
to	0
serum	0
in	0
stably	0
transfected	0
NIH-3T3	0
cells	0
.	0

Two	0
transcriptional	0
elements	0
in	0
the	0
TSP	9
1	10
promoter	0
,	0
a	0
distal	0
element	0
at	0
-1280	0
and	0
a	0
proximal	0
element	0
at	0
-65	0
,	0
were	0
required	0
for	0
the	0
response	0
of	0
the	0
human	0
TSP	0
1	0
gene	0
to	0
serum	0
.	0

The	0
distal	0
element	0
contains	0
the	0
5'-CC	0
(	0
A	0
+	0
T	0
)	0
6GG-3	0
'	0
consensus	0
sequence	0
characteristic	0
of	0
a	0
serum-response	0
element	0
(	0
SRE	0
)	0
.	0

Deletions	0
or	0
mutations	0
in	0
this	0
element	0
reduced	0
the	0
serum	0
response	0
of	0
the	0
TSP	1
1	2
gene	2
by	0
80-90	0
%	0
.	0

In	0
gel-shift	0
assays	0
,	0
the	0
-1280	1
element	2
and	0
the	0
c-fos	1
SRE	2
cross	2
-competed	0
,	0
whereas	0
their	0
functional	0
and	0
binding	1
mutants	2
did	0
not	0
.	0

The	0
proximal	1
element	2
contains	0
the	0
sequence	0
5'-GGCCAATGGG-3	0
'	0
,	0
which	0
closely	0
resembles	0
the	0
consensus	0
binding	0
motif	0
for	0
the	0
CCAAT-binding	1
factor	2
NF-Y	9
(	0
CBF	9
,	0
CP1	9
,	0
alpha	9
CP1	10
)	0
.	0

Deletions	0
or	0
mutations	0
in	0
this	0
element	0
also	0
reduced	0
the	0
serum	0
response	0
by	0
80-90	0
%	0
.	0

Methylation	0
interference	0
analysis	0
of	0
the	0
-65	1
region	2
identified	0
a	0
pattern	0
of	0
contacts	0
with	0
nuclear	9
factors	10
resembling	0
that	0
for	0
NF-Y	9
,	0
and	0
an	0
NF-Y-binding	1
site	2
and	0
the	0
proximal	1
TSP	2
1	2
element	2
cross-competed	0
in	0
gel-shift	0
assays	0
,	0
whereas	0
their	0
binding	1
mutants	2
did	0
not	0
.	0

Finally	0
,	0
an	0
abbreviated	1
TSP	2
1	2
promoter/5'-flank	2
,	0
containing	0
the	0
SRE-	1
and	2
NF-Y-binding	2
sites	2
,	0
mediated	0
a	0
serum	0
response	0
that	0
was	0
close	0
in	0
magnitude	0
to	0
that	0
of	0
the	0
parent	1
promoter	2
.	0

We	0
conclude	0
that	0
the	0
serum	0
response	0
of	0
the	0
human	0
TSP	1
1	2
gene	2
requires	0
the	0
coordinated	0
function	0
of	0
an	0
SRE-	1
and	2
NF-Y-binding	2
site	2
.	0

Cell-type-specific	0
transactivation	0
of	0
the	0
parathyroid	1
hormone-related	2
protein	2
gene	2
promoter	2
by	0
the	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
I	10
(	10
HTLV-I	10
)	10
tax	10
and	0
HTLV-II	9
tax	10
proteins	10
.	0

The	0
human	9
T-cell	10
leukemia	10
virus	10
type	10
I	10
(	10
HTLV-I	10
)	10
and	10
HTLV-II	10
Tax	10
proteins	10
are	0
potent	0
transactivators	9
of	0
viral	0
and	0
cellular	0
gene	0
expression	0
.	0

Using	0
deletion	1
mutants	2
,	0
the	0
downstream	0
parathyroid	1
hormone-related	2
protein	2
(	2
PTHrP	2
)	2
promoter	2
is	0
shown	0
to	0
be	0
responsive	0
to	0
both	0
HTLV-I	9
and	10
HTLV-II	10
Tax	10
as	0
well	0
as	0
the	0
AP1/c-jun	1
proto-oncogene	2
.	0

Transactivation	0
of	0
PTHrP	9
by	0
Tax	9
was	0
seen	0
in	0
T	7
cells	8
but	0
not	0
in	0
B-cell	5
lines	6
or	0
fibroblasts	5
.	0

A	0
carboxy	1
terminal	2
Tax	2
deletion	2
mutant	2
was	0
deficient	0
in	0
transactivation	0
of	0
both	0
the	0
PTHrP	1
and	2
IL2R	2
alpha	2
promoters	2
but	0
not	0
the	0
HTLV-I	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

Exogenous	0
provision	0
of	0
NFkB	9
rescued	0
IL2R	9
alpha	0
expression	0
but	0
not	0
the	0
PTHrP	1
promoter	2
.	0

Thus	0
,	0
HTLV-I	9
Tax	10
,	0
HTLV-II	9
Tax	10
,	0
and	0
c-jun	9
transactivate	0
PTHrP	9
and	0
may	0
contribute	0
to	0
the	0
pathogenesis	0
of	0
hypercalcemia	0
in	0
adult	0
T-cell	0
leukemia	0
.	0

Involvement	0
of	0
Alu	1
sequences	2
in	0
the	0
cell-specific	0
regulation	0
of	0
transcription	0
of	0
the	0
gamma	9
chain	10
of	0
Fc	9
and	0
T	9
cell	10
receptors	10
.	0

The	0
Fc	9
epsilon	10
RI-gamma	10
chains	10
are	0
expressed	0
in	0
a	0
variety	0
of	0
hematopoietic	7
cells	8
where	0
they	0
play	0
a	0
critical	0
role	0
in	0
signal	0
transduction	0
.	0

They	0
are	0
part	0
of	0
the	0
high	9
affinity	10
IgE	10
receptor	10
in	0
mast	7
cells	8
,	0
basophils	7
,	0
Langerhans	7
cells	8
,	0
and	0
possibly	0
other	0
cells	0
;	0
a	0
component	0
of	0
the	0
low	0
affinity	0
receptor	0
for	0
IgG	9
(	0
Fc	9
gamma	10
RIIIA	10
or	0
CD16	9
)	0
in	0
natural	0
killer	7
cells	8
and	0
macrophages	7
;	0
and	0
part	0
of	0
the	0
T	9
cell	10
antigen	10
receptor	10
in	0
subsets	0
of	0
T	7
cells	8
.	0

Here	0
we	0
have	0
investigated	0
the	0
transcriptional	0
regulation	0
of	0
the	0
gamma	9
chain	10
gene	0
by	0
analyzing	0
the	0
2.5-kilobase	1
sequence	2
upstream	0
of	0
the	0
transcription	0
start	0
site	0
.	0

This	0
sequence	0
contains	0
a	0
promoter	1
specific	0
to	0
cells	7
of	8
hematopoietic	8
lineage	8
.	0

However	0
,	0
the	0
tissue	0
specificity	0
of	0
this	0
promoter	1
is	0
only	0
partial	0
because	0
it	0
is	0
active	0
in	0
all	0
of	0
the	0
hematopoietic	7
cells	8
tested	0
here	0
,	0
regardless	0
of	0
whether	0
they	0
constitutively	0
express	0
Fc	0
epsilon	0
RI-	0
gamma	9
chain	10
transcripts	0
.	0

We	0
have	0
identified	0
two	0
adjacent	0
cis-acting	0
regulatory	0
elements	0
,	0
both	0
of	0
which	0
are	0
part	0
of	0
an	0
Alu	0
repeat	0
.	0

The	0
first	0
(	0
-445/-366	0
)	0
is	0
a	0
positive	0
element	0
active	0
in	0
both	0
basophils	7
and	0
T	7
cells	8
.	0

The	0
second	0
(	0
-365/-264	0
)	0
binds	0
to	0
nuclear	9
factors	10
,	0
which	0
appear	0
to	0
be	0
different	0
in	0
basophils	7
and	0
T	7
cells	8
,	0
and	0
acts	0
as	0
a	0
negative	0
element	0
in	0
basophils	7
and	0
as	0
a	0
positive	0
one	0
in	0
T	7
cells	8
.	0

Thus	0
,	0
this	0
Alu	1
repeat	2
(	0
90	0
%	0
identical	0
to	0
Alu	1
consensus	2
sequences	2
)	0
has	0
evolved	0
to	0
become	0
both	0
a	0
positive	0
and	0
negative	0
regulator	0
.	0

Chlorinated	0
dibenzo-p-dioxins	0
and	0
dibenzofurans	0
and	0
the	0
human	0
immune	0
system	0
.	0

1	0
.	0
Blood	9
cell	10
receptors	10
in	0
volunteers	0
with	0
moderately	0
increased	0
body	0
burdens	0
.	0

Using	0
monoclonal	9
antibodies	10
(	0
mAbs	9
)	0
and	0
flow	0
cytometry	0
,	0
we	0
studied	0
a	0
variety	0
of	0
surface	9
receptors	10
on	0
lymphocyte	7
subpopulations	8
of	0
workers	0
with	0
moderately	0
increased	0
body	0
burdens	0
of	0
2	0
,	0
3	0
,	0
7	0
,	0
8-tetrachlorodibenzo-p-dioxin	0
(	0
TCDD	0
)	0
and	0
of	0
other	0
polychlorinated	0
dibenzo-p-dioxins	0
and	0
dibenzofurans	0
(	0
PCDD/PCDF	0
)	0
,	0
expressed	0
here	0
as	0
International-Toxicity	0
Equivalencies	0
(	0
I-TE	0
)	0
.	0

The	0
hypothesis	0
to	0
be	0
tested	0
was	0
whether	0
or	0
not	0
humans	0
exhibit	0
a	0
similar	0
susceptibility	0
to	0
PCDDs/PCDFs	0
with	0
respect	0
to	0
the	0
surface	9
receptors	10
found	0
previously	0
to	0
respond	0
to	0
small	0
doses	0
of	0
2	0
,	0
3	0
,	0
7	0
,	0
8-tetrachlorodibenzo-p-dioxin	0
(	0
TCDD	0
)	0
in	0
Callithrix	0
jacchus	0
.	0

These	0
are	0
:	0
helper-inducer	7
(	8
memory	8
)	8
T	8
cells	8
(	0
CD4+CD45R0+CD45RA-CD29highCD11a+	7
)	0
,	0
CD20+	7
B	8
cells	8
,	0
and	0
cytotoxic	7
T	8
cells	8
(	0
CD8+CD56+/CD57+	7
)	0
.	0

Furthermore	0
,	0
68	0
triple-labellings	0
with	0
mAbs	9
were	0
performed	0
on	0
the	0
cells	0
of	0
each	0
volunteer	0
to	0
possibly	0
generate	0
further	0
hypotheses	0
.	0

It	0
was	0
evaluated	0
whether	0
any	0
of	0
the	0
variables	0
might	0
be	0
used	0
as	0
a	0
biomarker	0
of	0
effects	0
for	0
this	0
class	0
of	0
compounds	0
.	0

There	0
were	0
two	0
main	0
goals	0
:	0
(	0
1	0
)	0
to	0
evaluate	0
whether	0
workers	0
with	0
a	0
moderately	0
increased	0
PCDD/PCDF-body	0
burden	0
[	0
25-140	0
ppt	0
TCDD	0
or	0
104-522	0
ppt	0
I-TE	0
in	0
blood	0
fat	0
]	0
exhibit	0
changes	0
in	0
the	0
surface	9
receptors	10
of	0
white	7
blood	8
cells	8
,	0
as	0
observed	0
in	0
previous	0
studies	0
in	0
non-human	0
primates	0
,	0
and	0
(	0
2	0
)	0
to	0
clarify	0
whether	0
persons	0
at	0
the	0
upper	0
range	0
[	0
10-23	0
ppt	0
TCDD	0
or	0
30-90	0
ppt	0
I-TE	0
in	0
blood	0
fat	0
]	0
of	0
the	0
body	0
burden	0
reference	0
values	0
of	0
a	0
not	0
particularly	0
exposed	0
population	0
show	0
detectable	0
deviations	0
in	0
these	0
immunological	0
variables	0
,	0
when	0
compared	0
with	0
persons	0
at	0
the	0
lower	0
and	0
medium	0
range	0
[	0
1-3	0
ppt	0
TCDD	0
or	0
9-29	0
ppt	0
I-TE	0
]	0
of	0
these	0
body	0
burden	0
reference	0
values	0
.	0

Regression	0
analysis	0
of	0
our	0
data	0
revealed	0
slight	0
trends	0
for	0
some	0
of	0
the	0
biomarkers	0
(	0
e.g.	0
CD45R0+	0
)	0
.	0

With	0
one	0
exception	0
,	0
these	0
were	0
all	0
increases	0
.	0

None	0
of	0
the	0
alterations	0
observed	0
are	0
of	0
medical	0
relevance	0
.	0

The	0
slight	0
increase	0
in	0
the	0
percentage	0
of	0
CD4+CD45R0+	7
cells	8
remained	0
significant	0
even	0
after	0
covariant	0
analysis	0
taking	0
age-related	0
changes	0
into	0
account	0
.	0

Altogether	0
,	0
the	0
data	0
do	0
not	0
provide	0
any	0
evidence	0
to	0
support	0
an	0
assumption	0
that	0
moderately	0
increased	0
body	0
burdens	0
of	0
PCDDs/PCDFs	0
in	0
adults	0
induce	0
decreases	0
in	0
the	0
cellular	0
components	0
of	0
the	0
human	0
immune	0
system	0
.	0

Adult	0
humans	0
certainly	0
are	0
less	0
susceptible	0
to	0
this	0
action	0
of	0
PCDDs/PCDFs	0
than	0
adolescent	0
Callithrix	0
jacchus	0

Inhibition	0
of	0
HIV-1	0
latency	0
reactivation	0
by	0
dehydroepiandrosterone	0
(	0
DHEA	0
)	0
and	0
an	0
analog	0
of	0
DHEA	0
.	0

The	0
initial	0
infection	0
with	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
in	0
most	0
individuals	0
usually	0
results	0
in	0
the	0
establishment	0
of	0
a	0
latent	0
or	0
chronic	0
infection	0
before	0
eventual	0
progression	0
toward	0
acquired	0
immunodeficiency	0
syndrome	0
.	0

HIV-1	0
can	0
also	0
establish	0
a	0
latent	0
or	0
persistent	0
infection	0
in	0
some	0
T	5
cell	6
lines	6
that	0
show	0
minimal	0
constitutive	0
virus	0
expression	0
.	0

However	0
,	0
activation	0
of	0
the	0
T	5
cell	6
lines	6
leading	0
to	0
enhanced	0
HIV-1	0
replication	0
can	0
be	0
induced	0
by	0
antigens	9
,	0
mitogens	0
,	0
and	0
cytokines	9
(	0
tumor	9
necrosis	10
factor	10
alpha	10
[	0
TNF-alpha	9
]	0
,	0
interleukin	9
1	10
,	0
and	0
interleukin-2	9
)	0
.	0

Various	0
gene	0
products	0
from	0
other	0
viruses	0
(	0
HTLV-1	0
,	0
HSV	0
,	0
EBV	0
,	0
CMV	0
,	0
HBV	0
,	0
and	0
HHV-6	0
)	0
can	0
also	0
enhance	0
HIV-1	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
-driven	0
reporter	1
gene	2
activity	0
.	0

On	0
the	0
basis	0
of	0
these	0
observations	0
,	0
it	0
has	0
been	0
proposed	0
that	0
reactivation	0
of	0
latent	0
HIV-1	0
harbored	0
in	0
chronically	7
infected	8
T	8
lymphocytes	8
,	0
monocytes	7
,	0
or	0
macrophages	7
plays	0
an	0
important	0
role	0
in	0
the	0
pathogenesis	0
of	0
AIDS	0
.	0

So	0
far	0
,	0
there	0
are	0
no	0
drugs	0
or	0
therapy	0
available	0
that	0
can	0
provide	0
protection	0
against	0
HIV-1	0
latency	0
reactivation	0
.	0

ACH-2	5
,	0
derived	0
from	0
a	0
human	5
T	6
cell	6
line	6
(	0
CEM	5
)	0
,	0
is	0
chronically	0
infected	0
with	0
HIV-1	0
,	0
with	0
low	0
levels	0
of	0
constitutive	0
virus	0
expression	0
.	0

ACH-2	5
can	0
be	0
converted	0
to	0
productive	0
infection	0
by	0
stimulation	0
of	0
the	0
cells	0
with	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
,	0
mitogen	0
or	0
cytokines	9
(	0
TNF-alpha	9
)	0
,	0
or	0
infection	0
with	0
HSV	0
.	0

Therefore	0
the	0
ACH-2	5
cell	0
line	0
is	0
a	0
good	0
candidate	0
for	0
studying	0
the	0
effects	0
of	0
drugs	0
on	0
HIV-1	0
activation	0
.	0

Previously	0
,	0
we	0
have	0
reported	0
that	0
DHEA	0
and	0
synthetic	0
analogs	0
of	0
DHEA	0
can	0
be	0
modest	0
inhibitors	0
of	0
HIV-1	0
IIIB	0
replication	0
in	0
phytohemagglutinin-stimulated	5
peripheral	6
blood	6
lymphocyte	6
cultures	6
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Occurrence	0
of	0
a	0
silencer	1
of	0
the	0
interleukin-2	1
gene	2
in	0
naive	0
but	0
not	0
in	0
memory	7
resting	8
T	8
helper	8
lymphocytes	8
.	0

In	0
the	0
immune	0
system	0
the	0
first	0
activation	0
of	0
a	0
naive	7
T	8
cell	8
by	0
antigen	0
is	0
a	0
key	0
step	0
in	0
the	0
shaping	0
of	0
the	0
peripheral	0
T	0
cell	0
specificity	0
repertoire	0
and	0
maintenance	0
of	0
self-tolerance	0
.	0

In	0
the	0
present	0
study	0
,	0
analysis	0
of	0
the	0
interleukin-2	1
(	2
IL-2	2
)	2
gene	2
activation	0
shows	0
that	0
naive	7
human	8
helper	8
T	8
cells	8
(	0
cord	7
blood	8
CD4+	8
T	8
cells	8
,	0
adult	7
CD4+CD45RO-	8
T	8
cells	8
)	0
regulate	0
IL-2	9
transcription	0
by	0
a	0
mechanism	0
involving	0
both	0
a	0
silencer	1
and	0
an	0
activator	1
acting	0
on	0
the	0
purine-rich	1
IL-2	2
promoter	2
elements	2
(	0
NF-AT	1
binding	2
sites	2
)	0
.	0

By	0
contrast	0
,	0
memory	0
cells	0
,	0
either	0
in	0
vitro	5
activated	6
helper	6
T	6
cells	6
reverting	0
to	0
a	0
resting	0
state	0
,	0
or	0
CD4+	5
T	6
(	6
memory	6
)	6
clones	6
,	0
or	0
CD4+CD45RO+	5
T	6
cells	6
isolated	0
ex	0
vivo	0
,	0
no	0
longer	0
have	0
a	0
silencer	1
.	0

Their	0
IL-2	9
transcription	0
seems	0
to	0
be	0
controlled	0
solely	0
by	0
the	0
transition	0
from	0
inactive	0
to	0
active	0
functional	0
state	0
of	0
a	0
positive	9
transcription	10
factor	10
binding	0
to	0
these	0
promoter	0
elements	0
as	0
well	0
as	0
its	0
cytoplasmic	0
or	0
nuclear	0
location	0
:	0
in	0
resting	7
memory	8
T	8
cells	8
the	0
activator	1
is	0
located	0
in	0
the	0
cytoplasm	0
and	0
is	0
inactive	0
,	0
whereas	0
in	0
stimulated	5
cells	6
it	0
is	0
functional	0
in	0
promoting	0
transcription	0
and	0
now	0
resides	0
in	0
the	0
nucleus	0
.	0

Thus	0
,	0
the	0
regulation	0
of	0
the	0
gene	0
coding	0
for	0
the	0
main	0
T	9
cell	10
growth	10
factor	10
changes	0
irreversibly	0
after	0
the	0
first	0
encounter	0
of	0
T	0
cells	0
with	0
antigen	0
.	0

It	0
is	0
most	0
likely	0
that	0
the	0
presence	0
of	0
a	0
silencer	1
contributes	0
to	0
the	0
more	0
stringent	0
activation	0
requirements	0
of	0
naive	7
CD4+	8
T	8
cells	8
.	0

Expression	0
of	0
mRNA	3
for	0
the	0
GATA-binding	9
proteins	10
in	0
human	7
eosinophils	8
and	0
basophils	7
:	0
potential	0
role	0
in	0
gene	0
transcription	0
.	0

The	0
expression	0
of	0
the	0
hematopoietic	9
transcription	10
factors	10
GATA-1	9
,	0
GATA-2	9
,	0
and	0
GATA-3	9
was	0
studied	0
in	0
eosinophils	7
and	0
basophils	7
.	0

Eosinophils	7
express	0
mRNA	3
for	0
GATA-1	9
,	0
GATA-2	9
,	0
and	0
GATA-3	9
.	0

Basophils	7
express	0
GATA-2	9
and	0
GATA-3	9
.	0

Treatment	0
of	0
HL-60	5
eosinophilic	6
sublines	6
with	0
either	0
interleukin-5	9
or	0
butyric	0
acid	0
increased	0
the	0
expression	0
of	0
GATA-1	3
mRNA	4
concomitant	0
with	0
the	0
expression	0
of	0
eosinophil-specific	1
genes	2
,	0
whereas	0
levels	0
of	0
GATA-2	3
mRNA	4
remained	0
relatively	0
constant	0
.	0

The	0
presence	0
of	0
mRNA	3
for	0
these	0
proteins	0
in	0
eosinophils	7
and	0
basophils	7
suggests	0
that	0
gene	0
transcription	0
in	0
these	0
lineages	0
may	0
be	0
regulated	0
by	0
GATA-binding	9
proteins	10
.	0

Oxidoreductive	0
regulation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
.	0

Involvement	0
of	0
a	0
cellular	0
reducing	0
catalyst	0
thioredoxin	9
.	0

We	0
have	0
investigated	0
an	0
oxidoreductive	0
regulatory	0
pathway	0
for	0
the	0
DNA	0
binding	0
activity	0
of	0
a	0
pleiotropic	9
cellular	10
transcription	10
factor	10
,	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF	9
kappa	10
B	10
)	0
,	0
has	0
been	0
investigated	0
by	0
using	0
NF	9
kappa	10
B	10
prepared	0
from	0
the	0
nucleus	0
and	0
the	0
cytosol	0
of	0
the	0
primary	7
human	8
T	8
lymphocytes	8
.	0

We	0
show	0
that	0
a	0
cellular	0
reducing	0
catalyst	0
thioredoxin	9
(	0
Trx	9
)	0
plays	0
a	0
major	0
role	0
in	0
activation	0
of	0
the	0
DNA	0
binding	0
of	0
NF	9
kappa	10
B	10
in	0
vitro	0
and	0
stimulation	0
of	0
transcription	0
from	0
the	0
NF	9
kappa	10
B	10
-dependent	0
gene	0
expression	0
.	0

We	0
demonstrate	0
evidence	0
suggesting	0
that	0
redox	0
regulation	0
of	0
NF	9
kappa	10
B	10
by	0
Trx	9
might	0
be	0
exerted	0
at	0
a	0
step	0
after	0
dissociation	0
of	0
the	0
inhibitory	0
molecule	0
I	9
kappa	10
B	10
,	0
a	0
cytosolic-anchoring	9
protein	10
for	0
NF	9
kappa	10
B	10
.	0

To	0
examine	0
the	0
effect	0
of	0
Trx	9
in	0
intact	0
cells	0
,	0
we	0
performed	0
transient	0
assay	0
with	0
a	0
chloramphenicol	1
acetyltransferase-expressing	2
plasmid	2
under	0
the	0
control	0
of	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
long	2
terminal	2
repeat	2
and	0
an	0
effector	1
plasmid	2
expressing	0
human	9
Trx	10
.	0

The	0
promoter	0
activity	0
from	0
HIV	1
long	2
terminal	2
repeat	2
was	0
greatly	0
augmented	0
by	0
co-transfecting	0
the	0
Trx-expressing	1
plasmid	2
,	0
whose	0
effect	0
was	0
dependent	0
on	0
the	0
NF	9
kappa	10
B	10
-binding	0
sites	0
.	0

These	0
findings	0
have	0
suggested	0
that	0
cysteine	0
residue	0
(	0
s	0
)	0
of	0
NF	9
kappa	10
B	10
might	0
be	0
involved	0
in	0
the	0
DNA-recognition	0
by	0
NF	9
kappa	10
B	10
and	0
that	0
the	0
redox	0
control	0
mechanism	0
mediated	0
by	0
Trx	9
might	0
have	0
a	0
regulatory	0
role	0
in	0
the	0
NF	9
kappa	10
B	10
-mediated	0
gene	0
expression	0
.	0

These	0
results	0
may	0
also	0
provide	0
a	0
clue	0
to	0
understanding	0
of	0
the	0
molecular	0
process	0
of	0
AIDS	0
pathogenesis	0
and	0
its	0
possible	0
biochemical	0
intervention	0
.	0

Synergism	0
between	0
the	0
CD3	0
antigen-	0
and	0
CD2	0
antigen-derived	0
signals	0
.	0

Exploration	0
at	0
the	0
level	0
of	0
induction	0
of	0
DNA-binding	9
proteins	10
and	0
characterization	0
of	0
the	0
inhibitory	0
activity	0
of	0
cyclosporine	0
.	0

We	0
have	0
demonstrated	0
earlier	0
that	0
the	0
crosslinkage	0
of	0
the	0
CD3/TCR	9
complex	10
with	0
the	0
CD2	9
antigen	10
results	0
in	0
the	0
proliferation	0
of	0
normal	7
human	8
T	8
cells	8
.	0

The	0
effect	0
of	0
this	0
synergism	0
was	0
perceptible	0
at	0
the	0
level	0
of	0
induction	0
of	0
the	0
IL-2	1
gene	2
,	0
a	0
process	0
critical	0
for	0
T	0
cell	0
growth	0
.	0

To	0
further	0
understand	0
the	0
molecular	0
and	0
nuclear	0
basis	0
for	0
this	0
synergism	0
,	0
we	0
have	0
explored	0
the	0
induction	0
of	0
DNA-binding	9
proteins	10
in	0
highly	0
purified	0
normal	7
human	8
T	8
cells	8
signaled	0
via	0
the	0
CD3	9
and/or	0
CD2	9
proteins	10
.	0

The	0
effect	0
of	0
transmembrane	0
signaling	0
of	0
T	7
cells	8
with	0
ionomycin	0
,	0
and/or	0
sn-1	0
,	0
2	0
dioctanoyl	0
glycerol	0
,	0
was	0
also	0
determined	0
.	0

The	0
emergence	0
of	0
nuclear	9
binding	10
proteins	10
was	0
investigated	0
using	0
interleukin-2	1
sequence	2
specific	2
oligonucleotide	2
probes	2
in	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

Our	0
studies	0
demonstrate	0
for	0
the	0
first	0
time	0
that	0
CD3	9
antigen-derived	0
signals	0
and	0
CD2	9
antigen	10
-derived	0
signals	0
are	0
synergistic	0
in	0
inducing	0
the	0
emergence	0
of	0
transcription	9
factors	10
that	0
bind	0
to	0
the	0
NF-AT1	1
,	2
AP-1	2
,	2
and	2
NF-kB	2
sites	2
located	0
in	0
the	0
promoter/enhancer	1
region	2
of	0
the	0
IL-2	9
gene	0
.	0

Moreover	0
,	0
cyclosporine	0
,	0
at	0
concentrations	0
readily	0
accomplished	0
in	0
clinical	0
practice	0
,	0
was	0
found	0
to	0
inhibit	0
the	0
emergence	0
of	0
these	0
DNA-binding	9
proteins	10
in	0
normal	7
human	8
T	8
cells	8
signaled	0
via	0
cell	0
surface	0
proteins	0
implicated	0
in	0
antigen-dependent	0
T	0
cell	0
activation	0
and	0
in	0
T	7
cells	8
stimulated	0
by	0
mobilization	0
of	0
cellular	0
calcium	0
and	0
activation	0
of	0
protein	9
kinase	10
C	10
.	0

Induced	0
myeloid	0
differentiation	0
of	0
K562	5
cells	6
with	0
downregulation	0
of	0
erythroid	9
and	10
megakaryocytic	10
transcription	10
factors	10
:	0
a	0
novel	0
experimental	0
model	0
for	0
hemopoietic	0
lineage	0
restriction	0
.	0

The	0
human	5
erythroleukemia	6
cell	6
line	6
K562	6
can	0
be	0
induced	0
to	0
differentiate	0
along	0
the	0
erythroid	0
and	0
megakaryocytic	0
lineages	0
.	0

Here	0
we	0
demonstrate	0
that	0
hexamethylene	0
bisacetamide	0
(	0
HMBA	0
)	0
induced	0
K562	5
cells	6
to	0
differentiate	0
along	0
a	0
third	0
pathway	0
.	0

This	0
was	0
accompanied	0
by	0
downregulation	0
of	0
two	0
transcription	9
factors	10
normally	0
expressed	0
in	0
erythroid	7
,	8
mast	8
and	8
megakaryocyte	8
lineages	8
.	0

Northern	0
analysis	0
demonstrated	0
coordinate	0
downregulation	0
of	0
alpha	9
globin	10
and	0
gamma	9
globin	10
in	0
addition	0
to	0
the	0
two	0
lineage-restricted	0
transcription	9
factors	10
,	0
SCL	9
and	0
GATA-1	9
.	0

Proliferation	0
of	0
the	0
K562	5
cells	6
was	0
also	0
suppressed	0
.	0

Clonal	0
assay	0
showed	0
that	0
the	0
suppression	0
was	0
irreversible	0
and	0
appeared	0
analogous	0
to	0
the	0
commitment	0
of	0
murine	5
erythroleukemia	6
(	6
MEL	6
)	6
cells	6
to	0
terminal	0
differentiation	0
.	0

In	0
contrast	0
to	0
MEL	5
cells	6
,	0
however	0
,	0
K562	5
cells	6
acquired	0
a	0
macrophage-like	0
morphology	0
and	0
exhibited	0
a	0
complete	0
failure	0
to	0
generate	0
benzidine-positive	5
cells	6
.	0

Electron	0
microscopy	0
revealed	0
a	0
marked	0
increase	0
in	0
granules	0
resembling	0
those	0
specific	0
for	0
eosinophils	7
.	0

Surface	0
marker	0
analysis	0
showed	0
that	0
HMBA-induced	5
cells	6
expressed	0
reduced	0
levels	0
of	0
glycophorin	9
A	10
,	0
CD5	9
,	0
CD7	9
and	0
CD11b	9
.	0

No	0
upregulation	0
of	0
megakaryocyte	9
or	10
lymphoid	10
markers	10
occurred	0
.	0

Thus	0
the	0
response	0
of	0
K562	5
cells	6
to	0
HMBA	0
may	0
provide	0
a	0
useful	0
experimental	0
system	0
for	0
studying	0
the	0
molecular	0
mechanisms	0
responsible	0
for	0
downmodulation	0
of	0
lineage-restricted	0
transcription	9
factors	10
during	0
hemopoietic	0
lineage	0
commitment	0
.	0

Activation	0
of	0
primary	7
human	8
T-lymphocytes	8
through	0
CD2	9
plus	10
CD28	10
adhesion	10
molecules	10
induces	0
long-term	0
nuclear	0
expression	0
of	0
NF-kappa	9
B	10
.	0

Stimulation	0
of	0
highly	7
purified	8
human	8
T-cells	8
via	0
CD2	9
and	10
CD28	10
adhesion	10
molecules	10
induces	0
and	0
maintains	0
proliferation	0
for	0
more	0
than	0
3	0
weeks	0
.	0

This	0
potent	0
interleukin	9
2	10
(	0
IL-2	9
)	0
-dependent	0
activation	0
does	0
not	0
require	0
monocytes	7
or	0
accessory	7
cells	8
.	0

Long-lasting	0
IL-2	9
receptivity	0
is	0
associated	0
with	0
high-level	0
expression	0
of	0
the	0
inducible	0
IL-2	1
receptor	2
alpha	2
chain	2
(	2
IL-2R	2
alpha	2
)	2
gene	2
that	0
is	0
regulated	0
at	0
both	0
transcriptional	0
and	0
posttranscriptional	0
levels	0
.	0

Increase	0
of	0
IL-2R	1
alpha	2
gene	2
transcription	0
involves	0
the	0
enhanced	0
binding	0
of	0
the	0
transcription	0
factor	0
NF-kappa	9
B	10
to	0
its	0
consensus	1
sequence	2
in	0
the	0
5'-regulatory	1
region	2
of	0
the	0
IL-2R	1
alpha	2
gene	2
.	0

To	0
dissect	0
the	0
molecular	0
basis	0
for	0
the	0
unusually	0
persistent	0
transcription	0
of	0
the	0
IL-2R	1
alpha	2
gene	2
,	0
we	0
analyzed	0
nuclear	0
NF-kappa	9
B	10
binding	0
to	0
a	0
radiolabeled	0
IL-2R	9
alpha	10
kappa	0
B-specific	0
oligonucleotide	0
probe	0
during	0
the	0
time	0
course	0
of	0
CD2	9
+	0
CD28	9
activation	0
.	0

Resting	0
T-cell	0
nuclear	0
extracts	0
contained	0
KBF1/p50	9
homodimer	10
.	0

After	0
stimulation	0
,	0
two	0
new	0
kappa	9
B-specific	10
complexes	10
were	0
identified	0
as	0
NF-kappa	9
B	10
p50-p65	9
heterodimer	10
and	0
putative	0
c-Rel	9
homodimer	10
or	0
c-Rel-p65	9
heterodimer	10
.	0

Both	0
inducible	0
complexes	0
persisted	0
for	0
at	0
least	0
3	0
weeks	0
.	0

Their	0
relative	0
levels	0
were	0
very	0
similar	0
for	0
the	0
duration	0
of	0
proliferation	0
.	0

In	0
parallel	0
,	0
CD2	9
+	0
CD28	9
activation	0
triggered	0
a	0
significant	0
intracellular	0
thiol	0
decrease	0
,	0
suggesting	0
that	0
oxygen	0
radicals	0
are	0
involved	0
in	0
the	0
signaling	0
pathway	0
of	0
adhesion	9
molecules	10
.	0

Finally	0
,	0
micromolar	0
amounts	0
of	0
pyrrolidine	0
dithiocarbamate	0
,	0
an	0
oxygen	0
radical	0
scavenger	0
that	0
efficiently	0
blocked	0
the	0
nuclear	0
appearance	0
of	0
NF-kappa	9
B	10
in	0
T-lymphocytes	7
,	0
also	0
inhibited	0
IL-2	9
secretion	0
,	0
IL-2R	9
alpha	10
cell	0
surface	0
expression	0
,	0
and	0
T-cell	0
proliferation	0
.	0

Together	0
,	0
these	0
results	0
suggest	0
that	0
NF-kappa	9
B	10
plays	0
an	0
important	0
role	0
in	0
long-term	0
activation	0
of	0
human	7
primary	8
T-lymphocytes	8
via	0
CD2	9
+	0
CD28	9
.	0

Immobilization	0
and	0
recovery	0
of	0
fusion	9
proteins	10
and	0
B-lymphocyte	7
cells	8
using	0
magnetic	0
separation	0
.	0

A	0
new	0
approach	0
to	0
facilitate	0
immobilization	0
and	0
affinity	0
purification	0
of	0
recombinant	9
proteins	10
and	0
selected	0
human	7
B	8
lymphocytes	8
has	0
been	0
developed	0
.	0

Using	0
magnetic	0
beads	0
with	0
attached	0
DNA	0
containing	0
the	0
Escherichia	1
coli	2
lac	2
operator	2
,	0
fusion	9
proteins	10
comprising	0
the	0
DNA-binding	1
lac	2
repressor	2
could	0
be	0
affinity-purified	0
and	0
recovered	0
by	0
gentle	0
elution	0
conditions	0
,	0
such	0
as	0
with	0
a	0
lactose	0
analogue	0
or	0
by	0
enzymatic	0
means	0
using	0
either	0
deoxyribonuclease	9
(	0
DNase	9
)	0
or	0
restriction	9
endonucleases	10
.	0

The	0
results	0
show	0
for	0
the	0
first	0
time	0
that	0
a	0
DNA-binding	9
protein	10
can	0
be	0
used	0
for	0
affinity	0
purification	0
of	0
fusion	9
proteins	10
as	0
exemplified	0
by	0
the	0
specific	0
and	0
gentle	0
recovery	0
of	0
beta-galactosidase	9
and	0
alkaline	9
phosphatase	10
from	0
bacterial	0
lysates	0
using	0
immunomagnetic	0
separation	0
.	0

The	0
approach	0
was	0
further	0
extended	0
to	0
cell	0
separation	0
by	0
the	0
efficient	0
recovery	0
and	0
elution	0
of	0
human	5
CD37	6
B	6
lymphocytes	6
from	0
peripheral	0
blood	0
.	0

ras	9
protein	10
activity	0
is	0
essential	0
for	0
T-cell	9
antigen	10
receptor	10
signal	0
transduction	0
.	0

In	0
a	0
Jurkat	5
cell	6
model	6
of	0
T-cell	0
activation	0
an	0
interleukin-2	1
promoter/reporter	2
gene	2
construct	2
was	0
activated	0
by	0
antigen	9
receptor	10
agonism	0
in	0
combination	0
with	0
the	0
lymphokine	9
interleukin-1	9
.	0

Antigen	0
receptor	0
signals	0
could	0
be	0
mimicked	0
by	0
suboptimal	0
activation	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
with	0
phorbol	0
esters	0
in	0
combination	0
with	0
calcium	0
mobilization	0
by	0
an	0
ionophore	0
.	0

In	0
cotransfection	0
experiments	0
,	0
oncogenic	0
rats	0
obviated	0
the	0
need	0
for	0
PKC	9
stimulation	0
but	0
did	0
not	0
replace	0
either	0
the	0
calcium	0
signal	0
or	0
interleukin-1	9
.	0

Activated	0
ras	9
expression	0
also	0
replaced	0
the	0
requirement	0
for	0
PKC	9
stimulation	0
in	0
activation	0
of	0
the	0
T-cell	9
transcription	10
factor	10
NF-AT	9
.	0

A	0
dominant	9
inhibitory	10
ras	10
mutant	10
specifically	0
blocked	0
antigen	0
receptor	0
agonism	0
,	0
indicating	0
that	0
ras	9
activity	0
is	0
required	0
for	0
antigen	9
receptor	10
signaling	0
.	0

In	0
addition	0
,	0
an	0
inhibitor	0
of	0
PKC	9
blocked	0
both	0
activated	0
ras	9
and	0
phorbol	0
ester	0
stimulation	0
,	0
suggesting	0
a	0
role	0
for	0
ras	9
upstream	0
of	0
PKC	9
.	0

Expression	0
of	0
the	0
Tat	9
protein	10
of	0
HIV1	0
in	0
human	5
promonocytic	6
U937	6
cells	6
.	0

Numerous	0
studies	0
have	0
shown	0
that	0
,	0
upon	0
HIV1	0
infection	0
,	0
human	5
promonocytic	6
U937	6
cells	6
were	0
induced	0
to	0
differentiate	0
,	0
as	0
indicated	0
,	0
for	0
example	0
,	0
by	0
increased	0
expression	0
of	0
adhesion	9
molecules	10
.	0

One	0
of	0
the	0
viral	0
proteins	0
involved	0
in	0
this	0
process	0
might	0
be	0
the	0
Tat	9
protein	10
.	0

Indeed	0
,	0
this	0
viral	9
protein	10
,	0
which	0
is	0
essential	0
for	0
productive	0
infection	0
,	0
has	0
also	0
been	0
shown	0
to	0
display	0
growth-stimulating	0
properties	0
and	0
immunomodulatory	0
activities	0
.	0

In	0
order	0
to	0
apprehend	0
the	0
role	0
of	0
the	0
HIV1	1
tat	2
gene	2
in	0
inducing	0
the	0
differentiation	0
of	0
HIV1-infected	5
U937	6
cells	6
,	0
we	0
have	0
successfully	0
introduced	0
this	0
gene	0
into	0
U937	5
cells	6
by	0
infecting	0
them	0
with	0
retroviral	0
particles	0
transducing	0
tat	1
.	0

The	0
effect	0
of	0
the	0
Tat	9
protein	10
constitutively	0
expressed	0
by	0
these	0
cells	0
upon	0
their	0
differentiation	0
was	0
then	0
evaluated	0
by	0
looking	0
for	0
the	0
expression	0
of	0
the	0
c-fos	1
and	0
of	0
the	0
c-fms	1
proto-oncogenes	2
which	0
are	0
linked	0
to	0
the	0
differentiation	0
of	0
myelomonoblastic	7
cells	8
.	0

Northern	0
blot	0
analysis	0
revealed	0
in	0
these	0
cells	0
,	0
an	0
increase	0
in	0
the	0
transcription	0
of	0
these	0
two	0
proto-oncogenes	1
,	0
and	0
this	0
increase	0
was	0
amplified	0
after	0
treatment	0
with	0
phorbol	0
myristate	0
acetate	0
.	0

No	0
such	0
increase	0
was	0
observed	0
in	0
control	0
U937	5
cells	6
.	0

These	0
results	0
indicate	0
that	0
,	0
among	0
HIV1	9
gene	10
products	10
,	0
the	0
Tat	9
protein	10
appears	0
to	0
trigger	0
monocytic	0
differentiation	0
,	0
and	0
suggests	0
that	0
this	0
viral	9
protein	10
directs	0
progenitors	0
of	0
the	0
monocyte/macrophage	7
lineage	8
towards	0
a	0
differentiation	0
stage	0
in	0
which	0
production	0
of	0
viral	9
antigens	10
and	0
virions	0
might	0
be	0
more	0
efficient	0
.	0

Analysis	0
of	0
the	0
preexisting	0
and	0
nuclear	0
forms	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

The	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
3	0
is	0
an	0
inducible	0
DNA-binding	9
protein	10
that	0
is	0
essential	0
for	0
transcriptional	0
induction	0
of	0
the	0
IL-2	1
gene	2
during	0
T	0
cell	0
activation	0
.	0

NF-AT	9
is	0
thought	0
to	0
consist	0
of	0
two	0
components	0
:	0
a	0
ubiquitous	9
,	10
inducible	10
nuclear	10
component	10
that	0
we	0
have	0
identified	0
as	0
Fos	9
and	0
Jun	9
proteins	10
,	0
and	0
a	0
preexisting	0
,	0
T	9
cell-specific	10
component	10
(	0
NF-ATp	9
)	0
which	0
is	0
the	0
target	0
for	0
the	0
immunosuppressive	0
agents	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
.	0

We	0
have	0
previously	0
shown	0
that	0
nuclear	0
extracts	0
from	0
activated	7
T	8
cells	8
form	0
two	0
inducible	0
NF-AT	9
complexes	10
with	0
an	0
oligonucleotide	0
corresponding	0
to	0
the	0
distal	1
NF-AT	2
site	2
of	0
the	0
murine	1
IL-2	2
promoter	2
,	0
although	0
hypotonic	0
extracts	0
of	0
unstimulated	0
T	7
cells	8
form	0
a	0
single	0
complex	0
containing	0
NF-ATp	9
.	0

We	0
show	0
that	0
the	0
ability	0
to	0
detect	0
NF-ATp	9
in	0
a	0
gel	0
shift	0
assay	0
,	0
which	0
is	0
essential	0
for	0
purification	0
and	0
biochemical	0
studies	0
of	0
this	0
protein	0
,	0
is	0
strikingly	0
dependent	0
on	0
the	0
precise	0
sequence	0
of	0
the	0
NF-AT	9
oligonucleotide	0
used	0
as	0
the	0
labeled	0
probe	0
.	0

Moreover	0
we	0
present	0
evidence	0
that	0
the	0
component	0
that	0
forms	0
the	0
faster-migrating	0
(	0
``	0
lower	0
''	0
)	0
nuclear	9
NF-AT	10
complex	10
is	0
derived	0
by	0
a	0
calcium-dependent	0
,	0
cyclosporin-sensitive	0
,	0
posttranslational	0
modification	0
of	0
NF-ATp	9
,	0
and	0
that	0
Fos	9
and	0
Jun	9
proteins	0
stabilize	0
its	0
interaction	0
with	0
DNA	0
.	0

The	0
results	0
are	0
discussed	0
in	0
the	0
context	0
of	0
a	0
model	0
relating	0
the	0
two	0
nuclear	0
NF-AT	9
complexes	10
to	0
NF-ATp	9
.	0

Cell	0
cycle	0
analysis	0
of	0
E2F	9
in	0
primary	7
human	8
T	8
cells	8
reveals	0
novel	9
E2F	10
complexes	10
and	0
biochemically	0
distinct	0
forms	0
of	0
free	0
E2F	9
.	0

The	0
transcription	9
factor	10
E2F	9
activates	0
the	0
expression	0
of	0
multiple	0
genes	1
involved	0
in	0
cell	0
proliferation	0
,	0
such	0
as	0
c-myc	1
and	0
the	0
dihydrofolate	1
reductase	2
gene	2
.	0

Regulation	0
of	0
E2F	9
involves	0
its	0
interactions	0
with	0
other	0
cellular	9
proteins	10
,	0
including	0
the	0
retinoblastoma	9
protein	10
(	0
Rb	9
)	0
,	0
the	0
Rb-related	9
protein	10
p107	9
,	0
cyclin	9
A	10
,	0
and	0
cdk2	9
.	0

We	0
undertook	0
a	0
detailed	0
analysis	0
of	0
E2F	9
DNA-binding	0
activities	0
and	0
their	0
cell	0
cycle	0
behavior	0
in	0
primary	0
human	0
T	7
cells	8
.	0

Three	0
E2F	9
DNA-binding	0
activities	0
were	0
identified	0
in	0
resting	0
(	0
G0	0
)	0
T	7
cells	8
with	0
mobilities	0
in	0
gel	0
shift	0
assays	0
distinct	0
from	0
those	0
of	0
previously	0
defined	0
E2F	9
complexes	0
.	0

One	0
of	0
these	0
activities	0
was	0
found	0
to	0
be	0
a	0
novel	0
,	0
less	0
abundant	0
,	0
Rb-	0
E2F	9
complex	0
.	0

The	0
most	0
prominent	0
E2F	9
activity	0
in	0
resting	0
T	7
cells	8
(	0
termed	0
complex	0
X	0
)	0
was	0
abundant	0
in	0
both	0
G0	0
and	0
G1	0
but	0
disappeared	0
as	0
cells	0
entered	0
S	0
phase	0
,	0
suggesting	0
a	0
possible	0
role	0
in	0
negatively	0
regulating	0
E2F	9
function	0
.	0

Complex	9
X	10
could	0
be	0
dissociated	0
by	0
adenovirus	0
E1A	0
with	0
a	0
requirement	0
for	0
an	0
intact	0
E1A	1
conserved	2
region	2
2	2
.	0

However	0
,	0
X	9
failed	0
to	0
react	0
with	0
a	0
variety	0
of	0
antibodies	0
against	0
Rb	9
or	0
p107	9
,	0
implicating	0
the	0
involvement	0
of	0
an	0
E1A-binding	9
protein	10
other	0
than	0
Rb	9
or	0
p107	9
.	0

In	0
addition	0
to	0
these	0
novel	9
E2F	10
complexes	10
,	0
three	0
distinct	0
forms	0
of	0
unbound	0
(	0
free	0
)	0
E2F	9
were	0
resolved	0
in	0
gel	0
shift	0
experiments	0
.	0

These	0
species	0
showed	0
different	0
cell	0
cycle	0
kinetics	0
.	0

UV	0
cross-linking	0
experiments	0
suggested	0
that	0
a	0
distinct	0
E2F	9
DNA-binding	0
protein	0
is	0
uniquely	0
associated	0
with	0
the	0
S-phase	9
p107	10
complex	10
and	0
is	0
not	0
associated	0
with	0
Rb	9
.	0

Together	0
,	0
these	0
results	0
suggest	0
that	0
E2F	9
consists	0
of	0
multiple	0
,	0
biochemically	0
distinct	0
DNA-binding	9
proteins	10
which	0
function	0
at	0
different	0
points	0
in	0
the	0
cell	0
cycle	0
.	0

Defective	0
translocation	0
of	0
protein	9
kinase	10
C	10
in	0
multidrug-resistant	5
HL-60	6
cells	6
confers	0
a	0
reversible	0
loss	0
of	0
phorbol	0
ester-induced	0
monocytic	0
differentiation	0
.	0

Previous	0
studies	0
have	0
demonstrated	0
that	0
human	5
HL-60	6
myeloid	6
leukemia	6
cells	6
differentiate	0
in	0
response	0
to	0
phorbol	0
esters	0
.	0

This	0
event	0
is	0
associated	0
with	0
induction	0
of	0
the	0
c-jun	1
early	2
response	2
gene	2
and	0
appearance	0
of	0
a	0
monocytic	0
phenotype	0
.	0

The	0
present	0
studies	0
have	0
examined	0
the	0
effects	0
of	0
vincristine-selected	0
,	0
multidrug	0
resistance	0
on	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
-induced	0
HL-60	0
cell	0
differentiation	0
.	0

The	0
results	0
demonstrate	0
that	0
multidrug-resistant	5
HL-60	6
cells	6
,	0
designated	0
HL-60/vinc	0
,	0
fail	0
to	0
respond	0
to	0
TPA	0
with	0
an	0
increase	0
in	0
c-jun	3
transcripts	4
or	0
other	0
phenotypic	0
characteristics	0
of	0
monocytic	0
differentiation	0
.	0

By	0
contrast	0
,	0
treatment	0
of	0
HL-60/vinc	5
cells	6
with	0
okadaic	0
acid	0
,	0
an	0
inhibitor	0
of	0
serine/threonine	9
protein	10
phosphatases	10
,	0
induces	0
c-jun	1
transcription	0
,	0
growth	0
arrest	0
,	0
and	0
expression	0
of	0
the	0
c-fms	1
gene	2
.	0

Studies	0
were	0
also	0
performed	0
with	0
an	0
HL-60/vinc	5
revertant	6
(	0
HL-60/vinc/R	5
)	0
line	0
that	0
has	0
regained	0
partial	0
sensitivity	0
to	0
vincristine	0
.	0

The	0
finding	0
that	0
HL-60/vinc/R	5
cells	6
respond	0
to	0
TPA	0
with	0
induction	0
of	0
a	0
monocytic	0
phenotype	0
,	0
but	0
not	0
c-jun	1
expression	0
,	0
suggests	0
that	0
c-jun	1
induction	0
is	0
not	0
obligatory	0
for	0
monocytic	0
differentiation	0
.	0

Other	0
studies	0
further	0
demonstrate	0
that	0
the	0
jun-B	1
and	0
fra-1	1
genes	1
are	0
induced	0
by	0
TPA	0
in	0
both	0
HL-60/vinc	5
and	0
HL-60/vinc/R	5
cells	6
,	0
whereas	0
c-fos	1
expression	0
is	0
attenuated	0
in	0
the	0
HL-60/vinc	0
line	0
.	0

Since	0
TPA	0
activates	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
,	0
we	0
examined	0
translocation	0
of	0
PKC	9
from	0
the	0
cytosol	0
to	0
the	0
membrane	0
fraction	0
.	0

Although	0
HL-60	5
and	0
HL-60/vinc/R	5
cells	6
demonstrated	0
translocation	0
of	0
PKC	9
activity	0
,	0
this	0
subcellular	0
redistribution	0
was	0
undetectable	0
in	0
HL-60/vinc	5
cells	6
.	0

Activity	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
family	10
with	0
associated	0
phosphorylation	0
of	0
c-Jun	9
Y-peptide	10
was	0
markedly	0
diminished	0
in	0
TPA-treated	5
HL-60/vinc	6
cells	6
,	0
but	0
not	0
in	0
response	0
to	0
okadaic	0
acid	0
.	0

Taken	0
together	0
,	0
these	0
findings	0
suggest	0
that	0
vincristine	0
resistance	0
confers	0
insensitivity	0
to	0
TPA-induced	0
differentiation	0
and	0
can	0
include	0
defects	0
in	0
PKC	9
-mediated	0
signaling	0
events	0
and	0
induction	0
of	0
jun/fos	1
early	2
response	2
gene	2
expression	0
.	0

Molecular	0
basis	0
of	0
a	0
multiple	0
lymphokine	9
deficiency	0
in	0
a	0
patient	0
with	0
severe	0
combined	0
immunodeficiency	0
.	0

We	0
have	0
previously	0
reported	0
that	0
the	0
T	7
lymphocytes	8
of	0
a	0
child	0
with	0
severe	0
combined	0
immunodeficiency	0
are	0
defective	0
in	0
the	0
transcription	0
of	0
several	0
lymphokine	1
genes	2
that	0
include	0
IL2	1
,	0
IL3	1
,	0
IL4	1
,	0
and	0
IL5	1
,	0
which	0
encode	0
interleukins	9
2	0
,	0
3	0
,	0
4	0
,	0
and	0
5	0
(	0
IL-2	9
,	0
-3	9
,	0
-4	9
,	0
and	0
-5	9
)	0
.	0

To	0
determine	0
whether	0
the	0
defect	0
in	0
the	0
patient	0
's	0
T	7
lymphocytes	8
involved	0
a	0
trans-acting	9
factor	10
common	0
to	0
the	0
affected	0
lymphokine	1
genes	2
,	0
we	0
examined	0
the	0
ability	0
of	0
nuclear	9
factors	10
from	0
the	0
patient	0
's	0
T	7
lymphocytes	8
to	0
bind	0
response	0
elements	0
present	0
in	0
the	0
regulatory	1
region	2
of	0
IL2	1
.	0

Nuclear	9
factor	10
NF-kB	10
,	0
activation	9
protein	10
1	10
(	0
AP-1	9
)	0
,	0
OCT-1	9
,	0
and	0
NF-IL-2B	9
binding	0
activity	0
were	0
normal	0
.	0

In	0
contrast	0
,	0
the	0
binding	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
to	0
its	0
response	0
element	0
in	0
the	0
IL2	1
enhancer	2
and	0
to	0
an	0
NF-AT-like	1
response	2
element	2
present	0
in	0
the	0
IL4	1
enhancer	2
was	0
abnormal	0
.	0

To	0
ascertain	0
whether	0
the	0
abnormal	0
NF-AT	9
binding	0
activity	0
was	0
related	0
to	0
an	0
impaired	0
function	0
,	0
we	0
transfected	0
patient	0
and	0
control	0
T	7
lymphocytes	8
with	0
constructs	0
containing	0
the	0
reporter	0
gene	0
encoding	0
chloramphenicol	9
acetyl	10
transferase	10
(	0
CAT	9
)	0
under	0
the	0
control	0
of	0
the	0
entire	0
IL2	1
regulatory	2
region	2
or	0
of	0
multimers	0
of	0
individual	0
enhancer	1
sequences	2
.	0

CAT	0
expression	0
directed	0
by	0
the	0
IL2	1
regulatory	2
region	2
or	0
by	0
a	0
multimer	0
of	0
the	0
NF-AT-binding	1
site	2
was	0
markedly	0
lower	0
in	0
the	0
patient	0
relative	0
to	0
controls	0
.	0

In	0
contrast	0
,	0
CAT	1
gene	2
expression	0
directed	0
by	0
a	0
multimer	0
of	0
the	0
OCT-1	1
proximal	2
(	2
OCT-1p	2
)	2
-binding	2
site	2
was	0
equivalent	0
in	0
patient	0
and	0
controls	0
.	0

These	0
results	0
indicate	0
that	0
an	0
abnormality	0
of/or	0
influencing	0
NF-AT	9
may	0
underlie	0
the	0
multiple	0
lymphokine	9
deficiency	0
in	0
this	0
patient	0
.	0

FK506	0
and	0
ciclosporin	0
:	0
molecular	0
probes	0
for	0
studying	0
intracellular	0
signal	0
transduction	0
.	0

The	0
immunosuppressants	0
ciclosporin	0
and	0
FK506	0
block	0
the	0
Ca	0
(	0
2+	0
)	0
-dependent	0
signal-transduction	0
pathway	0
emanating	0
from	0
the	0
T-cell	9
receptor	10
,	0
thereby	0
inhibiting	0
the	0
activation	0
of	0
helper	7
T	8
cells	8
.	0

Using	0
these	0
drugs	0
as	0
probes	0
,	0
chemists	0
and	0
biologists	0
have	0
uncovered	0
several	0
intracellular	0
signalling	0
molecules	0
bridging	0
the	0
generation	0
of	0
second-messenger	0
Ca2+	0
ions	0
and	0
the	0
transcriptional	0
activation	0
of	0
IL-2	9
,	0
among	0
which	0
are	0
calmodulin	9
,	0
calcineurin	9
and	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
.	0

Hence	0
,	0
Ca2+	0
binds	0
to	0
calmodulin	9
,	0
leading	0
to	0
the	0
binding	0
of	0
calmodulin	9
to	0
calcineurin	9
;	0
the	0
activated	0
calcineurin	9
,	0
in	0
turn	0
,	0
may	0
dephosphorylate	0
the	0
cytoplasmic	9
subunit	10
of	10
NF-AT	10
,	0
resulting	0
in	0
its	0
translocation	0
from	0
the	0
cytoplasm	0
into	0
the	0
nucleus	0
to	0
form	0
a	0
competent	9
transcriptional	10
activator	10
.	0

As	0
described	0
by	0
Jun	9
Liu	0
,	0
these	0
drugs	0
manifest	0
their	0
effects	0
in	0
an	0
unprecedented	0
fashion	0
.	0

They	0
do	0
not	0
directly	0
intercept	0
intracellular	0
signalling	0
molecules	0
.	0

Instead	0
,	0
they	0
form	0
tight	0
complexes	0
with	0
two	0
different	0
classes	0
of	0
abundant	0
cytosolic	9
receptors	10
called	0
immunophilins	9
upon	0
entering	0
the	0
cell	0
,	0
and	0
consequently	0
inhibit	0
their	0
peptidyl	9
prolyl	10
cis-trans	10
isomerase	10
activities	0
.	0

The	0
two	0
structurally	0
distinct	0
immunophilin-drug	9
complexes	10
bind	0
to	0
,	0
and	0
inhibit	0
,	0
the	0
phosphatase	9
activity	0
of	0
calcineurin	9
.	0

p105	9
and	0
p98	9
precursor	9
proteins	10
play	0
an	0
active	0
role	0
in	0
NF-kappa	9
B	10
-mediated	0
signal	0
transduction	0
.	0

The	0
Rel/NF-kappa	9
B	10
family	10
of	0
transcription	9
factors	10
is	0
composed	0
of	0
two	0
distinct	0
subgroups	0
,	0
proteins	0
that	0
undergo	0
proteolytic	0
processing	0
and	0
contain	0
SWI6/ankyrin	9
repeats	10
in	0
their	0
carboxyl	9
termini	10
(	0
p105	9
,	0
p98	9
)	0
,	0
and	0
those	0
without	0
such	0
repeats	0
that	0
do	0
not	0
require	0
processing	0
(	0
p65	9
,	0
c-Rel	9
,	0
RelB	9
,	0
and	0
Dorsal	9
)	0
.	0

We	0
demonstrate	0
that	0
the	0
p105	9
and	0
p98	9
precursors	0
share	0
functional	0
properties	0
with	0
the	0
I	9
kappa	10
B	10
proteins	10
,	0
which	0
also	0
contain	0
SWI6/ankyrin	9
repeats	10
.	0

Both	0
p105	9
and	0
p98	9
were	0
found	0
to	0
form	0
stable	0
complexes	0
with	0
other	0
Rel/NF-kappa	9
B	10
family	10
members	10
,	0
including	0
p65	9
and	0
c-Rel	9
.	0

Association	0
with	0
the	0
precursors	0
is	0
sufficient	0
for	0
cytoplasmic	0
retention	0
of	0
either	0
p65	9
or	0
c-Rel	9
,	0
both	0
of	0
which	0
are	0
otherwise	0
nuclear	0
.	0

These	0
complexes	0
undergo	0
stimulus-responsive	0
processing	0
to	0
produce	0
active	0
p50/c-Rel	9
and	0
p55/c-Rel	9
complexes	0
.	0

These	0
observations	0
suggest	0
a	0
second	0
pathway	0
leading	0
to	0
NF-kappa	9
B	10
induction	0
,	0
in	0
which	0
processing	0
of	0
the	0
precursors	0
rather	0
than	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
plays	0
a	0
major	0
role	0
.	0

NF-kappa	9
B	10
controls	0
expression	0
of	0
inhibitor	0
I	9
kappa	10
B	10
alpha	10
:	0
evidence	0
for	0
an	0
inducible	0
autoregulatory	0
pathway	0
.	0

The	0
eukaryotic	0
transcription	9
factor	10
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
participates	0
in	0
many	0
parts	0
of	0
the	0
genetic	0
program	0
mediating	0
T	7
lymphocyte	8
activation	0
and	0
growth	0
.	0

Nuclear	0
expression	0
of	0
NF-kappa	9
B	10
occurs	0
after	0
its	0
induced	0
dissociation	0
from	0
its	0
cytoplasmic	0
inhibitor	0
I	9
kappa	10
B	10
alpha	10
.	0

Phorbol	0
ester	0
and	0
tumor	9
necrosis	10
factor-alpha	10
induction	0
of	0
nuclear	9
NF-kappa	10
B	10
is	0
associated	0
with	0
both	0
the	0
degradation	0
of	0
performed	0
I	9
kappa	10
B	10
alpha	10
and	0
the	0
activation	0
of	0
I	9
kappa	10
B	10
alpha	0
gene	0
expression	0
.	0

Transfection	0
studies	0
indicate	0
that	0
the	0
I	1
kappa	2
B	2
alpha	2
gene	2
is	0
specifically	0
induced	0
by	0
the	0
65-kilodalton	9
transactivating	10
subunit	10
of	0
NF-kappa	9
B	10
.	0

Association	0
of	0
the	0
newly	0
synthesized	0
I	9
kappa	10
B	10
alpha	10
with	0
p65	9
restores	0
intracellular	0
inhibition	0
of	0
NF-kappa	9
B	10
DNA	0
binding	0
activity	0
and	0
prolongs	0
the	0
survival	0
of	0
this	0
labile	0
inhibitor	0
.	0

Together	0
,	0
these	0
results	0
show	0
that	0
NF-kappa	9
B	10
controls	0
the	0
expression	0
of	0
I	9
kappa	10
B	10
alpha	0
by	0
means	0
of	0
an	0
inducible	0
autoregulatory	0
pathway	0
.	0

The	0
human	1
prointerleukin	2
1	2
beta	2
gene	2
requires	0
DNA	0
sequences	0
both	0
proximal	0
and	0
distal	0
to	0
the	0
transcription	1
start	2
site	2
for	0
tissue-specific	0
induction	0
.	0

In	0
these	0
studies	0
,	0
we	0
have	0
identified	0
DNA	1
sequences	2
and	0
specific	0
protein	0
interactions	0
necessary	0
for	0
transcriptional	0
regulation	0
of	0
the	0
human	1
prointerleukin	2
1	2
beta	2
(	2
proIL-1	2
beta	2
)	2
gene	2
.	0

A	0
cell-type-independent	1
lipopolysaccharide	2
(	2
LPS	2
)	2
-responsive	2
enhancer	2
element	2
located	0
between	0
-3757	1
and	2
-2729	2
bp	2
upstream	2
from	0
the	0
transcription	1
start	2
site	2
(	0
cap	1
site	2
)	0
consisted	0
of	0
at	0
least	0
six	0
discrete	0
subregions	0
which	0
were	0
essential	0
to	0
the	0
maximal	0
induction	0
by	0
LPS	0
in	0
transfected	5
monocytes	6
.	0

The	0
enhancer	0
also	0
appeared	0
to	0
mediate	0
phorbol	0
myristate	0
acetate	0
induction	0
in	0
monocytes	7
and	0
IL-1	9
responsiveness	0
in	0
fibroblasts	7
.	0

Deletion	0
and	0
base	0
substitution	0
mutations	0
along	0
with	0
DNA	0
binding	0
studies	0
demonstrated	0
that	0
the	0
enhancer	0
contained	0
a	0
minimum	0
of	0
three	0
functional	0
protein	1
binding	2
sequences	2
,	0
two	0
of	0
which	0
appeared	0
to	0
be	0
important	0
for	0
gene	0
induction	0
.	0

One	0
of	0
the	0
essential	0
proteins	0
which	0
bound	0
to	0
the	0
enhancer	0
was	0
similar	0
or	0
identical	0
to	0
members	0
of	0
the	0
C/EBP	9
family	10
of	0
transcription	9
factors	10
required	0
for	0
both	0
IL-1	9
-and	0
LPS-specific	0
induction	0
of	0
the	0
IL-6	1
gene	2
(	0
i.e.	0
,	0
the	0
NF-IL6	1
proteins	2
)	0
.	0

When	0
ligated	0
to	0
the	0
proIL-1	1
beta	2
cap	2
site	2
-proximal	1
region	2
(	0
located	0
between	0
-131	0
to	0
+12	0
)	0
,	0
both	0
the	0
proIL-1	1
beta	2
and	2
the	2
simian	2
virus	2
40	2
enhancer	2
elements	2
functioned	0
more	0
efficiently	0
in	0
monocytes	7
than	0
in	0
HeLa	7
cells	8
,	0
which	0
are	0
not	0
normally	0
competent	0
for	0
IL-1	9
beta	10
expression	0
.	0

When	0
ligated	0
to	0
the	0
murine	1
c-fos	2
promoter	2
,	0
however	0
,	0
the	0
proIL-1	1
beta	2
enhancer	2
was	0
inducible	0
in	0
phorbol	5
myristate	6
acetate-stimulated	6
HeLa	6
cells	6
,	0
suggesting	0
the	0
existence	0
of	0
a	0
proIL-1	9
beta	10
promoter-proximal	0
requirement	0
for	0
tissue	0
specificity	0
.	0

Lymphocytes	7
from	0
the	0
site	0
of	0
disease	0
suggest	0
adenovirus	0
is	0
one	0
cause	0
of	0
persistent	0
or	0
recurrent	0
inflammatory	0
arthritis	0
.	0

The	0
assessment	0
of	0
synovial	0
lymphocyte	0
reactivity	0
to	0
adenovirus	0
antigen	0
stimulation	0
was	0
undertaken	0
in	0
patients	0
with	0
persistent	0
or	0
recurrent	0
inflammatory	0
arthritis	0
.	0

The	0
3H-thymidine	0
uptake	0
procedure	0
was	0
employed	0
,	0
incorporating	0
multiple	0
microbiological	9
antigens	10
.	0

Five	0
patients	0
were	0
found	0
with	0
repeated	0
maximal	0
responses	0
to	0
adenovirus	9
antigen	10
;	0
in	0
one	0
of	0
these	0
adenovirus	1
nucleotide	2
sequences	2
were	0
present	0
in	0
a	0
synovial	0
biopsy	0
specimen	0
.	0

It	0
is	0
concluded	0
that	0
adenovirus	0
may	0
be	0
one	0
cause	0
of	0
persistent	0
or	0
recurrent	0
inflammatory	0
arthritis	0
.	0

Expression	0
of	0
PILOT	9
,	0
a	0
putative	0
transcription	9
factor	10
,	0
requires	0
two	0
signals	0
and	0
is	0
cyclosporin	0
A	0
sensitive	0
in	0
T	7
cells	8
.	0

Few	0
known	0
genes	1
(	0
IL-2	9
,	0
members	0
of	0
the	0
IL-8	1
family	2
,	0
interferon-gamma	1
)	0
are	0
induced	0
in	0
T	7
cells	8
only	0
through	0
the	0
combined	0
effect	0
of	0
phorbol	0
myristic	0
acetate	0
(	0
PMA	0
)	0
and	0
a	0
Ca	0
(	0
2+	0
)	0
-ionophore	0
,	0
and	0
expression	0
of	0
only	0
these	0
genes	1
can	0
be	0
fully	0
suppressed	0
by	0
Cyclosporin	0
A	0
(	0
CyA	0
)	0
.	0

We	0
have	0
identified	0
a	0
putative	0
transcription	9
factor	10
,	0
designated	0
PILOT	9
,	0
with	0
an	0
identical	0
dual	0
signal	0
requirement	0
for	0
expression	0
.	0

Induction	0
of	0
the	0
PILOT	9
gene	0
is	0
detectable	0
in	0
human	0
T	7
cells	8
20	0
min	0
following	0
activation	0
in	0
the	0
presence	0
of	0
cycloheximide	0
and	0
is	0
fully	0
suppressed	0
by	0
CyA	0
.	0

The	0
PILOT	9
protein	0
has	0
a	0
calculated	0
M	0
(	0
r	0
)	0
of	0
42.6	0
kDa	0
and	0
contains	0
three	0
zinc	9
fingers	10
of	0
the	0
C2H2-type	9
at	0
the	0
carboxyl-terminus	9
which	0
are	0
highly	0
homologous	0
to	0
the	0
zinc	9
finger	10
regions	10
of	0
the	0
transcription	9
factors	10
EGR1	9
,	0
EGR2	9
,	0
and	0
pAT	9
133	10
.	0

In	0
contrast	0
to	0
T	7
cells	8
,	0
in	0
fibroblasts	7
PILOT	9
gene	0
expression	0
requires	0
only	0
one	0
signal	0
(	0
PMA	0
)	0
and	0
is	0
not	0
affected	0
by	0
CyA	0
.	0

This	0
observation	0
directly	0
demonstrates	0
the	0
existence	0
of	0
a	0
Ca2+	9
signal-dependent	10
regulatory	10
element	10
obligatory	0
for	0
expression	0
of	0
some	0
genes	1
in	0
T	7
cells	8
but	0
not	0
in	0
fibroblasts	7
.	0

This	0
differential	0
expression	0
model	0
will	0
be	0
valuable	0
in	0
the	0
dissection	0
of	0
the	0
dual	0
signal	0
pathway	0
in	0
T	7
cells	8
and	0
the	0
effects	0
of	0
CyA	0
upon	0
it	0
.	0

Antisense	0
oligonucleotides	0
to	0
the	0
p65	9
subunit	10
of	0
NF-kappa	9
B	10
block	0
CD11b	9
expression	0
and	0
alter	0
adhesion	0
properties	0
of	0
differentiated	0
HL-60	5
granulocytes	6
.	0

NF-kappa	9
B	10
is	0
a	0
pleiotropic	9
regulator	10
of	0
a	0
variety	0
of	0
genes	0
implicated	0
in	0
the	0
cellular	0
response	0
to	0
injury	0
.	0

This	0
function	0
has	0
been	0
attributed	0
to	0
the	0
coordinated	0
binding	0
of	0
subunits	0
of	0
NF-kappa	9
B	10
to	0
distinct	0
regions	0
of	0
the	0
promoter	1
elements	2
of	0
numerous	0
genes	0
,	0
including	0
cytokines	9
,	0
growth	9
factor	10
receptors	10
,	0
and	0
adhesion	9
molecules	10
.	0

Antisense	0
phosphorothioate	0
oligonucleotides	0
to	0
the	0
p50	9
and	0
p65	9
subunits	10
of	0
the	0
NF-kappa	9
B	10
complex	10
were	0
used	0
to	0
define	0
the	0
physiologic	0
role	0
of	0
this	0
transcription	9
factor	10
in	0
resting	5
and	6
stimulated	6
granulocytes	6
.	0

A	0
reduction	0
in	0
the	0
expression	0
of	0
p65	9
was	0
produced	0
by	0
treatment	0
with	0
the	0
phosphorothioate	0
antisense	0
oligodeoxynucleotide	0
.	0

This	0
reduction	0
was	0
accompanied	0
by	0
rapid	0
changes	0
in	0
the	0
cellular	0
adhesion	0
of	0
dimethyl	5
sulfoxide-differentiated	6
HL-60	6
leukemia	6
cells	6
stimulated	0
by	0
12-O-tetradecanoylphorbol	0
13-acetate	0
(	0
TPA	0
)	0
.	0

These	0
effects	0
were	0
characterized	0
by	0
a	0
marked	0
reduction	0
in	0
CD11b	9
integrin	9
expression	0
on	0
the	0
surface	0
of	0
treated	5
cells	6
.	0

Furthermore	0
,	0
the	0
p65	9
antisense	0
oligomer	0
effectively	0
abolished	0
an	0
upregulation	0
of	0
CD11b	9
that	0
was	0
produced	0
by	0
formyl-met-leu-phe	0
and	0
TPA	0
.	0

However	0
,	0
the	0
p65	9
antisense	0
phosphorothioate	0
oligodeoxynucleotide	0
had	0
no	0
significant	0
effect	0
on	0
the	0
production	0
of	0
reactive	0
oxygen	0
intermediates	0
or	0
on	0
phagocytosis	0
by	0
these	0
cells	0
.	0

These	0
findings	0
indicate	0
that	0
antisense	0
oligomers	0
to	0
p65	9
can	0
be	0
used	0
to	0
define	0
the	0
role	0
of	0
NF-kappa	9
B	10
in	0
the	0
activation	0
pathways	0
of	0
neutrophils	7
.	0

The	0
p65	9
subunit	10
of	0
NF-kappa	9
B	10
regulates	0
I	9
kappa	10
B	10
by	0
two	0
distinct	0
mechanisms	0
.	0

Transcription	0
factor	0
NF-kappa	9
B	10
(	0
p50/p65	9
)	0
is	0
generally	0
localized	0
to	0
the	0
cytoplasm	0
by	0
its	0
inhibitor	0
I	9
kappa	10
B	10
.	0

Overproduced	0
I	9
kappa	10
B	10
,	0
free	0
from	0
NF-kappa	9
B	10
,	0
is	0
rapidly	0
degraded	0
.	0

Overexpression	0
of	0
p65	9
increases	0
endogenous	0
I	9
kappa	10
B	10
protein	0
in	0
both	0
carcinoma	7
and	8
lymphoid	8
cells	8
by	0
two	0
mechanisms	0
:	0
protein	0
stabilization	0
and	0
increased	0
transcription	0
of	0
I	3
kappa	4
B	4
mRNA	4
.	0

In	0
contrast	0
,	0
p65	9
delta	10
,	0
a	0
naturally	0
occurring	0
splice	0
variant	0
,	0
fails	0
to	0
markedly	0
augment	0
I	9
kappa	10
B	10
protein	0
levels	0
.	0

Both	0
overexpressed	0
p65	9
and	0
coexpressed	0
p50	9
are	0
cytoplasmic	0
,	0
whereas	0
p65	9
delta	10
is	0
partly	0
nuclear	0
,	0
indicating	0
that	0
the	0
I	9
kappa	10
B	10
induced	0
by	0
p65	9
can	0
maintain	0
NF-kappa	9
B	10
in	0
the	0
cytoplasm	0
.	0

Thus	0
,	0
p65	9
and	0
I	9
kappa	10
B	10
are	0
linked	0
in	0
an	0
autoregulatory	0
loop	0
,	0
ensuring	0
that	0
NF-kappa	9
B	10
is	0
held	0
in	0
the	0
cytoplasm	0
until	0
cells	0
are	0
specifically	0
induced	0
to	0
translocate	0
it	0
to	0
the	0
nucleus	0
.	0

Lipopolysaccharide	0
induces	0
phosphorylation	0
of	0
MAD3	9
and	0
activation	0
of	0
c-Rel	9
and	0
related	0
NF-kappa	9
B	10
proteins	0
in	0
human	5
monocytic	6
THP-1	6
cells	6
.	0

Many	0
effects	0
of	0
lipopolysaccharide	0
(	0
LPS	0
)	0
on	0
gene	0
expression	0
,	0
including	0
that	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
,	0
in	0
monocytic	7
cells	8
are	0
mediated	0
by	0
activation	0
of	0
kappa	0
B	0
DNA-binding	0
proteins	0
.	0

However	0
,	0
the	0
specific	0
members	0
of	0
the	0
NF-kappa	9
B/Rel	10
transcription	10
factor	10
family	10
involved	0
in	0
the	0
LPS	0
response	0
,	0
and	0
the	0
mechanisms	0
through	0
which	0
LPS-generated	0
signals	0
are	0
transduced	0
remain	0
unclear	0
.	0

Here	0
we	0
show	0
that	0
LPS	0
induces	0
nuclear	0
expression	0
of	0
c-Rel/p50	9
heterodimers	10
as	0
well	0
as	0
p50/p65	9
(	0
NF-kappa	9
B	10
)	0
kappa	0
B	0
DNA-binding	0
complexes	0
in	0
human	5
monocytic	6
THP-1	6
cells	6
.	0

Nuclear	0
localization	0
of	0
these	0
proteins	0
occurred	0
concomitantly	0
with	0
a	0
rapid	0
decrease	0
in	0
their	0
cytosolic	0
levels	0
and	0
was	0
independent	0
of	0
phorbol	9
ester-sensitive	10
protein	10
kinase	10
C	10
.	0

Within	0
24	0
h	0
following	0
LPS	0
stimulation	0
there	0
was	0
a	0
striking	0
increase	0
in	0
the	0
levels	0
of	0
c-Rel	9
,	0
p105	9
,	0
and	0
p50	9
in	0
the	0
cytosol	0
.	0

The	0
increased	0
levels	0
of	0
these	0
proteins	0
correlated	0
with	0
increases	0
in	0
the	0
amounts	0
of	0
their	0
mRNAs	3
during	0
LPS	0
activation	0
of	0
THP-1	5
cells	6
.	0

LPS	0
activation	0
of	0
THP-1	5
cells	6
resulted	0
in	0
phosphorylation	0
of	0
MAD3	9
(	0
an	0
I	9
kappa	10
B	10
-like	0
protein	0
)	0
,	0
a	0
rapid	0
increase	0
in	0
MAD3	3
mRNA	4
,	0
and	0
an	0
increase	0
in	0
MAD3	9
protein	0
by	0
2	0
h	0
.	0

Thus	0
,	0
LPS	0
activation	0
of	0
human	0
monocytic	7
cells	8
results	0
in	0
nuclear	0
expression	0
of	0
c-Rel/p50	9
and	0
p50/p65	9
(	0
NF-kappa	9
B	10
)	0
and	0
induces	0
phosphorylation	0
of	0
MAD3	9
.	0

A	0
chimeric	9
type	10
II/type	10
I	10
interleukin-1	10
receptor	10
can	0
mediate	0
interleukin-1	9
induction	0
of	0
gene	0
expression	0
in	0
T	7
cells	8
.	0

The	0
type	9
I	10
interleukin-1	10
receptor	10
(	0
IL-1R	9
)	0
is	0
capable	0
of	0
transducing	0
a	0
signal	0
resulting	0
in	0
promoter	0
activation	0
in	0
T	7
cells	8
.	0

This	0
signal	0
transduction	0
is	0
dependent	0
on	0
the	0
cytoplasmic	9
domain	10
,	0
which	0
consists	0
of	0
213	0
amino	0
acids	0
.	0

In	0
contrast	0
to	0
the	0
type	9
I	10
receptor	10
,	0
the	0
type	9
II	10
IL-1R	10
has	0
a	0
small	0
cytoplasmic	9
tail	10
,	0
and	0
it	0
is	0
not	0
clear	0
whether	0
this	0
receptor	0
is	0
a	0
signal-transducing	9
or	0
a	0
regulatory	9
molecule	10
.	0

Here	0
we	0
report	0
that	0
the	0
type	9
II	10
IL-1R	10
does	0
not	0
mediate	0
gene	0
activation	0
in	0
Jurkat	5
cells	6
.	0

However	0
,	0
a	0
hybrid	0
receptor	0
composed	0
of	0
the	0
extracellular	9
and	10
transmembrane	10
regions	10
of	0
the	0
human	9
type	10
II	10
interleukin-1	10
fused	0
to	0
the	0
cytoplasmic	9
domain	10
of	0
the	0
human	9
type	10
I	10
IL-1R	10
was	0
capable	0
of	0
transducing	0
a	0
signal	0
across	0
the	0
membrane	0
resulting	0
in	0
a	0
pattern	0
of	0
gene	0
activation	0
identical	0
to	0
that	0
mediated	0
by	0
the	0
type	9
I	10
IL-1R	10
.	0

Our	0
results	0
indicated	0
that	0
the	0
extracellular	9
domain	10
of	0
the	0
type	9
II	10
IL-1R	10
was	0
capable	0
of	0
functionally	0
interacting	0
with	0
interleukin-1	9
and	0
transmitting	0
the	0
resulting	0
signal	0
to	0
a	0
heterologous	9
cytoplasmic	10
domain	10
.	0

A	0
mutation	0
of	0
the	0
glucocorticoid	9
receptor	10
in	0
primary	0
cortisol	0
resistance	0
.	0

The	0
precise	0
molecular	0
abnormalities	0
that	0
cause	0
primary	0
cortisol	0
resistance	0
have	0
not	0
been	0
completely	0
described	0
.	0

In	0
a	0
subject	0
with	0
primary	0
cortisol	0
resistance	0
we	0
have	0
observed	0
glucocorticoid	9
receptors	10
(	0
hGR	9
)	0
with	0
a	0
decreased	0
affinity	0
for	0
dexamethasone	0
.	0

We	0
hypothesize	0
that	0
a	0
mutation	0
of	0
the	0
hGR	9
glucocorticoid-binding	10
domain	10
is	0
the	0
cause	0
of	0
cortisol	0
resistance	0
.	0

Total	0
RNA	0
isolated	0
from	0
the	0
index	0
subject	0
's	0
mononuclear	7
leukocytes	8
was	0
used	0
to	0
produce	0
first	0
strand	0
hGR	1
cDNAs	2
,	0
and	0
the	0
entire	0
hGR	1
cDNA	2
was	0
amplified	0
in	0
segments	0
and	0
sequenced	0
.	0

At	0
nucleotide	0
2	0
,	0
317	0
we	0
identified	0
a	0
homozygous	0
A	0
for	0
G	0
point	0
mutation	0
that	0
predicts	0
an	0
isoleucine	0
(	0
ATT	0
)	0
for	0
valine	0
(	0
GTT	0
)	0
substitution	0
at	0
amino	0
acid	0
729	0
.	0

When	0
the	0
wild-type	9
hGR	10
and	0
hGR-Ile	9
729	10
were	0
expressed	0
in	0
COS-1	5
cells	6
and	0
assayed	0
for	0
[	0
3H	0
]	0
-Dexamethasone	0
binding	0
,	0
the	0
dissociation	0
constants	0
were	0
0.799	0
+/-	0
0.068	0
and	0
1.54	0
+/-	0
0.06	0
nM	0
(	0
mean	0
+/-	0
SEM	0
)	0
(	0
P	0
<	0
0.01	0
)	0
,	0
respectively	0
.	0

When	0
the	0
wild-type	9
hGR	10
and	0
hGR-Ile	9
729	10
were	0
expressed	0
in	0
CV-1	5
cells	6
that	0
were	0
cotransfected	0
with	0
the	0
mouse	1
mammary	2
tumor	2
virus	2
long	2
terminal	2
repeat	2
fused	0
to	0
the	0
chloramphenicol	1
acetyl	2
transferase	2
(	2
CAT	2
)	2
gene	2
,	0
the	0
hGR-Ile	9
729	10
conferred	0
a	0
fourfold	0
decrease	0
in	0
apparent	0
potency	0
on	0
dexamethasone	0
stimulation	0
of	0
CAT	9
activity	0
.	0

The	0
isoleucine	0
for	0
valine	0
substitution	0
at	0
amino	0
acid	0
729	0
impairs	0
the	0
function	0
of	0
the	0
hGR	9
and	0
is	0
the	0
likely	0
cause	0
of	0
primary	0
cortisol	0
resistance	0
in	0
this	0
subject	0
.	0

The	0
transcriptionally	9
active	10
factors	10
mediating	0
the	0
effect	0
of	0
the	0
HTLV-I	9
Tax	10
transactivator	10
on	0
the	0
IL-2R	1
alpha	2
kappa	2
B	2
enhancer	2
include	0
the	0
product	0
of	0
the	0
c-rel	1
proto-oncogene	2
.	0

The	0
transactivator	0
HTLV-I	9
Tax	10
activates	0
the	0
promoter	1
of	0
the	0
gene	0
coding	0
for	0
the	0
interleukin	9
2	10
alpha-chain	10
receptor	10
(	0
IL-2R	9
alpha	10
)	0
via	0
a	0
kappa	1
B	2
site	2
that	0
can	0
bind	0
several	0
protein	0
species	0
of	0
the	0
rel	9
family	10
.	0

Tax1	9
strongly	0
activates	0
the	0
enhancer	0
activity	0
of	0
this	0
motif	0
,	0
in	0
both	0
epithelial	5
HeLa	6
and	0
lymphoid	0
Jurkat	5
cells	6
.	0

This	0
activation	0
was	0
not	0
observed	0
in	0
undifferentiated	0
embryocarcinoma	0
F9	0
cells	0
.	0

Overexpression	0
of	0
the	0
p50	9
,	0
p65	9
and	0
Rel	9
proteins	10
in	0
these	0
cells	0
showed	0
that	0
significant	0
activation	0
of	0
the	0
IL-2R	9
alpha	10
kappa	1
B	2
site	2
was	0
observed	0
only	0
with	0
Rel	9
and	0
Rel	9
plus	0
p65	9
.	0

Moreover	0
,	0
whereas	0
both	0
Tax	9
and	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
are	0
able	0
to	0
efficiently	0
induce	0
the	0
binding	0
of	0
NF-kappa	9
B	10
to	0
the	0
IL-2R	1
alpha	2
kappa	2
B	2
site	2
,	0
PMA	0
is	0
functionally	0
inactive	0
.	0

Using	0
the	0
DNA	0
affinity	0
precipitation	0
assay	0
,	0
we	0
observed	0
that	0
Tax1	9
is	0
able	0
to	0
efficiently	0
induce	0
the	0
binding	0
of	0
Rel	0
,	0
whereas	0
PMA	0
is	0
not	0
.	0

This	0
established	0
a	0
clear	0
difference	0
between	0
both	0
stimuli	0
,	0
indicating	0
that	0
Rel	9
is	0
the	0
functionally	9
active	10
factor	10
.	0

We	0
conclude	0
from	0
these	0
results	0
that	0
the	0
functional	0
activity	0
of	0
members	0
of	0
the	0
rel	9
family	10
is	0
regulated	0
by	0
their	0
interaction	0
with	0
DNA	0
and	0
that	0
Rel	9
can	0
be	0
a	0
potent	0
transcriptional	0
activator	0
on	0
specific	0
kappa	1
B	2
sites	2
.	0

Transcriptional	0
regulation	0
of	0
interleukin	9
3	10
(	0
IL3	9
)	0
in	0
primary	7
human	8
T	8
lymphocytes	8
.	0

Role	0
of	0
AP-1-	9
and	10
octamer-binding	10
proteins	10
in	0
control	0
of	0
IL3	9
gene	0
expression	0
.	0

We	0
have	0
investigated	0
the	0
molecular	0
and	0
biochemical	0
basis	0
for	0
activation	0
of	0
interleukin	9
3	10
(	0
IL3	9
)	0
gene	0
expression	0
in	0
primary	7
human	8
T	8
lymphocytes	8
following	0
CD3	0
and	0
CD2	0
receptor	0
stimulation	0
or	0
activation	0
by	0
phytohemagglutinin	9
plus	0
phorbol	0
12-myristate	0
13-acetate	0
.	0

Using	0
transfection	0
and	0
reporter	0
gene	0
assays	0
specifically	0
designed	0
for	0
primary	7
T	8
lymphocytes	8
in	0
conjunction	0
with	0
gel	0
retardation	0
assays	0
,	0
Western	0
blot	0
analyses	0
and	0
UV	0
cross-linking	0
studies	0
,	0
we	0
found	0
that	0
c-Jun	9
,	0
c-Fos	9
,	0
and	0
octamer-binding	9
proteins	10
play	0
a	0
major	0
role	0
in	0
transcriptional	0
activation	0
of	0
the	0
IL3	1
gene	2
via	0
their	0
interaction	0
with	0
two	0
specific	0
regions	0
contained	0
within	0
the	0
IL3	1
5'-flanking	2
sequence	2
.	0

Additionally	0
,	0
the	0
region	0
between	0
bases	0
-107	1
and	2
-59	2
of	0
the	0
IL3	1
promoter	2
containing	0
putative	0
AP-2	1
and	2
Sp1	2
binding	2
motifs	2
appears	0
necessary	0
for	0
basal	0
level	0
expression	0
of	0
the	0
IL3	9
gene	0
.	0

The	0
data	0
also	0
indicate	0
that	0
CD2	9
receptor	0
activation	0
and	0
phytohemagglutinin	9
plus	0
phorbol	0
12-myristate	0
13-acetate	0
stimulation	0
augment	0
T	0
cell	0
IL3	9
gene	0
expression	0
through	0
the	0
same	0
cis-	0
and	0
trans-activating	0
signals	0
.	0

These	0
results	0
should	0
contribute	0
to	0
a	0
better	0
understanding	0
of	0
the	0
regulation	0
of	0
IL3	9
gene	0
expression	0
in	0
human	7
T	8
lymphocytes	8
.	0

Dimerization	0
of	0
NF-KB2	9
with	0
RelA	9
(	10
p65	10
)	10
regulates	0
DNA	0
binding	0
,	0
transcriptional	0
activation	0
,	0
and	0
inhibition	0
by	0
an	0
I	9
kappa	10
B-alpha	10
(	0
MAD-3	9
)	0
.	0

Inducible	0
expression	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
is	0
regulated	0
by	0
a	0
cellular	0
transcription	9
factor	10
,	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

NF-kappa	9
B	10
is	0
composed	0
of	0
distinct	0
subunits	0
;	0
five	0
independent	0
genes	0
,	0
NFKB1	1
(	0
p105	9
)	0
,	0
NFKB2	1
(	0
p100	9
)	0
,	0
RelA	9
(	10
p65	10
)	10
,	0
c-rel	1
and	0
relB	1
,	0
that	0
encode	0
related	0
proteins	0
that	0
bind	0
to	0
kappa	1
B	2
DNA	2
elements	2
have	0
been	0
isolated	0
.	0

We	0
have	0
previously	0
found	0
that	0
NFKB2	9
(	10
p49/p52	10
)	10
acts	0
in	0
concert	0
with	0
RelA	9
(	10
p65	10
)	10
to	0
stimulate	0
the	0
HIV	1
enhancer	2
in	0
Jurkat	0
T-leukemia	5
cells	6
.	0

Here	0
we	0
examine	0
the	0
biochemical	0
basis	0
for	0
the	0
transcriptional	0
regulation	0
of	0
HIV	0
by	0
NFKB2	9
.	0

Using	0
Scatchard	0
analysis	0
,	0
we	0
have	0
determined	0
the	0
dissociation	0
constants	0
of	0
homodimeric	9
p49	10
and	0
heterodimeric	9
p49/p65	10
for	0
binding	0
to	0
the	0
HIV	1
kappa	2
B	2
site	2
.	0

p49	9
has	0
a	0
approximately	0
18-fold-lower	0
affinity	0
for	0
the	0
HIV	0
kappa	1
B	2
site	2
(	0
KD	0
=	0
69.1	0
pM	0
)	0
than	0
does	0
the	0
approximately	0
50-kDa	0
protein	0
NFKB1	9
(	10
p50	10
)	10
derived	0
from	0
p105	9
(	0
KD	0
=	0
3.9	0
pM	0
)	0
.	0

In	0
contrast	0
,	0
the	0
affinity	0
of	0
heterodimeric	9
NFKB2	10
(	10
p49	10
)	10
/RelA	10
(	10
p65	10
)	10
for	0
this	0
site	0
is	0
approximately	0
6-fold	0
higher	0
(	0
KD	0
=	0
11.8	0
pM	0
)	0
than	0
that	0
of	0
p49	9
alone	0
.	0

Consistent	0
with	0
these	0
findings	0
,	0
in	0
vitro	0
transcription	0
was	0
stimulated	0
18-fold	0
by	0
the	0
addition	0
of	0
preformed	0
,	0
heterodimeric	9
NFKB2	10
(	10
p49	10
)	10
/RelA	10
(	10
p65	10
)	10
protein	10
.	0

Transcriptional	0
activation	0
of	0
the	0
HIV	0
enhancer	0
was	0
also	0
subject	0
to	0
regulation	0
by	0
recently	0
cloned	0
I	9
kappa	10
B-alpha	10
(	0
MAD-3	9
)	0
.	0

Recombinant	0
I	0
kappa	0
B-alpha	0
(	0
MAD-3	9
)	0
inhibited	0
the	0
DNA	0
binding	0
activity	0
of	0
p65	9
,	0
p49/p65	9
,	0
and	0
p50/p65	9
but	0
stimulated	0
the	0
binding	0
of	0
NFKB2	9
(	0
p49	9
)	0
or	0
NFKB1	0
(	0
p50	0
)	0
.	0

Functional	0
activation	0
of	0
an	0
HIV	0
reporter	0
plasmid	0
by	0
p49/p65	9
in	0
transiently	5
transfected	6
Jurkat	6
T-leukemia	6
cells	6
was	0
also	0
inhibited	0
by	0
coexpression	0
of	0
MAD-3	9
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

The	0
c-rel	9
protooncogene	10
product	10
represses	0
NF-kappa	9
B	10
p65	9
-mediated	0
transcriptional	0
activation	0
of	0
the	0
long	0
terminal	0
repeat	0
of	0
type	0
1	0
human	0
immunodeficiency	0
virus	0
.	0

The	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
the	0
type	0
1	0
human	0
immunodeficiency	0
virus	0
(	0
HIV-1	0
)	0
and	0
the	0
5	1
'	2
regulatory	2
region	2
of	0
the	0
gene	0
encoding	0
the	0
interleukin	9
2	10
receptor	10
alpha	10
subunit	10
(	0
IL-2R	9
alpha	10
)	0
share	0
functional	0
kappa	1
B	2
enhancer	2
elements	2
involved	0
in	0
the	0
regulation	0
of	0
these	0
inducible	0
transcription	0
units	0
during	0
T-cell	0
activation	0
.	0

These	0
kappa	1
B	2
enhancer	2
elements	2
are	0
recognized	0
by	0
a	0
structurally	0
related	0
family	0
of	0
interactive	0
proteins	0
that	0
includes	0
p50	9
,	0
p65	9
,	0
and	0
the	0
product	0
of	0
the	0
c-rel	1
protooncogene	2
(	0
c-Rel	9
)	0
.	0

Recent	0
biochemical	0
studies	0
have	0
shown	0
that	0
p65	9
and	0
p50	9
form	0
the	0
prototypical	0
NF-kappa	9
B	10
complex	10
,	0
which	0
is	0
rapidly	0
translocated	0
from	0
the	0
cytoplasm	0
to	0
the	0
nucleus	0
during	0
T-cell	0
activation	0
.	0

This	0
intracellular	0
signaling	0
complex	0
potently	0
stimulates	0
kappa	0
B-directed	0
transcription	0
from	0
either	0
the	0
HIV-1	1
LTR	2
or	0
the	0
IL-2R	1
alpha	2
promoter	2
via	0
the	0
strong	0
transactivation	0
domain	0
present	0
in	0
p65	9
.	0

We	0
now	0
demonstrate	0
that	0
nuclear	0
expression	0
of	0
human	0
c-Rel	9
,	0
which	0
is	0
induced	0
by	0
either	0
phorbol	0
ester	0
or	0
tumor	9
necrosis	10
factor	10
alpha	10
with	0
delayed	0
kinetics	0
relative	0
to	0
p65	9
,	0
markedly	0
represses	0
p65	9
-mediated	0
activation	0
of	0
these	0
transcription	0
units	0
.	0

These	0
inhibitory	0
effects	0
of	0
c-Rel	9
correlate	0
with	0
its	0
DNA-binding	0
activity	0
but	0
not	0
with	0
its	0
ability	0
to	0
heterodimerize	0
with	0
p50	9
,	0
suggesting	0
that	0
c-Rel	9
inhibition	0
involves	0
competition	0
with	0
p50/p65	9
for	0
occupancy	0
of	0
the	0
kappa	0
B	0
enhancer	0
element	0
.	0

Together	0
,	0
these	0
findings	0
suggest	0
that	0
one	0
function	0
of	0
c-Rel	9
is	0
as	0
a	0
physiologic	0
repressor	0
of	0
the	0
HIV-1	1
LTR	2
and	0
IL-2R	9
alpha	10
promoters	0
,	0
serving	0
to	0
efficiently	0
counter	0
the	0
strong	0
transcriptional	0
activating	0
effects	0
of	0
p65	9
.	0

Ras	1
oncogene	2
transformation	0
of	0
human	7
B	8
lymphoblasts	8
is	0
associated	0
with	0
lymphocyte	0
activation	0
and	0
with	0
a	0
block	0
of	0
differentiation	0
.	0

The	0
p21ras	9
small	10
GTP	10
binding	10
proteins	10
participate	0
in	0
signal	0
transduction	0
from	0
cell	0
surface	0
receptors	0
and	0
affect	0
neoplastic	0
transformation	0
and	0
development	0
in	0
many	0
different	0
cell	0
types	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
examined	0
the	0
relationship	0
between	0
ras	0
transformation	0
and	0
differentiation	0
of	0
human	7
B	8
lymphocytes	8
.	0

We	0
show	0
that	0
the	0
constitutive	0
expression	0
of	0
the	0
T24	1
Ha-ras	2
oncogene	2
in	0
EBV-immortalized	5
B	6
lymphoblasts	6
was	0
associated	0
with	0
the	0
induction	0
of	0
the	0
interleukin	9
2	10
receptor	10
alpha	10
subunit	10
,	0
with	0
an	0
impaired	0
immunoglobulin	1
gene	2
expression	0
,	0
altered	0
adhesion	0
properties	0
and	0
increased	0
survival	0
in	0
serum-free	0
medium	0
.	0

Since	0
induction	0
of	0
the	0
IL-2	9
receptor	10
alpha	10
subunit	10
is	0
a	0
hallmark	0
of	0
lymphocyte	7
activation	0
,	0
we	0
suggest	0
that	0
p21ras	9
naturally	0
triggers	0
B	7
cell	8
activation	0
.	0

The	0
ras-transformed	5
lymphocytes	6
displayed	0
a	0
fully	0
functional	0
IL-2r	9
,	0
as	0
assessed	0
by	0
c-fos	1
induction	0
following	0
treatment	0
with	0
IL-2	9
;	0
nevertheless	0
,	0
they	0
were	0
not	0
growth	0
stimulated	0
by	0
this	0
lymphokine	9
.	0

The	0
decreased	0
expression	0
of	0
immunoglobulin	1
genes	2
indicates	0
that	0
the	0
ras	1
oncogene	2
blocks	0
terminal	0
differentiation	0
to	0
plasma	7
cells	8
,	0
possibly	0
by	0
inhibiting	0
the	0
activity	0
of	0
lymphocyte-specific	9
transcription	10
factors	10
.	0

Somewhat	0
unexpectedly	0
,	0
the	0
constitutive	0
p21ras	9
activity	0
did	0
not	0
cause	0
an	0
increased	0
DNA	0
binding	0
of	0
transcription	9
factors	10
PEA1	9
(	0
AP1	9
)	0
,	0
PEA3	9
,	0
Oct-2	9
or	0
NF-kB	9

Comparative	0
analysis	0
of	0
NFAT	9
(	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
)	0
complex	0
in	0
human	7
T	8
and	8
B	8
lymphocytes	8
.	0

Nuclear	0
factor	0
of	0
activated	0
T	0
cells	0
(	0
NFAT	9
)	0
is	0
a	0
transcriptional	9
activator	10
that	0
binds	0
to	0
sequences	0
in	0
the	0
interleukin-2	1
(	2
IL-2	2
)	2
promoter	2
and	0
is	0
thought	0
to	0
be	0
largely	0
responsible	0
for	0
the	0
T	0
cell-specific	0
inducibility	0
of	0
IL-2	9
expression	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
(	0
EMSA	0
)	0
showed	0
that	0
specific	0
NFAT	9
binding	0
activity	0
could	0
also	0
be	0
induced	0
in	0
human	7
B	8
cells	8
.	0

The	0
B	9
cell	10
NFAT	10
complex	10
,	0
however	0
,	0
was	0
not	0
functional	0
,	0
since	0
it	0
failed	0
to	0
activate	0
transcription	0
from	0
an	0
NFAT-driven	1
chloramphenicol	2
acetyltransferase	2
(	2
CAT	2
)	2
construct	2
.	0

Competition	0
with	0
an	0
AP-1	1
motif	2
or	0
with	0
anti-Jun	9
and	0
anti-Fos	9
antibodies	10
abolished	0
binding	0
to	0
the	0
NFAT	1
motif	2
in	0
both	0
T	7
and	8
B	8
cells	8
,	0
indicating	0
that	0
Jun	0
and	0
Fos	0
are	0
critical	0
for	0
NFAT	9
complex	10
formation	0
in	0
both	0
cell	0
types	0
.	0

Purified	0
recombinant	0
Jun	9
and	10
Fos	10
proteins	10
failed	0
to	0
bind	0
directly	0
to	0
the	0
NFAT	1
motif	2
.	0

However	0
,	0
when	0
combined	0
with	0
unstimulated	0
B	0
or	0
T	0
cell	0
extracts	0
,	0
full-length	0
,	0
but	0
not	0
truncated	0
,	0
Jun/Fos	0
heterodimers	0
were	0
able	0
to	0
form	0
an	0
NFAT	9
complex	10
,	0
indicating	0
the	0
presence	0
of	0
a	0
constitutively	9
expressed	10
nuclear	10
factor	10
(	0
s	0
)	0
in	0
B	7
and	8
T	8
cells	8
necessary	0
for	0
the	0
formation	0
of	0
the	0
NFAT	9
complex	10
in	0
both	0
cell	0
types	0
.	0

An	0
NFAT	9
oligonucleotide	0
carrying	0
mutations	0
in	0
the	0
5	1
'	2
purine-rich	2
part	2
of	0
the	0
NFAT	1
sequence	2
failed	0
to	0
form	0
a	0
complex	0
and	0
to	0
compete	0
with	0
the	0
wild	0
type	0
motif	0
for	0
NFAT	9
complex	10
formation	0
in	0
both	0
T	7
and	8
B	8
cells	8
.	0

We	0
therefore	0
propose	0
a	0
model	0
whereby	0
a	0
core	0
NFAT	9
complex	10
consisting	0
of	0
Jun	9
,	0
Fos	9
,	0
and	0
a	0
constitutive	9
nuclear	10
factor	10
is	0
formed	0
in	0
both	0
T	7
and	8
B	8
cells	8
,	0
but	0
an	0
additional	0
factor	0
and/or	0
post-translational	0
modification	0
of	0
a	0
factor	0
,	0
missing	0
in	0
B	7
cells	8
,	0
might	0
be	0
required	0
for	0
transactivation	0
by	0
NFAT	9
.	0

Differential	0
autoregulation	0
of	0
glucocorticoid	9
receptor	10
expression	0
in	0
human	5
T-	6
and	6
B-cell	6
lines	6
.	0

Regulation	0
of	0
glucocorticoid	9
receptor	10
(	0
GR	0
)	0
expression	0
by	0
its	0
cognate	0
ligand	0
was	0
examined	0
in	0
the	0
glucocorticoid-sensitive	5
human	6
leukemic	6
T-cell	6
line	6
6TG1.1	6
and	0
in	0
the	0
human	5
B-cell	6
line	6
IM-9	6
.	0

In	0
contrast	0
to	0
the	0
decrease	0
in	0
GR	3
mRNA	4
seen	0
in	0
IM-9	5
cells	6
after	0
treatment	0
with	0
1	0
microM	0
dexamethasone	0
for	0
16-18	0
h	0
,	0
treatment	0
of	0
6TG1.1	5
cells	6
resulted	0
in	0
an	0
8-fold	0
increase	0
in	0
GR	3
mRNA	4
,	0
as	0
determined	0
by	0
Northern	0
blot	0
and	0
RNase	9
protection	0
analysis	0
,	0
with	0
a	0
corresponding	0
3-	0
to	0
4-fold	0
increase	0
in	0
GR	9
protein	10
.	0

Half-maximal	0
induction	0
of	0
GR	3
mRNA	4
and	0
protein	0
in	0
6TG1.1	5
cells	6
was	0
observed	0
between	0
10-100	0
nM	0
dexamethasone	0
,	0
and	0
inclusion	0
of	0
1	0
microM	0
RU	0
38486	0
completely	0
blocked	0
the	0
effects	0
of	0
100	0
nM	0
dexamethasone	0
,	0
demonstrating	0
that	0
positive	0
autoregulation	0
of	0
GR	9
expression	0
in	0
6TG1.1	5
cells	6
is	0
a	0
receptor-mediated	0
response	0
.	0

Positive	0
autoregulation	0
of	0
GR	9
expression	0
was	0
also	0
observed	0
in	0
glucocorticoid-resistant	5
CEM-C1	6
cells	6
,	0
which	0
contain	0
functional	0
GR	9
,	0
but	0
whose	0
growth	0
is	0
unaffected	0
by	0
glucocorticoids	0
.	0

Thus	0
,	0
positive	0
autoregulation	0
is	0
neither	0
a	0
consequence	0
nor	0
the	0
sole	0
cause	0
of	0
growth	0
arrest	0
.	0

The	0
degree	0
of	0
negative	0
autoregulation	0
in	0
IM-9	5
cells	6
and	0
positive	0
autoregulation	0
in	0
6TG1.1	5
cells	6
was	0
unaffected	0
by	0
inhibition	0
of	0
protein	0
synthesis	0
with	0
cycloheximide	0
.	0

Measurement	0
of	0
GR	3
mRNA	4
turnover	0
in	0
6TG1.1	5
cells	6
treated	0
with	0
actinomycin-D	0
revealed	0
a	0
half-life	0
of	0
2.5	0
h	0
,	0
which	0
was	0
unaffected	0
by	0
dexamethasone	0
treatment	0
.	0

A	0
similar	0
half-life	0
was	0
determined	0
in	0
IM-9	5
cells	6
and	0
was	0
also	0
unaffected	0
by	0
steroid	0
treatment	0
.	0

These	0
results	0
are	0
consistent	0
with	0
the	0
interpretation	0
that	0
glucocorticoid-mediated	0
autoregulation	0
of	0
GR	0
expression	0
is	0
a	0
tissue-specific	0
primary	0
transcriptional	0
response	0
.	0

Induction	0
of	0
CD8	9
antigen	10
and	0
suppressor	0
activity	0
by	0
glucocorticoids	0
in	0
a	0
CEM	5
human	6
leukemic	6
cell	6
clone	6
.	0

The	0
relationship	0
between	0
glucocorticoid	0
effect	0
and	0
regulation	0
of	0
cell	9
surface	10
antigens	10
was	0
investigated	0
in	0
two	0
models	0
of	0
leukemic	5
cell	6
lines	6
,	0
CEM	5
C7	6
denoted	0
(	0
r+	0
,	0
ly+	0
)	0
and	0
CEM	5
C1	6
(	0
r+	0
,	0
ly-	0
)	0
.	0

The	0
reactivity	0
of	0
murine	9
monoclonal	10
antibodies	10
,	0
anti-CD4-FITC	9
,	0
anti-CD8-FITC	9
,	0
anti-CD2-FITC	9
and	0
anti-calla-FITC	9
,	0
were	0
analyzed	0
using	0
flow	0
cytometry	0
.	0

The	0
suppressor	0
function	0
was	0
determined	0
using	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
into	0
phytohemagglutinin-activated	5
peripheral	6
blood	6
lymphocytes	6
.	0

Dexamethasone	0
treatment	0
of	0
a	0
human	5
leukemic	6
cell	6
clone	6
CEM	6
C7	6
caused	0
an	0
increase	0
in	0
a	0
subset	0
of	0
cells	0
expressing	0
the	0
surface	9
antigen	10
CD8	10
,	0
which	0
is	0
present	0
on	0
suppressor	0
and	0
cytotoxic	7
T-lymphocytes	8
.	0

By	0
comparison	0
,	0
there	0
was	0
no	0
modification	0
of	0
the	0
expression	0
of	0
CD4	9
antigen	10
,	0
which	0
is	0
expressed	0
at	0
high	0
levels	0
in	0
these	0
cells	0
.	0

After	0
two	0
days	0
of	0
treatment	0
with	0
5	0
x	0
10	0
(	0
-8	0
)	0
M	0
dexamethasone	0
,	0
CEM	5
C7	6
cells	6
showed	0
a	0
two-fold	0
increase	0
in	0
suppressor	0
activity	0
compared	0
to	0
untreated	0
cells	0
.	0

In	0
contrast	0
,	0
there	0
was	0
no	0
regulation	0
by	0
glucocorticoids	0
of	0
either	0
the	0
CD8	9
or	0
CD4	9
antigens	10
in	0
the	0
leukemic	5
clone	6
CEM	6
C1	6
.	0

Furthermore	0
,	0
no	0
modification	0
of	0
the	0
suppressor	0
function	0
in	0
CEM	5
C1	6
cells	6
by	0
dexamethasone	0
was	0
observed	0
.	0

In	0
the	0
human	0
leukemic	0
cells	0
studied	0
here	0
,	0
the	0
ability	0
to	0
induce	0
CD8	9
antigen	10
expression	0
in	0
a	0
CD4+	5
cells	6
correlates	0
with	0
the	0
ability	0
to	0
induce	0
cell	0
lysis	0
in	0
a	0
glucocorticoid	5
receptor	6
positive	6
cell	6
population	6
.	0

Adenovirus	0
E1A	0
inhibits	0
IFN	9
-induced	0
resistance	0
to	0
cytolysis	0
by	0
natural	7
killer	8
cells	8
.	0

Infection	0
of	0
target	7
cells	8
with	0
cytopathic	0
viruses	0
inhibits	0
IFN	9
induction	0
of	0
cytolytic	0
resistance	0
to	0
NK	0
cell-mediated	0
cytolysis	0
[	0
IFN	9
-mediated	0
cytoprotection	0
(	0
IFN	9
-MCP	0
)	0
]	0
.	0

It	0
has	0
been	0
thought	0
that	0
the	0
virally	0
induced	0
inhibition	0
of	0
IFN	9
-MCP	0
is	0
secondary	0
to	0
the	0
shutdown	0
of	0
cellular	0
macromolecular	0
synthesis	0
that	0
accompanies	0
cytopathic	0
virus	0
infections	0
.	0

Group	0
C	0
,	0
adenovirus	0
serotype	0
5	0
(	0
Ad5	0
)	0
infection	0
inhibits	0
both	0
IFN	9
-MCP	0
and	0
cellular	9
protein	10
synthesis	0
.	0

This	0
study	0
determined	0
if	0
the	0
Ad5-induced	0
inhibition	0
of	0
IFN	9
-MCP	0
was	0
independent	0
of	0
adenovirus	0
(	0
Ad	0
)	0
infection	0
and	0
secondary	0
only	0
to	0
the	0
expression	0
of	0
the	0
Ad	1
early	2
region	2
1A	2
gene	2
(	0
E1A	1
)	0
.	0

To	0
test	0
this	0
hypothesis	0
,	0
4-h	0
NK	0
cytolysis	0
assays	0
were	0
performed	0
on	0
IFN-gamma-treated	5
human	6
cells	6
infected	0
with	0
an	0
Ad5	0
E1A	1
deletion	0
mutant	0
,	0
dl343	0
,	0
or	0
transfected	0
with	0
the	0
Ad5	1
E1A	2
gene	2
.	0

IFN	9
-MCP	0
was	0
not	0
inhibited	0
by	0
infection	0
with	0
dl343	0
,	0
despite	0
the	0
production	0
of	0
large	0
amounts	0
of	0
both	0
early	0
(	0
E1B	9
,	0
p55	9
)	0
and	0
late	0
(	0
hexon	9
)	0
Ad	9
proteins	10
.	0

In	0
contrast	0
to	0
E1A-negative	5
,	6
parental	6
cell	6
lines	6
,	0
IFN	9
-MCP	0
was	0
blocked	0
in	0
Ad5	0
E1A-transfected	5
epithelial	6
and	0
fibroblastic	5
cell	6
lines	6
.	0

Genetic	0
mapping	0
studies	0
within	0
the	0
E1A	1
gene	2
demonstrated	0
that	0
expression	0
of	0
only	0
the	0
first	0
exon	0
of	0
E1A	1
was	0
sufficient	0
to	0
inhibit	0
IFN	9
-MCP	0
.	0

DNA	0
sequence	0
homology	0
of	0
E1A	1
genes	0
between	0
different	0
Ad	0
groups	0
(	0
group	0
A	0
,	0
Ad12	0
;	0
group	0
C	0
,	0
Ad5	0
)	0
is	0
limited	0
almost	0
entirely	0
to	0
three	0
conserved	0
regions	0
located	0
within	0
the	0
first	0
exon	0
of	0
E1A	1
.	0

Because	0
IFN	9
-MCP	0
was	0
also	0
blocked	0
in	0
Ad12	5
E1A-transfected	6
cell	6
lines	6
,	0
expression	0
of	0
one	0
or	0
more	0
of	0
the	0
E1A-conserved	1
regions	2
may	0
be	0
necessary	0
to	0
inhibit	0
IFN	9
-MCP	0
.	0

In	0
summary	0
,	0
the	0
expression	0
of	0
E1A	9
gene	10
products	10
inhibited	0
IFN	9
-MCP	0
independently	0
of	0
virus	0
infection	0
.	0

E1A	1
's	0
inhibition	0
of	0
IFN	9
-MCP	0
has	0
the	0
net	0
effect	0
of	0
promoting	0
the	0
selective	0
NK	0
cell-mediated	0
clearance	0
of	0
Ad-infected	0
or	0
Ad-transformed	5
human	6
cells	6
.	0

A	0
protein	0
of	0
the	0
AP-1	9
family	10
is	0
a	0
component	0
of	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

Nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NF-AT	9
)	0
is	0
a	0
transcriptional	9
activator	10
involved	0
in	0
the	0
induction	0
of	0
IL-2	9
gene	0
expression	0
.	0

The	0
response	0
element	0
for	0
NF-AT	9
is	0
a	0
sequence	0
localized	0
between	0
-285/-254	1
in	0
the	0
IL-2	1
regulatory	2
region	2
.	0

The	0
composition	0
of	0
NF-AT	9
protein	0
is	0
still	0
not	0
fully	0
elucidated	0
.	0

We	0
demonstrate	0
that	0
,	0
in	0
normal	0
human	0
T	7
cells	8
,	0
an	0
AP-1	9
protein	10
is	0
a	0
component	0
of	0
the	0
NF-AT	9
protein	10
complex	10
.	0

This	0
was	0
evidenced	0
by	0
the	0
ability	0
of	0
the	0
AP-1	1
site	2
to	0
compete	0
with	0
the	0
NF-AT	9
site	0
for	0
binding	0
to	0
NF-AT	9
and	0
by	0
the	0
capacity	0
of	0
immobilized	9
anti-Jun	10
and	0
anti-Fos	9
antibodies	0
to	0
deplete	0
NF-AT	9
-binding	0
activity	0
from	0
nuclear	0
extracts	0
of	0
activated	7
T	8
cells	8
.	0

There	0
was	0
no	0
detectable	0
binding	0
of	0
in	0
vitro	0
translated	0
Jun/Fos	9
heterodimer	10
(	0
AP-1	9
)	0
to	0
the	0
NF-AT	9
sequence	0
,	0
and	0
the	0
NF-AT	1
sequence	2
was	0
unable	0
to	0
inhibit	0
the	0
binding	0
of	0
Jun/Fos	9
to	0
the	0
AP-1	1
sequence	2
.	0

The	0
presence	0
of	0
an	0
AP-1	9
protein	0
in	0
the	0
NF-AT	9
protein	0
complex	0
may	0
regulate	0
NF-AT	9
-binding	0
activity	0
through	0
protein-protein	0
interaction	0
.	0

Interaction	0
between	0
NF-kappa	9
B	10
-and	0
serum	9
response	10
factor	10
-binding	0
elements	0
activates	0
an	0
interleukin-2	1
receptor	2
alpha-chain	2
enhancer	2
specifically	0
in	0
T	7
lymphocytes	8
.	0

We	0
find	0
that	0
a	0
short	0
enhancer	0
element	0
containing	0
the	0
NF-kappa	1
B	2
binding	2
site	2
from	0
the	0
interleukin-2	1
receptor	2
alpha-chain	2
gene	2
(	0
IL-2R	9
alpha	10
)	0
is	0
preferentially	0
activated	0
in	0
T	7
cells	8
.	0

The	0
IL-2R	9
alpha	10
enhancer	0
binds	0
NF-kappa	9
B	10
poorly	0
and	0
is	0
only	0
weakly	0
activated	0
by	0
the	0
NF-kappa	1
B	2
site	2
alone	0
.	0

Serum	9
response	10
factor	10
(	0
SRF	9
)	0
binds	0
to	0
a	0
site	0
adjacent	0
to	0
the	0
NF-kappa	1
B	2
site	2
in	0
the	0
IL-2R	1
enhancer	2
,	0
and	0
both	0
sites	0
together	0
have	0
strong	0
transcriptional	0
activity	0
specifically	0
in	0
T	7
cells	8
.	0

Surprisingly	0
,	0
the	0
levels	0
of	0
SRF	9
constitutively	0
expressed	0
in	0
T	7
cells	8
are	0
consistently	0
higher	0
than	0
in	0
other	0
cell	0
types	0
.	0

Overexpression	0
of	0
SRF	9
in	0
B	7
cells	8
causes	0
the	0
IL-2R	1
enhancer	2
to	0
function	0
as	0
well	0
as	0
it	0
does	0
in	0
T	7
cells	8
,	0
suggesting	0
that	0
the	0
high	0
level	0
of	0
SRF	9
binding	0
in	0
T	7
cells	8
is	0
functionally	0
important	0
.	0

Mutual	0
regulation	0
of	0
the	0
transcriptional	9
activator	10
NF-kappa	9
B	10
and	0
its	0
inhibitor	0
,	0
I	9
kappa	10
B-alpha	10
.	0

The	0
NK-kappa	9
B	10
transcription	10
factor	10
complex	10
is	0
sequestered	0
in	0
the	0
cytoplasm	0
by	0
the	0
inhibitory	0
protein	0
I	9
kappa	10
B-alpha	10
(	0
MAD-3	9
)	0
.	0

Various	0
cellular	0
stimuli	0
relieve	0
this	0
inhibition	0
by	0
mechanisms	0
largely	0
unknown	0
,	0
leading	0
to	0
NF-kappa	9
B	10
nuclear	0
localization	0
and	0
transactivation	0
of	0
its	0
target	0
genes	0
.	0

It	0
is	0
demonstrated	0
here	0
with	0
human	7
T	8
lymphocytes	8
and	0
monocytes	7
that	0
different	0
stimuli	0
,	0
including	0
tumor	9
necrosis	10
factor	10
alpha	10
and	0
phorbol	0
12-myristate	0
13-acetate	0
,	0
cause	0
rapid	0
degradation	0
of	0
I	9
kappa	10
B-alpha	10
,	0
with	0
concomitant	0
activation	0
of	0
NF-kappa	9
B	10
,	0
followed	0
by	0
a	0
dramatic	0
increase	0
in	0
I	3
kappa	4
B-alpha	4
mRNA	4
and	0
protein	0
synthesis	0
.	0

Transfection	0
studies	0
reveal	0
that	0
the	0
I	3
kappa	4
B-alpha	4
mRNA	4
and	0
the	0
encoded	0
protein	0
are	0
potently	0
induced	0
by	0
NF-kappa	9
B	10
and	0
by	0
homodimers	0
of	0
p65	9
and	0
of	0
c-Rel	9
.	0

We	0
propose	0
a	0
model	0
in	0
which	0
NF-kappa	9
B	10
and	0
I	9
kappa	10
B-alpha	10
mutually	0
regulate	0
each	0
other	0
in	0
a	0
cycle	0
:	0
saturating	0
amounts	0
of	0
the	0
inhibitory	0
I	9
kappa	10
B-alpha	10
protein	0
are	0
destroyed	0
upon	0
stimulation	0
,	0
allowing	0
rapid	0
activation	0
of	0
NF-kappa	9
B	10
.	0

Subsequently	0
,	0
I	3
kappa	4
B-alpha	4
mRNA	4
and	0
protein	0
levels	0
are	0
quickly	0
induced	0
by	0
the	0
activated	0
NF-kappa	9
B	10
.	0

This	0
resurgence	0
of	0
I	9
kappa	10
B-alpha	10
protein	0
acts	0
to	0
restore	0
an	0
equilibrium	0
in	0
which	0
NF-kappa	9
B	10
is	0
again	0
inhibited	0
.	0

Replication	0
of	0
type	0
1	0
human	0
immunodeficiency	0
viruses	0
containing	0
linker	0
substitution	0
mutations	0
in	0
the	0
-201	1
to	2
-130	2
region	2
of	0
the	0
long	1
terminal	2
repeat	2
.	0

In	0
previous	0
transfection	0
analyses	0
using	0
the	0
chloramphenicol	9
acetyltransferase	10
reporter	1
gene	2
system	0
,	0
we	0
determined	0
that	0
linker	0
substitution	0
(	0
LS	0
)	0
mutations	0
between	0
-201	1
and	2
-130	2
(	0
relative	0
to	0
the	0
transcription	0
start	0
site	0
)	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
caused	0
moderate	0
decreases	0
in	0
LTR	1
transcriptional	0
activity	0
in	0
a	0
T-cell	5
line	6
(	0
S.L.Zeichner	0
,	0
J.Y.H.	0
Kim	0
,	0
and	0
J.C.Alwine	0
,	0
J.Virol.65	0
:	0
2436-2444	0
,	0
1991	0
)	0
.	0

In	0
order	0
to	0
confirm	0
the	0
significance	0
of	0
this	0
region	0
in	0
the	0
context	0
of	0
viral	0
replication	0
,	0
we	0
constructed	0
several	0
of	0
these	0
LS	0
mutations	0
(	0
-201	1
to	2
-	2
184	2
,	0
-183	1
to	2
-166	2
,	0
-165	1
to	2
-148	2
,	0
and	0
-148	1
to	2
-130	2
)	0
in	0
proviruses	0
and	0
prepared	0
viral	0
stocks	0
by	0
cocultivation	0
of	0
transfected	5
RD	6
cells	6
with	0
CEMx174	5
cells	6
.	0

In	0
addition	0
,	0
two	0
mutations	0
between	0
-93	1
and	2
-76	2
and	0
between	0
-75	1
and	2
-58	2
were	0
utilized	0
,	0
since	0
they	0
affect	0
the	0
nuclear	1
factor	2
kappa	2
B	2
(	2
NF-kappa	2
B	2
)	2
-	2
and	2
Sp1-binding	2
sites	2
and	0
were	0
expected	0
to	0
diminish	0
viral	0
replication	0
.	0

Our	0
results	0
suggest	0
that	0
while	0
transfection	0
analyses	0
offer	0
an	0
adequate	0
approximation	0
of	0
the	0
effects	0
of	0
the	0
LS	0
mutations	0
,	0
the	0
analysis	0
of	0
viral	0
replication	0
using	0
a	0
mutant	0
viral	0
stock	0
presents	0
a	0
more	0
accurate	0
picture	0
,	0
which	0
is	0
sometimes	0
at	0
variance	0
with	0
the	0
transfection	0
results	0
.	0

Three	0
mutants	0
(	0
-201/-184	0
NXS	0
,	0
-165/-148	0
NXS	0
,	0
and	0
-147/-130	0
NXS	0
)	0
had	0
effects	0
on	0
viral	0
replication	0
that	0
were	0
much	0
more	0
severe	0
than	0
the	0
effects	0
predicted	0
from	0
their	0
performance	0
in	0
transfection	0
analyses	0
,	0
and	0
the	0
effects	0
of	0
two	0
LS	0
mutations	0
(	0
-201/-184	0
NXS	0
and	0
-183/-166	0
NXS	0
)	0
were	0
not	0
predicted	0
by	0
their	0
effects	0
in	0
transfection	0
.	0

In	0
addition	0
,	0
we	0
observed	0
cell	0
type-specific	0
permissiveness	0
to	0
replication	0
of	0
some	0
mutant	0
viruses	0
.	0

In	0
the	0
cell	0
types	0
tested	0
,	0
the	0
LS	0
mutations	0
indicated	0
an	0
apparent	0
requirement	0
not	0
only	0
for	0
the	0
intact	0
NF-kappa	9
B	10
and	0
SP1-binding	1
sites	2
but	0
also	0
for	0
several	0
regions	0
between	0
-201	1
and	2
-130	2
not	0
previously	0
associated	0
with	0
viral	0
infectivity	0
.	0

Transcription	9
factor	10
GATA-1	9
and	0
erythroid	0
development	0
.	0

In	0
summary	0
,	0
we	0
derived	0
an	0
experimental	0
system	0
that	0
allows	0
us	0
to	0
dissect	0
the	0
function	0
of	0
GATA-1	9
in	0
red	7
cell	8
development	0
at	0
a	0
genetic	0
level	0
.	0

We	0
have	0
established	0
the	0
essential	0
nature	0
of	0
GATA-1	9
during	0
both	0
primitive	0
and	0
definitive	0
erythropoiesis	0
.	0

By	0
ablating	0
the	0
expression	0
of	0
the	0
endogenous	0
GATA-1	1
gene	2
,	0
we	0
are	0
in	0
a	0
position	0
to	0
introduce	0
a	0
variety	0
of	0
constructs	0
that	0
harbor	0
subtle	0
modifications	0
in	0
flanking	0
or	0
protein-coding	1
sequences	2
.	0

We	0
can	0
now	0
study	0
regulatory	0
regions	0
and	0
functional	0
domains	0
of	0
the	0
protein	0
in	0
the	0
context	0
of	0
a	0
true	0
erythroid	0
environment	0
,	0
experiments	0
that	0
have	0
not	0
been	0
possible	0
heretofore	0
.	0

Although	0
the	0
assay	0
involves	0
the	0
dramatic	0
loss	0
of	0
red	0
cell	0
production	0
,	0
it	0
should	0
be	0
possible	0
to	0
define	0
important	0
regulatory	0
domains	0
that	0
can	0
then	0
be	0
assayed	0
using	0
less	0
stringent	0
systems	0
,	0
such	0
as	0
cell-free	0
extracts	0
for	0
in	0
vitro	0
transcription	0
.	0

The	0
ideal	0
situation	0
would	0
be	0
analyses	0
conducted	0
in	0
GATA-1	5
-erythroid	6
cells	6
.	0

However	0
,	0
these	0
cells	0
have	0
been	0
impossible	0
to	0
generate	0
given	0
the	0
requirement	0
of	0
GATA-1	9
for	0
Epo	9
receptor	10
expression	0
and	0
red	7
cell	8
viability	0
(	0
C.	0
Simon	0
and	0
S.	0
Orkin	0
,	0
unpublished	0
observations	0
)	0
.	0

It	0
may	0
be	0
possible	0
to	0
produce	0
such	0
cells	0
by	0
first	0
expressing	0
the	0
Epo	9
receptor	10
under	0
the	0
influence	0
of	0
a	0
constitutive	0
promoter	0
and	0
then	0
targeting	0
the	0
GATA-1	1
gene	2
.	0

If	0
GATA-1	5
-red	6
cells	6
were	0
available	0
,	0
the	0
analyses	0
would	0
involve	0
the	0
actual	0
transcription	0
of	0
or	0
chromatin	0
structure	0
surrounding	0
the	0
globin	1
genes	2
.	0

Structure-function	0
studies	0
of	0
the	0
GATA-1	9
protein	0
could	0
be	0
greatly	0
simplified	0
and	0
a	0
larger	0
number	0
of	0
mutants	0
studied	0
.	0

However	0
,	0
the	0
ES	0
cell	0
system	0
can	0
be	0
used	0
as	0
an	0
alternative	0
until	0
targeted	5
erythroleukemia	6
cells	6
become	0
available	0
.	0

Other	0
applications	0
involve	0
the	0
introduction	0
of	0
other	0
GATA-binding	9
protein	10
family	10
members	10
to	0
determine	0
whether	0
they	0
rescue	0
the	0
mutation	0
.	0

If	0
they	0
can	0
not	0
,	0
chimeric	9
proteins	10
can	0
be	0
tested	0
to	0
identify	0
which	0
amino	0
acids	0
distinguish	0
the	0
different	0
family	0
members	0
.	0

We	0
feel	0
that	0
these	0
experiments	0
are	0
vital	0
to	0
understanding	0
the	0
function	0
of	0
GATA-1	9
during	0
erythroid	0
ontogeny	0
.	0

How	0
does	0
GATA-1	9
regulate	0
red	1
cell	2
genes	2
like	0
globin	1
or	0
the	0
Epo	9
receptor	10
?	0
Once	0
we	0
identify	0
the	0
functional	0
domains	0
of	0
the	0
GATA-binding	9
proteins	10
,	0
we	0
hope	0
to	0
learn	0
what	0
proteins	0
GATA-1	9
binds	0
to	0
in	0
the	0
basic	0
transcription	0
machinery	0
or	0
in	0
chromatin	0
.	0

Is	0
GATA-1	9
necessary	0
for	0
globin	0
gene	0
switching	0
?	0
GATA-1	9
may	0
be	0
modified	0
differently	0
during	0
development	0
so	0
that	0
the	0
locus	0
control	0
region	0
can	0
interact	0
with	0
different	0
globin	1
promoters	2
.	0

We	0
may	0
find	0
that	0
one	0
region	0
of	0
the	0
protein	0
is	0
required	0
for	0
embryonic	0
expression	0
and	0
another	0
for	0
adult	0
globin	1
gene	2
expression	0
.	0

A	0
human	1
putative	2
lymphocyte	2
G0/G1	2
switch	2
gene	2
homologous	0
to	0
a	0
rodent	1
gene	2
encoding	0
a	0
zinc-binding	9
potential	10
transcription	10
factor	10
.	0

G0S24	1
is	0
a	0
member	0
of	0
a	0
set	0
of	0
genes	0
(	0
putative	1
G0/G1	2
switch	2
regulatory	2
genes	2
)	0
that	0
are	0
expressed	0
transiently	0
within	0
1-2	0
hr	0
of	0
the	0
addition	0
of	0
lectin	9
or	0
cycloheximide	0
to	0
human	7
blood	8
mononuclear	8
cells	8
.	0

Comparison	0
of	0
a	0
full-length	1
cDNA	2
sequence	2
with	0
the	0
corresponding	0
genomic	0
sequence	0
reveals	0
an	0
open	1
reading	2
frame	2
of	0
326	0
amino	0
acids	0
,	0
distributed	0
across	0
two	0
exons	1
.	0

Potential	0
phosphorylation	9
sites	10
include	0
the	0
sequence	0
PSPTSPT	9
,	0
which	0
resembles	0
an	0
RNA	9
polymerase	10
II	10
repeat	10
reported	0
to	0
be	0
a	0
target	0
of	0
the	0
cell	9
cycle	10
control	10
kinase	10
cdc2	10
.	0

Comparison	0
of	0
the	0
derived	0
protein	0
sequence	0
with	0
those	0
of	0
rodent	0
homologs	0
allows	0
classification	0
into	0
three	0
groups	0
.	0

Group	0
1	0
contains	0
G0S24	1
and	0
the	0
rat	1
and	2
mouse	2
TIS11	2
genes	2
(	0
also	0
known	0
as	0
TTP	1
,	0
Nup475	1
,	0
and	0
Zfp36	1
)	0
.	0

Members	0
of	0
this	0
group	0
have	0
three	9
tetraproline	10
repeats	10
.	0

Groups	0
1	0
and	0
2	0
have	0
a	0
serine-rich	9
region	10
and	0
an	0
``	0
arginine	9
element	10
``	0
(	0
RRLPIF	9
)	0
at	0
the	0
carboxyl	9
terminus	10
.	0

All	0
groups	0
contain	0
cysteine-	9
and	10
histidine-rich	10
putative	10
zinc	10
finger	10
domains	10
and	0
a	0
serine-phenylalanine	9
``	10
SFS	10
''	10
domain	10
similar	0
to	0
part	0
of	0
the	0
large	0
subunit	0
of	0
eukaryotic	9
RNA	10
polymerase	10
II	10
.	0

Comparison	0
of	0
group	0
1	0
human	1
and	2
mouse	2
genomic	2
sequences	2
shows	0
high	0
conservation	0
in	0
the	0
5	1
'	2
flank	2
and	0
exons	1
.	0

A	0
CpG	0
island	0
suggests	0
expression	0
in	0
the	0
germ	0
line	0
.	0

G0S24	1
has	0
potential	0
sites	0
for	0
transcription	9
factors	10
in	0
the	0
5	1
'	2
flank	2
and	0
intron	1
;	0
these	0
include	0
a	0
serum	1
response	2
element	2
.	0

Protein	0
and	0
genomic	0
sequences	0
show	0
similarities	0
with	0
those	0
of	0
a	0
variety	0
of	0
proteins	0
involved	0
in	0
transcription	0
,	0
suggesting	0
that	0
the	0
G0S24	9
product	10
has	0
a	0
similar	0
role	0
.	0

Regulation	0
of	0
lymphoid-specific	1
immunoglobulin	2
mu	2
heavy	2
chain	2
gene	2
enhancer	2
by	0
ETS-domain	0
proteins	0
.	0

The	0
enhancer	1
for	0
the	0
immunoglobulin	1
mu	2
heavy	2
chain	2
gene	2
(	0
IgH	9
)	0
activates	0
a	0
heterologous	1
gene	2
at	0
the	0
pre-B	0
cell	0
stage	0
of	0
B	7
lymphocyte	8
differentiation	0
.	0

A	0
lymphoid-specific	1
element	2
,	0
microB	1
,	0
is	0
necessary	0
for	0
enhancer	1
function	0
in	0
pre-B	7
cells	8
.	0

A	0
microB	9
binding	10
protein	10
is	0
encoded	0
by	0
the	0
PU.1/Spi-1	1
proto-oncogene	2
.	0

Another	0
sequence	1
element	2
,	0
microA	1
,	0
was	0
identified	0
in	0
the	0
mu	1
enhancer	2
that	0
binds	0
the	0
product	0
of	0
the	0
ets-1	1
proto-oncogene	2
.	0

The	0
microA	1
motif	0
was	0
required	0
for	0
microB-dependent	1
enhancer	2
activity	0
,	0
which	0
suggests	0
that	0
a	0
minimal	1
B	2
cell-specific	2
enhancer	2
is	0
composed	0
of	0
both	0
the	0
PU.1	1
and	2
Ets-1	2
binding	2
sites	2
.	0

Co-expression	0
of	0
both	0
PU.1	9
and	0
Ets-1	9
in	0
nonlymphoid	7
cells	8
trans-activated	1
reporter	2
plasmids	2
that	0
contained	0
the	0
minimal	0
mu	1
enhancer	2
.	0

These	0
results	0
implicate	0
two	0
members	0
of	0
the	0
Ets	9
family	10
in	0
the	0
activation	0
of	0
IgH	1
gene	2
expression	0
.	0

1	0
,	0
25-Dihydroxy	0
vitamin	0
D3	0
and	0
12-O-tetradecanoyl	0
phorbol-13-acetate	0
synergistically	0
induce	0
monocytic	7
cell	8
differentiation	0
:	0
FOS	9
and	0
RB	9
expression	0
.	0

1	0
,	0
25-dihydroxy	0
vitamin	0
D3	0
and	0
12-O-tetradecanoyl	0
phorbol-13-acetate	0
(	0
TPA	0
)	0
interact	0
synergistically	0
to	0
induce	0
monocytic	0
differentiation	0
of	0
U937	5
histiocytic	6
lymphoma	6
cells	6
.	0

Addition	0
of	0
TPA	0
causes	0
an	0
otherwise	0
ineffective	0
dose	0
of	0
1	0
,	0
25-dihydroxy	0
vitamin	0
D3	0
to	0
induce	0
differentiation	0
.	0

The	0
induced	0
differentiation	0
depends	0
on	0
the	0
simultaneous	0
(	0
vs.	0
sequential	0
)	0
presence	0
of	0
both	0
agents	0
.	0

The	0
kinetics	0
of	0
induced	0
differentiation	0
are	0
consistent	0
with	0
a	0
G1	0
specific	0
cellular	0
response	0
to	0
initiate	0
the	0
metabolic	0
cascade	0
culminating	0
in	0
cell	0
differentiation	0
.	0

The	0
induced	0
differentiation	0
occurs	0
with	0
down-regulation	0
of	0
c-fos	9
protein	10
and	0
an	0
accompanying	0
up-regulation	0
of	0
RB	9
protein	10
expression	0
,	0
consistent	0
with	0
a	0
possible	0
need	0
for	0
up-regulated	0
RB	9
expression	0
to	0
maintain	0
a	0
given	0
differentiated	0
phenotype	0
and	0
suppress	0
transcriptional	9
activators	10
that	0
might	0
typically	0
be	0
associated	0
with	0
proliferation	0
.	0

Ectopic	0
expression	0
of	0
a	0
conditional	0
GATA-2/estrogen	9
receptor	10
chimera	10
arrests	0
erythroid	0
differentiation	0
in	0
a	0
hormone-dependent	0
manner	0
.	0

The	0
GATA	9
factors	10
are	0
a	0
family	0
of	0
transcriptional	9
regulatory	10
proteins	10
in	0
eukaryotes	0
that	0
share	0
extensive	0
homology	0
in	0
their	0
DNA-binding	9
domains	10
.	0

One	0
enigmatic	0
aspect	0
of	0
GATA	9
factor	10
expression	0
is	0
that	0
several	0
GATA	9
proteins	10
,	0
which	0
ostensibly	0
share	0
the	0
same	0
DNA-binding	9
site	10
specificity	0
,	0
are	0
coexpressed	0
in	0
erythroid	0
cells	0
.	0

To	0
elucidate	0
the	0
roles	0
of	0
individual	0
GATA	9
factors	10
in	0
erythropoiesis	0
,	0
conditional	0
alleles	0
of	0
GATA-1	9
,	0
GATA-2	9
,	0
and	0
GATA-3	9
were	0
prepared	0
by	0
fusing	0
each	0
of	0
the	0
factors	0
to	0
the	0
hormone-binding	9
domain	10
of	0
the	0
human	9
estrogen	10
receptor	10
(	0
ER	9
)	0
.	0

These	0
GATA/ER	9
chimeric	10
factors	10
were	0
shown	0
to	0
be	0
hormone-inducible	9
trans-activating	10
proteins	10
in	0
transient	0
transfection	0
assays	0
.	0

When	0
stably	0
introduced	0
into	0
primary	7
erythroblasts	8
or	0
conditionally	5
transformed	6
erythroid	6
progenitors	6
cells	6
,	0
exogenous	0
GATA-2/ER	9
promoted	0
proliferation	0
and	0
inhibited	0
terminal	0
differentiation	0
in	0
an	0
estrogen-dependent	0
manner	0
.	0

These	0
phenotypic	0
effects	0
are	0
specifically	0
attributable	0
to	0
the	0
action	0
of	0
ectopically	0
expressed	0
GATA-2/ER	9
because	0
erythroblasts	0
expressing	0
exogenous	0
GATA-2	9
are	0
constitutively	0
arrested	0
in	0
differentiation	0
and	0
because	0
erythroid	5
progenitors	6
expressing	0
either	0
Gal/ER	9
or	0
GATA-3/ER	9
do	0
not	0
display	0
a	0
hormone-responsive	0
block	0
in	0
differentiation	0
.	0

Thus	0
,	0
the	0
GATA-2	9
transcription	10
factor	10
appears	0
to	0
play	0
a	0
role	0
in	0
regulating	0
the	0
self-renewal	0
capacity	0
of	0
early	7
erythroid	8
progenitor	8
cells	8
.	0

Mice	0
deficient	0
for	0
the	0
55	9
kd	10
tumor	10
necrosis	10
factor	10
receptor	10
are	0
resistant	0
to	0
endotoxic	0
shock	0
,	0
yet	0
succumb	0
to	0
L.	0
monocytogenes	0
infection	0
.	0

The	0
multiple	0
biological	0
activities	0
of	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
are	0
mediated	0
by	0
two	0
distinct	0
cell	9
surface	10
receptors	10
of	0
55	9
kd	10
(	0
TNFRp55	9
)	0
and	0
75	9
kd	10
(	0
TNFRp75	9
)	0
.	0

Using	0
gene	0
targeting	0
,	0
we	0
generated	0
a	0
TNFRp55	9
-deficient	0
mouse	0
strain	0
.	0

Cells	0
from	0
TNFRp55-/-mutant	0
mice	0
lack	0
expression	0
of	0
TNFRp55	9
but	0
display	0
normal	0
numbers	0
of	0
high	9
affinity	10
TNFRp75	10
molecules	10
.	0

Thymocyte	7
development	0
and	0
lymphocyte	7
populations	8
are	0
unaltered	0
,	0
and	0
clonal	0
deletion	0
of	0
potentially	0
self-reactive	7
T	8
cells	8
is	0
not	0
impaired	0
.	0

However	0
,	0
TNF	9
signaling	0
is	0
largely	0
abolished	0
,	0
as	0
judged	0
by	0
the	0
failure	0
of	0
TNF	9
to	0
induce	0
NF-kappa	9
B	10
in	0
T	7
lymphocytes	8
from	0
TNFRp55	9
-deficient	0
mice	0
.	0

The	0
loss	0
of	0
TNFRp55	9
function	0
renders	0
mice	0
resistant	0
to	0
lethal	0
dosages	0
of	0
either	0
lipopolysaccharides	0
or	0
S.	9
aureus	10
enterotoxin	10
B	10
.	0

In	0
contrast	0
,	0
TNFRp55-deficient	0
mice	0
are	0
severely	0
impaired	0
to	0
clear	0
L.	0
monocytogenes	0
and	0
readily	0
succumb	0
to	0
infection	0
.	0

Thus	0
,	0
the	0
55	9
kd	10
TNFR	10
plays	0
a	0
decisive	0
role	0
in	0
the	0
host	0
's	0
defense	0
against	0
microorganisms	0
and	0
their	0
pathogenic	0
factors	0
.	0

Costimulation	0
of	0
peripheral	7
blood	8
T	8
cell	8
activation	0
by	0
human	7
endothelial	8
cells	8
.	0

Enhanced	0
IL-2	9
transcription	0
correlates	0
with	0
increased	0
c-fos	9
synthesis	0
and	0
increased	0
Fos	9
content	0
of	0
AP-1	9
.	0

Endothelial	7
cells	8
(	0
EC	7
)	0
act	0
as	0
APC	0
for	0
resting	7
PBL	8
in	0
vitro	0
,	0
and	0
may	0
have	0
important	0
roles	0
in	0
vivo	0
in	0
the	0
pathogenesis	0
of	0
allograft	0
rejection	0
and	0
delayed	0
hypersensitivity	0
.	0

We	0
previously	0
reported	0
that	0
human	7
umbilical	8
vein	8
EC	8
provide	0
costimulatory	0
signals	0
to	0
PHA-stimulated	7
PBL	8
via	0
CD2	9
:	10
lymphocyte	10
function-associated	10
Ag-3	10
and	0
an	0
unidentified	0
ligand	0
pair	0
,	0
resulting	0
in	0
a	0
three-	0
to	0
eight-fold	0
enhancement	0
of	0
IL-2	9
production	0
.	0

The	0
physiologic	0
relevance	0
of	0
this	0
increase	0
was	0
demonstrated	0
by	0
the	0
proliferative	0
advantage	0
provided	0
by	0
EC	7
to	0
PBL	7
suboptimally	0
stimulated	0
with	0
mAb	9
OKT3	10
.	0

We	0
now	0
report	0
that	0
EC	7
costimulation	0
causes	0
increased	0
levels	0
of	0
IL-2	3
mRNA	4
as	0
a	0
result	0
of	0
increased	0
IL-2	9
transcription	0
in	0
PBL	7
.	0

We	0
therefore	0
examined	0
the	0
effects	0
of	0
EC	7
on	0
T	9
cell	10
nuclear	10
factors	10
known	0
to	0
regulate	0
IL-2	9
transcription	0
,	0
including	0
c-jun	9
and	0
c-fos-two	9
components	10
of	0
the	0
transcription	9
factor	10
AP-1	9
,	0
NFAT	9
,	0
and	0
others	0
.	0

PBL	7
constitutively	0
express	0
c-jun	9
transcripts	10
,	0
and	0
the	0
level	0
of	0
c-jun	3
mRNA	4
is	0
not	0
altered	0
by	0
PHA	9
activation	0
in	0
the	0
absence	0
or	0
presence	0
of	0
EC	7
.	0

In	0
contrast	0
,	0
c-fos	3
mRNA	4
is	0
absent	0
from	0
resting	0
T	7
cells	8
and	0
is	0
induced	0
on	0
PHA	9
activation	0
.	0

EC	7
alone	0
do	0
not	0
induce	0
c-fos	3
mRNA	4
but	0
augment	0
the	0
level	0
of	0
c-fos	3
mRNA	4
in	0
PHA-activated	7
T	8
cells	8
by	0
3-	0
to	0
10-fold	0
.	0

This	0
effect	0
is	0
largely	0
independent	0
of	0
the	0
CD2	0
:	0
lymphocyte	0
function-associated	0
Ag-3	0
pathway	0
.	0

Gel-shift	0
analysis	0
reveals	0
the	0
constitutive	0
presence	0
of	0
nuclear	0
factors	0
in	0
resting	7
PBL	8
that	0
bind	0
to	0
the	0
proximal	1
AP-1	2
site	2
of	0
the	0
IL-2	1
promoter	2
and	0
that	0
contain	0
immunoreactive	0
c-Jun	9
but	0
not	0
c-Fos	9
protein	0
.	0

In	0
contrast	0
,	0
AP-1	9
from	0
PHA-activated	7
cells	8
contains	0
c-Jun	9
and	0
low	0
levels	0
of	0
c-Fos	9
.	0

Strikingly	0
,	0
costimulation	0
with	0
EC	7
results	0
in	0
a	0
dramatic	0
increase	0
(	0
up	0
to	0
15-fold	0
)	0
in	0
the	0
c-Fos	9
content	0
of	0
AP-1	9
.	0

Levels	0
of	0
other	0
nuclear	9
factors	10
involved	0
in	0
IL-2	9
regulation	0
were	0
not	0
altered	0
by	0
EC	7
,	0
although	0
NFAT-DNA	9
complexes	10
migrated	0
at	0
a	0
slightly	0
different	0
mobility	0
.	0

In	0
summary	0
,	0
our	0
data	0
suggest	0
that	0
changes	0
in	0
the	0
composition	0
of	0
transcription	9
factor	10
AP-1	9
is	0
a	0
key	0
molecular	0
mechanism	0
for	0
increasing	0
IL-2	9
transcription	0
and	0
may	0
underlie	0
the	0
phenomenon	0
of	0
costimulation	0
by	0
EC	7
.	0

Transcriptional	0
activation	0
of	0
human	1
zeta	2
2	2
globin	2
promoter	2
by	0
the	0
alpha	1
globin	2
regulatory	2
element	2
(	0
HS-40	1
)	0
:	0
functional	0
role	0
of	0
specific	0
nuclear	9
factor-DNA	10
complexes	10
.	0

We	0
studied	0
the	0
functional	0
interaction	0
between	0
human	1
embryonic	2
zeta	2
2	2
globin	2
promoter	2
and	0
the	0
alpha	1
globin	2
regulatory	2
element	2
(	0
HS-40	1
)	0
located	0
40	1
kb	2
upstream	2
of	0
the	0
zeta	1
2	2
globin	2
gene	2
.	0

It	0
was	0
shown	0
by	0
transient	0
expression	0
assay	0
that	0
HS-40	1
behaved	0
as	0
an	0
authentic	0
enhancer	1
for	0
high-level	0
zeta	1
2	2
globin	2
promoter	2
activity	0
in	0
K562	5
cells	6
,	0
an	0
erythroid	0
cell	0
line	0
of	0
embryonic	0
and/or	0
fetal	0
origin	0
.	0

Although	0
sequences	0
located	0
between	0
-559	0
and	0
-88	0
of	0
the	0
zeta	1
2	2
globin	2
gene	2
were	0
dispensable	0
for	0
its	0
expression	0
on	0
enhancerless	1
plasmids	2
,	0
they	0
were	0
required	0
for	0
the	0
HS-40	1
enhancer	2
-mediated	0
activity	0
of	0
the	0
zeta	1
2	2
globin	2
promoter	2
.	0

Site-directed	0
mutagenesis	0
demonstrated	0
that	0
this	0
HS-40	1
enhancer-	0
zeta	1
2	2
globin	2
promoter	2
interaction	0
is	0
mediated	0
by	0
the	0
two	0
GATA-1	0
factor	0
binding	0
motifs	0
located	0
at	0
-230	0
and	0
-104	0
,	0
respectively	0
.	0

The	0
functional	0
domains	0
of	0
HS-40	1
were	0
also	0
mapped	0
.	0

Bal	0
31	0
deletion	0
mapping	0
data	0
suggested	0
that	0
one	0
GATA-1	0
motif	0
,	0
one	0
GT	0
motif	0
,	0
and	0
two	0
NF-E2/AP1	0
motifs	0
together	0
formed	0
the	0
functional	0
core	0
of	0
HS-40	1
in	0
the	0
erythroid-specific	0
activation	0
of	0
the	0
zeta	1
2	2
globin	2
promoter	2
.	0

Site-directed	0
mutagenesis	0
further	0
demonstrated	0
that	0
the	0
enhancer	1
function	0
of	0
one	0
of	0
the	0
two	0
NF-E2/AP1	0
motifs	0
of	0
HS-40	1
is	0
mediated	0
through	0
its	0
binding	0
to	0
NF-E2	9
but	0
not	0
AP1	9
transcription	10
factor	10
.	0

Finally	0
,	0
we	0
did	0
genomic	0
footprinting	0
of	0
the	0
HS-40	1
enhancer	2
region	2
in	0
K562	5
cells	6
,	0
adult	5
nucleated	6
erythroblasts	6
,	0
and	0
different	0
nonerythroid	7
cells	8
.	0

All	0
sequence	0
motifs	0
within	0
the	0
functional	0
core	0
of	0
HS-40	1
,	0
as	0
mapped	0
by	0
transient	0
expression	0
analysis	0
,	0
appeared	0
to	0
bind	0
a	0
nuclear	9
factor	10
(	0
s	0
)	0
in	0
living	0
K562	5
cells	6
but	0
not	0
in	0
nonerythroid	7
cells	8
.	0

On	0
the	0
other	0
hand	0
,	0
only	0
one	0
of	0
the	0
apparently	0
nonfunctional	1
sequence	2
motifs	2
was	0
bound	0
with	0
factors	0
in	0
vivo	0
.	0

In	0
comparison	0
to	0
K562	5
,	0
nucleated	5
erythroblasts	6
from	0
adult	0
human	0
bone	0
marrow	0
exhibited	0
a	0
similar	0
but	0
nonidentical	0
pattern	0
of	0
nuclear	9
factor	10
binding	0
in	0
vivo	0
at	0
the	0
HS-40	1
region	0
.	0

These	0
data	0
suggest	0
that	0
transcriptional	0
activation	0
of	0
human	1
embryonic	2
zeta	2
2	2
globin	2
gene	2
and	0
the	0
fetal/adult	1
alpha	2
globin	2
genes	2
is	0
mediated	0
by	0
erythroid	0
cell-specific	0
and	0
developmental	9
stage-specific	10
nuclear	10
factor-DNA	10
complexes	10
which	0
form	0
at	0
the	0
enhancer	1
(	0
HS-40	1
)	0
and	0
the	0
globin	1
promoters	2
.	0

Transcriptional	0
regulation	0
of	0
the	0
pyruvate	1
kinase	2
erythroid-specific	2
promoter	2
.	0

Mammal	9
pyruvate	10
kinases	10
are	0
encoded	0
by	0
two	0
genes	0
.	0

The	0
L	1
gene	2
produces	0
the	0
erythroid	9
(	0
R-PK	9
)	0
or	0
the	0
hepatic	9
(	10
L-PK	10
)	10
isozymes	10
by	0
the	0
alternative	0
use	0
of	0
two	0
promoters	1
.	0

We	0
report	0
the	0
characterization	0
of	0
the	0
cis-	1
and	2
trans-acting	2
elements	2
involved	0
in	0
the	0
tissue-specific	0
activity	0
of	0
the	0
L	1
gene	2
erythroid	2
promoter	2
.	0

A	0
R-PK	1
DNA	2
fragment	2
extending	0
from	0
-870	0
to	0
+54	0
relative	0
to	0
the	0
cap	1
site	2
confers	0
erythroid	0
specificity	0
to	0
a	0
reporter	1
gene	2
.	0

Within	0
this	0
region	0
,	0
we	0
define	0
a	0
minimal	1
promoter	2
(	0
-62	0
to	0
+54	0
)	0
that	0
displays	0
erythroid-specific	0
activity	0
and	0
contains	0
two	0
DNA	0
binding	0
sites	0
.	0

One	0
,	0
located	0
at	0
-50	0
,	0
binds	0
members	0
of	0
the	0
CCACC/Sp1	9
family	10
and	0
the	0
other	0
,	0
located	0
at	0
-20	0
,	0
binds	0
the	0
erythroid	9
factor	10
GATA-1	10
.	0

Although	0
the	0
-20	0
GATA	1
binding	2
site	2
(	0
AGATAA	0
)	0
is	0
also	0
a	0
potential	0
TFIID	1
binding	2
site	2
,	0
it	0
does	0
not	0
bind	0
TFIID	9
.	0

Furthermore	0
,	0
the	0
substitution	0
of	0
this	0
GATA	1
binding	2
site	2
by	0
a	0
canonical	0
TFIID	1
binding	2
site	2
suppresses	0
the	0
promoter	0
activity	0
.	0

Mutations	0
and	0
deletions	0
of	0
both	0
sites	0
indicate	0
that	0
only	0
the	0
association	0
of	0
CCACC/Sp1	9
and	0
GATA	1
binding	2
sites	2
can	0
drive	0
efficient	0
and	0
tissue-specific	0
expression	0
of	0
this	0
R-PK	9
minimal	1
promoter	2
.	0

Finally	0
,	0
by	0
co-transfection	0
experiments	0
,	0
we	0
study	0
the	0
elements	0
involved	0
in	0
the	0
hGATA-1	0
transactivation	0
of	0
the	0
R-PK	1
promoter	2
in	0
HeLa	5
cells	6
.	0

Protease	0
treatment	0
of	0
nuclear	0
extracts	0
distinguishes	0
between	0
class	9
II	10
MHC	10
X1	10
box	10
DNA-binding	10
proteins	10
in	0
wild-type	5
and	6
class	6
II-deficient	6
B	6
cells	6
.	0

The	0
X	1
box	2
region	2
is	0
critical	0
for	0
directing	0
the	0
expression	0
of	0
class	1
II	2
major	2
histocompatibility	2
complex	2
genes	2
in	0
B	7
lymphocytes	8
.	0

Although	0
several	0
class	9
II	10
promoter-specific	10
DNA	10
binding	10
factors	10
have	0
been	0
described	0
,	0
only	0
the	0
X	1
box	2
region	2
factor	0
,	0
RFX	9
,	0
shows	0
a	0
genetic	0
correlation	0
with	0
class	0
II	0
expression	0
,	0
being	0
deficient	0
in	0
some	0
B	5
cell	6
lines	6
derived	0
from	0
patients	0
with	0
class	0
II-deficient	0
congenital	0
immunodeficiency	0
.	0

To	0
further	0
evaluate	0
the	0
role	0
of	0
X	9
box	10
DNA-binding	10
proteins	10
in	0
class	1
II	2
gene	2
expression	0
,	0
the	0
role	0
of	0
the	0
X	1
box	2
region	2
was	0
examined	0
in	0
both	0
class	5
II-positive	6
and	0
-negative	5
lymphoid	6
cells	6
.	0

In	0
addition	0
to	0
the	0
wild-type	5
B	6
cell	6
line	6
Raji	6
,	0
two	5
class	6
II	6
transcriptional	6
mutant	6
cell	6
lines	6
,	0
SJO	5
and	0
RJ2.2.5	5
,	0
and	0
Jurkat	5
,	0
a	0
class	5
II	6
negative	6
T	6
cell	6
line	6
,	0
were	0
examined	0
.	0

In	0
contrast	0
to	0
wild-type	5
B	6
cells	6
,	0
neither	0
of	0
the	0
class	5
II	6
mutant	6
cell	6
lines	6
could	0
use	0
the	0
X	1
box	2
region	2
to	0
direct	0
the	0
expression	0
of	0
a	0
transiently	0
transfected	0
reporter	1
gene	2
,	0
indicating	0
that	0
the	0
X	0
box-dependent	0
transcriptional	0
pathway	0
is	0
defective	0
in	0
these	0
cells	0
.	0

The	0
binding	0
activity	0
of	0
the	0
X1	9
box	10
DNA-binding	10
protein	10
RFX	9
was	0
examined	0
and	0
found	0
to	0
be	0
present	0
in	0
wild-type	5
B	6
cells	6
and	0
the	0
mutant	0
RJ2.2.5	5
but	0
was	0
absent	0
in	0
SJO	5
and	0
Jurkat	5
.	0

However	0
,	0
other	0
X1	0
box-specific	0
activities	0
were	0
detected	0
in	0
all	0
these	0
cell	5
lines	6
.	0

To	0
determine	0
whether	0
these	0
different	0
X1	0
box	0
activities	0
represented	0
distinct	0
DNA	9
binding	10
proteins	10
or	0
multimeric	0
forms	0
of	0
the	0
same	0
factor	0
(	0
s	0
)	0
,	0
protease	9
treatment	0
of	0
the	0
crude	0
nuclear	0
extracts	0
followed	0
by	0
DNA-binding	0
assays	0
were	0
carried	0
out	0
and	0
demonstrated	0
that	0
B	0
cell	0
extracts	0
contain	0
at	0
least	0
two	0
X1-specific	9
factors	10
.	0

One	0
of	0
these	0
cleaved	0
products	0
(	0
band	0
1	0
pk	0
)	0
correlates	0
with	0
RFX	9
activity	0
.	0

A	0
similar	0
comparison	0
with	0
protease-treated	0
extracts	0
prepared	0
from	0
Jurkat	5
cells	6
demonstrated	0
the	0
presence	0
of	0
the	0
band	0
1pk	0
activity	0
despite	0
an	0
absence	0
of	0
the	0
native	0
RFX	9
activity	0
.	0

In	0
contrast	0
,	0
protease	0
treatment	0
and	0
analysis	0
of	0
SJO	5
extracts	0
showed	0
no	0
detectable	0
levels	0
of	0
the	0
band	0
1pk	0
activity	0
.	0

These	0
results	0
demonstrate	0
that	0
multiple	0
X1	0
box-specific	0
DNA-binding	0
activities	0
exist	0
in	0
all	0
lymphoid	7
cells	8
,	0
but	0
the	0
presence	0
of	0
an	0
actively	0
binding	0
RFX	9
species	0
correlates	0
with	0
class	0
II	0
transcription	0
.	0

Human	0
immunodeficiency	0
viruses	0
containing	0
heterologous	1
enhancer/promoters	2
are	0
replication	0
competent	0
and	0
exhibit	0
different	0
lymphocyte	0
tropisms	0
.	0

The	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
type	2
1	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
contains	0
binding	0
sites	0
for	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
and	0
the	0
constitutively	0
expressed	0
transcription	9
factor	10
Sp1	10
,	0
both	0
of	0
which	0
are	0
highly	0
conserved	0
in	0
HIV	0
and	0
simian	0
immunodeficiency	0
virus	0
isolates	0
.	0

To	0
delineate	0
the	0
effects	0
of	0
these	0
motifs	0
on	0
the	0
replicative	0
capacity	0
of	0
HIV	0
and	0
to	0
explore	0
the	0
possibility	0
of	0
extending	0
the	0
virus	0
host	0
range	0
,	0
known	0
heterologous	1
enhancer/promoters	2
were	0
inserted	0
into	0
the	0
HIV-1	1
LTR	2
in	0
place	0
of	0
the	0
NF-kappa	9
B	10
and	0
Sp1	1
binding	2
sites	2
.	0

The	0
effects	0
of	0
these	0
substitutions	0
on	0
viral	0
replication	0
in	0
transfected	0
HeLa	5
cells	6
and	0
on	0
HIV	0
infection	0
of	0
human	7
peripheral	8
blood	8
lymphocytes	8
or	0
continuous	5
T-leukemia	6
cell	6
lines	6
were	0
evaluated	0
.	0

HIVs	0
in	0
which	0
the	0
NF-kappa	1
B/Sp1	2
enhancer	2
plus	0
the	0
downstream	1
TATA	2
element	2
were	0
replaced	0
with	0
heterologous	1
enhancer/promoters	2
were	0
also	0
constructed	0
.	0

Viruses	0
containing	0
the	0
human	1
cytomegalovirus	2
immediate-early	2
enhancer	2
exhibited	0
infectious	0
kinetics	0
similar	0
to	0
that	0
of	0
wild-type	0
HIV	0
in	0
activated	7
human	8
peripheral	8
blood	8
lymphocytes	8
and	0
AA2	5
cells	6
but	0
replicated	0
less	0
efficiently	0
in	0
H9	5
and	6
CEM	6
cells	6
.	0

These	0
studies	0
indicate	0
that	0
heterologous	1
enhancer	2
elements	2
are	0
capable	0
of	0
restoring	0
Tat	9
responsiveness	0
to	0
the	0
HIV	1
LTR	2
in	0
the	0
context	0
of	0
directing	0
reporter	1
gene	2
expression	0
as	0
well	0
as	0
in	0
the	0
production	0
of	0
infectious	0
progeny	0
virions	0
.	0

Tyrosine	0
phosphorylation	0
is	0
a	0
mandatory	0
proximal	0
step	0
in	0
radiation-induced	0
activation	0
of	0
the	0
protein	9
kinase	10
C	10
signaling	0
pathway	0
in	0
human	7
B-lymphocyte	8
precursors	8
[	0
published	0
erratum	0
appears	0
in	0
Proc	0
Natl	0
Acad	0
Sci	0
U	0
S	0
A	0
1993	0
Apr	0
15	0
;	0
90	0
(	0
8	0
)	0
:	0
3775	0
]	0

Ionizing	0
radiation	0
triggers	0
a	0
signal	0
in	0
human	7
B-lymphocyte	8
precursors	8
that	0
is	0
intimately	0
linked	0
to	0
an	0
active	0
protein-tyrosine	9
kinase	10
regulatory	0
pathway	0
.	0

We	0
show	0
that	0
in	0
B-lymphocyte	7
precursors	8
,	0
irradiation	0
with	0
gamma-rays	0
leads	0
to	0
(	0
i	0
)	0
stimulation	0
of	0
phosphatidylinositol	0
turnover	0
;	0
(	0
ii	0
)	0
downstream	0
activation	0
by	0
covalent	0
modification	0
of	0
multiple	0
serine-specific	9
protein	10
kinases	10
,	0
including	0
protein	9
kinase	10
C	10
;	0
and	0
(	0
iii	0
)	0
activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
.	0

All	0
of	0
the	0
radiation-induced	0
signals	0
were	0
effectively	0
prevented	0
by	0
the	0
protein-tyrosine	9
kinase	10
inhibitors	10
genistein	10
and	10
herbimycin	10
A	10
.	0

Thus	0
,	0
tyrosine	0
phosphorylation	0
is	0
an	0
important	0
and	0
perhaps	0
mandatory	0
proximal	0
step	0
in	0
the	0
activation	0
of	0
the	0
protein	9
kinase	10
C	10
signaling	0
cascade	0
in	0
human	7
B-lymphocyte	8
precursors	8
.	0

Our	0
report	0
expands	0
current	0
knowledge	0
of	0
the	0
radiation-induced	0
signaling	0
cascade	0
by	0
clarifying	0
the	0
chronological	0
sequence	0
of	0
biochemical	0
events	0
that	0
follow	0
irradiation	0
.	0

Detection	0
of	0
adenovirus	1
DNA	2
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
by	0
polymerase	0
chain	0
reaction	0
assay	0
.	0

Adenovirus	0
can	0
establish	0
persistent	0
infections	0
which	0
may	0
reactivate	0
and	0
cause	0
disease	0
in	0
immunocompromised	0
hosts	0
.	0

Lymphocytes	7
have	0
been	0
postulated	0
to	0
serve	0
as	0
a	0
site	0
of	0
adenoviral	0
persistence	0
based	0
upon	0
the	0
ability	0
to	0
isolate	0
adenovirus	0
from	0
tonsils	0
and	0
to	0
detect	0
adenovirus	1
DNA	2
by	0
Southern	0
blot	0
hybridization	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

To	0
test	0
this	0
hypothesis	0
,	0
a	0
more	0
sensitive	0
and	0
specific	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
assay	0
was	0
developed	0
to	0
detect	0
adenovirus	1
DNA	2
.	0

Two	0
sets	0
of	0
nested	1
primers	2
were	0
designed	0
to	0
conserved	0
sequences	0
in	0
the	0
adenovirus	1
E1A	2
and	2
hexon	2
genes	2
.	0

The	0
E1A	1
and	2
hexon	2
primers	2
amplified	0
DNA	0
from	0
representative	0
adenoviral	0
serotypes	0
in	0
all	0
six	0
adenoviral	0
groups	0
(	0
A-F	0
)	0
.	0

Both	0
primers	0
detected	0
a	0
single	0
copy	0
of	0
the	0
adenovirus	1
type	2
2	2
genome	2
but	0
were	0
less	0
sensitive	0
for	0
the	0
group	0
B	0
type	0
35	0
.	0

None	0
of	0
33	0
PBMC	7
specimens	0
from	0
healthy	0
adults	0
and	0
only	0
one	0
of	0
40	0
pediatric	0
samples	0
was	0
positive	0
(	0
at	0
a	0
low	0
level	0
)	0
for	0
adenovirus	1
DNA	2
by	0
nested	0
PCR	0
assay	0
.	0

In	0
comparison	0
,	0
PBMC	7
from	0
two	0
children	0
with	0
fatal	0
adenoviral	0
infection	0
were	0
both	0
strongly	0
positive	0
for	0
adenovirus	1
DNA	2
.	0

It	0
is	0
concluded	0
that	0
,	0
in	0
contrast	0
to	0
a	0
previous	0
study	0
,	0
PBMC	7
are	0
not	0
a	0
common	0
site	0
of	0
persistent	0
group	0
C	0
adenoviral	0
infection	0
.	0

In	0
addition	0
,	0
assay	0
of	0
PBMC	7
by	0
the	0
adenovirus-specific	0
PCR	0
may	0
help	0
detect	0
early	0
invasive	0
disease	0
and	0
warrants	0
further	0
evaluation	0
.	0

Tumor	9
necrosis	10
factor	10
receptor	10
expression	0
and	0
signal	0
transduction	0
in	0
HIV-1-infected	7
cells	8
.	0

OBJECTIVE	0
:	0
To	0
examine	0
the	0
inter-relationship	0
between	0
HIV-1	0
infection	0
and	0
the	0
cell	0
surface	0
receptors	0
for	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
,	0
an	0
immunoregulatory	0
cytokine	0
that	0
can	0
enhance	0
HIV-1	0
replication	0
.	0

DESIGN	0
:	0
Infected	0
promyelocytic	7
and	0
promonocytic	7
cells	8
were	0
examined	0
because	0
they	0
normally	0
express	0
both	0
types	0
of	0
TNF	9
receptors	10
.	0

METHODS	0
:	0
TNF	9
receptor	0
surface	0
expression	0
was	0
determined	0
by	0
specific	0
monoclonal	9
antibody	10
recognition	0
and	0
flow	0
cytometry	0
,	0
and	0
signal	0
transduction	0
was	0
detected	0
by	0
gel	0
shift	0
analysis	0
.	0

HIV-1	0
activation	0
and	0
expression	0
was	0
quantitated	0
by	0
reverse	9
transcriptase	10
assay	0
.	0

RESULTS	0
:	0
In	0
the	0
OM-10.1	0
promyelocytic	0
model	0
of	0
chronic	0
infection	0
,	0
TNF-alpha-induced	0
HIV-1	0
expression	0
also	0
resulted	0
in	0
a	0
substantial	0
increase	0
in	0
75	9
kd	10
TNF	10
receptor	10
(	0
TR75	9
)	0
expression	0
although	0
55	9
kD	10
TNF	10
receptor	10
(	0
TR55	9
)	0
levels	0
were	0
not	0
dramatically	0
altered	0
.	0

A	0
series	0
of	0
uninfected	5
parental	6
HL-60	6
subclones	6
all	0
reduced	0
TR75	9
surface	0
expression	0
in	0
response	0
to	0
TNF-alpha	9
treatment	0
.	0

Enhanced	0
TR75	9
expression	0
on	0
OM-10.1	0
cells	0
followed	0
the	0
same	0
TNF-alpha	9
-dose	0
dependency	0
as	0
that	0
observed	0
for	0
HIV-1	0
production	0
.	0

An	0
increase	0
in	0
TR75	9
expression	0
was	0
also	0
evident	0
during	0
the	0
peak	0
of	0
an	0
acute	0
HIV-1	0
infection	0
of	0
HL-60	5
promyelocytes	6
.	0

Although	0
TR55	9
expression	0
was	0
unaltered	0
during	0
TNF-alpha	9
-induced	0
HIV	0
activation	0
,	0
this	0
receptor	0
was	0
still	0
involved	0
in	0
the	0
viral	0
activation	0
process	0
.	0

Antibody	0
cross-linking	0
of	0
TR55	9
,	0
in	0
the	0
absence	0
of	0
exogenous	9
TNF-alpha	10
,	0
induced	0
maximal	0
HIV-1	0
expression	0
,	0
an	0
up-modulation	0
of	0
surface	0
TR75	9
,	0
and	0
nuclear	0
NF-kappa	9
B	10
activity	0
in	0
OM-10.1	0
cultures	0
.	0

Surprisingly	0
,	0
this	0
was	0
the	0
case	0
even	0
when	0
an	0
antagonistic	9
anti-TR55	10
antibody	10
was	0
used	0
.	0

Anti-TR55	9
antibody	10
cross-linking	0
in	0
chronically	5
infected	6
U1	6
promonocytic	6
cultures	6
could	0
only	0
partially	0
substitute	0
for	0
TNF-alpha-induced	0
HIV-1	0
expression	0
.	0

CONCLUSIONS	0
:	0
Our	0
results	0
demonstrated	0
that	0
HIV-1	0
infection	0
can	0
selectively	0
influence	0
the	0
surface	0
expression	0
of	0
TNF	9
receptors	10
,	0
potentially	0
influencing	0
its	0
own	0
expression	0
and	0
altering	0
normal	0
immunoregulatory	9
signal	0
transduction	0
.	0

Comparative	0
mapping	0
of	0
SRY	1
in	0
the	0
great	0
apes	0
.	0

Cytogenetic	0
studies	0
of	0
the	0
primate	1
Y	2
chromosomes	2
have	0
suggested	0
that	0
extensive	0
rearrangements	0
have	0
occurred	0
during	0
evolution	0
of	0
the	0
great	0
apes	0
.	0

We	0
have	0
used	0
in	0
situ	0
hybridization	0
to	0
define	0
these	0
rearrangements	0
at	0
the	0
molecular	0
level	0
.	0

pHU-14	1
,	0
a	0
probe	0
including	0
sequences	0
from	0
the	0
sex	1
determining	2
gene	2
SRY	2
,	0
hybridizes	0
close	0
to	0
the	0
early	0
replicating	0
pseudoautosomal	0
segment	0
in	0
a	0
telomeric	0
or	0
subtelomeric	0
position	0
of	0
the	0
Y	1
chromosomes	2
of	0
all	0
great	0
apes	0
.	0

The	0
low	1
copy	2
repeat	2
detected	0
by	0
the	0
probe	0
Fr35-II	1
is	0
obviously	0
included	0
in	0
Y	0
chromosomal	0
rearrangements	0
during	0
hominid	0
evolution	0
.	0

These	0
results	0
,	0
combined	0
with	0
previous	0
studies	0
,	0
suggest	0
that	0
the	0
Y	0
chromosome	0
in	0
great	0
apes	0
has	0
a	0
conserved	0
region	0
including	0
the	0
pseudoautosomal	1
region	2
and	0
the	0
testis-determining	0
region	0
.	0

The	0
rest	0
of	0
the	0
Y	1
chromosome	2
has	0
undergone	0
several	0
rearrangements	0
in	0
the	0
different	0
great	0
apes	0
.	0

Calcium	0
dependent	0
activation	0
of	0
the	0
NF-AT	9
transcription	10
factor	10
by	0
p59fyn	9
.	0

A	0
reporter	1
gene	2
under	0
the	0
control	0
of	0
a	0
T-cell	1
antigen	2
receptor	2
element	2
was	0
activated	0
in	0
Jurkat	5
cells	6
by	0
antigen	0
receptor	0
triggering	0
or	0
by	0
a	0
combination	0
of	0
phorbol	0
myristate	0
acetate	0
,	0
which	0
activates	0
protein	9
kinase	10
C	10
,	0
and	0
a	0
calcium	0
ionophore	0
.	0

Both	0
these	0
signals	0
were	0
necessary	0
for	0
expression	0
of	0
the	0
reporter	1
gene	2
.	0

When	0
co-transfected	0
with	0
a	0
construct	0
capable	0
of	0
overexpressing	0
the	0
tyrosine	9
kinase	10
p59fyn	9
,	0
the	0
reporter	1
gene	2
was	0
activated	0
by	0
PMA	9
alone	0
.	0

Thus	0
p59fyn	9
could	0
replace	0
the	0
calcium	0
ionophore	0
but	0
not	0
activation	0
of	0
protein	9
kinase	10
C	10
.	0

The	0
activation	0
by	0
p59fyn	9
plus	0
PMA	9
was	0
blocked	0
by	0
EGTA	0
and	0
by	0
the	0
immunosuppressant	0
drug	0
cyclosporin	0
A	0
.	0

Dependence	0
for	0
the	0
proliferative	0
response	0
to	0
erythropoietin	9
on	0
an	0
established	0
erythroid	0
differentiation	0
program	0
in	0
a	0
human	5
hematopoietic	6
cell	6
line	6
,	0
UT-7	5
.	0

Erythroid	0
differentiation	0
involves	0
the	0
activation	0
of	0
a	0
number	0
of	0
erythroid-specific	0
genes	0
,	0
most	0
of	0
which	0
,	0
including	0
the	0
globin	1
genes	2
and	0
the	0
erythropoietin	1
receptor	2
(	2
Epo-R	2
)	2
gene	2
,	0
are	0
,	0
at	0
least	0
in	0
part	0
,	0
regulated	0
by	0
the	0
transcription	9
factor	10
GATA-1	9
.	0

In	0
order	0
to	0
understand	0
the	0
relationship	0
,	0
if	0
any	0
,	0
between	0
expression	0
of	0
GATA-1	9
,	0
response	0
to	0
Epo	0
and	0
erythroid	0
differentiation	0
,	0
we	0
analyzed	0
the	0
expression	0
of	0
GATA-1	9
,	0
Epo-R	9
and	0
globin	1
genes	2
in	0
an	0
Epo-dependent	0
human	0
cell	0
line	0
,	0
UT-7	5
Epo	0
.	0

The	0
results	0
were	0
compared	0
to	0
those	0
obtained	0
with	0
the	0
parental	5
granulocyte-macrophage	6
colony-stimulating	6
factor	6
(	6
GM-CSF	6
)	6
-dependent	6
cell	6
line	6
,	0
UT-7	5
,	0
which	0
has	0
a	0
predominantly	0
megakaryoblastic	0
phenotype	0
and	0
is	0
unable	0
to	0
proliferate	0
continuously	0
in	0
the	0
presence	0
of	0
Epo	9
.	0

UT-7	9
Epo	10
and	0
UT-7	5
expressed	0
similar	0
levels	0
of	0
GATA-1	3
mRNA	4
and	0
binding	0
activity	0
.	0

The	0
two	0
lines	0
also	0
expressed	0
comparable	0
levels	0
of	0
Epo-R	3
mRNA	4
while	0
the	0
number	0
of	0
Epo	9
-binding	0
sites	0
on	0
UT-7	5
Epo	6
cells	6
was	0
one-sixth	0
the	0
number	0
of	0
UT-7	5
cells	6
(	0
2400	0
+/-	0
3	0
vs.	0
13	0
,	0
800	0
+/-	0
300	0
)	0
.	0

This	0
difference	0
in	0
the	0
number	0
of	0
binding	0
sites	0
could	0
be	0
due	0
to	0
differences	0
in	0
cell	0
surface	0
(	0
UT-7	5
cells	6
are	0
20	0
%	0
smaller	0
than	0
the	0
parental	0
UT-7	5
cells	6
)	0
or	0
in	0
receptor	0
turnover	0
.	0

By	0
Northern	0
analysis	0
,	0
UT-7	5
cells	6
expressed	0
detectable	0
levels	0
of	0
beta-	9
and	10
gamma-globin	10
but	0
not	0
alpha-globin	9
.	0

In	0
comparison	0
,	0
UT-7	5
Epo	6
cells	6
expressed	0
alpha-globin	0
and	0
higher	0
levels	0
of	0
gamma-globin	9
(	0
5-fold	0
)	0
and	0
beta-globin	9
(	0
from	0
barely	0
to	0
clearly	0
detectable	0
)	0
.	0

Globin	9
chains	10
(	0
alpha	9
,	0
beta	9
and	0
gamma	9
)	0
were	0
clearly	0
detectable	0
by	0
affinity	0
chromatography	0
in	0
UT-7	9
Epo	10
but	0
not	0
in	0
UT-7	5
cells	6
.	0

The	0
frequency	0
of	0
the	0
cells	0
which	0
expressed	0
beta-	1
and	2
gamma-	2
globin	2
genes	2
in	0
the	0
two	0
cell	0
populations	0
was	0
measured	0
by	0
immunofluorescence	0
with	0
beta-	9
and	10
gamma-specific	10
antibodies	10
.	0

The	0
number	0
of	0
gamma-positive	5
cells	6
and	0
their	0
fluorescence	0
intensity	0
were	0
higher	0
in	0
UT-7	9
Epo	10
than	0
in	0
UT-7	5
cells	6
(	0
0	0
to	0
17	0
%	0
barely	0
positive	0
cells	0
and	0
23	0
to	0
40	0
%	0
clearly	0
positive	0
cells	0
,	0
respectively	0
)	0
,	0
indicating	0
that	0
the	0
increase	0
in	0
globin	3
mRNA	4
observed	0
in	0
UT-7	9
Epo	10
is	0
due	0
to	0
both	0
an	0
increase	0
of	0
gene	0
expression	0
per	0
cell	0
and	0
an	0
increase	0
in	0
numbers	0
of	0
cells	0
containing	0
gamma-globin	9
.	0

The	0
levels	0
of	0
GATA-1	9
,	0
Epo-R	9
and	0
globin	3
mRNA	4
expressed	0
were	0
not	0
affected	0
by	0
a	0
24-hour	0
incubation	0
of	0
either	0
cell	0
line	0
with	0
Epo	9
,	0
GM-CSF	9
or	0
interleukin-3	9
(	0
IL-3	9
)	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
400	0
WORDS	0
)	0

The	0
Sp1	9
transcription	10
factor	10
binds	0
the	0
CD11b	1
promoter	2
specifically	0
in	0
myeloid	0
cells	0
in	0
vivo	0
and	0
is	0
essential	0
for	0
myeloid-specific	1
promoter	2
activity	0
.	0

The	0
myeloid	9
integrin	10
CD11b	10
is	0
expressed	0
selectively	0
on	0
the	0
surface	0
of	0
mature	7
macrophages	8
,	0
monocytes	7
,	0
neutrophils	7
,	0
and	0
natural	7
killer	8
cells	8
.	0

Lineage-specific	0
expression	0
is	0
controlled	0
at	0
the	0
level	0
of	0
mRNA	0
transcription	0
.	0

Recent	0
isolation	0
of	0
the	0
CD11b	1
promoter	2
shows	0
that	0
92	0
base	0
pairs	0
(	0
bp	0
)	0
of	0
5'-flanking	1
DNA	2
are	0
sufficient	0
to	0
direct	0
myeloid-specific	0
expression	0
of	0
a	0
reporter	1
gene	2
.	0

To	0
characterize	0
regulatory	0
sequences	0
important	0
for	0
promoter	0
activity	0
,	0
we	0
performed	0
linker	0
scanning	0
analysis	0
of	0
the	0
92-bp	1
CD11b	2
promoter	2
and	0
demonstrate	0
that	0
a	0
sequence	0
at	0
bp	0
-60	0
is	0
essential	0
for	0
CD11b	1
promoter	2
activity	0
.	0

We	0
show	0
that	0
this	0
sequence	0
binds	0
the	0
transcription	9
factor	10
Sp1	9
in	0
vitro	0
and	0
in	0
vivo	0
.	0

In	0
vivo	0
the	0
Sp1	1
site	2
is	0
bound	0
only	0
in	0
myeloid	5
(	6
U937	6
)	6
cells	6
,	0
not	0
in	0
cervical	5
carcinoma	6
(	6
HeLa	6
)	6
cells	6
.	0

In	0
addition	0
,	0
the	0
macrophage	0
transcription	9
factor	10
PU.1	0
binds	0
the	0
CD11b	1
promoter	2
in	0
vitro	0
and	0
in	0
vivo	0
close	0
to	0
the	0
Sp1	1
site	2
.	0

We	0
propose	0
a	0
model	0
in	0
which	0
binding	0
of	0
a	0
myeloid-specific	9
factor	10
(	0
PU.1	9
)	0
allows	0
a	0
general	0
factor	0
(	0
Sp1	9
)	0
to	0
bind	0
in	0
a	0
tissue-specific	0
fashion	0
thereby	0
contributing	0
to	0
the	0
myeloid-specific	0
expression	0
of	0
CD11b	5
.	0

Transcription	0
factor	0
jun-B	0
is	0
target	0
of	0
autoreactive	7
T-cells	8
in	0
IDDM	0
.	0

Target	0
antigens	0
defined	0
by	0
autoantibodies	9
in	0
IDDM	0
include	0
insulin	0
,	0
a	0
putative	0
glycolipid	0
that	0
reacts	0
with	0
islet	9
cell	10
antibodies	10
,	0
and	0
a	0
64	9
,	10
000-M	10
(	10
r	10
)	10
protein	10
recently	0
identified	0
as	0
glutamic	9
acid	10
decarboxylase	10
.	0

In	0
addition	0
,	0
some	0
IDDM	0
sera	0
that	0
contain	0
antibodies	9
to	0
glutamic	9
acid	10
decarboxylase	10
also	0
coprecipitate	0
a	0
38	9
,	10
000-M	10
(	10
r	10
)	10
protein	10
from	0
islets	0
.	0

This	0
study	0
used	0
a	0
high	0
titer	0
anti-38	0
,	0
000-M	0
(	0
r	0
)	0
serum	0
to	0
screen	0
bacteriophage	1
lambda	2
cDNA	2
expression	0
libraries	0
and	0
identified	0
human	7
islet	8
and	0
placental	5
clones	6
encoding	0
jun-B	9
,	0
the	0
nuclear	9
transcription	10
protein	10
,	0
of	0
predicted	0
38	0
,	0
000	0
M	0
(	0
r	0
)	0
.	0

Peripheral	7
blood	8
T-cells	8
exhibited	0
significant	0
proliferation	0
in	0
response	0
to	0
a	0
recombinant	0
fragment	0
of	0
jun-B	9
(	0
amino	0
acids	0
1-180	0
)	0
in	0
12	0
of	0
17	0
(	0
71	0
%	0
)	0
recent-onset	0
IDDM	0
subjects	0
,	0
8	0
of	0
16	0
(	0
50	0
%	0
)	0
ICA-positive	0
first-degree	0
relatives	0
of	0
IDDM	0
subjects	0
who	0
were	0
at	0
risk	0
,	0
3	0
of	0
12	0
(	0
25	0
%	0
)	0
other	0
autoimmune	0
disease	0
subjects	0
,	0
and	0
0	0
of	0
10	0
healthy	0
control	0
subjects	0
.	0

Proliferation	0
to	0
tetanus	0
toxoid	0
did	0
not	0
differ	0
significantly	0
between	0
the	0
groups	0
.	0

Responses	0
to	0
jun-B	9
were	0
not	0
related	0
to	0
age	0
,	0
sex	0
,	0
or	0
human	9
leukocyte	10
antigen	10
status	0
.	0

Thus	0
,	0
autoreactive	7
T-cells	8
identify	0
a	0
novel	9
antigen	10
,	0
p38	9
jun-B	10
,	0
in	0
IDDM	0
and	0
appear	0
to	0
indicate	0
subjects	0
at	0
risk	0
for	0
the	0
development	0
of	0
clinical	0
disease	0
.	0

Stimulation	0
of	0
interleukin-1	9
alpha	10
and	0
interleukin-1	9
beta	10
production	0
in	0
human	7
monocytes	8
by	0
protein	0
phosphatase	0
1	0
and	0
2A	0
inhibitors	0
.	0

Protein	9
phosphatases	10
1	10
and	10
2A	10
are	0
important	0
in	0
regulating	0
cellular	0
functions	0
by	0
controlling	0
the	0
phosphorylation	0
state	0
of	0
their	0
substrates	0
.	0

In	0
human	7
monocytes	8
,	0
the	0
inhibitors	0
of	0
these	0
phosphatases	9
,	0
okadaic	0
acid	0
and	0
calyculin	0
A	0
,	0
were	0
found	0
to	0
increase	0
the	0
mRNA	0
accumulation	0
and	0
cytokine	0
production	0
of	0
interleukin-1	9
beta	10
and	0
interleukin-1	9
alpha	10
.	0

The	0
increased	0
mRNA	3
accumulation	0
was	0
found	0
to	0
be	0
primarily	0
because	0
of	0
the	0
increase	0
in	0
the	0
transcription	0
rate	0
of	0
the	0
interleukin-1	1
genes	2
.	0

Stimulation	0
of	0
interleukin-1	1
gene	2
transcription	0
may	0
be	0
caused	0
by	0
the	0
stimulation	0
of	0
transcription	9
factor	10
activities	0
,	0
including	0
those	0
of	0
AP-1	9
,	0
by	0
these	0
protein	9
phosphatase	10
inhibitors	0
.	0

Okadaic	0
acid	0
increased	0
the	0
synthesis	0
of	0
the	0
interleukin-1	9
beta	10
precursor	0
and	0
mature	0
forms	0
and	0
their	0
secretion	0
.	0

This	0
increased	0
processing	0
and	0
secretion	0
correlated	0
with	0
the	0
stimulation	0
of	0
IL-1	3
beta	4
convertase	4
mRNA	4
accumulation	0
.	0

The	0
stimulation	0
of	0
interleukin-1	9
alpha	10
production	0
by	0
okadaic	0
acid	0
was	0
more	0
modest	0
than	0
that	0
of	0
interleukin-1	9
beta	10
.	0

However	0
,	0
the	0
phosphorylation	0
of	0
the	0
precursor	9
interleukin-1	10
alpha	10
cytokine	10
was	0
increased	0
.	0

These	0
results	0
show	0
that	0
protein	0
phosphatase	0
1	0
and	0
2A	0
inhibitors	0
exert	0
multiple	0
effects	0
on	0
cytokine	0
production	0
in	0
human	7
monocytes	8
and	0
suggest	0
that	0
these	0
two	0
phosphatases	9
play	0
important	0
roles	0
in	0
regulating	0
interleukin-1	9
production	0
.	0

The	0
interleukin	9
2	10
CD28-responsive	10
complex	10
contains	0
at	0
least	0
three	0
members	0
of	0
the	0
NF	9
kappa	10
B	10
family	10
:	0
c-Rel	9
,	0
p50	9
,	0
and	0
p65	9
.	0

Optimal	0
activation	0
of	0
T	7
cells	8
requires	0
at	0
least	0
two	0
signals	0
.	0

One	0
signal	0
can	0
be	0
delivered	0
by	0
the	0
antigen-specific	9
T-cell	10
receptor	10
,	0
and	0
the	0
second	0
signal	0
is	0
provided	0
by	0
the	0
costimulatory	0
molecule	0
(	0
s	0
)	0
delivered	0
by	0
the	0
antigen-presenting	7
cell	8
.	0

CD28	9
is	0
a	0
T-cell	9
surface	10
molecule	10
and	0
stimulation	0
through	0
this	0
protein	0
plays	0
an	0
important	0
role	0
in	0
delivering	0
the	0
second	0
activation	0
signal	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
in	0
human	7
peripheral	8
blood	8
T	8
cells	8
,	0
CD28	9
-mediated	0
signal	0
transduction	0
involves	0
the	0
rel	9
family	10
proteins	10
--	0
c-Rel	9
,	0
p50	9
,	0
and	0
p65	9
.	0

Treatment	0
of	0
peripheral	7
blood	8
T	8
cells	8
with	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
anti-CD28	9
monoclonal	10
antibody	10
(	0
mAb	9
)	0
results	0
in	0
augmentation	0
of	0
nuclear	9
c-Rel	10
,	0
p50	9
,	0
and	0
p65	9
,	0
and	0
this	0
augmentation	0
can	0
occur	0
in	0
the	0
presence	0
of	0
the	0
immunosuppressant	0
cyclosporin	0
A	0
.	0

It	0
is	0
also	0
shown	0
in	0
this	0
report	0
that	0
,	0
in	0
response	0
to	0
PMA/anti-CD28	9
mAb	10
or	0
anti-CD3/anti-CD28	9
mAb	10
,	0
c-Rel	9
,	0
p50	9
,	0
and	0
p65	9
are	0
associated	0
with	0
CD28-responsive	1
element	2
present	0
in	0
the	0
promoter	1
of	0
the	0
human	1
interleukin	2
2	2
gene	2
.	0

The	0
functional	0
significance	0
of	0
c-Rel	9
involvement	0
in	0
the	0
CD28-responsive	9
complex	10
is	0
demonstrated	0
by	0
transient	0
transfection	0
analysis	0
,	0
where	0
cotransfection	0
of	0
c-Rel	9
augments	0
the	0
level	0
of	0
expression	0
of	0
a	0
chloramphenicol	1
acetyltransferase	2
reporter	2
gene	2
linked	0
to	0
the	0
CD28-responsive	1
element	2
.	0

Expression	0
of	0
tal-1	9
and	0
GATA-binding	9
proteins	10
during	0
human	0
hematopoiesis	0
.	0

Tal-1	9
rearrangements	0
are	0
associated	0
with	0
nearly	0
30	0
%	0
of	0
human	0
T	0
acute	0
lymphoblastic	0
leukemia	0
.	0

Tal-1	1
gene	2
encodes	0
a	0
putative	0
transcription	9
factor	10
with	0
a	0
basic	9
helix-loop-helix	10
domain	10
and	0
is	0
known	0
to	0
be	0
predominantly	0
expressed	0
in	0
hematopoietic	7
cells	8
.	0

We	0
investigated	0
the	0
pattern	0
of	0
tal-1	9
expression	0
in	0
purified	7
human	8
hematopoietic	8
cells	8
by	0
in	0
situ	0
hybridization	0
and	0
reverse	9
transcriptase	10
polymerase	10
chain	0
reaction	0
analysis	0
.	0

Both	0
methods	0
demonstrated	0
that	0
the	0
tal-1	9
gene	0
is	0
expressed	0
in	0
megakaryocytes	0
and	0
erythroblasts	0
as	0
well	0
as	0
in	0
basophilic	7
granulocytes	8
.	0

In	0
addition	0
,	0
our	0
results	0
indicate	0
that	0
the	0
tal-1	1
1A	2
promoter	2
,	0
which	0
contains	0
two	0
consensus	0
GATA-binding	1
sites	2
,	0
is	0
active	0
mainly	0
in	0
these	0
lineages	0
.	0

Because	0
the	0
GATA-1	1
gene	2
is	0
known	0
to	0
transactivate	0
several	0
genes	0
specific	0
for	0
the	0
erythroid	7
,	8
megakaryocytic	8
,	8
and	8
mastocytic/basophilic	8
lineages	8
,	0
we	0
studied	0
GATA-1	9
expression	0
in	0
these	0
purified	0
hematopoietic	7
cells	8
.	0

We	0
found	0
that	0
GATA-1	1
and	2
tal-1	2
genes	2
are	0
coexpressed	0
in	0
these	0
three	0
lineages	0
.	0

Remarkably	0
,	0
the	0
expression	0
of	0
both	0
genes	0
is	0
downmodulated	0
during	0
erythroid	0
and	0
megakaryocytic	0
terminal	0
maturation	0
.	0

In	0
immature	7
hematopoietic	8
cells	8
,	0
tal-1	1
and	2
GATA-1	2
genes	2
are	0
coexpressed	0
in	0
committed	7
progenitors	8
cells	8
(	0
CD34+/CD38	5
(	6
2+	6
)	6
)	0
,	0
whereas	0
they	0
are	0
not	0
detectable	0
in	0
the	0
most	0
primitive	7
cells	8
(	0
CD34	5
(	6
2+	6
)	6
/CD38-	6
)	0
.	0

In	0
contrast	0
,	0
GATA-2	9
is	0
strongly	0
expressed	0
in	0
both	0
most	7
primitive	8
and	8
committed	8
progenitors	8
cells	8
,	0
whereas	0
GATA-3	9
is	0
mostly	0
detected	0
in	0
most	0
primitive	0
ones	0
.	0

Altogether	0
our	0
results	0
strongly	0
suggest	0
that	0
GATA-1	9
modulates	0
the	0
transcription	0
of	0
tal-1	9
during	0
the	0
differentiation	0
of	0
the	0
erythroid	7
,	8
megakaryocytic	8
,	8
and	8
basosophilic	8
lineages	8
.	0

The	0
lytic	0
transition	0
of	0
Epstein-Barr	0
virus	0
is	0
imitated	0
by	0
recombinant	5
B-cells	6
.	0

Lytic	0
transition	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
initiated	0
by	0
distinct	0
immediate	0
early	0
regulators	0
of	0
the	0
viral	0
cycle	0
,	0
in	0
synchronization	0
to	0
temporary	0
,	0
permissive	0
conditions	0
during	0
host	0
cell	0
differentiation	0
.	0

We	0
developed	0
eukaryotic	0
vectors	0
suitable	0
to	0
imitate	0
the	0
processes	0
involved	0
in	0
lytic	0
transition	0
in	0
cell	0
culture	0
systems	0
.	0

Two	0
stable	0
B	5
cell	6
lines	6
were	0
established	0
:	0
R59Z	5
activator	6
cells	6
were	0
used	0
to	0
induce	0
lytic	0
EBV	0
expression	0
in	0
a	0
constitutive	0
manner	0
by	0
the	0
production	0
of	0
the	0
BZLF	9
1	10
trans-activator	10
(	0
Zta	9
)	0
.	0

R7-57	5
reporter	6
cells	6
,	0
on	0
the	0
other	0
hand	0
,	0
signaled	0
induced	0
activity	0
of	0
the	0
lytic	1
origin	2
of	2
EBV	2
replication	2
(	0
ori	1
Lyt	2
)	0
.	0

Different	0
modes	0
,	0
like	0
chemical	0
induction	0
,	0
lytic	0
superinfection	0
with	0
EBV	0
and	0
single	0
gene	0
trans-activation	0
converted	0
the	0
recombinant	1
ori	2
Lyt	2
element	2
in	0
R7-57	5
reporter	6
cells	6
.	0

BZLF	9
1	10
,	0
transiently	0
expressed	0
in	0
R7-57	5
reporter	6
cells	6
,	0
was	0
the	0
only	0
EBV	9
trans-activator	10
found	0
,	0
sufficient	0
in	0
inducing	0
the	0
viral	0
lytic	0
cycle	0
.	0

Basing	0
on	0
these	0
experiments	0
,	0
trans-cellular	0
activation	0
of	0
EBV	0
was	0
tested	0
by	0
cocultivation	0
of	0
BZLF	7
1-expressing	8
R59Z	8
activator	8
cells	8
with	0
the	0
R7-57	5
reporter	6
line	6
.	0

No	0
lytic	0
effect	0
on	0
the	0
reporter	0
cells	0
could	0
be	0
measured	0
,	0
neither	0
by	0
cocultivation	0
of	0
activator	5
cells	6
nor	0
by	0
coincubation	0
of	0
BZLF	9
1	10
-containing	0
cell	0
lysates	0
.	0

Latency	0
breaking	0
activity	0
,	0
however	0
,	0
was	0
transferred	0
from	0
activator	5
to	0
reporter	5
cells	6
when	0
active	0
,	0
exogenous	0
virus	0
was	0
added	0
.	0

The	0
cell	0
system	0
described	0
in	0
these	0
experiments	0
provides	0
a	0
tool	0
for	0
the	0
detection	0
of	0
EBV	0
reactivation	0
and	0
demonstrates	0
the	0
potential	0
of	0
the	0
lytic	0
regulatory	1
gene	2
BZLF	2
1	2

Costimulation	0
of	0
cAMP	0
and	0
protein	9
kinase	10
C	10
pathways	0
inhibits	0
the	0
CD3	9
-dependent	0
T	0
cell	0
activation	0
and	0
leads	0
to	0
a	0
persistent	0
expression	0
of	0
the	0
AP-1	9
transcription	10
factor	10
.	0

The	0
effects	0
mediated	0
by	0
a	0
combined	0
stimulation	0
of	0
cAMP	0
-and	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
-dependent	0
pathways	0
have	0
been	0
investigated	0
in	0
different	0
cellular	0
systems	0
,	0
and	0
it	0
has	0
been	0
shown	0
that	0
they	0
may	0
complement	0
each	0
other	0
in	0
activating	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
upon	0
the	0
stimulation	0
of	0
both	0
pathways	0
T	7
lymphocytes	8
became	0
refractory	0
to	0
activation	0
via	0
the	0
CD3/T	9
cell	10
receptor	10
(	0
TcR	9
)	0
complex	0
.	0

T	7
cells	8
preincubated	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
dibutyryl	0
cAMP	0
(	0
Bt2cAMP	0
)	0
displayed	0
a	0
deficient	0
proliferative	0
ability	0
in	0
response	0
to	0
anti-CD3	9
mAb	10
stimulation	0
,	0
whereas	0
lymphocytes	7
treated	0
individually	0
with	0
either	0
Bt2cAMP	0
or	0
PMA	0
responded	0
comparably	0
to	0
untreated	0
samples	0
.	0

We	0
detected	0
an	0
association	0
between	0
the	0
reduced	0
mitogenic	0
response	0
and	0
low	0
expression	0
of	0
both	0
interleukin-2	9
(	0
IL-2	9
)	0
and	0
the	0
alpha	9
chain	10
(	0
CD25	9
)	0
of	0
the	0
IL-2	9
receptor	10
(	0
IL-2R	9
)	0
.	0

Analysis	0
of	0
intracellular	0
Ca2+	0
mobilization	0
suggested	0
that	0
the	0
CD3	9
/	0
TcR	9
-dependent	0
signal	0
transduction	0
was	0
impaired	0
in	0
PMA/Bt2cAMP-treated	5
cells	6
.	0

Remarkably	0
,	0
we	0
observed	0
that	0
these	0
samples	0
displayed	0
a	0
persistent	0
expression	0
of	0
the	0
c-fos	1
protooncogene	2
,	0
associated	0
to	0
an	0
increased	0
AP-1	9
DNA-binding	0
activity	0
,	0
whereas	0
no	0
variations	0
of	0
CREB	9
or	0
NF-kB	9
were	0
detected	0
.	0

Neither	0
Bt2cAMP	0
nor	0
PMA	0
individually	0
mediated	0
these	0
sustained	0
effects	0
,	0
which	0
therefore	0
appear	0
as	0
a	0
consequence	0
of	0
the	0
interplay	0
between	0
both	0
metabolic	0
stimuli	0
.	0

Altogether	0
,	0
the	0
data	0
provide	0
the	0
evidence	0
that	0
both	0
pathways	0
complement	0
each	0
other	0
in	0
regulating	0
gene	0
expression	0
and	0
,	0
conversely	0
,	0
downregulate	0
the	0
TcR	9
transduction	0
mechanisms	0
.	0

The	0
lymphotoxin	1
promoter	2
is	0
stimulated	0
by	0
HTLV-I	9
tax	10
activation	0
of	0
NF-kappa	9
B	10
in	0
human	5
T-cell	6
lines	6
.	0

The	0
HTLV-I	9
transcriptional	10
activator	10
tax	10
was	0
used	0
to	0
gain	0
insight	0
into	0
the	0
mechanism	0
of	0
lymphotoxin	1
(	2
LT	2
;	2
TNF-beta	2
)	2
gene	2
induction	0
.	0

Tax-expressing	5
cell	6
lines	6
produce	0
LT	9
biologic	0
activity	0
.	0

An	0
LT	1
promoter	2
(	2
LT-293	2
)	2
CAT	2
construct	2
that	0
contained	0
an	0
NF-kappa	1
B	2
site	2
was	0
active	0
in	0
the	0
LT-producing	5
C81-66-45	6
cell	6
line	6
,	0
which	0
contains	0
defective	0
HTLV-I	0
but	0
expresses	0
tax	9
.	0

The	0
observation	0
that	0
a	0
mutated	1
LT-kappa	2
B	2
construct	2
(	0
M1-CAT	1
)	0
was	0
inactive	0
in	0
C81-66-45	5
,	0
confirmed	0
the	0
importance	0
of	0
NF-kappa	9
B	10
in	0
LT	9
gene	0
expression	0
.	0

Tax	9
was	0
transfected	0
into	0
HTLV-I-negative	5
human	6
T-cell	6
lines	6
.	0

Jurkat	5
T	6
cells	6
stably	0
expressing	0
tax	9
contained	0
elevated	0
levels	0
of	0
NF-kappa	9
B	10
that	0
directly	0
bound	0
to	0
the	0
LT-kappa	1
B	2
site	2
.	0

Tax	9
co-transfected	0
with	0
reporter	1
constructs	2
into	0
Jurkat	5
cells	6
maximally	0
activated	0
HTLV-I-LTR-CAT	9
and	0
kappa	9
B-fos-CAT	10
and	0
also	0
activated	0
LT-293	1
to	0
a	0
lesser	0
extent	0
.	0

In	0
JM	5
T	6
cells	6
,	0
tax	9
induced	0
LT-293	1
activity	0
by	0
two-	0
to	0
four-fold	0
,	0
though	0
there	0
was	0
no	0
induction	0
of	0
M1-CAT	9
.	0

The	0
increase	0
in	0
LT-293	1
CAT	9
activity	0
mirrored	0
the	0
increase	0
in	0
LT	9
biologic	0
activity	0
seen	0
under	0
these	0
conditions	0
.	0

These	0
studies	0
,	0
the	0
first	0
to	0
demonstrate	0
induction	0
of	0
LT	1
promoter	2
activity	0
over	0
basal	0
levels	0
,	0
indicate	0
that	0
HTLV-I	9
tax	10
causes	0
low-level	0
activation	0
of	0
both	0
endogenous	0
LT	9
and	0
the	0
LT	1
promoter	2
,	0
at	0
least	0
in	0
part	0
through	0
activation	0
of	0
NF-kappa	9
B	10
.	0

A	0
concatenated	0
form	0
of	0
Epstein-Barr	1
viral	2
DNA	2
in	0
lymphoblastoid	5
cell	6
lines	6
induced	0
by	0
transfection	0
with	0
BZLF1	9
.	0

The	0
replicative	0
form	0
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
DNA	0
was	0
studied	0
using	0
two	0
lymphoblastoid	5
cell	6
lines	6
,	0
X50-7	0
and	0
6F11	0
,	0
which	0
are	0
latently	0
infected	0
by	0
Epstein-Barr	0
virus	0
.	0

The	0
lytic	0
cycle	0
of	0
EBV	0
infection	0
was	0
induced	0
by	0
transfection	0
of	0
the	0
cells	0
with	0
the	0
BRLF1/BZLF1	1
coding	2
region	2
of	0
the	0
P3HR-1	1
defective	2
genome	2
.	0

We	0
combined	0
two	0
techniques	0
to	0
identify	0
the	0
productive	0
replicative	0
form	0
of	0
Epstein-Barr	1
viral	2
DNA	2
in	0
the	0
lytic	5
cycle-induced	6
cells	6
.	0

Restriction	0
enzyme	0
analysis	0
followed	0
by	0
Southern	0
blot	0
hybridization	0
identified	0
a	0
significant	0
increase	0
in	0
the	0
fused	0
fragment	0
encompassing	0
both	0
ends	0
of	0
EBV	1
DNA	2
.	0

This	0
indicates	0
an	0
increase	0
in	0
either	0
episomal	1
DNA	2
or	0
concatameric	1
linear	2
DNA	2
.	0

Southern	0
blot	0
analysis	0
of	0
in	0
situ	0
lysing	0
gels	0
revealed	0
that	0
the	0
cellular	0
content	0
of	0
linear	1
EBV	2
DNA	2
was	0
also	0
increased	0
significantly	0
after	0
the	0
initiation	0
of	0
the	0
viral	0
lytic	0
cycle	0
,	0
while	0
the	0
amount	0
of	0
circular	0
DNA	0
remained	0
approximately	0
constant	0
.	0

We	0
propose	0
from	0
these	0
results	0
that	0
the	0
source	0
of	0
the	0
fused	0
fragment	0
encompassing	0
both	0
ends	0
of	0
EBV	1
DNA	2
is	0
a	0
concatenated	1
linear	2
EBV	2
DNA	2
molecule	2
,	0
and	0
that	0
such	0
a	0
concatenated	0
molecule	0
most	0
likely	0
represents	0
a	0
replicative	0
form	0
of	0
EBV	1
DNA	2
in	0
productively	0
infected	0
cells	0
.	0

Expression	0
levels	0
of	0
the	0
thyrotropin	1
receptor	2
gene	2
in	0
autoimmune	0
thyroid	0
disease	0
:	0
coregulation	0
with	0
parameters	0
of	0
thyroid	0
function	0
and	0
inverse	0
relation	0
to	0
major	9
histocompatibility	10
complex	10
classes	10
I	10
and	10
II	10
.	0

Using	0
a	0
human	1
TSH	2
receptor	2
(	2
TSH-R	2
)	2
cDNA	2
probe	2
,	0
we	0
investigated	0
TSH-R	9
transcript	0
levels	0
in	0
13	0
human	0
thyroid	0
fragments	0
by	0
Northern	0
blot	0
analysis	0
;	0
7	0
Graves	0
'	0
disease	0
,	0
2	0
Hashimoto	0
's	0
disease	0
,	0
3	0
endemic	0
goiter	0
,	0
and	0
1	0
healthy	0
thyroid	0
gland	0
were	0
studied	0
.	0

TSH-R	9
expression	0
levels	0
were	0
variable	0
,	0
but	0
displayed	0
a	0
close	0
correlation	0
to	0
the	0
expression	0
of	0
thyroid	9
peroxidase	10
(	0
r	0
=	0
0.703	0
;	0
P	0
<	0
0.05	0
)	0
,	0
thyroglobulin	9
(	0
r	0
=	0
0.817	0
;	0
P	0
<	0
0.01	0
)	0
,	0
and	0
the	0
nuclear	1
oncogene	2
c-fos	2
(	0
r	0
=	0
0.935	0
;	0
P	0
<	0
0.001	0
)	0
,	0
but	0
not	0
c-myc	9
.	0

Overall	0
,	0
TSH-R	9
transcript	0
levels	0
were	0
low	0
or	0
absent	0
in	0
those	0
thyroids	0
in	0
which	0
expression	0
of	0
the	0
major	9
histocompatibility	10
complex	10
class	10
I	10
or	10
II	10
(	0
MHC	9
I	10
or	10
II	10
)	0
was	0
high	0
,	0
thus	0
establishing	0
an	0
inverse	0
relation	0
(	0
MHC	9
I	10
,	0
r	0
=	0
-0.791	0
;	0
P	0
<	0
0.01	0
;	0
MHC	9
II	10
,	0
r	0
=	0
-0.784	0
;	0
P	0
<	0
0.01	0
)	0
.	0

In	0
situ	0
hybridization	0
showed	0
that	0
apart	0
from	0
lymphocytes	7
,	0
thyroid	7
cells	8
themselves	0
were	0
the	0
source	0
of	0
MHC	9
II	10
transcripts	10
.	0

gamma-Interferon	9
expression	0
was	0
only	0
detectable	0
in	0
1	0
Hashimoto	0
's	0
goiter	0
.	0

Our	0
findings	0
suggest	0
that	0
next	0
to	0
lymphocyte	0
infiltration	0
,	0
active	0
regulatory	0
events	0
in	0
the	0
thyrocyte	7
are	0
responsible	0
for	0
the	0
inverse	0
relation	0
between	0
functional	0
parameters	0
(	0
TSH-R	9
,	0
thyroid	9
peroxidase	10
,	0
thyroglobulin	9
,	0
and	0
c-fos	0
)	0
and	0
immunological	0
markers	0
(	0
MHC	9
I	10
and	10
II	10
)	0
.	0

Functional	0
antagonism	0
between	0
vitamin	0
D3	0
and	0
retinoic	0
acid	0
in	0
the	0
regulation	0
of	0
CD14	0
and	0
CD23	0
expression	0
during	0
monocytic	0
differentiation	0
of	0
U-937	5
cells	6
.	0

1	0
,	0
25	0
alpha-Dihydroxicholecalciferol	0
(	0
VitD3	0
)	0
and	0
retinoic	0
acid	0
(	0
RA	0
)	0
are	0
important	0
regulators	0
of	0
the	0
proliferation	0
and	0
differentiation	0
of	0
several	0
cell	0
types	0
.	0

This	0
paper	0
describes	0
how	0
the	0
expression	0
of	0
the	0
monocyte-macrophage	9
Ag	10
,	0
CD14	9
,	0
and	0
the	0
low	0
affinity	9
Fc	10
receptor	10
for	0
IgE	9
,	0
CD23	9
,	0
were	0
inversely	0
regulated	0
during	0
VitD3	0
-and	0
RA-induced	0
monocytic	0
differentiation	0
of	0
human	5
U-937	6
monoblasts	6
.	0

PMA	0
induced	0
the	0
expression	0
of	0
both	0
CD14	9
and	0
CD23	3
mRNA	4
and	0
protein	0
.	0

Exposure	0
to	0
VitD3	0
rapidly	0
induced	0
the	0
de	0
novo	0
expression	0
of	0
CD14	3
mRNA	4
and	0
protein	0
.	0

The	0
addition	0
of	0
cycloheximide	0
completely	0
blocked	0
the	0
VitD3	0
induction	0
of	0
CD14	3
mRNA	4
expression	0
,	0
indicating	0
that	0
the	0
induction	0
was	0
dependent	0
on	0
ongoing	0
protein	0
synthesis	0
.	0

While	0
inducing	0
CD14	9
expression	0
,	0
VitD3	0
concomitantly	0
suppressed	0
the	0
basal	0
,	0
PMA-	0
,	0
and	0
RA-inducible	0
CD23	9
expression	0
in	0
a	0
dose-dependent	0
manner	0
.	0

In	0
contrast	0
,	0
U-937	5
cells	6
induced	0
by	0
RA	0
strongly	0
increased	0
their	0
expression	0
of	0
CD23	3
mRNA	4
and	0
protein	0
,	0
whereas	0
they	0
completely	0
lacked	0
detectable	0
CD14	0
cell	0
surface	0
or	0
mRNA	0
expression	0
.	0

Furthermore	0
,	0
the	0
VitD3	0
-and	0
the	0
PMA-induced	0
CD14	9
expression	0
was	0
inhibited	0
as	0
a	0
temporal	0
consequence	0
of	0
the	0
RA-induced	0
differentiation	0
.	0

The	0
results	0
suggest	0
that	0
there	0
exists	0
a	0
functional	0
antagonism	0
between	0
VitD3	0
and	0
RA	0
that	0
may	0
have	0
important	0
implications	0
for	0
the	0
regulation	0
of	0
certain	0
immune	0
and	0
inflammatory	0
responses	0
through	0
their	0
inverse	0
effects	0
on	0
CD14	0
and	0
CD23	0
gene	0
expression	0
.	0

Cell-specific	0
bifunctional	0
role	0
of	0
Jun	1
oncogene	2
family	2
members	2
on	0
glucocorticoid	9
receptor	10
-dependent	0
transcription	0
.	0

Interaction	0
between	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
-	0
and	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
-mediated	0
signaling	0
is	0
suggested	0
by	0
the	0
ability	0
of	0
the	0
PKC	9
activating	0
phorbol	0
ester	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
to	0
inhibit	0
GR	9
-dependent	0
transcription	0
of	0
the	0
mouse	0
mammary	0
tumor	0
virus	0
(	0
MMTV	0
)	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

Here	0
we	0
report	0
that	0
this	0
interference	0
is	0
cell	0
specific	0
,	0
as	0
TPA	0
augmented	0
dexamethasone-induced	0
transcriptional	0
activation	0
of	0
the	0
MMTV	1
LTR	2
in	0
several	0
T	5
cell	6
lines	6
but	0
was	0
inhibitory	0
in	0
NIH-3T3	5
fibroblasts	6
.	0

TPA-GR	0
synergism	0
was	0
determined	0
to	0
have	0
occurred	0
at	0
the	0
GR-responsive	1
element	2
(	0
GRE	1
)	0
level	0
by	0
functional	0
analysis	0
of	0
deletion	1
mutants	2
or	0
synthetic	1
GRE	2
oligonucleotides	2
driving	0
chloramphenicol	9
acetyl-transferase	10
expression	0
.	0

Synergism	0
required	0
an	0
intact	0
GR	9
DNA-binding	10
domain	10
,	0
whereas	0
amino-	9
or	10
carboxyl-terminal	10
domains	10
were	0
dispensable	0
.	0

The	0
effect	0
was	0
abrogated	0
by	0
the	0
PKC	9
inhibitor	0
staurosporine	0
,	0
suggesting	0
a	0
role	0
for	0
PKC	9
.	0

Increased	0
c-jun	9
,	0
jun-B	9
,	0
and	0
jun-D	9
expression	0
above	0
basal	0
levels	0
and	0
increased	0
transcriptional	0
activity	0
of	0
AP-1/TPA	1
responsive	2
elements	2
fused	0
to	0
chloramphenicol	1
acetyl-transferase	2
vectors	2
were	0
observed	0
in	0
T	7
cells	8
treated	0
with	0
TPA	0
alone	0
or	0
in	0
combination	0
with	0
dexamethasone	0
.	0

The	0
ability	0
of	0
Jun	9
proteins	10
to	0
cooperate	0
with	0
GR	9
in	0
T	7
cells	8
has	0
been	0
investigated	0
after	0
transfection	0
of	0
c-jun	1
,	2
jun-B	2
,	2
or	2
jun-D	2
expression	2
vectors	2
,	0
which	0
augmented	0
GR	9
-dependent	0
transcription	0
from	0
either	0
MMTV	1
LTR	2
or	0
GRE	1
.	0

Conversely	0
,	0
c-jun	9
and	0
jun-B	9
transfection	0
blunted	0
GR	9
-dependent	0
transcription	0
in	0
HeLa	5
cells	6
.	0

The	0
presence	0
of	0
c-fos	9
had	0
a	0
negative	0
influence	0
on	0
GR	9
function	0
and	0
correlated	0
with	0
the	0
cell-specific	0
synergistic	0
or	0
antagonistic	0
activity	0
of	0
Jun	9
with	0
respect	0
to	0
GR	9
;	0
high	0
basal	0
expression	0
of	0
c-fos	9
as	0
well	0
as	0
AP-1	9
DNA	0
binding	0
and	0
transcriptional	0
activity	0
were	0
observed	0
in	0
HeLa	5
cells	6
,	0
but	0
not	0
in	0
T	7
cells	8
.	0

Furthermore	0
overexpression	0
of	0
exogenous	9
c-fos	10
has	0
an	0
inhibitory	0
effect	0
on	0
GR	9
-dependent	0
transcription	0
from	0
GRE	1
in	0
T	7
cells	8
.	0

We	0
propose	0
that	0
Jun	9
plays	0
a	0
bifunctional	0
role	0
on	0
GR	9
-dependent	0
transcriptional	0
activation	0
of	0
GRE	1
,	0
selecting	0
either	0
synergistic	0
or	0
antagonistic	0
activity	0
depending	0
on	0
the	0
cell-specific	0
microenvironment	0
.	0

In	0
this	0
regard	0
,	0
intracellular	0
levels	0
of	0
c-fos	9
appear	0
to	0
be	0
influential	0
.	0

Cell	0
type-	0
and	0
stage-specific	0
expression	0
of	0
the	0
CD20/B1	9
antigen	10
correlates	0
with	0
the	0
activity	0
of	0
a	0
diverged	0
octamer	0
DNA	0
motif	0
present	0
in	0
its	0
promoter	1
.	0

The	0
CD20	1
(	2
B1	2
)	2
gene	2
encodes	0
a	0
B	9
cell-specific	10
protein	10
involved	0
in	0
the	0
regulation	0
of	0
human	0
B	0
cell	0
proliferation	0
and	0
differentiation	0
.	0

Studies	0
with	0
5	1
'	2
deletion	2
CD20	2
promoter-CAT	2
constructs	2
have	0
previously	0
revealed	0
two	0
regions	0
of	0
the	0
promoter	1
between	0
bases	0
-186	0
and	0
-280	0
and	0
between	0
bases	0
-280	0
and	0
-454	0
which	0
contained	0
positive	1
regulatory	2
elements	2
.	0

In	0
this	0
study	0
we	0
identified	0
a	0
sequence	1
element	2
present	0
in	0
the	0
most	0
proximal	0
region	0
located	0
between	0
bases	0
-214	0
and	0
-201	0
,	0
TTCTTCTAATTAA	0
,	0
which	0
is	0
important	0
in	0
the	0
high	0
constitutive	0
expression	0
of	0
CD20	9
in	0
mature	0
B	0
cells	0
and	0
the	0
induction	0
of	0
CD20	9
in	0
pre-B	7
cells	8
.	0

This	0
sequence	1
element	2
was	0
referred	0
to	0
as	0
the	0
BAT	1
box	2
and	0
its	0
deletion	0
significantly	0
reduced	0
the	0
activity	0
of	0
a	0
CD20	0
promoter-CAT	0
construct	0
in	0
B	0
cells	0
.	0

Mobility	0
shift	0
assays	0
with	0
various	0
mutant	0
probes	0
and	0
B	0
cell	0
nuclear	0
extracts	0
demonstrated	0
that	0
the	0
core	0
sequence	0
TAAT	0
was	0
essential	0
for	0
binding	0
to	0
this	0
site	0
.	0

Cross	0
competition	0
experiments	0
with	0
an	0
octamer	0
sequence	0
from	0
the	0
Ig	0
heavy	0
chain	0
promoter	0
,	0
the	0
BAT	1
box	2
,	0
and	0
a	0
TA-rich	0
sequence	0
present	0
in	0
the	0
CD21	1
promoter	2
revealed	0
that	0
all	0
three	0
sequences	0
bound	0
the	0
same	0
nuclear	9
proteins	10
suggesting	0
that	0
the	0
BAT	9
box	10
binding	10
proteins	10
were	0
Oct-1	9
and	0
Oct-2	9
.	0

Southwestern	0
blotting	0
and	0
UV	0
cross-linking	0
studies	0
confirmed	0
that	0
the	0
BAT	9
box	10
binding	10
proteins	10
were	0
Oct-1	9
and	0
Oct-2	9
.	0

The	0
affinity	0
of	0
the	0
BAT	9
box	10
binding	10
proteins	10
for	0
the	0
BAT	1
box	2
was	0
approximately	0
25-fold	0
less	0
than	0
for	0
the	0
octamer	1
sequence	2
and	0
the	0
BAT	9
box	10
binding	10
proteins	10
dissociated	0
from	0
the	0
BAT	1
box	2
10-fold	0
more	0
rapidly	0
than	0
from	0
the	0
octamer	1
sequence	2
.	0

Despite	0
this	0
lower	0
affinity	0
,	0
a	0
trimer	0
of	0
the	0
BAT	1
box	2
sequence	2
was	0
as	0
efficiently	0
transactivated	0
by	0
an	0
Oct-2	1
expression	2
vector	2
as	0
was	0
a	0
trimer	0
of	0
the	0
octamer	1
sequence	2
in	0
HeLa	5
cells	6
.	0

The	0
BAT	1
box	2
and	0
Oct-2	9
were	0
also	0
implicated	0
in	0
the	0
induction	0
of	0
CD20	9
in	0
the	0
pre-B	5
cell	6
line	6
,	0
PB-697	5
,	0
via	0
phorbol	0
esters	0
.	0

The	0
induction	0
of	0
CD20	3
mRNA	4
was	0
temporally	0
associated	0
with	0
induction	0
of	0
Oct-2	3
mRNA	4
and	0
a	0
BAT	1
box-deleted	2
CD20-CAT	2
construct	2
,	0
in	0
contrast	0
to	0
the	0
wild	0
type	0
,	0
was	0
poorly	0
induced	0
by	0
phorbol	0
esters	0
.	0

Together	0
these	0
results	0
suggest	0
that	0
the	0
BAT	9
box	10
binding	10
proteins	10
are	0
important	0
in	0
the	0
B	0
cell	0
specific	0
expression	0
of	0
CD20	9
and	0
perhaps	0
CD21	9
.	0

Human	7
CD4	8
lymphocytes	8
specifically	0
recognize	0
a	0
peptide	0
representing	0
the	0
fusion	0
region	0
of	0
the	0
hybrid	9
protein	10
pml/RAR	9
alpha	10
present	0
in	0
acute	7
promyelocytic	8
leukemia	8
cells	8
.	0

Fusion	0
proteins	0
present	0
in	0
leukemic	7
cells	8
frequently	0
contain	0
a	0
new	0
amino	0
acid	0
at	0
the	0
fusion	9
point	10
.	0

We	0
tested	0
whether	0
a	0
peptide	0
(	0
BCR1/25	0
)	0
encompassing	0
the	0
fusion	9
region	10
of	0
the	0
hybrid	0
molecule	0
pml/RAR	9
alpha	10
,	0
which	0
is	0
selectively	0
expressed	0
by	0
acute	7
promyelocytic	8
leukemia	8
(	8
APL	8
)	8
cells	8
,	0
can	0
be	0
recognized	0
by	0
human	7
T	8
lymphocytes	8
in	0
vitro	0
.	0

CD4+	7
lymphocytes	8
,	0
at	0
both	0
polyclonal	0
and	0
clonal	0
level	0
,	0
recognized	0
peptide	0
BCR1/25	0
in	0
an	0
HLA-DR	9
--	0
restricted	0
fashion	0
on	0
presentation	0
by	0
autologous	7
antigen-presenting	8
cell	8
(	0
APC	7
)	0
or	0
by	0
APC	7
expressing	0
the	0
HLA-DR11	9
restricting	10
molecule	10
.	0

Control	0
peptides	0
corresponding	0
to	0
the	0
normal	0
pml	9
and	0
RAR	9
alpha	10
proteins	10
were	0
not	0
recognized	0
.	0

One	0
clone	0
(	0
DEG5	5
)	0
also	0
exerted	0
a	0
high	0
and	0
specific	0
cytotoxicity	0
against	0
autologous	5
cells	6
pulsed	0
with	0
BCR1/25	0
.	0

The	0
autologous	5
DE	6
LCL	6
containing	0
a	0
transduced	0
pml/RAR	1
alpha	2
fusion	2
gene	2
and	0
expressing	0
a	0
bcr1	0
type	0
of	0
the	0
pml/RAR	9
alpha	10
hybrid	0
protein	0
induced	0
the	0
proliferation	0
of	0
DE	5
anti-BCR1/25	6
T	6
cell	6
clones	6
.	0

It	0
is	0
concluded	0
that	0
the	0
bcr1	9
type-pml/RAR	10
alpha	10
fusion	10
protein	10
of	0
APL	5
contains	0
an	0
antigenic	0
site	0
,	0
absent	0
from	0
the	0
normal	0
parent	0
molecules	0
and	0
recognized	0
by	0
human	5
CD4+	6
lymphocytes	6
.	0

The	0
zinc	9
finger	10
transcription	10
factor	10
Egr-1	9
is	0
essential	0
for	0
and	0
restricts	0
differentiation	0
along	0
the	0
macrophage	7
lineage	8
.	0

We	0
have	0
isolated	0
cDNA	1
clones	2
of	0
myeloid	1
differentiation	2
primary	2
response	2
(	2
MyD	2
)	2
genes	2
,	0
activated	0
in	0
the	0
absence	0
of	0
de	0
novo	0
protein	0
synthesis	0
following	0
induction	0
for	0
differentiation	0
along	0
either	0
the	0
macrophage	7
or	0
granulocyte	7
lineage	8
in	0
human	0
myeloblastic	5
leukemia	6
HL-60	6
cells	6
.	0

One	0
cDNA	1
clone	2
of	0
a	0
primary	0
response	0
gene	0
,	0
expressed	0
upon	0
macrophage	0
differentiation	0
,	0
encoded	0
for	0
Egr-1	9
,	0
a	0
zinc	9
finger	10
transcription	10
factor	10
.	0

The	0
Egr-1	1
gene	2
was	0
observed	0
to	0
be	0
transcriptionally	0
silent	0
in	0
HL-60	5
cells	6
,	0
but	0
active	0
in	0
U-937	5
and	0
M1	5
cells	6
,	0
the	0
latter	0
two	0
being	0
predetermined	0
for	0
macrophage	0
differentiation	0
.	0

Egr-1	9
antisense	0
oligomers	0
in	0
the	0
culture	0
media	0
blocked	0
macrophage	0
differentiation	0
in	0
both	0
myeloid	5
leukemia	6
cell	6
lines	6
and	0
normal	0
myeloblasts	7
.	0

HL-60	5
cells	6
constitutively	0
expressing	0
an	0
Egr-1	1
transgene	2
(	0
HL-60Egr-1	1
)	0
could	0
be	0
induced	0
for	0
macrophage	7
,	0
but	0
not	0
granulocyte	7
,	0
differentiation	0
.	0

These	0
observations	0
indicate	0
that	0
expression	0
of	0
Egr-1	9
is	0
essential	0
for	0
and	0
restricts	0
differentiation	0
of	0
myeloblasts	7
along	0
the	0
macrophage	7
lineage	8
.	0

The	0
Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
interacts	0
with	0
an	0
EBNA2	1
responsive	2
cis-element	2
of	0
the	0
terminal	1
protein	2
1	2
gene	2
promoter	2
.	0

The	0
Epstein-Barr	9
virus	10
protein	10
EBNA2	10
acts	0
as	0
a	0
transcriptional	9
activator	10
of	0
cellular	1
and	2
viral	2
genes	2
and	0
plays	0
a	0
crucial	0
role	0
in	0
the	0
immortalization	0
of	0
human	7
primary	8
B-cells	8
by	0
EBV	0
.	0

We	0
have	0
shown	0
previously	0
that	0
EBNA2	9
transactivates	0
the	0
promoters	0
of	0
the	0
latent	9
membrane	10
antigens	10
LMP	9
,	0
TP1	9
and	0
TP2	9
.	0

The	0
promoter	1
of	0
the	0
TP1	1
gene	2
was	0
chosen	0
as	0
a	0
model	0
system	0
to	0
study	0
the	0
molecular	0
mechanism	0
of	0
EBNA2	9
mediated	0
transactivation	0
.	0

To	0
identify	0
an	0
EBNA2	1
dependent	2
cis-acting	2
element	2
,	0
various	0
TP1	1
promoter-reporter	2
gene	2
constructs	2
were	0
transfected	0
in	0
the	0
absence	0
and	0
presence	0
of	0
an	0
EBNA2	1
expression	2
vector	2
into	0
the	0
established	0
B-cell	5
line	6
BL41-P3HR1	6
.	0

We	0
were	0
able	0
to	0
delineate	0
an	0
81	1
bp	2
EBNA2	2
responsive	2
region	2
between	0
-258	0
and	0
-177	0
relative	0
to	0
the	0
TP1	1
RNA	2
start	2
site	2
.	0

The	0
element	0
worked	0
in	0
either	0
orientation	0
and	0
could	0
mediate	0
EBNA2	9
dependent	0
transactivation	0
on	0
a	0
heterologous	1
promoter	2
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
revealed	0
three	0
specific	0
protein-DNA	9
complexes	10
formed	0
with	0
sequences	0
of	0
the	0
EBNA2	1
responsive	2
element	2
.	0

Two	0
of	0
these	0
were	0
not	0
cell	0
type	0
specific	0
,	0
but	0
the	0
third	0
was	0
detected	0
only	0
in	0
EBNA2	9
positive	0
cell	0
extracts	0
.	0

Gel-shift	0
analysis	0
in	0
the	0
presence	0
of	0
EBNA2	9
specific	0
monoclonal	0
antibodies	0
revealed	0
that	0
EBNA2	9
is	0
a	0
component	0
of	0
the	0
third	0
complex	0
.	0

Thus	0
,	0
these	0
experiments	0
demonstrate	0
that	0
EBNA2	9
interacts	0
with	0
an	0
EBNA2	1
responsive	2
cis-element	2
of	0
the	0
TP1	1
promoter	2

Minimally	0
modified	0
low	0
density	0
lipoprotein	9
-induced	0
inflammatory	0
responses	0
in	0
endothelial	7
cells	8
are	0
mediated	0
by	0
cyclic	0
adenosine	0
monophosphate	0
.	0

We	0
have	0
previously	0
shown	0
that	0
minimally	5
oxidized	6
LDL	6
(	6
MM-LDL	6
)	6
activated	6
endothelial	6
cells	6
to	0
increase	0
their	0
interaction	0
with	0
monocytes	7
but	0
not	0
neutrophils	7
,	0
inducing	0
monocyte	0
but	0
not	0
neutrophil	0
binding	0
and	0
synthesis	0
of	0
monocyte	9
chemotactic	10
protein-1	10
and	0
monocyte	9
colony-stimulating	10
factor	10
(	0
M-CSF	9
)	0
.	0

In	0
the	0
present	0
studies	0
we	0
have	0
examined	0
the	0
signaling	0
pathways	0
by	0
which	0
this	0
monocyte-specific	0
response	0
is	0
induced	0
.	0

Both	0
induction	0
of	0
monocyte	0
binding	0
and	0
mRNA	0
levels	0
for	0
M-CSF	9
by	0
MM-LDL	9
were	0
not	0
inhibited	0
in	0
protein	0
kinase	0
C-depleted	0
endothelial	7
cells	8
.	0

A	0
number	0
of	0
our	0
studies	0
indicate	0
that	0
cAMP	0
is	0
the	0
second	0
messenger	0
for	0
the	0
effects	0
of	0
MM-LDL	9
cited	0
above	0
.	0

Incubation	0
of	0
endothelial	7
cells	8
with	0
MM-LDL	9
caused	0
a	0
173	0
%	0
increase	0
in	0
intracellular	0
cAMP	0
levels	0
.	0

Agents	0
which	0
increased	0
cAMP	0
levels	0
,	0
including	0
cholera	0
toxin	0
,	0
pertussis	0
toxin	0
,	0
dibutyryl	0
cAMP	0
,	0
and	0
isoproterenol	0
mimicked	0
the	0
actions	0
of	0
MM-LDL	9
.	0

Agents	0
which	0
elevated	0
cAMP	0
were	0
also	0
shown	0
to	0
activate	0
NF	9
kappa	10
B	10
,	0
suggesting	0
a	0
role	0
for	0
this	0
transcription	0
factor	0
in	0
activation	0
of	0
monocyte-endothelial	0
interactions	0
.	0

Although	0
endothelial	3
leukocyte	4
adhesion	4
molecule	4
(	4
ELAM	4
)	4
mRNA	4
synthesis	0
can	0
be	0
regulated	0
by	0
NF	9
kappa	10
B	10
,	0
ELAM	9
was	0
not	0
expressed	0
and	0
ELAM	3
mRNA	4
was	0
only	0
slightly	0
elevated	0
in	0
response	0
to	0
MM-LDL	9
.	0

We	0
present	0
evidence	0
that	0
induction	0
of	0
neutrophil	7
binding	0
by	0
LPS	0
is	0
actually	0
suppressed	0
by	0
agents	0
that	0
elevated	0
cAMP	0
levels	0
.	0

Human	9
T	10
cell	10
transcription	10
factor	10
GATA-3	9
stimulates	0
HIV-1	0
expression	0
.	0

A	0
family	0
of	0
transcriptional	0
activating	0
proteins	0
,	0
the	0
GATA	9
factors	10
,	0
has	0
been	0
shown	0
to	0
bind	0
to	0
a	0
consensus	0
motif	0
through	0
a	0
highly	9
conserved	10
C4	10
zinc	10
finger	10
DNA	10
binding	10
domain	10
.	0

One	0
member	0
of	0
this	0
multigene	0
family	0
,	0
GATA-3	9
,	0
is	0
most	0
abundantly	0
expressed	0
in	0
T	7
lymphocytes	8
,	0
a	0
cellular	0
target	0
for	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
and	0
replication	0
.	0

In	0
vitro	0
DNase	9
I	10
footprinting	0
analysis	0
revealed	0
six	0
hGATA-3	1
binding	2
sites	2
in	0
the	0
U3	1
region	2
(	0
the	0
transcriptional	1
regulatory	2
domain	2
)	0
of	0
the	0
HIV-1	1
LTR	2
.	0

Cotransfection	0
of	0
an	0
hGATA-3	1
expression	2
plasmid	2
with	0
a	0
reporter	1
plasmid	2
whose	0
transcription	0
is	0
directed	0
by	0
the	0
HIV-1	1
LTR	2
resulted	0
in	0
6-	0
to	0
10-fold	0
stimulation	0
of	0
LTR	1
-mediated	0
transcription	0
,	0
whereas	0
site	0
specific	0
mutation	0
of	0
these	0
GATA	1
sites	2
resulted	0
in	0
virtual	0
abrogation	0
of	0
the	0
activation	0
by	0
hGATA-3	9
.	0

Further	0
,	0
deletion	0
of	0
the	0
hGATA-3	1
transcriptional	2
activation	2
domain	2
abolished	0
GATA-dependent	0
HIV-1	0
trans-activation	0
,	0
showing	0
that	0
the	0
stimulation	0
of	0
viral	0
transcription	0
observed	0
is	0
a	0
direct	0
effect	0
of	0
cotransfected	9
hGATA-3	10
.	0

Introduction	0
of	0
the	0
HIV-1	1
plasmids	2
in	0
which	0
the	0
GATA	1
sites	2
have	0
been	0
mutated	0
into	0
human	0
T	7
lymphocytes	8
also	0
caused	0
a	0
significant	0
reduction	0
in	0
LTR	1
-mediated	0
transcription	0
at	0
both	0
the	0
basal	0
level	0
and	0
in	0
(	0
PHA-	0
plus	0
PMA-	0
)	0
stimulated	5
T	6
cells	6
.	0

These	0
observations	0
suggest	0
that	0
in	0
addition	0
to	0
its	0
normal	0
role	0
in	0
T	7
lymphocyte	8
gene	0
regulation	0
,	0
hGATA-3	9
may	0
also	0
play	0
a	0
significant	0
role	0
in	0
HIV-1	0
transcriptional	0
activation	0
.	0

Cytokine	0
modulation	0
of	0
HIV	0
expression	0
.	0

Cytokines	9
,	0
the	0
peptide	9
hormones	10
which	0
control	0
the	0
homeostasis	0
of	0
the	0
immune	0
system	0
and	0
also	0
play	0
a	0
fundamental	0
role	0
in	0
inflammatory	0
and	0
immune	0
mediated	0
reactions	0
,	0
have	0
been	0
involved	0
at	0
multiple	0
levels	0
in	0
the	0
pathogenesis	0
of	0
the	0
acquired	0
immune	0
deficiency	0
syndrome	0
(	0
AIDS	0
)	0
.	0

Infection	0
with	0
the	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
has	0
been	0
shown	0
to	0
induce	0
production	0
of	0
several	0
cytokines	9
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

Conversely	0
,	0
several	0
cytokines	9
modulate	0
the	0
levels	0
of	0
HIV	0
expression	0
in	0
infected	0
cells	0
of	0
both	0
T	7
lymphocytic	8
and	8
mononuclear	8
phagocytic	8
lineage	8
.	0

Activated	7
mononuclear	8
cells	8
,	0
particularly	0
B	7
cells	8
which	0
are	0
in	0
a	0
state	0
of	0
chronic	0
activation	0
in	0
HIV	0
infected	0
individuals	0
,	0
release	0
HIV-inductive	9
cytokines	10
and	0
thus	0
play	0
a	0
potentially	0
important	0
role	0
in	0
the	0
pathogenesis	0
of	0
HIV	0
infection	0
.	0

Cloning	0
and	0
functional	0
characterization	0
of	0
early	9
B-cell	10
factor	10
,	0
a	0
regulator	0
of	0
lymphocyte-specific	0
gene	0
expression	0
.	0

Early	9
B-cell	10
factor	10
(	0
EBF	9
)	0
was	0
identified	0
previously	0
as	0
a	0
tissue-specific	0
and	0
differentiation	0
stage-specific	0
DNA-binding	9
protein	10
that	0
participates	0
in	0
the	0
regulation	0
of	0
the	0
pre-B	1
and	2
B	2
lymphocyte-specific	2
mb-1	2
gene	2
.	0

Partial	0
amino	0
acid	0
sequences	0
obtained	0
from	0
purified	0
EBF	9
were	0
used	0
to	0
isolate	0
cDNA	1
clones	2
,	0
which	0
by	0
multiple	0
criteria	0
encode	0
EBF	9
.	0

The	0
recombinant	9
polypeptide	10
formed	0
sequence-specific	0
complexes	0
with	0
the	0
EBF-binding	1
site	2
in	0
the	0
mb-1	1
promoter	2
.	0

The	0
cDNA	1
hybridized	0
to	0
multiple	0
transcripts	0
in	0
pre-B	5
and	6
B-cell	6
lines	6
,	0
but	0
transcripts	0
were	0
not	0
detected	0
at	0
significant	0
levels	0
in	0
plasmacytoma	5
,	0
T-cell	5
,	0
and	0
nonlymphoid	5
cell	6
lines	6
.	0

Expression	0
of	0
recombinant	0
EBF	9
in	0
transfected	5
nonlymphoid	6
cells	6
strongly	0
activated	0
transcription	0
from	0
reporter	0
plasmids	0
containing	0
functional	0
EBF-binding	1
sites	2
.	0

Analysis	0
of	0
DNA	0
binding	0
by	0
deletion	0
mutants	0
of	0
EBF	9
identified	0
an	0
amino-terminal	9
cysteine-rich	10
DNA-binding	10
domain	10
lacking	0
obvious	0
sequence	0
similarity	0
to	0
known	0
transcription	9
factors	10
.	0

DNA-binding	0
assays	0
with	0
cotranslated	0
wild-type	0
and	0
truncated	0
forms	0
of	0
EBF	9
indicated	0
that	0
the	0
protein	0
interacts	0
with	0
its	0
site	0
as	0
a	0
homodimer	9
.	0

Deletions	0
delineated	0
a	0
carboxy-terminal	9
dimerization	10
region	10
containing	0
two	0
repeats	0
of	0
15	0
amino	0
acids	0
that	0
show	0
similarity	0
with	0
the	0
dimerization	9
domains	10
of	0
basic-helix-loop-helix	9
proteins	10
.	0

Together	0
,	0
these	0
data	0
suggest	0
that	0
EBF	9
represents	0
a	0
novel	0
regulator	0
of	0
B	0
lymphocyte-specific	0
gene	0
expression	0
.	0

Cell-specific	0
expression	0
of	0
helix-loop-helix	9
transcription	10
factors	10
encoded	0
by	0
the	0
E2A	1
gene	2
.	0

The	0
E2A	1
gene	2
encodes	0
transcription	9
factors	10
of	0
the	0
helix-loop-helix	9
family	10
that	0
are	0
implicated	0
in	0
cell-specific	0
gene	0
expression	0
as	0
part	0
of	0
dimeric	9
complexes	10
that	0
interact	0
with	0
E	1
box	2
enhancer	2
elements	2
.	0

It	0
has	0
previously	0
been	0
shown	0
that	0
transcripts	0
of	0
the	0
E2A	1
gene	2
can	0
be	0
detected	0
in	0
a	0
wide	0
range	0
of	0
cell	0
types	0
.	0

We	0
have	0
now	0
examined	0
expression	0
of	0
the	0
mouse	1
E2A	2
gene	2
at	0
the	0
protein	0
level	0
using	0
polyclonal	0
antisera	0
directed	0
against	0
distinct	0
portions	0
of	0
the	0
E2A	9
protein	10
to	0
probe	0
blots	0
of	0
cellular	0
extracts	0
.	0

A	0
73	9
kDa	10
protein	10
was	0
identified	0
by	0
this	0
analysis	0
:	0
this	0
protein	0
is	0
highly	0
enriched	0
in	0
cell	5
lines	6
of	6
B	6
lymphoid	6
origin	6
as	0
compared	0
to	0
pancreatic	7
beta-cells	8
and	0
fibroblast	7
cells	8
.	0

The	0
detection	0
of	0
this	0
protein	0
selectively	0
in	0
extracts	0
of	0
lymphoid	7
cells	8
correlates	0
with	0
the	0
presence	0
of	0
the	0
E	1
box	2
-binding	0
activity	0
LEF1/BCF1	9
in	0
these	0
cells	0
;	0
this	0
binding	0
activity	0
was	0
previously	0
shown	0
to	0
be	0
efficiently	0
recognized	0
by	0
antiserum	0
directed	0
against	0
E2A	9
gene	10
products	10
.	0

Transfection	0
of	0
cells	0
with	0
full	0
length	0
E2A	1
cDNA	2
leads	0
to	0
appearance	0
of	0
protein	0
co-migrating	0
with	0
the	0
73	9
kDa	10
protein	10
on	0
SDS	0
gel	0
electrophoresis	0
and	0
co-migrating	0
with	0
LEF1/BCF1	9
on	0
mobility	0
shift	0
analysis	0
.	0

Our	0
results	0
are	0
consistent	0
with	0
the	0
view	0
that	0
the	0
DNA-binding	0
activity	0
LEF1/BCF1	9
is	0
a	0
homodimer	9
of	10
E2A	10
proteins	10
;	0
the	0
selective	0
appearance	0
of	0
this	0
putative	0
cell-specific	0
transcription	0
factor	0
in	0
B	7
lymphoid	8
cells	8
seems	0
to	0
be	0
attributable	0
,	0
at	0
least	0
in	0
part	0
,	0
to	0
the	0
elevated	0
E2A	9
protein	10
concentrations	0
in	0
these	0
cells	0
.	0

Hypertension	0
in	0
pregnancy	0
.	0

Pregnancy-induced	0
hypertension	0
(	0
PIH	0
)	0
is	0
a	0
frequent	0
cause	0
of	0
maternal	0
and	0
neonatal	0
morbidity	0
and	0
mortality	0
.	0

In	0
the	0
present	0
study	0
we	0
focused	0
on	0
the	0
pathophysiology	0
of	0
PIH	0
,	0
mainly	0
on	0
the	0
role	0
of	0
mineralocorticoids	0
,	0
reversed	0
blood	0
pressure	0
patterns	0
,	0
and	0
the	0
resulting	0
necessity	0
of	0
continuous	0
monitoring	0
of	0
the	0
preeclamptic	0
mother	0
.	0

Problems	0
of	0
antihypertensive	0
therapy	0
are	0
discussed	0
and	0
the	0
first	0
results	0
of	0
a	0
pilot	0
study	0
with	0
Urapidil	0
are	0
presented	0
.	0

To	0
examine	0
the	0
role	0
of	0
mineralocorticoids	0
in	0
the	0
pathophysiology	0
of	0
PIH	0
,	0
we	0
studied	0
plasma	0
aldosterone	0
and	0
18-hydroxy-corticosterone	0
(	0
18-OH-B	0
)	0
levels	0
in	0
25	0
women	0
with	0
PIH	0
and	0
in	0
25	0
healthy	0
pregnant	0
women	0
.	0

Furthermore	0
,	0
we	0
evaluated	0
the	0
mineralocorticoid	9
receptor	10
(	0
MR	9
)	0
count	0
in	0
mononuclear	7
leukocytes	8
in	0
the	0
2	0
groups	0
.	0

The	0
MR-count	0
was	0
significantly	0
decreased	0
in	0
the	0
PIH-group	0
.	0

The	0
values	0
of	0
plasma	0
aldosterone	0
and	0
18-OH-B	0
were	0
also	0
low	0
.	0

These	0
results	0
can	0
not	0
be	0
explained	0
by	0
receptor	0
down-regulation	0
due	0
to	0
higher	0
level	0
of	0
mineralocorticoids	0
of	0
the	0
zona	0
glomerulosa	0
.	0

Perhaps	0
deoxycorticosterone	0
or	0
a	0
hitherto	0
unknown	0
mineralocorticoid	0
is	0
responsible	0
for	0
the	0
hypertension	0
and	0
altered	0
MR	9
-status	0
.	0

The	0
first	0
results	0
of	0
continuous	0
blood	0
pressure	0
measurements	0
with	0
a	0
noninvasive	0
,	0
real-time	0
blood	0
pressure	0
monitor	0
(	0
Finapres	0
)	0
are	0
presented	0
.	0

The	0
comparison	0
of	0
the	0
obtained	0
values	0
with	0
intraarterial	0
measurements	0
demonstrates	0
a	0
good	0
correlation	0
between	0
the	0
two	0
methods	0
.	0

We	0
also	0
report	0
on	0
the	0
first	0
experiences	0
with	0
Urapidil	0
in	0
the	0
treatment	0
of	0
hypertension	0
in	0
severe	0
preeclampsia	0
.	0

The	0
data	0
show	0
that	0
hypertension	0
in	0
preeclamptic	0
women	0
can	0
be	0
treated	0
by	0
Urapidil	0
without	0
side	0
effects	0
or	0
reflex-tachycardia	0
.	0

Further	0
studies	0
will	0
have	0
to	0
prove	0
if	0
Urapidil	0
is	0
suited	0
for	0
prepartal	0
treatment	0
of	0
PIH	0
as	0
well	0
.	0

Suppression	0
of	0
a	0
cellular	0
differentiation	0
program	0
by	0
phorbol	0
esters	0
coincides	0
with	0
inhibition	0
of	0
binding	0
of	0
a	0
cell-specific	9
transcription	10
factor	10
(	0
NF-E2	9
)	0
to	0
an	0
enhancer	1
element	2
required	0
for	0
expression	0
of	0
an	0
erythroid-specific	1
gene	2
.	0

Induction	0
by	0
hemin	0
increases	0
,	0
while	0
induction	0
with	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
represses	0
,	0
erythroid-specific	1
gene	2
expression	0
in	0
the	0
human	5
cell	6
line	6
K562	6
.	0

We	0
analyzed	0
the	0
effects	0
of	0
hemin	0
or	0
TPA	0
induction	0
on	0
the	0
binding	0
and	0
activity	0
of	0
transcription	9
factors	10
at	0
a	0
regulatory	1
element	2
found	0
within	0
the	0
transcriptional	1
regulatory	2
sequences	2
of	0
many	0
erythroid-specific	1
genes	2
.	0

TPA	0
induction	0
increases	0
the	0
binding	0
of	0
ubiquitous	9
AP-1	10
factors	10
to	0
this	0
element	0
.	0

TPA	0
induction	0
inhibits	0
the	0
binding	0
of	0
the	0
lineage	9
limited	10
transcription	10
factor	10
NF-E2	9
to	0
this	0
transcriptional	1
control	2
element	2
.	0

Hemin	0
induction	0
of	0
K562	5
cells	6
does	0
not	0
facilitate	0
the	0
binding	0
of	0
NF-E2	9
to	0
its	0
recognition	0
site	0
.	0

Hemin	0
induction	0
appears	0
to	0
nonspecifically	0
increase	0
the	0
expression	0
of	0
transiently	0
transfected	0
genes	0
in	0
K562	5
cells	6
.	0

Beyond	0
this	0
nonspecific	0
increase	0
in	0
gene	0
expression	0
,	0
hemin	9
induction	0
acts	0
to	0
increase	0
the	0
activity	0
of	0
the	0
lineage	9
limited	10
transcription	10
factor	10
NF-E2	0
.	0

The	0
divergent	0
effects	0
of	0
hemin	0
and	0
TPA	0
on	0
gene	0
expression	0
in	0
K562	5
cells	6
are	0
mediated	0
,	0
in	0
part	0
,	0
by	0
their	0
contrasting	0
effects	0
on	0
the	0
transcription	9
factor	10
NF-E2	9
.	0

Interleukin-3	9
expression	0
by	0
activated	7
T	8
cells	8
involves	0
an	0
inducible	0
,	0
T-cell-specific	9
factor	10
and	0
an	0
octamer	9
binding	10
protein	10
.	0

Interleukin-3	9
(	0
IL-3	9
)	0
is	0
exclusively	0
expressed	0
by	0
activated	7
T	8
and	0
natural	7
killer	8
cells	8
,	0
a	0
function	0
that	0
is	0
tightly	0
controlled	0
both	0
in	0
a	0
lineage-specific	0
and	0
in	0
a	0
stimulation-dependent	0
manner	0
.	0

We	0
have	0
investigated	0
the	0
protein	0
binding	0
characteristics	0
and	0
functional	0
importance	0
of	0
the	0
ACT-1-activating	1
region	2
of	0
the	0
IL-3	9
promoter	0
.	0

This	0
region	0
binds	0
an	0
inducible	0
,	0
T-cell-specific	9
factor	10
over	0
its	0
5	1
'	2
end	2
,	0
a	0
site	0
that	0
is	0
necessary	0
for	0
the	0
expression	0
of	0
IL-3	9
in	0
the	0
absence	0
of	0
other	0
upstream	0
elements	0
.	0

Over	0
its	0
3	1
'	2
end	2
,	0
it	0
binds	0
a	0
factor	0
that	0
is	0
ubiquitously	0
and	0
constitutively	0
expressed	0
.	0

This	0
factor	0
is	0
Oct-1	9
or	0
an	0
immunologically	9
related	10
octamer-binding	10
protein	10
,	0
and	0
it	0
plays	0
a	0
role	0
in	0
coordinating	0
the	0
activity	0
of	0
several	0
regulatory	1
elements	2
.	0

These	0
characteristics	0
make	0
the	0
ACT-1	1
site	2
analogous	0
to	0
the	0
activating	0
ARRE-1	1
site	2
in	0
the	0
IL-2	1
promoter	2
.	0

Furthermore	0
,	0
and	0
despite	0
a	0
lack	0
of	0
sequence	0
homology	0
,	0
the	0
promoters	0
of	0
IL-3	9
and	0
IL-2	9
share	0
an	0
organizational	0
pattern	0
of	0
regulatory	0
elements	0
that	0
is	0
likely	0
to	0
be	0
important	0
for	0
the	0
T-cell-specific	0
expression	0
of	0
these	0
genes	0
.	0

Interleukin-4	9
inhibits	0
the	0
lipopolysaccharide-induced	0
expression	0
of	0
c-jun	3
and	4
c-fos	4
messenger	4
RNA	4
and	0
activator	9
protein-1	10
binding	0
activity	0
in	0
human	7
monocytes	8
.	0

We	0
studied	0
the	0
effect	0
of	0
interleukin-4	9
(	0
IL-4	9
)	0
on	0
the	0
lipopolysaccharide	0
(	0
LPS	0
)	0
induction	0
of	0
two	0
immediate	0
early	0
genes	0
c-fos	1
and	0
c-jun	1
.	0

These	0
genes	0
encode	0
proteins	0
that	0
form	0
the	0
dimeric	9
complex	10
activator	9
protein-1	10
(	0
AP-1	9
)	0
,	0
which	0
is	0
active	0
as	0
a	0
transcriptional	9
factor	10
.	0

Maximal	0
accumulation	0
of	0
either	0
c-fos	3
and	4
c-jun	4
messenger	4
RNA	4
(	0
mRNA	0
)	0
occurred	0
30	0
minutes	0
after	0
LPS	0
addition	0
.	0

When	0
cells	0
were	0
treated	0
with	0
IL-4	9
for	0
5	0
hours	0
before	0
LPS	0
activation	0
,	0
both	0
the	0
c-fos	0
and	0
the	0
c-jun	0
mRNA	0
expression	0
was	0
decreased	0
.	0

The	0
inhibition	0
of	0
c-fos	1
and	0
c-jun	0
expression	0
by	0
IL-4	9
in	0
LPS-treated	7
cells	8
was	0
shown	0
to	0
be	0
due	0
to	0
a	0
lower	0
transcription	0
rate	0
of	0
the	0
c-fos	1
and	2
c-jun	2
genes	2
.	0

IL-4	9
did	0
not	0
affect	0
the	0
stability	0
of	0
the	0
c-fos	9
and	0
c-jun	9
transcripts	10
.	0

Finally	0
,	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
evidence	0
was	0
obtained	0
that	0
IL-4	9
inhibits	0
LPS-induced	0
expression	0
of	0
AP-1	9
protein	0
.	0

These	0
data	0
indicate	0
that	0
IL-4	9
suppresses	0
the	0
induction	0
of	0
transcription	9
factors	10
in	0
human	7
activated	8
monocytes	8
.	0

Transient	0
pseudohypoaldosteronism	0
in	0
obstructive	0
renal	0
disease	0
with	0
transient	0
reduction	0
of	0
lymphocytic	9
aldosterone	10
receptors	10
.	0

Results	0
in	0
two	0
affected	0
infants	0
.	0

We	0
report	0
two	0
patients	0
with	0
transient	0
pseudohypoaldosteronism	0
due	0
to	0
obstructive	0
renal	0
disease	0
.	0

Both	0
patients	0
presented	0
with	0
a	0
salt-losing	0
episode	0
simulating	0
adrenal	0
insufficiency	0
.	0

In	0
one	0
patient	0
,	0
transient	0
reduction	0
of	0
aldosterone	9
receptors	10
could	0
be	0
documented	0
,	0
while	0
in	0
the	0
second	0
patient	0
the	0
clinical	0
and	0
biochemical	0
parameters	0
were	0
consistent	0
with	0
transient	0
pseudohypoaldosteronism	0
.	0

Aldosterone	9
receptors	10
were	0
normal	0
in	0
both	0
patients	0

Aldosterone-specific	9
membrane	10
receptors	10
and	0
rapid	0
non-genomic	0
actions	0
of	0
mineralocorticoids	0
.	0

Functional	0
studies	0
in	0
extrarenal	7
,	8
non-epithelial	8
cells	8
such	0
as	0
smooth	7
muscle	8
cells	8
and	0
more	0
recently	0
circulating	7
human	8
lymphocytes	8
have	0
provided	0
increasing	0
evidence	0
that	0
aldosterone	0
produces	0
not	0
only	0
classical	0
genomic	0
effects	0
,	0
but	0
also	0
rapid	0
,	0
non-genomic	0
effects	0
on	0
transmembrane	0
electrolyte	0
movements	0
.	0

These	0
involve	0
activation	0
of	0
the	0
sodium/proton	9
exchanger	10
of	0
the	0
cell	0
membrane	0
at	0
very	0
low	0
,	0
physiological	0
concentrations	0
of	0
aldosterone	0
with	0
an	0
acute	0
onset	0
within	0
1-2	0
min	0
.	0

A	0
second	0
messenger	0
cascade	0
involved	0
is	0
the	0
inositol	0
1	0
,	0
4	0
,	0
5-trisphosphate/calcium	0
pathway	0
which	0
responds	0
over	0
the	0
same	0
rapid	0
time	0
course	0
.	0

Such	0
changes	0
clearly	0
can	0
not	0
be	0
explained	0
by	0
genomic	0
mechanisms	0
,	0
which	0
are	0
responsible	0
for	0
later	0
effects	0
than	0
the	0
membrane	0
related	0
rapid	0
responses	0
.	0

The	0
mechanisms	0
underlying	0
these	0
rapid	0
effects	0
of	0
aldosterone	0
on	0
electrolytes	0
have	0
been	0
extensively	0
studied	0
in	0
human	7
lymphocytes	8
,	0
which	0
thus	0
may	0
represent	0
valuable	0
tools	0
in	0
the	0
delineation	0
of	0
the	0
receptor-effector	0
mechanisms	0
involved	0
.	0

The	0
unique	0
characteristics	0
of	0
this	0
new	0
pathway	0
for	0
steroid	0
action	0
include	0
its	0
rapid	0
time	0
course	0
,	0
10	0
,	0
000-fold	0
selectivity	0
for	0
aldosterone	0
over	0
cortisol	0
and	0
the	0
ineffectiveness	0
of	0
spironolactones	0
,	0
classical	0
mineralocorticoid	0
antagonists	0
,	0
as	0
antagonists	0
of	0
the	0
response	0
.	0

Human	9
immunodeficiency	10
virus	10
type	10
1	10
Nef	10
protein	10
inhibits	0
NF-kappa	9
B	10
induction	0
in	0
human	7
T	8
cells	8
.	0

Human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
can	0
establish	0
a	0
persistent	0
and	0
latent	0
infection	0
in	0
CD4+	7
T	8
lymphocytes	8
(	0
W.C.Greene	0
,	0
N.Engl.J.	0
Med.324	0
:	0
308-317	0
,	0
1991	0
;	0
S.M.Schnittman	0
,	0
M.C.Psallidopoulos	0
,	0
H.C.	0
Lane	0
,	0
L.Thompson	0
,	0
M.Baseler	0
,	0
F.Massari	0
,	0
C.H.Fox	0
,	0
N.P.Salzman	0
,	0
and	0
A.S.Fauci	0
,	0
Science	0
245	0
:	0
305-308	0
,	0
1989	0
)	0
.	0

Production	0
of	0
HIV-1	0
from	0
latently	0
infected	0
cells	0
requires	0
host	0
cell	0
activation	0
by	0
T-cell	9
mitogens	10
(	0
T.Folks	0
,	0
D.M.Powell	0
,	0
M.M.Lightfoote	0
,	0
S.Benn	0
,	0
M.A.	0
Martin	0
,	0
and	0
A.S.Fauci	0
,	0
Science	0
231	0
:	0
600-602	0
,	0
1986	0
;	0
D.Zagury	0
,	0
J.	0
Bernard	0
,	0
R.Leonard	0
,	0
R.Cheynier	0
,	0
M.Feldman	0
,	0
P.S.Sarin	0
,	0
and	0
R.C.	0
Gallo	0
,	0
Science	0
231	0
:	0
850-853	0
,	0
1986	0
)	0
.	0

This	0
activation	0
is	0
mediated	0
by	0
the	0
host	9
transcription	10
factor	10
NF-kappa	9
B	10
[	0
G.Nabel	0
and	0
D.Baltimore	0
,	0
Nature	0
(	0
London	0
)	0
326	0
:	0
711-717	0
,	0
1987	0
]	0
.	0

We	0
report	0
here	0
that	0
the	0
HIV-1-encoded	9
Nef	10
protein	10
inhibits	0
the	0
induction	0
of	0
NF-kappa	9
B	10
DNA-binding	0
activity	0
by	0
T-	9
cell	10
mitogens	10
.	0

However	0
,	0
Nef	9
does	0
not	0
affect	0
the	0
DNA-binding	0
activity	0
of	0
other	0
transcription	9
factors	10
implicated	0
in	0
HIV-1	0
regulation	0
,	0
including	0
SP-1	9
,	0
USF	9
,	0
URS	9
,	0
and	0
NF-AT	9
.	0

Additionally	0
,	0
Nef	9
inhibits	0
the	0
induction	0
of	0
HIV-1-	0
and	0
interleukin	0
2-directed	0
gene	0
expression	0
,	0
and	0
the	0
effect	0
on	0
HIV-1	0
transcription	0
depends	0
on	0
an	0
intact	0
NF-kappa	1
B-binding	2
site	2
.	0

These	0
results	0
indicate	0
that	0
defective	0
recruitment	0
of	0
NF-kappa	9
B	10
may	0
underlie	0
Nef	9
's	0
negative	0
transcriptional	0
effects	0
on	0
the	0
HIV-1	1
and	2
interleukin	2
2	2
promoters	2
.	0

Further	0
evidence	0
suggests	0
that	0
Nef	9
inhibits	0
NF-kappa	9
B	10
induction	0
by	0
interfering	0
with	0
a	0
signal	0
derived	0
from	0
the	0
T-cell	9
receptor	10
complex	10
.	0

Expression	0
of	0
c-fos	1
,	0
c-jun	1
and	0
jun	1
B	2
in	0
peripheral	0
blood	0
lymphocytes	0
from	0
young	0
and	0
elderly	0
adults	0
.	0

The	0
expression	0
of	0
c-fos	1
,	2
c-jun	2
and	2
jun	2
B	2
proto-oncogenes	2
was	0
studied	0
in	0
phytohemagglutinin	5
(	6
PHA	6
)	6
activated	6
peripheral	6
blood	6
lymphocytes	6
(	0
PBL	7
)	0
from	0
young	0
and	0
aged	0
humans	0
.	0

Specific	0
mRNAs	3
for	0
c-fos	1
and	0
c-jun	1
were	0
detectable	0
within	0
30	0
min	0
after	0
cell	0
activation	0
and	0
reached	0
maximal	0
levels	0
within	0
2	0
h	0
.	0

Both	0
c-fos	3
and	4
jun	4
B	4
mRNAs	4
decreased	0
to	0
pre-activation	0
levels	0
within	0
6	0
h	0
,	0
while	0
c-jun	3
mRNA	4
remained	0
elevated	0
.	0

In	0
PHA-activated	5
PBL	6
,	0
no	0
age-related	0
differences	0
were	0
observed	0
in	0
c-fos	0
or	0
jun	0
B	0
mRNA	0
expression	0
.	0

However	0
,	0
c-jun	3
mRNA	4
levels	0
decreased	0
significantly	0
(	0
1.73	0
+/-	0
0.08	0
vs.	0
1.16	0
+/-	0
0.09	0
arbitrary	0
units	0
,	0
P	0
<	0
0.01	0
,	0
young	0
vs.	0
old	0
)	0
in	0
PBL	7
from	0
elderly	0
individuals	0
activated	0
with	0
PHA	9
.	0

Because	0
previous	0
work	0
has	0
demonstrated	0
that	0
T	7
cells	8
from	0
elderly	0
individuals	0
may	0
display	0
normal	0
proliferative	0
responses	0
when	0
activated	0
via	0
the	0
anti-CD2	9
pathway	0
,	0
c-jun	0
and	0
jun	0
B	0
mRNA	0
expression	0
was	0
also	0
studied	0
in	0
anti-CD2-activated	5
purified	6
T	6
cells	6
.	0

No	0
age-related	0
differences	0
were	0
found	0
in	0
the	0
expression	0
of	0
either	0
of	0
these	0
two	0
proto-oncogenes	1
by	0
anti-CD2	0
activated	0
T	0
cells	0
.	0

These	0
results	0
suggest	0
that	0
the	0
decreased	0
IL-2	9
production	0
and	0
proliferative	0
response	0
displayed	0
by	0
PHA-activated	5
PBL	6
from	0
elderly	0
adults	0
may	0
be	0
related	0
to	0
age-related	0
changes	0
in	0
c-jun	3
mRNA	4
expression	0
and	0
in	0
the	0
ratio	0
of	0
c-fos	0
to	0
c-jun	3
mRNA	4
.	0

Oct2	9
transactivation	0
from	0
a	0
remote	1
enhancer	2
position	2
requires	0
a	0
B-cell-restricted	0
activity	0
.	0

Previous	0
cotransfection	0
experiments	0
had	0
demonstrated	0
that	0
ectopic	0
expression	0
of	0
the	0
lymphocyte-specific	9
transcription	10
factor	10
Oct2	9
could	0
efficiently	0
activate	0
a	0
promoter	1
containing	0
an	0
octamer	0
motif	0
.	0

Oct2	9
expression	0
was	0
unable	0
to	0
stimulate	0
a	0
multimerized	1
octamer	2
enhancer	2
element	2
in	0
HeLa	5
cells	6
,	0
however	0
.	0

We	0
have	0
tested	0
a	0
variety	0
of	0
Oct2	9
isoforms	10
generated	0
by	0
alternative	0
splicing	0
for	0
the	0
capability	0
to	0
activate	0
an	0
octamer	1
enhancer	2
in	0
nonlymphoid	7
cells	8
and	0
a	0
B-cell	5
line	6
.	0

Our	0
analyses	0
show	0
that	0
several	0
Oct2	9
isoforms	10
can	0
stimulate	0
from	0
a	0
remote	0
position	0
but	0
that	0
this	0
stimulation	0
is	0
restricted	0
to	0
B	7
cells	8
.	0

This	0
result	0
indicates	0
the	0
involvement	0
of	0
either	0
a	0
B-cell-specific	9
cofactor	10
or	0
a	0
specific	0
modification	0
of	0
a	0
cofactor	9
or	0
the	0
Oct2	9
protein	10
in	0
Oct2	9
-mediated	0
enhancer	0
activation	0
.	0

Mutational	0
analyses	0
indicate	0
that	0
the	0
carboxy-terminal	9
domain	10
of	0
Oct2	9
is	0
critical	0
for	0
enhancer	0
activation	0
.	0

Moreover	0
,	0
this	0
domain	0
conferred	0
enhancing	0
activity	0
when	0
fused	0
to	0
the	0
Oct1	9
protein	10
,	0
which	0
by	0
itself	0
was	0
unable	0
to	0
stimulate	0
from	0
a	0
remote	0
position	0
.	0

The	0
glutamine-rich	9
activation	10
domain	10
present	0
in	0
the	0
amino-terminal	9
portion	10
of	10
Oct2	10
and	0
the	0
POU	9
domain	10
contribute	0
only	0
marginally	0
to	0
the	0
transactivation	0
function	0
from	0
a	0
distal	0
position	0
.	0

The	0
promoter	1
of	0
the	0
CD19	1
gene	2
is	0
a	0
target	0
for	0
the	0
B-cell-specific	9
transcription	10
factor	10
BSAP	9
.	0

The	0
CD19	9
protein	10
is	0
expressed	0
on	0
the	0
surface	0
of	0
all	0
B-lymphoid	7
cells	8
with	0
the	0
exception	0
of	0
terminally	7
differentiated	8
plasma	8
cells	8
and	0
has	0
been	0
implicated	0
as	0
a	0
signal-transducing	0
receptor	0
in	0
the	0
control	0
of	0
proliferation	0
and	0
differentiation	0
.	0

Here	0
we	0
demonstrate	0
complete	0
correlation	0
between	0
the	0
expression	0
pattern	0
of	0
the	0
CD19	1
gene	2
and	0
the	0
B-cell-specific	9
transcription	10
factor	10
BSAP	9
in	0
a	0
large	0
panel	0
of	0
B-lymphoid	5
cell	6
lines	6
.	0

The	0
human	1
CD19	2
gene	2
has	0
been	0
cloned	0
,	0
and	0
several	0
BSAP-binding	1
sites	2
have	0
been	0
mapped	0
by	0
in	0
vitro	0
protein-DNA	0
binding	0
studies	0
.	0

In	0
particular	0
,	0
a	0
high-affinity	1
BSAP-binding	2
site	2
instead	0
of	0
a	0
TATA	1
sequence	2
is	0
located	0
in	0
the	0
-30	1
promoter	2
region	2
upstream	0
of	0
a	0
cluster	0
of	0
heterogeneous	0
transcription	0
start	0
sites	0
.	0

Moreover	0
,	0
this	0
site	0
is	0
occupied	0
by	0
BSAP	9
in	0
vivo	0
in	0
a	0
CD19-expressing	5
B-cell	6
line	6
but	0
not	0
in	0
plasma	7
or	0
HeLa	5
cells	6
.	0

This	0
high-affinity	1
site	2
has	0
been	0
conserved	0
in	0
the	0
promoters	1
of	0
both	0
human	1
and	2
mouse	2
CD19	2
genes	2
and	0
was	0
furthermore	0
shown	0
to	0
confer	0
B-cell	0
specificity	0
to	0
a	0
beta-globin	0
reporter	0
gene	0
in	0
transient	0
transfection	0
experiments	0
.	0

In	0
addition	0
,	0
BSAP	9
was	0
found	0
to	0
be	0
the	0
only	0
abundant	0
DNA-binding	0
activity	0
of	0
B-cell	0
nuclear	0
extracts	0
that	0
interacts	0
with	0
the	0
CD19	1
promoter	2
.	0

Together	0
,	0
this	0
evidence	0
strongly	0
implicates	0
BSAP	9
in	0
the	0
regulation	0
of	0
the	0
CD19	1
gene	2
.	0

Eicosanoids	0
in	0
breast	0
cancer	0
patients	0
before	0
and	0
after	0
mastectomy	0
.	0

In	0
19	0
patients	0
with	0
a	0
malignant	0
breast	0
tumor	0
,	0
tumor	0
tissue	0
and	0
blood	0
were	0
taken	0
to	0
determine	0
the	0
eicosanoid	0
profile	0
and	0
platelet	7
aggregation	0
.	0

Values	0
were	0
compared	0
with	0
those	0
of	0
patients	0
with	0
benign	0
tumors	0
(	0
n	0
=	0
4	0
)	0
,	0
or	0
undergoing	0
a	0
mammary	0
reduction	0
(	0
n	0
=	0
7	0
)	0
.	0

Postoperatively	0
,	0
blood	0
was	0
taken	0
as	0
well	0
in	0
order	0
to	0
compare	0
pre-	0
and	0
postoperative	0
values	0
.	0

Eicosanoids	0
were	0
measured	0
in	0
peripheral	7
blood	8
monocytes	8
and	0
mammary	0
tissue	0
by	0
means	0
of	0
HPLC	0
;	0
furthermore	0
,	0
TXA2	0
,	0
6-keto-PGF1	0
alpha	0
,	0
and	0
PGE2	0
were	0
determined	0
by	0
RIA	0
.	0

Differences	0
in	0
pre-	0
and	0
postoperative	0
values	0
of	0
cancer	0
patients	0
were	0
seen	0
in	0
plasma	0
RIA	0
values	0
:	0
PGE2	0
and	0
6-k-PGF1	0
alpha	0
were	0
significantly	0
higher	0
preoperatively	0
when	0
compared	0
with	0
postoperatively	0
,	0
however	0
,	0
such	0
differences	0
were	0
seen	0
in	0
the	0
control	0
groups	0
as	0
well	0
.	0

Compared	0
to	0
benign	0
tumor	0
or	0
mammary	0
reduction	0
test	0
material	0
the	0
eicosanoid	0
profile	0
of	0
tissue	0
obtained	0
from	0
malignant	0
mammary	0
tumors	0
showed	0
important	0
differences	0
.	0

Except	0
for	0
PGF2	0
alpha	0
,	0
HHT	0
and	0
15-HETE	0
no	0
detectable	0
quantities	0
of	0
eicosanoids	0
were	0
found	0
in	0
the	0
non-tumor	0
material	0
,	0
whereas	0
in	0
the	0
malignant	0
tumor	0
material	0
substantial	0
quantities	0
of	0
a	0
number	0
of	0
eicosanoid	0
metabolites	0
were	0
present	0
.	0

Statistically	0
significant	0
correlations	0
could	0
be	0
established	0
between	0
patient/histopathology	0
data	0
and	0
the	0
results	0
of	0
the	0
platelet	7
aggregation	0
assays	0
,	0
e.g.	0
between	0
menopausal	0
status	0
and	0
ADP	0
aggregation	0
;	0
oestrogen	9
receptor	10
(	0
+/-	0
)	0
and	0
collagen	9
and	0
arachidonic	0
acid	0
aggregation	0
,	0
inflammatory	0
cell	0
infiltration	0
score	0
and	0
arachidonic	0
acid	0
aggregation	0
and	0
fibrosis	0
score	0
and	0
ADP	0
aggregation	0
.	0

The	0
results	0
show	0
that	0
eicosanoid	0
synthesis	0
in	0
material	0
from	0
mammary	0
cancer	0
patients	0
is	0
different	0
from	0
that	0
in	0
benign	0
mammary	0
tissue	0
.	0

The	0
implications	0
,	0
in	0
particular	0
,	0
in	0
relation	0
to	0
future	0
prognosis	0
of	0
the	0
patient	0
,	0
remain	0
obscure	0
.	0

Mineralocorticoids	0
and	0
mineralocorticoid	9
receptors	10
in	0
mononuclear	7
leukocytes	8
in	0
patients	0
with	0
pregnancy-induced	0
hypertension	0
.	0

To	0
examine	0
the	0
role	0
of	0
mineralocorticoids	0
in	0
the	0
pathophysiology	0
of	0
pregnancy-induced	0
hypertension	0
(	0
PIH	0
)	0
,	0
we	0
studied	0
plasma	0
aldosterone	0
and	0
18-hydroxycorticosterone	0
levels	0
in	0
25	0
women	0
with	0
PIH	0
and	0
25	0
normal	0
pregnant	0
women	0
,	0
as	0
controls	0
.	0

Furthermore	0
,	0
we	0
evaluated	0
the	0
mineralocorticoid	9
receptor	10
(	0
MR	9
)	0
status	0
in	0
mononuclear	7
leukocytes	8
in	0
the	0
2	0
groups	0
.	0

MR	9
count	0
was	0
significantly	0
(	0
P	0
less	0
than	0
0.0005	0
)	0
decreased	0
in	0
the	0
PIH	0
group	0
(	0
148	0
+/-	0
9	0
binding	0
sites/cell	0
)	0
compared	0
with	0
the	0
control	0
group	0
(	0
300	0
+/-	0
17	0
binding	0
sites/cell	0
;	0
mean	0
+/-	0
SEM	0
)	0
.	0

Plasma	0
aldosterone	0
in	0
women	0
with	0
PIH	0
was	0
281	0
+/-	0
61	0
pmol/L	0
;	0
in	0
normal	0
pregnant	0
women	0
it	0
was	0
697	0
+/-	0
172	0
pmol/L	0
(	0
P	0
less	0
than	0
0.025	0
)	0
.	0

Plasma	0
18-hydroxycorticosterone	0
was	0
also	0
significantly	0
(	0
P	0
less	0
than	0
0.025	0
)	0
lower	0
(	0
PIH	0
,	0
1071	0
+/-	0
149	0
pmol/L	0
;	0
controls	0
,	0
1907	0
+/-	0
318	0
pmol/L	0
)	0
.	0

These	0
values	0
were	0
determined	0
at	0
the	0
onset	0
of	0
clinical	0
symptoms	0
of	0
PIH	0
.	0

These	0
results	0
can	0
not	0
be	0
explained	0
by	0
receptor	0
down-regulation	0
due	0
to	0
higher	0
levels	0
of	0
mineralocorticoids	0
in	0
PIH	0
;	0
a	0
hitherto	0
unknown	0
mineralocorticoid	0
may	0
,	0
thus	0
,	0
be	0
responsible	0
for	0
the	0
hypertension	0
and	0
altered	0
MR	9
status	0
.	0

Structure	0
function	0
analysis	0
of	0
vitamin	0
D	0
analogs	0
with	0
C-ring	0
modifications	0
.	0

Analogs	0
of	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
)	0
with	0
substitutions	0
on	0
C-11	0
were	0
synthesized	0
.	0

Small	0
apolar	0
substitutions	0
(	0
11	0
alpha-methyl	0
,	0
11	0
alpha-fluoromethyl	0
)	0
did	0
not	0
markedly	0
decrease	0
the	0
affinity	0
for	0
the	0
vitamin	9
D	10
receptor	10
,	0
but	0
larger	0
(	0
11	0
alpha-chloromethyl	0
or	0
11	0
alpha-	0
or	0
11	0
beta-phenyl	0
)	0
or	0
more	0
polar	0
substitutions	0
(	0
11	0
alpha-hydroxymethyl	0
,	0
11	0
alpha-	0
(	0
2-hydroxyethyl	0
]	0
decreased	0
the	0
affinity	0
to	0
less	0
than	0
5	0
%	0
of	0
that	0
of	0
1	0
alpha	0
,	0
25-OH	0
)	0
2D3	0
.	0

Their	0
affinity	0
for	0
the	0
vitamin	9
D-binding	10
protein	10
,	0
however	0
,	0
increased	0
up	0
to	0
4-fold	0
.	0

The	0
biological	0
activity	0
of	0
11	0
alpha-methyl-1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
closely	0
resembled	0
that	0
of	0
the	0
natural	0
hormone	0
on	0
normal	0
and	0
leukemic	7
cell	8
proliferation	0
and	0
bone	0
resorption	0
,	0
whereas	0
its	0
in	0
vivo	0
effect	0
on	0
calcium	0
metabolism	0
of	0
the	0
rachitic	0
chick	0
was	0
about	0
50	0
%	0
of	0
that	0
of	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
.	0

The	0
11	0
beta-methyl	0
analog	0
had	0
a	0
greater	0
than	0
10-fold	0
lower	0
activity	0
.	0

The	0
differentiating	0
effects	0
of	0
the	0
other	0
C-11	0
analogs	0
on	0
human	5
promyeloid	6
leukemia	6
cells	6
(	0
HL-60	5
)	0
agreed	0
well	0
with	0
their	0
bone-resorbing	0
activity	0
and	0
receptor	0
affinity	0
,	0
but	0
they	0
demonstrated	0
lower	0
calcemic	0
effects	0
in	0
vivo	0
.	0

Large	0
or	0
polar	0
substitutions	0
on	0
C-11	0
of	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
thus	0
impair	0
the	0
binding	0
of	0
the	0
vitamin	9
D	10
receptor	10
but	0
increase	0
the	0
affinity	0
to	0
vitamin	9
D-binding	10
protein	10
.	0

The	0
effects	0
of	0
many	0
C-11-substituted	0
1	0
alpha	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
analogs	0
on	0
HL-60	5
cell	0
differentiation	0
exceeded	0
their	0
activity	0
on	0
calcium	0
metabolism	0
.	0

Glucocorticoid	9
receptor	10
binding	0
in	0
three	0
different	0
cell	0
types	0
in	0
major	0
depressive	0
disorder	0
:	0
lack	0
of	0
evidence	0
of	0
receptor	0
binding	0
defect	0
.	0

1	0
.	0

In	0
order	0
to	0
further	0
understand	0
the	0
apparent	0
glucocorticoid	0
resistance	0
in	0
major	0
depressive	0
disorder	0
,	0
circadian	0
variation	0
in	0
cortisol	0
concentration	0
,	0
dexamethasone	0
suppression	0
and	0
glucocorticoid	0
receptor	0
binding	0
in	0
mononuclear	7
leukocytes	8
,	0
polymorphonuclear	7
leukocytes	8
and	0
cultured	5
skin	6
fibroblasts	6
were	0
measured	0
in	0
rigidly	0
defined	0
major	0
depressive	0
disorder	0
patients	0
and	0
non-depressed	0
psychiatric	0
controls	0
.	0

2	0
.	0

Mononuclear	7
leukocytes	8
binding	0
to	0
glucocorticoid	0
correlated	0
significantly	0
with	0
polymorphonuclear	7
leukocytes	8
binding	0
to	0
glucocorticoid	0
,	0
but	0
both	0
determinations	0
failed	0
to	0
differentiate	0
major	0
depressive	0
disorder	0
and	0
control	0
subjects	0
.	0

3	0
.	0

Initial	0
and	0
post-dexamethasone	0
in	0
vitro	0
fibroblast	0
binding	0
to	0
glucocorticoid	0
was	0
not	0
different	0
between	0
major	0
depressive	0
disorder	0
and	0
non-depressed	0
control	0
subjects	0
.	0

4	0
.	0

The	0
phenomenon	0
of	0
glucocorticoid	0
resistance	0
in	0
major	0
depressive	0
disorder	0
remains	0
unexplained	0
.	0

High	0
affinity	0
aldosterone	0
binding	0
to	0
plasma	0
membrane	0
rich	0
fractions	0
from	0
mononuclear	7
leukocytes	8
:	0
is	0
there	0
a	0
membrane	9
receptor	10
for	0
mineralocorticoids	0
?	0

In	0
vitro	0
effects	0
of	0
aldosterone	0
on	0
the	0
intracellular	0
concentrations	0
of	0
sodium	0
,	0
potassium	0
and	0
calcium	0
,	0
cell	0
volume	0
and	0
the	0
sodium-proton-antiport	9
have	0
been	0
described	0
in	0
intact	0
human	7
mononuclear	8
leukocytes	8
(	0
HML	7
)	0
.	0

In	0
the	0
present	0
paper	0
,	0
the	0
binding	0
of	0
a	0
[	0
125I	0
]	0
-labeled	0
aldosterone	0
derivative	0
to	0
plasma	0
membrane	0
rich	0
fractions	0
of	0
HML	7
was	0
studied	0
.	0

High	0
affinity	0
binding	0
of	0
the	0
radioligand	0
with	0
an	0
apparent	0
Kd	0
of	0
approximately	0
0.1	0
nM	0
was	0
found	0
.	0

Aldosterone	0
displaced	0
the	0
tracer	0
at	0
a	0
similar	0
Kd	0
.	0

Both	0
canrenone	0
and	0
cortisol	0
were	0
inactive	0
as	0
ligands	0
up	0
to	0
concentrations	0
of	0
0.1	0
microM	0
.	0

The	0
findings	0
are	0
the	0
first	0
to	0
demonstrate	0
membrane	0
binding	0
sites	0
with	0
a	0
high	0
affinity	0
for	0
aldosterone	0
,	0
but	0
not	0
for	0
cortisol	0
.	0

These	0
data	0
are	0
perfectly	0
compatible	0
with	0
major	0
properties	0
of	0
steroidal	0
effects	0
on	0
the	0
sodium-proton-antiport	9
in	0
HML	7
and	0
thus	0
very	0
likely	0
represent	0
membrane	9
receptors	10
for	0
aldosterone	0
.	0

Natural	0
variants	0
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
:	0
analysis	0
of	0
promoters	1
with	0
duplicated	0
DNA	1
regulatory	2
motifs	2
.	0

Sequence	0
variation	0
in	0
the	0
long	1
terminal	2
repeat	2
(	2
LTR	2
)	2
region	2
of	0
HIV-1	0
was	0
analyzed	0
in	0
viral	0
isolates	0
of	0
17	0
infected	0
individuals	0
.	0

Two	0
classes	0
of	0
LTR	0
size	0
variants	0
were	0
found	0
.	0

One	0
HIV-1	0
variant	0
was	0
detected	0
containing	0
an	0
additional	0
binding	0
site	0
for	0
the	0
transcription	0
factor	0
Sp1	0
.	0

Another	0
LTR	1
size	2
variation	2
was	0
observed	0
in	0
four	0
patients	0
in	0
a	0
region	0
just	0
upstream	0
of	0
the	0
NF-kappa	1
B	2
enhancer	2
.	0

This	0
variation	0
was	0
the	0
result	0
of	0
a	0
duplication	0
of	0
a	0
short	1
DNA	2
sequence	2
(	0
CTG-motif	1
)	0
.	0

Cell	0
culture	0
experiments	0
demonstrated	0
that	0
the	0
natural	0
variant	0
with	0
four	0
Sp1	1
sites	2
had	0
a	0
slightly	0
higher	0
promoter	0
activity	0
and	0
viral	0
replication	0
rate	0
than	0
the	0
isogenic	1
control	2
LTR	2
with	0
three	0
Sp1	1
sites	2
.	0

No	0
positive	0
effect	0
of	0
the	0
duplicated	0
CTG-motif	1
could	0
be	0
detected	0
.	0

In	0
order	0
to	0
measure	0
small	0
differences	0
in	0
virus	0
production	0
more	0
accurately	0
,	0
equal	0
amounts	0
of	0
a	0
size	0
variant	0
and	0
the	0
wild-type	1
plasmid	2
were	0
cotransfected	0
into	0
T-cells	7
.	0

The	0
virus	0
with	0
four	0
Sp1	0
sites	0
did	0
outgrow	0
the	0
three	0
Sp1	0
virus	0
in	0
35	0
days	0
of	0
culture	0
and	0
CTG-monomer	0
virus	0
outcompeted	0
the	0
CTG-dimer	0
virus	0
in	0
42	0
days	0
.	0

Based	0
on	0
these	0
results	0
we	0
estimate	0
a	0
5-10	0
%	0
difference	0
in	0
virus	0
production	0
of	0
the	0
LTR	1
variants	2
when	0
compared	0
to	0
that	0
of	0
wild-type	0
.	0

A	0
novel	9
B	10
cell-derived	10
coactivator	10
potentiates	0
the	0
activation	0
of	0
immunoglobulin	1
promoters	2
by	0
octamer-binding	9
transcription	10
factors	10
.	0

A	0
novel	0
B	0
cell-restricted	0
activity	0
,	0
required	0
for	0
high	0
levels	0
of	0
octamer	1
/	0
Oct	1
-dependent	0
transcription	0
from	0
an	0
immunoglobulin	1
heavy	2
chain	2
(	2
IgH	2
)	2
promoter	2
,	0
was	0
detected	0
in	0
an	0
in	0
vitro	0
system	0
consisting	0
of	0
HeLa	5
cell	6
-derived	0
extracts	0
complemented	0
with	0
fractionated	9
B	10
cell	10
nuclear	10
proteins	10
.	0

The	0
factor	0
responsible	0
for	0
this	0
activity	0
was	0
designated	0
Oct	9
coactivator	10
from	0
B	7
cells	8
(	0
OCA-B	9
)	0
.	0

OCA-B	9
stimulates	0
the	0
transcription	0
from	0
an	0
IgH	1
promoter	2
in	0
conjunction	0
with	0
either	0
Oct-1	9
or	0
Oct-2	9
but	0
shows	0
no	0
significant	0
effect	0
on	0
the	0
octamer	1
/	0
Oct	1
-dependent	0
transcription	0
of	0
the	0
ubiquitously	1
expressed	2
histone	2
H2B	2
promoter	2
and	0
the	0
transcription	0
of	0
USF-	1
and	2
Sp1-regulated	2
promoters	2
.	0

Taken	0
together	0
,	0
our	0
results	0
suggest	0
that	0
OCA-B	9
is	0
a	0
tissue-	9
,	10
promoter-	10
,	10
and	10
factor-specific	10
coactivator	10
and	0
that	0
OCA-B	9
may	0
be	0
a	0
major	0
determinant	0
for	0
B	0
cell-specific	0
activation	0
of	0
immunoglobulin	1
promoters	2
.	0

In	0
light	0
of	0
the	0
evidence	0
showing	0
physical	0
and	0
functional	0
interactions	0
between	0
Oct	9
factors	10
and	0
OCA-B	9
,	0
we	0
propose	0
a	0
mechanism	0
of	0
action	0
for	0
OCA-B	9
and	0
discuss	0
the	0
implications	0
of	0
OCA-B	9
for	0
the	0
transcriptional	0
regulation	0
of	0
other	0
tissue-specific	1
promoters	2
.	0

SCL	9
and	0
related	0
hemopoietic	9
helix-loop-helix	10
transcription	10
factors	10
.	0

The	0
helix-loop-helix	9
(	10
HLH	10
)	10
proteins	10
are	0
a	0
family	0
of	0
transcription	9
factors	10
that	0
include	0
proteins	0
critical	0
to	0
differentiation	0
and	0
development	0
in	0
species	0
ranging	0
from	0
plants	0
to	0
mammals	0
.	0

Five	0
members	0
of	0
this	0
family	0
(	0
MYC	9
,	0
SCL	9
,	0
TAL-2	9
,	0
LYL-1	9
and	0
E2A	9
)	0
are	0
implicated	0
in	0
oncogenic	0
events	0
in	0
human	0
lymphoid	0
tumors	0
because	0
of	0
their	0
consistent	0
involvement	0
in	0
chromosomal	0
translocations	0
.	0

Although	0
activated	0
in	0
T	0
cell	0
leukemias	0
,	0
expression	0
of	0
SCL	9
and	0
LYL-1	9
is	0
low	0
or	0
undetectable	0
in	0
normal	7
T	8
cell	8
populations	8
.	0

SCL	9
is	0
expressed	0
in	0
erythroid	7
,	8
megakaryocyte	8
and	8
mast	8
cell	8
populations	8
(	0
the	0
same	0
cell	0
lineages	0
as	0
GATA-1	9
,	0
a	0
zinc-finger	9
transcription	10
factor	10
)	0
.	0

In	0
addition	0
,	0
both	0
SCL	9
and	0
GATA-1	9
undergo	0
coordinate	0
modulation	0
during	0
chemically	0
induced	0
erythroid	0
differentiation	0
of	0
mouse	7
erythroleukemia	8
cells	8
and	0
are	0
down-modulated	0
during	0
myeloid	0
differentiation	0
of	0
human	5
K562	6
cells	6
,	0
thus	0
implying	0
a	0
role	0
for	0
SCL	9
in	0
erythroid	0
differentiation	0
events	0
.	0

However	0
,	0
in	0
contrast	0
to	0
GATA-1	9
,	0
SCL	9
is	0
expressed	0
in	0
the	0
developing	0
brain	0
.	0

Studies	0
of	0
the	0
function	0
of	0
SCL	9
suggest	0
it	0
is	0
also	0
important	0
in	0
proliferation	0
and	0
self-renewal	0
events	0
in	0
erythroid	7
cells	8
.	0

Induction	0
of	0
the	0
POU	9
domain	10
transcription	10
factor	10
Oct-2	9
during	0
T-cell	7
activation	0
by	0
cognate	0
antigen	0
.	0

Oct-2	9
is	0
a	0
transcription	9
factor	10
that	0
binds	0
specifically	0
to	0
octamer	1
DNA	2
motifs	2
in	0
the	0
promoters	1
of	0
immunoglobulin	1
and	2
interleukin-2	2
genes	2
.	0

All	0
tumor	5
cell	6
lines	6
from	0
the	0
B-cell	7
lineage	8
and	0
a	0
few	0
from	0
the	0
T-cell	7
lineage	8
express	0
Oct-2	9
.	0

To	0
address	0
the	0
role	0
of	0
Oct-2	9
in	0
the	0
T-cell	7
lineage	8
,	0
we	0
studied	0
the	0
expression	0
of	0
Oct-2	3
mRNA	4
and	0
protein	0
in	0
nontransformed	5
human	6
and	6
mouse	6
T	6
cells	6
.	0

Oct-2	9
was	0
found	0
in	0
CD4+	5
and	6
CD8+	6
T	6
cells	6
prepared	0
from	0
human	0
peripheral	0
blood	0
and	0
in	0
mouse	7
lymph	8
node	8
T	8
cells	8
.	0

In	0
a	0
T-cell	5
clone	6
specific	0
for	0
pigeon	9
cytochrome	10
c	10
in	0
the	0
context	0
of	0
I-Ek	9
,	0
Oct-2	9
was	0
induced	0
by	0
antigen	0
stimulation	0
,	0
with	0
the	0
increase	0
in	0
Oct-2	9
protein	10
seen	0
first	0
at	0
3	0
h	0
after	0
activation	0
and	0
continuing	0
for	0
at	0
least	0
24	0
h	0
.	0

Oct-2	3
mRNA	4
induction	0
during	0
antigen-driven	0
T-cell	7
activation	0
was	0
blocked	0
by	0
cyclosporin	0
A	0
,	0
as	0
well	0
as	0
by	0
protein	0
synthesis	0
inhibitors	0
.	0

These	0
results	0
suggest	0
that	0
Oct-2	9
participates	0
in	0
transcriptional	0
regulation	0
during	0
T-cell	7
activation.	0
The	0
relatively	0
delayed	0
kinetics	0
of	0
Oct-2	9
induction	0
suggests	0
that	0
Oct-2	9
mediates	0
the	0
changes	0
in	0
gene	0
expression	0
which	0
occur	0
many	0
hours	0
or	0
days	0
following	0
antigen	0
stimulation	0
of	0
T	7
lymphocytes	8
.	0

Glucocorticoid	9
receptor	10
in	0
patients	0
with	0
lupus	0
nephritis	0
:	0
relationship	0
between	0
receptor	0
levels	0
in	0
mononuclear	7
leukocytes	8
and	0
effect	0
of	0
glucocorticoid	0
therapy	0
.	0

We	0
investigated	0
the	0
clinical	0
significance	0
of	0
glucocorticoid	9
receptor	10
determination	0
in	0
20	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
who	0
afterwards	0
developed	0
nephrotic	0
syndrome	0
.	0

Glucocorticoid	9
receptor	10
concentrations	0
in	0
mononuclear	7
leukocytes	8
(	0
MNL	7
)	0
in	0
these	0
patients	0
were	0
comparable	0
with	0
those	0
in	0
both	0
other	0
patients	0
with	0
SLE	0
and	0
healthy	0
persons	0
.	0

Improvement	0
in	0
urinary	0
protein	0
excretion	0
and	0
in	0
disease	0
activity	0
,	0
which	0
was	0
scored	0
according	0
to	0
the	0
SLE	0
Disease	0
Activity	0
Index	0
system	0
of	0
the	0
University	0
of	0
Toronto	0
,	0
closely	0
related	0
to	0
the	0
glucocorticoid	9
receptor	10
concentrations	0
in	0
MNL	7
isolated	0
from	0
the	0
corresponding	0
patients	0
.	0

In	0
summary	0
,	0
glucocorticoid	9
receptor	10
determination	0
in	0
patients	0
with	0
lupus	0
nephritis	0
may	0
be	0
a	0
predictive	0
clue	0
for	0
assessing	0
responsiveness	0
to	0
glucocorticoid	0
therapy	0
.	0

[	0
Changes	0
in	0
plasma	9
interleukin-1	10
and	0
their	0
possible	0
relationship	0
with	0
the	0
changes	0
in	0
glucocorticoid	9
receptor	10
in	0
aged	0
long-distance	0
runner	0
]	0

For	0
the	0
study	0
of	0
the	0
changes	0
in	0
plasma	9
interleukin-1	10
(	0
IL-1	9
)	0
and	0
their	0
possible	0
relationship	0
with	0
the	0
changes	0
in	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
,	0
plasma	9
IL-1	10
and	0
GR	9
in	0
peripheral	7
blood	8
leukocytes	8
in	0
aged	0
long-distance	0
runner	0
were	0
measured	0
simultaneously	0
.	0

The	0
activity	0
of	0
IL-1	9
was	0
expressed	0
as	0
its	0
ability	0
to	0
stimulate	0
3H-TdR	9
incorporation	0
in	0
the	0
thymocytes	7
of	0
C57	0
mice	0
.	0

GR	9
was	0
determined	0
by	0
whole	0
cell	0
assay	0
with	0
3H-Dex	0
.	0

The	0
results	0
showed	0
that	0
the	0
activity	0
of	0
plasma	0
IL-1	9
in	0
aged	0
long-distance	0
runner	0
was	0
209	0
%	0
,	0
223	0
%	0
and	0
145	0
%	0
of	0
the	0
control	0
at	0
14.7-18.7	0
,	0
3.8-7.0	0
and	0
1.5-2.6	0
KD	0
fractions	0
.	0

The	0
GR	9
in	0
peripheral	7
blood	8
leukocytes	8
in	0
aged	0
runner	0
was	0
65	0
%	0
of	0
the	0
control	0
.	0

Possible	0
relationship	0
between	0
the	0
changes	0
in	0
IL-1	9
and	0
GR	9
in	0
aged	0
long-distance	0
runner	0
and	0
its	0
physiological	0
significance	0
are	0
discussed	0
.	0

Mineralocorticoid	0
effector	0
mechanism	0
in	0
preeclampsia	0
.	0

Mineralocorticoid	0
effector	0
mechanisms	0
were	0
evaluated	0
in	0
29	0
patients	0
with	0
preeclampsia	0
and	0
in	0
25	0
uncomplicated	0
pregnancies	0
by	0
measurement	0
of	0
plasma	0
aldosterone	0
,	0
levels	0
of	0
mineralocorticoid	9
receptor	10
(	0
MR	9
)	0
in	0
mononuclear	7
leucocytes	8
,	0
and	0
subtraction	0
potential	0
difference	0
(	0
SPD	0
;	0
rectal	0
minus	0
oral	0
values	0
)	0
.	0

Mean	0
values	0
for	0
plasma	0
aldosterone	0
were	0
not	0
different	0
between	0
the	0
two	0
groups	0
,	0
but	0
significant	0
differences	0
were	0
observed	0
for	0
MR	9
(	0
preeclampsia	0
,	0
81	0
+/-	0
44	0
receptors/cell	0
;	0
controls	0
,	0
306	0
+/-	0
168	0
)	0
and	0
SPD	0
(	0
preeclampsia	0
,	0
65	0
+/-	0
7	0
mV	0
;	0
controls	0
,	0
12	0
+/-	0
5	0
mV	0
)	0
.	0

In	0
six	0
cases	0
we	0
determined	0
MR	9
,	0
plasma	0
aldosterone	0
,	0
and	0
SPD	0
in	0
patients	0
with	0
preeclampsia	0
before	0
and	0
3	0
months	0
after	0
delivery	0
.	0

MR	9
were	0
reduced	0
before	0
delivery	0
(	0
96	0
+/-	0
27	0
receptors/cell	0
)	0
,	0
and	0
SPD	0
increased	0
(	0
64	0
+/-	0
8	0
mV	0
)	0
,	0
with	0
both	0
parameters	0
normalizing	0
after	0
delivery	0
(	0
MR	9
,	0
242	0
+/-	0
79	0
;	0
SPD	0
,	0
14.0	0
+/-	0
4	0
mV	0
)	0
.	0

Aldosterone	0
levels	0
returned	0
to	0
normal	0
nonpregnant	0
values	0
after	0
delivery	0
.	0

These	0
data	0
suggest	0
an	0
important	0
role	0
for	0
abnormalities	0
in	0
mineralocorticoid	0
effector	0
mechanisms	0
in	0
the	0
etiology	0
of	0
preeclampsia	0
and	0
could	0
be	0
an	0
useful	0
marker	0
for	0
diagnosis	0
.	0

Kinetics	0
of	0
nuclear	0
translocation	0
and	0
turnover	0
of	0
the	0
vitamin	9
D	10
receptor	10
in	0
human	5
HL60	6
leukemia	6
cells	6
and	0
peripheral	7
blood	8
lymphocytes	8
--	0
coincident	0
rise	0
of	0
DNA-relaxing	0
activity	0
in	0
nuclear	0
extracts	0
.	0

High	9
affinity	10
receptors	10
(	0
VDR	9
)	0
for	0
1	0
,	0
25-dihydroxycholecalciferol	0
(	0
calcitriol	0
)	0
are	0
expressed	0
in	0
HL60	0
human	0
leukemia	0
cells	0
and	0
in	0
low	0
numbers	0
in	0
peripheral	7
blood	8
lymphocytes	8
(	0
PBL	7
)	0
.	0

HL60	5
cells	6
,	0
expressing	0
some	0
characteristics	0
of	0
promyelocytes	5
,	0
can	0
be	0
induced	0
to	0
monocytoid	0
differentiation	0
by	0
calcitriol	0
.	0

Specific	0
nuclear	0
translocation	0
of	0
[	9
3H	10
]	10
calcitriol/VDR	10
was	0
examined	0
after	0
exposure	0
of	0
whole	7
cells	8
to	0
10	0
(	0
-9	0
)	0
M/l	0
calcitriol	0
in	0
the	0
presence	0
and	0
absence	0
of	0
a	0
500-fold	0
excess	0
of	0
unlabeled	0
ligand	0
and	0
subsequent	0
isolation	0
of	0
nuclei	0
.	0

Specific	0
nuclear	0
translocation	0
of	0
[	9
3H	10
]	10
calcitriol/VDR	10
was	0
found	0
to	0
be	0
time	0
dependent	0
reaching	0
a	0
maximum	0
of	0
approximately	0
2100	0
binding	0
sites/nucleus	0
after	0
3	0
h	0
of	0
incubation	0
in	0
HL60	5
cells	6
,	0
whereas	0
a	0
maximum	0
of	0
approximately	0
310	0
binding	0
sites/nucleus	0
was	0
found	0
after	0
3	0
h	0
in	0
PBL	7
.	0

Pulse	0
exposure	0
of	0
HL60	5
to	0
radiolabeled	0
hormone	0
for	0
3	0
h	0
followed	0
by	0
culture	0
in	0
medium	0
without	0
serum	0
and	0
calcitriol	0
lead	0
to	0
nuclear	0
retention	0
of	0
approximately	0
1600	9
radiolabeled	10
VDR	10
by	0
8	0
h	0
and	0
approximately	0
1000	0
VDR	9
by	0
24	0
h	0
.	0

Radiolabeled	9
VDR	10
disappeared	0
from	0
the	0
nuclear	0
compartment	0
with	0
a	0
halflife	0
of	0
approximately	0
30	0
min	0
if	0
cells	0
were	0
cultured	0
with	0
identical	0
concentrations	0
of	0
unlabeled	0
hormone	0
after	0
the	0
pulse	0
(	0
pulse/chase-experiments	0
)	0
.	0

No	0
difference	0
of	0
VDR	9
retention	0
in	0
pulse	0
and	0
pulse/chase-experiments	0
was	0
seen	0
in	0
PBL	7
,	0
where	0
VDR	9
halflife	0
was	0
approximately	0
30	0
min	0
.	0

No	0
specific	0
translocation	0
into	0
the	0
nuclear	0
compartment	0
was	0
seen	0
when	0
isolated	0
nuclei	0
were	0
incubated	0
in	0
[	0
3H	0
]	0
calcitriol	0
.	0

Radiolabeled	9
hormone/receptor	10
complexes	10
of	0
nuclei	0
isolated	0
from	0
cells	0
exposed	0
for	0
3	0
h	0
to	0
radiolabeled	0
hormone	0
--	0
in	0
contrast	0
to	0
identical	0
experiments	0
with	0
intact	0
cells	0
--	0
did	0
not	0
disappear	0
from	0
the	0
nuclear	0
compartment	0
upon	0
incubation	0
of	0
nuclei	0
with	0
identical	0
concentrations	0
of	0
the	0
unlabeled	0
compound	0
.	0

The	0
activity	0
of	0
DNA	9
relaxing	10
enzymes	10
(	0
e.g	0
.	0
topoisomerases	9
I	10
and	10
II	10
)	0
in	0
nuclear	0
extracts	0
was	0
measured	0
using	0
a	0
PBR	0
322-relaxation-assay	0
.	0

Enhanced	0
overall	0
enzyme	0
activity	0
was	0
found	0
in	0
nuclear	0
extracts	0
by	0
1	0
h	0
after	0
incubation	0
with	0
calcitriol	0
(	0
final	0
ethanol	0
concentration	0
0.0001	0
%	0
v/v	0
)	0
in	0
HL60	5
and	0
PBL	7
.	0

The	0
enhanced	0
activity	0
disappeared	0
after	0
2	0
h	0
in	0
PBL	7
,	0
whereas	0
it	0
was	0
still	0
enhanced	0
by	0
4	0
h	0
in	0
HL60	5
.	0

No	0
effect	0
was	0
seen	0
in	0
ethanol	5
treated	6
controls	6
.	0

We	0
conclude	0
that	0
a	0
specific	0
nuclear	0
translocation	0
mechanism	0
exists	0
for	0
calcitriol	0
in	0
both	0
cell	0
types	0
examined	0
,	0
most	0
likely	0
due	0
to	0
translocation	0
of	0
receptor	9
proteins	10
after	0
hormone	0
binding	0
.	0

Translocated	9
hormone/receptor	10
complexes	10
compete	0
for	0
a	0
limited	0
number	0
of	0
specific	0
nuclear	0
binding	0
sites	0
.	0

Enhanced	0
activity	0
of	0
topoisomerases	9
in	0
nuclear	0
extracts	0
upon	0
translocation	0
of	0
VDR	9
might	0
reflect	0
interaction	0
of	0
both	0
within	0
the	0
nuclear	0
compartment	0
,	0
thus	0
initiating	0
DNA-unwinding	0
,	0
a	0
prerequisite	0
of	0
transcription	0
initiation	0
.	0

Influence	0
of	0
estradiol	0
and	0
tamoxifen	0
on	0
susceptibility	0
of	0
human	5
breast	6
cancer	6
cell	6
lines	6
to	0
lysis	0
by	0
lymphokine-activated	7
killer	8
cells	8
.	0

The	0
design	0
of	0
combination	0
hormonal	0
and	0
immunotherapeutic	0
protocols	0
for	0
breast	0
cancer	0
patients	0
may	0
be	0
facilitated	0
by	0
analysis	0
of	0
preclinical	0
in	0
vitro	0
model	0
systems	0
.	0

Estrogen	5
receptor	6
positive	6
(	6
ER+	6
:	6
MCF-7	6
)	6
and	6
negative	6
(	6
ER-	6
:	6
MDA-MB-231	6
)	6
human	6
breast	6
cancer	6
cell	6
lines	6
were	0
utilized	0
to	0
evaluate	0
the	0
effects	0
of	0
tamoxifen	0
(	0
TAM	0
)	0
and	0
estradiol	0
(	0
E2	0
)	0
on	0
modulation	0
of	0
breast	0
cancer	0
target	0
susceptibility	0
to	0
lysis	0
by	0
lymphokine-activated	7
killer	8
(	8
LAK	8
)	8
cells	8
.	0

E2-stimulated	5
ER+	6
cells	6
were	0
more	0
susceptible	0
to	0
lysis	0
by	0
LAK	7
cells	8
than	0
corresponding	0
TAM-treated	5
or	0
control	7
cells	8
,	0
while	0
treatment	0
of	0
ER-	5
cells	6
with	0
either	0
E2	0
or	0
TAM	0
alone	0
did	0
not	0
alter	0
from	0
control	0
their	0
susceptibility	0
to	0
this	0
immune-mediated	0
lysis	0
.	0

All	0
ER+	5
and	6
ER-	6
cells	6
tested	0
remained	0
sensitive	0
after	0
treatment	0
with	0
TAM	0
to	0
lysis	0
by	0
LAK	7
cells	8
.	0

In	0
addition	0
,	0
an	0
adenocarcinoma	9
reactive	10
human-mouse	10
chimeric	10
monoclonal	10
antibody	10
(	0
ING-1	9
)	0
was	0
able	0
to	0
significantly	0
boost	0
in	0
vivo	0
generated	0
LAK	0
cell-mediated	0
lysis	0
of	0
control	5
,	6
E2-treated	6
,	6
and	6
TAM-treated	6
ER+	6
and	6
ER-	6
cells	6
.	0

These	0
in	0
vitro	0
results	0
provide	0
a	0
preclinical	0
rationale	0
for	0
in	0
vivo	0
testing	0
of	0
TAM	0
,	0
interleukin-2	9
(	0
IL-2	9
)	0
,	0
and	0
breast	0
cancer	0
reactive	0
antibody-dependent	0
cellular	0
cytotoxicity	0
facilitating	0
antibody	0
in	0
patients	0
with	0
refractory	0
or	0
high	0
risk	0
breast	0
cancer	0
.	0

The	0
cellular	1
oncogene	2
c-myb	1
can	0
interact	0
synergistically	0
with	0
the	0
Epstein-Barr	9
virus	10
BZLF1	10
transactivator	10
in	0
lymphoid	7
cells	8
.	0

Regulation	0
of	0
replicative	0
functions	0
in	0
the	0
Epstein-Barr	1
virus	2
(	2
EBV	2
)	2
genome	2
is	0
mediated	0
through	0
activation	0
of	0
a	0
virally	9
encoded	10
transcription	10
factor	10
,	0
Z	9
(	0
BZLF1	9
)	0
.	0

We	0
have	0
shown	0
that	0
the	0
Z	9
gene	10
product	10
,	0
which	0
binds	0
to	0
AP-1	1
sites	2
as	0
a	0
homodimer	0
and	0
has	0
sequence	0
similarity	0
to	0
c-Fos	1
,	0
can	0
efficiently	0
activate	0
the	0
EBV	1
early	2
promoter	2
,	0
BMRF1	1
,	0
in	0
certain	0
cell	0
types	0
(	0
i.e.	0
,	0
HeLa	5
cells	6
)	0
but	0
not	0
others	0
(	0
i.e.	0
,	0
Jurkat	5
cells	6
)	0
.	0

Here	0
we	0
demonstrate	0
that	0
the	0
c-myb	9
proto-oncogene	10
product	10
,	0
which	0
is	0
itself	0
a	0
DNA-binding	9
protein	10
and	0
transcriptional	9
transactivator	10
,	0
can	0
interact	0
synergistically	0
with	0
Z	9
in	0
activating	0
the	0
BMRF1	1
promoter	2
in	0
Jurkat	5
cells	6
(	0
a	0
T-cell	5
line	6
)	0
or	0
Raji	5
cells	6
(	0
an	0
EBV-positive	5
B-cell	6
)	0
,	0
whereas	0
the	0
c-myb	9
gene	10
product	10
by	0
itself	0
has	0
little	0
effect	0
.	0

The	0
simian	1
virus	2
40	2
early	2
promoter	2
is	0
also	0
synergistically	0
activated	0
by	0
the	0
Z/c-myb	9
combination	10
.	0

Synergistic	0
transactivation	0
of	0
the	0
BMRF1	1
promoter	2
by	0
the	0
Z/c-myb	9
combination	10
appears	0
to	0
involve	0
direct	0
binding	0
by	0
the	0
Z	9
protein	10
but	0
not	0
the	0
c-myb	9
protein	10
.	0

A	0
30-bp	1
sequence	2
in	0
the	0
BMRF1	1
promoter	2
which	0
contains	0
a	0
Z	1
binding	2
site	2
(	0
a	0
consensus	1
AP-1	2
site	2
)	0
is	0
sufficient	0
to	0
transfer	0
high-level	0
lymphoid-specific	0
responsiveness	0
to	0
the	0
Z/c-myb	9
combination	10
to	0
a	0
heterologous	1
promoter	2
.	0

That	0
the	0
c-myb	9
oncogene	10
product	10
can	0
interact	0
synergistically	0
with	0
an	0
EBV-encoded	9
member	10
of	0
the	0
leucine	9
zipper	10
protein	10
family	10
suggests	0
c-myb	1
is	0
likely	0
to	0
engage	0
in	0
similar	0
interactions	0
with	0
cellularly	9
encoded	10
transcription	10
factors	10
.	0

Alpha-lipoic	0
acid	0
is	0
a	0
potent	0
inhibitor	0
of	0
NF-kappa	9
B	10
activation	0
in	0
human	7
T	8
cells	8
.	0

Acquired	0
immunodeficiency	0
syndrome	0
(	0
AIDS	0
)	0
results	0
from	0
infection	0
with	0
a	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
.	0

The	0
long	1
terminal	2
repeat	2
(	2
LTR	2
)	2
region	2
of	0
HIV	1
proviral	2
DNA	2
contains	0
binding	0
sites	0
for	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
and	0
this	0
transcriptional	9
activator	10
appears	0
to	0
regulate	0
HIV	0
activation	0
.	0

Recent	0
findings	0
suggest	0
an	0
involvement	0
of	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
in	0
signal	0
transduction	0
pathways	0
leading	0
to	0
NF-kappa	9
B	10
activation	0
.	0

The	0
present	0
study	0
was	0
based	0
on	0
reports	0
that	0
antioxidants	0
which	0
eliminate	0
ROS	0
should	0
block	0
the	0
activation	0
of	0
NF-kappa	9
B	10
and	0
subsequently	0
HIV	0
transcription	0
,	0
and	0
thus	0
antioxidants	0
can	0
be	0
used	0
as	0
therapeutic	0
agents	0
for	0
AIDS	0
.	0

Incubation	0
of	0
Jurkat	5
T	6
cells	6
(	0
1	0
x	0
10	0
(	0
6	0
)	0
cells/ml	0
)	0
with	0
a	0
natural	0
thiol	0
antioxidant	0
,	0
alpha-lipoic	0
acid	0
,	0
prior	0
to	0
the	0
stimulation	0
of	0
cells	0
was	0
found	0
to	0
inhibit	0
NF-kappa	9
B	10
activation	0
induced	0
by	0
tumor	9
necrosis	10
factor-alpha	10
(	0
25	0
ng/ml	0
)	0
or	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
50	0
ng/ml	0
)	0
.	0

The	0
inhibitory	0
action	0
of	0
alpha-lipoic	0
acid	0
was	0
found	0
to	0
be	0
very	0
potent	0
as	0
only	0
4	0
mM	0
was	0
needed	0
for	0
a	0
complete	0
inhibition	0
,	0
whereas	0
20	0
mM	0
was	0
required	0
for	0
N-acetylcysteine	0
.	0

These	0
results	0
indicate	0
that	0
alpha-lipoic	0
acid	0
may	0
be	0
effective	0
in	0
AIDS	0
therapeutics	0
.	0

Reticuloendotheliosis	1
virus	2
long	2
terminal	2
repeat	2
elements	2
are	0
efficient	0
promoters	1
in	0
cells	0
of	0
various	0
species	0
and	0
tissue	0
origin	0
,	0
including	0
human	7
lymphoid	8
cells	8
.	0

Promiscuous	0
transcriptional	0
activity	0
of	0
the	0
reticuloendotheliosis	1
virus	2
(	2
REV	2
)	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
was	0
detected	0
in	0
transient	0
expression	0
assays	0
using	0
LTR-chloramphenicol	1
acetyltransferase-encoding	2
gene	2
chimeras	2
,	0
and	0
cells	0
of	0
diverse	0
species	0
and	0
tissue	0
type	0
;	0
levels	0
of	0
expression	0
from	0
two	0
different	0
REV	1
LTRs	2
correlate	0
with	0
reports	0
of	0
pathogenicity	0
of	0
the	0
respective	0
viruses	0
in	0
vivo	0
.	0

REVs	0
do	0
not	0
encode	0
a	0
transactivator	0
targeted	0
to	0
the	0
viral	1
LTR	2
,	0
and	0
cells	0
infected	0
with	0
Marek	0
's	0
disease	0
virus	0
,	0
a	0
herpesvirus	0
with	0
an	0
overlapping	0
host	0
range	0
,	0
do	0
not	0
express	0
factors	0
that	0
preferentially	0
enhance	0
expression	0
from	0
REV	0
or	0
avian	1
sarcoma/leukemia	2
virus	2
LTRs	2
.	0

REV	1
LTRs	2
work	0
efficiently	0
in	0
human	7
lymphoid	8
cells	8
,	0
and	0
are	0
viable	0
alternatives	0
to	0
promoters	1
commonly	0
used	0
for	0
expression	0
of	0
cloned	1
genes	2
.	0

They	0
may	0
also	0
prove	0
useful	0
in	0
the	0
identification	0
of	0
new	0
,	0
ubiquitous	9
cellular	10
transcription	10
factors	10
.	0

A	0
novel	0
Ets-related	9
transcription	10
factor	10
,	0
Elf-1	9
,	0
binds	0
to	0
human	1
immunodeficiency	2
virus	2
type	2
2	2
regulatory	2
elements	2
that	0
are	0
required	0
for	0
inducible	0
trans	0
activation	0
in	0
T	7
cells	8
.	0

Human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
and	0
HIV-2	0
are	0
structurally	0
related	0
retroviruses	0
which	0
both	0
cause	0
AIDS	0
in	0
humans	0
.	0

Although	0
both	0
viruses	0
establish	0
latency	0
in	0
quiescent	0
human-peripheral-blood	7
T	8
cells	8
,	0
the	0
asymptomatic	0
phase	0
of	0
HIV-2	0
infection	0
may	0
be	0
more	0
prolonged	0
than	0
that	0
of	0
HIV-1	0
.	0

The	0
latent	0
phases	0
of	0
both	0
HIV-1	0
and	0
HIV-2	0
infection	0
have	0
been	0
shown	0
to	0
be	0
disrupted	0
by	0
T-cell	0
activation	0
,	0
a	0
process	0
that	0
requires	0
host	0
cell	0
transcription	0
factors	0
.	0

In	0
the	0
case	0
of	0
HIV-1	0
,	0
the	0
transcription	0
factor	0
NF-kappa	9
B	10
is	0
sufficient	0
for	0
inducible	0
transcriptional	0
activation	0
.	0

In	0
contrast	0
,	0
factors	0
in	0
addition	0
to	0
NF-kappa	9
B	10
are	0
required	0
to	0
activate	0
HIV-2	0
transcription	0
in	0
infected	7
T	8
cells	8
.	0

In	0
this	0
report	0
,	0
we	0
demonstrate	0
that	0
a	0
novel	0
Ets-related	9
transcription	10
factor	10
,	0
Elf-1	9
,	0
binds	0
specifically	0
to	0
two	1
purine-rich	2
motifs	2
in	0
the	0
HIV-2	1
enhancer	2
.	0

Mutagenesis	0
experiments	0
demonstrated	0
that	0
these	0
Elf-1	1
binding	2
sites	2
are	0
required	0
for	0
induction	0
of	0
HIV-2	0
transcription	0
following	0
T-cell-receptor-mediated	0
T-cell	0
activation	0
.	0

Moreover	0
,	0
Elf-1	9
is	0
the	0
only	0
factor	0
present	0
in	0
activated	0
T-cell	0
nuclear	0
extracts	0
that	0
binds	0
to	0
these	0
sites	0
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

Thus	0
,	0
Elf-1	9
is	0
a	0
novel	9
transcription	10
factor	10
that	0
appears	0
to	0
be	0
required	0
for	0
the	0
T-cell-receptor-mediated	0
trans	0
activation	0
of	0
HIV-2	0
gene	0
expression	0
.	0

These	0
results	0
may	0
explain	0
differences	0
in	0
the	0
clinical	0
spectra	0
of	0
diseases	0
caused	0
by	0
HIV-1	0
and	0
HIV-2	0
and	0
may	0
also	0
have	0
implications	0
for	0
the	0
design	0
of	0
therapeutic	0
approaches	0
to	0
HIV-2	0
infection	0
.	0

Okadaic	0
acid	0
is	0
a	0
potent	0
inducer	0
of	0
AP-1	9
,	0
NF-kappa	9
B	10
,	0
and	0
tumor	9
necrosis	10
factor-alpha	10
in	0
human	7
B	8
lymphocytes	8
.	0

Treatment	0
of	0
human	7
B	8
lymphocytes	8
with	0
an	0
optimal	0
concentration	0
of	0
okadaic	0
acid	0
,	0
an	0
inhibitor	0
of	0
phosphatases	9
1	10
and	10
2A	10
,	0
resulted	0
in	0
the	0
induction	0
of	0
the	0
transcription	9
factor	10
,	0
AP-1	9
and	0
a	0
marked	0
increase	0
in	0
NF-kappa	9
B	10
levels	0
.	0

In	0
contrast	0
,	0
no	0
effect	0
on	0
the	0
levels	0
of	0
the	0
octamer	9
binding	10
proteins	10
,	0
Oct-1	9
or	0
Oct-2	9
,	0
were	0
found	0
.	0

Since	0
both	0
AP-1	9
and	0
NF-kappa	9
B	10
have	0
been	0
reported	0
to	0
be	0
important	0
in	0
the	0
induction	0
of	0
the	0
tumor	1
necrosis	2
factor-alpha	2
(	2
TNF-alpha	2
)	2
gene	2
we	0
examined	0
the	0
effects	0
of	0
okadaic	0
acid	0
on	0
TNF-alpha	3
mRNA	4
levels	0
.	0

Treatment	0
with	0
okadaic	0
acid	0
resulted	0
in	0
a	0
striking	0
increase	0
in	0
TNF-alpha	3
mRNA	4
transcripts	0
within	0
1	0
h	0
of	0
stimulation	0
and	0
large	0
amounts	0
of	0
TNF-alpha	9
were	0
released	0
into	0
the	0
culture	0
media	0
.	0

Although	0
okadaic	0
acid	0
provides	0
a	0
potent	0
inductive	0
signal	0
for	0
AP-1	9
and	0
NF-kappa	9
B	10
it	0
did	0
not	0
induce	0
either	0
B	0
cell	0
proliferation	0
or	0
immunoglobulin	9
secretion	0
.	0

Heterodimerization	0
and	0
transcriptional	0
activation	0
in	0
vitro	0
by	0
NF-kappa	9
B	10
proteins	10
.	0

The	0
NF-kappa	9
B	10
family	10
of	0
transcription	9
proteins	10
represents	0
multiple	0
DNA	0
binding	0
,	0
rel	9
related	10
polypeptides	10
that	0
contribute	0
to	0
regulation	0
of	0
genes	0
involved	0
in	0
immune	0
responsiveness	0
and	0
inflammation	0
,	0
as	0
well	0
as	0
activation	0
of	0
the	0
HIV	1
long	2
terminal	2
repeat	2
.	0

In	0
this	0
study	0
multiple	0
NF-kappa	9
B	10
related	10
polypeptides	10
ranging	0
from	0
85	0
to	0
45	0
kDa	0
were	0
examined	0
for	0
their	0
capacity	0
to	0
interact	0
with	0
the	0
PRDII	1
regulatory	2
element	2
of	0
interferon	1
beta	2
and	0
were	0
shown	0
to	0
possess	0
distinct	0
intrinsic	0
DNA	0
binding	0
affinities	0
for	0
this	0
NF-kappa	1
B	2
site	2
and	0
form	0
multiple	9
DNA	10
binding	10
homo-	10
and	10
heterodimer	10
complexes	10
in	0
co-renaturation	0
experiments	0
.	0

Furthermore	0
,	0
using	0
DNA	1
templates	2
containing	0
two	0
copies	0
of	0
the	0
PRDII	1
domain	2
linked	0
to	0
the	0
rabbit	1
beta	2
globin	2
gene	2
,	0
the	0
purified	0
polypeptides	0
specifically	0
stimulated	0
NF-kappa	9
B	10
dependent	0
transcription	0
in	0
an	0
in	0
vitro	0
reconstitution	0
assay	0
as	0
heterodimers	0
but	0
not	0
as	0
p50	9
homodimers	10
.	0

These	0
experiments	0
emphasize	0
the	0
role	0
of	0
NF-kappa	9
B	10
dimerization	0
as	0
a	0
distinct	0
level	0
of	0
transcriptional	0
control	0
that	0
may	0
permit	0
functional	0
diversification	0
of	0
a	0
limited	0
number	0
of	0
regulatory	9
proteins	10
.	0

c-myc	3
mRNA	4
expression	0
in	0
minor	0
salivary	0
glands	0
of	0
patients	0
with	0
Sjogren	0
's	0
syndrome	0
.	0

c-myc	1
protooncogene	2
is	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
B	0
cell	0
lymphoid	0
malignancies	0
and	0
high	0
levels	0
of	0
c-myc	3
mRNA	4
expression	0
are	0
observed	0
in	0
activated	7
blood	8
mononuclear	8
cells	8
.	0

Sjogren	0
's	0
syndrome	0
(	0
SS	0
)	0
is	0
characterized	0
by	0
lymphocytic	7
infiltrates	8
of	0
exocrine	0
glands	0
,	0
remarkable	0
B	0
cell	0
hyperreactivity	0
and	0
a	0
strong	0
predisposition	0
to	0
B	0
cell	0
neoplasia	0
.	0

In	0
this	0
study	0
,	0
c-myc	3
protooncogene	4
mRNA	4
expression	0
in	0
29	0
labial	0
minor	0
salivary	0
gland	0
biopsies	0
from	0
patients	0
with	0
primary	0
SS	0
and	0
15	0
controls	0
was	0
examined	0
using	0
in	0
situ	0
hybridization	0
histochemistry	0
.	0

Two	0
40mer	0
oligonucleotides	0
from	0
the	0
1st	1
and	2
the	2
2nd	2
exon	2
of	0
the	0
c-myc	1
gene	2
,	0
labeled	0
with	0
35S	0
,	0
were	0
used	0
as	0
probes	0
.	0

To	0
detect	0
the	0
origin	0
of	0
the	0
cell	0
hybridized	0
with	0
a	0
c-myc	1
probe	2
,	0
a	0
combined	0
immunochemistry	0
in	0
situ	0
hybridization	0
histochemistry	0
technique	0
was	0
used	0
.	0

High	0
c-myc	3
mRNA	4
expression	0
was	0
detected	0
on	0
acinar	7
epithelial	8
cells	8
.	0

c-myc	9
did	0
not	0
correlate	0
with	0
c-fos	9
and	0
c-jun	9
protein	0
expression	0
.	0

Stronger	0
c-myc	3
mRNA	4
expression	0
was	0
detected	0
in	0
labial	0
salivary	0
glands	0
of	0
patients	0
with	0
longer	0
disease	0
duration	0
(	0
p	0
less	0
than	0
or	0
equal	0
to	0
0.002	0
)	0
and	0
more	0
intense	0
T	7
lymphocyte	8
infiltrates	8
(	0
p	0
less	0
than	0
0.05	0
)	0
although	0
these	0
patients	0
revealed	0
no	0
hypergammaglobulinemia	0
.	0

No	0
correlation	0
was	0
observed	0
between	0
c-myc	3
mRNA	4
and	0
B	0
lymphocyte	0
monoclonicity	0
or	0
lymphoma	0
.	0

In	0
conclusion	0
,	0
strong	0
c-myc	3
mRNA	4
expression	0
was	0
observed	0
on	0
epithelial	7
cells	8
of	0
labial	0
salivary	0
glands	0
from	0
patients	0
with	0
primary	0
SS	0
.	0

Our	0
findings	0
may	0
indicate	0
the	0
presence	0
of	0
a	0
reactivated	0
virus	0
hosted	0
in	0
these	0
cells	0
.	0

Corticosteroid	9
receptors	10
and	0
lymphocyte	7
subsets	8
in	0
mononuclear	7
leukocytes	8
in	0
aging	0
.	0

Plasma	0
cortisol	0
and	0
aldosterone	0
levels	0
and	0
number	0
of	0
related	0
receptors	0
in	0
mononuclear	7
leukocytes	8
were	0
measured	0
in	0
49	0
healthy	0
aged	0
subjects	0
(	0
62-97	0
yr	0
)	0
and	0
in	0
21	0
adult	0
controls	0
(	0
21-50	0
yr	0
)	0
.	0

In	0
all	0
subjects	0
,	0
in	0
addition	0
,	0
lymphocyte	7
subsets	8
were	0
determined	0
as	0
an	0
index	0
of	0
corticosteroid	0
action	0
.	0

The	0
mean	0
number	0
of	0
type	9
I	10
and	10
type	10
II	10
receptors	10
was	0
significantly	0
lower	0
in	0
aged	0
subjects	0
than	0
in	0
controls	0
(	0
respectively	0
,	0
198	0
+/-	0
96	0
and	0
272	0
+/-	0
97	0
receptors	9
/cell	0
for	0
type	9
I	10
,	0
and	0
1	0
,	0
794	0
+/-	0
803	0
and	0
3	0
,	0
339	0
+/-	0
918	0
for	0
type	0
II	9
receptors	10
)	0
.	0

Plasma	0
aldosterone	0
and	0
cortisol	0
and	0
lymphocyte	7
subsets	8
were	0
not	0
different	0
in	0
the	0
two	0
groups	0
.	0

All	0
of	0
the	0
parameters	0
were	0
also	0
tested	0
for	0
correlation	0
,	0
and	0
a	0
significant	0
inverse	0
correlation	0
was	0
found	0
between	0
age	0
and	0
type	9
I	10
and	0
type	9
II	10
receptors	10
when	0
all	0
subjects	0
were	0
plotted	0
and	0
between	0
aged	0
and	0
CD4	7
and	0
age	0
and	0
CD4/CD8	7
in	0
the	0
aged	0
group	0
.	0

These	0
data	0
show	0
that	0
aged	0
subjects	0
have	0
reductions	0
of	0
corticosteroid	9
receptors	10
that	0
are	0
not	0
associated	0
with	0
increase	0
of	0
related	0
steroids	0
and	0
that	0
this	0
situation	0
probably	0
represents	0
a	0
concomitant	0
of	0
the	0
normal	0
aging	0
process	0
.	0

T	0
cell-specific	0
negative	0
regulation	0
of	0
transcription	0
of	0
the	0
human	9
cytokine	10
IL-4	10
.	0

IL-4	9
secreted	0
by	0
activated	7
T	8
cells	8
is	0
a	0
pleiotropic	9
cytokine	10
affecting	0
growth	0
and	0
differentiation	0
of	0
diverse	0
cell	0
types	0
such	0
as	0
T	7
cells	8
,	0
B	7
cells	8
,	0
and	0
mast	7
cells	8
.	0

We	0
investigated	0
the	0
upstream	1
regulatory	2
elements	2
of	0
the	0
human	1
IL-4	2
promoter	2
.	0

A	0
novel	1
T	2
cell-specific	2
negative	2
regulatory	2
element	2
(	0
NRE	1
)	0
composed	0
of	0
two	0
protein-binding	0
sites	0
were	0
mapped	0
in	0
the	0
5	0
'	0
flanking	0
region	0
of	0
the	0
IL-4	1
gene	2
:	0
-311CTCCCTTCT-303	0
(	0
NRE-I	1
)	0
and	0
-288CTTTTTGCTT-TGC-300	0
(	0
NRE-II	1
)	0
.	0

A	0
T	9
cell-specific	10
protein	10
Neg-1	9
and	0
a	0
ubiquitous	9
protein	10
Neg-2	9
binding	0
to	0
NRE-I	1
and	0
NRE-II	1
,	0
respectively	0
,	0
were	0
identified	0
.	0

Furthermore	0
,	0
a	0
positive	1
regulatory	2
element	2
was	0
found	0
45	1
bp	2
downstream	2
of	0
the	0
NRE	1
.	0

The	0
enhancer	0
activity	0
of	0
the	0
PRE	1
was	0
completely	0
suppressed	0
when	0
the	0
NRE	1
was	0
present	0
.	0

These	0
data	0
suggest	0
that	0
IL-4	1
promoter	2
activity	0
is	0
normally	0
down-regulated	0
by	0
an	0
NRE	1
via	0
repression	0
of	0
the	0
enhancer	1
positive	2
regulatory	2
element	2
.	0

These	0
data	0
may	0
have	0
implications	0
for	0
the	0
stringent	0
control	0
of	0
IL-4	9
expression	0
in	0
T	7
cells	8
.	0

Interleukin	0
6-induced	0
differentiation	0
of	0
a	0
human	5
B	6
cell	6
line	6
into	0
IgM-secreting	7
plasma	8
cells	8
is	0
mediated	0
by	0
c-fos	1
.	0

The	0
role	0
of	0
the	0
protooncogene	1
c-fos	2
in	0
interleukin	9
(	10
IL	10
)	10
6	10
-induced	0
B	0
cell	0
differentiation	0
was	0
assessed	0
.	0

Treatment	0
of	0
SKW	0
6.4	0
cells	0
with	0
IL	9
6	10
induced	0
a	0
transient	0
and	0
early	0
stimulation	0
of	0
c-fos	3
sense	4
mRNA	4
expression	0
.	0

The	0
effect	0
appeared	0
within	0
30	0
min	0
and	0
returned	0
to	0
basal	0
levels	0
after	0
2	0
h	0
.	0

The	0
addition	0
of	0
antisense	0
oligonucleotides	0
to	0
c-fos	1
significantly	0
inhibited	0
IL	9
6	10
-induced	0
IgM	9
production	0
by	0
SKW	5
6.4	6
cells	6
(	0
p	0
less	0
than	0
0.001	0
)	0
,	0
whereas	0
control	0
oligonucleotides	0
had	0
no	0
inhibitory	0
effect	0
.	0

These	0
results	0
indicate	0
that	0
activation	0
of	0
c-fos	1
is	0
involved	0
in	0
IL	9
6	10
-induced	0
differentiation	0
of	0
SKW	5
6.4	6
cells	6
into	0
IgM-secreting	5
cells	6
.	0

Transcriptional	0
regulation	0
during	0
T-cell	7
development	0
:	0
the	0
alpha	1
TCR	2
gene	2
as	0
a	0
molecular	0
model	0
.	0

The	0
regulation	0
of	0
gene	0
expression	0
during	0
lymphocyte	7
differentiation	0
is	0
a	0
complex	0
process	0
involving	0
interactions	0
between	0
multiple	1
positive	2
and	2
negative	2
transcriptional	2
regulatory	2
elements	2
.	0

In	0
this	0
article	0
,	0
transcriptional	0
regulation	0
of	0
the	0
archetypal	1
T-cell-specific	2
gene	2
,	0
alpha	1
TCR	2
,	0
is	0
discussed	0
.	0

Major	0
recent	0
developments	0
,	0
including	0
the	0
identification	0
of	0
novel	0
families	0
of	0
transcription	1
factors	2
that	0
regulate	0
multiple	0
T-cell	1
genes	2
during	0
thymocyte	0
ontogeny	0
and	0
T-cell	7
activation	0
,	0
are	0
described	0
.	0

Photoaffinity	0
labeling	0
of	0
plasma	9
membrane	10
receptors	10
for	0
aldosterone	0
from	0
human	7
mononuclear	8
leukocytes	8
.	0

Non-genomic	0
effects	0
of	0
aldosterone	0
on	0
the	0
sodium-proton-antiport	9
have	0
been	0
shown	0
in	0
human	7
mononuclear	8
leukocytes	8
which	0
could	0
be	0
related	0
to	0
a	0
new	0
aldosterone	9
membrane	10
receptor	10
.	0

In	0
the	0
present	0
paper	0
plasma	0
membranes	0
from	0
human	7
mononuclear	8
leukocytes	8
were	0
covalently	0
photolabeled	0
with	0
a	0
[	0
125I	0
]	0
-aldosterone	0
derivative	0
.	0

Sodium	0
dodecyl	0
sulfate-polyacrylamide	0
gel	0
electrophoresis	0
showed	0
significant	0
aldosterone	0
binding	0
at	0
a	0
molecular	0
weight	0
of	0
approximately	0
50000	0
Dalton	0
which	0
was	0
absent	0
with	0
1	0
microM	0
cold	0
aldosterone	0
,	0
but	0
not	0
cortisol	0
in	0
the	0
binding	0
media	0
.	0

The	0
presence	0
of	0
the	0
sulfhydryl	0
agent	0
dithiothreitol	0
did	0
not	0
affect	0
results	0
suggesting	0
the	0
absence	0
of	0
disulfide	9
bridges	10
in	0
the	0
steroid	9
binding	10
domain	10
of	0
the	0
receptor	0
.	0

These	0
data	0
are	0
the	0
first	0
to	0
define	0
the	0
molecular	0
weight	0
of	0
the	0
membrane	9
receptor	10
for	0
aldosterone	0
.	0

Redox	0
status	0
of	0
cells	0
influences	0
constitutive	0
or	0
induced	0
NF-kappa	9
B	10
translocation	0
and	0
HIV	1
long	2
terminal	2
repeat	2
activity	0
in	0
human	5
T	6
and	6
monocytic	6
cell	6
lines	6
.	0

We	0
have	0
tested	0
the	0
hypothesis	0
that	0
cellular	0
activation	0
events	0
occurring	0
in	0
T	7
lymphocytes	8
and	0
monocytes	7
and	0
mediated	0
through	0
translocation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
are	0
dependent	0
upon	0
the	0
constitutive	0
redox	0
status	0
of	0
these	0
cells	0
.	0

We	0
used	0
phenolic	0
,	0
lipid-soluble	0
,	0
chain-breaking	0
antioxidants	0
(	0
butylated	0
hydroxyanisole	0
(	0
BHA	0
)	0
,	0
nordihydroquairetic	0
acid	0
,	0
or	0
alpha-tocopherol	0
(	0
vitamin	0
E	0
)	0
to	0
show	0
that	0
peroxyl	0
radical	0
scavenging	0
in	0
unstimulated	5
and	6
PMA-	6
or	6
TNF-stimulated	6
cells	6
blocks	0
the	0
functions	0
depending	0
on	0
NF-kappa	9
B	10
activation	0
.	0

BHA	0
was	0
found	0
to	0
suppress	0
not	0
only	0
PMA-	0
or	0
TNF-induced	0
,	0
but	0
also	0
constitutive	0
,	0
HIV-enhancer	0
activity	0
concomitant	0
to	0
an	0
inhibition	0
of	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
both	0
lymphoblastoid	5
T	6
(	0
J.Jhan	5
)	0
and	0
monocytic	5
(	6
U937	6
)	6
cell	6
lines	6
.	0

This	0
was	0
also	0
true	0
for	0
KBF	0
(	0
p50	0
homodimer	0
)	0
binding	0
activity	0
in	0
U937	5
cells	6
.	0

Secretion	0
of	0
TNF	9
,	0
the	0
product	0
of	0
another	0
NF-kappa	1
B-dependent	2
gene	2
,	0
was	0
abolished	0
by	0
BHA	0
in	0
PMA-stimulated	5
U937	6
cells	6
.	0

The	0
anti-oxidative	0
effect	0
of	0
BHA	0
was	0
accompanied	0
by	0
an	0
increase	0
in	0
thiol	0
,	0
but	0
not	0
glutathione	0
,	0
content	0
in	0
stimulated	5
and	6
unstimulated	6
T	6
cell	6
,	0
whereas	0
TNF	9
stimulation	0
itself	0
barely	0
modified	0
the	0
cellular	0
thiol	0
level	0
.	0

Oxidative	0
stress	0
obtained	0
by	0
the	0
addition	0
of	0
H2O2	0
to	0
the	0
culture	0
medium	0
of	0
J.Jhan	5
or	0
U937	5
cells	6
could	0
not	0
by	0
itself	0
induce	0
NF-kappa	9
B	10
activation	0
.	0

These	0
observations	0
suggest	0
that	0
TNF	9
and	0
PMA	9
do	0
not	0
lead	0
to	0
NF-kappa	9
B	10
activation	0
through	0
induction	0
of	0
changes	0
in	0
the	0
cell	0
redox	0
status	0
.	0

Rather	0
,	0
TNF	9
and	0
PMA	9
can	0
exert	0
their	0
effect	0
only	0
if	0
cells	0
are	0
in	0
an	0
appropriate	0
redox	0
status	0
,	0
because	0
prior	0
modification	0
toward	0
reduction	0
with	0
BHA	0
treatment	0
prevents	0
this	0
activation	0
.	0

It	0
appears	0
that	0
a	0
basal	0
redox	0
equilibrium	0
tending	0
toward	0
oxidation	0
is	0
a	0
prerequisite	0
for	0
full	0
activation	0
of	0
transduction	0
pathways	0
regulating	0
the	0
activity	0
of	0
NF-kappa	1
B-dependent	2
genes	2
.	0

Selection	0
of	0
optimal	0
kappa	0
B/Rel	0
DNA-binding	0
motifs	0
:	0
interaction	0
of	0
both	0
subunits	0
of	0
NF-kappa	9
B	10
with	0
DNA	0
is	0
required	0
for	0
transcriptional	0
activation	0
.	0

Analysis	0
of	0
the	0
p50	9
and	0
p65	9
subunits	10
of	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
complex	10
has	0
revealed	0
that	0
both	0
proteins	0
can	0
interact	0
with	0
related	0
DNA	0
sequences	0
through	0
either	0
homo-	0
or	0
heterodimer	0
formation	0
.	0

In	0
addition	0
,	0
the	0
product	0
of	0
the	0
proto-oncogene	1
c-rel	2
can	0
bind	0
to	0
similar	0
DNA	0
motifs	0
by	0
itself	0
or	0
as	0
a	0
heterodimer	0
with	0
p50	9
or	0
p65	9
.	0

However	0
,	0
these	0
studies	0
have	0
used	0
a	0
limited	0
number	0
of	0
known	0
kappa	0
B	0
DNA	0
motifs	0
,	0
and	0
the	0
question	0
of	0
the	0
optimal	0
DNA	0
sequences	0
preferred	0
by	0
each	0
homodimer	0
has	0
not	0
been	0
addressed	0
.	0

Using	0
purified	0
recombinant	0
p50	9
,	0
p65	9
,	0
and	0
c-Rel	9
proteins	10
,	0
optimal	0
DNA-binding	0
motifs	0
were	0
selected	0
from	0
a	0
pool	0
of	0
random	0
oligonucleotides	0
.	0

Alignment	0
of	0
the	0
selected	0
sequences	0
allowed	0
us	0
to	0
predict	0
a	0
consensus	0
sequence	0
for	0
binding	0
of	0
the	0
individual	0
homodimeric	9
Rel-related	10
proteins	10
,	0
and	0
DNA-protein	0
binding	0
analysis	0
of	0
the	0
selected	0
DNA	0
sequences	0
revealed	0
sequence	0
specificity	0
of	0
the	0
proteins	0
.	0

Contrary	0
to	0
previous	0
assumptions	0
,	0
we	0
observed	0
that	0
p65	9
homodimers	0
can	0
interact	0
with	0
a	0
subset	0
of	0
DNA	0
sequences	0
not	0
recognized	0
by	0
p50	9
homodimers	10
.	0

Differential	0
binding	0
affinities	0
were	0
also	0
obtained	0
with	0
p50-	1
and	2
c-Rel-selected	2
sequences	2
.	0

Using	0
either	0
a	0
p50-	0
or	0
p65-	0
selected	0
kappa	0
B	0
motif	0
,	0
which	0
displayed	0
differential	0
binding	0
with	0
respect	0
to	0
the	0
other	0
protein	0
,	0
little	0
to	0
no	0
binding	0
was	0
observed	0
with	0
the	0
heterodimeric	9
NF-kappa	10
B	10
complex	10
.	0

Similarly	0
,	0
in	0
transfection	0
experiments	0
in	0
which	0
the	0
selective	1
kappa	2
B	2
binding	2
sites	2
were	0
used	0
to	0
drive	0
the	0
expression	0
of	0
a	0
chloramphenicol	1
acetyltransferase	2
reporter	2
construct	2
,	0
the	0
p65	1
-and	2
p50-selected	2
motifs	2
were	0
activated	0
only	0
in	0
the	0
presence	0
of	0
p65	9
and	0
p50/65	9
(	0
a	0
chimeric	9
protein	10
with	0
the	0
p50	9
DNA	10
binding	10
domain	10
and	0
p65	9
activation	10
domain	10
)	0
expression	0
vectors	0
,	0
respectively	0
,	0
and	0
neither	0
demonstrated	0
a	0
significant	0
response	0
to	0
stimuli	0
that	0
induce	0
NF-kappa	9
B	10
activity	0
.	0

These	0
findings	0
demonstrate	0
that	0
interaction	0
of	0
both	0
subunits	0
of	0
the	0
heterodimeric	9
NF-kappa	10
B	10
complex	10
with	0
DNA	0
is	0
required	0
for	0
DNA	0
binding	0
and	0
transcriptional	0
activation	0
and	0
suggest	0
that	0
transcriptional	0
activation	0
mediated	0
by	0
the	0
individual	0
rel-related	9
proteins	10
will	0
differ	0
dramatically	0
,	0
depending	0
on	0
the	0
specific	0
kappa	0
B	0
motifs	0
present	0
.	0

NF-kappa	9
B	10
-dependent	0
induction	0
of	0
the	0
NF-kappa	9
B	10
p50	1
subunit	2
gene	2
promoter	2
underlies	0
self-perpetuation	0
of	0
human	0
immunodeficiency	0
virus	0
transcription	0
in	0
monocytic	7
cells	8
.	0

The	0
molecular	0
mechanisms	0
underlying	0
the	0
sustained	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B	10
observed	0
in	0
U937	5
monocytic	6
cells	6
chronically	0
infected	0
with	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
were	0
studied	0
.	0

The	0
activity	0
of	0
the	0
promoter	1
regulating	0
the	0
synthesis	0
of	0
the	0
p105	9
precursor	10
of	0
the	0
NF-kappa	9
B	10
p50	10
subunit	10
was	0
enhanced	0
in	0
these	0
cells	0
.	0

Deletions	0
in	0
this	0
promoter	1
indicated	0
that	0
this	0
upregulation	0
was	0
mediated	0
through	0
the	0
NF-kappa	0
B-	0
but	0
not	0
the	0
AP-1-binding	1
motif	2
,	0
by	0
bona	0
fide	0
p50/p65	9
heterodimers	10
.	0

Analysis	0
of	0
cytosolic	0
extracts	0
indicated	0
that	0
NF-kappa	9
B	10
levels	0
were	0
increased	0
in	0
HIV-infected	7
cells	8
.	0

In	0
contrast	0
to	0
the	0
transient	0
NF-kappa	9
B	10
activation	0
induced	0
by	0
phorbol	0
ester	0
,	0
the	0
permanent	0
NF-kappa	9
B	10
translocation	0
induced	0
by	0
HIV	0
infection	0
was	0
not	0
dependent	0
on	0
PKC	9
isoenzymes	10
alpha	10
and	10
beta	10
as	0
shown	0
by	0
the	0
use	0
of	0
a	0
specific	0
inhibitor	0
(	0
GF	0
109203X	0
)	0
.	0

These	0
observations	0
indicate	0
that	0
during	0
chronic	0
HIV	0
infection	0
of	0
U937	5
cells	6
,	0
continuous	0
NF-kappa	9
B	10
(	0
p50/p65	9
)	0
translocation	0
results	0
in	0
p105	0
promoter	0
upregulation	0
with	0
subsequent	0
cytosolic	0
NF-kappa	9
B	10
accumulation	0
,	0
ready	0
for	0
further	0
translocation	0
.	0

This	0
HIV-mediated	0
mechanism	0
results	0
in	0
a	0
self-perpetuating	0
loop	0
of	0
NF-kappa	9
B	10
production	0
.	0

Activation	0
of	0
NF-kappa	9
B	10
by	0
interleukin	9
2	10
in	0
human	7
blood	8
monocytes	8
.	0

We	0
report	0
here	0
that	0
interleukin	9
2	10
(	0
IL-2	9
)	0
acts	0
on	0
human	7
blood	8
monocytes	8
by	0
enhancing	0
binding	0
activity	0
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
to	0
its	0
consensus	0
sequence	0
in	0
the	0
5	0
'	0
regulatory	0
enhancer	0
region	0
of	0
the	0
IL-2	1
receptor	2
alpha	2
chain	2
(	0
p55	9
)	0
.	0

Similarly	0
,	0
IL-2	9
activates	0
NF-kappa	9
B	10
in	0
the	0
human	5
monocytic	6
cell	6
line	6
U	6
937	6
,	0
but	0
not	0
in	0
resting	7
human	8
T-cells	8
.	0

This	0
effect	0
is	0
detectable	0
within	0
15	0
min	0
and	0
peaks	0
1	0
h	0
after	0
exposure	0
to	0
IL-2	9
.	0

Enhanced	0
NF-kappa	9
B	10
binding	0
activity	0
is	0
followed	0
by	0
functional	0
activation	0
in	0
that	0
inducibility	0
of	0
the	0
IL-2	9
receptor	10
alpha	10
chain	10
is	0
mediated	0
by	0
enhanced	0
NF-kappa	9
B	10
binding	0
and	0
that	0
a	0
heterologous	0
promoter	0
containing	0
the	0
NF-kappa	1
B	2
consensus	2
sequence	2
(	0
-291	1
to	2
-245	2
)	0
of	0
the	0
IL-2	1
receptor	2
alpha	2
chain	2
gene	2
is	0
activated	0
.	0

In	0
addition	0
,	0
IL-2	9
is	0
capable	0
of	0
increasing	0
transcript	0
levels	0
of	0
the	0
p50	9
gene	0
coding	0
for	0
the	0
p50	9
subunit	10
of	0
the	0
NF-kappa	9
B	10
transcription	0
factor	0
,	0
whereas	0
mRNA	0
levels	0
of	0
the	0
p65	9
NF-kappa	1
B	2
gene	2
remained	0
unchanged	0
.	0

Studies	0
on	0
the	0
biological	0
activity	0
of	0
triiodothyronine	0
sulfate	0
.	0

Hepatic	7
microsomes	8
and	0
isolated	7
hepatocytes	8
in	0
short	0
term	0
culture	0
desulfate	0
T3	0
sulfate	0
(	0
T3SO4	0
)	0
.	0

We	0
,	0
therefore	0
,	0
wished	0
to	0
determine	0
whether	0
T3SO4	0
could	0
mimic	0
the	0
action	0
of	0
thyroid	0
hormone	0
in	0
vitro	0
.	0

T3SO4	0
had	0
no	0
thyromimetic	0
effect	0
on	0
the	0
activity	0
of	0
Ca	9
(	10
2+	10
)	10
-ATPase	10
in	0
human	0
erythrocyte	0
membranes	0
at	0
doses	0
up	0
to	0
10	0
,	0
000	0
times	0
the	0
maximally	0
effective	0
dose	0
of	0
T3	0
(	0
10	0
(	0
-10	0
)	0
mol/L	0
)	0
.	0

In	0
GH4C1	5
pituitary	6
cells	6
,	0
T3SO4	0
failed	0
to	0
displace	0
[	0
125I	0
]	0
T3	0
from	0
nuclear	9
receptors	10
in	0
intact	5
cells	6
or	0
soluble	0
preparations	0
.	0

Thus	0
,	0
T3SO4	0
was	0
not	0
directly	0
thyromimetic	0
in	0
either	0
an	0
isolated	0
human	0
membrane	0
system	0
or	0
a	0
pituitary	0
cell	0
system	0
in	0
which	0
nuclear	0
receptor	0
occupancy	0
correlates	0
with	0
GH	0
synthesis	0
.	0

Thyroid	0
hormones	0
inhibit	0
[	0
3H	0
]	0
glycosaminoglycan	0
synthesis	0
by	0
cultured	5
human	6
dermal	6
fibroblasts	6
,	0
and	0
T3SO4	0
displayed	0
about	0
0.5	0
%	0
the	0
activity	0
of	0
T3	0
at	0
72	0
h	0
.	0

Human	7
fibroblasts	8
contained	0
roughly	0
the	0
same	0
level	0
of	0
microsomal	0
p-nitrophenyl	9
sulfatase	10
activity	0
as	0
that	0
previously	0
observed	0
in	0
hepatic	7
microsomes	8
.	0

Propylthiouracil	0
(	0
50	0
mumol/L	0
)	0
did	0
not	0
affect	0
the	0
action	0
of	0
T3SO4	0
,	0
suggesting	0
that	0
deiodination	0
was	0
not	0
important	0
for	0
this	0
activity	0
of	0
T3SO4	0
.	0

Thus	0
,	0
it	0
appears	0
T3SO4	0
has	0
no	0
intrinsic	0
biological	0
activity	0
,	0
but	0
,	0
under	0
certain	0
circumstances	0
,	0
may	0
be	0
reactivated	0
by	0
desulfation	0
.	0

Human	0
T	0
cell	0
activation	0
through	0
the	0
activation-inducer	9
molecule/CD69	10
enhances	0
the	0
activity	0
of	0
transcription	9
factor	10
AP-1	10
.	0

The	0
induction	0
of	0
the	0
AP-1	9
transcription	10
factor	10
has	0
been	0
ascribed	0
to	0
the	0
early	0
events	0
leading	0
to	0
T	0
cell	0
differentiation	0
and	0
activation	0
.	0

We	0
have	0
studied	0
the	0
regulation	0
of	0
AP-1	9
activity	0
in	0
human	7
peripheral	8
blood	8
T	8
lymphocytes	8
stimulated	0
through	0
the	0
activation	0
inducer	0
molecule	0
(	0
AIM	0
)	0
/	0
CD69	9
activation	0
pathway	0
.	0

Phorbol	0
esters	0
are	0
required	0
to	0
induce	0
AIM/CD69	9
cell-surface	0
expression	0
as	0
well	0
as	0
for	0
triggering	0
the	0
proliferation	0
of	0
T	7
cells	8
in	0
conjunction	0
with	0
anti-AIM	9
mAb	10
.	0

Mobility	0
shift	0
assays	0
showed	0
that	0
addition	0
of	0
anti-AIM	9
mAb	10
to	0
PMA-treated	7
T	8
lymphocytes	8
markedly	0
enhanced	0
the	0
binding	0
activity	0
of	0
AP-1	9
to	0
its	0
cognate	0
sequence	0
,	0
the	0
phorbol	1
ester	2
response	2
element	2
.	0

In	0
contrast	0
,	0
anti-AIM	9
mAb	10
did	0
not	0
induce	0
any	0
change	0
in	0
the	0
binding	0
activity	0
of	0
NF-kappa	9
B	10
,	0
a	0
transcription	9
factor	10
whose	0
activity	0
is	0
also	0
regulated	0
by	0
protein	9
kinase	10
C	10
.	0

The	0
increase	0
in	0
AP-1	9
-binding	0
activity	0
was	0
accompanied	0
by	0
the	0
marked	0
stimulation	0
of	0
the	0
transcription	0
of	0
c-fos	9
but	0
not	0
that	0
of	0
c-jun	9
.	0

Blockade	0
of	0
the	0
DNA-binding	9
complexes	10
with	0
an	0
anti-Fos	9
mAb	10
demonstrated	0
a	0
direct	0
participation	0
of	0
c-Fos	9
in	0
the	0
AP-1	9
complexes	10
induced	0
by	0
anti-AIM	9
mAb	10
.	0

Most	0
of	0
the	0
AP-1	9
activity	0
could	0
be	0
eliminated	0
when	0
the	0
anti-AIM	9
mAb	10
was	0
added	0
to	0
the	0
culture	0
medium	0
in	0
the	0
presence	0
of	0
cycloheximide	0
,	0
suggesting	0
that	0
de	0
novo	0
protein	0
synthesis	0
is	0
crucial	0
for	0
the	0
induction	0
of	0
AP-1	9
-binding	0
activity	0
.	0

These	0
data	0
provide	0
the	0
evidence	0
that	0
activation	0
of	0
human	7
peripheral	8
blood	8
T	8
cells	8
through	0
the	0
AIM	0
activation	0
pathway	0
regulate	0
the	0
activity	0
of	0
AP-1	9
.	0

Therefore	0
,	0
this	0
pathway	0
appears	0
as	0
a	0
crucial	0
step	0
in	0
the	0
initiation	0
of	0
early	0
T	0
cell	0
activation	0
events	0
.	0

Gangliosides	0
suppress	0
tumor	9
necrosis	10
factor	10
production	0
in	0
human	7
monocytes	8
.	0

Both	0
normal	7
and	8
malignant	8
cells	8
contain	0
gangliosides	0
as	0
important	0
cell	0
membrane	0
constituents	0
that	0
,	0
after	0
being	0
shed	0
,	0
may	0
influence	0
cells	0
of	0
the	0
immune	0
system	0
.	0

We	0
have	0
studied	0
the	0
impact	0
of	0
gangliosides	0
on	0
the	0
expression	0
of	0
TNF	9
in	0
blood	7
monocytes	8
and	0
in	0
the	0
monocytic	5
cell	6
line	6
Mono	6
Mac	6
6	6
.	0

Although	0
under	0
standard	0
culture	0
conditions	0
,	0
bovine	0
brain	0
gangliosides	0
(	0
100	0
micrograms/ml	0
)	0
suppressed	0
LPS-stimulated	0
TNF	9
production	0
5-fold	0
in	0
PBMC	7
and	0
10-fold	0
in	0
Mono	5
Mac	6
6	6
cells	6
,	0
suppression	0
was	0
more	0
efficient	0
under	0
serum-free	0
conditions	0
.	0

Looking	0
at	0
highly	0
purified	0
gangliosides	0
,	0
GD3	0
,	0
GD1a	0
,	0
GM3	0
,	0
GM2	0
,	0
and	0
GM1	0
were	0
all	0
effective	0
in	0
reducing	0
TNF	9
production	0
in	0
PBMC	7
,	0
and	0
in	0
Mono	5
Mac	6
6	6
by	0
factor	0
10	0
to	0
50	0
.	0

The	0
suppressive	0
activity	0
was	0
lost	0
in	0
molecules	0
,	0
lacking	0
the	0
sugar	0
moiety	0
or	0
the	0
lipid	0
moiety	0
.	0

Gangliosides	0
appear	0
to	0
act	0
at	0
an	0
early	0
step	0
of	0
activation	0
in	0
that	0
TNF	3
transcripts	4
were	0
reduced	0
and	0
the	0
mobilization	0
of	0
the	0
nuclear	9
factor	10
kappa	10
B	10
was	0
blocked	0
.	0

Furthermore	0
,	0
in	0
time	0
kinetics	0
,	0
gangliosides	0
were	0
effective	0
for	0
up	0
to	0
30	0
min	0
after	0
addition	0
of	0
LPS	0
,	0
but	0
not	0
thereafter	0
.	0

However	0
,	0
the	0
expression	0
of	0
the	0
CD14	9
Ag	10
,	0
a	0
receptor	9
molecule	10
for	0
LPS-LPS	9
binding	10
protein	10
complexes	10
,	0
was	0
unaffected	0
by	0
gangliosides	0
.	0

Finally	0
,	0
when	0
using	0
Staphylococcus	0
aureus	0
or	0
platelet	9
activating	10
factor	10
as	0
a	0
stimulus	0
,	0
gangliosides	0
were	0
able	0
to	0
suppress	0
TNF	9
production	0
in	0
Mono	5
Mac	6
6	6
cells	6
by	0
factor	0
5	0
to	0
10	0
,	0
as	0
well	0
.	0

On	0
the	0
other	0
hand	0
,	0
phorbol	0
ester-induced	0
production	0
of	0
O2-	0
was	0
similar	0
in	0
cells	0
treated	0
with	0
and	0
without	0
gangliosides	0
.	0

Taken	0
together	0
,	0
our	0
data	0
demonstrate	0
that	0
TNF	9
gene	0
expression	0
in	0
monocytes	7
induced	0
by	0
different	0
types	0
of	0
stimuli	0
can	0
be	0
blocked	0
by	0
gangliosides	0
at	0
an	0
early	0
step	0
of	0
signal	0
transduction	0
.	0

A	0
novel	0
mitogen-inducible	9
gene	10
product	10
related	0
to	0
p50/p105-NF-kappa	9
B	10
participates	0
in	0
transactivation	0
through	0
a	0
kappa	1
B	2
site	2
.	0

A	0
Rel-related	9
,	10
mitogen-inducible	10
,	10
kappa	10
B-binding	10
protein	10
has	0
been	0
cloned	0
as	0
an	0
immediate-early	1
activation	2
gene	2
of	0
human	7
peripheral	8
blood	8
T	8
cells	8
.	0

The	0
cDNA	1
has	0
an	0
open	1
reading	2
frame	2
of	0
900	1
amino	2
acids	2
capable	0
of	0
encoding	0
a	0
97-kDa	9
protein	10
.	0

This	0
protein	0
is	0
most	0
similar	0
to	0
the	0
105-kDa	0
precursor	0
polypeptide	0
of	0
p50-NF-kappa	9
B	10
.	0

Like	0
the	0
105-kDa	0
precursor	0
,	0
it	0
contains	0
an	0
amino-terminal	9
Rel-related	10
domain	10
of	0
about	0
300	0
amino	0
acids	0
and	0
a	0
carboxy-terminal	9
domain	10
containing	0
six	0
full	9
cell	10
cycle	10
or	0
ankyrin	9
repeats	10
.	0

In	0
vitro-translated	9
proteins	10
,	0
truncated	0
downstream	0
of	0
the	0
Rel	1
domain	2
and	0
excluding	0
the	0
repeats	0
,	0
bind	0
kappa	1
B	2
sites	2
.	0

We	0
refer	0
to	0
the	0
kappa	9
B-binding	10
,	10
truncated	10
protein	10
as	0
p50B	9
by	0
analogy	0
with	0
p50-NF-kappa	9
B	10
and	0
to	0
the	0
full-length	0
protein	0
as	0
p97	9
.	0

p50B	9
is	0
able	0
to	0
form	0
heteromeric	9
kappa	10
B-binding	10
complexes	10
with	0
RelB	9
,	0
as	0
well	0
as	0
with	0
p65	9
and	0
p50	9
,	0
the	0
two	0
subunits	0
of	0
NF-kappa	9
B	10
.	0

Transient-transfection	0
experiments	0
in	0
embryonal	5
carcinoma	6
cells	6
demonstrate	0
a	0
functional	0
cooperation	0
between	0
p50B	9
and	0
RelB	9
or	0
p65	9
in	0
transactivation	0
of	0
a	0
reporter	1
plasmid	2
dependent	0
on	0
a	0
kappa	1
B	2
site	2
.	0

The	0
data	0
imply	0
the	0
existence	0
of	0
a	0
complex	0
family	0
of	0
NF-kappa	9
B-like	10
transcription	10
factors	10
.	0

Surrogate	0
thyroglobulin	9
receptors	10
and	0
T	0
cell	0
proliferation	0
in	0
Hashimoto	0
's	0
thyroiditis	0
.	0

Immunoglobulin	9
molecules	10
on	0
the	0
surface	0
of	0
a	0
B	7
lymphocyte	8
are	0
the	0
endogenous	0
``	0
receptors	0
''	0
to	0
which	0
specific	0
antigens	0
bind	0
.	0

Studies	0
in	0
mice	0
have	0
shown	0
that	0
a	0
monoclonal	9
antibody	10
,	0
conjugated	0
with	0
palmitate	0
to	0
provide	0
a	0
lipid	0
tail	0
,	0
can	0
be	0
inserted	0
into	0
the	0
cell	0
membrane	0
to	0
provide	0
a	0
``	0
surrogate	0
''	0
antigen	0
receptor	0
.	0

We	0
have	0
investigated	0
whether	0
a	0
palmitate	9
conjugate	10
of	0
a	0
human	9
monoclonal	10
antibody	10
specific	0
for	0
thyroglobulin	9
(	0
TG	9
)	0
could	0
function	0
as	0
a	0
surrogate	9
TG	10
receptor	10
on	0
blood	7
mononuclear	8
cells	8
separated	0
into	0
fractions	0
enriched	0
for	0
T	7
cells	8
or	0
depleted	0
of	0
T	7
cells	8
(	0
non-T	7
cells	8
)	0
.	0

Using	0
flow	0
cytometry	0
,	0
we	0
detected	0
surrogate	9
TG	10
receptors	10
on	0
non-T	7
(	8
but	8
not	8
on	8
T	8
)	8
cells	8
from	0
11	0
of	0
11	0
individuals	0
studied	0
(	0
5	0
Hashimoto	0
patients	0
and	0
6	0
control	0
donors	0
)	0
.	0

In	0
contrast	0
,	0
endogenous	9
TG	10
receptors	10
could	0
only	0
be	0
detected	0
on	0
non-T	7
cells	8
from	0
1	0
of	0
3	0
Hashimoto	0
patients	0
and	0
from	0
0	0
of	0
4	0
control	0
donors	0
.	0

Because	0
of	0
the	0
efficient	0
binding	0
of	0
TG	9
by	0
surrogate	9
receptors	10
on	0
non-T	7
cells	8
,	0
we	0
assessed	0
the	0
ability	0
of	0
such	0
cells	0
to	0
present	0
TG	9
to	0
T	7
cells	8
.	0

Proliferation	0
in	0
response	0
to	0
TG	9
was	0
observed	0
in	0
T	7
cells	8
from	0
only	0
1	0
of	0
5	0
Hashimoto	0
patients	0
.	0

This	0
low	0
frequency	0
of	0
response	0
was	0
no	0
different	0
from	0
that	0
previously	0
detected	0
using	0
cultures	0
of	0
T	7
cells	8
and	0
autologous	7
dendritic	8
cells	8
.	0

Therefore	0
,	0
the	0
successful	0
generation	0
of	0
surrogate	9
receptors	10
on	0
non-T	7
cells	8
is	0
not	0
associated	0
with	0
more	0
efficient	0
TG	9
presentation	0
of	0
T	7
cells	8
.	0

Furthermore	0
,	0
the	0
significance	0
of	0
the	0
present	0
study	0
is	0
that	0
the	0
T	7
cells	8
,	0
not	0
the	0
antigen-presenting	7
cells	8
,	0
are	0
likely	0
to	0
be	0
the	0
limiting	0
element	0
in	0
the	0
T	0
cell	0
proliferative	0
response	0
to	0
TG	9
and	0
other	0
thyroid	9
autoantigens	10
.	0

Targeted	0
degradation	0
of	0
c-Fos	9
,	0
but	0
not	0
v-Fos	9
,	0
by	0
a	0
phosphorylation-dependent	9
signal	10
on	0
c-Jun	9
.	0

The	0
proto-oncogene	9
products	10
c-Fos	9
and	0
c-Jun	9
heterodimerize	0
through	0
their	0
leucine	9
zippers	10
to	0
form	0
the	0
AP-1	9
transcription	10
factor	10
.	0

The	0
transcriptional	0
activity	0
of	0
the	0
heterodimer	0
is	0
regulated	0
by	0
signal-dependent	0
phosphorylation	0
and	0
dephosphorylation	0
events	0
.	0

The	0
stability	0
of	0
c-Fos	9
was	0
found	0
to	0
also	0
be	0
controlled	0
by	0
intracellular	0
signal	0
transduction	0
.	0

In	0
transient	0
expression	0
and	0
in	0
vitro	0
degradation	0
experiments	0
,	0
the	0
stability	0
of	0
c-Fos	9
was	0
decreased	0
when	0
the	0
protein	0
was	0
dimerized	0
with	0
phosphorylated	9
c-Jun	10
.	0

c-Jun	9
protein	0
isolated	0
from	0
phorbol	5
ester-induced	6
cells	6
did	0
not	0
target	0
c-Fos	9
for	0
degradation	0
,	0
which	0
suggests	0
that	0
c-Fos	9
is	0
transiently	0
stabilized	0
after	0
stimulation	0
of	0
cell	0
growth	0
.	0

v-Fos	9
protein	10
,	0
the	0
retroviral	0
counterpart	0
of	0
c-Fos	9
,	0
was	0
not	0
susceptible	0
to	0
degradation	0
targeted	0
by	0
c-Jun	9
.	0

The	0
regulation	0
of	0
the	0
human	1
tumor	2
necrosis	2
factor	2
alpha	2
promoter	2
region	2
in	0
macrophage	5
,	0
T	5
cell	6
,	0
and	0
B	5
cell	6
lines	6
.	0

The	0
1311-base	1
pair	2
human	2
tumor	2
necrosis	2
factor	2
(	2
TNF	2
)	2
alpha	2
promoter	2
region	2
was	0
fused	0
to	0
the	0
luciferase	1
(	2
Luc	2
)	2
reporter	2
gene	2
and	0
studied	0
in	0
a	0
transient	0
transfection	0
system	0
in	0
three	0
TNF	5
producing	6
cell	6
lines	6
,	0
the	0
U937	5
macrophage	6
cell	6
line	6
,	0
the	0
MLA	5
144	6
T	6
cell	6
line	6
,	0
and	0
the	0
729-6	5
B	6
cell	6
line	6
.	0

This	0
full	0
length	0
promoter	0
construct	0
can	0
be	0
induced	0
by	0
phorbol	0
13-myristate	0
acetate	0
(	0
PMA	0
)	0
in	0
each	0
of	0
these	0
cell	0
types	0
.	0

Analysis	0
of	0
a	0
series	0
of	0
5'-truncations	1
showed	0
several	0
peaks	0
of	0
basal	0
and	0
PMA	0
induced	0
activity	0
suggesting	0
the	0
presence	0
of	0
several	0
positive	1
and	0
negative	0
regulatory	0
elements	0
.	0

A	0
PMA	1
responsive	2
element	2
was	0
localized	0
to	0
a	0
region	0
between	0
-95	1
and	2
-36	2
bp	2
relative	0
to	0
the	0
transcription	1
start	2
site	2
.	0

Within	0
this	0
region	0
,	0
single	0
AP-2-	1
and	2
AP-1-	2
like	2
consensus	2
sequences	2
were	0
noted	0
.	0

These	0
AP-2	1
and	0
AP-1	1
sites	2
were	0
each	0
modified	0
with	0
a	0
double	0
point	0
mutation	0
.	0

A	0
modest	0
(	0
20-50	0
%	0
)	0
reduction	0
in	0
TNF	1
promoter	2
activity	0
was	0
observed	0
with	0
the	0
AP-2	1
site	2
mutation	2
.	0

However	0
,	0
mutation	0
of	0
the	0
AP-1	1
site	2
markedly	0
diminished	0
both	0
the	0
basal	0
and	0
PMA-activated	0
promoter	0
activity	0
.	0

Also	0
co-transfections	0
of	0
the	0
wild-type	1
promoter	2
construct	2
with	0
an	0
AP-1/c-jun	1
expression	2
vector	2
resulted	0
in	0
augmented	0
basal	0
and	0
PMA-induced	0
promoter	0
activity	0
.	0

Stable	0
expression	0
of	0
transdominant	9
Rev	10
protein	10
in	0
human	7
T	8
cells	8
inhibits	0
human	0
immunodeficiency	0
virus	0
replication	0
.	0

The	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
Rev	9
protein	10
is	0
essential	0
for	0
viral	0
structural	0
protein	0
expression	0
(	0
Gag	9
,	0
Pol	9
,	0
and	0
Env	9
)	0
and	0
,	0
hence	0
,	0
for	0
viral	0
replication	0
.	0

In	0
transient	0
transfection	0
assays	0
,	0
mutant	0
forms	0
of	0
Rev	9
have	0
been	0
identified	0
that	0
inhibit	0
wild-type	0
Rev	9
activity	0
and	0
therefore	0
suppress	0
viral	0
replication	0
.	0

To	0
determine	0
whether	0
such	0
transdominant	9
Rev	10
proteins	10
could	0
provide	0
long-term	0
protection	0
against	0
HIV	0
infection	0
without	0
affecting	0
T	0
cell	0
function	0
,	0
T	5
leukemia	6
cell	6
lines	6
were	0
stably	0
transduced	0
with	0
a	0
retroviral	1
vector	2
encoding	0
a	0
transdominant	0
mutant	0
of	0
the	0
Rev	9
protein	10
,	0
M10	9
.	0

While	0
all	0
the	0
M10-expressing	5
cell	6
lines	6
remained	0
infectable	0
by	0
HIV-1	0
,	0
these	0
same	0
cells	0
failed	0
to	0
support	0
a	0
productive	0
replication	0
cycle	0
when	0
infected	0
with	0
a	0
cloned	0
isolate	0
of	0
HIV-1	0
.	0

In	0
addition	0
,	0
two	0
out	0
of	0
three	0
M10-expressing	5
CEM	6
clones	6
were	0
also	0
resistant	0
to	0
highly	0
productive	0
infection	0
by	0
a	0
heterogeneous	0
HIV-1	0
pool	0
.	0

Expression	0
of	0
M10	9
did	0
not	0
affect	0
induction	0
of	0
HIV	0
transcription	0
mediated	0
by	0
the	0
kappa	1
B	2
regulatory	2
element	2
or	0
Tat	9
.	0

Importantly	0
,	0
constitutive	0
expression	0
of	0
Rev	9
M10	10
did	0
not	0
alter	0
the	0
secretion	0
of	0
interleukin	9
2	10
in	0
response	0
to	0
mitogen	0
stimulation	0
of	0
EL-4	5
and	0
Jurkat	5
cells	6
.	0

The	0
inhibition	0
of	0
HIV	0
infection	0
in	0
cells	0
stably	0
expressing	0
a	0
transdominant	9
Rev	10
protein	10
,	0
in	0
the	0
absence	0
of	0
any	0
deleterious	0
effect	0
on	0
T	0
cell	0
function	0
,	0
suggests	0
that	0
such	0
a	0
strategy	0
could	0
provide	0
a	0
therapeutic	0
effect	0
in	0
the	0
T	7
lymphocytes	8
of	0
acquired	0
immunodeficiency	0
syndrome	0
patients	0
.	0

Simple	0
derivation	0
of	0
TFIID-dependent	0
RNA	9
polymerase	10
II	10
transcription	0
systems	0
from	0
Schizosaccharomyces	0
pombe	0
and	0
other	0
organisms	0
,	0
and	0
factors	0
required	0
for	0
transcriptional	0
activation	0
.	0

Resolution	0
of	0
whole	0
cell	0
extract	0
through	0
two	0
chromatographic	0
steps	0
yields	0
a	0
single	0
protein	0
fraction	0
requiring	0
only	0
the	0
addition	0
of	0
TFIID	9
for	0
the	0
initiation	0
of	0
transcription	0
at	0
RNA	1
polymerase	2
II	2
promoters	2
.	0

This	0
approach	0
allows	0
the	0
convenient	0
generation	0
of	0
RNA	9
polymerase	10
II	10
transcription	0
systems	0
from	0
Saccharomyces	0
cerevisiae	0
,	0
human	7
lymphocytes	8
,	0
and	0
Schizosaccharomyces	0
pombe	0
.	0

TFIIDs	9
from	0
all	0
three	0
organisms	0
are	0
interchangeable	0
among	0
all	0
three	0
systems	0
.	0

The	0
S.	0
cerevisiae	0
and	0
Sch.	0
pombe	0
systems	0
support	0
effects	0
of	0
acidic	9
activator	10
proteins	10
,	0
provided	0
a	0
further	0
protein	0
fraction	0
from	0
S.	0
cerevisiae	0
is	0
supplied	0
.	0

This	0
further	0
fraction	0
is	0
distinct	0
from	0
the	0
mediator	0
of	0
transcriptional	0
activation	0
described	0
previously	0
and	0
represents	0
a	0
second	0
component	0
in	0
addition	0
to	0
general	9
initiation	10
factors	10
that	0
may	0
facilitate	0
a	0
response	0
to	0
acidic	9
activators	10
.	0

Regulation	0
of	0
c-jun	1
expression	0
during	0
induction	0
of	0
monocytic	0
differentiation	0
by	0
okadaic	0
acid	0
.	0

The	0
present	0
work	0
has	0
examined	0
the	0
effects	0
of	0
okadaic	0
acid	0
,	0
an	0
inhibitor	0
of	0
type	9
1	10
and	10
2A	10
protein	10
phosphatases	10
,	0
on	0
the	0
regulation	0
of	0
c-jun	1
expression	0
during	0
monocytic	0
differentiation	0
of	0
U-937	5
leukemia	6
cells	6
.	0

The	0
results	0
demonstrate	0
that	0
okadaic	0
acid	0
treatment	0
is	0
associated	0
with	0
induction	0
of	0
a	0
differentiated	0
monocyte	0
phenotype	0
characterized	0
by	0
:	0
(	0
a	0
)	0
growth	0
arrest	0
;	0
(	0
b	0
)	0
increases	0
in	0
Mac-1	9
cell	10
surface	10
antigen	10
expression	0
;	0
(	0
c	0
)	0
down-regulation	0
of	0
c-myc	9
transcripts	10
;	0
and	0
(	0
d	0
)	0
induction	0
of	0
tumor	1
necrosis	2
factor	2
gene	2
expression	0
.	0

This	0
induction	0
of	0
monocytic	0
differentiation	0
was	0
associated	0
with	0
transient	0
increases	0
in	0
c-jun	3
mRNA	4
levels	0
,	0
which	0
were	0
maximal	0
at	0
6	0
h	0
.	0

Similar	0
effects	0
were	0
obtained	0
for	0
the	0
c-fos	1
gene	2
.	0

Run-on	0
analysis	0
demonstrated	0
detectable	0
levels	0
of	0
c-jun	1
transcription	0
in	0
U-937	5
cells	6
and	0
that	0
this	0
rate	0
is	0
increased	0
approximately	0
40-fold	0
following	0
okadaic	0
acid	0
exposure	0
.	0

c-jun	3
mRNA	4
levels	0
were	0
superinduced	0
in	0
cells	0
treated	0
with	0
both	0
okadaic	0
acid	0
and	0
cycloheximide	0
,	0
whereas	0
inhibition	0
of	0
protein	0
synthesis	0
had	0
little	0
,	0
if	0
any	0
,	0
effect	0
on	0
okadaic	0
acid-induced	0
c-jun	1
transcription	0
.	0

The	0
half-life	0
of	0
c-jun	3
mRNA	4
was	0
similar	0
(	0
45-50	0
min	0
)	0
in	0
both	0
untreated	0
and	0
okadaic	5
acid-induced	6
cells	6
.	0

In	0
contrast	0
,	0
treatment	0
with	0
both	0
okadaic	0
acid	0
and	0
cycloheximide	0
was	0
associated	0
with	0
stabilization	0
(	0
t	0
1/2	0
=	0
90	0
min	0
)	0
of	0
c-jun	9
transcripts	10
.	0

Taken	0
together	0
,	0
these	0
findings	0
indicate	0
that	0
the	0
induction	0
of	0
c-jun	1
transcription	0
by	0
okadaic	0
acid	0
is	0
controlled	0
primarily	0
by	0
a	0
transcriptional	0
mechanism	0
.	0

Since	0
previous	0
studies	0
have	0
demonstrated	0
that	0
the	0
c-jun	1
gene	2
is	0
autoinduced	0
by	0
Jun/AP-1	9
,	0
we	0
also	0
studied	0
transcription	0
of	0
c-jun	1
promoter	2
(	2
positions	2
-132/+170	2
)	2
-reporter	2
gene	2
constructs	2
with	0
and	0
without	0
a	0
mutated	0
AP-1	1
element	2
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Mitogen	0
stimulation	0
of	0
T-cells	0
increases	0
c-Fos	9
and	0
c-Jun	9
protein	0
levels	0
,	0
AP-1	0
binding	0
and	0
AP-1	0
transcriptional	0
activity	0
.	0

We	0
have	0
analysed	0
the	0
effect	0
of	0
mitogenic	0
lectins	0
on	0
c-Fos	9
and	0
c-Jun	9
protein	0
levels	0
as	0
well	0
as	0
on	0
activator	0
protein-1	0
(	0
AP-1	0
)	0
binding	0
and	0
enhancer	0
activity	0
in	0
Jurkat	0
T-cells	0
.	0

Both	0
c-Fos	9
and	0
c-Jun	9
protein	0
levels	0
were	0
increased	0
after	0
Con	0
A	0
and	0
PHA	0
stimulation	0
.	0

Since	0
T-cell	0
stimulation	0
increases	0
both	0
intracellular	0
Ca2+	0
and	0
cAMP	0
levels	0
and	0
activates	0
protein	0
kinase	0
C	0
(	0
PKC	0
)	0
,	0
the	0
possible	0
involvement	0
of	0
these	0
intracellular	0
messengers	0
in	0
c-Fos	9
and	0
c-Jun	9
induction	0
was	0
tested	0
.	0

PMA	0
,	0
which	0
directly	0
activates	0
PKC	0
,	0
mimicked	0
the	0
effect	0
of	0
the	0
lectins	0
on	0
c-Fos	0
and	0
c-Jun	9
,	0
but	0
elevation	0
of	0
either	0
intracellular	0
Ca2+	0
or	0
cAMP	0
levels	0
had	0
little	0
or	0
no	0
effect	0
.	0

The	0
mitogen-induced	0
increase	0
of	0
c-Fos	9
and	0
c-Jun	9
immunoreactivity	0
was	0
inhibited	0
by	0
H-7	0
,	0
a	0
kinase	0
inhibitor	0
with	0
relatively	0
high	0
specificity	0
for	0
PKC	0
,	0
and	0
less	0
efficiently	0
by	0
H-8	0
,	0
a	0
structurally	0
related	0
kinase	0
inhibitor	0
less	0
active	0
on	0
PKC	0
,	0
but	0
more	0
active	0
on	0
cyclic	0
nucleotide-dependent	0
kinases	0
.	0

Con	0
A	0
stimulation	0
was	0
found	0
to	0
increase	0
both	0
binding	0
of	0
AP-1	0
to	0
the	0
AP-1	0
consensus	0
sequence	0
,	0
TRE	0
,	0
and	0
AP-1	0
enhancer	0
activity	0
,	0
in	0
Jurkat	5
cells	6
.	0

PMA	0
was	0
also	0
found	0
to	0
increase	0
the	0
AP-1	0
enhancer	0
activity	0
,	0
whereas	0
elevation	0
of	0
Ca2+	0
or	0
cAMP	0
had	0
only	0
minor	0
effects	0
.	0

We	0
conclude	0
that	0
stimulation	0
with	0
mitogenic	0
lectins	0
is	0
sufficient	0
to	0
increase	0
both	0
c-Fos	9
and	0
c-Jun	9
protein	0
levels	0
,	0
AP-1	0
binding	0
and	0
AP-1	0
enhancer	0
activity	0
in	0
Jurkat	5
cells	6
and	0
that	0
they	0
act	0
via	0
mechanisms	0
that	0
could	0
involve	0
the	0
activation	0
of	0
PKC	0
.	0

An	0
11-base-pair	0
DNA	0
sequence	0
motif	0
apparently	0
unique	0
to	0
the	0
human	1
interleukin	2
4	2
gene	2
confers	0
responsiveness	0
to	0
T-cell	0
activation	0
signals	0
.	0

We	0
have	0
identified	0
a	0
DNA	1
segment	2
that	0
confers	0
responsiveness	0
to	0
antigen	0
stimulation	0
signals	0
on	0
the	0
human	1
interleukin	2
(	2
IL	2
)	2
4	2
gene	2
in	0
Jurkat	5
cells	6
.	0

The	0
human	1
IL-4	2
gene	2
,	0
of	0
10	0
kilobases	0
,	0
is	0
composed	0
of	0
four	0
exons	1
and	0
three	0
introns	1
.	0

A	0
cis-acting	1
element	2
(	0
P	1
sequence	2
)	0
resides	0
in	0
the	0
5	1
'	2
upstream	2
region	2
;	0
no	0
additional	0
DNA	1
segments	2
with	0
enhancer	0
activity	0
were	0
identified	0
in	0
the	0
human	1
IL-4	2
gene	2
.	0

For	0
further	0
mapping	0
purposes	0
,	0
a	0
fusion	1
promoter	2
was	0
constructed	0
with	0
the	0
granulocyte/macrophage	1
colony-stimulating	2
factor	2
basic	2
promoter	2
containing	0
60	1
base	2
pairs	2
of	2
sequence	2
upstream	0
from	0
the	0
cap	1
site	2
of	0
the	0
mouse	1
granulocyte/macrophage	2
colony-stimulating	2
factor	2
gene	2
and	0
various	0
lengths	0
of	0
the	0
5	1
'	2
upstream	2
sequence	2
of	0
the	0
IL-4	1
gene	2
.	0

The	0
P	1
sequence	2
was	0
located	0
between	0
positions	0
-79	0
and	0
-69	0
relative	0
to	0
the	0
transcription	1
start	2
site	2
of	0
the	0
human	1
IL-4	2
gene	2
,	0
and	0
this	0
location	0
was	0
confirmed	0
by	0
base-substitution	0
mutations	0
.	0

The	0
plasmids	0
carrying	0
multiple	0
copies	0
of	0
the	0
P	1
sequence	2
showed	0
higher	0
responsiveness	0
to	0
the	0
stimulation	0
.	0

The	0
binding	9
protein	10
(	0
s	0
)	0
that	0
recognize	0
the	0
P	1
sequence	2
of	0
the	0
IL-4	1
gene	2
were	0
identified	0
by	0
DNA-mobility-shift	0
assays	0
.	0

The	0
binding	0
of	0
NF	9
(	10
P	10
)	10
(	0
a	0
DNA	9
binding	10
protein	10
that	0
specifically	0
recognizes	0
the	0
P	1
sequence	2
)	0
to	0
the	0
P	1
sequence	2
was	0
abolished	0
when	0
oligonucleotides	0
carrying	0
base	0
substitutions	0
were	0
used	0
,	0
indicating	0
that	0
the	0
NF	9
(	10
P	10
)	10
interaction	0
is	0
sequence-specific	0
and	0
that	0
binding	0
specificity	0
of	0
the	0
protein	0
paralleled	0
the	0
sequence	0
requirements	0
for	0
IL-4	9
expression	0
in	0
vivo	0
.	0

The	0
P	1
sequence	2
does	0
not	0
share	0
homology	0
with	0
the	0
5	1
'	2
upstream	2
sequence	2
of	0
the	0
IL-2	1
gene	2
,	0
even	0
though	0
surrounding	0
sequences	0
of	0
the	0
IL-4	1
gene	2
share	0
high	0
homology	0
with	0
the	0
IL-2	1
gene	2
.	0

We	0
conclude	0
that	0
a	0
different	0
set	0
of	0
proteins	9
recognize	0
IL-2	1
and	2
IL-4	2
genes	2
.	0

Leukotriene	0
B4	0
stimulates	0
c-fos	0
and	0
c-jun	0
gene	0
transcription	0
and	0
AP-1	9
binding	0
activity	0
in	0
human	7
monocytes	8
.	0

We	0
have	0
examined	0
the	0
effect	0
of	0
leukotriene	0
B4	0
(	0
LTB4	0
)	0
,	0
a	0
potent	0
lipid	0
proinflammatory	9
mediator	10
,	0
on	0
the	0
expression	0
of	0
the	0
proto-oncogenes	1
c-jun	2
and	2
c-fos	2
.	0

In	0
addition	0
,	0
we	0
looked	0
at	0
the	0
modulation	0
of	0
nuclear	9
factors	10
binding	0
specifically	0
to	0
the	0
AP-1	1
element	2
after	0
LTB4	0
stimulation	0
.	0

LTB4	0
increased	0
the	0
expression	0
of	0
the	0
c-fos	1
gene	2
in	0
a	0
time-	0
and	0
concentration-dependent	0
manner	0
.	0

The	0
c-jun	3
mRNA	4
,	0
which	0
is	0
constitutively	0
expressed	0
in	0
human	7
peripheral-blood	8
monocytes	8
at	0
relatively	0
high	0
levels	0
,	0
was	0
also	0
slightly	0
augmented	0
by	0
LTB4	0
,	0
although	0
to	0
a	0
much	0
lower	0
extent	0
than	0
c-fos	1
.	0

The	0
kinetics	0
of	0
expression	0
of	0
the	0
two	0
genes	0
were	0
also	0
slightly	0
different	0
,	0
with	0
c-fos	3
mRNA	4
reaching	0
a	0
peak	0
at	0
15	0
min	0
after	0
stimulation	0
and	0
c-jun	1
at	0
30	0
min	0
.	0

Both	0
messages	0
rapidly	0
declined	0
thereafter	0
.	0

Stability	0
of	0
the	0
c-fos	1
and	0
c-jun	3
mRNA	4
was	0
not	0
affected	0
by	0
LTB4	0
,	0
as	0
assessed	0
after	0
actinomycin	0
D	0
treatment	0
.	0

Nuclear	0
transcription	0
studies	0
in	0
vitro	0
showed	0
that	0
LTB4	0
increased	0
the	0
transcription	0
of	0
the	0
c-fos	1
gene	2
7-fold	0
and	0
the	0
c-jun	1
gene	2
1.4-fold	0
.	0

Resting	7
monocytes	8
contained	0
nuclear	9
factors	10
binding	0
to	0
the	0
AP-1	1
element	2
,	0
but	0
stimulation	0
of	0
monocytes	7
with	0
LTB4	0
induced	0
greater	0
AP-1	9
-binding	0
activity	0
of	0
nuclear	9
proteins	10
.	0

These	0
results	0
indicate	0
that	0
LTB4	0
may	0
regulate	0
the	0
production	0
of	0
different	0
cytokines	9
by	0
modulating	0
the	0
yield	0
and/or	0
the	0
function	0
of	0
transcription	9
factors	10
such	0
as	0
AP-1	9
-binding	0
proto-oncogene	9
products	10
.	0

Modulation	0
of	0
normal	0
erythroid	0
differentiation	0
by	0
the	0
endogenous	0
thyroid	0
hormone	0
and	0
retinoic	9
acid	10
receptors	10
:	0
a	0
possible	0
target	0
for	0
v-erbA	1
oncogene	2
action	0
.	0

The	0
v-erbA	1
oncogene	2
,	0
a	0
mutated	0
version	0
of	0
the	0
thyroid	9
hormone	10
receptor	10
alpha	10
(	0
c-erbA/TR-alpha	9
)	0
,	0
inhibits	0
erythroid	0
differentiation	0
and	0
constitutively	0
represses	0
transcription	0
of	0
certain	0
erythrocyte	1
genes	2
,	0
suggesting	0
a	0
normal	0
function	0
of	0
the	0
proto-oncogene	1
c-erbA	2
in	0
erythropoiesis	0
.	0

Here	0
we	0
demonstrate	0
that	0
the	0
endogenous	0
thyroid	9
hormone	10
receptor	10
alpha	10
(	0
c-erbA/TR-alpha	9
)	0
and	0
the	0
closely	0
related	0
retinoic	9
acid	10
receptor	10
alpha	10
(	0
RAR-alpha	9
)	0
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
normal	0
erythroid	0
differentiation	0
.	0

Retinoic	0
acid	0
(	0
RA	0
)	0
distinctly	0
modulated	0
the	0
erythroid	0
differentiation	0
program	0
of	0
normal	7
erythroid	8
progenitors	8
and	0
erythroblasts	0
reversibly	0
transformed	0
by	0
a	0
conditional	0
tyrosine	1
kinase	2
oncogene	2
.	0

When	0
added	0
pulsewise	0
to	0
immature	7
cells	8
,	0
differentiation	0
was	0
accelerated	0
while	0
more	0
mature	7
cells	8
underwent	0
premature	0
cell	0
death	0
.	0

Thyroid	0
hormone	0
(	0
T3	0
)	0
alone	0
caused	0
similar	0
but	0
weaker	0
effects	0
.	0

Interestingly	0
,	0
T3	0
strongly	0
enhanced	0
the	0
action	0
of	0
RA	0
,	0
suggesting	0
cooperative	0
action	0
of	0
the	0
two	0
receptors	0
in	0
modulating	0
erythroid	0
differentiation	0
.	0

Expression	0
of	0
the	0
human	9
RAR-alpha	10
in	0
receptor-negative	5
erythroblasts	6
conferred	0
RA-induced	0
regulation	0
of	0
differentiation	0
to	0
the	0
otherwise	0
unresponsive	7
cells	8
,	0
thus	0
showing	0
that	0
the	0
RAR-alpha	9
is	0
essential	0
for	0
the	0
RA	0
effect	0
.	0

Likewise	0
,	0
enhanced	0
expression	0
of	0
exogenous	9
c-erbA/TR-alpha	10
in	0
erythroblasts	7
rendered	0
them	0
susceptible	0
to	0
modulation	0
of	0
differentiation	0
by	0
T3	0
,	0
suggesting	0
a	0
similar	0
function	0
of	0
both	0
receptors	0
.	0

Activation	0
of	0
lymphokine	1
genes	2
in	0
T	7
cells	8
:	0
role	0
of	0
cis-acting	1
DNA	2
elements	2
that	0
respond	0
to	0
T	0
cell	0
activation	0
signals	0
.	0

Activation	0
of	0
T	7
cells	8
is	0
initiated	0
by	0
the	0
recognition	0
of	0
antigen	0
on	0
antigen	7
presenting	8
cells	8
to	0
exert	0
the	0
effector	0
functions	0
in	0
immune	0
and	0
inflammatory	0
responses	0
.	0

Two	0
types	0
of	0
helper	5
T	6
cell	6
(	6
Th	6
)	6
clones	6
(	0
Th1	5
and	0
Th2	5
)	0
are	0
defined	0
on	0
the	0
basis	0
of	0
different	0
patterns	0
of	0
cytokine	9
(	0
lymphokine	9
)	0
secretion	0
.	0

They	0
determine	0
the	0
outcome	0
of	0
an	0
antigenic	0
response	0
toward	0
humoral	0
or	0
cell-mediated	0
immunity	0
.	0

Although	0
lymphokine	1
genes	2
are	0
coordinately	0
regulated	0
upon	0
antigen	0
stimulation	0
,	0
they	0
are	0
regulated	0
by	0
the	0
mechanisms	0
common	0
to	0
all	0
as	0
well	0
as	0
those	0
which	0
are	0
unique	0
to	0
each	0
gene	0
.	0

For	0
most	0
lymphokine	1
genes	2
,	0
a	0
combination	0
of	0
phorbol	0
esters	0
(	0
phorbol	0
12-myristate	0
13	0
acetate	0
,	0
PMA	0
)	0
and	0
calcium	0
ionophores	0
(	0
A23187	0
)	0
is	0
required	0
for	0
their	0
maximal	0
induction	0
.	0

Yet	0
phorbol	0
ester	0
alone	0
or	0
calcium	0
ionophore	0
alone	0
produce	0
several	0
lymphokines	9
.	0

The	0
production	0
of	0
the	0
granulocyte-macrophage	9
colony	10
stimulating	10
factor	10
(	0
GM-CSF	9
)	0
is	0
completely	0
dependent	0
on	0
the	0
two	0
signals	0
.	0

We	0
have	0
previously	0
found	0
a	0
cis-acting	1
region	2
spanning	0
the	0
GM-CSF	1
promoter	2
region	2
(	0
positions	0
-95	0
to	0
+27	0
)	0
that	0
confers	0
inducibility	0
to	0
reporter	1
genes	2
in	0
transient	0
transfection	0
assays	0
.	0

Further	0
analysis	0
identified	0
three	0
elements	0
required	0
for	0
efficient	0
induction	0
,	0
referred	0
to	0
as	0
GM2	1
,	0
GC-box	1
and	0
conserved	1
lymphokine	2
element	2
(	0
CLE0	1
)	0
.	0

GM2	1
defines	0
a	0
binding	1
site	2
for	0
protein	0
(	0
s	0
)	0
whose	0
binding	0
is	0
inducible	0
by	0
PMA	0
.	0

One	0
protein	0
,	0
NF-GM2	9
is	0
similar	0
to	0
the	0
transcription	9
factor	10
NF-kB	9
.	0

GC-box	1
is	0
a	0
binding	1
site	2
for	0
constitutively	9
bound	10
proteins	10
.	0

CLEO	0
defines	0
a	0
binding	1
site	2
for	0
protein	0
(	0
s	0
)	0
whose	0
optimum	0
binding	0
is	0
stimulated	0
by	0
PMA	0
and	0
A23187	0
.	0

Viral	9
trans-activators	10
such	0
as	0
Tax	9
(	0
human	0
T	0
cell	0
leukemia	0
virus-1	0
,	0
HTLV-1	0
)	0
and	0
E2	9
(	0
bovine	0
papilloma	0
virus	0
,	0
BPV	0
)	0
proteins	0
are	0
other	0
agents	0
which	0
activate	0
lymphokine	1
gene	2
expression	0
by	0
bypassing	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
mediated	0
signaling	0
.	0

The	0
trans-activation	0
domain	0
of	0
E2	9
and	0
Tax	9
is	0
interchangeable	0
although	0
they	0
have	0
no	0
obvious	0
sequence	0
homology	0
between	0
them	0
.	0

The	0
viral	9
trans-activators	10
appear	0
to	0
target	0
specific	0
DNA	9
binding	10
protein	10
such	0
as	0
NF-kB	9
and	0
Sp1	9
to	0
cis-acting	1
DNA	2
site	2
and	0
promote	0
lymphokine	1
gene	2
expression	0
without	0
TCR	9
-mediated	0
stimulation	0
.	0

Mutations	0
in	0
the	0
Pit-1	1
gene	2
in	0
children	0
with	0
combined	0
pituitary	0
hormone	0
deficiency	0
.	0

Pit-1	9
is	0
a	0
pituitary-specific	9
transcription	10
factor	10
that	0
binds	0
to	0
and	0
transactivates	0
promoters	1
of	0
growth	1
hormone	2
and	2
prolactin	2
genes	2
.	0

In	0
three	0
unrelated	0
Japanese	0
children	0
with	0
combined	0
pituitary	0
hormone	0
deficiency	0
,	0
we	0
identified	0
three	0
point	0
mutations	0
in	0
the	0
Pit-1	1
gene	2
,	0
Pro24Leu	1
,	0
Arg143Gln	1
,	0
and	0
Arg271Trp	1
,	0
located	0
on	0
the	0
major	1
transactivation	2
region	2
,	0
POU-specific	1
domain	2
,	0
and	0
POU-homeodomain	1
,	0
respectively	0
.	0

Activation	0
of	0
protein	9
kinase	10
C	10
and	0
elevation	0
of	0
cAMP	0
interact	0
synergistically	0
to	0
raise	0
c-Fos	9
and	0
AP-1	9
activity	0
in	0
Jurkat	0
cells	0
.	0

We	0
have	0
earlier	0
found	0
that	0
in	0
Jurkat	0
cells	0
activation	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
enhances	0
the	0
cyclic	0
adenosine	0
monophosphate	0
(	0
cAMP	0
)	0
accumulation	0
induced	0
by	0
adenosine	0
receptor	0
stimulation	0
or	0
activation	0
of	0
Gs	9
.	0

Here	0
we	0
have	0
therefore	0
examined	0
the	0
effect	0
of	0
the	0
phorbol	0
ester	0
PMA	0
(	0
phorbol	0
12-myristate	0
13-acetate	0
)	0
which	0
stimulates	0
PKC	9
and	0
a	0
combination	0
of	0
the	0
adenosine	9
receptor	10
agonist	0
NECA	0
(	0
5'-	0
(	0
N-ethyl	0
)	0
-carboxamido	0
adenosine	0
)	0
and	0
forskolin	0
to	0
raise	0
cAMP	0
,	0
on	0
the	0
levels	0
of	0
c-Fos	9
and	0
Jun	9
and	0
on	0
the	0
binding	0
and	0
transcriptional	0
activity	0
of	0
the	0
transcription	9
factor	10
,	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
.	0

PMA	0
treatment	0
caused	0
a	0
concentration-	0
and	0
time-dependent	0
increase	0
in	0
both	0
c-Fos	0
and	0
Jun	0
immunoreactivity	0
in	0
contrast	0
to	0
cAMP	0
elevation	0
that	0
had	0
only	0
a	0
slight	0
effect	0
.	0

Both	0
PMA	0
and	0
the	0
combination	0
of	0
NECA	0
and	0
forskolin	0
acted	0
together	0
either	0
to	0
increase	0
(	0
c-Fos	9
)	0
or	0
decrease	0
(	0
Jun	9
)	0
protein	0
levels	0
as	0
well	0
as	0
increasing	0
AP-1	9
binding	0
,	0
as	0
judged	0
by	0
gel-shift	0
assay	0
,	0
and	0
AP-1	9
transcriptional	0
activity	0
.	0

Furthermore	0
there	0
was	0
a	0
clear-cut	0
synergy	0
between	0
the	0
PKC	9
stimulator	0
and	0
the	0
cAMP	0
elevating	0
agents	0
.	0

The	0
results	0
demonstrate	0
that	0
the	0
simultaneous	0
activation	0
of	0
PKC	9
and	0
elevation	0
of	0
cAMP	0
leads	0
to	0
an	0
enhanced	0
AP-1	9
transcriptional	0
activity	0
in	0
a	0
T-leukemia	5
cell	6
line	6
,	0
suggesting	0
that	0
the	0
previously	0
observed	0
interaction	0
between	0
the	0
parallel	0
signal	0
transduction	0
pathways	0
may	0
have	0
functional	0
consequences	0
at	0
the	0
level	0
of	0
gene	0
transcription	0
.	0

Inhibition	0
of	0
anti-CD3	9
monoclonal	10
antibody	10
-induced	0
T-cell	0
proliferation	0
by	0
dexamethasone	0
,	0
isoproterenol	0
,	0
or	0
prostaglandin	0
E2	0
either	0
alone	0
or	0
in	0
combination	0
.	0

1	0
.	0

The	0
purpose	0
of	0
these	0
studies	0
was	0
to	0
investigate	0
the	0
modulation	0
of	0
the	0
proliferation	0
of	0
human	7
T	8
cells	8
obtained	0
from	0
peripheral	0
blood	0
by	0
dexamethasone	0
(	0
DEX	0
)	0
,	0
isoproterenol	0
(	0
ISO	0
)	0
,	0
and	0
prostaglandin	0
E2	0
(	0
PGE2	0
)	0
.	0

The	0
former	0
two	0
substances	0
interact	0
with	0
T	7
cells	8
via	0
the	0
glucocorticoid	9
and	10
beta-adrenergic	10
receptors	10
respectively	0
.	0

When	0
occupied	0
by	0
their	0
natural	0
ligands	0
,	0
glucocorticosteroids	0
and	0
catecholamines	0
,	0
these	0
receptors	0
have	0
a	0
role	0
in	0
modulating	0
T-cell	0
function	0
during	0
stress	0
.	0

During	0
the	0
inflammatory	0
response	0
increased	0
levels	0
of	0
PGE2	0
bind	0
to	0
their	0
receptors	0
on	0
T	7
cells	8
and	0
thus	0
alter	0
responsiveness	0
.	0

Proliferation	0
of	0
T	7
cells	8
was	0
induced	0
by	0
immobilized	0
anti-CD3	9
monoclonal	10
antibody	10
(	0
mAb	9
)	0
in	0
the	0
presence	0
or	0
absence	0
of	0
an	0
additional	0
costimulatory	0
signal	0
delivered	0
by	0
anti-CD28	9
mAb	10
.	0

2	0
.	0

Various	0
physiologic	0
concentrations	0
of	0
DEX	0
,	0
ISO	0
,	0
or	0
PGE2	0
were	0
added	0
at	0
the	0
time	0
of	0
initiation	0
of	0
the	0
cultures	0
and	0
subsequent	0
proliferation	0
of	0
the	0
unstimulated	0
T	7
cells	8
was	0
determined	0
.	0

The	0
results	0
demonstrate	0
that	0
physiologic	0
concentrations	0
of	0
all	0
three	0
of	0
these	0
agents	0
inhibit	0
the	0
anti-CD3	9
mAb	10
-induced	0
proliferation	0
of	0
T	7
cells	8
.	0

3	0
.	0

Although	0
DEX	0
and	0
PGE2	0
were	0
equipotent	0
in	0
suppressing	0
T-cell	0
proliferation	0
,	0
ISO	0
was	0
much	0
less	0
effective	0
.	0

4	0
.	0

Because	0
concomitant	0
elevations	0
in	0
the	0
peripheral	0
levels	0
of	0
these	0
substances	0
may	0
occur	0
,	0
experiments	0
were	0
performed	0
to	0
determine	0
the	0
T-cell	0
inhibitory	0
effects	0
of	0
DEX	0
together	0
with	0
either	0
PGE2	0
or	0
ISO	0
.	0

Synergistic	0
suppression	0
of	0
T-cell	0
proliferation	0
was	0
observed	0
when	0
various	0
concentrations	0
of	0
DEX	0
and	0
PGE2	0
,	0
but	0
not	0
DEX	0
and	0
ISO	0
,	0
were	0
added	0
to	0
cultures	0
.	0

This	0
synergistic	0
suppression	0
could	0
not	0
be	0
explained	0
by	0
an	0
increase	0
in	0
cAMP	0
accumulation	0
in	0
T	7
cells	8
stimulated	0
with	0
DEX	0
and	0
PGE2	0
.	0

5	0
.	0

Finally	0
,	0
the	0
addition	0
of	0
anti-CD28	9
mAb	10
to	0
anti-CD3	7
mAb-stimulated	8
T	8
cells	8
overcame	0
much	0
of	0
the	0
suppression	0
of	0
proliferation	0
induced	0
by	0
PGE2	0
or	0
ISO	0
but	0
less	0
so	0
than	0
that	0
induced	0
by	0
DEX	0
.	0

In	0
vivo	0
footprint	0
analysis	0
of	0
the	0
HLA-DRA	1
gene	2
promoter	2
:	0
cell-specific	0
interaction	0
at	0
the	0
octamer	1
site	2
and	0
up-regulation	0
of	0
X	0
box	0
binding	0
by	0
interferon	9
gamma	10
.	0

Analysis	0
of	0
the	0
major	1
histocompatibility	2
complex	2
class	2
II	2
gene	2
promoter	2
DRA	1
has	0
previously	0
identified	0
at	0
least	0
five	0
cis-acting	1
regions	2
required	0
for	0
maximal	0
expression	0
.	0

We	0
have	0
examined	0
the	0
DRA	1
promoter	2
for	0
protein-DNA	0
interactions	0
in	0
the	0
intact	7
cell	8
,	0
which	0
may	0
mediate	0
transcriptional	0
activation	0
.	0

Using	0
in	0
vivo	0
genomic	0
footprinting	0
we	0
identified	0
interactions	0
in	0
B-cell	5
lines	6
at	0
the	0
octamer	1
site	2
and	0
the	0
Y	1
,	2
X1	2
,	2
and	2
X2	2
boxes	2
.	0

Class	5
II	6
antigen	6
expressing	6
T-cell	6
lines	6
maintained	0
contacts	0
identical	0
to	0
B-cell	5
lines	6
,	0
while	0
class	5
II-negative	6
T-cell	6
lines	6
exhibited	0
no	0
interactions	0
.	0

In	0
lymphoid	5
cell	6
lines	6
,	0
the	0
octamer	1
site	2
is	0
occupied	0
and	0
required	0
for	0
maximal	0
expression	0
.	0

This	0
is	0
most	0
likely	0
due	0
to	0
the	0
presence	0
of	0
the	0
lymphoid-specific	9
OTF-2	10
factor	10
.	0

In	0
contrast	0
,	0
the	0
class	5
II-positive	6
nonlymphoid	6
glioblastoma	6
cell	6
line	6
does	0
not	0
exhibit	0
interactions	0
at	0
the	0
octamer	1
site	2
despite	0
the	0
presence	0
of	0
the	0
ubiquitous	9
OTF-1	10
factor	10
and	0
an	0
open	1
binding	2
site	2
.	0

Thus	0
,	0
the	0
DRA	1
promoter	2
discriminates	0
against	0
OTF-1	9
activation	0
at	0
the	0
level	0
of	0
DNA	0
binding	0
in	0
the	0
glioblastoma	5
line	6
.	0

Interferon	9
gamma	10
induces	0
class	0
II	0
expression	0
in	0
this	0
glioblastoma	5
cell	6
line	6
and	0
,	0
in	0
parallel	0
,	0
up-regulates	0
X1	0
and	0
X2	0
box	0
protein-DNA	0
interactions	0
,	0
while	0
all	0
other	0
interactions	0
remain	0
unchanged	0
.	0

These	0
results	0
suggest	0
that	0
interferon	9
gamma	10
functions	0
on	0
a	0
poised	1
promoter	2
by	0
altering	0
weak	0
,	0
nonproductive	0
interactions	0
at	0
the	0
X	1
boxes	2
to	0
strong	0
interactions	0
.	0

These	0
findings	0
provide	0
direct	0
in	0
vivo	0
evidence	0
to	0
strongly	0
suggest	0
that	0
the	0
modulation	0
of	0
X1	1
and	0
X2	1
interactions	0
is	0
an	0
important	0
constituent	0
of	0
the	0
interferon	9
gamma	10
induction	0
pathway	0
.	0

Estrogen	0
binding	0
sites	0
in	0
peripheral	7
blood	8
monocytes	8
and	0
effects	0
of	0
danazol	0
on	0
their	0
sites	0
in	0
vitro	0
.	0

1	0
.	0

This	0
study	0
was	0
designed	0
to	0
investigate	0
the	0
presence	0
of	0
estrogen	0
type	0
I	0
(	0
high	0
affinity	0
,	0
low	0
capacity	0
)	0
and	0
type	0
II	0
(	0
low	0
affinity	0
,	0
high	0
capacity	0
)	0
binding	0
sites	0
in	0
human	0
peripheral	7
blood	8
monocytes	8
and	0
the	0
effects	0
of	0
danazol	0
on	0
these	0
sites	0
.	0

2	0
.	0

These	0
two	0
types	0
of	0
estrogen	0
binding	0
sites	0
existed	0
in	0
human	7
peripheral	8
blood	8
monocytes	8
.	0

3	0
.	0

Danazol	0
bound	0
to	0
these	0
sites	0
in	0
high	0
concentration	0
(	0
10	0
(	0
-6	0
)	0
M	0
,	0
clinical	0
serum	0
concentration	0
during	0
danazol	0
therapy	0
)	0
and	0
decreased	0
the	0
number	0
of	0
both	0
sites	0
.	0

4	0
.	0

It	0
is	0
suggested	0
that	0
danazol	0
has	0
an	0
anti-estrogenic	0
action	0
to	0
the	0
monocytes	0
through	0
the	0
competition	0
and	0
suppression	0
of	0
estrogen	0
binding	0
sites	0
as	0
seen	0
in	0
the	0
estrogen	0
target	0
organ	0
.	0

A	0
microtitre	0
assay	0
system	0
for	0
glucocorticoid	9
receptors	10
:	0
decreased	0
receptor	0
concentration	0
in	0
myocardial	0
infarction	0
.	0

A	0
major	0
difficulty	0
in	0
determination	0
of	0
glucocorticoid	0
receptor	0
sites	0
is	0
the	0
very	0
complicated	0
assay	0
procedure	0
.	0

Therefore	0
,	0
we	0
describe	0
a	0
microtitre	0
assay	0
system	0
for	0
glucocorticoid	9
receptors	10
which	0
is	0
a	0
whole-cell	0
competitive	0
binding	0
radioassay	0
using	0
[	0
3H	0
]	0
-dexamethasone	0
as	0
radioligand	0
.	0

This	0
modification	0
of	0
a	0
previously	0
described	0
protocol	0
simplifies	0
and	0
reduces	0
laboratory	0
work	0
and	0
allows	0
assay	0
reproducibility	0
to	0
be	0
controlled	0
more	0
reliably	0
.	0

Thus	0
enabled	0
to	0
perform	0
the	0
test	0
on	0
multiple	0
blood	7
samples	8
in	0
parallel	0
,	0
we	0
investigated	0
cardiac	0
infarction	0
patients	0
over	0
a	0
12-day	0
period	0
to	0
test	0
if	0
glucocorticoid	9
receptor	10
binding	0
is	0
altered	0
in	0
this	0
'stressful	0
'	0
disease	0
.	0

On	0
the	0
first	0
day	0
of	0
the	0
disease	0
,	0
glucocorticoid	9
receptor	10
capacity	0
was	0
significantly	0
decreased	0
without	0
alteration	0
of	0
the	0
receptor-ligand	0
affinity	0
,	0
whereas	0
on	0
days	0
4	0
and	0
12	0
the	0
number	0
of	0
receptor	0
sites	0
was	0
normal	0
again	0
.	0

This	0
result	0
fits	0
well	0
into	0
the	0
general	0
observation	0
of	0
stress-induced	0
down-regulation	0
of	0
immune	0
responses	0
.	0

SRC-related	1
proto-oncogenes	2
and	0
transcription	9
factors	10
in	0
primary	0
human	7
T	8
cells	8
:	0
modulation	0
by	0
cyclosporin	0
A	0
and	0
FK506	0
.	0

Activation	0
of	0
T	7
lymphocytes	8
induces	0
transcription	0
of	0
genes	1
encoding	0
for	0
lymphokines	9
.	0

Interleukin-2	1
(	2
IL-2	2
)	2
gene	2
expression	0
is	0
controlled	0
transcriptionally	0
by	0
the	0
cooperative	0
activity	0
of	0
specific	0
trans-activating	9
factors	10
that	0
bind	0
to	0
the	0
IL-2	1
enhancer	2
.	0

Cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
inhibit	0
the	0
production	0
of	0
IL-2	9
in	0
T	7
lymphocytes	8
at	0
the	0
level	0
of	0
gene	0
transcription	0
.	0

A	0
member	0
of	0
the	0
src	1
gene	2
family	2
,	0
the	0
lymphocyte-specific	9
protein	10
tyrosine	10
kinase	10
,	0
p56lck	9
,	0
has	0
been	0
implicated	0
in	0
IL-2	9
production	0
.	0

CsA	0
was	0
found	0
not	0
to	0
inhibit	0
lck	9
gene	0
expression	0
,	0
nor	0
the	0
activity	0
of	0
the	0
lck	1
gene	2
product	0
.	0

However	0
,	0
CsA	0
and	0
FK506	0
inhibit	0
the	0
appearance	0
of	0
DNA	0
binding	0
activity	0
of	0
factors	0
that	0
bind	0
to	0
the	0
NF-AT	1
and	0
AP-1	1
sites	2
in	0
the	0
IL-2	1
enhancer	2
.	0

Since	0
the	0
induction	0
of	0
NF-AT	9
and	0
AP-1	9
is	0
induced	0
by	0
the	0
same	0
stimuli	0
that	0
stimulate	0
IL-2	9
production	0
,	0
these	0
results	0
indicate	0
that	0
the	0
immunosuppressant	0
action	0
of	0
CsA	0
and	0
FK506	0
is	0
exerted	0
at	0
the	0
level	0
of	0
these	0
trans-activating	9
factors	10
.	0

The	0
AP-1	1
site	2
at	0
-150	1
bp	2
,	0
but	0
not	0
the	0
NF-kappa	1
B	2
site	2
,	0
is	0
likely	0
to	0
represent	0
the	0
major	0
target	0
of	0
protein	9
kinase	10
C	10
in	0
the	0
interleukin	1
2	2
promoter	2
.	0

Stimulation	0
of	0
T	7
cells	8
with	0
antigen	0
results	0
in	0
activation	0
of	0
several	0
kinases	9
,	0
including	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
,	0
that	0
may	0
mediate	0
the	0
later	0
induction	0
of	0
activation-related	0
genes	0
.	0

We	0
have	0
examined	0
the	0
potential	0
role	0
of	0
PKC	9
in	0
induction	0
of	0
the	0
interleukin	1
2	2
(	2
IL-2	2
)	2
gene	2
in	0
T	7
cells	8
stimulated	0
through	0
the	0
T	9
cell	10
receptor/CD3	10
complex	10
.	0

We	0
have	0
previously	0
shown	0
that	0
prolonged	0
treatment	0
of	0
the	0
untransformed	0
T	5
cell	6
clone	6
Ar-5	6
with	0
phorbol	0
esters	0
results	0
in	0
downmodulation	0
of	0
the	0
alpha	9
and	10
beta	10
isozymes	10
of	0
PKC	9
,	0
and	0
abrogates	0
induction	0
of	0
IL-2	3
mRNA	4
and	0
protein	9
.	0

Here	0
we	0
show	0
that	0
phorbol	0
ester	0
treatment	0
also	0
abolishes	0
induction	0
of	0
chloramphenicol	9
acetyltransferase	10
activity	0
in	0
Ar-5	5
cells	6
transfected	0
with	0
a	0
plasmid	1
containing	0
the	0
IL-2	1
promoter	2
linked	0
to	0
this	0
reporter	1
gene	2
.	0

The	0
IL-2	1
promoter	2
contains	0
binding	1
sites	2
for	0
nuclear	9
factors	10
including	0
NFAT-1	9
,	0
Oct	9
,	0
NF-kappa	9
B	10
,	0
and	0
AP-1	9
,	0
which	0
are	0
all	0
potentially	0
sensitive	0
to	0
activation	0
of	0
PKC	9
.	0

We	0
show	0
that	0
induction	0
of	0
a	0
trimer	0
of	0
the	0
NFAT	1
and	2
Oct	2
sites	2
is	0
not	0
sensitive	0
to	0
phorbol	0
ester	0
treatment	0
,	0
and	0
that	0
mutations	0
in	0
the	0
NF-kappa	1
B	2
site	2
have	0
no	0
effect	0
on	0
inducibility	0
of	0
the	0
IL-2	1
promoter	2
.	0

In	0
contrast	0
,	0
mutations	0
in	0
the	0
AP-1	1
site	2
located	0
at	0
-150	1
bp	2
almost	0
completely	0
abrogate	0
induction	0
of	0
the	0
IL-2	1
promoter	2
,	0
and	0
appearance	0
of	0
an	0
inducible	9
nuclear	10
factor	10
binding	0
to	0
this	0
site	0
is	0
sensitive	0
to	0
PKC	9
depletion	0
.	0

Moreover	0
,	0
cotransfections	0
with	0
c-fos	0
and	0
c-jun	0
expression	0
plasmids	0
markedly	0
enhance	0
induction	0
of	0
the	0
IL-2	1
promoter	2
in	0
minimally	5
stimulated	6
T	6
cells	6
.	0

Our	0
results	0
indicate	0
that	0
the	0
AP-1	1
site	2
at	0
-150	1
bp	2
represents	0
a	0
major	0
,	0
if	0
not	0
the	0
only	0
,	0
site	0
of	0
PKC	9
responsiveness	0
in	0
the	0
IL-2	1
promoter	2
.	0

[	0
Effect	0
of	0
antihypertensive	0
therapy	0
with	0
captopril	0
on	0
gluco-	9
and	10
mineralocorticoid	10
receptors	10
of	0
peripheral	7
blood	8
lymphocytes	8
in	0
hypertensive	0
patients	0
of	0
various	0
age	0
]	0

Binding	0
of	0
3H-dexamethasone	0
and	0
3H-aldosterone	0
by	0
peripheral	9
lymphocyte	10
receptors	10
was	0
investigated	0
in	0
healthy	0
persons	0
and	0
hypertensive	0
patients	0
before	0
and	0
after	0
2-week	0
captopril	0
treatment	0
.	0

The	0
number	0
of	0
glucocorticoid	9
and	10
mineralocorticoid	10
binding	10
sites	10
was	0
increased	0
in	0
hypertensives	0
vs	0
normotensives	0
.	0

The	0
treatment	0
with	0
the	0
ACE	0
inhibitor	0
captopril	0
led	0
to	0
activation	0
of	0
hormone-receptor	0
interactions	0
.	0

There	0
was	0
a	0
more	0
marked	0
rise	0
of	0
the	0
number	0
of	0
receptors	9
in	0
middle-aged	0
(	0
44-55	0
years	0
)	0
hypertensives	0
vs	0
elderly	0
(	0
61-80	0
years	0
)	0
subjects	0
after	0
captopril	0
treatment	0
.	0

The	0
use	0
of	0
interferon-gamma-treated	5
U937	6
cells	6
in	0
chemiluminescence	0
assays	0
to	0
detect	0
red	9
cell	10
,	10
platelet	10
and	10
granulocyte	10
antibodies	10
of	0
potential	0
clinical	0
significance	0
.	0

The	0
chemiluminescent	0
(	0
CL	0
)	0
response	0
of	0
interferon-gamma-treated	5
U937	6
(	6
IFN-U937	6
)	6
cells	6
to	0
sensitized	0
target	0
cells	0
has	0
been	0
used	0
to	0
detect	0
red	9
cell	10
,	0
platelet	9
and	0
granulocyte	9
antibodies	10
.	0

A	0
clone	0
of	0
U937	5
cells	6
was	0
selected	0
which	0
expressed	0
Fc	9
receptor	10
I	10
(	0
Fc	9
gamma	10
RI	10
)	0
and	0
which	0
,	0
after	0
incubation	0
with	0
IFN-gamma	9
for	0
72	0
h	0
,	0
was	0
capable	0
of	0
generating	0
high	0
levels	0
of	0
lucigenin-enhanced	0
CL	0
.	0

The	0
CL	0
responses	0
of	0
IFN-U937	5
cells	6
and	0
peripheral	7
blood	8
human	8
monocytes	8
to	0
sensitized	7
red	8
cells	8
,	0
platelets	7
or	0
granulocytes	7
were	0
then	0
compared	0
.	0

Assays	0
using	0
monocytes	7
or	0
IFN-U937	5
cells	6
were	0
of	0
comparable	0
sensitivity	0
for	0
detection	0
of	0
antibodies	9
against	0
all	0
three	0
types	0
of	0
target	0
cell	0
.	0

In	0
addition	0
,	0
the	0
use	0
of	0
IFN-U937	5
cells	6
reduced	0
interassay	0
variation	0
and	0
simplified	0
assay	0
performance	0
.	0

The	0
potential	0
clinical	0
usefulness	0
of	0
these	0
CL	0
assays	0
was	0
suggested	0
by	0
the	0
ability	0
of	0
both	0
monocytes	7
and	0
IFN-U937	5
cells	6
to	0
respond	0
to	0
red	7
cells	8
,	0
platelets	7
or	0
granulocytes	7
sensitized	0
with	0
sera	0
from	0
pregnant	0
women	0
whose	0
babies	0
had	0
either	0
haemolytic	0
disease	0
of	0
the	0
newborn	0
(	0
HDN	0
)	0
,	0
alloimmune	0
thrombocytopenia	0
or	0
alloimmune	0
neutropenia	0
respectively	0
.	0

In	0
addition	0
,	0
monocytes	7
and	0
IFN-U937	5
cells	6
both	0
responded	0
to	0
red	7
cells	8
sensitized	0
with	0
antibodies	9
against	0
a	0
variety	0
of	0
specificities	0
of	0
assumed	0
(	0
although	0
not	0
documented	0
)	0
clinical	0
significance	0
for	0
blood	0
transfusion	0
recipients	0
.	0

In	0
contrast	0
,	0
monocytes	7
and	0
IFN-U937	5
cells	6
responded	0
only	0
weakly	0
to	0
red	7
cells	8
sensitized	0
with	0
either	0
anti-D	9
in	0
sera	0
from	0
mothers	0
of	0
babies	0
unaffected	0
by	0
HDN	0
,	0
or	0
with	0
antisera	0
containing	0
high	9
titre	10
antibodies	10
with	0
specificities	0
not	0
normally	0
associated	0
with	0
significantly	0
reduced	0
red	7
cell	8
survival	0
.	0

Ablation	0
of	0
transplanted	0
HTLV-I	0
Tax-transformed	0
tumors	0
in	0
mice	0
by	0
antisense	0
inhibition	0
of	0
NF-kappa	9
B	10
[	0
published	0
erratum	0
appears	0
in	0
Science	0
1993	0
Mar	0
12	0
;	0
259	0
(	0
5101	0
)	0
:	0
1523	0
]	0

Mice	0
transgenic	0
for	0
the	0
human	1
T	2
cell	2
leukemia	2
virus	2
(	2
HTLV-I	2
)	2
Tax	2
gene	2
develop	0
fibroblastic	0
tumors	0
that	0
express	0
NF-kappa	1
B-inducible	2
early	2
genes	2
.	0

In	0
vitro	0
inhibition	0
of	0
NF-kappa	9
B	10
expression	0
by	0
antisense	0
oligodeoxynucleotides	0
(	0
ODNs	0
)	0
inhibited	0
growth	0
of	0
these	0
culture-adapted	5
Tax-transformed	6
fibroblasts	6
as	0
well	0
as	0
an	0
HTLV-I-transformed	5
human	6
lymphocyte	6
line	6
.	0

In	0
contrast	0
,	0
antisense	0
inhibition	0
of	0
Tax	9
itself	0
had	0
no	0
apparent	0
effect	0
on	0
cell	0
growth	0
.	0

Mice	0
treated	0
with	0
antisense	0
to	0
NF-kappa	9
B	10
ODNs	0
showed	0
rapid	0
regression	0
of	0
transplanted	0
fibrosarcomas	0
.	0

This	0
suggests	0
that	0
NF-kappa	9
B	10
expression	0
may	0
be	0
necessary	0
for	0
the	0
maintenance	0
of	0
the	0
malignant	0
phenotype	0
and	0
provides	0
a	0
therapeutic	0
approach	0
for	0
HTLV-I-associated	0
disease	0
.	0

Membrane	9
receptors	10
for	0
aldosterone	0
:	0
a	0
novel	0
pathway	0
for	0
mineralocorticoid	0
action	0
.	0

Rapid	0
nongenomic	0
in	0
vitro	0
effects	0
of	0
aldosterone	0
on	0
intracellular	0
electrolytes	0
,	0
cell	0
volume	0
,	0
and	0
Na	9
(	10
+	10
)	10
-H+	10
antiport	10
have	0
been	0
found	0
in	0
human	7
mononuclear	8
leukocytes	8
(	0
HML	7
)	0
.	0

Binding	0
of	0
125I-labeled	0
aldosterone	0
to	0
plasma	0
membranes	0
of	0
HML	7
shares	0
important	0
features	0
with	0
these	0
functional	0
data	0
.	0

This	0
includes	0
a	0
very	0
low	0
apparent	0
dissociation	0
constant	0
(	0
Kd	0
)	0
of	0
0.1	0
nM	0
for	0
both	0
aldosterone	0
and	0
the	0
effect	0
on	0
the	0
Na	9
(	10
+	10
)	10
-H	10
(	10
+	10
)	10
-antiport	10
,	0
a	0
high	0
turnover	0
rate	0
,	0
and	0
the	0
almost	0
exclusive	0
binding	0
selectivity	0
for	0
aldosterone	0
.	0

Dexamethasone	0
,	0
RU	0
26988	0
,	0
corticosterone	0
,	0
ouabain	0
,	0
amiloride	0
,	0
and	0
18-hydroxyprogesterone	0
were	0
inactive	0
as	0
ligands	0
.	0

Deoxycorticosterone	0
acetate	0
had	0
an	0
intermediate	0
activity	0
with	0
an	0
apparent	0
Kd	0
of	0
100	0
nM	0
.	0

These	0
findings	0
are	0
the	0
first	0
to	0
demonstrate	0
membrane	0
binding	0
of	0
aldosterone	0
being	0
compatible	0
with	0
major	0
aspects	0
of	0
its	0
nongenomic	0
effects	0
.	0

Leukotriene	0
B4	0
transcriptionally	0
activates	0
interleukin-6	9
expression	0
involving	0
NK-chi	9
B	10
and	0
NF-IL6	9
.	0

Leukotriene	0
B4	0
(	0
LTB4	0
)	0
is	0
a	0
notable	0
participant	0
in	0
inflammation	0
and	0
chemotaxis	0
.	0

It	0
is	0
,	0
however	0
,	0
still	0
unclear	0
whether	0
LTB4	0
acts	0
in	0
this	0
regard	0
directly	0
or	0
indirectly	0
by	0
stimulating	0
the	0
release	0
of	0
chemotactic	0
and	0
inflammatory	9
cytokines	10
.	0

Here	0
we	0
report	0
that	0
LTB4	0
induces	0
synthesis	0
of	0
interleukin	9
(	10
IL	10
)	10
-6	10
by	0
human	7
blood	8
monocytes	8
through	0
transcriptional	0
activation	0
of	0
the	0
IL-6	1
gene	2
.	0

We	0
furthermore	0
demonstrate	0
that	0
this	0
process	0
involves	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-chi	9
B	10
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
of	0
NF-IL6	9
,	0
while	0
the	0
activity	0
of	0
the	0
transcription	9
factor	10
AP-1	9
,	0
shown	0
to	0
otherwise	0
confer	0
IL-6	9
inducibility	0
,	0
appeared	0
to	0
be	0
unaffected	0
by	0
LTB4	0
.	0

Involvement	0
of	0
NF-chi	9
B	10
and	0
NF-IL6	9
in	0
induction	0
of	0
IL-6	9
transcription	0
by	0
monocytes	0
was	0
demonstrated	0
using	0
deleted	0
forms	0
of	0
the	0
IL-6	1
promoter	2
.	0

Activation	0
of	0
the	0
IL-6	1
promoter	2
by	0
LTB4	0
was	0
not	0
only	0
associated	0
with	0
accumulation	0
of	0
the	0
respective	0
transcripts	0
but	0
resulted	0
in	0
synthesis	0
of	0
functional	0
IL-6	9
protein	10
as	0
well	0
.	0

In	0
addition	0
,	0
LTB4	0
mediated	0
transactivation	0
of	0
a	0
heterologous	1
promoter	2
construct	2
containing	0
the	0
NF-chi	1
B	2
or	0
the	0
NF-IL6	1
enhancer	2
,	0
but	0
not	0
the	0
AP-1	1
enhancer	2
.	0

The	0
signaling	0
events	0
mediating	0
this	0
effect	0
appeared	0
to	0
involve	0
the	0
release	0
of	0
H2O2	0
,	0
since	0
LTB4	0
failed	0
to	0
induce	0
NF-chi	9
B	10
or	0
NF-IL6	9
in	0
the	0
presence	0
of	0
the	0
scavenger	0
of	0
H2O2	0
,	0
N-acetyl-L-cysteine	0
.	0

Bcl-2	9
:	0
a	0
repressor	0
of	0
lymphocyte	7
death	0
.	0

The	0
genes	0
and	0
mechanisms	0
that	0
control	0
programmed	0
cell	0
death	0
are	0
currently	0
the	0
subject	0
of	0
intense	0
study	0
.	0

The	0
bcl-2	1
gene	2
,	0
a	0
repressor	0
of	0
lymphocyte	7
death	0
,	0
is	0
perhaps	0
the	0
best	0
understood	0
of	0
the	0
programmed	0
cell	0
death	0
associated	0
genes	0
.	0

Here	0
,	0
Stanley	0
Korsmeyer	0
provides	0
a	0
brief	0
overview	0
of	0
bcl-2	9
,	0
concentrating	0
on	0
its	0
roles	0
in	0
B-	0
and	0
T-cell	0
development	0
and	0
in	0
oncogenesis	0
.	0

Cytoplasmic	0
domain	0
heterogeneity	0
and	0
functions	0
of	0
IgG	9
Fc	10
receptors	10
in	0
B	7
lymphocytes	8
.	0

B	7
lymphocytes	8
and	0
macrophages	0
express	0
closely	0
related	0
immunoglobulin	9
G	10
(	10
IgG	10
)	10
Fc	10
receptors	10
(	0
Fc	9
gamma	10
RII	10
)	0
that	0
differ	0
only	0
in	0
the	0
structures	0
of	0
their	0
cytoplasmic	9
domains	10
.	0

Because	0
of	0
cell	0
type-specific	0
alternative	0
messenger	0
RNA	0
splicing	0
,	0
B-cell	9
Fc	10
gamma	10
RII	10
contains	0
an	0
insertion	0
of	0
47	0
amino	0
acids	0
that	0
participates	0
in	0
determining	0
receptor	0
function	0
in	0
these	0
cells	0
.	0

Transfection	0
of	0
an	0
Fc	5
gamma	6
RII-negative	6
B-cell	6
line	6
with	0
complementary	0
DNA	0
's	0
encoding	0
the	0
two	0
splice	0
products	0
and	0
various	0
receptor	0
mutants	0
indicated	0
that	0
the	0
insertion	0
was	0
responsible	0
for	0
preventing	0
both	0
Fc	9
gamma	10
RII	10
-mediated	0
endocytosis	0
and	0
Fc	9
gamma	10
RII	10
-mediated	0
antigen	0
presentation	0
.	0

The	0
insertion	0
was	0
not	0
required	0
for	0
Fc	9
gamma	10
RII	10
to	0
modulate	0
surface	9
immunoglobulin	10
-triggered	0
B-cell	0
activation	0
.	0

Instead	0
,	0
regulation	0
of	0
activation	0
involved	0
a	0
region	0
of	0
the	0
cytoplasmic	9
domain	10
common	0
to	0
both	0
the	0
lymphocyte	9
and	10
macrophage	10
receptor	10
isoforms	10
.	0

In	0
contrast	0
,	0
the	0
insertion	0
did	0
contribute	0
to	0
the	0
formation	0
of	0
caps	0
in	0
response	0
to	0
receptor	0
cross-linking	0
,	0
consistent	0
with	0
suggestions	0
that	0
the	0
lymphocyte	0
but	0
not	0
macrophage	0
form	0
of	0
the	0
receptor	0
can	0
associate	0
with	0
the	0
detergent-insoluble	0
cytoskeleton	0
.	0

[	0
Age-related	0
changes	0
in	0
glucocorticoid	9
and	10
mineralocorticoid	10
receptors	10
in	0
lymphocytes	7
of	0
healthy	0
persons	0
and	0
patients	0
with	0
hypertension	0
]	0

It	0
has	0
been	0
found	0
that	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
of	0
the	0
peripheral	0
blood	0
of	0
healthy	0
elderly	0
subjects	0
increases	0
,	0
while	0
the	0
number	0
of	0
mineralocorticoid	0
receptors	0
decreases	0
.	0

The	0
mechanisms	0
of	0
hormone-receptor	0
interactions	0
in	0
hypertension	0
are	0
activated	0
:	0
the	0
number	0
of	0
glucocorticoid	9
and	10
mineralocorticoid	10
binding	10
sites	10
grows	0
in	0
hypertensive	0
patients	0
.	0

Still	0
a	0
more	0
essential	0
rise	0
in	0
the	0
number	0
of	0
receptors	0
is	0
observed	0
in	0
mid-age	0
hypertensive	0
patients	0
than	0
in	0
elderly	0
ones	0
.	0

The	0
mechanism	0
of	0
action	0
of	0
cyclosporin	0
A	0
and	0
FK506	0
.	0

CsA	0
and	0
FK506	0
are	0
powerful	0
suppressors	0
of	0
the	0
immune	0
system	0
,	0
most	0
notably	0
of	0
T	7
cells	8
.	0

They	0
act	0
at	0
a	0
point	0
in	0
activation	0
that	0
lies	0
between	0
receptor	0
ligation	0
and	0
the	0
transcription	0
of	0
early	1
genes	2
.	0

Here	0
,	0
Stuart	0
Schreiber	0
and	0
Gerald	0
Crabtree	0
review	0
recent	0
findings	0
that	0
indicate	0
CsA	0
and	0
FK506	0
operate	0
as	0
prodrugs	0
:	0
they	0
bind	0
endogenous	9
intracellular	10
receptors	10
,	0
the	0
immunophilins	9
,	0
and	0
the	0
resulting	0
complex	0
targets	0
the	0
protein	9
phosphatase	10
,	10
calcineurin	9
,	0
to	0
exert	0
the	0
immunosuppressive	0
effect	0
.	0

Induction	0
of	0
monocytic	0
differentiation	0
and	0
NF-kappa	9
B	10
-like	0
activities	0
by	0
human	0
immunodeficiency	0
virus	0
1	0
infection	0
of	0
myelomonoblastic	7
cells	8
.	0

The	0
effects	0
of	0
human	0
immunodeficiency	0
virus	0
1	0
(	0
HIV-1	0
)	0
infection	0
on	0
cellular	0
differentiation	0
and	0
NF-kappa	9
B	10
DNA	0
binding	0
activity	0
have	0
been	0
investigated	0
in	0
a	0
new	0
model	0
of	0
myeloid	0
differentiation	0
.	0

PLB-985	5
cells	6
represent	0
a	0
bipotential	5
myelomonoblastic	6
cell	6
population	6
capable	0
of	0
either	0
granulocytic	0
or	0
monocytic	0
differentiation	0
after	0
induction	0
with	0
appropriate	0
inducers	0
.	0

By	0
virtue	0
of	0
the	0
presence	0
of	0
CD4	9
on	0
the	0
cell	0
surface	0
,	0
PLB-985	5
cells	6
were	0
chronically	0
infected	0
with	0
HIV-1	0
strain	0
IIIB	0
.	0

PLB-IIIB	5
cells	6
clearly	0
possessed	0
a	0
more	0
monocytic	0
phenotype	0
than	0
the	0
parental	7
myeloblasts	8
,	0
as	0
determined	0
by	0
differential	0
staining	0
,	0
increased	0
expression	0
of	0
the	0
myeloid-specific	9
surface	10
markers	10
,	0
and	0
transcription	0
of	0
the	0
c-fms	1
proto-oncogene	2
.	0

NF-kappa	9
B	10
binding	0
activity	0
was	0
inducible	0
by	0
tumor	9
necrosis	10
factor	10
and	0
phorbol	0
myristate	0
acetate	0
in	0
PLB-985	5
.	0

However	0
,	0
in	0
PLB-IIIB	5
cells	6
,	0
constitutive	0
expression	0
of	0
a	0
novel	0
NF-kappa	9
B	10
complex	10
was	0
detected	0
,	0
composed	0
of	0
proteins	0
ranging	0
between	0
70	0
and	0
110	0
kD	0
.	0

These	0
proteins	0
interacted	0
specifically	0
with	0
the	0
symmetric	1
NF-kappa	2
B	2
site	2
from	0
the	0
interferon	1
beta	2
(	2
IFN-beta	2
)	2
promoter	2
.	0

Mutations	0
affecting	0
the	0
5	1
'	2
guanine	2
residues	2
of	0
the	0
kappa	1
B	2
site	2
were	0
unable	0
to	0
compete	0
for	0
these	0
NF-kappa	9
B-related	10
proteins	10
.	0

Inducibility	0
of	0
endogenous	0
IFN-beta	3
and	4
IFN-alpha	4
RNA	4
was	0
also	0
increased	0
in	0
PLB-IIIB	5
cells	6
.	0

These	0
studies	0
indicate	0
that	0
HIV-1	0
infection	0
of	0
myelomonoblastic	7
cells	8
may	0
select	0
for	0
a	0
more	0
mature	0
monocytic	0
phenotype	0
and	0
that	0
unique	0
subunit	0
associations	0
of	0
NF-kappa	9
B	10
DNA	10
binding	10
proteins	10
may	0
contribute	0
to	0
differential	0
NF-kappa	9
B	10
-mediated	0
gene	0
expression	0
.	0

Cortisol	0
receptor	0
resistance	0
:	0
the	0
variability	0
of	0
its	0
clinical	0
presentation	0
and	0
response	0
to	0
treatment	0
.	0

Primary	0
(	0
partial	0
)	0
cortisol	9
receptor	10
resistance	0
was	0
previously	0
reported	0
in	0
a	0
total	0
of	0
7	0
patients	0
and	0
14	0
asymptomatic	0
family	0
members	0
.	0

Its	0
occurrence	0
is	0
considered	0
to	0
be	0
extremely	0
rare	0
.	0

In	0
the	0
present	0
study	0
we	0
report	0
on	0
6	0
patients	0
(	0
2	0
males	0
and	0
4	0
females	0
)	0
with	0
the	0
syndrome	0
.	0

The	0
first	0
male	0
patient	0
presented	0
with	0
mild	0
hypertension	0
.	0

Hydrochlorothiazide	0
therapy	0
resulted	0
in	0
life-threatening	0
hypokalemia	0
.	0

The	0
second	0
male	0
patient	0
had	0
slight	0
hypertension	0
without	0
hypokalemia	0
.	0

All	0
four	0
female	0
patients	0
presented	0
between	0
the	0
age	0
of	0
20-30	0
yr	0
with	0
acne	0
,	0
hirsutism	0
,	0
and	0
irregular	0
menstruations	0
.	0

Low	0
dose	0
dexamethasone	0
therapy	0
(	0
1-1.5	0
mg/day	0
)	0
was	0
of	0
clinical	0
benefit	0
in	0
these	0
patients	0
.	0

All	0
patients	0
showed	0
insufficient	0
suppression	0
of	0
serum	0
cortisol	0
concentrations	0
in	0
the	0
overnight	0
1-mg	0
dexamethasone	0
test	0
.	0

The	0
diurnal	0
rhythm	0
of	0
ACTH	0
and	0
cortisol	0
was	0
intact	0
,	0
albeit	0
at	0
an	0
elevated	0
level	0
.	0

There	0
was	0
a	0
normal	0
increase	0
in	0
ACTH	0
,	0
cortisol	0
,	0
and	0
GH	0
(	0
except	0
in	0
one	0
obese	0
patient	0
)	0
in	0
response	0
to	0
insulin-induced	0
hypoglycemia	0
,	0
while	0
cortisol	0
production	0
was	0
elevated	0
in	0
three	0
patients	0
.	0

Circulating	0
adrenal	0
androgen	0
levels	0
were	0
increased	0
in	0
all	0
patients	0
.	0

Glucocorticoid	9
receptors	10
were	0
investigated	0
in	0
a	0
whole	0
cell	0
dexamethasone	0
binding	0
assay	0
in	0
mononuclear	7
leukocytes	8
.	0

In	0
the	0
first	0
male	0
patient	0
,	0
the	0
number	0
of	0
receptors	0
was	0
very	0
low	0
,	0
while	0
the	0
affinity	0
was	0
lower	0
than	0
that	0
in	0
controls	0
.	0

A	0
lowered	0
affinity	0
to	0
dexamethasone	0
was	0
found	0
in	0
one	0
female	0
patient	0
,	0
while	0
a	0
lowered	0
number	0
of	0
receptors	0
was	0
found	0
in	0
three	0
patients	0
.	0

In	0
the	0
second	0
male	0
patient	0
,	0
no	0
abnormalities	0
were	0
found	0
.	0

As	0
a	0
bioassay	0
for	0
glucocorticoid	0
action	0
we	0
also	0
measured	0
dexamethasone	0
suppressibility	0
of	0
mitogen-stimulated	0
incorporation	0
of	0
[	0
3H	0
]	0
thymidine	0
in	0
mononuclear	7
leukocytes	8
.	0

In	0
the	0
male	0
patient	0
with	0
normal	0
receptor	0
status	0
,	0
dexamethasone	0
suppressibility	0
of	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
was	0
significantly	0
lower	0
than	0
that	0
in	0
healthy	0
controls	0
with	0
respect	0
to	0
both	0
maximal	0
suppression	0
and	0
IC50	0
.	0

Partial	0
cortisol	0
receptor	0
resistance	0
might	0
be	0
less	0
rare	0
than	0
previously	0
thought	0
.	0

In	0
the	0
six	0
patients	0
presented	0
,	0
at	0
least	0
three	0
different	0
forms	0
can	0
be	0
recognized	0
.	0

Therapy	0
with	0
dexamethasone	0
was	0
successful	0
in	0
female	0
patients	0
with	0
acne	0
and	0
hirsutism	0
,	0
as	0
the	0
secondary	0
increase	0
in	0
the	0
production	0
of	0
adrenal	0
androgens	0
was	0
effectively	0
controlled	0
.	0

The	0
development	0
of	0
functionally	0
responsive	0
T	7
cells	8
.	0

The	0
work	0
reviewed	0
in	0
this	0
article	0
separates	0
T	0
cell	0
development	0
into	0
four	0
phases	0
.	0

First	0
is	0
an	0
expansion	0
phase	0
prior	0
to	0
TCR	9
rearrangement	0
,	0
which	0
appears	0
to	0
be	0
correlated	0
with	0
programming	0
of	0
at	0
least	0
some	0
response	0
genes	0
for	0
inducibility	0
.	0

This	0
phase	0
can	0
occur	0
to	0
some	0
extent	0
outside	0
of	0
the	0
thymus	0
.	0

However	0
,	0
the	0
profound	0
T	0
cell	0
deficit	0
of	0
nude	0
mice	0
indicates	0
that	0
the	0
thymus	0
is	0
by	0
far	0
the	0
most	0
potent	0
site	0
for	0
inducing	0
the	0
expansion	0
per	0
se	0
,	0
even	0
if	0
other	0
sites	0
can	0
induce	0
some	0
response	0
acquisition	0
.	0

Second	0
is	0
a	0
controlled	0
phase	0
of	0
TCR	1
gene	2
rearrangement	0
.	0

The	0
details	0
of	0
the	0
regulatory	0
mechanism	0
that	0
selects	0
particular	0
loci	1
for	0
rearrangement	0
are	0
still	0
not	0
known	0
.	0

It	0
seems	0
that	0
the	0
rearrangement	0
of	0
the	0
TCR	1
gamma	2
loci	2
in	0
the	0
gamma	7
delta	8
lineage	8
may	0
not	0
always	0
take	0
place	0
at	0
a	0
developmental	0
stage	0
strictly	0
equivalent	0
to	0
the	0
rearrangement	0
of	0
TCR	1
beta	2
in	0
the	0
alpha	7
beta	8
lineage	8
,	0
and	0
it	0
is	0
not	0
clear	0
just	0
how	0
early	0
the	0
two	0
lineages	0
diverge	0
.	0

In	0
the	0
TCR	7
alpha	8
beta	8
lineage	8
,	8
however	0
,	0
the	0
final	0
gene	0
rearrangement	0
events	0
are	0
accompanied	0
by	0
rapid	0
proliferation	0
and	0
an	0
interruption	0
in	0
cellular	0
response	0
gene	0
inducibility	0
.	0

The	0
loss	0
of	0
conventional	0
responsiveness	0
is	0
probably	0
caused	0
by	0
alterations	0
at	0
the	0
level	0
of	0
signaling	0
,	0
and	0
may	0
be	0
a	0
manifestation	0
of	0
the	0
physiological	0
state	0
that	0
is	0
a	0
precondition	0
for	0
selection	0
.	0

Third	0
is	0
the	0
complex	0
process	0
of	0
selection	0
.	0

Whereas	0
peripheral	7
T	8
cells	8
can	0
undergo	0
forms	0
of	0
positive	0
selection	0
(	0
by	0
antigen-driven	0
clonal	0
expansion	0
)	0
and	0
negative	0
selection	0
(	0
by	0
abortive	0
stimulation	0
leading	0
to	0
anergy	0
or	0
death	0
)	0
,	0
neither	0
is	0
exactly	0
the	0
same	0
phenomenon	0
that	0
occurs	0
in	0
the	0
thymic	0
cortex	0
.	0

Negative	0
selection	0
in	0
the	0
cortex	0
appears	0
to	0
be	0
a	0
suicidal	0
inversion	0
of	0
antigen	0
responsiveness	0
:	0
instead	0
of	0
turning	0
on	0
IL-2	9
expression	0
,	0
the	0
activated	7
cell	8
destroys	0
its	0
own	0
chromatin	1
.	0

The	0
genes	0
that	0
need	0
to	0
be	0
induced	0
for	0
this	0
response	0
are	0
not	0
yet	0
identified	0
,	0
but	0
it	0
is	0
unquestionably	0
a	0
form	0
of	0
activation	0
.	0

It	0
is	0
interesting	0
that	0
in	0
humans	0
and	0
rats	0
,	0
cortical	7
thymocytes	8
undergoing	0
negative	0
selection	0
can	0
still	0
induce	0
IL-2R	9
alpha	10
expression	0
and	0
even	0
be	0
rescued	0
in	0
vitro	0
,	0
if	0
exogenous	9
IL-2	10
is	0
provided	0
.	0

Perhaps	0
murine	7
thymocytes	8
are	0
denied	0
this	0
form	0
of	0
rescue	0
because	0
they	0
shut	0
off	0
IL-2R	9
beta	10
chain	10
expression	0
at	0
an	0
earlier	0
stage	0
or	0
because	0
they	0
may	0
be	0
uncommonly	0
Bcl-2	9
deficient	0
(	0
cf.	0
Sentman	0
et	0
al.	0
,	0
1991	0
;	0
Strasser	0
et	0
al.	0
,	0
1991	0
)	0
.	0

Even	0
so	0
,	0
medullary	7
thymocytes	8
remain	0
at	0
least	0
partially	0
susceptible	0
to	0
negative	0
selection	0
even	0
as	0
they	0
continue	0
to	0
mature	0
.	0

I	9
kappa	10
B/MAD-3	10
masks	0
the	0
nuclear	0
localization	0
signal	0
of	0
NF-kappa	9
B	10
p65	10
and	0
requires	0
the	0
transactivation	9
domain	10
to	0
inhibit	0
NF-kappa	9
B	10
p65	10
DNA	0
binding	0
.	0

The	0
active	0
nuclear	0
form	0
of	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
complex	10
is	0
composed	0
of	0
two	0
DNA	9
binding	10
subunits	10
,	0
NF-kappa	9
B	10
p65	10
and	0
NF-kappa	9
B	10
p50	10
,	0
both	0
of	0
which	0
share	0
extensive	0
N-terminal	0
sequence	0
homology	0
with	0
the	0
v-rel	9
oncogene	10
product	10
.	0

The	0
NF-kappa	9
B	10
p65	10
subunit	10
provides	0
the	0
transactivation	0
activity	0
in	0
this	0
complex	0
and	0
serves	0
as	0
an	0
intracellular	0
receptor	0
for	0
a	0
cytoplasmic	0
inhibitor	0
of	0
NF-kappa	9
B	10
,	0
termed	0
I	0
kappa	0
B	0
.	0

In	0
contrast	0
,	0
NF-kappa	9
B	10
p50	10
alone	0
fails	0
to	0
stimulate	0
kappa	0
B-directed	0
transcription	0
,	0
and	0
based	0
on	0
prior	0
in	0
vitro	0
studies	0
,	0
is	0
not	0
directly	0
regulated	0
by	0
I	9
kappa	10
B	10
.	0

To	0
investigate	0
the	0
molecular	0
basis	0
for	0
the	0
critical	0
regulatory	0
interaction	0
between	0
NF-kappa	9
B	10
and	0
I	9
kappa	10
B/MAD-3	10
,	0
a	0
series	0
of	0
human	9
NF-kappa	10
B	10
p65	10
mutants	10
was	0
identified	0
that	0
functionally	0
segregated	0
DNA	0
binding	0
,	0
I	9
kappa	10
B	10
-mediated	0
inhibition	0
,	0
and	0
I	9
kappa	10
B	10
-induced	0
nuclear	0
exclusion	0
of	0
this	0
transcription	9
factor	10
.	0

Results	0
from	0
in	0
vivo	0
expression	0
studies	0
performed	0
with	0
these	0
NF-kappa	9
B	10
p65	10
mutants	10
revealed	0
the	0
following	0
:	0
1	0
)	0
I	9
kappa	10
B/MAD-3	10
completely	0
inhibits	0
NF-kappa	9
B	10
p65	10
-dependent	0
transcriptional	0
activation	0
mediated	0
through	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
kappa	2
B	2
enhancer	2
in	0
human	7
T	8
lymphocytes	8
,	0
2	0
)	0
the	0
binding	0
of	0
I	9
kappa	10
B/MAD-3	10
to	0
NF-kappa	9
B	10
p65	10
is	0
sufficient	0
to	0
retarget	0
NF-kappa	9
B	10
p65	10
from	0
the	0
nucleus	0
to	0
the	0
cytoplasm	0
,	0
3	0
)	0
selective	0
deletion	0
of	0
the	0
functional	0
nuclear	0
localization	0
signal	0
present	0
in	0
the	0
Rel	9
homology	10
domain	10
of	0
NF-kappa	9
B	10
p65	10
disrupts	0
its	0
ability	0
to	0
engage	0
I	9
kappa	10
B/MAD-3	10
,	0
and	0
4	0
)	0
the	0
unique	0
C-terminus	9
of	0
NF-kappa	9
B	10
p65	10
attenuates	0
its	0
own	0
nuclear	0
localization	0
and	0
contains	0
sequences	0
that	0
are	0
required	0
for	0
I	9
kappa	10
B	10
-mediated	0
inhibition	0
of	0
NF-kappa	9
B	10
p65	10
DNA	0
binding	0
activity	0
.	0

Together	0
,	0
these	0
findings	0
suggest	0
that	0
the	0
nuclear	0
localization	0
signal	0
and	0
transactivation	9
domain	10
of	0
NF-kappa	9
B	10
p65	10
constitute	0
a	0
bipartite	0
system	0
that	0
is	0
critically	0
involved	0
in	0
the	0
inhibitory	0
function	0
of	0
I	9
kappa	10
B/MAD-3	10
.	0

Unexpectedly	0
,	0
our	0
in	0
vivo	0
studies	0
also	0
demonstrate	0
that	0
I	9
kappa	10
B/MAD-3	10
binds	0
directly	0
to	0
NF-kappa	9
B	10
p50	10
.	0

This	0
interaction	0
is	0
functional	0
as	0
it	0
leads	0
to	0
retargeting	0
of	0
NF-kappa	9
B	10
p50	10
from	0
the	0
nucleus	0
to	0
the	0
cytoplasm	0
.	0

However	0
,	0
no	0
loss	0
of	0
DNA	0
binding	0
activity	0
is	0
observed	0
,	0
presumably	0
reflecting	0
the	0
unique	0
C-terminal	9
domain	10
that	0
is	0
distinct	0
from	0
that	0
present	0
in	0
NF-kappa	9
B	10
p65	10
.	0

Characterization	0
of	0
a	0
new	0
tissue-specific	0
transcription	9
factor	10
binding	0
to	0
the	0
simian	1
virus	2
40	2
enhancer	2
TC-II	2
(	2
NF-kappa	2
B	2
)	2
element	2
.	0

We	0
have	0
biochemically	0
and	0
functionally	0
characterized	0
a	0
new	0
transcription	9
factor	10
,	0
NP-TCII	9
,	0
which	0
is	0
present	0
in	0
nuclei	0
from	0
unstimulated	5
T	6
and	6
B	6
lymphocytes	6
but	0
is	0
not	0
found	0
in	0
nonhematopoietic	7
cells	8
.	0

This	0
factor	0
has	0
a	0
DNA-binding	0
specificity	0
similar	0
to	0
that	0
of	0
NF-kappa	9
B	10
but	0
is	0
unrelated	0
to	0
this	0
or	0
other	0
Rel	9
proteins	10
by	0
functional	0
and	0
biochemical	0
criteria	0
.	0

It	0
can	0
also	0
be	0
distinguished	0
from	0
other	0
previously	0
described	0
lymphocyte-specific	9
DNA-binding	10
proteins	10
.	0

The	0
candidate	9
oncoprotein	10
Bcl-3	10
is	0
an	0
antagonist	0
of	0
p50/NF-kappa	9
B	10
-mediated	0
inhibition	0
.	0

The	0
candidate	1
oncogene	2
bcl-3	2
was	0
discovered	0
as	0
a	0
translocation	0
into	0
the	0
immunoglobulin	1
alpha-locus	2
in	0
some	0
cases	0
of	0
B-cell	0
chronic	0
lymphocytic	0
leukaemias	0
.	0

The	0
protein	9
Bcl-3	10
contains	0
seven	0
so-called	0
ankyrin	9
repeats	10
.	0

Similar	0
repeat	9
motifs	10
are	0
found	0
in	0
a	0
number	0
of	0
diverse	9
regulatory	10
proteins	10
but	0
the	0
motifs	0
of	0
Bcl-3	9
are	0
most	0
closely	0
related	0
to	0
those	0
found	0
in	0
I	9
kappa	10
B	10
proteins	10
in	0
which	0
the	0
ankyrin	9
repeat	10
domain	0
is	0
thought	0
to	0
be	0
directly	0
involved	0
in	0
inhibition	0
of	0
NF-kappa	9
B	10
activity	0
.	0

No	0
biological	0
function	0
has	0
yet	0
been	0
described	0
for	0
Bcl-3	9
,	0
but	0
it	0
was	0
noted	0
recently	0
that	0
Bcl-3	9
interferes	0
with	0
DNA-binding	0
of	0
the	0
p50	9
subunit	10
of	0
NF-kappa	9
B	10
in	0
vitro	0
.	0

Here	0
we	0
demonstrate	0
that	0
Bcl-3	9
can	0
aid	0
kappa	1
B	2
site	2
-dependent	0
transcription	0
in	0
vivo	0
by	0
counteracting	0
the	0
inhibitory	0
effects	0
of	0
p50/NF-kappa	9
B	10
homodimers	10
.	0

Bcl-3	9
may	0
therefore	0
aid	0
activation	0
of	0
select	0
NF-kappa	1
B-regulated	2
genes	2
,	0
including	0
those	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
.	0

[	0
Mechanism	0
of	0
action	0
of	0
steroid	0
hormones.	0
I.	0
Estrogens	0
]	0

The	0
steroid	0
hormone	0
are	0
very	0
versatile	0
molecules	0
:	0
although	0
they	0
are	0
related	0
among	0
them	0
by	0
their	0
chemical	0
structure	0
,	0
they	0
have	0
very	0
diverse	0
functions	0
and	0
including	0
antagonic	0
.	0

Their	0
action	0
mechanism	0
is	0
not	0
completely	0
cleared	0
.	0

The	0
estrogens	0
participate	0
in	0
the	0
regulation	0
of	0
practically	0
all	0
the	0
reproductive	0
and	0
sexual	0
events	0
of	0
the	0
female	0
,	0
although	0
the	0
intracellular	0
actions	0
by	0
which	0
they	0
take	0
place	0
are	0
not	0
well	0
known	0
and	0
the	0
proposed	0
models	0
do	0
not	0
adequately	0
satisfy	0
the	0
questions	0
.	0

Currently	0
it	0
is	0
accepted	0
the	0
existence	0
of	0
a	0
cytoplasmic	9
and/or	10
nuclear	10
receptor	10
,	0
without	0
explaining	0
satisfactorily	0
how	0
the	0
hormones	0
come	0
to	0
the	0
nucleus	0
.	0

The	0
endocrine	0
events	0
that	0
are	0
rapidly	0
expressed	0
(	0
seconds	0
)	0
are	0
due	0
to	0
a	0
possible	0
interaction	0
with	0
cellular	0
membrane	0
.	0

The	0
purpose	0
of	0
this	0
review	0
is	0
to	0
analyze	0
and	0
concilliate	0
the	0
reported	0
data	0
on	0
the	0
mechanism	0
of	0
action	0
of	0
estrogens	0
.	0

Reduced	0
susceptibility	0
to	0
HIV-1	0
infection	0
of	0
ethyl-methanesulfonate-treated	5
CEM	6
subclones	6
correlates	0
with	0
a	0
blockade	0
in	0
their	0
protein	9
kinase	10
C	10
signaling	0
pathway	0
.	0

We	0
have	0
described	0
the	0
isolation	0
of	0
chemically	0
induced	0
CEM	5
subclones	6
that	0
express	0
CD4	9
receptors	10
and	0
bind	0
soluble	0
gp120	9
,	0
yet	0
show	0
a	0
markedly	0
reduced	0
susceptibility	0
to	0
infection	0
with	0
HIV-1	0
.	0

Two	0
subclones	0
were	0
found	0
to	0
have	0
an	0
abnormal	0
response	0
to	0
the	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
activator	0
PMA	0
.	0

PMA	0
treatment	0
induced	0
CD3	9
and	10
CD25	10
(	10
IL-2R	10
)	10
receptors	10
on	0
the	0
parental	0
line	0
and	0
on	0
other	0
ethyl-methanesulfonate-derived	5
subclones	6
,	0
but	0
not	0
on	0
these	0
two	0
mutants	0
.	0

Direct	0
assays	0
of	0
PKC	9
activity	0
were	0
conducted	0
.	0

Total	0
cellular	0
PKC	9
enzymatic	0
activity	0
was	0
found	0
to	0
be	0
normal	0
in	0
these	0
subclones	0
.	0

PMA-induced	0
CD4	9
down-modulation	0
occurred	0
normally	0
.	0

In	0
addition	0
,	0
activation	0
of	0
c-raf	9
kinase	10
was	0
normal	0
.	0

Since	0
HIV-1	1
long	2
terminal	2
repeat	2
contains	0
two	0
functional	0
nuclear	1
factor	2
kB	2
(	2
NF-kB	2
)	2
regulatory	2
elements	2
,	0
we	0
studied	0
the	0
ability	0
of	0
PMA	0
to	0
induce	0
NF-kB	9
binding	0
activity	0
by	0
different	0
assays	0
.	0

Chloramphenicol	9
acetyl	10
transferase	10
(	0
CAT	9
)	0
assays	0
using	0
the	0
HIV-1	1
(	2
-139	2
)	2
long	2
terminal	2
repeat-CAT	2
construct	2
showed	0
no	0
PMA	0
induction	0
of	0
CAT	9
activity	0
in	0
these	0
subclones	0
(	0
unlike	0
the	0
parental	0
line	0
and	0
other	0
subclones	0
)	0
.	0

Okadaic	0
acid	0
,	0
an	0
inhibitor	0
of	0
phosphatases	9
1	10
and	10
2A	10
,	0
did	0
not	0
overcome	0
the	0
defect	0
in	0
these	0
subclones	0
.	0

Gel	0
retardation	0
assays	0
,	0
using	0
a	0
32P-probe	0
containing	0
the	0
HIV-1	0
NF-kB	9
probe	0
and	0
nuclear	0
extracts	0
from	0
PMA-treated	7
cells	8
,	0
showed	0
significantly	0
reduced	0
induction	0
of	0
nuclear	9
NF-kB	10
binding	10
proteins	10
in	0
these	0
two	0
subclones	0
compared	0
with	0
wild	9
type	10
CEM	10
and	0
a	0
control	0
subclone	0
.	0

Deoxycholate	0
treatment	0
of	0
cytoplasmic	0
extracts	0
from	0
these	0
subclones	0
released	0
much	0
reduced	0
NF-kB	9
binding	10
proteins	10
from	0
their	0
cytoplasmic	0
pools	0
.	0

Thus	0
,	0
reduced	0
levels	0
of	0
PKC	9
-induced	0
nuclear	0
NF-kB	9
activity	0
in	0
two	0
T	0
cell	0
subclones	0
did	0
not	0
affect	0
their	0
normal	0
cell	0
growth	0
,	0
but	0
correlated	0
with	0
a	0
pronounced	0
reduction	0
in	0
their	0
susceptibility	0
to	0
HIV-1	0
infection	0
.	0

Nuclear	9
factor	10
of	0
activated	7
T	8
cells	8
contains	0
Fos	9
and	0
Jun	9
.	0

The	0
nuclear	9
factor	10
NF-AT	10
(	0
ref.	0
1	0
)	0
is	0
induced	0
in	0
T	7
cells	8
stimulated	0
through	0
the	0
T-cell	9
receptor/CD3	10
complex	10
,	0
and	0
is	0
required	0
for	0
interleukin-2	1
(	2
IL-2	2
)	2
gene	2
induction	0
.	0

Although	0
NF-AT	9
has	0
not	0
been	0
cloned	0
or	0
purified	0
,	0
there	0
is	0
evidence	0
that	0
it	0
is	0
a	0
major	0
target	0
for	0
immunosuppression	0
by	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
and	0
FK506	0
(	0
refs	0
2-7	0
)	0
.	0

NF-AT	9
induction	0
may	0
require	0
two	0
activation-dependent	0
events	0
:	0
the	0
CsA-sensitive	0
translocation	0
of	0
a	0
pre-existing	0
component	0
and	0
the	0
CsA-resistant	0
synthesis	0
of	0
a	0
nuclear	9
component	10
.	0

Here	0
we	0
report	0
that	0
the	0
newly	0
synthesized	0
nuclear	9
component	10
of	0
NF-AT	9
is	0
the	0
transcription	9
factor	10
AP-1	9
.	0

We	0
show	0
that	0
the	0
inducible	0
nuclear	0
form	0
of	0
NF-AT	9
contains	0
Fos	9
and	0
Jun	9
proteins	0
.	0

Furthermore	0
,	0
we	0
identify	0
a	0
pre-existing	9
NF-AT-binding	10
factor	10
that	0
is	0
present	0
in	0
hypotonic	0
extracts	0
of	0
unstimulated	7
T	8
cells	8
.	0

On	0
the	0
basis	0
of	0
binding	0
,	0
reconstitution	0
and	0
cotransfection	0
experiments	0
,	0
we	0
propose	0
that	0
activation	0
of	0
NF-AT	9
occurs	0
in	0
at	0
least	0
two	0
stages	0
:	0
a	0
CsA-sensitive	0
stage	0
involving	0
modification	0
and/or	0
translocation	0
of	0
the	0
pre-existing	0
NF-AT	9
complex	10
,	0
and	0
a	0
CsA-insensitive	0
stage	0
involving	0
the	0
addition	0
of	0
newly	0
synthesized	0
Fos	9
or	0
Fos/Jun	9
proteins	10
to	0
the	0
pre-existing	9
complex	10
.	0

A	0
lymphoid	9
cell-specific	10
nuclear	10
factor	10
containing	0
c-Rel-like	9
proteins	10
preferentially	0
interacts	0
with	0
interleukin-6	1
kappa	2
B-related	2
motifs	2
whose	0
activities	0
are	0
repressed	0
in	0
lymphoid	7
cells	8
.	0

The	0
proto-oncoprotein	9
c-Rel	10
is	0
a	0
member	0
of	0
the	0
nuclear	9
factor	10
kappa	10
B	10
transcription	10
factor	10
family	10
,	0
which	0
includes	0
the	0
p50	9
and	0
p65	9
subunits	10
of	0
nuclear	9
factor	10
kappa	10
B	10
.	0

We	0
show	0
here	0
that	0
c-Rel	9
binds	0
to	0
kappa	1
B	2
sites	2
as	0
homodimers	9
as	0
well	0
as	0
heterodimers	9
with	0
p50	9
.	0

These	0
homodimers	9
and	0
heterodimers	9
show	0
distinct	0
DNA-binding	0
specificities	0
and	0
affinities	0
for	0
various	0
kappa	1
B	2
motifs	2
.	0

In	0
particular	0
,	0
the	0
c-Rel	9
homodimer	10
has	0
a	0
high	0
affinity	0
for	0
interleukin-6	9
(	0
IL-6	9
)	0
and	0
beta	1
interferon	2
kappa	2
B	2
sites	2
.	0

In	0
spite	0
of	0
its	0
association	0
with	0
p50	9
in	0
vitro	0
,	0
however	0
,	0
we	0
found	0
a	0
lymphoid	9
cell-specific	10
nuclear	10
factor	10
in	0
vivo	0
that	0
contains	0
c-Rel	9
but	0
not	0
p50	9
epitopes	10
;	0
this	0
factor	0
,	0
termed	0
IL-6	9
kappa	10
B	10
binding	10
factor	10
II	10
,	0
appears	0
to	0
contain	0
the	0
c-Rel	9
homodimer	10
and	0
preferentially	0
recognizes	0
several	0
IL-6	1
kappa	2
B-related	2
kappa	2
B	2
motifs	2
.	0

Although	0
it	0
has	0
been	0
previously	0
shown	0
that	0
the	0
IL-6	1
kappa	2
B	2
motif	2
functions	0
as	0
a	0
potent	0
IL-1/tumor	1
necrosis	2
factor-responsive	2
element	2
in	0
nonlymphoid	7
cells	8
,	0
its	0
activity	0
was	0
found	0
to	0
be	0
repressed	0
in	0
lymphoid	7
cells	8
such	0
as	0
a	0
Jurkat	5
T-cell	6
line	6
.	0

We	0
also	0
present	0
evidence	0
that	0
IL-6	9
kappa	10
B	10
binding	10
factor	10
II	10
functions	0
as	0
a	0
repressor	0
specific	0
for	0
IL-6	1
kappa	2
B-related	2
kappa	2
B	2
motifs	2
in	0
lymphoid	7
cells	8
.	0

Cortisol	0
resistance	0
in	0
acquired	0
immunodeficiency	0
syndrome	0
.	0

This	0
study	0
concerns	0
9	0
iv	0
drug	0
abusers	0
with	0
acquired	0
immunodeficiency	0
syndrome	0
(	0
AIDS	0
)	0
who	0
developed	0
hypercortisolism	0
without	0
the	0
clinical	0
signs	0
or	0
metabolic	0
consequences	0
of	0
hypercortisolism	0
.	0

All	0
patients	0
were	0
characterized	0
by	0
an	0
Addisonian	0
picture	0
(	0
weakness	0
,	0
weight	0
loss	0
,	0
hypotension	0
,	0
hyponatremia	0
,	0
and	0
intense	0
mucocutaneous	0
melanosis	0
)	0
.	0

An	0
acquired	0
form	0
of	0
peripheral	0
resistance	0
to	0
glucocorticoids	0
was	0
suspected	0
.	0

We	0
,	0
therefore	0
,	0
examined	0
glucocorticoid	9
receptor	10
characteristics	0
on	0
mononuclear	7
leukocytes	8
by	0
measuring	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
and	0
the	0
effect	0
of	0
dexamethasone	0
on	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
,	0
which	0
is	0
one	0
of	0
the	0
effects	0
of	0
glucocorticoid	9
receptor	10
activation	0
.	0

Glucocorticoid	9
receptor	10
density	0
was	0
increased	0
in	0
AIDS	0
patients	0
with	0
an	0
Addisonian	0
picture	0
(	0
group	0
1	0
;	0
16.2	0
+/-	0
9.4	0
fmol/million	0
cells	0
)	0
compared	0
to	0
values	0
in	0
12	0
AIDS	0
patients	0
without	0
an	0
Addisonian	0
picture	0
(	0
group	0
2	0
;	0
6.05	0
+/-	0
2.6	0
fmol/million	0
cells	0
;	0
P	0
less	0
than	0
0.01	0
)	0
and	0
sex-	0
and	0
age-matched	0
controls	0
(	0
3.15	0
+/-	0
2.3	0
fmol/million	0
cells	0
;	0
P	0
less	0
than	0
0.01	0
)	0
.	0

The	0
affinity	0
of	0
glucocorticoid	9
receptors	10
(	0
Kd	0
)	0
was	0
strikingly	0
decreased	0
(	0
9.36	0
+/-	0
3.44	0
nM	0
in	0
group	0
1	0
;	0
3.2	0
+/-	0
1.5	0
nM	0
in	0
group	0
2	0
;	0
2.0	0
+/-	0
0.8	0
nM	0
in	0
controls	0
;	0
P	0
less	0
than	0
0.01	0
)	0
.	0

[	0
3H	0
]	0
Thymidine	0
incorporation	0
was	0
decreased	0
dose-dependently	0
by	0
dexamethasone	0
in	0
controls	0
and	0
patients	0
;	0
the	0
effect	0
was	0
significantly	0
blunted	0
(	0
P	0
less	0
than	0
0.05	0
)	0
in	0
group	0
1	0
patients	0
,	0
which	0
suggests	0
that	0
activation	0
of	0
glucocorticoid	9
receptor	10
is	0
impaired	0
as	0
a	0
result	0
of	0
the	0
glucocorticoid	9
receptor	10
abnormality	0
.	0

In	0
conclusion	0
,	0
AIDS	0
patients	0
with	0
hypercortisolism	0
and	0
clinical	0
features	0
of	0
peripheral	0
resistance	0
to	0
glucocorticoids	0
are	0
characterized	0
by	0
abnormal	9
glucocorticoid	10
receptors	10
on	0
lymphocytes	7
.	0

Resistance	0
to	0
glucocorticoids	0
implies	0
a	0
complex	0
change	0
in	0
immune-endocrine	0
function	0
,	0
which	0
may	0
be	0
important	0
in	0
the	0
course	0
of	0
immunodeficiency	0
syndrome	0
.	0

A	0
novel	0
primer	0
extension	0
method	0
to	0
detect	0
the	0
number	0
of	0
CAG	0
repeats	0
in	0
the	0
androgen	1
receptor	2
gene	2
in	0
families	0
with	0
X-linked	0
spinal	0
and	0
bulbar	0
muscular	0
atrophy	0
.	0

X-linked	0
spinal	0
and	0
bulbar	0
muscular	0
atrophy	0
(	0
SBMA	0
)	0
,	0
an	0
adult-onset	0
form	0
of	0
motor	0
neuron	0
disease	0
,	0
was	0
recently	0
reported	0
to	0
be	0
caused	0
by	0
amplification	0
of	0
the	0
CAG	0
repeats	0
in	0
the	0
androgen	1
receptor	2
gene	2
.	0

We	0
report	0
here	0
a	0
simple	0
and	0
rapid	0
strategy	0
to	0
detect	0
the	0
precise	0
number	0
of	0
the	0
CAGs	0
.	0

After	0
the	0
DNA	1
fragment	2
containing	0
the	0
CAG	1
repeats	2
is	0
amplified	0
by	0
the	0
polymerase	0
chain	0
reaction	0
,	0
a	0
primer	0
extension	0
is	0
carried	0
out	0
;	0
the	0
extension	0
of	0
the	0
end-labelled	1
reverse	2
primer	2
adjacent	0
to	0
3	1
'	2
end	2
of	0
CAG	1
repeats	2
stops	0
at	0
the	0
first	0
T	0
after	0
CAG	1
repeats	2
with	0
the	0
incorporation	0
of	0
dideoxy	0
ATP	0
in	0
the	0
reaction	0
mixture	0
.	0

The	0
resultant	0
primer	1
products	2
are	0
analysed	0
by	0
denaturing	0
polyacrylamide	0
gel	0
electrophoresis	0
and	0
autoradiography	0
.	0

This	0
method	0
could	0
be	0
quite	0
useful	0
to	0
detect	0
not	0
only	0
CAG	1
repeats	2
in	0
SBMA	0
but	0
also	0
other	0
polymorphic	1
dinucleotide	2
and	0
trinucleotide	1
repeats	2
.	0

Cellular	0
immune	0
and	0
cytokine	0
pathways	0
resulting	0
in	0
tissue	9
factor	10
expression	0
and	0
relevance	0
to	0
septic	0
shock	0
.	0

Cells	0
of	0
monocyte	0
lineage	0
serve	0
as	0
effector	7
cells	8
in	0
the	0
cellular	0
immune	0
response	0
.	0

In	0
addition	0
,	0
they	0
respond	0
to	0
LPS	0
and	0
cytokines	0
with	0
activation	0
and	0
expression	0
of	0
inflammatory	9
effector	10
gene	10
products	10
similar	0
to	0
those	0
elicited	0
by	0
the	0
antigen	0
driven	0
response	0
.	0

The	0
response	0
to	0
antigen	0
proceeds	0
at	0
the	0
T	7
helper	8
cell	8
level	0
through	0
two	0
independent	0
forms	0
of	0
cellular	0
collaboration	0
,	0
contact	0
and	0
lymphokine	9
.	0

We	0
review	0
the	0
control	0
of	0
expression	0
of	0
the	0
Tissue	1
Factor	2
(	2
TF	2
)	2
gene	2
and	0
the	0
function	0
of	0
the	0
TF	9
protein	10
.	0

The	0
enhanced	0
initiation	0
of	0
transcription	0
of	0
the	0
TF	0
gene	0
appears	0
to	0
require	0
engagement	0
of	0
a	0
56	0
bp	0
LPS	1
Response	2
Element	2
,	0
an	0
enhancer	0
that	0
is	0
engaged	0
by	0
both	0
AP-1	9
type	10
heterodimeric	10
complexes	10
as	0
well	0
as	0
NF	9
kappa	10
B	10
like	10
heterodimeric	10
complexes	10
.	0

Dissociation	0
of	0
NF	9
kappa	10
B	10
from	0
Ig	9
kappa	10
B	10
by	0
cytokine	0
and	0
LPS	0
stimulation	0
,	0
and	0
possibly	0
activated	7
T	8
cells	8
,	0
may	0
represent	0
a	0
common	0
pathway	0
to	0
induction	0
of	0
the	0
TF	1
and	2
other	2
inflammatory	2
genes	2
.	0

Enhancement	0
of	0
expression	0
of	0
TF	9
is	0
observed	0
upon	0
adhesion	0
of	0
Mo	0
to	0
endothelial	7
cells	8
and	0
extracellular	0
matrix	0
proteins	0
,	0
as	0
well	0
as	0
upon	0
engagement	0
of	0
leukocyte	9
integrins	10
.	0

The	0
biological	0
effects	0
that	0
follow	0
from	0
expression	0
of	0
TF	9
by	0
vascular	0
cells	0
have	0
been	0
resolved	0
by	0
analysis	0
of	0
function	0
aided	0
by	0
the	0
use	0
of	0
recombinant	9
full	10
length	10
TF	10
and	0
truncated	9
surface	10
domain	10
of	0
TF	9
.	0

The	0
rules	0
of	0
assembly	0
of	0
the	0
cognate	0
ligands	0
of	0
TF	9
,	0
namely	0
the	0
zymogen	9
plasma	10
factors	10
VII	10
and	0
the	0
serine	9
protease	10
factor	10
VIIa	10
,	0
with	0
the	0
soluble	9
surface	10
domain	10
of	0
TF	9
in	0
free	0
solution	0
,	0
in	0
the	0
presence	0
of	0
phospholipid	0
surfaces	0
and	0
cell	0
surface	0
and	0
of	0
the	0
anchored	9
TF	10
molecule	10
have	0
been	0
described	0
.	0

It	0
is	0
evident	0
that	0
assembly	0
of	0
the	0
surface	9
domain	10
of	0
TF	9
with	0
VIIa	9
to	0
form	0
the	0
binary	0
TF.VIIa	9
complex	10
induces	0
a	0
significant	0
increase	0
in	0
the	0
Kcat	0
of	0
the	0
catalytic	9
domain	10
of	0
VIIa	9
for	0
small	0
peptidyl	0
substrates	0
and	0
more	0
profoundly	0
for	0
protein	9
substrate	10
.	0

This	0
provides	0
substantial	0
evidence	0
for	0
an	0
allosteric	0
effect	0
on	0
the	0
catalytic	0
cleft	0
of	0
VIIa	9
that	0
is	0
imparted	0
by	0
binding	0
to	0
TF	9
,	0
its	0
cognate	0
catalytic	0
cofactor	9
.	0

It	0
is	0
also	0
evident	0
that	0
the	0
TF.VIIa	9
complex	10
is	0
proteolytically	0
active	0
and	0
can	0
activate	0
the	0
zymogen	9
plasma	10
factor	10
X	10
to	0
the	0
serine	9
protease	10
Xa	10
in	0
free	0
solution	0
,	0
inferring	0
that	0
extended	0
substrate	0
recognition	0
by	0
induced	0
structural	0
loci	0
of	0
the	0
TF.VIIa	9
complex	10
are	0
created	0
from	0
either	0
or	0
both	0
proteins	0
to	0
constitute	0
a	0
new	9
recognition	10
structure	10
.	0

It	0
is	0
also	0
evident	0
that	0
association	0
of	0
X	9
with	0
charged	0
phospholipid	0
surfaces	0
enhances	0
the	0
proteolytic	0
activation	0
of	0
this	0
zymogen	9
by	0
increasing	0
recognition	0
and	0
susceptibility	0
of	0
the	0
sessile	0
peptide	0
bond	0
deduced	0
from	0
the	0
markedly	0
decreased	0
Km	0
and	0
increased	0
Kcat	0
.	0

Phorbol	0
ester	0
reduces	0
constitutive	9
nuclear	10
NF	10
kappa	10
B	10
and	0
inhibits	0
HIV-1	0
production	0
in	0
mature	7
human	8
monocytic	8
cells	8
.	0

NF	9
kappa	10
B	10
is	0
a	0
potent	0
mediator	0
of	0
specific	0
gene	0
expression	0
in	0
human	0
monocytes	0
and	0
has	0
been	0
shown	0
to	0
play	0
a	0
role	0
in	0
transcription	0
of	0
the	0
HIV-1	0
genome	0
in	0
promonocytic	0
leukemias	0
.	0

There	0
is	0
little	0
information	0
available	0
on	0
the	0
response	0
of	0
NF	9
kappa	10
B	10
to	0
cytokines	9
in	0
normal	7
human	8
monocytes	8
.	0

We	0
have	0
used	0
a	0
32P-labeled	0
oligonucleotide	0
derived	0
from	0
human	1
immunodeficiency	2
virus	2
(	2
HIV-1	2
)	2
long	2
terminal	2
repeat	2
,	0
which	0
contains	0
a	0
tandem	0
repeat	0
of	0
the	0
NF	1
kappa	2
B	2
binding	2
sequence	2
,	0
as	0
a	0
probe	0
in	0
a	0
gel	0
retardation	0
assay	0
to	0
study	0
this	0
transcription	9
factor	10
.	0

Using	0
this	0
assay	0
,	0
we	0
have	0
detected	0
NF	9
kappa	10
B	10
in	0
extracts	0
of	0
nuclei	0
from	0
normal	7
human	8
monocytes	8
.	0

Treatment	0
of	0
normal	7
monocytes	8
with	0
12-0-tetradecanoyl	0
phorbol-13-acetate	0
(	0
TPA	0
)	0
for	0
4-24	0
h	0
caused	0
the	0
complete	0
disappearance	0
of	0
NF	9
kappa	10
B	10
from	0
nuclear	0
extracts	0
of	0
monocytes	0
.	0

A	0
similar	0
result	0
was	0
obtained	0
with	0
the	0
mature	5
monocytic	6
leukemia	6
cell	6
line	6
THP-1	5
.	0

The	0
constitutive	9
transcription	10
factor	10
SP1	9
was	0
unaffected	0
by	0
addition	0
of	0
TPA	0
.	0

The	0
disappearance	0
of	0
NF	9
kappa	10
B	10
from	0
the	0
nucleus	0
was	0
concentration	0
dependent	0
between	0
10	0
and	0
50	0
ng/ml	0
of	0
phorbol	0
ester	0
.	0

In	0
THP-1	0
cells	0
,	0
TPA	0
also	0
induced	0
a	0
new	0
,	0
faster-migrating	9
NF	10
kappa	10
B	10
species	10
not	0
induced	0
in	0
monocytes	7
.	0

Protein	0
kinase	0
C	0
inhibitor	0
staurosporine	0
,	0
but	0
not	0
cyclic	0
nucleotide-dependent	0
protein	0
kinase	0
inhibitor	0
HA-1004	0
,	0
also	0
dramatically	0
reduced	0
constitutive	0
levels	0
of	0
nuclear	9
NF	10
kappa	10
B	10
.	0

Finally	0
,	0
TPA	0
addition	0
to	0
monocytes	7
infected	0
with	0
HIV-1	0
inhibited	0
HIV-1	0
replication	0
,	0
as	0
determined	0
by	0
reverse	9
transcriptase	10
assays	0
,	0
in	0
a	0
concentration-dependent	0
manner	0
.	0

These	0
results	0
are	0
in	0
striking	0
contrast	0
to	0
the	0
increase	0
in	0
nuclear	0
NF	9
kappa	10
B	10
and	0
HIV-1	0
replication	0
induced	0
by	0
phorbol	0
esters	0
in	0
promonocytic	5
leukemia	6
cells	6
U937	6
and	0
HL-60	5
,	0
and	0
emphasize	0
the	0
importance	0
of	0
studying	0
cytokine	9
regulation	0
of	0
HIV-1	0
in	0
normal	7
monocytes	8
.	0

A	0
mechanism	0
for	0
the	0
antiinflammatory	0
effects	0
of	0
corticosteroids	0
:	0
the	0
glucocorticoid	9
receptor	10
regulates	0
leukocyte	0
adhesion	0
to	0
endothelial	7
cells	8
and	0
expression	0
of	0
endothelial-leukocyte	9
adhesion	10
molecule	10
1	10
and	0
intercellular	9
adhesion	10
molecule	10
1	10
.	0

Corticosteroids	0
are	0
the	0
preeminent	0
antiinflammatory	0
agents	0
although	0
the	0
molecular	0
mechanisms	0
that	0
impart	0
their	0
efficacy	0
have	0
not	0
been	0
defined	0
.	0

The	0
endothelium	0
plays	0
a	0
critical	0
role	0
in	0
inflammation	0
by	0
directing	0
circulating	7
leukocytes	8
into	0
extravascular	0
tissues	0
by	0
expressing	0
adhesive	9
molecules	10
for	0
leukocytes	7
[	0
e.g.	0
,	0
endothelial-leukocyte	9
adhesion	10
molecule	10
1	10
(	0
ELAM-1	9
)	0
and	0
intercellular	9
adhesion	10
molecule	10
1	10
(	0
ICAM-1	9
)	0
]	0
.	0

We	0
therefore	0
determined	0
whether	0
corticosteroids	0
suppress	0
inflammation	0
by	0
inhibiting	0
endothelial	0
expression	0
of	0
adhesion	9
molecules	10
for	0
neutrophils	7
(	0
polymorphonuclear	7
leukocytes	8
)	0
.	0

Preincubation	0
of	0
endothelial	7
cells	8
with	0
endotoxin	0
[	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
1	0
microgram/ml	0
]	0
led	0
to	0
a	0
4-fold	0
increase	0
in	0
subsequent	0
adherence	0
of	0
polymorphonuclear	7
leukocytes	8
(	0
P	0
<	0
0.0001	0
,	0
n	0
=	0
10	0
)	0
to	0
endothelial	7
cells	8
,	0
an	0
increase	0
that	0
was	0
markedly	0
attenuated	0
when	0
endothelial	7
cells	8
were	0
treated	0
with	0
dexamethasone	0
(	0
IC50	0
<	0
1	0
nM	0
,	0
P	0
<	0
0.0001	0
,	0
n	0
=	0
6	0
or	0
7	0
)	0
during	0
preincubation	0
with	0
LPS	0
.	0

Moreover	0
,	0
the	0
steroid	9
receptor	10
agonist	0
cortisol	0
(	0
10	0
microM	0
)	0
,	0
but	0
not	0
its	0
inactive	0
metabolite	0
tetrahydrocortisol	0
(	0
10	0
microM	0
)	0
,	0
diminished	0
LPS-induced	0
endothelial	0
cell	0
adhesiveness	0
.	0

Further	0
evidence	0
that	0
the	0
action	0
of	0
dexamethasone	0
was	0
mediated	0
through	0
ligation	0
of	0
corticosteroid	9
receptors	10
[	0
human	9
glucocorticoid	10
receptors	10
(	0
hGRs	9
)	0
]	0
was	0
provided	0
by	0
experiments	0
utilizing	0
the	0
steroid	0
antagonist	0
RU-486	0
.	0

RU-486	0
(	0
10	0
microM	0
)	0
,	0
which	0
prevents	0
translocation	0
of	0
ligated	0
hGR	9
to	0
the	0
nucleus	0
by	0
inhibiting	0
dissociation	0
of	0
hGR	9
from	0
heat	0
shock	0
protein	0
90	0
,	0
completely	0
aborted	0
the	0
effect	0
of	0
dexamethasone	0
on	0
adhesiveness	0
of	0
endothelial	7
cells	8
(	0
P	0
<	0
0.0005	0
,	0
n	0
=	0
3	0
)	0
.	0

Treatment	0
of	0
endothelial	7
cells	8
with	0
LPS	0
(	0
1	0
microgram/ml	0
)	0
stimulated	0
transcription	0
of	0
ELAM-1	9
,	0
as	0
shown	0
by	0
Northern	0
blot	0
analysis	0
,	0
and	0
expression	0
of	0
membrane-associated	9
ELAM-1	10
and	0
ICAM-1	9
,	0
as	0
shown	0
by	0
quantitative	0
immunofluorescence	0
(	0
both	0
P	0
<	0
0.001	0
,	0
n	0
=	0
9	0
)	0
.	0

Dexamethasone	0
markedly	0
inhibited	0
LPS-stimulated	0
accumulation	0
of	0
mRNA	0
for	0
ELAM-1	9
and	0
expression	0
of	0
ELAM-1	9
and	0
ICAM-1	9
(	0
IC50	0
<	0
10	0
nM	0
,	0
both	0
P	0
<	0
0.001	0
,	0
n	0
=	0
4-9	0
)	0
;	0
inhibition	0
of	0
expression	0
by	0
dexamethasone	0
was	0
reversed	0
by	0
RU-486	0
(	0
both	0
P	0
<	0
0.005	0
,	0
n	0
=	0
4-6	0
)	0
.	0

As	0
in	0
the	0
adhesion	0
studies	0
,	0
cortisol	0
but	0
not	0
tetrahydrocortisol	0
inhibited	0
expression	0
of	0
ELAM-1	9
and	0
ICAM-1	9
(	0
both	0
P	0
<	0
0.005	0
,	0
n	0
=	0
3	0
or	0
4	0
)	0
.	0

In	0
contrast	0
,	0
sodium	0
salicylate	0
(	0
1	0
mM	0
)	0
inhibited	0
neither	0
adhesion	0
nor	0
expression	0
of	0
these	0
adhesion	9
molecules	10
.	0

These	0
studies	0
suggest	0
that	0
antagonism	0
by	0
dexamethasone	0
of	0
endotoxin	9
-induced	0
inflammation	0
is	0
a	0
specific	0
instance	0
of	0
the	0
general	0
biological	0
principle	0
that	0
the	0
glucocorticoid	9
receptor	10
is	0
a	0
hormone-dependent	0
regulator	0
of	0
transcription	0
.	0

Pax-5	1
encodes	0
the	0
transcription	9
factor	10
BSAP	9
and	0
is	0
expressed	0
in	0
B	7
lymphocytes	8
,	0
the	0
developing	0
CNS	0
,	0
and	0
adult	0
testis	0
.	0

BSAP	9
has	0
been	0
identified	0
previously	0
as	0
a	0
transcription	9
factor	10
that	0
is	0
expressed	0
at	0
early	0
,	0
but	0
not	0
late	0
,	0
stages	0
of	0
B-cell	0
differentiation	0
.	0

Biochemical	0
purification	0
and	0
cDNA	0
cloning	0
has	0
now	0
revealed	0
that	0
BSAP	9
belongs	0
to	0
the	0
family	0
of	0
paired	9
domain	10
proteins	10
.	0

BSAP	9
is	0
encoded	0
by	0
the	0
Pax-5	1
gene	2
and	0
has	0
been	0
highly	0
conserved	0
between	0
human	0
and	0
mouse	0
.	0

An	0
intact	0
paired	0
domain	0
was	0
shown	0
to	0
be	0
both	0
necessary	0
and	0
sufficient	0
for	0
DNA	0
binding	0
of	0
BSAP	9
.	0

Binding	0
studies	0
with	0
several	0
BSAP	1
recognition	2
sequences	2
demonstrated	0
that	0
the	0
sequence	0
specificity	0
of	0
BSAP	9
differs	0
from	0
that	0
of	0
the	0
distantly	0
related	0
paired	9
domain	10
protein	10
Pax-1	10
.	0

During	0
embryogenesis	0
,	0
the	0
BSAP	1
gene	2
is	0
transiently	0
expressed	0
in	0
the	0
mesencephalon	0
and	0
spinal	0
cord	0
with	0
a	0
spatial	0
and	0
temporal	0
expression	0
pattern	0
that	0
is	0
distinct	0
from	0
that	0
of	0
other	0
Pax	1
genes	2
in	0
the	0
developing	0
central	0
nervous	0
system	0
(	0
CNS	0
)	0
.	0

Later	0
,	0
the	0
expression	0
of	0
the	0
BSAP	1
gene	2
shifts	0
to	0
the	0
fetal	0
liver	0
where	0
it	0
correlates	0
with	0
the	0
onset	0
of	0
B	0
lymphopoiesis	0
.	0

BSAP	9
expression	0
persists	0
in	0
B	7
lymphocytes	8
and	0
is	0
also	0
seen	0
in	0
the	0
testis	0
of	0
the	0
adult	0
mouse	0
.	0

All	0
of	0
this	0
evidence	0
indicates	0
that	0
the	0
transcription	9
factor	10
BSAP	9
may	0
not	0
only	0
play	0
an	0
important	0
role	0
in	0
B-cell	0
differentiation	0
but	0
also	0
in	0
neural	0
development	0
and	0
spermatogenesis	0
.	0

Cell	0
cycle-dependent	0
initiation	0
and	0
lineage-dependent	0
abrogation	0
of	0
GATA-1	9
expression	0
in	0
pure	7
differentiating	8
hematopoietic	8
progenitors	8
.	0

The	0
programmed	0
activation/repression	0
of	0
transcription	9
factors	10
in	0
early	0
hematopoietic	0
differentiation	0
has	0
not	0
yet	0
been	0
explored	0
.	0

The	0
DNA-binding	9
protein	10
GATA-1	9
is	0
required	0
for	0
normal	0
erythroid	0
development	0
and	0
regulates	0
erythroid-expressed	1
genes	2
in	0
maturing	7
erythroblasts	8
.	0

We	0
analyzed	0
GATA-1	9
expression	0
in	0
early	0
human	0
adult	0
hematopoiesis	0
by	0
using	0
an	0
in	0
vitro	0
system	0
in	0
which	0
``	0
pure	0
''	0
early	7
hematopoietic	8
progenitors	8
are	0
induced	0
to	0
gradual	0
and	0
synchronized	0
differentiation	0
selectively	0
along	0
the	0
erythroid	0
or	0
granulocyte-macrophage	0
pathway	0
by	0
differential	0
treatment	0
with	0
hematopoietic	0
growth	0
factors	0
.	0

The	0
GATA-1	1
gene	2
,	0
though	0
virtually	0
silent	0
in	0
quiescent	7
progenitors	8
,	0
is	0
activated	0
after	0
entrance	0
into	0
the	0
cell	0
cycle	0
upon	0
stimulation	0
with	0
hematopoietic	0
growth	0
factors	0
.	0

Subsequently	0
,	0
increasing	0
expression	0
along	0
the	0
erythroid	0
pathway	0
contrasts	0
with	0
an	0
abrupt	0
downregulation	0
in	0
the	0
granulocyte-macrophage	7
lineage	8
.	0

These	0
results	0
suggest	0
a	0
microenvironment-directed	0
,	0
two-step	0
model	0
for	0
GATA-1	9
expression	0
in	0
differentiating	7
hematopoietic	8
progenitors	8
that	0
involves	0
(	0
i	0
)	0
cycle-dependent	0
initiation	0
and	0
(	0
ii	0
)	0
lineage-dependent	0
maintenance	0
or	0
suppression	0
.	0

Hypothetically	0
,	0
on/off	0
switches	0
of	0
lineage-restricted	9
transactivators	10
may	0
underlie	0
the	0
binary	0
fate	0
decisions	0
of	0
hematopoietic	7
progenitors	8
.	0

Specific	0
NF-kappa	9
B	10
subunits	10
act	0
in	0
concert	0
with	0
Tat	9
to	0
stimulate	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
transcription	0
.	0

NF-kappa	9
B	10
is	0
a	0
protein	9
complex	10
which	0
functions	0
in	0
concert	0
with	0
the	0
tat-I	9
gene	10
product	10
to	0
stimulate	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
transcription	0
.	0

To	0
determine	0
whether	0
specific	0
members	0
of	0
the	0
NF-kappa	9
B	10
family	10
contribute	0
to	0
this	0
effect	0
,	0
we	0
have	0
examined	0
the	0
abilities	0
of	0
different	0
NF-kappa	9
B	10
subunits	10
to	0
act	0
with	0
Tat-I	9
to	0
stimulate	0
transcription	0
of	0
HIV	0
in	0
Jurkat	7
T-leukemia	8
cells	8
.	0

We	0
have	0
found	0
that	0
the	0
p49	9
(	10
100	10
)	10
DNA	10
binding	10
subunit	10
,	0
together	0
with	0
p65	9
,	0
can	0
act	0
in	0
concert	0
with	0
Tat-I	9
to	0
stimulate	0
the	0
expression	0
of	0
HIV-CAT	1
plasmid	2
.	0

Little	0
effect	0
was	0
observed	0
with	0
50-kDa	9
forms	10
of	0
p105	9
NF-kappa	9
B	10
or	0
rel	9
,	0
in	0
combination	0
with	0
p65	9
or	0
full-length	9
c-rel	10
,	0
which	0
do	0
not	0
stimulate	0
the	0
HIV	1
enhancer	2
in	0
these	0
cells	0
.	0

These	0
findings	0
suggest	0
that	0
the	0
combination	0
of	0
p49	9
(	10
100	10
)	10
and	0
p65	9
NF-kappa	9
B	10
can	0
act	0
in	0
concert	0
with	0
the	0
tat-I	9
gene	10
product	10
to	0
stimulate	0
the	0
synthesis	0
of	0
HIV	3
RNA	4
.	0

Stable	0
expression	0
of	0
HB24	1
,	0
a	0
diverged	1
human	2
homeobox	2
gene	2
,	0
in	0
T	0
lymphocytes	0
induces	0
genes	0
involved	0
in	0
T	0
cell	0
activation	0
and	0
growth	0
.	0

A	0
diverged	1
homeobox	2
gene	2
,	0
HB24	1
,	0
which	0
is	0
known	0
to	0
be	0
induced	0
following	0
lymphocyte	0
activation	0
,	0
was	0
introduced	0
into	0
Jurkat	5
T	6
cells	6
under	0
the	0
control	0
of	0
a	0
constitutive	1
promoter	2
.	0

Stable	0
transfectants	0
of	0
HB24	1
were	0
established	0
that	0
expressed	0
high	0
levels	0
of	0
HB24	3
mRNA	4
and	0
possessed	0
an	0
altered	0
phenotype	0
suggestive	0
of	0
activated	7
T	8
cells	8
.	0

A	0
number	0
of	0
genes	0
known	0
to	0
be	0
induced	0
following	0
T	0
cell	0
activation	0
and	0
associated	0
with	0
cell	0
growth	0
were	0
increased	0
in	0
the	0
transfectants	5
,	0
including	0
c-fos	1
,	0
c-myc	1
,	0
c-myb	1
,	0
HLA-DR	1
,	0
lck	1
,	0
NF-kappa	9
B	10
,	0
interleukin-2	1
and	0
interleukin-2	1
receptor	2
alpha	2
(	0
IL-2R	1
alpha	2
)	0
.	0

Analysis	0
of	0
IL-2R	9
alpha	10
expression	0
by	0
transient	0
transfection	0
of	0
IL-2R	1
alpha	2
promoter	2
constructs	2
into	0
the	0
HB24	5
transfectants	6
revealed	0
constitutive	0
expression	0
(	0
about	0
60	0
%	0
of	0
phytohemagglutinin-	5
and	6
phorbol	6
ester-activated	6
Jurkat	6
cells	6
)	0
that	0
was	0
dependent	0
on	0
the	0
kappa	1
B	2
site	2
in	0
the	0
IL-2R	1
alpha	2
promoter	2
.	0

Furthermore	0
,	0
as	0
a	0
consequence	0
of	0
the	0
increased	0
HB24	3
mRNA	4
levels	0
,	0
the	0
Jurkat	5
HB24	6
transfectants	6
proliferated	0
more	0
rapidly	0
than	0
control	5
cell	6
lines	6
.	0

Thus	0
,	0
stable	0
expression	0
of	0
HB24	1
confers	0
an	0
activation	0
phenotype	0
on	0
a	0
human	5
T	6
cell	6
line	6
,	0
implicating	0
this	0
gene	0
as	0
an	0
important	0
transcriptional	9
factor	10
during	0
T	0
cell	0
activation	0
and	0
growth	0
.	0

Functional	0
interaction	0
between	0
the	0
two	0
zinc	9
finger	10
domains	10
of	0
the	0
v-erb	9
A	10
oncoprotein	10
.	0

The	0
v-erb	1
A	2
oncogene	2
of	0
avian	0
erythroblastosis	0
virus	0
is	0
a	0
mutated	0
and	0
virally	0
transduced	0
copy	0
of	0
a	0
host	1
cell	2
gene	2
encoding	0
a	0
thyroid	9
hormone	10
receptor	10
.	0

The	0
protein	0
expressed	0
by	0
the	0
v-erb	1
A	2
oncogene	2
binds	0
to	0
DNA	0
and	0
acts	0
as	0
a	0
dominant	0
negative	0
inhibitor	0
of	0
both	0
the	0
thyroid	9
hormone	10
receptor	10
and	0
the	0
closely	0
related	0
retinoic	9
acid	10
receptor	10
.	0

The	0
v-erb	9
A	10
protein	10
has	0
sustained	0
two	0
amino	0
acid	0
alterations	0
within	0
its	0
DNA-binding	9
domain	10
relative	0
to	0
that	0
of	0
c-erb	9
A	10
,	0
one	0
of	0
which	0
,	0
at	0
serine	0
61	0
,	0
is	0
known	0
to	0
be	0
important	0
for	0
v-erb	9
A	10
function	0
in	0
the	0
neoplastic	7
cell	8
.	0

We	0
report	0
here	0
that	0
the	0
second	0
alteration	0
,	0
at	0
threonine	0
78	0
,	0
also	0
plays	0
an	0
important	0
,	0
although	0
more	0
indirect	0
,	0
role	0
:	0
alteration	0
of	0
the	0
sequence	0
at	0
threonine	0
78	0
such	0
that	0
it	0
resembles	0
that	0
of	0
c-erb	9
A	10
can	0
act	0
as	0
an	0
intragenic	0
suppressor	0
and	0
can	0
partially	0
restore	0
function	0
to	0
a	0
v-erb	9
A	10
protein	10
rendered	0
defective	0
due	0
to	0
a	0
mutation	0
at	0
position	9
61	10
.	0

Threonine	0
78	0
lies	0
within	0
the	0
D-box	9
of	0
the	0
v-erb	9
A	10
protein	10
,	0
a	0
region	0
thought	0
to	0
mediate	0
receptor-receptor	0
dimerizations	0
,	0
and	0
is	0
not	0
in	0
physical	0
proximity	0
to	0
the	0
serine	0
at	0
position	9
61	10
.	0

It	0
therefore	0
appears	0
that	0
an	0
indirect	0
interaction	0
occurs	0
between	0
these	0
two	0
sites	0
and	0
that	0
this	0
interaction	0
is	0
crucial	0
for	0
v-erb	9
A	10
function	0
.	0

cis-acting	1
sequences	2
required	0
for	0
inducible	0
interleukin-2	1
enhancer	2
function	0
bind	0
a	0
novel	0
Ets-related	9
protein	10
,	0
Elf-1	9
.	0

The	0
recent	0
definition	0
of	0
a	0
consensus	0
DNA	1
binding	2
sequence	2
for	0
the	0
Ets	9
family	10
of	0
transcription	9
factors	10
has	0
allowed	0
the	0
identification	0
of	0
potential	0
Ets	1
binding	2
sites	2
in	0
the	0
promoters	1
and	0
enhancers	1
of	0
many	0
inducible	1
T-cell	2
genes	2
.	0

In	0
the	0
studies	0
described	0
in	0
this	0
report	0
,	0
we	0
have	0
identified	0
two	0
potential	0
Ets	1
binding	2
sites	2
,	0
EBS1	0
and	0
EBS2	1
,	0
which	0
are	0
conserved	0
in	0
both	0
the	0
human	1
and	2
murine	2
interleukin-2	2
enhancers	2
.	0

Within	0
the	0
human	1
enhancer	2
,	0
these	0
two	0
sites	0
are	0
located	0
within	0
the	0
previously	0
defined	0
DNase	9
I	10
footprints	0
,	0
NFAT-1	1
and	0
NFIL-2B	1
,	0
respectively	0
.	0

Electrophoretic	0
mobility	0
shift	0
and	0
methylation	0
interference	0
analyses	0
demonstrated	0
that	0
EBS1	0
and	0
EBS2	1
are	0
essential	0
for	0
the	0
formation	0
of	0
the	0
NFAT-1	9
and	10
NFIL-2B	10
nuclear	10
protein	10
complexes	10
.	0

Furthermore	0
,	0
in	0
vitro	0
mutagenesis	0
experiments	0
demonstrated	0
that	0
inducible	0
interleukin-2	1
enhancer	2
function	0
requires	0
the	0
presence	0
of	0
either	0
EBS1	0
or	0
EBS2	1
.	0

Two	0
well-characterized	0
Ets	9
family	10
members	10
,	0
Ets-1	9
and	0
Ets-2	9
,	0
are	0
reciprocally	0
expressed	0
during	0
T-cell	0
activation	0
.	0

Surprisingly	0
,	0
however	0
,	0
neither	0
of	0
these	0
proteins	0
bound	0
in	0
vitro	0
to	0
EBS1	0
or	0
EBS2	1
.	0

We	0
therefore	0
screened	0
a	0
T-cell	1
cDNA	2
library	0
under	0
low-stringency	0
conditions	0
with	0
a	0
probe	0
from	0
the	0
DNA	9
binding	10
domain	10
of	0
Ets-1	9
and	0
isolated	0
a	0
novel	9
Ets	10
family	10
member	10
,	0
Elf-1	9
.	0

Elf-1	9
contains	0
a	0
DNA	9
binding	10
domain	10
that	0
is	0
nearly	0
identical	0
to	0
that	0
of	0
E74	9
,	0
the	0
ecdysone-inducible	9
Drosophila	10
transcription	10
factor	10
required	0
for	0
metamorphosis	0
(	0
hence	0
the	0
name	0
Elf-1	9
,	0
for	0
E74-like	9
factor	10
1	10
)	0
.	0

Elf-1	9
bound	0
specifically	0
to	0
both	0
EBS1	0
and	0
EBS2	1
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

It	0
also	0
bound	0
to	0
the	0
purine-rich	1
CD3R	2
element	2
from	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
2	2
long	2
terminal	2
repeat	2
,	0
which	0
is	0
required	0
for	0
inducible	0
virus	0
expression	0
in	0
response	0
to	0
signalling	0
through	0
the	0
T-cell	9
receptor	10
.	0

Taken	0
together	0
,	0
these	0
results	0
demonstrate	0
that	0
multiple	9
Ets	10
family	10
members	10
with	0
apparently	0
distinct	0
DNA	0
binding	0
specificities	0
regulate	0
differential	0
gene	0
expression	0
in	0
resting	7
and	8
activated	8
T	8
cells	8
.	0

Binding	0
of	0
erythroid	9
and	10
non-erythroid	10
nuclear	10
proteins	10
to	0
the	0
silencer	1
of	0
the	0
human	1
epsilon-globin-encoding	2
gene	2
.	0

To	0
clarify	0
the	0
molecular	0
mechanisms	0
involved	0
in	0
the	0
developmental	0
control	0
of	0
hemoglobin-encoding	1
genes	2
we	0
have	0
been	0
studying	0
the	0
expression	0
of	0
these	0
genes	1
in	0
human	7
cells	8
in	0
continuous	0
culture	0
.	0

We	0
have	0
previously	0
reported	0
the	0
presence	0
of	0
a	0
transcriptional	1
control	2
element	2
with	0
the	0
properties	0
of	0
a	0
silencer	1
extending	0
from	0
-392	1
to	2
-177	2
bp	2
relative	0
to	0
the	0
cap	1
site	2
of	0
the	0
human	1
epsilon-globin-encoding	2
gene	2
[	0
Cao	0
et	0
al.	0
,	0
Proc.Natl.Acad.Sci.USA	0
86	0
(	0
1989	0
)	0
5306-5309	0
]	0
.	0

We	0
also	0
showed	0
that	0
this	0
silencer	1
has	0
stronger	0
inhibitory	0
activity	0
in	0
HeLa	5
cells	6
,	0
as	0
compared	0
to	0
K562	5
human	6
erythroleukemia	6
cells	6
.	0

Using	0
deletion	1
mutants	2
and	0
cis-cloned	0
synthetic	0
oligodeoxyribonucleotides	0
in	0
transient	0
expression	0
assays	0
,	0
nucleotide	0
sequences	0
responsible	0
for	0
this	0
effect	0
have	0
now	0
been	0
further	0
delimited	0
to	0
44	0
bp	0
located	0
from	0
-294	1
to	2
-251	2
bp	2
.	0

Gel	0
electrophoresis	0
mobility	0
shift	0
assays	0
and	0
DNaseI	9
footprinting	0
assays	0
demonstrate	0
that	0
these	0
negative	0
regulatory	0
sequences	0
are	0
recognized	0
differently	0
by	0
proteins	0
present	0
in	0
nuclear	0
extracts	0
obtained	0
from	0
HeLa	5
and	0
K562	5
cells	6
.	0

Two	0
binding	0
proteins	0
are	0
detected	0
in	0
K562	0
nuclear	0
extracts	0
,	0
while	0
only	0
one	0
is	0
found	0
in	0
extracts	0
from	0
HeLa	5
cells	6
.	0

Possible	0
mechanisms	0
by	0
which	0
these	0
proteins	0
may	0
regulate	0
transcription	0
of	0
the	0
epsilon-globin-encoding	1
gene	2
in	0
erythroid	7
and	8
non-erythroid	8
cells	8
are	0
discussed	0
.	0

Calcitriol	0
:	0
a	0
hematolymphopoietrope	0
?	0
[	0
editorial	0
]	0

A	0
MEDLINE	0
search	0
of	0
the	0
English-language	0
literature	0
was	0
conducted	0
using	0
the	0
indexing	0
terms	0
'immunology	0
,	0
calcitriol	0
and	0
vitamin	0
D	0
'	0
to	0
identify	0
studies	0
indicating	0
a	0
role	0
for	0
calcitriol	0
as	0
a	0
primary	0
immunomodulator	0
.	0

Sixty-six	0
papers	0
published	0
between	0
January	0
1956	0
and	0
June	0
1991	0
were	0
identified	0
.	0

Forty-five	0
of	0
these	0
reports	0
are	0
cited	0
in	0
this	0
review	0
.	0

The	0
data	0
strongly	0
suggest	0
an	0
endocrine	0
,	0
autocrine	0
and/or	0
paracrine	0
role	0
for	0
calcitriol	0
in	0
immune	0
regulation	0
.	0

No	0
unifying	0
hypothesis	0
has	0
yet	0
emerged	0
explaining	0
this	0
collection	0
of	0
data	0
.	0

This	0
paper	0
provides	0
a	0
brief	0
review	0
of	0
immune	0
properties	0
currently	0
attributed	0
to	0
calcitriol	0
.	0

Transcription	0
of	0
the	0
hypersensitive	1
site	2
HS2	2
enhancer	2
in	0
erythroid	7
cells	8
.	0

In	0
the	0
human	1
genome	2
,	0
the	0
erythroid-specific	1
hypersensitive	2
site	2
HS2	2
enhancer	2
regulates	0
the	0
transcription	0
of	0
the	0
downstream	1
beta-like	2
globin	2
genes	2
10-50	1
kilobases	2
away	0
.	0

The	0
mechanism	0
of	0
HS2	1
enhancer	2
function	0
is	0
not	0
known	0
.	0

The	0
present	0
study	0
employs	0
RNA	0
protection	0
assays	0
to	0
analyze	0
the	0
transcriptional	0
status	0
of	0
the	0
HS2	1
enhancer	2
in	0
transfected	1
recombinant	2
chloramphenicol	2
acetyltransferase	2
(	2
CAT	2
)	2
plasmids	2
.	0

In	0
erythroid	5
K562	6
cells	6
in	0
which	0
the	0
HS2	1
enhancer	2
is	0
active	0
,	0
the	0
HS2	1
sequence	2
directs	0
the	0
synthesis	0
of	0
long	0
enhancer	0
transcripts	0
that	0
are	0
initiated	0
apparently	0
from	0
within	0
the	0
enhancer	1
and	0
elongated	0
through	0
the	0
intervening	0
DNA	0
into	0
the	0
cis-linked	1
CAT	2
gene	2
.	0

In	0
nonerythroid	5
HL-60	6
cells	6
in	0
which	0
the	0
HS2	1
enhancer	2
is	0
inactive	0
,	0
long	3
enhancer	4
transcripts	4
are	0
not	0
detectable	0
.	0

Splitting	0
the	0
HS2	1
enhancer	2
between	0
two	0
tandem	1
Ap1	2
sites	2
abolishes	0
the	0
synthesis	0
of	0
a	0
group	0
of	0
long	3
enhancer	4
transcripts	4
and	0
results	0
in	0
loss	0
of	0
enhancer	0
function	0
and	0
transcriptional	0
silencing	0
of	0
the	0
cis-linked	0
CAT	0
gene	0
.	0

In	0
directing	0
the	0
synthesis	0
of	0
RNA	3
through	0
the	0
intervening	0
DNA	1
and	0
the	0
gene	0
by	0
a	0
tracking	0
and	0
transcription	0
mechanism	0
,	0
the	0
HS2	1
enhancer	2
may	0
(	0
i	0
)	0
open	0
up	0
the	0
chromatin	1
structure	2
of	0
a	0
gene	1
domain	2
and	0
(	0
ii	0
)	0
deliver	0
enhancer	9
binding	10
proteins	10
to	0
the	0
promoter	0
sequence	0
where	0
they	0
may	0
stimulate	0
the	0
transcription	0
of	0
the	0
gene	0
at	0
the	0
cap	1
site	2
.	0

Characterization	0
of	0
a	0
novel	9
T	10
lymphocyte	10
protein	10
which	0
binds	0
to	0
a	0
site	0
related	0
to	0
steroid/thyroid	1
hormone	2
receptor	2
response	2
elements	2
in	0
the	0
negative	1
regulatory	2
sequence	2
of	0
the	0
human	1
immunodeficiency	2
virus	2
long	2
terminal	2
repeat	2
.	0

We	0
have	0
previously	0
identified	0
a	0
T	9
lymphocyte	10
protein	10
which	0
binds	0
to	0
a	0
site	0
within	0
the	0
LTR	1
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
and	0
exerts	0
an	0
inhibitory	0
effect	0
on	0
virus	0
gene	0
expression	0
.	0

The	0
palindromic	1
site	2
(	0
site	1
B	2
)	0
recognized	0
by	0
this	0
protein	0
is	0
related	0
to	0
the	0
palindromic	1
binding	2
sites	2
of	0
members	0
of	0
the	0
steroid/thyroid	9
hormone	10
receptor	10
family	10
.	0

Here	0
we	0
characterize	0
the	0
T	9
cell	10
protein	10
binding	0
to	0
this	0
site	0
as	0
a	0
100	0
kD	0
protein	0
which	0
is	0
most	0
abundant	0
in	0
T	7
cells	8
and	0
which	0
binds	0
to	0
site	1
B	2
as	0
a	0
200	9
kD	10
complex	10
.	0

This	0
protein	0
is	0
distinct	0
from	0
other	0
members	0
of	0
the	0
steroid/thyroid	9
hormone	10
receptor	10
family	10
including	0
the	0
COUP	9
protein	10
which	0
has	0
a	0
closely	0
related	0
DNA	0
binding	0
specificity	0
.	0

TAR	1
-independent	0
transactivation	0
by	0
Tat	9
in	0
cells	0
derived	0
from	0
the	0
CNS	0
:	0
a	0
novel	0
mechanism	0
of	0
HIV-1	0
gene	0
regulation	0
.	0

The	0
Tat	9
protein	10
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
is	0
essential	0
for	0
productive	0
infection	0
and	0
is	0
a	0
potential	0
target	0
for	0
antiviral	0
therapy	0
.	0

Tat	9
,	0
a	0
potent	0
activator	0
of	0
HIV-1	0
gene	0
expression	0
,	0
serves	0
to	0
greatly	0
increase	0
the	0
rate	0
of	0
transcription	0
directed	0
by	0
the	0
viral	1
promoter	2
.	0

This	0
induction	0
,	0
which	0
seems	0
to	0
be	0
an	0
important	0
component	0
in	0
the	0
progression	0
of	0
acquired	0
immune	0
deficiency	0
syndrome	0
(	0
AIDS	0
)	0
,	0
may	0
be	0
due	0
to	0
increased	0
transcriptional	0
initiation	0
,	0
increased	0
transcriptional	0
elongation	0
,	0
or	0
a	0
combination	0
of	0
these	0
processes	0
.	0

Much	0
attention	0
has	0
been	0
focused	0
on	0
the	0
interaction	0
of	0
Tat	9
with	0
a	0
specific	0
RNA	3
target	4
termed	0
TAR	3
(	0
transactivation	3
responsive	4
)	0
which	0
is	0
present	0
in	0
the	0
leader	0
sequence	0
of	0
all	0
HIV-1	3
mRNAs	4
.	0

This	0
interaction	0
is	0
believed	0
to	0
be	0
an	0
important	0
component	0
of	0
the	0
mechanism	0
of	0
transactivation	0
.	0

In	0
this	0
report	0
we	0
demonstrate	0
that	0
in	0
certain	0
CNS-derived	5
cells	6
Tat	9
is	0
capable	0
of	0
activating	0
HIV-1	0
through	0
a	0
TAR	1
-independent	0
pathway	0
.	0

A	0
Tat-responsive	1
element	2
is	0
found	0
upstream	0
within	0
the	0
viral	1
promoter	2
that	0
in	0
glial-derived	5
cell	6
lines	6
allows	0
transactivation	0
in	0
the	0
absence	0
of	0
TAR	3
.	0

Deletion	0
mapping	0
and	0
hybrid	1
promoter	2
constructs	2
demonstrate	0
that	0
the	0
newly	0
identified	0
Tat-responsive	1
element	2
corresponds	0
to	0
a	0
sequence	0
within	0
the	0
viral	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
previously	0
identified	0
as	0
the	0
HIV-1	1
enhancer	2
,	0
or	0
NF-kappa	1
B	2
domain	2
.	0

DNA	0
band-shift	0
analysis	0
reveals	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
glial	0
cells	0
that	0
differs	0
from	0
that	0
present	0
in	0
T	7
lymphoid	8
cells	8
.	0

Further	0
,	0
we	0
observe	0
that	0
TAR-deleted	1
mutants	2
of	0
HIV-1	0
demonstrate	0
normal	0
late	0
gene	0
expression	0
in	0
glial	7
cells	8
as	0
evidenced	0
by	0
syncytia	0
formation	0
and	0
production	0
of	0
viral	9
p24	10
antigen	10
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Transcription	9
factor	10
AP-2	10
activates	0
gene	0
expression	0
of	0
HTLV-I	0
.	0

The	0
HTLV-I	1
LTR	2
contains	0
three	0
conserved	0
regulatory	1
elements	2
known	0
as	0
21	1
base	2
pair	2
repeats	2
which	0
are	0
required	0
for	0
stimulation	0
of	0
gene	0
expression	0
by	0
the	0
transactivator	9
protein	10
tax	9
.	0

Mutagenesis	0
indicates	0
that	0
the	0
21	1
bp	2
repeats	2
can	0
be	0
subdivided	0
into	0
three	0
motifs	0
,	0
A	0
,	0
B	0
and	0
C	0
,	0
each	0
of	0
which	0
influences	0
the	0
level	0
of	0
tax	9
activation	0
.	0

The	0
A	1
site	2
in	0
the	0
21	1
bp	2
repeat	2
has	0
strong	0
homology	0
with	0
previously	0
described	0
binding	1
sites	2
for	0
the	0
transcription	9
factor	10
AP-2	10
.	0

We	0
demonstrated	0
that	0
AP-2	3
mRNA	4
was	0
present	0
in	0
T-lymphocytes	7
and	0
that	0
cellular	0
factors	0
from	0
both	0
non-transformed	0
and	0
transformed	0
T-lymphocytes	7
specifically	0
bound	0
to	0
the	0
consensus	1
motif	2
for	0
AP-2	9
in	0
each	0
21	0
bp	0
.	0

To	0
determine	0
the	0
role	0
of	0
AP-2	9
in	0
the	0
regulation	0
of	0
the	0
HTLV-I	1
LTR	2
gene	0
expression	0
,	0
we	0
used	0
an	0
AP-2	1
cDNA	2
in	0
DNA	0
binding	0
and	0
transient	0
expression	0
assays	0
.	0

Gel	0
retardation	0
and	0
methylation	0
interference	0
studies	0
revealed	0
that	0
bacterially	9
produced	10
AP-2	10
bound	0
specifically	0
and	0
with	0
high	0
affinity	0
to	0
all	0
three	0
21	1
bp	2
repeats	2
,	0
and	0
that	0
it	0
required	0
the	0
core	1
sequence	2
AGGC	0
for	0
specific	0
binding	0
.	0

Binding	0
of	0
AP-2	9
prevented	0
the	0
subsequent	0
binding	0
of	0
members	0
of	0
the	0
CREB/ATF	9
family	10
to	0
an	0
adjacent	1
regulatory	2
motif	2
in	0
the	0
21	1
bp	2
repeat	2
.	0

Transfection	0
of	0
an	0
AP-2	1
expression	2
construct	2
into	0
T-lymphocytes	7
activated	0
gene	0
expression	0
from	0
the	0
HTLV-I	1
LTR	2
.	0

At	0
least	0
two	0
21	1
bp	2
repeats	2
were	0
required	0
for	0
high	0
levels	0
of	0
AP-2	9
activation	0
and	0
mutagenesis	0
of	0
the	0
AP-2	1
consensus	2
binding	2
sequences	2
in	0
the	0
21	1
bp	2
repeats	2
eliminate	0
this	0
activation	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Activation	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
enhancer	2
is	0
not	0
dependent	0
on	0
NFAT-1	9
.	0

The	0
function	0
of	0
a	0
putative	1
NFAT-1	2
site	2
in	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
enhancer	2
has	0
been	0
analyzed	0
.	0

Activation	0
by	0
the	0
T-cell	9
antigen	10
receptor	10
is	0
minimal	0
in	0
Jurkat	5
cells	6
and	0
is	0
mediated	0
by	0
the	0
kappa	1
B	2
sites	2
.	0

The	0
putative	1
NFAT-1	2
region	2
is	0
not	0
required	0
for	0
the	0
response	0
to	0
anti-CD3	9
or	0
to	0
mitogens	9
in	0
T-cell	5
,	0
B-cell	5
,	0
or	0
monocyte/macrophage	5
leukemia	6
lines	6
,	0
nor	0
is	0
it	0
a	0
cis-acting	1
negative	2
regulatory	2
element	2
.	0

The	0
B	9
cell-specific	10
nuclear	10
factor	10
OTF-2	9
positively	0
regulates	0
transcription	0
of	0
the	0
human	1
class	2
II	2
transplantation	2
gene	2
,	0
DRA	1
.	0

The	0
promoter	0
of	0
the	0
major	1
histocompatibility	2
class	2
II	2
gene	2
DRA	1
contains	0
an	0
octamer	1
element	2
(	0
ATTTGCAT	0
)	0
that	0
is	0
required	0
for	0
efficient	0
DRA	1
expression	0
in	0
B	7
cells	8
.	0

Several	0
DNA-binding	9
proteins	10
are	0
known	0
to	0
bind	0
this	0
sequence	0
.	0

The	0
best	0
characterized	0
are	0
the	0
B	9
cell-specific	10
OTF-2	10
and	0
the	0
ubiquitous	0
OTF-1	9
.	0

This	0
report	0
directly	0
demonstrates	0
that	0
OTF-2	9
but	0
not	0
OTF-1	9
regulates	0
the	0
DRA	1
gene	2
.	0

In	0
vitro	0
transcription	0
analysis	0
using	0
protein	0
fractions	0
enriched	0
for	0
the	0
octamer-binding	0
protein	0
OTF-2	9
demonstrate	0
a	0
positive	0
functional	0
role	0
for	0
OTF-2	9
in	0
DRA	1
gene	2
transcription	0
.	0

In	0
contrast	0
,	0
OTF-1	9
-enriched	0
protein	0
fractions	0
did	0
not	0
affect	0
DRA	1
gene	2
transcription	0
although	0
it	0
functionally	0
enhanced	0
the	0
transcription	0
of	0
another	0
gene	0
.	0

Recombinant	9
OTF-2	10
protein	10
produced	0
by	0
in	0
vitro	0
transcription/translation	0
could	0
also	0
enhance	0
DRA	1
gene	2
transcription	0
in	0
vitro	0
.	0

In	0
vivo	0
transient	0
transfection	0
studies	0
utilizing	0
an	0
OTF-2	1
expression	2
vector	2
resulted	0
in	0
similar	0
findings	0
:	0
that	0
OTF-2	9
protein	10
enhanced	0
DRA	1
gene	2
transcription	0
,	0
and	0
that	0
this	0
effect	0
requires	0
an	0
intact	0
octamer	1
element	2
.	0

Together	0
these	0
results	0
constitute	0
the	0
first	0
direct	0
evidence	0
of	0
a	0
positive	0
role	0
for	0
the	0
lymphoid-specific	9
octamer-binding	10
factor	10
in	0
DRA	0
gene	0
transcription	0
.	0

Interferon-gamma	9
potentiates	0
the	0
antiviral	0
activity	0
and	0
the	0
expression	0
of	0
interferon-stimulated	1
genes	2
induced	0
by	0
interferon-alpha	5
in	6
U937	6
cells	6
.	0

Binding	0
of	0
type	9
I	10
interferon	10
(	10
IFN-alpha/beta	10
)	10
to	10
specific	10
receptors	10
results	0
in	0
the	0
rapid	0
transcriptional	0
activation	0
,	0
independent	0
of	0
protein	0
synthesis	0
,	0
of	0
IFN-alpha-stimulated	1
genes	2
(	0
ISGs	1
)	0
in	0
human	7
fibroblasts	8
and	0
HeLa	5
and	0
Daudi	5
cell	6
lines	6
.	0

The	0
binding	0
of	0
ISGF3	9
(	0
IFN-stimulated	9
gene	10
factor	10
3	10
)	0
to	0
the	0
conserved	0
IFN-stimulated	1
response	2
element	2
(	0
ISRE	1
)	0
results	0
in	0
transcriptional	0
activation	0
.	0

This	0
factor	0
is	0
composed	0
of	0
a	0
DNA-binding	9
protein	10
(	0
ISGF3	9
gamma	10
)	0
,	0
which	0
normally	0
is	0
present	0
in	0
the	0
cytoplasm	0
,	0
and	0
other	0
IFN-alpha-activated	9
proteins	10
which	0
preexist	0
as	0
latent	9
cytoplasmic	10
precursors	10
(	0
ISGF3	9
alpha	10
)	0
.	0

We	0
have	0
found	0
that	0
ISG	0
expression	0
in	0
the	0
monocytic	5
U937	6
cell	6
line	6
differs	0
from	0
most	0
cell	5
lines	6
previously	0
examined	0
.	0

U937	5
cells	6
express	0
both	0
type	9
I	10
and	10
type	10
II	10
IFN	10
receptors	10
,	0
but	0
only	0
IFN-alpha	9
is	0
capable	0
of	0
inducing	0
antiviral	0
protection	0
in	0
these	0
cells	0
.	0

Pretreatment	0
with	0
IFN-gamma	9
potentiates	0
the	0
IFN-alpha	9
-induced	0
protection	0
,	0
but	0
IFN-gamma	9
alone	0
does	0
not	0
have	0
any	0
antiviral	0
activity	0
.	0

ISG15	3
mRNA	4
accumulation	0
in	0
U937	5
cells	6
is	0
not	0
detectable	0
before	0
6	0
h	0
of	0
IFN-alpha	9
treatment	0
,	0
peaks	0
at	0
24	0
h	0
,	0
and	0
requires	0
protein	0
synthesis	0
.	0

Although	0
IFN-gamma	9
alone	0
does	0
not	0
induce	0
ISG	0
expression	0
,	0
IFN-gamma	9
pretreatment	0
markedly	0
increases	0
and	0
hastens	0
ISG	0
expression	0
and	0
transcriptional	0
induction	0
.	0

Nuclear	0
extracts	0
assayed	0
for	0
the	0
presence	0
of	0
ISRE	9
binding	10
factors	10
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
show	0
that	0
ISGF3	9
is	0
induced	0
by	0
IFN-alpha	9
within	0
6	0
h	0
from	0
undetectable	0
basal	0
levels	0
in	0
untreated	0
U937	5
cells	6
.	0

Activation	0
of	0
ISGF3	9
alpha	10
,	0
the	0
latent	0
component	0
of	0
ISGF3	9
,	0
occurs	0
rapidly	0
.	0

However	0
,	0
the	0
increase	0
in	0
ISGF3	9
activity	0
ultimately	0
correlates	0
with	0
the	0
accumulation	0
of	0
ISGF3	9
gamma	10
induced	0
by	0
IFN-alpha	9
or	0
IFN-gamma	9
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Single	0
point	0
estimation	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
of	0
normal	0
subjects	0
and	0
of	0
children	0
under	0
long	0
term	0
glucocorticoid	0
treatment	0
.	0

A	0
single	0
point	0
assay	0
of	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
human	0
lymphocytes	7
based	0
on	0
the	0
measurement	0
of	0
specific	0
dexamethasone	0
binding	0
has	0
been	0
developed	0
and	0
compared	0
with	0
a	0
common	0
multi-point	0
Scatchard	0
analysis	0
.	0

The	0
assay	0
conditions-concentration	0
of	0
the	0
ligand	0
20	0
nmol/l	0
,	0
incubation	0
time	0
2	0
h	0
and	0
the	0
cell	0
count	0
2-6	0
mil	0
.	0

cells/tube	0
in	0
the	0
assay	0
volume	0
0.25	0
ml	0
were	0
found	0
to	0
be	0
optimal	0
.	0

An	0
attempt	0
was	0
also	0
undertaken	0
to	0
use	0
a	0
cell	0
harvester	0
for	0
the	0
separation	0
of	0
cells	0
from	0
unbound	0
ligand	0
.	0

Though	0
specifically	0
bound	0
dexamethasone	0
measured	0
by	0
whole-cell	0
assay	0
and	0
that	0
using	0
cell	0
harvester	0
correlated	0
well	0
,	0
almost	0
by	0
one	0
order	0
lower	0
values	0
obtained	0
with	0
the	0
latter	0
method	0
render	0
it	0
non-applicable	0
for	0
receptor	0
quantitation	0
.	0

The	0
results	0
from	0
9	0
healthy	0
volunteers	0
(	0
average	0
GR	9
concentration	0
7131	0
+/-	0
1256	0
sites/cell	0
)	0
correlated	0
excellently	0
with	0
those	0
obtained	0
by	0
the	0
Scatchard	0
analysis	0
.	0

The	0
single	0
point	0
assay	0
has	0
been	0
also	0
applied	0
for	0
determination	0
of	0
GH	0
in	0
10	0
children	0
treated	0
with	0
large	0
doses	0
of	0
prednisone	0
.	0

The	0
average	0
values	0
from	0
healthy	0
volunteers	0
did	0
not	0
differ	0
significantly	0
from	0
those	0
found	0
in	0
these	0
children	0
,	0
though	0
much	0
broader	0
range	0
was	0
found	0
in	0
patients	0
.	0

Glucocorticoid	9
receptor	10
and	0
inhibition	0
of	0
3-O-methyl-D-glucose	0
uptake	0
by	0
glucocorticoids	0
in	0
peripheral	7
blood	8
leukocytes	8
from	0
normal	0
humans	0
:	0
correlation	0
between	0
receptor	0
level	0
and	0
hormone	0
effect	0
in	0
vitro	0
.	0

We	0
have	0
measured	0
the	0
glucocorticoid	9
receptor	10
concentration	0
in	0
mononuclear	7
and	0
polymorphonuclear	7
leukocytes	8
,	0
both	0
of	0
which	0
were	0
isolated	0
from	0
peripheral	0
blood	0
from	0
ten	0
healthy	0
male	0
volunteers	0
.	0

In	0
parallel	0
,	0
the	0
inhibitory	0
effect	0
of	0
dexamethasone	0
on	0
3-O-methyl-D-glucose	0
uptake	0
was	0
assayed	0
in	0
the	0
corresponding	0
mononuclear	7
leukocytes	8
.	0

The	0
glucocorticoid	9
receptor	10
levels	0
in	0
mononuclear	7
leukocytes	8
correlated	0
with	0
those	0
in	0
polymorphonuclear	7
leukocytes	8
,	0
and	0
there	0
was	0
a	0
linear	0
relationship	0
between	0
the	0
cellular	0
glucocorticoid	9
receptor	10
levels	0
and	0
glucocorticoid-mediated	0
inhibition	0
of	0
the	0
uptake	0
of	0
3-O-methyl-D-glucose	0
in	0
mononuclear	7
leukocytes	8
.	0

When	0
mononuclear	7
leukocytes	8
were	0
incubated	0
in	0
the	0
presence	0
of	0
8-bromo-cAMP	0
,	0
cellular	0
glucocorticoid	9
receptor	10
levels	0
increased	0
and	0
a	0
more	0
pronounced	0
inhibitory	0
effect	0
of	0
dexamethasone	0
was	0
observed	0
on	0
the	0
transport	0
of	0
3-O-methyl-D-glucose	0
.	0

We	0
conclude	0
that	0
the	0
cellular	0
glucocorticoid	9
receptor	10
levels	0
in	0
peripheral	7
blood	8
leukocytes	8
reflect	0
in	0
vitro	0
responsiveness	0
to	0
glucocorticoids	0
in	0
mononuclear	7
leukocytes	8
from	0
healthy	0
males	0
,	0
and	0
that	0
the	0
individual	0
responsiveness	0
may	0
alter	0
upon	0
changes	0
in	0
the	0
cellular	0
levels	0
of	0
glucocorticoid	9
receptor	10
.	0

Transcription	9
factor	10
activation	0
and	0
functional	0
stimulation	0
of	0
human	7
monocytes	8
.	0

Activation	0
of	0
expression	0
of	0
genes	1
encoding	0
transcription	9
factors	10
:	0
c-fos	1
and	0
c-jun	1
and	0
formation	0
of	0
AP1	9
transcriptional	10
complex	10
in	0
human	7
monocytes	8
was	0
investigated	0
.	0

It	0
was	0
found	0
that	0
lipopolysaccharide	0
induced	0
strongly	0
both	0
c-fos	1
and	0
c-jun	1
expression	0
as	0
well	0
as	0
AP1	9
formation	0
.	0

Interferon	9
gamma	10
activated	0
strongly	0
c-fos	1
and	0
weakly	0
c-jun	1
and	0
AP1	9
.	0

Tumor	9
necrosis	10
factor	10
induced	0
slightly	0
c-fos	1
and	0
had	0
almost	0
no	0
effect	0
on	0
c-jun	1
and	0
AP1	9
.	0

The	0
data	0
suggest	0
that	0
differences	0
in	0
functional	0
responses	0
elicited	0
in	0
monocytes	7
by	0
all	0
three	0
factors	9
may	0
be	0
dependent	0
on	0
different	0
routes	0
on	0
nuclear	0
signalling	0
employed	0
by	0
the	0
factors	9
.	0

Regulation	0
of	0
interleukin-1	9
beta	10
production	0
by	0
glucocorticoids	0
in	0
human	7
monocytes	8
:	0
the	0
mechanism	0
of	0
action	0
depends	0
on	0
the	0
activation	0
signal	0
.	0

Glucocorticoids	0
are	0
known	0
to	0
downregulate	0
interleukin-1	9
beta	10
production	0
in	0
monocytic	7
cells	8
by	0
two	0
different	0
mechanims	0
:	0
direct	0
inhibition	0
of	0
the	0
gene	0
transcription	0
and	0
destabilization	0
of	0
the	0
preformed	0
interleukin-1	3
beta	4
mRNA	4
.	0

Now	0
we	0
have	0
examined	0
the	0
effect	0
of	0
the	0
nature	0
of	0
the	0
monocyte	0
activating	0
signal	0
on	0
these	0
two	0
inhibitory	0
mechanims	0
.	0

When	0
human	7
monocytes	8
were	0
preincubated	0
with	0
dexamethasone	0
for	0
1	0
hour	0
and	0
then	0
stimulated	0
either	0
with	0
bacterial	0
lipopolysaccharide	0
or	0
phorbol	0
myristate	0
,	0
it	0
was	0
found	0
that	0
dexamethasone	0
inhibited	0
the	0
lipopolysaccharide-induced	0
interleukin-1	9
beta	10
protein	0
production	0
,	0
but	0
the	0
phorbol	0
myristate-induced	0
production	0
was	0
increased	0
3-10	0
fold	0
.	0

This	0
difference	0
was	0
also	0
seen	0
at	0
the	0
mRNA	0
level	0
.	0

When	0
dexamethasone	0
was	0
added	0
to	0
the	0
cultures	0
3	0
hours	0
after	0
the	0
stimulators	0
,	0
it	0
clearly	0
decreased	0
the	0
interleukin-1	3
beta	4
mRNA	4
levels	0
regardless	0
of	0
the	0
stimulator	0
used	0
(	0
although	0
the	0
effect	0
was	0
clearly	0
weaker	0
on	0
the	0
PMA-induced	3
mRNA	4
)	0
.	0

Thus	0
these	0
data	0
suggest	0
that	0
the	0
phorbol	0
myristate-induced	0
signal	0
(	0
prolonged	0
protein	9
kinase	10
C	10
activation	0
?	0
)	0
can	0
not	0
be	0
inhibited	0
by	0
prior	0
incubation	0
with	0
dexamethasone	0
and	0
it	0
also	0
protects	0
the	0
induced	3
mRNA	4
for	0
the	0
degradative	0
action	0
of	0
dexamethasone	0
.	0

Nuclear	9
transcription	10
factors	10
that	0
bind	0
to	0
elements	0
of	0
the	0
IL-2	1
promoter	2
.	0

Induction	0
requirements	0
in	0
primary	7
human	8
T	8
cells	8
.	0

Prior	0
studies	0
have	0
identified	0
several	0
elements	0
that	0
contribute	0
to	0
the	0
activity	0
of	0
the	0
IL-2	1
promoter	2
in	0
the	0
stimulated	0
T	5
cell	6
line	6
,	0
Jurkat	5
.	0

The	0
sites	0
and	0
their	0
corresponding	0
nuclear	0
binding	0
factors	0
include	0
:	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
AP-3	9
,	0
OCT-1	9
,	0
and	0
NF-AT	9
.	0

The	0
latter	0
``	0
nuclear	9
factor	10
for	10
activated	10
T	10
cells	10
``	0
likely	0
contributes	0
to	0
the	0
tissue	0
specificity	0
of	0
IL-2	1
gene	2
expression	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
we	0
have	0
studied	0
these	0
transcription	9
factors	10
in	0
primary	7
T	8
cells	8
from	0
human	0
blood	0
to	0
verify	0
their	0
presence	0
in	0
a	0
physiologic	0
setting	0
and	0
to	0
identify	0
the	0
signals	0
that	0
stimulate	0
factor	0
activity	0
.	0

All	0
factors	0
are	0
induced	0
in	0
the	0
nuclei	0
of	0
T	7
cells	8
upon	0
activation	0
with	0
mitogens	9
but	0
not	0
with	0
exogenous	9
IL-2	10
growth	10
factor	10
.	0

However	0
,	0
the	0
signaling	0
requirements	0
and	0
sensitivity	0
to	0
protein	0
synthesis	0
inhibitors	0
differ	0
considerably	0
.	0

Only	0
the	0
activities	0
for	0
NF-AT	1
and	2
AP-1	2
sites	2
require	0
two	0
signals	0
for	0
optimal	0
induction	0
,	0
i.e.	0
,	0
PMA	0
plus	0
either	0
lectin	9
or	0
antibody	9
to	0
the	0
CD3	9
or	0
CD28	9
surface	10
molecules	10
.	0

Other	0
factors	0
are	0
induced	0
by	0
lectin	9
,	0
antibody	9
,	0
and/or	0
PMA	0
alone	0
.	0

After	0
appropriate	0
stimulation	0
,	0
both	0
NF-AT	9
and	0
AP-1	9
are	0
peculiarly	0
sensitive	0
to	0
the	0
protein	0
synthesis	0
inhibitor	0
anisomycin	0
.	0

Our	0
data	0
correlate	0
the	0
activity	0
of	0
NF-AT	9
and	0
AP-1	9
in	0
gel	0
shift	0
assays	0
with	0
the	0
two	0
signals	0
requirements	0
for	0
IL-2	1
gene	2
expression	0
.	0

NF-kappa	9
B	10
activity	0
in	0
T	7
cells	8
stably	0
expressing	0
the	0
Tax	9
protein	10
of	0
human	0
T	0
cell	0
lymphotropic	0
virus	0
type	0
I	0
.	0

The	0
effect	0
of	0
constitutive	0
Tax	9
expression	0
on	0
the	0
interaction	0
of	0
NF-kappa	9
B	10
with	0
its	0
recognition	1
sequence	2
and	0
on	0
NF-kappa	9
B	10
-dependent	0
gene	0
expression	0
was	0
examined	0
in	0
T	5
lymphoid	6
Jurkat	6
cell	6
lines	6
(	0
19D	5
and	0
9J	5
)	0
stably	0
transformed	0
with	0
a	0
Tax	1
expression	2
vector	2
.	0

Tax	5
expressing	6
T	6
cell	6
lines	6
contained	0
a	0
constitutive	0
level	0
of	0
NF-kappa	9
B	10
binding	0
activity	0
,	0
detectable	0
by	0
mobility	0
shift	0
assay	0
and	0
uv	0
cross-linking	0
using	0
a	0
palindromic	1
NF-kappa	2
B	2
probe	2
homologous	0
to	0
the	0
interferon	1
beta	2
PRDII	2
site	2
.	0

In	0
Jurkat	0
and	0
NC2.10	0
induction	0
with	0
phorbol	0
esters	0
resulted	0
in	0
the	0
appearance	0
of	0
new	0
DNA	9
binding	10
proteins	10
of	0
85	9
,	10
75	10
,	10
and	10
54	10
kDa	10
,	0
whereas	0
in	0
Tax	5
expressing	6
cells	6
the	0
85-kDa	9
protein	10
and	0
a	0
92-kDa	9
DNA	10
binding	10
protein	10
were	0
constitutively	0
induced	0
.	0

Expression	0
of	0
Tax	9
protein	10
in	0
19D	5
and	0
9J	5
resulted	0
in	0
transcription	0
of	0
the	0
endogenous	1
NF-kappa	2
B-dependent	2
granulocyte-macrophage	2
colony	2
stimulating	2
factor	2
gene	2
and	0
increased	0
basal	0
level	0
expression	0
of	0
transfected	0
NF-kappa	1
B-regulated	2
promoters	2
.	0

Nonetheless	0
transcription	0
of	0
both	0
the	0
endogenous	0
and	0
the	0
transfected	0
gene	0
was	0
inducible	0
by	0
PMA	0
treatment	0
.	0

Tax	9
expression	0
in	0
Jurkat	5
T	6
cells	6
may	0
alter	0
the	0
stoichiometry	0
of	0
NF-kappa	9
B	10
DNA	9
binding	10
proteins	10
and	0
thus	0
change	0
the	0
expression	0
of	0
NF-kappa	1
B-regulated	2
promoters	2
.	0

A	0
nuclear	9
factor	10
NF-GM2	9
that	0
interacts	0
with	0
a	0
regulatory	1
region	2
of	0
the	0
GM-CSF	1
gene	2
essential	0
for	0
its	0
induction	0
in	0
responses	0
to	0
T-cell	0
activation	0
:	0
purification	0
from	0
human	0
T-cell	5
leukemia	6
line	6
Jurkat	6
cells	6
and	0
similarity	0
to	0
NF-kappa	9
B	10
.	0

Activation	0
of	0
T	7
cells	8
by	0
antigen	0
,	0
lectin	9
,	0
or	0
a	0
combination	0
of	0
phorbol-12-myristate	0
acetate	0
(	0
PMA	0
)	0
and	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
leads	0
to	0
the	0
induction	0
of	0
genes	0
for	0
a	0
set	0
of	0
lymphokines	9
,	0
including	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
.	0

We	0
demonstrated	0
in	0
earlier	0
studies	0
that	0
the	0
upstream	1
region	2
of	0
the	0
mouse	1
GM-CSF	2
promoter	2
at	0
positions	0
between	0
-95	1
and	2
-73	2
is	0
essential	0
for	0
transcriptional	0
activation	0
in	0
response	0
to	0
PMA/A23187	0
.	0

This	0
region	0
contains	0
two	0
DNA-binding	1
motifs	2
,	0
GM2	1
and	0
GC-box	1
.	0

The	0
GM2	1
sequence	2
(	0
GGTAGTTCCC	0
)	0
is	0
recognized	0
by	0
an	0
inducible	9
factor	10
NF-GM2	10
;	0
the	0
other	0
(	0
CCGCCC	0
)	0
by	0
constitutive	9
factors	10
A1	9
,	0
A2	9
,	0
and	0
B	9
.	0

To	0
elucidate	0
the	0
mechanism	0
of	0
GM-CSF	9
gene	0
activation	0
,	0
we	0
have	0
purified	0
the	0
inducible	9
factor	10
NF-GM2	10
from	0
the	0
nuclear	0
extract	0
of	0
stimulated	0
Jurkat	5
cells	6
on	0
the	0
basis	0
of	0
specific	0
DNA-binding	0
activity	0
.	0

The	0
purified	0
NF-GM2	9
consists	0
of	0
50	0
(	0
p50	9
)	0
and	0
65	0
kDa	0
(	0
p65	9
)	0
polypeptides	0
and	0
has	0
a	0
binding	0
activity	0
specific	0
for	0
both	0
the	0
GM-CSF	9
and	0
immunoglobulin	1
kappa	2
(	2
GGAAAGTCCC	2
)	2
enhancers	2
.	0

Electrophoretically	0
purified	0
p50	9
alone	0
can	0
form	0
a	0
protein-DNA	9
complex	10
,	0
but	0
in	0
the	0
mixture	0
,	0
p50	9
associates	0
preferentially	0
with	0
p65	9
to	0
form	0
the	0
NF-GM2	9
complex	10
.	0

In	0
addition	0
,	0
p65	9
gave	0
per	0
se	0
,	0
with	0
low	0
affinity	0
,	0
a	0
protein-DNA	9
complex	10
that	0
migrated	0
more	0
slowly	0
than	0
native	0
NF-GM2	9
complex	10
.	0

Furthermore	0
,	0
an	0
antiserum	0
against	0
KBF1	9
(	0
identical	0
to	0
50	9
kDa	10
NF-kappa	10
B	10
protein	10
)	0
reacted	0
with	0
the	0
p50	9
of	0
NF-GM2	9
,	0
indicating	0
that	0
the	0
NF-GM2	9
polypeptide	10
can	0
not	0
be	0
immunologically	0
differentiated	0
from	0
the	0
50	9
kDa	10
subunit	10
of	0
NF-kappa	9
B	10
.	0

The	0
purified	0
NF-GM2	9
activated	0
in	0
vitro	0
transcription	0
from	0
the	0
kappa	1
B	2
enhancer	2
,	0
while	0
it	0
failed	0
to	0
stimulate	0
transcription	0
from	0
the	0
GM-CSF	1
promoter	2
harboring	0
the	0
GM2	0
sequence	0
.	0

This	0
suggests	0
that	0
the	0
activation	0
mechanism	0
of	0
the	0
GM-CSF	1
gene	2
through	0
the	0
GM2/GC-box	1
sequence	2
is	0
different	0
from	0
that	0
of	0
genes	0
carrying	0
the	0
kappa	1
B	2
enhancer	2
alone	0
.	0

Characterization	0
of	0
an	0
immediate-early	1
gene	2
induced	0
in	0
adherent	7
monocytes	8
that	0
encodes	0
I	9
kappa	10
B	10
-like	0
activity	0
.	0

We	0
have	0
cloned	0
a	0
group	0
of	0
cDNAs	1
representing	0
mRNAs	3
that	0
are	0
rapidly	0
induced	0
following	0
adherence	0
of	0
human	7
monocytes	8
.	0

One	0
of	0
the	0
induced	0
transcripts	0
(	0
MAD-3	3
)	0
encodes	0
a	0
protein	0
of	0
317	0
amino	0
acids	0
with	0
one	0
domain	0
containing	0
five	9
tandem	10
repeats	10
of	0
the	0
cdc10/ankyrin	9
motif	10
,	0
which	0
is	0
60	0
%	0
similar	0
(	0
46	0
%	0
identical	0
)	0
to	0
the	0
ankyrin	9
repeat	10
region	10
of	0
the	0
precursor	0
of	0
NF-kappa	9
B/KBF1	10
p50	10
.	0

The	0
C-terminus	9
has	0
a	0
putative	0
protein	9
kinase	10
C	10
phosphorylation	10
site	10
.	0

In	0
vitro	0
translated	0
MAD-3	9
protein	10
was	0
found	0
to	0
specifically	0
inhibit	0
the	0
DNA-binding	0
activity	0
of	0
the	0
p50/p65	9
NF-kappa	10
B	10
complex	10
but	0
not	0
that	0
of	0
the	0
p50/p50	9
KBF1	10
factor	10
or	0
of	0
other	0
DNA-binding	9
proteins	10
.	0

The	0
MAD-3	1
cDNA	2
encodes	0
an	0
I	9
kappa	10
B-like	10
protein	10
that	0
is	0
likely	0
to	0
be	0
involved	0
in	0
regulation	0
of	0
transcriptional	0
responses	0
to	0
NF-kappa	9
B	10
,	0
including	0
adhesion-dependent	0
pathways	0
of	0
monocyte	0
activation	0
.	0

Cortivazol	0
mediated	0
induction	0
of	0
glucocorticoid	3
receptor	4
messenger	4
ribonucleic	4
acid	4
in	0
wild-type	5
and	0
dexamethasone-resistant	5
human	6
leukemic	6
(	6
CEM	6
)	6
cells	6
.	0

Cortivazol	0
is	0
a	0
phenylpyrazolo	0
glucocorticoid	0
of	0
high	0
potency	0
and	0
unusual	0
structure	0
.	0

In	0
both	0
wild-type	5
and	0
highly	0
dexamethasone	5
(	6
dex	6
)	6
-resistant	6
clones	6
of	0
the	0
human	5
leukemic	6
cell	6
line	6
CEM	6
,	0
exposure	0
to	0
cortivazol	0
leads	0
to	0
cell	0
death	0
.	0

It	0
has	0
been	0
shown	0
recently	0
that	0
in	0
wild-type	5
CEM	6
cells	6
but	0
not	0
in	0
a	0
dex-resistant	5
,	6
glucocorticoid	6
receptor	6
(	6
GR	6
)	6
-defective	6
clone	6
ICR-27	5
TK-3	6
,	0
dex	0
induces	0
GR	3
mRNA	4
.	0

To	0
test	0
the	0
hypothesis	0
that	0
cortivazol	0
acts	0
in	0
dex-resistant	5
cells	6
by	0
making	0
use	0
of	0
the	0
residual	0
GR	9
found	0
there	0
,	0
wild-type	0
and	0
dex-resistant	5
clones	6
were	0
treated	0
with	0
various	0
concentrations	0
of	0
cortivazol	0
and	0
induction	0
of	0
GR	3
mRNA	4
was	0
studied	0
.	0

Cortivazol	0
significantly	0
induced	0
GR	3
mRNA	4
in	0
the	0
normal	5
CEM-C7	6
as	0
well	0
as	0
in	0
two	0
classes	0
of	0
dex-resistant	5
clones	6
,	0
although	0
the	0
dex-resistant	5
clones	6
needed	0
at	0
least	0
10	0
times	0
more	0
cortivazol	0
than	0
the	0
normal	7
cells	8
for	0
significant	0
GR	3
mRNA	4
induction	0
.	0

Increased	0
levels	0
of	0
GR	3
mRNA	4
were	0
noticed	0
as	0
early	0
as	0
3	0
h	0
after	0
treatment	0
.	0

A	0
general	0
correlation	0
between	0
induction	0
of	0
GR	3
mRNA	4
and	0
lysis	0
of	0
the	0
normal	0
and	0
dex-resistant	5
cells	6
was	0
found	0
.	0

Positive	0
induction	0
of	0
GR	3
mRNA	4
might	0
be	0
one	0
of	0
the	0
earliest	0
crucial	0
steps	0
in	0
the	0
lysis	0
of	0
normal	5
and	6
dex-resistant	6
CEM	6
cells	6
,	0
or	0
might	0
serve	0
as	0
a	0
marker	0
for	0
the	0
process	0
.	0

However	0
,	0
the	0
lysis	0
pathway	0
in	0
the	0
dex-resistant	5
cells	6
is	0
defective	0
in	0
that	0
dex-resistant	5
clones	6
needed	0
significantly	0
more	0
cortivazol	0
than	0
the	0
normal	5
cells	6
for	0
lysis	0
of	0
the	0
cells	0
.	0

HIV	1
enhancer	2
activity	0
perpetuated	0
by	0
NF-kappa	9
B	10
induction	0
on	0
infection	0
of	0
monocytes	7
[	0
see	0
comments	0
]	0

Permissiveness	0
to	0
replication	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
differs	0
in	0
T	7
lymphocytes	8
and	0
macrophages	7
.	0

In	0
T	7
cells	8
,	0
HIV	0
transcription	0
is	0
poorly	0
detected	0
in	0
vivo	0
.	0

Cloned	0
,	0
normal	0
T	7
lymphocytes	8
show	0
very	0
little	0
,	0
if	0
any	0
,	0
basal	0
activity	0
of	0
the	0
HIV	1
enhancer	2
and	0
low	0
nuclear	0
expression	0
of	0
NF-kappa	9
B	10
,	0
a	0
potent	9
transcriptional	10
activator	10
of	0
the	0
HIV	1
enhancer	2
.	0

In	0
contrast	0
,	0
fixed	0
tissue	0
macrophages	7
express	0
detectable	0
HIV	9
proteins	10
,	0
indicating	0
permanent	0
virus	0
transcription	0
.	0

One	0
explanation	0
for	0
the	0
perpetuation	0
of	0
virus	0
infection	0
in	0
macrophages	7
could	0
be	0
sustained	0
nuclear	0
NF-kappa	9
B	10
expression	0
.	0

However	0
,	0
the	0
U937	5
monocytic	6
cell	6
line	6
,	0
which	0
is	0
fully	0
permissive	0
to	0
HIV	0
replication	0
,	0
is	0
known	0
to	0
express	0
only	0
low	0
levels	0
of	0
nuclear	9
NF-kappa	10
B	10
.	0

We	0
show	0
here	0
that	0
chronic	0
HIV	0
infection	0
results	0
in	0
both	0
induction	0
of	0
a	0
nuclear	9
factor	10
with	0
antigenic	0
properties	0
indistinguishable	0
from	0
those	0
of	0
NF-kappa	9
B	10
and	0
permanently	0
increased	0
HIV	1
enhancer	2
activity	0
.	0

This	0
phenomenon	0
,	0
which	0
is	0
independent	0
of	0
tumour	9
necrosis	10
factor	10
,	0
is	0
associated	0
with	0
HIV	0
replication	0
,	0
and	0
is	0
thus	0
likely	0
to	0
explain	0
at	0
least	0
in	0
part	0
the	0
perpetuation	0
of	0
HIV	0
infection	0
in	0
monocytes	7
.	0

Isolation	0
of	0
a	0
rel-related	1
human	2
cDNA	2
that	0
potentially	0
encodes	0
the	0
65-kD	9
subunit	10
of	0
NF-kappa	9
B	10
[	0
published	0
erratum	0
appears	0
in	0
Science	0
1991	0
Oct	0
4	0
;	0
254	0
(	0
5028	0
)	0
:	0
11	0
]	0

A	0
DNA	1
probe	2
that	0
spanned	0
a	0
domain	0
conserved	0
among	0
the	0
proto-oncogene	1
c-rel	2
,	0
the	0
Drosophila	9
morphogen	10
dorsal	10
,	0
and	0
the	0
p50	9
DNA	10
binding	10
subunit	10
of	0
NF-kappa	9
B	10
was	0
generated	0
from	0
Jurkat	1
T	2
cell	2
complementary	2
DNA	2
with	0
the	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
and	0
degenerate	0
oligonucleotides	0
.	0

This	0
probe	0
was	0
used	0
to	0
identify	0
a	0
rel-related	1
complementary	2
DNA	2
that	0
hybridized	0
to	0
a	0
2.6-kilobase	3
messenger	4
RNA	4
present	0
in	0
human	7
T	8
and	8
B	8
lymphocytes	8
.	0

In	0
vitro	0
transcription	0
and	0
translation	0
of	0
the	0
complementary	1
DNA	2
resulted	0
in	0
the	0
synthesis	0
of	0
a	0
protein	0
with	0
an	0
apparent	0
molecular	0
size	0
of	0
65	9
kilodaltons	10
(	0
kD	0
)	0
.	0

The	0
translated	0
protein	0
showed	0
weak	0
DNA	0
binding	0
with	0
a	0
specificity	0
for	0
the	0
kappa	0
B	0
binding	0
motif	0
.	0

This	0
protein-DNA	9
complex	10
comigrated	0
with	0
the	0
complex	0
obtained	0
with	0
the	0
purified	9
human	10
p65	10
NF-kappa	10
B	10
subunit	10
and	0
binding	0
was	0
inhibited	0
by	0
I	9
kappa	10
B-alpha	10
and	0
-beta	0
proteins	0
.	0

In	0
addition	0
,	0
the	0
65-kD	9
protein	10
associated	0
with	0
the	0
p50	9
subunit	10
of	0
NF-kappa	9
B	10
and	0
the	0
kappa	1
B	2
probe	2
to	0
form	0
a	0
complex	0
with	0
the	0
same	0
electrophoretic	0
mobility	0
as	0
the	0
NF-kappa	9
B-DNA	10
complex	10
.	0

Therefore	0
the	0
rel-related	9
65-kD	10
protein	10
may	0
represent	0
the	0
p65	9
subunit	10
of	0
the	0
active	9
NF-kappa	10
B	10
transcription	10
factor	10
complex	10
.	0

The	0
human	5
myelomonocytic	6
cell	6
line	6
U-937	6
as	0
a	0
model	0
for	0
studying	0
alterations	0
in	0
steroid-induced	0
monokine	0
gene	0
expression	0
:	0
marked	0
enhancement	0
of	0
lipopolysaccharide-stimulated	3
interleukin-1	4
beta	4
messenger	4
RNA	4
levels	0
by	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
.	0

The	0
active	0
metabolite	0
of	0
vitamin	0
D	0
,	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
[	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
]	0
,	0
is	0
a	0
potent	0
regulator	0
of	0
human	0
monocyte/macrophage	0
function	0
in	0
vitro	0
.	0

To	0
establish	0
a	0
model	0
for	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
regulation	0
of	0
human	0
monocyte	0
monokine	0
synthesis	0
,	0
three	0
human	5
cell	6
lines	6
(	0
U-937	5
,	0
THP-1	5
,	0
and	0
HL-60	5
)	0
were	0
examined	0
for	0
:	0
1	0
)	0
the	0
presence	0
of	0
functional	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
receptors	0
;	0
2	0
)	0
the	0
accumulation	0
of	0
interleukin-1	3
beta	4
(	4
IL-1	4
beta	4
)	4
mRNA	4
and	0
IL-1	9
beta	10
protein	10
in	0
response	0
to	0
lipopolysaccharide	0
(	0
LPS	0
)	0
;	0
and	0
3	0
)	0
the	0
regulation	0
of	0
this	0
response	0
by	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
.	0

All	0
three	0
cell	0
lines	0
expressed	0
vitamin	0
D	0
receptor	0
and	0
had	0
increased	0
levels	0
of	0
IL-1	3
beta	4
mRNA	4
in	0
response	0
to	0
LPS	0
.	0

Preincubation	0
of	0
cells	0
with	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
augmented	0
IL-1	3
beta	4
mRNA	4
levels	0
only	0
in	0
U-937	5
and	0
HL-60	5
cells	0
.	0

From	0
these	0
data	0
,	0
and	0
taking	0
into	0
consideration	0
their	0
state	0
of	0
differentiation	0
and	0
relative	0
ease	0
of	0
culture	0
,	0
U-937	5
was	0
chosen	0
over	0
HL-60	5
and	0
THP-1	5
as	0
the	0
cell	0
line	0
we	0
further	0
characterized	0
.	0

In	0
U-937	5
cells	6
,	0
optimum	0
time	0
and	0
dose	0
of	0
pretreatment	0
with	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
were	0
determined	0
to	0
be	0
12-24	0
h	0
at	0
a	0
receptor	0
saturating	0
concentration	0
of	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
(	0
10	0
nM	0
)	0
.	0

Preincubation	0
of	0
cells	0
with	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
had	0
no	0
effect	0
on	0
the	0
time	0
course	0
of	0
IL-1	3
beta	4
mRNA	4
appearance	0
in	0
response	0
to	0
LPS	0
.	0

However	0
,	0
exposure	0
of	0
U-937	5
cells	6
to	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
increased	0
by	0
200	0
%	0
the	0
level	0
of	0
IL-1	3
beta	4
mRNA	4
detected	0
and	0
decreased	0
by	0
three	0
orders	0
of	0
magnitude	0
the	0
concentration	0
of	0
LPS	0
required	0
to	0
achieve	0
steady	0
state	0
mRNA	0
levels	0
equivalent	0
to	0
those	0
observed	0
in	0
U-937	5
cells	6
not	0
preincubated	0
with	0
the	0
hormone.2+o	0

Regulation	0
of	0
M-CSF	9
expression	0
by	0
M-CSF	9
:	0
role	0
of	0
protein	9
kinase	10
C	10
and	0
transcription	9
factor	10
NF	10
kappa	10
B	10
.	0

Macrophage-colony-stimulating	9
factor	10
(	0
M-CSF	9
)	0
,	0
also	0
referred	0
to	0
as	0
CSF-1	9
,	0
regulates	0
the	0
survival	0
,	0
growth	0
,	0
differentiation	0
and	0
functional	0
activity	0
of	0
monocytes	7
by	0
binding	0
to	0
a	0
single	0
class	0
of	0
high-affinity	9
cell	10
surface	10
receptors	10
,	0
known	0
to	0
be	0
the	0
product	0
of	0
the	0
c-fms	1
protooncogene	2
.	0

The	0
detection	0
of	0
both	0
M-CSF	0
and	0
c-fms	0
expression	0
by	0
cells	0
of	0
the	0
monocyte	7
lineage	8
has	0
suggested	0
that	0
M-CSF	9
may	0
act	0
by	0
an	0
autocrine	0
mechanism	0
.	0

Interestingly	0
,	0
it	0
has	0
been	0
shown	0
that	0
M-CSF	9
can	0
induce	0
the	0
expression	0
of	0
its	0
own	0
gene	0
.	0

Although	0
sensitivity	0
to	0
M-CSF	9
can	0
be	0
modulated	0
by	0
regulation	0
of	0
receptor	0
expression	0
and	0
function	0
,	0
M-CSF	9
responsiveness	0
is	0
largely	0
determined	0
at	0
a	0
postreceptor	0
level	0
.	0

To	0
date	0
,	0
little	0
is	0
known	0
about	0
the	0
intracellular	0
pathway	0
of	0
M-CSF	9
signal	0
transduction	0
.	0

We	0
have	0
therefore	0
investigated	0
the	0
changes	0
in	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
activity	0
upon	0
exposure	0
of	0
monocytes	7
to	0
M-CSF	9
.	0

We	0
show	0
that	0
M-CSF	9
activates	0
and	0
translocates	0
PKC	9
.	0

Inhibition	0
of	0
PKC	9
by	0
the	0
isoquinoline	0
derivative	0
H7	0
abolishes	0
induction	0
of	0
M-CSF	9
by	0
M-CSF	9
.	0

Furthermore	0
,	0
activation	0
of	0
PKC	9
was	0
pertussis-toxin-sensitive	0
and	0
was	0
associated	0
with	0
the	0
detection	0
of	0
an	0
NF	9
kappa	10
B	10
protein	10
in	0
nuclear	0
extracts	0
of	0
M-CSF-induced	5
blood	6
monocytes	6
but	0
not	0
in	0
monocytes	7
exposed	0
to	0
medium	0
treatment	0
only	0
.	0

The	0
results	0
suggest	0
that	0
M-CSF	9
induction	0
of	0
M-CSF	9
involves	0
G	9
proteins	10
,	0
PKC	9
and	0
NF	9
kappa	10
B	10
.	0

Clone	1
pAT	2
133	2
identifies	0
a	0
gene	0
that	0
encodes	0
another	0
human	0
member	0
of	0
a	0
class	0
of	0
growth	1
factor-induced	2
genes	2
with	0
almost	0
identical	0
zinc-finger	9
domains	10
.	0

We	0
report	0
the	0
structure	0
and	0
regulation	0
of	0
a	0
gene	0
represented	0
by	0
clone	1
pAT	2
133	2
,	0
which	0
is	0
induced	0
upon	0
transition	0
from	0
a	0
resting	0
state	0
(	0
G0	0
)	0
through	0
the	0
early	0
phase	0
of	0
the	0
cell	0
cycle	0
(	0
G1	0
)	0
.	0

The	0
pAT	1
133	2
gene	2
is	0
immediately	0
induced	0
,	0
with	0
FOS	9
-like	0
kinetics	0
,	0
in	0
human	7
T	8
cells	8
and	0
in	0
fibroblasts	7
.	0

Primary	0
structure	0
analysis	0
showed	0
that	0
the	0
encoded	0
protein	0
contains	0
three	0
tandem	9
zinc-finger	10
sequences	10
of	0
the	0
type	0
Cys2-Xaa12-His2	9
.	0

This	0
zinc-finger	9
region	10
,	0
which	0
is	0
thought	0
to	0
bind	0
DNA	0
in	0
a	0
sequence-specific	0
manner	0
,	0
is	0
similar	0
(	0
greater	0
than	0
80	0
%	0
on	0
the	0
amino	0
acid	0
level	0
)	0
to	0
two	0
previously	0
described	0
transcription	9
factors	10
pAT	9
225/EGR1	10
and	0
pAT	0
591/EGR2	9
.	0

Except	0
for	0
the	0
conserved	0
zinc-finger	9
domains	10
,	0
the	0
amino	9
acid	10
sequences	10
of	0
the	0
three	0
proteins	0
are	0
distinct	0
.	0

This	0
structural	0
similarity	0
suggests	0
that	0
the	0
pAT	1
133	2
gene	2
encodes	0
a	0
transcription	9
factor	10
with	0
a	0
specific	0
biological	0
function	0
.	0

Comparing	0
the	0
regulation	0
of	0
these	0
related	0
zinc-finger-encoding	1
genes	2
showed	0
coordinate	0
induction	0
upon	0
mitogenic	0
stimulation	0
of	0
resting	7
T	8
lymphocytes	8
and	0
of	0
resting	7
fibroblasts	8
.	0

However	0
,	0
upon	0
transition	0
from	0
a	0
proliferating	0
(	0
G1	0
)	0
to	0
a	0
resting	0
state	0
of	0
the	0
cell	0
cycle	0
the	0
three	0
genes	0
were	0
differently	0
regulated	0
.	0

In	0
human	3
histiocytic	4
U937	4
cells	4
mRNA	4
of	0
clone	0
pAT	0
133	0
was	0
constitutively	0
expressed	0
,	0
whereas	0
mRNA	3
of	0
pAT	9
225/EGR1	10
was	0
induced	0
upon	0
induction	0
of	0
terminal	0
differentiation	0
.	0

In	0
contrast	0
mRNA	0
representing	0
pAT	0
591/EGR2	9
was	0
not	0
expressed	0
in	0
these	0
cells	0
.	0

This	0
difference	0
in	0
gene	0
regulation	0
suggests	0
distinct	0
biological	0
roles	0
in	0
the	0
control	0
of	0
cell	0
proliferation	0
for	0
the	0
respective	0
proteins	0
.	0

v-erbA	9
overexpression	0
is	0
required	0
to	0
extinguish	0
c-erbA	9
function	0
in	0
erythroid	7
cell	8
differentiation	0
and	0
regulation	0
of	0
the	0
erbA	1
target	2
gene	2
CAII	1
.	0

The	0
v-erbA	9
oncoprotein	10
represents	0
a	0
retrovirus-transduced	0
oncogenic	0
version	0
of	0
the	0
thyroid	9
hormone	10
(	10
T3/T4	10
)	10
receptor	10
c-erbA	9
(	10
type	10
alpha	10
)	10
.	0

It	0
contributes	0
to	0
virus-induced	0
erythroleukemia	0
by	0
efficiently	0
arresting	0
differentiation	0
of	0
red	7
cell	8
progenitors	8
and	0
by	0
suppressing	0
transcription	0
of	0
erythrocyte-specific	1
genes	2
.	0

Here	0
,	0
we	0
show	0
that	0
v-erbA	9
and	0
c-erbA	9
bind	0
directly	0
to	0
sequences	0
within	0
the	0
promoter	1
of	0
the	0
erythrocyte-specific	9
carbonic	10
anhydrase	10
II	10
(	0
CAII	1
)	0
,	0
a	0
gene	0
whose	0
transcription	0
is	0
efficiently	0
suppressed	0
by	0
v-erbA	9
.	0

This	0
erbA-binding	1
site	2
confers	0
thyroid	0
hormone	0
responsiveness	0
to	0
a	0
heterologous	1
promoter	2
in	0
transient	0
expression	0
experiments	0
and	0
is	0
a	0
target	0
for	0
efficient	0
down-regulation	0
of	0
CAII	1
transcription	0
by	0
the	0
v-erbA	9
oncoprotein	10
.	0

In	0
stably	5
transformed	6
erythroblasts	6
coexpressing	0
the	0
v-erbA	9
oncoprotein	10
and	0
the	0
c-erbA/T3	9
receptor	10
at	0
an	0
approximately	0
equimolar	0
ratio	0
,	0
c-erbA	9
activity	0
is	0
dominant	0
over	0
v-erbA	9
.	0

T3	0
efficiently	0
induced	0
erythroid	0
differentiation	0
in	0
these	0
cells	0
,	0
thus	0
overcoming	0
the	0
v-erbA	9
-mediated	0
differentiation	0
arrest	0
.	0

Likewise	0
,	0
T3	0
activated	0
CAII	1
transcription	0
as	0
well	0
as	0
transient	0
expression	0
of	0
a	0
T3-responsive	1
reporter	2
gene	2
containing	0
the	0
CAII-specific	1
erbA-binding	2
site	2
.	0

The	0
c-erbA	9
-dependent	0
activation	0
of	0
this	0
CAII	1
reporter	2
construct	2
could	0
only	0
be	0
suppressed	0
by	0
very	0
high	0
amounts	0
of	0
v-erbA	9
.	0

Our	0
results	0
suggest	0
that	0
overexpression	0
of	0
v-erbA	9
is	0
required	0
for	0
its	0
function	0
as	0
an	0
oncoprotein	9
.	0

Anti-CD2	9
receptor	10
antibodies	10
activate	0
the	0
HIV	1
long	2
terminal	2
repeat	2
in	0
T	7
lymphocytes	8
.	0

The	0
CD2	9
T	10
lymphocyte	10
glycoprotein	10
surface	10
molecule	10
mediates	0
both	0
cell	0
to	0
cell	0
adhesion	0
and	0
T	0
cell	0
activation	0
,	0
two	0
processes	0
that	0
are	0
involved	0
in	0
the	0
spread	0
of	0
HIV	0
infection	0
.	0

Treatment	0
of	0
chronically	5
HIV-infected	6
PBMC	6
with	0
anti-CD2	9
mAb	10
has	0
been	0
shown	0
to	0
induce	0
the	0
expression	0
of	0
infectious	0
virus	0
from	0
these	0
cultures	0
.	0

In	0
this	0
study	0
we	0
investigated	0
the	0
mechanisms	0
whereby	0
anti-CD2	9
antibodies	10
stimulate	0
viral	0
production	0
.	0

We	0
demonstrate	0
that	0
treatment	0
of	0
transiently	0
transfected	0
T	7
lymphocytes	8
with	0
anti-CD2	9
antibodies	10
results	0
in	0
activation	0
of	0
the	0
HIV	1
long	2
terminal	2
repeat	2
.	0

Furthermore	0
,	0
CAT	9
assays	0
using	0
mutated	0
HIV	1
long	2
terminal	2
repeat-CAT	2
constructs	2
and	0
gel	0
shift	0
assays	0
demonstrate	0
that	0
this	0
activation	0
is	0
dependent	0
on	0
the	0
NF-kappa	1
B	2
enhancer	2
.	0

These	0
studies	0
suggest	0
that	0
interaction	0
of	0
CD2	9
with	0
its	0
natural	0
ligand	0
,	0
LFA-3	9
,	0
may	0
play	0
a	0
role	0
in	0
regulation	0
of	0
HIV	0
expression	0
.	0

Reactive	0
oxygen	0
intermediates	0
as	0
apparently	0
widely	0
used	0
messengers	0
in	0
the	0
activation	0
of	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
and	0
HIV-1	0
.	0

Hydrogen	0
peroxide	0
and	0
oxygen	0
radicals	0
are	0
agents	0
commonly	0
produced	0
during	0
inflammatory	0
processes	0
.	0

In	0
this	0
study	0
,	0
we	0
show	0
that	0
micromolar	0
concentrations	0
of	0
H2O2	0
can	0
induce	0
the	0
expression	0
and	0
replication	0
of	0
HIV-1	0
in	0
a	0
human	5
T	6
cell	6
line	6
.	0

The	0
effect	0
is	0
mediated	0
by	0
the	0
NF-kappa	9
B	10
transcription	9
factor	10
which	0
is	0
potently	0
and	0
rapidly	0
activated	0
by	0
an	0
H2O2	0
treatment	0
of	0
cells	0
from	0
its	0
inactive	9
cytoplasmic	10
form	10
.	0

N-acetyl-L-cysteine	0
(	0
NAC	0
)	0
,	0
a	0
well	0
characterized	0
antioxidant	0
which	0
counteracts	0
the	0
effects	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROI	0
)	0
in	0
living	0
cells	0
,	0
prevented	0
the	0
activation	0
of	0
NF-kappa	9
B	10
by	0
H2O2	0
.	0

NAC	0
and	0
other	0
thiol	0
compounds	0
also	0
blocked	0
the	0
activation	0
of	0
NF-kappa	9
B	10
by	0
cycloheximide	0
,	0
double-stranded	3
RNA	4
,	0
calcium	0
ionophore	0
,	0
TNF-alpha	9
,	0
active	0
phorbol	0
ester	0
,	0
interleukin-1	9
,	0
lipopolysaccharide	0
and	0
lectin	9
.	0

This	0
suggests	0
that	0
diverse	0
agents	0
thought	0
to	0
activate	0
NF-kappa	9
B	10
by	0
distinct	0
intracellular	0
pathways	0
might	0
all	0
act	0
through	0
a	0
common	0
mechanism	0
involving	0
the	0
synthesis	0
of	0
ROI	0
.	0

ROI	0
appear	0
to	0
serve	0
as	0
messengers	0
mediating	0
directly	0
or	0
indirectly	0
the	0
release	0
of	0
the	0
inhibitory	9
subunit	10
I	9
kappa	10
B	10
from	0
NF-kappa	9
B	10
.	0

Inhibition	0
of	0
transcription	9
factors	10
belonging	0
to	0
the	0
rel/NF-kappa	9
B	10
family	10
by	0
a	0
transdominant	9
negative	10
mutant	10
.	0

The	0
KBF1	9
factor	10
,	0
which	0
binds	0
to	0
the	0
enhancer	1
A	2
located	0
in	0
the	0
promoter	1
of	0
the	0
mouse	1
MHC	2
class	2
I	2
gene	2
H-2Kb	1
,	0
is	0
indistinguishable	0
from	0
the	0
p50	9
DNA	10
binding	10
subunit	10
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
,	0
which	0
regulates	0
a	0
series	0
of	0
genes	0
involved	0
in	0
immune	0
and	0
inflammatory	0
responses	0
.	0

The	0
KBF1/p50	9
factor	10
binds	0
as	0
a	0
homodimer	9
but	0
can	0
also	0
form	0
heterodimers	9
with	0
the	0
products	0
of	0
other	0
members	0
of	0
the	0
same	0
family	0
,	0
like	0
the	0
c-rel	1
and	2
v-rel	2
(	2
proto	2
)	2
oncogenes	2
.	0

The	0
dimerization	9
domain	10
of	0
KBF1/p50	9
is	0
contained	0
between	9
amino	10
acids	10
201	10
and	10
367	10
.	0

A	0
mutant	0
of	0
KBF1/p50	9
(	0
delta	9
SP	10
)	0
,	0
unable	0
to	0
bind	0
to	0
DNA	0
but	0
able	0
to	0
form	0
homo-	0
or	0
heterodimers	9
,	0
has	0
been	0
constructed	0
.	0

This	0
protein	0
reduces	0
or	0
abolishes	0
in	0
vitro	0
the	0
DNA	0
binding	0
activity	0
of	0
wild-type	9
proteins	10
of	0
the	0
same	0
family	0
(	0
KBF1/p50	9
,	0
c-	9
and	10
v-rel	10
)	0
.	0

This	0
mutant	0
also	0
functions	0
in	0
vivo	0
as	0
a	0
trans-acting	9
dominant	10
negative	10
regulator	10
:	0
the	0
transcriptional	0
inducibility	0
of	0
the	0
HIV	1
long	2
terminal	2
repeat	2
(	0
which	0
contains	0
two	0
potential	0
NF-kappa	9
B	10
binding	0
sites	0
)	0
by	0
phorbol	0
ester	0
(	0
PMA	0
)	0
is	0
inhibited	0
when	0
it	0
is	0
co-transfected	0
into	0
CD4+	5
T	6
cells	6
with	0
the	0
delta	9
SP	10
mutant	0
.	0

Similarly	0
the	0
basal	0
as	0
well	0
as	0
TNF	9
or	0
IL1-induced	0
activity	0
of	0
the	0
MHC	1
class	2
I	2
H-2Kb	2
promoter	2
can	0
be	0
inhibited	0
by	0
this	0
mutant	0
in	0
two	0
different	0
cell	5
lines	6
.	0

These	0
results	0
constitute	0
the	0
first	0
formal	0
demonstration	0
that	0
these	0
genes	0
are	0
regulated	0
by	0
members	0
of	0
the	0
rel/NF-kappa	9
B	10
family	10
.	0

Tissue-specific	0
expression	0
of	0
the	0
platelet	1
GPIIb	2
gene	2
.	0

One	0
of	0
the	0
major	0
objectives	0
in	0
the	0
study	0
of	0
thrombogenesis	0
is	0
to	0
determine	0
the	0
mechanisms	0
by	0
which	0
a	0
hematopoietic	7
progenitor	8
is	0
activated	0
and	0
committed	0
to	0
the	0
megakaryocytic	7
lineage	8
.	0

Recent	0
development	0
of	0
primary	5
cultures	6
of	0
human	5
megakaryocytes	6
and	0
the	0
molecular	0
cloning	0
of	0
genes	0
that	0
are	0
specific	0
to	0
this	0
lineage	0
offer	0
the	0
possibility	0
of	0
getting	0
some	0
insights	0
into	0
the	0
genetic	0
mechanisms	0
that	0
control	0
megakaryocytopoiesis	0
.	0

One	0
gene	0
of	0
interest	0
is	0
the	0
glycoprotein	1
IIb	2
(	2
GPIIb	2
)	2
gene	2
;	0
GPIIb	1
,	0
the	0
alpha	9
subunit	10
of	0
the	0
platelet	9
cytoadhesin	10
GPIIb-IIIa	10
,	0
is	0
produced	0
in	0
megakaryocytes	5
at	0
an	0
early	0
stage	0
of	0
the	0
differentiation	0
,	0
whereas	0
the	0
other	0
subunit	0
of	0
this	0
complex	0
,	0
GPIIIa	9
,	0
is	0
expressed	0
in	0
other	0
cells	0
.	0

For	0
these	0
reasons	0
,	0
the	0
5'-flanking	1
region	2
of	0
the	0
GPIIb	1
gene	2
was	0
used	0
to	0
identify	0
the	0
regions	0
that	0
interact	0
with	0
DNA-binding	9
nuclear	10
factors	10
.	0

A	0
fragment	0
extending	0
from	0
-643	1
to	2
+33	2
is	0
capable	0
of	0
controlling	0
the	0
tissue-specific	0
expression	0
of	0
the	0
CAT	1
gene	2
in	0
transfection	0
experiments	0
.	0

Within	0
this	0
region	0
,	0
we	0
have	0
identified	0
several	0
sequences	0
that	0
are	0
implicated	0
in	0
DNA	0
protein	0
interactions	0
as	0
shown	0
in	0
DNAse	9
I	10
footprints	0
and	0
gel	0
mobility	0
shift	0
assays	0
.	0

One	0
region	0
,	0
centered	0
at	0
-54	0
,	0
is	0
similar	0
to	0
a	0
nuclear	1
factor	2
E1-binding	2
site	2
,	0
and	0
a	0
region	0
located	0
at	0
position	0
-233	0
contains	0
a	0
CCAAT	1
motif	2
.	0

Two	0
domains	0
centered	0
at	0
positions	0
-345	0
and	0
-540	0
,	0
respectively	0
,	0
bind	0
proteins	0
that	0
are	0
present	0
in	0
megakaryocytic	5
cells	6
and	0
nonrelated	7
cells	8
as	0
well	0
.	0

Finally	0
,	0
two	0
other	0
domains	0
,	0
located	0
at	0
positions	0
-460	0
and	0
-510	0
,	0
interact	0
with	0
proteins	0
that	0
are	0
only	0
present	0
in	0
megakaryocytic	5
cells	6
.	0

In	0
addition	0
,	0
deletion	0
of	0
the	0
region	0
containing	0
these	0
two	0
domains	0
results	0
in	0
a	0
significant	0
decrease	0
of	0
the	0
promoter	1
activity	0
.	0

It	0
is	0
very	0
likely	0
that	0
these	0
domains	0
bind	0
megakaryocyte-specific	9
nuclear	10
proteins	10
acting	0
as	0
positive	9
transcription	10
factors	10
.	0

Lymphocyte	0
glucocorticoid	9
receptor	10
binding	0
during	0
depression	0
and	0
after	0
clinical	0
recovery	0
.	0

Lymphocyte	9
glucocorticoid	10
receptor	10
binding	0
parameters	0
were	0
studied	0
in	0
15	0
severely	0
depressed	0
patients	0
during	0
depression	0
and	0
after	0
clinical	0
recovery	0
,	0
and	0
in	0
15	0
healthy	0
controls	0
.	0

There	0
was	0
no	0
difference	0
in	0
glucocorticoid	9
receptor	10
number	0
or	0
affinity	0
between	0
depressed	0
patients	0
and	0
recovered	0
or	0
control	0
subjects	0
.	0

Afternoon	0
ACTH	0
and	0
cortisol	0
concentrations	0
did	0
not	0
differ	0
significantly	0
between	0
the	0
three	0
groups	0
.	0

No	0
relationship	0
could	0
be	0
established	0
between	0
glucocorticoid	9
receptor	10
binding	0
and	0
antidepressant	0
medication	0
.	0

These	0
data	0
support	0
the	0
view	0
of	0
an	0
impaired	0
ligand-induced	0
plasticity	0
of	0
glucocorticoid	9
receptor	10
regulation	0
rather	0
than	0
the	0
hypothesis	0
of	0
decreased	0
glucocorticoid	9
receptor	10
numbers	0
during	0
depression	0
.	0

Every	0
enhancer	0
works	0
with	0
every	0
promoter	1
for	0
all	0
the	0
combinations	0
tested	0
:	0
could	0
new	0
regulatory	0
pathways	0
evolve	0
by	0
enhancer	0
shuffling	0
?	0

The	0
promoters	1
and	0
enhancers	1
of	0
cell	0
type-specific	0
genes	0
are	0
often	0
conserved	0
in	0
evolution	0
,	0
and	0
hence	0
one	0
might	0
expect	0
that	0
a	0
given	0
enhancer	1
has	0
evolved	0
to	0
work	0
best	0
with	0
its	0
own	0
promoter	1
.	0

While	0
this	0
expectation	0
may	0
be	0
realized	0
in	0
some	0
cases	0
,	0
we	0
have	0
not	0
found	0
evidence	0
for	0
it	0
.	0

A	0
total	0
of	0
27	0
combinations	0
of	0
different	0
promoters	1
and	0
enhancers	1
were	0
tested	0
by	0
transfection	0
into	0
cultured	5
cells	6
.	0

We	0
found	0
that	0
the	0
relative	0
efficiency	0
of	0
the	0
enhancers	1
is	0
approximately	0
the	0
same	0
,	0
irrespective	0
of	0
the	0
type	0
of	0
promoter	1
used	0
,	0
i.e.	0
,	0
there	0
was	0
no	0
strong	0
preference	0
for	0
any	0
given	0
enhancer/	0
promoter	1
combination	0
.	0

Notably	0
,	0
we	0
do	0
not	0
see	0
particularly	0
strong	0
transcription	0
when	0
the	0
immunoglobulin	1
kappa	2
enhancer	2
(	0
or	0
the	0
immunoglobulin	1
heavy	2
chain	2
enhancer	2
)	0
is	0
used	0
to	0
activate	0
a	0
kappa	0
gene	0
promoter	1
.	0

We	0
propose	0
that	0
a	0
generally	0
permissive	0
enhancer/	0
promoter	1
interaction	0
is	0
of	0
evolutionary	0
benefit	0
for	0
higher	0
eukaryotes	0
:	0
by	0
enhancer	0
shuffling	0
,	0
genes	0
could	0
be	0
easily	0
brought	0
under	0
a	0
new	0
type	0
of	0
inducibility/cell	0
type	0
specificity	0
.	0

Towards	0
a	0
molecular	0
understanding	0
of	0
T-cell	0
differentiation	0
.	0

Lymphoid	0
differentiation	0
is	0
one	0
of	0
the	0
best	0
studied	0
examples	0
of	0
mammalian	0
development	0
.	0

Here	0
Hans	0
Clevers	0
and	0
Michael	0
Owen	0
describe	0
how	0
the	0
cloning	0
of	0
the	0
genes	0
that	0
encode	0
T-cell-specific	9
membrane	10
proteins	10
allows	0
the	0
identification	0
of	0
transcription	9
factors	10
that	0
control	0
the	0
expression	0
of	0
these	0
T-cell	1
genes	2
.	0

Such	0
transcription	9
factors	10
play	0
a	0
key	0
role	0
in	0
the	0
development	0
of	0
the	0
mature	0
T-cell	0
phenotype	0
by	0
functioning	0
as	0
'master	0
regulators	0
of	0
T-cell	0
differentiation'	0
.	0

A	0
study	0
on	0
the	0
circadian	0
rhythm	0
of	0
glucocorticoid	9
receptor	10
.	0

Circadian	0
rhythm	0
in	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
was	0
studied	0
in	0
the	0
rat	7
liver	8
and	0
human	7
peripheral	8
leukocytes	8
.	0

For	0
rats	0
exposed	0
to	0
a	0
natural	0
environmental	0
photic	0
cycle	0
or	0
a	0
12L	0
:	0
12D	0
artificial	0
light	0
regime	0
,	0
peak	0
values	0
of	0
hepatic	9
GR	10
were	0
detected	0
between	0
23	0
:	0
00	0
and	0
02	0
:	0
00	0
h	0
.	0

Except	0
for	0
a	0
4-hour	0
advancement	0
of	0
the	0
peak	0
,	0
a	0
similar	0
circadian	0
rhythm	0
of	0
hepatic	9
GR	10
was	0
detected	0
in	0
rats	0
reared	0
under	0
a	0
reversed	0
lighting	0
regimen	0
(	0
12D	0
:	0
12L	0
;	0
lights	0
on	0
between	0
18	0
:	0
30	0
and	0
06	0
:	0
30	0
h	0
)	0
.	0

In	0
human	7
leukocytes	8
,	0
the	0
peak	0
value	0
of	0
GR	9
was	0
found	0
to	0
parallel	0
that	0
of	0
plasma	0
cortisol	0
with	0
high	0
and	0
low	0
values	0
detected	0
at	0
04	0
:	0
00-08	0
:	0
00	0
h	0
and	0
23	0
:	0
00-24	0
:	0
00	0
h	0
,	0
respectively	0
.	0

In	0
patients	0
suffering	0
from	0
Cushing	0
's	0
syndrome	0
,	0
the	0
circadian	0
rhythm	0
of	0
plasma	0
cortisol	0
either	0
disappeared	0
or	0
was	0
inverted	0
while	0
that	0
of	0
GR	9
did	0
not	0
significantly	0
deviate	0
from	0
the	0
normal	0
subjects	0
.	0

For	0
apoplexic	0
patients	0
with	0
lesions	0
localized	0
to	0
the	0
base	0
of	0
the	0
brain	0
as	0
indicated	0
by	0
computerized	0
tomography	0
,	0
the	0
diurnal	0
variation	0
of	0
GR	9
was	0
abolished	0
.	0

Conversely	0
,	0
diurnal	0
rhythmicity	0
persisted	0
in	0
apoplexy	0
patients	0
whose	0
lesions	0
were	0
in	0
the	0
cerebral	0
cortex	0
.	0

Thus	0
,	0
we	0
postulated	0
that	0
the	0
circadian	0
modification	0
of	0
GR	9
was	0
independent	0
of	0
the	0
diurnal	0
fluctuations	0
in	0
plasma	0
cortisol	0
level	0
or	0
the	0
circadian	0
variations	0
in	0
environmental	0
lighting	0
and	0
that	0
the	0
rhythmicity	0
might	0
be	0
regulated	0
by	0
the	0
'circadian	0
pacemaker	0
'	0
located	0
in	0
the	0
human	0
basal	0
brain	0
.	0

These	0
diurnal	0
variations	0
in	0
GR	9
might	0
serve	0
to	0
coordinate	0
the	0
reactivity	0
of	0
the	0
target	7
cells	8
to	0
cortisol	0
because	0
the	0
diurnal	0
rhythms	0
of	0
a	0
GR	9
-mediated	0
response	0
,	0
the	0
fractional	0
inhibition	0
of	0
chemotactic	0
migration	0
rate	0
of	0
polymorphonuclear	7
leukocytes	8
by	0
cortisol	0
,	0
were	0
found	0
to	0
be	0
synchronous	0
with	0
those	0
of	0
GR	9
.	0

Transcription	9
factor	10
requirements	0
for	0
U2	3
snRNA	4
-encoding	0
gene	0
activation	0
in	0
B	7
lymphoid	8
cells	8
.	0

Transcription	0
of	0
a	0
human	0
U2	1
small	2
nuclear	2
RNA	2
(	2
snRNA	2
)	2
-encoding	2
gene	2
in	0
HeLa	5
cells	6
requires	0
a	0
distal	1
enhancer	2
element	2
,	0
which	0
is	0
composed	0
of	0
one	0
octamer	1
motif	2
(	0
Oct	1
)	0
and	0
three	0
Sp	1
1-binding	2
sites	2
.	0

To	0
study	0
the	0
transcription	9
factor	10
requirement	0
in	0
B-cells	7
,	0
different	0
U2	1
enhancer	2
constructions	2
were	0
transfected	0
into	0
the	0
lymphoid	5
cell	6
line	6
,	0
BJA-B	5
.	0

The	0
results	0
showed	0
that	0
the	0
activation	0
of	0
U2	0
snRNA	0
transcription	0
in	0
B-cells	7
also	0
requires	0
an	0
enhancer	0
comprising	0
both	0
the	0
Oct	1
and	0
at	0
least	0
one	0
Sp	1
1-binding	2
site	2
.	0

Deletion	0
of	0
all	0
the	0
Sp	1
1-binding	2
sites	2
from	0
the	0
enhancer	1
reduces	0
transcription	0
by	0
80-90	0
%	0
in	0
HeLa	0
,	0
as	0
well	0
as	0
in	0
BJA-B	5
cells	6
,	0
whereas	0
the	0
removal	0
of	0
the	0
octamer-binding	1
site	2
reduces	0
transcription	0
to	0
levels	0
below	0
detection	0
in	0
both	0
cell	0
types	0
.	0

Enhancers	0
containing	0
a	0
single	0
Oct	1
have	0
,	0
nevertheless	0
,	0
the	0
capacity	0
to	0
partially	0
activate	0
U2	3
snRNA	4
transcription	0
in	0
both	0
HeLa	5
cells	6
,	0
in	0
which	0
only	0
OTF-1	0
is	0
expressed	0
,	0
and	0
in	0
BJA-B	5
cells	6
in	0
which	0
OTF-2	9
is	0
the	0
predominantly	0
expressed	0
octamer-binding	9
factor	10
.	0

The	0
most	0
likely	0
interpretation	0
of	0
our	0
results	0
is	0
that	0
both	0
the	0
ubiquitous	0
transcription	9
factor	10
,	0
OTF-1	9
,	0
and	0
the	0
B-cell-specific	9
transcription	10
factor	10
,	0
OTF-2	9
,	0
can	0
activate	0
U2	3
snRNA	4
transcription	0
.	0

The	0
results	0
also	0
revealed	0
a	0
similar	0
functional	0
cooperation	0
between	0
the	0
transcription	0
factors	0
which	0
bind	0
to	0
the	0
Oct	1
and	0
the	0
adjacent	0
Sp	1
1-binding	2
site	2
in	0
BJA-B	5
cells	6
,	0
as	0
has	0
been	0
observed	0
in	0
HeLa	5
cells	6
,	0
since	0
a	0
template	0
which	0
contains	0
a	0
weak	0
binding	0
site	0
for	0
OTFs	1
expresses	0
wild-type	0
levels	0
of	0
U2	3
snRNA	4
in	0
both	0
cell	0
types	0
when	0
the	0
weak	0
octamer-binding	1
site	2
is	0
combined	0
with	0
a	0
Sp	1
1-binding	2
site	2
.	0

One	0
base	0
pair	0
change	0
abolishes	0
the	0
T	0
cell-restricted	0
activity	0
of	0
a	0
kB-like	1
proto-enhancer	2
element	2
from	0
the	0
interleukin	1
2	2
promoter	2
.	0

The	0
inducible	0
,	0
T	1
cell-specific	2
enhancers	2
of	0
murine	1
and	2
human	2
Interleukin	2
2	2
(	2
Il-2	2
)	2
genes	2
contain	0
the	0
kB-like	1
sequence	2
GGGATTTCACC	0
as	0
an	0
essential	1
cis-acting	2
enhancer	2
motif	2
.	0

When	0
cloned	0
in	0
multiple	0
copies	0
this	0
so-called	0
TCEd	1
(	0
distal	1
T	2
cell	2
element	2
)	0
acts	0
as	0
an	0
inducible	0
proto-enhancer	1
element	2
in	0
E14	5
T	6
lymphoma	6
cells	6
,	0
but	0
not	0
in	0
HeLa	5
cells	6
.	0

In	0
extracts	0
of	0
induced	0
,	0
Il-2	5
secreting	6
El4	6
cells	6
three	0
individual	0
protein	9
factors	10
bind	0
to	0
TCEd	1
DNA	2
.	0

The	0
binding	0
of	0
the	0
most	0
prominent	0
factor	0
,	0
named	0
TCF-1	9
(	0
T	9
cell	10
factor	10
1	10
)	0
,	0
is	0
correlated	0
with	0
the	0
proto-enhancer	0
activity	0
of	0
TCEd	0
.	0

TCF-1	9
consists	0
of	0
two	0
polypeptides	0
of	0
about	0
50	0
kD	0
and	0
105	0
kD	0
;	0
the	0
former	0
seems	0
to	0
be	0
related	0
to	0
the	0
50	9
kD	10
polypeptide	10
of	0
NF-kB	9
.	0

Purified	9
NF-kB	10
is	0
also	0
able	0
to	0
bind	0
to	0
the	0
TCEd	1
,	0
but	0
TCF-1	9
binds	0
stronger	0
than	0
NF-kB	9
to	0
TCEd	1
DNA	0
.	0

The	0
conversion	0
of	0
the	0
TCEd	1
to	0
a	0
'perfect	1
'	2
NF-kB	2
binding	2
site	2
leads	0
to	0
a	0
tighter	0
binding	0
of	0
NF-kB	9
to	0
TCEd	1
DNA	2
and	0
,	0
as	0
a	0
functional	0
consequence	0
,	0
to	0
the	0
activity	0
of	0
the	0
'converted	1
'	2
TCEd	2
motifs	2
in	0
HeLa	5
cells	6
.	0

Thus	0
,	0
the	0
substitution	0
of	0
the	0
underlined	0
A	0
residue	0
to	0
a	0
C	0
within	0
the	0
GGGATTTCACC	1
motif	2
abolishes	0
its	0
T	0
cell-restricted	0
activity	0
and	0
leads	0
to	0
its	0
functioning	0
in	0
both	0
El4	5
cells	6
and	0
HeLa	5
cells	6
.	0

These	0
results	0
indicate	0
that	0
lymphocyte-specific	0
factors	0
binding	0
to	0
the	0
TCEd	1
are	0
involved	0
in	0
the	0
control	0
of	0
T	0
cell	0
specific-transcription	0
of	0
the	0
Il-2	1
gene	2
.	0

An	0
erythroid	1
specific	2
enhancer	2
upstream	0
to	0
the	0
gene	0
encoding	0
the	0
cell-type	9
specific	10
transcription	10
factor	10
GATA-1	9
.	0

The	0
transcription	9
factor	10
GATA-1	9
is	0
expressed	0
in	0
a	0
subset	0
of	0
hemopoietic	7
cells	8
,	0
where	0
it	0
mediates	0
the	0
cell-type	0
specific	0
expression	0
of	0
several	0
genes	0
.	0

We	0
have	0
cloned	0
the	0
mouse	0
and	0
human	0
GATA-1	1
genes	2
.	0

A	0
region	0
upstream	0
to	0
the	0
first	0
exon	0
,	0
and	0
highly	0
conserved	0
between	0
mouse	0
and	0
man	0
,	0
acts	0
as	0
an	0
erythroid	0
specific	0
enhancer	0
in	0
transient	0
assays	0
,	0
if	0
linked	0
to	0
the	0
GATA-1	9
or	0
to	0
the	0
SV40	0
promoter	0
.	0

The	0
activity	0
of	0
the	0
enhancer	0
is	0
almost	0
completely	0
dependent	0
on	0
the	0
integrity	0
of	0
a	0
dimeric	1
GATA-1	2
binding	2
site	2
.	0

Demonstration	0
of	0
a	0
1	9
,	10
25-dihydroxyvitamin	10
D3-responsive	10
protein	10
in	0
human	7
lymphocytes	8
:	0
immunologic	0
crossreactivity	0
and	0
inverse	0
regulation	0
with	0
the	0
vitamin	9
D	10
receptor	10
.	0

Using	0
Western	0
blot	0
analysis	0
with	0
a	0
monoclonal	9
antibody	10
recognizing	0
a	0
17-amino	9
acid	10
epitope	10
of	0
the	0
1	9
,	10
25-dihydroxyvitamin	10
D3	10
[	10
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
]	10
receptor	10
,	0
we	0
have	0
detected	0
two	0
crossreacting	9
proteins	10
in	0
activated	7
normal	8
human	8
lymphocytes	8
.	0

The	0
smaller	0
of	0
the	0
two	0
proteins	0
(	0
50	9
kDa	10
)	0
was	0
indistinguishable	0
from	0
the	0
classical	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
and	0
,	0
similar	0
to	0
the	0
classical	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
,	0
was	0
upregulated	0
in	0
a	0
dose-dependent	0
fashion	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

The	0
larger	0
crossreacting	0
protein	0
exhibited	0
an	0
electrophoretic	0
mobility	0
of	0
80	0
kDa	0
,	0
was	0
localized	0
in	0
the	0
cell	0
cytosol	0
,	0
and	0
appeared	0
to	0
be	0
specific	0
for	0
activated	7
lymphocytes	8
since	0
it	0
was	0
not	0
detected	0
in	0
several	0
other	0
human	7
cells	8
including	0
monocytes	7
.	0

More	0
strikingly	0
,	0
the	0
80-kDa	9
protein	10
was	0
downregulated	0
in	0
a	0
dose-dependent	0
fashion	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
;	0
this	0
effect	0
was	0
independent	0
of	0
the	0
mode	0
of	0
lymphocyte	0
activation	0
and	0
specific	0
for	0
the	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
metabolite	0
of	0
vitamin	0
D3	0
.	0

However	0
,	0
two	0
potent	0
immunosuppressive	0
agents	0
,	0
glucocorticoids	0
and	0
cyclosporin	0
A	0
,	0
also	0
inhibited	0
the	0
80-kDa	9
protein	10
.	0

Regulation	0
of	0
glucocorticoid	9
receptors	10
in	0
human	7
mononuclear	8
cells	8
:	0
effects	0
of	0
glucocorticoid	0
treatment	0
,	0
Cushing	0
's	0
disease	0
and	0
ketoconazole	0
.	0

Glucocorticoid	9
receptors	10
(	0
GcR	9
)	0
were	0
determined	0
by	0
a	0
whole	0
cell	0
assay	0
in	0
human	7
mononulear	8
leukocytes	8
(	0
hMNL	7
)	0
from	0
control	0
subjects	0
,	0
patients	0
receiving	0
glucocorticoid	0
therapy	0
for	0
systemic	0
diseases	0
and	0
Cushing	0
's	0
disease	0
patients	0
with	0
or	0
without	0
ketoconazole	0
therapy	0
.	0

Prolonged	0
corticosteroid	0
treatment	0
resulted	0
in	0
down-regulation	0
of	0
GcR	9
,	0
while	0
the	0
mean	0
level	0
of	0
GcR	9
in	0
Cushing	0
's	0
disease	0
was	0
normal	0
.	0

In	0
this	0
group	0
,	0
however	0
,	0
receptor	0
levels	0
and	0
morning	0
plasma	0
cortisol	0
values	0
showed	0
a	0
negative	0
correlation	0
,	0
indicating	0
a	0
subtle	0
down-regulatory	0
effect	0
.	0

Furthermore	0
,	0
GcR	9
were	0
unaltered	0
after	0
these	0
patients	0
received	0
ketoconazole	0
,	0
in	0
spite	0
of	0
a	0
marked	0
reduction	0
in	0
morning	0
plasma	0
cortisol	0
and	0
urinary	0
free	0
cortisol	0
.	0

We	0
also	0
observed	0
that	0
ketoconazole	0
was	0
a	0
weak	0
competitor	0
of	0
GcR	9
in	0
intact	7
cells	8
,	0
although	0
it	0
significantly	0
inhibited	0
[	0
3H	0
]	0
dexamethasone	0
binding	0
in	0
cytosolic	0
preparations	0
from	0
rat	0
tissues	0
.	0

The	0
results	0
suggested	0
that	0
GcR	9
in	0
hMNL	7
are	0
down-regulated	0
by	0
synthetic	0
steroids	0
given	0
in	0
vivo	0
,	0
but	0
they	0
showed	0
very	0
mild	0
down-regulation	0
in	0
hypercortisolemic	0
patients	0
suffering	0
from	0
Cushing	0
's	0
disease	0
.	0

Finally	0
,	0
we	0
did	0
not	0
observed	0
either	0
up-regulation	0
or	0
antagonism	0
of	0
GcR	9
by	0
ketoconazole	0
treatment	0
,	0
at	0
the	0
time	0
that	0
cortisol	0
levels	0
of	0
patients	0
with	0
Cushing	0
's	0
disease	0
were	0
reduced	0
.	0

This	0
indicates	0
that	0
the	0
beneficial	0
effects	0
of	0
ketoconazole	0
in	0
Cushing	0
's	0
disease	0
are	0
due	0
to	0
adrenal	0
cortisol	0
suppression	0
and	0
not	0
to	0
interaction	0
with	0
GcR	9
of	0
target	7
cells	8
,	0
and	0
that	0
the	0
process	0
of	0
GcR	9
regulation	0
in	0
hMNL	7
is	0
a	0
complex	0
phenomenon	0
awaiting	0
further	0
elucidation	0
.	0

HTLV-1	9
Tax	10
induces	0
expression	0
of	0
various	0
immediate	1
early	2
serum	2
responsive	2
genes	2
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
is	0
an	0
etiological	0
agent	0
of	0
adult	0
T-cell	0
leukemia	0
(	0
ATL	0
)	0
.	0

We	0
showed	0
here	0
by	0
mobility-shift	0
assay	0
that	0
T-cell	5
lines	6
transformed	0
with	0
the	0
virus	0
contained	0
high	0
levels	0
of	0
AP-1	9
activities	0
.	0

Consistent	0
with	0
this	0
result	0
,	0
these	0
cell	0
lines	0
expressed	0
increased	0
levels	0
of	0
mRNAs	3
encoding	0
the	0
AP-1	9
proteins	10
,	0
c-Fos	9
,	0
Fra-1	9
,	0
c-Jun	9
,	0
JunB	9
,	0
and	0
JunD	9
.	0

Previously	0
,	0
transcription	0
of	0
the	0
c-fos	1
gene	2
has	0
been	0
reported	0
to	0
be	0
transactivated	0
by	0
the	0
viral	9
transcription	10
factor	10
,	0
Tax1	9
.	0

By	0
using	0
the	0
human	5
T-cell	6
line	6
(	0
JPX-9	5
)	0
,	0
in	0
which	0
expression	0
of	0
the	0
Tax1	9
is	0
inducible	0
,	0
we	0
showed	0
that	0
expression	0
of	0
mRNAs	3
for	0
Fra-1	9
,	0
c-Jun	9
,	0
and	0
JunD	9
was	0
also	0
transactivated	0
by	0
Tax1	9
.	0

Moreover	0
,	0
Tax1	9
activated	0
expression	0
of	0
two	0
other	0
transcription	9
factors	10
having	0
zinc	9
finger	10
motifs	10
,	0
Egr-1	9
and	0
Egr-2	9
,	0
in	0
the	0
same	0
cells	0
.	0

The	0
Tax1-inducible	9
transcription	10
factors	10
identified	0
here	0
are	0
encoded	0
by	0
the	0
members	0
of	0
immediate	1
early	2
genes	2
under	0
the	0
control	0
of	0
growth	0
signals	0
.	0

Thus	0
,	0
Tax1	9
was	0
suggested	0
to	0
replace	0
growth	0
signals	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
this	0
mechanism	0
.	0

Glucocorticoid	9
receptor	10
characteristics	0
in	0
monocytes	7
of	0
patients	0
with	0
corticosteroid-resistant	0
bronchial	0
asthma	0
.	0

The	0
mechanism	0
of	0
corticosteroid	0
resistance	0
in	0
bronchial	0
asthma	0
has	0
been	0
studied	0
by	0
determining	0
the	0
rank	0
order	0
of	0
potency	0
for	0
different	0
corticosteroids	0
in	0
inhibiting	0
the	0
generation	0
of	0
a	0
3	0
kD	0
molecule	0
from	0
peripheral	7
blood	8
monocytes	8
isolated	0
from	0
corticosteroid-sensitive	0
(	0
CS	0
)	0
and	0
corticosteroid-resistant	0
(	0
CR	0
)	0
asthmatic	0
subjects	0
,	0
which	0
augments	0
leukotriene	0
B4	0
(	0
LTB4	9
)	0
generation	0
by	0
human	7
neutrophils	8
(	0
PMN	7
)	0
stimulated	0
by	0
calcium	0
ionophore	0
.	0

In	0
addition	0
,	0
binding	0
studies	0
with	0
(	0
3H	0
)	0
dexamethasone	0
have	0
been	0
performed	0
to	0
determine	0
the	0
dissociation	0
constant	0
(	0
Kd	0
)	0
and	0
receptor	0
numbers	0
(	0
Ro	0
)	0
in	0
the	0
monocytes	7
of	0
these	0
two	0
groups	0
of	0
subjects	0
.	0

The	0
concentration	0
of	0
corticosteroid	0
producing	0
50	0
%	0
inhibition	0
(	0
IC50	0
)	0
was	0
600	0
nM	0
,	0
70	0
nM	0
,	0
and	0
0.5	0
nM	0
for	0
hydrocortisone	0
,	0
methylprednisolone	0
,	0
and	0
dexamethasone	0
,	0
respectively	0
,	0
in	0
monocytes	7
from	0
CS	0
individuals	0
.	0

There	0
was	0
only	0
weak	0
inhibition	0
of	0
the	0
generation	0
of	0
enhancing	0
activity	0
by	0
the	0
corticosteroids	0
in	0
the	0
CR	0
asthmatic	0
individuals	0
.	0

The	0
dexamethasone	0
Kd	0
was	0
2.45	0
+/-	0
0.58	0
nM	0
(	0
mean	0
+/-	0
SEM	0
,	0
n	0
=	0
6	0
)	0
in	0
the	0
CS	0
group	0
and	0
1.6	0
+/-	0
0.35	0
nM	0
(	0
mean	0
+/-	0
SEM	0
,	0
n	0
=	0
6	0
)	0
in	0
the	0
CR	0
group	0
of	0
patients	0
(	0
p	0
=	0
0.14	0
)	0
.	0

The	0
Ro	0
in	0
the	0
CS	0
group	0
was	0
3	0
,	0
605	0
+/-	0
984	0
binding	0
sites	0
per	0
nucleus	0
(	0
mean	0
+/-	0
SEM	0
,	0
n	0
=	0
6	0
)	0
and	0
4	0
,	0
757	0
+/-	0
692	0
binding	0
sites	0
per	0
nucleus	0
(	0
mean	0
+/-	0
SEM	0
,	0
n	0
=	0
6	0
)	0
in	0
the	0
CR	0
group	0
(	0
p	0
=	0
0.23	0
)	0
.	0

These	0
findings	0
indicate	0
that	0
corticosteroid	0
resistance	0
in	0
bronchial	0
asthma	0
can	0
not	0
be	0
explained	0
by	0
abnormalities	0
in	0
corticosteroid	0
receptor	0
characteristics	0
.	0

Vitamin	9
D	10
receptor	10
expression	0
in	0
human	7
lymphocytes	8
.	0

Signal	0
requirements	0
and	0
characterization	0
by	0
western	0
blots	0
and	0
DNA	0
sequencing	0
.	0

The	0
signals	0
controlling	0
the	0
expression	0
of	0
the	0
receptor	9
protein	10
for	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
in	0
normal	0
human	7
lymphocytes	8
and	0
the	0
relationship	0
of	0
this	0
protein	0
to	0
the	0
classical	9
vitamin	10
D	10
receptor	10
were	0
examined	0
.	0

Lymphocytes	7
activated	0
with	0
the	0
OKT3	9
antibody	10
to	0
the	0
T-cell	9
antigen	10
receptor	10
expressed	0
fewer	0
binding	0
sites	0
as	0
compared	0
to	0
lymphocytes	7
that	0
were	0
activated	0
by	0
the	0
polyclonal	0
activator	0
phytohemagglutinin	9
(	0
PHA	9
)	0
.	0

However	0
,	0
combination	0
of	0
OKT3	9
and	0
phorbol	0
myristate	0
acetate	0
produced	0
a	0
concentration	0
of	0
binding	0
sites	0
similar	0
to	0
the	0
PHA-activated	5
cells	6
.	0

The	0
receptor	0
from	0
OKT3	9
and	0
OKT3	9
+	0
phorbol	0
myristate	0
acetate	0
-activated	7
lymphocytes	8
exhibited	0
decreased	0
binding	0
to	0
DNA-cellulose	0
compared	0
to	0
PHA-activated	7
lymphocytes	8
.	0

In	0
lymphocytes	7
activated	0
either	0
by	0
PHA	9
or	0
OKT3	9
(	0
but	0
not	0
in	0
resting	7
cells	8
)	0
,	0
a	0
50-kDa	9
species	10
cross-reacting	0
with	0
a	0
monoclonal	9
antibody	10
against	0
the	0
intestinal	9
vitamin	10
D	10
receptor	10
was	0
detected	0
.	0

Finally	0
,	0
RNA	0
from	0
activated	7
lymphocytes	8
was	0
amplified	0
by	0
polymerase	0
chain	0
reaction	0
using	0
oligonucleotide	0
primers	0
flanking	0
the	0
196	1
base	2
pair	2
long	2
region	2
encoding	0
the	0
DNA-binding	9
domain	10
of	0
the	0
human	9
intestinal	10
receptor	10
.	0

The	0
amplified	0
product	0
showed	0
an	0
identical	1
nucleotide	2
sequence	2
to	0
the	0
DNA-binding	9
domain	10
of	0
the	0
human	9
intestinal	10
receptor	10
.	0

These	0
findings	0
suggest	0
that	0
expression	0
of	0
the	0
1	9
,	10
25-	10
(	10
OH	10
)	10
2D3	10
receptor	10
in	0
lymphocytes	7
is	0
triggered	0
by	0
distinct	0
and	0
contingent	0
signals	0
,	0
and	0
that	0
the	0
protein	0
and	0
the	0
mRNA	3
encoding	0
it	0
are	0
identical	0
to	0
the	0
classical	9
vitamin	10
D	10
receptor	10
.	0

Comparison	0
of	0
constitutive	0
and	0
inducible	0
transcriptional	0
enhancement	0
mediated	0
by	0
kappa	1
B-related	2
sequences	2
:	0
modulation	0
of	0
activity	0
in	0
B	7
cells	8
by	0
human	1
T-cell	2
leukemia	2
virus	2
type	2
I	2
tax	2
gene	2
.	0

The	0
kappa	1
B	2
sequence	2
(	0
GGGACTTTCC	0
)	0
binds	0
a	0
factor	0
,	0
NF-kappa	9
B	10
,	0
that	0
is	0
constitutively	0
found	0
in	0
its	0
functional	0
,	0
DNA	0
binding	0
form	0
only	0
in	0
B	7
lymphocytes	8
.	0

A	0
factor	0
with	0
apparently	0
indistinguishable	0
sequence	0
specificity	0
can	0
be	0
induced	0
in	0
many	0
other	0
cell	0
types	0
,	0
where	0
it	0
is	0
used	0
to	0
regulate	0
inducible	0
gene	0
expression	0
.	0

For	0
example	0
,	0
kappa	1
B-related	2
sequences	2
have	0
been	0
shown	0
to	0
be	0
important	0
for	0
the	0
transcription	0
of	0
a	0
few	0
inducible	0
genes	0
,	0
such	0
as	0
the	0
interleukin	1
2	2
receptor	2
alpha-chain	2
gene	2
and	0
the	0
beta-interferon	1
gene	2
.	0

However	0
,	0
these	0
genes	0
are	0
not	0
constitutively	0
active	0
in	0
B	7
lymphocytes	8
,	0
suggesting	0
that	0
other	0
regulatory	0
mechanisms	0
must	0
play	0
a	0
role	0
in	0
determining	0
the	0
patterns	0
of	0
expression	0
.	0

We	0
have	0
investigated	0
the	0
constitutive	0
and	0
inducible	0
transcriptional	0
activity	0
mediated	0
by	0
five	0
kappa	1
B-related	2
sequence	2
elements	2
in	0
two	0
different	0
cell	0
types	0
.	0

We	0
show	0
that	0
in	0
S194	5
plasma	6
cells	6
the	0
activity	0
of	0
each	0
element	0
correlates	0
well	0
with	0
the	0
relative	0
affinity	0
of	0
B-cell-derived	9
NF-kappa	10
B	10
for	0
that	0
element	0
.	0

This	0
leads	0
to	0
significantly	0
lower	0
transcription	0
enhancement	0
by	0
sites	0
derived	0
from	0
the	0
interleukin	9
2	10
receptor	10
or	0
T-cell	1
receptor	2
genes	2
in	0
S194	5
cells	6
.	0

However	0
,	0
in	0
either	0
EL-4	5
(	6
T	6
)	6
cells	6
or	0
S194	5
cells	6
,	0
both	0
lower-affinity	0
sites	0
can	0
be	0
significantly	0
induced	0
by	0
the	0
tax	9
gene	10
product	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
,	0
showing	0
that	0
NF-kappa	9
B	10
activity	0
can	0
be	0
modulated	0
even	0
in	0
a	0
B-cell	5
line	6
that	0
constitutively	0
expresses	0
this	0
factor	0
.	0

Specific	0
depletion	0
of	0
the	0
B-cell	5
population	6
induced	0
by	0
aberrant	0
expression	0
of	0
human	1
interferon	2
regulatory	2
factor	2
1	2
gene	2
in	0
transgenic	0
mice	0
.	0

Interferons	9
(	0
IFNs	9
)	0
are	0
well	0
known	0
both	0
as	0
antiviral	9
proteins	10
and	0
as	0
potent	0
regulators	0
of	0
cell	0
growth	0
and	0
differentiation	0
.	0

In	0
fact	0
,	0
IFNs	9
inhibit	0
growth	0
of	0
various	0
normal	7
and	0
transformed	7
cell	8
types	8
.	0

Previously	0
,	0
a	0
nuclear	9
factor	10
,	0
IRF-1	9
(	0
interferon	9
regulatory	10
factor	10
1	10
)	0
,	0
which	0
binds	0
to	0
type	1
I	2
IFN	2
and	0
some	0
IFN-inducible	1
gene	2
promoters	2
,	0
was	0
identified	0
and	0
cloned	0
.	0

Since	0
the	0
IRF-1	9
gene	0
is	0
both	0
virus	0
and	0
IFN	9
inducible	0
,	0
an	0
intriguing	0
issue	0
is	0
raised	0
as	0
to	0
whether	0
the	0
IRF-1	1
gene	2
is	0
functioning	0
in	0
IFN	9
-mediated	0
regulation	0
of	0
cell	0
growth	0
and	0
differentiation	0
.	0

In	0
this	0
study	0
,	0
we	0
generated	0
transgenic	0
mice	0
carrying	0
the	0
human	1
IRF-1	2
gene	2
linked	0
to	0
the	0
human	1
immunoglobulin	2
heavy-chain	2
enhancer	2
.	0

In	0
the	0
transgenic	0
mice	0
,	0
all	0
the	0
lymphoid	0
tissues	0
examined	0
showed	0
a	0
dramatic	0
reduction	0
in	0
the	0
number	0
of	0
B	7
lymphocytes	8
(	0
B	7
cells	8
)	0
.	0

Preparation	0
and	0
analysis	0
of	0
bone	7
marrow	8
cells	8
from	0
the	0
chimeric	0
mice	0
indicated	0
that	0
the	0
bone	0
marrow	0
is	0
the	0
effective	0
site	0
for	0
specific	0
depletion	0
of	0
the	0
B-cell	7
population	8
.	0

In	0
fact	0
,	0
transgenic	5
bone	6
marrow	6
cells	6
cocultured	0
with	0
a	0
bone	5
marrow-derived	6
stromal	6
cell	6
line	6
revealed	0
an	0
altered	0
B-cell	7
maturation	0
pattern	0
.	0

Characterization	0
of	0
a	0
cofactor	9
that	0
regulates	0
dimerization	0
of	0
a	0
mammalian	9
homeodomain	10
protein	10
.	0

Dimerization	0
among	0
transcription	9
factors	10
has	0
become	0
a	0
recurrent	0
theme	0
in	0
the	0
regulation	0
of	0
eukaryotic	0
gene	0
expression	0
.	0

Hepatocyte	9
nuclear	10
factor-1	10
alpha	10
(	0
HNF-1	9
alpha	10
)	0
is	0
a	0
homeodomain-containing	9
protein	10
that	0
functions	0
as	0
a	0
dimer	9
.	0

A	0
dimerization	9
cofactor	10
of	0
HNF-1	9
alpha	10
(	0
DCoH	9
)	0
was	0
identified	0
that	0
displayed	0
a	0
restricted	0
tissue	0
distribution	0
and	0
did	0
not	0
bind	0
to	0
DNA	0
,	0
but	0
,	0
rather	0
,	0
selectively	0
stabilized	0
HNF-1	9
alpha	10
dimers	10
.	0

The	0
formation	0
of	0
a	0
stable	0
tetrameric	9
DCoH-HNF-1	10
alpha	10
complex	10
,	0
which	0
required	0
the	0
dimerization	9
domain	10
of	0
HNF-1	9
alpha	10
,	0
did	0
not	0
change	0
the	0
DNA	0
binding	0
characteristics	0
of	0
HNF-1	9
alpha	10
,	0
but	0
enhanced	0
its	0
transcriptional	0
activity	0
.	0

However	0
,	0
DCoH	9
did	0
not	0
confer	0
transcriptional	0
activation	0
to	0
the	0
GAL4	9
DNA	10
binding	10
domain	10
.	0

These	0
results	0
indicate	0
that	0
DCoH	9
regulates	0
formation	0
of	0
transcriptionally	0
active	0
tetrameric	9
complexes	10
and	0
may	0
contribute	0
to	0
the	0
developmental	0
specificity	0
of	0
the	0
complex	9
.	0

Glucocorticoid	0
resistance	0
in	0
chronic	0
asthma	0
.	0

Glucocorticoid	0
pharmacokinetics	0
,	0
glucocorticoid	9
receptor	10
characteristics	0
,	0
and	0
inhibition	0
of	0
peripheral	7
blood	8
T	8
cell	8
proliferation	0
by	0
glucocorticoids	0
in	0
vitro	0
.	0

A	0
total	0
of	0
37	0
chronic	0
,	0
severe	0
,	0
nonsmoking	0
asthmatic	0
patients	0
with	0
documented	0
reversible	0
airways	0
obstruction	0
were	0
classified	0
as	0
glucocorticoid-sensitive	0
or	0
-resistant	0
on	0
the	0
basis	0
of	0
changes	0
in	0
FEV1	0
,	0
FVC	0
,	0
and	0
peak	0
expiratory	0
flow	0
(	0
PEF	0
)	0
after	0
oral	0
prednisolone	0
.	0

The	0
resistant	0
patients	0
showed	0
no	0
significant	0
improvements	0
in	0
airflow	0
limitation	0
.	0

Phytohemagglutinin	9
(	0
PHA	9
)	0
-induced	0
proliferation	0
of	0
peripheral	7
blood	8
T	8
lymphocytes	8
from	0
the	0
sensitive	0
but	0
not	0
the	0
resistant	0
asthmatic	0
patients	0
was	0
significantly	0
(	0
p	0
less	0
than	0
0.01	0
)	0
inhibited	0
by	0
dexamethasone	0
(	0
10	0
(	0
-7	0
)	0
mol/L	0
)	0
,	0
reflecting	0
a	0
shift	0
of	0
the	0
dose-response	0
curve	0
.	0

When	0
all	0
the	0
asthmatic	0
patients	0
were	0
analyzed	0
together	0
,	0
there	0
was	0
a	0
significant	0
correlation	0
between	0
the	0
degree	0
of	0
sensitivity	0
of	0
T	7
cells	8
to	0
dexamethasone	0
and	0
the	0
clinical	0
responsiveness	0
to	0
prednisolone	0
(	0
p	0
less	0
than	0
0.01	0
)	0
.	0

No	0
differences	0
were	0
observed	0
between	0
six	0
of	0
the	0
sensitive	0
and	0
resistant	0
patients	0
in	0
the	0
clearance	0
of	0
plasma	0
prednisolone	0
derived	0
from	0
orally	0
administered	0
prednisone	0
.	0

Peripheral	9
blood	10
mononuclear	10
cell	10
glucocorticoid	10
receptors	10
were	0
also	0
characterized	0
in	0
five	0
sensitive	0
and	0
seven	0
resistant	0
patients	0
.	0

The	0
numbers	0
and	0
binding	0
affinities	0
of	0
these	0
receptors	9
could	0
not	0
account	0
for	0
the	0
observed	0
difference	0
in	0
the	0
susceptibility	0
of	0
these	0
cells	0
to	0
functional	0
inhibition	0
by	0
dexamethasone	0
in	0
vitro	0
.	0

These	0
results	0
suggest	0
that	0
clinical	0
glucocorticoid	0
resistance	0
in	0
chronic	0
asthma	0
does	0
not	0
reflect	0
abnormal	0
glucocorticoid	0
clearance	0
but	0
may	0
be	0
due	0
at	0
least	0
partly	0
to	0
a	0
relative	0
insensitivity	0
of	0
T	7
lymphocytes	8
to	0
glucocorticoids	0
.	0

This	0
lack	0
of	0
sensitivity	0
is	0
unexplained	0
but	0
is	0
not	0
attributable	0
to	0
abnormalities	0
of	0
cellular	9
glucocorticoid	10
receptors	10
.	0

Inhibition	0
of	0
phorbol	0
ester-induced	0
monocytic	0
differentiation	0
by	0
dexamethasone	0
is	0
associated	0
with	0
down-regulation	0
of	0
c-fos	1
and	0
c-jun	1
(	0
AP-1	1
)	0
.	0

Previous	0
studies	0
have	0
shown	0
that	0
treatment	0
of	0
human	7
myeloid	8
leukemia	8
cells	8
with	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
is	0
associated	0
with	0
induction	0
of	0
monocytic	0
differentiation	0
and	0
expression	0
of	0
the	0
c-jun	1
and	2
c-fos	2
early	2
response	2
genes	2
.	0

The	0
present	0
work	0
demonstrates	0
that	0
the	0
glucocorticoid	0
dexamethasone	0
inhibits	0
TPA-induced	0
increases	0
in	0
c-jun	0
and	0
c-fos	0
mRNA	0
levels	0
in	0
U-937	5
leukemia	6
cells	6
.	0

These	0
findings	0
were	0
associated	0
with	0
a	0
block	0
in	0
appearance	0
of	0
the	0
monocytic	7
phenotype	8
,	0
including	0
inhibition	0
of	0
TPA-induced	0
increases	0
in	0
lamin	3
A	4
,	4
lamin	4
C	4
,	4
and	4
vimentin	4
transcripts	4
.	0

Other	0
studies	0
have	0
demonstrated	0
that	0
TPA-induced	0
monocytic	0
differentiation	0
and	0
expression	0
of	0
the	0
c-jun	1
and	0
c-fos	1
genes	2
in	0
myeloid	7
leukemia	8
cells	8
are	0
regulated	0
by	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
.	0

The	0
finding	0
that	0
dexamethasone	0
has	0
no	0
effect	0
on	0
TPA-induced	0
activation	0
of	0
PKC	9
suggests	0
that	0
this	0
glucocorticoid	0
inhibits	0
signals	0
downstream	0
or	0
parallel	0
to	0
this	0
enzyme	9
.	0

Nuclear	0
run-on	0
assays	0
demonstrate	0
that	0
:	0
(	0
1	0
)	0
induction	0
of	0
c-jun	0
and	0
c-fos	0
expression	0
by	0
TPA	0
is	0
regulated	0
by	0
transcriptional	0
mechanisms	0
,	0
(	0
2	0
)	0
TPA-induced	0
expression	0
of	0
c-jun	1
and	0
c-fos	9
does	0
not	0
require	0
protein	0
synthesis	0
,	0
and	0
(	0
3	0
)	0
TPA-induced	0
expression	0
of	0
both	0
genes	0
is	0
inhibited	0
at	0
the	0
transcriptional	0
level	0
by	0
dexamethasone	0
.	0

To	0
further	0
define	0
the	0
effects	0
of	0
dexamethasone	0
at	0
the	0
molecular	0
level	0
,	0
we	0
prepared	0
a	0
series	0
of	0
deleted	0
c-jun	1
promoter	2
fragments	2
linked	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
gene	2
.	0

Increases	0
in	0
CAT	9
activity	0
during	0
transient	0
expression	0
of	0
these	0
constructs	0
in	0
TPA-treated	5
U-937	6
cells	6
could	0
be	0
assigned	0
to	0
the	0
region	0
(	0
-97	0
to	0
-20	0
)	0
of	0
the	0
promoter	1
that	0
contains	0
the	0
AP-1	1
binding	2
site	2
.	0

This	0
induction	0
of	0
CAT	9
activity	0
was	0
sensitive	0
to	0
dexamethasone	0
.	0

These	0
findings	0
suggest	0
that	0
dexamethasone	0
down-regulates	0
TPA-induced	0
transcription	0
of	0
the	0
c-jun	1
gene	0
during	0
monocytic	0
differentiation	0
by	0
inhibiting	0
activation	0
of	0
the	0
AP-1	1
site	2
.	0

Tumor	3
necrosis	4
factor-alpha	4
mRNA	4
accumulation	0
in	0
human	5
myelomonocytic	6
cell	6
lines	6
.	0

Role	0
of	0
transcriptional	0
regulation	0
by	0
DNA	1
sequence	2
motifs	2
and	0
mRNA	0
stabilization	0
.	0

The	0
cytokine	9
TNF	9
mediates	0
many	0
of	0
the	0
pathologic	0
signs	0
of	0
cachexia	0
,	0
inflammation	0
,	0
and	0
sepsis	0
.	0

The	0
current	0
work	0
describes	0
the	0
regulation	0
of	0
TNF	9
in	0
human	5
myelomonocytic	6
cell	6
lines	6
after	0
PMA	0
stimulation	0
.	0

The	0
cell	5
lines	6
exhibit	0
a	0
low	0
level	0
of	0
constitutive	0
TNF	3
mRNA	4
expression	0
.	0

Within	0
2	0
to	0
4	0
h	0
of	0
PMA	0
exposure	0
,	0
steady	0
state	0
levels	0
of	0
TNF	3
mRNA	4
are	0
markedly	0
elevated	0
in	0
all	0
myelomonocytic	5
cell	6
lines	6
studied	0
.	0

This	0
rise	0
is	0
due	0
to	0
increased	0
mRNA	0
stability	0
,	0
which	0
increased	0
by	0
almost	0
twofold	0
,	0
and	0
to	0
an	0
overall	0
increase	0
in	0
transcription	0
,	0
which	0
rises	0
by	0
more	0
than	0
sixfold	0
.	0

At	0
the	0
level	0
of	0
the	0
genomic	1
TNF	2
gene	2
,	0
a	0
DNase	1
I	2
hypersensitive	2
site	2
is	0
detected	0
within	0
the	0
TNF	1
promoter	2
between	0
-200	0
to	0
-100	0
bp	0
relative	0
to	0
the	0
transcription	1
initiation	2
site	2
.	0

Although	0
absent	0
in	0
nonexpressing	5
erythroleukemia	6
cell	6
lines	6
,	0
the	0
DNase	1
I	2
site	2
is	0
present	0
in	0
uninduced	5
myelomonocytic	6
cell	6
lines	6
and	0
is	0
not	0
changed	0
after	0
PMA	0
induction	0
.	0

The	0
PMA	0
induction	0
of	0
c-fos	3
mRNA	4
correlated	0
well	0
with	0
TNF	9
gene	0
induction	0
;	0
expression	0
of	0
genes	0
encoding	0
other	0
proteins	0
in	0
the	0
AP-1	9
complex	10
(	0
junB	9
and	0
junD	9
)	0
were	0
also	0
induced	0
by	0
PMA	0
.	0

The	0
nuclear	0
extracts	0
from	0
resting	0
and	0
induced	5
ML-1	6
cells	6
contain	0
proteins	0
binding	0
specifically	0
to	0
the	0
AP-1	1
,	2
AP-2	2
,	2
and	2
NF	2
kappa	2
B	2
sequence	2
located	0
within	0
the	0
TNF	1
promoter	2
.	0

PMA	0
induction	0
increases	0
the	0
level	0
of	0
a	0
number	0
of	0
specific	9
binding	10
complexes	10
relative	0
to	0
the	0
resting	7
cells	8
.	0

The	0
regulatory	0
mechanisms	0
of	0
the	0
human	1
and	2
murine	2
TNF	2
genes	2
are	0
discussed	0
.	0

Enhancement	0
of	0
human	0
immunodeficiency	0
virus	0
1	0
replication	0
in	0
monocytes	7
by	0
1	0
,	0
25-dihydroxycholecalciferol	0
.	0

Human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
expression	0
and	0
replication	0
are	0
under	0
tight	0
regulatory	0
control	0
.	0

We	0
demonstrate	0
that	0
1	0
,	0
25-dihydroxycholecalciferol	0
[	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
]	0
enhances	0
the	0
replication	0
of	0
monocyte-	0
and	0
lymphocyte-tropic	0
strains	0
of	0
HIV-1	0
up	0
to	0
10	0
,	0
000-fold	0
in	0
monocyte	5
cell	6
lines	6
,	0
peripheral	7
blood	8
monocytes	8
,	0
and	0
unfractionated	7
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
is	0
therefore	0
one	0
of	0
the	0
most	0
potent	0
regulators	0
of	0
HIV-1	0
replication	0
described	0
to	0
date	0
.	0

Precursors	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
enhance	0
HIV-1	0
replication	0
in	0
proportion	0
to	0
their	0
affinity	0
for	0
the	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
intracellular	10
receptor	10
,	0
suggesting	0
that	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
influences	0
HIV-1	0
replication	0
by	0
mechanisms	0
involving	0
this	0
receptor	0
.	0

These	0
studies	0
may	0
have	0
important	0
implications	0
for	0
the	0
design	0
of	0
effective	0
therapy	0
of	0
HIV-1	0
infection	0
.	0

Transforming	9
growth	10
factor-beta	10
suppresses	0
human	9
B	10
lymphocyte	10
Ig	10
production	0
by	0
inhibiting	0
synthesis	0
and	0
the	0
switch	0
from	0
the	0
membrane	3
form	4
to	0
the	0
secreted	3
form	4
of	0
Ig	3
mRNA	4
.	0

Transforming	9
growth	10
factor-beta	10
(	0
TGF-beta	9
)	0
inhibits	0
B	7
cell	8
Ig	9
secretion	0
and	0
reduces	0
B	7
cell	8
membrane	0
Ig	9
expression	0
.	0

The	0
addition	0
of	0
TGF-beta	9
to	0
human	5
B	6
lymphocyte	6
cultures	6
stimulated	0
with	0
Staphylococcus	0
aureus	0
Cowan	0
strain	0
I	0
and	0
IL-2	9
completely	0
inhibited	0
B	7
cell	8
Ig	9
secretion	0
(	0
greater	0
than	0
90	0
%	0
)	0
and	0
decreased	0
B	7
cell	8
surface	0
IgM	0
,	0
IgD	0
,	0
kappa	0
L	0
chain	0
,	0
and	0
lambda	0
L	0
chain	0
expression	0
.	0

In	0
contrast	0
,	0
TGF-beta	9
had	0
only	0
minimal	0
effects	0
on	0
two	0
other	0
B	9
cell	10
membrane	10
proteins	10
,	0
HLA-DR	9
and	0
CD20	9
.	0

Internal	0
labeling	0
with	0
[	0
35S	0
]	0
methionine	0
and	0
immunoprecipitation	0
with	0
anti-IgM	9
,	0
anti-kappa	9
,	0
and	0
anti-lambda	9
antibodies	10
revealed	0
a	0
striking	0
reduction	0
in	0
kappa	9
L	10
chain	10
in	0
the	0
presence	0
of	0
TGF-beta	9
.	0

A	0
less	0
pronounced	0
reduction	0
in	0
lambda	9
L	10
chain	10
and	0
microH	9
chain	10
was	0
also	0
noted	0
.	0

Northern	0
blot	0
analysis	0
of	0
RNA	0
purified	0
from	0
B	7
cells	8
treated	0
with	0
TGF-beta	9
for	0
varying	0
time	0
intervals	0
revealed	0
a	0
significant	0
decrease	0
in	0
steady	0
state	0
kappa	0
and	0
lambda	0
L	0
chain	0
mRNA	0
levels	0
.	0

Furthermore	0
,	0
a	0
significant	0
decrease	0
in	0
the	0
switch	0
from	0
the	0
membrane	3
forms	4
of	0
mu	3
and	0
gamma	3
to	0
their	0
respective	0
secreted	3
forms	4
was	0
noted	0
in	0
the	0
presence	0
of	0
TGF-beta	9
.	0

Nuclear	0
run-on	0
experiments	0
demonstrated	0
decreased	0
transcription	0
of	0
kappa	9
L	10
chain	10
.	0

The	0
effects	0
of	0
TGF-beta	9
on	0
two	0
transcriptional	9
regulatory	10
factors	10
,	0
Oct-2	9
and	0
nuclear	9
factor	10
(	10
NF	10
)	10
kappa	10
B	10
,	0
known	0
to	0
be	0
important	0
in	0
Ig	9
gene	0
transcription	0
were	0
examined	0
.	0

Oct-2	3
mRNA	4
levels	0
and	0
both	0
Oct-2	9
and	0
NF-kappa	9
B	10
proteins	10
in	0
nuclear	0
extracts	0
were	0
not	0
altered	0
by	0
treatment	0
with	0
TGF-beta	9
.	0

In	0
contrast	0
,	0
levels	0
of	0
the	0
transcriptional	9
factor	10
AP-1	10
,	0
which	0
is	0
not	0
known	0
to	0
be	0
important	0
in	0
B	7
cell	8
Ig	9
production	0
,	0
were	0
reduced	0
by	0
TGF-beta	9
.	0

These	0
findings	0
demonstrate	0
that	0
TGF-beta	9
decreases	0
B	0
lymphocyte	0
Ig	9
secretion	0
by	0
inhibiting	0
the	0
synthesis	0
of	0
Ig	3
mRNA	4
and	0
inhibiting	0
the	0
switch	0
from	0
the	0
membrane	3
form	4
to	0
the	0
secreted	3
forms	4
of	0
mu	3
and	4
gamma	4
mRNA	4
.	0

The	0
mechanism	0
by	0
which	0
TGF-beta	9
inhibits	0
Ig	0
chain	0
synthesis	0
is	0
unclear	0
although	0
it	0
does	0
not	0
involve	0
inhibition	0
of	0
the	0
binding	0
of	0
NF-kappa	9
B	10
or	0
Oct-2	9
to	0
their	0
respective	0
target	0
sequences	0
.	0

Murine	9
and	10
human	10
T-lymphocyte	10
GATA-3	10
factors	10
mediate	0
transcription	0
through	0
a	0
cis-regulatory	1
element	2
within	0
the	0
human	1
T-cell	2
receptor	2
delta	2
gene	2
enhancer	2
.	0

A	0
family	0
of	0
transcriptional	9
activators	10
has	0
recently	0
been	0
identified	0
in	0
chickens	0
;	0
these	0
transcriptional	9
activators	10
recognize	0
a	0
common	0
consensus	1
motif	2
(	0
WGATAR	1
)	0
through	0
a	0
conserved	0
C4	9
zinc	10
finger	10
DNA-binding	10
domain	10
.	0

One	0
of	0
the	0
members	0
of	0
this	0
multigene	0
family	0
,	0
cGATA-3	9
,	0
is	0
most	0
abundantly	0
expressed	0
in	0
the	0
T-lymphocyte	7
cell	8
lineage	8
.	0

Analysis	0
of	0
human	9
and	10
murine	10
GATA-3	10
factors	10
shows	0
a	0
striking	0
degree	0
of	0
amino	0
acid	0
sequence	0
identity	0
and	0
similar	0
patterns	0
of	0
tissue	0
specificity	0
of	0
expression	0
in	0
these	0
three	0
organisms	0
.	0

The	0
murine	9
and	10
human	10
factors	10
are	0
abundantly	0
expressed	0
in	0
a	0
variety	0
of	0
human	5
and	6
murine	6
T-cell	6
lines	6
and	0
can	0
activate	0
transcription	0
through	0
a	0
tissue-specific	1
GATA-binding	2
site	2
identified	0
within	0
the	0
human	1
T-cell	2
receptor	2
delta	2
gene	2
enhancer	2
.	0

We	0
infer	0
that	0
the	0
murine	9
and	10
human	10
GATA-3	10
proteins	10
play	0
a	0
central	0
and	0
highly	0
conserved	0
role	0
in	0
vertebrate	0
T-cell-specific	0
transcriptional	0
regulation	0
.	0

Processing	0
of	0
the	0
precursor	0
of	0
NF-kappa	9
B	10
by	0
the	0
HIV-1	9
protease	10
during	0
acute	0
infection	0
.	0

Transcription	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
type-1	2
(	2
HIV-1	2
)	2
genome	2
is	0
regulated	0
in	0
part	0
by	0
cellular	9
factors	10
and	0
is	0
stimulated	0
by	0
activation	0
of	0
latently	7
infected	8
T	8
cells	8
.	0

T-cell	0
activation	0
also	0
correlates	0
with	0
the	0
induction	0
of	0
the	0
factor	0
NF-kappa	9
B	10
which	0
binds	0
to	0
two	0
adjacent	0
sites	0
in	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
.	0

This	0
factor	0
consists	0
of	0
two	0
DNA-binding	9
subunits	10
of	0
relative	0
molecular	0
mass	0
50	0
,	0
000	0
(	0
50K	0
)	0
associated	0
with	0
two	0
65K	9
subunits	10
.	0

It	0
is	0
located	0
in	0
the	0
nucleus	0
in	0
mature	7
B	8
cells	8
,	0
but	0
is	0
present	0
in	0
other	0
cell	0
types	0
as	0
an	0
inactive	9
cytoplasmic	10
complex	10
.	0

External	0
stimuli	0
,	0
including	0
those	0
that	0
activate	0
T	7
cells	8
,	0
result	0
in	0
nuclear	0
translocation	0
of	0
active	0
NF-kappa	9
B	10
.	0

The	0
cloning	0
of	0
the	0
complementary	1
DNA	2
for	0
the	0
50K	9
subunit	10
helped	0
to	0
identify	0
an	0
exclusively	0
cytoplasmic	9
105K	10
precursor	10
(	0
p105	9
)	0
(	0
V.B.	0
,	0
P.K.	0
and	0
A.I.	0
,	0
manuscript	0
submitted	0
)	0
.	0

The	0
expression	0
of	0
active	0
NF-kappa	9
B	10
might	0
therefore	0
also	0
be	0
regulated	0
by	0
the	0
extent	0
of	0
processing	0
of	0
p105	9
.	0

Because	0
HIV-1	0
requires	0
active	0
NF-kappa	9
B	10
for	0
efficient	0
transcription	0
,	0
we	0
tested	0
the	0
effect	0
of	0
HIV-1	0
infection	0
on	0
the	0
processing	0
of	0
the	0
human	9
105K	10
precursor	10
.	0

We	0
show	0
here	0
that	0
the	0
HIV-1	0
protease	0
can	0
process	0
p105	9
and	0
increases	0
levels	0
of	0
active	0
nuclear	9
NF-kappa	10
B	10
complex	10
.	0

1	3
,	4
25-Dihydroxyvitamin	4
D3	4
receptor	4
RNA	4
:	0
expression	0
in	0
hematopoietic	7
cells	8
.	0

1	0
,	0
25-Dihydroxyvitamin	0
D3	0
[	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
]	0
induces	0
differentiation	0
and	0
inhibits	0
proliferation	0
of	0
myeloid	7
leukemic	8
cells	8
from	0
various	0
lines	0
and	0
patients	0
;	0
these	0
effects	0
are	0
probably	0
mediated	0
through	0
the	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
.	0

Little	0
is	0
known	0
of	0
expression	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
in	0
hematopoietic	7
cells	8
.	0

We	0
examined	0
the	0
expression	0
and	0
modulation	0
of	0
expression	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
in	0
various	0
proliferating	7
and	8
nonproliferating	8
hematopoietic	8
cells	8
.	0

Constitutive	0
expression	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
was	0
detected	0
in	0
various	0
kinds	0
of	0
hematopoietic	7
cells	8
,	0
including	0
macrophages	0
and	0
activated	0
T	7
lymphocytes	8
,	0
as	0
well	0
as	0
in	0
cell	0
lines	0
KG-1	5
(	0
myeloblasts	5
)	0
,	0
HL-60	5
(	0
promyelocytes	5
)	0
,	0
ML-3	5
(	0
myelomonoblasts	5
)	0
,	0
U937	5
,	0
THP-1	5
(	0
monoblasts	5
)	0
,	0
K562	5
(	0
erythroblasts	5
)	0
,	0
and	0
S-LB1	5
(	0
HTLV-1-transfected	5
T	6
lymphocytes	6
)	0
.	0

Receptor	3
transcripts	4
were	0
4.6	0
kilobases	0
(	0
kb	0
)	0
,	0
and	0
no	0
variant	0
sizes	0
were	0
observed	0
.	0

All	0
cell	0
lines	0
examined	0
in	0
this	0
group	0
also	0
expressed	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
.	0

Most	0
B	5
lymphocyte	6
lines	6
expressed	0
negligible	0
levels	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
and	0
protein	0
;	0
however	0
;	0
analysis	0
of	0
a	0
lymphoid/myeloid	5
somatic	6
hybrid	6
suggested	0
that	0
suppression	0
of	0
expression	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
in	0
B	7
lymphocytes	8
may	0
be	0
a	0
dominant	0
characteristic	0
.	0

HL-60	5
cells	6
were	0
cultured	0
with	0
10	0
(	0
-7	0
)	0
mol/L	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
for	0
24	0
to	0
72	0
hours	0
,	0
and	0
levels	0
of	0
expression	0
of	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
and	0
its	0
RNA	0
were	0
examined	0
.	0

Levels	0
of	0
RNA	0
coding	0
for	0
the	0
receptor	9
were	0
not	0
modulated	0
by	0
exposure	0
to	0
high	0
levels	0
of	0
ligand	0
.	0

Levels	0
of	0
occupied	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
protein	10
increased	0
in	0
these	0
HL-60	5
cells	6
;	0
but	0
the	0
total	0
number	0
of	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
decreased	0
about	0
50	0
%	0
at	0
24	0
hours	0
and	0
returned	0
toward	0
normal	0
at	0
72	0
hours	0
.	0

Steady-state	0
levels	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
were	0
not	0
affected	0
by	0
terminal	0
differentiation	0
of	0
HL-60	5
toward	0
either	0
granulocytes	7
or	0
macrophages	7
.	0

Nondividing	0
macrophages	7
from	0
normal	0
individuals	0
also	0
expressed	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
.	0

In	0
contrast	0
,	0
nondividing	7
peripheral	8
blood	8
lymphocytes	8
from	0
normal	0
individuals	0
did	0
not	0
express	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
;	0
with	0
stimulation	0
of	0
proliferation	0
of	0
these	0
cells	0
,	0
accumulation	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
increased	0
markedly	0
.	0

Half-life	0
(	0
t1/2	0
)	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
in	0
T	7
lymphocytes	8
was	0
short	0
(	0
1	0
hour	0
)	0
as	0
determined	0
by	0
measuring	0
decay	0
of	0
the	0
message	0
after	0
addition	0
of	0
actinomycin	0
D	0
.	0

Consistent	0
with	0
this	0
short	0
t1/2	0
,	0
accumulation	0
of	0
1	3
,	4
25	4
(	4
OH	4
)	4
2D3	4
receptor	4
RNA	4
increased	0
in	0
cells	0
as	0
their	0
protein	0
synthesis	0
was	0
inhibited	0
.	0

Further	0
studies	0
are	0
required	0
to	0
understand	0
the	0
physiologic	0
role	0
of	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
in	0
myeloid	7
cells	8
and	0
proliferating	7
T	8
lymphocytes	8
.	0

Expression	0
of	0
c-jun	1
,	2
jun	2
B	2
and	2
jun	2
D	2
proto-oncogenes	2
in	0
human	7
peripheral-blood	8
granulocytes	8
.	0

We	0
have	0
found	0
that	0
purified	7
human	8
peripheral-blood	8
granulocytes	8
express	0
constitutively	0
significant	0
levels	0
of	0
proto-oncogenes	1
c-jun	3
,	4
jun	4
B	4
and	4
jun	4
D	4
mRNA	4
.	0

Upon	0
functional	0
activation	0
of	0
granulocytes	7
by	0
4	0
beta-phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
,	0
the	0
levels	0
of	0
c-jun	3
,	4
jun	4
B	4
and	4
jun	4
D	4
transcripts	4
were	0
increased	0
.	0

The	0
three	0
jun	1
genes	2
showed	0
a	0
similar	0
time	0
course	0
in	0
their	0
induction	0
by	0
PMA	0
,	0
maximal	0
mRNA	0
levels	0
being	0
reached	0
after	0
60	0
min	0
of	0
induction	0
.	0

These	0
results	0
suggest	0
that	0
expression	0
of	0
c-jun	1
,	0
jun	1
B	2
and	0
jun	1
D	2
genes	2
might	0
be	0
involved	0
in	0
terminal	7
granulocyte	8
differentiation	0
or	0
in	0
regulating	0
granulocyte	7
functionality	0
.	0

The	0
29-kDa	9
proteins	10
phosphorylated	0
in	0
thrombin-activated	5
human	6
platelets	6
are	0
forms	0
of	0
the	0
estrogen	9
receptor-related	10
27-kDa	10
heat	10
shock	10
protein	10
.	0

Thrombin	9
plays	0
a	0
critical	0
role	0
in	0
platelet	0
activation	0
,	0
hemostasis	0
,	0
and	0
thrombosis	0
.	0

Cellular	0
activation	0
by	0
thrombin	0
leads	0
to	0
the	0
phosphorylation	0
of	0
multiple	9
proteins	10
,	0
most	0
of	0
which	0
are	0
unidentified	0
.	0

We	0
have	0
characterized	0
several	0
29-kDa	9
proteins	10
that	0
are	0
rapidly	0
phosphorylated	0
following	0
exposure	0
of	0
intact	7
human	8
platelets	8
to	0
thrombin	9
.	0

A	0
murine	9
monoclonal	10
antibody	10
raised	0
to	0
an	0
unidentified	9
estrogen	10
receptor-related	10
29-kDa	10
protein	10
selectively	0
recognized	0
these	0
proteins	0
as	0
well	0
as	0
a	0
more	0
basic	0
,	0
unphosphorylated	9
27-kDa	10
protein	10
.	0

Cellular	0
activation	0
by	0
thrombin	9
led	0
to	0
a	0
marked	0
shift	0
in	0
the	0
proportion	0
of	0
protein	0
from	0
the	0
27-kDa	9
unphosphorylated	10
form	10
to	0
the	0
29-kDa	9
phosphoprotein	10
species	10
.	0

Using	0
this	0
antibody	0
,	0
we	0
isolated	0
and	0
sequenced	0
a	0
human	0
cDNA	1
clone	2
encoding	0
a	0
protein	0
that	0
was	0
identical	0
to	0
the	0
mammalian	9
27-kDa	10
heat	10
shock	10
protein	10
(	0
HSP27	9
)	0
,	0
a	0
protein	0
of	0
uncertain	0
function	0
that	0
is	0
known	0
to	0
be	0
phosphorylated	0
to	0
several	0
forms	0
and	0
to	0
be	0
transcriptionally	0
induced	0
by	0
estrogen	0
.	0

The	0
29-kDa	9
proteins	10
were	0
confirmed	0
to	0
be	0
phosphorylated	0
forms	0
of	0
HSP27	9
by	0
immunoprecipitation	0
studies	0
.	0

Thus	0
,	0
the	0
``	0
estrogen	0
receptor-related	0
protein	0
''	0
is	0
HSP27	9
,	0
and	0
the	0
three	0
major	0
29-kDa	9
proteins	10
phosphorylated	0
in	0
thrombin-activated	7
platelets	8
are	0
forms	0
of	0
HSP27	9
.	0

These	0
data	0
suggest	0
a	0
role	0
for	0
HSP27	9
in	0
the	0
signal	0
transduction	0
events	0
of	0
platelet	7
activation	0
.	0

Isolation	0
of	0
a	0
candidate	0
repressor/activator	0
,	0
NF-E1	9
(	0
YY-1	9
,	0
delta	9
)	0
,	0
that	0
binds	0
to	0
the	0
immunoglobulin	1
kappa	2
3	2
'	2
enhancer	2
and	0
the	0
immunoglobulin	1
heavy-chain	2
mu	2
E1	2
site	2
.	0

We	0
have	0
determined	0
that	0
the	0
developmental	0
control	0
of	0
immunoglobulin	1
kappa	2
3	2
'	2
enhancer	2
(	0
kappa	1
E3	2
'	2
)	0
activity	0
is	0
the	0
result	0
of	0
the	0
combined	0
influence	0
of	0
positive-	1
and	2
negative-acting	2
elements	2
.	0

We	0
show	0
that	0
a	0
central	0
core	0
in	0
the	0
kappa	1
E3	2
'	2
enhancer	2
is	0
active	0
at	0
the	0
pre-B-cell	0
stage	0
but	0
is	0
repressed	0
by	0
flanking	1
negative-acting	2
elements	2
.	0

The	0
negative-acting	1
sequences	2
repress	0
enhancer	0
activity	0
in	0
a	0
position-	0
and	0
orientation-independent	0
manner	0
at	0
the	0
pre-B-cell	0
stage	0
.	0

We	0
have	0
isolated	0
a	0
human	1
cDNA	2
clone	2
encoding	0
a	0
zinc	9
finger	10
protein	10
(	0
NF-E1	9
)	0
that	0
binds	0
to	0
the	0
negative-acting	1
segment	2
of	0
the	0
kappa	1
E3	2
'	2
enhancer	2
.	0

This	0
protein	0
also	0
binds	0
to	0
the	0
immunoglobulin	1
heavy-chain	2
enhancer	2
mu	2
E1	2
site	2
.	0

NF-E1	9
is	0
encoded	0
by	0
the	0
same	0
gene	0
as	0
the	0
YY-1	9
protein	10
,	0
which	0
binds	0
to	0
the	0
adeno-associated	1
virus	2
P5	2
promoter	2
.	0

NF-E1	9
is	0
also	0
the	0
human	9
homologue	10
of	0
the	0
mouse	1
delta	2
protein	2
,	0
which	0
binds	0
to	0
ribosomal	1
protein	2
gene	2
promoters	2
.	0

The	0
predicted	0
amino	0
acid	0
sequence	0
of	0
this	0
protein	0
contains	0
features	0
characteristic	0
of	0
transcriptional	9
activators	10
as	0
well	0
as	0
transcriptional	9
repressors	10
.	0

Cotransfection	0
studies	0
with	0
this	0
cDNA	1
indicate	0
that	0
it	0
can	0
repress	0
basal	1
promoter	2
activity	0
.	0

The	0
apparent	0
dual	0
function	0
of	0
this	0
protein	0
is	0
discussed	0
.	0

A	0
human	1
putative	2
lymphocyte	2
G0/G1	2
switch	2
gene	2
containing	0
a	0
CpG-rich	1
island	2
encodes	0
a	0
small	9
basic	10
protein	10
with	0
the	0
potential	0
to	0
be	0
phosphorylated	0
.	0

Genes	0
actively	0
involved	0
in	0
the	0
G0/G1	1
switch	2
(	0
G0S	3
genes	4
)	0
may	0
be	0
differentially	0
expressed	0
during	0
the	0
lectin	9
-induced	0
switch	0
of	0
lymphocytes	7
from	0
the	0
G0	0
to	0
the	0
G1	0
phases	0
of	0
the	0
cell	0
cycle	0
.	0

This	0
paper	0
presents	0
studies	0
of	0
G0S2	1
,	0
a	0
member	0
of	0
a	0
set	0
of	0
putative	0
G0S	3
genes	4
,	0
for	0
which	0
cDNAs	1
were	0
cloned	0
and	0
selected	0
on	0
the	0
basis	0
of	0
differential	0
cDNA	0
hybridization	0
.	0

G0S2	3
mRNA	4
increases	0
transiently	0
within	0
1-2	0
hr	0
of	0
the	0
addition	0
of	0
lectin	9
or	0
cycloheximide	0
to	0
cultured	7
blood	8
mononuclear	8
cells	8
.	0

Comparison	0
of	0
a	0
nearly	1
full-length	2
cDNA	2
sequence	2
with	0
the	0
corresponding	0
genomic	1
sequence	2
reveals	0
one	0
small	0
intron	0
and	0
an	0
open	1
reading	2
frame	2
in	0
the	0
second	0
exon	1
.	0

The	0
derived	0
103-amino-acid	9
basic	10
protein	10
has	0
two	0
potential	0
alpha-helical	9
domains	10
separated	0
by	0
a	0
hydrophobic	9
region	10
with	0
the	0
potential	0
to	0
generate	0
turns	0
and	0
assume	0
a	0
beta-sheet	0
conformation	0
.	0

Consistent	0
with	0
involvement	0
in	0
the	0
G0/G1	1
switch	2
,	0
the	0
protein	0
contains	0
potential	0
sites	0
for	0
phosphorylation	0
by	0
protein	9
kinase	10
C	10
and	0
casein	9
kinase	10
II	10
.	0

The	0
gene	0
contains	0
a	0
CpG-rich	9
island	10
suggesting	0
expression	0
in	0
the	0
germ	0
line	0
.	0

An	0
upstream	1
segment	2
contains	0
tandem	1
dinucleotide	2
repeats	2
(	1
CT	2
)	2
19/	2
(	2
CA	2
)	2
16	2
.	0

There	0
is	0
a	0
suitably	0
located	0
TATA	1
box	2
,	0
but	0
potential	0
sites	0
for	0
CCAAT-box	9
binding	10
factors	10
are	0
far	0
upstream	0
,	0
embedded	0
in	0
a	0
42-nucleotide	1
repeat	2
element	2
.	0

Potential	0
sites	0
for	0
transcription	9
factors	10
AP1	9
,	0
AP2	9
,	0
and	0
AP3	9
are	0
consistent	0
with	0
rapid	0
transcriptional	0
activation	0
in	0
response	0
to	0
inducing	0
agents	0
.	0

USF-related	9
transcription	10
factor	10
,	0
HIV-TF1	9
,	0
stimulates	0
transcription	0
of	0
human	0
immunodeficiency	0
virus-1	0
.	0

The	0
transcription	9
factor	10
HIV-TF1	9
,	0
which	0
binds	0
to	0
a	0
region	0
about	0
60	1
bp	2
upstream	2
from	0
the	0
enhancer	0
of	0
the	0
human	0
immunodeficiency	0
virus-1	0
(	0
HIV-1	0
)	0
,	0
was	0
purified	0
from	0
human	7
B	8
cells	8
.	0

HIV-TF1	9
had	0
a	0
molecular	0
weight	0
of	0
39	0
,	0
000	0
.	0

Binding	0
of	0
HIV-TF1	9
to	0
the	0
HIV	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
activated	0
transcription	0
from	0
the	0
HIV	1
promoter	2
in	0
vitro	0
.	0

The	0
HIV-TF1-binding	1
site	2
in	0
HIV	1
LTR	2
was	0
similar	0
to	0
the	0
site	0
recognized	0
by	0
upstream	9
stimulatory	10
factor	10
(	0
USF	9
)	0
in	0
the	0
adenovirus	1
major	2
late	2
promoter	2
.	0

DNA-binding	0
properties	0
of	0
HIV-TF1	9
suggested	0
that	0
HIV-TF1	9
might	0
be	0
identical	0
or	0
related	0
to	0
USF	9
.	0

Interestingly	0
,	0
treatment	0
of	0
purified	0
HIV-TF1	9
by	0
phosphatase	9
greatly	0
reduced	0
its	0
DNA-binding	0
activity	0
,	0
suggesting	0
that	0
phosphorylation	0
of	0
HIV-TF1	9
was	0
essential	0
for	0
DNA	0
binding	0
.	0

The	0
disruption	0
of	0
HIV-TF1-binding	1
site	2
induced	0
a	0
60	0
%	0
decrease	0
in	0
the	0
level	0
of	0
transcription	0
from	0
the	0
HIV	1
promoter	2
in	0
vivo	0
.	0

These	0
results	0
suggest	0
that	0
HIV-TF1	9
is	0
involved	0
in	0
transcriptional	0
regulation	0
of	0
HIV-1	0
.	0

Severe	0
5-fluorouracil	0
toxicity	0
secondary	0
to	0
dihydropyrimidine	9
dehydrogenase	10
deficiency	0
.	0

A	0
potentially	0
more	0
common	0
pharmacogenetic	0
syndrome	0
.	0

This	0
study	0
describes	0
the	0
inheritance	0
of	0
a	0
defect	0
in	0
pyrimidine	0
catabolism	0
and	0
its	0
association	0
with	0
drug-induced	0
toxicity	0
in	0
a	0
patient	0
receiving	0
5-fluorouracil	0
(	0
FUra	0
)	0
as	0
adjuvant	0
chemotherapy	0
for	0
breast	0
carcinoma	0
.	0

The	0
study	0
population	0
included	0
the	0
affected	0
patient	0
(	0
proband	0
)	0
,	0
nine	0
of	0
her	0
blood	0
relatives	0
,	0
and	0
seven	0
healthy	0
volunteers	0
.	0

The	0
activity	0
of	0
dihydropyrimidine	9
dehydrogenase	10
(	0
DPD	9
)	0
,	0
the	0
initial	0
enzyme	9
of	0
pyrimidine	0
(	0
and	0
FUra	0
)	0
catabolism	0
,	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
was	0
measured	0
in	0
each	0
subject	0
by	0
a	0
specific	0
radiometric	0
assay	0
using	0
FUra	0
as	0
the	0
substrate	0
.	0

The	0
proband	0
had	0
no	0
detectable	0
DPD	9
activity	0
.	0

When	0
enzyme	0
levels	0
in	0
the	0
proband	0
and	0
relatives	0
were	0
compared	0
with	0
that	0
in	0
controls	0
,	0
an	0
autosomal	0
recessive	0
pattern	0
of	0
inheritance	0
was	0
demonstrated	0
.	0

This	0
is	0
the	0
third	0
patient	0
with	0
severe	0
FUra	0
toxicity	0
secondary	0
to	0
an	0
alteration	0
in	0
pyrimidine	0
catabolism	0
and	0
the	0
second	0
from	0
our	0
clinic	0
population	0
suggesting	0
that	0
the	0
frequency	0
of	0
this	0
genetic	0
defect	0
may	0
be	0
greater	0
than	0
previously	0
thought	0
.	0

Monitoring	0
DPD	9
activity	0
may	0
be	0
important	0
in	0
the	0
management	0
of	0
patients	0
experiencing	0
severe	0
toxicity	0
secondary	0
to	0
FUra	0
chemotherapy	0
.	0

Transactivation	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
promoter	2
by	0
human	0
herpesvirus	0
6	0
(	0
HHV-6	0
)	0
strains	0
GS	0
and	0
Z-29	0
in	0
primary	7
human	8
T	8
lymphocytes	8
and	0
identification	0
of	0
transactivating	1
HHV-6	2
(	2
GS	2
)	2
gene	2
fragments	2
.	0

Human	0
herpesvirus	0
6	0
(	0
HHV-6	0
)	0
can	0
activate	0
the	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
promoter	2
and	0
accelerate	0
cytopathic	0
effects	0
in	0
HIV-infected	7
human	8
T	8
cells	8
.	0

This	0
study	0
examines	0
the	0
regions	0
of	0
the	0
HIV	1
promoter	2
required	0
for	0
HHV-6	0
transactivation	0
in	0
a	0
heterogeneous	0
population	0
of	0
primary	7
human	8
T	8
lymphocytes	8
with	0
or	0
without	0
antigenic	0
stimulation	0
.	0

Two	0
different	0
strains	0
of	0
HHV-6	0
,	0
GS	0
and	0
Z29	0
,	0
transactivated	0
the	0
HIV	1
promoter	2
.	0

The	0
GS	0
strain	0
transactivated	0
the	0
promoter	1
in	0
both	0
stimulated	0
and	0
resting	0
T	7
cells	8
,	0
while	0
the	0
Z29	0
strain	0
increased	0
HIV	1
promoter	2
activity	0
only	0
in	0
stimulated	7
T	8
cells	8
.	0

Three	0
DNA	0
clones	0
containing	0
HHV-6	1
(	2
GS	2
)	2
genomic	2
fragments	2
transactivated	0
the	0
HIV	1
promoter	2
in	0
cotransfected	5
T	6
cells	6
.	0

A	0
21.4-kb	1
DNA	2
clone	2
,	0
pZVB70	1
,	0
showed	0
the	0
highest	0
transactivating	0
ability	0
,	0
while	0
two	0
other	0
DNA	1
fragments	2
,	0
pZVB10	1
(	0
6.2	0
kb	0
)	0
and	0
pZVH14	1
(	0
8.7	0
kb	0
)	0
,	0
showed	0
lower	0
activity	0
.	0

One	0
of	0
these	0
clones	0
,	0
pZVH14	1
,	0
activated	0
the	0
HIV	1
promoter	2
construct	2
containing	0
a	0
mutation	0
in	0
the	0
NF	1
kappa	2
B	2
site	2
.	0

However	0
,	0
this	0
mutated	1
NF	2
kappa	2
B	2
promoter	2
was	0
not	0
transactivated	0
during	0
HHV-6	0
(	0
GS	0
)	0
infection	0
or	0
after	0
cotransfection	0
with	0
pZVB70	1
or	0
pZVB10	1
.	0

These	0
data	0
indicate	0
that	0
the	0
NF	1
kappa	2
B	2
sites	2
of	0
the	0
HIV	1
promoter	2
are	0
essential	0
for	0
its	0
transactivation	0
during	0
HHV-6	0
(	0
GS	0
)	0
infection	0
.	0

By	0
increasing	0
HIV	1
promoter	2
activity	0
in	0
primary	7
T	8
lymphocytes	8
,	0
HHV-6	0
may	0
consequently	0
increase	0
HIV	0
replication	0
,	0
leading	0
to	0
an	0
increase	0
in	0
the	0
cytopathic	0
effect	0
on	0
coinfected	7
human	8
T	8
cells	8
.	0

Inhibition	0
of	0
HIV-1	0
replication	0
and	0
NF-kappa	9
B	10
activity	0
by	0
cysteine	0
and	0
cysteine	0
derivatives	0
.	0

HIV-1	1
proviral	2
DNA	2
contains	0
two	0
binding	1
sites	2
for	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
.	0

HIV-1-infected	0
individuals	0
have	0
,	0
on	0
average	0
,	0
abnormally	0
high	0
levels	0
of	0
tumour	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
and	0
abnormally	0
low	0
plasma	0
cysteine	0
levels	0
.	0

We	0
therefore	0
investigated	0
the	0
effects	0
of	0
cysteine	0
and	0
related	0
thiols	0
on	0
HIV-1	0
replication	0
and	0
NF-kappa	9
B	10
expression	0
.	0

The	0
experiments	0
in	0
this	0
report	0
show	0
that	0
cysteine	0
or	0
N-acetylcysteine	0
(	0
NAC	0
)	0
raise	0
the	0
intracellular	0
glutathione	0
(	0
GSH	0
)	0
level	0
and	0
inhibit	0
HIV-1	0
replication	0
in	0
persistently	0
infected	0
Molt-4	5
and	0
U937	5
cells	6
.	0

However	0
,	0
inhibition	0
of	0
HIV-1	0
replication	0
appears	0
not	0
to	0
be	0
directly	0
correlated	0
with	0
GSH	0
levels	0
.	0

Cysteine	0
and	0
NAC	0
also	0
inhibit	0
NF-kappa	9
B	10
activity	0
as	0
determined	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
and	0
chloramphenicol	9
acetyl-transferase	10
(	0
CAT	9
)	0
gene	0
expression	0
under	0
control	0
of	0
NF-kappa	9
B	10
binding	1
sites	2
in	0
uninfected	7
cells	8
.	0

This	0
suggests	0
that	0
the	0
cysteine	0
deficiency	0
in	0
HIV-1-infected	0
individuals	0
may	0
cause	0
an	0
over-expression	0
of	0
NF-kappa	1
B-dependent	2
genes	2
and	0
enhance	0
HIV-1	0
replication	0
.	0

NAC	0
may	0
be	0
considered	0
for	0
the	0
treatment	0
of	0
HIV-1-infected	0
individuals	0
.	0

A	0
thymus-specific	9
member	10
of	0
the	0
HMG	9
protein	10
family	10
regulates	0
the	0
human	1
T	2
cell	2
receptor	2
C	2
alpha	2
enhancer	2
.	0

The	0
human	9
T	10
cell-specific	10
transcription	10
factor	10
TCF-1	9
alpha	10
plays	0
a	0
key	0
role	0
in	0
the	0
tissue-specific	0
activation	0
of	0
the	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
C	0
alpha	0
enhancer	0
and	0
binds	0
to	0
pyrimidine-rich	1
elements	2
(	0
5'-PyCTTTG-3	0
'	0
)	0
present	0
in	0
a	0
variety	0
of	0
other	0
T	1
cell-specific	2
control	2
regions	2
.	0

Using	0
amino	0
acid	0
sequence	0
information	0
derived	0
from	0
the	0
DNA	9
affinity-purified	10
protein	10
,	0
we	0
have	0
now	0
isolated	0
cDNA	1
clones	2
encoding	0
TCF-1	9
alpha	10
.	0

The	0
TCF-1	1
alpha	2
cDNA	2
contains	0
a	0
single	0
68-amino-acid	9
domain	10
that	0
is	0
homologous	0
to	0
a	0
region	0
conserved	0
among	0
high-mobility	9
group	10
(	0
HMG	9
)	0
and	0
nonhistone	9
chromosomal	10
proteins	10
.	0

Expression	0
of	0
full-length	1
and	0
mutant	1
cDNA	2
clones	2
in	0
bacteria	0
reveal	0
that	0
the	0
single	9
HMG	10
motif	10
,	0
which	0
is	0
predicted	0
to	0
contain	0
two	0
extended	0
alpha-helical	9
segments	10
,	0
is	0
sufficient	0
to	0
direct	0
the	0
sequence-specific	0
binding	0
of	0
TCF-1	9
alpha	10
to	0
DNA	0
.	0

Northern	0
blot	0
experiments	0
demonstrate	0
further	0
that	0
TCF-1	3
alpha	4
mRNA	4
is	0
highly	0
tissue	0
specific	0
,	0
found	0
primarily	0
in	0
the	0
thymus	5
or	6
T	6
cell	6
lines	6
.	0

The	0
immature	5
CEM	6
T	6
cell	6
line	6
expresses	0
relatively	0
low	0
levels	0
of	0
TCF-1	3
alpha	4
mRNA	4
,	0
which	0
are	0
increased	0
upon	0
activation	0
of	0
these	0
cells	0
by	0
phorbol	0
esters	0
.	0

Interestingly	0
,	0
the	0
cloned	0
TCF-1	9
alpha	10
protein	10
is	0
a	0
potent	0
transcriptional	9
activator	10
of	0
the	0
human	1
TCR	2
alpha	2
enhancer	2
in	0
nonlymphoid	5
cell	6
lines	6
,	0
whereas	0
the	0
activity	0
of	0
the	0
endogenous	9
protein	10
in	0
T	5
cell	6
lines	6
is	0
strongly	0
dependent	0
on	0
an	0
additional	0
T	5
cell-specific	6
protein	6
that	0
interacts	0
with	0
the	0
core	0
enhancer	0
.	0

TCF-1	9
alpha	10
is	0
currently	0
unique	0
among	0
the	0
newly	0
emerging	0
family	0
of	0
DNA-binding	9
regulatory	10
proteins	10
that	0
share	0
the	0
HMG	9
motif	10
in	0
that	0
it	0
is	0
a	0
highly	9
tissue-specific	10
RNA	10
polymerase	10
II	10
transcription	9
factor	10
.	0

A	0
novel	0
HIV-1	0
isolate	0
containing	0
alterations	0
affecting	0
the	0
NF-kappa	1
B	2
element	2
.	0

Three	0
molecular	0
clones	0
of	0
HIV-1	0
,	0
derived	0
from	0
a	0
single	0
isolate	0
(	0
AL1	0
)	0
,	0
exhibited	0
distinct	0
replicative	0
and	0
cytopathic	0
properties	0
during	0
propagation	0
in	0
a	0
human	5
T	6
cell	6
line	6
.	0

The	0
phenotypic	0
differences	0
observed	0
were	0
attributable	0
,	0
in	0
large	0
part	0
,	0
to	0
changes	0
affecting	0
the	0
viral	1
LTR	2
.	0

Nucleotide	0
sequence	0
and	0
PCR	0
analyses	0
demonstrated	0
the	0
presence	0
of	0
novel	0
duplications	0
or	0
deletions	0
involving	0
the	0
NF-kappa	1
B	2
motif	2
.	0

These	0
changes	0
in	0
the	0
enhancer	1
element	2
were	0
identified	0
in	0
the	0
original	0
AL1	0
virus	0
stock	0
.	0

Subcloning	0
of	0
the	0
variant	1
NF-kappa	2
B	2
segments	2
into	0
LTR-driven	1
CAT	2
expression	2
vectors	2
confirmed	0
a	0
correlation	0
between	0
promoter	0
activity	0
and	0
replicative/cytopathic	0
capacity	0
.	0

Multiple	0
Oct2	9
isoforms	10
are	0
generated	0
by	0
alternative	0
splicing	0
.	0

The	0
interaction	0
of	0
the	0
Oct2	9
transcription	10
factor	10
with	0
the	0
cognate	1
octamer	2
motif	2
ATGCAAAT	0
is	0
a	0
critical	0
determinant	0
of	0
the	0
lymphoid-specific	0
expression	0
of	0
immunoglobulin	1
genes	2
.	0

Ectopic	0
expression	0
of	0
cloned	1
Oct2	2
cDNA	2
was	0
shown	0
to	0
be	0
sufficient	0
to	0
reconstitute	0
at	0
least	0
some	0
aspects	0
of	0
this	0
regulation	0
in	0
non-lymphoid	7
cells	8
.	0

We	0
describe	0
the	0
isolation	0
and	0
characterization	0
of	0
multiple	1
cDNAs	2
encoding	0
mouse	9
Oct2	10
from	0
a	0
mature	5
B-cell	6
line	6
and	0
we	0
show	0
that	0
a	0
variety	0
of	0
isoforms	0
of	0
this	0
transcription	9
factor	10
is	0
generated	0
from	0
a	0
single	0
gene	0
by	0
an	0
alternative	0
splicing	0
mechanism	0
.	0

All	0
the	0
isoforms	9
retain	0
the	0
previously	0
characterized	0
POU-domain	0
and	0
are	0
therefore	0
able	0
to	0
bind	0
to	0
the	0
octamer	1
motif	2
.	0

Different	0
amounts	0
of	0
the	0
various	0
isoforms	9
are	0
present	0
within	0
the	0
same	0
B-cell	7
regardless	0
of	0
the	0
developmental	0
stage	0
of	0
B-cell	7
differentiation	0
and	0
at	0
least	0
some	0
of	0
the	0
isoforms	9
are	0
conserved	0
between	0
mouse	0
and	0
humans	0
.	0

In	0
cotransfection	0
experiments	0
we	0
show	0
that	0
all	0
the	0
isoforms	9
are	0
able	0
to	0
activate	0
an	0
octamer	1
containing	0
promoter	1
element	2
in	0
fibroblasts	0
revealing	0
an	0
unexpected	0
functional	0
redundancy	0
.	0

Finally	0
,	0
we	0
show	0
that	0
one	0
of	0
the	0
isoforms	9
encodes	0
the	0
previously	0
described	0
lymphoid-specific	9
Oct2B	10
protein	10
which	0
has	0
been	0
suggested	0
to	0
be	0
involved	0
in	0
the	0
function	0
of	0
the	0
octamer	1
motif	2
in	0
the	0
context	0
of	0
the	0
immunoglobulin	1
heavy-chain	2
(	2
IgH	2
)	2
enhancer	2
.	0

[	0
Regulation	0
of	0
intracellular	0
cholesterol	0
synthesis	0
in	0
hypercholesterolemia	0
by	0
glucocorticoids	0
]	0

The	0
rate	0
of	0
endogenous	0
cholesterol	0
synthesis	0
in	0
blood	7
lymphocytes	8
and	0
skin	7
fibroblasts	8
from	0
patients	0
with	0
type	0
IIa	0
hyperlipidemia	0
was	0
found	0
to	0
be	0
increased	0
in	0
comparison	0
with	0
healthy	0
donors	0
.	0

The	0
cells	0
of	0
hyperlipidemic	0
patients	0
had	0
lowered	0
levels	0
of	0
glucocorticoid	9
receptors	10
concomitantly	0
with	0
a	0
partial	0
loss	0
of	0
their	0
sensitivity	0
to	0
glucocorticoids	0
.	0

In	0
fibroblasts	7
from	0
patients	0
with	0
hereditary	0
hypercholesteremia	0
of	0
homozygous	0
type	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
did	0
not	0
exceed	0
10	0
%	0
of	0
their	0
content	0
in	0
normal	7
cells	8
.	0

The	0
decrease	0
of	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
patients	0
with	0
type	0
IIa	0
hyperlipidemia	0
seems	0
to	0
be	0
a	0
compensatory	0
response	0
of	0
cells	0
culminating	0
in	0
activation	0
of	0
endogenous	0
cholesterol	0
synthesis	0
.	0

Negative	0
regulation	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
expression	0
in	0
monocytes	0
:	0
role	0
of	0
the	0
65-kDa	9
plus	0
50-kDa	9
NF-kappa	10
B	10
dimer	10
.	0

Although	0
monocytic	0
cells	0
can	0
provide	0
a	0
reservoir	0
for	0
viral	0
production	0
in	0
vivo	0
,	0
their	0
regulation	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
transcription	0
can	0
be	0
either	0
latent	0
,	0
restricted	0
,	0
or	0
productive	0
.	0

These	0
differences	0
in	0
gene	0
expression	0
have	0
not	0
been	0
molecularly	0
defined	0
.	0

In	0
THP-1	5
cells	6
with	0
restricted	0
HIV	0
expression	0
,	0
there	0
is	0
an	0
absence	0
of	0
DNA-protein	9
binding	10
complex	10
formation	0
with	0
the	0
HIV-1	1
promoter-enhancer	2
associated	0
with	0
markedly	0
less	0
viral	3
RNA	4
production	0
.	0

This	0
absence	0
of	0
binding	0
was	0
localized	0
to	0
the	0
NF-kappa	1
B	2
region	2
of	0
the	0
HIV-1	1
enhancer	2
;	0
the	0
65-kDa	9
plus	10
50-kDa	10
NF-kappa	10
B	10
heterodimer	10
was	0
preferentially	0
lost	0
.	0

Adding	0
purified	0
NF-kappa	9
B	10
protein	10
to	0
nuclear	0
extracts	0
from	0
cells	0
with	0
restricted	0
expression	0
overcomes	0
this	0
lack	0
of	0
binding	0
.	0

In	0
addition	0
,	0
treatment	0
of	0
these	0
nuclear	0
extracts	0
with	0
sodium	0
deoxycholate	0
restored	0
their	0
ability	0
to	0
form	0
the	0
heterodimer	9
,	0
suggesting	0
the	0
presence	0
of	0
an	0
inhibitor	0
of	0
NF-kappa	9
B	10
activity	0
.	0

Furthermore	0
,	0
treatment	0
of	0
nuclear	0
extracts	0
from	0
these	0
cells	0
that	0
had	0
restricted	0
expression	0
with	0
lipopolysaccharide	0
increased	0
viral	0
production	0
and	0
NF-kappa	9
B	10
activity	0
.	0

Antiserum	0
specific	0
for	0
NF-kappa	9
B	10
binding	10
proteins	10
,	0
but	0
not	0
c-rel-specific	0
antiserum	0
,	0
disrupted	0
heterodimer	9
complex	10
formation	0
.	0

Thus	0
,	0
both	0
NF-kappa	9
B-binding	10
complexes	10
are	0
needed	0
for	0
optimal	0
viral	0
transcription	0
.	0

Binding	0
of	0
the	0
65-kDa	9
plus	0
50-kDa	9
heterodimer	10
to	0
the	0
HIV-1	1
enhancer	2
can	0
be	0
negatively	0
regulated	0
in	0
monocytes	7
,	0
providing	0
one	0
mechanism	0
restricting	0
HIV-1	1
gene	2
expression	0
.	0

Glucocorticoid	9
receptors	10
in	0
normal	7
leukocytes	8
:	0
effects	0
of	0
age	0
,	0
gender	0
,	0
season	0
,	0
and	0
plasma	0
cortisol	0
concentrations	0
.	0

We	0
measured	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
mononuclear	7
leukocytes	8
(	0
MNL	7
)	0
isolated	0
from	0
peripheral	0
blood	0
of	0
145	0
apparently	0
healthy	0
volunteers	0
(	0
86	0
men	0
and	0
59	0
women	0
)	0
.	0

An	0
age-related	0
decrease	0
in	0
the	0
number	0
of	0
GR	9
was	0
suggested	0
between	0
subjects	0
younger	0
than	0
20	0
years	0
and	0
elderly	0
subjects	0
;	0
there	0
was	0
no	0
apparent	0
seasonal	0
variation	0
in	0
GR	9
.	0

Gender	0
difference	0
in	0
the	0
number	0
of	0
GR	9
was	0
not	0
significant	0
,	0
although	0
women	0
showed	0
slightly	0
fewer	0
GR	9
.	0

Eight	0
patients	0
with	0
dermatomyositis/polymyositis	0
were	0
examined	0
to	0
determine	0
whether	0
the	0
number	0
of	0
GR	9
in	0
MNL	7
could	0
be	0
down-regulated	0
by	0
their	0
cognate	0
ligands	0
.	0

The	0
number	0
of	0
GR	9
in	0
MNL	7
from	0
these	0
patients	0
was	0
significantly	0
decreased	0
one	0
month	0
after	0
the	0
initiation	0
of	0
prednisolone	0
therapy	0
.	0

However	0
,	0
in	0
normal	0
subjects	0
,	0
the	0
GR	9
in	0
MNL	7
did	0
not	0
demonstrate	0
circadian	0
variation	0
,	0
in	0
contrast	0
to	0
concentrations	0
of	0
plasma	0
cortisol	0
.	0

Synergism	0
between	0
two	0
distinct	0
elements	0
of	0
the	0
HTLV-I	1
enhancer	2
during	0
activation	0
by	0
the	0
trans-activator	9
of	0
HTLV-I	0
.	0

We	0
have	0
conducted	0
functional	0
studies	0
of	0
the	0
enhancer	1
elements	2
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
using	0
the	0
human	5
T-cell	6
lines	6
Jurkat	5
and	0
MOLT	5
4	6
,	0
which	0
are	0
negative	0
for	0
HTLV-I	0
,	0
and	0
MT-2	0
and	0
TL-Mor	0
,	0
which	0
carry	0
the	0
proviral	0
genome	0
of	0
HTLV-I	0
.	0

Two	0
distinct	0
elements	0
have	0
been	0
implicated	0
in	0
function	0
of	0
the	0
HTLV-I	1
enhancer	2
.	0

One	0
is	0
the	0
21-base-pair	1
(	2
bp	2
)	2
core	2
element	2
that	0
is	0
responsible	0
for	0
trans-activation	0
by	0
the	0
HTLV-I	0
trans-activator	9
p40tax	9
and	0
that	0
has	0
the	0
ability	0
to	0
bind	0
to	0
cyclic-AMP	9
responsive	10
element	10
binding	10
factor	10
(	10
CREB	10
)	10
-like	10
factor	10
(	0
s	0
)	0
.	0

The	0
other	0
is	0
a	0
region	0
interposed	0
between	0
the	0
21-bp	1
elements	2
.	0

In	0
this	0
study	0
we	0
demonstrate	0
that	0
a	0
subfragment	0
(	0
C26	0
)	0
in	0
the	0
region	0
between	0
the	0
21-bp	1
elements	2
is	0
involved	0
in	0
trans-activation	0
by	0
p40tax	9
,	0
possibly	0
through	0
binding	0
to	0
an	0
NF-kappa	9
B-like	10
nuclear	10
factor	10
or	0
factors	0
.	0

Formation	0
of	0
the	0
protein-DNA	9
complex	10
with	0
the	0
C26	9
subfragment	10
was	0
positively	0
affected	0
by	0
p40tax	9
.	0

The	0
C26	1
element	2
conferred	0
partial	0
responsiveness	0
to	0
p40tax	9
when	0
linked	0
to	0
one	0
copy	0
of	0
the	0
21-bp	1
element	2
that	0
,	0
by	0
itself	0
,	0
showed	0
little	0
activation	0
in	0
response	0
to	0
p40tax	9
.	0

However	0
,	0
the	0
C26	1
element	2
alone	0
,	0
even	0
when	0
repeated	0
,	0
could	0
not	0
be	0
activated	0
by	0
p40tax	9
,	0
unlike	0
other	0
NF-kappa	1
B-binding	2
elements	2
.	0

In	0
contrast	0
,	0
the	0
C26	1
element	2
itself	0
was	0
profoundly	0
activated	0
upon	0
stimulation	0
with	0
12-O-tetradecanoylphorbol-13-acetate	0
.	0

These	0
findings	0
therefore	0
suggest	0
that	0
the	0
HTLV-I	1
enhancer	2
contains	0
multiple	1
functional	2
elements	2
,	0
including	0
binding	0
sites	0
for	0
at	0
least	0
CREB-	9
and	10
NF-kappa	10
B-like	10
factors	10
,	0
which	0
synergistically	0
cooperate	0
in	0
activation	0
of	0
the	0
HTLV-I	1
enhancer	2
in	0
response	0
to	0
p40tax	9
.	0

Our	0
results	0
also	0
demonstrate	0
that	0
TPA-dependent	0
activation	0
of	0
the	0
HTLV-I	1
enhancer	2
may	0
be	0
mediated	0
through	0
the	0
C26	1
element	2
.	0

Human	0
tumor	9
necrosis	10
factor	10
alpha	10
gene	0
regulation	0
in	0
phorbol	0
ester	0
stimulated	5
T	6
and	6
B	6
cell	6
lines	6
.	0

The	0
minimal	0
region	0
of	0
the	0
human	1
tumor	2
necrosis	2
factor	2
alpha	2
(	2
TNF-alpha	2
)	2
gene	2
promoter	2
necessary	0
for	0
its	0
transcriptional	0
induction	0
by	0
phorbol	0
esters	0
(	0
PMA	0
)	0
in	0
human	5
T	6
and	6
B	6
lymphocyte	6
cell	6
lines	6
has	0
been	0
localized	0
between	0
-52	1
and	2
+89	2
nucleotides	2
(	0
nt	0
)	0
relative	0
to	0
the	0
gene	0
's	0
transcriptional	1
start	2
site	2
.	0

Comparison	0
of	0
these	0
sequences	0
to	0
those	0
required	0
to	0
mediate	0
virus	0
or	0
lipopolysaccharide	0
(	0
LPS	0
)	0
induction	0
of	0
the	0
gene	0
reveal	0
significant	0
differences	0
,	0
and	0
thus	0
,	0
the	0
sequence	0
requirements	0
for	0
PMA	0
induction	0
are	0
distinct	0
from	0
those	0
that	0
mediate	0
induction	0
by	0
virus	0
or	0
LPS	0
.	0

Although	0
three	0
sites	0
in	0
the	0
TNF-alpha	1
promoter	2
(	0
kappa	0
1	0
,	0
kappa	0
2	0
,	0
and	0
kappa	0
3	0
)	0
specifically	0
bind	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
in	0
lymphoid	0
nuclear	0
extracts	0
,	0
TNF-alpha	3
mRNA	4
induction	0
by	0
PMA	0
does	0
not	0
correlate	0
with	0
NF-kappa	9
B	10
binding	0
activities	0
displayed	0
by	0
different	0
T	5
and	6
B	6
cell	6
lines	6
.	0

Moreover	0
,	0
kappa	1
1-kappa	2
3	2
can	0
each	0
be	0
deleted	0
from	0
the	0
TNF-alpha	1
promoter	2
with	0
little	0
effect	0
on	0
the	0
gene	0
's	0
inducibility	0
by	0
PMA	0
.	0

Therefore	0
,	0
TNF-alpha	3
mRNA	4
induction	0
by	0
PMA	0
,	0
like	0
its	0
induction	0
by	0
virus	0
and	0
LPS	0
,	0
is	0
not	0
primarily	0
mediated	0
by	0
NF-kappa	9
B	10
,	0
but	0
rather	0
is	0
mediated	0
through	0
other	0
sequences	0
and	0
protein	9
factors	10
.	0

Surprisingly	0
,	0
multimers	0
of	0
kappa	0
1-kappa	0
3	0
can	0
confer	0
PMA	0
inducibility	0
on	0
a	0
heterologous	1
promoter	2
in	0
a	0
B	5
(	6
Raji	6
)	6
,	6
but	6
not	6
a	6
T	6
(	6
HUT78	6
)	6
cell	6
line	6
.	0

However	0
they	0
are	0
not	0
functional	0
on	0
a	0
truncated	0
TNF-alpha	1
promoter	2
,	0
indicating	0
that	0
promoter	0
context	0
and	0
cell	0
type	0
specificity	0
influence	0
the	0
PMA	0
inducible	0
function	0
of	0
these	0
NF-kappa	1
B	2
binding	2
sites	2
.	0

Differentiation-associated	0
expression	0
of	0
the	0
Epstein-Barr	9
virus	10
BZLF1	10
transactivator	10
protein	10
in	0
oral	0
hairy	0
leukoplakia	0
.	0

The	0
BZLF1	9
protein	10
of	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
a	0
key	0
immediate-early	9
protein	10
which	0
has	0
been	0
shown	0
to	0
disrupt	0
virus	0
latency	0
in	0
EBV-infected	7
B	8
cells	8
.	0

We	0
have	0
generated	0
a	0
monoclonal	9
antibody	10
,	0
BZ1	9
,	0
to	0
BZLF1	9
which	0
reacts	0
in	0
immunohistology	0
,	0
immunoblotting	0
,	0
and	0
immunoprecipitation	0
and	0
which	0
recognizes	0
both	0
the	0
active	9
,	10
dimeric	10
form	10
and	0
the	0
inactive	9
,	10
monomeric	10
form	10
of	0
the	0
protein	0
.	0

Biopsies	0
of	0
oral	0
hairy	0
leukoplakia	0
,	0
an	0
AIDS-associated	0
lesion	0
characterized	0
by	0
high-level	0
EBV	0
replication	0
,	0
were	0
examined	0
by	0
immunohistochemistry	0
using	0
the	0
BZ1	9
monoclonal	9
antibody	10
.	0

A	0
differentiation-associated	0
pattern	0
of	0
BZLF1	9
expression	0
was	0
observed	0
,	0
BZ1	9
reacting	0
with	0
nuclei	0
of	0
the	0
upper	0
spinous	0
layer	0
of	0
the	0
lesion	0
.	0

This	0
finding	0
suggests	0
that	0
the	0
BZLF1	1
promoter	2
may	0
be	0
regulated	0
by	0
the	0
degree	0
of	0
squamous	0
differentiation	0
.	0

A	0
comparison	0
of	0
in	0
situ	0
hybridization	0
to	0
EBV	1
DNA	2
and	0
viral	9
capsid	10
antigen	10
staining	0
with	0
BZ1	9
reactivity	0
suggested	0
that	0
BZLF1	9
expression	0
precedes	0
rampant	0
virus	0
replication	0
.	0

The	0
inability	0
to	0
detect	0
EBV	0
in	0
the	0
lower	0
epithelial	0
layers	0
of	0
oral	0
hairy	0
leukoplakia	0
raises	0
questions	0
concerning	0
the	0
nature	0
of	0
EBV	0
latency	0
and	0
persistence	0
in	0
stratified	0
squamous	0
epithelium	0
.	0

[	0
Changes	0
in	0
levels	0
of	0
leucocytic	9
estrogen	10
receptor	10
in	0
patients	0
with	0
menopausal	0
type	0
II	0
diabetes	0
and	0
its	0
significance	0
]	0

The	0
number	0
of	0
estrogen	9
receptors	10
(	0
ER	9
)	0
in	0
human	7
peripheral	8
leucocytes	8
in	0
12	0
women	0
with	0
menopausal	0
type	0
II	0
diabetes	0
was	0
measured	0
with	0
radio-ligand	0
binding	0
method	0
.	0

The	0
results	0
were	0
compared	0
with	0
those	0
of	0
12	0
menopausal	0
women	0
without	0
diabetes	0
and	0
12	0
normal	0
women	0
of	0
childbearing	0
age	0
.	0

It	0
was	0
found	0
that	0
the	0
number	0
of	0
ER	9
in	0
the	0
patients	0
was	0
significantly	0
decreased	0
.	0

Our	0
data	0
indicate	0
that	0
decrease	0
of	0
ER	9
level	0
in	0
leukocytes	7
may	0
be	0
related	0
to	0
the	0
pathogenesis	0
of	0
type	0
II	0
diabetes	0
in	0
menopausal	0
period	0
.	0

Lymphocyte	0
glucocorticoid	9
receptor	10
number	0
in	0
posttraumatic	0
stress	0
disorder	0
.	0

OBJECTIVE	0
:	0
The	0
authors	0
'	0
objective	0
was	0
to	0
investigate	0
the	0
possibility	0
that	0
glucocorticoid	9
receptor	10
changes	0
may	0
be	0
involved	0
in	0
the	0
dysregulation	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
(	0
HPA	0
)	0
axis	0
in	0
posttraumatic	0
stress	0
disorder	0
(	0
PTSD	0
)	0
.	0

METHOD	0
:	0
They	0
measured	0
the	0
number	0
of	0
lymphocyte	9
cytosolic	10
glucocorticoid	10
receptors	10
and	0
plasma	0
cortisol	0
concentrations	0
in	0
15	0
consecutively	0
admitted	0
male	0
combat	0
Vietnam	0
veterans	0
with	0
PTSD	0
and	0
in	0
a	0
normal	0
comparison	0
group	0
of	0
11	0
subjects	0
.	0

RESULTS	0
:	0
Both	0
the	0
patients	0
and	0
the	0
normal	0
comparison	0
subjects	0
showed	0
a	0
morning-to-afternoon	0
decline	0
in	0
glucocorticoid	9
receptor	10
concentrations	0
,	0
paralleling	0
the	0
normal	0
diurnal	0
decline	0
in	0
cortisol	0
levels	0
.	0

The	0
number	0
of	0
glucocorticoid	9
receptors	10
was	0
63	0
%	0
greater	0
in	0
the	0
morning	0
and	0
26	0
%	0
greater	0
in	0
the	0
afternoon	0
in	0
the	0
patients	0
with	0
PTSD	0
than	0
in	0
the	0
normal	0
subjects	0
.	0

No	0
group	0
differences	0
in	0
cortisol	0
levels	0
were	0
observed	0
,	0
nor	0
were	0
glucocorticoid	9
receptor	10
number	0
and	0
cortisol	0
levels	0
correlated	0
.	0

The	0
number	0
of	0
morning	9
glucocorticoid	10
receptors	10
was	0
positively	0
correlated	0
with	0
symptoms	0
of	0
PTSD	0
and	0
anxiety	0
.	0

CONCLUSIONS	0
:	0
These	0
results	0
provide	0
further	0
evidence	0
for	0
a	0
dysregulation	0
of	0
the	0
HPA	0
axis	0
in	0
PTSD	0
.	0

The	0
finding	0
that	0
patients	0
with	0
PTSD	0
had	0
a	0
substantially	0
greater	0
number	0
of	0
lymphocyte	9
glucocorticoid	10
receptors	10
than	0
normal	0
comparison	0
subjects	0
is	0
consistent	0
with	0
the	0
authors	0
'	0
previous	0
observations	0
of	0
low	0
24-hour	0
urinary	0
cortisol	0
excretion	0
in	0
subjects	0
with	0
PTSD	0
.	0

Furthermore	0
,	0
the	0
receptor	0
changes	0
observed	0
are	0
opposite	0
of	0
those	0
reported	0
in	0
major	0
depressive	0
disorder	0
.	0

The	0
present	0
data	0
,	0
along	0
with	0
other	0
findings	0
of	0
HPA	0
abnormalities	0
in	0
PTSD	0
,	0
support	0
the	0
possibility	0
of	0
a	0
greater	0
negative	0
feedback	0
sensitivity	0
at	0
one	0
or	0
more	0
levels	0
of	0
the	0
HPA	0
axis	0
.	0

Induction	0
of	0
NF-kappa	9
B	10
during	0
monocyte	0
differentiation	0
is	0
associated	0
with	0
activation	0
of	0
HIV-gene	0
expression	0
.	0

Cells	0
of	0
the	0
monocyte-macrophage	7
lineage	8
are	0
important	0
targets	0
of	0
HIV	0
infection	0
.	0

We	0
report	0
here	0
that	0
the	0
phenotypic	0
differentiation	0
of	0
monocyte	5
cell	6
lines	6
induced	0
by	0
phorbol	0
esters	0
or	0
tumour	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
is	0
associated	0
with	0
expression	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

In	0
parallel	0
with	0
such	0
differentiation	0
,	0
HIV	0
transcription	0
,	0
monitored	0
using	0
an	0
HIV	1
long	2
terminal	2
repeat	2
reporter	2
gene	2
construct	2
,	0
is	0
activated	0
in	0
such	0
cells	0
under	0
the	0
influence	0
of	0
enhanced	0
NF-kappa	9
B	10
expression	0
.	0

Also	0
,	0
in	0
a	0
promonocyte	5
cell	6
line	6
chronically	0
infected	0
with	0
HIV	0
,	0
NF-kappa	9
B	10
expression	0
and	0
HIV	0
transcription	0
were	0
enhanced	0
on	0
stimulation	0
with	0
phorbol	0
ester	0
or	0
TNF	9
alpha	10
.	0

Thus	0
,	0
stimulation	0
of	0
monocyte	5
cell	6
lines	6
by	0
phorbol	0
esters	0
or	0
TNF	9
alpha	10
induces	0
cell	0
differentiation	0
and	0
activates	0
HIV	0
transcription	0
.	0

Such	0
a	0
process	0
may	0
have	0
fundamental	0
implications	0
in	0
AIDS	0
pathogenesis	0
in	0
vivo	0
and	0
may	0
be	0
important	0
in	0
disease	0
progression	0
induced	0
by	0
opportunistic	0
infections	0
directly	0
or	0
indirectly	0
involving	0
macrophages	7
.	0

Demonstration	0
of	0
estrogen	9
and	10
progesterone	10
receptors	10
as	0
well	0
as	0
Ki-67	9
and	10
p-145	10
antigens	10
in	0
single	7
tumor	8
cells	8
from	0
blood	0
and	0
pleural	0
effusions	0
using	0
a	0
slide	0
assay	0
.	0

We	0
describe	0
a	0
slide	0
assay	0
that	0
allows	0
the	0
demonstration	0
of	0
antigens	9
localized	0
in	0
the	0
nucleus	0
from	0
isolated	7
white	8
blood	8
cells	8
as	0
well	0
as	0
from	0
single	7
tumor	8
cells	8
derived	0
from	0
malignant	0
effusions	0
.	0

With	0
the	0
antibodies	0
Ki-67	9
and	0
anti-p-145	9
an	0
increased	0
rate	0
of	0
nuclear	0
and	0
nucleolar	0
staining	0
resulted	0
in	0
cells	0
from	0
highly	0
malignant	0
lymphomas	0
.	0

An	0
almost	0
identical	0
reaction	0
was	0
obtained	0
when	0
tumor	7
cells	8
from	0
malignant	0
effusions	0
were	0
tested	0
.	0

Cells	0
isolated	0
from	0
the	0
blood	0
of	0
patients	0
with	0
leukemic	0
spread	0
of	0
lymphomas	0
of	0
low	0
malignancy	0
yielded	0
a	0
weak	0
staining	0
comparable	0
to	0
that	0
of	0
normal	7
mesothelial	8
cells	8
from	0
non-tumorous	0
cavity	0
fluids	0
.	0

The	0
detection	0
of	0
estrogen	9
and	0
progesterone	9
receptors	10
(	0
ER	9
and	0
PR	9
)	0
localized	0
in	0
the	0
cell	0
nucleus	0
can	0
be	0
achieved	0
by	0
the	0
same	0
assay	0
.	0

The	0
reaction	0
is	0
enhanced	0
by	0
incubation	0
of	0
the	0
tumor	7
cells	8
for	0
30	0
min	0
at	0
37	0
degrees	0
C	0
prior	0
to	0
fixation	0
.	0

Pleural	0
effusions	0
from	0
20	0
patients	0
with	0
breast	0
cancer	0
were	0
tested	0
.	0

ER	9
was	0
positive	0
in	0
13	0
and	0
PR	9
was	0
positive	0
in	0
12	0
of	0
the	0
20	0
samples	0
.	0

In	0
5	0
cases	0
there	0
was	0
a	0
divergent	0
reaction	0
with	0
ER	9
and	0
PR	9
antibody	0
.	0

The	0
hormone	9
receptors	10
of	0
the	0
primary	0
tumor	0
were	0
known	0
in	0
15	0
(	0
ER	9
)	0
and	0
14	0
(	0
PR	9
)	0
patients	0
,	0
respectively	0
.	0

In	0
each	0
cohort	0
there	0
was	0
only	0
one	0
case	0
with	0
a	0
negative	0
reaction	0
of	0
the	0
primary	0
tumor	0
and	0
a	0
positive	0
reaction	0
with	0
the	0
isolated	0
tumor	7
cells	8
from	0
the	0
pleural	0
effusions	0
.	0

These	0
results	0
indicate	0
that	0
the	0
demonstration	0
of	0
hormone	9
receptor	10
proteins	10
in	0
cells	0
from	0
malignant	0
effusions	0
is	0
possible	0
and	0
that	0
there	0
is	0
a	0
correlation	0
with	0
the	0
status	0
of	0
the	0
primary	0
site	0
of	0
cancer	0
.	0

Constitutive	0
activation	0
of	0
NF-kB	9
in	0
human	7
thymocytes	8
.	0

NF-kB	9
is	0
a	0
eukaryotic	9
transcription	10
regulatory	10
factor	10
.	0

In	0
T	7
cells	8
and	0
T	5
cell	6
lines	6
,	0
NF-kB	9
is	0
bound	0
to	0
a	0
cytoplasmic	9
proteic	10
inhibitor	10
,	0
the	0
IkB	9
.	0

Treatment	0
of	0
T	7
cells	8
with	0
mitogens	0
(	0
phorbol	0
esters	0
)	0
or	0
cytokines	9
(	0
TNF	9
alpha	10
)	0
induces	0
NF-kB	9
nuclear	0
translocation	0
and	0
the	0
subsequent	0
expression	0
of	0
NF-kB	1
dependent	2
T	2
cell	2
genes	2
.	0

Here	0
we	0
examined	0
the	0
activation	0
of	0
NF-kB	9
in	0
human	7
T	8
cell	8
thymic	8
progenitors	8
.	0

We	0
report	0
differences	0
in	0
(	0
Ca2+	0
)	0
i	0
requirement	0
for	0
NF-kB	9
activation	0
in	0
thymocytes	7
as	0
compared	0
to	0
mature	0
T	7
cells	8
.	0

Furthermore	0
,	0
our	0
results	0
indicated	0
that	0
thymocytes	7
have	0
a	0
constitutively	9
active	10
form	10
of	0
NF-kB	9
,	0
suggesting	0
that	0
they	0
are	0
activated	0
in	0
vivo	0
.	0

TCF-1	9
,	0
a	0
T	9
cell-specific	10
transcription	10
factor	10
of	0
the	0
HMG	9
box	10
family	10
,	0
interacts	0
with	0
sequence	1
motifs	2
in	0
the	0
TCR	1
beta	2
and	2
TCR	2
delta	2
enhancers	2
.	0

We	0
have	0
recently	0
identified	0
and	0
cloned	0
TCF-1	9
,	0
a	0
T	9
cell-specific	10
transcription	10
factor	10
with	0
specificity	0
for	0
the	0
AACAAAG	0
motif	0
in	0
the	0
CD3	0
epsilon	0
enhancer	0
and	0
for	0
the	0
TTCAAAG	1
motif	2
in	0
the	0
TCR	1
alpha	2
enhancer	2
.	0

TCF-1	9
belongs	0
to	0
the	0
family	0
of	0
transcription-regulating	9
proteins	10
which	0
share	0
a	0
region	0
of	0
homology	0
termed	0
the	0
HMG-box	9
.	0

Here	0
,	0
we	0
show	0
by	0
gel	0
retardation	0
analysis	0
that	0
TCF-1	9
specifically	0
recognizes	0
the	0
T	1
beta	2
5	2
element	2
of	0
the	0
TCR	1
beta	2
enhancer	2
and	0
the	0
T	1
delta	2
7	2
element	2
of	0
the	0
TCR	1
delta	2
enhancer	2
.	0

Comparison	0
of	0
the	0
sequences	0
of	0
all	0
elements	1
recognized	0
by	0
TCF-1	9
defines	0
a	0
consensus	1
motif	2
A/T	1
A/T	2
C	2
A	2
A/G	2
A	2
G	2
.	0

These	0
observations	0
imply	0
that	0
TCF-1	9
is	0
involved	0
in	0
the	0
control	0
of	0
several	0
T	1
cell-specific	2
genes	2
and	0
might	0
thus	0
play	0
an	0
important	0
role	0
in	0
the	0
establishment	0
and	0
maintenance	0
of	0
the	0
mature	7
T	8
cell	8
phenotype	8
.	0

[	0
Regulatory	0
effect	0
of	0
insulin	9
on	0
glucocorticoid	9
receptor	10
in	0
human	7
peripheral	8
leukocytes	8
]	0

The	0
regulatory	0
effect	0
of	0
insulin	9
on	0
the	0
specific	0
binding	0
power	0
of	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
of	0
human	7
leukocytes	8
was	0
assessed	0
by	0
the	0
unoccupied	9
receptor	10
sites	10
capable	0
of	0
combining	0
with	0
[	0
3H	0
]	0
labelled	0
dexamethasone	0
measured	0
at	0
3	0
and	0
24	0
h	0
after	0
incubation	0
with	0
various	0
concentrations	0
of	0
insulin	9
added	0
to	0
the	0
medium	0
.	0

After	0
3	0
h	0
incubation	0
the	0
specific	0
binding	0
power	0
with	0
[	0
3H	0
]	0
Dex	0
was	0
decreased	0
by	0
23.3	0
+/-	0
10.0	0
,	0
32.2	0
+/-	0
13.2	0
and	0
54.3	0
+/-	0
9.2	0
%	0
(	0
P	0
greater	0
than	0
0.05	0
,	0
P	0
greater	0
than	0
0.05	0
and	0
P	0
less	0
than	0
0.01	0
as	0
compared	0
with	0
the	0
control	0
value	0
of	0
100	0
in	0
the	0
absence	0
of	0
insulin	9
)	0
respectively	0
in	0
the	0
presence	0
of	0
20	0
mU/L	0
(	0
physiological	0
testing	0
concentration	0
)	0
,	0
200	0
mU/L	0
(	0
physiological	0
upper	0
limit	0
)	0
and	0
2	0
,	0
000	0
mU/L	0
(	0
pharmacological	0
concentration	0
)	0
insulin	9
in	0
the	0
incubation	0
medium	0
.	0

After	0
24	0
h	0
incubation	0
the	0
decrease	0
of	0
these	0
values	0
increased	0
respectively	0
to	0
43.5	0
+/-	0
19.0	0
,	0
56.1	0
+/-	0
20.7	0
and	0
80.2	0
+/-	0
15.5	0
(	0
P	0
less	0
than	0
0.05	0
,	0
P	0
less	0
than	0
0.01	0
and	0
P	0
less	0
than	0
0.01	0
compared	0
with	0
control	0
)	0
.	0

Thus	0
the	0
inhibitory	0
effect	0
of	0
insulin	9
on	0
the	0
GR	9
binding	0
power	0
is	0
both	0
dose-	0
and	0
time-dependent	0
,	0
which	0
strongly	0
suggests	0
that	0
GR	9
is	0
tonically	0
controlled	0
by	0
insulin	9
concentration	0
change	0
under	0
physiological	0
conditions	0
.	0

The	0
effect	0
of	0
toremifene	0
therapy	0
on	0
serum	9
immunoglobulin	10
levels	0
in	0
breast	0
cancer	0
.	0

Estrogens	0
and	0
anti-estrogens	0
enhance	0
the	0
number	0
of	0
immunoglobulin	7
(	8
Ig	8
)	8
-secreting	8
cells	8
in	0
pokeweed	5
mitogen	6
(	6
PWM	6
)	6
-stimulated	6
lymphocyte	6
cultures	6
.	0

Lymphocytes	7
from	0
patients	0
who	0
have	0
received	0
anti-estrogen	0
therapy	0
show	0
similar	0
enhancement	0
of	0
Ig-secreting	7
cells	8
after	0
PWM	9
stimulation	0
.	0

In	0
this	0
study	0
the	0
effect	0
of	0
anti-estrogen	0
(	0
toremifene	0
)	0
therapy	0
on	0
serum	9
immunoglobulin	10
(	0
IgA	9
,	0
IgM	9
,	0
IgG	9
)	0
levels	0
in	0
breast	0
cancer	0
patients	0
was	0
investigated	0
.	0

Serum	0
Ig	0
levels	0
were	0
followed	0
up	0
to	0
two	0
years	0
after	0
or	0
during	0
the	0
therapy	0
.	0

An	0
unexpected	0
finding	0
was	0
that	0
the	0
Ig	0
levels	0
decreased	0
during	0
the	0
follow-up	0
period	0
.	0

This	0
decrease	0
was	0
seen	0
in	0
patients	0
who	0
responded	0
to	0
the	0
therapy	0
as	0
well	0
as	0
in	0
those	0
who	0
did	0
not	0
.	0

Human	9
erythroid	10
5-aminolevulinate	10
synthase	10
:	0
promoter	1
analysis	0
and	0
identification	0
of	0
an	0
iron-responsive	1
element	2
in	0
the	0
mRNA	3
.	0

5-Aminolevulinate	9
synthase	10
(	0
ALAS	9
)	0
catalyzes	0
the	0
first	0
step	0
of	0
the	0
heme	9
biosynthetic	0
pathway	0
.	0

cDNA	1
clones	2
for	0
the	0
human	9
erythroid	10
ALAS	10
isozyme	10
were	0
isolated	0
from	0
a	0
fetal	0
liver	0
library	0
.	0

It	0
can	0
be	0
deduced	0
that	0
the	0
erythroid	9
ALAS	10
precursor	10
protein	10
has	0
a	0
molecular	0
weight	0
of	0
64.6	0
kd	0
,	0
and	0
is	0
similar	0
in	0
size	0
to	0
the	0
previously	0
isolated	0
human	9
housekeeping	10
ALAS	10
precursor	10
of	0
molecular	0
weight	0
70.6	0
kd	0
.	0

The	0
mature	0
mitochondrial	0
forms	0
of	0
the	0
erythroid	0
and	0
housekeeping	9
ALAS	10
isozymes	10
are	0
predicted	0
to	0
have	0
molecular	0
weights	0
of	0
59.5	0
kd	0
and	0
64.6	0
kd	0
,	0
respectively	0
.	0

The	0
two	0
isozymes	9
show	0
little	0
amino	0
acid	0
identity	0
in	0
their	0
N-terminal	9
signal	10
sequences	10
but	0
have	0
considerable	0
sequence	0
identity	0
in	0
the	0
C-terminal	9
two-thirds	10
of	0
their	0
proteins	0
.	0

An	0
analysis	0
of	0
the	0
immediate	1
promoter	2
of	0
the	0
human	1
erythroid	2
ALAS	2
gene	2
revealed	0
several	0
putative	0
erythroid-specific	1
cis-acting	2
elements	2
including	0
both	0
a	0
GATA-1	1
and	0
an	0
NF-E2	1
binding	2
site	2
.	0

An	0
iron-responsive	3
element	4
(	4
IRE	4
)	4
motif	4
has	0
been	0
identified	0
in	0
the	0
5'-untranslated	0
region	0
of	0
the	0
human	3
erythroid	4
ALAS	4
mRNA	4
,	0
but	0
is	0
not	0
present	0
in	0
the	0
housekeeping	3
ALAS	4
mRNA	4
.	0

Gel	0
retardation	0
experiments	0
established	0
that	0
this	0
IRE	3
motif	4
formed	0
a	0
protein	9
-	10
RNA	10
complex	10
with	0
cytosolic	0
extracts	0
from	0
human	5
K562	6
cells	6
and	0
this	0
binding	0
was	0
strongly	0
competed	0
with	0
IRE	3
transcripts	4
from	0
ferritin	3
or	4
transferrin	4
receptor	4
mRNAs	4
.	0

A	0
transcript	0
of	0
the	0
ALAS	1
IRE	2
,	0
mutated	0
in	0
the	0
conserved	0
loop	0
of	0
the	0
IRE	1
,	0
did	0
not	0
readily	0
form	0
this	0
protein	9
-	10
RNA	10
complex	10
.	0

These	0
results	0
suggest	0
that	0
the	0
IRE	3
motif	4
in	0
the	0
ALAS	3
mRNA	4
is	0
functional	0
and	0
imply	0
that	0
translation	0
of	0
the	0
mRNA	3
is	0
controlled	0
by	0
cellular	0
iron	0
availability	0
during	0
erythropoiesis	0
.	0

Regulation	0
of	0
jun	0
and	0
fos	0
gene	0
expression	0
in	0
human	7
monocytes	8
by	0
the	0
macrophage	9
colony-stimulating	10
factor	10
.	0

The	0
macrophage	9
colony-stimulating	10
factor	10
(	0
M-CSF	9
)	0
is	0
required	0
for	0
the	0
growth	0
and	0
differentiation	0
of	0
mononuclear	7
phagocytes	8
.	0

However	0
,	0
the	0
signaling	0
events	0
responsible	0
for	0
these	0
effects	0
remain	0
unclear	0
.	0

The	0
present	0
studies	0
have	0
examined	0
the	0
effects	0
of	0
M-CSF	9
on	0
potential	0
signaling	0
pathways	0
involving	0
expression	0
of	0
the	0
jun	1
and	2
fos	2
early	2
response	2
genes	2
.	0

Low	0
levels	0
of	0
c-jun	9
transcripts	10
were	0
detectable	0
in	0
resting	7
human	8
peripheral	8
blood	8
monocytes	8
.	0

Treatment	0
of	0
these	0
cells	0
with	0
10	0
(	0
3	0
)	0
units/ml	0
human	9
recombinant	10
M-CSF	10
was	0
associated	0
with	0
rapid	0
and	0
transient	0
increases	0
in	0
c-jun	3
mRNA	4
levels	0
.	0

Nuclear	0
run-on	0
assays	0
and	0
mRNA	0
stability	0
studies	0
demonstrated	0
that	0
M-CSF	9
regulates	0
c-jun	1
expression	0
by	0
both	0
an	0
increase	0
in	0
transcription	0
rate	0
and	0
a	0
prolongation	0
in	0
the	0
half-life	0
of	0
c-jun	3
transcripts	4
.	0

M-CSF	9
treatment	0
was	0
also	0
associated	0
with	0
a	0
rapid	0
induction	0
of	0
the	0
jun-B	1
gene	2
,	0
although	0
expression	0
of	0
this	0
gene	0
was	0
prolonged	0
compared	0
to	0
that	0
of	0
c-jun	1
.	0

We	0
further	0
demonstrate	0
that	0
M-CSF	9
increases	0
c-fos	3
mRNA	4
levels	0
in	0
human	7
monocytes	8
through	0
control	0
at	0
both	0
the	0
transcriptional	0
and	0
posttranscriptional	0
levels	0
.	0

Maximal	0
induction	0
of	0
the	0
c-fos	1
gene	2
was	0
followed	0
by	0
that	0
for	0
the	0
fos-B	1
gene	2
.	0

Moreover	0
,	0
M-CSF	9
-induced	0
expression	0
of	0
the	0
fos-related	1
gene	2
,	0
fra-1	1
,	0
was	0
delayed	0
compared	0
to	0
that	0
for	0
both	0
c-fos	1
and	0
fos-B	1
.	0

Taken	0
together	0
,	0
the	0
results	0
indicate	0
that	0
M-CSF	9
treatment	0
is	0
associated	0
with	0
differential	0
activation	0
of	0
multiple	0
members	0
of	0
the	0
jun/fos	1
family	2
and	0
that	0
expression	0
of	0
these	0
genes	0
could	0
contribute	0
to	0
nuclear	0
signaling	0
mechanisms	0
that	0
regulate	0
a	0
specific	0
program	0
of	0
monocyte	0
differentiation	0
.	0

Glucocorticoid	9
receptors	10
in	0
systemic	0
lupus	0
erythematosus	0
.	0

Glucocorticosteroids	0
remain	0
the	0
major	0
treatment	0
modality	0
for	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
,	0
but	0
their	0
mechanism	0
of	0
action	0
is	0
unclear	0
.	0

Over	0
the	0
past	0
decade	0
it	0
has	0
become	0
clear	0
that	0
glucocorticosteroid	9
receptors	10
play	0
a	0
significant	0
role	0
in	0
the	0
mechanism	0
of	0
glucocorticosteroid	0
action	0
.	0

We	0
studied	0
glucocorticosteroid	9
receptor	10
density	0
and	0
affinity	0
on	0
peripheral	7
blood	8
mononuclear	8
cells	8
by	0
the	0
glucocorticosteroid	0
binding	0
assay	0
in	0
33	0
patients	0
with	0
SLE	0
who	0
had	0
taken	0
no	0
glucocorticosteroid	0
for	0
the	0
previous	0
6	0
months	0
and	0
in	0
32	0
healthy	0
controls	0
.	0

Patients	0
'	0
disease	0
activity	0
was	0
measured	0
by	0
the	0
SLE	0
Disease	0
Activity	0
Index	0
(	0
SLEDAI	0
)	0
.	0

Glucocorticosteroid	9
receptors	10
on	0
leukocytes	7
of	0
patients	0
with	0
SLE	0
were	0
significantly	0
higher	0
than	0
in	0
healthy	0
controls	0
(	0
4419	0
+/-	0
306	0
vs	0
3369	0
+/-	0
196	0
,	0
p	0
less	0
than	0
0.005	0
)	0
.	0

The	0
binding	0
affinity	0
was	0
not	0
different	0
between	0
patients	0
and	0
controls	0
.	0

There	0
was	0
no	0
correlation	0
between	0
glucocorticosteroid	9
receptor	10
number	0
and	0
SLE	0
disease	0
activity	0
.	0

Kappa	9
B	10
binding	10
proteins	10
are	0
constitutively	0
expressed	0
in	0
an	0
IL-2	5
autocrine	6
human	6
T	6
cell	6
line	6
.	0

The	0
IL-2	1
and	2
the	2
IL-2-R	2
alpha	2
genes	2
are	0
both	0
expressed	0
transiently	0
in	0
normal	7
T	8
lymphocytes	8
after	0
Ag	0
or	0
mitogen	0
activation	0
.	0

In	0
contrast	0
,	0
the	0
human	5
T	6
cell	6
line	6
,	0
IARC	5
301	6
,	0
expresses	0
these	0
two	0
genes	0
constitutively	0
and	0
we	0
have	0
previously	0
demonstrated	0
that	0
its	0
growth	0
depends	0
on	0
the	0
autocrine	0
production	0
of	0
this	0
T	9
cell	10
growth	10
factor	10
and	0
high	9
affinity	10
IL-2R	10
.	0

To	0
dissect	0
the	0
molecular	0
basis	0
for	0
the	0
unusual	0
persistent	0
expression	0
of	0
the	0
IL-2	1
and	2
IL-2-R	2
alpha	2
genes	2
in	0
these	0
IARC	5
301	6
T	7
cells	8
,	0
we	0
have	0
analyzed	0
the	0
interactions	0
of	0
constitutively	9
expressed	10
nuclear	10
proteins	10
with	0
the	0
5	1
'	2
flanking	2
regions	2
of	0
the	0
IL-2	1
and	2
IL-2-R	2
alpha	2
genes	2
using	0
both	0
DNase	9
I	10
footprinting	0
and	0
gel	0
retardation	0
techniques	0
.	0

We	0
have	0
found	0
that	0
a	0
region	0
in	0
both	0
genes	0
(	0
-276	0
to	0
-250	0
for	0
IL-2-R	1
alpha	2
and	0
-203	0
to	0
-183	0
for	0
IL-2	1
)	0
,	0
which	0
corresponds	0
to	0
a	0
kappa	1
B	2
enhancer	2
element	2
,	2
is	0
specifically	0
protected	0
by	0
nuclear	9
proteins	10
from	0
IARC	5
301	6
.	0

In	0
agreement	0
with	0
this	0
finding	0
,	0
both	0
the	0
IL-2	1
and	2
IL-2-R	2
alpha	2
promoters	2
are	0
active	0
in	0
transient	0
transfection	0
assays	0
in	0
IARC	5
301	6
cells	6
.	0

In	0
contrast	0
,	0
mutation	0
of	0
the	0
kappa	9
B	10
enhancer	10
results	0
in	0
markedly	0
attenuated	0
activities	0
of	0
both	0
promoters	1
.	0

Two	0
proteins	0
binding	0
the	0
kappa	1
B	2
sequence	2
,	0
NF-kappa	9
B	10
and	0
KBF1	9
,	0
are	0
constitutively	0
expressed	0
in	0
IARC	5
301	6
nuclei	0
and	0
induced	0
by	0
PMA	0
and	0
PHA	9
in	0
Jurkat	5
.	0

They	0
bind	0
to	0
the	0
kappa	1
B	2
motifs	2
with	0
different	0
relative	0
affinities	0
that	0
may	0
reflect	0
their	0
different	0
contribution	0
in	0
the	0
expression	0
of	0
various	0
promoters	1
.	0

HIV1	0
infection	0
of	0
human	7
monocytes	8
and	0
macrophages	7
promotes	0
induction	0
or	0
translocation	0
of	0
NF-KB-related	9
factors	10
.	0

In	0
1991	0
,	0
we	0
demonstrated	0
,	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
that	0
3	0
different	0
factors	0
(	0
termed	0
B1	9
,	0
B2	9
and	0
B3	9
)	0
with	0
affinity	0
for	0
the	0
KB-enhancer	1
target	2
sequence	2
were	0
specifically	0
detected	0
in	0
nuclear	0
extracts	0
from	0
HIV1-infected	7
monocytes	8
and	0
macrophages	7
.	0

The	0
B2	9
factor	10
was	0
induced	0
in	0
the	0
nuclei	0
of	0
these	0
cells	0
only	0
upon	0
HIV1	0
infection	0
.	0

The	0
B3	9
factor	10
was	0
only	0
slightly	0
evident	0
in	0
nuclei	0
of	0
uninfected	7
cells	8
but	0
was	0
readily	0
detectable	0
in	0
nuclei	0
of	0
infected	7
monocytes	8
.	0

Its	0
expression	0
remained	0
very	0
low	0
in	0
nuclei	0
of	0
HIV1-infected	7
macrophages	8
.	0

In	0
this	0
paper	0
,	0
we	0
demonstrate	0
that	0
the	0
B2	9
factor	10
is	0
expressed	0
in	0
the	0
cytosol	0
of	0
monocytes	7
and	0
macrophages	7
as	0
a	0
DNA-binding	9
protein	10
,	0
indicating	0
that	0
it	0
is	0
not	0
associated	0
with	0
an	0
inhibitor	0
(	0
IKB	0
)	0
.	0

This	0
factor	0
remained	0
clustered	0
in	0
the	0
cytosol	0
and	0
was	0
translocated	0
to	0
the	0
nuclei	0
only	0
after	0
HIV1	0
infection	0
.	0

The	0
B3	9
factor	10
is	0
detected	0
in	0
the	0
cytosol	0
only	0
when	0
cells	0
are	0
HIV1-infected	0
.	0

The	0
role	0
of	0
HIV1	0
infection	0
in	0
the	0
expression	0
and	0
the	0
translocation	0
of	0
these	0
factors	0
is	0
discussed	0
.	0

Identification	0
and	0
cloning	0
of	0
TCF-1	9
,	0
a	0
T	9
lymphocyte-specific	10
transcription	10
factor	10
containing	0
a	0
sequence-specific	9
HMG	10
box	10
.	0

CD3	9
-epsilon	0
expression	0
is	0
controlled	0
by	0
a	0
downstream	1
T	2
lymphocyte-specific	2
enhancer	2
element	2
.	0

We	0
report	0
the	0
identification	0
of	0
a	0
T	9
cell-specific	10
transcription	10
factor	10
,	0
TCF-1	9
,	0
binding	0
to	0
this	0
element	0
.	0

The	0
multimerized	9
recognition	10
motif	10
of	0
TCF-1	9
constituted	0
a	0
T	0
cell-specific	0
enhancer	0
.	0

Subsequent	0
cloning	0
of	0
TCF-1	9
identified	0
three	0
splice	9
alternatives	10
.	0

TCF-1	9
contained	0
a	0
single	0
DNA-binding	9
HMG	10
box	10
most	0
closely	0
related	0
to	0
similar	0
boxes	0
in	0
the	0
putative	1
mammalian	2
sex-determining	2
gene	2
SRY	1
and	0
in	0
the	0
Schizosaccharomyces	1
pombe	2
Mc	2
mating	2
type	2
gene	2
.	0

TCF-1	3
mRNA	4
was	0
expressed	0
uniquely	0
in	0
T	7
lymphocytes	8
.	0

Upon	0
cotransfection	0
into	0
non-T	7
cells	8
,	0
TCF-1	9
could	0
transactivate	0
through	0
its	0
cognate	0
motif	0
.	0

These	0
results	0
identify	0
TCF-1	9
as	0
a	0
T	9
cell-specific	10
transcription	10
factor	10
,	0
which	0
might	0
play	0
a	0
role	0
in	0
the	0
establishment	0
of	0
the	0
mature	7
T	8
cell	8
phenotype	8
.	0

Identification	0
of	0
transcriptional	9
suppressor	10
proteins	10
that	0
bind	0
to	0
the	0
negative	1
regulatory	2
element	2
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
.	0

Two	0
different	0
proteins	0
which	0
independently	0
bound	0
to	0
neighboring	0
sequences	0
within	0
the	0
negative	1
regulatory	2
element	2
(	0
NRE	1
)	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
were	0
detected	0
in	0
the	0
nuclear	0
extract	0
of	0
a	0
virus-infected	5
human	6
T	6
cell	6
line	6
.	0

One	0
of	0
the	0
factors	0
bound	0
to	0
a	0
novel	1
dyad	2
symmetrical	2
sequence	2
.	0

This	0
sequence	0
is	0
well	0
conserved	0
in	0
various	0
HIV-1	0
isolates	0
and	0
partial	0
homology	0
was	0
found	0
with	0
the	0
promoter	1
region	2
of	0
the	0
human	1
retinoblastoma	2
gene	2
.	0

Similar	0
DNA	0
binding	0
activity	0
was	0
detected	0
in	0
a	0
variety	0
of	0
virus-uninfected	5
human	6
T	6
cell	6
lines	6
and	0
HeLa	5
cells	6
by	0
means	0
of	0
a	0
gel	0
mobility	0
shift	0
assay	0
.	0

The	0
other	0
factor	0
bound	0
to	0
a	0
putative	1
AP-1	2
recognition	2
sequence	2
predicted	0
for	0
the	0
HIV-1	0
NRE	1
.	0

However	0
,	0
this	0
factor	0
did	0
not	0
bind	0
to	0
a	0
typical	0
AP-1	1
site	2
.	0

The	0
insertion	0
of	0
multiple	0
copies	0
of	0
the	0
binding	1
site	2
for	0
the	0
former	0
or	0
latter	0
factor	0
into	0
a	0
heterologous	1
promoter	2
reduced	0
the	0
promoter	0
activity	0
to	0
one-tenth	0
or	0
one-third	0
,	0
respectively	0
.	0

Thus	0
,	0
each	0
factor	0
may	0
function	0
as	0
a	0
novel	9
negative	10
regulator	10
of	0
transcription	0
.	0

Protein	9
kinase	10
C	10
activation	0
and	0
protooncogene	1
expression	0
in	0
differentiation/retrodifferentiation	0
of	0
human	5
U-937	6
leukemia	6
cells	6
.	0

Human	5
U-937	6
leukemia	6
cells	6
differentiate	0
along	0
the	0
monocytic	7
lineage	8
following	0
3-day	0
exposures	0
to	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
.	0

This	0
induction	0
of	0
differentiation	0
is	0
accompanied	0
by	0
adherence	0
and	0
loss	0
of	0
proliferation	0
,	0
as	0
well	0
as	0
expression/repression	0
of	0
differentiation-associated	1
genes	2
.	0

Long	0
term	0
culture	0
of	0
TPA-differentiated	7
U-937	8
cells	8
in	0
the	0
absence	0
of	0
phorbol	0
ester	0
for	0
32-36	0
days	0
resulted	0
in	0
a	0
process	0
of	0
retrodifferentiation	0
.	0

The	0
retrodifferentiated	0
cells	0
detached	0
from	0
the	0
substrate	0
and	0
reinitiated	0
proliferation	0
.	0

Other	0
cellular	0
parameters	0
,	0
such	0
as	0
glycosidase	0
activities	0
,	0
cytokine	9
release	0
,	0
and	0
filament	0
expression	0
,	0
returned	0
to	0
levels	0
similar	0
to	0
that	0
observed	0
in	0
uninduced	7
cells	8
.	0

Treatment	0
of	0
U-937	5
cells	6
with	0
TPA	0
resulted	0
in	0
a	0
rapid	0
translocation	0
of	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
from	0
the	0
cytosol	0
to	0
cell	0
membrane	0
fractions	0
within	0
2-8	0
min	0
.	0

Increased	0
levels	0
of	0
membrane-associated	0
PKC	9
activity	0
persisted	0
until	0
17-29	0
days	0
.	0

However	0
,	0
longer	0
periods	0
of	0
incubation	0
were	0
associated	0
with	0
a	0
return	0
to	0
the	0
distribution	0
of	0
PKC	9
in	0
control	0
cells	0
.	0

Activation	0
of	0
PKC	9
has	0
been	0
implicated	0
in	0
the	0
regulation	0
of	0
certain	0
immediate	1
early	2
response	2
genes	2
,	0
and	0
in	0
the	0
present	0
studies	0
,	0
TPA	0
rapidly	0
induced	0
c-fos	1
and	0
c-jun	1
gene	2
expression	2
.	0

Levels	0
of	0
c-fos	3
and	4
c-jun	4
transcripts	4
remained	0
elevated	0
during	0
periods	0
of	0
PKC	9
activation	0
and	0
also	0
returned	0
to	0
levels	0
observed	0
in	0
control	0
cells	0
by	0
30-36	0
days	0
,	0
when	0
the	0
cells	0
entered	0
retrodifferentiation	0
.	0

Staurosporine	0
,	0
a	0
nonspecific	0
inhibitor	0
of	0
PKC	9
,	0
partially	0
blocked	0
TPA-induced	0
adherence	0
and	0
growth	0
inhibition	0
and	0
concomitantly	0
prevented	0
TPA-induced	0
c-fos	0
and	0
c-jun	0
gene	0
expression	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Kappa	9
B-specific	10
DNA	10
binding	10
proteins	10
are	0
differentially	0
inhibited	0
by	0
enhancer	0
mutations	0
and	0
biological	0
oxidation	0
.	0

Kappa	9
B	10
(	10
kappa	10
B	10
)	10
enhancer	10
binding	10
proteins	10
isolated	0
from	0
the	0
nuclei	0
of	0
activated	0
human	7
T	8
cells	8
produce	0
two	0
distinct	0
nucleoprotein	9
complexes	10
when	0
incubated	0
with	0
the	0
kappa	1
B	2
element	2
from	0
the	0
interleukin-2	1
receptor-alpha	2
(	2
IL-2R	2
alpha	2
)	2
gene	2
.	0

These	0
two	0
DNA-protein	9
complexes	10
are	0
composed	0
of	0
at	0
least	0
four	0
host	0
proteins	0
(	0
p50	9
,	0
p55	9
,	0
p75	9
,	0
p85	9
)	0
,	0
each	0
of	0
which	0
shares	0
structural	0
similarity	0
with	0
the	0
v-rel	9
oncogene	10
product	10
.	0

Nuclear	0
expression	0
of	0
these	0
proteins	0
is	0
induced	0
with	0
distinctly	0
biphasic	0
kinetics	0
following	0
phorbol	0
ester	0
activation	0
of	0
T	7
cells	8
(	0
p55/p75	9
early	10
and	0
p50/p85	9
late	10
)	0
.	0

DNA-protein	0
crosslinking	0
studies	0
have	0
revealed	0
that	0
the	0
more	0
rapidly	0
migrating	0
B2	9
complex	10
contains	0
both	0
p50	9
and	0
p55	9
while	0
the	0
more	0
slowly	0
migrating	0
B1	9
complex	10
is	0
composed	0
of	0
p50	9
,	0
p55	9
,	0
p75	9
,	0
and	0
p85	9
.	0

Site-directed	0
mutagenesis	0
of	0
the	0
wild-type	1
IL-2R	2
alpha	2
kappa	2
B	2
enhancer	2
(	0
GGGGAATCTCCC	0
)	0
has	0
revealed	0
that	0
the	0
binding	0
of	0
p50	0
and	0
p55	9
(	0
B2	9
complex	10
)	0
is	0
particularly	0
sensitive	0
to	0
alteration	0
of	0
the	0
5	1
'	2
triplet	2
of	0
deoxyguanosine	0
residues	0
.	0

In	0
contrast	0
,	0
formation	0
of	0
the	0
B1	9
complex	10
,	0
reflecting	0
the	0
binding	0
of	0
p75	9
and	0
p85	9
,	0
critically	0
depends	0
upon	0
the	0
more	0
3	0
'	0
sequences	0
of	0
this	0
enhancer	1
element	2
.	0

DNA	0
binding	0
by	0
all	0
four	0
of	0
these	0
Rel-related	9
factors	10
is	0
blocked	0
by	0
selective	0
chemical	0
modification	0
of	0
lysine	0
and	0
arginine	0
residues	0
,	0
suggesting	0
that	0
both	0
of	0
these	0
basic	0
amino	0
acids	0
are	0
required	0
for	0
binding	0
to	0
the	0
kappa	1
B	2
element	2
.	0

Similarly	0
,	0
covalent	0
modification	0
of	0
free	0
sulfhydryl	0
groups	0
with	0
diamide	0
(	0
reversible	0
)	0
or	0
N-ethylmaleimide	0
(	0
irreversible	0
)	0
results	0
in	0
a	0
complete	0
loss	0
of	0
DNA	0
binding	0
activity	0
.	0

In	0
contrast	0
,	0
mild	0
oxidation	0
with	0
glucose	9
oxidase	10
selectively	0
inhibits	0
p75	9
and	0
p85	9
binding	0
while	0
not	0
blocking	0
p50	9
and	0
p55	9
interactions	0
.	0

These	0
findings	0
suggest	0
that	0
reduced	0
cysteine	0
thiols	0
play	0
an	0
important	0
role	0
in	0
the	0
DNA	0
binding	0
activity	0
of	0
this	0
family	0
of	0
Rel-related	9
transcription	10
factors	10
.	0

[	0
Changes	0
in	0
leucocytic	0
estrogen	9
receptor	10
levels	0
in	0
patients	0
with	0
climacteric	0
syndrome	0
and	0
therapeutic	0
effect	0
of	0
liuwei	0
dihuang	0
pills	0
]	0

The	0
numbers	0
of	0
estrogen	9
receptor	10
(	0
ER	9
)	0
in	0
human	7
peripheral	8
leucocytes	8
in	0
22	0
women	0
with	0
climacteric	0
syndrome	0
were	0
measured	0
by	0
radioligand	0
method	0
.	0

The	0
results	0
were	0
compared	0
with	0
those	0
of	0
12	0
normal	0
child-bearing-age	0
women	0
.	0

It	0
wat	0
found	0
that	0
the	0
contents	0
of	0
leucocytic	9
ER	10
in	0
climacteric	0
syndrome	0
patients	0
were	0
significantly	0
lower	0
than	0
normal	0
child-bearing-age	0
women	0
.	0

The	0
authors	0
used	0
a	0
Chinese	0
prescription	0
--	0
Liuwei	0
Dihuang	0
Pills	0
(	0
LDP	0
)	0
to	0
treat	0
the	0
patients	0
for	0
2	0
months	0
.	0

The	0
numbers	0
of	0
leucocytic	9
ER	10
were	0
significantly	0
increased	0
after	0
treatment	0
.	0

The	0
data	0
indicate	0
that	0
decrease	0
of	0
ER	9
levels	0
in	0
cell	0
may	0
involve	0
in	0
the	0
pathogenesis	0
of	0
climacteric	0
syndrome	0
.	0

LDP	0
not	0
only	0
increases	0
plasma	0
estradiol	0
levels	0
,	0
but	0
also	0
increases	0
the	0
leucocytic	0
ER	9
levels	0
.	0

This	0
may	0
be	0
the	0
basis	0
of	0
the	0
therapeutic	0
effect	0
on	0
the	0
disease	0
.	0

Evaluation	0
of	0
the	0
role	0
of	0
ligand	0
and	0
thermal	0
activation	0
of	0
specific	0
DNA	0
binding	0
by	0
in	9
vitro	10
synthesized	10
human	10
glucocorticoid	10
receptor	10
.	0

We	0
have	0
used	0
a	0
DNA-binding/immunoprecipitation	0
assay	0
to	0
analyze	0
the	0
capacity	0
of	0
human	9
glucocorticoid	10
receptor	10
(	0
hGR	9
)	0
,	0
generated	0
in	0
rabbit	0
reticulocyte	0
lysates	0
,	0
to	0
bind	0
DNA	0
.	0

In	9
vitro	10
translated	10
hGR	10
was	0
indistinguishable	0
from	0
native	9
hGR	10
,	0
as	0
determined	0
by	0
migration	0
on	0
sodium	0
dodecyl	0
sulfate-polyacrylamide	0
gels	0
,	0
sedimentation	0
on	0
sucrose	0
density	0
gradients	0
,	0
and	0
reactivity	0
with	0
antipeptide	9
antibodies	10
generated	0
against	0
hGR	9
.	0

In	0
addition	0
,	0
cell-free	9
synthesized	10
hGR	10
was	0
capable	0
of	0
specific	0
binding	0
to	0
glucocorticoid	1
response	2
element	2
(	2
GRE	2
)	2
-containing	2
DNA	2
fragments	2
.	0

Using	0
this	0
assay	0
system	0
,	0
we	0
have	0
evaluated	0
the	0
contributions	0
of	0
ligand	0
binding	0
and	0
heat	0
activation	0
to	0
DNA	0
binding	0
by	0
these	0
glucocorticoid	9
receptors	10
.	0

In	9
vitro	10
translated	10
hGR	10
was	0
capable	0
of	0
selective	0
DNA	0
binding	0
even	0
in	0
the	0
absence	0
of	0
glucocorticoid	0
.	0

Treatment	0
with	0
dexamethasone	0
or	0
the	0
antiglucocorticoid	0
RU486	0
had	0
no	0
additional	0
effect	0
on	0
the	0
DNA-binding	0
capacity	0
when	0
receptor	0
preparations	0
were	0
maintained	0
at	0
0	0
C	0
(	0
no	0
activation	0
)	0
.	0

In	0
contrast	0
,	0
addition	0
of	0
either	0
ligand	0
or	0
antagonist	0
in	0
combination	0
with	0
a	0
heat	0
activation	0
step	0
promoted	0
DNA	0
binding	0
by	0
approximately	0
3-fold	0
over	0
that	0
of	0
heat-activated	0
unliganded	9
receptors	10
.	0

Agonist	0
(	0
dexamethasone	0
)	0
was	0
slightly	0
more	0
effective	0
in	0
supporting	0
specific	0
DNA	0
binding	0
than	0
antagonist	0
(	0
RU486	0
)	0
.	0

DNA	0
binding	0
by	0
in	9
vitro	10
synthesized	10
GR	10
was	0
blocked	0
by	0
the	0
addition	0
of	0
sodium	0
molybdate	0
to	0
the	0
receptor	0
preparations	0
before	0
steroid	0
addition	0
and	0
thermal	0
activation	0
.	0

Addition	0
of	0
KCl	0
resulted	0
in	0
less	0
DNA	0
binding	0
either	0
due	0
to	0
blockage	0
of	0
DNA-	0
receptor	9
complex	10
formation	0
or	0
disruption	0
of	0
the	0
complexes	0
.	0

The	0
specificity	0
of	0
DNA	0
binding	0
by	0
cell-free	9
synthesized	10
hGR	10
was	0
analyzed	0
further	0
by	0
examining	0
the	0
abilities	0
of	0
various	1
DNAs	2
to	0
compete	0
for	0
binding	0
to	0
a	0
naturally	0
occurring	0
GRE	1
found	0
in	0
the	0
mouse	1
mammary	2
tumor	2
virus-long	2
terminal	2
repeat	2
.	0

Oligonucleotides	0
containing	0
the	0
consensus	1
GRE	2
were	0
the	0
most	0
efficient	0
competitors	0
,	0
and	0
fragments	0
containing	0
regulatory	1
sequences	2
from	0
glucocorticoid-repressible	1
genes	2
were	0
somewhat	0
competitive	0
,	0
whereas	0
single	0
stranded	0
oligonucleotides	0
were	0
unable	0
to	0
compete	0
for	0
mouse	1
mammary	2
tumor	2
virus-long	2
terminal	2
repeat	2
DNA	0
binding	0
,	0
except	0
when	0
competitor	0
was	0
present	0
at	0
extremely	0
high	0
concentrations	0
.	0

Together	0
these	0
studies	0
indicate	0
that	0
hGR	9
synthesized	0
in	0
rabbit	0
reticulocyte	0
lysates	0
displays	0
many	0
of	0
the	0
same	0
properties	0
,	0
including	0
GRE	1
-specific	0
DNA	0
binding	0
,	0
observed	0
for	0
glucocorticoid	9
receptor	10
present	0
in	0
cytosolic	0
extracts	0
of	0
mammalian	7
cells	8
and	0
tissues	0
.	0

Similarities	0
between	0
the	0
effects	0
of	0
dexamethasone	0
and	0
RU486	0
suggest	0
that	0
the	0
antiglucocorticoid	0
properties	0
of	0
RU486	0
do	0
not	0
occur	0
at	0
the	0
level	0
of	0
specific	0
DNA	0
binding	0
.	0

Expression	0
of	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
on	0
alveolar	7
lymphocytes	8
from	0
patients	0
with	0
pulmonary	0
granulomatous	0
diseases	0
.	0

1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
is	0
known	0
to	0
be	0
produced	0
at	0
sites	0
of	0
granulomatous	0
reactions	0
.	0

In	0
order	0
to	0
characterize	0
the	0
cell	0
types	0
that	0
are	0
targets	0
for	0
this	0
immunoregulatory	0
hormone	0
,	0
we	0
have	0
evaluated	0
the	0
expression	0
of	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
on	0
peripheral	7
blood	8
T-lymphocytes	8
and	0
those	0
recovered	0
from	0
the	0
lung	0
by	0
bronchoalveolar	0
lavage	0
from	0
patients	0
with	0
pulmonary	0
granulomatous	0
diseases	0
(	0
tuberculosis	0
and	0
sarcoidosis	0
)	0
and	0
from	0
normal	0
control	0
subjects	0
using	0
combined	0
autoradiographic	0
and	0
immunohistochemical	0
techniques	0
.	0

Lavage	0
T-lymphocytes	0
from	0
patients	0
with	0
tuberculosis	0
or	0
with	0
sarcoidosis	0
,	0
but	0
not	0
those	0
from	0
normal	0
control	0
subjects	0
,	0
expressed	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
as	0
demonstrated	0
by	0
binding	0
of	0
[	0
3H	0
]	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
which	0
was	0
inhibited	0
by	0
the	0
presence	0
of	0
excess	0
unlabeled	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
but	0
not	0
by	0
the	0
presence	0
of	0
unlabeled	0
25	0
(	0
OH	0
)	0
D3	0
(	0
receptor-positive	7
lymphocytes	8
:	0
sarcoidosis	0
,	0
20	0
+/-	0
12	0
%	0
;	0
tuberculosis	0
,	0
31	0
+/-	0
17	0
%	0
)	0
.	0

In	0
contrast	0
,	0
blood	7
lymphocytes	8
from	0
patients	0
with	0
granulomatous	0
diseases	0
did	0
not	0
express	0
detectable	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
.	0

The	0
percentage	0
of	0
lavage	7
T-lymphocytes	8
expressing	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
was	0
significantly	0
greater	0
for	0
patients	0
with	0
tuberculosis	0
presenting	0
with	0
isolated	0
hilar	0
adenopathy	0
than	0
for	0
patients	0
with	0
pulmonary	0
infiltrates	0
and/or	0
cavities	0
.	0

1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
were	0
expressed	0
to	0
a	0
greater	0
extent	0
on	0
CD8+	7
T-lymphocytes	8
than	0
on	0
CD4+	7
T-lymphocytes	8
in	0
sarcoidosis	0
,	0
whereas	0
a	0
greater	0
proportion	0
of	0
CD4+	7
than	0
of	0
CD8+	7
T-lymphocytes	8
from	0
patients	0
with	0
tuberculosis	0
were	0
receptor-positive	0
.	0

These	0
findings	0
support	0
the	0
conclusion	0
that	0
the	0
interaction	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
with	0
its	0
receptor	0
on	0
T-lymphocytes	7
may	0
play	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
granulomatous	0
reactions	0
,	0
but	0
because	0
these	0
receptors	0
are	0
expressed	0
on	0
different	0
lymphocyte	7
populations	8
,	0
the	0
net	0
effect	0
of	0
this	0
potent	0
immunoregulatory	9
molecule	10
is	0
likely	0
different	0
in	0
sarcoidosis	0
and	0
tuberculosis	0
.	0

Role	0
for	0
the	0
Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
in	0
viral	1
promoter	2
switching	0
during	0
initial	0
stages	0
of	0
infection	0
.	0

During	0
latent	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
infection	0
of	0
human	7
B	8
lymphocytes	8
,	0
six	9
viral	10
nuclear	10
antigen	10
(	0
EBNAs	9
)	0
are	0
expressed	0
from	0
long	3
primary	4
transcripts	4
by	0
means	0
of	0
alternative	3
splicing	4
and	0
alternative	3
polyadenylylation	4
sites	4
.	0

These	0
transcripts	0
initiate	0
from	0
one	0
of	0
two	0
promoters	1
,	0
Cp	1
or	0
Wp	0
,	0
that	0
function	0
in	0
a	0
mutually	0
exclusive	0
fashion	0
.	0

Wp	0
is	0
exclusively	0
utilized	0
during	0
the	0
initial	0
stages	0
of	0
infection	0
of	0
primary	7
B	8
lymphocytes	8
,	0
followed	0
by	0
a	0
switch	0
to	0
Cp	1
usage	0
.	0

These	0
studies	0
have	0
been	0
extended	0
to	0
show	0
that	0
(	0
i	0
)	0
a	0
mutant	0
EBV	0
strain	0
lacking	0
the	0
gene	0
encoding	0
EBNA	9
2	10
fails	0
to	0
switch	0
from	0
Wp	0
to	0
Cp	1
usage	0
in	0
primary	7
B	8
lymphocytes	8
,	0
although	0
the	0
virus	0
contains	0
a	0
functional	0
Cp	1
;	0
(	0
ii	0
)	0
a	0
region	0
from	0
-429	1
to	2
-245	2
base	2
pairs	2
upstream	0
of	0
Cp	1
is	0
essential	0
for	0
Cp	1
activity	0
in	0
B	7
lymphocytes	8
,	0
but	0
only	0
in	0
the	0
context	0
of	0
upstream	1
and	2
downstream	2
sequences	2
;	0
(	0
iii	0
)	0
this	0
region	0
contains	0
an	0
EBNA	1
2-dependent	2
enhancer	2
;	0
and	0
(	0
iv	0
)	0
DNase	9
I	10
protection	0
employing	0
nuclear	0
extracts	0
from	0
B	7
and	8
T	8
lymphocytes	8
revealed	0
a	0
B-cell-specific	1
footprint	2
in	0
the	0
region	0
of	0
the	0
EBNA	1
2-dependent	2
enhancer	2
.	0

These	0
results	0
support	0
a	0
model	0
for	0
viral	1
promoter	2
switching	0
during	0
the	0
initial	0
stages	0
of	0
infection	0
in	0
which	0
Wp	0
activity	0
leads	0
to	0
the	0
expression	0
of	0
EBNA	9
2	10
,	0
followed	0
by	0
activation	0
of	0
Cp	1
through	0
the	0
EBNA	1
2-dependent	2
enhancer	2
.	0

Immune	0
response	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
to	0
HBx-antigen	9
of	0
hepatitis	0
B	0
virus	0
.	0

The	0
hepatitis	1
B	2
virus	2
genome	2
encodes	0
a	0
transcriptional	9
transactivator	10
protein	10
designated	0
HBxAg	9
.	0

We	0
have	0
investigated	0
whether	0
this	0
antigen	0
is	0
a	0
target	0
structure	0
for	0
human	7
T-lymphocytes	8
.	0

Using	0
recombinant	9
HBxAg	10
protein	10
,	0
we	0
found	0
HBxAg	9
-specific	0
stimulation	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
in	0
patients	0
with	0
acute	0
hepatitis	0
B	0
virus	0
infection	0
(	0
6	0
of	0
6	0
)	0
and	0
chronic	0
hepatitis	0
B	0
virus	0
infection	0
(	0
6	0
of	0
17	0
)	0
but	0
not	0
in	0
healthy	0
individuals	0
.	0

With	0
HBxAg	9
-specific	0
synthetic	0
polypeptides	0
,	0
several	0
T-cell	0
epitopes	0
were	0
identified	0
.	0

Most	0
were	0
located	0
in	0
the	0
carboxyterminal	9
half	10
of	0
the	0
HBxAg	9
protein	10
.	0

Five	0
T-cell	5
clones	6
specific	0
for	0
a	0
T-cell	9
epitope	10
located	0
at	0
the	0
carboxyterminal	9
region	10
of	0
HBxAg	9
were	0
established	0
and	0
found	0
to	0
belong	0
to	0
the	0
CD2/CD4-positive	5
,	6
CD8-negative	6
subtype	6
.	0

These	0
data	0
establish	0
for	0
the	0
first	0
time	0
HBxAg	9
as	0
an	0
antigen	0
in	0
the	0
cellular	0
immune	0
response	0
.	0

[	0
Changes	0
in	0
leucocytic	9
estrogen	10
receptor	10
levels	0
in	0
patients	0
with	0
gynecomastia	0
]	0

The	0
number	0
of	0
estrogen	9
receptor	10
(	0
ER	9
)	0
in	0
human	7
peripheral	8
leucocytes	8
in	0
13	0
men	0
with	0
gynecomastia	0
were	0
measured	0
by	0
radioligand	0
binding	0
method.	0
The	0
results	0
were	0
compared	0
with	0
those	0
of	0
13	0
sex-and	0
age-matched	0
healthy	0
subjects	0
.	0

It	0
was	0
found	0
that	0
the	0
number	0
of	0
ER	9
in	0
leucocytes	7
was	0
significantly	0
increased	0
in	0
gynecomastia	0
(	0
Rs	0
of	0
leucocytes	7
were	0
1054	0
+/-	0
254	0
sites/cell	0
)	0
.	0

It	0
suggested	0
that	0
increase	0
of	0
ER	0
levels	0
play	0
an	0
important	0
role	0
in	0
the	0
pathogenesis	0
of	0
gynecomastia	0
.	0

The	0
NF	1
kappa	2
B	2
independent	2
cis-acting	2
sequences	2
in	0
HIV-1	1
LTR	2
responsive	0
to	0
T-cell	0
activation	0
.	0

The	0
rate	0
of	0
transcription	0
initiation	0
directed	0
by	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	0
)	0
of	0
HIV-1	0
increases	0
in	0
response	0
to	0
mitogenic	0
stimuli	0
of	0
T	7
cells	8
.	0

Here	0
we	0
show	0
that	0
the	0
response	0
of	0
the	0
HIV-1	1
LTR	2
may	0
be	0
governed	0
by	0
two	0
independent	0
sequences	0
located	0
5	0
'	0
to	0
the	0
site	0
of	0
transcription	0
initiation	0
sequences	0
that	0
bind	0
either	0
NFAT-1	9
or	0
NF	9
kappa	10
B	10
.	0

The	0
rate	0
of	0
LTR	1
-directed	0
gene	0
expression	0
increased	0
in	0
response	0
to	0
treatment	0
with	0
either	0
a	0
phorbol	0
ester	0
or	0
tumor	9
necrosis	10
factor	10
alpha	10
if	0
either	0
the	0
NFAT-1	9
or	0
NF	1
kappa	2
B	2
binding	2
sites	2
were	0
deleted	0
,	0
but	0
failed	0
to	0
respond	0
to	0
these	0
mitogenic	0
stimuli	0
if	0
both	0
sequences	0
were	0
absent	0
.	0

The	0
HIV-1	0
mutant	0
virus	0
containing	0
both	0
NF	1
kappa	2
B	2
and	2
NFAT-1	2
deletion	2
was	0
able	0
to	0
replicate	0
although	0
at	0
a	0
much	0
decreased	0
growth	0
rate	0
,	0
while	0
the	0
deletion	0
of	0
NFAT-1	9
alone	0
increased	0
the	0
viral	0
growth	0
rate	0
in	0
Jurkat	5
cells	6
.	0

Neither	0
deletion	0
of	0
NF	9
kappa	10
B	10
nor	0
deletion	0
of	0
NFAT-1	9
decreased	0
activation	0
of	0
viral	0
replication	0
by	0
phorbol	0
ester	0
.	0

cAMP-dependent	0
regulation	0
of	0
proenkephalin	0
by	0
JunD	9
and	0
JunB	9
:	0
positive	0
and	0
negative	0
effects	0
of	0
AP-1	9
proteins	10
.	0

We	0
demonstrate	0
that	0
JunD	9
,	0
a	0
component	0
of	0
the	0
AP-1	9
transcription	10
factor	10
complex	10
,	0
activates	0
transcription	0
of	0
the	0
human	1
proenkephalin	2
gene	2
in	0
a	0
fashion	0
that	0
is	0
completely	0
dependent	0
upon	0
the	0
cAMP-dependent	9
protein	10
kinase	10
,	0
protein	9
kinase	10
A	10
.	0

Activation	0
of	0
proenkephalin	0
transcription	0
by	0
JunD	9
is	0
dependent	0
upon	0
a	0
previously	0
characterized	0
cAMP-	1
,	2
phorbol	2
ester-	2
,	2
and	2
Ca	2
(	2
2+	2
)	2
-inducible	2
enhancer	2
,	0
and	0
JunD	9
is	0
shown	0
to	0
bind	0
the	0
enhancer	1
as	0
a	0
homodimer	9
.	0

Another	0
component	0
of	0
the	0
AP-1	9
transcription	10
complex	10
,	0
JunB	9
,	0
is	0
shown	0
to	0
inhibit	0
activation	0
mediated	0
by	0
JunD	9
.	0

As	0
a	0
homodimer	0
JunB	9
is	0
unable	0
to	0
bind	0
the	0
enhancer	0
;	0
however	0
in	0
the	0
presence	0
of	0
c-Fos	9
,	0
high-affinity	0
binding	0
is	0
observed	0
.	0

Furthermore	0
,	0
JunD	9
is	0
shown	0
to	0
activate	0
transcription	0
of	0
genes	0
linked	0
to	0
both	0
cAMP	0
and	0
phorbol	0
ester	0
response	0
elements	0
in	0
a	0
protein	9
kinase	10
A	10
-dependent	0
fashion	0
,	0
further	0
blurring	0
the	0
distinction	0
between	0
these	0
response	1
elements	2
.	0

These	0
results	0
demonstrate	0
that	0
the	0
transcriptional	0
activity	0
of	0
an	0
AP-1-related	9
protein	10
is	0
regulated	0
by	0
the	0
cAMP-dependent	0
second-messenger	0
pathway	0
and	0
suggest	0
that	0
JunD	9
and	0
other	0
AP-1-related	9
proteins	10
may	0
play	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
gene	0
expression	0
by	0
cAMP-dependent	0
intracellular	0
signaling	0
pathways	0
.	0

[	0
Plasma	0
cortisol	0
concentration	0
and	0
blood	0
leukocyte	0
content	0
of	0
glucocorticoid	9
receptors	10
in	0
patients	0
with	0
deficiency-cold	0
vs	0
deficiency-heat	0
syndromes	0
]	0

Plasma	0
cortisol	0
concentration	0
and	0
blood	0
leukocyte	0
content	0
of	0
glucocorticoid	9
receptors	10
(	0
GCR	9
)	0
were	0
assayed	0
in	0
20	0
patients	0
with	0
deficiency	0
syndromes	0
,	0
10	0
cold	0
in	0
property	0
(	0
deficiency-cold	0
)	0
,	0
the	0
other	0
10	0
hot	0
in	0
property	0
(	0
deficiency-heat	0
)	0
,	0
and	0
also	0
in	0
10	0
healthy	0
individuals	0
as	0
normal	0
control	0
for	0
the	0
purpose	0
of	0
investigating	0
the	0
nature	0
of	0
cold	0
and	0
heat	0
syndromes	0
.	0

As	0
a	0
result	0
,	0
the	0
cases	0
of	0
deficiency-cold	0
syndrome	0
(	0
DCS	0
)	0
had	0
a	0
normal	0
concentration	0
of	0
plasma	0
cortisol	0
but	0
a	0
lowered	0
content	0
of	0
GCR	9
in	0
leukocytes	7
when	0
compared	0
with	0
the	0
normal	0
control	0
(	0
P	0
less	0
than	0
0.05	0
)	0
;	0
the	0
cases	0
of	0
deficiency-heat	0
syndrome	0
(	0
DHS	0
)	0
had	0
a	0
higher	0
concentration	0
of	0
plasma	0
cortisol	0
than	0
the	0
normal	0
control	0
(	0
P	0
less	0
than	0
0.05	0
)	0
and	0
a	0
slightly	0
higher	0
content	0
of	0
GCR	9
in	0
leukocytes	7
.	0

It	0
was	0
concluded	0
that	0
the	0
DCS	0
is	0
characterized	0
by	0
diminished	0
biological	0
effects	0
of	0
adrenocortical	0
activity	0
,	0
while	0
the	0
DHS	0
,	0
by	0
augmented	0
biological	0
effects	0
of	0
adrenocortical	0
activity	0
.	0

The	0
role	0
of	0
jun	1
and	2
fos	2
gene	2
family	2
members	2
in	0
12-O-tetradecanoylphorbol-13-acetate	0
induced	0
hemopoietic	0
differentiation	0
.	0

Terminal	0
differentiation	0
of	0
the	0
leukemic	5
cell	6
lines	6
U-937	5
and	0
HL-60	5
by	0
12-O-tetradecanoylphorbol-13-acetate	0
is	0
accompanied	0
by	0
marked	0
changes	0
in	0
gene	0
expression	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
the	0
expression	0
of	0
jun	1
and	2
fos	2
gene	2
family	2
members	2
is	0
induced	0
with	0
variable	0
kinetics	0
during	0
12-O-tetradecanoylphorbol-13-acetate	0
induced	0
differentiation	0
,	0
with	0
c-jun	1
expression	0
best	0
paralleling	0
differentiation	0
.	0

The	0
generation	0
of	0
AP-1	9
complexes	10
,	0
as	0
measured	0
by	0
DNA	0
binding	0
activity	0
,	0
closely	0
parallels	0
morphological	0
differentiation	0
.	0

Furthermore	0
,	0
the	0
ability	0
of	0
these	0
complexes	0
to	0
regulate	0
gene	0
expression	0
is	0
demonstrated	0
by	0
increased	0
transcription	0
from	0
an	0
AP-1	1
driven	2
reporter	2
construct	2
and	0
marked	0
increases	0
in	0
the	0
expression	0
of	0
endogenous	1
AP-1	2
regulated	2
genes	2
.	0

Differentiation	0
assays	0
using	0
water	0
soluble	0
phorbol	0
esters	0
reveal	0
that	0
differentiation	0
becomes	0
irreversible	0
soon	0
after	0
AP-1	9
appears	0
.	0

This	0
tight	0
correlation	0
between	0
c-jun	1
expression	0
,	0
the	0
generation	0
of	0
AP-1	9
activity	0
,	0
and	0
differentiation	0
suggests	0
a	0
critical	0
role	0
for	0
this	0
gene	0
and	0
transcriptional	9
complex	10
during	0
this	0
process	0
.	0

Nuclear	0
association	0
of	0
a	0
T-cell	9
transcription	10
factor	10
blocked	0
by	0
FK-506	0
and	0
cyclosporin	0
A	0
[	0
see	0
comments	0
]	0

Cyclosporin	0
A	0
and	0
FK506	0
inhibit	0
T-	0
and	0
B-cell	0
activation	0
and	0
other	0
processes	0
essential	0
to	0
an	0
effective	0
immune	0
response	0
.	0

In	0
T	7
lymphocytes	8
these	0
drugs	0
disrupt	0
an	0
unknown	0
step	0
in	0
the	0
transmission	0
of	0
signals	0
from	0
the	0
T-cell	9
antigen	10
receptor	10
to	0
cytokine	1
genes	2
that	0
coordinate	0
the	0
immune	0
response	0
.	0

The	0
putative	9
intracellular	10
receptors	10
for	0
FK506	0
and	0
cyclosporin	0
are	0
cis-trans	0
prolyl	0
isomerases	0
.	0

Binding	0
of	0
the	0
drug	0
inhibits	0
isomerase	9
activity	0
,	0
but	0
studies	0
with	0
other	0
prolyl	0
isomerase	9
inhibitors	0
and	0
analysis	0
of	0
cyclosporin-resistant	5
mutants	6
in	0
yeast	0
suggest	0
that	0
the	0
effects	0
of	0
the	0
drug	0
result	0
from	0
the	0
formation	0
of	0
an	0
inhibitory	9
complex	10
between	0
the	0
drug	0
and	0
isomerase	9
,	0
and	0
not	0
from	0
inhibition	0
of	0
isomerase	9
activity	0
.	0

A	0
transcription	9
factor	10
,	0
NF-AT	9
,	0
which	0
is	0
essential	0
for	0
early	0
T-cell	0
gene	0
activation	0
,	0
seems	0
to	0
be	0
a	0
specific	0
target	0
of	0
cyclosporin	0
A	0
and	0
FK506	0
action	0
because	0
transcription	0
directed	0
by	0
this	0
protein	0
is	0
blocked	0
in	0
T	7
cells	8
treated	0
with	0
these	0
drugs	0
,	0
with	0
little	0
or	0
no	0
effect	0
on	0
other	0
transcription	9
factors	10
such	0
as	0
AP-1	9
and	0
NF-kappa	9
B	10
.	0

Here	0
we	0
demonstrate	0
that	0
NF-AT	9
is	0
formed	0
when	0
a	0
signal	0
from	0
the	0
antigen	9
receptor	10
induces	0
a	0
pre-existing	0
cytoplasmic	0
subunit	0
to	0
translocate	0
to	0
the	0
nucleus	0
and	0
combine	0
with	0
a	0
newly	0
synthesized	0
nuclear	0
subunit	0
of	0
NF-AT	9
.	0

FK506	0
and	0
cyclosporin	0
A	0
block	0
translocation	0
of	0
the	0
cytoplasmic	9
component	10
without	0
affecting	0
synthesis	0
of	0
the	0
nuclear	9
subunit	10
.	0

Glucocorticoid	9
receptors	10
in	0
lymphocytes	7
in	0
anorexia	0
nervosa	0
.	0

OBJECTIVE	0
:	0
The	0
aim	0
was	0
to	0
explore	0
the	0
down-regulation	0
of	0
the	0
glucocorticoid	9
receptors	10
during	0
hypercortisolaemia	0
in	0
anorexia	0
nervosa	0
.	0

DESIGN	0
:	0
Urine	0
and	0
plasma	0
samples	0
were	0
obtained	0
for	0
cortisol	0
determination	0
and	0
blood	7
lymphocytes	8
were	0
isolated	0
for	0
receptor	0
binding	0
studies	0
.	0

PATIENTS	0
:	0
Sixteen	0
anorexic	0
patients	0
,	0
aged	0
16-27	0
years	0
,	0
with	0
a	0
mean	0
+/-	0
SEM	0
body	0
mass	0
index	0
of	0
14.2	0
+/-	0
2.0	0
(	0
ranging	0
from	0
11.1	0
to	0
17.4	0
)	0
,	0
and	0
15	0
normal	0
women	0
were	0
studied	0
.	0

Six	0
patients	0
were	0
reinvestigated	0
after	0
a	0
significant	0
weight	0
gain	0
.	0

MEASUREMENTS	0
:	0
The	0
binding	0
capacity	0
and	0
affinity	0
of	0
the	0
glucocorticoid	9
receptors	10
were	0
measured	0
with	0
dexamethasone	0
as	0
ligand	0
on	0
lymphocytes	7
.	0

RESULTS	0
:	0
In	0
patients	0
,	0
both	0
total	0
and	0
free	0
plasma	0
cortisol	0
concentrations	0
were	0
higher	0
than	0
in	0
the	0
normal	0
women	0
,	0
as	0
was	0
their	0
urinary	0
free	0
cortisol	0
;	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
per	0
cell	0
(	0
Ro	0
)	0
and	0
the	0
binding	0
affinity	0
(	0
Kd	0
)	0
for	0
dexamethasone	0
were	0
,	0
however	0
,	0
not	0
significantly	0
different	0
(	0
Ro	0
:	0
7687	0
+/-	0
1750	0
vs	0
7347	0
+/-	0
1285	0
sites/cell	0
;	0
Kd	0
:	0
7.7	0
+/-	0
2.4	0
vs	0
7.4	0
+/-	0
1.7	0
nM	0
at	0
24	0
degrees	0
C	0
)	0
.	0

After	0
weight	0
gain	0
(	0
14	0
+/-	0
2	0
to	0
16	0
+/-	0
2	0
kg/m2	0
)	0
,	0
receptor	0
numbers	0
were	0
8421	0
+/-	0
2126	0
(	0
pre	0
)	0
and	0
9011	0
+/-	0
500	0
(	0
post	0
)	0
sites/cell	0
,	0
which	0
are	0
not	0
significantly	0
different	0
(	0
P	0
greater	0
than	0
0.2	0
)	0
;	0
the	0
Kd	0
was	0
unchanged	0
(	0
9.3	0
+/-	0
2.6	0
vs	0
9.2	0
+/-	0
2.4	0
nM	0
)	0
.	0

CONCLUSIONS	0
Hypercortisolaemia	0
does	0
not	0
down-regulate	0
the	0
lymphocyte	0
glucocorticoid	9
receptors	10
in	0
anorexia	0
nervosa	0
and	0
a	0
post-receptor	0
defect	0
might	0
be	0
involved	0
in	0
peripheral	0
tissue	0
resistance	0
to	0
the	0
effects	0
of	0
glucocorticoid	0
hormones	0
in	0
undernutrition	0
.	0

Inhibition	0
of	0
protein	9
phosphatases	10
by	0
okadaic	0
acid	0
induces	0
AP1	9
in	0
human	7
T	8
cells	8
.	0

To	0
examine	0
the	0
role	0
of	0
protein	9
phosphatases	10
in	0
T	0
cell	0
activation	0
,	0
Jurkat	5
cells	6
were	0
treated	0
with	0
okadaic	0
acid	0
,	0
an	0
inhibitor	0
of	0
type	9
1	10
and	10
2A	10
phosphatases	10
,	0
and	0
nuclear	0
extracts	0
were	0
examined	0
for	0
the	0
presence	0
of	0
AP1	9
as	0
a	0
measure	0
of	0
early	0
T	0
cell	0
activation	0
.	0

Okadaic	0
acid	0
was	0
found	0
to	0
be	0
a	0
potent	0
inducer	0
of	0
AP1	9
.	0

In	0
contrast	0
to	0
phorbol	0
esters	0
such	0
as	0
phorbol	0
myristate	0
acetate	0
(	0
PMA	0
)	0
,	0
the	0
induction	0
of	0
AP1	9
by	0
okadaic	0
acid	0
occurs	0
predominantly	0
by	0
transcriptional	0
activation	0
of	0
the	0
jun	1
and	2
fos	2
family	2
of	0
proto-oncogenes	1
.	0

Surprisingly	0
,	0
while	0
the	0
addition	0
of	0
phytohemagglutinin	9
further	0
enhanced	0
the	0
induction	0
of	0
AP1	9
,	0
the	0
addition	0
of	0
PMA	0
inhibited	0
it	0
.	0

Okadaic	0
acid	0
treatment	0
was	0
found	0
to	0
dramatically	0
increase	0
mRNA	3
transcripts	4
of	0
the	0
jun	1
family	2
of	2
proto-oncogenes	2
including	0
c-jun	1
,	0
junD	1
,	0
and	0
junB	1
and	0
to	0
a	0
lesser	0
extent	0
the	0
fos	1
family	2
including	0
c-fos	1
and	0
fra-1	1
.	0

By	0
comparison	0
,	0
PMA	0
is	0
a	0
very	0
inefficient	0
inducer	0
of	0
the	0
jun	1
gene	2
family	2
in	0
Jurkat	5
cells	6
.	0

Similar	0
to	0
its	0
effect	0
on	0
the	0
induction	0
of	0
AP1	9
by	0
okadaic	0
acid	0
,	0
PMA	0
inhibits	0
the	0
induction	0
of	0
c-jun	3
mRNA	4
by	0
okadaic	0
acid	0
.	0

Transfection	0
of	0
c-jun	1
promoter	2
constructs	2
confirmed	0
the	0
marked	0
difference	0
between	0
PMA	0
and	0
okadaic	0
acid	0
in	0
inducing	0
c-jun	1
transcription	0
.	0

The	0
induction	0
of	0
AP1	9
by	0
okadaic	0
acid	0
suggests	0
that	0
protein	9
phosphatases	10
1	10
and	10
2A	10
(	0
PP1	9
and	0
PP2A	9
)	0
may	0
be	0
involved	0
in	0
T	0
cell	0
activation	0
as	0
important	0
negative	0
regulators	0
of	0
the	0
transcription	9
factor	10
AP1	9
.	0

Cloning	0
of	0
murine	9
TCF-1	10
,	0
a	0
T	0
cell-specific	0
transcription	9
factor	10
interacting	0
with	0
functional	1
motifs	2
in	0
the	0
CD3-epsilon	1
and	2
T	2
cell	2
receptor	2
alpha	2
enhancers	2
.	0

CD3	9
-epsilon	0
gene	0
expression	0
is	0
confined	0
to	0
the	0
T	5
cell	6
lineage	6
.	0

We	0
have	0
recently	0
identified	0
and	0
cloned	0
a	0
human	9
transcription	10
factor	10
,	0
TCF-1	9
,	0
that	0
binds	0
to	0
a	0
functional	0
element	0
in	0
the	0
T	0
lymphocyte-specific	0
enhancer	0
of	0
CD3-epsilon	0
.	0

In	0
a	0
panel	0
of	0
human	0
cell	0
lines	0
,	0
TCF-1	9
expression	0
was	0
restricted	0
to	0
T	7
lineage	8
cells	8
.	0

TCF-1	9
belonged	0
to	0
a	0
novel	0
family	0
of	0
genes	0
that	0
contain	0
the	0
so-called	0
high	0
mobility	1
group	2
1	2
(	2
HMG	2
)	2
box	2
.	0

Here	0
we	0
report	0
the	0
cloning	0
of	0
murine	9
TCF-1	10
.	0

Two	0
splice	0
alternatives	0
were	0
identified	0
that	0
were	0
not	0
previously	0
observed	0
in	0
human	9
TCF-1	10
.	0

Murine	9
and	10
human	10
TCF-1	10
displayed	0
a	0
95.5	0
%	0
overall	0
amino	0
acid	0
homology	0
.	0

Recombinant	9
murine	10
and	10
human	10
TCF-1	10
recognized	0
the	0
same	0
sequence	0
motif	0
in	0
the	0
CD3-epsilon	1
enhancer	2
as	0
judged	0
by	0
gel	0
retardation	0
and	0
methylation	0
interference	0
assays	0
.	0

With	0
the	0
murine	1
cDNA	2
clones	2
several	0
aspects	0
of	0
TCF-1	9
were	0
analyzed	0
.	0

First	0
,	0
deletion	0
analysis	0
revealed	0
that	0
a	0
region	0
of	0
TCF-1	9
containing	0
the	0
HMG	1
box	2
was	0
sufficient	0
for	0
sequence-specific	0
binding	0
.	0

Second	0
,	0
by	0
high	0
stringency	0
Northern	0
blotting	0
and	0
in	0
situ	0
hybridization	0
,	0
TCF-1	9
expression	0
was	0
shown	0
to	0
be	0
confined	0
to	0
the	0
thymus	0
and	0
to	0
the	0
T	0
cell	0
areas	0
of	0
the	0
spleen	0
.	0

Third	0
,	0
TCF-1	9
bound	0
specifically	0
to	0
a	0
functional	0
T	1
cell-specific	2
element	2
in	0
the	0
T	1
cell	2
receptor	2
alpha	2
(	2
TCR-alpha	2
)	2
enhancer	2
.	0

The	0
T	0
lineage-specific	0
expression	0
and	0
the	0
affinity	0
for	0
functional	0
motifs	0
in	0
the	0
TCR-alpha	1
and	2
CD3-epsilon	2
enhancers	2
imply	0
an	0
important	0
role	0
for	0
TCF-1	9
in	0
the	0
establishment	0
of	0
the	0
mature	7
T	8
cell	8
phenotype	8
.	0

Cloning	0
of	0
a	0
human	1
homeobox	2
gene	2
that	0
resembles	0
a	0
diverged	1
Drosophila	2
homeobox	2
gene	2
and	0
is	0
expressed	0
in	0
activated	0
lymphocytes	7
.	0

A	0
new	0
homeobox	1
gene	2
,	0
HB24	1
,	0
has	0
been	0
isolated	0
from	0
a	0
human	0
B-lymphocyte	0
cDNA	0
library	0
.	0

Northern	0
blot	0
analysis	0
of	0
polyadenylated	3
RNA	4
purified	0
from	0
activated	7
human	8
B	8
cells	8
revealed	0
a	0
single	3
mRNA	4
transcript	4
of	0
approximately	0
2.3	0
kb	0
.	0

Two	0
cDNA	1
clones	2
were	0
sequenced	0
and	0
provided	0
2	0
,	0
250	0
nucleotides	0
(	0
nt	0
)	0
of	0
DNA	1
sequence	2
information	0
.	0

There	0
is	0
a	0
single	0
methionine	1
codon-initiated	2
open	2
reading	2
frame	2
of	0
1	0
,	0
458	0
nt	0
in	0
frame	0
with	0
a	0
homeobox	1
and	0
a	0
CAX	1
repeat	2
,	0
and	0
the	0
open	1
reading	2
frame	2
is	0
predicted	0
to	0
encode	0
a	0
protein	0
of	0
51	0
,	0
659	0
daltons	0
.	0

When	0
the	0
homeodomain	1
from	0
HB24	1
was	0
compared	0
to	0
known	0
mammalian	1
and	2
Drosophila	2
homeodomains	2
it	0
was	0
found	0
to	0
be	0
only	0
moderately	0
conserved	0
,	0
but	0
when	0
it	0
was	0
compared	0
to	0
a	0
highly	0
diverged	0
Drosophila	1
homeodomain	2
,	0
H2.0	0
,	0
it	0
was	0
found	0
to	0
be	0
80	0
%	0
identical	0
.	0

The	0
HB24	3
mRNA	4
was	0
absent	0
or	0
present	0
at	0
low	0
levels	0
in	0
normal	0
B	0
and	0
T	7
lymphocytes	8
;	0
however	0
,	0
with	0
the	0
appropriate	0
activation	0
signal	0
HB24	3
mRNA	4
was	0
induced	0
within	0
several	0
hours	0
even	0
in	0
the	0
presence	0
of	0
cycloheximide	0
.	0

Characterization	0
of	0
HB24	1
expression	0
in	0
lymphoid	0
and	0
select	0
developing	0
tissues	0
was	0
performed	0
by	0
in	0
situ	0
hybridization	0
.	0

Positive	0
hybridization	0
was	0
found	0
in	0
thymus	0
,	0
tonsil	0
,	0
bone	0
marrow	0
,	0
developing	0
vessels	0
,	0
and	0
in	0
fetal	0
brain	0
.	0

HB24	1
is	0
likely	0
to	0
have	0
an	0
important	0
role	0
in	0
lymphocytes	7
as	0
well	0
as	0
in	0
certain	0
developing	0
tissues	0
.	0

Platelet-activating	9
factor	10
induces	0
phospholipid	0
turnover	0
,	0
calcium	0
flux	0
,	0
arachidonic	0
acid	0
liberation	0
,	0
eicosanoid	0
generation	0
,	0
and	0
oncogene	1
expression	0
in	0
a	0
human	5
B	6
cell	6
line	6
.	0

Platelet-activating	9
factor	10
is	0
a	0
potent	0
mediator	0
of	0
the	0
inflammatory	0
response	0
.	0

Studies	0
of	0
the	0
actions	0
of	0
platelet-activating	9
factor	10
have	0
centered	0
mainly	0
around	0
neutrophils	7
,	0
monocytes	7
,	0
and	0
platelets	7
.	0

In	0
this	0
report	0
we	0
begin	0
to	0
uncover	0
the	0
influence	0
of	0
platelet-activating	9
factor	10
on	0
B	7
lymphocytes	8
.	0

Employing	0
the	0
EBV-transformed	5
human	6
B	6
cell	6
line	6
SKW6.4	5
,	0
we	0
demonstrate	0
that	0
platelet-activating	9
factor	10
significantly	0
alters	0
membrane	0
phospholipid	0
metabolism	0
indicated	0
by	0
the	0
incorporation	0
of	0
32P	0
into	0
phosphatidylcholine	0
,	0
phosphatidylinositol	0
,	0
and	0
phosphatidic	0
acid	0
but	0
not	0
significantly	0
into	0
phosphatidylethanolamine	0
at	0
concentrations	0
ranging	0
from	0
10	0
(	0
-9	0
)	0
to	0
10	0
(	0
-6	0
)	0
M	0
.	0

The	0
inactive	0
precursor	0
,	0
lyso-platelet-activating	9
factor	10
,	0
at	0
a	0
concentration	0
as	0
high	0
as	0
10	0
(	0
-7	0
)	0
M	0
had	0
no	0
effect	0
on	0
any	0
of	0
the	0
membrane	0
phospholipids	0
.	0

We	0
also	0
show	0
that	0
platelet-activating	9
factor	10
from	0
10	0
(	0
-12	0
)	0
to	0
10	0
(	0
-6	0
)	0
M	0
induced	0
rapid	0
and	0
significant	0
elevation	0
in	0
intracellular	0
calcium	0
levels	0
,	0
whereas	0
lyso-	0
platelet-activating	9
factor	10
was	0
again	0
ineffective	0
.	0

We	0
further	0
demonstrate	0
the	0
impact	0
of	0
platelet-activating	9
factor	10
binding	0
to	0
B	7
cells	8
by	0
measuring	0
platelet-activating	9
factor	10
induced	0
arachidonic	0
acid	0
release	0
and	0
5-hydroxyeicosatetraenoic	0
acid	0
production	0
.	0

Moreover	0
,	0
platelet-activating	9
factor	10
was	0
capable	0
of	0
inducing	0
transcription	0
of	0
the	0
nuclear	1
proto-oncogenes	2
c-fos	1
and	0
c-jun	1
.	0

Finally	0
we	0
explored	0
the	0
possible	0
role	0
of	0
5-hydroxyeicosatetraenoic	0
acid	0
as	0
a	0
regulator	0
of	0
arachidonic	0
acid	0
liberation	0
demonstrating	0
that	0
endogenous	0
5-lipoxygenase	9
activity	0
modulates	0
platelet-activating	9
factor	10
induced	0
arachidonic	0
acid	0
release	0
perhaps	0
acting	0
at	0
the	0
level	0
of	0
phospholipase	9
A2	10
.	0

In	0
summary	0
,	0
platelet-activating	9
factor	10
is	0
shown	0
here	0
to	0
have	0
a	0
direct	0
and	0
profound	0
effect	0
on	0
a	0
pure	5
B	6
cell	6
line	6
.	0

Positive	0
and	0
negative	0
regulation	0
of	0
immunoglobulin	1
gene	2
expression	0
by	0
a	0
novel	0
B-cell-specific	1
enhancer	2
element	2
.	0

A	0
new	0
B-cell-specific	1
enhancer	2
element	2
has	0
been	0
identified	0
3	0
'	0
of	0
E4	1
and	2
the	2
octamerlike	2
motifs	2
in	0
the	0
human	1
immunoglobulin	2
heavy-chain	2
gene	2
enhancer	2
.	0

Tandem	0
copies	0
of	0
this	0
67-bp	1
MnlI-AluI	2
fragment	2
,	0
when	0
fused	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
gene	2
driven	0
by	0
the	0
conalbumin	1
promoter	2
,	0
stimulated	0
transcription	0
in	0
B	7
cells	8
but	0
not	0
in	0
Jurkat	5
T	6
cells	6
or	0
HeLa	5
cells	6
.	0

Footprinting	0
analysis	0
revealed	0
that	0
the	0
identical	0
sequence	0
CCGAAACTGAAAAGG	0
,	0
designated	0
E6	1
,	0
was	0
protected	0
by	0
nuclear	0
extracts	0
from	0
B	7
cells	8
,	0
T	7
cells	8
,	0
or	0
HeLa	0
cells	0
.	0

Gel	0
mobility	0
shift	0
assays	0
using	0
a	0
synthetic	1
E6	2
motif	2
detected	0
a	0
B-cell-specific	9
complex	10
in	0
addition	0
to	0
a	0
ubiquitous	0
band	0
found	0
also	0
in	0
T	7
cells	8
and	0
HeLa	5
cells	6
.	0

In	0
agreement	0
with	0
the	0
results	0
of	0
gel	0
retardation	0
assays	0
,	0
tandem	0
copies	0
of	0
the	0
E6	1
motif	2
stimulated	0
transcription	0
in	0
ARH77	5
and	0
Raji	5
cells	6
but	0
not	0
in	0
Jurkat	5
or	0
HeLa	5
cells	6
.	0

Furthermore	0
,	0
a	0
mutant	1
E6	2
motif	2
lost	0
both	0
in	0
vitro	0
binding	0
activity	0
and	0
in	0
vivo	0
enhancer	0
activity	0
.	0

In	0
striking	0
contrast	0
to	0
the	0
mouse	1
Ig	2
heavy-chain	2
enhancer	2
,	0
in	0
which	0
the	0
octamer	1
motif	2
acts	0
as	0
a	0
B-cell-specific	1
enhancer	2
element	2
,	0
the	0
human	1
enhancer	2
contains	0
an	0
octamerlike	1
sequence	2
with	0
one	0
base	0
substitution	0
which	0
bound	0
octamer-binding	9
proteins	10
with	0
only	0
very	0
low	0
affinity	0
and	0
showed	0
no	0
enhancer	0
activity	0
of	0
its	0
own	0
.	0

Interestingly	0
,	0
the	0
MnlI-AluI	1
fragment	2
could	0
suppress	0
the	0
basal-level	0
activity	0
of	0
the	0
conalbumin	1
promoter	2
in	0
both	0
Jurkat	5
and	0
HeLa	5
cells	6
.	0

Moreover	0
,	0
simian	0
virus	0
40	0
enhancer	0
activity	0
was	0
blocked	0
by	0
the	0
MnlI-AluI	1
fragment	2
in	0
HeLa	5
cells	6
but	0
not	0
in	0
B	7
cells	8
.	0

Thus	0
,	0
the	0
novel	0
enhancer	0
element	0
identified	0
in	0
this	0
study	0
is	0
probably	0
a	0
target	0
site	0
for	0
both	0
positive	9
and	10
negative	10
factors	10
.	0

Charybdotoxin-sensitive	0
,	0
Ca	0
(	0
2+	0
)	0
-dependent	0
membrane	0
potential	0
changes	0
are	0
not	0
involved	0
in	0
human	0
T	7
or	8
B	8
cell	8
activation	0
and	0
proliferation	0
.	0

The	0
involvement	0
of	0
ion	0
channels	0
in	0
B	0
and	0
T	0
lymphocyte	0
activation	0
is	0
supported	0
by	0
many	0
reports	0
of	0
changes	0
in	0
ion	0
fluxes	0
and	0
membrane	0
potential	0
after	0
mitogen	9
binding	0
.	0

Human	7
T	8
and	8
B	8
lymphocytes	8
demonstrate	0
an	0
early	0
and	0
transient	0
hyperpolarization	0
after	0
ligand	0
binding	0
.	0

Inasmuch	0
as	0
the	0
change	0
in	0
membrane	0
potential	0
is	0
dependent	0
on	0
elevation	0
of	0
free	0
cytosolic	0
calcium	0
,	0
the	0
hyperpolarization	0
is	0
presumably	0
through	0
opening	0
of	0
Ca	0
(	0
2+	0
)	0
-stimulated	0
K+	0
channels	0
.	0

We	0
have	0
used	0
charybdotoxin	0
,	0
a	0
known	0
inhibitor	0
of	0
Ca	9
(	10
2+	10
)	10
-dependent	10
K+	10
channels	10
,	0
to	0
study	0
the	0
role	0
of	0
these	0
channels	0
in	0
lymphocyte	0
activation	0
and	0
mitogenesis	0
.	0

We	0
demonstrate	0
that	0
charybdotoxin	0
inhibits	0
the	0
ligand-induced	0
transient	0
membrane	0
hyperpolarization	0
in	0
B	7
and	8
T	8
cells	8
in	0
a	0
dose-dependent	0
fashion	0
,	0
without	0
affecting	0
changes	0
in	0
cytosolic	0
Ca2+	0
.	0

However	0
,	0
blockade	0
of	0
the	0
Ca	9
(	10
2+	10
)	10
-activated	10
K+	10
channel	10
is	0
not	0
associated	0
with	0
changes	0
in	0
cell-cycle	0
gene	0
activation	0
,	0
IL-2	9
production	0
,	0
IL-2R	9
expression	0
or	0
B	0
and	0
T	0
cell	0
mitogenesis	0
.	0

These	0
results	0
imply	0
that	0
membrane	0
potential	0
changes	0
secondary	0
to	0
the	0
ligand-dependent	0
opening	0
of	0
Ca	9
(	10
2+	10
)	10
-activated	10
K+	10
channels	10
are	0
not	0
involved	0
in	0
B	7
and	8
T	8
lymphocyte	8
activation	0
and	0
mitogenesis	0
.	0

Activity	0
of	0
the	0
kappa	1
B	2
enhancer	2
of	0
the	0
interleukin-2	9
receptor	10
alpha	10
chain	10
in	0
somatic	5
cell	6
hybrids	6
is	0
accompanied	0
by	0
the	0
nuclear	0
localization	0
of	0
NF-kappa	9
B	10
.	0

The	0
two	9
nuclear	10
proteins	10
NF-kappa	9
B	10
(	0
consisting	0
of	0
subunits	0
p50	9
an	0
dp65	9
)	0
and	0
the	0
DNA-binding	9
subunit	10
of	0
NF-kappa	9
B	10
(	0
p50	9
)	0
by	0
itself	0
,	0
also	0
called	0
KBF1	9
,	0
are	0
constitutively	0
expressed	0
and	0
localized	0
in	0
the	0
nucleus	0
of	0
the	0
human	5
T-cell	6
line	6
IARC	5
301.5	6
.	0

In	0
order	0
to	0
define	0
the	0
roles	0
of	0
these	0
two	0
factors	9
,	0
which	0
bind	0
to	0
the	0
same	0
kappa	1
B	2
enhancers	2
,	0
in	0
transcription	0
activation	0
we	0
have	0
prepared	0
somatic	0
cell	0
hybrids	0
between	0
IARC	5
301.5	6
and	0
a	0
murine	5
myeloma	6
.	0

Most	0
hybrids	0
express	0
both	0
KBF1	9
and	0
NF-kappa	9
B	10
in	0
their	0
nuclei	0
,	0
but	0
one	0
hybrid	0
expresses	0
only	0
KBF1	9
.	0

The	0
kappa	1
B	2
enhancer	2
of	0
the	0
gene	0
encoding	0
the	0
interleukin-2	9
(	10
IL-2	10
)	10
receptor	10
alpha	10
chain	10
(	0
IL-2R	9
alpha	10
)	0
is	0
functional	0
only	0
in	0
the	0
hybrids	5
expressing	0
nuclear	9
NF-kappa	10
B	10
.	0

These	0
findings	0
show	0
that	0
nuclear	9
NF-kappa	10
B	10
is	0
necessary	0
to	0
activate	0
the	0
kappa	1
B	2
enhancer	2
,	0
while	0
KBF1	9
by	0
itself	0
is	0
not	0
sufficient	0
.	0

We	0
propose	0
that	0
KBF1	9
is	0
a	0
competitive	0
inhibitor	0
of	0
NF-kappa	9
B	10
and	0
discuss	0
how	0
these	0
factors	0
may	0
be	0
involved	0
in	0
the	0
transient	0
expression	0
of	0
IL-2	9
and	0
IL-2	9
alpha	10
genes	0
during	0
the	0
immune	0
response	0
.	0

T-helper-cell	9
determinants	10
in	0
protein	9
antigens	10
are	0
preferentially	0
located	0
in	0
cysteine-rich	9
antigen	10
segments	10
resistant	0
to	0
proteolytic	0
cleavage	0
by	0
cathepsin	9
B	10
,	10
L	10
,	10
and	10
D	10
.	0

We	0
report	0
on	0
a	0
computer	0
algorithm	0
capable	0
of	0
predicting	0
the	0
location	0
of	0
T-helper-cell	9
epitopes	10
in	0
protein	9
antigen	10
(	0
Ag	9
)	0
by	0
analysing	0
the	0
Ag	9
amino	9
acid	10
sequence	10
.	0

The	0
algorithm	0
was	0
constructed	0
with	0
the	0
aim	0
of	0
identifying	0
segments	0
in	0
Ag	9
which	0
are	0
resistant	0
to	0
proteolytic	0
degradation	0
by	0
the	0
enzymes	0
cathepsin	9
B	10
,	10
L	10
,	10
and	10
D	10
.	0

These	0
are	0
prominent	0
enzymes	9
in	0
the	0
endocytic	0
pathway	0
through	0
which	0
soluble	9
protein	10
Ag	10
enter	0
APC	9
,	0
and	0
resistant	9
segments	10
in	0
Ag	9
may	0
,	0
therefore	0
,	0
be	0
expected	0
to	0
contain	0
more	0
T-cell	9
determinants	10
than	0
susceptible	9
segments	10
.	0

From	0
information	0
available	0
in	0
the	0
literature	0
on	0
the	0
substrate	0
specificity	0
of	0
the	0
three	0
enzymes	9
,	0
it	0
is	0
clear	0
that	0
a	0
cysteine	0
is	0
not	0
accepted	0
in	0
any	0
of	0
the	0
S2	9
,	10
S1	10
,	10
S1	10
'	10
,	10
and	10
S2	10
'	10
subsites	10
of	0
cathepsin	9
B	10
and	10
L	10
,	0
and	0
not	0
in	0
the	0
S1	9
and	0
S1	9
'	10
subsites	0
of	0
cathepsin	9
D	10
.	0

Moreover	0
,	0
we	0
have	0
noticed	0
that	0
cysteine-containing	9
T-cell	10
determinants	10
in	0
a	0
number	0
of	0
protein	9
Ag	10
are	0
particularly	0
rich	0
in	0
the	0
amino	0
acids	0
alanine	0
,	0
glycine	0
,	0
lysine	0
,	0
leucine	0
,	0
serine	0
,	0
threonine	0
,	0
and	0
valine	0
.	0

By	0
searching	0
protein	0
Ag	9
for	0
clusters	0
of	0
amino	0
acids	0
containing	0
cysteine	0
and	0
two	0
of	0
the	0
other	0
amino	0
acids	0
we	0
were	0
able	0
to	0
predict	0
17	0
out	0
of	0
23	0
empirically	0
known	0
T-cell	9
determinants	10
in	0
the	0
Ag	9
with	0
a	0
relatively	0
low	0
number	0
of	0
false	0
(	0
positive	0
)	0
predictions	0
.	0

Furthermore	0
,	0
we	0
present	0
a	0
new	0
principle	0
for	0
searching	0
Ag	9
for	0
potential	0
amphipatic	9
alpha-helical	10
protein	10
segments	10
.	0

Such	0
segments	0
accord	0
well	0
with	0
empirically	0
known	0
T-cell	9
determinants	10
and	0
our	0
algorithm	0
produces	0
a	0
lower	0
number	0
of	0
false	0
positive	0
predictions	0
than	0
the	0
principle	0
based	0
on	0
discrete	0
Fourier	0
transformations	0
previously	0
described	0
.	0

Contribution	0
of	0
NF-kappa	9
B	10
and	0
Sp1	1
binding	2
motifs	2
to	0
the	0
replicative	0
capacity	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
:	0
distinct	0
patterns	0
of	0
viral	0
growth	0
are	0
determined	0
by	0
T-cell	7
types	8
.	0

Starting	0
with	0
a	0
replication-incompetent	0
molecular	0
clone	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
,	0
lacking	0
all	0
the	0
NF-kappa	1
B	2
and	2
Sp1	2
binding	2
sites	2
present	0
in	0
the	0
native	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
,	0
proviruses	0
containing	0
reconstructed	1
LTRs	2
with	0
individual	0
or	0
combinations	0
of	0
NF-kappa	1
B	2
and	2
Sp1	2
elements	2
were	0
generated	0
and	0
evaluated	0
for	0
their	0
capacity	0
to	0
produce	0
virus	0
progeny	0
following	0
transfection-cocultivation	0
.	0

Virus	0
stocks	0
obtained	0
from	0
these	0
experiments	0
exhibited	0
a	0
continuum	0
of	0
replicative	0
capacities	0
in	0
different	0
human	7
T-cell	8
types	8
depending	0
on	0
which	0
element	1
(	0
s	0
)	0
was	0
present	0
in	0
the	0
LTR	1
.	0

For	0
example	0
,	0
in	0
experiments	0
involving	0
proviral	0
clones	0
with	0
LTRs	1
containing	0
one	0
or	0
two	0
NF-kappa	1
B	2
elements	2
(	0
and	0
no	0
Sp1	1
binding	2
sites	2
)	0
,	0
a	0
hierarchy	0
of	0
cellular	0
permissivity	0
to	0
virus	0
replication	0
(	0
peripheral	7
blood	8
lymphocytes	8
=	0
MT4	5
greater	0
than	0
H9	5
greater	0
than	0
CEM	5
greater	0
than	0
Jurkat	5
)	0
was	0
observed	0
.	0

Of	0
note	0
was	0
the	0
associated	0
emergence	0
of	0
second-site	1
LTR	2
revertants	0
which	0
involved	0
an	0
alteration	0
of	0
the	0
TATA	1
box	2
.	0

These	0
results	0
suggest	0
that	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
LTR	2
possesses	0
functional	0
redundancy	0
which	0
ensures	0
virus	0
replication	0
in	0
different	0
T-cell	7
types	8
and	0
is	0
capable	0
of	0
changing	0
depending	0
on	0
the	0
particular	0
combination	0
of	0
transcriptional	9
factors	10
present	0
.	0

Stimulation	0
of	0
interferon	1
beta	2
gene	2
transcription	0
in	0
vitro	0
by	0
purified	0
NF-kappa	9
B	10
and	0
a	0
novel	0
TH	9
protein	10
.	0

The	0
human	1
interferon	2
beta	2
(	2
IFN-beta	2
)	2
regulatory	2
element	2
consists	0
of	0
multiple	0
enhanson	1
domains	2
which	0
are	0
targets	0
for	0
transcription	9
factors	10
involved	0
in	0
inducible	0
expression	0
of	0
the	0
promoter	1
.	0

To	0
further	0
characterize	0
the	0
protein-DNA	0
interactions	0
mediating	0
IFN-beta	9
induction	0
,	0
positive	9
regulatory	10
domain	10
(	10
PRD	10
)	10
II	10
binding	10
proteins	10
were	0
purified	0
from	0
phorbol	0
ester	0
induced	0
Jurkat	5
T-cells	6
and	0
from	0
IFN	5
primed	6
,	6
cycloheximide/polyinosinic-polycytidylic	6
acid	6
treated	6
HeLa	6
S3	6
cells	6
.	0

From	0
HeLa	5
cells	6
,	0
two	0
major	0
proteins	0
of	0
52	9
and	10
45	10
kilodaltons	10
(	10
kD	10
)	10
copurified	0
with	0
DNA	0
binding	0
activity	0
,	0
whereas	0
from	0
T-cells	7
,	0
four	0
proteins	0
--	0
a	0
major	9
protein	10
of	0
52	9
kD	10
and	0
three	0
minor	9
proteins	10
of	0
82	9
,	0
67	9
,	0
and	0
43-47	9
kD	10
--	0
were	0
purified	0
.	0

Also	0
,	0
an	0
induction	0
specific	9
DNA	10
binding	10
protein	10
was	0
purified	0
from	0
HeLa	5
cells	6
that	0
interacted	0
with	0
the	0
(	0
AAGTGA	0
)	0
4	0
tetrahexamer	1
sequence	2
and	0
the	0
PRDI	1
domain	2
.	0

This	0
protein	0
is	0
immunologically	0
distinct	0
from	0
IRF-1/ISGF2	9
.	0

Uninduced	0
or	0
Sendai	0
virus	0
induced	0
HeLa	0
extracts	0
were	0
used	0
to	0
examine	0
transcription	0
in	0
vitro	0
using	0
a	0
series	0
of	0
IFN	1
beta	2
promoter	2
deletions	2
.	0

Deletions	0
upstream	0
of	0
the	0
PRDII	1
element	2
increased	0
transcription	0
in	0
the	0
uninduced	0
extract	0
,	0
indicating	0
predominantly	0
negative	0
regulation	0
of	0
the	0
promoter	1
.	0

A	0
2-4-fold	0
increase	0
in	0
IFN-beta	1
promoter	2
transcription	0
was	0
observed	0
in	0
Sendai	0
virus	0
induced	0
extracts	0
,	0
and	0
deletion	0
of	0
PRDI	1
and	0
PRDII	1
elements	2
decreased	0
this	0
induced	0
level	0
of	0
transcription	0
.	0

When	0
purified	0
PRDII	9
and	10
tetrahexamer	10
binding	10
proteins	10
were	0
added	0
to	0
the	0
induced	0
extract	0
,	0
a	0
4-fold	0
increase	0
in	0
transcription	0
was	0
observed	0
.	0

These	0
experiments	0
demonstrate	0
that	0
it	0
is	0
possible	0
to	0
modulate	0
IFN-beta	0
transcription	0
in	0
vitro	0
but	0
indicate	0
that	0
additional	0
proteins	0
may	0
be	0
required	0
to	0
fully	0
activate	0
IFN-beta	9
transcription	0
.	0

The	0
rhombotin	1
family	2
of	0
cysteine-rich	1
LIM-domain	2
oncogenes	2
:	0
distinct	0
members	0
are	0
involved	0
in	0
T-cell	1
translocations	2
to	0
human	1
chromosomes	2
11p15	2
and	2
11p13	2
.	0

A	0
chromosomal	0
translocation	0
in	0
a	0
T-cell	0
leukemia	0
involving	0
the	0
short	1
arm	2
of	0
human	1
chromosome	2
11	2
at	0
band	1
11p15	2
disrupts	0
the	0
rhombotin	1
gene	2
.	0

This	0
gene	0
encodes	0
a	0
protein	0
with	0
duplicated	0
cysteine-rich	9
regions	10
called	0
LIM	9
domains	10
,	0
which	0
show	0
homology	0
to	0
zinc-binding	9
proteins	10
and	0
to	0
iron-sulfur	9
centers	10
of	0
ferredoxins	9
.	0

Two	0
homologues	0
of	0
the	0
rhombotin	1
gene	2
have	0
now	0
been	0
isolated	0
.	0

One	0
of	0
these	0
,	0
designated	0
Rhom-2	1
,	0
is	0
located	0
on	0
human	1
chromosome	2
11	2
at	0
band	1
11p13	2
,	0
where	0
a	0
cluster	0
of	0
T-cell	1
leukemia-specific	2
translocations	2
occur	0
;	0
all	0
translocation	0
breakpoints	0
at	0
11p13	1
are	0
upstream	0
of	0
the	0
Rhom-2	1
gene	2
.	0

Human	1
and	2
mouse	2
Rhom-2	2
are	0
highly	0
conserved	0
and	0
,	0
like	0
rhombotin	1
,	0
encode	0
two	0
tandem	1
cysteine-rich	2
LIM	2
domains	2
.	0

Rhom-2	3
mRNA	4
is	0
expressed	0
in	0
early	0
mouse	0
development	0
in	0
central	0
nervous	0
system	0
,	0
lung	0
,	0
kidney	0
,	0
liver	0
,	0
and	0
spleen	0
but	0
only	0
very	0
low	0
levels	0
occur	0
in	0
thymus	0
.	0

The	0
other	0
gene	0
,	0
designated	0
Rhom-3	1
,	0
is	0
not	0
on	0
chromosome	0
11	0
but	0
also	0
retains	0
homology	0
to	0
the	0
LIM	1
domain	2
of	0
rhombotin	1
.	0

Since	0
the	0
Rhom-2	1
gene	2
is	0
such	0
a	0
common	0
site	0
of	0
chromosomal	0
damage	0
in	0
T-cell	7
tumors	8
,	0
the	0
consistency	0
of	0
translocations	0
near	0
the	0
rhombotin	1
gene	2
was	0
further	0
examined	0
.	0

A	0
second	0
translocation	0
adjacent	0
to	0
rhombotin	1
was	0
found	0
and	0
at	0
the	0
same	0
position	0
as	0
in	0
the	0
previous	0
example	0
.	0

Therefore	0
,	0
chromosome	1
bands	2
11p15	2
(	0
rhombotin	1
)	0
and	0
11p13	1
(	0
Rhom-2	1
)	0
are	0
consistent	0
sites	0
of	0
chromosome	0
translocation	0
in	0
T-cell	0
leukemia	0
,	0
with	0
the	0
11p15	1
target	2
more	0
rarely	0
involved	0
.	0

The	0
results	0
define	0
the	0
rhombotin	1
gene	0
family	0
as	0
a	0
class	0
of	0
T-cell	1
oncogenes	2
with	0
duplicated	0
cysteine-rich	1
LIM	2
domains	2
.	0

NF-kappa	9
B	10
activation	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
in	0
the	0
Jurkat	5
T	6
cell	6
line	6
is	0
independent	0
of	0
protein	9
kinase	10
A	10
,	0
protein	9
kinase	10
C	10
,	0
and	0
Ca	9
(	10
2+	10
)	10
-regulated	10
kinases	10
.	0

NF-kappa	9
B	10
is	0
a	0
DNA-binding	9
regulatory	10
factor	10
able	0
to	0
control	0
transcription	0
of	0
a	0
number	0
of	0
genes	0
,	0
including	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
genes	2
.	0

In	0
T	7
cells	8
,	0
NF-kappa	9
B	10
is	0
activated	0
upon	0
cellular	0
treatment	0
by	0
phorbol	0
esters	0
and	0
the	0
cytokine	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF	9
alpha	10
)	0
.	0

In	0
the	0
present	0
work	0
,	0
we	0
investigated	0
the	0
molecular	0
events	0
leading	0
to	0
NF-kappa	9
B	10
activation	0
by	0
TNF	9
alpha	10
in	0
a	0
human	5
T	6
cell	6
line	6
(	0
Jurkat	5
)	0
and	0
its	0
subclone	0
JCT6	5
,	0
which	0
presents	0
a	0
deficiency	0
in	0
the	0
PKA	9
transduction	0
pathway	0
.	0

We	0
found	0
that	0
in	0
both	0
cell	0
lines	0
,	0
both	0
phorbol	0
ester	0
and	0
TNF	9
alpha	10
were	0
able	0
to	0
activate	0
NF-kappa	9
B	10
.	0

Phorbol	0
activation	0
was	0
positively	0
modulated	0
by	0
Ca2+	0
influx	0
while	0
TNF	9
alpha	10
activation	0
was	0
not	0
.	0

Furthermore	0
,	0
while	0
PMA	0
activation	0
was	0
inhibited	0
by	0
the	0
PKC	9
inhibitor	0
staurosporin	0
,	0
the	0
TNF	9
alpha	10
effect	0
was	0
unchanged	0
.	0

TNF	9
alpha	10
did	0
not	0
activate	0
cAMP	0
production	0
and	0
its	0
signal	0
was	0
not	0
modulated	0
by	0
cAMP	0
activators	0
.	0

Moreover	0
,	0
cAMP	0
activators	0
did	0
not	0
activate	0
NF-kappa	9
B	10
in	0
Jurkat	5
cells	6
.	0

Thus	0
,	0
TNF	9
alpha	10
-induced	0
NF-kappa	9
B	10
activation	0
was	0
found	0
to	0
be	0
mediated	0
by	0
none	0
of	0
the	0
major	0
signal-mediating	9
kinases	10
such	0
as	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
,	0
protein	9
kinase	10
A	10
,	0
or	0
Ca	9
(	10
2+	10
)	10
-regulated	10
kinases	10
.	0

Furthermore	0
,	0
we	0
found	0
that	0
cytoplasmic	0
acidification	0
facilitated	0
NF-kappa	9
B	10
activation	0
by	0
both	0
TNF	9
alpha	10
and	0
PKC	9
,	0
by	0
a	0
mechanism	0
that	0
increases	0
NF-kappa	9
B	10
/I	9
kappa	10
B	10
dissociation	0
without	0
affecting	0
the	0
NF-kappa	9
B	10
translocation	0
step	0
.	0

The	0
functional	0
domains	0
of	0
the	0
murine	1
Thy-1	2
gene	2
promoter	2
.	0

The	0
Thy-1	1
gene	2
promoter	2
resembles	0
a	0
``	1
housekeeping	2
''	2
promoter	2
in	0
that	0
it	0
is	0
located	0
within	0
a	0
methylation-free	1
island	2
,	0
lacks	0
a	0
canonical	1
TATA	2
box	2
,	0
and	0
displays	0
heterogeneity	0
in	0
the	0
5'-end	3
termini	4
of	0
the	0
mRNA	3
.	0

Using	0
transgenic	0
mice	0
,	0
we	0
show	0
that	0
this	0
promoter	1
does	0
not	0
confer	0
any	0
tissue	0
specificity	0
and	0
is	0
active	0
only	0
in	0
a	0
position-dependent	0
manner	0
.	0

It	0
can	0
only	0
be	0
activated	0
in	0
a	0
tissue-specific	0
manner	0
by	0
elements	0
that	0
lie	0
downstream	0
of	0
the	0
initiation	1
site	2
.	0

We	0
have	0
analyzed	0
the	0
functional	0
domains	0
of	0
the	0
minimal	1
Thy-1	2
promoter	2
and	0
show	0
that	0
the	0
dominant	1
promoter	2
elements	2
consist	0
of	0
multiple	1
binding	2
sites	2
for	0
the	0
transcription	9
factor	10
Sp1	9
,	0
an	0
inverted	0
CCAAT	1
box	2
,	0
and	0
sequences	0
proximal	0
to	0
the	0
transcription	1
start	2
site	2
.	0

DNase	0
I	0
and	0
gel	0
mobility	0
shift	0
assays	0
show	0
the	0
binding	0
of	0
a	0
number	0
of	0
nuclear	9
factors	10
to	0
these	0
elements	1
,	0
including	0
Sp1	9
and	0
CP1	9
.	0

Our	0
results	0
show	0
that	0
the	0
structure	0
of	0
this	0
promoter	1
only	0
permits	0
productive	0
interactions	0
of	0
the	0
two	0
transcription	9
factors	10
Sp1	9
and	0
CP1	9
with	0
the	0
basal	0
transcription	0
machinery	0
in	0
the	0
presence	0
of	0
enhancer	1
sequences	2
.	0

Nuclear	9
factor	10
kappa	10
B	10
activates	0
proenkephalin	0
transcription	0
in	0
T	7
lymphocytes	8
.	0

Upon	0
activation	0
,	0
T	7
lymphocytes	8
accumulate	0
high	0
levels	0
of	0
the	0
neuropeptide	0
enkephalin	0
which	0
correlate	0
with	0
high	0
levels	0
of	0
proenkephalin	3
mRNA	4
in	0
the	0
cells	0
.	0

Here	0
we	0
investigated	0
the	0
transcriptional	0
basis	0
for	0
these	0
changes	0
.	0

The	0
proenkephalin	0
promoter	0
contains	0
a	0
sequence	0
GGGGACGTCCCC	0
,	0
named	0
B2	1
,	0
which	0
is	0
similar	0
to	0
the	0
kappa	1
B	2
sequence	2
GGGGACTTTCC	0
,	0
the	0
binding	0
site	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
.	0

Activation	0
of	0
T	7
lymphocytes	8
induces	0
an	0
NF-kappa	9
B	10
-like	0
binding	0
activity	0
to	0
the	0
B2	1
site	0
,	0
concomitant	0
with	0
activation	0
of	0
the	0
proenkephalin	1
promoter	2
.	0

Mutations	0
at	0
the	0
B2	1
site	0
abolish	0
this	0
transcriptional	0
activation	0
.	0

The	0
purified	0
homodimer	9
(	0
two	0
p50s	9
)	0
of	0
the	0
DNA-binding	9
subunit	10
of	0
NF-kappa	9
B	10
binds	0
the	0
B2	1
site	0
of	0
proenkephalin	0
relatively	0
better	0
than	0
does	0
the	0
heterotetramer	9
(	0
two	0
p65s	9
plus	0
two	0
p50s	9
)	0
form	0
of	0
the	0
factor	0
.	0

Thus	0
,	0
it	0
appears	0
that	0
the	0
T-cell-specific	0
activation	0
of	0
the	0
proenkephalin	1
promoter	2
is	0
mediated	0
by	0
NF-kappa	9
B	10
.	0

However	0
,	0
as	0
NF-kappa	9
B	10
is	0
ubiquitous	0
and	0
the	0
transcriptional	0
activation	0
through	0
the	0
B2	1
site	0
is	0
T	0
cell	0
specific	0
,	0
yet	0
another	0
T-cell-specific	9
factor	10
which	0
synergizes	0
with	0
NF-kappa	9
B	10
should	0
be	0
considered	0
.	0

Induction	0
of	0
NF-KB	9
during	0
monocyte	7
differentiation	0
by	0
HIV	0
type	0
1	0
infection	0
.	0

The	0
production	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
progeny	0
was	0
followed	0
in	0
the	0
U937	5
promonocytic	6
cell	6
line	6
after	0
stimulation	0
either	0
with	0
retinoic	0
acid	0
or	0
PMA	0
,	0
and	0
in	0
purified	7
human	8
monocytes	8
and	8
macrophages	8
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
and	0
Southwestern	0
blotting	0
experiments	0
were	0
used	0
to	0
detect	0
the	0
binding	0
of	0
cellular	9
transactivation	10
factor	10
NF-KB	9
to	0
the	0
double	1
repeat-KB	2
enhancer	2
sequence	2
located	0
in	0
the	0
long	1
terminal	2
repeat	2
.	0

PMA	0
treatment	0
,	0
and	0
not	0
retinoic	0
acid	0
treatment	0
of	0
the	0
U937	5
cells	6
acts	0
in	0
inducing	0
NF-KB	9
expression	0
in	0
the	0
nuclei	0
.	0

In	0
nuclear	0
extracts	0
from	0
monocytes	7
or	0
macrophages	7
,	0
induction	0
of	0
NF-KB	9
occurred	0
only	0
if	0
the	0
cells	0
were	0
previously	0
infected	0
with	0
HIV-1	0
.	0

When	0
U937	5
cells	6
were	0
infected	0
with	0
HIV-1	0
,	0
no	0
induction	0
of	0
NF-KB	9
factor	10
was	0
detected	0
,	0
whereas	0
high	0
level	0
of	0
progeny	0
virions	0
was	0
produced	0
,	0
suggesting	0
that	0
this	0
factor	0
was	0
not	0
required	0
for	0
viral	0
replication	0
.	0

These	0
results	0
indicate	0
that	0
in	0
monocytic	5
cell	6
lineage	6
,	0
HIV-1	0
could	0
mimic	0
some	0
differentiation/activation	0
stimuli	0
allowing	0
nuclear	0
NF-KB	9
expression	0
.	0

Disruption	0
of	0
the	0
human	1
SCL	2
locus	2
by	0
``	0
illegitimate	0
''	0
V-	0
(	0
D	0
)	0
-J	0
recombinase	0
activity	0
.	0

A	0
fusion	1
complementary	2
DNA	2
in	0
the	0
T	5
cell	6
line	6
HSB-2	6
elucidates	0
a	0
provocative	0
mechanism	0
for	0
the	0
disruption	0
of	0
the	0
putative	0
hematopoietic	9
transcription	10
factor	10
SCL	9
.	0

The	0
fusion	1
cDNA	2
results	0
from	0
an	0
interstitial	0
deletion	0
between	0
a	0
previously	0
unknown	1
locus	2
,	0
SIL	1
(	0
SCL	1
interrupting	2
locus	2
)	0
,	0
and	0
the	0
5	1
'	2
untranslated	2
region	2
of	0
SCL	9
.	0

Similar	0
to	0
1	0
;	0
14	0
translocations	0
,	0
this	0
deletion	0
disrupts	0
the	0
SCL	1
5	2
'	2
regulatory	2
region	2
.	0

This	0
event	0
is	0
probably	0
mediated	0
by	0
V-	0
(	0
D	0
)	0
-J	0
recombinase	0
activity	0
,	0
although	0
neither	0
locus	0
is	0
an	0
immunoglobulin	9
or	0
a	0
T	9
cell	10
receptor	10
.	0

Two	0
other	0
T	5
cell	6
lines	6
,	0
CEM	5
and	0
RPMI	5
8402	6
,	0
have	0
essentially	0
identical	0
deletions	0
.	0

Thus	0
,	0
in	0
lymphocytes	7
,	0
growth-affecting	1
genes	2
other	0
than	0
immune	9
receptors	10
risk	0
rearrangements	0
.	0

Thyroid	9
hormone	10
receptors	10
form	0
distinct	0
nuclear	9
protein-dependent	10
and	10
independent	10
complexes	10
with	0
a	0
thyroid	1
hormone	2
response	2
element	2
.	0

We	0
have	0
examined	0
the	0
binding	0
of	0
nuclear	9
proteins	10
and	0
recombinant	9
thyroid	10
hormone	10
receptors	10
(	0
TRs	9
)	0
to	0
the	0
palindromic	1
thyroid	2
hormone	2
responsive	2
element	2
AGGTCATGACCT	0
(	0
TREp	1
)	0
using	0
a	0
gel	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

Four	0
specific	0
protein-DNA	9
complexes	10
were	0
detected	0
after	0
incubation	0
of	0
nuclear	0
extracts	0
(	0
NE	0
)	0
from	0
T3-responsive	5
pituitary	6
(	6
GH3	6
)	6
cells	6
with	0
a	0
TREp-containing	1
DNA	2
fragment	2
.	0

This	0
was	0
compared	0
with	0
the	0
TREp	1
binding	0
of	0
reticulocyte	9
lysate-synthesized	10
TRs	10
.	0

TR	9
alpha	10
1	10
and	0
TR	9
beta	10
2	10
each	0
formed	0
a	0
single	0
major	0
TR	9
:	10
TREp	10
complex	10
which	0
comigrated	0
with	0
the	0
least	0
retarded	0
complex	0
formed	0
by	0
GH3	0
NE	0
,	0
while	0
TR	9
beta	10
1	10
formed	0
multiple	0
complexes	0
suggesting	0
that	0
it	0
can	0
bind	0
to	0
TREp	1
as	0
an	0
oligomer	9
.	0

Interestingly	0
,	0
coincubation	0
of	0
35S-TR	9
alpha	10
1	10
,	0
GH3	0
NE	0
,	0
and	0
unlabeled	0
TREp	1
resulted	0
in	0
not	0
only	0
the	0
35S-TR	9
:	10
TREp	10
complex	10
,	0
but	0
in	0
two	0
additional	0
more	0
greatly	0
retarded	0
complexes	0
containing	0
35S-TR	9
alpha	10
1	10
and	0
comigrating	0
with	0
those	0
formed	0
by	0
GH3	0
extract	0
alone	0
.	0

Incubation	0
of	0
each	0
of	0
the	0
TRs	9
with	0
NE	0
from	0
COS-7	5
cells	6
,	0
which	0
do	0
not	0
possess	0
sufficient	0
endogenous	0
TRs	9
to	0
mediate	0
T3-responses	0
,	0
resulted	0
in	0
formation	0
of	0
a	0
new	0
,	0
more	0
greatly	9
shifted	10
complex	10
.	0

A	0
similar	0
,	0
heat	0
labile	0
activity	0
which	0
altered	0
mobility	0
of	0
the	0
TR	9
:	10
TRE	10
complex	10
was	0
also	0
present	0
in	0
NE	0
from	0
T3-unresponsive	5
JEG-3	6
cells	6
.	0

At	0
high	0
concentration	0
of	0
NE	0
,	0
all	0
of	0
the	0
TR	9
bound	0
to	0
TREp	1
was	0
more	0
greatly	0
retarded	0
than	0
in	0
the	0
absence	0
of	0
NE	0
.	0

Truncation	0
of	0
TR	9
alpha	10
1	10
at	0
amino	9
acid	10
210	10
prevented	0
additional	0
complex	0
formation	0
in	0
the	0
presence	0
of	0
NE	0
without	0
affecting	0
DNA	0
binding	0
,	0
suggesting	0
that	0
the	0
carboxyl-terminus	9
of	0
the	0
TRs	9
is	0
essential	0
for	0
interaction	0
with	0
nuclear	9
proteins	10
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Cell-specific	0
differences	0
in	0
activation	0
of	0
NF-kappa	1
B	2
regulatory	2
elements	2
of	0
human	1
immunodeficiency	2
virus	2
and	2
beta	2
interferon	2
promoters	2
by	0
tumor	9
necrosis	10
factor	10
.	0

Three	0
aspects	0
of	0
the	0
involvement	0
of	0
tumor	9
necrosis	10
factor	10
in	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
pathogenesis	0
were	0
examined	0
.	0

Tumor	3
necrosis	4
factor	4
alpha	4
(	4
TNF-alpha	4
)	4
mRNA	4
production	0
was	0
analyzed	0
by	0
polymerase	0
chain	0
reaction	0
amplification	0
in	0
monocytic	5
U937	6
cells	6
and	0
in	0
a	0
chronically	5
HIV	6
infected	6
U937	6
cell	6
line	6
(	0
U9-IIIB	5
)	0
.	0

TNF-alpha	3
RNA	4
was	0
undetectable	0
in	0
U937	5
cells	6
,	0
whereas	0
a	0
low	0
constitutive	0
level	0
was	0
detected	0
in	0
U9-IIIB	5
cells	6
.	0

Paramyxovirus	0
infection	0
induced	0
a	0
5-	0
to	0
10-fold	0
increase	0
in	0
the	0
steady-state	0
level	0
of	0
TNF-alpha	3
RNA	4
in	0
U9-IIIB	5
cells	6
compared	0
with	0
U937	5
cells	6
,	0
suggesting	0
that	0
HIV-infected	5
monocytic	6
cells	6
produced	0
higher	0
levels	0
of	0
TNF-alpha	9
than	0
did	0
normal	0
cells	0
after	0
a	0
secondary	0
virus	0
infection	0
.	0

The	0
effects	0
of	0
TNF-alpha	9
on	0
gene	0
expression	0
were	0
examined	0
by	0
transient	0
expression	0
assays	0
using	0
reporter	1
chloramphenicol	2
acetyltransferase	2
plasmids	2
linked	0
to	0
regulatory	1
elements	2
from	0
the	0
HIV	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
and	0
the	0
beta	1
interferon	2
promoter	2
.	0

In	0
U937	5
and	6
Jurkat	6
T	6
lymphoid	6
cells	6
,	0
the	0
inducibility	0
of	0
the	0
different	0
hybrid	1
promoters	2
by	0
TNF-alpha	9
or	0
phorbol	0
ester	0
varied	0
in	0
a	0
cell	0
type-	0
and	0
promoter	0
context-specific	0
manner	0
;	0
the	0
levels	0
of	0
gene	0
activity	0
of	0
NF-kappa	1
B-containing	2
plasmids	2
correlated	0
directly	0
with	0
induction	0
of	0
NF-kappa	9
B	10
DNA-binding	0
activity	0
.	0

Although	0
the	0
intact	0
beta	1
interferon	2
promoter	2
was	0
only	0
weakly	0
stimulated	0
by	0
phorbol	0
ester	0
or	0
TNF-alpha	9
,	0
multimers	0
of	0
the	0
PRDII	1
NF-kappa	2
B-binding	2
domain	2
were	0
inducible	0
by	0
both	0
agents	0
.	0

TNF-alpha	9
was	0
able	0
to	0
increase	0
expression	0
of	0
the	0
HIV	1
LTR	2
in	0
T	7
cells	8
,	0
but	0
in	0
monocytic	7
cells	8
,	0
TNF-alpha	9
did	0
not	0
induce	0
the	0
HIV	1
LTR	2
above	0
a	0
constitutive	0
level	0
of	0
activity	0
.	0

This	0
level	0
of	0
NF-kappa	9
B	10
-independent	0
activity	0
appears	0
to	0
be	0
sufficient	0
for	0
virus	0
multiplication	0
,	0
since	0
TNF-alpha	9
treatment	0
had	0
no	0
effect	0
on	0
the	0
kinetics	0
of	0
de	0
novo	0
HIV	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
and	0
viral	3
RNA	4
production	0
in	0
U937	5
cells	6
.	0

However	0
,	0
in	0
Jurkat	5
cells	6
,	0
TNF-alpha	9
dramatically	0
enhanced	0
the	0
spread	0
of	0
HIV-1	0
through	0
the	0
cell	0
population	0
and	0
increased	0
viral	3
RNA	4
synthesis	0
,	0
indicating	0
that	0
in	0
T	7
cells	8
HIV-1	0
multiplication	0
was	0
stimulated	0
by	0
TNF-alpha	9
treatment	0
.	0

Functional	0
analysis	0
of	0
cis-linked	1
regulatory	2
sequences	2
in	0
the	0
HLA	1
DRA	2
promoter	2
by	0
transcription	0
in	0
vitro	0
.	0

Two	0
consensus	0
sequences	0
,	0
called	0
X	1
and	2
Y	2
boxes	2
,	0
capable	0
of	0
binding	0
nuclear	9
proteins	10
and	0
regulating	0
expression	0
in	0
B	7
cells	8
have	0
been	0
defined	0
within	0
the	0
immediate	0
upstream	0
region	0
of	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
promoters	2
.	0

Unlike	0
other	0
class	1
II	2
promoters	2
,	0
the	0
HLA-DR	1
alpha	2
(	2
DRA	2
)	2
promoter	2
also	0
contains	0
one	0
element	0
identical	0
to	0
the	0
``	1
octamer	2
''	2
motif	2
of	0
immunoglobulin	1
variable	2
region	2
promoters	2
that	0
is	0
responsible	0
for	0
B	0
cell-specific	0
transcription	0
.	0

This	0
``	0
octamer	1
``	0
in	0
the	0
context	0
of	0
DRA	9
appears	0
capable	0
of	0
binding	0
both	0
the	0
ubiquitous	9
(	0
OTF-1	9
)	0
and	0
lymphoid-specific	9
(	10
OTF-2	10
)	10
``	10
octamer	10
''	10
binding	10
proteins	10
,	0
but	0
at	0
least	0
one	0
other	0
distinct	0
``	9
octamer	10
''	10
complex	10
was	0
found	0
.	0

In	0
order	0
to	0
characterize	0
the	0
function	0
of	0
cis-acting	1
elements	2
,	0
we	0
have	0
developed	0
an	0
in	0
vitro	0
system	0
in	0
which	0
a	0
DRA	1
promoter	2
construct	2
is	0
transcribed	0
more	0
efficiently	0
in	0
extracts	0
from	0
B	7
cells	8
than	0
in	0
extracts	0
from	0
class	5
II-negative	6
HeLa	6
cells	6
.	0

5	0
'	0
deletion	0
constructs	0
which	0
lacked	0
the	0
Y	1
box	2
,	0
but	0
retained	0
the	0
``	1
octamer	2
''	2
motif	2
and	0
TATA	1
box	2
were	0
completely	0
inactive	0
,	0
and	0
internal	0
deletion	0
of	0
the	0
Y	1
box	2
reduced	0
transcription	0
by	0
95	0
%	0
.	0

Using	0
supercoiled	0
,	0
but	0
not	0
linear	0
templates	0
,	0
we	0
observed	0
differences	0
in	0
transcription	0
efficiencies	0
from	0
templates	0
lacking	0
or	0
disrupting	0
the	0
X	1
consensus	2
element	2
that	0
reflect	0
effects	0
of	0
random	0
replacement	0
of	0
X	1
box	2
sequences	2
in	0
transient	0
expression	0
assays	0
.	0

Demonstration	0
of	0
the	0
complete	0
dependence	0
on	0
the	0
Y	1
box	2
in	0
this	0
system	0
suggests	0
that	0
,	0
despite	0
its	0
demonstrated	0
importance	0
in	0
the	0
DRA	1
promoter	2
,	0
the	0
DRA	1
``	2
octamer	2
''	2
does	0
not	0
utilize	0
OTF-2	9
in	0
a	0
manner	0
analogous	0
to	0
immunoglobulin	1
promoters	2
in	0
B	7
cells	8
.	0

Lipopolysaccharide	0
is	0
a	0
potent	0
monocyte/macrophage-specific	0
stimulator	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
expression	0
.	0

Lipopolysaccharide	0
(	0
LPS	0
)	0
potently	0
stimulates	0
human	1
immunodeficiency	2
virus	2
type	2
1-long	2
terminal	2
repeat	2
(	2
HIV-1-LTR	2
)	2
CAT	2
constructs	2
transfected	0
into	0
monocyte/macrophage-like	5
cell	6
lines	6
but	0
not	0
a	0
T	5
cell	6
line	6
.	0

This	0
effect	0
appears	0
to	0
be	0
mediated	0
through	0
the	0
induction	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
demonstrate	0
that	0
LPS	0
induces	0
a	0
DNA	0
binding	0
activity	0
indistinguishable	0
from	0
NF-kappa	9
B	10
in	0
U937	5
and	0
THP-1	5
cells	6
.	0

LPS	0
is	0
also	0
shown	0
to	0
dramatically	0
increase	0
HIV-1	0
production	0
from	0
a	0
chronically	5
infected	6
monocyte/macrophage-like	6
cloned	6
cell	6
line	6
,	0
U1	5
,	0
which	0
produces	0
very	0
low	0
levels	0
of	0
HIV-1	0
at	0
baseline	0
.	0

The	0
stimulation	0
of	0
viral	0
production	0
from	0
this	0
cell	0
line	0
occurs	0
only	0
if	0
these	0
cells	0
are	0
treated	0
with	0
granulocyte/macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
before	0
treatment	0
with	0
LPS	0
.	0

This	0
stimulation	0
of	0
HIV-1	0
production	0
is	0
correlated	0
with	0
an	0
increase	0
in	0
the	0
level	0
of	0
HIV-1	3
RNA	4
and	0
and	0
activation	0
of	0
NF-kappa	9
B	10
.	0

LPS	0
is	0
not	0
able	0
to	0
induce	0
HIV-1	0
production	0
in	0
a	0
cloned	0
T	5
cell	6
line	6
.	0

The	0
effect	0
of	0
LPS	0
on	0
HIV-1	0
replication	0
occurs	0
at	0
picogram	0
per	0
milliliter	0
concentrations	0
and	0
may	0
be	0
clinically	0
significant	0
in	0
understanding	0
the	0
variability	0
of	0
the	0
natural	0
history	0
of	0
HIV-1	0
infection	0
.	0

Steroid	0
dose	0
sparing	0
:	0
pharmacodynamic	0
responses	0
to	0
single	0
versus	0
divided	0
doses	0
of	0
methylprednisolone	0
in	0
man	0
.	0

Inhibitory	0
drug	0
interactions	0
affecting	0
the	0
metabolism	0
of	0
methylprednisolone	0
(	0
MP	0
)	0
may	0
produce	0
either	0
steroid	0
sparing	0
or	0
adverse	0
effects	0
partly	0
by	0
increasing	0
the	0
exposure	0
time	0
to	0
the	0
steroid	0
.	0

This	0
phenomenon	0
can	0
be	0
mimicked	0
by	0
administering	0
MP	0
in	0
divided	0
doses	0
.	0

Two	0
types	0
of	0
responses	0
were	0
compared	0
after	0
a	0
single	0
MP	0
dose	0
(	0
40	0
mg	0
bolus	0
)	0
and	0
a	0
divided	0
regimen	0
(	0
20	0
mg	0
bolus	0
and	0
a	0
5	0
mg	0
bolus	0
8	0
hours	0
later	0
)	0
in	0
six	0
healthy	0
male	0
volunteers	0
.	0

The	0
suppression	0
of	0
basophils	7
measured	0
as	0
whole	0
blood	0
histamine	0
and	0
plasma	0
cortisol	0
concentrations	0
was	0
assessed	0
during	0
32	0
hours	0
.	0

The	0
37.5	0
%	0
reduction	0
in	0
dose	0
produced	0
a	0
23	0
%	0
overall	0
decreased	0
blood	0
histamine	0
response	0
.	0

A	0
pharmacodynamic	0
model	0
for	0
basophil	0
cell	0
distribution	0
to	0
and	0
from	0
an	0
extravascular	0
compartment	0
describes	0
the	0
effects	0
of	0
MP	0
after	0
both	0
regimens	0
.	0

A	0
slower	0
initial	0
decline	0
in	0
blood	0
histamine	0
after	0
the	0
divided	0
regimen	0
may	0
be	0
related	0
to	0
incomplete	0
suppression	0
of	0
basophil	7
cell	8
return	0
to	0
blood	0
.	0

The	0
50	0
%	0
inhibitory	0
concentrations	0
of	0
MP	0
of	0
about	0
5	0
ng/ml	0
were	0
similar	0
for	0
both	0
regimens	0
.	0

The	0
decline	0
and	0
return	0
of	0
cortisol	0
concentrations	0
were	0
similar	0
between	0
MP	0
treatments	0
with	0
suppression	0
continuing	0
for	0
24	0
hours	0
.	0

The	0
50	0
%	0
inhibitory	0
concentrations	0
of	0
MP	0
values	0
for	0
adrenal	0
suppression	0
were	0
about	0
1	0
ng/ml	0
.	0

Pharmacodynamic	0
modeling	0
is	0
useful	0
in	0
quantitating	0
corticosteroid	0
responses	0
and	0
generally	0
predicted	0
the	0
``	0
dose-sparing	0
''	0
effects	0
that	0
were	0
achieved	0
by	0
prolonging	0
MP	0
plasma	0
concentrations	0
.	0

This	0
study	0
supports	0
previous	0
clinical	0
observations	0
that	0
patients	0
may	0
require	0
morning	0
through	0
evening	0
exposure	0
to	0
MP	0
to	0
optimize	0
efficacy	0
while	0
adrenal	0
suppression	0
is	0
being	0
minimized	0
.	0

1	0
,	0
25	0
(	0
OH	0
)	0
2D2	0
production	0
by	0
T	7
lymphocytes	8
and	0
alveolar	7
macrophages	8
recovered	0
by	0
lavage	0
from	0
normocalcemic	0
patients	0
with	0
tuberculosis	0
.	0

To	0
compare	0
extra-renal	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
production	0
in	0
different	0
types	0
of	0
granulomatous	0
disease	0
,	0
and	0
to	0
identify	0
the	0
cell	0
types	0
responsible	0
,	0
we	0
have	0
evaluated	0
the	0
conversion	0
of	0
25	0
(	0
OH	0
)	0
D3	0
in	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
by	0
uncultured	7
cells	8
recovered	0
by	0
bronchoalveolar	0
lavage	0
and	0
blood	7
mononuclear	8
cells	8
from	0
normocalcemic	0
patients	0
with	0
sarcoidosis	0
and	0
tuberculosis	0
.	0

1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
was	0
produced	0
both	0
by	0
lavage	7
cells	8
(	0
12/12	0
tuberculosis	0
patients	0
,	0
2/6	0
sarcoidosis	0
patients	0
)	0
and	0
blood	7
mononuclear	8
cells	8
(	0
3/5	0
tuberculosis	0
patients	0
,	0
0/3	0
sarcoidosis	0
patients	0
)	0
from	0
patients	0
but	0
not	0
controls	0
,	0
but	0
significantly	0
greater	0
amounts	0
were	0
produced	0
by	0
lavage	0
cells	0
from	0
tuberculosis	0
patients	0
than	0
those	0
of	0
sarcoidosis	0
patients	0
(	0
P	0
less	0
than	0
0.001	0
)	0
.	0

1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
production	0
by	0
lavage	7
cells	8
from	0
tuberculosis	0
patients	0
correlated	0
with	0
the	0
number	0
of	0
CD8+	0
T	7
lymphocytes	8
present	0
but	0
not	0
other	0
cell	0
types	0
.	0

T	7
lymphocytes	8
appeared	0
to	0
be	0
an	0
important	0
source	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
production	0
,	0
since	0
purified	0
T	7
lymphocytes	8
from	0
all	0
patients	0
with	0
tuberculosis	0
produced	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
and	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
production	0
by	0
these	0
cells	0
correlated	0
closely	0
with	0
that	0
produced	0
by	0
unseparated	0
lavage	7
cells	8
.	0

Because	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
can	0
improve	0
the	0
capacity	0
of	0
macrophages	7
to	0
kill	0
mycobacteria	0
,	0
our	0
results	0
support	0
the	0
conclusion	0
that	0
macrophage-lymphocyte	0
interactions	0
,	0
mediated	0
at	0
least	0
in	0
part	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
may	0
be	0
an	0
important	0
component	0
of	0
a	0
successful	0
antituberculous	0
immune	0
response	0
.	0

Megakaryocytic	5
and	6
erythrocytic	6
lineages	6
share	0
specific	0
transcription	9
factors	10
.	0

Erythroid-specific	1
genes	2
contain	0
binding	0
sites	0
for	0
NF-E1	9
(	0
also	0
called	0
GF-1	9
and	0
Eryf-1	9
;	0
refs	0
1-3	0
respectively	0
)	0
,	0
the	0
principal	0
DNA-binding	9
protein	10
of	0
the	0
erythrocytic	7
lineage	8
.	0

NF-E1	9
expression	0
seems	0
to	0
be	0
restricted	0
to	0
the	0
erythrocytic	7
lineage	8
.	0

A	0
closely	0
related	0
(	0
if	0
not	0
identical	0
)	0
protein	0
is	0
found	0
in	0
both	0
a	0
human	5
megakaryocytic	6
cell	6
line	6
and	0
purified	5
human	6
megakaryocytes	6
;	0
it	0
binds	0
to	0
promoter	1
regions	2
of	0
two	0
megakaryocytic-specific	1
genes	2
.	0

The	0
binding	0
sites	0
and	0
partial	0
proteolysis	0
profile	0
of	0
this	0
protein	0
are	0
indistinguishable	0
from	0
those	0
of	0
the	0
erythroid	9
protein	10
;	0
also	0
,	0
NF-E1	3
messenger	4
RNA	4
is	0
the	0
same	0
size	0
in	0
both	0
the	0
megakaryocytic	5
and	6
erythroid	6
cell	6
lines	6
.	0

Furthermore	0
,	0
point	0
mutations	0
that	0
abolish	0
binding	0
of	0
NF-E1	9
result	0
in	0
a	0
70	0
%	0
decrease	0
in	0
the	0
transcriptional	0
activity	0
of	0
a	0
megakaryocytic-specific	1
promoter	2
.	0

We	0
also	0
find	0
that	0
NF-E2	9
,	0
another	0
trans-acting	9
factor	10
of	0
the	0
erythrocytic	7
lineage	8
,	0
is	0
present	0
in	0
megakaryocytes	5
.	0

Transcriptional	0
effects	0
in	0
both	0
lineages	0
might	0
then	0
be	0
mediated	0
in	0
part	0
by	0
the	0
same	0
specific	0
trans-acting	9
factors	10
.	0

Our	0
data	0
strengthen	0
the	0
idea	0
of	0
a	0
close	0
association	0
between	0
the	0
erythrocytic	5
and	6
the	6
megakaryocytic	6
lineages	6
and	0
could	0
also	0
explain	0
the	0
expression	0
of	0
markers	0
specific	0
to	0
the	0
erythrocytic	7
and	8
megakaryocytic	8
lineages	8
in	0
most	0
erythroblastic	5
and	6
megakaryoblastic	6
permanent	6
cell	6
lines	6
.	0

Transcriptional	0
down-regulation	0
of	0
c-myc	1
expression	0
by	0
protein	0
synthesis-dependent	0
and	0
-independent	0
pathways	0
in	0
a	0
human	5
T	6
lymphoblastic	6
tumor	6
cell	6
line	6
.	0

We	0
show	0
that	0
in	0
the	0
human	5
T	6
lymphoblastic	6
tumor	6
cell	6
line	6
Molt4	3
c-myc	4
mRNA	4
and	0
protein	0
expression	0
is	0
down-regulated	0
after	0
exposure	0
to	0
dimethyl	0
sulfoxide	0
,	0
to	0
phorbol	0
myristate	0
acetate	0
,	0
or	0
to	0
the	0
calcium	0
ionophore	0
A23187	0
,	0
which	0
raises	0
the	0
intracellular	0
calcium	0
concentration	0
.	0

A	0
block	0
to	0
RNA	0
elongation	0
is	0
largely	0
responsible	0
for	0
decreased	0
c-myc	1
transcription	0
.	0

Although	0
negative	0
regulation	0
by	0
dimethyl	0
sulfoxide	0
takes	0
place	0
even	0
when	0
protein	0
synthesis	0
is	0
inhibited	0
by	0
cycloheximide	0
,	0
the	0
phorbol	0
myristate	0
acetate	0
effect	0
is	0
blocked	0
to	0
some	0
extent	0
only	0
by	0
cycloheximide	0
.	0

The	0
calcium	0
ionophore-induced	0
c-myc	1
suppression	0
,	0
however	0
,	0
strictly	0
requires	0
de	0
novo	0
protein	0
synthesis	0
.	0

Therefore	0
,	0
two	0
different	0
negative	0
regulatory	0
pathways	0
are	0
involved	0
in	0
c-myc	1
regulation	0
:	0
one	0
which	0
is	0
independent	0
and	0
one	0
which	0
depends	0
on	0
de	0
novo	0
protein	0
synthesis	0
.	0

The	0
latter	0
one	0
appears	0
to	0
be	0
mediated	0
by	0
a	0
rapidly	0
calcium-dependent	9
induced	10
gene	10
product	10
.	0

Oestrogen	9
receptor	10
(	0
ER	9
)	0
analysis	0
in	0
B-cell	0
chronic	0
lymphocytic	0
leukemia	0
:	0
correlation	0
of	0
biochemical	0
and	0
immunocytochemical	0
methods	0
.	0

Oestrogen	9
receptors	10
(	0
ER	9
)	0
are	0
present	0
in	0
neoplastic	7
lymphoid	8
cells	8
and	0
have	0
been	0
considered	0
a	0
physiological	0
marker	0
of	0
growth	0
rate	0
or	0
differentiation	0
.	0

Tamoxifen	0
,	0
an	0
oestrogen	0
antagonist	0
,	0
has	0
been	0
given	0
in	0
some	0
patients	0
with	0
CLL	0
and	0
Hodgkin	0
's	0
disease	0
,	0
with	0
dramatic	0
response	0
in	0
single	0
cases	0
.	0

Until	0
now	0
,	0
ER	9
status	0
has	0
been	0
assessed	0
using	0
a	0
steroid	0
binding	0
assay	0
(	0
SBA	0
)	0
which	0
has	0
many	0
inherent	0
problems	0
.	0

Recently	0
,	0
the	0
development	0
of	0
monoclonal	0
antibodies	0
directed	0
against	0
ER	9
has	0
been	0
applied	0
to	0
the	0
study	0
of	0
breast	0
carcinomas	0
and	0
results	0
obtained	0
show	0
good	0
correlation	0
with	0
the	0
quantitative	0
SBA	0
.	0

We	0
studied	0
49	0
cases	0
of	0
B-cell	0
chronic	0
lymphocytic	0
leukemia	0
(	0
CLL	0
)	0
using	0
immunostaining	0
of	0
cytospin	0
preparations	0
.	0

In	0
30	0
of	0
these	0
cases	0
ER	9
enzyme	0
immunoassay	0
(	0
ER	9
-EIA	0
)	0
was	0
also	0
performed	0
.	0

Cultured	5
MCF-7	6
cells	6
,	0
derived	0
from	0
a	0
pleural	0
effusion	0
of	0
a	0
breast	0
cancer	0
patient	0
,	0
known	0
to	0
contain	0
high	0
levels	0
of	0
ER	9
were	0
used	0
as	0
a	0
positive	0
control	0
(	0
40-48	0
%	0
ER	7
positive	8
cells	8
by	0
immunocytochemistry	0
;	0
200	0
fmol/mg	0
protein	0
by	0
EIA	0
)	0
.	0

All	0
of	0
the	0
CLL	0
cases	0
except	0
two	0
(	0
96	0
%	0
)	0
were	0
negative	0
for	0
ER	9
(	0
less	0
than	0
1	0
%	0
staining	0
;	0
less	0
than	0
4	0
fmol/mg	0
protein	0
)	0
.	0

The	0
two	0
positive	0
cases	0
expressed	0
granular	0
ER	9
staining	0
over	0
the	0
nucleus	0
(	0
9.2	0
and	0
12.1	0
%	0
positive	0
cells	0
)	0
and	0
were	0
positive	0
by	0
EIA	0
and	0
SBA	0
.	0

It	0
is	0
concluded	0
that	0
(	0
i	0
)	0
patients	0
with	0
CLL	0
rarely	0
express	0
ER	9
and	0
(	0
ii	0
)	0
immunocytochemical	0
staining	0
of	0
cytospin	0
preparations	0
is	0
a	0
valid	0
technique	0
for	0
the	0
measurement	0
of	0
ER	9
.	0

It	0
is	0
of	0
interest	0
that	0
one	0
of	0
the	0
positive	0
cases	0
was	0
diagnosed	0
as	0
CLL	0
with	0
Richter	0
's	0
transformation	0
confirming	0
earlier	0
findings	0
.	0

Type-II	9
estrogen	10
binding	10
sites	10
in	0
a	0
lymphoblastoid	5
cell	6
line	6
and	0
growth-inhibitory	0
effect	0
of	0
estrogen	0
,	0
anti-estrogen	0
and	0
bioflavonoids	0
.	0

Type-II	9
estrogen-binding	10
sites	10
(	0
type-II	9
EBS	10
)	0
have	0
been	0
demonstrated	0
in	0
the	0
human	5
lymphoblastoid	6
cell	6
line	6
IM-9	5
using	0
a	0
whole-cell	0
assay	0
with	0
(	0
6	0
,	0
7-3H	0
)	0
estradiol	0
(	0
3H-E2	0
)	0
as	0
tracer	0
.	0

Competition	0
analysis	0
showed	0
that	0
the	0
anti-estrogen	0
tamoxifen	0
and	0
the	0
flavonoids	0
quercetin	0
and	0
rutin	0
competed	0
for	0
(	0
3H	0
)	0
-E2	0
binding	0
to	0
type-II	9
EBS	10
.	0

Growth	0
experiments	0
demonstrated	0
that	0
diethylstilbestrol	0
(	0
DES	0
)	0
tamoxifen	0
(	0
TAM	0
)	0
,	0
quercetin	0
and	0
rutin	0
exerted	0
a	0
reversible	0
dose-dependent	0
inhibition	0
of	0
cell	0
proliferation	0
in	0
the	0
range	0
of	0
concentrations	0
between	0
10	0
nM	0
and	0
10	0
microM	0
.	0

The	0
relative	0
binding	0
affinity	0
of	0
quercetin	0
,	0
rutin	0
,	0
DES	0
and	0
TAM	0
for	0
type-II	9
EBS	10
correlated	0
well	0
with	0
their	0
potency	0
as	0
cell	0
growth	0
inhibitors	0
.	0

Moreover	0
,	0
hesperidin	0
,	0
a	0
flavonoid	0
which	0
does	0
not	0
bind	0
to	0
type-II	9
EBS	10
,	0
was	0
ineffective	0
in	0
inhibiting	0
cell	0
growth	0
.	0

Cell-cycle	0
analysis	0
showed	0
that	0
the	0
growth-inhibitory	0
effect	0
of	0
DES	0
,	0
TAM	0
or	0
quercetin	0
was	0
due	0
to	0
a	0
blocking	0
effect	0
in	0
the	0
G0-G1	0
phases	0
.	0

Our	0
results	0
suggest	0
that	0
high	0
estrogen	0
and	0
anti-estrogen	0
concentrations	0
and	0
flavonoids	0
may	0
regulate	0
IM-9	5
cell	0
growth	0
through	0
a	0
common	0
mechanism	0
involving	0
a	0
binding	0
interaction	0
with	0
type-II	9
EBS	10
.	0

[	0
Glucocorticoid	9
receptors	10
in	0
peripheral	7
blood	8
lymphocytes	8
of	0
patients	0
with	0
bronchial	0
asthma	0
]	0

Quantitation	0
of	0
glucocorticoid	9
receptors	10
(	0
GCR	9
)	0
and	0
the	0
study	0
of	0
their	0
affinity	0
for	0
glucocorticosteroids	0
(	0
GCS	0
)	0
were	0
made	0
in	0
peripheral	7
blood	8
lymphocytes	8
of	0
bronchial	0
asthma	0
(	0
BA	0
)	0
patients	0
in	0
consideration	0
of	0
GCR	9
treatment	0
and	0
serum	0
levels	0
of	0
endogenous	0
cortisol	0
.	0

It	0
is	0
stated	0
that	0
GCR	9
of	0
healthy	0
controls	0
and	0
GCS-untreated	0
patients	0
outnumbered	0
those	0
of	0
cortisol-dependent	0
BA	0
patients	0
on	0
hormone	0
therapy	0
.	0

Following	0
discontinuation	0
of	0
glucocorticoid	0
drugs	0
GCR	9
count	0
in	0
cortisol-dependent	0
BA	0
tends	0
to	0
rise	0
.	0

Endogenous	0
cortisol	0
has	0
no	0
effect	0
on	0
GCR	9
level	0
estimated	0
by	0
3H-triamcinolone	0
acetonide	0
.	0

Two	0
glucocorticoid	9
binding	10
sites	10
on	0
the	0
human	9
glucocorticoid	10
receptor	10
.	0

Glucocorticoids	0
are	0
known	0
to	0
have	0
a	0
lytic	0
effect	0
in	0
leukemic	7
cells	8
via	0
interactions	0
with	0
the	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
.	0

Cortisol	0
and	0
various	0
synthetic	0
glucocorticoids	0
bind	0
to	0
the	0
GR	9
with	0
one-site	0
kinetics	0
.	0

Cortivazol	0
(	0
CVZ	0
)	0
is	0
a	0
unique	0
,	0
high	0
potency	0
synthetic	0
glucocorticoid	0
,	0
which	0
has	0
a	0
phenylpyrazol	0
fused	0
to	0
the	0
A-ring	0
of	0
the	0
steroid	0
nucleus	0
and	0
displays	0
binding	0
consistent	0
with	0
two	0
or	0
more	0
sites	0
in	0
the	0
cytosol	0
from	0
CEM	5
C7	6
cells	6
(	0
a	0
human	5
acute	6
lymphoblastic	6
T-cell	6
line	6
)	0
.	0

It	0
has	0
previously	0
been	0
shown	0
that	0
the	0
lower	0
affinity	0
class	0
of	0
sites	0
are	0
similar	0
in	0
affinity	0
and	0
site	0
molarity	0
to	0
those	0
recognized	0
by	0
dexamethasone	0
.	0

The	0
higher	0
affinity	0
sites	0
bind	0
CVZ	0
with	0
20-	0
to	0
50-fold	0
greater	0
affinity	0
,	0
consistent	0
with	0
CVZ	0
's	0
enhanced	0
biological	0
effects	0
.	0

In	0
mutant	0
leukemic	7
cells	8
resistant	0
to	0
the	0
lytic	0
effects	0
of	0
dexamethasone	0
,	0
CVZ	0
both	0
lyses	0
the	0
cells	0
and	0
recognizes	0
a	0
single	0
class	0
of	0
sites	0
similar	0
to	0
the	0
high	0
affinity	0
site	0
in	0
CEM	5
C7	6
cells	6
.	0

We	0
have	0
carried	0
out	0
experiments	0
to	0
define	0
the	0
nature	0
of	0
the	0
higher	9
affinity	10
CVZ	10
binding	10
site	10
.	0

We	0
now	0
show	0
that	0
:	0
1	0
)	0
CVZ	0
has	0
more	0
than	0
one	0
binding	0
site	0
in	0
a	0
second	0
,	0
independent	0
,	0
B-cell	5
line	6
,	0
IM-9	5
;	0
2	0
)	0
the	0
antiglucocorticoid	0
RU	0
38486	0
is	0
able	0
to	0
block	0
both	0
CVZ	0
's	0
higher	0
and	0
lower	0
affinity	0
sites	0
;	0
3	0
)	0
all	0
of	0
CVZ	9
's	10
binding	10
sites	10
are	0
on	0
a	0
protein	0
immunologically	0
indistinguishable	0
from	0
the	0
human	0
GR	9
;	0
and	0
4	0
)	0
freshly	0
isolated	0
clones	0
of	0
CVZ-resistant	0
cells	0
have	0
lost	0
all	0
binding	0
sites	0
for	0
CVZ	0
.	0

These	0
data	0
indicate	0
that	0
CVZ	0
is	0
recognizing	0
two	0
glucocorticoid	9
binding	10
sites	10
on	0
the	0
human	0
GR	9
or	0
a	0
protein	0
very	0
similar	0
to	0
it	0
.	0

Retroviral	0
mediated	0
transfer	0
and	0
expression	0
of	0
exogenous	1
genes	2
in	0
primary	7
lymphoid	8
cells	8
:	0
assaying	0
for	0
a	0
viral	0
transactivator	9
activity	0
in	0
normal	7
and	8
malignant	8
cells	8
.	0

In	0
this	0
report	0
we	0
describe	0
the	0
use	0
of	0
recombinant	0
retroviruses	0
to	0
characterize	0
the	0
activity	0
of	0
an	0
exogenous	1
promoter	2
in	0
primary	0
cells	0
obtained	0
from	0
patients	0
with	0
lymphoproliferative	0
disorders	0
.	0

The	0
infection	0
of	0
a	0
variety	0
of	0
cultured	0
and	0
primary	7
lymphoid	8
cells	8
with	0
a	0
recombinant	0
retrovirus	0
containing	0
a	0
histone	1
promoter-driven	2
beta-galactosidase	2
gene	2
is	0
shown	0
to	0
result	0
in	0
the	0
expression	0
of	0
beta-galactosidase	9
in	0
50	0
%	0
to	0
100	0
%	0
of	0
the	0
cells	0
.	0

A	0
similar	0
infection	0
with	0
a	0
recombinant	0
retrovirus	0
containing	0
the	0
beta-galactosidase	1
gene	2
with	0
an	0
adenovirus	1
E2	2
promoter	2
,	0
results	0
in	0
beta-galactosidase	9
activity	0
in	0
a	0
limited	0
number	0
of	0
cultured	5
and	0
primary	7
cells	8
.	0

Since	0
the	0
adenovirus	1
E2	2
promoter	2
has	0
been	0
well	0
characterized	0
and	0
is	0
known	0
to	0
be	0
regulated	0
by	0
transactivators	9
encoded	0
by	0
many	0
viruses	0
,	0
the	0
activity	0
of	0
this	0
promoter	0
in	0
specific	0
cell	0
types	0
is	0
discussed	0
in	0
reference	0
to	0
both	0
the	0
biology	0
of	0
the	0
cell	0
and	0
the	0
possible	0
presence	0
of	0
as	0
yet	0
undetected	0
viral	9
gene	10
products	10
.	0

[	0
The	0
effect	0
of	0
24	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
dioxyvit	0
)	0
on	0
Ca	0
metabolism	0
and	0
immune	0
status	0
during	0
chronic	0
kidney	0
failure	0
]	0

Active	0
metabolite	0
of	0
vitamin	0
D3	0
,	0
24R	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
(	0
dioxyvit	0
)	0
was	0
used	0
at	0
a	0
daily	0
dose	0
of	0
100	0
micrograms	0
in	0
treatment	0
of	0
children	0
affected	0
with	0
tubulointerstitial	0
disease	0
of	0
kidney	0
and	0
with	0
chronic	0
glomerulonephritis	0
under	0
conditions	0
of	0
kidney	0
insufficiency	0
.	0

The	0
drug	0
exhibited	0
distinct	0
normalizing	0
effect	0
on	0
patterns	0
of	0
calcium	0
metabolism	0
:	0
increase	0
of	0
total	0
and	0
ionized	0
Ca2+	0
and	0
of	0
25-OHD	0
,	0
decrease	0
in	0
concentration	0
of	0
parath	0
hormone	0
and	0
osteocalcine	0
in	0
blood	0
serum	0
as	0
well	0
as	0
on	0
immunological	0
parameters	0
:	0
restoration	0
of	0
decreased	0
content	0
of	0
T-	7
and	8
0-lymphocytes	8
.	0

Concentration	0
of	0
receptors	0
of	0
hormonal	0
form	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
was	0
found	0
to	0
be	0
minimal	0
in	0
lymphocytes	7
under	0
conditions	0
of	0
chronic	0
kidney	0
insufficiency	0
,	0
while	0
their	0
expression	0
,	0
after	0
the	0
dioxyvit	0
action	0
,	0
was	0
detected	0
only	0
in	0
patients	0
with	0
glomerulonephritis	0
.	0

Specific	0
calcitropic	0
effect	0
of	0
dioxyvit	0
with	0
simultaneous	0
correction	0
of	0
vitamin	0
D	0
deficiency	0
were	0
apparently	0
responsible	0
for	0
high	0
efficacy	0
of	0
the	0
drug	0
in	0
treatment	0
of	0
calcium	0
metabolism	0
and	0
immunity	0
impairments	0
in	0
children	0
with	0
renal	0
deteriorations	0
at	0
the	0
step	0
of	0
chronic	0
kidney	0
insufficiency	0
.	0

[	0
The	0
role	0
of	0
glucocorticoid	9
receptors	10
and	0
HLA	9
antigens	10
in	0
the	0
pathogenesis	0
of	0
Cushing	0
's	0
syndrome	0
]	0

Lymphocytic	0
levels	0
of	0
glucocorticoid	9
receptors	10
were	0
evaluated	0
in	0
114	0
patients	0
suffering	0
from	0
Icenko-Cushing	0
's	0
syndrome	0
.	0

Incidence	0
of	0
HLA	9
antigens	10
was	0
determined	0
in	0
94	0
of	0
them	0
.	0

A	0
significant	0
rise	0
of	0
A10	9
and	0
B27	9
antigen	10
incidence	0
compared	0
to	0
that	0
in	0
normal	0
subjects	0
allows	0
these	0
antigens	0
to	0
be	0
considered	0
genetic	0
markers	0
of	0
Icenko-Cushing	0
's	0
syndrome	0
.	0

The	0
levels	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
of	0
the	0
patients	0
are	0
lower	0
than	0
in	0
normal	0
subjects	0
both	0
in	0
the	0
active	0
stage	0
of	0
the	0
disease	0
and	0
following	0
bilateral	0
total	0
adrenalectomy	0
.	0

The	0
patients	0
carrying	0
B27	9
antigen	10
had	0
lymphocytic	0
receptor	0
concentrations	0
under	0
the	0
levels	0
of	0
such	0
in	0
patients	0
free	0
of	0
the	0
antigen	0
carriage	0
.	0

Antigen	9
B27	10
seems	0
to	0
be	0
a	0
cause	0
of	0
lower	0
levels	0
of	0
glucocorticoid	9
receptors	10
in	0
blood	7
lymphocytes	8
.	0

Effects	0
of	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
on	0
the	0
human	5
chronic	6
myelogenous	6
leukemia	6
cell	6
line	6
RWLeu-4	5
.	0

The	0
effects	0
of	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
VD3	0
)	0
on	0
proliferation	0
,	0
differentiation	0
,	0
and	0
macromolecular	0
synthesis	0
in	0
the	0
new	0
Philadelphia	5
chromosome-positive	6
chronic	6
myelogenous	6
leukemia	6
cell	6
line	6
,	0
RWLeu-4	5
,	0
were	0
investigated	0
.	0

Binding	0
of	0
[	0
3H	0
]	0
VD3	0
was	0
saturable	0
,	0
with	0
approximately	0
2000-3000	0
sites/cell	0
,	0
and	0
half-maximal	0
binding	0
occurring	0
at	0
0.21-0.33	0
nM	0
.	0

Treatment	0
of	0
RWLeu-4	5
cells	6
with	0
VD3	0
induced	0
24R-hydroxylase	9
activity	0
,	0
a	0
marker	0
of	0
vitamin	0
D3	0
responsiveness	0
in	0
many	0
tissues	0
.	0

Exposure	0
of	0
RWLeu-4	5
cells	6
to	0
VD3	0
also	0
inhibited	0
proliferation	0
and	0
DNA	0
synthesis	0
with	0
a	0
50	0
%	0
effective	0
dose	0
of	0
3.5-10	0
nM	0
within	0
72	0
h	0
;	0
in	0
addition	0
,	0
protein	0
and	0
RNA	0
synthesis	0
were	0
inhibited	0
by	0
VD3	0
treatment	0
.	0

Exposure	0
of	0
RWLeu-4	5
cells	6
to	0
5	0
nM	0
VD3	0
for	0
72	0
h	0
caused	0
50	0
%	0
of	0
the	0
cells	0
to	0
differentiate	0
into	0
macrophage/monocyte	7
type	8
cells	8
as	0
judged	0
by	0
nitroblue	0
tetrazolium	0
staining	0
and	0
adherence	0
to	0
plastic	0
.	0

Progressive	0
expression	0
of	0
cell	9
surface	10
maturation-specific	10
antigens	10
of	0
the	0
monocyte/macrophage	7
lineage	8
was	0
induced	0
by	0
treatment	0
of	0
RWLeu-4	5
cells	6
with	0
VD3	0
for	0
24	0
to	0
72	0
h	0
at	0
doses	0
that	0
inhibited	0
cellular	0
proliferation	0
.	0

c-myc	3
RNA	4
,	0
which	0
is	0
constitutively	0
expressed	0
in	0
RWLeu-4	5
cells	6
,	0
increased	0
after	0
0.5	0
h	0
of	0
treatment	0
with	0
50	0
nM	0
VD3	0
and	0
then	0
rapidly	0
decreased	0
to	0
barely	0
detectable	0
levels	0
after	0
4	0
h	0
of	0
treatment	0
.	0

Finally	0
,	0
the	0
in	0
vitro	0
tyrosine	0
kinase	0
activity	0
associated	0
with	0
the	0
p210bcr-abl	9
oncogene	10
product	10
was	0
decreased	0
approximately	0
50	0
%	0
by	0
VD3	0
treatment	0
.	0

Because	0
of	0
the	0
presence	0
of	0
a	0
functional	0
receptor-effector	0
system	0
for	0
VD3	0
and	0
multiple	0
biological	0
responses	0
to	0
the	0
hormone	0
,	0
these	0
cells	0
provide	0
a	0
unique	0
model	0
system	0
with	0
which	0
to	0
probe	0
the	0
specific	0
effects	0
of	0
VD3	0
on	0
cell	0
growth	0
and	0
differentiation	0
in	0
chronic	0
myelogenous	0
leukemia	0
.	0

A	0
new	0
member	0
of	0
the	0
leucine	9
zipper	10
class	10
of	0
proteins	0
that	0
binds	0
to	0
the	0
HLA	1
DR	2
alpha	2
promoter	2
.	0

Several	0
mutants	0
derived	0
from	0
transformed	5
human	6
B	6
cell	6
lines	6
are	0
defective	0
in	0
expressing	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
class	2
II	2
genes	2
.	0

The	0
failure	0
to	0
express	0
a	0
class	1
II	2
gene	2
in	0
at	0
least	0
one	0
such	0
mutant	5
line	6
has	0
been	0
mapped	0
to	0
the	0
MHC	1
class	2
II	2
X	2
box	2
,	0
a	0
conserved	1
transcriptional	2
element	2
in	0
the	0
promoter	1
region	2
.	0

A	0
complementary	1
DNA	2
encoding	0
a	0
DNA-binding	9
protein	10
(	0
human	9
X	10
box	10
binding	10
protein	10
,	0
hXBP-1	9
)	0
whose	0
target	0
is	0
the	0
human	1
DR	2
alpha	2
X	2
box	2
and	0
the	0
3	1
'	2
flanking	2
region	2
has	0
now	0
been	0
cloned	0
.	0

This	0
complementary	1
DNA	2
encoded	0
a	0
protein	0
with	0
structural	0
similarities	0
to	0
the	0
c-jun	9
proto-oncogene	10
product	10
,	0
and	0
its	0
target	0
sequence	0
was	0
closely	0
related	0
to	0
the	0
palindromic	1
target	2
sequence	2
of	0
c-jun	1
.	0

Mutation	0
of	0
the	0
hXBP-1	1
DNA	2
target	2
sequence	2
decreased	0
DR	1
alpha	2
promoter	2
activity	0
in	0
vivo	0
.	0

These	0
studies	0
suggest	0
that	0
the	0
hXBP-1	9
protein	10
acts	0
as	0
a	0
transcription	9
factor	10
in	0
B	7
cells	8
.	0

Pseudohypoaldosteronism	0
in	0
eight	0
families	0
:	0
different	0
forms	0
of	0
inheritance	0
are	0
evidence	0
for	0
various	0
genetic	0
defects	0
.	0

Pseudohypoaldosteronism	0
is	0
a	0
rare	0
hereditary	0
disorder	0
presenting	0
in	0
early	0
infancy	0
with	0
renal	0
salt	0
loss	0
leading	0
to	0
hyponatremia	0
and	0
hyperkalemia	0
despite	0
high	0
levels	0
of	0
plasma	0
aldosterone	0
.	0

The	0
patients	0
are	0
insensitive	0
to	0
mineralocorticoids	0
;	0
however	0
,	0
sodium	0
supplementation	0
is	0
able	0
to	0
correct	0
electrolyte	0
abnormalities	0
.	0

Absent	0
or	0
greatly	0
diminished	0
type	0
I	9
aldosterone	10
receptors	10
in	0
peripheral	7
mononuclear	8
leucocytes	8
have	0
been	0
recently	0
demonstrated	0
and	0
explain	0
the	0
lack	0
of	0
response	0
to	0
mineralocorticoids	0
.	0

We	0
have	0
studied	0
the	0
mode	0
of	0
inheritance	0
in	0
eight	0
families	0
with	0
a	0
total	0
of	0
nine	0
patients	0
.	0

There	0
was	0
evidence	0
for	0
an	0
autosomal	0
recessive	0
form	0
of	0
inheritance	0
in	0
four	0
families	0
,	0
while	0
the	0
other	0
four	0
families	0
appeared	0
to	0
have	0
an	0
autosomal	0
dominant	0
mode	0
of	0
transmission	0
.	0

In	0
three	0
families	0
the	0
autosomal	0
recessive	0
form	0
was	0
characterized	0
by	0
normal	9
receptor	10
as	0
well	0
as	0
hormone	0
data	0
in	0
both	0
parents	0
,	0
while	0
in	0
one	0
family	0
receptor	0
levels	0
in	0
both	0
parents	0
were	0
greatly	0
reduced	0
,	0
but	0
hormone	0
levels	0
were	0
normal	0
.	0

In	0
the	0
four	0
families	0
with	0
an	0
autosomal	0
dominant	0
mode	0
of	0
transmission	0
there	0
was	0
always	0
one	0
parent	0
with	0
reduced	0
receptor	0
binding	0
in	0
peripheral	7
mononuclear	8
leucocytes	8
and	0
elevated	0
serum	0
hormone	0
levels	0
.	0

These	0
parents	0
were	0
entirely	0
asymptomatic	0
.	0

In	0
an	0
extended	0
family	0
we	0
were	0
able	0
to	0
study	0
an	0
aunt	0
and	0
her	0
newborn	0
daughter	0
,	0
who	0
were	0
both	0
also	0
biochemically	0
affected	0
but	0
clinically	0
asymptomatic	0
.	0

It	0
,	0
therefore	0
,	0
appears	0
that	0
this	0
dual	0
pattern	0
of	0
genetic	0
transmission	0
may	0
indicate	0
differing	0
genetic	0
defects	0
which	0
cause	0
the	0
same	0
clinical	0
picture	0
of	0
pseudohypoaldosteronism	0
.	0

Perceived	0
social	0
support	0
and	0
tumor	0
estrogen/progesterone	9
receptor	10
status	0
as	0
predictors	0
of	0
natural	7
killer	8
cell	8
activity	0
in	0
breast	0
cancer	0
patients	0
.	0

This	0
report	0
is	0
concerned	0
with	0
the	0
prediction	0
of	0
natural	0
killer	7
(	8
NK	8
)	8
cell	8
activity	0
in	0
61	0
Stage	0
I	0
and	0
II	0
breast	0
cancer	0
patients	0
,	0
between	0
the	0
ages	0
of	0
25	0
and	0
70	0
,	0
who	0
were	0
accrued	0
to	0
this	0
project	0
.	0

All	0
baseline	0
interview	0
and	0
testing	0
data	0
were	0
obtained	0
either	0
just	0
before	0
patients	0
were	0
discharged	0
from	0
the	0
hospital	0
,	0
or	0
at	0
their	0
first	0
outpatient	0
visit	0
,	0
within	0
two	0
weeks	0
of	0
discharge	0
.	0

A	0
major	0
interest	0
of	0
this	0
project	0
is	0
the	0
predictive	0
value	0
of	0
perceived	0
social	0
support	0
,	0
as	0
a	0
potential	0
``	0
stress	0
''	0
buffer	0
,	0
related	0
to	0
NK	0
activity	0
.	0

In	0
the	0
main	0
model	0
reported	0
here	0
,	0
we	0
found	0
that	0
a	0
significant	0
amount	0
of	0
NK	0
activity	0
variance	0
could	0
be	0
explained	0
by	0
five	0
variables	0
.	0

Higher	0
NK	0
activity	0
could	0
be	0
predicted	0
by	0
the	0
perception	0
of	0
high	0
quality	0
emotional	0
support	0
from	0
a	0
spouse	0
or	0
intimate	0
other	0
,	0
perceived	0
social	0
support	0
from	0
the	0
patient	0
's	0
physician	0
,	0
estrogen	9
receptor	10
-negative	0
tumor	0
status	0
,	0
having	0
an	0
excisional	0
biopsy	0
as	0
surgical	0
treatment	0
,	0
and	0
actively	0
seeking	0
social	0
support	0
as	0
a	0
major	0
coping	0
strategy	0
(	0
R2	0
=	0
0.33	0
,	0
F	0
(	0
5	0
,	0
55	0
)	0
=	0
5.5	0
,	0
p	0
less	0
than	0
0.0004	0
)	0
.	0

Findings	0
are	0
discussed	0
in	0
terms	0
of	0
host	0
interaction	0
with	0
tumor	0
endocrine	0
status	0
,	0
and	0
the	0
role	0
that	0
social	0
support	0
might	0
play	0
in	0
modulating	0
such	0
activity	0
.	0

[	0
Estrogen	9
receptor	10
content	0
of	0
peripheral	7
blood	8
lymphocytes	8
in	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
]	0

ER	0
content	0
in	0
lymphocytes	7
of	0
peripheral	0
blood	0
from	0
27	0
SLE	0
patients	0
and	0
20	0
healthy	0
controls	0
were	0
determined	0
by	0
dextran-coated	0
charcoal	0
assay	0
.	0

ER	9
content	0
in	0
lymphocytes	7
of	0
each	0
sample	0
was	0
expressed	0
by	0
both	0
fmol/mg	0
of	0
lymphocyte	9
cytosolic	10
protein	10
and	0
fmol/micrograms	0
of	0
lymphocyte	1
DNA	2
.	0

The	0
results	0
showed	0
that	0
there	0
was	0
no	0
significant	0
difference	0
between	0
the	0
ER	9
content	0
of	0
lymphocytes	7
from	0
the	0
controls	0
and	0
that	0
from	0
patients	0
with	0
SLE	0
.	0

But	0
the	0
logarithmic	0
mean	0
of	0
ER	9
content	0
in	0
lymphocytes	7
,	0
expressed	0
by	0
fmol/mg	0
of	0
cytosolic	9
protein	10
,	0
in	0
14	0
patients	0
with	0
active	0
SLE	0
(	0
0.9356	0
+/-	0
0.31	0
)	0
was	0
significantly	0
higher	0
than	0
that	0
in	0
13	0
patients	0
with	0
inactive	0
SLE	0
(	0
0.2979	0
+/-	0
0.23	0
,	0
P	0
less	0
than	0
0.001	0
)	0
and	0
in	0
the	0
controls	0
(	0
0.6204	0
+/-	0
0.52	0
,	0
P	0
less	0
than	0
0.001	0
)	0
.	0

The	0
normal	0
upper	0
limit	0
of	0
ER	9
content	0
in	0
lymphocytes	7
,	0
expressed	0
by	0
fmol/micrograms	0
of	0
DNA	0
,	0
was	0
0.136	0
.	0

The	0
elevated	0
rate	0
of	0
ER	9
content	0
in	0
lymphocytes	7
in	0
14	0
active	0
SLE	0
(	0
92.9	0
%	0
)	0
was	0
also	0
higher	0
than	0
that	0
in	0
quieiescent	0
patients	0
(	0
23.1	0
%	0
,	0
P	0
less	0
than	0
0.001	0
)	0
and	0
in	0
the	0
controls	0
(	0
10	0
%	0
,	0
P	0
less	0
than	0
0.001	0
)	0
.	0

Moreover	0
,	0
the	0
elevated	0
level	0
of	0
ER	9
content	0
was	0
found	0
to	0
be	0
related	0
to	0
the	0
positive	0
antidsDNA	9
antibody	10
and	0
hypocomplementemia	0
.	0

An	0
in	0
vitro	0
globin	1
gene	2
switching	0
model	0
based	0
on	0
differentiated	7
embryonic	8
stem	8
cells	8
.	0

We	0
used	0
mouse	7
embryonic	8
stem	8
(	8
ES	8
)	8
cells	8
to	0
study	0
globin	1
gene	2
expression	0
and	0
switching	0
in	0
vitro	0
.	0

We	0
show	0
that	0
ES-derived	7
embryoid	8
bodies	8
express	0
the	0
full	0
complement	0
of	0
mouse	1
embryonic	2
globin	2
genes	2
in	0
the	0
correct	0
temporal	0
order	0
and	0
that	0
on	0
further	0
differentiation	0
,	0
a	0
switch	0
occurs	0
to	0
the	0
fetal/adult	1
genes	2
.	0

In	0
addition	0
,	0
the	0
erythroid-specific	9
transcription	10
factor	10
NF-E1	9
was	0
shown	0
to	0
be	0
expressed	0
coordinately	0
with	0
that	0
of	0
globin	9
in	0
embryoid	7
bodies	8
.	0

We	0
conclude	0
from	0
these	0
experiments	0
that	0
the	0
ES	0
cell	0
system	0
provides	0
a	0
good	0
model	0
to	0
study	0
hematopoietic	0
development	0
.	0

When	0
the	0
human	1
epsilon-	2
or	2
beta-globin	2
genes	2
driven	0
by	0
the	0
dominant	1
control	2
region	2
(	0
DCR	1
)	0
are	0
introduced	0
into	0
this	0
system	0
,	0
the	0
human	1
epsilon-globin	2
gene	2
,	0
in	0
contrast	0
to	0
the	0
beta-globin	1
gene	2
,	0
is	0
not	0
deregulated	0
by	0
the	0
presence	0
of	0
the	0
DCR	1
and	0
is	0
expressed	0
strictly	0
as	0
an	0
embryonic	1
gene	2
.	0

We	0
conclude	0
from	0
this	0
that	0
the	0
epsilon-globin	1
gene	2
is	0
not	0
regulated	0
by	0
competition	0
with	0
other	0
genes	0
in	0
the	0
human	1
beta-globin	2
locus	2
.	0

Cloning	0
of	0
a	0
mitogen-inducible	1
gene	2
encoding	0
a	0
kappa	9
B	10
DNA-binding	10
protein	10
with	0
homology	0
to	0
the	0
rel	1
oncogene	2
and	0
to	0
cell-cycle	1
motifs	2
.	0

We	0
have	0
cloned	0
and	0
characterized	0
a	0
mitogen-inducible	1
gene	2
isolated	0
from	0
human	7
T	8
cells	8
that	0
predicts	0
a	0
protein	0
of	0
968	9
amino	10
acids	10
.	0

The	0
amino-terminal	9
domain	10
has	0
regions	0
homologous	0
to	0
the	0
oncogene	1
rel	2
and	0
to	0
the	0
developmentally	0
important	0
gene	0
dorsal	1
of	0
Drosophila	0
.	0

The	0
carboxy-terminal	9
domain	10
contains	0
repeat	0
structures	0
found	0
in	0
a	0
variety	0
of	0
proteins	0
that	0
are	0
involved	0
in	0
cell-cycle	0
control	0
of	0
yeast	0
and	0
in	0
tissue	0
differentiation	0
in	0
Drosophila	0
and	0
Ceanorhabditis	0
elegans	0
,	0
as	0
well	0
as	0
in	0
the	0
putative	1
human	2
oncogene	2
bcl-3	2
and	0
in	0
the	0
ankyrin	9
protein	10
.	0

A	0
truncated	0
form	0
of	0
the	0
product	0
of	0
this	0
gene	0
translated	0
in	0
vitro	0
is	0
a	0
DNA-binding	9
protein	10
which	0
interacts	0
specifically	0
with	0
the	0
kappa	1
B	2
binding	2
site	2
found	0
in	0
many	0
inducible	1
genes	2
,	0
including	0
the	0
enhancer	0
in	0
human	0
immunodeficiency	0
virus	0
.	0

This	0
gene	0
is	0
yet	0
another	0
in	0
a	0
growing	0
list	0
of	0
important	0
regulatory	0
molecules	0
whose	0
expression	0
is	0
transcriptionally	0
induced	0
upon	0
cellular	0
activation	0
.	0

Extrarenal	0
receptor-effector-mechanisms	0
for	0
aldosterone	0
:	0
the	0
sequence	0
of	0
effects	0
on	0
the	0
cellular	0
electrolyte	0
transport	0
in	0
human	7
lymphocytes	8
and	0
their	0
implications	0
for	0
disorders	0
of	0
the	0
water	0
and	0
electrolyte	0
balances	0
.	0

High	0
affinity	0
aldosterone	0
binding	0
sites	0
have	0
not	0
only	0
been	0
described	0
in	0
the	0
classic	0
target	0
tissues	0
such	0
as	0
the	0
renal	0
tubules	0
,	0
but	0
also	0
in	0
non-classic	0
target	0
tissues	0
such	0
as	0
the	0
hippocampus	0
,	0
mammary	0
gland	0
,	0
endothelial	7
cells	8
and	0
,	0
recently	0
,	0
human	7
mononuclear	8
leukocytes	8
.	0

An	0
in	0
vitro	0
effect	0
of	0
aldosterone	0
on	0
intracellular	0
sodium	0
,	0
potassium	0
and	0
calcium	0
concentrations	0
and	0
cell	0
volume	0
was	0
shown	0
in	0
human	7
mononuclear	8
leukocytes	8
.	0

In	0
the	0
absence	0
of	0
aldosterone	0
,	0
the	0
intracellular	0
Na+	0
,	0
K+	0
and	0
Ca2+	0
concentrations	0
and	0
the	0
cell	0
volume	0
decreased	0
significantly	0
,	0
but	0
remained	0
constant	0
when	0
aldosterone	0
(	0
1.4	0
nmol/l	0
)	0
was	0
added	0
to	0
the	0
incubation	0
medium	0
.	0

These	0
effects	0
of	0
aldosterone	0
were	0
blocked	0
by	0
the	0
aldosterone	0
antagonist	0
canrenone	0
(	0
140	0
nmol/l	0
)	0
.	0

The	0
sodium/proton	9
exchanger	10
of	0
the	0
cell	0
membrane	0
could	0
be	0
identified	0
as	0
the	0
primary	0
target	0
of	0
the	0
aldosterone	0
action	0
,	0
possibly	0
non-genomically	0
mediated	0
through	0
membrane	9
receptors	10
.	0

The	0
clinical	0
significance	0
of	0
this	0
model	0
was	0
underlined	0
by	0
the	0
demonstration	0
of	0
absent	0
or	0
a	0
decreased	0
number	0
of	0
mineralocorticoid	9
receptors	10
and	0
the	0
lack	0
of	0
electrolyte	0
response	0
to	0
aldosterone	0
in	0
human	7
mononuclear	8
leukocytes	8
of	0
patients	0
with	0
pseudohypoaldosteronism	0
and	0
aldosteronism	0
.	0

Additionally	0
,	0
an	0
abnormal	0
effector	0
mechanism	0
could	0
be	0
demonstrated	0
in	0
human	7
mononuclear	8
leukocytes	8
from	0
essential	0
hypertensives	0
.	0

These	0
studies	0
are	0
the	0
first	0
to	0
demonstrate	0
the	0
significance	0
of	0
extrarenal	9
,	10
nonepithelial	10
mineralocorticoid	10
receptors	10
and	0
the	0
related	0
effector	0
mechanism	0
in	0
different	0
disorders	0
of	0
the	0
water	0
and	0
electrolyte	0
balance	0
in	0
man	0
.	0

Immunohistochemical	0
study	0
of	0
steroid	0
hormones	0
and	0
an	0
estrogen	0
binding	0
assay	0
in	0
malignant	7
soft	8
tissue	8
tumors	8
.	0

Immunohistochemically	0
,	0
the	0
immunoreaction	0
against	0
5	0
steroid	0
hormone	0
anti-sera	0
(	0
estradiol	0
,	0
estriol	0
,	0
cortisol	0
,	0
progesterone	0
and	0
testosterone	0
)	0
was	0
examined	0
in	0
39	0
cases	0
with	0
the	0
malignant	7
soft	8
tissue	8
tumors	8
(	0
fibrosarcoma	0
:	0
8	0
,	0
malignant	0
fibrous	0
histiocytoma	0
:	0
6	0
,	0
rhabdomyosarcoma	0
:	0
10	0
,	0
leiomyosarcoma	0
:	0
10	0
,	0
liposarcoma	0
:	0
5	0
)	0
.	0

Seventeen	0
cases	0
revealed	0
distinct	0
immunostaining	0
against	0
at	0
least	0
1	0
of	0
the	0
5	0
steroid	0
hormones	0
.	0

Immunostained	7
tumor	8
cells	8
were	0
more	0
frequently	0
distributed	0
in	0
the	0
area	0
where	0
tumor	0
cell	0
infiltration	0
was	0
more	0
invasive	0
.	0

The	0
majority	0
of	0
the	0
positive	0
cases	0
occurred	0
in	0
female	0
cases	0
.	0

Furthermore	0
,	0
the	0
existence	0
of	0
estrogen	9
receptor	10
(	0
estrogen	0
binding	0
activity	0
)	0
was	0
examined	0
histochemically	0
in	0
39	0
cases	0
and	0
it	0
was	0
detected	0
in	0
8	0
.	0

We	0
concluded	0
that	0
steroid	0
hormones	0
might	0
be	0
closely	0
related	0
to	0
tumor	0
cell	0
infiltration	0
of	0
some	0
malignant	7
soft	8
tissue	8
tumors	8
.	0

Involvement	0
of	0
cyclic	9
AMP-dependent	10
protein	10
kinases	10
in	0
the	0
signal	0
transduction	0
pathway	0
for	0
interleukin-1	9
.	0

Expression	0
of	0
a	0
highly	0
specific	0
protein	0
inhibitor	0
for	0
cyclic	9
AMP-dependent	10
protein	10
kinases	10
in	0
interleukin-1	5
(	6
IL-1	6
)	6
-responsive	6
cells	6
blocked	0
IL-1-induced	1
gene	2
transcription	0
that	0
was	0
driven	0
by	0
the	0
kappa	1
immunoglobulin	2
enhancer	2
or	0
the	0
human	1
immunodeficiency	2
virus	2
long	2
terminal	2
repeat	2
.	0

This	0
inhibitor	0
did	0
not	0
affect	0
protein	9
kinase	10
C	10
-mediated	0
gene	0
transcription	0
,	0
suggesting	0
that	0
cyclic	9
AMP-dependent	10
protein	10
kinases	10
are	0
involved	0
in	0
the	0
signal	0
transduction	0
pathway	0
for	0
IL-1	9
in	0
a	0
number	0
of	0
responsive	7
cell	8
types	8
.	0

The	0
Epstein-Barr	1
virus	2
(	2
EBV	2
)	2
ORI1yt	2
enhancer	2
is	0
not	0
B-cell	0
specific	0
and	0
does	0
not	0
respond	0
synergistically	0
to	0
the	0
EBV	9
transcription	10
factors	10
R	10
and	10
Z	10
.	0

The	0
Epstein-Barr	1
virus	2
DR	2
promoter	2
is	0
located	0
upstream	0
of	0
the	0
PstI	1
repeats	2
,	0
and	0
in	0
addition	0
to	0
the	0
TATA	1
box	2
,	0
it	0
contains	0
an	0
upstream	1
region	2
(	0
positions	0
-69	0
to	0
-220	0
)	0
responsive	0
to	0
EB1	9
(	10
Z	10
)	10
(	0
the	0
BZLF1-encoded	9
transcription	10
factor	10
)	0
and	0
an	0
enhancer	1
with	0
two	0
functionally	0
distinct	0
domains	0
,	0
A	0
and	0
B	1
.	0

Domain	1
B	2
has	0
been	0
described	0
as	0
a	0
B-cell-specific	1
EB1-responsive	2
element	2
(	0
P.M.Lieberman	0
,	0
J.M.Hardwick	0
,	0
and	0
S.D.Hayward	0
,	0
J.Virol.63	0
:	0
3040-3050	0
,	0
1989	0
)	0
activated	0
synergistically	0
by	0
EB1	9
and	0
R	9
,	0
an	0
EBV	9
early	10
product	10
encoded	0
by	0
the	0
open	1
reading	2
frame	2
BRLF1	2
(	0
M.A.	0
Cox	0
,	0
J.Leahy	0
,	0
and	0
J.M.Hardwick	0
,	0
J.Virol.64	0
:	0
313-321	0
,	0
1990	0
)	0
.	0

We	0
show	0
here	0
that	0
domain	1
B	2
is	0
an	0
R-responsive	1
element	2
in	0
HeLa	5
cells	6
and	0
is	0
therefore	0
not	0
an	0
EB1-responsive	1
B-cell-specific	2
element	2
.	0

However	0
,	0
there	0
is	0
an	0
EB1-binding	1
site	2
(	0
ZRE-B	1
)	0
located	0
within	0
the	0
R-responsive	1
enhancer	2
region	2
.	0

ZRE-B	1
can	0
be	0
deleted	0
without	0
affecting	0
the	0
R-dependent	0
enhancer	0
activity	0
.	0

Moreover	0
,	0
there	0
is	0
no	0
cooperation	0
or	0
synergy	0
between	0
R	9
and	0
EB1	9
when	0
activating	0
the	0
B	1
domain	2
(	0
ZRE-B	1
plus	0
the	0
R-responsive	1
element	2
)	0
positioned	0
as	0
an	0
enhancer	1
.	0

ZRE-B	1
is	0
therefore	0
not	0
part	0
of	0
the	0
R-	1
inducible	2
enhancer	2
.	0

We	0
have	0
tested	0
several	0
subregions	0
of	0
the	0
DR	1
enhancer	2
B	1
domain	2
,	0
either	0
alone	0
or	0
in	0
combination	0
,	0
for	0
their	0
capacity	0
to	0
transmit	0
the	0
R-activating	0
signal	0
to	0
the	0
rabbit	1
beta-globin	2
promoter	2
.	0

We	0
found	0
that	0
the	0
R-responsive	1
element	2
is	0
composed	0
of	0
four	0
protoenhancers	1
that	0
span	0
the	0
whole	0
B	1
domain	2
.	0

These	0
protoenhancers	1
alone	0
are	0
weakly	0
or	0
not	0
responsive	0
to	0
R	9
.	0

One	0
of	0
the	0
protoenhancers	1
contains	0
the	0
overlapping	1
palindromes	2
5'-TTGTCCcgtGGACAAaTGTCC-3'	0
.	0

However	0
,	0
one	0
palindrome	1
,	0
either	0
alone	0
or	0
duplicated	0
,	0
or	0
the	0
overlapping	1
palindromes	2
did	0
not	0
respond	0
to	0
R	0
.	0

Nuclear	0
3	9
,	10
5	10
,	10
3'-triiodothyronine	10
receptors	10
(	0
T3R	9
)	0
of	0
circulating	7
human	8
lymphocytes	8
in	0
hyper-	0
and	0
hypothyroidism	0
and	0
nonthyroidal	0
diseases	0
.	0

The	0
clinical	0
implications	0
of	0
nuclear	0
T3R	9
alterations	0
of	0
circulating	7
lymphocytes	8
in	0
hyperthyroidism	0
,	0
hypothyroidism	0
and	0
nonthyroidal	0
diseases	0
were	0
investigated	0
.	0

Nuclear	0
T3R	9
in	0
lymphocytes	7
was	0
determined	0
by	0
radio-ligand	0
binding	0
analysis	0
.	0

The	0
results	0
showed	0
that	0
in	0
hyper-	0
and	0
hypothyroid	0
patients	0
the	0
nuclear	0
affinity	0
(	0
Ka	0
)	0
for	0
T3	0
was	0
similar	0
to	0
that	0
of	0
normal	0
subjects	0
.	0

In	0
hyperthyroidism	0
nuclear	0
T3	0
maximal	0
binding	0
capacity	0
(	0
MBC	0
)	0
was	0
unaltered	0
,	0
whereas	0
in	0
hypothyroidism	0
the	0
MBC	0
was	0
significantly	0
increased	0
.	0

In	0
the	0
patients	0
with	0
diabetes	0
mellitus	0
,	0
chronic	0
renal	0
failure	0
and	0
hepatic	0
cirrhosis	0
,	0
the	0
nuclear	9
T3R	10
MBC	0
of	0
lymphocytes	7
was	0
about	0
1.5-1.6	0
times	0
of	0
the	0
normal	0
controls	0
.	0

It	0
was	0
concluded	0
that	0
there	0
existed	0
hormonal	0
regulation	0
of	0
nuclear	9
T3R	10
,	0
and	0
up-regulation	0
was	0
seen	0
in	0
hypothyroidism	0
and	0
low	0
T3	0
syndrome	0
.	0

Lymphocyte	5
cell	6
lines	6
from	0
vitamin	0
D-dependent	0
rickets	0
type	0
II	0
show	0
functional	0
defects	0
in	0
the	0
1	9
alpha	10
,	10
25-dihydroxyvitamin	10
D3	10
receptor	10
.	0

Lymphocyte	5
cell	6
lines	6
were	0
established	0
from	0
five	0
patients	0
with	0
vitamin	0
D-dependent	0
rickets	0
,	0
type	0
II	0
(	0
VDDR-II	0
)	0
.	0

These	0
lines	0
were	0
established	0
by	0
infection	0
with	0
human	0
T-lymphotrophic	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
.	0

Binding	0
of	0
[	0
3H	0
]	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
)	0
to	0
its	0
receptor	0
in	0
these	0
cell	0
lines	0
was	0
compared	0
to	0
binding	0
studies	0
using	0
a	0
T-lymphocyte	5
cell	6
line	6
(	0
S-LB1	5
)	0
from	0
a	0
normal	0
individual	0
.	0

The	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
receptor	0
of	0
S-LB1	5
was	0
comparable	0
to	0
the	0
well-characterized	0
chick	9
intestinal	10
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
in	0
terms	0
of	0
its	0
ligand	0
binding	0
affinity	0
and	0
capacity	0
,	0
its	0
mobility	0
on	0
5-20	0
%	0
sucrose	0
gradients	0
,	0
and	0
its	0
adsorption	0
to	0
and	0
elution	0
properties	0
from	0
DNA-cellulose	0
.	0

Three	0
cell	5
lines	6
established	0
from	0
patients	0
with	0
VDDR-II	0
(	0
Rh-	0
VDR	9
,	0
Sh-	0
VDR	9
,	0
and	0
Ab-	0
VDR	9
)	0
showed	0
no	0
specific	0
binding	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
to	0
a	0
receptor	9
and	0
treatment	0
of	0
the	0
cultured	5
cells	6
with	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
did	0
not	0
stimulate	0
production	0
of	0
24	0
,	0
25-dihydroxy-vitamin	0
D3	0
(	0
24	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
)	0
,	0
a	0
response	0
which	0
is	0
diagnostic	0
of	0
the	0
presence	0
of	0
a	0
functional	9
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
.	0

In	0
a	0
fourth	0
cell	5
line	6
,	0
A1-VDR	5
,	0
the	0
receptor	0
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
had	0
a	0
low	0
binding	0
capacity	0
and	0
25	9
(	10
OH	10
)	10
D3-24-hydroxylase	10
activity	0
was	0
not	0
detectable	0
.	0

Induction	0
of	0
24	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
synthesis	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
was	0
observed	0
in	0
the	0
fifth	0
cell	5
line	6
,	0
designated	0
Ro-VDR	5
,	0
although	0
the	0
sensitivity	0
to	0
hormone	0
treatment	0
was	0
lower	0
than	0
in	0
the	0
control	5
cell	6
line	6
from	0
a	0
normal	0
donor	0
.	0

The	0
capacity	0
of	0
the	0
receptor	9
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
was	0
low	0
in	0
Ro-VDR	5
.	0

In	0
all	0
cell	5
lines	6
where	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
binding	0
to	0
a	0
receptor	9
was	0
detectable	0
,	0
the	0
receptor	9
had	0
the	0
typical	0
sedimentation	0
coefficient	0
of	0
3.7	0
S	0
on	0
sucrose	0
density	0
gradient	0
analysis	0
.	0

Binding	0
and	0
elution	0
properties	0
to	0
DNA-cellulose	0
,	0
however	0
,	0
differed	0
from	0
normal	0
in	0
both	0
Ro-VDR	5
and	0
A1-VDR	5
cells	6
where	0
elution	0
from	0
DNA-cellulose	0
occurred	0
at	0
a	0
lower	0
salt	0
concentration	0
than	0
is	0
typical	0
of	0
the	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
.	0

While	0
Ro-VDR	5
cells	6
showed	0
typical	0
nuclear	0
localization	0
of	0
the	0
unoccupied	9
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
,	0
neither	0
the	0
unoccupied	0
nor	0
the	0
occupied	0
receptor	9
from	0
A1-VDR	5
cells	6
was	0
completely	0
localized	0
in	0
the	0
nucleus	0
.	0

In	0
a	0
series	0
of	0
functional	0
studies	0
we	0
found	0
that	0
modulation	0
of	0
the	0
level	0
of	0
the	0
mRNAs	3
coding	0
for	0
both	0
the	0
c-myc	1
oncogene	2
and	0
the	0
growth	0
factor	0
known	0
as	0
granulocyte-monocyte	0
colony	0
stimulating	0
activity	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
correlated	0
with	0
the	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptor	10
status	0
of	0
these	0
cells	0
.	0

Use	0
of	0
these	0
cell	5
lines	6
will	0
facilitate	0
further	0
study	0
of	0
the	0
molecular	0
defect	0
(	0
s	0
)	0
in	0
the	0
receptor	9
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
in	0
vitamin	0
D-dependent	0
rickets	0
type	0
II	0
and	0
will	0
allow	0
a	0
correlation	0
with	0
impairment	0
of	0
cellular	0
functions	0
.	0

Transcriptional	0
and	0
post-transcriptional	0
regulation	0
of	0
c-jun	1
expression	0
during	0
monocytic	0
differentiation	0
of	0
human	5
myeloid	6
leukemic	6
cells	6
.	0

AP-1	9
,	0
the	0
polypeptide	0
product	0
of	0
c-jun	1
,	0
recognizes	0
and	0
binds	0
to	0
specific	0
DNA	0
sequences	0
and	0
stimulates	0
transcription	0
of	0
genes	1
responsive	0
to	0
certain	0
growth	0
factors	0
and	0
phorbol	0
esters	0
such	0
as	0
12-O-tetradecanoylphorbol-13-acetate	0
(	0
TPA	0
)	0
.	0

We	0
studied	0
the	0
effects	0
of	0
TPA	0
on	0
the	0
regulation	0
of	0
c-jun	1
gene	0
expression	0
in	0
HL-60	5
cells	6
during	0
monocytic	0
differentiation	0
.	0

Low	0
levels	0
of	0
c-jun	3
transcripts	4
were	0
detectable	0
in	0
untreated	5
HL-60	6
leukemic	6
cells	6
,	0
increased	0
significantly	0
by	0
6	0
h	0
,	0
and	0
reached	0
near	0
maximal	0
levels	0
by	0
24	0
h	0
of	0
exposure	0
to	0
32	0
nM	0
TPA	0
.	0

Similar	0
kinetics	0
of	0
c-jun	1
induction	0
by	0
TPA	0
were	0
observed	0
in	0
human	5
U-937	6
and	0
THP-1	5
monocytic	6
leukemia	6
cells	6
.	0

Similar	0
findings	0
were	0
obtained	0
with	0
bryostatin	0
1	0
(	0
10	0
nM	0
)	0
,	0
another	0
activator	0
of	0
protein	9
kinase	10
C	10
and	0
inducer	0
of	0
monocytic	0
differentiation	0
.	0

Furthermore	0
,	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
0.5	0
microM	0
)	0
,	0
a	0
structurally	0
distinct	0
agent	0
which	0
also	0
induces	0
HL-60	0
monocytic	0
differentiation	0
,	0
increased	0
c-jun	1
expression	0
.	0

TPA	0
treatment	0
of	0
HL-60	5
cells	6
in	0
the	0
presence	0
of	0
cycloheximide	0
was	0
associated	0
with	0
superinduction	0
of	0
c-jun	1
transcripts	0
.	0

Run-on	0
analysis	0
demonstrated	0
detectable	0
levels	0
of	0
c-jun	1
gene	0
transcription	0
in	0
untreated	5
HL-60	6
cells	6
,	0
and	0
that	0
exposure	0
to	0
TPA	0
increases	0
this	0
rate	0
3.3-fold	0
.	0

Treatment	0
of	0
HL-60	5
cells	6
with	0
both	0
TPA	0
and	0
cycloheximide	0
had	0
no	0
effect	0
on	0
the	0
rates	0
of	0
c-jun	1
transcription	0
.	0

The	0
half-life	0
of	0
c-jun	3
RNA	4
as	0
determined	0
by	0
treating	0
HL-60	5
cells	6
with	0
TPA	0
and	0
actinomycin	0
D	0
was	0
30	0
min	0
.	0

In	0
contrast	0
,	0
the	0
half-life	0
of	0
c-jun	3
RNA	4
in	0
TPA-treated	5
HL-60	6
cells	6
exposed	0
to	0
cycloheximide	0
and	0
actinomycin	0
D	0
was	0
greater	0
than	0
2	0
h	0
.	0

These	0
findings	0
suggested	0
that	0
the	0
increase	0
in	0
c-jun	3
RNA	4
observed	0
during	0
TPA-induced	0
monocytic	0
differentiation	0
is	0
mediated	0
by	0
both	0
transcriptional	0
and	0
post-transcriptional	0
mechanisms	0
.	0

[	0
Hormonal	0
interactions	0
and	0
glucocorticoid	9
receptors	10
in	0
patients	0
with	0
the	0
nephrotic	0
syndrome	0
]	0

As	0
many	0
as	0
27	0
children	0
aged	0
6	0
to	0
15	0
years	0
with	0
morphologically	0
verified	0
nephropathies	0
were	0
examined	0
.	0

Four	0
variants	0
of	0
changes	0
in	0
the	0
thyroid	0
status	0
,	0
characteristic	0
of	0
children	0
with	0
different	0
variants	0
of	0
nephrotic	0
syndrome	0
were	0
distinguished	0
:	0
1	0
)	0
biochemical	0
signs	0
of	0
primary	0
hypothyroidism	0
,	0
2	0
)	0
biochemical	0
signs	0
of	0
secondary	0
hypothyroidism	0
,	0
3	0
)	0
low	0
content	0
of	0
T3	0
,	0
4	0
)	0
dysfunction	0
of	0
the	0
hypophyseal	0
and	0
thyroid	0
system	0
.	0

It	0
is	0
shown	0
that	0
the	0
low	0
level	0
of	0
steroid	9
receptors	10
,	0
thyroid	0
hormones	0
that	0
the	0
low	0
level	0
of	0
steroid	9
receptors	10
,	0
thyroid	0
hormones	0
(	0
T3	0
and	0
T4	0
)	0
and	0
cortisol	0
is	0
typical	0
of	0
children	0
with	0
the	0
signs	0
of	0
renal	0
dysplasia	0
.	0

It	0
is	0
assumed	0
that	0
superaddition	0
under	0
such	0
conditions	0
of	0
immune	0
glomerulopathy	0
(	0
glomerulonephritis	0
and	0
nephrotic	0
syndrome	0
)	0
gives	0
rise	0
to	0
the	0
resistance	0
to	0
the	0
treatment	0
with	0
glucocorticoids	0
.	0

Lymphoid	0
specific	0
gene	0
expression	0
of	0
the	0
adenovirus	1
early	2
region	2
3	2
promoter	2
is	0
mediated	0
by	0
NF-kappa	1
B	2
binding	2
motifs	2
.	0

A	0
primary	0
site	0
of	0
infection	0
by	0
human	0
adenoviruses	0
is	0
lymphoid	7
cells	8
.	0

However	0
,	0
analysis	0
of	0
the	0
viral	1
control	2
elements	2
and	0
the	0
cellular	9
factors	10
that	0
regulate	0
adenoviral	0
gene	0
expression	0
in	0
lymphocytes	7
has	0
not	0
been	0
reported	0
.	0

The	0
adenovirus	9
early	10
region	10
3	10
(	10
ES	10
)	10
gene	10
products	10
are	0
involved	0
in	0
the	0
maintenance	0
of	0
viral	0
persistence	0
by	0
complexing	0
with	0
the	0
class	9
I	10
MHC	10
antigens	10
,	0
thus	0
preventing	0
their	0
cell	0
surface	0
expression	0
with	0
a	0
resultant	0
decrease	0
in	0
host	0
immunologic	0
destruction	0
.	0

To	0
determine	0
whether	0
different	0
cellular	9
factors	10
were	0
involved	0
in	0
E3	0
regulation	0
in	0
lymphocytes	7
as	0
compared	0
with	0
HeLa	5
cells	6
,	0
both	0
DNA	0
binding	0
and	0
transfection	0
analysis	0
with	0
the	0
E3	1
promoter	2
in	0
both	0
cell	0
types	0
were	0
performed	0
.	0

These	0
studies	0
detected	0
two	0
novel	1
domains	2
referred	0
to	0
as	0
L1	1
and	0
L2	1
with	0
a	0
variety	0
of	0
lymphoid	0
but	0
not	0
HeLa	0
extracts	0
.	0

Each	0
of	0
these	0
domains	0
possessed	0
strong	0
homology	0
to	0
motifs	0
previously	0
found	0
to	0
bind	0
the	0
cellular	9
factor	10
NF-kappa	10
B	10
.	0

Transfections	0
of	0
E3	1
constructs	2
linked	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
gene	2
revealed	0
that	0
mutagenesis	0
of	0
the	0
distal	1
NF-kappa	2
B	2
motif	2
(	0
L2	1
)	0
had	0
minimal	0
effects	0
on	0
promoter	0
expression	0
in	0
HeLa	5
cells	6
,	0
but	0
resulted	0
in	0
dramatic	0
decreases	0
in	0
expression	0
by	0
lymphoid	7
cells	8
.	0

In	0
contrast	0
,	0
mutagenesis	0
of	0
proximal	1
NF-kappa	2
B	2
motif	2
(	0
L1	1
)	0
had	0
minimal	0
effects	0
on	0
gene	0
expression	0
in	0
both	0
HeLa	5
cells	6
and	0
lymphoid	7
cells	8
but	0
resulted	0
in	0
a	0
small	0
,	0
but	0
reproducible	0
,	0
increase	0
in	0
gene	0
expression	0
in	0
lymphoid	7
cells	8
when	0
coupled	0
to	0
the	0
L2	1
mutation	0
.	0

Reversing	0
the	0
position	0
and	0
subsequent	0
mutagenesis	0
of	0
the	0
L1	1
and	0
L2	1
domains	2
indicated	0
that	0
the	0
primary	1
sequence	2
of	0
these	0
motifs	0
rather	0
than	0
their	0
position	0
in	0
the	0
E3	1
promoter	2
was	0
critical	0
for	0
regulating	0
gene	0
expression	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Characterization	0
of	0
defensin	9
resistance	0
phenotypes	0
associated	0
with	0
mutations	0
in	0
the	0
phoP	1
virulence	2
regulon	2
of	0
Salmonella	0
typhimurium	0
.	0

The	0
defensin	9
sensitivities	0
of	0
Salmonella	0
typhimurium	0
strains	0
with	0
mutations	0
in	0
the	0
phoP/phoQ	1
two-component	2
virulence	2
regulon	2
were	0
tested	0
by	0
using	0
purified	9
defensins	10
NP-1	9
and	0
NP-2	9
.	0

Strains	0
with	0
mutations	0
in	0
either	0
gene	0
of	0
the	0
regulatory	1
pair	2
(	0
phoP	1
[	0
transcriptional	1
activator	2
]	0
or	0
phoQ	1
[	0
membrane	9
sensor	10
kinase	10
]	0
)	0
had	0
increased	0
sensitivities	0
to	0
defensin	9
.	0

The	0
predicted	0
periplasmic	9
domain	10
of	0
the	0
PhoQ	9
protein	10
contained	0
a	0
markedly	0
anionic	0
domain	0
that	0
could	0
interact	0
with	0
cationic	9
proteins	10
and	0
that	0
could	0
be	0
responsible	0
for	0
resistance	0
to	0
defensin	9
.	0

Because	0
insertion	0
mutations	0
in	0
phoP	1
are	0
polar	0
on	0
phoQ	1
,	0
we	0
constructed	0
strains	0
that	0
expressed	0
the	0
PhoQ	9
protein	10
in	0
the	0
absence	0
of	0
PhoP	9
to	0
test	0
whether	0
resistance	0
to	0
defensin	0
requires	0
only	0
the	0
phoQ	9
gene	10
product	10
.	0

We	0
found	0
that	0
resistance	0
to	0
defensin	0
requires	0
the	0
function	0
of	0
both	0
components	0
of	0
this	0
regulatory	0
system	0
,	0
because	0
strains	0
expressing	0
PhoQ	9
without	0
PhoP	9
were	0
still	0
markedly	0
sensitive	0
to	0
defensins	9
.	0

This	0
implied	0
that	0
a	0
pag	9
(	10
phoP-activated	10
gene	10
)	10
product	10
is	0
responsible	0
for	0
defensin	9
resistance	0
.	0

We	0
also	0
tested	0
for	0
the	0
ability	0
of	0
defensins	9
NP-1	9
,	0
NP-5	9
,	0
and	0
HNP-1	9
to	0
activate	0
pag	1
expression	0
and	0
found	0
that	0
these	0
peptides	0
have	0
no	0
effect	0
.	0

Defensin	0
resistance	0
is	0
not	0
the	0
only	0
virulence	0
characteristic	0
controlled	0
by	0
the	0
PhoP-PhoQ	9
regulon	10
because	0
mutations	0
in	0
pagC	1
,	0
as	0
well	0
as	0
ones	0
in	0
the	0
phoP	1
locus	2
that	0
resulted	0
in	0
constitutive	0
pag	1
activation	0
(	0
phenotype	0
PhoPc	9
)	0
,	0
had	0
no	0
effect	0
on	0
defensin	9
resistance	0
,	0
even	0
though	0
they	0
rendered	0
the	0
organism	0
avirulent	0
and	0
deficient	0
in	0
survival	0
within	0
macrophages	7
.	0

The	0
virulence	0
defect	0
conferred	0
by	0
mutations	0
in	0
the	0
phoP	1
-phoQ	1
two-component	0
regulatory	0
system	0
is	0
not	0
completely	0
explained	0
by	0
alterations	0
in	0
resistance	0
to	0
cationic	9
proteins	10
and	0
involves	0
the	0
control	0
of	0
other	0
proteins	0
necessary	0
for	0
S.	0
typhimurium	0
survival	0
within	0
macrophages	7
.	0

Stimulation	0
of	0
a	0
human	5
T-cell	6
clone	6
with	0
anti-CD3	9
or	0
tumor	9
necrosis	10
factor	10
induces	0
NF-kappa	9
B	10
translocation	0
but	0
not	0
human	0
immunodeficiency	0
virus	0
1	0
enhancer-dependent	0
transcription	0
.	0

The	0
expression	0
of	0
transiently	0
transfected	0
expression	0
vectors	0
under	0
the	0
control	0
of	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
or	0
its	0
enhancer	1
sequence	2
and	0
the	0
translocation	0
of	0
the	0
HIV	9
enhancer-binding	10
protein	10
NF-kappa	9
B	10
were	0
analyzed	0
in	0
two	0
human	0
T-cell	5
clones	6
stimulated	0
through	0
their	0
T-cell	9
receptor	10
complex	10
or	0
by	0
tumor	9
necrosis	10
factor	10
or	0
phorbol	0
12-myristate	0
13-acetate	0
.	0

We	0
found	0
a	0
dissociation	0
of	0
NF-kappa	9
B	10
translocation	0
from	0
transactivation	0
of	0
either	0
the	0
HIV	1
LTR	2
or	0
the	0
HIV	1
enhancer	2
.	0

Interleukin	9
2	10
induced	0
proliferation	0
but	0
not	0
NF-kappa	9
B	10
translocation	0
or	0
LTR	1
transactivation	0
.	0

Phorbol	0
ester	0
or	0
specific	0
antigen	0
recognition	0
induced	0
HIV	1
LTR	2
transactivation	0
,	0
whereas	0
stimulation	0
with	0
tumor	9
necrosis	10
factor	10
or	0
antibody	0
to	0
CD3	9
did	0
not	0
.	0

The	0
two	0
latter	0
signals	0
were	0
nevertheless	0
able	0
to	0
induce	0
NF-kappa	9
B	10
translocation	0
with	0
a	0
pattern	0
in	0
the	0
band-shift	0
assay	0
indistinguishable	0
from	0
that	0
observed	0
using	0
phorbol	0
ester	0
.	0

Our	0
finding	0
that	0
induction	0
of	0
NF-kappa	9
B	10
by	0
tumor	9
necrosis	10
factor	10
or	0
antibody	9
to	10
CD3	10
is	0
not	0
sufficient	0
to	0
induce	0
HIV	1
enhancer	2
-dependent	0
transcription	0
in	0
cloned	5
T	6
cells	6
contrasts	0
with	0
results	0
obtained	0
in	0
most	0
lymphoblastoid	5
T-cell	6
lines	6
and	0
indicates	0
that	0
normal	0
T	7
lymphocytes	8
differ	0
from	0
tumoral	7
T	8
cells	8
in	0
terms	0
of	0
requirements	0
for	0
HIV	1
LTR	2
activation	0
.	0

Furthermore	0
,	0
our	0
results	0
suggest	0
that	0
events	0
linked	0
to	0
T-cell	0
activation	0
,	0
in	0
addition	0
to	0
NF-kappa	9
B	10
translocation	0
per	0
se	0
,	0
induce	0
functional	0
interactions	0
of	0
the	0
NF-kappa	9
B	10
complex	10
with	0
the	0
HIV	1
enhancer	2
.	0

Decreased	0
concentration	0
of	0
1	9
,	10
25-dihydroxyvitamin	10
D3	10
receptors	10
in	0
peripheral	7
mononuclear	8
cells	8
of	0
patients	0
with	0
X-linked	0
hypophosphatemic	0
rickets	0
:	0
effect	0
of	0
phosphate	0
supplementation	0
.	0

Abnormal	0
renal	0
tubular	0
phosphate	0
transport	0
is	0
considered	0
to	0
be	0
the	0
primary	0
defect	0
in	0
X-linked	0
hypophosphatemic	0
rickets	0
(	0
XLH	0
)	0
.	0

However	0
,	0
the	0
resistance	0
to	0
vitamin	0
D	0
treatment	0
in	0
XLH	0
can	0
not	0
be	0
explained	0
by	0
hypophosphatemia	0
alone	0
.	0

Since	0
most	0
of	0
the	0
actions	0
of	0
vitamin	0
D	0
are	0
mediated	0
by	0
its	0
receptors	0
(	0
VDR	9
)	0
,	0
abnormalities	0
of	0
VDR	9
have	0
been	0
postulated	0
in	0
XLH	0
.	0

In	0
order	0
to	0
investigate	0
this	0
possibility	0
,	0
we	0
measured	0
the	0
concentration	0
of	0
VDR	9
in	0
PHA-activated	5
peripheral	6
mononuclear	6
cells	6
from	0
10	0
XLH	0
patients	0
.	0

Patients	0
without	0
phosphate	0
supplementation	0
showed	0
significantly	0
lower	0
concentration	0
(	0
21.7	0
+/-	0
5.1	0
fmol/mg	0
protein	0
,	0
mean	0
+/-	0
SEM	0
)	0
compared	0
to	0
the	0
normal	0
controls	0
(	0
60.7	0
+/-	0
4.0	0
)	0
.	0

On	0
the	0
contrary	0
,	0
there	0
was	0
no	0
significant	0
difference	0
between	0
the	0
phosphate-supplemented	0
patients	0
(	0
58.3	0
+/-	0
2.7	0
)	0
and	0
controls	0
.	0

There	0
was	0
a	0
significant	0
positive	0
correlation	0
between	0
VDR	9
concentration	0
and	0
serum	0
phosphate	0
(	0
P	0
less	0
than	0
0.05	0
)	0
.	0

In	0
two	0
patients	0
,	0
VDR	9
was	0
increased	0
after	0
daily	0
phosphate	0
supplementation	0
was	0
started	0
.	0

These	0
results	0
indicate	0
that	0
a	0
decreased	0
concentration	0
of	0
VDR	9
secondary	0
to	0
persistent	0
hypophosphatemia	0
is	0
one	0
of	0
the	0
causes	0
of	0
vitamin	0
D	0
resistance	0
in	0
XLH	0
.	0

Two	0
distinct	0
forms	0
of	0
active	9
transcription	10
factor	10
CREB	10
(	0
cAMP	9
response	10
element	10
binding	10
protein	10
)	0
.	0

Mammalian	7
cells	8
express	0
two	0
distinct	0
forms	0
of	0
transcription	9
factor	10
CREB	10
(	0
cAMP	9
response	10
element	10
binding	10
protein	10
)	0
that	0
are	0
apparently	0
the	0
products	0
of	0
alternative	0
splicing	0
of	0
the	0
CREB	3
gene	4
transcript	4
.	0

The	0
two	0
proteins	0
differ	0
by	0
a	0
14-amino	9
acid	10
serine-rich	10
insertion	10
present	0
in	0
one	0
of	0
the	0
CREB	9
isoforms	10
.	0

We	0
show	0
that	0
both	0
CREB	9
isoforms	10
are	0
expressed	0
in	0
many	7
cell	8
types	8
and	0
mammalian	0
species	0
.	0

Both	0
encode	0
proteins	0
that	0
bind	0
specifically	0
to	0
a	0
cAMP	1
response	2
element	2
in	2
vitro	2
.	0

As	0
expected	0
for	0
proteins	0
of	0
this	0
class	0
,	0
the	0
CREB	9
proteins	10
bind	0
DNA	0
as	0
dimers	0
.	0

Both	0
proteins	0
impart	0
cAMP-regulated	0
transcriptional	0
activity	0
to	0
a	0
heterologous	1
DNA-binding	2
domain	2
,	0
showing	0
that	0
cAMP	0
directly	0
modulates	0
the	0
transcriptional	0
stimulatory	0
activity	0
of	0
CREB	9
.	0

The	0
presence	0
of	0
multiple	0
CREB	9
isoforms	10
with	0
identical	0
DNA-binding	0
specificities	0
but	0
differences	0
in	0
the	0
presumed	0
regulatory	9
domain	10
raises	0
the	0
possibility	0
that	0
CREB	9
proteins	10
may	0
be	0
able	0
to	0
integrate	0
distinct	0
regulatory	0
signals	0
at	0
the	0
level	0
of	0
gene	0
transcription	0
.	0

Human	0
immunodeficiency	0
virus	0
vpr	0
product	0
is	0
a	0
virion-associated	9
regulatory	10
protein	10
.	0

The	0
vpr	9
product	10
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
acts	0
in	0
trans	0
to	0
accelerate	0
virus	0
replication	0
and	0
cytopathic	0
effect	0
in	0
T	7
cells	8
.	0

Here	0
it	0
is	0
shown	0
that	0
the	0
HIV-1	0
viral	0
particle	0
contains	0
multiple	0
copies	0
of	0
the	0
vpr	9
protein	10
.	0

The	0
vpr	9
product	10
is	0
the	0
first	0
regulatory	0
protein	0
of	0
HIV-1	0
to	0
be	0
found	0
in	0
the	0
virus	0
particle	0
.	0

This	0
observation	0
raises	0
the	0
possibility	0
that	0
vpr	1
acts	0
to	0
facilitate	0
the	0
early	0
steps	0
of	0
infection	0
before	0
de	0
novo	0
viral	0
protein	0
synthesis	0
occurs	0
.	0

A	0
novel	0
B-cell	9
lineage-specific	10
transcription	10
factor	10
present	0
at	0
early	0
but	0
not	0
late	0
stages	0
of	0
differentiation	0
.	0

A	0
novel	0
B-cell-specific	9
transcription	10
factor	10
,	0
BSAP	9
,	0
was	0
identified	0
as	0
a	0
mammalian	9
homolog	10
of	0
the	0
sea	9
urchin	10
protein	10
TSAP	9
,	0
which	0
interacts	0
with	0
the	0
promoters	1
of	0
four	0
tissue-specific	1
late	2
histone	2
H2A-2	2
and	2
H2B-2	2
genes	2
.	0

As	0
shown	0
by	0
mobility-shift	0
,	0
methylation	0
interference	0
,	0
and	0
mutational	0
analyses	0
,	0
the	0
mammalian	9
protein	10
BSAP	9
recognizes	0
all	0
four	0
sea	1
urchin	2
binding	2
sites	2
in	0
a	0
manner	0
indistinguishable	0
from	0
TSAP	9
;	0
however	0
,	0
the	0
two	0
proteins	0
differ	0
in	0
molecular	0
weight	0
.	0

BSAP	9
is	0
exclusively	0
restricted	0
to	0
the	0
B-cell	0
lineage	0
of	0
lymphoid	0
differentiation	0
.	0

Its	0
expression	0
appears	0
to	0
be	0
activated	0
during	0
pro-B-cell	0
development	0
,	0
is	0
abundant	0
at	0
the	0
pre-B-	0
and	0
mature	0
B-cell	0
stages	0
,	0
but	0
is	0
absent	0
in	0
terminally	7
differentiated	8
plasma	8
cells	8
.	0

Moreover	0
,	0
BSAP	9
is	0
clearly	0
a	0
B-cell-specific	9
transcription	10
factor	10
,	0
as	0
a	0
wild-type	1
but	0
not	0
a	0
mutant	1
TSAP-binding	2
site	2
of	0
the	0
sea	0
urchin	0
functions	0
only	0
in	0
transfected	5
B	6
cells	6
as	0
an	0
upstream	1
promoter	2
element	2
.	0

Competition	0
experiments	0
did	0
not	0
reveal	0
any	0
high-affinity	1
binding	2
site	2
for	0
BSAP	9
in	0
known	0
regulatory	1
regions	2
of	0
immunoglobulin	1
and	2
class	2
II	2
major	2
histocompatibility	2
(	2
MHC	2
)	2
genes	2
,	0
suggesting	0
that	0
BSAP	9
is	0
a	0
regulator	0
of	0
a	0
different	0
set	0
of	0
B-lymphoid-specific	1
genes	2
.	0

Octamer	9
transcription	10
factors	10
and	0
the	0
cell	1
type-specificity	2
of	2
immunoglobulin	2
gene	2
expression	0
.	0

Antibodies	9
are	0
produced	0
exclusively	0
in	0
B	7
lymphocytes	8
.	0

The	0
expression	0
of	0
the	0
antibody-encoding	1
genes	2
,	0
the	0
immunoglobulin	1
(	2
Ig	2
)	2
genes	2
,	0
is	0
also	0
restricted	0
to	0
B	7
cells	8
.	0

The	0
octamer	1
sequence	2
ATGCAAAT	0
is	0
present	0
in	0
the	0
promoter	1
and	0
the	0
enhancer	1
of	0
Ig	1
genes	2
,	0
and	0
plays	0
an	0
important	0
role	0
in	0
its	0
tissue-specific	0
expression	0
.	0

This	0
sequence	1
motif	2
is	0
a	0
binding	0
site	0
for	0
nuclear	9
proteins	10
,	0
the	0
so-called	0
octamer	9
transcription	10
factors	10
(	0
Oct	9
or	0
OTF	9
factors	10
)	0
.	0

The	0
Oct-1	9
protein	10
is	0
present	0
in	0
all	0
cell	0
types	0
analyzed	0
so	0
far	0
,	0
whereas	0
Oct-2A	9
and	0
Oct-2B	9
are	0
found	0
mainly	0
in	0
B	7
lymphocytes	8
.	0

All	0
three	0
proteins	0
show	0
the	0
same	0
sequence	0
specificity	0
and	0
binding	0
affinity	0
.	0

It	0
appears	0
that	0
the	0
B	0
cell-specific	0
expression	0
of	0
Ig	1
genes	2
is	0
mediated	0
at	0
least	0
in	0
part	0
by	0
cell	0
type-specific	9
Oct	10
factors	10
,	0
and	0
that	0
there	0
are	0
both	0
quantitative	0
and	0
qualitative	0
differences	0
between	0
Oct-1	9
and	0
Oct-2	9
factors	10
.	0

Recently	0
,	0
a	0
number	0
of	0
other	0
octamer	9
factor	10
variants	10
were	0
identified	0
.	0

Many	0
of	0
these	0
may	0
be	0
created	0
by	0
alternative	0
splicing	0
of	0
a	0
primary	3
transcript	4
of	0
one	0
Oct	0
factor	0
gene	0
and	0
may	0
serve	0
a	0
specific	0
function	0
in	0
the	0
fine	0
tuning	0
of	0
gene	0
expression	0
.	0

A	0
factor	0
known	0
to	0
bind	0
to	0
endogenous	1
Ig	2
heavy	2
chain	2
enhancer	2
only	0
in	0
lymphocytes	7
is	0
a	0
ubiquitously	9
active	10
transcription	10
factor	10
.	0

The	0
transcriptional	1
enhancer	2
located	0
in	0
the	0
first	0
intron	0
of	0
the	0
immunoglobulin	1
heavy	2
chain	2
constant	2
region	2
is	0
a	0
major	0
determinant	0
of	0
B-cell-specific	0
expression	0
of	0
immunoglobulin	1
genes	2
.	0

Like	0
other	0
enhancers	1
,	0
the	0
Ig	1
heavy	2
chain	2
enhancer	2
contains	0
several	0
short	0
sequence	1
motifs	2
that	0
bind	0
specific	9
transcription	10
factors	10
.	0

Each	0
binding	1
site	2
contributes	0
to	0
the	0
overall	0
activity	0
of	0
the	0
enhancer	1
,	0
however	0
no	0
single	0
element	0
seems	0
absolutely	0
required	0
for	0
activity	0
.	0

For	0
a	0
better	0
understanding	0
of	0
the	0
Ig	1
heavy	2
chain	2
enhancer	2
components	2
,	0
we	0
have	0
cloned	0
and	0
analyzed	0
individual	0
sequence	1
elements	2
.	0

We	0
find	0
that	0
the	0
factor	0
that	0
binds	0
to	0
the	0
E3	1
enhancer	2
motif	2
,	0
CATGTGGC	0
,	0
is	0
a	0
ubiquitous	9
transcription	10
factor	10
.	0

It	0
is	0
present	0
in	0
an	0
active	0
form	0
in	0
both	0
B	7
cells	8
and	0
non-B	7
cells	8
,	0
where	0
it	0
can	0
mediate	0
transcriptional	0
activation	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

However	0
,	0
despite	0
its	0
ability	0
to	0
activate	0
transcription	0
of	0
a	0
transfected	1
reporter	2
gene	2
,	0
the	0
factor	0
is	0
apparently	0
unable	0
to	0
bind	0
to	0
the	0
endogenous	1
Ig	2
heavy	2
chain	2
enhancer	2
in	0
non-lymphoid	7
cells	8
:	0
In	0
previous	0
experiments	0
by	0
others	0
,	0
the	0
characteristic	0
in	0
vivo	0
footprint	0
of	0
this	0
factor	0
,	0
designated	0
NF-muE3	9
,	0
was	0
detected	0
in	0
B	7
cells	8
but	0
not	0
in	0
non-B	7
cells	8
.	0

From	0
this	0
and	0
other	0
findings	0
the	0
picture	0
emerges	0
that	0
there	0
are	0
at	0
least	0
three	0
categories	0
of	0
factors	0
which	0
mediate	0
cell-type-specific	0
transcription	0
in	0
B	7
lymphocytes	8
:	0
(	0
a	0
)	0
cell-specific	9
factors	10
such	0
as	0
Oct-2A	9
and	0
Oct-2B	9
that	0
are	0
not	0
expressed	0
in	0
most	0
other	0
cell	0
types	0
:	0
(	0
b	0
)	0
ubiquitous	9
factors	10
such	0
as	0
NF-kappa	9
B	10
that	0
are	0
constitutively	0
active	0
in	0
B	7
cells	8
but	0
are	0
sequestered	0
in	0
an	0
inactive	0
form	0
in	0
other	0
cells	0
;	0
(	0
c	0
)	0
ubiquitously	9
active	10
factors	10
,	0
exemplified	0
by	0
the	0
one	0
binding	0
to	0
the	0
E3	1
sequence	2
motif	2
.	0

This	0
factor	0
is	0
present	0
in	0
an	0
active	0
form	0
in	0
a	0
variety	0
of	0
cell	0
types	0
but	0
is	0
apparently	0
unable	0
to	0
bind	0
to	0
the	0
endogenous	1
Ig	2
heavy	2
chain	2
enhancer	2
in	0
non-B	7
cells	8
,	0
perhaps	0
due	0
to	0
a	0
non-permissive	0
chromatin	1
structure	0
of	0
the	0
Ig	1
heavy	2
chain	2
locus	2
.	0

[	0
Endocrine	0
status	0
changes	0
in	0
children	0
with	0
bronchial	0
asthma	0
]	0

A	0
study	0
was	0
made	0
of	0
adrenocortical	0
function	0
by	0
measuring	0
blood	0
plasma	0
cortisol	0
concentration	0
and	0
amount	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
as	0
well	0
as	0
thyroid	0
function	0
by	0
measuring	0
blood	0
plasma	0
triidothyronine	0
and	0
thyroxine	0
concentration	0
in	0
58	0
bronchial	0
asthma	0
children	0
aged	0
1	0
to	0
14	0
years	0
.	0

The	0
authors	0
revealed	0
alterations	0
in	0
the	0
functional	0
activity	0
of	0
the	0
indicated	0
endocrine	0
glands	0
depending	0
on	0
the	0
intensity	0
of	0
bronchial	0
patency	0
disorders	0
and	0
the	0
nature	0
of	0
the	0
therapeutic	0
measures	0
carried	0
out	0
.	0

TAR	1
independent	0
activation	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
in	0
phorbol	0
ester	0
stimulated	0
T	7
lymphocytes	8
.	0

Multiple	1
regulatory	2
elements	2
in	0
the	0
human	1
immunodeficiency	2
virus	2
long	2
terminal	2
repeat	2
(	0
HIV	1
LTR	2
)	0
are	0
required	0
for	0
activation	0
of	0
HIV	0
gene	0
expression	0
.	0

Previous	0
transfection	0
studies	0
of	0
HIV	1
LTR	2
constructs	2
linked	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
gene	2
indicated	0
that	0
multiple	0
regulatory	1
regions	2
including	0
the	0
enhancer	1
,	0
SP1	1
,	0
TATA	1
and	0
TAR	1
regions	2
were	0
important	0
for	0
HIV	0
gene	0
expression	0
.	0

To	0
characterize	0
these	0
regulatory	1
elements	2
further	0
,	0
mutations	0
in	0
these	0
regions	0
were	0
inserted	0
into	0
both	0
the	0
5	0
'	0
and	0
3	0
'	0
HIV	1
LTRs	2
and	0
infectious	0
proviral	0
constructs	0
were	0
assembled	0
.	0

These	0
constructs	0
were	0
transfected	0
into	0
either	0
HeLa	5
cells	6
,	0
Jurkat	5
cells	6
or	0
U937	5
cells	6
in	0
both	0
the	0
presence	0
and	0
absence	0
of	0
phorbol	0
esters	0
which	0
have	0
previously	0
been	0
demonstrated	0
to	0
activate	0
HIV	0
gene	0
expression	0
.	0

Viral	0
gene	0
expression	0
was	0
assayed	0
by	0
the	0
level	0
of	0
p24	9
gag	10
protein	10
released	0
from	0
cultures	0
transfected	0
with	0
the	0
proviral	0
constructs	0
.	0

Results	0
in	0
all	0
cell	0
lines	0
indicated	0
that	0
mutations	0
of	0
the	0
SP1	1
,	0
TATA	1
and	0
the	0
TAR	0
loop	0
and	0
stem	0
secondary	0
structure	0
resulted	0
in	0
marked	0
decreases	0
in	0
gene	0
expression	0
while	0
mutations	0
of	0
the	0
enhancer	1
motif	2
or	0
TAR	1
primary	2
sequence	2
resulted	0
in	0
only	0
slight	0
decreases	0
.	0

However	0
,	0
viruses	0
containing	0
mutations	0
in	0
either	0
the	0
TAR	1
loop	2
sequences	2
or	0
stem	0
secondary	0
structure	0
which	0
were	0
very	0
defective	0
for	0
gene	0
expression	0
in	0
untreated	0
Jurkat	5
cells	6
,	0
gave	0
nearly	0
wild-type	0
levels	0
of	0
gene	0
expression	0
in	0
phorbol	5
ester-treated	6
Jurkat	6
cells	6
but	0
not	0
in	0
phorbol	5
ester-treated	6
HeLa	6
or	0
U937	5
cells	6
.	0

High	0
level	0
gene	0
expression	0
of	0
these	0
TAR	1
mutant	2
constructs	2
in	0
phorbol	5
ester-treated	6
Jurkat	6
cells	6
was	0
eliminated	0
by	0
second	0
site	0
mutations	0
in	0
the	0
enhancer	1
region	2
or	0
by	0
disruption	0
of	0
the	0
tat	1
gene	2
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

A	0
case	0
of	0
hypersensitivity	0
to	0
thyroid	0
hormones	0
with	0
normally	0
functioning	0
thyroid	0
gland	0
and	0
increased	0
nuclear	0
triiodothyronine	9
receptors	10
.	0

A	0
52-year-old	0
male	0
presented	0
himself	0
with	0
tachycardia	0
crises	0
which	0
appeared	0
first	0
during	0
childhood	0
,	0
increased	0
in	0
frequency	0
without	0
goiter	0
or	0
exophthalmos	0
.	0

Cardiac	0
and	0
adrenergic	0
diseases	0
were	0
excluded	0
.	0

The	0
thyroid	0
function	0
was	0
normal	0
regarding	0
T4	0
,	0
free	0
T4	0
and	0
T3	0
,	0
TBG	0
,	0
radioiodine	0
uptake	0
,	0
TSH	0
and	0
T3	0
suppressibility	0
;	0
however	0
the	0
TSH	0
response	0
to	0
TRH	0
was	0
decreased	0
.	0

The	0
lymphocyte	9
nuclear	10
T3	10
receptor	10
was	0
found	0
with	0
an	0
affinity	0
close	0
to	0
that	0
of	0
normal	0
volunteers	0
(	0
Ka	0
:	0
1.42	0
x	0
10	0
(	0
10	0
)	0
M-1	0
vs	0
1.95	0
+/-	0
0.35	0
x	0
10	0
(	0
10	0
)	0
M-1	0
)	0
and	0
a	0
binding	0
capacity	0
markedly	0
increased	0
(	0
9.9	0
vs	0
3.7	0
+/-	0
0.4	0
fmol	0
T3/100	0
micrograms	0
DNA	0
)	0
.	0

Pindolol	0
was	0
inefficient	0
on	0
the	0
dysrhythmia	0
which	0
disappeared	0
with	0
carbimazole	0
and	0
relapsed	0
after	0
withdrawal	0
of	0
the	0
antithyroid	0
drug	0
.	0

Under	0
carbimazole	0
,	0
the	0
plasma	0
T4	0
markedly	0
decreased	0
(	0
27.7	0
+/-	0
3.6	0
nmol/l	0
)	0
but	0
the	0
patient	0
remained	0
euthyroid	0
.	0

The	0
clinical	0
course	0
and	0
the	0
laboratory	0
data	0
suggest	0
that	0
the	0
tachycardia	0
crises	0
are	0
the	0
consequence	0
of	0
a	0
hypersensitivity	0
of	0
the	0
heart	0
to	0
thyroid	0
hormones	0
,	0
associated	0
with	0
an	0
increased	0
number	0
of	0
T3	9
nuclear	10
receptor	10
sites	0
in	0
lymphocytes	7
.	0

Induction	0
of	0
immediate	1
early	2
response	2
genes	2
by	0
macrophage	9
colony-stimulating	10
factor	10
in	0
normal	7
human	8
monocytes	8
.	0

A	0
group	0
of	0
coordinately	0
induced	0
protooncogenes	1
,	0
cytoskeletal	1
,	2
and	2
extracellular	2
matrix	2
genes	2
have	0
been	0
termed	0
immediate	1
early	2
response	2
genes	2
,	0
and	0
their	0
induction	0
has	0
been	0
associated	0
with	0
growth	9
factor	10
-stimulated	0
cell	0
proliferation	0
.	0

We	0
have	0
investigated	0
the	0
induction	0
of	0
these	0
genes	0
by	0
macrophage-CSF	9
(	0
M-CSF	9
)	0
in	0
human	7
monocytes	8
that	0
do	0
not	0
proliferate	0
in	0
response	0
to	0
M-CSF	9
but	0
require	0
the	0
factor	0
for	0
optimal	0
cell	0
differentiation	0
.	0

Normal	0
human	7
monocytes	8
were	0
isolated	0
,	0
carefully	0
washed	0
,	0
and	0
incubated	0
for	0
36	0
to	0
48	0
h	0
in	0
fetal	0
bovine	0
serum-containing	0
medium	0
.	0

At	0
the	0
end	0
of	0
this	0
incubation	0
the	0
resting	7
cells	8
were	0
stimulated	0
with	0
M-CSF	9
,	0
and	0
RNA	0
was	0
isolated	0
for	0
analysis	0
by	0
Northern	0
blotting	0
.	0

RNA	0
from	0
control	0
resting	7
cells	8
contained	0
low	0
to	0
undetectable	0
levels	0
of	0
c-jun	3
,	0
fibronectin	3
receptor	4
,	0
and	0
actin	3
mRNA	4
.	0

Within	0
15	0
to	0
30	0
min	0
of	0
addition	0
of	0
M-CSF	9
,	0
however	0
,	0
there	0
was	0
a	0
dramatic	0
coordinate	0
induction	0
of	0
these	0
genes	0
.	0

The	0
c-jun	1
gene	2
expression	0
was	0
very	0
transient	0
and	0
was	0
not	0
detectable	0
by	0
60	0
min	0
after	0
M-CSF	9
addition	0
.	0

In	0
contrast	0
,	0
the	0
expression	0
of	0
actin	3
and	4
fibronectin	4
receptor	4
mRNA	4
was	0
more	0
sustained	0
,	0
and	0
the	0
expression	0
of	0
these	0
genes	0
remained	0
elevated	0
at	0
24	0
to	0
48	0
h	0
after	0
M-CSF	9
addition	0
.	0

We	0
also	0
observed	0
the	0
induction	0
of	0
the	0
myelomonocytic	1
specific	2
tyrosine	2
kinase	2
hck	2
gene	2
simultaneously	0
with	0
the	0
other	0
immediate	1
early	2
response	2
genes	2
.	0

The	0
protein	0
synthesis	0
inhibitor	0
cycloheximide	0
did	0
not	0
block	0
the	0
induction	0
of	0
any	0
of	0
these	0
genes	0
,	0
and	0
in	0
fact	0
,	0
super-induced	0
the	0
expression	0
of	0
c-jun	1
and	0
hck	1
.	0

Nuclear	0
run	0
on	0
transcription	0
of	0
the	0
c-jun	1
,	0
hck	1
,	0
and	0
actin	1
genes	2
.	0

Therefore	0
,	0
in	0
normal	7
human	8
monocytes	8
M-CSF	9
induces	0
immediate	1
early	2
response	2
genes	2
without	0
inducing	0
cell	0
proliferation	0
.	0

These	0
genes	0
may	0
then	0
play	0
a	0
role	0
in	0
altering	0
the	0
physiologic	0
status	0
of	0
the	0
cells	0
in	0
response	0
to	0
CSF	9
.	0

Inducible	0
nuclear	9
factor	10
binding	0
to	0
the	0
kappa	1
B	2
elements	2
of	0
the	0
human	1
immunodeficiency	2
virus	2
enhancer	2
in	0
T	7
cells	8
can	0
be	0
blocked	0
by	0
cyclosporin	0
A	0
in	0
a	0
signal-dependent	0
manner	0
.	0

Cyclosporin	0
A	0
(	0
CsA	0
)	0
is	0
thought	0
to	0
exert	0
its	0
immunosuppressive	0
effects	0
by	0
inhibiting	0
the	0
expression	0
of	0
a	0
distinct	0
set	0
of	0
lymphokine	1
genes	2
which	0
are	0
induced	0
upon	0
T-cell	0
activation	0
,	0
among	0
them	0
the	0
gene	0
coding	0
for	0
interleukin-2	9
.	0

In	0
addition	0
,	0
the	0
activation	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
is	0
partially	0
suppressed	0
.	0

To	0
better	0
understand	0
the	0
molecular	0
mechanisms	0
underlying	0
suppression	0
by	0
CsA	0
,	0
we	0
have	0
investigated	0
the	0
effects	0
of	0
this	0
drug	0
on	0
transcription	9
factors	10
in	0
T	7
cells	8
.	0

Here	0
we	0
report	0
that	0
the	0
formation	0
of	0
two	0
distinct	0
mitogen-inducible	9
DNA-binding	10
complexes	10
,	0
the	0
kappa	9
B	10
complex	10
within	0
the	0
HIV	1
enhancer	2
and	0
the	0
NFAT-1	9
complex	10
within	0
the	0
interleukin-2	1
enhancer	2
,	0
is	0
inhibited	0
in	0
the	0
presence	0
of	0
CsA	0
.	0

The	0
kappa	0
B-binding	0
activity	0
with	0
the	0
HIV	1
enhancer	2
is	0
inhibited	0
only	0
if	0
it	0
is	0
activated	0
via	0
the	0
mitogen	9
phytohemagglutinin	9
whereas	0
phorbol	0
myristate	0
acetate-mediated	0
activation	0
is	0
completely	0
insensitive	0
to	0
the	0
drug	0
.	0

This	0
suggests	0
a	0
model	0
in	0
which	0
functionally	0
indistinguishable	0
kappa	9
B	10
complexes	10
can	0
be	0
activated	0
via	0
two	0
separate	0
pathways	0
of	0
signal	0
transduction	0
distinguishable	0
by	0
CsA	0
.	0

Purification	0
of	0
TCF-1	9
alpha	10
,	0
a	0
T-cell-specific	9
transcription	10
factor	10
that	0
activates	0
the	0
T-cell	1
receptor	2
C	2
alpha	2
gene	2
enhancer	2
in	0
a	0
context-dependent	0
manner	0
.	0

The	0
differentiation	0
of	0
T	7
cells	8
into	0
functionally	0
diverse	0
subpopulations	0
is	0
controlled	0
in	0
part	0
,	0
by	0
transcriptional	0
activation	0
and	0
silencing	0
;	0
however	0
,	0
little	0
is	0
known	0
in	0
detail	0
about	0
the	0
proteins	0
that	0
influence	0
this	0
developmental	0
process	0
.	0

We	0
have	0
purified	0
a	0
new	0
T-cell-specific	9
factor	10
,	0
TCF-1	9
alpha	10
,	0
that	0
is	0
implicated	0
in	0
the	0
activation	0
of	0
genes	0
encoding	0
a	0
major	0
component	0
of	0
the	0
human	9
T-cell	10
receptor	10
(	0
TCR	9
)	0
.	0

TCF-1	9
alpha	10
,	0
originally	0
identified	0
and	0
purified	0
through	0
its	0
binding	0
sites	0
on	0
the	0
HIV-1	1
promoter	2
,	0
was	0
found	0
to	0
bind	0
to	0
the	0
TCR	1
alpha	2
enhancer	2
and	0
to	0
promoters	1
for	0
several	0
genes	1
expressed	0
at	0
significantly	0
earlier	0
stages	0
of	0
T-cell	0
development	0
than	0
the	0
TCR	1
alpha	2
gene	2
(	0
e.g.	0
,	0
p56lck	1
and	0
CD3	1
delta	2
)	0
.	0

Sequences	0
related	0
to	0
the	0
TCF-1	1
alpha	2
binding	2
motif	2
(	0
5'-GGCACCCTTTGA-3	0
'	0
)	0
are	0
also	0
found	0
in	0
the	0
human	1
TCR	2
delta	2
(	0
and	0
possibly	0
TCR	1
beta	2
)	0
enhancers	1
.	0

Southwestern	0
and	0
gel	0
renaturation	0
experiments	0
with	0
the	0
use	0
of	0
purified	0
protein	0
fractions	0
revealed	0
that	0
TCF-1	9
alpha	10
activity	0
is	0
derived	0
from	0
a	0
family	0
of	0
57-	9
to	10
53-kD	10
proteins	10
that	0
are	0
abundantly	0
expressed	0
in	0
mature	5
and	6
immature	6
T-cell	6
lines	6
(	0
Jurkat	5
,	0
CCRF-CEM	5
)	0
and	0
not	0
in	0
mature	5
B	6
cells	6
(	0
JY	5
,	0
Namalwa	5
)	0
or	0
nonlymphoid	5
(	6
HeLa	6
)	6
cell	6
lines	6
.	0

A	0
small	0
95-bp	0
fragment	0
of	0
the	0
TCR	1
alpha	2
control	2
region	2
that	0
contains	0
the	0
TCF-1	1
alpha	2
binding	2
site	2
juxtaposed	0
between	0
a	0
cAMP-response	1
element	2
(	0
the	0
CRE	1
or	0
T	1
alpha	2
1	2
motif	2
)	0
and	0
the	0
binding	1
site	2
for	0
a	0
distinct	0
lymphoid-specific	9
protein	10
(	0
TCF-2	9
alpha	10
)	0
behaved	0
as	0
a	0
potent	0
T-cell-specific	1
enhancer	2
in	0
vivo	0
.	0

Tandem	0
copies	0
of	0
this	0
enhancer	0
functioned	0
synergistically	0
in	0
mature	5
(	6
Jurkat	6
)	6
T-cell	6
lines	6
as	0
well	0
as	0
resting	0
and	0
activated	0
immature	5
(	6
CCRF-CEM	6
)	6
T-cell	6
lines	6
.	0

Mutation	0
of	0
the	0
TCF-1	1
alpha	2
binding	2
site	2
diminished	0
enhancer	0
activity	0
and	0
disrupted	0
the	0
synergism	0
observed	0
in	0
vivo	0
between	0
tandem	1
enhancer	2
repeats	2
.	0

The	0
TCF-1	1
alpha	2
binding	2
site	2
was	0
also	0
required	0
for	0
TCR	9
alpha	0
enhancer	0
activity	0
in	0
transcriptionally	0
active	0
extracts	0
from	0
Jurkat	5
but	0
not	0
HeLa	5
cells	6
,	0
confirming	0
that	0
TCF-1	9
alpha	10
is	0
a	0
T-cell-specific	9
transcription	10
factor	10
.	0

Curiously	0
,	0
the	0
TCF-1	9
alpha	10
binding	0
element	0
was	0
inactive	0
in	0
vivo	0
when	0
removed	0
from	0
its	0
neighboring	0
elements	0
on	0
the	0
TCR	1
alpha	2
enhancer	2
and	0
positioned	0
in	0
one	0
or	0
more	0
copies	0
upstream	0
of	0
a	0
heterologous	1
promoter	2
.	0

Thus	0
,	0
the	0
transcriptional	0
activity	0
of	0
TCF-1	9
alpha	10
appears	0
to	0
depend	0
on	0
the	0
TCF-2	9
alpha	10
and	0
T	9
alpha	10
1	10
(	0
CREB	9
)	0
transcription	9
factors	10
and	0
the	0
context	0
of	0
its	0
binding	0
site	0
within	0
the	0
TCR	1
alpha	2
enhancer	2
.	0

Tandem	1
AP-1-binding	2
sites	2
within	0
the	0
human	1
beta-globin	2
dominant	2
control	2
region	2
function	0
as	0
an	0
inducible	1
enhancer	2
in	0
erythroid	7
cells	8
.	0

A	0
powerful	0
enhancer	0
has	0
been	0
mapped	0
to	0
an	0
18-bp	1
DNA	2
segment	2
located	0
11	0
kb	0
5	0
'	0
to	0
the	0
human	1
epsilon-globin	2
gene	2
within	0
the	0
dominant	1
control	2
or	0
locus-activating	1
region	2
.	0

This	0
enhancer	1
is	0
inducible	0
in	0
K562	5
human	6
erythroleukemia	6
cells	6
,	0
increasing	0
linked	0
gamma-globin	1
promoter	2
/luciferase	9
gene	0
expression	0
to	0
170-fold	0
over	0
an	0
enhancerless	1
construct	2
.	0

The	0
enhancer	1
consists	0
of	0
tandem	1
AP-1-binding	2
sites	2
,	0
phased	0
10	0
bp	0
apart	0
,	0
which	0
are	0
both	0
required	0
for	0
full	0
activity	0
.	0

DNA-protein	0
binding	0
assays	0
with	0
nuclear	0
extracts	0
from	0
induced	0
cells	0
demonstrate	0
a	0
high	9
molecular	10
weight	10
complex	10
on	0
the	0
enhancer	1
.	0

The	0
formation	0
of	0
this	0
complex	0
also	0
requires	0
both	0
AP-1	1
sites	2
and	0
correlates	0
with	0
maximal	0
enhancer	1
activity	0
.	0

Induction	0
of	0
the	0
enhancer	1
may	0
have	0
a	0
role	0
in	0
the	0
increase	0
in	0
globin	1
gene	2
transcription	0
that	0
characterizes	0
erythroid	0
maturation	0
.	0

Enhancer	0
activity	0
appears	0
to	0
be	0
mediated	0
by	0
the	0
binding	0
of	0
a	0
complex	0
of	0
proteins	0
from	0
the	0
jun	1
and	2
fos	2
families	2
to	0
tandem	1
AP-1	2
consensus	2
sequences	2
.	0

Identification	0
of	0
a	0
novel	9
factor	10
that	0
interacts	0
with	0
an	0
immunoglobulin	1
heavy-chain	2
promoter	2
and	0
stimulates	0
transcription	0
in	0
conjunction	0
with	0
the	0
lymphoid	9
cell-specific	10
factor	10
OTF2	9
.	0

The	0
tissue-specific	0
expression	0
of	0
the	0
MOPC	1
141	2
immunoglobulin	2
heavy-chain	2
gene	2
was	0
studied	0
by	0
using	0
in	0
vitro	0
transcription	0
.	0

B-cell-specific	0
transcription	0
of	0
this	0
gene	0
was	0
dependent	0
on	0
the	0
octamer	1
element	2
5'-ATGCAAAG-3	0
'	0
,	0
located	0
in	0
the	0
upstream	1
region	2
of	0
this	0
promoter	1
and	0
in	0
the	0
promoters	1
of	0
all	0
other	0
immunoglobulin	1
heavy-	2
and	2
light-chain	2
genes	2
.	0

The	0
interaction	0
of	0
purified	0
octamer	9
transcription	10
factors	10
1	0
and	0
2	0
(	0
OTF1	9
and	0
OTF2	9
)	0
with	0
the	0
MOPC	1
141	2
promoter	2
was	0
studied	0
by	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
and	0
DNase	9
I	10
footprinting	0
.	0

Purified	0
OTF1	9
from	0
HeLa	5
cells	6
and	0
OTF1	9
and	0
OTF2	9
from	0
B	7
cells	8
bound	0
to	0
identical	0
sequences	0
within	0
the	0
heavy-chain	1
promoter	2
.	0

The	0
OTF	0
interactions	0
we	0
observed	0
extended	0
over	0
the	0
heptamer	1
element	2
5'-CTCAGGA-3	0
'	0
,	0
and	0
it	0
seems	0
likely	0
that	0
the	0
binding	0
of	0
the	0
purified	9
factors	10
involves	0
cooperation	0
between	0
octamer	1
and	2
heptamer	2
sites	2
in	0
this	0
promoter	1
.	0

In	0
addition	0
to	0
these	0
elements	0
,	0
we	0
identified	0
a	0
second	0
regulatory	1
element	2
,	0
the	0
N	1
element	2
with	0
the	0
sequence	0
5'-GGAACCTCCCCC-3'	0
.	0

The	0
N	1
element	2
could	0
independently	0
mediate	0
low	0
levels	0
of	0
transcription	0
in	0
both	0
B-cell	0
and	0
HeLa-cell	0
extracts	0
,	0
and	0
,	0
in	0
conjunction	0
with	0
the	0
octamer	1
element	2
,	0
it	0
can	0
promote	0
high	0
levels	0
of	0
transcription	0
in	0
B-cell	0
extracts	0
.	0

The	0
N	1
element	2
bound	0
a	0
transcription	9
factor	10
,	0
NTF	9
,	0
that	0
is	0
ubiquitous	0
in	0
cell-type	0
distribution	0
,	0
and	0
NTF	9
was	0
distinct	0
from	0
any	0
of	0
the	0
previously	9
described	10
proteins	10
that	0
bind	0
to	0
similar	0
sequences	0
.	0

Based	0
on	0
these	0
results	0
,	0
we	0
propose	0
that	0
NTF	9
and	0
OTF2	9
interactions	0
(	0
both	0
with	0
their	0
cognate	1
DNA	2
elements	2
and	0
possibly	0
at	0
the	0
protein-protein	0
level	0
)	0
may	0
be	0
critical	0
to	0
B-cell-specific	0
expression	0
and	0
that	0
these	0
interactions	0
provide	0
additional	0
pathways	0
for	0
regulating	0
gene	0
expression	0
.	0

NF-kappa	9
B	10
as	0
inducible	0
transcriptional	9
activator	10
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
gene	2
.	0

The	0
expression	0
of	0
the	0
gene	0
encoding	0
the	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
is	0
induced	0
upon	0
activation	0
of	0
T	7
cells	8
with	0
phytohemagglutinin	9
and	0
active	0
phorbolester	0
and	0
upon	0
expression	0
of	0
tax1	9
,	0
a	0
transactivating	9
protein	10
of	0
the	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
.	0

The	0
same	0
agents	0
induce	0
transcription	0
from	0
the	0
interleukin-2	1
receptor	2
alpha-chain	2
and	2
interleukin-2	2
genes	2
,	0
depending	0
on	0
promoter	1
elements	2
that	0
bind	0
the	0
inducible	9
transcription	10
factor	10
NF-kappa	9
B	10
(	0
or	0
an	0
NF-kappa	9
B-like	10
factor	10
)	0
.	0

We	0
therefore	0
tested	0
the	0
possibility	0
that	0
the	0
GM-CSF	1
gene	2
is	0
also	0
regulated	0
by	0
a	0
cognate	0
motif	0
for	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
.	0

A	0
recent	0
functional	0
analysis	0
by	0
Miyatake	0
et	0
al.	0
(	0
S.	0
Miyatake	0
,	0
M.	0
Seiki	0
,	0
M.	0
Yoshida	0
,	0
and	0
K.	0
Arai	0
,	0
Mol.	0
Cell.	0
Biol.	0
8	0
:	0
5581-5587	0
,	0
1988	0
)	0
described	0
a	0
short	1
promoter	2
region	2
in	0
the	0
GM-CSF	1
gene	2
that	0
conferred	0
strong	0
inducibility	0
by	0
T-cell-activating	0
signals	0
and	0
tax1	9
,	0
but	0
no	0
NF-kappa	1
B-binding	2
motifs	2
were	0
identified	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
we	0
showed	0
binding	0
of	0
purified	0
human	9
NF-kappa	10
B	10
and	0
of	0
the	0
NF-kappa	9
B	10
activated	0
in	0
Jurkat	5
T	6
cells	6
to	0
an	0
oligonucleotide	0
comprising	0
the	0
GM-CSF	1
promoter	2
element	2
responsible	0
for	0
mediating	0
responsiveness	0
to	0
T-cell-activating	0
signals	0
and	0
tax1	9
.	0

As	0
shown	0
by	0
a	0
methylation	0
interference	0
analysis	0
and	0
oligonucleotide	0
competition	0
experiments	0
,	0
purified	0
NF-kappa	9
B	10
binds	0
at	0
positions	1
-82	2
to	2
-91	2
(	0
GGGAACTACC	0
)	0
of	0
the	0
GM-CSF	1
promoter	2
sequence	0
with	0
an	0
affinity	0
similar	0
to	0
that	0
with	0
which	0
it	0
binds	0
to	0
the	0
biologically	1
functional	2
kappa	2
B	2
motif	2
in	0
the	0
beta	1
interferon	2
promoter	2
(	0
GGGAAATTCC	0
)	0
.	0

Two	0
kappa	1
B-like	2
motifs	2
at	0
positions	1
-98	2
to	2
-108	2
of	0
the	0
GM-CSF	1
promoter	2
were	0
also	0
recognized	0
but	0
with	0
much	0
lower	0
affinities	0
.	0

Our	0
data	0
provide	0
strong	0
evidence	0
that	0
the	0
expression	0
of	0
the	0
GM-CSF	1
gene	2
following	0
T-cell	0
activation	0
is	0
controlled	0
by	0
binding	0
of	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
to	0
a	0
high-affinity	1
binding	2
site	2
in	0
the	0
GM-CSF	1
promoter	2
.	0

Effects	0
of	0
mitogenic	0
agents	0
upon	0
glucocorticoid	0
action	0
in	0
human	7
tonsillar	8
T-lymphocytes	8
.	0

The	0
treatment	0
of	0
human	7
tonsillar	8
T-lymphocytes	8
with	0
4-phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
,	0
resulted	0
in	0
about	0
two	0
fold	0
increase	0
in	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
number	0
,	0
without	0
any	0
significant	0
change	0
in	0
the	0
receptor	0
affinity	0
.	0

This	0
increase	0
disappeared	0
in	0
the	0
presence	0
of	0
cycloheximide	0
.	0

Alone	0
,	0
PMA	0
and	0
calcium	0
ionophore	0
A23187	0
did	0
not	0
affect	0
,	0
but	0
together	0
stimulated	0
,	0
like	0
phytohaemagglutinin	9
(	0
PHA	9
)	0
,	0
leucine	0
and	0
,	0
in	0
particular	0
,	0
thymidine	0
incorporation	0
.	0

PMA	0
enhanced	0
slightly	0
the	0
stimulatory	0
effect	0
of	0
PHA	9
.	0

Alone	0
,	0
these	0
agents	0
failed	0
to	0
alter	0
the	0
suppressive	0
effect	0
of	0
dexamethasone	0
on	0
thymidine	0
and	0
leucine	0
incorporation	0
;	0
however	0
,	0
PMA-A23187	0
and	0
PMA	0
-PHA	9
combinations	0
appeared	0
to	0
antagonize	0
the	0
suppression	0
by	0
dexamethasone	0
.	0

To	0
be	0
or	0
not	0
to	0
be	0
a	0
responder	0
in	0
T-cell	0
responses	0
:	0
ubiquitous	0
oligopeptides	0
in	0
all	0
proteins	0
.	0

Amino	0
acid	0
sequences	0
of	0
all	0
proteins	0
are	0
essays	0
written	0
in	0
the	0
same	0
language	0
.	0

Accordingly	0
,	0
the	0
same	0
set	0
of	0
words	0
and	0
phrases	0
(	0
oligopeptides	0
)	0
appear	0
in	0
totally	0
unrelated	0
proteins	0
.	0

The	0
reason	0
that	0
only	0
certain	0
individuals	0
of	0
particular	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
haplotypes	10
can	0
mount	0
T-cell	0
responses	0
against	0
a	0
given	0
antigen	0
of	0
pathogens	0
is	0
found	0
in	0
the	0
fact	0
that	0
T-cell	9
receptors	10
are	0
designed	0
to	0
recognize	0
18-20	0
residue-long	0
peptide	0
fragments	0
sandwiched	0
between	0
two	0
alpha-helices	9
of	0
class	9
I	10
or	0
class	0
II	0
MHC	0
molecules	0
.	0

At	0
this	0
range	0
of	0
peptide	0
lengths	0
,	0
most	0
would	0
appear	0
as	0
self	0
,	0
while	0
nonselfness	0
of	0
the	0
remainders	0
are	0
destined	0
to	0
be	0
quite	0
ambiguous	0
,	0
hence	0
creating	0
responders	0
and	0
nonresponders	0
.	0

Two	0
distinct	0
signal	0
transmission	0
pathways	0
in	0
T	7
lymphocytes	8
are	0
inhibited	0
by	0
complexes	0
formed	0
between	0
an	0
immunophilin	9
and	0
either	0
FK506	0
or	0
rapamycin	0
.	0

Proliferation	0
and	0
immunologic	0
function	0
of	0
T	7
lymphocytes	8
are	0
initiated	0
by	0
signals	0
from	0
the	0
antigen	9
receptor	10
that	0
are	0
inhibited	0
by	0
the	0
immunosuppressant	0
FK506	0
but	0
not	0
by	0
its	0
structural	0
analog	0
,	0
rapamycin	0
.	0

On	0
the	0
other	0
hand	0
,	0
interleukin	9
2	10
(	0
IL-2	9
)	0
-induced	0
signals	0
are	0
blocked	0
by	0
rapamycin	0
but	0
not	0
by	0
FK506	0
.	0

Remarkably	0
,	0
these	0
two	0
drugs	0
inhibit	0
each	0
other	0
's	0
actions	0
,	0
raising	0
the	0
possibility	0
that	0
both	0
act	0
by	0
means	0
of	0
a	0
common	0
immunophilin	9
(	0
immunosuppressant	9
binding	10
protein	10
)	0
.	0

We	0
find	0
that	0
the	0
dissociation	0
constant	0
of	0
rapamycin	0
to	0
the	0
FK506	9
binding	10
protein	10
FKBP	9
(	0
Kd	0
=	0
0.2	0
nM	0
)	0
is	0
close	0
to	0
the	0
dissociation	0
constant	0
of	0
FK506	0
to	0
FKBP	9
(	0
Kd	0
=	0
0.4	0
nM	0
)	0
and	0
to	0
their	0
effective	0
biologic	0
inhibitory	0
concentrations	0
.	0

However	0
,	0
an	0
excess	0
of	0
rapamycin	0
is	0
needed	0
to	0
revert	0
FK506-mediated	0
inhibition	0
of	0
IL-2	9
production	0
,	0
apoptosis	0
,	0
and	0
transcriptional	0
activation	0
of	0
NF-AT	9
,	0
a	0
T-cell-specific	9
transcription	10
factor	10
necessary	0
for	0
IL-2	1
gene	2
activation	0
.	0

Similarly	0
,	0
an	0
excess	0
of	0
FK506	0
is	0
needed	0
to	0
revert	0
rapamycin-mediated	0
inhibition	0
of	0
IL-2	9
-induced	0
proliferation	0
.	0

The	0
drug	0
concentrations	0
required	0
for	0
antagonism	0
may	0
be	0
explained	0
by	0
the	0
relative	0
affinity	0
of	0
the	0
drugs	0
to	0
,	0
and	0
by	0
the	0
abundance	0
of	0
,	0
the	0
immunophilin	9
FKBP	9
.	0

FKBP	9
has	0
been	0
shown	0
to	0
catalyze	0
the	0
interconversion	0
of	0
the	0
cis-	0
and	0
trans-rotamers	0
of	0
the	0
peptidyl-prolyl	9
amide	10
bond	10
of	0
peptide	0
substrates	0
;	0
here	0
we	0
show	0
that	0
rapamycin	0
,	0
like	0
FK506	0
,	0
is	0
a	0
potent	0
inhibitor	0
of	0
the	0
rotamase	0
activity	0
of	0
FKBP	9
(	0
Ki	0
=	0
0.2	0
nM	0
)	0
.	0

Neither	0
FKBP	9
binding	0
nor	0
inhibition	0
of	0
rotamase	0
activity	0
of	0
FKBP	9
alone	0
is	0
sufficient	0
to	0
explain	0
the	0
biologic	0
actions	0
of	0
these	0
drugs	0
.	0

Rather	0
,	0
these	0
findings	0
suggest	0
that	0
immunophilin	9
bound	0
to	0
FK506	0
interferes	0
with	0
antigen	9
receptor	10
-induced	0
signals	0
,	0
while	0
rapamycin	0
bound	0
to	0
the	0
immunophilin	9
interferes	0
with	0
IL-2	9
-induced	0
signals	0
.	0

Adherence-dependent	0
increase	0
in	0
human	3
monocyte	4
PDGF	4
(	4
B	4
)	4
mRNA	4
is	0
associated	0
with	0
increases	0
in	0
c-fos	3
,	4
c-jun	4
,	4
and	4
EGR2	4
mRNA	4
.	0

Adherence	0
is	0
an	0
important	0
initial	0
step	0
in	0
the	0
transition	0
of	0
a	0
circulating	7
monocyte	8
to	0
a	0
tissue	7
macrophage	8
.	0

This	0
differentiation	0
is	0
accompanied	0
by	0
an	0
augmented	0
capacity	0
to	0
generate	0
growth	9
factors	10
.	0

We	0
hypothesized	0
that	0
adherence	0
itself	0
might	0
be	0
an	0
important	0
trigger	0
for	0
a	0
sequence	0
of	0
gene	0
activation	0
culminating	0
in	0
cells	0
with	0
increased	0
mRNA	3
encoding	0
profibrotic	0
growth	9
factors	10
such	0
as	0
platelet-derived	9
growth	10
factor	10
B	10
subunit	10
(	0
PDGF	9
[	10
B	10
]	10
)	0
and	0
transforming	9
growth	10
factor-beta	10
(	0
TGF-beta	9
)	0
.	0

After	0
in	0
vitro	0
adherence	0
,	0
human	0
monocytes	0
had	0
a	0
biphasic	0
increase	0
in	0
PDGF	3
(	4
B	4
)	4
mRNA	4
with	0
peaks	0
at	0
6	0
h	0
and	0
13	0
d	0
.	0

No	0
increase	0
in	0
TGF-beta	3
mRNA	4
was	0
observed	0
.	0

The	0
6-h	0
increase	0
in	0
PDGF	3
(	4
B	4
)	4
mRNA	4
was	0
adherence	0
dependent	0
,	0
and	0
in	0
addition	0
,	0
was	0
abrogated	0
when	0
the	0
cytoskeletal	0
integrity	0
was	0
compromised	0
by	0
cytochalasin	0
D	0
.	0

The	0
6-h	0
increase	0
in	0
PDGF	3
(	4
B	4
)	4
mRNA	4
was	0
unaltered	0
by	0
adherence	0
in	0
the	0
presence	0
of	0
the	0
monocyte	0
stimulus	0
lipopolysaccharide	0
.	0

Adherence	0
to	0
either	0
fibronectin	0
or	0
collagen-coated	0
plastic	0
had	0
little	0
consistent	0
effect	0
on	0
PDGF	3
(	4
B	4
)	4
mRNA	4
accumulation	0
.	0

The	0
increased	0
PDGF	3
(	4
B	4
)	4
mRNA	4
observed	0
in	0
adherent	7
monocytes	8
was	0
accompanied	0
by	0
increases	0
in	0
mRNAs	3
of	0
the	0
early	1
growth	2
response	2
genes	2
c-fos	1
(	0
maximal	0
at	0
20	0
min	0
)	0
,	0
c-jun	0
,	0
and	0
EGR2	0
(	0
maximal	0
at	0
6-24	0
h	0
)	0
.	0

The	0
increase	0
in	0
c-jun	0
and	0
EGR2	0
,	0
but	0
not	0
c-fos	1
,	0
mRNA	0
was	0
also	0
abrogated	0
by	0
cytochalasin	0
D	0
.	0

These	0
observations	0
suggest	0
that	0
adherence	0
results	0
in	0
increases	0
of	0
c-fos	3
,	4
c-jun	4
,	4
EGR2	4
,	4
and	4
PDGF	4
(	4
B	4
)	4
mRNA	4
.	0

In	0
addition	0
,	0
the	0
increases	0
in	0
c-jun	1
,	0
EGR2	1
,	0
and	0
PDGF	9
(	10
B	10
)	10
may	0
depend	0
on	0
cytoskeletal	0
rearrangement	0
.	0

Modulation	0
of	0
these	0
events	0
at	0
the	0
time	0
of	0
adherence	0
offers	0
a	0
mechanism	0
by	0
which	0
differential	0
priming	0
of	0
the	0
cells	0
may	0
be	0
accomplished	0
.	0

Single	0
cell	0
assay	0
of	0
a	0
transcription	9
factor	10
reveals	0
a	0
threshold	0
in	0
transcription	0
activated	0
by	0
signals	0
emanating	0
from	0
the	0
T-cell	9
antigen	10
receptor	10
.	0

Stimulation	0
of	0
T	7
lymphocytes	8
through	0
their	0
antigen	9
receptor	10
leads	0
to	0
the	0
appearance	0
of	0
several	0
transcription	9
factors	10
,	0
including	0
NF-AT	9
and	0
NF-kappa	9
B	10
,	0
which	0
are	0
involved	0
in	0
regulating	0
genes	0
required	0
for	0
immunologic	0
activation	0
.	0

To	0
investigate	0
the	0
activity	0
of	0
a	0
single	0
transcription	9
factor	10
in	0
individual	7
viable	8
cells	8
,	0
we	0
have	0
applied	0
an	0
assay	0
that	0
uses	0
the	0
fluorescence-activated	0
cell	0
sorter	0
to	0
quantitate	0
beta-galactosidase	9
(	0
beta-gal	9
)	0
.	0

We	0
have	0
analyzed	0
the	0
distribution	0
of	0
NF-AT	9
transcriptional	0
activity	0
among	0
T	7
cells	8
undergoing	0
activation	0
by	0
using	0
a	0
construct	0
in	0
which	0
three	0
tandem	0
copies	0
of	0
the	0
NF-AT-binding	1
site	2
directs	0
transcription	0
of	0
the	0
lacZ	1
gene	2
.	0

Unexpectedly	0
,	0
stimulation	0
of	0
cloned	5
stably	6
transfected	6
Jurkat	6
T	6
cells	6
leads	0
to	0
a	0
bimodal	0
pattern	0
of	0
beta-gal	0
expression	0
in	0
which	0
some	0
cells	0
express	0
no	0
beta-gal	9
and	0
others	0
express	0
high	0
levels	0
.	0

This	0
expression	0
pattern	0
can	0
not	0
be	0
accounted	0
for	0
by	0
cell-cycle	0
position	0
or	0
heritable	0
variation	0
.	0

Further	0
results	0
,	0
in	0
which	0
beta-gal	9
activity	0
is	0
correlated	0
with	0
NF-AT	9
-binding	0
activity	0
,	0
indicate	0
that	0
the	0
concentration	0
of	0
NF-AT	9
must	0
exceed	0
a	0
critical	0
threshold	0
before	0
transcription	0
initiates	0
.	0

This	0
threshold	0
likely	0
reflects	0
the	0
NF-AT	9
concentration-dependent	0
assembly	0
of	0
transcription	9
complexes	10
at	0
the	0
promoter	1
.	0

Similar	0
constructs	0
controlled	0
by	0
NF-kappa	9
B	10
or	0
the	0
entire	0
interleukin-2	1
enhancer	2
show	0
bimodal	0
expression	0
patterns	0
during	0
induction	0
,	0
suggesting	0
that	0
thresholds	0
set	0
by	0
the	0
concentration	0
of	0
transcription	9
factors	10
may	0
be	0
a	0
common	0
property	0
of	0
inducible	1
genes	2
.	0

The	0
Epstein-Barr	1
virus	2
(	2
EBV	2
)	2
BMRF1	2
promoter	2
for	0
early	9
antigen	10
(	0
EA-D	9
)	0
is	0
regulated	0
by	0
the	0
EBV	9
transactivators	10
,	0
BRLF1	9
and	0
BZLF1	9
,	0
in	0
a	0
cell-specific	0
manner	0
.	0

The	0
Epstein-Barr	9
virus	10
early	10
antigen	10
diffuse	10
component	10
(	0
EA-D	9
)	0
is	0
essential	0
for	0
Epstein-Barr	0
virus	1
DNA	2
polymerase	0
activity	0
,	0
and	0
its	0
activity	0
is	0
suppressed	0
during	0
latent	0
infection	0
.	0

We	0
investigated	0
the	0
regulation	0
of	0
the	0
promoter	1
(	0
BMRF1	1
)	0
for	0
this	0
early	0
gene	0
by	0
studying	0
its	0
responsiveness	0
in	0
vitro	0
to	0
two	0
immediate-early	9
viral	10
transactivators	10
,	0
BZLF1	9
(	0
Z	9
)	0
and	0
BRLF1	9
(	0
R	9
)	0
,	0
focusing	0
on	0
the	0
differences	0
in	0
response	0
in	0
lymphoid	7
cells	8
and	0
epithelial	7
cells	8
.	0

In	0
lymphoid	7
cells	8
,	0
Z	9
or	0
R	9
alone	0
produced	0
only	0
small	0
increases	0
in	0
EA-D	1
promoter	2
activity	0
,	0
whereas	0
both	0
transactivators	9
together	0
produced	0
a	0
large	0
stimulatory	0
effect	0
.	0

In	0
epithelial	7
cells	8
,	0
the	0
Z	9
transactivator	10
alone	0
produced	0
maximal	0
stimulation	0
of	0
the	0
EA-D	1
promoter	2
;	0
the	0
effect	0
of	0
R	9
and	0
Z	9
together	0
was	0
no	0
greater	0
than	0
that	0
of	0
Z	9
alone	0
.	0

Deletional	0
analysis	0
and	0
site-directed	0
mutagenesis	0
of	0
the	0
EA-D	1
promoter	2
demonstrated	0
that	0
in	0
epithelial	7
cells	8
the	0
potential	0
AP-1	1
binding	2
site	2
plays	0
an	0
essential	0
role	0
in	0
Z	9
responsiveness	0
,	0
although	0
sequences	0
further	0
upstream	0
are	0
also	0
important	0
.	0

In	0
lymphoid	7
cells	8
,	0
only	0
the	0
upstream	1
sequences	2
are	0
required	0
for	0
transactivation	0
by	0
the	0
Z/R	9
combination	0
,	0
and	0
the	0
AP-1	9
site	10
is	0
dispensable	0
.	0

These	0
data	0
suggest	0
that	0
EA-D	1
(	2
BMRF1	2
)	2
promoter	2
regulation	0
by	0
Z	9
and	0
R	9
is	0
cell	0
type	0
specific	0
and	0
appears	0
to	0
involve	0
different	0
mechanisms	0
in	0
each	0
cell	0
type	0
.	0

Complementary	1
DNA	2
encoding	0
the	0
human	9
T-cell	10
FK506-binding	10
protein	10
,	0
a	0
peptidylprolyl	9
cis-trans	10
isomerase	10
distinct	0
from	0
cyclophilin	9
.	0

The	0
recently	0
discovered	0
macrolide	0
FK506	0
has	0
been	0
demonstrated	0
to	0
have	0
potent	0
immunosuppressive	0
activity	0
at	0
concentrations	0
100-fold	0
lower	0
than	0
cyclosporin	0
A	0
,	0
a	0
cyclic	0
undecapeptide	0
that	0
is	0
used	0
to	0
prevent	0
rejection	0
after	0
transplantation	0
of	0
bone	0
marrow	0
and	0
organs	0
,	0
such	0
as	0
kidney	0
,	0
heart	0
,	0
and	0
liver	0
.	0

After	0
the	0
recent	0
discovery	0
that	0
the	0
cyclosporin	9
A-binding	10
protein	10
cyclophilin	9
is	0
identical	0
to	0
peptidylprolyl	9
cis-trans	10
isomerase	10
,	0
a	0
cellular	9
binding	10
protein	10
for	0
FK506	0
was	0
found	0
to	0
be	0
distinct	0
from	0
cyclophilin	9
but	0
to	0
have	0
the	0
same	0
enzymatic	0
activity	0
.	0

In	0
this	0
study	0
,	0
we	0
isolated	0
a	0
cDNA	1
coding	0
for	0
FK506-binding	0
protein	0
(	0
FKBP	9
)	0
from	0
human	0
peripheral	0
blood	0
T	7
cells	8
by	0
using	0
mixed	0
20-mer	0
oligonucleotide	0
probes	0
synthesized	0
on	0
the	0
basis	0
of	0
the	0
sequence	0
,	0
Glu-Asp-Gly-Lys-Lys-Phe-Asp	0
,	0
reported	0
for	0
bovine	9
FKBP	10
.	0

The	0
DNA	0
isolated	0
contained	0
an	0
open	0
reading	0
frame	0
encoding	0
108	0
amino	0
acid	0
residues	0
.	0

The	0
first	0
40	0
residues	0
of	0
the	0
deduced	0
amino	0
acid	0
sequence	0
were	0
identical	0
to	0
those	0
of	0
the	0
reported	0
amino-terminal	0
sequence	0
of	0
bovine	0
FKBP	9
,	0
indicating	0
that	0
the	0
DNA	0
sequence	0
isolated	0
represents	0
the	0
gene	0
coding	0
for	0
FKBP	9
.	0

Computer-assisted	0
analysis	0
of	0
the	0
deduced	0
amino	0
acid	0
sequence	0
indicates	0
that	0
FKBP	9
exhibits	0
no	0
internal	0
homology	0
and	0
does	0
not	0
have	0
significant	0
sequence	0
similarity	0
to	0
any	0
other	0
amino	0
acid	0
sequences	0
of	0
known	0
proteins	0
,	0
including	0
cyclophilin	9
.	0

This	0
result	0
suggests	0
that	0
two	0
catalytically	0
similar	0
proteins	0
,	0
cyclophilin	9
and	0
FKBP	9
,	0
evolved	0
independently	0
.	0

In	0
Northern	0
blot	0
analysis	0
,	0
mRNA	3
species	4
of	0
approximately	0
1.8	0
kilobases	0
that	0
hybridized	0
with	0
human	1
FKBP	2
cDNA	2
were	0
detected	0
in	0
poly	3
(	4
A	4
)	4
+	4
RNAs	4
from	0
brain	0
,	0
lung	0
,	0
liver	0
,	0
and	0
placental	7
cells	8
and	0
leukocytes	7
.	0

Induction	0
of	0
Jurkat	5
leukemic	6
T	6
cells	6
with	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
ionomycin	0
did	0
not	0
affect	0
the	0
level	0
of	0
FKBP	3
mRNA	4
.	0

Southern	0
blot	0
analysis	0
of	0
human	1
genomic	2
DNA	2
digested	0
with	0
different	0
restriction	9
enzymes	10
suggests	0
the	0
existence	0
of	0
only	0
a	0
few	0
copies	0
of	0
the	0
DNA	0
sequence	0
encoding	0
FKBP	9
.	0

This	0
is	0
in	0
contrast	0
to	0
the	0
result	0
that	0
as	0
many	0
as	0
20	0
copies	0
of	0
the	0
cyclophilin	1
gene	2
and	0
possible	0
pseudogenes	0
may	0
be	0
present	0
in	0
the	0
mammalian	1
genome	2
.	0

Involvement	0
of	0
a	0
second	0
lymphoid-specific	1
enhancer	2
element	2
in	0
the	0
regulation	0
of	0
immunoglobulin	1
heavy-chain	2
gene	2
expression	0
.	0

To	0
determine	0
whether	0
enhancer	1
elements	2
in	0
addition	0
to	0
the	0
highly	0
conserved	0
octamer	1
(	2
OCTA	2
)	2
-nucleotide	2
motif	2
are	0
important	0
for	0
lymphoid-specific	0
expression	0
of	0
the	0
immunoglobulin	1
heavy-chain	2
(	2
IgH	2
)	2
gene	2
,	0
we	0
have	0
investigated	0
the	0
effect	0
of	0
mutating	0
the	0
binding	1
site	2
for	0
a	0
putative	9
additional	10
lymphoid-specific	10
transcription	10
factor	10
,	0
designated	0
NF-microB	9
,	0
in	0
the	0
murine	1
IgH	2
enhancer	2
.	0

We	0
demonstrate	0
that	0
the	0
NF-microB-binding	1
site	2
plays	0
a	0
critical	0
role	0
in	0
the	0
IgH	1
enhancer	2
,	0
because	0
mutation	0
of	0
the	0
microB	0
DNA	0
motif	0
decreased	0
transcriptional	0
activity	0
of	0
the	0
IgH	1
enhancer	2
in	0
cells	0
of	0
the	0
B-cell	7
lineage	8
but	0
not	0
in	0
nonlymphoid	7
cells	8
.	0

This	0
effect	0
was	0
comparable	0
to	0
or	0
even	0
stronger	0
than	0
the	0
effect	0
of	0
a	0
mutation	0
in	0
the	0
OCTA	1
site	2
.	0

Moreover	0
,	0
combined	0
mutation	0
of	0
both	0
microB	1
and	0
OCTA	1
sites	2
further	0
reduced	0
enhancer	0
activity	0
in	0
lymphoid	7
cells	8
.	0

Interestingly	0
,	0
alteration	0
of	0
either	0
the	0
microB	1
or	0
E3	1
site	2
in	0
a	0
70-base-pair	1
fragment	2
of	0
the	0
IgH	1
enhancer	2
that	0
lacks	0
the	0
binding	0
site	0
for	0
OCTA	0
abolished	0
enhancer	0
activity	0
in	0
lymphoid	7
cells	8
completely	0
.	0

Nevertheless	0
,	0
a	0
multimer	0
of	0
the	0
microB	1
motif	2
alone	0
showed	0
no	0
enhancer	0
activity	0
.	0

DNase	0
footprinting	0
analysis	0
corroborated	0
the	0
functional	0
data	0
showing	0
that	0
a	0
lymphoid-specific	9
protein	10
binds	0
to	0
the	0
microB	1
DNA	2
motif	2
.	0

Our	0
results	0
suggest	0
that	0
the	0
microB	1
element	2
is	0
a	0
new	0
crucial	0
element	0
important	0
for	0
lymphoid-specific	0
expression	0
of	0
the	0
IgH	0
gene	0
but	0
that	0
interaction	0
with	0
another	0
enhancer	1
element	2
is	0
essential	0
for	0
its	0
activity	0
.	0

Stimulation	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
2	0
(	0
HIV-2	0
)	0
gene	0
expression	0
by	0
the	0
cytomegalovirus	0
and	0
HIV-2	1
transactivator	2
gene	2
.	0

Human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
often	0
causes	0
latent	0
infection	0
.	0

Transactivation	0
by	0
some	0
DNA	0
viruses	0
has	0
been	0
implicated	0
in	0
inducing	0
HIV-1	0
replication	0
and	0
pathogenesis	0
.	0

The	0
transactivator	1
(	2
IE-2	2
)	2
gene	2
of	0
the	0
human	0
cytomegalovirus	0
(	0
CMV	0
)	0
can	0
enhance	0
HIV-2	0
as	0
well	0
as	0
HIV-1	0
gene	0
expression	0
in	0
vitro	0
.	0

This	0
inducer	0
can	0
act	0
in	0
concert	0
with	0
the	0
HIV-2	1
tat	2
gene	2
and	0
T-cell	0
activation	0
in	0
enhancing	0
gene	0
expression	0
in	0
human	7
CD4+	8
lymphocytes	8
.	0

While	0
the	0
HIV-2	0
and	0
HIV-1	1
tat	2
genes	2
and	0
T-cell	9
activators	10
apparently	0
employ	0
independent	0
modes	0
of	0
action	0
,	0
the	0
CMV	1
transactivator	2
in	0
combination	0
with	0
the	0
HIV-2	1
tat	2
or	0
T-cell	9
activators	10
may	0
employ	0
a	0
gene	0
activation	0
pathway	0
with	0
some	0
common	0
and	0
some	0
distinct	0
components	0
.	0

Both	0
HIV-2	0
and	0
CMV	1
transactivators	2
enhance	0
HIV-2	0
gene	0
expression	0
by	0
transcriptional	0
activation	0
involving	0
transcript	0
initiation	0
as	0
well	0
as	0
elongation	0
,	0
with	0
CMV	1
transactivator	2
affecting	0
elongation	0
more	0
than	0
the	0
initiation	0
.	0

A	0
significant	0
proportion	0
of	0
transcripts	3
appear	0
to	0
terminate	0
prematurely	0
in	0
the	0
absence	0
of	0
transactivators	9
.	0

Deletion	0
mutation	0
analysis	0
of	0
the	0
HIV-2	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
suggests	0
that	0
the	0
element	0
that	0
responds	0
to	0
CMV	0
transactivation	0
in	0
human	7
CD4+	8
lymphocytes	8
is	0
either	0
a	0
diffuse	0
one	0
or	0
located	0
downstream	0
of	0
the	0
HIV-2	1
enhancer	2
element	2
.	0

Quantitative	0
immunohistochemical	0
analysis	0
of	0
mononuclear	7
infiltrates	8
in	0
breast	0
carcinomas	0
--	0
correlation	0
with	0
tumour	0
differentiation	0
.	0

Inflammatory	7
infiltrates	8
were	0
analysed	0
in	0
tissue	0
sections	0
of	0
76	0
breast	0
carcinomas	0
by	0
counting	0
the	0
percentage	0
of	0
macrophages	7
,	0
IgA+	7
and	8
IgG+	8
plasma	8
cells	8
,	0
T	7
cells	8
with	0
their	0
subpopulations	0
,	0
and	0
natural	7
killer	8
cells	8
,	0
and	0
by	0
measuring	0
postcapillary	0
venules	0
(	0
PCVs	0
,	0
found	0
in	0
12	0
cases	0
)	0
within	0
the	0
infiltrates	0
.	0

These	0
parameters	0
were	0
correlated	0
with	0
nuclear	0
grade	0
and	0
biochemically	0
determined	0
hormone	0
receptor	0
status	0
,	0
known	0
markers	0
of	0
tumour	0
differentiation	0
.	0

A	0
direct	0
correlation	0
was	0
found	0
between	0
the	0
extent	0
of	0
inflammation	0
and	0
nuclear	0
grade	0
(	0
P	0
less	0
than	0
0.0001	0
)	0
,	0
and	0
an	0
inverse	0
correlation	0
between	0
inflammation	0
and	0
oestrogen	9
receptor	10
(	0
OR	9
)	0
positivity	0
(	0
P	0
less	0
than	0
0.05	0
)	0
as	0
well	0
as	0
inflammation	0
and	0
progesterone	9
receptor	10
(	0
PR	9
)	0
positivity	0
(	0
P	0
less	0
than	0
0.05	0
)	0
.	0

The	0
percentage	0
of	0
the	0
OKT8+	5
suppressor/cytotoxic	6
T	6
cells	6
increased	0
when	0
the	0
inflammation	0
expanded	0
from	0
scanty	0
to	0
moderate	0
(	0
P	0
less	0
than	0
0.02	0
)	0
.	0

The	0
diameter	0
of	0
the	0
PCVs	0
also	0
increased	0
with	0
increasing	0
inflammatory	0
infiltrate	0
(	0
P	0
less	0
than	0
0.02	0
)	0
.	0

In	0
addition	0
,	0
a	0
direct	0
correlation	0
exists	0
between	0
the	0
diameter	0
of	0
the	0
PCVs	0
and	0
both	0
the	0
percentage	0
of	0
the	0
OKT8+	5
T	6
cells	6
(	0
P	0
less	0
than	0
0.04	0
)	0
and	0
the	0
Leu-7+	0
natural	7
killer	8
cells	8
(	0
P	0
less	0
than	0
0.03	0
)	0
.	0

Reactivity	0
of	0
lymphocytes	5
to	0
a	0
progesterone	9
receptor-specific	10
monoclonal	10
antibody	10
.	0

In	0
this	0
study	0
we	0
present	0
evidence	0
for	0
reactivity	0
of	0
pregnancy	7
lymphocytes	8
,	0
but	0
not	0
nonpregnancy	7
lymphocytes	8
,	0
with	0
the	0
progesterone	9
receptor-specific	10
monoclonal	10
antibody	10
mPRI	9
.	0

Using	0
an	0
avidin	9
-biotin	9
peroxidase	10
detection	0
system	0
,	0
we	0
found	0
a	0
nuclear	0
staining	0
in	0
14.6	0
+/-	0
3.7	0
%	0
(	0
mean	0
+/-	0
SEM	0
,	0
N	0
=	0
27	0
)	0
of	0
pregnancy	7
lymphocytes	8
,	0
while	0
only	0
0.47	0
+/-	0
0.33	0
%	0
(	0
mean	0
+/-	0
SEM	0
,	0
N	0
=	0
15	0
)	0
of	0
nonpregnancy	7
lymphocytes	8
reacted	0
with	0
the	0
antibody	0
.	0

To	0
characterize	0
the	0
receptor-bearing	0
subset	0
,	0
CD8+	5
and	6
CD4+	6
cells	6
were	0
depleted	0
by	0
complement-dependent	0
lysis	0
.	0

Depletion	0
of	0
CD8+	5
cells	6
was	0
accompanied	0
by	0
62	0
+/-	0
18	0
%	0
loss	0
of	0
progesterone	5
receptor-bearing	6
cells	6
,	0
while	0
depletion	0
of	0
CD4+	5
cells	6
resulted	0
in	0
a	0
twofold	0
increase	0
in	0
the	0
number	0
of	0
positively	0
staining	0
lymphocytes	5
.	0

In	0
nonpregnancy	5
lymphocytes	6
a	0
3-day	0
PHA	9
treatment	0
,	0
as	0
well	0
as	0
allogeneic	0
stimulation	0
,	0
resulted	0
in	0
a	0
significant	0
increase	0
in	0
the	0
number	0
of	0
receptor-containing	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
pregnancy	0
,	0
but	0
not	0
nonpregnancy	0
,	0
lymphocytes	5
contain	0
progesterone	9
binding	10
structures	10
,	0
and	0
that	0
these	0
are	0
inducible	0
by	0
mitogenic	0
or	0
alloantigenic	0
stimuli	0
.	0

Activation	0
of	0
human	5
CD4	6
T	6
lymphocytes	6
.	0

Interaction	0
of	0
fibronectin	9
with	0
VLA-5	9
receptor	10
on	0
CD4	5
cells	6
induces	0
the	0
AP-1	9
transcription	10
factor	10
.	0

Fibronectin	9
synergized	0
with	0
anti-CD3	9
antibody	10
to	0
promote	0
CD4	9
cell	0
proliferation	0
in	0
a	0
serum-free	0
culture	0
system	0
whereas	0
no	0
proliferation	0
was	0
observed	0
when	0
CD4	5
cells	6
were	0
cultured	0
with	0
anti-CD3	9
alone	0
or	0
fibronectin	9
alone	0
.	0

In	0
addition	0
,	0
anti-CD29	9
(	0
integrin	9
beta	10
1	10
)	0
as	0
well	0
as	0
anti-VLA-5	9
(	0
human	9
fibronectin	10
receptor	10
)	0
antibodies	0
blocked	0
this	0
CD4	5
cell	6
activation	0
in	0
this	0
system	0
.	0

Although	0
anti-CD3	9
alone	0
or	0
fibronectin	9
alone	0
can	0
not	0
induce	0
IL-2	9
message	0
by	0
CD4	5
cells	6
,	0
the	0
combination	0
of	0
anti-CD3	9
plus	0
fibronectin	9
induced	0
IL-2	9
message	0
by	0
CD4	5
cells	6
.	0

In	0
an	0
analysis	0
of	0
the	0
molecular	0
mechanism	0
by	0
which	0
IL-2	9
message	0
was	0
generated	0
,	0
we	0
showed	0
that	0
a	0
fibronectin	9
-VLA-5	0
fibronectin	9
receptor	10
interaction	0
may	0
contribute	0
an	0
independent	0
signal	0
distinct	0
from	0
the	0
CD3	9
pathway	0
of	0
activation	0
by	0
the	0
induction	0
of	0
an	0
AP-1	9
transcriptional	10
factor	10
.	0

Thus	0
the	0
VLA-5	9
fibronectin	10
receptor	10
on	0
CD4	5
cells	6
can	0
play	0
a	0
complementary	0
role	0
in	0
CD3	9
-	0
TCR	9
-mediated	0
signal	0
transduction	0
through	0
its	0
interaction	0
with	0
fibronectin	9
.	0

Glucocorticoid	9
receptors	10
on	0
mononuclear	7
leukocytes	8
in	0
Alzheimer	0
's	0
disease	0
.	0

Several	0
lines	0
of	0
evidence	0
suggest	0
disturbances	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
(	0
HPA	0
)	0
system	0
in	0
Alzheimer	0
's	0
disease	0
(	0
AD	0
)	0
.	0

In	0
an	0
exploration	0
of	0
the	0
potential	0
role	0
of	0
the	0
glucocorticoid	0
receptor	0
(	0
GR	0
)	0
in	0
AD	0
,	0
GR	0
density	0
and	0
affinity	0
were	0
assessed	0
on	0
mononuclear	7
leukocytes	8
of	0
12	0
AD	0
patients	0
and	0
12	0
healthy	0
controls	0
.	0

GR	0
binding	0
characteristics	0
did	0
not	0
differ	0
between	0
patients	0
and	0
controls	0
or	0
between	0
patients	0
subdivided	0
according	0
to	0
diagnosis	0
or	0
associated	0
clinical	0
features	0
.	0

These	0
data	0
suggest	0
that	0
the	0
abnormalities	0
of	0
the	0
HPA	0
system	0
in	0
AD	0
are	0
not	0
related	0
to	0
a	0
GR	9
deficiency	0
.	0

Oncogene	0
amplification	0
correlates	0
with	0
dense	0
lymphocyte	0
infiltration	0
in	0
human	0
breast	0
cancers	0
:	0
a	0
role	0
for	0
hematopoietic	9
growth	10
factor	10
release	0
by	0
tumor	7
cells	8
?	0

One	0
hundred	0
six	0
primary	0
breast	0
cancer	0
samples	0
were	0
analysed	0
for	0
c-erbB2	0
,	0
int-2	0
,	0
and	0
c-myc	0
gene	0
amplification	0
.	0

Surgically	0
confirmed	0
nodal	0
involvement	0
was	0
observed	0
in	0
42	0
%	0
.	0

Level	0
of	0
gene	0
amplification	0
was	0
studied	0
by	0
Southern	0
and/or	0
slot	0
blot	0
techniques	0
.	0

Amplified	0
c-erbB2	1
gene	2
sequences	2
were	0
present	0
in	0
21.5	0
%	0
of	0
all	0
samples	0
.	0

Int-2	1
was	0
amplified	0
in	0
13.1	0
%	0
and	0
c-myc	1
was	0
amplified	0
in	0
10.3	0
%	0
.	0

In	0
a	0
non-parametric	0
test	0
(	0
Kruskal-Wallis	0
)	0
a	0
strong	0
negative	0
association	0
was	0
found	0
between	0
high	0
levels	0
of	0
c-erbB2	1
amplification	0
and	0
absence	0
of	0
estrogen	0
receptor	0
(	0
ER	0
)	0
(	0
P	0
=	0
.0009	0
)	0
or	0
progesterone	9
receptor	10
(	0
PR	9
)	0
(	0
P	0
=	0
.011	0
)	0
expression	0
.	0

No	0
correlations	0
were	0
found	0
between	0
all	0
or	0
high	0
levels	0
of	0
amplification	0
of	0
each	0
oncogene	0
separately	0
or	0
combined	0
with	0
T	0
,	0
N	0
,	0
grade	0
,	0
multifocality	0
of	0
tumor	0
,	0
or	0
associated	0
carcinoma	0
in	0
situ	0
.	0

There	0
was	0
a	0
trend	0
approaching	0
statistical	0
significance	0
for	0
patients	0
with	0
c-erbB2	1
amplifications	0
to	0
have	0
positive	0
lymph	0
nodes	0
at	0
surgery	0
(	0
P	0
=	0
0.09	0
)	0
.	0

A	0
somewhat	0
surprising	0
finding	0
however	0
was	0
a	0
very	0
strong	0
association	0
between	0
oncogene	1
amplification	0
and	0
dense	0
lymphocyte	0
infiltration	0
of	0
the	0
tumor	0
(	0
P	0
=	0
.05	0
)	0
.	0
This	0
correlation	0
is	0
even	0
stronger	0
when	0
only	0
high	0
levels	0
of	0
amplification	0
are	0
considered	0
,	0
either	0
for	0
each	0
oncogene	0
separately	0
(	0
P	0
=	0
.0048	0
)	0
or	0
in	0
combination	0
(	0
P	0
=	0
.0007	0
)	0
.	0

We	0
propose	0
that	0
malignant	0
cell	0
cytokine	9
production	0
may	0
help	0
explain	0
this	0
observation	0
.	0

Suppression	0
of	0
signals	0
required	0
for	0
activation	0
of	0
transcription	9
factor	10
NF-kappa	10
B	10
in	0
cells	0
constitutively	0
expressing	0
the	0
HTLV-I	9
Tax	10
protein	10
.	0

Transient	0
short-term	0
expression	0
of	0
the	0
Tax	9
protein	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type-I	0
(	0
HTLV-I	0
)	0
leads	0
to	0
activation	0
of	0
the	0
pleiotropic	0
transcription	9
factor	10
NF-kappa	10
B	10
.	0

Consistent	0
with	0
findings	0
obtained	0
with	0
transient	0
expression	0
assays	0
,	0
we	0
observed	0
marked	0
accumulation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
in	0
the	0
nucleus	0
of	0
Namalwa	5
B	6
lymphoid	6
cells	6
,	0
which	0
constitutively	0
express	0
Tax	9
.	0

In	0
contrast	0
,	0
NF-kappa	9
B	10
activity	0
was	0
not	0
detected	0
in	0
the	0
nucleus	0
following	0
long-term	0
expression	0
of	0
Tax	9
in	0
Jurkat	5
T	6
lymphocytes	6
.	0

The	0
ability	0
of	0
both	0
mitogens	0
and	0
cytokines	9
to	0
activate	0
NF-kappa	9
B	10
was	0
also	0
blocked	0
in	0
Jurkat	5
cells	6
constitutively	0
expressing	0
Tax	9
.	0

However	0
,	0
the	0
activation	0
of	0
other	0
mitogen-inducible	9
transcription	10
factors	10
,	0
such	0
as	0
Fos	9
and	0
Jun	9
,	0
was	0
unaffected	0
.	0

Thus	0
,	0
depending	0
on	0
the	0
cellular	0
environment	0
,	0
the	0
short-	0
and	0
long-term	0
effects	0
of	0
Tax	9
expression	0
can	0
be	0
quite	0
different	0
.	0

Consequently	0
,	0
one	0
function	0
of	0
Tax	9
in	0
cells	0
infected	0
with	0
HTLV-I	0
might	0
involve	0
cell-type-specific	0
suppression	0
,	0
as	0
opposed	0
to	0
activation	0
,	0
of	0
distinct	0
signal	0
pathways	0
.	0

The	0
cells	0
lines	0
described	0
here	0
should	0
be	0
useful	0
for	0
the	0
delineation	0
of	0
signaling	0
pathways	0
utilized	0
in	0
the	0
selective	0
regulation	0
of	0
gene	0
expression	0
.	0

Interferon-gamma	9
and	0
the	0
sexual	0
dimorphism	0
of	0
autoimmunity	0
.	0

The	0
sexual	0
difference	0
in	0
the	0
incidence	0
of	0
autoimmune	0
diseases	0
has	0
remained	0
an	0
enigma	0
for	0
many	0
years	0
.	0

In	0
the	0
examination	0
of	0
the	0
induction	0
of	0
autoimmunity	0
in	0
transgenic	0
mice	0
,	0
evidence	0
has	0
been	0
obtained	0
further	0
implicating	0
the	0
lymphokine	9
interferon-gamma	9
in	0
the	0
etiology	0
of	0
autoimmunity	0
.	0

Sex	0
steroid	0
regulation	0
of	0
the	0
production	0
of	0
this	0
molecule	0
,	0
as	0
well	0
as	0
other	0
cytokines	9
,	0
may	0
help	0
explain	0
the	0
gender-specific	0
differences	0
in	0
the	0
immune	0
system	0
,	0
including	0
autoimmunity	0
.	0

Cloning	0
of	0
a	0
transcriptionally	9
active	10
human	10
TATA	10
binding	10
factor	10
.	0

Transcription	9
factor	10
IID	10
(	0
TFIID	9
)	0
binds	0
to	0
the	0
TATA	1
box	2
promoter	2
element	2
and	0
regulates	0
the	0
expression	0
of	0
most	0
eukaryotic	1
genes	2
transcribed	0
by	0
RNA	9
polymerase	10
II	10
.	0

Complementary	1
DNA	2
(	0
cDNA	1
)	0
encoding	0
a	0
human	9
TFIID	10
protein	10
has	0
been	0
cloned	0
.	0

The	0
human	9
TFIID	10
polypeptide	10
has	0
339	0
amino	0
acids	0
and	0
a	0
molecular	0
size	0
of	0
37	0
,	0
745	0
daltons	0
.	0

The	0
carboxyl-terminal	9
181	10
amino	10
acids	10
of	0
the	0
human	9
TFIID	10
protein	10
shares	0
80	0
%	0
identity	0
with	0
the	0
TFIID	9
protein	0
from	0
Saccharomyces	0
cerevisiae	0
.	0

The	0
amino	9
terminus	10
contains	0
an	0
unusual	0
repeat	0
of	0
38	0
consecutive	0
glutamine	0
residues	0
and	0
an	0
X-Thr-Pro	9
repeat	10
.	0

Expression	0
of	0
DNA	0
in	0
reticulocyte	0
lysates	0
or	0
in	0
Escherichia	0
coli	0
yielded	0
a	0
protein	0
that	0
was	0
competent	0
for	0
both	0
DNA	0
binding	0
and	0
transcription	0
activation	0
.	0

A	0
novel	0
T-cell	9
trans-activator	10
that	0
recognizes	0
a	0
phorbol	1
ester-inducible	2
element	2
of	0
the	0
interleukin-2	1
promoter	2
.	0

The	0
interleukin	1
2	2
(	2
IL-2	2
)	2
gene	2
promoter	2
is	0
recognized	0
by	0
several	0
cell-type-specific	9
and	10
ubiquitous	10
transcriptional	10
regulators	10
that	0
integrate	0
information	0
transmitted	0
by	0
various	0
signaling	0
systems	0
leading	0
to	0
IL-2	9
production	0
and	0
T-cell	7
activation	0
.	0

Using	0
a	0
combination	0
of	0
transfection	0
,	0
protein-DNA	0
binding	0
,	0
and	0
in	0
vitro	0
transcription	0
methods	0
,	0
we	0
have	0
discovered	0
the	0
novel	9
T-cell-specific	10
transcriptional	10
activator	10
TCF-1	9
(	0
for	0
T-Cell	9
Factor-1	10
)	0
,	0
which	0
recognizes	0
a	0
T-cell-specific	1
response	2
element	2
(	0
TCE	1
)	0
located	0
within	0
the	0
IL-2	1
promoter	2
.	0

Although	0
the	0
TCE	1
is	0
similar	0
in	0
sequence	0
to	0
a	0
consensus	1
NF	2
kappa	2
B	2
site	2
,	0
several	0
criteria	0
indicate	0
that	0
TCF-1	9
is	0
distinct	0
from	0
NF	9
kappa	10
B	10
.	0

However	0
,	0
like	0
NF	9
kappa	10
B	10
,	0
TCF-1	9
activity	0
is	0
induced	0
by	0
phorbol	0
esters	0
and	0
other	0
T-cell	0
activators	0
.	0

Risk	0
factors	0
for	0
breast	0
recurrence	0
in	0
premenopausal	0
and	0
postmenopausal	0
patients	0
with	0
ductal	0
cancers	0
treated	0
by	0
conservation	0
therapy	0
.	0

Risk	0
factors	0
for	0
local	0
failure	0
were	0
evaluated	0
for	0
496	0
clinical	0
Stage	0
I-II	0
patients	0
with	0
infiltrating	0
ductal	0
carcinomas	0
(	0
median	0
follow-up	0
,	0
71	0
months	0
)	0
treated	0
by	0
conservative	0
surgery	0
and	0
radiotherapy	0
.	0

Monofactorial	0
analysis	0
identified	0
the	0
following	0
factors	0
to	0
be	0
correlated	0
with	0
increased	0
risk	0
:	0
moderate/marked	0
mononuclear	0
cell	0
reaction	0
(	0
MCR	0
)	0
,	0
high	0
histologic	0
grade	0
(	0
G	0
)	0
,	0
extensive	0
intraductal	0
component	0
(	0
EIC	0
)	0
,	0
tumor	0
necrosis	0
,	0
macroscopic	0
multiplicity	0
,	0
estrogen	9
receptor	10
negativity	0
,	0
anatomic	0
tumor	0
size	0
,	0
age	0
younger	0
than	0
40	0
years	0
,	0
and	0
vascular	0
invasion	0
.	0

Only	0
MCR	0
,	0
G	0
,	0
and	0
EIC	0
proved	0
significant	0
in	0
Cox	0
multivariate	0
analysis	0
.	0

These	0
risk	0
factors	0
were	0
highly	0
age	0
dependent	0
,	0
with	0
EIC	0
markedly	0
more	0
prevalent	0
in	0
women	0
younger	0
than	0
50	0
,	0
MCR	0
and	0
G	0
in	0
women	0
younger	0
than	0
40	0
.	0

Separate	0
Cox	0
analysis	0
for	0
premenopausal	0
patients	0
showed	0
that	0
MCR/EIC	0
determined	0
risk	0
independent	0
of	0
resection	0
margins	0
:	0
tumors	0
with	0
MCR	0
had	0
a	0
28	0
%	0
,	0
and	0
with	0
EIC	0
a	0
22	0
%	0
probability	0
of	0
recurring	0
locally	0
by	0
5	0
years	0
.	0

Premenopausal	0
patients	0
with	0
neither	0
risk	0
factor	0
had	0
a	0
very	0
low	0
failure	0
rate	0
(	0
2.6	0
%	0
at	0
5	0
years	0
)	0
,	0
regardless	0
of	0
age	0
.	0

For	0
postmenopausal	0
patients	0
risk	0
of	0
breast	0
recurrence	0
was	0
determined	0
both	0
by	0
adequacy	0
of	0
resection	0
margins	0
and	0
grade	0
,	0
with	0
a	0
high	0
local	0
failure	0
rate	0
for	0
patients	0
having	0
G3	0
tumors	0
with	0
positive	0
or	0
indeterminate	0
margins	0
(	0
31	0
%	0
at	0
5	0
years	0
)	0
.	0

The	0
authors	0
conclude	0
that	0
the	0
microscopic	0
examination	0
is	0
the	0
only	0
useful	0
tool	0
for	0
assessing	0
the	0
risk	0
of	0
local	0
failure	0
,	0
which	0
is	0
quite	0
low	0
for	0
the	0
majority	0
of	0
patients	0
treated	0
with	0
breast	0
conservation	0
.	0

High-risk	0
patients	0
can	0
be	0
recognized	0
morphologically	0
.	0

The	0
age	0
dependence	0
of	0
morphologic	0
risk	0
factors	0
appears	0
to	0
explain	0
the	0
high	0
local	0
failure	0
rate	0
seen	0
in	0
patients	0
younger	0
than	0
40	0
.	0

Tax	9
-independent	0
binding	0
of	0
multiple	0
cellular	9
factors	10
to	0
Tax-response	1
element	2
DNA	2
of	0
HTLV-I	0
.	0

The	0
human	1
T-cell	2
leukemia	2
virus	2
type	2
I	2
(	2
HTLV-I	2
)	2
promoter	2
contains	0
three	0
copies	0
of	0
imperfect	0
repeats	0
of	0
a	0
21-base	0
pair	0
sequence	0
designated	0
here	0
as	0
TRE	1
(	0
Tax-response	1
element	2
)	0
that	0
is	0
responsive	0
to	0
the	0
virally	9
encoded	10
transactivator	10
protein	10
Tax	9
.	0

We	0
have	0
identified	0
and	0
separated	0
four	0
nuclear	9
proteins	10
from	0
C81-66-45	0
cells	0
,	0
an	0
HTLV-I	5
immortalized	6
Tax-expressing	6
human	6
T-lymphocyte	6
line	6
(	0
Salahuddin	0
et	0
al.	0
,	0
1983	0
)	0
,	0
that	0
interact	0
with	0
the	0
TRE-DNA	1
,	0
none	0
of	0
which	0
are	0
identical	0
with	0
the	0
Tax-protein	9
.	0

The	0
proteins	0
identified	0
have	0
molecular	0
weights	0
of	0
about	0
32	0
,	0
36	0
to	0
42	0
,	0
50	0
and	0
110	0
kD	0
.	0

Four	0
different	0
methods	0
were	0
used	0
to	0
identify	0
the	0
proteins	0
.	0

First	0
,	0
from	0
different	0
cell	0
lines	0
three	0
or	0
all	0
four	0
of	0
the	0
nuclear	9
proteins	10
were	0
specifically	0
cross-linked	0
by	0
UV	0
irradiation	0
to	0
the	0
radioactively	0
labeled	0
TRE-DNA	1
fragment	2
.	0

Second	0
,	0
TRE-DNA	9
binding	10
proteins	10
sedimented	0
through	0
a	0
glycerol	0
density	0
gradient	0
at	0
rates	0
corresponding	0
to	0
proteins	0
of	0
native	0
molecular	0
weights	0
of	0
35	0
to	0
50	0
kD	0
and	0
110	0
kD	0
.	0

Third	0
,	0
only	0
the	0
50	9
kD	10
protein	10
was	0
retained	0
on	0
a	0
biotinylated	0
DNA-streptavidin	0
matrix	0
when	0
the	0
DNA	0
fragment	0
contained	0
the	0
TRE-DNA	1
.	0

Fourth	0
,	0
extensive	0
purification	0
by	0
several	0
cycles	0
of	0
TRE	1
-DNA	0
affinity	0
chromatography	0
resulted	0
in	0
the	0
32	9
,	10
36	10
to	10
42	10
and	10
110	10
kD	10
proteins	10
and	0
to	0
less	0
extent	0
the	0
50	9
kD	10
factor	10
.	0

Two	0
abundant	0
proteins	0
of	0
75	0
and	0
80	0
kD	0
were	0
competed	0
out	0
by	0
poly	0
[	0
d	0
(	0
I-C	0
)	0
]	0
in	0
all	0
reactions	0
.	0

The	0
cAMP-response	1
element	2
CRE	1
,	0
TGACGTCA	0
,	0
present	0
in	0
the	0
21	1
base-pair	2
sequence	2
,	0
appears	0
to	0
be	0
essential	0
for	0
specific	0
protein-	0
TRE	1
-DNA	0
interactions	0
because	0
mutation	0
of	0
the	0
two	0
G	0
's	0
destroys	0
this	0
complex	0
.	0

This	0
result	0
suggests	0
that	0
the	0
cAMP	9
response	10
element	10
binding	10
protein	10
,	0
CREB	9
,	0
is	0
involved	0
in	0
the	0
protein-TRE-DNA	9
complex	10
and	0
in	0
mediating	0
the	0
Tax	9
response	0
.	0

Two	0
distinct	0
transcription	9
factors	10
that	0
bind	0
the	0
immunoglobulin	1
enhancer	2
microE5/kappa	1
2	2
motif	2
.	0

Activity	0
of	0
the	0
immunoglobulin	1
heavy	2
and	2
kappa	2
light	2
chain	2
gene	2
enhancers	2
depends	0
on	0
a	0
complex	0
interplay	0
of	0
ubiquitous	9
and	10
developmentally	10
regulated	10
proteins	10
.	0

Two	0
complementary	1
DNAs	2
were	0
isolated	0
that	0
encode	0
proteins	0
,	0
denoted	0
ITF-1	9
and	0
ITF-2	9
,	0
that	0
are	0
expressed	0
in	0
a	0
variety	0
of	0
cell	0
types	0
and	0
bind	0
the	0
microE5/kappa	1
2	2
motif	2
found	0
in	0
both	0
heavy	1
and	2
kappa	2
light	2
chain	2
enhancers	2
.	0

The	0
complementary	1
DNAs	2
are	0
the	0
products	0
of	0
distinct	0
genes	0
,	0
yet	0
both	0
ITF-1	9
and	0
ITF-2	9
are	0
structurally	0
and	0
functionally	0
similar	0
.	0

The	0
two	0
proteins	0
interact	0
with	0
one	0
another	0
through	0
their	0
putative	0
helix-loop-helix	9
motifs	10
and	0
each	0
possesses	0
a	0
distinct	0
domain	0
that	0
dictates	0
transcription	0
activation	0
.	0

Elevated	0
glucocorticoid	9
receptor	10
concentrations	0
before	0
and	0
after	0
glucocorticoid	0
therapy	0
in	0
peripheral	7
mononuclear	8
leukocytes	8
of	0
patients	0
with	0
atopic	0
dermatitis	0
.	0

The	0
number	0
and	0
affinity	0
of	0
glucocorticoid	0
binding	0
sites	0
in	0
peripheral	7
mononuclear	8
leukocytes	8
of	0
patients	0
with	0
atopic	0
dermatitis	0
(	0
AD	0
)	0
and	0
healthy	0
controls	0
were	0
determined	0
under	0
baseline	0
conditions	0
and	0
after	0
a	0
defined	0
oral	0
glucocorticoid	0
treatment	0
.	0

Patients	0
with	0
AD	0
(	0
n	0
=	0
15	0
)	0
exhibited	0
significantly	0
more	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
per	0
cell	0
than	0
the	0
control	0
group	0
(	0
n	0
=	0
22	0
)	0
,	0
while	0
the	0
GR	9
affinity	0
did	0
not	0
differ	0
.	0

Methylprednisolone	0
treatment	0
resulted	0
in	0
a	0
significant	0
reduction	0
of	0
the	0
GR	9
sites	0
per	0
cell	0
in	0
the	0
steroid-treated	0
control	0
group	0
(	0
n	0
=	0
10	0
)	0
in	0
contrast	0
to	0
the	0
patients	0
.	0

The	0
dissociation	0
constant	0
was	0
not	0
affected	0
by	0
methylprednisolone	0
treatment	0
in	0
either	0
group	0
.	0

In	0
view	0
of	0
the	0
therapeutic	0
efficiency	0
of	0
glucocorticoids	0
in	0
AD	0
and	0
findings	0
of	0
abnormal	0
cAMP	0
and	0
cAMP-phosphodiesterase	0
activity	0
,	0
the	0
elevated	0
GR	9
concentrations	0
in	0
AD	0
lend	0
support	0
to	0
the	0
hypothesis	0
of	0
a	0
compensatory	0
GR	9
upregulation	0
due	0
to	0
an	0
insufficient	0
action	0
of	0
endogenous	0
cortisol	0
or	0
to	0
altered	0
cAMP-induced	0
GR	9
expression	0
.	0

The	0
actions	0
of	0
cyclosporin	0
A	0
and	0
FK506	0
suggest	0
a	0
novel	0
step	0
in	0
the	0
activation	0
of	0
T	7
lymphocytes	8
.	0

Cyclosporin	0
A	0
and	0
FK506	0
are	0
immunosuppressive	0
compounds	0
that	0
have	0
similar	0
inhibitory	0
effects	0
on	0
the	0
expression	0
of	0
several	0
lymphokines	9
produced	0
by	0
T	7
lymphocytes	8
.	0

Despite	0
their	0
similar	0
effects	0
the	0
drugs	0
bind	0
to	0
two	0
different	0
cytosolic	9
protein	10
,	0
cyclophilin	9
and	0
FKBP	9
respectively	0
,	0
which	0
raises	0
the	0
possibility	0
that	0
they	0
have	0
different	0
modes	0
of	0
action	0
.	0

Using	0
constructs	0
in	0
which	0
mRNA	3
production	0
controlled	0
by	0
a	0
specific	0
transcription	9
factor	10
could	0
be	0
readily	0
measured	0
we	0
found	0
that	0
both	0
cyclosporin	0
A	0
and	0
FK506	0
completely	0
inhibited	0
transcription	0
activated	0
by	0
NF-AT	9
,	0
NFIL2	9
A	10
,	0
NFIL2	9
B	10
and	0
partially	0
inhibited	0
transcription	0
activated	0
by	0
NF	9
kappa	10
B	10
.	0

Cyclosporin	0
A	0
and	0
FK506	0
inhibited	0
only	0
transcriptional	0
activation	0
that	0
was	0
dependent	0
on	0
Ca2+	0
mobilization	0
.	0

However	0
,	0
cyclosporin	0
A	0
and	0
FK506	0
did	0
not	0
inhibit	0
Ca2+	0
mobilization	0
dependent	0
expression	0
of	0
c-fos	3
mRNA	4
indicating	0
that	0
only	0
a	0
subset	0
of	0
signalling	0
pathways	0
regulated	0
by	0
Ca2+	0
is	0
sensitive	0
to	0
these	0
drugs	0
.	0

Furthermore	0
,	0
we	0
did	0
not	0
observe	0
any	0
qualitative	0
differences	0
between	0
the	0
effect	0
of	0
cyclosporin	0
A	0
and	0
FK506	0
on	0
six	0
different	0
transcription	9
factors	10
which	0
suggests	0
that	0
these	0
drugs	0
may	0
interfere	0
with	0
the	0
activity	0
of	0
a	0
novel	0
Ca2+	0
dependent	0
step	0
that	0
regulates	0
several	0
transcription	9
factors	10
.	0

The	0
internal	0
methionine	0
codons	0
of	0
human	1
T-cell	2
leukemia	2
virus	2
type	2
II	2
rex	2
gene	2
are	0
not	0
required	0
for	0
p24rex	9
production	0
or	0
virus	0
replication	0
and	0
transformation	0
.	0

Human	0
T-cell	0
leukemia	0
virus	0
types	0
I	0
(	0
HTLV-I	0
)	0
and	0
II	0
(	0
HTLV-II	0
)	0
have	0
two	0
nonstructural	1
trans-acting	2
regulatory	2
genes	2
,	0
tax	1
and	0
rex	1
,	0
located	0
in	0
the	0
3	1
'	2
region	2
of	0
the	0
viral	1
genome	2
.	0

The	0
tax	9
gene	10
product	10
(	0
HTLV-I	9
p40tax	10
and	0
HTLV-II	9
p37tax	10
)	0
is	0
the	0
transcriptional	0
activator	0
of	0
the	0
viral	1
long	2
terminal	2
repeat	2
.	0

The	0
rex	1
gene	2
encodes	0
two	0
protein	0
products	0
,	0
p27rex/p21rex	9
and	0
p26rex/p24rex	9
in	0
HTLV-I	0
and	0
HTLV-II	0
,	0
respectively	0
.	0

Rex	9
acts	0
posttranscriptionally	0
to	0
facilitate	0
accumulation	0
of	0
full-length	0
gag/pol	9
and	0
singly	0
spliced	0
env	3
mRNA	4
in	0
the	0
cytoplasm	0
of	0
HTLV-infected	7
cells	8
.	0

Previous	0
studies	0
showed	0
that	0
the	0
first	0
ATG	0
of	0
the	0
rex	1
gene	2
is	0
critical	0
for	0
Rex	9
production	0
and	0
function	0
.	0

The	0
importance	0
of	0
the	0
internal	0
ATGs	0
to	0
Rex	9
function	0
is	0
not	0
known	0
.	0

However	0
,	0
in	0
vitro	0
mutagenesis	0
of	0
the	0
HTLV-I	0
rex	1
gene	2
has	0
provided	0
indirect	0
evidence	0
which	0
suggests	0
that	0
p21rex	9
,	0
and	0
by	0
analogy	0
HTLV-II	0
p24rex	9
,	0
results	0
from	0
initiation	0
at	0
an	0
internal	0
AUG	0
of	0
the	0
tax/rex	3
mRNA	4
.	0

By	0
using	0
an	0
infectious	0
molecular	0
clone	0
of	0
HTLV-II	0
,	0
we	0
investigated	0
the	0
importance	0
of	0
the	0
internal	0
ATGs	0
of	0
the	0
rex	1
gene	2
on	0
Rex	9
protein	0
production	0
and	0
function	0
.	0

Our	0
results	0
indicate	0
that	0
p24rex	9
of	0
HTLV-II	0
is	0
not	0
initiated	0
at	0
an	0
internal	0
AUG	0
and	0
that	0
the	0
internal	0
methionine	0
codons	0
are	0
not	0
crucial	0
to	0
the	0
function	0
of	0
the	0
rex	1
gene	2
and	0
,	0
ultimately	0
,	0
the	0
transforming	0
properties	0
of	0
the	0
virus	0
.	0

Astrocytes	7
and	0
glioblastoma	7
cells	8
express	0
novel	0
octamer-DNA	9
binding	10
proteins	10
distinct	0
from	0
the	0
ubiquitous	9
Oct-1	10
and	10
B	10
cell	10
type	10
Oct-2	10
proteins	10
.	0

The	0
'octamer	1
'	2
sequence	2
,	0
ATGCAAAT	0
or	0
its	0
complement	0
ATTTGCAT	0
,	0
is	0
a	0
key	0
element	0
for	0
the	0
transcriptional	0
regulation	0
of	0
immunoglobulin	1
genes	2
in	0
B-lymphocytes	7
as	0
well	0
as	0
a	0
number	0
of	0
housekeeping	1
genes	2
in	0
all	0
cell	0
types	0
.	0

In	0
lymphocytes	7
,	0
the	0
octamer-binding	9
protein	10
Oct-2A	9
and	0
variants	0
thereof	0
are	0
thought	0
to	0
contribute	0
to	0
the	0
B-cell	1
specific	2
gene	2
expression	0
,	0
while	0
the	0
ubiquitous	0
protein	0
Oct-1	0
seems	0
to	0
control	0
general	0
octamer	1
site	2
-dependent	0
transcription	0
.	0

Various	0
other	0
genes	0
,	0
for	0
example	0
interleukin-1	1
and	2
MHC	2
class	2
II	2
genes	2
,	0
contain	0
an	0
octamer	1
sequence	2
in	0
the	0
promoter	1
and	0
are	0
expressed	0
in	0
cells	0
of	0
both	0
the	0
immune	0
and	0
nervous	0
systems	0
.	0

This	0
prompted	0
us	0
to	0
analyze	0
the	0
octamer-binding	9
proteins	10
in	0
the	0
latter	0
cells	0
.	0

Using	0
the	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
at	0
least	0
six	0
novel	0
octamer	9
binding	10
proteins	10
were	0
detected	0
in	0
nuclear	0
extracts	0
of	0
cultured	7
mouse	8
astrocytes	8
.	0

These	0
proteins	0
are	0
differentially	0
expressed	0
in	0
human	5
glioblastoma	6
and	6
neuroblastoma	6
cell	6
lines	6
.	0

The	0
nervous	9
system-derived	10
(	10
N-Oct	10
)	10
proteins	10
bound	0
to	0
the	0
octamer	1
DNA	2
sequence	2
in	0
a	0
manner	0
which	0
is	0
indistinguishable	0
from	0
the	0
Oct-1	9
and	0
Oct-2A	9
proteins	10
.	0

The	0
relationship	0
of	0
the	0
N-Oct	9
proteins	10
to	0
Oct-1	9
and	0
Oct-2A	9
was	0
analyzed	0
by	0
proteolytic	0
clipping	0
bandshift	0
assays	0
and	0
by	0
their	0
reactivity	0
towards	0
antisera	0
raised	0
against	0
recombinant	0
Oct-1	9
and	0
Oct-2A	9
proteins	0
.	0

On	0
the	0
basis	0
of	0
these	0
assays	0
,	0
all	0
N-Oct-factors	9
were	0
found	0
to	0
be	0
distinct	0
from	0
the	0
ubiquitous	9
Oct-1	10
and	0
the	0
lymphoid-specific	9
Oct-2A	10
proteins	0
.	0

In	0
melanoma	7
cells	8
that	0
contain	0
the	0
N-Oct-3	9
factor	10
,	0
a	0
transfected	0
lymphocyte-specific	0
promoter	0
was	0
neither	0
activated	0
nor	0
was	0
it	0
repressed	0
upon	0
contransfection	0
with	0
an	0
Oct-2A	1
expression	2
vector	2
.	0

We	0
therefore	0
speculate	0
that	0
N-Oct-3	9
and	0
other	0
N-Oct	9
factors	10
have	0
a	0
specific	0
role	0
in	0
gene	0
expression	0
in	0
cells	0
of	0
the	0
nervous	0
system	0
.	0

Detection	0
in	0
non-erythroid	7
cells	8
of	0
a	0
factor	0
with	0
the	0
binding	0
characteristics	0
of	0
the	0
erythroid	9
cell	10
transcription	10
factor	10
EF1	9
.	0

The	0
erythroid	9
transcription	10
factor	10
erythroid	9
factor-1	10
(	0
EF1	9
)	0
plays	0
a	0
critical	0
role	0
in	0
the	0
transcription	0
of	0
erythroid-specific	1
genes	2
.	0

Here	0
we	0
report	0
the	0
presence	0
of	0
a	0
factor	0
with	0
the	0
mobility	0
and	0
sequence-specific	0
DNA-binding	0
characteristics	0
of	0
EF1	9
at	0
low	0
abundance	0
in	0
a	0
wide	0
variety	0
of	0
non-erythroid	7
cell	8
types	8
.	0

This	0
is	0
the	0
first	0
report	0
of	0
an	0
EF1	9
-like	0
activity	0
in	0
non-erythroid	7
cells	8
and	0
indicates	0
that	0
this	0
factor	0
may	0
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
genes	1
expressed	0
in	0
such	0
cells	0
.	0

Protein	0
kinase	0
inhibitor	0
H-7	0
blocks	0
accumulation	0
of	0
unspliced	3
mRNA	4
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
.	0

Rex	9
,	0
the	0
post-transcriptional	9
regulator	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
,	0
is	0
known	0
to	0
induce	0
accumulation	0
of	0
the	0
unspliced	3
viral	4
gag-pol	4
mRNA	4
.	0

Rex	9
is	0
a	0
phosphoprotein	9
found	0
in	0
the	0
cell	0
nucleolus	0
,	0
whose	0
function	0
may	0
be	0
regulated	0
by	0
its	0
localization	0
and	0
phosphorylation	0
.	0

We	0
have	0
examined	0
the	0
role	0
of	0
phosphorylation	0
on	0
Rex	9
function	0
by	0
using	0
a	0
protein	0
kinase	0
inhibitor	0
,	0
H-7	0
[	0
1-	0
(	0
5-isoquinolinyl-sulfonyl	0
)	0
-2-methylpiperazine	0
]	0
.	0

Treatment	0
of	0
an	0
HTLV-I	5
infected	6
human	6
T-cell	6
line	6
with	0
H-7	0
blocked	0
specifically	0
accumulation	0
of	0
the	0
unspliced	3
gag-pol	4
mRNA	4
,	0
resulting	0
in	0
the	0
decreased	0
Gag	9
protein	10
synthesis	0
that	0
corresponds	0
with	0
the	0
decreased	0
in	0
vivo	0
phosphorylation	0
of	0
Rex	9
.	0

In	0
contrast	0
,	0
other	0
viral	0
and	0
cellular	0
products	0
have	0
not	0
been	0
influenced	0
by	0
the	0
level	0
of	0
H-7	0
used	0
.	0

Therefore	0
,	0
the	0
phosphorylation	0
of	0
Rex	9
is	0
required	0
for	0
the	0
viral	0
RNA	0
partition	0
of	0
HTLV-I	0
.	0

Increased	0
glucocorticoid	0
responsiveness	0
of	0
CD4+	5
T-cell	6
clonal	6
lines	6
grown	0
in	0
serum-free	0
media	0
.	0

CEM-C7	5
,	0
a	0
human	5
leukemic	6
CD4+	6
T-lymphocyte	6
cell	6
line	6
and	0
three	0
of	0
its	0
subclones	0
,	0
CEM-4R4	5
,	0
CEM-3R43	5
,	0
and	0
ICR-27	5
,	0
previously	0
cultured	0
in	0
a	0
medium	0
supplemented	0
with	0
5	0
to	0
10	0
%	0
fetal	0
bovine	0
serum	0
,	0
have	0
been	0
adapted	0
to	0
serum-free	0
media	0
.	0

The	0
best	0
medium	0
of	0
those	0
tested	0
was	0
RPMI	0
1640	0
supplemented	0
with	0
5	0
micrograms/ml	0
each	0
transferrin	9
and	0
insulin	9
+	0
5	0
ng/ml	0
sodium	0
selenite	0
+/-	0
0.1	0
%	0
bovine	9
serum	10
albumin	10
.	0

While	0
growing	0
either	0
with	0
or	0
without	0
albumin	0
,	0
the	0
several	0
clonal	5
lines	6
of	0
CEM	5
cells	0
displayed	0
growth	0
similar	0
to	0
serum-supplemented	0
cultures	0
.	0

Cell	0
proliferation	0
of	0
CEM-C7	5
cells	0
cultured	0
in	0
both	0
serum-free	0
media	0
has	0
been	0
sustained	0
for	0
3	0
mo	0
.	0

with	0
culture	0
doubling	0
times	0
of	0
about	0
25	0
h	0
for	0
both	0
serum-supplemented	5
and	6
serum-free	6
cultures	6
(	0
viability	0
greater	0
than	0
or	0
equal	0
to	0
90	0
%	0
)	0
.	0

Cell	0
morphology	0
remained	0
essentially	0
the	0
same	0
in	0
serum-free	0
or	0
serum	0
containing	0
media	0
.	0

The	0
expression	0
of	0
CD4	9
,	0
a	0
marker	0
for	0
T-derived	7
lymphoid	8
cells	8
,	0
was	0
not	0
significantly	0
different	0
in	0
serum-free	0
medium	0
.	0

When	0
grown	0
in	0
serum-free	0
medium	0
,	0
CEM-C7	5
cells	0
exhibited	0
increased	0
steroid	0
responsiveness	0
as	0
evidenced	0
by	0
increased	0
glucocorticoid	9
receptor	10
binding	0
sites	0
,	0
increased	0
induction	0
of	0
glutamine	9
synthetase	10
,	0
and	0
cell	0
lysis	0
at	0
lower	0
concentrations	0
of	0
steroid	0
.	0

Receptor	0
mutant	0
subclones	0
of	0
CEM-C7	5
,	0
which	0
are	0
proven	0
to	0
be	0
completely	0
unresponsive	0
to	0
micromolar	0
concentrations	0
of	0
dexamethasone	0
when	0
grown	0
in	0
serum-supplemented	0
medium	0
,	0
become	0
partially	0
sensitive	0
to	0
the	0
hormone	0
after	0
growth	0
in	0
defined	0
medium	0
.	0

The	0
increased	0
sensitivity	0
of	0
CEM-C7	5
cells	6
and	0
its	0
subclones	0
to	0
dexamethasone	0
in	0
serum-free	0
medium	0
returned	0
to	0
previous	0
levels	0
when	0
these	0
cells	0
were	0
recultured	0
in	0
serum-containing	0
medium	0
.	0

Our	0
results	0
suggest	0
that	0
substances	0
in	0
serum	0
influence	0
steroid	0
effects	0
on	0
these	0
cells	0
and	0
that	0
the	0
molecular	0
details	0
of	0
glucocorticoid	0
hormone	0
action	0
may	0
be	0
pursued	0
more	0
precisely	0
in	0
a	0
clearly	0
defined	0
culture	0
medium	0
.	0

[	0
Glucocorticoid	9
receptors	10
on	0
human	7
peripheral	8
mononuclear	8
and	8
polymorphonuclear	8
leucocytes	8
:	0
changes	0
in	0
patients	0
with	0
yang-deficiency	0
]	0

It	0
was	0
found	0
that	0
,	0
in	0
former	0
works	0
,	0
the	0
glucocorticoid	9
receptors	10
(	0
GCR	9
)	0
on	0
peripheral	7
mixed	8
leucocytes	8
in	0
patients	0
with	0
Yang-deficiency	0
were	0
decreased	0
.	0

In	0
this	0
work	0
,	0
the	0
mixed	7
leucocytes	8
were	0
further	0
separated	0
into	0
mononuclear	7
(	8
MNL	8
)	8
and	8
polymorphonuclear	8
(	8
PML	8
)	8
leucocytes	8
,	0
and	0
GCR	9
were	0
determined	0
in	0
each	0
part	0
of	0
leucocytes	7
.	0

GCR	9
on	0
MNL	7
and	0
PML	7
in	0
6	0
Yang	0
deficient	0
patients	0
were	0
3473	0
+/-	0
413	0
and	0
4433	0
+/-	0
651	0
sites/cell	0
respectively	0
,	0
statistically	0
significant	0
from	0
the	0
normal	0
control	0
group	0
(	0
4462	0
+/-	0
962	0
and	0
5622	0
+/-	0
782	0
sites/cell	0
respectively	0
,	0
P	0
less	0
than	0
0.05	0
)	0
.	0

GCR	9
on	0
MNL	7
,	0
PML	7
and	0
mixed	7
leucocytes	8
in	0
5	0
patients	0
were	0
determined	0
simultaneously	0
,	0
and	0
all	0
lowered	0
from	0
the	0
control	0
group	0
.	0

The	0
results	0
were	0
3369	0
+/-	0
370	0
,	0
4986	0
+/-	0
419	0
and	0
4524	0
+/-	0
852	0
sites/cell	0
respectively	0
,	0
with	0
the	0
lowest	0
GCR	9
on	0
MNL	7
and	0
highest	0
on	0
PML	7
.	0

The	0
ubiquitous	9
octamer-binding	10
protein	10
(	0
s	0
)	0
is	0
sufficient	0
for	0
transcription	0
of	0
immunoglobulin	1
genes	2
.	0

All	0
immunoglobulin	1
genes	2
contain	0
a	0
conserved	0
octanucleotide	1
promoter	2
element	2
,	0
ATGCAAAT	0
,	0
which	0
has	0
been	0
shown	0
to	0
be	0
required	0
for	0
their	0
normal	0
B-cell-specific	0
transcription	0
.	0

Proteins	0
that	0
bind	0
this	0
octamer	0
have	0
been	0
purified	0
,	0
and	0
cDNAs	1
encoding	0
octamer-binding	9
proteins	10
have	0
been	0
cloned	0
.	0

Some	0
of	0
these	0
proteins	0
(	0
referred	0
to	0
as	0
OTF-2	9
)	0
are	0
lymphoid	0
specific	0
,	0
whereas	0
at	0
least	0
one	0
other	0
,	0
and	0
possibly	0
more	0
(	0
referred	0
to	0
as	0
OTF-1	9
)	0
,	0
is	0
found	0
ubiquitously	0
in	0
all	0
cell	0
types	0
.	0

The	0
exact	0
role	0
of	0
these	0
different	0
proteins	0
in	0
directing	0
the	0
tissue-specific	0
expression	0
of	0
immunoglobulin	1
genes	2
is	0
unclear	0
.	0

We	0
have	0
identified	0
two	0
human	5
pre-B-cell	6
lines	6
that	0
contain	0
extremely	0
low	0
levels	0
of	0
OTF-2	9
yet	0
still	0
express	0
high	0
levels	0
of	0
steady-state	3
immunoglobulin	4
heavy-chain	4
mRNA	4
in	0
vivo	0
and	0
efficiently	0
transcribe	0
an	0
immunoglobulin	1
gene	2
in	0
vitro	0
.	0

Addition	0
of	0
a	0
highly	0
enriched	0
preparation	0
of	0
OTF-1	9
made	0
from	0
one	0
of	0
these	0
pre-B	5
cells	6
or	0
from	0
HeLa	5
cells	6
specifically	0
stimulated	0
in	0
vitro	0
transcription	0
of	0
an	0
immunoglobulin	1
gene	2
.	0

Furthermore	0
,	0
OFT-1	0
appeared	0
to	0
have	0
approximately	0
the	0
same	0
transactivation	0
ability	0
as	0
OTF-2	9
when	0
normalized	0
for	0
binding	0
activity	0
.	0

These	0
results	0
suggest	0
that	0
OTF-1	9
,	0
without	0
OTF-2	9
,	0
is	0
sufficient	0
for	0
transcription	0
of	0
immunoglobulin	1
genes	2
and	0
that	0
OTF-2	9
alone	0
is	0
not	0
responsible	0
for	0
the	0
B-cell-specific	0
regulation	0
of	0
immunoglobulin	1
gene	2
expression	0
.	0

Effects	0
of	0
aldosterone	0
on	0
intralymphocytic	0
sodium	0
and	0
potassium	0
in	0
patients	0
with	0
essential	0
hypertension	0
.	0

In	0
vitro	0
binding	0
of	0
aldosterone	0
to	0
mineralocorticoid	9
receptors	10
on	0
human	7
mononuclear	8
leukocytes	8
(	0
HML	7
)	0
and	0
its	0
effects	0
on	0
the	0
intracellular	0
sodium	0
and	0
potassium	0
concentrations	0
of	0
HML	7
have	0
already	0
been	0
described	0
.	0

In	0
the	0
present	0
paper	0
this	0
easily	0
accessible	0
human	0
cell	0
model	0
was	0
investigated	0
in	0
13	0
patients	0
with	0
essential	0
hypertension	0
.	0

In	0
only	0
four	0
patients	0
sodium	0
in	0
HML	7
without	0
incubation	0
was	0
elevated	0
compared	0
with	0
the	0
range	0
for	0
normal	0
persons	0
.	0

A	0
decrease	0
of	0
intracellular	0
sodium	0
or	0
potassium	0
occurred	0
during	0
incubation	0
without	0
aldosterone	0
(	0
P	0
less	0
than	0
0.02	0
)	0
.	0

The	0
addition	0
of	0
1.4	0
nM	0
aldosterone	0
did	0
not	0
prevent	0
this	0
loss	0
of	0
electrolytes	0
as	0
observed	0
in	0
normal	0
persons	0
.	0

Plasma	9
renin	10
activity	0
and	0
aldosterone	0
were	0
not	0
correlated	0
with	0
the	0
electrolyte	0
response	0
and	0
were	0
within	0
the	0
normal	0
limits	0
.	0

The	0
number	0
of	0
mineralocorticoid	9
receptors	10
/cell	0
were	0
within	0
or	0
close	0
to	0
the	0
normal	0
range	0
(	0
n	0
=	0
9	0
)	0
.	0

The	0
independence	0
of	0
intracellular	0
electrolytes	0
from	0
aldosterone	0
despite	0
a	0
normal	0
number	0
of	0
mineralocorticoid	9
receptors	10
may	0
reflect	0
an	0
impairment	0
of	0
the	0
mineralocorticoid	0
effector	0
mechanism	0
in	0
the	0
HML	7
of	0
patients	0
with	0
essential	0
hypertension	0
.	0

[	0
Differential	0
diagnostic	0
value	0
of	0
receptors	0
of	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
calcitriol	0
)	0
determination	0
in	0
lymphocytes	7
of	0
children	0
with	0
rickets	0
and	0
rickets-like	0
diseases	0
]	0

The	0
authors	0
provide	0
the	0
results	0
of	0
studying	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
calcitriol	0
)	0
in	0
lymphocytes	7
of	0
children	0
with	0
rickets	0
and	0
rickets-like	0
diseases	0
.	0

It	0
is	0
proposed	0
that	0
the	0
character	0
of	0
their	0
expression	0
under	0
the	0
influence	0
of	0
vitamin	0
D	0
may	0
be	0
used	0
with	0
differential	0
diagnostic	0
purposes	0
in	0
view	0
.	0

Regulation	0
of	0
gene	0
expression	0
with	0
double-stranded	0
phosphorothioate	0
oligonucleotides	0
.	0

Alteration	0
of	0
gene	0
transcription	0
by	0
inhibition	0
of	0
specific	0
transcriptional	9
regulatory	10
proteins	10
is	0
necessary	0
for	0
determining	0
how	0
these	0
factors	0
participate	0
in	0
cellular	0
differentiation	0
.	0

The	0
functions	0
of	0
these	0
proteins	0
can	0
be	0
antagonized	0
by	0
several	0
methods	0
,	0
each	0
with	0
specific	0
limitations	0
.	0

Inhibition	0
of	0
sequence-specific	9
DNA-binding	10
proteins	10
was	0
achieved	0
with	0
double-stranded	0
(	0
ds	0
)	0
phosphorothioate	0
oligonucleotides	0
that	0
contained	0
octamer	1
or	2
kappa	2
B	2
consensus	2
sequences	2
.	0

The	0
phosphorothioate	0
oligonucleotides	0
specifically	0
bound	0
either	0
octamer	9
transcription	10
factor	10
or	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
.	0

The	0
modified	0
oligonucleotides	0
accumulated	0
in	0
cells	0
more	0
effectively	0
than	0
standard	0
ds	0
oligonucleotides	0
and	0
modulated	0
gene	0
expression	0
in	0
a	0
specific	0
manner	0
.	0

Octamer-dependent	0
activation	0
of	0
a	0
reporter	1
plasmid	2
or	0
NF-kappa	9
B	10
-dependent	0
activation	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
enhancer	2
was	0
inhibited	0
when	0
the	0
appropriate	0
phosphorothioate	0
oligonucleotide	0
was	0
added	0
to	0
a	0
transiently	5
transfected	6
B	6
cell	6
line	6
.	0

Addition	0
of	0
phosphorothioate	0
oligonucleotides	0
that	0
contained	0
the	0
octamer	1
consensus	2
to	0
Jurkat	5
T	6
leukemia	6
cells	6
inhibited	0
interleukin-2	9
(	0
IL-2	9
)	0
secretion	0
to	0
a	0
degree	0
similar	0
to	0
that	0
observed	0
with	0
a	0
mutated	1
octamer	2
site	2
in	0
the	0
IL-2	1
enhancer	2
.	0

The	0
ds	0
phosphorothioate	0
oligonucleotides	0
probably	0
compete	0
for	0
binding	0
of	0
specific	0
transcription	0
factors	0
and	0
may	0
provide	0
anti-viral	0
,	0
immunosuppressive	0
,	0
or	0
other	0
therapeutic	0
effects	0
.	0

[	0
Effect	0
of	0
the	0
regimen	0
of	0
kidney-tonifying	0
and	0
qi-invigorating	0
on	0
aging	0
changes	0
of	0
glucocorticoid	9
receptor	10
]	0

The	0
plasma	0
cortisol	0
concentration	0
and	0
the	0
sites	0
of	0
glucocorticoid	9
receptor	10
(	0
GCR	9
)	0
in	0
the	0
peripheral	7
lymphocytes	8
were	0
measured	0
in	0
32	0
healthy	0
aged	0
persons	0
and	0
13	0
young	0
adults	0
.	0

In	0
animal	0
experiment	0
,	0
GCR	9
of	0
spleen	7
lymphocytic	8
cell	8
was	0
also	0
measured	0
in	0
18	0
aged	0
rats	0
and	0
9	0
young	0
rats	0
.	0

The	0
results	0
showed	0
that	0
GCR	9
was	0
significantly	0
lower	0
in	0
the	0
aged	0
persons	0
or	0
rats	0
than	0
that	0
in	0
the	0
young	0
while	0
the	0
plasma	0
cortisol	0
level	0
did	0
n't	0
change	0
with	0
aging	0
.	0

So	0
we	0
think	0
that	0
GCR	9
is	0
more	0
sensitive	0
than	0
the	0
plasma	0
cortisol	0
level	0
to	0
reflect	0
the	0
aging	0
change	0
of	0
the	0
adrenal	0
cortex	0
function	0
.	0

After	0
the	0
treatment	0
with	0
the	0
regimen	0
of	0
Kidney-tonifying	0
and	0
Qi-invigorating	0
,	0
the	0
GCR	9
of	0
the	0
aged	0
persons	0
and	0
rats	0
was	0
enhanced	0
,	0
and	0
in	0
this	0
way	0
,	0
the	0
function	0
of	0
the	0
aged	0
adrenal	0
cortex	0
was	0
improved	0
.	0

Interferon	0
affects	0
nuclear	9
proteins	10
in	0
cells	0
of	0
clinically	0
sensitive	0
chronic	0
myelogenous	0
leukemia	0
patients	0
.	0

Cytoplasmic	0
protein	0
extracts	0
from	0
chronic	7
myelogenous	8
leukemia	8
(	8
CML	8
)	8
cells	8
contained	0
an	0
activity	0
that	0
altered	0
the	0
electrophoretic	0
mobility	0
of	0
complexes	0
formed	0
between	0
nuclear	9
proteins	10
and	0
the	0
transcriptional	0
enhancers	0
of	0
interferon	0
(	0
IFN	0
)	0
-inducible	0
genes	0
.	0

Exposure	0
of	0
CML	7
cells	8
to	0
IFN-alpha	9
diminished	0
the	0
effect	0
of	0
the	0
CML	9
cytoplasmic	10
proteins	10
on	0
these	0
nuclear	9
protein-DNA	10
complexes	10
.	0

The	0
presence	0
of	0
clinical	0
responsiveness	0
to	0
IFN-alpha	9
correlated	0
with	0
the	0
sensitivity	0
to	0
the	0
IFN	9
-induced	0
change	0
in	0
the	0
electrophoretic	0
mobility	0
of	0
nuclear	9
protein-DNA	10
complexes	10
.	0

These	0
data	0
suggest	0
that	0
the	0
action	0
of	0
IFN-alpha	9
in	0
CML	0
may	0
be	0
linked	0
to	0
a	0
pathway	0
that	0
can	0
result	0
in	0
posttranslational	0
modification	0
of	0
nuclear	9
proteins	10
.	0

Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
transactivates	0
latent	9
membrane	10
protein	10
LMP1	9
.	0

Several	0
lines	0
of	0
evidence	0
are	0
compatible	0
with	0
the	0
hypothesis	0
that	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
nuclear	10
antigen	10
2	10
(	0
EBNA-2	9
)	0
or	0
leader	9
protein	10
(	0
EBNA-LP	9
)	0
affects	0
expression	0
of	0
the	0
EBV	9
latent	10
infection	10
membrane	10
protein	10
LMP1	9
.	0

We	0
now	0
demonstrate	0
the	0
following	0
.	0

(	0
i	0
)	0
Acute	0
transfection	0
and	0
expression	0
of	0
EBNA-2	9
under	0
control	0
of	0
simian	1
virus	2
40	2
or	2
Moloney	2
murine	2
leukemia	2
virus	2
promoters	2
resulted	0
in	0
increased	0
LMP1	9
expression	0
in	0
P3HR-1-infected	5
Burkitt	6
's	6
lymphoma	6
cells	6
and	0
the	0
P3HR-1	5
or	0
Daudi	5
cell	6
line	6
.	0

(	0
ii	0
)	0
Transfection	0
and	0
expression	0
of	0
EBNA-LP	9
alone	0
had	0
no	0
effect	0
on	0
LMP1	9
expression	0
and	0
did	0
not	0
act	0
synergistically	0
with	0
EBNA-2	9
to	0
affect	0
LMP1	9
expression	0
.	0

(	0
iii	0
)	0
LMP1	9
expression	0
in	0
Daudi	5
and	0
P3HR-1-infected	5
cells	6
was	0
controlled	0
at	0
the	0
mRNA	3
level	0
,	0
and	0
EBNA-2	9
expression	0
in	0
Daudi	5
cells	6
increased	0
LMP1	3
mRNA	4
.	0

(	0
iv	0
)	0
No	0
other	0
EBV	1
genes	2
were	0
required	0
for	0
EBNA-2	9
transactivation	0
of	0
LMP1	9
since	0
cotransfection	0
of	0
recombinant	1
EBNA-2	2
expression	2
vectors	2
and	0
genomic	0
LMP1	1
DNA	2
fragments	2
enhanced	0
LMP1	9
expression	0
in	0
the	0
EBV-negative	5
B-lymphoma	6
cell	6
lines	6
BJAB	5
,	0
Louckes	5
,	0
and	0
BL30	5
.	0

(	0
v	0
)	0
An	0
EBNA-2-responsive	1
element	2
was	0
found	0
within	0
the	0
-512	1
to	2
+40	2
LMP1	2
DNA	2
since	0
this	0
DNA	0
linked	0
to	0
a	0
chloramphenicol	1
acetyltransferase	2
reporter	2
gene	2
was	0
transactivated	0
by	0
cotransfection	0
with	0
an	0
EBNA-2	1
expression	2
vector	2
.	0

(	0
vi	0
)	0
The	0
EBV	0
type	0
2	0
EBNA-2	9
transactivated	0
LMP1	9
as	0
well	0
as	0
the	0
EBV	9
type	10
1	10
EBNA-2	10
.	0

(	0
vii	0
)	0
Two	0
deletions	0
within	0
the	0
EBNA-2	9
gene	0
which	0
rendered	0
EBV	0
transformation	0
incompetent	0
did	0
not	0
transactivate	0
LMP1	9
,	0
whereas	0
a	0
transformation-competent	1
EBNA-2	2
deletion	2
mutant	2
did	0
transactivate	0
LMP1	9
.	0

LMP1	9
is	0
a	0
potent	0
effector	0
of	0
B-lymphocyte	0
activation	0
and	0
can	0
act	0
synergistically	0
with	0
EBNA-2	9
to	0
induce	0
cellular	0
CD23	0
gene	0
expression	0
.	0

Thus	0
,	0
EBNA-2	9
transactivation	0
of	0
LMP1	9
amplifies	0
the	0
biological	0
impact	0
of	0
EBNA-2	9
and	0
underscores	0
its	0
central	0
role	0
in	0
EBV-induced	0
growth	0
transformation	0
.	0

The	0
expression	0
of	0
c-fos	1
,	0
c-jun	1
,	0
and	0
c-myc	1
genes	2
is	0
regulated	0
by	0
heat	0
shock	0
in	0
human	7
lymphoid	8
cells	8
.	0

The	0
effect	0
of	0
heat	0
shock	0
on	0
the	0
expression	0
of	0
the	0
nuclear	1
protooncogenes	2
c-fos	1
,	0
c-jun	1
,	0
and	0
c-myc	1
was	0
studied	0
in	0
human	7
lymphoid	8
cells	8
.	0

Heat	0
shock	0
caused	0
an	0
increase	0
in	0
c-fos	0
and	0
c-jun	0
mRNA	0
levels	0
and	0
a	0
decrease	0
in	0
c-myc	3
mRNA	4
levels	0
in	0
pre-B	5
(	6
Hyon	6
)	6
and	6
T	6
(	6
DND-41	6
)	6
cell	6
lines	6
as	0
well	0
as	0
in	0
freshly	0
isolated	0
normal	0
human	0
thymocytes	0
.	0

The	0
changes	0
in	0
the	0
mRNA	0
levels	0
of	0
these	0
protooncogenes	1
in	0
Hyon	5
cells	6
were	0
most	0
pronounced	0
at	0
42	0
and	0
43	0
degrees	0
C	0
;	0
kinetic	0
analysis	0
demonstrated	0
that	0
the	0
changes	0
could	0
be	0
detected	0
within	0
30	0
min	0
of	0
heat	0
shock	0
.	0

Altered	0
transcription	0
of	0
c-fos	1
and	0
c-myc	1
genes	2
was	0
the	0
primary	0
effect	0
of	0
heat	0
shock	0
.	0

Secondarily	0
,	0
heat	0
shock	0
of	0
Hyon	5
cells	6
stabilized	0
the	0
c-myc	3
mRNA	4
level	0
by	0
increasing	0
its	0
half-life	0
from	0
24	0
to	0
45	0
min	0
.	0

The	0
overall	0
effect	0
of	0
heat	0
shock	0
on	0
c-myc	3
mRNA	4
level	0
,	0
however	0
,	0
was	0
a	0
marked	0
inhibition	0
of	0
its	0
transcription	0
.	0

These	0
results	0
demonstrate	0
that	0
the	0
transcription	0
of	0
nuclear	1
protooncogenes	2
is	0
regulated	0
by	0
heat	0
shock	0
indicating	0
a	0
role	0
for	0
nuclear	1
protooncogenes	2
in	0
the	0
stress	0
response	0
of	0
lymphoid	7
cells	8
.	0

Mapping	0
of	0
B-cell	9
epitopes	10
of	0
the	0
human	9
hepatitis	10
B	10
virus	10
X	10
protein	10
.	0

The	0
immune	0
response	0
to	0
the	0
X	9
protein	10
of	0
human	0
hepatitis	0
B	0
virus	0
(	0
HBV	0
)	0
was	0
studied	0
by	0
epitope	0
mapping	0
by	0
using	0
a	0
set	0
of	0
MS2-HBx	9
fusion	10
proteins	10
and	0
synthetic	0
peptides	0
.	0

Antibodies	0
in	0
sera	0
of	0
patients	0
with	0
acute	0
and	0
chronic	0
HBV	0
infection	0
showed	0
a	0
multispecific	0
immune	0
response	0
.	0

Each	0
serum	0
contained	0
antibodies	9
to	0
a	0
different	0
set	0
of	0
epitopes	9
,	0
which	0
taken	0
together	0
cover	0
most	0
of	0
the	0
HBx	9
sequence	10
.	0

Some	0
of	0
the	0
epitopes	0
were	0
detectable	0
only	0
by	0
immunoblotting	0
with	0
fusion	9
proteins	10
;	0
others	0
were	0
detectable	0
only	0
by	0
an	0
enzyme-linked	0
immunosorbent	0
assay	0
(	0
ELISA	0
)	0
with	0
synthetic	0
peptides	0
.	0

The	0
carboxy-terminal	9
half	10
of	0
the	0
HBx	9
protein	10
was	0
preferentially	0
recognized	0
by	0
antibodies	9
from	0
patients	0
with	0
chronic	0
hepatitis	0
and	0
contained	0
a	0
short	0
immunodominant	9
antigenic	10
region	10
with	0
at	0
least	0
two	0
major	0
nonoverlapping	9
epitopes	10
.	0

Anti-	0
HBx	9
antibody	0
titers	0
as	0
revealed	0
by	0
peptide	0
ELISAs	0
were	0
highest	0
and	0
most	0
frequent	0
in	0
patients	0
with	0
chronic	0
hepatitis	0
and	0
usually	0
low	0
in	0
acutely	0
infected	0
patients	0
and	0
asymptomatic	0
carriers	0
.	0

The	0
data	0
demonstrate	0
a	0
remarkable	0
qualitative	0
and	0
quantitative	0
heterogeneity	0
of	0
the	0
humoral	0
HBx	9
immune	0
response	0
which	0
can	0
be	0
monitored	0
by	0
HBx	9
-specific	0
peptide	0
ELISAs	0
.	0

Such	0
tests	0
may	0
become	0
useful	0
diagnostic	0
tools	0
.	0

[	0
The	0
inhibitory	0
effect	0
of	0
hydrocortisone	0
on	0
the	0
chemotactic	0
migration	0
of	0
human	7
leukocytes	8
]	0

Random	0
migration	0
(	0
RM	0
)	0
and	0
chemotactic	0
migration	0
(	0
ChtM	0
)	0
of	0
human	7
leukocytes	8
to	0
yeast	0
activated	0
serum	0
were	0
studied	0
with	0
the	0
modified	0
Boyden	0
chamber	0
method	0
.	0

Both	0
RM	0
and	0
ChtM	0
showed	0
circadian	0
rhythm	0
.	0

Leukocytes	7
migrated	0
most	0
rapidly	0
at	0
night	0
.	0

The	0
difference	0
between	0
the	0
peak	0
(	0
0	0
:	0
00	0
)	0
and	0
trough	0
values	0
(	0
8	0
:	0
00	0
)	0
of	0
RM	0
and	0
ChtM	0
was	0
significant	0
statistically	0
(	0
P	0
less	0
than	0
0.01	0
)	0
.	0

ChtM	0
was	0
inhibited	0
by	0
hydrocortisone	0
(	0
F	0
)	0
of	0
physiological	0
concentration	0
(	0
10	0
(	0
-9	0
)	0
-10	0
(	0
-7	0
)	0
mol/L	0
)	0
which	0
was	0
dose-dependent	0
and	0
completely	0
antagonized	0
by	0
the	0
competitive	0
antagonist	0
,	0
RU38486	0
.	0

The	0
inhibitory	0
effect	0
was	0
much	0
more	0
evident	0
with	0
higher	0
dose	0
(	0
more	0
than	0
10	0
(	0
-5	0
)	0
mol/L	0
)	0
and	0
it	0
was	0
also	0
reversed	0
by	0
RU38486	0
,	0
but	0
only	0
partially	0
.	0

It	0
is	0
suggested	0
that	0
glucocorticoids	0
(	0
GC	0
)	0
may	0
be	0
a	0
physiological	0
regulator	0
of	0
the	0
activity	0
of	0
leukocytes	7
and	0
its	0
inhibitory	0
action	0
on	0
ChtM	0
may	0
be	0
involved	0
in	0
antiinflammatory	0
mechanisms	0
of	0
GC	0
of	0
pharmacological	0
doses	0
.	0

The	0
action	0
of	0
physiological	0
and	0
pharmacological	0
concentration	0
of	0
GC	0
may	0
be	0
mediated	0
by	0
low	9
affinity	10
specific	10
binding	10
sites	10
of	0
glucocorticoid	9
receptors	10
.	0

Heterogeneity	0
of	0
antigen	9
molecules	10
recognized	0
by	0
anti-tax1	9
monoclonal	10
antibody	10
Lt-4	9
in	0
cell	0
lines	0
bearing	0
human	0
T	0
cell	0
leukemia	0
virus	0
type	0
I	0
and	0
related	0
retroviruses	0
.	0

Using	0
a	0
monoclonal	9
antibody	10
,	0
Lt-4	9
,	0
directed	0
against	0
human	9
T	10
cell	10
leukemia	10
virus	10
type	10
I	10
(	10
HTLV-I	10
)	10
trans-activator	10
(	10
tax1	10
)	10
antigen	10
,	0
we	0
examined	0
the	0
expression	0
of	0
tax1	9
and	0
related	0
antigens	9
in	0
a	0
variety	0
of	0
T	5
cell	6
lines	6
bearing	0
HTLV-I	0
and	0
related	0
retroviruses	0
,	0
simian	0
T	0
cell	0
leukemia	0
virus	0
type	0
I	0
(	0
STLV-I	0
)	0
and	0
HTLV-II	0
,	0
by	0
immunofluorescence	0
and	0
immunoblot	0
assays	0
.	0

Lt-4	9
reacted	0
with	0
all	0
HTLV-I-bearing	5
cell	6
lines	6
tested	0
and	0
five	0
out	0
of	0
eight	0
simian	5
cell	6
lines	6
bearing	0
STLV-I	0
,	0
but	0
not	0
with	0
an	0
HTLV-II-bearing	5
cell	6
line	6
.	0

Lt-4	9
detected	0
40	0
kd	0
tax1	9
antigen	10
molecules	10
in	0
most	0
HTLV-I-bearing	5
cell	6
lines	6
except	0
one	0
cell	0
line	0
that	0
expressed	0
39	9
kd	10
tax1	10
antigen	10
.	0

In	0
the	0
STLV-I-bearing	5
T	6
cell	6
lines	6
,	0
tax1-related	9
antigen	10
molecules	10
detected	0
by	0
Lt-4	9
were	0
heterogeneous	0
,	0
having	0
molecular	0
weights	0
in	0
the	0
range	0
of	0
36-41	0
kd	0
.	0

Characterization	0
of	0
the	0
human	9
immunodeficiency	10
virus	10
type	10
1	10
enhancer-binding	10
proteins	10
from	0
the	0
human	5
T-cell	6
line	6
Jurkat	5
.	0

The	0
transcription	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
is	0
under	0
the	0
control	0
of	0
cellular	9
proteins	10
that	0
bind	0
to	0
the	0
viral	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

Among	0
the	0
protein-binding	0
regions	0
of	0
the	0
HIV-1	1
LTR	2
is	0
the	0
transcription-enhancer	1
region	2
.	0

We	0
show	0
that	0
at	0
least	0
one	0
inducible	9
,	0
C1	9
,	0
and	0
one	0
constitutive	9
,	10
C2	10
,	10
protein	10
can	0
bind	0
to	0
the	0
HIV	1
enhancer	2
in	0
Jurkat	5
cells	6
.	0

The	0
two	0
proteins	0
differ	0
in	0
their	0
surface	0
charge	0
,	0
since	0
they	0
are	0
separable	0
by	0
anion-exchange	0
chromatography	0
.	0

Bivalent	0
cations	0
such	0
as	0
Mg2+	0
and	0
Zn2+	0
differentially	0
affect	0
their	0
binding	0
to	0
oligonucleotides	0
which	0
contain	0
the	0
HIV-enhancer	1
domain	2
.	0

Both	0
C1	9
and	0
C2	9
proteins	10
also	0
bind	0
to	0
a	0
similar	0
sequence	0
found	0
in	0
the	0
interleukin-2-receptor	1
alpha-subunit	2
enhancer	2
.	0

The	0
inducible	9
C1	10
protein	10
was	0
partially	0
purified	0
by	0
three	0
chromatographic	0
steps	0
and	0
characterized	0
by	0
u.v.	0
cross-linking	0
as	0
a	0
47	9
kDa	10
protein	10
.	0

Differences	0
in	0
transcriptional	1
enhancers	2
of	0
HIV-1	0
and	0
HIV-2	0
.	0

Response	0
to	0
T	7
cell	8
activation	0
signals	0
.	0

T	7
cell	8
activation	0
results	0
in	0
high	0
levels	0
of	0
HIV	0
replication	0
and	0
is	0
thought	0
to	0
be	0
one	0
mechanism	0
leading	0
to	0
the	0
conversion	0
from	0
latent	0
to	0
active	0
viral	0
infection	0
.	0

In	0
HIV-1	0
,	0
the	0
sequences	0
that	0
respond	0
to	0
these	0
signaling	0
events	0
are	0
found	0
in	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
and	0
comprise	0
the	0
transcriptional	1
enhancer	2
,	0
which	0
contains	0
two	0
conserved	1
binding	2
sites	2
for	0
the	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF	9
kappa	10
B	10
)	0
.	0

The	0
corresponding	0
region	0
in	0
the	0
second	0
AIDS	0
retrovirus	0
,	0
HIV-2	0
,	0
contains	0
a	0
conserved	0
and	0
a	0
divergent	0
NF	1
kappa	2
B	2
binding	2
site	2
.	0

We	0
demonstrate	0
that	0
the	0
HIV-1	1
LTR	2
responds	0
better	0
than	0
the	0
HIV-2	1
LTR	2
to	0
T	0
cell	0
activation	0
signals	0
.	0

These	0
qualitative	0
differences	0
in	0
the	0
response	0
to	0
T	7
cell	8
activation	0
are	0
reproduced	0
not	0
only	0
when	0
HIV-1	1
or	2
HIV-2	2
enhancers	2
are	0
placed	0
upstream	0
of	0
a	0
heterologous	1
promoter	2
but	0
also	0
when	0
these	0
enhancers	1
are	0
switched	0
between	0
their	0
respective	0
LTR	1
.	0

In	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
NF	9
kappa	10
B	10
binds	0
to	0
both	0
conserved	0
sites	0
in	0
the	0
HIV-1	1
transcriptional	2
enhancer	2
and	0
only	0
to	0
the	0
single	0
conserved	0
site	0
in	0
the	0
HIV-2	1
transcriptional	2
enhancer	2
.	0

Instead	0
of	0
NF	9
kappa	10
B	10
,	0
the	0
activator	9
protein	10
3	10
binds	0
to	0
the	0
divergent	0
site	0
in	0
HIV-2	0
.	0

In	0
conclusion	0
,	0
HIV-1	0
and	0
HIV-2	0
are	0
differentially	0
regulated	0
by	0
T	0
cell	0
activation	0
signals	0
,	0
and	0
this	0
difference	0
may	0
account	0
for	0
the	0
longer	0
period	0
of	0
viral	0
latency	0
observed	0
with	0
HIV-2	0
than	0
with	0
HIV-1	0
infection	0
.	0

NF-X2	9
that	0
binds	0
to	0
the	0
DRA	1
X2-box	2
is	0
activator	9
protein	10
1	10
.	0

Expression	0
cloning	0
of	0
c-Jun	9
.	0

Human	9
class	10
II	10
MHC	10
Ag	10
are	0
a	0
family	0
of	0
cell	9
surface	10
glycoproteins	10
.	0

Their	0
constitutive	0
expression	0
is	0
limited	0
to	0
B	7
lymphocytes	8
and	0
thymic	7
epithelial	8
cells	8
.	0

In	0
many	0
other	0
cells	0
their	0
expression	0
can	0
be	0
induced	0
by	0
IFN-gamma	9
.	0

Conserved	0
upstream	0
promoter	0
sequences	0
regulate	0
this	0
tissue-specific	0
expression	0
of	0
class	1
II	2
genes	2
.	0

In	0
the	0
DRA	1
promoter	2
,	0
one	0
of	0
these	0
cis-acting	1
regulatory	2
motifs	2
is	0
the	0
X2-box	1
to	0
which	0
nuclear	9
factor	10
X2	10
(	0
NF-X2	9
)	0
binds	0
.	0

Here	0
,	0
we	0
present	0
the	0
isolation	0
and	0
characterization	0
of	0
the	0
full-length	1
cDNA	2
clone	2
encoding	0
NF-X2	9
.	0

This	0
cDNA	1
clone	2
was	0
isolated	0
by	0
expression	0
cDNA	1
cloning	0
,	0
and	0
encodes	0
the	0
human	9
c-Jun	10
protein	10
,	0
which	0
together	0
with	0
c-Fos	9
forms	0
the	0
heterodimeric	9
activator	10
protein-1	10
transcription	10
complex	10
.	0

Whereas	0
c-Fos/c-Jun	9
heterodimers	10
do	0
not	0
exist	0
in	0
B	5
cells	6
,	0
they	0
form	0
and	0
bind	0
to	0
the	0
X2-box	1
in	0
class	5
II	6
nonexpressing	6
cells	6
.	0

Thus	0
,	0
c-Fos/c-Jun	9
heterodimers	10
might	0
contribute	0
to	0
the	0
repression	0
of	0
DRA	1
gene	2
expression	0
.	0

Synthesis	0
of	0
4	0
,	0
19-disubstituted	0
derivatives	0
of	0
DOC	0
.	0

Radioreceptor	0
assay	0
of	0
some	0
corticosteroid	0
derivatives	0
in	0
human	7
mononuclear	8
leukocytes	8
.	0

Several	0
new	0
4	0
,	0
19-substituted	0
steroids	0
and	0
previously	0
synthesized	0
corticosteroids	0
were	0
assayed	0
for	0
affinity	0
to	0
type	9
1	10
receptors	10
in	0
human	7
mononuclear	8
leukocytes	8
.	0

11	0
beta	0
,	0
19-epoxy-4	0
,	0
21-dihydroxypregn-4-ene-3	0
,	0
20-dione	0
(	0
2	0
)	0
was	0
hydrogenated	0
with	0
Pd-C	0
to	0
yield	0
a	0
mixture	0
of	0
all	0
four	0
dihydro	0
derivatives	0
5	0
,	0
accompanied	0
by	0
4	0
,	0
21-diacetoxy-11	0
beta	0
,	0
19-epoxy-3-hydroxypregnan-20-one	0
(	0
6	0
)	0
and	0
21-acetoxy-11	0
beta	0
,	0
19-epoxy-4-hydroxypregnane-3	0
,	0
20-dione	0
(	0
7	0
)	0
.	0

With	0
hot	0
acetic	0
+	0
p-toluenesulfonic	0
acid	0
5	0
underwent	0
rearrangement	0
to	0
21-acetoxy-11	0
beta	0
,	0
19-epoxypregn-5-ene-4	0
,	0
20-dione	0
(	0
8	0
)	0
Pd-C	0
hydrogenation	0
of	0
3	0
,	0
21-diacetoxy-5	0
beta	0
,	0
19-cyclopregna-2	0
,	0
9	0
(	0
11	0
)	0
-diene-4	0
,	0
20-dione	0
(	0
10	0
)	0
gave	0
3	0
,	0
21-diacetoxy-5	0
beta	0
,	0
19-cyclopregn-5-ene-4	0
,	0
20-dione	0
(	0
11	0
)	0
and	0
the	0
9	0
,	0
11-dihydro	0
derivative	0
of	0
the	0
latter	0
.	0

Treatment	0
of	0
10	0
with	0
warm	0
HCl	0
furnished	0
19-chloro-4	0
,	0
21-dihydroxypregna-4	0
,	0
9	0
(	0
11	0
)	0
-diene-3	0
,	0
20-dione	0
(	0
13	0
)	0
.	0

Pd-C	0
hydrogenation	0
of	0
its	0
diacetate	0
14	0
afforded	0
the	0
4	0
,	0
5-dihydro	0
derivative	0
18	0
,	0
19-chloro-21-acetoxypregn-9	0
(	0
11	0
)	0
-en-20-one	0
(	0
15	0
)	0
,	0
its	0
4-acetoxy	0
derivative	0
16	0
and	0
the	0
3	0
,	0
4-diacetoxy	0
derivative	0
17	0
.	0

When	0
tested	0
in	0
a	0
radioreceptor	0
assay	0
in	0
human	7
mononuclear	8
leukocytes	8
the	0
synthesized	0
compounds	0
showed	0
only	0
low	0
relative	0
binding	0
affinities	0
(	0
RBA	0
)	0
to	0
type	9
1	10
receptor	10
,	0
the	0
highest	0
being	0
0.72	0
%	0
for	0
13	0
(	0
aldosterone	0
=	0
100	0
%	0
)	0
.	0

For	0
comparison	0
,	0
other	0
RBA	0
in	0
this	0
system	0
were	0
:	0
19-noraldosterone	0
,	0
20	0
%	0
;	0
18-deoxyaldosterone	0
,	0
5.8	0
%	0
;	0
18-deoxy-19-noraldosterone	0
,	0
4.7	0
%	0
;	0
18	0
,	0
21-anhydroaldosterone	0
,	0
0.37	0
%	0
;	0
17-isoaldosterone	0
,	0
7.6	0
%	0
and	0
apoaldosterone	0
,	0
4.3	0
%	0

Cell	0
type	0
specificity	0
and	0
activation	0
requirements	0
for	0
NFAT-1	9
(	0
nuclear	9
factor	10
of	0
activated	7
T-cells	8
)	0
transcriptional	0
activity	0
determined	0
by	0
a	0
new	0
method	0
using	0
transgenic	0
mice	0
to	0
assay	0
transcriptional	0
activity	0
of	0
an	0
individual	0
nuclear	9
factor	10
.	0

Nuclear	9
factor	10
of	0
activated	7
T-cells	8
(	0
NFAT-1	9
)	0
is	0
a	0
transcription	9
factor	10
which	0
is	0
considered	0
to	0
be	0
an	0
important	0
regulator	0
in	0
early	0
T-cell	0
activation	0
.	0

We	0
have	0
developed	0
a	0
system	0
to	0
monitor	0
the	0
transcriptional	0
activity	0
of	0
NFAT-1	9
at	0
the	0
single	0
cell	0
level	0
in	0
whole	0
animals	0
.	0

The	0
system	0
is	0
based	0
on	0
the	0
use	0
of	0
an	0
oligomerized	0
NFAT-1	9
binding	0
motif	0
that	0
directs	0
transcription	9
of	10
SV40	10
T-antigen	10
in	0
transgenic	0
mice	0
.	0

This	0
report	0
represents	0
the	0
first	0
demonstration	0
that	0
a	0
multimerized	0
short	0
binding	0
motif	0
can	0
function	0
appropriately	0
in	0
transgenic	0
mice	0
.	0

NFAT-1	9
activity	0
had	0
previously	0
been	0
thought	0
to	0
be	0
confined	0
to	0
activated	7
T-lymphocytes	8
upon	0
release	0
of	0
intracellular	7
calcium	8
.	0

By	0
targeting	0
NFAT-1	9
-dependent	0
gene	0
expression	0
in	0
transgenic	0
mice	0
we	0
discovered	0
new	0
sites	0
of	0
NFAT-1	9
activity	0
.	0

Besides	0
in	0
T-lymphocytes	7
NFAT-1	9
activity	0
could	0
also	0
be	0
induced	0
in	0
T-lymphocyte-depleted	7
spleen	8
cells	8
and	0
purified	7
B-lymphocytes	8
and	0
requires	0
agents	0
that	0
both	0
release	0
intracellular	0
calcium	0
and	0
activate	0
protein	9
kinase	10
C	10
.	0

A	0
difference	0
in	0
the	0
time	0
course	0
of	0
appearance	0
of	0
NFAT-1	9
activity	0
between	0
T-lymphocytes	7
and	0
non-T-lymphocytes	7
was	0
revealed	0
.	0

Constitutive	0
expression	0
was	0
observed	0
in	0
a	0
small	0
population	0
of	0
cells	0
in	0
the	0
dermis	0
and	0
some	0
mice	0
have	0
developed	0
skin	0
lesions	0
.	0

Interestingly	0
,	0
the	0
tissue	0
pattern	0
of	0
expression	0
of	0
the	0
NFAT-1	9
activity	0
resembles	0
the	0
expression	0
pattern	0
described	0
for	0
HIV-LTR/tat	0
transgenic	0
mice	0
(	0
Vogel	0
,	0
J.	0
,	0
Hinrichs	0
,	0
S.	0
H.	0
,	0
Reynolds	0
,	0
R.	0
K.	0
,	0
Luciw	0
,	0
P.	0
A.	0
,	0
and	0
Jay	0
,	0
G.	0
(	0
1988	0
)	0
Nature	0
335	0
,	0
606-611	0
)	0
.	0

This	0
similarity	0
in	0
expression	0
and	0
the	0
fact	0
that	0
NFAT-1	9
has	0
been	0
shown	0
to	0
bind	0
functional	1
sequences	2
in	0
HIV-LTR	1
suggest	0
a	0
role	0
for	0
NFAT-1	9
in	0
dermal	0
activation	0
of	0
the	0
HIV-LTR	1
.	0

A	0
novel	0
T-cell	9
protein	10
which	0
recognizes	0
a	0
palindromic	1
sequence	2
in	0
the	0
negative	1
regulatory	2
element	2
of	0
the	0
human	1
immunodeficiency	2
virus	2
long	2
terminal	2
repeat	2
.	0

Two	0
major	1
protein-binding	2
sites	2
within	0
the	0
negative	1
regulatory	2
element	2
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
have	0
been	0
identified	0
.	0

One	0
(	0
site	1
B	2
)	0
contained	0
a	0
palindromic	1
sequence	2
with	0
homology	0
to	0
steroid/thyroid	1
hormone	2
response	2
elements	2
but	0
was	0
distinct	0
from	0
previously	0
described	0
binding	0
sites	0
of	0
this	0
class	0
.	0

A	0
novel	0
T-cell	9
protein	10
recognized	0
the	0
palindromic	1
sequence	2
within	0
site	1
B	2
and	0
also	0
bound	0
estrogen-	1
or	2
thyroid	2
hormone-response	2
elements	2
with	0
lower	0
affinity	0
.	0

A	0
7-base-pair	0
mutation	0
in	0
the	0
site	1
B	2
palindrome	2
,	0
which	0
destroyed	0
protein	0
binding	0
,	0
resulted	0
in	0
increased	0
expression	0
from	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
in	0
T	7
cells	8
.	0

Progesterone	0
suppression	0
of	0
pregnancy	7
lymphocytes	8
is	0
not	0
mediated	0
by	0
glucocorticoid	0
effect	0
.	0

This	0
study	0
investigated	0
whether	0
the	0
suppressive	0
effect	0
of	0
progesterone	0
on	0
pregnancy	7
lymphocytes	8
is	0
mediated	0
by	0
specific	0
progesterone	9
receptors	10
.	0

The	0
effects	0
of	0
a	0
competitive	0
progesterone	0
antagonist	0
(	0
RU486	0
)	0
and	0
a	0
specific	0
glucocorticoid	9
receptor	10
blocker	0
(	0
RU43044	0
)	0
were	0
tested	0
on	0
the	0
release	0
of	0
a	0
blocking	9
factor	10
by	0
progesterone-treated	5
pregnancy	6
lymphocytes	6
.	0

RU	0
486	0
tested	0
at	0
an	0
equal	0
concentration	0
as	0
progesterone	0
significantly	0
inhibited	0
the	0
production	0
of	0
the	0
blocking	9
factor	10
,	0
while	0
RU	0
43044	0
was	0
without	0
effect	0
.	0

These	0
data	0
suggest	0
that	0
in	0
pregnancy	0
,	0
lymphocyte	0
progesterone	0
acts	0
on	0
specific	0
progesterone	9
receptors	10
and	0
glucocorticoid	9
binding	10
sites	10
are	0
not	0
involved	0
.	0

The	0
56-59-kilodalton	9
protein	10
identified	0
in	0
untransformed	9
steroid	10
receptor	10
complexes	10
is	0
a	0
unique	9
protein	10
that	0
exists	0
in	0
cytosol	0
in	0
a	0
complex	0
with	0
both	0
the	0
70-	9
and	10
90-kilodalton	10
heat	10
shock	10
proteins	10
.	0

It	0
has	0
previously	0
been	0
shown	0
that	0
9S	9
,	0
untransformed	9
progestin	10
,	10
estrogen	10
,	10
androgen	10
,	10
and	10
glucocorticoid	10
receptor	10
complexes	10
in	0
rabbit	0
uterine	0
and	0
liver	0
cytosols	0
contain	0
a	0
59-kDa	9
protein	10
[	0
Tai	0
,	0
P.K.	0
,	0
Maeda	0
,	0
Y.	0
,	0
Nakao	0
,	0
K.	0
,	0
Wakim	0
,	0
N.G.	0
,	0
Duhring	0
,	0
J.L.	0
,	0
&	0
Faber	0
,	0
L.E.	0
(	0
1986	0
)	0
Biochemistry	0
25	0
,	0
5269-5275	0
]	0
.	0

In	0
this	0
work	0
we	0
show	0
that	0
the	0
monoclonal	9
antibody	10
KN	10
382/EC1	10
raised	0
against	0
the	0
rabbit	9
59-kDa	10
protein	10
reacts	0
with	0
9S	9
,	0
untransformed	9
glucocorticoid	10
receptor	10
complexes	10
in	0
cytosol	0
prepared	0
from	0
human	5
IM-9	6
lymphocytes	6
but	0
not	0
with	0
4S	9
salt-transformed	10
receptors	10
.	0

The	0
human	0
protein	0
recognized	0
by	0
the	0
EC1	9
antibody	10
is	0
a	0
56-kDa	9
protein	10
(	0
p56	9
)	0
of	0
moderate	0
abundance	0
located	0
predominantly	0
in	0
the	0
cytoplasm	0
by	0
indirect	0
immunofluorescence	0
.	0

There	0
are	0
at	0
least	0
six	0
isomorphs	9
of	0
p56	9
by	0
two-dimensional	0
gel	0
analysis	0
.	0

N-Terminal	0
sequencing	0
(	0
20	0
amino	0
acids	0
)	0
shows	0
that	0
p56	9
is	0
a	0
unique	9
human	10
protein	10
.	0

When	0
p56	9
is	0
immunoadsorbed	0
from	0
IM-9	5
cell	6
cytosol	0
,	0
both	0
the	0
70-	9
and	10
90-kDa	10
heat	10
shock	10
proteins	10
are	0
coadsorbed	0
in	0
an	0
immune-specific	0
manner	0
.	0

Neither	0
heat	9
shock	10
protein	10
reacts	0
directly	0
with	0
the	0
EC1	9
antibody	10
.	0

We	0
conclude	0
that	0
p56	9
exists	0
in	0
cytosol	0
in	0
a	0
higher	0
order	0
complex	0
containing	0
hsp70	9
and	0
hsp90	9
,	0
both	0
of	0
which	0
in	0
turn	0
have	0
been	0
found	0
to	0
be	0
associated	0
with	0
untransformed	9
steroid	10
receptors	10
.	0

Sequence-specific	0
DNA	0
binding	0
of	0
the	0
proto-oncoprotein	9
ets-1	9
defines	0
a	0
transcriptional	1
activator	2
sequence	2
within	0
the	0
long	1
terminal	2
repeat	2
of	0
the	0
Moloney	0
murine	0
sarcoma	0
virus	0
.	0

The	0
ets	1
proto-oncogene	2
family	2
is	0
a	0
group	0
of	0
sequence-related	1
genes	2
whose	0
normal	0
cellular	0
function	0
is	0
unknown	0
.	0

In	0
a	0
study	0
of	0
cellular	9
proteins	10
involved	0
in	0
the	0
transcriptional	0
regulation	0
of	0
murine	0
retroviruses	0
in	0
T	7
lymphocytes	8
,	0
we	0
have	0
discovered	0
that	0
a	0
member	0
of	0
the	0
ets	1
gene	2
family	2
encodes	0
a	0
sequence-specific	9
DNA-binding	10
protein	10
.	0

A	0
mouse	1
ets-1	2
cDNA	2
clone	2
was	0
obtained	0
by	0
screening	0
a	0
mouse	0
thymus	0
cDNA	0
expression	0
library	0
with	0
a	0
double-stranded	1
oligonucleotide	2
probe	2
representing	0
20	0
bp	0
of	0
the	0
Moloney	0
murine	0
sarcoma	0
virus	0
(	0
MSV	0
)	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
.	0

The	0
cDNA	1
sequence	2
has	0
an	0
813-bp	1
open	2
reading	2
frame	2
(	0
ORF	1
)	0
whose	0
predicted	0
amino	0
acid	0
sequence	0
is	0
97.6	0
%	0
identical	0
to	0
the	0
272	9
carboxy-terminal	10
amino	10
acids	10
of	0
the	0
human	9
ets-1	10
protein	10
.	0

The	0
ORF	1
was	0
expressed	0
in	0
bacteria	0
,	0
and	0
the	0
30-kD	9
protein	10
product	10
was	0
shown	0
to	0
bind	0
DNA	0
in	0
a	0
sequence-specific	0
manner	0
by	0
mobility-shift	0
assays	0
,	0
Southwestern	0
blot	0
analysis	0
,	0
and	0
methylation	0
interference	0
.	0

A	0
mutant	1
LTR	2
containing	0
four	0
base	0
pair	0
substitutions	0
in	0
the	0
ets-1	1
binding	2
site	2
was	0
constructed	0
and	0
was	0
shown	0
to	0
have	0
reduced	0
binding	0
in	0
vitro	0
.	0

Transcriptional	0
efficiency	0
of	0
the	0
MSV	1
LTR	2
promoter	2
containing	0
this	0
disrupted	0
ets-1	1
binding	2
site	2
was	0
compared	0
to	0
the	0
activity	0
of	0
a	0
wild-type	1
promoter	2
in	0
mouse	7
T	8
lymphocytes	8
in	0
culture	0
,	0
and	0
15-	0
to	0
20-fold	0
reduction	0
in	0
expression	0
of	0
a	0
reporter	1
gene	2
was	0
observed	0
.	0

We	0
propose	0
that	0
ets-1	9
functions	0
as	0
a	0
transcriptional	0
activator	0
of	0
mammalian	0
type-C	0
retroviruses	0
and	0
speculate	0
that	0
ets-related	1
genes	2
constitute	0
a	0
new	0
group	0
of	0
eukaryotic	9
DNA-binding	10
proteins	10
.	0

Type	9
II	10
estrogen	10
binding	10
sites	10
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
:	0
variations	0
during	0
the	0
menstrual	0
cycle	0
.	0

We	0
have	0
previously	0
reported	0
that	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
contain	0
type	0
II	9
estrogen	10
binding	10
sites	10
(	0
type	9
II	10
EBS	10
)	0
.	0

In	0
this	0
study	0
,	0
the	0
fluctuations	0
of	0
type	9
II	10
EBS	10
during	0
the	0
menstrual	0
cycle	0
were	0
analyzed	0
in	0
6	0
normally	0
menstruating	0
women	0
.	0

Approximately	0
3	0
times	0
higher	0
levels	0
of	0
type	9
II	10
EBS	10
were	0
found	0
in	0
the	0
periovulatory	0
period	0
with	0
respect	0
to	0
both	0
follicular	0
and	0
luteal	0
phases	0
.	0

In	0
postmenopausal	0
women	0
the	0
mean	0
type	9
II	10
EBS	10
levels	0
were	0
similar	0
to	0
those	0
observed	0
in	0
the	0
follicular	0
phase	0
of	0
the	0
cycle	0
.	0

However	0
,	0
in	0
3	0
postmenopausal	0
patients	0
a	0
short	0
course	0
of	0
estrogen	0
or	0
tamoxifen	0
resulted	0
in	0
a	0
marked	0
increase	0
of	0
type	9
II	10
EBS	10
levels	0
.	0

Tamoxifen	0
was	0
also	0
found	0
to	0
compete	0
with	0
17	0
beta-estradiol	0
for	0
type	9
II	10
EBS	10
in	0
PBMC	7
,	0
although	0
to	0
a	0
lesser	0
extent	0
than	0
diethylstilbestrol	0
.	0

Mononuclear	7
leukocyte	8
glucocorticoid	9
receptor	10
binding	0
characteristics	0
and	0
down-regulation	0
in	0
major	0
depression	0
.	0

Some	0
patients	0
with	0
major	0
depressive	0
disorder	0
(	0
MDD	0
)	0
have	0
elevated	0
plasma	0
cortisol	0
concentrations	0
and	0
show	0
failure	0
to	0
suppress	0
cortisol	0
secretion	0
upon	0
administration	0
of	0
dexamethasone	0
(	0
DEX	0
)	0
,	0
yet	0
they	0
do	0
not	0
have	0
Cushingoid	0
features	0
.	0

To	0
study	0
whether	0
this	0
represents	0
glucocorticoid	0
(	0
GC	0
)	0
resistance	0
,	0
[	0
3H	0
]	0
-DEX-binding	0
assays	0
were	0
used	0
to	0
measure	0
,	0
in	0
vitro	0
,	0
the	0
GC	9
receptor	10
affinity	0
(	0
1/Kd	0
)	0
and	0
number	0
(	0
Bmax	0
)	0
in	0
mononuclear	7
leukocytes	8
of	0
11	0
MDD	0
patients	0
and	0
15	0
control	0
subjects	0
.	0

No	0
receptor	0
abnormalities	0
were	0
detected	0
in	0
the	0
MDD	0
group	0
;	0
thus	0
any	0
cellular	0
defect	0
leading	0
to	0
a	0
lack	0
of	0
responsiveness	0
to	0
GC	0
in	0
the	0
MDD	0
patients	0
,	0
if	0
present	0
,	0
probably	0
lies	0
beyond	0
the	0
initial	0
receptor	0
binding	0
.	0

DEX	0
(	0
1.0	0
mg	0
orally	0
)	0
was	0
administered	0
to	0
study	0
in	0
vivo	9
GC	10
receptor	10
down-regulation	0
.	0

Compared	0
to	0
the	0
control	0
group	0
,	0
fewer	0
depressed	0
subjects	0
down-regulated	0
Bmax	0
after	0
DEX	0
.	0

By	0
paired	0
t-test	0
,	0
Bmax	0
decreased	0
significantly	0
in	0
the	0
control	0
group	0
but	0
not	0
in	0
the	0
depressed	0
group	0
.	0

Receptor	0
number	0
on	0
the	0
control	0
day	0
did	0
not	0
correlate	0
significantly	0
with	0
the	0
degree	0
of	0
receptor	0
down-regulation	0
,	0
severity	0
of	0
depression	0
or	0
cortisol	0
concentrations	0
across	0
all	0
the	0
subjects	0
.	0

These	0
results	0
do	0
not	0
lend	0
support	0
to	0
previous	0
reports	0
suggesting	0
that	0
GC	0
resistance	0
in	0
MDD	0
results	0
from	0
a	0
GC	0
receptor-binding	0
abnormality	0
,	0
and	0
they	0
emphasize	0
the	0
importance	0
of	0
considering	0
receptor	0
studies	0
in	0
the	0
context	0
of	0
GC-mediated	0
cell	0
processes	0
in	0
order	0
to	0
identify	0
the	0
exact	0
cellular	0
defect	0
(	0
s	0
)	0
leading	0
to	0
GC	0
resistance	0
.	0

Ras-related	9
GTP-binding	10
proteins	10
and	0
leukocyte	7
signal	0
transduction	0
.	0

Many	0
aspects	0
of	0
leukocyte	7
function	0
are	0
regulated	0
by	0
both	0
heterotrimeric	9
and	0
Ras-related	9
GTP-binding	10
proteins	10
,	0
but	0
there	0
is	0
little	0
definite	0
information	0
about	0
their	0
roles	0
in	0
the	0
specialized	0
processes	0
utilized	0
by	0
leukocytes	7
for	0
cell	0
killing	0
.	0

Recent	0
progress	0
in	0
understanding	0
the	0
regulation	0
of	0
the	0
phagocyte	9
NADPH	10
oxidase	10
by	0
the	0
Rac	9
GTP-binding	10
proteins	10
provides	0
a	0
basis	0
for	0
defining	0
the	0
operational	0
characteristics	0
of	0
one	0
such	0
phagocyte	0
system	0
.	0

It	0
is	0
clear	0
from	0
various	0
studies	0
that	0
the	0
activity	0
of	0
the	0
NADPH	9
oxidase	10
can	0
be	0
modulated	0
through	0
the	0
regulation	0
of	0
the	0
GTP-GDP	0
state	0
of	0
Rac	9
.	0

Proteins	0
exist	0
in	0
leukocytes	7
able	0
to	0
modify	0
GTP-binding	9
protein	10
function	0
in	0
this	0
manner	0
,	0
and	0
their	0
activity	0
may	0
be	0
regulated	0
by	0
signals	0
generated	0
on	0
phagocyte	0
stimulation	0
.	0

Proteins	0
of	0
the	0
Ras	9
superfamily	10
are	0
likely	0
to	0
be	0
involved	0
in	0
a	0
variety	0
of	0
normal	0
phagocyte	0
functions	0
through	0
their	0
ability	0
to	0
modulate	0
the	0
assembly	0
of	0
actin	9
filaments	10
,	0
direct	0
vesicle	0
trafficking	0
and	0
fusion	0
,	0
and	0
so	0
forth	0
.	0

BSAP	9
:	0
a	0
key	0
regulator	0
of	0
B-cell	7
development	0
and	0
differentiation	0
.	0

B-cell-specific	9
activator	10
protein	10
(	0
BSAP	9
)	0
is	0
a	0
recently	0
identified	0
member	0
of	0
the	0
Pax-gene	1
family	2
of	0
transcription	9
factors	10
;	0
in	0
the	0
lymphoid	0
system	0
,	0
BSAP	9
is	0
produced	0
only	0
in	0
B	7
cells	8
.	0

Here	0
,	0
Markus	0
Neurath	0
,	0
Eckhard	0
Stuber	0
and	0
Warren	0
Strober	0
describe	0
the	0
molecular	0
structure	0
of	0
BSAP	9
and	0
focus	0
on	0
the	0
ability	0
of	0
this	0
protein	0
to	0
regulate	0
the	0
expression	0
of	0
B-cell-specific	1
genes	2
.	0

They	0
propose	0
that	0
BSAP	9
is	0
a	0
key	9
protein	10
of	0
B	7
cells	8
and	0
that	0
it	0
not	0
only	0
influence	0
B-cell	0
development	0
but	0
also	0
influences	0
the	0
balance	0
between	0
B-cell	0
proliferation	0
and	0
immunoglobulin	9
secretion	0
at	0
later	0
stages	0
of	0
B-cell	0
differentiation	0
.	0

Down-regulation	0
of	0
NF-kappa	9
B	10
protein	10
levels	0
in	0
activated	0
human	0
lymphocytes	0
by	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
[	0
published	0
erratum	0
appears	0
in	0
Proc	0
Natl	0
Acad	0
Sci	0
U	0
S	0
A	0
1996	0
Jan	0
9	0
;	0
93	0
(	0
1	0
)	0
:	0
524	0
]	0

The	0
effect	0
of	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
[	0
1	0
,	0
25	0
(	0
OH	0
)	0
2	0
)	0
D3	0
]	0
,	0
a	0
steroid	0
hormone	0
with	0
immunomodulating	0
properties	0
,	0
on	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
proteins	0
was	0
examined	0
in	0
in	5
vitro	6
activated	6
normal	6
human	6
lymphocytes	6
by	0
Western	0
blot	0
analysis	0
.	0

Over	0
a	0
72-hr	0
period	0
of	0
activation	0
,	0
the	0
expression	0
of	0
the	0
50-kDa	9
NF-kappa	10
B	10
,	0
p50	9
,	0
and	0
its	0
precursor	0
,	0
p105	9
,	0
was	0
increased	0
progressively	0
.	0

When	0
cells	0
were	0
activated	0
in	0
the	0
presence	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
,	0
the	0
levels	0
of	0
the	0
mature	0
protein	0
as	0
well	0
as	0
its	0
precursor	0
were	0
decreased	0
.	0

The	0
effect	0
of	0
the	0
hormone	0
on	0
the	0
levels	0
of	0
p50	9
was	0
demonstrable	0
in	0
the	0
cytosolic	0
and	0
nuclear	0
compartments	0
;	0
it	0
required	0
between	0
4	0
and	0
8	0
hr	0
and	0
was	0
specific	0
,	0
as	0
25-hydroxyvitamin	0
D3	0
and	0
24	0
,	0
25-dihydroxyvitamin	0
D3	0
were	0
ineffective	0
.	0

Besides	0
p50	9
,	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
decreased	0
the	0
levels	0
of	0
another	0
NF-kappa	9
B	10
protein	10
,	0
namely	0
c-rel	9
.	0

In	0
addition	0
,	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
decreased	0
the	0
abundance	0
of	0
a	0
specific	9
DNA-protein	10
complex	10
formed	0
upon	0
incubation	0
of	0
nuclear	0
extracts	0
from	0
activated	0
lymphocytes	0
with	0
a	0
labeled	0
NF-kappa	9
B	10
DNA	10
binding	10
motif	10
.	0

Further	0
,	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
inhibited	0
the	0
transcriptional	0
activity	0
of	0
NF-kappa	9
B	10
in	0
Jurkat	5
cells	6
transiently	0
transfected	0
with	0
a	0
construct	1
containing	0
four	0
tandem	1
repeats	2
of	0
the	0
NF-kappa	1
B	2
binding	2
sequence	2
of	0
the	0
immunoglobulin	1
kappa	2
light	2
chain	2
gene	2
linked	0
to	0
the	0
chloramphenicol	1
acetyltransferase	2
reporter	2
gene	2
.	0

These	0
observations	0
demonstrate	0
directly	0
that	0
there	0
is	0
de	0
novo	0
synthesis	0
of	0
NF-kappa	9
B	10
during	0
human	0
lymphocyte	0
activation	0
and	0
suggest	0
that	0
this	0
process	0
is	0
hormonally	0
regulated	0
.	0

The	0
myeloid	1
zinc	2
finger	2
gene	2
,	0
MZF-1	1
,	0
regulates	0
the	0
CD34	1
promoter	2
in	0
vitro	0
.	0

MZF-1	1
is	0
a	0
C2H2	1
zinc	2
finger	2
gene	2
encoding	0
a	0
putative	9
transcriptional	10
regulator	10
of	0
myeloid	0
differentiation	0
.	0

The	0
MZF-1	1
protein	0
contains	0
13	0
C2H2	9
zinc	10
fingers	10
arranged	0
in	0
bipartite	0
DNA	9
binding	10
domains	10
containing	0
zinc	9
fingers	10
through	0
4	0
and	0
,	0
in	0
the	0
carboxy-terminus	9
,	0
5	0
through	0
13	0
.	0

We	0
previously	0
identified	0
the	0
DNA	1
consensus	2
binding	2
site	2
recognized	0
by	0
the	0
two	0
DNA	9
binding	10
domains	10
.	0

To	0
assess	0
the	0
transcription	0
regulatory	0
function	0
of	0
MZF-1	1
,	0
the	0
full-length	0
MZF-1	1
coding	0
region	0
was	0
fused	0
to	0
the	0
DNA	9
binding	10
domain	10
of	0
the	0
yeast	9
transactivator	10
GAL4	10
.	0

The	0
expression	0
vector	0
was	0
cotransfected	0
with	0
the	0
chloramphenicol	1
acetyl	2
transferase	2
(	2
CAT	2
)	2
reporter	2
gene	2
regulated	0
by	0
the	0
thymidine	1
kinase	2
promoter	2
containing	0
GAL4	1
DNA	2
binding	2
sites	2
into	0
NIH	5
3T3	6
,	0
293	5
,	0
K562	5
,	0
and	0
Jurkat	5
cell	6
lines	6
.	0

MZF-1	1
represses	0
CAT	1
reporter	2
gene	2
expression	0
via	0
GAL4	9
binding	0
sites	0
in	0
the	0
nonhematopoietic	5
cell	6
lines	6
NIH	5
3T3	6
and	0
293	5
.	0

In	0
contrast	0
,	0
MZF-1	1
activates	0
CAT	1
reporter	2
gene	2
expression	0
in	0
the	0
hematopoietic	5
cell	6
lines	6
K562	5
and	0
Jurkat	5
.	0

The	0
MZF-1	1
binding	2
sites	2
are	0
present	0
in	0
the	0
promoters	1
of	0
several	0
genes	1
expressed	0
during	0
myeloid	0
differentiation	0
,	0
including	0
the	0
CD34	1
promoter	2
.	0

MZF-1	1
transcriptional	0
regulation	0
of	0
this	0
physiologically	1
relevant	2
promoter	2
was	0
assessed	0
in	0
both	0
hematopoietic	5
and	0
nonhematopoietic	5
cell	6
lines	6
.	0

Recombinant	9
MZF-1	10
protein	10
specifically	0
binds	0
to	0
the	0
consensus	1
binding	2
sites	2
in	0
the	0
CD34	1
promoter	2
in	0
mobility	0
shift	0
assays	0
.	0

MZF-1	1
expression	0
vectors	0
were	0
cotransfected	0
with	0
the	0
luciferase	1
reporter	2
plasmids	2
regulated	0
by	0
the	0
CD34	1
promoter	2
into	0
both	0
nonhematopoietic	5
and	6
hematopoietic	6
cell	6
lines	6
.	0

As	0
with	0
the	0
heterologous	0
DNA	9
binding	10
domain	10
,	0
MZF-1	1
represses	0
reporter	1
gene	2
expression	0
in	0
nonhematopoietic	5
cell	6
lines	6
and	0
activates	0
expression	0
in	0
hematopoietic	5
cell	6
lines	6
.	0

Activation	0
of	0
CD34	9
expression	0
in	0
hematopoietic	5
cell	6
lines	6
is	0
dependent	0
on	0
the	0
presence	0
of	0
intact	0
MZF-1	1
binding	2
sites	2
.	0

The	0
cell	0
type-specific	0
regulation	0
of	0
the	0
CD34	1
promoter	2
by	0
MZF-1	1
suggests	0
the	0
presence	0
of	0
tissue-specific	0
regulators/adapters	0
or	0
differential	0
MZF-1	1
modifications	0
that	0
determine	0
MZF-1	1
transcriptional	0
regulatory	0
function	0
.	0

The	0
murine	0
BCL6	1
gene	2
is	0
induced	0
in	0
activated	7
lymphocytes	8
as	0
an	0
immediate	1
early	2
gene	2
.	0

The	0
chromosomal	0
translocation	0
involving	0
3q27	1
is	0
often	0
detected	0
in	0
human	7
B-cell	8
lymphomas	8
,	0
especially	0
diffuse	0
lymphomas	0
with	0
a	0
large-cell	0
component	0
.	0

The	0
BCL6	1
gene	2
has	0
been	0
isolated	0
from	0
the	0
chromosomal	0
breakpoint	0
in	0
these	0
lymphomas	0
.	0

Here	0
we	0
cloned	0
the	0
murine	1
BCL6	2
(	2
mBCL6	2
)	2
cDNA	2
from	0
the	0
muscle	1
cDNA	2
library	2
using	0
the	0
human	1
BCL6	2
(	2
hBCL6	2
)	2
cDNA	2
as	0
a	0
probe	0
.	0

The	0
predicted	0
amino	0
acid	0
sequence	0
was	0
95	0
%	0
identical	0
to	0
that	0
of	0
hBCL6	9
.	0

It	0
contains	0
six	0
repeats	0
of	0
the	0
Kruppel-like	9
zinc-finger	10
motif	10
that	0
are	0
completely	0
identical	0
to	0
those	0
of	0
hBCL6	9
,	0
indicating	0
that	0
the	0
BCL6	1
gene	2
is	0
well	0
conserved	0
between	0
humans	0
and	0
mice	0
.	0

Expression	0
of	0
the	0
mBCL6	1
gene	2
was	0
ubiquitously	0
detected	0
in	0
adult	0
mouse	0
tissues	0
including	0
lymphatic	0
organs	0
.	0

Furthermore	0
,	0
it	0
was	0
induced	0
in	0
lymphocytes	7
activated	0
with	0
phorbol	0
ester	0
and	0
Ca2+	0
ionophore	0
within	0
30	0
min	0
after	0
stimulation	0
.	0

This	0
induction	0
was	0
not	0
inhibited	0
by	0
treatment	0
of	0
the	0
cells	0
with	0
a	0
protein	0
synthesis	0
inhibitor	0
,	0
cycloheximide	0
.	0

These	0
results	0
suggest	0
that	0
BCL6	9
plays	0
a	0
role	0
in	0
activated	7
lymphocytes	8
as	0
an	0
immediate	0
early	0
gene	0
.	0

The	0
role	0
of	0
BSAP	9
(	0
Pax-5	9
)	0
in	0
B-cell	0
development	0
.	0

The	0
hierarchy	0
of	0
transcriptional	0
control	0
in	0
B-cell	0
development	0
has	0
recently	0
been	0
analyzed	0
by	0
targeted	0
gene	0
inactivation	0
in	0
the	0
mouse	0
.	0

In	0
this	0
manner	0
,	0
the	0
paired	1
box	2
containing	2
gene	2
Pax-5	1
,	0
encoding	0
the	0
B	9
cell	10
specific	10
transcription	10
factor	10
BSAP	9
,	0
has	0
been	0
shown	0
to	0
play	0
a	0
key	0
role	0
in	0
early	0
B	0
lymphopoiesis	0
.	0

Other	0
experimental	0
strategies	0
have	0
implicated	0
BSAP	9
in	0
the	0
control	0
of	0
cell	0
proliferation	0
,	0
isotype	0
switching	0
and	0
transcription	0
of	0
the	0
immunoglobulin	9
heavy-chain	10
gene	0
at	0
late	0
stages	0
of	0
B-cell	0
differentiation	0
.	0

The	0
DNA-binding	0
properties	0
of	0
two	9
heat	10
shock	10
factors	10
,	0
HSF1	9
and	0
HSF3	9
,	0
are	0
induced	0
in	0
the	0
avian	5
erythroblast	6
cell	6
line	6
HD6	5
.	0

Avian	0
cells	0
express	0
three	0
heat	1
shock	2
transcription	2
factor	2
(	2
HSF	2
)	2
genes	2
corresponding	0
to	0
a	0
novel	9
factor	10
,	0
HSF3	9
,	0
and	0
homologs	0
of	0
mouse	0
and	0
human	0
HSF1	9
and	0
HSF2	9
.	0

Analysis	0
of	0
the	0
biochemical	0
and	0
cell	0
biological	0
properties	0
of	0
these	0
HSFs	9
reveals	0
that	0
HSF3	9
has	0
properties	0
in	0
common	0
with	0
both	0
HSF1	9
and	0
HSF2	9
and	0
yet	0
has	0
features	0
which	0
are	0
distinct	0
from	0
both	0
.	0

HSF3	9
is	0
constitutively	0
expressed	0
in	0
the	0
erythroblast	5
cell	6
line	6
HD6	6
,	0
the	0
lymphoblast	5
cell	6
line	6
MSB	6
,	0
and	0
embryo	5
fibroblasts	6
,	0
and	0
yet	0
its	0
DNA-binding	0
activity	0
is	0
induced	0
only	0
upon	0
exposure	0
of	0
HD6	0
cells	0
to	0
heat	0
shock	0
.	0

Acquisition	0
of	0
HSF3	9
DNA-binding	0
activity	0
in	0
HD6	5
cells	6
is	0
accompanied	0
by	0
oligomerization	0
from	0
a	0
non-DNA-binding	9
dimer	10
to	0
a	0
DNA-binding	9
trimer	10
,	0
whereas	0
the	0
effect	0
of	0
heat	0
shock	0
on	0
HSF1	9
is	0
oligomerization	0
of	0
an	0
inert	9
monomer	10
to	0
a	0
DNA-binding	9
trimer	10
.	0

Induction	0
of	0
HSF3	9
DNA-binding	0
activity	0
is	0
delayed	0
compared	0
with	0
that	0
of	0
HSF1	9
.	0

As	0
occurs	0
for	0
HSF1	9
,	0
heat	0
shock	0
leads	0
to	0
the	0
translocation	0
of	0
HSF3	9
to	0
the	0
nucleus	0
.	0

HSF	0
exhibits	0
the	0
properties	0
of	0
a	0
transcriptional	9
activator	10
,	0
as	0
judged	0
from	0
the	0
stimulatory	0
activity	0
of	0
transiently	9
overexpressed	10
HSF3	10
measured	0
by	0
using	0
a	0
heat	1
shock	2
element-containing	2
reporter	2
construct	2
and	0
as	0
independently	0
assayed	0
by	0
the	0
activity	0
of	0
a	0
chimeric	9
GAL4-HSF3	10
protein	10
on	0
a	0
GAL4	1
reporter	2
construct	2
.	0

These	0
results	0
reveal	0
that	0
HSF3	9
is	0
negatively	0
regulated	0
in	0
avian	7
cells	8
and	0
acquires	0
DNA-binding	0
activity	0
in	0
certain	0
cells	0
upon	0
heat	0
shock	0
.	0

Direct	0
demonstration	0
of	0
NFATp	9
dephosphorylation	0
and	0
nuclear	0
localization	0
in	0
activated	5
HT-2	6
cells	6
using	0
a	0
specific	0
NFATp	9
polyclonal	10
antibody	10
.	0

Nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
regulates	0
transcription	0
of	0
a	0
number	0
of	0
cytokine	9
genes	10
,	0
and	0
NFAT	9
DNA	0
binding	0
activity	0
is	0
stimulated	0
following	0
T	0
cell	0
activation	0
.	0

Several	0
lines	0
of	0
evidence	0
have	0
suggested	0
that	0
NFAT	9
is	0
a	0
substrate	0
for	0
calcineurin	9
,	0
a	0
serine/threonine	9
phosphatase	10
.	0

Using	0
a	0
polyclonal	0
antibody	0
to	0
murine	9
NFATp	10
,	0
Western	0
blot	0
analysis	0
of	0
various	0
mouse	0
tissues	0
demonstrated	0
that	0
the	0
110-130-kDa	0
NFATp	9
protein	10
was	0
highly	0
expressed	0
in	0
thymus	0
and	0
spleen	0
.	0

Treatment	0
of	0
immunoprecipitated	0
NFATp	9
from	0
untreated	0
HT-2	5
cells	6
with	0
calcineurin	9
resulted	0
in	0
the	0
dephosphorylation	0
of	0
NFATp	9
,	0
demonstrating	0
that	0
NFATp	9
is	0
an	0
in	0
vitro	0
substrate	0
for	0
calcineurin	9
.	0

NFATp	9
immunoprecipitated	0
from	0
32P-labeled	5
HT-2	6
cells	6
migrated	0
as	0
an	0
approximately	0
120-kDa	0
protein	0
that	0
was	0
localized	0
to	0
the	0
cytosol	0
of	0
the	0
cells	0
.	0

Treatment	0
of	0
the	0
cells	0
with	0
ionomycin	0
resulted	0
in	0
a	0
decrease	0
in	0
the	0
molecular	0
weight	0
of	0
NFATp	9
and	0
a	0
loss	0
of	0
32P	0
,	0
consistent	0
with	0
NFATp	9
dephosphorylation	0
.	0

The	0
dephosphorylation	0
of	0
NFATp	9
was	0
accompanied	0
by	0
localization	0
of	0
the	0
protein	0
to	0
the	0
nuclear	0
fraction	0
.	0

Both	0
of	0
these	0
events	0
were	0
blocked	0
by	0
preincubation	0
of	0
the	0
cells	0
with	0
FK506	0
,	0
a	0
calcineurin	9
inhibitor	0
,	0
consistent	0
with	0
the	0
hypothesis	0
that	0
NFATp	9
is	0
a	0
calcineurin	9
substrate	0
in	0
cells	0
.	0

Activation	0
and	0
expression	0
of	0
the	0
nuclear	9
factors	10
of	0
activated	7
T	8
cells	8
,	0
NFATp	9
and	0
NFATc	9
,	0
in	0
human	7
natural	8
killer	8
cells	8
:	0
regulation	0
upon	0
CD16	9
ligand	0
binding	0
.	0

The	0
putative	0
factors	0
that	0
couple	0
the	0
signal	0
transduction	0
from	0
surface	0
receptors	0
to	0
the	0
activation	0
of	0
cytokine	9
synthesis	0
in	0
natural	7
killer	8
(	8
NK	8
)	8
cells	8
have	0
not	0
been	0
elucidated	0
.	0

We	0
report	0
here	0
that	0
the	0
nuclear	9
factor	10
of	0
activated	7
T	8
cells	8
(	0
NFATp	9
)	0
,	0
a	0
cyclosporin	9
A	10
(	10
CsA	10
)	10
-sensitive	10
factor	10
that	0
regulates	0
the	0
transcription	0
of	0
several	0
cytokines	9
,	0
mediates	0
CD16	9
-induced	0
activation	0
of	0
cytokine	9
genes	10
in	0
human	7
NK	8
cells	8
.	0

CD16	9
(	0
Fc	9
gamma	10
RIIIA	10
)	0
-induced	0
expression	0
of	0
cytokine	3
mRNA	4
in	0
NK	7
cells	8
occurs	0
via	0
a	0
CsA-sensitive	0
and	0
Ca	0
(	0
2+	0
)	0
-dependent	0
mechanism	0
.	0

Stimulation	0
of	0
NK	7
cells	8
with	0
CD16	9
ligands	0
induces	0
NFAT	9
-like	0
DNA	0
binding	0
activity	0
in	0
the	0
nuclear	0
extracts	0
from	0
these	0
cells	0
,	0
as	0
detected	0
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

This	0
occurs	0
with	0
fast	0
kinetics	0
after	0
stimulation	0
,	0
via	0
a	0
CsA-sensitive	0
and	0
Ca	0
(	0
2+	0
)	0
-dependent	0
mechanism	0
that	0
does	0
not	0
require	0
de	0
novo	0
protein	0
synthesis	0
.	0

NK	9
cell	10
NFAT	10
is	0
present	0
in	0
the	0
cytosol	0
of	0
nonstimulated	7
cells	8
,	0
migrates	0
to	0
the	0
nucleus	0
upon	0
stimulation	0
,	0
and	0
can	0
associate	0
with	0
AP-1	9
.	0

Two	0
distinct	0
molecules	0
,	0
NFATp	9
and	0
NFATc	9
,	0
have	0
been	0
reported	0
to	0
mediate	0
NFAT	9
activity	0
.	0

The	0
results	0
of	0
supershift	0
assays	0
using	0
NFATp-	9
and	10
NFATc-	10
specific	10
antibodies	10
indicate	0
that	0
NK	0
cell	0
activation	0
early	0
after	0
CD16	9
ligand	0
binding	0
involves	0
primarily	0
,	0
if	0
not	0
exclusively	0
,	0
NFATp	9
,	0
and	0
Western	0
blot	0
analysis	0
shows	0
that	0
this	0
has	0
the	0
same	0
electrophoretic	0
mobility	0
(	0
approximately	0
120	0
kD	0
)	0
as	0
that	0
of	0
T	7
lymphocytes	8
.	0

NK	7
cells	8
do	0
not	0
express	0
NFATc	9
constitutively	0
,	0
but	0
NFATc	3
mRNA	4
accumulation	0
is	0
induced	0
in	0
these	0
cells	0
within	0
2	0
h	0
of	0
stimulation	0
with	0
CD16	0
ligands	0
.	0

However	0
,	0
supershift	0
assays	0
using	0
the	0
available	0
mAb	9
recognizing	0
the	0
T	9
cell	10
NFATc	10
revealed	0
no	0
detectable	0
NFATc	9
protein	0
in	0
nuclear	0
and	0
cytoplasmic	0
extracts	0
from	0
CD16-	0
or	0
phorbol	5
ester-stimulated	6
cells	6
at	0
any	0
time	0
tested	0
,	0
up	0
to	0
4	0
h	0
.	0

These	0
results	0
provide	0
the	0
first	0
direct	0
evidence	0
that	0
both	0
CsA-sensitive	9
transcription	10
factors	10
,	0
NFATp	9
and	0
NFATc	9
,	0
are	0
expressed	0
in	0
human	0
NK	7
cells	8
,	0
and	0
that	0
their	0
activation	0
and/or	0
expression	0
can	0
be	0
regulated	0
in	0
primary	0
cells	0
by	0
a	0
single	0
stimulus	0
,	0
that	0
,	0
in	0
the	0
case	0
of	0
CD16	0
in	0
NK	7
cells	8
,	0
results	0
in	0
early	0
activation	0
of	0
NFATp	9
and	0
subsequently	0
induced	0
expression	0
of	0
NFATc	3
mRNA	4
.	0

Interleukin	0
2	0
signaling	0
involves	0
the	0
phosphorylation	0
of	0
Stat	9
proteins	10
.	0

One	0
of	0
the	0
most	0
important	0
cytokines	9
involved	0
in	0
immune	0
response	0
regulation	0
is	0
interleukin	0
2	0
(	0
IL-2	0
)	0
,	0
a	0
potent	0
activator	0
of	0
the	0
proliferation	0
and	0
function	0
of	0
T	7
lymphocytes	8
and	0
natural	7
killer	8
cells	8
.	0

The	0
mechanisms	0
by	0
which	0
the	0
effects	0
of	0
IL-2	9
are	0
propagated	0
within	0
cells	0
are	0
not	0
understood	0
.	0

While	0
the	0
binding	0
of	0
IL-2	9
to	0
its	0
receptor	0
was	0
recently	0
shown	0
to	0
lead	0
to	0
the	0
activation	0
of	0
two	0
kinases	9
,	0
Jak-1	9
and	0
Jak-3	9
,	0
subsequent	0
steps	0
in	0
the	0
signaling	0
pathway	0
to	0
the	0
nucleus	0
that	0
lead	0
to	0
the	0
activation	0
of	0
specific	0
genes	0
had	0
not	0
been	0
characterized	0
.	0

Since	0
many	0
cytokines	9
that	0
activate	0
Jak	9
kinases	10
also	0
lead	0
to	0
the	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
members	0
of	0
the	0
Stat	9
family	10
of	0
transcription	9
factors	10
,	0
the	0
ability	0
of	0
IL-2	9
to	0
trigger	0
Stat	0
phosphorylation	0
was	0
examined	0
.	0

Exposure	0
of	0
activated	0
human	7
T	8
lymphocytes	8
or	0
of	0
a	0
natural	5
killer	6
cell	6
line	6
(	0
NKL	5
)	0
to	0
IL-2	9
leads	0
to	0
the	0
phosphorylation	0
of	0
Stat1	9
alpha	10
,	0
Stat1	0
beta	0
,	0
and	0
Stat3	9
,	0
as	0
well	0
as	0
of	0
two	0
Stat-related	9
proteins	10
,	0
p94	9
and	0
p95	9
.	0

p94	9
and	0
p95	9
share	0
homology	0
with	0
Stat1	9
at	0
the	0
phosphorylation	9
site	10
and	0
in	0
the	0
Src	9
homology	10
2	10
(	10
SH2	10
)	10
domain	10
,	0
but	0
otherwise	0
are	0
immunologically	0
distinct	0
from	0
Stat1	9
.	0

These	0
Stat	9
proteins	10
were	0
found	0
to	0
translocate	0
to	0
the	0
nucleus	0
and	0
to	0
bind	0
to	0
a	0
specific	1
DNA	2
sequence	2
.	0

These	0
findings	0
suggest	0
a	0
mechanism	0
by	0
which	0
IL-2	9
binding	0
to	0
its	0
receptor	0
may	0
activate	0
specific	1
genes	2
involved	0
in	0
immune	0
cell	0
function	0
.	0

Expression	0
of	0
c-fos	1
correlates	0
with	0
IFN-alpha	9
responsiveness	0
in	0
Philadelphia	0
chromosome	0
positive	0
chronic	0
myelogenous	0
leukemia	0
.	0

This	0
study	0
evaluates	0
(	0
i	0
)	0
constitutive	0
levels	0
of	0
oncogene	1
and	0
p53	3
transcripts	4
in	0
chronic	0
phase	0
CML	0
patients	0
and	0
(	0
ii	0
)	0
their	0
modulations	0
subsequent	0
to	0
in	0
vivo	0
therapy	0
with	0
rIFN-alpha	9
2c	10
.	0

Peripheral	7
blood	8
mononuclear	8
cells	8
(	0
pbmc	7
)	0
and	0
bone	7
marrow	8
cells	8
of	0
26	0
patients	0
were	0
examined	0
for	0
c-fos	0
,	0
c-myc	0
,	0
p53	0
and	0
the	0
hybrid	0
bcr/abl	0
mRNA	0
levels	0
.	0

Results	0
indicated	0
that	0
(	0
i	0
)	0
constitutive	0
c-fos	3
transcript	4
levels	0
are	0
significantly	0
higher	0
in	0
patients	0
subsequently	0
responding	0
to	0
IFN-alpha	9
therapy	0
(	0
p	0
<	0
0.01	0
)	0
and	0
positively	0
correlated	0
with	0
the	0
proportion	0
of	0
lymphocytes	7
(	0
r	0
=	0
0.6895	0
,	0
p	0
<	0
0.01	0
)	0
and	0
negatively	0
with	0
the	0
proportion	0
of	0
immature	7
cells	8
(	0
r	0
=	0
-0.568	0
,	0
p	0
<	0
0.01	0
)	0
contained	0
in	0
the	0
pbmc	7
preparations	0
tested	0
,	0
(	0
ii	0
)	0
constitutive	3
mRNA	4
levels	0
of	0
the	0
hybrid	1
bcr/abl	2
,	0
c-myc	1
and	0
p53	1
are	0
positively	0
correlated	0
with	0
each	0
other	0
,	0
but	0
failed	0
to	0
relate	0
to	0
disease	0
parameters	0
,	0
and	0
(	0
iii	0
)	0
acute	0
and	0
chronic	0
in	0
vivo	0
exposure	0
to	0
IFN-alpha	9
is	0
accompanied	0
by	0
upregulation	0
of	0
c-fos	1
and	0
downregulation	0
of	0
c-myc	3
mRNA	4
levels	0
in	0
responder	0
patients	0
.	0

Menopause	0
is	0
associated	0
with	0
a	0
significant	0
increase	0
in	0
blood	0
monocyte	0
number	0
and	0
a	0
relative	0
decrease	0
in	0
the	0
expression	0
of	0
estrogen	9
receptors	10
in	0
human	7
peripheral	8
monocytes	8
.	0

PROBLEM	0
:	0
The	0
clinical	0
significance	0
of	0
the	0
differential	0
expression	0
of	0
estrogen	9
receptor	10
(	0
ER	9
)	0
in	0
human	7
monocytes	8
was	0
evaluated	0
.	0

METHOD	0
:	0
Two	0
color	0
flow	0
cytometry	0
analysis	0
was	0
used	0
on	0
peripheral	0
blood	0
samples	0
of	0
young	0
and	0
postmenopausal	0
females	0
and	0
postmenopausal	0
females	0
treated	0
with	0
estrogen	0
replacement	0
therapy	0
.	0

In	0
addition	0
,	0
the	0
monocyte	0
and	0
lymphocyte	0
counts	0
and	0
the	0
blood	0
estrogen	0
levels	0
of	0
each	0
patient	0
were	0
determine	0
.	0

RESULTS	0
:	0
During	0
menopause	0
there	0
is	0
a	0
significant	0
decrease	0
in	0
the	0
percentage	0
of	0
ER	7
positive	8
monocytes	8
,	0
and	0
an	0
increase	0
in	0
blood	7
monocyte	8
number	0
,	0
which	0
declines	0
following	0
estrogen	0
replacement	0
therapy	0
to	0
values	0
of	0
the	0
young	0
.	0

CONCLUSIONS	0
:	0
These	0
findings	0
suggest	0
that	0
estrogen	0
modulates	0
the	0
monocyte	7
numbers	0
and	0
its	0
effects	0
may	0
be	0
mediated	0
through	0
the	0
ER	9
in	0
the	0
monocytes	7
.	0

Staphylococcal	9
enterotoxins	10
modulate	0
interleukin	9
2	10
receptor	10
expression	0
and	0
ligand-induced	0
tyrosine	0
phosphorylation	0
of	0
the	0
Janus	9
protein-tyrosine	10
kinase	10
3	10
(	0
Jak3	9
)	0
and	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
Stat	9
proteins	10
)	0
.	0

Staphylococcal	9
enterotoxins	10
(	0
SE	9
)	0
stimulate	0
T	7
cells	8
expressing	0
the	0
appropriate	0
variable	9
region	10
beta	10
chain	10
of	10
(	10
V	10
beta	10
)	10
T-cell	10
receptors	10
and	0
have	0
been	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
several	0
autoimmune	0
diseases	0
.	0

Depending	0
on	0
costimulatory	0
signals	0
,	0
SE	9
induce	0
either	0
proliferation	0
or	0
anergy	0
in	0
T	7
cells	8
.	0

In	0
addition	0
,	0
SE	9
can	0
induce	0
an	0
interleukin-2	9
(	0
IL-2	9
)	0
nonresponsive	0
state	0
and	0
apoptosis	0
.	0

Here	0
,	0
we	0
show	0
that	0
SE	9
induce	0
dynamic	0
changes	0
in	0
the	0
expression	0
of	0
and	0
signal	0
transduction	0
through	0
the	0
IL-2	9
receptor	10
(	10
IL-2R	10
)	10
beta	10
and	10
gamma	10
chains	10
(	0
IL-2R	9
beta	10
and	0
IL-2R	9
gamma	10
)	0
in	0
human	5
antigen-specific	6
CD4+	6
T-cell	6
lines	6
.	0

Thus	0
,	0
after	0
4	0
hr	0
of	0
exposure	0
to	0
SEA	9
and	0
SEB	9
,	0
the	0
expression	0
of	0
IL-2R	9
beta	10
was	0
down-regulated	0
,	0
IL-2R	9
gamma	10
was	0
slightly	0
up-regulated	0
,	0
while	0
IL-2R	9
alpha	10
remained	0
largely	0
unaffected	0
.	0

The	0
changes	0
in	0
the	0
composition	0
of	0
IL-2Rs	9
were	0
accompanied	0
by	0
inhibition	0
of	0
IL-2	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
the	0
Janus	9
protein-tyrosine	10
kinase	10
3	10
(	0
Jak3	9
)	0
and	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
called	0
Stat3	9
and	0
Stat5	9
.	0

In	0
parallel	0
experiments	0
,	0
IL-2	9
-driven	0
proliferation	0
was	0
inhibited	0
significantly	0
.	0

After	0
16	0
hr	0
of	0
exposure	0
to	0
SE	9
,	0
the	0
expression	0
of	0
IL-2R	9
beta	10
remained	0
low	0
,	0
while	0
that	0
of	0
IL2R	9
alpha	10
and	0
IL2R	9
gamma	10
was	0
further	0
up-regulated	0
,	0
and	0
ligand-induced	0
tyrosine	0
phosphorylation	0
of	0
Jak3	9
and	0
Stat	9
proteins	10
was	0
partly	0
normalized	0
.	0

Yet	0
,	0
IL-2	9
-driven	0
proliferation	0
remained	0
profoundly	0
inhibited	0
,	0
suggesting	0
that	0
signaling	0
events	0
other	0
than	0
Jak3	9
/Stat	9
activation	0
had	0
also	0
been	0
changed	0
following	0
SE	9
stimulation	0
.	0

In	0
conclusion	0
,	0
our	0
data	0
suggest	0
that	0
SE	9
can	0
modulate	0
IL-2R	9
expression	0
and	0
signal	0
transduction	0
involving	0
the	0
Jak/Stat	9
pathway	0
in	0
CD4+	5
T-cell	6
lines	6
.	0

Constitutive	0
NF-kappa	9
B	10
activation	0
,	0
enhanced	0
granulopoiesis	0
,	0
and	0
neonatal	0
lethality	0
in	0
I	9
kappa	10
B	10
alpha	10
-deficient	0
mice	0
.	0

Transcription	9
factors	10
belonging	0
to	0
the	0
NF-kappa	9
B	10
family	10
are	0
controlled	0
by	0
inhibitory	9
I	10
kappa	10
B	10
proteins	10
,	0
mainly	0
I	9
kappa	10
B	10
alpha	10
and	0
I	9
kappa	10
B	10
beta	10
.	0

Apparently	0
normal	0
at	0
birth	0
,	0
I	9
kappa	10
B	10
alpha	10
-/-	0
mice	0
exhibit	0
severe	0
runting	0
,	0
skin	0
defects	0
,	0
and	0
extensive	0
granulopoiesis	0
postnatally	0
,	0
typically	0
dying	0
by	0
8	0
days	0
.	0

Hematopoietic	0
tissues	0
from	0
these	0
mice	0
display	0
elevated	0
levels	0
of	0
both	0
nuclear	9
NF-kappa	10
B	10
and	0
mRNAs	3
of	0
some	0
,	0
but	0
not	0
all	0
,	0
genes	0
thought	0
to	0
be	0
regulated	0
by	0
NF-kappa	9
B	10
.	0

NF-kappa	9
B	10
elevation	0
results	0
in	0
these	0
phenotypic	0
abnormalities	0
because	0
mice	0
lacking	0
both	0
I	9
kappa	10
B	10
alpha	10
and	0
the	0
p50	9
subunit	10
of	0
NF-kappa	9
B	10
show	0
a	0
dramatically	0
delayed	0
onset	0
of	0
abnormalities	0
.	0

In	0
contrast	0
to	0
hematopoietic	7
cells	8
,	0
I	5
kappa	6
B	6
alpha-/-	6
embryonic	6
fibroblasts	6
show	0
minimal	0
constitutive	9
NF-kappa	10
B	10
,	0
as	0
well	0
as	0
normal	0
signal-dependent	0
NF-kappa	9
B	10
activation	0
that	0
is	0
concomitant	0
with	0
I	9
kappa	10
B	10
beta	10
degradation	0
.	0

Our	0
results	0
indicate	0
that	0
I	0
kappa	0
b	0
beta	0
,	0
but	0
not	0
I	9
kappa	10
B	10
alpha	10
,	0
is	0
required	0
for	0
the	0
signal-dependent	0
activation	0
of	0
NF-kappa	9
B	10
in	0
fibroblasts	7
.	0

However	0
,	0
I	9
kappa	10
B	10
alpha	10
is	0
required	0
for	0
the	0
postinduction	0
repression	0
of	0
NF-kappa	9
B	10
in	0
fibroblasts	7
.	0

These	0
results	0
define	0
distinct	0
roles	0
for	0
the	0
two	0
forms	0
of	0
I	9
kappa	10
B	10
and	0
demonstrate	0
the	0
necessity	0
for	0
stringent	0
control	0
of	0
NF-kappa	9
B	10
.	0

Interleukin-7	9
can	0
induce	0
the	0
activation	0
of	0
Jak	9
1	10
,	0
Jak	9
3	10
and	0
STAT	9
5	10
proteins	10
in	0
murine	0
T	7
cells	8
.	0

The	0
activation	0
of	0
Janus	9
protein	10
tyrosine	10
kinases	10
(	0
Jak	9
)	0
and	0
STAT	9
(	10
signal	10
transducer	10
and	10
activator	10
of	10
transcription	10
)	10
proteins	10
has	0
recently	0
been	0
linked	0
to	0
the	0
signal	0
transduction	0
mechanism	0
of	0
several	0
cytokines	9
.	0

IL-7	9
was	0
observed	0
to	0
induce	0
a	0
rapid	0
and	0
dose-dependent	0
tyrosine	0
phosphorylation	0
of	0
Jak	9
1	10
and	0
Jak	9
3	10
and	0
concomitantly	0
,	0
the	0
tyrosine	0
phosphorylation	0
and	0
DNA	0
binding	0
activity	0
of	0
multiple	0
STAT	9
proteins	10
.	0

The	0
STAT	9
proteins	10
utilized	0
by	0
IL-7	9
were	0
identical	0
to	0
those	0
induced	0
by	0
IL-2	9
and	0
could	0
be	0
identified	0
as	0
various	0
STAT	9
5	10
isoforms	10
.	0

Moreover	0
,	0
the	0
induction	0
of	0
both	0
Jak	9
1	10
and	10
3	10
,	0
and	0
STAT	9
5	10
activity	0
strongly	0
correlated	0
with	0
the	0
growth-promoting	0
effects	0
of	0
IL-7	9
,	0
suggesting	0
that	0
this	0
signal	0
transduction	0
mechanism	0
may	0
play	0
a	0
key	0
role	0
in	0
IL-7	9
-induced	0
proliferation	0
.	0

Cytokine	9
-modulating	0
activity	0
of	0
tepoxalin	0
,	0
a	0
new	0
potential	0
antirheumatic	0
.	0

Tepoxalin	0
is	0
a	0
new	0
dual	0
cyclooxygenase/5-lipoxygenase	0
anti-inflammatory	0
compound	0
currently	0
under	0
clinical	0
investigation	0
.	0

It	0
has	0
been	0
shown	0
to	0
possess	0
anti-inflammatory	0
activity	0
in	0
a	0
variety	0
of	0
animal	0
models	0
and	0
more	0
recently	0
to	0
inhibit	0
IL-2	9
induced	0
signal	0
transduction	0
.	0

The	0
current	0
study	0
was	0
conducted	0
to	0
evaluate	0
the	0
cytokine	9
modulating	0
activity	0
of	0
tepoxalin	0
and	0
the	0
role	0
of	0
iron	0
in	0
these	0
effects	0
.	0

In	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
stimulated	0
with	0
OKT3/PMA	0
,	0
tepoxalin	0
inhibited	0
lymphocyte	7
proliferation	0
with	0
an	0
IC50	0
of	0
6	0
microM	0
.	0

Additionally	0
,	0
it	0
inhibited	0
the	0
production	0
of	0
LTB4	9
(	0
IC50	0
=	0
0.5	0
microM	0
)	0
and	0
the	0
cytokines	9
IL-2	9
,	0
IL-6	9
and	0
TNF	9
alpha	10
(	0
IC50	0
=	0
10-12	0
microM	0
)	0
.	0

Cytotoxicity	0
was	0
not	0
demonstrated	0
at	0
these	0
concentrations	0
.	0

Add-back	0
experiments	0
with	0
either	0
cytokines	9
(	0
IL-2	9
or	0
IL-6	9
)	0
,	0
LTB4	9
or	0
conditioned	0
media	0
failed	0
to	0
restore	0
the	0
proliferative	0
response	0
in	0
the	0
presence	0
of	0
tepoxalin	0
.	0

However	0
,	0
the	0
concurrent	0
addition	0
of	0
iron	0
(	0
in	0
the	0
form	0
of	0
ferrous	0
or	0
ferric	0
chloride	0
and	0
other	0
iron	0
salts	0
)	0
reversed	0
the	0
inhibition	0
of	0
proliferation	0
caused	0
by	0
tepoxalin	0
.	0

Tepoxalin	0
also	0
inhibits	0
the	0
activation	0
of	0
NF	9
kappa	10
B	10
,	0
a	0
transcription	9
factor	10
which	0
acts	0
on	0
several	0
cytokine	1
genes	2
.	0

Tepoxalin	0
's	0
effect	0
on	0
NF	9
kappa	10
B	10
is	0
also	0
reversed	0
by	0
the	0
addition	0
of	0
iron	0
salts	0
.	0

These	0
data	0
suggest	0
that	0
the	0
action	0
of	0
tepoxalin	0
to	0
inhibit	0
proliferation	0
in	0
PBMC	7
may	0
be	0
at	0
least	0
in	0
part	0
due	0
to	0
its	0
ability	0
to	0
reduce	0
the	0
amount	0
of	0
available	0
iron	0
resulting	0
in	0
decreased	0
activation	0
of	0
NF	9
kappa	10
B	10
and	0
subsequent	0
inhibition	0
of	0
cytokine	9
production	0
.	0

N-	9
and	10
C-terminal	10
sequences	10
control	0
degradation	0
of	0
MAD3/I	9
kappa	10
B	10
alpha	10
in	0
response	0
to	0
inducers	0
of	0
NF-kappa	9
B	10
activity	0
.	0

The	0
proteolytic	0
degradation	0
of	0
the	0
inhibitory	9
protein	10
MAD3/I	9
kappa	10
B	10
alpha	10
in	0
response	0
to	0
extracellular	0
stimulation	0
is	0
a	0
prerequisite	0
step	0
in	0
the	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
.	0

Analysis	0
of	0
the	0
expression	0
of	0
human	9
I	10
kappa	10
B	10
alpha	10
protein	10
in	0
stable	0
transfectants	0
of	0
mouse	5
70Z/3	6
cells	6
shows	0
that	0
,	0
as	0
for	0
the	0
endogenous	0
murine	0
protein	0
,	0
exogenous	0
I	9
kappa	10
B	10
alpha	10
is	0
degraded	0
in	0
response	0
to	0
inducers	0
of	0
NF-kappa	9
B	10
activity	0
,	0
such	0
as	0
phorbol	0
myristate	0
acetate	0
or	0
lipopolysaccharide	0
.	0

In	0
addition	0
,	0
pretreatment	0
of	0
the	0
cells	0
with	0
the	0
proteasome	9
inhibitor	0
N-Ac-Leu-Leu-norleucinal	0
inhibits	0
this	0
ligand-induced	0
degradation	0
and	0
,	0
in	0
agreement	0
with	0
previous	0
studies	0
,	0
stabilizes	0
a	0
hyperphosphorylated	0
form	0
of	0
the	0
human	9
I	10
kappa	10
B	10
alpha	10
protein	10
.	0

By	0
expressing	0
mutant	0
forms	0
of	0
the	0
human	0
protein	0
in	0
this	0
cell	5
line	6
,	0
we	0
have	0
been	0
able	0
to	0
delineate	0
the	0
sequences	0
responsible	0
for	0
both	0
the	0
ligand-induced	0
phosphorylation	0
and	0
the	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

Our	0
results	0
show	0
that	0
deletion	0
of	0
the	0
C	9
terminus	10
of	0
the	0
I	9
kappa	10
B	10
alpha	10
molecule	0
up	0
to	0
amino	9
acid	10
279	10
abolishes	0
constitutive	0
but	0
not	0
ligand-inducible	0
phosphorylation	0
and	0
inhibits	0
ligand-inducible	0
degradation	0
.	0

Further	0
analysis	0
reveals	0
that	0
the	0
inducible	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
maps	0
to	0
two	0
serines	0
in	0
the	0
N	9
terminus	10
of	0
the	0
protein	0
(	0
residues	0
32	0
and	0
36	0
)	0
and	0
that	0
the	0
mutation	0
of	0
either	0
residue	0
is	0
sufficient	0
to	0
abolish	0
ligand-induced	0
degradation	0
,	0
whereas	0
both	0
residues	0
must	0
be	0
mutated	0
to	0
abolish	0
inducible	0
phosphorylation	0
of	0
the	0
protein	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Microtubules	9
mediate	0
cellular	0
25-hydroxyvitamin	0
D3	0
trafficking	0
and	0
the	0
genomic	0
response	0
to	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
in	0
normal	0
human	7
monocytes	8
.	0

The	0
genomic	0
actions	0
of	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
)	0
are	0
mediated	0
by	0
the	0
intracellular	0
vitamin	9
D	10
receptor	10
(	0
VDR	9
)	0
.	0

Although	0
immunocytochemistry	0
has	0
shown	0
that	0
disruption	0
of	0
microtubular	0
assembly	0
prevents	0
nuclear	0
access	0
of	0
the	0
sterol-VDR	9
complex	10
,	0
the	0
role	0
of	0
microtubules	9
in	0
the	0
response	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
has	0
not	0
been	0
studied	0
in	0
viable	7
cells	8
.	0

Our	0
studies	0
examined	0
this	0
interaction	0
in	0
normal	0
human	7
monocytes	8
.	0

Monocytes	0
convert	0
25	0
(	0
OH	0
)	0
D3	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
and	0
to	0
24-hydroxylated	0
metabolites	0
more	0
polar	0
than	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

Microtubule	0
disruption	0
totally	0
abolished	0
the	0
ability	0
of	0
exogenous	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
to	0
suppress	0
its	0
own	0
synthesis	0
and	0
to	0
induce	0
24-hydroxylase	3
mRNA	4
and	0
activity	0
,	0
without	0
affecting	0
either	0
total	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
uptake	0
or	0
maximal	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
-VDR	9
binding	0
.	0

Thus	0
,	0
intact	0
microtubules	9
are	0
essential	0
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3-dependent	0
modulation	0
of	0
gene	0
transcription	0
.	0

Interestingly	0
,	0
microtubule	9
disruption	0
also	0
decreased	0
monocyte	7
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
synthesis	0
,	0
not	0
by	0
decreasing	0
the	0
Vmax	0
of	0
monocyte	9
mitochondrial	10
1	10
alpha-hydroxylase	10
but	0
through	0
an	0
increase	0
in	0
the	0
Km	0
for	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

We	0
examined	0
25	0
(	0
OH	0
)	0
D3	0
transport	0
.	0

Microtubule	0
disruption	0
did	0
not	0
affect	0
total	0
cellular	0
25	0
(	0
OH	0
)	0
D3	0
uptake	0
but	0
reduced	0
its	0
intracellular	0
trafficking	0
to	0
the	0
mitochondria	0
.	0

Thus	0
,	0
microtubules	9
participate	0
in	0
intracellular	0
25	0
(	0
OH	0
)	0
D3	0
transport	0
,	0
and	0
their	0
integrity	0
determines	0
normal	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
synthesis	0
.	0

Relationship	0
between	0
Rap1	9
protein	10
phosphorylation	0
and	0
regulation	0
of	0
Ca2+	0
transport	0
in	0
platelets	7
:	0
a	0
new	0
approach	0
.	0

Although	0
the	0
interrelationship	0
between	0
the	0
two	0
messengers	0
Ca2+	0
and	0
cyclic	0
AMP	0
in	0
platelet	0
function	0
is	0
well	0
documented	0
,	0
its	0
mechanism	0
of	0
action	0
still	0
remains	0
to	0
be	0
established	0
.	0

We	0
investigated	0
here	0
the	0
question	0
of	0
the	0
regulation	0
of	0
platelet	9
Ca	10
(	10
2+	10
)	10
-ATPases	10
by	0
cyclic	0
AMP	0
through	0
the	0
phosphorylation	0
of	0
the	0
Rap1	9
protein	10
using	0
a	0
pathological	0
model	0
.	0

We	0
first	0
found	0
experimental	0
conditions	0
where	0
Ca	0
(	0
2+	0
)	0
-transport	0
by	0
platelet	0
membrane	0
vesicles	0
appeared	0
to	0
be	0
dependent	0
on	0
the	0
phosphorylation	0
of	0
the	0
Rap1	9
protein	10
.	0

Then	0
,	0
we	0
studied	0
platelets	7
of	0
patients	0
with	0
congestive	0
heart	0
failure	0
for	0
their	0
expression	0
of	0
the	0
potential	0
97	9
kDa	10
Ca	10
(	10
2+	10
)	10
-ATPase	10
target	10
of	0
regulation	0
through	0
the	0
Rap1	9
protein	10
as	0
well	0
as	0
the	0
phosphorylation	0
of	0
the	0
Rap1	9
protein	10
using	0
the	0
catalytic	9
subunit	10
of	0
the	0
cyclic	9
AMP-dependent	10
protein	10
kinase	10
(	0
C.	9
Sub	10
.	10
)	0
.	0

In	0
the	0
first	0
patients	0
studied	0
,	0
we	0
found	0
no	0
significant	0
modification	0
in	0
the	0
expression	0
of	0
the	0
97	9
kDa	10
Ca	10
(	10
2+	10
)	10
-ATPase	10
by	0
Western	0
blotting	0
using	0
the	0
PL/IM	9
430	10
monoclonal	10
antibody	10
which	0
specifically	0
recognized	0
this	0
isoform	0
.	0

In	0
contrast	0
,	0
the	0
Rap1	9
protein	10
was	0
differentially	0
phosphorylated	0
when	0
using	0
15	0
micrograms/ml	0
of	0
the	0
C.	9
Sub	10
.	10

These	0
results	0
allowed	0
us	0
to	0
use	0
these	0
pathological	0
platelets	7
to	0
study	0
the	0
relationship	0
between	0
the	0
expression	0
of	0
Rap1	9
protein	10
and	0
the	0
regulation	0
of	0
Ca2+	0
transport	0
by	0
selecting	0
a	0
patient	0
with	0
severe	0
heart	0
failure	0
.	0

We	0
could	0
show	0
a	0
decrease	0
in	0
the	0
expression	0
as	0
well	0
as	0
in	0
the	0
phosphorylation	0
of	0
Rap1	9
protein	10
and	0
demonstrate	0
a	0
lower	0
effect	0
of	0
C.	9
Sub	10
.	10
on	0
Ca2+	0
transport	0
.	0

Finally	0
,	0
by	0
studying	0
a	0
further	0
series	0
of	0
patients	0
,	0
we	0
could	0
confirm	0
that	0
the	0
decrease	0
in	0
Rap1	9
protein	10
expression	0
in	0
heart	0
failure	0
,	0
whatever	0
its	0
extent	0
,	0
was	0
variable	0
,	0
and	0
could	0
strictly	0
correlate	0
the	0
expression	0
of	0
Rap1	9
protein	10
with	0
the	0
stimulatory	0
effect	0
of	0
C.	9
Sub	10
.	10
on	0
Ca2+	0
transport	0
.	0

Besides	0
the	0
evidence	0
for	0
regulation	0
of	0
the	0
expression	0
of	0
the	0
Rap1	9
protein	10
in	0
platelets	7
from	0
patients	0
with	0
heart	0
failure	0
,	0
these	0
findings	0
constitute	0
a	0
new	0
approach	0
in	0
favour	0
of	0
the	0
regulation	0
of	0
platelet	0
Ca2+	0
transport	0
through	0
the	0
phosphorylation	0
of	0
the	0
Rap1	9
protein	10
.	0

An	0
IRF-1	9
-dependent	0
pathway	0
of	0
DNA	0
damage-induced	0
apoptosis	0
in	0
mitogen-activated	5
T	6
lymphocytes	6
.	0

Lymphocytes	5
are	0
particularly	0
susceptible	0
to	0
DNA	0
damage-induced	0
apoptosis	0
,	0
a	0
response	0
which	0
may	0
serve	0
as	0
a	0
form	0
of	0
'altruistic	0
suicide	0
'	0
to	0
counter	0
their	0
intrinsic	0
high	0
potential	0
for	0
mutation	0
and	0
clonal	0
expansion	0
.	0

The	0
tumour	9
suppressor	10
p53	10
has	0
been	0
shown	0
to	0
regulate	0
this	0
type	0
of	0
apoptosis	0
in	0
thymocytes	7
,	0
but	0
an	0
as	0
yet	0
unknown	0
,	0
p53	9
-independent	0
pathway	0
(	0
s	0
)	0
appears	0
to	0
mediate	0
the	0
same	0
event	0
in	0
mitogen-activated	5
mature	6
T	6
lymphocytes	6
.	0

Here	0
we	0
show	0
DNA	0
damage-induced	0
apoptosis	0
in	0
these	0
T	7
lymphocytes	8
is	0
dependent	0
on	0
the	0
antioncogenic	9
transcription	10
factor	10
interferon	10
regulatory	10
factor	10
(	9
IRF	10
)	10
-1	10
.	0

Thus	0
two	0
different	0
anti-onco-genic	9
transcription	10
factors	10
,	0
p53	9
and	0
IRF-1	9
,	0
are	0
required	0
for	0
distinct	0
apoptotic	0
pathways	0
in	0
T	7
lymphocytes	8
.	0

We	0
also	0
show	0
that	0
mitogen	0
induction	0
of	0
the	0
interleukin-1	1
beta	2
converting	2
enzyme	2
(	2
ICE	2
)	2
gene	2
,	0
a	0
mammalian	9
homologue	10
of	0
the	0
Caenorhabditis	1
elegans	2
cell	2
death	2
gene	2
ced-3	1
,	0
is	0
IRF-1	9
-dependent	0
.	0

Ectopic	0
overexpression	0
of	0
IRF-1	9
results	0
in	0
the	0
activation	0
of	0
the	0
endogenous	1
gene	2
for	0
ICE	9
and	0
enhances	0
the	0
sensitivity	0
of	0
cells	0
to	0
radiation-induced	0
apoptosis	0
.	0

Circadian	0
rhythm	0
of	0
glucocorticoid	9
receptors	10
in	0
human	7
peripheral	8
leukocytes	8
and	0
their	0
reactivity	0
to	0
glucocorticoids	0
.	0

1	0
)	0
There	0
exists	0
a	0
CR	0
of	0
GR	9
in	0
human	7
leukocytes	8
,	0
PMN	7
,	0
and	0
monocytes	7
with	0
the	0
peak	0
values	0
from	0
0400	0
to	0
0800	0
hr	0
and	0
the	0
trough	0
values	0
between	0
2300	0
and	0
0000	0
hr	0
.	0

The	0
difference	0
between	0
them	0
was	0
significant	0
statistically	0
.	0

2	0
)	0
The	0
FI	0
of	0
the	0
chemotactic	0
migration	0
rate	0
of	0
PMN	7
by	0
cortisol	0
also	0
showed	0
diurnal	0
changes	0
which	0
were	0
synchronous	0
with	0
that	0
of	0
GR	9
.	0

This	0
indicates	0
that	0
the	0
CR	0
of	0
GR	9
may	0
be	0
of	0
functional	0
significance	0
.	0

3	0
)	0
In	0
Cushing	0
's	0
syndrome	0
,	0
the	0
CR	0
of	0
GR	9
was	0
normal	0
in	0
spite	0
of	0
the	0
fact	0
that	0
the	0
CR	0
of	0
plasma	0
cortisol	0
was	0
disturbed	0
.	0

This	0
indicates	0
the	0
independency	0
of	0
the	0
CR	0
of	0
GR	9
from	0
that	0
of	0
cortisol	0
.	0

4	0
)	0
In	0
apoplexy	0
caused	0
by	0
brain	0
ischemia	0
,	0
the	0
CR	0
of	0
GR	9
was	0
abolished	0
in	0
patients	0
with	0
basal	0
lesions	0
but	0
preserved	0
when	0
the	0
lesions	0
were	0
located	0
in	0
the	0
cerebral	0
cortex	0
.	0

These	0
results	0
strongly	0
suggest	0
that	0
the	0
main	0
``	0
circadian	0
pacemaker	0
''	0
of	0
GR	9
is	0
located	0
in	0
the	0
basal	0
brain	0
,	0
most	0
probably	0
in	0
the	0
suprachiasmatic	0
nuclei	0
as	0
has	0
been	0
suggested	0
for	0
rodents	0
.	0

B-lymphoblastoid	5
cell	6
lines	6
from	0
multiple	0
sclerosis	0
patients	0
and	0
a	0
healthy	0
control	0
producing	0
a	0
putative	0
new	0
human	0
retrovirus	0
and	0
Epstein-Barr	0
virus	0
.	0

On	0
several	0
occasions	0
we	0
have	0
observed	0
retrovirus-like	0
particles	0
(	0
RVLPs	0
)	0
by	0
transmission	0
electron	0
microscopy	0
(	0
EM	0
)	0
of	0
cultured	5
T	6
cells	6
from	0
a	0
patient	0
with	0
MS	0
.	0

Later	0
we	0
established	0
spontaneously	0
formed	0
B-lymphoblastoid	5
cell	6
lines	6
(	0
LCLs	5
)	0
from	0
a	0
patient	0
with	0
an	0
MS-like	0
disease	0
and	0
from	0
another	0
patient	0
with	0
MS	0
who	0
had	0
a	0
reactivated	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
infection	0
.	0

Both	0
LCLs	5
were	0
found	0
by	0
EM	0
to	0
produce	0
RVLP	0
and	0
EBV	0
particles	0
.	0

Reverse	0
transcriptase	0
(	0
RT	0
)	0
assays	0
were	0
positive	0
in	0
purified	0
viral	0
material	0
from	0
both	0
LCLs	5
.	0

To	0
substantiate	0
these	0
findings	0
we	0
initiated	0
an	0
intensified	0
culturing	0
procedure	0
and	0
were	0
able	0
to	0
establish	0
LCLs	5
from	0
5	0
out	0
of	0
21	0
consecutive	0
MS	0
patients	0
and	0
1	0
out	0
of	0
13	0
consecutive	0
healthy	0
controls	0
.	0

All	0
LCLs	5
were	0
found	0
to	0
produce	0
both	0
RVLP	0
and	0
EBV	0
particles	0
by	0
EM	0
.	0

Whether	0
the	0
putative	0
new	0
retrovirus	0
(	0
es	0
)	0
and	0
EBV	0
have	0
any	0
causal	0
relationship	0
to	0
MS	0
is	0
still	0
not	0
known	0
,	0
but	0
the	0
findings	0
support	0
this	0
possibility	0
.	0

Identification	0
of	0
an	0
ionomycin/cyclosporin	1
A-responsive	2
element	2
within	0
the	0
human	1
T	2
cell	2
receptor	2
gamma	2
enhancer	2
.	0

Activation	0
through	0
the	0
Ca2+/	0
calcineurin	9
pathway	0
is	0
essential	0
to	0
the	0
transcription	0
of	0
many	0
cytokine	1
genes	2
.	0

The	0
conserved	1
cis-acting	2
sequence	2
,	0
GGAAAA	0
,	0
and	0
transcription	9
factors	10
binding	0
to	0
this	0
sequence	0
are	0
involved	0
in	0
the	0
response	0
to	0
increased	0
intracellular	0
Ca2+	0
concentrations	0
.	0

Here	0
we	0
report	0
the	0
identification	0
and	0
importance	0
of	0
the	0
same	0
sequence	0
in	0
a	0
non-cytokine	1
gene	2
,	0
the	0
human	1
T	2
cell	2
receptor	2
gamma	2
(	2
TCRG	2
)	2
enhancer	2
.	0

Results	0
from	0
site-directed	0
mutations	0
and	0
electrophoretic	0
mobility	0
shift	0
assays	0
strongly	0
suggest	0
that	0
this	0
sequence	0
mediates	0
the	0
ionomycin-induced	0
activation	0
of	0
the	0
TCRG	1
enhancer	2
.	0

Our	0
studies	0
provide	0
an	0
explanation	0
for	0
a	0
previous	0
observation	0
that	0
TCRG	3
mRNA	4
levels	0
,	0
but	0
not	0
mRNA	0
levels	0
for	0
T	9
cell	10
receptor	10
alpha	10
and	10
-beta	10
,	0
are	0
increased	0
by	0
ionomycin	0
treatment	0
.	0

Coexpression	0
of	0
NF-kappa	9
B/Rel	10
and	0
Sp1	9
transcription	9
factors	10
in	0
human	0
immunodeficiency	0
virus	0
1-induced	0
,	0
dendritic	0
cell-T-cell	0
syncytia	0
.	0

Productive	0
infection	0
of	0
T	7
cells	8
with	0
human	0
immunodeficiency	0
virus	0
1	0
(	0
HIV-1	0
)	0
typically	0
requires	0
that	0
the	0
T	7
cells	8
be	0
stimulated	0
with	0
antigens	0
or	0
mitogens	0
.	0

This	0
requirement	0
has	0
been	0
attributed	0
to	0
the	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	9
B	10
,	0
which	0
synergizes	0
with	0
the	0
constitutive	9
transcription	10
factor	10
Sp1	9
to	0
drive	0
the	0
HIV-1	1
promoter	2
.	0

Recently	0
,	0
we	0
have	0
found	0
that	0
vigorous	0
replication	0
of	0
HIV-1	0
takes	0
place	0
in	0
nonactivated	0
memory	7
T	8
cells	8
after	0
syncytium	0
formation	0
with	0
dendritic	7
cells	8
(	0
DCs	7
)	0
.	0

These	0
syncytia	0
lack	0
activated	7
cells	8
as	0
determined	0
by	0
an	0
absence	0
of	0
staining	0
for	0
Ki-67	0
cell	0
cycle	0
antigen	0
.	0

The	0
expression	0
and	0
activity	0
of	0
NF-kappa	9
B	10
and	0
Sp1	9
were	0
,	0
therefore	0
,	0
analyzed	0
in	0
isolated	0
T	7
cells	8
and	0
DCs	7
from	0
humans	0
and	0
mice	0
.	0

We	0
have	0
used	0
immunolabeling	0
,	0
Western	0
blot	0
analysis	0
,	0
and	0
electrophoretic	0
mobility	0
shift	0
and	0
supershift	0
assays	0
.	0

T	7
cells	8
lack	0
active	0
NF-kappa	9
B	10
but	0
express	0
Sp1	9
as	0
expected	0
.	0

DCs	7
express	0
high	0
levels	0
of	0
all	0
known	0
NF-kappa	9
B	10
and	0
Rel	9
proteins	10
,	0
with	0
activity	0
residing	0
primarily	0
within	0
RelB	9
,	0
p50	9
,	0
and	0
p65	9
.	0

However	0
,	0
DCs	7
lack	0
Sp1	9
,	0
which	0
may	0
explain	0
the	0
failure	0
of	0
HIV-1	0
to	0
replicate	0
in	0
purified	0
DCs	7
.	0

Coexpression	0
of	0
NF-kappa	9
B	10
and	0
Sp1	9
occurs	0
in	0
the	0
heterologous	7
DC-T-cell	8
syncytia	8
that	0
are	0
induced	0
by	0
HIV-1	0
.	0

Therefore	0
,	0
HIV-1-induced	0
cell	0
fusion	0
brings	0
together	0
factors	0
that	0
upregulate	0
virus	0
transcription	0
.	0

Since	0
DCs	7
and	0
memory	0
T	7
cells	8
frequently	0
traffic	0
together	0
in	0
situ	0
,	0
these	0
unusual	0
heterologous	7
syncytia	8
could	0
develop	0
in	0
infected	0
individuals	0
and	0
lead	0
to	0
chronic	0
HIV-1	0
replication	0
without	0
ostensible	0
immune	0
stimulation	0
.	0

Cupric	0
ion	0
blocks	0
NF	9
kappa	10
B	10
activation	0
through	0
inhibiting	0
the	0
signal-induced	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

A	0
transcription	9
factor	10
NF	9
kappa	10
B	10
,	0
which	0
regulates	0
expression	0
of	0
various	0
cellular	0
genes	0
involved	0
in	0
immune	0
responses	0
and	0
viral	1
genes	2
including	0
HIV	0
,	0
is	0
sequestered	0
in	0
the	0
cytoplasm	0
as	0
a	0
complex	0
with	0
an	0
inhibitory	9
protein	10
I	10
kappa	10
B	10
.	0

Various	0
extracellular	0
signals	0
induce	0
phosphorylation	0
and	0
rapid	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
to	0
release	0
NF	9
kappa	10
B	10
.	0

Cu2+	0
was	0
found	0
to	0
inhibit	0
the	0
activation	0
of	0
NF	9
kappa	10
B	10
induced	0
by	0
TNF-alpha	9
,	0
TPA	0
,	0
or	0
H2O2	0
.	0

Deoxycholate	0
treatment	0
of	0
the	0
cytoplasmic	0
extract	0
prepared	0
from	0
cells	0
stimulated	0
by	0
TNF-alpha	9
in	0
the	0
presence	0
of	0
Cu2+	0
resulted	0
in	0
the	0
release	0
of	0
NF	9
kappa	10
B	10
from	0
I	9
kappa	10
B	10
alpha	10
,	0
indicating	0
that	0
Cu2+	0
interferes	0
with	0
the	0
dissociation	0
of	0
the	0
NF	9
kappa	10
B-I	10
kappa	10
B	10
complex	10
.	0

Neither	0
phosphorylation	0
nor	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
was	0
observed	0
upon	0
TNF-alpha	9
stimulation	0
in	0
the	0
presence	0
of	0
Cu2+	0
.	0

These	0
results	0
indicate	0
that	0
Cu2+	0
inhibits	0
the	0
release	0
of	0
NF	9
kappa	10
B	10
by	0
blockade	0
of	0
a	0
signal	0
leading	0
to	0
the	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
.	0

Cloning	0
a	0
cDNA	1
from	0
human	0
NK/T	7
cells	8
which	0
codes	0
for	0
a	0
protein	0
with	0
high	0
proline	0
content	0
.	0

A	0
cDNA	1
clone	2
,	0
B4-2	1
,	0
was	0
isolated	0
from	0
a	0
natural	1
killer	2
(	2
NK	2
)	2
minus	2
T	2
cell	2
subtractive	2
library	2
.	0

The	0
B4-2	1
clone	0
coded	0
for	0
an	0
mRNA	3
of	0
2061	0
bp	0
in	0
length	0
.	0

It	0
encodes	0
a	0
deduced	0
327	9
aa	10
protein	10
with	0
a	0
calculated	0
molecular	0
mass	0
of	0
35.2	0
kDa	0
.	0

Searching	0
of	0
B4-2	1
DNA	2
and	0
protein	0
sequences	0
against	0
various	0
databases	0
revealed	0
no	0
high	0
homology	0
to	0
other	0
sequences	0
.	0

However	0
,	0
B4-2	1
has	0
an	0
unusually	0
high	0
proline	0
content	0
(	0
13	0
%	0
)	0
,	0
contains	0
a	0
putative	0
nuclear	9
targeting	10
sequence	10
,	0
and	0
has	0
several	0
SPXX	9
motifs	10
which	0
are	0
frequently	0
found	0
in	0
gene	9
regulatory	10
proteins	10
.	0

One	0
of	0
the	0
stretches	0
of	0
prolines	0
in	0
B4-2	1
closely	0
resembles	0
the	0
ligand	0
for	0
proteins	0
with	0
SH3	9
domains	10
.	0

Northern	0
hybridization	0
data	0
showed	0
that	0
B4-2	1
is	0
not	0
a	0
lymphoid	1
specific	2
gene	2
and	0
is	0
expressed	0
in	0
a	0
hepatoma	5
cell	6
line	6
and	0
also	0
weakly	0
transcribed	0
or	0
absent	0
in	0
a	0
variety	0
of	0
other	0
cells	0
.	0

A	0
polyclonal	0
antiserum	0
raised	0
against	0
recombinant	9
B4-2	10
recognizes	0
a	0
32-34	9
kDa	10
protein	10
in	0
lymphocytes	7
.	0

Activation	0
of	0
JAK3	9
,	0
but	0
not	0
JAK1	9
,	0
is	0
critical	0
for	0
IL-2	9
-induced	0
proliferation	0
and	0
STAT5	9
recruitment	0
by	0
a	0
COOH-terminal	9
region	10
of	0
the	0
IL-2	9
receptor	10
beta-chain	10
.	0

A	0
number	0
of	0
cytokines	9
and	0
growth	9
factors	10
use	0
the	0
JAK	9
-STAT	9
pathway	0
to	0
signal	0
from	0
the	0
cell	0
membrane	0
to	0
the	0
nucleus	0
.	0

While	0
homodimerizing	9
cytokine	10
receptors	10
may	0
transmit	0
signal	0
via	0
a	0
single	0
form	0
of	0
JAK	9
(	0
i.e	0
.	0
growth	9
hormone	10
receptors	10
)	0
,	0
several	0
multicomponent	9
cytokine	10
receptors	10
have	0
been	0
shown	0
to	0
require	0
simultaneous	0
activation	0
of	0
pairs	0
of	0
different	0
JAK	9
kinases	10
(	0
i.e	0
.	0
interferon	9
receptors	10
)	0
.	0

Recent	0
evidence	0
for	0
a	0
preferential	0
coupling	0
of	0
JAK3	9
to	0
interleukin-2	9
receptor-gamma	10
(	0
IL-2R	9
gamma	10
)	0
and	0
JAK1	9
to	0
IL-2R	9
beta	10
supports	0
the	0
concept	0
of	0
heterotrans-activation	0
of	0
JAK1	9
and	0
JAK3	9
caused	0
by	0
IL-2	9
-induced	0
heterodimerization	0
of	0
their	0
receptor	0
partners	0
.	0

The	0
present	0
study	0
verified	0
the	0
ability	0
of	0
IL-2	9
to	0
cause	0
tyrosine	0
phosphorylation	0
and	0
activation	0
of	0
JAK1	9
and	0
JAK3	9
,	0
but	0
demonstrated	0
that	0
IL-2	9
stimulated	0
JAK3	9
to	0
a	0
significantly	0
larger	0
extent	0
than	0
JAK1	9
in	0
human	7
T	8
lymphocytes	8
and	0
the	0
YT	5
cell	6
line	6
.	0

This	0
conclusion	0
was	0
based	0
upon	0
several	0
independent	0
criteria	0
,	0
including	0
more	0
vigorous	0
tyrosine	0
phosphorylation	0
of	0
JAK3	9
,	0
more	0
marked	0
enzymatic	0
activation	0
of	0
JAK3	9
as	0
well	0
as	0
higher	0
abundance	0
of	0
JAK3	9
in	0
activated	0
IL-2	9
receptor	10
complexes	10
.	0

Furthermore	0
,	0
when	0
human	9
IL-2R	10
beta	10
was	0
stably	0
expressed	0
in	0
murine	5
BA/F3	6
cells	6
,	0
robust	0
IL-2	9
-induced	0
proliferation	0
and	0
JAK3	9
activation	0
occurred	0
without	0
detectable	0
involvement	0
of	0
either	0
JAK1	9
,	0
JAK2	9
or	0
TYK2	9
.	0

We	0
therefore	0
propose	0
that	0
IL-2	9
receptor	10
signal	0
transduction	0
does	0
not	0
depend	0
on	0
equimolar	0
heterodimerization	0
of	0
JAK1	9
and	0
JAK3	9
following	0
IL-2	9
-induced	0
heterodimerization	0
of	0
IL-2R	9
beta	10
and	0
IL-2R	9
gamma	10
.	0

Nonetheless	0
,	0
a	0
membrane-proximal	9
region	10
of	0
human	0
IL-2R	9
beta	10
(	0
Asn240-Leu335	9
)	0
was	0
critical	0
for	0
JAK3	9
activation	0
,	0
and	0
the	0
amount	0
of	0
JAK3	9
present	0
in	0
activated	0
IL-2	9
receptor	10
complexes	10
increased	0
with	0
time	0
,	0
suggesting	0
that	0
stabilization	0
of	0
JAK3	9
binding	0
to	0
the	0
receptor	9
complex	10
relies	0
on	0
both	0
IL-2R	9
beta	10
and	0
IL-2R	9
gamma	10
.	0

Moreover	0
,	0
STAT5	9
was	0
found	0
to	0
be	0
the	0
predominant	0
STAT	9
transcription	10
factor	10
used	0
by	0
IL-2	9
in	0
human	7
T	8
cells	8
,	0
and	0
specifically	0
required	0
a	0
COOH-terminal	9
region	10
of	0
IL-2R	9
beta	10
(	0
Ser386-Val525	9
)	0
,	0
while	0
STAT5	9
recruitment	0
was	0
not	0
correlated	0
to	0
activation	0
of	0
IL-2R	9
gamma	10
or	0
JAK3	9
.	0

Up-regulation	0
of	0
high-affinity	0
dehydroepiandrosterone	0
binding	0
activity	0
by	0
dehydroepiandrosterone	0
in	0
activated	0
human	7
T	8
lymphocytes	8
.	0

Although	0
evidence	0
indicates	0
that	0
dehydroepiandrosterone	0
(	0
DHEA	0
)	0
exerts	0
direct	0
physiological	0
effects	0
,	0
its	0
mechanism	0
of	0
action	0
remains	0
unknown	0
.	0

DHEA	0
binding	0
sites	0
were	0
examined	0
using	0
a	0
whole-cell	0
binding	0
assay	0
in	0
a	0
human	5
T	6
lymphoid	6
cell	6
line	6
,	0
PEER	5
,	0
revealing	0
that	0
a	0
single	0
class	0
of	0
high-affinity	0
binding	0
sites	0
for	0
DHEA	0
(	0
dissociation	0
constant	0
=	0
7.4	0
+/-	0
0.53	0
nmol/L	0
,	0
mean	0
+/-	0
SE	0
,	0
n	0
=	0
4	0
)	0
was	0
greatly	0
increased	0
when	0
treated	0
with	0
DHEA	0
,	0
phorbol-12-myristate-13-acetate	0
,	0
and	0
the	0
Ca2+	0
ionophore	0
A23187	0
.	0

Bound	0
[	0
3H	0
]	0
DHEA	0
was	0
displaced	0
sensitively	0
by	0
DHEA	0
and	0
secondarily	0
by	0
dihydrotestosterone	0
,	0
but	0
not	0
effectively	0
by	0
other	0
steroids	0
,	0
including	0
DHEA	0
sulfate	0
.	0

These	0
results	0
not	0
only	0
indicate	0
the	0
existence	0
of	0
a	0
DHEA	9
receptor	10
,	0
but	0
also	0
suggest	0
that	0
T	7
cells	8
become	0
susceptible	0
to	0
regulation	0
by	0
DHEA	0
during	0
the	0
process	0
of	0
signal-induced	0
activation	0
.	0

Ubiquitin-mediated	0
processing	0
of	0
NF-kappa	9
B	10
transcriptional	9
activator	10
precursor	10
p105	9
.	0

Reconstitution	0
of	0
a	0
cell-free	0
system	0
and	0
identification	0
of	0
the	0
ubiquitin-carrier	9
protein	10
,	0
E2	9
,	0
and	0
a	0
novel	0
ubiquitin-protein	9
ligase	10
,	0
E3	9
,	0
involved	0
in	0
conjugation	0
.	0

In	0
most	0
cases	0
,	0
the	0
transcriptional	9
factor	10
NF-kappa	9
B	10
is	0
a	0
heterodimer	9
consisting	0
of	0
two	0
subunits	0
,	0
p50	9
and	0
p65	9
,	0
which	0
are	0
encoded	0
by	0
two	0
distinct	0
genes	0
of	0
the	0
Rel	1
family	2
.	0

p50	9
is	0
translated	0
as	0
a	0
precursor	0
of	0
105	9
kDa	10
.	0

The	0
C-terminal	9
domain	10
of	0
the	0
precursor	0
is	0
rapidly	0
degraded	0
,	0
forming	0
the	0
mature	9
p50	10
subunit	10
consisted	0
of	0
the	0
N-terminal	9
region	10
of	0
the	0
molecule	0
.	0

The	0
mechanism	0
of	0
generation	0
of	0
p50	9
is	0
not	0
known	0
.	0

It	0
has	0
been	0
suggested	0
that	0
the	0
ubiquitin	9
-proteasome	9
system	0
is	0
involved	0
in	0
the	0
process	0
;	0
however	0
,	0
the	0
specific	0
enzymes	9
involved	0
and	0
the	0
mechanism	0
of	0
limited	0
proteolysis	0
,	0
in	0
which	0
half	0
of	0
the	0
molecule	0
is	0
spared	0
,	0
have	0
been	0
obscure	0
.	0

Palombella	0
and	0
colleagues	0
(	0
Palombella	0
,	0
V.J.	0
,	0
Rando	0
,	0
O.J.	0
,	0
Goldberg	0
,	0
A.L.	0
,	0
and	0
Maniatis	0
,	0
T.	0
(	0
1994	0
)	0
Cell	0
78	0
,	0
773-785	0
)	0
have	0
shown	0
that	0
ubiquitin	9
is	0
required	0
for	0
the	0
processing	0
in	0
a	0
cell-free	0
system	0
of	0
a	0
truncated	0
,	0
artificially	0
constructed	0
,	0
60-kDa	9
precursor	10
.	0

They	0
have	0
also	0
shown	0
that	0
proteasome	9
inhibitors	0
block	0
the	0
processing	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
reconstitution	0
of	0
a	0
cell-free	0
processing	0
system	0
and	0
demonstrate	0
directly	0
that	0
:	0
(	0
a	0
)	0
the	0
ubiquitin	9
-proteasome	9
system	0
is	0
involved	0
in	0
processing	0
of	0
the	0
intact	0
p105	9
precursor	0
,	0
(	0
b	0
)	0
conjugation	0
of	0
ubiquitin	9
to	0
the	0
precursor	0
is	0
an	0
essential	0
intermediate	0
step	0
in	0
the	0
processing	0
,	0
(	0
c	0
)	0
the	0
recently	0
discovered	0
novel	0
species	0
of	0
the	0
ubiquitin-carrier	9
protein	10
,	0
E2-F1	9
,	0
that	0
is	0
involved	0
in	0
the	0
conjugation	0
and	0
degradation	0
of	0
p53	9
,	0
is	0
also	0
required	0
for	0
the	0
limited	0
processing	0
of	0
the	0
p105	9
precursor	10
,	0
and	0
(	0
d	0
)	0
a	0
novel	0
,	0
approximately	0
320-kDa	9
species	10
of	0
ubiquitin-protein	9
ligase	10
,	0
is	0
involved	0
in	0
the	0
process	0
.	0

This	0
novel	0
enzyme	0
is	0
distinct	0
from	0
E6-AP	9
,	0
the	0
p53-conjugating	9
ligase	10
,	0
and	0
from	0
E3	9
alpha	10
,	0
the	0
``	9
N-end	10
rule	10
''	10
ligase	10
.	0

Flutamide	0
in	0
the	0
treatment	0
of	0
hirsutism	0
:	0
long-term	0
clinical	0
effects	0
,	0
endocrine	0
changes	0
,	0
and	0
androgen	9
receptor	10
behavior	0
.	0

OBJECTIVE	0
:	0
To	0
investigate	0
the	0
long-term	0
effects	0
of	0
treatment	0
with	0
low	0
doses	0
of	0
flutamide	0
on	0
clinical	0
and	0
hormonal	0
parameters	0
,	0
as	0
well	0
as	0
on	0
the	0
androgen	9
receptor	10
status	0
,	0
in	0
hirsute	0
women	0
.	0

DESIGN	0
:	0
Eighteen	0
hirsute	0
patients	0
with	0
regular	0
menses	0
were	0
studied	0
basally	0
and	0
during	0
treatment	0
with	0
125	0
mg	0
flutamide	0
,	0
three	0
times	0
per	0
day	0
for	0
12	0
months	0
.	0

Barrier	0
or	0
intrauterine	0
contraception	0
was	0
used	0
during	0
the	0
study	0
in	0
sexually	0
active	0
women	0
.	0

Safety	0
parameters	0
were	0
assessed	0
throughout	0
the	0
study	0
.	0

Hirsutism	0
,	0
graded	0
by	0
the	0
modified	0
Ferriman-Gallwey	0
score	0
,	0
and	0
hormonal	0
parameters	0
were	0
evaluated	0
basally	0
and	0
at	0
4-month	0
intervals	0
during	0
treatment	0
.	0

Gonadotropin-releasing	0
hormone	0
and	0
ACTH	0
stimulation	0
tests	0
were	0
performed	0
before	0
and	0
after	0
3	0
to	0
4	0
months	0
of	0
therapy	0
.	0

In	0
addition	0
,	0
the	0
concentration	0
of	0
androgen	9
receptors	10
in	0
mononuclear	7
leukocytes	8
was	0
measured	0
,	0
in	0
both	0
the	0
follicular	0
and	0
luteal	0
phases	0
of	0
the	0
menstrual	0
cycle	0
,	0
basally	0
and	0
after	0
4	0
months	0
of	0
flutamide	0
treatment	0
.	0

RESULTS	0
:	0
Flutamide	0
was	0
well	0
tolerated	0
in	0
all	0
women	0
,	0
with	0
the	0
noticeable	0
exception	0
of	0
one	0
patient	0
who	0
presented	0
increased	0
serum	9
transaminase	10
after	0
8	0
months	0
of	0
therapy	0
.	0

Hirsutism	0
markedly	0
improved	0
in	0
all	0
women	0
during	0
the	0
treatment	0
(	0
Ferriman-Gallwey	0
score	0
after	0
1	0
year	0
:	0
4.1	0
+/-	0
0.5	0
versus	0
14.1	0
+/-	0
0.9	0
)	0
.	0

A	0
reduction	0
of	0
serum	0
androgens	0
was	0
found	0
,	0
whereas	0
no	0
change	0
was	0
observed	0
in	0
either	0
basal	0
or	0
GnRH-stimulated	0
gonadotropins	0
or	0
in	0
the	0
cortisol	0
and	0
17	0
alpha-hydroxyprogesterone	0
response	0
to	0
ACTH	0
.	0

Cycles	0
remained	0
ovulatory	0
.	0

Before	0
treatment	0
,	0
the	0
number	0
of	0
androgen	9
receptors	10
was	0
higher	0
in	0
the	0
luteal	0
than	0
in	0
the	0
follicular	0
phase	0
.	0

This	0
rhythmic	0
differentiation	0
disappeared	0
after	0
the	0
patients	0
had	0
been	0
given	0
the	0
antiandrogen	0
drug	0
.	0

CONCLUSIONS	0
:	0
Flutamide	0
is	0
effective	0
in	0
the	0
treatment	0
of	0
hirsutism	0
but	0
requires	0
constant	0
surveillance	0
of	0
liver	0
function	0
.	0

Androgen	0
receptor	0
blockade	0
might	0
be	0
potentiated	0
by	0
a	0
reduction	0
of	0
serum	0
androgens	0
.	0

Flutamide	0
affects	0
androgen	9
receptor	10
behavior	0
during	0
the	0
menstrual	0
cycle	0
.	0

The	0
meaning	0
of	0
this	0
finding	0
remains	0
to	0
be	0
elucidated	0
.	0

Constitutive	0
expression	0
of	0
HIV-1	9
tat	10
protein	10
in	0
human	5
Jurkat	6
T	6
cells	6
using	0
a	0
BK	0
virus	0
vector	0
.	0

The	0
production	0
and	0
characterization	0
of	0
Jurkat	5
cell	6
lines	6
that	0
constitutively	0
express	0
functional	0
human	9
immune	10
deficiency	10
virus	10
type	10
1	10
(	10
HIV-1	10
)	10
tat	10
protein	10
,	0
using	0
a	0
BK	0
virus	0
plasmid	0
expression	0
vector	0
and	0
HIV-1	1
tat	2
cDNA	2
,	0
is	0
described	0
.	0

An	0
increased	0
growth	0
rate	0
of	0
these	0
Jurkat-tat	5
cell	6
lines	6
as	0
compared	0
with	0
control	5
cell	6
lines	6
was	0
observed	0
.	0

A	0
PEBP2	9
alpha/AML-1-related	10
factor	10
increases	0
osteocalcin	1
promoter	2
activity	0
through	0
its	0
binding	0
to	0
an	0
osteoblast-specific	1
cis-acting	2
element	2
.	0

To	0
identify	0
osteoblast-specific	1
cis-acting	2
elements	2
and	0
trans-acting	9
factors	10
,	0
we	0
initiated	0
an	0
analysis	0
of	0
the	0
promoter	1
of	0
a	0
mouse	1
osteocalcin	2
gene	2
,	0
an	0
osteoblast-specific	1
gene	2
.	0

In	0
this	0
promoter	0
,	0
we	0
identified	0
two	0
osteoblast-specific	1
cis-acting	2
elements	2
(	0
Ducy	0
,	0
P.and	0
Karsenty	0
,	0
G.	0
(	0
1995	0
)	0
Mol.Cell.Biol.15	0
,	0
1858-1869	0
)	0
.	0

The	0
sequence	0
of	0
one	0
of	0
these	0
elements	1
,	0
OSE2	0
,	0
is	0
identical	0
to	0
the	0
DNA-binding	1
site	2
of	0
the	0
PEBP2	9
alpha/AML-1	10
transcription	10
factors	10
,	0
the	0
mammalian	9
homologues	10
of	0
the	0
Drosophila	9
Runt	10
protein	10
.	0

Here	0
we	0
show	0
,	0
using	0
nuclear	0
extracts	0
,	0
recombinant	9
protein	10
,	0
and	0
a	0
specific	0
antiserum	0
against	0
AML-1	9
proteins	10
in	0
DNA-binding	0
assays	0
,	0
that	0
one	0
member	0
of	0
this	0
family	0
,	0
AML-1B	9
,	0
binds	0
specifically	0
to	0
OSE2	0
and	0
is	0
immunologically	0
related	0
to	0
OSF2	9
,	0
the	0
factor	0
present	0
in	0
osteoblast	0
nuclear	0
extracts	0
that	0
binds	0
to	0
OSE2	0
.	0

By	0
DNA	0
cotransfection	0
experiments	0
,	0
we	0
also	0
demonstrate	0
that	0
AML-1B	9
can	0
increase	0
the	0
activity	0
of	0
a	0
short	0
osteocalcin	1
promoter	2
through	0
its	0
binding	0
to	0
OSE2	0
.	0

Lastly	0
,	0
the	0
different	0
mobilities	0
of	0
osteoblast	9
nuclear	10
extract-DNA	10
complexes	10
compared	0
with	0
T-cell	9
nuclear	10
extract-DNA	10
complexes	10
,	0
along	0
with	0
the	0
inability	0
of	0
OSF2	9
to	0
be	0
upregulated	0
by	0
retinoic	0
acid	0
,	0
unlike	0
the	0
other	0
PEBP2	9
alpha	10
factors	10
,	0
suggest	0
that	0
OSF2	9
is	0
a	0
new	0
member	0
of	0
this	0
family	0
of	0
transcription	9
factors	10
.	0

Thus	0
,	0
this	0
study	0
demonstrates	0
that	0
AML-1B	9
can	0
increase	0
gene	0
expression	0
of	0
an	0
osteoblast-specific	1
gene	2
through	0
its	0
binding	0
to	0
an	0
osteoblast-specific	1
cis-acting	2
element	2
and	0
presents	0
evidence	0
that	0
OSF2	9
is	0
a	0
member	0
of	0
the	0
PEBP2	9
alpha/AML-1	10
family	10
of	0
transcription	9
factors	10
.	0

Initiation	9
binding	10
repressor	10
,	0
a	0
factor	0
that	0
binds	0
to	0
the	0
transcription	1
initiation	2
site	2
of	0
the	0
histone	1
h5	2
gene	2
,	0
is	0
a	0
glycosylated	9
member	10
of	0
a	0
family	0
of	0
cell	9
growth	10
regulators	10
[	0
corrected	0
]	0
[	0
published	0
erratum	0
appears	0
in	0
Mol	0
Cell	0
Biol	0
1996	0
Feb	0
;	0
16	0
(	0
2	0
)	0
:	0
735	0
]	0

Initiation	9
binding	10
repressor	10
[	0
corrected	0
]	0
(	0
IBR	9
)	0
is	0
a	0
chicken	9
erythrocyte	10
factor	10
(	0
apparent	0
molecular	0
mass	0
,	0
70	0
to	0
73	0
kDa	0
)	0
that	0
binds	0
to	0
the	0
sequences	0
spanning	0
the	0
transcription	1
initiation	2
site	2
of	0
the	0
histone	1
h5	2
gene	2
,	0
repressing	0
its	0
transcription	0
.	0

A	0
variety	0
of	0
other	0
cells	0
,	0
including	0
transformed	7
erythroid	8
precursors	8
,	0
do	0
not	0
have	0
IBR	9
but	0
a	0
factor	0
referred	0
to	0
as	0
IBF	9
(	0
68	0
to	0
70	0
kDa	0
)	0
that	0
recognizes	0
the	0
same	0
IBR	9
sites	0
.	0

We	0
have	0
cloned	0
the	0
IBR	1
cDNA	2
and	0
studied	0
the	0
relationship	0
of	0
IBR	9
and	0
IBF	9
.	0

IBR	9
is	0
a	0
503-amino-acid-long	9
acidic	10
protein	10
which	0
is	0
99.0	0
%	0
identical	0
to	0
the	0
recently	0
reported	0
human	9
NRF-1/alpha-Pal	10
factor	10
and	0
highly	0
related	0
to	0
the	0
invertebrate	0
transcription	9
factors	10
P3A2	9
and	0
erected	9
wing	10
gene	10
product	10
(	0
EWG	9
)	0
.	0

We	0
present	0
evidence	0
that	0
IBR	9
and	0
IBF	9
are	0
most	0
likely	0
identical	0
proteins	0
,	0
differing	0
in	0
their	0
degree	0
of	0
glycosylation	0
.	0

We	0
have	0
analyzed	0
several	0
molecular	0
aspects	0
of	0
IBR/F	9
and	0
shown	0
that	0
the	0
factor	0
associates	0
as	0
stable	0
homodimers	9
and	0
that	0
the	0
dimer	9
is	0
the	0
relevant	9
DNA-binding	10
species	10
.	0

The	0
evolutionarily	0
conserved	0
N-terminal	9
half	10
of	0
IBR/F	9
harbors	0
the	0
DNA-binding/dimerization	9
domain	10
(	0
outer	0
limits	0
,	0
127	0
to	0
283	0
)	0
,	0
one	0
or	0
several	0
casein	9
kinase	10
II	10
sites	10
(	0
37	0
to	0
67	0
)	0
,	0
and	0
a	0
bipartite	9
nuclear	10
localization	10
signal	10
(	0
89	0
to	0
106	0
)	0
which	0
appears	0
to	0
be	0
necessary	0
for	0
nuclear	0
targeting	0
.	0

Binding	0
site	0
selection	0
revealed	0
that	0
the	0
alternating	9
RCGCRYGCGY	10
consensus	10
constitutes	0
high-affinity	0
IBR/F	1
binding	2
sites	2
and	0
that	0
the	0
direct-repeat	1
palindrome	2
TGCGCATGCGCA	0
is	0
the	0
optimal	1
site	2
.	0

A	0
survey	0
of	0
genes	1
potentially	0
regulated	0
by	0
this	0
family	0
of	0
factors	9
primarily	0
revealed	0
genes	1
involved	0
in	0
growth-related	0
metabolism	0
.	0

Triggering	0
of	0
the	0
human	0
interleukin-6	0
gene	0
by	0
interferon-gamma	0
and	0
tumor	0
necrosis	0
factor-alpha	0
in	0
monocytic	0
cells	0
involves	0
cooperation	0
between	0
interferon	9
regulatory	10
factor-1	10
,	0
NF	9
kappa	10
B	10
,	0
and	0
Sp1	9
transcription	9
factors	10
.	0

We	0
investigated	0
the	0
molecular	0
basis	0
of	0
the	0
synergistic	0
induction	0
by	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
/	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
of	0
human	1
interleukin-6	2
(	2
IL-6	2
)	2
gene	2
in	0
THP-1	7
monocytic	8
cells	8
,	0
and	0
compared	0
it	0
with	0
the	0
basis	0
of	0
this	0
induction	0
by	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

Functional	0
studies	0
with	0
IL-6	1
promoter	2
demonstrated	0
that	0
three	0
regions	0
are	0
the	0
targets	0
of	0
the	0
IFN-gamma	9
and/or	0
TNF-alpha	9
action	0
,	0
whereas	0
only	0
one	0
of	0
these	0
regions	0
seemed	0
to	0
be	0
implicated	0
in	0
LPS	0
activation	0
.	0

The	0
three	0
regions	0
concerned	0
are	0
:	0
1	0
)	0
a	0
region	0
between	0
-73	0
and	0
-36	0
,	0
which	0
is	0
the	0
minimal	1
element	2
inducible	0
by	0
LPS	0
or	0
TNF-alpha	9
;	0
2	0
)	0
an	0
element	0
located	0
between	0
-181	0
and	0
-73	0
,	0
which	0
appeared	0
to	0
regulate	0
the	0
response	0
to	0
IFN-gamma	9
and	0
TNF-alpha	9
negatively	0
;	0
and	0
3	0
)	0
a	0
distal	1
element	2
upstream	2
of	0
-224	0
,	0
which	0
was	0
inducible	0
by	0
IFN-gamma	9
alone	0
.	0

LPS	0
signaling	0
was	0
found	0
to	0
involve	0
NF	9
kappa	10
B	10
activation	0
by	0
the	0
p50/p65	9
heterodimers	10
.	0

Synergistic	0
induction	0
of	0
the	0
IL-6	1
gene	2
by	0
IFN-gamma	9
and	0
TNF-alpha	9
,	0
in	0
monocytic	7
cells	8
,	0
involved	0
cooperation	0
between	0
the	0
IRF-1	9
and	0
NF	9
kappa	10
B	10
p65	10
homodimers	10
with	0
concomitant	0
removal	0
of	0
the	0
negative	0
effect	0
of	0
the	0
retinoblastoma	1
control	2
element	2
present	0
in	0
the	0
IL-6	1
promoter	2
.	0

This	0
removal	0
occurred	0
by	0
activation	0
of	0
the	0
constitutive	9
Sp1	10
factor	10
,	0
whose	0
increased	0
binding	0
activity	0
and	0
phosphorylation	0
were	0
mediated	0
by	0
IFN-gamma	9
.	0

Mutation	0
of	0
Jak3	9
in	0
a	0
patient	0
with	0
SCID	0
:	0
essential	0
role	0
of	0
Jak3	9
in	0
lymphoid	0
development	0
.	0

Males	0
with	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
(	0
XSCID	0
)	0
have	0
defects	0
in	0
the	0
common	0
cytokine	1
receptor	2
gamma	2
chain	2
(	2
gamma	2
c	2
)	2
gene	2
that	0
encodes	0
a	0
shared	0
,	0
essential	0
component	0
of	0
the	0
receptors	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
,	0
IL-4	9
,	0
IL-7	9
,	0
IL-9	9
,	0
and	0
IL-15	9
.	0

The	0
Janus	9
family	10
tyrosine	10
kinase	10
Jak3	9
is	0
the	0
only	0
signaling	0
molecule	0
known	0
to	0
be	0
associated	0
with	0
gamma	9
c	10
,	0
so	0
it	0
was	0
hypothesized	0
that	0
defects	0
in	0
Jak3	9
might	0
cause	0
an	0
XSCID-like	0
phenotype	0
.	0

A	0
girl	0
with	0
immunological	0
features	0
indistinguishable	0
from	0
those	0
of	0
XSCID	0
was	0
therefore	0
selected	0
for	0
analysis	0
.	0

An	0
Epstein-Barr	5
virus	6
(	6
EBV	6
)	6
-transformed	6
cell	6
line	6
derived	0
from	0
her	0
lymphocytes	7
had	0
normal	0
gamma	9
c	10
expression	0
but	0
lacked	0
Jak3	9
protein	10
and	0
had	0
greatly	0
diminished	0
Jak3	3
messenger	4
RNA	4
.	0

Sequencing	0
revealed	0
a	0
different	0
mutation	0
on	0
each	0
allele	0
:	0
a	0
single	0
nucleotide	0
insertion	0
resulting	0
in	0
a	0
frame	0
shift	0
and	0
premature	0
termination	0
in	0
the	0
Jak3	9
JH4	10
domain	10
and	0
a	0
nonsense	0
mutation	0
in	0
the	0
Jak3	9
JH2	0
domain	0
.	0

The	0
lack	0
of	0
Jak3	9
expression	0
correlated	0
with	0
impaired	0
B	0
cell	0
signaling	0
,	0
as	0
demonstrated	0
by	0
the	0
inability	0
of	0
IL-4	9
to	0
activate	0
Stat6	9
in	0
the	0
EBV-transformed	5
cell	6
line	6
from	0
the	0
patient.	0
These	0
observations	0
indicate	0
that	0
the	0
functions	0
of	0
gamma	9
c	10
are	0
dependent	0
on	0
Jak3	9
and	0
that	0
Jak3	9
is	0
essential	0
for	0
lymphoid	0
development	0
and	0
signaling	0
.	0

Constitutive	0
overexpression	0
of	0
the	0
L-selectin	1
gene	2
in	0
fresh	0
leukemic	7
cells	8
of	0
adult	0
T-cell	0
leukemia	0
that	0
can	0
be	0
transactivated	0
by	0
human	9
T-cell	10
lymphotropic	10
virus	10
type	10
1	10
Tax	10
.	0

L-selectin	9
is	0
an	0
adhesion	0
molecule	0
of	0
the	0
selectin	0
family	0
that	0
mediates	0
the	0
initial	0
step	0
of	0
leukocyte	0
adhesion	0
to	0
vascular	0
endothelium	0
.	0

Upon	0
cellular	0
activation	0
,	0
expression	0
of	0
the	0
L-selectin	1
gene	2
is	0
downregulated	0
at	0
both	0
the	0
protein	0
and	0
mRNA	0
levels	0
.	0

To	0
understand	0
the	0
mechanism	0
of	0
leukemic	7
cell	8
infiltration	0
into	0
organs	0
,	0
we	0
studied	0
the	0
expression	0
and	0
regulation	0
of	0
L-selectin	3
mRNA	4
in	0
fresh	0
leukemic	7
cells	8
of	0
adult	0
T-cell	0
leukemia	0
(	0
ATL	0
)	0
patients	0
and	0
investigated	0
the	0
response	0
of	0
the	0
L-selectin	1
promoter	2
to	0
human	9
T-cell	10
lymphotropic	10
virus	10
type	10
1	10
(	10
HTLV-1	10
)	10
Tax	10
,	0
which	0
is	0
a	0
viral	9
transcriptional	10
transactivator	10
.	0

Flow	0
cytometry	0
showed	0
that	0
L-selectin	9
was	0
expressed	0
on	0
fresh	0
ATL	5
cells	6
along	0
with	0
other	0
activation	9
antigens	10
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
ATL	5
cells	6
overexpressed	0
that	0
L-selectin	3
mRNA	4
and	0
that	0
the	0
level	0
was	0
aberrantly	0
upregulated	0
after	0
PMA	0
stimulation	0
.	0

Studies	0
using	0
in	0
situ	0
hybridization	0
showed	0
expression	0
of	0
the	0
L-selectin	3
mRNA	4
in	0
the	0
infiltrating	0
leukemic	7
cells	8
in	0
the	0
liver	0
of	0
two	0
ATL	0
patients	0
.	0

Intravenous	0
injection	0
of	0
a	0
rat	5
T-cell	6
line	6
that	0
overexpresses	0
L-selectin	9
showed	0
increased	0
organ	0
infiltration	0
.	0

The	0
induction	0
of	0
Tax	9
expression	0
in	0
JPX9	5
cells	6
resulted	0
in	0
about	0
a	0
twofold	0
increase	0
in	0
the	0
mRNA	3
expression	0
levels	0
compared	0
with	0
the	0
basal	0
level	0
.	0

Chloramphenicol	9
acetyltransferase	10
(	0
CAT	9
)	0
assay	0
after	0
transient	0
cotransfection	0
showed	0
about	0
a	0
fivefold	0
transactivation	0
of	0
the	0
L-selectin	1
promoter	2
by	0
Tax	9
.	0

The	0
serum	0
level	0
of	0
the	0
shed	0
form	0
of	0
L-selectin	9
was	0
significantly	0
increased	0
in	0
ATL	0
patients	0
(	0
mean	0
+/-	0
SD	0
,	0
4	0
,	0
215.4	0
+/-	0
4	0
,	0
111	0
ng/mL	0
)	0
compared	0
with	0
those	0
of	0
asymptomatic	0
carriers	0
and	0
healthy	0
blood	0
donors	0
(	0
mean	0
+/-	0
SD	0
,	0
1	0
,	0
148.0	0
+/-	0
269.0	0
ng/mL	0
and	0
991.9	0
+/-	0
224	0
ng/mL	0
,	0
respectively	0
)	0
.	0

These	0
results	0
indicated	0
that	0
ATL	5
cells	6
constitutively	0
overexpress	0
the	0
L-selectin	1
gene	2
that	0
can	0
be	0
transactivated	0
by	0
HTLV-1	0
Tax	9
.	0

The	0
overexpression	0
of	0
L-selectin	9
,	0
as	0
well	0
as	0
of	0
inflammatory	9
cytokines	10
,	0
by	0
ATL	5
cells	6
may	0
provide	0
a	0
basis	0
for	0
ATL	5
cells	6
to	0
attach	0
the	0
vascular	0
endothelium	0
,	0
leading	0
to	0
transmigration	0
and	0
organ	0
infitration	0
.	0

Human	0
herpesvirus	0
6	0
variant	0
A	0
,	0
but	0
not	0
variant	0
B	0
,	0
infects	0
EBV-positive	5
B	6
lymphoid	6
cells	6
,	0
activating	0
the	0
latent	1
EBV	2
genome	2
through	0
a	0
BZLF-1	9
-dependent	0
mechanism	0
.	0

Human	0
herpesvirus	0
6	0
,	0
a	0
predominantly	0
T	0
lymphotropic	0
virus	0
,	0
has	0
been	0
recently	0
shown	0
to	0
infect	0
some	0
EBV-positive	5
B	6
cell	6
lines	6
,	0
and	0
to	0
induce	0
in	0
them	0
the	0
activation	0
of	0
the	0
EBV	0
lytic	0
cycle	0
.	0

Here	0
we	0
have	0
confirmed	0
and	0
extended	0
such	0
observations	0
,	0
showing	0
that	0
(	0
1	0
)	0
this	0
phenomenon	0
is	0
restricted	0
to	0
the	0
variant	0
A	0
of	0
HHV-6	0
:	0
in	0
fact	0
two	0
isolates	0
belonging	0
to	0
the	0
HHV-6	0
variant	0
B	0
(	0
BA92	0
and	0
Z29	0
)	0
were	0
neither	0
able	0
to	0
infect	0
any	0
B	5
cell	6
line	6
,	0
independently	0
of	0
the	0
EBV	0
status	0
,	0
nor	0
to	0
induce	0
the	0
EBV	0
genome	0
expression	0
.	0

The	0
only	0
exception	0
is	0
represented	0
by	0
the	0
P3HR1	5
cells	6
,	0
in	0
which	0
,	0
however	0
,	0
the	0
infection	0
by	0
the	0
variant	0
B	0
does	0
not	0
determine	0
induction	0
of	0
EBV	9
antigens	10
;	0
(	0
2	0
)	0
the	0
presence	0
of	0
the	0
EBV	1
genome	2
contributes	0
to	0
the	0
susceptibility	0
of	0
the	0
B	5
cell	6
lines	6
to	0
HHV-6	0
infection	0
,	0
increasing	0
the	0
binding	0
sites	0
and	0
the	0
percentage	0
of	0
infectable	7
cells	8
,	0
as	0
detected	0
by	0
immunoelectron	0
microscopy	0
;	0
and	0
(	0
3	0
)	0
HHV-6	5
infected	6
T	6
cells	6
,	0
transfected	0
with	0
plasmids	1
bearing	0
the	0
promoter	1
regions	2
of	0
the	0
EBV	0
early	0
genes	0
BZLF1	0
and	0
BMRF1	1
,	0
show	0
a	0
strong	0
transactivation	0
of	0
these	0
promoters	1
.	0

Evidence	0
for	0
normal	0
vitamin	3
D	4
receptor	4
messenger	4
ribonucleic	4
acid	4
and	0
genotype	0
in	0
absorptive	0
hypercalciuria	0
.	0

Absorptive	0
hypercalciuria	0
(	0
a	0
stone-forming	0
condition	0
)	0
is	0
characterized	0
by	0
gut	0
hyperabsorption	0
of	0
calcium	0
,	0
hypercalciuria	0
,	0
and	0
reduced	0
bone	0
density	0
.	0

Inasmuch	0
as	0
these	0
features	0
implicate	0
enhanced	0
calcitriol	0
action	0
in	0
gut	0
and	0
bone	0
,	0
we	0
analyzed	0
the	0
vitamin	1
D	2
receptor	2
(	2
VDR	2
)	2
gene	2
to	0
ascertain	0
whether	0
an	0
abnormality	0
of	0
this	0
gene	0
marks	0
patients	0
with	0
intestinal	0
hyperabsorption	0
of	0
calcium	0
.	0

We	0
have	0
compared	0
the	0
frequency	0
of	0
a	0
restriction	1
fragment	2
length	2
polymorphism	2
(	0
Bsm	0
I	0
)	0
associated	0
with	0
different	0
alleles	0
of	0
the	0
VDR	1
gene	2
in	0
a	0
group	0
of	0
33	0
well	0
characterized	0
absorptive	0
hypercalciuric	0
patients	0
and	0
a	0
group	0
of	0
36	0
normal	0
race-	0
and	0
age-matched	0
control	0
subjects	0
.	0

There	0
was	0
no	0
difference	0
between	0
the	0
distribution	0
of	0
the	0
VDR	9
alleles	0
in	0
the	0
patient	0
population	0
when	0
compared	0
with	0
the	0
normal	0
population	0
.	0

The	0
coding	0
region	0
of	0
VDR	3
messenger	4
RNA	4
was	0
also	0
normal	0
,	0
as	0
determined	0
by	0
both	0
DNA	1
sequence	2
analysis	0
and	0
chemical	0
mismatch	0
cleavage	0
analysis	0
of	0
copy	0
DNA	0
from	0
11	0
index	0
absorptive	0
hypercalciuric	0
patients	0
.	0

On	0
the	0
basis	0
of	0
these	0
results	0
,	0
we	0
propose	0
that	0
the	0
enhanced	0
intestinal	0
calcium	0
absorption	0
invariably	0
seen	0
in	0
absorptive	0
hypercalciuria	0
and	0
attendant	0
symptoms	0
of	0
this	0
disorder	0
are	0
not	0
attributable	0
to	0
mutations	0
of	0
the	0
VDR	9
and	0
are	0
not	0
linked	0
to	0
a	0
common	0
VDR	1
genotype	2
.	0

Transcriptional	0
regulation	0
of	0
the	0
gene	0
encoding	0
the	0
human	9
C-type	10
lectin	10
leukocyte	10
receptor	10
AIM/CD69	9
and	0
functional	0
characterization	0
of	0
its	0
tumor	1
necrosis	2
factor-alpha-responsive	2
elements	2
.	0

The	0
human	9
activation	10
antigen	10
CD69	9
is	0
a	0
member	0
of	0
the	0
C-type	9
animal	10
lectin	10
superfamily	10
that	0
functions	0
as	0
a	0
signal-transmitting	9
receptor	10
.	0

Although	0
the	0
expression	0
of	0
CD69	9
can	0
be	0
induced	0
in	0
vitro	0
on	0
cells	0
of	0
most	0
hematopoietic	0
lineages	0
with	0
a	0
wide	0
variety	0
of	0
stimuli	0
,	0
in	0
vivo	0
it	0
is	0
mainly	0
expressed	0
by	0
T-lymphocytes	7
located	0
in	0
the	0
inflammatory	0
infiltrates	0
of	0
several	0
human	0
diseases	0
.	0

To	0
elucidate	0
the	0
mechanisms	0
that	0
regulate	0
the	0
constitutive	0
and	0
inducible	0
expression	0
of	0
CD69	9
by	0
leukocytes	7
,	0
we	0
isolated	0
the	0
promoter	1
region	2
of	0
the	0
CD69	9
gene	0
and	0
carried	0
out	0
its	0
functional	0
characterization	0
.	0

Sequence	0
analysis	0
of	0
the	0
5'-flanking	1
region	2
of	0
the	0
CD69	1
gene	2
revealed	0
the	0
presence	0
of	0
a	0
potential	0
TATA	1
element	2
30	1
base	2
pairs	2
upstream	2
of	0
the	0
major	0
transcription	1
initiation	2
site	2
and	0
several	0
putative	0
binding	0
sequences	0
for	0
inducible	0
transcription	9
factors	10
(	0
NF-kappa	9
B	10
,	0
Egr-1	9
,	0
AP-1	9
)	0
,	0
which	0
might	0
mediate	0
the	0
inducible	0
expression	0
of	0
this	0
gene	0
.	0

Transient	0
expression	0
of	0
CD69	1
promoter-based	2
reporter	2
gene	2
constructs	2
in	0
K562	5
cells	6
indicated	0
that	0
the	0
proximal	1
promoter	2
region	2
spanning	0
positions	0
-78	0
to	0
+16	0
contained	0
the	0
cis-acting	1
sequences	2
necessary	0
for	0
basal	0
and	0
phorbol	0
12-myristate	0
13-acetate-inducible	0
transcription	0
of	0
the	0
CD69	1
gene	2
.	0

Removal	0
of	0
the	0
upstream	0
sequences	0
located	0
between	0
positions	0
-78	0
and	0
-38	0
resulted	0
in	0
decreased	0
promoter	0
strength	0
and	0
abolished	0
the	0
response	0
to	0
phorbol	0
12-myristate	0
13-acetate	0
.	0

We	0
also	0
found	0
that	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
is	0
capable	0
of	0
inducing	0
the	0
surface	0
expression	0
of	0
the	0
CD69	9
molecule	0
as	0
well	0
as	0
the	0
promoter	0
activity	0
of	0
fusion	0
plasmids	0
that	0
contain	0
5'-flanking	0
sequences	0
of	0
the	0
CD69	9
gene	0
,	0
suggesting	0
that	0
this	0
cytokine	0
may	0
regulate	0
in	0
vivo	0
the	0
expression	0
of	0
CD69	9
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Characterization	0
of	0
5	1
'	2
end	2
of	2
human	2
thromboxane	2
receptor	2
gene	2
.	0

Organizational	0
analysis	0
and	0
mapping	0
of	0
protein	1
kinase	2
C	2
--	2
responsive	2
elements	2
regulating	0
expression	0
in	0
platelets	7
.	0

Platelet	9
thromboxane	10
receptors	10
are	0
acutely	0
and	0
reversibly	0
upregulated	0
after	0
acute	0
myocardial	0
infarction	0
.	0

To	0
determine	0
if	0
platelet	0
thromboxane	9
receptors	10
are	0
under	0
transcriptional	0
control	0
,	0
we	0
isolated	0
and	0
characterized	0
human	1
genomic	2
DNA	2
clones	2
containing	0
the	0
5	1
'	2
flanking	2
region	2
of	0
the	0
thromboxane	1
receptor	2
gene	2
.	0

The	0
exon-intron	1
structure	2
of	0
the	0
5	1
'	2
portion	2
of	0
the	0
thromboxane	1
receptor	2
gene	2
was	0
determined	0
initially	0
by	0
comparing	0
the	0
nucleotide	1
sequence	2
of	0
the	0
5	1
'	2
flanking	2
genomic	2
clone	2
with	0
that	0
of	0
a	0
novel	1
human	2
uterine	2
thromboxane	2
receptor	2
cDNA	2
that	0
extended	0
the	0
mRNA	3
141	1
bp	2
further	2
upstream	2
than	0
the	0
previously	1
identified	2
human	2
placental	2
cDNA	2
.	0

A	0
major	0
transcription	1
initiation	2
site	2
was	0
located	0
in	0
three	0
human	0
tissues	0
approximately	0
560	1
bp	2
upstream	2
from	0
the	0
translation	1
initiation	2
codon	2
and	0
380	1
bp	2
upstream	2
from	0
any	0
previously	0
identified	0
transcription	1
initiation	2
site	2
.	0

The	0
thromboxane	1
receptor	2
gene	2
has	0
neither	0
a	0
TATA	1
nor	0
a	0
CAAT	1
consensus	2
site	2
.	0

Promoter	0
function	0
of	0
the	0
5	1
'	2
flanking	2
region	2
of	0
the	0
thromboxane	1
receptor	2
gene	2
was	0
evaluated	0
by	0
transfection	0
of	0
thromboxane	1
receptor	2
gene	2
promoter/chloramphenicol	2
acetyltransferase	2
(	2
CAT	2
)	2
chimera	2
plasmids	2
into	0
platelet-like	0
K562	5
cells	6
.	0

Thromboxane	0
receptor	1
promoter	2
activity	0
,	0
as	0
assessed	0
by	0
CAT	9
expression	0
,	0
was	0
relatively	0
weak	0
but	0
was	0
significantly	0
enhanced	0
by	0
phorbol	0
ester	0
treatment	0
.	0

Functional	0
analysis	0
of	0
5	1
'	2
deletion	2
constructs	2
in	0
transfected	0
K562	5
cells	6
and	0
gel	0
mobility	0
shift	0
localized	0
the	0
major	0
phorbol	0
ester-responsive	0
motifs	0
in	0
the	0
thromboxane	1
receptor	2
gene	2
promoter	0
to	0
a	0
cluster	0
of	0
activator	1
protein-2	2
(	2
AP-2	2
)	2
binding	2
consensus	2
sites	2
located	0
approximately	0
1.8	0
kb	0
5	0
'	0
from	0
the	0
transcription	1
initiation	2
site	2
.	0

These	0
studies	0
are	0
the	0
first	0
to	0
determine	0
the	0
structure	0
and	0
organization	0
of	0
the	0
5	0
'	0
end	0
of	0
the	0
thromboxane	1
receptor	2
gene	2
and	0
demonstrate	0
that	0
thromboxane	1
receptor	2
gene	2
expression	0
can	0
be	0
regulated	0
by	0
activation	0
of	0
protein	9
kinase	10
C	10
via	0
induction	0
of	0
an	0
AP-2-like	9
nuclear	10
factor	10
binding	0
to	0
upstream	1
promoter	2
elements	2
.	0

These	0
findings	0
strongly	0
suggest	0
that	0
the	0
mechanism	0
for	0
previously	0
described	0
upregulation	0
of	0
platelet	9
thromboxane	10
receptors	10
after	0
acute	0
myocardial	0
infarction	0
is	0
increased	0
thromboxane	1
receptor	2
gene	2
transcription	0
in	0
platelet-progenitor	7
cells	8
.	0

Estrogen	9
receptor	10
concentration	0
and	0
social	0
factors	0
as	0
predictors	0
of	0
natural	0
killer	0
cell	0
activity	0
in	0
early-stage	0
breast	0
cancer	0
patients	0
.	0

Confirmation	0
of	0
a	0
model	0
.	0

Previous	0
work	0
of	0
ours	0
has	0
demonstrated	0
that	0
a	0
significant	0
amount	0
of	0
natural	0
killer	0
(	0
NK	0
)	0
activity	0
variance	0
after	0
surgery	0
in	0
stage	0
I	0
and	0
II	0
breast	0
cancer	0
patients	0
could	0
be	0
accounted	0
for	0
by	0
both	0
the	0
estrogen	9
receptor	10
(	0
ER	9
)	0
status	0
of	0
the	0
tumor	0
and	0
by	0
social	0
factors	0
,	0
namely	0
,	0
perceived	0
social	0
support	0
and	0
seeking	0
social	0
support	0
as	0
a	0
general	0
coping	0
strategy	0
.	0

As	0
considerable	0
evidence	0
has	0
accumulated	0
that	0
social	0
support	0
in	0
both	0
animal	0
and	0
human	0
populations	0
may	0
have	0
survival	0
value	0
,	0
we	0
sought	0
to	0
test	0
the	0
reliability	0
of	0
this	0
regression	0
model	0
,	0
using	0
coping	0
and	0
perceived	0
support	0
factor	0
values	0
obtained	0
at	0
3	0
months	0
after	0
surgery	0
to	0
account	0
for	0
concurrent	0
follow-up	0
NK	0
activity	0
in	0
this	0
serially	0
assessed	0
group	0
of	0
patients	0
.	0

It	0
was	0
found	0
that	0
the	0
most	0
significant	0
variable	0
predicting	0
NK	0
activity	0
at	0
follow-up	0
was	0
tumor	0
ER	9
concentration	0
,	0
with	0
higher	0
NK	0
activity	0
associated	0
with	0
ER	9
-status	0
.	0

In	0
addition	0
,	0
seeking	0
social	0
support	0
as	0
a	0
coping	0
strategy	0
,	0
as	0
well	0
as	0
the	0
perceived	0
quality	0
of	0
support	0
,	0
also	0
entered	0
the	0
model	0
to	0
account	0
for	0
a	0
significant	0
amount	0
of	0
NK	0
activity	0
variance	0
(	0
multivariate	0
F	0
=	0
5.25	0
,	0
p	0
less	0
than	0
0.001	0
)	0
.	0

If	0
,	0
as	0
the	0
literature	0
suggests	0
,	0
NK	0
activity	0
is	0
relevant	0
to	0
breast	0
cancer	0
control	0
,	0
and	0
since	0
ER	9
-tumors	0
have	0
a	0
worse	0
prognosis	0
,	0
we	0
suggest	0
here	0
that	0
perhaps	0
such	0
tumors	0
are	0
resistant	0
to	0
control	0
by	0
NK	7
cells	8
because	0
they	0
lack	0
the	0
ability	0
to	0
attract	0
an	0
accumulation	0
of	0
effector	7
cells	8
to	0
the	0
tumor	0
site	0
,	0
or	0
because	0
blocking	0
factors	0
at	0
the	0
site	0
of	0
the	0
tumor	0
prevent	0
local	0
tumor	0
control	0
at	0
the	0
site	0
of	0
action	0
.	0

The	0
finding	0
related	0
to	0
social	0
support	0
also	0
replicates	0
results	0
from	0
an	0
independent	0
sample	0
of	0
breast	0
cancer	0
patients	0
.	0

This	0
finding	0
,	0
taken	0
together	0
with	0
other	0
evidence	0
that	0
this	0
social	0
variable	0
is	0
associated	0
with	0
longer	0
survival	0
in	0
breast	0
cancer	0
populations	0
,	0
underscores	0
the	0
potential	0
importance	0
of	0
this	0
social	0
support	0
variable	0
.	0

Our	0
findings	0
also	0
suggest	0
one	0
possible	0
immunological	0
variable	0
involved	0
,	0
with	0
potential	0
clinical	0
significance	0
,	0
for	0
this	0
patient	0
population	0
.	0

Solution	0
structure	0
of	0
the	0
sequence-specific	1
HMG	2
box	2
of	0
the	0
lymphocyte	9
transcriptional	10
activator	10
Sox-4	9
.	0

Two	0
groups	0
of	0
HMG	9
box	10
proteins	10
are	0
distinguished	0
.	0

Proteins	0
in	0
the	0
first	0
group	0
contain	0
multiple	0
HMG	9
boxes	10
,	0
are	0
non-sequence-specific	0
,	0
and	0
recognize	0
structural	0
features	0
as	0
found	0
in	0
cruciform	1
DNA	2
and	0
cross-over	1
DNA	2
.	0

The	0
abundant	0
chromosomal	9
protein	10
HMG-1	9
belongs	0
to	0
this	0
subgroup	0
.	0

Proteins	0
in	0
the	0
second	0
group	0
carry	0
a	0
single	9
HMG	10
box	10
with	0
affinity	0
for	0
the	0
minor	0
groove	0
of	0
the	0
heptamer	1
motif	2
AACAAAG	0
or	0
variations	0
thereof	0
.	0

A	0
solution	0
structure	0
for	0
the	0
non-sequence-specific	0
C-terminal	9
HMG	10
box	10
of	0
HMG-1	9
has	0
recently	0
been	0
proposed	0
.	0

Now	0
,	0
we	0
report	0
the	0
solution	0
structure	0
of	0
the	0
sequence-specific	9
HMG-box	10
of	0
the	0
SRY-related	9
protein	10
Sox-4	9
.	0

NMR	0
analysis	0
demonstrated	0
the	0
presence	0
of	0
three	0
alpha-helices	9
(	0
Val10-Gln22	9
,	0
Glu30-Leu41	9
and	0
Phe50-Tyr65	9
)	0
connected	0
by	0
loop	9
regions	10
(	0
Ser23-Ala49	9
and	0
Leu42-Pro49	9
)	0
.	0

Helices	9
I	10
and	10
II	10
are	0
positioned	0
in	0
an	0
antiparallel	9
mode	10
and	0
form	0
one	0
arm	0
of	0
the	0
HMG	9
box	10
.	0

Helix	9
III	10
is	0
less	0
rigid	0
,	0
makes	0
an	0
average	0
angle	0
of	0
about	0
90	0
degrees	0
with	0
helices	9
I	10
and	10
II	10
,	0
and	0
constitutes	0
the	0
other	0
arm	0
of	0
the	0
molecule	0
.	0

As	0
in	0
HMG1B	9
,	0
the	0
overall	0
structure	0
of	0
the	0
Sox-4	9
HMG	9
box	10
is	0
L-shaped	0
and	0
is	0
maintained	0
by	0
a	0
cluster	0
of	0
conserved	0
,	0
mainly	0
aromatic	0
residues	0
.	0

Nuclear	9
factor-IL6	10
activates	0
the	0
human	1
IL-4	2
promoter	2
in	0
T	7
cells	8
.	0

Positive	1
regulatory	2
element	2
I	2
(	0
PRE-I	1
)	0
is	0
a	0
strong	0
enhancer	1
element	2
essential	0
for	0
expression	0
of	0
the	0
human	1
IL-4	2
gene	2
.	0

To	0
identify	0
transcription	9
factors	10
binding	0
to	0
PRE-I	1
,	0
we	0
screened	0
a	0
cDNA	1
expression	2
library	2
from	0
Jurkat	5
T	6
cells	6
and	0
isolated	0
a	0
cDNA	1
encoding	0
nuclear	9
factor	10
(	9
NF	10
)	10
-IL6	10
(	0
also	0
known	0
as	0
C/EBP	9
beta	10
)	0
.	0

NF-IL6	3
mRNA	4
was	0
found	0
in	0
human	5
Jurkat	6
T	6
cells	6
and	0
in	0
the	0
mouse	5
Th2	6
clone	6
D10	5
,	0
but	0
not	0
in	0
Th1	5
clone	6
29	6
.	0

rNF-IL6	9
expressed	0
in	0
bacteria	0
was	0
shown	0
to	0
specifically	0
bind	0
to	0
PRE-I	1
.	0

PRE-I	1
forms	0
multiple	9
DNA-protein	10
complexes	10
with	0
nuclear	0
extracts	0
from	0
Jurkat	5
cells	6
.	0

Some	0
of	0
these	0
complexes	0
were	0
demonstrated	0
to	0
contain	0
NF-IL6	9
by	0
using	0
anti-C/EBP	9
beta	10
Abs	10
.	0

Overexpression	0
of	0
NF-IL6	9
enhanced	0
expression	0
of	0
the	0
chloramphenicol	1
acetyl	2
transferase	2
reporter	2
gene	2
linked	0
to	0
the	0
PRE-I-thymidine	9
kinase	10
or	0
the	0
human	1
IL-4	2
promoter	2
more	0
than	0
10-fold	0
in	0
Jurkat	5
cells	6
.	0

Promoter	0
deletion	0
studies	0
revealed	0
two	0
additional	0
NF-IL6	1
binding	2
sites	2
located	0
at	0
positions	0
-44	0
to	0
-36	0
(	0
C/EBP	9
proximal	10
)	0
and	0
-87	0
to	0
-79	0
(	0
C/EBP	9
medial	10
)	0
,	0
respectively	0
.	0

Our	0
results	0
demonstrate	0
that	0
NF-IL6	9
is	0
involved	0
in	0
transcriptional	0
activation	0
of	0
the	0
human	1
IL-4	2
promoter	2
in	0
T	7
cells	8
.	0

Identification	0
of	0
an	0
I	9
kappa	10
B	10
alpha-associated	10
protein	10
kinase	10
in	0
a	0
human	5
monocytic	6
cell	6
line	6
and	0
determination	0
of	0
its	0
phosphorylation	9
sites	10
on	0
I	9
kappa	10
B	10
alpha	10
.	0

Nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
stored	0
in	0
the	0
cytoplasm	0
as	0
an	0
inactive	0
form	0
through	0
interaction	0
with	0
I	9
kappa	10
B	10
.	0

Stimulation	0
of	0
cells	0
leads	0
to	0
a	0
rapid	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
alpha	10
,	0
which	0
is	0
presumed	0
to	0
be	0
important	0
for	0
the	0
subsequent	0
degradation	0
.	0

We	0
have	0
recently	0
reported	0
the	0
establishment	0
of	0
a	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-dependent	0
cell-free	0
activation	0
system	0
of	0
NF-kappa	9
B	10
in	0
association	0
with	0
the	0
induction	0
of	0
I	9
kappa	10
B	10
alpha	10
phosphorylation	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
identified	0
a	0
kinase	9
in	0
cell	0
extracts	0
from	0
the	0
LPS-stimulated	5
human	6
monocytic	6
cell	6
line	6
,	0
THP-1	5
,	0
that	0
specifically	0
binds	0
and	0
phosphorylates	0
I	9
kappa	10
B	10
alpha	10
.	0

LPS	0
stimulation	0
transiently	0
enhanced	0
the	0
I	9
kappa	10
B	10
alpha	10
-bound	9
kinase	10
activity	0
in	0
THP-1	5
cells	6
.	0

Mutational	0
analyses	0
of	0
I	9
kappa	10
B	10
alpha	0
and	0
competition	0
experiments	0
with	0
the	0
synthetic	0
peptides	0
identified	0
major	0
phosphorylation	9
sites	10
by	0
the	0
bound	0
kinase	9
as	0
Ser	0
and	0
Thr	0
residues	0
in	0
the	0
C-terminal	9
acidic	10
domain	10
of	0
I	9
kappa	10
B	10
alpha	10
.	0

Moreover	0
,	0
we	0
show	0
that	0
the	0
peptide	0
,	0
corresponding	0
to	0
the	0
C-terminal	9
acidic	10
domain	10
of	0
I	9
kappa	10
B	10
alpha	10
,	0
blocked	0
the	0
LPS-induced	0
NF-kappa	9
B	10
activation	0
as	0
well	0
as	0
inducible	0
phosphorylation	0
of	0
endogenous	0
I	9
kappa	10
B	10
alpha	10
in	0
a	0
cell-free	0
system	0
using	0
THP-1	5
cells	6
.	0

These	0
results	0
suggested	0
that	0
the	0
bound	9
kinase	10
is	0
involved	0
in	0
the	0
signaling	0
pathway	0
of	0
LPS	0
by	0
inducing	0
the	0
phosphorylation	0
of	0
the	0
C-terminal	9
region	10
of	0
I	9
kappa	10
B	10
alpha	10
and	0
subsequent	0
dissociation	0
of	0
the	0
NF-kappa	9
B	10
.	0
I	9
kappa	10
B	10
alpha	10
complex	10
.	0

Bik	9
,	0
a	0
novel	0
death-inducing	9
protein	10
shares	0
a	0
distinct	0
sequence	0
motif	0
with	0
Bcl-2	9
family	10
proteins	10
and	0
interacts	0
with	0
viral	0
and	0
cellular	9
survival-promoting	10
proteins	10
.	0

The	0
survival-promoting	0
activity	0
of	0
the	0
Bcl-2	9
family	10
of	0
proteins	0
appears	0
to	0
be	0
modulated	0
by	0
interactions	0
between	0
various	0
cellular	9
proteins	10
.	0

We	0
have	0
identified	0
a	0
novel	0
cellular	9
protein	10
,	0
Bik	9
,	0
that	0
interacts	0
with	0
the	0
cellular	9
survival-promoting	10
proteins	10
,	0
Bcl-2	9
and	0
Bcl-xL	9
,	0
as	0
well	0
as	0
the	0
viral	9
survival-promoting	10
proteins	10
,	0
Epstein	9
Barr	10
virus-BHRF1	10
and	0
adenovirus	9
E1B-19	10
kDa	10
.	0

In	0
transient	0
transfection	0
assays	0
,	0
Bik	9
promotes	0
cell	0
death	0
in	0
a	0
manner	0
similar	0
to	0
the	0
death-promoting	9
members	10
of	0
the	0
Bcl-2	9
family	10
,	0
Bax	9
and	0
Bak	9
.	0

This	0
death-promoting	0
activity	0
of	0
Bik	9
can	0
be	0
suppressed	0
by	0
coexpression	0
of	0
Bcl-2	9
,	0
Bcl-XL	9
,	0
EBV-BHRF1	9
and	0
E1B-19	9
kDa	10
proteins	0
suggesting	0
that	0
Bik	9
may	0
be	0
a	0
common	0
target	0
for	0
both	0
cellular	9
and	10
viral	10
anti-apoptotic	10
proteins	10
.	0

While	0
Bik	9
does	0
not	0
show	0
overt	0
homology	0
to	0
the	0
BH1	9
and	0
BH2	9
conserved	0
domains	0
characteristic	0
of	0
the	0
Bcl-2	9
family	10
,	0
it	0
does	0
share	0
a	0
9	0
amino	9
acid	10
domain	10
(	0
BH3	9
)	0
with	0
Bax	9
and	0
Bak	9
which	0
may	0
be	0
a	0
critical	0
determinant	0
for	0
the	0
death-promoting	0
activity	0
of	0
these	0
proteins	0
.	0

The	0
human	1
TCF-1	2
gene	2
encodes	0
a	0
nuclear	9
DNA-binding	10
protein	10
uniquely	0
expressed	0
in	0
normal	5
and	6
neoplastic	6
T-lineage	6
lymphocytes	6
.	0

The	0
TCF-1	1
gene	2
encodes	0
a	0
putative	9
transcription	10
factor	10
with	0
affinity	0
for	0
a	0
sequence	0
motif	0
occurring	0
in	0
a	0
number	0
of	0
T-cell	1
enhancers	2
.	0

TCF-1	3
mRNA	4
was	0
originally	0
found	0
to	0
be	0
expressed	0
in	0
a	0
T	0
cell-specific	0
fashion	0
within	0
a	0
set	0
of	0
human	5
and	6
mouse	6
cell	6
lines	6
.	0

In	0
contrast	0
,	0
expression	0
reportedly	0
occurs	0
in	0
multiple	0
nonlymphoid	0
tissues	0
during	0
murine	0
embryogenesis	0
.	0

We	0
have	0
now	0
raised	0
a	0
monoclonal	9
antibody	10
to	0
document	0
expression	0
and	0
biochemistry	0
of	0
the	0
human	9
TCF-1	10
protein	10
.	0

As	0
expected	0
,	0
the	0
TCF-1	9
protein	10
was	0
detectable	0
only	0
in	0
cell	5
lines	6
of	6
T	6
lineage	6
.	0

Its	0
expression	0
was	0
always	0
restricted	0
to	0
the	0
nucleus	0
.	0

Immunohistochemistry	0
on	0
a	0
panel	0
of	0
human	0
tissues	0
revealed	0
that	0
the	0
TCF-1	9
protein	10
was	0
found	0
exclusively	0
in	0
thymocytes	0
and	0
in	0
CD3+	5
T	6
cells	6
in	0
peripheral	0
lymphoid	0
tissues	0
.	0

Western	0
blotting	0
yielded	0
a	0
set	0
of	0
bands	0
ranging	0
from	0
25	0
kD	0
to	0
55	0
kD	0
,	0
resulting	0
from	0
extensive	0
alternative	0
splicing	0
.	0

The	0
TCF-1	9
protein	0
was	0
detectable	0
in	0
all	0
samples	0
of	0
a	0
set	0
of	0
22	0
T-cell	7
malignancies	8
of	0
various	0
stages	0
of	0
maturation	0
,	0
but	0
was	0
absent	0
from	0
a	0
large	0
number	0
of	0
other	0
hematologic	7
neoplasms	8
.	0

These	0
observations	0
imply	0
a	0
T	0
cell-specific	0
function	0
for	0
TCF-1	9
,	0
a	0
notion	0
corroborated	0
by	0
recent	0
observations	0
on	0
Tcf-1	0
knock-out	0
mice	0
.	0

In	0
addition	0
,	0
these	0
results	0
indicate	0
that	0
nuclear	0
TCF-1	9
expression	0
can	0
serve	0
as	0
a	0
pan-T-lineage	0
marker	0
in	0
the	0
diagnosis	0
of	0
lymphoid	0
malignancies	0
.	0

Cross-linking	0
of	0
Fc	9
gamma	10
receptors	10
activates	0
HIV-1	1
long	2
terminal	2
repeat	2
-driven	0
transcription	0
in	0
human	7
monocytes	8
.	0

Elevation	0
of	0
the	0
levels	0
of	0
circulating	9
immune	10
complexes	10
frequently	0
accompanies	0
HIV-1	0
infection	0
and	0
is	0
a	0
prognostic	0
indicator	0
of	0
clinical	0
progression	0
from	0
asymptomatic	0
infection	0
to	0
AIDS	0
.	0

Here	0
we	0
report	0
that	0
cross-linking	0
of	0
Fc	9
gamma	10
RI	10
or	0
Fc	9
gamma	10
RII	10
by	0
adherent	9
human	10
IgG	10
or	0
by	0
specific	0
anti-Fc	9
gamma	10
R	10
mAb	10
activates	0
HIV-1	0
gene	0
expression	0
in	0
the	0
human	5
monocytic	6
cell	6
line	6
BF24	5
and	0
increased	0
HIV	3
RNA	4
expression	0
in	0
monocytes	7
from	0
HIV	0
infected	0
patients	0
as	0
assayed	0
by	0
reverse	0
transcription-PCR	0
.	0

In	0
THP-1	5
cells	6
,	0
Fc	9
gamma	10
R	10
cross-linking	0
induced	0
NF-kappa	9
B	10
,	0
which	0
is	0
known	0
to	0
bind	0
to	0
the	0
regulatory	1
region	2
of	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
HIV-1	0
and	0
to	0
activate	0
HIV-1	0
transcription	0
.	0
Anti-TNF-alpha	9
antibody	10
but	0
not	0
anti-IL-1	9
beta	10
antibody	10
strongly	0
inhibited	0
both	0
the	0
induction	0
of	0
HIV-1-	0
LTR	1
-driven	0
transcription	0
and	0
the	0
induction	0
of	0
NF-kappa	9
B	10
by	0
Fc	9
gamma	10
R	10
cross-linking	0
.	0

These	0
results	0
indicate	0
that	0
Fc	9
gamma	10
R	10
can	0
mediate	0
a	0
TNF-alpha	9
-dependent	0
induction	0
of	0
HIV-1	1
gene	2
transcription	0
and	0
suggest	0
that	0
immune	9
complexes	10
may	0
contribute	0
to	0
the	0
pathophysiology	0
of	0
HIV-1	0
infection	0
by	0
augmenting	0
viral	0
replication	0
in	0
monocytes	7
.	0

Signalling	0
via	0
CD28	9
of	0
human	5
naive	6
neonatal	6
T	6
lymphocytes	6
.	0

Accessory	0
molecules	0
play	0
a	0
crucial	0
role	0
in	0
the	0
development	0
of	0
the	0
T	0
cell	0
response	0
to	0
antigenic	0
challenge	0
.	0

We	0
have	0
examined	0
the	0
role	0
of	0
CD28	9
in	0
modulating	0
the	0
'naive	0
'	0
neonatal	0
T	0
cell	0
response	0
to	0
anti-CD2	9
-mediated	0
activation	0
.	0

To	0
compare	0
the	0
role	0
of	0
CD28	9
,	0
neonatal	7
and	0
adult	7
T	8
cells	8
were	0
stimulated	0
with	0
a	0
pair	0
of	0
mitogenic	9
anti-CD2	10
antibodies	10
in	0
the	0
presence	0
or	0
absence	0
of	0
anti-CD28	9
MoAb	10
.	0

With	0
anti-CD2	9
alone	0
,	0
neonatal	7
T	8
cells	8
proliferated	0
slightly	0
but	0
produced	0
no	0
detectable	0
IL-2	9
,	0
whereas	0
adult	0
T	7
cells	8
proliferated	0
vigorously	0
,	0
with	0
significant	0
IL-2	9
production	0
.	0

Costimulation	0
with	0
anti-CD28	9
MoAb	10
greatly	0
enhanced	0
the	0
proliferative	0
response	0
of	0
neonatal	7
T	8
cells	8
to	0
levels	0
equivalent	0
to	0
those	0
of	0
adult	7
T	8
cells	8
,	0
whereas	0
adult	7
T	8
cells	8
showed	0
only	0
slight	0
increases	0
.	0

Although	0
IL-2	9
secretion	0
was	0
increased	0
in	0
the	0
presence	0
of	0
anti-CD28	9
MoAb	10
,	0
neonatal	7
T	8
cell	8
IL-2	9
production	0
remained	0
lower	0
than	0
in	0
adults	0
.	0

In	0
contrast	0
,	0
enhancement	0
of	0
IL-2	3
mRNA	4
expression	0
in	0
neonates	0
was	0
similar	0
to	0
adult	0
levels	0
.	0

Anti-	0
CD28	9
MoAb	10
costimulation	0
increased	0
NF	9
kappa	10
B	10
levels	0
in	0
neonates	0
,	0
albeit	0
to	0
levels	0
lower	0
than	0
that	0
of	0
adults	0
.	0

The	0
cellular	0
mechanism	0
governing	0
the	0
diminished	0
proliferative	0
response	0
of	0
neonatal	7
T	8
lymphocytes	8
to	0
anti-CD2	9
may	0
therefore	0
be	0
due	0
to	0
decreased	0
NF	9
kappa	10
B	10
induction	0
,	0
reduced	0
IL-2	3
mRNA	4
expression	0
and	0
deficient	0
IL-2	9
production	0
.	0

Although	0
anti-CD28	9
MoAb	10
costimulation	0
enhances	0
all	0
of	0
the	0
above	0
signals	0
,	0
NF	0
kappa	0
B	0
and	0
IL-2	0
levels	0
remain	0
lower	0
than	0
in	0
adults	0
,	0
suggesting	0
the	0
need	0
for	0
further	0
activation	0
requirements	0
in	0
the	0
neonate	0
.	0

TCL1	0
oncogene	0
activation	0
in	0
preleukemic	7
T	8
cells	8
from	0
a	0
case	0
of	0
ataxia-telangiectasia	0
.	0

The	0
TCL1	1
oncogene	2
on	0
human	1
chromosome	2
14q32.1	1
is	0
involved	0
in	0
chromosome	0
translocations	0
[	0
t	1
(	2
14	2
;	2
14	2
)	2
(	2
q11	2
;	2
q32.1	2
)	2
and	0
t	1
(	2
7	2
;	2
14	2
)	2
(	2
q35	2
;	2
q32.1	2
)	2
]	0
and	0
inversions	0
[	0
inv14	1
(	2
q11	2
;	2
q32.1	2
)	2
]	0
with	0
TCR	1
alpha/beta	2
loci	2
in	0
T-cell	0
leukemias	0
,	0
such	0
as	0
T-prolymphocytic	0
(	0
T-PLL	0
)	0
.	0

It	0
is	0
also	0
involved	0
in	0
T-	0
acute	0
and-	0
chronic	0
leukemias	0
arising	0
in	0
cases	0
of	0
ataxia-telangiectasia	0
(	0
AT	0
)	0
,	0
an	0
immunodeficiency	0
syndrome	0
.	0

Similar	0
chromosomal	0
rearrangements	0
occur	0
also	0
in	0
the	0
clonally	0
expanded	0
T	7
cells	8
in	0
AT	0
patients	0
before	0
the	0
appearance	0
of	0
the	0
overt	0
leukemia	0
.	0

We	0
have	0
analyzed	0
the	0
expression	0
of	0
TCL1	3
mRNA	4
and	0
protein	9
in	0
peripheral	7
blood	8
lymphocytes	8
(	0
PBLs	7
)	0
from	0
four	0
AT	0
cases	0
and	0
from	0
healthy	0
controls	0
.	0

We	0
found	0
that	0
the	0
TCL1	1
gene	2
was	0
overexpressed	0
in	0
the	0
PBLs	7
of	0
an	0
AT	0
patient	0
with	0
a	0
large	5
clonal	6
T-cell	6
population	6
exhibiting	0
the	0
t	0
(	0
14	0
;	0
14	0
)	0
translocation	0
but	0
not	0
in	0
the	0
lymphocytes	7
of	0
the	0
other	0
cases	0
.	0

Fluorescence	0
in	0
situ	0
hybridization	0
of	0
the	0
TCL1	1
genomic	2
locus	2
to	0
lymphocyte	0
metaphases	0
from	0
the	0
AT	0
patient	0
with	0
the	0
T-cell	0
clonal	0
expansion	0
showed	0
that	0
the	0
breakpoint	0
of	0
the	0
t	0
(	0
14	0
;	0
14	0
)	0
translocation	0
lies	0
within	0
the	0
TCL1	1
locus	2
and	0
is	0
accompanied	0
by	0
an	0
inverted	0
duplication	0
of	0
the	0
distal	1
part	2
of	0
chromosome	1
14	2
.	0

These	0
data	0
indicate	0
that	0
TCL1	1
is	0
activated	0
in	0
preleukemic	5
clonal	6
cells	6
as	0
a	0
consequence	0
of	0
chromosome	0
translocation	0
involving	0
sequences	0
from	0
the	0
TCR	1
locus	2
at	0
14q11	1
.	0

Deregulation	0
of	0
TCL1	1
is	0
the	0
first	0
event	0
in	0
the	0
initiation	0
of	0
malignancy	0
in	0
these	0
types	0
of	0
leukemias	0
and	0
represents	0
a	0
potential	0
tool	0
for	0
clinical	0
evaluation	0
.	0

C/EBP	9
proteins	10
activate	0
transcription	0
from	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
in	0
macrophages/	0
monocytes	7
.	0

Three	0
binding	0
sites	0
for	0
C/EBP	9
proteins	10
are	0
found	0
in	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
(	2
HIV-1	2
)	2
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
(	0
V.M.	0
Tesmer	0
,	0
A.Rajadhyaksha	0
,	0
J.Babin	0
,	0
and	0
M.Bina	0
,	0
Proc.Natl.Acad.Sci.	0
USA	0
90	0
:	0
7298-7302	0
,	0
1993	0
)	0
.	0

We	0
have	0
determined	0
the	0
functional	0
role	0
of	0
C/EBP	9
proteins	10
and	0
C/EBP	1
sites	2
in	0
regulating	0
transcription	0
from	0
the	0
HIV-	1
1	2
LTR	2
in	0
monocytes/macrophages	7
.	0

Inhibition	0
of	0
endogenous	9
C/EBP	10
proteins	10
,	0
using	0
either	0
an	0
excess	0
of	0
C/EBP	1
binding	2
sites	2
or	0
a	0
trans-	1
dominant	2
negative	2
inhibitor	2
,	0
demonstrated	0
that	0
C/EBP	9
proteins	10
are	0
required	0
for	0
basal	0
and	0
activated	0
levels	0
of	0
HIV-1	1
LTR	2
transcription	0
in	0
the	0
promonocytic	5
cell	6
line	6
U937	6
.	0

Northern	0
(	0
RNA	0
)	0
blots	0
and	0
binding	0
assays	0
showed	0
that	0
NF-IL6	9
is	0
the	0
only	0
known	0
C/EBP	9
family	10
member	10
which	0
is	0
increased	0
when	0
U937	5
cells	6
are	0
activated	0
.	0

Mutational	0
analyses	0
of	0
the	0
HIV-1	1
LTR	2
showed	0
that	0
one	0
C/EBP	1
site	2
is	0
required	0
for	0
normal	0
LTR	1
transcription	0
both	0
before	0
and	0
after	0
cellular	0
activation	0
and	0
that	0
the	0
two	0
3	0
'	0
C/EBP	1
sites	2
are	0
functionally	0
equivalent	0
.	0

However	0
,	0
transcription	0
from	0
crippled	1
HIV-1	2
LTRs	2
lacking	0
C/EBP	1
sites	2
can	0
still	0
be	0
induced	0
following	0
activation	0
of	0
U937	5
cells	6
.	0

Several	0
models	0
are	0
suggested	0
for	0
how	0
elevated	0
NF-IL6	9
may	0
participate	0
in	0
an	0
autostimulatory	0
loop	0
involving	0
HIV	0
infection	0
,	0
macrophage	0
activation	0
,	0
cytokine	9
expression	0
,	0
and	0
HIV	0
replication	0
.	0

Human	0
immunodeficiency	0
virus	0
type-2	0
gene	0
expression	0
:	0
two	0
enhancers	1
and	0
their	0
activation	0
by	0
T-cell	7
activators	0
.	0

The	0
human	0
immunodeficiency	0
viruses	0
(	0
HIVs	0
)	0
may	0
include	0
a	0
spectrum	0
of	0
retroviruses	0
with	0
varying	0
potential	0
to	0
infect	0
their	0
host	0
,	0
undergo	0
long	0
periods	0
of	0
latent	0
infection	0
,	0
and	0
induce	0
pathology	0
.	0

Since	0
expression	0
of	0
the	0
viruses	0
is	0
in	0
large	0
part	0
regulated	0
by	0
the	0
sequence	1
elements	2
in	0
their	0
long	1
terminal	2
repeats	2
(	0
LTRs	1
)	0
,	0
this	0
study	0
was	0
directed	0
to	0
an	0
analysis	0
of	0
the	0
regulatory	1
elements	2
in	0
the	0
HIV-2	1
LTR	2
.	0

The	0
HIV-2	1
LTR	2
was	0
found	0
to	0
contain	0
two	0
enhancers	1
.	0

One	0
of	0
these	0
enhancers	1
is	0
,	0
in	0
part	0
,	0
identical	0
to	0
the	0
HIV-1	1
enhancer	2
.	0

This	0
enhancer	1
in	0
HIV-1	0
is	0
the	0
T-cell	1
activation	2
response	2
element	2
;	0
in	0
HIV-2	0
,	0
however	0
,	0
it	0
is	0
the	0
second	1
enhancer	2
that	0
is	0
mainly	0
responsible	0
for	0
activation	0
in	0
response	0
to	0
T-cell	0
activators	0
.	0

The	0
second	0
enhancer	1
interacts	0
with	0
two	0
nuclear	9
binding	10
proteins	10
(	0
85	0
kD	0
and	0
27	0
kD	0
mobility	0
)	0
that	0
appear	0
to	0
be	0
required	0
for	0
optimal	0
enhancer	0
function	0
and	0
activation	0
.	0

Observations	0
such	0
as	0
these	0
encourage	0
the	0
speculation	0
that	0
there	0
may	0
be	0
subtle	0
differences	0
in	0
the	0
regulation	0
of	0
HIV-1	0
and	0
HIV-2	0
expression	0
that	0
may	0
be	0
relevant	0
to	0
the	0
possible	0
longer	0
latency	0
and	0
reduced	0
pathogenicity	0
of	0
HIV-2	0
.	0

NF-M	9
(	0
chicken	9
C/EBP	10
beta	10
)	0
induces	0
eosinophilic	0
differentiation	0
and	0
apoptosis	0
in	0
a	0
hematopoietic	5
progenitor	6
cell	6
line	6
.	0

CAAT/enhancer	9
binding	10
proteins	10
(	0
C/EBPs	9
)	0
are	0
transcriptional	0
activators	0
implicated	0
in	0
the	0
differentiation	0
processes	0
of	0
various	0
cell	0
lineages	0
.	0

We	0
have	0
shown	0
earlier	0
that	0
NF-M	9
,	0
the	0
chicken	9
homolog	10
of	0
C/EBP	9
beta	10
,	0
is	0
specifically	0
expressed	0
in	0
myelomonocytic	7
and	8
eosinophilic	8
cells	8
of	0
the	0
hematopoietic	0
system	0
.	0

To	0
investigate	0
the	0
role	0
of	0
NF-M	9
in	0
hematopoietic	5
cell	6
lineage	6
commitment	0
,	0
we	0
constructed	0
a	0
conditional	0
form	0
of	0
the	0
protein	0
by	0
fusing	0
it	0
to	0
the	0
hormone	9
binding	10
domain	10
of	0
the	0
human	9
estrogen	10
receptor	10
.	0

This	0
construct	0
was	0
stably	0
expressed	0
in	0
a	0
multipotent	5
progenitor	6
cell	6
line	6
transformed	0
by	0
the	0
Myb-Ets	9
oncoprotein	10
.	0

We	0
report	0
here	0
that	0
both	0
NF-M-dependent	1
promoter	2
constructs	2
and	0
resident	0
genes	0
could	0
be	0
activated	0
by	0
addition	0
of	0
beta-estradiol	0
to	0
the	0
NF-M-estrogen	5
receptor	6
expressing	6
progenitors	6
.	0

At	0
the	0
same	0
time	0
,	0
we	0
observed	0
a	0
down-regulation	0
of	0
progenitor-specific	9
surface	10
markers	10
and	0
the	0
up-regulation	0
of	0
differentiation	9
markers	10
restricted	0
to	0
the	0
eosinophil	7
and	0
myeloid	7
lineages	8
.	0

In	0
addition	0
to	0
the	0
onset	0
of	0
differentiation	0
,	0
cell	0
death	0
was	0
induced	0
with	0
typical	0
apoptotic	0
features	0
.	0

Our	0
results	0
suggest	0
that	0
NF-M	9
plays	0
an	0
important	0
role	0
in	0
commitment	0
along	0
the	0
eosinophil	7
lineage	8
and	0
in	0
the	0
induction	0
of	0
apoptosis	0
.	0

Prolactin	9
and	0
interleukin-2	9
receptors	10
in	0
T	7
lymphocytes	8
signal	0
through	0
a	0
MGF-STAT5-like	9
transcription	10
factor	10
.	0

The	0
cell	0
surface	0
receptors	0
for	0
PRL	9
and	0
interleukin-2	9
(	0
IL-2	9
)	0
are	0
structurally	0
distinct	0
,	0
but	0
share	0
regulatory	0
tasks	0
in	0
T	7
lymphocytes	8
.	0

They	0
can	0
stimulate	0
proliferation	0
and	0
activate	0
transcription	0
of	0
over-lapping	0
sets	0
of	0
genes	0
of	0
T	7
cells	8
.	0

PRL	9
and	0
IL-2	9
receptor	0
activation	0
are	0
both	0
linked	0
to	0
the	0
Jak/Stat	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
)	0
pathway	0
.	0

We	0
investigated	0
the	0
ability	0
of	0
PRL	9
and	0
IL-2	9
to	0
activate	0
Stat	9
proteins	10
in	0
different	0
T	5
cell	6
lines	6
.	0

The	0
DNA	0
binding	0
specificities	0
,	0
the	0
reactivities	0
toward	0
Stat-specific	0
antisera	0
,	0
and	0
the	0
mol	0
wt	0
of	0
IL-2	9
-and	0
PRL-induced	9
DNA-binding	10
proteins	10
in	0
Nb2	5
and	6
C196	6
T	6
cell	6
lines	6
were	0
investigated	0
.	0

A	0
comparison	0
with	0
the	0
Stat	9
proteins	10
induced	0
by	0
interferon-gamma	9
,	0
PRL	9
,	0
and	0
IL-6	9
in	0
T47D	5
mammary	6
tumor	6
cells	6
was	0
made	0
.	0

We	0
found	0
that	0
these	0
parameters	0
were	0
indistinguishable	0
for	0
one	0
of	0
the	0
PRL-	9
and	10
IL-2-induced	10
factors	10
.	0

A	0
transcription	0
factor	0
closely	0
related	0
to	0
mammary	9
gland	10
factor-Stat5	10
is	0
rapidly	0
activated	0
upon	0
interaction	0
of	0
IL-2	9
and	0
PRL	9
with	0
their	0
respective	0
receptors	0
.	0

Activation	0
of	0
a	0
second	0
protein	0
related	0
to	0
Stat1	9
was	0
also	0
observed	0
.	0

Our	0
results	0
emphasize	0
the	0
role	0
of	0
PRL	9
as	0
a	0
regulator	0
of	0
the	0
immune	0
response	0
and	0
indicate	0
that	0
the	0
Stat	9
factors	10
mammary	9
gland	10
factor-Stat5	10
and	0
Stat1	9
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
gene	0
expression	0
during	0
T	0
cell	0
development	0
.	0

ETS1	9
transactivates	0
the	0
human	1
GM-CSF	2
promoter	2
in	0
Jurkat	5
T	6
cells	6
stimulated	0
with	0
PMA	0
and	0
ionomycin	0
.	0

Activation	0
of	0
T	7
helper	8
cells	8
results	0
in	0
coordinate	0
expression	0
of	0
a	0
number	0
of	0
cytokines	9
involved	0
in	0
differentiation	0
,	0
proliferation	0
and	0
activation	0
of	0
the	0
haematopoietic	0
system	0
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
is	0
one	0
such	0
cytokine	9
whose	0
increased	0
expression	0
results	0
partly	0
from	0
increases	0
in	0
transcription	0
.	0

Cis-acting	1
elements	2
with	0
NF	9
kappa	10
B	10
,	0
AP-1	9
and	0
ETS-like	1
motifs	2
have	0
been	0
identified	0
in	0
the	0
promoter	0
region	0
of	0
the	0
GM-CSF	1
gene	2
,	0
which	0
are	0
important	0
for	0
transcriptional	0
activity	0
following	0
PMA	0
and	0
ionomycin	0
stimulation	0
.	0

A	0
number	0
of	0
the	0
ETS	9
family	10
of	0
transcription	9
factors	10
are	0
expressed	0
in	0
T	7
cells	8
,	0
including	0
ETS1	9
and	0
ELF1	9
.	0

Here	0
we	0
describe	0
the	0
ability	0
of	0
these	0
factors	0
to	0
interact	0
with	0
a	0
site	0
(	0
GM5	1
)	0
,	0
located	0
within	0
the	0
CLE0	1
element	2
,	0
-47	1
to	2
-40	2
upstream	2
of	0
the	0
GM-CSF	1
transcription	2
initiation	2
site	2
.	0

Exogenous	0
ETS1	9
,	0
but	0
not	0
ELF1	9
,	0
can	0
transactivate	0
GM-CSF	9
,	0
through	0
the	0
GM5	1
site	0
,	0
in	0
a	0
PMA/ionomycin	0
dependent	0
manner	0
.	0

Other	0
unidentified	0
ETS-like	9
factors	10
present	0
in	0
Jurkat	5
cells	6
are	0
also	0
capable	0
of	0
binding	0
GM5	1
.	0

Mutation	0
of	0
the	0
core	0
ETS	1
binding	2
site	2
from	0
-GGAA-	1
to	2
-GGAT-	2
prevents	0
the	0
binding	0
of	0
ETS-like	9
factors	10
with	0
the	0
exception	0
of	0
ETS1	9
.	0

The	0
GM-CSF	1
promoter	2
,	0
modified	0
in	0
this	0
way	0
to	0
be	0
ETS1	9
specific	0
,	0
is	0
fully	0
responsive	0
to	0
PMA/ionomycin	0
induction	0
,	0
in	0
addition	0
to	0
ETS1	9
transactivation	0
in	0
the	0
presence	0
of	0
PMA	0
and	0
ionomycin	0
.	0

Together	0
these	0
data	0
suggest	0
that	0
ETS1	9
may	0
be	0
involved	0
in	0
mediating	0
the	0
increased	0
GM-CSF	9
production	0
associated	0
with	0
T	7
cell	8
activation	0
.	0

Quantitation	0
of	0
beta	3
1	4
triiodothyronine	4
receptor	4
mRNA	4
in	0
human	0
tissues	0
by	0
competitive	0
reverse	0
transcription	0
polymerase	0
chain	0
reaction	0
.	0

Thyroid	0
hormones	0
act	0
by	0
binding	0
to	0
nuclear	9
receptor	10
proteins	10
,	0
the	0
thyroid	9
hormone	10
receptors	10
(	10
TR	10
)	10
alpha	10
and	10
beta	10
.	0

Data	0
from	0
cell	0
culture	0
and	0
animal	0
studies	0
indicate	0
that	0
TR	9
expression	0
may	0
be	0
regulated	0
to	0
modulate	0
target	0
organ	0
responsiveness	0
to	0
thyroid	0
hormone	0
.	0

To	0
investigate	0
whether	0
such	0
adaptive	0
changes	0
in	0
TR	9
expression	0
occur	0
in	0
humans	0
,	0
we	0
determined	0
the	0
mRNA	0
levels	0
of	0
the	0
hTR	9
beta	10
1	10
in	0
various	0
thyroid	0
states	0
.	0

Patients	0
with	0
overt	0
hypo	0
-or	0
hyperthyroidism	0
were	0
enrolled	0
in	0
the	0
study	0
.	0

Total	0
RNA	0
was	0
isolated	0
from	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
determined	0
by	0
quantitative	0
competitive	0
reverse	0
transcription	0
PCR	0
.	0

For	0
comparison	0
,	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
were	0
determined	0
in	0
lymphocytes	7
and	0
normal	0
thyroid	0
tissue	0
of	0
euthyroid	0
patients	0
.	0

Human	3
TR	4
beta	4
1	4
mRNA	4
levels	0
in	0
lymphocytes	7
were	0
1.8	0
+/-	0
0.4	0
,	0
1.9	0
+/-	0
0.5	0
,	0
1.1	0
+/-	0
0.4	0
10	0
(	0
-18	0
)	0
mol/microgram	0
RNA	0
in	0
hypo-	0
,	0
eu	0
-and	0
hyperthyroid	0
patients	0
,	0
respectively	0
,	0
corresponding	0
to	0
an	0
estimated	0
0.5	0
-2	0
molecules	0
per	0
cell	0
.	0

Although	0
the	0
mean	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
were	0
40	0
%	0
lower	0
in	0
hyperthyroid	0
than	0
in	0
euthyroid	0
subjects	0
,	0
this	0
difference	0
did	0
not	0
reach	0
statistical	0
significance	0
.	0

Similar	0
levels	0
of	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
were	0
detected	0
in	0
thyroid	0
gland	0
from	0
euthyroid	0
patients	0
.	0

In	0
summary	0
,	0
we	0
developed	0
an	0
assay	0
for	0
the	0
quantitative	0
determination	0
of	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
in	0
small	0
human	0
tissue	0
samples	0
,	0
containing	0
as	0
little	0
as	0
50	0
ng	0
of	0
total	0
RNA	0
.	0

Absolute	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
are	0
very	0
low	0
with	0
an	0
estimated	0
one	0
molecule	0
of	0
mRNA	3
being	0
present	0
in	0
a	0
mononuclear	7
blood	8
cell	8
or	0
thyrocyte	7
.	0

No	0
up-regulation	0
of	0
hTR	9
beta	10
1	10
was	0
seen	0
in	0
hypothyroid	0
relative	0
to	0
euthyroid	0
patients	0
.	0

However	0
,	0
there	0
is	0
a	0
non-significant	0
trend	0
towards	0
a	0
down-regulation	0
of	0
hTR	3
beta	4
1	4
mRNA	4
levels	0
in	0
hyperthyroid	0
patients	0
.	0

Multiple	0
proteins	0
interact	0
with	0
the	0
nuclear	1
inhibitory	2
protein	2
repressor	2
element	2
in	0
the	0
human	1
interleukin-3	2
promoter	2
.	0

T	0
cell	0
expression	0
of	0
interleukin	9
3	10
(	0
IL-3	9
)	0
is	0
directed	0
by	0
positive	1
and	2
negative	2
cis-acting	2
DNA	2
elements	2
clustered	0
within	0
300	0
base	0
pairs	0
of	0
the	0
transcriptional	1
start	2
site	2
.	0

A	0
strong	0
repressor	9
element	10
,	0
termed	0
nuclear	9
inhibitory	10
protein	10
(	0
NIP	9
)	0
,	0
was	0
previously	0
mapped	0
to	0
a	0
segment	0
of	0
the	0
IL-3	1
promoter	2
between	0
nucleotides	1
-271	2
and	2
-250	2
.	0

Functional	0
characterization	0
of	0
this	0
element	0
demonstrates	0
that	0
it	0
can	0
mediate	0
repression	0
when	0
linked	0
in	0
cis	0
to	0
a	0
heterologous	1
promoter	2
.	0

DNA	0
binding	0
experiments	0
were	0
carried	0
out	0
to	0
characterize	0
the	0
repressor	0
activity	0
.	0

Using	0
varying	0
conditions	0
,	0
three	0
distinct	0
complexes	0
were	0
shown	0
to	0
interact	0
specifically	0
with	0
the	0
NIP	1
region	2
,	0
although	0
only	0
one	0
correlates	0
with	0
repressor	0
activity	0
.	0

Complex	9
1	10
results	0
from	0
binding	0
of	0
a	0
ubiquitous	0
polypeptide	0
that	0
recognizes	0
the	0
3	1
'	2
portion	2
of	0
this	0
sequence	0
and	0
is	0
not	0
required	0
for	0
repression	0
.	0

Complex	9
2	10
corresponds	0
to	0
binding	0
of	0
transcription	9
factor	10
(	0
upstream	9
stimulatory	10
factor	10
)	0
to	0
an	0
E-box	1
motif	2
in	0
the	0
5	1
'	2
portion	2
of	0
the	0
NIP	1
region	2
.	0

DNA	0
binding	0
specificity	0
of	0
complex	0
3	0
overlaps	0
with	0
that	0
of	0
upstream	9
stimulatory	10
factor	10
but	0
is	0
clearly	0
distinct	0
.	0

To	0
determine	0
which	0
of	0
the	0
latter	0
two	0
complexes	0
represents	0
NIP	9
activity	0
,	0
we	0
incorporated	0
small	0
alterations	0
into	0
the	0
NIP	1
site	2
of	0
an	0
IL-3	1
promoter-linked	2
reporter	2
construct	2
and	0
examined	0
their	0
effects	0
on	0
NIP	9
-mediated	0
repression	0
.	0

Functional	0
specificity	0
for	0
repression	0
matches	0
the	0
DNA	0
binding	0
specificity	0
of	0
complex	9
3	10
;	0
both	0
repressor	0
activity	0
and	0
complex	9
3	10
binding	0
require	0
the	0
consensus	1
sequence	2
CTCACNTNC	0
.	0

The	0
hematopoietic	9
transcription	10
factor	10
PU.1	9
is	0
downregulated	0
in	0
human	5
multiple	6
myeloma	6
cell	6
lines	6
.	0

PU.1	9
is	0
a	0
hematopoietic	9
transcription	10
factor	10
belonging	0
to	0
the	0
Ets-family	9
.	0

It	0
is	0
identical	0
to	0
the	0
Spi-1	1
oncogene	2
,	0
which	0
is	0
implicated	0
in	0
spleen	0
focus-forming	0
virus-induced	0
murine	0
erythroleukemias	0
.	0

PU.1	9
seems	0
to	0
be	0
required	0
for	0
early	0
development	0
of	0
multiple	7
hematopoietic	8
lineages	8
,	0
but	0
its	0
expression	0
in	0
mature	7
cells	8
is	0
preferentially	0
observed	0
in	0
cells	0
of	0
the	0
B-cell-and	7
monocyte/macrophage-differentiation	8
lineage	8
.	0

It	0
binds	0
the	0
so-called	0
Pu	1
box	2
,	0
an	0
important	0
tissue-specific	1
regulatory	2
DNA	2
element	2
present	0
in	0
a	0
number	0
of	0
genes	0
expressed	0
in	0
these	0
cell	7
lineages	8
.	0

We	0
have	0
analyzed	0
the	0
expression	0
and	0
activity	0
of	0
PU.1	9
during	0
human	0
B-cell	0
development	0
using	0
a	0
panel	0
of	0
B-cell	5
lines	6
representing	0
different	0
stages	0
of	0
maturation	0
,	0
from	0
early	5
precursors	6
to	0
differentiated	5
plasma	6
cells	6
.	0

PU.1	3
mRNA	4
expression	0
and	0
PU.1	9
DNA	0
binding	0
activity	0
,	0
as	0
measured	0
by	0
Northern	0
blot	0
analysis	0
and	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
respectively	0
,	0
were	0
evident	0
in	0
cell	5
lines	6
representing	0
pro-B	5
,	6
pre-B	6
,	6
and	6
mature	6
B	6
cells	6
.	0

We	0
could	0
also	0
show	0
Pu	1
box	2
-dependent	0
transactivation	0
of	0
a	0
reporter	0
gene	0
in	0
transient	0
transfections	0
in	0
these	0
cell	5
lines	6
.	0

In	0
contrast	0
,	0
in	0
a	0
number	0
of	0
multiple	5
myeloma	6
cell	6
lines	6
,	0
representing	0
differentiated	7
,	8
plasma	8
cell-like	8
B	8
cells	8
,	0
PU.1	9
DNA	0
binding	0
activity	0
,	0
mRNA	0
expression	0
,	0
and	0
Pu	1
box	2
-dependent	0
transactivation	0
were	0
absent	0
or	0
detectable	0
at	0
a	0
very	0
low	0
level	0
.	0

In	0
lymphoblastoid	5
cell	6
lines	6
,	0
which	0
exemplify	0
an	0
intermediate	0
stage	0
of	0
B-cell	0
differentiation	0
,	0
a	0
reduced	0
expression	0
and	0
activity	0
were	0
observed	0
.	0

The	0
findings	0
in	0
the	0
human	5
multiple	6
myeloma	6
cell	6
lines	6
represent	0
the	0
first	0
examples	0
of	0
B	7
cells	8
with	0
downregulated	0
PU.1	9
expression	0
and	0
apparently	0
contradict	0
observations	0
in	0
the	0
murine	0
system	0
in	0
which	0
PU.1	9
is	0
expressed	0
and	0
active	0
in	0
plasmacytoma	5
cell	6
lines	6
.	0

At	0
present	0
,	0
it	0
is	0
unclear	0
whether	0
the	0
lack	0
of	0
PU.1	9
expression	0
and	0
activity	0
in	0
human	5
multiple	6
myeloma	6
cell	6
lines	6
represents	0
a	0
malignancy-associated	0
defect	0
in	0
these	0
cells	0
or	0
exemplifies	0
a	0
normal	0
developmental	0
regulation	0
in	0
terminally	7
differentiated	8
B	8
cells	8
.	0

Regulation	0
of	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
and	0
E-selectin	9
expression	0
in	0
endothelial	7
cells	8
by	0
cyclosporin	0
A	0
and	0
the	0
T-cell	9
transcription	10
factor	10
NFAT	9
.	0

Nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
was	0
originally	0
described	0
as	0
a	0
T-cell-specific	9
transcription	10
factor	10
athat	0
supported	0
the	0
activation	0
of	0
cytokine	9
gene	0
expression	0
and	0
mediated	0
the	0
immunoregulatory	9
effects	0
of	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
.	0

As	0
we	0
observed	0
that	0
activated	7
endothelial	8
cells	8
also	0
expressed	0
NFAT	9
,	0
we	0
tested	0
the	0
antiinflammatory	0
properties	0
of	0
CsA	0
in	0
endothelial	7
cells	8
.	0

Significantly	0
,	0
CsA	0
completely	0
suppressed	0
the	0
induction	0
of	0
NFAT	9
in	0
endothelial	7
cells	8
and	0
inhibited	0
the	0
activity	0
of	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
gene	2
regulatory	2
elements	2
that	0
use	0
NFAT	9
by	0
60	0
%	0
.	0

CsA	0
similarly	0
mediated	0
a	0
reduction	0
of	0
up	0
to	0
65	0
%	0
in	0
GM-CSF	3
mRNA	4
and	0
protein	0
expression	0
in	0
activated	7
endothelial	8
cells	8
.	0

CsA	0
also	0
suppressed	0
E-selectin	9
,	0
but	0
not	0
vascular	9
cell	10
adhesion	10
molecule-1	10
(	0
VCAM-1	9
)	0
expression	0
in	0
endothelial	0
cells	0
,	0
even	0
though	0
the	0
E-selectin	1
promoter	2
is	0
activated	0
by	0
NF-kappa	9
B	10
rather	0
than	0
NFAT	9
.	0

Hence	0
,	0
induction	0
of	0
cell	0
surface	0
expression	0
of	0
this	0
leukocyte	9
adhesion	10
molecule	10
by	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
was	0
reduced	0
by	0
40	0
%	0
in	0
the	0
presence	0
of	0
CsA	0
,	0
and	0
this	0
was	0
reflected	0
by	0
a	0
29	0
%	0
decrease	0
in	0
neutrophil	7
adhesion	0
.	0

The	0
effects	0
of	0
CsA	0
on	0
endothelial	7
cells	8
were	0
also	0
detected	0
at	0
the	0
chromatin	1
structure	0
level	0
,	0
as	0
DNasel	1
hypersensitive	2
sites	2
within	0
both	0
the	0
GM-CSF	9
enhancer	0
and	0
the	0
E-selectin	1
promoter	2
were	0
suppressed	0
by	0
CsA	0
.	0

This	0
represents	0
the	0
first	0
report	0
of	0
NFAT	9
in	0
endothelial	7
cells	8
and	0
suggests	0
mechanisms	0
by	0
which	0
CsA	0
could	0
function	0
as	0
an	0
antiinflammatory	0
agent	0
.	0

Costimulation	0
requirement	0
for	0
AP-1	9
and	0
NF-kappa	9
B	10
transcription	0
factor	0
activation	0
in	0
T	7
cells	8
.	0

The	0
transcriptional	0
activity	0
of	0
the	0
IL-2	1
promoter	2
requires	0
T-cell	7
costimulation	0
delivered	0
by	0
the	0
TCR	9
and	0
the	0
auxiliary	9
receptor	10
CD28	10
.	0

Several	0
transcription	9
factors	10
participate	0
in	0
IL-2	9
promoter	0
activation	0
,	0
among	0
which	0
are	0
AP-1-like	9
factors	10
and	0
NF-kappa	9
B	10
.	0

Protein	0
phosphorylation	0
has	0
an	0
important	0
role	0
in	0
the	0
regulation	0
of	0
these	0
two	0
factors	0
:	0
(	0
1	0
)	0
it	0
induces	0
the	0
transactivating	0
capacity	0
of	0
the	0
AP-1	9
protein	10
c-Jun	9
;	0
and	0
(	0
2	0
)	0
it	0
is	0
involved	0
in	0
the	0
release	0
of	0
the	0
cytoplasmic	9
inhibitor	10
,	0
I	9
kappa	10
B	10
,	0
from	0
NF-kappa	9
B	10
,	0
allowing	0
translocation	0
of	0
the	0
latter	0
into	0
the	0
nucleus	0
.	0

We	0
have	0
recently	0
shown	0
that	0
both	0
phosphorylation	0
processes	0
require	0
T-cell	0
costimulation	0
.	0

Furthermore	0
,	0
in	0
activated	7
T	8
cells	8
,	0
the	0
kinetics	0
of	0
the	0
two	0
phosphorylation	0
events	0
are	0
essentially	0
similar	0
.	0

According	0
to	0
our	0
results	0
,	0
however	0
,	0
the	0
kinases	0
responsible	0
for	0
the	0
two	0
processes	0
are	0
distinct	0
entities	0
.	0

Whereas	0
TPCK	9
inhibits	0
phosphorylation	0
of	0
I	9
kappa	10
B	10
and	0
,	0
consequently	0
,	0
activation	0
of	0
NF-kappa	9
B	10
,	0
it	0
markedly	0
enhances	0
the	0
activity	0
of	0
JNK	9
,	0
the	0
MAP	9
kinase-related	10
kinase	10
that	0
phosphorylates	0
the	0
transactivation	9
domain	10
of	0
c-Jun	9
.	0

We	0
,	0
therefore	0
,	0
propose	0
the	0
activation	0
scheme	0
presented	0
in	0
FIGURE	0
3	0
for	0
T-cell	0
costimulation	0
.	0

Costimulation	0
results	0
in	0
the	0
activation	0
of	0
a	0
signaling	0
pathway	0
that	0
leads	0
to	0
the	0
simultaneous	0
induction	0
of	0
the	0
two	0
transcription	9
factors	10
,	0
AP-1	9
and	0
NF-kappa	9
B	10
.	0

Integration	0
of	0
the	0
signals	0
generated	0
by	0
TCR	9
and	0
CD28	9
engagement	0
occurs	0
along	0
this	0
pathway	0
,	0
which	0
then	0
bifurcates	0
to	0
induce	0
I	9
kappa	10
B	10
phosphorylation	0
and	0
NF-kappa	9
B	10
activation	0
on	0
the	0
one	0
hand	0
,	0
and	0
JNK	9
activation	0
and	0
c-Jun	9
phosphorylation	0
on	0
the	0
other	0
.	0

We	0
are	0
currently	0
engaged	0
in	0
defining	0
where	0
the	0
two	0
signals	0
integrate	0
along	0
the	0
AP-1	9
/	0
NF-kappa	9
B	10
pathway	0
.	0

Regulation	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
and	0
cytokine	0
gene	0
expression	0
in	0
myeloid	7
cells	8
by	0
NF-kappa	9
B/Rel	10
transcription	9
factors	10
.	0

CD4+	5
macrophages	6
in	0
tissues	0
such	0
as	0
lung	0
,	0
skin	0
,	0
and	0
lymph	0
nodes	0
,	0
promyelocytic	7
cells	8
in	0
bone	0
marrow	0
,	0
and	0
peripheral	7
blood	8
monocytes	8
serve	0
as	0
important	0
targets	0
and	0
reservoirs	0
for	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replication	0
.	0

HIV-1-infected	0
myeloid	7
cells	8
are	0
often	0
diminished	0
in	0
their	0
ability	0
to	0
participate	0
in	0
chemotaxis	0
,	0
phagocytosis	0
,	0
and	0
intracellular	0
killing	0
.	0

HIV-1	0
infection	0
of	0
myeloid	7
cells	8
can	0
lead	0
to	0
the	0
expression	0
of	0
surface	9
receptors	10
associated	0
with	0
cellular	0
activation	0
and/or	0
differentiation	0
that	0
increase	0
the	0
responsiveness	0
of	0
these	0
cells	0
to	0
cytokines	9
secreted	0
by	0
neighboring	0
cells	0
as	0
well	0
as	0
to	0
bacteria	0
or	0
other	0
pathogens	0
.	0

Enhancement	0
of	0
HIV-1	0
replication	0
is	0
related	0
in	0
part	0
to	0
increased	0
DNA-binding	0
activity	0
of	0
cellular	9
transcription	10
factors	10
such	0
as	0
NF-kappa	9
B	10
.	0

NF-kappa	9
B	10
binds	0
to	0
the	0
HIV-1	1
enhancer	2
region	0
of	0
the	0
long	1
terminal	2
repeat	2
and	0
contributes	0
to	0
the	0
inducibility	0
of	0
HIV-1	0
gene	0
expression	0
in	0
response	0
to	0
multiple	0
activating	0
agents	0
.	0

Phosphorylation	0
and	0
degradation	0
of	0
the	0
cytoplasmic	9
inhibitor	10
I	9
kappa	10
B	10
alpha	0
are	0
crucial	0
regulatory	0
events	0
in	0
the	0
activation	0
of	0
NF-kappa	9
B	10
DNA-binding	0
activity	0
.	0

Both	0
N-	0
and	0
C-terminal	0
residues	0
of	0
I	9
kappa	10
B	10
alpha	0
are	0
required	0
for	0
inducer-mediated	0
degradation	0
.	0

Chronic	0
HIV-1	0
infection	0
of	0
myeloid	7
cells	8
leads	0
to	0
constitutive	0
NF-kappa	9
B	10
DNA-binding	0
activity	0
and	0
provides	0
an	0
intranuclear	0
environment	0
capable	0
of	0
perpetuating	0
HIV-1	0
replication	0
.	0

Increased	0
intracellular	0
stores	0
of	0
latent	9
NF-kappa	10
B	10
may	0
also	0
result	0
in	0
rapid	0
inducibility	0
of	0
NF-kappa	9
B	10
-dependent	0
cytokine	9
gene	0
expression	0
.	0

In	0
response	0
to	0
secondary	0
pathogenic	0
infections	0
or	0
antigenic	0
challenge	0
,	0
cytokine	9
gene	0
expression	0
is	0
rapidly	0
induced	0
,	0
enhanced	0
,	0
and	0
sustained	0
over	0
prolonged	0
periods	0
in	0
HIV-1-infected	5
myeloid	6
cells	6
compared	0
with	0
uninfected	7
cells	8
.	0

Elevated	0
levels	0
of	0
several	0
inflammatory	9
cytokines	10
have	0
been	0
detected	0
in	0
the	0
sera	0
of	0
HIV-1-infected	0
individuals	0
.	0

Secretion	0
of	0
myeloid	9
cell-derived	10
cytokines	10
may	0
both	0
increase	0
virus	0
production	0
and	0
contribute	0
to	0
AIDS-associated	0
disorders	0
.	0

Steroid	0
mediated	0
lysis	0
of	0
lymphoblasts	7
requires	0
the	0
DNA	0
binding	0
region	0
of	0
the	0
steroid	0
hormone	0
receptor	0
.	0

Glucocorticoids	0
kill	0
certain	0
types	0
of	0
lymphoblasts	7
,	0
but	0
the	0
mechanisms	0
are	0
unknown	0
.	0

It	0
is	0
clear	0
that	0
sufficient	0
numbers	0
of	0
functional	0
glucocorticoid	9
receptors	10
are	0
required	0
to	0
mediate	0
lysis	0
,	0
but	0
whether	0
they	0
do	0
so	0
through	0
the	0
classical	0
model	0
of	0
steroid	0
hormone	0
activation	0
and	0
modulation	0
of	0
gene	0
expression	0
has	0
not	0
been	0
established	0
.	0

In	0
this	0
report	0
we	0
have	0
asked	0
which	0
region	0
(	0
s	0
)	0
of	0
the	0
steroid	9
receptor	10
are	0
important	0
for	0
mediating	0
lysis	0
in	0
leukemic	7
T	8
lymphoblasts	8
.	0

CEM-ICR	5
27	6
leukemic	6
lymphoblasts	6
,	0
a	0
clone	0
of	0
CEM	5
cells	6
which	0
lack	0
functional	0
glucocorticoid	9
receptors	10
and	0
therefore	0
are	0
neither	0
lysed	0
by	0
dexamethasone	0
nor	0
capable	0
of	0
showing	0
glutamine	9
synthetase	10
induction	0
,	0
were	0
provided	0
with	0
steroid	9
receptors	10
by	0
DNA	0
transfections	0
of	0
various	0
receptor	0
gene	0
constructs	0
.	0

We	0
measured	0
steroid	0
mediated	0
lysis	0
,	0
receptor	0
number	0
and	0
induction	0
of	0
glutamine	9
synthetase	10
in	0
the	0
transfected	5
cells	6
.	0

Our	0
results	0
provide	0
evidence	0
that	0
the	0
lysis	0
mechanism	0
in	0
the	0
ICR27	5
lymphoblasts	6
is	0
restored	0
when	0
functional	0
receptor	0
number	0
is	0
restored	0
.	0

The	0
DNA	9
binding	10
region	10
specifying	0
high	0
affinity	0
for	0
GRE	1
sites	2
is	0
required	0
.	0

Lysis	0
is	0
mediated	0
by	0
any	0
steroid	0
that	0
allows	0
for	0
activation	0
of	0
the	0
receptor	0
containing	0
such	0
a	0
region	0
.	0

Our	0
data	0
support	0
the	0
view	0
that	0
steroid-mediated	0
cell	0
death	0
occurs	0
by	0
a	0
process	0
requiring	0
direct	0
interaction	0
of	0
steroid-receptor	9
complexes	10
with	0
the	0
genome	0
.	0

Functional	0
characterization	0
of	0
the	0
murine	9
homolog	10
of	0
the	0
B	9
cell-specific	10
coactivator	10
BOB.1/OBF.1	9
.	0

B	0
cell-specific	0
transcriptional	0
promoter	0
activity	0
mediated	0
by	0
the	0
octamer	1
motif	2
requires	0
the	0
Oct1	9
or	0
Oct2	9
protein	10
and	0
additional	0
B	9
cell-restricted	10
cofactors	10
.	0

One	0
such	0
cofactor	9
,	0
BOB.1/OBF.1	9
,	0
was	0
recently	0
isolated	0
from	0
human	7
B	8
cells	8
.	0

Here	0
,	0
we	0
describe	0
the	0
isolation	0
and	0
detailed	0
characterization	0
of	0
the	0
murine	9
homolog	10
.	0

Full-length	0
cDNAs	1
and	0
genomic	1
clones	2
were	0
isolated	0
,	0
and	0
the	0
gene	0
structure	0
was	0
determined.	0
Comparison	0
of	0
the	0
deduced	0
amino	0
acids	0
shows	0
88	0
%	0
sequence	0
identity	0
between	0
mouse	9
and	10
human	10
BOB.1/OBF.1	10
.	0

The	0
NH2-terminal	9
126	10
amino	10
acids	10
of	0
BOB.1/OBF.1	9
are	0
both	0
essential	0
and	0
sufficient	0
for	0
interaction	0
with	0
the	0
POU	9
domains	10
of	0
either	0
Oct1	9
or	0
Oct2	9
.	0

This	0
protein-protein	0
interaction	0
does	0
not	0
require	0
the	0
simultaneous	0
binding	0
of	0
Oct	9
proteins	10
to	0
DNA	0
,	0
and	0
high	0
resolution	0
footprinting	0
of	0
the	0
Oct	1
-DNA	0
interaction	0
reveals	0
that	0
binding	0
of	0
BOB.1/OBF.1	9
to	0
Oct1	9
or	0
Oct2	9
does	0
not	0
alter	0
the	0
interaction	0
with	0
DNA	0
.	0

BOB.1/OBF.1	9
can	0
efficiently	0
activate	0
octamer-dependent	0
promoters	0
in	0
fibroblasts	7
;	0
however	0
,	0
it	0
fails	0
to	0
stimulate	0
octamer-dependent	1
enhancer	2
activity	0
.	0

Fusion	0
of	0
subdomains	0
of	0
BOB.1/OBF.1	9
with	0
the	0
GAL4	9
DNA	10
binding	10
domain	10
reveals	0
that	0
both	0
NH2-	9
and	10
COOH-terminal	10
domains	10
of	0
BOB.1/OBF.1	9
contribute	0
to	0
full	0
transactivation	0
function	0
,	0
the	0
COOH-terminal	9
domain	10
is	0
more	0
efficient	0
in	0
this	0
transactivation	0
assay	0
.	0

Consistent	0
with	0
the	0
failure	0
of	0
full-length	9
BOB.1/OBF.1	10
to	0
stimulate	0
octamer-dependent	1
enhancer	2
elements	2
in	0
non	7
B	8
cells	8
,	0
the	0
GAL4	9
fusions	10
likewise	0
only	0
stimulate	0
from	0
a	0
promoter-proximal	0
position	0
.	0

Anti-immunoglobulin	9
M	10
activates	0
nuclear	9
calcium/calmodulin-dependent	10
protein	10
kinase	10
II	10
in	0
human	7
B	8
lymphocytes	8
.	0

We	0
and	0
others	0
have	0
previously	0
shown	0
that	0
the	0
nuclear	9
protein	10
,	0
Ets-1	9
,	0
is	0
phosphorylated	0
in	0
a	0
calcium-dependent	0
manner	0
after	0
ligation	0
of	0
immunoglobulin	0
(	0
Ig	0
)	0
M	0
on	0
B	7
lymphocytes	8
.	0

As	0
this	0
phosphorylation	0
was	0
independent	0
of	0
protein	9
kinase	10
C	10
activity	0
,	0
we	0
tested	0
whether	0
a	0
calcium/calmodulin-dependent	9
protein	10
kinase	10
(	0
CaM	9
kinase	10
)	0
might	0
phosphorylate	0
the	0
Ets-1	9
protein	10
after	0
elevation	0
of	0
intracellular	0
free	0
calcium	0
concentrations	0
.	0

The	0
dephosphorylated	0
form	0
of	0
Ets-1	9
has	0
been	0
shown	0
to	0
bind	0
to	0
chromatin	0
,	0
suggesting	0
that	0
the	0
operative	9
kinase	10
should	0
be	0
detectable	0
in	0
the	0
nucleus	0
.	0

We	0
prepared	0
nuclear	0
extracts	0
from	0
two	0
human	5
B	6
cell	6
lines	6
in	0
which	0
increased	0
intracellular	0
free	0
calcium	0
levels	0
correlated	0
with	0
increased	0
phosphorylation	0
of	0
the	0
Ets-1	9
protein	0
.	0

Activity	0
of	0
the	0
CaM	9
kinases	10
was	0
determined	0
using	0
a	0
synthetic	0
peptide	0
substrate	0
both	0
in	0
the	0
absence	0
and	0
presence	0
of	0
an	0
inhibitor	0
specific	0
for	0
the	0
CaM	9
kinase	10
family	10
,	0
KN-62	0
.	0

Stimulation	0
of	0
cells	0
with	0
anti-IgM	9
led	0
to	0
increased	0
activity	0
of	0
a	0
nuclear	9
kinase	10
that	0
could	0
phosphorylate	0
the	0
peptide	0
,	0
and	0
this	0
activity	0
was	0
reduced	0
by	0
10	0
microM	0
KN-62	0
.	0

Kinase	0
activity	0
was	0
reduced	0
in	0
lysates	0
preadsorbed	0
using	0
an	0
antibody	9
specific	0
for	0
CaM	9
kinase	10
II	10
.	0

Two-dimensional	0
phosphopeptide	0
maps	0
of	0
the	0
Ets-1	9
protein	0
from	0
cells	0
incubated	0
with	0
ionomycin	0
or	0
anti-IgM	9
contained	0
two	0
unique	0
phosphopeptides	0
that	0
were	0
absent	0
in	0
untreated	0
cells	0
.	0

Incubation	0
of	0
isolated	9
Ets-1	10
protein	10
with	0
purified	0
CaM	9
kinase	10
II	10
produced	0
phosphorylation	0
of	0
peptides	0
that	0
migrated	0
identically	0
to	0
those	0
found	0
in	0
cells	0
incubated	0
with	0
either	0
anti-IgM	9
or	0
ionomycin	0
.	0

These	0
data	0
suggest	0
a	0
model	0
of	0
signal	0
transduction	0
by	0
the	0
antigen	9
receptor	10
on	0
B	7
lymphocytes	8
in	0
which	0
increased	0
intracellular	0
free	0
calcium	0
can	0
rapidly	0
activate	0
nuclear	9
CaM	10
kinase	10
II	10
,	0
potentially	0
resulting	0
in	0
phosphorylation	0
and	0
regulation	0
of	0
DNA-binding	9
proteins	10
.	0

Transcriptional	0
activation	0
and	0
repression	0
,	0
two	0
properties	0
of	0
the	0
lymphoid-specific	9
transcription	10
factor	10
Oct-2a	9
.	0

The	0
lymphoid-specific	9
transcription	10
factor	10
Oct-2a	9
contains	0
two	0
transcriptional	9
activation	10
domains	10
which	0
are	0
located	0
within	0
the	0
N-terminal	9
and	0
C-terminal	9
regions	10
.	0

To	0
study	0
their	0
differential	0
activation	0
properties	0
,	0
we	0
linked	0
the	0
isolated	0
effector	9
domains	10
to	0
the	0
GAL4	9
DNA-binding	10
domain	10
.	0

We	0
have	0
shown	0
that	0
both	0
activating	0
regions	0
of	0
Oct-2a	9
,	0
isolated	0
from	0
their	0
natural	0
context	0
,	0
can	0
activate	0
transcription	0
as	0
promoter	9
factors	10
.	0

In	0
contrast	0
to	0
the	0
C-terminus	9
,	0
activation	0
by	0
the	0
N-terminal	9
domain	10
is	0
dependent	0
on	0
a	0
yet	0
unidentified	0
factor	0
(	0
s	0
)	0
binding	0
to	0
the	0
simian	1
virus	2
40	2
enhancer	2
.	0

The	0
results	0
obtained	0
by	0
duplication	0
of	0
activation	9
domains	10
or	0
their	0
mixed	0
combination	0
suggest	0
that	0
the	0
domains	0
are	0
functionally	0
independent	0
.	0

However	0
,	0
activation	0
from	0
a	0
remote	0
position	0
could	0
only	0
be	0
achieved	0
with	0
the	0
C-terminus	9
of	0
Oct-2a	9
in	0
B	7
cells	8
.	0

In	0
lymphoid	7
cells	8
,	0
higher	0
activation	0
levels	0
were	0
observed	0
,	0
suggesting	0
that	0
distinct	0
B-cell-specific	9
cofactors	10
in	0
concert	0
with	0
the	0
effector	9
domains	10
of	0
Oct-2a	9
might	0
be	0
involved	0
in	0
mediating	0
transcription	0
from	0
proximal	0
and	0
remote	0
positions	0
.	0

Furthermore	0
,	0
we	0
identified	0
a	0
repression	0
domain	0
at	0
the	0
N-terminus	0
of	0
Oct-2a	9
.	0

When	0
transferred	0
to	0
a	0
potent	0
activator	0
,	0
transcriptional	0
stimulation	0
was	0
inhibited	0
efficiently	0
.	0

These	0
results	0
underscore	0
the	0
modular	0
structure	0
of	0
Oct-2a	9
with	0
separable	0
domains	0
for	0
activation	0
and	0
repression	0
and	0
suggest	0
that	0
Oct-2a	9
might	0
have	0
complex	0
regulatory	0
functions	0
in	0
vivo	0
.	0

Nonopsonic	0
phagocytosis	0
of	0
Pseudomonas	0
aeruginosa	0
by	0
macrophages	7
and	0
polymorphonuclear	7
leukocytes	8
requires	0
the	0
presence	0
of	0
the	0
bacterial	0
flagellum	0
.	0

Whereas	0
the	0
mechanism	0
of	0
nonopsonic	0
phagocytosis	0
of	0
Pseudomonas	0
aeruginosa	0
has	0
been	0
described	0
,	0
the	0
bacterial	0
ligands	0
required	0
are	0
poorly	0
understood	0
.	0

To	0
identify	0
the	0
requisite	0
bacterial	0
ligands	0
,	0
studies	0
with	0
isogenic	0
mutants	0
of	0
P.	0
aeruginosa	0
PAK	0
lacking	0
pili	0
,	0
flagella	0
,	0
and	0
the	0
RpoN	9
sigma	10
factor	10
were	0
undertaken	0
.	0

The	0
RpoN	0
mutant	0
,	0
lacking	0
pili	0
,	0
flagella	0
,	0
and	0
nonpilus	9
adhesins	10
,	0
bound	0
poorly	0
and	0
was	0
resistant	0
to	0
ingestion	0
by	0
both	0
macrophages	7
and	0
neutrophils	7
.	0

Pili	0
were	0
not	0
absolutely	0
required	0
for	0
binding	0
or	0
phagocytosis	0
of	0
P.	0
aeruginosa	0
.	0

The	0
presence	0
of	0
a	0
flagellum	0
was	0
not	0
required	0
for	0
binding	0
of	0
P.	0
aeruginosa	0
to	0
macrophages	7
but	0
was	0
critical	0
for	0
the	0
subsequent	0
internalization	0
of	0
the	0
bacterium	0
,	0
suggesting	0
that	0
this	0
factor	0
or	0
a	0
surface	0
ligand	0
associated	0
with	0
its	0
assembly	0
was	0
responsible	0
for	0
stimulation	0
of	0
nonopsonic	0
phagocytosis	0
.	0

Identification	0
of	0
essential	0
GATA	1
and	0
Ets	1
binding	2
motifs	2
within	0
the	0
promoter	0
of	0
the	0
platelet	1
glycoprotein	2
Ib	2
alpha	2
gene	2
.	0

Platelet	9
glycoprotein	10
(	0
GP	9
)	0
Ib-IX-V	9
is	0
a	0
multisubunit	9
adhesion	10
receptor	10
that	0
supports	0
platelet	0
attachment	0
to	0
thrombogenic	0
surfaces	0
at	0
sites	0
of	0
vascular	0
injury	0
.	0

The	0
congenital	0
absence	0
of	0
the	0
receptor	0
results	0
in	0
a	0
bleeding	0
disorder	0
associated	0
with	0
``	7
giant	8
''	8
platelets	8
,	0
a	0
condition	0
linking	0
the	0
expression	0
of	0
the	0
complex	0
to	0
platelet	0
morphogenesis	0
.	0

To	0
understand	0
better	0
the	0
expression	0
of	0
the	0
GP	9
Ib-IX-V	10
complex	10
,	0
studies	0
were	0
undertaken	0
to	0
define	0
the	0
essential	0
genetic	1
elements	2
supporting	0
the	0
expression	0
of	0
the	0
alpha-subunit	9
of	0
the	0
complex	0
(	0
GP	9
Ib	10
alpha	10
)	0
.	0

GP	1
Ib	2
alpha	2
promoter	2
activity	0
was	0
evaluated	0
by	0
transfection	0
of	0
human	7
erythroleukemia	8
cells	8
with	0
reporter	0
plasmids	0
coding	0
for	0
the	0
enzyme	9
,	0
luciferase	9
.	0

Studies	0
were	0
initiated	0
with	0
a	0
fragment	0
extending	0
2	0
,	0
738	0
nucleotides	0
5	0
'	0
to	0
the	0
transcription	1
start	2
site	2
and	0
lead	0
to	0
the	0
identification	0
of	0
253	0
nucleotides	0
retaining	0
full	0
promoter	0
activity	0
in	0
human	7
erythroleukemia	8
cells	8
.	0

In	0
cells	0
of	0
nonhematopoietic	7
lineage	8
,	0
human	7
endothelial	8
and	0
HeLa	7
cells	8
,	0
the	0
GP	1
Ib	2
alpha	2
promoter	2
activity	0
was	0
no	0
greater	0
than	0
background	0
levels	0
obtained	0
with	0
promoterless	1
constructs	2
.	0

Gel	0
shift	0
assays	0
and	0
site-directed	0
mutagenesis	0
studies	0
defined	0
essential	0
GATA	1
and	0
Ets	1
binding	2
motifs	2
93	1
and	2
150	2
nucleotides	2
upstream	2
of	0
the	0
transcription	1
start	2
site	2
,	0
a	0
finding	0
which	0
further	0
substantiates	0
these	0
elements	0
as	0
important	0
determinants	0
of	0
megakaryocytic	0
gene	0
expression	0
.	0

The	0
results	0
define	0
essential	0
cis-acting	1
elements	2
responsible	0
for	0
the	0
expression	0
of	0
GP	9
Ib	10
alpha	10
and	0
provide	0
insights	0
into	0
molecular	0
events	0
coinciding	0
with	0
the	0
release	0
of	0
normal	7
platelets	8
into	0
the	0
bloodstream	0
.	0

CD30	9
ligation	0
induces	0
nuclear	9
factor-kappa	10
B	10
activation	0
in	0
human	5
T	6
cell	6
lines	6
.	0

CD30	9
is	0
a	0
recently	0
described	0
member	0
of	0
the	0
tumor	9
necrosis	10
factor/nerve	10
growth	10
factor	10
receptor	10
superfamily	10
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
following	0
incubation	0
of	0
L540	5
cells	6
(	0
Hodgkin	5
's	6
disease-derived	6
,	6
T	6
cell-like	6
,	6
CD30+	6
cells	6
)	0
with	0
the	0
agonistic	9
anti-CD30	10
monoclonal	10
antibodies	10
(	0
mAb	9
)	0
M44	9
and	0
M67	9
,	0
two	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
DNA	0
binding	0
activities	0
were	0
induced	0
in	0
nuclear	0
extracts	0
,	0
as	0
determined	0
in	0
gel	0
retardation	0
assays	0
.	0

The	0
effect	0
of	0
the	0
mAb	9
towards	0
NF-kappa	9
B	10
activation	0
was	0
rapid	0
,	0
as	0
it	0
occurred	0
within	0
20	0
min	0
,	0
and	0
was	0
sustained	0
for	0
up	0
to	0
6	0
h	0
.	0

By	0
comparison	0
,	0
an	0
isotype-matched	9
antibody	10
had	0
no	0
effect	0
on	0
NF-kappa	9
B	10
activation	0
.	0

Moreover	0
,	0
in	0
human	5
T	6
helper	6
(	6
Th	6
)	6
clones	6
functionally	0
characterized	0
as	0
being	0
of	0
the	0
type	0
0	0
,	0
type	0
1	0
and	0
type	0
2	0
(	0
28	0
%	0
,	0
<	0
1	0
%	0
und	0
93	0
%	0
CD30+	0
,	0
respectively	0
)	0
,	0
the	0
extent	0
of	0
CD30	9
-mediated	0
NF-kappa	9
B	10
activation	0
correlated	0
with	0
the	0
proportion	0
of	0
CD30+	5
cells	6
.	0

In	0
all	0
cell	0
lines	0
investigated	0
,	0
the	0
NF-kappa	9
B	10
complexes	10
induced	0
following	0
CD30	9
engagement	0
were	0
shown	0
to	0
contain	0
p50	9
NF-kappa	10
B1	10
,	0
p65	9
RelA	10
,	0
and	0
possibly	0
other	0
transcription	9
factors	10
.	0

Collectively	0
,	0
our	0
results	0
demonstrate	0
that	0
nuclear	0
translocation	0
and	0
activation	0
of	0
NF-kappa	9
B	10
rank	0
among	0
the	0
short-term	0
cellular	0
responses	0
elicited	0
following	0
CD30	9
ligation	0
.	0

Pathogenesis	0
of	0
atherosclerosis	0
.	0

The	0
earliest	0
lesion	0
in	0
the	0
development	0
of	0
an	0
atherosclerotic	0
plaque	0
is	0
the	0
fatty	0
streak	0
.	0

This	0
chronic	0
inflammatory	0
reaction	0
results	0
from	0
a	0
sequence	0
of	0
events	0
that	0
begins	0
with	0
the	0
trapping	0
of	0
low	0
density	0
lipoprotein	0
(	0
LDL	0
)	0
in	0
the	0
subendothelial	0
space	0
of	0
the	0
artery	0
wall	0
.	0

The	0
trapped	0
LDL	0
is	0
seeded	0
with	0
oxidative	0
species	0
released	0
by	0
the	0
overlying	0
endothelium	0
,	0
and	0
lipid	0
oxidation	0
is	0
initiated	0
within	0
the	0
LDL	0
particle.	0
Some	0
of	0
the	0
lipids	0
that	0
result	0
lead	0
to	0
the	0
activation	0
of	0
NFkB-like	9
transcription	10
factors	10
that	0
cause	0
the	0
expression	0
of	0
genes	0
whose	0
protein	9
products	10
mediate	0
monocyte	0
binding	0
,	0
monocyte	7
chemotaxis	0
into	0
the	0
subendothelial	0
space	0
,	0
and	0
conversion	0
into	0
macrophages	7
.	0

At	0
least	0
1	0
major	1
gene	2
modulates	0
the	0
oxidation	0
of	0
LDL	0
lipids	0
and/or	0
the	0
biologic	0
response	0
to	0
these	0
lipids	0
.	0

The	0
inverse	0
relation	0
between	0
high	0
density	0
lipoprotein	0
(	0
HDL	0
)	0
and	0
atherosclerotic	0
events	0
may	0
in	0
part	0
be	0
due	0
to	0
enzymes	9
associated	0
with	0
HDL	0
that	0
destroy	0
the	0
biologically	0
active	0
lipids	0
generated	0
in	0
LDL	0
.	0

Estrogen	9
and	0
progesterone	9
receptors	10
in	0
vernal	0
keratoconjunctivitis	0
.	0

PURPOSE	0
:	0
Sex-related	0
influences	0
have	0
been	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
vernal	0
keratoconjunctivitis	0
(	0
VKC	0
)	0
,	0
an	0
allergic	0
eosinophilic	0
disease	0
.	0

METHODS	0
:	0
The	0
authors	0
evaluated	0
tarsal	0
and	0
bulbar	0
conjunctival	0
biopsies	0
from	0
seven	0
patients	0
with	0
severe	0
and	0
symptomatic	0
VKC	0
for	0
the	0
presence	0
of	0
estrogen	9
and	0
progesterone	9
receptors	10
by	0
using	0
monoclonal	9
antibodies	10
with	0
a	0
peroxidase-antiperoxidase	0
technique	0
.	0

RESULTS	0
:	0
Both	0
the	0
epithelium	0
and	0
subepithelium	0
of	0
the	0
tarsal	0
and	0
bulbar	0
conjunctiva	0
of	0
patients	0
with	0
VKC	0
,	0
but	0
not	0
those	0
of	0
four	0
nonatopic	0
control	0
subjects	0
,	0
showed	0
intense	0
positive	0
staining	0
for	0
estrogen	0
and	0
progesterone	9
receptors	10
.	0

Immunofluorescence	0
colocalization	0
of	0
both	0
estrogen	9
and	0
progesterone	9
receptors	10
with	0
eosinophil	9
cationic	10
protein	10
showed	0
that	0
approximately	0
70	0
%	0
of	0
positive	7
cells	8
were	0
eosinophils	7
.	0

CONCLUSIONS	0
:	0
Sexual	0
hormones	0
,	0
through	0
their	0
receptors	9
,	0
may	0
influence	0
the	0
activity	0
of	0
eosinophils	7
in	0
patients	0
with	0
VKC	0
.	0

CIITA	9
activates	0
the	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
in	0
mouse	0
T	0
cells	0
.	0

It	0
has	0
long	0
been	0
a	0
puzzle	0
that	0
MHC	9
class	10
II	10
molecules	10
are	0
expressed	0
in	0
human	7
T	8
cells	8
after	0
activation	0
but	0
not	0
in	0
mouse	7
T	8
cells	8
;	0
this	0
expression	0
is	0
believed	0
to	0
play	0
a	0
role	0
in	0
the	0
cell	0
mediated	0
immune	0
response	0
.	0

Recently	0
the	0
MHC	9
class	10
II	10
transactivator	10
(	0
CIITA	9
)	0
has	0
been	0
reported	0
to	0
be	0
a	0
major	9
regulatory	10
factor	10
for	0
both	0
the	0
constitutive	0
and	0
IFN	0
inducible	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
.	0

Here	0
we	0
show	0
that	0
human	7
T	8
cells	8
expressing	0
MHC	0
class	0
II	0
have	0
CIITA	9
transcripts	0
while	0
MHC	0
class	0
II-negative	0
human	7
T	8
cells	8
and	0
mouse	7
T	8
cells	8
do	0
not	0
.	0

The	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
in	0
mouse	7
T	8
cells	8
can	0
be	0
reconstituted	0
upon	0
transfection	0
with	0
the	0
human	1
CIITA	2
cDNA	2
.	0

These	0
data	0
indicate	0
that	0
the	0
expression	0
of	0
CIITA	9
explains	0
the	0
expression	0
or	0
lack	0
of	0
expression	0
of	0
MHC	9
class	10
II	10
in	0
human	7
and	0
mouse	7
T	8
cells	8
respectively	0
.	0

Anti-Ro	9
(	10
SSA	10
)	10
autoantibodies	10
are	0
associated	0
with	0
T	1
cell	2
receptor	2
beta	2
genes	2
in	0
systemic	0
lupus	0
erythematosus	0
patients	0
.	0

Several	0
of	0
the	0
heterogeneous	0
clinical	0
manifestations	0
of	0
systemic	0
lupus	0
erythematosus	0
have	0
been	0
associated	0
with	0
specific	0
autoantibodies	9
.	0

Associations	0
between	0
HLA	9
class	10
II	10
antigens	10
and	0
autoantibodies	9
to	0
the	0
ribonucleoproteins	9
Ro	9
(	10
SSA	10
)	10
and	0
La	9
(	10
SSB	10
)	10
have	0
been	0
reported	0
in	0
these	0
patients	0
.	0

Because	0
HLA	9
class	10
II	10
molecules	10
present	0
antigen	0
to	0
T	9
cell	10
receptors	10
(	0
TCRs	9
)	0
,	0
we	0
have	0
searched	0
for	0
a	0
TCR	1
gene	2
associated	0
with	0
the	0
production	0
of	0
anti-Ro	9
(	10
SSA	10
)	10
antibodies	10
.	0

A	0
pair	0
of	0
restriction	1
fragment	2
length	2
polymorphisms	2
(	0
RFLPs	1
)	0
,	0
one	0
of	0
which	0
hybridizes	0
to	0
the	0
TCR	1
constant	2
region	2
C	2
beta	2
1	2
and	0
the	0
other	0
to	0
the	0
C	1
beta	2
2	2
gene	2
,	0
has	0
been	0
identified	0
,	0
suggesting	0
these	0
may	0
be	0
genotypic	0
markers	0
for	0
an	0
extended	0
region	0
of	0
the	0
TCR	1
beta	2
locus	2
.	0

This	0
RFLP	1
pair	2
occurs	0
in	0
76	0
%	0
of	0
patients	0
with	0
Ro	9
(	10
SSA	10
)	10
precipitins	0
,	0
84	0
%	0
of	0
anti-	0
Ro	9
(	10
SSA	10
)	10
-positive	0
patients	0
lacking	0
La	9
(	10
SSB	10
)	10
precipitins	9
,	0
but	0
only	0
41	0
%	0
of	0
the	0
patients	0
lacking	0
both	0
precipitins	9
(	0
P	0
=	0
0.0004	0
)	0
.	0

This	0
disproportionate	0
occurrence	0
in	0
a	0
subset	0
of	0
lupus	0
patients	0
indicates	0
that	0
these	0
RFLPs	1
are	0
not	0
disease	0
susceptibility	0
markers	0
,	0
but	0
rather	0
are	0
important	0
markers	0
for	0
TCR	1
genes	2
whose	0
products	0
are	0
involved	0
in	0
the	0
production	0
of	0
anti-Ro	9
(	10
SSA	10
)	10
antibodies	10
.	0

The	0
majority	0
of	0
patients	0
who	0
have	0
these	0
RFLPs	1
and	0
HLA	9
class	10
II	10
antigens	10
previously	0
associated	0
with	0
the	0
anti-	0
Ro	9
(	10
SSA	10
)	10
response	0
make	0
this	0
antibody	0
,	0
suggesting	0
that	0
interactions	0
between	0
products	0
of	0
these	0
loci	1
occur	2
in	0
response	0
to	0
Ro	9
(	10
SSA	10
)	10
.	0

Inhibition	0
of	0
NF-AT	9
-dependent	0
transcription	0
by	0
NF-kappa	9
B	10
:	0
implications	0
for	0
differential	0
gene	0
expression	0
in	0
T	7
helper	8
cell	8
subsets	8
.	0

Activation	0
of	0
individual	0
CD4+	5
T	6
cells	6
results	0
in	0
differential	0
lymphokine	9
expression	0
:	0
interleukin	9
2	10
(	0
IL-2	9
)	0
is	0
preferentially	0
produced	0
by	0
T	5
helper	6
type	6
1	6
(	6
TH1	6
)	6
cells	6
,	0
which	0
are	0
involved	0
in	0
cell-mediated	0
immune	0
responses	0
,	0
whereas	0
IL-4	9
is	0
synthesized	0
by	0
TH2	5
cells	6
,	0
which	0
are	0
essential	0
for	0
humoral	0
immunity	0
.	0

The	0
Ca	9
(	10
2+	10
)	10
-dependent	10
factor	10
NF-ATp	9
plays	0
a	0
key	0
role	0
in	0
the	0
inducible	0
transcription	0
of	0
both	0
these	0
lymphokine	1
genes	2
.	0

However	0
,	0
while	0
IL2	9
expression	0
requires	0
the	0
contribution	0
of	0
Ca	0
(	0
2+	0
)	0
-	0
and	0
protein	9
kinase	10
C	10
-dependent	0
signals	0
,	0
we	0
report	0
that	0
activation	0
of	0
human	9
IL4	10
transcription	0
through	0
the	0
Ca	0
(	0
2+	0
)	0
-dependent	0
pathway	0
is	0
diminished	0
by	0
protein	9
kinase	10
C	10
stimulation	0
in	0
Jurkat	5
T	6
cells	6
.	0

This	0
phenomenon	0
is	0
due	0
to	0
mutually	0
exclusive	0
binding	0
of	0
NF-ATp	9
and	0
NF-kappa	9
B	10
to	0
the	0
P	1
sequence	2
,	0
an	0
element	0
located	0
69	1
bp	2
upstream	2
of	0
the	0
IL4	1
transcription	2
initiation	2
site	2
.	0

Human	1
IL4	2
promoter	2
-mediated	0
transcription	0
is	0
downregulated	0
in	0
Jurkat	5
cells	6
stimulated	0
with	0
the	0
NF-kappa	9
B-activating	10
cytokine	10
tumor	9
necrosis	10
factor	10
alpha	10
and	0
suppressed	0
in	0
RelA-overexpressing	5
cells	6
.	0

In	0
contrast	0
,	0
protein	9
kinase	10
C	10
stimulation	0
or	0
RelA	9
overexpression	0
does	0
not	0
affect	0
the	0
activity	0
of	0
a	0
human	1
IL4	2
promoter	2
containing	0
a	0
mouse	1
P	2
sequence	2
,	0
which	0
is	0
a	0
higher-affinity	1
site	2
for	0
NF-ATp	9
and	0
a	0
lower-affinity	1
site	2
for	0
RelA	9
.	0

Thus	0
,	0
competition	0
between	0
two	0
general	0
transcriptional	9
activators	10
,	0
RelA	9
and	0
NF-ATp	9
,	0
mediates	0
the	0
inhibitory	0
effect	0
of	0
protein	9
kinase	10
C	10
stimulation	0
on	0
IL4	9
expression	0
and	0
may	0
contribute	0
to	0
differential	0
gene	0
expression	0
in	0
TH	5
cells	6
.	0

Regulation	0
of	0
the	0
balance	0
of	0
cytokine	9
production	0
and	0
the	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	0
(	0
STAT	9
)	0
transcription	0
factor	0
activity	0
by	0
cytokines	9
and	0
inflammatory	0
synovial	0
fluids	0
.	0

The	0
balance	0
between	0
type	0
1	0
and	0
2	0
T	0
helper	0
cell	0
cytokine	0
production	0
plays	0
an	0
important	0
role	0
in	0
several	0
animal	0
models	0
of	0
autoimmunity	0
,	0
and	0
skewed	0
patterns	0
of	0
cytokine	9
expression	0
have	0
been	0
described	0
in	0
human	0
inflammatory	0
diseases	0
.	0

Many	0
cytokines	9
activate	0
signal	9
transducer	10
and	10
activation	10
of	10
transcription	10
(	10
STAT	10
)	10
transcription	10
factors	10
,	0
which	0
,	0
in	0
turn	0
,	0
activate	0
transcription	0
of	0
inflammatory	0
effector	0
genes	0
.	0

We	0
used	0
mononuclear	5
cell	6
priming	6
cultures	6
and	0
inflammatory	7
synovial	8
fluids	8
(	0
SFs	7
)	0
derived	0
from	0
arthritis	0
patients	0
to	0
examine	0
the	0
regulation	0
of	0
cytokine	9
production	0
and	0
STAT	9
activity	0
by	0
an	0
inflammatory	0
synovial	0
microenvironment	0
.	0

Exposure	0
to	0
SFs	7
during	0
priming	0
resulted	0
in	0
an	0
81	0
%	0
inhibition	0
of	0
interferon	9
(	10
IFN	10
)	10
-gamma	10
,	0
but	0
not	0
interleukin	9
(	10
IL	10
)	10
4	10
,	0
production	0
by	0
effector	7
cells	8
generated	0
in	0
priming	0
cultures	0
.	0

SF	0
suppression	0
was	0
mediated	0
by	0
IL-4	9
and	0
IL-10	9
and	0
inhibition	0
of	0
IL-12	9
expression	0
,	0
and	0
it	0
was	0
reversed	0
in	0
a	0
dominant	0
fashion	0
by	0
exogenous	0
IL-12	0
.	0

SFs	7
blocked	0
the	0
sustained	0
activity	0
of	0
transcription	9
factor	10
Stat1	10
,	0
but	0
not	0
Stat3	9
,	0
during	0
the	0
priming	0
period	0
,	0
and	0
Stat1	9
activity	0
was	0
differentially	0
regulated	0
by	0
cytokines	9
in	0
parallel	0
with	0
their	0
positive	0
or	0
negative	0
regulation	0
of	0
IFN-gamma	9
production	0
.	0

Active	0
Stat3	9
,	0
but	0
not	0
Stat1	9
,	0
was	0
detected	0
in	0
cells	0
from	0
inflamed	0
joints	0
.	0

These	0
results	0
suggest	0
a	0
role	0
for	0
altered	0
balance	0
of	0
Stat1	0
and	0
Stat3	0
transcriptional	0
activity	0
in	0
the	0
regulation	0
of	0
T	7
cell	8
differentiation	0
and	0
in	0
the	0
pathogenesis	0
of	0
inflammatory	0
synovitis	0
.	0

Triggering	0
of	0
complement	9
receptors	10
CR1	9
(	0
CD35	9
)	0
and	0
CR3	9
(	0
CD11b/CD18	9
)	0
induces	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B	10
(	0
p50/p65	9
)	0
in	0
human	7
monocytes	8
and	0
enhances	0
viral	0
replication	0
in	0
HIV-infected	7
monocytic	8
cells	8
.	0

Monocyte/macrophages	7
may	0
harbor	0
HIV	0
in	0
a	0
nonproductive	0
fashion	0
for	0
prolonged	0
periods	0
of	0
time	0
.	0

Viral	0
gene	0
expression	0
may	0
be	0
reactivated	0
by	0
stimulation	0
of	0
the	0
cells	0
with	0
LPS	0
or	0
cytokines	9
such	0
as	0
TNF-alpha	9
in	0
vitro	0
.	0

The	0
effect	0
of	0
LPS	0
and	0
TNF-alpha	9
is	0
mediated	0
by	0
their	0
ability	0
to	0
induce	0
nuclear	0
translocation	0
of	0
the	0
DNA-binding	9
heterodimer	10
NF-kappa	9
B	10
(	0
p50/p65	9
)	0
,	0
which	0
binds	0
to	0
a	0
specific	0
sequence	0
in	0
the	0
HIV-long	1
terminal	2
repeat	2
.	0

The	0
present	0
study	0
demonstrates	0
that	0
triggering	0
of	0
complement	9
receptors	10
CR1	9
(	0
CD35	9
)	0
and	0
CR3	9
(	0
CD11b/CD18	9
)	0
enhances	0
viral	0
replication	0
in	0
HIV-infected	5
human	6
monocytic	6
cells	6
.	0

Monocytic	5
cell	6
lines	6
and	0
normal	0
peripheral	0
blood	0
monocytes	0
were	0
infected	0
with	0
HIV-1	0
in	0
vitro	0
and	0
cultured	0
in	0
the	0
presence	0
or	0
absence	0
of	0
F	9
(	10
ab	10
'	10
)	10
2	10
fragments	10
of	0
monoclonal	9
anti-CR1	10
or	0
anti-CR3	9
Abs	10
or	0
with	0
C3	9
fragments	10
.	0

Stimulation	0
of	0
CR1	9
or	0
CR3	9
induces	0
a	0
two-	0
to	0
fourfold	0
increase	0
in	0
the	0
amount	0
of	0
cell-associated	0
and	0
released	0
p24	9
Ag	10
in	0
cell	5
cultures	6
that	0
was	0
equivalent	0
to	0
that	0
observed	0
in	0
control	5
cultures	6
triggered	0
with	0
LPS	0
.	0

We	0
further	0
observed	0
that	0
stimulation	0
of	0
CR1	9
or	0
CR3	9
induces	0
the	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B	10
p50/p65	9
in	0
infected	7
cells	8
.	0

Translocation	0
of	0
NF-kappa	9
B	10
p50/p65	9
was	0
also	0
observed	0
following	0
stimulation	0
of	0
CR1	9
or	0
CR3	9
of	0
uninfected	7
peripheral	8
blood	8
monocytes	8
from	0
HIV-seronegative	0
donors	0
.	0

The	0
amount	0
of	0
protein	0
translocated	0
was	0
similar	0
to	0
that	0
observed	0
when	0
cells	0
were	0
stimulated	0
with	0
rhTNF-alpha	9
.	0

TNF-alpha	9
did	0
not	0
mediate	0
the	0
translocation	0
of	0
NF-kappa	9
B	10
p50/p65	9
induced	0
by	0
triggering	0
of	0
complement	9
receptors	10
.	0

Taken	0
together	0
,	0
these	0
observations	0
suggest	0
that	0
HIV	0
gene	0
expression	0
may	0
be	0
activated	0
in	0
infected	7
monocytes	8
through	0
interaction	0
of	0
the	0
cells	0
with	0
complement-opsonized	9
particles	10
and	0
that	0
enhanced	0
viral	0
replication	0
is	0
associated	0
with	0
C3	9
receptor	10
-mediated	0
nuclear	0
translocation	0
of	0
the	0
NF-kappa	9
B	10
complex	10
.	0

Attenuation	0
of	0
gamma	9
interferon	10
-induced	0
tyrosine	0
phosphorylation	0
in	0
mononuclear	7
phagocytes	8
infected	0
with	0
Leishmania	0
donovani	0
:	0
selective	0
inhibition	0
of	0
signaling	0
through	0
Janus	9
kinases	10
and	0
Stat1	9
.	0

The	0
induction	0
of	0
gene	0
transcription	0
in	0
response	0
to	0
gamma	9
interferon	10
is	0
impaired	0
in	0
mononuclear	7
phagocytes	8
infected	0
with	0
Leishmania	0
donovani	0
,	0
and	0
the	0
mechanisms	0
involved	0
are	0
not	0
fully	0
understood	0
.	0

The	0
changes	0
in	0
gene	0
expression	0
brought	0
about	0
by	0
gamma	9
interferon	10
are	0
thought	0
to	0
involve	0
transient	0
increases	0
in	0
the	0
activities	0
of	0
cellular	9
protein	10
tyrosine	10
kinases	10
,	0
including	0
the	0
Janus	9
kinases	10
Jak1	9
and	0
Jak2	9
,	0
leading	0
to	0
tyrosine	0
phosphorylation	0
of	0
the	0
transcription	9
factor	10
Stat1	10
.	0

To	0
investigate	0
the	0
mechanisms	0
accounting	0
for	0
the	0
impaired	0
responses	0
to	0
gamma	9
interferon	10
,	0
a	0
model	0
system	0
for	0
examining	0
overall	0
changes	0
in	0
protein	0
tyrosine	0
phosphorylation	0
,	0
activation	0
of	0
Jak1	9
and	0
Jak2	9
and	0
phosphorylation	0
of	0
Stat1	9
was	0
developed	0
in	0
phorbol	5
12-myristate	6
13-acetate-differentiated	6
U-937	6
cells	6
.	0

Analysis	0
of	0
whole-cell	0
lysates	0
by	0
antiphosphotyrosine	0
immunoblotting	0
showed	0
that	0
incubation	0
with	0
gamma	9
interferon	10
brought	0
about	0
specific	0
increases	0
in	0
phosphotyrosine	0
labeling	0
of	0
several	0
proteins	0
.	0

Increased	0
labeling	0
of	0
these	0
proteins	0
occurred	0
to	0
similar	0
extents	0
in	0
control	7
cells	8
and	0
in	0
cells	0
that	0
had	0
been	0
infected	0
with	0
L.	0
donovani	0
for	0
16	0
h	0
.	0

Jak1	9
,	0
Jak2	9
,	0
and	0
Stat1	9
were	0
immunoprecipitated	0
from	0
control	0
and	0
interferon-treated	5
cells	6
,	0
and	0
tyrosine	0
phosphorylation	0
of	0
these	0
proteins	0
,	0
detected	0
by	0
antiphosphotyrosine	0
immunoblotting	0
was	0
used	0
to	0
measured	0
their	0
activation	0
.	0

Tyrosine	0
phosphorylation	0
of	0
Jak1	9
,	0
Jak2	9
,	0
and	0
Stat1	9
increased	0
markedly	0
,	0
in	0
a	0
dose-dependent	0
manner	0
,	0
in	0
U-937	5
cells	6
incubated	0
with	0
gamma	9
interferon	10
.	0

In	0
contrast	0
,	0
in	0
cells	0
infected	0
with	0
L.	0
donovani	0
,	0
tyrosine	0
phosphorylation	0
of	0
Jak1	9
,	0
Jak2	9
,	0
and	0
Stat1	9
was	0
markedly	0
impaired	0
.	0

This	0
effect	0
was	0
dependent	0
upon	0
the	0
duration	0
of	0
exposure	0
to	0
L.	0
donovani	0
and	0
was	0
maximal	0
and	0
complete	0
at	0
16	0
h	0
.	0

Results	0
similar	0
to	0
those	0
observed	0
with	0
U-937	5
cells	6
were	0
also	0
obtained	0
with	0
human	7
peripheral	8
blood	8
monocytes	8
.	0

These	0
findings	0
indicate	0
that	0
infection	0
of	0
human	7
mononuclear	8
phagocytes	8
with	0
L.	0
donovani	0
leads	0
to	0
impaired	0
gamma	9
interferon	10
-mediated	0
tyrosine	0
phosphorylation	0
and	0
selective	0
effects	0
on	0
the	0
Jak-	0
Stat1	9
pathway	0
.	0

Unresponsiveness	0
to	0
gamma	9
interferon	10
for	0
activation	0
of	0
this	0
pathway	0
may	0
explain	0
impaired	0
transcriptional	0
responses	0
in	0
leishmania-infected	7
cells	8
.	0

Mutually	0
exclusive	0
interaction	0
of	0
a	0
novel	0
matrix	9
attachment	10
region	10
binding	10
protein	10
and	0
the	0
NF-muNR	9
enhancer	10
repressor	10
.	0

Implications	0
for	0
regulation	0
of	0
immunoglobulin	9
heavy	10
chain	10
expression	0
.	0

The	0
immunoglobulin	9
heavy	10
chain	10
(	0
IgH	9
)	0
intronic	0
enhancer	0
stimulates	0
transcription	0
from	0
functional	0
promoters	0
in	0
B	0
lymphocytes	0
but	0
not	0
other	0
cell	0
types	0
.	0

The	0
observation	0
that	0
binding	0
sites	0
for	0
the	0
nuclear	9
factor-mu	10
negative	10
regulator	10
(	10
NF-muNR	10
)	10
enhancer	10
repressor	10
overlap	10
nuclear	10
matrix	10
attachment	10
regions	10
(	0
MARs	9
)	0
in	0
this	0
enhancer	1
has	0
lead	0
to	0
the	0
hypothesis	0
that	0
the	0
cell	0
type	0
specificity	0
of	0
the	0
enhancer	1
might	0
be	0
controlled	0
by	0
regulating	0
nuclear	0
matrix	0
attachment	0
(	0
Scheuermann	0
,	0
R.	0
H.	0
,	0
and	0
Chen	0
,	0
U.	0
(	0
1989	0
)	0
Genes	0
&	0
Dev.	0
3	0
,	0
1255-1266	0
)	0
.	0

To	0
understand	0
the	0
role	0
of	0
MARs	9
in	0
IgH	1
enhancer	2
regulation	0
,	0
we	0
have	0
identified	0
a	0
novel	0
MAR-binding	9
protein	10
,	0
MAR-BP1	9
,	0
from	0
soluble	0
nuclear	0
matrix	0
preparations	0
based	0
on	0
its	0
ability	0
to	0
bind	0
to	0
the	0
MARs	9
associated	0
with	0
the	0
IgH	1
enhancer	2
.	0

Purified	0
MAR-BP1	9
migrates	0
as	0
a	0
33-kDa	9
protein	10
,	0
and	0
it	0
can	0
be	0
found	0
in	0
nuclear	0
matrix	0
preparations	0
from	0
a	0
number	0
of	0
different	0
types	0
of	0
lymphoid	5
cell	6
lines	6
.	0

Although	0
specific	0
binding	0
sites	0
have	0
been	0
difficult	0
to	0
localize	0
by	0
chemical	0
or	0
enzymatic	0
footprinting	0
procedures	0
,	0
NF-muNR	9
binding	0
sites	0
are	0
critical	0
for	0
efficient	0
MAR-BP1	9
binding	0
.	0

Indeed	0
,	0
binding	0
of	0
the	0
IgH	1
enhancer	2
to	0
either	0
intact	0
nuclear	0
matrix	0
preparations	0
or	0
to	0
MAR-BP1	9
is	0
mutually	0
exclusive	0
to	0
NF-muNR	9
binding	0
.	0

These	0
results	0
are	0
consistent	0
with	0
a	0
model	0
for	0
cell-type	0
specific	0
regulation	0
in	0
which	0
binding	0
of	0
the	0
NF-muNR	9
repressor	10
to	0
the	0
IgH	1
enhancer	2
prevents	0
nuclear	0
matrix	0
attachment	0
in	0
inappropriate	0
cells	0
by	0
interfering	0
with	0
MAR-BP1	9
/enhancer	1
interaction	0
.	0

PU.1	9
(	0
Spi-1	9
)	0
and	0
C/EBP	9
alpha	10
regulate	0
expression	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
receptor	2
alpha	2
gene	2
.	0

Growth	9
factor	10
receptors	10
play	0
an	0
important	0
role	0
in	0
hematopoiesis	0
.	0

In	0
order	0
to	0
further	0
understand	0
the	0
mechanisms	0
directing	0
the	0
expression	0
of	0
these	0
key	0
regulators	0
of	0
hematopoiesis	0
,	0
we	0
initiated	0
a	0
study	0
investigating	0
the	0
transcription	9
factors	10
activating	0
the	0
expression	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
receptor	2
alpha	2
gene	2
.	0

Here	0
,	0
we	0
demonstrate	0
that	0
the	0
human	1
GM-CSF	2
receptor	2
alpha	2
promoter	2
directs	0
reporter	1
gene	2
activity	0
in	0
a	0
tissue-specific	0
fashion	0
in	0
myelomonocytic	7
cells	8
,	0
which	0
correlates	0
with	0
its	0
expression	0
pattern	0
as	0
analyzed	0
by	0
reverse	0
transcription	0
PCR	0
.	0

The	0
GM-CSF	1
receptor	2
alpha	2
promoter	2
contains	0
an	0
important	0
functional	0
site	0
between	0
positions	0
-53	0
and	0
-41	0
as	0
identified	0
by	0
deletion	0
analysis	0
of	0
reporter	1
constructs	2
.	0

We	0
show	0
that	0
the	0
myeloid	0
and	0
B	9
cell	10
transcription	10
factor	10
PU.1	9
binds	0
specifically	0
to	0
this	0
site	0
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
a	0
CCAAT	1
site	2
located	0
upstream	0
of	0
the	0
PU.1	1
site	2
between	0
positions	0
-70	0
and	0
-54	0
is	0
involved	0
in	0
positive-negative	0
regulation	0
of	0
the	0
GM-CSF	1
receptor	2
alpha	2
promoter	2
activity	0
.	0

C/EBP	9
alpha	10
is	0
the	0
major	0
CCAAT/enhancer-binding	9
protein	10
(	0
C/EBP	9
)	0
form	0
binding	0
to	0
this	0
site	0
in	0
nuclear	0
extracts	0
of	0
U937	5
cells	6
.	0

Point	0
mutations	0
of	0
either	0
the	0
PU.1	1
site	2
or	0
the	0
C/EBP	1
site	2
that	0
abolish	0
the	0
binding	0
of	0
the	0
respective	0
factors	0
result	0
in	0
a	0
significant	0
decrease	0
of	0
GM-CSF	1
receptor	2
alpha	2
promoter	2
activity	0
in	0
myelomonocytic	7
cells	8
only	0
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
in	0
myeloid	0
and	0
B	0
cell	0
extracts	0
,	0
PU.1	9
forms	0
a	0
novel	0
,	0
specific	0
,	0
more	0
slowly	0
migrating	0
complex	0
(	0
PU-SF	9
)	0
when	0
binding	0
the	0
GM-CSF	9
receptor	10
alpha	10
promoter	0
PU.1	1
site	2
.	0

This	0
is	0
the	0
first	0
demonstration	0
of	0
a	0
specific	0
interaction	0
with	0
PU.1	9
on	0
a	0
myeloid	1
PU.1	2
binding	2
site	2
.	0

The	0
novel	0
complex	0
is	0
distinct	0
from	0
that	0
described	0
previously	0
as	0
binding	0
to	0
B	1
cell	2
enhancer	2
sites	2
and	0
can	0
be	0
formed	0
by	0
addition	0
of	0
PU.1	9
to	0
extracts	0
from	0
certain	0
nonmyeloid	7
cell	8
types	8
which	0
do	0
not	0
express	0
PU.1	9
,	0
including	0
T	7
cells	8
and	0
epithelial	7
cells	8
,	0
but	0
not	0
from	0
erythroid	7
cells	8
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
the	0
PU-SF	9
complex	10
binds	0
to	0
PU.1	9
sites	0
found	0
on	0
a	0
number	0
of	0
myeloid	1
promoters	2
,	0
and	0
its	0
formation	0
requires	0
an	0
intact	0
PU.1	1
site	2
adjacent	0
to	0
a	0
single-stranded	0
region	0
.	0

Expression	0
of	0
PU.1	9
in	0
nonmyeloid	7
cells	8
can	0
activate	0
the	0
GM-CSF	1
receptor	2
alpha	2
promoter	2
.	0

Deletion	0
of	0
the	0
amino-terminal	9
region	10
of	0
PU.1	9
results	0
in	0
a	0
failure	0
to	0
form	0
the	0
PU-SF	9
complex	0
and	0
in	0
a	0
concomitant	0
loss	0
of	0
transactivation	0
,	0
suggesting	0
that	0
formation	0
of	0
the	0
PU-SF	9
complex	10
is	0
of	0
functional	0
importance	0
for	0
the	0
activity	0
of	0
the	0
GM-CSF	1
receptor	2
alpha	2
promoter	2
.	0

Finally	0
,	0
we	0
demonstrate	0
that	0
C/EBP	9
alpha	10
can	0
also	0
active	0
the	0
GM-CSF	1
receptor	2
alpha	2
promoter	2
in	0
nonmyeloid	7
cells	8
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
400	0
WORDS	0
)	0

HMG-I	9
binds	0
to	0
GATA	1
motifs	2
:	0
implications	0
for	0
an	0
HPFH	0
syndrome	0
.	0

We	0
have	0
examined	0
binding	0
of	0
the	0
nuclear	9
protein	10
HMG-I	9
to	0
the	0
human	1
gamma-globin	2
promoter	2
.	0

We	0
find	0
that	0
HMG-I	9
binds	0
preferentially	0
to	0
the	0
more	0
3	0
'	0
of	0
a	0
pair	0
of	0
GATA	1
motifs	2
in	0
the	0
gamma-globin	1
promoter	2
;	0
this	0
paired	0
motif	0
is	0
bound	0
by	0
the	0
erythroid	9
factor	10
GATA-1	10
.	0

A	0
naturally	0
occurring	0
mutation	0
(	0
-175	0
T-C	0
)	0
in	0
the	0
area	0
bound	0
by	0
HMG-I	9
results	0
in	0
overexpression	0
of	0
gamma-globin	9
in	0
adult	7
red	8
blood	8
cells	8
(	0
HPFH	7
)	0
and	0
up-regulation	0
of	0
the	0
gamma-globin	1
promoter	2
in	0
in	0
vitro	0
expression	0
assays	0
;	0
HMG-I	9
does	0
not	0
bind	0
to	0
this	0
mutant	1
sequence	2
.	0

A	0
survey	0
of	0
GATA	1
motifs	2
from	0
other	0
globin	1
cis-elements	2
demonstrates	0
HMG-I	9
binding	0
to	0
most	0
of	0
them	0
.	0

These	0
findings	0
implicate	0
HMG-I	9
in	0
the	0
HPFH	7
phenotype	0
;	0
we	0
speculate	0
that	0
it	0
may	0
participate	0
in	0
the	0
formation	0
of	0
multiprotein	9
complexes	10
that	0
regulate	0
globin	0
gene	0
expression	0
.	0

Constitutive	0
activation	0
of	0
different	0
Jak	9
tyrosine	10
kinases	10
in	0
human	9
T	10
cell	10
leukemia	10
virus	10
type	10
1	10
(	10
HTLV-1	10
)	10
tax	10
protein	10
or	0
virus-transformed	5
cells	6
.	0

HTLV-1	0
infection	0
causes	0
an	0
adult	0
T	0
cell	0
leukemia	0
in	0
humans	0
.	0

The	0
viral	9
encoded	10
protein	10
tax	9
,	0
is	0
thought	0
to	0
play	0
an	0
important	0
role	0
in	0
oncogenesis	0
.	0

Our	0
previous	0
data	0
obtained	0
from	0
a	0
tax	9
transgenic	0
mouse	0
model	0
revealed	0
that	0
tax	9
transforms	0
mouse	7
fibroblasts	8
but	0
not	0
thymocytes	7
,	0
despite	0
comparable	0
levels	0
of	0
tax	9
expression	0
in	0
both	0
tissues	0
.	0

Constitutive	0
tyrosine	0
phosphorylation	0
of	0
a	0
130-kD	9
protein	10
(	0
s	0
)	0
was	0
observed	0
in	0
the	0
tax	9
transformed	5
fibroblast	6
B	6
line	6
and	0
in	0
HTLV-1	5
transformed	6
human	6
lymphoid	6
lines	6
,	0
but	0
not	0
in	0
thymocytes	7
from	0
Thy-tax	0
transgenic	0
mice	0
.	0

Phosphotyrosine	0
immunoprecipitation	0
followed	0
by	0
Western	0
blot	0
analysis	0
with	0
a	0
set	0
of	0
Jak	9
kinase	10
specific	10
antibodies	10
,	0
identified	0
p130	0
as	0
Jak2	9
in	0
the	0
tax	9
transformed	0
mouse	5
fibroblastic	6
cell	6
line	6
and	0
Jak3	9
in	0
HTLV-1	5
transformed	6
human	6
T	6
cell	6
lines	6
.	0

Phosphorylation	0
of	0
Jak2	9
in	0
tax	5
transformed	6
cells	6
resulted	0
from	0
high	0
expression	0
of	0
IL-6	0
.	0

Tyrosine	0
phosphorylation	0
of	0
this	0
protein	0
could	0
also	0
be	0
induced	0
in	0
Balb/c3T3	5
cells	6
using	0
a	0
supernatant	0
from	0
the	0
B	5
line	6
,	0
which	0
was	0
associated	0
with	0
induction	0
of	0
cell	0
proliferation	0
.	0

Both	0
phosphorylation	0
and	0
proliferation	0
were	0
inhibited	0
by	0
IL-6	9
neutralizing	10
antibodies	10
.	0

Constitutive	0
phosphorylation	0
of	0
Jak	9
kinases	10
may	0
facilitate	0
tumor	0
growth	0
in	0
both	0
HTLV-1	7
infected	8
human	8
T	8
cells	8
and	0
the	0
transgenic	0
mouse	0
model	0
.	0

Regulation	0
of	0
c-jun	3
mRNA	4
expression	0
by	0
hydroxyurea	0
in	0
human	5
K562	6
cells	6
during	0
erythroid	0
differentiation	0
[	0
published	0
erratum	0
appears	0
in	0
Biochim	0
Biophys	0
Acta	0
1995	0
Dec	0
27	0
;	0
1264	0
(	0
3	0
)	0
:	0
409	0
]	0

Hydroxyurea	0
(	0
HU	0
)	0
is	0
an	0
antitumor	0
agent	0
which	0
also	0
induces	0
hemoglobinization	0
during	0
erythroid	0
differentiation	0
.	0

In	0
addition	0
,	0
HU	0
stimulates	0
the	0
synthesis	0
of	0
fetal	9
hemoglobin	10
in	0
sickle	0
cell	0
anemia	0
patients	0
.	0

To	0
further	0
understand	0
its	0
mechanism	0
of	0
action	0
,	0
we	0
investigated	0
the	0
effects	0
of	0
HU	0
on	0
regulation	0
of	0
c-jun	1
expression	0
prior	0
to	0
the	0
onset	0
of	0
erythroid	0
differentiation	0
of	0
K562	5
cells	6
.	0

HU	0
induced	0
a	0
dose-dependent	0
stimulation	0
of	0
c-jun	1
synthesis	0
.	0

The	0
levels	0
of	0
c-jun	3
mRNA	4
was	0
elevated	0
4	0
to	0
7.5-fold	0
by	0
HU	0
within	0
2	0
h	0
.	0

This	0
was	0
followed	0
by	0
a	0
gradual	0
decline	0
to	0
the	0
basal	0
level	0
by	0
24	0
h	0
.	0

Both	0
nuclear	0
run-on	0
and	0
actinomycin	0
D	0
pulse	0
experiments	0
strongly	0
indicate	0
that	0
HU	0
regulates	0
c-jun	3
mRNA	4
expression	0
by	0
increasing	0
the	0
rate	0
of	0
synthesis	0
as	0
well	0
as	0
stabilizing	0
the	0
c-jun	3
mRNA	4
.	0

In	0
addition	0
,	0
the	0
level	0
of	0
jun	9
protein	10
was	0
elevated	0
by	0
2	0
to	0
5-fold	0
within	0
4	0
h	0
in	0
HU	5
treated	6
cells	6
.	0

Furthermore	0
,	0
concentrations	0
of	0
HU	0
below	0
250	0
microM	0
slightly	0
increased	0
the	0
5X	0
AP-1	9
/CAT	9
activity	0
.	0

These	0
results	0
strongly	0
suggest	0
that	0
HU	0
induces	0
both	0
transcriptional	0
and	0
post-transcription	0
regulation	0
of	0
c-jun	1
during	0
erythroid	0
differentiation	0
.	0

In	0
vivo	0
and	0
in	0
vitro	0
effects	0
of	0
glucocorticoids	0
on	0
lymphocyte	0
proliferation	0
in	0
man	0
:	0
relationship	0
to	0
glucocorticoid	9
receptors	10
.	0

Interrelations	0
between	0
the	0
hypothalamic-pituitary-adrenal	0
system	0
(	0
HPA	0
)	0
and	0
the	0
immune	0
system	0
represent	0
a	0
well-documented	0
biological	0
phenomenon	0
.	0

While	0
in	0
vitro	0
administration	0
of	0
glucocorticoids	0
may	0
inhibit	0
concanavalin	0
A	0
(	0
Con	0
A	0
)	0
-	0
and	0
phytohemagglutinin	0
(	0
PHA	0
)	0
-induced	0
T-cell	0
proliferation	0
,	0
pokeweed	9
mitogen	10
(	0
PWM	9
)	0
-driven	0
B-cell	0
mitogenesis	0
is	0
relatively	0
resistant	0
to	0
glucocorticoids	0
.	0

To	0
further	0
explore	0
the	0
link	0
between	0
the	0
HPA	0
and	0
the	0
immune	0
system	0
in	0
relation	0
to	0
glucocorticoid	9
receptor	10
function	0
,	0
dose-response	0
curves	0
were	0
obtained	0
for	0
Con	0
A	0
-and	0
PHA	9
-induced	0
T-cell	0
mitogenesis	0
,	0
PWM	9
-generated	0
B-cell	0
mitogenesis	0
and	0
spontaneous	0
lymphocyte	0
proliferation	0
in	0
13	0
healthy	0
controls	0
.	0

Glucocorticoid	0
effects	0
were	0
assessed	0
in	0
vivo	0
by	0
depletion	0
of	0
endogenous	0
glucocorticoids	0
after	0
oral	0
administration	0
of	0
1.5	0
g	0
metyrapone	0
(	0
MET	0
)	0
and	0
subsequent	0
glucocorticoid	0
replacement	0
,	0
and	0
in	0
vitro	0
by	0
incubation	0
of	0
the	0
cells	0
with	0
different	0
doses	0
of	0
dexamethasone	0
(	0
DEX	0
)	0
.	0

There	0
was	0
a	0
significant	0
decrease	0
in	0
PWM	9
-induced	0
B-cell	0
mitogenesis	0
and	0
a	0
more	0
pronounced	0
effect	0
of	0
DEX	0
administered	0
in	0
vitro	0
on	0
spontaneous	0
lymphocyte	0
proliferation	0
after	0
MET	0
treatment	0
when	0
compared	0
with	0
the	0
DEX	0
plus	0
MET	0
pretreated	0
condition	0
in	0
vivo	0
.	0

These	0
data	0
suggest	0
that	0
the	0
inhibition	0
of	0
spontaneous	0
lymphocyte	0
proliferation	0
by	0
glucocorticoids	0
in	0
vitro	0
is	0
related	0
to	0
glucocorticoid	9
receptor	10
function	0
.	0

The	0
decrease	0
in	0
PWM	9
-generated	0
B-cell	0
proliferation	0
following	0
cortisol	0
depletion	0
by	0
MET	0
may	0
be	0
seen	0
in	0
connection	0
with	0
impaired	0
glucocorticoid-mediated	0
induction	0
of	0
interleukin-1	9
receptor	10
synthesis	0
.	0

Transcription	0
specific	0
differences	0
visualized	0
by	0
fluorescence	0
in	0
situ	0
hybridization	0
pattern	0
on	0
interphase	0
nuclei	0
of	0
different	0
cell	0
types	0
.	0

Application	0
of	0
a	0
``	0
formamide	0
free	0
''	0
and	0
thus	0
``	0
material	0
preserving	0
''	0
in	0
situ	0
hybridization	0
technique	0
using	0
the	0
cDNA	1
of	0
the	0
myf3	1
gene	2
revealed	0
the	0
following	0
results	0
:	0
Human	7
rhabdomyosarcoma	8
cells	8
,	0
characterized	0
by	0
a	0
high	0
expression	0
of	0
myf3	1
show	0
intensive	0
hybridization	0
signals	0
in	0
their	0
interphase	0
.	0

RNase	9
treatment	0
prior	0
to	0
hybridization	0
considerably	0
reduces	0
the	0
size	0
of	0
this	0
signals	0
.	0

In	0
comparison	0
,	0
isolated	0
nuclei	0
of	0
human	7
lymphocytes	8
in	0
which	0
no	0
need	0
for	0
the	0
expression	0
of	0
this	0
gene	0
exists	0
,	0
show	0
barely	0
hybridization	0
signals	0
.	0

Correspondingly	0
,	0
RNase	9
treatment	0
had	0
no	0
effect	0
on	0
hybridization	0
pattern	0
at	0
all	0
.	0

In	0
conclusion	0
an	0
increased	0
transcription	0
efficiency	0
of	0
a	0
cell	0
type	0
specific	0
gene	0
is	0
accompanied	0
by	0
a	0
higher	0
hybridization	0
accessibility	0
in	0
the	0
corresponding	0
cell	0
nuclei	0
.	0

Oncogenicity	0
of	0
human	5
papillomavirus-	6
or	6
adenovirus-transformed	6
cells	6
correlates	0
with	0
resistance	0
to	0
lysis	0
by	0
natural	7
killer	8
cells	8
.	0

The	0
reasons	0
for	0
the	0
dissimilar	0
oncogenicities	0
of	0
human	0
adenoviruses	0
and	0
human	0
papillomaviruses	0
(	0
HPV	0
)	0
in	0
humans	0
are	0
unknown	0
but	0
may	0
relate	0
to	0
differences	0
in	0
the	0
capacities	0
of	0
the	0
E1A	9
and	0
E7	9
proteins	10
to	0
target	7
cells	8
for	0
rejection	0
by	0
the	0
host	7
natural	8
killer	8
(	8
NK	8
)	8
cell	8
response	0
.	0

As	0
one	0
test	0
of	0
this	0
hypothesis	0
,	0
we	0
compared	0
the	0
abilities	0
of	0
E1A	9
-and	0
E7	9
-expressing	0
human	5
fibroblastic	6
or	6
keratinocyte-derived	6
human	6
cells	6
to	0
be	0
selectively	0
killed	0
by	0
either	0
unstimulated	7
or	0
interferon	5
(	6
IFN	6
)	6
-activated	6
NK	6
cells	6
.	0

Cells	0
expressing	0
the	0
E1A	9
oncoprotein	10
were	0
selectively	0
killed	0
by	0
unstimulated	5
NK	6
cells	6
,	0
while	0
the	0
same	0
parental	7
cells	8
but	0
expressing	0
the	0
HPV	0
type	0
16	0
(	0
HPV-16	0
)	0
or	0
HPV-18	0
E7	9
oncoprotein	10
were	0
resistant	0
to	0
NK	0
cell	0
lysis	0
.	0

The	0
ability	0
of	0
IFN-activated	5
NK	6
cells	6
to	0
selectively	0
kill	0
virally	0
transformed	0
cells	0
depends	0
on	0
IFN	9
's	0
ability	0
to	0
induce	0
resistance	0
to	0
NK	0
cell	0
lysis	0
in	0
normal	0
(	0
i.e.	0
,	0
non-viral	5
oncogene-expressing	6
)	0
but	0
not	0
virally	5
transformed	6
cells	6
.	0

E1A	9
blocked	0
IFN	9
's	0
induction	0
of	0
cytolytic	0
resistance	0
,	0
resulting	0
in	0
the	0
selective	0
lysis	0
of	0
adenovirus-transformed	5
cells	6
by	0
IFN-activated	5
NK	6
cells	6
.	0

The	0
extent	0
of	0
IFN	9
-induced	0
NK	0
cell	0
killing	0
of	0
E1A-expressing	5
cells	6
was	0
proportional	0
to	0
the	0
level	0
of	0
E1A	9
expression	0
and	0
correlated	0
with	0
the	0
ability	0
of	0
E1A	9
to	0
block	0
IFN	9
-stimulated	0
gene	0
expression	0
in	0
target	7
cells	8
.	0

In	0
contrast	0
,	0
E7	9
blocked	0
neither	0
IFN	9
-stimulated	0
gene	0
expression	0
nor	0
IFN	9
's	0
induction	0
of	0
cytolytic	0
resistance	0
,	0
thereby	0
precluding	0
the	0
selective	0
lysis	0
of	0
HPV-transformed	5
cells	6
by	0
IFN-activated	5
NK	6
cells	6
.	0

In	0
conclusion	0
,	0
E1A	9
expression	0
marks	0
cells	0
for	0
destruction	0
by	0
the	0
host	0
NK	7
cell	8
response	0
,	0
whereas	0
the	0
E7	9
oncoprotein	10
lacks	0
this	0
activity	0
.	0

Regulation	0
of	0
IkB	9
alpha	10
phosphorylation	0
by	0
PKC-	0
and	0
Ca	0
(	0
2+	0
)	0
-dependent	0
signal	0
transduction	0
pathways	0
.	0

The	0
Ca	9
(	10
2+	10
)	10
-dependent	10
phosphatase	10
calcineurin	9
,	0
a	0
target	0
of	0
FK506	0
and	0
CsA	0
,	0
synergizes	0
with	0
PKC	9
-induced	0
activation	0
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
in	0
T	5
cell	6
lines	6
.	0

We	0
have	0
investigated	0
whether	0
this	0
synergy	0
is	0
present	0
in	0
other	0
cell	0
types	0
and	0
the	0
mechanism	0
(	0
s	0
)	0
by	0
which	0
these	0
two	0
pathways	0
lead	0
to	0
NF-kappa	9
B	10
activation	0
.	0

While	0
this	0
synergy	0
is	0
present	0
in	0
other	0
cell	0
types	0
,	0
in	0
the	0
monocytic	5
cell	6
line	6
U937	6
calcineurin	9
is	0
also	0
sufficient	0
to	0
activate	0
NF-kappa	9
B	10
.	0

Having	0
previously	0
shown	0
that	0
Ca	0
(	0
2+	0
)	0
-	0
and	0
PKC-dependent	0
pathways	0
synergize	0
by	0
accelerating	0
the	0
degradation	0
of	0
IkB	9
alpha	10
,	0
we	0
focused	0
on	0
the	0
regulation	0
of	0
IkB	9
alpha	10
phosphorylation	0
.	0

While	0
PKC	9
-dependent	0
pathways	0
sequentially	0
result	0
in	0
the	0
phosphorylation	0
and	0
in	0
an	0
incomplete	0
degradation	0
of	0
IkB	9
alpha	10
in	0
T	5
cell	6
lines	6
,	0
co-activation	0
of	0
Ca	0
(	0
2+	0
)	0
-dependent	0
pathways	0
accelerates	0
the	0
rate	0
of	0
IkB	9
alpha	10
phosphorylation	0
and	0
results	0
in	0
its	0
complete	0
degradation	0
.	0

Activation	0
of	0
Ca	0
(	0
2+	0
)	0
-dependent	0
pathways	0
alone	0
do	0
not	0
result	0
in	0
the	0
phosphorylation	0
and/or	0
degradation	0
of	0
IkB	9
alpha	10
in	0
Jurkat	5
T	6
or	0
in	0
U937	5
cells	6
.	0

Treatment	0
of	0
T	7
cells	8
with	0
the	0
selective	0
PKC	9
inhibitor	0
GF109203X	0
abrogates	0
the	0
PMA-induced	0
IkB	9
alpha	10
phosphorylation/degradation	0
irrespective	0
of	0
activation	0
of	0
Ca	0
(	0
2+	0
)	0
-dependent	0
pathways	0
,	0
but	0
not	0
the	0
phosphorylation	0
and	0
degradation	0
of	0
IkB	9
alpha	10
induced	0
by	0
TNF-alpha	9
,	0
a	0
PKC	9
-independent	0
stimulus	0
.	0

Contrary	0
to	0
the	0
interaction	0
with	0
PKC	9
,	0
Ca	0
(	0
2+	0
)	0
-dependent	0
pathways	0
synergize	0
with	0
TNF-alpha	9
not	0
at	0
the	0
level	0
of	0
IkB	9
alpha	10
phosphorylation	0
,	0
but	0
at	0
the	0
level	0
of	0
its	0
degradation	0
.	0

These	0
results	0
indicate	0
that	0
Ca	0
(	0
2+	0
)	0
-dependent	0
pathways	0
,	0
including	0
the	0
phosphatase	9
calcineurin	9
,	0
participate	0
in	0
the	0
regulation	0
of	0
NF-kappa	9
B	10
in	0
a	0
cell	0
specific	0
fashion	0
and	0
synergize	0
with	0
PKC	9
-dependent	0
and	0
-independent	0
pathways	0
at	0
the	0
level	0
of	0
IkB	9
alpha	10
phosphorylation	0
and	0
degradation	0
.	0

Vitamin	0
E	0
therapy	0
of	0
acute	0
CCl4-induced	0
hepatic	0
injury	0
in	0
mice	0
is	0
associated	0
with	0
inhibition	0
of	0
nuclear	9
factor	10
kappa	10
B	10
binding	0
.	0

Oxidative	0
stress	0
,	0
with	0
reactive	0
oxygen	0
intermediate	0
formation	0
,	0
may	0
represent	0
a	0
common	0
mechanism	0
by	0
which	0
liver	0
injury	0
is	0
induced	0
by	0
diverse	0
etiologies	0
.	0

Oxidative	0
stress	0
enhances	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activity	0
,	0
and	0
NF-kappa	9
B	10
activity	0
has	0
been	0
shown	0
to	0
enhance	0
the	0
expression	0
of	0
cytotoxic	9
cytokines	10
.	0

Acute	0
hepatic	0
injury	0
caused	0
by	0
reactive	0
oxygen	0
intermediate	0
production	0
was	0
induced	0
by	0
an	0
intraperitoneal	0
injection	0
of	0
CCl4	0
in	0
mice	0
.	0

This	0
injury	0
was	0
significantly	0
inhibited	0
by	0
intravenous	0
pretreatment	0
of	0
the	0
mice	0
with	0
a	0
water-soluble	0
emulsion	0
of	0
alpha-tocopherol	0
.	0

Alpha-tocopherol	0
treatment	0
of	0
the	0
mice	0
given	0
the	0
CCl4	0
also	0
reduced	0
the	0
NF-kappa	9
B	10
binding	0
to	0
levels	0
approaching	0
those	0
found	0
in	0
normal	0
mice	0
.	0

In	0
vitro	0
treatment	0
of	0
a	0
monocyte/macrophage	0
cell	0
line	0
with	0
CCl4	0
led	0
to	0
enhanced	0
NF-kappa	9
B	10
binding	0
and	0
an	0
increase	0
in	0
tumor	3
necrosis	4
factor-alpha	4
(	4
TNF-alpha	4
)	4
messenger	4
RNA	4
levels	0
.	0

Liver	0
specimens	0
taken	0
from	0
patients	0
with	0
acute	0
fulminant	0
hepatitis	0
had	0
markedly	0
increased	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
comparison	0
with	0
the	0
binding	0
of	0
normal	0
livers	0
.	0

These	0
data	0
demonstrate	0
that	0
abolishing	0
acute	0
hepatic	0
injury	0
with	0
alpha-tocopherol	0
,	0
a	0
free	0
radical	0
scavenger	0
,	0
also	0
eliminated	0
increased	0
NF-kappa	9
B	10
binding	0
.	0

It	0
is	0
tempting	0
to	0
speculate	0
that	0
enhanced	0
NF-kappa	9
B	10
expression	0
caused	0
by	0
free	0
radical	0
production/oxidative	0
stress	0
may	0
modulate	0
liver	0
injury	0
,	0
perhaps	0
through	0
an	0
effect	0
on	0
cytotoxic	9
cytokine	10
synthesis	0
.	0

Immunosuppression	0
by	0
glucocorticoids	0
:	0
inhibition	0
of	0
NF-kappa	9
B	10
activity	0
through	0
induction	0
of	0
I	9
kappa	10
B	10
synthesis	0
[	0
see	0
comments	0
]	0

Glucocorticoids	0
are	0
among	0
the	0
most	0
potent	0
anti-inflammatory	0
and	0
immunosuppressive	0
agents	0
.	0

They	0
inhibit	0
synthesis	0
of	0
almost	0
all	0
known	0
cytokines	9
and	0
of	0
several	0
cell	9
surface	10
molecules	10
required	0
for	0
immune	0
function	0
,	0
but	0
the	0
mechanism	0
underlying	0
this	0
activity	0
has	0
been	0
unclear.	0
Here	0
it	0
is	0
shown	0
that	0
glucocorticoids	0
are	0
potent	0
inhibitors	0
of	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
activation	0
in	0
mice	0
and	0
cultured	5
cells	6
.	0

This	0
inhibition	0
is	0
mediated	0
by	0
induction	0
of	0
the	0
I	9
kappa	10
B	10
alpha	0
inhibitory	0
protein	0
,	0
which	0
traps	0
activated	0
NF-kappa	9
B	10
in	0
inactive	9
cytoplasmic	10
complexes	10
.	0

Because	0
NF-kappa	9
B	10
activates	0
many	0
immunoregulatory	1
genes	2
in	0
response	0
to	0
pro-inflammatory	0
stimuli	0
,	0
the	0
inhibition	0
of	0
its	0
activity	0
can	0
be	0
a	0
major	0
component	0
of	0
the	0
anti-inflammatory	0
activity	0
of	0
glucocorticoids	0
.	0

Transcriptional	0
repression	0
of	0
the	0
interleukin-2	1
gene	2
by	0
vitamin	0
D3	0
:	0
direct	0
inhibition	0
of	0
NFATp/AP-1	9
complex	10
formation	0
by	0
a	0
nuclear	9
hormone	10
receptor	10
.	0

T-lymphocyte	0
proliferation	0
is	0
suppressed	0
by	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
[	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
]	0
,	0
the	0
active	0
metabolite	0
of	0
vitamin	0
D3	0
,	0
and	0
is	0
associated	0
with	0
a	0
decrease	0
in	0
interleukin	0
2	0
(	0
IL-2	0
)	0
,	0
gamma	0
interferon	0
,	0
and	0
granulocyte-macrophage	0
colony-stimulating	0
factor	0
mRNA	0
levels	0
.	0

We	0
report	0
here	0
that	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3-mediated	0
repression	0
in	0
Jurkat	5
cells	6
is	0
cycloheximide	0
resistant	0
,	0
suggesting	0
that	0
it	0
is	0
a	0
direct	0
transcriptional	0
repressive	0
effect	0
on	0
IL-2	9
expression	0
by	0
the	0
vitamin	9
D3	10
receptor	10
(	0
VDR	9
)	0
.	0

We	0
therefore	0
examined	0
vitamin	0
D3-mediated	0
repression	0
of	0
activated	0
IL-2	9
expression	0
by	0
cotransfecting	0
Jurkat	5
cells	6
with	0
IL-2	1
promoter/reporter	2
constructs	2
and	0
a	0
VDR	1
overexpression	2
vector	2
and	0
by	0
DNA	0
binding	0
.	0

We	0
delineated	0
an	0
element	0
conferring	0
both	0
DNA	0
binding	0
by	0
the	0
receptor	0
in	0
vitro	0
and	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3-mediated	0
repression	0
in	0
vivo	0
to	0
a	0
short	0
40-bp	1
region	2
encompassing	0
an	0
important	0
positive	1
regulatory	2
element	2
,	0
NF-AT-1	1
,	0
which	0
is	0
bound	0
by	0
a	0
T-cell-specific	9
transcription	10
factor	10
,	0
NFATp	9
,	0
as	0
well	0
as	0
by	0
AP-1	9
.	0

VDR	9
DNA-binding	10
mutants	10
were	0
unable	0
to	0
either	0
bind	0
to	0
this	0
element	0
in	0
vitro	0
or	0
repress	0
in	0
vivo	0
;	0
the	0
VDR	9
DNA-binding	10
domain	10
alone	0
,	0
however	0
,	0
bound	0
the	0
element	0
but	0
also	0
could	0
not	0
repress	0
IL-2	9
expression	0
.	0

These	0
results	0
indicate	0
that	0
DNA	0
binding	0
by	0
VDR	9
is	0
necessary	0
but	0
not	0
sufficient	0
to	0
mediate	0
IL-2	9
repression	0
.	0

By	0
combining	0
partially	9
purified	10
proteins	10
in	0
vitro	0
,	0
we	0
observed	0
the	0
loss	0
of	0
the	0
bound	0
NFATp/AP-1-DNA	9
complex	10
upon	0
inclusion	0
of	0
VDR	9
or	0
VDR-retinoid	9
X	10
receptor	10
.	0

Order	0
of	0
addition	0
and	0
off-rate	0
experiments	0
indicate	0
that	0
the	0
VDR-retinoid	9
X	10
receptor	10
heterodimer	10
blocks	0
NFATp/AP-1	9
complex	10
formation	0
and	0
then	0
stably	0
associates	0
with	0
the	0
NF-AT-1	1
element	2
.	0

This	0
direct	0
inhibition	0
by	0
a	0
nuclear	0
hormone	0
receptor	0
of	0
transcriptional	9
activators	10
of	0
the	0
IL-2	1
gene	2
may	0
provide	0
a	0
mechanistic	0
explanation	0
of	0
how	0
vitamin	0
derivatives	0
can	0
act	0
as	0
potent	0
immunosuppressive	0
agents	0
.	0

Tissue-specific	0
regulation	0
of	0
the	0
rabbit	1
15-lipoxygenase	2
gene	2
in	0
erythroid	7
cells	8
by	0
a	0
transcriptional	1
silencer	2
.	0

The	0
15-lipoxygenase	1
(	2
lox	2
)	2
gene	2
is	0
expressed	0
in	0
a	0
tissue-specific	0
manner	0
,	0
predominantly	0
in	0
erythroid	7
cells	8
but	0
also	0
in	0
airway	7
epithelial	8
cells	8
and	0
eosinophils	7
.	0

We	0
demonstrate	0
in	0
this	0
report	0
that	0
the	0
5	1
'	2
flanking	2
DNA	2
of	0
the	0
15-lox	1
gene	2
contains	0
sequences	0
which	0
down-regulate	0
its	0
activity	0
in	0
a	0
variety	0
of	0
non-erythroid	5
cell	6
lines	6
but	0
not	0
in	0
two	0
erythroid	5
cell	6
lines	6
.	0

The	0
element	0
has	0
characteristics	0
of	0
a	0
transcriptional	1
'silencer	2
'	2
since	0
it	0
functions	0
in	0
both	0
orientations	0
.	0

The	0
main	0
activity	0
of	0
the	0
silencer	1
has	0
been	0
mapped	0
to	0
the	0
first	0
900	0
bp	0
of	0
5	1
'	2
flanking	2
DNA	2
,	0
which	0
contains	0
nine	0
binding	0
sites	0
for	0
a	0
nuclear	9
factor	10
present	0
in	0
non-	0
erythroid	7
cells	8
but	0
not	0
in	0
erythroid	7
cells	8
.	0

These	0
binding	0
sites	0
have	0
similar	0
sequences	0
and	0
multiple	0
copies	0
of	0
the	0
binding	1
sites	2
confer	0
tissue-specific	0
down-regulation	0
when	0
attached	0
to	0
a	0
minimal	1
lox	2
promoter	2
fragment	2
.	0

The	0
5	1
'	2
flanking	2
DNA	2
also	0
contains	0
a	0
cluster	0
of	0
three	0
binding	1
sites	2
for	0
the	0
GATA	9
family	10
of	0
transcription	9
factors	10
.	0

Phosphorylation	0
of	0
the	0
transcription	9
factor	10
NFATp	9
inhibits	0
its	0
DNA	0
binding	0
activity	0
in	0
cyclosporin	5
A-treated	6
human	6
B	6
and	0
T	7
cells	8
.	0

Cyclosporin	0
A	0
(	0
CsA	0
)	0
exerts	0
its	0
immunosuppressive	0
effect	0
by	0
inhibiting	0
the	0
activity	0
of	0
nuclear	9
factor	10
of	0
activated	0
T	7
cells	8
(	0
NFAT	9
)	0
,	0
thus	0
preventing	0
transcriptional	0
induction	0
of	0
several	0
cytokine	0
genes	0
.	0

This	0
effect	0
is	0
thought	0
to	0
be	0
largely	0
mediated	0
through	0
inactivation	0
of	0
the	0
phosphatase	0
calcineurin	9
,	0
which	0
in	0
turn	0
inhibits	0
translocation	0
of	0
an	0
NFAT	9
component	0
to	0
the	0
nucleus	0
.	0

Here	0
we	0
report	0
that	0
CsA	0
treatment	0
of	0
Raji	5
B	6
and	0
Jurkat	5
T	6
cell	6
lines	6
yields	0
a	0
phosphorylated	0
form	0
of	0
NFATp	9
that	0
is	0
inhibited	0
in	0
DNA-binding	0
and	0
in	0
its	0
ability	0
to	0
form	0
an	0
NFAT	9
complex	10
with	0
Fos	9
and	0
Jun	9
.	0

Immunoblot	0
analyses	0
and	0
metabolic	0
labeling	0
with	0
[	0
32P	0
]	0
orthophosphate	0
show	0
that	0
CsA	0
alters	0
NFATp	9
migration	0
on	0
SDS-polyacrylamide	0
gel	0
electrophoresis	0
by	0
increasing	0
its	0
phosphorylation	0
level	0
without	0
affecting	0
subcellular	0
distribution	0
.	0

Dephosphorylation	0
by	0
in	0
vitro	0
treatment	0
with	0
calcineurin	9
or	0
alkaline	9
phosphatase	10
restores	0
NFATp	9
DNA	0
binding	0
activity	0
and	0
its	0
ability	0
to	0
reconstitute	0
an	0
NFAT	9
complex	10
with	0
Fos	9
and	0
Jun	9
proteins	0
.	0

These	0
data	0
point	0
to	0
a	0
new	0
mechanism	0
for	0
CsA-sensitive	0
regulation	0
of	0
NFATp	9
in	0
which	0
dephosphorylation	0
is	0
critical	0
for	0
DNA	0
binding	0
.	0

Transcription	9
factors	10
as	0
targets	0
for	0
oxidative	0
signalling	0
during	0
lymphocyte	0
activation	0
.	0

We	0
previously	0
have	0
demonstrated	0
a	0
requirement	0
for	0
oxidative	0
events	0
during	0
cell	0
cycle	0
entry	0
in	0
T	7
lymphocytes	8
and	0
have	0
hypothesised	0
that	0
reactive	0
oxygen	0
species	0
may	0
act	0
as	0
intracellular	0
signalling	0
agents	0
during	0
lymphocyte	0
activation	0
.	0

In	0
the	0
current	0
study	0
,	0
cysteamine	0
,	0
an	0
aminothiol	0
compound	0
with	0
antioxidant	0
activity	0
,	0
has	0
been	0
used	0
to	0
further	0
investigate	0
the	0
role	0
of	0
oxidative	0
signalling	0
during	0
lymphocyte	0
activation	0
.	0

Treatment	0
of	0
normal	0
human	7
peripheral	8
blood	8
lymphocytes	8
with	0
cysteamine	0
in	0
vitro	0
was	0
found	0
to	0
inhibit	0
proliferation	0
in	0
a	0
dose-dependent	0
manner	0
,	0
with	0
essentially	0
complete	0
inhibition	0
occurring	0
at	0
a	0
dose	0
of	0
400	0
microM	0
.	0

This	0
inhibitory	0
effect	0
was	0
limited	0
to	0
the	0
first	0
2	0
h	0
after	0
mitogenic	0
activation	0
,	0
localizing	0
the	0
time-frame	0
of	0
action	0
of	0
cysteamine	0
to	0
within	0
the	0
commitment	0
period	0
.	0

It	0
therefore	0
was	0
of	0
interest	0
to	0
establish	0
which	0
,	0
if	0
any	0
,	0
commitment	0
events	0
were	0
affected	0
by	0
oxidative	0
signalling	0
during	0
cell	0
cycle	0
entry	0
.	0

Taking	0
the	0
IL-2	1
gene	2
as	0
a	0
candidate	0
,	0
we	0
examined	0
the	0
effect	0
of	0
cysteamine	0
treatment	0
on	0
early	1
gene	2
expression	0
during	0
lymphocyte	0
activation	0
,	0
and	0
on	0
the	0
activity	0
of	0
transcription	9
factors	10
AP-1	9
,	0
NF-kappa	9
B	10
,	0
NF-AT	9
and	0
Oct1	9
,	0
whose	0
functions	0
are	0
required	0
for	0
expression	0
of	0
the	0
IL-2	9
mRNA	0
.	0

Cysteamine	0
treatment	0
inhibited	0
both	0
expression	0
of	0
the	0
IL-2	3
mRNA	4
and	0
secretion	0
of	0
IL-2	9
into	0
the	0
culture	0
medium	0
.	0

The	0
inhibitory	0
effect	0
of	0
cysteamine	0
may	0
be	0
mediated	0
at	0
least	0
in	0
part	0
by	0
an	0
effect	0
on	0
transcription	9
factor	10
function	0
,	0
as	0
the	0
DNA	0
binding	0
activities	0
of	0
AP-1	9
and	0
NF-kappa	9
B	10
extracted	0
from	0
mitogen-stimulated	7
cells	8
were	0
significantly	0
inhibited	0
by	0
cysteamine	0
treatment	0
.	0

Interestingly	0
,	0
Oct1	0
and	0
NF-AT	0
DNA	0
binding	0
activity	0
were	0
not	0
affected	0
by	0
cysteamine	0
treatment	0
,	0
suggesting	0
that	0
oxidative	0
signalling	0
processes	0
operate	0
in	0
a	0
selective	0
manner	0
.	0

The	0
identification	0
of	0
regulatory	9
proteins	10
,	0
such	0
as	0
transcription	9
factors	10
,	0
as	0
molecular	0
targets	0
for	0
oxidative	0
signalling	0
provides	0
further	0
evidence	0
to	0
implicate	0
oxidative	0
signalling	0
as	0
being	0
intimately	0
involved	0
in	0
the	0
G0	0
to	0
G1	0
phase	0
transition	0
in	0
T	7
lymphocytes	8
.	0

Sex	0
and	0
age	0
distribution	0
of	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
normal	0
human	0
subjects	0
.	0

Specific	0
receptors	0
for	0
1	0
,	0
25	0
Dihydroxyvitamin	0
D3	0
have	0
been	0
described	0
in	0
human	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
.	0

We	0
have	0
tried	0
to	0
find	0
out	0
whether	0
these	0
receptors	0
could	0
show	0
any	0
difference	0
in	0
sex	0
or	0
age	0
distribution	0
.	0

Twenty	0
two	0
healthy	0
men	0
aged	0
21-66	0
yr	0
(	0
mean	0
+/-	0
SD	0
41.0	0
+/-	0
13.6	0
)	0
and	0
nineteen	0
healthy	0
women	0
aged	0
22-60	0
yr	0
(	0
38.9	0
+/-	0
13.9	0
)	0
have	0
been	0
studied	0
.	0

The	0
mean	0
dissociation	0
constant	0
(	0
Kd	0
)	0
was	0
similar	0
in	0
both	0
sexes	0
(	0
1.35	0
+/-	0
0.70	0
x	0
10	0
(	0
-10	0
)	0
M	0
in	0
males	0
,	0
1.13	0
+/-	0
0.66	0
x	0
10	0
(	0
-10	0
)	0
M	0
in	0
females	0
)	0
,	0
but	0
the	0
concentration	0
of	0
binding	0
sites	0
(	0
Nmax	0
)	0
was	0
significantly	0
lower	0
in	0
females	0
(	0
2.32	0
+/-	0
0.92	0
fmol/10	0
(	0
7	0
)	0
PBMC	7
vs	0
4.43	0
+/-	0
1.38	0
fmol/10	0
(	0
7	0
)	0
PBMC	7
in	0
males	0
;	0
p	0
=	0
0.0001	0
)	0
.	0

Neither	0
Kd	0
nor	0
Nmax	0
were	0
significantly	0
correlated	0
with	0
age	0
.	0

No	0
difference	0
was	0
found	0
between	0
pre	0
and	0
postmenopausal	0
women	0
.	0

Further	0
studies	0
are	0
needed	0
to	0
elucidate	0
if	0
this	0
sex	0
difference	0
in	0
PBMC	9
receptors	10
for	0
1.25	0
Dihydroxyvitamin	0
D3	0
is	0
of	0
any	0
pathophysiological	0
relevance	0
.	0

Expression	0
of	0
Id2	0
and	0
Id3	0
mRNA	0
in	0
human	7
lymphocytes	8
.	0

Helix-loop-helix	9
(	10
HLH	10
)	10
transcription	10
factors	10
are	0
involved	0
in	0
cellular	0
growth	0
and	0
differentiation	0
.	0

The	0
Id	9
(	0
inhibitor	0
of	0
DNA	0
binding	0
and	0
differentiation	0
)	0
HLH	9
proteins	10
,	0
in	0
a	0
dominantly	0
negative	0
fashion	0
,	0
regulate	0
transcriptional	0
activities	0
of	0
basic	9
HLH	10
proteins	10
.	0

We	0
examined	0
by	0
northern	0
hybridization	0
the	0
expression	0
of	0
Id2	3
and	4
Id3	4
mRNA	4
in	0
human	5
leukemia/lymphoma	6
lines	6
and	0
patient	0
samples	0
,	0
as	0
well	0
as	0
resting	0
and	0
activated	5
normal	6
human	6
lymphocytes	6
from	0
peripheral	0
blood	0
(	0
PBL	7
)	0
.	0

The	0
Id2	3
mRNA	4
was	0
abundantly	0
expressed	0
in	0
5/12	5
T-cell	6
and	0
3/4	5
B-cell	6
lines	6
,	0
and	0
Id3	3
mRNA	4
was	0
detected	0
in	0
4/12	5
T-cell	6
and	0
3/4	5
B-cell	6
lines	6
.	0

Interestingly	0
,	0
Id2	3
,	0
but	0
not	0
Id3	3
,	0
mRNA	0
was	0
strongly	0
expressed	0
in	0
4/5	5
T-cell	6
lines	6
infected	0
with	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
(	0
ATL-1k	5
,	0
MT-2	5
,	0
S-LB1	5
)	0
and	0
type	0
II	0
(	0
Mo	5
)	0
.	0

Another	0
unexpected	0
finding	0
was	0
that	0
T-cell	0
leukemias	0
and	0
T-cell	5
lines	6
often	0
expressed	0
either	0
Id2	3
or	0
Id3	3
mRNA	4
.	0

In	0
addition	0
,	0
resting	7
PBL	8
constitutively	0
expressed	0
prominent	0
levels	0
of	0
Id2	3
mRNA	4
,	0
but	0
not	0
Id3	3
mRNA	4
.	0

Upon	0
PHA	9
-stimulation	0
,	0
Id2	9
expression	0
decreased	0
and	0
Id3	9
levels	0
increased	0
with	0
biphasic	0
kinetics	0
.	0

Taken	0
together	0
,	0
our	0
studies	0
revealed	0
three	0
unexpected	0
findings	0
which	0
require	0
further	0
analysis	0
:	0
(	0
1	0
)	0
expression	0
of	0
Id2	3
mRNA	4
is	0
often	0
associated	0
with	0
lymphocytic	0
transformation	0
by	0
HTLV-I	0
or	0
-II	0
;	0
(	0
2	0
)	0
T-cells	0
usually	0
express	0
either	0
Id2	9
or	0
Id3	3
mRNA	4
,	0
but	0
B-cells	0
often	0
express	0
both	0
simultaneously	0
;	0
(	0
3	0
)	0
non-dividing	0
,	0
normal	0
PBL	7
express	0
high	0
levels	0
of	0
Id2	9
and	0
no	0
Id3	3
mRNA	4
;	0
and	0
with	0
the	0
onset	0
of	0
cellular	0
proliferation	0
,	0
levels	0
of	0
Id2	3
mRNA	4
decrease	0
while	0
levels	0
of	0
Id3	3
mRNA	4
increase	0
,	0
suggesting	0
that	0
regulation	0
of	0
expression	0
of	0
these	0
closely	0
related	0
genes	1
is	0
disparate	0
.	0

Salicylates	0
inhibit	0
lipopolysaccharide-induced	0
transcriptional	0
activation	0
of	0
the	0
tissue	0
factor	0
gene	0
in	0
human	7
monocytic	8
cells	8
.	0

Binding	0
of	0
plasma	9
Factor	10
VII/VIIa	10
to	0
the	0
tissue	9
factor	10
(	10
TF	10
)	10
receptor	10
initiates	0
the	0
coagulation	9
protease	10
cascades	0
.	0

TF	0
expression	0
by	0
circulating	7
monocytes	8
is	0
associated	0
with	0
thrombotic	0
and	0
inflammatory	0
complications	0
in	0
a	0
variety	0
of	0
diseases	0
.	0

Transcriptional	0
activation	0
of	0
the	0
human	1
TF	2
gene	2
in	0
monocytic	7
cells	8
exposed	0
to	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
is	0
mediated	0
by	0
binding	0
of	0
c-Rel/p65	9
heterodimers	10
to	0
a	0
kappa	1
B	2
site	2
in	0
the	0
TF	1
promoter	2
.	0

Here	0
,	0
we	0
report	0
that	0
a	0
family	0
of	0
anti-inflammatory	0
agents	0
,	0
known	0
as	0
the	0
salicylates	0
,	0
inhibited	0
LPS	0
induction	0
of	0
TF	0
activity	0
and	0
TF	1
gene	2
transcription	0
in	0
human	7
monocytes	8
and	0
monocytic	5
THP-1	6
cells	6
at	0
clinically	0
relevant	0
doses	0
.	0

Furthermore	0
,	0
sodium	0
salicylate	0
blocked	0
the	0
LPS-induced	0
proteolytic	0
degradation	0
of	0
I	9
kappa	10
B	10
alpha	10
,	0
which	0
prevented	0
the	0
nuclear	0
translocation	0
of	0
c-Rel/p65	9
heterodimers	10
.	0

In	0
contrast	0
,	0
two	0
other	0
nonsteroidal	0
anti-inflammatory	0
drugs	0
,	0
ibuprofen	0
and	0
indomethacin	0
,	0
did	0
not	0
inhibit	0
LPS	0
induction	0
of	0
the	0
TF	1
gene	2
.	0

These	0
results	0
indicated	0
that	0
salicylates	0
inhibited	0
LPS	0
induction	0
of	0
TF	1
gene	2
transcription	0
in	0
monocytic	7
cells	8
by	0
preventing	0
nuclear	0
translocation	0
of	0
c-Rel/p65	9
heterodimers	10
.	0

The	0
clinical	0
benefits	0
of	0
salicylates	0
in	0
the	0
treatment	0
of	0
several	0
diseases	0
,	0
including	0
atherosclerosis	0
and	0
rheumatoid	0
arthritis	0
,	0
may	0
be	0
related	0
to	0
their	0
ability	0
to	0
reduce	0
monocyte	0
gene	0
expression	0
.	0

Activation	0
of	0
the	0
signal	0
transducer	0
and	0
transcription	0
(	0
STAT	9
)	0
signaling	0
pathway	0
in	0
a	0
primary	0
T	0
cell	0
response	0
.	0

Critical	0
role	0
for	0
IL-6	9
.	0

The	0
T	0
cell	0
activation	0
is	0
initiated	0
by	0
interaction	0
of	0
specific	0
Ags	9
with	0
TCR	9
,	0
followed	0
by	0
activation	0
of	0
intracellular	0
biochemical	0
events	0
leading	0
to	0
activation	0
of	0
several	0
genes	0
.	0

The	0
activation	0
of	0
signal	0
transducer	0
and	0
activator	0
of	0
transcription	9
(	10
STAT	10
)	10
proteins	10
in	0
a	0
primary	0
TCR	9
-mediated	0
activation	0
of	0
T	7
cells	8
have	0
been	0
explored	0
.	0

In	0
purified	7
human	8
peripheral	8
blood	8
T	8
cells	8
,	0
nuclear	9
STAT	10
proteins	10
were	0
activated	0
approximately	0
3	0
h	0
after	0
activation	0
by	0
cross-linked	0
anti-CD3	9
Abs	10
.	0

These	0
STAT	9
proteins	10
were	0
detected	0
by	0
using	0
the	0
IFN-gamma-activated	1
sequence	2
(	0
GAS	1
)	0
and	0
related	0
oligonucleotides	0
as	0
probes	0
in	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

Analysis	0
of	0
the	0
nuclear	0
extracts	0
with	0
anti-STAT	9
Abs	10
indicated	0
that	0
they	0
contained	0
STAT-3	9
and	0
additional	0
proteins	0
crossreactive	0
with	0
the	0
STAT	9
family	10
.	0

The	0
induction	0
of	0
STAT	9
activity	0
was	0
inhibited	0
completely	0
by	0
pretreatment	0
with	0
either	0
cycloheximide	0
or	0
cyclosporin	0
A	0
,	0
thus	0
indicating	0
that	0
the	0
induction	0
was	0
due	0
to	0
a	0
secondary	9
factor	10
produced	0
by	0
the	0
activated	0
T	7
cells	8
.	0

As	0
neutralizing	9
anti-IL-6	10
Abs	10
effectively	0
down-regulated	0
the	0
early	0
induction	0
of	0
STAT	9
proteins	10
and	0
as	0
exogenously	0
added	0
IL-6	9
rapidly	0
activated	0
DNA	0
binding	0
similar	0
to	0
TCR	9
-mediated	0
bindings	0
,	0
it	0
can	0
be	0
concluded	0
that	0
IL-6	9
is	0
the	0
factor	0
responsible	0
for	0
the	0
activation	0
of	0
STAT	9
proteins	10
in	0
a	0
primary	0
T	0
cell	0
response	0
.	0

The	0
normal	0
cell	0
cycle	0
activation	0
program	0
is	0
exploited	0
during	0
the	0
infection	0
of	0
quiescent	7
B	8
lymphocytes	8
by	0
Epstein-Barr	0
virus	0
.	0

B	7
lymphocytes	8
in	0
the	0
peripheral	0
circulation	0
are	0
maintained	0
in	0
a	0
non-proliferative	0
state	0
.	0

Antigen	0
recognition	0
stimulates	0
limited	0
proliferation	0
,	0
whereas	0
infection	0
with	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
results	0
in	0
continual	0
proliferation	0
and	0
the	0
outgrowth	0
of	0
immortal	5
cell	6
lines	6
.	0

Because	0
it	0
is	0
not	0
clear	0
at	0
which	0
point	0
in	0
cell	0
cycle	0
the	0
peripheral	7
B	8
lymphocytes	8
are	0
arrested	0
,	0
we	0
characterized	0
the	0
expression	0
of	0
several	0
cell	1
cycle-associated	2
genes	2
in	0
quiescent	7
and	8
stimulated	8
cells	8
.	0

We	0
show	0
that	0
the	0
expression	0
of	0
four	0
cell	1
genes	2
,	0
cdc-2	1
,	0
cyclin	1
E	2
,	0
CD23	1
,	0
and	0
cyclin	1
D2	2
,	0
are	0
up-regulated	0
approximately	0
100-fold	0
as	0
a	0
result	0
of	0
EBV-mediated	0
immortalization	0
.	0

Because	0
these	0
genes	0
play	0
a	0
positive	0
role	0
in	0
cell	0
proliferation	0
,	0
we	0
suggest	0
that	0
this	0
regulatory	0
switch	0
contributes	0
to	0
controlling	0
entry	0
into	0
the	0
cell	0
cycle	0
.	0

Transient	0
stimulation	0
of	0
quiescent	7
B	8
lymphocytes	8
with	0
either	0
a	0
cocktail	0
of	0
anti-CD40	9
,	0
anti-IgM	9
,	0
and	0
IL4	9
,	0
or	0
EBV	0
results	0
in	0
the	0
rapid	0
expression	0
of	0
the	0
same	0
four	0
genes	0
,	0
suggesting	0
that	0
,	0
after	0
infection	0
,	0
EBV	0
exploits	0
the	0
normal	0
program	0
of	0
B-lymphocyte	7
cell	0
cycle	0
activation	0
.	0

Expression	0
of	0
the	0
chemokine	9
receptor	10
BLR2/EBI1	9
is	0
specifically	0
transactivated	0
by	0
Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
.	0

In	0
our	0
attempt	0
to	0
identify	0
chemokine	9
receptors	10
that	0
are	0
related	0
to	0
Burkitt	9
's	10
lymphoma	10
receptor	10
1	10
(	0
BLR1	9
)	0
and	0
are	0
expressed	0
in	0
activated	7
lymphocytes	8
we	0
used	0
RT-PCR	0
resulting	0
in	0
the	0
isolation	0
of	0
a	0
cDNA	0
encoding	0
a	0
seven	9
transmembrane	10
receptor	10
termed	0
BLR2	9
.	0

The	0
protein	0
shows	0
significant	0
sequence	0
similarities	0
to	0
the	0
family	0
of	0
G-protein	9
coupled	10
chemokine	10
receptors	10
and	0
turned	0
out	0
to	0
be	0
identical	0
to	0
the	0
recently	0
described	0
receptor	9
EBI1	10
.	0

Northern	0
blot	0
analysis	0
revealed	0
that	0
BLR2	3
mRNA	4
could	0
be	0
highly	0
stimulated	0
in	0
mitogen-	5
and	6
anti-CD3-treated	6
peripheral	6
blood	6
lymphocytes	6
.	0

BLR2-specific	3
mRNA	4
could	0
be	0
detected	0
in	0
all	0
Epstein-Barr	5
virus	6
positive	6
B	6
cell	6
lines	6
.	0

We	0
show	0
that	0
transcription	0
of	0
the	0
BLR2	1
gene	2
could	0
be	0
specifically	0
induced	0
in	0
Epstein-Barr	5
virus	6
negative	6
BL	6
41	6
cells	6
via	0
estrogen-mediated	0
activation	0
of	0
Epstein-Barr	9
virus	10
nuclear	10
antigen	10
2	10
,	0
a	0
key	0
regulator	0
of	0
viral	1
and	2
cellular	2
genes	2
in	0
immortalized	5
B	6
cells	6
.	0

Our	0
data	0
suggest	0
an	0
involvement	0
of	0
BLR2	9
in	0
the	0
regulation	0
of	0
migration	0
in	0
activated	7
lymphocytes	8
and	0
in	0
viral	0
pathogenesis	0
.	0

A	0
central	0
role	0
for	0
a	0
single	1
c-Myb	2
binding	2
site	2
in	0
a	0
thymic	1
locus	2
control	2
region	2
.	0

Locus	1
control	2
regions	2
(	0
LCRs	1
)	0
are	0
powerful	0
assemblies	0
of	0
cis	1
elements	2
that	0
organize	0
the	0
actions	0
of	0
cell-type-specific	9
trans-acting	10
factors	10
.	0

A	0
2.3-kb	9
LCR	10
in	0
the	0
human	1
adenosine	2
deaminase	2
(	2
ADA	2
)	2
gene	2
first	2
intron	2
,	0
which	0
controls	0
expression	0
in	0
thymocytes	7
,	0
is	0
composed	0
of	0
a	0
200-bp	1
enhancer	2
domain	2
and	0
extended	0
flanking	0
sequences	0
that	0
facilitate	0
activation	0
from	0
within	0
chromatin	1
.	0

Prior	0
analyses	0
have	0
demonstrated	0
that	0
the	0
enhancer	1
contains	0
a	0
28-bp	1
core	2
region	2
and	0
local	0
adjacent	0
augmentative	0
cis	1
elements	2
.	0

We	0
now	0
show	0
that	0
the	0
core	0
contains	0
a	0
single	0
critical	0
c-Myb	1
binding	2
site	2
.	0

In	0
both	0
transiently	5
cotransfected	6
human	6
cells	6
and	0
stable	0
chromatin-integrated	5
yeast	6
cells	6
,	0
c-Myb	9
strongly	0
transactivated	1
reporter	2
constructs	2
that	0
contained	0
polymerized	1
core	2
sequences	2
.	0

c-Myb	9
protein	10
was	0
strongly	0
evident	0
in	0
T	7
lymphoblasts	8
in	0
which	0
the	0
enhancer	1
was	0
active	0
and	0
was	0
localized	0
within	0
discrete	0
nuclear	0
structures	0
.	0

Fetal	0
murine	0
thymus	0
exhibited	0
a	0
striking	0
concordance	0
of	0
endogenous	0
c-myb	1
expression	0
with	0
that	0
of	0
mouse	1
ADA	2
and	0
human	1
ADA	2
LCR	2
-directed	0
transgene	0
expression	0
.	0

Point	0
mutation	0
of	0
the	0
c-Myb	1
site	2
within	0
the	0
intact	0
2.3-kb	9
LCR	10
severely	0
attenuated	0
enhancer	0
activity	0
in	0
transfections	0
and	0
LCR	1
activity	0
in	0
transgenic	5
thymocytes	6
.	0

Within	0
the	0
context	0
of	0
a	0
complex	1
enhancer	2
and	0
LCR	1
,	0
c-Myb	9
can	0
act	0
as	0
an	0
organizer	0
of	0
thymocyte-specific	1
gene	2
expression	0
via	0
a	0
single	0
binding	0
site	0
.	0

A	0
regulatory	1
element	2
in	0
the	0
human	1
interleukin	2
2	2
gene	2
promoter	2
is	0
a	0
binding	1
site	2
for	0
the	0
zinc	9
finger	10
proteins	10
Sp1	9
and	0
EGR-1	9
.	0

Activation	0
of	0
the	0
interleukin	1
2	2
(	2
IL-2	2
)	2
gene	2
after	0
antigen	0
recognition	0
is	0
a	0
critical	0
event	0
for	0
T	0
cell	0
proliferation	0
and	0
effector	0
function	0
.	0

Prior	0
studies	0
have	0
identified	0
several	0
transcription	9
factors	10
that	0
contribute	0
to	0
the	0
activity	0
of	0
the	0
IL-2	1
promoter	2
in	0
stimulated	7
T	8
lymphocytes	8
.	0

Here	0
we	0
describe	0
a	0
novel	0
regulatory	1
element	2
within	0
the	0
IL-2	1
promoter	2
located	0
immediately	0
upstream	0
of	0
the	0
nuclear	1
factor	2
of	2
activated	2
T	2
cell	2
(	2
NFAT	2
)	2
domain	2
.	0

This	0
region	0
(	0
termed	0
the	0
zinc	1
finger	2
protein	2
binding	2
region	2
(	0
ZIP	1
)	0
)	0
serves	0
as	0
binding	0
site	0
for	0
two	0
differently	0
regulated	0
zinc	9
finger	10
proteins	10
:	0
the	0
constitutively	9
expressed	10
transcription	10
factor	10
Sp1	9
and	0
the	0
inducible	9
early	10
growth	10
response	10
protein	10
EGR-1	9
.	0

In	0
unstimulated	7
cells	8
which	0
do	0
not	0
secrete	0
IL-2	9
,	0
only	0
Sp1	9
binds	0
to	0
this	0
region	0
,	0
while	0
in	0
stimulated	5
IL-2	6
secreting	6
cells	6
the	0
inducible	9
EGR-1	10
protein	10
recognizes	0
this	0
element	0
.	0

In	0
Jurkat	5
T	6
cells	6
,	0
the	0
ZIP	1
site	2
serves	0
as	0
an	0
activator	0
for	0
IL-2	9
gene	0
expression	0
,	0
and	0
a	0
combination	0
of	0
ZIP	1
and	0
NFAT	1
binding	2
sites	2
is	0
required	0
for	0
maximal	0
IL-2	1
promoter	2
activity	0
.	0

These	0
results	0
suggest	0
a	0
critical	0
role	0
of	0
the	0
ZIP	1
site	2
for	0
IL-2	1
promoter	2
activity	0
.	0

Activation	0
of	0
the	0
HIV-1	1
enhancer	2
by	0
the	0
LEF-1	9
HMG	10
protein	10
on	0
nucleosome-assembled	1
DNA	2
in	0
vitro	0
.	0

Lymphoid	9
enhancer-binding	10
factor	10
1	10
(	0
LEF-1	9
)	0
is	0
a	0
regulatory	9
high	10
mobility	10
group	10
(	10
HMG	10
)	10
protein	10
that	0
activates	0
the	0
T	1
cell	2
receptor	2
alpha	2
(	2
TCR	2
alpha	2
)	2
enhancer	2
in	0
a	0
context-restricted	0
manner	0
in	0
T	7
cells	8
.	0

In	0
this	0
paper	0
we	0
demonstrate	0
that	0
the	0
distal	0
region	0
of	0
the	0
human	1
immunodeficiency	2
virus-1	2
(	2
HIV-1	2
)	2
enhancer	2
,	0
which	0
contains	0
DNA-binding	1
sites	2
for	0
LEF-1	9
and	0
Ets-1	0
,	0
also	0
provides	0
a	0
functional	0
context	0
for	0
activation	0
by	0
LEF-1	9
.	0

First	0
,	0
we	0
show	0
that	0
mutations	0
in	0
the	0
LEF-1-binding	1
site	2
inhibit	0
the	0
activity	0
of	0
multimerized	1
copies	2
of	0
the	0
HIV-1	1
enhancer	2
in	0
Jurkat	5
T	6
cells	6
,	0
and	0
that	0
LEF-1/GAL4	9
can	0
activate	0
a	0
GAL4-substituted	1
HIV-1	2
enhancer	2
80-	0
to	0
100-fold	0
in	0
vivo	0
.	0

Second	0
,	0
recombinant	9
LEF-1	10
is	0
shown	0
to	0
activate	0
HIV-1	0
transcription	0
on	0
chromatin-assembled	1
DNA	2
in	0
vitro	0
.	0

By	0
using	0
a	0
nucleosome	9
-assembly	0
system	0
derived	0
from	0
Drosophila	0
embryos	0
,	0
we	0
find	0
that	0
the	0
packaging	0
of	0
DNA	0
into	0
chromatin	1
in	0
vitro	0
strongly	0
represses	0
HIV-1	0
transcription	0
and	0
that	0
repression	0
can	0
be	0
counteracted	0
efficiently	0
by	0
preincubation	0
of	0
the	0
DNA	0
with	0
LEF-1	9
(	0
or	0
LEF-1	9
and	0
Ets-1	9
)	0
supplemented	0
with	0
fractions	0
containing	0
the	0
promoter-binding	9
protein	10
,	0
Sp1	9
.	0

Addition	0
of	0
TFE-3	9
,	0
which	0
binds	0
to	0
an	0
E-box	1
motif	2
upstream	0
of	0
the	0
LEF-1	1
and	2
Ets-1	2
sites	2
,	0
further	0
augments	0
transcription	0
in	0
this	0
system	0
.	0

Individually	0
or	0
collectively	0
,	0
none	0
of	0
the	0
three	0
enhancer-binding	9
proteins	10
(	0
LEF-1	9
,	0
Ets-1	9
,	0
and	0
TFE-3	9
)	0
could	0
activate	0
transcription	0
in	0
the	0
absence	0
of	0
Sp1	9
.	0

A	0
truncation	9
mutant	10
of	0
LEF-1	9
(	0
HMG-88	9
)	0
,	0
which	0
contains	0
the	0
HMG	9
box	10
but	0
lacks	0
the	0
trans-activation	9
domain	10
,	0
did	0
not	0
activate	0
transcription	0
from	0
nucleosomal	1
DNA	2
,	0
indicating	0
that	0
bending	0
of	0
DNA	0
by	0
the	0
HMG	9
domain	10
is	0
not	0
sufficient	0
to	0
activate	0
transcription	0
in	0
vitro	0
.	0

We	0
conclude	0
that	0
transcription	0
activation	0
by	0
LEF-1	9
in	0
vitro	0
is	0
a	0
chromatin	1
-dependent	0
process	0
that	0
requires	0
a	0
functional	0
trans-activation	9
domain	10
in	0
addition	0
to	0
the	0
HMG	9
domain	10
.	0

HIV-1	9
envelope	10
glycoproteins	10
induce	0
activation	0
of	0
activated	0
protein-1	9
in	0
CD4+	7
T	8
cells	8
[	0
published	0
erratum	0
appears	0
in	0
J	0
Biol	0
Chem	0
1995	0
Dec	0
1	0
;	0
270	0
(	0
48	0
)	0
:	0
29038	0
]	0

Activation	0
of	0
CD4	7
positive	8
T	8
cells	8
is	0
a	0
primary	0
requirement	0
for	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
entry	0
,	0
efficient	0
HIV	0
replication	0
,	0
and	0
progression	0
to	0
AIDS	0
,	0
Utilizing	0
CD4	5
positive	6
T	6
cell	6
lines	6
and	0
purified	7
T	8
cells	8
from	0
normal	0
individuals	0
,	0
we	0
have	0
demonstrated	0
that	0
native	9
envelope	10
glycoproteins	10
of	0
HIV	0
,	0
gp	9
160	10
,	0
can	0
induce	0
activation	0
of	0
transcription	9
factor	10
,	10
activated	10
protein-1	10
(	0
AP-1	9
)	0
.	0

The	0
stimulatory	0
effects	0
of	0
gp160	9
are	0
mediated	0
through	0
the	0
CD4	9
molecule	10
,	0
since	0
treatment	0
of	0
gp160	9
with	0
soluble	0
CD4-IgG	9
abrogates	0
its	0
activity	0
,	0
and	0
CD4	5
negative	6
T	6
cell	6
lines	6
fail	0
to	0
be	0
stimulated	0
with	0
gp160	9
.	0

Immunoprecipitation	0
of	0
the	0
gp	9
160	10
-induced	0
nuclear	0
extracts	0
with	0
polyclonal	9
antibodies	10
to	0
Fos	9
and	0
Jun	9
proteins	10
indicates	0
that	0
AP-1	9
complex	10
is	0
comprised	0
of	0
members	0
of	0
these	0
family	0
of	0
proteins	0
.	0

The	0
gp160-induced	9
AP-1	10
complex	10
is	0
dependent	0
upon	0
protein	0
tyrosine	0
phosphorylation	0
and	0
is	0
protein	0
synthesis-independent	0
.	0

This	0
stimulation	0
can	0
also	0
be	0
abolished	0
by	0
inhibitors	0
of	0
protein	9
kinase	10
C	10
,	0
but	0
it	0
is	0
unaffected	0
by	0
calcium	0
channel	0
blocker	0
or	0
cyclosporine	0
A	0
.	0

This	0
gp160	9
treatment	0
adversely	0
affects	0
the	0
functional	0
capabilities	0
of	0
T	7
cells	8
:	0
pre-treatment	0
of	0
CD4+	7
T	8
cells	8
with	0
gp160	9
for	0
4	0
h	0
at	0
37	0
degrees	0
C	0
inhibited	0
anti-CD3	9
-induced	0
interleukin-2	9
secretion	0
.	0

Effects	0
similar	0
to	0
gp160	9
were	0
seen	0
with	0
anti-CD4	9
mAb	10
.	0

The	0
aberrant	0
activation	0
of	0
AP-1	9
by	0
gp160	9
in	0
CD4	7
positive	8
T	8
cells	8
could	0
result	0
in	0
up-regulation	0
of	0
cytokines	9
containing	0
AP-1	1
sites	2
,	0
e.g	0
.	0
interleukin-3	9
and	0
granulocyte	9
macrophage	10
colony-stimulating	10
factor	10
,	0
and	0
concurrently	0
lead	0
to	0
T	7
cell	8
unresponsiveness	0
by	0
inhibiting	0
interleukin-2	9
secretion	0
.	0

